


APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

46th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2026

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2025.

46th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2026

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

PREFACE TO FORTY SIXTH EDITION..... iv

1.0 INTRODUCTION vi
1.1 Content and Exclusion vi
1.2 Therapeutic Equivalence-Related Terms vii
1.3 Further Guidance on Bioequivalence ix
1.4 RLD and Reference Standard x
1.5 General Policies and Legal Status xi
1.6 Practitioner/User Responsibilities xi
1.7 Therapeutic Equivalence Evaluations Codes xii
1.8 Description of Certain Special Situations xx
1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product xxiii
1.11 Discontinued Drug Product List xxiv
1.12 Changes to the Orange Book xxiv
1.13 Availability of the Edition xxv

2.0 HOW TO USE THE DRUG PRODUCTS LISTS 2-1
2.1 Key Sections for Using the Drug Product Lists 2-1
2.2 Drug Product Illustration 2-3
2.3 Therapeutic Equivalence Evaluations Illustration 2-4

DRUG PRODUCT LISTS
Prescription Drug Product List 3-1
OTC Drug Product List 4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List 5-1
Discontinued Drug Product List 6-1
Orphan Products Designations and Approvals List 7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 8-1

APPENDICES
A. Product Name Index A-1
B. Product Name Index Listed by Applicant B-1
C. Uniform Terms C-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM AD1
A. Patent and Exclusivity Lists ADA1
B. Patent and Exclusivity Terms ADB1

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO FORTY SIXTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or effectiveness reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of healthcare costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate revisions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under Section 505(b) of the FD&C Act or an ANDA under Section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Orange Book Publication and Regulatory Assessment (DOBPRA), Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations (Prescription Drug Product List); (2) approved Over-the-Counter (OTC) drug products (OTC Drug Product List); (3) Drug Products with Approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research List; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or effectiveness reasons subsequent to being discontinued from marketing (Discontinued Drug Product List).[1] This publication also includes Appendices of information from prescription and OTC drug products lists:

(1) Appendix A, which is an alphabetical list of proprietary names, if one exists (brand name or trade name), and the name of the active ingredient.
(2) Appendix B, which is an alphabetical list—of applicant names which have been abbreviated for this publication.
(3) Appendix C, which is an alphabetical list of uniform terms.

The *Addendum* contains patent and exclusivity information for the products contained in the Prescription Drug Product, OTC Drug Product, Discontinued Drug Product, and the Drug Products with Approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research Lists. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and effectiveness and for which NDAs are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. For these drug products subject to scheduling, the Agency will list the drug product on FDA's website Drugs@FDA upon approval under Section 505(c) of the FD&C Act, and will list the drug product in the Orange Book upon the date of approval as determined under Section 505(x).

[1] Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the OTC Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Division of Orange Book Publication and Regulatory Assessment is otherwise notified before publication. See Section 1.12.

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250 mg capsules vs. tetracycline phosphate complex, 250 mg capsules; quinidine sulfate, 200 mg tablets vs. quinidine sulfate, 200 mg capsules).[3] Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[4] Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[5]

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they may meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to

[2] 21 CFR 314.3(b).
[3] See 21 CFR 314.3(b).
[4] 21 CFR 314.3(b).
[5] 21 CFR 314.3(b).

drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[6] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety.[7] For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200 MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and

[6] 21 CFR 314.3(b).

[7] Active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent bonds (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance. 21 CFR 314.3(b).

becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.[8]

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.[9] Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (RLD)(see Section 1.4) shall be considered bioequivalent:

> (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.[10]

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[11]

---

[8] 21 CFR 314.3(b).
[9] 21 CFR 314.3(b).
[10] 21 CFR 320.24.
[11] We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development.

1.4 RLD and Reference Standard

An RLD is the listed drug[12] identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.[13] FDA's general practice is to designate as RLDs drug products that have been approved for safety and effectiveness under Section 505(c) of the FD&C Act. For an ANDA based on an approved suitability petition (a petitioned ANDA), the RLD generally is the listed drug referenced in the approved suitability petition.[14]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.[15] FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the RLD as the reference standard. However, in some instances, the RLD and the reference standard may be different. For example, where the RLD has been withdrawn from sale for reasons other than safety or effectiveness, FDA may select an ANDA that is therapeutically equivalent to this RLD as the reference standard.

FDA identifies RLDs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as RLDs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the RLDs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

If FDA has not designated an RLD for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate an RLD for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes* (*products meeting necessary bioequivalence requirements*), explains the character coding system (e.g., **AB, AB1, AB2, AB3**...) for multisource prescription drug products listed under the same heading with two or more RLDs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale.

---

[12] A "listed drug" is a new drug product that has been approved under Section 505(c) of the FD&C Act for safety and effectiveness or under Section 505(j) of the FD&C Act, which has not been withdrawn or suspended under Section 505(e)(1) through (5) or Section 505(j)(6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (Orange Book or the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

[13] 21 CFR 314.3(b).

[14] 21 CFR 314.94(a)(3)(i).

[15] 21 CFR 314.3(b).

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available (i.e., not on the Discontinued Drug Product list) from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product, even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory[16] and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or effectiveness reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, prescription drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved prescription drug product (e.g., a particular strength of an approved drug that is not on the Discontinued Drug Product List) as therapeutically

[16] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory.

equivalent to other pharmaceutically equivalent prescription drug products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN, BP**, **BR**, **BS**, **BT**, **BX,** or **B***.

Individual drug products have been evaluated as therapeutically equivalent in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned to such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem,

an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed drug. When such changes in the listed drug are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical alternatives and, thus, are not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the

same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude healthcare professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength)* generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three-character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one RLD of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to an RLD, the generic drug product will be given the same three-character code as the RLD it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2** (the assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference). Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant’s drug product if the applicant’s drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon in vitro methodology. If bioequivalence needs to be demonstrated by *in vivo* methodology, then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products are available as solutions (e.g., concentrated sterile solutions for dilution or sterile solutions ready for injection) or powders for reconstitution (e.g., a lyophilized powder for injection). Solutions and powders for reconstitution are considered different dosage forms, and thus not pharmaceutical equivalent drug products, but may be considered pharmaceutical alternative drug products. Therefore, they are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are expected to have similar clinical effects and safety profile under the conditions of use described in the labeling. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. Historically, the dosage form of a parenteral product was listed as “injectable” while the product physically was generally either a solution or powder. Thus, different products listed with the historical term “injectable” do not necessarily have the same dosage form.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of a parenteral solution generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA. In the past, the strength of parenteral solutions in the Orange Book has not been fully displayed. Rather, the strength of parenteral solutions in the Orange Book has been displayed in terms of concentration, expressed as x mg/milliliter (mL).[17] Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book generally displays the strength of new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g., 1 mg/mL. For example, if this application had a 125 mL and 250 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g., 125 mg/125 mL (1 mg/mL) and 250 mg/250 mL (1 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted,or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and BT in the absence of such data.

[17] The concentrations of certain parenteral drug products, including contrast agents, may be expressed as a percentage rather than as x mg/mL.

"B" CODES

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of “enteric” coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients may be subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an active ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these active ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the RLD must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.[18] Because there are multiple RLDs for levothyroxine sodium tablets and some RLD applicants have conducted studies to establish their drugs' therapeutic equivalence to other RLDs, FDA has determined that its usual practice of assigning two- or three-character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as an RLD or reference standard, it may be difficult to determine to which therapeutic equivalence code the RLDs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the RLD and reference standard, but it is unclear that the RLD and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) an RLD for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[19]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e., AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3, and therefore, Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3 MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3 MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2 MG	N021301	RLD	RS

[18] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all 0.025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

[19] The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at https://www.fda.gov/media/72973/download. Please consult the Active Section for information on other strengths.

AB4	THYRO-TABS	ALVOGEN INC	0.3 MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[20]	MYLAN	0.3 MG	A076187	–	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its RLD because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the RLD, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the RLD described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its RLD, the RLD that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the RLD for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the RLD that served as the basis for the approved suitability petition[21] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not an RLD, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the RLD).

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Information Addendum of the Orange Book. If a drug product has qualified for this exclusivity, FDA will not accept for review and/or will not approve, as applicable, other applications blocked by the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for an ANDA or 505(b)(2) application that relies on the listed drug will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all applications that might otherwise be blocked by such exclusivity. If an NDA holder waives its exclusivity, qualified applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose

[20] Alvogen, Inc.'s tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other RLDs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other RLDs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

[21] If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the RLD identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's

most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications might not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).[22]

1.11 Discontinued Drug Product List

The drug products in the Discontinued Drug Product List of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[23] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform DOBPRA of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, application holders must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that application holders notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to DOBPRA by the end of the month in which the product is approved

[22] Section 3222 of the Food and Drug Omnibus Reform Act of 2022 (enacted December 29, 2022) amended the FD&C Act by adding a new provision to Section 505(j)(7)(A). Section 505(j)(7)(A)(v)(I) sets forth certain conditions under which FDA considers therapeutic equivalence evaluation requests in an application for an eligible drug submitted or approved pursuant to Section 505(b)(2) of the FD&C Act.

[23] See, e.g., Section 506I(d) of the FD&C Act.

to ensure that the product is not included in the Active Section of the next published Orange Book update. The Prescription Drug Product List and the OTC Drug Product List are collectively referred to as the "Active Section."

In addition, DOBPRA generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact DOBPRA by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 KEY SECTIONS FOR USING THE DRUG PRODUCT LISTS

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration* (see Section 2.2) and the *Therapeutic Equivalence Evaluations Illustration* (see Section 2.3) are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by “N” is a New Drug Application (NDA or commonly the innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and

compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.


Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.


2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4


MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/ML**	**A077950**	**001**	Mar 14, 2018
AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001**	Sep 26, 2016

ZIAGEN

AA	**+!**	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001**	Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001**	Dec 17, 2012
AB		CHARTWELL RX	**EQ 300MG BASE**	**A091050**	**001**	Oct 28, 2016
AB		CIPLA	**EQ 300MG BASE**	**A078119**	**001**	Nov 21, 2017
AB	**!**	HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001**	Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001**	Jun 18, 2012

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001	Aug 22, 2014

TABLET, FOR SUSPENSION;ORAL

TRIUMEQ PD

	+!	VIIV HLTHCARE	EQ 60MG BASE;EQ 5MG BASE;30MG	N215413	001	Mar 30, 2022

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	**EQ 600MG BASE;300MG**	**A090159**	**001**	Nov 15, 2018
AB		CHARTWELL RX	**EQ 600MG BASE;300MG**	**A204990**	**001**	Mar 28, 2017
AB	**!**	CIPLA	**EQ 600MG BASE;300MG**	**A091144**	**001**	Mar 28, 2017
AB		HETERO LABS LTD V	**EQ 600MG BASE;300MG**	**A205412**	**001**	Apr 16, 2025
AB		LAURUS	**EQ 600MG BASE;300MG**	**A216332**	**001**	Jul 25, 2022

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

	+!	RADIUS	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017

ABEMACICLIB

TABLET;ORAL

VERZENIO

	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017
	+		100MG	N208716	002	Sep 28, 2017
	+		150MG	N208716	003	Sep 28, 2017
	+!		200MG	N208716	004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		AMNEAL PHARMS	**250MG**	**A208327**	**001**	Jan 07, 2019
AB			**500MG**	**A208327**	**002**	Dec 23, 2020
AB		APOTEX	**250MG**	**A208453**	**001**	Oct 31, 2018
AB		DR REDDYS	**250MG**	**A208416**	**001**	May 18, 2020
AB			**500MG**	**A208416**	**002**	Sep 01, 2023
AB		FLORIDA	**500MG**	**A215086**	**001**	Mar 23, 2023
AB		GLENMARK SPECLT	**250MG**	**A209227**	**001**	Oct 16, 2019
AB			**500MG**	**A209227**	**002**	May 19, 2022
AB		HIKMA	**250MG**	**A208339**	**001**	Oct 31, 2018
AB		MSN	**250MG**	**A210686**	**001**	Jul 10, 2019
AB			**500MG**	**A210686**	**002**	Apr 24, 2024
AB		MYLAN	**250MG**	**A208446**	**001**	Oct 31, 2018
AB			**500MG**	**A208446**	**002**	Dec 14, 2020
AB		NOVUGEN	**250MG**	**A215947**	**001**	Jan 05, 2022
AB			**500MG**	**A215947**	**002**	Jan 05, 2022
AB		QILU	**250MG**	**A212462**	**001**	Sep 27, 2019
AB			**500MG**	**A212462**	**002**	Jun 25, 2021
AB		RISING	**250MG**	**A208371**	**001**	Feb 25, 2019
AB		WOCKHARDT BIO AG	**250MG**	**A208380**	**001**	Feb 27, 2019

ZYTIGA

AB	**+**	JANSSEN BIOTECH	**250MG**	**N202379**	**001**	Apr 28, 2011
AB	**+!**		**500MG**	**N202379**	**002**	Apr 14, 2017

YONSA

	+!	SUN PHARM	125MG	N210308	001	May 22, 2018

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

TABLET;ORAL

AKEEGA

+	JANSSEN BIOTECH	500MG;EQ 50MG BASE	N216793	001	Aug 11, 2023
+!		500MG;EQ 100MG BASE	N216793	002	Aug 11, 2023

ABROCITINIB

TABLET;ORAL

CIBINQO

+	PFIZER	50MG	N213871	001	Jan 14, 2022
+		100MG	N213871	002	Jan 14, 2022
+!		200MG	N213871	003	Jan 14, 2022

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

+!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017

ACALABRUTINIB MALEATE

TABLET;ORAL

CALQUENCE

+!	ASTRAZENECA	EQ 100MG BASE	N216387	001	Aug 03, 2022

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		BIONPHARMA	**333MG**	**A219904**	**001**	Sep 18, 2025
AB	!	GLENMARK PHARMS LTD	**333MG**	**A202229**	**001**	Jul 16, 2013
AB		MYLAN	**333MG**	**A200142**	**001**	Mar 11, 2014
AB		ZYDUS PHARMS	**333MG**	**A205995**	**001**	May 26, 2017

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		AVET LIFESCIENCES	**25MG**	**A202271**	**001**	Feb 07, 2012
AB			**50MG**	**A202271**	**002**	Feb 07, 2012
AB			**100MG**	**A202271**	**003**	Feb 07, 2012
AB		HIKMA	**25MG**	**A078470**	**001**	May 07, 2008
AB			**50MG**	**A078470**	**002**	May 07, 2008
AB			**100MG**	**A078470**	**003**	May 07, 2008
AB		IMPAX LABS	**25MG**	**A078441**	**001**	May 14, 2009
AB			**50MG**	**A078441**	**002**	May 14, 2009
AB			**100MG**	**A078441**	**003**	May 14, 2009
AB		SOMERSET THERAPS LLC	**25MG**	**A091343**	**001**	Oct 17, 2013
AB			**50MG**	**A091343**	**002**	Oct 17, 2013
AB			**100MG**	**A091343**	**003**	Oct 17, 2013
AB	!	STRIDES PHARMA	**25MG**	**A090912**	**001**	Jul 27, 2011
AB			**50MG**	**A090912**	**002**	Jul 27, 2011
AB			**100MG**	**A090912**	**003**	Jul 27, 2011
AB		WATSON LABS	**25MG**	**A077532**	**001**	May 07, 2008
AB			**50MG**	**A077532**	**002**	May 07, 2008
AB			**100MG**	**A077532**	**003**	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	!	AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001**	Dec 30, 1999
AB	!		**EQ 400MG BASE**	**A075047**	**002**	Dec 30, 1999
AB		ANI PHARMS	**EQ 200MG BASE**	**A074007**	**001**	Oct 18, 1995
AB			**EQ 400MG BASE**	**A074007**	**002**	Oct 18, 1995

ACECLIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VIZZ

+!	LENZ THERAP	EQ 1.44% BASE	N218585	001	Jul 31, 2025

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP	**+!**	B BRAUN MEDICAL	**500MG/50ML (10MG/ML)**	**N204957**	**001**	Feb 18, 2021
AP		GLAND	**500MG/50ML (10MG/ML)**	**A219215**	**001**	Apr 02, 2025
AP1		ASPIRO	**1GM/100ML (10MG/ML)**	**A216617**	**001**	Jul 27, 2022
AP1		BAXTER HLTHCARE CORP	**1GM/100ML (10MG/ML)**	**A214331**	**001**	Sep 17, 2021
AP1		CAPLIN	**1GM/100ML (10MG/ML)**	**A219096**	**001**	Dec 05, 2025
AP1		EUGIA PHARMA	**1GM/100ML (10MG/ML)**	**A210969**	**001**	Oct 21, 2020

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1		HIKMA	**1GM/100ML (10MG/ML)**	**A202605**	**001**	Jun 13, 2016
AP1		INFORLIFE	**1GM/100ML (10MG/ML)**	**A215403**	**001**	May 03, 2023
AP1		MYLAN	**1GM/100ML (10MG/ML)**	**A213255**	**001**	Aug 07, 2020
AP1	!	SANDOZ	**1GM/100ML (10MG/ML)**	**A204052**	**001**	Mar 22, 2016
AP1		WOCKHARDT BIO AG	**1GM/100ML (10MG/ML)**	**A205746**	**001**	Apr 18, 2023
AP2	+!	B BRAUN MEDICAL	**1GM/100ML (10MG/ML)**	**N204957**	**002**	Feb 18, 2021
AP2		GLAND	**1GM/100ML (10MG/ML)**	**A219215**	**002**	Apr 02, 2025
	!	BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015
	+!	HIKMA	1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA	!	DR REDDYS LABS SA	**300MG;50MG**	**A207313**	**001**	Dec 27, 2017
AA		GRANULES	**300MG;50MG**	**A213115**	**001**	Nov 22, 2019

TABLET;ORAL

ALLZITAL

AA	!	PHARMOBEDIENT	**325MG;25MG**	**A203484**	**001**	Dec 04, 2015

BUTALBITAL AND ACETAMINOPHEN

AA		ANDA REPOSITORY	**300MG;50MG**	**A207386**	**001**	Nov 15, 2016
AA	!	LGM PHARMA	**300MG;50MG**	**A090956**	**001**	Aug 23, 2011
AA		NE RX PHARMA	**300MG;50MG**	**A214955**	**001**	Aug 16, 2022
AA		PHARMOBEDIENT	**325MG;50MG**	**A203484**	**002**	Dec 04, 2015
AA		QUAGEN	**300MG;50MG**	**A214305**	**001**	Feb 01, 2024
AA			**325MG;50MG**	**A214291**	**001**	Jan 18, 2024
AA		SENORES PHARMS	**300MG;50MG**	**A214088**	**001**	Apr 07, 2022
AA			**325MG;25MG**	**A214088**	**002**	Apr 07, 2022
AA			**325MG;50MG**	**A214088**	**003**	Apr 07, 2022

BUTAPAP

AA	!	ANDA REPOSITORY	**325MG;50MG**	**A089987**	**001**	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	**325MG;50MG;40MG**	**A204733**	**001**	Sep 26, 2018
AA		DR REDDYS LABS SA	**300MG;50MG;40MG**	**A210817**	**001**	Dec 17, 2019
AA	!		**325MG;50MG;40MG**	**A089007**	**001**	Mar 17, 1986
AA		GRANULES	**300MG;50MG;40MG**	**A213321**	**001**	Apr 08, 2020
AA		LANNETT CO INC	**300MG;50MG;40MG**	**A212082**	**001**	Dec 17, 2019
AA			**325MG;50MG;40MG**	**A212083**	**001**	Dec 17, 2019
AA	!	LGM PHARMA	**300MG;50MG;40MG**	**A040885**	**001**	Nov 16, 2009
AA		NOVAST LABS	**300MG;50MG;40MG**	**A215047**	**001**	Nov 17, 2021
AA		NUVO PHARMS INC	**300MG;50MG;40MG**	**A207118**	**001**	Oct 28, 2016
AA		QUAGEN	**300MG;50MG;40MG**	**A214288**	**001**	Feb 08, 2024
AA			**325MG;50MG;40MG**	**A216376**	**001**	Mar 12, 2024
AA		SENORES PHARMS	**300MG;50MG;40MG**	**A214087**	**001**	Aug 13, 2021
AA			**325MG;50MG;40MG**	**A214087**	**002**	Aug 13, 2021
AA		TARO	**300MG;50MG;40MG**	**A213046**	**001**	Jul 01, 2020

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	GENUS	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	**325MG;50MG;40MG**	**A211106**	**001**	Sep 26, 2018
AA	+	ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001**	Nov 09, 1984
AA		GRANULES	**325MG;50MG;40MG**	**A040864**	**001**	Dec 01, 2008
AA		LANNETT CO INC	**325MG;50MG;40MG**	**A200243**	**001**	Sep 13, 2012
AA		LGM PHARMA	**325MG;50MG;40MG**	**A209587**	**001**	Oct 31, 2018
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001**	Jan 21, 1987
AA		QUAGEN	**325MG;50MG;40MG**	**A214287**	**001**	Jan 18, 2024
AA	!	STRIDES PHARMA INTL	**325MG;50MG;40MG**	**A040511**	**001**	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA	**300MG;50MG;40MG;30MG**	**A215138**	**002**	Jan 26, 2022
AB			**325MG;50MG;40MG;30MG**	**A215138**	**001**	Jan 26, 2022
AB		LGM PHARMA	**300MG;50MG;40MG;30MG**	**A076560**	**002**	Jul 19, 2012
AB			**325MG;50MG;40MG;30MG**	**A076560**	**001**	Jun 10, 2004

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB	**+!**	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001**	Jul 30, 1992

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	**300MG;30MG**	**A040779**	**001**	May 29, 2008
AA		AUROLIFE PHARMA LLC	**300MG;15MG**	**A202800**	**001**	Apr 15, 2013
AA			**300MG;30MG**	**A202800**	**002**	Apr 15, 2013
AA			**300MG;60MG**	**A202800**	**003**	Apr 15, 2013
AA		ELITE LABS INC	**300MG;15MG**	**A212418**	**001**	Sep 10, 2019
AA			**300MG;30MG**	**A212418**	**002**	Sep 10, 2019
AA			**300MG;60MG**	**A212418**	**003**	Sep 10, 2019
AA		HIBROW HLTHCARE	**300MG;15MG**	**A211610**	**001**	Jun 27, 2019
AA			**300MG;30MG**	**A211610**	**002**	Jun 27, 2019
AA			**300MG;60MG**	**A211610**	**003**	Jun 27, 2019
AA	**!**	SPECGX LLC	**300MG;15MG**	**A040419**	**001**	May 31, 2001
AA	**!**		**300MG;30MG**	**A040419**	**002**	May 31, 2001
AA	**!**		**300MG;60MG**	**A040419**	**003**	May 31, 2001
AA		STRIDES PHARMA INTL	**300MG;15MG**	**A089990**	**001**	Sep 30, 1988
AA			**300MG;30MG**	**A089805**	**001**	Sep 30, 1988
AA			**300MG;60MG**	**A089828**	**001**	Sep 30, 1988
AA		SUN PHARM INDS LTD	**300MG;60MG**	**A087083**	**001**	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		GENUS	**325MG/15ML;7.5MG/15ML**	**A040894**	**001**	Jul 19, 2011
AA		PHARM ASSOC	**325MG/15ML;7.5MG/15ML**	**A040838**	**001**	May 10, 2013
AA	**!**	WES PHARMA INC	**325MG/15ML;7.5MG/15ML**	**A211023**	**001**	Mar 08, 2019
	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA	**!**	SPECGX LLC	**325MG;5MG**	**A040409**	**001**	Oct 20, 2000

ANEXSIA 7.5/325

AA	**!**	SPECGX LLC	**325MG;7.5MG**	**A040405**	**001**	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	**300MG;5MG**	**A209036**	**001**	Jun 21, 2017
AA			**300MG;7.5MG**	**A209036**	**002**	Jun 21, 2017
AA			**300MG;10MG**	**A209036**	**003**	Jun 21, 2017
AA			**325MG;5MG**	**A209037**	**001**	Jun 21, 2017
AA			**325MG;7.5MG**	**A209037**	**002**	Jun 21, 2017
AA			**325MG;10MG**	**A209037**	**003**	Jun 21, 2017
AA		AMNEAL PHARMS NY	**325MG;5MG**	**A040736**	**001**	Aug 25, 2006
AA			**325MG;7.5MG**	**A040746**	**002**	May 10, 2016
AA			**325MG;10MG**	**A040746**	**001**	Aug 25, 2006
AA	**!**	ASCENT PHARMS INC	**325MG;2.5MG**	**A211487**	**001**	Nov 07, 2018
AA			**325MG;5MG**	**A211487**	**002**	Nov 07, 2018
AA			**325MG;7.5MG**	**A211487**	**003**	Nov 07, 2018
AA			**325MG;10MG**	**A211487**	**004**	Nov 07, 2018
AA		AUROLIFE PHARMA LLC	**300MG;5MG**	**A207709**	**001**	Sep 13, 2018
AA			**300MG;7.5MG**	**A207709**	**002**	Sep 13, 2018
AA			**300MG;10MG**	**A207709**	**003**	Sep 13, 2018
AA			**325MG;5MG**	**A201013**	**001**	Apr 11, 2012
AA			**325MG;7.5MG**	**A201013**	**002**	Apr 11, 2012
AA			**325MG;10MG**	**A201013**	**003**	Apr 11, 2012
AA		ELITE LABS INC	**325MG;2.5MG**	**A209924**	**001**	Nov 16, 2018
AA			**325MG;5MG**	**A209924**	**002**	Nov 16, 2018
AA			**325MG;7.5MG**	**A209924**	**003**	Nov 16, 2018
AA			**325MG;10MG**	**A209924**	**004**	Nov 16, 2018
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203863**	**001**	Mar 30, 2018
AA			**325MG;7.5MG**	**A203863**	**002**	Mar 30, 2018
AA			**325MG;10MG**	**A203863**	**003**	Mar 30, 2018
AA		GRANULES	**325MG;5MG**	**A211729**	**001**	Jan 03, 2020
AA			**325MG;7.5MG**	**A211729**	**002**	Jan 03, 2020
AA			**325MG;10MG**	**A211729**	**003**	Jan 03, 2020
AA		HIBROW HLTHCARE	**300MG;5MG**	**A207509**	**001**	Oct 29, 2018

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA			**300MG;7.5MG**	**A207509**	**002**	Oct 29, 2018
AA			**300MG;10MG**	**A207509**	**003**	Oct 29, 2018
AA		RHODES PHARMS	**325MG;5MG**	**A202991**	**001**	Apr 12, 2016
AA			**325MG;7.5MG**	**A202991**	**002**	Apr 12, 2016
AA			**325MG;10MG**	**A202991**	**003**	Apr 12, 2016
AA	!	SPECGX LLC	**300MG;5MG**	**A206718**	**001**	Mar 31, 2017
AA	!		**300MG;7.5MG**	**A206718**	**002**	Mar 31, 2017
AA	!		**300MG;10MG**	**A206718**	**003**	Mar 31, 2017
AA	!		**325MG;10MG**	**A040400**	**001**	Jul 26, 2000
AA		STRIDES PHARMA INTL	**325MG;5MG**	**A040655**	**001**	Jan 19, 2006
AA			**325MG;5MG**	**A202935**	**002**	Jun 15, 2016
AA			**325MG;7.5MG**	**A040656**	**001**	Jan 19, 2006
AA			**325MG;7.5MG**	**A202935**	**003**	Jun 15, 2016
AA			**325MG;10MG**	**A040355**	**001**	May 31, 2000
AA			**325MG;10MG**	**A202935**	**004**	Jun 15, 2016
AA		TRIS PHARMA INC	**300MG;5MG**	**A202214**	**004**	Mar 15, 2016
AA			**300MG;7.5MG**	**A202214**	**005**	Mar 15, 2016
AA			**300MG;10MG**	**A202214**	**006**	Mar 15, 2016
AA			**325MG;5MG**	**A202214**	**001**	Mar 27, 2013
AA			**325MG;7.5MG**	**A202214**	**002**	Mar 27, 2013
AA			**325MG;10MG**	**A202214**	**003**	Mar 27, 2013
AA		WES PHARMA INC	**325MG;5MG**	**A210211**	**001**	Oct 30, 2017
AA			**325MG;7.5MG**	**A210211**	**002**	Oct 30, 2017
AA			**325MG;10MG**	**A210211**	**003**	Oct 30, 2017

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

	+!	AFT PHARMS US	325MG;97.5MG	N209471	001	Mar 01, 2023

ACETAMINOPHEN; IBUPROFEN SODIUM

SOLUTION;INTRAVENOUS

COMBOGESIC IV

	+!	HIKMA	1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML)	N215320	001	Oct 17, 2023

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

	!	ABHAI LLC	325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018
		MIKART	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018

TABLET;ORAL

OXYCET

AA		SPECGX LLC	**325MG;5MG**	**A087463**	**001**	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA		ABHAI LLC	**325MG;2.5MG**	**A210644**	**001**	Feb 09, 2018
AA			**325MG;5MG**	**A210644**	**002**	Feb 09, 2018
AA			**325MG;7.5MG**	**A210644**	**003**	Feb 09, 2018
AA			**325MG;10MG**	**A210644**	**004**	Feb 09, 2018
AA		ACTAVIS ELIZABETH	**325MG;2.5MG**	**A201447**	**001**	Apr 12, 2013
AA			**325MG;5MG**	**A201447**	**002**	Apr 12, 2013
AA			**325MG;7.5MG**	**A201447**	**003**	Apr 12, 2013
AA			**325MG;10MG**	**A201447**	**004**	Apr 12, 2013
AA		ALVOGEN	**325MG;5MG**	**A202677**	**003**	Mar 08, 2016
AA			**325MG;7.5MG**	**A202677**	**001**	Jul 26, 2012
AA			**325MG;10MG**	**A202677**	**002**	Jul 26, 2012
AA		AMNEAL PHARMS	**325MG;5MG**	**A040777**	**001**	Nov 27, 2007
AA		AMNEAL PHARMS NY	**325MG;7.5MG**	**A040778**	**002**	Jun 27, 2014
AA			**325MG;10MG**	**A040778**	**001**	Nov 27, 2007
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A207419**	**001**	Mar 22, 2017
AA			**325MG;5MG**	**A207419**	**002**	Mar 22, 2017
AA			**325MG;7.5MG**	**A207419**	**003**	Mar 22, 2017
AA			**325MG;10MG**	**A207419**	**004**	Mar 22, 2017
AA		AUROLIFE PHARMA LLC	**325MG;2.5MG**	**A201972**	**001**	Jul 15, 2013
AA			**325MG;5MG**	**A201972**	**002**	Jul 15, 2013
AA			**325MG;7.5MG**	**A201972**	**003**	Jul 15, 2013
AA			**325MG;10MG**	**A201972**	**004**	Jul 15, 2013
AA		ELITE LABS INC	**325MG;5MG**	**A209385**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A209385**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A209385**	**003**	Jul 02, 2018
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203864**	**001**	Jul 02, 2018

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A203864**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A203864**	**003**	Jul 02, 2018
AA		GRANULES	**325MG;2.5MG**	**A211708**	**001**	Oct 31, 2019
AA			**325MG;5MG**	**A211708**	**002**	Oct 31, 2019
AA			**325MG;7.5MG**	**A211708**	**003**	Oct 31, 2019
AA			**325MG;10MG**	**A211708**	**004**	Oct 31, 2019
AA		NOVEL LABS INC	**325MG;2.5MG**	**A204407**	**001**	Feb 24, 2017
AA			**325MG;5MG**	**A204407**	**002**	Feb 24, 2017
AA			**325MG;7.5MG**	**A204407**	**003**	Feb 24, 2017
AA			**325MG;10MG**	**A204407**	**004**	Feb 24, 2017
AA		RHODES PHARMS	**325MG;5MG**	**A201278**	**001**	Aug 28, 2014
AA			**325MG;7.5MG**	**A201278**	**002**	Aug 28, 2014
AA			**325MG;10MG**	**A201278**	**003**	Aug 28, 2014
AA		SPECGX LLC	**325MG;7.5MG**	**A040545**	**001**	Jun 30, 2004
AA			**325MG;10MG**	**A040545**	**002**	Jun 30, 2004
AA		WES PHARMA INC	**325MG;5MG**	**A207510**	**001**	Mar 21, 2018
AA			**325MG;7.5MG**	**A207510**	**002**	Mar 21, 2018
AA			**325MG;10MG**	**A207510**	**003**	Mar 21, 2018

PERCOCET

AA	**!**	ENDO OPERATIONS	**325MG;2.5MG**	**A040330**	**001**	Jun 25, 1999
AA	**!**		**325MG;5MG**	**A040330**	**002**	Jun 25, 1999
AA	**!**		**325MG;7.5MG**	**A040330**	**003**	Nov 23, 2001
AA	**!**		**325MG;10MG**	**A040330**	**004**	Nov 23, 2001

OXYCODONE AND ACETAMINOPHEN

	!	MIKART	300MG;2.5MG	A040608	001	Dec 30, 2005
	!		300MG;5MG	A040608	002	Dec 30, 2005
	!		300MG;7.5MG	A040608	003	Dec 30, 2005
	!		300MG;10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	**325MG;37.5MG**	**A202076**	**001**	Mar 30, 2012
AB	**!**	AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001**	Dec 09, 2009
AB		AUROBINDO PHARMA	**325MG;37.5MG**	**A207152**	**001**	Mar 22, 2017
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001**	Dec 14, 2012
AB		RISING	**325MG;37.5MG**	**A077858**	**001**	Sep 26, 2008
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001**	Sep 06, 2012

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ACCORD HLTHCARE	**500MG**	**A207659**	**001**	Oct 18, 2018
AB		ALEMBIC	**500MG**	**A210423**	**001**	Feb 19, 2019
AB	**!**	CADILA	**500MG**	**A205301**	**001**	Jan 16, 2019
AB		HERITAGE PHARMA	**500MG**	**A040904**	**001**	Dec 10, 2008
AB		INDICUS PHARMA	**500MG**	**A090779**	**001**	Jul 14, 2011
AB		MICRO LABS LTD INDIA	**500MG**	**A207401**	**001**	Oct 01, 2020
AB		MPP PHARMA	**500MG**	**A204691**	**001**	Mar 29, 2016
AB		NOVAST LABS	**500MG**	**A203434**	**001**	Sep 30, 2016

TABLET;ORAL

ACETAZOLAMIDE

AB		AUROBINDO PHARMA LTD	**125MG**	**A212089**	**001**	May 30, 2025
AB			**250MG**	**A212089**	**002**	May 30, 2025
AB		CHARTWELL MOLECULAR	**250MG**	**A084840**	**001**	
AB		EPIC PHARMA LLC	**125MG**	**A218023**	**001**	May 14, 2024
AB			**250MG**	**A218023**	**002**	May 14, 2024
AB		HERITAGE PHARMA	**125MG**	**A205530**	**001**	Oct 27, 2016
AB			**250MG**	**A205530**	**002**	Oct 27, 2016
AB		HIBROW HLTHCARE	**125MG**	**A211556**	**001**	Oct 18, 2019
AB			**250MG**	**A211556**	**002**	Oct 18, 2019
AB		MANKIND PHARMA	**125MG**	**A214282**	**001**	Oct 07, 2020
AB			**250MG**	**A214282**	**002**	Oct 07, 2020
AB		NE RX PHARMA	**125MG**	**A217197**	**001**	May 09, 2023
AB			**250MG**	**A217197**	**002**	May 09, 2023
AB		NOVITIUM PHARMA	**125MG**	**A210588**	**001**	Oct 17, 2019
AB			**250MG**	**A210588**	**002**	Oct 17, 2019

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB		RUBICON RESEARCH	**125MG**	**A215101**	**001**	Aug 19, 2021
AB			**250MG**	**A215101**	**002**	Aug 19, 2021
AB		SOMERSET THERAPS LLC	**125MG**	**A211372**	**001**	Feb 22, 2021
AB			**250MG**	**A211372**	**002**	Feb 22, 2021
AB		STRIDES PHARMA	**125MG**	**A209734**	**001**	Nov 20, 2017
AB			**250MG**	**A209734**	**002**	Nov 20, 2017
AB		TARO	**125MG**	**A040195**	**001**	May 28, 1997
AB	!		**250MG**	**A040195**	**002**	May 28, 1997
AB		ZYDUS LIFESCIENCES	**125MG**	**A211069**	**001**	Apr 04, 2023
AB			**250MG**	**A211069**	**002**	Apr 04, 2023

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		AVET LIFESCIENCES	**EQ 500MG BASE/VIAL**	**A202693**	**001**	Dec 19, 2014
AP		GLAND	**EQ 500MG BASE/VIAL**	**A219775**	**001**	Jun 17, 2025
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A040089**	**001**	Feb 28, 1995
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A200880**	**001**	May 09, 2012
AP	!	XGEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001**	Dec 10, 2008
AP		ZYDUS PHARMS	**EQ 500MG BASE/VIAL**	**A206533**	**001**	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**	
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001**	Feb 19, 1982
AT	+!	OTSUKA ICU MEDCL	**250MG/100ML**	**N017656**	**001**	

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		RISING	**2%**	**A207280**	**001**	Mar 09, 2018
AT	!	SCIEGEN PHARMS	**2%**	**A040607**	**001**	Feb 24, 2005

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		COSETTE	**2%;1%**	**A040609**	**001**	Feb 06, 2006
AT	+!	TARO	**2%;1%**	**A088759**	**001**	Mar 04, 1985

VOSOL HC

AT	+!	SAPTALIS PHARMS	**2%;1%**	**N012770**	**001**	

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

AP	+!	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001**	Jan 23, 2004

ACETYLCYSTEINE

AP		EUGIA PHARMA	**6GM/30ML (200MG/ML)**	**A207358**	**001**	Feb 29, 2016
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001**	Nov 07, 2012
AP		GLENMARK PHARMS INC	**6GM/30ML (200MG/ML)**	**A213693**	**001**	Feb 03, 2022
AP		ONESOURCE SPECIALTY	**6GM/30ML (200MG/ML)**	**A217182**	**001**	Apr 19, 2023
AP		REGCON HOLDINGS	**6GM/30ML (200MG/ML)**	**A215620**	**001**	Feb 23, 2022
AP		RISING	**6GM/30ML (200MG/ML)**	**A203173**	**001**	Mar 24, 2015
AP		SAGENT PHARMS INC	**6GM/30ML (200MG/ML)**	**A091684**	**001**	Oct 31, 2017
AP		SOMERSET THERAPS LLC	**6GM/30ML (200MG/ML)**	**A218397**	**001**	Jun 07, 2024
AP		ZYDUS PHARMS	**6GM/30ML (200MG/ML)**	**A208166**	**001**	Jul 20, 2018

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		ALVOGEN	**10%**	**A204674**	**001**	Feb 11, 2014
AN			**20%**	**A203853**	**001**	Jun 21, 2012
AN	!	AM REGENT	**10%**	**A072489**	**001**	Jul 28, 1995
AN	!		**20%**	**A072547**	**001**	Jul 28, 1995
AN		CONBA USA	**10%**	**A214177**	**001**	Mar 14, 2025

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN			**20%**	**A214177**	**002**	Mar 14, 2025
AN		HOSPIRA	**10%**	**A073664**	**001**	Aug 30, 1994
AN			**20%**	**A074037**	**001**	Aug 30, 1994
AN		SOMERSET THERAPS LLC	**10%**	**A219194**	**001**	Feb 12, 2025
AN			**20%**	**A219194**	**002**	Feb 12, 2025

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		ALEMBIC	**10MG**	**A217774**	**001**	Aug 05, 2024
AB			**17.5MG**	**A217774**	**002**	Aug 05, 2024
AB			**25MG**	**A217774**	**003**	Aug 05, 2024
AB		BARR LABS INC	**10MG**	**A091455**	**001**	Apr 04, 2013
AB			**25MG**	**A091455**	**002**	Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001**	Dec 23, 2015
AB			**17.5MG**	**A202552**	**002**	Dec 23, 2015
AB			**22.5MG**	**A202552**	**003**	Dec 23, 2015
AB			**25MG**	**A202552**	**004**	Dec 23, 2015
AB		MYLAN	**10MG**	**A202148**	**001**	Sep 10, 2015
AB			**25MG**	**A202148**	**002**	Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001**	May 22, 2015
AB			**17.5MG**	**A204633**	**002**	May 22, 2015
AB			**22.5MG**	**A204633**	**003**	May 22, 2015
AB	**!**		**25MG**	**A204633**	**004**	May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001**	Apr 04, 2013
AB			**22.5MG**	**A202897**	**002**	Apr 04, 2013

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	COVIS	0.4MG/INH	N202450	001	Jul 23, 2012

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

	+!	COVIS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019

ACOLTREMON

SOLUTION/DROPS;OPHTHALMIC

TRYPTYR

	+!	ALCON LABS INC	0.003%	N217370	001	May 28, 2025

ACORAMIDIS HYDROCHLORIDE

TABLET;ORAL

ATTRUBY

	+!	BRIDGEBIO PHARMA	EQ 356MG BASE	N216540	001	Nov 22, 2024

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	**!**	APOTEX	**200MG**	**A075677**	**001**	Sep 28, 2005
AB		CADILA	**200MG**	**A204313**	**001**	Mar 25, 2016
AB		CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	**200MG**	**A206261**	**001**	Aug 16, 2017
AB		HERITAGE	**200MG**	**A074889**	**001**	Oct 31, 1997
AB		REGCON HOLDINGS	**200MG**	**A075090**	**001**	Jan 26, 1999
AB		TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997
AB		YILING	**200MG**	**A212173**	**001**	Sep 14, 2020

CREAM;TOPICAL

ACYCLOVIR

AB		ALEMBIC	**5%**	**A212361**	**001**	Nov 21, 2023
AB		AMNEAL	**5%**	**A208766**	**001**	Nov 09, 2020
AB	**!**	PADAGIS ISRAEL	**5%**	**A208702**	**001**	Feb 04, 2019
AB		SUN PHARMA CANADA	**5%**	**A205470**	**001**	Jun 12, 2024

ZOVIRAX

AB	**+**	BAUSCH	**5%**	**N021478**	**001**	Dec 30, 2002

ACYCLOVIR

BX		ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023

OINTMENT;TOPICAL

ACYCLOVIR

AB		ALEMBIC	**5%**	**A209000**	**001**	Apr 06, 2018
AB		AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014

ACYCLOVIR

OINTMENT;TOPICAL

ACYCLOVIR

AB		CHARTWELL RX	**5%**	**A212495**	**001**	Apr 07, 2020
AB		FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB		GLENMARK SPECLT	**5%**	**A205510**	**001**	Jul 31, 2017
AB		MACLEODS PHARMS LTD	**5%**	**A212444**	**001**	May 19, 2021
AB		PHARMOBEDIENT	**5%**	**A202459**	**001**	Apr 03, 2013
AB		SUN PHARMA CANADA	**5%**	**A205469**	**001**	Dec 21, 2016
AB		TORRENT	**5%**	**A209971**	**001**	Jan 11, 2019
AB		XIROMED	**5%**	**A201501**	**001**	Jan 29, 2020
AB		ZYDUS LIFESCIENCES	**5%**	**A205974**	**001**	Mar 15, 2019

ZOVIRAX

AB	**+!**	BAUSCH	**5%**	**N018604**	**001**	Mar 29, 1982

SUSPENSION;ORAL

ACYCLOVIR

AB		ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB		AUROBINDO PHARMA	**200MG/5ML**	**A216331**	**001**	Mar 31, 2022
AB		CHARTWELL RX	**200MG/5ML**	**A212718**	**001**	Apr 23, 2020
AB		HETERO LABS LTD III	**200MG/5ML**	**A215669**	**001**	Jul 01, 2022
AB		MSN	**200MG/5ML**	**A217393**	**001**	Mar 09, 2023
AB	**!**	NOVITIUM PHARMA	**200MG/5ML**	**A212252**	**001**	Jul 10, 2020
AB		RUBICON RESEARCH	**200MG/5ML**	**A215724**	**001**	Aug 18, 2022

TABLET;ORAL

ACYCLOVIR

AB		APOTEX	**400MG**	**A077309**	**001**	Sep 29, 2005
AB			**800MG**	**A077309**	**002**	Sep 29, 2005
AB		AUROBINDO PHARMA USA	**400MG**	**A075211**	**001**	Sep 28, 1998
AB			**800MG**	**A075211**	**002**	Sep 28, 1998
AB		CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB			**800MG**	**A202168**	**002**	Nov 15, 2013
AB		CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB			**800MG**	**A075382**	**002**	Apr 30, 1999
AB		HERITAGE	**400MG**	**A074891**	**001**	Oct 31, 1997
AB			**800MG**	**A074891**	**002**	Oct 31, 1997
AB		HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB	**!**		**800MG**	**A203834**	**002**	Oct 29, 2013
AB		SQUARE PHARMS	**400MG**	**A209366**	**001**	Oct 07, 2019
AB			**800MG**	**A209366**	**002**	Oct 07, 2019
AB		STRIDES PHARMA INTL	**400MG**	**A074946**	**001**	Nov 19, 1997
AB			**800MG**	**A074946**	**002**	Nov 19, 1997
AB		TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB			**800MG**	**A074556**	**003**	Apr 22, 1997
AB		YILING	**400MG**	**A210401**	**001**	Mar 07, 2018
AB			**800MG**	**A210401**	**002**	Mar 07, 2018
AB		ZYDUS PHARMS	**400MG**	**A204314**	**001**	Aug 19, 2014
AB			**800MG**	**A204314**	**002**	Aug 19, 2014

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP		EUGIA PHARMA	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
AP			**EQ 50MG BASE/ML**	**A215404**	**001**	Jun 25, 2024
AP		SLATE RUN PHARMA	**EQ 50MG BASE/ML**	**A218111**	**001**	Jan 08, 2024
AP		ZYDUS PHARMS	**EQ 50MG BASE/ML**	**A206535**	**001**	Aug 31, 2018

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

	+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009

ADAGRASIB

TABLET;ORAL

KRAZATI

	+!	BRISTOL	200MG	N216340	001	Dec 12, 2022

ADAPALENE

CREAM;TOPICAL

ADAPALENE

AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000

GEL;TOPICAL

ADAPALENE

AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		ALEMBIC	**0.3%**	**A213508**	**001**	Jun 18, 2020
AB		ENCUBE ETHICALS	**0.3%**	**A200298**	**001**	Jun 14, 2012
AB		SUN PHARMA CANADA	**0.3%**	**A208322**	**001**	Jun 23, 2016

DIFFERIN

AB	**+!**	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007

SOLUTION;TOPICAL

ADAPALENE

AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB			**0.1%**	**A204593**	**001**	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	**0.3%;2.5%**	**A209641**	**001**	Jun 22, 2022
AB		ALEMBIC	**0.3%;2.5%**	**A214185**	**001**	Aug 04, 2022
AB		ENCUBE	**0.1%;2.5%**	**A206164**	**001**	May 23, 2018
AB		GLENMARK PHARMS LTD	**0.1%;2.5%**	**A208108**	**001**	Nov 08, 2019
AB		PADAGIS ISRAEL	**0.1%;2.5%**	**A205033**	**001**	Jan 23, 2018
AB			**0.3%;2.5%**	**A212464**	**001**	May 31, 2022
AB		SUN PHARMA CANADA	**0.1%;2.5%**	**A206959**	**001**	Jan 24, 2018
AB			**0.3%;2.5%**	**A209148**	**001**	Oct 17, 2018
AB		ZYDUS PHARMS	**0.3%;2.5%**	**A214553**	**001**	Jun 03, 2022

EPIDUO

AB	**+!**	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008

EPIDUO FORTE

AB	**+!**	GALDERMA LABS	**0.3%;2.5%**	**N207917**	**001**	Jul 15, 2015

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CABTREO

	+!	BAUSCH	0.15%;3.1%;1.2%	N216632	001	Oct 20, 2023

ADEFOVIR DIPIVOXIL

TABLET;ORAL

ADEFOVIR DIPIVOXIL

AB		APOTEX	**10MG**	**A205459**	**001**	Jul 06, 2018
AB	**!**	SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP			**3MG/ML**	**A205568**	**001**	Apr 16, 2018
AP		GLAND	**3MG/ML**	**A206778**	**001**	Feb 16, 2018
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP		HIKMA	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004
AP		MYLAN LABS LTD	**3MG/ML**	**A078686**	**001**	May 13, 2009
AP	**!**	RISING	**3MG/ML**	**A078076**	**001**	Oct 31, 2008

SOLUTION;INTRAVENOUS

ADENOSINE

AP		AVET LIFESCIENCES	**60MG/20ML (3MG/ML)**	**A202313**	**001**	Sep 15, 2014
AP			**90MG/30ML (3MG/ML)**	**A202313**	**002**	Sep 15, 2014
AP		EUGIA PHARMA	**60MG/20ML (3MG/ML)**	**A205331**	**001**	Nov 02, 2017
AP			**90MG/30ML (3MG/ML)**	**A205331**	**002**	Nov 02, 2017
AP		FRESENIUS KABI USA	**60MG/20ML (3MG/ML)**	**A077897**	**001**	Nov 27, 2017
AP			**90MG/30ML (3MG/ML)**	**A077897**	**002**	Nov 27, 2017
AP	**!**	MEITHEAL	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**!**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013
AP		MYLAN ASI	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014
AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP		RISING	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014

AFAMELANOTIDE							
IMPLANT;SUBCUTANEOUS							
SCENESSE							
	+!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019
AFATINIB DIMALEATE							
TABLET;ORAL							
GILOTRIF							
	+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
	+		EQ 30MG BASE	N201292	002	Jul 12, 2013
	+!		EQ 40MG BASE	N201292	003	Jul 12, 2013
AFICAMTEN							
TABLET;ORAL							
MYQORZO							
	+!	CYTOKINETICS	5MG	N219083	001	Dec 19, 2025
	+		10MG	N219083	002	Dec 19, 2025
	+		15MG	N219083	003	Dec 19, 2025
	+		20MG	N219083	004	Dec 19, 2025
AIR POLYMER-TYPE A							
FOAM;INTRAUTERINE							
EXEM FOAM KIT							
	+!	GISKIT	10ML	N212279	001	Nov 07, 2019
ALBENDAZOLE							
TABLET;ORAL							
ALBENDAZOLE							
AB		ACTAVIS ELIZABETH	**200MG**	**A208094**	**001**	May 20, 2019
AB		ALEMBIC	**200MG**	**A215652**	**001**	Sep 04, 2024
AB	**!**	DR REDDYS	**200MG**	**A211034**	**001**	Jan 26, 2021
AB		EDENBRIDGE PHARMS	**200MG**	**A211117**	**001**	May 14, 2019
AB		MSN	**200MG**	**A213435**	**001**	Jan 21, 2021
AB		ZYDUS PHARMS	**200MG**	**A208979**	**001**	Dec 14, 2018
ALBUMIN HUMAN							
INJECTABLE;INJECTION							
OPTISON							
	+!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997
ALBUTEROL SULFATE							
AEROSOL, METERED;INHALATION							
ALBUTEROL SULFATE							
AB1		CIPLA	**EQ 0.09MG BASE/INH**	**A209959**	**001**	Apr 08, 2020
AB1		SANDOZ	**EQ 0.09MG BASE/INH**	**A207085**	**001**	Jun 01, 2021
PROVENTIL-HFA							
AB1	**+!**	KINDEVA	**EQ 0.09MG BASE/INH**	**N020503**	**001**	Aug 15, 1996
ALBUTEROL SULFATE							
AB2		AMNEAL IRELAND LTD	**EQ 0.09MG BASE/INH**	**A211600**	**001**	Dec 01, 2025
AB2		ARMSTRONG PHARMS	**EQ 0.09MG BASE/INH**	**A212447**	**001**	May 21, 2024
AB2		LUPIN	**EQ 0.09MG BASE/INH**	**A209954**	**001**	Aug 24, 2020
AB2		PADAGIS US	**EQ 0.09MG BASE/INH**	**A203760**	**001**	Feb 24, 2020
PROAIR HFA							
AB2	**+!**	TEVA BRANDED PHARM	**EQ 0.09MG BASE/INH**	**N021457**	**001**	Oct 29, 2004
VENTOLIN HFA							
BX	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001
POWDER, METERED;INHALATION							
PROAIR RESPICLICK							
	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015
SOLUTION;INHALATION							
ALBUTEROL SULFATE							
AN		LEXENPHARM	**EQ 0.021% BASE**	**A215571**	**001**	May 03, 2024
AN			**EQ 0.042% BASE**	**A215571**	**002**	May 03, 2024
AN		LUOXIN AUROVITAS	**EQ 0.021% BASE**	**A211888**	**001**	Apr 20, 2020
AN			**EQ 0.042% BASE**	**A211888**	**002**	Apr 20, 2020
AN			**EQ 0.083% BASE**	**A206224**	**001**	Oct 17, 2017
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010
AN	**!**		**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	**!**		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN	**!**		**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN	**!**	RITEDOSE CORP	**EQ 0.021% BASE**	**A214531**	**001**	Dec 28, 2021
AN			**EQ 0.042% BASE**	**A214531**	**002**	Dec 28, 2021
AN			**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN			**EQ 0.5% BASE**	**A218386**	**001**	Mar 12, 2025
AN		SENTISS	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

AN		SUN PHARM	**EQ 0.083% BASE**	**A207857**	**001**	Jul 21, 2017

SYRUP;ORAL

ALBUTEROL SULFATE

AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		CHARTWELL MOLECULAR	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA		CHARTWELL RX	**EQ 2MG BASE/5ML**	**A077788**	**001**	Jun 26, 2007
AA		QUAGEN	**EQ 2MG BASE/5ML**	**A212197**	**001**	Sep 06, 2019
AA	**!**	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992

TABLET;ORAL

ALBUTEROL SULFATE

AB		ACERTIS PHARMS	**EQ 2MG BASE**	**A211397**	**001**	Oct 26, 2018
AB			**EQ 4MG BASE**	**A211397**	**002**	Oct 26, 2018
AB		AMNEAL PHARMS CO	**EQ 2MG BASE**	**A208804**	**001**	May 21, 2018
AB			**EQ 4MG BASE**	**A208804**	**002**	May 21, 2018
AB		DASH PHARMS NATCO	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	**!**		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		RISING	**EQ 2MG BASE**	**A207046**	**001**	Jun 29, 2018
AB			**EQ 4MG BASE**	**A207046**	**002**	Jun 29, 2018
AB		SUN PHARM INDUSTRIES	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989
AB			**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989
AB		ZYDUS PHARMS	**EQ 2MG BASE**	**A208884**	**001**	Oct 22, 2020
AB			**EQ 4MG BASE**	**A208884**	**002**	Oct 22, 2020
BX		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019
BX			EQ 4MG BASE	A210948	002	Mar 15, 2019

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

	+!	ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH	N214070	001	Jan 10, 2023

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		CIPLA	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN	**!**	NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN		RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN		SUN PHARM	**EQ 0.083% BASE;0.017%**	**A207875**	**001**	Aug 07, 2017

SPRAY, METERED;INHALATION

COMBIVENT RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB		SUN PHARMA CANADA	**0.05%**	**A076587**	**001**	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB		SUN PHARMA CANADA	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

AP	**+!**	BPI LABS	**99% (5ML)**	**N207987**	**002**	Jun 21, 2018

DEHYDRATED ALCOHOL

AP		ACCORD HLTHCARE	**99% (5ML)**	**A217845**	**001**	Jun 23, 2025
AP		BRECKENRIDGE	**99% (5ML)**	**A219444**	**001**	Jun 23, 2025
AP		INGENUS PHARMS LLC	**99% (5ML)**	**A219569**	**001**	Jul 09, 2025
AP		XGEN PHARMS	**99% (5ML)**	**A219400**	**001**	Jun 23, 2025

SOLUTION;INTRAVENOUS

DEHYDRATED ALCOHOL

	+!	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

	+!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

AA	**!**	HIKMA	**EQ 70MG BASE/75ML**	**A090520**	**001**	Feb 25, 2013
AA		NOVITIUM PHARMA	**EQ 70MG BASE/75ML**	**A214512**	**001**	May 11, 2023

TABLET;ORAL

ALENDRONATE SODIUM

AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A090124**	**001**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A090124**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A090124**	**003**	Aug 04, 2008
AB		CIPLA	**EQ 5MG BASE**	**A076768**	**001**	Aug 04, 2008
AB			**EQ 10MG BASE**	**A076768**	**002**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A076768**	**003**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076768**	**004**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076768**	**005**	Aug 04, 2008
AB		HANGZHOU BINJIANG	**EQ 5MG BASE**	**A090258**	**001**	Sep 24, 2009
AB			**EQ 10MG BASE**	**A090258**	**002**	Sep 24, 2009
AB			**EQ 35MG BASE**	**A090258**	**003**	Sep 24, 2009
AB			**EQ 70MG BASE**	**A090258**	**004**	Sep 24, 2009
AB		IPCA LABS LTD	**EQ 10MG BASE**	**A206387**	**001**	Jun 04, 2024
AB			**EQ 35MG BASE**	**A206387**	**002**	Jun 04, 2024
AB			**EQ 40MG BASE**	**A206387**	**003**	Jun 04, 2024
AB			**EQ 70MG BASE**	**A206387**	**004**	Jun 04, 2024
AB		SUN PHARM	**EQ 5MG BASE**	**A090022**	**001**	Sep 10, 2008
AB			**EQ 10MG BASE**	**A090022**	**002**	Sep 10, 2008
AB			**EQ 35MG BASE**	**A090022**	**003**	Sep 10, 2008
AB			**EQ 70MG BASE**	**A090022**	**004**	Sep 10, 2008
AB		WATSON LABS	**EQ 35MG BASE**	**A076984**	**001**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076984**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076984**	**003**	Aug 04, 2008

FOSAMAX

AB	**+!**	ORGANON	**EQ 70MG BASE**	**N020560**	**005**	Oct 20, 2000

TABLET, EFFERVESCENT;ORAL

BINOSTO

	+!	RADIUS	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

	+	ORGANON LLC	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005
	+!		EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

	+!	RISING	EQ 0.5MG BASE/ML	N019353	001	Dec 29, 1986

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB		AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB		INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB		UNICHEM	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+!**	ADVANZ PHARMA	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		PH HEALTH	**EQ 150MG BASE**	**A206665**	**001**	Mar 22, 2019
AB			**EQ 300MG BASE**	**A206665**	**002**	Mar 22, 2019

TEKTURNA

AB	**+**	NODEN PHARMA	**EQ 150MG BASE**	**N021985**	**001**	Mar 05, 2007
AB	**+!**		**EQ 300MG BASE**	**N021985**	**002**	Mar 05, 2007

ALITRETINOIN							
GEL;TOPICAL							
PANRETIN							
	+!	ADVANZ PHARMA	EQ 0.1% BASE		N020886	001	Feb 02, 1999
ALLOPURINOL							
TABLET;ORAL							
ALLOPURINOL							
AB		ACCORD HLTHCARE	**100MG**		**A203154**	**001**	May 06, 2013
AB			**300MG**		**A203154**	**002**	May 06, 2013
AB		AUROBINDO PHARMA LTD	**100MG**		**A215091**	**001**	Apr 14, 2025
AB			**300MG**		**A215091**	**002**	Apr 14, 2025
AB		CHARTWELL	**100MG**		**A077353**	**001**	Sep 08, 2005
AB			**300MG**		**A077353**	**002**	Sep 08, 2005
AB		HARMAN FINOCHEM	**100MG**		**A214443**	**001**	Mar 07, 2022
AB			**200MG**		**A214443**	**003**	Jun 17, 2024
AB			**300MG**		**A214443**	**002**	Mar 07, 2022
AB		HETERO LABS LTD V	**100MG**		**A217748**	**001**	Aug 03, 2023
AB			**300MG**		**A217748**	**002**	Aug 03, 2023
AB		MYLAN	**100MG**		**A018659**	**001**	Oct 24, 1986
AB			**300MG**		**A018659**	**002**	Oct 24, 1986
AB		PH HEALTH	**100MG**		**A075798**	**001**	Jun 27, 2003
AB			**300MG**		**A075798**	**002**	Jun 27, 2003
AB		REGCON HOLDINGS	**100MG**		**A204467**	**001**	Jul 28, 2016
AB			**200MG**		**A204467**	**003**	May 22, 2025
AB			**300MG**		**A204467**	**002**	Jul 28, 2016
AB		SUN PHARM INDUSTRIES	**100MG**		**A071450**	**002**	Jan 09, 1987
AB			**300MG**		**A071450**	**001**	Jan 09, 1987
AB		UNICHEM	**100MG**		**A211820**	**001**	Mar 12, 2019
AB	!		**300MG**		**A211820**	**002**	Mar 12, 2019
AB		WATSON LABS	**100MG**		**N018832**	**002**	Sep 28, 1984
AB			**300MG**		**N018877**	**001**	Sep 28, 1984
AB		ZYDUS PHARMS	**100MG**		**A210117**	**001**	Oct 12, 2017
AB			**200MG**		**A210117**	**003**	Jun 13, 2025
AB			**300MG**		**A210117**	**002**	Oct 12, 2017
LOPURIN							
AB		DR REDDYS	**100MG**		**A071586**	**001**	Apr 02, 1987
AB			**300MG**		**A071587**	**001**	Apr 02, 1987
ZYLOPRIM							
AB	+	CASPER PHARMA LLC	**100MG**		**N016084**	**001**	
AB	+		**200MG**		**N016084**	**003**	Aug 04, 2022
AB	+		**300MG**		**N016084**	**002**	
ALLOPURINOL SODIUM							
INJECTABLE;INJECTION							
ALLOPURINOL SODIUM							
AP		GLAND	**EQ 500MG BASE/VIAL**		**A212363**	**001**	Jan 26, 2022
AP		HIKMA	**EQ 500MG BASE/VIAL**		**A076870**	**001**	Aug 26, 2004
ALOPRIM							
AP	+!	MYLAN	**EQ 500MG BASE/VIAL**		**N020298**	**001**	May 17, 1996
ALMOTRIPTAN MALATE							
TABLET;ORAL							
ALMOTRIPTAN MALATE							
AB		AJANTA PHARMA LTD	**EQ 6.25MG BASE**		**A205523**	**001**	Mar 03, 2016
AB	!		**EQ 12.5MG BASE**		**A205523**	**002**	Mar 03, 2016
AB		MYLAN	**EQ 6.25MG BASE**		**A205171**	**001**	Nov 09, 2015
AB			**EQ 12.5MG BASE**		**A205171**	**002**	Nov 09, 2015
AB		TEVA PHARMS USA	**EQ 6.25MG BASE**		**A078027**	**001**	Jul 07, 2015
AB			**EQ 12.5MG BASE**		**A078027**	**002**	Jul 07, 2015
ALOGLIPTIN BENZOATE							
TABLET;ORAL							
NESINA							
	+	TAKEDA PHARMS USA	EQ 6.25MG BASE		N022271	001	Jan 25, 2013
	+		EQ 12.5MG BASE		N022271	002	Jan 25, 2013
	+!		EQ 25MG BASE		N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+!		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+!		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB			**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB		HIBROW HLTHCARE	**EQ 0.5MG BASE**	**A211621**	**001**	Sep 16, 2019
AB			**EQ 1MG BASE**	**A211621**	**002**	Sep 16, 2019
AB		MANKIND PHARMA	**EQ 0.5MG BASE**	**A213614**	**001**	Sep 09, 2020
AB			**EQ 1MG BASE**	**A213614**	**002**	Sep 09, 2020
AB		RISING	**EQ 0.5MG BASE**	**A209180**	**001**	Jan 14, 2019
AB			**EQ 1MG BASE**	**A209180**	**002**	Jan 14, 2019

LOTRONEX

AB	**+**	LEGACY PHARMA	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB	**+!**		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPELISIB

GRANULES;ORAL

VIJOICE

+!	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024

TABLET;ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019
+		150MG	N212526	002	May 24, 2019
+!		200MG	N212526	003	May 24, 2019

VIJOICE

+	NOVARTIS	50MG	N215039	001	Apr 05, 2022
+		125MG	N215039	002	Apr 05, 2022
+!		200MG	N215039	003	Apr 05, 2022

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000
+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021163	002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

!	HIKMA	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB			**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB			**1MG**	**A074342**	**003**	Oct 31, 1993
AB			**2MG**	**A074342**	**004**	Oct 31, 1993
AB		AUROBINDO PHARMA	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB			**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB			**1MG**	**A203346**	**003**	Jul 31, 2015
AB			**2MG**	**A203346**	**004**	Jul 31, 2015
AB		NATCO	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB			**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB			**1MG**	**A200739**	**003**	Apr 15, 2015
AB			**2MG**	**A200739**	**004**	Apr 15, 2015
AB		NOVITIUM PHARMA	**0.25MG**	**A074174**	**001**	Oct 19, 1993

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

AB			**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB			**1MG**	**A074174**	**003**	Oct 19, 1993
AB			**2MG**	**A074174**	**004**	Oct 19, 1993
AB		SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB			**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB			**1MG**	**A074112**	**003**	Dec 29, 1995
AB			**2MG**	**A074909**	**001**	Mar 25, 1998
AB		STRIDES PHARMA INTL	**0.25MG**	**A090248**	**001**	Sep 17, 2010
AB			**0.5MG**	**A090248**	**002**	Sep 17, 2010
AB			**1MG**	**A090248**	**003**	Sep 17, 2010
AB			**2MG**	**A090248**	**004**	Sep 17, 2010

XANAX

AB	**+**	UPJOHN	**0.25MG**	**N018276**	**001**	
AB	**+**		**0.5MG**	**N018276**	**002**	
AB	**+!**		**1MG**	**N018276**	**003**	
AB	**+**		**2MG**	**N018276**	**004**	Nov 27, 1985

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.5MG**	**A078056**	**001**	Feb 13, 2007
AB			**1MG**	**A078056**	**002**	Feb 13, 2007
AB			**2MG**	**A078056**	**003**	Feb 13, 2007
AB			**3MG**	**A078056**	**004**	Feb 13, 2007
AB		AMNEAL PHARMS NY	**0.5MG**	**A078387**	**001**	May 30, 2008
AB			**1MG**	**A078387**	**002**	May 30, 2008
AB			**2MG**	**A078387**	**003**	May 30, 2008
AB			**3MG**	**A078387**	**004**	May 30, 2008
AB		AUROBINDO PHARMA	**0.5MG**	**A090871**	**001**	Jun 07, 2011
AB			**1MG**	**A090871**	**002**	Jun 07, 2011
AB			**2MG**	**A090871**	**003**	Jun 07, 2011
AB			**3MG**	**A090871**	**004**	Jun 07, 2011

XANAX XR

AB	**+**	UPJOHN	**0.5MG**	**N021434**	**001**	Jan 17, 2003
AB	**+**		**1MG**	**N021434**	**002**	Jan 17, 2003
AB	**+**		**2MG**	**N021434**	**003**	Jan 17, 2003
AB	**+!**		**3MG**	**N021434**	**004**	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A078561**	**001**	Mar 16, 2010
AB			**0.5MG**	**A078561**	**002**	Mar 16, 2010
AB			**1MG**	**A078561**	**003**	Mar 16, 2010
AB			**2MG**	**A078561**	**004**	Mar 16, 2010
AB		PH HEALTH	**0.25MG**	**A078088**	**001**	Jan 09, 2009
AB			**0.5MG**	**A078088**	**002**	Jan 09, 2009
AB	**!**		**1MG**	**A078088**	**003**	Jan 09, 2009
AB			**2MG**	**A078088**	**004**	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		HIKMA	**0.5MG/ML**	**A074815**	**001**	Jan 20, 1998
AP		MEITHEAL	**0.5MG/ML**	**A075196**	**001**	Apr 30, 1999

CAVERJECT

AP	**+**	PFIZER	**0.01MG/VIAL**	**N020379**	**001**	Jul 06, 1995
AP	**+!**		**0.02MG/VIAL**	**N020379**	**002**	Jul 06, 1995
AP	**+!**		**0.04MG/VIAL**	**N020379**	**004**	May 19, 1997

EDEX

AP	**+**	ENDO OPERATIONS	**0.01MG/VIAL**	**N020649**	**002**	Jun 12, 1997
AP	**+**		**0.02MG/VIAL**	**N020649**	**003**	Jun 12, 1997
AP	**+!**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997

PROSTIN VR PEDIATRIC

AP	**+!**	PFIZER	**0.5MG/ML**	**N018484**	**001**	

CAVERJECT IMPULSE

		PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+!	ENDO OPERATIONS	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+!		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+!		0.04MG/VIAL	N020649	007	Jul 30, 1998

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		HIKMA	**12MG**	**A217753**	**001**	Aug 31, 2023
AB		PH HEALTH	**12MG**	**A216843**	**001**	Jan 24, 2023
AB	!	WATSON LABS TEVA	**12MG**	**A208295**	**001**	Dec 19, 2019

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC	**100MG**	**A208966**	**001**	Jun 21, 2017
AB	!	BIONPHARMA	**100MG**	**A078720**	**001**	May 29, 2008
AB		HERITAGE PHARMA	**100MG**	**A209171**	**001**	Jun 12, 2017
AB		HUMANWELL PURACAP	**100MG**	**A214580**	**001**	Dec 20, 2022
AB		ONESOURCE SPECIALTY	**100MG**	**A211354**	**001**	Feb 18, 2022
AB		RISING	**100MG**	**A210129**	**001**	Mar 02, 2020
AB		RUBICON RESEARCH	**100MG**	**A212044**	**001**	May 21, 2020
AB		SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987
AB		STRIDES PHARMA	**100MG**	**A209047**	**001**	Jun 07, 2017
AB		UPSHER SMITH LABS	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		ZYDUS PHARMS	**100MG**	**A208278**	**001**	May 31, 2016

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

	+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	!	AUROBINDO PHARMA USA	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	!	CHARTWELL RX	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	!	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995
AA		PHARMOBEDIENT	**50MG/5ML**	**A075060**	**001**	Dec 24, 1998
AA		SHREE HARI INTL	**50MG/5ML**	**A214178**	**001**	Aug 20, 2021

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC	**100MG**	**A214284**	**001**	Oct 15, 2020
AB		ATHEM	**100MG**	**A210215**	**001**	Mar 10, 2020
AB		STRIDES PHARMA	**100MG**	**A209035**	**001**	Jun 09, 2017
AB	!	UPSHER SMITH LABS	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016
AB		ZHEJIANG JUTAI PHARM	**100MG**	**A218598**	**001**	Sep 26, 2024

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB		APOTEX	**5MG**	**A210701**	**001**	May 19, 2022
AB			**10MG**	**A210701**	**002**	May 19, 2022
AB		AUROBINDO PHARMA	**5MG**	**A216531**	**001**	Jul 21, 2022
AB			**10MG**	**A216531**	**002**	Jul 21, 2022
AB		CIPLA	**5MG**	**A210715**	**001**	Apr 26, 2019
AB			**10MG**	**A210715**	**002**	Apr 26, 2019
AB		MYLAN	**5MG**	**A208441**	**001**	Mar 28, 2019
AB			**10MG**	**A208441**	**002**	Mar 28, 2019
AB		SIGMAPHARM LABS LLC	**5MG**	**A208354**	**001**	Apr 10, 2019
AB			**10MG**	**A208354**	**002**	Apr 10, 2019
AB		SUN PHARM	**5MG**	**A210784**	**001**	Mar 28, 2019
AB			**10MG**	**A210784**	**002**	Mar 28, 2019
AB		WATSON LABS INC	**5MG**	**A208252**	**001**	Mar 28, 2019
AB			**10MG**	**A208252**	**002**	Mar 28, 2019
AB		ZYDUS PHARMS	**5MG**	**A210058**	**001**	Mar 28, 2019
AB			**10MG**	**A210058**	**002**	Mar 28, 2019

LETAIRIS

AB	+	GILEAD	**5MG**	**N022081**	**001**	Jun 15, 2007
AB	+!		**10MG**	**N022081**	**002**	Jun 15, 2007

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

AB	!	GENUS LIFESCIENCES	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002

LOTION;TOPICAL

AMCINONIDE

	!	SOLUBIOMIX	0.1%	A076329	001	Nov 06, 2002

AMCINONIDE
OINTMENT;TOPICAL
AMCINONIDE
! GENUS 0.1% A076096 001 Nov 19, 2002

AMIFAMPRIDINE PHOSPHATE
TABLET;ORAL
FIRDAPSE
+! CATALYST PHARMS EQ 10MG BASE N208078 001 Nov 28, 2018

AMIKACIN SULFATE
INJECTABLE;INJECTION
AMIKACIN SULFATE
AP ! AVET LIFESCIENCES EQ 250MG BASE/ML A204040 001 Dec 12, 2013
AP FRESENIUS KABI USA EQ 250MG BASE/ML A205604 001 Dec 09, 2015
AP HIKMA EQ 250MG BASE/ML A063315 001 Apr 11, 1994
AP MEITHEAL EQ 250MG BASE/ML A064045 002 Sep 28, 1993
AP QILU EQ 250MG BASE/ML A218146 001 Mar 19, 2024
AP SAGENT PHARMS INC EQ 250MG BASE/ML A203323 001 May 12, 2016
! HIKMA EQ 50MG BASE/ML A063313 001 Apr 11, 1994
SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT
+! INSMED INC EQ 590MG BASE/8.4ML N207356 001 Sep 28, 2018

AMILORIDE HYDROCHLORIDE
TABLET;ORAL
AMILORIDE HYDROCHLORIDE
AB ! PH HEALTH 5MG A070346 001 Jan 22, 1986
AB SIGMAPHARM LABS LLC 5MG A079133 001 Jan 30, 2009
MIDAMOR
AB + PADAGIS US 5MG N018200 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
AB BARR EQ 5MG ANHYDROUS;50MG A071111 001 May 10, 1988
AB ! RISING EQ 5MG ANHYDROUS;50MG A073209 001 Oct 31, 1991

AMINO ACIDS
INJECTABLE;INJECTION
AMINO ACIDS
B BRAUN 15%(150GM/1000ML) A091112 001 Apr 13, 2012
15%(300GM/2000ML) A091112 002 Apr 13, 2012
AMINOSYN II 10% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL 10% (10GM/100ML) N020015 001 Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL 15% (15GM/100ML) N020041 001 Dec 19, 1991
AMINOSYN-PF 10%
OTSUKA ICU MEDCL 10% (10GM/100ML) N019492 002 Oct 17, 1986
AMINOSYN-PF 7%
OTSUKA ICU MEDCL 7% (7GM/100ML) N019398 001 Sep 06, 1985
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER HLTHCARE 15% (15GM/100ML) A020512 001 Aug 30, 1996
PREMASOL 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10% (10GM/100ML) A075880 002 Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER
BAXTER HLTHCARE 6% (6GM/100ML) A075880 001 Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
+! BAXTER HLTHCARE 20% (20GM/100ML) N020849 001 Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10% (10MG/100ML) N018931 003 Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5% (5.5GM/100ML) N018931 001 Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5% (8.5GM/100ML) N018931 002 Aug 23, 1984
TROPHAMINE
+! B BRAUN 6% (6GM/100ML) N019018 001 Jul 20, 1984
TROPHAMINE 10%
+! B BRAUN 10% (10GM/100ML) N019018 003 Sep 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+!	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+!	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014
+!		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656	002	Aug 25, 2014
+!		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP		GEN ILAC	**250MG/ML**	**A215374**	**001**	Aug 28, 2025
AP		LUITPOLD	**250MG/ML**	**A071192**	**001**	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	**!**	HOSPIRA	**250MG/ML**	**A070010**	**001**	Mar 09, 1987

SOLUTION;ORAL

AMICAR

AA	**+**	HIKMA	**0.25GM/ML**	**N015230**	**002**	

AMINOCAPROIC ACID

AA		AJENAT PHARMS	**0.25GM/ML**	**A213825**	**001**	Apr 08, 2021
AA		AMNEAL	**0.25GM/ML**	**A212780**	**001**	Aug 23, 2019
AA		ANNORA PHARMA	**0.25GM/ML**	**A216464**	**001**	Nov 04, 2022
AA		AUROBINDO PHARMA	**0.25GM/ML**	**A216804**	**001**	Sep 26, 2022
AA		MSN	**0.25GM/ML**	**A215100**	**001**	Sep 26, 2024
AA		PHARMOBEDIENT	**0.25GM/ML**	**A214140**	**001**	Jan 26, 2021
AA		REGCON HOLDINGS	**0.25GM/ML**	**A215510**	**001**	Mar 23, 2022
AA		SCIEGEN PHARMS	**0.25GM/ML**	**A213216**	**001**	May 19, 2025
AA		SUNNY	**0.25GM/ML**	**A213213**	**001**	Dec 27, 2023
AA	**!**	TP ANDA HOLDINGS	**0.25GM/ML**	**A212494**	**001**	Aug 11, 2020

TABLET;ORAL

AMICAR

AB	**+**	HIKMA	**500MG**	**N015197**	**001**	
AB	**+**		**1GM**	**N015197**	**002**	Jun 24, 2004

AMINOCAPROIC ACID

AB		AMNEAL	**500MG**	**A212492**	**001**	Nov 26, 2019
AB		MSN	**500MG**	**A212938**	**001**	Nov 06, 2020
AB			**1GM**	**A212938**	**002**	Sep 13, 2023
AB		PHARMOBEDIENT	**500MG**	**A213928**	**001**	Feb 12, 2021
AB			**1GM**	**A213928**	**002**	Feb 12, 2021
AB		SOMERSET THERAPS LLC	**500MG**	**A213944**	**001**	Sep 14, 2022
AB			**1GM**	**A213944**	**002**	Sep 14, 2022
AB		SUNNY	**500MG**	**A209060**	**001**	Nov 27, 2018
AB	**!**		**1GM**	**A209060**	**002**	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN

	+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017

GEL;TOPICAL

AMELUZ

	+!	BIOFRONTERA	10%	N208081	001	May 10, 2016

SOLUTION;TOPICAL

LEVULAN

	+!	SUN PHARM INDS INC	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE
INJECTABLE;INJECTION
AMINOPHYLLINE

	+!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983

AMINOSALICYLIC ACID
GRANULE, DELAYED RELEASE;ORAL
PASER

	!	ADAPTIS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE
INJECTABLE;INJECTION
AMIODARONE HYDROCHLORIDE

AP		ACELLA	**50MG/ML**	**A077610**	**001**	Oct 30, 2008
AP			**50MG/ML**	**A077834**	**001**	Oct 30, 2008
AP	**!**	FRESENIUS KABI USA	**50MG/ML**	**A075761**	**001**	Oct 15, 2002
AP	**!**	GLAND PHARMA LTD	**50MG/ML**	**A077161**	**001**	Apr 20, 2005
AP		HIKMA FARMACEUTICA	**50MG/ML**	**A077234**	**001**	Feb 25, 2008
AP	**!**	MYLAN INSTITUTIONAL	**50MG/ML**	**A076217**	**001**	Oct 15, 2002
AP		ZHEJIANG POLY PHARM	**50MG/ML**	**A218253**	**001**	Sep 11, 2024

NEXTERONE

	+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
	+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET;ORAL
AMIODARONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016
AB		CHARTWELL RX	**100MG**	**A077069**	**003**	Oct 04, 2016
AB			**200MG**	**A077069**	**001**	Apr 08, 2005
AB			**400MG**	**A077069**	**002**	Apr 08, 2005
AB		DR REDDYS LABS SA	**100MG**	**A075389**	**002**	Dec 28, 2017
AB			**200MG**	**A075389**	**001**	Jan 25, 2001
AB			**400MG**	**A075389**	**003**	Dec 28, 2017
AB		RUBICON RESEARCH	**100MG**	**A078578**	**002**	Feb 26, 2021
AB			**200MG**	**A078578**	**001**	Nov 06, 2008
AB			**400MG**	**A078578**	**003**	Feb 26, 2021
AB		TARO	**100MG**	**A075424**	**002**	Dec 18, 2002
AB	**!**		**200MG**	**A075424**	**001**	Mar 30, 2001
AB		TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998
AB		UNICHEM	**200MG**	**A213446**	**001**	Jul 21, 2020
AB		ZYDUS PHARMS USA INC	**100MG**	**A079029**	**002**	Jan 06, 2023
AB			**200MG**	**A079029**	**001**	Sep 16, 2008
AB			**400MG**	**A079029**	**003**	Jan 06, 2023

PACERONE

AB		UPSHER SMITH LABS	**100MG**	**A075135**	**002**	Apr 12, 2005
AB			**200MG**	**A075135**	**001**	Apr 30, 1998
AB			**400MG**	**A075135**	**003**	Jul 02, 2020

AMISULPRIDE
SOLUTION;INTRAVENOUS
BARHEMSYS

	+!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020
	+!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020

AMITRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB			**25MG**	**A202446**	**002**	Jun 04, 2014
AB			**50MG**	**A202446**	**003**	Jun 04, 2014
AB			**75MG**	**A202446**	**004**	Jun 04, 2014
AB			**100MG**	**A202446**	**005**	Jun 04, 2014
AB			**150MG**	**A202446**	**006**	Jun 04, 2014
AB		AIPING PHARM INC	**10MG**	**A212654**	**002**	Sep 29, 2021
AB			**25MG**	**A212654**	**001**	Apr 07, 2020
AB			**50MG**	**A212654**	**003**	Sep 29, 2021
AB			**75MG**	**A212654**	**004**	Sep 29, 2021
AB			**100MG**	**A212654**	**005**	Sep 29, 2021
AB			**150MG**	**A212654**	**006**	Sep 29, 2021
AB		MANKIND PHARMA	**10MG**	**A213999**	**001**	Feb 19, 2021
AB			**25MG**	**A213999**	**002**	Feb 19, 2021
AB			**50MG**	**A213999**	**003**	Feb 19, 2021
AB			**75MG**	**A213999**	**004**	Feb 19, 2021
AB			**100MG**	**A213999**	**005**	Feb 19, 2021

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB			**150MG**	**A213999**	**006**	Feb 19, 2021
AB		RISING	**10MG**	**A217411**	**001**	May 19, 2023
AB			**25MG**	**A217411**	**002**	May 19, 2023
AB			**50MG**	**A217411**	**003**	May 19, 2023
AB			**75MG**	**A217411**	**004**	May 19, 2023
AB			**100MG**	**A217411**	**005**	May 19, 2023
AB			**150MG**	**A217411**	**006**	May 19, 2023
AB	+	SANDOZ	**10MG**	**A085968**	**004**	
AB	+!		**25MG**	**A085968**	**002**	
AB	+		**50MG**	**A085968**	**001**	
AB	+		**75MG**	**A085968**	**006**	
AB	+		**100MG**	**A085968**	**003**	
AB	+		**150MG**	**A085968**	**005**	
AB		SUN PHARM INDS INC	**10MG**	**A089399**	**002**	Jul 14, 1987
AB			**25MG**	**A089399**	**001**	Jul 14, 1987
AB			**50MG**	**A089399**	**003**	Jul 14, 1987
AB			**75MG**	**A089399**	**004**	Jul 14, 1987
AB			**100MG**	**A089399**	**005**	Jul 14, 1987
AB			**150MG**	**A089399**	**006**	Jul 14, 1987
AB		UNICHEM	**10MG**	**A214548**	**001**	May 19, 2021
AB			**25MG**	**A214548**	**002**	May 19, 2021
AB			**50MG**	**A214548**	**003**	May 19, 2021
AB			**75MG**	**A214548**	**004**	May 19, 2021
AB			**100MG**	**A214548**	**005**	May 19, 2021
AB			**150MG**	**A214548**	**006**	May 19, 2021
AB		UNIQUE PHARM	**10MG**	**A218389**	**001**	Jun 23, 2025
AB			**25MG**	**A218389**	**002**	Jun 23, 2025
AB			**50MG**	**A218389**	**003**	Jun 23, 2025
AB			**75MG**	**A218389**	**004**	Jun 23, 2025
AB			**100MG**	**A218389**	**005**	Jun 23, 2025
AB			**150MG**	**A218389**	**006**	Jun 23, 2025
AB		ZYDUS PHARMS	**10MG**	**A210086**	**001**	Oct 06, 2017
AB			**25MG**	**A210086**	**002**	Oct 06, 2017
AB			**50MG**	**A210086**	**003**	Oct 06, 2017
AB			**75MG**	**A210086**	**004**	Oct 06, 2017
AB			**100MG**	**A210086**	**005**	Oct 06, 2017
AB			**150MG**	**A210086**	**006**	Oct 06, 2017
BX		RUBICON RESEARCH	10MG	A215376	001	May 01, 2023
BX			25MG	A215376	002	May 01, 2023
BX			50MG	A215376	003	May 01, 2023
BX			75MG	A215376	004	May 01, 2023
BX			100MG	A215376	005	May 01, 2023
BX			150MG	A215376	006	May 01, 2023

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
!		25MG;2MG	A071443	004	Nov 10, 1988
!		25MG;4MG	A071443	005	Nov 10, 1988
!		50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

+!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022

TABLET;ORAL

AMLODIPINE BESYLATE

AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A202553**	**001**	Apr 29, 2013

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB			**EQ 5MG BASE**	**A202553**	**002**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202553**	**003**	Apr 29, 2013
AB		ALKEM	**EQ 2.5MG BASE**	**A078925**	**001**	May 04, 2009
AB			**EQ 5MG BASE**	**A078925**	**002**	May 04, 2009
AB			**EQ 10MG BASE**	**A078925**	**003**	May 04, 2009
AB		AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A078021**	**001**	Jul 17, 2007
AB			**EQ 5MG BASE**	**A078021**	**002**	Jul 17, 2007
AB			**EQ 10MG BASE**	**A078021**	**003**	Jul 17, 2007
AB		CHARTWELL RX	**EQ 2.5MG BASE**	**A076692**	**001**	Jul 20, 2007
AB			**EQ 5MG BASE**	**A076692**	**002**	Jul 20, 2007
AB			**EQ 10MG BASE**	**A076692**	**003**	Jul 20, 2007
AB		CHINA RESOURCES	**EQ 2.5MG BASE**	**A090752**	**003**	May 16, 2016
AB			**EQ 5MG BASE**	**A090752**	**001**	Apr 15, 2011
AB			**EQ 10MG BASE**	**A090752**	**002**	Apr 15, 2011
AB		CIPLA	**EQ 2.5MG BASE**	**A077073**	**001**	Sep 26, 2007
AB			**EQ 5MG BASE**	**A077073**	**002**	Sep 26, 2007
AB			**EQ 10MG BASE**	**A077073**	**003**	Sep 26, 2007
AB		COREPHARMA	**EQ 2.5MG BASE**	**A076719**	**001**	May 23, 2007
AB			**EQ 5MG BASE**	**A076719**	**002**	May 23, 2007
AB			**EQ 10MG BASE**	**A076719**	**003**	May 23, 2007
AB		EPIC PHARMA LLC	**EQ 2.5MG BASE**	**A078552**	**001**	Apr 08, 2009
AB			**EQ 5MG BASE**	**A078552**	**002**	Apr 08, 2009
AB			**EQ 10MG BASE**	**A078552**	**003**	Apr 08, 2009
AB		GRAVITI PHARMS	**EQ 5MG BASE**	**A201380**	**001**	Apr 13, 2012
AB			**EQ 10MG BASE**	**A201380**	**002**	Apr 13, 2012
AB		INVAGEN PHARMS	**EQ 2.5MG BASE**	**A077955**	**001**	Aug 28, 2007
AB			**EQ 2.5MG BASE**	**A206367**	**001**	Dec 10, 2015
AB			**EQ 5MG BASE**	**A077955**	**002**	Aug 28, 2007
AB			**EQ 5MG BASE**	**A206367**	**002**	Dec 10, 2015
AB			**EQ 10MG BASE**	**A077955**	**003**	Aug 28, 2007
AB			**EQ 10MG BASE**	**A206367**	**003**	Dec 10, 2015
AB		LUPIN	**EQ 2.5MG BASE**	**A078043**	**001**	Jul 12, 2007
AB			**EQ 5MG BASE**	**A078043**	**002**	Jul 12, 2007
AB			**EQ 10MG BASE**	**A078043**	**003**	Jul 12, 2007
AB		ORBION PHARMS	**EQ 2.5MG BASE**	**A078453**	**001**	Jul 02, 2009
AB			**EQ 5MG BASE**	**A078453**	**002**	Jul 02, 2009
AB			**EQ 10MG BASE**	**A078453**	**003**	Jul 02, 2009
AB		OXFORD PHARMS	**EQ 2.5MG BASE**	**A078414**	**001**	Apr 07, 2010
AB			**EQ 5MG BASE**	**A078414**	**002**	Apr 07, 2010
AB			**EQ 10MG BASE**	**A078414**	**003**	Apr 07, 2010
AB		PURACAP LABS BLU	**EQ 2.5MG BASE**	**A207821**	**001**	Jul 11, 2016
AB			**EQ 5MG BASE**	**A207821**	**002**	Jul 11, 2016
AB			**EQ 10MG BASE**	**A207821**	**003**	Jul 11, 2016
AB		STRIDES PHARMA	**EQ 2.5MG BASE**	**A077516**	**001**	Jul 11, 2007
AB			**EQ 5MG BASE**	**A077516**	**002**	Jul 11, 2007
AB			**EQ 10MG BASE**	**A077516**	**003**	Jul 11, 2007
AB		TEVA	**EQ 2.5MG BASE**	**A076846**	**001**	Jun 28, 2007
AB			**EQ 5MG BASE**	**A076846**	**002**	Jun 28, 2007
AB			**EQ 10MG BASE**	**A076846**	**003**	Jun 28, 2007
AB		UNICHEM	**EQ 2.5MG BASE**	**A203245**	**001**	Oct 21, 2013
AB			**EQ 5MG BASE**	**A203245**	**002**	Oct 21, 2013
AB			**EQ 10MG BASE**	**A203245**	**003**	Oct 21, 2013
AB		ZYDUS PHARMS USA	**EQ 2.5MG BASE**	**A078226**	**001**	Jul 09, 2007
AB			**EQ 5MG BASE**	**A078226**	**002**	Jul 09, 2007
AB			**EQ 10MG BASE**	**A078226**	**003**	Jul 09, 2007

NORVASC

AB	**+**	VIATRIS	**EQ 2.5MG BASE**	**N019787**	**001**	Jul 31, 1992
AB	**+**		**EQ 5MG BASE**	**N019787**	**002**	Jul 31, 1992
AB	**+!**		**EQ 10MG BASE**	**N019787**	**003**	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ALEMBIC	**EQ 2.5MG BASE;EQ 10MG BASE**	**A217279**	**001**	May 22, 2025
AB			**EQ 2.5MG BASE;EQ 20MG BASE**	**A217279**	**002**	May 22, 2025
AB			**EQ 2.5MG BASE;EQ 40MG BASE**	**A217279**	**003**	May 22, 2025
AB			**EQ 5MG BASE;EQ 10MG BASE**	**A217279**	**004**	May 22, 2025
AB			**EQ 5MG BASE;EQ 20MG BASE**	**A217279**	**005**	May 22, 2025
AB			**EQ 5MG BASE;EQ 40MG BASE**	**A217279**	**006**	May 22, 2025
AB			**EQ 5MG BASE;EQ 80MG BASE**	**A217279**	**007**	May 22, 2025

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025
AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025
AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025
AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025
AB	APOTEX	EQ 5MG BASE;EQ 10MG BASE	A205199	001	Nov 18, 2019
AB		EQ 5MG BASE;EQ 20MG BASE	A205199	002	Nov 18, 2019
AB		EQ 5MG BASE;EQ 40MG BASE	A205199	003	Nov 18, 2019
AB		EQ 5MG BASE;EQ 80MG BASE	A205199	004	Nov 18, 2019
AB		EQ 10MG BASE;EQ 10MG BASE	A205199	005	Nov 18, 2019
AB		EQ 10MG BASE;EQ 20MG BASE	A205199	006	Nov 18, 2019
AB		EQ 10MG BASE;EQ 40MG BASE	A205199	007	Nov 18, 2019
AB		EQ 10MG BASE;EQ 80MG BASE	A205199	008	Nov 18, 2019
AB	DR REDDYS	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014
AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014
AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014
AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014
AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014
AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014
AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014
AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014
AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014
AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014
AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014
AB	MYLAN	EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013
AB		EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013
AB		EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013
AB		EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013
AB		EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013
AB		EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013
AB		EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013
AB		EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013
AB	NEOCUBES PHARMA	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019

CADUET

AB	+	PHARMACIA	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
AB	+!		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012
AB		EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012
AB		EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012
AB		EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012
AB		EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012
AB		EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012
AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183	001	Apr 15, 2010
AB		EQ 5MG BASE;10MG	A077183	002	Apr 15, 2010
AB		EQ 5MG BASE;20MG	A077183	003	Apr 15, 2010
AB		EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011
AB	HERITAGE	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013
AB		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013
AB		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013
AB		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013
AB		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013
AB		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013
AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010
AB		EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010
AB		EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010
AB		EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010
AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011
AB	WATSON LABS	EQ 2.5MG BASE;10MG	A077890	001	Oct 14, 2010
AB		EQ 5MG BASE;10MG	A077890	002	Oct 14, 2010
AB		EQ 5MG BASE;20MG	A077890	003	Oct 14, 2010
AB		EQ 10MG BASE;20MG	A077890	004	Oct 14, 2010
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011
AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011

LOTREL

AB	+ SANDOZ	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995
AB	+	EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995
AB	+	EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995
AB	+	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006
AB	+	EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002
AB	+!	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	HETERO LABS LTD V	EQ 5MG BASE;12.5MG;20MG	A209242	001	Oct 06, 2025
AB		EQ 5MG BASE;12.5MG;40MG	A209242	002	Oct 06, 2025
AB		EQ 5MG BASE;25MG;40MG	A209242	003	Oct 06, 2025
AB		EQ 10MG BASE;12.5MG;40MG	A209242	004	Oct 06, 2025
AB		EQ 10MG BASE;25MG;40MG	A209242	005	Oct 06, 2025
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A207088	001	Jul 18, 2025
AB		EQ 5MG BASE;12.5MG;40MG	A207088	002	Jul 18, 2025
AB		EQ 5MG BASE;25MG;40MG	A207088	003	Jul 18, 2025
AB		EQ 10MG BASE;12.5MG;40MG	A207088	004	Jul 18, 2025
AB		EQ 10MG BASE;25MG;40MG	A207088	005	Jul 18, 2025
AB	MICRO LABS	EQ 5MG BASE;12.5MG;20MG	A207437	001	Nov 24, 2025
AB		EQ 5MG BASE;12.5MG;40MG	A207437	002	Nov 24, 2025
AB		EQ 5MG BASE;25MG;40MG	A207437	003	Nov 24, 2025
AB		EQ 10MG BASE;12.5MG;40MG	A207437	004	Nov 24, 2025
AB		EQ 10MG BASE;25MG;40MG	A207437	005	Nov 24, 2025
AB	PH HEALTH	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016
AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016
AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016
AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025
AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025
AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025
AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025
AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016
AB	TORRENT	EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016
AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016

TRIBENZOR

AB	+ COSETTE	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
AB	+	EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
AB	+	EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
AB	+	EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
AB	+!	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**EQ 5MG BASE;12.5MG;160MG**	**A206180**	**001**	Dec 19, 2017
AB			**EQ 5MG BASE;25MG;160MG**	**A206180**	**002**	Dec 19, 2017
AB			**EQ 10MG BASE;12.5MG;160MG**	**A206180**	**003**	Dec 19, 2017
AB			**EQ 10MG BASE;25MG;160MG**	**A206180**	**004**	Dec 19, 2017
AB			**EQ 10MG BASE;25MG;320MG**	**A206180**	**005**	Dec 19, 2017
AB		LUPIN LTD	**EQ 5MG BASE;12.5MG;160MG**	**A200797**	**001**	Jun 03, 2015
AB			**EQ 5MG BASE;25MG;160MG**	**A200797**	**002**	Jun 03, 2015
AB			**EQ 10MG BASE;12.5MG;160MG**	**A200797**	**003**	Jun 03, 2015
AB			**EQ 10MG BASE;25MG;160MG**	**A200797**	**004**	Jun 03, 2015
AB			**EQ 10MG BASE;25MG;320MG**	**A200797**	**005**	Jun 03, 2015
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;12.5MG;160MG**	**A207299**	**001**	Jan 07, 2025
AB			**EQ 5MG BASE;25MG;160MG**	**A207299**	**002**	Jan 07, 2025
AB			**EQ 10MG BASE;12.5MG;160MG**	**A207299**	**003**	Jan 07, 2025
AB			**EQ 10MG BASE;25MG;160MG**	**A207299**	**004**	Jan 07, 2025
AB			**EQ 10MG BASE;25MG;320MG**	**A207299**	**005**	Jan 07, 2025
AB		STRIDES PHARMA INTL	**EQ 5MG BASE;12.5MG;160MG**	**A201087**	**001**	Jun 01, 2015
AB			**EQ 5MG BASE;25MG;160MG**	**A201087**	**002**	Jun 01, 2015
AB			**EQ 10MG BASE;12.5MG;160MG**	**A201087**	**003**	Jun 01, 2015
AB			**EQ 10MG BASE;25MG;160MG**	**A201087**	**004**	Jun 01, 2015
AB			**EQ 10MG BASE;25MG;320MG**	**A201087**	**005**	Jun 01, 2015

EXFORGE HCT

AB	+	NOVARTIS	**EQ 5MG BASE;12.5MG;160MG**	**N022314**	**001**	Apr 30, 2009
AB	+		**EQ 5MG BASE;25MG;160MG**	**N022314**	**002**	Apr 30, 2009
AB	+		**EQ 10MG BASE;12.5MG;160MG**	**N022314**	**003**	Apr 30, 2009
AB	+		**EQ 10MG BASE;25MG;160MG**	**N022314**	**004**	Apr 30, 2009
AB	+!		**EQ 10MG BASE;25MG;320MG**	**N022314**	**005**	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		AJANTA PHARMA LTD	**EQ 5MG BASE;20MG**	**A207216**	**001**	Oct 28, 2016
AB			**EQ 5MG BASE;40MG**	**A207216**	**002**	Oct 28, 2016
AB			**EQ 10MG BASE;20MG**	**A207216**	**003**	Oct 28, 2016
AB			**EQ 10MG BASE;40MG**	**A207216**	**004**	Oct 28, 2016
AB		ALEMBIC	**EQ 5MG BASE;20MG**	**A207073**	**001**	Jul 17, 2017
AB			**EQ 5MG BASE;40MG**	**A207073**	**002**	Jul 17, 2017
AB			**EQ 10MG BASE;20MG**	**A207073**	**003**	Jul 17, 2017
AB			**EQ 10MG BASE;40MG**	**A207073**	**004**	Jul 17, 2017
AB		ALKEM LABS LTD	**EQ 5MG BASE;20MG**	**A209042**	**001**	Aug 14, 2017
AB			**EQ 5MG BASE;40MG**	**A209042**	**002**	Aug 14, 2017
AB			**EQ 10MG BASE;20MG**	**A209042**	**003**	Aug 14, 2017
AB			**EQ 10MG BASE;40MG**	**A209042**	**004**	Aug 14, 2017
AB		AUROBINDO PHARMA	**EQ 5MG BASE;20MG**	**A206906**	**001**	May 15, 2017
AB			**EQ 5MG BASE;40MG**	**A206906**	**002**	May 15, 2017
AB			**EQ 10MG BASE;20MG**	**A206906**	**003**	May 15, 2017
AB			**EQ 10MG BASE;40MG**	**A206906**	**004**	May 15, 2017
AB		HETERO LABS LTD V	**EQ 5MG BASE;20MG**	**A209591**	**001**	Feb 14, 2025
AB			**EQ 5MG BASE;40MG**	**A209591**	**002**	Feb 14, 2025
AB			**EQ 10MG BASE;20MG**	**A209591**	**003**	Feb 14, 2025
AB			**EQ 10MG BASE;40MG**	**A209591**	**004**	Feb 14, 2025
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;20MG**	**A206884**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;40MG**	**A206884**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;20MG**	**A206884**	**002**	Oct 26, 2016
AB			**EQ 10MG BASE;40MG**	**A206884**	**004**	Oct 26, 2016
AB		MICRO LABS	**EQ 5MG BASE;20MG**	**A207435**	**001**	Nov 02, 2017
AB			**EQ 5MG BASE;40MG**	**A207435**	**002**	Nov 02, 2017
AB			**EQ 10MG BASE;20MG**	**A207435**	**003**	Nov 02, 2017
AB			**EQ 10MG BASE;40MG**	**A207435**	**004**	Nov 02, 2017
AB		SCIEGEN PHARMS	**EQ 5MG BASE;20MG**	**A209010**	**001**	Dec 03, 2018
AB			**EQ 5MG BASE;40MG**	**A209010**	**002**	Dec 03, 2018
AB			**EQ 10MG BASE;20MG**	**A209010**	**003**	Dec 03, 2018
AB			**EQ 10MG BASE;40MG**	**A209010**	**004**	Dec 03, 2018
AB		ZYDUS PHARMS	**EQ 5MG BASE;20MG**	**A207771**	**001**	Sep 22, 2017
AB			**EQ 5MG BASE;40MG**	**A207771**	**002**	Sep 22, 2017
AB			**EQ 10MG BASE;20MG**	**A207771**	**003**	Sep 22, 2017
AB			**EQ 10MG BASE;40MG**	**A207771**	**004**	Sep 22, 2017

AZOR

AB	+	COSETTE	**EQ 5MG BASE;20MG**	**N022100**	**001**	Sep 26, 2007
AB	+		**EQ 5MG BASE;40MG**	**N022100**	**002**	Sep 26, 2007
AB	+		**EQ 10MG BASE;20MG**	**N022100**	**003**	Sep 26, 2007

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AZOR

AB	**+!**		**EQ 10MG BASE;40MG**	**N022100 004**	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB		LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586 001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A201586 003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A201586 002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A201586 004**	Jan 08, 2014
AB		MYLAN	**EQ 5MG BASE;40MG**	**A202516 001**	Aug 26, 2014
AB			**EQ 5MG BASE;80MG**	**A202516 003**	Aug 26, 2014
AB			**EQ 10MG BASE;40MG**	**A202516 002**	Aug 26, 2014
AB	**!**		**EQ 10MG BASE;80MG**	**A202516 004**	Aug 26, 2014

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC	**EQ 5MG BASE;160MG**	**A202713 001**	Apr 03, 2015
AB			**EQ 5MG BASE;320MG**	**A202713 003**	Apr 03, 2015
AB			**EQ 10MG BASE;160MG**	**A202713 002**	Apr 03, 2015
AB			**EQ 10MG BASE;320MG**	**A202713 004**	Apr 03, 2015
AB		AUROBINDO PHARMA	**EQ 5MG BASE;160MG**	**A206512 001**	Apr 22, 2016
AB			**EQ 5MG BASE;320MG**	**A206512 002**	Apr 22, 2016
AB			**EQ 10MG BASE;160MG**	**A206512 003**	Apr 22, 2016
AB			**EQ 10MG BASE;320MG**	**A206512 004**	Apr 22, 2016
AB		HETERO LABS	**EQ 5MG BASE;160MG**	**A205137 001**	Sep 16, 2016
AB			**EQ 5MG BASE;320MG**	**A205137 003**	Sep 16, 2016
AB			**EQ 10MG BASE;160MG**	**A205137 002**	Sep 16, 2016
AB			**EQ 10MG BASE;320MG**	**A205137 004**	Sep 16, 2016
AB		LUPIN	**EQ 5MG BASE;160MG**	**A090245 001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090245 003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090245 002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090245 004**	Mar 30, 2015
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;160MG**	**A207292 001**	Oct 11, 2024
AB			**EQ 5MG BASE;320MG**	**A207292 003**	Oct 11, 2024
AB			**EQ 10MG BASE;160MG**	**A207292 002**	Oct 11, 2024
AB			**EQ 10MG BASE;320MG**	**A207292 004**	Oct 11, 2024
AB		MYLAN	**EQ 5MG BASE;160MG**	**A090483 001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090483 003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090483 002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090483 004**	Mar 30, 2015
AB		NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829 001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202829 003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202829 002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202829 004**	Mar 30, 2015
AB		STRIDES PHARMA INTL	**EQ 5MG BASE;160MG**	**A090011 001**	Mar 28, 2013
AB			**EQ 5MG BASE;320MG**	**A090011 003**	Mar 28, 2013
AB			**EQ 10MG BASE;160MG**	**A090011 002**	Mar 28, 2013
AB			**EQ 10MG BASE;320MG**	**A090011 004**	Mar 28, 2013

EXFORGE

AB	**+**	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990 002**	Jun 20, 2007
AB	**+**		**EQ 5MG BASE;320MG**	**N021990 004**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;160MG**	**N021990 003**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;320MG**	**N021990 005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779 001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352 001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783 001**	Oct 30, 2014
AP		CARDINAL HLTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700 001**	Feb 25, 2013
AP	**+!**	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119 001**	Aug 23, 2007
AP		GEN HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025 001**	Feb 03, 2016
AP		IONETIX	**22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)**	**A210524 001**	Dec 21, 2018
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514 001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938 001**	Dec 09, 2013
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321 001**	Feb 25, 2013
AP		METHODIST	**3.75mCi-260mCi/ML**	**A215083 001**	Jul 09, 2021
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457 001**	Nov 18, 2015

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		NCM USA BRONX LLC	**3.75mCi-260mCi/ML**	**A204515**	**001**	Feb 04, 2015
AP		NUKEMED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		PRECISION NUCLEAR	**3.75mCi-260mCi/ML**	**A204547**	**001**	Aug 14, 2015
AP		SOFIE	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP	!		**3.75mCi-260mCi/ML**	**A203543**	**001**	Dec 14, 2012
AP		UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP		UNIV ALAHAMA BIRM	**15mCi-150mCi/4ML (3.75-37.5mCi/ML)**	**A211698**	**001**	Nov 03, 2022
AP		UNIV TX SW MEDCTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A209507**	**001**	Nov 01, 2019
AP		UNIV WISCONSIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A211740**	**001**	Sep 09, 2020
AP		WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	!	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	!	PADAGIS ISRAEL	**EQ 12% BASE**	**A075774**	**001**	May 01, 2002
AB		SUN PHARMA CANADA	**EQ 12% BASE**	**A075883**	**001**	Apr 10, 2003

LOTION;TOPICAL

AMMONIUM LACTATE

AB	!	PADAGIS ISRAEL	**EQ 12% BASE**	**A075570**	**001**	Jun 23, 2004
AB		SUN PHARMA CANADA	**EQ 12% BASE**	**A076216**	**001**	May 28, 2004

AMOXAPINE

TABLET;ORAL

AMOXAPINE

AB		CHARTWELL RX	**25MG**	**A072879**	**002**	Jun 28, 1991
AB			**50MG**	**A072879**	**003**	Jun 28, 1991
AB			**100MG**	**A072879**	**004**	Jun 28, 1991
AB			**150MG**	**A072879**	**001**	Jun 28, 1991
AB		WATSON LABS	**25MG**	**A072691**	**002**	Aug 28, 1992
AB			**50MG**	**A072691**	**003**	Aug 28, 1992
AB			**100MG**	**A072691**	**004**	Aug 28, 1992
AB	!		**150MG**	**A072691**	**001**	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB		AUROBINDO	**250MG**	**A065271**	**001**	Nov 09, 2005
AB			**500MG**	**A065271**	**002**	Nov 09, 2005
AB		CHARTWELL	**250MG**	**A062058**	**001**	
AB			**500MG**	**A062058**	**002**	
AB		HIKMA PHARMS	**250MG**	**A065291**	**001**	Feb 05, 2007
AB			**500MG**	**A065291**	**002**	Feb 05, 2007
AB		MICRO LABS	**250MG**	**A207471**	**001**	Jun 24, 2022
AB			**500MG**	**A207471**	**002**	Jun 24, 2022
AB		SANDOZ	**250MG**	**A064076**	**001**	Sep 30, 1994
AB			**500MG**	**A064076**	**002**	Sep 30, 1994
AB		TEVA	**250MG**	**A061926**	**001**	
AB	!		**500MG**	**A061926**	**003**	

AMOXIL

AB		US ANTIBIOTICS	**250MG**	**A062216**	**001**	
AB			**500MG**	**A062216**	**004**	

FOR SUSPENSION;ORAL

AMOXICILLIN

AB		AUROBINDO	**200MG/5ML**	**A065334**	**001**	Dec 28, 2006
AB			**400MG/5ML**	**A065334**	**002**	Dec 28, 2006
AB		AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030**	**001**	Sep 15, 2014
AB			**250MG/5ML**	**A204030**	**002**	Sep 15, 2014
AB		CHARTWELL RX	**400MG/5ML**	**A065319**	**002**	Jun 18, 2007
AB		HIKMA	**125MG/5ML**	**A065322**	**002**	Jun 19, 2006
AB			**200MG/5ML**	**A065325**	**002**	Jun 19, 2006
AB			**250MG/5ML**	**A065322**	**001**	Jun 19, 2006
AB			**400MG/5ML**	**A065325**	**001**	Jun 19, 2006
AB		SANDOZ	**125MG/5ML**	**A065387**	**001**	Mar 26, 2007

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

AB			**200MG/5ML**	**A065378**	**001**	Mar 26, 2007
AB			**250MG/5ML**	**A065387**	**002**	Mar 26, 2007
AB			**400MG/5ML**	**A065378**	**002**	Mar 26, 2007
AB		TEVA	**200MG/5ML**	**A065119**	**001**	Dec 04, 2002
AB	!		**250MG/5ML**	**A061931**	**002**	
AB	!		**400MG/5ML**	**A065119**	**002**	Dec 04, 2002

AMOXICILLIN PEDIATRIC

AB		TEVA	**50MG/ML**	**A061931**	**003**	Dec 01, 1982

AMOXIL

AB		US ANTIBIOTICS	**50MG/ML**	**A062226**	**005**	
AB			**125MG/5ML**	**A062226**	**001**	
AB			**250MG/5ML**	**A062226**	**002**	
AB	+		**400MG/5ML**	**N050760**	**002**	Apr 15, 1999

LAROTID

AB		US ANTIBIOTICS	**125MG/5ML**	**A062226**	**003**	
AB			**250MG/5ML**	**A062226**	**004**	

TABLET;ORAL

AMOXICILLIN

AB		AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005
AB			**875MG**	**A065256**	**002**	Nov 09, 2005
AB		HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006
AB		SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005
AB			**875MG**	**A065228**	**002**	Jul 13, 2005
AB		TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000
AB	!		**875MG**	**A065056**	**002**	Sep 18, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995
	!		250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

AB	!	RISING	**500MG;500MG;30MG**	**A206006**	**001**	Oct 07, 2016
AB		SANDOZ	**500MG;500MG;30MG**	**A202588**	**001**	Mar 04, 2014

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PAK

	+!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA	**125MG/5ML;EQ 31.25MG BASE/5ML**	**A209371**	**001**	Apr 19, 2019
AB			**250MG/5ML;EQ 62.5MG BASE/5ML**	**A209371**	**002**	Apr 19, 2019
AB		AUROBINDO PHARMA LTD	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A201090**	**001**	Dec 20, 2011
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A201090**	**002**	Dec 20, 2011
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A201091**	**001**	Dec 20, 2011
AB		CIPLA	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A065431**	**001**	Nov 25, 2008
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065420**	**001**	Dec 02, 2013
AB		DEVA HOLDING AS	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A210374**	**001**	Nov 29, 2023
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A210416**	**001**	Dec 11, 2023
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A209351**	**001**	Sep 13, 2023
AB		HIKMA PHARMS	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065191**	**002**	Jan 25, 2005
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065191**	**001**	Jan 25, 2005
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065373**	**001**	Nov 09, 2007
AB		MICRO LABS	**600MG/5ML;EQ 42.9MG BASE/5ML**	**A217805**	**001**	Dec 08, 2023
AB		MICRO LABS LTD INDIA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A205187**	**001**	May 21, 2021
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A205187**	**002**	May 21, 2021
AB		SANDOZ	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065066**	**001**	Jun 05, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065066**	**002**	Jun 05, 2002
AB		SANDOZ INC	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065098**	**001**	Dec 16, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065098**	**002**	Dec 16, 2002
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065358**	**001**	Aug 13, 2007
AB		TEVA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065089**	**001**	May 25, 2004
AB	!		**400MG/5ML;EQ 57MG BASE/5ML**	**A065089**	**002**	May 25, 2004
AB	!		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065162**	**001**	Mar 12, 2004

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AUGMENTIN '125'

AB	+	US ANTIBIOTICS	**125MG/5ML;EQ 31.25MG BASE/5ML**	**N050575**	**001**	Aug 06, 1984

AUGMENTIN '250'

AB	+!	US ANTIBIOTICS	**250MG/5ML;EQ 62.5MG BASE/5ML**	**N050575**	**002**	Aug 06, 1984

AUGMENTIN ES-600

AB	+	US ANTIBIOTICS	**600MG/5ML;EQ 42.9MG BASE/5ML**	**N050755**	**001**	Jun 22, 2001

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**250MG;EQ 125MG BASE**	**A091569**	**001**	Jan 20, 2012
AB	!		**500MG;EQ 125MG BASE**	**A091569**	**002**	Jan 20, 2012
AB			**875MG;EQ 125MG BASE**	**A091568**	**001**	Jan 20, 2012
AB		DEVA HOLDING AS	**500MG;EQ 125MG BASE**	**A209992**	**001**	Sep 15, 2023
AB			**875MG;EQ 125MG BASE**	**A209991**	**001**	Sep 15, 2023
AB		HIKMA PHARMS	**875MG;EQ 125MG BASE**	**A203824**	**001**	Aug 23, 2016
AB		MICRO LABS LTD INDIA	**250MG;EQ 125MG BASE**	**A205707**	**001**	Dec 30, 2016
AB			**500MG;EQ 125MG BASE**	**A205707**	**002**	Dec 30, 2016
AB			**875MG;EQ 125MG BASE**	**A204755**	**003**	Dec 30, 2016
AB	!	SANDOZ	**250MG;EQ 125MG BASE**	**A065189**	**001**	Aug 23, 2005
AB			**500MG;EQ 125MG BASE**	**A065064**	**001**	Mar 15, 2002
AB	!		**875MG;EQ 125MG BASE**	**A065063**	**001**	Mar 14, 2002
AB		SANDOZ INC	**875MG;EQ 125MG BASE**	**A065093**	**001**	Nov 21, 2002
AB		TEVA	**500MG;EQ 125MG BASE**	**A065101**	**001**	Oct 30, 2002
AB		TEVA PHARMS USA	**875MG;EQ 125MG BASE**	**A065096**	**001**	Oct 29, 2002

AUGMENTIN '875'

AB	+	US ANTIBIOTICS	**875MG;EQ 125MG BASE**	**N050720**	**001**	Feb 13, 1996

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
	!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE;ORAL

TALICIA

	+!	TALICIA HOLDINGS	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PAK

	+!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

AB	+	NEOS THERAPS	**EQ 3.1MG BASE**	**N204326**	**001**	Jan 27, 2016
AB	+		**EQ 6.3MG BASE**	**N204326**	**002**	Jan 27, 2016
AB	+		**EQ 9.4MG BASE**	**N204326**	**003**	Jan 27, 2016
AB	+		**EQ 12.5MG BASE**	**N204326**	**004**	Jan 27, 2016
AB	+		**EQ 15.7MG BASE**	**N204326**	**005**	Jan 27, 2016
AB	+!		**EQ 18.8MG BASE**	**N204326**	**006**	Jan 27, 2016

AMPHETAMINE

AB		ACTAVIS LABS FL INC	**EQ 3.1MG BASE**	**A209253**	**001**	Jun 22, 2023
AB			**EQ 6.3MG BASE**	**A209253**	**002**	Jun 22, 2023
AB			**EQ 9.4MG BASE**	**A209253**	**003**	Jun 22, 2023
AB			**EQ 12.5MG BASE**	**A209253**	**004**	Jun 22, 2023
AB			**EQ 15.7MG BASE**	**A209253**	**005**	Jun 22, 2023
AB			**EQ 18.8MG BASE**	**A209253**	**006**	Jun 22, 2023

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB1	+	TAKEDA PHARMS USA	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001

ADDERALL XR 15

AB1	+	TAKEDA PHARMS USA	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002

ADDERALL XR 20

AB1	+	TAKEDA PHARMS USA	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 25						
AB1	+	TAKEDA PHARMS USA	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002
ADDERALL XR 30						
AB1	+!	TAKEDA PHARMS USA	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001
ADDERALL XR 5						
AB1	+	TAKEDA PHARMS USA	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB1		ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB1			**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB1		ANI PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A205401**	**001**	Jan 22, 2019
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A205401**	**002**	Jan 22, 2019
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A205401**	**003**	Jan 22, 2019
AB1			**5MG;5MG;5MG;5MG**	**A205401**	**004**	Jan 22, 2019
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A205401**	**005**	Jan 22, 2019
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A205401**	**006**	Jan 22, 2019
AB1		ASCENT PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214959**	**001**	Sep 29, 2021
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214959**	**002**	Sep 29, 2021
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214959**	**003**	Sep 29, 2021
AB1			**5MG;5MG;5MG;5MG**	**A214959**	**004**	Sep 29, 2021
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214959**	**005**	Sep 29, 2021
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214959**	**006**	Sep 29, 2021
AB1		ELITE LABS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A212037**	**001**	Dec 11, 2019
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A212037**	**002**	Dec 11, 2019
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A212037**	**003**	Dec 11, 2019
AB1			**5MG;5MG;5MG;5MG**	**A212037**	**004**	Dec 11, 2019
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A212037**	**005**	Dec 11, 2019
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A212037**	**006**	Dec 11, 2019
AB1		GRANULES	**1.25MG;1.25MG;1.25MG;1.25MG**	**A217027**	**001**	Jan 23, 2023
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A217027**	**002**	Jan 23, 2023
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A217027**	**003**	Jan 23, 2023
AB1			**5MG;5MG;5MG;5MG**	**A217027**	**004**	Jan 23, 2023
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A217027**	**005**	Jan 23, 2023
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A217027**	**006**	Jan 23, 2023
AB1		IMPAX LABS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076852**	**001**	Feb 16, 2016
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A076852**	**002**	Feb 16, 2016
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A076852**	**003**	Feb 16, 2016
AB1			**5MG;5MG;5MG;5MG**	**A076852**	**004**	Feb 16, 2016
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A076852**	**005**	Feb 16, 2016
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A076852**	**006**	Feb 16, 2016
AB1		LANNETT CO INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214403**	**001**	Nov 26, 2021
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214403**	**002**	Nov 26, 2021
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214403**	**003**	Nov 26, 2021
AB1			**5MG;5MG;5MG;5MG**	**A214403**	**004**	Nov 26, 2021
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214403**	**005**	Nov 26, 2021
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214403**	**006**	Nov 26, 2021
AB1		LUPIN	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214777**	**001**	Nov 07, 2024
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214777**	**002**	Nov 07, 2024
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214777**	**003**	Nov 07, 2024
AB1			**5MG;5MG;5MG;5MG**	**A214777**	**004**	Nov 07, 2024
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214777**	**005**	Nov 07, 2024
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214777**	**006**	Nov 07, 2024
AB1		RHODES PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A210651**	**001**	May 17, 2019
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A210651**	**002**	May 17, 2019
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A210651**	**003**	May 17, 2019
AB1			**5MG;5MG;5MG;5MG**	**A210651**	**004**	May 17, 2019
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A210651**	**005**	May 17, 2019
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A210651**	**006**	May 17, 2019
AB1		SPECGX LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A211547**	**001**	Apr 22, 2019
AB1			**2.5MG;2.5MG;2.5MG;2.5MG**	**A211547**	**002**	Apr 22, 2019
AB1			**3.75MG;3.75MG;3.75MG;3.75MG**	**A211547**	**003**	Apr 22, 2019
AB1			**5MG;5MG;5MG;5MG**	**A211547**	**004**	Apr 22, 2019
AB1			**6.25MG;6.25MG;6.25MG;6.25MG**	**A211547**	**005**	Apr 22, 2019
AB1			**7.5MG;7.5MG;7.5MG;7.5MG**	**A211547**	**006**	Apr 22, 2019
AB2			**3.125MG;3.125MG;3.125MG;3.125MG**	**A211546**	**001**	Aug 31, 2023
AB2			**6.25MG;6.25MG;6.25MG;6.25MG**	**A211546**	**002**	Aug 31, 2023
AB2			**9.375MG;9.375MG;9.375MG;9.375MG**	**A211546**	**003**	Aug 31, 2023

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB2			12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023
AB2		SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023
AB2			6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023
AB2			9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023
AB2			12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023
AB2		TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022
AB2			6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022
AB2			9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022
AB2			12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022

MYDAYIS

AB2	+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
AB2	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
AB2	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
AB2	+!		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB			1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB			2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB			3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB			3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB			5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB			7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB		ALKEM LABS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A217787	001	Oct 06, 2023
AB			1.875MG;1.875MG;1.875MG;1.875MG	A217787	002	Oct 06, 2023
AB			2.5MG;2.5MG;2.5MG;2.5MG	A217787	003	Oct 06, 2023
AB			3.125MG;3.125MG;3.125MG;3.125MG	A217787	004	Oct 06, 2023
AB			3.75MG;3.75MG;3.75MG;3.75MG	A217787	005	Oct 06, 2023
AB			5MG;5MG;5MG;5MG	A217787	006	Oct 06, 2023
AB			7.5MG;7.5MG;7.5MG;7.5MG	A217787	007	Oct 06, 2023
AB		ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB			1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB			2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB			3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB			3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017
AB			5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB			7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021
AB			1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021
AB			2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021
AB			3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021
AB			3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021
AB			5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021
AB			7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021
AB		AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB			1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB			2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB			3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB			3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB			5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB			7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB		BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB			1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB			2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB			3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB			3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB			5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB	!		7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB		CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022
AB			2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022
AB			3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022
AB			5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022
AB			7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022
AB		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB			1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB			2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB			3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB			3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB			5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A215771	001	Dec 28, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215771	002	Dec 28, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215771	003	Dec 28, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215771	004	Dec 28, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215771	005	Dec 28, 2021
AB		5MG;5MG;5MG;5MG	A215771	006	Dec 28, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215771	007	Dec 28, 2021
AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022
AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003
AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003
AB	ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA		ALKEM LABS LTD	**5MG**	**A213720**	**001**	Oct 27, 2020
AA			**10MG**	**A213720**	**002**	Oct 27, 2020
AA		AMNEAL PHARMS	**5MG**	**A211139**	**001**	Sep 26, 2018
AA			**10MG**	**A211139**	**002**	Sep 26, 2018
AA		AUROLIFE PHARMA LLC	**5MG**	**A211639**	**001**	Apr 17, 2019
AA			**10MG**	**A211639**	**002**	Apr 17, 2019
AA		BIONPHARMA	**5MG**	**A212919**	**001**	Nov 22, 2019
AA			**10MG**	**A212919**	**002**	Nov 22, 2019
AA		EPIC PHARMA LLC	**5MG**	**A213980**	**001**	Oct 27, 2020
AA			**10MG**	**A213980**	**002**	Oct 27, 2020
AA		GRANULES	**5MG**	**A212619**	**001**	Aug 05, 2019
AA			**10MG**	**A212619**	**002**	Aug 05, 2019
AA		PRINSTON INC	**5MG**	**A211861**	**001**	Mar 11, 2020
AA			**10MG**	**A211861**	**002**	Mar 11, 2020
AA		SANALUZ	**5MG**	**A212582**	**001**	Feb 04, 2020
AA			**10MG**	**A212582**	**002**	Feb 04, 2020
AA		SENORES PHARMS	**5MG**	**A212901**	**001**	May 22, 2020
AA			**10MG**	**A212901**	**002**	May 22, 2020
AA		SPECGX LLC	**5MG**	**A213583**	**001**	Jan 22, 2021
AA			**10MG**	**A213583**	**002**	Jan 22, 2021

EVEKEO

AA		AZURITY	**5MG**	**A200166**	**001**	Aug 09, 2012
AA	**!**		**10MG**	**A200166**	**002**	Aug 09, 2012

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

SUSPENSION, EXTENDED RELEASE;ORAL

DYANAVEL XR

+!	TRIS PHARMA INC	2MG/ML;EQ 0.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, EXTENDED RELEASE;ORAL

DYANAVEL XR 10

+	TRIS PHARMA INC	8MG;EQ 2MG BASE	N210526	002	Nov 04, 2021

DYANAVEL XR 15

+	TRIS PHARMA INC	12MG;EQ 3MG BASE	N210526	003	Nov 04, 2021

DYANAVEL XR 20

+!	TRIS PHARMA INC	16MG;EQ 4MG BASE	N210526	004	Nov 04, 2021

DYANAVEL XR 5

+	TRIS PHARMA INC	4MG;EQ 1MG BASE	N210526	001	Nov 04, 2021

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

AB	**+!**	ASTELLAS	**50MG/VIAL**	**N050740**	**001**	Aug 11, 1997

AMPHOTERICIN B

AB		AVET LIFESCIENCES	**50MG/VIAL**	**A215354**	**001**	Jun 02, 2025
AB		EUGIA PHARMA	**50MG/VIAL**	**A214010**	**001**	Nov 17, 2022
AB		MYLAN LABS LTD	**50MG/VIAL**	**A212967**	**001**	Jun 30, 2025
AB		SPIL	**50MG/VIAL**	**A212514**	**001**	Dec 14, 2021

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	**EQ 10GM BASE/VIAL**	**A090889**	**001**	Apr 03, 2013
AP		ANTIBIOTICE	**EQ 250MG BASE/VIAL**	**A090354**	**001**	Dec 28, 2009
AP			**EQ 500MG BASE/VIAL**	**A090354**	**002**	Dec 28, 2009
AP			**EQ 1GM BASE/VIAL**	**A090354**	**003**	Dec 28, 2009
AP			**EQ 2GM BASE/VIAL**	**A090354**	**004**	Dec 28, 2009
AP		EUGIA PHARMA SPECLTS	**EQ 250MG BASE/VIAL**	**A065499**	**002**	Aug 17, 2010
AP			**EQ 500MG BASE/VIAL**	**A065499**	**003**	Aug 17, 2010
AP			**EQ 1GM BASE/VIAL**	**A065499**	**004**	Aug 17, 2010
AP			**EQ 2GM BASE/VIAL**	**A065499**	**005**	Aug 17, 2010
AP			**EQ 10GM BASE/VIAL**	**A065493**	**001**	Aug 17, 2010
AP		HQ SPECLT PHARMA	**EQ 250MG BASE/VIAL**	**A062772**	**006**	Apr 15, 1993
AP			**EQ 500MG BASE/VIAL**	**A062772**	**007**	Apr 15, 1993
AP			**EQ 1GM BASE/VIAL**	**A062772**	**001**	Apr 15, 1993
AP			**EQ 2GM BASE/VIAL**	**A062772**	**003**	Apr 15, 1993
AP			**EQ 10GM BASE/VIAL**	**A063142**	**001**	Apr 15, 1993
AP		ISTITUTO BIO ITA	**EQ 10GM BASE/VIAL**	**A201404**	**001**	Dec 20, 2013

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

		SPA				
AP			**EQ 250MG BASE/VIAL**	**A062719**	**001**	May 12, 1987
AP			**EQ 500MG BASE/VIAL**	**A062719**	**003**	May 12, 1987
AP			**EQ 1GM BASE/VIAL**	**A062719**	**002**	May 12, 1987
AP			**EQ 2GM BASE/VIAL**	**A062797**	**002**	Jul 12, 1993
AP		ONESOURCE SPECIALTY	**EQ 1GM BASE/VIAL**	**A201025**	**003**	Apr 09, 2014
AP			**EQ 2GM BASE/VIAL**	**A201025**	**004**	Apr 09, 2014
AP			**EQ 10GM BASE/VIAL**	**A202198**	**001**	Apr 07, 2014
AP		SAGENT PHARMS INC	**EQ 125MG BASE/VIAL**	**A090583**	**001**	Nov 27, 2015
AP			**EQ 250MG BASE/VIAL**	**A090583**	**002**	Nov 27, 2015
AP			**EQ 500MG BASE/VIAL**	**A090583**	**003**	Nov 27, 2015
AP			**EQ 1GM BASE/VIAL**	**A090583**	**004**	Nov 27, 2015
AP			**EQ 2GM BASE/VIAL**	**A090583**	**005**	Nov 27, 2015
AP			**EQ 10GM BASE/VIAL**	**A090581**	**001**	Oct 20, 2015
AP	**!**	SANDOZ	**EQ 125MG BASE/VIAL**	**A061395**	**001**	
AP	**!**		**EQ 250MG BASE/VIAL**	**A061395**	**002**	
AP	**!**		**EQ 500MG BASE/VIAL**	**A061395**	**003**	
AP	**!**		**EQ 1GM BASE/VIAL**	**A061395**	**004**	
AP	**!**		**EQ 2GM BASE/VIAL**	**A061395**	**005**	
AP	**!**		**EQ 10GM BASE/VIAL**	**A061395**	**006**	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065406**	**001**	Dec 22, 2009
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065406**	**002**	Dec 22, 2009
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065403**	**001**	Dec 23, 2009
AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201406**	**001**	Dec 07, 2015
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201406**	**002**	Dec 07, 2015
AP		EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090349**	**001**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090349**	**002**	Sep 20, 2010
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090339**	**001**	Sep 20, 2010
AP		HIKMA	**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065076**	**001**	Mar 19, 2002
AP		HQ SPECLT PHARMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065176**	**001**	Nov 30, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065176**	**002**	Nov 30, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065188**	**001**	Nov 25, 2005
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065222**	**001**	Nov 29, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065222**	**002**	Nov 29, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065314**	**001**	Nov 27, 2006
AP		ONESOURCE SPECIALTY	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201024**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201024**	**002**	Apr 07, 2014
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A202197**	**001**	Apr 07, 2014
AP		SANDOZ	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065241**	**001**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065241**	**002**	Jul 25, 2006
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065240**	**001**	Jul 25, 2006

UNASYN

AP	**+!**	PFIZER	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050608**	**002**	Dec 31, 1986
AP	**+!**		**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**N050608**	**001**	Dec 31, 1986
AP	**+!**		**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**N050608**	**005**	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A216554**	**002**	Oct 31, 2023
AB	**!**	SANDOZ	**EQ 500MG BASE**	**A064082**	**002**	Aug 29, 1995
		AUROBINDO PHARMA	EQ 250MG BASE	A216554	001	Oct 31, 2023

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

AB		TAKEDA PHARMS USA	**EQ 0.5MG BASE**	**N020333**	**001**	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

AB		CIPLA	**EQ 0.5MG BASE**	**A076468**	**001**	Apr 18, 2005
AB	**!**		**EQ 1MG BASE**	**A076468**	**002**	Apr 18, 2005
AB		IMPAX LABS	**EQ 0.5MG BASE**	**A076910**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076910**	**002**	Apr 18, 2005
AB		NOVITIUM PHARMA	**EQ 0.5MG BASE**	**A076811**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076811**	**002**	Apr 18, 2005
AB		TORRENT	**EQ 0.5MG BASE**	**A209151**	**001**	Jun 30, 2017

ANAGRELIDE HYDROCHLORIDE						
CAPSULE;ORAL						
ANAGRELIDE HYDROCHLORIDE						
AB			**EQ 1MG BASE**	**A209151**	**002**	Jun 30, 2017
ANASTROZOLE						
TABLET;ORAL						
ANASTROZOLE						
AB		ACCORD HLTHCARE	**1MG**	**A090568**	**001**	Jun 28, 2010
AB		BEIJING YILING	**1MG**	**A206037**	**001**	Nov 09, 2018
AB		CIPLA	**1MG**	**A091164**	**001**	Jun 28, 2010
AB		EUGIA PHARMA	**1MG**	**A212434**	**001**	Jul 24, 2020
AB		KENTON	**1MG**	**A078944**	**001**	Jun 28, 2010
AB		NATCO PHARMA LTD	**1MG**	**A079220**	**001**	Jun 28, 2010
AB		TEVA PHARMS	**1MG**	**A078058**	**001**	Jun 28, 2010
AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001**	Jun 28, 2010
ARIMIDEX						
AB	**+!**	ANI PHARMS	**1MG**	**N020541**	**001**	Dec 27, 1995
ANGIOTENSIN II ACETATE						
SOLUTION;INTRAVENOUS						
ANGIOTENSIN II ACETATE						
AP		GLAND	**EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)**	**A216966**	**001**	Jun 03, 2025
GIAPREZA						
AP	**+!**	LA JOLLA PHARMA	**EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)**	**N209360**	**001**	Dec 21, 2017
	+!		EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	N209360	003	Dec 23, 2021
ANIDULAFUNGIN						
POWDER;INTRAVENOUS						
ERAXIS						
	+!	VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006
	+!		100MG/VIAL	N021632	002	Nov 14, 2006
APALUTAMIDE						
TABLET;ORAL						
APALUTAMIDE						
AB		ZYDUS	**60MG**	**A217113**	**001**	Mar 17, 2025
ERLEADA						
AB	**+**	JANSSEN BIOTECH	**60MG**	**N210951**	**001**	Feb 14, 2018
	+!		240MG	N210951	002	Feb 17, 2023
APIXABAN						
FOR SUSPENSION;ORAL						
ELIQUIS SPRINKLE						
	+!	BRISTOL	0.15MG	N220073	001	Apr 17, 2025
TABLET;ORAL						
APIXABAN						
AB		ACCORD HLTHCARE	**2.5MG**	**A210180**	**001**	Jul 28, 2020
AB			**5MG**	**A210180**	**002**	Jul 28, 2020
AB		REGCON HOLDINGS	**2.5MG**	**A209898**	**001**	Sep 11, 2020
AB			**5MG**	**A209898**	**002**	Sep 11, 2020
ELIQUIS						
AB	**+**	BRISTOL MYERS SQUIBB	**2.5MG**	**N202155**	**001**	Dec 28, 2012
AB	**+!**		**5MG**	**N202155**	**002**	Dec 28, 2012
TABLET, FOR SUSPENSION;ORAL						
ELIQUIS						
	+!	BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025
APOMORPHINE HYDROCHLORIDE						
INJECTABLE;SUBCUTANEOUS						
APOKYN						
AP	**+!**	MDD US	**30MG/3ML (10MG/ML)**	**N021264**	**002**	Apr 20, 2004
APOMORPHINE HYDROCHLORIDE						
AP		TP ANDA HOLDINGS	**30MG/3ML (10MG/ML)**	**A212025**	**001**	Feb 23, 2022
SOLUTION;SUBCUTANEOUS						
ONAPGO						
	+!	MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025

APRACLONIDINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE						
AT		RISING	**EQ 0.5% BASE**	**A077764**	**001**	Mar 12, 2009
IOPIDINE						
AT	**+!**	HARROW EYE	**EQ 0.5% BASE**	**N020258**	**001**	Jul 30, 1993
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987

APREMILAST
TABLET;ORAL

APREMILAST						
AB		ALKEM LABS LTD	**10MG**	**A211761**	**001**	Sep 21, 2021
AB			**20MG**	**A211761**	**002**	Sep 21, 2021
AB			**30MG**	**A211761**	**003**	Sep 21, 2021
AB		ANNORA	**10MG**	**A211878**	**001**	Jul 26, 2023
AB			**20MG**	**A211878**	**002**	Jul 26, 2023
AB			**30MG**	**A211878**	**003**	Jul 26, 2023
AB		MANKIND PHARMA	**10MG**	**A211734**	**001**	Feb 07, 2024
AB			**20MG**	**A211734**	**002**	Feb 07, 2024
AB			**30MG**	**A211734**	**003**	Feb 07, 2024
AB		MSN	**10MG**	**A211887**	**001**	Dec 16, 2024
AB			**20MG**	**A211887**	**002**	Dec 16, 2024
AB			**30MG**	**A211887**	**003**	Dec 16, 2024
AB		SHILPA	**10MG**	**A211774**	**001**	Apr 07, 2023
AB			**20MG**	**A211774**	**002**	Apr 07, 2023
AB			**30MG**	**A211774**	**003**	Apr 07, 2023
OTEZLA						
AB	**+**	AMGEN INC	**10MG**	**N205437**	**001**	Mar 21, 2014
AB	**+**		**20MG**	**N205437**	**002**	Mar 21, 2014
AB	**+!**		**30MG**	**N205437**	**003**	Mar 21, 2014

TABLET, EXTENDED RELEASE;ORAL

OTEZLA XR						
	+!	AMGEN INC	75MG	N210745	001	Aug 29, 2025

APREPITANT
CAPSULE;ORAL

APREPITANT						
AB		GLENMARK SPECLT	**40MG**	**A207777**	**001**	Oct 12, 2017
AB			**80MG**	**A207777**	**002**	Oct 12, 2017
AB			**125MG**	**A207777**	**003**	Oct 12, 2017
AB		SANDOZ	**40MG**	**A090999**	**001**	Sep 24, 2012
AB			**80MG**	**A090999**	**002**	Sep 24, 2012
AB			**125MG**	**A090999**	**003**	Sep 24, 2012
AB		TORRENT	**40MG**	**A211835**	**001**	Oct 21, 2020
AB			**80MG**	**A211835**	**002**	Oct 21, 2020
AB			**125MG**	**A211835**	**003**	Oct 21, 2020
EMEND						
AB	**+**	MSD	**80MG**	**N021549**	**001**	Mar 26, 2003
AB	**+!**		**125MG**	**N021549**	**002**	Mar 26, 2003

EMULSION;INTRAVENOUS

APONVIE						
	+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022
CINVANTI						
	+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	N209296	001	Nov 09, 2017

FOR SUSPENSION;ORAL

EMEND						
	+!	MSD MERCK CO	125MG/KIT	N207865	001	Dec 17, 2015

APROCITENTAN
TABLET;ORAL

TRYVIO						
	+!	IDORSIA	12.5MG	N217686	001	Mar 19, 2024

ARFORMOTEROL TARTRATE
SOLUTION;INHALATION

ARFORMOTEROL TARTRATE						
AN		AIPING PHARM INC	**EQ 0.015MG BASE/2ML**	**A214901**	**001**	Apr 02, 2024
AN		ALEMBIC	**EQ 0.015MG BASE/2ML**	**A214779**	**001**	May 10, 2022
AN		AUCTA	**EQ 0.015MG BASE/2ML**	**A218380**	**001**	Feb 03, 2025
AN		CIPLA	**EQ 0.015MG BASE/2ML**	**A207306**	**001**	Jun 22, 2021
AN		DR REDDYS	**EQ 0.015MG BASE/2ML**	**A215032**	**001**	Jun 03, 2024
AN		LEXENPHARM	**EQ 0.015MG BASE/2ML**	**A218156**	**001**	Nov 18, 2024
AN		LUPIN	**EQ 0.015MG BASE/2ML**	**A213068**	**001**	Feb 07, 2022
AN	**!**	MANKIND PHARMA	**EQ 0.015MG BASE/2ML**	**A216128**	**001**	Nov 15, 2022

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		MICRO LABS	**EQ 0.015MG BASE/2ML**	**A218555**	**001**	Mar 07, 2025
AN		NEOCUBES PHARMA	**EQ 0.015MG BASE/2ML**	**A216303**	**001**	May 17, 2024
AN		RITEDOSE CORP	**EQ 0.015MG BASE/2ML**	**A214736**	**001**	Mar 02, 2022
AN		SABA ILAC SANAYI	**EQ 0.015MG BASE/2ML**	**A218429**	**001**	Apr 25, 2025
AN		SLATE RUN PHARMA	**EQ 0.015MG BASE/2ML**	**A213762**	**001**	Jun 22, 2021
AN		SUN PHARM	**EQ 0.015MG BASE/2ML**	**A215385**	**001**	May 26, 2022
AN		TEVA PHARMS USA	**EQ 0.015MG BASE/2ML**	**A200293**	**001**	Nov 09, 2021
AN		WILSHIRE PHARMS INC	**EQ 0.015MG BASE/2ML**	**A216815**	**001**	Nov 25, 2022

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP		AMNEAL PHARMS CO	**250MG/2.5ML (100MG/ML)**	**A206698**	**001**	Jan 26, 2018
AP		CAPLIN	**50MG/50ML (1MG/ML)**	**A214235**	**001**	Jan 21, 2021
AP		GLAND	**50MG/50ML (1MG/ML)**	**A217848**	**001**	Jul 31, 2023
AP	**+!**	HIKMA PHARM CO LTD	**50MG/50ML (1MG/ML)**	**N203049**	**002**	Sep 30, 2016
AP	**+!**		**250MG/2.5ML (100MG/ML)**	**N203049**	**001**	Jan 05, 2012
AP	**!**	HOSPIRA	**250MG/2.5ML (100MG/ML)**	**A204120**	**001**	Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001**	Jun 30, 2014
AP		PH HEALTH	**250MG/2.5ML (100MG/ML)**	**A091665**	**001**	Jun 30, 2014

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP		GLAND	**125MG/125ML (1MG/ML)**	**A205570**	**001**	May 22, 2017
AP	**+!**	PLANO PHARMS	**125MG/125ML (1MG/ML)**	**N022485**	**001**	May 09, 2011

SOLUTION;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

	+!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021
		EUGIA PHARMA SPECLTS	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018

ARGININE HYDROCHLORIDE

INJECTABLE;INJECTION

R-GENE 10

	+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	

ARIMOCLOMOL CITRATE

CAPSULE;ORAL

MIPLYFFA

	+	ZEVRA DENMARK	EQ 47MG BASE	N214927	001	Sep 20, 2024
	+		EQ 62MG BASE	N214927	002	Sep 20, 2024
	+		EQ 93MG BASE	N214927	003	Sep 20, 2024
	+!		EQ 124MG BASE	N214927	004	Sep 20, 2024

ARIPIPRAZOLE

FILM;ORAL

OPIPZA

	+	XIAMEN LP PHARM CO	2MG	N216655	001	Jul 22, 2024
	+		5MG	N216655	002	Jul 22, 2024
	+!		10MG	N216655	003	Jul 22, 2024

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013
	+		300MG	N202971	003	Sep 29, 2014
	+!		400MG/VIAL	N202971	002	Feb 28, 2013
	+!		400MG	N202971	004	Sep 29, 2014

SOLUTION;ORAL

ARIPIPRAZOLE

AA	**!**	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001**	Aug 14, 2015
AA		APOTEX	**1MG/ML**	**A204094**	**001**	Sep 30, 2015
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A210479**	**001**	Jan 29, 2019
AA		CHARTWELL RX	**1MG/ML**	**A215595**	**001**	Oct 25, 2022
AA		HETERO LABS LTD III	**1MG/ML**	**A216150**	**001**	Nov 01, 2023
AA		LANNETT CO INC	**1MG/ML**	**A204171**	**001**	Aug 14, 2015
AA		QUAGEN	**1MG/ML**	**A215582**	**001**	Oct 22, 2025
AA		RUBICON RESEARCH	**1MG/ML**	**A216351**	**001**	Oct 27, 2022
AA		VISTAPHARM LLC	**1MG/ML**	**A212870**	**001**	Dec 26, 2019

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY ASIMTUFII

	+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023
	+!		960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023

ARIPIPRAZOLE

TABLET;ORAL

ABILIFY							
AB	+	OTSUKA	**2MG**	**N021436**	**006**	Nov 15, 2002
AB	+		**5MG**	**N021436**	**005**	Nov 15, 2002
AB	+!		**10MG**	**N021436**	**001**	Nov 15, 2002
AB	+		**15MG**	**N021436**	**002**	Nov 15, 2002
AB	+		**20MG**	**N021436**	**003**	Nov 15, 2002
AB	+		**30MG**	**N021436**	**004**	Nov 15, 2002
ARIPIPRAZOLE							
AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001**	Dec 07, 2016
AB			**5MG**	**A206251**	**002**	Dec 07, 2016
AB			**10MG**	**A206251**	**003**	Dec 07, 2016
AB			**15MG**	**A206251**	**004**	Dec 07, 2016
AB			**20MG**	**A206251**	**005**	Dec 07, 2016
AB			**30MG**	**A206251**	**006**	Dec 07, 2016
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001**	Sep 12, 2016
AB			**5MG**	**A206174**	**002**	Sep 12, 2016
AB			**10MG**	**A206174**	**003**	Sep 12, 2016
AB			**15MG**	**A206174**	**004**	Sep 12, 2016
AB			**20MG**	**A206174**	**005**	Sep 12, 2016
AB			**30MG**	**A206174**	**006**	Sep 12, 2016
AB		ALEMBIC	**2MG**	**A202101**	**001**	Apr 28, 2015
AB			**5MG**	**A202101**	**002**	Apr 28, 2015
AB			**10MG**	**A202101**	**003**	Apr 28, 2015
AB			**15MG**	**A202101**	**004**	Apr 28, 2015
AB			**20MG**	**A202101**	**005**	Apr 28, 2015
AB			**30MG**	**A202101**	**006**	Apr 28, 2015
AB		ALKEM LABS LTD	**2MG**	**A207105**	**001**	Feb 21, 2019
AB			**5MG**	**A207105**	**002**	Feb 21, 2019
AB			**10MG**	**A207105**	**003**	Feb 21, 2019
AB			**15MG**	**A207105**	**004**	Feb 21, 2019
AB			**20MG**	**A207105**	**005**	Feb 21, 2019
AB			**30MG**	**A207105**	**006**	Feb 21, 2019
AB		AMNEAL PHARMS	**2MG**	**A204838**	**001**	Jun 17, 2016
AB			**5MG**	**A204838**	**002**	Jun 17, 2016
AB			**10MG**	**A204838**	**003**	Jun 17, 2016
AB			**15MG**	**A204838**	**004**	Jun 17, 2016
AB			**20MG**	**A204838**	**005**	Jun 17, 2016
AB			**30MG**	**A204838**	**006**	Jun 17, 2016
AB		APOTEX	**2MG**	**A078583**	**001**	Jul 24, 2015
AB			**5MG**	**A078583**	**002**	Jul 24, 2015
AB			**10MG**	**A078583**	**003**	Jul 24, 2015
AB			**15MG**	**A078583**	**004**	Jul 24, 2015
AB			**20MG**	**A078583**	**005**	Jul 24, 2015
AB			**30MG**	**A078583**	**006**	Jul 24, 2015
AB		AUROBINDO PHARMA	**2MG**	**A203908**	**001**	Oct 08, 2015
AB			**5MG**	**A203908**	**002**	Oct 08, 2015
AB			**10MG**	**A203908**	**003**	Oct 08, 2015
AB			**15MG**	**A203908**	**004**	Oct 08, 2015
AB			**20MG**	**A203908**	**005**	Oct 08, 2015
AB			**30MG**	**A203908**	**006**	Oct 08, 2015
AB		HETERO LABS LTD V	**2MG**	**A205064**	**001**	Apr 28, 2015
AB			**5MG**	**A205064**	**002**	Apr 28, 2015
AB			**10MG**	**A205064**	**003**	Apr 28, 2015
AB			**15MG**	**A205064**	**004**	Apr 28, 2015
AB			**20MG**	**A205064**	**005**	Apr 28, 2015
AB			**30MG**	**A205064**	**006**	Apr 28, 2015
AB		MACLEODS PHARMS LTD	**2MG**	**A204111**	**001**	Oct 07, 2016
AB			**5MG**	**A204111**	**002**	Oct 07, 2016
AB			**10MG**	**A204111**	**003**	Oct 07, 2016
AB			**15MG**	**A204111**	**004**	Oct 07, 2016
AB			**20MG**	**A204111**	**005**	Oct 07, 2016
AB			**30MG**	**A204111**	**006**	Oct 07, 2016
AB		ORBION PHARMS	**2MG**	**A202683**	**001**	May 23, 2017
AB			**5MG**	**A202683**	**002**	May 23, 2017
AB			**10MG**	**A202683**	**003**	May 23, 2017
AB			**15MG**	**A202683**	**004**	May 23, 2017
AB			**20MG**	**A202683**	**005**	May 23, 2017
AB			**30MG**	**A202683**	**006**	May 23, 2017
AB		PRINSTON INC	**2MG**	**A205363**	**001**	Dec 04, 2017
AB			**5MG**	**A205363**	**002**	Dec 04, 2017

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

AB		**10MG**	**A205363**	**003**	Dec 04, 2017
AB		**15MG**	**A205363**	**004**	Dec 04, 2017
AB		**20MG**	**A205363**	**005**	Dec 04, 2017
AB		**30MG**	**A205363**	**006**	Dec 04, 2017
AB	SCIEGEN PHARMS	**2MG**	**A206383**	**001**	Sep 29, 2016
AB		**5MG**	**A206383**	**002**	Sep 29, 2016
AB		**10MG**	**A206383**	**003**	Sep 29, 2016
AB		**15MG**	**A206383**	**004**	Sep 29, 2016
AB		**20MG**	**A206383**	**005**	Sep 29, 2016
AB		**30MG**	**A206383**	**006**	Sep 29, 2016
AB	SUNSHINE	**2MG**	**A213037**	**001**	Oct 02, 2023
AB		**5MG**	**A213037**	**002**	Oct 02, 2023
AB		**10MG**	**A213037**	**003**	Oct 02, 2023
AB	TORRENT	**2MG**	**A201519**	**001**	Apr 28, 2015
AB		**10MG**	**A201519**	**003**	Apr 28, 2015
AB		**5MG**	**A201519**	**002**	Apr 28, 2015
AB		**15MG**	**A201519**	**004**	Apr 28, 2015
AB		**20MG**	**A201519**	**005**	Apr 28, 2015
AB		**30MG**	**A201519**	**006**	Apr 28, 2015
AB	UNICHEM	**2MG**	**A203025**	**001**	Dec 01, 2021
AB		**5MG**	**A203025**	**002**	Dec 01, 2021
AB		**10MG**	**A203025**	**003**	Dec 01, 2021
AB		**15MG**	**A203025**	**004**	Dec 01, 2021
AB		**20MG**	**A203025**	**005**	Dec 01, 2021
AB		**30MG**	**A203025**	**006**	Dec 01, 2021

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

AB	! ALEMBIC	**10MG**	**A202102**	**001**	Apr 28, 2015
AB		**15MG**	**A202102**	**002**	Apr 28, 2015
AB	ORBION PHARMS	**10MG**	**A202547**	**001**	Dec 11, 2017
AB		**15MG**	**A202547**	**002**	Dec 11, 2017
AB	SCIEGEN PHARMS	**10MG**	**A207240**	**001**	Apr 18, 2018
AB		**15MG**	**A207240**	**002**	Apr 18, 2018
AB	SQUARE PHARMS	**10MG**	**A090165**	**001**	Aug 28, 2018
AB		**15MG**	**A090165**	**002**	Aug 28, 2018
		20MG	A090165	003	Aug 28, 2018
		30MG	A090165	004	Aug 28, 2018

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+!		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARISTADA INITIO KIT

+!	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB	AUROBINDO PHARMA LTD	**50MG**	**A206069**	**001**	Mar 06, 2018
AB		**150MG**	**A206069**	**002**	Mar 06, 2018
AB		**200MG**	**A206069**	**004**	Dec 07, 2018
AB		**250MG**	**A206069**	**003**	Mar 06, 2018
AB	LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB		**150MG**	**A200751**	**003**	Nov 28, 2016
AB		**200MG**	**A200751**	**004**	Nov 28, 2016
AB		**250MG**	**A200751**	**005**	Nov 28, 2016
AB	MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB		**100MG**	**A200043**	**004**	May 09, 2019
AB		**150MG**	**A200043**	**002**	Jun 01, 2012
AB		**200MG**	**A200043**	**005**	May 09, 2019
AB		**250MG**	**A200043**	**003**	Jun 01, 2012
AB	NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB		**100MG**	**A202768**	**004**	Sep 28, 2017
AB		**150MG**	**A202768**	**002**	Nov 28, 2016
AB		**200MG**	**A202768**	**005**	Sep 28, 2017
AB		**250MG**	**A202768**	**003**	Nov 28, 2016

ARMODAFINIL

TABLET;ORAL

NUVIGIL

AB	**+**	NUVO PHARMS	**50MG**	**N021875**	**001**	Jun 15, 2007
AB	**+**		**150MG**	**N021875**	**003**	Jun 15, 2007
AB	**+**		**200MG**	**N021875**	**005**	Mar 26, 2009
AB	**+!**		**250MG**	**N021875**	**004**	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP		AMNEAL	**1MG/ML**	**A210739**	**001**	Jan 25, 2021
AP			**2MG/ML**	**A210739**	**002**	Aug 19, 2021
AP		AMRING PHARMS	**1MG/ML**	**A210802**	**001**	Nov 13, 2018
AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A208231**	**001**	Aug 31, 2018
AP		GLAND	**1MG/ML**	**A215059**	**002**	Apr 22, 2022
AP			**2MG/ML**	**A215059**	**001**	Oct 07, 2021
AP		MSN	**1MG/ML**	**A217413**	**001**	Apr 20, 2023
AP			**2MG/ML**	**A217413**	**002**	Apr 20, 2023
AP		NEXUS	**1MG/ML**	**A209780**	**001**	Nov 15, 2018
AP		NOVAST LABS	**1MG/ML**	**A209315**	**001**	Nov 15, 2018
AP		PENN LIFE	**1MG/ML**	**A209873**	**001**	May 06, 2019
AP		SANDOZ	**2MG/ML**	**A215359**	**001**	Dec 02, 2021
AP		ZYDUS PHARMS	**1MG/ML**	**A206228**	**001**	Nov 13, 2018
AP			**2MG/ML**	**A206228**	**002**	Aug 30, 2019

TRISENOX

AP	**+!**	CEPHALON	**2MG/ML**	**N021248**	**002**	Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM

	+!	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

	+!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYKLX

	+!	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

ORABLOC

	+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
	+!		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010

SEPTOCAINE

	+!	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971	002	Mar 30, 2006
	+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL

SCEMBLIX

	+	NOVARTIS	EQ 20MG BASE	N215358	001	Oct 29, 2021
	+		EQ 40MG BASE	N215358	002	Oct 29, 2021
	+!		EQ 100MG BASE	N215358	003	Apr 18, 2024

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR

AP	**+!**	MCGUFF	**25,000MG/50ML (500MG/ML)**	**N209112**	**001**	Oct 02, 2017

ASCORBIC ACID

AP		FRESENIUS KABI USA	**25,000MG/50ML (500MG/ML)**	**A217131**	**001**	Aug 07, 2025

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

AA	**+!**	SALIX PHARMS	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**N021881**	**001**	Aug 02, 2006

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

AA		NOVEL LABS INC	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**A090145**	**001**	Jan 25, 2012

PLENVU

	+!	SALIX	7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	N209381	001	May 04, 2018

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

	+!	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019
	+		5.7MG/24HR	N212268	002	Oct 11, 2019
	+		7.6MG/24HR	N212268	003	Oct 11, 2019

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

AB		ALEMBIC	**EQ 2.5MG BASE**	**A206098**	**003**	Jul 19, 2021
AB			**EQ 5MG BASE**	**A206098**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206098**	**002**	Dec 10, 2020
AB		BRECKENRIDGE	**EQ 2.5MG BASE**	**A205960**	**001**	Dec 10, 2020
AB			**EQ 5MG BASE**	**A205960**	**003**	Mar 08, 2021
AB			**EQ 10MG BASE**	**A205960**	**002**	Dec 10, 2020
AB		SIGMAPHARM LABS LLC	**EQ 5MG BASE**	**A206107**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206107**	**002**	Dec 10, 2020

SAPHRIS

AB	**+**	ALLERGAN	**EQ 2.5MG BASE**	**N022117**	**003**	Mar 12, 2015
AB	**+**		**EQ 5MG BASE**	**N022117**	**001**	Aug 13, 2009
AB	**+!**		**EQ 10MG BASE**	**N022117**	**002**	Aug 13, 2009

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		MPP PHARMA	**325MG;50MG;40MG**	**A078149**	**001**	Jun 13, 2007

LANORINAL

AA	**!**	SANDOZ	**325MG;50MG;40MG**	**A086996**	**002**	Oct 11, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		LGM PHARMA	**325MG;50MG;40MG;30MG**	**A075231**	**001**	Nov 30, 2001
AB	**!**	STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001**	Aug 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC

		GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998

ORPHENGESIC FORTE

	!	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001**	Mar 08, 2016
AB		BARR	**25MG;200MG**	**A078804**	**001**	Aug 14, 2009
AB		DR REDDYS	**25MG;200MG**	**A209048**	**001**	Oct 10, 2018
AB	**!**	GLENMARK SPECLT	**25MG;200MG**	**A210318**	**001**	May 24, 2019
AB		MICRO LABS	**25MG;200MG**	**A209929**	**001**	Aug 11, 2021
AB		PH HEALTH	**25MG;200MG**	**A207944**	**001**	Jan 18, 2017
AB		SANDOZ	**25MG;200MG**	**A206739**	**001**	Jan 18, 2017
AB		ZYDUS PHARMS	**25MG;200MG**	**A206753**	**001**	Aug 29, 2017

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

	!	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		EPIC PHARMA LLC	**325MG;4.8355MG**	**A040910**	**001**	Jul 16, 2020

PERCODAN

AA	**+!**	ENDO OPERATIONS	**325MG;4.8355MG**	**N007337**	**007**	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A204806**	**001**	Jun 25, 2018
AB			**EQ 150MG BASE**	**A204806**	**002**	Jun 25, 2018
AB			**EQ 200MG BASE**	**A204806**	**003**	Jun 25, 2018
AB			**EQ 300MG BASE**	**A204806**	**004**	Jun 25, 2018
AB		HETERO LABS LTD III	**EQ 150MG BASE**	**A212278**	**001**	Feb 02, 2022
AB			**EQ 200MG BASE**	**A212278**	**002**	Feb 02, 2022
AB			**EQ 300MG BASE**	**A212278**	**003**	Feb 02, 2022
AB		LAURUS	**EQ 150MG BASE**	**A212579**	**001**	Apr 30, 2021
AB			**EQ 200MG BASE**	**A212579**	**002**	Apr 30, 2021
AB			**EQ 300MG BASE**	**A212579**	**003**	Apr 30, 2021
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091673**	**001**	Apr 22, 2014
AB			**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB			**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB			**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	**+**	BRISTOL MYERS SQUIBB	**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB	**+!**		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

POWDER;ORAL

REYATAZ

	+!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+!	BRISTOL	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		AIPING PHARM INC	**25MG**	**A072304**	**002**	Jul 31, 1992
AB			**50MG**	**A072304**	**003**	Jul 18, 1988
AB			**100MG**	**A072304**	**001**	Jul 15, 1988
AB		AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB			**50MG**	**A078512**	**002**	Oct 31, 2007
AB			**100MG**	**A078512**	**003**	Oct 31, 2007
AB		MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB			**50MG**	**A073457**	**003**	Jan 24, 1992
AB			**100MG**	**A073457**	**001**	Jan 24, 1992
AB		PHARMOBEDIENT	**25MG**	**A073026**	**002**	May 01, 1992
AB			**50MG**	**A073026**	**003**	Sep 17, 1991
AB			**100MG**	**A073026**	**001**	Sep 17, 1991
AB		TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB			**50MG**	**A074056**	**001**	Jan 18, 1995
AB			**100MG**	**A074056**	**002**	Jan 18, 1995
AB		UNICHEM	**25MG**	**A213136**	**001**	Nov 21, 2019
AB			**50MG**	**A213136**	**002**	Nov 21, 2019
AB			**100MG**	**A213136**	**003**	Nov 21, 2019
AB		UNIQUE	**25MG**	**A077443**	**001**	Sep 13, 2006
AB			**50MG**	**A077443**	**002**	Sep 13, 2006
AB			**100MG**	**A077443**	**003**	Sep 13, 2006
AB		ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB			**50MG**	**A076900**	**002**	Jan 28, 2005
AB			**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	**+**	TWI PHARMS	**25MG**	**N018240**	**004**	Apr 09, 1990
AB	**+**		**50MG**	**N018240**	**001**	
AB	**+!**		**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		AIPING PHARM INC	**50MG;25MG**	**A072302**	**002**	May 31, 1990
AB			**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB		NOVITIUM PHARMA	**50MG;25MG**	**A215560**	**001**	Oct 25, 2021
AB			**100MG;25MG**	**A215560**	**002**	Oct 25, 2021
AB		UNICHEM	**50MG;25MG**	**A213302**	**001**	Nov 25, 2020
AB			**100MG;25MG**	**A213302**	**002**	Nov 25, 2020
AB		WATSON LABS	**50MG;25MG**	**A073665**	**001**	Jul 02, 1992
AB			**100MG;25MG**	**A073665**	**002**	Jul 02, 1992
AB		ZYDUS PHARMS	**50MG;25MG**	**A210028**	**001**	Mar 08, 2019
AB			**100MG;25MG**	**A210028**	**002**	Mar 08, 2019

TENORETIC 100

AB	**+!**	TWI PHARMS	**100MG;25MG**	**N018760**	**001**	Jun 08, 1984

TENORETIC 50

AB	**+**	TWI PHARMS	**50MG;25MG**	**N018760**	**002**	Jun 08, 1984

ATOGEPANT

TABLET;ORAL

QULIPTA

+	ABBVIE	10MG	N215206	001	Sep 28, 2021
+		30MG	N215206	002	Sep 28, 2021
+!		60MG	N215206	003	Sep 28, 2021

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A078983**	**001**	May 30, 2017
AB			**EQ 18MG BASE**	**A078983**	**002**	May 30, 2017
AB			**EQ 25MG BASE**	**A078983**	**003**	May 30, 2017
AB			**EQ 40MG BASE**	**A078983**	**004**	May 30, 2017
AB			**EQ 60MG BASE**	**A078983**	**005**	May 30, 2017
AB			**EQ 80MG BASE**	**A078983**	**006**	May 30, 2017
AB			**EQ 100MG BASE**	**A078983**	**007**	May 30, 2017
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A079016**	**001**	May 30, 2017
AB			**EQ 18MG BASE**	**A079016**	**002**	May 30, 2017
AB			**EQ 25MG BASE**	**A079016**	**003**	May 30, 2017
AB			**EQ 40MG BASE**	**A079016**	**004**	May 30, 2017
AB			**EQ 60MG BASE**	**A079016**	**005**	May 30, 2017
AB			**EQ 80MG BASE**	**A079016**	**006**	May 30, 2017
AB			**EQ 100MG BASE**	**A079016**	**007**	May 30, 2017
AB		DR REDDYS	**EQ 10MG BASE**	**A090609**	**001**	Feb 23, 2018
AB			**EQ 18MG BASE**	**A090609**	**002**	Feb 23, 2018
AB			**EQ 25MG BASE**	**A090609**	**003**	Feb 23, 2018
AB			**EQ 40MG BASE**	**A090609**	**004**	Feb 23, 2018
AB			**EQ 60MG BASE**	**A090609**	**005**	Feb 23, 2018
AB			**EQ 80MG BASE**	**A090609**	**006**	Feb 23, 2018
AB			**EQ 100MG BASE**	**A090609**	**007**	Feb 23, 2018
AB		GLENMARK PHARMS LTD	**EQ 10MG BASE**	**A079019**	**001**	May 30, 2017
AB			**EQ 18MG BASE**	**A079019**	**002**	May 30, 2017
AB			**EQ 25MG BASE**	**A079019**	**003**	May 30, 2017
AB			**EQ 40MG BASE**	**A079019**	**004**	May 30, 2017
AB			**EQ 60MG BASE**	**A079019**	**005**	May 30, 2017
AB			**EQ 80MG BASE**	**A079019**	**006**	May 30, 2017
AB			**EQ 100MG BASE**	**A079019**	**007**	May 30, 2017
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202682**	**001**	Mar 11, 2021
AB			**EQ 18MG BASE**	**A202682**	**002**	Mar 11, 2021
AB			**EQ 25MG BASE**	**A202682**	**003**	Mar 11, 2021
AB			**EQ 40MG BASE**	**A202682**	**004**	Mar 11, 2021
AB	**!**		**EQ 60MG BASE**	**A202682**	**005**	Mar 11, 2021
AB			**EQ 80MG BASE**	**A202682**	**006**	Mar 11, 2021
AB			**EQ 100MG BASE**	**A202682**	**007**	Mar 11, 2021
AB		STRIDES PHARMA	**EQ 10MG BASE**	**A079021**	**001**	Feb 18, 2021
AB			**EQ 18MG BASE**	**A079021**	**002**	Feb 18, 2021
AB			**EQ 25MG BASE**	**A079021**	**003**	Feb 18, 2021
AB			**EQ 40MG BASE**	**A079021**	**004**	Feb 18, 2021
AB			**EQ 60MG BASE**	**A079021**	**005**	Feb 18, 2021
AB			**EQ 80MG BASE**	**A079021**	**006**	Feb 18, 2021
AB			**EQ 100MG BASE**	**A079021**	**007**	Feb 18, 2021
AB		TEVA PHARMS USA	**EQ 10MG BASE**	**A079022**	**001**	May 30, 2017
AB			**EQ 18MG BASE**	**A079022**	**002**	May 30, 2017
AB			**EQ 25MG BASE**	**A079022**	**003**	May 30, 2017

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		**EQ 40MG BASE**	**A079022**	**004**	May 30, 2017
AB		**EQ 60MG BASE**	**A079022**	**005**	May 30, 2017
AB		**EQ 80MG BASE**	**A079022**	**006**	May 30, 2017
AB		**EQ 100MG BASE**	**A079022**	**007**	May 30, 2017
AB	ZYDUS PHARMS USA INC	**EQ 10MG BASE**	**A079017**	**007**	Apr 05, 2023
AB		**EQ 18MG BASE**	**A079017**	**001**	Sep 16, 2010
AB		**EQ 25MG BASE**	**A079017**	**002**	Sep 16, 2010
AB		**EQ 40MG BASE**	**A079017**	**003**	Sep 16, 2010
AB		**EQ 60MG BASE**	**A079017**	**004**	Sep 16, 2010
AB		**EQ 80MG BASE**	**A079017**	**005**	Sep 16, 2010
AB		**EQ 100MG BASE**	**A079017**	**006**	Sep 16, 2010

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+!	CMP DEV LLC	20MG/5ML	N213260	001	Feb 01, 2023

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ACCORD HLTHCARE	**EQ 10MG BASE**	**A207687**	**001**	Mar 30, 2018
AB		**EQ 20MG BASE**	**A207687**	**002**	Mar 30, 2018
AB		**EQ 40MG BASE**	**A207687**	**003**	Mar 30, 2018
AB		**EQ 80MG BASE**	**A207687**	**004**	Mar 30, 2018
AB	ALKEM LABS LTD	**EQ 10MG BASE**	**A209288**	**001**	Dec 21, 2018
AB		**EQ 20MG BASE**	**A209288**	**002**	Dec 21, 2018
AB		**EQ 40MG BASE**	**A209288**	**003**	Dec 21, 2018
AB		**EQ 80MG BASE**	**A209288**	**004**	Dec 21, 2018
AB	APOTEX	**EQ 10MG BASE**	**A214969**	**001**	Sep 02, 2021
AB		**EQ 20MG BASE**	**A214969**	**002**	Sep 02, 2021
AB		**EQ 40MG BASE**	**A214969**	**003**	Sep 02, 2021
AB		**EQ 80MG BASE**	**A214969**	**004**	Sep 02, 2021
AB	APOTEX INC	**EQ 10MG BASE**	**A090548**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A090548**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A090548**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A090548**	**004**	May 29, 2012
AB	AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A217118**	**001**	Feb 13, 2024
AB		**EQ 20MG BASE**	**A217118**	**002**	Feb 13, 2024
AB		**EQ 40MG BASE**	**A217118**	**003**	Feb 13, 2024
AB		**EQ 80MG BASE**	**A217118**	**004**	Feb 13, 2024
AB	BIOCON PHARMA	**EQ 10MG BASE**	**A216436**	**001**	Nov 23, 2022
AB		**EQ 20MG BASE**	**A216436**	**002**	Nov 23, 2022
AB		**EQ 40MG BASE**	**A216436**	**003**	Nov 23, 2022
AB		**EQ 80MG BASE**	**A216436**	**004**	Nov 23, 2022
AB	CHARTWELL RX	**EQ 10MG BASE**	**A077575**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A077575**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A077575**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A077575**	**004**	May 29, 2012
AB	DR REDDYS	**EQ 10MG BASE**	**A214659**	**001**	Jul 14, 2021
AB		**EQ 20MG BASE**	**A214659**	**002**	Jul 14, 2021
AB		**EQ 40MG BASE**	**A214659**	**003**	Jul 14, 2021
AB		**EQ 80MG BASE**	**A214659**	**004**	Jul 14, 2021
AB	DR REDDYS LABS LTD	**EQ 10MG BASE**	**A091650**	**001**	Jul 17, 2012
AB		**EQ 20MG BASE**	**A091650**	**002**	Jul 17, 2012
AB		**EQ 40MG BASE**	**A091650**	**003**	Jul 17, 2012
AB		**EQ 80MG BASE**	**A202357**	**001**	Jul 17, 2012
AB	GRAVITI PHARMS	**EQ 10MG BASE**	**A209912**	**001**	Jun 18, 2018
AB		**EQ 20MG BASE**	**A209912**	**002**	Jun 18, 2018
AB		**EQ 40MG BASE**	**A209912**	**003**	Jun 18, 2018
AB		**EQ 80MG BASE**	**A209912**	**004**	Jun 18, 2018
AB	HETERO LABS LTD V	**EQ 10MG BASE**	**A214344**	**001**	Sep 12, 2023
AB		**EQ 20MG BASE**	**A214344**	**002**	Sep 12, 2023
AB		**EQ 40MG BASE**	**A214344**	**003**	Sep 12, 2023
AB		**EQ 80MG BASE**	**A214344**	**004**	Sep 12, 2023
AB	LANNETT CO INC	**EQ 10MG BASE**	**A091624**	**001**	Apr 05, 2013
AB		**EQ 20MG BASE**	**A091624**	**002**	Apr 05, 2013
AB		**EQ 40MG BASE**	**A091624**	**003**	Apr 05, 2013
AB		**EQ 80MG BASE**	**A091624**	**004**	Apr 05, 2013
AB	LAURUS	**EQ 10MG BASE**	**A214513**	**001**	Jan 22, 2024
AB		**EQ 20MG BASE**	**A214513**	**002**	Jan 22, 2024

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		**EQ 40MG BASE**	**A214513**	**003**	Jan 22, 2024
AB		**EQ 80MG BASE**	**A214513**	**004**	Jan 22, 2024
AB	MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A208480**	**001**	Jun 03, 2024
AB		**EQ 20MG BASE**	**A208480**	**002**	Jun 03, 2024
AB		**EQ 40MG BASE**	**A208480**	**003**	Jun 03, 2024
AB		**EQ 80MG BASE**	**A208480**	**004**	Jun 03, 2024
AB	MANKIND PHARMA	**EQ 10MG BASE**	**A217081**	**001**	Jan 05, 2024
AB		**EQ 20MG BASE**	**A217081**	**002**	Jan 05, 2024
AB		**EQ 40MG BASE**	**A217081**	**003**	Jan 05, 2024
AB		**EQ 80MG BASE**	**A217081**	**004**	Jan 05, 2024
AB	MICRO LABS LTD INDIA	**EQ 10MG BASE**	**A205945**	**001**	Nov 07, 2019
AB		**EQ 20MG BASE**	**A205945**	**002**	Nov 07, 2019
AB		**EQ 40MG BASE**	**A205945**	**003**	Nov 07, 2019
AB		**EQ 80MG BASE**	**A205945**	**004**	Nov 07, 2019
AB	MSN	**EQ 10MG BASE**	**A211933**	**001**	Feb 08, 2019
AB		**EQ 20MG BASE**	**A211933**	**002**	Feb 08, 2019
AB		**EQ 40MG BASE**	**A211933**	**003**	Feb 08, 2019
AB		**EQ 80MG BASE**	**A211933**	**004**	Feb 08, 2019
AB	MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001**	May 29, 2012
AB		**EQ 20MG BASE**	**A091226**	**002**	May 29, 2012
AB		**EQ 40MG BASE**	**A091226**	**003**	May 29, 2012
AB		**EQ 80MG BASE**	**A091226**	**004**	May 29, 2012
AB	SCIEGEN PHARMS	**EQ 10MG BASE**	**A205519**	**001**	May 19, 2016
AB		**EQ 20MG BASE**	**A205519**	**002**	May 19, 2016
AB		**EQ 40MG BASE**	**A205519**	**003**	May 19, 2016
AB		**EQ 80MG BASE**	**A205519**	**004**	May 19, 2016
AB	SHANDONG XINHUA	**EQ 10MG BASE**	**A211886**	**001**	Jan 25, 2024
AB		**EQ 20MG BASE**	**A211886**	**002**	Jan 25, 2024
AB		**EQ 40MG BASE**	**A211886**	**003**	Jan 25, 2024
AB		**EQ 80MG BASE**	**A211886**	**004**	Jan 25, 2024
AB	TEVA PHARMS INC	**EQ 10MG BASE**	**A220276**	**001**	Nov 13, 2025
AB		**EQ 20MG BASE**	**A220276**	**002**	Nov 13, 2025
AB		**EQ 40MG BASE**	**A220276**	**003**	Nov 13, 2025
AB		**EQ 80MG BASE**	**A220276**	**004**	Nov 13, 2025
AB	TEVA PHARMS USA	**EQ 10MG BASE**	**A205300**	**001**	Mar 27, 2017
AB		**EQ 20MG BASE**	**A205300**	**002**	Mar 27, 2017
AB		**EQ 40MG BASE**	**A205300**	**003**	Mar 27, 2017
AB		**EQ 80MG BASE**	**A205300**	**004**	Mar 27, 2017
AB	ZYDUS PHARMS	**EQ 10MG BASE**	**A206536**	**001**	Nov 20, 2018
AB		**EQ 20MG BASE**	**A206536**	**002**	Nov 20, 2018
AB		**EQ 40MG BASE**	**A206536**	**003**	Nov 20, 2018
AB		**EQ 80MG BASE**	**A206536**	**004**	Nov 20, 2018

LIPITOR

AB	**+** UPJOHN	**EQ 10MG BASE**	**N020702**	**001**	Dec 17, 1996
AB	**+**	**EQ 20MG BASE**	**N020702**	**002**	Dec 17, 1996
AB	**+**	**EQ 40MG BASE**	**N020702**	**003**	Dec 17, 1996
AB	**+!**	**EQ 80MG BASE**	**N020702**	**004**	Apr 07, 2000

ATORVASTATIN CALCIUM

BX	UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020
BX		EQ 20MG BASE	A213853	002	Aug 19, 2020
BX		EQ 40MG BASE	A213853	003	Aug 19, 2020
BX		EQ 80MG BASE	A213853	004	Aug 19, 2020

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LYPQOZET

	PHARMOBEDIENT	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	ABHAI LLC	**750MG/5ML**	**A210510**	**001**	May 31, 2019
AB	AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001**	Mar 18, 2014
AB	BIONPHARMA	**750MG/5ML**	**A212918**	**001**	Mar 30, 2021
AB	CHARTWELL RX	**750MG/5ML**	**A207833**	**001**	Apr 28, 2017
AB	GLENMARK SPECLT	**750MG/5ML**	**A209685**	**001**	Nov 21, 2018
AB	HETERO LABS LTD III	**750MG/5ML**	**A210692**	**001**	Oct 11, 2018

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		PAI HOLDINGS	**750MG/5ML**	**A214272**	**001**	Oct 25, 2021

MEPRON

AB	**+!**	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001**	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	**62.5MG;25MG**	**A091211**	**002**	Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001**	Jan 12, 2011
AB		MYLAN	**62.5MG;25MG**	**A202362**	**001**	May 27, 2014
AB			**250MG;100MG**	**A202362**	**002**	May 27, 2014

MALARONE

AB	**+!**	GLAXOSMITHKLINE	**250MG;100MG**	**N021078**	**001**	Jul 14, 2000

MALARONE PEDIATRIC

AB	**+**	GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078**	**002**	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	**!**	HIKMA	**10MG/ML**	**A074901**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090761**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091489**	**001**	Feb 17, 2012

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	**!**	HIKMA	**10MG/ML**	**A074900**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090782**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091488**	**001**	Feb 17, 2012

ATRASENTAN HYDROCHLORIDE

TABLET;ORAL

VANRAFIA

	+!	NOVARTIS	EQ 0.75MG BASE	N219208	001	Apr 02, 2025

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**0.25MG/5ML (0.05MG/ML)**	**A212868**	**001**	Jul 26, 2021
AP			**0.5MG/5ML (0.1MG/ML)**	**A212868**	**002**	Jul 26, 2021
AP			**1MG/10ML (0.1MG/ML)**	**A212868**	**003**	Jul 26, 2021
AP	**+**		**1MG/ML (1MG/ML)**	**N214652**	**002**	Sep 29, 2020
AP	**!**	AM REGENT	**0.4MG/ML (0.4MG/ML)**	**A216120**	**001**	May 26, 2022
AP	**!**		**1MG/ML (1MG/ML)**	**A216120**	**002**	May 26, 2022
AP		AMNEAL	**0.5MG/5ML (0.1MG/ML)**	**A215342**	**001**	Jan 26, 2022
AP			**1MG/10ML (0.1MG/ML)**	**A215342**	**002**	Oct 25, 2023
AP		HIKMA	**0.4MG/ML (0.4MG/ML)**	**A217345**	**001**	Oct 24, 2025
AP			**1MG/ML (1MG/ML)**	**A217345**	**002**	Oct 24, 2025
AP	**+!**	HOSPIRA	**0.25MG/5ML (0.05MG/ML)**	**N021146**	**002**	Jul 09, 2001
AP	**+!**		**0.5MG/5ML (0.1MG/ML)**	**N021146**	**001**	Jul 09, 2001
AP	**+!**		**1MG/10ML (0.1MG/ML)**	**N021146**	**003**	Jul 09, 2001
AP		INTL MEDICATION SYS	**1MG/10ML (0.1MG/ML)**	**A212461**	**001**	Oct 05, 2020
AP		MEDEFIL INC	**1MG/10ML (0.1MG/ML)**	**A214970**	**001**	Nov 04, 2022
AP		SOMERSET THERAPS LLC	**0.4MG/ML (0.4MG/ML)**	**A215969**	**001**	Jul 03, 2024
AP			**1MG/ML (1MG/ML)**	**A215969**	**002**	Jul 03, 2024

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**8MG/20ML (0.4MG/ML)**	**A213424**	**001**	Mar 19, 2021
AP	**+!**	FRESENIUS KABI USA	**8MG/20ML (0.4MG/ML)**	**N209260**	**001**	Jan 26, 2018
AP		HIKMA	**8MG/20ML (0.4MG/ML)**	**A213561**	**001**	Dec 01, 2021
AP		SOMERSET THERAPS LLC	**8MG/20ML (0.4MG/ML)**	**A215005**	**001**	Nov 29, 2024

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AT1	**!**	AMNEAL	**1%**	**A214752**	**001**	Jul 14, 2022
AT1		APOTEX	**1%**	**A215624**	**001**	Nov 26, 2021
AT1		MANKIND PHARMA	**1%**	**A218148**	**001**	Jan 08, 2024
AT1	**+**	RISING	**1%**	**N206289**	**001**	Jul 18, 2014
AT1		SOMERSET THERAPS LLC	**1%**	**A215618**	**001**	Jul 01, 2024
AT2		SOMERSET	**1%**	**A217791**	**001**	Apr 29, 2024

ISOPTO ATROPINE

AT2	**+!**	ALCON LABS INC	**1%**	**N208151**	**001**	Dec 01, 2016

ATROPINE SULFATE
SOLUTION/DROPS;OPHTHALMIC
ATROPINE SULFATE

	+!	BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
TABLET;ORAL
MOTOFEN

	+!	LEGACY PHARMA	0.025MG;1MG	N017744	002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
SOLUTION;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	+!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982

TABLET;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS	**0.025MG;2.5MG**	**A086727**	**001**	
AA		CHARTWELL RX	**0.025MG;2.5MG**	**A207128**	**001**	Oct 21, 2020
AA		LANNETT	**0.025MG;2.5MG**	**A085372**	**001**	
AA		LEADING	**0.025MG;2.5MG**	**A213413**	**001**	Feb 20, 2020
AA		SPECGX LLC	**0.025MG;2.5MG**	**A213335**	**001**	Oct 06, 2020
AA		UNICHEM	**0.025MG;2.5MG**	**A210819**	**001**	Nov 13, 2018
AA		WINDER LABS LLC	**0.025MG;2.5MG**	**A211362**	**001**	Jan 27, 2021

LOMOTIL

AA	**+!**	PFIZER	**0.025MG;2.5MG**	**N012462**	**001**	

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE;INTRAMUSCULAR
DUODOTE

	+!	MMT	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006

AURANOFIN
CAPSULE;ORAL
RIDAURA

	+!	LEGACY PHARMA	3MG	N018689	001	May 24, 1985

AVACINCAPTAD PEGOL SODIUM
SOLUTION;INTRAVITREAL
IZERVAY

	+!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023

AVACOPAN
CAPSULE;ORAL
TAVNEOS

	+!	CHEMOCENTRYX	10MG	N214487	001	Oct 07, 2021

AVANAFIL
TABLET;ORAL
AVANAFIL

AB		HETERO LABS LTD V	**50MG**	**A209266**	**001**	Jun 14, 2024
AB			**100MG**	**A209266**	**002**	Jun 14, 2024
AB			**200MG**	**A209266**	**003**	Jun 14, 2024

STENDRA

AB	**+**	VIVUS LLC	**50MG**	**N202276**	**001**	Apr 27, 2012
AB	**+**		**100MG**	**N202276**	**002**	Apr 27, 2012
AB	**+!**		**200MG**	**N202276**	**003**	Apr 27, 2012

AVAPRITINIB
TABLET;ORAL
AYVAKIT

	+	BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021
	+		50MG	N212608	005	Jun 16, 2021
	+		100MG	N212608	001	Jan 09, 2020
	+		200MG	N212608	002	Jan 09, 2020
	+!		300MG	N212608	003	Jan 09, 2020

AVATROMBOPAG MALEATE
GRANULE;ORAL
DOPTELET SPRINKLE

	+!	AKARX INC	EQ 10MG BASE	N219696	001	Jul 24, 2025

TABLET;ORAL
DOPTELET

	+!	AKARX INC	EQ 20MG BASE	N210238	001	May 21, 2018

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS

EMBLAVEO

+!	ABBVIE	EQ 0.5GM BASE/VIAL;1.5GM/VIAL	N217906	001	Feb 07, 2025

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+!	ABBVIE	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

+!	VERASTEM INC	EQ 0.8MG BASE;EQ 200MG BASE	N219616	001	May 08, 2025

AXITINIB

TABLET;ORAL

AXITINIB

AB		APOTEX	**1MG**	**A211650**	**001**	Oct 30, 2025
AB			**5MG**	**A211650**	**002**	Oct 30, 2025

INLYTA

AB	+	PF PRISM CV	**1MG**	**N202324**	**001**	Jan 27, 2012
AB	+!		**5MG**	**N202324**	**002**	Jan 27, 2012

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		ACCORD HLTHCARE	**100MG/VIAL**	**A207475**	**001**	Jul 02, 2018
AP		ACTAVIS LLC	**100MG/VIAL**	**N208216**	**001**	Apr 29, 2016
AP		AMNEAL	**100MG/VIAL**	**A211549**	**001**	Feb 03, 2022
AP		CIPLA	**100MG/VIAL**	**A209540**	**001**	May 04, 2018
AP		DR REDDYS	**100MG/VIAL**	**A201537**	**001**	Sep 16, 2013
AP		EUGIA PHARMA	**100MG/VIAL**	**A215066**	**001**	Dec 30, 2022
AP		EUROHLTH INTL SARL	**100MG/VIAL**	**A209337**	**001**	Jun 08, 2020
AP		HETERO LABS LTD VI	**100MG/VIAL**	**A215765**	**001**	Oct 15, 2024
AP		JIANGSU HANSOH PHARM	**100MG/VIAL**	**A215905**	**001**	Jun 28, 2023
AP		MEITHEAL	**100MG/VIAL**	**A212128**	**001**	Nov 02, 2020
AP		MSN LABS PVT LTD	**100MG/VIAL**	**A212580**	**001**	May 16, 2024
AP		NATCO PHARMA LTD	**100MG/VIAL**	**A207234**	**001**	Jun 23, 2017
AP		RELIANCE LIFE	**100MG/VIAL**	**A217453**	**001**	May 20, 2025
AP		SHILPA MEDICARE	**100MG/VIAL**	**A207518**	**001**	Sep 29, 2016

VIDAZA

AP	**+!**	BRISTOL-MYERS	**100MG/VIAL**	**N050794**	**001**	May 19, 2004

TABLET;ORAL

ONUREG

+	BRISTOL	200MG	N214120	001	Sep 01, 2020
+!		300MG	N214120	002	Sep 01, 2020

AZATHIOPRINE

TABLET;ORAL

AZASAN

AB		AAIPHARMA LLC	**25MG**	**A075252**	**002**	Feb 03, 2003
AB			**50MG**	**A075252**	**001**	Jun 07, 1999
AB			**75MG**	**A075252**	**003**	Feb 03, 2003
AB			**100MG**	**A075252**	**004**	Feb 03, 2003

AZATHIOPRINE

AB		ALKEM LABS LTD	**25MG**	**A208687**	**001**	Mar 27, 2020
AB			**50MG**	**A208687**	**002**	Mar 27, 2020
AB			**75MG**	**A208687**	**003**	Mar 27, 2020
AB			**100MG**	**A208687**	**004**	Mar 27, 2020
AB		AMNEAL	**50MG**	**A074069**	**001**	Feb 16, 1996
AB			**75MG**	**A074069**	**002**	Nov 02, 2021
AB			**100MG**	**A074069**	**003**	Nov 02, 2021
AB		RISING	**50MG**	**A075568**	**001**	Dec 13, 1999
AB		ZYDUS PHARMS USA	**25MG**	**A077621**	**002**	Sep 05, 2008
AB			**50MG**	**A077621**	**001**	Mar 15, 2007
AB			**75MG**	**A077621**	**003**	Sep 05, 2008
AB			**100MG**	**A077621**	**004**	Sep 05, 2008

IMURAN

AB	**+!**	LEGACY PHARMA	**50MG**	**N016324**	**001**

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

AZATHIOPRINE SODIUM

	!	HIKMA	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

	+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015

CREAM;TOPICAL

AZELEX

	+!	ALMIRALL	20%	N020428	001	Sep 13, 1995

GEL;TOPICAL

AZELAIC ACID

AB		ACTAVIS LABS UT INC	**15%**	**A208011**	**001**	Nov 19, 2018
AB		ENCUBE	**15%**	**A208724**	**001**	Nov 19, 2018
AB		GLENMARK SPECLT	**15%**	**A204637**	**001**	Nov 19, 2018
AB		SUN PHARMA CANADA	**15%**	**A210549**	**001**	Aug 23, 2019

FINACEA

AB	**+!**	LEO PHARMA AS	**15%**	**N021470**	**001**	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALEMBIC	**0.05%**	**A209620**	**001**	Mar 20, 2019
AT		APOTEX	**0.05%**	**A078621**	**001**	Aug 03, 2009
AT		GLAND	**0.05%**	**A210092**	**001**	Feb 25, 2020
AT	!	SANDOZ	**0.05%**	**A202305**	**001**	May 31, 2012
AT		SOMERSET THERAPS LLC	**0.05%**	**A207411**	**001**	Mar 29, 2019

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**0.137MG/SPRAY**	**A208156**	**001**	Aug 18, 2017
AB		AMNEAL	**0.137MG/SPRAY**	**A204660**	**001**	Aug 28, 2017
AB	!	APOTEX INC	**0.137MG/SPRAY**	**A077954**	**001**	Apr 30, 2009
AB		AUROBINDO PHARMA LTD	**0.137MG/SPRAY**	**A212289**	**001**	May 08, 2020
AB		EPIC PHARMA LLC	**0.137MG/SPRAY**	**A207610**	**001**	May 17, 2019
AB		ZYDUS PHARMS	**0.137MG/SPRAY**	**A091409**	**001**	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	!	APOTEX	**0.137MG/SPRAY;0.05MG/SPRAY**	**A207712**	**001**	Apr 28, 2017
AB		PADAGIS ISRAEL	**0.137MG/SPRAY;0.05MG/SPRAY**	**A208111**	**001**	Feb 18, 2021
AB		TEVA PHARMS USA INC	**0.137MG/SPRAY;0.05MG/SPRAY**	**A208436**	**001**	Apr 08, 2025

DYMISTA

AB	**+**	MYLAN SPECIALITY LP	**0.137MG/SPRAY;0.05MG/SPRAY**	**N202236**	**001**	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

	+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
	+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB		ALKEM LABS LTD	**EQ 40MG MEDOXOMIL;12.5MG**	**A217490**	**001**	Jan 21, 2025
AB			**EQ 40MG MEDOXOMIL;25MG**	**A217490**	**002**	Jan 21, 2025

EDARBYCLOR

AB	**+**	AZURITY	**EQ 40MG MEDOXOMIL;12.5MG**	**N202331**	**001**	Dec 20, 2011
AB	**+!**		**EQ 40MG MEDOXOMIL;25MG**	**N202331**	**002**	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE/5ML**	**A209201**	**001**	Oct 09, 2018
AB			**EQ 200MG BASE/5ML**	**A209201**	**002**	Oct 09, 2018
AB		CHARTWELL RX	**EQ 100MG BASE/5ML**	**A065488**	**001**	May 15, 2015
AB			**EQ 200MG BASE/5ML**	**A065488**	**002**	May 15, 2015
AB		EPIC PHARMA LLC	**EQ 100MG BASE/5ML**	**A207531**	**001**	Apr 09, 2018
AB			**EQ 200MG BASE/5ML**	**A207531**	**002**	Apr 09, 2018
AB		PLIVA	**EQ 100MG BASE/5ML**	**A065246**	**002**	Jul 05, 2006
AB			**EQ 200MG BASE/5ML**	**A065246**	**001**	Jul 05, 2006

AZITHROMYCIN							
FOR SUSPENSION;ORAL							
AZITHROMYCIN							
AB		ZHEJIANG POLY PHARM	**EQ 100MG BASE/5ML**	**A217036**	**001**	Jul 27, 2023
AB			**EQ 200MG BASE/5ML**	**A217036**	**002**	Jul 27, 2023
AB		ZYDUS LIFESCIENCES	**EQ 100MG BASE/5ML**	**A211147**	**001**	Jul 31, 2018
AB			**EQ 200MG BASE/5ML**	**A211147**	**002**	Jul 31, 2018
ZITHROMAX							
AB	**+**	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB	**+!**		**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995
INJECTABLE;INJECTION							
AZITHROMYCIN							
AP		EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP		SLATE RUN PHARMA	**EQ 500MG BASE/VIAL**	**A203412**	**001**	Oct 09, 2018
ZITHROMAX							
AP	**+!**	PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997
SOLUTION/DROPS;OPHTHALMIC							
AZASITE							
	+!	THEA PHARMA	1%	N050810	001	Apr 27, 2007
TABLET;ORAL							
AZITHROMYCIN							
AB		ALEMBIC	**EQ 250MG BASE**	**A211791**	**001**	Jan 28, 2020
AB			**EQ 500MG BASE**	**A211792**	**001**	Jan 28, 2020
AB			**EQ 600MG BASE**	**A211793**	**001**	Jan 27, 2020
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A207370**	**001**	Jul 05, 2018
AB			**EQ 500MG BASE**	**A207398**	**001**	Jul 05, 2018
AB		BIONPHARMA	**EQ 250MG BASE**	**A210000**	**001**	Feb 26, 2019
AB			**EQ 500MG BASE**	**A210001**	**001**	Feb 26, 2019
AB			**EQ 600MG BASE**	**A209999**	**001**	Dec 26, 2018
AB		CHARTWELL RX	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB			**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008
AB			**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
AB		CSPC OUYI	**EQ 250MG BASE**	**A208250**	**001**	Apr 17, 2019
AB			**EQ 500MG BASE**	**A208249**	**001**	Oct 25, 2018
AB			**EQ 600MG BASE**	**A207566**	**001**	Sep 24, 2018
AB		LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB			**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB			**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB		PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005
AB	**!**		**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB		SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB			**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB			**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB		STRIDES PHARMA	**EQ 250MG BASE**	**A215772**	**001**	Jul 15, 2022
AB			**EQ 500MG BASE**	**A215773**	**001**	Jul 12, 2022
AB		SUNSHINE	**EQ 250MG BASE**	**A209045**	**001**	Dec 07, 2018
AB			**EQ 500MG BASE**	**A209044**	**001**	Dec 07, 2018
AB			**EQ 600MG BASE**	**A209043**	**001**	Dec 06, 2018
AB		TEVA	**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB		YUNG SHIN PHARM	**EQ 600MG BASE**	**A211068**	**001**	May 08, 2020
ZITHROMAX							
AB	**+**	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB	**+**		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002
AZTREONAM							
FOR SOLUTION;INHALATION							
CAYSTON							
	+!	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010
INJECTABLE;INJECTION							
AZACTAM							
AP	**+!**	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP	**+!**		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986
AZTREONAM							
AP		FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP			**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
AP		HOSPIRA	**1GM/VIAL**	**A206517**	**001**	Nov 08, 2021
AP			**2GM/VIAL**	**A206517**	**002**	Nov 08, 2021

AZTREONAM

INJECTABLE;INJECTION

AZTREONAM

		FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

	!	PADAGIS US	500 UNITS/GM	A061212	001	

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	!	PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

	!	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	**+**	CASPER PHARMA LLC	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050417**	**001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064064**	**001**	Oct 30, 1995
AT		PADAGIS US	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A060764**	**002**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	**!**	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**	**A064046**	**001**	Jan 26, 1995
AT		PADAGIS US	**500 UNITS/GM;10,000 UNITS/GM**	**A065022**	**001**	Feb 27, 2002

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP		AMNEAL	**0.05MG/ML**	**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**	**A091193**	**002**	May 03, 2016
AP			**2MG/ML**	**A091193**	**003**	May 03, 2016
AP		MAIA PHARMS INC	**0.05MG/ML**	**A210777**	**001**	Jan 15, 2021
AP			**0.5MG/ML**	**A210048**	**001**	Sep 11, 2019
AP			**1MG/ML**	**A210315**	**001**	Jul 30, 2019
AP			**2MG/ML**	**A210048**	**002**	Sep 11, 2019
AP		PHARMOBEDIENT	**0.5MG/ML**	**A209592**	**001**	Mar 21, 2018
AP			**1MG/ML**	**A209594**	**001**	Mar 06, 2018
AP			**2MG/ML**	**A209592**	**002**	Mar 21, 2018
AP		RUBICON RESEARCH	**0.5MG/ML**	**A217324**	**001**	Feb 22, 2023
AP			**1MG/ML**	**A217324**	**002**	Feb 22, 2023
AP			**2MG/ML**	**A217324**	**003**	Feb 22, 2023

GABLOFEN

AP	**+!**	PIRAMAL CRITICAL	**0.05MG/ML**	**N022462**	**001**	Nov 19, 2010
AP	**+!**		**0.5MG/ML**	**N022462**	**002**	Nov 19, 2010
AP	**+!**		**1MG/ML**	**N022462**	**004**	Jun 22, 2012
AP	**+!**		**2MG/ML**	**N022462**	**003**	Nov 19, 2010

LIORESAL

AP	**+!**	AMNEAL	**0.05MG/ML**	**N020075**	**003**	Nov 07, 1996
AP	**+!**		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	**+!**		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

SOLUTION;ORAL

BACLOFEN

AA		RUBICON RESEARCH	**10MG/5ML**	**A214445**	**002**	Jun 03, 2025

OZOBAX DS

AA	**+!**	METACEL PHARMS LLC	**10MG/5ML**	**N208193**	**002**	Oct 12, 2023

BACLOFEN

		RUBICON RESEARCH	5MG/5ML	A214445	001	Dec 06, 2024

SUSPENSION;ORAL

BACLOFEN

AB		ANI PHARMS	**25MG/5ML**	**A217252**	**001**	Jun 08, 2023

FLEQSUVY

AB	**+!**	AZURITY	**25MG/5ML**	**N215602**	**001**	Feb 04, 2022

BACLOFEN

TABLET;ORAL

BACLOFEN

AB		ANDAS 5 HOLDING	**5MG**	**A212378**	**003**	Apr 30, 2021
AB			**10MG**	**A212378**	**001**	Oct 09, 2020
AB			**20MG**	**A212378**	**002**	Oct 09, 2020
AB		AUROBINDO PHARMA LTD	**5MG**	**A214099**	**003**	Nov 21, 2025
AB			**10MG**	**A214099**	**001**	Jul 13, 2021
AB			**20MG**	**A214099**	**002**	Jul 13, 2021
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	!		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		LANNETT CO INC	**5MG**	**A077241**	**003**	Sep 22, 2021
AB			**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		MANKIND PHARMA	**5MG**	**A215885**	**001**	Jan 25, 2022
AB			**10MG**	**A215885**	**002**	Jan 25, 2022
AB			**20MG**	**A215885**	**003**	Jan 25, 2022
AB		MICRO LABS	**5MG**	**A217687**	**001**	Nov 08, 2023
AB			**10MG**	**A217687**	**002**	Nov 08, 2023
AB			**20MG**	**A217687**	**003**	Nov 08, 2023
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077088**	**002**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		PH HEALTH	**10MG**	**A077068**	**002**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005
AB		REGCON HOLDINGS	**5MG**	**A214114**	**003**	Sep 19, 2023
AB			**10MG**	**A214114**	**001**	Jul 16, 2021
AB			**20MG**	**A214114**	**002**	Jul 16, 2021
AB		RISING	**5MG**	**A214374**	**001**	Mar 05, 2021
AB			**5MG**	**A217788**	**003**	Oct 24, 2024
AB			**10MG**	**A214374**	**002**	Mar 05, 2021
AB			**10MG**	**A217788**	**001**	Jan 10, 2024
AB			**20MG**	**A214374**	**003**	Mar 05, 2021
AB			**20MG**	**A217788**	**002**	Jan 10, 2024
AB	!	RUBICON RESEARCH	**5MG**	**A209102**	**001**	Nov 28, 2017
AB			**10MG**	**A209102**	**002**	Nov 28, 2017
AB			**15MG**	**A209102**	**004**	Feb 05, 2024
AB			**20MG**	**A209102**	**003**	Nov 28, 2017
AB		SOMERSET THERAPS LLC	**5MG**	**A090334**	**003**	Jan 31, 2025
AB		UNICHEM	**5MG**	**A212067**	**003**	Mar 09, 2023
AB			**10MG**	**A212067**	**001**	Jul 09, 2020
AB			**20MG**	**A212067**	**002**	Jul 09, 2020
AB		YILING	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		ZYDUS LIFESCIENCES	**5MG**	**A211659**	**003**	Apr 17, 2020
AB			**10MG**	**A211659**	**001**	Nov 23, 2018
AB			**15MG**	**A211659**	**004**	Feb 13, 2024
AB			**20MG**	**A211659**	**002**	Nov 23, 2018
BX		HIBROW HLTHCARE	5MG	A211555	003	Nov 30, 2021
BX			10MG	A211555	001	Feb 01, 2019
BX			20MG	A211555	002	Feb 01, 2019

BALOXAVIR MARBOXIL

FOR SUSPENSION;ORAL

XOFLUZA

+!		GENENTECH INC	2MG/ML	N214410	001	Nov 23, 2020
+			30MG/PACKET	N214410	002	May 30, 2025
+!			40MG/PACKET	N214410	003	May 30, 2025

TABLET;ORAL

XOFLUZA

+		GENENTECH INC	40MG	N210854	002	Oct 24, 2018
+!			80MG	N210854	003	Mar 18, 2021

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		APOTEX	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		HIKMA	**750MG**	**A077806**	**001**	Dec 28, 2007
AB		NOVITIUM PHARMA	**750MG**	**A077807**	**001**	Dec 28, 2007
AB		PHARMOBEDIENT	**750MG**	**A219422**	**001**	Apr 03, 2025

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		ZYDUS LIFESCIENCES	**750MG**	**A217592**	**001**	Jun 08, 2023

COLAZAL

AB	**+!**	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000

BARICITINIB

TABLET;ORAL

OLUMIANT

AB	**+**	ELI LILLY AND CO	**1MG**	**N207924**	**002**	Oct 08, 2019
AB	**+**		**2MG**	**N207924**	**001**	May 31, 2018
AB	**+!**		**4MG**	**N207924**	**003**	May 10, 2022
AB		MSN	**1MG**	**A217585**	**001**	Aug 08, 2025
AB			**2MG**	**A217585**	**002**	Aug 08, 2025
AB			**4MG**	**A217585**	**003**	Aug 08, 2025

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+!	BRACCO	98%	N208036	001	Jan 11, 2016

E-Z-PAQUE

+!	BRACCO	96%	N208036	002	Apr 07, 2017

VARIBAR THIN LIQUID

+!	BRACCO	81%	N208036	004	Apr 30, 2019

PASTE;ORAL

VARIBAR PUDDING

	BRACCO	40%	N208844	001	Oct 14, 2016

SUSPENSION;ORAL

ENTERO VU 24%

+!	BRACCO	24%	N208143	008	May 29, 2020

LIQUID E-Z-PAQUE

+!	BRACCO	60%	N208143	003	Mar 01, 2017

READI-CAT 2

+!	BRACCO	2%	N208143	001	Jan 15, 2016

READI-CAT 2 SMOOTHIE

+!	BRACCO	2%	N208143	002	Jan 15, 2016

TAGITOL V

+!	BRACCO	40%	N208143	005	Aug 04, 2017

VARIBAR HONEY

+!	BRACCO	40%	N208143	007	Mar 26, 2018

VARIBAR NECTAR

+!	BRACCO	40%	N208143	004	Jul 07, 2017

VARIBAR THIN HONEY

+!	BRACCO	40%	N208143	006	Jan 23, 2018

TABLET;ORAL

E-Z-DISK

+!	BRACCO	700MG	N219840	001	Aug 01, 2025

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

BECLOMETHASONE DIPROPIONATE

!	AMNEAL IRELAND LTD	0.04MG/INH	A213811	001	Dec 16, 2025
!		0.08MG/INH	A213811	002	Dec 16, 2025

QVAR REDIHALER

+!	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017
+!		0.08MG/INH	N207921	002	Aug 03, 2017

AEROSOL, METERED;NASAL

QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014
+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+	JANSSEN THERAP	EQ 20MG BASE	N204384	002	May 27, 2020
+!		EQ 100MG BASE	N204384	001	Dec 28, 2012

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

	+!	ACROTECH BIOPHARMA	500MG/VIAL	N206256	001	Jul 03, 2014

BELUMOSUDIL MESYLATE

TABLET;ORAL

REZUROCK

	+!	KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021

BELZUTIFAN

TABLET;ORAL

WELIREG

	+!	MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021

BEMPEDOIC ACID

TABLET;ORAL

NEXLETOL

	+!	ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL

NEXLIZET

	+!	ESPERION THERAPS INC	180MG;10MG	N211617	001	Feb 26, 2020

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	**5MG**	**A076820**	**001**	Feb 03, 2006
AB			**10MG**	**A076820**	**002**	Feb 03, 2006
AB			**20MG**	**A076820**	**003**	Feb 03, 2006
AB			**40MG**	**A076820**	**004**	Feb 03, 2006
AB		ANI PHARMS	**5MG**	**A076333**	**001**	Feb 11, 2004
AB			**10MG**	**A076333**	**002**	Feb 11, 2004
AB			**20MG**	**A076333**	**003**	Feb 11, 2004
AB			**40MG**	**A076333**	**004**	Feb 11, 2004
AB		AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB			**20MG**	**A078212**	**002**	May 22, 2008
AB	**!**		**40MG**	**A078212**	**003**	May 22, 2008
AB		CHARTWELL RX	**5MG**	**A076402**	**001**	Feb 11, 2004
AB			**10MG**	**A076402**	**002**	Feb 11, 2004
AB			**20MG**	**A076402**	**003**	Feb 11, 2004
AB			**40MG**	**A076402**	**004**	Feb 11, 2004
AB		COREPHARMA	**5MG**	**A077128**	**001**	Mar 08, 2006
AB			**10MG**	**A077128**	**002**	Mar 08, 2006
AB			**20MG**	**A077128**	**003**	Mar 08, 2006
AB			**40MG**	**A077128**	**004**	Mar 08, 2006
AB		HERITAGE PHARMA	**5MG**	**A076267**	**001**	Feb 11, 2004
AB			**10MG**	**A076267**	**002**	Feb 11, 2004
AB			**20MG**	**A076267**	**003**	Feb 11, 2004
AB			**40MG**	**A076267**	**004**	Feb 11, 2004
AB		PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB			**10MG**	**A076118**	**002**	Feb 11, 2004
AB			**20MG**	**A076118**	**003**	Feb 11, 2004
AB			**40MG**	**A076118**	**004**	Feb 11, 2004
AB		SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB			**10MG**	**A076344**	**002**	Feb 11, 2004
AB			**20MG**	**A076344**	**003**	Feb 11, 2004
AB			**40MG**	**A076344**	**004**	Feb 11, 2004
AB		TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB			**10MG**	**A076211**	**002**	Feb 11, 2004
AB			**20MG**	**A076211**	**003**	Feb 11, 2004
AB			**40MG**	**A076211**	**004**	Feb 11, 2004
AB		ZYDUS LIFESCIENCES	**5MG**	**A078848**	**001**	May 23, 2008
AB			**10MG**	**A078848**	**002**	May 23, 2008
AB			**20MG**	**A078848**	**003**	May 23, 2008
AB			**40MG**	**A078848**	**004**	May 23, 2008

LOTENSIN

AB	**+**	VALIDUS PHARMS	**10MG**	**N019851**	**002**	Jun 25, 1991
AB	**+**		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	**+**		**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS	**5MG;6.25MG**	**A076342**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076342**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076342**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076342**	**004**	Feb 11, 2004
AB		APOTEX	**5MG;6.25MG**	**A078794**	**001**	Aug 21, 2014
AB			**10MG;12.5MG**	**A078794**	**002**	Aug 21, 2014
AB			**20MG;12.5MG**	**A078794**	**003**	Aug 21, 2014
AB			**20MG;25MG**	**A078794**	**004**	Aug 21, 2014
AB		SANDOZ	**5MG;6.25MG**	**A076631**	**001**	Feb 11, 2004
AB			**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076631**	**004**	Feb 11, 2004

LOTENSIN HCT

AB	**+**	VALIDUS PHARMS	**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB	**+**		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	**+!**		**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**25MG/VIAL**	**A205574**	**001**	Dec 07, 2022
AP			**100MG/VIAL**	**A205574**	**002**	Dec 07, 2022
AP		DR REDDYS	**25MG/VIAL**	**A205376**	**001**	Dec 07, 2022
AP			**100MG/VIAL**	**A205376**	**002**	Dec 07, 2022
AP		EUGIA PHARMA	**25MG/VIAL**	**A214739**	**001**	Jun 05, 2023
AP			**100MG/VIAL**	**A214739**	**002**	Jun 05, 2023
AP		MEITHEAL	**25MG/VIAL**	**A211001**	**001**	Jun 05, 2023
AP			**100MG/VIAL**	**A211001**	**002**	Jun 05, 2023

TREANDA

AP	**+!**	CEPHALON	**25MG/VIAL**	**N022249**	**002**	May 01, 2009
AP	**+!**		**100MG/VIAL**	**N022249**	**001**	Mar 20, 2008

SOLUTION;INTRAVENOUS

BELRAPZO

AP	**+!**	EAGLE PHARMS	**100MG/4ML (25MG/ML)**	**N205580**	**001**	May 15, 2018

BENDAMUSTINE HYDROCHLORIDE

AP	**+!**	APOTEX	**100MG/4ML (25MG/ML)**	**N215033**	**001**	Dec 07, 2022
AP	**+!**	BAXTER HLTHCARE CORP	**100MG/4ML (25MG/ML)**	**N216078**	**001**	Dec 15, 2022

BENDEKA

	+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

VIVIMUSTA

	+!	AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

	+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582	001	Dec 14, 2017

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

	+!	BAUSCH LOMB IRELAND	0.4%;0.3%	N211039	001	Mar 09, 2020

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE;ORAL

ZUNVEYL

	+!	ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024
	+		EQ 10MG BASE	N218549	002	Jul 26, 2024
	+		EQ 15MG BASE	N218549	003	Jul 26, 2024

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

	+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
	+!		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		ASCENT PHARMS INC	**100MG**	**A211518**	**001**	Feb 22, 2019
AA			**200MG**	**A211518**	**003**	Feb 22, 2019
AA		BIONPHARMA	**100MG**	**A081297**	**001**	Jan 29, 1993
AA			**200MG**	**A081297**	**002**	Oct 30, 2007
AA		CSPC-NBP PHARM	**100MG**	**A202765**	**002**	Aug 25, 2017
AA			**200MG**	**A202765**	**001**	Jul 31, 2015

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA		HERITAGE PHARMS LABS	**100MG**	**A040682**	**001**	Jul 30, 2007
AA			**200MG**	**A040682**	**002**	Jul 30, 2007
AA		ONESOURCE SPECIALTY	**100MG**	**A091133**	**001**	Jul 30, 2015
AA			**200MG**	**A091133**	**002**	Jul 30, 2015
AA	**!**	PURACAP PHARM LLC	**100MG**	**A206948**	**001**	Dec 19, 2018
AA	**!**		**200MG**	**A206948**	**002**	Dec 19, 2018
AA		THEPHARMANETWORK LLC	**100MG**	**A040627**	**001**	Mar 30, 2007
AA			**200MG**	**A040627**	**002**	Jul 25, 2007
AA		ZYDUS PHARMS USA	**100MG**	**A040597**	**001**	Jun 08, 2007
AA			**200MG**	**A040597**	**002**	Jun 08, 2007

TESSALON

AA	**+**	PFIZER	**100MG**	**N011210**	**001**	

BENZONATATE

	!	THEPHARMANETWORK LLC	150MG	A040627	003	Sep 24, 2014

BENZOYL PEROXIDE

CREAM;TOPICAL

EPSOLAY

	+!	MAYNE PHARMA	5%	N214510	001	Apr 22, 2022

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB	**+!**	BAUSCH	**2.5%;EQ 1.2% BASE**	**N050819**	**001**	Oct 23, 2008

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128**	**001**	Jun 19, 2015
AB		ENCUBE	**2.5%;EQ 1.2% BASE**	**A207194**	**001**	Aug 19, 2019
AB			**5%;EQ 1% BASE**	**A204087**	**001**	Jun 27, 2017
AB			**5%;1.2%**	**A212433**	**001**	Apr 28, 2021
AB	**!**	GLENMARK SPECLT	**5%;EQ 1% BASE**	**A209252**	**001**	Mar 14, 2019
AB		MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443**	**001**	Aug 11, 2009
AB		PADAGIS ISRAEL	**2.5%;EQ 1.2% BASE**	**A205397**	**001**	Sep 09, 2019
AB			**3.75%;EQ 1.2% BASE**	**A209610**	**001**	Aug 20, 2024
AB			**5%;EQ 1% BASE**	**A202440**	**001**	Sep 21, 2015
AB	**!**		**5%;1.2%**	**A090979**	**001**	Jun 26, 2012
AB		SUN PHARMA CANADA	**2.5%;EQ 1.2% BASE**	**A206575**	**001**	Aug 19, 2019
AB			**3.75%;EQ 1.2% BASE**	**A208683**	**001**	Jun 05, 2018
AB			**5%;EQ 1% BASE**	**A208776**	**001**	May 25, 2018
AB			**5%;1.2%**	**A206218**	**001**	Dec 15, 2017
AB		ZYDUS PHARMS	**5%;1.2%**	**A210794**	**001**	Dec 28, 2018

DUAC

AB	**+**	STIEFEL	**5%;1.2%**	**N050741**	**001**	Aug 26, 2002

ONEXTON

AB	**+!**	BAUSCH	**3.75%;EQ 1.2% BASE**	**N050819**	**002**	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN

AB	**+!**	VALEANT INTL	**5%;3%**	**N050557**	**001**	Oct 26, 1984

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		RISING	**5%;3%**	**A065385**	**001**	Sep 18, 2015

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL

TWYNEO

	+!	MAYNE PHARMA	3%;0.1%	N214902	001	Jul 26, 2021

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		CHARTWELL	**50MG**	**A090473**	**002**	Sep 15, 2010
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	**!**	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
		CHARTWELL	25MG	A090473	001	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA	**1MG/ML**	**A209442**	**001**	Oct 14, 2021
AP	!	HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013

TABLET;ORAL

BENZTROPINE MESYLATE

AA		AIPING PHARM INC	**0.5MG**	**A040103**	**001**	Dec 12, 1996
AA			**1MG**	**A040103**	**002**	Dec 12, 1996
AA			**2MG**	**A040103**	**003**	Dec 12, 1996
AA		CHARTWELL RX	**0.5MG**	**A081265**	**003**	Nov 29, 2023
AA			**1MG**	**A081265**	**002**	Jan 23, 1992
AA			**2MG**	**A081265**	**001**	Jan 23, 1992
AA		EPIC PHARMA LLC	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		LEADING	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA	!	NUVO PHARM	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA	!		**1MG**	**A204713**	**002**	Apr 14, 2015
AA	!		**2MG**	**A204713**	**003**	Apr 14, 2015
AA		PH HEALTH	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA		QUAGEN	**0.5MG**	**A212694**	**001**	Feb 11, 2025
AA			**1MG**	**A212694**	**002**	Feb 11, 2025
AA			**2MG**	**A212694**	**003**	Feb 11, 2025

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT		ALEMBIC	**1.5%**	**A214588**	**001**	Apr 05, 2023
AT		APOTEX	**1.5%**	**A206066**	**001**	Mar 05, 2019
AT		MYLAN	**1.5%**	**A206220**	**001**	Mar 18, 2019
AT		SOMERSET THERAPS LLC	**1.5%**	**A217770**	**001**	Aug 14, 2024

BEPREVE

AT	**+!**	BAUSCH AND LOMB INC	**1.5%**	**N022288**	**001**	Sep 08, 2009

BERDAZIMER SODIUM

GEL;TOPICAL

ZELSUVMI

	+!	LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024

BEROTRALSTAT DIHYDROCHLORIDE

CAPSULE;ORAL

ORLADEYO

	+	BIOCRYST	EQ 110MG BASE	N214094	001	Dec 03, 2020
	+!		EQ 150MG BASE	N214094	002	Dec 03, 2020

PELLETS;ORAL

ORLADEYO

	+	BIOCRYST	EQ 72MG BASE/PACKET	N219776	001	Dec 11, 2025
	+		EQ 96MG BASE/PACKET	N219776	002	Dec 11, 2025
	+		EQ 108MG BASE/PACKET	N219776	003	Dec 11, 2025
	+!		EQ 132MG BASE/PACKET	N219776	004	Dec 11, 2025

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BESIVANCE

	+!	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE

FOR SOLUTION;ORAL

BETAINE

AB		ETON	**1GM/SCOOPFUL**	**A210508**	**001**	Jan 28, 2022
AB		NOVITIUM PHARMA	**1GM/SCOOPFUL**	**A214864**	**001**	Nov 23, 2021

CYSTADANE

AB	**+!**	RECORDATI RARE	**1GM/SCOOPFUL**	**N020576**	**001**	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB		AM REGENT	**3MG/ML;EQ 3MG BASE/ML**	**A090747**	**001**	Jul 31, 2009
AB		HIKMA	**3MG/ML;EQ 3MG BASE/ML**	**A077838**	**001**	Jan 17, 2023

CELESTONE SOLUSPAN

AB	**+!**	ORGANON	**3MG/ML;EQ 3MG BASE/ML**	**N014602**	**001**	

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070885**	**001**	Feb 03, 1987
AB		COSETTE	**EQ 0.05% BASE**	**A210217**	**001**	Oct 12, 2018
AB	**+!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**N019137**	**001**	Jun 26, 1984
AB		SUN PHARMA CANADA	**EQ 0.05% BASE**	**A073552**	**001**	Apr 30, 1992
AB		ZYDUS PHARMS	**EQ 0.05% BASE**	**A208885**	**001**	Jan 11, 2019

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A076215**	**001**	Dec 09, 2003
AB		PADAGIS ISRAEL	**EQ 0.05% BASE**	**A076592**	**001**	Dec 09, 2003
AB	**!**	SUN PHARMA CANADA	**EQ 0.05% BASE**	**A076543**	**001**	Dec 09, 2003

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**A075276**	**001**	May 13, 2003
AB		SUN PHARMA CANADA	**EQ 0.05% BASE**	**A076508**	**001**	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		COSETTE	**EQ 0.05% BASE**	**A071467**	**001**	Aug 10, 1987
AB	**!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**A070275**	**001**	Aug 12, 1985
AB		PADAGIS US	**EQ 0.05% BASE**	**A072538**	**001**	Jan 31, 1990

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ENCUBE	**EQ 0.05% BASE**	**A206389**	**001**	Feb 13, 2018
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A077111**	**001**	May 21, 2007
AB	**!**	SUN PHARMA CANADA	**EQ 0.05% BASE**	**A077477**	**001**	May 21, 2007

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A071012**	**001**	Feb 03, 1987
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**N019141**	**001**	Sep 04, 1984
AB		PADAGIS ISRAEL	**EQ 0.05% BASE**	**A215847**	**001**	Apr 12, 2022
AB		TP ANDA HOLDINGS	**EQ 0.05% BASE**	**A215186**	**001**	Feb 18, 2022
AB		ZYDUS LIFESCIENCES	**EQ 0.05% BASE**	**A214048**	**001**	Jul 14, 2020

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A074304**	**001**	Aug 31, 1995
AB		AUROBINDO PHARMA LTD	**EQ 0.05% BASE**	**A218289**	**001**	Apr 10, 2024
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A075373**	**001**	Jun 22, 1999
AB		LUPIN LTD	**EQ 0.05% BASE**	**A209106**	**001**	Dec 18, 2019

DIPROLENE

AB	**+!**	ORGANON	**EQ 0.05% BASE**	**N018741**	**001**	Jul 27, 1983

SPRAY;TOPICAL

SERNIVO

	+!	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

	+!	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015

CREAM;TOPICAL

WYNZORA

	+!	MC2	0.064%;0.005%	N213422	001	Jul 20, 2020

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	**0.064%;0.005%**	**A200174**	**001**	Dec 12, 2014

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N021852**	**001**	Jan 09, 2006

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		COSETTE	**0.064%;0.005%**	**A210765**	**001**	May 11, 2020
AB		SUN PHARMA CANADA	**0.064%;0.005%**	**A213269**	**001**	Sep 02, 2020

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N022185**	**001**	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002**	**001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502**	**001**	Jun 05, 2001
AB	**!**	TARO	**EQ 0.05% BASE;1%**	**A075673**	**001**	May 29, 2001

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516**	**001**	Jun 16, 2005
AB	**!**	SUN PHARMA CANADA	**EQ 0.05% BASE;1%**	**A076493**	**001**	Jul 28, 2004

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		ALEMBIC	**0.12%**	**A215832**	**001**	Aug 22, 2024
AB		PADAGIS ISRAEL	**0.12%**	**A078337**	**001**	Nov 26, 2012
AB	**!**	TARO	**0.12%**	**A208204**	**001**	May 24, 2017
AB		XIROMED	**0.12%**	**A210639**	**001**	Apr 18, 2023

CREAM;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**N018642**	**001**	Mar 24, 1983

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018861**	**001**	Aug 31, 1983

DERMABET

AB		SUN PHARMA CANADA	**EQ 0.1% BASE**	**A072041**	**001**	Jan 06, 1988

VALNAC

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050**	**001**	Oct 10, 1984

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018866**	**001**	Aug 31, 1983
AB		SENORES PHARMS	**EQ 0.1% BASE**	**A070052**	**001**	Jul 31, 1985

OINTMENT;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**A070069**	**001**	Dec 19, 1985

BETAMETHASONE VALERATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051**	**001**	Oct 10, 1984
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018865**	**001**	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		CHARTWELL RX	**EQ 0.5% BASE**	**A078694**	**001**	Nov 16, 2009
AT		MEDIMETRIKS PHARMS	**EQ 0.5% BASE**	**A075630**	**001**	Apr 12, 2001

BETOPTIC

AT	**+!**	SANDOZ	**EQ 0.5% BASE**	**N019270**	**001**	Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

	+!	NOVARTIS	EQ 0.25% BASE	N019845	001	Dec 29, 1989

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

AB		EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	**!**		**20MG**	**A075541**	**002**	Oct 22, 1999
AB		KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB			**20MG**	**A078962**	**002**	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	**!**	AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA	**!**		**10MG**	**A040855**	**002**	Nov 21, 2007
AA	**!**		**25MG**	**A040855**	**003**	Nov 21, 2007
AA	**!**		**50MG**	**A040855**	**004**	Nov 21, 2007
AA		CHARTWELL RX	**5MG**	**A040728**	**002**	Oct 26, 2007
AA			**10MG**	**A040728**	**003**	Oct 26, 2007
AA			**25MG**	**A040728**	**004**	Oct 26, 2007
AA			**50MG**	**A040728**	**001**	Oct 26, 2007
AA		HERITAGE PHARMA	**5MG**	**A091256**	**001**	May 04, 2010

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA			**10MG**	**A091256**	**002**	May 04, 2010
AA			**25MG**	**A091256**	**003**	May 04, 2010
AA			**50MG**	**A091256**	**004**	May 04, 2010
AA		UPSHER SMITH LABS	**5MG**	**A040633**	**001**	Jun 01, 2005
AA			**10MG**	**A040634**	**001**	Jun 01, 2005
AA			**25MG**	**A040635**	**001**	Jun 01, 2005
AA			**50MG**	**A040636**	**001**	Jun 01, 2005

DUVOID

AA		CHARTWELL RX	**10MG**	**A086262**	**001**	
AA			**25MG**	**A086263**	**001**	
AA			**50MG**	**A085882**	**003**	

BEXAGLIFLOZIN

TABLET;ORAL

BRENZAVVY

	+!	THERACOSBIO	20MG	N214373	001	Jan 20, 2023

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		AMNEAL PHARMS NY	**75MG**	**A210105**	**001**	Sep 04, 2018
AB		ANI PHARMS	**75MG**	**A209861**	**001**	May 08, 2018
AB		ASCENT PHARMS INC	**75MG**	**A208628**	**001**	Sep 06, 2024
AB		BIONPHARMA	**75MG**	**A203174**	**001**	Aug 12, 2014
AB		HIKMA	**75MG**	**A203663**	**001**	Jun 16, 2020
AB		TEVA PHARMS USA	**75MG**	**A209931**	**001**	Jan 14, 2021
AB		UPSHER SMITH LABS	**75MG**	**A209886**	**001**	Jul 25, 2018

TARGRETIN

AB	**+!**	BAUSCH	**75MG**	**N021055**	**001**	Dec 29, 1999

GEL;TOPICAL

BEXAROTENE

AB		AMNEAL	**1%**	**A215398**	**001**	Apr 27, 2022

TARGRETIN

AB	**+!**	BAUSCH	**1%**	**N021056**	**001**	Jun 28, 2000

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		ADAPTIS	**50MG**	**A079089**	**001**	Jul 06, 2009
AB		CHARTWELL RX	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		SUN PHARM	**50MG**	**A079110**	**001**	Jul 06, 2009
AB		WATSON LABS TEVA	**50MG**	**A078634**	**001**	Aug 28, 2009

CASODEX

AB	**+!**	ANI PHARMS	**50MG**	**N020498**	**001**	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

BIKTARVY

	+	GILEAD SCIENCES INC	EQ 30MG BASE;120MG;EQ 15MG BASE	N210251	002	Oct 07, 2021
	+!		EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

GEL;OPHTHALMIC

ZOLYMBUS

	+!	THEA PHARMA	0.01%	N217307	001	Sep 09, 2025

IMPLANT;OPHTHALMIC

DURYSTA

	+!	ABBVIE	10MCG	N211911	001	Mar 04, 2020

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AB		AMNEAL	**0.01%**	**A217289**	**001**	Sep 22, 2025
AB		MANKIND PHARMA	**0.01%**	**A218196**	**001**	Mar 17, 2025

LUMIGAN

AB	**+!**	ABBVIE	**0.01%**	**N022184**	**001**	Aug 31, 2010

BIMATOPROST

AT	**!**	ALEMBIC	**0.03%**	**A210263**	**001**	Apr 12, 2019
AT		APOTEX	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT		EUGIA PHARMA	**0.03%**	**A205537**	**001**	Oct 06, 2022
AT		GLAND	**0.03%**	**A210126**	**001**	Mar 22, 2019
AT		MICRO LABS	**0.03%**	**A202505**	**001**	Sep 08, 2020

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT		SANDOZ	**0.03%**	**A202565**	**001**	May 05, 2015
AT		SOMERSET THERAPS LLC	**0.03%**	**A207601**	**001**	Jun 19, 2019

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		ALEMBIC	**0.03%**	**A210515**	**001**	Jan 21, 2020
AT		APOTEX	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		SANDOZ	**0.03%**	**A202719**	**001**	Apr 19, 2016

LATISSE

AT	**+!**	ABBVIE	**0.03%**	**N022369**	**001**	Dec 24, 2008

BINIMETINIB

TABLET;ORAL

MEKTOVI

	+!	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BIRCH TRITERPENES

GEL;TOPICAL

FILSUVEZ

	+!	CHIESI	10%	N215064	001	Dec 18, 2023

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

AB		NOVAST LABS	**140MG;125MG;125MG**	**A217511**	**001**	Jul 03, 2023
AB		PH HEALTH	**140MG;125MG;125MG**	**A205770**	**001**	Mar 06, 2023

PYLERA

AB	**+!**	LABS JUVISE	**140MG;125MG;125MG**	**N050786**	**001**	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

	!	AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		ALEMBIC	**5MG**	**A204891**	**001**	Jan 11, 2017
AB			**10MG**	**A204891**	**002**	Jan 11, 2017
AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		HARMAN FINOCHEM	**5MG**	**A217617**	**001**	Jan 18, 2024
AB			**10MG**	**A217617**	**002**	Jan 18, 2024
AB		NOVITIUM PHARMA	**5MG**	**A215563**	**001**	Oct 29, 2021
AB			**10MG**	**A215563**	**002**	Oct 29, 2021
AB		PRINSTON INC	**5MG**	**A217368**	**001**	Jul 14, 2023
AB			**10MG**	**A217368**	**002**	Jul 14, 2023
AB		RUBICON RESEARCH	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		TP ANDA HOLDINGS	**5MG**	**A075474**	**001**	Oct 25, 2002
AB			**10MG**	**A075474**	**002**	Oct 25, 2002
AB		UNICHEM	**5MG**	**A078635**	**001**	Aug 18, 2009
AB	**!**		**10MG**	**A078635**	**002**	Aug 18, 2009
AB		UNIQUE PHARM	**5MG**	**A219044**	**001**	Apr 16, 2025
AB			**10MG**	**A219044**	**002**	Apr 16, 2025
AB		ZYDUS LIFESCIENCES	**5MG**	**A215680**	**001**	Jul 25, 2022
AB			**10MG**	**A215680**	**002**	Jul 25, 2022
		RUBICON RESEARCH	2.5MG	A075643	003	Mar 07, 2025

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		CADILA	**2.5MG;6.25MG**	**A215666**	**001**	Nov 04, 2022
AB			**5MG;6.25MG**	**A215666**	**002**	Nov 04, 2022
AB			**10MG;6.25MG**	**A215666**	**003**	Nov 04, 2022
AB		EDENBRIDGE PHARMS	**2.5MG;6.25MG**	**A212678**	**001**	Jul 09, 2020
AB			**5MG;6.25MG**	**A212678**	**002**	Jul 09, 2020
AB			**10MG;6.25MG**	**A212678**	**003**	Jul 09, 2020
AB		EPIC PHARMA LLC	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB		GLENMARK PHARMS LTD	**2.5MG;6.25MG**	**A215995**	**001**	Jan 26, 2022

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB			**5MG;6.25MG**	**A215995**	**002**	Jan 26, 2022
AB			**10MG;6.25MG**	**A215995**	**003**	Jan 26, 2022
AB		MYLAN	**2.5MG;6.25MG**	**A075768**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075768**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075768**	**003**	Sep 25, 2000
AB		NOVITIUM PHARMA	**2.5MG;6.25MG**	**A215562**	**001**	Nov 04, 2021
AB			**5MG;6.25MG**	**A215562**	**002**	Nov 04, 2021
AB			**10MG;6.25MG**	**A215562**	**003**	Nov 04, 2021
AB		UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB			**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010
AB			**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	+	TEVA BRANDED PHARM	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB	+		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB	+!		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	+!	SANDOZ	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP		ACCORD HLTHCARE	**250MG/VIAL**	**A206551**	**001**	Nov 22, 2017
AP		DR REDDYS	**250MG/VIAL**	**A201577**	**001**	May 26, 2017
AP		FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP		MEITHEAL	**250MG/VIAL**	**A091602**	**001**	Jul 16, 2018
AP		MYLAN INSTITUTIONAL	**250MG/VIAL**	**A202471**	**001**	Jun 01, 2018
AP		SHUANGCHENG	**250MG/VIAL**	**A210031**	**001**	Oct 23, 2019
AP		SLATE RUN PHARMA	**250MG/VIAL**	**A213078**	**001**	May 28, 2021

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

	+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	!	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP	!		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP		HIKMA	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001
AP		HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP		MEITHEAL	**EQ 15 UNITS BASE/VIAL**	**A205030**	**001**	Apr 20, 2018
AP			**EQ 30 UNITS BASE/VIAL**	**A205030**	**002**	Apr 20, 2018

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP		APOTEX	**3.5MG/VIAL**	**A205533**	**001**	May 02, 2022
AP		DR REDDYS	**3.5MG/VIAL**	**A202963**	**001**	Jul 26, 2022
AP		EUGIA PHARMA	**3.5MG/VIAL**	**A212825**	**001**	May 02, 2022
AP		FRESENIUS KABI USA	**3.5MG/VIAL**	**A209659**	**001**	May 02, 2022
AP		HETERO LABS LTD VI	**3.5MG/VIAL**	**A212204**	**001**	May 03, 2024
AP		HOSPIRA	**3.5MG/VIAL**	**A208460**	**001**	Jul 26, 2022
AP		JIANGSU HANSOH PHARM	**3.5MG/VIAL**	**A215011**	**001**	Jul 26, 2022
AP		MEITHEAL	**3.5MG/VIAL**	**A212958**	**001**	Jul 26, 2022
AP		MSN	**3.5MG/VIAL**	**A209622**	**001**	Jul 26, 2022
AP		PHARMASCIENCE INC	**3.5MG/VIAL**	**A208392**	**001**	May 02, 2022
AP		QILU PHARM HAINAN	**3.5MG/VIAL**	**A210824**	**001**	May 02, 2022
AP		RELIANCE LIFE SCI	**3.5MG/VIAL**	**A211898**	**001**	Oct 11, 2022
AP		SANDOZ	**3.5MG/VIAL**	**A203654**	**001**	Jul 26, 2022
AP		SHUANGCHENG	**3.5MG/VIAL**	**A216528**	**001**	Dec 17, 2025
AP		VILIN BIO MED	**3.5MG/VIAL**	**A218688**	**001**	Jun 02, 2025
AP		ZYDUS PHARMS	**3.5MG/VIAL**	**A210204**	**001**	May 02, 2022

VELCADE

AP	+!	TAKEDA PHARMS USA	**3.5MG/VIAL**	**N021602**	**001**	May 13, 2003

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP		GLAND	**1MG/VIAL**	**A219167**	**001**	Jan 06, 2026
AP			**2.5MG/VIAL**	**A219167**	**002**	Jan 06, 2026
AP	+!	HOSPIRA	**1MG/VIAL**	**N209191**	**001**	May 02, 2022

BORTEZOMIB						
POWDER;INTRAVENOUS, SUBCUTANEOUS						
BORTEZOMIB						
AP	**+!**		**2.5MG/VIAL**	**N209191**	**002**	May 02, 2022
SOLUTION;INTRAVENOUS, SUBCUTANEOUS						
BORTEZOMIB						
	+!	SHILPA	3.5MG/1.4ML (2.5MG/ML)	N212782	001	Aug 26, 2024
BOSENTAN						
TABLET;ORAL						
BOSENTAN						
AB		SUN PHARM	**62.5MG**	**A209324**	**001**	Apr 26, 2019
AB			**125MG**	**A209324**	**002**	Apr 26, 2019
AB		WATSON LABS INC	**62.5MG**	**A207110**	**001**	Apr 26, 2019
AB			**125MG**	**A207110**	**002**	Apr 26, 2019
AB		ZYDUS PHARMS	**62.5MG**	**A207760**	**001**	Apr 26, 2019
AB			**125MG**	**A207760**	**002**	Apr 26, 2019
TRACLEER						
AB	**+**	ACTELION	**62.5MG**	**N021290**	**001**	Nov 20, 2001
AB	**+!**		**125MG**	**N021290**	**002**	Nov 20, 2001
TABLET, FOR SUSPENSION;ORAL						
BOSENTAN						
AB		NATCO PHARMA LTD	**32MG**	**A213154**	**001**	Feb 05, 2025
TRACLEER						
AB	**+!**	ACTELION	**32MG**	**N209279**	**001**	Sep 05, 2017
BOSUTINIB MONOHYDRATE						
CAPSULE;ORAL						
BOSULIF						
	+	PF PRISM CV	EQ 50MG BASE	N217729	001	Sep 26, 2023
	+!		EQ 100MG BASE	N217729	002	Sep 26, 2023
TABLET;ORAL						
BOSULIF						
AB	**+!**	PF PRISM CV	**EQ 100MG BASE**	**N203341**	**001**	Sep 04, 2012
AB	**+**		**EQ 500MG BASE**	**N203341**	**002**	Sep 04, 2012
BOSUTINIB MONOHYDRATE						
AB		ALEMBIC	**EQ 100MG BASE**	**A209543**	**001**	May 23, 2025
AB			**EQ 500MG BASE**	**A209543**	**002**	May 23, 2025
BOSULIF						
	+	PF PRISM CV	EQ 400MG BASE	N203341	003	Oct 27, 2017
BREMELANOTIDE ACETATE						
SOLUTION;SUBCUTANEOUS						
VYLEESI (AUTOINJECTOR)						
	+!	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019
BRENSOCATIB						
TABLET;ORAL						
BRINSUPRI						
	+	INSMED INC	10MG	N217673	001	Aug 12, 2025
	+!		25MG	N217673	002	Aug 12, 2025
BREXPIPRAZOLE						
TABLET;ORAL						
BREXPIPRAZOLE						
AB		ALEMBIC	**0.25MG**	**A213683**	**001**	Jan 13, 2025
AB			**0.5MG**	**A213683**	**002**	Jan 13, 2025
AB			**1MG**	**A213683**	**003**	Jan 13, 2025
AB			**2MG**	**A213683**	**004**	Jan 13, 2025
AB			**3MG**	**A213683**	**005**	Jan 13, 2025
AB			**4MG**	**A213683**	**006**	Jan 13, 2025
REXULTI						
AB	**+**	OTSUKA	**0.25MG**	**N205422**	**001**	Jul 10, 2015
AB	**+**		**0.5MG**	**N205422**	**002**	Jul 10, 2015
AB	**+**		**1MG**	**N205422**	**003**	Jul 10, 2015
AB	**+!**		**2MG**	**N205422**	**004**	Jul 10, 2015
AB	**+**		**3MG**	**N205422**	**005**	Jul 10, 2015
AB	**+**		**4MG**	**N205422**	**006**	Jul 10, 2015

BRIGATINIB
TABLET;ORAL
ALUNBRIG

	+	TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017
	+		90MG	N208772	002	Apr 28, 2017
	+!		180MG	N208772	003	Oct 02, 2017

BRILLIANT BLUE G
SOLUTION;OPHTHALMIC
TISSUEBLUE

	+!	DUTCH OPHTHALMIC	0.025%	N209569	001	Dec 20, 2019

BRIMONIDINE TARTRATE
GEL;TOPICAL

BRIMONIDINE TARTRATE						
AB		PADAGIS ISRAEL	**EQ 0.33% BASE**	**A209158**	**001**	Sep 23, 2021
MIRVASO						
AB	**+!**	GALDERMA LABS LP	**EQ 0.33% BASE**	**N204708**	**001**	Aug 23, 2013

SOLUTION/DROPS;OPHTHALMIC

ALPHAGAN P						
AB	**+!**	ABBVIE	**0.1%**	**N021770**	**001**	Aug 19, 2005
BRIMONIDINE TARTRATE						
AB		ALEMBIC	**0.1%**	**A216909**	**001**	Aug 01, 2023
AB		APOTEX	**0.1%**	**A078480**	**001**	Dec 21, 2022
AB		LUPIN LTD	**0.1%**	**A213215**	**001**	Aug 26, 2024
AB		SANDOZ	**0.1%**	**A203172**	**001**	Mar 04, 2024
AB		SOMERSET THERAPS LLC	**0.1%**	**A216906**	**001**	Aug 09, 2024
ALPHAGAN P						
AT	**+!**	ABBVIE	**0.15%**	**N021262**	**001**	Mar 16, 2001
BRIMONIDINE TARTRATE						
AT		ALEMBIC	**0.15%**	**A215225**	**001**	Mar 29, 2023
AT		APOTEX	**0.15%**	**A078479**	**001**	Jan 31, 2022
AT	**!**	BAUSCH AND LOMB	**0.2%**	**A076260**	**001**	May 28, 2003
AT		MICRO LABS	**0.2%**	**A217846**	**001**	Nov 22, 2023
AT		REGCON HOLDINGS	**0.2%**	**A091691**	**001**	Nov 18, 2014
AT		RISING	**0.2%**	**A076439**	**001**	Mar 14, 2006
AT		SANDOZ	**0.2%**	**A076254**	**001**	Sep 16, 2003
AT			**0.2%**	**A078075**	**001**	Jan 30, 2008
AT		SOMERSET THERAPS LLC	**0.2%**	**A208992**	**001**	Mar 11, 2019
QOLIANA						
AT	**+!**	SANDOZ	**0.15%**	**N021764**	**001**	May 22, 2006

BRIMONIDINE TARTRATE; BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

	+!	ALCON LABS INC	0.2%;1%	N204251	001	Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE						
AB		ALEMBIC	**0.2%;EQ 0.5% BASE**	**A215230**	**001**	Aug 25, 2023
AB		APOTEX	**0.2%;EQ 0.5% BASE**	**A091442**	**001**	Apr 20, 2022
AB		CAPLIN	**0.2%;EQ 0.5% BASE**	**A219093**	**001**	Feb 25, 2025
AB		GLENMARK PHARMS LTD	**0.2%;EQ 0.5% BASE**	**A214987**	**001**	May 16, 2024
AB		REGCON HOLDINGS	**0.2%;EQ 0.5% BASE**	**A201949**	**001**	Oct 04, 2022
AB		SANDOZ	**0.2%;EQ 0.5% BASE**	**A091087**	**001**	Apr 04, 2022
AB		SENTISS	**0.2%;EQ 0.5% BASE**	**A091086**	**001**	Oct 31, 2022
AB		SOMERSET	**0.2%;EQ 0.5% BASE**	**A216114**	**001**	Sep 10, 2024
AB		UPSHER SMITH LABS	**0.2%;EQ 0.5% BASE**	**A215598**	**001**	Dec 12, 2022
COMBIGAN						
AB	**+!**	ABBVIE	**0.2%;EQ 0.5% BASE**	**N021398**	**001**	Oct 30, 2007

BRINCIDOFOVIR
SUSPENSION;ORAL
TEMBEXA

	+!	EMERGENT BIODEFENSE	10MG/ML	N214460	001	Jun 04, 2021

TABLET;ORAL
TEMBEXA

	+!	EMERGENT BIODEFENSE	100MG	N214461	001	Jun 04, 2021

BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC

	AZOPT					
AB	**+!**	SANDOZ	**1%**	**N020816**	**001**	Apr 01, 1998
	BRINZOLAMIDE					
AB		BAUSCH AND LOMB	**1%**	**A204884**	**001**	Aug 18, 2021
AB		WATSON LABS INC	**1%**	**A209406**	**001**	Nov 27, 2020

BRIVARACETAM
SOLUTION;INTRAVENOUS

	BRIVIACT					
	+!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016

SOLUTION;ORAL

	BRIVIACT					
	+!	UCB INC	10MG/ML	N205838	001	May 12, 2016

TABLET;ORAL

	BRIVARACETAM					
AB		MSN	**10MG**	**A214921**	**001**	Nov 13, 2025
AB			**25MG**	**A214921**	**002**	Nov 13, 2025
AB			**50MG**	**A214921**	**003**	Nov 13, 2025
AB			**75MG**	**A214921**	**004**	Nov 13, 2025
AB			**100MG**	**A214921**	**005**	Nov 13, 2025
	BRIVIACT					
AB	**+**	UCB INC	**10MG**	**N205836**	**001**	May 12, 2016
AB	**+**		**25MG**	**N205836**	**002**	May 12, 2016
AB	**+**		**50MG**	**N205836**	**003**	May 12, 2016
AB	**+**		**75MG**	**N205836**	**004**	May 12, 2016
AB	**+!**		**100MG**	**N205836**	**005**	May 12, 2016

BROMFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC

	BROMFENAC SODIUM					
AB		ALEMBIC	**EQ 0.07% ACID**	**A214340**	**001**	Jul 08, 2024
AB		AMNEAL	**EQ 0.07% ACID**	**A210962**	**001**	Jul 29, 2024
AB		APOTEX	**EQ 0.07% ACID**	**A207334**	**001**	Jul 08, 2024
AB		LUPIN LTD	**EQ 0.07% ACID**	**A206027**	**001**	Nov 22, 2023
AB			**EQ 0.075% ACID**	**A211239**	**001**	Feb 02, 2024
	BROMSITE					
AB	**+!**	SUN PHARM	**EQ 0.075% ACID**	**N206911**	**001**	Apr 08, 2016
	PROLENSA					
AB	**+!**	BAUSCH AND LOMB	**EQ 0.07% ACID**	**N203168**	**001**	Apr 05, 2013
	BROMFENAC SODIUM					
AT2	**!**	ALEMBIC	**EQ 0.09% ACID**	**A210560**	**001**	Jun 21, 2019
AT2		EUGIA PHARMA	**EQ 0.09% ACID**	**A204813**	**001**	Mar 18, 2022
AT2		GLAND	**EQ 0.09% ACID**	**A211029**	**001**	Mar 17, 2020
AT2		LUPIN LTD	**EQ 0.09% ACID**	**A202903**	**001**	Aug 15, 2023
AT2		SENTISS	**EQ 0.09% ACID**	**A203395**	**001**	Jan 22, 2014

BROMOCRIPTINE MESYLATE
CAPSULE;ORAL

	BROMOCRIPTINE MESYLATE					
AB	**!**	MYLAN	**EQ 5MG BASE**	**A077226**	**001**	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A078899**	**001**	Jul 30, 2008
	PARLODEL					
AB	**+**	ESJAY PHARMA	**EQ 5MG BASE**	**N017962**	**002**	Mar 01, 1982

TABLET;ORAL

	BROMOCRIPTINE MESYLATE					
AB	**!**	PADAGIS US	**EQ 2.5MG BASE**	**A077646**	**001**	Oct 01, 2008
AB		SANDOZ	**EQ 2.5MG BASE**	**A074631**	**001**	Jan 13, 1998
	PARLODEL					
AB	**+**	ESJAY PHARMA	**EQ 2.5MG BASE**	**N017962**	**001**	
	CYCLOSET					
	+!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SYRUP;ORAL

	BROMFED-DM					
AA	**+**	PHARMOBEDIENT	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001**	Jun 07, 1985
	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA		ACELLA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001**	Sep 20, 2016
AA		ALKEM LABS LTD	**2MG/5ML;10MG/5ML;30MG/5ML**	**A210647**	**001**	Jul 14, 2020
AA		BIONPHARMA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203997**	**001**	Sep 30, 2020
AA		CHARTWELL MOLECULAR	**2MG/5ML;10MG/5ML;30MG/5ML**	**A213125**	**001**	Apr 17, 2020
AA		DR REDDYS LABS SA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A207676**	**001**	Dec 04, 2018

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		HIBROW HLTHCARE	**2MG/5ML;10MG/5ML;30MG/5ML**	**A211170**	**001**	Jun 16, 2020
AA	**!**	PADAGIS US	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001**	Jul 15, 2014
AA		PHARM ASSOC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A202940**	**001**	Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB	**!**	PADAGIS ISRAEL	**2MG/ACTUATION**	**A215328**	**001**	Apr 12, 2023

UCERIS

AB	**+**	SALIX	**2MG/ACTUATION**	**N205613**	**001**	Oct 07, 2014

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

AB		AMNEAL PHARMS	**3MG**	**A206200**	**001**	Jul 31, 2017
AB		AUROBINDO PHARMA USA	**3MG**	**A090410**	**001**	May 16, 2011
AB		DR REDDYS LABS SA	**3MG**	**A206623**	**001**	Apr 08, 2016
AB		RISING	**3MG**	**A207367**	**001**	Apr 07, 2017
AB		ZYDUS PHARMS	**3MG**	**A206134**	**001**	May 04, 2017

ENTOCORT EC

AB	**+!**	PADAGIS US	**3MG**	**N021324**	**001**	Oct 02, 2001

TARPEYO

	+!	CALLIDITAS	4MG	N215935	001	Dec 15, 2021

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+!	CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006
	+!		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDE

AN		CIPLA	**0.25MG/2ML**	**A205710**	**001**	Nov 16, 2017
AN			**0.5MG/2ML**	**A205710**	**002**	Nov 16, 2017
AN			**1MG/2ML**	**A205710**	**003**	Nov 16, 2017
AN		EUGIA PHARMA	**0.5MG/2ML**	**A216667**	**001**	Nov 29, 2023
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001**	Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002**	Jul 31, 2012
AN		LUPIN	**0.5MG/2ML**	**A210897**	**001**	Nov 09, 2018
AN		NEPHRON	**0.25MG/2ML**	**A078202**	**001**	Mar 30, 2009
AN			**0.5MG/2ML**	**A078202**	**002**	Mar 30, 2009
AN		SUN PHARM	**0.25MG/2ML**	**A211922**	**001**	Apr 14, 2021
AN			**0.5MG/2ML**	**A211922**	**002**	Apr 14, 2021
AN			**1MG/2ML**	**A211922**	**003**	Apr 14, 2021
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001**	Nov 18, 2008
AN			**0.5MG/2ML**	**A077519**	**002**	Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001**	Mar 08, 2016

PULMICORT RESPULES

AN	**+**	ASTRAZENECA	**0.25MG/2ML**	**N020929**	**001**	Aug 08, 2000
AN	**+**		**0.5MG/2ML**	**N020929**	**002**	Aug 08, 2000
AN	**+!**		**1MG/2ML**	**N020929**	**003**	Aug 08, 2000

SUSPENSION;ORAL

EOHILIA

	+!	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024

TABLET, EXTENDED RELEASE;ORAL

BUDESONIDE

AB		ACTAVIS LABS FL INC	**9MG**	**A205457**	**001**	Jul 03, 2018
AB		MYLAN	**9MG**	**A208851**	**001**	Sep 17, 2020

UCERIS

AB	**+!**	SALIX	**9MG**	**N203634**	**001**	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

	+!	ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BREYNA

AB		MYLAN	**0.08MG/INH;0.0045MG/INH**	**A211699**	**001**	Mar 15, 2022
AB			**0.16MG/INH;0.0045MG/INH**	**A211699**	**002**	Mar 15, 2022

SYMBICORT

AB	**+!**	ASTRAZENECA	**0.08MG/INH;0.0045MG/INH**	**N021929**	**001**	Jul 21, 2006
AB	**+!**		**0.16MG/INH;0.0045MG/INH**	**N021929**	**002**	Jul 21, 2006

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BREZTRI AEROSPHERE

	+!	ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.009MG/INH	N212122	001	Jul 23, 2020

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		ASPIRO	**0.25MG/ML**	**A218746**	**001**	Feb 27, 2025
AP		GLAND	**0.25MG/ML**	**A216434**	**001**	May 26, 2022
AP		LUPIN LTD	**0.25MG/ML**	**A217153**	**001**	Sep 17, 2024
AP		MSN	**0.25MG/ML**	**A215364**	**001**	Aug 04, 2022
AP		QILU PHARM HAINAN	**0.25MG/ML**	**A219116**	**001**	Sep 19, 2024
AP		SAGENT	**0.25MG/ML**	**A074441**	**001**	Jan 27, 1995
AP	!	WEST-WARD PHARMS INT	**0.25MG/ML**	**A079196**	**001**	Apr 30, 2008

SPRAY;NASAL

ENBUMYST

	+!	CORSTASIS THERAP	0.5MG/SPRAY	N219500	001	Sep 12, 2025

TABLET;ORAL

BUMETANIDE

AB		AMNEAL PHARMS CO	**0.5MG**	**A209724**	**001**	Oct 18, 2017
AB			**1MG**	**A209724**	**002**	Oct 18, 2017
AB			**2MG**	**A209724**	**003**	Oct 18, 2017
AB		APPCO	**0.5MG**	**A212931**	**001**	Sep 18, 2024
AB			**1MG**	**A212931**	**002**	Sep 18, 2024
AB			**2MG**	**A212931**	**003**	Sep 18, 2024
AB		HERITAGE PHARMA	**0.5MG**	**A074225**	**001**	Apr 24, 1995
AB			**1MG**	**A074225**	**002**	Apr 24, 1995
AB			**2MG**	**A074225**	**003**	Apr 24, 1995
AB		JUBILANT GENERICS	**0.5MG**	**A212470**	**001**	Aug 05, 2025
AB			**1MG**	**A212470**	**002**	Aug 05, 2025
AB			**2MG**	**A212470**	**003**	Aug 05, 2025
AB		MANKIND PHARMA	**0.5MG**	**A219291**	**001**	Apr 03, 2025
AB			**1MG**	**A219291**	**002**	Apr 03, 2025
AB			**2MG**	**A219291**	**003**	Apr 03, 2025
AB		RISING	**0.5MG**	**A212019**	**001**	Dec 12, 2019
AB			**1MG**	**A212019**	**002**	Dec 12, 2019
AB			**2MG**	**A212019**	**003**	Dec 12, 2019
AB		RUBICON RESEARCH	**0.5MG**	**A213942**	**001**	Dec 27, 2024
AB			**1MG**	**A213942**	**002**	Dec 27, 2024
AB			**2MG**	**A213942**	**003**	Dec 27, 2024
AB		SANDOZ	**0.5MG**	**A074700**	**001**	Nov 21, 1996
AB			**1MG**	**A074700**	**002**	Nov 21, 1996
AB	!		**2MG**	**A074700**	**003**	Nov 21, 1996
AB		TARO	**0.5MG**	**A213458**	**001**	Jul 24, 2023
AB			**1MG**	**A213458**	**002**	Jul 24, 2023
AB			**2MG**	**A213458**	**003**	Jul 24, 2023
AB		UPSHER SMITH LABS	**0.5MG**	**A209916**	**001**	Jan 23, 2018
AB			**1MG**	**A209916**	**002**	Jan 23, 2018
AB			**2MG**	**A209916**	**003**	Jan 23, 2018
AB		ZYDUS PHARMS	**0.5MG**	**A202900**	**001**	Apr 30, 2018
AB			**1MG**	**A202900**	**002**	Apr 30, 2018
AB			**2MG**	**A202900**	**003**	Apr 30, 2018

BUMEX

AB	+	VALIDUS PHARMS	**0.5MG**	**N018225**	**002**	Feb 28, 1983
AB	+		**1MG**	**N018225**	**001**	Feb 28, 1983
AB	+		**2MG**	**N018225**	**003**	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
	+!		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		ASPIRO	**0.25%**	**A217821**	**001**	Mar 27, 2024
AP			**0.5%**	**A217821**	**002**	Mar 27, 2024
AP			**0.75%**	**A217821**	**003**	Mar 27, 2024
AP		EUGIA PHARMA	**0.25%**	**A207183**	**001**	May 13, 2016
AP			**0.5%**	**A207183**	**002**	May 13, 2016
AP		HIKMA PHARMS	**0.25%**	**A205141**	**001**	Feb 11, 2021

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP			**0.5%**	**A205141**	**002**	Feb 11, 2021
AP		HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP			**0.25%**	**A070590**	**001**	Feb 17, 1987
AP			**0.5%**	**A070584**	**001**	Feb 17, 1986
AP			**0.5%**	**A070597**	**001**	Mar 03, 1987
AP			**0.5%**	**A070609**	**001**	Mar 03, 1987
AP			**0.75%**	**A070585**	**001**	Mar 03, 1987
AP		MEITHEAL	**0.25%**	**A216039**	**001**	Jun 23, 2023
AP			**0.25%**	**A216040**	**001**	Dec 27, 2023
AP			**0.5%**	**A216039**	**002**	Jun 23, 2023
AP			**0.5%**	**A216040**	**002**	Dec 27, 2023
AP			**0.75%**	**A216040**	**003**	Dec 27, 2023
AP		ONESOURCE SPECIALTY	**0.25%**	**A091503**	**001**	Oct 18, 2011
AP			**0.5%**	**A091503**	**002**	Oct 18, 2011
AP		SOMERSET	**0.25%**	**A217792**	**001**	Nov 20, 2023
AP			**0.5%**	**A217792**	**002**	Nov 20, 2023

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		EUGIA PHARMA	**0.25%**	**A203895**	**001**	Nov 05, 2013
AP			**0.5%**	**A203895**	**002**	Nov 05, 2013
AP			**0.75%**	**A203895**	**003**	Nov 05, 2013
AP		HIKMA PHARMS	**0.25%**	**A204842**	**001**	Feb 11, 2021
AP			**0.5%**	**A204842**	**002**	Feb 11, 2021
AP			**0.75%**	**A204842**	**003**	Feb 11, 2021
AP		ONESOURCE SPECIALTY	**0.25%**	**A091487**	**002**	Oct 18, 2011
AP			**0.5%**	**A091487**	**001**	Oct 18, 2011
AP			**0.75%**	**A091487**	**003**	Oct 18, 2011

MARCAINE HYDROCHLORIDE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**001**	
AP	**+!**		**0.5%**	**N016964**	**006**	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**012**	
AP	**+!**		**0.5%**	**N016964**	**005**	
AP	**+!**		**0.75%**	**N016964**	**009**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986
AP	**+**		**0.25%**	**N018304**	**001**	
AP			**0.5%**	**A070553**	**001**	May 21, 1986
AP	**+**		**0.5%**	**N018304**	**002**	
AP			**0.75%**	**A070554**	**001**	May 21, 1986
AP	**+**		**0.75%**	**N018304**	**003**	

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		B BRAUN MEDICAL	**0.75%**	**A209087**	**001**	Apr 02, 2019
AP		HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987
AP		HUONS	**0.75%**	**A212822**	**001**	Dec 30, 2019

MARCAINE

AP	**+!**	HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	**!**	HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988
AP			**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988
	!		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**008**	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**007**	
AP	**+!**		**0.75%;0.0091MG/ML**	**N016964**	**010**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987
AP			**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987
AP	**+**		**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE						
INJECTABLE;INJECTION						
SENSORCAINE						
AP	**+**		**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983
VIVACAINE						
	!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006
BUPIVACAINE; MELOXICAM						
SOLUTION, EXTENDED RELEASE;PERIARTICULAR						
ZYNRELEF KIT						
	+!	HERON THERAPS INC	200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021
	+!		400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021
BUPRENORPHINE						
FILM, EXTENDED RELEASE;TRANSDERMAL						
BUPRENORPHINE						
AB		AMNEAL	**5MCG/HR**	**A211586**	**001**	Apr 14, 2020
AB			**7.5MCG/HR**	**A211586**	**002**	Apr 14, 2020
AB			**10MCG/HR**	**A211586**	**003**	Apr 14, 2020
AB			**15MCG/HR**	**A211586**	**004**	Apr 14, 2020
AB			**20MCG/HR**	**A211586**	**005**	Apr 14, 2020
AB		DIFGEN PHARMS	**5MCG/HR**	**A210272**	**001**	Sep 23, 2021
AB			**7.5MCG/HR**	**A210272**	**002**	Sep 23, 2021
AB			**10MCG/HR**	**A210272**	**003**	Sep 23, 2021
AB			**15MCG/HR**	**A210272**	**004**	Sep 23, 2021
AB			**20MCG/HR**	**A210272**	**005**	Sep 23, 2021
AB		STRIDES PHARMA INTL	**5MCG/HR**	**A207490**	**001**	May 17, 2022
AB			**10MCG/HR**	**A207490**	**002**	May 17, 2022
AB			**15MCG/HR**	**A207490**	**003**	May 17, 2022
AB			**20MCG/HR**	**A207490**	**004**	May 17, 2022
AB		WATSON LABS TEVA	**5MCG/HR**	**A204937**	**001**	Nov 20, 2018
AB			**7.5MCG/HR**	**A204937**	**005**	Jun 29, 2021
AB			**10MCG/HR**	**A204937**	**002**	Nov 20, 2018
AB			**15MCG/HR**	**A204937**	**003**	Nov 20, 2018
AB			**20MCG/HR**	**A204937**	**004**	Nov 20, 2018
BUTRANS						
AB	**+**	PURDUE PHARMA LP	**5MCG/HR**	**N021306**	**001**	Jun 30, 2010
AB	**+**		**7.5MCG/HR**	**N021306**	**005**	Jun 30, 2014
AB	**+**		**10MCG/HR**	**N021306**	**002**	Jun 30, 2010
AB	**+**		**15MCG/HR**	**N021306**	**004**	Jul 25, 2013
AB	**+!**		**20MCG/HR**	**N021306**	**003**	Jun 30, 2010
SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS						
BRIXADI						
	+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023
	+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023
	+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023
	+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023
	+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023
	+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023
	+!		128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023
SUBLOCADE						
	+	INDIVIOR	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
	+!		300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017
BUPRENORPHINE HYDROCHLORIDE						
FILM;BUCCAL						
BELBUCA						
	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015
	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015
	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015
	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015
	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015
	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015
INJECTABLE;INJECTION						
BUPRENORPHINE HYDROCHLORIDE						
AP		HIKMA	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005
AP		HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP	**!**	PH HEALTH	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015
AP		SOMERSET THERAPS LLC	**EQ 0.3MG BASE/ML**	**A219302**	**001**	Jan 30, 2025

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB			**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB		ASCENT PHARMS INC	**EQ 2MG BASE**	**A219401**	**001**	Dec 18, 2025
AB			**EQ 8MG BASE**	**A219401**	**002**	Dec 18, 2025
AB		ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB			**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB		HIKMA	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	**!**		**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009
AB		RHODES PHARMS	**EQ 2MG BASE**	**A207276**	**001**	Mar 27, 2017
AB			**EQ 8MG BASE**	**A207276**	**002**	Mar 27, 2017
AB		RUBICON RESEARCH	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB			**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB		SPECGX LLC	**EQ 2MG BASE**	**A218473**	**001**	Dec 10, 2025
AB			**EQ 8MG BASE**	**A218473**	**002**	Dec 10, 2025
AB		SUN PHARM	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB			**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ALVOGEN	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205954**	**001**	Jan 24, 2019
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205954**	**002**	Jan 24, 2019
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205954**	**003**	Jan 24, 2019
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205954**	**004**	Jan 24, 2019
AB		DIFGEN PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A212756**	**003**	Feb 13, 2025
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A212756**	**004**	Feb 13, 2025
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A212756**	**001**	Jun 02, 2022
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A212756**	**002**	Jun 02, 2022
AB		DR REDDYS LABS SA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205299**	**001**	Jun 14, 2018
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205806**	**001**	Jun 14, 2018
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205299**	**002**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205806**	**002**	Jun 14, 2018
AB		MYLAN TECHNOLOGIES	**EQ 2MG BASE;EQ 0.5MG BASE**	**A211785**	**001**	Apr 17, 2020
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A211785**	**002**	Apr 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207607**	**001**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A207607**	**002**	Jun 14, 2018

SUBOXONE

AB	**+**	INDIVIOR	**EQ 2MG BASE;EQ 0.5MG BASE**	**N022410**	**001**	Aug 30, 2010
AB	**+**		**EQ 4MG BASE;EQ 1MG BASE**	**N022410**	**003**	Aug 10, 2012
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**N022410**	**002**	Aug 30, 2010
AB	**+!**		**EQ 12MG BASE;EQ 3MG BASE**	**N022410**	**004**	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001**	Feb 22, 2013
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002**	Feb 22, 2013
AB		ALKEM LABS LTD	**EQ 2MG BASE;EQ 0.5MG BASE**	**A214930**	**001**	Jun 15, 2021
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A214930**	**002**	Jun 15, 2021
AB		AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001**	Feb 22, 2013
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002**	Feb 22, 2013
AB		ASCENT PHARMS INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A219727**	**001**	Dec 15, 2025
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A219727**	**002**	Dec 15, 2025
AB		ETHYPHARM	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001**	Oct 16, 2015
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002**	Oct 16, 2015
AB		HIKMA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001**	Jun 27, 2014
AB	**!**		**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002**	Jun 27, 2014
AB		LANNETT CO INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001**	Sep 19, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002**	Sep 19, 2016
AB		RHODES PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205601**	**001**	Mar 30, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205601**	**002**	Mar 30, 2020
AB		SPECGX LLC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A207000**	**001**	Dec 13, 2017
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207000**	**002**	Dec 13, 2017
AB		SUN PHARM	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001**	Aug 05, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002**	Aug 05, 2016
AB		WES PHARMA INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A209069**	**001**	Jul 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A209069**	**002**	Jul 17, 2020

ZUBSOLV

	+	EDENBRIDGE PHARMS	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016
	+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013
	+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015
	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014
+!		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+!		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	ALEMBIC	**75MG**	**A203013**	**001**	Jun 08, 2018
AB		**100MG**	**A203013**	**002**	Jun 08, 2018
AB	APNAR PHARMA LP	**75MG**	**A075584**	**001**	Feb 07, 2000
AB		**100MG**	**A075584**	**002**	Feb 07, 2000
AB	APOTEX	**75MG**	**A076143**	**001**	Jan 17, 2006
AB !		**100MG**	**A076143**	**002**	Jan 17, 2006
AB	AUROBINDO PHARMA USA	**75MG**	**A075491**	**001**	Apr 17, 2000
AB		**100MG**	**A075491**	**002**	Apr 17, 2000
AB	CADILA PHARMS LTD	**75MG**	**A208606**	**001**	Jan 16, 2020
AB		**100MG**	**A208606**	**002**	Jan 16, 2020
AB	HERITAGE PHARMA	**75MG**	**A206975**	**001**	Aug 19, 2016
AB		**100MG**	**A206975**	**002**	Aug 19, 2016
AB	MICRO LABS	**75MG**	**A207403**	**001**	Apr 17, 2020
AB		**100MG**	**A207403**	**002**	Apr 17, 2020

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	**100MG**	**A079095**	**001**	Mar 24, 2009
AB1		**150MG**	**A079095**	**002**	Mar 24, 2009
AB1		**200MG**	**A079095**	**003**	Mar 24, 2009
AB1	ANNORA PHARMA	**100MG**	**A216800**	**001**	May 31, 2023
AB1		**150MG**	**A216800**	**002**	May 31, 2023
AB1		**200MG**	**A216800**	**003**	May 31, 2023
AB1	AUROBINDO PHARMA USA	**100MG**	**A090325**	**001**	Apr 08, 2010
AB1		**150MG**	**A090325**	**002**	Apr 08, 2010
AB1		**200MG**	**A090325**	**003**	Apr 08, 2010
AB1	EPIC PHARMA LLC	**100MG**	**A075932**	**001**	Nov 25, 2003
AB1		**150MG**	**A075932**	**002**	Mar 22, 2004
AB1		**200MG**	**A075932**	**003**	Jun 22, 2005
AB1	GRANULES	**100MG**	**A218385**	**001**	Oct 17, 2024
AB1		**150MG**	**A218385**	**002**	Oct 17, 2024
AB1		**200MG**	**A218385**	**003**	Oct 17, 2024
AB1	IMPAX LABS	**100MG**	**A075913**	**001**	Jan 28, 2004
AB1		**150MG**	**A075913**	**002**	Mar 22, 2004
AB1	IPCA LABS LTD	**100MG**	**A207874**	**001**	May 02, 2025
AB1		**150MG**	**A207874**	**002**	May 02, 2025
AB1		**200MG**	**A207874**	**003**	May 02, 2025
AB1	PRINSTON INC	**100MG**	**A202304**	**001**	May 26, 2015
AB1		**150MG**	**A202304**	**002**	May 26, 2015
AB1		**200MG**	**A202304**	**003**	May 26, 2015
AB1	SCIEGEN PHARMS	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1		**150MG**	**A205794**	**002**	Mar 01, 2016
AB1		**200MG**	**A205794**	**003**	Mar 01, 2016
AB1	YICHANG HUMANWELL	**100MG**	**A211347**	**001**	Oct 16, 2018
AB1		**150MG**	**A211347**	**002**	Oct 16, 2018
AB1		**200MG**	**A211347**	**003**	Oct 16, 2018

WELLBUTRIN SR

AB1 +	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1 +		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1 +!		**200MG**	**N020358**	**004**	Jun 14, 2002

BUPROPION HYDROCHLORIDE

AB2 !	ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2	IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2	SANDOZ	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2	SCIEGEN PHARMS	**150MG**	**A206122**	**001**	Aug 17, 2016
AB2	YICHANG HUMANWELL	**150MG**	**A216766**	**001**	Jan 09, 2023
AB3	ACCORD HLTHCARE	**150MG**	**A210497**	**001**	Oct 31, 2018

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3			**300MG**	**A210497**	**002**	Oct 31, 2018
AB3		ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3		ANBISON LAB	**150MG**	**A207224**	**001**	Jun 30, 2017
AB3			**300MG**	**A207224**	**002**	Jun 30, 2017
AB3		ANNORA PHARMA	**150MG**	**A217898**	**001**	Oct 01, 2025
AB3			**300MG**	**A217898**	**002**	Oct 01, 2025
AB3		GRANULES	**150MG**	**A215568**	**001**	Feb 02, 2022
AB3			**300MG**	**A215568**	**002**	Feb 02, 2022
AB3		GRAVITI PHARMS	**150MG**	**A211020**	**001**	Jan 28, 2019
AB3			**300MG**	**A211020**	**002**	Jan 28, 2019
AB3		LUPIN LTD	**150MG**	**A090693**	**001**	Apr 06, 2017
AB3			**300MG**	**A090693**	**002**	Apr 06, 2017
AB3		SCIEGEN PHARMS	**150MG**	**A207479**	**001**	Apr 12, 2017
AB3			**300MG**	**A207479**	**002**	Apr 12, 2017
AB3		SINOTHERAPEUTICS INC	**150MG**	**A208652**	**001**	Aug 21, 2017
AB3			**300MG**	**A208652**	**002**	Aug 21, 2017
AB3		WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3			**300MG**	**A077285**	**002**	Aug 15, 2008
AB3		WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3			**300MG**	**A202189**	**002**	Jan 28, 2022
AB3		YICHANG HUMANWELL	**150MG**	**A210015**	**001**	Jun 14, 2018
AB3			**300MG**	**A210015**	**002**	Jun 14, 2018
AB3		ZHEJIANG JUTAI PHARM	**150MG**	**A211200**	**002**	Apr 29, 2020
AB3			**300MG**	**A211200**	**001**	Sep 05, 2019
AB3		ZYDUS PHARMS	**150MG**	**A201567**	**002**	Jul 23, 2018
AB3			**300MG**	**A201567**	**001**	Jan 17, 2014

WELLBUTRIN XL

AB3	**+**	BAUSCH	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3	**+!**		**300MG**	**N021515**	**002**	Aug 28, 2003

FORFIVO XL

+!	TWI PHARMS	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

+!	AXSOME	105MG;45MG	N215430	001	Aug 18, 2022

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUCAPSOL

	EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025
		10MG	A218628	002	Mar 13, 2025
!		15MG	A218628	003	Mar 13, 2025

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB			**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB			**10MG**	**A202557**	**003**	Dec 30, 2014
AB			**15MG**	**A202557**	**004**	Dec 30, 2014
AB			**30MG**	**A202557**	**005**	Dec 30, 2014
AB		AIPING PHARM INC	**5MG**	**A202087**	**001**	Dec 16, 2015
AB			**7.5MG**	**A202087**	**005**	Jul 03, 2025
AB			**10MG**	**A202087**	**002**	Dec 16, 2015
AB			**15MG**	**A202087**	**003**	Dec 16, 2015
AB			**30MG**	**A202087**	**004**	Dec 16, 2015
AB		AUROBINDO PHARMA LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB			**7.5MG**	**A078246**	**005**	Feb 21, 2020
AB			**10MG**	**A078246**	**002**	Feb 27, 2009
AB			**15MG**	**A078246**	**003**	Feb 27, 2009
AB			**30MG**	**A078246**	**004**	Feb 27, 2009
AB		HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB			**10MG**	**A204582**	**002**	Sep 18, 2015
AB			**15MG**	**A204582**	**003**	Sep 18, 2015

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB			**30MG**	**A204582**	**004**	Sep 18, 2015
AB		IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB			**10MG**	**A074253**	**002**	Mar 28, 2001
AB			**15MG**	**A074253**	**003**	Mar 13, 2002
AB		MYLAN	**5MG**	**A076008**	**003**	Mar 01, 2002
AB			**7.5MG**	**A076008**	**002**	Jul 08, 2013
AB			**10MG**	**A076008**	**004**	Mar 01, 2002
AB			**15MG**	**A076008**	**005**	Mar 28, 2001
AB			**30MG**	**A076008**	**001**	Jun 28, 2001
AB		OXFORD PHARMS	**5MG**	**A075388**	**001**	May 09, 2002
AB			**10MG**	**A075388**	**002**	May 09, 2002
AB			**15MG**	**A075388**	**003**	May 09, 2002
AB			**30MG**	**A078302**	**001**	Dec 17, 2007
AB		RISING	**5MG**	**A075413**	**001**	Mar 19, 2002
AB			**7.5MG**	**A075413**	**004**	Oct 06, 2025
AB			**10MG**	**A075413**	**002**	Mar 19, 2002
AB			**15MG**	**A075413**	**003**	Mar 19, 2002
AB			**30MG**	**A075413**	**005**	Oct 06, 2025
AB		RUBICON RESEARCH	**5MG**	**A075521**	**001**	Apr 05, 2002
AB			**7.5MG**	**A075521**	**004**	Mar 16, 2021
AB			**10MG**	**A075521**	**002**	Apr 05, 2002
AB			**15MG**	**A075521**	**003**	Apr 05, 2002
AB			**30MG**	**A075521**	**005**	Mar 16, 2021
AB		STRIDES PHARMA	**5MG**	**A202330**	**001**	Aug 25, 2014
AB			**7.5MG**	**A202330**	**005**	Feb 17, 2017
AB			**10MG**	**A202330**	**002**	Aug 25, 2014
AB			**15MG**	**A202330**	**003**	Aug 25, 2014
AB			**30MG**	**A202330**	**004**	Aug 25, 2014
AB		TEVA	**5MG**	**A075022**	**001**	Feb 28, 2002
AB			**10MG**	**A075022**	**002**	Feb 28, 2002
AB			**15MG**	**A075022**	**003**	Feb 28, 2002
AB			**30MG**	**A075022**	**004**	Mar 25, 2004
AB		UNICHEM	**5MG**	**A210907**	**001**	Nov 14, 2019
AB			**10MG**	**A210907**	**002**	Nov 14, 2019
AB	**!**		**15MG**	**A210907**	**003**	Nov 14, 2019
AB			**30MG**	**A210907**	**004**	Nov 14, 2019
AB		ZYDUS PHARMS	**5MG**	**A078888**	**001**	Feb 07, 2014
AB			**7.5MG**	**A078888**	**005**	Mar 21, 2023
AB			**10MG**	**A078888**	**002**	Feb 07, 2014
AB			**15MG**	**A078888**	**003**	Feb 07, 2014
AB			**30MG**	**A078888**	**004**	Feb 07, 2014
BX		EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019
BX			7.5MG	A208972	002	Apr 16, 2019
BX			10MG	A208972	003	Apr 16, 2019
BX			15MG	A208972	004	Apr 16, 2019
BX			30MG	A208972	005	Apr 16, 2019
BX		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018
BX			7.5MG	A209696	002	May 03, 2018
BX			10MG	A209696	003	May 03, 2018
BX			15MG	A209696	004	May 03, 2018
BX			30MG	A209696	005	May 03, 2018

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		ACCORD HLTHCARE INC	**6MG/ML**	**A210148**	**001**	Feb 22, 2019
AP		AMNEAL	**6MG/ML**	**A209580**	**001**	Dec 18, 2017
AP		HOSPIRA	**6MG/ML**	**A205672**	**001**	Jul 31, 2018
AP		MEITHEAL	**6MG/ML**	**A212127**	**001**	Oct 23, 2020
AP		MYLAN INSTITUTIONAL	**6MG/ML**	**A208536**	**001**	Nov 20, 2017
AP		PHARMASCIENCE INC	**6MG/ML**	**A207050**	**001**	Mar 24, 2017
AP		PRINSTON INC	**6MG/ML**	**A215235**	**001**	Sep 11, 2024
AP		SHILPA	**6MG/ML**	**A210931**	**001**	Apr 18, 2019

BUSULFEX

AP	**+!**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001**	Feb 04, 1999

TABLET;ORAL

MYLERAN

	+!	WAYLIS THERAP	2MG	N009386	001

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

GYNAZOLE-1

	!	PADAGIS ISRAEL	2%	A200923	001	May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

AP		HIKMA	**2MG/ML**	**A075046**	**001**	Aug 12, 1998
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001**	May 01, 2009
AP			**2MG/ML**	**A078400**	**002**	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		HIKMA	**1MG/ML**	**A075045**	**001**	Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002**	Aug 12, 1998
AP	**!**	HOSPIRA	**1MG/ML**	**A074626**	**001**	Jan 23, 1997
AP	**!**		**2MG/ML**	**A074626**	**002**	Jan 23, 1997

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE

AB		APOTEX	**1MG/SPRAY**	**A075499**	**001**	Dec 04, 2002
AB	**!**	HIKMA	**1MG/SPRAY**	**A075824**	**001**	Mar 12, 2002

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

AP		ACCORD HLTHCARE	**60MG/1.5ML (40MG/ML)**	**A207693**	**001**	Oct 26, 2022
AP		DR REDDYS	**60MG/1.5ML (40MG/ML)**	**A207718**	**001**	Feb 10, 2023

JEVTANA KIT

AP	**+!**	SANOFI AVENTIS US	**60MG/1.5ML (40MG/ML)**	**N201023**	**001**	Jun 17, 2010

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB		AMNEAL	**0.5MG**	**A218618**	**001**	Jun 26, 2024
AB	**!**	INGENUS PHARMS LLC	**0.5MG**	**A204735**	**001**	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750**	**001**	Mar 07, 2007
AB		SOMERSET THERAPS LLC	**0.5MG**	**A218109**	**001**	Sep 09, 2024
AB		STRIDES PHARMA INTL	**0.5MG**	**A076310**	**001**	Dec 29, 2005

CABOTEGRAVIR

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

APRETUDE

	+!	VIIV HLTHCARE	600MG/3ML (200MG/ML)	N215499	001	Dec 20, 2021

CABOTEGRAVIR SODIUM

TABLET;ORAL

VOCABRIA

	+!	VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT

	+!	VIIV HLTHCARE	400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021
	+!		600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

	+	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+!		EQ 80MG BASE	N203756	002	Nov 29, 2012

TABLET;ORAL

CABOMETYX

	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016
	+		EQ 40MG BASE	N208692	002	Apr 25, 2016
	+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT

AP	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**001**	Sep 21, 1999

CAFFEINE CITRATE

AP		AM REGENT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906**	**001**	May 15, 2007
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233**	**001**	Sep 21, 2006

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997**	**001**	Jul 20, 2007
AP		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A207400**	**001**	Dec 14, 2017
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827**	**001**	Aug 29, 2012

SOLUTION;ORAL

CAFFEINE CITRATE

AA	**!**	EXELA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304**	**001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002**	**001**	Jan 31, 2008
AA		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213202**	**001**	Dec 16, 2019
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102**	**001**	Aug 29, 2012

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

	+!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

	!	ANDA REPOSITORY	100MG;1MG	A040590	001	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

	+!	EIRGEN	0.03MG	N208010	001	Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

	+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010

CREAM;TOPICAL

CALCIPOTRIENE

AB		GLENMARK SPECLT	**0.005%**	**A205772**	**001**	Jun 09, 2015

DOVONEX

AB	**+!**	LEO PHARMA AS	**0.005%**	**N020554**	**001**	Jul 22, 1996

OINTMENT;TOPICAL

CALCIPOTRIENE

AB	**!**	GLENMARK PHARMS INC	**0.005%**	**A090633**	**001**	Mar 24, 2010

DOVONEX

AB	**+**	LEO PHARMA AS	**0.005%**	**N020273**	**001**	Dec 29, 1993

SOLUTION;TOPICAL

CALCIPOTRIENE

AT		CHARTWELL RX	**0.005%**	**A207163**	**001**	Dec 26, 2017
AT	**!**	COSETTE	**0.005%**	**A078468**	**001**	Mar 24, 2011
AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001**	May 06, 2008

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP		AMNEAL	**200 IU/ML**	**A216294**	**001**	Sep 26, 2025
AP		CIPLA	**200 IU/ML**	**A213766**	**001**	Sep 20, 2024
AP		CUSTOPHARM INC	**200 IU/ML**	**A212416**	**001**	May 14, 2021
AP		DR REDDYS	**200 IU/ML**	**A215715**	**001**	Apr 11, 2024
AP		FRESENIUS KABI USA	**200 IU/ML**	**A212675**	**001**	Dec 05, 2024
AP		PH HEALTH	**200 IU/ML**	**A209358**	**001**	Nov 10, 2021
AP		SAGENT	**200 IU/ML**	**A219196**	**001**	Jul 09, 2025

MIACALCIN

AP	**+!**	MYLAN IRELAND LTD	**200 IU/ML**	**N017808**	**002**	Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON

AB	**!**	APOTEX INC	**200 IU/SPRAY**	**A076396**	**001**	Nov 17, 2008
AB		PH HEALTH	**200 IU/SPRAY**	**A076979**	**001**	Jun 08, 2009

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		AMNEAL PHARMS	**0.25MCG**	**A203289**	**002**	Jun 14, 2017
AB			**0.5MCG**	**A203289**	**001**	Jun 14, 2017
AB		BIONPHARMA	**0.25MCG**	**A091174**	**001**	May 24, 2013
AB			**0.5MCG**	**A091174**	**002**	May 24, 2013
AB		HIKMA	**0.25MCG**	**A076917**	**001**	Mar 27, 2006
AB		ONESOURCE SPECIALTY	**0.25MCG**	**A091356**	**001**	Dec 12, 2014
AB	**!**		**0.5MCG**	**A091356**	**002**	Dec 12, 2014
AB		TEVA	**0.25MCG**	**A075765**	**001**	Oct 12, 2001
AB			**0.5MCG**	**A075765**	**002**	Oct 12, 2001

CALCITRIOL

CAPSULE;ORAL

ROCALTROL

AB	**+**	ESJAY PHARMA	**0.25MCG**	**N018044**	**001**	
AB	**+**		**0.5MCG**	**N018044**	**002**	

INJECTABLE;INJECTION

CALCITRIOL

AP		GLAND	**0.001MG/ML**	**A211030**	**001**	Feb 03, 2020
AP	**!**	LONG GROVE PHARMS	**0.001MG/ML**	**A078066**	**001**	Jan 29, 2008

OINTMENT;TOPICAL

VECTICAL

	+!	GALDERMA LABS LP	3MCG/GM	N022087	001	Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		ANDA REPOSITORY	**1MCG/ML**	**A203973**	**001**	Jul 28, 2023
AA		HIKMA	**1MCG/ML**	**A076242**	**001**	Jul 18, 2003
AA		RISING	**1MCG/ML**	**A209798**	**001**	Nov 21, 2018

ROCALTROL

AA	**+!**	ESJAY PHARMA	**1MCG/ML**	**N021068**	**001**	Nov 20, 1998

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		CHARTWELL RX	**667MG**	**A091312**	**001**	Jun 01, 2012
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001**	Jun 29, 2015
AB		HIKMA	**667MG**	**A077728**	**001**	Feb 26, 2008
AB	**!**	INVAGEN PHARMS	**667MG**	**A203135**	**001**	Feb 07, 2013
AB		LUPIN LTD	**667MG**	**A202127**	**001**	Jul 09, 2015
AB		MPP PHARMA	**667MG**	**A203179**	**001**	Oct 26, 2015
AB		SQUARE PHARMS	**667MG**	**A217205**	**001**	Mar 13, 2023
AB		SUVEN PHARMS	**667MG**	**A211038**	**001**	Feb 21, 2020

TABLET;ORAL

CALCIUM ACETATE

AB	**!**	CHARTWELL MOLECULAR	**667MG**	**A202420**	**001**	Feb 05, 2013
AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001**	Jan 22, 2015
AB		PADAGIS US	**667MG**	**A091561**	**001**	Apr 13, 2011

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	**100MG/ML**	**A209088**	**001**	Jul 27, 2017
AP		AMNEAL	**100MG/ML**	**A217524**	**001**	Jul 08, 2024
AP		EXTROVIS	**100MG/ML**	**A219342**	**001**	Nov 27, 2024
AP		INTL MEDICATION SYS	**100MG/ML**	**A203477**	**001**	May 09, 2018
AP		MEDEFIL INC	**100MG/ML**	**A211553**	**001**	May 01, 2019
AP		SOMERSET	**100MG/ML**	**A218133**	**001**	Dec 17, 2024
AP		SQUARE PHARMS PLC	**100MG/ML**	**A217463**	**001**	Sep 29, 2025

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100MG/ML**	**N021117**	**001**	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

BSS PLUS

	+!	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N018469	001	

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09	N021703	003	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

			GM/1000ML;6.46GM/1000ML (5000ML)			

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**002**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**004**	Dec 04, 1992

DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**012**	Jan 10, 1989

DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**013**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**015**	Jul 11, 1990

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**004**	
AT	**+**		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**005**	
AT	**+**		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	VANTIVE US HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT	**+**		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**003**	Dec 04, 1992

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	

DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER

+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	**+**	OTSUKA ICU MEDCL	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**		

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988	

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**		

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985	
AP			**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985	
AP	**+**	OTSUKA ICU MEDCL	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988	

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985	

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985	
		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985	

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895	001	Jul 20, 1984	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT		B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010	

BSS

AT	**+!**	ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10	N207026	001	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000
AT		FRESENIUS KABI USA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A214623**	**001**	Feb 18, 2022

PLEGISOL IN PLASTIC CONTAINER

AT	**+!**	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		OTSUKA ICU MEDCL	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		OTSUKA ICU MEDCL	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		FRESENIUS KABI USA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**A209338**	**001**	Jan 28, 2019
AP		OTSUKA ICU MEDCL	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	**+!**		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	**+!**	OTSUKA ICU MEDCL	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

AP		AMNEAL	**1GM/10ML (100MG/ML)**	**A216611**	**001**	May 10, 2024
AP			**5GM/50ML (100MG/ML)**	**A216611**	**002**	May 10, 2024
AP			**10GM/100ML (100MG/ML)**	**A216611**	**003**	May 10, 2024
AP		B BRAUN MEDICAL	**10GM/100ML (100MG/ML)**	**A216541**	**001**	Aug 21, 2023
AP	**+!**	FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**N208418**	**001**	Jun 15, 2017
AP	**+!**		**5GM/50ML (100MG/ML)**	**N208418**	**002**	Jun 15, 2017
AP	**+!**		**10GM/100ML (100MG/ML)**	**N208418**	**003**	Jun 15, 2017
AP		NIVAGEN PHARMS INC	**1GM/10ML (100MG/ML)**	**A213071**	**001**	Oct 14, 2022
AP			**5GM/50ML (100MG/ML)**	**A213071**	**002**	Oct 19, 2023
AP			**10GM/100ML (100MG/ML)**	**A213071**	**003**	Apr 30, 2024
AP		SOMERSET	**5GM/50ML (100MG/ML)**	**A217689**	**001**	Oct 19, 2023
AP			**10GM/100ML (100MG/ML)**	**A217689**	**002**	Oct 19, 2023

CALCIUM GLUCONATE IN SODIUM CHLORIDE

AP	**!**	AMNEAL	**1GM/50ML (20MG/ML)**	**A217174**	**001**	Sep 05, 2023
AP	**!**		**2GM/100ML (20MG/ML)**	**A217174**	**002**	Sep 05, 2023
AP		SAGENT	**1GM/50ML (20MG/ML)**	**A219619**	**001**	Dec 30, 2025
AP			**2GM/100ML (20MG/ML)**	**A219619**	**002**	Dec 30, 2025
	+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
	+!		1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021
	+!		2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION;ORAL

XYWAV

+!	JAZZ	0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+!		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
+		50MG;1GM	N204353	002	Aug 08, 2014
+		150MG;500MG	N204353	003	Aug 08, 2014
+!		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+!		150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	**+**	ANI PHARMS	**4MG**	**N020838**	**001**	Jun 04, 1998
AB	**+**		**8MG**	**N020838**	**002**	Jun 04, 1998
AB	**+**		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	**+!**		**32MG**	**N020838**	**004**	Jun 04, 1998

CANDESARTAN CILEXETIL

AB		ALEMBIC	**4MG**	**A210302**	**001**	Dec 04, 2018
AB			**8MG**	**A210302**	**002**	Dec 04, 2018
AB			**16MG**	**A210302**	**003**	Dec 04, 2018
AB			**32MG**	**A209119**	**001**	Jun 20, 2017
AB		MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB			**8MG**	**A203813**	**002**	Dec 05, 2016
AB			**16MG**	**A203813**	**003**	Dec 05, 2016
AB			**32MG**	**A203813**	**004**	Dec 05, 2016
AB		MYLAN	**4MG**	**A078702**	**001**	May 03, 2013
AB			**8MG**	**A078702**	**002**	May 03, 2013
AB			**16MG**	**A078702**	**003**	May 03, 2013
AB			**32MG**	**A078702**	**004**	May 03, 2013
AB		PRINSTON INC	**8MG**	**A206233**	**001**	Aug 21, 2023
AB			**16MG**	**A206233**	**002**	Aug 21, 2023
AB			**32MG**	**A206233**	**003**	Aug 21, 2023
AB		ZYDUS LIFESCIENCES	**4MG**	**A091390**	**001**	Aug 23, 2017
AB			**8MG**	**A091390**	**002**	Aug 23, 2017
AB			**16MG**	**A091390**	**003**	Aug 23, 2017
AB			**32MG**	**A091390**	**004**	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	**+**	ANI PHARMS	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB	**+**		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	**+!**		**32MG;25MG**	**N021093**	**003**	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		ANDA REPOSITORY	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB			**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB			**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB		MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015
AB			**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB			**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB		PHARMOBEDIENT	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB			**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB			**32MG;25MG**	**A090704**	**003**	Dec 04, 2012
AB		PRINSTON INC	**16MG;12.5MG**	**A207455**	**001**	Apr 11, 2018
AB			**32MG;12.5MG**	**A207455**	**002**	Apr 11, 2018
AB			**32MG;25MG**	**A207455**	**003**	Apr 11, 2018
AB		ZYDUS LIFESCIENCES	**16MG;12.5MG**	**A203466**	**001**	Nov 27, 2017
AB			**32MG;12.5MG**	**A203466**	**002**	Nov 27, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB			**32MG;25MG**	**A203466**	**003**	Nov 27, 2017

CANGRELOR

POWDER;INTRAVENOUS

CANGRELOR

AP		GLAND	**50MG/VIAL**	**A213551**	**001**	Aug 11, 2025

KENGREAL

AP	**+!**	CHIESI	**50MG/VIAL**	**N204958**	**001**	Jun 22, 2015

CANNABIDIOL

SOLUTION;ORAL

EPIDIOLEX

	+!	JAZZ PHARMS RES	100MG/ML	N210365	001	Sep 28, 2018

CANTHARIDIN

SOLUTION;TOPICAL

YCANTH

	+!	VERRICA PHARMS	0.7%	N212905	001	Jul 21, 2023

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB			**500MG**	**A202593**	**002**	Apr 23, 2015
AB		ALKEM LABS LTD	**150MG**	**A207652**	**001**	Nov 24, 2017
AB			**500MG**	**A207652**	**002**	Nov 24, 2017
AB		DR REDDYS	**150MG**	**A204345**	**001**	Dec 04, 2020
AB			**500MG**	**A204345**	**002**	Dec 04, 2020
AB		EUGIA PHARMA	**150MG**	**A210604**	**001**	Apr 17, 2018
AB			**500MG**	**A210604**	**002**	Apr 17, 2018
AB		HETERO LABS LTD V	**150MG**	**A210203**	**001**	Mar 05, 2024
AB			**500MG**	**A210203**	**002**	Mar 05, 2024
AB		MSN	**150MG**	**A209365**	**001**	Jul 02, 2018
AB			**500MG**	**A209365**	**002**	Jul 02, 2018
AB		RELIANCE LIFE	**150MG**	**A211724**	**001**	Apr 27, 2020
AB			**500MG**	**A211724**	**002**	Apr 27, 2020
AB		RISING	**150MG**	**A090943**	**001**	Aug 08, 2014
AB			**500MG**	**A090943**	**002**	Aug 08, 2014
AB		SHILPA	**150MG**	**A207456**	**001**	Dec 12, 2016
AB			**500MG**	**A207456**	**002**	Dec 12, 2016
AB		TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB			**500MG**	**A091649**	**002**	Sep 16, 2013

XELODA

AB	**+**	CHEPLAPHARM	**150MG**	**N020896**	**001**	Apr 30, 1998
AB	**+!**		**500MG**	**N020896**	**002**	Apr 30, 1998

CAPECITABINE

BX		TEYRO LABS	150MG	A217237	001	Oct 23, 2023
BX			500MG	A217237	002	Oct 23, 2023

CAPIVASERTIB

TABLET;ORAL

TRUQAP

	+	ASTRAZENECA	160MG	N218197	001	Nov 16, 2023
	+!		200MG	N218197	002	Nov 16, 2023

CAPMATINIB HYDROCHLORIDE

TABLET;ORAL

TABRECTA

	+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020
	+!		EQ 200MG BASE	N213591	002	May 06, 2020

CAPSAICIN

PATCH;TOPICAL

QUTENZA

	+!	AVERITAS	8%	N022395	001	Nov 16, 2009

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB		AIPING PHARM INC	**12.5MG**	**A214442**	**001**	Jan 27, 2023
AB			**25MG**	**A214442**	**002**	Jan 27, 2023
AB			**50MG**	**A214442**	**003**	Jan 27, 2023
AB			**100MG**	**A214442**	**004**	Jan 27, 2023

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB		AJANTA PHARMA LTD	**12.5MG**	**A212809**	**001**	Dec 13, 2019
AB			**25MG**	**A212809**	**002**	Dec 13, 2019
AB			**50MG**	**A212809**	**003**	Dec 13, 2019
AB			**100MG**	**A212809**	**004**	Dec 13, 2019
AB		ANDAS 5 HOLDING	**12.5MG**	**A074677**	**004**	May 30, 1997
AB			**25MG**	**A074677**	**002**	May 30, 1997
AB			**50MG**	**A074677**	**001**	May 30, 1997
AB			**100MG**	**A074677**	**003**	May 30, 1997
AB		COREPHARMA	**12.5MG**	**A074737**	**001**	Oct 28, 1998
AB			**25MG**	**A074737**	**002**	Oct 28, 1998
AB			**50MG**	**A074737**	**003**	Oct 28, 1998
AB			**100MG**	**A074737**	**004**	Oct 28, 1998
AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB	**!**		**100MG**	**A074505**	**004**	Feb 13, 1996
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		WOCKHARDT BIO AG	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	RISING	25MG;15MG	A074896	001	Dec 29, 1997
!		25MG;25MG	A074896	002	Dec 29, 1997
!		50MG;15MG	A074896	004	Dec 29, 1997
		50MG;25MG	A074896	003	Dec 29, 1997

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

+!	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ANI PHARMS	**100MG**	**A076697**	**001**	May 20, 2011
AB			**200MG**	**A076697**	**002**	May 20, 2011
AB			**300MG**	**A076697**	**003**	May 20, 2011
AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB	**+**	TAKEDA PHARMS USA	**100MG**	**N020712**	**003**	Sep 30, 1997
AB	**+**		**200MG**	**N020712**	**001**	Sep 30, 1997
AB	**+!**		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+!		300MG	N021710	003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB		CHARTWELL RX	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002
AB		NOVITIUM PHARMA	**100MG/5ML**	**A214277**	**001**	Oct 06, 2022

TEGRETOL

AB	**+!**	NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987

TERIL

AB		TARO	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE

AB		ALEMBIC	**200MG**	**A216623**	**001**	Apr 16, 2025
AB		APOTEX	**200MG**	**A075948**	**001**	Feb 27, 2002
AB		BIONPHARMA	**200MG**	**A218221**	**001**	Feb 16, 2024

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

AB		TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB		TORRENT PHARMS	**200MG**	**A077272**	**002**	Dec 07, 2005
AB		UNICHEM	**200MG**	**A213284**	**001**	Aug 22, 2022

EPITOL

AB		TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986

TEGRETOL

AB	**+!**	NOVARTIS	**200MG**	**N016608**	**001**	

CARBAMAZEPINE

BX		UMEDICA	100MG	A207798	001	Apr 15, 2020
BX			200MG	A207798	002	Apr 15, 2020

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB		TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000
AB		TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001

EPITOL

AB		TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992

CARBAMAZEPINE

	!	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ALEMBIC	**100MG**	**A219939**	**001**	Jul 25, 2025
AB			**200MG**	**A219939**	**002**	Jul 25, 2025
AB			**400MG**	**A219939**	**003**	Jul 25, 2025
AB		ALKEM LABS LTD	**100MG**	**A217277**	**001**	Jan 14, 2025
AB			**200MG**	**A217277**	**002**	Jan 14, 2025
AB			**400MG**	**A217277**	**003**	Jan 14, 2025
AB		ANBISON LAB	**100MG**	**A212948**	**001**	Sep 30, 2021
AB			**200MG**	**A212948**	**002**	Sep 30, 2021
AB			**400MG**	**A212948**	**003**	Sep 30, 2021
AB		CSPC OUYI	**100MG**	**A213311**	**001**	Apr 13, 2021
AB			**200MG**	**A213311**	**002**	Apr 13, 2021
AB			**400MG**	**A213311**	**003**	Apr 13, 2021
AB		NOVAST LABS	**100MG**	**A216404**	**001**	Dec 02, 2022
AB			**200MG**	**A216404**	**002**	Dec 02, 2022
AB			**400MG**	**A216404**	**003**	Dec 02, 2022
AB		SCIECURE PHARMA INC	**100MG**	**A216235**	**001**	Mar 02, 2023
AB			**200MG**	**A216235**	**002**	Mar 02, 2023
AB			**400MG**	**A216235**	**003**	Mar 02, 2023
AB		TARO	**100MG**	**A078115**	**001**	Mar 31, 2009
AB			**200MG**	**A078115**	**002**	Mar 31, 2009
AB			**400MG**	**A078115**	**003**	Mar 31, 2009
AB		TORRENT	**100MG**	**A212524**	**001**	Jan 13, 2025
AB			**200MG**	**A212524**	**002**	Jan 13, 2025
AB			**400MG**	**A212524**	**003**	Jan 13, 2025
AB		UMEDICA	**100MG**	**A216594**	**001**	Aug 18, 2022
AB			**200MG**	**A216594**	**002**	Aug 18, 2022
AB			**400MG**	**A216594**	**003**	Aug 18, 2022
AB		UNIQUE PHARM	**100MG**	**A211623**	**001**	Apr 24, 2020
AB			**200MG**	**A211623**	**002**	Apr 24, 2020
AB			**400MG**	**A211623**	**003**	Apr 24, 2020
AB		YICHANG HUMANWELL	**100MG**	**A219072**	**001**	Jan 16, 2025
AB			**200MG**	**A219072**	**002**	Jan 16, 2025
AB			**400MG**	**A219072**	**003**	Jan 16, 2025
AB		ZHEJIANG JIUZHOU	**100MG**	**A215591**	**001**	Mar 31, 2022
AB			**200MG**	**A215591**	**002**	Mar 31, 2022
AB			**400MG**	**A215591**	**003**	Mar 31, 2022
AB		ZYDUS PHARMS	**100MG**	**A205571**	**001**	Feb 07, 2019
AB			**200MG**	**A205571**	**002**	Feb 07, 2019
AB			**400MG**	**A205571**	**003**	Feb 07, 2019

TEGRETOL-XR

AB	**+**	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996
AB	**+**		**200MG**	**N020234**	**002**	Mar 25, 1996
AB	**+!**		**400MG**	**N020234**	**003**	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		AUROBINDO PHARMA	**25MG**	**A211055**	**001**	Oct 21, 2019
AB		EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016
AB		NOVEL LABS INC	**25MG**	**A204763**	**001**	Oct 20, 2017
AB		REGCON HOLDINGS	**25MG**	**A217961**	**001**	Dec 11, 2023
AB		ZYDUS PHARMS	**25MG**	**A209910**	**001**	May 07, 2018

LODOSYN

AB	**+!**	ATON	**25MG**	**N017830**	**001**	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		MACLEODS PHARMS LTD	**12.5MG;200MG;50MG**	**A214495**	**001**	Apr 15, 2025
AB			**18.75MG;200MG;75MG**	**A214495**	**002**	Apr 15, 2025
AB			**25MG;200MG;100MG**	**A214495**	**003**	Apr 15, 2025
AB			**31.25MG;200MG;125MG**	**A214495**	**004**	Apr 15, 2025
AB			**37.5MG;200MG;150MG**	**A214495**	**005**	Apr 15, 2025
AB			**50MG;200MG;200MG**	**A214495**	**006**	Apr 15, 2025
AB		RISING	**12.5MG;200MG;50MG**	**A213212**	**001**	Jan 25, 2022
AB			**18.75MG;200MG;75MG**	**A213212**	**002**	Jan 25, 2022
AB			**25MG;200MG;100MG**	**A213212**	**003**	Jan 25, 2022
AB			**31.25MG;200MG;125MG**	**A213212**	**004**	Jan 25, 2022
AB			**37.5MG;200MG;150MG**	**A213212**	**005**	Jan 25, 2022
AB			**50MG;200MG;200MG**	**A213212**	**006**	Jan 25, 2022

STALEVO 100

AB	**+**	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003

STALEVO 125

AB	**+**	ORION PHARMA	**31.25MG;200MG;125MG**	**N021485**	**006**	Aug 29, 2008

STALEVO 150

AB	**+**	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003

STALEVO 200

AB	**+!**	ORION PHARMA	**50MG;200MG;200MG**	**N021485**	**004**	Aug 02, 2007

STALEVO 50

AB	**+!**	ORION PHARMA	**12.5MG;200MG;50MG**	**N021485**	**001**	Jun 11, 2003

STALEVO 75

AB	**+**	ORION PHARMA	**18.75MG;200MG;75MG**	**N021485**	**005**	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

CREXONT

	+	IMPAX	35MG;140MG	N217186	001	Aug 07, 2024
	+		52.5MG;210MG	N217186	002	Aug 07, 2024
	+		70MG;280MG	N217186	003	Aug 07, 2024
	+!		87.5MG;350MG	N217186	004	Aug 07, 2024

RYTARY

	+	IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015
	+		36.25MG;145MG	N203312	002	Jan 07, 2015
	+		48.75MG;195MG	N203312	003	Jan 07, 2015
	+!		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION;ENTERAL

DUOPA

	+!	ABBVIE	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB	**!**		**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		ASCENT PHARMS INC	**10MG;100MG**	**A218939**	**001**	Jan 14, 2025
AB			**25MG;100MG**	**A218939**	**002**	Jan 14, 2025
AB			**25MG;250MG**	**A218939**	**003**	Jan 14, 2025
AB		AUROBINDO PHARMA LTD	**10MG;100MG**	**A216537**	**001**	Nov 28, 2022
AB			**25MG;100MG**	**A216537**	**002**	Nov 28, 2022
AB			**25MG;250MG**	**A216537**	**003**	Nov 28, 2022
AB		DR REDDYS LABS SA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		PHARMOBEDIENT	**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB		RUBICON RESEARCH	**10MG;100MG**	**A216505**	**001**	Sep 21, 2022
AB			**25MG;100MG**	**A216505**	**002**	Sep 21, 2022
AB			**25MG;250MG**	**A216505**	**003**	Sep 21, 2022
AB		SCIEGEN PHARMS	**10MG;100MG**	**A214092**	**001**	May 07, 2021

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB			**25MG;100MG**	**A214092**	**002**	May 07, 2021
AB			**25MG;250MG**	**A214092**	**003**	May 07, 2021
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008

SINEMET

AB	**+**	ORGANON	**10MG;100MG**	**N017555**	**001**	
AB	**+**		**25MG;100MG**	**N017555**	**003**	
AB	**+**		**25MG;250MG**	**N017555**	**002**	

DHIVY

	+!	AVION PHARMS	25MG;100MG	N214869	001	Nov 12, 2021

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		ALEMBIC	**25MG;100MG**	**A210341**	**001**	Jun 05, 2019
AB			**50MG;200MG**	**A210341**	**002**	Jun 05, 2019
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		RUBICON RESEARCH	**25MG;100MG**	**A217482**	**001**	Jun 04, 2024
AB			**50MG;200MG**	**A217482**	**002**	Jun 04, 2024
AB		SCIEGEN PHARMS	**25MG;100MG**	**A214091**	**001**	Oct 05, 2021
AB	**!**		**50MG;200MG**	**A214091**	**002**	Oct 05, 2021
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB			**50MG;200MG**	**A077828**	**002**	Aug 23, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB		RISING	**10MG;100MG**	**A078893**	**001**	Sep 18, 2008
AB			**25MG;100MG**	**A078893**	**002**	Sep 18, 2008
AB			**25MG;250MG**	**A078893**	**003**	Sep 18, 2008
AB		SUN PHARM	**10MG;100MG**	**A078690**	**001**	Jul 31, 2009
AB			**25MG;100MG**	**A078690**	**002**	Jul 31, 2009
AB	**!**		**25MG;250MG**	**A078690**	**003**	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	!	GENUS	4MG/5ML	A040458	001	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

	+!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

AA	**!**	GENUS	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		LEADING	**6MG**	**A215476**	**001**	Dec 19, 2024
AA	**!**	MIKART	**6MG**	**A207484**	**001**	May 31, 2016
AA		MISSION PHARMACAL	**4MG**	**A090756**	**001**	May 27, 2011

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	**50MG/5ML (10MG/ML)**	**A206775**	**001**	Feb 09, 2017
AP			**150MG/15ML (10MG/ML)**	**A206775**	**002**	Feb 09, 2017
AP			**450MG/45ML (10MG/ML)**	**A206775**	**003**	Feb 09, 2017
AP			**600MG/60ML (10MG/ML)**	**A206775**	**004**	Feb 09, 2017
AP		EPIC PHARMA LLC	**50MG/5ML (10MG/ML)**	**A090475**	**001**	Jul 29, 2009
AP			**150MG/15ML (10MG/ML)**	**A090475**	**002**	Jul 29, 2009
AP			**450MG/45ML (10MG/ML)**	**A090475**	**003**	Jul 29, 2009
AP			**600MG/60ML (10MG/ML)**	**A091268**	**002**	Jul 28, 2010
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A205487**	**001**	Mar 28, 2016
AP			**150MG/15ML (10MG/ML)**	**A205487**	**002**	Mar 28, 2016
AP			**450MG/45ML (10MG/ML)**	**A205487**	**003**	Mar 28, 2016
AP			**600MG/60ML (10MG/ML)**	**A205487**	**004**	Aug 03, 2020
AP		FRESENIUS KABI USA	**450MG/45ML (10MG/ML)**	**A077266**	**003**	Feb 15, 2006
AP			**600MG/60ML (10MG/ML)**	**A077266**	**004**	Feb 15, 2006
AP		GLAND	**50MG/5ML (10MG/ML)**	**A207324**	**001**	Feb 15, 2017
AP			**150MG/15ML (10MG/ML)**	**A207324**	**002**	Feb 15, 2017
AP			**450MG/45ML (10MG/ML)**	**A207324**	**003**	Feb 15, 2017

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP			**600MG/60ML (10MG/ML)**	**A207324**	**004**	Feb 15, 2017
AP		HIKMA	**50MG/5ML (10MG/ML)**	**A077244**	**001**	Oct 15, 2004
AP			**150MG/15ML (10MG/ML)**	**A077244**	**002**	Oct 15, 2004
AP			**450MG/45ML (10MG/ML)**	**A077244**	**003**	Oct 15, 2004
AP			**600MG/60ML (10MG/ML)**	**A077244**	**004**	Jan 20, 2006
AP	**!**	HOSPIRA	**50MG/5ML (10MG/ML)**	**A076517**	**001**	Oct 14, 2004
AP	**!**		**150MG/15ML (10MG/ML)**	**A076517**	**002**	Oct 14, 2004
AP	**!**		**450MG/45ML (10MG/ML)**	**A076517**	**003**	Oct 14, 2004
AP	**!**		**600MG/60ML (10MG/ML)**	**A077059**	**001**	Nov 23, 2004
AP		NOVAST LABS	**50MG/5ML (10MG/ML)**	**A208487**	**001**	Apr 26, 2017
AP			**150MG/15ML (10MG/ML)**	**A208487**	**002**	Apr 26, 2017
AP			**450MG/45ML (10MG/ML)**	**A208487**	**003**	Apr 26, 2017
AP			**600MG/60ML (10MG/ML)**	**A208487**	**004**	Apr 26, 2017
AP		PHARMACHEMIE BV	**50MG/5ML (10MG/ML)**	**A077269**	**001**	Oct 14, 2004
AP			**150MG/15ML (10MG/ML)**	**A077269**	**002**	Oct 14, 2004
AP			**450MG/45ML (10MG/ML)**	**A077269**	**003**	Oct 14, 2004
AP			**600MG/60ML (10MG/ML)**	**A077269**	**004**	Dec 28, 2007
AP		SANDOZ	**50MG/5ML (10MG/ML)**	**A078280**	**001**	May 08, 2008
AP			**150MG/15ML (10MG/ML)**	**A078280**	**002**	May 08, 2008
AP			**450MG/45ML (10MG/ML)**	**A078280**	**003**	May 08, 2008
AP		SUN PHARM	**50MG/5ML (10MG/ML)**	**A077926**	**001**	Sep 19, 2008
AP			**150MG/15ML (10MG/ML)**	**A077926**	**002**	Sep 19, 2008
AP			**450MG/45ML (10MG/ML)**	**A077926**	**003**	Sep 19, 2008
AP		TEYRO LABS	**50MG/5ML (10MG/ML)**	**A077861**	**001**	Jan 18, 2007
AP			**150MG/15ML (10MG/ML)**	**A077861**	**002**	Jan 18, 2007
AP			**450MG/45ML (10MG/ML)**	**A077861**	**003**	Jan 18, 2007
AP			**600MG/60ML (10MG/ML)**	**A077861**	**004**	Jan 18, 2007
	!	ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020

SOLUTION;INTRAVENOUS

KYXATA

	+!	AVYXA HOLDINGS	80MG/8ML (10MG/ML)	N219921	002	Aug 08, 2025
	+!		500MG/50ML (10MG/ML)	N219921	003	Aug 08, 2025

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		ALEMBIC	**EQ 0.25MG BASE/ML**	**A217198**	**001**	Jun 15, 2023
AP		AMNEAL	**EQ 0.25MG BASE/ML**	**A215337**	**001**	Jan 27, 2022
AP		CAPLIN	**EQ 0.25MG BASE/ML**	**A216882**	**001**	Feb 13, 2023
AP		DR REDDYS	**EQ 0.25MG BASE/ML**	**A211941**	**001**	Jul 02, 2019
AP		EUGIA PHARMA	**EQ 0.25MG BASE/ML**	**A216939**	**001**	May 25, 2023
AP		GLAND	**EQ 0.25MG BASE/ML**	**A217657**	**001**	Aug 07, 2023
AP		LONG GROVE PHARMS	**EQ 0.25MG BASE/ML**	**A214499**	**001**	Aug 09, 2022
AP		MICRO LABS	**EQ 0.25MG BASE/ML**	**A218013**	**001**	Apr 03, 2024
AP		ONESOURCE SPECIALTY	**EQ 0.25MG BASE/ML**	**A216897**	**001**	Jul 25, 2023
AP		SOLA PHARMS	**EQ 0.25MG BASE/ML**	**A216824**	**001**	May 19, 2023
AP		SUNNY	**EQ 0.25MG BASE/ML**	**A213118**	**001**	Mar 25, 2021

HEMABATE

AP	**+!**	PFIZER	**EQ 0.25MG BASE/ML**	**N017989**	**001**	

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

AP		DR REDDYS	**60MG/VIAL**	**A209422**	**001**	Sep 09, 2019

KYPROLIS

AP	**+!**	ONYX PHARMS AMGEN	**60MG/VIAL**	**N202714**	**001**	Jul 20, 2012
	+!		10MG/VIAL	N202714	003	Jun 07, 2018
	+!		30MG/VIAL	N202714	002	Jun 03, 2016

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARBAGLU

AB	**+!**	RECORDATI RARE	**200MG**	**N022562**	**001**	Mar 18, 2010

CARGLUMIC ACID

AB		NAVINTA LLC	**200MG**	**A213395**	**001**	Jun 22, 2022
AB		NOVITIUM PHARMA	**200MG**	**A213729**	**001**	Oct 13, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**EQ 1.5MG BASE**	**A213982**	**001**	Dec 16, 2025
AB			**EQ 3MG BASE**	**A213982**	**002**	Dec 16, 2025
AB			**EQ 6MG BASE**	**A213982**	**003**	Dec 16, 2025
VRAYLAR						
AB	**+!**	ABBVIE	**EQ 1.5MG BASE**	**N204370**	**001**	Sep 17, 2015
AB	**+**		**EQ 3MG BASE**	**N204370**	**002**	Sep 17, 2015
AB	**+**		**EQ 6MG BASE**	**N204370**	**004**	Sep 17, 2015
	+		EQ 0.5MG BASE	N204370	005	Dec 18, 2025
	+		EQ 0.75MG BASE	N204370	006	Dec 18, 2025
	+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL						
AA		ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA		AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA		CHARTWELL RX	**350MG**	**A040245**	**001**	Sep 08, 1997
AA		HERITAGE	**350MG**	**A205126**	**002**	Jul 08, 2015
AA		MPP PHARMA	**350MG**	**A207237**	**002**	Sep 21, 2020
AA		NATCO	**350MG**	**A090988**	**001**	Oct 28, 2014
AA		NOVAST LABS	**350MG**	**A040823**	**001**	Oct 22, 2008
AA		ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA		OXFORD PHARMS	**350MG**	**A040188**	**001**	Mar 07, 1997
AA		POINTVIEW HLDINGS	**350MG**	**A211789**	**001**	Oct 20, 2021
AA		SCIEGEN PHARMS	**350MG**	**A203374**	**001**	Jan 27, 2014
AA		SENORES PHARMS	**350MG**	**A081025**	**001**	Apr 13, 1989
AA		WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
SOMA						
AA	**+**	MYLAN SPECIALITY LP	**350MG**	**N011792**	**001**	
CARISOPRODOL						
AB		AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016
AB		HERITAGE	**250MG**	**A205126**	**001**	Jul 08, 2015
AB		MPP PHARMA	**250MG**	**A207237**	**001**	May 11, 2017
SOMA						
AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL						
	+!	AZURITY	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION

BICNU						
AP	**+!**	AVET LIFESCIENCES	**100MG/VIAL**	**N017422**	**001**	
CARMUSTINE						
AP		ALEMBIC	**100MG/VIAL**	**A215730**	**001**	Oct 20, 2023
AP		AMNEAL	**100MG/VIAL**	**A211229**	**001**	Oct 16, 2018
AP		DR REDDYS	**100MG/VIAL**	**A213207**	**001**	Oct 22, 2020
AP		MEITHEAL	**100MG/VIAL**	**A213460**	**001**	Aug 02, 2021
AP		MSN	**100MG/VIAL**	**A214814**	**001**	May 11, 2023
AP		NAVINTA LLC	**100MG/VIAL**	**A210179**	**001**	Sep 11, 2018
AP		PENN LIFE	**100MG/VIAL**	**A209278**	**001**	Apr 02, 2019

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE						
	!	SANDOZ	1%	A075476	001	Jan 03, 2000

CARVEDILOL

TABLET;ORAL

CARVEDILOL						
AB		AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB			**25MG**	**A078332**	**004**	Sep 05, 2007
AB		CHARTWELL MOLECULAR	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB			**25MG**	**A077474**	**004**	Sep 05, 2007
AB		GLENMARK PHARMS LTD	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078251**	**002**	Sep 05, 2007

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB			**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB			**25MG**	**A078251**	**004**	Sep 05, 2007
AB		LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB			**25MG**	**A078217**	**004**	Sep 05, 2007
AB		MLV	**3.125MG**	**A078786**	**001**	Dec 22, 2009
AB			**6.25MG**	**A078786**	**002**	Dec 22, 2009
AB			**12.5MG**	**A078786**	**003**	Dec 22, 2009
AB			**25MG**	**A078786**	**004**	Dec 22, 2009
AB		REGCON HOLDINGS	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB			**25MG**	**A078384**	**004**	Sep 05, 2007
AB		RISING	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076649**	**003**	Sep 05, 2007
AB			**25MG**	**A076649**	**004**	Sep 05, 2007
AB		RUBICON RESEARCH	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB			**25MG**	**A078165**	**004**	Sep 05, 2007
AB		SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078227**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB			**25MG**	**A078227**	**004**	Sep 05, 2007
AB		TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB			**25MG**	**A076373**	**004**	Sep 05, 2007
AB		ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB			**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	+	WAYLIS THERAP	**3.125MG**	**N020297**	**004**	May 29, 1997
AB	+		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	+!		**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB	+		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

AB		IMPAX LABS INC	**10MG**	**A204717**	**001**	May 07, 2018
AB			**20MG**	**A204717**	**002**	May 07, 2018
AB			**40MG**	**A204717**	**003**	May 07, 2018
AB			**80MG**	**A204717**	**004**	May 07, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A090132**	**001**	Oct 25, 2017
AB			**20MG**	**A090132**	**002**	Oct 25, 2017
AB	!		**40MG**	**A090132**	**003**	Oct 25, 2017
AB			**80MG**	**A090132**	**004**	Oct 25, 2017

COREG CR

AB	+	WAYLIS THERAP	**10MG**	**N022012**	**001**	Oct 20, 2006
AB	+		**20MG**	**N022012**	**002**	Oct 20, 2006
AB	+		**40MG**	**N022012**	**003**	Oct 20, 2006
AB	+		**80MG**	**N022012**	**004**	Oct 20, 2006

CASIMERSEN

SOLUTION;INTRAVENOUS

AMONDYS 45

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP		AREVA PHARMS	**50MG/VIAL**	**A211263**	**001**	Oct 01, 2021
AP			**70MG/VIAL**	**A211263**	**002**	Oct 01, 2021
AP		FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016
AP			**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP		GLAND	**50MG/VIAL**	**A207092**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207092**	**002**	Sep 29, 2017
AP		HANGZHOU ZHONGMEI	**50MG/VIAL**	**A216506**	**001**	Jul 18, 2025
AP			**70MG/VIAL**	**A216506**	**002**	Jul 18, 2025
AP	**!**	HENGRUI PHARMA	**50MG/VIAL**	**A200833**	**001**	Jun 28, 2018
AP	**!**		**70MG/VIAL**	**A200833**	**002**	Jun 28, 2018

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

+!	TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020

CEFACLOR

CAPSULE;ORAL

CEFACLOR

	YUNG SHIN PHARM	EQ 250MG BASE	A065146	001	Jan 22, 2004
!		EQ 500MG BASE	A065146	002	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACLOR

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001**	Jan 25, 2007
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001**	May 29, 2007
AB	**!**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001**	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001**	Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002**	Apr 25, 2013
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001**	Feb 21, 2008
AB	**!**		**EQ 500MG BASE/5ML**	**A065396**	**002**	Feb 21, 2008

TABLET;ORAL

CEFADROXIL

!	TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001**	Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002**	Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001**	Oct 22, 2008
AP	**!**	HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001**	Sep 18, 2001
AP	**!**		**EQ 1GM BASE/VIAL**	**A065047**	**002**	Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001**	Oct 18, 2004
AP		QILU ANTIBIOTICS	**EQ 1GM BASE/VIAL**	**A203661**	**001**	Dec 28, 2015
AP	**!**		**EQ 10GM BASE/VIAL**	**A209217**	**001**	Oct 17, 2018
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002**	Dec 09, 1988
AP			**EQ 10GM BASE/VIAL**	**A062831**	**003**	Sep 25, 1992

CEFAZOLIN AND DEXTROSE

+!	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012
+!		EQ 3GM BASE/VIAL	N050779	004	Aug 26, 2024

CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022
!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

POWDER;INTRAVENOUS

CEFAZOLIN SODIUM

+!	HIKMA	EQ 2GM BASE/VIAL	N216109	001	Oct 07, 2022

CEFAZOLIN SODIUM

POWDER;INTRAVENOUS

CEFAZOLIN SODIUM

+!		EQ 3GM BASE/VIAL	N216109	002	Oct 07, 2022
+!	HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023

SOLUTION;INTRAVENOUS

CEFAZOLIN IN DEXTROSE

+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015
+!		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB		ALKEM LABS LTD	**300MG**	**A210220**	**001**	Feb 19, 2021
AB		ANDA REPOSITORY	**300MG**	**A065418**	**001**	Jul 18, 2007
AB		AURO BINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB	**!**	CHARTWELL RX	**300MG**	**A065330**	**001**	Apr 06, 2007
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB		ALKEM LABS LTD	**125MG/5ML**	**A210534**	**001**	Feb 19, 2021
AB			**250MG/5ML**	**A210534**	**002**	Feb 19, 2021
AB		ANDA REPOSITORY	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		AURO BINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007
AB	**!**		**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB			**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A214402**	**001**	May 22, 2024
AP			**EQ 2GM BASE/VIAL**	**A214402**	**002**	May 22, 2024
AP	**!**	QILU ANTIBIOTICS	**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP	**!**		**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS INC	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

+!	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
+!		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010

CEFEPIME HYDROCHLORIDE

!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016

CEFEPIME IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

POWDER;INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER;INTRAVENOUS

FETROJA

+!	SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019

CEFIXIME

CAPSULE;ORAL

CEFIXIME

AB		ALKEM LABS LTD	**400MG**	**A210574**	**001**	Oct 09, 2018

SUPRAX

AB	**+!**	LUPIN LTD	**400MG**	**N203195**	**001**	Jun 01, 2012

FOR SUSPENSION;ORAL

CEFIXIME

AB		AJENAT PHARMS	**100MG/5ML**	**A206938**	**001**	Feb 06, 2017
AB			**200MG/5ML**	**A206938**	**002**	Feb 06, 2017
AB			**500MG/5ML**	**A206939**	**001**	Feb 06, 2017

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB		ALKEM LABS LTD	**100MG/5ML**	**A211775**	**001**	Feb 19, 2021
AB			**200MG/5ML**	**A211775**	**002**	Feb 19, 2021
AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015

SUPRAX

AB	**+!**	LUPIN LTD	**500MG/5ML**	**N202091**	**001**	Feb 20, 2013
AB	**!**	LUPIN PHARMS	**200MG/5ML**	**A065355**	**001**	Apr 10, 2007

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

AP	**+**	PAI HOLDINGS PHARM	**EQ 1GM BASE/VIAL**	**N050588**	**001**	Dec 27, 1985
AP	**+**		**EQ 2GM BASE/VIAL**	**N050588**	**002**	Dec 27, 1985

CEFOTETAN

AP	**!**	FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A065374**	**001**	Aug 09, 2007
AP	**!**		**EQ 2GM BASE/VIAL**	**A065374**	**002**	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE;INJECTION

CEFOXITIN

AP	**!**	ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	**!**		**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	**!**		**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP			**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP			**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP			**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP			**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214**	**001**	Mar 10, 2006
AP	**+!**		**EQ 2GM BASE/VIAL**	**N065214**	**002**	Mar 10, 2006

POWDER;INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

		AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007
	!		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		ALKEM LABS LTD	**EQ 100MG BASE**	**A210568**	**001**	May 18, 2022
AB			**EQ 200MG BASE**	**A210568**	**002**	May 18, 2022
AB		ANDA REPOSITORY	**EQ 100MG BASE**	**A065388**	**001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388**	**002**	Nov 14, 2007
AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370**	**001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370**	**002**	Jun 11, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462**	**001**	May 28, 2008
AB	**!**		**EQ 200MG BASE**	**A065462**	**002**	May 28, 2008

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381**	**001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381**	**002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261**	**001**	Dec 19, 2005
AB	**!**		**250MG/5ML**	**A065261**	**002**	Dec 19, 2005

TABLET;ORAL

CEFPROZIL

AB		ALKEM LABS LTD	**250MG**	**A090857**	**001**	Apr 09, 2024
AB			**500MG**	**A090857**	**002**	Apr 09, 2024
AB		AUROBINDO PHARMA	**250MG**	**A065340**	**001**	May 24, 2007
AB			**500MG**	**A065340**	**002**	May 24, 2007
AB		CHARTWELL RX	**250MG**	**A065235**	**001**	Nov 14, 2005
AB			**500MG**	**A065235**	**002**	Nov 14, 2005
AB		LUPIN	**250MG**	**A065276**	**001**	Dec 08, 2005
AB	**!**		**500MG**	**A065276**	**002**	Dec 08, 2005
AB		TEVA	**250MG**	**A065208**	**001**	Dec 06, 2005

CEFPROZIL
TABLET;ORAL
CEFPROZIL

AB			**500MG**	**A065208**	**002**	Dec 06, 2005

CEFTAROLINE FOSAMIL
POWDER;INTRAVENOUS
TEFLARO

	+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010
	+!		600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME
INJECTABLE;INJECTION
CEFTAZIDIME

AP	**!**	ACS DOBFAR	**1GM/VIAL**	**A062640**	**002**	Nov 20, 1985
AP	**!**		**2GM/VIAL**	**A062640**	**003**	Nov 20, 1985
AP	**!**		**6GM/VIAL**	**A062640**	**004**	Feb 03, 1992

TAZICEF

AP		HOSPIRA	**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986

CEFTOBIPROLE MEDOCARIL SODIUM
POWDER;INTRAVENOUS
ZEVTERA

	+!	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM
POWDER;INTRAVENOUS
ZERBAXA

	+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM
INJECTABLE;INJECTION
CEFTRIAXONE

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		APOTEX	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006
AP		QILU ANTIBIOTICS	**EQ 10GM BASE/VIAL**	**A209218**	**001**	Oct 17, 2018
AP	**!**	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	**!**	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005

CEFTRIAXONE SODIUM

AP		ANDA REPOSITORY	**EQ 10GM BASE/VIAL**	**A091117**	**001**	Jan 20, 2017
AP		HIKMA	**EQ 10GM BASE/VIAL**	**A090701**	**001**	Oct 04, 2017

CEFTRIAXONE

		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFTRIAXONE

AP		EPIC PHARMA LLC	**EQ 250MG BASE/VIAL**	**A065305**	**001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305**	**002**	Jan 11, 2008
AP			**EQ 1GM BASE/VIAL**	**A065305**	**003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305**	**004**	Jan 11, 2008
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342**	**001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342**	**002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342**	**003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342**	**004**	Jan 10, 2008
AP		QILU ANTIBIOTICS	**EQ 250MG BASE/VIAL**	**A203702**	**001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702**	**002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702**	**003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702**	**004**	Jun 29, 2016
AP	**!**	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169**	**001**	May 09, 2005
AP	**!**		**EQ 500MG BASE/VIAL**	**A065169**	**002**	May 09, 2005
AP	**!**		**EQ 1GM BASE/VIAL**	**A065169**	**003**	May 09, 2005
AP	**!**		**EQ 2GM BASE/VIAL**	**A065169**	**004**	May 09, 2005

CEFTRIAXONE SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		WOCKHARDT BIO AG	**EQ 250MG BASE/VIAL**	**A065391**	**001**	Apr 12, 2007
AP			**EQ 500MG BASE/VIAL**	**A065391**	**002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391**	**003**	Apr 12, 2007

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496**	**001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496**	**002**	Jun 07, 2010
AB		ANDA REPOSITORY	**EQ 125MG BASE**	**A065359**	**001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359**	**002**	Feb 15, 2008
AB			**EQ 500MG BASE**	**A065359**	**003**	Feb 15, 2008
AB		AUROBINDO PHARMA	**EQ 125MG BASE**	**A065308**	**001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308**	**002**	Mar 29, 2006
AB	**!**		**EQ 500MG BASE**	**A065308**	**003**	Mar 29, 2006
AB		CHARTWELL RX	**EQ 125MG BASE**	**A065166**	**001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166**	**002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166**	**003**	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP		ACS DOBFAR SPA	**EQ 1.5GM BASE/VIAL**	**A064125**	**002**	May 30, 1997
AP	**!**	HIKMA	**EQ 1.5GM BASE/VIAL**	**A065048**	**002**	Jan 09, 2004

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		ACS DOBFAR SPA	**EQ 750MG BASE/VIAL**	**A064125**	**001**	May 30, 1997
AB	**!**	HIKMA	**EQ 750MG BASE/VIAL**	**A065048**	**001**	Jan 09, 2004

CELECOXIB

CAPSULE;ORAL

CELEBREX

AB	**+**	UPJOHN	**50MG**	**N020998**	**004**	Dec 15, 2006
AB	**+**		**100MG**	**N020998**	**001**	Dec 31, 1998
AB	**+**		**200MG**	**N020998**	**002**	Dec 31, 1998
AB	**+!**		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB

AB		ALEMBIC	**50MG**	**A204519**	**001**	Aug 21, 2015
AB			**100MG**	**A204519**	**002**	Aug 21, 2015
AB			**200MG**	**A204519**	**003**	Aug 21, 2015
AB			**400MG**	**A204519**	**004**	Aug 21, 2015
AB		APOTEX	**50MG**	**A204197**	**001**	Jun 02, 2015
AB			**100MG**	**A204197**	**002**	Jun 02, 2015
AB			**200MG**	**A204197**	**003**	Jun 02, 2015
AB		AUROBINDO PHARMA	**50MG**	**A206827**	**001**	Feb 01, 2016
AB			**100MG**	**A206827**	**002**	Feb 01, 2016
AB			**200MG**	**A206827**	**003**	Feb 01, 2016
AB			**400MG**	**A206827**	**004**	Feb 01, 2016
AB		CADILA PHARMS LTD	**50MG**	**A208701**	**001**	Nov 14, 2019
AB			**100MG**	**A208701**	**002**	Nov 14, 2019
AB			**200MG**	**A208701**	**003**	Nov 14, 2019
AB			**400MG**	**A208701**	**004**	Nov 14, 2019
AB		CIPLA	**50MG**	**A207446**	**001**	Sep 23, 2015
AB			**100MG**	**A207446**	**002**	Sep 23, 2015
AB			**200MG**	**A207446**	**003**	Sep 23, 2015
AB			**400MG**	**A207446**	**004**	Sep 23, 2015
AB		CSPC OUYI	**50MG**	**A210071**	**001**	Jan 23, 2018
AB			**100MG**	**A210071**	**002**	Jan 23, 2018
AB			**200MG**	**A210071**	**003**	Jan 23, 2018
AB		LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB			**100MG**	**A202240**	**002**	Jun 09, 2015
AB			**200MG**	**A202240**	**003**	Jun 09, 2015
AB			**400MG**	**A202240**	**004**	Jun 09, 2015
AB		MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB			**100MG**	**A204590**	**002**	Mar 16, 2016
AB			**200MG**	**A204590**	**003**	Mar 16, 2016
AB			**400MG**	**A204590**	**004**	Mar 16, 2016
AB		MICRO LABS	**50MG**	**A204776**	**001**	Apr 30, 2018
AB			**100MG**	**A204776**	**002**	Apr 30, 2018
AB			**200MG**	**A204776**	**003**	Apr 30, 2018
AB			**400MG**	**A204776**	**004**	Apr 30, 2018

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	NANJING	**200MG**	**A213598**	**001**	May 13, 2020
AB	QINGDAO BAHEAL PHARM	**50MG**	**A208856**	**001**	Aug 07, 2019
AB		**100MG**	**A208856**	**002**	Aug 07, 2019
AB		**200MG**	**A208856**	**003**	Aug 07, 2019
AB		**400MG**	**A208856**	**004**	Aug 07, 2019
AB	SCIEGEN PHARMS	**50MG**	**A205129**	**001**	Dec 03, 2020
AB		**100MG**	**A205129**	**002**	Dec 03, 2020
AB		**200MG**	**A205129**	**003**	Dec 03, 2020
AB		**400MG**	**A205129**	**004**	Dec 03, 2020
AB	TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB		**100MG**	**A076898**	**002**	May 30, 2014
AB		**200MG**	**A076898**	**003**	May 30, 2014
AB		**400MG**	**A076898**	**004**	May 30, 2014
AB	TIANJIN TIANYAO	**50MG**	**A207872**	**001**	Feb 25, 2020
AB		**100MG**	**A207872**	**002**	Feb 25, 2020
AB		**200MG**	**A207872**	**003**	Feb 25, 2020
AB		**400MG**	**A207872**	**004**	Feb 25, 2020
AB	TORRENT	**50MG**	**A207677**	**001**	Dec 23, 2015
AB		**100MG**	**A207677**	**002**	Dec 23, 2015
AB		**200MG**	**A207677**	**003**	Dec 23, 2015
AB		**400MG**	**A207677**	**004**	Dec 23, 2015
AB	UMEDICA	**50MG**	**A210628**	**001**	Nov 27, 2019
AB		**100MG**	**A210628**	**002**	Nov 27, 2019
AB		**200MG**	**A210628**	**003**	Nov 27, 2019
AB		**400MG**	**A210628**	**004**	Nov 27, 2019
AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015
AB	YILING	**50MG**	**A211412**	**001**	Mar 06, 2020
AB		**100MG**	**A211412**	**002**	Mar 06, 2020
AB		**200MG**	**A211412**	**003**	Mar 06, 2020
AB		**400MG**	**A211412**	**004**	Mar 06, 2020

SOLUTION;ORAL

ELYXYB

+!	SCILEX PHARMS	25MG/ML	N212157	001	May 05, 2020

SUSPENSION;ORAL

VYSCOXA

+!	CARWIN PHARM ASSOC	10MG/ML	N211759	001	Jul 29, 2025

CENOBAMATE

TABLET;ORAL

XCOPRI

+!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020
+		25MG	N212839	002	Mar 10, 2020
+		50MG	N212839	003	Mar 10, 2020
+		100MG	N212839	004	Mar 10, 2020
+		150MG	N212839	005	Mar 10, 2020
+		200MG	N212839	006	Mar 10, 2020

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	AJENAT PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB !		**EQ 750MG BASE**	**A090836**	**004**	Mar 29, 2013
AB	ANDA REPOSITORY	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB		**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB	AUROBINDO PHARMA	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB		**EQ 750MG BASE**	**A065253**	**003**	Dec 06, 2023
AB	CHARTWELL RX	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005
AB		**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB	TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB		**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

AB		ALKEM LABS LTD	**EQ 125MG BASE/5ML**	**A210221**	**001**	Mar 26, 2019
AB			**EQ 250MG BASE/5ML**	**A210221**	**002**	Mar 26, 2019
AB		LUPIN	**EQ 125MG BASE/5ML**	**A065234**	**001**	Aug 17, 2005
AB			**EQ 250MG BASE/5ML**	**A065234**	**002**	Aug 17, 2005
AB		TEVA	**EQ 125MG BASE/5ML**	**A062703**	**001**	Feb 13, 1987
AB	**!**		**EQ 250MG BASE/5ML**	**A062703**	**002**	Feb 13, 1987
AB		YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065336**	**001**	Jul 25, 2007
AB			**EQ 250MG BASE/5ML**	**A065336**	**002**	Jul 25, 2007

TABLET;ORAL

CEPHALEXIN

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A218947**	**001**	Sep 27, 2024
AB			**EQ 500MG BASE**	**A218947**	**002**	Sep 27, 2024
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A218817**	**001**	Sep 27, 2024
AB			**EQ 500MG BASE**	**A218817**	**002**	Sep 27, 2024
		TEVA	EQ 250MG BASE	A063024	002	Jan 12, 1989
	!		EQ 500MG BASE	A063024	001	Jan 12, 1989

CERITINIB

TABLET;ORAL

ZYKADIA

	+!	NOVARTIS	150MG	N211225	001	Mar 18, 2019

CETIRIZINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

QUZYTTIR

	+!	JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML**	**A090766**	**001**	Oct 07, 2009
AA		APOZEAL PHARMS	**5MG/5ML**	**A078870**	**001**	Apr 27, 2009
AA		BAJAJ	**5MG/5ML**	**A090191**	**001**	Nov 12, 2009
AA		BIONPHARMA	**5MG/5ML**	**A078488**	**001**	Oct 06, 2008
AA		CHARTWELL MOLECULAR	**5MG/5ML**	**A078876**	**001**	May 11, 2012
AA	**!**	PADAGIS US	**5MG/5ML**	**A078398**	**001**	Jun 17, 2008
AA		PHARM ASSOC	**5MG/5ML**	**A078412**	**001**	Jun 18, 2008
AA		TARO	**5MG/5ML**	**A076601**	**001**	Jun 20, 2008

SOLUTION/DROPS;OPHTHALMIC

ZERVIATE

	+!	HARROW EYE	EQ 0.24% BASE	N208694	001	May 30, 2017

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP		GLAND	**EQ 0.25MG BASE/VIAL**	**A218150**	**001**	Apr 25, 2024
AP		LIVZON GRP	**EQ 0.25MG BASE/VIAL**	**A214540**	**001**	Apr 24, 2024
AP		QILU	**EQ 0.25MG BASE/VIAL**	**A217776**	**001**	Apr 16, 2024
AP		TEVA PHARMS INC	**EQ 0.25MG BASE/VIAL**	**A215737**	**001**	Aug 12, 2022
AP		XIROMED	**EQ 0.25MG BASE/VIAL**	**A218061**	**001**	Jun 03, 2025

CETROTIDE

AP	**+!**	EMD SERONO INC	**EQ 0.25MG BASE/VIAL**	**N021197**	**001**	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**30MG**	**A215056**	**001**	Apr 18, 2023
AB		BIONPHARMA	**30MG**	**A218290**	**001**	Nov 08, 2023
AB		HIKMA	**30MG**	**A091591**	**001**	Jul 08, 2013
AB		MACLEODS PHARMS LTD	**30MG**	**A206808**	**001**	Sep 20, 2024
AB		NOVEL LABS INC	**30MG**	**A204746**	**001**	Dec 30, 2016
AB		RISING	**30MG**	**A203775**	**001**	Jun 04, 2014
AB		RUBICON RESEARCH	**30MG**	**A216682**	**001**	Apr 06, 2023

EVOXAC

AB	**+!**	COSETTE	**30MG**	**N020989**	**002**	Jan 11, 2000

CHENODIOL

TABLET;ORAL

CHENODIOL

	!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009

CTEXLI

	+!	MIRUM	250MG	N219488	001	Feb 21, 2025

CHLORAMBUCIL

TABLET;ORAL

LEUKERAN

	+!	WAYLIS THERAP	2MG	N010669	002	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768**	**001**	
AB			**10MG**	**A083116**	**001**	
AB	!		**25MG**	**A084769**	**001**	
AB		CHARTWELL RX	**5MG**	**A084678**	**001**	
AB			**10MG**	**A084041**	**001**	
AB			**25MG**	**A084679**	**002**	

LIBRIUM

AB	+	BAUSCH	**25MG**	**A085475**	**001**	
AB	+	VALEANT PHARM INTL	**5MG**	**A085461**	**001**	
AB	+		**10MG**	**A085472**	**001**	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		ALEMBIC	**5MG;2.5MG**	**A216969**	**001**	Sep 15, 2023
AB		ALKEM LABS LTD	**5MG;2.5MG**	**A214065**	**001**	Apr 26, 2021
AB		AMNEAL	**5MG;2.5MG**	**A215555**	**001**	Oct 25, 2021
AB		AUROBINDO PHARMA LTD	**5MG;2.5MG**	**A216419**	**001**	Sep 14, 2023
AB		CHARTWELL RX	**5MG;2.5MG**	**A213530**	**001**	Oct 20, 2020
AB		COREPHARMA	**5MG;2.5MG**	**A215453**	**001**	Jul 29, 2022
AB		DR REDDYS	**5MG;2.5MG**	**A214698**	**001**	May 10, 2021
AB		MICRO LABS	**5MG;2.5MG**	**A215835**	**001**	Jul 19, 2022
AB		MISEMER	**5MG;2.5MG**	**A210579**	**001**	Jul 29, 2020
AB		NUVO PHARMS INC	**5MG;2.5MG**	**A211421**	**001**	Jul 07, 2020
AB		WINDER LABS LLC	**5MG;2.5MG**	**A212344**	**001**	Jul 08, 2024

LIBRAX

AB	+!	BAUSCH	**5MG;2.5MG**	**N012750**	**001**	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT		BAJAJ	**0.12%**	**A075561**	**001**	Nov 14, 2000
AT		CHARTWELL RX	**0.12%**	**A075006**	**001**	Mar 03, 2004
AT		LYNE	**0.12%**	**A074291**	**001**	Dec 28, 1995
AT		PHARM ASSOC	**0.12%**	**A074522**	**001**	Dec 15, 1995
AT		PHARMOBEDIENT	**0.12%**	**A077789**	**001**	Jun 18, 2009

PERIDEX

AT	+!	3M	**0.12%**	**N019028**	**001**	Aug 13, 1986

PERIOGARD

AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212**	**001**	Jan 28, 2016

CHLOROPROCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

IHEEZO

	+!	HARROW EYE	3%	N216227	001	Sep 27, 2022

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP		HIKMA	**2%**	**A040273**	**001**	Sep 09, 1998
AP			**3%**	**A040273**	**002**	Sep 09, 1998

NESACAINE

AP	+	FRESENIUS KABI USA	**2%**	**N009435**	**002**	

NESACAINE-MPF

AP	+!	FRESENIUS KABI USA	**2%**	**N009435**	**006**	May 02, 1996
AP	+!		**3%**	**N009435**	**007**	May 02, 1996

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA		IMPAX LABS	**250MG**	**A080880**	**001**	
AA			**500MG**	**A040516**	**001**	Aug 29, 2003
AA	!	NATCO PHARMA LTD	**250MG**	**A091621**	**001**	Jan 21, 2011
AA	!		**500MG**	**A090612**	**001**	Jan 21, 2011
AA		SUVEN PHARMS	**500MG**	**A214756**	**001**	Sep 03, 2021

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

+!	SALIX PHARMS	250MG/5ML	N011870	001		

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP	AM REGENT	**EQ 500MG BASE/VIAL**	**A202561**	**001**	Apr 22, 2013	
AP	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896**	**001**	Oct 16, 2009	
AP	GLAND	**EQ 500MG BASE/VIAL**	**A218630**	**001**	Oct 03, 2024	
AP !	SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A202462**	**001**	May 29, 2015	
AP	SUN PHARM	**EQ 500MG BASE/VIAL**	**A091546**	**001**	Jul 26, 2011	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

TUXARIN ER

MAINPOINTE	8MG;54.3MG	N206323	001	Jun 22, 2015	

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

! PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

! TRIS PHARMA INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091632	001	Oct 01, 2010	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB !	GENUS	**30MG/ML**	**A214542**	**001**	Jun 02, 2021	
AB !		**100MG/ML**	**A214542**	**002**	Jun 02, 2021	
AB	RUBICON	**30MG/ML**	**A216678**	**001**	Oct 10, 2025	
AB		**100MG/ML**	**A216678**	**002**	Oct 10, 2025	

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP	ASPIRO	**25MG/ML**	**A218272**	**001**	Nov 18, 2024	
AP	DEVA HLDING	**25MG/ML**	**A218229**	**001**	Sep 24, 2024	
AP	DR REDDYS	**25MG/ML**	**A080365**	**001**		
AP	EUGIA PHARMA	**25MG/ML**	**A211816**	**001**	Jul 07, 2020	
AP	GLAND	**25MG/ML**	**A216911**	**001**	Oct 04, 2024	
AP +!	HIKMA	**25MG/ML**	**A083329**	**001**		
AP	THINQ PHARM-CRO PVT	**25MG/ML**	**A216724**	**001**	Dec 10, 2024	
AP	ZYDUS PHARMS	**25MG/ML**	**A217275**	**001**	Mar 13, 2024	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ALEMBIC	**10MG**	**A217350**	**001**	Jul 18, 2023	
AB		**25MG**	**A217350**	**002**	Jul 18, 2023	
AB		**50MG**	**A217350**	**003**	Jul 18, 2023	
AB		**100MG**	**A217350**	**004**	Jul 18, 2023	
AB		**200MG**	**A217350**	**005**	Jul 18, 2023	
AB	AMNEAL PHARMS CO	**10MG**	**A209755**	**001**	Sep 10, 2018	
AB		**25MG**	**A209755**	**002**	Sep 10, 2018	
AB		**50MG**	**A209755**	**003**	Sep 10, 2018	
AB		**100MG**	**A209755**	**004**	Sep 10, 2018	
AB		**200MG**	**A209755**	**005**	Sep 10, 2018	
AB	AUROBINDO PHARMA LTD	**10MG**	**A216788**	**001**	Apr 25, 2025	
AB		**25MG**	**A216788**	**002**	Apr 25, 2025	
AB		**50MG**	**A216788**	**003**	Apr 25, 2025	
AB		**100MG**	**A216788**	**004**	Apr 25, 2025	
AB		**200MG**	**A216788**	**005**	Apr 25, 2025	
AB	CHARTWELL RX	**10MG**	**A212630**	**001**	Nov 29, 2021	
AB		**25MG**	**A212630**	**002**	Nov 29, 2021	
AB		**50MG**	**A212630**	**003**	Nov 29, 2021	
AB		**100MG**	**A212630**	**004**	Nov 29, 2021	
AB		**200MG**	**A212630**	**005**	Nov 29, 2021	
AB	GLENMARK PHARMS LTD	**10MG**	**A212144**	**001**	Mar 23, 2021	
AB		**25MG**	**A212144**	**002**	Mar 23, 2021	
AB		**50MG**	**A212144**	**003**	Mar 23, 2021	
AB		**100MG**	**A212144**	**004**	Mar 23, 2021	
AB		**200MG**	**A212144**	**005**	Mar 23, 2021	

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		LANNETT CO INC	10MG	A212996	001	Jan 22, 2021
AB			25MG	A212996	002	Jan 22, 2021
AB			50MG	A212996	003	Jan 22, 2021
AB			100MG	A212996	004	Jan 22, 2021
AB			200MG	A212996	005	Jan 22, 2021
AB		LUPIN	10MG	A213327	001	Jul 13, 2023
AB			25MG	A213327	002	Jul 13, 2023
AB			50MG	A213327	003	Jul 13, 2023
AB			100MG	A213327	004	Jul 13, 2023
AB			200MG	A213327	005	Jul 13, 2023
AB		MSN	25MG	A214827	001	Jan 27, 2022
AB			50MG	A214827	002	Jan 27, 2022
AB			100MG	A214827	003	Jan 27, 2022
AB			200MG	A214827	004	Jan 27, 2022
AB		SOMERSET THERAPS LLC	10MG	A213590	001	Aug 31, 2020
AB			25MG	A213590	002	Aug 31, 2020
AB			50MG	A213590	003	Aug 31, 2020
AB			100MG	A213590	004	Aug 31, 2020
AB			200MG	A213590	005	Aug 31, 2020
AB		TEVA PHARMS	10MG	A215659	001	Oct 25, 2021
AB			25MG	A215659	002	Oct 25, 2021
AB			50MG	A215659	003	Oct 25, 2021
AB			100MG	A215659	004	Oct 25, 2021
AB			200MG	A215659	005	Oct 25, 2021
AB	+	UPSHER SMITH LABS	10MG	A083386	001	
AB	+!		25MG	A084112	001	
AB	+		50MG	A084113	001	
AB	+!		100MG	A084114	001	
AB	+		200MG	A084115	001	
AB		ZYDUS LIFESCIENCES	10MG	A213368	001	Jan 17, 2020
AB			25MG	A213368	002	Jan 17, 2020
AB			50MG	A213368	003	Jan 17, 2020
AB			100MG	A213368	004	Jan 17, 2020
AB			200MG	A213368	005	Jan 17, 2020

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		AJANTA PHARMA LTD	25MG	A214129	001	Nov 27, 2020
AB			50MG	A214129	002	Nov 27, 2020
AB		ALEMBIC	25MG	A216262	001	Aug 26, 2022
AB			50MG	A216262	002	Aug 26, 2022
AB		ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020
AB			50MG	A213412	002	Feb 11, 2020
AB		AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019
AB			50MG	A207204	002	Jul 01, 2019
AB		APPCO	25MG	A210742	001	Oct 12, 2018
AB			50MG	A210742	002	Oct 12, 2018
AB		CHARTWELL RX	25MG	A211063	001	Feb 26, 2019
AB			50MG	A211063	002	Feb 26, 2019
AB		INVENTIA	25MG	A211320	001	Feb 09, 2022
AB			50MG	A211320	002	Feb 09, 2022
AB		IPCA LABS LTD	25MG	A209162	001	Nov 12, 2024
AB			50MG	A209162	002	Nov 12, 2024
AB		MANKIND PHARMA	25MG	A215587	001	Aug 04, 2022
AB			50MG	A215587	002	Aug 04, 2022
AB	+	MYLAN	25MG	A086831	002	
AB	+!		50MG	A086831	001	
AB		NOVAST LABS	25MG	A206904	001	Mar 30, 2017
AB			50MG	A206904	002	Mar 30, 2017
AB		PHARMOBEDIENT	25MG	A212878	001	Feb 24, 2022
AB			50MG	A212875	001	Feb 24, 2022
AB		SUN PHARM INDUSTRIES	25MG	A089286	002	Jul 21, 1986
AB			50MG	A089286	001	Jul 21, 1986
AB		UMEDICA	25MG	A207222	001	May 24, 2018
AB			50MG	A207222	002	May 24, 2018
AB		UNICHEM	25MG	A211627	001	Aug 06, 2019
AB			50MG	A211627	002	Aug 06, 2019

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		ZYDUS PHARMS	**25MG**	**A207813**	**001**	May 10, 2019
AB			**50MG**	**A207813**	**002**	May 10, 2019

THALITONE

BX	+!	CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992

HEMICLOR

	+!	PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025

THALITONE

	+	CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		AJENAT PHARMS	**250MG**	**A215540**	**001**	Jan 24, 2023
AA	!	ANDA REPOSITORY	**250MG**	**A207483**	**001**	Jun 24, 2016
AA			**500MG**	**A210961**	**001**	Jan 22, 2024
AA		AUROBINDO PHARMA LTD	**500MG**	**A089853**	**001**	May 04, 1988
AA		COREPHARMA	**250MG**	**A214702**	**001**	Apr 10, 2023
AA			**500MG**	**A214941**	**002**	Oct 20, 2022
AA		DR REDDYS LABS SA	**500MG**	**A211849**	**002**	Jul 21, 2020
AA		NOVITIUM PHARMA	**500MG**	**A212254**	**001**	Sep 12, 2019
AA		RISING	**250MG**	**A216925**	**001**	Aug 09, 2023
AA			**500MG**	**A213126**	**002**	Apr 05, 2022
AA		SENORES PHARMS	**250MG**	**A215158**	**001**	Jul 29, 2021
AA	!	WATSON LABS	**500MG**	**A089859**	**001**	May 04, 1988
AB	!	ANDA REPOSITORY	**375MG**	**A040861**	**001**	Jun 01, 2010
AB	!		**750MG**	**A040861**	**002**	Jun 01, 2010
AB		AUROBINDO PHARMA LTD	**375MG**	**A089853**	**002**	Aug 17, 2023
AB			**750MG**	**A089853**	**003**	Aug 17, 2023
AB		COREPHARMA	**375MG**	**A214941**	**001**	Oct 20, 2022
AB			**750MG**	**A214941**	**003**	Oct 20, 2022
AB		DR REDDYS LABS SA	**375MG**	**A211849**	**001**	Jul 21, 2020
AB			**750MG**	**A211849**	**003**	Jul 21, 2020
AB		NOVITIUM PHARMA	**375MG**	**A212253**	**001**	Nov 27, 2019
AB			**750MG**	**A212253**	**002**	Nov 27, 2019
AB		PH HEALTH	**375MG**	**A212743**	**002**	Apr 29, 2021
AB			**750MG**	**A212743**	**001**	Nov 02, 2020
AB		RISING	**375MG**	**A213126**	**001**	Apr 05, 2022
AB			**750MG**	**A213126**	**003**	Apr 05, 2022
AB		SOMERSET THERAPS LLC	**375MG**	**A212047**	**001**	Jan 27, 2023
AB			**750MG**	**A212047**	**002**	Jan 27, 2023

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	**EQ 4GM RESIN/PACKET**	**A211119**	**001**	Apr 06, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211119**	**002**	Apr 06, 2020
AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211856**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211856**	**002**	Oct 19, 2021
AB	!	EPIC PHARMA LLC	**EQ 4GM RESIN/PACKET**	**A074557**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557**	**002**	Aug 15, 1996
AB		MACLEODS PHARMS LTD	**EQ 4GM RESIN/PACKET**	**A207294**	**001**	Nov 21, 2024
AB			**EQ 4GM RESIN/SCOOPFUL**	**A207294**	**002**	Nov 21, 2024
AB		PH HEALTH	**EQ 4GM RESIN/PACKET**	**A077204**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204**	**002**	Aug 26, 2005
AB		TAGI	**EQ 4GM RESIN/PACKET**	**A209597**	**001**	Mar 09, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209597**	**002**	Mar 09, 2021
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202901**	**001**	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211799**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211799**	**002**	Oct 19, 2021
AB	!	EPIC PHARMA LLC	**EQ 4GM RESIN/PACKET**	**A074558**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558**	**002**	Aug 15, 1996
AB		PH HEALTH	**EQ 4GM RESIN/PACKET**	**A077203**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203**	**002**	Aug 26, 2005
AB		PHARMOBEDIENT CNSLTG	**EQ 4GM RESIN/PACKET**	**A209599**	**001**	Nov 12, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209599**	**002**	Nov 12, 2020
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202902**	**001**	Apr 25, 2017

CHOLESTYRAMINE

POWDER;ORAL

LOCHOLEST

AB		CHARTWELL RX	**EQ 4GM RESIN/PACKET**	**A074561**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074561**	**002**	Aug 15, 1996

LOCHOLEST LIGHT

AB		CHARTWELL RX	**EQ 4GM RESIN/PACKET**	**A074562**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074562**	**002**	Aug 15, 1996

PREVALITE

AB		AIPING PHARM INC	**EQ 4GM RESIN/PACKET**	**A073263**	**001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263**	**002**	Oct 30, 1997

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

	+	MIRUM	50MG	N205750	001	Mar 17, 2015
	+!		250MG	N205750	002	Mar 17, 2015

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP		DECATUR	**4-33.1mCi/ML**	**A206319**	**001**	Nov 13, 2015
AP	**+!**	MCPRF	**4-33.1mCi/ML**	**N203155**	**001**	Sep 12, 2012

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920**	**001**	Oct 07, 2015
AB			**EQ 135MG FENOFIBRIC ACID**	**A200920**	**002**	Oct 07, 2015
AB		ALEMBIC	**EQ 45MG FENOFIBRIC ACID**	**A208705**	**001**	May 12, 2017
AB			**EQ 135MG FENOFIBRIC ACID**	**A208705**	**002**	May 12, 2017
AB		AUROBINDO PHARMA LTD	**EQ 45MG FENOFIBRIC ACID**	**A212598**	**001**	Jul 25, 2019
AB	**!**		**EQ 135MG FENOFIBRIC ACID**	**A212598**	**002**	Jul 25, 2019
AB		CHARTWELL RX	**EQ 45MG FENOFIBRIC ACID**	**A200750**	**001**	Dec 04, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200750**	**002**	Dec 04, 2013
AB		IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264**	**001**	Sep 07, 2016
AB			**EQ 135MG FENOFIBRIC ACID**	**A200264**	**002**	Sep 07, 2016
AB		MICRO LABS	**EQ 45MG FENOFIBRIC ACID**	**A213450**	**001**	Jun 16, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A213450**	**002**	Jun 16, 2020
AB		RISING	**EQ 45MG FENOFIBRIC ACID**	**A211626**	**001**	Jul 18, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A211626**	**002**	Jul 18, 2019
AB		YICHANG HUMANWELL	**EQ 45MG FENOFIBRIC ACID**	**A212562**	**001**	Dec 23, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A212562**	**002**	Dec 23, 2020

CHROMIC CHLORIDE

INJECTABLE;INJECTION

CHROMIC CHLORIDE

AP		RK PHARMA	**EQ 0.004MG CHROMIUM/ML**	**A218538**	**001**	Nov 18, 2024

CHROMIC CHLORIDE IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**EQ 0.004MG CHROMIUM/ML**	**N018961**	**001**	Jun 26, 1986

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

	+!	COVIS	0.08MG/INH	N021658	002	Jan 10, 2008
	+!		0.16MG/INH	N021658	003	Jan 10, 2008

SPRAY, METERED;NASAL

OMNARIS

	+!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB		COSETTE	**0.77%**	**A078463**	**001**	Dec 20, 2010
AB		FOUGERA PHARMS	**0.77%**	**A076435**	**001**	Dec 29, 2004
AB		GLENMARK PHARMS	**0.77%**	**A090273**	**001**	Nov 10, 2009
AB		PADAGIS ISRAEL	**0.77%**	**A077364**	**001**	Mar 03, 2006
AB		SUN PHARMA CANADA	**0.77%**	**A076790**	**001**	Apr 12, 2005

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001**	Dec 30, 1982

GEL;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A077896**	**001**	Jun 10, 2008
AB	**!**	GLENMARK PHARMS INC	**0.77%**	**A091595**	**001**	Feb 29, 2012
AB		PADAGIS US	**0.77%**	**A078266**	**001**	Jan 07, 2009

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**1%**	**A090490**	**001**	Nov 24, 2009
AT		ENCUBE	**1%**	**A209975**	**001**	Apr 05, 2018
AT		FOUGERA PHARMS	**1%**	**A090146**	**001**	May 25, 2010
AT	!	PADAGIS US	**1%**	**A078594**	**001**	Feb 16, 2010
AT		SUN PHARMA CANADA	**1%**	**A090269**	**001**	Feb 23, 2011

SOLUTION;TOPICAL

CICLOPIROX

AT		ACELLA	**8%**	**A078172**	**001**	Sep 18, 2007
AT		CHARTWELL RX	**8%**	**A078046**	**001**	Sep 18, 2007
AT		ENCUBE	**8%**	**A077687**	**001**	Sep 18, 2007
AT	!	PADAGIS US	**8%**	**A077623**	**001**	Sep 18, 2007
AT		RISING	**8%**	**A078124**	**001**	Sep 18, 2007

SUSPENSION;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001**	Aug 06, 2004
AB		PADAGIS ISRAEL	**0.77%**	**A077676**	**001**	Dec 15, 2006

LOPROX

AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001**	Dec 30, 1988

CIDOFOVIR

SOLUTION;INTRAVENOUS

CIDOFOVIR

AP		AVET LIFESCIENCES	**EQ 375MG BASE/5ML (EQ 75MG BASE/ML)**	**A202501**	**001**	Jul 26, 2012
AP	!	MYLAN INSTITUTIONAL	**EQ 375MG BASE/5ML (EQ 75MG BASE/ML)**	**A201276**	**001**	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002**	Dec 21, 2011
AP		HQ SPCLT PHARMA	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A207594**	**001**	Dec 12, 2019

PRIMAXIN

AP	**+!**	MERCK	**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

IMIPENEM AND CILASTATIN

	!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577	001	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER;INTRAVENOUS

RECARBRIO

	+!	MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819	001	Jul 16, 2019

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		CHARTWELL RX	**50MG**	**A077831**	**002**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		EPIC PHARMA LLC	**50MG**	**A077022**	**002**	Mar 11, 2005
AB			**100MG**	**A077022**	**001**	Nov 23, 2004
AB		SLATE RUN PHARMA	**50MG**	**A077208**	**002**	Mar 29, 2006
AB			**100MG**	**A077208**	**001**	Mar 29, 2006
AB	!	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	!		**100MG**	**A077027**	**002**	Nov 24, 2004

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		AUROBINDO PHARMA LTD	**200MG**	**A218997**	**001**	Nov 12, 2024
AB			**300MG**	**A218997**	**002**	Nov 12, 2024
AB			**400MG**	**A218997**	**003**	Nov 12, 2024
AB			**800MG**	**A218997**	**004**	Nov 12, 2024
AB		BIONPHARMA	**200MG**	**A218220**	**001**	Nov 07, 2024
AB			**300MG**	**A218220**	**002**	Nov 07, 2024
AB			**400MG**	**A218220**	**003**	Nov 07, 2024
AB			**800MG**	**A218220**	**004**	Nov 07, 2024
AB		CHARTWELL MOLECULES	**200MG**	**A074329**	**002**	May 17, 1994
AB			**300MG**	**A074329**	**003**	May 17, 1994
AB			**400MG**	**A074329**	**004**	May 17, 1994
AB			**800MG**	**A074329**	**001**	May 17, 1994

CIMETIDINE						
TABLET;ORAL						
CIMETIDINE						
AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	!		**800MG**	**A074246**	**004**	May 17, 1994
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994
CIMETIDINE HYDROCHLORIDE						
SOLUTION;ORAL						
CIMETIDINE HYDROCHLORIDE						
AA		CHARTWELL MOLECULAR	**EQ 300MG BASE/5ML**	**A074251**	**001**	Dec 22, 1994
AA	!	PAI HOLDINGS PHARM	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
CINACALCET HYDROCHLORIDE						
TABLET;ORAL						
CINACALCET HYDROCHLORIDE						
AB		ACCORD HLTHCARE	**EQ 30MG BASE**	**A211892**	**001**	May 15, 2020
AB			**EQ 60MG BASE**	**A211892**	**002**	May 15, 2020
AB			**EQ 90MG BASE**	**A211892**	**003**	May 15, 2020
AB		ALKEM LABS LTD	**EQ 30MG BASE**	**A210570**	**001**	May 17, 2019
AB			**EQ 60MG BASE**	**A210570**	**002**	May 17, 2019
AB			**EQ 90MG BASE**	**A210570**	**003**	May 17, 2019
AB		AUROBINDO PHARMA LTD	**EQ 30MG BASE**	**A206125**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A206125**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A206125**	**003**	Mar 08, 2018
AB		CHARTWELL RX	**EQ 30MG BASE**	**A213325**	**001**	May 18, 2020
AB			**EQ 60MG BASE**	**A213325**	**002**	May 18, 2020
AB			**EQ 90MG BASE**	**A213325**	**003**	May 18, 2020
AB		CIPLA	**EQ 30MG BASE**	**A208915**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A208915**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A208915**	**003**	Mar 08, 2018
AB		DR REDDYS	**EQ 30MG BASE**	**A208368**	**001**	Sep 18, 2020
AB			**EQ 60MG BASE**	**A208368**	**002**	Sep 18, 2020
AB			**EQ 90MG BASE**	**A208368**	**003**	Sep 18, 2020
AB		HETERO LABS LTD V	**EQ 30MG BASE**	**A209403**	**001**	Oct 07, 2020
AB			**EQ 60MG BASE**	**A209403**	**002**	Oct 07, 2020
AB			**EQ 90MG BASE**	**A209403**	**003**	Oct 07, 2020
AB		PIRAMAL	**EQ 30MG BASE**	**A210207**	**001**	Aug 01, 2018
AB			**EQ 60MG BASE**	**A210207**	**002**	Aug 01, 2018
AB			**EQ 90MG BASE**	**A210207**	**003**	Aug 01, 2018
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209226**	**001**	Apr 30, 2018
AB			**EQ 60MG BASE**	**A209226**	**002**	Apr 30, 2018
AB	!		**EQ 90MG BASE**	**A209226**	**003**	Apr 30, 2018
AB		SUN PHARM	**EQ 60MG BASE**	**A207008**	**002**	Oct 11, 2018
AB		WATSON LABS TEVA	**EQ 30MG BASE**	**A204377**	**001**	Dec 27, 2018
AB			**EQ 60MG BASE**	**A204377**	**002**	Dec 27, 2018
AB			**EQ 90MG BASE**	**A204377**	**003**	Dec 27, 2018
CIPROFLOXACIN						
FOR SUSPENSION;ORAL						
CIPRO						
AB	+	BAYER HLTHCARE	**250MG/5ML**	**N020780**	**001**	Sep 26, 1997
AB	+!		**500MG/5ML**	**N020780**	**002**	Sep 26, 1997
CIPROFLOXACIN						
AB		CHARTWELL	**250MG/5ML**	**A200563**	**001**	Mar 05, 2014
AB			**500MG/5ML**	**A200563**	**002**	Mar 05, 2014
INJECTABLE;INJECTION						
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	!	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP	!		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008
AP		INFORLIFE	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078252**	**002**	Mar 18, 2008
CIPROFLOXACIN						
	!	HIKMA FARMACEUTICA	200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009
	!		400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

	+!	SANDOZ	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

CILOXAN

AT	**+!**	SANDOZ	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

AT		ALTAIRE PHARMS INC	**EQ 0.3% BASE**	**A204613**	**001**	May 03, 2018
AT		FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT		RISING	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT		RUBICON RESEARCH	**EQ 0.3% BASE**	**A075928**	**001**	Jun 09, 2004
AT		WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005

SOLUTION/DROPS;OTIC

CETRAXAL

AB	**+!**	LAB SALVAT	**EQ 0.2% BASE**	**N021918**	**001**	May 01, 2009

CIPROFLOXACIN HYDROCHLORIDE

AB		NEW HEIGHTSRX	**EQ 0.2% BASE**	**A217887**	**001**	Nov 05, 2024

TABLET;ORAL

CIPRO

AB	**+**	BAYER HLTHCARE	**EQ 250MG BASE**	**N019537**	**002**	Oct 22, 1987
AB	**+!**		**EQ 500MG BASE**	**N019537**	**003**	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

AB	AIPING PHARM INC	**EQ 250MG BASE**	**A076593**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076593**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076593**	**004**	Jun 09, 2004
AB	AMNEAL	**EQ 250MG BASE**	**A075939**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075939**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075939**	**004**	Jun 09, 2004
AB	AUROBINDO PHARMA	**EQ 250MG BASE**	**A077859**	**001**	Apr 26, 2007
AB		**EQ 500MG BASE**	**A077859**	**002**	Apr 26, 2007
AB		**EQ 750MG BASE**	**A077859**	**003**	Apr 26, 2007
AB	CARLSBAD	**EQ 250MG BASE**	**A076126**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076126**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076126**	**004**	Jun 09, 2004
AB	CHARTWELL	**EQ 250MG BASE**	**A076896**	**001**	Nov 04, 2004
AB		**EQ 500MG BASE**	**A076896**	**002**	Nov 04, 2004
AB		**EQ 750MG BASE**	**A076896**	**003**	Nov 04, 2004
AB	DR REDDYS LABS LTD	**EQ 250MG BASE**	**A075593**	**003**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075593**	**004**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075593**	**001**	Jun 09, 2004
AB	HIKMA	**EQ 250MG BASE**	**A076558**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076558**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076558**	**004**	Jun 09, 2004
AB	IVAX SUB TEVA PHARMS	**EQ 250MG BASE**	**A076089**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076089**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076089**	**004**	Jun 09, 2004
AB	RISING	**EQ 500MG BASE**	**A075817**	**003**	Jun 09, 2004
AB	UNIQUE	**EQ 250MG BASE**	**A076639**	**001**	Sep 10, 2004
AB		**EQ 500MG BASE**	**A076639**	**002**	Sep 10, 2004
AB		**EQ 750MG BASE**	**A076639**	**003**	Sep 10, 2004
AB	WATSON LABS	**EQ 250MG BASE**	**A076794**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076794**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076794**	**004**	Jun 09, 2004
AB	YILING	**EQ 250MG BASE**	**A208921**	**001**	Jun 22, 2018
AB		**EQ 500MG BASE**	**A208921**	**002**	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

	+!	LAB SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

AB	**+!**	SANDOZ	**EQ 0.2% BASE;1%**	**N020805**	**001**	Feb 10, 1998

CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE

AB		COSETTE PHARMS NC	**EQ 0.2% BASE;1%**	**A218273**	**001**	Nov 10, 2025

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	!	DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

AB	**+!**	SANDOZ	**0.3%;0.1%**	**N021537**	**001**	Jul 18, 2003

CIPROFLOXACIN AND DEXAMETHASONE

AB		AMNEAL	**0.3%;0.1%**	**A216501**	**001**	Mar 22, 2024
AB		DR REDDYS	**0.3%;0.1%**	**A205548**	**001**	Aug 10, 2020
AB		SENTISS	**0.3%;0.1%**	**A215768**	**001**	Jun 09, 2023
AB		SUN PHARM	**0.3%;0.1%**	**A210470**	**001**	Aug 30, 2022
AB		UPSHER SMITH LABS	**0.3%;0.1%**	**A216487**	**001**	Jan 06, 2026

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		CAPLIN	**EQ 2MG BASE/ML**	**A217725**	**001**	Jun 09, 2023
AP			**EQ 10MG BASE/ML**	**A217725**	**002**	Jun 09, 2023
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP		GLAND	**EQ 2MG BASE/ML**	**A215516**	**001**	May 24, 2022
AP			**EQ 2MG BASE/ML**	**A215516**	**003**	Dec 14, 2022
AP			**EQ 10MG BASE/ML**	**A215516**	**002**	May 24, 2022
AP		HENGRUI PHARMA	**EQ 2MG BASE/ML**	**A204960**	**003**	Aug 30, 2017
AP		HIKMA	**EQ 2MG BASE/ML**	**A203078**	**001**	Jun 28, 2022
AP			**EQ 2MG BASE/ML**	**A203079**	**001**	Apr 19, 2023
AP			**EQ 10MG BASE/ML**	**A203078**	**002**	Dec 18, 2023
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A203236**	**001**	Mar 30, 2018
AP			**EQ 2MG BASE/ML**	**A203238**	**001**	Mar 30, 2018
AP			**EQ 10MG BASE/ML**	**A203236**	**002**	Mar 30, 2018
AP	!	MEITHEAL	**EQ 2MG BASE/ML**	**A211668**	**001**	Apr 25, 2019
AP	!		**EQ 2MG BASE/ML**	**A211669**	**001**	Apr 25, 2019
AP	!		**EQ 10MG BASE/ML**	**A211668**	**002**	Apr 25, 2019
AP		SAGENT PHARMS INC	**EQ 2MG BASE/ML**	**A201836**	**001**	Nov 06, 2020
AP			**EQ 2MG BASE/ML**	**A201851**	**001**	Nov 06, 2020
AP			**EQ 10MG BASE/ML**	**A201836**	**002**	Nov 06, 2020
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012
AP		SOMERSET	**EQ 2MG BASE/ML**	**A209132**	**001**	Apr 24, 2019
AP		ZYDUS PHARMS	**EQ 2MG BASE/ML**	**A212171**	**001**	Nov 04, 2019
AP			**EQ 10MG BASE/ML**	**A212171**	**002**	Nov 04, 2019

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP			**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP		HENGRUI PHARMA	**EQ 2MG BASE/ML**	**A204960**	**001**	Jan 27, 2017
AP			**EQ 10MG BASE/ML**	**A204960**	**002**	Sep 19, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP			**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012
AP		SOMERSET THERAPS LLC	**EQ 2MG BASE/ML**	**A206791**	**001**	Feb 20, 2019
AP			**EQ 10MG BASE/ML**	**A206791**	**002**	Feb 20, 2019

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	!	FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP		GLAND	**1MG/ML**	**A207323**	**001**	Mar 17, 2017
AP		HIKMA	**1MG/ML**	**A075036**	**001**	Nov 07, 2000
AP	+	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP		PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000
AP		QILU	**1MG/ML**	**A218868**	**001**	May 10, 2024
	+!	HQ SPCLT PHARMA	50MG/VIAL	N018057	002	

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

	+!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA	**EQ 10MG BASE/5ML**	**A077812**	**001**	Aug 28, 2006
AA		CHARTWELL MOLECULAR	**EQ 10MG BASE/5ML**	**A077629**	**001**	Jun 14, 2006
AA		HETERO LABS LTD III	**EQ 10MG BASE/5ML**	**A201450**	**001**	Dec 15, 2015
AA	!	HIKMA	**EQ 10MG BASE/5ML**	**A077043**	**001**	Dec 13, 2004

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	**+**	ABBVIE	**EQ 10MG BASE**	**N020822**	**001**	Apr 27, 2000
AB	**+**		**EQ 20MG BASE**	**N020822**	**002**	Jul 17, 1998
AB	**+!**		**EQ 40MG BASE**	**N020822**	**003**	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS NY	**EQ 10MG BASE**	**A077289**	**001**	Nov 30, 2006
AB		**EQ 20MG BASE**	**A077289**	**002**	Nov 30, 2006
AB		**EQ 40MG BASE**	**A077289**	**003**	Nov 30, 2006
AB	AUROBINDO	**EQ 10MG BASE**	**A077031**	**001**	Oct 28, 2004
AB		**EQ 20MG BASE**	**A077031**	**002**	Oct 28, 2004
AB		**EQ 40MG BASE**	**A077031**	**003**	Oct 28, 2004
AB	CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A077044**	**001**	Nov 05, 2004
AB		**EQ 20MG BASE**	**A077044**	**002**	Nov 05, 2004
AB		**EQ 40MG BASE**	**A077044**	**003**	Nov 05, 2004
AB	DR REDDYS LABS LTD	**EQ 10MG BASE**	**A077038**	**001**	Oct 28, 2004
AB		**EQ 20MG BASE**	**A077038**	**002**	Oct 28, 2004
AB		**EQ 40MG BASE**	**A077038**	**003**	Oct 28, 2004
AB	EPIC PHARMA	**EQ 10MG BASE**	**A077045**	**003**	Apr 29, 2005
AB		**EQ 20MG BASE**	**A077045**	**002**	Apr 29, 2005
AB		**EQ 40MG BASE**	**A077045**	**001**	Apr 29, 2005
AB	INVAGEN PHARMS	**EQ 10MG BASE**	**A077534**	**001**	Oct 03, 2006
AB		**EQ 20MG BASE**	**A077534**	**002**	Oct 03, 2006
AB		**EQ 40MG BASE**	**A077534**	**003**	Oct 03, 2006
AB	MYLAN	**EQ 10MG BASE**	**A077042**	**001**	Nov 05, 2004
AB		**EQ 20MG BASE**	**A077042**	**002**	Nov 05, 2004
AB		**EQ 40MG BASE**	**A077042**	**003**	Nov 05, 2004
AB	TORRENT PHARMS	**EQ 10MG BASE**	**A078216**	**001**	Mar 27, 2007
AB		**EQ 20MG BASE**	**A078216**	**002**	Mar 27, 2007
AB		**EQ 40MG BASE**	**A078216**	**003**	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+!	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXXI

+!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

!	HETERO LABS LTD V	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	A212789	001	Jul 18, 2022

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+!	MERIDIAN BIOSCIENCE	4GM;75MG	N021314	001	Dec 17, 2002

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A076571**	**001**	Apr 22, 2004
AP		HIKMA	**1MG/ML**	**A075405**	**001**	Feb 28, 2000
AP		HISUN PHARM HANGZHOU	**1MG/ML**	**A210856**	**001**	Nov 25, 2019

TABLET;ORAL

CLADRIBINE

AB	APOTEX	**10MG**	**A218425**	**001**	Nov 24, 2025

MAVENCLAD

AB	**+!**	EMD SERONO INC	**10MG**	**N022561**	**001**	Mar 29, 2019

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

	SANDOZ	125MG/5ML	A065283	002	Sep 04, 2007
!		250MG/5ML	A065283	003	Sep 04, 2007

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB		ALEMBIC	**250MG**	**A210459**	**001**	Jan 31, 2022
AB			**500MG**	**A210459**	**002**	Jan 31, 2022
AB	**!**	AUROBINDO	**250MG**	**A065489**	**001**	Jul 25, 2012
AB	**!**		**500MG**	**A065489**	**002**	Jul 25, 2012
AB		CHARTWELL	**250MG**	**A065384**	**001**	Aug 20, 2007
AB			**500MG**	**A065384**	**002**	Aug 20, 2007
AB		HEC PHARM	**250MG**	**A203584**	**001**	Sep 28, 2015
AB			**500MG**	**A203584**	**002**	Sep 28, 2015
AB		NOVITIUM PHARMA	**250MG**	**A202710**	**001**	Jun 10, 2013
AB			**500MG**	**A202710**	**002**	Jun 10, 2013
AB		SANDOZ	**250MG**	**A065144**	**001**	Oct 18, 2005
AB			**500MG**	**A065136**	**001**	Aug 25, 2005

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		ACTAVIS LABS FL INC	**500MG**	**A065145**	**001**	Jun 24, 2004
AB	**!**	DR REDDYS LABS SA	**500MG**	**A065154**	**001**	May 18, 2005
AB		MPP PHARMA	**500MG**	**A203243**	**001**	Feb 29, 2016
AB		SUNSHINE	**500MG**	**A208987**	**001**	Jul 09, 2018

CLASCOTERONE

CREAM;TOPICAL

WINLEVI

	+!	SUN PHARM	1%	N213433	001	Aug 26, 2020

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

AA	**!**	GENUS	**EQ 0.5MG BASE/5ML**	**A073399**	**001**	Jun 30, 1994
AA		NEW HEIGHTSRX	**EQ 0.5MG BASE/5ML**	**A074884**	**001**	Dec 17, 1997

TABLET;ORAL

CLEMASTINE FUMARATE

	!	GENUS	2.68MG	A073283	001	Jan 31, 1992

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

	+!	CHIESI	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+!		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLEOCIN HYDROCHLORIDE

AB	**+**	PFIZER	**EQ 75MG BASE**	**N050162**	**001**	
AB	**+**		**EQ 150MG BASE**	**N050162**	**002**	
AB	**+!**		**EQ 300MG BASE**	**N050162**	**003**	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 150MG BASE**	**A065442**	**001**	Aug 26, 2009
AB			**EQ 300MG BASE**	**A065442**	**002**	Aug 26, 2009
AB		CHARTWELL MOLECULAR	**EQ 75MG BASE**	**A065243**	**002**	Aug 12, 2005
AB		EPIC PHARMA LLC	**EQ 150MG BASE**	**A065194**	**001**	Mar 22, 2004
AB			**EQ 300MG BASE**	**A065194**	**002**	Mar 22, 2004
AB		GLENMARK PHARMS LTD	**EQ 75MG BASE**	**A216957**	**001**	Mar 10, 2023
AB			**EQ 150MG BASE**	**A216957**	**002**	Mar 10, 2023
AB			**EQ 300MG BASE**	**A216957**	**003**	Mar 10, 2023
AB		MICRO LABS	**EQ 75MG BASE**	**A207402**	**001**	Nov 05, 2018
AB			**EQ 150MG BASE**	**A207402**	**002**	Nov 05, 2018
AB			**EQ 300MG BASE**	**A207402**	**003**	Nov 05, 2018
AB		SUN PHARM INDS LTD	**EQ 150MG BASE**	**A065061**	**001**	Feb 02, 2001
AB			**EQ 300MG BASE**	**A065061**	**002**	Feb 02, 2001
AB		ZYDUS PHARMS USA	**EQ 75MG BASE**	**A065217**	**001**	Jan 31, 2005
AB			**EQ 150MG BASE**	**A065217**	**002**	Jan 31, 2005
AB			**EQ 300MG BASE**	**A065217**	**003**	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

AA	**!**	PFIZER	**EQ 75MG BASE/5ML**	**A062644**	**001**	Apr 07, 1986

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 75MG BASE/5ML**	**A203513**	**001**	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**	**A202409**	**001**	Apr 30, 2013
AA		CHARTWELL RX	**EQ 75MG BASE/5ML**	**A206958**	**001**	May 05, 2017

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		PADAGIS US	**EQ 75MG BASE/5ML**	**A090902**	**001**	Jul 07, 2010
AA		RISING	**EQ 75MG BASE/5ML**	**A201821**	**001**	Aug 28, 2012
AA		SOMERSET THERAPS LLC	**EQ 75MG BASE/5ML**	**A207047**	**001**	May 11, 2018

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		GLENMARK PHARMS LTD	**1%**	**A210778**	**001**	Sep 20, 2021
AT	!	PADAGIS ISRAEL	**1%**	**A090785**	**001**	Mar 31, 2010
AT		TARO	**1%**	**A210004**	**001**	Mar 11, 2020

CREAM;VAGINAL

CLEOCIN

AB	**+!**	PFIZER	**EQ 2% BASE**	**N050680**	**002**	Mar 02, 1998

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	**EQ 2% BASE**	**A065139**	**001**	Dec 27, 2004

CLINDESSE

	+!	PADAGIS US	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL;TOPICAL

CLEOCIN T

AB1	**+!**	PFIZER	**EQ 1% BASE**	**N050615**	**001**	Jan 07, 1987

CLINDAMYCIN PHOSPHATE

AB1		ALEMBIC	**EQ 1% BASE**	**A212466**	**001**	Apr 02, 2024
AB1		ENCUBE	**EQ 1% BASE**	**A212438**	**001**	Mar 11, 2021
AB1		FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000
AB1		GLENMARK PHARMS LTD	**EQ 1% BASE**	**A214251**	**001**	Feb 10, 2021
AB1		PADAGIS ISRAEL	**EQ 1% BASE**	**A212104**	**001**	Dec 31, 2020
AB1		QUAGEN	**EQ 1% BASE**	**A211872**	**001**	Jul 29, 2020
AB1		SUN PHARMA CANADA	**EQ 1% BASE**	**A214052**	**001**	Nov 10, 2020
AB1		ZYDUS LIFESCIENCES	**EQ 1% BASE**	**A216587**	**001**	Sep 19, 2023

CLINDAGEL

AB2	**+!**	BAUSCH	**EQ 1% BASE**	**N050782**	**001**	Nov 27, 2000

CLINDAMYCIN PHOSPHATE

AB2		AMNEAL	**EQ 1% BASE**	**A214668**	**001**	Aug 05, 2022
AB2		SOLARIS PHARMA CORP	**EQ 1% BASE**	**A212842**	**001**	Aug 13, 2021

GEL;VAGINAL

XACIATO

	+!	ORGANON LLC	EQ 2% BASE	N215650	001	Dec 07, 2021

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		PFIZER	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	**+!**		**EQ 150MG BASE/ML**	**N050441**	**001**	

CLINDAMYCIN PHOSPHATE

AP		HIKMA	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
AP			**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004
AP		SAGENT PHARMS INC	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP			**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**EQ 6MG BASE/ML**	**A208084**	**001**	Jun 28, 2017
AP			**EQ 12MG BASE/ML**	**A208084**	**002**	Jun 28, 2017
AP			**EQ 18MG BASE/ML**	**A208084**	**003**	Jun 28, 2017
AP		RISING	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP			**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP			**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP	!	SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP	!		**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP	!		**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP		HIKMA	**EQ 6MG BASE/ML**	**A214401**	**001**	Apr 05, 2023
AP			**EQ 12MG BASE/ML**	**A214401**	**002**	Apr 05, 2023
AP			**EQ 18MG BASE/ML**	**A214401**	**003**	Apr 05, 2023
	+!	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T

AB	**+!**	PFIZER	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989

CLINDAMYCIN PHOSPHATE

AB		ENCUBE	**EQ 1% BASE**	**A215607**	**001**	Jan 18, 2022
AB		FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002
AB		PADAGIS ISRAEL	**EQ 1% BASE**	**A214604**	**001**	Mar 08, 2021

CLINDAMYCIN PHOSPHATE

LOTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB		SUN PHARMA CANADA	**EQ 1% BASE**	**A214526**	**001**	Jun 28, 2021

SOLUTION;INTRAVENOUS

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017
	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017
	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017

SOLUTION;TOPICAL

CLINDA-DERM

AT		PADAGIS US	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992

CLINDAMYCIN PHOSPHATE

AT		CHARTWELL RX	**EQ 1% BASE**	**A209846**	**001**	Feb 08, 2018
AT		ENCUBE ETHICALS	**EQ 1% BASE**	**A209914**	**001**	Jan 28, 2019
AT		FOUGERA PHARMS INC	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT	!	PADAGIS US	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995
AT		TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
AT		ZYDUS LIFESCIENCES	**EQ 1% BASE**	**A208767**	**001**	Jul 16, 2018

SUPPOSITORY;VAGINAL

CLEOCIN

	+!	PFIZER	100MG	N050767	001	Aug 13, 1999

SWAB;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		CARNEGIE	**EQ 1% BASE**	**A219612**	**001**	Jun 13, 2025
AT		EPIC PHARMA LLC	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT	!	PADAGIS US	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000

CLINDETS

AT		PADAGIS US	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1		ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015

ZIANA

AB1	**+!**	BAUSCH	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB2		ENCUBE	**1.2%;0.025%**	**A216943**	**001**	Sep 01, 2023
AB2		SOLARIS PHARMA CORP	**1.2%;0.025%**	**A212845**	**001**	Feb 10, 2022

VELTIN

AB2	**+!**	ALMIRALL	**1.2%;0.025%**	**N050803**	**001**	Jul 16, 2010

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	ASSERTIO SPECLTY	5MG	N210833	001	Nov 01, 2018
	+		10MG	N210833	002	Nov 01, 2018
	+!		20MG	N210833	003	Nov 01, 2018

SUSPENSION;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**2.5MG/ML**	**A213039**	**001**	May 06, 2021
AB		AMNEAL	**2.5MG/ML**	**A210039**	**001**	Oct 22, 2018
AB		AUROBINDO PHARMA LTD	**2.5MG/ML**	**A214404**	**001**	Mar 24, 2022
AB		BIONPHARMA	**2.5MG/ML**	**A208819**	**001**	Oct 22, 2018
AB		CHARTWELL MOLECULAR	**2.5MG/ML**	**A213110**	**001**	Apr 24, 2020
AB		HETERO LABS LTD III	**2.5MG/ML**	**A209796**	**001**	Feb 24, 2020
AB		TARO	**2.5MG/ML**	**A210978**	**001**	Apr 15, 2019

ONFI

AB	**+!**	LUNDBECK PHARMS LLC	**2.5MG/ML**	**N203993**	**001**	Dec 14, 2012

TABLET;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**10MG**	**A212714**	**001**	Sep 06, 2019
AB			**20MG**	**A212714**	**002**	Sep 06, 2019
AB		AMNEAL PHARMS CO	**10MG**	**A209718**	**001**	Oct 22, 2018
AB			**20MG**	**A209718**	**002**	Oct 22, 2018
AB		BIONPHARMA	**10MG**	**A208825**	**001**	Oct 22, 2018
AB			**20MG**	**A208825**	**002**	Oct 22, 2018
AB		HETERO LABS LTD III	**10MG**	**A209795**	**001**	Oct 22, 2018
AB			**20MG**	**A209795**	**002**	Oct 22, 2018
AB		LUPIN LTD	**10MG**	**A210545**	**001**	Dec 14, 2018
AB			**20MG**	**A210545**	**002**	Dec 14, 2018

CLOBAZAM

TABLET;ORAL

CLOBAZAM

AB		MICRO LABS	**10MG**	**A211711**	**001**	Jan 30, 2019
AB			**20MG**	**A211711**	**002**	Jan 30, 2019
AB		MSN	**10MG**	**A213404**	**001**	May 11, 2021
AB			**20MG**	**A213404**	**002**	May 11, 2021
AB		PIRAMAL	**10MG**	**A209808**	**001**	Oct 22, 2018
AB			**20MG**	**A209808**	**002**	Oct 22, 2018
AB		UPSHER SMITH LABS	**10MG**	**A209687**	**001**	Oct 22, 2018
AB			**20MG**	**A209687**	**002**	Oct 22, 2018
AB		ZYDUS PHARMS	**10MG**	**A211449**	**001**	Oct 22, 2018
AB			**20MG**	**A211449**	**002**	Oct 22, 2018

ONFI

AB	+	LUNDBECK PHARMS LLC	**10MG**	**N202067**	**002**	Oct 21, 2011
AB	+!		**20MG**	**N202067**	**003**	Oct 21, 2011

CLOBAZAM

		ALKEM LABS LTD	5MG	A212714	003	Dec 21, 2020

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEMBIC	**0.05%**	**A215838**	**001**	Apr 21, 2022
AB1		GLENMARK PHARMS LTD	**0.05%**	**A210809**	**001**	Feb 15, 2019
AB1		PADAGIS ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
AB1	!	TARO	**0.05%**	**A208779**	**001**	Oct 04, 2018
AB1		XIROMED	**0.05%**	**A210638**	**001**	Nov 20, 2025
AB2		GLENMARK PHARMS LTD	**0.05%**	**A211450**	**001**	Sep 09, 2019
AB2	!	PADAGIS ISRAEL	**0.05%**	**A201402**	**001**	Aug 14, 2012

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEMBIC	**0.05%**	**A213291**	**001**	Jan 27, 2020
AB1		AMNEAL	**0.05%**	**A211256**	**001**	Dec 26, 2018
AB1		AUROBINDO PHARMA USA	**0.05%**	**A075338**	**001**	Feb 09, 2001
AB1	!	ENCUBE	**0.05%**	**A212982**	**001**	Aug 28, 2020
AB1		FOUGERA PHARMS INC	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1		LUPIN LTD	**0.05%**	**A210208**	**001**	Jan 30, 2018
AB1		RISING	**0.05%**	**A211401**	**001**	Jan 11, 2019
AB1		SUN PHARMA CANADA	**0.05%**	**A074249**	**001**	Jul 08, 1996
AB1		TORRENT	**0.05%**	**A211836**	**001**	Dec 30, 2019
AB1		XIROMED	**0.05%**	**A210034**	**001**	Jun 15, 2018
AB1		ZYDUS PHARMS	**0.05%**	**A211074**	**001**	Oct 15, 2018

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2		BEACH PRODS	**0.05%**	**A209411**	**001**	Aug 21, 2017
AB2	!	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		SUN PHARMA CANADA	**0.05%**	**A075633**	**001**	May 17, 2000

IMPOYZ

	+!	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	!	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PADAGIS US	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		SUN PHARMA CANADA	**0.05%**	**A075279**	**001**	May 28, 1999

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008
AB		LUPIN LTD	**0.05%**	**A209147**	**001**	Sep 22, 2017
AB		SUN PHARMA CANADA	**0.05%**	**A200302**	**001**	Jul 02, 2012
AB		ZYDUS LIFESCIENCES	**0.05%**	**A205249**	**001**	Sep 24, 2019

CLOBEX

AB	+!	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		ALEMBIC	**0.05%**	**A211800**	**001**	Mar 04, 2019
AB		AUROBINDO PHARMA USA	**0.05%**	**A075057**	**001**	Aug 12, 1998
AB		COSETTE	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB	!	ENCUBE	**0.05%**	**A211295**	**001**	Nov 15, 2019
AB		FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		MACLEODS PHARMS LTD	**0.05%**	**A215990**	**001**	Dec 28, 2023
AB		NOVEL LABS INC	**0.05%**	**A208841**	**001**	May 04, 2018

CLOBETASOL PROPIONATE						
OINTMENT;TOPICAL						
CLOBETASOL PROPIONATE						
AB		SUN PHARMA CANADA	**0.05%**	**A074248**	**001**	Jul 12, 1996
AB		XIROMED	**0.05%**	**A209701**	**001**	Apr 17, 2018
AB		ZYDUS PHARMS	**0.05%**	**A210199**	**001**	Oct 27, 2017
SHAMPOO;TOPICAL						
CLOBETASOL PROPIONATE						
AB		ALEMBIC	**0.05%**	**A213290**	**001**	May 18, 2020
AB		AMNEAL	**0.05%**	**A214895**	**001**	Jun 14, 2021
AB		PADAGIS ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012
AB		SUN PHARMA CANADA	**0.05%**	**A214867**	**001**	Mar 25, 2021
CLOBEX						
AB	**+!**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004
SOLUTION;TOPICAL						
CLOBETASOL PROPIONATE						
AT		ALEMBIC	**0.05%**	**A212881**	**001**	Oct 21, 2019
AT		ENCUBE	**0.05%**	**A076977**	**001**	Aug 05, 2005
AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		MACLEODS PHARMS LTD	**0.05%**	**A209361**	**001**	Oct 25, 2017
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		QUAGEN	**0.05%**	**A211240**	**001**	Feb 17, 2022
AT		SAPTALIS PHARMS	**0.05%**	**A211494**	**001**	Oct 02, 2019
AT	**!**	SUN PHARMA CANADA	**0.05%**	**A075224**	**001**	Nov 16, 1998
SPRAY;TOPICAL						
CLOBETASOL PROPIONATE						
AT		ALEMBIC	**0.05%**	**A211191**	**001**	Oct 02, 2019
AT		PADAGIS US	**0.05%**	**A090898**	**001**	Jun 16, 2011
AT		SUN PHARMA CANADA	**0.05%**	**A208842**	**001**	Mar 26, 2018
AT		ZYDUS PHARMS	**0.05%**	**A206378**	**001**	Feb 16, 2017
CLOBEX						
AT	**+!**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005
SUSPENSION/DROPS;OPHTHALMIC						
BYQLOVI						
	+!	HARROW EYE	0.05%	N218158	001	Mar 04, 2024
CLOCORTOLONE PIVALATE						
CREAM;TOPICAL						
CLOCORTOLONE PIVALATE						
AB		TARO	**0.1%**	**A206370**	**001**	Apr 21, 2020
CLODERM						
AB	**+!**	LEGACY PHARMA	**0.1%**	**N017765**	**001**	
CLOFARABINE						
SOLUTION;INTRAVENOUS						
CLOFARABINE						
AP		ACCORD HLTHCARE	**20MG/20ML (1MG/ML)**	**A212034**	**001**	Feb 22, 2019
AP		AMNEAL	**20MG/20ML (1MG/ML)**	**A208857**	**001**	Nov 06, 2017
AP		DR REDDYS	**20MG/20ML (1MG/ML)**	**A205375**	**001**	Nov 06, 2017
AP		GLAND	**20MG/20ML (1MG/ML)**	**A207831**	**001**	Oct 31, 2018
AP	**!**	MEITHEAL	**20MG/20ML (1MG/ML)**	**A213461**	**001**	Oct 23, 2020
AP		MSN	**20MG/20ML (1MG/ML)**	**A209775**	**001**	Dec 06, 2017
AP		PHARMOBEDIENT	**20MG/20ML (1MG/ML)**	**A208860**	**001**	Nov 06, 2017
AP		SCINOPHARM TAIWAN	**20MG/20ML (1MG/ML)**	**A216233**	**001**	Jan 03, 2025
CLOMIPHENE CITRATE						
TABLET;ORAL						
CLOMIPHENE CITRATE						
AB		ACCORD HLTHCARE	**50MG**	**A219406**	**001**	Oct 03, 2025
AB		APPCO	**50MG**	**A216739**	**001**	Nov 08, 2024
AB	**!**	COSETTE	**50MG**	**A075528**	**001**	Aug 30, 1999
AB		NOVITIUM PHARMA	**50MG**	**A219781**	**001**	Oct 17, 2025
AB		RUBICON	**50MG**	**A216545**	**001**	Nov 12, 2024
MILOPHENE						
AB		GRANATA BIO CORP	**50MG**	**A072196**	**001**	Dec 20, 1988
CLOMIPRAMINE HYDROCHLORIDE						
CAPSULE;ORAL						
ANAFRANIL						
AB	**+!**	SPECGX LLC	**25MG**	**N019906**	**001**	Dec 29, 1989
AB	**+**		**50MG**	**N019906**	**002**	Dec 29, 1989
AB	**+**		**75MG**	**N019906**	**003**	Dec 29, 1989
CLOMIPRAMINE HYDROCHLORIDE						
AB		ALEMBIC	**25MG**	**A211822**	**001**	Aug 04, 2021

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB			**50MG**	**A211822**	**002**	Aug 04, 2021
AB			**75MG**	**A211822**	**003**	Aug 04, 2021
AB		AUROBINDO PHARMA	**25MG**	**A216440**	**001**	Mar 20, 2023
AB			**50MG**	**A216440**	**002**	Mar 20, 2023
AB			**75MG**	**A216440**	**003**	Mar 20, 2023
AB		CHARTWELL RX	**25MG**	**A074364**	**001**	Mar 29, 1996
AB			**50MG**	**A074364**	**002**	Mar 29, 1996
AB			**75MG**	**A074364**	**003**	Mar 29, 1996
AB		IXORA LIFESCIENCE	**25MG**	**A211364**	**001**	Feb 07, 2020
AB			**50MG**	**A211364**	**002**	Feb 07, 2020
AB			**75MG**	**A211364**	**003**	Feb 07, 2020
AB		JUBILANT CADISTA	**25MG**	**A212218**	**001**	Oct 21, 2019
AB			**50MG**	**A212218**	**002**	Oct 21, 2019
AB			**75MG**	**A212218**	**003**	Oct 21, 2019
AB		LUPIN LTD	**25MG**	**A209294**	**001**	Nov 21, 2018
AB			**50MG**	**A209294**	**002**	Nov 21, 2018
AB			**75MG**	**A209294**	**003**	Nov 21, 2018
AB		MANKIND PHARMA	**25MG**	**A211767**	**001**	Apr 08, 2019
AB			**50MG**	**A211767**	**002**	Apr 08, 2019
AB			**75MG**	**A211767**	**003**	Apr 08, 2019
AB		MICRO LABS	**25MG**	**A213219**	**001**	Jun 22, 2020
AB			**50MG**	**A213219**	**002**	Jun 22, 2020
AB			**75MG**	**A213219**	**003**	Jun 22, 2020
AB		SANDOZ	**25MG**	**A074953**	**001**	Jun 25, 1997
AB			**50MG**	**A074953**	**002**	Jun 25, 1997
AB			**75MG**	**A074953**	**003**	Jun 25, 1997
AB		TARO	**25MG**	**A074694**	**001**	Dec 31, 1996
AB			**50MG**	**A074694**	**002**	Dec 31, 1996
AB			**75MG**	**A074694**	**003**	Dec 31, 1996
AB		TP ANDA HOLDINGS	**25MG**	**A210653**	**001**	Apr 03, 2020
AB			**50MG**	**A210653**	**002**	Apr 03, 2020
AB			**75MG**	**A210653**	**003**	Apr 03, 2020
AB		UNIQUE	**25MG**	**A212285**	**001**	Aug 07, 2020
AB			**50MG**	**A212285**	**002**	Aug 07, 2020
AB			**75MG**	**A212285**	**003**	Aug 07, 2020
AB		ZYDUS PHARMS	**25MG**	**A208961**	**001**	Dec 27, 2017
AB			**50MG**	**A208961**	**002**	Dec 27, 2017
AB			**75MG**	**A208961**	**003**	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB		ACCORD HLTHCARE	**0.5MG**	**A077147**	**001**	May 02, 2005
AB			**1MG**	**A077147**	**002**	May 02, 2005
AB			**2MG**	**A077147**	**003**	May 02, 2005
AB		ACTAVIS ELIZABETH	**0.5MG**	**A074869**	**001**	Oct 31, 1996
AB			**1MG**	**A074869**	**002**	Oct 31, 1996
AB			**2MG**	**A074869**	**003**	Oct 31, 1996
AB		AUROBINDO PHARMA USA	**0.5MG**	**A075150**	**001**	Oct 05, 1998
AB			**1MG**	**A075150**	**002**	Oct 05, 1998
AB			**2MG**	**A075150**	**003**	Oct 05, 1998
AB		PRINSTON INC	**0.5MG**	**A077856**	**001**	Jun 28, 2006
AB			**1MG**	**A077856**	**002**	Jun 28, 2006
AB			**2MG**	**A077856**	**003**	Jun 28, 2006
AB		RUBICON RESEARCH	**0.5MG**	**A075468**	**001**	Oct 06, 2000
AB			**1MG**	**A075468**	**002**	Oct 06, 2000
AB			**2MG**	**A075468**	**003**	Oct 06, 2000
AB		SANDOZ	**0.5MG**	**A074979**	**001**	Aug 29, 1997
AB			**1MG**	**A074979**	**002**	Aug 29, 1997
AB			**2MG**	**A074979**	**003**	Aug 29, 1997
AB		TEVA	**0.5MG**	**A074569**	**001**	Sep 10, 1996
AB			**1MG**	**A074569**	**002**	Sep 10, 1996
AB			**2MG**	**A074569**	**003**	Sep 10, 1996

KLONOPIN

AB	**+**	CHEPLAPHARM	**0.5MG**	**N017533**	**001**	
AB	**+!**		**1MG**	**N017533**	**002**	
AB	**+**		**2MG**	**N017533**	**003**	

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		ALEMBIC	**0.125MG**	**A211033**	**001**	Jun 28, 2019
AB			**0.25MG**	**A211033**	**002**	Jun 28, 2019
AB			**0.5MG**	**A211033**	**003**	Jun 28, 2019
AB			**1MG**	**A211033**	**004**	Jun 28, 2019
AB			**2MG**	**A211033**	**005**	Jun 28, 2019
AB		BARR	**0.125MG**	**A077194**	**001**	Aug 10, 2005
AB			**0.25MG**	**A077194**	**002**	Aug 10, 2005
AB			**0.5MG**	**A077194**	**003**	Aug 10, 2005
AB			**1MG**	**A077194**	**004**	Aug 10, 2005
AB			**2MG**	**A077194**	**005**	Aug 10, 2005
AB		PH HEALTH	**0.125MG**	**A077171**	**001**	Aug 03, 2005
AB			**0.25MG**	**A077171**	**002**	Aug 03, 2005
AB			**0.5MG**	**A077171**	**003**	Aug 03, 2005
AB	**!**		**1MG**	**A077171**	**004**	Aug 03, 2005
AB			**2MG**	**A077171**	**005**	Aug 03, 2005

CLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB	**+**	LAVIPHARM	**0.1MG/24HR**	**N018891**	**001**	Oct 10, 1984

CATAPRES-TTS-2

AB	**+**	LAVIPHARM	**0.2MG/24HR**	**N018891**	**002**	Oct 10, 1984

CATAPRES-TTS-3

AB	**+!**	LAVIPHARM	**0.3MG/24HR**	**N018891**	**003**	Oct 10, 1984

CLONIDINE

AB		ACTAVIS LABS UT INC	**0.1MG/24HR**	**A090873**	**001**	May 06, 2014
AB			**0.2MG/24HR**	**A090873**	**002**	May 06, 2014
AB			**0.3MG/24HR**	**A090873**	**003**	May 06, 2014
AB		DR REDDYS LABS SA	**0.1MG/24HR**	**A079090**	**001**	Aug 20, 2010
AB			**0.2MG/24HR**	**A079090**	**002**	Aug 20, 2010
AB			**0.3MG/24HR**	**A079090**	**003**	Aug 20, 2010
AB		MYLAN TECHNOLOGIES	**0.1MG/24HR**	**A076166**	**001**	Jul 16, 2010
AB			**0.2MG/24HR**	**A076166**	**002**	Jul 16, 2010
AB			**0.3MG/24HR**	**A076166**	**003**	Jul 16, 2010

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

		ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/10ML (0.1MG/ML)**	**A200673**	**001**	Jul 08, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200673**	**002**	Jul 08, 2011
AP		HIKMA FARMACEUTICA	**1MG/10ML (0.1MG/ML)**	**A200300**	**001**	Jan 26, 2011
AP	**!**		**5MG/10ML (0.5MG/ML)**	**A200300**	**002**	Jan 26, 2011
AP		XGEN PHARMS	**1MG/10ML (0.1MG/ML)**	**A203167**	**001**	Oct 29, 2013
AP			**5MG/10ML (0.5MG/ML)**	**A203167**	**002**	Oct 29, 2013
AP		ZYDUS PHARMS	**1MG/10ML (0.1MG/ML)**	**A202601**	**001**	Feb 20, 2014
AP			**5MG/10ML (0.5MG/ML)**	**A202601**	**002**	Feb 20, 2014

DURACLON

AP	**+**	MYLAN INSTITUTIONAL	**1MG/10ML (0.1MG/ML)**	**N020615**	**001**	Oct 02, 1996

SOLUTION;ORAL

JAVADIN

	+!	AZURITY	0.02MG/ML	N220256	001	Oct 23, 2025

SUSPENSION, EXTENDED RELEASE;ORAL

ONYDA XR

	+!	TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.1MG**	**A070974**	**001**	Dec 16, 1986
AB			**0.2MG**	**A070975**	**001**	Dec 16, 1986
AB			**0.3MG**	**A070976**	**001**	Dec 16, 1986
AB		ALEMBIC PHARMS LTD	**0.1MG**	**A091368**	**001**	Dec 06, 2011
AB			**0.2MG**	**A091368**	**002**	Dec 06, 2011
AB			**0.3MG**	**A091368**	**003**	Dec 06, 2011
AB		AUROBINDO PHARMA LTD	**0.1MG**	**A070886**	**002**	Aug 31, 1988
AB			**0.2MG**	**A070886**	**001**	Aug 31, 1988
AB			**0.3MG**	**A070886**	**003**	Aug 31, 1988
AB		CHARTWELL MOLECULES	**0.1MG**	**A071785**	**002**	Apr 05, 1988
AB			**0.2MG**	**A071785**	**003**	Apr 05, 1988

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB			0.3MG	A071785	001	Apr 05, 1988
AB		IMPAX LABS	0.1MG	A078099	001	Aug 27, 2009
AB			0.2MG	A078099	002	Aug 27, 2009
AB			0.3MG	A078099	003	Aug 27, 2009
AB		PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007
AB			0.2MG	A077901	002	Mar 09, 2007
AB			0.3MG	A077901	003	Mar 09, 2007
AB		TP ANDA HOLDINGS	0.1MG	A070923	003	Sep 04, 1987
AB			0.2MG	A070923	002	Sep 04, 1987
AB			0.3MG	A070923	001	Sep 04, 1987
AB		UNICHEM	0.1MG	A078895	001	Aug 26, 2009
AB			0.2MG	A078895	002	Aug 26, 2009
AB	!		0.3MG	A078895	003	Aug 26, 2009
AB		YUNG SHIN PHARM	0.1MG	A202297	001	Jun 13, 2013
AB			0.2MG	A202297	002	Jun 13, 2013
AB			0.3MG	A202297	003	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		ACTAVIS ELIZABETH	0.1MG	A203320	001	May 15, 2015
AB1	!	AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017
AB1		CHARTWELL RX	0.1MG	A209285	001	Oct 23, 2017
AB1		JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018
AB1		NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019
AB1		SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018
AB1		XIAMEN LP PHARM CO	0.1MG	A209757	001	Nov 20, 2017

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012
AB		ALKEM LABS LTD	EQ 75MG BASE	A203632	001	Dec 08, 2023
AB		AMNEAL PHARMS	EQ 75MG BASE	A203751	001	Apr 11, 2014
AB		APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012
AB	!		EQ 300MG BASE	A076274	002	Mar 04, 2014
AB		AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012
AB		DR REDDYS	EQ 75MG BASE	A076273	001	Jan 14, 2008
AB		DR REDDYS LABS LTD	EQ 75MG BASE	A091023	002	Aug 05, 2024
AB			EQ 300MG BASE	A091023	001	May 17, 2012
AB		HETERO LABS LTD V	EQ 75MG BASE	A205345	001	Aug 04, 2023
AB			EQ 300MG BASE	A205345	002	Aug 04, 2023
AB		MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014
AB		MSN	EQ 75MG BASE	A215388	001	Sep 20, 2024
AB		PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018
AB			EQ 300MG BASE	A206376	002	May 07, 2018
AB		PURACAP LABS BLU	EQ 75MG BASE	A213351	001	Jul 17, 2020
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020
AB		RISING	EQ 75MG BASE	A204359	001	Feb 02, 2017
AB		SCIEGEN PHARMS	EQ 75MG BASE	A204165	001	Sep 15, 2014
AB			EQ 300MG BASE	A204165	002	Sep 15, 2014
AB		TEVA	EQ 75MG BASE	A076999	001	May 17, 2012
AB		TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012

PLAVIX

AB	+	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997
AB	+		EQ 300MG BASE	N020839	002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		AUROBINDO PHARMA	3.75MG	A071858	002	Jul 17, 1987
AB			7.5MG	A071858	003	Jul 17, 1987
AB	!		15MG	A071858	001	Jul 17, 1987
AB		COREPHARMA	3.75MG	A215566	001	Jun 14, 2022
AB			7.5MG	A215566	002	Jun 14, 2022
AB			15MG	A215566	003	Jun 14, 2022
AB		NOVITIUM PHARMA	3.75MG	A213730	001	Jun 16, 2022
AB			7.5MG	A213730	002	Jun 16, 2022
AB			15MG	A213730	003	Dec 16, 2022
AB		TARO	3.75MG	A075731	003	Apr 27, 2000
AB			7.5MG	A075731	002	Apr 27, 2000

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB			**15MG**	**A075731**	**001**	Apr 27, 2000

TRANXENE

AB	**+**	AJENAT PHARMS	**7.5MG**	**N017105**	**007**	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	**!**	SUN PHARMA CANADA	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT		NOVITIUM PHARMA	**1%**	**A209815**	**001**	Feb 14, 2019
AT		SCIEGEN PHARMS	**1%**	**A216569**	**001**	Oct 16, 2023
AT	**!**	SUN PHARMA CANADA	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995
AT		TP ANDA HOLDINGS	**1%**	**A212281**	**001**	Jul 25, 2019

SOLUTION/DROPS;OTIC

CLOTIC

	+!	CARWIN PHARM ASSOC	1%	N217628	001	Sep 26, 2025

TROCHE/LOZENGE;ORAL

CLOTRIMAZOLE

AB	**!**	HIKMA	**10MG**	**A076387**	**001**	Jul 29, 2004
AB		PADAGIS US	**10MG**	**A076763**	**001**	Oct 28, 2005
AB		THINQ PHARM-CRO PVT	**10MG**	**A215641**	**001**	Feb 29, 2024

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

	+!	DOUGLAS PHARMS	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MYLAN	**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010
AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010

CLOZARIL

AB	**+**	HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	**+!**		**100MG**	**N019758**	**002**	Sep 26, 1989

CLOZAPINE

		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		AUROBINDO PHARMA	**12.5MG**	**A212923**	**001**	Dec 12, 2024
AB			**25MG**	**A212923**	**002**	Dec 12, 2024
AB			**100MG**	**A212923**	**003**	Dec 12, 2024
AB			**150MG**	**A212923**	**004**	Dec 12, 2024
AB			**200MG**	**A212923**	**005**	Dec 12, 2024
AB		BARR LABS INC	**12.5MG**	**A090308**	**003**	Apr 09, 2018
AB			**25MG**	**A090308**	**001**	Nov 25, 2015
AB	**!**		**100MG**	**A090308**	**002**	Nov 25, 2015
AB			**150MG**	**A090308**	**004**	Nov 25, 2015
AB			**200MG**	**A090308**	**005**	Nov 25, 2015
AB		MYLAN	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
AB			**150MG**	**A201824**	**004**	Aug 07, 2023
AB			**200MG**	**A201824**	**005**	Aug 07, 2023

COBICISTAT

TABLET;ORAL

TYBOST

	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

	+	JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025
	+!		150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMTUZA

	+!	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

	+!	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

	+!	LXO IRELAND	4%	N209963	001	Dec 14, 2017

NUMBRINO

	+!	OMNIVIUM PHARMS	4%	N209575	001	Jan 10, 2020

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	**!**	GENUS LIFESCIENCES	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040660**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A200963**	**001**	Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;6.25MG/5ML**	**A200894**	**001**	Apr 24, 2013
AA		CHARTWELL RX	**10MG/5ML;6.25MG/5ML**	**A090180**	**001**	Mar 17, 2010
AA	**!**	COSETTE	**10MG/5ML;6.25MG/5ML**	**A200386**	**001**	Jun 29, 2012
AA		PHARMOBEDIENT	**10MG/5ML;6.25MG/5ML**	**A088875**	**001**	Dec 17, 1984
AA		QUAGEN	**10MG/5ML;6.25MG/5ML**	**A214238**	**001**	Oct 08, 2020

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

	!	ANIMA	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB	**+**	HIKMA	**15MG**	**N022402**	**001**	Jul 16, 2009
AB	**+**		**30MG**	**N022402**	**002**	Jul 16, 2009
AB	**+!**		**60MG**	**N022402**	**003**	Jul 16, 2009
AB		LANNETT CO INC	**15MG**	**A203046**	**001**	Jun 13, 2014
AB			**30MG**	**A203046**	**002**	Jun 13, 2014
AB			**60MG**	**A203046**	**003**	Jun 13, 2014

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB		ANNORA PHARMA	**0.6MG**	**A217620**	**001**	Apr 29, 2024
AB		AUROBINDO PHARMA LTD	**0.6MG**	**A215463**	**001**	Apr 29, 2024
AB		GRANULES	**0.6MG**	**A210757**	**001**	Apr 29, 2024
AB		PH HEALTH	**0.6MG**	**A208678**	**001**	Nov 29, 2018

COLCHICINE

CAPSULE;ORAL

MITIGARE

AB	**+!**	HIKMA INTL PHARMS	**0.6MG**	**N204820**	**001**	Sep 26, 2014

SOLUTION;ORAL

GLOPERBA

	+!	SCILEX PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	**0.6MG**	**A211250**	**001**	Feb 08, 2019
AB		AMNEAL PHARMS	**0.6MG**	**A204711**	**001**	Sep 28, 2016
AB		AUROBINDO PHARMA LTD	**0.6MG**	**A215444**	**001**	Jan 06, 2022
AB		DR REDDYS	**0.6MG**	**A209876**	**001**	Sep 06, 2019
AB		GRANULES	**0.6MG**	**A210425**	**001**	Feb 05, 2020
AB		HETERO LABS LTD V	**0.6MG**	**A208993**	**001**	Aug 13, 2021
AB		MYLAN	**0.6MG**	**A209470**	**001**	Sep 16, 2019
AB	**!**	PH HEALTH	**0.6MG**	**A203976**	**001**	Aug 12, 2021
AB		STRIDES PHARMA	**0.6MG**	**A209173**	**001**	Mar 10, 2022
AB		WATSON LABS INC	**0.6MG**	**A204461**	**001**	Jul 31, 2019
AB		ZYDUS PHARMS	**0.6MG**	**A211519**	**001**	Feb 19, 2019
			0.3MG	A211519	002	Nov 14, 2019

LODOCO

	+!	AGEPHA PHARMA FZ	0.5MG	N215727	001	Jun 16, 2023

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	**+!**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**	

PROBENECID AND COLCHICINE

AB		NOVAST LABS	**0.5MG;500MG**	**A040618**	**001**	May 13, 2008
AB		RISING	**0.5MG;500MG**	**A217030**	**001**	Oct 24, 2023

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**3.75GM/PACKET**	**A210316**	**001**	May 06, 2019
AB		GLENMARK PHARMS LTD	**3.75GM/PACKET**	**A202190**	**002**	Jul 16, 2018

WELCHOL

AB	**+!**	COSETTE	**3.75GM/PACKET**	**N022362**	**002**	Oct 02, 2009

COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**625MG**	**A209038**	**001**	Oct 05, 2018
AB		BEIJING TIDE PHARM	**625MG**	**A206036**	**001**	Oct 14, 2021
AB		BIONPHARMA	**625MG**	**A208670**	**001**	Sep 13, 2019
AB		DR REDDYS	**625MG**	**A210889**	**001**	Oct 05, 2018
AB		GLENMARK PHARMS LTD	**625MG**	**A203480**	**001**	May 18, 2018
AB		IMPAX LABS INC	**625MG**	**A091600**	**001**	May 16, 2018
AB		INVENTIA	**625MG**	**A212050**	**001**	Dec 04, 2020
AB		ZHEJIANG JINGXIN	**625MG**	**A209946**	**001**	Jul 15, 2020
AB		ZYDUS PHARMS	**625MG**	**A207765**	**001**	Oct 07, 2019

WELCHOL

AB	**+!**	COSETTE	**625MG**	**N021176**	**001**	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

AB	**+**	PFIZER	**5GM/SCOOPFUL**	**N017563**	**003**	Sep 22, 1995
AB	**+!**		**5GM/PACKET**	**N017563**	**004**	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001**	May 02, 2006
AB			**5GM/PACKET**	**A077277**	**002**	May 02, 2006

TABLET;ORAL

COLESTID

AB	**+**	PFIZER	**1GM**	**N020222**	**001**	Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB		ANI PHARMS	**1GM**	**A216517**	**001**	Mar 10, 2023
AB		EDENBRIDGE PHARMS	**1GM**	**A217667**	**001**	Aug 16, 2024
AB	**!**	IMPAX LABS	**1GM**	**A077510**	**001**	Oct 24, 2006
AB		PHARMOBEDIENT	**1GM**	**A220012**	**001**	Sep 15, 2025
AB		RICONPHARMA LLC	**1GM**	**A217462**	**001**	Dec 03, 2024
AB		ZYDUS PHARMS	**1GM**	**A215223**	**001**	Mar 10, 2022

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		AVET LIFESCIENCES	**EQ 150MG BASE/VIAL**	**A202359**	**001**	Sep 28, 2012
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001**	Apr 17, 2008
AP		SAGENT PHARMS INC	**EQ 150MG BASE/VIAL**	**A201365**	**001**	Feb 19, 2014
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001**	May 29, 2015

COLY-MYCIN M

AP	**+!**	PH HEALTH	**EQ 150MG BASE/VIAL**	**N050108**	**002**	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

	+!	PH HEALTH	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+!	CUMBERLAND	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPPER

SYSTEM;INTRAUTERINE

MIUDELLA

	+!	SEBELA WOMENS HLTH	N/A	N218201	001	Feb 24, 2025

PARAGARD T 380A

	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984

COPPER CU-64 DOTATATE

SOLUTION;INTRAVENOUS

DETECTNET

	+!	CURIUM	4mL (1mCi/ML)	N213227	001	Sep 03, 2020

CORTICOTROPIN

INJECTABLE;INJECTION

ACTHAR GEL

	+!	MALLINCKRODT IRELAND	80 UNITS/ML	N008372	008	

ACTHAR GEL (AUTOINJECTOR)

	+!	MALLINCKRODT IRELAND	40 UNITS/0.5ML	N008372	003	Feb 29, 2024
	+!		80 UNITS/ML	N008372	004	Feb 29, 2024

PURIFIED CORTROPHIN GEL

	+!	ANI PHARMS	80 UNITS/ML	N008975	002	

COSYNTROPIN

INJECTABLE;INJECTION

CORTROSYN

AP	**+!**	AMPHASTAR PHARMS INC	**0.25MG/VIAL**	**N016750**	**001**	

COSYNTROPIN

AP		SANDOZ	**0.25MG/VIAL**	**A202147**	**001**	Jun 29, 2012

CRINECERFONT

CAPSULE;ORAL

CRENESSITY

	+	NEUROCRINE	25MG	N218808	001	Dec 13, 2024
	+		50MG	N218808	002	Dec 13, 2024
	+!		100MG	N218808	003	Dec 13, 2024

SOLUTION;ORAL

CRENESSITY

	+!	NEUROCRINE	50MG/ML	N218820	001	Dec 13, 2024

CRISABOROLE

OINTMENT;TOPICAL

EUCRISA

	+!	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016

CRIZOTINIB

CAPSULE;ORAL

XALKORI

	+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
	+!		250MG	N202570	002	Aug 26, 2011

CAPSULE, PELLETS;ORAL

XALKORI

	+	PF PRISM CV	20MG	N217581	001	Sep 07, 2023
	+		50MG	N217581	002	Sep 07, 2023
	+!		150MG	N217581	003	Sep 07, 2023

CROFELEMER
TABLET, DELAYED RELEASE;ORAL
MYTESI

	+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012

CROMOLYN SODIUM
CONCENTRATE;ORAL
CROMOLYN SODIUM

AA		AILEX PHARMS LLC	**100MG/5ML**	**A209264**	**001**	Oct 16, 2017
AA		MICRO LABS LTD INDIA	**100MG/5ML**	**A202745**	**001**	Apr 04, 2013
AA		RISING	**100MG/5ML**	**A202583**	**001**	Oct 27, 2011

GASTROCROM

AA	**+!**	VIATRIS SPECIALTY	**100MG/5ML**	**N020479**	**001**	Feb 29, 1996

SOLUTION;INHALATION
CROMOLYN SODIUM

AN		AILEX PHARMS LLC	**10MG/ML**	**A209453**	**001**	Oct 16, 2017
AN		FERA PHARMS LLC	**10MG/ML**	**A075437**	**001**	Apr 21, 2000
AN		MICRO LABS	**10MG/ML**	**A213658**	**001**	Apr 29, 2022
AN	!	TEVA PHARMS	**10MG/ML**	**A075271**	**001**	Jan 18, 2000
AN		WOCKHARDT BIO AG	**10MG/ML**	**A075346**	**001**	Oct 25, 1999

SOLUTION/DROPS;OPHTHALMIC
CROMOLYN SODIUM

	!	SANDOZ	4%	A075282	001	Jun 16, 1999

CROTAMITON
LOTION;TOPICAL
CROTAN

AT		LEGACY PHARMA	**10%**	**A087204**	**001**	

EURAX

AT	**+!**	JOURNEY	**10%**	**N009112**	**003**	

CUPRIC CHLORIDE
INJECTABLE;INJECTION
CUPRIC CHLORIDE

AP		EXELA PHARMA	**EQ 0.4MG COPPER/ML**	**A212071**	**001**	Oct 31, 2022
AP		RK PHARMA	**EQ 0.4MG COPPER/ML**	**A217626**	**001**	Apr 30, 2024
AP		SOMERSET	**EQ 0.4MG COPPER/ML**	**A216113**	**001**	Apr 30, 2024

CUPRIC CHLORIDE IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**EQ 0.4MG COPPER/ML**	**N018960**	**001**	Jun 26, 1986

CUPRIC SULFATE
INJECTABLE;INJECTION
CUPRIC SULFATE

	!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE
SOLUTION;INTRAVENOUS
MULTRYS

	+!	AM REGENT	EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML)	N209376	003	Jun 30, 2021

TRALEMENT

	+!	AM REGENT	EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML)	N209376	001	Jul 02, 2020
	+!		EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML)	N209376	002	Dec 02, 2020

CYANOCOBALAMIN
INJECTABLE;INJECTION
CYANOCOBALAMIN

AP	**+!**	AM REGENT	**1MG/ML**	**A080737**	**001**	
AP		EUGIA PHARMA	**1MG/ML**	**A213874**	**001**	Dec 08, 2020
AP		GLAND	**1MG/ML**	**A214390**	**001**	Sep 24, 2020
AP		MANKIND PHARMA	**1MG/ML**	**A217839**	**001**	Jul 10, 2024
AP		MEITHEAL	**1MG/ML**	**A214316**	**001**	Nov 15, 2024
AP		PHARMOBEDIENT	**1MG/ML**	**A204829**	**001**	Jun 05, 2017
AP		SAGENT PHARMS INC	**1MG/ML**	**A215107**	**001**	Nov 15, 2022
AP		SANDOZ	**1MG/ML**	**A212915**	**001**	Jan 04, 2021
AP		SOLA PHARMS	**1MG/ML**	**A215417**	**001**	Apr 15, 2022
AP		SOMERSET THERAPS LLC	**1MG/ML**	**A206503**	**001**	Dec 11, 2015
AP			**1MG/ML**	**A209429**	**001**	Dec 18, 2018
AP		VITRUVIAS THERAP	**1MG/ML**	**A209255**	**001**	Dec 18, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A080515**	**002**	
AP		ZYDUS PHARMS	**1MG/ML**	**A214655**	**001**	Apr 15, 2022

CYANOCOBALAMIN

INJECTABLE;INJECTION

VIBISONE

AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**A080557**	**003**	

SPRAY, METERED;NASAL

CYANOCOBALAMIN

AB		LUPIN	**0.5MG/SPRAY**	**A210629**	**001**	Jun 30, 2023
AB	**!**	PADAGIS ISRAEL	**0.5MG/SPRAY**	**A212458**	**001**	Sep 09, 2020

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMRIX

AB	**+**	TEVA PHARMS INTL	**15MG**	**N021777**	**001**	Feb 01, 2007
AB	**+!**		**30MG**	**N021777**	**002**	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	**15MG**	**A207314**	**001**	Jul 22, 2024
AB			**30MG**	**A207314**	**002**	Jul 22, 2024
AB		NOVAST LABS	**15MG**	**A214732**	**001**	Aug 27, 2024
AB			**30MG**	**A214732**	**002**	Aug 27, 2024
AB		TWI PHARMS INC	**15MG**	**A091281**	**001**	Jan 31, 2013
AB			**30MG**	**A091281**	**002**	Jan 31, 2013

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG**	**A071611**	**002**	Feb 03, 2006
AB			**7.5MG**	**A071611**	**003**	Feb 03, 2006
AB			**10MG**	**A071611**	**001**	May 03, 1989
AB		AUROBINDO PHARMA	**5MG**	**A078643**	**001**	Sep 26, 2008
AB			**10MG**	**A078643**	**002**	Sep 26, 2008
AB		CHARTWELL RX	**5MG**	**A078218**	**002**	Jun 19, 2015
AB			**7.5MG**	**A078218**	**003**	Nov 03, 2020
AB			**10MG**	**A078218**	**001**	Apr 18, 2008
AB		INVAGEN PHARMS	**5MG**	**A090478**	**001**	Jul 23, 2010
AB			**10MG**	**A090478**	**002**	Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**	**A077563**	**001**	Apr 19, 2006
AB			**7.5MG**	**A077563**	**003**	Aug 25, 2017
AB			**10MG**	**A077563**	**002**	Apr 19, 2006
AB		KVK TECH	**5MG**	**A078048**	**001**	Feb 28, 2011
AB			**10MG**	**A078048**	**002**	Feb 28, 2011
AB		OXFORD PHARMS	**5MG**	**A077209**	**002**	Feb 03, 2006
AB			**10MG**	**A077209**	**001**	Oct 04, 2005
AB		PRINSTON INC	**5MG**	**A077797**	**001**	Feb 28, 2007
AB			**10MG**	**A077797**	**002**	Feb 28, 2007
AB		RISING	**5MG**	**A218936**	**001**	Sep 12, 2024
AB			**7.5MG**	**A218936**	**002**	Sep 12, 2024
AB			**10MG**	**A218936**	**003**	Sep 12, 2024
AB		RUBICON RESEARCH	**5MG**	**A208170**	**001**	May 31, 2017
AB			**7.5MG**	**A208170**	**002**	May 31, 2017
AB	**!**		**10MG**	**A208170**	**003**	May 31, 2017
AB		TP ANDA HOLDINGS	**5MG**	**A073541**	**002**	Apr 06, 2006
AB			**10MG**	**A073541**	**001**	May 23, 1995
AB		UNICHEM	**5MG**	**A213324**	**001**	Jul 06, 2020
AB			**7.5MG**	**A213324**	**002**	Jul 06, 2020
AB			**10MG**	**A213324**	**003**	Jul 05, 2020

TABLET;SUBLINGUAL

TONMYA

	+!	TONIX	2.8MG	N219428	001	Aug 15, 2025

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

AT		RISING	**1%**	**A040164**	**001**	Jan 13, 1997
AT			**2%**	**A040165**	**001**	Jan 13, 1997

CYCLOGYL

AT	**+!**	ALCON LABS INC	**1%**	**A084110**	**001**	
AT	**+!**		**2%**	**A084108**	**001**	

PENTOLAIR

AT		BAUSCH AND LOMB	**1%**	**A040075**	**001**	Apr 29, 1994

CYCLOGYL

+!	ALCON LABS INC	0.5%	A084109	001	

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

	+!	ALCON LABS INC	0.2%;1%	A084300	001

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB		ALEMBIC	**25MG**	**A215892**	**001**	Nov 10, 2022
AB			**50MG**	**A215892**	**002**	Nov 10, 2022
AB		CIPLA	**25MG**	**A211608**	**001**	Jan 18, 2019
AB			**50MG**	**A211608**	**002**	Jan 18, 2019
AB		EIRGEN	**25MG**	**A218282**	**001**	Dec 03, 2024
AB			**50MG**	**A218282**	**002**	Dec 03, 2024
AB	+	HIKMA	**25MG**	**N203856**	**001**	Sep 16, 2013
AB	+!		**50MG**	**N203856**	**002**	Sep 16, 2013
AB		SENORES PHARMS	**25MG**	**A209872**	**001**	May 07, 2018
AB			**50MG**	**A209872**	**002**	May 07, 2018
AB		ZYDUS LIFESCIENCES	**25MG**	**A211552**	**001**	Dec 13, 2023
AB			**50MG**	**A211552**	**002**	Dec 13, 2023

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP		AMNEAL	**500MG/VIAL**	**A210046**	**001**	May 25, 2018
AP			**1GM/VIAL**	**A210046**	**002**	May 25, 2018
AP			**2GM/VIAL**	**A210046**	**003**	May 25, 2018
AP	!	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001**	May 21, 2008
AP	!		**1GM/VIAL**	**A040745**	**002**	May 21, 2008
AP	!		**2GM/VIAL**	**A040745**	**003**	May 21, 2008
AP		EPIC PHARMA LLC	**500MG/VIAL**	**A218644**	**001**	Dec 19, 2024
AP			**1GM/VIAL**	**A218644**	**002**	Dec 19, 2024
AP			**2GM/VIAL**	**A218644**	**003**	Dec 19, 2024
AP		HAINAN POLY	**1GM/VIAL**	**A218632**	**002**	Dec 26, 2024
AP			**2GM/VIAL**	**A218632**	**003**	Dec 26, 2024
AP			**500MG/VIAL**	**A218632**	**001**	Dec 26, 2024
AP		HENGRUI PHARMA	**500MG/VIAL**	**A204555**	**001**	Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002**	Oct 31, 2014
AP			**2GM/VIAL**	**A204555**	**003**	Oct 31, 2014
AP		HIKMA	**500MG/VIAL**	**A216958**	**001**	Dec 18, 2023
AP			**1GM/VIAL**	**A216958**	**002**	Dec 18, 2023
AP			**2GM/VIAL**	**A216958**	**003**	Dec 18, 2023
AP		SAGENT PHARMS INC	**500MG/VIAL**	**A214529**	**001**	Jul 17, 2023
AP			**1GM/VIAL**	**A214529**	**002**	Jul 17, 2023
AP			**2GM/VIAL**	**A214529**	**003**	Jul 17, 2023
AP		SUNNY	**500MG/VIAL**	**A215089**	**001**	Oct 26, 2023
AP			**1GM/VIAL**	**A215089**	**002**	Oct 26, 2023
AP			**2GM/VIAL**	**A215089**	**003**	Oct 26, 2023
AP		XGEN PHARMS	**500MG/VIAL**	**A211757**	**001**	Oct 18, 2022
AP			**1GM/VIAL**	**A211757**	**002**	Oct 18, 2022
AP			**2GM/VIAL**	**A211757**	**003**	Oct 18, 2022

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

AP	+!	DR REDDYS	**500MG/2.5ML (200MG/ML)**	**N212501**	**001**	Jul 30, 2020
AP	+!		**1GM/5ML (200MG/ML)**	**N212501**	**002**	Jul 30, 2020
AP		NEXUS	**500MG/2.5ML (200MG/ML)**	**A216783**	**001**	Oct 29, 2024
AP			**1GM/5ML (200MG/ML)**	**A216783**	**002**	Oct 29, 2024
	+!	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023
	+!		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023
	+!	DR REDDYS	2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021
	+!	EUGIA PHARMA SPECLTS	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021
	+!		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021
	+!		2GM/10ML (200MG/ML)	N210735	003	Nov 20, 2023
	+!	SANDOZ	500MG/5ML (100MG/ML)	N217150	001	Sep 12, 2023
	+!		1GM/10ML (100MG/ML)	N217150	002	Sep 12, 2023
	+!		2GM/20ML (100MG/ML)	N217150	003	Sep 12, 2023

FRINDOVYX

	+!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023
	+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023
	+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023

TABLET;ORAL

CYTOXAN

	+	BAXTER HLTHCARE	25MG	N012141	002	

CYCLOPHOSPHAMIDE

TABLET;ORAL

CYTOXAN

+!		50MG	N012141	001	

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

!	SANALUZ	250MG	A060593	001	

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1		APOTEX	**25MG**	**A210721**	**001**	Jul 10, 2019
AB1			**50MG**	**A210721**	**002**	Jul 10, 2019
AB1			**100MG**	**A210721**	**003**	Jul 10, 2019
AB1		DR REDDYS LABS SA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1			**100MG**	**A065044**	**001**	Dec 20, 2000
AB1		IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1			**50MG**	**A065110**	**001**	Mar 29, 2005
AB1			**100MG**	**A065110**	**002**	Mar 29, 2005
AB1		ONESOURCE SPECIALTY	**25MG**	**A216046**	**001**	Aug 02, 2022
AB1			**50MG**	**A216046**	**002**	Aug 02, 2022
AB1			**100MG**	**A216046**	**003**	Aug 02, 2022
AB1		QILU	**25MG**	**A219049**	**001**	Sep 15, 2025
AB1			**100MG**	**A219049**	**002**	Sep 15, 2025
AB1		SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1			**100MG**	**A065017**	**001**	Jan 13, 2000

GENGRAF

AB1		ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1			**100MG**	**A065003**	**003**	May 12, 2000

NEORAL

AB1	**+**	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1	**+!**		**100MG**	**N050715**	**002**	Jul 14, 1995

CYCLOSPORINE

AB2		APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2			**100MG**	**A065040**	**002**	May 09, 2002

SANDIMMUNE

AB2	**+**	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2	**+!**		**100MG**	**N050625**	**002**	Mar 02, 1990
BX	+		50MG	N050625	003	Nov 23, 1992

EMULSION;OPHTHALMIC

CYCLOSPORINE

AB		AMNEAL	**0.05%**	**A211909**	**001**	Nov 28, 2025
AB		DEVA HOLDING AS	**0.05%**	**A209811**	**001**	May 21, 2024
AB		MYLAN	**0.05%**	**A205894**	**001**	Feb 02, 2022
AB		SAPTALIS PHARMS	**0.05%**	**A211943**	**001**	Jul 05, 2024
AB		TEVA PHARMS USA INC	**0.05%**	**A203880**	**001**	Dec 14, 2023

RESTASIS

AB	**+!**	ABBVIE	**0.05%**	**N050790**	**001**	Dec 23, 2002

RESTASIS MULTIDOSE

+!		ABBVIE	0.05%	N050790	002	Oct 27, 2016

VERKAZIA

+!		HARROW EYE	0.1%	N214965	001	Jun 23, 2021

INJECTABLE;INJECTION

CYCLOSPORINE

AP		HIKMA	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
AP		PADAGIS US	**50MG/ML**	**A065151**	**001**	Oct 07, 2003

SANDIMMUNE

AP	**+!**	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983

SOLUTION;OPHTHALMIC

CEQUA

+!		SUN PHARM	0.09%	N210913	001	Aug 14, 2018

VEVYE

+!		HARROW EYE	0.1%	N217469	001	May 30, 2023

SOLUTION;ORAL

CYCLOSPORINE

AB1		IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005

NEORAL

AB1	**+!**	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995

CYCLOSPORINE

SOLUTION;ORAL

SANDIMMUNE

	+!	NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		CHARTWELL MOLECULAR	**2MG/5ML**	**A203191**	**001**	Jul 13, 2017
AA		INVATECH	**2MG/5ML**	**A209108**	**001**	Oct 16, 2018
AA		QUAGEN	**2MG/5ML**	**A212423**	**001**	May 22, 2019
AA	!	RISING	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APPCO	**4MG**	**A206553**	**001**	Nov 29, 2016
AA		CHARTWELL RX	**4MG**	**A088212**	**001**	May 26, 1983
AA		KENTON	**4MG**	**A040644**	**001**	May 30, 2006
AA		MOUNTAIN	**4MG**	**A040537**	**001**	Sep 30, 2003
AA		NOVAST LABS	**4MG**	**A205087**	**001**	Sep 23, 2015
AA		QUAGEN	**4MG**	**A212491**	**001**	Feb 24, 2021
AA		REGCON HOLDINGS	**4MG**	**A206676**	**001**	Apr 12, 2019
AA		RISING	**4MG**	**A207555**	**001**	Jan 31, 2017
AA		STRIDES PHARMA INTL	**4MG**	**A209172**	**001**	Apr 11, 2018
AA	!	ZYDUS PHARMS	**4MG**	**A208938**	**001**	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

	+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
	+!		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

	+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013
	+!		EQ 75MG BASE	N203389	002	Apr 30, 2013

GRANULE, DELAYED RELEASE;ORAL

PROCYSBI

	+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020
	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTADROPS

	+!	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020

CYSTARAN

	+!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

	+!	EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	!	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP		GLAND	**100MG/VIAL**	**A211937**	**001**	Dec 23, 2019
AP			**2GM/VIAL**	**A211938**	**001**	Dec 23, 2019
AP		HIKMA	**100MG/VIAL**	**A071471**	**001**	Aug 02, 1989
AP	!	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	!		**20MG/ML**	**A072168**	**001**	Aug 31, 1990
AP	!		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MEITHEAL	**20MG/ML**	**A208485**	**001**	Feb 28, 2022
AP			**100MG/ML**	**A205696**	**001**	Jul 17, 2018
AP		RISING	**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
AP	!	WEST-WARD PHARMS INT	**2GM/VIAL**	**A074245**	**002**	Aug 31, 1994
	!	HIKMA	500MG/VIAL	A071472	001	Aug 02, 1989
	!	WEST-WARD PHARMS INT	1GM/VIAL	A074245	001	Aug 31, 1994

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS

VYXEOS

+!	JAZZ PHARMS THERAP	100MG;44MG	N209401	001	Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALEMBIC	**EQ 75MG BASE**	**A215233**	**001**	Jun 14, 2024
AB		**EQ 110MG BASE**	**A215233**	**003**	Aug 12, 2024
AB		**EQ 150MG BASE**	**A215233**	**002**	Jun 14, 2024
AB	ALKEM LABS LTD	**EQ 75MG BASE**	**A208040**	**001**	Mar 11, 2020
AB		**EQ 110MG BASE**	**A208040**	**003**	Sep 11, 2024
AB		**EQ 150MG BASE**	**A208040**	**002**	Mar 11, 2020
AB	APOTEX	**EQ 75MG BASE**	**A208070**	**001**	Dec 15, 2023
AB		**EQ 110MG BASE**	**A208070**	**002**	Dec 15, 2023
AB		**EQ 150MG BASE**	**A208070**	**003**	Dec 15, 2023
AB	AUROBINDO PHARMA	**EQ 75MG BASE**	**A208039**	**001**	May 14, 2025
AB		**EQ 110MG BASE**	**A208039**	**002**	May 14, 2025
AB		**EQ 150MG BASE**	**A208039**	**003**	May 14, 2025
AB	DR REDDYS	**EQ 75MG BASE**	**A208048**	**001**	Jan 28, 2025
AB		**EQ 110MG BASE**	**A208048**	**002**	Jan 28, 2025
AB		**EQ 150MG BASE**	**A208048**	**003**	Jan 28, 2025
AB	HETERO LABS LTD III	**EQ 75MG BASE**	**A207961**	**001**	May 06, 2020
AB		**EQ 110MG BASE**	**A207961**	**003**	Aug 13, 2024
AB		**EQ 150MG BASE**	**A207961**	**002**	May 06, 2020
AB	MSN	**EQ 75MG BASE**	**A213879**	**001**	May 22, 2024
AB		**EQ 110MG BASE**	**A213879**	**003**	Aug 12, 2024
AB		**EQ 150MG BASE**	**A213879**	**002**	May 22, 2024
AB	MYLAN	**EQ 75MG BASE**	**A208067**	**001**	Feb 03, 2025
AB		**EQ 150MG BASE**	**A208067**	**002**	Feb 03, 2025

PRADAXA

AB +	BOEHRINGER INGELHEIM	**EQ 75MG BASE**	**N022512**	**001**	Oct 19, 2010
AB +		**EQ 110MG BASE**	**N022512**	**003**	Nov 20, 2015
AB +!		**EQ 150MG BASE**	**N022512**	**002**	Oct 19, 2010

PELLETS;ORAL

PRADAXA

+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021
+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021
+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021
+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021
+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021
+!		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

+	NOVARTIS	EQ 50MG BASE	N202806	001	May 29, 2013
+!		EQ 75MG BASE	N202806	002	May 29, 2013

TABLET, FOR SUSPENSION;ORAL

TAFINLAR

+!	NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP !	FRESENIUS KABI USA	**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999
AP	HIKMA	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001
AP		**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002
AP	MEITHEAL	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998
AP !		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000
!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999

DACOMITINIB

TABLET;ORAL

VIZIMPRO

+	PFIZER	15MG	N211288	001	Sep 27, 2018
+		30MG	N211288	002	Sep 27, 2018
+!		45MG	N211288	003	Sep 27, 2018

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

AP	**!**	EUGIA PHARMA	**0.5MG/VIAL**	**A203385**	**001**	Nov 09, 2017
AP		HISUN PHARM HANGZHOU	**0.5MG/VIAL**	**A207232**	**001**	Jul 16, 2019
AP		MEITHEAL	**0.5MG/VIAL**	**A213463**	**001**	Nov 13, 2020
AP		XGEN PHARMS	**0.5MG/VIAL**	**A203999**	**001**	May 20, 2019

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

DALBAVANCIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A217591**	**001**	Nov 10, 2025
AP		KINDOS	**EQ 500MG BASE/VIAL**	**A218929**	**001**	Nov 26, 2025
AP		TEVA PHARMS INC	**EQ 500MG BASE/VIAL**	**A219465**	**001**	Oct 23, 2025

DALVANCE

AP	**+!**	ABBVIE	**EQ 500MG BASE/VIAL**	**N021883**	**001**	May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	**+!**	MERZ	**10MG**	**N022250**	**001**	Jan 22, 2010

DALFAMPRIDINE

AB		ACCORD HLTHCARE	**10MG**	**A206863**	**001**	Jul 11, 2018
AB		ACTAVIS LABS FL INC	**10MG**	**A206836**	**001**	Jan 23, 2017
AB		ALKEM LABS LTD	**10MG**	**A206765**	**001**	Jul 30, 2018
AB		AURO BINDO PHARMA	**10MG**	**A206811**	**001**	Jan 23, 2017
AB		MICRO LABS	**10MG**	**A210158**	**001**	Mar 11, 2019

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

+	PFIZER	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
+		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
+		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
+		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
+		10,000IU/4ML (2,500IU/ML)	N020287	012	Mar 15, 2022
+		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
+		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
+		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
+!		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE;ORAL

DANAZOL

AB		BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB			**100MG**	**A074582**	**002**	May 29, 1998
AB	**!**		**200MG**	**A074582**	**001**	Aug 09, 1996
AB		LANNETT CO INC	**50MG**	**A077246**	**002**	Apr 19, 2007
AB			**100MG**	**A077246**	**003**	Apr 19, 2007
AB			**200MG**	**A077246**	**001**	Sep 28, 2005

DANICOPAN

TABLET;ORAL

VOYDEYA

+	ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024
+!		100MG	N218037	002	Mar 29, 2024

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

AB	**+**	PH HEALTH	**25MG**	**N017443**	**001**	
AB	**+**		**50MG**	**N017443**	**003**	
AB	**+!**		**100MG**	**N017443**	**002**	

DANTROLENE SODIUM

AB		ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB			**50MG**	**A076686**	**002**	Oct 24, 2005
AB			**100MG**	**A076686**	**003**	Oct 24, 2005
AB		IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB			**50MG**	**A076856**	**002**	Mar 01, 2005
AB			**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX

+!	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014

DANTROLENE SODIUM

INJECTABLE;INJECTION

DANTRIUM

AP	**+!**	PH HEALTH	**20MG/VIAL**	**N018264**	**001**	

DANTROLENE SODIUM

AP		HIKMA	**20MG/VIAL**	**A204762**	**001**	Jun 19, 2017

REVONTO

AP		USWM	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014
	+!		10MG	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

	+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017
	+		5MG;500MG	N205649	001	Oct 29, 2014
	+		5MG;1GM	N205649	002	Oct 29, 2014
	+		10MG;500MG	N205649	003	Oct 29, 2014
	+!		10MG;1GM	N205649	004	Oct 29, 2014

DAPSONE

GEL;TOPICAL

ACZONE

AB	**+!**	ALMIRALL	**5%**	**N021794**	**001**	Jul 07, 2005
AB	**+!**		**7.5%**	**N207154**	**001**	Feb 24, 2016

DAPSONE

AB		ALEMBIC	**7.5%**	**A215718**	**001**	Oct 27, 2023
AB		AMNEAL	**5%**	**A209890**	**001**	Oct 19, 2023
AB			**7.5%**	**A212701**	**001**	May 31, 2023
AB		AUROBINDO PHARMA LTD	**5%**	**A218457**	**001**	Apr 04, 2025
AB		COSETTE	**5%**	**A210178**	**001**	Mar 31, 2022
AB		ENCUBE	**5%**	**A212383**	**001**	Oct 13, 2023
AB		MYLAN	**7.5%**	**A213847**	**001**	Feb 04, 2022
AB		SUN PHARMA CANADA	**5%**	**A209506**	**001**	Oct 16, 2017
AB			**7.5%**	**A210191**	**001**	Jun 26, 2019
AB		TORRENT	**7.5%**	**A214722**	**001**	Feb 10, 2022
AB		TP ANDA HOLDINGS	**5%**	**A213907**	**001**	Jun 06, 2023
AB			**7.5%**	**A213636**	**001**	Aug 26, 2024
AB		ZYDUS LIFESCIENCES	**7.5%**	**A214019**	**001**	May 08, 2024

TABLET;ORAL

DAPSONE

AB		ACTAVIS LLC	**25MG**	**A204380**	**001**	Mar 23, 2017
AB			**100MG**	**A204380**	**002**	Mar 23, 2017
AB	**+**	EVEREST LIFE SCI	**25MG**	**A086841**	**001**	
AB	**+**		**100MG**	**A086842**	**001**	
AB		NOVITIUM PHARMA	**25MG**	**A206505**	**001**	Dec 01, 2016
AB	**!**		**100MG**	**A206505**	**002**	Dec 01, 2016
AB		RISING	**25MG**	**A207165**	**002**	Jul 20, 2023
AB			**100MG**	**A207165**	**001**	May 08, 2019
AB		SOLIS PHARMS	**25MG**	**A203887**	**001**	May 06, 2016
AB			**100MG**	**A203887**	**002**	May 06, 2016

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP		ACCORD HLTHCARE	**350MG/VIAL**	**A212667**	**001**	Jul 12, 2019
AP			**500MG/VIAL**	**A211961**	**001**	Jun 24, 2019
AP		ASPIRO	**350MG/VIAL**	**A216445**	**001**	Dec 23, 2022
AP			**500MG/VIAL**	**A216413**	**001**	Sep 23, 2022
AP		BE PHARMS	**350MG/VIAL**	**A213425**	**001**	Aug 20, 2020
AP			**500MG/VIAL**	**A212513**	**001**	Jun 26, 2019
AP		BIOCON PHARMA	**500MG/VIAL**	**A217215**	**001**	Aug 29, 2024
AP		DR REDDYS	**350MG/VIAL**	**A211403**	**001**	Aug 31, 2020
AP			**500MG/VIAL**	**A208375**	**001**	May 01, 2019
AP		EUGIA PHARMA	**500MG/VIAL**	**A213171**	**001**	Sep 02, 2021
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A206077**	**001**	Apr 11, 2018
AP		HAINAN POLY PHARM	**500MG/VIAL**	**A215890**	**001**	Aug 18, 2022
AP		HENGRUI PHARMA	**500MG/VIAL**	**A212022**	**001**	Aug 22, 2019
AP		HISUN PHARM HANGZHOU	**500MG/VIAL**	**A212250**	**001**	Apr 21, 2021

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP		MEITHEAL	**350MG/VIAL**	**A213786**	**001**	Jun 29, 2021
AP			**500MG/VIAL**	**A213623**	**001**	Jun 29, 2021
AP		MYLAN	**500MG/VIAL**	**A213966**	**001**	Aug 07, 2023
AP		MYLAN LABS LTD	**500MG/VIAL**	**A205037**	**001**	Jun 05, 2018
AP	**!**	QILU PHARM HAINAN	**500MG/VIAL**	**A215316**	**001**	Aug 24, 2021
AP	**+!**	SAGENT PHARMS INC	**350MG/VIAL**	**N208385**	**001**	Sep 12, 2017
AP			**500MG/VIAL**	**A207104**	**001**	Nov 15, 2019
AP		TEVA PHARMS USA	**500MG/VIAL**	**A091039**	**001**	Mar 25, 2016
AP		XELLIA PHARMS APS	**500MG/VIAL**	**A206005**	**001**	Jun 15, 2016
	+!	HIKMA	350MG/VIAL	N209949	001	Oct 20, 2017
	+!		350MG/VIAL	N217415	001	Jan 30, 2023
	+!		500MG/VIAL	N217415	002	Jan 30, 2023
	+!	HOSPIRA	350MG/VIAL	N210282	001	Jun 21, 2021
	+!		500MG/VIAL	N210282	002	Jun 21, 2021
	+!	MAIA PHARMS INC	500MG/VIAL	N217630	002	Nov 21, 2024

SOLUTION;INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023
	+!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023
	+!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023
	+!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL

QUVIVIQ

	+	IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022
	+!		EQ 50MG BASE	N214985	002	Apr 07, 2022

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	**EQ 7.5MG BASE**	**A207302**	**001**	Jul 28, 2017
AB	**!**		**EQ 15MG BASE**	**A207302**	**002**	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

AB		ALEMBIC	**EQ 7.5MG BASE**	**A207681**	**001**	Dec 08, 2017
AB			**EQ 15MG BASE**	**A207681**	**002**	Dec 08, 2017
AB		AUROBINDO PHARMA	**EQ 7.5MG BASE**	**A206743**	**001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743**	**002**	Sep 19, 2016
AB		CIPLA	**EQ 7.5MG BASE**	**A207664**	**001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664**	**002**	Sep 01, 2016
AB		PURACAP LABS BLU	**EQ 7.5MG BASE**	**A211045**	**001**	Jan 06, 2020
AB			**EQ 15MG BASE**	**A211045**	**002**	Jan 06, 2020
AB		TORRENT	**EQ 7.5MG BASE**	**A205209**	**001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209**	**002**	Nov 17, 2016

DAROLUTAMIDE

TABLET;ORAL

NUBEQA

	+!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019

DARUNAVIR

SUSPENSION;ORAL

PREZISTA

	+!	JANSSEN PRODS	100MG/ML	N202895	001	Dec 16, 2011

TABLET;ORAL

DARUNAVIR

AB		AMNEAL	**600MG**	**A212493**	**001**	Dec 08, 2023
AB			**800MG**	**A212493**	**002**	Dec 08, 2023
AB		ANNORA PHARMA	**600MG**	**A216168**	**001**	Jan 21, 2025
AB			**800MG**	**A216168**	**002**	Jan 21, 2025
AB		AUROBINDO PHARMA LTD	**600MG**	**A210677**	**001**	Nov 28, 2023
AB			**800MG**	**A210677**	**002**	Nov 28, 2023
AB		CIPLA	**600MG**	**A206288**	**001**	Nov 28, 2023
AB			**800MG**	**A206288**	**002**	Nov 28, 2023
AB		DR REDDYS	**600MG**	**A211578**	**001**	Nov 28, 2023
AB			**800MG**	**A211578**	**002**	Nov 28, 2023
AB		HETERO LABS LTD III	**400MG**	**A202083**	**001**	Sep 14, 2023
AB			**600MG**	**A202083**	**002**	Sep 14, 2023
AB		LUPIN LTD	**600MG**	**A202073**	**001**	Sep 29, 2022
AB			**800MG**	**A202073**	**002**	Sep 29, 2022

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB		MSN	**600MG**	**A215389**	**001**	Nov 28, 2023
AB			**800MG**	**A215389**	**002**	Nov 28, 2023
AB		MYLAN	**75MG**	**A202136**	**001**	Jul 22, 2025
AB			**150MG**	**A202136**	**002**	Jul 22, 2025
AB			**400MG**	**A202136**	**004**	Jul 22, 2025
AB			**600MG**	**A202136**	**005**	Jul 22, 2025
AB		ZYDUS LIFESCIENCES	**600MG**	**A214085**	**001**	Dec 13, 2023
AB			**800MG**	**A214085**	**002**	Dec 13, 2023

PREZISTA

AB	+	JANSSEN PRODS	**75MG**	**N021976**	**004**	Dec 18, 2008
AB	+		**150MG**	**N021976**	**005**	Dec 18, 2008
AB	+		**600MG**	**N021976**	**002**	Feb 25, 2008
AB	+!		**800MG**	**N021976**	**006**	Nov 09, 2012

DARUNAVIR

		MYLAN	300MG	A202136	003	Jul 22, 2025

DASATINIB

TABLET;ORAL

DASATINIB

AB		ALEMBIC	**20MG**	**A216261**	**001**	Nov 06, 2025
AB			**50MG**	**A216261**	**002**	Nov 06, 2025
AB			**70MG**	**A216261**	**003**	Nov 06, 2025
AB			**80MG**	**A216261**	**004**	Nov 06, 2025
AB			**100MG**	**A216261**	**005**	Nov 06, 2025
AB			**140MG**	**A216261**	**006**	Nov 06, 2025
AB		APOTEX	**20MG**	**A202103**	**001**	Jun 10, 2016
AB			**50MG**	**A202103**	**002**	Jun 10, 2016
AB			**70MG**	**A202103**	**003**	Jun 10, 2016
AB			**80MG**	**A203180**	**001**	Nov 23, 2021
AB			**100MG**	**A202103**	**004**	Jun 10, 2016
AB			**140MG**	**A203180**	**002**	Nov 23, 2021
AB		BIOCON PHARMA	**20MG**	**A217217**	**001**	Mar 03, 2025
AB			**50MG**	**A217217**	**002**	Mar 03, 2025
AB			**70MG**	**A217217**	**003**	Mar 03, 2025
AB			**80MG**	**A217217**	**004**	Mar 03, 2025
AB			**100MG**	**A217217**	**005**	Mar 03, 2025
AB			**140MG**	**A217217**	**006**	Mar 03, 2025
AB		DR REDDYS	**20MG**	**A213383**	**001**	Mar 03, 2025
AB			**50MG**	**A213383**	**002**	Mar 03, 2025
AB			**70MG**	**A213383**	**003**	Mar 03, 2025
AB			**80MG**	**A213383**	**004**	Mar 03, 2025
AB			**100MG**	**A213383**	**005**	Mar 03, 2025
AB			**140MG**	**A213383**	**006**	Mar 03, 2025
AB		EUGIA PHARMA	**20MG**	**A216547**	**001**	Apr 22, 2025
AB			**50MG**	**A216547**	**002**	Apr 22, 2025
AB			**70MG**	**A216547**	**003**	Apr 22, 2025
AB			**80MG**	**A216547**	**004**	Apr 22, 2025
AB			**100MG**	**A216547**	**005**	Apr 22, 2025
AB			**140MG**	**A216547**	**006**	Apr 22, 2025
AB		LUPIN	**20MG**	**A214350**	**001**	Aug 25, 2025
AB			**50MG**	**A214350**	**002**	Aug 25, 2025
AB			**70MG**	**A214350**	**003**	Aug 25, 2025
AB			**80MG**	**A214350**	**004**	Aug 25, 2025
AB			**100MG**	**A214350**	**005**	Aug 25, 2025
AB			**140MG**	**A214350**	**006**	Aug 25, 2025
AB		TEVA PHARMS USA	**20MG**	**A211094**	**001**	Aug 27, 2025
AB			**50MG**	**A211094**	**002**	Aug 27, 2025
AB			**70MG**	**A211094**	**003**	Aug 27, 2025
AB			**80MG**	**A211094**	**004**	Aug 27, 2025
AB			**100MG**	**A211094**	**005**	Aug 27, 2025
AB			**140MG**	**A211094**	**006**	Aug 27, 2025
AB		ZYDUS PHARMS	**20MG**	**A218719**	**001**	Mar 03, 2025
AB			**50MG**	**A218719**	**002**	Mar 03, 2025
AB			**70MG**	**A218719**	**003**	Mar 03, 2025
AB			**80MG**	**A218719**	**004**	Mar 03, 2025
AB			**100MG**	**A218719**	**005**	Mar 03, 2025
AB			**140MG**	**A218719**	**006**	Mar 03, 2025

SPRYCEL

AB	+	BRISTOL MYERS SQUIBB	**20MG**	**N021986**	**001**	Jun 28, 2006

DASATINIB

TABLET;ORAL

SPRYCEL

AB	**+**		**50MG**	**N021986**	**002**	Jun 28, 2006
AB	**+**		**70MG**	**N021986**	**003**	Jun 28, 2006
AB	**+**		**80MG**	**N021986**	**005**	Oct 28, 2010
AB	**+!**		**100MG**	**N021986**	**004**	May 30, 2008
AB	**+**		**140MG**	**N021986**	**006**	Oct 28, 2010

PHYRAGO

+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023
+		50MG	N216099	002	Dec 05, 2023
+		70MG	N216099	003	Dec 05, 2023
+		80MG	N216099	004	Dec 05, 2023
+!		100MG	N216099	005	Dec 05, 2023
+		140MG	N216099	006	Dec 05, 2023

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021

ZEGALOGUE (AUTOINJECTOR)

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

AP	**!**	HIKMA	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995

DAUNORUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP	**+!**	HIKMA	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
AP		HISUN PHARM HANGZHOU	**EQ 5MG BASE/ML**	**A208759**	**001**	Apr 12, 2019
AP		MEITHEAL	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP		ACCORD HLTHCARE	**50MG/VIAL**	**A203475**	**001**	Feb 27, 2017
AP		CHEMI SPA	**50MG/VIAL**	**A206033**	**001**	Sep 22, 2017
AP	**!**	DR REDDYS	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP		GLAND	**50MG/VIAL**	**A205539**	**001**	Nov 23, 2020
AP		HETERO LABS LTD VI	**50MG/VIAL**	**A215355**	**001**	May 10, 2024
AP		JIANGSU HANSOH PHARM	**50MG/VIAL**	**A213472**	**001**	Apr 15, 2022
AP		MEITHEAL	**50MG/VIAL**	**A212959**	**001**	Jul 02, 2021
AP		MSN	**50MG/VIAL**	**A212265**	**001**	Aug 28, 2019
AP		NIVAGEN PHARMS INC	**50MG/VIAL**	**A212117**	**001**	Dec 07, 2020
AP		NOVAST LABS	**50MG/VIAL**	**A210984**	**001**	Sep 16, 2019
AP		PHARMASCIENCE INC	**50MG/VIAL**	**A204607**	**001**	May 31, 2017
AP		QILU PHARM HAINAN	**50MG/VIAL**	**A212826**	**001**	Apr 12, 2021
AP		RELIANCE LIFE SCI	**50MG/VIAL**	**A217814**	**001**	Dec 19, 2025
AP		SAGENT PHARMS INC	**50MG/VIAL**	**A207100**	**001**	Mar 16, 2018
AP		SANDOZ	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014
AP		WOCKHARDT BIO AG	**50MG/VIAL**	**A209056**	**001**	Apr 09, 2019
AP		ZYDUS PHARMS	**50MG/VIAL**	**A214486**	**001**	Nov 19, 2021

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB		ALKEM LABS LTD	**90MG**	**A213374**	**001**	Jul 14, 2020
AB			**180MG**	**A213374**	**002**	Jul 14, 2020
AB			**360MG**	**A213374**	**003**	Jul 14, 2020
AB		ANNORA PHARMA	**90MG**	**A216229**	**003**	Mar 16, 2023
AB			**180MG**	**A216229**	**001**	Sep 22, 2022
AB			**360MG**	**A216229**	**002**	Sep 22, 2022
AB		AUCTA	**90MG**	**A214559**	**001**	Mar 09, 2021
AB			**180MG**	**A214559**	**002**	Mar 09, 2021
AB			**360MG**	**A214559**	**003**	Mar 09, 2021
AB		AUROBINDO PHARMA	**90MG**	**A215137**	**001**	Sep 08, 2025
AB			**180MG**	**A215137**	**002**	Sep 08, 2025
AB			**360MG**	**A215137**	**003**	Sep 08, 2025
AB		CIPLA	**90MG**	**A215026**	**001**	Feb 23, 2022
AB			**180MG**	**A215026**	**002**	Feb 23, 2022

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB			**360MG**	**A215026**	**003**	Feb 23, 2022
AB		MSN	**90MG**	**A214650**	**003**	Apr 20, 2022
AB			**180MG**	**A214650**	**001**	Mar 17, 2021
AB			**360MG**	**A214650**	**002**	Mar 17, 2021

JADENU SPRINKLE

AB	+	NOVARTIS	**90MG**	**N207968**	**001**	May 18, 2017
AB	+		**180MG**	**N207968**	**002**	May 18, 2017
AB	+!		**360MG**	**N207968**	**003**	May 18, 2017

TABLET;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**90MG**	**A208697**	**001**	Dec 13, 2019
AB			**180MG**	**A208697**	**002**	Dec 13, 2019
AB			**360MG**	**A208697**	**003**	Dec 13, 2019
AB		ALEMBIC	**90MG**	**A211824**	**001**	Nov 20, 2019
AB			**180MG**	**A211824**	**003**	Jun 15, 2020
AB			**360MG**	**A211824**	**002**	Nov 20, 2019
AB		ALKEM LABS LTD	**90MG**	**A210555**	**001**	Mar 30, 2020
AB			**180MG**	**A210555**	**003**	Jul 02, 2020
AB			**360MG**	**A210555**	**002**	Mar 30, 2020
AB		ANNORA PHARMA	**90MG**	**A214341**	**001**	May 14, 2021
AB			**180MG**	**A214341**	**002**	May 14, 2021
AB			**360MG**	**A214341**	**003**	May 14, 2021
AB		AUROBINDO PHARMA LTD	**90MG**	**A214474**	**001**	Oct 16, 2023
AB			**180MG**	**A214474**	**002**	Oct 16, 2023
AB			**360MG**	**A214474**	**003**	Oct 16, 2023
AB		CHARTWELL RX	**90MG**	**A212669**	**001**	May 27, 2021
AB			**180MG**	**A212669**	**002**	May 27, 2021
AB			**360MG**	**A212669**	**003**	May 27, 2021
AB		JUBILANT GENERICS	**90MG**	**A211660**	**001**	Apr 11, 2025
AB			**180MG**	**A211660**	**002**	Apr 11, 2025
AB			**360MG**	**A211660**	**003**	Apr 11, 2025
AB		MSN	**90MG**	**A210945**	**001**	Nov 20, 2019
AB			**180MG**	**A210945**	**003**	Jun 16, 2020
AB			**360MG**	**A210945**	**002**	Nov 20, 2019
AB		PHARMOBEDIENT	**90MG**	**A211395**	**001**	Mar 22, 2024
AB			**180MG**	**A211395**	**002**	Mar 22, 2024
AB			**360MG**	**A211395**	**003**	Mar 22, 2024
AB		PIRAMAL	**90MG**	**A212995**	**001**	Dec 30, 2019
AB			**180MG**	**A212995**	**003**	Jun 15, 2020
AB			**360MG**	**A212995**	**002**	Dec 30, 2019
AB		ZYDUS PHARMS	**90MG**	**A211383**	**001**	Nov 20, 2019
AB			**180MG**	**A211383**	**003**	Jun 15, 2020
AB			**360MG**	**A211383**	**002**	Nov 20, 2019

JADENU

AB	+	NOVARTIS PHARMS CORP	**90MG**	**N206910**	**001**	Mar 30, 2015
AB	+		**180MG**	**N206910**	**002**	Mar 30, 2015
AB	+!		**360MG**	**N206910**	**003**	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB			**250MG**	**A203560**	**002**	Jan 26, 2016
AB			**500MG**	**A203560**	**003**	Jan 26, 2016
AB		ALEMBIC	**125MG**	**A210060**	**001**	Nov 20, 2019
AB			**250MG**	**A210060**	**002**	Nov 20, 2019
AB			**500MG**	**A210060**	**003**	Nov 20, 2019
AB		ALKEM LABS LTD	**125MG**	**A210519**	**001**	Nov 20, 2019
AB			**250MG**	**A210519**	**002**	Nov 20, 2019
AB			**500MG**	**A210519**	**003**	Nov 20, 2019
AB		BIONPHARMA	**125MG**	**A210920**	**001**	Nov 20, 2019
AB			**250MG**	**A210920**	**002**	Nov 20, 2019
AB			**500MG**	**A210920**	**003**	Nov 20, 2019
AB		GLENMARK SPECLT	**125MG**	**A209433**	**001**	Jan 06, 2020
AB			**250MG**	**A209433**	**002**	Jan 06, 2020
AB			**500MG**	**A209433**	**003**	Jan 06, 2020
AB		MSN	**125MG**	**A209878**	**001**	Nov 20, 2019
AB			**250MG**	**A209878**	**002**	Nov 20, 2019
AB			**500MG**	**A209878**	**003**	Nov 20, 2019
AB		SUN PHARM	**125MG**	**A209782**	**001**	Nov 20, 2019

DEFERASIROX

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB			**250MG**	**A209782**	**002**	Nov 20, 2019
AB			**500MG**	**A209782**	**003**	Nov 20, 2019
AB		TEVA PHARMS USA	**125MG**	**A207124**	**001**	Sep 23, 2022
AB			**250MG**	**A207124**	**002**	Sep 23, 2022
AB			**500MG**	**A207124**	**003**	Sep 23, 2022

EXJADE

AB	**+**	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB	**+**		**250MG**	**N021882**	**002**	Nov 02, 2005
AB	**+!**		**500MG**	**N021882**	**003**	Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

	+!	CHIESI	100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

DEFERIPRONE

AB		HIKMA	**500MG**	**A213239**	**001**	Mar 29, 2021
AB	**!**		**1GM**	**A213239**	**002**	Feb 08, 2022
AB		SENORES PHARMS	**500MG**	**A220132**	**001**	Dec 11, 2025
AB			**1GM**	**A220132**	**002**	Dec 11, 2025
AB		TARO	**500MG**	**A208800**	**001**	Feb 08, 2019
AB			**1GM**	**A208800**	**002**	Nov 22, 2023

FERRIPROX

AB	**+**	CHIESI	**500MG**	**N021825**	**001**	Oct 14, 2011
AB	**+**		**1GM**	**N021825**	**002**	Jul 25, 2019
	+!		1GM	N212269	001	May 19, 2020

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP			**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP		GLAND	**500MG/VIAL**	**A207384**	**001**	Sep 29, 2017
AP			**2GM/VIAL**	**A207384**	**002**	Sep 29, 2017
AP		HIKMA	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP			**2GM/VIAL**	**A078086**	**002**	May 30, 2007
AP		HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP	**!**		**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004

DESFERAL

AP	**+!**	MITEM PHARMA	**500MG/VIAL**	**N016267**	**001**	

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

	+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

DEFLAZACORT

SUSPENSION;ORAL

DEFLAZACORT

AB		TRIS PHARMA INC	**22.75MG/ML**	**A217813**	**001**	Apr 25, 2024
AB		UPSHER SMITH LABS	**22.75MG/ML**	**A216992**	**001**	Aug 11, 2025
AB		ZYDUS LIFESCIENCES	**22.75MG/ML**	**A220042**	**001**	Oct 03, 2025

EMFLAZA

AB	**+!**	PTC THERAP	**22.75MG/ML**	**N208685**	**001**	Feb 09, 2017

PYQUVI

AB		AUCTA	**22.75MG/ML**	**A219417**	**001**	Jun 30, 2025

TABLET;ORAL

DEFLAZACORT

AB		AMNEAL	**6MG**	**A217173**	**001**	Dec 12, 2025
AB			**18MG**	**A217173**	**002**	Dec 12, 2025
AB			**30MG**	**A217173**	**003**	Dec 12, 2025
AB			**36MG**	**A217173**	**004**	Dec 12, 2025
AB		AUROBINDO PHARMA LTD	**6MG**	**A217123**	**001**	Feb 09, 2024
AB			**18MG**	**A217123**	**002**	Feb 09, 2024
AB			**30MG**	**A217123**	**003**	Feb 09, 2024
AB			**36MG**	**A217123**	**004**	Feb 09, 2024
AB		SUN PHARM	**6MG**	**A217741**	**001**	Mar 18, 2025
AB			**18MG**	**A217741**	**002**	Mar 18, 2025
AB			**30MG**	**A217741**	**003**	Mar 18, 2025
AB			**36MG**	**A217741**	**004**	Mar 18, 2025
AB		UPSHER SMITH LABS	**6MG**	**A216720**	**001**	Nov 05, 2024

DEFLAZACORT

TABLET;ORAL

DEFLAZACORT

AB			**18MG**	**A216720**	**002**	Nov 05, 2024
AB			**30MG**	**A216720**	**003**	Nov 05, 2024
AB			**36MG**	**A216720**	**004**	Nov 05, 2024

EMFLAZA

AB	**+**	PTC THERAP	**6MG**	**N208684**	**001**	Feb 09, 2017
AB	**+**		**18MG**	**N208684**	**002**	Feb 09, 2017
AB	**+**		**30MG**	**N208684**	**003**	Feb 09, 2017
AB	**+!**		**36MG**	**N208684**	**004**	Feb 09, 2017

JAYTHARI

AB		ZYDUS LIFESCIENCES	**6MG**	**A219254**	**001**	Apr 08, 2025
AB			**18MG**	**A219254**	**002**	Apr 08, 2025
AB			**30MG**	**A219254**	**003**	Apr 08, 2025
AB			**36MG**	**A219254**	**004**	Apr 08, 2025

DEGARELIX ACETATE

POWDER;SUBCUTANEOUS

FIRMAGON

	+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
	+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER;INTRAVENOUS

BAXDELA

	+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017

TABLET;ORAL

BAXDELA

	+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DELGOCITINIB

CREAM;TOPICAL

ANZUPGO

	+!	LEO PHARMA AS	2%	N219155	001	Jul 23, 2025

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		AMNEAL PHARM	**150MG**	**A065425**	**001**	Feb 27, 2008
AB	**!**		**300MG**	**A065425**	**002**	Feb 27, 2008
AB		EPIC PHARMA LLC	**150MG**	**A065389**	**001**	Dec 01, 2008
AB			**150MG**	**A065447**	**001**	Aug 18, 2015
AB			**300MG**	**A065389**	**002**	Dec 01, 2008
AB			**300MG**	**A065447**	**002**	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

DEOXYCHOLIC ACID

AP		WILSHIRE PHARMS INC	**20MG/2ML (10MG/ML)**	**A212296**	**001**	Apr 02, 2021

KYBELLA

AP	**+!**	ABBVIE	**20MG/2ML (10MG/ML)**	**N206333**	**001**	Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN		SHANGHAI HENGRUI	**100%**	**A208234**	**001**	Feb 26, 2018

SUPRANE

AN	**+!**	BAXTER HLTHCARE	**100%**	**N020118**	**001**	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	**10MG**	**A074430**	**001**	Feb 09, 1996
AB			**25MG**	**A071601**	**001**	Jun 05, 1987
AB			**50MG**	**A071588**	**001**	Jun 05, 1987
AB			**75MG**	**A071602**	**001**	Oct 05, 1987
AB			**100MG**	**A071766**	**001**	Oct 05, 1987
AB			**150MG**	**A074430**	**002**	Feb 09, 1996
AB		ALEMBIC	**10MG**	**A209785**	**001**	Jul 07, 2021
AB			**25MG**	**A209785**	**002**	Jul 07, 2021
AB			**50MG**	**A209785**	**003**	Jul 07, 2021
AB			**75MG**	**A209785**	**004**	Jul 07, 2021
AB			**100MG**	**A209785**	**005**	Jul 07, 2021
AB			**150MG**	**A209785**	**006**	Jul 07, 2021
AB		AMNEAL PHARMS CO	**10MG**	**A208105**	**001**	Mar 17, 2016

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB			**25MG**	**A208105**	**002**	Mar 17, 2016
AB			**50MG**	**A208105**	**003**	Mar 17, 2016
AB			**75MG**	**A208105**	**004**	Mar 17, 2016
AB			**100MG**	**A208105**	**005**	Mar 17, 2016
AB			**150MG**	**A208105**	**006**	Mar 17, 2016
AB		CHARTWELL RX	**10MG**	**A072103**	**002**	May 24, 1988
AB			**25MG**	**A072103**	**003**	May 24, 1988
AB			**50MG**	**A072103**	**004**	May 24, 1988
AB			**75MG**	**A072103**	**005**	Jun 20, 1988
AB			**100MG**	**A072103**	**001**	Jun 20, 1988
AB			**150MG**	**A072103**	**006**	Jun 20, 1988
AB		HERITAGE	**10MG**	**A207433**	**001**	May 05, 2016
AB			**25MG**	**A207433**	**002**	May 05, 2016
AB			**50MG**	**A207433**	**003**	May 05, 2016
AB			**75MG**	**A207433**	**004**	May 05, 2016
AB			**100MG**	**A207433**	**005**	May 05, 2016
AB			**150MG**	**A207433**	**006**	May 05, 2016
AB		NOVAST LABS	**10MG**	**A204963**	**001**	Dec 26, 2017
AB			**25MG**	**A204963**	**002**	Dec 26, 2017
AB			**50MG**	**A204963**	**003**	Dec 26, 2017
AB			**75MG**	**A204963**	**004**	Dec 26, 2017
AB			**100MG**	**A204963**	**005**	Dec 26, 2017
AB			**150MG**	**A204963**	**006**	Dec 26, 2017

NORPRAMIN

AB	+	VALIDUS PHARMS	**10MG**	**N014399**	**007**	Feb 11, 1982
AB	+		**25MG**	**N014399**	**001**	
AB	+		**50MG**	**N014399**	**003**	
AB	+		**75MG**	**N014399**	**004**	
AB	+!		**100MG**	**N014399**	**005**	
AB	+		**150MG**	**N014399**	**006**	

DESLORATADINE

SOLUTION;ORAL

DESLORATADINE

!	TARO	0.5MG/ML	A202936	001	May 26, 2016

TABLET;ORAL

CLARINEX

AB	+!	ORGANON	**5MG**	**N021165**	**001**	Dec 21, 2001

DESLORATADINE

AB		AJENAT PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB		LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB		ORBION PHARMS	**5MG**	**A078357**	**001**	Feb 19, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

DESLORATADINE

	REDDYS	2.5MG	A078367	001	Jul 12, 2010
!		5MG	A078367	002	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX-D 12 HOUR

+!	ORGANON LLC	2.5MG;120MG	N021313	001	Feb 01, 2006

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

!	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DDAVP

AP	+!	NORDIC PHARMA	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984

DESMOPRESSIN ACETATE

AP		DR REDDYS	**0.004MG/ML**	**A215961**	**001**	Aug 19, 2022
AP		GLAND	**0.004MG/ML**	**A216904**	**001**	Mar 20, 2023
AP			**0.004MG/ML**	**A216922**	**001**	Nov 16, 2022
AP		MEITHEAL	**0.004MG/ML**	**A074888**	**001**	Oct 15, 1997
AP		SAGENT PHARMS INC	**0.004MG/ML**	**A204695**	**001**	Aug 22, 2017
AP			**0.004MG/ML**	**A204751**	**001**	Aug 22, 2017
AP		UBI	**0.004MG/ML**	**A210218**	**001**	Feb 14, 2020
AP			**0.004MG/ML**	**A210223**	**001**	Sep 17, 2020

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE

AB	**!**	BAUSCH	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB	**!**	APOTEX	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB		ZYDUS PHARMS	**0.01MG/SPRAY**	**A091345**	**001**	Oct 03, 2017

TABLET;ORAL

DDAVP

AB	**+**	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	**+!**		**0.2MG**	**N019955**	**002**	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ABHAI LLC	**0.1MG**	**A210371**	**001**	Jan 28, 2019
AB			**0.2MG**	**A210371**	**002**	Jan 28, 2019
AB		APOTEX	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB			**0.2MG**	**A077414**	**002**	Mar 07, 2006
AB		AUROBINDO PHARMA	**0.1MG**	**A213095**	**001**	Mar 21, 2024
AB			**0.2MG**	**A213095**	**002**	Mar 21, 2024
AB		HERITAGE PHARMA	**0.1MG**	**A207880**	**001**	May 26, 2017
AB			**0.2MG**	**A207880**	**002**	May 26, 2017
AB		NOVAST LABS	**0.1MG**	**A208357**	**001**	Jun 06, 2019
AB			**0.2MG**	**A208357**	**002**	Jun 06, 2019

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

AVERI

		AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025

TABLET;ORAL-28

AVERI

AB		AVION PHARMS	**0.15MG;0.03MG**	**A218933**	**002**	May 02, 2025

BEKYREE

AB		LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015

CYCLESSA

AB	**+!**	ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000

DESOGESTREL AND ETHINYL ESTRADIOL

AB	**!**	DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB		NAARI PTE	**0.15MG,N/A;0.02MG,0.01MG**	**A209170**	**001**	Jun 05, 2017
AB			**0.15MG;0.03MG**	**A207067**	**001**	Sep 13, 2018
AB		NOVAST LABS	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB		WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005
AB		XIROMED	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013

ENSKYCE

AB		LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013

ISIBLOOM

AB		XIROMED	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015

KALLIGA

AB		AUROBINDO PHARMA	**0.15MG;0.03MG**	**A207081**	**001**	May 17, 2017

KARIVA

AB	**!**	BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002

PIMTREA

AB		NOVAST LABS	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013

SIMLIYA

AB		AUROBINDO PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A206853**	**001**	Mar 22, 2017

VELIVET

AB		DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004

VIORELE

AB		GLENMARK PHARMS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012

VOLNEA

AB		XIROMED	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE

CREAM;TOPICAL

DESONIDE

AB		ALEMBIC	**0.05%**	**A214396**	**001**	Dec 08, 2022
AB	**!**	CADILA	**0.05%**	**A210198**	**001**	Nov 20, 2019
AB		COSETTE	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB		SUN PHARMA CANADA	**0.05%**	**A073548**	**001**	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

DESONIDE							
GEL;TOPICAL							
DESONIDE							
	!	SENORES PHARMS	0.05%		A202470	001	May 11, 2020
LOTION;TOPICAL							
DESONIDE							
AB	**!**	ALEMBIC	**0.05%**		**A213632**	**001**	Aug 24, 2020
AB		FOUGERA PHARMS	**0.05%**		**A075860**	**001**	Mar 19, 2002
AB		TARO	**0.05%**		**A202161**	**001**	Oct 31, 2014
OINTMENT;TOPICAL							
DESONIDE							
AB		ALEMBIC	**0.05%**		**A212473**	**001**	Oct 23, 2019
AB		ENCUBE ETHICALS	**0.05%**		**A210998**	**001**	Jan 30, 2019
AB		FOUGERA PHARMS	**0.05%**		**A075751**	**001**	Mar 12, 2001
AB	**+!**	PADAGIS US	**0.05%**		**N017426**	**001**	
AB		SUN PHARMA CANADA	**0.05%**		**A074254**	**001**	Aug 03, 1994
DESOXIMETASONE							
CREAM;TOPICAL							
DESOXIMETASONE							
AB		ACTAVIS MID ATLANTIC	**0.25%**		**A205082**	**001**	Sep 04, 2015
AB		FOUGERA PHARMS	**0.25%**		**A078369**	**001**	Jun 29, 2010
AB		LUPIN	**0.05%**		**A208163**	**001**	Jan 10, 2017
AB			**0.25%**		**A208164**	**001**	Jan 09, 2017
AB		PADAGIS ISRAEL	**0.25%**		**A076510**	**001**	Jul 01, 2003
AB		RISING	**0.05%**		**A210980**	**001**	Dec 21, 2018
AB			**0.25%**		**A205594**	**001**	Jul 02, 2018
AB		ZYDUS LIFESCIENCES	**0.25%**		**A205620**	**001**	Sep 28, 2018
TOPICORT							
AB	**!**	TARO	**0.05%**		**A073210**	**001**	Nov 30, 1990
AB	**!**		**0.25%**		**A073193**	**001**	Nov 30, 1990
GEL;TOPICAL							
DESOXIMETASONE							
AB		EPIC PHARMA LLC	**0.05%**		**A090727**	**001**	Mar 10, 2011
AB		PADAGIS US	**0.05%**		**A077552**	**001**	Jan 09, 2006
AB		RISING	**0.05%**		**A204675**	**001**	Aug 12, 2016
TOPICORT							
AB	**!**	TARO	**0.05%**		**A074904**	**001**	Jul 14, 1998
OINTMENT;TOPICAL							
DESOXIMETASONE							
AB		ACTAVIS MID ATLANTIC	**0.25%**		**A204965**	**001**	Nov 07, 2016
AB		EPIC PHARMA LLC	**0.25%**		**A201005**	**001**	Apr 24, 2014
AB		FOUGERA PHARMS	**0.25%**		**A078657**	**001**	Sep 28, 2012
AB		LUPIN	**0.05%**		**A208044**	**001**	Dec 12, 2016
AB			**0.25%**		**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**		**A206792**	**001**	May 10, 2016
AB		PADAGIS ISRAEL	**0.25%**		**A077770**	**001**	Apr 20, 2015
AB		RISING	**0.25%**		**A204272**	**001**	Nov 30, 2016
AB		THE J MOLNER	**0.05%**		**A209973**	**001**	Oct 23, 2018
AB	**!**	ZYDUS LIFESCIENCES	**0.25%**		**A205206**	**001**	Sep 19, 2017
TOPICORT							
AB	**+!**	TARO	**0.05%**		**N018594**	**001**	Jan 17, 1985
SPRAY;TOPICAL							
DESOXIMETASONE							
AT		LUPIN	**0.25%**		**A208124**	**001**	Mar 16, 2018
AT		PADAGIS ISRAEL	**0.25%**		**A206441**	**001**	Jan 20, 2017
TOPICORT							
AT	**+!**	SUN PHARMA CANADA	**0.25%**		**N204141**	**001**	Apr 11, 2013
DESVENLAFAXINE							
TABLET, EXTENDED RELEASE;ORAL							
DESVENLAFAXINE							
	+	ALEMBIC PHARMS LTD	50MG		N204150	001	Mar 04, 2013
	+!		100MG		N204150	002	Mar 04, 2013
DESVENLAFAXINE SUCCINATE							
TABLET, EXTENDED RELEASE;ORAL							
DESVENLAFAXINE SUCCINATE							
AB		ACTAVIS LABS FL	**EQ 25MG BASE**		**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**		**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**		**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC	**EQ 25MG BASE**		**A204003**	**003**	Sep 14, 2018

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB			**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		HIKMA	**EQ 25MG BASE**	**A204083**	**002**	Feb 16, 2016
AB			**EQ 50MG BASE**	**A204083**	**003**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
AB		LUPIN LTD	**EQ 25MG BASE**	**A204172**	**003**	Apr 13, 2022
AB			**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		MACLEODS PHARMS LTD	**EQ 50MG BASE**	**A211427**	**001**	Jan 15, 2025
AB			**EQ 100MG BASE**	**A211427**	**002**	Jan 15, 2025
AB		MEDICAP LABS	**EQ 50MG BASE**	**A204805**	**001**	May 07, 2019
AB			**EQ 100MG BASE**	**A204805**	**002**	May 07, 2019
AB		RUBICON RESEARCH	**EQ 25MG BASE**	**A204028**	**003**	Dec 07, 2023
AB			**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		YICHANG HUMANWELL	**EQ 25MG BASE**	**A210014**	**003**	Oct 13, 2020
AB			**EQ 50MG BASE**	**A210014**	**001**	Oct 01, 2018
AB			**EQ 100MG BASE**	**A210014**	**002**	Oct 01, 2018
AB		ZYDUS PHARMS	**EQ 25MG BASE**	**A204020**	**003**	Nov 30, 2022
AB			**EQ 50MG BASE**	**A204020**	**001**	Oct 11, 2017
AB			**EQ 100MG BASE**	**A204020**	**002**	Oct 11, 2017

PRISTIQ

AB	**+**	PF PRISM CV	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	**+**		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	**+!**		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEUCRAVACITINIB

TABLET;ORAL

SOTYKTU

+!	BRISTOL	6MG	N214958	001	Sep 09, 2022

DEURUXOLITINIB PHOSPHATE

TABLET;ORAL

LEQSELVI

+!	SUN PHARM INDS INC	EQ 8MG BASE	N217900	001	Jul 25, 2024

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+!		12MG	N208082	003	Apr 03, 2017

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

+	TEVA	6MG	N216354	001	Feb 17, 2023
+		12MG	N216354	002	Feb 17, 2023
+		18MG	N216354	008	Jul 01, 2024
+		24MG	N216354	003	Feb 17, 2023
+		30MG	N216354	004	May 29, 2024
+		36MG	N216354	005	May 29, 2024
+		42MG	N216354	006	May 29, 2024
+!		48MG	N216354	007	May 29, 2024

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM

TABLET;ORAL

ALYFTREK

+	VERTEX PHARMS INC	50MG;20MG;EQ 4MG BASE	N218730	001	Dec 20, 2024
+!		125MG;50MG;EQ 10MG BASE	N218730	002	Dec 20, 2024

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL

DEXAMETHASONE

AA		CHARTWELL MOLECULAR	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA	**!**	KANCHAN HLTHCARE	**0.5MG/5ML**	**A084754**	**001**	
AA		RISING	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011

IMPLANT;INTRAVITREAL

OZURDEX

+!	ABBVIE	0.7MG	N022315	001	Jun 17, 2009

DEXAMETHASONE

INSERT;OPHTHALMIC

DEXTENZA

	+!	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018

SOLUTION;ORAL

DEXAMETHASONE

	+!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION;INTRAOCULAR

DEXYCU KIT

	+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

	+!	HARROW EYE	0.1%	N013422	001	

TABLET;ORAL

DEXAMETHASONE

AB		ALVOGEN	**4MG**	**A088481**	**004**	Apr 28, 1983
AB			**6MG**	**A088481**	**001**	Nov 28, 1983
AB		AMNEAL	**2MG**	**A216295**	**001**	Sep 08, 2022
AB			**4MG**	**A215106**	**001**	Oct 14, 2021
AB			**6MG**	**A215106**	**002**	Oct 14, 2021
AB		APOTEX	**0.5MG**	**A217695**	**001**	Aug 23, 2023
AB			**0.75MG**	**A217695**	**002**	Aug 23, 2023
AB			**1MG**	**A217695**	**003**	Aug 23, 2023
AB			**1.5MG**	**A217695**	**004**	Aug 23, 2023
AB			**2MG**	**A217695**	**005**	Aug 23, 2023
AB			**4MG**	**A217695**	**006**	Aug 23, 2023
AB			**6MG**	**A217695**	**007**	Aug 23, 2023
AB		BIONPHARMA	**2MG**	**A217538**	**001**	Apr 26, 2023
AB			**4MG**	**A217001**	**001**	Apr 19, 2023
AB			**6MG**	**A217001**	**002**	Apr 19, 2023
AB		COREPHARMA	**0.5MG**	**A218372**	**001**	Sep 17, 2024
AB			**0.75MG**	**A218372**	**002**	Sep 17, 2024
AB			**1MG**	**A218372**	**003**	Sep 17, 2024
AB			**1.5MG**	**A218372**	**004**	Sep 17, 2024
AB			**2MG**	**A218372**	**005**	Sep 17, 2024
AB			**4MG**	**A218372**	**006**	Sep 17, 2024
AB			**6MG**	**A218372**	**007**	Sep 17, 2024
AB	+	HIKMA	**0.5MG**	**A084612**	**002**	
AB	+		**0.75MG**	**A084612**	**003**	
AB	+!		**1MG**	**A084612**	**004**	Sep 15, 1983
AB	+		**1.5MG**	**A084612**	**005**	
AB	+!		**2MG**	**A084612**	**006**	
AB	+		**4MG**	**A084612**	**001**	
AB	+!		**6MG**	**A084612**	**007**	Sep 15, 1983
AB		NOVITIUM PHARMA	**0.5MG**	**A215604**	**004**	Oct 05, 2023
AB			**0.75MG**	**A215604**	**005**	Oct 05, 2023
AB			**1.5MG**	**A215604**	**001**	Aug 08, 2022
AB			**2MG**	**A217696**	**001**	May 09, 2023
AB			**4MG**	**A215604**	**002**	Aug 08, 2022
AB			**6MG**	**A215604**	**003**	Aug 08, 2022
AB		PHARMOBEDIENT	**1.5MG**	**A201270**	**001**	Jul 17, 2017
AB		PRASCO	**4MG**	**A080399**	**002**	Apr 20, 2022
AB		ZYDUS LIFESCIENCES	**0.5MG**	**A216282**	**001**	Feb 07, 2024
AB			**0.75MG**	**A216282**	**002**	Feb 07, 2024
AB			**1MG**	**A216284**	**001**	May 09, 2024
AB			**1.5MG**	**A216282**	**003**	Feb 07, 2024
AB			**2MG**	**A216283**	**001**	Feb 07, 2024
AB			**4MG**	**A216282**	**004**	Feb 07, 2024
AB			**6MG**	**A216282**	**005**	Feb 07, 2024
BP		ALVOGEN	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983

HEMADY

	+!	DEXCEL	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	**EQ 4MG PHOSPHATE/ML**	**A208689**	**001**	Aug 22, 2018
AP		EUGIA PHARMA	**EQ 10MG PHOSPHATE/ML**	**A210966**	**001**	Jun 05, 2020
AP	+!	FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	!		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP			**EQ 10MG PHOSPHATE/ML**	**A209192**	**001**	Jul 06, 2018

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		GLAND	**EQ 4MG PHOSPHATE/ML**	**A215654**	**001**	Aug 04, 2021
AP			**EQ 10MG PHOSPHATE/ML**	**A215654**	**002**	Sep 25, 2023
AP		HIKMA	**EQ 4MG PHOSPHATE/ML**	**A084282**	**001**	
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982
AP		MICRO LABS	**EQ 10MG PHOSPHATE/ML**	**A217797**	**001**	Mar 27, 2024
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
AP		SOMERSET	**EQ 4MG PHOSPHATE/ML**	**A207521**	**001**	Jun 08, 2018
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A211036**	**001**	May 10, 2019

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL	**EQ 10MG PHOSPHATE/ML**	**A208690**	**001**	Aug 22, 2018
AP	**!**	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A207442**	**001**	Apr 19, 2018

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	**+!**	SANDOZ	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**	

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001**	Jul 25, 1994
AT		PADAGIS US	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001**	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001**	Sep 13, 1995

MAXITROL

AT	**+!**	HARROW EYE	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**	
AT		SANDOZ	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001**	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

	+!	NOVARTIS	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	**+!**	SANDOZ	**0.1%;0.3%**	**N050592**	**001**	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001**	Oct 27, 1999
AB		PADAGIS US	**0.1%;0.3%**	**A212715**	**001**	Feb 11, 2022

TOBRADEX ST

	+!	HARROW EYE	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLMON

	!	PHARMOBEDIENT	2MG/5ML	A202520	001	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	**+**	TAKEDA PHARMS USA	**30MG**	**N022287**	**001**	Jan 30, 2009
AB	**+!**		**60MG**	**N022287**	**002**	Jan 30, 2009

DEXLANSOPRAZOLE

AB		ALEMBIC	**30MG**	**A219115**	**001**	Nov 12, 2025
AB			**60MG**	**A219115**	**002**	Nov 12, 2025
AB		MYLAN	**30MG**	**A205205**	**001**	Jan 19, 2024
AB			**60MG**	**A205205**	**002**	Jan 19, 2024
AB		PH HEALTH	**30MG**	**A202294**	**002**	Jun 16, 2022
AB			**60MG**	**A202294**	**001**	Apr 19, 2017
AB		TWI PHARMS	**30MG**	**A202666**	**001**	Sep 16, 2022
AB			**60MG**	**A202666**	**002**	Sep 16, 2022

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

+!	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022
+!		EQ 0.18MG BASE	N215390	002	Apr 05, 2022

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001**	Feb 09, 2016
AP	ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001**	Oct 17, 2016
AP	AMNEAL	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A216604**	**001**	May 15, 2023
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A216604**	**002**	May 15, 2023
AP	AMNEAL PHARMS CO	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A207551**	**001**	May 20, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A207551**	**002**	May 20, 2020
AP	BAXTER HLTHCARE CORP	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208532**	**001**	Aug 21, 2018
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208532**	**002**	Aug 21, 2018
AP	EUGIA PHARMA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001**	Mar 17, 2016
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A210321**	**001**	Dec 07, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A210321**	**002**	Dec 07, 2020
AP	FRESENIUS KABI USA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A208129**	**001**	Nov 29, 2018
AP		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001**	Sep 18, 2015
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208129**	**002**	Nov 29, 2018
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208129**	**003**	Nov 29, 2018
AP	GLAND	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001**	Aug 20, 2015
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209307**	**001**	Jun 03, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209307**	**002**	Jun 03, 2020
AP	HENGRUI PHARMA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A209065**	**002**	Jun 12, 2020
AP		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A209065**	**001**	Sep 19, 2017
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209065**	**003**	Jun 12, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209065**	**004**	Jun 12, 2020
AP	HIKMA	**EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)**	**A206407**	**003**	May 30, 2025
AP		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205046**	**001**	Apr 26, 2017
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A206407**	**001**	Jan 30, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A206407**	**002**	Jan 30, 2020
AP	MEITHEAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204843**	**001**	Jan 18, 2019
AP	MILLA PHARMS	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A217308**	**001**	Jun 07, 2023
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A217308**	**002**	Jun 07, 2023
AP	MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001**	Aug 18, 2014
AP	MYLAN LABS LTD	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212571**	**001**	Aug 27, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212571**	**002**	Aug 27, 2020
AP	PH HEALTH	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001**	Aug 18, 2014
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208266**	**001**	Sep 15, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208266**	**002**	Sep 15, 2020
AP	RISING	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001**	Nov 24, 2014
AP	SANDOZ	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001**	Jun 14, 2016
AP	TAGI	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A212857**	**001**	Nov 23, 2020
AP		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212857**	**002**	Nov 23, 2020
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212857**	**003**	Nov 23, 2020
AP	TEVA PHARMS USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205272**	**001**	Nov 28, 2017
AP	WILSHIRE PHARMS INC	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212791**	**001**	Dec 04, 2019
AP		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212791**	**002**	Dec 04, 2019
AP	ZYDUS PHARMS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A206798**	**001**	Feb 27, 2018

PRECEDEX

AP	**+!**	HOSPIRA	**EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)**	**N021038**	**005**	Jan 31, 2020
AP	**+!**		**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**N021038**	**004**	Nov 14, 2014
AP	**+!**		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001**	Dec 17, 1999
AP	**+!**		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**N021038**	**002**	Mar 13, 2013
AP	**+!**		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**N021038**	**003**	Mar 13, 2013

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

AP	**+!**	HQ SPCLT PHARMA	**EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)**	**N206628**	**002**	Oct 21, 2015
AP	**+**		**EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)**	**N206628**	**001**	Oct 21, 2015
AP		SOMERSET	**EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)**	**A218112**	**002**	Sep 24, 2024
AP			**EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)**	**A218112**	**001**	Sep 24, 2024
	+	HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ADARE PHARMS INC	5MG	A210279	001	Oct 09, 2018
AB			10MG	A210279	002	Oct 09, 2018
AB			15MG	A210279	003	Oct 09, 2018
AB			20MG	A210279	004	Oct 09, 2018
AB			25MG	A210279	005	Oct 09, 2018
AB			30MG	A210279	006	Oct 09, 2018
AB			35MG	A210279	007	Oct 09, 2018
AB			40MG	A210279	008	Oct 09, 2018
AB		ASCENT PHARMS INC	5MG	A215523	001	Dec 08, 2021
AB			10MG	A215523	002	Dec 08, 2021
AB			15MG	A215523	003	Dec 08, 2021
AB			20MG	A215523	004	Dec 08, 2021
AB			25MG	A215523	005	Dec 08, 2021
AB			30MG	A215523	006	Dec 08, 2021
AB			35MG	A215523	007	Dec 08, 2021
AB			40MG	A215523	008	Dec 08, 2021
AB		GRANULES	5MG	A213813	001	Sep 09, 2020
AB			10MG	A213813	002	Sep 09, 2020
AB			15MG	A213813	003	Sep 09, 2020
AB			20MG	A213813	004	Sep 09, 2020
AB			25MG	A213813	005	Sep 09, 2020
AB			30MG	A213813	006	Sep 09, 2020
AB			35MG	A213813	007	Sep 09, 2020
AB			40MG	A213813	008	Sep 09, 2020
AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015
AB			10MG	A079108	002	Aug 05, 2015
AB			15MG	A079108	003	May 19, 2014
AB			20MG	A079108	004	Dec 21, 2015
AB			25MG	A203614	001	Jul 05, 2017
AB			30MG	A079108	005	Nov 21, 2013
AB			35MG	A203614	002	Jul 05, 2017
AB		MEDICAP LABS	5MG	A078992	001	Nov 23, 2021
AB			10MG	A078992	002	Nov 23, 2021
AB			15MG	A078992	003	Nov 18, 2013
AB			30MG	A078992	004	Nov 18, 2013
AB			20MG	A078992	005	Nov 23, 2021
AB			40MG	A078992	006	Nov 23, 2021
AB		PH HEALTH	5MG	A202842	001	Nov 30, 2016
AB			10MG	A202842	002	Nov 30, 2016
AB			15MG	A202842	003	Nov 30, 2016
AB			20MG	A202842	004	Nov 30, 2016
AB			25MG	A202842	005	Nov 30, 2016
AB			30MG	A202842	006	Nov 30, 2016
AB			35MG	A202842	007	Nov 30, 2016
AB			40MG	A202842	008	Nov 30, 2016
AB		TEVA PHARMS USA	5MG	A078908	001	Nov 19, 2013
AB			10MG	A078908	002	Nov 19, 2013
AB			15MG	A078908	004	May 19, 2014
AB			20MG	A078908	003	Nov 19, 2013
AB			25MG	A202731	001	Jul 05, 2017
AB			30MG	A202731	003	May 19, 2014
AB			35MG	A202731	004	Jul 05, 2017
AB			40MG	A202731	002	Nov 19, 2013

FOCALIN XR

AB	+	SANDOZ	5MG	N021802	001	May 26, 2005
AB	+		10MG	N021802	002	May 26, 2005
AB	+		15MG	N021802	004	Aug 01, 2006
AB	+		20MG	N021802	003	May 26, 2005
AB	+		25MG	N021802	008	Apr 21, 2011
AB	+		30MG	N021802	005	Oct 23, 2009
AB	+		35MG	N021802	007	Apr 21, 2011
AB	+!		40MG	N021802	006	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI LLC	2.5MG	A206931	001	Dec 04, 2015
AB			5MG	A206931	002	Dec 04, 2015
AB			10MG	A206931	003	Dec 04, 2015
AB		ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019
AB			5MG	A212631	002	Jul 19, 2019

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB			**10MG**	**A212631**	**003**	Jul 19, 2019
AB		CEDIPROF INC	**5MG**	**A209211**	**001**	Sep 19, 2018
AB			**10MG**	**A209211**	**002**	Sep 19, 2018
AB		NOVEL LABS INC	**2.5MG**	**A204534**	**001**	Dec 04, 2015
AB			**5MG**	**A204534**	**002**	Dec 04, 2015
AB			**10MG**	**A204534**	**003**	Dec 04, 2015
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A201231**	**001**	Sep 24, 2015
AB			**5MG**	**A201231**	**002**	Sep 24, 2015
AB			**10MG**	**A201231**	**003**	Sep 24, 2015
AB		TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB			**5MG**	**A207901**	**002**	Aug 26, 2016
AB			**10MG**	**A207901**	**003**	Aug 26, 2016

FOCALIN

AB	**+**	SANDOZ	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB	**+**		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	**+!**		**10MG**	**N021278**	**003**	Nov 13, 2001

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021
+!		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	**!**	EUGIA PHARMA	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP	**!**		**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP		GLAND	**EQ 250MG BASE/VIAL**	**A207321**	**002**	Dec 16, 2019
AP			**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP		HIKMA	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP			**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004
AP		MSN	**EQ 250MG BASE/VIAL**	**A216748**	**001**	Mar 26, 2025
AP			**EQ 500MG BASE/VIAL**	**A216748**	**002**	Mar 26, 2025

DEXTROAMPHETAMINE

SYSTEM;TRANSDERMAL

XELSTRYM

+	NOVEN PHARMS INC	4.5MG/9HR	N215401	001	Mar 22, 2022
+		9MG/9HR	N215401	002	Mar 22, 2022
+		13.5MG/9HR	N215401	003	Mar 22, 2022
+!		18MG/9HR	N215401	004	Mar 22, 2022

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE SPANSULE

AB	**+**	IMPAX LABS INC	**5MG**	**N017078**	**001**	
AB	**+**		**10MG**	**N017078**	**002**	
AB	**+!**		**15MG**	**N017078**	**003**	

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012
AB			**10MG**	**A203901**	**002**	Nov 30, 2012
AB			**15MG**	**A203901**	**003**	Nov 30, 2012
AB		SPECGX LLC	**5MG**	**A076353**	**001**	May 06, 2003
AB			**10MG**	**A076353**	**002**	May 06, 2003
AB			**15MG**	**A076353**	**003**	May 06, 2003
AB		STRIDES PHARMA INTL	**5MG**	**A205673**	**001**	Oct 31, 2017
AB			**10MG**	**A205673**	**002**	Oct 31, 2017
AB			**15MG**	**A205673**	**003**	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	**!**	PRASCO	**5MG/5ML**	**A040776**	**001**	Jan 29, 2008
AA		TRIS PHARMA INC	**5MG/5ML**	**A203644**	**001**	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	**5MG**	**A202893**	**001**	Jul 31, 2013
AA			**10MG**	**A202893**	**002**	Jul 31, 2013
AA		AVANTHI INC	**5MG**	**A203548**	**001**	Nov 23, 2015
AA			**10MG**	**A203548**	**002**	Nov 23, 2015
AA		AZURITY	**2.5MG**	**A090533**	**001**	Oct 25, 2011

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA			5MG	A090533	002	Oct 25, 2011
AA			7.5MG	A090533	003	Oct 25, 2011
AA			10MG	A090533	004	Oct 25, 2011
AA			15MG	A090533	005	Oct 25, 2011
AA			20MG	A090533	006	Oct 25, 2011
AA			30MG	A090533	007	Oct 25, 2011
AA		BARR	5MG	A040361	001	Jan 31, 2001
AA	!		10MG	A040361	002	Jan 31, 2001
AA		NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016
AA			10MG	A204330	002	Mar 16, 2016
AA		NUVO PHARM	5MG	A210059	001	Oct 18, 2017
AA			10MG	A210059	002	Oct 18, 2017
AA		SPECGX LLC	5MG	A040436	001	Jan 29, 2002
AA			10MG	A040436	002	Jan 29, 2002
AA		WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021
AA			5MG	A212160	002	Jun 07, 2021
AA			7.5MG	A212160	003	Jun 07, 2021
AA			10MG	A212160	004	Jun 07, 2021
AA			15MG	A212160	005	Jun 07, 2021
AA			20MG	A212160	006	Jun 07, 2021
AA			30MG	A212160	007	Jun 07, 2021

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	!	PAI HOLDINGS	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011
AA	+	ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984
AA		COSETTE	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		PHARMOBEDIENT	15MG/5ML;6.25MG/5ML	A088864	001	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	20MG;10MG	A202934	001	Oct 10, 2017
AB		HETERO LABS LTD III	20MG;10MG	A218426	001	Aug 28, 2024

NUEDEXTA

AB	+!	AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+!	B BRAUN	10GM/100ML	N019626	004	Feb 02, 1988
AP	+!	BAXTER HLTHCARE	10GM/100ML	N016694	001	
AP		FRESENIUS KABI USA	10GM/100ML	A209448	001	Jul 16, 2018
AP	+!	OTSUKA ICU MEDCL	10GM/100ML	N018080	001	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+!	B BRAUN	50MG/ML	N016730	002	
AP	+!		5GM/100ML	N016730	001	
AP	+!		5GM/100ML	N019626	002	Feb 02, 1988
AP	+!	BAXTER HLTHCARE	50MG/ML	N016673	003	Oct 30, 1985
AP	+!		50MG/ML	N020179	002	Dec 07, 1992
AP	+!		5GM/100ML	N016673	001	
AP	+!		5GM/100ML	N020179	001	Dec 07, 1992
AP		FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016
AP	+!	HOSPIRA	5GM/100ML	N019466	001	Jul 15, 1985
AP	+!		5GM/100ML	N019479	001	Sep 17, 1985
AP	+!	OTSUKA ICU MEDCL	50MG/ML	N016367	002	

DEXTROSE 50%

AP	+	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986
AP		INTL MEDICATION SYS	500MG/ML	A203451	001	Mar 26, 2021

DEXTROSE 50% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	50GM/100ML	N020047	001	Jul 02, 1991
AP	+!	OTSUKA ICU MEDCL	50GM/100ML	N018563	001	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	+!	B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015
AP	+!	BAXTER HLTHCARE	70GM/100ML	N020047	003	Jul 02, 1991
AP	+!	OTSUKA ICU MEDCL	70GM/100ML	N018561	001	Mar 23, 1982
AP	+!		70GM/100ML	N019893	001	Dec 26, 1989

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 20% IN PLASTIC CONTAINER					
+!	OTSUKA ICU MEDCL	20GM/100ML	N018564	001	Mar 23, 1982
DEXTROSE 25%					
+!	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998
DEXTROSE 30% IN PLASTIC CONTAINER					
+!	OTSUKA ICU MEDCL	30GM/100ML	N019345	001	Jan 26, 1985
DEXTROSE 40% IN PLASTIC CONTAINER					
+!	OTSUKA ICU MEDCL	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER					
	OTSUKA ICU MEDCL	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER					
	OTSUKA ICU MEDCL	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER					
	OTSUKA ICU MEDCL	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%						
AP	FRESENIUS KABI USA	**5GM/100ML;75MG/100ML**	**A212346**	**001**	Sep 10, 2020
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER						
AP +	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML**	**N017634**	**004**	
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%						
AP	FRESENIUS KABI USA	**5GM/100ML;150MG/100ML**	**A212346**	**002**	Sep 10, 2020
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER						
AP +	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
AP +	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
	OTSUKA ICU MEDCL	5GM/100ML;149MG/100ML	N018371	001		

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ					
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP		**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)					
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ					
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**008**	Apr 13, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)					
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**001**	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037 005	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037 009	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037 002	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037 003	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 005	Mar 23, 1982
AP			5GM/100ML;150MG/100ML;330MG/100ML	N018629 002	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 003	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629 004	Mar 23, 1982
AP			5GM/100ML;300MG/100ML;330MG/100ML	N018629 006	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629 007	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629 008	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629 001	Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 010	

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630 008	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630 014	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630 020	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630 026	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630 010	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024	Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030	Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348 001	Jul 30, 2021

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523 001	Mar 09, 2021
AP			5GM/100ML;149MG/100ML;450MG/100ML	A213523 005	Oct 11, 2022

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005	Apr 28, 1982
AP			5GM/100ML;150MG/100ML;450MG/100ML	N018008 006	Apr 28, 1982
AP	+!	OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009	Jul 05, 1983
AP	+!		5GM/100ML;149MG/100ML;450MG/100ML	N018362 005	Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348 002	Jul 30, 2021
AP	+!	OTSUKA ICU MEDCL	5GM/100ML;149MG/100ML;225MG/100ML	N018365 001	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523 002	Mar 09, 2021

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007	Apr 28, 1982
AP	+!	OTSUKA ICU MEDCL	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010	Jul 05, 1983

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445 001	Mar 09, 2021

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005	Apr 05, 1985

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	OTSUKA ICU MEDCL	**5GM/100ML;149MG/100ML;900MG/100ML**	**N019691**	**005**	Mar 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;224MG/100ML;450MG/100ML**	**A213523**	**003**	Mar 09, 2021

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018008**	**008**	Apr 28, 1982
AP	**+!**	OTSUKA ICU MEDCL	**5GM/100ML;224MG/100ML;450MG/100ML**	**N018362**	**002**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	**5GM/100ML;298MG/100ML;450MG/100ML**	**A213523**	**004**	Mar 09, 2021

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**009**	Apr 28, 1982
AP	**+!**	OTSUKA ICU MEDCL	**5GM/100ML;298MG/100ML;450MG/100ML**	**N018362**	**003**	

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**5GM/100ML;298MG/100ML;900MG/100ML**	**A213445**	**002**	Mar 09, 2021

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;900MG/100ML**	**N019308**	**007**	Apr 05, 1985
AP	**+!**	OTSUKA ICU MEDCL	**5GM/100ML;298MG/100ML;900MG/100ML**	**N019691**	**009**	Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630	031	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630	037	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630	043	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630	001	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630	007	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630	013	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;450MG/100ML	N019630	019	Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;37MG/100ML;900MG/100ML	N019630	025	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;200MG/100ML	N019630	032	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;450MG/100ML	N019630	038	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;75MG/100ML;900MG/100ML	N019630	044	Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;75MG/100ML;300MG/100ML	N019630	049	May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;75MG/100ML;110MG/100ML	N019630	002	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;110MG/100ML;200MG/100ML	N019630	033	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;110MG/100ML;450MG/100ML	N019630	039	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;110MG/100ML;900MG/100ML	N019630	045	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;110MG/100ML;300MG/100ML	N019630	050	May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML;110MG/100ML	N019630	003	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML;200MG/100ML	N019630	009	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML;330MG/100ML	N019630	015	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML;450MG/100ML	N019630	021	Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML;900MG/100ML	N019630	027	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;150MG/100ML;200MG/100ML	N019630	034	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;150MG/100ML;450MG/100ML	N019630	040	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;150MG/100ML;900MG/100ML	N019630	046	Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;150MG/100ML;300MG/100ML	N019630	051	May 07, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;900MG/100ML N019630 047 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML;300MG/100ML N019630 052 May 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;110MG/100ML N019630 005 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N019630 011 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N019630 017 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N019630 023 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;900MG/100ML N019630 029 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;200MG/100ML N019630 036 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;450MG/100ML N019630 042 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;900MG/100ML N019630 048 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML;300MG/100ML N019630 053 May 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;110MG/100ML N019630 006 Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;75MG/100ML;900MG/100ML N019308 004 Apr 05, 1985
5GM/100ML;150MG/100ML;900MG/100ML N019308 002 Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML N019308 003 Apr 05, 1985

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;224MG/100ML;900MG/100ML N019308 006 Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML N018008 004

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML N019308 001 Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP B BRAUN **2.5GM/100ML;450MG/100ML** **N019631 004** Feb 24, 1988

AP **+!** BAXTER HLTHCARE **2.5GM/100ML;450MG/100ML** **N016697 001**

AP FRESENIUS KABI USA **2.5GM/100ML;450MG/100ML** **A211190 001** Dec 20, 2019

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;200MG/100ML** **N019631 007** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225%

AP FRESENIUS KABI USA **5GM/100ML;225MG/100ML** **A211221 001** Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP **+!** OTSUKA ICU MEDCL **5GM/100ML;225MG/100ML** **N017606 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP FRESENIUS KABI USA **5GM/100ML;300MG/100ML** **A211194 001** Aug 26, 2020

AP **+!** OTSUKA ICU MEDCL **5GM/100ML;300MG/100ML** **N017799 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;330MG/100ML** **N019631 008** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP FRESENIUS KABI USA **5GM/100ML;450MG/100ML** **A211276 001** Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;450MG/100ML** **N019631 009** Feb 24, 1988

AP **+** OTSUKA ICU MEDCL **5GM/100ML;450MG/100ML** **N017607 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP FRESENIUS KABI USA **5GM/100ML;900MG/100ML** **A211211 001** Sep 14, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP B BRAUN **5GM/100ML;900MG/100ML** **N019631 010** Feb 24, 1988

AP **+!** OTSUKA ICU MEDCL **5GM/100ML;900MG/100ML** **N017585 001**

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;200MG/100ML**	**N016689**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;330MG/100ML**	**N016687**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;450MG/100ML**	**N016683**	**001**	

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML;900MG/100ML**	**N016678**	**001**	

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

		B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DIATRIZOATE MEGLUMINE

SOLUTION;URETHRAL

CYSTOGRAFIN

	+	BRACCO	30%	N010040	018	

CYSTOGRAFIN DILUTE

	+	BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

AA		ANDA REPOSITORY	**66%;10%**	**A214201**	**001**	Jun 27, 2022
AA		ANNORA PHARMA	**66%;10%**	**A215049**	**001**	Nov 17, 2023

GASTROGRAFIN

AA	**+!**	BRACCO	**66%;10%**	**N011245**	**003**	

MD-GASTROVIEW

AA		LIEBEL-FLARSHEIM	**66%;10%**	**A087388**	**001**	

DIAZEPAM

CONCENTRATE;ORAL

DIAZEPAM

AA		CHARTWELL MOLECULAR	**5MG/ML**	**A204433**	**001**	Apr 14, 2014

DIAZEPAM INTENSOL

AA	**!**	HIKMA	**5MG/ML**	**A071415**	**001**	Apr 03, 1987

GEL;RECTAL

DIASTAT

AB	**+!**	BAUSCH	**2.5MG/0.5ML (5MG/ML)**	**N020648**	**001**	Jul 29, 1997

DIASTAT ACUDIAL

AB	**+!**	BAUSCH	**10MG/2ML (5MG/ML)**	**N020648**	**007**	Sep 15, 2005
AB	**+!**		**20MG/4ML (5MG/ML)**	**N020648**	**006**	Sep 15, 2005

DIAZEPAM

AB		NAVINTA LLC	**2.5MG/0.5ML (5MG/ML)**	**A217468**	**001**	Nov 14, 2025
AB			**10MG/2ML (5MG/ML)**	**A217468**	**002**	Nov 14, 2025
AB			**20MG/4ML (5MG/ML)**	**A217468**	**003**	Nov 14, 2025
AB		NOVEL LABS INC	**10MG/2ML (5MG/ML)**	**A091076**	**001**	May 30, 2023
AB			**20MG/4ML (5MG/ML)**	**A091076**	**002**	May 30, 2023

INJECTABLE;INJECTION

DIAZEPAM

AP		ALEMBIC	**10MG/2ML (5MG/ML)**	**A218450**	**001**	Apr 25, 2024
AP		DR REDDYS	**10MG/2ML (5MG/ML)**	**A218422**	**001**	Jul 18, 2024
AP		FRESENIUS KABI USA	**10MG/2ML (5MG/ML)**	**A214745**	**001**	Nov 10, 2022
AP		GALENICUM HLTH	**50MG/10ML (5MG/ML)**	**A216422**	**001**	May 19, 2025

DIAZEPAM						
INJECTABLE;INJECTION						
DIAZEPAM						
AP		HIKMA	**10MG/2ML (5MG/ML)**	**A070313**	**001**	Dec 16, 1985
AP			**50MG/10ML (5MG/ML)**	**A070311**	**001**	Dec 16, 1985
AP		HOSPIRA	**10MG/2ML (5MG/ML)**	**A072079**	**001**	Dec 20, 1988
AP	**!**		**50MG/10ML (5MG/ML)**	**A071583**	**001**	Oct 13, 1987
AP		LONG GROVE PHARMS	**10MG/2ML (5MG/ML)**	**A217178**	**001**	Dec 31, 2024
AP	**!**	REGCON HOLDINGS	**10MG/2ML (5MG/ML)**	**A210363**	**001**	Mar 18, 2019
AP			**50MG/10ML (5MG/ML)**	**A211998**	**001**	Dec 26, 2019
SOLUTION;ORAL						
DIAZEPAM						
AA		CHARTWELL MOLECULAR	**5MG/5ML**	**A206477**	**001**	Jun 24, 2016
AA	**!**	HIKMA	**5MG/5ML**	**A070928**	**001**	Apr 03, 1987
SPRAY;NASAL						
VALTOCO						
	+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020
	+		7.5MG/SPRAY	N211635	002	Jan 10, 2020
	+!		10MG/SPRAY	N211635	003	Jan 10, 2020
TABLET;ORAL						
DIAZEPAM						
AB		AUROBINDO PHARMA LTD	**2MG**	**A217843**	**001**	Dec 14, 2023
AB			**5MG**	**A217843**	**002**	Dec 14, 2023
AB			**10MG**	**A217843**	**003**	Dec 14, 2023
AB		DR REDDYS LABS SA	**2MG**	**A071134**	**001**	Feb 03, 1987
AB			**5MG**	**A071135**	**001**	Feb 03, 1987
AB			**10MG**	**A071136**	**001**	Feb 03, 1987
AB		IVAX SUB TEVA PHARMS	**2MG**	**A071307**	**001**	Dec 10, 1986
AB			**5MG**	**A071321**	**001**	Dec 10, 1986
AB			**10MG**	**A071322**	**001**	Dec 10, 1986
AB		MYLAN	**2MG**	**A070325**	**002**	Sep 04, 1985
AB			**5MG**	**A070325**	**003**	Sep 04, 1985
AB			**10MG**	**A070325**	**001**	Sep 04, 1985
AB		NUVO PHARM	**2MG**	**A070464**	**002**	Sep 10, 2024
AB			**5MG**	**A070464**	**003**	Sep 10, 2024
AB			**10MG**	**A070464**	**001**	Feb 25, 1986
AB		STRIDES PHARMA INTL	**2MG**	**A077749**	**001**	Mar 31, 2006
AB			**5MG**	**A077749**	**002**	Mar 31, 2006
AB			**10MG**	**A077749**	**003**	Mar 31, 2006
VALIUM						
AB	**+**	WAYLIS THERAP	**2MG**	**N013263**	**002**	
AB	**+**		**5MG**	**N013263**	**004**	
AB	**+!**		**10MG**	**N013263**	**006**	
DIAZOXIDE						
SUSPENSION;ORAL						
DIAZOXIDE						
AB		E5 PHARMA INC	**50MG/ML**	**A211050**	**001**	Dec 20, 2019
AB		NOVITIUM PHARMA	**50MG/ML**	**A210799**	**001**	Jul 08, 2020
PROGLYCEM						
AB	**+!**	TEVA BRANDED PHARM	**50MG/ML**	**N017453**	**001**	
DIAZOXIDE CHOLINE						
TABLET, EXTENDED RELEASE;ORAL						
VYKAT XR						
	+	SOLENO THERAP	25MG	N216665	001	Mar 26, 2025
	+		75MG	N216665	002	Mar 26, 2025
	+!		150MG	N216665	003	Mar 26, 2025
DICHLORPHENAMIDE						
TABLET;ORAL						
DICHLORPHENAMIDE						
AB		RISING	**50MG**	**A218783**	**001**	Nov 18, 2025
KEVEYIS						
AB	**+!**	XERIS	**50MG**	**N011366**	**002**	Aug 07, 2015
ORMALVI						
AB		TORRENT	**50MG**	**A215924**	**001**	Dec 29, 2022

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

FLECTOR

+!	IBSA	1.3%	N021234	001	Jan 31, 2007

LICART

+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	AUROBINDO PHARMA LTD	**25MG**	**A213875**	**001**	Oct 19, 2021
AB	BIONPHARMA	**25MG**	**A204648**	**001**	Feb 23, 2016
AB	ONESOURCE SPECIALTY	**25MG**	**A210078**	**001**	Dec 03, 2019

ZIPSOR

AB	**+!**	ASIO HOLDINGS	**25MG**	**N022202**	**001**	Jun 16, 2009

FOR SOLUTION;ORAL

CAMBIA

AB	**+!**	ASIO HOLDINGS	**50MG**	**N022165**	**001**	Jun 17, 2009

DICLOFENAC POTASSIUM

AB		ALKEM LABS LTD	**50MG**	**A216635**	**001**	Jul 20, 2022
AB		ANNORA PHARMA	**50MG**	**A215375**	**001**	Mar 04, 2022
AB		PH HEALTH	**50MG**	**A202964**	**001**	May 02, 2016
AB		TARO	**50MG**	**A218011**	**001**	Jun 14, 2024
AB		TORRENT	**50MG**	**A215891**	**001**	Jan 22, 2025
AB		UMEDICA	**50MG**	**A217010**	**001**	Aug 29, 2025

TABLET;ORAL

CATAFLAM

AB		AMICI PHARMA	**25MG**	**A076561**	**002**	Jul 21, 2021
AB			**50MG**	**A076561**	**001**	Mar 18, 2004

DICLOFENAC POTASSIUM

AB		NOVAST LABS	**50MG**	**A215585**	**001**	Oct 08, 2021
AB		RK PHARMA	**50MG**	**A075463**	**001**	Jul 26, 1999
AB		RUBICON RESEARCH	**25MG**	**A075229**	**002**	Sep 16, 2021
AB	**!**		**50MG**	**A075229**	**001**	Nov 20, 1998
AB		SENORES PHARMS	**25MG**	**A215787**	**002**	Nov 09, 2023
AB			**50MG**	**A215787**	**001**	Mar 15, 2023
AB		TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998
AB		UMEDICA	**25MG**	**A215750**	**002**	Jun 30, 2025
AB			**50MG**	**A215750**	**001**	May 11, 2022

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB		ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015
AB		AMNEAL	**3%**	**A200936**	**001**	Oct 28, 2013
AB		GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016
AB		PADAGIS ISRAEL	**3%**	**A210893**	**001**	Jul 27, 2018
AB	**!**	SUN PHARMA CANADA	**3%**	**A206298**	**001**	Apr 28, 2016
BX		ALEMBIC	3%	A212351	001	Jul 27, 2022

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB		ALEMBIC	**2%**	**A212506**	**001**	Nov 29, 2022
AB		AMNEAL	**2%**	**A208198**	**001**	Aug 18, 2022
AB		APOTEX	**2%**	**A207714**	**001**	May 06, 2022
AB		AUROLIFE PHARMA LLC	**2%**	**A213040**	**001**	Feb 03, 2023
AB		ENCUBE	**2%**	**A217646**	**001**	Apr 09, 2025
AB	**!**	LUPIN PHARMS	**2%**	**A208021**	**001**	Sep 20, 2022
AB		SUN PHARMA CANADA	**2%**	**A208098**	**001**	Sep 29, 2022
AT		AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016
AT		EPIC PHARMA LLC	**1.5%**	**A206655**	**001**	Jan 28, 2021
AT		LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015
AT		NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT	**!**	SUN PHARMA CANADA	**1.5%**	**A203818**	**001**	Nov 26, 2014
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014
AT		ZYDUS LIFESCIENCES	**1.5%**	**A206411**	**001**	Apr 17, 2018

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT	**!**	BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING	**0.1%**	**A078553**	**001**	Dec 28, 2007
AT		RUBICON RESEARCH	**0.1%**	**A077600**	**001**	Nov 13, 2008
AT		SANDOZ	**0.1%**	**A078031**	**001**	Feb 06, 2008

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996
AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		AUROBINDO PHARMA USA	**50MG**	**A075281**	**002**	Feb 12, 2002
AB			**75MG**	**A075281**	**003**	Feb 12, 2002
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB		RUBICON RESEARCH	**25MG**	**A216548**	**001**	May 11, 2023
AB			**50MG**	**A216548**	**002**	May 11, 2023
AB			**75MG**	**A216548**	**003**	May 11, 2023
AB		UMEDICA	**25MG**	**A219945**	**001**	Nov 05, 2025
AB			**50MG**	**A219945**	**002**	Nov 05, 2025
AB			**75MG**	**A219945**	**003**	Nov 05, 2025
AB	!	UNIQUE	**25MG**	**A090066**	**001**	Dec 01, 2010
AB	!		**50MG**	**A090066**	**002**	Dec 01, 2010
AB	!		**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	!	DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		NOVAST LABS	**100MG**	**A216275**	**001**	Sep 23, 2022
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

AB	+	PFIZER	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	+!		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		MICRO LABS	**50MG;0.2MG**	**A204355**	**001**	Jul 15, 2021
AB			**75MG;0.2MG**	**A204355**	**002**	Jul 15, 2021
AB		YUNG SHIN PHARM	**50MG;0.2MG**	**A205143**	**001**	Feb 19, 2020
AB			**75MG;0.2MG**	**A205143**	**002**	Feb 19, 2020

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A216845**	**001**	Sep 23, 2022
AB			**EQ 500MG BASE**	**A216845**	**002**	Sep 23, 2022
AB		TEVA	**EQ 250MG BASE**	**A062286**	**001**	Jun 03, 1982
AB	!		**EQ 500MG BASE**	**A062286**	**002**	Jun 03, 1982

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		ANNORA PHARMA	**10MG**	**A218018**	**001**	Jul 01, 2024
AB		AUROBINDO PHARMA USA	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		COREPHARMA	**10MG**	**A216639**	**001**	Mar 24, 2023
AB	!	LANNETT	**10MG**	**A084285**	**001**	
AB		PRINSTON INC	**10MG**	**A217531**	**001**	Aug 30, 2023
AB		RISING	**10MG**	**A219242**	**001**	Jun 23, 2025
AB		TWI PHARMS	**10MG**	**A217054**	**001**	Dec 27, 2022
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986
AB		WEST WARD	**10MG**	**A040204**	**001**	Feb 28, 1997

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP		AM REGENT	**10MG/ML**	**A208353**	**001**	Feb 17, 2017
AP	!	FOSUN PHARMA	**10MG/ML**	**A210979**	**001**	Jul 02, 2018
AP		FRESENIUS KABI USA	**10MG/ML**	**A210257**	**001**	Jan 25, 2019
AP		SLATE RUN PHARMA	**10MG/ML**	**A207076**	**001**	Nov 02, 2018
AP		SOMERSET THERAPS LLC	**10MG/ML**	**A214332**	**001**	Nov 01, 2024
AP			**10MG/ML**	**A214333**	**001**	Nov 01, 2024

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP	!	HIKMA	**10MG/ML**	**A040465**	**001**	Jun 30, 2003

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

AA		HIKMA	**10MG/5ML**	**A212286**	**001**	May 22, 2020
AA		NOVITIUM PHARMA	**10MG/5ML**	**A214721**	**001**	Apr 23, 2021
AA	**!**	PH HEALTH	**10MG/5ML**	**A040169**	**001**	Mar 24, 2005

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		ANNORA PHARMA	**20MG**	**A217566**	**001**	May 07, 2024
AB		AUROBINDO PHARMA USA	**20MG**	**A040317**	**001**	Sep 07, 1999
AB		BIONPHARMA	**20MG**	**A217916**	**001**	Aug 04, 2023
AB		COREPHARMA	**20MG**	**A216760**	**001**	Nov 28, 2022
AB		HIKMA PHARMS	**20MG**	**A040161**	**001**	Oct 01, 1996
AB		LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB		PRINSTON INC	**20MG**	**A218310**	**001**	Jun 06, 2025
AB		RISING	**20MG**	**A218952**	**001**	Nov 15, 2024
AB		RUBICON RESEARCH	**20MG**	**A216736**	**001**	Dec 14, 2022
AB		TWI PHARMS	**20MG**	**A216782**	**001**	Jun 01, 2023
AB	**!**	WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986
	!	RUBICON RESEARCH	40MG	A216736	002	Mar 25, 2025

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+!	BAYER HLTHCARE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA		AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA	**!**	LANNETT CO INC	**25MG**	**A200177**	**001**	Jul 18, 2011

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

	!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011

DIFELIKEFALIN ACETATE

SOLUTION;INTRAVENOUS

KORSUVA

	+!	VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	!	SUN PHARMA CANADA	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		AVONDALE PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB		RISING	**0.05%**	**A207440**	**001**	Feb 27, 2017
AB	**!**	SUN PHARMA CANADA	**0.05%**	**A075331**	**001**	May 14, 1999
AB		THE J MOLNER	**0.05%**	**A210753**	**001**	Jun 12, 2018

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	**!**	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992
AB		ZYDUS PHARMS	**500MG**	**A203547**	**001**	Jun 16, 2017
		HERITAGE PHARMA	250MG	A202845	002	Aug 16, 2024
			375MG	A202845	003	Aug 16, 2024

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

AB		AMNEAL	**0.05%**	**A211526**	**001**	Nov 17, 2021
AB		CAPLIN	**0.05%**	**A219441**	**001**	Dec 13, 2024
AB		CIPLA	**0.05%**	**A211776**	**001**	Aug 09, 2021
AB		DR REDDYS	**0.05%**	**A214894**	**001**	Nov 16, 2022
AB		EPIC PHARMA LLC	**0.05%**	**A207284**	**001**	May 14, 2024
AB		MYLAN LABS LTD	**0.05%**	**A212566**	**001**	Mar 20, 2025
AB		UPSHER SMITH LABS	**0.05%**	**A218191**	**001**	Feb 11, 2025

DUREZOL

AB	**+!**	SANDOZ	**0.05%**	**N022212**	**001**	Jun 23, 2008

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA		AMICI PHARMA	**0.05MG/ML**	**A215209**	**001**	Mar 11, 2022
AA	**+!**	HIKMA	**0.05MG/ML**	**N021648**	**001**	Aug 26, 2004
AA		VISTAPHARM LLC	**0.05MG/ML**	**A213000**	**001**	Oct 04, 2019

INJECTABLE;INJECTION

DIGOXIN

AP		HIKMA	**0.25MG/ML**	**A083391**	**001**	
AP		SANDOZ	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003

LANOXIN

AP	**+!**	COVIS	**0.25MG/ML**	**N009330**	**002**	

LANOXIN PEDIATRIC

	+!	COVIS	0.1MG/ML	N009330	004	

TABLET;ORAL

DIGOXIN

AB		AUROBINDO PHARMA LTD	**0.0625MG**	**A214982**	**001**	Feb 08, 2022
AB			**0.125MG**	**A214982**	**002**	Feb 08, 2022
AB			**0.25MG**	**A214982**	**003**	Feb 08, 2022
AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007
AB		NOVITIUM PHARMA	**0.0625MG**	**A215307**	**003**	Aug 25, 2022
AB			**0.125MG**	**A215307**	**001**	Nov 22, 2021
AB			**0.25MG**	**A215307**	**002**	Nov 22, 2021
AB		RISING	**0.125MG**	**A040282**	**001**	Dec 23, 1999
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003

LANOXIN

AB	**+**	ADVANZ PHARMA	**0.0625MG**	**N020405**	**001**	Sep 30, 1997
AB	**+**		**0.125MG**	**N020405**	**002**	Sep 30, 1997
AB	**+!**		**0.25MG**	**N020405**	**004**	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		GLAND	**1MG/ML**	**A215623**	**001**	Aug 18, 2023
AP		HIKMA	**1MG/ML**	**A040453**	**001**	Jun 09, 2003
AP	**!**	HIKMA PHARMS	**1MG/ML**	**A206621**	**001**	Sep 15, 2017
AP		MILLA PHARMS	**1MG/ML**	**A212046**	**001**	Jan 07, 2020
AP		PADAGIS US	**1MG/ML**	**A040475**	**001**	Apr 28, 2003
AP		SAGENT PHARMS INC	**1MG/ML**	**A207264**	**001**	Jul 11, 2018

POWDER;NASAL

ATZUMI

	+!	SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025

SOLUTION;SUBCUTANEOUS

BREKIYA (AUTOINJECTOR)

	+!	AMNEAL	1MG/ML	N215400	001	May 14, 2025

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB		CIPLA	**0.5MG/SPRAY**	**A212907**	**001**	May 20, 2020
AB		HIKMA	**0.5MG/SPRAY**	**A211393**	**001**	Feb 28, 2020
AB		RUBICON RESEARCH	**0.5MG/SPRAY**	**A216881**	**001**	Jun 22, 2023
AB		SOMERSET THERAPS LLC	**0.5MG/SPRAY**	**A215228**	**001**	Feb 26, 2025

MIGRANAL

AB	**+!**	BAUSCH	**0.5MG/SPRAY**	**N020148**	**001**	Dec 08, 1997

TRUDHESA

	+!	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1		DR REDDYS LABS SA	**60MG**	**A215775**	**001**	May 05, 2022
AB1			**90MG**	**A215775**	**002**	May 05, 2022
AB1			**120MG**	**A215775**	**003**	May 05, 2022
AB1		GLENMARK PHARMS LTD	**60MG**	**A212317**	**001**	Mar 22, 2021
AB1			**90MG**	**A212317**	**002**	Mar 22, 2021
AB1			**120MG**	**A212317**	**003**	Mar 22, 2021
AB1		MYLAN	**60MG**	**A074910**	**001**	May 02, 1997
AB1			**90MG**	**A074910**	**002**	May 02, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE							
AB1	!		**120MG**	**A074910**	**003**	May 02, 1997
AB1		NOVAST LABS	**60MG**	**A218032**	**001**	Jul 02, 2025
AB1			**90MG**	**A218032**	**002**	Jul 02, 2025
AB1			**120MG**	**A218032**	**003**	Jul 02, 2025
AB1		TWI PHARMS	**60MG**	**A217377**	**001**	Mar 01, 2023
AB1			**90MG**	**A217377**	**002**	Mar 01, 2023
AB1			**120MG**	**A217377**	**003**	Mar 01, 2023
AB1		UTOPIC PHARMS	**60MG**	**A219073**	**001**	Mar 24, 2025
AB1			**90MG**	**A219073**	**002**	Mar 24, 2025
AB1			**120MG**	**A219073**	**003**	Mar 24, 2025
AB2		ACCORD HLTHCARE	**120MG**	**A206997**	**001**	Apr 28, 2020
AB2			**180MG**	**A206997**	**002**	Apr 28, 2020
AB2			**240MG**	**A206997**	**003**	Apr 28, 2020
AB2		ALEMBIC	**120MG**	**A218587**	**001**	Oct 18, 2024
AB2			**180MG**	**A218587**	**002**	Oct 18, 2024
AB2			**240MG**	**A218587**	**003**	Oct 18, 2024
AB2		APOTEX	**120MG**	**A074943**	**003**	Dec 19, 2000
AB2			**180MG**	**A074943**	**002**	Dec 19, 2000
AB2	!		**240MG**	**A074943**	**001**	Aug 06, 1998
AB2		UTOPIC PHARMS	**120MG**	**A216304**	**001**	Aug 08, 2022
AB2			**180MG**	**A216304**	**002**	Aug 08, 2022
AB2			**240MG**	**A216304**	**003**	Aug 08, 2022
CARDIZEM CD							
AB3	+	BAUSCH	**120MG**	**N020062**	**001**	Aug 10, 1992
AB3	+		**180MG**	**N020062**	**002**	Dec 27, 1991
AB3	+		**240MG**	**N020062**	**003**	Dec 27, 1991
AB3	+		**300MG**	**N020062**	**004**	Dec 27, 1991
AB3	+!		**360MG**	**N020062**	**005**	Aug 24, 1999
CARTIA XT							
AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998
DILTIAZEM HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012
AB3		ALEMBIC	**120MG**	**A216968**	**001**	Nov 08, 2024
AB3			**180MG**	**A216968**	**002**	Nov 08, 2024
AB3			**240MG**	**A216968**	**003**	Nov 08, 2024
AB3			**300MG**	**A216968**	**004**	Nov 08, 2024
AB3			**360MG**	**A216968**	**005**	Nov 08, 2024
AB3		NOVAST LABS	**120MG**	**A208783**	**001**	Jun 14, 2019
AB3			**180MG**	**A208783**	**002**	Jun 14, 2019
AB3			**240MG**	**A208783**	**003**	Jun 14, 2019
AB3			**300MG**	**A208783**	**004**	Jun 14, 2019
AB3			**360MG**	**A208783**	**005**	Jun 14, 2019
AB3		PH HEALTH	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3		SUN PHARM	**360MG**	**A203023**	**005**	Jun 08, 2017
AB3		TWI PHARMS	**120MG**	**A205231**	**001**	Aug 30, 2018
AB3			**180MG**	**A205231**	**002**	Aug 30, 2018
AB3			**240MG**	**A205231**	**003**	Aug 30, 2018
AB3			**300MG**	**A205231**	**004**	Aug 30, 2018
AB3			**360MG**	**A205231**	**005**	Aug 30, 2018
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999
AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB3		ZYDUS PHARMS	**120MG**	**A206534**	**001**	Aug 08, 2017
AB3			**180MG**	**A206534**	**002**	Aug 08, 2017
AB3			**240MG**	**A206534**	**003**	Aug 08, 2017
AB3			**300MG**	**A206534**	**004**	Aug 08, 2017
AB3			**360MG**	**A206534**	**005**	Aug 08, 2017
AB4		CHARTWELL RX	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		ZYDUS PHARMS	**120MG**	**A206641**	**001**	Aug 11, 2017
AB4			**180MG**	**A206641**	**002**	Aug 11, 2017
AB4			**240MG**	**A206641**	**003**	Aug 11, 2017
AB4			**300MG**	**A206641**	**004**	Aug 11, 2017
AB4			**360MG**	**A206641**	**005**	Aug 11, 2017
AB4			**420MG**	**A206641**	**006**	Aug 11, 2017

TIAZAC

AB4	**+**	BAUSCH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4	**+**		**180MG**	**N020401**	**002**	Sep 11, 1995
AB4	**+**		**240MG**	**N020401**	**003**	Sep 11, 1995
AB4	**+**		**300MG**	**N020401**	**004**	Sep 11, 1995
AB4	**+**		**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	**+!**		**420MG**	**N020401**	**006**	Oct 16, 1998

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		HIKMA	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
AP		RISING	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	**!**	SAGENT	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

SOLUTION;INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

+!	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025
+!		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025

TABLET;ORAL

CARDIZEM

AB	**+**	BAUSCH	**30MG**	**N018602**	**001**	Nov 05, 1982
AB	**+**		**60MG**	**N018602**	**002**	Nov 05, 1982
AB	**+**		**90MG**	**N018602**	**003**	Dec 08, 1986
AB	**+!**		**120MG**	**N018602**	**004**	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

AB		ALEMBIC	**30MG**	**A217633**	**001**	Nov 14, 2025
AB			**60MG**	**A217633**	**002**	Nov 14, 2025
AB			**90MG**	**A217633**	**003**	Nov 14, 2025
AB			**120MG**	**A217633**	**004**	Nov 14, 2025
AB		SCIEGEN PHARMS	**30MG**	**A216521**	**001**	Sep 23, 2022
AB			**60MG**	**A216521**	**002**	Sep 23, 2022
AB			**90MG**	**A216521**	**003**	Sep 23, 2022
AB			**120MG**	**A216521**	**004**	Sep 23, 2022
AB		TEVA	**30MG**	**A074185**	**001**	May 31, 1995
AB			**60MG**	**A074185**	**002**	May 31, 1995
AB			**90MG**	**A074185**	**003**	May 31, 1995
AB			**120MG**	**A074185**	**004**	May 31, 1995
AB		ZYDUS LIFESCIENCES	**30MG**	**A219253**	**001**	Aug 08, 2025
AB			**60MG**	**A219253**	**002**	Aug 08, 2025
AB			**90MG**	**A219253**	**003**	Aug 08, 2025
AB			**120MG**	**A219253**	**004**	Aug 08, 2025

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	**+**	BAUSCH	**120MG**	**N021392**	**001**	Feb 06, 2003
AB	**+**		**180MG**	**N021392**	**002**	Feb 06, 2003
AB	**+**		**240MG**	**N021392**	**003**	Feb 06, 2003
AB	**+**		**300MG**	**N021392**	**004**	Feb 06, 2003
AB	**+**		**360MG**	**N021392**	**005**	Feb 06, 2003
AB	**+!**		**420MG**	**N021392**	**006**	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**120MG**	**A077686**	**006**	Mar 15, 2010
AB			**180MG**	**A077686**	**005**	Mar 15, 2010
AB			**240MG**	**A077686**	**004**	Mar 15, 2010
AB			**300MG**	**A077686**	**003**	Mar 15, 2010
AB			**360MG**	**A077686**	**002**	Mar 15, 2010
AB			**420MG**	**A077686**	**001**	Mar 15, 2010
AB		AMTA	**120MG**	**A216439**	**001**	Mar 07, 2023
AB			**180MG**	**A216439**	**002**	Mar 07, 2023
AB			**240MG**	**A216439**	**003**	Mar 07, 2023
AB			**300MG**	**A216439**	**004**	Mar 07, 2023
AB			**360MG**	**A216439**	**005**	Mar 07, 2023
AB			**420MG**	**A216439**	**006**	Mar 07, 2023
AB		SCIEGEN PHARMS	**120MG**	**A216327**	**001**	Apr 06, 2023

DILTIAZEM HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB		**180MG**	**A216327**	**002**	Apr 06, 2023
AB		**240MG**	**A216327**	**003**	Apr 06, 2023
AB		**300MG**	**A216327**	**004**	Apr 06, 2023
AB		**360MG**	**A216327**	**005**	Apr 06, 2023
AB		**420MG**	**A216327**	**006**	Apr 06, 2023

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE;INJECTION

BAL

+!	PROVEPHARM SAS	10%	N005939	001	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	ACCORD HLTHCARE	**120MG**	**A210499**	**001**	Sep 24, 2020
AB		**240MG**	**A210499**	**002**	Sep 24, 2020
AB	ALKEM LABS LTD	**120MG**	**A210440**	**001**	Sep 24, 2020
AB		**240MG**	**A210440**	**002**	Sep 24, 2020
AB	AMNEAL	**120MG**	**A210402**	**001**	Sep 24, 2020
AB		**240MG**	**A210402**	**002**	Sep 24, 2020
AB	AUROBINDO PHARMA	**120MG**	**A210385**	**001**	Dec 22, 2022
AB		**240MG**	**A210385**	**002**	Dec 22, 2022
AB	GLENMARK PHARMS LTD	**120MG**	**A210309**	**001**	Oct 06, 2020
AB		**240MG**	**A210309**	**002**	Oct 06, 2020
AB	HETERO LABS LTD III	**120MG**	**A210500**	**001**	Sep 24, 2020
AB		**240MG**	**A210500**	**002**	Sep 24, 2020
AB	LUPIN	**120MG**	**A210226**	**001**	Oct 05, 2020
AB		**240MG**	**A210226**	**002**	Oct 05, 2020
AB	MACLEODS PHARMS LTD	**120MG**	**A210377**	**001**	Jun 26, 2024
AB		**240MG**	**A210377**	**002**	Jun 26, 2024
AB	MSN	**120MG**	**A210460**	**001**	Sep 24, 2020
AB		**240MG**	**A210460**	**002**	Sep 24, 2020
AB	MYLAN	**120MG**	**A210531**	**001**	Aug 17, 2020
AB		**240MG**	**A210531**	**002**	Aug 17, 2020
AB	PRINSTON INC	**120MG**	**A210414**	**001**	Oct 18, 2022
AB		**240MG**	**A210414**	**002**	Oct 18, 2022
AB	SOLA PHARMS	**120MG**	**A210436**	**001**	Mar 26, 2021
AB		**240MG**	**A210436**	**002**	Mar 26, 2021
AB	TWI PHARMS	**120MG**	**A210382**	**001**	Oct 14, 2020
AB		**240MG**	**A210382**	**002**	Oct 14, 2020

TECFIDERA

AB **+**	BIOGEN INC	**120MG**	**N204063**	**001**	Mar 27, 2013
AB **+!**		**240MG**	**N204063**	**002**	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

RIMSO-50

+!	MYLAN INSTITUTIONAL	50%	N017788	001	

DINOPROSTONE

GEL;ENDOCERVICAL

PREPIDIL

+!	PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

+!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	APP PHARMS	**50MG/ML**	**A040466**	**001**	May 28, 2002
AP	AVET LIFESCIENCES	**50MG/ML**	**A205336**	**001**	Jun 24, 2025
AP		**50MG/ML**	**A205337**	**001**	Nov 14, 2025
AP	GLAND	**50MG/ML**	**A218448**	**001**	Mar 20, 2024

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP		MICRO LABS	**50MG/ML**	**A205723**	**001**	Aug 22, 2018
AP			**50MG/ML**	**A219845**	**001**	Aug 22, 2025
AP	**!**	PHARMOBEDIENT	**50MG/ML**	**A040498**	**001**	Jul 12, 2005
AP	**+!**	WEST-WARD PHARMS INT	**50MG/ML**	**A080817**	**002**	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**50MG/ML**	**A091526**	**001**	Mar 26, 2013

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	**!**	CHARTWELL INJECTABLE	**5MG/ML**	**A074939**	**001**	Apr 13, 1998
AP		HIKMA	**5MG/ML**	**A074521**	**001**	Oct 18, 1996

TABLET;ORAL

DIPYRIDAMOLE

AB		BARR	**25MG**	**A087184**	**001**	Oct 03, 1990
AB			**50MG**	**A087716**	**001**	Oct 03, 1990
AB		BARR LABS	**75MG**	**A087717**	**001**	Oct 03, 1990
AB		IMPAX LABS	**25MG**	**A040782**	**001**	Jul 18, 2007
AB			**50MG**	**A040782**	**002**	Jul 18, 2007
AB	**!**		**75MG**	**A040782**	**003**	Jul 18, 2007
AB		OXFORD PHARMS	**25MG**	**A040542**	**001**	Apr 21, 2006
AB			**50MG**	**A040542**	**002**	Apr 21, 2006
AB			**75MG**	**A040542**	**003**	Apr 21, 2006
AB		RISING	**25MG**	**A040733**	**001**	Feb 13, 2007
AB			**50MG**	**A040733**	**002**	Feb 13, 2007
AB			**75MG**	**A040733**	**003**	Feb 13, 2007
AB		ZYDUS PHARMS USA INC	**25MG**	**A040874**	**001**	Jan 28, 2008
AB			**50MG**	**A040874**	**002**	Jan 28, 2008
AB			**75MG**	**A040874**	**003**	Jan 28, 2008

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIROXIMEL FUMARATE

AB		ZYDUS	**231MG**	**A218596**	**001**	Nov 12, 2025

VUMERITY

AB	**+!**	BIOGEN INC	**231MG**	**N211855**	**001**	Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		DR REDDYS LABS SA	**EQ 100MG BASE**	**A070173**	**001**	May 31, 1985
AB			**EQ 150MG BASE**	**A070173**	**002**	May 31, 1985
AB		TEVA	**EQ 100MG BASE**	**A070101**	**001**	Feb 22, 1985
AB			**EQ 150MG BASE**	**A070102**	**001**	Feb 22, 1985

NORPACE

AB	**+**	PFIZER	**EQ 100MG BASE**	**N017447**	**001**	
AB	**+!**		**EQ 150MG BASE**	**N017447**	**002**	

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	PFIZER	EQ 100MG BASE	N018655	001	Jul 20, 1982
	+!		EQ 150MG BASE	N018655	002	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN	**250MG**	**A091681**	**001**	Aug 08, 2013
AB		CHARTWELL MOLECULES	**250MG**	**A091563**	**001**	Dec 31, 2012
AB	**!**		**500MG**	**A091563**	**002**	Dec 31, 2012
AB		SIGMAPHARM LABS LLC	**250MG**	**A091619**	**001**	Mar 28, 2011
AB			**500MG**	**A091619**	**002**	Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	**+!**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N019680**	**001**	Sep 12, 1989

DIVALPROEX SODIUM

AB		AJANTA PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A213181**	**001**	Mar 02, 2020
AB		ALEMBIC	**EQ 125MG VALPROIC ACID**	**A218793**	**001**	Dec 19, 2024
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078979**	**001**	Jan 23, 2009

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

AB		MANKIND PHARMA	**EQ 125MG VALPROIC ACID**	**A217358**	**001**	Aug 12, 2025
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A078919**	**001**	Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	+	ABBVIE	**EQ 125MG VALPROIC ACID**	**N018723**	**003**	Oct 26, 1984
AB	+		**EQ 250MG VALPROIC ACID**	**N018723**	**001**	Mar 10, 1983
AB	+!		**EQ 500MG VALPROIC ACID**	**N018723**	**002**	Mar 10, 1983

DIVALPROEX SODIUM

AB		AUROBINDO PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A090554**	**001**	Apr 21, 2011
AB			**EQ 250MG VALPROIC ACID**	**A090554**	**002**	Apr 21, 2011
AB			**EQ 500MG VALPROIC ACID**	**A090554**	**003**	Apr 21, 2011
AB		CHARTWELL RX	**EQ 125MG VALPROIC ACID**	**A077296**	**001**	Jul 31, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077296**	**002**	Jul 31, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077296**	**003**	Jul 31, 2008
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078755**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078755**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078755**	**003**	Jul 29, 2008
AB		INVATECH	**EQ 125MG VALPROIC ACID**	**A078290**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078290**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078290**	**001**	Jul 29, 2008
AB		LUPIN	**EQ 125MG VALPROIC ACID**	**A078790**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078790**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078790**	**003**	Jul 29, 2008
AB		ORBION PHARMS	**EQ 125MG VALPROIC ACID**	**A078853**	**001**	Nov 25, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078853**	**002**	Nov 25, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078853**	**003**	Nov 25, 2008
AB		PRINSTON INC	**EQ 125MG VALPROIC ACID**	**A090210**	**001**	Nov 30, 2009
AB			**EQ 250MG VALPROIC ACID**	**A090210**	**002**	Nov 30, 2009
AB			**EQ 500MG VALPROIC ACID**	**A090210**	**003**	Nov 30, 2009
AB		SUN PHARM INDS	**EQ 125MG VALPROIC ACID**	**A078597**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078597**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078597**	**003**	Jul 29, 2008
AB		UNICHEM LABS LTD	**EQ 125MG VALPROIC ACID**	**A079163**	**001**	Apr 05, 2011
AB			**EQ 250MG VALPROIC ACID**	**A079163**	**002**	Apr 05, 2011
AB			**EQ 500MG VALPROIC ACID**	**A079163**	**003**	Apr 05, 2011
AB		UPSHER SMITH LABS	**EQ 125MG VALPROIC ACID**	**A078182**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078182**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078182**	**003**	Jul 29, 2008
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A077100**	**001**	Mar 05, 2009
AB			**EQ 250MG VALPROIC ACID**	**A077100**	**002**	Mar 05, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077100**	**003**	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

AB	+	ABBVIE	**EQ 250MG VALPROIC ACID**	**N021168**	**002**	May 31, 2002
AB	+		**EQ 500MG VALPROIC ACID**	**N021168**	**001**	Aug 04, 2000

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	**EQ 250MG VALPROIC ACID**	**A203730**	**001**	May 29, 2015
AB	!		**EQ 500MG VALPROIC ACID**	**A203730**	**002**	May 29, 2015
AB		ANNORA PHARMA	**EQ 250MG VALPROIC ACID**	**A215527**	**001**	Sep 26, 2023
AB			**EQ 500MG VALPROIC ACID**	**A215527**	**002**	Sep 26, 2023
AB		AUROBINDO PHARMA LTD	**EQ 250MG VALPROIC ACID**	**A202419**	**001**	Jun 02, 2014
AB			**EQ 500MG VALPROIC ACID**	**A202419**	**002**	Jun 02, 2014
AB		DR REDDYS LABS LTD	**EQ 250MG VALPROIC ACID**	**A090161**	**001**	Mar 15, 2012
AB		LUPIN LTD	**EQ 250MG VALPROIC ACID**	**A209286**	**001**	Oct 18, 2019
AB			**EQ 500MG VALPROIC ACID**	**A209286**	**002**	Oct 18, 2019
AB		MYLAN	**EQ 250MG VALPROIC ACID**	**A077567**	**001**	Jan 29, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077567**	**002**	Jan 29, 2009
AB		REDDYS	**EQ 500MG VALPROIC ACID**	**A090070**	**001**	Mar 12, 2012
AB		SCIEGEN PHARMS	**EQ 250MG VALPROIC ACID**	**A078705**	**002**	Feb 10, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078705**	**001**	Aug 04, 2009
AB		UNICHEM	**EQ 250MG VALPROIC ACID**	**A214643**	**001**	Feb 25, 2022
AB			**EQ 500MG VALPROIC ACID**	**A214643**	**002**	Feb 25, 2022
AB		ZYDUS PHARMS USA INC	**EQ 250MG VALPROIC ACID**	**A078239**	**001**	Feb 27, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078239**	**002**	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP		HIKMA	**EQ 12.5MG BASE/ML**	**A074277**	**001**	Oct 31, 1994
AP	**!**	HOSPIRA	**EQ 12.5MG BASE/ML**	**A074086**	**001**	Nov 29, 1993
AP		SLATE RUN PHARMA	**EQ 12.5MG BASE/ML**	**A216131**	**001**	Dec 21, 2022

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N020255**	**001**	Oct 19, 1993
AP	**+!**		**EQ 100MG BASE/100ML**	**N020255**	**003**	Oct 19, 1993
AP	**+!**		**EQ 200MG BASE/100ML**	**N020255**	**004**	Oct 19, 1993
AP	**+!**		**EQ 400MG BASE/100ML**	**N020255**	**005**	Oct 19, 1993
AP	**+!**	HOSPIRA	**EQ 50MG BASE/100ML**	**N020201**	**003**	Oct 19, 1993
AP	**+!**		**EQ 100MG BASE/100ML**	**N020201**	**002**	Oct 19, 1993
AP	**+!**		**EQ 200MG BASE/100ML**	**N020201**	**001**	Oct 19, 1993
AP	**+!**		**EQ 400MG BASE/100ML**	**N020201**	**006**	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	**+**	ACCORD HLTHCARE	**20MG/ML (20MG/ML)**	**N201195**	**003**	Apr 20, 2012
AP	**+**		**80MG/4ML (20MG/ML)**	**N201195**	**004**	Apr 20, 2012
AP	**+!**		**160MG/8ML (20MG/ML)**	**N201195**	**005**	Apr 20, 2012
AP		ACTAVIS	**20MG/ML (20MG/ML)**	**N203551**	**001**	Apr 12, 2013
AP			**80MG/4ML (20MG/ML)**	**N203551**	**002**	Apr 12, 2013
AP			**160MG/8ML (20MG/ML)**	**N203551**	**004**	Sep 21, 2015
AP		ALEMBIC	**20MG/2ML (10MG/ML)**	**A215744**	**001**	Feb 28, 2023
AP			**80MG/8ML (10MG/ML)**	**A215744**	**002**	Feb 28, 2023
AP			**160MG/16ML (10MG/ML)**	**A215744**	**003**	Feb 28, 2023
AP	**!**	AMNEAL	**20MG/ML (20MG/ML)**	**A209640**	**001**	Jan 19, 2018
AP	**!**		**80MG/4ML (20MG/ML)**	**A209640**	**002**	Jan 19, 2018
AP	**!**		**160MG/8ML (20MG/ML)**	**A209640**	**003**	Jan 19, 2018
AP		DR REDDYS	**20MG/ML (20MG/ML)**	**A204193**	**001**	Nov 05, 2014
AP			**80MG/4ML (20MG/ML)**	**A204193**	**002**	Nov 05, 2014
AP		GLAND	**20MG/2ML (10MG/ML)**	**A213510**	**001**	Jul 01, 2021
AP			**80MG/8ML (10MG/ML)**	**A213510**	**002**	Jul 01, 2021
AP			**160MG/16ML (10MG/ML)**	**A213510**	**003**	Jul 01, 2021
AP		GUANGDONG SUNHO	**20MG/ML (20MG/ML)**	**A213768**	**001**	May 13, 2025
AP			**80MG/4ML (20MG/ML)**	**A213768**	**002**	May 13, 2025
AP		HENGRUI PHARMA	**20MG/ML (20MG/ML)**	**A207252**	**001**	Aug 09, 2017
AP			**80MG/4ML (20MG/ML)**	**A207252**	**002**	Aug 09, 2017
AP			**160MG/8ML (20MG/ML)**	**A207252**	**003**	Aug 09, 2017
AP		HERITAGE	**80MG/4ML (20MG/ML)**	**A216677**	**002**	Feb 28, 2024
AP			**160MG/8ML (20MG/ML)**	**A216677**	**003**	Nov 26, 2024
AP			**20MG/ML (20MG/ML)**	**A216677**	**001**	Feb 28, 2024
AP		HIKMA	**20MG/ML (20MG/ML)**	**A204490**	**001**	Jan 14, 2021
AP			**80MG/4ML (20MG/ML)**	**A204490**	**002**	Jan 14, 2021
AP	**+!**	HOSPIRA INC	**20MG/2ML (10MG/ML)**	**N022234**	**001**	Mar 08, 2011
AP	**+!**		**80MG/8ML (10MG/ML)**	**N022234**	**002**	Mar 08, 2011
AP	**+!**		**160MG/16ML (10MG/ML)**	**N022234**	**003**	Mar 08, 2011
AP		MEITHEAL	**20MG/2ML (10MG/ML)**	**A209634**	**001**	Aug 24, 2018
AP			**80MG/8ML (10MG/ML)**	**A209634**	**002**	Aug 24, 2018
AP			**160MG/16ML (10MG/ML)**	**A209634**	**003**	Aug 24, 2018
AP		MYLAN LABS LTD	**20MG/2ML (10MG/ML)**	**A210072**	**001**	Jul 02, 2018
AP			**80MG/8ML (10MG/ML)**	**A210848**	**001**	Jul 06, 2018
AP			**160MG/8ML (20MG/ML)**	**A208137**	**001**	Apr 01, 2019
AP			**160MG/16ML (10MG/ML)**	**A208859**	**001**	Apr 30, 2018
AP		NOVAST LABS	**80MG/8ML (10MG/ML)**	**A207563**	**002**	Aug 31, 2017
AP			**160MG/16ML (10MG/ML)**	**A207563**	**003**	Aug 31, 2017
AP		SANDOZ	**20MG/2ML (10MG/ML)**	**N201525**	**001**	Jun 29, 2011
AP			**80MG/8ML (10MG/ML)**	**N201525**	**002**	Jun 29, 2011
AP			**160MG/16ML (10MG/ML)**	**N201525**	**003**	Jun 29, 2011
AP		SHILPA	**20MG/ML (20MG/ML)**	**A210327**	**001**	May 16, 2019
AP	**+!**		**20MG/ML (20MG/ML)**	**N205934**	**001**	Dec 22, 2015
AP			**80MG/4ML (20MG/ML)**	**A210327**	**002**	May 16, 2019
AP	**+!**		**80MG/4ML (20MG/ML)**	**N205934**	**002**	Dec 22, 2015
AP			**160MG/8ML (20MG/ML)**	**A210327**	**003**	May 16, 2019
AP	**+!**		**160MG/8ML (20MG/ML)**	**N205934**	**003**	Dec 22, 2015

TAXOTERE

AP	**+**	SANOFI AVENTIS US	**160MG/8ML (20MG/ML)**	**N020449**	**005**	Apr 13, 2012

DOCETAXEL

		ACTAVIS	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

+		160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017

SOLUTION;INTRAVENOUS

BEIZRAY

+!	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024

DOCIVYX

+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022
+!		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022
+!		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022

DOFETILIDE

CAPSULE;ORAL

DOFETILDE

AB	AUROBINDO PHARMA LTD	**0.125MG**	**A210740**	**001**	Jan 22, 2019
AB		**0.25MG**	**A210740**	**002**	Jan 22, 2019
AB		**0.5MG**	**A210740**	**003**	Jan 22, 2019

DOFETILIDE

AB	ACCORD HLTHCARE	**0.125MG**	**A213338**	**001**	Jun 19, 2020
AB		**0.25MG**	**A213338**	**002**	Jun 19, 2020
AB		**0.5MG**	**A213338**	**003**	Jun 19, 2020
AB	BIONPHARMA	**0.125MG**	**A208625**	**001**	Apr 10, 2018
AB		**0.25MG**	**A208625**	**002**	Apr 10, 2018
AB		**0.5MG**	**A208625**	**003**	Apr 10, 2018
AB	DR REDDYS LABS SA	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB		**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB		**0.5MG**	**A207058**	**003**	Jun 06, 2016
AB	GRANULES	**0.125MG**	**A212750**	**001**	Oct 14, 2021
AB		**0.25MG**	**A212750**	**002**	Oct 14, 2021
AB		**0.5MG**	**A212750**	**003**	Oct 14, 2021
AB	MSN	**0.125MG**	**A213220**	**001**	Jan 29, 2020
AB		**0.25MG**	**A213220**	**002**	Jan 29, 2020
AB		**0.5MG**	**A213220**	**003**	Jan 29, 2020
AB	SIGMAPHARM LABS LLC	**0.125MG**	**A207746**	**001**	Mar 26, 2018
AB		**0.25MG**	**A207746**	**002**	Mar 26, 2018
AB		**0.5MG**	**A207746**	**003**	Mar 26, 2018
AB	STRIDES PHARMA INTL	**0.125MG**	**A208519**	**001**	Oct 09, 2018
AB		**0.25MG**	**A208519**	**002**	Oct 09, 2018
AB		**0.5MG**	**A208519**	**003**	Oct 09, 2018
AB	SUN PHARM	**0.125MG**	**A210466**	**001**	Oct 09, 2018
AB		**0.25MG**	**A210466**	**002**	Oct 09, 2018
AB		**0.5MG**	**A210466**	**003**	Oct 09, 2018

TIKOSYN

AB +	PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999
AB +		**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB +!		**0.5MG**	**N020931**	**003**	Oct 01, 1999

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

+!	VIIV HLTHCARE	EQ 50MG BASE	N204790	001	Aug 12, 2013

TABLET, FOR SUSPENSION;ORAL

TIVICAY PD

+!	VIIV HLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO

+!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

+!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192	001	Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

ARICEPT

AB +	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB +!		**10MG**	**N020690**	**001**	Nov 25, 1996
AB +!		**23MG**	**N022568**	**001**	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB			**10MG**	**A201724**	**002**	Feb 25, 2013
AB		AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB			**10MG**	**A090056**	**002**	May 31, 2011
AB		CADILA PHARMS LTD	**5MG**	**A204609**	**001**	Sep 19, 2017
AB			**10MG**	**A204609**	**002**	Sep 19, 2017
AB		CHARTWELL RX	**5MG**	**A090425**	**001**	May 31, 2011
AB			**10MG**	**A090425**	**002**	May 31, 2011
AB		CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011
AB			**10MG**	**A077518**	**002**	May 31, 2011
AB		DEXCEL	**23MG**	**A203713**	**001**	Feb 19, 2016
AB		DR REDDYS	**23MG**	**A202723**	**001**	Jul 24, 2013
AB		DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB			**10MG**	**A201001**	**002**	May 31, 2011
AB		HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB			**10MG**	**A203034**	**002**	Jan 30, 2015
AB		JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB			**10MG**	**A090768**	**002**	May 31, 2011
AB		LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB			**10MG**	**A201146**	**002**	Aug 17, 2012
AB			**23MG**	**A202631**	**001**	Jan 22, 2014
AB		NOVITIUM PHARMA	**5MG**	**A090551**	**001**	May 31, 2011
AB			**10MG**	**A090551**	**002**	May 31, 2011
AB		PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB			**10MG**	**A200292**	**002**	May 31, 2011
AB		RISING	**5MG**	**A202114**	**001**	Jul 05, 2013
AB			**10MG**	**A202114**	**002**	Jul 05, 2013
AB		SCIEGEN PHARMS	**5MG**	**A203907**	**001**	Oct 29, 2014
AB			**10MG**	**A203907**	**002**	Oct 29, 2014
AB		STRIDES PHARMA	**5MG**	**A078662**	**001**	May 31, 2011
AB			**10MG**	**A078662**	**002**	May 31, 2011
AB		TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011
AB			**10MG**	**A090686**	**002**	May 31, 2011
AB		TWI PHARMS	**23MG**	**A203104**	**001**	Oct 29, 2014
AB		ZYDUS LIFESCIENCES	**5MG**	**A090100**	**001**	Oct 24, 2012
AB			**10MG**	**A090100**	**002**	Oct 24, 2012
AB		ZYDUS PHARMS	**23MG**	**A203162**	**001**	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HISUN PHARM HANGZHOU	**5MG**	**A205269**	**001**	Jul 27, 2018
AB			**10MG**	**A205269**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001**	Dec 14, 2012
AB	**!**		**10MG**	**A201787**	**002**	Dec 14, 2012

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	**10MG;7MG**	**A208328**	**003**	Feb 27, 2025
AB			**10MG;14MG**	**A208328**	**001**	Jan 27, 2017
AB			**10MG;21MG**	**A208328**	**004**	Feb 27, 2025
AB			**10MG;28MG**	**A208328**	**002**	Jan 27, 2017
AB		ANI PHARMS	**10MG;21MG**	**A208237**	**001**	Dec 15, 2023
AB		MACLEODS PHARMS LTD	**10MG;14MG**	**A208672**	**001**	Jul 15, 2025
AB			**10MG;28MG**	**A208672**	**002**	Jul 15, 2025
AB		XIAMEN LP PHARM CO	**10MG;14MG**	**A216901**	**001**	Jul 15, 2025
AB			**10MG;28MG**	**A216901**	**002**	Jul 15, 2025

NAMZARIC

AB	**+**	ABBVIE	**10MG;7MG**	**N206439**	**003**	Jul 18, 2016
AB	**+**		**10MG;14MG**	**N206439**	**001**	Dec 23, 2014
AB	**+**		**10MG;21MG**	**N206439**	**004**	Jul 18, 2016
AB	**+!**		**10MG;28MG**	**N206439**	**002**	Dec 23, 2014

DONIDALORSEN SODIUM

SOLUTION;SUBCUTANEOUS

DAWNZERA (AUTOINJECTOR)

	+!	IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N219407	001	Aug 21, 2025

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	**40MG/ML**	**A207707**	**001**	Apr 11, 2018
AP			**80MG/ML**	**A207707**	**002**	Apr 11, 2018
AP	**+!**	HOSPIRA	**40MG/ML**	**N018132**	**001**	
AP	**+!**		**80MG/100ML**	**N018132**	**002**	Feb 04, 1982
AP	**+!**		**80MG/ML**	**N018132**	**004**	Jul 09, 1982
AP	**+!**		**160MG/100ML**	**N018132**	**003**	Feb 04, 1982

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001**	Mar 27, 1987
AP	**+!**		**160MG/100ML**	**N019615**	**002**	Mar 27, 1987
AP	**+!**		**320MG/100ML**	**N019615**	**003**	Mar 27, 1987
AP	**+!**	HOSPIRA	**80MG/100ML**	**N018826**	**001**	Sep 30, 1983
AP	**+!**		**160MG/100ML**	**N018826**	**002**	Sep 30, 1983
AP	**+!**		**320MG/100ML**	**N018826**	**003**	Sep 30, 1983
	+!	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET;ORAL

PIFELTRO

	+!	MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

DELSTRIGO

	+!	MSD MERCK CO	100MG;300MG;300MG	N210807	001	Aug 30, 2018

DORDAVIPRONE HYDROCHLORIDE

CAPSULE;ORAL

MODEYSO

	+!	CHIMERIX	EQ 125MG BASE	N219876	001	Aug 06, 2025

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		ALEMBIC	**EQ 2% BASE**	**A212639**	**001**	Aug 09, 2019
AT		BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT		FDC LTD	**EQ 2% BASE**	**A205294**	**001**	Jan 24, 2019
AT		GLAND	**EQ 2% BASE**	**A215660**	**001**	Jan 27, 2022
AT	**!**	MICRO LABS	**EQ 2% BASE**	**A204778**	**001**	Nov 08, 2019
AT		REGCON HOLDINGS	**EQ 2% BASE**	**A202053**	**001**	Sep 11, 2014
AT		RUBICON RESEARCH	**EQ 2% BASE**	**A078395**	**001**	Oct 28, 2008
AT		SANDOZ	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008
AT			**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009
AT		SOMERSET THERAPS LLC	**EQ 2% BASE**	**A215004**	**001**	Feb 11, 2025

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT1	**+!**	THEA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT1		ALEMBIC	**EQ 2% BASE;EQ 0.5% BASE**	**A213099**	**001**	May 04, 2021
AT1		BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT1		EPIC PHARMA LLC	**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT1		EUGIA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A207629**	**001**	May 14, 2021
AT1		FDC LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A205295**	**001**	Jun 13, 2019
AT1		GLAND	**EQ 2% BASE;EQ 0.5% BASE**	**A215520**	**001**	Sep 19, 2022
AT1		MICRO LABS	**EQ 2% BASE;EQ 0.5% BASE**	**A204777**	**001**	May 28, 2020
AT1		REGCON HOLDINGS	**EQ 2% BASE;EQ 0.5% BASE**	**A202054**	**001**	Sep 03, 2014
AT1		SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT1			**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT1		SOMERSET	**EQ 2% BASE;EQ 0.5% BASE**	**A207523**	**001**	Jun 25, 2019

COSOPT PF

AT2	**+!**	THEA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**N202667**	**001**	Feb 01, 2012

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		EUGIA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A207630**	**001**	Jul 24, 2018
AT2		INGENUS PHARMS LLC	**EQ 2% BASE;EQ 0.5% BASE**	**A217260**	**001**	May 01, 2023
AT2		MICRO LABS	**EQ 2% BASE;EQ 0.5% BASE**	**A215936**	**001**	Jan 25, 2022
AT2		NEW HEIGHTSRX	**EQ 2% BASE;EQ 0.5% BASE**	**A216308**	**001**	Feb 18, 2025

DOXAPRAM HYDROCHLORIDE						
INJECTABLE;INJECTION						
DOPRAM						
AP	**+!**	HIKMA	**20MG/ML**	**N014879**	**001**	
DOXAPRAM HYDROCHLORIDE						
AP		CHARTWELL INJECTABLE	**20MG/ML**	**A076266**	**001**	Jan 10, 2003
DOXAZOSIN MESYLATE						
TABLET;ORAL						
CARDURA						
AB	**+!**	VIATRIS	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB	**+**		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB	**+**		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB	**+**		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990
DOXAZOSIN MESYLATE						
AB		ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB			**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB			**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB			**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB		APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB		AUROBINDO PHARMA USA	**EQ 1MG BASE**	**A075509**	**001**	Oct 19, 2000
AB			**EQ 2MG BASE**	**A075509**	**002**	Oct 19, 2000
AB			**EQ 4MG BASE**	**A075509**	**003**	Oct 19, 2000
AB			**EQ 8MG BASE**	**A075509**	**004**	Oct 19, 2000
AB		HERITAGE PHARMA	**EQ 1MG BASE**	**A205210**	**001**	Feb 13, 2018
AB			**EQ 2MG BASE**	**A205210**	**002**	Feb 13, 2018
AB			**EQ 4MG BASE**	**A205210**	**003**	Feb 13, 2018
AB			**EQ 8MG BASE**	**A205210**	**004**	Feb 13, 2018
AB		RISING	**EQ 1MG BASE**	**A212727**	**001**	Mar 15, 2022
AB			**EQ 2MG BASE**	**A212727**	**002**	Mar 15, 2022
AB			**EQ 4MG BASE**	**A212727**	**003**	Mar 15, 2022
AB			**EQ 8MG BASE**	**A212727**	**004**	Mar 15, 2022
AB		SOMERSET THERAPS LLC	**EQ 1MG BASE**	**A209013**	**001**	Apr 17, 2018
AB			**EQ 2MG BASE**	**A209013**	**002**	Apr 17, 2018
AB			**EQ 4MG BASE**	**A209013**	**003**	Apr 17, 2018
AB			**EQ 8MG BASE**	**A209013**	**004**	Apr 17, 2018
AB		TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000
AB		UNICHEM	**EQ 1MG BASE**	**A212329**	**001**	Jan 10, 2024
AB			**EQ 2MG BASE**	**A212329**	**002**	Jan 10, 2024
AB			**EQ 4MG BASE**	**A212329**	**003**	Jan 10, 2024
AB			**EQ 8MG BASE**	**A212329**	**004**	Jan 10, 2024
AB		ZYDUS PHARMS	**EQ 1MG BASE**	**A208719**	**001**	Jul 07, 2017
AB			**EQ 2MG BASE**	**A208719**	**002**	Jul 07, 2017
AB			**EQ 4MG BASE**	**A208719**	**003**	Jul 07, 2017
AB			**EQ 8MG BASE**	**A208719**	**004**	Jul 07, 2017
TABLET, EXTENDED RELEASE;ORAL						
CARDURA XL						
	+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005
	+!		EQ 8MG BASE	N021269	002	Feb 22, 2005
DOXECITINE; DOXRIBTIMINE						
FOR SOLUTION;ORAL						
KYGEVVI						
	+!	UCB INC	2GM/PACKET;2GM/PACKET	N219792	001	Nov 03, 2025
DOXEPIN HYDROCHLORIDE						
CAPSULE;ORAL						
DOXEPIN HYDROCHLORIDE						
AB		AIPING PHARM INC	**EQ 10MG BASE**	**A213474**	**001**	Jul 28, 2020
AB			**EQ 25MG BASE**	**A213474**	**002**	Jul 28, 2020
AB			**EQ 50MG BASE**	**A213474**	**003**	Jul 28, 2020
AB			**EQ 75MG BASE**	**A213474**	**004**	Jul 28, 2020
AB			**EQ 100MG BASE**	**A213474**	**005**	Jul 28, 2020
AB		AJANTA PHARMA LTD	**EQ 10MG BASE**	**A212624**	**001**	Sep 13, 2019
AB			**EQ 25MG BASE**	**A212624**	**002**	Sep 13, 2019

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB			**EQ 50MG BASE**	**A212624**	**003**	Sep 13, 2019
AB			**EQ 75MG BASE**	**A212624**	**004**	Sep 13, 2019
AB			**EQ 100MG BASE**	**A212624**	**005**	Sep 13, 2019
AB		ALEMBIC	**EQ 10MG BASE**	**A215076**	**001**	Apr 21, 2021
AB			**EQ 25MG BASE**	**A215076**	**002**	Apr 21, 2021
AB			**EQ 50MG BASE**	**A215076**	**003**	Apr 21, 2021
AB			**EQ 75MG BASE**	**A215076**	**004**	Apr 21, 2021
AB			**EQ 100MG BASE**	**A215076**	**005**	Apr 21, 2021
AB		AMNEAL PHARMS CO	**EQ 10MG BASE**	**A207482**	**001**	Jun 28, 2017
AB			**EQ 25MG BASE**	**A207482**	**002**	Jun 28, 2017
AB			**EQ 50MG BASE**	**A207482**	**003**	Jun 28, 2017
AB			**EQ 75MG BASE**	**A207482**	**004**	Jun 28, 2017
AB			**EQ 100MG BASE**	**A207482**	**005**	Jun 28, 2017
AB		APPCO	**EQ 10MG BASE**	**A214908**	**001**	Apr 01, 2021
AB			**EQ 25MG BASE**	**A214908**	**002**	Apr 01, 2021
AB			**EQ 50MG BASE**	**A214908**	**003**	Apr 01, 2021
AB			**EQ 75MG BASE**	**A214908**	**004**	Apr 01, 2021
AB			**EQ 100MG BASE**	**A214908**	**005**	Apr 01, 2021
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A211603**	**001**	Mar 27, 2019
AB			**EQ 25MG BASE**	**A211603**	**002**	Mar 27, 2019
AB			**EQ 50MG BASE**	**A211603**	**003**	Mar 27, 2019
AB			**EQ 75MG BASE**	**A211603**	**004**	Mar 27, 2019
AB			**EQ 100MG BASE**	**A211603**	**005**	Mar 27, 2019
AB		CHARTWELL RX	**EQ 10MG BASE**	**A210268**	**001**	Sep 04, 2020
AB			**EQ 25MG BASE**	**A210268**	**002**	Sep 04, 2020
AB			**EQ 50MG BASE**	**A210268**	**003**	Sep 04, 2020
AB			**EQ 75MG BASE**	**A210268**	**004**	Sep 04, 2020
AB			**EQ 100MG BASE**	**A210268**	**005**	Sep 04, 2020
AB		EPIC PHARMA LLC	**EQ 10MG BASE**	**A210675**	**001**	Oct 16, 2020
AB			**EQ 25MG BASE**	**A210675**	**002**	Oct 16, 2020
AB			**EQ 50MG BASE**	**A210675**	**004**	Mar 03, 2022
AB			**EQ 75MG BASE**	**A210675**	**005**	Mar 03, 2022
AB			**EQ 100MG BASE**	**A210675**	**003**	Oct 16, 2020
AB		IXORA LIFESCIENCE	**EQ 10MG BASE**	**A211619**	**001**	Mar 09, 2021
AB			**EQ 25MG BASE**	**A211619**	**002**	Mar 09, 2021
AB			**EQ 50MG BASE**	**A211619**	**003**	Mar 09, 2021
AB			**EQ 75MG BASE**	**A211619**	**004**	Mar 09, 2021
AB			**EQ 100MG BASE**	**A211619**	**005**	Mar 09, 2021
AB		JUBILANT CADISTA	**EQ 10MG BASE**	**A215483**	**001**	Mar 14, 2022
AB			**EQ 25MG BASE**	**A215483**	**002**	Mar 14, 2022
AB			**EQ 50MG BASE**	**A215483**	**003**	Mar 14, 2022
AB			**EQ 75MG BASE**	**A215483**	**004**	Mar 14, 2022
AB			**EQ 100MG BASE**	**A215483**	**005**	Mar 14, 2022
AB		MANKIND PHARMA	**EQ 10MG BASE**	**A215710**	**001**	Feb 09, 2022
AB			**EQ 25MG BASE**	**A215710**	**002**	Feb 09, 2022
AB			**EQ 50MG BASE**	**A215710**	**003**	Feb 09, 2022
AB			**EQ 75MG BASE**	**A215710**	**004**	Feb 09, 2022
AB			**EQ 100MG BASE**	**A215710**	**005**	Feb 09, 2022
AB		MICRO LABS	**EQ 10MG BASE**	**A217688**	**001**	Jun 27, 2023
AB			**EQ 25MG BASE**	**A217688**	**002**	Jun 27, 2023
AB			**EQ 50MG BASE**	**A217688**	**003**	Jun 27, 2023
AB			**EQ 75MG BASE**	**A217688**	**004**	Jun 27, 2023
AB			**EQ 100MG BASE**	**A217688**	**005**	Jun 27, 2023
AB		MSN	**EQ 10MG BASE**	**A215113**	**001**	Jun 24, 2022
AB			**EQ 25MG BASE**	**A215113**	**002**	Jun 24, 2022
AB			**EQ 50MG BASE**	**A215113**	**003**	Jun 24, 2022
AB			**EQ 75MG BASE**	**A215113**	**004**	Jun 24, 2022
AB			**EQ 100MG BASE**	**A215113**	**005**	Jun 24, 2022
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A070791**	**002**	May 13, 1986
AB	**!**		**EQ 25MG BASE**	**A070791**	**003**	May 13, 1986
AB			**EQ 50MG BASE**	**A070791**	**001**	May 13, 1986
AB			**EQ 75MG BASE**	**A070791**	**004**	May 13, 1986
AB	**!**		**EQ 100MG BASE**	**A070791**	**005**	May 13, 1986
AB	**!**	PH HEALTH	**EQ 150MG BASE**	**A071422**	**006**	Nov 09, 1987
AB		PTS CONSULTING	**EQ 10MG BASE**	**A217975**	**001**	Aug 21, 2023
AB			**EQ 25MG BASE**	**A217975**	**002**	Aug 21, 2023
AB			**EQ 50MG BASE**	**A217975**	**003**	Aug 21, 2023
AB			**EQ 75MG BASE**	**A217975**	**004**	Aug 21, 2023
AB			**EQ 100MG BASE**	**A217975**	**005**	Aug 21, 2023

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		VELZEN PHARMA PVT	**EQ 150MG BASE**	**A211618**	**001**	Mar 01, 2021
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

	!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB		AMNEAL	**5%**	**A212357**	**001**	Aug 16, 2023
AB		TEVA PHARMS	**5%**	**A215408**	**001**	Feb 17, 2023

ZONALON

AB	**+!**	MYLAN	**5%**	**N020126**	**001**	Apr 01, 1994

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 3MG BASE**	**A201951**	**001**	Jul 26, 2013
AB			**EQ 6MG BASE**	**A201951**	**002**	Jul 26, 2013
AB		AJANTA PHARMA LTD	**EQ 3MG BASE**	**A218564**	**001**	Jul 01, 2024
AB			**EQ 6MG BASE**	**A218564**	**002**	Jul 01, 2024
AB		AUROBINDO PHARMA LTD	**EQ 3MG BASE**	**A216041**	**001**	Jul 25, 2024
AB			**EQ 6MG BASE**	**A216041**	**002**	Jul 25, 2024
AB		RK PHARMA	**EQ 3MG BASE**	**A202337**	**001**	Jan 20, 2016
AB			**EQ 6MG BASE**	**A202337**	**002**	Jan 20, 2016
AB		STRIDES PHARMA INTL	**EQ 3MG BASE**	**A202510**	**001**	Jul 24, 2020
AB			**EQ 6MG BASE**	**A202510**	**002**	Jul 24, 2020
AB		TARO	**EQ 3MG BASE**	**A219058**	**001**	Aug 06, 2025
AB			**EQ 6MG BASE**	**A219058**	**002**	Aug 06, 2025
AB		ZYDUS LIFESCIENCES	**EQ 3MG BASE**	**A202761**	**001**	Aug 16, 2023
AB			**EQ 6MG BASE**	**A202761**	**002**	Aug 16, 2023

SILENOR

AB	**+**	CURRAX	**EQ 3MG BASE**	**N022036**	**001**	Mar 17, 2010
AB	**+!**		**EQ 6MG BASE**	**N022036**	**002**	Mar 17, 2010

DOXEPIN HYDROCHLORIDE

BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		AVET	**0.5MCG**	**A205360**	**001**	Sep 15, 2020
AB			**1MCG**	**A205360**	**002**	Sep 15, 2020
AB	**!**		**2.5MCG**	**A205360**	**003**	Sep 15, 2020
AB		RISING	**0.5MCG**	**A201518**	**001**	Sep 09, 2016
AB			**1MCG**	**A201518**	**002**	Sep 09, 2016
AB			**2.5MCG**	**A201518**	**003**	Sep 09, 2016

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		ALEMBIC	**4MCG/2ML (2MCG/ML)**	**A215810**	**001**	Jun 15, 2023
AP		EUGIA PHARMA	**4MCG/2ML (2MCG/ML)**	**A213717**	**002**	Jan 24, 2022
AP		GLAND	**4MCG/2ML (2MCG/ML)**	**A210452**	**001**	Sep 26, 2019
AP		HIKMA	**4MCG/2ML (2MCG/ML)**	**A091101**	**001**	Aug 30, 2013
AP	**!**	MEITHEAL	**4MCG/2ML (2MCG/ML)**	**A211670**	**001**	Feb 07, 2020
AP		SANDOZ	**4MCG/2ML (2MCG/ML)**	**A091333**	**001**	May 05, 2014
AP			**4MCG/2ML (2MCG/ML)**	**A200926**	**001**	Feb 04, 2014

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	**2MG/ML**	**A203622**	**001**	Jun 27, 2014
AP			**200MG/100ML**	**A203622**	**002**	Jun 27, 2014
AP		AMNEAL	**20MG/VIAL**	**A208888**	**001**	Feb 17, 2017
AP			**50MG/VIAL**	**A208888**	**002**	Feb 17, 2017
AP		FRESENIUS KABI USA	**2MG/ML**	**A063277**	**001**	Oct 26, 1995
AP		GLAND	**2MG/ML**	**A209825**	**001**	Aug 11, 2017
AP		HIKMA	**2MG/ML**	**A062975**	**001**	Mar 17, 1989
AP	**!**		**20MG/VIAL**	**A062921**	**002**	Mar 17, 1989
AP	**!**		**50MG/VIAL**	**A062921**	**003**	Mar 17, 1989

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP			**200MG/100ML**	**A064097**	**001**	Sep 13, 1994
AP		MYLAN LABS LTD	**50MG/VIAL**	**A200170**	**002**	Oct 28, 2011
AP	**+!**	PFIZER	**2MG/ML**	**N050629**	**001**	Dec 23, 1987
AP	**+!**		**200MG/100ML**	**N050629**	**002**	May 03, 1988
AP		SAGENT PHARMS	**2MG/ML**	**A091495**	**001**	Mar 18, 2013
AP		SUN PHARM INDS	**2MG/ML**	**A091418**	**001**	Feb 15, 2012
	!	HIKMA	10MG/VIAL	A062921	001	Mar 17, 1989

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB	**+**	BAXTER HLTHCARE CORP	**20MG/10ML (2MG/ML)**	**N050718**	**001**	Nov 17, 1995
AB	**+**		**50MG/25ML (2MG/ML)**	**N050718**	**002**	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		ALEMBIC	**20MG/10ML (2MG/ML)**	**A219199**	**001**	Jun 27, 2025
AB			**50MG/25ML (2MG/ML)**	**A219199**	**002**	Jun 27, 2025
AB		AYANA PHARMA LTD	**20MG/10ML (2MG/ML)**	**A207228**	**001**	Oct 12, 2021
AB			**50MG/25ML (2MG/ML)**	**A207228**	**002**	Oct 12, 2021
AB		BAXTER HLTHCARE CORP	**20MG/10ML (2MG/ML)**	**A212219**	**001**	Oct 19, 2022
AB			**50MG/25ML (2MG/ML)**	**A212219**	**002**	Oct 19, 2022
AB		DR REDDYS	**20MG/10ML (2MG/ML)**	**A208657**	**001**	May 15, 2017
AB			**50MG/25ML (2MG/ML)**	**A208657**	**002**	May 15, 2017
AB		LUPIN	**20MG/10ML (2MG/ML)**	**A215178**	**001**	Jul 16, 2024
AB			**50MG/25ML (2MG/ML)**	**A215178**	**002**	Jul 16, 2024
AB	**!**	SUN PHARM	**20MG/10ML (2MG/ML)**	**A203263**	**001**	Feb 04, 2013
AB	**!**		**50MG/25ML (2MG/ML)**	**A203263**	**002**	Feb 04, 2013
AB		ZYDUS LIFESCIENCES	**20MG/10ML (2MG/ML)**	**A212299**	**001**	Sep 10, 2020
AB			**50MG/25ML (2MG/ML)**	**A212299**	**002**	Sep 10, 2020

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		ALEMBIC	**40MG**	**A217674**	**001**	Jun 27, 2024
AB			**EQ 75MG BASE**	**A209165**	**001**	Jul 28, 2017
AB			**EQ 100MG BASE**	**A209165**	**002**	Jul 28, 2017
AB		APOTEX	**40MG**	**A217170**	**001**	Jul 11, 2024
AB		CHANGZHOU PHARM	**40MG**	**A219978**	**001**	Oct 01, 2025
AB		DR REDDYS	**40MG**	**A218034**	**001**	Apr 08, 2024
AB		DR REDDYS LABS SA	**EQ 50MG BASE**	**A209396**	**001**	Sep 29, 2017
AB			**EQ 75MG BASE**	**A209396**	**002**	Sep 29, 2017
AB			**EQ 100MG BASE**	**A209396**	**003**	Sep 29, 2017
AB		LUPIN	**40MG**	**A216631**	**001**	Apr 08, 2024
AB		LUPIN LTD	**EQ 50MG BASE**	**A204234**	**001**	Mar 05, 2014
AB			**EQ 75MG BASE**	**A204234**	**002**	Mar 05, 2014
AB			**EQ 100MG BASE**	**A204234**	**003**	Mar 05, 2014
AB		MACLEODS PHARMS LTD	**40MG**	**A210381**	**001**	Mar 27, 2025
AB		PRINSTON INC	**40MG**	**A217098**	**001**	Jan 27, 2025
AB		STRIDES PHARMA INTL	**EQ 50MG BASE**	**A065055**	**001**	Dec 01, 2000
AB			**EQ 100MG BASE**	**A065055**	**002**	Dec 01, 2000
AB	**!**		**EQ 150MG BASE**	**A065055**	**003**	Jul 15, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065053**	**001**	Nov 22, 2000
AB			**EQ 75MG BASE**	**A065053**	**003**	Sep 10, 2003
AB	**!**		**EQ 100MG BASE**	**A065053**	**002**	Nov 22, 2000
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A205115**	**001**	Feb 18, 2016
AB			**EQ 75MG BASE**	**A205115**	**002**	Feb 18, 2016
AB			**EQ 100MG BASE**	**A205115**	**003**	Feb 18, 2016

MONODOX

AB	**+**	CHARTWELL RX	**EQ 50MG BASE**	**N050641**	**002**	Feb 10, 1992
AB	**+**		**EQ 75MG BASE**	**N050641**	**003**	Oct 18, 2006
AB	**+**		**EQ 100MG BASE**	**N050641**	**001**	Dec 29, 1989
AB	**+**		**EQ 150MG BASE**	**N050641**	**004**	Feb 17, 2022

ORACEA

AB	**+!**	GALDERMA LABS LP	**40MG**	**N050805**	**001**	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL	**EQ 25MG BASE/5ML**	**A065454**	**001**	Jul 16, 2008
AB	**!**	LUPIN LTD	**EQ 25MG BASE/5ML**	**A201678**	**001**	Mar 18, 2013

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE	**EQ 50MG BASE**	**A091605**	**001**	Dec 20, 2011

DOXYCYCLINE

TABLET;ORAL

DOXYCYCLINE

AB		**EQ 75MG BASE**	**A091605**	**002**	Dec 20, 2011
AB		**EQ 100MG BASE**	**A091605**	**003**	Dec 20, 2011
AB	!	**EQ 150MG BASE**	**A091605**	**004**	Dec 20, 2011
AB	LANNETT CO INC	**EQ 50MG BASE**	**A065285**	**001**	Dec 08, 2005
AB		**EQ 75MG BASE**	**A065285**	**003**	Jul 30, 2008
AB		**EQ 100MG BASE**	**A065285**	**002**	Dec 08, 2005
AB		**EQ 150MG BASE**	**A065285**	**004**	Jul 30, 2008
AB	STRIDES PHARMA INTL	**EQ 50MG BASE**	**A065070**	**001**	Dec 15, 2000
AB		**EQ 75MG BASE**	**A065070**	**003**	Dec 30, 2002
AB		**EQ 100MG BASE**	**A065070**	**002**	Dec 15, 2000
AB		**EQ 150MG BASE**	**A065070**	**004**	Jul 14, 2005
AB	SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065356**	**001**	May 31, 2006
AB		**EQ 75MG BASE**	**A065356**	**002**	May 31, 2006
AB		**EQ 100MG BASE**	**A065356**	**003**	May 31, 2006
AB		**EQ 150MG BASE**	**A065356**	**004**	Jul 29, 2010
AB	ZYDUS PHARMS	**EQ 50MG BASE**	**A209582**	**001**	Sep 28, 2017
AB		**EQ 75MG BASE**	**A209582**	**002**	Sep 28, 2017
AB		**EQ 100MG BASE**	**A209582**	**003**	Sep 28, 2017
AB		**EQ 150MG BASE**	**A209582**	**004**	Sep 28, 2017

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB		**EQ 100MG BASE**	**A062031**	**001**	
AB	ALEMBIC	**EQ 50MG BASE**	**A210527**	**001**	Jun 13, 2018
AB		**EQ 100MG BASE**	**A210527**	**002**	Jun 13, 2018
AB	AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB	CHANGZHOU PHARM	**EQ 100MG BASE**	**A209402**	**001**	Oct 07, 2019
AB	CHARTWELL	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB		**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB	HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB	!	**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB	MACLEODS PHARMS LTD	**EQ 100MG BASE**	**A211137**	**001**	Dec 09, 2025
AB	STRIDES PHARMA	**EQ 50MG BASE**	**A062337**	**001**	Mar 29, 1982
AB		**EQ 100MG BASE**	**A062337**	**002**	Mar 29, 1982
AB	SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A062676**	**002**	Jul 10, 1986
AB		**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986
AB	ZYDUS LIFESCIENCES	**EQ 50MG BASE**	**A207774**	**001**	May 31, 2018
AB		**EQ 100MG BASE**	**A207774**	**002**	May 31, 2018

INJECTABLE;INJECTION

DOXY 100

AP	! FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983

DOXY 200

AP	! FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A062475**	**002**	Dec 09, 1983

DOXYCYCLINE

AP	MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP	! ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A207757**	**001**	Sep 28, 2017
AP		**EQ 200MG BASE/VIAL**	**A207757**	**002**	Sep 28, 2017

DOXYCYCLINE HYCLATE

AP	ASPIRO	**EQ 100MG BASE/VIAL**	**A218888**	**001**	Aug 05, 2025
AP	DR REDDYS	**EQ 100MG BASE/VIAL**	**A218753**	**001**	Jul 01, 2025
AP	GLAND	**EQ 100MG BASE/VIAL**	**A215583**	**001**	Apr 12, 2023
AP	HERITAGE	**EQ 100MG BASE/VIAL**	**A217854**	**001**	Jul 23, 2024
AP	KINDOS	**EQ 100MG BASE/VIAL**	**A218053**	**001**	Oct 28, 2024
AP	LUPIN LTD	**EQ 100MG BASE/VIAL**	**A217794**	**001**	Mar 14, 2024
AP	PH HEALTH	**EQ 100MG BASE/VIAL**	**A216690**	**001**	Dec 07, 2022
AP	PRECISION DOSE INC	**EQ 100MG BASE/VIAL**	**A217078**	**001**	Feb 21, 2025
AP	SLATE RUN PHARMA	**EQ 100MG BASE/VIAL**	**A217685**	**001**	Jun 21, 2024
AP		**EQ 200MG BASE/VIAL**	**A217685**	**002**	Jun 21, 2024
AP	STERISCIENCE	**EQ 100MG BASE/VIAL**	**A217972**	**001**	Nov 06, 2025
AP	WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062992**	**001**	Feb 16, 1989
AP		**EQ 200MG BASE/VIAL**	**A062992**	**002**	Feb 16, 1989

TABLET;ORAL

ACTICLATE

AB	+ CHARTWELL RX	**EQ 75MG BASE**	**N205931**	**001**	Jul 25, 2014
AB	+!	**EQ 150MG BASE**	**N205931**	**002**	Jul 25, 2014

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB		ACELLA	**EQ 100MG BASE**	**A210664**	**001**	Mar 16, 2020
AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		AJANTA PHARMA LTD	**EQ 75MG BASE**	**A211584**	**001**	Jun 01, 2020
AB			**EQ 150MG BASE**	**A211584**	**002**	Jun 01, 2020
AB		ALEMBIC	**EQ 20MG BASE**	**A210537**	**001**	Mar 03, 2020
AB			**EQ 50MG BASE**	**A210536**	**002**	Sep 14, 2021
AB			**EQ 75MG BASE**	**A211744**	**001**	Jun 30, 2020
AB			**EQ 150MG BASE**	**A211744**	**002**	Jun 30, 2020
AB		APOTEX	**EQ 75MG BASE**	**A209243**	**001**	Apr 15, 2019
AB			**EQ 150MG BASE**	**A209243**	**002**	Apr 15, 2019
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A211343**	**001**	Oct 09, 2019
AB		CHARTWELL	**EQ 50MG BASE**	**A062505**	**002**	Jul 27, 2021
AB			**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB	**!**	CHARTWELL MOLECULAR	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		DR REDDYS LABS SA	**EQ 75MG BASE**	**A208765**	**001**	Jun 14, 2017
AB			**EQ 150MG BASE**	**A208765**	**002**	Jun 14, 2017
AB		EPIC PHARMA LLC	**EQ 20MG BASE**	**A065182**	**001**	May 13, 2005
AB			**EQ 50MG BASE**	**A062269**	**003**	Oct 05, 1983
AB			**EQ 75MG BASE**	**A214207**	**001**	Dec 16, 2020
AB	**!**		**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB			**EQ 150MG BASE**	**A214207**	**002**	Dec 16, 2020
AB		HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB		LUPIN LTD	**EQ 75MG BASE**	**A208818**	**001**	Sep 27, 2017
AB			**EQ 150MG BASE**	**A208818**	**002**	Sep 27, 2017
AB		MACLEODS PHARMS LTD	**EQ 100MG BASE**	**A211418**	**001**	Nov 19, 2025
AB		NOVEL LABS INC	**EQ 100MG BASE**	**A207558**	**001**	Sep 06, 2017
AB		PHARMOBEDIENT	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		STRIDES PHARMA INTL	**EQ 50MG BASE**	**A062538**	**002**	Nov 24, 2025
AB			**EQ 100MG BASE**	**A062538**	**001**	Apr 07, 1986
AB		SUN PHARM INDUSTRIES	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986
AB		ZYDUS LIFESCIENCES	**EQ 100MG BASE**	**A207773**	**001**	Oct 30, 2017

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	**+**	MAYNE PHARMA	**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	**EQ 50MG BASE**	**A090134**	**003**	May 22, 2018
AB			**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011
AB			**EQ 200MG BASE**	**A090134**	**004**	May 22, 2018
AB		ALEMBIC	**EQ 75MG BASE**	**A213075**	**001**	Jan 03, 2022
AB			**EQ 100MG BASE**	**A213075**	**002**	Jan 03, 2022
AB			**EQ 150MG BASE**	**A213075**	**003**	Jan 03, 2022
AB			**EQ 200MG BASE**	**A213075**	**004**	Jan 03, 2022
AB		HERITAGE	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB	**!**		**EQ 200MG BASE**	**A200856**	**004**	Nov 13, 2018
AB		PRINSTON INC	**EQ 50MG BASE**	**A207494**	**003**	Feb 19, 2019
AB			**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB			**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016

DORYX

	+	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013

DORYX MPC

	+	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	**+!**	DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016
AB		BIONPHARMA	**10MG;10MG**	**A217000**	**001**	Aug 04, 2023
AB		PH HEALTH	**10MG;10MG**	**A208518**	**001**	Dec 06, 2017
AB		PHARMOBEDIENT	**10MG;10MG**	**A207825**	**001**	Jul 06, 2020

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		ASCENT PHARMS INC	**2.5MG**	**A207421**	**001**	Feb 07, 2020
AB			**5MG**	**A207421**	**002**	Feb 07, 2020
AB			**10MG**	**A207421**	**003**	Feb 07, 2020

MARINOL

AB	+	ALKEM LABS LTD	**2.5MG**	**N018651**	**001**	May 31, 1985
AB	+!		**5MG**	**N018651**	**002**	May 31, 1985
AB	+		**10MG**	**N018651**	**003**	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

AB		LUPIN	**EQ 400MG BASE**	**A205904**	**001**	Jan 31, 2024

MULTAQ

AB	+!	SANOFI AVENTIS US	**EQ 400MG BASE**	**N022425**	**001**	Jul 01, 2009

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

AP	!	AM REGENT	**2.5MG/ML**	**A072123**	**001**	Oct 24, 1988
AP		HIKMA	**2.5MG/ML**	**A208197**	**001**	Dec 14, 2017

DROSPIRENONE

TABLET;ORAL

SLYND

	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019

DROSPIRENONE; ESTETROL

TABLET;ORAL

NEXTSTELLIS

	+!	MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

AB	+!	BAYER HLTHCARE	**0.5MG;1MG**	**N021355**	**002**	Sep 28, 2005

DROSPIRENONE AND ESTRADIOL

AB		NOVAST LABS	**0.5MG;1MG**	**A218031**	**001**	Oct 28, 2025

ANGELIQ

	+	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB		HETERO LABS	**3MG;0.02MG**	**A211944**	**001**	Mar 22, 2019
AB		PHARMOBEDIENT	**3MG;0.02MG**	**A203291**	**001**	Jul 18, 2017
AB		WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011
AB		XIROMED	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015

LO-ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.02MG**	**A209632**	**001**	Feb 27, 2018

LORYNA

AB		XIROMED	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011

MELAMISA

AB		NOVAST LABS	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016

NIKKI

AB		LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014

YAZ

AB	+!	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		DR REDDYS LABS SA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
AB		GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016
AB		HETERO LABS	**3MG;0.03MG**	**A213034**	**001**	Jan 24, 2020
AB		LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB		NAARI PTE	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016
AB		XIROMED	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015

SYEDA

AB		XIROMED	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011

YAELA

AB		NOVAST LABS	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL-28

YASMIN

AB	**+!**	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.03MG**	**A209407**	**001**	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB		LUPIN LTD	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A205947**	**001**	Jun 13, 2018
AB		WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016
AB			**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016

SAFYRAL

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

TYDEMY

AB		LUPIN LTD	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A205948**	**001**	Dec 12, 2017

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		ADAPTIS	**100MG**	**A215265**	**001**	Nov 01, 2021
AB			**200MG**	**A215265**	**002**	Nov 01, 2021
AB			**300MG**	**A215265**	**003**	Nov 01, 2021
AB		ALKEM LABS LTD	**100MG**	**A213911**	**001**	Feb 18, 2021
AB			**200MG**	**A213911**	**002**	Feb 18, 2021
AB			**300MG**	**A213911**	**003**	Feb 18, 2021
AB		ANNORA	**100MG**	**A211726**	**002**	Aug 09, 2021
AB			**200MG**	**A211726**	**003**	Aug 09, 2021
AB			**300MG**	**A211726**	**001**	Feb 18, 2021
AB		AUROBINDO PHARMA LTD	**100MG**	**A214387**	**001**	Feb 18, 2021
AB			**200MG**	**A214387**	**002**	Feb 18, 2021
AB			**300MG**	**A214387**	**003**	Feb 18, 2021
AB		BIONPHARMA	**100MG**	**A213033**	**001**	Apr 28, 2021
AB			**200MG**	**A213033**	**002**	Apr 28, 2021
AB			**300MG**	**A213033**	**003**	Apr 28, 2021
AB		JUBILANT CADISTA	**100MG**	**A214391**	**001**	Feb 18, 2021
AB			**200MG**	**A214391**	**002**	Feb 18, 2021
AB			**300MG**	**A214391**	**003**	Feb 18, 2021
AB		MSN PHARMS INC	**100MG**	**A211741**	**001**	Feb 18, 2021
AB			**200MG**	**A211741**	**002**	Feb 18, 2021
AB			**300MG**	**A211741**	**003**	Feb 18, 2021
AB		SCIEGEN PHARMS	**100MG**	**A214017**	**001**	Feb 18, 2021
AB			**200MG**	**A214017**	**002**	Feb 18, 2021
AB			**300MG**	**A214017**	**003**	Feb 18, 2021
AB		SOMERSET THERAPS LLC	**100MG**	**A214543**	**001**	May 05, 2021
AB			**200MG**	**A214543**	**002**	May 05, 2021
AB			**300MG**	**A214543**	**003**	May 05, 2021
AB		SUN PHARM	**100MG**	**A214384**	**001**	Feb 18, 2021
AB			**200MG**	**A214384**	**002**	Feb 18, 2021
AB			**300MG**	**A214384**	**003**	Feb 18, 2021
AB		ZYDUS PHARMS	**100MG**	**A211818**	**001**	Feb 18, 2021
AB			**200MG**	**A211818**	**002**	Feb 18, 2021
AB			**300MG**	**A211818**	**003**	Feb 18, 2021

NORTHERA

AB	**+**	LUNDBECK NA LTD	**100MG**	**N203202**	**001**	Feb 18, 2014
AB	**+**		**200MG**	**N203202**	**002**	Feb 18, 2014
AB	**+!**		**300MG**	**N203202**	**003**	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB			**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB			**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB			**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB			**EQ 40MG BASE**	**A208706**	**004**	Mar 11, 2019
AB	**!**		**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB		ALEMBIC	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB			**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB			**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB			**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB			**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB		BRECKENRIDGE	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB			**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB			**EQ 40MG BASE**	**A203088**	**004**	May 18, 2018
AB			**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB		CSPC OUYI	**EQ 20MG BASE**	**A211310**	**001**	Oct 16, 2018
AB			**EQ 30MG BASE**	**A211310**	**002**	Oct 16, 2018
AB			**EQ 60MG BASE**	**A211310**	**003**	Oct 16, 2018
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB			**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB			**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB		INVENTIA	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB			**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015
AB			**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB		LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB			**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB			**EQ 40MG BASE**	**A090694**	**003**	Dec 11, 2013
AB			**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204815**	**001**	Mar 23, 2017
AB			**EQ 30MG BASE**	**A204815**	**002**	Mar 23, 2017
AB			**EQ 60MG BASE**	**A204815**	**003**	Mar 23, 2017
AB		PRINSTON INC	**EQ 20MG BASE**	**A206653**	**001**	May 18, 2017
AB			**EQ 30MG BASE**	**A206653**	**002**	May 18, 2017
AB			**EQ 60MG BASE**	**A206653**	**003**	May 18, 2017
AB		QINGDAO BAHEAL PHARM	**EQ 20MG BASE**	**A210599**	**001**	Apr 17, 2019
AB			**EQ 30MG BASE**	**A210599**	**002**	Apr 17, 2019
AB			**EQ 60MG BASE**	**A210599**	**003**	Apr 17, 2019
AB		SUNSHINE	**EQ 20MG BASE**	**A212328**	**001**	Feb 11, 2021
AB			**EQ 30MG BASE**	**A212328**	**002**	Feb 11, 2021
AB			**EQ 60MG BASE**	**A212328**	**003**	Feb 11, 2021
AB		ZYDUS HLTHCARE	**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB			**EQ 40MG BASE**	**A090739**	**004**	Apr 18, 2023
AB			**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB			**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB			**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014

DRIZALMA SPRINKLE

	+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019
	+!		EQ 60MG BASE	N212516	004	Jul 19, 2019

DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

POWDER;INTRAVENOUS

XACDURO (COPACKAGED)

	+!	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N216974	001	May 23, 2023

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	**+!**	WAYLIS THERAP	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB		ACELLA	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB		ADAPTIS	**0.5MG**	**A204376**	**001**	Apr 07, 2017
AB		AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB		ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB		BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010

DUTASTERIDE
CAPSULE;ORAL
DUTASTERIDE

AB		CHARTWELL	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB		HUMANWELL PURACAP	**0.5MG**	**A209909**	**001**	Nov 21, 2017
AB		ONESOURCE SPECIALTY	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB		ZYDUS LIFESCIENCES	**0.5MG**	**A204373**	**001**	Oct 04, 2017

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE
CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA	**0.5MG;0.4MG**	**A213300**	**001**	Jul 18, 2024
AB		PH HEALTH	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014
AB	!	ZYDUS PHARMS	**0.5MG;0.4MG**	**A207769**	**001**	May 24, 2018

JALYN

AB	+	WAYLIS THERAP	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010

DUVELISIB
CAPSULE;ORAL
COPIKTRA

	+	SECURA	15MG	N211155	001 Sep 24, 2018
	+		25MG	N211155	002 Sep 24, 2018

DYCLONINE HYDROCHLORIDE
SOLUTION;TOPICAL
DYCLOPRO

	!	SEPTODONT	0.5%	A200480	001 Nov 20, 2018
	!		1%	A200480	002 Nov 20, 2018

ECHOTHIOPHATE IODIDE
FOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

	+!	FERA PHARMS LLC	0.125%	N011963	001

ECONAZOLE NITRATE
AEROSOL, FOAM;TOPICAL
ECOZA

	+!	RESILIA PHARMS	1%	N205175	001 Oct 24, 2013

CREAM;TOPICAL
ECONAZOLE NITRATE

AB	!	PADAGIS ISRAEL	**1%**	**A076479**	**001**	Jun 23, 2004
AB		SUN PHARMA CANADA	**1%**	**A076005**	**001**	Nov 26, 2002

EDARAVONE
SOLUTION;INTRAVENOUS
EDARAVONE

AP		DR REDDYS	**60MG/100ML (0.6MG/ML)**	**A215917**	**001**	May 06, 2024
AP	!	GLAND	**30MG/100ML (0.3MG/ML)**	**A216199**	**001**	May 06, 2024
AP			**60MG/100ML (0.6MG/ML)**	**A216199**	**002**	May 06, 2024
AP		HIKMA	**30MG/100ML (0.3MG/ML)**	**A215508**	**001**	May 06, 2024
AP		PHARMOBEDIENT	**30MG/100ML (0.3MG/ML)**	**A217565**	**001**	Oct 31, 2024
AP	!		**60MG/100ML (0.6MG/ML)**	**A217565**	**002**	Oct 31, 2024
AP		SANDOZ	**30MG/100ML (0.3MG/ML)**	**A216902**	**001**	Dec 23, 2024

RADICAVA

AP	+	TANABE PHARMA	**60MG/100ML (0.6MG/ML)**	**N209176**	**002**	Nov 15, 2018

SUSPENSION;ORAL
RADICAVA ORS

	+!	KK BCJ-94	105MG/5ML	N215446	001 May 12, 2022

EDETATE CALCIUM DISODIUM
INJECTABLE;INJECTION
EDETATE CALCIUM DISODIUM

	!	CASPER PHARMA LLC	200MG/ML	A216435	001 May 03, 2023

EDOXABAN TOSYLATE
TABLET;ORAL
SAVAYSA

	+	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001 Jan 08, 2015
	+		EQ 30MG BASE	N206316	002 Jan 08, 2015
	+!		EQ 60MG BASE	N206316	003 Jan 08, 2015

EFAVIRENZ

CAPSULE;ORAL

EFAVIRENZ

		AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017
			100MG	A078064	002	Dec 15, 2017
	!		200MG	A078064	003	Dec 15, 2017

TABLET;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**600MG**	**A077673**	**001**	Sep 21, 2018
AB		CIPLA	**600MG**	**A204766**	**001**	Jun 15, 2018
AB	**!**	HETERO LABS LTD III	**600MG**	**A078886**	**001**	Apr 27, 2018
AB		MACLEODS PHARMS LTD	**600MG**	**A091579**	**001**	May 10, 2024
AB		PHARMOBEDIENT	**600MG**	**A204869**	**001**	Mar 12, 2018

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB	**!**	AUROBINDO PHARMA	**600MG;200MG;300MG**	**A203041**	**001**	Sep 04, 2018
AB		CIPLA	**600MG;200MG;300MG**	**A206894**	**001**	Jun 03, 2019
AB		HETERO LABS LTD V	**600MG;200MG;300MG**	**A203053**	**001**	Jan 24, 2022
AB		LAURUS	**600MG;200MG;300MG**	**A213541**	**001**	Dec 22, 2021
AB		MACLEODS PHARMS LTD	**600MG;200MG;300MG**	**A204287**	**001**	Sep 13, 2021
AB		TEVA PHARMS USA	**600MG;200MG;300MG**	**A091215**	**001**	Nov 09, 2018

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS	**600MG;300MG;300MG**	**A212786**	**001**	May 14, 2020

SYMFI

AB	**+!**	MYLAN LABS LTD	**600MG;300MG;300MG**	**N022142**	**001**	Mar 22, 2018

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

	!	LAURUS	400MG;300MG;300MG	A213038	001	May 14, 2020

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB		TEVA PHARMS USA	**10%**	**A211827**	**001**	Dec 16, 2020
AB		UMEDICA	**10%**	**A211969**	**001**	Jun 21, 2021

JUBLIA

AB	**+!**	BAUSCH	**10%**	**N203567**	**001**	Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

TABLET;ORAL

IWILFIN

	+!	USWM	EQ 192MG BASE	N215500	001	Dec 13, 2023

ELACESTRANT HYDROCHLORIDE

TABLET;ORAL

ORSERDU

	+	STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023
	+!		EQ 345MG BASE	N217639	002	Jan 27, 2023

ELAFIBRANOR

TABLET;ORAL

IQIRVO

	+!	IPSEN	80MG	N218860	001	Jun 10, 2024

ELAGOLIX SODIUM

TABLET;ORAL

ORILISSA

	+	ABBVIE	EQ 150MG BASE	N210450	001	Jul 23, 2018
	+!		EQ 200MG BASE	N210450	002	Jul 23, 2018

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE;ORAL

ORIAHNN (COPACKAGED)

	+!	ABBVIE	EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020

ELAMIPRETIDE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

FORZINITY

	+!	STEALTH BIOTHERAPS	EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)	N215244	001	Sep 19, 2025

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		ANNORA PHARMA	**EQ 20MG BASE**	**A219143**	**001**	Jul 07, 2025
AB			**EQ 40MG BASE**	**A219143**	**002**	Jul 07, 2025
AB		AUROBINDO PHARMA	**EQ 20MG BASE**	**A210708**	**001**	Jan 15, 2019
AB			**EQ 40MG BASE**	**A210708**	**002**	Jan 15, 2019
AB		CHARTWELL RX	**EQ 20MG BASE**	**A205186**	**001**	Aug 29, 2017
AB			**EQ 40MG BASE**	**A205186**	**002**	Aug 29, 2017
AB		MYLAN	**EQ 20MG BASE**	**A205152**	**001**	Aug 11, 2017
AB			**EQ 40MG BASE**	**A205152**	**002**	Aug 11, 2017
AB		REGCON HOLDINGS	**EQ 20MG BASE**	**A215467**	**001**	Jul 13, 2022
AB			**EQ 40MG BASE**	**A215467**	**002**	Jul 13, 2022
AB		TEVA PHARMS USA	**EQ 20MG BASE**	**A202040**	**001**	Jun 27, 2017
AB			**EQ 40MG BASE**	**A202040**	**002**	Jun 27, 2017
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206409**	**001**	Jun 16, 2017
AB			**EQ 40MG BASE**	**A206409**	**002**	Jun 16, 2017

RELPAX

AB	**+**	UPJOHN	**EQ 20MG BASE**	**N021016**	**001**	Dec 26, 2002
AB	**+!**		**EQ 40MG BASE**	**N021016**	**002**	Dec 26, 2002

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES;ORAL

TRIKAFTA (COPACKAGED)

+	VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023
+!		100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023

TABLET;ORAL

TRIKAFTA (COPACKAGED)

+	VERTEX PHARMS INC	50MG,37.5MG,25MG; 75MG	N212273	002	Jun 08, 2021
+!		100MG,75MG,50MG; 150MG	N212273	001	Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

CERDELGA

AB	**+!**	GENZYME CORP	**EQ 84MG BASE**	**N205494**	**001**	Aug 19, 2014

ELIGLUSTAT TARTRATE

AB		AIZANT	**EQ 84MG BASE**	**A212463**	**001**	Sep 08, 2021
AB		CIPLA	**EQ 84MG BASE**	**A212369**	**001**	Dec 10, 2024
AB		UPSHER SMITH LABS	**EQ 84MG BASE**	**A212420**	**001**	May 02, 2023

ELINZANETANT

CAPSULE;ORAL

LYNKUET

+!	BAYER HLTHCARE	60MG	N219469	001	Oct 24, 2025

ELTROMBOPAG CHOLINE

TABLET;ORAL

ALVAIZ

+	TEVA PHARMS INC	EQ 9MG BASE	N216774	001	Nov 29, 2023
+		EQ 18MG BASE	N216774	002	Nov 29, 2023
+		EQ 36MG BASE	N216774	003	Nov 29, 2023
+!		EQ 54MG BASE	N216774	004	Nov 29, 2023

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

ELTROMBOPAG OLAMINE

AB		ANNORA PHARMA	**EQ 12.5MG ACID/PACKET**	**A216620**	**001**	Apr 18, 2024
AB			**EQ 25MG ACID/PACKET**	**A216620**	**002**	Apr 18, 2024

PROMACTA KIT

AB	**+**	NOVARTIS	**EQ 12.5MG ACID/PACKET**	**N207027**	**002**	Sep 27, 2018
AB	**+!**		**EQ 25MG ACID/PACKET**	**N207027**	**001**	Aug 24, 2015

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	**EQ 12.5MG ACID**	**A206788**	**001**	Jan 17, 2025
AB			**EQ 25MG ACID**	**A206788**	**002**	Jan 17, 2025
AB			**EQ 50MG ACID**	**A206788**	**003**	Jan 17, 2025
AB			**EQ 75MG ACID**	**A206788**	**004**	Jan 17, 2025

PROMACTA

AB	**+**	NOVARTIS	**EQ 12.5MG ACID**	**N022291**	**004**	Oct 20, 2011
AB	**+**		**EQ 25MG ACID**	**N022291**	**001**	Nov 20, 2008
AB	**+**		**EQ 50MG ACID**	**N022291**	**002**	Nov 20, 2008
AB	**+!**		**EQ 75MG ACID**	**N022291**	**003**	Sep 08, 2009

ELUXADOLINE
TABLET;ORAL
VIBERZI
+ ABBVIE 75MG N206940 001 May 27, 2015
+! 100MG N206940 002 May 27, 2015

EMPAGLIFLOZIN
TABLET;ORAL
JARDIANCE
+ BOEHRINGER INGELHEIM 10MG N204629 001 Aug 01, 2014
+! 25MG N204629 002 Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL
GLYXAMBI
+ BOEHRINGER INGELHEIM 10MG;5MG N206073 001 Jan 30, 2015
+! 25MG;5MG N206073 002 Jan 30, 2015

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR
+ BOEHRINGER INGELHEIM 5MG;2.5MG;1GM N212614 001 Jan 27, 2020
+ 10MG;5MG;1GM N212614 002 Jan 27, 2020
+ 12.5MG;2.5MG;1GM N212614 003 Jan 27, 2020
+! 25MG;5MG;1GM N212614 004 Jan 27, 2020

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
SYNJARDY
+ BOEHRINGER INGELHEIM 5MG;500MG N206111 001 Aug 26, 2015
+ 5MG;1GM N206111 002 Aug 26, 2015
+ 12.5MG;500MG N206111 003 Aug 26, 2015
+! 12.5MG;1GM N206111 004 Aug 26, 2015
TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR
+ BOEHRINGER INGELHEIM 5MG;1GM N208658 001 Dec 09, 2016
+ 10MG;1GM N208658 002 Dec 09, 2016
+ 12.5MG;1GM N208658 003 Dec 09, 2016
+! 25MG;1GM N208658 004 Dec 09, 2016

EMTRICITABINE
CAPSULE;ORAL
EMTRICITABINE
AB AUROBINDO PHARMA LTD **200MG** **A079188 001** Mar 15, 2023
AB CIPLA **200MG** **A091168 001** Jul 02, 2018
EMTRIVA
AB **+!** GILEAD **200MG** **N021500 001** Jul 02, 2003
SOLUTION;ORAL
EMTRIVA
+! GILEAD 10MG/ML N021896 001 Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
ODEFSEY
+! GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
COMPLERA
AB **+!** GILEAD SCIENCES INC **200MG;EQ 25MG BASE;300MG** **N202123 001** Aug 10, 2011
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
AB MYLAN **200MG;EQ 25MG BASE;300MG** **A208452 001** May 20, 2025

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
DESCOVY
AB **+!** GILEAD SCIENCES INC **200MG;EQ 25MG BASE** **N208215 001** Apr 04, 2016
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
AB LUPIN LTD **200MG;EQ 25MG BASE** **A213926 001** Dec 13, 2024
DESCOVY
+ GILEAD SCIENCES INC 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		HETERO LABS LTD III	**200MG;300MG**	**A201806**	**001**	Oct 07, 2021
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
AB		AMNEAL PHARMS CO	**100MG;150MG**	**A209721**	**001**	Aug 22, 2018
AB			**133MG;200MG**	**A209721**	**002**	Aug 22, 2018
AB			**167MG;250MG**	**A209721**	**003**	Aug 22, 2018
AB			**200MG;300MG**	**A209721**	**004**	Aug 22, 2018
AB		AUROBINDO PHARMA	**200MG;300MG**	**A090513**	**001**	Jan 26, 2018
AB		AUROBINDO PHARMA LTD	**100MG;150MG**	**A211640**	**001**	Mar 09, 2023
AB			**133MG;200MG**	**A211640**	**002**	Mar 09, 2023
AB			**167MG;250MG**	**A211640**	**003**	Mar 09, 2023
AB		CHARTWELL RX	**200MG;300MG**	**A204131**	**001**	Jun 04, 2021
AB		HETERO LABS LTD III	**100MG;150MG**	**A201806**	**002**	Mar 03, 2025
AB			**133MG;200MG**	**A201806**	**003**	Mar 03, 2025
AB			**167MG;250MG**	**A201806**	**004**	Mar 03, 2025
AB		LAURUS	**200MG;300MG**	**A212114**	**001**	Jul 26, 2019
AB		MACLEODS PHARMS LTD	**200MG;300MG**	**A203442**	**001**	May 15, 2020
AB		PHARMOBEDIENT	**200MG;300MG**	**A206436**	**001**	Apr 09, 2018
AB		STRIDES PHARMA	**200MG;300MG**	**A091055**	**001**	Jan 13, 2021
AB		TEVA PHARMS USA	**200MG;300MG**	**A090894**	**001**	Jun 08, 2017
AB		ZYDUS PHARMS	**100MG;150MG**	**A212689**	**002**	Jul 01, 2021
AB			**133MG;200MG**	**A212689**	**003**	Jul 01, 2021
AB			**167MG;250MG**	**A212689**	**004**	Jul 01, 2021
AB			**200MG;300MG**	**A212689**	**001**	Feb 28, 2020
TRUVADA						
AB	**+**	GILEAD	**100MG;150MG**	**N021752**	**002**	Mar 10, 2016
AB	**+**		**133MG;200MG**	**N021752**	**003**	Mar 10, 2016
AB	**+**		**167MG;250MG**	**N021752**	**004**	Mar 10, 2016
AB	**+!**		**200MG;300MG**	**N021752**	**001**	Aug 02, 2004

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE						
AB		ALKEM LABS LTD	**1MG/ML**	**A213714**	**001**	Mar 30, 2022
AB		AMNEAL	**1MG/ML**	**A212894**	**001**	Jun 29, 2022
AB		ANNORA PHARMA	**1MG/ML**	**A214467**	**001**	Feb 24, 2022
AB		AUROBINDO PHARMA	**1MG/ML**	**A216458**	**001**	Jan 08, 2024
AB		BIONPHARMA	**1MG/ML**	**A212408**	**001**	Aug 10, 2021
EPANED						
AB	**+!**	AZURITY	**1MG/ML**	**N208686**	**001**	Sep 20, 2016

TABLET;ORAL

ENALAPRIL MALEATE						
AB		AIPING PHARM INC	**2.5MG**	**A075178**	**002**	Mar 23, 2001
AB			**5MG**	**A075178**	**001**	Mar 23, 2001
AB			**10MG**	**A075178**	**003**	Mar 23, 2001
AB			**20MG**	**A075178**	**004**	Mar 23, 2001
AB		HERITAGE PHARMA	**2.5MG**	**A075479**	**001**	Aug 22, 2000
AB			**5MG**	**A075479**	**002**	Aug 22, 2000
AB			**10MG**	**A075479**	**003**	Aug 22, 2000
AB			**20MG**	**A075479**	**004**	Aug 22, 2000
AB		PRINSTON INC	**2.5MG**	**A213273**	**001**	Jul 07, 2022
AB			**5MG**	**A213273**	**002**	Jul 07, 2022
AB			**10MG**	**A213273**	**003**	Jul 07, 2022
AB			**20MG**	**A213273**	**004**	Jul 07, 2022
AB		SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB			**5MG**	**A075496**	**002**	Aug 22, 2000
AB			**10MG**	**A075459**	**001**	Aug 22, 2000
AB			**20MG**	**A075459**	**002**	Aug 22, 2000
AB		SENORES PHARMS	**2.5MG**	**A075483**	**001**	Aug 22, 2000
AB			**5MG**	**A075483**	**002**	Aug 22, 2000
AB			**10MG**	**A075483**	**003**	Aug 22, 2000
AB			**20MG**	**A075483**	**004**	Aug 22, 2000
AB		TARO	**2.5MG**	**A075657**	**001**	Jan 23, 2001
AB			**5MG**	**A075657**	**002**	Jan 23, 2001
AB			**10MG**	**A075657**	**003**	Jan 23, 2001
AB			**20MG**	**A075657**	**004**	Jan 23, 2001
AB		UNIQUE PHARM	**2.5MG**	**A218531**	**001**	Sep 19, 2024
AB			**5MG**	**A218531**	**002**	Sep 19, 2024
AB			**10MG**	**A218531**	**003**	Sep 19, 2024
AB			**20MG**	**A218531**	**004**	Sep 19, 2024

ENALAPRIL MALEATE

TABLET;ORAL

VASOTEC

AB	**+**	BAUSCH	**2.5MG**	**N018998**	**005**	Jul 26, 1988
AB	**+**		**5MG**	**N018998**	**001**	Dec 24, 1985
AB	**+**		**10MG**	**N018998**	**002**	Dec 24, 1985
AB	**+!**		**20MG**	**N018998**	**003**	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		SENORES PHARMS	**5MG;12.5MG**	**A075909**	**001**	Oct 15, 2001
AB			**10MG;25MG**	**A075909**	**002**	Oct 15, 2001
AB		TARO PHARM INDS	**5MG;12.5MG**	**A075788**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075788**	**002**	Sep 18, 2001

VASERETIC

AB	**+**	BAUSCH	**5MG;12.5MG**	**N019221**	**003**	Jul 12, 1995
AB	**+!**		**10MG;25MG**	**N019221**	**001**	Oct 31, 1986

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP		CHARTWELL INJECTABLE	**1.25MG/ML**	**A075634**	**001**	Aug 22, 2000
AP		DR REDDYS	**1.25MG/ML**	**A075578**	**001**	Aug 22, 2000
AP	**!**	HIKMA FARMACEUTICA	**1.25MG/ML**	**A078687**	**001**	Dec 23, 2008

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	BRISTOL MYERS SQUIBB	EQ 50MG BASE	N209606	001	Aug 01, 2017
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+!	ARRAY BIOPHARMA INC	75MG	N210496	002	Jun 27, 2018

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		AMPHASTAR PHARMS INC	**300MG/3ML (100MG/ML)**	**A208600**	**001**	Mar 14, 2019
AB		EMERGE BIOSCIENCE	**300MG/3ML (100MG/ML)**	**A214856**	**001**	Jun 14, 2022
AB		SANDOZ INC	**300MG/3ML (100MG/ML)**	**A078660**	**001**	Nov 28, 2011

LOVENOX

AB	**+**	SANOFI AVENTIS US	**300MG/3ML (100MG/ML)**	**N020164**	**009**	Jan 23, 2003

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	**30MG/0.3ML (100MG/ML)**	**A076684**	**001**	Sep 19, 2011
AP			**40MG/0.4ML (100MG/ML)**	**A076684**	**002**	Sep 19, 2011
AP			**60MG/0.6ML (100MG/ML)**	**A076684**	**003**	Sep 19, 2011
AP			**80MG/0.8ML (100MG/ML)**	**A076684**	**004**	Sep 19, 2011
AP			**100MG/ML (100MG/ML)**	**A076684**	**005**	Sep 19, 2011
AP			**120MG/0.8ML (150MG/ML)**	**A076684**	**006**	Sep 19, 2011
AP			**150MG/ML (150MG/ML)**	**A076684**	**007**	Sep 19, 2011
AP		BE PHARMS	**30MG/0.3ML (100MG/ML)**	**A214646**	**001**	Jun 06, 2023
AP			**40MG/0.4ML (100MG/ML)**	**A214646**	**002**	Jun 06, 2023
AP			**60MG/0.6ML (100MG/ML)**	**A214646**	**003**	Jun 06, 2023
AP			**80MG/0.8ML (100MG/ML)**	**A214646**	**004**	Jun 06, 2023
AP			**100MG/ML (100MG/ML)**	**A214646**	**005**	Jun 06, 2023
AP			**120MG/0.8ML (150MG/ML)**	**A214646**	**006**	Jun 06, 2023
AP			**150MG/ML (150MG/ML)**	**A214646**	**007**	Jun 06, 2023
AP		EMERGE BIOSCIENCE	**30MG/0.3ML (100MG/ML)**	**A206834**	**001**	Nov 29, 2019
AP			**40MG/0.4ML (100MG/ML)**	**A206834**	**002**	Nov 29, 2019
AP			**60MG/0.6ML (100MG/ML)**	**A206834**	**003**	Nov 29, 2019
AP			**80MG/0.8ML (100MG/ML)**	**A206834**	**004**	Nov 29, 2019
AP			**100MG/ML (100MG/ML)**	**A206834**	**005**	Nov 29, 2019
AP			**120MG/0.8ML (150MG/ML)**	**A206834**	**006**	Nov 29, 2019
AP			**150MG/ML (150MG/ML)**	**A206834**	**007**	Nov 29, 2019
AP		GLAND	**30MG/0.3ML (100MG/ML)**	**A078990**	**001**	Sep 28, 2018
AP			**40MG/0.4ML (100MG/ML)**	**A078990**	**002**	Sep 28, 2018
AP			**60MG/0.6ML (100MG/ML)**	**A078990**	**003**	Sep 28, 2018
AP			**80MG/0.8ML (100MG/ML)**	**A078990**	**004**	Sep 28, 2018

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP			**100MG/ML (100MG/ML)**	**A078990**	**005**	Sep 28, 2018
AP			**120MG/0.8ML (150MG/ML)**	**A078990**	**006**	Sep 28, 2018
AP			**150MG/ML (150MG/ML)**	**A078990**	**007**	Sep 28, 2018
AP		HEBEI CHANGSHAN	**30MG/0.3ML (100MG/ML)**	**A218775**	**001**	Jan 07, 2026
AP			**40MG/0.4ML (100MG/ML)**	**A218775**	**002**	Jan 07, 2026
AP			**60MG/0.6ML (100MG/ML)**	**A218775**	**003**	Jan 07, 2026
AP			**80MG/0.8ML (100MG/ML)**	**A218775**	**004**	Jan 07, 2026
AP			**100MG/ML (100MG/ML)**	**A218775**	**005**	Jan 07, 2026
AP			**120MG/0.8ML (150MG/ML)**	**A218775**	**006**	Jan 07, 2026
AP			**150MG/ML (150MG/ML)**	**A218775**	**007**	Jan 07, 2026
AP		SANDOZ	**30MG/0.3ML (100MG/ML)**	**A077857**	**002**	Jul 23, 2010
AP			**40MG/0.4ML (100MG/ML)**	**A077857**	**003**	Jul 23, 2010
AP			**60MG/0.6ML (100MG/ML)**	**A077857**	**004**	Jul 23, 2010
AP			**80MG/0.8ML (100MG/ML)**	**A077857**	**005**	Jul 23, 2010
AP			**100MG/ML (100MG/ML)**	**A077857**	**001**	Jul 23, 2010
AP			**120MG/0.8ML (150MG/ML)**	**A077857**	**006**	Jul 23, 2010
AP			**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP		SHENZHEN TECHDOW	**30MG/0.3ML (100MG/ML)**	**A205660**	**001**	Mar 15, 2023
AP			**40MG/0.4ML (100MG/ML)**	**A205660**	**002**	Mar 15, 2023
AP			**60MG/0.6ML (100MG/ML)**	**A205660**	**003**	Mar 15, 2023
AP			**80MG/0.8ML (100MG/ML)**	**A205660**	**004**	Mar 15, 2023
AP			**100MG/ML (100MG/ML)**	**A205660**	**005**	Mar 15, 2023
AP			**120MG/0.8ML (150MG/ML)**	**A205660**	**006**	Mar 15, 2023
AP			**150MG/ML (150MG/ML)**	**A205660**	**007**	Mar 15, 2023
AP		ZYDUS PHARMS	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP			**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP			**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP			**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014
AP			**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP			**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP			**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014

LOVENOX (PRESERVATIVE FREE)

AP	+	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP	+		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP	+		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP	+		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	+!		**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP	+		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP	+		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000

ENSARTINIB HYDROCHLORIDE

CAPSULE;ORAL

ENSACOVE

+	XCOVERY	EQ 25MG BASE	N218171	001	Dec 18, 2024
+!		EQ 100MG BASE	N218171	002	Dec 18, 2024

ENSIFENTRINE

SUSPENSION;INHALATION

OHTUVAYRE

+!	VERONA PHARMA	3MG/2.5ML	N217389	001	Jun 26, 2024

ENTACAPONE

TABLET;ORAL

COMTAN

AB	**+!**	ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999

ENTACAPONE

AB		AJANTA PHARMA LTD	**200MG**	**A205792**	**001**	Aug 31, 2017
AB		ALEMBIC	**200MG**	**A212601**	**001**	Jan 04, 2022
AB		AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB		MACLEODS PHARMS LTD	**200MG**	**A207210**	**001**	Jun 05, 2017
AB		SUN PHARM	**200MG**	**A090690**	**001**	Jul 16, 2012
AB		SUNSHINE	**200MG**	**A206669**	**001**	Oct 03, 2018
AB		WOCKHARDT BIO AG	**200MG**	**A078941**	**001**	Aug 16, 2012

ENTECAVIR

SOLUTION;ORAL

BARACLUDE

+!	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

ENTECAVIR							
TABLET;ORAL							
BARACLUDE							
AB	**+**	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	**+!**		**1MG**	**N021797**	**002**	Mar 29, 2005
ENTECAVIR							
AB		AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB			**1MG**	**A206652**	**002**	Nov 12, 2015
AB		AUROBINDO PHARMA	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB			**1MG**	**A206217**	**002**	Aug 26, 2015
AB		BRIGHTGENE	**0.5MG**	**A212126**	**001**	Sep 25, 2019
AB			**1MG**	**A212126**	**002**	Sep 25, 2019
AB		CIPLA	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB			**1MG**	**A206872**	**002**	Dec 06, 2016
AB		CONBA USA	**0.5MG**	**A216857**	**001**	Dec 23, 2024
AB			**1MG**	**A216857**	**002**	Dec 23, 2024
AB		HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB			**1MG**	**A205740**	**002**	Aug 21, 2015
AB		YUNG SHIN PHARM	**0.5MG**	**A208195**	**001**	Nov 10, 2021
AB			**1MG**	**A208195**	**002**	Nov 10, 2021
AB		ZYDUS PHARMS	**0.5MG**	**A206745**	**001**	Jun 23, 2017
AB			**1MG**	**A206745**	**002**	Jun 23, 2017
ENTRECTINIB							
CAPSULE;ORAL							
ROZLYTREK							
	+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019
	+!		200MG	N212725	002	Aug 15, 2019
PELLETS;ORAL							
ROZLYTREK							
	+!	GENENTECH INC	50MG/PACKET	N218550	001	Oct 20, 2023
ENZALUTAMIDE							
CAPSULE;ORAL							
XTANDI							
	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012
TABLET;ORAL							
XTANDI							
	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020
	+!		80MG	N213674	002	Aug 04, 2020
EPHEDRINE SULFATE							
SOLUTION;INTRAVENOUS							
AKOVAZ							
AP	**+!**	EXELA PHARMA	**50MG/ML (50MG/ML)**	**N208289**	**001**	Apr 29, 2016
CORPHEDRA							
AP		PH HEALTH	**50MG/ML (50MG/ML)**	**N208943**	**001**	Jan 27, 2017
EPHEDRINE SULFATE							
AP		AMNEAL	**50MG/ML (50MG/ML)**	**A212932**	**001**	Oct 23, 2019
AP		CAPLIN	**50MG/ML (50MG/ML)**	**A219050**	**001**	Jul 18, 2024
AP		CIVICA	**50MG/ML (50MG/ML)**	**A215593**	**001**	Dec 23, 2025
AP		DR REDDYS	**50MG/ML (50MG/ML)**	**A212649**	**001**	Oct 03, 2020
AP		EUGIA PHARMA	**50MG/ML (50MG/ML)**	**A214579**	**001**	Jun 14, 2021
AP		FRESENIUS KABI USA	**50MG/ML (50MG/ML)**	**A209646**	**001**	Aug 04, 2020
AP		GLAND	**50MG/ML (50MG/ML)**	**A216146**	**001**	Feb 25, 2022
AP		HIKMA	**50MG/ML (50MG/ML)**	**A214334**	**001**	Dec 15, 2020
AP		MANKIND PHARMA	**50MG/ML (50MG/ML)**	**A216129**	**001**	Apr 14, 2022
AP		SAGENT PHARMS INC	**50MG/ML (50MG/ML)**	**A214528**	**001**	Mar 09, 2023
AP		SANDOZ	**50MG/ML (50MG/ML)**	**A209784**	**001**	Aug 23, 2017
AP		XIROMED	**50MG/ML (50MG/ML)**	**A215825**	**001**	Apr 21, 2022
EMERPHED							
AP1	**+!**	NEXUS	**50MG/10ML (5MG/ML)**	**N213407**	**001**	Apr 17, 2020
EPHEDRINE SULFATE							
AP1		GLAND	**50MG/10ML (5MG/ML)**	**A218211**	**001**	Jan 16, 2025
AP2		FRESENIUS KABI USA	**25MG/5ML (5MG/ML)**	**A218271**	**001**	Mar 11, 2025
AP2			**50MG/10ML (5MG/ML)**	**A218271**	**002**	Mar 11, 2025
AP2	**+!**	PH HEALTH	**25MG/5ML (5MG/ML)**	**N213994**	**002**	Apr 22, 2022
AP2	**+!**		**50MG/10ML (5MG/ML)**	**N213994**	**001**	Oct 16, 2020
AKOVAZ							
AP3	**+!**	EXELA PHARMA	**25MG/5ML (5MG/ML)**	**N208289**	**002**	Aug 02, 2021
EPHEDRINE SULFATE							
AP3		HIKMA	**25MG/5ML (5MG/ML)**	**A217721**	**001**	Oct 11, 2024

EPHEDRINE SULFATE							
SOLUTION;INTRAVENOUS							
EMERPHED							
	+!	NEXUS	25MG/5ML (5MG/ML)	N213407	002	Feb 28, 2023	
EPINASTINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
EPINASTINE HYDROCHLORIDE							
AT		APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011	
AT	!	SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011	
EPINEPHRINE							
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE (AUTOINJECTOR)							
AB		TEVA PHARMS USA	**0.15MG/DELIVERY**	**A090589**	**002**	Aug 16, 2018	
AB			**0.3MG/DELIVERY**	**A090589**	**001**	Aug 16, 2018	
EPIPEN							
AB	**+!**	VIATRIS	**0.3MG/DELIVERY**	**N019430**	**001**	Dec 22, 1987	
EPIPEN JR.							
AB	**+!**	VIATRIS	**0.15MG/DELIVERY**	**N019430**	**002**	Dec 22, 1987	
ADRENACLICK							
BX	+!	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	
BX	+!		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
ADRENALIN							
AP	**+!**	PH HEALTH	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**N204200**	**001**	Dec 07, 2012	
AP	**+!**		**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**N204640**	**001**	Dec 18, 2013	
EPINEPHRINE							
AP		AM REGENT	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**A217192**	**001**	Sep 06, 2024	
AP		AMNEAL	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A218208**	**001**	Dec 08, 2025	
AP			**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**A217485**	**001**	Oct 14, 2025	
AP	**+!**	BPI LABS	**10MG/10ML (1MG/ML)**	**N205029**	**002**	Feb 04, 2022	
AP	**+!**		**30MG/30ML (1MG/ML)**	**N205029**	**004**	Feb 14, 2024	
AP		GLAND	**10MG/10ML (1MG/ML)**	**A219239**	**001**	Feb 06, 2025	
AP			**30MG/30ML (1MG/ML)**	**A219239**	**002**	Oct 02, 2025	
AP		INTL MEDICATION SYS	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**A211880**	**001**	Apr 24, 2020	
	+!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	
	+!	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
AUVI-Q							
BX	+!	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	
BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	
	+		EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017	
SYMJEPI							
	+!	ADAMIS PHARMS CORP	0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017	
SOLUTION;INTRAVENOUS							
ADRENALIN							
	+!	PH HEALTH	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	
	+!		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	
	+!		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	
	+!		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	
	+!		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	
EPINEPHRINE							
	+!	HOSPIRA	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	
	+!	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022	
SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE							
AP	**+!**	BPI LABS	**1MG/ML (1MG/ML)**	**N205029**	**001**	Jul 29, 2014	
AP		FRESENIUS KABI USA	**1MG/ML (1MG/ML)**	**A213708**	**001**	Nov 20, 2024	
AP		GLAND	**1MG/ML (1MG/ML)**	**A218144**	**001**	Jun 03, 2025	
SPRAY;NASAL							
NEFFY							
	+!	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	
	+!		2MG/SPRAY	N214697	001	Aug 09, 2024	
EPINEPHRINE BITARTRATE							
SOLUTION;INTRAVENOUS							
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
	+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

+!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985

LIGNOSPAN STANDARD

+!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CITANEST FORTE DENTAL

AP	**+!**	DENTSPLY PHARM	**0.005MG/ML;4%**	**N021383**	**001**	

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	**0.005MG/ML;4%**	**A078959**	**001**	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		B BRAUN MEDICAL	**0.005MG/ML;1.5%**	**A208475**	**001**	Sep 08, 2021
AP		HOSPIRA	**0.005MG/ML;0.5%**	**A089635**	**001**	Jun 21, 1988
AP			**0.005MG/ML;1.5%**	**A088571**	**001**	Sep 13, 1985
AP			**0.005MG/ML;1.5%**	**A089645**	**001**	Jun 21, 1988
AP			**0.005MG/ML;2%**	**A089651**	**001**	Jun 21, 1988
AP			**0.01MG/ML;1%**	**A089644**	**001**	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

AP	**+!**	FRESENIUS KABI USA	**0.005MG/ML;0.5%**	**N006488**	**012**	
AP	**+!**		**0.005MG/ML;1.5%**	**N006488**	**017**	
AP	**+!**		**0.005MG/ML;2%**	**N006488**	**019**	Nov 13, 1986
AP	**+!**		**0.01MG/ML;1%**	**N006488**	**004**	

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

!	HOSPIRA	0.01MG/ML;2%	A089646	001	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

+!	FRESENIUS KABI USA	0.005MG/ML;1%	N006488	018	Nov 13, 1986
+!		0.02MG/ML;2%	N006488	005	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ELLENCE

AP	**+!**	PFIZER INC	**200MG/100ML (2MG/ML)**	**N050778**	**001**	Sep 15, 1999
AP	**+**		**50MG/25ML (2MG/ML)**	**N050778**	**002**	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	**50MG/25ML (2MG/ML)**	**A065361**	**001**	Oct 22, 2007
AP			**200MG/100ML (2MG/ML)**	**A065361**	**002**	Oct 22, 2007
AP		EPIC PHARMA LLC	**50MG/25ML (2MG/ML)**	**A090163**	**001**	Jun 24, 2009
AP		HIKMA	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP			**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007
AP		IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP			**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ACCORD HLTHCARE	**25MG**	**A206922**	**001**	Jul 13, 2017
AB			**50MG**	**A206922**	**002**	Jul 13, 2017
AB		ADAPTIS	**25MG**	**A212765**	**001**	Aug 10, 2020
AB			**50MG**	**A212765**	**002**	Aug 10, 2020
AB		ANNORA PHARMA	**25MG**	**A213812**	**001**	Jun 02, 2023
AB			**50MG**	**A213812**	**002**	Jun 02, 2023
AB		BRECKENRIDGE	**25MG**	**A208283**	**001**	Sep 14, 2018
AB			**50MG**	**A208283**	**002**	Sep 14, 2018
AB		CHARTWELL RX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB			**50MG**	**A078482**	**002**	Jul 30, 2008
AB		RISING	**25MG**	**A214663**	**001**	Mar 23, 2022
AB			**50MG**	**A214663**	**002**	Mar 23, 2022
AB		SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB			**50MG**	**A078510**	**002**	Aug 01, 2008
AB		WESTMINSTER PHARMS	**25MG**	**A207842**	**001**	Oct 25, 2021
AB			**50MG**	**A207842**	**002**	Oct 25, 2021

INSPRA

AB	**+**	UPJOHN	**25MG**	**N021437**	**001**	Sep 27, 2002
AB	**+!**		**50MG**	**N021437**	**002**	Sep 27, 2002

EPLONTERSEN SODIUM							
SOLUTION;SUBCUTANEOUS							
WAINUA (AUTOINJECTOR)							
	+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023
EPOPROSTENOL SODIUM							
INJECTABLE;INJECTION							
EPOPROSTENOL SODIUM							
AP2		GLAND	**EQ 0.5MG BASE/VIAL**	**A219237**	**001**	Dec 29, 2025
AP2			**EQ 1.5MG BASE/VIAL**	**A219237**	**002**	Dec 29, 2025
AP2		MYLAN	**EQ 0.5MG BASE/VIAL**	**A213913**	**001**	Jun 12, 2024
AP2			**EQ 1.5MG BASE/VIAL**	**A213913**	**002**	Jun 12, 2024
AP2	**!**	SUN PHARM	**EQ 0.5MG BASE/VIAL**	**A210473**	**001**	Jan 15, 2021
AP2			**EQ 1.5MG BASE/VIAL**	**A210473**	**002**	Jan 15, 2021
VELETRI							
AP2	**+**	ACTELION	**EQ 0.5MG BASE/VIAL**	**N022260**	**002**	Jun 28, 2012
AP2	**+!**		**EQ 1.5MG BASE/VIAL**	**N022260**	**001**	Jun 27, 2008
EPOPROSTENOL SODIUM							
	!	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008
	!		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008
EPTIFIBATIDE							
INJECTABLE;INJECTION							
EPTIFIBATIDE							
AP		BAXTER HLTHCARE CORP	**75MG/100ML**	**A208554**	**002**	Nov 23, 2018
AP		EUGIA PHARMA	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP			**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP		MEITHEAL	**2MG/ML**	**A213599**	**001**	May 09, 2024
AP			**75MG/100ML**	**A213599**	**002**	May 09, 2024
AP	**!**	MYLAN LABS LTD	**2MG/ML**	**A203258**	**001**	Jul 20, 2018
AP	**!**		**75MG/100ML**	**A203258**	**002**	Jul 20, 2018
AP		SAGENT PHARMS INC	**2MG/ML**	**A204693**	**001**	Mar 07, 2018
AP			**75MG/100ML**	**A204693**	**002**	Mar 07, 2018
AP		SHUANGCHENG	**2MG/ML**	**A213081**	**001**	Sep 07, 2021
AP			**75MG/100ML**	**A213081**	**002**	Apr 20, 2022
AP		SLATE RUN PHARMA	**2MG/ML**	**A209864**	**001**	Jan 25, 2019
AP			**75MG/100ML**	**A209864**	**002**	Jan 25, 2019
AP		TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015
ERAVACYCLINE DIHYDROCHLORIDE							
POWDER;INTRAVENOUS							
XERAVA							
	+!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018
	+!		EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020
ERDAFITINIB							
TABLET;ORAL							
BALVERSA							
	+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019
	+		4MG	N212018	002	Apr 12, 2019
	+!		5MG	N212018	003	Apr 12, 2019
ERGOCALCIFEROL							
CAPSULE;ORAL							
DRISDOL							
AA	**+**	ESJAY PHARMA	**50,000 IU**	**N003444**	**001**	
ERGOCALCIFEROL							
AA		CHARTWELL RX	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA	**!**	ONESOURCE SPECIALTY	**50,000 IU**	**A090455**	**001**	Aug 03, 2010
AA		PURACAP PHARM LLC	**50,000 IU**	**A204276**	**001**	Dec 07, 2018
VITAMIN D							
AA		BIONPHARMA	**50,000 IU**	**A080704**	**001**	
ERGOTAMINE TARTRATE							
TABLET;SUBLINGUAL							
ERGOMAR							
	!	PANGEA	2MG	A087693	001	Feb 24, 1983
ERIBULIN MESYLATE							
SOLUTION;INTRAVENOUS							
ERIBULIN MESYLATE							
AP		BAXTER HLTHCARE CORP	**1MG/2ML (0.5MG/ML)**	**A217250**	**001**	Oct 01, 2024
AP		CHIA TAI TIANQING	**1MG/2ML (0.5MG/ML)**	**A218743**	**001**	Mar 04, 2025
AP		DR REDDYS	**1MG/2ML (0.5MG/ML)**	**A217473**	**001**	Jul 03, 2025

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

AP		GLAND	**1MG/2ML (0.5MG/ML)**	**A218047**	**001**	Apr 05, 2024
AP		GLENMARK PHARMS INC	**1MG/2ML (0.5MG/ML)**	**A218142**	**001**	Aug 05, 2025
AP		JIANGXI KVVIT PHARM	**1MG/2ML (0.5MG/ML)**	**A218281**	**001**	Jun 28, 2024
AP		LONG GROVE PHARMS	**1MG/2ML (0.5MG/ML)**	**A214850**	**001**	Jul 18, 2024
AP		SANDOZ	**1MG/2ML (0.5MG/ML)**	**A214310**	**001**	Jun 09, 2025

HALAVEN

AP	**+!**	EISAI INC	**1MG/2ML (0.5MG/ML)**	**N201532**	**001**	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		ALEMBIC	**EQ 25MG BASE**	**A214719**	**001**	Jul 08, 2021
AB			**EQ 100MG BASE**	**A214719**	**002**	Jul 08, 2021
AB			**EQ 150MG BASE**	**A214719**	**003**	Jul 08, 2021
AB		CHARTWELL RX	**EQ 25MG BASE**	**A203843**	**001**	Sep 13, 2024
AB			**EQ 150MG BASE**	**A203843**	**002**	Sep 13, 2024
AB		HETERO LABS LTD V	**EQ 25MG BASE**	**A209267**	**001**	May 24, 2024
AB			**EQ 100MG BASE**	**A209267**	**002**	May 24, 2024
AB			**EQ 150MG BASE**	**A209267**	**003**	May 24, 2024
AB		MSN	**EQ 25MG BASE**	**A214366**	**001**	May 10, 2021
AB			**EQ 100MG BASE**	**A214366**	**002**	May 10, 2021
AB			**EQ 150MG BASE**	**A214366**	**003**	May 10, 2021
AB		RISING	**EQ 25MG BASE**	**A091002**	**001**	Jun 11, 2014
AB			**EQ 100MG BASE**	**A091002**	**002**	Jun 11, 2014
AB			**EQ 150MG BASE**	**A091002**	**003**	Jun 11, 2014
AB		SHILPA	**EQ 25MG BASE**	**A211960**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A211960**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A211960**	**003**	Nov 05, 2019
AB		TEVA PHARMS USA INC	**EQ 25MG BASE**	**A091059**	**001**	Nov 09, 2020
AB			**EQ 100MG BASE**	**A091059**	**002**	Aug 28, 2015
AB			**EQ 150MG BASE**	**A091059**	**003**	Aug 28, 2015
AB		ZYDUS PHARMS	**EQ 25MG BASE**	**A213065**	**001**	Apr 16, 2020
AB			**EQ 100MG BASE**	**A213065**	**002**	Apr 16, 2020
AB	**!**		**EQ 150MG BASE**	**A213065**	**003**	Apr 16, 2020

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A208790**	**001**	Apr 16, 2018
AP		EUGIA PHARMA	**EQ 1GM BASE/VIAL**	**A209133**	**001**	Jun 25, 2018
AP		GLAND	**EQ 1GM BASE/VIAL**	**A212040**	**001**	Mar 26, 2021
AP		QILU ANTIBIOTICS	**EQ 1GM BASE/VIAL**	**A218067**	**001**	Oct 31, 2024
AP		SAVIOR LIFETEC CORP	**EQ 1GM BASE/VIAL**	**A207647**	**001**	Mar 19, 2019

INVANZ

AP	**+!**	MSD SUB MERCK	**EQ 1GM BASE/VIAL**	**N021337**	**001**	Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017
	+!		15MG	N209803	002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

	+	MSD SUB MERCK	2.5MG;500MG	N209806	001	Dec 19, 2017
	+		2.5MG;1GM	N209806	002	Dec 19, 2017
	+		7.5MG;500MG	N209806	003	Dec 19, 2017
	+!		7.5MG;1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

	+	MSD SUB MERCK	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017
	+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB	**+!**	DR REDDYS LABS SA	**250MG**	**N050536**	**001**	

ERYTHROMYCIN

AB		PHARMOBEDIENT	**250MG**	**A062746**	**001**	Dec 22, 1986

GEL;TOPICAL

ERYTHROMYCIN

AT		FOUGERA PHARMS	**2%**	**A064184**	**001**	Sep 30, 1997
AT	**!**	PADAGIS US	**2%**	**A063211**	**001**	Jan 29, 1993

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT	**!**	BAUSCH AND LOMB	**0.5%**	**A064067**	**001**	Jul 29, 1994
AT		SENTISS	**0.5%**	**A064030**	**001**	Jul 18, 1996

SOLUTION;TOPICAL

ERYTHRA-DERM

AT		MICRO LABS	**2%**	**A062687**	**001**	Feb 05, 1988

ERYTHROMYCIN

AT	**!**	PADAGIS US	**2%**	**A063038**	**001**	Jan 11, 1991

SWAB;TOPICAL

ERYTHROMYCIN

AT		EPIC PHARMA LLC	**2%**	**A090215**	**001**	May 12, 2010
AT	**!**	PADAGIS US	**2%**	**A064126**	**001**	Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

AB		ABON PHARMS LLC	**250MG**	**A219691**	**001**	Sep 23, 2025
AB			**500MG**	**A219691**	**002**	Sep 23, 2025
AB		ALEMBIC	**250MG**	**A215661**	**001**	Aug 24, 2023
AB			**500MG**	**A215661**	**002**	Aug 24, 2023
AB		ALKEM LABS LTD	**250MG**	**A216066**	**001**	Jul 13, 2022
AB			**500MG**	**A216066**	**002**	Jul 13, 2022
AB		CADILA PHARMS LTD	**250MG**	**A213628**	**001**	Jun 28, 2021
AB	**!**		**500MG**	**A213628**	**002**	Jun 28, 2021
AB		PHARMOBEDIENT	**250MG**	**A061621**	**001**	
AB			**500MG**	**A061621**	**002**	
AB		TEVA PHARMS USA INC	**250MG**	**A214549**	**001**	Feb 11, 2021
AB			**500MG**	**A214549**	**002**	Feb 11, 2021
AB		TORRENT	**250MG**	**A212015**	**001**	Jul 06, 2020
AB			**500MG**	**A212015**	**002**	Jul 06, 2020
AB		ZYDUS LIFESCIENCES	**250MG**	**A212693**	**001**	Mar 07, 2023
AB			**500MG**	**A212693**	**002**	Mar 07, 2023

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB		PHARMOBEDIENT	**250MG**	**A062298**	**001**	
AB			**333MG**	**A062298**	**003**	Mar 29, 1982
AB	**!**		**500MG**	**A062298**	**002**	

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	**250MG**	**A210954**	**001**	Jul 02, 2019
AB			**333MG**	**A210954**	**002**	Jul 02, 2019
AB			**500MG**	**A210954**	**003**	Jul 02, 2019
AB		TORRENT	**250MG**	**A211975**	**001**	Jul 26, 2021
AB			**333MG**	**A211975**	**003**	Aug 13, 2024
AB			**500MG**	**A211975**	**002**	Jul 26, 2021

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	**+**	CARNEGIE	**EQ 200MG BASE/5ML**	**N050207**	**001**	

ERYPED

AB	**+**	CARNEGIE	**EQ 200MG BASE/5ML**	**N050207**	**003**	Mar 30, 1987
AB	**+!**		**EQ 400MG BASE/5ML**	**N050207**	**002**	

ERYTHROMYCIN ETHYLSUCCINATE

AB		AMNEAL PHARMS	**EQ 200MG BASE/5ML**	**A211204**	**001**	Nov 01, 2019
AB			**EQ 400MG BASE/5ML**	**A211204**	**002**	Nov 01, 2019
AB		ANI PHARMS	**EQ 200MG BASE/5ML**	**A062055**	**001**	
AB			**EQ 200MG BASE/5ML**	**A062055**	**003**	Nov 02, 2018
AB			**EQ 400MG BASE/5ML**	**A062055**	**002**	Nov 02, 2018
AB		CADILA PHARMS LTD	**EQ 200MG BASE/5ML**	**A216212**	**001**	Nov 21, 2022
AB			**EQ 400MG BASE/5ML**	**A216212**	**002**	Nov 21, 2022

TABLET;ORAL

E.E.S. 400

BX	!	PHARMOBEDIENT	EQ 400MG BASE	A061905	002	Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	PHARMOBEDIENT	EQ 400MG BASE	A061904	001	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638**	**001**	Oct 31, 1986
AP	**+!**		**EQ 500MG BASE/VIAL**	**N050609**	**001**	Sep 24, 1986

ERYTHROMYCIN LACTOBIONATE

AP		GLAND	**EQ 500MG BASE/VIAL**	**A216761**	**001**	Nov 19, 2024
AP		NEXUS	**EQ 500MG BASE/VIAL**	**A215290**	**001**	Feb 14, 2022

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM

	+!	ALMATICA	EQ 15MG BASE	N219130	001	Aug 29, 2025

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227**	**001**	Mar 14, 2012
AA		AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062**	**001**	Apr 02, 2012
AA		CHARTWELL MOLECULAR	**EQ 5MG BASE/5ML**	**A090477**	**001**	Jun 12, 2013
AA	**!**	HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221**	**001**	Jun 12, 2012
AA		MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754**	**001**	Mar 31, 2016

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202389**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202389**	**003**	Sep 11, 2012
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205619**	**001**	May 17, 2017
AB			**EQ 10MG BASE**	**A205619**	**002**	May 17, 2017
AB			**EQ 20MG BASE**	**A205619**	**003**	May 17, 2017
AB		ASCENT PHARMS INC	**EQ 5MG BASE**	**A215177**	**001**	Jul 15, 2025
AB			**EQ 10MG BASE**	**A215177**	**002**	Jul 15, 2025
AB			**EQ 20MG BASE**	**A215177**	**003**	Jul 15, 2025
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090432**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090432**	**003**	Sep 11, 2012
AB		CHARTWELL RX	**EQ 5MG BASE**	**A078169**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078169**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078169**	**003**	Sep 11, 2012
AB		GRAVITI PHARMS	**EQ 5MG BASE**	**A078777**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078777**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078777**	**003**	Sep 11, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078604**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078604**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078604**	**003**	Sep 11, 2012
AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A202280**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A202280**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A202280**	**003**	Sep 12, 2012
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A202210**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202210**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202210**	**003**	Sep 11, 2012
AB		PRINSTON INC	**EQ 5MG BASE**	**A078032**	**001**	Aug 28, 2015
AB			**EQ 10MG BASE**	**A078032**	**002**	Aug 28, 2015
AB			**EQ 20MG BASE**	**A078032**	**003**	Aug 28, 2015
AB		TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012
AB		ZYDUS LIFESCIENCES	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012

LEXAPRO

AB	**+**	ABBVIE	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB	**+**		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+!**		**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL

SPRAVATO

	+!	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

AB	+	SUMITOMO PHARMA AM	**200MG**	**N022416**	**001**	Nov 08, 2013
AB	+		**400MG**	**N022416**	**002**	Nov 08, 2013
AB	+		**600MG**	**N022416**	**003**	Nov 08, 2013
AB	+!		**800MG**	**N022416**	**004**	Nov 08, 2013

ESLICARBAZEPINE ACETATE

AB		ALKEM LABS LTD	**200MG**	**A211199**	**001**	Oct 06, 2023
AB			**400MG**	**A211199**	**002**	Oct 06, 2023
AB			**600MG**	**A211199**	**003**	Oct 06, 2023
AB			**800MG**	**A211199**	**004**	Oct 06, 2023
AB		APOTEX	**200MG**	**A211236**	**001**	Dec 07, 2023
AB			**400MG**	**A211236**	**002**	Dec 07, 2023
AB			**600MG**	**A211236**	**003**	Dec 07, 2023
AB			**800MG**	**A211236**	**004**	Dec 07, 2023
AB		DR REDDYS	**200MG**	**A211238**	**001**	Jun 29, 2021
AB			**400MG**	**A211238**	**002**	Jun 29, 2021
AB			**600MG**	**A211238**	**003**	Jun 29, 2021
AB			**800MG**	**A211238**	**004**	Jun 29, 2021
AB		HETERO LABS LTD V	**200MG**	**A211186**	**001**	Aug 03, 2023
AB			**400MG**	**A211186**	**002**	Aug 03, 2023
AB			**600MG**	**A211186**	**003**	Aug 03, 2023
AB			**800MG**	**A211186**	**004**	Aug 03, 2023
AB		JUBILANT GENERICS	**200MG**	**A211219**	**001**	Aug 04, 2025
AB			**400MG**	**A211219**	**002**	Aug 04, 2025
AB			**600MG**	**A211219**	**003**	Aug 04, 2025
AB			**800MG**	**A211219**	**004**	Aug 04, 2025
AB		LUPIN LTD	**200MG**	**A211246**	**001**	Mar 27, 2024
AB			**400MG**	**A211246**	**002**	Mar 27, 2024
AB			**600MG**	**A211246**	**003**	Mar 27, 2024
AB			**800MG**	**A211246**	**004**	Mar 27, 2024
AB		SPH ZHONGXI PHARM	**200MG**	**A211247**	**001**	Nov 03, 2025
AB			**400MG**	**A211247**	**002**	Nov 03, 2025
AB			**600MG**	**A211247**	**003**	Nov 03, 2025
AB			**800MG**	**A211247**	**004**	Nov 03, 2025
AB		TORRENT	**200MG**	**A211227**	**001**	Feb 27, 2024
AB			**400MG**	**A211227**	**002**	Feb 27, 2024
AB			**600MG**	**A211227**	**003**	Feb 27, 2024
AB			**800MG**	**A211227**	**004**	Feb 27, 2024

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

AP	+!	BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**2GM/100ML**	**N019386**	**005**	Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**1GM/100ML**	**N019386**	**004**	Feb 16, 2001

ESMOLOL HYDROCHLORIDE

AP		AMNEAL	**1GM/100ML**	**A216603**	**001**	Dec 13, 2022
AP			**2GM/100ML**	**A216603**	**002**	Dec 13, 2022
AP		EUGIA PHARMA	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP			**1GM/100ML**	**A216244**	**001**	Mar 21, 2022
AP			**2GM/100ML**	**A216244**	**002**	Mar 21, 2022
AP		GLAND	**10MG/ML**	**A208538**	**001**	Aug 14, 2019
AP		HIKMA	**10MG/ML**	**A076323**	**001**	Aug 10, 2004
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A214172**	**001**	Dec 02, 2022
AP			**2GM/100ML**	**A214172**	**002**	Dec 02, 2022
AP		MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP		MYLAN LABS LTD	**1GM/100ML**	**A206608**	**001**	Jun 08, 2018
AP			**2GM/100ML**	**A206608**	**002**	Jun 08, 2018
AP		SAGENT PHARMS INC	**1GM/100ML**	**A207107**	**001**	Jun 08, 2018
AP			**2GM/100ML**	**A207107**	**002**	Jun 08, 2018

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

	+!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

	+!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A208333**	**001**	Oct 20, 2017
AB			**EQ 40MG BASE**	**A208333**	**002**	Oct 20, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB			**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB		CISEN	**EQ 20MG BASE**	**A213158**	**001**	Sep 22, 2020
AB			**EQ 40MG BASE**	**A213158**	**002**	Sep 22, 2020
AB		CSPC OUYI	**EQ 20MG BASE**	**A212949**	**001**	Oct 02, 2020
AB			**EQ 40MG BASE**	**A212949**	**002**	Oct 02, 2020
AB		DR REDDYS	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB			**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB		ETHYPHARM	**EQ 20MG BASE**	**A090841**	**001**	Mar 31, 2021
AB			**EQ 40MG BASE**	**A090841**	**002**	Mar 31, 2021
AB		GRANULES	**EQ 20MG BASE**	**A217427**	**001**	Oct 18, 2023
AB			**EQ 40MG BASE**	**A217427**	**002**	Oct 18, 2023
AB		GRAVITI PHARMS	**EQ 20MG BASE**	**A213486**	**001**	Mar 19, 2021
AB			**EQ 40MG BASE**	**A213486**	**002**	Mar 19, 2021
AB		GUANGZHOU NOVAKEN	**EQ 20MG BASE**	**A213859**	**001**	Nov 18, 2020
AB			**EQ 40MG BASE**	**A213859**	**002**	Nov 18, 2020
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A211977**	**001**	Jun 02, 2020
AB			**EQ 40MG BASE**	**A211977**	**002**	Jun 02, 2020
AB		INDCHEMIE HEALTH	**EQ 20MG BASE**	**A210559**	**001**	Feb 26, 2021
AB			**EQ 40MG BASE**	**A210559**	**002**	Feb 26, 2021
AB		LANNETT CO INC	**EQ 20MG BASE**	**A205563**	**001**	Sep 01, 2017
AB			**EQ 40MG BASE**	**A205563**	**002**	Sep 01, 2017
AB		MYLAN	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB			**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB		PRINSTON INC	**EQ 20MG BASE**	**A214920**	**001**	Mar 28, 2023
AB			**EQ 40MG BASE**	**A214920**	**002**	Mar 28, 2023
AB		SUN PHARM	**EQ 20MG BASE**	**A209735**	**001**	Apr 30, 2018
AB			**EQ 40MG BASE**	**A209735**	**002**	Apr 30, 2018
AB		ZHEJIANG YONGTAI	**EQ 20MG BASE**	**A217022**	**001**	Dec 27, 2023
AB			**EQ 40MG BASE**	**A217022**	**002**	Dec 27, 2023
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206296**	**001**	May 22, 2019
AB			**EQ 40MG BASE**	**A206296**	**002**	May 22, 2019

NEXIUM

AB	+	ASTRAZENECA	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	+!		**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE/PACKET**	**A218948**	**001**	Apr 15, 2025
AB			**EQ 10MG BASE/PACKET**	**A219213**	**001**	Apr 15, 2025
AB			**EQ 20MG BASE/PACKET**	**A218948**	**002**	Apr 15, 2025
AB			**EQ 40MG BASE/PACKET**	**A218948**	**003**	Apr 15, 2025
AB		CIPLA	**EQ 2.5MG BASE/PACKET**	**A217714**	**001**	Jan 07, 2025
AB			**EQ 5MG BASE/PACKET**	**A217714**	**002**	Jan 07, 2025
AB			**EQ 10MG BASE/PACKET**	**A211752**	**001**	Mar 23, 2020
AB			**EQ 20MG BASE/PACKET**	**A211751**	**001**	Mar 23, 2020
AB			**EQ 40MG BASE/PACKET**	**A211751**	**002**	Mar 23, 2020
AB		TORRENT	**EQ 2.5MG BASE/PACKET**	**A212651**	**001**	Mar 05, 2025
AB			**EQ 5MG BASE/PACKET**	**A212651**	**002**	Mar 05, 2025
AB			**EQ 10MG BASE/PACKET**	**A212652**	**001**	Mar 05, 2025
AB			**EQ 20MG BASE/PACKET**	**A212651**	**003**	Mar 05, 2025
AB			**EQ 40MG BASE/PACKET**	**A212651**	**004**	Mar 05, 2025
AB		ZYDUS PHARMS	**EQ 20MG BASE/PACKET**	**A206055**	**001**	Jun 07, 2023
AB			**EQ 40MG BASE/PACKET**	**A206055**	**002**	Jun 07, 2023

NEXIUM

AB	+	ASTRAZENECA	**EQ 2.5MG BASE/PACKET**	**N021957**	**003**	Dec 15, 2011
AB	+		**EQ 5MG BASE/PACKET**	**N021957**	**004**	Dec 15, 2011
AB	+		**EQ 10MG BASE/PACKET**	**N022101**	**001**	Feb 27, 2008
AB	+		**EQ 20MG BASE/PACKET**	**N021957**	**001**	Oct 20, 2006
AB	+!		**EQ 40MG BASE/PACKET**	**N021957**	**002**	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		AJANTA PHARMA LTD	**EQ 20MG BASE;375MG**	**A213699**	**001**	Oct 06, 2022
AB			**EQ 20MG BASE;500MG**	**A213699**	**002**	Oct 06, 2022
AB		DR REDDYS	**EQ 20MG BASE;375MG**	**A204206**	**001**	Feb 18, 2020
AB	**!**		**EQ 20MG BASE;500MG**	**A204206**	**002**	Feb 18, 2020
AB		SCIEGEN PHARMS	**EQ 20MG BASE;375MG**	**A217738**	**001**	Oct 11, 2023
AB			**EQ 20MG BASE;500MG**	**A217738**	**002**	Oct 11, 2023

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A207181**	**001**	Mar 06, 2017
AP		EPIC PHARMA LLC	**EQ 40MG BASE/VIAL**	**A214046**	**001**	Jan 08, 2025
AP		GLAND	**EQ 40MG BASE/VIAL**	**A203349**	**002**	Apr 01, 2020
AP	**!**	SLATE RUN PHARMA	**EQ 40MG BASE/VIAL**	**A215732**	**001**	Feb 10, 2022
	!	GLAND	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB		DR REDDYS LABS SA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB	**!**		**2MG**	**A074921**	**002**	Jul 10, 1997
AB		NOVITIUM PHARMA	**1MG**	**A074826**	**001**	Jul 03, 1997
AB			**2MG**	**A074826**	**002**	Jul 03, 1997
AB		WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB			**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	**+!**	ALLERGAN	**0.01%**	**A086069**	**001**	Jan 31, 1984

ESTRADIOL

AB		ENCUBE	**0.01%**	**A209767**	**001**	Mar 05, 2018
AB		MYLAN	**0.01%**	**A208788**	**001**	Dec 29, 2017
AB		PADAGIS ISRAEL	**0.01%**	**A210194**	**001**	Jan 22, 2018
AB		PRASCO	**0.01%**	**A212313**	**001**	Jul 15, 2021
AB		TEVA PHARMS USA	**0.01%**	**A210488**	**001**	Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB2	**+**	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2	**+**		**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB2	**+**		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2	**+**		**0.06MG/24HR**	**N020375**	**006**	May 27, 2003
AB2	**+**		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2	**+!**		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2			**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB2			**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2			**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006
AB2			**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2			**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
AB2		ZYDUS PHARMS	**0.025MG/24HR**	**A202985**	**001**	Mar 29, 2023
AB2			**0.0375MG/24HR**	**A202985**	**002**	Mar 29, 2023
AB2			**0.05MG/24HR**	**A202985**	**003**	Mar 29, 2023
AB2			**0.06MG/24HR**	**A202985**	**004**	Mar 29, 2023
AB2			**0.075MG/24HR**	**A202985**	**005**	Mar 29, 2023
AB2			**0.1MG/24HR**	**A202985**	**006**	Mar 29, 2023
AB3		AMNEAL	**0.025MG/24HR**	**A211396**	**001**	Sep 28, 2020
AB3			**0.0375MG/24HR**	**A211396**	**002**	Sep 28, 2020
AB3			**0.05MG/24HR**	**A211396**	**003**	Sep 28, 2020
AB3			**0.075MG/24HR**	**A211396**	**004**	Sep 28, 2020
AB3			**0.1MG/24HR**	**A211396**	**005**	Sep 28, 2020
AB3		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A206685**	**001**	Aug 15, 2018
AB3			**0.0375MG/24HR**	**A206685**	**002**	Aug 15, 2018
AB3			**0.05MG/24HR**	**A206685**	**003**	Aug 15, 2018
AB3			**0.075MG/24HR**	**A206685**	**004**	Aug 15, 2018
AB3			**0.1MG/24HR**	**A206685**	**005**	Aug 15, 2018

MINIVELLE

AB3	**+**	NOVEN	**0.025MG/24HR**	**N203752**	**005**	Sep 23, 2014
AB3	**+**		**0.0375MG/24HR**	**N203752**	**001**	Oct 29, 2012
AB3	**+**		**0.05MG/24HR**	**N203752**	**003**	Oct 29, 2012

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

MINIVELLE

AB3	**+**		**0.075MG/24HR**	**N203752**	**002**	Oct 29, 2012
AB3	**+!**		**0.1MG/24HR**	**N203752**	**004**	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

AB	**+!**	VERTICAL PHARMS	**0.1% (0.25GM/PACKET)**	**N022038**	**001**	Jun 04, 2007
AB	**+!**		**0.1% (0.5GM/PACKET)**	**N022038**	**002**	Jun 04, 2007
AB	**+!**		**0.1% (1GM/PACKET)**	**N022038**	**003**	Jun 04, 2007
AB	**+!**		**0.1% (0.75GM/PACKET)**	**N022038**	**004**	Aug 17, 2018
AB	**+!**		**0.1% (1.25GM/PACKET)**	**N022038**	**005**	Dec 12, 2019

ESTRADIOL

AB		AMNEAL	**0.1% (0.25GM/PACKET)**	**A216055**	**001**	Jul 12, 2024
AB			**0.1% (0.5GM/PACKET)**	**A216055**	**002**	Jul 12, 2024
AB			**0.1% (0.75GM/PACKET)**	**A216055**	**003**	Jul 12, 2024
AB			**0.1% (1GM/PACKET)**	**A216055**	**004**	Jul 12, 2024
AB			**0.1% (1.25GM/PACKET)**	**A216055**	**005**	Jul 12, 2024
AB		CHEMO RESEARCH SL	**0.1% (0.25GM/PACKET)**	**A211783**	**001**	Aug 10, 2022
AB			**0.1% (0.5GM/PACKET)**	**A211783**	**002**	Aug 10, 2022
AB			**0.1% (1GM/PACKET)**	**A211783**	**003**	Aug 10, 2022
AB		ENCUBE	**0.1% (0.25GM/PACKET)**	**A218507**	**001**	Mar 05, 2025
AB			**0.1% (0.5GM/PACKET)**	**A218507**	**002**	Mar 05, 2025
AB			**0.1% (0.75GM/PACKET)**	**A218507**	**003**	Mar 05, 2025
AB			**0.1% (1.25GM/PACKET)**	**A218507**	**005**	Mar 05, 2025
AB			**0.1% (1GM/PACKET)**	**A218507**	**004**	Mar 05, 2025
AB		NOVITIUM PHARMA	**0.1% (0.25GM/PACKET)**	**A217610**	**001**	Aug 24, 2023
AB			**0.1% (0.5GM/PACKET)**	**A217610**	**002**	Aug 24, 2023
AB			**0.1% (0.75GM/PACKET)**	**A217610**	**003**	Aug 24, 2023
AB			**0.1% (1GM/PACKET)**	**A217610**	**004**	Aug 24, 2023
AB			**0.1% (1.25GM/PACKET)**	**A217610**	**005**	Aug 24, 2023
AB		PADAGIS ISRAEL	**0.1% (0.25GM/PACKET)**	**A216524**	**001**	Nov 14, 2023
AB			**0.1% (0.5GM/PACKET)**	**A216524**	**002**	Nov 14, 2023
AB			**0.1% (0.75GM/PACKET)**	**A216524**	**003**	Nov 14, 2023
AB			**0.1% (1GM/PACKET)**	**A216524**	**004**	Nov 14, 2023
AB			**0.1% (1.25GM/PACKET)**	**A216524**	**005**	Nov 14, 2023
AB		QUAGEN	**0.1% (0.25GM/PACKET)**	**A217863**	**001**	Jul 12, 2024
AB			**0.1% (0.5GM/PACKET)**	**A217863**	**002**	Jul 12, 2024
AB			**0.1% (0.75GM/PACKET)**	**A217863**	**003**	Jul 12, 2024
AB			**0.1% (1GM/PACKET)**	**A217863**	**004**	Jul 12, 2024
AB			**0.1% (1.25GM/PACKET)**	**A217863**	**005**	Jul 12, 2024

GEL, METERED;TRANSDERMAL

ESTRADIOL

AB		NOVITIUM PHARMA	**0.06% (1.25GM/ACTIVATION)**	**A217882**	**001**	Oct 23, 2024
AB		SOLARIS PHARMA CORP	**0.06% (1.25GM/ACTIVATION)**	**A216160**	**001**	Apr 22, 2024

ESTROGEL

AB	**+!**	ASCEND THERAPS US	**0.06% (1.25GM/ACTIVATION)**	**N021166**	**002**	Feb 09, 2004

ELESTRIN

	+!	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

INSERT;VAGINAL

ESTRADIOL

AB		TEVA PHARMS USA INC	**0.004MG**	**A214137**	**001**	Dec 08, 2025
AB			**0.01MG**	**A214137**	**002**	Dec 08, 2025

IMVEXXY

AB	**+!**	MAYNE PHARMA	**0.004MG**	**N208564**	**001**	May 29, 2018
AB	**+!**		**0.01MG**	**N208564**	**002**	May 29, 2018

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

	+!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

	+!	PADAGIS US	1.53MG/SPRAY	N022014	001	Jul 27, 2007

SYSTEM;TRANSDERMAL

ESTRADIOL

AB		ZYDUS PHARMS	**0.014MG/24HR**	**A204379**	**001**	Apr 17, 2023

MENOSTAR

AB	**+!**	BAYER HLTHCARE	**0.014MG/24HR**	**N021674**	**001**	Jun 08, 2004

ESTRADIOL

AB1		AMNEAL	**0.025MG/24HR**	**A211293**	**001**	Feb 04, 2019
AB1			**0.0375MG/24HR**	**A211293**	**002**	Feb 04, 2019
AB1			**0.05MG/24HR**	**A211293**	**003**	Feb 04, 2019
AB1			**0.075MG/24HR**	**A211293**	**004**	Feb 04, 2019

ESTRADIOL

SYSTEM;TRANSDERMAL

ESTRADIOL

AB1			**0.1MG/24HR**	**A211293**	**005**	Feb 04, 2019
AB1		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1			**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1			**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1			**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1			**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014
AB1		ZYDUS PHARMS	**0.025MG/24HR**	**A206241**	**001**	Dec 01, 2022
AB1			**0.0375MG/24HR**	**A206241**	**002**	Dec 01, 2022
AB1			**0.05MG/24HR**	**A206241**	**003**	Dec 01, 2022
AB1			**0.075MG/24HR**	**A206241**	**004**	Dec 01, 2022
AB1			**0.1MG/24HR**	**A206241**	**005**	Dec 01, 2022

VIVELLE-DOT

AB1	+	SANDOZ	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1	+		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1	+		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1	+		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1	+!		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999

TABLET;ORAL

ESTRADIOL

AB		BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB			**1MG**	**A040197**	**002**	Oct 22, 1997
AB	!		**2MG**	**A040197**	**003**	Oct 22, 1997
AB		EPIC PHARMA LLC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB			**1MG**	**A040275**	**002**	Dec 29, 1998
AB			**2MG**	**A040275**	**003**	Dec 29, 1998
AB		NOVITIUM PHARMA	**0.5MG**	**A217334**	**001**	Sep 06, 2023
AB			**1MG**	**A217334**	**002**	Sep 06, 2023
AB			**2MG**	**A217334**	**003**	Sep 06, 2023

TABLET;VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
AB		AUROBINDO PHARMA	**10MCG**	**A216550**	**001**	Aug 02, 2024
AB		GLENMARK PHARMS LTD	**10MCG**	**A210264**	**001**	Sep 14, 2018
AB		TEVA PHARMS USA	**10MCG**	**A206388**	**001**	Jul 21, 2017

VAGIFEM

AB	+!	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	+	MILLICENT PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
	+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

	!	PFIZER	5MG/ML	A085470	003	

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

AO	+!	PH HEALTH	**10MG/ML**	**N009402**	**002**	
AO	+!		**20MG/ML**	**N009402**	**004**	

ESTRADIOL VALERATE

AO		AM REGENT	**20MG/ML**	**A090920**	**001**	Jan 19, 2010
AO			**40MG/ML**	**A090920**	**002**	Jan 19, 2010
AO		HIKMA	**10MG/ML**	**A203723**	**001**	Apr 21, 2020
AO			**20MG/ML**	**A203723**	**002**	Apr 21, 2020
AO			**40MG/ML**	**A203723**	**003**	Apr 21, 2020
AO		XIROMED	**10MG/ML**	**A216656**	**001**	Apr 28, 2023
AO			**20MG/ML**	**A216656**	**002**	Apr 28, 2023
AO	!		**40MG/ML**	**A216656**	**003**	Apr 28, 2023

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

	+!	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE						
FILM, EXTENDED RELEASE;TRANSDERMAL						
COMBIPATCH						
	+	NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998
	+!		0.05MG/24HR;0.25MG/24HR	N020870	002	Aug 07, 1998
TABLET;ORAL						
ACTIVELLA						
AB	**+!**	AMNEAL	**1MG;0.5MG**	**N020907**	**001**	Nov 18, 1998
ESTRADIOL AND NORETHINDRONE ACETATE						
AB		BARR	**1MG;0.5MG**	**A079193**	**001**	May 11, 2010
AB		BRECKENRIDGE PHARM	**0.5MG;0.1MG**	**A078324**	**002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324**	**001**	Apr 17, 2008
AB		NAARI PTE	**1MG;0.5MG**	**A210233**	**001**	Feb 28, 2018
AB		NOVAST LABS	**0.5MG;0.1MG**	**A210612**	**001**	Apr 03, 2019
AB			**1MG;0.5MG**	**A210612**	**002**	Apr 03, 2019
AB		XIROMED	**0.5MG;0.1MG**	**A207261**	**001**	Feb 10, 2017
AB			**1MG;0.5MG**	**A207261**	**002**	Feb 10, 2017
AMABELZ						
BX		LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016
BX			1MG;0.5MG	A203339	002	Jun 20, 2016
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX						
TABLET;ORAL						
MYFEMBREE						
	+!	SUMITOMO PHARMA AM	1MG;0.5MG;40MG	N214846	001	May 26, 2021
ESTRADIOL; PROGESTERONE						
CAPSULE;ORAL						
BIJUVA						
	+	MAYNE PHARMA	0.5MG;100MG	N210132	002	Dec 28, 2021
	+!		1MG;100MG	N210132	001	Oct 28, 2018
ESTROGENS, CONJUGATED						
CREAM;TOPICAL, VAGINAL						
PREMARIN						
	+!	WYETH PHARMS	0.625MG/GM	N020216	001	
INJECTABLE;INJECTION						
PREMARIN						
	+!	WYETH PHARMS	25MG/VIAL	N010402	001	
TABLET;ORAL						
CONJUGATED ESTROGENS						
AB		NOVAST LABS	**0.3MG**	**A214025**	**001**	Oct 15, 2025
AB			**0.45MG**	**A214025**	**002**	Oct 15, 2025
AB			**0.625MG**	**A214025**	**003**	Oct 15, 2025
AB			**0.9MG**	**A214023**	**001**	Oct 15, 2025
AB			**1.25MG**	**A214023**	**002**	Oct 15, 2025
PREMARIN						
AB	**+**	WYETH PHARMS	**0.3MG**	**N004782**	**003**	
AB	**+**		**0.45MG**	**N004782**	**006**	Jul 16, 2003
AB	**+!**		**0.625MG**	**N004782**	**004**	
AB	**+!**		**0.9MG**	**N004782**	**005**	Jan 26, 1984
AB	**+!**		**1.25MG**	**N004782**	**001**	
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
TABLET;ORAL-28						
PREMPHASE 14/14						
	+!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995
PREMPRO						
	+!	WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003
	+!		0.45MG;1.5MG	N020527	004	Mar 12, 2003
	+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995
	+!		0.625MG;5MG	N020527	003	Jan 09, 1998
ESTROPIPATE						
TABLET;ORAL						
OGEN 5						
	+	PFIZER	6MG	A083220	004	
ESZOPICLONE						
TABLET;ORAL						
ESZOPICLONE						
AB		AUROBINDO PHARMA	**1MG**	**A208451**	**001**	Sep 15, 2016
AB			**2MG**	**A208451**	**002**	Sep 15, 2016
AB			**3MG**	**A208451**	**003**	Sep 15, 2016
AB		DR REDDYS	**1MG**	**A091024**	**001**	Apr 15, 2014

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB			**2MG**	**A091024**	**002**	Apr 15, 2014
AB			**3MG**	**A091024**	**003**	Apr 15, 2014
AB		GLENMARK PHARMS LTD	**1MG**	**A091166**	**001**	Apr 15, 2014
AB			**2MG**	**A091166**	**002**	Apr 15, 2014
AB			**3MG**	**A091166**	**003**	Apr 15, 2014
AB		HETERO LABS LTD V	**1MG**	**A205504**	**001**	Jan 04, 2024
AB			**2MG**	**A205504**	**002**	Jan 04, 2024
AB			**3MG**	**A205504**	**003**	Jan 04, 2024
AB		LUPIN LTD	**1MG**	**A091124**	**001**	Sep 13, 2011
AB			**2MG**	**A091124**	**002**	Sep 13, 2011
AB			**3MG**	**A091124**	**003**	Sep 13, 2011
AB		MACLEODS PHARMS LTD	**1MG**	**A202929**	**001**	Jan 30, 2015
AB			**2MG**	**A202929**	**002**	Jan 30, 2015
AB			**3MG**	**A202929**	**003**	Jan 30, 2015
AB		MYLAN PHARMS INC	**1MG**	**A091151**	**001**	Mar 26, 2013
AB			**2MG**	**A091151**	**002**	Mar 26, 2013
AB			**3MG**	**A091151**	**003**	Mar 26, 2013
AB		ORBION PHARMS	**1MG**	**A091113**	**001**	Jun 10, 2014
AB			**2MG**	**A091113**	**002**	Jun 10, 2014
AB			**3MG**	**A091113**	**003**	Jun 10, 2014
AB		SUN PHARM	**1MG**	**A091103**	**001**	Apr 03, 2013
AB			**2MG**	**A091103**	**002**	Apr 03, 2013
AB			**3MG**	**A091103**	**003**	Apr 03, 2013
AB		TEVA	**1MG**	**A091169**	**001**	May 23, 2011
AB			**2MG**	**A091169**	**002**	May 23, 2011
AB			**3MG**	**A091169**	**003**	May 23, 2011

LUNESTA

AB	**+**	WAYLIS THERAP	**1MG**	**N021476**	**001**	Dec 15, 2004
AB	**+**		**2MG**	**N021476**	**002**	Dec 15, 2004
AB	**+!**		**3MG**	**N021476**	**003**	Dec 15, 2004

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

+!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION;INTRAVENOUS

EXONDYS 51

+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

AP	**+!**	BAUSCH	**EQ 50MG BASE/VIAL**	**N016093**	**001**	

ETHACRYNATE SODIUM

AP		PH HEALTH	**EQ 50MG BASE/VIAL**	**A205473**	**001**	Jul 29, 2015
AP		STERIMAX	**EQ 50MG BASE/VIAL**	**A208663**	**001**	Jun 09, 2020
AP		ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A207758**	**001**	Nov 17, 2017

ETHACRYNIC ACID

TABLET;ORAL

EDECRIN

AB	**+!**	BAUSCH	**25MG**	**N016092**	**001**	

ETHACRYNIC ACID

AB		ADAPTIS	**25MG**	**A205609**	**001**	Jun 30, 2016
AB		AGNITIO	**25MG**	**A211809**	**001**	Jul 12, 2019
AB		AMNEAL PHARMS CO	**25MG**	**A208805**	**001**	May 08, 2018
AB		CHARTWELL RX	**25MG**	**A213240**	**001**	Oct 19, 2020
AB		LUPIN LTD	**25MG**	**A211719**	**001**	Sep 06, 2019
AB		SCIEGEN PHARMS	**25MG**	**A211232**	**001**	Aug 27, 2019
AB		UPSHER SMITH LABS	**25MG**	**A212417**	**001**	Feb 19, 2020

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		EPIC PHARMA LLC	**100MG**	**A075095**	**001**	Nov 30, 1999
AB			**400MG**	**A075095**	**002**	Nov 30, 1999
AB		LUPIN	**100MG**	**A078939**	**001**	Jun 17, 2009
AB			**400MG**	**A078939**	**002**	Jun 17, 2009

MYAMBUTOL

AB	**+**	KANCHAN HLTHCARE	**100MG**	**N016320**	**001**	
AB	**+!**		**400MG**	**N016320**	**003**	

ETHANOLAMINE OLEATE

INJECTABLE;INJECTION

ETHAMOLIN

	+!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		XIROMED	**0.035MG;1MG**	**A204703**	**001**	Jul 28, 2016
AB			**0.05MG;1MG**	**A204704**	**001**	Feb 09, 2016

KELNOR

AB		BARR	**0.035MG;1MG**	**A076785**	**001**	May 23, 2005

KELNOR 1/50

AB	**!**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001**	Dec 30, 1991

LO-MALMOREDE

AB		NOVAST LABS	**0.035MG;1MG**	**A209548**	**001**	Feb 11, 2019

MALMOREDE

AB		NOVAST LABS	**0.05MG;1MG**	**A209547**	**001**	Jul 25, 2018

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ELURYNG

AB		AMNEAL	**0.015MG/24HR;0.12MG/24HR**	**A210830**	**001**	Dec 11, 2019

ENILLORING

AB		XIROMED	**0.015MG/24HR;0.12MG/24HR**	**A211157**	**001**	Jun 29, 2023

ETHINYL ESTRADIOL; ETONOGESTREL

AB		TEVA PHARMS USA INC	**0.015MG/24HR;0.12MG/24HR**	**A204305**	**001**	Jan 13, 2021

HALOETTE

AB		DR REDDYS LABS SA	**0.015MG/24HR;0.12MG/24HR**	**A211328**	**001**	Aug 05, 2022

NUVARING

AB	**+!**	ORGANON USA ORGANON	**0.015MG/24HR;0.12MG/24HR**	**N021187**	**001**	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

	+!	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020

TABLET;ORAL

ASHLYNA

AB		GLENMARK PHARMS LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001**	Feb 23, 2015

DAYSEE

AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001**	Apr 10, 2013

DOLISHALE

AB		NOVAST LABS	**0.02MG;0.09MG**	**A091692**	**001**	Oct 22, 2020

ICLEVIA

AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206850**	**001**	Jun 29, 2018

INTROVALE

AB		XIROMED	**0.03MG;0.15MG**	**A079064**	**001**	Sep 27, 2010

JAIMIESS

AB		XIROMED	**0.03MG,0.01MG;0.15MG,N/A**	**A203770**	**001**	Dec 27, 2017

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**0.02MG;0.09MG**	**A202791**	**001**	Apr 09, 2015
AB			**0.03MG;0.15MG**	**A203164**	**001**	Jun 12, 2015
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB		NAARI PTE	**0.03MG;0.15MG**	**A203871**	**001**	Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001**	Dec 22, 2015
AB	**!**	WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
AB		XIROMED	**0.03MG;0.15MG**	**A200490**	**001**	Apr 21, 2015

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB		DR REDDYS LABS SA	**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
AB		LUPIN LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A091674**	**001**	Oct 26, 2011
AB		XIROMED	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**A206053**	**001**	Oct 02, 2017
AB			**0.02MG,0.1MG;0.01MG,N/A**	**A200493**	**001**	Jun 17, 2015

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB			**0.02MG,0.1MG;0.01MG,N/A**	**A205131**	**001**	Dec 14, 2017
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
	LO SIMPESSE					
AB		AUROBINDO PHARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A206852**	**001**	Apr 28, 2017
	LOSEASONIQUE					
AB		TEVA BRANDED PHARM	**0.02MG,0.1MG;0.01MG,N/A**	**N022262**	**001**	Oct 24, 2008
	QUARTETTE					
AB	**+!**	TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
	QUASENSE					
AB		WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
	SEASONALE					
AB	**+!**	TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
	SEASONIQUE					
AB	**+!**	TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
	SETLAKIN					
AB		NOVAST LABS	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014
	SIMPESSE					
AB		AUROBINDO PHARMA	**0.03MG,0.01MG;0.15MG,N/A**	**A206851**	**001**	Apr 07, 2017
	BALCOLTRA					
AB3	**+!**	AVION PHARMS	**0.02MG;0.1MG**	**N208612**	**001**	Jan 09, 2018
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB3		XIROMED	**0.02MG;0.1MG**	**A214640**	**001**	Aug 16, 2023
	MINZOYA					
AB3		LUPIN LTD	**0.02MG;0.1MG**	**A217087**	**001**	Feb 15, 2024
	TYBLUME					
	+!	EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020

TABLET;ORAL-28

	ALTAVERA					
AB		XIROMED	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
	AYUNA					
AB		AUROBINDO PHARMA	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
	ENPRESSE-28					
AB		DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001
	KURVELO					
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012
	LEVONEST					
AB		NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB		LUPIN LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A200248**	**001**	Nov 19, 2015
AB		NAARI PTE	**0.03MG;0.15MG**	**A207033**	**001**	Oct 09, 2020
AB		XIROMED	**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
	LEVORA 0.15/30-28					
AB	**!**	DR REDDYS LABS SA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993
	MARLISSA					
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
	MYZILRA					
AB		PH HEALTH	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011
	PORTIA-28					
AB		BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
	TRIVORA-28					
AB	**!**	DR REDDYS LABS SA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
	AFIRMELLE					
AB1		AUROBINDO PHARMA	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
	AVIANE-28					
AB1		DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
	FALMINA					
AB1		NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	**!**	DR REDDYS LABS SA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
AB1		HETERO LABS	**0.02MG;0.1MG**	**A212298**	**001**	Feb 13, 2023
AB1		LUPIN LTD	**0.02MG;0.1MG**	**A091425**	**001**	Jan 18, 2013
AB1		NAARI PTE	**0.02MG;0.1MG**	**A207065**	**001**	Aug 17, 2020
AB1		XIROMED	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

VIENVA

AB1		XIROMED	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015

LESSINA-28

AB2		BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	!	DR REDDYS LABS SA	**0.02MG;0.1MG**	**A077681**	**001**	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB		AMNEAL	**0.035MG/24HR;0.15MG/24HR**	**A213950**	**001**	Feb 25, 2021
AB		ZYDUS PHARMS	**0.035MG/24HR;0.15MG/24HR**	**A214594**	**001**	Sep 14, 2023

ONSURA

AB		TEVA PHARMS USA	**0.035MG/24HR;0.15MG/24HR**	**A213977**	**001**	Aug 25, 2021

XULANE

AB	!	MYLAN TECHNOLOGIES	**0.035MG/24HR;0.15MG/24HR**	**A200910**	**001**	Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

NEXESTA FE

AB		AUROBINDO PHARMA	**0.035MG;0.4MG**	**A207535**	**001**	Feb 02, 2017

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016
AB		NAARI PTE	**0.035MG;0.4MG**	**A207066**	**001**	Mar 29, 2017
AB	!	XIROMED	**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015

TABLET;ORAL-21

NORTREL 1/35-21

AB		BARR	**0.035MG;1MG**	**A072693**	**001**	Feb 28, 1992

NORTREL 7/7/7

		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET;ORAL-28

ALYACEN 1/35

AB		GLENMARK PHARMS LTD	**0.035MG;1MG**	**A091634**	**001**	Jan 19, 2012

ALYACEN 7/7/7

AB		GLENMARK PHARMS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A091636**	**001**	Jan 19, 2012

ARANELLE

AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**A076783**	**001**	Sep 29, 2004

BALZIVA-28

AB	!	BARR	**0.035MG;0.4MG**	**A076238**	**001**	Apr 22, 2004

BRIELLYN

AB		GLENMARK PHARMS LTD	**0.035MG;0.4MG**	**A090538**	**001**	Mar 22, 2011

CYONANZ

AB		AUROBINDO PHARMA	**0.035MG;0.5MG**	**A207055**	**001**	Oct 21, 2016

DASETTA 1/35

AB		NOVAST LABS LTD	**0.035MG;1MG**	**A090948**	**001**	Dec 22, 2011

DASETTA 7/7/7

AB	!	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A090946**	**001**	Dec 22, 2011

GILDAGIA

AB		PH HEALTH	**0.035MG;0.4MG**	**A078376**	**001**	Nov 06, 2012

NORETHINDRONE AND ETHINYL ESTRADIOL

AB		NAARI PTE	**0.035MG;1MG**	**A206864**	**001**	Apr 28, 2017
AB		WATSON LABS	**0.035MG;0.4MG**	**A078323**	**001**	Feb 04, 2010
AB		WATSON LABS TEVA	**0.035MG;1MG**	**A070687**	**001**	Jan 29, 1987

NORTREL 0.5/35-28

AB		BARR LABS	**0.035MG;0.5MG**	**A072695**	**001**	Feb 28, 1992

NORTREL 1/35-28

AB	!	BARR LABS	**0.035MG;1MG**	**A072696**	**001**	Feb 28, 1992

NORTREL 7/7/7

AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A075478**	**002**	Aug 30, 2002

NYLIA 1/35

AB		AUROBINDO PHARMA	**0.035MG;1MG**	**A207056**	**001**	Oct 21, 2016

NYLIA 7/7/7

AB		AUROBINDO PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A207054**	**001**	Oct 21, 2016

PHILITH

AB		NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

TRI-NORINYL 28-DAY

AB	**+!**	DR REDDYS LABS SA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984

VYFEMLA

AB		LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013

WERA

AB	**!**	NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

		WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

KAITLIB FE

AB	**!**	LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		XIROMED	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY

AB		XIROMED	**0.02MG;1MG**	**A213317**	**001**	Nov 09, 2020

MERZEE

AB		WILSHIRE PHARMS INC	**0.02MG;1MG**	**A212706**	**001**	Dec 18, 2020

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A213418**	**001**	Jul 27, 2022

TAYTULLA

AB	**+!**	APIL	**0.02MG;1MG**	**N204426**	**001**	Apr 19, 2013

TABLET;ORAL

AUROVELA 24 FE

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207504**	**001**	Jun 15, 2017

BLISOVI 24 FE

AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015

FINZALA

AB		TEVA PHARMS USA INC	**0.02MG;1MG**	**A210087**	**001**	Apr 07, 2020

FYAVOLV

AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015

GILDESS 24 FE

AB		PH HEALTH	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014

HAILEY 24 FE

AB	**!**	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A204847**	**001**	Nov 17, 2017

LARIN 24 FE

AB		NOVAST LABS	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015

LERIBANE

AB		NOVAST LABS	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016

MIBELAS 24 FE

AB		LUPIN	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	**!**	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK PHARMS LTD	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		BARR LABS	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014
AB	**!**	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A210369**	**001**	Dec 26, 2017
AB		XIROMED	**0.02MG;1MG**	**A209609**	**001**	Jul 16, 2018

LO LOESTRIN FE

	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET;ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA	**0.03MG;1.5MG**	**A207581**	**001**	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207506**	**001**	Jun 16, 2017

HAILEY 1.5/30

AB		GLENMARK SPECLT	**0.03MG;1.5MG**	**A209297**	**001**	Jun 05, 2018

JUNEL 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003

JUNEL 1/20

AB		BARR LABS	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB		XIROMED	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB			**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB		AUROBINDO PHARMA	**0.03MG;1.5MG**	**A207580**	**001**	Jun 15, 2017

AUROVELA FE 1/20

AB		AUROBINDO PHARMA	**0.02MG;1MG**	**A207505**	**001**	Jun 16, 2017

BLISOVI FE 1.5/30

AB		LUPIN LTD	**0.03MG;1.5MG**	**A201585**	**001**	Nov 18, 2015

BLISOVI FE 1/20

AB		LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015

CHABELINA FE

AB	**!**	NOVAST LABS	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A202962**	**001**	Apr 15, 2020

HAILEY FE 1.5/30

AB		GLENMARK SPECLT	**0.03MG;1.5MG**	**A209031**	**001**	Jun 05, 2018

HAILEY FE 1/20

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206597**	**001**	Nov 21, 2017

JUNEL FE 1.5/30

AB	**!**	BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003

JUNEL FE 1/20

AB		BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003

LARIN FE 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013

LARIN FE 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		XIROMED	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB			**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A205069**	**001**	Jun 22, 2018
AB			**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015

TRI-LEGEST FE

AB		BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

FEMLYV

	+!	MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB		XIROMED	**0.035MG;0.25MG**	**A090794**	**001**	Jan 30, 2013

MILI

AB		AUROBINDO PHARMA LTD	**0.035MG;0.25MG**	**A205449**	**001**	Jul 07, 2016

MONO-LINYAH

AB		NOVAST LABS LTD	**0.035MG;0.25MG**	**A090523**	**001**	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	**!**	GLENMARK PHARMS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200494**	**001**	Jun 17, 2011
AB			**0.035MG;0.25MG**	**A200538**	**001**	Apr 05, 2012
AB	**!**	GLENMARK SPECLT	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A204057**	**001**	Feb 23, 2016
AB		LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205588**	**001**	Apr 26, 2016
AB			**0.035MG;0.25MG**	**A205630**	**001**	Oct 27, 2016
AB		LUPIN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A200541**	**001**	Jun 25, 2012
AB		NAARI PTE	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200383**	**001**	Apr 07, 2015
AB			**0.035MG;0.25MG**	**A200384**	**001**	Apr 07, 2015
AB			**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A203873**	**001**	May 12, 2016

PREVIFEM

AB		PH HEALTH	**0.035MG;0.25MG**	**A076334**	**001**	Jan 09, 2004

SPRINTEC

AB	**!**	BARR	**0.035MG;0.25MG**	**A075804**	**001**	Sep 25, 2002

TRI LO SPRINTEC

AB		BARR LABS INC	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A076784**	**001**	Jun 29, 2009

TRI-ESTARYLLA

AB		XIROMED	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090793**	**001**	Jan 30, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

TRI-LINYAH

AB		NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090524**	**001**	May 30, 2012

TRI-LO-ESTARYLLA

AB		XIROMED	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A091232**	**001**	Jun 29, 2015

TRI-LO-LINYAH

AB		NOVAST LABS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A090541**	**001**	Sep 02, 2022

TRI-LO-MILI

AB		AUROBINDO PHARMA	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A205762**	**001**	Nov 04, 2016

TRI-MILI

AB		AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205441**	**001**	Jul 06, 2016

TRI-SPRINTEC

AB		BARR	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A075808**	**001**	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

CRYSELLE

AB		DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001

TABLET;ORAL-28

CRYSELLE

AB	**!**	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001

ELINEST

AB		NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012

LOW-OGESTREL-28

AB		DR REDDYS LABS SA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999

TURQOZ

AB		LUPIN LTD	**0.03MG;0.3MG**	**A202980**	**001**	Jul 31, 2023

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

	+!	MAYNE PHARMA	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

	+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		BIONPHARMA	**250MG**	**A040430**	**001**	Oct 28, 2002
AB		EPIC PHARMA LLC	**250MG**	**A040686**	**001**	May 28, 2008
AB		HERITAGE PHARMS INC	**250MG**	**A200892**	**001**	Sep 25, 2012
AB		ONESOURCE SPECIALTY	**250MG**	**A211928**	**001**	Feb 19, 2019
AB		PURACAP PHARM LLC	**250MG**	**A210654**	**001**	Mar 16, 2020

ZARONTIN

AB	**+!**	PARKE DAVIS	**250MG**	**N012380**	**001**	

SYRUP;ORAL

ETHOSUXIMIDE

AA		CHARTWELL RX	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA		PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000

ZARONTIN

AA	**+!**	PARKE-DAVIS	**250MG/5ML**	**A080258**	**001**	

ETODOLAC

CAPSULE;ORAL

ETODOLAC

AB		ANI PHARMS	**200MG**	**A075126**	**001**	Sep 16, 1999
AB			**300MG**	**A075126**	**002**	Sep 16, 1999
AB		APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB			**300MG**	**A075419**	**002**	Jul 28, 2000
AB		IPCA LABS LTD	**200MG**	**A205448**	**001**	Aug 01, 2024
AB			**300MG**	**A205448**	**002**	Aug 01, 2024
AB		TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**!**		**300MG**	**A075078**	**002**	Apr 30, 1998

ETODOLAC

TABLET;ORAL

ETODOLAC

AB		ADAPTIS	**400MG**	**A209888**	**001**	Nov 30, 2018
AB			**500MG**	**A209888**	**002**	Nov 30, 2018
AB		AMNEAL PHARMS CO	**400MG**	**A208834**	**001**	Jun 07, 2018
AB			**500MG**	**A208834**	**002**	Jun 07, 2018
AB		APOTEX	**400MG**	**A076004**	**001**	Dec 03, 2002
AB			**500MG**	**A076004**	**002**	Dec 03, 2002
AB		IPCA LABS LTD	**400MG**	**A204729**	**001**	May 01, 2024
AB			**500MG**	**A204729**	**002**	May 01, 2024
AB		PANGEA	**400MG**	**A074903**	**001**	Apr 11, 1997
AB			**500MG**	**A074903**	**002**	Apr 19, 1999
AB		PHARMACO	**400MG**	**A210704**	**001**	Dec 16, 2020
AB			**500MG**	**A210704**	**002**	Dec 16, 2020
AB		TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**!**		**500MG**	**A075074**	**002**	Apr 25, 2000

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB		TARO	**400MG**	**A076174**	**001**	Mar 13, 2003
AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	**!**		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		UNICHEM	**400MG**	**A212263**	**001**	Nov 24, 2020
AB			**500MG**	**A212263**	**002**	Nov 24, 2020
AB			**600MG**	**A212263**	**003**	Nov 24, 2020
AB		ZYDUS PHARMS	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014

ETOMIDATE

INJECTABLE;INJECTION

AMIDATE

AP	**+!**	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982

ETOMIDATE

AP		CAPLIN	**2MG/ML**	**A215028**	**001**	Dec 18, 2020
AP		EUGIA PHARMA	**2MG/ML**	**A206126**	**001**	Feb 24, 2017
AP		GLAND	**2MG/ML**	**A209058**	**001**	Apr 18, 2017
AP		HIKMA	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP			**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		MYLAN LABS LTD	**2MG/ML**	**A201044**	**001**	Feb 07, 2017
AP		ZYDUS PHARMS	**2MG/ML**	**A202360**	**001**	Jul 18, 2014

ETONOGESTREL

IMPLANT;IMPLANTATION

NEXPLANON

	+!	ORGANON	68MG/IMPLANT	N021529	002	May 13, 2011

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

	!	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE;INJECTION

ETOPOSIDE

AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	**!**	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		HIKMA	**20MG/ML**	**A074290**	**001**	Jul 17, 1995
AP		MEITHEAL	**20MG/ML**	**A074529**	**001**	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE;INJECTION

ETOPOPHOS PRESERVATIVE FREE

	+!	CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRASIMOD ARGININE

TABLET;ORAL

VELSIPITY

	+!	PFIZER	EQ 2MG BASE	N216956	001	Oct 12, 2023

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

AB		AMNEAL	**100MG**	**A214196**	**002**	Jun 14, 2021
AB			**200MG**	**A214196**	**003**	Jun 14, 2021
AB		BIONPHARMA	**100MG**	**A219152**	**001**	Oct 02, 2025
AB			**200MG**	**A219152**	**002**	Oct 02, 2025
AB		CARNEGIE	**100MG**	**A215402**	**001**	Apr 13, 2022
AB			**200MG**	**A215402**	**002**	Apr 13, 2022

INTELENCE

AB	**+**	JANSSEN R AND D	**100MG**	**N022187**	**001**	Jan 18, 2008
AB	**+!**		**200MG**	**N022187**	**002**	Dec 22, 2010
	+		25MG	N022187	003	Mar 26, 2012

ETRIPAMIL

SPRAY;NASAL

CARDAMYST

	+!	MILESTONE PHARMS USA	70MG	N218571	001	Dec 12, 2025

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB	**+**	NOVARTIS	**2.5MG**	**N022334**	**003**	Jul 09, 2010
AB	**+!**		**5MG**	**N022334**	**001**	Mar 30, 2009
AB	**+**		**7.5MG**	**N022334**	**004**	Mar 30, 2012
AB	**+**		**10MG**	**N022334**	**002**	Mar 30, 2009

EVEROLIMUS

AB		ALKEM LABS LTD	**0.25MG**	**A214138**	**001**	Nov 26, 2021
AB			**0.5MG**	**A214138**	**002**	Nov 26, 2021
AB			**0.75MG**	**A214138**	**003**	Nov 26, 2021
AB			**1MG**	**A214138**	**004**	Nov 26, 2021
AB		BIOCON PHARMA	**0.25MG**	**A216140**	**001**	Apr 09, 2025
AB			**0.5MG**	**A216140**	**002**	Apr 09, 2025
AB			**0.75MG**	**A216140**	**003**	Apr 09, 2025
AB			**1MG**	**A216140**	**004**	Apr 09, 2025
AB			**2.5MG**	**A214182**	**001**	Feb 11, 2021
AB			**5MG**	**A214182**	**002**	Feb 11, 2021
AB			**7.5MG**	**A214182**	**003**	Feb 11, 2021
AB			**10MG**	**A214182**	**004**	Feb 11, 2021
AB		BRECKENRIDGE	**0.25MG**	**A205432**	**001**	May 20, 2021
AB			**0.5MG**	**A205432**	**002**	May 20, 2021
AB			**0.75MG**	**A205432**	**003**	May 20, 2021
AB			**1MG**	**A205432**	**004**	Sep 03, 2025
AB			**2.5MG**	**A205426**	**001**	Mar 05, 2021
AB			**5MG**	**A205426**	**002**	Mar 05, 2021
AB			**7.5MG**	**A205426**	**003**	Mar 05, 2021
AB			**10MG**	**A205426**	**004**	Mar 05, 2021
AB		HIKMA	**0.25MG**	**A206133**	**001**	Apr 12, 2018
AB			**0.5MG**	**A206133**	**002**	Apr 12, 2018
AB			**0.75MG**	**A206133**	**003**	Apr 12, 2018
AB			**1MG**	**A206133**	**004**	Nov 18, 2021
AB			**2.5MG**	**A207486**	**001**	Jun 08, 2020
AB			**5MG**	**A207486**	**002**	Jun 08, 2020
AB			**7.5MG**	**A207486**	**003**	Jun 08, 2020
AB			**10MG**	**A207486**	**004**	Nov 23, 2021
AB		NOVUGEN	**2.5MG**	**A219955**	**001**	Oct 30, 2025
AB			**5MG**	**A219955**	**002**	Oct 30, 2025
AB			**7.5MG**	**A219955**	**003**	Oct 30, 2025
AB			**10MG**	**A219955**	**004**	Oct 30, 2025
AB		PH HEALTH	**0.25MG**	**A205775**	**001**	Oct 18, 2021
AB			**0.5MG**	**A205775**	**002**	Oct 18, 2021
AB			**0.75MG**	**A205775**	**003**	Oct 18, 2021
AB			**1MG**	**A205775**	**004**	Oct 18, 2021
AB			**2.5MG**	**A207934**	**001**	Dec 09, 2019
AB			**5MG**	**A207934**	**002**	Dec 09, 2019
AB			**7.5MG**	**A207934**	**003**	Dec 09, 2019
AB			**10MG**	**A207934**	**004**	Dec 09, 2020
AB		TEVA PHARMS USA	**2.5MG**	**A210050**	**001**	Dec 09, 2019
AB			**5MG**	**A210050**	**002**	Dec 09, 2019
AB			**7.5MG**	**A210050**	**003**	Dec 09, 2019
AB			**10MG**	**A210050**	**004**	Dec 09, 2019

EVEROLIMUS

TABLET;ORAL

ZORTRESS

AB	+	NOVARTIS	**0.25MG**	**N021560**	**001**	Apr 20, 2010
AB	+		**0.5MG**	**N021560**	**002**	Apr 20, 2010
AB	+		**0.75MG**	**N021560**	**003**	Apr 20, 2010
AB	+!		**1MG**	**N021560**	**004**	Aug 10, 2018

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

AB	+	NOVARTIS PHARM	**2MG**	**N203985**	**001**	Aug 29, 2012
AB	+		**3MG**	**N203985**	**002**	Aug 29, 2012
AB	+!		**5MG**	**N203985**	**003**	Aug 29, 2012

EVEROLIMUS

AB		AMNEAL	**2MG**	**A218863**	**001**	Jan 10, 2025
AB			**3MG**	**A218863**	**002**	Jan 10, 2025
AB			**5MG**	**A218863**	**003**	Jan 10, 2025
AB		NATCO	**2MG**	**A217640**	**001**	Jan 28, 2025
AB			**3MG**	**A217640**	**002**	Jan 28, 2025
AB			**5MG**	**A217640**	**003**	Jan 28, 2025

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	+!	PFIZER	**25MG**	**N020753**	**001**	Oct 21, 1999

EXEMESTANE

AB		BRECKENRIDGE	**25MG**	**A211031**	**001**	Feb 21, 2019
AB		CIPLA	**25MG**	**A210323**	**001**	Apr 27, 2018
AB		EUGIA PHARMA	**25MG**	**A216454**	**001**	May 20, 2022
AB		QILU	**25MG**	**A213547**	**001**	Apr 13, 2020
AB		RISING	**25MG**	**A203315**	**001**	Mar 10, 2017
AB		UPSHER SMITH LABS	**25MG**	**A209208**	**001**	Jul 26, 2017
AB		ZYDUS PHARMS	**25MG**	**A202602**	**001**	Oct 03, 2018

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

EXENATIDE SYNTHETIC

	!	AMNEAL	300MCG/1.2ML (250MCG/ML)	A206697	001	Nov 19, 2024
	!		600MCG/2.4ML (250MCG/ML)	A206697	002	Nov 19, 2024

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	**10MG**	**A211550**	**001**	Oct 26, 2018
AB		ALKEM LABS LTD	**10MG**	**A209234**	**001**	Dec 21, 2017
AB		AMNEAL PHARMS CO	**10MG**	**A208803**	**001**	Jun 12, 2017
AB		AUROBINDO PHARMA	**10MG**	**A209838**	**001**	Aug 25, 2017
AB		GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
AB		HETERO LABS LTD III	**10MG**	**A210859**	**001**	Jul 26, 2022
AB		OHM LABS INC	**10MG**	**A207311**	**001**	Jun 12, 2017
AB		ORIENT PHARMA	**10MG**	**A215693**	**001**	Sep 13, 2022
AB		SANDOZ	**10MG**	**A203931**	**001**	Jun 12, 2017
AB		SCIEGEN PHARMS	**10MG**	**A210673**	**001**	Oct 23, 2020
AB		WATSON LABS INC	**10MG**	**A200831**	**001**	Jun 12, 2017
AB		ZYDUS PHARMS	**10MG**	**A204331**	**001**	Jun 12, 2017

ZETIA

AB	+!	ORGANON	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	**10MG;10MG**	**A209222**	**001**	Dec 22, 2017
AB			**10MG;20MG**	**A209222**	**002**	Dec 22, 2017
AB			**10MG;40MG**	**A209222**	**003**	Dec 22, 2017
AB			**10MG;80MG**	**A209222**	**004**	Dec 22, 2017
AB		AUROBINDO PHARMA USA	**10MG;10MG**	**A200082**	**001**	Dec 17, 2020
AB			**10MG;20MG**	**A200082**	**002**	Dec 17, 2020
AB			**10MG;40MG**	**A200082**	**003**	Dec 17, 2020
AB			**10MG;80MG**	**A200082**	**004**	Dec 17, 2020
AB		DR REDDYS LABS SA	**10MG;10MG**	**A200909**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A200909**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A200909**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A200909**	**004**	Apr 26, 2017
AB		GLENMARK PHARMS LTD	**10MG;10MG**	**A208699**	**001**	Jun 27, 2019
AB			**10MG;20MG**	**A208699**	**002**	Jun 27, 2019

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB			**10MG;40MG**	**A208699**	**003**	Jun 27, 2019
AB			**10MG;80MG**	**A208699**	**004**	Jun 27, 2019
AB		WATSON LABS INC	**10MG;10MG**	**A202968**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A202968**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A202968**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A202968**	**004**	Apr 26, 2017

VYTORIN

AB	+	ORGANON	**10MG;10MG**	**N021687**	**001**	Jul 23, 2004
AB	+		**10MG;20MG**	**N021687**	**002**	Jul 23, 2004
AB	+		**10MG;40MG**	**N021687**	**003**	Jul 23, 2004
AB	+!		**10MG;80MG**	**N021687**	**004**	Jul 23, 2004

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB			**250MG**	**A091480**	**002**	Jul 22, 2011
AB			**500MG**	**A091480**	**003**	Jul 22, 2011
AB		AUROBINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB			**250MG**	**A091114**	**002**	Mar 21, 2011
AB			**500MG**	**A091114**	**003**	Mar 21, 2011
AB		HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB			**250MG**	**A202438**	**002**	Sep 10, 2014
AB			**500MG**	**A202438**	**003**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB			**250MG**	**A201022**	**002**	Jan 12, 2012
AB			**500MG**	**A201022**	**003**	Jan 12, 2012
AB		TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB			**250MG**	**A077487**	**002**	Aug 24, 2007
AB	!		**500MG**	**A077487**	**003**	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		AJANTA PHARMA LTD	**40MG/5ML**	**A217529**	**001**	Sep 18, 2023
AB		ALKEM LABS LTD	**40MG/5ML**	**A216400**	**001**	May 15, 2023
AB		AMNEAL	**40MG/5ML**	**A216427**	**001**	Aug 04, 2022
AB		ANNORA PHARMA	**40MG/5ML**	**A217330**	**001**	Aug 17, 2023
AB		AUROBINDO PHARMA LTD	**40MG/5ML**	**A219091**	**001**	Jul 09, 2025
AB		EPIC PHARMA LLC	**40MG/5ML**	**A218344**	**001**	Oct 16, 2024
AB		LANNETT CO INC	**40MG/5ML**	**A217982**	**001**	Jun 02, 2025
AB		LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		MICRO LABS	**40MG/5ML**	**A217842**	**001**	Sep 14, 2023
AB		MSN	**40MG/5ML**	**A219863**	**001**	Jul 24, 2025
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012
AB		NOVITIUM PHARMA	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB	!		**40MG/5ML**	**A215043**	**001**	Apr 20, 2021
AB		PHARMOBEDIENT	**40MG/5ML**	**A217137**	**001**	Jul 07, 2023
AB		SOMERSET THERAPS LLC	**40MG/5ML**	**A217655**	**001**	Jun 16, 2023
AB		UNICHEM	**40MG/5ML**	**A217605**	**001**	Jan 16, 2024

INJECTABLE;INJECTION

FAMOTIDINE

AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP	!	HIKMA	**10MG/ML**	**A075488**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008
AP		SAGENT	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP	!	HIKMA	**10MG/ML**	**A075486**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008
AP		SAGENT	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

FAMOTIDINE

SOLUTION;INTRAVENOUS

FAMOTIDINE

	+!	SAGENT	20MG/5ML (4MG/ML)	N219935	001	Jul 16, 2025
	+!		40MG/10ML (4MG/ML)	N219935	002	Jul 16, 2025
	+!		200MG/50ML (4MG/ML)	N219935	003	Jul 16, 2025

TABLET;ORAL

FAMOTIDINE

AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		ALKEM LABS LTD	**20MG**	**A215630**	**001**	Jan 07, 2022
AB			**20MG**	**A217375**	**001**	Apr 24, 2023
AB			**40MG**	**A215630**	**002**	Jan 07, 2022
AB			**40MG**	**A217375**	**002**	Apr 24, 2023
AB		ANNORA PHARMA	**20MG**	**A215767**	**001**	Nov 04, 2021
AB			**40MG**	**A215767**	**002**	Nov 04, 2021
AB		ASCENT PHARMS INC	**20MG**	**A215689**	**001**	Oct 15, 2021
AB			**40MG**	**A215689**	**002**	Oct 15, 2021
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB	!		**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001
AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		CHARTWELL RX	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001
AB		CONTRACT PHARMACAL	**20MG**	**A217669**	**001**	Dec 20, 2023
AB			**40MG**	**A217669**	**002**	Dec 20, 2023
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		MANKIND PHARMA	**20MG**	**A075302**	**001**	Apr 16, 2001
AB			**40MG**	**A075302**	**002**	Apr 16, 2001
AB		MSN	**20MG**	**A217400**	**001**	Aug 06, 2024
AB			**40MG**	**A217400**	**002**	Aug 06, 2024
AB		REGCON HOLDINGS	**20MG**	**A218631**	**001**	Mar 25, 2025
AB			**40MG**	**A218631**	**002**	Mar 25, 2025
AB		RISING	**20MG**	**A075704**	**001**	Apr 16, 2001
AB			**20MG**	**A218181**	**001**	Dec 22, 2023
AB			**40MG**	**A075704**	**002**	Apr 16, 2001
AB			**40MG**	**A218181**	**002**	Dec 22, 2023
AB		ZYDUS PHARMS	**20MG**	**A216441**	**001**	Jun 03, 2022
AB			**40MG**	**A216441**	**002**	Jun 03, 2022

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB	!	ALKEM LABS LTD	**26.6MG;800MG**	**A211890**	**001**	Aug 03, 2021
AB		ASCENT PHARMS INC	**26.6MG;800MG**	**A216814**	**001**	Mar 15, 2023
AB		PH HEALTH	**26.6MG;800MG**	**A203658**	**001**	Mar 22, 2024
AB		ZYDUS PHARMS	**26.6MG;800MG**	**A218684**	**001**	Feb 20, 2025

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		ALEMBIC	**40MG**	**A205421**	**001**	Jul 01, 2019
AB			**80MG**	**A205421**	**002**	Jul 01, 2019
AB		ALKEM LABS LTD	**40MG**	**A212924**	**001**	Dec 07, 2021
AB			**80MG**	**A212924**	**002**	Dec 07, 2021
AB		AUROBINDO PHARMA LTD	**40MG**	**A210741**	**001**	Oct 25, 2023
AB			**80MG**	**A210741**	**002**	Oct 25, 2023
AB		DR REDDYS	**40MG**	**A205374**	**001**	Oct 22, 2020
AB			**80MG**	**A205374**	**002**	Oct 22, 2020
AB		HIKMA	**40MG**	**A205414**	**001**	Oct 15, 2019
AB			**80MG**	**A205414**	**002**	Oct 15, 2019
AB		MACLEODS PHARMS LTD	**40MG**	**A207293**	**001**	Sep 28, 2023
AB			**80MG**	**A207293**	**002**	Sep 28, 2023
AB		MSN	**40MG**	**A210461**	**001**	Dec 30, 2019
AB			**80MG**	**A210461**	**002**	Dec 30, 2019
AB		PRINSTON INC	**40MG**	**A206266**	**001**	Mar 28, 2022
AB			**80MG**	**A206266**	**002**	Mar 28, 2022
AB		REGCON HOLDINGS	**40MG**	**A210292**	**001**	Dec 30, 2019

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB			**80MG**	**A210292**	**002**	Dec 30, 2019
AB		SUN PHARM	**40MG**	**A205467**	**001**	Jul 01, 2019
AB			**80MG**	**A205467**	**002**	Jul 01, 2019
AB		SUNSHINE	**40MG**	**A213069**	**001**	Jun 02, 2020
AB			**80MG**	**A213069**	**002**	Jun 02, 2020
AB		ZYDUS LIFESCIENCES	**40MG**	**A205443**	**001**	Jan 09, 2023
AB			**80MG**	**A205443**	**002**	Jan 09, 2023

ULORIC

AB	**+**	TAKEDA PHARMS USA	**40MG**	**N021856**	**001**	Feb 13, 2009
AB	**+!**		**80MG**	**N021856**	**002**	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

	+!	BRISTOL-MYERS	EQ 100MG BASE	N212327	001	Aug 16, 2019

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
AB	**!**	NOVITIUM PHARMA	**600MG/5ML**	**A211333**	**001**	May 31, 2019
AB		TARO	**600MG/5ML**	**A206314**	**001**	Jun 16, 2017

TABLET;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011
AB			**600MG**	**A201680**	**002**	Sep 13, 2011
AB		ANI PHARMS	**400MG**	**A202284**	**001**	Nov 04, 2015
AB			**600MG**	**A202284**	**002**	Nov 04, 2015
AB		TARO	**400MG**	**A207093**	**001**	Apr 20, 2017
AB			**600MG**	**A207093**	**002**	Apr 20, 2017
AB		ZYDUS LIFESCIENCES	**400MG**	**A208970**	**001**	May 30, 2017
AB			**600MG**	**A208970**	**002**	May 30, 2017

FELBATOL

AB	**+**	MYLAN SPECIALITY LP	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	**+!**		**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A203417**	**001**	Jan 17, 2013
AB			**5MG**	**A203417**	**002**	Jan 17, 2013
AB			**10MG**	**A203417**	**003**	Jan 17, 2013
AB		GLENMARK PHARMS LTD	**2.5MG**	**A090365**	**001**	Dec 17, 2010
AB			**5MG**	**A090365**	**002**	Dec 17, 2010
AB			**10MG**	**A090365**	**003**	Dec 17, 2010
AB		HERITAGE	**2.5MG**	**A201964**	**001**	Nov 08, 2013
AB			**5MG**	**A201964**	**002**	Nov 08, 2013
AB			**10MG**	**A201964**	**003**	Nov 08, 2013
AB		ORBION PHARMS	**2.5MG**	**A203032**	**001**	May 21, 2015
AB			**5MG**	**A203032**	**002**	May 21, 2015
AB			**10MG**	**A203032**	**003**	May 21, 2015
AB		PH HEALTH	**2.5MG**	**A200815**	**001**	Oct 28, 2011
AB			**5MG**	**A200815**	**002**	Oct 28, 2011
AB			**10MG**	**A200815**	**003**	Oct 28, 2011
AB		SUN PHARM INDS LTD	**2.5MG**	**A091200**	**001**	Dec 13, 2013
AB			**5MG**	**A091200**	**002**	Dec 13, 2013
AB			**10MG**	**A091200**	**003**	Dec 13, 2013
AB		TORRENT PHARMS LTD	**2.5MG**	**A202170**	**001**	Nov 28, 2011
AB			**5MG**	**A202170**	**002**	Nov 28, 2011
AB	**!**		**10MG**	**A202170**	**003**	Nov 28, 2011
AB		YILING	**2.5MG**	**A210847**	**001**	Oct 26, 2018
AB			**5MG**	**A210847**	**002**	Oct 26, 2018
AB			**10MG**	**A210847**	**003**	Oct 26, 2018
AB		YUNG SHIN PHARM	**2.5MG**	**A204800**	**001**	Apr 29, 2019
AB			**5MG**	**A204800**	**002**	Apr 29, 2019
AB			**10MG**	**A204800**	**003**	Apr 29, 2019

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

+!	UCB INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

AB	**+**	LUPIN	**43MG**	**N021695**	**001**	Nov 30, 2004
AB	**+!**		**130MG**	**N021695**	**003**	Nov 30, 2004

FENOFIBRATE (MICRONIZED)

AB		AJANTA PHARMA LTD	**67MG**	**A210705**	**001**	Sep 10, 2018
AB			**134MG**	**A210705**	**002**	Sep 10, 2018
AB	**!**		**200MG**	**A210705**	**003**	Sep 10, 2018
AB		ALEMBIC	**67MG**	**A213842**	**001**	Oct 19, 2020
AB			**134MG**	**A213842**	**002**	Oct 19, 2020
AB			**200MG**	**A213842**	**003**	Oct 19, 2020
AB		ANI PHARMS	**67MG**	**A209504**	**001**	Apr 30, 2018
AB			**134MG**	**A209504**	**002**	Apr 30, 2018
AB			**200MG**	**A209504**	**003**	Apr 30, 2018
AB		APOTEX	**43MG**	**A202252**	**001**	Jul 26, 2013
AB			**130MG**	**A202252**	**002**	Jul 26, 2013
AB		AUROBINDO PHARMA LTD	**67MG**	**A212232**	**001**	Sep 20, 2021
AB			**134MG**	**A212232**	**002**	Sep 20, 2021
AB			**200MG**	**A212232**	**003**	Sep 20, 2021
AB		CHARTWELL	**67MG**	**A211407**	**001**	Jan 31, 2024
AB			**134MG**	**A211407**	**002**	Jan 31, 2024
AB			**200MG**	**A211407**	**003**	Jan 31, 2024
AB		CHARTWELL RX	**43MG**	**A090859**	**001**	Mar 01, 2012
AB			**130MG**	**A090859**	**002**	Mar 01, 2012
AB		GLENMARK PHARMS LTD	**67MG**	**A205566**	**001**	Apr 07, 2017
AB			**134MG**	**A205566**	**002**	Apr 07, 2017
AB			**200MG**	**A205566**	**003**	Apr 07, 2017
AB		REYOUNG	**67MG**	**A207805**	**001**	Nov 16, 2017
AB			**134MG**	**A207805**	**002**	Nov 16, 2017
AB			**200MG**	**A207805**	**003**	Nov 16, 2017
AB		RHODES PHARMS	**67MG**	**A075753**	**001**	Sep 03, 2002
AB			**134MG**	**A075753**	**002**	Apr 09, 2002
AB			**200MG**	**A075753**	**003**	Apr 09, 2002
AB		TORRENT	**67MG**	**A210782**	**001**	Jun 26, 2018
AB			**134MG**	**A210782**	**002**	Jun 26, 2018
AB			**200MG**	**A210782**	**003**	Jun 26, 2018

LIPOFEN

+	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
+!		150MG	N021612	003	Jan 11, 2006

TABLET;ORAL

FENOFIBRATE

AB		AJANTA PHARMA LTD	**54MG**	**A210138**	**001**	Jul 23, 2018
AB			**160MG**	**A210138**	**002**	Jul 23, 2018
AB		ALEMBIC	**48MG**	**A210476**	**001**	Aug 09, 2019
AB			**145MG**	**A210476**	**002**	Aug 09, 2019
AB		AMNEAL	**48MG**	**A209951**	**001**	Feb 09, 2018
AB			**54MG**	**A209950**	**001**	Mar 19, 2018
AB			**145MG**	**A209951**	**002**	Feb 09, 2018
AB			**160MG**	**A209950**	**002**	Mar 19, 2018
AB		AUROBINDO PHARMA	**48MG**	**A205118**	**001**	May 05, 2016
AB			**54MG**	**A216798**	**001**	Sep 27, 2022
AB	**!**		**145MG**	**A205118**	**002**	May 05, 2016
AB			**160MG**	**A216798**	**002**	Sep 27, 2022
AB		BOSTAL	**48MG**	**A208476**	**001**	Feb 10, 2021
AB			**54MG**	**A207803**	**001**	Dec 19, 2017
AB			**145MG**	**A208476**	**002**	Feb 10, 2021
AB			**160MG**	**A207803**	**002**	Dec 19, 2017
AB		CHARTWELL RX	**54MG**	**A209660**	**001**	Feb 11, 2019
AB			**160MG**	**A209660**	**002**	Feb 11, 2019
AB		CIPLA	**48MG**	**A208709**	**001**	Dec 15, 2016
AB			**145MG**	**A208709**	**002**	Dec 15, 2016
AB		CREEKWOOD PHARMS	**40MG**	**A217732**	**001**	Sep 07, 2023
AB			**120MG**	**A217732**	**002**	Sep 07, 2023
AB		DR REDDYS	**54MG**	**A210670**	**001**	Sep 06, 2019
AB			**160MG**	**A210670**	**002**	Sep 06, 2019
AB		HETERO LABS LTD III	**48MG**	**A204598**	**001**	Jul 12, 2016

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

AB			**145MG**	**A204598**	**002**	Jul 12, 2016
AB		IMPAX LABS	**54MG**	**A076509**	**001**	Mar 26, 2008
AB	!		**160MG**	**A076509**	**002**	Mar 26, 2008
AB		LUPIN LTD	**48MG**	**A090856**	**001**	Dec 23, 2011
AB			**54MG**	**A204019**	**001**	Aug 17, 2015
AB			**145MG**	**A090856**	**002**	Dec 23, 2011
AB			**160MG**	**A204019**	**002**	Aug 17, 2015
AB		MACLEODS PHARMS LTD	**48MG**	**A210248**	**001**	Nov 13, 2024
AB			**145MG**	**A210248**	**002**	Nov 13, 2024
AB		MANKIND PHARMA	**54MG**	**A213864**	**001**	Jun 12, 2020
AB			**160MG**	**A213864**	**002**	Jun 12, 2020
AB		MYLAN PHARMS INC	**40MG**	**A204475**	**001**	Jun 23, 2016
AB			**48MG**	**A202856**	**001**	Dec 07, 2012
AB	!		**120MG**	**A204475**	**002**	Jun 23, 2016
AB			**145MG**	**A202856**	**002**	Dec 07, 2012
AB		PRINSTON INC	**48MG**	**A211080**	**001**	Aug 28, 2018
AB			**145MG**	**A211080**	**002**	Aug 28, 2018
AB		RHODES PHARMS	**54MG**	**A076433**	**001**	May 13, 2005
AB			**160MG**	**A076433**	**002**	May 13, 2005
AB		RISING	**48MG**	**A211122**	**001**	Mar 18, 2020
AB			**54MG**	**A210606**	**001**	Aug 17, 2018
AB			**145MG**	**A211122**	**002**	Mar 18, 2020
AB			**160MG**	**A210606**	**002**	Aug 17, 2018
AB		YICHANG HUMANWELL	**54MG**	**A218548**	**001**	Apr 24, 2024
AB			**160MG**	**A218548**	**002**	Apr 24, 2024
		SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

	RISING	EQ 200MG BASE	A214475	002	Jul 26, 2024
		EQ 300MG BASE	A214475	003	Jul 26, 2024
!		EQ 400MG BASE	A214475	001	Jul 18, 2022

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB		DIFGEN PHARMS	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB		KINDEVA	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB		SPECGX LLC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011

FENTANYL-12

AB		DIFGEN PHARMS	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015
AB		KINDEVA	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
AB		SPECGX LLC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015

FENTANYL-25

AB		DIFGEN PHARMS	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB		KINDEVA	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB	!	SPECGX LLC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011

FENTANYL-37

AB		DIFGEN PHARMS	**37.5MCG/HR**	**A077449**	**006**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**37.5MCG/HR**	**A076258**	**006**	Dec 29, 2014
AB		SPECGX LLC	**37.5MCG/HR**	**A077154**	**006**	Jan 14, 2020

FENTANYL-50

AB		DIFGEN PHARMS	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB		KINDEVA	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB		SPECGX LLC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011

FENTANYL-62

AB		DIFGEN PHARMS	**62.5MCG/HR**	**A077449**	**007**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**62.5MCG/HR**	**A076258**	**007**	Dec 29, 2014
AB		SPECGX LLC	**62.5MCG/HR**	**A077154**	**007**	Jan 14, 2020

FENTANYL-75

AB		DIFGEN PHARMS	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB		KINDEVA	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB		MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB		SPECGX LLC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011

FENTANYL
FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-87

AB		DIFGEN PHARMS	**87.5MCG/HR**	**A077449**	**008**	Dec 06, 2017
AB		MYLAN TECHNOLOGIES	**87.5MCG/HR**	**A076258**	**008**	Dec 29, 2014

FENTANYL CITRATE
INJECTABLE;INJECTION
FENTANYL CITRATE

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A212086**	**001**	Sep 01, 2020
AP	**+!**	HIKMA	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A210762**	**001**	May 03, 2019

SUBLIMAZE PRESERVATIVE FREE

AP	**+!**	RISING	**EQ 0.05MG BASE/ML**	**N016619**	**001**	

FENTANYL CITRATE

	+!	HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023

FERRIC CARBOXYMALTOSE
SOLUTION;INTRAVENOUS
INJECTAFER

	+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013
	+!		100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022
	+!		500MG IRON/10ML (50MG IRON/ML)	N203565	002	Oct 08, 2020
	+!		1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021

FERRIC CITRATE
TABLET;ORAL
AURYXIA

	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014

FERRIC DERISOMALTOSE
SOLUTION;INTRAVENOUS
MONOFERRIC

	+!	PHARMACOSMOS	1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020

FERRIC HEXACYANOFERRATE(II)
CAPSULE;ORAL
RADIOGARDASE (PRUSSIAN BLUE)

	+!	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERRIC MALTOL
CAPSULE;ORAL
ACCRUFER

	+!	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019

FERRIC OXYHYDROXIDE
TABLET, CHEWABLE;ORAL
VELPHORO

	+!	VIFOR FRESENIUS	EQ 500MG IRON	N205109	001	Nov 27, 2013

FERUMOXYTOL
SOLUTION;INTRAVENOUS
FERAHEME

AB	**+!**	COVIS	**EQ 510MG IRON/17ML (EQ 30MG IRON/ML)**	**N022180**	**001**	Jun 30, 2009

FERUMOXYTOL

AB		SANDOZ	**EQ 510MG IRON/17ML (EQ 30MG IRON/ML)**	**A206604**	**001**	Jan 15, 2021

FERABRIGHT

	+!	COVIS	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025
	+!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB		ALEMBIC	**4MG**	**A204973**	**001**	Jan 04, 2023
AB			**8MG**	**A204973**	**002**	Jan 04, 2023
AB		ALKEM LABS LTD	**4MG**	**A204827**	**001**	Dec 10, 2015
AB			**8MG**	**A204827**	**002**	Dec 10, 2015
AB		AMNEAL PHARMS NY	**4MG**	**A205002**	**001**	Jan 04, 2023
AB			**8MG**	**A205002**	**002**	Jan 04, 2023
AB		AUROBINDO PHARMA	**4MG**	**A205007**	**001**	Feb 17, 2017
AB			**8MG**	**A205007**	**002**	Feb 17, 2017
AB		DR REDDYS	**4MG**	**A204975**	**001**	Aug 13, 2019
AB			**8MG**	**A204975**	**002**	Aug 13, 2019
AB		HETERO LABS LTD V	**4MG**	**A204792**	**001**	Jan 09, 2024
AB			**8MG**	**A204792**	**002**	Jan 09, 2024

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB		ZYDUS PHARMS	**4MG**	**A204946**	**001**	Oct 03, 2017
AB			**8MG**	**A204946**	**002**	Oct 03, 2017

TOVIAZ

AB	+	PFIZER	**4MG**	**N022030**	**001**	Oct 31, 2008
AB	+!		**8MG**	**N022030**	**002**	Oct 31, 2008

FEXINIDAZOLE

TABLET;ORAL

FEXINIDAZOLE

	+!	SANOFI	600MG	N214429	001	Jul 16, 2021

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		RISING	**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005

FEZOLINETANT

TABLET;ORAL

VEOZAH

	+!	ASTELLAS	45MG	N216578	001	May 12, 2023

FIDAXOMICIN

FOR SUSPENSION;ORAL

DIFICID

	+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020

TABLET;ORAL

DIFICID

AB	**+!**	CUBIST PHARMS LLC	**200MG**	**N201699**	**001**	May 27, 2011

FIDAXOMICIN

AB		ACTAVIS LABS FL	**200MG**	**A208443**	**001**	Jan 16, 2024

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB		ACCORD HLTHCARE	**1MG**	**A091643**	**001**	Nov 05, 2013
AB			**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017
AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		SUN PHARM	**1MG**	**A090508**	**001**	Jul 01, 2013
AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009

PROPECIA

AB	**+!**	ORGANON	**1MG**	**N020788**	**001**	Dec 19, 1997

PROSCAR

AB	**+!**	ORGANON	**5MG**	**N020180**	**001**	Jun 19, 1992

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

FINASTERIDE AND TADALAFIL

		NOVITIUM PHARMA	5MG;5MG	A218499	001	Mar 19, 2025

FINERENONE

TABLET;ORAL

KERENDIA

	+	BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021
	+!		20MG	N215341	002	Jul 09, 2021
	+		40MG	N215341	003	Jul 11, 2025

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A207991**	**001**	Oct 28, 2020
AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A208004**	**001**	Dec 30, 2020
AB		APOTEX	**EQ 0.5MG BASE**	**A207993**	**001**	Dec 18, 2020
AB		AUROBINDO PHARMA LTD	**EQ 0.5MG BASE**	**A207983**	**001**	Feb 28, 2024
AB		BIOCON LTD	**EQ 0.5MG BASE**	**A207979**	**001**	Dec 04, 2019
AB		BIONPHARMA	**EQ 0.5MG BASE**	**A210252**	**001**	May 24, 2023
AB		DR REDDYS	**EQ 0.5MG BASE**	**A208000**	**001**	Mar 05, 2021
AB		EZRA VENTURES	**EQ 0.5MG BASE**	**A207945**	**001**	Dec 06, 2023
AB		GLENMARK PHARMS LTD	**EQ 0.5MG BASE**	**A207985**	**001**	Jun 18, 2020
AB		HEC PHARM CO LTD	**EQ 0.5MG BASE**	**A207939**	**001**	Nov 10, 2021
AB		HETERO LABS LTD V	**EQ 0.5MG BASE**	**A207933**	**001**	May 18, 2020
AB		PRINSTON INC	**EQ 0.5MG BASE**	**A208003**	**001**	Sep 07, 2022
AB		TEVA PHARMS USA	**EQ 0.5MG BASE**	**A208008**	**001**	Jul 02, 2020
AB		ZYDUS PHARMS	**EQ 0.5MG BASE**	**A207994**	**001**	Oct 14, 2020

GILENYA

AB	**+!**	NOVARTIS	**EQ 0.5MG BASE**	**N022527**	**001**	Sep 21, 2010
	+		EQ 0.25MG BASE	N022527	002	May 11, 2018

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENSO ODT

	+	CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021
	+!		EQ 0.5MG BASE	N214962	002	Dec 09, 2022

FISH OIL TRIGLYCERIDES

EMULSION;INTRAVENOUS

OMEGAVEN

	+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001	Jul 27, 2018
	+!		10GM/100ML (0.1GM/ML)	N210589	002	Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

	+!	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003	Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (1000ML)	N207648	004	Aug 10, 2018

FITUSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

QFITLIA

	+!	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025
	+!		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835**	**001**	Nov 30, 2005
AB	**!**	PADAGIS US	**100MG**	**A076831**	**001**	Dec 16, 2004

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442**	**001**	Jul 31, 2001
AB			**100MG**	**A075442**	**002**	Jul 31, 2001
AB			**150MG**	**A075442**	**003**	Jul 31, 2001
AB		ANI PHARMS	**50MG**	**A075882**	**001**	Oct 28, 2002
AB			**100MG**	**A075882**	**002**	Oct 28, 2002
AB			**150MG**	**A075882**	**003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821**	**001**	Nov 03, 2017
AB			**100MG**	**A202821**	**002**	Nov 03, 2017

FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE

AB			**150MG**	**A202821**	**003**	Nov 03, 2017
AB		HIKMA	**50MG**	**A076278**	**001**	Jan 14, 2003
AB			**100MG**	**A076278**	**002**	Jan 14, 2003
AB	**!**		**150MG**	**A076278**	**003**	Jan 14, 2003
AB		REGCON HOLDINGS	**50MG**	**A210683**	**001**	Sep 16, 2020
AB			**100MG**	**A210683**	**002**	Sep 16, 2020
AB			**150MG**	**A210683**	**003**	Sep 16, 2020
AB		SUN PHARM INDS LTD	**50MG**	**A076421**	**001**	Mar 28, 2003
AB			**100MG**	**A076421**	**002**	Mar 28, 2003
AB			**150MG**	**A076421**	**003**	Mar 28, 2003
AB		YICHANG HUMANWELL	**50MG**	**A215599**	**001**	Sep 08, 2022
AB			**100MG**	**A215599**	**002**	Sep 08, 2022
AB			**150MG**	**A215599**	**003**	Sep 08, 2022

FLIBANSERIN
TABLET;ORAL
ADDYI

	+!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015

FLORBETABEN F-18
SOLUTION;INTRAVENOUS
NEURACEQ

	+!	LIFE MOLECULAR	1.4-135mCi/ML	N204677	001	Mar 19, 2014

FLORBETAPIR F-18
SOLUTION;INTRAVENOUS
AMYVID

	+!	AVID RADIOPHARMS INC	10-100ML (13.5-51mCi/ML)	N202008	004	Oct 13, 2023
	+!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012

FLORTAUCIPIR F-18
SOLUTION;INTRAVENOUS
TAUVID

	+!	AVID RADIOPHARMS INC	50ML (8.1-100mCi/ML)	N212123	003	Jul 01, 2022
	+!		100ML (8.1-100mCi/ML)	N212123	004	Jul 01, 2022

FLOTUFOLASTAT F-18 GALLIUM
SOLUTION;INTRAVENOUS
POSLUMA

	+!	BLUE EARTH	25ML (8-158mCi/ML)	N216023	001	May 25, 2023

FLOXURIDINE
INJECTABLE;INJECTION
FLOXURIDINE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837**	**001**	Feb 22, 2001
AP	**!**	HIKMA	**500MG/VIAL**	**A075387**	**001**	Apr 16, 2000

FLUCICLOVINE F-18
SOLUTION;INTRAVENOUS
AXUMIN

	+!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016

FLUCONAZOLE
FOR SUSPENSION;ORAL
DIFLUCAN

AB	**+**	PFIZER	**50MG/5ML**	**N020090**	**001**	Dec 23, 1993
AB	**+!**		**200MG/5ML**	**N020090**	**002**	Dec 23, 1993

FLUCONAZOLE

AB		AUROBINDO PHARMA	**50MG/5ML**	**A079150**	**001**	Sep 18, 2009
AB			**200MG/5ML**	**A079150**	**002**	Sep 18, 2009
AB		ZHEJIANG POLY PHARM	**200MG/5ML**	**A215738**	**001**	Sep 21, 2023

INJECTABLE;INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002**	Jul 29, 2004
AP		HIKMA	**200MG/100ML (2MG/ML)**	**A076087**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001**	Aug 23, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002**	Jul 29, 2004
AP		HIKMA	**200MG/100ML (2MG/ML)**	**A078107**	**001**	Jul 30, 2008

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP			**400MG/200ML (2MG/ML)**	**A078107**	**002**	Jul 30, 2008
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001**	Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002**	Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002**	Jul 29, 2004
AP	!	INFORLIFE	**200MG/100ML (2MG/ML)**	**A079104**	**001**	Jul 30, 2009
AP	!		**400MG/200ML (2MG/ML)**	**A079104**	**002**	Jul 30, 2009
AP		WOODWARD	**200MG/100ML (2MG/ML)**	**A077909**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002**	May 26, 2010

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		HIKMA	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET;ORAL

DIFLUCAN

AB	+	PFIZER	**50MG**	**N019949**	**001**	Jan 29, 1990
AB	+		**100MG**	**N019949**	**002**	Jan 29, 1990
AB	+		**150MG**	**N019949**	**004**	Jun 30, 1994
AB	+!		**200MG**	**N019949**	**003**	Jan 29, 1990

FLUCONAZOLE

AB		ANI PHARMS	**50MG**	**A078423**	**001**	Mar 07, 2011
AB			**100MG**	**A078423**	**002**	Mar 07, 2011
AB			**150MG**	**A078423**	**003**	Mar 07, 2011
AB			**200MG**	**A078423**	**004**	Mar 07, 2011
AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001**	Oct 07, 2008
AB			**100MG**	**A077731**	**002**	Oct 07, 2008
AB			**150MG**	**A077731**	**003**	Oct 07, 2008
AB			**200MG**	**A077731**	**004**	Oct 07, 2008
AB		CHARTWELL	**50MG**	**A076665**	**001**	Jul 29, 2004
AB			**100MG**	**A076665**	**002**	Jul 29, 2004
AB			**150MG**	**A076665**	**003**	Jul 29, 2004
AB			**200MG**	**A076665**	**004**	Jul 29, 2004
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001**	Jul 29, 2004
AB			**100MG**	**A076658**	**002**	Jul 29, 2004
AB			**150MG**	**A076658**	**003**	Jul 29, 2004
AB			**200MG**	**A076658**	**004**	Jul 29, 2004
AB		FDC LTD	**50MG**	**A218692**	**001**	Jan 08, 2026
AB			**100MG**	**A218692**	**002**	Jan 08, 2026
AB			**150MG**	**A218692**	**003**	Jan 08, 2026
AB			**200MG**	**A218692**	**004**	Jan 08, 2026
AB		GLENMARK PHARMS LTD	**50MG**	**A077253**	**001**	Jan 25, 2006
AB			**100MG**	**A077253**	**002**	Jan 25, 2006
AB			**150MG**	**A077253**	**003**	Jan 25, 2006
AB			**200MG**	**A077253**	**004**	Jan 25, 2006
AB		THINQ PHARM-CRO PVT	**50MG**	**A076957**	**001**	Sep 28, 2005
AB			**100MG**	**A076957**	**002**	Sep 28, 2005
AB			**150MG**	**A076957**	**004**	Feb 27, 2017
AB			**200MG**	**A076957**	**003**	Sep 28, 2005
AB		ZYDUS PHARMS	**50MG**	**A208963**	**001**	Feb 16, 2017
AB			**100MG**	**A208963**	**002**	Feb 16, 2017
AB			**150MG**	**A208963**	**003**	Feb 16, 2017
AB			**200MG**	**A208963**	**004**	Feb 16, 2017

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	+	BAUSCH	**250MG**	**N017001**	**001**	
AB	+!		**500MG**	**N017001**	**002**	

FLUCYTOSINE

AB		AUROBINDO PHARMA LTD	**250MG**	**A213665**	**001**	May 01, 2020
AB			**500MG**	**A213665**	**002**	May 01, 2020
AB		LAURUS	**250MG**	**A218005**	**001**	Jul 23, 2025
AB			**500MG**	**A218005**	**002**	Jul 23, 2025
AB		NOVEL LABS INC	**250MG**	**A204652**	**001**	Jul 07, 2017
AB			**500MG**	**A204652**	**002**	Jul 07, 2017
AB		SIGMAPHARM LABS LLC	**250MG**	**A201566**	**001**	Jun 28, 2011
AB			**500MG**	**A201566**	**002**	Jun 28, 2011
AB		STRIDES PHARMA	**250MG**	**A212632**	**001**	Apr 17, 2020
AB			**500MG**	**A212632**	**002**	Apr 17, 2020

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	!	ACTAVIS TOTOWA	**50MG/VIAL**	**A078610**	**001**	Feb 11, 2009
AP		FRESENIUS KABI USA	**50MG/VIAL**	**A078544**	**001**	Oct 15, 2007
AP		HIKMA	**50MG/VIAL**	**A076349**	**001**	Aug 28, 2003
AP1		AREVA PHARMS	**50MG/2ML (25MG/ML)**	**A090724**	**001**	Sep 27, 2010
AP1		FRESENIUS KABI USA	**50MG/2ML (25MG/ML)**	**A078393**	**001**	Oct 15, 2007
AP1		SAGENT PHARMS INC	**50MG/2ML (25MG/ML)**	**A076661**	**001**	Apr 28, 2004

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	**20-300mCi/ML**	**A203778**	**001**	Oct 30, 2015
AP		BAMF	**20-400mCi/ML**	**A216125**	**001**	Mar 11, 2025
AP		BIOMEDCL RES FDN	**20-300mCi/ML**	**A203710**	**001**	May 01, 2015
AP			**20-300mCi/ML**	**A203837**	**001**	May 01, 2015
AP		BRIGHAM WOMENS	**20-300mCi/ML**	**A203816**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**20-300mCi/ML**	**A203603**	**001**	Nov 13, 2015
AP	!		**20-500mCi/ML**	**A203603**	**002**	Sep 27, 2018
AP		CHILDRENS HOSP MI	**20-300mCi/ML**	**A204385**	**001**	Oct 29, 2014
AP	+!	FEINSTEIN	**20-400mCi/ML**	**N021870**	**002**	Nov 21, 2008
AP		ISOLOGIC INNOVATIVE	**20-300mCi/ML**	**A204525**	**001**	Oct 29, 2014
AP		JUBILANT DRAXIMAGE	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015
AP		KETTERING MEDCTR	**4-40mCi/ML**	**A204759**	**001**	Oct 27, 2015
AP		KREITCHMAN PET CTR	**10-100mCi/ML**	**A203942**	**001**	Apr 11, 2016
AP		MA GENERAL HOSP	**20-300mCi/ML**	**A204333**	**001**	Sep 25, 2014
AP		MCPRF	**20-240mCi/ML**	**A203612**	**001**	Aug 05, 2013
AP		METHODIST HOSP RES	**20-300mCi/ML**	**A203904**	**001**	Apr 23, 2015
AP		MIPS CRF	**20-300mCi/ML**	**A204472**	**001**	Sep 11, 2015
AP		NCM USA BRONX LLC	**20-300mCi/ML**	**A204512**	**001**	Jan 07, 2015
AP	!	PETNET	**20-200mCi/ML**	**A079086**	**001**	Feb 25, 2011
AP		PHARMALOGIC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		PHARMALOGIC HLDGS	**20-200mCi/ML**	**A203664**	**001**	Feb 04, 2014
AP		PRECISION NUCLEAR	**20-500mCi/ML**	**A204546**	**001**	Apr 07, 2015
AP	!	QUEEN HAMAMATSU PET	**10-100mCi/ML**	**A203771**	**001**	Aug 31, 2015
AP		SOFIE	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
AP			**20-300mCi/ML**	**A204463**	**001**	Oct 21, 2014
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	!	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV SOUTHERN CA	**20-300mCi/ML**	**A209341**	**001**	Dec 16, 2020
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
		NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB	!	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002
AB		NOVITIUM PHARMA	**0.1MG**	**A215279**	**001**	May 31, 2022
AB		ZYDUS LIFESCIENCES	**0.1MG**	**A219251**	**001**	Oct 16, 2024

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		BAXTER HLTHCARE CORP	**0.5MG/5ML (0.1MG/ML)**	**A076755**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076755**	**001**	Oct 12, 2004
AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP	!		**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		RISING	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012
AP		SANDOZ	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	**!**	BAUSCH	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		RICONPHARMA LLC	**0.025MG/SPRAY**	**A207802**	**001**	Jun 16, 2022
AB		RISING	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT			**0.025%**	**A210747**	**001**	Nov 05, 2018
AT		FOUGERA PHARMS INC	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	**+!**		**0.025%**	**N012787**	**002**	
AT	**+!**		**0.025%**	**N012787**	**005**	

IMPLANT;INTRAVITREAL

ILUVIEN

+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

YUTIQ

+!	ALIMERA SCIENCES INC	0.18MG	N210331	001	Oct 12, 2018

OIL;TOPICAL

DERMA-SMOOTHE/FS

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	**+!**		**0.01%**	**N019452**	**002**	Nov 09, 2005

FLUOCINOLONE ACETONIDE

AT		NOVEL LABS INC	**0.01%**	**A207345**	**001**	Jul 31, 2023
AT			**0.01%**	**A207347**	**001**	Aug 07, 2023
AT		PADAGIS ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		QUAGEN	**0.01%**	**A212760**	**001**	Apr 02, 2021
AT			**0.01%**	**A212761**	**001**	Apr 02, 2021
AT		RISING	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		SUN PHARMA CANADA	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016

OIL/DROPS;OTIC

DERMOTIC

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLAC

AT		ANDA REPOSITORY	**0.01%**	**A210736**	**001**	Apr 11, 2018

FLUOCINOLONE ACETONIDE

AT		PADAGIS ISRAEL	**0.01%**	**A202849**	**001**	Jul 17, 2017
AT		QUAGEN	**0.01%**	**A212762**	**001**	Apr 02, 2021
AT		RISING	**0.01%**	**A203378**	**001**	Apr 25, 2016
AT		TP ANDA HOLDINGS	**0.01%**	**A213264**	**001**	Feb 05, 2021

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		FOUGERA PHARMS INC	**0.025%**	**A088168**	**001**	Dec 16, 1982

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		CHARTWELL RX	**0.01%**	**A209596**	**001**	Dec 26, 2017
AT		ENCUBE ETHICALS	**0.01%**	**A209913**	**001**	Feb 13, 2019
AT		FOUGERA PHARMS INC	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		LUPIN	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		SUN PHARMA CANADA	**0.01%**	**A089124**	**001**	Sep 11, 1985

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+!	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS INC	**0.1%**	**A200735**	**001**	Jul 14, 2014
AB		SUN PHARMA CANADA	**0.1%**	**A200734**	**001**	Jul 14, 2014
AB		ZYDUS LIFESCIENCES	**0.1%**	**A208989**	**001**	Feb 10, 2020

VANOS

AB	**+!**	BAUSCH	**0.1%**	**N021758**	**001**	Feb 11, 2005

FLUOCINONIDE

AB1	**!**	AMNEAL	**0.05%**	**A210554**	**001**	Aug 21, 2018
AB1		COSETTE	**0.05%**	**A073085**	**001**	Feb 14, 1992
AB1		ENCUBE	**0.05%**	**A211410**	**001**	Oct 16, 2018
AB1		FOUGERA PHARMS INC	**0.05%**	**A073030**	**001**	Oct 17, 1994
AB1		SUN PHARMA CANADA	**0.05%**	**A071500**	**001**	Jun 10, 1987
AB1		TEVA	**0.05%**	**A072488**	**001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		COSETTE	**0.05%**	**A074204**	**001**	Jun 13, 1995
AB2		FOUGERA PHARMS	**0.05%**	**A076586**	**001**	Jun 23, 2004
AB2	**!**	TARO	**0.05%**	**A072494**	**001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490**	**001**	Feb 07, 1989

GEL;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS INC	**0.05%**	**A072933**	**001**	Dec 30, 1994
AB		PADAGIS US	**0.05%**	**A209030**	**001**	Jun 19, 2018
AB	**!**	SUN PHARMA CANADA	**0.05%**	**A074935**	**001**	Jul 29, 1997

OINTMENT;TOPICAL

FLUOCINONIDE

AB		CHARTWELL RX	**0.05%**	**A207538**	**001**	Jul 31, 2017
AB		FOUGERA PHARMS	**0.05%**	**A074905**	**001**	Aug 26, 1997
AB	**!**	SUN PHARMA CANADA	**0.05%**	**A075008**	**001**	Jun 30, 1999
AB		TEVA	**0.05%**	**A073481**	**001**	Dec 27, 1991
AB		XIROMED	**0.05%**	**A212976**	**001**	Nov 26, 2019

SOLUTION;TOPICAL

FLUOCINONIDE

AT		CHARTWELL RX	**0.05%**	**A209118**	**001**	Apr 23, 2018
AT		ENCUBE ETHICALS	**0.05%**	**A209699**	**001**	Nov 29, 2018
AT		FOUGERA PHARMS INC	**0.05%**	**A072934**	**001**	Feb 27, 1995
AT		MACLEODS PHARMS LTD	**0.05%**	**A209283**	**001**	Apr 23, 2018
AT		NOVEL LABS INC	**0.05%**	**A206003**	**001**	Jul 21, 2017
AT		QUAGEN	**0.05%**	**A216389**	**001**	Feb 26, 2025
AT	**!**	SUN PHARMA CANADA	**0.05%**	**A074799**	**001**	Dec 31, 1996
AT		ZYDUS PHARMS	**0.05%**	**A208948**	**001**	Jul 17, 2018

FLUORESCEIN SODIUM

INJECTABLE;INTRAVENOUS

AK-FLUOR 10%

AP	**+!**	LONG GROVE PHARMS	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186**	**001**	Aug 08, 2008

FLUORESCEIN SODIUM

AP		NEXUS	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**A215709**	**001**	Sep 25, 2023

FLUORESCITE

AP	**+!**	ALCON LABS INC	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980**	**001**	Mar 28, 2006

FLUORESCEIN SODIUM

	!	NEXUS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023

FLUORODOPA F-18							
SOLUTION;INTRAVENOUS							
FLUORODOPA F18							
	+!	FEINSTEIN	1-40mCi/ML	N200655	001	Oct 10, 2019	
FLUOROESTRADIOL F-18							
SOLUTION;INTRAVENOUS							
CERIANNA							
	+!	GE HEALTHCARE	50ML (4-100mCi/ML)	N212155	001	May 20, 2020	
FLUOROMETHOLONE							
SUSPENSION/DROPS;OPHTHALMIC							
FLUOROMETHOLONE							
AB		AMNEAL	**0.1%**	**A216348**	**001**	Jan 09, 2024	
FML							
AB	**+!**	ABBVIE	**0.1%**	**N016851**	**002**	Jul 28, 1982	
FML FORTE							
	+!	ABBVIE	0.25%	N019216	001	Apr 23, 1986	
FLUOROMETHOLONE ACETATE							
SUSPENSION/DROPS;OPHTHALMIC							
FLAREX							
	+!	HARROW EYE	0.1%	N019079	001	Feb 11, 1986	
FLUOROURACIL							
CREAM;TOPICAL							
EFUDEX							
AB	**+!**	EXTROVIS	**5%**	**N016831**	**003**		
FLUOROURACIL							
AB		ACCORD HLTHCARE	**5%**	**A214845**	**001**	Oct 07, 2021	
AB		DR REDDYS LABS SA	**5%**	**A077524**	**001**	Apr 11, 2008	
AB		ENCUBE	**5%**	**A216942**	**001**	Feb 12, 2025	
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010	
CARAC							
	+!	EXTROVIS	0.5%	N020985	001	Oct 27, 2000	
TOLAK							
	+!	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	
INJECTABLE;INJECTION							
FLUOROURACIL							
AP		ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007	
AP			**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007	
AP			**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007	
AP	**!**	ALEMBIC	**2.5GM/50ML (50MG/ML)**	**A217295**	**001**	Mar 03, 2023	
AP			**5GM/100ML (50MG/ML)**	**A217676**	**001**	Oct 18, 2023	
AP		EUGIA PHARMA SPECLTS	**500MG/10ML (50MG/ML)**	**A202668**	**001**	Jul 17, 2012	
AP			**1GM/20ML (50MG/ML)**	**A202668**	**002**	Jul 17, 2012	
AP			**2.5GM/50ML (50MG/ML)**	**A202669**	**001**	Jul 17, 2012	
AP			**5GM/100ML (50MG/ML)**	**A202669**	**002**	Jul 17, 2012	
AP	**!**	FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998	
AP	**!**		**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998	
AP			**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998	
AP	**!**		**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998	
AP		GLAND	**500MG/10ML (50MG/ML)**	**A210123**	**001**	Oct 27, 2017	
AP			**1GM/20ML (50MG/ML)**	**A210123**	**002**	Oct 27, 2017	
AP			**2.5GM/50ML (50MG/ML)**	**A210124**	**001**	Dec 26, 2017	
AP			**5GM/100ML (50MG/ML)**	**A210124**	**002**	Dec 26, 2017	
AP		KINDOS	**2.5GM/50ML (50MG/ML)**	**A216494**	**001**	Sep 24, 2024	
AP			**5GM/100ML (50MG/ML)**	**A215699**	**001**	Feb 06, 2025	
AP		SAGENT PHARMS INC	**500MG/10ML (50MG/ML)**	**A203608**	**001**	May 11, 2017	
AP			**1GM/20ML (50MG/ML)**	**A203608**	**002**	May 11, 2017	
AP			**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016	
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016	
SOLUTION;TOPICAL							
EFUDEX							
AT	**+!**	EXTROVIS	**2%**	**N016831**	**001**		
FLUOROURACIL							
AT		ENCUBE	**5%**	**A215612**	**001**	Nov 02, 2023	
AT		TARO	**2%**	**A076526**	**001**	Nov 05, 2003	
AT	**!**		**5%**	**A076526**	**002**	Nov 05, 2003	

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		APNAR PHARMA LP	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		CADILA PHARMS LTD	**EQ 40MG BASE**	**A206993**	**003**	May 23, 2019
AB		HERITAGE	**EQ 40MG BASE**	**A201336**	**003**	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MARKSANS PHARMA	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		MICRO LABS	**EQ 40MG BASE**	**A216232**	**003**	Mar 29, 2022
AB		SCIEGEN PHARMS	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		STRIDES PHARMA INTL	**EQ 40MG BASE**	**A076922**	**003**	Dec 16, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002
PROZAC						
AB	**+!**	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999
FLUOXETINE HYDROCHLORIDE						
AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		APNAR PHARMA LP	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		CADILA PHARMS LTD	**EQ 10MG BASE**	**A206993**	**001**	May 23, 2019
AB1			**EQ 20MG BASE**	**A206993**	**002**	May 23, 2019
AB1		HERITAGE	**EQ 10MG BASE**	**A201336**	**001**	Oct 01, 2012
AB1			**EQ 20MG BASE**	**A201336**	**002**	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MARKSANS PHARMA	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		MICRO LABS	**EQ 10MG BASE**	**A216232**	**001**	Mar 29, 2022
AB1			**EQ 20MG BASE**	**A216232**	**002**	Mar 29, 2022
AB1		SCIEGEN PHARMS	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		STRIDES PHARMA INTL	**EQ 10MG BASE**	**A076922**	**001**	Dec 16, 2004
AB1			**EQ 20MG BASE**	**A076922**	**002**	Dec 16, 2004
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002
PROZAC						
AB1	**+**	ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1	**+**		**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE						
	!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE						
AA		AUROBINDO PHARMA	**EQ 20MG BASE/5ML**	**A079209**	**001**	Mar 20, 2009
AA		LANNETT CO INC	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA		NOVITIUM PHARMA	**EQ 20MG BASE/5ML**	**A216448**	**001**	Nov 09, 2022
AA	**!**	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		SCIEGEN PHARMS	**EQ 20MG BASE/5ML**	**A075525**	**001**	Jun 27, 2002
AA		SOLIS PHARMS	**EQ 20MG BASE/5ML**	**A075292**	**001**	Feb 07, 2002
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001
AA		UPSHER SMITH LABS	**EQ 20MG BASE/5ML**	**A216953**	**001**	Nov 15, 2022

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE						
AB		ALEMBIC	**EQ 10MG BASE**	**A208698**	**001**	Apr 05, 2017
AB			**EQ 20MG BASE**	**A208698**	**002**	Apr 05, 2017
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A213286**	**001**	Apr 08, 2020
AB	**!**		**EQ 20MG BASE**	**A213286**	**002**	Apr 08, 2020
AB	**!**		**EQ 60MG BASE**	**A213265**	**001**	Jun 10, 2020
AB		DR REDDYS	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB			**EQ 20MG BASE**	**A076006**	**002**	Apr 23, 2018
AB			**EQ 60MG BASE**	**A211721**	**001**	Jan 25, 2019
AB		INVENTIA HLTHCARE	**EQ 60MG BASE**	**A209695**	**001**	Nov 20, 2017

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		LUPIN LTD	**EQ 10MG BASE**	**A211653**	**001**	Apr 15, 2019
AB			**EQ 20MG BASE**	**A211653**	**002**	Apr 15, 2019
AB			**EQ 60MG BASE**	**A211632**	**001**	Feb 08, 2019
AB		PH HEALTH	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB			**EQ 60MG BASE**	**A209419**	**001**	Nov 16, 2017
AB		SCIEGEN PHARMS	**EQ 10MG BASE**	**A210935**	**001**	Mar 20, 2019
AB			**EQ 20MG BASE**	**A210935**	**002**	Mar 20, 2019
AB			**EQ 60MG BASE**	**A211282**	**001**	Jan 10, 2019
AB		SOMERSET THERAPS LLC	**EQ 60MG BASE**	**A211477**	**001**	Nov 21, 2018
AB		STRIDES PHARMA	**EQ 10MG BASE**	**A212684**	**001**	Apr 05, 2024
AB			**EQ 20MG BASE**	**A212684**	**002**	Apr 05, 2024
AB			**EQ 60MG BASE**	**A212683**	**001**	Sep 13, 2024
		TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016
	!		EQ 20MG BASE	A206937	002	Oct 21, 2016

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB		PH HEALTH	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB		TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB	**!**		**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO		EUGIA PHARMA	**25MG/ML**	**A207739**	**001**	Oct 17, 2017
AO	**!**	FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO		GLAND	**25MG/ML**	**A215509**	**001**	Mar 30, 2023
AO		HIKMA	**25MG/ML**	**A074531**	**001**	Aug 30, 1996
AO		MSN	**25MG/ML**	**A215365**	**001**	Nov 02, 2023
AO		MYLAN LABS LTD	**25MG/ML**	**A075918**	**001**	Aug 17, 2001
AO		PH HEALTH	**25MG/ML**	**A203732**	**001**	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996

INJECTABLE;INJECTION

FLUPHENAZINE HYDROCHLORIDE

!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**1MG**	**A217410**	**001**	Jan 05, 2023
AB			**2.5MG**	**A217410**	**002**	Jan 05, 2023
AB			**5MG**	**A217410**	**003**	Jan 05, 2023
AB			**10MG**	**A217410**	**004**	Jan 05, 2023
AB		ALEMBIC	**1MG**	**A218173**	**001**	Jul 23, 2024
AB			**2.5MG**	**A218173**	**002**	Jul 23, 2024
AB			**5MG**	**A218173**	**003**	Jul 23, 2024
AB			**10MG**	**A218173**	**004**	Jul 23, 2024
AB		AMNEAL	**1MG**	**A213647**	**001**	Jul 09, 2020
AB			**2.5MG**	**A213647**	**002**	Jul 09, 2020
AB			**5MG**	**A213647**	**003**	Jul 09, 2020
AB			**10MG**	**A213647**	**004**	Jul 09, 2020

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**1MG**	**A218055**	**001**	Aug 18, 2023
AB			**2.5MG**	**A218055**	**002**	Aug 18, 2023
AB			**5MG**	**A218055**	**003**	Aug 18, 2023
AB			**10MG**	**A218055**	**004**	Aug 18, 2023
AB		BRECKENRIDGE	**1MG**	**A216891**	**001**	Nov 15, 2022
AB			**2.5MG**	**A216891**	**002**	Nov 15, 2022
AB			**5MG**	**A216891**	**003**	Nov 15, 2022
AB			**10MG**	**A216891**	**004**	Nov 15, 2022
AB		CHARTWELL RX	**1MG**	**A215141**	**001**	Oct 20, 2021
AB			**2.5MG**	**A215141**	**002**	Oct 20, 2021
AB			**5MG**	**A215141**	**003**	Oct 20, 2021
AB			**10MG**	**A215141**	**004**	Oct 20, 2021
AB		DR REDDYS	**1MG**	**A214534**	**001**	Jan 07, 2021
AB			**2.5MG**	**A214534**	**002**	Jan 07, 2021
AB			**5MG**	**A214534**	**003**	Jan 07, 2021
AB			**10MG**	**A214534**	**004**	Jan 07, 2021
AB		GLENMARK PHARMS LTD	**1MG**	**A216350**	**001**	Nov 06, 2023
AB			**2.5MG**	**A216350**	**002**	Nov 06, 2023
AB			**5MG**	**A216350**	**003**	Nov 06, 2023
AB			**10MG**	**A216350**	**004**	Nov 06, 2023
AB		HETERO LABS LTD III	**1MG**	**A218769**	**001**	Nov 18, 2025
AB			**2.5MG**	**A218769**	**002**	Nov 18, 2025
AB			**5MG**	**A218769**	**003**	Nov 18, 2025
AB			**10MG**	**A218769**	**004**	Nov 18, 2025
AB		LANNETT CO INC	**1MG**	**A089743**	**002**	Aug 25, 1988
AB			**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB	!		**5MG**	**A089743**	**004**	Aug 25, 1988
AB			**10MG**	**A089743**	**001**	Aug 25, 1988
AB		MSN	**1MG**	**A217189**	**001**	Sep 11, 2023
AB			**2.5MG**	**A217189**	**002**	Sep 11, 2023
AB			**5MG**	**A217189**	**003**	Sep 11, 2023
AB			**10MG**	**A217189**	**004**	Sep 11, 2023
AB		NOVITIUM PHARMA	**1MG**	**A214674**	**001**	Mar 01, 2021
AB			**2.5MG**	**A214674**	**002**	Mar 01, 2021
AB			**5MG**	**A214674**	**003**	Mar 01, 2021
AB			**10MG**	**A214674**	**004**	Mar 01, 2021
AB		RISING	**1MG**	**A218283**	**001**	Jun 07, 2024
AB			**2.5MG**	**A218283**	**002**	Jun 07, 2024
AB			**5MG**	**A218283**	**003**	Jun 07, 2024
AB			**10MG**	**A218283**	**004**	Jun 07, 2024
AB		TARO	**1MG**	**A215674**	**001**	Apr 14, 2022
AB			**2.5MG**	**A215674**	**002**	Apr 14, 2022
AB			**5MG**	**A215674**	**003**	Apr 14, 2022
AB			**10MG**	**A215674**	**004**	Apr 14, 2022
AB		UPSHER SMITH LABS	**1MG**	**A213784**	**001**	Oct 24, 2022
AB			**2.5MG**	**A213784**	**002**	Oct 24, 2022
AB			**5MG**	**A213784**	**003**	Oct 24, 2022
AB			**10MG**	**A213784**	**004**	Oct 24, 2022
AB		ZYDUS LIFESCIENCES	**1MG**	**A214552**	**001**	May 27, 2021
AB			**2.5MG**	**A214552**	**002**	May 27, 2021
AB			**5MG**	**A214552**	**003**	May 27, 2021
AB			**10MG**	**A214552**	**004**	May 27, 2021

FLURANDRENOLIDE

LOTION;TOPICAL

FLURANDRENOLIDE

!	PADAGIS ISRAEL	0.05%	A207133	001	Aug 30, 2016

OINTMENT;TOPICAL

FLURANDRENOLIDE

!	TELIGENT	0.05%	A207851	001	Dec 30, 2016

TAPE;TOPICAL

CORDRAN

+!	ALMIRALL	0.004MG/SQ CM	N016455	001

FLURAZEPAM HYDROCHLORIDE
CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

AB		CHARTWELL RX	**15MG**	**A072368**	**001**	Mar 30, 1989
AB			**30MG**	**A072369**	**001**	Mar 30, 1989
AB		RISING	**15MG**	**A070345**	**002**	Nov 27, 1985
AB	**!**		**30MG**	**A070345**	**001**	Nov 27, 1985

FLURBIPROFEN
TABLET;ORAL
FLURBIPROFEN

!	NEW HEIGHTSRX	100MG	A074431	001	May 31, 1995

FLURBIPROFEN SODIUM
SOLUTION/DROPS;OPHTHALMIC
FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995

FLURPIRIDAZ F-18
SOLUTION;INTRAVENOUS
FLYRCADO

+!	GE HLTHCARE	5-55mCi/ML	N215168	001	Sep 27, 2024

FLUTAMIDE
CAPSULE;ORAL
FLUTAMIDE

!	WAYLIS THERAP	125MG	A075298	001	Sep 18, 2001

FLUTEMETAMOL F-18
INJECTABLE;INTRAVENOUS
VIZAMYL

+!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013

FLUTICASONE FUROATE
POWDER;INHALATION
ARNUITY ELLIPTA

+!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018
+!		0.1MG/INH	N205625	001	Aug 20, 2014
+!		0.2MG/INH	N205625	002	Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
POWDER;INHALATION
TRELEGY ELLIPTA

+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017
+!		0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	002	Sep 09, 2020

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA

+	GLAXO GRP LTD	0.05MG/INH;EQ 0.025MG BASE/INH	N204275	003	May 12, 2023
+!		0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013
+!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015

FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION
FLOVENT HFA

+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
+!		0.11MG/INH	N021433	002	May 14, 2004
+!		0.22MG/INH	N021433	001	May 14, 2004

CREAM;TOPICAL
FLUTICASONE PROPIONATE

AB		COSETTE	**0.05%**	**A077055**	**001**	Jun 30, 2006
AB		ENCUBE	**0.05%**	**A076633**	**001**	May 14, 2004
AB		FOUGERA PHARMS	**0.05%**	**A076451**	**001**	May 14, 2004
AB	**!**	PADAGIS ISRAEL	**0.05%**	**A076793**	**001**	May 14, 2004

LOTION;TOPICAL
FLUTICASONE PROPIONATE

!	PADAGIS ISRAEL	0.05%	A091553	001	Jul 30, 2013

OINTMENT;TOPICAL
FLUTICASONE PROPIONATE

AB		COSETTE	**0.005%**	**A077168**	**001**	Mar 03, 2006
AB	**!**	PADAGIS ISRAEL	**0.005%**	**A076668**	**001**	May 14, 2004

POWDER;INHALATION
FLOVENT DISKUS 100

+!	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLUTICASONE PROPIONATE							
POWDER;INHALATION							
FLOVENT DISKUS 250							
	+!	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000
FLOVENT DISKUS 50							
	+!	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000
SPRAY, METERED;NASAL							
FLUTICASONE PROPIONATE							
AB		APOTEX	**0.05MG/SPRAY**	**A077538**	**001**	Sep 12, 2007
AB		CHARTWELL RX	**0.05MG/SPRAY**	**A078492**	**001**	Jan 09, 2012
AB	**!**	HIKMA	**0.05MG/SPRAY**	**A076504**	**001**	Feb 22, 2006
AB		RUBICON RESEARCH	**0.05MG/SPRAY**	**A218321**	**001**	Jun 05, 2025
XHANCE							
	+!	PARATEK PHARMS	0.093MG	N209022	001	Sep 18, 2017
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE							
AEROSOL, METERED;INHALATION							
ADVAIR HFA							
	+!	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+!		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+!		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006
POWDER;INHALATION							
ADVAIR DISKUS 100/50							
AB	**+!**	GLAXO GRP LTD	**0.1MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**001**	Aug 24, 2000
ADVAIR DISKUS 250/50							
AB	**+!**	GLAXO GRP LTD	**0.25MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**002**	Aug 24, 2000
ADVAIR DISKUS 500/50							
AB	**+!**	GLAXO GRP LTD	**0.5MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**003**	Aug 24, 2000
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE							
AB		HIKMA	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A203433**	**001**	Dec 17, 2020
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A203433**	**002**	Dec 17, 2020
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A203433**	**003**	Dec 19, 2023
AB		TEVA PHARMS USA	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**001**	Dec 13, 2021
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**002**	Dec 13, 2021
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**003**	Dec 13, 2021
WIXELA INHUB							
AB		MYLAN	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**001**	Jan 30, 2019
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**002**	Jan 30, 2019
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**003**	Jan 30, 2019
AIRDUO RESPICLICK							
	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+!		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017
FLUVASTATIN SODIUM							
CAPSULE;ORAL							
FLUVASTATIN SODIUM							
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090595**	**001**	Apr 11, 2012
AB	**!**		**EQ 40MG BASE**	**A090595**	**002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078407**	**001**	Jun 12, 2012
AB			**EQ 40MG BASE**	**A078407**	**002**	Jun 12, 2012
TABLET, EXTENDED RELEASE;ORAL							
FLUVASTATIN SODIUM							
AB		BEIJING	**EQ 80MG BASE**	**A209397**	**001**	Apr 26, 2021
AB		TEVA PHARMS USA	**EQ 80MG BASE**	**A079011**	**001**	Jan 27, 2016
LESCOL XL							
AB	**+!**	SANDOZ	**EQ 80MG BASE**	**N021192**	**001**	Oct 06, 2000
FLUVOXAMINE MALEATE							
CAPSULE, EXTENDED RELEASE;ORAL							
FLUVOXAMINE MALEATE							
AB		ACTAVIS ELIZABETH	**100MG**	**A091482**	**001**	Apr 23, 2013
AB	**!**		**150MG**	**A091482**	**002**	Nov 18, 2013
AB		AJANTA PHARMA LTD	**100MG**	**A219055**	**001**	Oct 17, 2024
AB			**150MG**	**A219055**	**002**	Oct 17, 2024
AB		ANNORA PHARMA	**100MG**	**A217024**	**001**	Jul 30, 2025
AB			**150MG**	**A217024**	**002**	Jul 30, 2025
AB		BIONPHARMA	**100MG**	**A212182**	**002**	Sep 16, 2020
AB			**150MG**	**A212182**	**001**	May 11, 2020
AB		PH HEALTH	**100MG**	**A091476**	**001**	Mar 13, 2013
AB			**150MG**	**A091476**	**002**	Mar 13, 2013

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		AIPING PHARM INC	25MG	A075888	001	Nov 29, 2000
AB			50MG	A075888	002	Nov 29, 2000
AB	!		100MG	A075888	003	Nov 29, 2000
AB		APOTEX	25MG	A075902	001	May 07, 2001
AB			50MG	A075902	002	May 07, 2001
AB			100MG	A075902	003	May 07, 2001
AB		BIONPHARMA	25MG	A217917	001	Jan 22, 2024
AB			50MG	A217917	002	Jan 22, 2024
AB			100MG	A217917	003	Jan 22, 2024

LUVOX

AB	+	ANI PHARMS	25MG	N021519	001	Dec 20, 2007
AB	+		50MG	N021519	002	Dec 20, 2007
AB	+		100MG	N021519	003	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

AP	!	FRESENIUS KABI USA	5MG/ML	A089202	001	Feb 18, 1986
AP		XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019

TABLET;ORAL

FOLIC ACID

AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013
AA	!	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005
AA		CADILA PHARMS LTD	1MG	A202437	001	Jan 27, 2014
AA		CHARTWELL MOLECULAR	1MG	A090035	001	Jun 09, 2009
AA		LEADING	1MG	A040796	001	Jan 12, 2009
AA		NUVO PHARMS INC	1MG	A204418	001	Jul 28, 2015
AA		RISING	1MG	A211064	001	Mar 08, 2019
AA	+!	WATSON LABS	1MG	A080680	001	

FOMEPIZOLE

INJECTABLE;INJECTION

FOMEPIZOLE

AP		AM REGENT	1.5GM/1.5ML (1GM/ML)	A078368	001	Dec 14, 2007
AP		GLAND	1.5GM/1.5ML (1GM/ML)	A216791	001	Jul 06, 2023
AP	!	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A078639	001	Mar 03, 2008
AP		NAVINTA LLC	1.5GM/1.5ML (1GM/ML)	A078537	001	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

ARIXTRA

AP	+!	MYLAN IRELAND LTD	2.5MG/0.5ML	N021345	001	Dec 07, 2001
AP	+!		5MG/0.4ML	N021345	002	May 28, 2004
AP	+!		7.5MG/0.6ML	N021345	003	May 28, 2004
AP	+!		10MG/0.8ML	N021345	004	May 28, 2004

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011
AP			5MG/0.4ML	A091316	002	Jul 11, 2011
AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011
AP			10MG/0.8ML	A091316	004	Jul 11, 2011
AP		EUGIA PHARMA	2.5MG/0.5ML	A206918	001	Dec 26, 2017
AP			5MG/0.4ML	A206918	002	Dec 26, 2017
AP			7.5MG/0.6ML	A206918	003	Dec 26, 2017
AP			10MG/0.8ML	A206918	004	Dec 26, 2017
AP		HENGRUI PHARMA	2.5MG/0.5ML	A206812	001	May 15, 2018
AP			5MG/0.4ML	A206812	002	May 15, 2018
AP			7.5MG/0.6ML	A206812	003	May 15, 2018
AP			10MG/0.8ML	A206812	004	May 15, 2018
AP		SCINOPHARM TAIWAN	2.5MG/0.5ML	A208615	001	Nov 14, 2018
AP			5MG/0.4ML	A208615	002	Nov 14, 2018
AP			7.5MG/0.6ML	A208615	003	Nov 14, 2018
AP			10MG/0.8ML	A208615	004	Nov 14, 2018

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN		ALEMBIC	0.02MG/2ML	A215078	001	Nov 22, 2021
AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025
AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025
AN		LEXENPHARM	0.02MG/2ML	A216426	001	Oct 22, 2024
AN		LUPIN	0.02MG/2ML	A215053	001	Aug 22, 2022

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN		MANKIND PHARMA	**0.02MG/2ML**	**A215883**	**001**	Mar 22, 2023
AN		MICRO LABS	**0.02MG/2ML**	**A218304**	**001**	Jun 26, 2024
AN		RITEDOSE CORP	**0.02MG/2ML**	**A216486**	**001**	Nov 25, 2022
AN		TEVA PHARMS USA INC	**0.02MG/2ML**	**A091141**	**001**	Jun 22, 2021
AN		WILSHIRE PHARMS INC	**0.02MG/2ML**	**A215621**	**001**	Dec 13, 2022

PERFOROMIST

AN	**+!**	VIATRIS SPECIALTY	**0.02MG/2ML**	**N022007**	**001**	May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

	+!	ASTRAZENECA	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

	+!	ORGANON LLC	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019
	+!		0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
	+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB	**!**	MYLAN	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
AB		SUN PHARM	**EQ 700MG BASE**	**A204024**	**001**	Nov 20, 2019

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

AP	**+!**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010

FOSAPREPITANT DIMEGLUMINE

AP		ASPIRO	**EQ 150MG BASE/VIAL**	**A214616**	**001**	Jul 29, 2021
AP		BAXTER HLTHCARE CORP	**EQ 150MG BASE/VIAL**	**A211860**	**001**	Sep 05, 2019
AP		BE PHARMS	**EQ 150MG BASE/VIAL**	**A212309**	**001**	Sep 05, 2019
AP		CHIA TAI TIANQING	**EQ 150MG BASE/VIAL**	**A212143**	**001**	Mar 03, 2021
AP		DR REDDYS	**EQ 150MG BASE/VIAL**	**A211160**	**001**	Dec 09, 2020
AP		EUGIA PHARMA	**EQ 150MG BASE/VIAL**	**A210625**	**001**	Jan 12, 2021
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016
AP		MSN	**EQ 150MG BASE/VIAL**	**A209965**	**001**	Sep 05, 2019
AP		MYLAN LABS LTD	**EQ 150MG BASE/VIAL**	**A204015**	**002**	Sep 05, 2019
AP		QILU PHARM HAINAN	**EQ 150MG BASE/VIAL**	**A213106**	**001**	Sep 08, 2020
		TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019

SOLUTION;INTRAVENOUS

FOCINVEZ

	+!	STERISCIENCE	EQ 150MG BASE/50ML (EQ 3MG BASE/ML)	N216686	001	Aug 22, 2023

FOSCARBIDOPA; FOSLEVODOPA

SOLUTION;SUBCUTANEOUS

VYALEV

	+!	ABBVIE	120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML)	N216962	001	Oct 16, 2024

FOSCARNET SODIUM

SOLUTION;INTRAVENOUS

FOSCARNET SODIUM

AP		AMNEAL	**6GM/250ML (24MG/ML)**	**A216602**	**001**	Mar 01, 2024
AP		AVET LIFESCIENCES	**6GM/250ML (24MG/ML)**	**A213807**	**001**	Jun 05, 2023
AP		FRESENIUS KABI USA	**6GM/250ML (24MG/ML)**	**A212483**	**001**	Jan 29, 2021
AP		GLAND	**6GM/250ML (24MG/ML)**	**A213001**	**001**	Apr 21, 2021
AP		SCIECURE	**6GM/250ML (24MG/ML)**	**A213987**	**001**	Nov 29, 2023

FOSCAVIR

AP	**+!**	CLINIGEN HLTHCARE	**6GM/250ML (24MG/ML)**	**N020068**	**001**	Sep 27, 1991

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS

NULIBRY

	+!	SENTYNL THERAPS INC	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021

FOSFOMYCIN DISODIUM

POWDER;INTRAVENOUS

CONTEPO

	+!	MEITHEAL	EQ 6GM BASE/VIAL	N212271	001	Oct 22, 2025

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

AA		ALKEM LABS LTD	**EQ 3GM BASE/PACKET**	**A214554**	**001**	Oct 21, 2021
AA		AMNEAL	**EQ 3GM BASE/PACKET**	**A216600**	**001**	Mar 25, 2024
AA		AUROBINDO PHARMA LTD	**EQ 3GM BASE/PACKET**	**A217608**	**001**	Nov 14, 2025
AA		CIPLA	**EQ 3GM BASE/PACKET**	**A211881**	**001**	Jan 26, 2022
AA		PRECISION DOSE INC	**EQ 3GM BASE/PACKET**	**A217187**	**001**	Jun 03, 2025
AA	**!**	XIROMED	**EQ 3GM BASE/PACKET**	**A212548**	**001**	Oct 06, 2020

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		CHARTWELL RX	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004
AB			**40MG**	**A076483**	**003**	Apr 23, 2004
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016
AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	**!**		**40MG**	**A076139**	**003**	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB	**!**		**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS

AKYNZEO

	+!	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP	**+!**	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996

FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	**EQ 50MG PHENYTOIN NA/ML**	**A078052**	**001**	Aug 06, 2007
AP		GLAND	**EQ 50MG PHENYTOIN NA/ML**	**A214926**	**001**	Oct 13, 2023
AP		HIKMA	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		SUN PHARM	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WOCKHARDT BIO AG	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007

FOSTAMATINIB DISODIUM

TABLET;ORAL

TAVALISSE

	+	RIGEL PHARMS	EQ 100MG BASE	N209299	001	Apr 17, 2018
	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018

FOSTEMSAVIR TROMETHAMINE							
TABLET, EXTENDED RELEASE;ORAL							
RUKOBIA							
	+!	VIIV HLTHCARE	EQ 600MG BASE		N212950	001	Jul 02, 2020
FROVATRIPTAN SUCCINATE							
TABLET;ORAL							
FROVA							
AB	**+!**	ENDO OPERATIONS	**EQ 2.5MG BASE**		**N021006**	**001**	Nov 08, 2001
FROVATRIPTAN SUCCINATE							
AB		AMNEAL PHARMS CO	**EQ 2.5MG BASE**		**A211292**	**001**	Nov 06, 2018
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**		**A204730**	**001**	Mar 11, 2016
AB		LEADING	**EQ 2.5MG BASE**		**A216998**	**001**	Apr 16, 2025
AB		RENATA	**EQ 2.5MG BASE**		**A213891**	**001**	Apr 06, 2022
FRUQUINTINIB							
CAPSULE;ORAL							
FRUZAQLA							
	+	TAKEDA PHARMS USA	1MG		N217564	001	Nov 08, 2023
	+!		5MG		N217564	002	Nov 08, 2023
FULVESTRANT							
SOLUTION;INTRAMUSCULAR							
FASLODEX							
AO	**+!**	ASTRAZENECA	**250MG/5ML (50MG/ML)**		**N021344**	**001**	Apr 25, 2002
FULVESTRANT							
AO		ACCORD HLTHCARE	**250MG/5ML (50MG/ML)**		**A211689**	**001**	Nov 17, 2020
AO		ALEMBIC	**250MG/5ML (50MG/ML)**		**A215077**	**001**	Dec 22, 2022
AO		AMNEAL	**250MG/5ML (50MG/ML)**		**A210044**	**001**	Mar 04, 2019
AO		CHIA TAI TIANQING	**250MG/5ML (50MG/ML)**		**A211422**	**001**	Feb 07, 2020
AO		DR REDDYS	**250MG/5ML (50MG/ML)**		**A209246**	**001**	Aug 07, 2020
AO		EUGIA PHARMA	**250MG/5ML (50MG/ML)**		**A215169**	**001**	Jun 30, 2023
AO		FRESENIUS KABI USA	**250MG/5ML (50MG/ML)**		**N210326**	**001**	May 20, 2019
AO		GLENMARK PHARMS INC	**250MG/5ML (50MG/ML)**		**A207754**	**001**	Aug 22, 2019
AO		HBT LABS INC	**250MG/5ML (50MG/ML)**		**A209714**	**001**	Nov 21, 2019
AO		JIANGSU HANSOH PHARM	**250MG/5ML (50MG/ML)**		**A214682**	**001**	Feb 10, 2022
AO		SAGENT PHARMS INC	**250MG/5ML (50MG/ML)**		**A205871**	**001**	Aug 22, 2019
AO		SANDOZ	**250MG/5ML (50MG/ML)**		**A205935**	**001**	May 14, 2019
AO		XIROMED	**250MG/5ML (50MG/ML)**		**A213553**	**001**	Aug 13, 2021
AO		ZYDUS PHARMS	**250MG/5ML (50MG/ML)**		**A215234**	**001**	Jul 29, 2021
FUROSEMIDE							
INJECTABLE;INJECTION							
FUROSEMIDE							
AP		ACCORD HLTHCARE	**10MG/ML**		**A070017**	**001**	Dec 15, 1986
AP		AMNEAL PHARMS CO	**10MG/ML**		**A207552**	**001**	Jul 20, 2016
AP		APOTEX	**10MG/ML**		**A077941**	**001**	Mar 22, 2007
AP		AREVA PHARMS	**10MG/ML**		**A208435**	**001**	Dec 18, 2020
AP		ASPIRO	**10MG/ML**		**A217557**	**001**	Dec 13, 2024
AP		AVET LIFESCIENCES	**10MG/ML**		**A203428**	**001**	Aug 26, 2014
AP	**!**	BAXTER HLTHCARE CORP	**10MG/ML**		**A202747**	**001**	Jan 27, 2014
AP		EUGIA PHARMA	**10MG/ML**		**A212174**	**001**	May 03, 2019
AP		FRESENIUS KABI USA	**10MG/ML**		**N018902**	**001**	May 22, 1984
AP		GLAND	**10MG/ML**		**A213902**	**001**	Jul 01, 2020
AP		HIKMA	**10MG/ML**		**N018267**	**001**	
AP		HOSPIRA	**10MG/ML**		**A075241**	**001**	May 28, 1999
AP			**10MG/ML**		**N018667**	**001**	May 28, 1982
AP		MANKIND PHARMA	**10MG/ML**		**A216860**	**001**	Dec 16, 2022
AP		MEITHEAL	**10MG/ML**		**A212803**	**001**	Jan 27, 2022
AP		SABA ILAC SANAYIVE	**10MG/ML**		**A215856**	**001**	Apr 02, 2024
AP		SAGENT	**10MG/ML**		**A214766**	**001**	Jan 27, 2021
SOLUTION;ORAL							
FUROSEMIDE							
	!	HIKMA	10MG/ML		A070434	001	Apr 22, 1987
	!		40MG/5ML		A070433	001	Apr 22, 1987
SOLUTION;SUBCUTANEOUS							
FUROSCIX							
	+!	SCPHARMACEUTICALS	80MG/10ML (8MG/ML)		N209988	001	Oct 07, 2022
LASIX ONYU							
	+!	SQ INNOVATION	80MG/2.67ML (30MG/ML)		N217294	001	Oct 07, 2025

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

AB		AUROBINDO PHARMA LTD	**20MG**	**A218831**	**001**	Jul 17, 2025
AB			**40MG**	**A218831**	**002**	Jul 17, 2025
AB			**80MG**	**A218831**	**003**	Jul 17, 2025
AB		EPIC PHARMA LLC	**20MG**	**N018569**	**002**	
AB			**40MG**	**N018569**	**001**	
AB			**80MG**	**N018569**	**005**	Aug 14, 1984
AB		ESJAY PHARMA	**20MG**	**N018415**	**001**	Jul 27, 1982
AB			**40MG**	**N018415**	**002**	Jul 27, 1982
AB			**80MG**	**N018415**	**003**	Nov 26, 1984
AB		GRAVITI PHARMS	**20MG**	**A216629**	**001**	Oct 17, 2022
AB			**40MG**	**A216629**	**002**	Oct 17, 2022
AB	**!**		**80MG**	**A216629**	**003**	Oct 17, 2022
AB		HIKMA	**20MG**	**N018823**	**001**	Nov 10, 1983
AB			**40MG**	**N018823**	**002**	Nov 10, 1983
AB			**80MG**	**A070086**	**001**	Jan 24, 1986
AB		IPCA LABS LTD	**20MG**	**A078010**	**001**	Sep 18, 2006
AB			**40MG**	**A078010**	**002**	Sep 18, 2006
AB			**80MG**	**A078010**	**003**	Sep 18, 2006
AB		LEADING	**20MG**	**A077293**	**001**	Nov 09, 2005
AB			**40MG**	**A077293**	**002**	Nov 09, 2005
AB			**80MG**	**A077293**	**003**	Nov 09, 2005
AB		PRINSTON INC	**20MG**	**A076796**	**001**	Mar 26, 2004
AB			**40MG**	**A076796**	**002**	Mar 26, 2004
AB			**80MG**	**A076796**	**003**	Mar 26, 2004

FUTIBATINIB

TABLET;ORAL

LYTGOBI

+!	TAIHO ONCOLOGY	4MG	N214801	001	Sep 30, 2022
+		16MG	N214801	002	Jul 28, 2025

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		ACTAVIS ELIZABETH	**100MG**	**A075350**	**001**	Sep 12, 2003
AB			**300MG**	**A075350**	**002**	Sep 12, 2003
AB			**400MG**	**A075350**	**003**	Sep 12, 2003
AB		ALKEM	**100MG**	**A090858**	**001**	Dec 17, 2010
AB			**300MG**	**A090858**	**002**	Dec 17, 2010
AB			**400MG**	**A090858**	**003**	Dec 17, 2010
AB		AMNEAL PHARMS NY	**100MG**	**A078428**	**001**	Jul 25, 2007
AB			**300MG**	**A078428**	**002**	Jul 25, 2007
AB			**400MG**	**A078428**	**003**	Jul 25, 2007
AB		ASCENT PHARMS INC	**100MG**	**A214956**	**001**	May 10, 2021
AB			**300MG**	**A214956**	**002**	May 10, 2021
AB			**400MG**	**A214956**	**003**	May 10, 2021
AB		AUROBINDO PHARMA	**100MG**	**A078787**	**001**	Jan 31, 2008
AB			**300MG**	**A078787**	**002**	Jan 31, 2008
AB			**400MG**	**A078787**	**003**	Jan 31, 2008
AB		CSPC OUYI	**100MG**	**A075477**	**001**	Mar 23, 2005
AB			**300MG**	**A075477**	**002**	Mar 23, 2005
AB			**400MG**	**A075477**	**003**	Mar 23, 2005
AB		GRANULES	**100MG**	**A075360**	**001**	Apr 06, 2005
AB			**300MG**	**A075360**	**002**	Apr 06, 2005
AB			**400MG**	**A075360**	**003**	Apr 06, 2005
AB		INVAGEN PHARMS	**100MG**	**A090705**	**001**	Dec 30, 2009
AB			**300MG**	**A090705**	**002**	Dec 30, 2009
AB			**400MG**	**A090705**	**003**	Dec 30, 2009
AB		LAURUS	**100MG**	**A217546**	**001**	May 12, 2023
AB			**300MG**	**A217546**	**002**	May 12, 2023
AB			**400MG**	**A217546**	**003**	May 12, 2023
AB		MARKSANS PHARMA	**100MG**	**A090007**	**001**	Jul 21, 2011
AB			**300MG**	**A090007**	**002**	Jul 21, 2011
AB			**400MG**	**A090007**	**003**	Jul 21, 2011
AB		RISING	**100MG**	**A207099**	**001**	Mar 24, 2017
AB			**300MG**	**A207099**	**002**	Mar 24, 2017
AB			**400MG**	**A207099**	**003**	Mar 24, 2017
AB		SCIEGEN PHARMS	**100MG**	**A204989**	**001**	Feb 18, 2016
AB			**300MG**	**A204989**	**002**	Feb 18, 2016
AB			**400MG**	**A204989**	**003**	Feb 18, 2016

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		SENORES PHARMS	**100MG**	**A219319**	**001**	Aug 07, 2025
AB			**300MG**	**A219319**	**002**	Aug 07, 2025
AB			**400MG**	**A219319**	**003**	Aug 07, 2025
AB		STRIDES PHARMA	**100MG**	**A206943**	**001**	May 14, 2018
AB			**100MG**	**A211314**	**001**	Oct 16, 2018
AB			**300MG**	**A206943**	**002**	May 14, 2018
AB			**300MG**	**A211314**	**002**	Oct 16, 2018
AB			**400MG**	**A206943**	**003**	May 14, 2018
AB			**400MG**	**A211314**	**003**	Oct 16, 2018
AB		ZHEJIANG YONGTAI	**100MG**	**A213603**	**001**	Aug 17, 2020
AB			**300MG**	**A213603**	**002**	Aug 17, 2020
AB			**400MG**	**A213603**	**003**	Aug 17, 2020

NEURONTIN

AB	+	VIATRIS	**100MG**	**N020235**	**001**	Dec 30, 1993
AB	+		**300MG**	**N020235**	**002**	Dec 30, 1993
AB	+!		**400MG**	**N020235**	**003**	Dec 30, 1993

SOLUTION;ORAL

GABAPENTIN

AA		ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA		AJENAT PHARMS	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016
AA		AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA		ANNORA PHARMA	**250MG/5ML**	**A217682**	**001**	Jan 17, 2024
AA		MISSION PHARMACAL	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA		PAI HOLDINGS PHARM	**250MG/5ML**	**A211330**	**001**	Dec 03, 2019
AA		RUBICON RESEARCH	**250MG/5ML**	**A216492**	**001**	Jan 18, 2023

NEURONTIN

AA	+!	VIATRIS	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

TABLET;ORAL

GABAPENTIN

AB		ZYDUS PHARMS	**450MG**	**A203934**	**003**	Aug 25, 2025
AB			**750MG**	**A203934**	**004**	Aug 25, 2025
AB			**900MG**	**A203934**	**005**	Aug 25, 2025

GRALISE

AB	+	ALMATICA	**450MG**	**N022544**	**003**	Apr 18, 2023
AB	+		**750MG**	**N022544**	**004**	Apr 18, 2023
AB	+!		**900MG**	**N022544**	**005**	Apr 18, 2023

GABAPENTIN

AB1		ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB1			**800MG**	**A206402**	**002**	Dec 23, 2015
AB1		ASCENT PHARMS INC	**600MG**	**A214957**	**001**	Oct 01, 2021
AB1			**800MG**	**A214957**	**002**	Oct 01, 2021
AB1		AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB1			**800MG**	**A200651**	**002**	Oct 06, 2011
AB1		CSPC OUYI	**600MG**	**A207057**	**001**	Oct 26, 2017
AB1			**800MG**	**A207057**	**002**	Oct 26, 2017
AB1		GLENMARK PHARMS LTD	**600MG**	**A077662**	**001**	Aug 18, 2006
AB1			**800MG**	**A077662**	**002**	Aug 18, 2006
AB1		GRANULES	**600MG**	**A217116**	**001**	Mar 28, 2023
AB1			**800MG**	**A217116**	**002**	Mar 28, 2023
AB1		IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB1			**400MG**	**A076017**	**003**	Apr 28, 2004
AB1		LAURUS	**600MG**	**A217965**	**001**	Apr 08, 2024
AB1			**800MG**	**A217965**	**002**	Apr 08, 2024
AB1		RISING	**600MG**	**A217995**	**001**	Jul 19, 2023
AB1			**800MG**	**A217995**	**002**	Jul 19, 2023
AB1		RUBICON RESEARCH	**600MG**	**A077661**	**004**	Sep 13, 2006
AB1			**800MG**	**A077661**	**005**	Sep 13, 2006
AB1		SCIEGEN PHARMS	**600MG**	**A205101**	**001**	Feb 04, 2016
AB1			**800MG**	**A205101**	**002**	Feb 04, 2016
AB1		STRIDES PHARMA	**100MG**	**A211313**	**003**	Dec 20, 2024
AB1			**400MG**	**A211313**	**004**	Dec 20, 2024
AB1			**600MG**	**A203244**	**002**	Jul 12, 2013
AB1			**600MG**	**A211313**	**001**	Mar 04, 2024
AB1			**800MG**	**A203244**	**001**	Jul 12, 2013
AB1			**800MG**	**A211313**	**002**	Mar 04, 2024
AB1		ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB1			**800MG**	**A078926**	**002**	Feb 11, 2011

GABAPENTIN

TABLET;ORAL

NEURONTIN

AB1	**+**	VIATRIS	**600MG**	**N020882**	**001**	Oct 09, 1998
AB1	**+!**		**800MG**	**N020882**	**002**	Oct 09, 1998

GABAPENTIN

AB2		ABON PHARMS LLC	**600MG**	**A203643**	**001**	Sep 09, 2024
AB2		ANNORA PHARMA	**300MG**	**A218075**	**001**	Feb 26, 2024
AB2			**600MG**	**A218075**	**002**	Feb 26, 2024
AB2		HUMANWELL	**300MG**	**A216252**	**001**	Feb 26, 2024
AB2			**600MG**	**A216252**	**002**	Feb 26, 2024
AB2		SCIEGEN PHARMS	**300MG**	**A218491**	**001**	Sep 19, 2025
AB2			**600MG**	**A218491**	**002**	Sep 19, 2025
AB2		ZYDUS PHARMS	**300MG**	**A203934**	**001**	Jan 24, 2024
AB2			**600MG**	**A203934**	**002**	Jan 24, 2024

GRALISE

AB2	**+!**	ALMATICA	**300MG**	**N022544**	**001**	Jan 28, 2011
AB2	**+**		**600MG**	**N022544**	**002**	Jan 28, 2011

GABAPENTIN

		IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

	+	AZURITY	300MG	N022399	002	Dec 13, 2011
	+!		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

	+!	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
	+!		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
	+!		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
	+!		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

	+!	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
	+!		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

AP	**+!**	BAYER HLTHCARE	**1.20944GM/2ML (604.72MG/ML)**	**N201277**	**006**	Dec 18, 2013
AP	**+!**		**4.5354GM/7.5ML (604.72MG/ML)**	**N201277**	**001**	Mar 14, 2011
AP	**+!**		**6.0472GM/10ML (604.72MG/ML)**	**N201277**	**002**	Mar 14, 2011
AP	**+!**		**9.0708GM/15ML (604.72MG/ML)**	**N201277**	**003**	Mar 14, 2011
AP	**+!**		**18.1416GM/30ML (604.72MG/ML)**	**N201277**	**004**	Mar 14, 2011
AP	**+!**		**39.3068GM/65ML (604.72MG/ML)**	**N201277**	**005**	Mar 14, 2011

GADOBUTROL

AP		HAINAN POLY PHARM	**1.20944GM/2ML (604.72MG/ML)**	**A217480**	**003**	Apr 16, 2025
AP			**4.5354GM/7.5ML (604.72MG/ML)**	**A217480**	**001**	Mar 15, 2023
AP			**6.0472GM/10ML (604.72MG/ML)**	**A217480**	**004**	Apr 16, 2025
AP			**9.0708GM/15ML (604.72MG/ML)**	**A217480**	**002**	Mar 15, 2023
AP			**18.1416GM/30ML (604.72MG/ML)**	**A217480**	**005**	Apr 16, 2025
AP			**39.3068GM/65ML (604.72MG/ML)**	**A217480**	**006**	Apr 16, 2025
AP		HENGRUI PHARMA	**1.20944GM/2ML (604.72MG/ML)**	**A216081**	**003**	Nov 17, 2022
AP			**4.5354GM/7.5ML (604.72MG/ML)**	**A216081**	**004**	Nov 17, 2022
AP			**6.0472GM/10ML (604.72MG/ML)**	**A216081**	**005**	Nov 17, 2022
AP			**9.0708GM/15ML (604.72MG/ML)**	**A216081**	**006**	Nov 17, 2022
AP			**18.1416GM/30ML (604.72MG/ML)**	**A216081**	**001**	Sep 08, 2023
AP			**39.3068GM/65ML (604.72MG/ML)**	**A216081**	**002**	Sep 08, 2023

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

	+!	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993

GADOPICLENOL

SOLUTION;INTRAVENOUS

ELUCIREM

	+!	GUERBET	1.4553GM/3ML (485.1MG/ML)	N216986	001	Sep 21, 2022
	+!		3.63825GM/7.5ML (485.1MG/ML)	N216986	002	Sep 21, 2022
	+!		4.851GM/10ML (485.1MG/ML)	N216986	003	Sep 21, 2022
	+!		7.2765GM/15ML (485.1MG/ML)	N216986	004	Sep 21, 2022
	+!		14.553GM/30ML (485.1MG/ML)	N216986	005	Sep 21, 2022

GADOPICLENOL

SOLUTION;INTRAVENOUS

ELUCIREM

	+!		24.255GM/50ML (485.1MG/ML)	N216986	006	Sep 21, 2022
	+!		48.51GM/100ML (485.1MG/ML)	N216986	007	Sep 21, 2022

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

CLARISCAN

AP		GE HEALTHCARE	**7.538GM/20ML (376.9MG/ML)**	**A210016**	**003**	Nov 01, 2019
AP			**1.8845GM/5ML (376.9MG/ML)**	**A210016**	**005**	Nov 24, 2020
AP			**3.769GM/10ML (376.9MG/ML)**	**A210016**	**001**	Nov 01, 2019
AP			**5.6535GM/15ML (376.9MG/ML)**	**A210016**	**002**	Nov 01, 2019
AP			**37.69GM/100ML (376.9MG/ML)**	**A210016**	**004**	Aug 04, 2020

DOTAREM

AP	**+!**	GUERBET	**37.69GM/100ML (376.9MG/ML)**	**N204781**	**001**	Mar 20, 2013
AP	**+!**		**1.8845GM/5ML (376.9MG/ML)**	**N204781**	**005**	Mar 31, 2017
AP	**+!**		**3.769GM/10ML (376.9MG/ML)**	**N204781**	**002**	Mar 20, 2013
AP	**+!**		**5.6535GM/15ML (376.9MG/ML)**	**N204781**	**003**	Mar 20, 2013
AP	**+!**		**7.538GM/20ML (376.9MG/ML)**	**N204781**	**004**	Mar 20, 2013

GADOTERATE MEGLUMINE

AP		HAINAN POLY	**1.8845GM/5ML (376.9MG/ML)**	**A218073**	**001**	Jun 17, 2024
AP			**3.769GM/10ML (376.9MG/ML)**	**A218073**	**002**	Jun 17, 2024
AP			**5.6535GM/15ML (376.9MG/ML)**	**A218073**	**003**	Jun 17, 2024
AP			**7.538GM/20ML (376.9MG/ML)**	**A218073**	**004**	Jun 17, 2024
AP			**37.69GM/100ML (376.9MG/ML)**	**A218073**	**005**	Jun 17, 2024

GADOTERIDOL

INJECTABLE;INJECTION

GADOTERIDOL

AP		HAINAN POLY	**279.3MG/ML**	**A218749**	**001**	Feb 11, 2025

PROHANCE

AP	**+!**	BRACCO	**279.3MG/ML**	**N020131**	**001**	Nov 16, 1992

PROHANCE MULTIPACK

	+!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

	+!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
	+		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB	**!**	AUROBINDO PHARMA	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB			**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB			**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB		BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB			**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008
AB			**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008
AB		SUN PHARM	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB			**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB			**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB		WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB			**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008
AB			**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

	!	HIKMA	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		ANDA REPOSITORY	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB			**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB			**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB			**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011
AB			**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB		BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB			**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB			**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB		SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB			**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB			**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB	**!**	YABAO PHARM	**EQ 4MG BASE**	**A077604**	**001**	Feb 06, 2009
AB			**EQ 8MG BASE**	**A077604**	**002**	Feb 06, 2009
AB			**EQ 12MG BASE**	**A077604**	**003**	Feb 06, 2009
AB		ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB			**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB			**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001	

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+!	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016

GALLIUM GA-68 EDOTREOTIDE

SOLUTION;INTRAVENOUS

GALLIUM GA 68 EDOTREOTIDE

AP		METHODIST	**0.5-4mCi/ML**	**A218845**	**001**	Oct 10, 2025
AP	**+!**	UIHC PET IMAGING	**0.5-4mCi/ML**	**N210828**	**001**	Aug 21, 2019

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS

GOZELLIX

	+!	TELIX INNOVATIONS	N/A	N219592	001	Mar 20, 2025

ILLUCCIX

	+!	TELIX	N/A	N214032	001	Dec 17, 2021

LOCAMETZ

	+!	NOVARTIS	N/A	N215841	001	Mar 23, 2022

SOLUTION;INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

	+!	UNIV CA LOS ANGELES	0.5-5mCi/mL	N212642	001	Dec 01, 2020
	+!	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020

GANAXOLONE

SUSPENSION;ORAL

ZTALMY

	+!	MARINUS	50MG/ML	N215904	001	Jun 01, 2022

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

	+!	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658**	**001**	Jun 21, 2010
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A076222**	**001**	Jul 16, 2003
AP		PH HEALTH	**EQ 500MG BASE/VIAL**	**A204950**	**001**	Dec 06, 2016
AP	**!**	PHARMASCIENCE INC	**EQ 500MG BASE/VIAL**	**A207645**	**001**	Dec 08, 2017
AP		SLATE RUN PHARMA	**EQ 500MG BASE/VIAL**	**A204204**	**001**	Nov 08, 2018

GANIRELIX ACETATE

INJECTABLE;INJECTION

FYREMADEL

AP		SUN PHARM	**250MCG/0.5ML**	**A204246**	**001**	Nov 30, 2018

GANIRELIX ACETATE

AP		AMPHASTAR PHARMS INC	**250MCG/0.5ML**	**A212613**	**001**	Apr 07, 2022
AP		GLAND	**250MCG/0.5ML**	**A215658**	**001**	Feb 28, 2023
AP		LUPIN LTD	**250MCG/0.5ML**	**A216075**	**001**	Nov 16, 2023
AP		MEITHEAL	**250MCG/0.5ML**	**A214996**	**001**	Jun 06, 2022
AP	**+!**	ORGANON USA ORGANON	**250MCG/0.5ML**	**N021057**	**001**	Jul 29, 1999
AP		QILU	**250MCG/0.5ML**	**A218855**	**001**	Apr 23, 2025
AP		TRIS PHARMA INC	**250MCG/0.5ML**	**A219454**	**001**	Jun 27, 2025

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		CAPLIN	**0.5%**	**A213542**	**001**	Nov 03, 2021
AT		SANDOZ	**0.5%**	**A204227**	**001**	Jul 11, 2016

ZYMAXID

AT	**+!**	ABBVIE	**0.5%**	**N022548**	**001**	May 18, 2010

GEFITINIB

TABLET;ORAL

GEFITINIB

AB		ACTAVIS LABS FL INC	**250MG**	**A208913**	**001**	Apr 26, 2023
AB		APOTEX	**250MG**	**A209532**	**001**	Sep 23, 2022
AB		CIPLA	**250MG**	**A211826**	**001**	May 16, 2025
AB		NATCO	**250MG**	**A212827**	**001**	May 31, 2023
AB		QILU PHARM HAINAN	**250MG**	**A211591**	**001**	Feb 13, 2023

IRESSA

AB	**+!**	ASTRAZENECA	**250MG**	**N206995**	**001**	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997**	**001**	May 07, 2013
AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A090799**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090242**	**003**	May 16, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799**	**003**	May 16, 2011
AP		GLAND	**EQ 200MG BASE/VIAL**	**A204520**	**001**	Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520**	**002**	Jan 05, 2016
AP		HIKMA	**200MG/5.26ML (38MG/ML)**	**A213175**	**001**	Mar 07, 2023
AP			**1GM/26.3ML (38MG/ML)**	**A213175**	**002**	Mar 07, 2023
AP			**2GM/52.6ML (38MG/ML)**	**A213175**	**003**	Mar 07, 2023
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339**	**002**	Jul 25, 2011
AP	**+!**	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795**	**001**	Aug 04, 2011
AP	**+!**		**1GM/26.3ML (38MG/ML)**	**N200795**	**002**	Aug 04, 2011
AP	**!**		**EQ 2GM BASE/VIAL**	**A079183**	**001**	Nov 15, 2010
AP	**+!**		**2GM/52.6ML (38MG/ML)**	**N200795**	**003**	Aug 04, 2011
AP	**!**	JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485**	**001**	May 07, 2013
AP	**!**		**EQ 1GM BASE/VIAL**	**A202485**	**002**	May 07, 2013
AP		MEITHEAL	**200MG/5.26ML (38MG/ML)**	**A212129**	**001**	Dec 11, 2020
AP			**1GM/26.3ML (38MG/ML)**	**A212129**	**002**	Dec 11, 2020
AP			**2GM/52.6ML (38MG/ML)**	**A212129**	**003**	Dec 11, 2020
AP		MYLAN LABS LTD	**200MG/5.26ML (38MG/ML)**	**A205242**	**001**	Dec 06, 2017
AP			**1GM/26.3ML (38MG/ML)**	**A205242**	**002**	Dec 06, 2017
AP			**2GM/52.6ML (38MG/ML)**	**A205242**	**003**	Dec 06, 2017
AP		NOVAST LABS	**200MG/5.26ML (38MG/ML)**	**A210383**	**001**	Feb 14, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210383**	**002**	Feb 14, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210383**	**003**	Feb 14, 2019
AP		SAGENT PHARMS INC	**200MG/5.26ML (38MG/ML)**	**A209077**	**001**	Jul 20, 2018
AP			**1GM/26.3ML (38MG/ML)**	**A209077**	**002**	Jul 20, 2018
AP			**2GM/52.6ML (38MG/ML)**	**A209077**	**003**	Jul 20, 2018
AP		SHILPA	**EQ 200MG BASE/VIAL**	**A207575**	**001**	Feb 22, 2019
AP			**200MG/5.26ML (38MG/ML)**	**A210991**	**001**	Oct 04, 2019
AP			**EQ 1GM BASE/VIAL**	**A207575**	**002**	Feb 22, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210991**	**002**	Oct 04, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210991**	**003**	Oct 04, 2019
AP		SUN PHARM	**EQ 200MG BASE/VIAL**	**A078433**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078433**	**002**	Jul 25, 2011
AP		TEYRO LABS	**EQ 200MG BASE/VIAL**	**A078759**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759**	**002**	Jul 25, 2011

SOLUTION;INTRAVENOUS

AVGEMSI

	+!	AVYXA HOLDINGS	EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N219920	002	Jun 27, 2025
	+!		EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML)	N219920	003	Jun 27, 2025

GEMCITABINE HYDROCHLORIDE

	+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
	+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
	+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
	+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

GEMCITABINE HYDROCHLORIDE
SYSTEM;INTRAVESICAL
INLEXZO
+! JANSSEN BIOTECH EQ 225MG BASE N219683 001 Sep 09, 2025

GEMFIBROZIL
TABLET;ORAL
GEMFIBROZIL
AB ASCENT PHARMS INC **600MG** **A214603 001** Jan 13, 2021
AB AURORBINDO PHARMA LTD **600MG** **A202726 001** Sep 16, 2015
AB CADILA PHARMS LTD **600MG** **A203266 001** Jun 17, 2016
AB CHARTWELL MOLECULES **600MG** **A074270 001** Sep 27, 1993
AB EPIC PHARMA LLC **600MG** **A078012 001** Mar 26, 2007
AB IMPAX PHARMS **600MG** **A078207 001** Jun 01, 2007
AB INVAGEN PHARMS **600MG** **A077836 001** Jul 27, 2006
AB NORTHSTAR HLTHCARE **600MG** **A079072 001** Sep 13, 2010
LOPID
AB **+!** PFIZER PHARMS **600MG** **N018422 003** Nov 20, 1986

GENTAMICIN SULFATE
CREAM;TOPICAL
GENTAMICIN SULFATE
AT COSETTE **EQ 0.1% BASE** **A064056 001** Apr 29, 1994
AT **!** PADAGIS US **EQ 0.1% BASE** **A062307 001**
INJECTABLE;INJECTION
GENTAMICIN SULFATE
AP EUGIA PHARMA **EQ 40MG BASE/ML** **A215237 001** Jan 08, 2024
AP **!** FRESENIUS KABI USA **EQ 10MG BASE/ML** **A062366 002** Feb 06, 1986
AP **!** **EQ 40MG BASE/ML** **A062366 001** Aug 04, 1983
AP HIKMA **EQ 10MG BASE/ML** **A062251 002**
AP **EQ 40MG BASE/ML** **A062251 001**
AP HOSPIRA **EQ 10MG BASE/ML** **A062420 001** Aug 15, 1983
AP **EQ 40MG BASE/ML** **A062420 002** Aug 15, 1983
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE EQ 1.2MG BASE/ML A062373 007 Sep 07, 1982
EQ 1.6MG BASE/ML A062373 008 Sep 07, 1982
! EQ 2MG BASE/ML A062373 009 Sep 07, 1982
EQ 80MG BASE/100ML A062373 002 Sep 07, 1982
EQ 100MG BASE/100ML A062373 005 Sep 07, 1982
! EQ 120MG BASE/100ML A062373 006 Sep 07, 1982
OINTMENT;OPHTHALMIC
GENTAMICIN SULFATE
! FERA PHARMS LLC EQ 0.3% BASE A065024 001 Jul 30, 2004
OINTMENT;TOPICAL
GENTAMICIN SULFATE
AT COSETTE **EQ 0.1% BASE** **A064054 001** Apr 29, 1994
AT FOUGERA PHARMS INC **EQ 0.1% BASE** **A062533 001** Oct 05, 1984
AT **!** PADAGIS US **EQ 0.1% BASE** **A062351 001** Feb 18, 1982
SOLUTION/DROPS;OPHTHALMIC
GENTAMICIN SULFATE
AT BAUSCH AND LOMB **EQ 0.3% BASE** **A064048 001** May 11, 1994
AT PADAGIS US **EQ 0.3% BASE** **A065121 001** Jan 30, 2004
AT **!** SANDOZ **EQ 0.3% BASE** **A062196 001**

GEPIRONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
EXXUA
+! FABRE KRAMER EQ 18.2MG BASE N021164 001 Sep 22, 2023
+ EQ 36.3MG BASE N021164 002 Sep 22, 2023
+ EQ 54.5MG BASE N021164 003 Sep 22, 2023
+! EQ 72.6MG BASE N021164 004 Sep 22, 2023

GEPOTIDACIN MESYLATE
TABLET;ORAL
BLUJEPA
+! GLAXOSMITHKLINE EQ 750MG BASE N218230 001 Mar 25, 2025

GILTERITINIB FUMARATE
TABLET;ORAL
XOSPATA
+! ASTELLAS EQ 40MG BASE N211349 001 Nov 28, 2018

GIVINOSTAT HYDROCHLORIDE							
SUSPENSION;ORAL							
DUVYZAT							
	+!	ITALFARMACO SPA	EQ 8.86MG BASE/ML		N217865	001	Mar 21, 2024
GIVOSIRAN SODIUM							
SOLUTION;SUBCUTANEOUS							
GIVLAARI							
	+!	ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)		N212194	001	Nov 20, 2019
GLASDEGIB MALEATE							
TABLET;ORAL							
DAURISMO							
	+	PFIZER	EQ 25MG BASE		N210656	001	Nov 21, 2018
	+!		EQ 100MG BASE		N210656	002	Nov 21, 2018
GLATIRAMER ACETATE							
INJECTABLE;SUBCUTANEOUS							
COPAXONE							
AP	**+!**	TEVA PHARMS USA	**20MG/ML**		**N020622**	**002**	Feb 12, 2002
AP	**+!**		**40MG/ML**		**N020622**	**003**	Jan 28, 2014
GLATIRAMER ACETATE							
AP		CHEMI SPA	**20MG/ML**		**A208468**	**001**	May 07, 2025
AP			**40MG/ML**		**A208468**	**002**	May 07, 2025
AP		MYLAN	**20MG/ML**		**A091646**	**001**	Oct 03, 2017
AP			**40MG/ML**		**A206936**	**001**	Oct 03, 2017
AP		SCINOPHARM TAIWAN	**20MG/ML**		**A214741**	**001**	Dec 31, 2025
AP			**40MG/ML**		**A214741**	**002**	Dec 31, 2025
AP		SYNTHON PHARMS INC	**20MG/ML**		**A203857**	**001**	Sep 25, 2024
AP			**40MG/ML**		**A206873**	**001**	Sep 25, 2024
GLATOPA							
AP		SANDOZ	**20MG/ML**		**A090218**	**001**	Apr 16, 2015
AP			**40MG/ML**		**A206921**	**001**	Feb 12, 2018
GLECAPREVIR; PIBRENTASVIR							
PELLETS;ORAL							
MAVYRET							
	+!	ABBVIE	50MG;20MG/PACKET		N215110	001	Jun 10, 2021
TABLET;ORAL							
MAVYRET							
	+!	ABBVIE	100MG;40MG		N209394	001	Aug 03, 2017
GLIMEPIRIDE							
TABLET;ORAL							
GLIMEPIRIDE							
AB		ACCORD HLTHCARE	**1MG**		**A078181**	**001**	Aug 23, 2007
AB			**2MG**		**A078181**	**002**	Aug 23, 2007
AB			**4MG**		**A078181**	**003**	Aug 23, 2007
AB		AUROBINDO PHARMA LTD	**1MG**		**A202759**	**001**	Jun 29, 2012
AB			**2MG**		**A202759**	**002**	Jun 29, 2012
AB			**4MG**		**A202759**	**003**	Jun 29, 2012
AB		CARLSBAD	**1MG**		**A077911**	**001**	Sep 22, 2009
AB			**2MG**		**A077911**	**002**	Sep 22, 2009
AB			**4MG**		**A077911**	**003**	Sep 22, 2009
AB		CHARTWELL MOLECULAR	**1MG**		**A077295**	**001**	Oct 06, 2005
AB			**2MG**		**A077295**	**002**	Oct 06, 2005
AB			**4MG**		**A077295**	**003**	Oct 06, 2005
AB	**!**	DR REDDYS LABS LTD	**1MG**		**A077091**	**001**	Oct 06, 2005
AB			**2MG**		**A077091**	**002**	Oct 06, 2005
AB			**4MG**		**A077091**	**003**	Oct 06, 2005
AB		MICRO LABS	**1MG**		**A091220**	**001**	Jun 29, 2012
AB			**2MG**		**A091220**	**002**	Jun 29, 2012
AB			**4MG**		**A091220**	**004**	Jun 29, 2012
AB			**8MG**		**A091220**	**006**	Jun 29, 2012
AB		PRINSTON INC	**1MG**		**A077370**	**001**	Dec 23, 2005
AB			**2MG**		**A077370**	**002**	Dec 23, 2005
AB			**4MG**		**A077370**	**003**	Dec 23, 2005
AB			**8MG**		**A077370**	**004**	Dec 23, 2005
AB		REGCON HOLDINGS	**1MG**		**A202112**	**001**	Apr 17, 2013
AB			**2MG**		**A202112**	**002**	Apr 17, 2013
AB			**4MG**		**A202112**	**003**	Apr 17, 2013
		MICRO LABS	3MG		A091220	003	Jun 29, 2012
			6MG		A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

AB	**+!**	TAKEDA PHARMS USA	**2MG;30MG**	**N021925**	**001**	Jul 28, 2006
AB	**+**		**4MG;30MG**	**N021925**	**002**	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

AB		CHARTWELL RX	**2MG;30MG**	**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**	**A201049**	**002**	Jan 04, 2013

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		ANI PHARMS	**5MG**	**A074497**	**001**	Aug 31, 1995
AB			**10MG**	**A074497**	**002**	Aug 31, 1995
AB		APOTEX	**5MG**	**A075795**	**001**	Jun 13, 2001
AB	**!**		**10MG**	**A075795**	**002**	Jun 13, 2001
AB		AUROBINDO PHARMA USA	**5MG**	**A074226**	**001**	May 10, 1994
AB			**10MG**	**A074226**	**002**	May 10, 1994
AB		OXFORD PHARMS	**5MG**	**A074378**	**001**	Nov 28, 1994
AB			**10MG**	**A074378**	**002**	Nov 28, 1994
AB		RUBICON RESEARCH	**5MG**	**A214874**	**002**	Oct 03, 2023
AB			**10MG**	**A214874**	**003**	Oct 03, 2023
AB		WATSON LABS TEVA	**5MG**	**A074223**	**001**	Feb 27, 1995
AB			**10MG**	**A074223**	**002**	Feb 27, 1995
		RUBICON RESEARCH	2.5MG	A214874	001	Oct 03, 2023

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA	**2.5MG**	**A206928**	**001**	May 12, 2017
AB			**5MG**	**A206928**	**002**	May 12, 2017
AB			**10MG**	**A206928**	**003**	May 12, 2017
AB		UNIQUE	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB	**!**		**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003
AB		ZYDUS PHARMS	**2.5MG**	**A203499**	**001**	Jul 16, 2018
AB			**5MG**	**A203499**	**002**	Jul 16, 2018
AB			**10MG**	**A203499**	**003**	Jul 16, 2018

GLUCOTROL XL

AB	**+**	PFIZER	**5MG**	**N020329**	**001**	Apr 26, 1994
AB	**+**		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005
AB			**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	**!**		**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB		ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB			**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB			**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

AP	**!**	AMPHASTAR PHARMS INC	**1MG/VIAL**	**A208086**	**001**	Dec 28, 2020
AP		CIPLA	**1MG/VIAL**	**A218813**	**001**	Sep 15, 2025
AP		LUPIN LTD	**1MG/VIAL**	**A214457**	**001**	Jul 22, 2025
AP		MYLAN LABS LTD	**1MG/VIAL**	**A204468**	**001**	Dec 12, 2024

POWDER;NASAL

BAQSIMI

	+!	AMPHASTAR PHARMS INC	3MG	N210134	001	Jul 24, 2019

GLUCAGON

SOLUTION;INTRAVENOUS

GVOKE VIALDX

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025

SOLUTION;SUBCUTANEOUS

GVOKE HYPOPEN

+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019
+!		1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019

GVOKE KIT

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021

GVOKE PFS

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

GLUCAGON

+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1	CADILA PHARMS LTD	**1.25MG**	**A203379**	**001**	Jan 04, 2019
AB1		**2.5MG**	**A203379**	**002**	Jan 04, 2019
AB1		**5MG**	**A203379**	**003**	Jan 04, 2019
AB1	EPIC PHARMA LLC	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1		**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1		**5MG**	**A076257**	**003**	Jun 27, 2002
AB1	HERITAGE	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1		**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1		**5MG**	**A090937**	**003**	Feb 28, 2011
AB1	ORIENT PHARMA CO LTD	**1.25MG**	**A206483**	**001**	Feb 22, 2019
AB1		**2.5MG**	**A206483**	**002**	Feb 22, 2019
AB1		**5MG**	**A206483**	**003**	Feb 22, 2019
AB1	TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1		**2.5MG**	**A074388**	**002**	Aug 29, 1995
AB1 !		**5MG**	**A074388**	**003**	Aug 29, 1995
AB1	ZYDUS PHARMS	**1.25MG**	**A206749**	**001**	May 10, 2016
AB1		**2.5MG**	**A206749**	**002**	May 10, 2016
AB1		**5MG**	**A206749**	**003**	May 10, 2016

DIABETA

AB2 +	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2 +		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2 +!		**5MG**	**N017532**	**003**	May 01, 1984

GLYBURIDE

AB2	IMPAX LABS INC	**1.25MG**	**A206079**	**001**	Sep 30, 2015
AB2		**2.5MG**	**A206079**	**002**	Sep 30, 2015
AB2		**5MG**	**A206079**	**003**	Sep 30, 2015

GLYBURIDE (MICRONIZED)

	TEVA	1.5MG	A074686	001	Apr 20, 1999
		3MG	A074686	002	Apr 20, 1999
		4.5MG	A074686	003	Apr 20, 1999
!		6MG	A074686	004	Apr 20, 1999

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001**	Jun 28, 2005
AB		**2.5MG;500MG**	**A076716**	**002**	Jun 28, 2005
AB		**5MG;500MG**	**A076716**	**003**	Jun 28, 2005
AB	AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001**	Nov 14, 2007
AB !		**2.5MG;500MG**	**A077870**	**002**	Nov 14, 2007
AB		**5MG;500MG**	**A077870**	**003**	Nov 14, 2007
AB	HERITAGE	**1.25MG;250MG**	**A079009**	**001**	Jun 03, 2009
AB		**2.5MG;500MG**	**A079009**	**002**	Jun 03, 2009
AB		**5MG;500MG**	**A079009**	**003**	Jun 03, 2009
AB	IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001**	Feb 18, 2004
AB		**2.5MG;500MG**	**A076345**	**002**	Feb 18, 2004
AB		**5MG;500MG**	**A076345**	**003**	Feb 18, 2004
AB	ZYDUS PHARMS	**1.25MG;250MG**	**A206748**	**001**	Feb 29, 2016
AB		**2.5MG;500MG**	**A206748**	**002**	Feb 29, 2016

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB			**5MG;500MG**	**A206748**	**003**	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

AA		PH HEALTH	**1.1GM/ML**	**A205742**	**001**	Dec 02, 2021

RAVICTI

AA	**+!**	HORIZON THERAP US	**1.1GM/ML**	**N203284**	**001**	Feb 01, 2013

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	**+!**	BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**	

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**	
AT		OTSUKA ICU MEDCL	**1.5GM/100ML**	**N018315**	**001**	

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP		ACCORD HLTHCARE	**0.2MG/ML**	**A213238**	**001**	Jul 08, 2020
AP		ALEMBIC	**0.2MG/ML**	**A214635**	**001**	Oct 26, 2022
AP		AM REGENT	**0.2MG/ML**	**A089335**	**001**	Jul 23, 1986
AP		AMNEAL	**0.2MG/ML**	**A208973**	**001**	Jun 15, 2017
AP			**0.2MG/ML**	**A215333**	**001**	Oct 21, 2022
AP		CAPLIN	**0.2MG/ML**	**A211705**	**001**	Mar 20, 2019
AP		FRESENIUS KABI USA	**0.2MG/ML**	**A209024**	**001**	Oct 31, 2018
AP			**0.2MG/ML**	**A209328**	**001**	Oct 27, 2017
AP		GLAND	**0.2MG/ML**	**A212612**	**001**	Sep 30, 2019
AP	**!**	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001**	Sep 21, 2011
AP		MEITHEAL	**0.2MG/ML**	**A212802**	**001**	Jul 06, 2021
AP		OMNIVIUM PHARMS	**0.2MG/ML**	**A212871**	**001**	Nov 29, 2022
AP		PIRAMAL CRITICAL	**0.2MG/ML**	**A210842**	**001**	Oct 25, 2018
AP		PRINSTON INC	**0.2MG/ML**	**A210927**	**001**	Oct 31, 2018
AP		SAGENT	**0.2MG/ML**	**A210083**	**001**	Feb 21, 2020
AP		SANDOZ	**0.2MG/ML**	**A211334**	**001**	May 14, 2019
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A207639**	**001**	Jun 23, 2017
AP		UMEDICA	**0.2MG/ML**	**A212591**	**001**	Oct 13, 2021

ROBINUL

AP	**+**	HIKMA	**0.2MG/ML**	**N017558**	**001**	

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

	+!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022

GLYRX-PF

	+!	EXELA PHARMA	0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
	+!		1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020

SOLUTION;ORAL

CUVPOSA

AA	**+!**	MERZ PHARMS	**1MG/5ML**	**N022571**	**001**	Jul 28, 2010

GLYCOPYRROLATE

AA		AJENAT PHARMS	**1MG/5ML**	**A219267**	**001**	Oct 27, 2025
AA		ANNORA PHARMA	**1MG/5ML**	**A213698**	**001**	Jul 05, 2022
AA		AUROBINDO PHARMA LTD	**1MG/5ML**	**A214847**	**001**	Dec 31, 2024
AA		BIONPHARMA	**1MG/5ML**	**A220062**	**001**	Dec 23, 2025
AA		CHARTWELL RX	**1MG/5ML**	**A216368**	**001**	Aug 28, 2024
AA		GRANULES	**1MG/5ML**	**A214735**	**001**	Aug 19, 2024
AA		MSN	**1MG/5ML**	**A216084**	**001**	Apr 08, 2025
AA		PH HEALTH	**1MG/5ML**	**A204438**	**001**	Aug 09, 2021
AA		SCIEGEN PHARMS	**1MG/5ML**	**A216297**	**001**	Oct 07, 2024
AA		SUVEN PHARMS	**1MG/5ML**	**A212467**	**001**	Jul 05, 2022

TABLET;ORAL

GLYCOPYRROLATE

AA		ALEMBIC	**1MG**	**A203657**	**001**	Nov 30, 2018
AA			**2MG**	**A203657**	**002**	Nov 30, 2018
AA		APPCO	**1MG**	**A207201**	**001**	Jan 03, 2017
AA			**2MG**	**A207201**	**002**	Jan 03, 2017
AA		AUROBINDO PHARMA	**1MG**	**A202675**	**001**	Apr 15, 2013
AA			**2MG**	**A202675**	**002**	Oct 30, 2018
AA		CHARTWELL RX	**1MG**	**A040847**	**001**	Mar 21, 2008

GLYCOPYRROLATE

TABLET;ORAL

GLYCOPYRROLATE

AA			**2MG**	**A040847**	**002**	Mar 21, 2008
AA		NATCO	**1MG**	**A091413**	**001**	Jun 20, 2016
AA			**2MG**	**A091413**	**002**	Jun 20, 2016
AA		OXFORD PHARMS	**1MG**	**A090020**	**001**	Oct 19, 2011
AA			**2MG**	**A090020**	**002**	Oct 19, 2011
AA	!	PH HEALTH	**1MG**	**A040653**	**001**	Aug 31, 2006
AA	!		**2MG**	**A040653**	**002**	Aug 31, 2006
AA		QUAGEN	**1MG**	**A212696**	**001**	Jul 10, 2024
AA			**2MG**	**A212696**	**002**	Jul 10, 2024
AA		REGCON HOLDINGS	**1MG**	**A091182**	**001**	Feb 03, 2014
AA			**2MG**	**A091182**	**002**	Feb 03, 2014
AA		RISING	**1MG**	**A040821**	**001**	Dec 29, 2008
AA			**2MG**	**A040821**	**002**	Dec 29, 2008
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001**	Aug 18, 2009
AA			**2MG**	**A040844**	**002**	Aug 18, 2009
AA		VELZEN PHARMA PVT	**1MG**	**A090195**	**001**	Sep 21, 2012
AA			**2MG**	**A090195**	**002**	Sep 21, 2012

ROBINUL

AA	+	CASPER PHARMA LLC	**1MG**	**N012827**	**001**	

ROBINUL FORTE

AA	+	CASPER PHARMA LLC	**2MG**	**N012827**	**002**	

GLYCOPYRROLATE

	!	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

	+!	AZURITY	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

	+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GOLODIRSEN

SOLUTION;INTRAVENOUS

VYONDYS 53

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N211970	001	Dec 12, 2019

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+!	TERSERA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	!	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996
AT		SCIEGEN PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005

NEOSPORIN

AT	!	MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+!	CUMBERLAND	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTABLE;SUBCUTANEOUS

SUSTOL

	+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AMNEAL	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP		BIONPHARMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP	!	DR REDDYS	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001**	Dec 31, 2007

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	**!**		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001**	Jun 30, 2008
AP		FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP		HIKMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP		MYLAN ASI	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP		RISING	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP		SANDOZ	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP		SANDOZ INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002**	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BIONPHARMA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002**	Jun 30, 2008
AP	**!**	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001**	Jun 30, 2008

SOLUTION;ORAL

GRANISETRON HYDROCHLORIDE

	INTRA SANA LABS	EQ 2MG BASE/10ML	A219282	001	Mar 17, 2025

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB		CHARTWELL MOLECULAR	**EQ 1MG BASE**	**A078037**	**001**	Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001**	Feb 27, 2009
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001**	Jun 22, 2009
AB	**!**	ORBION PHARMS	**EQ 1MG BASE**	**A078678**	**001**	Feb 13, 2008

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	**!**	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001**	Jul 06, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065200**	**001**	Mar 02, 2005
AB		CIPLA	**125MG/5ML**	**A065354**	**001**	Sep 10, 2007
AB		COSETTE	**125MG/5ML**	**A065438**	**001**	Oct 08, 2010

TABLET;ORAL

FULVICIN-U/F

AB		CHARTWELL RX	**250MG**	**A060569**	**002**	
AB			**500MG**	**A060569**	**001**	

GRISEOFULVIN

AB		SANDOZ	**250MG**	**A091592**	**001**	Aug 07, 2013
AB	**!**		**500MG**	**A091592**	**002**	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001**	Oct 22, 2012

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

FULVICIN P/G

AB		CHARTWELL RX	**125MG**	**A061996**	**001**	
AB			**250MG**	**A061996**	**002**	

GRIS-PEG

AB	**+**	BAUSCH	**125MG**	**N050475**	**001**	
AB	**+**		**250MG**	**N050475**	**002**	

GRISEOFULVIN, ULTRAMICROSIZE

AB		MOUNTAIN	**125MG**	**A204371**	**001**	Jan 09, 2014
AB	**!**		**250MG**	**A204371**	**002**	Jan 09, 2014
AB		SANDOZ	**125MG**	**A202805**	**001**	Dec 26, 2018
AB			**250MG**	**A202805**	**002**	Dec 26, 2018

GRISEOFULVIN,ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001**	Oct 22, 2012
AB			**250MG**	**A202545**	**002**	Oct 22, 2012

FULVICIN P/G 165

CHARTWELL RX	165MG	A061996	003	Apr 06, 1982

FULVICIN P/G 330

CHARTWELL RX	330MG	A061996	004	Apr 06, 1982

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		AIPING PHARM INC	**EQ 1MG BASE**	**A216399**	**001**	Jun 08, 2022
AB			**EQ 2MG BASE**	**A216399**	**002**	Jun 08, 2022
AB		AJANTA PHARMA LTD	**EQ 1MG BASE**	**A217293**	**001**	Apr 27, 2023
AB			**EQ 2MG BASE**	**A217293**	**002**	Apr 27, 2023
AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001**	Nov 25, 1998
AB	!		**EQ 2MG BASE**	**A075109**	**002**	Nov 25, 1998
AB		AUROBINDO PHARMA USA	**EQ 1MG BASE**	**A074796**	**001**	Jan 27, 1997
AB			**EQ 2MG BASE**	**A074796**	**002**	Jan 27, 1997
AB		EPIC PHARMA LLC	**EQ 1MG BASE**	**A074673**	**001**	Feb 28, 1997
AB			**EQ 2MG BASE**	**A074673**	**002**	Feb 28, 1997
AB		I 3 PHARMS	**EQ 1MG BASE**	**A216828**	**001**	Oct 05, 2023
AB			**EQ 2MG BASE**	**A216828**	**002**	Oct 05, 2023
AB		UNICHEM	**EQ 1MG BASE**	**A214689**	**001**	Mar 03, 2021
AB			**EQ 2MG BASE**	**A214689**	**002**	Mar 03, 2021
AB		WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB			**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995
AB		XIROMED	**EQ 1MG BASE**	**A218326**	**001**	Feb 23, 2024
AB			**EQ 2MG BASE**	**A218326**	**002**	Feb 23, 2024
BX		RUBICON RESEARCH	EQ 1MG BASE	A216762	001	Oct 17, 2023
BX			EQ 2MG BASE	A216762	002	Oct 17, 2023

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB			**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB			**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB			**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB		ALEMBIC	**EQ 1MG BASE**	**A217269**	**001**	Aug 07, 2023
AB			**EQ 2MG BASE**	**A217269**	**002**	Aug 07, 2023
AB			**EQ 3MG BASE**	**A217269**	**003**	Aug 07, 2023
AB			**EQ 4MG BASE**	**A217269**	**004**	Aug 07, 2023
AB		APOTEX	**EQ 1MG BASE**	**A205430**	**001**	Jul 25, 2018
AB			**EQ 2MG BASE**	**A205430**	**002**	Jul 25, 2018
AB			**EQ 3MG BASE**	**A205430**	**003**	Jul 25, 2018
AB			**EQ 4MG BASE**	**A205430**	**004**	Jul 25, 2018
AB		FOSUN WANBANG	**EQ 1MG BASE**	**A217638**	**001**	Jun 12, 2024
AB			**EQ 2MG BASE**	**A217638**	**002**	Jun 12, 2024
AB			**EQ 3MG BASE**	**A217638**	**003**	Jun 12, 2024
AB			**EQ 4MG BASE**	**A217638**	**004**	Jun 12, 2024
AB		RUBICON RESEARCH	**EQ 1MG BASE**	**A219689**	**001**	Apr 15, 2025
AB			**EQ 2MG BASE**	**A219689**	**002**	Apr 15, 2025
AB			**EQ 3MG BASE**	**A219689**	**003**	Apr 15, 2025
AB			**EQ 4MG BASE**	**A219689**	**004**	Apr 15, 2025
AB		SANDOZ	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015
AB			**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB			**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB			**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB		TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB		TWI PHARMS	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015
AB		UNICHEM	**EQ 1MG BASE**	**A219033**	**001**	Nov 19, 2024
AB			**EQ 2MG BASE**	**A219033**	**002**	Nov 19, 2024
AB			**EQ 3MG BASE**	**A219033**	**003**	Nov 19, 2024
AB			**EQ 4MG BASE**	**A219033**	**004**	Nov 19, 2024
AB		YICHANG HUMANWELL	**EQ 1MG BASE**	**A213428**	**001**	Nov 25, 2020
AB			**EQ 2MG BASE**	**A213428**	**002**	Nov 25, 2020
AB			**EQ 3MG BASE**	**A213428**	**003**	Nov 25, 2020
AB			**EQ 4MG BASE**	**A213428**	**004**	Nov 25, 2020

INTUNIV

AB	+	TAKEDA PHARMS USA	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB	+		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB	+		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	+!		**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

HALCINONIDE						
CREAM;TOPICAL						
HALCINONIDE						
AB		CHARTWELL RX	**0.1%**	**A214723**	**001**	Sep 08, 2021
AB		MYLAN	**0.1%**	**A211027**	**001**	Aug 12, 2019
HALOG						
AB	**+!**	SUN PHARM INDS INC	**0.1%**	**N017556**	**001**	
SOLUTION;TOPICAL						
HALCINONIDE						
AT	**!**	ENCUBE	**0.1%**	**A217671**	**001**	May 29, 2024
HALOG						
AT	**+**	SUN PHARM INDS INC	**0.1%**	**N017823**	**001**	
HALOBETASOL PROPIONATE						
AEROSOL, FOAM;TOPICAL						
HALOBETASOL PROPIONATE						
AB		PADAGIS ISRAEL	**0.05%**	**A215266**	**001**	Aug 11, 2023
LEXETTE						
AB	**+!**	MAYNE PHARMA	**0.05%**	**N210566**	**001**	May 24, 2018
CREAM;TOPICAL						
HALOBETASOL PROPIONATE						
AB	**!**	COSETTE	**0.05%**	**A078162**	**001**	Apr 24, 2007
AB		FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004
AB		PADAGIS ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004
LOTION;TOPICAL						
BRYHALI						
	+!	BAUSCH	0.01%	N209355	001	Nov 06, 2018
ULTRAVATE						
	+!	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015
OINTMENT;TOPICAL						
HALOBETASOL PROPIONATE						
AB		COSETTE	**0.05%**	**A077109**	**001**	Jun 14, 2005
AB	**!**	PADAGIS ISRAEL	**0.05%**	**A076872**	**001**	Dec 16, 2004
AB		QUAGEN	**0.05%**	**A213560**	**001**	Oct 06, 2020
HALOBETASOL PROPIONATE; TAZAROTENE						
LOTION;TOPICAL						
DUOBRII						
AB	**+!**	BAUSCH	**0.01%;0.045%**	**N209354**	**001**	Apr 25, 2019
HALOBETASOL PROPIONATE AND TAZAROTENE						
AB		SUN PHARMA CANADA	**0.01%;0.045%**	**A217190**	**001**	May 02, 2025
HALOPERIDOL						
TABLET;ORAL						
HALOPERIDOL						
AB		AIPING PHARM INC	**2MG**	**A071130**	**001**	Feb 17, 1987
AB			**5MG**	**A071130**	**002**	Feb 17, 1987
AB			**10MG**	**A071130**	**003**	May 12, 1987
AB		APPCO	**0.5MG**	**A211061**	**001**	Jan 08, 2020
AB			**1MG**	**A211061**	**002**	Jan 08, 2020
AB			**2MG**	**A211061**	**003**	Jan 08, 2020
AB			**5MG**	**A211061**	**004**	Jan 08, 2020
AB			**10MG**	**A211061**	**005**	Jan 08, 2020
AB			**20MG**	**A211061**	**006**	Jan 08, 2020
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A218789**	**001**	Apr 19, 2024
AB			**1MG**	**A218789**	**002**	Apr 19, 2024
AB			**2MG**	**A218789**	**003**	Apr 19, 2024
AB			**5MG**	**A218789**	**004**	Apr 19, 2024
AB			**10MG**	**A218789**	**005**	Apr 19, 2024
AB			**20MG**	**A218789**	**006**	Apr 19, 2024
AB		CHARTWELL RX	**0.5MG**	**A071209**	**002**	Nov 17, 1986
AB			**1MG**	**A071209**	**003**	Nov 17, 1986
AB			**5MG**	**A071209**	**001**	Nov 17, 1986
AB			**10MG**	**A071210**	**001**	Mar 11, 1988
AB			**20MG**	**A071211**	**001**	Mar 11, 1988
AB		CREEKWOOD PHARMS	**0.5MG**	**A218162**	**001**	Dec 18, 2025
AB			**1MG**	**A218162**	**002**	Dec 18, 2025
AB			**2MG**	**A218162**	**003**	Dec 18, 2025
AB			**5MG**	**A218162**	**004**	Dec 18, 2025
AB			**10MG**	**A218162**	**005**	Dec 18, 2025
AB			**20MG**	**A218162**	**006**	Dec 18, 2025
AB		INNOGENIX	**0.5MG**	**A071173**	**002**	Jan 02, 1987
AB			**1MG**	**A071173**	**003**	Jan 02, 1987

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB			2MG	A071173	004	Jan 02, 1987
AB			5MG	A071173	005	Jan 07, 1988
AB			10MG	A071173	001	Jan 07, 1988
AB			20MG	A071173	006	Jan 07, 1988
AB		MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024
AB			1MG	A216918	002	Apr 11, 2024
AB			2MG	A216918	003	Apr 11, 2024
AB			5MG	A216918	004	Apr 11, 2024
AB			10MG	A216918	005	Apr 11, 2024
AB			20MG	A216918	006	Apr 11, 2024
AB		MSN	0.5MG	A216004	001	Nov 18, 2022
AB			1MG	A216004	002	Nov 18, 2022
AB			2MG	A216004	003	Nov 18, 2022
AB			5MG	A216004	004	Nov 18, 2022
AB			10MG	A216004	005	Nov 18, 2022
AB			20MG	A216004	006	Nov 18, 2022
AB		MYLAN	0.5MG	A070278	006	Jun 10, 1986
AB			1MG	A070278	004	Jun 10, 1986
AB	!		2MG	A070278	001	Jun 10, 1986
AB			5MG	A070278	005	Jun 10, 1986
AB			10MG	A070278	002	Jul 16, 2009
AB			20MG	A070278	003	Jul 16, 2009
AB		ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023
AB			1MG	A077580	002	Jan 17, 2023
AB			2MG	A077580	006	Jan 17, 2023
AB			5MG	A077580	003	Nov 29, 2007
AB			10MG	A077580	004	Nov 29, 2007
AB			20MG	A077580	005	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO		CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025
AO			EQ 100MG BASE/ML	A219168	002	May 13, 2025
AO		FRESENIUS KABI USA	EQ 50MG BASE/ML	A074893	001	Dec 19, 1997
AO			EQ 100MG BASE/ML	A074893	002	Dec 19, 1997
AO		GLAND	EQ 50MG BASE/ML	A205241	001	May 12, 2017
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017
AO		HIKMA	EQ 100MG BASE/ML	A075305	001	Sep 28, 1998
AO	!	MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023
AO	!		EQ 100MG BASE/ML	A216730	002	May 23, 2023
AO		MEITHEAL	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021
AO			EQ 100MG BASE/ML	A214507	002	Jul 26, 2021
AO		MYLAN LABS LTD	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000
AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000
AO		SOMERSET THERAPS LLC	EQ 50MG BASE/ML	A209101	001	Jul 03, 2018
AO			EQ 100MG BASE/ML	A209101	002	Jul 03, 2018
AO		ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019
AO			EQ 100MG BASE/ML	A211180	002	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		LANNETT CO INC	EQ 2MG BASE/ML	A073364	001	Sep 28, 1993
AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993
AA		RUBICON RESEARCH	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024

INJECTABLE;INJECTION

HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A075689	001	Mar 09, 2001
AP		HIKMA	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001
AP	!	MYLAN LABS LTD	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009
AP		SAGENT PHARMS	EQ 5MG BASE/ML	A091637	001	Sep 02, 2011
AP			EQ 5MG BASE/ML	A200742	001	Sep 02, 2011

HEPARIN SODIUM

INJECTABLE;INJECTION

		HEPARIN SODIUM					
AP		BE PHARMS	**1,000 UNITS/ML**	**A214804**	**001**	Dec 29, 2020
AP			**10,000 UNITS/ML**	**A214839**	**001**	Dec 29, 2020
AP		EMERGE BIOSCIENCE	**1,000 UNITS/ML**	**A211005**	**001**	Dec 14, 2018
AP			**1,000 UNITS/ML**	**A211007**	**001**	May 28, 2019
AP			**5,000 UNITS/ML**	**A211007**	**002**	May 28, 2019
AP			**5,000 UNITS/ML**	**A212061**	**001**	Jul 15, 2020
AP			**10,000 UNITS/ML**	**A211007**	**003**	May 28, 2019
AP			**20,000 UNITS/ML**	**A211004**	**001**	Feb 24, 2020
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**001**	
AP			**5,000 UNITS/ML**	**A206552**	**001**	Jun 10, 2016
AP	**+!**		**5,000 UNITS/ML**	**N017651**	**006**	
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**003**	
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**004**	
AP		GLAND	**1,000 UNITS/ML**	**A205323**	**002**	Nov 18, 2019
AP			**5,000 UNITS/ML**	**A205323**	**001**	Feb 06, 2017
AP	**+!**	HIKMA	**1,000 UNITS/ML**	**N017037**	**001**	
AP	**+!**		**5,000 UNITS/ML**	**N017037**	**002**	
AP	**+!**		**10,000 UNITS/ML**	**N017037**	**003**	
AP		HOSPIRA INC	**1,000 UNITS/ML**	**A090571**	**001**	Aug 31, 2009
AP			**5,000 UNITS/ML**	**A090571**	**002**	Aug 31, 2009
AP			**10,000 UNITS/ML**	**A090571**	**003**	Aug 31, 2009
AP		PHARMOBEDIENT	**1,000 UNITS/ML**	**A203851**	**001**	Nov 30, 2017
AP			**5,000 UNITS/ML**	**A203851**	**002**	Nov 30, 2017
AP			**10,000 UNITS/ML**	**A203851**	**003**	Nov 30, 2017
AP		PLANO PHARMS	**1,000 UNITS/ML**	**A091682**	**001**	Jun 08, 2011
AP			**5,000 UNITS/ML**	**A091682**	**002**	Jun 08, 2011
AP			**10,000 UNITS/ML**	**A201002**	**001**	Jun 08, 2011
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090808**	**001**	Jun 30, 2010
AP			**5,000 UNITS/ML**	**A090808**	**002**	Jun 30, 2010
AP			**10,000 UNITS/ML**	**A090808**	**003**	Jun 30, 2010
AP			**20,000 UNITS/ML**	**A090809**	**001**	Jun 30, 2010
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202957**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202733**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202957**	**002**	Jun 12, 2014
AP			**10,000 UNITS/ML**	**A203198**	**001**	Jun 12, 2014
AP			**20,000 UNITS/ML**	**A203198**	**002**	Jun 12, 2014
		HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**001**	Apr 28, 1982
		HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	**+!**	B BRAUN	**200 UNITS/100ML**	**N019953**	**001**	Jul 20, 1992
AP		FRESENIUS KABI USA	**200 UNITS/100ML**	**A212441**	**001**	Jul 24, 2020
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**010**	Jun 23, 1989
		HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		HOSPIRA	**10,000 UNITS/100ML**	**N019339**	**003**	Mar 27, 1985
		HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**002**	Apr 28, 1982
		HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		FRESENIUS KABI USA	**200 UNITS/100ML**	**A212441**	**002**	Jul 24, 2020
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**011**	Jun 23, 1989
		HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	**+!**	B BRAUN	**5,000 UNITS/100ML**	**N019952**	**004**	Jul 20, 1992
AP	**+!**		**10,000 UNITS/100ML**	**N019952**	**005**	Jul 20, 1992
AP		HOSPIRA	**5,000 UNITS/100ML**	**N019339**	**004**	Mar 27, 1985
AP			**10,000 UNITS/100ML**	**N019339**	**002**	Mar 27, 1985
		HEPARIN SODIUM IN PLASTIC CONTAINER				
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**013**	Dec 05, 1985
AP	**+!**		**5,000 UNITS/ML**	**N017029**	**014**	Dec 05, 1985
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**015**	Dec 05, 1985
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**016**	Dec 05, 1985
		HEPARIN SODIUM PRESERVATIVE FREE				
AP		EMERGE BIOSCIENCE	**10,000 UNITS/ML**	**A212060**	**001**	Apr 02, 2020
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**010**	Apr 28, 1986
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**019**	Nov 22, 2010
AP		HOSPIRA	**10,000 UNITS/ML**	**A089522**	**001**	May 04, 1987
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090810**	**001**	Jun 30, 2010
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202732**	**001**	Jun 12, 2014
		HEPARIN SODIUM				
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
		HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

!	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+!	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+!	B BRAUN	200 UNITS/100ML	N019953	002	Dec 15, 2023

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

+!	B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017
+!		100 UNITS/ML	N017029	023	Aug 24, 2017

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017
+!		100 UNITS/ML	N017029	025	Aug 24, 2017

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+!	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025
+!		10,000 UNITS/100ML	N019953	004	Mar 25, 2025
+!	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
+!		10,000 UNITS/100ML	N018916	008	Jan 31, 1984

HEPARIN SODIUM; TAUROLIDINE

SOLUTION;N/A

DEFENCATH

+!	CORMEDIX	3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML)	N214520	001	Nov 15, 2023
+!		5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML)	N214520	002	Nov 15, 2023

HEXACHLOROPHENE

SPONGE;TOPICAL

PRE-OP

AT	**+!**	DAVIS AND GECK	**480MG**	**N017433**	**001**	

PRE-OP II

AT	**+**	DAVIS AND GECK	**480MG**	**N017433**	**002**	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION;INTRAVESICAL

CYSVIEW KIT

+!	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS

SUPPRELIN LA

+!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYCODAN

AA	**+**	GENUS	**1.5MG/5ML;5MG/5ML**	**N005213**	**002**	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	**!**	ABHAI LLC	**1.5MG/5ML;5MG/5ML**	**A207487**	**001**	Feb 21, 2017
AA		ACTAVIS MID ATLANTIC	**1.5MG/5ML;5MG/5ML**	**A088017**	**001**	Jul 05, 1983
AA		NOVEL LABS INC	**1.5MG/5ML;5MG/5ML**	**A203535**	**001**	Feb 13, 2017
AA		PADAGIS US	**1.5MG/5ML;5MG/5ML**	**A205731**	**001**	Feb 15, 2017
AA		PHARMOBEDIENT	**1.5MG/5ML;5MG/5ML**	**A088008**	**001**	Mar 03, 1983

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	**!**	AVANTHI INC	**1.5MG;5MG**	**A207176**	**001**	Aug 07, 2017

HYCODAN

AA	**+**	GENUS	**1.5MG;5MG**	**N005213**	**001**	Jul 26, 1988

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		AM REGENT	**20MG/ML**	**A040136**	**001**	Jun 30, 1997
AP		BAXTER HLTHCARE CORP	**20MG/ML**	**A219797**	**001**	Jul 17, 2025
AP		EUGIA PHARMA	**20MG/ML**	**A215147**	**001**	Feb 13, 2023
AP	**!**	FRESENIUS KABI USA	**20MG/ML**	**A040388**	**001**	Mar 13, 2001
AP		HIKMA	**20MG/ML**	**A213667**	**001**	Dec 18, 2020
AP		KINDOS	**20MG/ML**	**A217501**	**001**	Jun 02, 2025

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		NAVINTA LLC	**20MG/ML**	**A202938**	**001**	Mar 28, 2013
AP		RISING	**20MG/ML**	**A040730**	**001**	Apr 21, 2009

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	**10MG**	**A200737**	**001**	Dec 07, 2012
AA			**25MG**	**A200737**	**002**	Dec 07, 2012
AA			**50MG**	**A200737**	**003**	Dec 07, 2012
AA			**100MG**	**A200737**	**004**	Dec 07, 2012
AA		CADILA PHARMS LTD	**25MG**	**A203845**	**001**	Sep 18, 2014
AA			**50MG**	**A203845**	**002**	Sep 18, 2014
AA			**100MG**	**A203845**	**003**	Sep 18, 2014
AA		GLENMARK PHARMS LTD	**10MG**	**A090527**	**001**	May 29, 2009
AA			**25MG**	**A090527**	**002**	May 29, 2009
AA			**50MG**	**A090527**	**003**	May 29, 2009
AA			**100MG**	**A090527**	**004**	May 29, 2009
AA		HERITAGE	**10MG**	**A086242**	**001**	Feb 04, 2010
AA			**25MG**	**A086242**	**003**	
AA			**50MG**	**A086242**	**002**	
AA			**100MG**	**A086242**	**004**	Feb 04, 2010
AA		HERITAGE PHARMS INC	**10MG**	**A040858**	**001**	Feb 26, 2010
AA			**25MG**	**A040858**	**002**	Feb 26, 2010
AA			**50MG**	**A040858**	**003**	Feb 26, 2010
AA			**100MG**	**A040858**	**004**	Feb 26, 2010
AA		HETERO LABS LTD III	**10MG**	**A040901**	**001**	Sep 12, 2008
AA			**25MG**	**A040901**	**002**	Sep 12, 2008
AA			**50MG**	**A040901**	**003**	Sep 12, 2008
AA			**100MG**	**A040901**	**004**	Sep 12, 2008
AA	**!**	PLIVA	**10MG**	**A089097**	**001**	Dec 18, 1985
AA	**+!**		**25MG**	**A088467**	**001**	May 01, 1984
AA	**+!**		**50MG**	**A088468**	**001**	May 01, 1984
AA	**!**		**100MG**	**A089098**	**001**	Dec 18, 1985
AA		SCIEGEN PHARMS	**10MG**	**A205236**	**001**	May 26, 2017
AA			**25MG**	**A205236**	**002**	May 26, 2017
AA			**50MG**	**A205236**	**003**	May 26, 2017
AA			**100MG**	**A205236**	**004**	May 26, 2017
AA		STRIDES PHARMA	**25MG**	**A200770**	**001**	May 03, 2013
AA			**50MG**	**A200770**	**002**	May 03, 2013
AA			**100MG**	**A200770**	**003**	May 03, 2013
AA		STRIDES PHARMA INTL	**10MG**	**A087836**	**001**	Oct 05, 1982
AA			**25MG**	**A086961**	**002**	
AA			**50MG**	**A086962**	**001**	
AA			**100MG**	**A088391**	**001**	Sep 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

		STRIDES PHARMA INTL	25MG;25MG	A088957	001	Oct 21, 1985
	!		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

AB	**+!**	AZURITY	**37.5MG;20MG**	**N020727**	**001**	Jun 23, 2005

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	**37.5MG;20MG**	**A215988**	**001**	Jan 17, 2024
AB		NOVAST LABS	**37.5MG;20MG**	**A215586**	**001**	Apr 06, 2022

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**12.5MG**	**A078164**	**001**	Sep 18, 2007
AB		JUBILANT CADISTA	**12.5MG**	**A078391**	**001**	Feb 11, 2008
AB		PRINSTON INC	**12.5MG**	**A075907**	**001**	Sep 17, 2002
AB		SCIEGEN PHARMS	**12.5MG**	**A203561**	**001**	Jan 14, 2019
AB		UNICHEM	**12.5MG**	**A090510**	**001**	Jan 19, 2010

MICROZIDE

AB	**+!**	TEVA BRANDED PHARM	**12.5MG**	**N020504**	**001**	Dec 27, 1996

FOR SUSPENSION;ORAL

INZIRQO

	+!	NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012
AB			25MG	A202556	002	Sep 24, 2012
AB			50MG	A202556	003	Sep 24, 2012
AB		ACTAVIS ELIZABETH	12.5MG	A040707	001	Feb 27, 2007
AB		AUROBINDO PHARMA	25MG	A040780	001	Jul 20, 2007
AB			50MG	A040780	002	Jul 20, 2007
AB		HERITAGE	12.5MG	A085182	003	May 02, 2023
AB			25MG	A085182	002	
AB			50MG	A085182	001	
AB	+	IVAX SUB TEVA PHARMS	12.5MG	A083177	003	Sep 19, 2024
AB	+		25MG	A083177	001	
AB	+!		50MG	A083177	002	
AB		LEADING	12.5MG	A040702	003	May 10, 2017
AB			25MG	A040702	001	Mar 16, 2007
AB			50MG	A040702	002	Mar 16, 2007
AB		OXFORD PHARMS	25MG	A087059	001	
AB			50MG	A087068	001	
AB		SCIEGEN PHARMS	25MG	A203018	001	Jul 23, 2014
AB			50MG	A203018	002	Jul 23, 2014
AB		UNICHEM	12.5MG	A040907	003	Apr 03, 2025
AB			25MG	A040907	001	Aug 15, 2008
AB			50MG	A040907	002	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB	+!	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
AB	+!		12.5MG;300MG	N020758	003	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	12.5MG;150MG	A091370	001	Oct 15, 2012
AB			12.5MG;300MG	A091370	002	Oct 15, 2012
AB			25MG;300MG	A091370	003	Oct 12, 2016
AB		AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013
AB			12.5MG;300MG	A203630	002	Feb 22, 2013
AB			25MG;300MG	A203630	003	Mar 31, 2016
AB		DR REDDYS LABS LTD	12.5MG;150MG	A203500	001	Sep 27, 2012
AB			12.5MG;300MG	A203500	002	Sep 27, 2012
AB		HIKMA	12.5MG;150MG	A090351	001	Oct 15, 2012
AB			12.5MG;300MG	A090351	002	Oct 15, 2012
AB			25MG;300MG	A090351	003	Jun 08, 2017
AB		HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016
AB			12.5MG;300MG	A207896	002	Oct 14, 2016
AB		MACLEODS PHARMS LTD	12.5MG;150MG	A202414	001	Sep 27, 2012
AB			12.5MG;300MG	A202414	002	Sep 27, 2012
AB		PRINSTON INC	12.5MG;150MG	A203072	001	May 09, 2014
AB			12.5MG;300MG	A203072	002	May 09, 2014
AB		SANDOZ	12.5MG;150MG	A077446	001	Sep 27, 2012
AB			12.5MG;300MG	A077446	002	Sep 27, 2012
AB		TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012
AB			12.5MG;300MG	A077369	002	Mar 30, 2012

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		AIPING PHARM INC	12.5MG;10MG	A076262	001	Jul 01, 2002
AB			12.5MG;20MG	A076262	002	Jul 01, 2002
AB			25MG;20MG	A076262	003	Jul 01, 2002
AB		AUROBINDO	12.5MG;10MG	A077606	001	Mar 14, 2006
AB			12.5MG;20MG	A077606	002	Mar 14, 2006
AB			25MG;20MG	A077606	003	Mar 14, 2006
AB		COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004
AB			12.5MG;20MG	A076674	002	Oct 05, 2004
AB			25MG;20MG	A076674	003	Oct 05, 2004
AB		INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017
AB	!		12.5MG;20MG	A204058	002	May 23, 2017
AB	!		25MG;20MG	A204058	003	May 23, 2017
AB		LUPIN	12.5MG;10MG	A077912	001	Sep 27, 2006
AB			12.5MG;20MG	A077912	002	Sep 27, 2006

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB			25MG;20MG	A077912	003	Sep 27, 2006
AB		PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002
AB			12.5MG;20MG	A076230	002	Jul 01, 2002
AB			25MG;20MG	A076230	003	Jul 01, 2002
AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002
AB			12.5MG;20MG	A076007	002	Jul 01, 2002
AB			25MG;20MG	A076007	003	Jul 01, 2002
AB		WATSON LABS	12.5MG;10MG	A076194	003	Jul 01, 2002
AB			12.5MG;20MG	A076194	001	Jul 01, 2002
AB			25MG;20MG	A076194	002	Jul 01, 2002

ZESTORETIC

AB	+	ALMATICA	12.5MG;10MG	N019888	003	Nov 18, 1993
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990
AB	+		25MG;20MG	N019888	002	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	+	ORGANON	12.5MG;50MG	N020387	001	Apr 28, 1995
AB	+		12.5MG;100MG	N020387	003	Oct 20, 2005
AB	+		25MG;100MG	N020387	002	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;50MG	A091617	001	Feb 17, 2012
AB			12.5MG;100MG	A091617	002	Feb 17, 2012
AB			25MG;100MG	A091617	003	Feb 17, 2012
AB		AUROBINDO PHARMA	12.5MG;50MG	A091629	001	Oct 06, 2010
AB			12.5MG;100MG	A091629	002	Oct 06, 2010
AB	!		25MG;100MG	A091629	003	Jan 06, 2010
AB		CHARTWELL RX	12.5MG;50MG	A077948	001	Oct 06, 2010
AB			12.5MG;100MG	A077948	003	Aug 19, 2010
AB			25MG;100MG	A077948	002	Oct 06, 2010
AB		JUBILANT CADISTA	12.5MG;50MG	A201845	001	Sep 18, 2012
AB			12.5MG;100MG	A201845	002	Sep 18, 2012
AB			25MG;100MG	A201845	003	Sep 18, 2012
AB		LUPIN LTD	12.5MG;50MG	A078245	001	Oct 06, 2010
AB			12.5MG;100MG	A078245	002	May 21, 2010
AB			25MG;100MG	A078245	003	Oct 06, 2010
AB		MACLEODS PHARMS LTD	12.5MG;50MG	A202289	001	Aug 09, 2012
AB			12.5MG;100MG	A202289	002	Aug 09, 2012
AB			25MG;100MG	A202289	003	Aug 09, 2012
AB		PRINSTON INC	12.5MG;50MG	A204901	001	Nov 06, 2017
AB			12.5MG;100MG	A204901	002	Nov 06, 2017
AB			25MG;100MG	A204901	003	Nov 06, 2017
AB		TEVA PHARMS	12.5MG;50MG	A077157	001	Apr 06, 2010
AB			12.5MG;100MG	A077157	002	Apr 06, 2010
AB			25MG;100MG	A077157	003	Apr 06, 2010
AB		UNICHEM	12.5MG;50MG	A204832	001	Jul 21, 2017
AB			12.5MG;100MG	A204832	002	Jul 21, 2017
AB			25MG;100MG	A204832	003	Jul 21, 2017
AB		ZYDUS PHARMS USA INC	12.5MG;50MG	A078385	001	Oct 06, 2010
AB			25MG;100MG	A078385	002	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	+	VALIDUS PHARMS	25MG;50MG	N018303	001	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	25MG;50MG	A202870	001	Nov 06, 2013
AB	!		25MG;100MG	A202870	002	Nov 06, 2013
AB			50MG;100MG	A202870	003	Nov 06, 2013
AB		MYLAN	25MG;50MG	A076792	001	Aug 20, 2004
AB			25MG;100MG	A076792	002	Aug 20, 2004
AB			50MG;100MG	A076792	003	Aug 20, 2004
AB		SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025
AB			25MG;100MG	A215789	002	Jan 08, 2025

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	TEVA	12.5MG;7.5MG	A076980	001	Mar 07, 2007
		12.5MG;15MG	A076980	003	Mar 07, 2007
!		25MG;15MG	A076980	002	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	+	COSETTE	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB	+		**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	+!		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	**12.5MG;20MG**	**A209281**	**001**	Feb 07, 2019
AB			**12.5MG;40MG**	**A209281**	**002**	Feb 07, 2019
AB			**25MG;40MG**	**A209281**	**003**	Feb 07, 2019
AB		ALEMBIC	**12.5MG;20MG**	**A204233**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A204233**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A204233**	**003**	Apr 24, 2017
AB		ALKEM LABS LTD	**12.5MG;20MG**	**A207037**	**001**	Jul 11, 2024
AB			**12.5MG;40MG**	**A207037**	**002**	Jul 11, 2024
AB			**25MG;40MG**	**A207037**	**003**	Jul 11, 2024
AB		AUROBINDO PHARMA	**12.5MG;20MG**	**A205391**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A205391**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A205391**	**003**	Apr 24, 2017
AB		HANGZHOU BINJIANG	**12.5MG;20MG**	**A214427**	**001**	Aug 20, 2025
AB			**12.5MG;40MG**	**A214427**	**002**	Aug 20, 2025
AB			**25MG;40MG**	**A214427**	**003**	Aug 20, 2025
AB		HETERO LABS LTD V	**12.5MG;20MG**	**A209199**	**001**	Jul 25, 2025
AB			**12.5MG;40MG**	**A209199**	**002**	Jul 25, 2025
AB			**25MG;40MG**	**A209199**	**003**	Jul 25, 2025
AB		MACLEODS PHARMS LTD	**12.5MG;20MG**	**A204801**	**001**	Jun 01, 2023
AB			**12.5MG;40MG**	**A204801**	**002**	Jun 01, 2023
AB			**25MG;40MG**	**A204801**	**003**	Jun 01, 2023
AB		MSN	**12.5MG;20MG**	**A217398**	**001**	Sep 26, 2025
AB			**12.5MG;40MG**	**A217398**	**002**	Sep 26, 2025
AB			**25MG;40MG**	**A217398**	**003**	Sep 26, 2025
AB		PRINSTON INC	**12.5MG;20MG**	**A207804**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A207804**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A207804**	**003**	Apr 24, 2017
AB		UMEDICA	**12.5MG;20MG**	**A208847**	**001**	Sep 17, 2019
AB			**12.5MG;40MG**	**A208847**	**003**	Sep 17, 2019
AB			**25MG;40MG**	**A208847**	**002**	Sep 17, 2019

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB	!		**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		CHARTWELL RX	**12.5MG;EQ 10MG BASE**	**A076374**	**001**	Mar 31, 2004
AB			**12.5MG;EQ 20MG BASE**	**A076374**	**002**	Mar 31, 2004
AB			**25MG;EQ 20MG BASE**	**A076374**	**003**	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

AB	+	PFIZER	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDUSTRIES	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

AB	+	BOEHRINGER INGELHEIM	**12.5MG;40MG**	**N021162**	**001**	Nov 17, 2000
AB	+		**12.5MG;80MG**	**N021162**	**002**	Nov 17, 2000
AB	+!		**25MG;80MG**	**N021162**	**003**	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	**12.5MG;40MG**	**A203010**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A203010**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A203010**	**003**	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	12.5MG;40MG	A208727	001	Dec 15, 2016
AB			12.5MG;80MG	A208727	002	Dec 15, 2016
AB			25MG;80MG	A208727	003	Dec 15, 2016
AB		GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019
AB			12.5MG;80MG	A202544	002	Mar 04, 2019
AB			25MG;80MG	A202544	003	Mar 04, 2019
AB		LUPIN LTD	12.5MG;40MG	A091351	001	Aug 07, 2014
AB			12.5MG;80MG	A091351	002	Aug 07, 2014
AB			25MG;80MG	A091351	003	Aug 07, 2014
AB		PRINSTON INC	12.5MG;40MG	A209028	001	Nov 06, 2017
AB			12.5MG;80MG	A209028	002	Nov 06, 2017
AB			25MG;80MG	A209028	003	Nov 06, 2017
AB		ZYDUS PHARMS	12.5MG;40MG	A204221	001	Aug 15, 2017
AB			12.5MG;80MG	A204221	002	Aug 15, 2017
AB			25MG;80MG	A204221	003	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019
AB		LANNETT CO INC	25MG;37.5MG	A201407	001	Dec 09, 2011
AB	!	SANDOZ	25MG;37.5MG	A074821	001	Jun 05, 1997

TABLET;ORAL

MAXZIDE

AB	+!	AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984

MAXZIDE-25

AB	+	AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	25MG;37.5MG	A071251	002	May 05, 1998
AB			50MG;75MG	A071251	001	Apr 17, 1988
AB		CHARTWELL RX	50MG;75MG	A072011	001	Jun 17, 1988
AB		RUBICON RESEARCH	25MG;37.5MG	A216211	001	Feb 23, 2022
AB			50MG;75MG	A216211	002	Feb 23, 2022
AB		SANDOZ	25MG;37.5MG	A073281	001	Apr 30, 1992
AB		WATSON LABS	25MG;37.5MG	A073449	001	Sep 23, 1993
AB			50MG;75MG	A071851	001	Nov 30, 1988
AB		ZYDUS PHARMS	25MG;37.5MG	A208360	001	Jun 29, 2018
AB			50MG;75MG	A208360	002	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB	+	NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998
AB	+		12.5MG;160MG	N020818	002	Mar 06, 1998
AB	+		12.5MG;320MG	N020818	004	Apr 28, 2006
AB	+		25MG;160MG	N020818	003	Jan 17, 2002
AB	+!		25MG;320MG	N020818	005	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC	12.5MG;80MG	A201662	001	Mar 21, 2013
AB			12.5MG;160MG	A201662	002	Mar 21, 2013
AB			12.5MG;320MG	A201662	003	Mar 21, 2013
AB			25MG;160MG	A201662	004	Mar 21, 2013
AB			25MG;320MG	A201662	005	Mar 21, 2013
AB		AMNEAL PHARMS	12.5MG;80MG	A204382	001	Aug 11, 2023
AB			12.5MG;160MG	A204382	002	Aug 11, 2023
AB			12.5MG;320MG	A204382	004	Aug 11, 2023
AB			25MG;160MG	A204382	003	Aug 11, 2023
AB			25MG;320MG	A204382	005	Aug 11, 2023
AB		AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013
AB			12.5MG;160MG	A202519	002	Mar 21, 2013
AB			12.5MG;320MG	A202519	003	Mar 21, 2013
AB			25MG;160MG	A202519	004	Mar 21, 2013
AB			25MG;320MG	A202519	005	Mar 21, 2013
AB		LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013
AB			12.5MG;160MG	A078946	004	Mar 21, 2013
AB			12.5MG;320MG	A078946	001	Mar 21, 2013
AB			25MG;160MG	A078946	005	Mar 21, 2013
AB			25MG;320MG	A078946	002	Mar 21, 2013

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB			**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB			**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB			**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB			**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB		MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB			**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB			**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB			**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB			**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB		PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB			**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB			**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB			**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB			**25MG;320MG**	**A206083**	**005**	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

!	ALVOGEN	10MG	A206986	001	Jan 21, 2020
		15MG	A206986	002	Jan 21, 2020
		20MG	A206986	003	Jan 21, 2020
		30MG	A206986	004	Jan 21, 2020
		40MG	A206986	005	Jan 21, 2020
		50MG	A206986	006	Jan 21, 2020

TABLET, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN	**20MG**	**A208269**	**001**	Mar 01, 2021
AB			**30MG**	**A208269**	**002**	Mar 01, 2021
AB			**40MG**	**A208269**	**003**	Mar 01, 2021
AB			**60MG**	**A208269**	**004**	Mar 01, 2021
AB			**80MG**	**A208269**	**005**	Mar 01, 2021
AB			**100MG**	**A208269**	**006**	Mar 01, 2021

HYSINGLA ER

AB	**+!**	PURDUE PHARMA LP	**20MG**	**N206627**	**001**	Nov 20, 2014
AB	**+**		**30MG**	**N206627**	**002**	Nov 20, 2014
AB	**+**		**40MG**	**N206627**	**003**	Nov 20, 2014
AB	**+**		**60MG**	**N206627**	**004**	Nov 20, 2014
AB	**+**		**80MG**	**N206627**	**005**	Nov 20, 2014
AB	**+**		**100MG**	**N206627**	**006**	Nov 20, 2014

HYDROCODONE BITARTRATE

	ALVOGEN	120MG	A208269	007	Mar 01, 2021

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		ACTAVIS LABS FL INC	**7.5MG;200MG**	**A076604**	**001**	Dec 31, 2003
AB	**!**	AMNEAL PHARMS NY	**7.5MG;200MG**	**A076642**	**001**	Oct 12, 2004
AB		AUROLIFE PHARMA LLC	**7.5MG;200MG**	**A204575**	**001**	Jun 02, 2016
		AMNEAL PHARMS NY	5MG;200MG	A076642	002	Mar 18, 2004

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT		CROWN LABS	**2.5%**	**A080706**	**007**	Jan 05, 2016
AT			**1%**	**A080706**	**006**	

ANUSOL HC

AT		SALIX PHARMS	**2.5%**	**A088250**	**001**	Jun 06, 1984

HYDROCORTISONE

AT		ACTAVIS MID ATLANTIC	**1%**	**A087795**	**001**	May 03, 1983
AT			**2.5%**	**A089682**	**001**	Mar 10, 1988
AT	**+!**	FOUGERA PHARMS INC	**1%**	**A080693**	**003**	
AT	**!**		**2.5%**	**A089414**	**001**	Dec 16, 1986
AT		PADAGIS US	**2.5%**	**A085025**	**001**	
AT		RISING	**2.5%**	**A040879**	**001**	Aug 20, 2010
AT		TARO	**2.5%**	**A088799**	**001**	Nov 09, 1984

ENEMA;RECTAL

COLOCORT

AB		CHARTWELL	**100MG/60ML**	**A075172**	**001**	Dec 03, 1999

HYDROCORTISONE							
ENEMA;RECTAL							
CORTENEMA							
AB	**+!**	ANI PHARMS	**100MG/60ML**	**N016199**	**001**		
GRANULE;ORAL							
ALKINDI SPRINKLE							
	+	ETON	0.5MG	N213876	001	Sep 29, 2020	
	+		1MG	N213876	002	Sep 29, 2020	
	+		2MG	N213876	003	Sep 29, 2020	
	+!		5MG	N213876	004	Sep 29, 2020	
LOTION;TOPICAL							
ALA-SCALP							
	+	LEGACY PHARMA	2%	A083231	001		
STIE-CORT							
	!	PADAGIS US	2.5%	A089074	001	Nov 26, 1985	
OINTMENT;TOPICAL							
HYDROCORTISONE							
AT	**+!**	FOUGERA PHARMS	**1%**	**A080692**	**001**		
AT	**!**	FOUGERA PHARMS INC	**2.5%**	**A081203**	**001**	May 28, 1993	
AT		PADAGIS US	**2.5%**	**A085027**	**001**		
HYDROCORTISONE IN ABSORBASE							
AT		CMP PHARMA INC	**1%**	**A088138**	**001**	Sep 06, 1985	
SOLUTION;ORAL							
KHINDIVI							
	+!	ETON	1MG/ML	N218980	001	May 28, 2025	
SOLUTION;TOPICAL							
TEXACORT							
	!	MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992	
TABLET;ORAL							
CORTEF							
AB	**+**	PHARMACIA AND UPJOHN	**5MG**	**N008697**	**003**		
AB	**+**		**10MG**	**N008697**	**001**		
AB	**+!**		**20MG**	**N008697**	**002**		
HYDROCORTISONE							
AB		AUROBINDO PHARMA LTD	**5MG**	**A214649**	**001**	Jul 17, 2023	
AB			**10MG**	**A214649**	**002**	Jul 17, 2023	
AB			**20MG**	**A214649**	**003**	Jul 17, 2023	
AB		HIBROW HLTHCARE	**5MG**	**A217160**	**001**	Nov 25, 2024	
AB			**10MG**	**A217160**	**002**	Nov 25, 2024	
AB			**20MG**	**A217160**	**003**	Nov 25, 2024	
AB		IMPAX LABS INC	**5MG**	**A040646**	**001**	Mar 30, 2007	
AB			**10MG**	**A040646**	**002**	Mar 30, 2007	
AB			**20MG**	**A040646**	**003**	Mar 30, 2007	
AB		NOVITIUM PHARMA	**5MG**	**A217881**	**001**	May 02, 2025	
AB			**10MG**	**A217881**	**002**	May 02, 2025	
AB			**20MG**	**A217881**	**003**	May 02, 2025	
AB		STRIDES PHARMA	**5MG**	**A207029**	**001**	Apr 27, 2017	
AB			**10MG**	**A207029**	**002**	Apr 27, 2017	
AB			**20MG**	**A207029**	**003**	Apr 27, 2017	
HYDROCORTISONE ACETATE							
AEROSOL, METERED;RECTAL							
CORTIFOAM							
	+!	VIATRIS	10%	N017351	001	Feb 10, 1982	
CREAM;TOPICAL							
MICORT-HC							
		LEGACY PHARMA	2.5%	A040396	001	Feb 27, 2001	
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE							
AEROSOL, METERED;TOPICAL							
EPIFOAM							
BX		MYLAN SPECIALITY LP	1%;1%	A086457	001		
PROCTOFOAM HC							
BX	+!	MYLAN SPECIALITY LP	1%;1%	A086195	001		
CREAM;TOPICAL							
PRAMOSONE							
		LEGACY PHARMA	0.5%;1%	A083778	001		
			1%;1%	A085368	001		
LOTION;TOPICAL							
PRAMOSONE							
		LEGACY PHARMA	1%;1%	A085980	001		
			2.5%;1%	A085979	001		

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE						
AB1		TARO PHARM INDS	**0.1%**	**A076654**	**001**	Aug 03, 2005
LOCOID						
AB1	**+!**	BAUSCH	**0.1%**	**N018514**	**001**	Mar 31, 1982
HYDROCORTISONE BUTYRATE						
AB2		ACTAVIS MID ATLANTIC	**0.1%**	**A205134**	**001**	Dec 08, 2017
LOCOID LIPOCREAM						
AB2	**+!**	PRECISION DERMAT	**0.1%**	**N020769**	**001**	Sep 08, 1997

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE						
AB	**!**	LUPIN LTD	**0.1%**	**A210209**	**001**	Aug 17, 2018
AB		THE J MOLNER	**0.1%**	**A209556**	**001**	Nov 21, 2017

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE						
AB		TARO	**0.1%**	**A076842**	**001**	Dec 27, 2004
LOCOID						
AB	**+!**	PRECISION DERMAT	**0.1%**	**N018652**	**001**	Oct 29, 1982

SOLUTION;TOPICAL

HYDROCORTISONE BUTYRATE						
AT		TARO PHARM INDS	**0.1%**	**A076364**	**001**	Jan 14, 2004
LOCOID						
AT	**+!**	BAUSCH	**0.1%**	**N019116**	**001**	Feb 25, 1987

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE						
AP		CIPLA	**EQ 100MG BASE/VIAL**	**A214050**	**001**	Sep 05, 2024
SOLU-CORTEF						
AP	**+!**	PHARMACIA AND UPJOHN	**EQ 100MG BASE/VIAL**	**N009866**	**001**	
	+!		EQ 250MG BASE/VIAL	N009866	002	
	+!		EQ 500MG BASE/VIAL	N009866	003	
	+!		EQ 1GM BASE/VIAL	N009866	004	

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE						
AB		COSETTE	**0.2%**	**A213724**	**001**	Feb 11, 2021
AB		ENCUBE ETHICALS	**0.2%**	**A211047**	**001**	Nov 04, 2021
AB		LUPIN LTD	**0.2%**	**A210307**	**001**	Aug 15, 2019
AB		PADAGIS ISRAEL	**0.2%**	**A075666**	**001**	May 24, 2000
AB	**!**	SUN PHARMA CANADA	**0.2%**	**A075042**	**001**	Aug 25, 1998

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE						
AB		COSETTE	**0.2%**	**A211764**	**001**	Mar 04, 2020
AB	**!**	SUN PHARMA CANADA	**0.2%**	**A075043**	**001**	Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMNEAL	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A217803**	**001**	Oct 29, 2025
AT	**!**	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001**	Dec 29, 1995
AT		SANDOZ	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001**	Aug 25, 1983

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988

SUSPENSION/DROPS;OTIC

CASPORYN HC						
AT	**+!**	CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMNEAL	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A217735**	**001**	Sep 30, 2025
AT		SANDOZ	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001**	Nov 06, 1985
AT		SCIEGEN PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001**	May 01, 2006
OTICAIR						
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001**	Aug 28, 1996

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION						
DILAUDID						
AP	**+!**	FRESENIUS KABI USA	**0.2MG/ML**	**N019034**	**006**	Jan 16, 2020
AP	**+!**		**0.5MG/0.5ML**	**N019034**	**007**	Feb 10, 2017
AP	**+!**		**1MG/ML**	**N019034**	**003**	Apr 30, 2009
AP	**+!**		**2MG/ML**	**N019034**	**004**	Apr 30, 2009
AP	**+!**		**4MG/ML**	**N019034**	**005**	Apr 30, 2009
HYDROMORPHONE HYDROCHLORIDE						
AP		HIKMA	**0.2MG/ML**	**A216899**	**001**	Feb 09, 2024
AP			**0.5MG/0.5ML**	**A216899**	**002**	Feb 09, 2024
AP			**1MG/ML**	**A216899**	**003**	Feb 09, 2024
AP			**2MG/ML**	**A202159**	**001**	Apr 27, 2018
AP			**2MG/ML**	**A216899**	**004**	Feb 09, 2024
AP		HOSPIRA INC	**1MG/ML**	**N200403**	**001**	Dec 01, 2011
AP			**2MG/ML**	**N200403**	**002**	Dec 01, 2011
AP			**4MG/ML**	**N200403**	**003**	Dec 01, 2011
AP			**10MG/ML**	**A078591**	**001**	Jun 17, 2008
AP		RISING	**10MG/ML**	**A078228**	**001**	Apr 14, 2010
AP			**10MG/ML**	**A078261**	**001**	Apr 14, 2010
		HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023
			0.5MG/0.5ML	N200403	004	Jun 13, 2022
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
HYDROMORPHONE HYDROCHLORIDE						
	+!	HIKMA	40MG/20ML (2MG/ML)	N217812	001	Dec 14, 2023
SOLUTION;ORAL						
DILAUDID						
AA	**+!**	RHODES PHARMS	**5MG/5ML**	**N019891**	**001**	Dec 07, 1992
HYDROMORPHONE HYDROCHLORIDE						
AA		ASCENT PHARMS INC	**5MG/5ML**	**A210176**	**001**	Oct 27, 2017
AA		HIKMA	**5MG/5ML**	**A074653**	**001**	Jul 29, 1998
TABLET;ORAL						
DILAUDID						
AB	**+**	RHODES PHARMS	**2MG**	**N019892**	**003**	Nov 09, 2007
AB	**+**		**4MG**	**N019892**	**002**	Nov 09, 2007
AB	**+!**		**8MG**	**N019892**	**001**	Dec 07, 1992
HYDROMORPHONE HYDROCHLORIDE						
AB		ASCENT PHARMS INC	**2MG**	**A210506**	**001**	Jan 17, 2018
AB			**4MG**	**A210506**	**002**	Jan 17, 2018
AB			**8MG**	**A210506**	**003**	Jan 17, 2018
AB		AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001**	May 13, 2016
AB			**4MG**	**A205814**	**002**	May 13, 2016
AB			**8MG**	**A205814**	**003**	May 13, 2016
AB		SPECGX LLC	**2MG**	**A076855**	**002**	Sep 19, 2007
AB			**4MG**	**A076855**	**003**	Sep 19, 2007
AB			**8MG**	**A076855**	**001**	Dec 23, 2004
TABLET, EXTENDED RELEASE;ORAL						
HYDROMORPHONE HYDROCHLORIDE						
AB		ASCENT PHARMS INC	**8MG**	**A212133**	**001**	Sep 23, 2020
AB			**12MG**	**A212133**	**002**	Sep 23, 2020
AB			**16MG**	**A212133**	**003**	Sep 23, 2020
AB			**32MG**	**A212133**	**004**	Sep 23, 2020
AB		OSMOTICA PHARM US	**8MG**	**A205629**	**001**	Jul 07, 2016
AB			**12MG**	**A205629**	**002**	Jul 07, 2016
AB			**16MG**	**A205629**	**003**	Jul 07, 2016
AB	**!**		**32MG**	**A205629**	**004**	Jul 07, 2016
AB		PADAGIS US	**8MG**	**A204278**	**001**	Apr 06, 2015
AB			**12MG**	**A204278**	**002**	Apr 06, 2015
AB			**16MG**	**A204278**	**003**	Apr 06, 2015
AB			**32MG**	**A204278**	**004**	Sep 20, 2017
		OSMOTICA PHARM US	24MG	A205629	005	Oct 30, 2024

HYDROXOCOBALAMIN

INJECTABLE;INJECTION						
CYANOKIT						
	+!	BTG INTL	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
HYDROXOCOBALAMIN						
	!	ACTAVIS	1MG/ML	A085998	001	

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ACCORD HLTHCARE	**100MG**	**A213342**	**002**	Aug 18, 2021
AB			**200MG**	**A213342**	**001**	Apr 07, 2020
AB			**300MG**	**A213342**	**003**	Aug 18, 2021
AB	**!**		**400MG**	**A213342**	**004**	Aug 18, 2021
AB		ALKALOIDA ZRT	**200MG**	**A201691**	**001**	May 08, 2018
AB		AMNEAL PHARMS CO	**200MG**	**A210577**	**001**	May 15, 2018
AB		ANDA REPOSITORY	**200MG**	**A212902**	**001**	May 14, 2020
AB	**!**	APPCO	**100MG**	**A210441**	**002**	Sep 19, 2022
AB			**200MG**	**A210441**	**001**	May 01, 2018
AB			**300MG**	**A210441**	**003**	Sep 19, 2022
AB			**400MG**	**A210441**	**004**	Sep 19, 2022
AB		AUROBINDO PHARMA USA	**200MG**	**A040274**	**001**	May 29, 1998
AB		CHARTWELL RX	**200MG**	**A210543**	**001**	Jul 06, 2018
AB		CREEKWOOD PHARMS	**200MG**	**A040150**	**001**	Jan 27, 1996
AB		IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB		LAURUS	**200MG**	**A210959**	**001**	Jan 15, 2019
AB		SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB		TEVA PHARMS	**200MG**	**A040081**	**001**	Sep 30, 1994
AB		ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007

PLAQUENIL

AB	**+!**	ADVANZ PHARMA	**200MG**	**N009768**	**001**	

SOVUNA

	+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022
	+!		300MG	N214581	002	Jan 14, 2022

HYDROXYUREA

CAPSULE;ORAL

HYDREA

AB	**+!**	WAYLIS THERAP	**500MG**	**N016295**	**001**	

HYDROXYUREA

AB		BARR	**500MG**	**A075143**	**001**	Oct 16, 1998
AB		LEADING	**500MG**	**A213438**	**001**	Apr 08, 2020
AB		PH HEALTH	**500MG**	**A075340**	**001**	Feb 24, 1999
AB		QILU	**500MG**	**A218021**	**001**	Mar 06, 2024

SOLUTION;ORAL

XROMI

	+!	NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024

TABLET;ORAL

SIKLOS

	+	THERAVIA	100MG	N208843	001	Dec 21, 2017
	+!		1GM	N208843	002	Dec 21, 2017

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

	+!	AM REGENT	25MG/ML	A087408	001	
	+!		50MG/ML	A087408	002	

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA		APOZEAL PHARMS	**10MG/5ML**	**A210634**	**001**	Feb 26, 2019
AA		BIONPHARMA	**10MG/5ML**	**A219289**	**001**	Apr 28, 2025
AA	**+!**	CHARTWELL RX	**10MG/5ML**	**A087294**	**001**	Apr 12, 1982
AA		LANNETT CO INC	**10MG/5ML**	**A201674**	**001**	Aug 21, 2013
AA		NOVITIUM PHARMA	**10MG/5ML**	**A219648**	**001**	Dec 16, 2025
AA		PAI HOLDINGS PHARM	**10MG/5ML**	**A040391**	**001**	Apr 10, 2002

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	**10MG**	**A040808**	**001**	Sep 24, 2008
AB			**25MG**	**A040808**	**002**	Sep 24, 2008
AB			**50MG**	**A040808**	**003**	Sep 24, 2008
AB		AUROBINDO PHARMA LTD	**10MG**	**A087871**	**002**	Dec 20, 1982
AB			**25MG**	**A087871**	**003**	Dec 20, 1982
AB			**50MG**	**A087871**	**001**	Dec 20, 1982
AB		CHARTWELL RX	**10MG**	**A040804**	**001**	Jun 30, 2008
AB			**25MG**	**A040804**	**002**	Jun 30, 2008
AB			**50MG**	**A040804**	**003**	Jun 30, 2008
AB		EPIC PHARMA LLC	**10MG**	**A040604**	**002**	Dec 28, 2004
AB			**25MG**	**A040604**	**003**	Dec 28, 2004

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB			**50MG**	**A040604**	**001**	Dec 28, 2004
AB		GRAVITI PHARMS	**10MG**	**A217652**	**001**	Aug 17, 2023
AB			**25MG**	**A217652**	**002**	Aug 17, 2023
AB	**!**		**50MG**	**A217652**	**003**	Aug 17, 2023
AB		HERITAGE	**10MG**	**A204279**	**001**	Aug 20, 2014
AB			**25MG**	**A204279**	**002**	Aug 20, 2014
AB			**50MG**	**A204279**	**003**	Aug 20, 2014
AB		HETERO LABS LTD III	**10MG**	**A040805**	**001**	May 29, 2008
AB			**25MG**	**A040805**	**002**	May 29, 2008
AB			**50MG**	**A040805**	**003**	May 29, 2008
AB		KVK TECH	**10MG**	**A040786**	**001**	Mar 20, 2007
AB			**25MG**	**A040786**	**002**	Mar 20, 2007
AB			**50MG**	**A040786**	**003**	Mar 20, 2007
AB		NORTHSTAR HLTHCARE	**10MG**	**A040840**	**002**	Mar 31, 2008
AB			**25MG**	**A040840**	**003**	Mar 31, 2008
AB			**50MG**	**A040840**	**001**	Mar 31, 2008
AB		NUVO PHARMS INC	**10MG**	**A207121**	**002**	Mar 29, 2017
AB			**25MG**	**A207121**	**001**	Mar 29, 2017
AB			**50MG**	**A207121**	**003**	Mar 29, 2017
AB	**+!**	PLIVA	**10MG**	**A088617**	**001**	Jan 10, 1986
AB	**+!**		**25MG**	**A088618**	**001**	Jan 10, 1986
AB	**+**		**50MG**	**A088619**	**001**	Jan 10, 1986
AB		PRINSTON INC	**10MG**	**A040580**	**003**	May 27, 2005
AB			**25MG**	**A040580**	**002**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		BARR	**EQ 25MG HYDROCHLORIDE**	**A088496**	**001**	Jun 15, 1984
AB		BARR LABS	**EQ 50MG HYDROCHLORIDE**	**A088487**	**001**	Jun 15, 1984
AB		HERITAGE PHARMA	**EQ 25MG HYDROCHLORIDE**	**A201507**	**001**	Jun 03, 2013
AB	**!**		**EQ 50MG HYDROCHLORIDE**	**A201507**	**002**	Jun 03, 2013
AB		IMPAX LABS INC	**EQ 25MG HYDROCHLORIDE**	**A040156**	**001**	Jul 15, 1996
AB			**EQ 50MG HYDROCHLORIDE**	**A040156**	**002**	Jul 15, 1996
AB		SANDOZ	**EQ 25MG HYDROCHLORIDE**	**A087479**	**001**	
AB			**EQ 50MG HYDROCHLORIDE**	**A086183**	**001**	

VISTARIL

AB	**+**	PFIZER	**EQ 25MG HYDROCHLORIDE**	**N011459**	**002**	
AB	**+**		**EQ 50MG HYDROCHLORIDE**	**N011459**	**004**	

HYDROXYZINE PAMOATE

		BARR LABS	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP		ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP	**!**	APOTEX	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP		CHEMI SPA	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP		EUGIA PHARMA	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP		PHARMOBEDIENT	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014

TABLET;ORAL

IBANDRONATE SODIUM

AB		APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB		AUROBINDO PHARMA	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB	**!**	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A206887**	**001**	Oct 31, 2017
AB		ORBION PHARMS	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012

IBREXAFUNGERP CITRATE

TABLET;ORAL

BREXAFEMME

	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N214900	001	Jun 01, 2021

IBRUTINIB

CAPSULE;ORAL

IMBRUVICA

	+	PHARMACYCLICS LLC	70MG	N205552	002	Dec 20, 2017
	+!		140MG	N205552	001	Nov 13, 2013

IBRUTINIB						
SUSPENSION;ORAL						
IMBRUVICA						
	+!	PHARMACYCLICS LLC	70MG/ML	N217003	001	Aug 24, 2022
TABLET;ORAL						
IMBRUVICA						
	+	PHARMACYCLICS LLC	140MG	N210563	001	Feb 16, 2018
	+		280MG	N210563	002	Feb 16, 2018
	+!		420MG	N210563	003	Feb 16, 2018
IBUPROFEN						
SOLUTION;INTRAVENOUS						
CALDOLOR						
	+!	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
	+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019
SUSPENSION;ORAL						
IBUPROFEN						
AB	!	ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998
AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A209178**	**001**	Feb 16, 2018
AB		PADAGIS US	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004
AB		STRIDES PHARMA	**100MG/5ML**	**A215311**	**001**	May 27, 2022
AB		SUN PHARMA CANADA	**100MG/5ML**	**A209204**	**001**	Jun 23, 2017
TABLET;ORAL						
IBUPROFEN						
AB		ALKEM LABS LTD	**400MG**	**A214699**	**001**	Sep 13, 2021
AB			**600MG**	**A214699**	**002**	Sep 13, 2021
AB			**800MG**	**A214699**	**003**	Sep 13, 2021
AB		AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB			**400MG**	**A078558**	**001**	Jun 18, 2007
AB			**600MG**	**A071335**	**001**	Nov 25, 1986
AB			**600MG**	**A078558**	**002**	Jun 18, 2007
AB			**800MG**	**A071935**	**001**	Oct 13, 1987
AB			**800MG**	**A078558**	**003**	Jun 18, 2007
AB		AUROBINDO PHARMA LTD	**400MG**	**A213794**	**001**	May 08, 2020
AB			**600MG**	**A213794**	**002**	May 08, 2020
AB			**800MG**	**A213794**	**003**	May 08, 2020
AB		CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB			**600MG**	**A071268**	**001**	Oct 15, 1986
AB			**800MG**	**A071268**	**003**	Jul 01, 1988
AB		DR REDDYS	**400MG**	**A075682**	**001**	Nov 14, 2001
AB			**600MG**	**A075682**	**002**	Nov 14, 2001
AB	!		**800MG**	**A075682**	**003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112**	**001**	Oct 31, 2001
AB			**600MG**	**A076112**	**002**	Oct 31, 2001
AB			**800MG**	**A076112**	**003**	Oct 31, 2001
AB		GRANULES	**400MG**	**A091625**	**001**	Sep 15, 2015
AB			**600MG**	**A091625**	**002**	Sep 15, 2015
AB			**800MG**	**A091625**	**003**	Sep 15, 2015
AB		MARKSANS PHARMA	**400MG**	**A090796**	**001**	Dec 21, 2010
AB			**600MG**	**A090796**	**002**	Dec 21, 2010
AB			**800MG**	**A090796**	**003**	Dec 21, 2010
AB		SHANDONG XINHUA	**400MG**	**A202413**	**001**	Nov 23, 2016
AB			**600MG**	**A202413**	**002**	Nov 23, 2016
AB			**800MG**	**A202413**	**003**	Nov 23, 2016
AB		STRIDES PHARMA	**400MG**	**A078329**	**001**	Feb 05, 2009
AB			**600MG**	**A078329**	**002**	Feb 05, 2009
AB			**800MG**	**A078329**	**003**	Feb 05, 2009
AB		YICHANG HUMANWELL	**400MG**	**A215318**	**001**	Mar 30, 2022
AB			**600MG**	**A215318**	**002**	Mar 30, 2022
AB			**800MG**	**A215318**	**003**	Mar 30, 2022
		SHANDONG XINHUA	300MG	A202413	004	Jul 05, 2024
IBUPROFEN LYSINE						
INJECTABLE;INTRAVENOUS						
IBUPROFEN LYSINE						
AP		XGEN PHARMS	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402**	**001**	Mar 30, 2016
NEOPROFEN						
AP	+!	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903**	**001**	Apr 13, 2006

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

CORVERT

AP	**+!**	PFIZER	**0.1MG/ML**	**N020491**	**001**	Dec 28, 1995

IBUTILIDE FUMARATE

AP		AVET LIFESCIENCES	**0.1MG/ML**	**A204146**	**001**	Apr 01, 2024
AP		PHARMOBEDIENT	**0.1MG/ML**	**A090643**	**001**	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	**+!**	TAKEDA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N022150**	**001**	Aug 25, 2011

ICATIBANT ACETATE

AP		ALEMBIC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213773**	**001**	Jun 14, 2024
AP		CIPLA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212446**	**001**	Jul 13, 2020
AP		EUGIA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213521**	**001**	Aug 14, 2023
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A208317**	**001**	Jun 18, 2020
AP		JIANGSU HANSOH PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211021**	**001**	Mar 09, 2020
AP		NANG KUANG PHARM CO	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212081**	**001**	Dec 16, 2020
AP		TEVA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A210118**	**001**	Jul 15, 2019
AP		WILSHIRE PHARMS INC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211501**	**001**	Sep 01, 2020

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

	+!	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB		APOTEX	**1GM**	**A209437**	**001**	Jun 30, 2021
AB		ASCENT PHARMS INC	**500MG**	**A216811**	**001**	Dec 07, 2023
AB			**1GM**	**A216811**	**002**	Feb 16, 2024
AB		DR REDDYS	**500MG**	**A209499**	**002**	Mar 08, 2023
AB			**1GM**	**A209499**	**001**	Aug 07, 2020
AB		HIKMA	**500MG**	**A209457**	**002**	Mar 08, 2023
AB			**1GM**	**A209457**	**001**	May 21, 2020
AB		HUMANWELL PURACAP	**500MG**	**A217919**	**001**	Dec 22, 2023
AB			**1GM**	**A217919**	**002**	Dec 22, 2023
AB		ONESOURCE SPECIALTY	**500MG**	**A217844**	**001**	Sep 22, 2023
AB			**1GM**	**A217844**	**002**	Sep 22, 2023
AB		PHARMOBEDIENT	**1GM**	**A218994**	**001**	Dec 20, 2024
AB		QILU	**1GM**	**A218899**	**001**	Nov 20, 2024
AB		TEVA PHARMS USA	**500MG**	**A209525**	**001**	Sep 11, 2020
AB			**1GM**	**A209525**	**002**	Sep 11, 2020
AB		XIAMEN LP PHARM CO	**1GM**	**A219156**	**001**	Aug 06, 2025
AB		ZYDUS LIFESCIENCES	**500MG**	**A217656**	**001**	Apr 20, 2023
AB			**1GM**	**A217656**	**002**	Apr 20, 2023

VASCEPA

AB	**+**	AMARIN PHARMS	**500MG**	**N202057**	**002**	Feb 16, 2017
AB	**+!**		**1GM**	**N202057**	**001**	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

IDAMYCIN PFS

AP	**+!**	PFIZER	**5MG/5ML (1MG/ML)**	**N050734**	**001**	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP		HIKMA	**5MG/5ML (1MG/ML)**	**A065275**	**001**	Dec 14, 2006
AP			**5MG/5ML (1MG/ML)**	**A065288**	**001**	May 15, 2007
AP			**10MG/10ML (1MG/ML)**	**A065275**	**002**	Dec 14, 2006
AP			**10MG/10ML (1MG/ML)**	**A065288**	**002**	May 15, 2007
AP			**20MG/20ML (1MG/ML)**	**A065275**	**003**	Dec 14, 2006
AP			**20MG/20ML (1MG/ML)**	**A065288**	**003**	May 15, 2007
AP		MEITHEAL	**5MG/5ML (1MG/ML)**	**A065036**	**001**	May 01, 2002
AP			**10MG/10ML (1MG/ML)**	**A065036**	**002**	May 01, 2002
AP			**20MG/20ML (1MG/ML)**	**A065036**	**003**	May 01, 2002
AP	**+!**	PFIZER	**10MG/10ML (1MG/ML)**	**N050734**	**002**	Feb 17, 1997
AP	**+!**		**20MG/20ML (1MG/ML)**	**N050734**	**003**	Feb 17, 1997

IDELALISIB

TABLET;ORAL

ZYDELIG

+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014
+!		150MG	N205858	002	Jul 23, 2014

IFOSFAMIDE

INJECTABLE;INJECTION

IFEX

AP	**+**	BAXTER HLTHCARE	**1GM/VIAL**	**N019763**	**001**	Dec 30, 1988
AP	**+**		**3GM/VIAL**	**N019763**	**002**	Dec 30, 1988

IFOSFAMIDE

AP	**!**	FRESENIUS KABI USA	**1GM/VIAL**	**A076078**	**001**	May 28, 2002
AP	**!**		**3GM/VIAL**	**A076078**	**002**	May 28, 2002
AP		HIKMA	**1GM/20ML (50MG/ML)**	**A076619**	**001**	Jun 29, 2011
AP			**3GM/60ML (50MG/ML)**	**A076619**	**002**	Jun 29, 2011
AP	**!**	MEITHEAL	**1GM/20ML (50MG/ML)**	**A076657**	**001**	Apr 04, 2007
AP	**!**		**3GM/60ML (50MG/ML)**	**A076657**	**002**	Apr 04, 2007

ILOPERIDONE

TABLET;ORAL

FANAPT

+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
+		2MG	N022192	002	May 06, 2009
+		4MG	N022192	003	May 06, 2009
+		6MG	N022192	004	May 06, 2009
+		8MG	N022192	005	May 06, 2009
+		10MG	N022192	006	May 06, 2009
+		12MG	N022192	007	May 06, 2009

ILOPROST

SOLUTION;INTRAVENOUS

AURLUMYN

+!	BTG INTL	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024

IMATINIB MESYLATE

SOLUTION;ORAL

IMKELDI

+!	SHORLA ONCOLOGY	EQ 80MG BASE/ML	N219097	001	Nov 22, 2024

TABLET;ORAL

GLEEVEC

AB	**+**	NOVARTIS	**EQ 100MG BASE**	**N021588**	**001**	Apr 18, 2003
AB	**+!**		**EQ 400MG BASE**	**N021588**	**002**	Apr 18, 2003

IMATINIB MESYLATE

AB	APOTEX	**EQ 100MG BASE**	**A079179**	**001**	Aug 05, 2016
AB		**EQ 400MG BASE**	**A079179**	**002**	Aug 05, 2016
AB	CHARTWELL RX	**EQ 100MG BASE**	**A208429**	**001**	Jan 17, 2019
AB		**EQ 400MG BASE**	**A208429**	**002**	Jan 17, 2019
AB	CSPC OUYI	**EQ 100MG BASE**	**A212193**	**001**	Apr 21, 2025
AB		**EQ 400MG BASE**	**A212193**	**002**	Apr 21, 2025
AB	DR REDDYS	**EQ 100MG BASE**	**A206547**	**001**	Aug 13, 2018
AB		**EQ 400MG BASE**	**A206547**	**002**	Aug 13, 2018
AB	EUGIA PHARMA	**EQ 100MG BASE**	**A212773**	**001**	Jul 23, 2020
AB		**EQ 400MG BASE**	**A212773**	**002**	Jul 23, 2020
AB	HETERO LABS LTD V	**EQ 100MG BASE**	**A212975**	**001**	Apr 14, 2025
AB		**EQ 400MG BASE**	**A212975**	**002**	Apr 14, 2025
AB	MYLAN	**EQ 100MG BASE**	**A204644**	**001**	Jun 21, 2017
AB		**EQ 400MG BASE**	**A204644**	**002**	Jun 21, 2017
AB	NATCO PHARMA LTD	**EQ 100MG BASE**	**A207818**	**001**	Mar 01, 2019
AB		**EQ 400MG BASE**	**A207818**	**002**	Mar 01, 2019
AB	QILU PHARM HAINAN	**EQ 100MG BASE**	**A212135**	**001**	Jun 21, 2022
AB		**EQ 400MG BASE**	**A212135**	**002**	Jun 21, 2022
AB	SHILPA	**EQ 100MG BASE**	**A208302**	**001**	Jan 17, 2019
AB		**EQ 400MG BASE**	**A208302**	**002**	Jan 17, 2019
AB	SUN PHARM	**EQ 100MG BASE**	**A078340**	**001**	Dec 03, 2015
AB		**EQ 400MG BASE**	**A078340**	**002**	Dec 03, 2015
AB	TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001**	Aug 04, 2016
AB		**EQ 400MG BASE**	**A204285**	**002**	Aug 04, 2016
AB	ZYDUS PHARMS	**EQ 100MG BASE**	**A210658**	**001**	Apr 08, 2020
AB		**EQ 400MG BASE**	**A210658**	**002**	Apr 08, 2020

IMETELSTAT SODIUM
POWDER;INTRAVENOUS
RYTELO

+!	GERON	EQ 47MG BASE/VIAL	N217779	001	Jun 06, 2024
+!		EQ 188MG BASE/VIAL	N217779	002	Jun 06, 2024

IMIPRAMINE HYDROCHLORIDE
TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB	LEADING	**10MG**	**A040903**	**001**	Oct 24, 2012
AB		**25MG**	**A040903**	**002**	Oct 24, 2012
AB !		**50MG**	**A040903**	**003**	Oct 24, 2012
AB	OXFORD PHARMS	**10MG**	**A040751**	**003**	Feb 28, 2008
AB		**25MG**	**A040751**	**002**	Feb 28, 2008
AB		**50MG**	**A040751**	**001**	Feb 28, 2008
AB	SANDOZ	**10MG**	**A084936**	**002**	
AB		**25MG**	**A083745**	**001**	
AB		**50MG**	**A084937**	**001**	
AB	STRIDES PHARMA INTL	**10MG**	**A088292**	**001**	Oct 21, 1983
AB		**25MG**	**A088262**	**001**	Oct 21, 1983
AB		**50MG**	**A088276**	**001**	Oct 21, 1983
AB	SUN PHARM INDUSTRIES	**25MG**	**A081049**	**001**	Jun 05, 1990
AB		**50MG**	**A081050**	**001**	Jun 05, 1990

IMIPRAMINE PAMOATE
CAPSULE;ORAL
IMIPRAMINE PAMOATE

AB !	HIKMA	**EQ 75MG HYDROCHLORIDE**	**A091099**	**001**	Apr 16, 2010
AB		**EQ 100MG HYDROCHLORIDE**	**A091099**	**002**	Apr 16, 2010
AB		**EQ 125MG HYDROCHLORIDE**	**A091099**	**003**	Apr 16, 2010
AB		**EQ 150MG HYDROCHLORIDE**	**A091099**	**004**	Apr 16, 2010
AB	LUPIN LTD	**EQ 75MG HYDROCHLORIDE**	**A090444**	**001**	Apr 16, 2010
AB		**EQ 100MG HYDROCHLORIDE**	**A090444**	**002**	Apr 16, 2010
AB		**EQ 125MG HYDROCHLORIDE**	**A090444**	**003**	Apr 16, 2010
AB		**EQ 150MG HYDROCHLORIDE**	**A090444**	**004**	Apr 16, 2010

IMIQUIMOD
CREAM;TOPICAL
IMIQUIMOD

AB	FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB !	GLENMARK PHARMS INC	**5%**	**A201994**	**001**	Mar 06, 2012
AB	PADAGIS ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB	TARO	**3.75%**	**A205971**	**001**	Jan 26, 2021
AB		**5%**	**A200173**	**001**	Apr 15, 2011

ZYCLARA

AB **+!**	BAUSCH	**3.75%**	**N022483**	**001**	Mar 25, 2010
+!		2.5%	N022483	002	Jul 15, 2011

IMLUNESTRANT TOSYLATE
TABLET;ORAL
INLURIYO

+!	ELI LILLY AND CO	EQ 200MG BASE	N218881	001	Sep 25, 2025

INAMRINONE LACTATE
INJECTABLE;INJECTION
AMRINONE LACTATE

!	HIKMA	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INAVOLISIB
TABLET;ORAL
ITOVEBI

+	GENENTECH INC	3MG	N219249	001	Oct 10, 2024
+!		9MG	N219249	002	Oct 10, 2024

INCLISIRAN SODIUM
SOLUTION;SUBCUTANEOUS
LEQVIO

+!	NOVARTIS	EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	N214012	001	Dec 22, 2021

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE

AB	ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB		**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB	ANI PHARMS	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB !		**2.5MG**	**A074299**	**001**	Jul 27, 1995

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE

AB		RISING	**1.25MG**	**A074461**	**002**	Mar 26, 1997
AB			**2.5MG**	**A074461**	**001**	Mar 27, 1996

INDIGOTINDISULFONATE SODIUM
SOLUTION;INTRAVENOUS
BLUDIGO

	+!	PROVEPHARM SAS	40MG/5ML (8MG/ML)	N216264	001	Jul 08, 2022

INDIUM IN-111 OXYQUINOLINE
INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

AP		BWXT ITG	**1mCi/ML**	**A202586**	**001**	Jul 25, 2018
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N019044**	**001**	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM
INJECTABLE;INTRATHECAL
MPI INDIUM DTPA IN 111

	+!	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT
INJECTABLE;INJECTION
INDIUM IN-111 PENTETREOTIDE KIT

AP		SUN PHARM INDS INC	**3mCi/ML**	**A212785**	**001**	Jul 01, 2024

OCTREOSCAN

AP	**+!**	CURIUM	**3mCi/ML**	**N020314**	**001**	Jun 02, 1994

INDOCYANINE GREEN
INJECTABLE;INJECTION
IC-GREEN

AP	**+**	RENEW PHARMS	**25MG/VIAL**	**N011525**	**001**	

INDOCYANINE GREEN

AP	**!**	RENEW PHARMS	**25MG/VIAL**	**A040811**	**001**	Nov 21, 2007

POWDER;INTRAVENOUS, INTERSTITIAL
SPY AGENT GREEN KIT

	+!	NOVADAQ TECH	25MG/VIAL	N211580	001	Nov 21, 2018

INDOMETHACIN
CAPSULE;ORAL
INDOMETHACIN

AB		CHARTWELL MOLECULES	**25MG**	**N018829**	**002**	Aug 06, 1984
AB			**50MG**	**A070651**	**001**	Mar 05, 1986
AB			**50MG**	**N018829**	**001**	Aug 06, 1984
AB		GLENMARK PHARMS LTD	**25MG**	**A091276**	**001**	Dec 22, 2010
AB	**!**		**50MG**	**A091276**	**002**	Dec 22, 2010
AB		HETERO LABS LTD III	**25MG**	**A091240**	**001**	Apr 12, 2011
AB			**50MG**	**A091240**	**002**	Apr 12, 2011
AB		SANDOZ	**25MG**	**A070673**	**001**	Apr 29, 1987
AB			**50MG**	**A070674**	**001**	Apr 29, 1987
AB		ZYDUS LIFESCIENCES	**25MG**	**A090403**	**001**	Nov 15, 2010
AB			**50MG**	**A090403**	**002**	Nov 15, 2010

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

AB		AMNEAL PHARMS	**75MG**	**A091549**	**001**	Dec 01, 2010
AB		AVANTHI INC	**75MG**	**A079175**	**001**	Mar 06, 2009
AB		CHARTWELL RX	**75MG**	**A200529**	**001**	Nov 30, 2010
AB		GLENMARK PHARMS LTD	**75MG**	**A203501**	**001**	Jun 22, 2017
AB	**!**	HETERO LABS LTD III	**75MG**	**A201807**	**001**	Sep 28, 2012
AB		NOVAST LABS	**75MG**	**A204853**	**001**	May 08, 2017
AB		ZYDUS PHARMS	**75MG**	**A202711**	**001**	Sep 25, 2017

INJECTABLE;INJECTION
INDOMETHACIN

	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010

SUPPOSITORY;RECTAL
INDOMETHACIN

AB		AMNEAL	**50MG**	**A215399**	**001**	Feb 24, 2025
AB		ANNORA PHARMA	**50MG**	**A216905**	**001**	Jul 03, 2025
AB	**!**	COSETTE	**50MG**	**A073314**	**001**	Aug 31, 1992
AB		HIKMA	**50MG**	**A215899**	**001**	Nov 19, 2024
AB		ZYDUS LIFESCIENCES	**50MG**	**A216184**	**001**	Aug 02, 2023

SUSPENSION;ORAL
INDOCIN

AB	**+!**	ZYLA	**25MG/5ML**	**N018332**	**001**	Oct 10, 1985

INDOMETHACIN
SUSPENSION;ORAL
INDOMETHACIN

AB		NOVITIUM PHARMA	**25MG/5ML**	**A217883**	**001**	Jan 12, 2024

IOBENGUANE SULFATE I-123
SOLUTION;INTRAVENOUS
ADREVIEW

	+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008

IODIXANOL
INJECTABLE;INJECTION
IODIXANOL

AP		HENGRUI PHARMA	**55%**	**A214271**	**001**	May 19, 2022
AP			**65.2%**	**A214271**	**002**	May 19, 2022

VISIPAQUE 270

AP	**+!**	GE HEALTHCARE	**55%**	**N020351**	**001**	Mar 22, 1996

VISIPAQUE 320

AP	**+!**	GE HEALTHCARE	**65.2%**	**N020351**	**002**	Mar 22, 1996
			65.2%	N020808	002	Aug 29, 1997

IOFLUPANE I-123
SOLUTION;INTRAVENOUS
DATSCAN

AP	**+!**	GE HLTHCARE INC	**5mCi/2.5ML (2mCi/ML)**	**N022454**	**001**	Jan 14, 2011

IOFLUPANE I-123

AP		CURIUM	**5mCi/2.5ML (2mCi/ML)**	**A213792**	**001**	Mar 30, 2022

IOHEXOL
INJECTABLE;INJECTION
OMNIPAQUE 140

	+!	GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988

SOLUTION;INJECTION, ORAL
OMNIPAQUE 350

	+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
			75.5%	N020608	003	Oct 24, 1995

SOLUTION;INJECTION, ORAL, RECTAL
IOHEXOL

AP		AMNEAL	**64.7%**	**A217737**	**001**	Nov 13, 2025

OMNIPAQUE 300

AP	**+!**	GE HEALTHCARE	**64.7%**	**N018956**	**003**	Dec 26, 1985

OMNIPAQUE 180

	+!	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985

OMNIPAQUE 240

	+!	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985

OMNIPAQUE 300

		GE HEALTHCARE	64.7%	N020608	002	Oct 24, 1995

SOLUTION;ORAL
OMNIPAQUE 12

	+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018

OMNIPAQUE 9

	+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018

IOPAMIDOL
INJECTABLE;INJECTION
IOPAMIDOL

AP		HAINAN POLY	**51%**	**A217134**	**002**	Apr 09, 2024
AP			**61%**	**A215382**	**002**	Feb 27, 2023
AP			**61%**	**A217134**	**003**	Apr 09, 2024
AP			**76%**	**A217134**	**004**	Apr 09, 2024

ISOVUE-250

AP	**+!**	BRACCO	**51%**	**N018735**	**007**	Jul 06, 1992

ISOVUE-300

AP	**+!**	BRACCO	**61%**	**N018735**	**002**	Dec 31, 1985

ISOVUE-370

AP	**+!**	BRACCO	**76%**	**N018735**	**003**	Dec 31, 1985

ISOVUE-M 300

AP	**+!**	BRACCO	**61%**	**N018735**	**004**	Dec 31, 1985

IOPAMIDOL

AP1		HAINAN POLY	**41%**	**A215382**	**001**	Feb 27, 2023

ISOVUE-M 200

AP1	**+!**	BRACCO	**41%**	**N018735**	**001**	Dec 31, 1985

IOPAMIDOL

AP2		HAINAN POLY	**41%**	**A217134**	**001**	Sep 27, 2023

IOPAMIDOL

INJECTABLE;INJECTION

ISOVUE-200

AP2	**+!**	BRACCO	**41%**	**N018735**	**006**	Jul 07, 1987

ISOVUE-300

+!	BRACCO	61%	N020327	003	Oct 12, 1994

ISOVUE-370

+!	BRACCO	76%	N020327	004	Oct 12, 1994

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)

+!	BAYER HLTHCARE	62.3%	N021425	001	Sep 20, 2002
+!		76.9%	N021425	002	Sep 20, 2002

ULTRAVIST 300

+!	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995

ULTRAVIST 370

+!	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

CONRAY

+!	LIEBEL-FLARSHEIM	60%	N013295	001	

SOLUTION;INTRAVESICAL

CYSTO-CONRAY II

	LIEBEL-FLARSHEIM	17.2%	N017057	002	

IOTHALAMATE SODIUM I-125

INJECTABLE;INJECTION

GLOFIL-125

	ISOTEX	250-300uCi/ML	N017279	001	

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 300

+!	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992

OPTIRAY 320

+!	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988
+!		68%	N020923	002	May 29, 1998

OPTIRAY 350

+!	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992
+!		74%	N020923	003	May 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA

+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

AN		LUOXIN AUROVITAS	**0.02%**	**A206543**	**001**	Oct 27, 2016
AN		NEPHRON	**0.02%**	**A075562**	**001**	Sep 27, 2001
AN	**!**	RITEDOSE CORP	**0.02%**	**A075693**	**001**	Jan 26, 2001

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB		AMNEAL	**0.021MG/SPRAY**	**A215104**	**001**	Aug 16, 2022
AB			**0.042MG/SPRAY**	**A215105**	**001**	Aug 16, 2022
AB		APOTEX INC	**0.021MG/SPRAY**	**A076156**	**001**	Apr 18, 2003
AB			**0.042MG/SPRAY**	**A076155**	**001**	Apr 18, 2003
AB		BAUSCH	**0.021MG/SPRAY**	**A076025**	**001**	Mar 31, 2003
AB			**0.042MG/SPRAY**	**A076103**	**001**	Mar 31, 2003
AB	**!**	HIKMA	**0.021MG/SPRAY**	**A076664**	**001**	Nov 05, 2003
AB	**!**		**0.042MG/SPRAY**	**A076598**	**001**	Nov 05, 2003
AB		LUPIN	**0.021MG/SPRAY**	**A217912**	**001**	Feb 07, 2025
AB			**0.042MG/SPRAY**	**A217886**	**001**	Jan 27, 2025
AB		RUBICON RESEARCH	**0.021MG/SPRAY**	**A219222**	**001**	Jan 14, 2025
AB			**0.042MG/SPRAY**	**A219221**	**001**	Nov 15, 2024

IPTACOPAN HYDROCHLORIDE

CAPSULE;ORAL

FABHALTA

+!	NOVARTIS	EQ 200MG BASE	N218276	001	Dec 05, 2023

IRBESARTAN

TABLET;ORAL

AVAPRO							
AB	**+**	SANOFI AVENTIS US	**150MG**	**N020757**	**002**	Sep 30, 1997
AB	**+!**		**300MG**	**N020757**	**003**	Sep 30, 1997
IRBESARTAN							
AB		ALEMBIC PHARMS LTD	**75MG**	**A091236**	**001**	Oct 15, 2012
AB			**150MG**	**A091236**	**002**	Oct 15, 2012
AB			**300MG**	**A091236**	**003**	Oct 15, 2012
AB		AMNEAL PHARMS	**75MG**	**A204740**	**001**	Apr 17, 2018
AB			**150MG**	**A204740**	**002**	Apr 17, 2018
AB			**300MG**	**A204740**	**003**	Apr 17, 2018
AB		AUROBINDO PHARMA LTD	**75MG**	**A203081**	**001**	Sep 27, 2012
AB			**150MG**	**A203081**	**002**	Sep 27, 2012
AB			**300MG**	**A203081**	**003**	Sep 27, 2012
AB		CHARTWELL MOLECULAR	**75MG**	**A077205**	**001**	Nov 14, 2012
AB			**150MG**	**A077205**	**002**	Nov 14, 2012
AB			**300MG**	**A077205**	**003**	Nov 14, 2012
AB		HETERO LABS LTD V	**75MG**	**A202910**	**001**	Sep 27, 2012
AB			**150MG**	**A202910**	**002**	Sep 27, 2012
AB			**300MG**	**A202910**	**003**	Sep 27, 2012
AB		HISUN PHARM HANGZHOU	**75MG**	**A206194**	**001**	Jun 14, 2016
AB			**150MG**	**A206194**	**002**	Jun 14, 2016
AB			**300MG**	**A206194**	**003**	Jun 14, 2016
AB		JUBILANT GENERICS	**75MG**	**A203534**	**001**	Feb 23, 2015
AB			**150MG**	**A203534**	**002**	Feb 23, 2015
AB			**300MG**	**A203534**	**003**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**75MG**	**A202254**	**001**	Oct 03, 2012
AB			**150MG**	**A202254**	**002**	Oct 03, 2012
AB			**300MG**	**A202254**	**003**	Oct 03, 2012
AB		MSN	**75MG**	**A219539**	**001**	Nov 04, 2025
AB			**150MG**	**A219539**	**002**	Nov 04, 2025
AB			**300MG**	**A219539**	**003**	Nov 04, 2025
AB		PRINSTON INC	**75MG**	**A203071**	**001**	Sep 27, 2012
AB			**150MG**	**A203071**	**002**	Sep 27, 2012
AB			**300MG**	**A203071**	**003**	Sep 27, 2012
AB		SANDOZ	**75MG**	**A077466**	**001**	Sep 27, 2012
AB			**150MG**	**A077466**	**002**	Sep 27, 2012
AB			**300MG**	**A077466**	**003**	Sep 27, 2012
AB		SCIEGEN PHARMS	**75MG**	**A204774**	**001**	Dec 07, 2015
AB			**150MG**	**A204774**	**002**	Dec 07, 2015
AB			**300MG**	**A204774**	**003**	Dec 07, 2015
AB		TEVA PHARMS	**75MG**	**A077159**	**001**	Mar 30, 2012
AB			**150MG**	**A077159**	**002**	Mar 30, 2012
AB			**300MG**	**A077159**	**003**	Mar 30, 2012
AB		UNICHEM	**75MG**	**A203020**	**001**	Dec 07, 2015
AB			**150MG**	**A203020**	**002**	Dec 07, 2015
AB			**300MG**	**A203020**	**003**	Dec 07, 2015
AB		ZYDUS PHARMS USA INC	**75MG**	**A079213**	**001**	Sep 27, 2012
AB			**150MG**	**A079213**	**002**	Sep 27, 2012
AB			**300MG**	**A079213**	**003**	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR							
AP	**+!**	PFIZER INC	**40MG/2ML (20MG/ML)**	**N020571**	**001**	Jun 14, 1996
AP	**+!**		**100MG/5ML (20MG/ML)**	**N020571**	**002**	Jun 14, 1996
AP	**+!**		**300MG/15ML (20MG/ML)**	**N020571**	**003**	Aug 05, 2010
IRINOTECAN HYDROCHLORIDE							
AP		ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP			**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP		ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP		EPIC PHARMA LLC	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP			**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP		EUGIA PHARMA	**40MG/2ML (20MG/ML)**	**A213278**	**001**	Nov 02, 2020
AP			**100MG/5ML (20MG/ML)**	**A213278**	**002**	Nov 02, 2020
AP			**300MG/15ML (20MG/ML)**	**A213278**	**003**	Nov 02, 2020
AP			**500MG/25ML (20MG/ML)**	**A213278**	**004**	Apr 11, 2022

IRINOTECAN HYDROCHLORIDE
INJECTABLE;INJECTION
IRINOTECAN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP		GLAND	**40MG/2ML (20MG/ML)**	**A212993**	**001**	Nov 18, 2019
AP			**100MG/5ML (20MG/ML)**	**A212993**	**002**	Nov 18, 2019
AP		HIKMA	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP			**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008
AP		HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP			**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP		HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP	**!**		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP		INTAS PHARMS USA	**40MG/2ML (20MG/ML)**	**A203054**	**001**	Aug 31, 2017
AP			**100MG/5ML (20MG/ML)**	**A203054**	**002**	Aug 31, 2017
AP		NOVAST LABS	**40MG/2ML (20MG/ML)**	**A206935**	**001**	May 26, 2017
AP			**100MG/5ML (20MG/ML)**	**A206935**	**002**	May 26, 2017
AP		PHARMOBEDIENT	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP			**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011
AP		QILU PHARM HAINAN	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP			**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP			**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP		SHILPA	**40MG/2ML (20MG/ML)**	**A208718**	**001**	Dec 28, 2018
AP			**100MG/5ML (20MG/ML)**	**A208718**	**002**	Dec 28, 2018
AP			**300MG/15ML (20MG/ML)**	**A208718**	**003**	Aug 16, 2019
AP		TEVA PHARMS USA	**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008

INJECTABLE, LIPOSOMAL;INTRAVENOUS
ONIVYDE

	+!	IPSEN	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

IRON DEXTRAN
INJECTABLE;INJECTION
INFED

BP	+!	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001	

IRON SUCROSE
INJECTABLE;INTRAVENOUS
IRON SUCROSE

AB		INTL MEDICATION SYS	**EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)**	**A208977**	**001**	Aug 08, 2025
AB			**EQ 100MG IRON/5ML (EQ 20MG IRON/ML)**	**A208977**	**002**	Aug 08, 2025
AB			**EQ 200MG IRON/10ML (EQ 20MG IRON/ML)**	**A208977**	**003**	Aug 08, 2025
AB		MYLAN LABS LTD	**EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)**	**A212559**	**001**	Aug 08, 2025
AB			**EQ 100MG IRON/5ML (EQ 20MG IRON/ML)**	**A212559**	**002**	Aug 08, 2025
AB			**EQ 200MG IRON/10ML (EQ 20MG IRON/ML)**	**A212559**	**003**	Aug 08, 2025
AB		SANDOZ	**EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)**	**A212340**	**001**	Aug 08, 2025
AB			**EQ 100MG IRON/5ML (EQ 20MG IRON/ML)**	**A212340**	**002**	Aug 08, 2025
AB			**EQ 200MG IRON/10ML (EQ 20MG IRON/ML)**	**A212340**	**003**	Aug 08, 2025

VENOFER

AB	**+**	AM REGENT	**EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)**	**N021135**	**002**	Mar 20, 2005
AB	**+!**		**EQ 100MG IRON/5ML (EQ 20MG IRON/ML)**	**N021135**	**001**	Nov 06, 2000
AB	**+**		**EQ 200MG IRON/10ML (EQ 20MG IRON/ML)**	**N021135**	**004**	Feb 09, 2007

ISAVUCONAZONIUM SULFATE
CAPSULE;ORAL
CRESEMBA

	+	ASTELLAS	74.5MG	N207500	002	Nov 22, 2022
	+!		186MG	N207500	001	Mar 06, 2015

POWDER;INTRAVENOUS
CRESEMBA

	+!	ASTELLAS	372MG	N207501	001	Mar 06, 2015

ISOCARBOXAZID
TABLET;ORAL
MARPLAN

	+!	LIFSA DRUGS	10MG	N011961	001	

ISOFLURANE
LIQUID;INHALATION
FORANE

AN	**+!**	BAXTER HLTHCARE	**99.9%**	**N017624**	**001**	

ISOFLURANE

AN		HALOCARBON PRODS	**99.9%**	**A075225**	**001**	Oct 20, 1999
AN		PIRAMAL CRITICAL	**99.9%**	**A074416**	**001**	Sep 30, 1994
AN		PIRAMAL PHARMA	**99.9%**	**A074502**	**001**	Jun 27, 1995

ISOFLURANE

LIQUID;INHALATION

ISOFLURANE

AN		SHANDONG	**99.9%**	**A216527**	**001**	Nov 04, 2025

ISONIAZID

INJECTABLE;INJECTION

ISONIAZID

	!	SANDOZ	100MG/ML	A040648	001	Jul 05, 2005

SYRUP;ORAL

ISONIAZID

AA		CHARTWELL RX	**50MG/5ML**	**A081118**	**001**	Jul 21, 1997
AA	**+!**	CMP PHARMA INC	**50MG/5ML**	**A088235**	**001**	Nov 10, 1983

TABLET;ORAL

ISONIAZID

AA	**!**	OMNIVIUM PHARMS	**100MG**	**A040090**	**001**	Jun 26, 1997
AA	**!**		**300MG**	**A040090**	**002**	Jun 26, 1997
AA		THEPHARMANETWORK LLC	**100MG**	**A202610**	**001**	Oct 29, 2014
AA			**300MG**	**A202610**	**002**	Oct 29, 2014

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		AMNEAL	**0.2MG/ML**	**A210576**	**001**	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	**0.2MG/ML**	**A210106**	**001**	Jun 18, 2018
AP		AMRING PHARMS	**0.2MG/ML**	**A211237**	**001**	May 19, 2021
AP		AVET LIFESCIENCES	**0.2MG/ML**	**A212189**	**001**	Nov 19, 2021
AP		DEVA HOLDING AS	**0.2MG/ML**	**A213305**	**001**	Dec 10, 2025
AP		GLAND	**0.2MG/ML**	**A217648**	**001**	Oct 03, 2024
AP		HIKMA	**0.2MG/ML**	**A211703**	**001**	Apr 26, 2023
AP		MICRO LABS	**0.2MG/ML**	**A210845**	**001**	Feb 16, 2021
AP	**!**	NEXUS	**0.2MG/ML**	**A206961**	**001**	Aug 02, 2017
AP		PENN LIFE	**0.2MG/ML**	**A215542**	**001**	Sep 20, 2022
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A211590**	**001**	Aug 06, 2024

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB	**+**	BAUSCH	**5MG**	**N012093**	**007**	Jul 29, 1988
AB	**+!**		**40MG**	**N012093**	**001**	Jul 29, 1988

ISOSORBIDE DINITRATE

AB		HIKMA INTL PHARMS	**5MG**	**A088088**	**003**	Oct 29, 1987
AB			**10MG**	**A088088**	**002**	Oct 29, 1987
AB			**20MG**	**A088088**	**001**	Nov 02, 1987
AB		PH HEALTH	**5MG**	**A086923**	**001**	Mar 12, 1987
AB			**10MG**	**A086925**	**001**	Mar 12, 1987
AB			**20MG**	**A087537**	**001**	Oct 02, 1987
AB	**!**		**30MG**	**A087946**	**001**	Jan 12, 1988
AB			**40MG**	**A211290**	**001**	Nov 23, 2021
AB		RUBICON	**5MG**	**A215723**	**001**	Jul 08, 2022
AB			**10MG**	**A215723**	**002**	Jul 08, 2022
AB			**20MG**	**A215723**	**003**	Jul 08, 2022
AB			**30MG**	**A215723**	**004**	Jul 08, 2022
AB			**40MG**	**A215723**	**005**	Jul 08, 2022
AB		SANDOZ	**5MG**	**A086221**	**001**	Jan 07, 1988
AB			**10MG**	**A086223**	**001**	Jan 07, 1988
AB			**20MG**	**A089367**	**001**	Apr 07, 1988
AB		ZYDUS LIFESCIENCES	**5MG**	**A213057**	**001**	Nov 20, 2019
AB			**10MG**	**A213057**	**002**	Nov 20, 2019
AB			**20MG**	**A213057**	**003**	Nov 20, 2019
AB			**30MG**	**A213057**	**004**	Nov 20, 2019
AB			**40MG**	**A213057**	**005**	Nov 20, 2019

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB		GENUS	**10MG**	**A075037**	**002**	Oct 30, 1998
AB			**20MG**	**A075037**	**001**	Oct 30, 1998

MONOKET

AB	**+**	OMNIVIUM PHARMS	**10MG**	**N020215**	**002**	Jun 30, 1993
AB	**+!**		**20MG**	**N020215**	**001**	Jun 30, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		AUROBINDO PHARMA	30MG	A216557	001	Nov 07, 2022
AB			60MG	A216557	002	Nov 07, 2022
AB			120MG	A216557	003	Nov 07, 2022
AB		CHARTWELL MOLECULAR	30MG	A075155	002	Jan 13, 2000
AB			60MG	A075155	001	Oct 30, 1998
AB			120MG	A075155	003	Aug 04, 2000
AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016
AB			60MG	A075522	001	Apr 17, 2000
AB			120MG	A210822	001	Aug 29, 2018
AB		RICONPHARMA LLC	30MG	A210918	001	Nov 05, 2018
AB			60MG	A210918	002	Nov 05, 2018
AB	!		120MG	A210918	003	Nov 05, 2018
AB		SHANDONG	30MG	A214115	002	Feb 08, 2024
AB			60MG	A214115	003	Feb 08, 2024
AB			120MG	A214115	001	Apr 29, 2022
AB		TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011
AB			60MG	A200495	001	Jun 03, 2011
AB			120MG	A200495	002	Jun 03, 2011
AB		ZYDUS HLTHCARE	30MG	A075395	001	Mar 16, 2000
AB			60MG	A075395	002	Mar 16, 2000
AB			120MG	A075395	003	Mar 16, 2000

ISOSULFAN BLUE

SOLUTION;SUBCUTANEOUS

ISOSULFAN BLUE

AP		AM REGENT	50MG/5ML (10MG/ML)	A210294	001	May 17, 2023
AP		MEITHEAL	50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021
AP		MSN	50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022
AP	!	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002
AB1			20MG	A075945	002	Nov 08, 2002
AB1			30MG	A075945	004	Mar 17, 2025
AB1			40MG	A075945	003	Nov 08, 2002

CLARAVIS

AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003
AB1			20MG	A076135	002	Apr 11, 2003
AB1			30MG	A076135	003	May 11, 2006
AB1	!		40MG	A076135	001	Apr 11, 2003

ISOTRETINOIN

AB1		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017
AB1			20MG	A207792	002	Sep 29, 2017
AB1			30MG	A207792	003	Sep 29, 2017
AB1			40MG	A207792	004	Sep 29, 2017
AB1		ZYDUS PHARMS	10MG	A211568	001	Aug 29, 2023
AB1			20MG	A211568	002	Aug 29, 2023
AB1			30MG	A211568	003	Aug 29, 2023
AB1			40MG	A211568	004	Aug 29, 2023

MYORISAN

AB1		UPSHER SMITH LABS	10MG	A076485	001	Jan 19, 2012
AB1			20MG	A076485	002	Jan 19, 2012
AB1			30MG	A076485	004	Aug 25, 2015
AB1			40MG	A076485	003	Jan 19, 2012

ZENATANE

AB1		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013
AB1			20MG	A202099	002	Mar 25, 2013
AB1			30MG	A202099	004	Feb 23, 2015
AB1			40MG	A202099	003	Mar 25, 2013

ABSORICA

AB2	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012
AB2	+		20MG	N021951	002	May 25, 2012
AB2	+		25MG	N021951	005	Aug 15, 2014
AB2	+		30MG	N021951	003	May 25, 2012
AB2	+		35MG	N021951	006	Aug 15, 2014
AB2	+!		40MG	N021951	004	May 25, 2012

ISOTRETINOIN

AB2		ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021

ISOTRETINOIN

CAPSULE;ORAL

ISOTRETINOIN

AB2			**20MG**	**A205063**	**002**	Mar 31, 2021
AB2			**25MG**	**A205063**	**003**	Mar 31, 2021
AB2			**30MG**	**A205063**	**004**	Mar 31, 2021
AB2			**35MG**	**A205063**	**005**	Mar 31, 2021
AB2			**40MG**	**A205063**	**006**	Mar 31, 2021
AB2		AMNEAL PHARMS NY	**10MG**	**A216097**	**001**	Oct 07, 2025
AB2			**20MG**	**A216097**	**002**	Oct 07, 2025
AB2			**25MG**	**A216097**	**003**	Oct 07, 2025
AB2			**30MG**	**A216097**	**004**	Oct 07, 2025
AB2			**35MG**	**A216097**	**005**	Oct 07, 2025
AB2			**40MG**	**A216097**	**006**	Oct 07, 2025
AB2		AUROBINDO PHARMA	**10MG**	**A218194**	**001**	Jan 29, 2024
AB2			**20MG**	**A218194**	**002**	Jan 29, 2024
AB2			**25MG**	**A218194**	**003**	Jan 29, 2024
AB2			**30MG**	**A218194**	**004**	Jan 29, 2024
AB2			**35MG**	**A218194**	**005**	Jan 29, 2024
AB2			**40MG**	**A218194**	**006**	Jan 29, 2024
AB2		UPSHER SMITH LABS	**10MG**	**A212333**	**001**	Sep 21, 2021
AB2			**20MG**	**A212333**	**002**	Sep 21, 2021
AB2			**30MG**	**A212333**	**003**	Sep 21, 2021
AB2			**40MG**	**A213571**	**001**	Apr 12, 2021
AB2		ZYDUS PHARMS	**10MG**	**A216633**	**001**	May 22, 2025
AB2			**20MG**	**A216633**	**002**	May 22, 2025
AB2			**25MG**	**A216633**	**003**	May 22, 2025
AB2			**30MG**	**A216633**	**004**	May 22, 2025
AB2			**35MG**	**A216633**	**005**	May 22, 2025
AB2			**40MG**	**A216633**	**006**	May 22, 2025
ABSORICA LD						
	+	SUN PHARM	8MG	N211913	001	Nov 05, 2019
	+		16MG	N211913	002	Nov 05, 2019
	+		24MG	N211913	004	Nov 05, 2019
	+!		32MG	N211913	006	Nov 05, 2019

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB			**5MG**	**A077169**	**002**	Apr 24, 2006
AB		WATSON LABS TEVA	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB	**!**		**5MG**	**A077317**	**002**	Jan 05, 2006

ISTRADEFYLLINE

TABLET;ORAL

NOURIANZ

	+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019
	+!		40MG	N022075	002	Aug 27, 2019

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB		ALEMBIC	**100MG**	**A206741**	**001**	Dec 13, 2016
AB		ALKEM LABS LTD	**100MG**	**A208591**	**001**	Jun 12, 2017
AB		AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB		RISING	**100MG**	**A205724**	**001**	Dec 13, 2016
AB		SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004
AB		TORRENT	**100MG**	**A209460**	**001**	Aug 24, 2018
AB		ZYDUS PHARMS	**100MG**	**A204672**	**001**	Sep 19, 2017

SPORANOX

AB	**+!**	JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992

TOLSURA

	+!	MAYNE PHARMA	65MG	N208901	001	Dec 11, 2018

SOLUTION;ORAL

ITRACONAZOLE

AA	**!**	AMNEAL PHARMS	**10MG/ML**	**A205573**	**001**	Oct 30, 2015
AA		ANNORA PHARMA	**10MG/ML**	**A212239**	**001**	Sep 01, 2020

IVABRADINE							
SOLUTION;ORAL							
CORLANOR							
	+!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019
IVABRADINE HYDROCHLORIDE							
TABLET;ORAL							
CORLANOR							
AB	**+**	AMGEN INC	**EQ 5MG BASE**	**N206143**	**001**	Apr 15, 2015
AB	**+!**		**EQ 7.5MG BASE**	**N206143**	**002**	Apr 15, 2015
IVABRADINE HYDROCHLORIDE							
AB		ALEMBIC	**EQ 5MG BASE**	**A215238**	**001**	Nov 08, 2024
AB			**EQ 7.5MG BASE**	**A215238**	**002**	Nov 08, 2024
AB		ANNORA PHARMA	**EQ 5MG BASE**	**A213366**	**001**	Oct 05, 2022
AB			**EQ 7.5MG BASE**	**A213366**	**002**	Oct 05, 2022
AB		BIONPHARMA	**EQ 5MG BASE**	**A213276**	**001**	Sep 05, 2024
AB			**EQ 7.5MG BASE**	**A213276**	**002**	Sep 05, 2024
AB		INGENUS PHARMS LLC	**EQ 5MG BASE**	**A214051**	**001**	Dec 30, 2021
AB			**EQ 7.5MG BASE**	**A214051**	**002**	Dec 30, 2021
AB		MSN	**EQ 5MG BASE**	**A213483**	**001**	Apr 28, 2025
AB			**EQ 7.5MG BASE**	**A213483**	**002**	Apr 28, 2025
AB		ZYDUS PHARMS	**EQ 5MG BASE**	**A213442**	**001**	Nov 29, 2023
AB			**EQ 7.5MG BASE**	**A213442**	**002**	Nov 29, 2023
IVACAFTOR							
GRANULE;ORAL							
KALYDECO							
	+	VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023
	+		13.4MG/PACKET	N207925	005	May 03, 2023
	+		25MG/PACKET	N207925	003	Apr 29, 2019
	+		50MG/PACKET	N207925	001	Mar 17, 2015
	+!		75MG/PACKET	N207925	002	Mar 17, 2015
TABLET;ORAL							
KALYDECO							
	+!	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012
IVACAFTOR; IVACAFTOR, TEZACAFTOR							
TABLET;ORAL							
SYMDEKO (COPACKAGED)							
	+	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019
	+!		150MG;150MG, 100MG	N210491	001	Feb 12, 2018
IVACAFTOR; LUMACAFTOR							
GRANULE;ORAL							
ORKAMBI							
	+	VERTEX PHARMS INC	94MG/PACKET;75MG/PACKET	N211358	003	Sep 02, 2022
	+		125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018
	+!		188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018
TABLET;ORAL							
ORKAMBI							
	+	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
	+!		125MG;200MG	N206038	001	Jul 02, 2015
IVERMECTIN							
CREAM;TOPICAL							
IVERMECTIN							
AB		PADAGIS ISRAEL	**1%**	**A210225**	**001**	Apr 13, 2020
AB		TEVA PHARMS USA	**1%**	**A210019**	**001**	Sep 13, 2019
AB		ZYDUS LIFESCIENCES	**1%**	**A215210**	**001**	Aug 02, 2022
SOOLANTRA							
AB	**+!**	GALDERMA LABS LP	**1%**	**N206255**	**001**	Dec 19, 2014
TABLET;ORAL							
IVERMECTIN							
AB		EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014
AB		EPIC PHARMA LLC	**3MG**	**A218805**	**001**	Sep 09, 2025
AB		RUBICON RESEARCH	**3MG**	**A215922**	**001**	Jan 22, 2025
AB		SENORES PHARMS	**3MG**	**A218324**	**001**	Oct 16, 2024
STROMECTOL							
AB	**+!**	MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998
IVERMECTIN							
		RUBICON RESEARCH	6MG	A215922	002	Jan 22, 2025

IVOSIDENIB

TABLET;ORAL

TIBSOVO

+!	SERVIER	250MG	N211192	001	Jul 20, 2018

IXABEPILONE

INJECTABLE;INTRAVENOUS

IXEMPRA KIT

+!	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
+!		45MG/VIAL	N022065	002	Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE;ORAL

NINLARO

+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
+		EQ 3MG BASE	N208462	002	Nov 20, 2015
+!		EQ 4MG BASE	N208462	003	Nov 20, 2015

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETALAR

AP	**+!**	PH HEALTH	**EQ 10MG BASE/ML**	**N016812**	**001**	
AP	**+**		**EQ 50MG BASE/ML**	**N016812**	**002**	
AP	**+**		**EQ 100MG BASE/ML**	**N016812**	**003**	

KETAMINE HYDROCHLORIDE

AP		CAPLIN	**EQ 10MG BASE/ML**	**A217858**	**001**	Aug 07, 2025
AP		EUGIA PHARMA	**EQ 10MG BASE/ML**	**A076092**	**001**	Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002**	Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003**	Oct 25, 2002
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A215808**	**001**	Jan 13, 2023
AP			**EQ 50MG BASE/ML**	**A215808**	**002**	Jan 13, 2023
AP			**EQ 100MG BASE/ML**	**A215808**	**003**	Apr 18, 2025
AP		GLAND	**EQ 10MG BASE/ML**	**A216809**	**001**	Jan 24, 2023
AP			**EQ 50MG BASE/ML**	**A216809**	**002**	Jan 24, 2023
AP			**EQ 100MG BASE/ML**	**A216809**	**003**	Jan 24, 2023
AP	**!**	HIKMA	**EQ 50MG BASE/ML**	**A074524**	**001**	Mar 22, 1996
AP	**!**		**EQ 100MG BASE/ML**	**A074524**	**002**	Mar 22, 1996
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001**	Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002**	Jun 27, 1996

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

KETAMINE HYDROCHLORIDE

!	BAXTER HLTHCARE CORP	EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A219684	001	Sep 17, 2025

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

KETOCONAZOLE

AB		PADAGIS ISRAEL	**2%**	**A091550**	**001**	Aug 25, 2011
AB	**!**	XIROMED	**2%**	**A213601**	**001**	May 21, 2021

CREAM;TOPICAL

KETOCONAZOLE

AB	**!**	ENCUBE	**2%**	**A212443**	**001**	May 20, 2021
AB		FOUGERA PHARMS	**2%**	**A076294**	**001**	Apr 28, 2004
AB		PADAGIS US	**2%**	**A215185**	**001**	Nov 17, 2021
AB		TEVA	**2%**	**A075581**	**001**	Apr 25, 2000

KETOZOLE

AB		SUN PHARMA CANADA	**2%**	**A075638**	**001**	Dec 18, 2002

SHAMPOO;TOPICAL

KETOCONAZOLE

AB		COSETTE	**2%**	**A076942**	**001**	Apr 11, 2005
AB		NOVITIUM PHARMA	**2%**	**A218498**	**001**	Sep 16, 2024
AB	**!**	PADAGIS ISRAEL	**2%**	**A076419**	**001**	Jan 07, 2004
AB		ZYDUS LIFESCIENCES	**2%**	**A218559**	**001**	Mar 07, 2025

TABLET;ORAL

KETOCONAZOLE

AB		NOVITIUM PHARMA	**200MG**	**A219129**	**001**	Jul 03, 2025
AB		SENORES PHARMS	**200MG**	**A075912**	**001**	Jan 10, 2002
AB		STRIDES PHARMA	**200MG**	**A210457**	**001**	Jun 18, 2018
AB	**!**	TARO	**200MG**	**A075319**	**001**	Jun 15, 1999

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

AB		MISEMER	**50MG**	**A074014**	**002**	Jan 29, 1993
AB		TEVA	**50MG**	**A073516**	**001**	Dec 22, 1992
		MISEMER	25MG	A074014	001	Jan 29, 1993
	!		75MG	A074014	003	Jan 29, 1993

CAPSULE, EXTENDED RELEASE;ORAL

KETOPROFEN

	!	MYLAN	200MG	A075679	001	Feb 20, 2002

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		ALEMBIC	**15MG/ML**	**A214456**	**001**	Nov 02, 2022
AP			**30MG/ML**	**A214456**	**002**	Nov 02, 2022
AP		APOTEX	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007
AP		ASPIRO	**15MG/ML**	**A217166**	**001**	Jun 20, 2023
AP			**30MG/ML**	**A217166**	**002**	Jun 20, 2023
AP		BAXTER HLTHCARE CORP	**15MG/ML**	**A209900**	**002**	Jul 25, 2018
AP			**30MG/ML**	**A209900**	**001**	Sep 15, 2017
AP		CAPLIN	**15MG/ML**	**A217789**	**001**	May 10, 2023
AP			**30MG/ML**	**A217789**	**002**	May 10, 2023
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001**	Jan 11, 2002
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015
AP		GLAND	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP		HIKMA	**15MG/ML**	**A075772**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A075772**	**002**	Jul 21, 2004
AP	!	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP	!		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP		NEPHRON	**30MG/ML**	**A211445**	**001**	Aug 20, 2020
AP		SAGENT PHARMS INC	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ	**30MG/ML**	**A076271**	**002**	Oct 06, 2004

SOLUTION/DROPS;OPHTHALMIC

ACULAR

AT	**+!**	ABBVIE	**0.5%**	**N019700**	**001**	Nov 09, 1992

ACULAR LS

AT	**+!**	ABBVIE	**0.4%**	**N021528**	**001**	May 30, 2003

KETOROLAC TROMETHAMINE

AT		APOTEX	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		CAPLIN	**0.5%**	**A218204**	**001**	Mar 26, 2024
AT		MICRO LABS LTD INDIA	**0.5%**	**A203410**	**001**	Apr 05, 2019
AT		SANDOZ	**0.5%**	**A076583**	**001**	Nov 05, 2009

ACUVAIL

	+!	ABBVIE	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

	+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		BIONPHARMA	**10MG**	**A216759**	**001**	Feb 23, 2023
AB		CHARTWELL RX	**10MG**	**A210616**	**001**	Aug 16, 2018
AB		HETERO LABS LTD III	**10MG**	**A216651**	**001**	Aug 25, 2022
AB		LEADING	**10MG**	**A215745**	**001**	Feb 23, 2023
AB		MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB		SENORES PHARMS	**10MG**	**A215788**	**001**	Mar 23, 2022
AB	!	TEVA	**10MG**	**A074754**	**001**	May 16, 1997
AB		ZYDUS LIFESCIENCES	**10MG**	**A217038**	**001**	Oct 21, 2022

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT		LUPIN LTD	**EQ 0.3% BASE;EQ 1% BASE**	**A210183**	**001**	Jul 01, 2019

OMIDRIA

AT	**+!**	RAYNER SURGICAL	**EQ 0.3% BASE;EQ 1% BASE**	**N205388**	**001**	May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

AA	+	EMMAUS MEDCL	**5GM/PACKET**	**N208587**	**001**	Jul 07, 2017

L-GLUTAMINE

AA		NOVITIUM PHARMA	**5GM/PACKET**	**A215647**	**001**	Jul 08, 2024

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		AMNEAL	**5MG/ML**	**A218870**	**001**	Oct 02, 2025
AP		BAXTER HLTHCARE CORP	**5MG/ML**	**A076051**	**001**	Jul 05, 2002
AP		CAPLIN	**5MG/ML**	**A214533**	**001**	Sep 07, 2021
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP		HIKMA	**5MG/ML**	**A075303**	**001**	May 28, 1999
AP	!	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	!		**5MG/ML**	**A075240**	**001**	Nov 29, 1999
AP		RISING	**5MG/ML**	**A075431**	**001**	Nov 29, 1999

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE

	+!	HIKMA	20MG/4ML (5MG/ML)	N213330	006	Aug 19, 2024

LABETALOL HYDROCHLORIDE IN DEXTROSE

	+!	HIKMA	200MG/200ML (1MG/ML)	N213330	001	Nov 09, 2020

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

	+!	HIKMA	100MG/100ML (1MG/ML)	N213330	002	Nov 09, 2020
	+!		200MG/200ML (1MG/ML)	N213330	003	Nov 09, 2020
	+!		300MG/300ML (1MG/ML)	N213330	004	Nov 09, 2020

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		AIPING PHARM INC	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	!		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998
AB		ANDAS 5 HOLDING	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999
AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		APPCO	**100MG**	**A209603**	**001**	Jun 20, 2018
AB			**200MG**	**A209603**	**002**	Jun 20, 2018
AB			**300MG**	**A209603**	**003**	Jun 20, 2018
AB		CADILA PHARMS LTD	**100MG**	**A211325**	**001**	May 13, 2019
AB			**200MG**	**A211325**	**002**	May 13, 2019
AB			**300MG**	**A211325**	**003**	May 13, 2019
AB		EPIC PHARMA LLC	**100MG**	**A212990**	**001**	Sep 30, 2020
AB			**200MG**	**A212990**	**002**	Sep 30, 2020
AB			**300MG**	**A212990**	**003**	Sep 30, 2020
AB		HERITAGE PHARMA	**100MG**	**A074787**	**001**	Aug 03, 1998
AB			**200MG**	**A074787**	**002**	Aug 03, 1998
AB			**300MG**	**A074787**	**003**	Aug 03, 1998
AB		HIBROW HLTHCARE	**100MG**	**A207863**	**001**	Feb 04, 2019
AB			**200MG**	**A207863**	**002**	Feb 04, 2019
AB			**300MG**	**A207863**	**003**	Feb 04, 2019
AB		MACLEODS PHARMS LTD	**100MG**	**A217949**	**001**	Sep 23, 2025
AB			**200MG**	**A217949**	**002**	Sep 23, 2025
AB			**300MG**	**A217949**	**003**	Sep 23, 2025
AB		PH HEALTH	**100MG**	**A200908**	**001**	Jul 10, 2012
AB	!		**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		RUBICON RESEARCH	**100MG**	**A211953**	**001**	Aug 18, 2021
AB			**200MG**	**A211953**	**002**	Aug 18, 2021
AB			**300MG**	**A211953**	**003**	Aug 18, 2021
AB		WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB			**200MG**	**A075133**	**002**	Aug 03, 1998
AB			**300MG**	**A075133**	**003**	Aug 03, 1998
AB		ZYDUS PHARMS	**100MG**	**A207743**	**001**	Sep 19, 2017
AB			**200MG**	**A207743**	**002**	Sep 19, 2017
AB			**300MG**	**A207743**	**003**	Sep 19, 2017
		APPCO	400MG	A209603	004	Oct 18, 2024

LACOSAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

MOTPOLY XR

+	AUCTA	100MG	N216185	001	May 04, 2023
+		150MG	N216185	002	May 04, 2023
+!		200MG	N216185	003	May 04, 2023

SOLUTION;INTRAVENOUS

LACOSAMIDE

AP	ACELLA	**200MG/20ML (10MG/ML)**	**A218464**	**001**	Nov 14, 2024
AP	APOTEX	**200MG/20ML (10MG/ML)**	**A216670**	**001**	Nov 13, 2023
AP	ASPIRO	**200MG/20ML (10MG/ML)**	**A216335**	**001**	Sep 14, 2022
AP	DR REDDYS	**200MG/20ML (10MG/ML)**	**A217718**	**001**	Mar 25, 2024
AP	FRESENIUS KABI USA	**200MG/20ML (10MG/ML)**	**A214677**	**001**	May 03, 2022
AP	GLAND	**200MG/20ML (10MG/ML)**	**A215628**	**001**	Sep 19, 2022
AP	HAINAN POLY	**200MG/20ML (10MG/ML)**	**A217311**	**001**	Feb 13, 2024
AP	HIKMA	**200MG/20ML (10MG/ML)**	**A216806**	**001**	Apr 05, 2024
AP	MSN	**200MG/20ML (10MG/ML)**	**A215979**	**001**	Feb 09, 2023
AP	REGCON HOLDINGS	**200MG/20ML (10MG/ML)**	**A214301**	**001**	Apr 07, 2022
AP	SOMERSET THERAPS LLC	**200MG/20ML (10MG/ML)**	**A214960**	**001**	Oct 09, 2024
AP	WESTMINSTER PHARMS	**200MG/20ML (10MG/ML)**	**A218706**	**001**	May 23, 2025
AP	ZYDUS PHARMS	**200MG/20ML (10MG/ML)**	**A209465**	**001**	Jun 29, 2022

VIMPAT

AP	**+!** UCB INC	**200MG/20ML (10MG/ML)**	**N022254**	**001**	Oct 28, 2008

SOLUTION;ORAL

LACOSAMIDE

AA	AJENAT PHARMS	**10MG/ML**	**A219699**	**001**	Jun 26, 2025
AA	ALKEM LABS LTD	**10MG/ML**	**A214672**	**001**	May 19, 2022
AA	APOTEX	**10MG/ML**	**A206355**	**001**	Sep 26, 2022
AA	AUROBINDO PHARMA LTD	**10MG/ML**	**A209224**	**001**	Jan 24, 2024
AA	CHARTWELL RX	**10MG/ML**	**A215154**	**001**	May 15, 2024
AA	HETERO LABS LTD III	**10MG/ML**	**A209301**	**001**	May 31, 2022
AA	KANCHAN HLTHCARE	**10MG/ML**	**A216461**	**001**	Feb 06, 2023
AA	MSN	**10MG/ML**	**A215379**	**001**	Dec 22, 2023
AA	NOVITIUM PHARMA	**10MG/ML**	**A216151**	**001**	Aug 26, 2022

VIMPAT

AA	**+!** UCB INC	**10MG/ML**	**N022255**	**001**	Apr 20, 2010

TABLET;ORAL

LACOSAMIDE

AB	ALEMBIC	**50MG**	**A204974**	**001**	Mar 17, 2022
AB		**100MG**	**A204974**	**002**	Mar 17, 2022
AB		**150MG**	**A204974**	**003**	Mar 17, 2022
AB		**200MG**	**A204974**	**004**	Mar 17, 2022
AB	ALKEM LABS LTD	**50MG**	**A214695**	**001**	Mar 31, 2022
AB		**100MG**	**A214695**	**002**	Mar 31, 2022
AB		**150MG**	**A214695**	**003**	Mar 31, 2022
AB		**200MG**	**A214695**	**004**	Mar 31, 2022
AB	AUROBINDO PHARMA LTD	**50MG**	**A204994**	**001**	Jan 05, 2023
AB		**100MG**	**A204994**	**002**	Jan 05, 2023
AB		**150MG**	**A204994**	**003**	Jan 05, 2023
AB		**200MG**	**A204994**	**004**	Jan 05, 2023
AB	GLENMARK PHARMS LTD	**50MG**	**A205006**	**001**	Mar 17, 2022
AB		**100MG**	**A205006**	**002**	Mar 17, 2022
AB		**150MG**	**A205006**	**003**	Mar 17, 2022
AB		**200MG**	**A205006**	**004**	Mar 17, 2022
AB	HETERO LABS LTD V	**50MG**	**A204787**	**001**	Mar 17, 2022
AB		**100MG**	**A204787**	**002**	Mar 17, 2022
AB		**150MG**	**A204787**	**003**	Mar 17, 2022
AB		**200MG**	**A204787**	**004**	Mar 17, 2022
AB	KANCHAN HLTHCARE	**50MG**	**A218014**	**001**	Apr 02, 2024
AB		**100MG**	**A218014**	**002**	Apr 02, 2024
AB		**150MG**	**A218014**	**003**	Apr 02, 2024
AB		**200MG**	**A218014**	**004**	Apr 02, 2024
AB	MACLEODS PHARMS LTD	**50MG**	**A208466**	**001**	May 24, 2024
AB		**100MG**	**A208466**	**002**	May 24, 2024
AB		**150MG**	**A208466**	**003**	May 24, 2024
AB		**200MG**	**A208466**	**004**	May 24, 2024
AB	MSN LABS PVT LTD	**50MG**	**A204921**	**001**	Mar 17, 2022
AB		**100MG**	**A204921**	**002**	Mar 17, 2022
AB		**150MG**	**A204921**	**003**	Mar 17, 2022
AB		**200MG**	**A204921**	**004**	Mar 17, 2022

LACOSAMIDE

TABLET;ORAL

LACOSAMIDE

AB		REGCON HOLDINGS	**50MG**	**A208308**	**001**	Mar 17, 2022
AB			**100MG**	**A208308**	**002**	Mar 17, 2022
AB			**150MG**	**A208308**	**003**	Mar 17, 2022
AB			**200MG**	**A208308**	**004**	Mar 17, 2022
AB		SCIEGEN PHARMS	**50MG**	**A205237**	**001**	Mar 17, 2022
AB			**100MG**	**A205237**	**002**	Mar 17, 2022
AB			**150MG**	**A205237**	**003**	Mar 17, 2022
AB			**200MG**	**A205237**	**004**	Mar 17, 2022
AB		SUN PHARM	**50MG**	**A205031**	**001**	Mar 17, 2022
AB			**100MG**	**A205031**	**002**	Mar 17, 2022
AB			**150MG**	**A205031**	**003**	Mar 17, 2022
AB			**200MG**	**A205031**	**004**	Mar 17, 2022
AB		UNICHEM	**50MG**	**A213109**	**001**	Sep 04, 2024
AB			**100MG**	**A213109**	**002**	Sep 04, 2024
AB			**150MG**	**A213109**	**003**	Sep 04, 2024
AB			**200MG**	**A213109**	**004**	Sep 04, 2024

VIMPAT

AB	+	UCB INC	**50MG**	**N022253**	**001**	Oct 28, 2008
AB	+		**100MG**	**N022253**	**002**	Oct 28, 2008
AB	+		**150MG**	**N022253**	**003**	Oct 28, 2008
AB	+!		**200MG**	**N022253**	**004**	Oct 28, 2008

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

AA	!	CUMBERLAND PHARMS	**10GM/PACKET**	**A074712**	**001**	Dec 10, 1997
AA	!		**20GM/PACKET**	**A074712**	**002**	Dec 10, 1997
AA		PAI HOLDINGS	**10GM/PACKET**	**A217914**	**001**	Mar 14, 2025
AA			**20GM/PACKET**	**A217914**	**002**	Mar 14, 2025

SOLUTION;ORAL

LACTULOSE

AA		APOZEAL PHARMS	**10GM/15ML**	**A207786**	**001**	Jun 11, 2018
AA		AUROBINDO PHARMA LTD	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996
AA		CHARTWELL RX	**10GM/15ML**	**A209517**	**001**	Nov 23, 2018
AA		FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA		LANNETT CO INC	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA	!	PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA		PHARMOBEDIENT	**10GM/15ML**	**A075911**	**001**	Feb 21, 2002
AA		TARO	**10GM/15ML**	**A218858**	**001**	Dec 13, 2024

SOLUTION;ORAL, RECTAL

GENERLAC

AA		CHARTWELL RX	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996

LACTULOSE

AA		BAJAJ	**10GM/15ML**	**A076645**	**001**	Jul 28, 2003
AA	!	FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		SCIEGEN PHARMS	**10GM/15ML**	**A203762**	**001**	Mar 27, 2015

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA	+!	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995

LAMIVUDINE

AA		AUROBINDO PHARMA	**10MG/ML**	**A077695**	**001**	Nov 21, 2016
AA		CHARTWELL MOLECULAR	**10MG/ML**	**A203564**	**001**	Oct 31, 2014
AA		HETERO LABS LTD III	**10MG/ML**	**A091475**	**001**	Oct 06, 2023

TABLET;ORAL

EPIVIR

AB	+	VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995
AB	+!		**300MG**	**N020564**	**003**	Jun 24, 2002

LAMIVUDINE

AB		ANNORA	**100MG**	**A211306**	**001**	Mar 21, 2019
AB	!	APOTEX	**100MG**	**A202941**	**001**	Jan 02, 2014
AB			**150MG**	**A091606**	**001**	Dec 02, 2011
AB			**300MG**	**A091606**	**002**	Dec 02, 2011
AB		AUROBINDO PHARMA	**150MG**	**A077464**	**001**	Nov 21, 2016
AB			**300MG**	**A077464**	**002**	Nov 21, 2016
AB		CIPLA	**150MG**	**A077221**	**001**	Mar 03, 2017
AB			**300MG**	**A077221**	**002**	Mar 03, 2017
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014
AB			**150MG**	**A203277**	**001**	Jan 06, 2014

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB			**300MG**	**A203277**	**002**	Jan 06, 2014
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014
AB			**300MG**	**A205217**	**002**	Dec 18, 2014
AB		MACLEODS PHARMS LTD	**150MG**	**A090198**	**001**	May 01, 2019
AB			**300MG**	**A090198**	**002**	May 01, 2019
AB		SOMERSET THERAPS LLC	**150MG**	**A206974**	**001**	Nov 21, 2016
AB			**300MG**	**A206974**	**002**	Nov 21, 2016
AB		STRIDES PHARMA	**150MG**	**A090457**	**001**	Apr 19, 2018
AB			**300MG**	**A090457**	**002**	Apr 19, 2018

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

CIMDUO

	+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		AUROBINDO PHARMA	**150MG;300MG**	**A077558**	**001**	May 05, 2017
AB		CIPLA	**150MG;300MG**	**A077411**	**001**	Sep 07, 2018
AB		EPIC PHARMA LLC	**150MG;300MG**	**A206375**	**001**	Apr 10, 2018
AB	**!**	HETERO LABS LTD III	**150MG;300MG**	**A079124**	**001**	Sep 17, 2015
AB		HETERO LABS LTD V	**150MG;300MG**	**A203259**	**001**	Feb 03, 2014
AB		MACLEODS PHARMS LTD	**150MG;300MG**	**A090679**	**001**	Aug 29, 2018
AB		PHARMOBEDIENT	**150MG;300MG**	**A079128**	**001**	May 13, 2015

LAMOTRIGINE

SUSPENSION;ORAL

SUBVENITE

	+!	OWP PHARMS	10MG/ML	N218879	001	Sep 16, 2025

TABLET;ORAL

LAMICTAL

AB	**+!**	GLAXOSMITHKLINE LLC	**25MG**	**N020241**	**005**	Dec 27, 1994
AB	**+**		**100MG**	**N020241**	**001**	Dec 27, 1994
AB	**+**		**150MG**	**N020241**	**002**	Dec 27, 1994
AB	**+**		**200MG**	**N020241**	**003**	Dec 27, 1994

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	**25MG**	**A090607**	**001**	Jan 13, 2011
AB			**100MG**	**A090607**	**002**	Jan 13, 2011
AB			**150MG**	**A090607**	**003**	Jan 13, 2011
AB			**200MG**	**A090607**	**004**	Jan 13, 2011
AB		ALKEM LABS LTD	**25MG**	**A200694**	**001**	Jun 14, 2013
AB			**100MG**	**A200694**	**002**	Jun 14, 2013
AB			**150MG**	**A200694**	**003**	Jun 14, 2013
AB			**200MG**	**A200694**	**004**	Jun 14, 2013
AB		AUROBINDO PHARMA	**25MG**	**A078956**	**001**	Jan 27, 2009
AB			**100MG**	**A078956**	**002**	Jan 27, 2009
AB			**150MG**	**A078956**	**003**	Jan 27, 2009
AB			**200MG**	**A078956**	**004**	Jan 27, 2009
AB		DR REDDYS LABS LTD	**25MG**	**A076708**	**001**	Jan 27, 2009
AB			**100MG**	**A076708**	**002**	Jan 27, 2009
AB			**150MG**	**A076708**	**003**	Jan 27, 2009
AB			**200MG**	**A076708**	**004**	Jan 27, 2009
AB		GLENMARK PHARMS LTD	**25MG**	**A090169**	**001**	May 04, 2012
AB			**100MG**	**A090169**	**002**	May 04, 2012
AB			**150MG**	**A090169**	**003**	May 04, 2012
AB			**200MG**	**A090169**	**004**	May 04, 2012
AB		IPCA LABS	**25MG**	**A204499**	**001**	Sep 26, 2024
AB			**100MG**	**A204499**	**002**	Sep 26, 2024
AB			**150MG**	**A204499**	**003**	Sep 26, 2024
AB			**200MG**	**A204499**	**004**	Sep 26, 2024
AB		JUBILANT CADISTA	**25MG**	**A079132**	**001**	Jan 27, 2009
AB			**100MG**	**A079132**	**002**	Jan 27, 2009
AB			**150MG**	**A079132**	**003**	Jan 27, 2009
AB			**200MG**	**A079132**	**004**	Jan 27, 2009
AB		LUPIN LTD	**25MG**	**A078691**	**001**	Jun 01, 2010
AB			**100MG**	**A078691**	**002**	Jun 01, 2010
AB			**150MG**	**A078691**	**003**	Jun 01, 2010
AB			**200MG**	**A078691**	**004**	Jun 01, 2010
AB		RUBICON RESEARCH	**25MG**	**A078625**	**001**	Jan 27, 2009

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

AB			**100MG**	**A078625**	**002**	Jan 27, 2009
AB			**150MG**	**A078625**	**003**	Jan 27, 2009
AB			**200MG**	**A078625**	**004**	Jan 27, 2009
AB		TARO PHARM INDS	**25MG**	**A078525**	**001**	Jan 27, 2009
AB			**100MG**	**A078525**	**002**	Jan 27, 2009
AB			**150MG**	**A078525**	**003**	Jan 27, 2009
AB			**200MG**	**A078525**	**004**	Jan 27, 2009
AB		TORRENT PHARMS	**25MG**	**A078947**	**001**	Jan 27, 2009
AB			**100MG**	**A078947**	**002**	Jan 27, 2009
AB			**150MG**	**A078947**	**003**	Jan 27, 2009
AB			**200MG**	**A078947**	**004**	Jan 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090170**	**001**	Oct 06, 2011
AB			**100MG**	**A090170**	**002**	Oct 06, 2011
AB			**150MG**	**A090170**	**003**	Oct 06, 2011
AB			**200MG**	**A090170**	**004**	Oct 06, 2011
AB		ZYDUS PHARMS USA	**25MG**	**A077633**	**001**	Jan 27, 2009
AB			**100MG**	**A077633**	**003**	Jan 27, 2009
AB			**150MG**	**A077633**	**004**	Jan 27, 2009
AB			**200MG**	**A077633**	**005**	Jan 27, 2009
			50MG	A077633	002	Jan 27, 2009
			250MG	A077633	006	Jan 27, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022115**	**001**	May 29, 2009
AB	+!		**50MG**	**N022115**	**002**	May 29, 2009
AB	+		**100MG**	**N022115**	**003**	May 29, 2009
AB	+!		**200MG**	**N022115**	**004**	May 29, 2009
AB	+		**250MG**	**N022115**	**006**	Jun 21, 2011
AB	+		**300MG**	**N022115**	**005**	Apr 14, 2010

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	**100MG**	**A200672**	**003**	Oct 17, 2013
AB			**200MG**	**A200672**	**004**	Oct 17, 2013
AB			**25MG**	**A200672**	**001**	Oct 17, 2013
AB			**50MG**	**A200672**	**002**	Oct 17, 2013
AB			**250MG**	**A200672**	**006**	Nov 13, 2013
AB			**300MG**	**A200672**	**005**	Oct 17, 2013
AB		ALEMBIC	**200MG**	**A211821**	**001**	Oct 01, 2024
AB			**250MG**	**A211821**	**002**	Oct 01, 2024
AB			**300MG**	**A211821**	**003**	Oct 01, 2024
AB		AMNEAL PHARMS	**25MG**	**A207497**	**001**	Nov 30, 2018
AB			**50MG**	**A207497**	**002**	Nov 30, 2018
AB			**100MG**	**A207497**	**003**	Nov 30, 2018
AB			**200MG**	**A207497**	**004**	Nov 30, 2018
AB			**250MG**	**A207497**	**005**	Nov 30, 2018
AB			**300MG**	**A207497**	**006**	Nov 30, 2018
AB		DR REDDYS LABS LTD	**25MG**	**A202383**	**001**	Jun 19, 2013
AB			**50MG**	**A202383**	**002**	Jun 19, 2013
AB			**100MG**	**A202383**	**003**	Jun 19, 2013
AB			**200MG**	**A202383**	**004**	Jun 19, 2013
AB			**250MG**	**A202383**	**006**	Sep 06, 2018
AB			**300MG**	**A202383**	**005**	Jun 19, 2013
AB		PH HEALTH	**25MG**	**A201374**	**001**	Dec 26, 2012
AB			**25MG**	**A201791**	**001**	Jan 18, 2013
AB			**50MG**	**A201374**	**002**	Dec 26, 2012
AB			**50MG**	**A201791**	**002**	Jan 18, 2013
AB			**100MG**	**A201374**	**003**	Dec 26, 2012
AB			**100MG**	**A201791**	**003**	Jan 18, 2013
AB			**200MG**	**A201374**	**004**	Dec 26, 2012
AB			**200MG**	**A201791**	**004**	Jan 18, 2013
AB			**250MG**	**A201374**	**005**	Dec 26, 2012
AB			**250MG**	**A201791**	**005**	Jan 18, 2013
AB			**300MG**	**A201374**	**006**	Dec 26, 2012
AB			**300MG**	**A201791**	**006**	Jan 18, 2013
AB		RUBICON RESEARCH	**100MG**	**A202887**	**003**	Jun 17, 2013
AB			**200MG**	**A202887**	**004**	Jun 17, 2013
AB		SCIEGEN PHARMS	**25MG**	**A202498**	**001**	Jan 04, 2013
AB			**50MG**	**A202498**	**002**	Jan 04, 2013
AB			**100MG**	**A202498**	**003**	Jan 04, 2013
AB			**200MG**	**A202498**	**004**	Jan 04, 2013

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB			**300MG**	**A202498**	**005**	Jan 04, 2013
AB		TORRENT	**25MG**	**A203370**	**001**	Dec 23, 2013
AB			**50MG**	**A203370**	**002**	Dec 23, 2013
AB			**100MG**	**A203370**	**003**	Dec 23, 2013
AB		YILING	**25MG**	**A213949**	**001**	Dec 08, 2021
AB			**50MG**	**A213949**	**002**	Dec 08, 2021
AB			**100MG**	**A213949**	**003**	Dec 08, 2021
AB			**200MG**	**A213949**	**004**	Dec 08, 2021
AB			**250MG**	**A213949**	**005**	Dec 08, 2021
AB			**300MG**	**A213949**	**006**	Dec 08, 2021
AB		ZYDUS PHARMS	**25MG**	**A207763**	**001**	Apr 01, 2020
AB			**50MG**	**A207763**	**002**	Apr 01, 2020
AB			**100MG**	**A207763**	**003**	Apr 01, 2020
AB			**200MG**	**A207763**	**004**	Apr 01, 2020
AB			**250MG**	**A207763**	**005**	Apr 01, 2020
AB			**300MG**	**A207763**	**006**	Apr 01, 2020

TABLET, FOR SUSPENSION;ORAL

LAMICTAL CD

AB	+	GLAXOSMITHKLINE LLC	**2MG**	**N020764**	**004**	Sep 08, 2000
AB	+		**5MG**	**N020764**	**001**	Aug 24, 1998
AB	+!		**25MG**	**N020764**	**002**	Aug 24, 1998

LAMOTRIGINE

AB		ALEMBIC	**5MG**	**A201168**	**001**	Jun 12, 2014
AB			**25MG**	**A201168**	**002**	Jun 12, 2014
AB		AUROBINDO PHARMA	**5MG**	**A090401**	**002**	Nov 04, 2009
AB			**25MG**	**A090401**	**003**	Nov 04, 2009
AB		DR REDDYS LABS LTD	**5MG**	**A076701**	**001**	Jan 22, 2009
AB			**25MG**	**A076701**	**002**	Jan 22, 2009
AB		GLENMARK PHARMS LTD	**5MG**	**A079099**	**001**	Feb 19, 2009
AB			**25MG**	**A079099**	**002**	Feb 19, 2009
AB		WATSON LABS	**2MG**	**A076928**	**001**	Jan 22, 2009
AB			**5MG**	**A076928**	**002**	Jan 22, 2009
AB			**25MG**	**A076928**	**003**	Jan 22, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A078009**	**002**	Jan 22, 2009
AB			**25MG**	**A078009**	**003**	Jan 22, 2009

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022251**	**001**	May 08, 2009
AB	+!		**50MG**	**N022251**	**002**	May 08, 2009
AB	+		**100MG**	**N022251**	**003**	May 08, 2009
AB	+		**200MG**	**N022251**	**004**	May 08, 2009

LAMOTRIGINE

AB		AJANTA PHARMA LTD	**25MG**	**A213271**	**001**	Jan 19, 2021
AB			**50MG**	**A213271**	**002**	Jan 19, 2021
AB			**100MG**	**A213271**	**003**	Jan 19, 2021
AB			**200MG**	**A213271**	**004**	Jan 19, 2021
AB		AMRING PHARMS	**25MG**	**A214124**	**001**	Feb 03, 2022
AB			**50MG**	**A214124**	**002**	Feb 03, 2022
AB			**100MG**	**A214124**	**003**	Feb 03, 2022
AB			**200MG**	**A214124**	**004**	Feb 03, 2022
AB		IMPAX LABS INC	**25MG**	**A200828**	**001**	Jul 15, 2013
AB			**50MG**	**A200828**	**002**	Jul 15, 2013
AB			**100MG**	**A200828**	**003**	Jul 15, 2013
AB			**200MG**	**A200828**	**004**	Jul 15, 2013
AB		PH HEALTH	**25MG**	**A204158**	**001**	Oct 27, 2015
AB			**50MG**	**A204158**	**002**	Oct 27, 2015
AB			**100MG**	**A204158**	**003**	Oct 27, 2015
AB			**200MG**	**A204158**	**004**	Oct 27, 2015
AB		SCIEGEN PHARMS	**25MG**	**A206382**	**001**	Jun 17, 2016
AB			**50MG**	**A206382**	**002**	Jun 17, 2016
AB			**100MG**	**A206382**	**003**	Jun 17, 2016
AB			**200MG**	**A206382**	**004**	Jun 17, 2016
AB		TARO	**25MG**	**A219677**	**001**	Oct 07, 2025
AB			**50MG**	**A219677**	**002**	Oct 07, 2025
AB			**100MG**	**A219677**	**003**	Oct 07, 2025
AB			**200MG**	**A219677**	**004**	Oct 07, 2025

LANDIOLOL HYDROCHLORIDE

POWDER;INTRAVENOUS

RAPIBLYK

	+!	AOP HLTH US	EQ 280MG BASE/VIAL	N217202	001	Nov 22, 2024

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

LANREOTIDE ACETATE

AB		INVAGEN PHARMS	**EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)**	**A217193**	**001**	May 21, 2024
AB			**EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)**	**A217193**	**002**	May 21, 2024
AB			**EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)**	**A217193**	**003**	May 21, 2024

SOMATULINE DEPOT

AB	**+!**	IPSEN PHARMA	**EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)**	**N022074**	**001**	Aug 30, 2007
AB	**+!**		**EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)**	**N022074**	**002**	Aug 30, 2007
AB	**+!**		**EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)**	**N022074**	**003**	Aug 30, 2007

LANREOTIDE ACETATE

	+!	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N215395	001	Dec 17, 2021
	+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N215395	002	Dec 17, 2021
	+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N215395	003	Dec 17, 2021

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		ALKEM LABS LTD	**15MG**	**A207394**	**001**	Jan 18, 2019
AB			**30MG**	**A207394**	**002**	Jan 18, 2019
AB		APOTEX	**15MG**	**A202176**	**001**	Sep 14, 2012
AB			**30MG**	**A202176**	**002**	Sep 14, 2012
AB		CHARTWELL MOLECULAR	**15MG**	**A207156**	**001**	Sep 28, 2017
AB			**30MG**	**A207156**	**002**	Sep 28, 2017
AB		DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB			**30MG**	**A091269**	**002**	Oct 15, 2010
AB		HETERO LABS LTD III	**15MG**	**A203083**	**001**	May 18, 2020
AB			**30MG**	**A203083**	**002**	May 18, 2020
AB		INVENTIA	**15MG**	**A205868**	**001**	Aug 30, 2017
AB			**30MG**	**A205868**	**002**	Aug 30, 2017
AB		MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB			**30MG**	**A090763**	**002**	Nov 10, 2009
AB		NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB			**30MG**	**A201921**	**002**	Dec 18, 2012
AB		TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB			**30MG**	**A077255**	**002**	Nov 10, 2009
AB		XIROMED	**15MG**	**A203203**	**001**	Jul 25, 2016
AB			**30MG**	**A203203**	**002**	Jul 25, 2016
AB		ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB			**30MG**	**A202366**	**002**	Aug 19, 2013

PREVACID

AB	**+!**	TAKEDA PHARMS USA	**30MG**	**N020406**	**002**	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

AB		AUROBINDO PHARMA LTD	**15MG**	**A207167**	**001**	Mar 28, 2023
AB			**30MG**	**A207167**	**002**	Mar 28, 2023
AB		DR REDDYS	**15MG**	**A210465**	**001**	Feb 01, 2021
AB			**30MG**	**A210465**	**002**	Feb 01, 2021
AB		MYLAN	**15MG**	**A202396**	**001**	Nov 28, 2018
AB			**30MG**	**A202396**	**002**	Nov 28, 2018
AB		TEVA PHARMS USA	**15MG**	**A208784**	**001**	Sep 21, 2017
AB			**30MG**	**A208784**	**002**	Sep 21, 2017
AB		ZYDUS PHARMS	**15MG**	**A200816**	**001**	Nov 27, 2018
AB			**30MG**	**A200816**	**002**	Nov 27, 2018

PREVACID

AB	**+**	TAKEDA PHARMS USA	**15MG**	**N021428**	**001**	Aug 30, 2002
AB	**+!**		**30MG**	**N021428**	**002**	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

	+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014
	+!		EQ 1GM BASE	N204734	002	Sep 24, 2014

LANTHANUM CARBONATE							
TABLET, CHEWABLE;ORAL							
FOSRENOL							
AB	**+**	TAKEDA PHARMS USA	**EQ 500MG BASE**	**N021468**	**002**	Oct 26, 2004
AB	**+**		**EQ 750MG BASE**	**N021468**	**003**	Nov 23, 2005
AB	**+!**		**EQ 1GM BASE**	**N021468**	**004**	Nov 23, 2005
LANTHANUM CARBONATE							
AB		ALKEM LABS LTD	**EQ 500MG BASE**	**A202329**	**001**	Mar 13, 2025
AB			**EQ 750MG BASE**	**A202329**	**002**	Mar 13, 2025
AB			**EQ 1GM BASE**	**A202329**	**003**	Mar 13, 2025
AB		BARR	**EQ 500MG BASE**	**A090977**	**001**	Jan 27, 2022
AB			**EQ 750MG BASE**	**A090977**	**002**	Jan 27, 2022
AB			**EQ 1GM BASE**	**A090977**	**003**	Jan 27, 2022
AB		INVAGEN PHARMS	**EQ 500MG BASE**	**A206868**	**001**	Jan 24, 2022
AB			**EQ 750MG BASE**	**A206868**	**002**	Jan 24, 2022
AB			**EQ 1GM BASE**	**A206868**	**003**	Jan 24, 2022
AB		NATCO PHARMA LTD	**EQ 500MG BASE**	**A090978**	**001**	Aug 11, 2017
AB			**EQ 750MG BASE**	**A090978**	**002**	Aug 11, 2017
AB			**EQ 1GM BASE**	**A090978**	**003**	Aug 11, 2017
LAPATINIB DITOSYLATE							
TABLET;ORAL							
LAPATINIB DITOSYLATE							
AB		NATCO PHARMA LTD	**EQ 250MG BASE**	**A203007**	**001**	Sep 29, 2020
AB		TEVA PHARMS USA INC	**EQ 250MG BASE**	**A217968**	**001**	Aug 16, 2024
TYKERB							
AB	**+!**	NOVARTIS	**EQ 250MG BASE**	**N022059**	**001**	Mar 13, 2007
LAROTRECTINIB SULFATE							
CAPSULE;ORAL							
VITRAKVI							
	+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018
	+!		EQ 100MG BASE	N210861	002	Nov 26, 2018
SOLUTION;ORAL							
VITRAKVI							
	+!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018
LASMIDITAN SUCCINATE							
TABLET;ORAL							
REYVOW							
	+	ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020
	+!		EQ 100MG BASE	N211280	002	Jan 31, 2020
LATANOPROST							
SOLUTION/DROPS;OPHTHALMIC							
LATANOPROST							
AT		AMRING PHARMS	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		GLAND	**0.005%**	**A218257**	**001**	Nov 26, 2024
AT		MANKIND PHARMA	**0.005%**	**A220360**	**001**	Dec 17, 2025
AT		MICRO LABS	**0.005%**	**A219306**	**001**	Apr 14, 2025
AT		SANDOZ	**0.005%**	**A091449**	**001**	Mar 22, 2011
AT		SOMERSET	**0.005%**	**A201786**	**001**	Mar 22, 2011
XALATAN							
AT	**+!**	UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996
IYUZEH							
	+!	THEA PHARMA	0.005%	N216472	001	Dec 13, 2022
LATANOPROST; NETARSUDIL DIMESYLATE							
SOLUTION/DROPS;OPHTHALMIC							
ROCKLATAN							
	+!	ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019
LATANOPROSTENE BUNOD							
SOLUTION/DROPS;OPHTHALMIC							
LATANOPROSTENE BUNOD							
AB		GLAND	**0.024%**	**A217387**	**001**	Apr 29, 2025
VYZULTA							
AB	**+!**	BAUSCH AND LOMB	**0.024%**	**N207795**	**001**	Nov 02, 2017

LAZERTINIB MESYLATE

TABLET;ORAL

LAZCLUZE

+	JANSSEN BIOTECH	EQ 80MG BASE	N219008	001	Aug 19, 2024
+!		EQ 240MG BASE	N219008	002	Aug 19, 2024

LEDIPASVIR; SOFOSBUVIR

PELLETS;ORAL

HARVONI

+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019
+!		45MG;200MG/PACKET	N212477	002	Aug 28, 2019

TABLET;ORAL

HARVONI

+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019
+!		90MG;400MG	N205834	001	Oct 10, 2014

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

+!	HONG KONG	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019

TABLET;ORAL

XENLETA

+!	HONG KONG	EQ 600MG BASE	N211672	001	Aug 19, 2019

LEFLUNOMIDE

TABLET;ORAL

ARAVA

AB	**+**	SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+!**		**20MG**	**N020905**	**002**	Sep 10, 1998

LEFLUNOMIDE

AB		ABHAI LLC	**10MG**	**A212453**	**001**	Jun 03, 2019
AB			**20MG**	**A212453**	**002**	Jun 03, 2019
AB		AET PHARMA	**10MG**	**A213497**	**001**	May 10, 2021
AB			**20MG**	**A213497**	**002**	May 10, 2021
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		AUROBINDO PHARMA	**10MG**	**A213652**	**001**	Mar 29, 2021
AB			**20MG**	**A213652**	**002**	Mar 29, 2021
AB		FOSUN WANBANG	**10MG**	**A077087**	**001**	Sep 13, 2005
AB			**20MG**	**A077087**	**002**	Sep 13, 2005
AB		HERITAGE	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		LUPIN LTD	**10MG**	**A211863**	**001**	Feb 04, 2020
AB			**20MG**	**A211863**	**002**	Feb 04, 2020
AB		ZYDUS LIFESCIENCES	**10MG**	**A212308**	**001**	Apr 24, 2019
AB			**20MG**	**A212308**	**002**	Apr 24, 2019

ARAVA

+!	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LEMBOREXANT

TABLET;ORAL

DAYVIGO

+	EISAI INC	5MG	N212028	001	Apr 07, 2020
+!		10MG	N212028	002	Apr 07, 2020

LENACAPAVIR SODIUM

SOLUTION;SUBCUTANEOUS

SUNLENCA

+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N215973	001	Dec 22, 2022

YEZTUGO

+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N220018	001	Jun 18, 2025

TABLET;ORAL

SUNLENCA

+!	GILEAD SCIENCES INC	EQ 300MG BASE	N215974	001	Dec 22, 2022

YEZTUGO

+!	GILEAD SCIENCES INC	EQ 300MG BASE	N220020	001	Jun 18, 2025

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	ACCORD HLTHCARE	2.5MG	A218872	001	Nov 14, 2025
AB		5MG	A218872	002	Nov 14, 2025
AB		10MG	A218872	003	Nov 14, 2025
AB		15MG	A218872	004	Nov 14, 2025
AB		20MG	A218872	005	Nov 14, 2025
AB		25MG	A218872	006	Nov 14, 2025
AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025
AB		5MG	A216213	002	Jan 31, 2025
AB		10MG	A216213	003	Jan 31, 2025
AB		15MG	A216213	004	Jan 31, 2025
AB		20MG	A216213	005	Jan 31, 2025
AB		25MG	A216213	006	Jan 31, 2025
AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023
AB		5MG	A211022	001	Aug 30, 2022
AB		10MG	A211022	002	Aug 30, 2022
AB		15MG	A211022	003	Aug 30, 2022
AB		20MG	A211022	006	Mar 07, 2023
AB		25MG	A211022	004	Aug 30, 2022
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023
AB		5MG	A201452	001	May 21, 2021
AB		10MG	A201452	002	May 21, 2021
AB		15MG	A201452	003	May 21, 2021
AB		20MG	A201452	006	Mar 06, 2023
AB		25MG	A201452	004	May 21, 2021
AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025
AB		5MG	A215759	002	Mar 03, 2025
AB		10MG	A215759	003	Mar 03, 2025
AB		15MG	A215759	004	Mar 03, 2025
AB		20MG	A215759	005	Mar 03, 2025
AB		25MG	A215759	006	Mar 03, 2025
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023
AB		5MG	A210435	001	Sep 06, 2022
AB		10MG	A210435	002	Sep 06, 2022
AB		15MG	A210435	003	Sep 06, 2022
AB		20MG	A210435	005	Mar 06, 2023
AB		25MG	A210435	004	Sep 06, 2022
AB	DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025
AB		5MG	A217554	002	May 22, 2025
AB		10MG	A217554	003	May 22, 2025
AB		15MG	A217554	004	May 22, 2025
AB		20MG	A217554	005	May 22, 2025
AB		25MG	A217554	006	May 22, 2025
AB	DR REDDYS	2.5MG	A209348	001	Oct 14, 2021
AB		5MG	A209348	003	Aug 30, 2022
AB		10MG	A209348	004	Aug 30, 2022
AB		15MG	A209348	005	Aug 30, 2022
AB		20MG	A209348	002	Oct 14, 2021
AB		25MG	A209348	006	Aug 30, 2022
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023
AB		5MG	A213885	002	Mar 06, 2023
AB		10MG	A213885	003	Mar 06, 2023
AB		15MG	A213885	004	Mar 06, 2023
AB		20MG	A213885	005	Mar 06, 2023
AB		25MG	A213885	006	Mar 06, 2023
AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023
AB		5MG	A212414	002	May 11, 2023
AB		10MG	A212414	003	May 11, 2023
AB		15MG	A212414	004	May 11, 2023
AB		20MG	A212414	005	May 11, 2023
AB		25MG	A212414	006	May 11, 2023
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023
AB		5MG	A210480	001	Aug 31, 2022
AB		10MG	A210480	002	Aug 31, 2022
AB		15MG	A210480	003	Aug 31, 2022
AB		20MG	A210480	006	Mar 06, 2023
AB		25MG	A210480	004	Aug 31, 2022
AB	LUPIN LTD	2.5MG	A214398	001	Sep 16, 2025
AB		5MG	A214398	002	Sep 16, 2025
AB		10MG	A214398	003	Sep 16, 2025

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB			**15MG**	**A214398**	**004**	Sep 16, 2025
AB			**20MG**	**A214398**	**005**	Sep 16, 2025
AB			**25MG**	**A214398**	**006**	Sep 16, 2025
AB		MYLAN	**2.5MG**	**A213912**	**005**	Mar 06, 2023
AB			**5MG**	**A213912**	**001**	Aug 30, 2022
AB			**10MG**	**A213912**	**002**	Aug 30, 2022
AB			**15MG**	**A213912**	**003**	Aug 30, 2022
AB			**20MG**	**A213912**	**006**	Mar 06, 2023
AB			**25MG**	**A213912**	**004**	Aug 30, 2022
AB		NOVUGEN	**2.5MG**	**A217281**	**001**	Sep 11, 2024
AB			**5MG**	**A217281**	**002**	Sep 11, 2024
AB			**10MG**	**A217281**	**003**	Sep 11, 2024
AB			**15MG**	**A217281**	**004**	Sep 11, 2024
AB			**20MG**	**A217281**	**005**	Sep 11, 2024
AB			**25MG**	**A217281**	**006**	Sep 11, 2024
AB		QILU	**2.5MG**	**A217265**	**001**	Feb 22, 2024
AB			**5MG**	**A217265**	**002**	Feb 22, 2024
AB			**10MG**	**A217265**	**003**	Feb 22, 2024
AB			**15MG**	**A217265**	**004**	Feb 22, 2024
AB			**20MG**	**A217265**	**005**	Feb 22, 2024
AB			**25MG**	**A217265**	**006**	Feb 22, 2024
AB		SUN PHARM	**2.5MG**	**A211846**	**005**	Mar 06, 2023
AB			**5MG**	**A211846**	**001**	Feb 08, 2023
AB			**10MG**	**A211846**	**002**	Feb 08, 2023
AB			**15MG**	**A211846**	**003**	Feb 08, 2023
AB			**20MG**	**A211846**	**006**	Mar 06, 2023
AB			**25MG**	**A211846**	**004**	Feb 08, 2023
AB		TORRENT	**15MG**	**A213405**	**004**	Nov 04, 2025
AB		ZYDUS PHARMS	**2.5MG**	**A210154**	**005**	Mar 06, 2023
AB			**5MG**	**A210154**	**001**	Sep 12, 2022
AB			**10MG**	**A210154**	**002**	Sep 12, 2022
AB			**15MG**	**A210154**	**003**	Sep 12, 2022
AB			**20MG**	**A210154**	**006**	Mar 06, 2023
AB			**25MG**	**A210154**	**004**	Sep 12, 2022

REVLIMID

AB	**+**	BRISTOL MYERS SQUIBB	**2.5MG**	**N021880**	**005**	Dec 21, 2011
AB	**+**		**5MG**	**N021880**	**001**	Dec 27, 2005
AB	**+**		**10MG**	**N021880**	**002**	Dec 27, 2005
AB	**+**		**15MG**	**N021880**	**003**	Jun 29, 2006
AB	**+**		**20MG**	**N021880**	**006**	Jun 05, 2013
AB	**+!**		**25MG**	**N021880**	**004**	Jun 29, 2006

LENIOLISIB PHOSPHATE

TABLET;ORAL

JOENJA

+!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
+!		EQ 10MG BASE	N206947	002	Feb 13, 2015

LETERMOVIR

PELLETS;ORAL

PREVYMIS

+	MSD	20MG/PACKET	N219104	001	Aug 30, 2024
+!		120MG/PACKET	N219104	002	Aug 30, 2024

SOLUTION;INTRAVENOUS

PREVYMIS

+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017

TABLET;ORAL

PREVYMIS

+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
+!		480MG	N209939	002	Nov 08, 2017

LETROZOLE

TABLET;ORAL

FEMARA

AB	**+!**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997

LETROZOLE

AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		BEIJING YILING	**2.5MG**	**A205869**	**001**	Nov 14, 2018
AB		EUGIA PHARMA	**2.5MG**	**A211717**	**001**	Jan 11, 2019
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		TEVA PHARMS	**2.5MG**	**A090289**	**001**	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

	+!	NOVARTIS	2.5MG;EQ 200MG BASE	N209935	001	May 04, 2017

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP		GLAND	**EQ 350MG BASE/VIAL**	**A218200**	**001**	Nov 12, 2025
AP		HAINAN POLY	**EQ 50MG BASE/VIAL**	**A217021**	**001**	Jul 10, 2023
AP			**EQ 100MG BASE/VIAL**	**A217021**	**002**	Jul 10, 2023
AP			**EQ 200MG BASE/VIAL**	**A217021**	**003**	Jul 10, 2023
AP			**EQ 350MG BASE/VIAL**	**A217021**	**005**	Dec 19, 2024
AP			**EQ 500MG BASE/VIAL**	**A217021**	**004**	Jul 10, 2023
AP	**!**	HIKMA	**EQ 50MG BASE/VIAL**	**A089384**	**001**	Sep 14, 1987
AP	**!**		**EQ 100MG BASE/VIAL**	**A089717**	**001**	Mar 28, 1988
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A216590**	**001**	Jul 19, 2023
AP			**EQ 100MG BASE/VIAL**	**A216590**	**002**	Jul 19, 2023
AP			**EQ 200MG BASE/VIAL**	**A216590**	**003**	Jul 19, 2023
AP			**EQ 350MG BASE/VIAL**	**A216590**	**004**	Jul 19, 2023
AP			**EQ 500MG BASE/VIAL**	**A216590**	**005**	Jul 19, 2023

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001**	Feb 26, 1999
AP	**!**		**EQ 500MG BASE/VIAL**	**A040286**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 200MG BASE/VIAL**	**A040056**	**001**	May 23, 1995
AP	**!**		**EQ 350MG BASE/VIAL**	**A040335**	**001**	Apr 20, 2000
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A203800**	**001**	May 19, 2017
AP			**EQ 200MG BASE/VIAL**	**A203800**	**002**	May 19, 2017
AP			**EQ 350MG BASE/VIAL**	**A203800**	**003**	May 19, 2017
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001**	Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002**	Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003**	Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001**	Sep 06, 2012
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A209110**	**001**	Oct 26, 2017

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

	!	FRESENIUS KABI USA	EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A207241	001	Mar 14, 2018
	!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A207226	001	Jul 27, 2018

TABLET;ORAL

LEUCOVORIN CALCIUM

AB		BARR	**EQ 5MG BASE**	**A071198**	**001**	Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001**	Sep 24, 1987
AB		EPIC PHARMA LLC	**EQ 5MG BASE**	**A074544**	**001**	Aug 28, 1997
AB			**EQ 10MG BASE**	**A074544**	**003**	May 19, 2021
AB			**EQ 15MG BASE**	**A074544**	**004**	May 19, 2021
AB			**EQ 25MG BASE**	**A074544**	**002**	Aug 28, 1997
AB		HIKMA	**EQ 5MG BASE**	**A072733**	**001**	Feb 22, 1993
AB			**EQ 10MG BASE**	**A072734**	**001**	Feb 22, 1993
AB			**EQ 15MG BASE**	**A072735**	**001**	Feb 22, 1993
AB	**!**		**EQ 25MG BASE**	**A072736**	**001**	Feb 22, 1993
AB		LEADING	**EQ 5MG BASE**	**A213929**	**001**	Oct 22, 2020
AB			**EQ 10MG BASE**	**A213929**	**002**	Oct 22, 2020
AB			**EQ 15MG BASE**	**A213929**	**003**	Oct 22, 2020
AB			**EQ 25MG BASE**	**A213929**	**004**	Oct 22, 2020
AB		NOVAST LABS	**EQ 5MG BASE**	**A211132**	**001**	Jul 30, 2020
AB			**EQ 10MG BASE**	**A211132**	**002**	Jul 30, 2020
AB			**EQ 15MG BASE**	**A211132**	**003**	Jul 30, 2020
AB			**EQ 25MG BASE**	**A211132**	**004**	Jul 30, 2020

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

+!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018

INJECTABLE;INJECTION

LUPRON DEPOT

+!	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
+!		7.5MG	N019732	001	Jan 26, 1989
+!		11.25MG	N020708	001	Mar 07, 1997
+		22.5MG	N020517	001	Dec 22, 1995
+!		30MG	N020517	002	May 30, 1997
+!		45MG	N020517	003	Jun 17, 2011

POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+!	ABBVIE ENDOCRINE INC	7.5MG	N020263	002	Apr 16, 1993
+!		11.25MG	N020263	005	Jan 21, 1994
+!		11.25MG	N020263	007	Aug 15, 2011
+!		15MG	N020263	006	Jan 21, 1994
+!		30MG	N020263	008	Aug 15, 2011
+!		45MG	N020263	009	Apr 14, 2023

POWDER;SUBCUTANEOUS

ELIGARD KIT

+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002
+!		22.5MG	N021379	001	Jul 24, 2002
+!		30MG	N021488	001	Feb 13, 2003
+!		45MG	N021731	001	Dec 14, 2004

FENSOLVI KIT

+!	TOLMAR	45MG	N213150	001	May 01, 2020

SOLUTION;SUBCUTANEOUS

LEUPROLIDE ACETATE

AP		AMNEAL	**14MG/2.8ML (1MG/0.2ML)**	**A215336**	**001**	Oct 28, 2022
AP		EUGIA PHARMA	**14MG/2.8ML (1MG/0.2ML)**	**A212963**	**001**	Jun 06, 2022
AP		MEITHEAL	**14MG/2.8ML (1MG/0.2ML)**	**A075471**	**001**	Oct 25, 2000
AP		RK PHARMA	**14MG/2.8ML (1MG/0.2ML)**	**A213829**	**001**	Aug 13, 2021
AP	!	SANDOZ	**14MG/2.8ML (1MG/0.2ML)**	**A074728**	**001**	Aug 04, 1998
AP		SUN PHARM	**14MG/2.8ML (1MG/0.2ML)**	**A078885**	**001**	Mar 09, 2009
AP		UBI	**14MG/2.8ML (1MG/0.2ML)**	**A217957**	**001**	Oct 17, 2024
AP		ZYDUS PHARMS	**14MG/2.8ML (1MG/0.2ML)**	**A215826**	**001**	Nov 13, 2025

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI ETM

+!	FORESEE PHARMS	EQ 21MG BASE	N219745	001	Aug 25, 2025

CAMCEVI KIT

+!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021

LEVACETYLLEUCINE

FOR SUSPENSION;ORAL

AQNEURSA

+!	INTRABIO	1GM/PACKET	N219132	001	Sep 24, 2024

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		CIPLA	**EQ 0.021% BASE**	**A078171**	**002**	Dec 13, 2013
AN			**EQ 0.042% BASE**	**A078171**	**003**	Dec 13, 2013
AN			**EQ 0.0103% BASE**	**A078171**	**001**	Dec 13, 2013
AN		IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN			**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN			**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN		LUOXIN AUROVITAS	**EQ 0.25% BASE**	**A207628**	**001**	Jan 31, 2017
AN			**EQ 0.0103% BASE**	**A207625**	**001**	Dec 30, 2016
AN			**EQ 0.021% BASE**	**A207625**	**002**	Dec 30, 2016
AN			**EQ 0.042% BASE**	**A207625**	**003**	Dec 30, 2016
AN	!	MYLAN SPECIALITY LP	**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009
AN		RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN			**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN			**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN		TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN	!	TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN	!		**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN	!		**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013

LEVALBUTEROL TARTRATE						
AEROSOL, METERED;INHALATION						
XOPENEX HFA						
	+!	LUPIN	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005
LEVETIRACETAM						
INJECTABLE;INTRAVENOUS						
KEPPRA						
AP	**+!**	UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006
LEVETIRACETAM						
AP		EUGIA PHARMA	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP		FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP		HAINAN POLY PHARM	**500MG/5ML (100MG/ML)**	**A209781**	**001**	Mar 20, 2018
AP		HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP		HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP		KNACK	**500MG/5ML (100MG/ML)**	**A215465**	**001**	Dec 02, 2025
AP		MICRO LABS	**500MG/5ML (100MG/ML)**	**A211954**	**001**	Aug 09, 2019
AP		MSN	**500MG/5ML (100MG/ML)**	**A215980**	**001**	Nov 15, 2022
AP		MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP		PRINSTON INC	**500MG/5ML (100MG/ML)**	**A209474**	**001**	Mar 28, 2022
AP		SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP		XGEN PHARMS	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011
LEVETIRACETAM IN SODIUM CHLORIDE						
AP		B BRAUN MEDICAL	**500MG/100ML (5MG/ML)**	**A209705**	**001**	Feb 27, 2024
AP			**1GM/100ML (10MG/ML)**	**A209705**	**002**	Feb 27, 2024
AP			**1.5GM/100ML (15MG/ML)**	**A209705**	**003**	Feb 27, 2024
AP		BAXTER HLTHCARE CORP	**500MG/100ML (5MG/ML)**	**A217059**	**001**	Oct 02, 2023
AP			**1GM/100ML (10MG/ML)**	**A217059**	**002**	Oct 02, 2023
AP			**1.5GM/100ML (15MG/ML)**	**A217059**	**003**	Oct 02, 2023
AP		CAPLIN	**500MG/100ML (5MG/ML)**	**A219562**	**001**	Jan 16, 2025
AP			**1GM/100ML (10MG/ML)**	**A219562**	**002**	Jan 16, 2025
AP			**1.5GM/100ML (15MG/ML)**	**A219562**	**003**	Jan 16, 2025
AP		EUGIA PHARMA	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP			**1GM/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP		FRESENIUS KABI USA	**500MG/100ML (5MG/ML)**	**A208619**	**001**	Jan 31, 2023
AP			**1GM/100ML (10MG/ML)**	**A208619**	**002**	Jan 31, 2023
AP			**1.5GM/100ML (15MG/ML)**	**A208619**	**003**	Jan 31, 2023
AP		GLAND	**500MG/100ML (5MG/ML)**	**A206880**	**001**	Oct 25, 2017
AP			**1GM/100ML (10MG/ML)**	**A206880**	**002**	Oct 25, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A206880**	**003**	Oct 25, 2017
AP		HIKMA	**500MG/100ML (5MG/ML)**	**A211356**	**001**	Feb 12, 2024
AP			**1GM/100ML (10MG/ML)**	**A211356**	**002**	Feb 12, 2024
AP			**1.5GM/100ML (15MG/ML)**	**A211356**	**003**	Feb 12, 2024
AP	**+!**	HQ SPCLT PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	**+!**		**1GM/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	**+!**		**1.5GM/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011
AP		NEXUS	**500MG/100ML (5MG/ML)**	**A213532**	**001**	Jul 06, 2020
AP			**1GM/100ML (10MG/ML)**	**A213532**	**002**	Jul 06, 2020
AP			**1.5GM/100ML (15MG/ML)**	**A213532**	**003**	Jul 06, 2020
SOLUTION;ORAL						
KEPPRA						
AA	**+!**	UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003
LEVETIRACETAM						
AA		ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009
AA		AJENAT PHARMS	**100MG/ML**	**A090461**	**001**	Sep 30, 2010
AA		ALEMBIC	**100MG/ML**	**A203067**	**001**	May 09, 2013
AA		AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009
AA		AUROBINDO PHARMA	**100MG/ML**	**A079063**	**001**	Jan 15, 2009
AA		BIONPHARMA	**100MG/ML**	**A079120**	**001**	Jan 16, 2009
AA		CHARTWELL MOLECULAR	**100MG/ML**	**A090263**	**001**	Apr 03, 2009
AA		GUARDIAN DRUG	**100MG/ML**	**A218080**	**001**	Nov 21, 2025
AA		HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013
AA		MSN	**100MG/ML**	**A214757**	**001**	Jul 15, 2022
AA		PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015
AA		QUAGEN	**100MG/ML**	**A090079**	**001**	Apr 11, 2012
AA		STRIDES PHARMA	**100MG/ML**	**A078582**	**001**	Jan 15, 2009
AA		TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009
TABLET;ORAL						
KEPPRA						
AB	**+**	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999

LEVETIRACETAM

TABLET;ORAL

KEPPRA						
AB	+	**500MG**	**N021035**	**002**	Nov 30, 1999	
AB	+	**750MG**	**N021035**	**003**	Nov 30, 1999	
AB	+!	**1GM**	**N021035**	**004**	Jan 06, 2006	
LEVETIRACETAM						
AB	ALKEM LABS LTD	**250MG**	**A216375**	**001**	May 27, 2022	
AB		**500MG**	**A216375**	**002**	May 27, 2022	
AB		**750MG**	**A216375**	**003**	May 27, 2022	
AB		**1GM**	**A216375**	**004**	May 27, 2022	
AB	ANDA REPOSITORY	**250MG**	**A076920**	**001**	Jan 15, 2009	
AB		**500MG**	**A076920**	**002**	Jan 15, 2009	
AB		**750MG**	**A076920**	**003**	Jan 15, 2009	
AB		**1GM**	**A078904**	**001**	Jan 15, 2009	
AB	AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009	
AB		**500MG**	**A078993**	**002**	Jan 15, 2009	
AB		**750MG**	**A078993**	**003**	Jan 15, 2009	
AB		**1GM**	**A078993**	**004**	Jan 15, 2009	
AB	CHARTWELL RX	**250MG**	**A201293**	**001**	Jun 14, 2011	
AB		**500MG**	**A201293**	**002**	Jun 14, 2011	
AB		**750MG**	**A201293**	**003**	Jun 14, 2011	
AB		**1GM**	**A201293**	**004**	Jun 14, 2011	
AB	HETERO LABS LTD III	**250MG**	**A090515**	**001**	Oct 08, 2010	
AB		**500MG**	**A090515**	**002**	Oct 08, 2010	
AB		**750MG**	**A090515**	**003**	Oct 08, 2010	
AB		**1GM**	**A090515**	**004**	Oct 08, 2010	
AB	INGENUS PHARMS LLC	**250MG**	**A079042**	**001**	Jan 15, 2009	
AB		**500MG**	**A079042**	**002**	Jan 15, 2009	
AB		**750MG**	**A079042**	**003**	Jan 15, 2009	
AB		**1GM**	**A079042**	**004**	Jan 15, 2009	
AB	LUPIN	**250MG**	**A078154**	**001**	Jan 15, 2009	
AB		**500MG**	**A078154**	**002**	Jan 15, 2009	
AB		**750MG**	**A078154**	**003**	Jan 15, 2009	
AB		**1GM**	**A090025**	**001**	Jan 15, 2009	
AB	MSN	**250MG**	**A214815**	**001**	Oct 07, 2022	
AB		**500MG**	**A214815**	**002**	Oct 07, 2022	
AB		**750MG**	**A214815**	**003**	Oct 07, 2022	
AB		**1GM**	**A214815**	**004**	Oct 07, 2022	
AB	MYLAN	**500MG**	**A076919**	**002**	Nov 04, 2008	
AB		**750MG**	**A076919**	**003**	Nov 04, 2008	
AB		**1GM**	**A090261**	**001**	Dec 08, 2009	
AB	ORBION PHARMS	**250MG**	**A078526**	**001**	Jan 15, 2009	
AB		**500MG**	**A078526**	**002**	Jan 15, 2009	
AB		**750MG**	**A078526**	**003**	Jan 15, 2009	
AB		**1GM**	**A090484**	**001**	Aug 05, 2010	
AB	OXFORD PHARMS	**250MG**	**A077319**	**001**	Mar 20, 2009	
AB		**500MG**	**A077319**	**002**	Mar 20, 2009	
AB		**750MG**	**A077319**	**003**	Mar 20, 2009	
AB	PRINSTON INC	**250MG**	**A078106**	**001**	Feb 10, 2009	
AB		**500MG**	**A078106**	**002**	Feb 10, 2009	
AB		**750MG**	**A078106**	**003**	Feb 10, 2009	
AB		**1GM**	**A078106**	**004**	Feb 10, 2009	
AB	RISING	**250MG**	**A090767**	**001**	Jul 28, 2010	
AB		**500MG**	**A090767**	**002**	Jul 28, 2010	
AB		**750MG**	**A090767**	**003**	Jul 28, 2010	
AB		**1GM**	**A090767**	**004**	Jul 28, 2010	
AB	SCIEGEN PHARMS	**250MG**	**A215069**	**003**	May 27, 2022	
AB		**500MG**	**A215069**	**004**	May 27, 2022	
AB		**750MG**	**A215069**	**001**	Jun 11, 2021	
AB		**1GM**	**A215069**	**002**	Jun 11, 2021	
AB	TORRENT PHARMS	**250MG**	**A078858**	**001**	Jan 15, 2009	
AB		**500MG**	**A078858**	**002**	Jan 15, 2009	
AB		**750MG**	**A078858**	**003**	Jan 15, 2009	
AB		**1GM**	**A078858**	**004**	Jan 15, 2009	
AB	VIWIT PHARM	**250MG**	**A078869**	**001**	Mar 13, 2009	
AB		**500MG**	**A078869**	**002**	Mar 13, 2009	
AB		**750MG**	**A078869**	**003**	Mar 13, 2009	
AB		**1GM**	**A078869**	**004**	Mar 13, 2009	
AB	ZHEJIANG JINGXIN	**250MG**	**A091491**	**001**	Dec 14, 2010	
AB		**500MG**	**A091491**	**002**	Dec 14, 2010	
AB		**750MG**	**A091491**	**003**	Dec 14, 2010	

LEVETIRACETAM							
TABLET;ORAL							
LEVETIRACETAM							
AB			**1GM**	**A091491**	**004**	Dec 14, 2010	
AB		ZYDUS PHARMS USA INC	**250MG**	**A078918**	**001**	Apr 29, 2009	
AB			**1GM**	**A078918**	**002**	Apr 29, 2009	
TABLET, EXTENDED RELEASE;ORAL							
KEPPRA XR							
AB	+	UCB INC	**500MG**	**N022285**	**001**	Sep 12, 2008	
AB	+!		**750MG**	**N022285**	**002**	Feb 12, 2009	
LEVETIRACETAM							
AB		ACTAVIS LABS FL INC	**500MG**	**A091093**	**001**	Sep 12, 2011	
AB			**750MG**	**A091093**	**002**	Sep 12, 2011	
AB		AIPING PHARM INC	**500MG**	**A204754**	**001**	Aug 26, 2016	
AB			**750MG**	**A204754**	**002**	Aug 26, 2016	
AB		ANDA REPOSITORY	**500MG**	**A204511**	**001**	Feb 23, 2016	
AB			**750MG**	**A204511**	**002**	Feb 23, 2016	
AB		APOTEX INC	**500MG**	**A091261**	**001**	Sep 12, 2011	
AB			**750MG**	**A091261**	**002**	Sep 12, 2011	
AB		HISUN PHARM HANGZHOU	**500MG**	**A207175**	**001**	Sep 28, 2017	
AB			**750MG**	**A207175**	**002**	Sep 28, 2017	
AB		LUPIN LTD	**500MG**	**A091399**	**001**	Sep 12, 2011	
AB			**750MG**	**A091399**	**002**	Sep 12, 2011	
AB		OVERSEAS	**500MG**	**A212688**	**002**	May 05, 2023	
AB			**750MG**	**A212688**	**001**	Jun 11, 2020	
AB		PRINSTON INC	**500MG**	**A203468**	**001**	May 21, 2015	
AB			**750MG**	**A203468**	**002**	May 21, 2015	
AB		SCIEGEN PHARMS	**500MG**	**A205130**	**001**	Nov 27, 2020	
AB			**750MG**	**A205130**	**002**	Nov 27, 2020	
AB		TORRENT PHARMS LTD	**500MG**	**A091338**	**001**	May 29, 2012	
AB			**750MG**	**A091338**	**002**	May 29, 2012	
TABLET, FOR SUSPENSION;ORAL							
SPRITAM							
	+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015	
	+!		500MG	N207958	002	Jul 31, 2015	
LEVOBUNOLOL HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
BETAGAN							
AT	**+!**	ALLERGAN	**0.5%**	**N019219**	**002**	Dec 19, 1985	
LEVOBUNOLOL HYDROCHLORIDE							
AT		BAUSCH AND LOMB	**0.5%**	**A074326**	**001**	Mar 04, 1994	
LEVOCARNITINE							
INJECTABLE;INJECTION							
CARNITOR							
AP	**+!**	LEADIANT BIOSCI INC	**200MG/ML**	**N020182**	**001**	Dec 16, 1992	
LEVOCARNITINE							
AP		AM REGENT	**200MG/ML**	**A075861**	**001**	Jun 22, 2001	
AP		DEVA HOLDING AS	**200MG/ML**	**A217430**	**001**	Jun 30, 2025	
AP		HIKMA	**200MG/ML**	**A075567**	**001**	Mar 29, 2001	
SOLUTION;ORAL							
CARNITOR							
AA	**+!**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**001**	Apr 10, 1986	
CARNITOR SF							
AA	**+**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**002**	Mar 28, 2007	
LEVOCARNITINE							
AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**001**	Aug 14, 2019	
AA		RISING	**1GM/10ML**	**A076851**	**001**	Aug 10, 2004	
AA		SCIEGEN PHARMS	**1GM/10ML**	**A212533**	**001**	Nov 10, 2021	
LEVOCARNITINE SF							
AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**002**	Aug 14, 2019	
TABLET;ORAL							
CARNITOR							
AB	**+!**	LEADIANT BIOSCI INC	**330MG**	**N018948**	**001**	Dec 27, 1985	
LEVOCARNITINE							
AB		NOVITIUM PHARMA	**330MG**	**A216384**	**001**	Dec 09, 2022	
AB		RISING	**330MG**	**A076858**	**001**	Sep 20, 2004	

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		CHARTWELL MOLECULAR	**2.5MG/5ML**	**A204599**	**001**	May 15, 2017
AA	!	PADAGIS US	**2.5MG/5ML**	**A091263**	**001**	Nov 07, 2011

LEVOCETIRIZINE HYDROCHLORIDE

AA		HETERO LABS LTD III	**2.5MG/5ML**	**A210914**	**001**	Apr 01, 2019

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	**5MG**	**A090392**	**001**	Feb 24, 2011
AB	!	GLENMARK PHARMS LTD	**5MG**	**A090385**	**001**	Feb 24, 2011
AB		HETERO LABS LTD III	**5MG**	**A091264**	**001**	Jun 29, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A205564**	**001**	Jan 11, 2016
AB		MICRO LABS LTD INDIA	**5MG**	**A202046**	**001**	Sep 17, 2013
AB		SCIEGEN PHARMS	**5MG**	**A203646**	**001**	Sep 09, 2014
AB		SUN PHARM	**5MG**	**A090362**	**001**	Jan 31, 2013
AB		SYNTHON BV	**5MG**	**A090229**	**001**	Nov 26, 2010
AB		TEVA PHARMS	**5MG**	**A090199**	**001**	Aug 22, 2011

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	MERZ	42MG	N209184	001	Dec 21, 2018

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP		GLAND	**EQ 500MG/20ML (EQ 25MG/ML)**	**A205540**	**001**	Apr 22, 2020
AP			**EQ 750MG/30ML (EQ 25MG/ML)**	**A205540**	**002**	Apr 22, 2020
AP	!	RISING	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091644**	**001**	Jun 20, 2011
AP	!		**EQ 750MG/30ML (EQ 25MG/ML)**	**A091644**	**002**	Jun 20, 2011

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A200674**	**001**	Jun 19, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A200674**	**002**	Jun 19, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A200674**	**003**	Jun 19, 2013
AP		GLAND	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206908**	**001**	Dec 30, 2020
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206908**	**002**	Dec 30, 2020
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206908**	**003**	Dec 30, 2020
AP		HIKMA FARMACEUTICA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091375**	**001**	Sep 16, 2011
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091375**	**002**	Sep 16, 2011
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091375**	**003**	Sep 16, 2011
AP		HOSPIRA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A078579**	**001**	Sep 03, 2015
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A078579**	**002**	Sep 03, 2015
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A078579**	**003**	Sep 03, 2015
AP	!	INFORLIFE	**EQ 250MG/50ML (EQ 5MG/ML)**	**A090343**	**001**	Jul 07, 2011
AP	!		**EQ 500MG/100ML (EQ 5MG/ML)**	**A090343**	**002**	Jul 07, 2011
AP	!		**EQ 750MG/150ML (EQ 5MG/ML)**	**A090343**	**003**	Jul 07, 2011

SOLUTION;ORAL

LEVOFLOXACIN

AA		LANNETT CO INC	**250MG/10ML**	**A205222**	**001**	May 25, 2018
AA	!	NOVITIUM PHARMA	**250MG/10ML**	**A091678**	**001**	Jun 20, 2011

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	!	RISING	**0.5%**	**A077700**	**001**	Dec 20, 2010
AT		RUBICON RESEARCH	**0.5%**	**A078282**	**001**	Dec 20, 2010
		MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019

TABLET;ORAL

LEVOFLOXACIN

AB		AUROBINDO PHARMA LTD	**250MG**	**A201043**	**001**	Jun 20, 2011
AB			**500MG**	**A201043**	**002**	Jun 20, 2011
AB	!		**750MG**	**A201043**	**003**	Jun 20, 2011
AB		CHARTWELL MOLECULAR	**250MG**	**A076890**	**001**	Mar 30, 2012
AB			**500MG**	**A076890**	**002**	Mar 30, 2012
AB			**750MG**	**A076890**	**003**	Mar 30, 2012
AB		DR REDDYS LABS INC	**250MG**	**A076710**	**001**	Jun 20, 2011
AB			**500MG**	**A076710**	**002**	Jun 20, 2011
AB			**750MG**	**A076710**	**003**	Jun 20, 2011
AB		GLENMARK PHARMS LTD	**250MG**	**A200250**	**001**	Jun 20, 2011
AB			**500MG**	**A200250**	**002**	Jun 20, 2011
AB			**750MG**	**A200250**	**003**	Jun 20, 2011
AB		HEC PHARM	**250MG**	**A204968**	**001**	Feb 05, 2019

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

AB			**500MG**	**A204968**	**002**	Feb 05, 2019
AB			**750MG**	**A204968**	**003**	Feb 05, 2019
AB		HETERO LABS LTD V	**250MG**	**A202801**	**001**	Jan 08, 2015
AB			**500MG**	**A202801**	**002**	Jan 08, 2015
AB			**750MG**	**A202801**	**003**	Jan 08, 2015
AB		LUPIN	**250MG**	**A078424**	**001**	Jun 20, 2011
AB			**500MG**	**A078424**	**002**	Jun 20, 2011
AB			**750MG**	**A078424**	**003**	Jun 20, 2011
AB		MACLEODS PHARMS LTD	**250MG**	**A200839**	**001**	Mar 22, 2012
AB			**500MG**	**A200839**	**002**	Mar 22, 2012
AB			**750MG**	**A200839**	**003**	Mar 22, 2012
AB		ORBION PHARMS	**250MG**	**A202200**	**001**	Jan 30, 2012
AB			**500MG**	**A202200**	**002**	Jan 30, 2012
AB			**750MG**	**A202200**	**003**	Jan 30, 2012
AB		TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB			**500MG**	**A076361**	**002**	Jun 20, 2011
AB			**750MG**	**A076361**	**003**	Jun 20, 2011
AB		ZYDUS LIFESCIENCES	**250MG**	**A077652**	**001**	Sep 07, 2012
AB			**500MG**	**A077652**	**002**	Sep 07, 2012
AB			**750MG**	**A077652**	**003**	Sep 07, 2012

LEVOKETOCONAZOLE

TABLET;ORAL

RECORLEV

+!	STRONGBRIDGE	150MG	N214133	001	Dec 30, 2021

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

+!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A207548**	**001**	Sep 08, 2017
AP		GLAND	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210892**	**001**	Sep 14, 2018
AP	**!**		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210892**	**002**	Sep 14, 2018
AP		HAINAN POLY PHARM	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A217314**	**001**	May 22, 2023
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A217314**	**002**	May 22, 2023
AP	**!**	MEITHEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A211002**	**001**	Aug 16, 2019
AP		SANDOZ	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

AB	**+**	ABBVIE	**EQ 20MG BASE**	**N204168**	**001**	Jul 25, 2013
AB	**+**		**EQ 40MG BASE**	**N204168**	**002**	Jul 25, 2013
AB	**+**		**EQ 80MG BASE**	**N204168**	**003**	Jul 25, 2013
AB	**+!**		**EQ 120MG BASE**	**N204168**	**004**	Jul 25, 2013

LEVOMILNACIPRAN HYDROCHLORIDE

AB		PRINSTON INC	**EQ 20MG BASE**	**A210771**	**001**	Mar 20, 2023
AB			**EQ 40MG BASE**	**A210771**	**002**	Mar 20, 2023
AB			**EQ 80MG BASE**	**A210771**	**003**	Mar 20, 2023
AB			**EQ 120MG BASE**	**A210771**	**004**	Mar 20, 2023

LEVONORGESTREL

SYSTEM;INTRAUTERINE

KYLEENA

+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016

LILETTA

+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015

MIRENA

+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000

SKYLA

+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB		ACERTIS PHARMS	**2MG**	**A211484**	**001**	Dec 13, 2018
AB		HIKMA	**2MG**	**A074278**	**001**	Mar 31, 2000
AB		SPECGX LLC	**2MG**	**A212024**	**001**	Dec 13, 2019
AB		SUN PHARM INDS INC	**2MG**	**A213906**	**001**	Jun 17, 2021
BX		NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021
BX			2MG	A213479	001	Jul 01, 2020
BX			3MG	A213479	002	Jan 12, 2021
	!	SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT

	+	IBSA	0.013MG	N021924	013	Aug 01, 2007
	+		0.025MG	N021924	002	Oct 13, 2006
	+		0.0375MG	N021924	014	Jun 22, 2022
	+		0.044MG	N021924	015	Jun 22, 2022
	+		0.05MG	N021924	003	Oct 13, 2006
	+		0.0625MG	N021924	016	Jun 22, 2022
	+		0.075MG	N021924	004	Oct 13, 2006
	+		0.088MG	N021924	010	Oct 02, 2009
	+		0.1MG	N021924	005	Oct 13, 2006
	+		0.112MG	N021924	008	Oct 02, 2009
	+		0.125MG	N021924	006	Oct 13, 2006
	+		0.137MG	N021924	009	Oct 02, 2009
	+		0.15MG	N021924	007	Oct 13, 2006
	+		0.175MG	N021924	011	Apr 25, 2017
	+!		0.2MG	N021924	012	Apr 25, 2017

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	**+!**	FRESENIUS KABI USA	**100MCG/VIAL**	**N202231**	**001**	Jun 24, 2011
AP	**+!**		**200MCG/VIAL**	**N202231**	**002**	Jun 24, 2011
AP	**+!**		**500MCG/VIAL**	**N202231**	**003**	Jun 24, 2011
AP		MAIA PHARMS INC	**100MCG/VIAL**	**A208749**	**001**	Dec 21, 2018
AP			**200MCG/VIAL**	**A208749**	**002**	Dec 21, 2018
AP			**500MCG/VIAL**	**A208749**	**003**	Dec 21, 2018
AP		ONESOURCE SPECIALTY	**100MCG/VIAL**	**A216729**	**001**	Mar 05, 2025
AP			**200MCG/VIAL**	**A216729**	**002**	Mar 05, 2025
AP			**500MCG/VIAL**	**A216729**	**003**	Mar 05, 2025
AP		PIRAMAL CRITICAL	**100MCG/VIAL**	**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**	**A206163**	**002**	Jun 29, 2016
AP		XIROMED	**100MCG/VIAL**	**A217495**	**001**	Nov 29, 2024
AP		ZYDUS PHARMS	**100MCG/VIAL**	**A217066**	**001**	Mar 24, 2023
AP			**200MCG/VIAL**	**A217066**	**002**	Mar 24, 2023
AP			**500MCG/VIAL**	**A217066**	**003**	Mar 24, 2023

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

	+!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019
	+!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019
	+!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019
	+!	HIKMA	100MCG/ML	N214253	001	May 17, 2021

SOLUTION;ORAL

ERMEZA

	+!	MYLAN	150MCG/5ML	N215809	001	Apr 29, 2022

THYQUIDITY

	+!	STEVENS J	100MCG/5ML	N214047	001	Nov 30, 2020

TIROSINT-SOL

	+	IBSA	13MCG/ML	N206977	001	Dec 15, 2016
	+		25MCG/ML	N206977	002	Dec 15, 2016
	+		37.5MCG/ML	N206977	013	Jan 13, 2021
	+		44MCG/ML	N206977	014	Jan 13, 2021
	+		50MCG/ML	N206977	003	Dec 15, 2016
	+		62.5MCG/ML	N206977	015	Jan 13, 2021
	+		75MCG/ML	N206977	004	Dec 15, 2016
	+		88MCG/ML	N206977	005	Dec 15, 2016
	+		100MCG/ML	N206977	006	Dec 15, 2016
	+		112MCG/ML	N206977	007	Dec 15, 2016
	+		125MCG/ML	N206977	008	Dec 15, 2016
	+		137MCG/ML	N206977	009	Dec 15, 2016
	+		150MCG/ML	N206977	010	Dec 15, 2016
	+		175MCG/ML	N206977	011	Dec 15, 2016

LEVOTHYROXINE SODIUM
SOLUTION;ORAL
TIROSINT-SOL

	+!		200MCG/ML		N206977 012	Dec 15, 2016

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL

SYNTHROID						
-->	+	ABBVIE	--> AB1,AB2	0.025MG	N021402 001	Jul 24, 2002
-->	+		--> AB1,AB2	0.05MG	N021402 002	Jul 24, 2002
-->	+		--> AB1,AB2	0.075MG	N021402 003	Jul 24, 2002
-->	+		--> AB1,AB2	0.088MG	N021402 004	Jul 24, 2002
-->	+		--> AB1,AB2	0.1MG	N021402 005	Jul 24, 2002
-->	+		--> AB1,AB2	0.112MG	N021402 006	Jul 24, 2002
-->	+		--> AB1,AB2	0.125MG	N021402 007	Jul 24, 2002
-->	+		--> AB1,AB2	0.137MG	N021402 008	Jul 24, 2002
-->	+		--> AB1,AB2	0.15MG	N021402 009	Jul 24, 2002
-->	+		--> AB1,AB2	0.175MG	N021402 010	Jul 24, 2002
-->	+		--> AB1,AB2	0.2MG	N021402 012	Jul 24, 2002
-->	+!		--> AB1,AB2	0.3MG	N021402 011	Jul 24, 2002
LEVO-T						
-->		CEDIPROF INC	--> AB1,AB2,AB3	0.025MG	N021342 001	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.05MG	N021342 002	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.075MG	N021342 003	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.088MG	N021342 004	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.1MG	N021342 005	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.112MG	N021342 006	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.125MG	N021342 007	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.137MG	N021342 012	Dec 08, 2003
-->			--> AB1,AB2,AB3	0.15MG	N021342 008	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.175MG	N021342 009	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.2MG	N021342 010	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.3MG	N021342 011	Mar 01, 2002
LEVOTHYROXINE SODIUM						
-->		LUPIN	--> AB1,AB2,AB3	0.025MG	A209713 001	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.05MG	A209713 002	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.075MG	A209713 003	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.088MG	A209713 004	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.1MG	A209713 005	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.112MG	A209713 006	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.125MG	A209713 007	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.137MG	A209713 008	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.15MG	A209713 009	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.175MG	A209713 010	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.2MG	A209713 011	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.3MG	A209713 012	Jan 18, 2019
UNITHROID						
-->	+	STEVENS J	--> AB1,AB2,AB3	0.025MG	N021210 001	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.05MG	N021210 002	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.075MG	N021210 003	Aug 21, 2000

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	UNITHROID					
-->	+	--> **AB1,AB2,AB3**	**0.088MG**	N021210	004	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.1MG**	N021210	005	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.112MG**	N021210	006	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.125MG**	N021210	007	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.137MG**	N021210	012	Feb 08, 2008
-->	+	--> **AB1,AB2,AB3**	**0.15MG**	N021210	008	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.175MG**	N021210	009	Aug 21, 2000
-->	+	--> **AB1,AB2,AB3**	**0.2MG**	N021210	010	Aug 21, 2000
-->	+!	--> **AB1,AB2,AB3**	**0.3MG**	N021210	011	Aug 21, 2000
	LEVOLET					
-->	GENUS LIFESCIENCES	--> **AB1,AB2,AB3,AB4**	**0.025MG**	N021137	001	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.05MG**	N021137	002	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.075MG**	N021137	003	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.088MG**	N021137	004	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.1MG**	N021137	005	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.112MG**	N021137	006	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.125MG**	N021137	007	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.137MG**	N021137	008	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.15MG**	N021137	009	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.175MG**	N021137	010	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.2MG**	N021137	011	Jun 06, 2003
-->		--> **AB1,AB2,AB3,AB4**	**0.3MG**	N021137	012	Jun 06, 2003
	LEVOTHYROXINE SODIUM					
-->	ACCORD HLTHCARE	--> **AB1,AB2,AB3,AB4**	**0.025MG**	A212399	001	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.05MG**	A212399	002	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.075MG**	A212399	003	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.088MG**	A212399	004	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.1MG**	A212399	005	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.112MG**	A212399	006	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.125MG**	A212399	007	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.137MG**	A212399	008	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.15MG**	A212399	009	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.175MG**	A212399	010	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.2MG**	A212399	011	Oct 19, 2020
-->		--> **AB1,AB2,AB3,AB4**	**0.3MG**	A212399	012	Oct 19, 2020
-->	MACLEODS PHARMS LTD	--> **AB1,AB2,AB3,AB4**	**0.025MG**	A211417	001	Dec 21, 2022
-->		--> **AB1,AB2,AB3,AB4**	**0.05MG**	A211417	002	Dec 21, 2022
-->		--> **AB1,AB2,AB3,AB4**	**0.075MG**	A211417	003	Dec 21, 2022
-->		--> **AB1,AB2,AB3,AB4**	**0.088MG**	A211417	004	Dec 21, 2022

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL

	LEVOTHYROXINE SODIUM						
-->		-->	**AB1,AB2,AB3,AB4**	**0.1MG**	A211417	005	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.112MG**	A211417	006	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.125MG**	A211417	007	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.137MG**	A211417	008	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.15MG**	A211417	009	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.175MG**	A211417	010	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.2MG**	A211417	011	Dec 21, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.3MG**	A211417	012	Dec 21, 2022
-->	MYLAN	-->	**AB1,AB2,AB3,AB4**	**0.025MG**	A076187	001	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.05MG**	A076187	002	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.075MG**	A076187	003	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.088MG**	A076187	004	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.1MG**	A076187	005	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.112MG**	A076187	006	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.125MG**	A076187	007	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.137MG**	A076187	012	Dec 13, 2006
-->		-->	**AB1,AB2,AB3,AB4**	**0.15MG**	A076187	008	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.175MG**	A076187	009	Jun 05, 2002
-->		-->	**AB1,AB2,AB3,AB4**	**0.2MG**	A076187	010	Jun 05, 2002
-->	!	-->	**AB1,AB2,AB3,AB4**	**0.3MG**	A076187	011	Jun 05, 2002
-->	WATSON LABS TEVA	-->	**AB1,AB2,AB3,AB4**	**0.025MG**	A207588	001	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.05MG**	A207588	002	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.075MG**	A207588	003	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.088MG**	A207588	004	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.1MG**	A207588	005	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.112MG**	A207588	006	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.125MG**	A207588	007	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.137MG**	A207588	008	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.15MG**	A207588	009	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.175MG**	A207588	010	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.2MG**	A207588	011	May 10, 2022
-->		-->	**AB1,AB2,AB3,AB4**	**0.3MG**	A207588	012	May 10, 2022
	THYRO-TABS						
-->	+ ALVOGEN	-->	**AB1,AB2,AB3,AB4**	**0.025MG**	N021116	001	Oct 24, 2002
-->	+	-->	**AB1,AB2,AB3,AB4**	**0.05MG**	N021116	002	Oct 24, 2002
-->	+	-->	**AB1,AB2,AB3,AB4**	**0.075MG**	N021116	003	Oct 24, 2002
-->	+	-->	**AB1,AB2,AB3,AB4**	**0.088MG**	N021116	010	Oct 24, 2002
-->	+	-->	**AB1,AB2,AB3,AB4**	**0.1MG**	N021116	004	Oct 24, 2002
-->	+	--> **AB1,AB2,**		**0.112MG**	N021116	011	Oct 24, 2002

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

THYRO-TABS

			AB3,AB4	**0.112MG**			
-->	+		-->	0.125MG	N021116	005	Oct 24, 2002
			AB1,AB2,AB3,AB4				
-->	+		-->	0.137MG	N021116	012	Dec 07, 2004
			AB1,AB2,AB3,AB4				
-->	+		-->	0.15MG	N021116	006	Oct 24, 2002
			AB1,AB2,AB3,AB4				
-->	+		-->	0.175MG	N021116	007	Oct 24, 2002
			AB1,AB2,AB3,AB4				
-->	+		-->	0.2MG	N021116	008	Oct 24, 2002
			AB1,AB2,AB3,AB4				
-->	+		-->	0.3MG	N021116	009	Oct 24, 2002
			AB1,AB2,AB3,AB4				

LEVOXYL

-->	+	KING PHARMS	--> AB1,AB3	0.025MG	N021301	001	May 25, 2001
-->	+		--> AB1,AB3	0.05MG	N021301	002	May 25, 2001
-->	+		--> AB1,AB3	0.075MG	N021301	003	May 25, 2001
-->	+		--> AB1,AB3	0.088MG	N021301	004	May 25, 2001
-->	+		--> AB1,AB3	0.1MG	N021301	005	May 25, 2001
-->	+		--> AB1,AB3	0.112MG	N021301	006	May 25, 2001
-->	+		--> AB1,AB3	0.125MG	N021301	007	May 25, 2001
-->	+		--> AB1,AB3	0.137MG	N021301	008	May 25, 2001
-->	+		--> AB1,AB3	0.15MG	N021301	009	May 25, 2001
-->	+		--> AB1,AB3	0.175MG	N021301	010	May 25, 2001
-->	+!		--> AB1,AB3	0.2MG	N021301	011	May 25, 2001

EUTHYROX

AB2	EMD SERONO INC	**0.025MG**	**N021292**	**001**	May 31, 2002
AB2		**0.05MG**	**N021292**	**002**	May 31, 2002
AB2		**0.075MG**	**N021292**	**003**	May 31, 2002
AB2		**0.088MG**	**N021292**	**004**	May 31, 2002
AB2		**0.1MG**	**N021292**	**005**	May 31, 2002
AB2		**0.112MG**	**N021292**	**006**	May 31, 2002
AB2		**0.125MG**	**N021292**	**007**	May 31, 2002
AB2		**0.137MG**	**N021292**	**008**	May 31, 2002
AB2		**0.15MG**	**N021292**	**009**	May 31, 2002
AB2		**0.175MG**	**N021292**	**010**	May 31, 2002
AB2		**0.2MG**	**N021292**	**011**	May 31, 2002

LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	**0.025MG**	**A215259**	**001**	Jan 18, 2023
AB4		**0.05MG**	**A215259**	**002**	Jan 18, 2023
AB4		**0.075MG**	**A215259**	**003**	Jan 18, 2023
AB4		**0.088MG**	**A215259**	**004**	Jan 18, 2023
AB4		**0.1MG**	**A215259**	**005**	Jan 18, 2023
AB4		**0.112MG**	**A215259**	**006**	Jan 18, 2023
AB4		**0.125MG**	**A215259**	**007**	Jan 18, 2023
AB4		**0.137MG**	**A215259**	**008**	Jan 18, 2023
AB4		**0.15MG**	**A215259**	**009**	Jan 18, 2023
AB4		**0.175MG**	**A215259**	**010**	Jan 18, 2023
AB4		**0.2MG**	**A215259**	**011**	Jan 18, 2023
AB4		**0.3MG**	**A215259**	**012**	Jan 18, 2023

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	ALKEM LABS LTD	**5%**	**A207810**	**001**	Mar 10, 2017
AT	AMNEAL PHARMS	**5%**	**A206297**	**001**	Aug 07, 2015
AT	AUROBINDO PHARMA LTD	**5%**	**A217117**	**001**	Jun 18, 2024
AT	CHARTWELL RX	**5%**	**A208660**	**001**	Jan 05, 2021
AT +!	FOUGERA PHARMS INC	**5%**	**A080198**	**001**	
AT	GLENMARK PHARMS LTD	**5%**	**A206498**	**001**	Sep 09, 2016
AT	MACLEODS PHARMS LTD	**5%**	**A211697**	**001**	Mar 16, 2020
AT	QUAGEN	**5%**	**A212695**	**001**	Apr 20, 2021
AT	SEPTODONT INC	**5%**	**A040911**	**001**	May 23, 2011
AT	STRIDES PHARMA	**5%**	**A210958**	**001**	Dec 11, 2018
AT	SUN PHARMA CANADA	**5%**	**A086724**	**001**	
BX	ALEMBIC	5%	A211469	001	Nov 23, 2018

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	**5%**	**A200675**	**001**	Aug 23, 2012

LIDOCAINE						
PATCH;TOPICAL						
LIDOCAINE						
AB		ALKEM LABS LTD	**5%**	**A216484**	**001**	Oct 06, 2025
AB		AMNEAL	**5%**	**A206463**	**001**	Aug 24, 2020
AB		DIFGEN PHARMS	**1.8%**	**A217221**	**001**	Mar 25, 2025
AB		IBSA	**5%**	**A209190**	**001**	Apr 30, 2020
AB		NAL PHARM	**5%**	**A205882**	**001**	Apr 29, 2021
AB		PHARMOBEDIENT	**5%**	**A202346**	**001**	Aug 07, 2015
LIDODERM						
AB	**+!**	TEIKOKU PHARMA USA	**5%**	**N020612**	**001**	Mar 19, 1999
ZTLIDO						
AB	**+!**	SCILEX PHARMS	**1.8%**	**N207962**	**001**	Feb 28, 2018
SYSTEM;TOPICAL						
BONDLIDO						
	+!	MEDRX USA	10%	N215029	001	Sep 24, 2025
LIDOCAINE HYDROCHLORIDE						
GEL;OPHTHALMIC						
AKTEN						
	+!	THEA PHARMA	3.5%	N022221	001	Oct 07, 2008
INJECTABLE;INJECTION						
LIDOCAINE HYDROCHLORIDE						
AP		AFAXYS	**1%**	**A215132**	**001**	Jun 09, 2022
AP		ANTHEA PHARMA	**1%**	**A219535**	**001**	Apr 02, 2025
AP		ASPIRO	**1%**	**A214336**	**001**	Nov 08, 2021
AP			**1%**	**A214339**	**001**	Nov 08, 2021
AP			**2%**	**A214336**	**002**	Dec 13, 2023
AP			**2%**	**A214339**	**002**	Nov 08, 2021
AP		B BRAUN MEDICAL	**1%**	**A208474**	**001**	Aug 03, 2018
AP		EUGIA PHARMA	**1%**	**A207182**	**001**	Oct 30, 2017
AP			**2%**	**A207182**	**002**	Oct 30, 2017
AP		FRESENIUS KABI USA	**1%**	**A088586**	**002**	
AP			**2%**	**A088586**	**003**	
AP		HOSPIRA	**0.5%**	**A088328**	**001**	May 17, 1984
AP			**1%**	**A088329**	**001**	May 17, 1984
AP			**2%**	**A040078**	**001**	Jun 23, 1995
AP			**2%**	**A088294**	**001**	May 17, 1984
AP		HUONS	**1%**	**A212821**	**001**	May 07, 2020
AP			**2%**	**A212821**	**002**	Jun 15, 2023
AP	**+**	INTL MEDICATION	**1%**	**A083173**	**001**	
AP			**2%**	**A083173**	**002**	
AP		MANKIND PHARMA	**1%**	**A217692**	**001**	Jun 16, 2023
AP			**1%**	**A217692**	**003**	Nov 29, 2023
AP			**1%**	**A217693**	**001**	Jul 11, 2023
AP			**2%**	**A217692**	**002**	Jun 16, 2023
AP			**2%**	**A217693**	**002**	Jul 11, 2023
AP		SPECTRA MDCL DEVICES	**1%**	**A208017**	**001**	Apr 18, 2018
AP		WEST-WARD PHARMS INT	**1%**	**A080407**	**001**	
AP			**2%**	**A080407**	**002**	
AP		YILING	**1%**	**A214267**	**001**	Sep 19, 2022
AP			**2%**	**A214267**	**002**	Sep 19, 2022
AP			**4%**	**A214269**	**001**	May 05, 2022
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP		BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP		BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP		BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP		HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP			**1%**	**A088299**	**001**	Jul 31, 1984
AP			**2%**	**A088327**	**001**	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP		EUGIA PHARMA	**1%**	**A203082**	**001**	Mar 14, 2013
AP			**2%**	**A203082**	**002**	Mar 14, 2013
AP		FRESENIUS KABI USA	**2%**	**N017584**	**001**	

LIDOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP			**4%**	**N017584**	**002**		
AP		HIKMA	**1%**	**A084625**	**001**		
AP			**2%**	**A084625**	**002**		
AP		HOSPIRA	**1%**	**A080408**	**001**		
AP			**1.5%**	**A080408**	**002**		
AP	**!**		**4%**	**A088295**	**001**	May 17, 1984	
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP		HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998	
AP			**2%**	**A040302**	**002**	Sep 28, 1998	
XYLOCAINE							
AP	**+!**	FRESENIUS KABI USA	**0.5%**	**N006488**	**008**		
AP	**+!**		**1%**	**N006488**	**007**		
AP	**+!**		**1.5%**	**N006488**	**010**		
AP	**+!**		**2%**	**N006488**	**002**		
INJECTABLE;SPINAL							
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%							
	+!	HOSPIRA	5%	A083914	001		
JELLY;TOPICAL							
GLYDO							
AT	**!**	SAGENT PHARMS INC	**2%**	**A201094**	**001**	Apr 28, 2014	
LIDOCAINE HYDROCHLORIDE							
AT		INTL MEDICATION	**2%**	**A086283**	**001**		
AT		SENTISS	**2%**	**A040433**	**001**	Feb 12, 2003	
SOLUTION;ORAL							
LIDOCAINE HYDROCHLORIDE							
AT		AUROBINDO PHARMA LTD	**2%**	**A219759**	**001**	Jul 29, 2025	
AT		PHARMOBEDIENT	**2%**	**A087872**	**001**	Nov 18, 1982	
AT	**!**	RUBICON RESEARCH	**2%**	**A216780**	**001**	Mar 28, 2023	
LIDOCAINE HYDROCHLORIDE VISCOUS							
AT		CHARTWELL MOLECULAR	**2%**	**A040708**	**001**	Feb 27, 2007	
AT		PAI HOLDINGS PHARM	**2%**	**A218138**	**001**	Feb 20, 2024	
LIDOCAINE VISCOUS							
AT		HIKMA	**2%**	**A088802**	**001**	Apr 26, 1985	
SOLUTION;TOPICAL							
LARYNG-O-JET KIT							
AT		INTL MEDICATION	**4%**	**A086364**	**001**		
LIDOCAINE HYDROCHLORIDE							
AT	**!**	HIKMA	**4%**	**A088803**	**001**	Apr 03, 1985	
AT		LANNETT CO INC	**4%**	**A040710**	**001**	Feb 27, 2007	
AT		NOVITIUM PHARMA	**4%**	**A216250**	**001**	Mar 23, 2022	
AT		PAI HOLDINGS PHARM	**4%**	**A204494**	**001**	Mar 12, 2014	
AT		PHARMOBEDIENT	**4%**	**A087881**	**001**	Nov 18, 1982	
AT		SUN PHARMA CANADA	**4%**	**A218182**	**001**	Dec 07, 2023	
AT		THE J MOLNER	**4%**	**A218411**	**001**	Apr 29, 2024	
SYSTEM;INTRADERMAL							
ZINGO							
		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	
LIDOCAINE; PRILOCAINE							
CREAM;TOPICAL							
LIDOCAINE AND PRILOCAINE							
AB		ALEMBIC	**2.5%;2.5%**	**A213923**	**001**	Apr 08, 2022	
AB		ENCUBE	**2.5%;2.5%**	**A076320**	**001**	Aug 27, 2003	
AB	**!**	FOUGERA PHARMS	**2.5%;2.5%**	**A076453**	**001**	Aug 18, 2003	
AB		PADAGIS US	**2.5%;2.5%**	**A212482**	**001**	Jul 27, 2021	
AB		ZYDUS LIFESCIENCES	**2.5%;2.5%**	**A219120**	**001**	Dec 17, 2024	
GEL;PERIODONTAL							
ORAQIX							
	+!	DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003	
LIDOCAINE; TETRACAINE							
CREAM;TOPICAL							
PLIAGLIS							
	+!	CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	

LIFITEGRAST
SOLUTION/DROPS;OPHTHALMIC
XIIDRA
+! BAUSCH AND LOMB INC 5% N208073 001 Jul 11, 2016

LINACLOTIDE
CAPSULE;ORAL
LINZESS
+! ABBVIE 72MCG N202811 003 Jan 25, 2017
+! 145MCG N202811 001 Aug 30, 2012
+ 290MCG N202811 002 Aug 30, 2012

LINAGLIPTIN
TABLET;ORAL
LINAGLIPTIN
AB AUROBINDO PHARMA LTD **5MG** **A208415 001** Nov 03, 2025
AB DR REDDYS **5MG** **A208428 001** Nov 03, 2025
AB INVAGEN PHARMS **5MG** **A208423 001** Sep 03, 2024
AB MSN **5MG** **A208457 001** Nov 03, 2025
AB MYLAN **5MG** **A208431 001** Nov 03, 2025
AB SUNSHINE **5MG** **A208335 001** Aug 31, 2021
AB ZYDUS PHARMS **5MG** **A208448 001** Mar 30, 2023
TRADJENTA
AB **+!** BOEHRINGER INGELHEIM **5MG** **N201280 001** May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
JENTADUETO
AB **+** BOEHRINGER INGELHEIM **2.5MG;500MG** **N201281 001** Jan 30, 2012
AB **+** **2.5MG;850MG** **N201281 002** Jan 30, 2012
AB **+!** **2.5MG;1GM** **N201281 003** Jan 30, 2012
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
AB DR REDDYS **2.5MG;500MG** **A208427 001** Nov 03, 2025
AB **2.5MG;850MG** **A208427 002** Nov 03, 2025
AB **2.5MG;1GM** **A208427 003** Nov 03, 2025
AB MSN **2.5MG;500MG** **A208459 001** Nov 03, 2025
AB **2.5MG;850MG** **A208459 002** Nov 03, 2025
AB **2.5MG;1GM** **A208459 003** Nov 03, 2025
AB SUNSHINE **2.5MG;500MG** **A208336 001** Aug 30, 2021
AB **2.5MG;850MG** **A208336 002** Aug 30, 2021
AB **2.5MG;1GM** **A208336 003** Aug 30, 2021
AB ZYDUS PHARMS **2.5MG;500MG** **A208449 001** Mar 30, 2023
AB **2.5MG;850MG** **A208449 002** Mar 30, 2023
AB **2.5MG;1GM** **A208449 003** Mar 30, 2023
TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR
+ BOEHRINGER INGELHEIM 2.5MG;1GM N208026 001 May 27, 2016
+! 5MG;1GM N208026 002 May 27, 2016

LINCOMYCIN HYDROCHLORIDE
INJECTABLE;INJECTION
LINCOCIN
AP **+!** PFIZER **EQ 300MG BASE/ML** **N050317 001**
LINCOMYCIN HYDROCHLORIDE
AP ARTHUR GRP **EQ 300MG BASE/ML** **A212770 001** Mar 12, 2021
AP GLAND **EQ 300MG BASE/ML** **A215657 001** Sep 26, 2022
AP MICRO LABS **EQ 300MG BASE/ML** **A215082 001** Nov 08, 2021
AP XGEN PHARMS **EQ 300MG BASE/ML** **A201746 001** Jun 04, 2015

LINEZOLID
FOR SUSPENSION;ORAL
LINEZOLID
AB HETERO LABS **100MG/5ML** **A211813 001** Oct 31, 2022
AB HIKMA **100MG/5ML** **A200068 001** Jun 03, 2015
ZYVOX
AB **+!** PFIZER **100MG/5ML** **N021132 001** Apr 18, 2000
SOLUTION;INTRAVENOUS
LINEZOLID
AP CAPLIN **600MG/300ML (2MG/ML)** **A219558 001** Dec 08, 2025
AP EUGIA PHARMA **600MG/300ML (2MG/ML)** **A206917 001** Aug 04, 2016
AP FRESENIUS KABI USA **600MG/300ML (2MG/ML)** **A204764 001** Mar 15, 2016
AP HIKMA **600MG/300ML (2MG/ML)** **A206454 001** Aug 22, 2022

LINEZOLID						
SOLUTION;INTRAVENOUS						
LINEZOLID						
AP		HQ SPCLT PHARMA	**200MG/100ML (2MG/ML)**	**A207001**	**001**	Jul 07, 2017
AP			**600MG/300ML (2MG/ML)**	**A207001**	**002**	Jul 07, 2017
AP		NANG KUANG PHARM CO	**200MG/100ML (2MG/ML)**	**A207354**	**001**	Dec 20, 2016
AP			**600MG/300ML (2MG/ML)**	**A207354**	**002**	Dec 20, 2016
AP		PHARMOBEDIENT	**200MG/100ML (2MG/ML)**	**A205154**	**001**	Dec 06, 2017
AP			**600MG/300ML (2MG/ML)**	**A205154**	**002**	Dec 06, 2017
AP		SAGENT PHARMS INC	**200MG/100ML (2MG/ML)**	**A204696**	**001**	Mar 02, 2017
AP			**600MG/300ML (2MG/ML)**	**A204696**	**002**	Mar 02, 2017
AP		SANDOZ	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
ZYVOX						
AP	+	PFIZER	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	+!		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+!	HOSPIRA	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
TABLET;ORAL						
LINEZOLID						
AB		ALEMBIC	**600MG**	**A205233**	**001**	Dec 21, 2015
AB	!	ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		CHARTWELL RX	**600MG**	**A210702**	**001**	Apr 25, 2019
AB		GLENMARK SPECLT	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		RISING	**600MG**	**A078845**	**001**	Dec 21, 2015
AB		ZYDUS PHARMS	**600MG**	**A206097**	**001**	Feb 22, 2017
LIOTHYRONINE SODIUM						
INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
	!	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005
TABLET;ORAL						
CYTOMEL						
AB	+	KING PHARMS	**EQ 0.005MG BASE**	**N010379**	**001**	
AB	+		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	+		**EQ 0.05MG BASE**	**N010379**	**003**	
LIOTHYRONINE SODIUM						
AB		BIOCON PHARMA	**EQ 0.005MG BASE**	**A218070**	**001**	Feb 06, 2024
AB			**EQ 0.025MG BASE**	**A218070**	**002**	Feb 06, 2024
AB			**EQ 0.05MG BASE**	**A218070**	**003**	Feb 06, 2024
AB		DR REDDYS LABS SA	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB			**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB			**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB		SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB			**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB	!		**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
AB		SUN PHARM	**EQ 0.005MG BASE**	**A091382**	**001**	Apr 20, 2016
AB			**EQ 0.025MG BASE**	**A091382**	**002**	Apr 20, 2016
AB			**EQ 0.05MG BASE**	**A091382**	**003**	Apr 20, 2016
AB		TEVA PHARMS USA	**EQ 0.005MG BASE**	**A211510**	**001**	Oct 26, 2018
AB			**EQ 0.025MG BASE**	**A211510**	**002**	Oct 26, 2018
AB			**EQ 0.05MG BASE**	**A211510**	**003**	Oct 26, 2018
AB		ZYDUS LIFESCIENCES	**EQ 0.005MG BASE**	**A214803**	**001**	Jan 22, 2021
AB			**EQ 0.025MG BASE**	**A214803**	**002**	Jan 22, 2021
AB			**EQ 0.05MG BASE**	**A214803**	**003**	Jan 22, 2021
LIRAGLUTIDE						
SOLUTION;SUBCUTANEOUS						
LIRAGLUTIDE						
AP1		HIKMA	**18MG/3ML (6MG/ML)**	**A215503**	**001**	Dec 23, 2024
AP1		LUPIN LTD	**18MG/3ML (6MG/ML)**	**A215421**	**001**	Jul 22, 2025
AP1		NANJING KING FRIEND	**18MG/3ML (6MG/ML)**	**A218115**	**001**	Apr 02, 2025
VICTOZA						
AP1	+!	NOVO NORDISK INC	**18MG/3ML (6MG/ML)**	**N022341**	**001**	Jan 25, 2010
LIRAGLUTIDE						
AP2		TEVA PHARMS	**18MG/3ML (6MG/ML)**	**A214568**	**001**	Aug 27, 2025
SAXENDA						
AP2	+!	NOVO	**18MG/3ML (6MG/ML)**	**N206321**	**001**	Dec 23, 2014

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ACTAVIS ELIZABETH	**10MG**	**A202802**	**001**	Aug 25, 2023
AB		**20MG**	**A202802**	**002**	Aug 25, 2023
AB		**30MG**	**A202802**	**003**	Aug 25, 2023
AB		**40MG**	**A202802**	**004**	Aug 25, 2023
AB		**50MG**	**A202802**	**005**	Aug 25, 2023
AB		**60MG**	**A202802**	**006**	Aug 25, 2023
AB		**70MG**	**A202802**	**007**	Aug 25, 2023
AB	ALKEM LABS LTD	**10MG**	**A217194**	**001**	Aug 25, 2023
AB		**20MG**	**A217194**	**002**	Aug 25, 2023
AB		**30MG**	**A217194**	**003**	Aug 25, 2023
AB		**40MG**	**A217194**	**004**	Aug 25, 2023
AB		**50MG**	**A217194**	**005**	Aug 25, 2023
AB		**60MG**	**A217194**	**006**	Aug 25, 2023
AB		**70MG**	**A217194**	**007**	Aug 25, 2023
AB	AMNEAL	**20MG**	**A202830**	**001**	Aug 25, 2023
AB		**30MG**	**A202830**	**002**	Aug 25, 2023
AB		**40MG**	**A202830**	**003**	Aug 25, 2023
AB		**50MG**	**A202830**	**004**	Aug 25, 2023
AB		**60MG**	**A202830**	**005**	Aug 25, 2023
AB		**70MG**	**A202830**	**006**	Aug 25, 2023
AB	APOTEX	**10MG**	**A216944**	**001**	Aug 25, 2023
AB		**20MG**	**A216944**	**002**	Aug 25, 2023
AB		**30MG**	**A216944**	**003**	Aug 25, 2023
AB		**40MG**	**A216944**	**004**	Aug 25, 2023
AB		**50MG**	**A216944**	**005**	Aug 25, 2023
AB		**60MG**	**A216944**	**006**	Aug 25, 2023
AB		**70MG**	**A216944**	**007**	Aug 25, 2023
AB	ASCENT PHARMS INC	**10MG**	**A217442**	**001**	Aug 25, 2023
AB		**20MG**	**A217442**	**002**	Aug 25, 2023
AB		**30MG**	**A217442**	**003**	Aug 25, 2023
AB		**40MG**	**A217442**	**004**	Aug 25, 2023
AB		**50MG**	**A217442**	**005**	Aug 25, 2023
AB		**60MG**	**A217442**	**006**	Aug 25, 2023
AB		**70MG**	**A217442**	**007**	Aug 25, 2023
AB	ELITE LABS INC	**10MG**	**A218604**	**001**	Nov 15, 2024
AB		**20MG**	**A218604**	**002**	Nov 15, 2024
AB		**30MG**	**A218604**	**003**	Nov 15, 2024
AB		**40MG**	**A218604**	**004**	Nov 15, 2024
AB		**50MG**	**A218604**	**005**	Nov 15, 2024
AB		**60MG**	**A218604**	**006**	Nov 15, 2024
AB		**70MG**	**A218604**	**007**	Nov 15, 2024
AB	GRANULES	**10MG**	**A218987**	**001**	Jan 29, 2025
AB		**20MG**	**A218987**	**002**	Jan 29, 2025
AB		**30MG**	**A218987**	**003**	Jan 29, 2025
AB		**40MG**	**A218987**	**004**	Jan 29, 2025
AB		**50MG**	**A218987**	**005**	Jan 29, 2025
AB		**60MG**	**A218987**	**006**	Jan 29, 2025
AB		**70MG**	**A218987**	**007**	Jan 29, 2025
AB	HIKMA	**10MG**	**A202827**	**007**	Jan 17, 2024
AB		**20MG**	**A202827**	**001**	Aug 25, 2023
AB		**30MG**	**A202827**	**002**	Aug 25, 2023
AB		**40MG**	**A202827**	**003**	Aug 25, 2023
AB		**50MG**	**A202827**	**004**	Aug 25, 2023
AB		**60MG**	**A202827**	**005**	Aug 25, 2023
AB		**70MG**	**A202827**	**006**	Aug 25, 2023
AB	LANNETT CO INC	**10MG**	**A215802**	**001**	Aug 25, 2023
AB		**20MG**	**A215802**	**002**	Aug 25, 2023
AB		**30MG**	**A215802**	**003**	Aug 25, 2023
AB		**40MG**	**A215802**	**004**	Aug 25, 2023
AB		**50MG**	**A215802**	**005**	Aug 25, 2023
AB		**60MG**	**A215802**	**006**	Aug 25, 2023
AB		**70MG**	**A215802**	**007**	Aug 25, 2023
AB	MYLAN	**10MG**	**A202835**	**001**	Aug 25, 2023
AB		**20MG**	**A202835**	**002**	Aug 25, 2023
AB		**30MG**	**A202835**	**003**	Aug 25, 2023
AB		**40MG**	**A202835**	**004**	Aug 25, 2023
AB		**50MG**	**A202835**	**005**	Aug 25, 2023
AB		**60MG**	**A202835**	**006**	Aug 25, 2023
AB		**70MG**	**A202835**	**007**	Aug 25, 2023

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		NORWICH	**10MG**	**A214547**	**001**	Aug 25, 2023
AB			**20MG**	**A214547**	**002**	Aug 25, 2023
AB			**30MG**	**A214547**	**003**	Aug 25, 2023
AB			**40MG**	**A214547**	**004**	Aug 25, 2023
AB			**50MG**	**A214547**	**005**	Aug 25, 2023
AB			**60MG**	**A214547**	**006**	Aug 25, 2023
AB			**70MG**	**A214547**	**007**	Aug 25, 2023
AB		PRINSTON INC	**10MG**	**A216266**	**001**	Aug 25, 2023
AB			**20MG**	**A216266**	**002**	Aug 25, 2023
AB			**30MG**	**A216266**	**003**	Aug 25, 2023
AB			**40MG**	**A216266**	**004**	Aug 25, 2023
AB			**50MG**	**A216266**	**005**	Aug 25, 2023
AB			**60MG**	**A216266**	**006**	Aug 25, 2023
AB			**70MG**	**A216266**	**007**	Aug 25, 2023
AB		RHODES PHARMS	**10MG**	**A215330**	**001**	Aug 25, 2023
AB			**20MG**	**A215330**	**002**	Aug 25, 2023
AB			**30MG**	**A215330**	**003**	Aug 25, 2023
AB			**40MG**	**A215330**	**004**	Aug 25, 2023
AB			**50MG**	**A215330**	**005**	Aug 25, 2023
AB			**60MG**	**A215330**	**006**	Aug 25, 2023
AB			**70MG**	**A215330**	**007**	Aug 25, 2023
AB		SANDOZ	**10MG**	**A202836**	**007**	Dec 26, 2024
AB			**20MG**	**A202836**	**001**	Jul 26, 2024
AB			**30MG**	**A202836**	**002**	Jul 26, 2024
AB			**40MG**	**A202836**	**003**	Jul 26, 2024
AB			**50MG**	**A202836**	**004**	Jul 26, 2024
AB			**60MG**	**A202836**	**005**	Jul 26, 2024
AB			**70MG**	**A202836**	**006**	Jul 26, 2024
AB		SPECGX LLC	**10MG**	**A211840**	**001**	Aug 25, 2023
AB			**20MG**	**A211840**	**002**	Aug 25, 2023
AB			**30MG**	**A211840**	**003**	Aug 25, 2023
AB			**40MG**	**A211840**	**004**	Aug 25, 2023
AB			**50MG**	**A211840**	**005**	Aug 25, 2023
AB			**60MG**	**A211840**	**006**	Aug 25, 2023
AB			**70MG**	**A211840**	**007**	Aug 25, 2023
AB		SUN PHARM INDS INC	**10MG**	**A214484**	**001**	Aug 25, 2023
AB			**20MG**	**A214484**	**002**	Aug 25, 2023
AB			**30MG**	**A214484**	**003**	Aug 25, 2023
AB			**40MG**	**A214484**	**004**	Aug 25, 2023
AB			**50MG**	**A214484**	**005**	Aug 25, 2023
AB			**60MG**	**A214484**	**006**	Aug 25, 2023
AB			**70MG**	**A214484**	**007**	Aug 25, 2023

VYVANSE

AB	**+**	TAKEDA PHARMS USA	**10MG**	**N021977**	**007**	Oct 30, 2014
AB	**+**		**20MG**	**N021977**	**004**	Dec 10, 2007
AB	**+**		**30MG**	**N021977**	**001**	Feb 23, 2007
AB	**+**		**40MG**	**N021977**	**005**	Dec 10, 2007
AB	**+**		**50MG**	**N021977**	**002**	Feb 23, 2007
AB	**+**		**60MG**	**N021977**	**006**	Dec 10, 2007
AB	**+!**		**70MG**	**N021977**	**003**	Feb 23, 2007

SOLUTION;ORAL

ARYNTA

	+!	AZURITY	10MG/ML	N219847	001	Jun 16, 2025

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		ASCENT PHARMS INC	**10MG**	**A217068**	**001**	Aug 25, 2023
AB			**20MG**	**A217068**	**002**	Aug 25, 2023
AB			**30MG**	**A217068**	**003**	Aug 25, 2023
AB			**40MG**	**A217068**	**004**	Aug 25, 2023
AB			**50MG**	**A217068**	**005**	Aug 25, 2023
AB			**60MG**	**A217068**	**006**	Aug 25, 2023
AB		GRANULES	**10MG**	**A219258**	**001**	Dec 16, 2024
AB			**20MG**	**A219258**	**002**	Dec 16, 2024
AB			**30MG**	**A219258**	**003**	Dec 16, 2024
AB			**40MG**	**A219258**	**004**	Dec 16, 2024
AB			**50MG**	**A219258**	**005**	Dec 16, 2024
AB			**60MG**	**A219258**	**006**	Dec 16, 2024
AB		MSN	**10MG**	**A218306**	**001**	Feb 02, 2024
AB			**20MG**	**A218306**	**002**	Feb 02, 2024

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB			**30MG**	**A218306**	**003**	Feb 02, 2024
AB			**40MG**	**A218306**	**004**	Feb 02, 2024
AB			**50MG**	**A218306**	**005**	Feb 02, 2024
AB			**60MG**	**A218306**	**006**	Feb 02, 2024
AB		SPECGX LLC	**10MG**	**A218850**	**001**	Dec 17, 2024
AB			**20MG**	**A218850**	**002**	Dec 17, 2024
AB			**30MG**	**A218850**	**003**	Dec 17, 2024
AB			**40MG**	**A218850**	**004**	Dec 17, 2024
AB			**50MG**	**A218850**	**005**	Dec 17, 2024
AB			**60MG**	**A218850**	**006**	Dec 17, 2024
AB		SUN PHARM INDS INC	**10MG**	**A214134**	**001**	Aug 25, 2023
AB			**20MG**	**A214134**	**002**	Aug 25, 2023
AB			**30MG**	**A214134**	**003**	Aug 25, 2023
AB			**40MG**	**A214134**	**004**	Aug 25, 2023
AB			**50MG**	**A214134**	**005**	Aug 25, 2023
AB			**60MG**	**A214134**	**006**	Aug 25, 2023
AB		TEVA PHARMS	**10MG**	**A215415**	**001**	Aug 25, 2023
AB			**20MG**	**A215415**	**002**	Aug 25, 2023
AB			**30MG**	**A215415**	**003**	Aug 25, 2023
AB			**40MG**	**A215415**	**004**	Aug 25, 2023
AB			**50MG**	**A215415**	**005**	Aug 25, 2023
AB			**60MG**	**A215415**	**006**	Aug 25, 2023

VYVANSE

AB	**+**	TAKEDA PHARMS USA	**10MG**	**N208510**	**001**	Jan 28, 2017
AB	**+**		**20MG**	**N208510**	**002**	Jan 28, 2017
AB	**+**		**30MG**	**N208510**	**003**	Jan 28, 2017
AB	**+**		**40MG**	**N208510**	**004**	Jan 28, 2017
AB	**+**		**50MG**	**N208510**	**005**	Jan 28, 2017
AB	**+!**		**60MG**	**N208510**	**006**	Jan 28, 2017

LISINOPRIL

SOLUTION;ORAL

QBRELIS

	+!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016

TABLET;ORAL

LISINOPRIL

AB		ANNORA PHARMA	**2.5MG**	**A075903**	**001**	Jul 01, 2002
AB			**5MG**	**A075903**	**002**	Jul 01, 2002
AB			**10MG**	**A075903**	**003**	Jul 01, 2002
AB			**20MG**	**A075903**	**004**	Jul 01, 2002
AB			**30MG**	**A075903**	**005**	Jul 01, 2002
AB			**40MG**	**A075903**	**006**	Jul 01, 2002
AB		AUROBINDO	**2.5MG**	**A077622**	**001**	Feb 22, 2006
AB			**5MG**	**A077622**	**002**	Feb 22, 2006
AB			**10MG**	**A077622**	**003**	Feb 22, 2006
AB			**20MG**	**A077622**	**004**	Feb 22, 2006
AB			**30MG**	**A077622**	**005**	Feb 22, 2006
AB			**40MG**	**A077622**	**006**	Feb 22, 2006
AB		CHARTWELL RX	**2.5MG**	**A075994**	**001**	Jul 01, 2002
AB			**5MG**	**A075994**	**002**	Jul 01, 2002
AB			**10MG**	**A075994**	**003**	Jul 01, 2002
AB			**20MG**	**A075994**	**004**	Jul 01, 2002
AB			**30MG**	**A075994**	**005**	Jul 01, 2002
AB			**40MG**	**A075994**	**006**	Jul 01, 2002
AB		COREPHARMA	**2.5MG**	**A076102**	**001**	Sep 30, 2002
AB			**5MG**	**A076102**	**002**	Sep 30, 2002
AB			**10MG**	**A076102**	**003**	Sep 30, 2002
AB			**20MG**	**A076102**	**004**	Sep 30, 2002
AB			**30MG**	**A076102**	**005**	Sep 30, 2002
AB			**40MG**	**A076102**	**006**	Sep 30, 2002
AB		INVAGEN PHARMS	**2.5MG**	**A203508**	**001**	Oct 29, 2013
AB			**5MG**	**A203508**	**002**	Oct 29, 2013
AB			**10MG**	**A203508**	**003**	Oct 29, 2013
AB			**20MG**	**A203508**	**004**	Oct 29, 2013
AB			**30MG**	**A203508**	**005**	Oct 29, 2013
AB			**40MG**	**A203508**	**006**	Oct 29, 2013
AB		LUPIN	**2.5MG**	**A077321**	**001**	Sep 09, 2005
AB			**5MG**	**A077321**	**002**	Sep 09, 2005
AB			**10MG**	**A077321**	**003**	Sep 09, 2005
AB			**20MG**	**A077321**	**004**	Sep 09, 2005

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB			30MG	A077321	005	Sep 09, 2005
AB			40MG	A077321	006	Sep 09, 2005
AB		PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002
AB			2.5MG	A076164	004	Jul 01, 2002
AB			5MG	A075743	002	Jul 01, 2002
AB			5MG	A076164	005	Jul 01, 2002
AB			10MG	A075743	003	Jul 01, 2002
AB			10MG	A076164	006	Jul 01, 2002
AB			20MG	A075743	004	Jul 01, 2002
AB			20MG	A076164	001	Jul 01, 2002
AB			30MG	A075743	005	Jul 01, 2002
AB			30MG	A076164	002	Jul 01, 2002
AB			40MG	A075743	006	Jul 01, 2002
AB			40MG	A076164	003	Jul 01, 2002
AB		SCIEGEN PHARMS	2.5MG	A212041	001	Sep 15, 2020
AB			5MG	A212041	002	Sep 15, 2020
AB			10MG	A212041	003	Sep 15, 2020
AB			20MG	A208920	001	Mar 04, 2021
AB			30MG	A208920	002	Mar 04, 2021
AB			40MG	A208920	003	Mar 04, 2021
AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002
AB			5MG	A075944	002	Jul 01, 2002
AB			10MG	A075944	003	Jul 01, 2002
AB			20MG	A075944	004	Jul 01, 2002
AB			30MG	A075944	006	Feb 11, 2003
AB			40MG	A075944	005	Jul 01, 2002
AB		WATSON LABS	2.5MG	A076059	001	Jul 01, 2002
AB			5MG	A076059	002	Jul 01, 2002
AB			10MG	A076059	003	Jul 01, 2002
AB			20MG	A076059	004	Jul 01, 2002
AB			30MG	A076059	005	Jul 01, 2002
AB			40MG	A076059	006	Jul 01, 2002
AB		WOCKHARDT BIO AG	2.5MG	A078402	001	Apr 19, 2007
AB			5MG	A078402	002	Apr 19, 2007
AB			10MG	A078402	003	Apr 19, 2007
AB			20MG	A078402	004	Apr 19, 2007
AB			30MG	A078402	005	Apr 19, 2007
AB			40MG	A078402	006	Apr 19, 2007

ZESTRIL

AB	+	TWI PHARMS	2.5MG	N019777	005	Apr 29, 1993
AB	+		5MG	N019777	001	May 19, 1988
AB	+		10MG	N019777	002	May 19, 1988
AB	+		20MG	N019777	003	May 19, 1988
AB	+		30MG	N019777	006	Jan 20, 1999
AB	+!		40MG	N019777	004	May 19, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC LTD	150MG	A079159	001	Jan 12, 2009
AB			300MG	A079159	002	Jan 12, 2009
AB			600MG	A079159	003	Jan 12, 2009
AB		GLENMARK PHARMS LTD	150MG	A079139	001	Feb 03, 2009
AB			300MG	A079139	002	Feb 03, 2009
AB			600MG	A079139	003	Feb 03, 2009
AB		HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009
AB			300MG	A090702	002	Sep 25, 2009
AB			600MG	A090702	003	Sep 25, 2009
AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987
AB	+		300MG	N017812	001	
AB	+!		600MG	N017812	003	Jan 28, 1987

TABLET;ORAL

LITHIUM CARBONATE

AB	+!	HIKMA	300MG	N018558	001	Jan 29, 1982
AB		SUN PHARM INDS INC	300MG	A091027	001	Jun 24, 2010

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		GLENMARK PHARMS INC	300MG	A091544	001	Dec 27, 2010
AB		GLENMARK PHARMS LTD	450MG	A091616	001	Feb 14, 2011
AB		HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016

LITHIUM CARBONATE
TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE						
AB		HIKMA	**300MG**	**A076832**	**001**	Oct 28, 2004
AB	!		**450MG**	**A076691**	**001**	Jan 05, 2004
AB		UNIQUE	**300MG**	**A204779**	**001**	Jul 27, 2015
AB			**450MG**	**A205663**	**001**	Jun 05, 2017
LITHOBID						
AB	+!	ANI PHARMS	**300MG**	**N018027**	**001**	

LITHIUM CITRATE
SYRUP;ORAL

LITHIUM CITRATE						
AA	!	RUBICON RESEARCH	**EQ 300MG CARBONATE/5ML**	**A218036**	**001**	Aug 14, 2023
AA		SCIEGEN PHARMS	**EQ 300MG CARBONATE/5ML**	**A217183**	**001**	Mar 18, 2024

LOFEXIDINE HYDROCHLORIDE
TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE						
AB		MSN	**EQ 0.18MG BASE**	**A218699**	**001**	Feb 24, 2025
AB		NOVITIUM PHARMA	**EQ 0.18MG BASE**	**A219917**	**001**	Oct 22, 2025
AB		REGCON HOLDINGS	**EQ 0.18MG BASE**	**A218613**	**001**	Aug 20, 2024
LUCEMYRA						
AB	+!	BIOCORRX PHARMS	**EQ 0.18MG BASE**	**N209229**	**001**	May 16, 2018

LOMITAPIDE MESYLATE
CAPSULE;ORAL

JUXTAPID						
+		CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012
+			EQ 10MG BASE	N203858	002	Dec 21, 2012
+			EQ 20MG BASE	N203858	003	Dec 21, 2012
+			EQ 30MG BASE	N203858	004	Apr 23, 2015

LOMUSTINE
CAPSULE;ORAL

GLEOSTINE						
AB	+	AZURITY	**10MG**	**N017588**	**001**	
AB	+!		**40MG**	**N017588**	**002**	
AB	+		**100MG**	**N017588**	**003**	
LOMUSTINE						
AB		CARNEGIE	**10MG**	**A219265**	**001**	Oct 27, 2025
AB			**40MG**	**A219265**	**002**	Oct 27, 2025
AB			**100MG**	**A219265**	**003**	Oct 27, 2025

LONAFARNIB
CAPSULE;ORAL

ZOKINVY						
+		SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020
+!			75MG	N213969	002	Nov 20, 2020

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**2MG**	**A218122**	**001**	Sep 05, 2023
AB		BIONPHARMA	**2MG**	**A215579**	**001**	Oct 22, 2021
AB		EDENBRIDGE PHARMS	**2MG**	**A215001**	**001**	Oct 06, 2021
AB		JUBILANT CADISTA	**2MG**	**A217840**	**001**	Jul 05, 2023
AB	!	MYLAN	**2MG**	**A072741**	**001**	Sep 18, 1991
AB		RUBICON RESEARCH	**2MG**	**A216876**	**001**	Jan 26, 2023
AB		TEVA	**2MG**	**A073192**	**001**	Apr 30, 1992
AB		ZYDUS LIFESCIENCES	**2MG**	**A217471**	**001**	Mar 23, 2023

LOPINAVIR; RITONAVIR
SOLUTION;ORAL

KALETRA						
+!		ABBVIE	80MG/ML;20MG/ML	N021251	001	Sep 15, 2000

TABLET;ORAL

KALETRA						
AB	+	ABBVIE	**100MG;25MG**	**N021906**	**002**	Nov 09, 2007
AB	+!		**200MG;50MG**	**N021906**	**001**	Oct 28, 2005
LOPINAVIR AND RITONAVIR						
AB		HETERO LABS LTD III	**100MG;25MG**	**A091677**	**001**	Jun 04, 2021
AB			**200MG;50MG**	**A091677**	**002**	Jun 04, 2021
AB		LAURUS	**100MG;25MG**	**A213857**	**001**	Mar 21, 2022
AB			**200MG;50MG**	**A213857**	**002**	Mar 21, 2022

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB		MACLEODS PHARMS LTD	**100MG;25MG**	**A204739**	**001**	Jul 25, 2024
AB			**200MG;50MG**	**A204739**	**002**	Jul 25, 2024
AB		MICRO LABS	**100MG;25MG**	**A214696**	**001**	Dec 11, 2025
AB			**200MG;50MG**	**A214696**	**002**	Dec 11, 2025
AB		MYLAN LABS LTD	**100MG;25MG**	**A079074**	**001**	Feb 07, 2024
AB			**200MG;50MG**	**A079074**	**002**	Feb 07, 2024

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

+	ALMATICA	1MG	N214826	001	Aug 27, 2021
+		1.5MG	N214826	004	Feb 16, 2022
+		2MG	N214826	002	Aug 27, 2021
+!		3MG	N214826	003	Aug 27, 2021

CONCENTRATE;ORAL

LORAZEPAM

AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001**	Dec 23, 2009
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001**	Jun 15, 2010

LORAZEPAM INTENSOL

AA	**!**	HIKMA	**2MG/ML**	**A072755**	**001**	Jun 28, 1991

INJECTABLE;INJECTION

ATIVAN

AP	**+!**	HIKMA	**2MG/ML**	**N018140**	**001**
AP	**+!**		**4MG/ML**	**N018140**	**002**

LORAZEPAM

AP		FRESENIUS KABI USA	**2MG/ML**	**A217598**	**001**	Nov 18, 2024
AP		HOSPIRA	**2MG/ML**	**A074243**	**001**	Apr 12, 1994
AP			**4MG/ML**	**A074243**	**002**	Apr 12, 1994
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001**	Nov 15, 2004
AP		RISING	**2MG/ML**	**A075025**	**001**	Jul 23, 1998

TABLET;ORAL

ATIVAN

AB	**+**	BAUSCH	**0.5MG**	**N017794**	**001**
AB	**+**		**1MG**	**N017794**	**002**
AB	**+!**		**2MG**	**N017794**	**003**

LORAZEPAM

AB		ANI PHARMS	**0.5MG**	**A077396**	**001**	Dec 13, 2006
AB			**1MG**	**A077396**	**002**	Dec 13, 2006
AB			**2MG**	**A077396**	**003**	Dec 13, 2006
AB		AUROBINDO PHARMA	**0.5MG**	**A203572**	**001**	Dec 22, 2017
AB			**1MG**	**A203572**	**002**	Dec 22, 2017
AB			**2MG**	**A203572**	**003**	Dec 22, 2017
AB		GRAVITI PHARMS	**0.5MG**	**A218597**	**001**	Jul 24, 2025
AB			**1MG**	**A218597**	**002**	Jul 24, 2025
AB			**2MG**	**A218597**	**003**	Jul 24, 2025
AB		LEADING	**0.5MG**	**A078203**	**001**	Jul 30, 2007
AB			**1MG**	**A078203**	**002**	Jul 30, 2007
AB			**2MG**	**A078203**	**003**	Jul 30, 2007
AB		OXFORD PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006
AB			**1MG**	**A077754**	**002**	May 10, 2006
AB			**2MG**	**A077754**	**003**	May 10, 2006
AB		SANDOZ	**0.5MG**	**A071141**	**002**	Apr 21, 1987
AB			**1MG**	**A071141**	**003**	Apr 21, 1987
AB			**2MG**	**A071141**	**001**	Apr 21, 1987
AB		SUN PHARM INDS LTD	**0.5MG**	**A076045**	**001**	Aug 29, 2001
AB			**1MG**	**A076045**	**002**	Aug 29, 2001
AB			**2MG**	**A076045**	**003**	Aug 29, 2001
AB		WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991
AB			**1MG**	**A072927**	**001**	Oct 31, 1991
AB			**2MG**	**A072928**	**001**	Oct 31, 1991

LORLATINIB

TABLET;ORAL

LORBRENA

+	PFIZER	25MG	N210868	001	Nov 02, 2018
+!		100MG	N210868	002	Nov 02, 2018

LOSARTAN POTASSIUM

SUSPENSION;ORAL

ARBLI

	+!	SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025

TABLET;ORAL

COZAAR

AB	**+**	ORGANON	**25MG**	**N020386**	**001**	Apr 14, 1995
AB	**+**		**50MG**	**N020386**	**002**	Apr 14, 1995
AB	**+!**		**100MG**	**N020386**	**003**	Oct 13, 1998

LOSARTAN POTASSIUM

AB		AIPING PHARM INC	**25MG**	**A090544**	**001**	Oct 06, 2010
AB			**50MG**	**A090544**	**002**	Oct 06, 2010
AB			**100MG**	**A090544**	**003**	Oct 06, 2010
AB		ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010
AB			**50MG**	**A090428**	**002**	Oct 06, 2010
AB			**100MG**	**A090428**	**003**	Oct 06, 2010
AB		AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010
AB			**50MG**	**A090083**	**002**	Oct 06, 2010
AB			**100MG**	**A090083**	**003**	Oct 06, 2010
AB		CHARTWELL RX	**25MG**	**A077424**	**001**	Oct 06, 2010
AB			**50MG**	**A077424**	**002**	Oct 06, 2010
AB			**100MG**	**A077424**	**003**	Oct 06, 2010
AB		GRANULES	**25MG**	**A215959**	**001**	Feb 23, 2023
AB			**50MG**	**A215959**	**002**	Feb 23, 2023
AB			**100MG**	**A215959**	**003**	Feb 23, 2023
AB		GRAVITI PHARMS	**25MG**	**A219859**	**001**	Sep 19, 2025
AB			**50MG**	**A219859**	**002**	Sep 19, 2025
AB			**100MG**	**A219859**	**003**	Sep 19, 2025
AB		HETERO LABS LTD V	**25MG**	**A203835**	**001**	Aug 12, 2015
AB			**50MG**	**A203835**	**002**	Aug 12, 2015
AB			**100MG**	**A203835**	**003**	Aug 12, 2015
AB		JUBILANT CADISTA	**25MG**	**A201170**	**001**	Sep 18, 2012
AB			**50MG**	**A201170**	**002**	Sep 18, 2012
AB			**100MG**	**A201170**	**003**	Sep 18, 2012
AB		LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010
AB			**50MG**	**A078232**	**002**	Oct 06, 2010
AB			**100MG**	**A078232**	**003**	Oct 06, 2010
AB		MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012
AB			**50MG**	**A202230**	**002**	May 30, 2012
AB			**100MG**	**A202230**	**003**	May 30, 2012
AB		MICRO LABS	**25MG**	**A091541**	**001**	Sep 24, 2012
AB			**50MG**	**A091541**	**002**	Sep 24, 2012
AB			**100MG**	**A091541**	**003**	Sep 24, 2012
AB		MSN	**25MG**	**A217396**	**001**	Aug 14, 2023
AB			**50MG**	**A217396**	**002**	Aug 14, 2023
AB			**100MG**	**A217396**	**003**	Aug 14, 2023
AB		PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB			**50MG**	**A091497**	**002**	Jun 06, 2011
AB			**100MG**	**A091497**	**003**	Jun 06, 2011
AB		STRIDES PHARMA	**25MG**	**A090382**	**001**	Oct 06, 2010
AB			**50MG**	**A090382**	**002**	Oct 06, 2010
AB			**100MG**	**A090382**	**003**	Oct 06, 2010
AB		UNICHEM	**25MG**	**A203030**	**001**	Oct 14, 2015
AB			**50MG**	**A203030**	**002**	Oct 14, 2015
AB			**100MG**	**A203030**	**003**	Oct 14, 2015
AB		WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB			**50MG**	**A091129**	**002**	Oct 06, 2010
AB			**100MG**	**A091129**	**003**	Oct 06, 2010
AB		ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB			**50MG**	**A078243**	**002**	Oct 06, 2010
AB			**100MG**	**A078243**	**003**	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

AB	**+!**	BAUSCH AND LOMB INC	**0.5%**	**N202872**	**001**	Sep 28, 2012

LOTEMAX SM

AB	**+!**	BAUSCH AND LOMB INC	**0.38%**	**N208219**	**001**	Feb 22, 2019

LOTEPREDNOL ETABONATE

AB		LUPIN LTD	**0.38%**	**A218087**	**001**	Jun 30, 2025
AB		SENTISS	**0.5%**	**A212080**	**001**	Feb 10, 2021
AB		SUN PHARM	**0.5%**	**A215384**	**001**	Aug 09, 2023

LOTEPREDNOL ETABONATE

OINTMENT;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

ALREX

AB	**+!**	BAUSCH AND LOMB	**0.2%**	**N020803**	**001**	Mar 09, 1998

LOTEMAX

AB	**+!**	BAUSCH AND LOMB	**0.5%**	**N020583**	**001**	Mar 09, 1998

LOTEPREDNOL ETABONATE

AB		AMNEAL	**0.2%**	**A216345**	**001**	Dec 13, 2024
AB			**0.5%**	**A217484**	**001**	May 20, 2025
AB		LUPIN LTD	**0.2%**	**A215550**	**001**	Dec 26, 2023
AB			**0.5%**	**A215719**	**001**	Apr 24, 2024
AB		PADAGIS US	**0.2%**	**A215203**	**001**	Jul 10, 2024
AB			**0.5%**	**A215204**	**001**	Jan 29, 2025
AB		SENTISS	**0.2%**	**A215933**	**001**	Apr 12, 2023
AB			**0.5%**	**A207609**	**001**	Apr 17, 2019
AB		SUN PHARM	**0.5%**	**A212450**	**001**	Feb 26, 2021

EYSUVIS

	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020

INVELTYS

	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE AND TOBRAMYCIN

AB		ALEMBIC	**0.5%;0.3%**	**A217597**	**001**	Dec 10, 2025

ZYLET

AB	**+!**	BAUSCH AND LOMB	**0.5%;0.3%**	**N050804**	**001**	Dec 14, 2004

LOTILANER

SOLUTION/DROPS;OPHTHALMIC

XDEMVY

	+!	TARSUS	0.25%	N217603	001	Jul 24, 2023

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB			**20MG**	**A075828**	**002**	Dec 17, 2001
AB			**40MG**	**A075828**	**003**	Dec 17, 2001
AB		CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB			**20MG**	**A075991**	**002**	Jun 05, 2002
AB	**!**		**40MG**	**A075991**	**003**	Jun 05, 2002
AB		CHARTWELL RX	**10MG**	**A075300**	**001**	Dec 17, 2001
AB			**20MG**	**A075300**	**002**	Dec 17, 2001
AB			**40MG**	**A075300**	**003**	Dec 17, 2001
AB		COREPHARMA	**10MG**	**A077748**	**001**	Feb 28, 2007
AB			**20MG**	**A077748**	**002**	Feb 28, 2007
AB			**40MG**	**A077748**	**003**	Feb 28, 2007
AB		EPIC PHARMA LLC	**10MG**	**A075636**	**001**	Dec 17, 2001
AB			**20MG**	**A075636**	**002**	Dec 17, 2001
AB			**40MG**	**A075636**	**003**	Dec 17, 2001
AB		LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB			**20MG**	**A078296**	**002**	Nov 01, 2007
AB			**40MG**	**A078296**	**003**	Nov 01, 2007
AB		TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001
AB			**20MG**	**A075551**	**002**	Dec 17, 2001
AB			**40MG**	**A075551**	**001**	Dec 17, 2001

LOXAPINE

POWDER;INHALATION

ADASUVE

	+!	NOVA PNEUMA	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001**	Aug 04, 2005
AB			**EQ 10MG BASE**	**A076868**	**002**	Aug 04, 2005
AB			**EQ 25MG BASE**	**A076868**	**003**	Aug 04, 2005
AB			**EQ 50MG BASE**	**A076868**	**004**	Aug 04, 2005
AB		LANNETT CO INC	**EQ 5MG BASE**	**A090695**	**001**	Sep 26, 2011
AB			**EQ 10MG BASE**	**A090695**	**002**	Sep 26, 2011

LOXAPINE SUCCINATE
CAPSULE;ORAL
LOXAPINE SUCCINATE

AB			**EQ 25MG BASE**	**A090695**	**003**	Sep 26, 2011
AB			**EQ 50MG BASE**	**A090695**	**004**	Sep 26, 2011
AB		WATSON LABS	**EQ 5MG BASE**	**A072204**	**001**	Jun 15, 1988
AB			**EQ 10MG BASE**	**A072205**	**001**	Jun 15, 1988
AB	**!**		**EQ 25MG BASE**	**A072206**	**001**	Jun 15, 1988
AB			**EQ 50MG BASE**	**A072062**	**001**	Jun 15, 1988

LUBIPROSTONE
CAPSULE;ORAL
AMITIZA

AB	**+**	SUCAMPO PHARMA LLC	**8MCG**	**N021908**	**002**	Apr 29, 2008
AB	**+!**		**24MCG**	**N021908**	**001**	Jan 31, 2006

LUBIPROSTONE

AB		ASCENT PHARMS INC	**8MCG**	**A218640**	**001**	Jan 02, 2025
AB			**24MCG**	**A218640**	**002**	Jan 02, 2025
AB		DR REDDYS	**8MCG**	**A206994**	**001**	Feb 08, 2022
AB			**24MCG**	**A206994**	**002**	Feb 08, 2022
AB		TEVA PHARMS USA INC	**8MCG**	**A209920**	**001**	Jan 18, 2022
AB			**24MCG**	**A209920**	**002**	Jan 18, 2022
AB		ZYDUS PHARMS	**8MCG**	**A214131**	**001**	Mar 23, 2023
AB			**24MCG**	**A214131**	**002**	Mar 23, 2023

LULICONAZOLE
CREAM;TOPICAL
LUZU

	+!	BAUSCH	1%	N204153	001	Nov 14, 2013

LUMASIRAN SODIUM
SOLUTION;SUBCUTANEOUS
OXLUMO

	+!	ALNYLAM PHARMS INC	EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)	N214103	001	Nov 23, 2020

LUMATEPERONE TOSYLATE
CAPSULE;ORAL
CAPLYTA

	+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022
	+		EQ 21MG BASE	N209500	003	Apr 22, 2022
	+!		EQ 42MG BASE	N209500	001	Dec 20, 2019

LURASIDONE HYDROCHLORIDE
TABLET;ORAL
LATUDA

AB	**+**	SUNOVION PHARMS INC	**20MG**	**N200603**	**003**	Dec 07, 2011
AB	**+!**		**40MG**	**N200603**	**001**	Oct 28, 2010
AB	**+**		**60MG**	**N200603**	**005**	Jul 12, 2013
AB	**+**		**80MG**	**N200603**	**002**	Oct 28, 2010
AB	**+**		**120MG**	**N200603**	**004**	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**20MG**	**A208049**	**001**	Jan 03, 2019
AB			**40MG**	**A208049**	**002**	Jan 03, 2019
AB			**60MG**	**A208049**	**003**	Jan 03, 2019
AB			**80MG**	**A208049**	**004**	Jan 03, 2019
AB			**120MG**	**A208049**	**005**	Jan 03, 2019
AB		ALEMBIC	**20MG**	**A213248**	**001**	May 13, 2021
AB			**40MG**	**A213248**	**002**	May 13, 2021
AB			**60MG**	**A213248**	**003**	May 13, 2021
AB			**80MG**	**A213248**	**004**	May 13, 2021
AB			**120MG**	**A213248**	**005**	May 13, 2021
AB		ALKEM LABS LTD	**20MG**	**A212244**	**001**	Dec 13, 2022
AB			**40MG**	**A212244**	**002**	Dec 13, 2022
AB			**60MG**	**A212244**	**003**	Dec 13, 2022
AB			**80MG**	**A212244**	**004**	Dec 13, 2022
AB			**120MG**	**A212244**	**005**	Dec 13, 2022
AB		ANNORA PHARMA	**20MG**	**A218174**	**001**	Aug 21, 2024
AB			**40MG**	**A218174**	**002**	Aug 21, 2024
AB			**60MG**	**A218174**	**003**	Aug 21, 2024
AB			**80MG**	**A218174**	**004**	Aug 21, 2024
AB			**120MG**	**A218174**	**005**	Aug 21, 2024
AB		AUROBINDO PHARMA LTD	**20MG**	**A208045**	**001**	Mar 10, 2023
AB			**40MG**	**A208045**	**002**	Mar 10, 2023

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		**60MG**	**A208045**	**003**	Mar 10, 2023
AB		**80MG**	**A208045**	**004**	Mar 10, 2023
AB		**120MG**	**A208045**	**005**	Mar 10, 2023
AB	CHARTWELL RX	**20MG**	**A212091**	**001**	Dec 28, 2020
AB		**40MG**	**A212091**	**002**	Dec 28, 2020
AB		**60MG**	**A212091**	**003**	Dec 28, 2020
AB		**80MG**	**A212091**	**004**	Dec 28, 2020
AB		**120MG**	**A212091**	**005**	Dec 28, 2020
AB	DR REDDYS	**20MG**	**A208047**	**001**	Aug 24, 2021
AB		**40MG**	**A208047**	**002**	Aug 24, 2021
AB		**60MG**	**A208047**	**003**	Aug 24, 2021
AB		**80MG**	**A208047**	**004**	Aug 24, 2021
AB	HERITAGE PHARMA AVET	**20MG**	**A208058**	**001**	Sep 04, 2019
AB		**40MG**	**A208058**	**002**	Sep 04, 2019
AB		**60MG**	**A208058**	**003**	Sep 04, 2019
AB		**80MG**	**A208058**	**004**	Sep 04, 2019
AB		**120MG**	**A208058**	**005**	Feb 28, 2023
AB	INVAGEN PHARMS	**20MG**	**A208028**	**001**	Jan 03, 2019
AB		**40MG**	**A208028**	**002**	Jan 03, 2019
AB		**60MG**	**A208028**	**003**	Jan 03, 2019
AB		**80MG**	**A208028**	**004**	Jan 03, 2019
AB		**120MG**	**A208028**	**005**	Jan 03, 2019
AB	JUBILANT GENERICS	**20MG**	**A210388**	**001**	Dec 06, 2024
AB		**40MG**	**A210388**	**002**	Dec 06, 2024
AB		**60MG**	**A210388**	**003**	Dec 06, 2024
AB		**80MG**	**A210388**	**004**	Dec 06, 2024
AB		**120MG**	**A210388**	**005**	Dec 06, 2024
AB	LUPIN LTD	**20MG**	**A208031**	**001**	Jan 03, 2019
AB		**40MG**	**A208031**	**002**	Jan 03, 2019
AB		**60MG**	**A208031**	**003**	Jan 03, 2019
AB		**80MG**	**A208031**	**004**	Jan 03, 2019
AB		**120MG**	**A208031**	**005**	Jan 03, 2019
AB	MACLEODS PHARMS LTD	**20MG**	**A212124**	**001**	Jun 09, 2023
AB		**40MG**	**A212124**	**002**	Jun 09, 2023
AB		**60MG**	**A212124**	**003**	Jun 09, 2023
AB		**80MG**	**A212124**	**004**	Jun 09, 2023
AB		**120MG**	**A212124**	**005**	Jun 09, 2023
AB	MSN	**20MG**	**A208037**	**001**	Sep 09, 2022
AB		**40MG**	**A208037**	**002**	Sep 09, 2022
AB		**60MG**	**A208037**	**003**	Sep 09, 2022
AB		**80MG**	**A208037**	**004**	Sep 09, 2022
AB		**120MG**	**A208037**	**005**	Sep 09, 2022
AB	SUN PHARM	**20MG**	**A208066**	**001**	Jan 04, 2019
AB		**40MG**	**A208066**	**002**	Jan 04, 2019
AB		**60MG**	**A208066**	**003**	Jan 04, 2019
AB		**80MG**	**A208066**	**004**	Jan 04, 2019
AB	TORRENT	**20MG**	**A208055**	**001**	Jan 03, 2019
AB		**40MG**	**A208055**	**002**	Jan 03, 2019
AB		**60MG**	**A208055**	**005**	Jan 13, 2025
AB		**80MG**	**A208055**	**003**	Jan 03, 2019
AB		**120MG**	**A208055**	**004**	Jan 03, 2019
AB	ZYDUS PHARMS	**20MG**	**A208052**	**001**	Mar 19, 2019
AB		**40MG**	**A208052**	**002**	Mar 19, 2019
AB		**60MG**	**A208052**	**003**	Mar 19, 2019
AB		**80MG**	**A208052**	**004**	Mar 19, 2019
AB		**120MG**	**A208052**	**005**	Mar 19, 2019

LURBINECTEDIN

POWDER;INTRAVENOUS

ZEPZELCA

+!	JAZZ	4MG/VIAL	N213702	001	Jun 15, 2020

LUSUTROMBOPAG

TABLET;ORAL

MULPLETA

+!	VANCOCIN ITALIA	3MG	N210923	001	Jul 31, 2018

LUTETIUM LU 177 DOTATATE

SOLUTION;INTRAVENOUS

LUTATHERA

	+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION;INTRAVENOUS

PLUVICTO

	+!	NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022

MACITENTAN

TABLET;ORAL

MACITENTAN

AB		ALEMBIC	**10MG**	**A211128**	**001**	Aug 18, 2025
AB		AUROBINDO PHARMA LTD	**10MG**	**A211198**	**001**	Apr 18, 2023
AB		LAURUS	**10MG**	**A211120**	**001**	Nov 05, 2025
AB		MSN	**10MG**	**A211136**	**001**	Aug 20, 2025
AB		SUN PHARM	**10MG**	**A211123**	**001**	Aug 26, 2025

OPSUMIT

AB	**+!**	ACTELION	**10MG**	**N204410**	**001**	Oct 18, 2013

MACITENTAN; TADALAFIL

TABLET;ORAL

OPSYNVI

	+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024
	+!		10MG;40MG	N218490	002	Mar 22, 2024

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

	+!	RISING	EQ 85MG BASE/GM	N016763	001	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	+!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP		FRESENIUS KABI USA	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**A215371**	**001**	Jun 08, 2022

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**N017378**	**002**	Nov 22, 1982

ISOLYTE S IN PLASTIC CONTAINER

		B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

		OTSUKA ICU MEDCL	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001	

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001	

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

		B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

		OTSUKA ICU MEDCL	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

	+!	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

	+!	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

AP		B BRAUN MEDICAL	**2GM/50ML (40MG/ML)**	**A207967**	**001**	Apr 26, 2021
AP			**4GM/100ML (40MG/ML)**	**A207967**	**002**	Apr 26, 2021
AP			**4GM/50ML (80MG/ML)**	**A207967**	**003**	Apr 26, 2021

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN MEDICAL	**1GM/100ML**	**A207966**	**001**	Oct 27, 2020
AP		BAXTER HLTHCARE CORP	**1GM/100ML**	**A211965**	**001**	Aug 11, 2020
AP		FRESENIUS KABI USA	**1GM/100ML**	**A206486**	**001**	Mar 07, 2016
AP	**+!**	HOSPIRA	**1GM/100ML**	**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A207349**	**001**	Mar 02, 2016
AP		PHARMOBEDIENT	**1GM/100ML**	**A209932**	**001**	Sep 10, 2018

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		AMNEAL	**2GM/50ML (40MG/ML)**	**A216597**	**001**	Feb 15, 2023
AP			**4GM/100ML (40MG/ML)**	**A216597**	**002**	Feb 15, 2023
AP		BAXTER HLTHCARE CORP	**2GM/50ML (40MG/ML)**	**A211966**	**001**	Jun 01, 2020
AP			**4GM/50ML (80MG/ML)**	**A211966**	**002**	Jun 01, 2020
AP			**4GM/100ML (40MG/ML)**	**A211966**	**003**	Jun 01, 2020
AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**	**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**	**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**	**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**	**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**	**A206485**	**005**	Mar 15, 2016
AP		GLAND	**2GM/50ML (40MG/ML)**	**A213917**	**001**	Jul 10, 2020
AP			**4GM/100ML (40MG/ML)**	**A213917**	**002**	Jul 10, 2020
AP	**+**	HOSPIRA	**2GM/50ML (40MG/ML)**	**N020309**	**003**	Jan 26, 2007
AP	**+!**		**4GM/100ML (40MG/ML)**	**N020309**	**001**	Jun 24, 1994
AP	**+!**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP	**+**		**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP	**+**		**40GM/1000ML (40MG/ML)**	**N020309**	**005**	Jan 18, 1995
AP		HQ SPCLT PHARMA	**2GM/50ML (40MG/ML)**	**A207350**	**001**	Dec 06, 2017
AP			**4GM/100ML (40MG/ML)**	**A207350**	**002**	Dec 06, 2017
AP			**4GM/50ML (80MG/ML)**	**A207350**	**003**	Dec 06, 2017
AP			**20GM/500ML (40MG/ML)**	**A207350**	**004**	Dec 06, 2017
AP			**40GM/1000ML (40MG/ML)**	**A207350**	**005**	Dec 06, 2017
AP		MILLA PHARMS	**2GM/50ML (40MG/ML)**	**A209642**	**001**	Nov 08, 2021
AP			**4GM/100ML (40MG/ML)**	**A209642**	**002**	Nov 08, 2021
AP			**4GM/50ML (80MG/ML)**	**A209642**	**003**	Nov 08, 2021
AP		MYLAN LABS LTD	**2GM/50ML (40MG/ML)**	**A209911**	**001**	Sep 14, 2018

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+!	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		ASPIRO	**1GM/2ML (500MG/ML)**	**A219777**	**001**	May 28, 2025
AP			**5GM/10ML (500MG/ML)**	**A219777**	**002**	May 28, 2025
AP			**10GM/20ML (500MG/ML)**	**A219777**	**003**	May 28, 2025
AP			**25GM/50ML (500MG/ML)**	**A219777**	**004**	May 28, 2025
AP	**+!**	FRESENIUS KABI USA	**1GM/2ML (500MG/ML)**	**N019316**	**002**	Sep 08, 1986
AP	**+!**		**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**+!**		**10GM/20ML (500MG/ML)**	**N019316**	**003**	Jan 29, 2016
AP	**+!**		**25GM/50ML (500MG/ML)**	**N019316**	**004**	Jan 29, 2016
AP	**!**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
AP			**10GM/20ML (500MG/ML)**	**A202411**	**001**	May 14, 2015

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

SUFLAVE

	+!	AZURITY	0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT	N215344	001	Jun 15, 2023

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018336**	**001**	

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

SUTAB

	+!	AZURITY	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		ALKEM LABS LTD	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A213924**	**001**	Dec 29, 2023
AA		ANNORA PHARMA	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A212903**	**001**	Oct 18, 2024
AA		BIONPHARMA	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A204135**	**001**	Jun 24, 2024
AA		NOVEL LABS INC	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A202511**	**001**	Feb 23, 2017
AA		PAI HOLDINGS	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A209941**	**001**	Jul 15, 2024
AA		STRIDES PHARMA INTL	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A215469**	**001**	Nov 22, 2023
AA		TARO	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A206431**	**001**	Mar 19, 2024

SUPREP BOWEL PREP KIT

AA	**+!**	AZURITY	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**N022372**	**001**	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

	!	SUVEN PHARMS	0.5%	A091559	001	May 23, 2012

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE

AP		FRESENIUS KABI USA	**EQ 0.1MG MANGANESE/ML**	**A217583**	**001**	Jul 07, 2025

MANGANESE CHLORIDE IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**EQ 0.1MG MANGANESE/ML**	**N018962**	**001**	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP		OTSUKA ICU MEDCL	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990

MANNITOL 25%

AP		FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP		HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	

OSMITROL 15% IN WATER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**004**	

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**008**	

OSMITROL 20% IN WATER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**003**	

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**007**	

OSMITROL 5% IN WATER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**001**	

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**005**	

POWDER;INHALATION

ARIDOL KIT

	+!	PHARMAXIS EUROPE	N/A,5MG,10MG,20MG,40MG	N022368	001	Oct 05, 2010

BRONCHITOL

	+!	PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

	+!	OTSUKA ICU MEDCL	540MG/100ML;2.7GM/100ML	N018316	001	

MARALIXIBAT CHLORIDE

SOLUTION;ORAL

LIVMARLI

+!	MIRUM	EQ 9.5MG BASE/ML	N214662	001	Sep 29, 2021
+!		EQ 19MG BASE/ML	N214662	002	Jul 24, 2024

TABLET;ORAL

LIVMARLI

+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025
+		EQ 15MG BASE	N219485	002	Apr 10, 2025
+		EQ 20MG BASE	N219485	003	Apr 10, 2025
+!		EQ 30MG BASE	N219485	004	Apr 10, 2025

MARAVIROC

SOLUTION;ORAL

SELZENTRY

+!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016

TABLET;ORAL

MARAVIROC

AB	HETERO LABS LTD III	**150MG**	**A203347**	**001**	Feb 07, 2022
AB		**300MG**	**A203347**	**002**	Feb 07, 2022
AB	I 3 PHARMS	**150MG**	**A217114**	**001**	Aug 17, 2023
AB		**300MG**	**A217114**	**002**	Aug 17, 2023
AB	NAVINTA LLC	**150MG**	**A217880**	**001**	May 13, 2025
AB		**300MG**	**A217880**	**002**	May 13, 2025
AB	RHODES PHARMS	**150MG**	**A216143**	**001**	Nov 04, 2025
AB		**300MG**	**A216143**	**002**	Nov 04, 2025

SELZENTRY

AB +	VIIV HLTHCARE	**150MG**	**N022128**	**001**	Aug 06, 2007
AB +!		**300MG**	**N022128**	**002**	Aug 06, 2007

MARIBAVIR

TABLET;ORAL

LIVTENCITY

+!	TAKEDA PHARMS USA	200MG	N215596	001	Nov 23, 2021

MAVACAMTEN

CAPSULE;ORAL

CAMZYOS

+	BRISTOL	2.5MG	N214998	001	Apr 28, 2022
+!		5MG	N214998	002	Apr 28, 2022
+		10MG	N214998	003	Apr 28, 2022
+		15MG	N214998	004	Apr 28, 2022

MAVORIXAFOR

CAPSULE;ORAL

XOLREMDI

+!	X4 PHARMS	100MG	N218709	001	Apr 26, 2024

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

!	LGM PHARMA	2.5MG	A204054	001	Mar 19, 2013

MECHLORETHAMINE HYDROCHLORIDE

GEL;TOPICAL

VALCHLOR

+!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

ANTIVERT

AA +	CASPER PHARMA LLC	**12.5MG**	**N010721**	**006**	
AA +		**25MG**	**N010721**	**004**	
AA +!		**50MG**	**N010721**	**001**	Jan 20, 1982

MECLIZINE HYDROCHLORIDE

AA !	AMNEAL PHARMS	**12.5MG**	**A201451**	**001**	Feb 23, 2011
AA !		**25MG**	**A201451**	**002**	Feb 23, 2011
AA		**50MG**	**A201451**	**003**	Feb 23, 2011
AA	APNAR PHARMA LP	**12.5MG**	**A087128**	**002**	
AA		**25MG**	**A087128**	**001**	
AA	AUROBINDO PHARMA	**12.5MG**	**A202640**	**001**	Sep 17, 2012

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

		USA				
AA			**25MG**	**A202640**	**002**	Sep 17, 2012
AA			**50MG**	**A202640**	**003**	Sep 17, 2012
AA		CHARTWELL RX	**12.5MG**	**A203003**	**001**	Aug 11, 2022
AA			**25MG**	**A203003**	**002**	Aug 11, 2022
AA			**50MG**	**A203003**	**003**	Aug 11, 2022
AA		EPIC PHARMA LLC	**12.5MG**	**A200294**	**001**	Apr 13, 2012
AA			**25MG**	**A200294**	**002**	Apr 13, 2012
AA		JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA			**25MG**	**A040659**	**002**	Jun 04, 2010
AA		SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
AA		SCIEGEN PHARMS	**25MG**	**A084092**	**003**	May 22, 1989
AA		ZYDUS LIFESCIENCES	**12.5MG**	**A213957**	**001**	Jun 23, 2020
AA			**25MG**	**A213957**	**002**	Jun 23, 2020

TABLET, CHEWABLE;ORAL

ANTIVERT

	+!	CASPER PHARMA LLC	25MG	N010721	005	

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

		MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
	!		EQ 100MG BASE	A071081	001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

DEPO-PROVERA

AB	**+!**	PFIZER	**150MG/ML**	**N020246**	**001**	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

AB		AMNEAL	**150MG/ML**	**A215397**	**001**	Jun 07, 2023
AB		AMPHASTAR PHARMS INC	**150MG/ML**	**A077235**	**001**	Nov 28, 2017
AB			**150MG/ML**	**A077334**	**001**	Nov 28, 2017
AB		EUGIA PHARMA	**150MG/ML**	**A212824**	**001**	Aug 22, 2022
AB			**150MG/ML**	**A212844**	**001**	Aug 31, 2022
AB		HONG KONG	**150MG/ML**	**A076553**	**001**	Jul 28, 2004
AB		XIROMED	**150MG/ML**	**A210227**	**001**	Oct 12, 2018

INJECTABLE;SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

	+!	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

AB		BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB			**5MG**	**A040159**	**002**	Aug 09, 1996
AB			**10MG**	**A040159**	**003**	Aug 09, 1996

PROVERA

AB	**+**	PFIZER	**2.5MG**	**N011839**	**001**	
AB	**+**		**5MG**	**N011839**	**003**	
AB	**+!**		**10MG**	**N011839**	**004**	

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

AB		AJENAT PHARMS	**250MG**	**A091608**	**001**	Jun 02, 2014
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS	**250MG**	**A090562**	**001**	Nov 19, 2010

PONSTEL

AB	**+!**	AVION PHARMS	**250MG**	**N015034**	**003**	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

AB	**!**	BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB		CHARTWELL RX	**250MG**	**A076175**	**001**	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

AB		NOVITIUM PHARMA	**40MG/ML**	**A077404**	**001**	Feb 16, 2006
AB		PHARMOBEDIENT	**40MG/ML**	**A076721**	**001**	Nov 01, 2004
AB	**!**	STRIDES PHARMA INTL	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
	!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014

MEGESTROL ACETATE

TABLET;ORAL

MEGESTROL ACETATE

AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		STRIDES PHARMA INTL	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	!		**40MG**	**A072423**	**001**	Aug 08, 1988

MELOXICAM

CAPSULE;ORAL

MELOXICAM

AB		LUPIN LTD	**5MG**	**A209487**	**001**	Jun 01, 2020
AB	!		**10MG**	**A209487**	**002**	Jun 01, 2020
AB		NOVITIUM PHARMA	**5MG**	**A211398**	**001**	Mar 09, 2021
AB			**10MG**	**A211398**	**002**	Mar 09, 2021

SOLUTION;INTRAVENOUS

QAMZOVA

+!	NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025

XIFYRM

+!	AZURITY	30MG/ML (30MG/ML)	N218395	001	Jun 05, 2025

SUSPENSION;ORAL

MELOXICAM

+!	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004

TABLET;ORAL

MELOXICAM

AB		AIPING PHARM INC	**7.5MG**	**A077920**	**001**	Jul 19, 2006
AB			**15MG**	**A077920**	**002**	Jul 19, 2006
AB		ASCENT PHARMS INC	**7.5MG**	**A217579**	**001**	Jun 07, 2023
AB			**15MG**	**A217579**	**002**	Jun 07, 2023
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		CIPLA	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006
AB		COREPHARMA	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		GLENMARK PHARMS LTD	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		NOVITIUM PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		RISING	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB			**15MG**	**A077927**	**002**	Dec 20, 2006
AB		YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB			**15MG**	**A077918**	**002**	Dec 07, 2006
AB		ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB	!		**15MG**	**A077921**	**002**	Jul 19, 2006

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET;ORAL

SYMBRAVO

+!	AXSOME	20MG;EQ 10MG BASE	N215431	001	Jan 30, 2025

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP		ARTHUR GRP	**EQ 50MG BASE/VIAL**	**A211463**	**001**	Sep 13, 2019
AP		AVET LIFESCIENCES	**EQ 50MG BASE/VIAL**	**A206523**	**001**	Oct 29, 2024
AP		BPI LABS	**EQ 50MG BASE/VIAL**	**A209197**	**001**	May 08, 2020
AP		DR REDDYS	**EQ 50MG BASE/VIAL**	**A203655**	**001**	Dec 08, 2017
AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A203393**	**001**	Dec 22, 2017
AP		GLAND	**EQ 50MG BASE/VIAL**	**A209826**	**001**	May 28, 2019
AP		HETERO LABS	**EQ 50MG BASE/VIAL**	**A215024**	**001**	May 23, 2024
AP		HIKMA	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A212960**	**001**	May 28, 2021
AP	!	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP		SAGENT PHARMS INC	**EQ 50MG BASE/VIAL**	**A201379**	**001**	Feb 28, 2017

POWDER;INTRA-ARTERIAL

HEPZATO

+!	DELCATH SYSTEMS INC	EQ 50MG BASE/VIAL	N201848	001	Aug 14, 2023

MELPHALAN HYDROCHLORIDE

POWDER;INTRAVENOUS

EVOMELA

+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

SOLUTION;INTRAVENOUS

IVRA

+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N217110	001	Aug 18, 2023

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB			**14MG**	**A205825**	**002**	Oct 12, 2016
AB			**21MG**	**A205825**	**003**	Oct 12, 2016
AB			**28MG**	**A205825**	**004**	Oct 12, 2016
AB		AUROBINDO PHARMA LTD	**7MG**	**A214651**	**001**	Aug 09, 2021
AB			**14MG**	**A214651**	**002**	Aug 09, 2021
AB			**21MG**	**A214651**	**003**	Aug 09, 2021
AB			**28MG**	**A214651**	**004**	Aug 09, 2021
AB		LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016
AB			**14MG**	**A206028**	**002**	Sep 28, 2016
AB			**21MG**	**A206028**	**003**	Sep 28, 2016
AB			**28MG**	**A206028**	**004**	Sep 28, 2016
AB		MACLEODS PHARMS LTD	**7MG**	**A206310**	**001**	Aug 28, 2025
AB			**14MG**	**A206310**	**002**	Aug 28, 2025
AB			**21MG**	**A206310**	**003**	Aug 28, 2025
AB			**28MG**	**A206310**	**004**	Aug 28, 2025
AB		RISING	**7MG**	**A206032**	**001**	Sep 28, 2016
AB			**14MG**	**A206032**	**002**	Sep 28, 2016
AB			**21MG**	**A206032**	**003**	Sep 28, 2016
AB			**28MG**	**A206032**	**004**	Sep 28, 2016
AB		VITRUVIAS	**7MG**	**A213985**	**001**	Oct 11, 2022
AB			**14MG**	**A213985**	**002**	Oct 11, 2022
AB			**21MG**	**A213985**	**004**	Feb 06, 2024
AB			**28MG**	**A213985**	**003**	Oct 11, 2022
AB		YICHANG HUMANWELL	**7MG**	**A211100**	**001**	Apr 02, 2021
AB			**14MG**	**A211100**	**002**	Apr 02, 2021
AB			**21MG**	**A211100**	**003**	Apr 02, 2021
AB			**28MG**	**A211100**	**004**	Apr 02, 2021
AB		ZYDUS PHARMS	**7MG**	**A203293**	**001**	Aug 03, 2017
AB			**14MG**	**A203293**	**002**	Aug 03, 2017
AB			**21MG**	**A203293**	**003**	Aug 03, 2017
AB	!		**28MG**	**A203293**	**004**	Aug 03, 2017

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX	**2MG/ML**	**A209955**	**001**	Feb 09, 2018
AA	!	CHARTWELL MOLECULAR	**2MG/ML**	**A204033**	**001**	Oct 13, 2015
AA		MACLEODS PHARMS LTD	**2MG/ML**	**A202790**	**001**	Oct 13, 2015
AA		SETON PHARMS	**2MG/ML**	**A210319**	**001**	Aug 31, 2020

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**5MG**	**A206528**	**001**	Nov 30, 2015
AB			**10MG**	**A206528**	**002**	Nov 30, 2015
AB		ALEMBIC	**5MG**	**A200891**	**001**	Oct 13, 2015
AB			**10MG**	**A200891**	**002**	Oct 13, 2015
AB		AMNEAL PHARMS	**5MG**	**A090041**	**001**	Apr 10, 2015
AB			**10MG**	**A090041**	**002**	Apr 10, 2015
AB		AUROBINDO PHARMA LTD	**5MG**	**A203175**	**001**	Oct 13, 2015
AB			**10MG**	**A203175**	**002**	Oct 13, 2015
AB		DR REDDYS LABS LTD	**5MG**	**A090048**	**001**	Apr 14, 2010
AB			**10MG**	**A090048**	**002**	Apr 14, 2010
AB		HETERO LABS LTD V	**5MG**	**A204389**	**001**	Sep 26, 2022
AB			**10MG**	**A204389**	**002**	Sep 26, 2022
AB		LUPIN LTD	**5MG**	**A090051**	**001**	Apr 10, 2015
AB			**10MG**	**A090051**	**002**	Apr 10, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A202840**	**001**	Oct 13, 2015
AB			**10MG**	**A202840**	**002**	Oct 13, 2015
AB		PURACAP LABS BLU	**5MG**	**A210587**	**001**	Dec 11, 2020
AB			**10MG**	**A210587**	**002**	Dec 11, 2020
AB		PURACAP PHARM LLC	**5MG**	**A206855**	**001**	Nov 17, 2015
AB			**10MG**	**A206855**	**002**	Nov 17, 2015

MEMANTINE HYDROCHLORIDE

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		SOMERSET THERAPS LLC	**5MG**	**A209527**	**001**	May 07, 2018
AB			**10MG**	**A209527**	**002**	May 07, 2018
AB		STRIDES PHARMA	**5MG**	**A202350**	**001**	May 23, 2017
AB			**10MG**	**A202350**	**002**	May 23, 2017
AB		SUN PHARM	**5MG**	**A090058**	**001**	May 05, 2010
AB			**10MG**	**A090058**	**002**	May 05, 2010
AB		UNICHEM	**5MG**	**A200022**	**001**	Oct 13, 2015
AB			**10MG**	**A200022**	**002**	Oct 13, 2015
AB		UPSHER SMITH LABS	**5MG**	**A090043**	**001**	Jul 31, 2015
AB			**10MG**	**A090043**	**002**	Jul 31, 2015
AB		YILING	**5MG**	**A212947**	**001**	Apr 03, 2020
AB			**10MG**	**A212947**	**002**	Apr 03, 2020
AB		ZYDUS LIFESCIENCES	**5MG**	**A090961**	**001**	Jul 10, 2017
AB			**10MG**	**A090961**	**002**	Jul 10, 2017

NAMENDA

AB	**+**	ABBVIE	**5MG**	**N021487**	**001**	Oct 16, 2003
AB	**+!**		**10MG**	**N021487**	**002**	Oct 16, 2003

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

AP	**+!**	HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+!**		**50MG/ML**	**N021171**	**002**	
AP	**+!**		**75MG/ML**	**N021171**	**003**	
AP	**+!**		**100MG/ML**	**N021171**	**004**	

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**25MG/ML**	**A080445**	**001**	
AP			**25MG/ML**	**A080455**	**007**	
AP			**50MG/ML**	**A080445**	**002**	
AP			**50MG/ML**	**A080455**	**008**	
AP			**75MG/ML**	**A080445**	**003**	
AP			**75MG/ML**	**A080455**	**009**	
AP			**100MG/ML**	**A080445**	**004**	
AP			**100MG/ML**	**A080455**	**010**	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	!	WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993

SYRUP;ORAL

MEPERIDINE HYDROCHLORIDE

	!	HIKMA	50MG/5ML	A088744	001	Jan 30, 1985

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

AA	**!**	EPIC PHARMA LLC	**50MG**	**A040331**	**001**	May 28, 1999
AA		GENUS	**50MG**	**A040893**	**001**	Jun 24, 2009
		EPIC PHARMA LLC	100MG	A040331	002	May 28, 1999

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

POLOCAINE

		FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986
			2%	A089410	001	Dec 01, 1986

POLOCAINE-MPF

		FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986
			1.5%	A089408	001	Dec 01, 1986
			2%	A089409	001	Dec 01, 1986

SCANDONEST PLAIN

	!	DEPROCO	3%	A088387	001	Oct 10, 1984

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	**!**	ALEMBIC PHARMS LTD	**200MG**	**A090122**	**001**	Feb 18, 2009
AA	**!**		**400MG**	**A090122**	**002**	Feb 18, 2009
AA		INVAGEN PHARMS	**200MG**	**A040797**	**001**	Feb 27, 2008
AA			**400MG**	**A040797**	**002**	Feb 27, 2008

MERCAPTOPURINE							
SUSPENSION;ORAL							
MERCAPTOPURINE							
AB		HIKMA	**20MG/ML**	**A216418**	**001**	Feb 26, 2025	
PURIXAN							
AB	**+!**	NOVA LABS LTD	**20MG/ML**	**N205919**	**001**	Apr 28, 2014	
TABLET;ORAL							
MERCAPTOPURINE							
AB		DR REDDYS LABS SA	**50MG**	**A040461**	**001**	Feb 11, 2004	
AB	**!**	HIKMA	**50MG**	**A040528**	**001**	Feb 13, 2004	
AB		MYLAN	**50MG**	**A040594**	**001**	Jul 01, 2005	
PURINETHOL							
AB	**+**	STASON PHARMS	**50MG**	**N009053**	**002**		
MEROPENEM							
INJECTABLE;INJECTION							
MEROPENEM							
AP	**!**	ACS DOBFAR	**500MG/VIAL**	**A091404**	**001**	Oct 26, 2011	
AP	**!**		**1GM/VIAL**	**A091404**	**002**	Oct 26, 2011	
AP		ACS DOBFAR SPA	**500MG/VIAL**	**A204139**	**001**	Jun 09, 2016	
AP			**1GM/VIAL**	**A204139**	**002**	Jun 09, 2016	
AP		AMNEAL PHARMS	**500MG/VIAL**	**A205883**	**001**	Apr 12, 2016	
AP			**1GM/VIAL**	**A205883**	**002**	Apr 12, 2016	
AP		BROOKS STERISCIENCE	**500MG/VIAL**	**A216154**	**001**	Aug 18, 2022	
AP			**1GM/VIAL**	**A216154**	**002**	Aug 18, 2022	
AP		EUGIA PHARMA	**500MG/VIAL**	**A205835**	**001**	Mar 27, 2017	
AP			**1GM/VIAL**	**A205835**	**002**	Mar 27, 2017	
AP		GLAND	**500MG/VIAL**	**A206141**	**001**	Jun 08, 2016	
AP			**1GM/VIAL**	**A206141**	**002**	Jun 08, 2016	
AP		HQ SPCLT PHARMA	**500MG/VIAL**	**A210773**	**001**	Aug 16, 2019	
AP			**1GM/VIAL**	**A210773**	**002**	Aug 16, 2019	
AP		QILU	**500MG/VIAL**	**A216424**	**001**	Jul 22, 2024	
AP			**1GM/VIAL**	**A216424**	**002**	Jul 22, 2024	
AP		SAVIOR LIFETEC CORP	**500MG/VIAL**	**A206086**	**001**	Apr 19, 2016	
AP			**1GM/VIAL**	**A206086**	**002**	Apr 19, 2016	
POWDER;INTRAVENOUS							
MEROPENEM							
AP		BROOKS STERISCIENCE	**2GM/VIAL**	**A219084**	**001**	Jun 23, 2025	
AP	**+!**	HQ SPCLT PHARMA	**2GM/VIAL**	**N215212**	**001**	Jul 26, 2023	
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER							
		B BRAUN MEDICAL	500MG/VIAL	N202106	001	Apr 30, 2015	
			1GM/VIAL	N202106	002	Apr 30, 2015	
MEROPENEM; VABORBACTAM							
POWDER;INTRAVENOUS							
VABOMERE							
	+!	REMPEX	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	
MESALAMINE							
CAPSULE, DELAYED RELEASE;ORAL							
MESALAMINE							
	!	TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	
CAPSULE, EXTENDED RELEASE;ORAL							
APRISO							
AB	**+!**	SALIX	**375MG**	**N022301**	**001**	Oct 31, 2008	
MESALAMINE							
AB		ALEMBIC	**375MG**	**A216967**	**001**	Oct 28, 2022	
AB		ALKEM LABS LTD	**375MG**	**A214242**	**001**	Jul 15, 2021	
AB		AMTA	**375MG**	**A217533**	**001**	Jun 06, 2023	
AB		ANNORA PHARMA	**375MG**	**A219864**	**001**	Aug 13, 2025	
AB		AUROBINDO PHARMA LTD	**375MG**	**A214477**	**001**	Mar 31, 2023	
AB		MYLAN	**375MG**	**A207271**	**001**	Nov 20, 2019	
AB		NOVAST LABS	**375MG**	**A218410**	**001**	Aug 22, 2024	
AB		SUN PHARM	**500MG**	**A214585**	**001**	May 11, 2022	
AB		ZYDUS PHARMS	**375MG**	**A208954**	**001**	Aug 12, 2021	
PENTASA							
AB	**+!**	TAKEDA PHARMS USA	**500MG**	**N020049**	**002**	Jul 08, 2004	
	+		250MG	N020049	001	May 10, 1993	
ENEMA;RECTAL							
MESALAMINE							
AB		ENCUBE	**4GM/60ML**	**A216941**	**001**	May 30, 2023	
AB		NOVITIUM PHARMA	**4GM/60ML**	**A215269**	**001**	Apr 16, 2025	
AB		PADAGIS ISRAEL	**4GM/60ML**	**A076751**	**001**	Sep 17, 2004	

MESALAMINE

ENEMA;RECTAL

ROWASA

AB	**+!**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**001**	Dec 24, 1987

SFROWASA

AB	**+**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**002**	Jun 20, 2008

SUPPOSITORY;RECTAL

CANASA

AB	**+!**	ABBVIE	**1GM**	**N021252**	**002**	Nov 05, 2004

MESALAMINE

AB		ACTAVIS MID ATLANTIC	**1GM**	**A205654**	**001**	Aug 14, 2020
AB		AMRING PHARMS	**1GM**	**A208362**	**001**	Jun 21, 2019
AB		ANNORA PHARMA	**1GM**	**A213377**	**001**	Mar 19, 2020
AB		QUAGEN	**1GM**	**A204354**	**001**	Nov 24, 2015
AB		RISING	**1GM**	**A207448**	**001**	Apr 19, 2019
AB			**1GM**	**A219028**	**001**	Apr 14, 2025
AB		SANDOZ	**1GM**	**A202065**	**001**	Jun 12, 2019
AB		ZYDUS PHARMS	**1GM**	**A208953**	**001**	Feb 12, 2020

TABLET, DELAYED RELEASE;ORAL

LIALDA

AB	**+!**	TAKEDA PHARMS USA	**1.2GM**	**N022000**	**001**	Jan 16, 2007

MESALAMINE

AB		ACTAVIS LABS FL	**1.2GM**	**A203817**	**001**	Mar 23, 2018
AB		AMNEAL	**800MG**	**A215067**	**001**	Feb 18, 2025
AB		ANNORA PHARMA	**1.2GM**	**A216334**	**001**	Feb 05, 2024
AB		SINOTHERAPEUTICS INC	**1.2GM**	**A217337**	**001**	May 12, 2023
AB		SUN PHARM	**1.2GM**	**A211858**	**001**	Jan 25, 2019
AB		TEVA PHARMS INC	**800MG**	**A213191**	**001**	Aug 22, 2024
AB	**!**	ZYDUS PHARMS	**800MG**	**A203286**	**001**	Jul 21, 2017
AB			**1.2GM**	**A091640**	**001**	Jun 05, 2017

MESNA

INJECTABLE;INTRAVENOUS

MESNA

AP		FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP		GLAND	**100MG/ML**	**A206992**	**001**	Dec 18, 2017
AP		HIKMA	**100MG/ML**	**A075739**	**001**	Jan 09, 2004
AP		SAGENT PHARMS INC	**100MG/ML**	**A090913**	**001**	Apr 13, 2010

MESNEX

AP	**+!**	BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL

MESNA

AB		NOVAST LABS	**400MG**	**A218871**	**001**	Jan 13, 2025

MESNEX

AB	**+!**	BAXTER HLTHCARE	**400MG**	**N020855**	**001**	Mar 21, 2002

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	!	CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992

METARAMINOL BITARTRATE

INJECTABLE;INJECTION

METARAMINOL BITARTRATE

		AZURITY	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021

METAXALONE

TABLET;ORAL

METAXALONE

AB		ACTAVIS LABS FL INC	**800MG**	**A203695**	**001**	Jun 15, 2017
AB	**!**	AMNEAL PHARMS	**800MG**	**A203399**	**001**	Jun 21, 2013
AB		LANNETT CO INC	**800MG**	**A204770**	**001**	Nov 22, 2016
AB		MOUNTAIN	**400MG**	**A040486**	**001**	Feb 27, 2015
AB		SANDOZ	**800MG**	**A040445**	**001**	Mar 31, 2010
AB		SCIEGEN PHARMS	**400MG**	**A207466**	**002**	Mar 13, 2020
AB			**800MG**	**A207466**	**001**	Aug 31, 2017
	+!	PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB		ANNORA PHARMA	**500MG/5ML**	**A215008**	**001**	Mar 13, 2025
AB		BIONPHARMA	**500MG/5ML**	**A219151**	**001**	Apr 14, 2025
AB	!	SAPTALIS PHARMS	**500MG/5ML**	**A211309**	**001**	Mar 03, 2020
AB		VISTAPHARM LLC	**500MG/5ML**	**A212677**	**001**	Aug 19, 2022

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB		ALKEM	**500MG**	**A091184**	**001**	Nov 01, 2010
AB			**850MG**	**A091184**	**002**	Nov 01, 2010
AB			**1GM**	**A091184**	**003**	Nov 01, 2010
AB		AUROBINDO	**500MG**	**A077095**	**001**	Jan 14, 2005
AB			**850MG**	**A077095**	**002**	Jan 14, 2005
AB			**1GM**	**A077095**	**003**	Jan 14, 2005
AB		CHARTWELL	**500MG**	**A075972**	**001**	Jan 24, 2002
AB			**850MG**	**A075972**	**002**	Jan 24, 2002
AB			**1GM**	**A075972**	**003**	Jan 24, 2002
AB		CSPC OUYI	**500MG**	**A205096**	**001**	Jul 11, 2016
AB			**850MG**	**A205096**	**002**	Jul 11, 2016
AB			**1GM**	**A205096**	**003**	Jul 11, 2016
AB		DR REDDYS LABS INC	**500MG**	**A077787**	**001**	Aug 23, 2006
AB			**850MG**	**A077787**	**002**	Aug 23, 2006
AB			**1GM**	**A077787**	**003**	Aug 23, 2006
AB		EPIC PHARMA LLC	**500MG**	**A075965**	**001**	Jan 25, 2002
AB			**850MG**	**A075965**	**002**	Jan 25, 2002
AB			**1GM**	**A075965**	**003**	Jan 25, 2002
AB		GRANULES INDIA	**500MG**	**A090564**	**001**	Apr 22, 2010
AB			**850MG**	**A090564**	**002**	Apr 22, 2010
AB	!		**1GM**	**A090564**	**003**	Apr 22, 2010
AB		HARMAN FINOCHEM	**500MG**	**A213320**	**001**	Dec 03, 2021
AB			**850MG**	**A213320**	**002**	Dec 03, 2021
AB			**1GM**	**A213320**	**003**	Dec 03, 2021
AB		LAURUS	**500MG**	**A209882**	**001**	Aug 27, 2018
AB			**850MG**	**A209882**	**002**	Aug 27, 2018
AB			**1GM**	**A209882**	**003**	Aug 27, 2018
AB		MARKSANS PHARMA	**500MG**	**A090888**	**001**	Mar 12, 2012
AB			**850MG**	**A090888**	**002**	Mar 12, 2012
AB			**1GM**	**A090888**	**003**	Mar 12, 2012
AB		MYLAN	**500MG**	**A075973**	**001**	Jan 25, 2002
AB			**850MG**	**A075973**	**002**	Jan 25, 2002
AB			**1GM**	**A075973**	**003**	Jan 25, 2002
AB		SCIEGEN PHARMS	**500MG**	**A203769**	**001**	Sep 11, 2013
AB			**850MG**	**A203769**	**002**	Sep 11, 2013
AB			**1GM**	**A203769**	**003**	Sep 11, 2013
AB		SENORES PHARMS	**500MG**	**A076033**	**001**	Jan 24, 2002
AB			**850MG**	**A076033**	**002**	Jan 24, 2002
AB			**1GM**	**A076033**	**003**	Jan 24, 2002
AB		ZYDUS HLTHCARE	**500MG**	**A203686**	**001**	Aug 28, 2014
AB			**850MG**	**A203686**	**002**	Aug 28, 2014
AB			**1GM**	**A203686**	**003**	Aug 28, 2014
AB		ZYDUS PHARMS USA	**500MG**	**A077064**	**001**	Apr 18, 2005
AB			**850MG**	**A077064**	**002**	Apr 18, 2005
AB			**1GM**	**A077064**	**003**	Apr 18, 2005
		CHARTWELL	625MG	A075972	005	Jan 24, 2002
			750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**750MG**	**A076869**	**001**	Apr 12, 2005
AB	!	ALKEM LABS LTD	**750MG**	**A206145**	**002**	Oct 22, 2018
AB		AMNEAL PHARMS NY	**750MG**	**A078596**	**002**	Jan 03, 2008
AB		AUROBINDO PHARMA LTD	**750MG**	**A079118**	**002**	Jul 20, 2012
AB		CSPC OUYI	**750MG**	**A078321**	**002**	Apr 17, 2008
AB		GRANULES	**750MG**	**A209313**	**002**	Mar 16, 2018
AB		HARMAN FINOCHEM	**750MG**	**A218673**	**002**	Jul 05, 2024
AB		LAURUS	**750MG**	**A217631**	**002**	Oct 05, 2023
AB		MACLEODS PHARMS LTD	**750MG**	**A206955**	**002**	Dec 07, 2016
AB		MARKSANS PHARMA	**750MG**	**A090295**	**002**	Apr 29, 2016
AB		MEDICAP LABS	**750MG**	**A202306**	**002**	Feb 23, 2017
AB		NOSTRUM PHARMS LLC	**750MG**	**A076756**	**002**	Dec 12, 2011
AB		PRINSTON INC	**750MG**	**A208880**	**002**	Sep 10, 2018
AB		REGCON HOLDINGS	**750MG**	**A207427**	**002**	Dec 13, 2016

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB	TEVA	**750MG**	**A076864**	**001**	Apr 12, 2005
AB	UNICHEM	**750MG**	**A213359**	**002**	Aug 11, 2021
AB	YICHANG HUMANWELL	**750MG**	**A211052**	**002**	Sep 24, 2018
AB	ZYDUS LIFESCIENCES	**750MG**	**A077078**	**001**	Apr 21, 2005
AB1	ALIGNSCIENCE PHARMA	**500MG**	**A209303**	**001**	Mar 19, 2018
AB1	ALKEM LABS LTD	**500MG**	**A206145**	**001**	Oct 22, 2018
AB1	AMNEAL PHARMS NY	**500MG**	**A078596**	**001**	Jan 03, 2008
AB1	AUROBINDO PHARMA LTD	**500MG**	**A079118**	**001**	Jul 20, 2012
AB1	CSPC OUYI	**500MG**	**A078321**	**001**	Apr 17, 2008
AB1	GRANULES	**500MG**	**A209313**	**001**	Mar 16, 2018
AB1	HARMAN FINOCHEM	**500MG**	**A218673**	**001**	Jul 05, 2024
AB1	INVENTIA	**500MG**	**A201991**	**001**	Jan 18, 2012
AB1	LAURUS	**500MG**	**A217631**	**001**	Oct 05, 2023
AB1	MACLEODS PHARMS LTD	**500MG**	**A206955**	**001**	Dec 07, 2016
AB1	MARKSANS PHARMA	**500MG**	**A090295**	**001**	Apr 29, 2016
AB1	MEDICAP LABS	**500MG**	**A202306**	**001**	Feb 23, 2017
AB1	NOSTRUM PHARMS LLC	**500MG**	**A076756**	**001**	Jul 26, 2006
AB1	PRINSTON INC	**500MG**	**A208880**	**001**	Sep 10, 2018
AB1	REGCON HOLDINGS	**500MG**	**A207427**	**001**	Dec 13, 2016
AB1	SANDOZ	**500MG**	**A076873**	**001**	Dec 14, 2004
AB1	TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1	UNICHEM	**500MG**	**A213359**	**001**	Aug 11, 2021
AB1	YICHANG HUMANWELL	**500MG**	**A211052**	**001**	Sep 24, 2018
AB1	ZYDUS LIFESCIENCES	**500MG**	**A077060**	**001**	Apr 20, 2005
AB2	AJANTA PHARMA LTD	**500MG**	**A213651**	**001**	Apr 09, 2020
AB2		**1GM**	**A213651**	**002**	Apr 09, 2020
AB2	AUROBINDO PHARMA	**500MG**	**A209694**	**001**	Oct 18, 2024
AB2		**1GM**	**A209694**	**002**	Oct 18, 2024
AB2	LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2 **!**		**1GM**	**A090692**	**002**	Jun 29, 2011
AB2	MPP PHARMA	**500MG**	**A203832**	**001**	Dec 26, 2017
AB2		**1GM**	**A203832**	**002**	Dec 26, 2017
AB2	MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2		**1GM**	**A200690**	**002**	Aug 01, 2012
AB2	NOVAST LABS	**500MG**	**A209674**	**001**	Nov 02, 2018
AB2		**1GM**	**A209674**	**002**	Nov 02, 2018
AB2	QINGDAO BAHEAL PHARM	**500MG**	**A209993**	**001**	Dec 27, 2018
AB2		**1GM**	**A209993**	**002**	Dec 27, 2018
AB2	SCIEGEN PHARMS	**500MG**	**A214629**	**001**	Feb 22, 2022
AB2		**1GM**	**A214629**	**002**	Feb 22, 2022
AB3	ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3		**1GM**	**A203755**	**002**	Aug 01, 2016
AB3	AJANTA PHARMA LTD	**500MG**	**A213962**	**001**	Mar 09, 2021
AB3 **!**		**1GM**	**A213962**	**002**	Mar 09, 2021
AB3	APOTEX	**500MG**	**A213356**	**001**	Dec 13, 2021
AB3		**1GM**	**A213356**	**002**	Dec 13, 2021
AB3	GLENMARK PHARMS LTD	**500MG**	**A212969**	**001**	Nov 25, 2019
AB3		**1GM**	**A212969**	**002**	Nov 25, 2019
AB3	GRANULES	**500MG**	**A213344**	**001**	Jan 12, 2021
AB3		**1GM**	**A213344**	**002**	Jan 12, 2021
AB3	LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3		**1GM**	**A091664**	**002**	Jul 19, 2013
AB3	MICRO LABS	**500MG**	**A212448**	**001**	Jan 10, 2023
AB3		**1GM**	**A212448**	**002**	Jan 10, 2023
AB3	PRINSTON INC	**500MG**	**A212681**	**001**	Jun 09, 2022
AB3		**1GM**	**A212681**	**002**	Jun 09, 2022
AB3	RK PHARMA	**500MG**	**A215629**	**001**	Jun 20, 2023
AB3		**1GM**	**A215629**	**002**	Jun 20, 2023
AB3	SCIEGEN PHARMS	**500MG**	**A213334**	**001**	Apr 16, 2021
AB3		**1GM**	**A213334**	**002**	Apr 16, 2021

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

AB **+!**	TAKEDA PHARMS USA	**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB			**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB		MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB			**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB		TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB			**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014
AB		TORRENT PHARMS LTD	**500MG;EQ 15MG BASE**	**A202001**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A202001**	**002**	Feb 13, 2013

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		DR REDDYS LABS SA	**500MG;EQ 5MG BASE**	**A207678**	**001**	Aug 09, 2023
AB			**1GM;EQ 2.5MG BASE**	**A207678**	**002**	Aug 09, 2023
AB	**!**		**1GM;EQ 5MG BASE**	**A207678**	**003**	Aug 09, 2023
AB		MYLAN	**500MG;EQ 5MG BASE**	**A205981**	**001**	Jul 31, 2023
AB			**1GM;EQ 2.5MG BASE**	**A205981**	**002**	Jul 31, 2023
AB			**1GM;EQ 5MG BASE**	**A205981**	**003**	Jul 31, 2023

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET;ORAL

ZITUVIMET

+	ZYDUS LIFESCIENCES	500MG;50MG	N216743	001	Nov 03, 2023
+!		1GM;50MG	N216743	002	Nov 03, 2023

TABLET, EXTENDED RELEASE;ORAL

ZITUVIMET XR

+	ZYDUS LIFESCIENCES	500MG;50MG	N216778	001	Jul 18, 2024
+		1GM;50MG	N216778	002	Jul 18, 2024
+!		1GM;100MG	N216778	003	Jul 18, 2024

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

AB	**+**	MSD SUB MERCK	**500MG;EQ 50MG BASE**	**N022044**	**001**	Mar 30, 2007
AB	**+!**		**1GM;EQ 50MG BASE**	**N022044**	**002**	Mar 30, 2007

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		SANDOZ	**500MG;EQ 50MG BASE**	**A202388**	**001**	Dec 02, 2025
AB			**1GM;EQ 50MG BASE**	**A202388**	**002**	Dec 02, 2025

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+!	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	**10MG/ML**	**A040180**	**001**	Apr 30, 1998
AA		LANNETT CO INC	**10MG/ML**	**A212093**	**001**	Nov 02, 2020
AA		SPECGX LLC	**10MG/ML**	**A207368**	**001**	Aug 22, 2019
AA		VISTAPHARM LLC	**10MG/ML**	**A040088**	**001**	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

AA		HIKMA	**10MG/ML**	**A089897**	**001**	Sep 06, 1988

METHADOSE

AA	**+!**	SPECGX LLC	**10MG/ML**	**N017116**	**002**

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		BRECKENRIDGE	**10MG/ML**	**A218252**	**001**	Dec 16, 2024
AP		HIKMA	**10MG/ML**	**A218609**	**001**	May 05, 2025
AP		LONG GROVE PHARMS	**10MG/ML**	**A208306**	**001**	Oct 27, 2017
AP	**+!**	MYLAN INSTITUTIONAL	**10MG/ML**	**N021624**	**001**	

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**5MG/5ML**	**A087393**	**001**	
AA	**+!**		**10MG/5ML**	**A087997**	**001**	Aug 30, 1982
AA		SPECGX LLC	**5MG/5ML**	**A207537**	**001**	Oct 02, 2019
AA			**10MG/5ML**	**A207537**	**002**	Oct 01, 2019

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	**5MG**	**A211228**	**001**	Jan 03, 2019
AA			**10MG**	**A211228**	**002**	Jan 03, 2019
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001**	Aug 31, 2015
AA			**10MG**	**A203502**	**002**	Aug 31, 2015
AA		ELITE LABS INC	**5MG**	**A210484**	**001**	Aug 02, 2018
AA			**10MG**	**A210484**	**002**	Aug 02, 2018
AA		EPIC PHARMA LLC	**5MG**	**A090065**	**001**	Aug 18, 2015
AA			**10MG**	**A090065**	**002**	Aug 18, 2015
AA		HIKMA	**5MG**	**A088109**	**002**	Mar 08, 1983
AA			**10MG**	**A088109**	**001**	Mar 08, 1983
AA	!	SPECGX LLC	**5MG**	**A040517**	**001**	Apr 27, 2004
AA	!		**10MG**	**A040517**	**002**	Apr 27, 2004
AA		THEPHARMANETWORK LLC	**5MG**	**A090635**	**002**	Sep 22, 2020
AA			**10MG**	**A090635**	**001**	Nov 25, 2009
AA		VISTAPHARM LLC	**10MG**	**A204166**	**001**	Mar 16, 2020

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	+!	HIKMA	**40MG**	**N017058**	**001**	
AA		SPECGX LLC	**40MG**	**A077142**	**001**	Jul 12, 2005
AA		VISTAPHARM LLC	**40MG**	**A075082**	**001**	Mar 25, 1998

METHADOSE

AA		SPECGX LLC	**40MG**	**A074184**	**001**	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	+!	AJENAT PHARMS	**5MG**	**N005378**	**002**	

METHAMPHETAMINE HYDROCHLORIDE

AA		DR REDDYS LABS SA	**5MG**	**A091189**	**001**	Apr 21, 2010
AA		HIKMA	**5MG**	**A203846**	**001**	Nov 17, 2015

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANDA REPOSITORY	**25MG**	**A040062**	**001**	Jan 27, 1994
AB	!		**50MG**	**A040062**	**002**	Jan 27, 1994
AB		ANI PHARMS	**25MG**	**A040001**	**001**	Jun 30, 1993
AB			**50MG**	**A040001**	**002**	Jun 30, 1993
AB		BAUSCH AND LOMB INC	**25MG**	**A207438**	**001**	Oct 05, 2018
AB			**50MG**	**A207438**	**002**	Oct 05, 2018
AB		CHARTWELL RX	**25MG**	**A040036**	**001**	Jun 30, 1993
AB			**50MG**	**A040036**	**002**	Jun 30, 1993
AB		TAGI	**25MG**	**A215615**	**001**	Oct 18, 2022
AB			**50MG**	**A215615**	**002**	Oct 18, 2022

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+	ESJAY PHARMA	**1GM**	**N017681**	**001**	

METHENAMINE HIPPURATE

AB	!	AUROBINDO PHARMA LTD	**1GM**	**A205661**	**001**	Jul 05, 2016
AB		JUBILANT CADISTA	**1GM**	**A217675**	**001**	Dec 01, 2023
AB		MICRO LABS	**1GM**	**A212172**	**001**	Aug 01, 2019
AB		NOVAST LABS	**1GM**	**A210068**	**001**	Nov 27, 2020
AB		ZYDUS LIFESCIENCES	**1GM**	**A219661**	**001**	Mar 10, 2025

UREX

AB		QUAGEN	**1GM**	**N016151**	**001**	

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		AIPING PHARM INC	**5MG**	**A040547**	**001**	Feb 18, 2005
AB			**10MG**	**A040547**	**002**	Feb 18, 2005
AB		BIONPHARMA	**5MG**	**A218149**	**001**	Sep 25, 2023
AB			**10MG**	**A218149**	**002**	Sep 25, 2023
AB		CHARTWELL RX	**5MG**	**A040411**	**001**	Mar 27, 2001
AB			**10MG**	**A040411**	**002**	Mar 27, 2001
AB		HERITAGE PHARMA	**5MG**	**A040734**	**001**	Dec 14, 2007
AB			**10MG**	**A040734**	**002**	Dec 14, 2007
AB		MACLEODS PHARMS LTD	**5MG**	**A209827**	**001**	May 24, 2023

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB			**10MG**	**A209827**	**002**	May 24, 2023
AB		MYLAN	**5MG**	**A040350**	**001**	Mar 29, 2000
AB	**!**		**10MG**	**A040350**	**002**	Mar 29, 2000
AB		RISING	**5MG**	**A202068**	**001**	Mar 07, 2012
AB			**10MG**	**A202068**	**002**	Mar 07, 2012
AB		SQUARE PHARMS PLC	**5MG**	**A218830**	**001**	Feb 05, 2025
AB			**10MG**	**A218830**	**002**	Feb 05, 2025

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		AM REGENT	**1GM/10ML (100MG/ML)**	**A207496**	**001**	Jun 22, 2017
AP		EUGIA PHARMA	**1GM/10ML (100MG/ML)**	**A206128**	**001**	May 27, 2016
AP		FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**A209331**	**001**	Apr 17, 2018
AP		GLAND	**1GM/10ML (100MG/ML)**	**A211504**	**001**	Oct 26, 2018
AP		MONTEREY PHARMS LLC	**1GM/10ML (100MG/ML)**	**A205354**	**001**	Oct 27, 2016
AP		SAGENT PHARMS INC	**1GM/10ML (100MG/ML)**	**A205404**	**001**	Jul 18, 2017
AP		SLATE RUN PHARMA	**1GM/10ML (100MG/ML)**	**A208116**	**001**	Jan 19, 2017
AP		SOMERSET THERAPS LLC	**1GM/10ML (100MG/ML)**	**A207522**	**001**	Jul 31, 2017

ROBAXIN

AP	**+!**	HIKMA	**1GM/10ML (100MG/ML)**	**N011790**	**001**	

SUSPENSION;ORAL

ATMEKSI

	+!	ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025

TABLET;ORAL

METHOCARBAMOL

AA		AUROBINDO PHARMA LTD	**500MG**	**A213967**	**002**	Feb 09, 2023
AA			**750MG**	**A213967**	**001**	Aug 12, 2020
AA		BOSTAL	**500MG**	**A200958**	**001**	Oct 21, 2011
AA			**750MG**	**A200958**	**002**	Oct 21, 2011
AA	**!**	GRANULES	**500MG**	**A209312**	**001**	May 07, 2018
AA	**!**		**750MG**	**A209312**	**002**	May 07, 2018
AA		HETERO LABS LTD III	**500MG**	**A090200**	**001**	Nov 06, 2009
AA			**750MG**	**A090200**	**002**	Nov 06, 2009
AA		OXFORD PHARMS	**500MG**	**A040489**	**001**	Jan 29, 2003
AA			**750MG**	**A040489**	**002**	Jan 29, 2003
AA		PHARMOBEDIENT	**500MG**	**A203550**	**001**	Feb 08, 2017
AA			**750MG**	**A203550**	**002**	Feb 08, 2017
AA		POINTVIEW HLDINGS	**500MG**	**A212623**	**001**	Apr 30, 2021
AA			**750MG**	**A212623**	**002**	Apr 30, 2021
AA		PRINSTON INC	**500MG**	**A086988**	**002**	
AA			**750MG**	**A086988**	**001**	
AA		REGCON HOLDINGS	**500MG**	**A208507**	**001**	Jul 21, 2017
AA			**750MG**	**A208507**	**002**	Jul 21, 2017
AB	**!**	BOSTAL	**1GM**	**A200958**	**003**	Dec 06, 2021
AB		MIKART	**1GM**	**A212707**	**001**	Jun 12, 2023

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

AP	**+!**	PH HEALTH	**500MG/VIAL**	**N011559**	**001**	

METHOHEXITAL SODIUM

AP		ONESOURCE SPECIALTY	**500MG/VIAL**	**A215488**	**001**	Oct 03, 2024

METHOTREXATE

SOLUTION;ORAL

JYLAMVO

	+!	SHORLA	2MG/ML	N212479	001	Nov 29, 2022

SOLUTION;SUBCUTANEOUS

RASUVO

	+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

METHOTREXATE SODIUM							
INJECTABLE;INJECTION							
METHOTREXATE PRESERVATIVE FREE							
AP		FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
METHOTREXATE SODIUM							
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
AP	**+!**	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
METHOTREXATE SODIUM PRESERVATIVE FREE							
AP	**!**	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP	**!**		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP	**!**	HIKMA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
AP	**!**		**EQ 1GM BASE/VIAL**	**A040632**	**001**	Aug 12, 2005
AP	**+!**	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP		PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040843**	**002**	Jan 11, 2010
AP			**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A040843**	**003**	Feb 27, 2012
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040843**	**004**	Jan 11, 2010
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP		SAGENT PHARMS INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A203407**	**001**	Aug 09, 2018
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A203407**	**002**	Aug 09, 2018
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A203407**	**003**	Aug 09, 2018
AP		SANDOZ	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
METHOTREXATE SODIUM							
	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
SOLUTION;ORAL							
XATMEP							
	+!	AZURITY	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017
TABLET;ORAL							
METHOTREXATE SODIUM							
AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A213343**	**001**	Jan 24, 2020
AB		ALEMBIC	**EQ 2.5MG BASE**	**A217552**	**001**	Jun 03, 2024
AB		BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB		DAITO	**EQ 2.5MG BASE**	**A213362**	**001**	Aug 07, 2023
AB		ELITE LABS INC	**EQ 2.5MG BASE**	**A216453**	**001**	May 16, 2024
AB		EUGIA PHARMA	**EQ 2.5MG BASE**	**A210454**	**001**	Jan 30, 2020
AB	**!**	HIKMA	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
AB		MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB		SUN PHARM	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A207812**	**001**	Jan 13, 2017
TREXALL							
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001
METHOXSALEN							
CAPSULE;ORAL							
METHOXSALEN							
AB		ONESOURCE SPECIALTY	**10MG**	**A202687**	**001**	Jun 05, 2014
OXSORALEN-ULTRA							
AB	**+!**	BAUSCH	**10MG**	**N019600**	**001**	Oct 30, 1986
INJECTABLE;INJECTION							
UVADEX							
	+!	THERAKOS DEVELOPMENT	0.02MG/ML	N020969	001	Feb 25, 1999
METHSCOPOLAMINE BROMIDE							
TABLET;ORAL							
METHSCOPOLAMINE BROMIDE							
AA		BRECKENRIDGE PHARM	**2.5MG**	**A040642**	**001**	Dec 06, 2011
AA			**5MG**	**A040642**	**002**	Dec 06, 2011
AA		NE RX PHARMA	**2.5MG**	**A216786**	**001**	Feb 01, 2024
AA			**5MG**	**A216786**	**002**	Feb 01, 2024
AA		UNICHEM	**2.5MG**	**A200602**	**001**	Sep 24, 2012
AA	**!**		**5MG**	**A200602**	**002**	Sep 24, 2012

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

AB	**+!**	PARKE DAVIS	**300MG**	**N010596**	**008**	

METHSUXIMIDE

AB		NOVITIUM PHARMA	**300MG**	**A217213**	**001**	May 01, 2023

METHYLDOPA

TABLET;ORAL

METHYLDOPA

		RISING	250MG	A070076	002	Apr 18, 1985
	!		500MG	A070076	001	Apr 18, 1985

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP		CHENGDU SHUODE	**50MG/10ML (5MG/ML)**	**A219550**	**001**	Dec 23, 2025
AP		HIKMA	**50MG/10ML (5MG/ML)**	**A216959**	**001**	Dec 17, 2024
AP		MEITHEAL	**50MG/10ML (5MG/ML)**	**A217380**	**001**	Jan 23, 2025
AP		NEXUS	**50MG/10ML (5MG/ML)**	**A217561**	**001**	Nov 21, 2024
AP		STERISCIENCE	**50MG/10ML (5MG/ML)**	**A216955**	**001**	Nov 22, 2024
AP		XIROMED	**50MG/10ML (5MG/ML)**	**A219363**	**001**	Jul 30, 2025
AP		ZYDUS LIFESCIENCES	**10MG/2ML (5MG/ML)**	**A215636**	**001**	Dec 05, 2023
AP			**50MG/10ML (5MG/ML)**	**A215636**	**002**	Dec 05, 2023

PROVAYBLUE

AP	**+!**	PROVEPHARM SAS	**10MG/2ML (5MG/ML)**	**N204630**	**002**	Jul 18, 2019
AP	**+!**		**50MG/10ML (5MG/ML)**	**N204630**	**001**	Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION

METHYLERGONOVINE MALEATE

AP	**!**	AM REGENT	**0.2MG/ML**	**A090193**	**001**	Nov 24, 2008
AP		BRECKENRIDGE	**0.2MG/ML**	**A040889**	**001**	Sep 13, 2010

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB		AMNEAL PHARMS	**0.2MG**	**A211483**	**001**	Sep 10, 2018
AB	**!**	CHARTWELL RX	**0.2MG**	**A091577**	**001**	May 02, 2011
AB		GRANULES	**0.2MG**	**A210424**	**001**	May 15, 2018
AB		RISING	**0.2MG**	**A211919**	**001**	Jan 15, 2021
AB		TEVA PHARMS USA	**0.2MG**	**A211455**	**001**	Mar 20, 2019
AB		TP ANDA HOLDINGS	**0.2MG**	**A212233**	**001**	May 01, 2020

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

RELISTOR

	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010

TABLET;ORAL

RELISTOR

	+!	SALIX	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

AB	**+**	NOVEN PHARMS INC	**10MG/9HR (1.1MG/HR)**	**N021514**	**001**	Apr 06, 2006
AB	**+**		**15MG/9HR (1.6MG/HR)**	**N021514**	**002**	Apr 06, 2006
AB	**+**		**20MG/9HR (2.2MG/HR)**	**N021514**	**003**	Apr 06, 2006
AB	**+!**		**30MG/9HR (3.3MG/HR)**	**N021514**	**004**	Apr 06, 2006

METHYLPHENIDATE

AB		MYLAN TECH VIATRIS	**10MG/9HR (1.1MG/HR)**	**A206497**	**001**	Mar 14, 2022
AB			**15MG/9HR (1.6MG/HR)**	**A206497**	**002**	Mar 14, 2022
AB			**20MG/9HR (2.2MG/HR)**	**A206497**	**003**	Mar 14, 2022
AB			**30MG/9HR (3.3MG/HR)**	**A206497**	**004**	Mar 14, 2022

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
	+		17.3MG	N205489	002	Jun 19, 2017
	+!		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1		DR REDDYS LABS SA	**10MG**	**A200886**	**001**	Feb 26, 2018
AB1			**20MG**	**A078458**	**001**	Dec 01, 2011
AB1			**30MG**	**A078458**	**002**	Dec 01, 2011
AB1			**40MG**	**A078458**	**003**	Dec 01, 2011
AB1	!		**60MG**	**A078458**	**004**	Jun 23, 2016
AB1		GRANULES	**10MG**	**A211796**	**001**	May 23, 2019
AB1			**20MG**	**A211796**	**002**	May 23, 2019
AB1			**30MG**	**A211796**	**003**	May 23, 2019
AB1			**40MG**	**A211796**	**004**	May 23, 2019
AB1			**60MG**	**A211796**	**005**	May 23, 2019

RITALIN LA

AB1	+	SANDOZ	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1	+		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1	+		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1	+		**40MG**	**N021284**	**003**	Jun 05, 2002

METADATE CD

AB2	+	AYTU BIOPHARMA	**10MG**	**N021259**	**003**	May 27, 2003
AB2	+		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2	+		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2	+		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2	+		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	+!		**60MG**	**N021259**	**006**	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

AB2		IMPAX LABS INC	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2			**20MG**	**A205105**	**002**	Jul 28, 2016
AB2			**30MG**	**A205105**	**003**	Jul 28, 2016
AB2			**40MG**	**A205105**	**004**	Jul 28, 2016
AB2			**50MG**	**A205105**	**005**	Jul 28, 2016
AB2			**60MG**	**A205105**	**006**	Jul 28, 2016
AB2		SPECGX LLC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2			**20MG**	**A203583**	**002**	Sep 29, 2015
AB2			**30MG**	**A203583**	**003**	Sep 29, 2015
AB2			**40MG**	**A203583**	**004**	Sep 29, 2015
AB2			**50MG**	**A203583**	**005**	Sep 29, 2015
AB2			**60MG**	**A203583**	**006**	Sep 29, 2015
AB2		TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2			**20MG**	**A077707**	**002**	Jul 19, 2012
AB2			**30MG**	**A077707**	**003**	Jul 19, 2012

APTENSIO XR

AB3	+	RHODES PHARMS	**10MG**	**N205831**	**001**	Apr 17, 2015
AB3	+		**15MG**	**N205831**	**002**	Apr 17, 2015
AB3	+		**20MG**	**N205831**	**003**	Apr 17, 2015
AB3	+		**30MG**	**N205831**	**004**	Apr 17, 2015
AB3	+		**40MG**	**N205831**	**005**	Apr 17, 2015
AB3	+		**50MG**	**N205831**	**006**	Apr 17, 2015
AB3	+!		**60MG**	**N205831**	**007**	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

AB3		ACTAVIS ELIZABETH	**10MG**	**A208861**	**001**	Dec 13, 2018
AB3			**15MG**	**A208861**	**002**	Dec 13, 2018
AB3			**20MG**	**A208861**	**003**	Dec 13, 2018
AB3			**30MG**	**A208861**	**004**	Dec 13, 2018
AB3			**40MG**	**A208861**	**005**	Dec 13, 2018
AB3			**50MG**	**A208861**	**006**	Dec 13, 2018
AB3			**60MG**	**A208861**	**007**	Dec 13, 2018

JORNAY PM

	+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
	+		40MG	N209311	002	Aug 08, 2018
	+		60MG	N209311	003	Aug 08, 2018
	+		80MG	N209311	004	Aug 08, 2018
	+!		100MG	N209311	005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG/ML**	**A206049**	**001**	May 17, 2018

QUILLIVANT XR

AB	+!	NEXTWAVE	**5MG/ML**	**N202100**	**001**	Sep 27, 2012

SOLUTION;ORAL

METHYLIN

AA	+!	SPECGX LLC	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	+!		**10MG/5ML**	**N021419**	**002**	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA		ABHAI LLC	5MG/5ML	A207485	001	Nov 18, 2016
AA			10MG/5ML	A207485	002	Nov 18, 2016
AA		ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020
AA			10MG/5ML	A211647	002	Mar 30, 2020
AA		ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020
AA			10MG/5ML	A210764	002	Apr 10, 2020
AA		ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021
AA			10MG/5ML	A207417	002	Jan 29, 2021
AA		HIBROW HLTHCARE	5MG/5ML	A210139	001	Oct 03, 2018
AA			10MG/5ML	A210139	002	Oct 03, 2018
AA		NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015
AA			10MG/5ML	A204602	002	Aug 14, 2015
AA		QUAGEN	5MG/5ML	A213567	001	Jun 04, 2020
AA			10MG/5ML	A213567	002	Jun 04, 2020
AA		TRIS PHARMA INC	5MG/5ML	A091601	001	Jul 23, 2010
AA			10MG/5ML	A091601	002	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI LLC	5MG	A206932	001	May 11, 2017
AB			10MG	A206932	002	May 11, 2017
AB			20MG	A206932	003	May 11, 2017
AB		ACCORD HLTHCARE	5MG	A213936	001	Oct 28, 2020
AB			10MG	A213936	002	Oct 28, 2020
AB			20MG	A213936	003	Oct 28, 2020
AB		ALKEM LABS LTD	5MG	A211779	001	Oct 04, 2019
AB			10MG	A211779	002	Oct 04, 2019
AB			20MG	A211779	003	Oct 04, 2019
AB		ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015
AB			10MG	A207416	002	Sep 22, 2015
AB			20MG	A207416	003	Sep 22, 2015
AB		BIONPHARMA	5MG	A209753	001	Mar 02, 2018
AB			10MG	A209753	002	Mar 02, 2018
AB			20MG	A209753	003	Mar 02, 2018
AB		CEDIPROF INC	5MG	A208737	001	Feb 01, 2019
AB			10MG	A208737	002	Feb 01, 2019
AB			20MG	A208737	003	Feb 01, 2019
AB		NOVEL LABS INC	5MG	A207884	001	Nov 13, 2015
AB			10MG	A207884	002	Nov 13, 2015
AB			20MG	A207884	003	Nov 13, 2015
AB		OXFORD PHARMS	5MG	A202892	001	Sep 23, 2014
AB			10MG	A202892	002	Sep 23, 2014
AB			20MG	A202892	003	Sep 23, 2014
AB		PRINSTON INC	5MG	A212697	001	Jul 23, 2020
AB			10MG	A212697	002	Jul 23, 2020
AB			20MG	A212697	003	Jul 23, 2020
AB		SPECGX LLC	5MG	A040300	001	Nov 27, 1998
AB			10MG	A040300	002	Nov 27, 1998
AB			20MG	A040300	003	Nov 27, 1998
AB		SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012
AB			10MG	A090710	002	Mar 15, 2012
AB			20MG	A090710	003	Mar 15, 2012

RITALIN

AB	+	SANDOZ	5MG	N010187	003	
AB	+		10MG	N010187	006	
AB	+!		20MG	N010187	010	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	2.5MG	A210354	001	Dec 29, 2017
AB			5MG	A210354	002	Dec 29, 2017
AB	!		10MG	A210354	003	Dec 29, 2017
AB		RISING	2.5MG	A205756	001	Nov 07, 2016
AB			5MG	A205756	002	Nov 07, 2016
AB			10MG	A205756	003	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	+	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000
AB	+		27MG	N021121	004	Apr 01, 2002
AB	+		36MG	N021121	002	Aug 01, 2000
AB	+!		54MG	N021121	003	Dec 08, 2000

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

AB	SPECGX LLC	**10MG**	**A075629**	**001**	May 09, 2000
AB		**20MG**	**A075629**	**002**	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI LLC	**10MG**	**A207488**	**001**	Jun 09, 2015
AB !		**20MG**	**A207488**	**002**	Jun 09, 2015
AB	ACTAVIS LABS FL	**18MG**	**A076772**	**001**	Mar 22, 2018
AB		**27MG**	**A076772**	**002**	Mar 22, 2018
AB		**36MG**	**A076772**	**003**	Mar 22, 2018
AB		**54MG**	**A076655**	**001**	Mar 21, 2018
AB		**72MG**	**A076655**	**002**	Feb 28, 2022
AB	ALKEM LABS LTD	**18MG**	**A214447**	**001**	May 23, 2023
AB		**20MG**	**A212288**	**001**	Oct 06, 2020
AB		**27MG**	**A214447**	**002**	May 23, 2023
AB		**36MG**	**A214447**	**003**	May 23, 2023
AB		**54MG**	**A214447**	**004**	May 23, 2023
AB	ANDOR PHARMS	**18MG**	**A211918**	**001**	Apr 24, 2019
AB		**27MG**	**A211918**	**002**	Apr 24, 2019
AB		**36MG**	**A211918**	**003**	Apr 24, 2019
AB		**54MG**	**A211918**	**004**	Apr 24, 2019
AB	ASCENT PHARMS INC	**18MG**	**A211009**	**001**	Sep 03, 2019
AB		**27MG**	**A211009**	**002**	Sep 03, 2019
AB		**36MG**	**A211009**	**003**	Sep 03, 2019
AB		**54MG**	**A211009**	**004**	Sep 03, 2019
AB	AUROLIFE PHARMA LLC	**18MG**	**A206726**	**001**	Oct 21, 2016
AB		**27MG**	**A206726**	**002**	Oct 21, 2016
AB		**36MG**	**A206726**	**003**	Oct 21, 2016
AB		**54MG**	**A206726**	**004**	Oct 21, 2016
AB	GRANULES	**10MG**	**A210992**	**001**	Nov 21, 2018
AB		**18MG**	**A213473**	**001**	Jul 29, 2020
AB		**20MG**	**A210992**	**002**	Nov 21, 2018
AB		**27MG**	**A213473**	**002**	Jul 29, 2020
AB		**36MG**	**A213473**	**003**	Jul 29, 2020
AB		**54MG**	**A213473**	**004**	Jul 29, 2020
AB	OSMOTICA PHARM US	**18MG**	**A205327**	**001**	Jul 28, 2017
AB		**27MG**	**A205327**	**002**	Jul 28, 2017
AB		**36MG**	**A205327**	**003**	Jul 28, 2017
AB		**54MG**	**A205327**	**004**	Jul 28, 2017
AB !		**72MG**	**A205327**	**005**	Jul 28, 2017
AB	SUN PHARM INDS INC	**18MG**	**A205135**	**001**	Aug 19, 2020
AB		**27MG**	**A205135**	**002**	Aug 19, 2020
AB		**36MG**	**A205135**	**003**	Aug 19, 2020
AB		**54MG**	**A205135**	**004**	Aug 19, 2020
AB		**72MG**	**A217229**	**001**	Aug 25, 2023
BX	LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012

RELEXXII

+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022
+		27MG	N216117	002	Jun 23, 2022
+		36MG	N216117	003	Jun 23, 2022
+		45MG	N216117	004	Jun 23, 2022
+		54MG	N216117	005	Jun 23, 2022
+		63MG	N216117	006	Jun 23, 2022
+!		72MG	N216117	007	Jun 23, 2022

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
+		30MG	N207960	002	Dec 04, 2015
+!		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	**+**	PFIZER	**4MG**	**N011153**	**001**	
AB	**+**		**8MG**	**N011153**	**004**	
AB	**+**		**16MG**	**N011153**	**003**	
AB	**+!**		**32MG**	**N011153**	**006**	

METHYLPREDNISOLONE

AB		JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB			**8MG**	**A040189**	**002**	Oct 31, 1997
AB			**16MG**	**A040189**	**003**	Jul 20, 2007
AB			**32MG**	**A040189**	**004**	Jul 20, 2007
AB		PH HEALTH	**4MG**	**A040183**	**001**	Dec 22, 1998
AB		SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB		TIANJIN TIANYAO	**4MG**	**A204072**	**001**	May 14, 2018
AB		WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997
AB		ZYDUS PHARMS	**4MG**	**A206751**	**001**	Apr 23, 2018
AB			**8MG**	**A206751**	**002**	Apr 23, 2018
AB			**16MG**	**A206751**	**003**	Apr 23, 2018
AB			**32MG**	**A206751**	**004**	Apr 23, 2018

MEDROL

	+	PFIZER	2MG	N011153	002

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	**+**	PFIZER	**40MG/ML**	**N011757**	**001**	
AB	**+**		**80MG/ML**	**N011757**	**004**	

METHYLPREDNISOLONE ACETATE

AB	**!**	AMNEAL	**40MG/ML**	**A210043**	**001**	May 20, 2019
AB			**40MG/ML**	**A216502**	**001**	Nov 03, 2023
AB	**!**		**80MG/ML**	**A210043**	**002**	May 20, 2019
AB			**80MG/ML**	**A216502**	**002**	Nov 03, 2023
AB		EUGIA PHARMA	**40MG/ML**	**A211930**	**001**	Apr 13, 2023
AB			**80MG/ML**	**A211930**	**002**	Apr 13, 2023
AB		HIKMA	**80MG/ML**	**A219145**	**001**	Apr 16, 2025
AB		HONG KONG	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB			**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB		PH HEALTH	**40MG/ML**	**A214297**	**001**	Jan 21, 2022
AB			**80MG/ML**	**A214297**	**002**	Jan 21, 2022
AB	**!**	SAGENT PHARMS INC	**40MG/ML**	**A201835**	**002**	Jun 27, 2018
AB	**!**		**80MG/ML**	**A201835**	**003**	Jun 27, 2018
AB		SANDOZ	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB			**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB			**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB			**80MG/ML**	**A040794**	**002**	Mar 05, 2009
AB		WILSHIRE PHARMS INC	**40MG/ML**	**A214870**	**002**	May 10, 2023
AB			**80MG/ML**	**A214870**	**001**	Jan 03, 2023

DEPO-MEDROL

	+!	PFIZER	20MG/ML	N011757	002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		AMNEAL	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP			**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP		FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP			**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP			**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP		HIKMA	**EQ 40MG BASE/VIAL**	**A203125**	**001**	Sep 26, 2022
AP			**EQ 125MG BASE/VIAL**	**A203125**	**002**	Sep 26, 2022
AP			**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP			**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP		SAGENT PHARMS INC	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP			**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011
AP			**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP			**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP			**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011
AP		TIANJIN KINGYORK	**EQ 40MG BASE/VIAL**	**A212396**	**001**	Apr 20, 2021
AP			**EQ 125MG BASE/VIAL**	**A212396**	**002**	Apr 20, 2021
AP			**EQ 500MG BASE/VIAL**	**A212396**	**003**	Apr 20, 2021
AP			**EQ 1GM BASE/VIAL**	**A212396**	**004**	Apr 20, 2021
AP			**EQ 2GM BASE/VIAL**	**A212396**	**005**	Apr 20, 2021

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

SOLU-MEDROL

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**	
AP	**+!**		**EQ 125MG BASE/VIAL**	**N011856**	**004**	
AP	**+!**		**EQ 500MG BASE/VIAL**	**N011856**	**005**	
AP	**+!**		**EQ 1GM BASE/VIAL**	**N011856**	**006**	
AP	**+!**		**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB	**!**	IMPAX LABS INC	**10MG**	**A204851**	**001**	Sep 21, 2015
AB		NOVITIUM PHARMA	**10MG**	**A215270**	**001**	Feb 18, 2022

TABLET;ORAL

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP		AVET LIFESCIENCES	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP	**!**	HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA	**!**	GENUS	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991

SPRAY, METERED;NASAL

GIMOTI

	+!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		AIPING PHARM INC	**EQ 5MG BASE**	**A072215**	**002**	Nov 05, 2024
AB			**EQ 10MG BASE**	**A072215**	**001**	Jan 30, 1990
AB		IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB			**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB		STRIDES PHARMA INTL	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB			**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB			**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006
AB		TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB			**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985

REGLAN

AB	**+**	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	**+!**		**EQ 10MG BASE**	**N017854**	**001**	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
	!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		ALEMBIC	**2.5MG**	**A213251**	**001**	Dec 02, 2020
AB			**5MG**	**A213251**	**002**	Dec 02, 2020
AB			**10MG**	**A213251**	**003**	Dec 02, 2020
AB		INNOGENIX	**2.5MG**	**A213827**	**001**	Mar 30, 2021
AB			**5MG**	**A213827**	**002**	Mar 30, 2021
AB			**10MG**	**A213827**	**003**	Mar 30, 2021
AB		IXORA LIFESCIENCE	**2.5MG**	**A218606**	**001**	Apr 17, 2024
AB			**5MG**	**A218606**	**002**	Apr 17, 2024
AB			**10MG**	**A218606**	**003**	Apr 17, 2024
AB		MICRO LABS	**2.5MG**	**A217563**	**001**	Nov 06, 2024
AB			**5MG**	**A217563**	**002**	Nov 06, 2024
AB			**10MG**	**A217563**	**003**	Nov 06, 2024
AB		MYLAN	**2.5MG**	**A076698**	**001**	Dec 23, 2003
AB			**5MG**	**A076698**	**002**	Oct 19, 2004
AB			**10MG**	**A076698**	**003**	Oct 19, 2004
AB		NE RX PHARMA	**2.5MG**	**A216216**	**001**	Oct 25, 2022
AB			**5MG**	**A216216**	**002**	Oct 25, 2022
AB			**10MG**	**A216216**	**003**	Oct 25, 2022
AB		RENATA	**2.5MG**	**A215616**	**001**	Oct 24, 2022

METOLAZONE

TABLET;ORAL

METOLAZONE

AB			**5MG**	**A215616**	**002**	Oct 24, 2022
AB			**10MG**	**A215616**	**003**	Oct 24, 2022
AB		RUBICON RESEARCH	**2.5MG**	**A215184**	**001**	Aug 20, 2021
AB			**5MG**	**A215184**	**002**	Aug 20, 2021
AB			**10MG**	**A215184**	**003**	Aug 20, 2021
AB		SANDOZ	**2.5MG**	**A076732**	**001**	Dec 19, 2003
AB	!		**5MG**	**A076466**	**001**	Dec 19, 2003
AB	!		**10MG**	**A076466**	**002**	Dec 19, 2003
AB		UNICHEM	**2.5MG**	**A214799**	**001**	Mar 30, 2021
AB			**5MG**	**A214799**	**002**	Mar 30, 2021
AB			**10MG**	**A214799**	**003**	Mar 30, 2021

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS ELIZABETH	**EQ 25MG TARTRATE**	**A204161**	**001**	Nov 25, 2016
AB			**EQ 50MG TARTRATE**	**A204161**	**002**	Nov 25, 2016
AB			**EQ 100MG TARTRATE**	**A204161**	**003**	Nov 25, 2016
AB			**EQ 200MG TARTRATE**	**A204161**	**004**	Nov 25, 2016
AB		ACTAVIS LABS FL INC	**EQ 50MG TARTRATE**	**A076862**	**001**	Aug 03, 2009
AB		ALKEM LABS LTD	**EQ 25MG TARTRATE**	**A211143**	**001**	Nov 25, 2020
AB			**EQ 50MG TARTRATE**	**A211143**	**002**	Nov 25, 2020
AB			**EQ 100MG TARTRATE**	**A211143**	**003**	Nov 25, 2020
AB			**EQ 200MG TARTRATE**	**A211143**	**004**	Nov 25, 2020
AB		CIPLA	**EQ 50MG TARTRATE**	**A207465**	**001**	Oct 26, 2018
AB			**EQ 100MG TARTRATE**	**A207465**	**002**	Oct 26, 2018
AB			**EQ 200MG TARTRATE**	**A207465**	**003**	Oct 26, 2018
AB		DR REDDYS LABS LTD	**EQ 25MG TARTRATE**	**A090617**	**001**	Aug 01, 2012
AB			**EQ 50MG TARTRATE**	**A090617**	**002**	Aug 01, 2012
AB		GRANULES	**EQ 25MG TARTRATE**	**A216916**	**001**	Jun 12, 2023
AB			**EQ 50MG TARTRATE**	**A216916**	**002**	Jun 12, 2023
AB			**EQ 100MG TARTRATE**	**A216916**	**003**	Jun 12, 2023
AB			**EQ 200MG TARTRATE**	**A216916**	**004**	Jun 12, 2023
AB		HETERO LABS LTD III	**EQ 25MG TARTRATE**	**A205541**	**001**	Nov 06, 2020
AB			**EQ 50MG TARTRATE**	**A205541**	**002**	Nov 06, 2020
AB			**EQ 100MG TARTRATE**	**A205541**	**003**	Nov 06, 2020
AB			**EQ 200MG TARTRATE**	**A205541**	**004**	Nov 06, 2020
AB		IPCA LABS LTD	**EQ 25MG TARTRATE**	**A206980**	**001**	Jun 25, 2025
AB			**EQ 50MG TARTRATE**	**A206980**	**002**	Jun 25, 2025
AB			**EQ 100MG TARTRATE**	**A206980**	**003**	Jun 25, 2025
AB			**EQ 200MG TARTRATE**	**A206980**	**004**	Jun 25, 2025
AB		MYLAN PHARMS INC	**EQ 25MG TARTRATE**	**A202033**	**001**	Dec 15, 2011
AB			**EQ 50MG TARTRATE**	**A202033**	**002**	Dec 15, 2011
AB			**EQ 100MG TARTRATE**	**A202033**	**003**	Dec 15, 2011
AB			**EQ 200MG TARTRATE**	**A202033**	**004**	Dec 15, 2011
AB		NOVAST LABS	**EQ 25MG TARTRATE**	**A204106**	**001**	Feb 06, 2018
AB			**EQ 50MG TARTRATE**	**A204106**	**002**	Feb 06, 2018
AB			**EQ 100MG TARTRATE**	**A204106**	**003**	Feb 06, 2018
AB			**EQ 200MG TARTRATE**	**A204106**	**004**	Feb 06, 2018
AB		PHARMADAX INC	**EQ 25MG TARTRATE**	**A203028**	**001**	Mar 31, 2020
AB			**EQ 50MG TARTRATE**	**A203028**	**002**	Mar 31, 2020
AB			**EQ 100MG TARTRATE**	**A203699**	**001**	Mar 30, 2020
AB			**EQ 200MG TARTRATE**	**A203699**	**002**	Mar 30, 2020
AB		REDDYS	**EQ 100MG TARTRATE**	**A078889**	**001**	Aug 15, 2012
AB			**EQ 200MG TARTRATE**	**A078889**	**002**	Aug 15, 2012
AB		SUNSHINE	**EQ 25MG TARTRATE**	**A214004**	**004**	May 23, 2024
AB			**EQ 50MG TARTRATE**	**A214004**	**001**	Sep 26, 2022
AB			**EQ 100MG TARTRATE**	**A214004**	**002**	Sep 26, 2022
AB			**EQ 200MG TARTRATE**	**A214004**	**003**	Sep 26, 2022
AB		VISUM PHARM	**EQ 25MG TARTRATE**	**A207206**	**001**	Dec 19, 2018
AB			**EQ 50MG TARTRATE**	**A207206**	**002**	Dec 19, 2018
AB			**EQ 100MG TARTRATE**	**A207206**	**003**	Dec 19, 2018
AB			**EQ 200MG TARTRATE**	**A207206**	**004**	Dec 19, 2018
AB		WOCKHARDT BIO AG	**EQ 25MG TARTRATE**	**A090615**	**001**	Jul 22, 2010

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB			**EQ 50MG TARTRATE**	**A090615**	**002**	Jul 22, 2010
AB			**EQ 100MG TARTRATE**	**A090615**	**003**	Jul 22, 2010
AB			**EQ 200MG TARTRATE**	**A090615**	**004**	Jul 22, 2010
AB		YICHANG HUMANWELL	**EQ 25MG TARTRATE**	**A213854**	**004**	Aug 01, 2022
AB			**EQ 50MG TARTRATE**	**A213854**	**003**	Nov 08, 2021
AB			**EQ 100MG TARTRATE**	**A213854**	**001**	Feb 12, 2021
AB			**EQ 200MG TARTRATE**	**A213854**	**002**	Feb 12, 2021
AB		ZHEJIANG JUTAI PHARM	**EQ 50MG TARTRATE**	**A214110**	**001**	Jul 26, 2024
AB			**EQ 100MG TARTRATE**	**A214110**	**002**	Jul 26, 2024
AB			**EQ 200MG TARTRATE**	**A214110**	**003**	Jul 26, 2024
AB		ZYDUS PHARMS	**EQ 25MG TARTRATE**	**A203894**	**001**	Mar 23, 2018
AB			**EQ 50MG TARTRATE**	**A203894**	**002**	Mar 23, 2018
AB			**EQ 100MG TARTRATE**	**A203894**	**003**	Mar 23, 2018
AB			**EQ 200MG TARTRATE**	**A203894**	**004**	Mar 23, 2018

TOPROL-XL

AB	**+**	MELINTA THERAP	**EQ 25MG TARTRATE**	**N019962**	**004**	Feb 05, 2001
AB	**+!**		**EQ 50MG TARTRATE**	**N019962**	**001**	Jan 10, 1992
AB	**+**		**EQ 100MG TARTRATE**	**N019962**	**002**	Jan 10, 1992
AB	**+!**		**EQ 200MG TARTRATE**	**N019962**	**003**	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	**1MG/ML**	**A078950**	**001**	Apr 29, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A091045**	**001**	Oct 25, 2010
AP		GLAND	**1MG/ML**	**A204205**	**001**	Aug 27, 2014
AP		HIKMA	**1MG/ML**	**A076495**	**001**	Jul 07, 2003
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A077761**	**001**	May 30, 2007
AP	**!**	HOSPIRA	**1MG/ML**	**A078085**	**001**	Apr 29, 2008
AP		SANDOZ	**1MG/ML**	**A077360**	**001**	Oct 02, 2007

SOLUTION;ORAL

LOPRESSOR

	+!	RUBICON RESEARCH	10MG/ML	N219373	001	Apr 10, 2025

TABLET;ORAL

LOPRESSOR

AB	**+**	VALIDUS PHARMS	**50MG**	**N017963**	**001**	
AB	**+**		**100MG**	**N017963**	**002**	

METOPROLOL TARTRATE

AB		ALEMBIC PHARMS LTD	**25MG**	**A202871**	**001**	May 28, 2013
AB			**50MG**	**A202871**	**002**	May 28, 2013
AB			**100MG**	**A202871**	**003**	May 28, 2013
AB		AUROBINDO PHARMA	**25MG**	**A077739**	**001**	Sep 11, 2007
AB			**37.5MG**	**A077739**	**004**	Dec 07, 2023
AB			**50MG**	**A077739**	**002**	Sep 11, 2007
AB			**75MG**	**A077739**	**005**	Dec 07, 2023
AB			**100MG**	**A077739**	**003**	Sep 11, 2007
AB		IPCA LABS LTD	**25MG**	**A078459**	**001**	Jun 17, 2008
AB			**50MG**	**A078459**	**002**	Jun 17, 2008
AB			**100MG**	**A078459**	**003**	Jun 17, 2008
AB		MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB			**37.5MG**	**A076704**	**004**	Mar 18, 2015
AB			**50MG**	**A076704**	**002**	Jan 16, 2004
AB			**75MG**	**A076704**	**005**	Mar 18, 2015
AB	**!**		**100MG**	**A076704**	**003**	Jan 16, 2004
AB		RENATA	**50MG**	**A074453**	**001**	Apr 27, 1995
AB			**100MG**	**A074453**	**002**	Apr 27, 1995
AB		RUBICON RESEARCH	**25MG**	**A200981**	**001**	Oct 28, 2014
AB			**37.5MG**	**A200981**	**004**	Aug 21, 2019
AB			**50MG**	**A200981**	**002**	Oct 28, 2014
AB			**75MG**	**A200981**	**005**	Aug 21, 2019
AB			**100MG**	**A200981**	**003**	Oct 28, 2014
AB		SCIEGEN PHARMS	**25MG**	**A208955**	**001**	Feb 05, 2020
AB			**50MG**	**A208955**	**002**	Feb 05, 2020
AB			**100MG**	**A208955**	**003**	Feb 05, 2020
AB		SUN PHARM INDS INC	**50MG**	**A074644**	**001**	Dec 10, 1996
AB			**100MG**	**A074644**	**002**	Dec 10, 1996

LOPRESSOR

	+!	XTM CONSULTING	12.5MG	N218698	001	Aug 28, 2025

METRONIDAZOLE							
CAPSULE;ORAL							
FLAGYL							
AB	**+!**	PFIZER	**375MG**	**N020334**	**001**	May 03, 1995	
METRONIDAZOLE							
AB		ALEMBIC	**375MG**	**A079065**	**001**	Jun 23, 2009	
AB		CHARTWELL RX	**375MG**	**A076522**	**001**	Jan 29, 2004	
CREAM;TOPICAL							
METROCREAM							
AB	**+**	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995	
METRONIDAZOLE							
AB		AUROBINDO PHARMA LTD	**0.75%**	**A219295**	**001**	Jul 09, 2025	
AB		COSETTE	**0.75%**	**A077549**	**001**	Dec 19, 2007	
AB	**!**	FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004	
BX		ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	
NORITATE							
	+!	BAUSCH	1%	N020743	001	Sep 26, 1997	
GEL;TOPICAL							
METROGEL							
AB	**+!**	GALDERMA LABS LP	**1%**	**N021789**	**001**	Jun 30, 2005	
METRONIDAZOLE							
AB		ALEMBIC	**1%**	**A212646**	**001**	Sep 03, 2021	
AB		AUROBINDO PHARMA LTD	**1%**	**A218941**	**001**	Oct 15, 2024	
AB	**!**	COSETTE	**0.75%**	**A078178**	**001**	Jan 19, 2011	
AB			**1%**	**A216692**	**001**	Jan 23, 2023	
AB		ENCUBE	**0.75%**	**A077547**	**001**	Jul 13, 2006	
AB		FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006	
AB		TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006	
AB			**1%**	**A204651**	**001**	Mar 14, 2017	
GEL;VAGINAL							
METRONIDAZOLE							
AB		COSETTE	**0.75%**	**A216323**	**001**	Jul 12, 2023	
AB	**!**	ENCUBE	**0.75%**	**A215610**	**001**	Jun 16, 2023	
AB		GLENMARK PHARMS LTD	**0.75%**	**A215794**	**001**	Jan 27, 2022	
AB		PADAGIS ISRAEL	**0.75%**	**A211786**	**001**	Jul 02, 2019	
AB		SCIEGEN PHARMS	**0.75%**	**A216750**	**001**	Dec 31, 2024	
AB		SOLARIS PHARMA CORP	**0.75%**	**A213648**	**001**	Oct 14, 2021	
VANDAZOLE							
BX	!	TEVA PHARMS	0.75%	N021806	001	May 20, 2005	
NUVESSA							
	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	
INJECTABLE;INJECTION							
FLAGYL I.V. RTU IN PLASTIC CONTAINER							
AP	**+!**	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**		
METRO I.V. IN PLASTIC CONTAINER							
AP	**+!**	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983	
METRONIDAZOLE IN PLASTIC CONTAINER							
AP		AMNEAL	**500MG/100ML**	**A217665**	**001**	May 24, 2023	
AP		GLAND	**500MG/100ML**	**A212435**	**001**	Aug 03, 2020	
AP	**+!**	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983	
AP		INFORLIFE	**500MG/100ML**	**A206191**	**001**	Feb 25, 2019	
LOTION;TOPICAL							
METROLOTION							
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998	
METRONIDAZOLE							
AB		FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006	
SUSPENSION;ORAL							
LIKMEZ							
	+!	SAPTALIS PHARMS	500MG/5ML	N216755	001	Sep 22, 2023	
TABLET;ORAL							
METRONIDAZOLE							
AB		ALEMBIC	**250MG**	**A208681**	**001**	Jun 20, 2017	
AB			**500MG**	**A208681**	**002**	Jun 20, 2017	
AB		ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009	
AB			**500MG**	**A079067**	**002**	Mar 13, 2009	
AB		AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015	
AB	**!**		**500MG**	**A203974**	**002**	May 29, 2015	
AB		CADILA	**250MG**	**A206560**	**001**	Nov 16, 2016	
AB			**500MG**	**A206560**	**002**	Nov 16, 2016	
AB		CADILA PHARMS LTD	**250MG**	**A209794**	**001**	Dec 12, 2017	

METRONIDAZOLE
TABLET;ORAL
METRONIDAZOLE

AB			**500MG**	**A209794**	**002**	Dec 12, 2017
AB		INNOGENIX	**250MG**	**A070772**	**001**	Jul 16, 1986
AB			**500MG**	**A070772**	**002**	Jul 16, 1986
AB		NOVITIUM PHARMA	**250MG**	**A208162**	**001**	May 25, 2016
AB			**500MG**	**A208162**	**002**	May 25, 2016
AB		PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB		SOMERSET THERAPS LLC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB			**500MG**	**A205245**	**002**	Sep 23, 2015
AB		TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB		UNICHEM	**250MG**	**A203458**	**001**	Jan 22, 2014
AB			**500MG**	**A203458**	**002**	Jan 22, 2014
AB		WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB		WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985
		INNOGENIX	125MG	A070772	003	Oct 29, 2024

METYRAPONE
CAPSULE;ORAL
METOPIRONE

	+!	ESTEVE	250MG	N012911	002	Aug 09, 1996

METYROSINE
CAPSULE;ORAL
DEMSER

AB	**+!**	BAUSCH	**250MG**	**N017871**	**001**	

METYROSINE

AB		AMNEAL	**250MG**	**A213734**	**001**	Jul 24, 2020
AB		DR REDDYS LABS SA	**250MG**	**A218620**	**001**	Apr 09, 2025
AB		LEADING	**250MG**	**A215541**	**001**	Sep 17, 2024

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

AB		ANI PHARMS	**150MG**	**A074450**	**001**	May 16, 1996
AB			**200MG**	**A074450**	**002**	May 16, 1996
AB			**250MG**	**A074450**	**003**	May 16, 1996
AB		ANNORA PHARMA	**150MG**	**A216463**	**001**	Nov 09, 2022
AB			**200MG**	**A216463**	**002**	Nov 09, 2022
AB			**250MG**	**A216463**	**003**	Nov 09, 2022
AB		CROSSMEDIKA SA	**150MG**	**A213500**	**001**	Jul 22, 2020
AB			**200MG**	**A213500**	**002**	Jul 22, 2020
AB			**250MG**	**A213500**	**003**	Jul 22, 2020
AB		NOVAST LABS	**150MG**	**A214352**	**001**	Jan 25, 2021
AB			**200MG**	**A214352**	**002**	Jan 25, 2021
AB			**250MG**	**A214352**	**003**	Jan 25, 2021
AB		QUAGEN	**150MG**	**A215876**	**001**	Feb 27, 2023
AB			**200MG**	**A215876**	**002**	Feb 27, 2023
AB			**250MG**	**A215876**	**003**	Feb 27, 2023
AB		RISING	**150MG**	**A215315**	**001**	Aug 26, 2022
AB			**200MG**	**A215315**	**002**	Aug 26, 2022
AB			**250MG**	**A215315**	**003**	Aug 26, 2022
AB		SENORES PHARMS	**150MG**	**A214089**	**001**	Oct 01, 2021
AB			**200MG**	**A214089**	**002**	Oct 01, 2021
AB			**250MG**	**A214089**	**003**	Oct 01, 2021
AB		TEVA	**150MG**	**A074377**	**001**	May 16, 1995
AB			**200MG**	**A074377**	**002**	May 16, 1995
AB	**!**		**250MG**	**A074377**	**003**	May 16, 1995

MICAFUNGIN SODIUM
INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP		BIOCON PHARMA	**EQ 50MG BASE/VIAL**	**A216438**	**001**	May 29, 2024
AP			**EQ 100MG BASE/VIAL**	**A216438**	**002**	May 29, 2024
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A207344**	**001**	May 17, 2019
AP	**!**		**EQ 100MG BASE/VIAL**	**A207344**	**002**	May 17, 2019
AP		HIKMA	**EQ 50MG BASE/VIAL**	**A213261**	**001**	Jul 09, 2021
AP			**EQ 100MG BASE/VIAL**	**A213261**	**002**	Jul 09, 2021
AP		JIANGSU HANSOH PHARM	**EQ 50MG BASE/VIAL**	**A213363**	**001**	Jul 09, 2021
AP			**EQ 100MG BASE/VIAL**	**A213363**	**002**	Jul 09, 2021
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A215381**	**001**	Sep 28, 2022
AP			**EQ 100MG BASE/VIAL**	**A215381**	**002**	Sep 28, 2022

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP		QILU PHARM HAINAN	**EQ 50MG BASE/VIAL**	**A219273**	**001**	Apr 03, 2025
AP			**EQ 100MG BASE/VIAL**	**A219273**	**002**	Apr 03, 2025
AP		XELLIA PHARMS APS	**EQ 50MG BASE/VIAL**	**A211713**	**001**	Jun 02, 2021
AP			**EQ 100MG BASE/VIAL**	**A211713**	**002**	Jun 02, 2021
AP		ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A215241**	**001**	Oct 24, 2022
AP			**EQ 100MG BASE/VIAL**	**A215241**	**002**	Oct 24, 2022

POWDER;INTRAVENOUS

MICAFUNGIN

	+!	PH HEALTH	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021
	+!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021

SOLUTION;INTRAVENOUS

MICAFUNGIN IN SODIUM CHLORIDE 0.9%

	+!	BAXTER HLTHCARE CORP	EQ 50MG BASE/50ML (EQ 1MG BASE/ML)	N216142	001	Sep 29, 2023
	+!		EQ 100MG BASE/100ML (EQ 1MG BASE/ML)	N216142	002	Sep 29, 2023
	+!		EQ 150MG BASE/150ML (EQ 1MG BASE/ML)	N216142	003	Sep 29, 2023

MICONAZOLE

TABLET;BUCCAL

ORAVIG

	+!	GALT PHARMS	50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	**200MG**	**A073508**	**001**	Nov 19, 1993

MONISTAT 3

AB	**+!**	MEDTECH PRODUCTS	**200MG**	**N018888**	**001**	Aug 15, 1984

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT;TOPICAL

VUSION

	+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

AP		GLAND	**50MG/50ML (1MG/ML)**	**A218993**	**001**	Aug 12, 2024
AP			**100MG/100ML (1MG/ML)**	**A218993**	**002**	Aug 12, 2024
AP		HIKMA	**50MG/50ML (1MG/ML)**	**A216159**	**001**	Apr 17, 2023
AP			**100MG/100ML (1MG/ML)**	**A216159**	**002**	Apr 17, 2023
AP	**+!**	INFORLIFE	**50MG/50ML (1MG/ML)**	**N211844**	**001**	Mar 22, 2021
AP	**+!**		**100MG/100ML (1MG/ML)**	**N211844**	**002**	Mar 22, 2021

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

	!	B BRAUN MEDICAL	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025
	!		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025

SPRAY;NASAL

NAYZILAM

	+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**	**A090850**	**001**	Jan 25, 2012
AP		HIKMA	**EQ 1MG BASE/ML**	**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**	**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075421**	**002**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A212847**	**001**	Dec 11, 2020
AP			**EQ 5MG BASE/ML**	**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**	**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075421**	**001**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A212847**	**002**	Dec 11, 2020
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**	**A075293**	**001**	Jun 20, 2000
AP	**!**		**EQ 5MG BASE/ML**	**A075293**	**002**	Jun 20, 2000
AP		MICRO LABS	**EQ 1MG BASE/ML**	**A217504**	**001**	Aug 21, 2023
AP			**EQ 5MG BASE/ML**	**A217504**	**002**	Aug 21, 2023
AP		RISING	**EQ 1MG BASE/ML**	**A075494**	**001**	Jun 30, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP			**EQ 5MG BASE/ML**	**A075494**	**002**	Jun 30, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**	**A203460**	**002**	Aug 22, 2014
AP	!	HOSPIRA	**EQ 1MG BASE/ML**	**A075857**	**001**	Jul 22, 2002
AP	!		**EQ 5MG BASE/ML**	**A075857**	**002**	Jul 22, 2002
AP		ONESOURCE SPECIALTY	**EQ 1MG BASE/ML**	**A090315**	**001**	Nov 29, 2010
AP			**EQ 5MG BASE/ML**	**A090315**	**002**	Nov 29, 2010

MIDOZALAM HYDROCHLORIDE

AP		ONESOURCE SPECIALTY	**EQ 1MG BASE/ML**	**A090316**	**001**	May 04, 2011
AP			**EQ 5MG BASE/ML**	**A090316**	**002**	May 04, 2011

SOLUTION;INTRAMUSCULAR

MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

	+!	RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA	!	HIKMA	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002
AA		PADAGIS US	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB		ALEMBIC	**2.5MG**	**A214734**	**001**	Jan 21, 2021
AB			**5MG**	**A214734**	**002**	Jan 21, 2021
AB			**10MG**	**A214734**	**003**	Jan 21, 2021
AB		APOTEX	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A212774**	**001**	Aug 10, 2020
AB			**5MG**	**A212774**	**002**	Aug 10, 2020
AB			**10MG**	**A212774**	**003**	Aug 10, 2020
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MANKIND PHARMA	**2.5MG**	**A217271**	**001**	Nov 01, 2023
AB			**5MG**	**A217271**	**002**	Nov 01, 2023
AB			**10MG**	**A217271**	**003**	Nov 01, 2023
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB			**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		NOVUGEN	**2.5MG**	**A211973**	**001**	Oct 17, 2023
AB			**5MG**	**A211973**	**002**	Oct 17, 2023
AB			**10MG**	**A211973**	**003**	Oct 17, 2023
AB		PH HEALTH	**2.5MG**	**A207169**	**001**	Oct 29, 2018
AB			**5MG**	**A207169**	**002**	Oct 29, 2018
AB			**10MG**	**A207169**	**003**	Oct 29, 2018
AB		RUBICON RESEARCH	**2.5MG**	**A212543**	**001**	Aug 19, 2019
AB			**5MG**	**A212543**	**002**	Aug 19, 2019
AB			**10MG**	**A212543**	**003**	Aug 19, 2019
AB		THINQ PHARM-CRO PVT	**2.5MG**	**A207613**	**001**	Nov 02, 2018
AB			**5MG**	**A207613**	**002**	Nov 02, 2018
AB			**10MG**	**A207613**	**003**	Nov 02, 2018
AB		XIROMED	**2.5MG**	**A207849**	**001**	Oct 01, 2020
AB			**5MG**	**A207849**	**002**	Oct 01, 2020
AB			**10MG**	**A207849**	**003**	Oct 01, 2020
AB		ZYDUS LIFESCIENCES	**2.5MG**	**A213055**	**001**	Sep 01, 2020
AB			**5MG**	**A213055**	**002**	Sep 01, 2020
AB			**10MG**	**A213055**	**003**	Sep 01, 2020

ORVATEN

AB		BEIJING YILING	**2.5MG**	**A076725**	**001**	Nov 03, 2004
AB	!		**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004

MIDOSTAURIN

CAPSULE;ORAL

MIDOSTAURIN

AB		DR REDDYS	**25MG**	**A215921**	**001**	Jun 28, 2024
AB		LUPIN	**25MG**	**A216015**	**001**	May 10, 2024

MIDOSTAURIN
CAPSULE;ORAL
RYDAPT

AB	**+!**	NOVARTIS	**25MG**	**N207997**	**001**	Apr 28, 2017

MIFEPRISTONE
TABLET;ORAL
KORLYM

AB	**+!**	CORCEPT THERAP	**300MG**	**N202107**	**001**	Feb 17, 2012

MIFEPREX

AB	**+!**	DANCO LABS LLC	**200MG**	**N020687**	**001**	Sep 28, 2000

MIFEPRISTONE

AB		EVITA SOLUTIONS	**200MG**	**A216616**	**001**	Sep 30, 2025
AB		GENBIOPRO	**200MG**	**A091178**	**001**	Apr 11, 2019
AB		TEVA PHARMS USA INC	**300MG**	**A211436**	**001**	Aug 03, 2020

MIGALASTAT HYDROCHLORIDE
CAPSULE;ORAL
GALAFOLD

	+!	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018

MIGLITOL
TABLET;ORAL
MIGLITOL

	!	WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015
			50MG	A203965	002	Feb 24, 2015
			100MG	A203965	003	Feb 24, 2015

MIGLUSTAT
CAPSULE;ORAL
MIGLUSTAT

AB		ANI PHARMS	**100MG**	**A208342**	**001**	Apr 17, 2018
AB		NAVINTA LLC	**100MG**	**A219111**	**001**	Mar 14, 2025

YARGESA

AB		EDENBRIDGE PHARMS	**100MG**	**A209821**	**001**	Aug 06, 2020

ZAVESCA

AB	**+!**	ACTELION	**100MG**	**N021348**	**001**	Jul 31, 2003

OPFOLDA

	+!	AMICUS THERAP US	65MG	N215211	001	Sep 28, 2023

MILNACIPRAN HYDROCHLORIDE
TABLET;ORAL
SAVELLA

	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009
	+		25MG	N022256	002	Jan 14, 2009
	+!		50MG	N022256	003	Jan 14, 2009
	+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE
INJECTABLE;INJECTION
MILRINONE LACTATE

AP		CAPLIN	**EQ 1MG BASE/ML**	**A214380**	**001**	Apr 16, 2021
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001**	May 28, 2002
AP		HIKMA	**EQ 1MG BASE/ML**	**A075530**	**001**	May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001**	May 28, 2002
AP	**!**	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001**	Dec 03, 2010
AP		HOSPIRA	**EQ 1MG BASE/ML**	**A203280**	**001**	Sep 03, 2014
AP		MEITHEAL	**EQ 1MG BASE/ML**	**A211671**	**001**	Mar 24, 2020
AP		SHANDONG	**EQ 1MG BASE/ML**	**A216373**	**001**	Jan 23, 2023

MILRINONE LACTATE IN DEXTROSE 5%

AP		CAPLIN	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A219170**	**001**	Sep 02, 2025
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A219170**	**002**	Sep 02, 2025
AP		EUGIA PHARMA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A209666**	**001**	Sep 03, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A209666**	**002**	Sep 03, 2020

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**!**	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001**	May 28, 2002
AP	**!**		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002**	May 28, 2002
AP		GLAND	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A213585**	**001**	Jul 16, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A213585**	**002**	Jul 16, 2020
AP		HIKMA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001**	May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002**	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001**	Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002**	Jan 21, 2010

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

	+!	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

	+!	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019

ZILXI

	+!	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020

CAPSULE;ORAL

MINOCIN

AB	**+**	BAUSCH	**EQ 50MG BASE**	**N050649**	**001**	May 31, 1990
AB	**+**		**EQ 100MG BASE**	**N050649**	**002**	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A065470**	**001**	Mar 11, 2008
AB			**EQ 75MG BASE**	**A065470**	**002**	Mar 11, 2008
AB			**EQ 100MG BASE**	**A065470**	**003**	Mar 11, 2008
AB		IMPAX LABS	**EQ 50MG BASE**	**A065005**	**001**	Mar 23, 1999
AB			**EQ 75MG BASE**	**A065005**	**003**	Apr 18, 2001
AB			**EQ 100MG BASE**	**A065005**	**002**	Mar 23, 1999
AB		TORRENT	**EQ 50MG BASE**	**A065062**	**001**	Nov 30, 2000
AB			**EQ 75MG BASE**	**A065062**	**002**	Nov 30, 2000
AB			**EQ 100MG BASE**	**A065062**	**003**	Nov 30, 2000
AB		WATSON LABS	**EQ 75MG BASE**	**A063065**	**002**	Jun 10, 1999
AB			**EQ 100MG BASE**	**A063065**	**001**	Dec 30, 1991
AB		WATSON LABS TEVA	**EQ 50MG BASE**	**A063181**	**001**	Dec 30, 1991
AB		ZYDUS	**EQ 50MG BASE**	**A063011**	**001**	Mar 02, 1992
AB			**EQ 75MG BASE**	**A063009**	**002**	Aug 12, 2003
AB	**!**		**EQ 100MG BASE**	**A063009**	**001**	Mar 02, 1992

CAPSULE, EXTENDED RELEASE;ORAL

EMROSI

	+!	JOURNEY	EQ 40MG BASE	N219015	001	Nov 01, 2024

INJECTABLE;INJECTION

MINOCIN

	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001	

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

	+!	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 50MG BASE**	**A213662**	**001**	May 01, 2020
AB			**EQ 75MG BASE**	**A213662**	**002**	May 01, 2020
AB			**EQ 100MG BASE**	**A213662**	**003**	May 01, 2020
AB		CHARTWELL RX	**EQ 50MG BASE**	**A065436**	**001**	Dec 26, 2007
AB			**EQ 75MG BASE**	**A065436**	**002**	Dec 26, 2007
AB			**EQ 100MG BASE**	**A065436**	**003**	Dec 26, 2007
AB		REGCON HOLDINGS	**EQ 50MG BASE**	**A215466**	**001**	May 27, 2022
AB			**EQ 75MG BASE**	**A215466**	**002**	May 27, 2022
AB			**EQ 100MG BASE**	**A215466**	**003**	May 27, 2022
AB		STRIDES PHARMA INTL	**EQ 50MG BASE**	**A065131**	**001**	Apr 16, 2003
AB			**EQ 75MG BASE**	**A065131**	**002**	Apr 16, 2003
AB	**!**		**EQ 100MG BASE**	**A065131**	**003**	Apr 16, 2003
AB		TORRENT	**EQ 50MG BASE**	**A065156**	**001**	Jan 06, 2004
AB			**EQ 75MG BASE**	**A065156**	**002**	Jan 06, 2004
AB			**EQ 100MG BASE**	**A065156**	**003**	Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 45MG BASE**	**A204453**	**001**	Sep 28, 2016
AB			**EQ 55MG BASE**	**A204453**	**008**	Dec 19, 2019
AB			**EQ 65MG BASE**	**A204453**	**006**	Mar 16, 2018
AB			**EQ 80MG BASE**	**A204453**	**002**	Sep 28, 2016
AB			**EQ 90MG BASE**	**A204453**	**003**	Sep 28, 2016
AB			**EQ 105MG BASE**	**A204453**	**004**	Sep 28, 2016
AB	**!**		**EQ 115MG BASE**	**A204453**	**007**	Mar 16, 2018
AB	**!**		**EQ 135MG BASE**	**A204453**	**005**	Sep 28, 2016
AB		AUROBINDO PHARMA LTD	**EQ 45MG BASE**	**A202261**	**001**	Nov 19, 2012
AB			**EQ 55MG BASE**	**A202261**	**008**	Aug 21, 2019
AB			**EQ 65MG BASE**	**A202261**	**002**	Sep 28, 2018
AB			**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB			**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB			**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB			**EQ 115MG BASE**	**A202261**	**004**	Sep 28, 2018
AB			**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB		CHARTWELL RX	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB			**EQ 55MG BASE**	**A091424**	**002**	Nov 30, 2011
AB			**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB			**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB		SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB			**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB			**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		PH HEALTH	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB			**10MG**	**A071839**	**001**	Nov 14, 1988
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A072709**	**002**	Dec 14, 1995
AB			**10MG**	**A072709**	**001**	Dec 14, 1995
AB		WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB	**!**		**10MG**	**A071345**	**001**	Mar 03, 1987

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

	+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		ALKEM LABS LTD	**25MG**	**A215948**	**001**	Feb 12, 2024
AB			**50MG**	**A215948**	**002**	Feb 12, 2024
AB		ASCENT PHARMS INC	**25MG**	**A218172**	**001**	Sep 24, 2025
AB			**50MG**	**A218172**	**002**	Sep 24, 2025
AB		LUPIN LTD	**25MG**	**A209485**	**001**	Sep 28, 2022
AB			**50MG**	**A209485**	**002**	Sep 28, 2022
AB		MSN	**25MG**	**A218543**	**001**	Nov 04, 2025
AB			**50MG**	**A218543**	**002**	Nov 04, 2025
AB		QILU	**25MG**	**A217989**	**001**	Jun 30, 2025
AB			**50MG**	**A217989**	**002**	Jun 30, 2025
AB		ZYDUS PHARMS	**25MG**	**A209488**	**001**	Sep 29, 2022
AB			**50MG**	**A209488**	**002**	Sep 29, 2022

MYRBETRIQ

AB	**+!**	APGDI	**25MG**	**N202611**	**001**	Jun 28, 2012
AB	**+!**		**50MG**	**N202611**	**002**	Jun 28, 2012

MIRDAMETINIB

CAPSULE;ORAL

GOMEKLI

	+	SPRINGWORKS	1MG	N219389	001	Feb 11, 2025
	+!		2MG	N219389	002	Feb 11, 2025

TABLET, FOR SUSPENSION;ORAL

GOMEKLI

	+!	SPRINGWORKS	1MG	N219379	001	Feb 11, 2025

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		ANNORA PHARMA	**7.5MG**	**A219721**	**001**	Oct 02, 2025
AB			**15MG**	**A219721**	**002**	Oct 02, 2025
AB			**30MG**	**A219721**	**003**	Oct 02, 2025
AB			**45MG**	**A219721**	**004**	Oct 02, 2025
AB		APOTEX	**15MG**	**A077666**	**001**	Aug 22, 2007
AB			**30MG**	**A077666**	**002**	Aug 22, 2007
AB			**45MG**	**A077666**	**003**	Aug 22, 2007
AB		AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB			**15MG**	**A076921**	**002**	Oct 22, 2004
AB			**30MG**	**A076921**	**003**	Oct 22, 2004
AB			**45MG**	**A076921**	**004**	Oct 22, 2004
AB		CHARTWELL RX	**15MG**	**A076219**	**001**	Jun 19, 2003
AB			**30MG**	**A076219**	**002**	Jun 19, 2003
AB			**45MG**	**A076219**	**003**	Jun 19, 2003
AB		MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB			**30MG**	**A076122**	**002**	Jun 19, 2003
AB			**45MG**	**A076122**	**003**	Jun 19, 2003
AB		PRASCO	**7.5MG**	**A216751**	**001**	Jan 18, 2023
AB			**15MG**	**A216751**	**002**	Jan 18, 2023
AB			**30MG**	**A216751**	**003**	Jan 18, 2023
AB			**45MG**	**A216751**	**004**	Jan 18, 2023
AB	!	SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB			**15MG**	**A076541**	**001**	Apr 22, 2004
AB			**30MG**	**A076541**	**002**	Apr 22, 2004
AB			**45MG**	**A076541**	**003**	Apr 22, 2004
AB		TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB			**30MG**	**A076119**	**002**	Jan 24, 2003
AB			**45MG**	**A076119**	**003**	Jun 19, 2003

REMERON

AB	+!	ORGANON	**15MG**	**N020415**	**001**	Jun 14, 1996
AB	+		**30MG**	**N020415**	**002**	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA	**15MG**	**A077376**	**002**	Dec 08, 2005
AB			**30MG**	**A077376**	**003**	Dec 08, 2005
AB			**45MG**	**A077376**	**004**	Feb 28, 2006
AB		SQUARE PHARMS PLC	**15MG**	**A205798**	**001**	Jun 01, 2017
AB			**30MG**	**A205798**	**002**	Jun 01, 2017
AB			**45MG**	**A205798**	**003**	Jun 01, 2017

REMERON SOLTAB

AB	+!	ORGANON USA ORGANON	**15MG**	**N021208**	**001**	Jan 12, 2001
AB	+		**30MG**	**N021208**	**002**	Jan 12, 2001
AB	+		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	+	PFIZER	**0.1MG**	**N019268**	**003**	Sep 21, 1990
AB	+!		**0.2MG**	**N019268**	**001**	Dec 27, 1988

MISOPROSTOL

AB		ACQ PHARMA	**0.1MG**	**A210201**	**001**	Jul 02, 2019
AB			**0.2MG**	**A210201**	**002**	Jul 02, 2019
AB		ANI PHARMS	**0.1MG**	**A076095**	**001**	Jul 10, 2002
AB			**0.2MG**	**A076095**	**002**	Jul 10, 2002
AB		MICRO LABS	**0.1MG**	**A216872**	**001**	Oct 17, 2022
AB			**0.2MG**	**A216872**	**002**	Oct 17, 2022

MITAPIVAT SULFATE

TABLET;ORAL

PYRUKYND

	+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022
	+		EQ 20MG BASE	N216196	002	Feb 17, 2022
	+!		EQ 50MG BASE	N216196	003	Feb 17, 2022

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

	+!	GLAUKOS	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE;INJECTION

MITOMYCIN

AP	!	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP			**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	!		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		FRESENIUS KABI USA	**5MG/VIAL**	**A211269**	**001**	Apr 05, 2024
AP			**20MG/VIAL**	**A211269**	**002**	Apr 05, 2024
AP			**40MG/VIAL**	**A211269**	**003**	Apr 05, 2024
AP		GLAND	**5MG/VIAL**	**A215687**	**001**	Oct 20, 2021
AP			**20MG/VIAL**	**A215687**	**002**	Oct 20, 2021
AP			**40MG/VIAL**	**A216648**	**001**	Nov 22, 2022
AP		HIKMA	**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064117**	**002**	Apr 19, 1995
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999
AP			**40MG/VIAL**	**A064117**	**003**	Jun 02, 1999
AP		MEITHEAL	**5MG/VIAL**	**A214505**	**001**	Sep 08, 2022
AP	!		**20MG/VIAL**	**A214505**	**002**	Sep 08, 2022
AP			**40MG/VIAL**	**A214504**	**001**	Sep 06, 2022

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP		RK PHARMA	**5MG/VIAL**	**A202670**	**001**	Oct 13, 2017
AP			**20MG/VIAL**	**A202670**	**002**	Oct 13, 2017
AP			**40MG/VIAL**	**A203386**	**001**	Oct 13, 2017

POWDER;INTRAVESICAL

ZUSDURI

	+!	UROGEN PHARMA	40MG/VIAL	N215793	001	Jun 12, 2025

POWDER;PYELOCALYCEAL

JELMYTO

	+!	UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020

MITOTANE

TABLET;ORAL

LYSODREN

	+!	ESTEVE	500MG	N016885	001	

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006
AP		HIKMA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006
AP	**!**	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006
AP	**!**		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006
AP	**!**		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006
AP		MEITHEAL	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006

MODAFINIL

TABLET;ORAL

MODAFINIL

AB		ALEMBIC	**100MG**	**A202700**	**001**	Oct 18, 2012
AB			**200MG**	**A202700**	**002**	Oct 18, 2012
AB		APOTEX	**100MG**	**A077667**	**001**	Feb 03, 2014
AB			**200MG**	**A077667**	**002**	Feb 03, 2014
AB		APPCO	**100MG**	**A207196**	**001**	Aug 16, 2017
AB			**200MG**	**A207196**	**002**	Aug 16, 2017
AB		AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012
AB			**200MG**	**A202566**	**002**	Sep 27, 2012
AB		CADILA	**100MG**	**A209966**	**001**	Sep 14, 2017
AB			**200MG**	**A209966**	**002**	Sep 14, 2017
AB		ORBION PHARMS	**100MG**	**A078963**	**001**	Sep 26, 2012
AB			**200MG**	**A078963**	**002**	Sep 26, 2012

PROVIGIL

AB	**+**	NUVO PHARMS	**100MG**	**N020717**	**001**	Dec 24, 1998
AB	**+!**		**200MG**	**N020717**	**002**	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB		CHARTWELL RX	**7.5MG**	**A077536**	**001**	Nov 30, 2006
AB			**15MG**	**A077536**	**002**	Nov 30, 2006
AB		GLENMARK PHARMS LTD	**7.5MG**	**A090416**	**001**	Mar 30, 2010
AB			**15MG**	**A090416**	**002**	Mar 30, 2010
AB		TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003
AB	**!**		**15MG**	**A076204**	**002**	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015
			10MG	A090453	002	Mar 20, 2015
	!		25MG	A090453	003	Mar 20, 2015

MOMELOTINIB DIHYDROCHLORIDE

TABLET;ORAL

OJJAARA

+		GLAXOSMITHKLINE	EQ 100MG BASE	N216873	001	Sep 15, 2023
+			EQ 150MG BASE	N216873	002	Sep 15, 2023
+!			EQ 200MG BASE	N216873	003	Sep 15, 2023

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

+!		ORGANON LLC	0.05MG/INH	N205641	003	Aug 12, 2019
+!			0.10MG/INH	N205641	001	Apr 25, 2014
+!			0.20MG/INH	N205641	002	Apr 25, 2014

CREAM;TOPICAL

MOMETASONE FUROATE

AB	**!**	COSETTE	**0.1%**	**A077447**	**001**	May 22, 2006
AB		SUN PHARMA CANADA	**0.1%**	**A076679**	**001**	Dec 21, 2004

IMPLANT;IMPLANTATION

SINUVA

+		INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017

LOTION;TOPICAL

MOMETASONE FUROATE

AB		ENCUBE	**0.1%**	**A076499**	**001**	Nov 21, 2007
AB		FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB	**!**	PADAGIS ISRAEL	**0.1%**	**A077180**	**001**	Apr 06, 2005

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB		FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB	**!**	PADAGIS US	**0.1%**	**A076067**	**001**	Mar 18, 2002
AB		TORRENT	**0.1%**	**A207899**	**001**	Jul 13, 2018

POWDER;INHALATION

ASMANEX TWISTHALER

+!		ORGANON LLC	0.11MG/INH	N021067	002	Feb 01, 2008
+!			0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	**0.05MG/SPRAY**	**A207989**	**001**	Apr 03, 2017
AB	**!**	APOTEX	**0.05MG/SPRAY**	**A091161**	**001**	Mar 22, 2016
AB		AUROBINDO PHARMA	**0.05MG/SPRAY**	**A215878**	**001**	Mar 18, 2024

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

RYALTRIS

+!		GLENMARK SPECLT	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

+!		BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE/PACKET**	**A213471**	**001**	Feb 18, 2020
AB		DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB		TORRENT	**EQ 4MG BASE/PACKET**	**A210431**	**001**	Jul 31, 2018

SINGULAIR

AB	**+!**	ORGANON	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A202717**	**001**	Sep 21, 2012
AB		AMNEAL PHARMS	**EQ 10MG BASE**	**A204604**	**001**	Sep 04, 2015
AB		ANBISON LAB	**EQ 10MG BASE**	**A205683**	**001**	Jan 12, 2016
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A202468**	**001**	Aug 03, 2012
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A201522**	**001**	Aug 03, 2012
AB		CIPLA	**EQ 10MG BASE**	**A207463**	**001**	Oct 28, 2016
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A201582**	**001**	Aug 06, 2012
AB		GLENMARK PHARMS LTD	**EQ 10MG BASE**	**A090926**	**001**	Aug 03, 2012
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202843**	**001**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A203366**	**001**	Sep 11, 2014

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB		PHARMOBEDIENT	**EQ 10MG BASE**	**A202859**	**001**	Oct 30, 2014
AB		RISING	**EQ 10MG BASE**	**A209012**	**001**	Apr 24, 2017
AB		SANDOZ INC	**EQ 10MG BASE**	**A200889**	**001**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 10MG BASE**	**A078605**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A201515**	**001**	Aug 03, 2012
AB		UNICHEM	**EQ 10MG BASE**	**A204290**	**001**	Oct 08, 2015

SINGULAIR

AB	**+!**	ORGANON	**EQ 10MG BASE**	**N020829**	**002**	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AMNEAL PHARMS	**EQ 4MG BASE**	**A205107**	**001**	Sep 04, 2020
AB			**EQ 5MG BASE**	**A205107**	**002**	Sep 04, 2020
AB		ANBISON LAB	**EQ 4MG BASE**	**A205695**	**001**	Nov 05, 2015
AB			**EQ 5MG BASE**	**A205695**	**002**	Nov 05, 2015
AB		ANDA REPOSITORY	**EQ 4MG BASE**	**A201581**	**001**	Aug 06, 2012
AB			**EQ 5MG BASE**	**A201581**	**002**	Aug 06, 2012
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A202096**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A202096**	**002**	Aug 03, 2012
AB		CHARTWELL MOLECULAR	**EQ 4MG BASE**	**A207464**	**001**	Dec 06, 2018
AB			**EQ 5MG BASE**	**A207464**	**002**	Dec 06, 2018
AB		HETERO LABS LTD V	**EQ 4MG BASE**	**A204093**	**001**	May 22, 2015
AB			**EQ 5MG BASE**	**A204093**	**002**	May 22, 2015
AB		LANNETT CO INC	**EQ 4MG BASE**	**A200405**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A200405**	**002**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 4MG BASE**	**A203582**	**001**	Mar 12, 2015
AB			**EQ 5MG BASE**	**A203582**	**002**	Mar 12, 2015
AB		PHARMOBEDIENT	**EQ 4MG BASE**	**A203037**	**001**	Oct 30, 2014
AB			**EQ 5MG BASE**	**A203037**	**002**	Oct 30, 2014
AB		RISING	**EQ 4MG BASE**	**A209011**	**001**	Apr 18, 2017
AB			**EQ 5MG BASE**	**A209011**	**002**	Apr 18, 2017
AB		TEVA PHARMS	**EQ 4MG BASE**	**A078723**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A078723**	**002**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 4MG BASE**	**A090984**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A090984**	**002**	Aug 03, 2012
AB		UNICHEM	**EQ 4MG BASE**	**A208621**	**001**	Jul 02, 2018
AB			**EQ 5MG BASE**	**A208621**	**002**	Jul 02, 2018

SINGULAIR

AB	**+**	ORGANON	**EQ 4MG BASE**	**N020830**	**002**	Mar 03, 2000
AB	**+!**		**EQ 5MG BASE**	**N020830**	**001**	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013
		UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013
			20MG	A202104	002	Jun 03, 2013
			30MG	A202104	003	Jun 03, 2013
			50MG	A202104	004	Jun 03, 2013
			60MG	A202104	005	Jun 03, 2013
			80MG	A202104	006	Jun 03, 2013
	!		100MG	A202104	007	Jun 03, 2013

INJECTABLE;INJECTION

DURAMORPH PF

AP	**+!**	HIKMA	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+!**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984

INFUMORPH

AP	**+!**	HIKMA	**10MG/ML**	**N018565**	**003**	Jul 19, 1991
AP	**+!**		**25MG/ML**	**N018565**	**004**	Jul 19, 1991

MITIGO

AP		PIRAMAL CRITICAL	**10MG/ML**	**A204393**	**001**	Jul 16, 2018
AP			**25MG/ML**	**A204393**	**002**	Jul 16, 2018

MORPHINE SULFATE

AP		HIKMA	**2MG/ML**	**A211452**	**001**	Jan 12, 2023
AP	**!**		**4MG/ML**	**A205758**	**001**	May 21, 2015

MORPHINE SULFATE

INJECTABLE;INJECTION

MORPHINE SULFATE

AP			**4MG/ML**	**A211452**	**002**	Jan 12, 2023
AP	**!**		**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**8MG/ML**	**A211452**	**003**	Jan 12, 2023
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP			**10MG/ML**	**A211452**	**004**	Jan 12, 2023
AP		HOSPIRA	**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+!**	HOSPIRA INC	**2MG/ML**	**N202515**	**001**	Nov 14, 2011
AP	**+**		**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
		HIKMA	15MG/ML	A211452	005	Jan 12, 2023
	+!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

	+!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION;ORAL

MORPHINE SULFATE

AA	**+**	HIKMA	**10MG/5ML**	**N022195**	**001**	Mar 17, 2008
AA	**+**		**20MG/5ML**	**N022195**	**002**	Mar 17, 2008
AA	**+!**		**100MG/5ML**	**N022195**	**003**	Jan 25, 2010
AA		PADAGIS US	**100MG/5ML**	**A201574**	**001**	Aug 06, 2012
AA		PHARM ASSOC	**10MG/5ML**	**A206573**	**002**	Sep 12, 2023
AA			**100MG/5ML**	**A206573**	**001**	Nov 14, 2016
AA		SPECGX LLC	**100MG/5ML**	**A202348**	**001**	Jul 15, 2011
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001**	May 12, 2015
AA			**100MG/5ML**	**A203518**	**002**	May 12, 2015
AA		WINDER LABS LLC	**10MG/5ML**	**A211454**	**001**	Feb 12, 2021
AA			**20MG/5ML**	**A211454**	**002**	Feb 12, 2021
AA			**100MG/5ML**	**A211454**	**003**	Feb 12, 2021

TABLET;ORAL

MORPHINE SULFATE

AB		ALKEM LABS LTD	**15MG**	**A212451**	**001**	Dec 03, 2020
AB			**30MG**	**A212451**	**002**	Dec 03, 2020
AB	**+**	HIKMA	**15MG**	**N022207**	**001**	Mar 17, 2008
AB	**+!**		**30MG**	**N022207**	**002**	Mar 17, 2008
AB		SPECGX LLC	**15MG**	**A215194**	**001**	Aug 21, 2023
AB			**30MG**	**A215194**	**002**	Aug 21, 2023
AB		UPSHER SMITH LABS	**15MG**	**A210610**	**001**	Jul 22, 2019
AB			**30MG**	**A210610**	**002**	Jul 22, 2019

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001**	Apr 06, 2015
AB			**30MG**	**A203849**	**002**	Apr 06, 2015
AB			**60MG**	**A203849**	**003**	Apr 06, 2015
AB			**100MG**	**A203849**	**004**	Apr 06, 2015
AB			**200MG**	**A203849**	**005**	Apr 06, 2015
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001**	Jan 28, 2000
AB		RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB			**30MG**	**A074862**	**002**	Jul 07, 1998
AB			**60MG**	**A074862**	**003**	Jul 07, 1998
AB			**100MG**	**A074769**	**001**	Jul 02, 1998
AB			**200MG**	**A074769**	**002**	Jul 02, 1998
AB		SPECGX LLC	**15MG**	**A076412**	**001**	Jul 31, 2003
AB			**30MG**	**A076412**	**002**	Jul 31, 2003
AB			**60MG**	**A076412**	**003**	Jul 31, 2003
AB			**100MG**	**A076438**	**001**	Jul 03, 2003
AB			**200MG**	**A076438**	**002**	Jul 03, 2003
AB		STRIDES PHARMA INTL	**15MG**	**A075295**	**001**	Oct 28, 1998
AB			**30MG**	**A075295**	**002**	Oct 28, 1998
AB			**60MG**	**A075295**	**003**	Oct 28, 1998
AB			**100MG**	**A075295**	**004**	Sep 15, 2000
AB			**200MG**	**A075295**	**005**	Sep 15, 2000
AB		SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB			**30MG**	**A078761**	**002**	May 11, 2012
AB			**60MG**	**A078761**	**003**	May 11, 2012

MORPHINE SULFATE
TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE						
AB			**100MG**	**A078761**	**004**	May 11, 2012
AB			**200MG**	**A078761**	**005**	May 11, 2012
MS CONTIN						
AB	**+**	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB	**+**		**30MG**	**N019516**	**001**	May 29, 1987
AB	**+**		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	**+!**		**100MG**	**N019516**	**004**	Jan 16, 1990
AB	**+**		**200MG**	**N019516**	**005**	Nov 08, 1993

MOTIXAFORTIDE ACETATE
POWDER;SUBCUTANEOUS

APHEXDA					
	+!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001 Sep 08, 2023

MOXIDECTIN
TABLET;ORAL

MOXIDECTIN					
	+!	MDGH	2MG	N210867	001 Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE
SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE					
	+!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001 Apr 03, 2015
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
	!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001 May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE						
AT1		ALEMBIC	**EQ 0.5% BASE**	**A209469**	**001**	Feb 13, 2019
AT1		APOTEX	**EQ 0.5% BASE**	**A090080**	**001**	Jun 30, 2017
AT1		EUGIA PHARMA	**EQ 0.5% BASE**	**A206242**	**001**	Oct 04, 2017
AT1		FDC LTD	**EQ 0.5% BASE**	**A219475**	**001**	Aug 04, 2025
AT1		GLAND	**EQ 0.5% BASE**	**A208778**	**001**	Mar 30, 2020
AT1		LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1		MANKIND PHARMA	**EQ 0.5% BASE**	**A217988**	**001**	Jan 27, 2025
AT1		REGCON HOLDINGS	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015
AT1		SOMERSET THERAPS LLC	**EQ 0.5% BASE**	**A209698**	**001**	Nov 14, 2024
AT1		UPSHER SMITH LABS	**EQ 0.5% BASE**	**A212616**	**001**	Feb 10, 2021
VIGAMOX						
AT1	**+!**	HARROW EYE	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003
MOXIFLOXACIN HYDROCHLORIDE						
	!	LUPIN LTD	EQ 0.5% BASE	A204079	001	May 28, 2015

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB		CHARTWELL RX	**EQ 400MG BASE**	**A207285**	**001**	Feb 13, 2017
AB		CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB	**!**	DR REDDYS	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB		HETERO LABS LTD V	**EQ 400MG BASE**	**A204836**	**001**	Mar 02, 2023
AB		MSN	**EQ 400MG BASE**	**A208682**	**001**	Sep 22, 2017
AB		SUNSHINE	**EQ 400MG BASE**	**A206295**	**001**	Sep 28, 2018
AB		TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014
AB		TORRENT	**EQ 400MG BASE**	**A200160**	**001**	Apr 03, 2014

MUPIROCIN
OINTMENT;TOPICAL

MUPIROCIN						
AB		ENCUBE	**2%**	**A217943**	**001**	May 13, 2025
AB		FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB		GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	**!**	PADAGIS ISRAEL	**2%**	**A065123**	**001**	Nov 07, 2003
AB		SUN PHARMA CANADA	**2%**	**A065170**	**001**	Sep 23, 2005
AB		TEVA	**2%**	**A065085**	**001**	Nov 07, 2003
CENTANY						
BX		PADAGIS US	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB		AMNEAL	**EQ 2% BASE**	**A214811**	**001**	Nov 15, 2022
AB		ENCUBE	**EQ 2% BASE**	**A213076**	**001**	Aug 31, 2021
AB	!	GLENMARK PHARMS INC	**EQ 2% BASE**	**A201587**	**001**	Jan 24, 2013
AB		SUN PHARMA CANADA	**EQ 2% BASE**	**A207116**	**001**	Apr 27, 2020
BX		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB		AUROBINDO PHARMA LTD	**250MG**	**A217828**	**001**	Jan 05, 2024
AB		CONCORD BIOTECH LTD	**250MG**	**A210181**	**001**	Jan 08, 2019
AB		HETERO LABS LTD V	**250MG**	**A207022**	**001**	Oct 22, 2024
AB		HIKMA	**250MG**	**A065410**	**001**	Jul 29, 2008
AB		MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB		SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB		WUXI	**250MG**	**A214079**	**001**	Nov 07, 2024
AB		ZHEJIANG HISUN PHARM	**250MG**	**A204077**	**001**	Nov 13, 2017

FOR SUSPENSION;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014
AB		AMNEAL	**200MG/ML**	**A214871**	**001**	Nov 02, 2021
AB		AUROBINDO PHARMA LTD	**200MG/ML**	**A218227**	**001**	Sep 26, 2024
AB		LANNETT CO INC	**200MG/ML**	**A214525**	**001**	Jul 29, 2021
AB		RISING	**200MG/ML**	**A213955**	**001**	Sep 11, 2023
AB		STRIDES PHARMA INTL	**200MG/ML**	**A212634**	**001**	Aug 29, 2023
AB		VISTAPHARM LLC	**200MG/ML**	**A210370**	**001**	Feb 12, 2019

SUSPENSION;ORAL

MYHIBBIN

	+!	AZURITY	200MG/ML	N216482	001	May 01, 2024

TABLET;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB		AUROBINDO PHARMA	**500MG**	**A217937**	**001**	Feb 20, 2024
AB		CONCORD BIOTECH LTD	**500MG**	**A212087**	**001**	Jul 31, 2020
AB		HETERO LABS LTD V	**500MG**	**A208119**	**001**	Oct 22, 2024
AB		HIKMA	**500MG**	**A065413**	**001**	Jul 29, 2008
AB		MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB		SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB		ZHEJIANG HISUN PHARM	**500MG**	**A204076**	**001**	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	**+!**	ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		BPI LABS	**500MG/VIAL**	**A214283**	**001**	Jun 01, 2023
AP		MEITHEAL	**500MG/VIAL**	**A212130**	**001**	Jan 15, 2021
AP		MYLAN LABS LTD	**500MG/VIAL**	**A203859**	**001**	Mar 31, 2017
AP		ONESOURCE SPECIALTY	**500MG/VIAL**	**A216390**	**001**	Dec 23, 2022
AP		PH HEALTH	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016
AP		RISING	**500MG/VIAL**	**A204043**	**001**	Feb 28, 2017
AP		ZYDUS PHARMS	**500MG/VIAL**	**A204473**	**001**	Aug 31, 2017

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLATE SODIUM

AB		ACCORD HLTHCARE	**EQ 180MG BASE**	**A202555**	**001**	Aug 23, 2017
AB			**EQ 360MG BASE**	**A202555**	**002**	Aug 23, 2017
AB		ALKEM LABS LTD	**EQ 180MG BASE**	**A208315**	**001**	Sep 23, 2021
AB			**EQ 360MG BASE**	**A208315**	**002**	Sep 23, 2021
AB		APOTEX INC	**EQ 180MG BASE**	**A091558**	**001**	Aug 21, 2012
AB			**EQ 360MG BASE**	**A091558**	**002**	Aug 19, 2014
AB		AUROBINDO PHARMA LTD	**EQ 180MG BASE**	**A218603**	**001**	Feb 27, 2024
AB			**EQ 360MG BASE**	**A218603**	**002**	Feb 27, 2024
AB		BIOCON PHARMA	**EQ 180MG BASE**	**A214630**	**001**	Nov 29, 2021
AB			**EQ 180MG BASE**	**A217031**	**001**	Nov 29, 2023
AB			**EQ 360MG BASE**	**A214630**	**002**	Nov 29, 2021
AB			**EQ 360MG BASE**	**A217031**	**002**	Nov 29, 2023
AB		CONCORD BIOTECH LTD	**EQ 180MG BASE**	**A211173**	**001**	Dec 13, 2019
AB			**EQ 360MG BASE**	**A211173**	**002**	Dec 13, 2019
AB		FOSUN WANBANG	**EQ 180MG BASE**	**A216637**	**001**	May 29, 2024
AB			**EQ 360MG BASE**	**A216637**	**002**	May 29, 2024
AB		RK PHARMA	**EQ 180MG BASE**	**A091248**	**002**	Jan 08, 2014
AB			**EQ 360MG BASE**	**A091248**	**001**	Jan 08, 2014
AB		TWI PHARMS	**EQ 180MG BASE**	**A214289**	**001**	Nov 03, 2021
AB			**EQ 360MG BASE**	**A214289**	**002**	Nov 03, 2021
AB		YICHANG HUMANWELL	**EQ 180MG BASE**	**A214376**	**001**	Feb 10, 2021
AB			**EQ 360MG BASE**	**A214376**	**002**	Feb 10, 2021

MYFORTIC

AB	**+**	NOVARTIS	**EQ 180MG BASE**	**N050791**	**001**	Feb 27, 2004
AB	**+!**		**EQ 360MG BASE**	**N050791**	**002**	Feb 27, 2004

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		ANNORA PHARMA	**500MG**	**A090445**	**001**	Jan 12, 2011
AB			**750MG**	**A090445**	**002**	Jan 12, 2011
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001**	Jan 24, 2003
AB			**750MG**	**A076009**	**002**	Jan 24, 2003
AB		CHARTWELL RX	**500MG**	**A075280**	**001**	Feb 25, 2002
AB			**750MG**	**A075280**	**002**	Feb 25, 2002
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001**	Mar 07, 2008
AB	**!**		**750MG**	**A078671**	**002**	Mar 07, 2008
AB		LGM PHARMA	**500MG**	**A203166**	**001**	Aug 30, 2019
AB			**750MG**	**A203166**	**002**	Aug 30, 2019
AB		NOVITIUM PHARMA	**500MG**	**A219118**	**001**	Jan 07, 2025
AB			**750MG**	**A219118**	**002**	Jan 07, 2025
AB		SCIEGEN PHARMS	**500MG**	**A078420**	**001**	Sep 24, 2008
AB			**750MG**	**A078420**	**002**	Sep 24, 2008
AB		WATSON LABS	**500MG**	**A091083**	**001**	Jun 13, 2011
AB			**750MG**	**A091083**	**002**	Jun 13, 2011
		LGM PHARMA	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET;ORAL

NADOLOL

AB		ALEMBIC	**20MG**	**A211763**	**001**	Jun 02, 2023
AB			**40MG**	**A211763**	**002**	Jun 02, 2023
AB			**80MG**	**A211763**	**003**	Jun 02, 2023
AB		AMNEAL PHARMS CO	**20MG**	**A208832**	**001**	Jun 02, 2017
AB			**40MG**	**A208832**	**002**	Jun 02, 2017
AB			**80MG**	**A208832**	**003**	Jun 02, 2017
AB		AUROBINDO PHARMA	**20MG**	**A201893**	**003**	Jun 07, 2022
AB			**40MG**	**A201893**	**001**	Sep 16, 2015
AB			**80MG**	**A201893**	**002**	Sep 16, 2015
AB		CHARTWELL RX	**20MG**	**A209309**	**001**	Oct 05, 2017
AB			**40MG**	**A209309**	**002**	Oct 05, 2017
AB			**80MG**	**A209309**	**003**	Oct 05, 2017
AB		INVAGEN PHARMS	**20MG**	**A203455**	**001**	Dec 18, 2015
AB			**40MG**	**A203455**	**002**	Dec 18, 2015
AB	**!**		**80MG**	**A203455**	**003**	Dec 18, 2015
AB		REGCON HOLDINGS	**20MG**	**A210955**	**001**	Jul 23, 2018
AB			**40MG**	**A210955**	**002**	Jul 23, 2018
AB			**80MG**	**A210955**	**003**	Jul 23, 2018
AB		RISING	**20MG**	**A074172**	**001**	Oct 31, 1993
AB			**40MG**	**A074172**	**002**	Oct 31, 1993

NADOLOL

TABLET;ORAL

NADOLOL

AB			**80MG**	**A074172**	**003**	Oct 31, 1993
AB		RK PHARMA	**20MG**	**A212856**	**001**	Sep 13, 2019
AB			**40MG**	**A212856**	**002**	Sep 13, 2019
AB			**80MG**	**A212856**	**003**	Sep 13, 2019
AB		SANDOZ	**20MG**	**A074501**	**001**	Nov 09, 1995
AB			**40MG**	**A074501**	**002**	Nov 09, 1995
AB			**80MG**	**A074501**	**003**	Nov 09, 1995
AB		ZYDUS PHARMS	**20MG**	**A207761**	**001**	Jul 28, 2017
AB			**40MG**	**A207761**	**002**	Jul 28, 2017
AB			**80MG**	**A207761**	**003**	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	PFIZER	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001**	Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002**	Oct 03, 2011
AP	**!**	EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL**	**A091613**	**001**	Dec 26, 2012
AP	**!**		**EQ 2GM BASE/VIAL**	**A091613**	**002**	Dec 26, 2012
AP	**!**		**EQ 10GM BASE/VIAL**	**A091614**	**001**	Dec 26, 2012
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001**	Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002**	Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001**	Apr 20, 2011
AP		ONESOURCE SPECIALTY	**EQ 1GM BASE/VIAL**	**A200002**	**001**	Apr 07, 2014
AP			**EQ 2GM BASE/VIAL**	**A200002**	**002**	Apr 07, 2014
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001**	Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002**	Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001**	Aug 24, 2012

NALLPEN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	**2%**	**A206960**	**001**	Apr 10, 2017
AB		SUN PHARMA CANADA	**2%**	**A206901**	**001**	Jan 06, 2016
AB		XIROMED	**2%**	**A210038**	**001**	Sep 22, 2020

NAFTIN

AB	**+!**	LEGACY PHARMA	**2%**	**N019599**	**002**	Jan 13, 2012

NAFTIFINE HYDROCHLORIDE

	!	SUN PHARMA CANADA	1%	A205975	001	Sep 08, 2016

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	**1%**	**A206165**	**001**	Mar 20, 2019
AB		SUN PHARMA CANADA	**2%**	**A208201**	**001**	Apr 10, 2019

NAFTIN

AB	**+!**	LEGACY PHARMA	**1%**	**N019356**	**001**	Jun 18, 1990
AB	**+!**		**2%**	**N204286**	**001**	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALBUPHINE HYDROCHLORIDE

AP	**!**	HOSPIRA	**10MG/ML (10MG/ML)**	**A070914**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML (20MG/ML)**	**A070916**	**001**	Feb 03, 1989
AP	**!**		**100MG/10ML (10MG/ML)**	**A070915**	**001**	Feb 03, 1989
AP	**!**		**200MG/10ML (20MG/ML)**	**A070918**	**001**	Feb 03, 1989
AP		SOMERSET THERAPS LLC	**10MG/ML (10MG/ML)**	**A216050**	**001**	Sep 19, 2024
AP			**20MG/ML (20MG/ML)**	**A216050**	**002**	Sep 19, 2024
AP			**100MG/10ML (10MG/ML)**	**A216049**	**001**	Sep 19, 2024
AP			**200MG/10ML (20MG/ML)**	**A216049**	**002**	Sep 19, 2024

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

AP		CHENGDU SHUODE	**EQ 2MG BASE/2ML (EQ 1MG BASE/ML)**	**A216007**	**002**	Nov 15, 2023
AP	**!**	PURDUE PHARMA LP	**EQ 2MG BASE/2ML (EQ 1MG BASE/ML)**	**A212955**	**001**	Feb 08, 2022
	!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

ZURNAI (AUTOINJECTOR)

+!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024

SPRAY;NASAL

OPVEE

+!	INDIVIOR	EQ 2.7MG BASE/SPRAY	N217470	001	May 22, 2023

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

+	AVERITAS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
+!		EQ 25MG BASE	N204760	002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

AP		HIKMA	**0.4MG/ML**	**A070299**	**001**	Sep 24, 1986

NALOXONE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**0.4MG/ML**	**A216624**	**001**	Oct 26, 2022
AP			**1MG/ML**	**A216624**	**002**	Oct 26, 2022
AP		BAXTER HLTHCARE CORP	**0.4MG/ML**	**A214785**	**001**	Jan 29, 2021
AP			**0.4MG/ML**	**A214792**	**001**	Nov 07, 2022
AP			**1MG/ML**	**A214785**	**002**	Jun 03, 2025
AP		BPI LABS	**1MG/ML**	**A216977**	**001**	Oct 06, 2023
AP		DR REDDYS	**1MG/ML**	**A213209**	**001**	Mar 16, 2020
AP		EUGIA PHARMA	**1MG/ML**	**A213279**	**001**	Jan 14, 2021
AP			**0.4MG/ML**	**A212456**	**001**	Nov 04, 2019
AP		FRESENIUS KABI USA	**0.4MG/ML**	**A213573**	**001**	Apr 02, 2024
AP			**1MG/ML**	**A213573**	**002**	Apr 02, 2024
AP		HIKMA	**0.4MG/ML**	**A212300**	**002**	Mar 07, 2024
AP			**1MG/ML**	**A212300**	**001**	Jun 10, 2022
AP	**!**	HOSPIRA	**0.4MG/ML**	**A070172**	**001**	Sep 24, 1986
AP	**!**		**0.4MG/ML**	**A070256**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070257**	**001**	Jan 07, 1987
AP	**!**	INTL MEDICATION	**1MG/ML**	**A072076**	**001**	Mar 24, 1988
AP		MANKIND PHARMA	**0.4MG/ML**	**A218404**	**001**	Feb 29, 2024
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001**	Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001**	Jun 29, 2016
AP		MYLAN LABS LTD	**1MG/ML**	**A213843**	**001**	Jun 09, 2022
AP		PH HEALTH	**1MG/ML**	**A215964**	**001**	Jul 29, 2022
AP		RISING	**0.4MG/ML**	**A208871**	**001**	Feb 28, 2017
AP			**0.4MG/ML**	**A208872**	**001**	Mar 14, 2017
AP		SOMERSET THERAPS LLC	**0.4MG/ML**	**A207633**	**001**	Aug 08, 2017
AP			**0.4MG/ML**	**A207634**	**001**	Jul 26, 2017
AP		STERINOVA INC	**0.4MG/ML**	**A214211**	**001**	Aug 21, 2025

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

ZIMHI

+!	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021

SPRAY;NASAL

KLOXXADO

+	HIKMA	4MG/SPRAY	N212045	002	Aug 25, 2025
+!		8MG/SPRAY	N212045	001	Apr 29, 2021

SPRAY, METERED;NASAL

REXTOVY

+!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		LUPIN	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001**	Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001**	Mar 17, 2000
AB	**!**	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001**	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

VIVITROL

	+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		CHARTWELL	**50MG**	**A207905**	**001**	Jul 21, 2017
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	**!**	SPECGX LLC	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARM	**50MG**	**A090356**	**001**	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	**+**	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987

NAPROXEN

AB		AMNEAL	**25MG/ML**	**A212705**	**001**	Jul 31, 2020
AB		AUROBINDO PHARMA	**25MG/ML**	**A216504**	**001**	Oct 03, 2025
AB		HETERO LABS LTD III	**25MG/ML**	**A215776**	**001**	Jun 07, 2022
AB	**!**	HIKMA	**25MG/ML**	**A074190**	**001**	Mar 30, 1994
AB		NOVITIUM PHARMA	**25MG/ML**	**A211910**	**001**	Mar 10, 2021

TABLET;ORAL

NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**500MG**	**N017581**	**004**	Apr 15, 1982

NAPROXEN

AB		ADAPTIS	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK PHARMS LTD	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		GRANULES	**250MG**	**A074140**	**001**	Dec 21, 1993
AB			**375MG**	**A074140**	**002**	Dec 21, 1993
AB			**500MG**	**A074140**	**003**	Dec 21, 1993
AB		SCIEGEN PHARMS	**250MG**	**A212517**	**001**	Feb 21, 2020
AB			**375MG**	**A212517**	**002**	Feb 21, 2020
AB			**500MG**	**A212517**	**003**	Feb 21, 2020
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	**+!**		**500MG**	**N020067**	**003**	Oct 14, 1994

NAPROXEN

AB		AUROBINDO PHARMA USA	**375MG**	**A075390**	**001**	Apr 19, 2001
AB			**500MG**	**A075390**	**002**	Apr 19, 2001
AB		NOVITIUM PHARMA	**375MG**	**A218497**	**001**	Jun 12, 2024
AB			**500MG**	**A218497**	**002**	Jun 12, 2024
AB		NUVO PHARMS INC	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998
AB			**500MG**	**A075227**	**002**	Jun 30, 1998
AB		TP ANDA HOLDINGS	**375MG**	**A216908**	**001**	May 31, 2023
AB			**500MG**	**A216908**	**002**	May 31, 2023

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX DS

AB	**+!**	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987

NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		SCIEGEN PHARMS	**EQ 250MG BASE**	**A212199**	**001**	Oct 30, 2019
AB			**EQ 500MG BASE**	**A212199**	**002**	Oct 30, 2019

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	**+**	TWI PHARMS	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB	**+**		**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	**+!**		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996

NAPROXEN SODIUM

AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**500MG;EQ 85MG BASE**	**A207457**	**001**	Feb 15, 2018
AB		RISING	**500MG;EQ 85MG BASE**	**A090872**	**001**	Sep 04, 2018
AB		SUN PHARM	**500MG;EQ 85MG BASE**	**A202803**	**001**	Jul 20, 2018

TREXIMET

AB	**+!**	CURRAX	**500MG;EQ 85MG BASE**	**N021926**	**001**	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

AB		HERITAGE	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB	**!**		**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		HIKMA	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010
AB		ORBION PHARMS	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADAGIS US	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

	+!	HARROW EYE	5%	N050514	001	

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB		CADILA PHARMS LTD	**60MG**	**A206432**	**001**	Apr 19, 2019
AB			**120MG**	**A206432**	**002**	Apr 19, 2019
AB		DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB			**120MG**	**A077461**	**002**	Sep 09, 2009
AB		RISING	**60MG**	**A205544**	**001**	Jun 18, 2018
AB			**120MG**	**A205544**	**002**	Jun 18, 2018
AB		STRIDES PHARMA INTL	**60MG**	**A077463**	**001**	Sep 09, 2009
AB			**120MG**	**A077463**	**002**	Sep 09, 2009
AB		WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB			**120MG**	**A077462**	**002**	Mar 30, 2011
AB		ZYDUS PHARMS	**60MG**	**A205248**	**001**	Jul 06, 2016
AB	**!**		**120MG**	**A205248**	**002**	Jul 06, 2016

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

AB	+	ALLERGAN	**EQ 2.5MG BASE**	**N021742**	**002**	Dec 17, 2007
AB	+		**EQ 5MG BASE**	**N021742**	**003**	Dec 17, 2007
AB	+		**EQ 10MG BASE**	**N021742**	**004**	Dec 17, 2007
AB	+!		**EQ 20MG BASE**	**N021742**	**005**	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE

AB		ANI PHARMS	**EQ 2.5MG BASE**	**A203659**	**001**	Apr 16, 2015
AB			**EQ 5MG BASE**	**A203659**	**002**	Apr 16, 2015
AB			**EQ 10MG BASE**	**A203659**	**003**	Apr 16, 2015
AB			**EQ 20MG BASE**	**A203659**	**004**	Apr 16, 2015
AB		AUROBINDO PHARMA LTD	**EQ 2.5MG BASE**	**A211053**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A211053**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A211053**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A211053**	**004**	Dec 17, 2021
AB		CADILA PHARMS LTD	**EQ 2.5MG BASE**	**A208717**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A208717**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A208717**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A208717**	**004**	Dec 17, 2021
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A203821**	**001**	May 25, 2017
AB			**EQ 5MG BASE**	**A203821**	**002**	May 25, 2017
AB			**EQ 10MG BASE**	**A203821**	**003**	May 25, 2017
AB			**EQ 20MG BASE**	**A203821**	**004**	May 25, 2017
AB		HETERO LABS LTD III	**EQ 2.5MG BASE**	**A203825**	**001**	Nov 03, 2020
AB			**EQ 5MG BASE**	**A203825**	**002**	Nov 03, 2020
AB			**EQ 10MG BASE**	**A203825**	**003**	Nov 03, 2020
AB			**EQ 20MG BASE**	**A203825**	**004**	Nov 03, 2020
AB		INDCHEMIE HEALTH	**EQ 2.5MG BASE**	**A203828**	**001**	Jul 29, 2015
AB			**EQ 5MG BASE**	**A203828**	**002**	Jul 29, 2015
AB			**EQ 10MG BASE**	**A203828**	**003**	Jul 29, 2015
AB			**EQ 20MG BASE**	**A203828**	**004**	Jul 29, 2015
AB		MACLEODS PHARMS LTD	**EQ 2.5MG BASE**	**A212661**	**001**	Jan 28, 2025
AB			**EQ 5MG BASE**	**A212661**	**002**	Jan 28, 2025
AB			**EQ 10MG BASE**	**A212661**	**003**	Jan 28, 2025
AB			**EQ 20MG BASE**	**A212661**	**004**	Jan 28, 2025
AB		MANKIND PHARMA	**EQ 2.5MG BASE**	**A216172**	**001**	Nov 14, 2022
AB			**EQ 5MG BASE**	**A216172**	**002**	Nov 14, 2022
AB			**EQ 10MG BASE**	**A216172**	**003**	Nov 14, 2022
AB			**EQ 20MG BASE**	**A216172**	**004**	Nov 14, 2022
AB		MSN	**EQ 2.5MG BASE**	**A217397**	**001**	Oct 01, 2024
AB			**EQ 5MG BASE**	**A217397**	**002**	Oct 01, 2024
AB			**EQ 10MG BASE**	**A217397**	**003**	Oct 01, 2024
AB			**EQ 20MG BASE**	**A217397**	**004**	Oct 01, 2024
AB		PRINSTON INC	**EQ 2.5MG BASE**	**A212682**	**001**	Apr 07, 2022
AB			**EQ 5MG BASE**	**A212682**	**002**	Apr 07, 2022
AB			**EQ 10MG BASE**	**A212682**	**003**	Apr 07, 2022
AB			**EQ 20MG BASE**	**A212682**	**004**	Apr 07, 2022
AB		REGCON HOLDINGS	**EQ 2.5MG BASE**	**A216568**	**001**	Mar 30, 2023
AB			**EQ 5MG BASE**	**A216568**	**002**	Mar 30, 2023
AB			**EQ 10MG BASE**	**A216568**	**003**	Mar 30, 2023
AB			**EQ 20MG BASE**	**A216568**	**004**	Mar 30, 2023
AB		REYOUNG	**EQ 2.5MG BASE**	**A212917**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A212917**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A212917**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A212917**	**004**	Dec 17, 2021
AB		TORRENT	**EQ 2.5MG BASE**	**A203966**	**001**	Mar 02, 2018
AB			**EQ 5MG BASE**	**A203966**	**002**	Mar 02, 2018
AB			**EQ 10MG BASE**	**A203966**	**003**	Mar 02, 2018
AB			**EQ 20MG BASE**	**A203966**	**004**	Mar 02, 2018
AB		UNICHEM	**EQ 2.5MG BASE**	**A213830**	**001**	Mar 15, 2022
AB			**EQ 5MG BASE**	**A213830**	**002**	Mar 15, 2022
AB			**EQ 10MG BASE**	**A213830**	**003**	Mar 15, 2022
AB			**EQ 20MG BASE**	**A213830**	**004**	Mar 15, 2022

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

VYDUO

	PRINSTON INC	EQ 5MG BASE;80MG	A210596	001	Sep 19, 2022

NEDOSIRAN SODIUM							
SOLUTION;INJECTION							
RIVFLOZA							
	+!	NOVO	EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML)	N215842	001	Sep 29, 2023
	+!		EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML)	N215842	002	Sep 29, 2023
	+!		EQ 160MG BASE/ML (EQ 160MG BASE/ML)	N215842	003	Sep 29, 2023
NEFAZODONE HYDROCHLORIDE							
TABLET;ORAL							
NEFAZODONE HYDROCHLORIDE							
		TEVA	50MG	A076037	001	Sep 16, 2003
			100MG	A076037	002	Sep 16, 2003
			150MG	A076037	003	Sep 16, 2003
			200MG	A076037	004	Sep 16, 2003
	!		250MG	A076037	005	Sep 16, 2003
NELARABINE							
INJECTABLE;INTRAVENOUS							
ARRANON							
AP	**+!**	SANDOZ	**250MG/50ML (5MG/ML)**	**N021877**	**001**	Oct 28, 2005
NELARABINE							
AP		ALEMBIC	**250MG/50ML (5MG/ML)**	**A218554**	**001**	Aug 01, 2024
AP		AMNEAL	**250MG/50ML (5MG/ML)**	**A216346**	**001**	Apr 04, 2023
AP		DR REDDYS	**250MG/50ML (5MG/ML)**	**A216934**	**001**	Dec 23, 2022
AP		GLAND	**250MG/50ML (5MG/ML)**	**A212605**	**001**	Jan 03, 2024
AP		MEITHEAL	**250MG/50ML (5MG/ML)**	**A216038**	**001**	Jan 10, 2023
AP		MSN	**250MG/50ML (5MG/ML)**	**A216948**	**001**	Sep 13, 2024
AP		NEXUS	**250MG/50ML (5MG/ML)**	**A215057**	**001**	Jun 02, 2023
AP		SHORLA	**250MG/50ML (5MG/ML)**	**A214809**	**001**	Mar 03, 2023
AP		XGEN PHARMS	**250MG/50ML (5MG/ML)**	**A216510**	**001**	Sep 05, 2024
AP		ZYDUS PHARMS	**250MG/50ML (5MG/ML)**	**A215037**	**001**	Nov 17, 2021
	!	SHORLA	375MG/75ML (5MG/ML)	A214809	002	Jul 16, 2025
NELFINAVIR MESYLATE							
TABLET;ORAL							
VIRACEPT							
	+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997
	+!		EQ 625MG BASE	N021503	001	Apr 30, 2003
NEOMYCIN SULFATE							
TABLET;ORAL							
NEOMYCIN SULFATE							
AA		AARXION ANDA HLDING	**500MG**	**A065220**	**001**	Jul 28, 2006
AA	**!**	TEVA	**500MG**	**A060304**	**001**	
NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
SOLUTION;IRRIGATION							
NEOMYCIN AND POLYMYXIN B SULFATE							
AT		WATSON LABS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A062664**	**001**	Apr 08, 1986
AT		XGEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001**	Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001**	Jan 31, 2006
NEOSPORIN G.U. IRRIGANT							
AT	**!**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**	
NEOSTIGMINE METHYLSULFATE							
SOLUTION;INTRAVENOUS							
NEOSTIGMINE METHYLSULFATE							
AP		AMNEAL	**5MG/10ML (0.5MG/ML)**	**A210051**	**001**	Jun 15, 2018
AP			**10MG/10ML (1MG/ML)**	**A210051**	**002**	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A209933**	**001**	Sep 25, 2017
AP			**10MG/10ML (1MG/ML)**	**A209933**	**002**	Sep 25, 2017
AP		AMRING PHARMS	**5MG/10ML (0.5MG/ML)**	**A210989**	**001**	Aug 22, 2018
AP			**10MG/10ML (1MG/ML)**	**A210989**	**002**	Aug 22, 2018
AP		AVET LIFESCIENCES	**5MG/10ML (0.5MG/ML)**	**A208230**	**001**	Nov 25, 2022
AP			**10MG/10ML (1MG/ML)**	**A208230**	**002**	Nov 25, 2022
AP		BE PHARMS	**5MG/10ML (0.5MG/ML)**	**A212512**	**001**	May 13, 2019
AP			**10MG/10ML (1MG/ML)**	**A212512**	**002**	May 13, 2019
AP		CAPLIN	**5MG/10ML (0.5MG/ML)**	**A213074**	**001**	Apr 20, 2021
AP			**10MG/10ML (1MG/ML)**	**A213074**	**002**	Apr 20, 2021
AP		DR REDDYS	**3MG/3ML (1MG/ML)**	**A216291**	**001**	Jul 06, 2022
AP			**5MG/10ML (0.5MG/ML)**	**A209135**	**001**	Jul 10, 2018
AP			**10MG/10ML (1MG/ML)**	**A209135**	**002**	Jul 10, 2018
AP	**+!**	FRESENIUS KABI USA	**3MG/3ML (1MG/ML)**	**N203629**	**003**	Sep 18, 2018
AP		GLAND	**5MG/10ML (0.5MG/ML)**	**A212968**	**001**	Oct 16, 2019
AP			**10MG/10ML (1MG/ML)**	**A212968**	**002**	Oct 16, 2019

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		HIKMA	**3MG/3ML (1MG/ML)**	**A216206**	**001**	Jul 13, 2022
AP	**!**		**5MG/10ML (0.5MG/ML)**	**A207042**	**001**	Dec 28, 2015
AP	**!**		**10MG/10ML (1MG/ML)**	**A207042**	**002**	Dec 28, 2015
AP		MEITHEAL	**5MG/10ML (0.5MG/ML)**	**A212804**	**001**	Apr 05, 2021
AP			**10MG/10ML (1MG/ML)**	**A212804**	**002**	Apr 05, 2021
AP		PH HEALTH	**5MG/10ML (0.5MG/ML)**	**A208405**	**001**	Apr 26, 2017
AP			**10MG/10ML (1MG/ML)**	**A208405**	**002**	Apr 26, 2017
AP		REGCON HOLDINGS	**5MG/10ML (0.5MG/ML)**	**A210652**	**001**	Oct 01, 2021
AP			**10MG/10ML (1MG/ML)**	**A210652**	**002**	Oct 01, 2021
AP		SAGENT PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A216542**	**001**	Feb 17, 2023
AP			**10MG/10ML (1MG/ML)**	**A216542**	**002**	Feb 17, 2023
AP		UMEDICA	**5MG/10ML (0.5MG/ML)**	**A212627**	**001**	Nov 03, 2022
AP			**10MG/10ML (1MG/ML)**	**A212627**	**002**	Nov 03, 2022

BLOXIVERZ

	+!	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023

NEOSTIGMINE METHYLSULFATE

	+!	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
	+!		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

	+!	HARROW EYE	0.3%	N203491	001	Oct 16, 2012

NEVANAC

	+!	HARROW EYE	0.1%	N021862	001	Aug 19, 2005

NERANDOMILAST

TABLET;ORAL

JASCAYD

	+	BOEHRINGER INGELHEIM	9MG	N218764	001	Oct 07, 2025
	+		9MG	N220449	001	Dec 19, 2025
	+!		18MG	N218764	002	Oct 07, 2025
	+!		18MG	N220449	002	Dec 19, 2025

NERATINIB MALEATE

TABLET;ORAL

NERLYNX

	+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

	+!	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL

AKYNZEO

	+!	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE

AA	**!**	AUROBINDO	**50MG/5ML**	**A077702**	**001**	May 22, 2012
AA		CIPLA	**50MG/5ML**	**A207684**	**001**	Aug 03, 2017

TABLET;ORAL

NEVIRAPINE

AB		AUROBINDO	**200MG**	**A077521**	**001**	May 22, 2012
AB		CIPLA	**200MG**	**A077956**	**001**	May 22, 2012
AB		HETERO LABS LTD III	**200MG**	**A078584**	**001**	May 22, 2012
AB	**!**	MACLEODS PHARMS LTD	**200MG**	**A090688**	**001**	Jan 14, 2019
AB		MICRO LABS LTD	**200MG**	**A203080**	**001**	May 22, 2012
AB		MYLAN PHARMS INC	**200MG**	**A202523**	**001**	May 22, 2012

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB	**!**	MACLEODS PHARMS LTD	**400MG**	**A206879**	**001**	Oct 06, 2017
AB		MYLAN	**400MG**	**A205651**	**001**	Oct 27, 2014
AB		SANDOZ	**400MG**	**A203411**	**001**	Apr 03, 2014

NIACIN

TABLET;ORAL

NIACOR

	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		AMNEAL PHARMS	**500MG**	**A203578**	**001**	Jul 24, 2015
AB			**750MG**	**A204178**	**001**	Dec 11, 2015
AB			**1GM**	**A203578**	**002**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**500MG**	**A209236**	**001**	Feb 01, 2018
AB			**750MG**	**A209236**	**002**	Feb 01, 2018
AB			**1GM**	**A209236**	**003**	Feb 01, 2018
AB		BARR	**500MG**	**A076378**	**001**	Apr 26, 2005
AB			**750MG**	**A076378**	**002**	Apr 26, 2005
AB			**1GM**	**A076250**	**001**	Apr 14, 2005
AB		CHARTWELL RX	**500MG**	**A090860**	**001**	Mar 20, 2014
AB			**750MG**	**A090892**	**001**	Mar 20, 2014
AB			**1GM**	**A090446**	**001**	Mar 20, 2014
AB		HIBROW HLTHCARE	**500MG**	**A213090**	**001**	Aug 25, 2023
AB			**750MG**	**A213090**	**002**	Aug 25, 2023
AB			**1GM**	**A213090**	**003**	Aug 25, 2023
AB		LANNETT CO INC	**500MG**	**A203899**	**001**	Jun 16, 2017
AB			**1GM**	**A203899**	**002**	Jun 16, 2017
AB		MACLEODS PHARMS LTD	**500MG**	**A204934**	**001**	Mar 03, 2022
AB			**1GM**	**A204934**	**002**	Mar 03, 2022
AB		MPP PHARMA	**500MG**	**A207726**	**001**	Jul 25, 2025
AB			**750MG**	**A207726**	**002**	Jul 25, 2025
AB			**1GM**	**A207726**	**003**	Jul 25, 2025
AB		SUN PHARM	**500MG**	**A200484**	**001**	Apr 23, 2014
AB	!		**750MG**	**A201273**	**001**	Apr 23, 2014
AB	!		**1GM**	**A200484**	**002**	Apr 23, 2014

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		AMNEAL	**20MG**	**A218202**	**001**	Apr 10, 2024
AB			**30MG**	**A218202**	**002**	Apr 10, 2024
AB		ANDA REPOSITORY	**20MG**	**A215377**	**001**	Jul 17, 2023
AB			**30MG**	**A215377**	**002**	Jul 17, 2023
AB		ANI PHARMS	**20MG**	**A074670**	**001**	Oct 28, 1996
AB			**30MG**	**A074670**	**002**	Oct 28, 1996
AB		BIONPHARMA	**20MG**	**A217555**	**001**	May 03, 2023
AB			**30MG**	**A217555**	**002**	May 03, 2023
AB		EPIC PHARMA LLC	**20MG**	**A074928**	**001**	Mar 19, 1998
AB	!		**30MG**	**A074928**	**002**	Mar 19, 1998
AB		GLENMARK PHARMS LTD	**20MG**	**A216357**	**001**	Dec 16, 2022
AB			**30MG**	**A216357**	**002**	Dec 16, 2022
AB		NAVINTA LLC	**20MG**	**A218638**	**001**	Jun 25, 2025
AB			**30MG**	**A218638**	**002**	Jun 25, 2025

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	!	AM REGENT	**25MG/10ML (2.5MG/ML)**	**A090534**	**001**	Nov 17, 2009
AP		CHENGDU SHUODE	**25MG/10ML (2.5MG/ML)**	**A217548**	**001**	Sep 06, 2024
AP		EUGIA PHARMA	**25MG/10ML (2.5MG/ML)**	**A211121**	**001**	Apr 08, 2021
AP	+!	HIKMA INTL PHARMS	**25MG/10ML (2.5MG/ML)**	**N022276**	**001**	Jul 24, 2008
AP		MANKIND PHARMA	**25MG/10ML (2.5MG/ML)**	**A090671**	**001**	Nov 17, 2009
AP		MICRO LABS	**25MG/10ML (2.5MG/ML)**	**A216420**	**001**	Jul 07, 2023
AP		NANJING KING FRIEND	**25MG/10ML (2.5MG/ML)**	**A216819**	**001**	Aug 20, 2025
AP		QILU PHARM HAINAN	**25MG/10ML (2.5MG/ML)**	**A219608**	**001**	Oct 28, 2025
AP		RK PHARMA	**25MG/10ML (2.5MG/ML)**	**A090664**	**001**	Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+!	CHIESI	**40MG/200ML (0.2MG/ML)**	**N019734**	**004**	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+!	CHIESI	**20MG/200ML (0.1MG/ML)**	**N019734**	**003**	Jul 31, 2008

NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE

AP		INFORLIFE	**40MG/200ML (0.2MG/ML)**	**A203978**	**002**	Apr 17, 2024

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

AP		INFORLIFE	**20MG/200ML (0.1MG/ML)**	**A203978**	**001**	Apr 17, 2024

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

AP		CAPLIN	**20MG/200ML (0.1MG/ML)**	**A220243**	**001**	Oct 22, 2025
AP			**40MG/200ML (0.2MG/ML)**	**A220243**	**002**	Oct 22, 2025

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

AP		CIPLA	**20MG/200ML (0.1MG/ML)**	**A215592**	**001**	Sep 24, 2024
AP			**40MG/200ML (0.2MG/ML)**	**A215592**	**002**	Sep 24, 2024
AP	**+!**	HIKMA INTL PHARMS	**20MG/200ML (0.1MG/ML)**	**N022276**	**002**	Apr 07, 2016
AP	**+!**		**40MG/200ML (0.2MG/ML)**	**N022276**	**003**	Apr 07, 2016

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

	+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICOTINE

SPRAY, METERED;NASAL

NICOTROL

	+!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACELLA	**10MG**	**A072781**	**001**	Jul 30, 1993
AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001**	Jan 08, 1991
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001**	Apr 25, 2013
AB			**20MG**	**A202644**	**002**	Apr 25, 2013
AB		VELZEN PHARMA PVT	**10MG**	**A073250**	**001**	Oct 08, 1991
AB			**20MG**	**A074045**	**001**	Apr 30, 1992

PROCARDIA

AB	**+!**	PFIZER	**10MG**	**N018482**	**001**	

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1		AUROBINDO PHARMA	**30MG**	**A213361**	**001**	Jul 19, 2021
AB1			**60MG**	**A213361**	**002**	Jul 19, 2021
AB1			**90MG**	**A213361**	**003**	Jul 19, 2021
AB1		NOVAST LABS	**30MG**	**A202987**	**001**	Aug 25, 2016
AB1	**!**		**60MG**	**A202987**	**002**	Aug 25, 2016
AB1	**!**		**90MG**	**A202987**	**003**	Aug 25, 2016
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269**	**001**	Dec 04, 2000
AB1			**60MG**	**A075269**	**002**	Dec 04, 2000
AB1			**90MG**	**A076070**	**001**	Aug 16, 2002
AB1		ZYDUS PHARMS	**30MG**	**A210184**	**001**	Jun 29, 2018
AB1			**60MG**	**A210184**	**002**	Jun 29, 2018
AB1			**90MG**	**A210184**	**003**	Jun 29, 2018
AB2		ALEMBIC	**30MG**	**A216896**	**001**	Nov 18, 2022
AB2			**60MG**	**A216896**	**002**	Nov 18, 2022
AB2			**90MG**	**A216896**	**003**	Nov 18, 2022
AB2		ALKEM LABS LTD	**30MG**	**A216067**	**001**	Mar 29, 2022
AB2			**60MG**	**A216067**	**002**	Mar 29, 2022
AB2			**90MG**	**A216067**	**003**	Mar 29, 2022
AB2		ELITE PHARM SOLUTION	**90MG**	**A212016**	**001**	Nov 18, 2020
AB2		NOVAST LABS	**30MG**	**A210614**	**001**	Mar 12, 2019
AB2			**60MG**	**A210614**	**002**	Mar 12, 2019
AB2			**90MG**	**A210614**	**003**	Mar 12, 2019
AB2		OSMOTICA PHARM US	**30MG**	**A077127**	**001**	Nov 21, 2005
AB2			**60MG**	**A077127**	**002**	Nov 21, 2005
AB2			**90MG**	**A077127**	**003**	Oct 03, 2007
AB2		TWI PHARMS	**30MG**	**A203126**	**001**	Apr 03, 2014
AB2			**60MG**	**A203126**	**002**	Apr 03, 2014
AB2			**90MG**	**A203126**	**003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289**	**002**	Feb 06, 2001
AB2			**60MG**	**A075289**	**001**	Sep 27, 2000
AB2		ZYDUS PHARMS	**30MG**	**A210012**	**001**	Dec 19, 2017
AB2			**60MG**	**A210012**	**002**	Dec 19, 2017
AB2			**90MG**	**A210012**	**003**	Dec 19, 2017

PROCARDIA XL

AB2	**+**	PFIZER	**30MG**	**N019684**	**001**	Sep 06, 1989
AB2	**+**		**60MG**	**N019684**	**002**	Sep 06, 1989
AB2	**+!**		**90MG**	**N019684**	**003**	Sep 06, 1989

NIFURTIMOX
TABLET;ORAL
LAMPIT

	+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020
	+!		120MG	N213464	002	Aug 06, 2020

NILOTINIB D-TARTRATE
CAPSULE;ORAL
NILOTINIB D-TARTRATE

	+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025
	+		EQ 150MG BASE	N218922	002	Feb 19, 2025
	+!		EQ 200MG BASE	N218922	003	Feb 19, 2025

NILOTINIB HYDROCHLORIDE
CAPSULE;ORAL
NILOTINIB HYDROCHLORIDE

AB		APOTEX	**EQ 50MG BASE**	**A203640**	**001**	Jan 05, 2024
AB			**EQ 150MG BASE**	**A203640**	**002**	Jan 05, 2024
AB			**EQ 200MG BASE**	**A203640**	**003**	Jan 05, 2024
AB		DR REDDYS	**EQ 50MG BASE**	**A218350**	**001**	Nov 19, 2025
AB			**EQ 150MG BASE**	**A218350**	**002**	Nov 19, 2025
AB			**EQ 200MG BASE**	**A218350**	**003**	Nov 19, 2025
AB		HETERO LABS LTD V	**EQ 150MG BASE**	**A209651**	**001**	Nov 19, 2025
AB			**EQ 200MG BASE**	**A209651**	**002**	Nov 19, 2025
AB		MSN	**EQ 50MG BASE**	**A218544**	**001**	Nov 19, 2025
AB			**EQ 150MG BASE**	**A218544**	**002**	Nov 19, 2025
AB			**EQ 200MG BASE**	**A218544**	**003**	Nov 19, 2025
AB		TORRENT	**EQ 150MG BASE**	**A218532**	**001**	Dec 15, 2025
AB			**EQ 200MG BASE**	**A218532**	**002**	Dec 15, 2025
	TASIGNA					
AB	**+**	NOVARTIS	**EQ 50MG BASE**	**N022068**	**003**	Mar 22, 2018
AB	**+**		**EQ 150MG BASE**	**N022068**	**002**	Jun 17, 2010
AB	**+!**		**EQ 200MG BASE**	**N022068**	**001**	Oct 29, 2007

NILOTINIB TARTRATE
TABLET;ORAL
DANZITEN

	+!	AZURITY	EQ 71MG BASE	N219293	001	Nov 07, 2024
	+!		EQ 95MG BASE	N219293	002	Nov 07, 2024

NILUTAMIDE
TABLET;ORAL
NILANDRON

AB	**+!**	ADVANZ PHARMA	**150MG**	**N020169**	**002**	Apr 30, 1999
	NILUTAMIDE					
AB		ANI PHARMS	**150MG**	**A207631**	**001**	Jul 15, 2016

NIMODIPINE
CAPSULE;ORAL
NIMODIPINE

AB	**!**	BIONPHARMA	**30MG**	**A076740**	**001**	Jan 17, 2008
AB		HERITAGE	**30MG**	**A077811**	**001**	May 02, 2007
AB		THEPHARMANETWORK LLC	**30MG**	**A090103**	**001**	Apr 07, 2014

SOLUTION;ORAL
NIMODIPINE

AB		ALKEM LABS LTD	**6MG/ML**	**A213409**	**001**	Jan 22, 2025
	NYMALIZE					
AB	**+!**	AZURITY	**6MG/ML**	**N203340**	**002**	Apr 08, 2020
	NIMODIPINE					
	!	ANNORA PHARMA	3MG/ML	A216937	001	Jul 09, 2024

NINTEDANIB ESYLATE
CAPSULE;ORAL
OFEV

	+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
	+!		EQ 150MG BASE	N205832	002	Oct 15, 2014

NIRAPARIB TOSYLATE
TABLET;ORAL
ZEJULA

	+	GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023
	+		EQ 200MG BASE	N214876	002	Apr 26, 2023
	+!		EQ 300MG BASE	N214876	003	Apr 26, 2023

NIRMATRELVIR; RITONAVIR
TABLET;ORAL
PAXLOVID (COPACKAGED)

	+!	PFIZER	150MG;100MG	N217188	001	May 25, 2023

NIROGACESTAT HYDROBROMIDE
TABLET;ORAL
OGSIVEO

	+	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023
	+		EQ 100MG BASE	N217677	002	Apr 04, 2024
	+!		EQ 150MG BASE	N217677	003	Apr 04, 2024

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

AB		AMTA	**17MG**	**A216606**	**002**	Dec 12, 2025
AB		MYLAN	**8.5MG**	**A091001**	**001**	Jan 26, 2011
AB			**17MG**	**A091001**	**002**	Jan 26, 2011
AB			**34MG**	**A091001**	**004**	Jan 26, 2011

SULAR

AB	**+!**	COVIS	**8.5MG**	**N020356**	**008**	Jan 02, 2008
AB	**+!**		**17MG**	**N020356**	**007**	Jan 02, 2008
AB	**+!**		**34MG**	**N020356**	**005**	Jan 02, 2008

NISOLDIPINE

	!	MYLAN	20MG	A079051	001	Jul 25, 2008
			25.5MG	A091001	003	Jan 26, 2011
			30MG	A079051	002	Jul 25, 2008
	!		40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE
TABLET;ORAL
NITAZOXANIDE

AB		ANI PHARMS	**500MG**	**A214844**	**001**	Feb 03, 2025
AB		ANNORA PHARMA	**500MG**	**A218701**	**001**	Apr 15, 2025
AB	**!**	RISING	**500MG**	**A213820**	**001**	Nov 27, 2020

NITISINONE
CAPSULE;ORAL
NITISINONE

AB		ETON	**2MG**	**A216201**	**001**	May 25, 2023
AB			**5MG**	**A216201**	**002**	May 25, 2023
AB			**10MG**	**A216201**	**003**	May 25, 2023
AB			**20MG**	**A216201**	**004**	May 25, 2023
AB		MEDUNIK	**2MG**	**A212390**	**001**	May 26, 2022
AB			**5MG**	**A212390**	**002**	May 26, 2022
AB			**10MG**	**A212390**	**003**	May 26, 2022
AB			**20MG**	**A212390**	**004**	Apr 27, 2023
AB		NOVITIUM PHARMA	**2MG**	**A211041**	**001**	Aug 26, 2019
AB			**5MG**	**A211041**	**002**	Aug 26, 2019
AB			**10MG**	**A211041**	**003**	Aug 26, 2019

ORFADIN

AB	**+**	SWEDISH ORPHAN	**2MG**	**N021232**	**001**	Jan 18, 2002
AB	**+**		**5MG**	**N021232**	**002**	Jan 18, 2002
AB	**+**		**10MG**	**N021232**	**003**	Jan 18, 2002
AB	**+!**		**20MG**	**N021232**	**004**	Jun 13, 2016

SUSPENSION;ORAL
ORFADIN

	+!	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016

TABLET;ORAL
HARLIKU

	+!	CYCLE	2MG	N209449	004	Jun 10, 2025

NITYR

	+	CYCLE	2MG	N209449	001	Jul 26, 2017
	+		5MG	N209449	002	Jul 26, 2017
	+!		10MG	N209449	003	Jul 26, 2017

NITRIC OXIDE
GAS;INHALATION
INOMAX

AA	**+!**	MALLINCKRODT IRELAND	**800PPM**	**N020845**	**003**	Dec 23, 1999

NOXIVENT

AA		LINDE GAS EQUIP	**800PPM**	**A207141**	**002**	Oct 02, 2018

ULSPIRA

AA		AIRGAS THERAP	**800PPM**	**A203144**	**001**	Jul 27, 2023

NITRIC OXIDE

GAS;INHALATION

GENOSYL

	+!	VERO BIOTECH INC	800PPM	N202860	001	Dec 20, 2019

INOMAX

	+!	MALLINCKRODT IRELAND	4880PPM	N020845	004	Jan 17, 2023

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

AB	**+**	CASPER PHARMA LLC	**25MG/5ML**	**N009175**	**001**	

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	**25MG/5ML**	**A205180**	**001**	May 03, 2016
AB		AMNEAL PHARMS	**25MG/5ML**	**A201679**	**001**	May 11, 2011
AB		ANNORA PHARMA	**25MG/5ML**	**A219495**	**001**	Jul 02, 2025
AB		AUROBINDO PHARMA	**25MG/5ML**	**A212607**	**001**	May 11, 2023
AB		BIOCON PHARMA	**25MG/5ML**	**A218346**	**001**	Oct 28, 2024
AB		NOVEL LABS INC	**25MG/5ML**	**A201693**	**001**	Sep 08, 2014
AB		NOVITIUM PHARMA	**25MG/5ML**	**A216385**	**001**	Apr 14, 2023
AB		SOMERSET THERAPS LLC	**25MG/5ML**	**A208909**	**001**	Jan 14, 2025
AB		STRIDES PHARMA	**25MG/5ML**	**A201355**	**001**	Aug 14, 2013

FURADANTIN

	+!	CASPER PHARMA LLC	50MG/5ML	N009175	002	Jun 09, 2023

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB	**+**	ALMATICA	**25MG**	**N016620**	**003**	
AB	**+**		**50MG**	**N016620**	**001**	
AB	**+!**		**100MG**	**N016620**	**002**	

NITROFURANTOIN

AB		ALEMBIC	**25MG**	**A211935**	**001**	Jun 25, 2021
AB			**50MG**	**A211935**	**002**	Jun 25, 2021
AB			**100MG**	**A211935**	**003**	Jun 25, 2021
AB		AUROBINDO PHARMA USA	**25MG**	**A077025**	**002**	Oct 02, 2024
AB			**50MG**	**A074967**	**001**	Jul 09, 1997
AB			**100MG**	**A074967**	**002**	Jul 09, 1997
AB			**100MG**	**A077025**	**001**	Aug 18, 2004
AB		IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993
AB			**100MG**	**A073652**	**001**	Jan 28, 1993
AB		MANKIND PHARMA	**25MG**	**A217272**	**001**	Mar 21, 2023
AB			**50MG**	**A217272**	**002**	Mar 21, 2023
AB			**100MG**	**A217272**	**003**	Mar 21, 2023
AB		NOVEL LABS INC	**50MG**	**A203233**	**001**	Jul 09, 2018
AB			**100MG**	**A203233**	**002**	Jul 09, 2018
AB		ZYDUS PHARMS	**50MG**	**A205005**	**001**	Dec 12, 2017
AB			**100MG**	**A205005**	**002**	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	**+!**	ALMATICA	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AUROBINDO PHARMA	**75MG;25MG**	**A209225**	**001**	Mar 30, 2023
AB		INVENTIA	**75MG;25MG**	**A211013**	**001**	Feb 18, 2022
AB		MANKIND PHARMA	**75MG;25MG**	**A217357**	**001**	Jul 11, 2023
AB		OMSAV PHARMA	**75MG;25MG**	**A217073**	**001**	Nov 03, 2023
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005
AB		SUNNY	**75MG;25MG**	**A208516**	**001**	May 24, 2018
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

	+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2	**!**	MYLAN TECHNOLOGIES	**0.1MG/HR**	**A074559**	**004**	Feb 06, 1998
AB2	**!**		**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996
AB2	**!**		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996
AB2	**!**		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2		ZYDUS PHARMS	**0.1MG/HR**	**A089885**	**002**	Oct 30, 2017
AB2			**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998

NITRO-DUR

+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995
+!		0.2MG/HR	N020145	002	Apr 04, 1995
+!		0.3MG/HR	N020145	003	Apr 04, 1995
+!		0.4MG/HR	N020145	004	Apr 04, 1995
+!		0.6MG/HR	N020145	005	Apr 04, 1995
+!		0.8MG/HR	N020145	006	Apr 04, 1995

INJECTABLE;INJECTION

NITROGLYCERIN

!	AM REGENT	5MG/ML	A072034	001	May 24, 1988

NITROGLYCERIN IN DEXTROSE 5%

+!	BAXTER HLTHCARE	10MG/100ML	N019970	001	Dec 29, 1989
+!		20MG/100ML	N019970	002	Dec 29, 1989
+!		40MG/100ML	N019970	003	Dec 29, 1989

OINTMENT;INTRA-ANAL

NITROGLYCERIN

AB		COSETTE	**0.4%**	**A216103**	**001**	Feb 16, 2024
AB		ENCUBE	**0.4%**	**A216452**	**001**	Dec 16, 2024
AB		SOLARIS PHARMA CORP	**0.4%**	**A218756**	**001**	Dec 18, 2025
AB		TP ANDA HOLDINGS	**0.4%**	**A212222**	**001**	Nov 29, 2024

RECTIV

AB	**+!**	ABBVIE	**0.4%**	**N021359**	**001**	Jun 21, 2011

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB		ENCUBE	**2%**	**A218235**	**001**	Apr 15, 2025
AB	**+!**	FOUGERA PHARMS INC	**2%**	**A087355**	**001**	Jul 08, 1988

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

AB		PADAGIS ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013

NITROLINGUAL PUMPSPRAY

AB	**+!**	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		AUROBINDO PHARMA	**0.3MG**	**A217879**	**001**	Oct 26, 2023
AB			**0.4MG**	**A217879**	**002**	Oct 26, 2023
AB			**0.6MG**	**A217879**	**003**	Oct 26, 2023
AB		DR REDDYS	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
AB		GLENMARK SPECLT	**0.3MG**	**A206391**	**001**	Sep 19, 2017
AB			**0.4MG**	**A206391**	**002**	Sep 19, 2017
AB			**0.6MG**	**A206391**	**003**	Sep 19, 2017
AB		MANKIND PHARMA	**0.3MG**	**A217970**	**001**	Dec 05, 2023
AB			**0.4MG**	**A217970**	**002**	Dec 05, 2023
AB			**0.6MG**	**A217970**	**003**	Dec 05, 2023
AB		NATCO	**0.3MG**	**A211604**	**001**	Apr 30, 2019
AB			**0.4MG**	**A211604**	**002**	Apr 30, 2019
AB			**0.6MG**	**A211604**	**003**	Apr 30, 2019
AB		RUBICON RESEARCH	**0.3MG**	**A209779**	**001**	May 03, 2021
AB			**0.4MG**	**A209779**	**002**	May 03, 2021
AB			**0.6MG**	**A209779**	**003**	May 03, 2021
AB		VIWIT PHARM	**0.3MG**	**A218583**	**001**	Oct 15, 2024
AB			**0.4MG**	**A218583**	**002**	Oct 15, 2024
AB			**0.6MG**	**A218583**	**003**	Oct 15, 2024

NITROSTAT

AB	**+**	VIATRIS	**0.3MG**	**N021134**	**001**	May 01, 2000
AB	**+**		**0.4MG**	**N021134**	**002**	May 01, 2000
AB	**+!**		**0.6MG**	**N021134**	**003**	May 01, 2000

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

AB		DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB			**300MG**	**A077314**	**002**	Sep 15, 2005
AB		EPIC PHARMA LLC	**150MG**	**A076178**	**001**	Jul 05, 2002
AB			**300MG**	**A076178**	**002**	Jul 05, 2002

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE						
AB		WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB	**!**		**300MG**	**A075616**	**002**	Jul 09, 2002

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHED						
AP	**+!**	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	
NOREPINEPHRINE BITARTRATE						
AP		AMNEAL	**EQ 1MG BASE/ML**	**A210839**	**001**	Dec 17, 2018
AP		ANTHEA PHARMA	**EQ 1MG BASE/ML**	**A219924**	**001**	Nov 25, 2025
AP		ASPIRO	**EQ 1MG BASE/ML**	**A219163**	**001**	Jan 31, 2025
AP		BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP		BIOCON PHARMA	**EQ 1MG BASE/ML**	**A219443**	**001**	Mar 21, 2025
AP		BRECKENRIDGE	**EQ 1MG BASE/ML**	**A214455**	**001**	Jan 22, 2021
AP		CAPLIN	**EQ 1MG BASE/ML**	**A217575**	**001**	Sep 15, 2023
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A211382**	**001**	Nov 03, 2020
AP		GLAND	**EQ 1MG BASE/ML**	**A214323**	**001**	May 06, 2021
AP		HIKMA	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
AP			**EQ 1MG BASE/ML**	**A203662**	**001**	Nov 07, 2018
AP		MEITHEAL	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003
AP		MSN	**EQ 1MG BASE/ML**	**A218595**	**001**	Dec 11, 2025
AP		MYLAN LABS LTD	**EQ 1MG BASE/ML**	**A211242**	**001**	Oct 04, 2018
AP		RISING	**EQ 1MG BASE/ML**	**A218758**	**001**	May 13, 2024
AP		SANDOZ	**EQ 1MG BASE/ML**	**A211359**	**001**	Oct 18, 2018

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE						
AP	**+!**	BAXTER HLTHCARE CORP	**EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)**	**N214313**	**001**	Jan 15, 2021
AP	**+!**		**EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)**	**N214313**	**002**	Jan 15, 2021
AP		SAGENT	**EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)**	**A219692**	**001**	Aug 11, 2025
AP			**EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)**	**A219692**	**002**	Aug 11, 2025
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
	+!	INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022
	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N215700	002	Sep 15, 2022
	+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N215700	003	Sep 15, 2022
	+!		EQ 32MG BASE/250ML (EQ 128MCG BASE/ML)	N215700	004	Oct 15, 2025
	+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022
	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022
	+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE						
	+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214313	003	Nov 21, 2023

NORETHINDRONE

TABLET;ORAL-28

CAMILA						
AB1		DR REDDYS LABS SA	**0.35MG**	**A076177**	**001**	Oct 21, 2002
HEATHER						
AB1		GLENMARK PHARMS LTD	**0.35MG**	**A090454**	**001**	Apr 23, 2010
INCASSIA						
AB1		AUROBINDO PHARMA	**0.35MG**	**A207304**	**001**	Sep 23, 2016
NOR-QD						
AB1	**+!**	TEVA BRANDED PHARM	**0.35MG**	**N017060**	**001**	
NORETHINDRONE						
AB1		LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011
AB1		NAARI PTE	**0.35MG**	**A206807**	**001**	Dec 13, 2016
AB1		NOVAST LABS	**0.35MG**	**A202014**	**001**	Sep 13, 2013
AB1		XIROMED	**0.35MG**	**A201483**	**001**	Jun 24, 2013
EMZAHH						
AB2		AUROBINDO PHARMA	**0.35MG**	**A216796**	**001**	Jan 06, 2023
ERRIN						
AB2		DR REDDYS LABS SA	**0.35MG**	**A076225**	**001**	Oct 21, 2002
JENCYCLA						
AB2		LUPIN LTD	**0.35MG**	**A091323**	**001**	Mar 28, 2013
NORETHINDRONE						
AB2		GLENMARK PHARMS LTD	**0.35MG**	**A091209**	**001**	Jul 22, 2010
AB2		NOVAST LABS	**0.35MG**	**A200961**	**001**	Sep 13, 2013
AB2	**!**	XIROMED	**0.35MG**	**A200980**	**001**	Jun 12, 2013

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		AMNEAL PHARMS	**5MG**	**A200275**	**001**	Jul 30, 2012
AB	!	BARR	**5MG**	**A075951**	**001**	May 25, 2001
AB		GLENMARK PHARMS LTD	**5MG**	**A091090**	**001**	Jul 21, 2010
AB		NOVAST LABS	**5MG**	**A206490**	**001**	Nov 05, 2018
AB		XIROMED	**5MG**	**A205278**	**001**	Nov 10, 2016

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		DR REDDYS LABS SA	**EQ 10MG BASE**	**A073556**	**002**	Mar 30, 1992
AB			**EQ 25MG BASE**	**A073556**	**003**	Mar 30, 1992
AB			**EQ 50MG BASE**	**A073556**	**004**	Mar 30, 1992
AB			**EQ 75MG BASE**	**A073556**	**001**	Mar 30, 1992
AB		TARO	**EQ 10MG BASE**	**A075520**	**004**	May 08, 2000
AB			**EQ 25MG BASE**	**A075520**	**003**	May 08, 2000
AB			**EQ 50MG BASE**	**A075520**	**001**	May 08, 2000
AB			**EQ 75MG BASE**	**A075520**	**002**	May 08, 2000
AB		TEVA	**EQ 10MG BASE**	**A074132**	**001**	Mar 27, 1995
AB			**EQ 25MG BASE**	**A074132**	**002**	Mar 27, 1995
AB			**EQ 50MG BASE**	**A074132**	**003**	Mar 27, 1995
AB	!		**EQ 75MG BASE**	**A074132**	**004**	Mar 27, 1995

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A075606**	**001**	Aug 23, 2000
AA		RUBICON RESEARCH	**EQ 10MG BASE/5ML**	**A217731**	**001**	Aug 15, 2023

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

	+!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062949**	**001**	Jun 13, 1988
AT		AUROBINDO PHARMA	**100,000 UNITS/GM**	**A219527**	**001**	Mar 21, 2025
AT		COSETTE	**100,000 UNITS/GM**	**A061966**	**001**	
AT		CROWN LABS INC	**100,000 UNITS/GM**	**A207733**	**001**	Sep 26, 2017
AT		FOUGERA PHARMS	**100,000 UNITS/GM**	**A062129**	**001**	
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM**	**A213566**	**001**	Aug 10, 2021
AT		PADAGIS US	**100,000 UNITS/GM**	**A062225**	**001**	
AT	!	SUN PHARMA CANADA	**100,000 UNITS/GM**	**A064022**	**001**	Jan 29, 1993
AT		TORRENT	**100,000 UNITS/GM**	**A212557**	**001**	Jul 24, 2019

OINTMENT;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062840**	**001**	Nov 13, 1987
AT		COSETTE	**100,000 UNITS/GM**	**A209114**	**001**	Oct 06, 2017
AT	!	FOUGERA PHARMS	**100,000 UNITS/GM**	**A062124**	**002**	Sep 23, 1982
AT		LYNE	**100,000 UNITS/GM**	**A209082**	**001**	May 21, 2018
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM**	**A213826**	**001**	Jan 14, 2021
AT		PADAGIS US	**100,000 UNITS/GM**	**A062472**	**001**	Feb 13, 1984
AT		TORRENT	**100,000 UNITS/GM**	**A211838**	**001**	Jan 28, 2019
AT		ZYDUS LIFESCIENCES	**100,000 UNITS/GM**	**A207767**	**001**	May 25, 2018

POWDER;TOPICAL

KLAYESTA

AT		EPIC PHARMA LLC	**100,000 UNITS/GM**	**A210532**	**001**	Apr 30, 2018

NYSTATIN

AT	!	DR REDDYS LABS SA	**100,000 UNITS/GM**	**A065203**	**001**	Jul 15, 2004
AT		LUPIN	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT		LYNE	**100,000 UNITS/GM**	**A208838**	**001**	May 30, 2017
AT		UPSHER SMITH LABS	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT		ZYDUS PHARMS	**100,000 UNITS/GM**	**A208581**	**001**	Jun 08, 2017

NYSTOP

AT		PADAGIS US	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

NYSTATIN

AA		FOUGERA PHARMS INC	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA		GENUS	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA		MLV	**100,000 UNITS/ML**	**A062832**	**001**	Dec 27, 1991

NYSTATIN

SUSPENSION;ORAL

NYSTATIN

AA		PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA		PHARMOBEDIENT	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984
AA	!	SENORES PHARMS	**100,000 UNITS/ML**	**A214346**	**001**	Mar 10, 2022

TABLET;ORAL

NYSTATIN

AA		HERITAGE	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA	!	TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEMBIC	**100,000 UNITS/GM;0.1%**	**A214090**	**001**	Mar 31, 2021
AT		AMNEAL	**100,000 UNITS/GM;0.1%**	**A209990**	**001**	Feb 15, 2018
AT		CHARTWELL RX	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207730**	**001**	Dec 26, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		LUPIN LTD	**100,000 UNITS/GM;0.1%**	**A208205**	**001**	May 31, 2018
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A214181**	**001**	Jul 13, 2022
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A208479**	**001**	Aug 14, 2017
AT	!	SUN PHARMA CANADA	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEMBIC	**100,000 UNITS/GM;0.1%**	**A214186**	**001**	Mar 04, 2022
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A207741**	**001**	Jan 31, 2017
AT		EPIC PHARMA LLC	**100,000 UNITS/GM;0.1%**	**A207217**	**001**	Aug 04, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A214751**	**001**	Aug 17, 2021
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RISING	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT	!	SUN PHARMA CANADA	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993
AT		ZYDUS LIFESCIENCES	**100,000 UNITS/GM;0.1%**	**A207764**	**001**	Nov 08, 2018

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

	+!	CHIESI	EQ 20MG BASE	N208232	001	Jun 26, 2020

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AB		MYLAN LABS LTD	**EQ 10MG BASE/VIAL**	**A216589**	**001**	Dec 12, 2025
AB			**EQ 20MG BASE/VIAL**	**A216589**	**002**	Dec 12, 2025
AB			**EQ 30MG BASE/VIAL**	**A216589**	**003**	Dec 12, 2025
AB		TEVA PHARMS USA INC	**EQ 10MG BASE/VIAL**	**A210317**	**001**	Dec 05, 2023
AB			**EQ 20MG BASE/VIAL**	**A210317**	**002**	Dec 05, 2023
AB			**EQ 30MG BASE/VIAL**	**A210317**	**003**	Dec 05, 2023

SANDOSTATIN LAR

AB	+	NOVARTIS	**EQ 10MG BASE/VIAL**	**N021008**	**001**	Nov 25, 1998
AB	+		**EQ 20MG BASE/VIAL**	**N021008**	**002**	Nov 25, 1998
AB	+!		**EQ 30MG BASE/VIAL**	**N021008**	**003**	Nov 25, 1998

OCTREOTIDE ACETATE

AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**	**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**	**A077450**	**002**	Feb 10, 2006
AP		GLAND	**EQ 0.1MG BASE/ML**	**A216839**	**002**	Jun 22, 2023
AP			**EQ 0.2MG BASE/ML**	**A216807**	**001**	Jun 13, 2023
AP			**EQ 0.5MG BASE/ML**	**A216839**	**001**	Jun 22, 2023
AP			**EQ 1MG BASE/ML**	**A216807**	**002**	Jun 13, 2023
AP		HERITAGE	**EQ 0.05MG BASE/ML**	**A204669**	**001**	Dec 27, 2018
AP			**EQ 0.1MG BASE/ML**	**A204669**	**002**	Dec 27, 2018
AP			**EQ 0.2MG BASE/ML**	**A203765**	**001**	Sep 07, 2018
AP			**EQ 0.5MG BASE/ML**	**A204669**	**003**	Dec 27, 2018
AP			**EQ 1MG BASE/ML**	**A203765**	**002**	Sep 07, 2018
AP		MEITHEAL	**EQ 0.05MG BASE/ML**	**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**	**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**	**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**	**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**	**A075959**	**002**	Nov 21, 2005
AP		SAGENT PHARMS INC	**EQ 0.2MG BASE/ML**	**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**	**A091041**	**002**	Nov 12, 2013
AP	!	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**	**A076330**	**001**	Apr 08, 2005
AP	!		**EQ 1MG BASE/ML**	**A076330**	**002**	Apr 08, 2005

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**	**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**	**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**	**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**	**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**	**A079198**	**003**	Feb 10, 2011
AP		SAGENT PHARMS INC	**EQ 0.05MG BASE/ML**	**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**	**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**	**A090834**	**003**	Nov 12, 2013
AP	!	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A076313**	**001**	Mar 28, 2005
AP	!		**EQ 0.1MG BASE/ML**	**A076313**	**003**	Mar 28, 2005
AP	!		**EQ 0.5MG BASE/ML**	**A076313**	**002**	Mar 28, 2005

SANDOSTATIN

AP	**+!**	NOVARTIS	**EQ 0.05MG BASE/ML**	**N019667**	**001**	Oct 21, 1988
AP	**+!**		**EQ 0.1MG BASE/ML**	**N019667**	**002**	Oct 21, 1988
AP	**+!**		**EQ 0.5MG BASE/ML**	**N019667**	**003**	Oct 21, 1988

SOLUTION;SUBCUTANEOUS

BYNFEZIA PEN

	+!	SUN PHARM	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	N213224	001	Sep 27, 2024

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

	+	IPSEN	0.4MG	N215498	002	Jul 20, 2021
	+!		1.2MG	N215498	004	Jul 20, 2021

CAPSULE, PELLETS;ORAL

BYLVAY

	+	IPSEN	0.2MG	N215498	001	Jul 20, 2021
	+!		0.6MG	N215498	003	Jul 20, 2021

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

AT	**+!**	ALLERGAN	**0.3%**	**N019921**	**001**	Jul 30, 1993

OFLOXACIN

AT		ALTAIRE PHARMS INC	**0.3%**	**A202692**	**001**	Apr 29, 2013
AT		APOTEX INC	**0.3%**	**A076513**	**001**	May 14, 2004
AT		BAUSCH AND LOMB	**0.3%**	**A076622**	**001**	May 14, 2004
AT		CAPLIN	**0.3%**	**A217904**	**001**	Apr 12, 2024
AT		FDC LTD	**0.3%**	**A078559**	**001**	Feb 25, 2009
AT		MANKIND PHARMA	**0.3%**	**A215886**	**001**	Nov 23, 2022
AT		SENTISS	**0.3%**	**A076407**	**001**	Apr 15, 2008
AT		SOMERSET	**0.3%**	**A213597**	**001**	Aug 01, 2024

SOLUTION/DROPS;OTIC

OFLOXACIN

AT		AMNEAL	**0.3%**	**A211525**	**001**	Aug 30, 2019
AT		APOTEX INC	**0.3%**	**A076527**	**001**	Sep 28, 2007
AT	!	BAUSCH AND LOMB	**0.3%**	**A076128**	**001**	Mar 17, 2008
AT		CAPLIN	**0.3%**	**A217903**	**001**	Jan 05, 2024
AT		FDC LTD	**0.3%**	**A215038**	**001**	Jan 19, 2022
AT		MANKIND PHARMA	**0.3%**	**A216130**	**001**	Jul 14, 2022
AT		SOMERSET THERAPS LLC	**0.3%**	**A216328**	**001**	Oct 15, 2024

TABLET;ORAL

OFLOXACIN

AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		CHARTWELL RX	**400MG**	**A076093**	**003**	Sep 02, 2003
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	!		**400MG**	**A076182**	**003**	Sep 02, 2003

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		ASPIRO	**10MG/VIAL**	**A217466**	**001**	Mar 22, 2023
AP		EUGIA PHARMA	**10MG/VIAL**	**A210968**	**001**	Oct 22, 2020
AP		QILU	**10MG/VIAL**	**A218116**	**001**	May 16, 2025
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011
AP		UBI	**10MG/VIAL**	**A211072**	**001**	Jun 11, 2025

ZYPREXA

AP	**+!**	CHEPLAPHARM	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004

TABLET;ORAL

OLANZAPINE

AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015
AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		CADILA PHARMS LTD	**2.5MG**	**A210022**	**001**	Feb 24, 2023
AB			**5MG**	**A210022**	**002**	Feb 24, 2023
AB			**7.5MG**	**A210022**	**003**	Feb 24, 2023
AB			**10MG**	**A210022**	**004**	Feb 24, 2023
AB			**15MG**	**A210022**	**005**	Feb 24, 2023
AB			**20MG**	**A210022**	**006**	Feb 24, 2023
AB		CHARTWELL MOLECULAR	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016
AB			**7.5MG**	**A203333**	**003**	Mar 15, 2016
AB			**10MG**	**A203333**	**004**	Mar 15, 2016
AB			**15MG**	**A203333**	**005**	Mar 15, 2016
AB			**20MG**	**A203333**	**006**	Mar 15, 2016
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		MACLEODS PHARMS LTD	**2.5MG**	**A202862**	**001**	Aug 15, 2014
AB			**5MG**	**A202862**	**002**	Aug 15, 2014
AB			**7.5MG**	**A202862**	**003**	Aug 15, 2014
AB			**10MG**	**A202862**	**004**	Aug 15, 2014
AB			**15MG**	**A202862**	**005**	Aug 15, 2014
AB			**20MG**	**A202862**	**006**	Aug 15, 2014
AB		ORBION PHARMS	**2.5MG**	**A202287**	**001**	Apr 23, 2012
AB			**5MG**	**A202287**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202287**	**003**	Apr 23, 2012
AB			**10MG**	**A202287**	**004**	Apr 23, 2012
AB			**15MG**	**A202287**	**005**	Apr 23, 2012
AB			**20MG**	**A202287**	**006**	Apr 23, 2012
AB		QILU	**2.5MG**	**A204319**	**001**	Jan 27, 2016
AB			**5MG**	**A204319**	**002**	Jan 27, 2016
AB			**7.5MG**	**A204319**	**003**	Jan 27, 2016
AB			**10MG**	**A204319**	**004**	Jan 27, 2016
AB			**15MG**	**A204319**	**005**	Jan 27, 2016
AB			**20MG**	**A204319**	**006**	Jan 27, 2016
AB		ZYDUS PHARMS	**2.5MG**	**A090459**	**001**	Jul 16, 2018
AB			**5MG**	**A090459**	**002**	Jul 16, 2018
AB			**7.5MG**	**A090459**	**003**	Jul 16, 2018
AB			**10MG**	**A090459**	**004**	Jul 16, 2018
AB			**15MG**	**A090459**	**005**	Jul 16, 2018

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB			**20MG**	**A090459**	**006**	Jul 16, 2018

ZYPREXA

AB	+	CHEPLAPHARM	**2.5MG**	**N020592**	**001**	Sep 30, 1996
AB	+!		**5MG**	**N020592**	**002**	Sep 30, 1996
AB	+		**7.5MG**	**N020592**	**003**	Sep 30, 1996
AB	+		**10MG**	**N020592**	**004**	Sep 30, 1996
AB	+		**15MG**	**N020592**	**005**	Sep 09, 1997
AB	+		**20MG**	**N020592**	**006**	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		APOTEX INC	**5MG**	**A091265**	**001**	Oct 24, 2011
AB			**10MG**	**A091265**	**002**	Oct 24, 2011
AB			**15MG**	**A091265**	**003**	Oct 24, 2011
AB			**20MG**	**A091265**	**004**	Oct 24, 2011
AB		AUROBINDO PHARMA LTD	**5MG**	**A203708**	**001**	May 15, 2014
AB			**10MG**	**A203708**	**002**	May 15, 2014
AB			**15MG**	**A203708**	**003**	May 15, 2014
AB			**20MG**	**A203708**	**004**	May 15, 2014
AB		BARR LABS INC	**5MG**	**A077243**	**001**	Jan 30, 2012
AB			**10MG**	**A077243**	**002**	Jan 30, 2012
AB			**15MG**	**A077243**	**003**	Jan 30, 2012
AB			**20MG**	**A077243**	**004**	Jan 30, 2012
AB		CHARTWELL MOLECULAR	**5MG**	**A203456**	**001**	Mar 16, 2016
AB			**10MG**	**A203456**	**002**	Mar 16, 2016
AB			**15MG**	**A203456**	**003**	Mar 16, 2016
AB			**20MG**	**A203456**	**004**	Mar 16, 2016
AB		DR REDDYS LABS LTD	**5MG**	**A076534**	**001**	Oct 24, 2011
AB			**10MG**	**A076534**	**002**	Oct 24, 2011
AB			**15MG**	**A076534**	**003**	Oct 24, 2011
AB			**20MG**	**A076534**	**004**	Oct 24, 2011
AB		HEC PHARM	**5MG**	**A208146**	**001**	Jul 02, 2018
AB			**10MG**	**A208146**	**002**	Jul 02, 2018
AB			**15MG**	**A208146**	**003**	Jul 02, 2018
AB			**20MG**	**A208146**	**004**	Jul 02, 2018
AB		HISUN PHARM HANGZHOU	**5MG**	**A206892**	**001**	Dec 31, 2020
AB			**10MG**	**A206892**	**002**	Dec 31, 2020
AB			**15MG**	**A206892**	**003**	Dec 31, 2020
AB			**20MG**	**A206892**	**004**	Dec 31, 2020
AB		JUBILANT GENERICS	**5MG**	**A200221**	**001**	Sep 12, 2012
AB			**10MG**	**A200221**	**002**	Sep 12, 2012
AB			**15MG**	**A200221**	**003**	Sep 12, 2012
AB			**20MG**	**A200221**	**004**	Sep 12, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A203044**	**001**	Feb 20, 2015
AB			**10MG**	**A203044**	**002**	Feb 20, 2015
AB			**15MG**	**A203044**	**003**	Feb 20, 2015
AB			**20MG**	**A203044**	**004**	Feb 20, 2015
AB		ORBION PHARMS	**5MG**	**A202937**	**001**	Mar 02, 2015
AB			**10MG**	**A202937**	**002**	Mar 02, 2015
AB			**15MG**	**A202937**	**003**	Mar 02, 2015
AB			**20MG**	**A202937**	**004**	Mar 02, 2015
AB		PHARMOBEDIENT	**5MG**	**A202285**	**001**	May 12, 2014
AB			**10MG**	**A202285**	**002**	May 12, 2014
AB			**15MG**	**A202285**	**003**	May 12, 2014
AB			**20MG**	**A202285**	**004**	May 12, 2014
AB		STRIDES PHARMA INTL	**5MG**	**A078109**	**001**	Oct 24, 2011
AB			**10MG**	**A078109**	**002**	Oct 24, 2011
AB			**15MG**	**A078109**	**003**	Oct 24, 2011
AB			**20MG**	**A078109**	**004**	Oct 24, 2011
AB		TORRENT	**5MG**	**A091415**	**001**	Oct 25, 2011
AB			**10MG**	**A091415**	**002**	Oct 25, 2011
AB			**15MG**	**A091415**	**003**	Oct 25, 2011
AB			**20MG**	**A091415**	**004**	Oct 25, 2011

ZYPREXA ZYDIS

AB	+!	CHEPLAPHARM	**5MG**	**N021086**	**001**	Apr 06, 2000
AB	+		**10MG**	**N021086**	**002**	Apr 06, 2000
AB	+		**15MG**	**N021086**	**003**	Apr 06, 2000
AB	+		**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+		CHEPLAPHARM	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+			EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+!			EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+!		ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021
+			10MG;EQ 10MG BASE	N213378	002	May 28, 2021
+			15MG;EQ 10MG BASE	N213378	003	May 28, 2021
+			20MG;EQ 10MG BASE	N213378	004	May 28, 2021

OLAPARIB

TABLET;ORAL

LYNPARZA

+		ASTRAZENECA	100MG	N208558	001	Aug 17, 2017
+!			150MG	N208558	002	Aug 17, 2017

OLEZARSEN SODIUM

SOLUTION;SUBCUTANEOUS

TRYNGOLZA (AUTOINJECTOR)

+!		IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N218614	001	Dec 19, 2024

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+!		BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

AB	+	COSETTE	**5MG**	**N021286**	**001**	Apr 25, 2002
AB	+		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	+!		**40MG**	**N021286**	**004**	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE	**5MG**	**A207662**	**001**	Apr 24, 2017
AB			**20MG**	**A207662**	**002**	Apr 24, 2017
AB			**40MG**	**A207662**	**003**	Apr 24, 2017
AB		ALEMBIC	**5MG**	**A203012**	**001**	Apr 24, 2017
AB			**20MG**	**A203012**	**002**	Apr 24, 2017
AB			**40MG**	**A203012**	**003**	Apr 24, 2017
AB		ALKEM LABS LTD	**5MG**	**A206763**	**001**	Apr 24, 2017
AB			**20MG**	**A206763**	**002**	Apr 24, 2017
AB			**40MG**	**A206763**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA	**5MG**	**A204798**	**001**	Apr 24, 2017
AB			**20MG**	**A204798**	**002**	Apr 24, 2017
AB			**40MG**	**A204798**	**003**	Apr 24, 2017
AB		CADILA PHARMS LTD	**5MG**	**A210682**	**001**	Nov 08, 2024
AB			**20MG**	**A210682**	**002**	Nov 08, 2024
AB			**40MG**	**A210682**	**003**	Nov 08, 2024
AB		CHARTWELL RX	**5MG**	**A206227**	**001**	Jan 25, 2024
AB			**20MG**	**A206227**	**002**	Jan 25, 2024
AB			**40MG**	**A206227**	**003**	Jan 25, 2024
AB		GLENMARK PHARMS LTD	**5MG**	**A203281**	**001**	May 25, 2017
AB			**20MG**	**A203281**	**002**	May 25, 2017
AB			**40MG**	**A203281**	**003**	May 25, 2017
AB		HETERO LABS LTD V	**5MG**	**A205499**	**001**	Oct 31, 2024
AB			**20MG**	**A205499**	**002**	Oct 31, 2024
AB			**40MG**	**A205499**	**003**	Oct 31, 2024
AB		INVENTIA	**5MG**	**A208659**	**001**	May 18, 2020
AB			**20MG**	**A208659**	**002**	May 18, 2020
AB			**40MG**	**A208659**	**003**	May 18, 2020
AB		JUBILANT GENERICS	**5MG**	**A205482**	**001**	Apr 24, 2017
AB			**20MG**	**A205482**	**002**	Apr 24, 2017
AB			**40MG**	**A205482**	**003**	Apr 24, 2017
AB		MACLEODS PHARMS LTD	**5MG**	**A204814**	**001**	Apr 24, 2017
AB			**20MG**	**A204814**	**002**	Apr 24, 2017
AB			**40MG**	**A204814**	**003**	Apr 24, 2017
AB		MICRO LABS	**5MG**	**A206372**	**001**	Sep 17, 2019
AB			**20MG**	**A206372**	**002**	Sep 17, 2019
AB			**40MG**	**A206372**	**003**	Sep 17, 2019

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		MSN	**5MG**	**A217399**	**001**	Jan 18, 2023
AB			**20MG**	**A217399**	**002**	Jan 18, 2023
AB			**40MG**	**A217399**	**003**	Jan 18, 2023
AB		PRINSTON INC	**5MG**	**A206720**	**001**	Dec 02, 2022
AB			**20MG**	**A206720**	**002**	Dec 02, 2022
AB			**40MG**	**A206720**	**003**	Dec 02, 2022
AB		QILU	**5MG**	**A210552**	**001**	Jan 10, 2019
AB			**20MG**	**A210552**	**002**	Jan 10, 2019
AB			**40MG**	**A210552**	**003**	Jan 10, 2019
AB		SCIEGEN PHARMS	**5MG**	**A208130**	**001**	Jun 29, 2018
AB			**20MG**	**A208130**	**002**	Jun 29, 2018
AB			**40MG**	**A208130**	**003**	Jun 29, 2018
AB		SUNSHINE	**5MG**	**A211049**	**001**	Feb 22, 2019
AB			**20MG**	**A211049**	**002**	Feb 22, 2019
AB			**40MG**	**A211049**	**003**	Feb 22, 2019
AB		UMEDICA	**5MG**	**A207135**	**001**	Jul 18, 2019
AB			**20MG**	**A207135**	**002**	Jul 18, 2019
AB			**40MG**	**A207135**	**003**	Jul 18, 2019
AB		ZYDUS PHARMS	**5MG**	**A205192**	**001**	Apr 24, 2017
AB			**20MG**	**A205192**	**002**	Apr 24, 2017
AB			**40MG**	**A205192**	**003**	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	**!**	AMNEAL	**0.665MG/SPRAY**	**A210901**	**001**	Jan 28, 2020
AB		APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
AB		PADAGIS ISRAEL	**0.665MG/SPRAY**	**A202853**	**001**	Jan 31, 2017

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

+!	MYLAN SPCLT VIATRIS	250MG	N019715	001	Jul 31, 1990

OLUTASIDENIB

CAPSULE;ORAL

REZLIDHIA

+!	RIGEL PHARMS	150MG	N215814	001	Dec 01, 2022

OMADACYCLINE TOSYLATE

POWDER;INTRAVENOUS

NUZYRA

+!	PARATEK PHARMS	EQ 100MG BASE/VIAL	N209817	001	Oct 02, 2018

TABLET;ORAL

NUZYRA

+!	PARATEK PHARMS	EQ 150MG BASE	N209816	001	Oct 02, 2018

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

+!	BIOGEN US	50MG	N216718	001	Feb 28, 2023

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	**+!**	WAYLIS THERAP	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A207420**	**001**	Feb 25, 2019
AB	CHARTWELL	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A206455**	**001**	Aug 07, 2019
AB	CSPC-NBP PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211979**	**001**	May 12, 2020
AB	GLW	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014
AB		**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A212504**	**001**	Aug 19, 2020
AB	MANKIND PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A215458**	**001**	Nov 15, 2021
AB	ONESOURCE SPECIALTY	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A203893**	**001**	Sep 19, 2017
AB	PURACAP PHARM LLC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210093**	**001**	Jun 15, 2020
AB	SOFGEN PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211355**	**001**	Jul 10, 2019
AB	WILSHIRE PHARMS INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211345**	**001**	Dec 07, 2023

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB		**20MG**	**A075347**	**002**	May 30, 2008
AB		**40MG**	**A075347**	**003**	May 30, 2008
AB	APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB		**20MG**	**A076048**	**002**	Oct 22, 2007
AB		**40MG**	**A076048**	**003**	Jan 21, 2009
AB	AUROBINDO PHARMA	**10MG**	**A203270**	**001**	Aug 19, 2015
AB		**20MG**	**A203270**	**002**	Aug 19, 2015
AB		**40MG**	**A203270**	**003**	Aug 19, 2015
AB	BRECKENRIDGE	**10MG**	**A203481**	**001**	Jul 03, 2017
AB		**20MG**	**A203481**	**002**	Jul 03, 2017
AB		**40MG**	**A203481**	**003**	Jul 03, 2017
AB	DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB		**10MG**	**A078490**	**002**	Mar 16, 2009
AB		**20MG**	**A075576**	**002**	Oct 22, 2007
AB		**20MG**	**A078490**	**003**	Mar 16, 2009
AB		**40MG**	**A075576**	**001**	Jan 21, 2009
AB		**40MG**	**A078490**	**001**	Apr 17, 2009
AB	GLENMARK PHARMS LTD	**10MG**	**A091672**	**001**	Oct 31, 2014
AB		**20MG**	**A091672**	**002**	Oct 31, 2014
AB		**40MG**	**A091672**	**003**	Oct 31, 2014
AB	HETERO LABS LTD III	**10MG**	**A204012**	**001**	Sep 26, 2019
AB		**20MG**	**A204012**	**002**	Sep 26, 2019
AB	IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB		**20MG**	**A075785**	**002**	Oct 22, 2007
AB		**40MG**	**A075785**	**003**	Jan 21, 2009
AB	LANNETT CO INC	**10MG**	**A075410**	**001**	Nov 01, 2002
AB		**20MG**	**A075410**	**002**	Nov 01, 2002
AB		**40MG**	**A075410**	**003**	Jan 23, 2009
AB	SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB !		**20MG**	**A075757**	**002**	Jan 28, 2003
AB !		**40MG**	**A076515**	**001**	Jan 21, 2009
AB	TEVA PHARMS USA	**20MG**	**A204661**	**001**	Jun 13, 2017
AB	XIROMED	**10MG**	**A212977**	**001**	Dec 10, 2020
AB		**20MG**	**A212977**	**002**	Dec 10, 2020
AB		**40MG**	**A212977**	**003**	Dec 27, 2024
AB	ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB		**20MG**	**A091352**	**002**	Nov 19, 2012
AB		**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+	COVIS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB	!		**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB		ANDA REPOSITORY	**20MG;1.1GM**	**A212587**	**001**	Apr 30, 2020
AB			**40MG;1.1GM**	**A212587**	**002**	Apr 30, 2020
AB		AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB			**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB		DR REDDYS	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB		SCIEGEN PHARMS	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB			**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016
AB		ZYDUS PHARMS	**20MG;1.1GM**	**A203290**	**001**	May 25, 2018
AB			**40MG;1.1GM**	**A203290**	**002**	May 25, 2018

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AB	!		**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016
AB		NOVITIUM PHARMA	**20MG/PACKET;1.68GM/PACKET**	**A219161**	**001**	Dec 10, 2025
AB			**40MG/PACKET;1.68GM/PACKET**	**A219161**	**002**	Dec 10, 2025
AB		STRIDES PHARMA INTL	**20MG/PACKET;1.68GM/PACKET**	**A079182**	**001**	Apr 19, 2013
AB			**40MG/PACKET;1.68GM/PACKET**	**A079182**	**002**	Apr 19, 2013

KONVOMEP

	+!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

	+!	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB	!		**8MG**	**A090469**	**002**	Apr 12, 2010
AB		CHARTWELL MOLECULES	**4MG**	**A077406**	**003**	Dec 26, 2006
AB			**8MG**	**A077406**	**004**	Dec 26, 2006
AB		GLENMARK PHARMS LTD	**4MG**	**A078152**	**001**	Jun 27, 2007
AB			**8MG**	**A078152**	**002**	Jun 27, 2007
AB		IPCA LABS LTD	**4MG**	**A209389**	**001**	Oct 30, 2023
AB			**8MG**	**A209389**	**002**	Oct 30, 2023
AB		SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007
AB			**8MG**	**A078050**	**002**	Aug 13, 2007
AB		SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB			**8MG**	**A077557**	**002**	Aug 02, 2007
	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006
	!		24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP		GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP	!		**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP		HIKMA	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP	!	QILU PHARM HAINAN	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP		SANDOZ	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP		WOCKHARDT BIO AG	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP		HIKMA	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP		SANDOZ	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP		WOCKHARDT BIO AG	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA		AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA		CHARTWELL MOLECULAR	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA	**!**	HIKMA	**EQ 4MG BASE/5ML**	**A076960**	**001**	Dec 26, 2006

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001**	Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002**	Jul 31, 2007
AB		CHARTWELL MOLECULES	**EQ 4MG BASE**	**A077303**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077303**	**002**	Jun 25, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003**	Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002**	Dec 26, 2006
AB		GLENMARK PHARMS LTD	**EQ 4MG BASE**	**A077535**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002**	Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001**	Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002**	Jan 23, 2014
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002**	Jun 25, 2007
	!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007

OPICAPONE

CAPSULE;ORAL

ONGENTYS

+	AMNEAL	25MG	N212489	001	Apr 24, 2020
+!		50MG	N212489	002	Apr 24, 2020

ORITAVANCIN DIPHOSPHATE

POWDER;INTRAVENOUS

KIMYRSA

+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021

ORBACTIV

+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014

ORLISTAT

CAPSULE;ORAL

XENICAL

+!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP		HIKMA	**30MG/ML**	**A040463**	**001**	Mar 04, 2003
AP	**!**	RISING	**30MG/ML**	**A040484**	**001**	May 24, 2006
AP		SAGENT PHARMS	**30MG/ML**	**A090585**	**001**	Aug 30, 2011
AP		WATSON LABS	**30MG/ML**	**A084779**	**001**	Mar 15, 1982

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB	**!**	LUPIN	**100MG**	**A040284**	**001**	Jun 19, 1998
AB		RISING	**100MG**	**A040249**	**001**	Jan 29, 1999
AB		SANDOZ	**100MG**	**A040327**	**001**	Feb 15, 2000
AB		UNICHEM	**100MG**	**A091158**	**001**	Jul 27, 2012

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	ALEMBIC	**EQ 30MG BASE**	**A211823**	**001**	Jun 24, 2019
AB		**EQ 45MG BASE**	**A211823**	**002**	Jun 24, 2019
AB		**EQ 75MG BASE**	**A211823**	**003**	Jun 24, 2019
AB	AMNEAL PHARMS	**EQ 30MG BASE**	**A209093**	**001**	May 17, 2017
AB		**EQ 45MG BASE**	**A209093**	**002**	May 17, 2017
AB		**EQ 75MG BASE**	**A209093**	**003**	May 17, 2017
AB	BEIJING JIALIN	**EQ 30MG BASE**	**A217133**	**001**	Oct 30, 2024
AB		**EQ 75MG BASE**	**A217133**	**002**	Oct 30, 2024
AB	CEDIPROF INC	**EQ 30MG BASE**	**A217451**	**001**	Dec 03, 2024
AB		**EQ 45MG BASE**	**A217451**	**002**	Dec 03, 2024
AB		**EQ 75MG BASE**	**A217451**	**003**	Dec 03, 2024
AB	EPIC PHARMA LLC	**EQ 30MG BASE**	**A215208**	**001**	Oct 01, 2021
AB		**EQ 45MG BASE**	**A215208**	**002**	Oct 01, 2021
AB		**EQ 75MG BASE**	**A215208**	**003**	Oct 01, 2021
AB	HETERO LABS LTD III	**EQ 30MG BASE**	**A209438**	**001**	Feb 23, 2018
AB		**EQ 45MG BASE**	**A209438**	**002**	Feb 23, 2018
AB		**EQ 75MG BASE**	**A209438**	**003**	Feb 23, 2018

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		INVAGEN PHARMS	**EQ 30MG BASE**	**A217467**	**001**	Oct 03, 2023
AB			**EQ 45MG BASE**	**A217467**	**002**	Oct 03, 2023
AB			**EQ 75MG BASE**	**A217467**	**003**	Oct 03, 2023
AB		LAURUS	**EQ 30MG BASE**	**A218565**	**001**	May 01, 2024
AB			**EQ 45MG BASE**	**A218565**	**002**	May 01, 2024
AB			**EQ 75MG BASE**	**A218565**	**003**	May 01, 2024
AB		LUPIN	**EQ 30MG BASE**	**A208348**	**001**	Jan 09, 2018
AB			**EQ 45MG BASE**	**A208348**	**002**	Jan 09, 2018
AB			**EQ 75MG BASE**	**A208348**	**003**	Jan 09, 2018
AB		MACLEODS PHARMS LTD	**EQ 30MG BASE**	**A207211**	**001**	Sep 14, 2017
AB			**EQ 45MG BASE**	**A207211**	**002**	Sep 14, 2017
AB			**EQ 75MG BASE**	**A207211**	**003**	Sep 14, 2017
AB		MSN	**EQ 30MG BASE**	**A212544**	**001**	May 20, 2020
AB			**EQ 45MG BASE**	**A212544**	**002**	May 20, 2020
AB			**EQ 75MG BASE**	**A212544**	**003**	May 20, 2020
AB		NATCO	**EQ 30MG BASE**	**A202595**	**001**	Aug 03, 2016
AB			**EQ 45MG BASE**	**A202595**	**002**	Aug 03, 2016
AB			**EQ 75MG BASE**	**A202595**	**003**	Aug 03, 2016
AB		SHANDONG	**EQ 30MG BASE**	**A217274**	**001**	Jul 09, 2025
AB			**EQ 45MG BASE**	**A217274**	**002**	Jul 09, 2025
AB			**EQ 75MG BASE**	**A217274**	**003**	Jul 09, 2025
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209421**	**001**	Jun 08, 2018
AB			**EQ 45MG BASE**	**A209421**	**002**	Jun 08, 2018
AB			**EQ 75MG BASE**	**A209421**	**003**	Jun 08, 2018
AB		SUNSHINE	**EQ 30MG BASE**	**A212739**	**001**	Mar 04, 2020
AB			**EQ 45MG BASE**	**A212739**	**002**	Mar 04, 2020
AB			**EQ 75MG BASE**	**A212739**	**003**	Mar 04, 2020
AB		ZHEJIANG POLY PHARM	**EQ 30MG BASE**	**A218009**	**002**	Oct 02, 2025
AB			**EQ 45MG BASE**	**A218009**	**003**	Oct 02, 2025
AB			**EQ 75MG BASE**	**A218009**	**001**	Nov 24, 2023
AB		ZYDUS PHARMS	**EQ 30MG BASE**	**A208578**	**001**	Feb 24, 2017
AB			**EQ 45MG BASE**	**A208578**	**002**	Feb 24, 2017
AB			**EQ 75MG BASE**	**A208578**	**003**	Feb 24, 2017

TAMIFLU

AB	**+!**	ROCHE	**EQ 75MG BASE**	**N021087**	**001**	Oct 27, 1999

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		AJANTA PHARMA LTD	**EQ 6MG BASE/ML**	**A212784**	**001**	May 27, 2020
AB		ALVOGEN	**EQ 6MG BASE/ML**	**A208823**	**001**	Oct 31, 2017
AB		AMNEAL PHARMS NY	**EQ 6MG BASE/ML**	**A210186**	**001**	Feb 27, 2018
AB		AUROBINDO PHARMA LTD	**EQ 6MG BASE/ML**	**A218131**	**001**	May 10, 2024
AB		EPIC PHARMA LLC	**EQ 6MG BASE/ML**	**A215538**	**001**	Feb 14, 2023
AB		HETERO LABS LTD V	**EQ 6MG BASE/ML**	**A209590**	**001**	Mar 28, 2022
AB		INVAGEN PHARMS	**EQ 6MG BASE/ML**	**A212858**	**001**	Aug 30, 2021
AB		JUBILANT GENERICS	**EQ 6MG BASE/ML**	**A213695**	**001**	Mar 03, 2025
AB		LUPIN	**EQ 6MG BASE/ML**	**A208347**	**001**	Feb 20, 2018
AB		MSN	**EQ 6MG BASE/ML**	**A215313**	**001**	May 02, 2022
AB		PHARMOBEDIENT	**EQ 6MG BASE/ML**	**A217303**	**001**	Jul 02, 2024
AB		STRIDES PHARMA	**EQ 6MG BASE/ML**	**A211894**	**001**	Jan 13, 2022
AB		SUNSHINE	**EQ 6MG BASE/ML**	**A213594**	**001**	Jan 05, 2022
AB		TEVA PHARMS USA	**EQ 6MG BASE/ML**	**A211125**	**001**	Feb 27, 2019
AB		ZYDUS PHARMS	**EQ 6MG BASE/ML**	**A209113**	**001**	Sep 14, 2017

TAMIFLU

AB	**+!**	ROCHE	**EQ 6MG BASE/ML**	**N021246**	**002**	Mar 21, 2011

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020
+		EQ 5MG BASE	N212801	002	Mar 06, 2020

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

+	ASTRAZENECA	EQ 40MG BASE	N208065	001	Nov 13, 2015
+!		EQ 80MG BASE	N208065	002	Nov 13, 2015

OSPEMIFENE
TABLET;ORAL
OSPHENA

	+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013

OTESECONAZOLE
CAPSULE;ORAL
VIVJOA

	+!	MYCOVIA PHARMS	150MG	N215888	001	Apr 26, 2022

OXACILLIN SODIUM
INJECTABLE;INJECTION
OXACILLIN SODIUM

AP		EUGIA PHARMA SPECLTS	**EQ 1GM BASE/VIAL**	**A201539**	**001**	Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002**	Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001**	Jan 18, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A206198**	**001**	Jul 20, 2020
AP	**!**		**EQ 2GM BASE/VIAL**	**A206198**	**002**	Jul 20, 2020
AP			**EQ 10GM BASE/VIAL**	**A206199**	**001**	Jul 27, 2020
AP		ONESOURCE SPECIALTY	**EQ 2GM BASE/VIAL**	**A091486**	**002**	Aug 25, 2014
AP	**!**	SAGENT PHARMS	**EQ 10GM BASE/VIAL**	**A091245**	**001**	Mar 30, 2012
AP		WOCKHARDT BIO AG	**EQ 1GM BASE/VIAL**	**A207147**	**001**	Jul 31, 2017
AP			**EQ 2GM BASE/VIAL**	**A207147**	**002**	Jul 31, 2017
AP			**EQ 10GM BASE/VIAL**	**A207148**	**001**	Nov 24, 2017

BACTOCILL IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+!		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN
INJECTABLE;INTRAVENOUS
OXALIPLATIN

AP		ACCORD HLTHCARE	**50MG/10ML (5MG/ML)**	**A207474**	**001**	Mar 21, 2017
AP			**100MG/20ML (5MG/ML)**	**A207474**	**002**	Mar 21, 2017
AP		ACTAVIS	**50MG/10ML (5MG/ML)**	**A204880**	**001**	Mar 05, 2018
AP			**100MG/20ML (5MG/ML)**	**A204880**	**002**	Mar 05, 2018
AP		FRESENIUS KABI USA	**50MG/10ML (5MG/ML)**	**A078811**	**001**	Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002**	Jun 10, 2010
AP			**50MG/VIAL**	**A078819**	**001**	Jun 02, 2010
AP			**100MG/VIAL**	**A078819**	**002**	Jun 02, 2010
AP	**!**	GLAND	**50MG/10ML (5MG/ML)**	**A207325**	**001**	Feb 10, 2017
AP			**50MG/VIAL**	**A207385**	**001**	May 23, 2017
AP	**!**		**100MG/20ML (5MG/ML)**	**A207325**	**002**	Feb 10, 2017
AP			**100MG/VIAL**	**A207385**	**002**	May 23, 2017
AP		HENGRUI PHARMA	**50MG/10ML (5MG/ML)**	**A203869**	**001**	Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002**	Jun 18, 2014
AP		HETERO LABS LTD VI	**50MG/10ML (5MG/ML)**	**A217925**	**001**	Jan 27, 2025
AP			**100MG/20ML (5MG/ML)**	**A217925**	**002**	Jan 27, 2025
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002**	Aug 07, 2009
AP		MEITHEAL	**50MG/10ML (5MG/ML)**	**A217348**	**001**	Jan 11, 2024
AP			**100MG/20ML (5MG/ML)**	**A217348**	**002**	Jan 11, 2024
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001**	Aug 07, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002**	Aug 07, 2012
AP		NOVAST LABS	**100MG/20ML (5MG/ML)**	**A207562**	**002**	Oct 16, 2018
AP		QILU PHARM HAINAN	**50MG/10ML (5MG/ML)**	**A204368**	**001**	Jun 07, 2016
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	**+!**	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	**+!**		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009
	!	QILU PHARM HAINAN	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXAPROZIN
CAPSULE;ORAL
COXANTO

	+!	SOLUBIOMIX	300MG	N217927	001	Oct 20, 2023

TABLET;ORAL
DAYPRO

AB	**+!**	PFIZER	**600MG**	**N018841**	**004**	Oct 29, 1992

OXAPROZIN

AB		AMNEAL PHARMS CO	**600MG**	**A208633**	**001**	May 04, 2017
AB		CHARTWELL	**600MG**	**A075987**	**001**	Sep 02, 2004

OXAPROZIN

TABLET;ORAL

OXAPROZIN

AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		PANGEA	**600MG**	**A075845**	**001**	Jan 31, 2001

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		ACTAVIS ELIZABETH	**10MG**	**A072253**	**002**	Apr 14, 1988
AB			**15MG**	**A072253**	**003**	Apr 14, 1988
AB	!		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		EPIC PHARMA LLC	**10MG**	**A071756**	**002**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071756**	**003**	Apr 19, 1988
AB		LEADING	**10MG**	**A218261**	**001**	Mar 03, 2025
AB			**15MG**	**A218261**	**002**	Mar 03, 2025
AB			**30MG**	**A218261**	**003**	Mar 03, 2025
AB		TP ANDA HOLDINGS	**10MG**	**A071026**	**002**	Aug 10, 1987
AB			**15MG**	**A071026**	**003**	Aug 10, 1987
AB			**30MG**	**A071026**	**001**	Aug 10, 1987

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB		ALKEM LABS LTD	**300MG/5ML**	**A213183**	**001**	Mar 18, 2023
AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		AUCTA	**300MG/5ML**	**A215332**	**001**	Nov 30, 2022
AB		BIOCON PHARMA	**300MG/5ML**	**A218278**	**001**	Mar 01, 2024
AB		BIONPHARMA	**300MG/5ML**	**A209652**	**001**	Nov 04, 2022
AB		CHARTWELL RX	**300MG/5ML**	**A212428**	**001**	Jun 21, 2021
AB		HETERO LABS LTD III	**300MG/5ML**	**A216749**	**001**	Oct 20, 2023
AB		KANCHAN HLTHCARE	**300MG/5ML**	**A217782**	**001**	Feb 14, 2024
AB		MACLEODS PHARMS LTD	**300MG/5ML**	**A207300**	**001**	Jul 11, 2025
AB		RUBICON RESEARCH	**300MG/5ML**	**A215726**	**001**	Aug 30, 2022
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009

TRILEPTAL

AB	**+!**	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001

TABLET;ORAL

OXCARBAZEPINE

AB		ANI PHARMS	**150MG**	**A078005**	**001**	Dec 11, 2007
AB			**300MG**	**A078005**	**002**	Dec 11, 2007
AB			**600MG**	**A078005**	**003**	Dec 11, 2007
AB		ANNORA PHARMA	**150MG**	**A215939**	**001**	Jan 11, 2022
AB			**300MG**	**A215939**	**002**	Jan 11, 2022
AB			**600MG**	**A215939**	**003**	Jan 11, 2022
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008
AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		GLENMARK PHARMS LTD	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007
AB		RUBICON RESEARCH	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**150MG**	**A207717**	**001**	Mar 05, 2024
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**300MG**	**A207717**	**002**	Mar 05, 2024
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB			**600MG**	**A207717**	**003**	Mar 05, 2024
AB		SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB			**300MG**	**A077794**	**002**	Oct 09, 2007
AB			**600MG**	**A077794**	**003**	Oct 09, 2007
AB		TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB			**300MG**	**A077801**	**002**	Nov 15, 2007
AB			**600MG**	**A077801**	**003**	Nov 15, 2007

TRILEPTAL

AB	**+**	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB	**+**		**300MG**	**N021014**	**002**	Jan 14, 2000
AB	**+!**		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB		AJANTA PHARMA LTD	**150MG**	**A217659**	**001**	Feb 22, 2024
AB			**300MG**	**A217659**	**002**	Feb 22, 2024
AB			**600MG**	**A217659**	**003**	Feb 22, 2024

OXCARBAZEPINE

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB		APOTEX	**150MG**	**A213369**	**001**	Jul 13, 2023
AB			**300MG**	**A213369**	**002**	Jul 13, 2023
AB			**600MG**	**A213369**	**003**	Jul 13, 2023
AB		RICONPHARMA LLC	**150MG**	**A215796**	**001**	Nov 22, 2024
AB			**300MG**	**A215796**	**002**	Nov 22, 2024
AB			**600MG**	**A215796**	**003**	Nov 22, 2024

OXTELLAR XR

AB	**+**	SUPERNUS PHARMS	**150MG**	**N202810**	**001**	Oct 19, 2012
AB	**+**		**300MG**	**N202810**	**002**	Oct 19, 2012
AB	**+!**		**600MG**	**N202810**	**003**	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		SUN PHARMA CANADA	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB	**+!**	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL

OXISTAT

	+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

	+!	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		CHARTWELL RX	**5MG/5ML**	**A075039**	**001**	Jan 29, 1999
AA	**!**	LANNETT CO INC	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	**5MG**	**A209335**	**001**	Dec 22, 2017
AB		AIPING PHARM INC	**5MG**	**A074625**	**001**	Jul 31, 1996
AB		LEADING	**5MG**	**A212798**	**001**	Apr 06, 2020
AB		NOVAST LABS	**5MG**	**A210611**	**001**	Oct 30, 2019
AB		NOVITIUM PHARMA	**5MG**	**A209823**	**001**	Oct 23, 2017
AB		REGCON HOLDINGS	**5MG**	**A213550**	**001**	Jul 14, 2022
AB		RISING	**5MG**	**A209025**	**001**	Dec 21, 2017
AB		STRIDES PHARMA	**5MG**	**A208165**	**001**	Dec 17, 2020
AB	**!**	STRIDES PHARMA INTL	**5MG**	**A075079**	**001**	Oct 31, 1997
AB		TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB		TP ANDA HOLDINGS	**5MG**	**A210125**	**001**	Sep 06, 2018
	!	RISING	2.5MG	A209025	002	Feb 07, 2023

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB			**10MG**	**A207138**	**002**	Feb 29, 2016
AB	**!**		**15MG**	**A207138**	**003**	Feb 29, 2016
AB		AJANTA PHARMA LTD	**5MG**	**A211655**	**001**	Feb 28, 2019
AB			**10MG**	**A211655**	**002**	Feb 28, 2019
AB			**15MG**	**A211655**	**003**	Feb 28, 2019
AB		AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015
AB			**10MG**	**A204010**	**002**	Nov 23, 2015
AB			**15MG**	**A204010**	**003**	Nov 23, 2015
AB		BIONPHARMA	**5MG**	**A210717**	**001**	Dec 17, 2019
AB			**10MG**	**A210717**	**002**	Dec 17, 2019
AB			**15MG**	**A210717**	**003**	Dec 17, 2019
AB		OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB			**10MG**	**A078503**	**002**	Feb 04, 2009
AB			**15MG**	**A078503**	**003**	Feb 04, 2009
AB		RUBICON RESEARCH	**5MG**	**A214415**	**001**	Oct 27, 2020
AB			**10MG**	**A214415**	**002**	Oct 27, 2020
AB			**15MG**	**A214415**	**003**	Oct 27, 2020
AB		UNIQUE	**5MG**	**A206121**	**001**	May 27, 2016
AB			**10MG**	**A206121**	**002**	May 27, 2016
AB			**15MG**	**A206121**	**003**	May 27, 2016
AB		ZYDUS PHARMS	**5MG**	**A202332**	**001**	Jun 26, 2017
AB			**10MG**	**A202332**	**002**	Jun 26, 2017
AB			**15MG**	**A202332**	**003**	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+!		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS	**5MG**	**A205177**	**001**	Mar 31, 2016
AB		AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	**+!**	GENUS LIFESCIENCES	**5MG**	**N200534**	**001**	Oct 20, 2010
AB		NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A208593**	**001**	Jul 21, 2017
AA			**100MG/5ML**	**A208593**	**002**	Jul 21, 2017
AA		ALKEM LABS LTD	**5MG/5ML**	**A211748**	**001**	Feb 07, 2019
AA			**100MG/5ML**	**A211749**	**001**	Feb 04, 2019
AA		ANI PHARMS	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA		ASCENT PHARMS INC	**5MG/5ML**	**A209021**	**001**	Nov 09, 2017
AA			**100MG/5ML**	**A209021**	**002**	Nov 09, 2017
AA	**+**	GENUS LIFESCIENCES	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA	**+!**		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA		HIBROW HLTHCARE	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016
AA			**100MG/5ML**	**A209897**	**001**	Sep 06, 2017
AA	**!**	HIKMA	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA		PHARM ASSOC	**5MG/5ML**	**A206914**	**001**	Feb 01, 2019
AA		QUAGEN	**5MG/5ML**	**A213761**	**001**	Jun 02, 2021
AA			**100MG/5ML**	**A213761**	**002**	Jun 02, 2021
AA		SPECGX LLC	**5MG/5ML**	**A210758**	**001**	Apr 30, 2018
AA			**100MG/5ML**	**A210758**	**002**	Apr 30, 2018

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ALVOGEN	**5MG**	**A202116**	**001**	Dec 30, 2011
AB			**15MG**	**A202116**	**002**	Dec 30, 2011
AB			**30MG**	**A202116**	**003**	Dec 30, 2011
AB		AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB			**10MG**	**A203638**	**002**	Jun 03, 2014
AB			**15MG**	**A203638**	**003**	Jun 03, 2014
AB			**20MG**	**A203638**	**004**	Jun 03, 2014
AB			**30MG**	**A203638**	**005**	Jun 03, 2014
AB		ASCENT PHARMS INC	**5MG**	**A207418**	**003**	Nov 14, 2025
AB			**10MG**	**A207418**	**004**	Nov 14, 2025
AB			**15MG**	**A207418**	**001**	Aug 07, 2017
AB			**20MG**	**A207418**	**005**	Nov 14, 2025
AB			**30MG**	**A207418**	**002**	Aug 07, 2017
AB		AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB			**15MG**	**A202160**	**002**	Nov 19, 2012
AB			**30MG**	**A202160**	**003**	Nov 19, 2012
AB		AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009
AB	**!**		**10MG**	**A091393**	**002**	Aug 31, 2009
AB			**15MG**	**A091393**	**003**	Aug 31, 2009
AB			**20MG**	**A091393**	**004**	Aug 31, 2009
AB			**30MG**	**A091393**	**005**	Aug 31, 2009
AB		EPIC PHARMA LLC	**5MG**	**A090895**	**001**	Aug 24, 2009
AB			**5MG**	**A202662**	**001**	Sep 22, 2015
AB			**10MG**	**A202662**	**002**	Sep 22, 2015
AB			**15MG**	**A090895**	**002**	Aug 24, 2009
AB			**15MG**	**A202662**	**003**	Sep 22, 2015
AB			**20MG**	**A202662**	**005**	Apr 27, 2017
AB			**30MG**	**A090895**	**003**	Aug 24, 2009
AB			**30MG**	**A202662**	**004**	Sep 22, 2015
AB		NUVO PHARM	**5MG**	**A207119**	**001**	Apr 12, 2016
AB			**10MG**	**A207119**	**002**	Apr 12, 2016
AB			**15MG**	**A207119**	**003**	Apr 12, 2016
AB			**20MG**	**A207119**	**004**	Apr 12, 2016
AB			**30MG**	**A207119**	**005**	Apr 12, 2016
AB		RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB			**10MG**	**A091490**	**002**	Mar 09, 2011

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB			**15MG**	**A091490**	**003**	Mar 09, 2011
AB			**20MG**	**A091490**	**004**	Mar 09, 2011
AB			**30MG**	**A091490**	**005**	Mar 09, 2011
AB		SPECGX LLC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB			**10MG**	**A076758**	**004**	Oct 12, 2021
AB			**15MG**	**A076758**	**001**	Jun 30, 2004
AB			**20MG**	**A076758**	**005**	Oct 12, 2021
AB			**30MG**	**A076758**	**002**	Jun 30, 2004
AB		STRIDES PHARMA INTL	**5MG**	**A077712**	**003**	Mar 02, 2009
AB			**10MG**	**A077712**	**004**	Apr 13, 2015
AB			**15MG**	**A077712**	**001**	Jan 31, 2007
AB			**20MG**	**A077712**	**005**	Apr 13, 2015
AB			**30MG**	**A077712**	**002**	Jan 31, 2007

ROXICODONE

AB	**+**	SPECGX LLC	**5MG**	**N021011**	**003**	May 15, 2009
AB	**+!**		**15MG**	**N021011**	**001**	Aug 31, 2000
AB	**+**		**30MG**	**N021011**	**002**	Aug 31, 2000

ROXYBOND

		PROTEGA PHARMS	5MG	N209777	001	Apr 20, 2017
			10MG	N209777	004	Sep 05, 2024
			15MG	N209777	002	Apr 20, 2017
			30MG	N209777	003	Apr 20, 2017

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

	+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
	+		15MG	N022272	002	Apr 05, 2010
	+		20MG	N022272	003	Apr 05, 2010
	+		30MG	N022272	004	Apr 05, 2010
	+!		40MG	N022272	005	Apr 05, 2010
	+		60MG	N022272	006	Apr 05, 2010
	+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

	+!	MAYNE PHARMA	1%	N208552	001	Jan 18, 2017

SOLUTION/DROPS;OPHTHALMIC

UPNEEQ

	+!	RVL PHARMS	0.1%	N212520	001	Jul 08, 2020

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

	+!	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**5MG**	**A210175**	**001**	Feb 02, 2018
AB			**10MG**	**A210175**	**002**	Feb 02, 2018
AB		AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB			**10MG**	**A204459**	**002**	Apr 26, 2016
AB		AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB	**!**		**10MG**	**A203601**	**002**	Jan 30, 2013
AB		EPIC PHARMA LLC	**5MG**	**A201187**	**001**	Dec 15, 2014
AB			**10MG**	**A201187**	**002**	Dec 15, 2014
AB		HIKMA	**5MG**	**A090964**	**001**	Sep 27, 2010
AB			**10MG**	**A090964**	**002**	Sep 27, 2010
AB		TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB			**10MG**	**A091443**	**001**	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

		IMPAX LABS	5MG	A079087	001	Jun 14, 2010
			7.5MG	A079087	002	Dec 21, 2010
			10MG	A079087	003	Jun 14, 2010
			15MG	A079087	004	Dec 21, 2010
			20MG	A079087	005	Jun 14, 2010
			30MG	A079087	006	Jul 22, 2010
	!		40MG	A079087	007	Jun 14, 2010

OXYTOCIN							
INJECTABLE;INJECTION							
OXYTOCIN							
AP	**+!**	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248**	**001**		
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248**	**002**		
AP	**+!**	HIKMA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243**	**001**		
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243**	**002**	Jan 10, 2007	
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219**	**001**	Feb 13, 2013	
AP		SAGENT PHARMS INC	**10USP UNITS/ML (10USP UNITS/ML)**	**A091676**	**001**	Jul 13, 2018	
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**A091676**	**002**	Jul 13, 2018	
PITOCIN							
AP	**+!**	PH HEALTH	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261**	**001**		
AP	**+**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261**	**002**	Jul 27, 2007	
OXYTOCIN							
	+!	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007	
PITOCIN							
	+	PH HEALTH	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	
OZANIMOD HYDROCHLORIDE							
CAPSULE;ORAL							
ZEPOSIA							
	+	BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	
	+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020	
	+!		EQ 0.92MG BASE	N209899	003	Mar 25, 2020	
PACLITAXEL							
INJECTABLE;INJECTION							
PACLITAXEL							
AP		ACCORD HLTHCARE	**6MG/ML**	**A205720**	**001**	Aug 17, 2018	
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130**	**001**	Dec 09, 2009	
AP		ALEMBIC	**6MG/ML**	**A216874**	**001**	Oct 20, 2022	
AP		FRESENIUS KABI USA	**6MG/ML**	**A077574**	**001**	Nov 27, 2006	
AP		GLAND	**6MG/ML**	**A207326**	**001**	Aug 23, 2016	
AP		HIKMA	**6MG/ML**	**A075190**	**001**	Jan 28, 2002	
AP	**!**	HOSPIRA	**6MG/ML**	**A076131**	**001**	May 08, 2002	
AP		MSN	**6MG/ML**	**A213434**	**001**	Aug 24, 2020	
AP		TEVA PHARMS	**6MG/ML**	**A075184**	**001**	Jan 25, 2002	
POWDER;INTRAVENOUS							
ABRAXANE							
AB	**+!**	BRISTOL-MYERS	**100MG/VIAL**	**N021660**	**001**	Jan 07, 2005	
PACLITAXEL							
AB	**+!**	AM REGENT	**100MG/VIAL**	**N211875**	**001**	Jul 27, 2022	
AB		CIPLA	**100MG/VIAL**	**A209657**	**001**	Apr 10, 2025	
AB		HENGRUI PHARMA	**100MG/VIAL**	**A212700**	**001**	Oct 08, 2024	
AB		MYLAN	**100MG/VIAL**	**A217877**	**001**	Aug 19, 2025	
AB		SHUANGCHENG	**100MG/VIAL**	**A216355**	**001**	May 15, 2025	
AB	**+!**	TEVA PHARMS INC	**100MG/VIAL**	**N216338**	**001**	May 11, 2023	
PACRITINIB CITRATE							
CAPSULE;ORAL							
VONJO							
	+!	SOBI	EQ 100MG BASE	N208712	001	Feb 28, 2022	
PAFOLACIANINE SODIUM							
SOLUTION;INTRAVENOUS							
CYTALUX							
	+!	ON TARGET LABS	EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	N214907	001	Nov 29, 2021	
PALBOCICLIB							
CAPSULE;ORAL							
IBRANCE							
	+	PFIZER	75MG	N207103	001	Feb 03, 2015	
	+		100MG	N207103	002	Feb 03, 2015	
	+!		125MG	N207103	003	Feb 03, 2015	
TABLET;ORAL							
IBRANCE							
	+	PFIZER	75MG	N212436	001	Nov 01, 2019	
	+		100MG	N212436	002	Nov 01, 2019	
	+!		125MG	N212436	003	Nov 01, 2019	

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA						
AB	+	JANSSEN PHARMS	**3MG**	**N021999**	**001**	Dec 19, 2006
AB	+!		**6MG**	**N021999**	**002**	Dec 19, 2006
AB	+		**9MG**	**N021999**	**003**	Dec 19, 2006
PALIPERIDONE						
AB		AJANTA PHARMA LTD	**1.5MG**	**A218514**	**001**	Jun 26, 2024
AB		ALEMBIC	**1.5MG**	**A218330**	**001**	Sep 26, 2024
AB			**3MG**	**A218330**	**002**	Sep 26, 2024
AB			**6MG**	**A218330**	**003**	Sep 26, 2024
AB			**9MG**	**A218330**	**004**	Sep 26, 2024
AB		AMNEAL PHARMS	**1.5MG**	**A204707**	**001**	Sep 23, 2019
AB			**3MG**	**A204707**	**002**	Sep 23, 2019
AB			**6MG**	**A204707**	**003**	Sep 23, 2019
AB			**9MG**	**A204707**	**004**	Sep 23, 2019
AB		ASCENT PHARMS INC	**1.5MG**	**A216174**	**001**	Aug 23, 2023
AB			**3MG**	**A216174**	**002**	Aug 23, 2023
AB			**6MG**	**A216174**	**003**	Aug 23, 2023
AB			**9MG**	**A216174**	**004**	Aug 23, 2023
AB		CSPC OUYI	**1.5MG**	**A212807**	**001**	Oct 29, 2020
AB			**3MG**	**A212807**	**002**	Oct 29, 2020
AB			**6MG**	**A212807**	**003**	Oct 29, 2020
AB			**9MG**	**A212807**	**004**	Oct 29, 2020
AB		DR REDDYS	**3MG**	**A205559**	**001**	Feb 19, 2025
AB			**6MG**	**A205559**	**002**	Feb 19, 2025
AB			**9MG**	**A205559**	**003**	Feb 19, 2025
AB		ESKAYEF	**1.5MG**	**A218755**	**001**	Sep 04, 2025
AB			**3MG**	**A218755**	**002**	Sep 04, 2025
AB			**6MG**	**A218755**	**003**	Sep 04, 2025
AB			**9MG**	**A218755**	**004**	Sep 04, 2025
AB		INVENTIA	**1.5MG**	**A204452**	**001**	Jun 12, 2019
AB			**3MG**	**A204452**	**002**	Jun 12, 2019
AB			**6MG**	**A204452**	**003**	Jun 12, 2019
AB			**9MG**	**A204452**	**004**	Jun 12, 2019
AB		RK PHARMA	**1.5MG**	**A203802**	**001**	Sep 24, 2015
AB			**3MG**	**A203802**	**002**	Sep 24, 2015
AB			**6MG**	**A203802**	**003**	Sep 24, 2015
AB			**9MG**	**A203802**	**004**	Sep 24, 2015
AB		SUN PHARM	**1.5MG**	**A205618**	**001**	Apr 06, 2018
AB			**3MG**	**A205618**	**002**	Apr 06, 2018
AB			**6MG**	**A205618**	**003**	Apr 06, 2018
AB			**9MG**	**A205618**	**004**	Apr 06, 2018
AB		ZYDUS PHARMS	**1.5MG**	**A217445**	**001**	Oct 08, 2024
AB			**3MG**	**A217445**	**002**	Oct 08, 2024
AB			**6MG**	**A217445**	**003**	Oct 08, 2024
AB			**9MG**	**A217445**	**004**	Oct 08, 2024

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ERZOFRI					
+!	LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024
+!		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024
+!		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024
+!		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024
+!		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024
+!		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024
INVEGA HAFYERA					
+	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021
+		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021
INVEGA SUSTENNA					
+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009
INVEGA TRINZA					
+!	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
+!		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
+!		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
+!		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		AVET LIFESCIENCES	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202951**	**002**	Jun 29, 2021
AP		BAXTER HLTHCARE CORP	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206916**	**001**	Nov 12, 2021
AP		CHARTWELL RX	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A209287**	**001**	Sep 19, 2018
AP	**!**	DR REDDYS	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002**	Apr 21, 2016
AP		EUGIA PHARMA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204702**	**001**	Nov 06, 2018
AP		FRESENIUS KABI USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206801**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206802**	**001**	Sep 19, 2018
AP		HOSPIRA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A207005**	**001**	Sep 19, 2018
AP		MEITHEAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A215861**	**001**	Aug 14, 2023
AP		MYLAN INSTITUTIONAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206416**	**001**	Sep 19, 2018
AP		QILU PHARM HAINAN	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205648**	**001**	Sep 19, 2018
AP		SAGENT PHARMS INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204289**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205870**	**001**	Sep 19, 2018
AP		SANDOZ	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001**	Oct 13, 2015
AP		TEVA PHARMS USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A090713**	**001**	Mar 23, 2018
	!	AVET LIFESCIENCES	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021

SOLUTION;INTRAVENOUS

POSFREA

	+!	AVYXA HOLDINGS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016

PALOPEGTERIPARATIDE

SOLUTION;SUBCUTANEOUS

YORVIPATH

	+!	ASCENDIS PHARMA BONE	EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024
	+		EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024
	+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024

PALOVAROTENE

CAPSULE;ORAL

SOHONOS

	+	IPSEN	1MG	N215559	001	Aug 16, 2023
	+		1.5MG	N215559	002	Aug 16, 2023
	+		2.5MG	N215559	003	Aug 16, 2023
	+		5MG	N215559	004	Aug 16, 2023
	+!		10MG	N215559	005	Aug 16, 2023

PALTUSOTINE HYDROCHLORIDE

TABLET;ORAL

PALSONIFY

	+	CRINETICS	EQ 20MG BASE	N219070	001	Sep 25, 2025
	+!		EQ 30MG BASE	N219070	002	Sep 25, 2025

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001**	Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003**	Nov 26, 2008
AP		DR REDDYS	**60MG/10ML (6MG/ML)**	**A078156**	**002**	Aug 19, 2008
AP		HIKMA	**30MG/VIAL**	**A075290**	**001**	Apr 30, 2001
AP			**90MG/VIAL**	**A075290**	**003**	Apr 30, 2001
AP	**!**	HOSPIRA	**60MG/10ML (6MG/ML)**	**A075841**	**002**	Jun 27, 2002
AP1	**+!**	HIKMA	**30MG/10ML (3MG/ML)**	**N021113**	**001**	Mar 04, 2002
AP1	**+!**		**90MG/10ML (9MG/ML)**	**N021113**	**002**	Mar 04, 2002
AP1		SAGENT PHARMS INC	**30MG/10ML (3MG/ML)**	**A078373**	**001**	Dec 23, 2008
AP1			**90MG/10ML (9MG/ML)**	**A078373**	**002**	Dec 23, 2008
AP2		DR REDDYS	**30MG/10ML (3MG/ML)**	**A078156**	**001**	Aug 19, 2008
AP2			**90MG/10ML (9MG/ML)**	**A078156**	**003**	Aug 19, 2008
AP2		HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001**	Jun 27, 2002
AP2			**90MG/10ML (9MG/ML)**	**A075841**	**003**	Jun 27, 2002
AP2		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001**	Oct 31, 2008
AP2			**90MG/10ML (9MG/ML)**	**A078520**	**002**	Oct 31, 2008
		AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990
!		2MG/ML	A072760	001	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	AJANTA PHARMA LTD	**EQ 40MG BASE**	**A217416**	**001**	Feb 09, 2023
AB	ANNORA PHARMA	**EQ 40MG BASE**	**A216139**	**001**	Oct 27, 2023
AB	AUROBINDO PHARMA LTD	**EQ 40MG BASE**	**A217923**	**001**	Mar 31, 2025
AB	CIPLA	**EQ 40MG BASE**	**A217458**	**001**	Mar 31, 2025
AB	DEXCEL	**EQ 40MG BASE**	**A216247**	**001**	Jun 16, 2023
AB	SUN PHARM	**EQ 40MG BASE**	**A213725**	**001**	Jun 30, 2020

PROTONIX

AB	**+!** WYETH PHARMS	**EQ 40MG BASE**	**N022020**	**001**	Nov 14, 2007

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	ALEMBIC	**EQ 40MG BASE/VIAL**	**A219230**	**001**	Mar 31, 2025
AP	ASPIRO	**EQ 40MG BASE/VIAL**	**A213778**	**001**	May 18, 2022
AP	BE PHARMS	**EQ 40MG BASE/VIAL**	**A216171**	**001**	May 18, 2022
AP	DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A215074**	**001**	May 16, 2025
AP	EPIC PHARMA LLC	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP	EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP	GLAND	**EQ 40MG BASE/VIAL**	**A204400**	**001**	May 18, 2022
AP	HANGZHOU ZHONGMEI	**EQ 40MG BASE/VIAL**	**A209524**	**001**	Aug 30, 2021
AP	KNACK	**EQ 40MG BASE/VIAL**	**A214680**	**001**	May 19, 2022
AP	MEITHEAL	**EQ 40MG BASE/VIAL**	**A215860**	**001**	Aug 29, 2022

PROTONIX IV

AP	**+!** WYETH PHARMS	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A216021**	**001**	Aug 01, 2024
AP	**+!** HIKMA	**EQ 40MG BASE/VIAL**	**N209463**	**001**	Jun 30, 2017

SOLUTION;INTRAVENOUS

PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024
+!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024
+!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB		**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB	APOTEX	**EQ 20MG BASE**	**A091231**	**001**	Jan 19, 2011
AB		**EQ 40MG BASE**	**A091231**	**002**	Jan 19, 2011
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB		**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011
AB		**EQ 40MG BASE**	**A077619**	**002**	Jan 19, 2011
AB	GRANULES	**EQ 20MG BASE**	**A217282**	**001**	Dec 11, 2023
AB		**EQ 40MG BASE**	**A217282**	**002**	Dec 11, 2023
AB	GRAVITI PHARMS	**EQ 20MG BASE**	**A219087**	**001**	Jan 16, 2025
AB		**EQ 40MG BASE**	**A219087**	**002**	Jan 16, 2025
AB	HETERO LABS LTD V	**EQ 20MG BASE**	**A202882**	**001**	Sep 10, 2014
AB		**EQ 40MG BASE**	**A202882**	**002**	Sep 10, 2014
AB	LANNETT CO INC	**EQ 20MG BASE**	**A078281**	**001**	Jan 20, 2011
AB		**EQ 40MG BASE**	**A078281**	**002**	Jan 20, 2011
AB	MANKIND PHARMA	**EQ 40MG BASE**	**A215880**	**001**	Jul 26, 2022
AB	MYLAN PHARMS INC	**EQ 20MG BASE**	**A090970**	**001**	Jan 19, 2011
AB		**EQ 40MG BASE**	**A090970**	**002**	Jan 19, 2011
AB	ORBION PHARMS	**EQ 20MG BASE**	**A202052**	**001**	Dec 02, 2014
AB		**EQ 40MG BASE**	**A202052**	**002**	Dec 02, 2014
AB	RUBICON RESEARCH	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB		**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB	TORRENT PHARMS	**EQ 20MG BASE**	**A090074**	**001**	Jan 19, 2011
AB		**EQ 40MG BASE**	**A090074**	**002**	Jan 19, 2011

PROTONIX

AB	**+** WYETH PHARMS	**EQ 20MG BASE**	**N020987**	**002**	Jun 12, 2001
AB	**+!**	**EQ 40MG BASE**	**N020987**	**001**	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		AMNEAL PHARMS	**1MCG**	**A204327**	**001**	Jan 13, 2016
AB			**2MCG**	**A204327**	**002**	Jan 13, 2016
AB			**4MCG**	**A204327**	**003**	Jan 13, 2016
AB		AUROBINDO PHARMA LTD	**1MCG**	**A207672**	**001**	Jan 14, 2016
AB			**2MCG**	**A207672**	**002**	Jan 14, 2016
AB			**4MCG**	**A207672**	**003**	Jan 14, 2016
AB		BIONPHARMA	**1MCG**	**A202539**	**001**	Mar 27, 2014
AB			**2MCG**	**A202539**	**002**	Mar 27, 2014
AB			**4MCG**	**A202539**	**003**	Mar 27, 2014
AB		CHARTWELL RX	**1MCG**	**A091412**	**001**	Jun 24, 2014
AB			**2MCG**	**A091412**	**002**	Jun 24, 2014
AB			**4MCG**	**A091412**	**003**	Jun 24, 2014
AB		MARKSANS PHARMA	**1MCG**	**A204948**	**001**	Oct 07, 2016
AB			**2MCG**	**A204948**	**002**	Oct 07, 2016
AB			**4MCG**	**A204948**	**003**	Oct 07, 2016
AB		RISING	**1MCG**	**A202124**	**001**	Jun 24, 2014
AB			**2MCG**	**A202124**	**002**	Jun 24, 2014
AB			**4MCG**	**A202124**	**003**	Jun 24, 2014
AB		TEVA PHARMS USA	**1MCG**	**A090829**	**001**	Sep 27, 2013
AB			**2MCG**	**A090829**	**002**	Sep 27, 2013
AB	**!**		**4MCG**	**A090829**	**003**	Sep 27, 2013

ZEMPLAR

AB	**+**	ABBVIE	**2MCG**	**N021606**	**002**	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP		ACCORD HLTHCARE	**0.002MG/ML (0.002MG/ML)**	**N207174**	**001**	Feb 04, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**N207174**	**002**	Feb 04, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**N207174**	**003**	Feb 04, 2016
AP		AMNEAL PHARMS CO	**0.002MG/ML (0.002MG/ML)**	**A206699**	**001**	Mar 09, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A206699**	**002**	Mar 09, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A206699**	**003**	Mar 09, 2017
AP		CAPLIN	**0.002MG/ML (0.002MG/ML)**	**A204910**	**001**	Aug 17, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**A204910**	**002**	Aug 17, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**A204910**	**003**	Aug 17, 2016
AP		EUGIA PHARMA	**0.002MG/ML (0.002MG/ML)**	**A205982**	**001**	Oct 09, 2018
AP			**0.005MG/ML (0.005MG/ML)**	**A205982**	**002**	Oct 09, 2018
AP			**0.01MG/2ML (0.005MG/ML)**	**A205982**	**003**	Oct 09, 2018
AP		RISING	**0.005MG/ML (0.005MG/ML)**	**A203897**	**002**	Nov 02, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A203897**	**003**	Nov 02, 2017
AP		SANDOZ	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011

ZEMPLAR

AP	**+!**	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	**+!**		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	**+!**		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

	!	HERITAGE	EQ 250MG BASE	A065173	001	Dec 14, 2007

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

	!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021

TABLET;ORAL

PAROXETINE

AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003
AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		CHARTWELL RX	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010
AB		YILING	**EQ 10MG BASE**	**A211248**	**001**	Nov 02, 2021
AB			**EQ 20MG BASE**	**A211248**	**002**	Nov 02, 2021
AB			**EQ 30MG BASE**	**A211248**	**003**	Nov 02, 2021
AB			**EQ 40MG BASE**	**A211248**	**004**	Nov 02, 2021
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007

PAXIL

AB	+	APOTEX	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB	+		**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992
AB	+		**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	+!		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		ALEMBIC	**EQ 25MG BASE**	**A217280**	**001**	Sep 24, 2025
AB			**EQ 37.5MG BASE**	**A217280**	**002**	Sep 24, 2025
AB		AUROBINDO PHARMA USA	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB			**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB			**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
AB		CADILA PHARMS LTD	**EQ 12.5MG BASE**	**A212645**	**001**	Aug 27, 2021
AB			**EQ 25MG BASE**	**A212645**	**002**	Aug 27, 2021
AB			**EQ 37.5MG BASE**	**A212645**	**003**	Aug 27, 2021
AB		CSPC OUYI	**EQ 12.5MG BASE**	**A213485**	**001**	Feb 16, 2021
AB			**EQ 25MG BASE**	**A213485**	**002**	Feb 16, 2021
AB			**EQ 37.5MG BASE**	**A213485**	**003**	Feb 16, 2021
AB		LANNETT CO INC	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB			**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB			**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB		LUPIN LTD	**EQ 12.5MG BASE**	**A204134**	**001**	Jan 20, 2017
AB			**EQ 25MG BASE**	**A204134**	**002**	Jan 20, 2017
AB			**EQ 37.5MG BASE**	**A204134**	**003**	Jan 20, 2017
AB		PRINSTON INC	**EQ 12.5MG BASE**	**A209748**	**001**	Jan 04, 2024
AB			**EQ 25MG BASE**	**A209748**	**002**	Jan 04, 2024
AB		SCIECURE PHARMA INC	**EQ 12.5MG BASE**	**A209293**	**001**	Jun 12, 2018
AB			**EQ 25MG BASE**	**A209293**	**002**	Jun 12, 2018
AB			**EQ 37.5MG BASE**	**A209293**	**003**	Jun 12, 2018

PAXIL CR

AB	+	APOTEX	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB	+		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB	+!		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	+!	LEGACY PHARMA	**EQ 7.5MG BASE**	**N204516**	**001**	Jun 28, 2013

PAROXETINE MESYLATE

AB		ACTAVIS LABS FL INC	**EQ 7.5MG BASE**	**A207139**	**001**	Jun 20, 2017
AB		PRINSTON INC	**EQ 7.5MG BASE**	**A207188**	**001**	Aug 18, 2017

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

	+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
	+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
	+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE						
FOR SUSPENSION;INTRAMUSCULAR						
SIGNIFOR LAR KIT						
+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014
PATIROMER SORBITEX CALCIUM						
POWDER;ORAL						
VELTASSA						
+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023
+		EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
+!		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
PATISIRAN SODIUM						
SOLUTION;INTRAVENOUS						
ONPATTRO						
+!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018
PAZOPANIB HYDROCHLORIDE						
TABLET;ORAL						
PAZOPANIB HYDROCHLORIDE						
AB	APOTEX	**EQ 200MG BASE**	**A217713**	**001**	Oct 19, 2023
AB	EUGIA PHARMA	**EQ 200MG BASE**	**A219034**	**001**	Dec 04, 2024
AB	NOVUGEN	**EQ 200MG BASE**	**A218231**	**001**	Apr 23, 2024
AB	SUN PHARM	**EQ 200MG BASE**	**A215837**	**001**	Oct 19, 2023
AB	TEVA PHARMS INC	**EQ 200MG BASE**	**A217517**	**001**	Oct 19, 2023
VOTRIENT						
AB **+!**	NOVARTIS	**EQ 200MG BASE**	**N022465**	**001**	Oct 19, 2009
PAZOPANIB HYDROCHLORIDE						
	TORRENT	EQ 400MG BASE	A219922	001	Sep 04, 2025
PEGCETACOPLAN						
SOLUTION;INTRAVITREAL						
SYFOVRE						
+!	APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023
SOLUTION;SUBCUTANEOUS						
EMPAVELI						
+!	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021
PEGULICIANINE ACETATE						
POWDER;INTRAVENOUS						
LUMISIGHT						
+!	LUMICELL	EQ 39MG BASE/VIAL	N214511	001	Apr 17, 2024
PEMETREXED						
SOLUTION;INTRAVENOUS						
PEMETREXED						
+!	ACTAVIS	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020
+!		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020
+!		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020
PEMFEXY						
+!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020
PEMETREXED DIPOTASSIUM						
POWDER;INTRAVENOUS						
AXTLE						
+!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024
+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024
PEMETREXED DISODIUM						
POWDER;INTRAVENOUS						
ALIMTA						
AP **+!**	LILLY	**EQ 100MG BASE/VIAL**	**N021462**	**002**	Sep 07, 2007
AP **+!**		**EQ 500MG BASE/VIAL**	**N021462**	**001**	Feb 04, 2004
PEMETREXED DISODIUM						
AP	ACCORD HLTHCARE	**EQ 100MG BASE/VIAL**	**A203485**	**001**	May 25, 2022
AP		**EQ 500MG BASE/VIAL**	**A203485**	**002**	May 25, 2022
AP		**EQ 1GM BASE/VIAL**	**A203485**	**003**	May 25, 2022
AP	APOTEX	**EQ 100MG BASE/VIAL**	**A203774**	**001**	May 25, 2022
AP		**EQ 500MG BASE/VIAL**	**A203774**	**002**	May 25, 2022
AP		**EQ 750MG BASE/VIAL**	**A209851**	**001**	May 25, 2022
AP		**EQ 1GM BASE/VIAL**	**A209085**	**001**	May 25, 2022
AP	DR REDDYS	**EQ 100MG BASE/VIAL**	**A202596**	**001**	May 25, 2022

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

AP			**EQ 500MG BASE/VIAL**	**A202596**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A202596**	**003**	May 25, 2022
AP		EUGIA PHARMA	**EQ 100MG BASE/VIAL**	**A214632**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A214632**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A214632**	**003**	May 25, 2022
AP		FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A090384**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A090384**	**002**	May 25, 2022
AP	**!**		**EQ 750MG BASE/VIAL**	**A090384**	**003**	May 25, 2022
AP	**!**		**EQ 1GM BASE/VIAL**	**A090384**	**004**	May 25, 2022
AP		HETERO LABS LTD VI	**EQ 100MG BASE/VIAL**	**A215460**	**001**	Jun 14, 2024
AP			**EQ 500MG BASE/VIAL**	**A215460**	**002**	Jun 14, 2024
AP		JIANGSU HANSOH PHARM	**EQ 100MG BASE/VIAL**	**A208696**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A208696**	**002**	May 25, 2022
AP		MEITHEAL	**EQ 100MG BASE/VIAL**	**A215479**	**001**	Dec 13, 2022
AP			**EQ 500MG BASE/VIAL**	**A215479**	**002**	Dec 13, 2022
AP			**EQ 750MG BASE/VIAL**	**A215479**	**003**	Dec 13, 2022
AP			**EQ 1GM BASE/VIAL**	**A215479**	**004**	Dec 13, 2022
AP		NANG KUANG PHARM CO	**EQ 100MG BASE/VIAL**	**A207352**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A207352**	**002**	May 25, 2022
AP		PRINSTON INC	**EQ 100MG BASE/VIAL**	**A216582**	**001**	Dec 11, 2023
AP		QILU PHARM HAINAN	**EQ 100MG BASE/VIAL**	**A204890**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A204890**	**002**	May 25, 2022
AP		RELIANCE LIFE	**EQ 100MG BASE/VIAL**	**A211899**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A211899**	**002**	May 25, 2022
AP		ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A214073**	**001**	May 25, 2022
AP			**EQ 500MG BASE/VIAL**	**A214073**	**002**	May 25, 2022
AP			**EQ 1GM BASE/VIAL**	**A214073**	**003**	May 25, 2022

SOLUTION;INTRAVENOUS

PEMETREXED

+!	SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023
+!		EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023
+!		EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023

PEMETREXED DISODIUM

+!	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022
+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022
+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022
+!	SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022
+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022
+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022

PEMIGATINIB

TABLET;ORAL

PEMAZYRE

+	INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020
+		9MG	N213736	002	Apr 17, 2020
+!		13.5MG	N213736	003	Apr 17, 2020

PENCICLOVIR

CREAM;TOPICAL

DENAVIR

AB	**+!**	MYLAN	**1%**	**N020629**	**001**	Sep 24, 1996

PENCICLOVIR

AB		AMNEAL	**1%**	**A214100**	**001**	Aug 22, 2025
AB		PADAGIS ISRAEL	**1%**	**A212368**	**001**	Sep 27, 2024
AB		TEVA PHARMS USA	**1%**	**A212710**	**001**	Nov 09, 2022
BX		TORRENT	1%	A216981	001	Aug 07, 2023

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

AB	**+!**	VALEANT PHARMS INTL	**250MG**	**N019853**	**001**	

PENICILLAMINE

AB		BRECKENRIDGE	**250MG**	**A215409**	**001**	Aug 23, 2021
AB		DR REDDYS	**250MG**	**A211867**	**001**	Aug 04, 2020
AB		GRANULES	**250MG**	**A211735**	**001**	Dec 02, 2020
AB		INVAGEN PHARMS	**250MG**	**A213293**	**001**	Aug 19, 2021
AB		NAVINTA LLC	**250MG**	**A214363**	**001**	Oct 08, 2021
AB		PH HEALTH	**250MG**	**A211231**	**001**	Dec 23, 2019
AB		WATSON LABS INC	**250MG**	**A210976**	**001**	Jun 24, 2019

PENICILLAMINE
TABLET;ORAL
DEPEN

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N019854**	**001**	

PENICILLAMINE

AB		LUPIN LTD	**250MG**	**A212933**	**001**	Nov 30, 2020
AB		PH HEALTH	**250MG**	**A211196**	**001**	Dec 23, 2019

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A

BC	+!	KING PHARMS LLC	600,000 UNITS/ML	N050141	001	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE
INJECTABLE;INJECTION
BICILLIN C-R

	+!	KING PHARMS LLC	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	

BICILLIN C-R 900/300

	+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ACS DOBFAR SPA	**20,000,000 UNITS/VIAL**	**A205043**	**002**	Oct 26, 2018
AP			**5,000,000 UNITS/VIAL**	**A205043**	**001**	Oct 26, 2018
AP		HQ SPECLT PHARMA	**5,000,000 UNITS/VIAL**	**A065149**	**002**	Jul 23, 2009
AP			**20,000,000 UNITS/VIAL**	**A065149**	**003**	Jul 23, 2009
AP		ISTITUTO BIO ITA SPA	**5,000,000 UNITS/VIAL**	**A065448**	**001**	Aug 18, 2009
AP			**20,000,000 UNITS/VIAL**	**A065448**	**002**	Aug 18, 2009
AP		SANDOZ	**5,000,000 UNITS/VIAL**	**A065079**	**002**	Aug 30, 2002
AP			**20,000,000 UNITS/VIAL**	**A065079**	**003**	Aug 30, 2002

PFIZERPEN

AP	**!**	PFIZER	**5,000,000 UNITS/VIAL**	**A060657**	**002**	
AP	**!**		**20,000,000 UNITS/VIAL**	**A060657**	**003**	

PENICILLIN G POTASSIUM

		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
	+!		40,000 UNITS/ML	N050638	002	Jun 25, 1990
	+!		60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE
INJECTABLE;INJECTION
PENICILLIN G PROCAINE

	!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002	
	!		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
PENICILLIN G SODIUM

	!	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL
PENICILLIN-VK

		TEVA	EQ 125MG BASE/5ML	A060456	001	
	!		EQ 250MG BASE/5ML	A060456	002	

TABLET;ORAL
PENICILLIN V POTASSIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A065435**	**001**	Apr 29, 2008
AB	**!**		**EQ 500MG BASE**	**A065435**	**002**	Apr 29, 2008
AB		CHARTWELL RX	**EQ 250MG BASE**	**A062936**	**001**	Nov 25, 1988
AB			**EQ 500MG BASE**	**A062935**	**001**	Nov 23, 1988
AB		HIKMA PHARMS	**EQ 250MG BASE**	**A090549**	**001**	Oct 11, 2013
AB			**EQ 500MG BASE**	**A090549**	**002**	Oct 11, 2013

PENICILLIN-VK

AB		TEVA	**EQ 250MG BASE**	**A060711**	**002**	
AB			**EQ 500MG BASE**	**A060711**	**003**	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

AN	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019887**	**001**	Jun 15, 1989

PENTAMIDINE ISETHIONATE

AN		SETON PHARMS	**300MG/VIAL**	**A206667**	**001**	Apr 24, 2019
AN		X-GEN PHARMS INC	**300MG/VIAL**	**A206983**	**001**	Jan 20, 2023

INJECTABLE;INJECTION

PENTAM

AP	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019264**	**001**	Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP		AVET LIFESCIENCES	**300MG/VIAL**	**A213806**	**001**	Jan 07, 2021
AP		PHARMOBEDIENT	**300MG/VIAL**	**A206982**	**001**	Mar 17, 2022
AP		SETON PHARMS	**300MG/VIAL**	**A206666**	**001**	Sep 28, 2017

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	**+!**	RISING	**50MG/ML**	**A083246**	**001**	

PENTOBARBITAL SODIUM

AP		BPI LABS	**50MG/ML**	**A206677**	**001**	Nov 27, 2017
AP		HIKMA	**50MG/ML**	**A203619**	**001**	Nov 13, 2017
AP		SAGENT PHARMS INC	**50MG/ML**	**A206404**	**001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE;ORAL

ELMIRON

	+!	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN

INJECTABLE;INJECTION

NIPENT

AP	**+!**	HOSPIRA INC	**10MG/VIAL**	**N020122**	**001**	Oct 11, 1991

PENTOSTATIN

AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841**	**001**	Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB		ANI PHARMS	**400MG**	**A074878**	**001**	Jul 09, 1997
AB	**!**	APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB		RISING	**400MG**	**A074425**	**001**	Jul 08, 1997

PERAMIVIR

SOLUTION;INTRAVENOUS

RAPIVAB

	+!	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

AB	**+!**	CATALYST PHARMS	**0.5MG/ML**	**N208277**	**001**	Apr 29, 2016

PERAMPANEL

AB		MSN	**0.5MG/ML**	**A218152**	**001**	Jul 11, 2025

TABLET;ORAL

FYCOMPA

AB	**+**	CATALYST PHARMS	**2MG**	**N202834**	**001**	Oct 22, 2012
AB	**+**		**4MG**	**N202834**	**002**	Oct 22, 2012
AB	**+**		**6MG**	**N202834**	**003**	Oct 22, 2012
AB	**+**		**8MG**	**N202834**	**004**	Oct 22, 2012
AB	**+**		**10MG**	**N202834**	**005**	Oct 22, 2012
AB	**+!**		**12MG**	**N202834**	**006**	Oct 22, 2012

PERAMPANEL

AB		MSN	**2MG**	**A218178**	**001**	Nov 25, 2025
AB			**4MG**	**A218178**	**002**	Nov 25, 2025
AB			**6MG**	**A218178**	**003**	Nov 25, 2025
AB			**8MG**	**A218178**	**004**	Nov 25, 2025
AB			**10MG**	**A218178**	**005**	Nov 25, 2025
AB			**12MG**	**A218178**	**006**	Nov 25, 2025
AB		TARO	**2MG**	**A209538**	**001**	Nov 25, 2025
AB			**4MG**	**A209538**	**002**	Nov 25, 2025
AB			**6MG**	**A209538**	**003**	Nov 25, 2025
AB			**8MG**	**A209538**	**004**	Nov 25, 2025
AB			**10MG**	**A209538**	**005**	Nov 25, 2025
AB			**12MG**	**A209538**	**006**	Nov 25, 2025

PERAMPANEL

TABLET;ORAL

PERAMPANEL

AB		TEVA PHARMS USA INC	**2MG**	**A209801**	**001**	May 23, 2025
AB			**4MG**	**A209801**	**002**	May 23, 2025
AB			**6MG**	**A209801**	**003**	May 23, 2025
AB			**8MG**	**A209801**	**004**	May 23, 2025
AB			**10MG**	**A209801**	**005**	May 23, 2025
AB			**12MG**	**A209801**	**006**	May 23, 2025

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS;OPHTHALMIC

MIEBO

	+!	BAUSCH AND LOMB INC	1.338GM/ML	N216675	001	May 18, 2023

PERFLUTREN

INJECTABLE;INTRAVENOUS

DEFINITY

	+!	LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	001	Jul 31, 2001

DEFINITY RT

	+!	LANTHEUS MEDCL	13.04MG/2ML (6.52MG/ML)	N021064	002	Nov 17, 2020

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

		AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009
			4MG	A079070	002	Nov 10, 2009
	!		8MG	A079070	003	Nov 10, 2009

PERMETHRIN

CREAM;TOPICAL

ELIMITE

AB	**+**	AUROBINDO PHARMA USA	**5%**	**N019855**	**001**	Aug 25, 1989

PERMETHRIN

AB		ACTAVIS LABS	**5%**	**A074806**	**001**	Jan 23, 1998
AB		ENCUBE ETHICALS	**5%**	**A211303**	**001**	Apr 03, 2019
AB	**!**	PADAGIS ISRAEL	**5%**	**A076369**	**001**	Apr 21, 2003

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		APPCO	**2MG**	**A210163**	**001**	May 18, 2022
AB			**4MG**	**A210163**	**002**	May 18, 2022
AB			**8MG**	**A210163**	**003**	May 18, 2022
AB			**16MG**	**A210163**	**004**	May 18, 2022
AB		JUBILANT GENERICS	**2MG**	**A213694**	**001**	Mar 18, 2025
AB			**4MG**	**A213694**	**002**	Mar 18, 2025
AB			**8MG**	**A213694**	**003**	Mar 18, 2025
AB			**16MG**	**A213694**	**004**	Mar 18, 2025
AB		MACLEODS PHARMS LTD	**2MG**	**A212545**	**001**	May 06, 2024
AB			**4MG**	**A212545**	**002**	May 06, 2024
AB			**8MG**	**A212545**	**003**	May 06, 2024
AB			**16MG**	**A212545**	**004**	May 06, 2024
AB		PH HEALTH	**2MG**	**A040226**	**001**	Dec 31, 1998
AB			**4MG**	**A040226**	**002**	Dec 31, 1998
AB			**8MG**	**A040226**	**003**	Dec 31, 1998
AB			**16MG**	**A040226**	**004**	Dec 31, 1998
AB		RISING	**2MG**	**A205056**	**001**	Mar 01, 2019
AB			**4MG**	**A205056**	**002**	Mar 01, 2019
AB			**8MG**	**A205056**	**003**	Mar 01, 2019
AB			**16MG**	**A205056**	**004**	Mar 01, 2019
AB		SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB			**4MG**	**A089685**	**003**	Dec 08, 1988
AB			**8MG**	**A089685**	**001**	Dec 08, 1988
AB	**!**		**16MG**	**A089685**	**004**	Dec 08, 1988
AB		WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB			**4MG**	**A207582**	**002**	Oct 17, 2016
AB			**8MG**	**A207582**	**003**	Oct 17, 2016
AB			**16MG**	**A207582**	**004**	Oct 17, 2016
AB		WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB			**4MG**	**A205973**	**002**	Dec 17, 2015
AB			**8MG**	**A205973**	**003**	Dec 17, 2015
AB			**16MG**	**A205973**	**004**	Dec 17, 2015
AB		ZYDUS PHARMS	**2MG**	**A205232**	**001**	Apr 06, 2020

PERPHENAZINE
TABLET;ORAL
PERPHENAZINE

AB			**4MG**	**A205232**	**002**	Apr 06, 2020
AB			**8MG**	**A205232**	**003**	Apr 06, 2020
AB			**16MG**	**A205232**	**004**	Apr 06, 2020

PEXIDARTINIB HYDROCHLORIDE
CAPSULE;ORAL
TURALIO

	+!	DAIICHI SANKYO INC	EQ 125MG BASE	N211810	002	Oct 14, 2022

PHENDIMETRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
PHENDIMETRAZINE TARTRATE

	+!	ACERTIS PHARMS	105MG	N018074	001	

TABLET;ORAL
BONTRIL PDM

AA	**+!**	BAUSCH	**35MG**	**A085272**	**001**	

PHENDIMETRAZINE TARTRATE

AA		ACERTIS PHARMS	**35MG**	**A085588**	**001**	
AA		CHARTWELL	**35MG**	**A089452**	**001**	Oct 30, 1991
AA		ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA		KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010

PHENELZINE SULFATE
TABLET;ORAL
NARDIL

AB	**+!**	PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	

PHENELZINE SULFATE

AB		NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010

PHENOBARBITAL SODIUM
POWDER;INTRAVENOUS
SEZABY

	+!	SUN PHARM INDS INC	100MG/VIAL	N215910	001	Nov 17, 2022

PHENOXYBENZAMINE HYDROCHLORIDE
CAPSULE;ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

AB		AMNEAL	**10MG**	**A212568**	**001**	Oct 27, 2020
AB		AUROBINDO PHARMA	**10MG**	**A215600**	**001**	May 08, 2023
AB		NOVITIUM PHARMA	**10MG**	**A215042**	**001**	Jul 19, 2022
AB	**!**	PH HEALTH	**10MG**	**A204522**	**001**	Jan 24, 2017
AB		RISING	**10MG**	**A204551**	**001**	Jun 20, 2023

PHENTERMINE HYDROCHLORIDE
CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA		AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016
AA			**30MG**	**A204318**	**002**	Nov 09, 2016
AA		ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012
AA			**30MG**	**A202248**	**002**	Sep 28, 2012
AA		KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008
AA			**30MG**	**A040875**	**001**	Mar 21, 2008
AA			**30MG**	**A040886**	**001**	Mar 31, 2008
AA			**37.5MG**	**A040887**	**001**	Apr 24, 2008
AA		NUVO PHARM	**15MG**	**A205019**	**001**	Dec 05, 2014
AA			**30MG**	**A205019**	**002**	Dec 05, 2014
AA	**!**		**37.5MG**	**A205017**	**001**	Sep 25, 2014
AA	**+!**	SANDOZ	**15MG**	**A087190**	**002**	
AA	**+!**		**30MG**	**A086945**	**001**	Jul 20, 1983
AA	**+!**		**30MG**	**A087190**	**001**	

TABLET;ORAL
ADIPEX-P

AA	**+!**	TEVA	**37.5MG**	**A085128**	**001**	

LOMAIRA

AA	**!**	AVANTHI INC	**8MG**	**A203495**	**001**	Sep 12, 2016

PHENTERMINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	**37.5MG**	**A203068**	**001**	Aug 06, 2014
AA		ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011
AA		ELITE LABS INC	**37.5MG**	**A040190**	**001**	May 30, 1997
AA		KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008
AA		KVK TECH INC	**8MG**	**A203436**	**001**	Mar 17, 2017
AA		NUVO PHARM	**37.5MG**	**A205008**	**001**	Sep 25, 2014

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA		PRINSTON INC	**37.5MG**	**A040377**	**001**	Jan 04, 2002
AA		PURACAP LABS BLU	**37.5MG**	**A206342**	**001**	Nov 18, 2016
AA		SUN PHARM INDUSTRIES	**37.5MG**	**A040526**	**001**	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

		ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017
			30MG	A204663	002	Jun 28, 2017
			37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		ACTAVIS LABS FL INC	**EQ 3.75MG BASE;23MG**	**A204982**	**001**	Jun 25, 2024
AB			**EQ 7.5MG BASE;46MG**	**A204982**	**002**	Jun 25, 2024
AB			**EQ 11.25MG BASE;69MG**	**A204982**	**003**	Jun 25, 2024
AB			**EQ 15MG BASE;92MG**	**A204982**	**004**	Jun 25, 2024
AB		DR REDDYS LABS SA	**EQ 7.5MG BASE;46MG**	**A208175**	**002**	Jun 12, 2025
AB			**EQ 11.25MG BASE;69MG**	**A208175**	**003**	Jun 12, 2025
AB			**EQ 15MG BASE;92MG**	**A208175**	**004**	Jun 12, 2025
AB			**EQ 3.75MG BASE;23MG**	**A208175**	**001**	Jun 12, 2025

OSYMIA

AB	+	VIVUS LLC	**EQ 3.75MG BASE;23MG**	**N022580**	**001**	Jul 17, 2012
AB	+		**EQ 7.5MG BASE;46MG**	**N022580**	**002**	Jul 17, 2012
AB	+		**EQ 11.25MG BASE;69MG**	**N022580**	**003**	Jul 17, 2012
AB	+!		**EQ 15MG BASE;92MG**	**N022580**	**004**	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP	!	HIKMA	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998
AP		PRECISION DOSE INC	**5MG/VIAL**	**A207686**	**001**	Jul 14, 2017

ORAVERSE

	+!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

SOLUTION;OPHTHALMIC

RYZUMVI

	+!	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

AP	**+!**	DR REDDYS LABS SA	**0.5MG/5ML (0.1MG/ML)**	**N212909**	**001**	Oct 21, 2019

PHENYLEPHRINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	**0.5MG/5ML (0.1MG/ML)**	**A215617**	**001**	Feb 14, 2025
AP1		AMNEAL	**10MG/ML (10MG/ML)**	**A211079**	**001**	Jul 05, 2018
AP1			**50MG/5ML (10MG/ML)**	**A211078**	**001**	Jul 19, 2018
AP1			**100MG/10ML (10MG/ML)**	**A211078**	**002**	Jul 19, 2018
AP1		ASPIRO	**10MG/ML (10MG/ML)**	**A218110**	**001**	May 10, 2024
AP1			**50MG/5ML (10MG/ML)**	**A218110**	**002**	May 10, 2024
AP1			**100MG/10ML (10MG/ML)**	**A218110**	**003**	May 10, 2024
AP1		CAPLIN	**10MG/ML (10MG/ML)**	**A213318**	**001**	Jun 11, 2020
AP1			**50MG/5ML (10MG/ML)**	**A213318**	**002**	Jun 11, 2020
AP1			**100MG/10ML (10MG/ML)**	**A213318**	**003**	Jun 11, 2020
AP1		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A210697**	**001**	Nov 13, 2020
AP1			**100MG/10ML (10MG/ML)**	**A210697**	**002**	Nov 13, 2020
AP1		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A210666**	**001**	Jan 30, 2019
AP1			**100MG/10ML (10MG/ML)**	**A210666**	**002**	Jan 30, 2019
AP1		GLAND	**10MG/ML (10MG/ML)**	**A211920**	**003**	Apr 08, 2021
AP1			**50MG/5ML (10MG/ML)**	**A211920**	**001**	Jun 05, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211920**	**002**	Jun 05, 2020
AP1		MANKIND PHARMA	**10MG/ML (10MG/ML)**	**A217069**	**001**	Aug 30, 2022
AP1			**50MG/5ML (10MG/ML)**	**A217069**	**002**	Aug 30, 2022
AP1			**100MG/10ML (10MG/ML)**	**A217069**	**003**	Aug 30, 2022
AP1		MEITHEAL	**50MG/5ML (10MG/ML)**	**A210333**	**001**	Apr 27, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210333**	**002**	Apr 27, 2018
AP1		MILLA PHARMS	**10MG/ML (10MG/ML)**	**A211081**	**001**	Jul 17, 2020
AP1			**50MG/5ML (10MG/ML)**	**A211081**	**002**	Jul 17, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211081**	**003**	Jul 17, 2020
AP1		PH HEALTH	**50MG/5ML (10MG/ML)**	**A210025**	**002**	Dec 21, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210025**	**003**	Dec 21, 2018

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		SAGENT PHARMS INC	**10MG/ML (10MG/ML)**	**A209967**	**001**	Jan 16, 2020
AP1			**50MG/5ML (10MG/ML)**	**A209967**	**002**	Jan 16, 2020
AP1			**100MG/10ML (10MG/ML)**	**A209967**	**003**	Jan 16, 2020
AP1	!	SANDOZ	**10MG/ML (10MG/ML)**	**A208905**	**001**	Jan 31, 2019
AP1	!		**50MG/5ML (10MG/ML)**	**A208905**	**002**	Jan 31, 2019
AP1	!		**100MG/10ML (10MG/ML)**	**A208905**	**003**	Jan 31, 2019
AP2		AVET LIFESCIENCES	**10MG/ML (10MG/ML)**	**A209968**	**001**	Feb 28, 2023
AP2		BE PHARMS	**10MG/ML (10MG/ML)**	**A217521**	**001**	Jun 26, 2023
AP2			**50MG/5ML (10MG/ML)**	**A217521**	**002**	Jun 26, 2023
AP2			**100MG/10ML (10MG/ML)**	**A217521**	**003**	Jun 26, 2023
AP2		EUGIA PHARMA	**10MG/ML (10MG/ML)**	**A210696**	**001**	Jan 07, 2021
AP2		FRESENIUS KABI USA	**10MG/ML (10MG/ML)**	**A210665**	**001**	Jan 29, 2019
AP2	+!	HIKMA	**10MG/ML (10MG/ML)**	**N203826**	**001**	Dec 20, 2012
AP2	+!		**50MG/5ML (10MG/ML)**	**N203826**	**002**	Jun 19, 2019
AP2	+!		**100MG/10ML (10MG/ML)**	**N203826**	**003**	Jun 19, 2019
AP2		MEITHEAL	**10MG/ML (10MG/ML)**	**A210334**	**001**	Apr 27, 2018
	IMMPHENTIV					
	+!	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023
	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023
	PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE					
	+!	DR REDDYS LABS SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+	ALCON	**2.5%**	**N207926**	**001**	Jan 15, 2015
AT	+		**10%**	**N207926**	**002**	Jan 15, 2015
AT		CAPLIN	**2.5%**	**A215183**	**001**	May 23, 2024
AT			**10%**	**A215183**	**002**	May 23, 2024
AT		GLAND	**2.5%**	**A218129**	**001**	Dec 18, 2024
AT			**10%**	**A218129**	**002**	Dec 18, 2024
AT	!	MANKIND PHARMA	**2.5%**	**A216859**	**001**	Sep 29, 2022
AT	!		**10%**	**A216496**	**001**	Jan 11, 2023
AT	+!	PARAGON BIOTECK	**2.5%**	**N203510**	**001**	Mar 21, 2013
AT	+!		**10%**	**N203510**	**002**	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+!	VIATRIS	**125MG/5ML**	**N008762**	**001**	

PHENYTOIN

AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004

TABLET, CHEWABLE;ORAL

DILANTIN

AB	+!	PHARMACIA	**50MG**	**A084427**	**001**	

PHENYTOIN

AB		EPIC PHARMA LLC	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		RISING	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

AB	+!	VIATRIS	**100MG EXTENDED**	**A084349**	**002**	

EXTENDED PHENYTOIN SODIUM

AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		AUROBINDO PHARMA	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015
AB		MANKIND PHARMA	**100MG EXTENDED**	**A219773**	**001**	Jan 02, 2026
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006
	DILANTIN					
	+!	VIATRIS	30MG EXTENDED	A084349	001	
	PHENYTEK					
		MYLAN	200MG EXTENDED	A040298	002	Dec 06, 2001
	!		300MG EXTENDED	A040298	003	Dec 06, 2001

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP		ACELLA	**50MG/ML**	**A040573**	**001**	Sep 13, 2006
AP	**+!**	HIKMA	**50MG/ML**	**A084307**	**001**	

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

AB		ALEMBIC	**1MG/0.5ML**	**A216444**	**001**	Sep 08, 2025
AB		AMNEAL	**1MG/0.5ML**	**A216601**	**001**	Nov 04, 2025
AB		CIPLA	**1MG/0.5ML**	**A214966**	**001**	Jan 03, 2025
AB	**+!**	INTL MEDICATION	**1MG/0.5ML**	**A083722**	**001**	
AB1		CAPLIN	**10MG/ML**	**A219212**	**001**	Apr 17, 2025
AB1		DR REDDYS	**10MG/ML**	**A207719**	**001**	May 22, 2019
AB1		GLAND	**10MG/ML**	**A217386**	**001**	Dec 10, 2024

VITAMIN K1

AB1	**+!**	HOSPIRA	**10MG/ML**	**A087955**	**001**	Jul 25, 1983
BP	+!		1MG/0.5ML	A087954	001	Jul 25, 1983

PHYTONADIONE

	!	CIPLA	1MG/0.5ML	A214596	001	Apr 22, 2022
	!		10MG/ML	A214596	002	Apr 22, 2022

TABLET;ORAL

PHYTONADIONE

AB		AGNITIO	**5MG**	**A213336**	**001**	Oct 12, 2023
AB		AMNEAL PHARMS CO	**5MG**	**A209373**	**001**	May 11, 2018
AB		SCIEGEN PHARMS	**5MG**	**A213329**	**001**	Jul 28, 2023
AB	**!**	ZYDUS LIFESCIENCES	**5MG**	**A210189**	**001**	Feb 20, 2019

PIFLUFOLASTAT F-18

SOLUTION;INTRAVENOUS

PYLARIFY

	+!	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021

PILOCARPINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AB		AMNEAL	**1.25%**	**A217733**	**001**	Apr 28, 2025

VUITY

AB	**+!**	ABBVIE	**1.25%**	**N214028**	**001**	Oct 28, 2021

ISOPTO CARPINE

AT	**+!**	SANDOZ	**1%**	**N200890**	**001**	Jun 22, 2010
AT	**+!**		**2%**	**N200890**	**002**	Jun 22, 2010
AT	**+!**		**4%**	**N200890**	**003**	Jun 22, 2010

PILOCARPINE HYDROCHLORIDE

AT		AMNEAL	**1%**	**A214193**	**001**	Sep 21, 2020
AT			**2%**	**A214193**	**002**	Sep 21, 2020
AT			**4%**	**A214193**	**003**	Sep 21, 2020
AT		FDC LTD	**1%**	**A217052**	**001**	Oct 02, 2025
AT			**2%**	**A217052**	**002**	Oct 02, 2025
AT			**4%**	**A217052**	**003**	Oct 02, 2025
AT		RISING	**1%**	**A204398**	**001**	Sep 27, 2017
AT			**2%**	**A204398**	**002**	Sep 27, 2017
AT			**4%**	**A204398**	**003**	Sep 27, 2017
AT		SOMERSET THERAPS LLC	**1%**	**A210384**	**001**	Nov 25, 2019
AT			**2%**	**A210384**	**002**	Nov 25, 2019
AT			**4%**	**A210384**	**003**	Nov 25, 2019

QLOSI

	+!	ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**5MG**	**A212377**	**001**	Aug 13, 2019
AB			**7.5MG**	**A212377**	**002**	Aug 13, 2019
AB		IMPAX LABS	**5MG**	**A077248**	**001**	Mar 31, 2006
AB			**7.5MG**	**A077248**	**002**	Mar 31, 2006
AB		INNOGENIX	**5MG**	**A076963**	**001**	Dec 22, 2004
AB			**7.5MG**	**A076963**	**002**	Feb 27, 2007
AB		LANNETT CO INC	**5MG**	**A077220**	**001**	Oct 14, 2005
AB			**7.5MG**	**A077220**	**002**	May 06, 2009
AB		PADAGIS US	**5MG**	**A076746**	**001**	Nov 16, 2004

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

SALAGEN

AB	**+**	ADVANZ PHARMA	**5MG**	**N020237**	**001**	Mar 22, 1994
AB	**+!**		**7.5MG**	**N020237**	**002**	Apr 18, 2003

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

	+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018

TABLET;ORAL

NUPLAZID

	+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

AB	**+!**	BAUSCH	**1%**	**N021302**	**001**	Dec 13, 2001

PIMECROLIMUS

AB		ACTAVIS LABS UT INC	**1%**	**A209345**	**001**	Dec 27, 2018
AB		GLENMARK PHARMS LTD	**1%**	**A211769**	**001**	Aug 29, 2019

PIMOZIDE

TABLET;ORAL

PIMOZIDE

		PH HEALTH	1MG	A204521	001	Sep 28, 2015
	!		2MG	A204521	002	Sep 28, 2015

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		ANI PHARMS	**5MG**	**A073609**	**002**	Mar 29, 1993
AB			**10MG**	**A073609**	**001**	Mar 29, 1993
AB		AUROBINDO PHARMA USA	**5MG**	**A074019**	**001**	Sep 03, 1992
AB	**!**		**10MG**	**A074019**	**002**	Sep 03, 1992
AB		MPP PHARMA	**5MG**	**A205415**	**001**	Jan 13, 2016
AB			**10MG**	**A205415**	**002**	Jan 13, 2016
AB		SUN PHARM INDUSTRIES	**5MG**	**A074063**	**001**	Jan 27, 1994
AB			**10MG**	**A074063**	**002**	Jan 27, 1994
AB		UNICHEM	**5MG**	**A211712**	**001**	Aug 01, 2019
AB			**10MG**	**A211712**	**002**	Aug 01, 2019

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOS

AB	**+**	TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073**	**001**	Jul 15, 1999
AB	**+**		**EQ 30MG BASE**	**N021073**	**002**	Jul 15, 1999
AB	**+!**		**EQ 45MG BASE**	**N021073**	**003**	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044**	**003**	Feb 13, 2013
AB		AIPING PHARM INC	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB		ANNORA PHARMA	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB			**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB			**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200268**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200268**	**003**	Feb 13, 2013
AB		CHARTWELL RX	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB			**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB			**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB		COREPHARMA	**EQ 15MG BASE**	**A210165**	**001**	Jan 22, 2021
AB			**EQ 30MG BASE**	**A210165**	**002**	Jan 22, 2021
AB			**EQ 45MG BASE**	**A210165**	**003**	Jan 22, 2021
AB		MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB			**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013
AB			**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB		PRINSTON INC	**EQ 15MG BASE**	**A207806**	**001**	Apr 17, 2018
AB			**EQ 30MG BASE**	**A207806**	**002**	Apr 17, 2018

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB			**EQ 45MG BASE**	**A207806**	**003**	Apr 17, 2018
AB		PURACAP PHARM LLC	**EQ 15MG BASE**	**A206738**	**001**	Oct 06, 2017
AB			**EQ 30MG BASE**	**A206738**	**002**	Oct 06, 2017
AB			**EQ 45MG BASE**	**A206738**	**003**	Oct 06, 2017
AB		TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB			**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB			**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB		ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

	!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
	!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
	!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
	!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	**!**	APOTEX	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A206996**	**001**	Mar 22, 2017
AP	**!**		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A206996**	**002**	Mar 22, 2017
AP	**!**		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A206996**	**003**	Mar 22, 2017
AP	**!**		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207146**	**001**	Mar 17, 2017
AP		EUGIA PHARMA SPECLTS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP		FRESENIUS KABI	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A203719**	**001**	May 18, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A203719**	**002**	May 18, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A203719**	**003**	May 18, 2018
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203720**	**001**	May 11, 2018
AP		ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP		MILLA PHARMS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A207847**	**001**	Jan 13, 2017
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A207847**	**002**	Jan 13, 2017
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207848**	**002**	Jan 13, 2017
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A207847**	**003**	Jan 13, 2017
AP			**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A207848**	**001**	May 11, 2018
AP		ONESOURCE SPECIALTY	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065458**	**001**	Aug 15, 2014
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065458**	**002**	Aug 15, 2014
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065458**	**003**	Aug 15, 2014
AP		SAGENT PHARMS INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A208674**	**001**	Feb 16, 2021
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A208674**	**002**	Feb 16, 2021
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A208674**	**003**	Feb 16, 2021
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A208675**	**001**	Feb 16, 2021
AP		SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP			**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010
AP	**!**		**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A203557**	**001**	Oct 29, 2014
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203557**	**002**	Jul 08, 2021
AP		SHANDONG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A204959**	**001**	Aug 10, 2018
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A204959**	**002**	Aug 10, 2018
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A204959**	**003**	Aug 10, 2018
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A217243**	**001**	Apr 14, 2023

ZOSYN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

POWDER;INTRAVENOUS

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	+!	B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025
	+!		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025
	+!		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

AB	**+!**	LEGACY PHARMA	**267MG**	**N022535**	**001**	Oct 15, 2014

PIRFENIDONE

AB		ACCORD HLTHCARE	**267MG**	**A212731**	**001**	Jan 20, 2022
AB		AMNEAL	**267MG**	**A212569**	**001**	Jan 03, 2022
AB		LAURUS	**267MG**	**A212724**	**001**	Jul 19, 2022
AB		MACLEODS PHARMS LTD	**267MG**	**A212748**	**001**	Dec 18, 2024
AB		SANDOZ	**267MG**	**A212600**	**001**	Jun 13, 2022
AB		SCIEGEN PHARMS	**267MG**	**A212077**	**001**	Aug 01, 2022

TABLET;ORAL

ESBRIET

AB	**+**	LEGACY PHARMA	**267MG**	**N208780**	**001**	Jan 11, 2017
AB	**+!**		**801MG**	**N208780**	**003**	Jan 11, 2017

PIRFENIDONE

AB		ACCORD HLTHCARE	**267MG**	**A212730**	**001**	Jan 25, 2022
AB			**801MG**	**A212730**	**002**	Jan 25, 2022
AB		AIZANT	**267MG**	**A212747**	**001**	Jul 21, 2022
AB			**534MG**	**A212747**	**002**	Jul 21, 2022
AB			**801MG**	**A212747**	**003**	Jul 21, 2022
AB		ALEMBIC	**267MG**	**A212708**	**001**	May 20, 2022
AB			**801MG**	**A212708**	**002**	May 20, 2022
AB		AMNEAL	**267MG**	**A212570**	**001**	Mar 25, 2022
AB			**801MG**	**A212570**	**002**	Mar 25, 2022
AB		APOTEX	**267MG**	**A212709**	**001**	May 31, 2023
AB			**801MG**	**A212709**	**002**	May 31, 2023
AB		AUROBINDO PHARMA	**267MG**	**A212596**	**001**	Aug 11, 2025
AB			**801MG**	**A212596**	**002**	Aug 11, 2025
AB		HETERO LABS LTD V	**267MG**	**A212674**	**001**	Sep 21, 2022
AB			**801MG**	**A212674**	**002**	Sep 21, 2022
AB		LAURUS	**267MG**	**A212722**	**001**	Jul 19, 2022
AB			**534MG**	**A212722**	**002**	Jul 19, 2022
AB			**801MG**	**A212722**	**003**	Jul 19, 2022
AB		MICRO LABS	**267MG**	**A212680**	**001**	May 18, 2022
AB			**801MG**	**A212680**	**002**	May 18, 2022
AB		MSN	**267MG**	**A212772**	**001**	May 24, 2022
AB			**801MG**	**A212772**	**002**	May 24, 2022
AB		SANDOZ	**267MG**	**A212560**	**001**	Apr 28, 2022
AB			**801MG**	**A212560**	**002**	Apr 28, 2022
AB		SCIEGEN PHARMS	**267MG**	**A212078**	**001**	Aug 01, 2022
AB			**801MG**	**A212078**	**002**	Aug 01, 2022
AB		TEVA PHARMS USA	**267MG**	**A212759**	**001**	Jan 25, 2022
AB			**801MG**	**A212759**	**002**	Jan 25, 2022

PIROXICAM

CAPSULE;ORAL

FELDENE

AB	**+**	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+!**		**20MG**	**N018147**	**003**	Apr 06, 1982

PIROXICAM

AB		MICRO LABS	**10MG**	**A206152**	**001**	Dec 29, 2017
AB			**20MG**	**A206152**	**002**	Dec 29, 2017
AB		SOLIS PHARMS	**10MG**	**A074118**	**002**	Jun 15, 1993
AB			**20MG**	**A074118**	**001**	Jun 15, 1993
AB		STRIDES PHARMA	**10MG**	**A210347**	**001**	Jan 26, 2018
AB			**20MG**	**A210347**	**002**	Jan 26, 2018
AB		TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB			**20MG**	**A074131**	**002**	Dec 11, 1992
AB		UNICHEM	**10MG**	**A208340**	**001**	Apr 13, 2017
AB			**20MG**	**A208340**	**002**	Apr 13, 2017
AB		ZYDUS LIFESCIENCES	**10MG**	**A205585**	**001**	Jul 17, 2018
AB			**20MG**	**A205585**	**002**	Jul 17, 2018

PIRTOBRUTINIB
TABLET;ORAL
JAYPIRCA

	+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023
	+!		100MG	N216059	002	Jan 27, 2023

PITAVASTATIN CALCIUM
TABLET;ORAL
LIVALO

AB	**+**	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB	**+**		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+!**		**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009

PITAVASTATIN CALCIUM

AB		AMNEAL PHARMS NY	**EQ 1MG BASE**	**A205961**	**001**	Aug 20, 2024
AB			**EQ 2MG BASE**	**A205961**	**002**	Aug 20, 2024
AB			**EQ 4MG BASE**	**A205961**	**003**	Aug 20, 2024
AB		AUROBINDO PHARMA	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB			**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB			**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016
AB		HETERO LABS LTD V	**EQ 1MG BASE**	**A205977**	**001**	Apr 30, 2024
AB			**EQ 2MG BASE**	**A205977**	**002**	Apr 30, 2024
AB			**EQ 4MG BASE**	**A205977**	**003**	Apr 30, 2024
AB		LUPIN LTD	**EQ 1MG BASE**	**A206029**	**001**	Nov 20, 2023
AB			**EQ 2MG BASE**	**A206029**	**002**	Nov 20, 2023
AB			**EQ 4MG BASE**	**A206029**	**003**	Nov 20, 2023
AB		MYLAN	**EQ 1MG BASE**	**A206070**	**001**	Apr 04, 2019
AB			**EQ 2MG BASE**	**A206070**	**002**	Apr 04, 2019
AB			**EQ 4MG BASE**	**A206070**	**003**	Apr 04, 2019
AB		ORIENT PHARMA CO LTD	**EQ 1MG BASE**	**A205932**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205932**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205932**	**003**	Feb 03, 2017
AB		SAWAI USA	**EQ 1MG BASE**	**A205955**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205955**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205955**	**003**	Feb 03, 2017
AB		ZYDUS PHARMS	**EQ 1MG BASE**	**A206047**	**001**	Feb 22, 2023
AB			**EQ 2MG BASE**	**A206047**	**002**	Feb 22, 2023
AB			**EQ 4MG BASE**	**A206047**	**003**	Feb 22, 2023

PITAVASTATIN MAGNESIUM
TABLET;ORAL
ZYPITAMAG

	+	MEDICURE	EQ 2MG BASE	N208379	002	Jul 14, 2017
	+!		EQ 4MG BASE	N208379	003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE
TABLET;ORAL
WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019
	+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019

PIVMECILLINAM HYDROCHLORIDE
TABLET;ORAL
PIVYA

	+!	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024

PLAZOMICIN SULFATE
SOLUTION;INTRAVENOUS
ZEMDRI

	+!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018

PLECANATIDE
TABLET;ORAL
TRULANCE

	+!	SALIX	3MG	N208745	001	Jan 19, 2017

PLERIXAFOR
SOLUTION;SUBCUTANEOUS
MOZOBIL

AP	**+!**	GENZYME	**24MG/1.2ML (20MG/ML)**	**N022311**	**001**	Dec 15, 2008

PLERIXAFOR

AP		AMNEAL	**24MG/1.2ML (20MG/ML)**	**A215334**	**001**	Jul 24, 2023
AP		DR REDDYS	**24MG/1.2ML (20MG/ML)**	**A205182**	**001**	Jul 24, 2023
AP		EUGIA PHARMA	**24MG/1.2ML (20MG/ML)**	**A213672**	**001**	Jul 24, 2023
AP		GLAND	**24MG/1.2ML (20MG/ML)**	**A206644**	**001**	May 03, 2024
AP		HETERO LABS LTD VI	**24MG/1.2ML (20MG/ML)**	**A217560**	**001**	Jun 16, 2025

PLERIXAFOR
SOLUTION;SUBCUTANEOUS
PLERIXAFOR

AP		MEITHEAL	**24MG/1.2ML (20MG/ML)**	**A215698**	**001**	Jul 24, 2023
AP		MSN	**24MG/1.2ML (20MG/ML)**	**A211901**	**001**	Jul 24, 2023
AP		TEVA PHARMS USA INC	**24MG/1.2ML (20MG/ML)**	**A205197**	**001**	Jul 24, 2023

PLOZASIRAN SODIUM
SOLUTION;SUBCUTANEOUS
REDEMPLO

	+!	ARROWHEAD	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N219947	001 Nov 18, 2025

PODOFILOX
GEL;TOPICAL
CONDYLOX

AB	**+!**	ALLERGAN	**0.5%**	**N020529**	**001**	Mar 13, 1997

PODOFILOX

AB		PADAGIS US	**0.5%**	**A211871**	**001**	Nov 22, 2023

SOLUTION;TOPICAL
CONDYLOX

AT	**+!**	TEVA BRANDED PHARM	**0.5%**	**N019795**	**001**	Dec 13, 1990

PODOFILOX

AT		PADAGIS US	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL
SOLUTION;INTRAVENOUS
ASCLERA

	+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001 Mar 30, 2010
	+!		20MG/2ML (10MG/ML)	N021201	002 Mar 30, 2010

VARITHENA

	+!	PROVENSIS	180MG/18ML (10MG/ML)	N205098	001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION;ORAL
NULYTELY

AA	**+!**	AZURITY	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991

NULYTELY-FLAVORED

AA	**+!**	AZURITY	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA		NOVEL LABS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090019**	**001**	May 27, 2009
AA		STRIDES PHARMA	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS
FOR SOLUTION;ORAL
GOLYTELY

AA	**+!**	AZURITY	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA		NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA		STRIDES PHARMA	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A204558**	**001**	Dec 21, 2018

PEG 3350 AND ELECTROLYTES

		NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009

POLYMYXIN B SULFATE
INJECTABLE;INJECTION
POLYMYXIN B SULFATE

AP		EUGIA PHARMA	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP		FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP		GLAND	**EQ 500,000 UNITS BASE/VIAL**	**A207322**	**001**	Apr 14, 2016
AP	**!**	XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997
AT		EPIC PHARMA LLC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT	**!**	SANDOZ	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998
AT		SOMERSET THERAPS	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A211572**	**001**	Aug 05, 2024

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

		LLC				

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

+		BRISTOL	1MG	N204026	001	Feb 08, 2013
+			2MG	N204026	002	Feb 08, 2013
+			3MG	N204026	003	Feb 08, 2013
+!			4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

+		TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020
+			EQ 15MG BASE	N203469	001	Dec 14, 2012
+			EQ 30MG BASE	N203469	003	Apr 23, 2015
+!			EQ 45MG BASE	N203469	002	Dec 14, 2012

PONESIMOD

TABLET;ORAL

PONVORY

+!		VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021
+			3MG	N213498	002	Mar 18, 2021
+			4MG	N213498	003	Mar 18, 2021
+			5MG	N213498	004	Mar 18, 2021
+			6MG	N213498	005	Mar 18, 2021
+			7MG	N213498	006	Mar 18, 2021
+			8MG	N213498	007	Mar 18, 2021
+			9MG	N213498	008	Mar 18, 2021
+			10MG	N213498	009	Mar 18, 2021
+			20MG	N213498	010	Mar 18, 2021

PORFIMER SODIUM

INJECTABLE;INJECTION

PHOTOFRIN

		PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

NOXAFIL POWDERMIX KIT

+!		MSD MERCK CO	300MG	N214770	001	May 31, 2021

SOLUTION;INTRAVENOUS

NOXAFIL

AP	**+!**	MERCK SHARP DOHME	**300MG/16.7ML (18MG/ML)**	**N205596**	**001**	Mar 13, 2014

POSACONAZOLE

AP		ASPIRO	**300MG/16.7ML (18MG/ML)**	**A219057**	**001**	Dec 23, 2024
AP		EUGIA PHARMA	**300MG/16.7ML (18MG/ML)**	**A214842**	**001**	Dec 26, 2023
AP		FRESENIUS KABI USA	**300MG/16.7ML (18MG/ML)**	**A209983**	**001**	Dec 26, 2023
AP		GLAND	**300MG/16.7ML (18MG/ML)**	**A217553**	**001**	Dec 26, 2023
AP		MYLAN LABS LTD	**300MG/16.7ML (18MG/ML)**	**A211500**	**001**	Dec 26, 2023
AP		PH HEALTH	**300MG/16.7ML (18MG/ML)**	**A208768**	**001**	May 25, 2022

SUSPENSION;ORAL

NOXAFIL

AB	**+!**	SCHERING	**40MG/ML**	**N022003**	**001**	Sep 15, 2006

POSACONAZOLE

AB		HIKMA	**40MG/ML**	**A208773**	**001**	May 15, 2020

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB	**!**	AET PHARMA	**100MG**	**A213454**	**001**	Feb 01, 2021
AB		AMNEAL	**100MG**	**A216626**	**001**	Dec 22, 2022
AB		AUROBINDO PHARMA	**100MG**	**A217119**	**001**	Jul 18, 2024
AB		BIOCON PHARMA	**100MG**	**A214476**	**001**	Feb 04, 2022
AB		DR REDDYS	**100MG**	**A212500**	**001**	Apr 07, 2022
AB		HETERO LABS LTD III	**100MG**	**A214321**	**001**	Dec 08, 2022
AB		I 3 PHARMS	**100MG**	**A216488**	**001**	Aug 28, 2023
AB		MSN	**100MG**	**A218434**	**001**	Feb 24, 2025
AB		QILU PHARM HAINAN	**100MG**	**A217720**	**001**	Apr 23, 2025
AB		SINOTHERAPEUTICS INC	**100MG**	**A212411**	**001**	Aug 21, 2019
AB		SPECGX LLC	**100MG**	**A212226**	**001**	May 10, 2022
AB		WESTMINSTER PHARMS	**100MG**	**A216326**	**001**	Jun 20, 2023

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

AP		EXELA PHARMA	**2MEQ/ML**	**A206203**	**001**	Dec 29, 2015
AP			**2MEQ/ML**	**A212692**	**001**	Oct 20, 2021
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A217515**	**001**	Nov 27, 2024
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018896**	**001**	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001**	Jun 02, 2008
AB	**!**		**10MEQ**	**A077419**	**002**	Jun 02, 2008
AB		ADARE PHARMS INC	**8MEQ**	**A208864**	**001**	Mar 17, 2017
AB			**10MEQ**	**A208864**	**002**	Mar 17, 2017
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001**	Feb 22, 2013
AB		GRANULES	**8MEQ**	**A214686**	**001**	Feb 16, 2021
AB			**10MEQ**	**A214686**	**002**	Feb 16, 2021
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001**	Aug 16, 2016
AB			**10MEQ**	**A204828**	**002**	Aug 16, 2016
AB		PADAGIS US	**8MEQ**	**A200185**	**001**	May 18, 2011
AB			**10MEQ**	**A200185**	**002**	May 18, 2011
AB		PRINSTON INC	**8MEQ**	**A209026**	**001**	Jun 11, 2019
AB			**10MEQ**	**A209026**	**002**	Jun 11, 2019
AB		ZYDUS PHARMS	**8MEQ**	**A208445**	**001**	Mar 11, 2019
AB			**10MEQ**	**A208445**	**002**	Mar 11, 2019

FOR SOLUTION;ORAL

KLOR-CON

AA		UPSHER SMITH LABS	**20MEQ**	**A209662**	**001**	Oct 23, 2017

POTASSIUM CHLORIDE

AA		AJENAT PHARMS	**20MEQ**	**A212183**	**001**	May 06, 2019
AA		AMNEAL	**20MEQ**	**A210902**	**001**	May 23, 2019
AA		ANDA REPOSITORY	**20MEQ**	**A219009**	**001**	Jul 11, 2025
AA		EPIC PHARMA LLC	**20MEQ**	**A210200**	**001**	Nov 23, 2018
AA	**+**	GENUS	**20MEQ**	**N208019**	**001**	Aug 19, 2015
AA		GRANULES	**20MEQ**	**A213467**	**001**	Jan 27, 2022
AA		NOVEL LABS INC	**20MEQ**	**A210241**	**001**	Nov 21, 2018
AA		NOVITIUM PHARMA	**20MEQ**	**A212816**	**001**	Jul 12, 2023
AA		RUBICON RESEARCH	**20MEQ**	**A214108**	**001**	Mar 24, 2022
AA		STRIDES PHARMA	**20MEQ**	**A211667**	**001**	Mar 11, 2021

POKONZA

	+	GENUS	10MEQ	N208019	002	Aug 25, 2023

POTASSIUM CHLORIDE

	+!	GENUS	40MEQ	N208019	003	Aug 25, 2023

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**	
AP	**+!**	HOSPIRA	**2MEQ/ML**	**A080205**	**001**	
AP		NEXUS	**2MEQ/ML**	**A217704**	**001**	Aug 14, 2023

POTASSIUM CHLORIDE 10MEQ

AP		FRESENIUS KABI USA	**14.9MG/ML**	**A211087**	**001**	Sep 09, 2020
AP			**746MG/100ML**	**A211087**	**002**	Sep 09, 2020
AP		NEXUS	**14.9MG/ML**	**A214727**	**001**	Mar 18, 2021
AP			**745MG/100ML**	**A214727**	**002**	Mar 18, 2021

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001**	Dec 26, 1989
AP	**+!**		**746MG/100ML**	**N019904**	**005**	Dec 17, 1990
AP	**+!**	OTSUKA ICU MEDCL	**14.9MG/ML**	**N020161**	**005**	Nov 30, 1992
AP	**+!**		**745MG/100ML**	**N020161**	**001**	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ

AP		FRESENIUS KABI USA	**29.8MG/ML**	**A211087**	**003**	Sep 09, 2020
AP			**1.49GM/100ML**	**A211087**	**005**	May 07, 2021
AP		NEXUS	**29.8MG/ML**	**A214727**	**003**	Mar 18, 2021
AP			**1.49GM/100ML**	**A214727**	**004**	Mar 18, 2021

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002**	Dec 26, 1989
AP	**+!**		**1.49GM/100ML**	**N019904**	**006**	Dec 17, 1990
AP	**+!**	OTSUKA ICU MEDCL	**29.8MG/ML**	**N020161**	**006**	Aug 11, 1998
AP	**+!**		**1.49GM/100ML**	**N020161**	**002**	Nov 30, 1992

POTASSIUM CHLORIDE 40MEQ

AP		FRESENIUS KABI USA	**2.98GM/100ML**	**A211087**	**004**	Sep 09, 2020
AP		NEXUS	**2.98GM/100ML**	**A214727**	**005**	Mar 18, 2021

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989
AP	**+!**	OTSUKA ICU MEDCL	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		AJENAT PHARMS	**20MEQ/15ML**	**A216156**	**001**	Mar 07, 2023
AA			**40MEQ/15ML**	**A216156**	**002**	Mar 07, 2023
AA		AMNEAL	**20MEQ/15ML**	**A210041**	**001**	Jul 19, 2018
AA			**40MEQ/15ML**	**A210041**	**002**	Jul 19, 2018
AA		ANDA REPOSITORY	**20MEQ/15ML**	**A214892**	**001**	Dec 30, 2022
AA			**40MEQ/15ML**	**A214892**	**002**	Dec 30, 2022
AA		APOTEX	**20MEQ/15ML**	**A211067**	**001**	Aug 08, 2018
AA			**40MEQ/15ML**	**A211067**	**002**	Aug 08, 2018
AA		ASCENT PHARMS INC	**20MEQ/15ML**	**A211992**	**001**	Apr 09, 2025
AA			**40MEQ/15ML**	**A211992**	**002**	Apr 09, 2025
AA		AUROBINDO PHARMA	**20MEQ/15ML**	**A216536**	**001**	Nov 20, 2025
AA			**40MEQ/15ML**	**A216536**	**002**	Nov 20, 2025
AA	**+**	GENUS LIFESCIENCES	**20MEQ/15ML**	**N206814**	**001**	Dec 22, 2014
AA	**+!**		**40MEQ/15ML**	**N206814**	**002**	Dec 22, 2014
AA		GRANULES	**20MEQ/15ML**	**A213392**	**001**	Jan 29, 2021
AA			**40MEQ/15ML**	**A213392**	**002**	Jan 29, 2021
AA		MACLEODS PHARMS LTD	**20MEQ/15ML**	**A218733**	**001**	Sep 10, 2025
AA			**40MEQ/15ML**	**A218733**	**002**	Sep 10, 2025
AA		NOVEL LABS INC	**20MEQ/15ML**	**A209786**	**001**	Aug 29, 2018
AA			**40MEQ/15ML**	**A209786**	**002**	Aug 29, 2018
AA		PHARM ASSOC	**20MEQ/15ML**	**A210766**	**001**	Mar 29, 2019
AA			**40MEQ/15ML**	**A210766**	**002**	Mar 29, 2019
AA		QUAGEN	**20MEQ/15ML**	**A215716**	**001**	Dec 22, 2025
AA			**40MEQ/15ML**	**A215716**	**002**	Dec 22, 2025
AA		RUBICON RESEARCH	**20MEQ/15ML**	**A214656**	**001**	Jan 13, 2022
AA			**40MEQ/15ML**	**A214656**	**002**	Jan 13, 2022
AA		SCIEGEN PHARMS	**20MEQ/15ML**	**A211648**	**001**	May 21, 2021
AA			**40MEQ/15ML**	**A211648**	**002**	May 21, 2021
AA		STRIDES PHARMA	**20MEQ/15ML**	**A211665**	**002**	Jan 16, 2024
AA		TARO	**20MEQ/15ML**	**A218960**	**001**	Jul 22, 2025
AA		WES PHARMA INC	**20MEQ/15ML**	**A213062**	**001**	Jun 06, 2022
AA			**40MEQ/15ML**	**A213062**	**002**	Jun 06, 2022

POKONZA

	+	GENUS LIFESCIENCES	10MEQ/15ML	N206814	003	Nov 25, 2025

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10

AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000

KLOR-CON M15

AB1		UPSHER SMITH LABS	**15MEQ**	**A074726**	**003**	Jun 06, 2003

KLOR-CON M20

AB1	**!**	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998

POTASSIUM CHLORIDE

AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002
AB1		ADARE PHARMS INC	**10MEQ**	**A076368**	**002**	Jun 05, 2019
AB1			**20MEQ**	**A076368**	**001**	Aug 18, 2004
AB1		ASCENT PHARMS INC	**10MEQ**	**A214422**	**001**	Dec 29, 2020
AB1			**15MEQ**	**A214422**	**002**	Dec 29, 2020
AB1			**20MEQ**	**A214422**	**003**	Dec 29, 2020
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016
AB1		GRANULES	**10MEQ**	**A214452**	**001**	Oct 21, 2020
AB1			**20MEQ**	**A214452**	**002**	Oct 21, 2020
AB1		GUANGZHOU NOVAKEN	**10MEQ**	**A214395**	**001**	Jan 28, 2021
AB1			**20MEQ**	**A214395**	**002**	Jan 28, 2021
AB1		MACLEODS PHARMS LTD	**10MEQ**	**A216269**	**001**	May 09, 2024
AB1			**15MEQ**	**A216269**	**002**	May 09, 2024
AB1			**20MEQ**	**A216269**	**003**	May 09, 2024
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1		PRINSTON INC	**10MEQ**	**A209922**	**001**	Apr 30, 2019
AB1			**15MEQ**	**A209922**	**002**	Apr 30, 2019
AB1			**20MEQ**	**A209922**	**003**	Apr 30, 2019
AB1		RUBICON RESEARCH	**10MEQ**	**A216321**	**001**	Jun 16, 2023
AB1			**15MEQ**	**A216321**	**002**	Jun 16, 2023
AB1			**20MEQ**	**A216321**	**003**	Jun 16, 2023
AB1		ZYDUS PHARMS	**10MEQ**	**A210395**	**001**	Sep 17, 2020
AB1			**20MEQ**	**A210395**	**002**	Sep 17, 2020

KLOR-CON

AB2	**+**	UPSHER SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986
AB2	**+!**		**10MEQ**	**N019123**	**002**	Apr 17, 1986

POTASSIUM CHLORIDE

AB2		AUROBINDO PHARMA	**8MEQ**	**A210921**	**001**	Dec 19, 2018
AB2			**10MEQ**	**A210921**	**002**	Dec 19, 2018
AB2		GRANULES	**8MEQ**	**A211797**	**001**	Mar 04, 2020
AB2			**10MEQ**	**A211797**	**002**	Mar 04, 2020
AB2		MACLEODS PHARMS LTD	**8MEQ**	**A212987**	**001**	Sep 06, 2024
AB2			**10MEQ**	**A212987**	**002**	Sep 06, 2024
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016
AB2		PADAGIS US	**8MEQ**	**A205993**	**001**	Nov 05, 2015
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015
AB2		PHARMOBEDIENT	**8MEQ**	**A204662**	**001**	Aug 21, 2014
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014
AB2		RISING	**8MEQ**	**A217412**	**001**	Dec 19, 2023
AB2			**10MEQ**	**A217412**	**002**	Dec 19, 2023
AB2		STRIDES PHARMA	**8MEQ**	**A210733**	**001**	Aug 31, 2018
AB2			**10MEQ**	**A210733**	**002**	Aug 31, 2018
AB2		TWI PHARMS	**8MEQ**	**A218979**	**001**	Oct 28, 2024
AB2			**10MEQ**	**A218979**	**002**	Oct 28, 2024
AB2		YICHANG HUMANWELL	**8MEQ**	**A209314**	**001**	Jun 22, 2018
AB2			**10MEQ**	**A209314**	**002**	Jun 22, 2018
AB3		RUBICON RESEARCH	**10MEQ**	**A215725**	**001**	Jul 25, 2022
AB3			**20MEQ**	**A215725**	**002**	Jul 25, 2022
AB3		TWI PHARMS	**10MEQ**	**A209688**	**001**	Jan 12, 2018
AB3	**!**		**20MEQ**	**A209688**	**002**	Jan 12, 2018
AB3		YICHANG HUMANWELL	**10MEQ**	**A212561**	**001**	Sep 30, 2019
AB3			**20MEQ**	**A212561**	**002**	Sep 30, 2019
	!	RUBICON RESEARCH	15MEQ	A215725	003	Aug 22, 2024

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		OTSUKA ICU MEDCL	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

AP	**+!**	BAXTER HLTHCARE	**150MG/100ML;450MG/100ML**	**N017648**	**005**	Nov 26, 2002
AP		FRESENIUS KABI USA	**150MG/100ML;450MG/100ML**	**A212347**	**001**	Sep 17, 2020

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

AP	**+!**	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	
AP		FRESENIUS KABI USA	**150MG/100ML;900MG/100ML**	**A212347**	**003**	Jun 02, 2021

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

AP	**+!**	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N017648**	**002**	
AP		FRESENIUS KABI USA	**300MG/100ML;900MG/100ML**	**A212347**	**002**	Sep 17, 2020

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		OTSUKA ICU MEDCL	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		OTSUKA ICU MEDCL	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		ANI PHARMS	**10MEQ**	**A212779**	**001**	Jan 14, 2020
AB			**15MEQ**	**A212779**	**002**	Jan 14, 2020
AB		ASCENT PHARMS INC	**5MEQ**	**A214420**	**001**	Feb 05, 2021
AB			**10MEQ**	**A214420**	**002**	Feb 05, 2021
AB			**15MEQ**	**A214420**	**003**	Feb 05, 2021
AB		BIONPHARMA	**10MEQ**	**A212799**	**001**	Jun 29, 2020
AB			**15MEQ**	**A212799**	**002**	Jun 29, 2020

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		HIBROW HLTHCARE	**5MEQ**	**A214426**	**001**	Feb 19, 2021
AB			**10MEQ**	**A214426**	**002**	Feb 19, 2021
AB			**15MEQ**	**A214426**	**003**	Feb 19, 2021
AB		RISING	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB			**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB		STRIDES PHARMA	**5MEQ**	**A206813**	**001**	Sep 11, 2017
AB			**10MEQ**	**A206813**	**002**	Sep 11, 2017
AB			**15MEQ**	**A206813**	**003**	Sep 11, 2017
AB		TEVA PHARMS USA INC	**5MEQ**	**A209758**	**001**	Mar 05, 2018
AB			**10MEQ**	**A209758**	**002**	Mar 05, 2018
AB			**15MEQ**	**A209758**	**003**	Mar 05, 2018
AB		ZYDUS PHARMS	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB			**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB			**15MEQ**	**A203546**	**003**	Aug 06, 2014

UROCIT-K

AB	+	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB	+		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	+!		**15MEQ**	**N019071**	**003**	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP		AM REGENT	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A216274**	**001**	Oct 02, 2023
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A216274**	**002**	Oct 02, 2023
AP			**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**A216274**	**003**	Oct 02, 2023
AP		AMNEAL	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A216344**	**001**	Oct 10, 2023
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A216344**	**002**	Oct 10, 2023
AP			**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**A216344**	**003**	Oct 10, 2023
AP		CIPLA	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A217892**	**001**	Jan 24, 2025
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A217892**	**002**	Jan 24, 2025
AP			**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**A217892**	**003**	Jan 24, 2025
AP	+!	FRESENIUS KABI USA	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**N212832**	**001**	Nov 26, 2019
AP	+!		**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**N212832**	**002**	Nov 26, 2019
AP	+!		**11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)**	**N212832**	**003**	Nov 26, 2019
AP		HOSPIRA	**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A217459**	**001**	Sep 11, 2025
AP		SOMERSET THERAPS LLC	**1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)**	**A217726**	**001**	Jul 11, 2024
AP			**3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)**	**A217726**	**002**	Jul 11, 2024

POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

	+!	AMNEAL	1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML)	N218343	001	Jul 26, 2024
	+!	FRESENIUS KABI USA	1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML)	N212832	004	May 09, 2025
	+!		1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML)	N212832	005	May 09, 2025

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

	+!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

AP	+	ACROTECH BIOPHARMA	**20MG/ML (20MG/ML)**	**N022468**	**001**	Sep 24, 2009
AP	+!		**40MG/2ML (20MG/ML)**	**N022468**	**002**	Sep 24, 2009

PRALATREXATE

AP		DR REDDYS	**20MG/ML (20MG/ML)**	**A206183**	**001**	Mar 10, 2025
AP			**40MG/2ML (20MG/ML)**	**A206183**	**002**	Mar 10, 2025

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PROTOPAM CHLORIDE

+!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRALSETINIB

CAPSULE;ORAL

GAVRETO

+!	RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	AURORBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB		**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB		**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB		**0.75MG**	**A202633**	**004**	Oct 26, 2012
AB		**1MG**	**A202633**	**005**	Oct 26, 2012
AB		**1.5MG**	**A202633**	**006**	Oct 26, 2012
AB	GLENMARK PHARMS LTD	**0.125MG**	**A090781**	**001**	Oct 08, 2010
AB !		**0.25MG**	**A090781**	**002**	Oct 08, 2010
AB		**0.5MG**	**A090781**	**003**	Oct 08, 2010
AB		**0.75MG**	**A090781**	**006**	Sep 11, 2015
AB		**1MG**	**A090781**	**004**	Oct 08, 2010
AB		**1.5MG**	**A090781**	**005**	Oct 08, 2010
AB	PHARMOBEDIENT	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB		**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB		**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB		**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB		**1MG**	**A090151**	**004**	Apr 30, 2012
AB		**1.5MG**	**A090151**	**005**	Apr 30, 2012
AB	RISING	**0.25MG**	**A211088**	**001**	Oct 03, 2018
AB		**0.5MG**	**A211088**	**002**	Oct 03, 2018
AB		**0.75MG**	**A211088**	**003**	Oct 03, 2018
AB		**1MG**	**A211088**	**004**	Oct 03, 2018
AB		**1.5MG**	**A211088**	**005**	Oct 03, 2018
AB	SCIEGEN PHARMS	**0.125MG**	**A203855**	**001**	Oct 28, 2014
AB		**0.25MG**	**A203855**	**002**	Oct 28, 2014
AB		**0.5MG**	**A203855**	**003**	Oct 28, 2014
AB		**0.75MG**	**A203855**	**004**	Oct 28, 2014
AB		**1MG**	**A203855**	**005**	Oct 28, 2014
AB		**1.5MG**	**A203855**	**006**	Oct 28, 2014
AB	STRIDES PHARMA	**0.125MG**	**A202702**	**001**	Jun 03, 2014
AB		**0.25MG**	**A202702**	**002**	Jun 03, 2014
AB		**0.5MG**	**A202702**	**003**	Jun 03, 2014
AB		**0.75MG**	**A202702**	**004**	Jun 03, 2014
AB		**1MG**	**A202702**	**005**	Jun 03, 2014
AB		**1.5MG**	**A202702**	**006**	Jun 03, 2014
AB	TORRENT PHARMS	**0.125MG**	**A090865**	**001**	Oct 08, 2010
AB		**0.25MG**	**A090865**	**002**	Oct 08, 2010
AB		**0.5MG**	**A090865**	**003**	Oct 08, 2010
AB		**0.75MG**	**A090865**	**004**	Oct 08, 2010
AB		**1MG**	**A090865**	**005**	Oct 08, 2010
AB		**1.5MG**	**A090865**	**006**	Oct 08, 2010
AB	ZYDUS PHARMS USA INC	**0.125MG**	**A078920**	**001**	Jul 06, 2010
AB		**0.25MG**	**A078920**	**002**	Jul 06, 2010
AB		**0.5MG**	**A078920**	**003**	Jul 06, 2010
AB		**0.75MG**	**A078920**	**006**	Nov 23, 2022
AB		**1MG**	**A078920**	**004**	Jul 06, 2010
AB		**1.5MG**	**A078920**	**005**	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**0.375MG**	**A201963**	**001**	Apr 21, 2016
AB		**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB		**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB		**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB		**3MG**	**A201963**	**004**	Apr 21, 2016
AB		**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB		**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB	ALEMBIC	**0.375MG**	**A204518**	**001**	Jan 02, 2019
AB		**0.75MG**	**A204518**	**002**	Jan 02, 2019

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB			**1.5MG**	**A204518**	**003**	Jan 02, 2019
AB			**2.25MG**	**A204518**	**004**	Jan 02, 2019
AB			**3MG**	**A204518**	**005**	Jan 02, 2019
AB			**3.75MG**	**A204518**	**006**	Jan 02, 2019
AB			**4.5MG**	**A204518**	**007**	Jan 02, 2019
AB		CHARTWELL RX	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB			**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB			**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB			**3MG**	**A202353**	**004**	Dec 04, 2014
AB			**4.5MG**	**A202353**	**005**	Dec 04, 2014
AB	**!**	DR REDDYS	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB			**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB			**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB			**3MG**	**A203354**	**004**	Aug 07, 2015
AB			**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB		MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016
AB			**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB			**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB			**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB			**3MG**	**A206156**	**005**	Jun 24, 2016
AB			**3.75MG**	**A206156**	**007**	Jan 23, 2017
AB			**4.5MG**	**A206156**	**006**	Jun 24, 2016
AB		NOVAST LABS	**0.375MG**	**A213444**	**001**	Feb 03, 2022
AB			**0.75MG**	**A213444**	**002**	Feb 03, 2022
AB			**1.5MG**	**A213444**	**003**	Feb 03, 2022
AB			**2.25MG**	**A213444**	**004**	Feb 03, 2022
AB			**3MG**	**A213444**	**005**	Feb 03, 2022
AB			**3.75MG**	**A213444**	**006**	Feb 03, 2022
AB			**4.5MG**	**A213444**	**007**	Feb 03, 2022
AB		XIAMEN LP PHARM CO	**0.375MG**	**A212797**	**001**	Jun 11, 2021
AB			**0.75MG**	**A212797**	**002**	Jun 11, 2021
AB		ZYDUS PHARMS	**0.375MG**	**A202891**	**001**	Dec 12, 2017
AB			**0.75MG**	**A202891**	**002**	Dec 12, 2017
AB			**1.5MG**	**A202891**	**003**	Dec 12, 2017
AB			**2.25MG**	**A202891**	**004**	Dec 12, 2017
AB			**3MG**	**A202891**	**005**	Dec 12, 2017
AB			**3.75MG**	**A202891**	**006**	Dec 12, 2017
AB			**4.5MG**	**A202891**	**007**	Dec 12, 2017

PRASTERONE

INSERT;VAGINAL

INTRAROSA

	+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

AB	**+**	COSETTE	**EQ 5MG BASE**	**N022307**	**001**	Jul 10, 2009
AB	**+!**		**EQ 10MG BASE**	**N022307**	**002**	Jul 10, 2009

PRASUGREL

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A205987**	**001**	Feb 02, 2018
AB			**EQ 10MG BASE**	**A205987**	**002**	Feb 02, 2018
AB		AUROBINDO PHARMA	**EQ 5MG BASE**	**A205888**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205888**	**002**	Oct 16, 2017
AB		HEC PHARM	**EQ 5MG BASE**	**A206021**	**001**	Jan 16, 2019
AB			**EQ 10MG BASE**	**A206021**	**002**	Jan 16, 2019
AB		MYLAN	**EQ 5MG BASE**	**A205927**	**001**	Jul 12, 2017
AB			**EQ 10MG BASE**	**A205927**	**002**	Jul 12, 2017
AB		PANACEA	**EQ 5MG BASE**	**A205897**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205897**	**002**	Oct 16, 2017

PRASUGREL HYDROCHLORIDE

AB		UNICHEM	**EQ 5MG BASE**	**A213315**	**001**	Aug 28, 2023
AB			**EQ 10MG BASE**	**A213315**	**002**	Aug 28, 2023

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		ACCORD HLTHCARE	**10MG**	**A207068**	**001**	Nov 17, 2016
AB			**20MG**	**A207068**	**002**	Nov 17, 2016
AB			**40MG**	**A207068**	**003**	Nov 17, 2016
AB			**80MG**	**A207068**	**004**	Nov 17, 2016

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		APNAR PHARMA LP	**10MG**	**A077491**	**002**	Oct 23, 2006
AB			**20MG**	**A077491**	**003**	Oct 23, 2006
AB			**40MG**	**A077491**	**004**	Oct 23, 2006
AB			**80MG**	**A077491**	**001**	Feb 11, 2008
AB		APOTEX	**10MG**	**A076341**	**001**	Oct 23, 2006
AB			**20MG**	**A076341**	**002**	Oct 23, 2006
AB			**40MG**	**A076341**	**003**	Oct 23, 2006
AB			**80MG**	**A076341**	**004**	Dec 28, 2007
AB		AUROBINDO PHARMA	**10MG**	**A203367**	**001**	Feb 02, 2017
AB			**20MG**	**A203367**	**002**	Feb 02, 2017
AB			**40MG**	**A203367**	**003**	Feb 02, 2017
AB			**80MG**	**A203367**	**004**	Feb 02, 2017
AB		AUROBINDO PHARMA USA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB			**20MG**	**A076056**	**002**	Apr 24, 2006
AB			**40MG**	**A076056**	**003**	Apr 24, 2006
AB	**!**		**80MG**	**A077793**	**001**	Jan 15, 2008
AB		BIOCON PHARMA	**10MG**	**A209869**	**001**	Apr 13, 2018
AB			**20MG**	**A209869**	**002**	Apr 13, 2018
AB			**40MG**	**A209869**	**003**	Apr 13, 2018
AB			**80MG**	**A209869**	**004**	Apr 13, 2018
AB		CHARTWELL RX	**10MG**	**A077917**	**001**	Jan 08, 2008
AB			**20MG**	**A077917**	**002**	Jan 08, 2008
AB			**40MG**	**A077917**	**003**	Jan 08, 2008
AB			**80MG**	**A077917**	**004**	Jan 08, 2008
AB		CIPLA	**10MG**	**A077904**	**001**	Oct 23, 2006
AB			**20MG**	**A077904**	**002**	Oct 23, 2006
AB			**40MG**	**A077904**	**003**	Oct 23, 2006
AB			**80MG**	**A077904**	**004**	Mar 22, 2016
AB		DR REDDYS LABS INC	**10MG**	**A076714**	**001**	Oct 23, 2006
AB			**20MG**	**A076714**	**002**	Oct 23, 2006
AB			**40MG**	**A076714**	**003**	Oct 23, 2006
AB			**80MG**	**A076714**	**004**	Dec 28, 2007
AB		GLENMARK PHARMS LTD	**10MG**	**A077987**	**001**	May 11, 2007
AB			**20MG**	**A077987**	**002**	May 11, 2007
AB			**40MG**	**A077987**	**003**	May 11, 2007
AB			**80MG**	**A077987**	**004**	Dec 28, 2007
AB		WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB			**20MG**	**A076939**	**003**	Oct 23, 2006
AB			**40MG**	**A076939**	**002**	Oct 23, 2006
AB			**80MG**	**A076939**	**001**	Dec 28, 2007
AB		ZYDUS PHARMS USA	**20MG**	**A077751**	**002**	Apr 30, 2008
AB			**40MG**	**A077751**	**003**	Apr 30, 2008
AB			**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL

TABLET;ORAL

PRAZIQUANTEL

	!	PH HEALTH	600MG	A208820	001	Nov 27, 2017

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIPRESS

AB	**+**	PFIZER	**EQ 1MG BASE**	**N017442**	**002**	
AB	**+!**		**EQ 2MG BASE**	**N017442**	**003**	
AB	**+**		**EQ 5MG BASE**	**N017442**	**001**	

PRAZOSIN HYDROCHLORIDE

AB		ALEMBIC	**EQ 1MG BASE**	**A217268**	**001**	Mar 06, 2023
AB			**EQ 2MG BASE**	**A217268**	**002**	Mar 06, 2023
AB			**EQ 5MG BASE**	**A217268**	**003**	Mar 06, 2023
AB		APPCO	**EQ 1MG BASE**	**A213406**	**001**	Oct 21, 2022
AB			**EQ 2MG BASE**	**A213406**	**002**	Oct 21, 2022
AB			**EQ 5MG BASE**	**A213406**	**003**	Oct 21, 2022
AB		AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A213052**	**001**	Mar 31, 2023
AB			**EQ 2MG BASE**	**A213052**	**002**	Mar 31, 2023
AB			**EQ 5MG BASE**	**A213052**	**003**	Mar 31, 2023
AB		GRANULES	**EQ 1MG BASE**	**A214608**	**001**	Dec 23, 2021
AB			**EQ 2MG BASE**	**A214608**	**002**	Dec 23, 2021
AB			**EQ 5MG BASE**	**A214608**	**003**	Dec 23, 2021
AB		MANKIND PHARMA	**EQ 1MG BASE**	**A215697**	**001**	Dec 30, 2022

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AB			**EQ 2MG BASE**	**A215697**	**002**	Dec 30, 2022
AB			**EQ 5MG BASE**	**A215697**	**003**	Dec 30, 2022
AB		MSN	**EQ 1MG BASE**	**A216727**	**001**	Sep 17, 2024
AB			**EQ 2MG BASE**	**A216727**	**002**	Sep 17, 2024
AB			**EQ 5MG BASE**	**A216727**	**003**	Sep 17, 2024
AB		MYLAN	**EQ 1MG BASE**	**A072575**	**003**	May 16, 1989
AB			**EQ 2MG BASE**	**A072575**	**002**	May 16, 1989
AB			**EQ 5MG BASE**	**A072575**	**001**	May 16, 1989
AB		NOVITIUM PHARMA	**EQ 1MG BASE**	**A210971**	**001**	Oct 03, 2018
AB			**EQ 2MG BASE**	**A210971**	**002**	Oct 03, 2018
AB			**EQ 5MG BASE**	**A210971**	**003**	Oct 03, 2018
AB		TEVA PHARMS	**EQ 1MG BASE**	**A071745**	**002**	Sep 12, 1988
AB			**EQ 2MG BASE**	**A071745**	**003**	Sep 12, 1988
AB			**EQ 5MG BASE**	**A071745**	**001**	Sep 12, 1988

PREDNICARBATE

OINTMENT;TOPICAL

PREDNICARBATE

	!	FOUGERA PHARMS	0.1%	A077236	001 Mar 09, 2007

PREDNISOLONE

SOLUTION;ORAL

PREDNISOLONE

AA	**!**	CHARTWELL RX	**15MG/5ML**	**A040323**	**001**	May 13, 1999
AA		LANNETT CO INC	**15MG/5ML**	**A040775**	**001**	Sep 21, 2007
AA		PHARM ASSOC	**15MG/5ML**	**A040571**	**001**	Aug 25, 2005
AA		TP ANDA HOLDINGS	**15MG/5ML**	**A219509**	**001**	Jun 23, 2025

PRELONE

AA		TEVA	**15MG/5ML**	**A089081**	**001**	Feb 04, 1986

TABLET;ORAL

PREDNISOLONE

AB		AUROBINDO PHARMA LTD	**5MG**	**A215673**	**001**	Mar 17, 2023
AB	**+!**	WATSON LABS	**5MG**	**A080354**	**001**	
AB		ZHEJIANG XIANJU	**5MG**	**A218083**	**001**	May 02, 2024
BX		CHARTWELL MOLECULAR	5MG	A080531	002	

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB	**+!**	SANDOZ	**1%**	**N017469**	**001**	

PRED FORTE

AB	**+!**	ABBVIE	**1%**	**N017011**	**001**	

PREDNISOLONE ACETATE

AB		AMNEAL	**1%**	**A218256**	**001**	Jun 11, 2025
AB		LUPIN LTD	**1%**	**A216935**	**001**	Aug 02, 2024

PRED MILD

	+!	ABBVIE	0.12%	N017100	001	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PEDIAPRED

AA	**+!**	SETON PHARM	**EQ 5MG BASE/5ML**	**N019157**	**001**	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

AA		AMNEAL	**EQ 15MG BASE/5ML**	**A216715**	**001**	Oct 25, 2022
AA		CHARTWELL RX	**EQ 5MG BASE/5ML**	**A075988**	**001**	May 25, 2004
AA		EDENBRIDGE PHARMS	**EQ 10MG BASE/5ML**	**A203559**	**001**	Dec 20, 2016
AA			**EQ 15MG BASE/5ML**	**A203559**	**003**	Feb 06, 2023
AA			**EQ 20MG BASE/5ML**	**A203559**	**002**	Dec 20, 2016
AA			**EQ 25MG BASE/5ML**	**A203559**	**004**	Feb 06, 2023
AA	**!**	MISSION PHARMA	**EQ 25MG BASE/5ML**	**A091396**	**001**	Sep 13, 2010
AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A078465**	**001**	Mar 07, 2008
AA	**!**		**EQ 15MG BASE/5ML**	**A076913**	**001**	Apr 25, 2005
AA	**!**		**EQ 20MG BASE/5ML**	**A078988**	**001**	Jun 09, 2008

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

	+	ADVANZ PHARMA	EQ 10MG BASE	N021959	001	Jun 01, 2006
	+		EQ 15MG BASE	N021959	002	Jun 01, 2006
	+!		EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995

PREDNISONE

SOLUTION;ORAL

PREDNISONE

	+!	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISONE INTENSOL

	+!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

PREDNISONE

AB		AMNEAL	**1MG**	**A213385**	**001**	Jun 16, 2020
AB			**5MG**	**A213385**	**002**	Jun 16, 2020
AB			**10MG**	**A213386**	**001**	Jun 24, 2020
AB			**20MG**	**A213386**	**002**	Jun 24, 2020
AB		AUROBINDO PHARMA LTD	**1MG**	**A215671**	**001**	Nov 16, 2021
AB			**2.5MG**	**A215672**	**001**	Mar 28, 2022
AB			**5MG**	**A215672**	**002**	Mar 28, 2022
AB			**10MG**	**A215672**	**003**	Mar 28, 2022
AB			**20MG**	**A215672**	**004**	Mar 28, 2022
AB			**50MG**	**A215672**	**005**	Mar 28, 2022
AB	**+!**	HIKMA	**1MG**	**A080352**	**002**	Apr 22, 1982
AB	**+!**		**2.5MG**	**A080352**	**003**	Apr 22, 1982
AB	**+!**		**5MG**	**A080352**	**001**	
AB	**+!**		**10MG**	**A080352**	**004**	
AB	**+!**		**20MG**	**A080352**	**005**	
AB	**+!**		**50MG**	**A080352**	**006**	
AB		JUBILANT CADISTA	**1MG**	**A040611**	**001**	Jun 06, 2005
AB			**2.5MG**	**A040362**	**004**	Apr 17, 2023
AB			**5MG**	**A040362**	**002**	Aug 29, 2001
AB			**10MG**	**A040362**	**001**	Aug 29, 2001
AB			**20MG**	**A040362**	**003**	Jun 29, 2005
AB			**50MG**	**A040362**	**005**	Apr 17, 2023
AB		MYLAN	**5MG**	**A083677**	**002**	
AB			**10MG**	**A083677**	**003**	Dec 04, 1985
AB			**20MG**	**A083677**	**001**	
AB		NOVITIUM PHARMA	**1MG**	**A215246**	**001**	Jul 06, 2021
AB			**2.5MG**	**A211575**	**001**	Nov 15, 2019
AB			**5MG**	**A211575**	**002**	Nov 15, 2019
AB			**10MG**	**A211575**	**003**	Nov 15, 2019
AB			**20MG**	**A211575**	**004**	Nov 15, 2019
AB			**50MG**	**A211575**	**005**	Nov 15, 2019
AB		PH HEALTH	**1MG**	**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**	**A040581**	**001**	Dec 21, 2004
AB			**5MG**	**A040256**	**001**	Jul 12, 2002
AB			**10MG**	**A040256**	**002**	Jul 12, 2002
AB			**20MG**	**A040392**	**001**	Feb 12, 2003
AB		POINTVIEW HLDINGS	**5MG**	**A212629**	**001**	Dec 05, 2023
AB			**10MG**	**A212629**	**002**	Dec 05, 2023
AB			**20MG**	**A212629**	**003**	Dec 05, 2023
AB		STRIDES PHARMA	**1MG**	**A210785**	**001**	Sep 02, 2020
AB			**2.5MG**	**A208412**	**004**	Nov 20, 2020
AB			**5MG**	**A208412**	**005**	Nov 20, 2020
AB			**10MG**	**A208412**	**001**	Feb 11, 2021
AB			**20MG**	**A208412**	**002**	Feb 11, 2021
AB			**50MG**	**A208412**	**003**	Jan 11, 2022
AB		SUN PHARM INDUSTRIES	**5MG**	**A089247**	**002**	Dec 04, 1985
AB			**10MG**	**A089247**	**003**	Dec 04, 1985
AB			**20MG**	**A089247**	**001**	Dec 04, 1985
AB		WATSON LABS	**5MG**	**A080356**	**001**	
AB			**10MG**	**A085162**	**001**	
AB			**20MG**	**A085161**	**001**	
BX		CHARTWELL MOLECULAR	20MG	A084275	001	

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

	!	DR REDDYS	1MG	A219477	001	Oct 01, 2025
			2MG	A219477	002	Oct 01, 2025

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	UPJOHN	**25MG**	**N021446**	**001**	Dec 30, 2004
AB	+		**50MG**	**N021446**	**002**	Dec 30, 2004
AB	+		**75MG**	**N021446**	**003**	Dec 30, 2004
AB	+		**100MG**	**N021446**	**004**	Dec 30, 2004
AB	+		**150MG**	**N021446**	**005**	Dec 30, 2004
AB	+		**200MG**	**N021446**	**006**	Dec 30, 2004
AB	+		**225MG**	**N021446**	**007**	Dec 30, 2004
AB	+!		**300MG**	**N021446**	**008**	Dec 30, 2004

PREGABALIN

AB	ADAPTIS	**25MG**	**A216197**	**001**	Jul 18, 2022
AB		**50MG**	**A216197**	**002**	Jul 18, 2022
AB		**75MG**	**A216197**	**003**	Jul 18, 2022
AB		**100MG**	**A216197**	**004**	Jul 18, 2022
AB		**150MG**	**A216197**	**005**	Jul 18, 2022
AB		**200MG**	**A216197**	**006**	Jul 18, 2022
AB		**225MG**	**A216197**	**007**	Jul 18, 2022
AB		**300MG**	**A216197**	**008**	Jul 18, 2022
AB	ALEMBIC	**25MG**	**A203459**	**001**	Jul 19, 2019
AB		**50MG**	**A203459**	**002**	Jul 19, 2019
AB		**75MG**	**A203459**	**003**	Jul 19, 2019
AB		**100MG**	**A203459**	**004**	Jul 19, 2019
AB		**150MG**	**A203459**	**005**	Jul 19, 2019
AB		**200MG**	**A203459**	**006**	Jul 19, 2019
AB		**225MG**	**A203459**	**007**	Jul 19, 2019
AB		**300MG**	**A203459**	**008**	Jul 19, 2019
AB	ALKEM LABS LTD	**25MG**	**A207799**	**007**	Sep 30, 2019
AB		**50MG**	**A207799**	**008**	Sep 30, 2019
AB		**75MG**	**A207799**	**001**	Jul 19, 2019
AB		**100MG**	**A207799**	**002**	Jul 19, 2019
AB		**150MG**	**A207799**	**003**	Jul 19, 2019
AB		**200MG**	**A207799**	**004**	Jul 19, 2019
AB		**225MG**	**A207799**	**005**	Jul 19, 2019
AB		**300MG**	**A207799**	**006**	Jul 19, 2019
AB	AMNEAL PHARMS CO	**25MG**	**A209743**	**001**	Jul 19, 2019
AB		**50MG**	**A209743**	**002**	Jul 19, 2019
AB		**75MG**	**A209743**	**003**	Jul 19, 2019
AB		**100MG**	**A209743**	**004**	Jul 19, 2019
AB		**150MG**	**A209743**	**005**	Jul 19, 2019
AB		**200MG**	**A209743**	**006**	Jul 19, 2019
AB		**225MG**	**A209743**	**007**	Jul 19, 2019
AB		**300MG**	**A209743**	**008**	Jul 19, 2019
AB	AUROBINDO PHARMA	**25MG**	**A205321**	**001**	Mar 29, 2023
AB		**50MG**	**A205321**	**002**	Mar 29, 2023
AB		**75MG**	**A205321**	**003**	Mar 29, 2023
AB		**100MG**	**A205321**	**004**	Mar 29, 2023
AB		**150MG**	**A205321**	**005**	Mar 29, 2023
AB		**200MG**	**A205321**	**006**	Mar 29, 2023
AB		**225MG**	**A205321**	**007**	Mar 29, 2023
AB		**300MG**	**A205321**	**008**	Mar 29, 2023
AB	CHANGZHOU PHARM	**25MG**	**A214322**	**008**	Sep 26, 2024
AB		**50MG**	**A214322**	**001**	Jul 15, 2021
AB		**75MG**	**A214322**	**002**	Jul 15, 2021
AB		**100MG**	**A214322**	**003**	Jul 15, 2021
AB		**150MG**	**A214322**	**004**	Jul 15, 2021
AB		**200MG**	**A214322**	**005**	Jul 15, 2021
AB		**225MG**	**A214322**	**006**	Jul 15, 2021
AB		**300MG**	**A214322**	**007**	Jul 15, 2021
AB	CHARTWELL RX	**50MG**	**A212865**	**001**	Mar 20, 2020
AB		**75MG**	**A212865**	**002**	Mar 20, 2020
AB		**100MG**	**A212865**	**003**	Mar 20, 2020
AB		**150MG**	**A212865**	**004**	Mar 20, 2020
AB	CREEKWOOD PHARMS	**25MG**	**A213423**	**001**	Mar 23, 2020
AB		**50MG**	**A213423**	**002**	Mar 23, 2020
AB		**75MG**	**A213423**	**003**	Mar 23, 2020
AB		**100MG**	**A213423**	**004**	Mar 23, 2020
AB		**150MG**	**A213423**	**005**	Mar 23, 2020
AB		**200MG**	**A213423**	**006**	Mar 23, 2020
AB		**225MG**	**A213423**	**007**	Mar 23, 2020
AB		**300MG**	**A213423**	**008**	Mar 23, 2020

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019
AB		50MG	A209664	002	Jul 19, 2019
AB		75MG	A209664	003	Jul 19, 2019
AB		100MG	A209664	004	Jul 19, 2019
AB		150MG	A209664	005	Jul 19, 2019
AB		200MG	A209664	006	Jul 19, 2019
AB		225MG	A209664	007	Jul 19, 2019
AB		300MG	A209664	008	Jul 19, 2019
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022
AB		50MG	A212988	002	Mar 08, 2022
AB		75MG	A212988	003	Mar 08, 2022
AB		100MG	A212988	004	Mar 08, 2022
AB		150MG	A212988	005	Mar 08, 2022
AB		200MG	A212988	006	Mar 08, 2022
AB		225MG	A212988	007	Mar 08, 2022
AB		300MG	A212988	008	Mar 08, 2022
AB	HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019
AB		50MG	A206912	002	Oct 08, 2019
AB		75MG	A206912	003	Oct 08, 2019
AB		100MG	A206912	004	Oct 08, 2019
AB		150MG	A206912	005	Oct 08, 2019
AB		200MG	A206912	006	Oct 08, 2019
AB		225MG	A206912	007	Oct 08, 2019
AB		300MG	A206912	008	Oct 08, 2019
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019
AB		50MG	A211384	002	Jul 19, 2019
AB		75MG	A211384	003	Jul 19, 2019
AB		100MG	A211384	004	Jul 19, 2019
AB		150MG	A211384	005	Jul 19, 2019
AB		200MG	A211384	006	Jul 19, 2019
AB		225MG	A211384	007	Jul 19, 2019
AB		300MG	A211384	008	Jul 19, 2019
AB	JUBILANT GENERICS	25MG	A209530	001	May 20, 2025
AB		50MG	A209530	002	May 20, 2025
AB		75MG	A209530	003	May 20, 2025
AB		100MG	A209530	004	May 20, 2025
AB		150MG	A209530	005	May 20, 2025
AB		200MG	A209530	006	May 20, 2025
AB		225MG	A209530	007	May 20, 2025
AB		300MG	A209530	008	May 20, 2025
AB	MSN	25MG	A209357	001	Jul 19, 2019
AB		50MG	A209357	002	Jul 19, 2019
AB		75MG	A209357	003	Jul 19, 2019
AB		100MG	A209357	004	Jul 19, 2019
AB		150MG	A209357	005	Jul 19, 2019
AB		200MG	A209357	006	Jul 19, 2019
AB		225MG	A209357	007	Jul 19, 2019
AB		300MG	A209357	008	Jul 19, 2019
AB	PHARMOBEDIENT	25MG	A091222	001	Feb 21, 2025
AB		50MG	A091222	002	Feb 21, 2025
AB		75MG	A091222	003	Feb 21, 2025
AB		100MG	A091222	004	Feb 21, 2025
AB		150MG	A091222	005	Feb 21, 2025
AB		200MG	A091222	006	Feb 21, 2025
AB		225MG	A091222	007	Feb 21, 2025
AB		300MG	A091222	008	Feb 21, 2025
AB	PRINSTON INC	25MG	A207883	001	Sep 01, 2022
AB		50MG	A207883	002	Sep 01, 2022
AB		75MG	A207883	003	Sep 01, 2022
AB		100MG	A207883	004	Sep 01, 2022
AB		150MG	A207883	005	Sep 01, 2022
AB		200MG	A207883	006	Sep 01, 2022
AB		225MG	A207883	007	Sep 01, 2022
AB		300MG	A207883	008	Sep 01, 2022
AB	REGCON HOLDINGS	25MG	A208113	001	May 17, 2024
AB		50MG	A208113	002	May 17, 2024
AB		75MG	A208113	004	May 17, 2024
AB		100MG	A208113	005	May 17, 2024
AB		150MG	A208113	003	May 17, 2024

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB			**200MG**	**A208113**	**006**	May 17, 2024
AB			**225MG**	**A208113**	**007**	May 17, 2024
AB			**300MG**	**A208113**	**008**	May 17, 2024
AB		RISING	**25MG**	**A210432**	**001**	Jul 19, 2019
AB			**50MG**	**A210432**	**002**	Jul 19, 2019
AB			**75MG**	**A210432**	**003**	Jul 19, 2019
AB			**100MG**	**A210432**	**004**	Jul 19, 2019
AB			**150MG**	**A210432**	**005**	Jul 19, 2019
AB			**200MG**	**A210432**	**006**	Jul 19, 2019
AB			**225MG**	**A210432**	**007**	Jul 19, 2019
AB			**300MG**	**A210432**	**008**	Jul 19, 2019
AB		SCIEGEN PHARMS	**25MG**	**A208677**	**001**	Jul 19, 2019
AB			**50MG**	**A208677**	**002**	Jul 19, 2019
AB			**75MG**	**A208677**	**003**	Jul 19, 2019
AB			**100MG**	**A208677**	**004**	Jul 19, 2019
AB			**150MG**	**A208677**	**005**	Jul 19, 2019
AB			**200MG**	**A208677**	**006**	Jul 19, 2019
AB			**225MG**	**A208677**	**007**	Jul 19, 2019
AB			**300MG**	**A208677**	**008**	Jul 19, 2019
AB		SOMERSET THERAPS LLC	**50MG**	**A210585**	**001**	Dec 26, 2019
AB			**75MG**	**A210585**	**002**	Dec 26, 2019
AB			**100MG**	**A210585**	**003**	Dec 26, 2019
AB			**150MG**	**A210585**	**004**	Dec 26, 2019
AB			**200MG**	**A210585**	**005**	Dec 26, 2019
AB			**300MG**	**A210585**	**006**	Dec 26, 2019
AB		STRIDES PHARMA	**25MG**	**A215755**	**001**	Apr 26, 2023
AB			**50MG**	**A215755**	**002**	Apr 26, 2023
AB			**75MG**	**A215755**	**003**	Apr 26, 2023
AB			**100MG**	**A215755**	**004**	Apr 26, 2023
AB			**150MG**	**A215755**	**005**	Apr 26, 2023
AB			**200MG**	**A215755**	**006**	Apr 26, 2023
AB			**225MG**	**A215755**	**007**	Apr 26, 2023
AB			**300MG**	**A215755**	**008**	Apr 26, 2023
AB		TORRENT	**25MG**	**A206942**	**001**	Feb 21, 2025
AB			**50MG**	**A206942**	**002**	Feb 21, 2025
AB			**75MG**	**A206942**	**003**	Feb 21, 2025
AB			**100MG**	**A206942**	**004**	Feb 21, 2025
AB			**150MG**	**A206942**	**005**	Feb 21, 2025
AB			**200MG**	**A206942**	**006**	Feb 21, 2025
AB			**225MG**	**A206942**	**007**	Feb 21, 2025
AB			**300MG**	**A206942**	**008**	Feb 21, 2025
AB		YILING	**75MG**	**A210891**	**001**	Sep 30, 2019
AB			**300MG**	**A210891**	**002**	Sep 30, 2019

SOLUTION;ORAL

LYRICA

AA	**+!**	UPJOHN	**20MG/ML**	**N022488**	**001**	Jan 04, 2010

PREGABALIN

AA		ALKEM LABS LTD	**20MG/ML**	**A207623**	**001**	Jul 19, 2019
AA		ANDA REPOSITORY	**20MG/ML**	**A212604**	**001**	Feb 18, 2022

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

AB	**+**	UPJOHN	**82.5MG**	**N209501**	**001**	Oct 11, 2017
AB	**+**		**165MG**	**N209501**	**002**	Oct 11, 2017
AB	**+!**		**330MG**	**N209501**	**003**	Oct 11, 2017

PREGABALIN

AB		AIPING PHARM INC	**330MG**	**A217857**	**001**	Jan 28, 2025
AB		EPIC PHARMA LLC	**82.5MG**	**A214496**	**001**	Jun 01, 2023
AB			**165MG**	**A214496**	**002**	Jun 01, 2023
AB			**330MG**	**A214496**	**003**	Jun 01, 2023
AB		MSN	**82.5MG**	**A213226**	**001**	Apr 13, 2021
AB			**165MG**	**A213226**	**002**	Apr 13, 2021
AB			**330MG**	**A213226**	**003**	Apr 13, 2021
AB		RUBICON RESEARCH	**82.5MG**	**A215249**	**001**	Mar 22, 2022
AB			**165MG**	**A215249**	**002**	Mar 22, 2022
AB			**330MG**	**A215249**	**003**	Mar 22, 2022

PRETOMANID
TABLET;ORAL
PRETOMANID

	+!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
PRILOCAINE HYDROCHLORIDE

	!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE
TABLET;ORAL
PRIMAQUINE

AB	**+!**	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		NOVAST LABS	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016
AB		UNICHEM	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014

PRIMIDONE
TABLET;ORAL
MYSOLINE

AB	**+!**	VALEANT	**50MG**	**N009170**	**003**	
AB	**+**		**250MG**	**N009170**	**002**	

PRIMIDONE

AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		OXFORD PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		PHARMOBEDIENT	**50MG**	**A218366**	**001**	Jan 23, 2024
AB			**250MG**	**A218366**	**002**	Jan 23, 2024
AB		RUBICON RESEARCH	**50MG**	**A214896**	**001**	Jun 28, 2022
AB			**250MG**	**A214896**	**002**	Jun 28, 2022
AB		TP ANDA HOLDINGS	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		WATSON LABS	**250MG**	**A083551**	**001**	
		RUBICON RESEARCH	125MG	A214896	003	Dec 28, 2022

PROBENECID
TABLET;ORAL
PROBALAN

AB		LANNETT	**500MG**	**A080966**	**001**	

PROBENECID

AB		RISING	**500MG**	**A217020**	**001**	Nov 20, 2023
AB	!	WATSON LABS TEVA	**500MG**	**A084442**	**004**	Mar 29, 1983

PROBENECID; SULOPENEM ETZADROXIL
TABLET;ORAL
ORLYNVAH

	+!	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP		CAPLIN	**100MG/ML**	**A218674**	**001**	Feb 04, 2025
AP			**500MG/ML**	**A218674**	**002**	Feb 04, 2025
AP		GLAND	**100MG/ML**	**A218135**	**001**	Jul 22, 2024
AP			**500MG/ML**	**A218135**	**002**	Jul 22, 2024
AP	!	HOSPIRA	**100MG/ML**	**A089069**	**001**	Feb 12, 1986
AP	!		**500MG/ML**	**A089070**	**001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636**	**001**	Jul 31, 1984
AP		NEXUS	**100MG/ML**	**A206332**	**001**	Oct 13, 2017
AP			**500MG/ML**	**A206332**	**002**	Oct 13, 2017

PROCARBAZINE HYDROCHLORIDE
CAPSULE;ORAL
MATULANE

	+!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL

COMPRO

AB		PADAGIS US	**25MG**	**A040246**	**001**	Jun 28, 2000

PROCHLORPERAZINE

AB	!	COSETTE	**25MG**	**A040058**	**001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP		AMNEAL	**EQ 5MG BASE/ML**	**A214192**	**001**	Nov 28, 2022
AP	!	AVET LIFESCIENCES	**EQ 5MG BASE/ML**	**A204147**	**001**	Oct 15, 2013
AP		CAPLIN	**EQ 5MG BASE/ML**	**A214379**	**001**	Apr 22, 2021
AP		EUGIA PHARMA	**EQ 5MG BASE/ML**	**A213873**	**001**	Jul 14, 2022
AP		GLAND	**EQ 5MG BASE/ML**	**A214107**	**001**	Sep 22, 2021
AP		HIKMA	**EQ 5MG BASE/ML**	**A089903**	**001**	Aug 29, 1989
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A210710**	**001**	Oct 25, 2018
AP		SAGENT	**EQ 5MG BASE/ML**	**A040540**	**001**	May 28, 2004
AP		SOMERSET THERAPS LLC	**EQ 5MG BASE/ML**	**A212257**	**001**	Sep 13, 2024
AP		VIWIT PHARM	**EQ 5MG BASE/ML**	**A213626**	**001**	Sep 28, 2021

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB		AJANTA PHARMA LTD	**EQ 5MG BASE**	**A218515**	**001**	May 09, 2024
AB			**EQ 10MG BASE**	**A218515**	**002**	May 09, 2024
AB		AMNEAL	**EQ 5MG BASE**	**A216598**	**001**	Apr 17, 2023
AB			**EQ 10MG BASE**	**A216598**	**002**	Apr 17, 2023
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A218734**	**001**	Sep 08, 2025
AB			**EQ 10MG BASE**	**A218734**	**002**	Sep 08, 2025
AB		BIONPHARMA	**EQ 5MG BASE**	**A217478**	**001**	Apr 04, 2023
AB			**EQ 10MG BASE**	**A217478**	**002**	Apr 04, 2023
AB		DR REDDYS LABS SA	**EQ 5MG BASE**	**A217847**	**001**	May 19, 2025
AB			**EQ 10MG BASE**	**A217847**	**002**	May 19, 2025
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A216595**	**001**	Mar 17, 2023
AB			**EQ 10MG BASE**	**A216595**	**002**	Mar 17, 2023
AB		LEADING	**EQ 5MG BASE**	**A218912**	**001**	Sep 30, 2024
AB			**EQ 10MG BASE**	**A218912**	**002**	Sep 30, 2024
AB		NOVITIUM PHARMA	**EQ 5MG BASE**	**A216202**	**001**	Jun 13, 2022
AB			**EQ 10MG BASE**	**A216202**	**002**	Jun 13, 2022
AB		ZYDUS LIFESCIENCES	**EQ 5MG BASE**	**A216495**	**001**	Aug 08, 2022
AB			**EQ 10MG BASE**	**A216495**	**002**	Aug 08, 2022

PROCOMP

AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268**	**001**	Feb 27, 1998
AB	!		**EQ 10MG BASE**	**A040268**	**002**	Feb 27, 1998

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		AMNEAL PHARMS NY	**100MG**	**A207724**	**001**	Sep 07, 2017
AB			**200MG**	**A207724**	**002**	Sep 07, 2017
AB		BIONPHARMA	**100MG**	**A200900**	**001**	Aug 16, 2013
AB			**200MG**	**A200900**	**002**	Aug 16, 2013
AB		DR REDDYS	**100MG**	**A208801**	**001**	Feb 28, 2017
AB			**200MG**	**A208801**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**100MG**	**A211285**	**001**	Oct 26, 2018
AB			**200MG**	**A211285**	**002**	Oct 26, 2018
AB		SOFGEN PHARMS	**100MG**	**A200456**	**001**	Sep 28, 2012
AB			**200MG**	**A200456**	**002**	Sep 28, 2012
AB		XIROMED	**100MG**	**A205229**	**001**	Oct 20, 2017
AB			**200MG**	**A205229**	**002**	Oct 20, 2017

PROMETRIUM

AB	+	ACERTIS PHARMS	**100MG**	**N019781**	**001**	May 14, 1998
AB	+!		**200MG**	**N019781**	**002**	Oct 15, 1999

GEL;VAGINAL

CRINONE

	+!	ABBVIE	4%	N020701	001	Jul 31, 1997
	+!		8%	N020701	002	Jul 31, 1997

INJECTABLE;INJECTION

PROGESTERONE

AO	!	EUGIA PHARMA	**50MG/ML**	**A210965**	**001**	Dec 06, 2018
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906**	**001**	Apr 25, 2001

PROGESTERONE

INJECTABLE;INJECTION

PROGESTERONE

AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033**	**001**	Oct 28, 2010
AO		XIROMED	**50MG/ML**	**A215634**	**001**	Jan 05, 2022

INSERT;VAGINAL

ENDOMETRIN

AB	**+!**	FERRING	**100MG**	**N022057**	**001**	Jun 21, 2007

PROGESTERONE

AB		XIROMED	**100MG**	**A218391**	**001**	Sep 19, 2025

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	**+!**	HIKMA	**25MG/ML**	**A083312**	**001**	
AP	**+!**		**50MG/ML**	**A083312**	**002**	
AP		XGEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		ANNORA PHARMA	**12.5MG**	**A216446**	**001**	Nov 02, 2022
AB			**25MG**	**A216446**	**002**	Nov 02, 2022
AB		COSETTE	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	**!**		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PADAGIS ISRAEL	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003

PROMETHEGAN

	!	COSETTE	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		CHARTWELL RX	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		COSETTE	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012
AA		PHARM ASSOC	**6.25MG/5ML**	**A040643**	**001**	Apr 26, 2006
AA		QUAGEN	**6.25MG/5ML**	**A213890**	**001**	Jul 12, 2021
AA		STRIDES PHARMA	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009

PROMETHAZINE PLAIN

AA	**+!**	PHARMOBEDIENT	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010
AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		PRINSTON INC	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		QUAGEN	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB	**+**	SANDOZ	**25MG**	**A084176**	**003**	
AB	**+!**		**50MG**	**A084176**	**001**	
AB		WATSON LABS	**25MG**	**A083426**	**001**	
AB			**50MG**	**A083711**	**001**	
AB		ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB			**25MG**	**A040596**	**002**	Nov 18, 2005
AB			**50MG**	**A040596**	**003**	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**225MG**	**A213096**	**001**	Feb 21, 2023
AB			**325MG**	**A213096**	**002**	Feb 21, 2023
AB			**425MG**	**A213096**	**003**	Feb 21, 2023
AB		GLENMARK PHARMS LTD	**225MG**	**A205268**	**001**	Sep 08, 2017
AB			**325MG**	**A205268**	**002**	Sep 08, 2017
AB			**425MG**	**A205268**	**003**	Sep 08, 2017
AB		RISING	**225MG**	**A205956**	**001**	Jul 02, 2018
AB			**325MG**	**A205956**	**002**	Jul 02, 2018
AB			**425MG**	**A205956**	**003**	Jul 02, 2018
AB		SINOTHERAPEUTICS INC	**225MG**	**A210339**	**001**	Jan 04, 2019

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB			325MG	A210339	002	Jan 04, 2019
AB			425MG	A210339	003	Jan 04, 2019
AB		STRIDES PHARMA INTL	225MG	A078540	001	Oct 18, 2010
AB			325MG	A078540	002	Oct 18, 2010
AB	!		425MG	A078540	003	Oct 18, 2010
AB		UPSHER SMITH LABS	225MG	A212744	001	Jun 25, 2020
AB			325MG	A212744	002	Jun 25, 2020
AB			425MG	A212744	003	Jun 25, 2020
AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015
AB			325MG	A202688	002	Aug 24, 2015
AB			425MG	A202688	003	Aug 24, 2015
AB		ZYDUS LIFESCIENCES	225MG	A214184	001	Apr 21, 2021
AB			325MG	A214184	002	Apr 21, 2021
AB			425MG	A214184	003	Apr 21, 2021

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS	150MG	A076550	001	Apr 23, 2004
AB			225MG	A076550	002	Apr 23, 2004
AB			300MG	A076550	003	Apr 23, 2004
AB		AUROBINDO PHARMA	150MG	A202445	001	May 11, 2016
AB			225MG	A202445	002	May 11, 2016
AB			300MG	A202445	003	May 11, 2016
AB		STRIDES PHARMA INTL	150MG	A075938	001	Oct 17, 2002
AB			225MG	A075938	002	Oct 17, 2002
AB	!		300MG	A075938	003	Oct 17, 2002
AB		WATSON LABS	150MG	A075203	001	Oct 24, 2000
AB			225MG	A075203	002	Oct 24, 2000

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

AT		ALCON LABS INC	0.5%	A080027	001	

PROPARACAINE HYDROCHLORIDE

AT	!	BAUSCH AND LOMB	0.5%	A040074	001	Sep 29, 1995
AT		MANKIND PHARMA	0.5%	A219136	001	May 21, 2025
AT		MICRO LABS	0.5%	A219294	001	Oct 20, 2025
AT		RISING	0.5%	A040277	001	Mar 16, 2000
AT		SOMERSET THERAPS LLC	0.5%	A215816	001	Aug 09, 2024

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

AB	+!	FRESENIUS KABI USA	10MG/ML	N019627	002	Jun 11, 1996

PROPOFOL

AB		AMNEAL	10MG/ML	A217525	001	Aug 15, 2024
AB		ASPIRO	10MG/ML	A217013	001	Jun 20, 2024
AB		AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021
AB		DR REDDYS	10MG/ML	A205067	001	Nov 15, 2018
AB		HIKMA	10MG/ML	A074848	001	Apr 19, 2005
AB		HOSPIRA	10MG/ML	A077908	001	Mar 17, 2006
AB		INNOPHARMA	10MG/ML	A205576	001	Sep 16, 2020
AB		NANJING KING FRIEND	10MG/ML	A217945	001	Dec 02, 2025
AB		SAGENT PHARMS INC	10MG/ML	A075102	001	Jan 04, 1999

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	+	ANI PHARMS	60MG	N018553	004	Mar 18, 1987
AB	+		80MG	N018553	002	Apr 19, 1983
AB	+		120MG	N018553	003	Apr 19, 1983
AB	+!		160MG	N018553	001	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	60MG	A078494	001	Aug 10, 2007
AB			80MG	A078494	002	Aug 10, 2007
AB			120MG	A078494	003	Aug 10, 2007
AB			160MG	A078494	004	Aug 10, 2007
AB		ADARE PHARMS INC	60MG	A078703	001	Jul 15, 2011
AB			80MG	A078703	002	Jul 15, 2011
AB			120MG	A078703	003	Jul 15, 2011
AB			160MG	A078703	004	Jul 15, 2011

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		AMTA	**60MG**	**A212026**	**001**	Jan 06, 2020
AB			**80MG**	**A212026**	**002**	Jan 06, 2020
AB			**120MG**	**A212026**	**003**	Jan 06, 2020
AB			**160MG**	**A212026**	**004**	Jan 06, 2020
AB		ANDA REPOSITORY	**60MG**	**A078065**	**001**	Jan 26, 2007
AB			**80MG**	**A078065**	**002**	Jan 26, 2007
AB			**120MG**	**A078065**	**003**	Jan 26, 2007
AB			**160MG**	**A078065**	**004**	Jan 26, 2007
AB		ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011
AB			**80MG**	**A090321**	**002**	Mar 25, 2011
AB			**120MG**	**A090321**	**003**	Mar 25, 2011
AB			**160MG**	**A090321**	**004**	Mar 25, 2011

INNOPRAN XL

BX	+	ANI PHARMS	80MG	N021438	001	Mar 12, 2003
BX	+!		120MG	N021438	002	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001
AP	**!**	HIKMA FARMACEUTICA	**1MG/ML**	**A077760**	**001**	Jan 31, 2008

SOLUTION;ORAL

HEMANGEOL

	+!	PIERRE	4.28MG/ML	N205410	001	Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

	!	HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!		40MG/5ML	A070690	001	May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988
AB			**20MG**	**A071972**	**002**	Apr 06, 1988
AB			**40MG**	**A071972**	**003**	Apr 06, 1988
AB			**60MG**	**A071976**	**002**	May 13, 1986
AB	**!**		**80MG**	**A071976**	**001**	Apr 06, 1988
AB		INNOGENIX	**10MG**	**A070322**	**002**	Oct 22, 1985
AB			**20MG**	**A070322**	**003**	Oct 22, 1985
AB			**40MG**	**A070322**	**004**	Oct 22, 1985
AB			**60MG**	**A070322**	**005**	Sep 24, 1986
AB			**80MG**	**A070322**	**001**	Aug 04, 1986
AB		IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008
AB			**20MG**	**A078955**	**002**	Jun 02, 2008
AB			**40MG**	**A078955**	**003**	Jun 02, 2008
AB			**60MG**	**A078955**	**004**	Jun 02, 2008
AB			**80MG**	**A078955**	**005**	Jun 02, 2008
AB		MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985
AB			**20MG**	**A070213**	**003**	Nov 19, 1985
AB			**40MG**	**A070213**	**001**	Nov 19, 1985
AB			**60MG**	**A070213**	**005**	Apr 08, 2011
AB			**80MG**	**A070213**	**004**	Nov 19, 1985
AB		PH HEALTH	**10MG**	**A070221**	**002**	Aug 01, 1986
AB			**20MG**	**A070221**	**003**	Aug 01, 1986
AB			**40MG**	**A070221**	**004**	Aug 01, 1986
AB			**60MG**	**A070221**	**005**	Sep 24, 1986
AB			**80MG**	**A070221**	**001**	Apr 14, 1986
AB		WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB			**20MG**	**A070176**	**001**	May 13, 1986
AB			**40MG**	**A070177**	**001**	May 13, 1986
AB			**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB		MACLEODS PHARMS LTD	**50MG**	**A208867**	**001**	May 10, 2023
AB	**+!**	PH HEALTH	**50MG**	**N006188**	**001**	
BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD		QUAGEN	50MG	A080154	001	

PROTAMINE SULFATE

SOLUTION;INTRAVENOUS

PROTAMINE SULFATE

!	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A089454	001	Apr 07, 1987
!		250MG/25ML (10MG/ML)	A089454	002	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB !		**10MG**	**A202220**	**002**	Nov 19, 2012
AB	SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB		**10MG**	**A090462**	**002**	May 03, 2010

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

MOTEGRITY

AB +	TAKEDA PHARMS USA	**EQ 1MG BASE**	**N210166**	**001**	Dec 14, 2018
AB +!		**EQ 2MG BASE**	**N210166**	**002**	Dec 14, 2018

PRUCALOPRIDE SUCCINATE

AB	ALKEM LABS LTD	**EQ 1MG BASE**	**A218295**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218295**	**002**	Jun 24, 2025
AB	AMNEAL	**EQ 1MG BASE**	**A218812**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218812**	**002**	Jun 24, 2025
AB	ANNORA PHARMA	**EQ 1MG BASE**	**A219160**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A219160**	**002**	Jun 24, 2025
AB	APOTEX	**EQ 1MG BASE**	**A218977**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218977**	**002**	Jun 24, 2025
AB	APPCO	**EQ 1MG BASE**	**A218963**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218963**	**002**	Jun 24, 2025
AB	H2-PHARMA	**EQ 1MG BASE**	**A219216**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A219216**	**002**	Jun 24, 2025
AB	HIKMA	**EQ 1MG BASE**	**A217662**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A217662**	**002**	Jun 24, 2025
AB	LUPIN LTD	**EQ 1MG BASE**	**A218847**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218847**	**002**	Jun 24, 2025
AB	MSN	**EQ 1MG BASE**	**A218177**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218177**	**002**	Jun 24, 2025
AB	NOVITIUM PHARMA	**EQ 1MG BASE**	**A218492**	**001**	Dec 26, 2024
AB		**EQ 2MG BASE**	**A218492**	**002**	Dec 26, 2024
AB	SOMERSET THERAP	**EQ 1MG BASE**	**A219078**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A219078**	**002**	Jun 24, 2025
AB	SPECGX LLC	**EQ 1MG BASE**	**A219193**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A219193**	**002**	Jun 24, 2025
AB	ZENARA	**EQ 1MG BASE**	**A218795**	**001**	Jun 24, 2025
AB		**EQ 2MG BASE**	**A218795**	**002**	Jun 24, 2025
AB	ZYDUS LIFESCIENCES	**EQ 1MG BASE**	**A218056**	**001**	Aug 07, 2025
AB		**EQ 2MG BASE**	**A218056**	**002**	Aug 07, 2025

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB !	HIKMA	**500MG**	**A081319**	**001**	Jun 30, 1992
AB	MACLEODS PHARMS LTD	**500MG**	**A212541**	**001**	Jul 27, 2020
AB +	NOVITIUM PHARMA	**500MG**	**A080157**	**001**	

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

MESTINON

AP +!	BAUSCH	**5MG/ML**	**N009830**	**001**	

REGONOL

AP	SANDOZ	**5MG/ML**	**N017398**	**001**	

SYRUP;ORAL

MESTINON

AA +!	BAUSCH	**60MG/5ML**	**N015193**	**001**	

PYRIDOSTIGMINE BROMIDE

AA	AMNEAL	**60MG/5ML**	**A212702**	**001**	Jan 10, 2020
AA	MILLA PHARMS	**60MG/5ML**	**A212405**	**001**	Apr 19, 2022
AA	MSN	**60MG/5ML**	**A216512**	**001**	Sep 21, 2023
AA	NOVITIUM PHARMA	**60MG/5ML**	**A211694**	**001**	Mar 08, 2019
AA	RISING	**60MG/5ML**	**A208797**	**001**	Jan 09, 2020

TABLET;ORAL

MESTINON

AB +!	BAUSCH	**60MG**	**N009829**	**002**	

PYRIDOSTIGMINE BROMIDE
TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

AB		ANI PHARMS	**60MG**	**A040512**	**001**	Oct 08, 2003
AB		IMPAX LABS	**30MG**	**A040502**	**002**	Jun 28, 2022
AB			**60MG**	**A040502**	**001**	Apr 24, 2003
AB		MLV	**30MG**	**A211181**	**002**	May 14, 2019
AB			**60MG**	**A211181**	**001**	Jul 20, 2018
AB		ZYDUS PHARMS	**60MG**	**A205650**	**001**	Jun 22, 2015

TABLET, EXTENDED RELEASE;ORAL
MESTINON

AB	**+!**	BAUSCH	**180MG**	**N011665**	**001**	

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN	**180MG**	**A204737**	**001**	Jun 26, 2015
AB		IMPAX LABS INC	**180MG**	**A203184**	**001**	Sep 15, 2015
AB		RISING	**180MG**	**A205464**	**001**	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE
INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

	+!	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE
TABLET;ORAL
DARAPRIM

AB	**+!**	TILDE SCIENCES	**25MG**	**N008578**	**001**	

PYRIMETHAMINE

AB		AUROBINDO PHARMA LTD	**25MG**	**A216983**	**001**	Oct 25, 2022
AB		SANALUZ	**25MG**	**A207127**	**001**	Feb 28, 2020
AB		TEVA PHARMS	**25MG**	**A215506**	**001**	Aug 13, 2021

QUAZEPAM
TABLET;ORAL
DORAL

	+!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A202152**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A202152**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A202152**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A202152**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A202152**	**006**	Mar 27, 2012
AB		ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001**	Feb 12, 2013
AB			**EQ 50MG BASE**	**A201504**	**002**	Feb 12, 2013
AB			**EQ 100MG BASE**	**A201504**	**003**	Feb 12, 2013
AB			**EQ 150MG BASE**	**A201504**	**004**	Feb 12, 2013
AB			**EQ 200MG BASE**	**A201504**	**005**	Feb 12, 2013
AB			**EQ 300MG BASE**	**A201504**	**006**	Feb 12, 2013
AB			**EQ 400MG BASE**	**A201504**	**007**	Feb 12, 2013
AB		AUROBINDO PHARMA LTD	**EQ 25MG BASE**	**A091388**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A091388**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A091388**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A091388**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A091388**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A091388**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A091388**	**007**	Mar 27, 2012
AB		HETERO LABS LTD V	**EQ 25MG BASE**	**A204316**	**001**	Jun 16, 2022
AB			**EQ 50MG BASE**	**A204316**	**002**	Jun 16, 2022
AB			**EQ 100MG BASE**	**A204316**	**003**	Jun 16, 2022
AB			**EQ 200MG BASE**	**A204316**	**004**	Jun 16, 2022
AB			**EQ 300MG BASE**	**A204316**	**005**	Jun 16, 2022
AB			**EQ 400MG BASE**	**A204316**	**006**	Jun 16, 2022
AB		HIKMA	**EQ 25MG BASE**	**A090120**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090749**	**001**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A090749**	**002**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A090749**	**003**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A090749**	**004**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A090749**	**005**	Mar 27, 2012
AB		LUPIN LTD	**EQ 25MG BASE**	**A201109**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A201109**	**002**	Mar 27, 2012

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		**EQ 100MG BASE**	**A201109**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A201109**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201109**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201109**	**006**	Mar 27, 2012
AB	MACLEODS PHARMS LTD	**EQ 25MG BASE**	**A203359**	**001**	May 17, 2016
AB		**EQ 50MG BASE**	**A203359**	**002**	May 17, 2016
AB		**EQ 100MG BASE**	**A203359**	**003**	May 17, 2016
AB		**EQ 200MG BASE**	**A203359**	**004**	May 17, 2016
AB		**EQ 300MG BASE**	**A203359**	**005**	May 17, 2016
AB		**EQ 400MG BASE**	**A203359**	**006**	May 17, 2016
AB	PRINSTON INC	**EQ 25MG BASE**	**A206954**	**001**	Aug 24, 2022
AB		**EQ 50MG BASE**	**A206954**	**002**	Aug 24, 2022
AB		**EQ 100MG BASE**	**A206954**	**003**	Aug 24, 2022
AB		**EQ 200MG BASE**	**A206954**	**004**	Aug 24, 2022
AB		**EQ 300MG BASE**	**A206954**	**005**	Aug 24, 2022
AB		**EQ 400MG BASE**	**A206954**	**006**	Aug 24, 2022
AB	RISING	**EQ 25MG BASE**	**A077380**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A077380**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A077380**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A077380**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A077380**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A077380**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A077380**	**007**	Mar 27, 2012
AB	SCIEGEN PHARMS	**EQ 25MG BASE**	**A090960**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A090960**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A090960**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A090960**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A090960**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A090960**	**006**	Mar 27, 2012
AB	SUN PHARM	**EQ 25MG BASE**	**A201190**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A201190**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A201190**	**003**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201190**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201190**	**006**	Mar 27, 2012
AB	TEVA PHARMS	**EQ 25MG BASE**	**A077745**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A077745**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A077745**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A077745**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A077745**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A077745**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A077745**	**007**	Mar 27, 2012
AB	UNICHEM	**EQ 25MG BASE**	**A202674**	**001**	Mar 08, 2016
AB		**EQ 50MG BASE**	**A202674**	**002**	Mar 08, 2016
AB		**EQ 100MG BASE**	**A202674**	**003**	Mar 08, 2016
AB		**EQ 200MG BASE**	**A202674**	**004**	Mar 08, 2016
AB		**EQ 300MG BASE**	**A202674**	**005**	Mar 08, 2016
AB		**EQ 400MG BASE**	**A202674**	**006**	Mar 08, 2016

SEROQUEL

AB	**+!**	CHEPLAPHARM	**EQ 25MG BASE**	**N020639**	**001**	Sep 26, 1997
AB	**+**		**EQ 50MG BASE**	**N020639**	**007**	Oct 04, 2005
AB	**+**		**EQ 100MG BASE**	**N020639**	**002**	Sep 26, 1997
AB	**+**		**EQ 200MG BASE**	**N020639**	**003**	Sep 26, 1997
AB	**+!**		**EQ 300MG BASE**	**N020639**	**005**	Jul 26, 2000
AB	**+**		**EQ 400MG BASE**	**N020639**	**006**	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	**EQ 50MG BASE**	**A206252**	**001**	Nov 29, 2017
AB		**EQ 150MG BASE**	**A090681**	**001**	May 09, 2017
AB		**EQ 200MG BASE**	**A090681**	**002**	May 09, 2017
AB		**EQ 300MG BASE**	**A090681**	**003**	May 09, 2017
AB		**EQ 400MG BASE**	**A090681**	**004**	Nov 01, 2016
AB	ALIGNSCIENCE PHARMA	**EQ 150MG BASE**	**A209497**	**001**	Sep 28, 2018
AB		**EQ 200MG BASE**	**A209497**	**002**	Sep 28, 2018
AB	AUROBINDO PHARMA	**EQ 50MG BASE**	**A207655**	**001**	Nov 29, 2017
AB		**EQ 150MG BASE**	**A207655**	**002**	Nov 29, 2017
AB		**EQ 200MG BASE**	**A207655**	**003**	Nov 29, 2017
AB		**EQ 300MG BASE**	**A207655**	**004**	Nov 29, 2017
AB		**EQ 400MG BASE**	**A207655**	**005**	Nov 29, 2017
AB	LUPIN LTD	**EQ 50MG BASE**	**A204203**	**001**	May 17, 2017

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB			**EQ 150MG BASE**	**A204203**	**002**	May 17, 2017
AB			**EQ 200MG BASE**	**A204203**	**003**	May 17, 2017
AB			**EQ 300MG BASE**	**A204203**	**004**	May 17, 2017
AB			**EQ 400MG BASE**	**A204203**	**005**	May 17, 2017
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A204253**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A204253**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A204253**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A204253**	**004**	Nov 29, 2017
AB		MEDICAP LABS	**EQ 50MG BASE**	**A202939**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A202939**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A202939**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A202939**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A202939**	**005**	May 09, 2017
AB		NOVAST LABS	**EQ 50MG BASE**	**A208947**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A208947**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A208947**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A208947**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A208947**	**005**	Nov 29, 2017
AB		PRINSTON INC	**EQ 50MG BASE**	**A208781**	**001**	Apr 26, 2022
AB			**EQ 150MG BASE**	**A208781**	**002**	Apr 26, 2022
AB			**EQ 200MG BASE**	**A208781**	**003**	Apr 26, 2022
AB			**EQ 300MG BASE**	**A208781**	**004**	Apr 26, 2022
AB			**EQ 400MG BASE**	**A208781**	**005**	Mar 11, 2024
AB		RISING	**EQ 50MG BASE**	**A211144**	**001**	Nov 26, 2024
AB			**EQ 150MG BASE**	**A211144**	**002**	Nov 26, 2024
AB			**EQ 200MG BASE**	**A211144**	**003**	Nov 26, 2024
AB			**EQ 300MG BASE**	**A211144**	**004**	Nov 26, 2024
AB			**EQ 400MG BASE**	**A211144**	**005**	Nov 26, 2024
AB		SCIEGEN PHARMS	**EQ 50MG BASE**	**A209635**	**005**	Nov 16, 2018
AB			**EQ 150MG BASE**	**A209635**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A209635**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A209635**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A209635**	**004**	Nov 29, 2017
AB		UNICHEM	**EQ 50MG BASE**	**A215478**	**001**	Aug 15, 2022
AB			**EQ 150MG BASE**	**A215478**	**002**	Aug 15, 2022
AB			**EQ 200MG BASE**	**A215478**	**003**	Aug 15, 2022
AB			**EQ 300MG BASE**	**A215478**	**004**	Aug 15, 2022
AB			**EQ 400MG BASE**	**A215478**	**005**	Aug 15, 2022

SEROQUEL XR

AB	**+**	CHEPLAPHARM	**EQ 50MG BASE**	**N022047**	**001**	May 17, 2007
AB	**+**		**EQ 150MG BASE**	**N022047**	**005**	Aug 11, 2008
AB	**+!**		**EQ 200MG BASE**	**N022047**	**002**	May 17, 2007
AB	**+**		**EQ 300MG BASE**	**N022047**	**003**	May 17, 2007
AB	**+**		**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		CHARTWELL RX	**EQ 5MG BASE**	**A076803**	**001**	Mar 02, 2005
AB			**EQ 10MG BASE**	**A076803**	**002**	Mar 02, 2005
AB			**EQ 20MG BASE**	**A076803**	**003**	Mar 02, 2005
AB			**EQ 40MG BASE**	**A076803**	**004**	Mar 02, 2005
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB	**!**		**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016
AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE						
AB		HIBROW HLTHCARE	**324MG**	**A212589**	**001**	Sep 17, 2021
AB	**!**	SUN PHARM INDUSTRIES	**324MG**	**A089338**	**001**	Feb 11, 1987

QUINIDINE SULFATE
TABLET;ORAL

QUINIDINE SULFATE						
	!	EPIC PHARMA LLC	200MG	A088072	002	
	!		300MG	A088072	001	Sep 26, 1983

QUININE SULFATE
CAPSULE;ORAL

QUININE SULFATE						
AB		AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB		LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB	**!**	NOVAST LABS	**324MG**	**A204372**	**001**	Jul 22, 2015
AB		TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

QUIZARTINIB DIHYDROCHLORIDE
TABLET;ORAL

VANFLYTA						
	+	DAIICHI SANKYO INC	EQ 17.7MG BASE	N216993	001	Jul 20, 2023
	+!		EQ 26.5MG BASE	N216993	002	Jul 20, 2023

RABEPRAZOLE SODIUM
TABLET, DELAYED RELEASE;ORAL

ACIPHEX						
AB	**+!**	WAYLIS THERAP	**20MG**	**N020973**	**002**	Aug 19, 1999
RABEPRAZOLE SODIUM						
AB		ALKEM LABS LTD	**20MG**	**A208644**	**001**	Apr 24, 2018
AB		AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA	**20MG**	**A205761**	**001**	Feb 17, 2017
AB		CHARTWELL RX	**20MG**	**A078964**	**001**	Nov 08, 2013
AB		DR REDDYS	**20MG**	**A076824**	**001**	Nov 08, 2013
AB		LANNETT CO INC	**20MG**	**A090678**	**001**	Nov 08, 2013
AB		RUBICON RESEARCH	**20MG**	**A204237**	**001**	Nov 18, 2015
AB		TORRENT	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE
SOLUTION;INTRAVENOUS

XOFIGO						
	+!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE
TABLET;ORAL

EVISTA						
AB	**+!**	LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997
RALOXIFENE HYDROCHLORIDE						
AB		AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB		AUROBINDO PHARMA	**60MG**	**A204310**	**001**	Aug 28, 2015
AB		CADILA PHARMS LTD	**60MG**	**A211324**	**001**	Aug 18, 2020
AB		GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB		INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB		SCIEGEN PHARMS	**60MG**	**A206384**	**001**	Oct 12, 2016
AB		TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB		WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM
POWDER;ORAL

ISENTRESS						
	+!	MSD SUB MERCK	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013

TABLET;ORAL

ISENTRESS HD						
AB	**+!**	MSD SUB MERCK	**EQ 600MG BASE**	**N022145**	**002**	May 26, 2017
RALTEGRAVIR POTASSIUM						
AB		LUPIN LTD	**EQ 600MG BASE**	**A217990**	**001**	May 06, 2025
ISENTRESS						
	+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007

TABLET, CHEWABLE;ORAL

ISENTRESS						
	+	MSD SUB MERCK	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB		ANDAS 5 HOLDING	**8MG**	**A215435**	**001**	Aug 24, 2022
AB		APPCO	**8MG**	**A213815**	**001**	Oct 26, 2020
AB		DR REDDYS LABS SA	**8MG**	**A091693**	**001**	Jul 26, 2013
AB		I3 PHARMS	**8MG**	**A212650**	**001**	Apr 10, 2020
AB		MICRO LABS	**8MG**	**A215243**	**001**	Feb 09, 2023
AB		ZYDUS PHARMS	**8MG**	**A211567**	**001**	Jul 22, 2019

ROZEREM

AB	**+!**	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMELTEON

BX		AURORBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023
BX		XIROMED	8MG	A216209	001	Nov 25, 2022

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB		ANDA REPOSITORY	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB			**5MG**	**A078191**	**003**	Jun 18, 2008
AB			**10MG**	**A078191**	**004**	Jun 18, 2008
AB		AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB			**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB			**5MG**	**A091604**	**003**	Jun 08, 2011
AB			**10MG**	**A091604**	**004**	Jun 08, 2011
AB		CHARTWELL MOLECULAR	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB			**5MG**	**A078745**	**003**	Jun 18, 2008
AB			**10MG**	**A078745**	**004**	Jun 18, 2008
AB		COREPHARMA	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB			**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB			**5MG**	**A079116**	**003**	Jun 20, 2008
AB			**10MG**	**A079116**	**004**	Jun 20, 2008
AB		HIKMA	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB			**5MG**	**A077900**	**003**	Jun 18, 2008
AB			**10MG**	**A077900**	**004**	Jun 18, 2008
AB		LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB			**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB			**5MG**	**A077626**	**003**	Jun 09, 2008
AB	**!**		**10MG**	**A077626**	**004**	Jun 09, 2008
AB		WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB			**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB			**10MG**	**A076549**	**004**	Oct 24, 2005
AB		ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008
AB			**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB			**5MG**	**A078832**	**003**	Sep 02, 2008
AB			**10MG**	**A078832**	**004**	Sep 02, 2008

SOLUTION;ORAL

VOSTALLY

	+!	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB			**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB		SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB	**!**		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB			**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB		SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB			**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB		VKT PHARMA	**EQ 150MG BASE**	**A211289**	**001**	Jan 31, 2019
AB			**EQ 300MG BASE**	**A211289**	**002**	Jan 31, 2019

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ACTAVIS ELIZABETH	**500MG**	**A208862**	**001**	May 28, 2019
AB			**1GM**	**A208862**	**002**	May 28, 2019
AB		AJANTA PHARMA LTD	**500MG**	**A210054**	**001**	May 28, 2019
AB			**1GM**	**A210054**	**002**	May 28, 2019
AB		ALKEM LABS LTD	**500MG**	**A209953**	**001**	Nov 30, 2020
AB			**1GM**	**A209953**	**002**	Nov 30, 2020
AB		ARTHUR GRP	**500MG**	**A212781**	**001**	Mar 23, 2020
AB			**1GM**	**A212781**	**002**	Mar 23, 2020
AB		AUROBINDO PHARMA	**500MG**	**A209081**	**001**	Dec 23, 2022
AB			**1GM**	**A209081**	**002**	Dec 23, 2022
AB		CADILA	**500MG**	**A210188**	**001**	Aug 19, 2019
AB	**!**		**1GM**	**A210188**	**002**	Aug 19, 2019
AB		CHARTWELL RX	**500MG**	**A201046**	**001**	Jul 29, 2013
AB			**1GM**	**A201046**	**002**	Jul 29, 2013
AB		GLENMARK PHARMS LTD	**500MG**	**A211082**	**001**	Jul 05, 2019
AB			**1GM**	**A211082**	**002**	Jul 05, 2019
AB		HETERO LABS LTD III	**500MG**	**A212788**	**001**	May 05, 2022
AB			**1GM**	**A212788**	**002**	May 05, 2022
AB		I3 PHARMS	**500MG**	**A213517**	**001**	Apr 27, 2022
AB			**1GM**	**A213517**	**002**	Apr 27, 2022
AB		JUBILANT GENERICS	**500MG**	**A211361**	**001**	Apr 15, 2025
AB			**1GM**	**A211361**	**002**	Apr 15, 2025
AB		MANKIND PHARMA	**500MG**	**A212284**	**001**	Feb 12, 2020
AB			**1GM**	**A212284**	**002**	Feb 12, 2020
AB		MICRO LABS	**500MG**	**A211745**	**001**	Feb 27, 2020
AB			**1GM**	**A211745**	**002**	Feb 27, 2020
AB		NOVAST LABS	**500MG**	**A210668**	**001**	Sep 27, 2023
AB			**1GM**	**A210668**	**002**	Sep 27, 2023
AB		RISING	**500MG**	**A212889**	**001**	Jan 28, 2021
AB			**1GM**	**A212889**	**002**	Jan 28, 2021
AB		SCIEGEN PHARMS	**500MG**	**A211829**	**001**	Jun 04, 2019
AB			**1GM**	**A211829**	**002**	Jun 04, 2019
AB		SUNSHINE	**500MG**	**A211865**	**001**	Mar 23, 2020
AB			**1GM**	**A211865**	**002**	Mar 23, 2020
AB		UNICHEM	**500MG**	**A213083**	**001**	Mar 16, 2023
AB			**1GM**	**A213083**	**002**	Mar 16, 2023
AB		VKT PHARMA	**500MG**	**A214035**	**001**	Jan 19, 2022
AB			**1GM**	**A214035**	**002**	Jan 19, 2022

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

AB	**+**	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB	**+!**		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A201889**	**001**	Oct 30, 2017
AB			**EQ 1MG BASE**	**A201889**	**002**	Oct 30, 2017
AB		AUROBINDO PHARMA USA	**EQ 0.5MG BASE**	**A201971**	**001**	May 15, 2017
AB			**EQ 1MG BASE**	**A201971**	**002**	May 15, 2017
AB		CARNEGIE	**EQ 0.5MG BASE**	**A201942**	**001**	Nov 18, 2021
AB			**EQ 1MG BASE**	**A201942**	**002**	Nov 18, 2021
AB		CHARTWELL RX	**EQ 0.5MG BASE**	**A201892**	**001**	Jul 27, 2018
AB			**EQ 1MG BASE**	**A201892**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**EQ 0.5MG BASE**	**A208866**	**001**	Jun 28, 2024
AB			**EQ 1MG BASE**	**A208866**	**002**	Jun 28, 2024
AB		MICRO LABS	**EQ 0.5MG BASE**	**A207004**	**001**	Mar 29, 2019
AB			**EQ 1MG BASE**	**A207004**	**002**	Mar 29, 2019
AB		ORBION PHARMS	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB			**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016
AB		REGCON HOLDINGS	**EQ 0.5MG BASE**	**A206153**	**001**	Oct 04, 2019
AB			**EQ 1MG BASE**	**A206153**	**002**	Oct 04, 2019
AB		RISING	**EQ 0.5MG BASE**	**A218163**	**001**	Apr 09, 2024
AB			**EQ 1MG BASE**	**A218163**	**002**	Apr 09, 2024
AB		TORRENT	**EQ 0.5MG BASE**	**A210150**	**001**	May 05, 2025
AB			**EQ 1MG BASE**	**A210150**	**002**	May 05, 2025

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP	**+!**	ASTELLAS	**0.4MG/5ML (0.08MG/ML)**	**N022161**	**001**	Apr 10, 2008

REGADENOSON

AP		ACCORD HLTHCARE	**0.4MG/5ML (0.08MG/ML)**	**A213236**	**001**	Apr 11, 2022
AP		APOTEX	**0.4MG/5ML (0.08MG/ML)**	**A207604**	**001**	Apr 11, 2022
AP		BAXTER HLTHCARE CORP	**0.4MG/5ML (0.08MG/ML)**	**A217455**	**001**	May 23, 2023
AP		DR REDDYS	**0.4MG/5ML (0.08MG/ML)**	**A213210**	**001**	Apr 11, 2022
AP		EUGIA PHARMA	**0.4MG/5ML (0.08MG/ML)**	**A216437**	**001**	Oct 26, 2022
AP		GE HEALTHCARE	**0.4MG/5ML (0.08MG/ML)**	**A215955**	**001**	Aug 05, 2024
AP		GLAND	**0.4MG/5ML (0.08MG/ML)**	**A207320**	**001**	Jul 12, 2022
AP		HIKMA	**0.4MG/5ML (0.08MG/ML)**	**A215827**	**001**	Feb 02, 2023
AP		HOSPIRA	**0.4MG/5ML (0.08MG/ML)**	**A214349**	**001**	Aug 31, 2022
AP		IMS LTD	**0.4MG/5ML (0.08MG/ML)**	**A214252**	**001**	May 23, 2022
AP		INDIES PHARMA	**0.4MG/5ML (0.08MG/ML)**	**A218054**	**001**	Aug 22, 2024
AP		MEITHEAL	**0.4MG/5ML (0.08MG/ML)**	**A212806**	**001**	Apr 11, 2022
AP		MYLAN	**0.4MG/5ML (0.08MG/ML)**	**A213856**	**001**	Apr 04, 2023

REGORAFENIB

TABLET;ORAL

STIVARGA

	+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

RELUGOLIX

TABLET;ORAL

ORGOVYX

	+!	SUMITOMO PHARMA AM	120MG	N214621	001	Dec 18, 2020

REMDESIVIR

POWDER;INTRAVENOUS

VEKLURY

	+!	GILEAD SCIENCES INC	100MG/VIAL	N214787	001	Oct 22, 2020

REMIBRUTINIB

TABLET;ORAL

RHAPSIDO

	+!	NOVARTIS	25MG	N218436	001	Sep 30, 2025

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/VIAL**	**A206223**	**001**	Jan 16, 2018
AP			**EQ 2MG BASE/VIAL**	**A206223**	**002**	Jan 16, 2018
AP			**EQ 5MG BASE/VIAL**	**A206223**	**003**	Jan 16, 2018
AP		HIKMA	**EQ 1MG BASE/VIAL**	**A210594**	**001**	Oct 13, 2020
AP			**EQ 2MG BASE/VIAL**	**A210594**	**002**	Oct 13, 2020
AP			**EQ 5MG BASE/VIAL**	**A210594**	**003**	Oct 13, 2020
AP		NIVAGEN PHARMS INC	**EQ 1MG BASE/VIAL**	**A215635**	**001**	Jun 28, 2024
AP			**EQ 2MG BASE/VIAL**	**A215635**	**002**	Jun 28, 2024
AP			**EQ 5MG BASE/VIAL**	**A215635**	**003**	Jun 28, 2024

ULTIVA

AP	**+**	MYLAN INSTITUTIONAL	**EQ 1MG BASE/VIAL**	**N020630**	**001**	Jul 12, 1996
AP	**+**		**EQ 2MG BASE/VIAL**	**N020630**	**002**	Jul 12, 1996
AP	**+!**		**EQ 5MG BASE/VIAL**	**N020630**	**003**	Jul 12, 1996

REMIMAZOLAM BESYLATE

POWDER;INTRAVENOUS

BYFAVO

	+!	ACACIA	EQ 20MG BASE/VIAL	N212295	001	Oct 06, 2020

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820**	**001**	Jan 22, 2014
AB			**1MG**	**A203820**	**002**	Jan 22, 2014
AB	**!**		**2MG**	**A203820**	**003**	Jan 22, 2014
AB		CHARTWELL RX	**0.5MG**	**A078555**	**001**	Nov 22, 2013
AB			**1MG**	**A078555**	**002**	Jan 22, 2014
AB			**2MG**	**A078555**	**003**	Jan 22, 2014
AB		MACLEODS PHARMS LTD	**0.5MG**	**A207209**	**001**	Mar 22, 2023
AB			**1MG**	**A207209**	**002**	Mar 22, 2023
AB			**2MG**	**A207209**	**003**	Mar 22, 2023
AB		PADAGIS US	**0.5MG**	**A201189**	**001**	Jul 17, 2013

REPAGLINIDE
TABLET;ORAL
REPAGLINIDE

AB			**1MG**	**A201189**	**002**	Jan 22, 2014
AB			**2MG**	**A201189**	**003**	Jan 22, 2014

REPOTRECTINIB
CAPSULE;ORAL
AUGTYRO

	+!	BRISTOL	40MG	N218213	001	Nov 15, 2023
	+!		160MG	N218213	002	Jun 11, 2024

RESMETIROM
TABLET;ORAL
REZDIFFRA

	+	MADRIGAL	60MG	N217785	001	Mar 14, 2024
	+		80MG	N217785	002	Mar 14, 2024
	+!		100MG	N217785	003	Mar 14, 2024

REVEFENACIN
SOLUTION;INHALATION
YUPELRI

	+!	MYLAN IRELAND LTD	175MCG/3ML	N210598	001	Nov 09, 2018

REVUMENIB CITRATE
TABLET;ORAL
REVUFORJ

	+	SYNDAX	EQ 25MG BASE	N218944	001	Nov 15, 2024
	+		EQ 110MG BASE	N218944	002	Nov 15, 2024
	+!		EQ 160MG BASE	N218944	003	Nov 15, 2024

REZAFUNGIN ACETATE
POWDER;INTRAVENOUS
REZZAYO

	+!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023

RIBAVIRIN
CAPSULE;ORAL
RIBAVIRIN

AB	**!**	AURODINDO PHARMA	**200MG**	**A079117**	**001**	Sep 17, 2009
AB		ZYDUS PHARMS USA	**200MG**	**A077224**	**001**	Oct 28, 2005

FOR SOLUTION;INHALATION
RIBAVIRIN

	!	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016

TABLET;ORAL
RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079111**	**001**	Sep 17, 2009
AB		SANDOZ	**200MG**	**A077743**	**001**	Oct 03, 2006
AB		ZYDUS PHARMS USA	**200MG**	**A077094**	**001**	Dec 05, 2005

RIBOCICLIB SUCCINATE
TABLET;ORAL
KISQALI

	+!	NOVARTIS	EQ 200MG BASE	N209092	001	Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM
SOLUTION/DROPS;OPHTHALMIC
EPIOXA HD/EPIOXA KIT

	+!	GLAUKOS	EQ 0.239% BASE/ML;EQ 0.177% BASE/ML	N219910	001	Oct 17, 2025

PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA

	+!	GLAUKOS	EQ 0.146% BASE/ML;EQ 0.146% BASE/ML	N203324	001	Apr 15, 2016

RIFABUTIN
CAPSULE;ORAL
MYCOBUTIN

AB	**+!**	PFIZER	**150MG**	**N050689**	**001**	Dec 23, 1992

RIFABUTIN

AB		NOVITIUM PHARMA	**150MG**	**A215041**	**001**	Dec 17, 2021

RIFAMPIN
CAPSULE;ORAL
RIFAMPIN

AB		CHARTWELL MOLECULAR	**150MG**	**A065390**	**001**	Mar 28, 2008
AB			**300MG**	**A065390**	**002**	Mar 28, 2008
AB		EPIC PHARMA LLC	**150MG**	**A064150**	**002**	Jan 02, 1998
AB			**300MG**	**A064150**	**001**	May 28, 1997
AB		LUPIN PHARMS	**150MG**	**A090034**	**001**	Aug 21, 2013

RIFAMPIN
CAPSULE;ORAL
RIFAMPIN

AB	**!**		**300MG**	**A090034**	**002**	Aug 21, 2013

RIMACTANE

AB		OXFORD PHARMS	**300MG**	**N050429**	**001**	

INJECTABLE;INJECTION
RIFADIN

AP	**+!**	SANOFI AVENTIS US	**600MG/VIAL**	**N050627**	**001**	May 25, 1989

RIFAMPIN

AP		EPIC PHARMA LLC	**600MG/VIAL**	**A065502**	**001**	Sep 21, 2010
AP		FRESENIUS KABI USA	**600MG/VIAL**	**A091181**	**001**	Aug 21, 2014
AP		HIKMA	**600MG/VIAL**	**A064217**	**001**	Oct 29, 1999
AP		HIKMA PHARMS	**600MG/VIAL**	**A205039**	**001**	Mar 03, 2016
AP		MYLAN LABS LTD	**600MG/VIAL**	**A065421**	**001**	May 22, 2008

RIFAPENTINE
TABLET;ORAL
PRIFTIN

	+!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN
TABLET;ORAL
XIFAXAN

	+!	SALIX PHARMS	200MG	N021361	001	May 25, 2004
	+!		550MG	N021361	002	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE
TABLET;ORAL
EDURANT

	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

TABLET, FOR SUSPENSION;ORAL
EDURANT PED

	+!	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024

RILUZOLE
SUSPENSION;ORAL
RILUZOLE

AB		ALKEM LABS LTD	**50MG/10ML**	**A216035**	**001**	Aug 22, 2024

TIGLUTIK KIT

AB	**+!**	ITALFARMACO SA	**50MG/10ML**	**N209080**	**001**	Sep 05, 2018

TABLET;ORAL
RILUZOLE

AB	**!**	ALKEM LABS LTD	**50MG**	**A204048**	**001**	Mar 30, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A091394**	**001**	Jun 18, 2013
AB		IMPAX LABS	**50MG**	**A076173**	**001**	Jan 29, 2003
AB		KENTON	**50MG**	**A206045**	**001**	Dec 09, 2019

RILZABRUTINIB
TABLET;ORAL
WAYRILZ

	+!	GENZYME CORP	400MG	N219685	001	Aug 29, 2025

RIMANTADINE HYDROCHLORIDE
TABLET;ORAL
RIMANTADINE HYDROCHLORIDE

	!	IMPAX LABS	100MG	A076132	001	Aug 30, 2002

RIMEGEPANT SULFATE
TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT

	+!	PFIZER	EQ 75MG BASE	N212728	001	Feb 27, 2020

RIOCIGUAT
TABLET;ORAL
ADEMPAS

AB	**+**	BAYER HLTHCARE	**0.5MG**	**N204819**	**001**	Oct 08, 2013
AB	**+**		**1MG**	**N204819**	**002**	Oct 08, 2013
AB	**+**		**1.5MG**	**N204819**	**003**	Oct 08, 2013
AB	**+**		**2MG**	**N204819**	**004**	Oct 08, 2013
AB	**+!**		**2.5MG**	**N204819**	**005**	Oct 08, 2013

RIOCIGUAT

AB		MSN	**0.5MG**	**A211135**	**001**	Sep 01, 2022
AB			**1MG**	**A211135**	**002**	Sep 01, 2022
AB			**1.5MG**	**A211135**	**003**	Sep 01, 2022
AB			**2MG**	**A211135**	**004**	Sep 01, 2022

RIOCIGUAT						
TABLET;ORAL						
RIOCIGUAT						
AB			**2.5MG**	**A211135**	**005**	Sep 01, 2022
RIPRETINIB						
TABLET;ORAL						
QINLOCK						
	+!	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020
RISDIPLAM						
FOR SOLUTION;ORAL						
EVRYSDI						
	+!	GENENTECH INC	0.75MG/ML	N213535	001	Aug 07, 2020
TABLET;ORAL						
EVRYSDI						
	+!	GENENTECH INC	5MG	N219285	001	Feb 11, 2025
RISEDRONATE SODIUM						
TABLET;ORAL						
ACTONEL						
AB	**+!**	APIL	**35MG**	**N020835**	**003**	May 25, 2002
AB	**+!**		**150MG**	**N020835**	**005**	Apr 22, 2008
RISEDRONATE SODIUM						
AB		APOTEX	**35MG**	**A090877**	**001**	Nov 30, 2015
AB			**75MG**	**A090877**	**002**	Jun 10, 2014
AB			**150MG**	**A090877**	**003**	Jun 10, 2014
AB		AUROBINDO PHARMA	**150MG**	**A206768**	**001**	Oct 21, 2016
AB		AUROBINDO PHARMA LTD	**5MG**	**A200296**	**001**	Nov 30, 2015
AB			**30MG**	**A200296**	**002**	Nov 30, 2015
AB			**35MG**	**A200296**	**003**	Nov 30, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A203533**	**001**	Dec 09, 2015
AB			**30MG**	**A203533**	**002**	Dec 09, 2015
AB			**35MG**	**A203533**	**003**	Nov 29, 2016
AB		ORBION PHARMS	**30MG**	**A205280**	**001**	May 13, 2019
AB			**35MG**	**A205280**	**002**	May 13, 2019
AB		SUN PHARM	**5MG**	**A090886**	**001**	Nov 30, 2015
AB			**30MG**	**A090886**	**002**	Nov 30, 2015
AB			**35MG**	**A090886**	**003**	Nov 30, 2015
AB			**75MG**	**A090886**	**004**	Jun 10, 2014
AB			**150MG**	**A090886**	**005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132**	**001**	Oct 05, 2007
AB			**30MG**	**A077132**	**002**	Oct 05, 2007
AB			**35MG**	**A077132**	**003**	Oct 05, 2007
AB			**150MG**	**A079215**	**001**	Jun 13, 2014
TABLET, DELAYED RELEASE;ORAL						
ATELVIA						
AB	**+!**	APIL	**35MG**	**N022560**	**001**	Oct 08, 2010
RISEDRONATE SODIUM						
AB		TEVA PHARMS USA	**35MG**	**A203217**	**001**	May 18, 2015
RISPERIDONE						
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR						
RYKINDO						
	+!	SHANDONG LUYE	25MG	N212849	002	Jan 13, 2023
	+		37.5MG	N212849	003	Jan 13, 2023
	+		50MG	N212849	004	Jan 13, 2023
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS						
PERSERIS KIT						
	+	INDIVIOR	90MG	N210655	001	Jul 27, 2018
	+!		120MG	N210655	002	Jul 27, 2018
INJECTABLE;INTRAMUSCULAR						
RISPERDAL CONSTA						
AB	**+**	JANSSEN PHARMS	**12.5MG/VIAL**	**N021346**	**004**	Apr 12, 2007
AB	**+!**		**25MG/VIAL**	**N021346**	**001**	Oct 29, 2003
AB	**+**		**37.5MG/VIAL**	**N021346**	**002**	Oct 29, 2003
AB	**+**		**50MG/VIAL**	**N021346**	**003**	Oct 29, 2003
RISPERIDONE						
AB		AMNEAL	**12.5MG/VIAL**	**A218586**	**001**	Sep 02, 2025
AB			**25MG/VIAL**	**A218586**	**002**	Sep 02, 2025
AB			**37.5MG/VIAL**	**A218586**	**003**	Sep 02, 2025
AB			**50MG/VIAL**	**A218586**	**004**	Sep 02, 2025
AB		NANOMI	**25MG/VIAL**	**A211220**	**001**	Sep 02, 2025
AB			**37.5MG/VIAL**	**A211220**	**002**	Sep 02, 2025

RISPERIDONE

INJECTABLE;INTRAMUSCULAR

RISPERIDONE

AB			**50MG/VIAL**	**A211220**	**003**	Sep 02, 2025
AB		TEVA PHARMS USA INC	**12.5MG/VIAL**	**A214068**	**001**	Dec 05, 2023
AB			**25MG/VIAL**	**A214068**	**002**	Dec 05, 2023
AB			**37.5MG/VIAL**	**A214068**	**003**	Dec 05, 2023
AB			**50MG/VIAL**	**A214068**	**004**	Dec 05, 2023

SOLUTION;ORAL

RISPERDAL

AA	**+!**	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001**	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001**	May 25, 2011
AA		ANI PHARMS	**1MG/ML**	**A076440**	**001**	Jan 30, 2009
AA		APOZEAL PHARMS	**1MG/ML**	**A078909**	**001**	Jul 29, 2009
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A078452**	**001**	Sep 04, 2009
AA		CHARTWELL MOLECULAR	**1MG/ML**	**A202386**	**001**	Jan 12, 2015
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001**	Dec 12, 2012

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

UZEDY

	+!	TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001 Apr 28, 2023
	+!		75MG/0.21ML (75MG/0.21ML)	N213586	002 Apr 28, 2023
	+!		100MG/0.28ML (100MG/0.28ML)	N213586	003 Apr 28, 2023
	+!		125MG/0.35ML (125MG/0.35ML)	N213586	004 Apr 28, 2023
	+!		150MG/0.42ML (150MG/0.42ML)	N213586	005 Apr 28, 2023
	+!		200MG/0.56ML (200MG/0.56ML)	N213586	006 Apr 28, 2023
	+!		250MG/0.7ML (250MG/0.7ML)	N213586	007 Apr 28, 2023

TABLET;ORAL

RISPERDAL

AB	**+**	JANSSEN PHARMS	**0.25MG**	**N020272**	**008**	May 10, 1999
AB	**+**		**0.5MG**	**N020272**	**007**	Jan 27, 1999
AB	**+!**		**1MG**	**N020272**	**001**	Dec 29, 1993
AB	**+**		**2MG**	**N020272**	**002**	Dec 29, 1993
AB	**+**		**3MG**	**N020272**	**003**	Dec 29, 1993
AB	**+**		**4MG**	**N020272**	**004**	Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001**	Aug 24, 2011
AB			**0.5MG**	**A201003**	**002**	Aug 24, 2011
AB			**1MG**	**A201003**	**003**	Aug 24, 2011
AB			**2MG**	**A201003**	**004**	Aug 24, 2011
AB			**3MG**	**A201003**	**005**	Aug 24, 2011
AB			**4MG**	**A201003**	**006**	Aug 24, 2011
AB		AMNEAL	**0.25MG**	**A078071**	**001**	Jun 17, 2009
AB			**0.5MG**	**A078071**	**002**	Jun 17, 2009
AB			**1MG**	**A078071**	**003**	Jun 17, 2009
AB			**2MG**	**A078071**	**004**	Jun 17, 2009
AB			**3MG**	**A078071**	**005**	Jun 17, 2009
AB			**4MG**	**A078071**	**006**	Jun 17, 2009
AB		CHARTWELL MOLECULAR	**0.25MG**	**A077543**	**001**	May 18, 2011
AB			**0.5MG**	**A077543**	**002**	May 18, 2011
AB			**1MG**	**A077543**	**003**	May 18, 2011
AB			**2MG**	**A077543**	**004**	May 18, 2011
AB			**3MG**	**A077543**	**005**	May 18, 2011
AB			**4MG**	**A077543**	**006**	May 18, 2011
AB		DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001**	Oct 24, 2008
AB			**0.5MG**	**A076879**	**002**	Oct 24, 2008
AB			**1MG**	**A076879**	**003**	Oct 24, 2008
AB			**2MG**	**A076879**	**004**	Oct 24, 2008
AB			**3MG**	**A076879**	**005**	Oct 24, 2008
AB			**4MG**	**A076879**	**006**	Oct 24, 2008
AB		IPCA LABS LTD	**0.25MG**	**A205104**	**001**	Jun 26, 2024
AB			**0.5MG**	**A205104**	**002**	Jun 26, 2024
AB			**1MG**	**A205104**	**003**	Jun 26, 2024
AB			**2MG**	**A205104**	**004**	Jun 26, 2024
AB			**3MG**	**A205104**	**005**	Jun 26, 2024
AB			**4MG**	**A205104**	**006**	Jun 26, 2024
AB		JUBILANT CADISTA	**0.25MG**	**A078828**	**001**	Mar 23, 2009
AB			**0.5MG**	**A078828**	**002**	Mar 23, 2009
AB			**1MG**	**A078828**	**003**	Mar 23, 2009
AB			**2MG**	**A078828**	**004**	Mar 23, 2009
AB			**3MG**	**A078828**	**005**	Mar 23, 2009
AB			**4MG**	**A078828**	**006**	Mar 23, 2009

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB	NOVITIUM PHARMA	0.25MG	A078871	001	Oct 09, 2008
AB		0.5MG	A078871	002	Oct 09, 2008
AB		1MG	A078871	003	Oct 09, 2008
AB		2MG	A078871	004	Oct 09, 2008
AB		3MG	A078871	005	Oct 09, 2008
AB		4MG	A078871	006	Oct 09, 2008
AB	PRINSTON INC	0.25MG	A077493	001	Nov 29, 2011
AB		0.5MG	A077493	002	Nov 29, 2011
AB		1MG	A077493	003	Nov 29, 2011
AB		2MG	A077493	004	Nov 29, 2011
AB		3MG	A077493	005	Nov 29, 2011
AB		4MG	A077493	006	Nov 29, 2011
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008
AB		0.5MG	A078707	002	Dec 29, 2008
AB		1MG	A078707	003	Dec 29, 2008
AB		2MG	A078707	004	Dec 29, 2008
AB		3MG	A078707	005	Dec 29, 2008
AB		4MG	A078707	006	Dec 29, 2008
AB	RISING	0.25MG	A078269	001	Oct 08, 2008
AB		0.5MG	A078269	002	Oct 08, 2008
AB		1MG	A078269	003	Oct 08, 2008
AB		2MG	A078269	004	Oct 08, 2008
AB		3MG	A078269	005	Oct 08, 2008
AB		4MG	A078269	006	Oct 08, 2008
AB	SANDOZ	0.25MG	A078528	001	Oct 16, 2009
AB		0.5MG	A078528	002	Oct 16, 2009
AB		1MG	A078528	003	Oct 16, 2009
AB		2MG	A078528	004	Oct 16, 2009
AB		3MG	A078528	005	Oct 16, 2009
AB		4MG	A078528	006	Oct 16, 2009
AB	TORRENT PHARMS	0.25MG	A079088	001	Oct 30, 2008
AB		0.5MG	A079088	002	Oct 30, 2008
AB		1MG	A079088	003	Oct 30, 2008
AB		2MG	A079088	004	Oct 30, 2008
AB		3MG	A079088	005	Oct 30, 2008
AB		4MG	A079088	006	Oct 30, 2008
AB	ZYDUS PHARMS USA INC	0.25MG	A078040	001	Oct 16, 2008
AB		0.5MG	A078040	002	Oct 16, 2008
AB		1MG	A078040	003	Oct 16, 2008
AB		2MG	A078040	004	Oct 16, 2008
AB		3MG	A078040	005	Oct 16, 2008
AB		4MG	A078040	006	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB	JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011
AB !		1MG	A090839	002	Nov 04, 2011
AB		2MG	A090839	003	Nov 04, 2011
AB		3MG	A090839	004	Nov 04, 2011
AB		4MG	A090839	005	Nov 04, 2011
AB	PH HEALTH	0.5MG	A077494	002	Apr 30, 2009
AB		1MG	A077494	003	Oct 26, 2009
AB		2MG	A077494	004	Apr 30, 2009
AB		3MG	A077494	005	Apr 30, 2009
AB		4MG	A077494	006	Apr 30, 2009
AB	SANDOZ	0.5MG	A078116	001	Dec 22, 2009
AB		1MG	A078116	002	Dec 22, 2009
AB		2MG	A078116	003	Dec 22, 2009
AB		3MG	A078116	004	Dec 22, 2009
AB		4MG	A078116	005	Dec 22, 2009
AB	SENORES PHARMS	0.5MG	A077328	001	Feb 24, 2009
AB		1MG	A077328	002	Oct 05, 2009
AB		2MG	A077328	003	Feb 24, 2009
AB		3MG	A077328	004	Nov 30, 2009
AB		4MG	A077328	005	Nov 30, 2009
AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010
AB		1MG	A077542	002	Aug 06, 2010
AB		2MG	A077542	003	Aug 06, 2010
AB		3MG	A078474	001	Aug 06, 2010
AB		4MG	A078474	002	Aug 06, 2010

RISPERIDONE
TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB		ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB			**2MG**	**A078516**	**003**	May 01, 2009
		PH HEALTH	0.25MG	A077494	001	Apr 30, 2009

RITLECITINIB TOSYLATE
CAPSULE;ORAL
LITFULO

	+!	PFIZER	EQ 50MG BASE	N215830	001	Jun 23, 2023

RITONAVIR
CAPSULE;ORAL
RITONAVIR

		QUAGEN	100MG	A205024	001	Feb 16, 2024

POWDER;ORAL
NORVIR

	+!	ABBVIE	100MG/PACKET	N209512	001	Jun 07, 2017

TABLET;ORAL
NORVIR

AB	**+!**	ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010

RITONAVIR

AB		AMNEAL	**100MG**	**A208890**	**001**	Sep 17, 2018
AB		AUROBINDO PHARMA LTD	**100MG**	**A206614**	**001**	Sep 17, 2018
AB		CIPLA	**100MG**	**A202573**	**001**	Jan 15, 2015
AB			**100MG**	**A203759**	**001**	May 10, 2022
AB		HETERO LABS LTD III	**100MG**	**A204587**	**001**	Sep 17, 2018

RIVAROXABAN
FOR SUSPENSION;ORAL
RIVAROXABAN

AB		ALKEM LABS LTD	**1MG/ML**	**A218502**	**001**	Jun 26, 2025
AB		LUPIN LTD	**1MG/ML**	**A218195**	**001**	Sep 25, 2025

XARELTO

AB	**+!**	JANSSEN PHARMS	**1MG/ML**	**N215859**	**001**	Dec 20, 2021

TABLET;ORAL
RIVAROXABAN

AB		AIPING PHARM INC	**10MG**	**A216995**	**001**	May 14, 2025
AB			**15MG**	**A216995**	**002**	May 14, 2025
AB			**20MG**	**A216995**	**003**	May 14, 2025
AB		ALEMBIC	**2.5MG**	**A210301**	**001**	May 14, 2025
AB			**10MG**	**A210301**	**002**	May 14, 2025
AB			**15MG**	**A210301**	**003**	May 14, 2025
AB			**20MG**	**A210301**	**004**	May 14, 2025
AB		APOTEX	**2.5MG**	**A217810**	**001**	May 02, 2025
AB			**10MG**	**A208579**	**001**	Nov 14, 2025
AB			**15MG**	**A208579**	**002**	Nov 14, 2025
AB			**20MG**	**A208579**	**003**	Nov 14, 2025
AB		ASCENT PHARMS INC	**2.5MG**	**A219332**	**001**	May 14, 2025
AB			**10MG**	**A219332**	**002**	May 14, 2025
AB			**15MG**	**A219332**	**003**	May 14, 2025
AB			**20MG**	**A219332**	**004**	May 14, 2025
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A208544**	**001**	Apr 10, 2025
AB			**10MG**	**A208544**	**002**	May 15, 2025
AB			**15MG**	**A208544**	**003**	May 15, 2025
AB			**20MG**	**A208544**	**004**	May 15, 2025
AB		BIOCON PHARMA	**2.5MG**	**A218107**	**001**	May 14, 2025
AB			**10MG**	**A218107**	**002**	May 14, 2025
AB			**15MG**	**A218107**	**003**	May 14, 2025
AB			**20MG**	**A218107**	**004**	May 14, 2025
AB		BRECKENRIDGE	**10MG**	**A208220**	**001**	May 15, 2025
AB			**15MG**	**A208220**	**002**	May 15, 2025
AB			**20MG**	**A208220**	**003**	May 15, 2025
AB		DR REDDYS	**2.5MG**	**A208534**	**001**	May 14, 2025
AB			**10MG**	**A208534**	**002**	May 14, 2025
AB			**15MG**	**A208534**	**003**	May 14, 2025
AB			**20MG**	**A208534**	**004**	May 14, 2025
AB		LUPIN LTD	**2.5MG**	**A208555**	**001**	Mar 03, 2025
AB			**10MG**	**A208555**	**002**	May 14, 2025
AB			**15MG**	**A208555**	**003**	May 14, 2025
AB			**20MG**	**A208555**	**004**	May 14, 2025

RIVAROXABAN

TABLET;ORAL

RIVAROXABAN

AB		MACLEODS PHARMS LTD	**2.5MG**	**A213114**	**001**	May 14, 2025
AB			**10MG**	**A213114**	**002**	May 14, 2025
AB			**15MG**	**A213114**	**003**	May 14, 2025
AB			**20MG**	**A213114**	**004**	May 14, 2025
AB		MSN	**2.5MG**	**A208546**	**001**	Oct 24, 2025
AB		REGCON HOLDINGS	**2.5MG**	**A218445**	**001**	Aug 11, 2025
AB			**10MG**	**A218445**	**002**	Aug 11, 2025
AB			**15MG**	**A218445**	**003**	Aug 11, 2025
AB			**20MG**	**A218445**	**004**	Aug 11, 2025
AB		SCIEGEN PHARMS	**2.5MG**	**A218117**	**001**	Jul 31, 2025
AB			**10MG**	**A218117**	**002**	Jul 31, 2025
AB			**15MG**	**A218117**	**003**	Jul 31, 2025
AB			**20MG**	**A218117**	**004**	Jul 31, 2025
AB		SUNSHINE	**10MG**	**A213348**	**001**	May 14, 2025
AB			**15MG**	**A213348**	**002**	May 14, 2025
AB			**20MG**	**A213348**	**003**	May 14, 2025
AB		TARO	**2.5MG**	**A208557**	**001**	Mar 03, 2025
AB			**10MG**	**A208557**	**002**	Oct 07, 2025
AB			**15MG**	**A208557**	**003**	Oct 07, 2025
AB			**20MG**	**A208557**	**004**	Oct 07, 2025

XARELTO

AB	+	JANSSEN PHARMS	**2.5MG**	**N022406**	**004**	Oct 11, 2018
AB	+		**10MG**	**N022406**	**001**	Jul 01, 2011
AB	+		**15MG**	**N022406**	**002**	Nov 04, 2011
AB	+!		**20MG**	**N022406**	**003**	Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB	+	SANDOZ	**4.6MG/24HR**	**N022083**	**001**	Jul 06, 2007
AB	+!		**9.5MG/24HR**	**N022083**	**002**	Jul 06, 2007
AB	+		**13.3MG/24HR**	**N022083**	**005**	Aug 31, 2012

RIVASTIGMINE

AB		AMNEAL PHARMS	**4.6MG/24HR**	**A207308**	**001**	Jan 08, 2019
AB			**9.5MG/24HR**	**A207308**	**002**	Jan 08, 2019
AB			**13.3MG/24HR**	**A207308**	**003**	Jan 08, 2019
AB		BRECKENRIDGE	**4.6MG/24HR**	**A209063**	**001**	Nov 26, 2019
AB			**9.5MG/24HR**	**A209063**	**002**	Nov 26, 2019
AB			**13.3MG/24HR**	**A209063**	**003**	Nov 26, 2019
AB		MYLAN TECHNOLOGIES	**4.6MG/24HR**	**A205622**	**001**	Jun 20, 2018
AB			**9.5MG/24HR**	**A205622**	**002**	Jun 20, 2018
AB			**13.3MG/24HR**	**A205622**	**003**	Jun 20, 2018
AB		YICHANG HUMANWELL	**4.6MG/24HR**	**A215445**	**001**	Sep 23, 2025
AB			**9.5MG/24HR**	**A215445**	**002**	Sep 23, 2025
AB			**13.3MG/24HR**	**A215445**	**003**	Sep 23, 2025
AB		ZYDUS PHARMS	**4.6MG/24HR**	**A206318**	**001**	Mar 04, 2019
AB			**9.5MG/24HR**	**A206318**	**002**	Mar 04, 2019
AB			**13.3MG/24HR**	**A206318**	**003**	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001**	Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002**	Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003**	Jun 12, 2012
AB			**EQ 6MG BASE**	**A091689**	**004**	Jun 12, 2012
AB		AUROBINDO PHARMA	**EQ 1.5MG BASE**	**A204572**	**001**	Mar 25, 2016
AB			**EQ 3MG BASE**	**A204572**	**002**	Mar 25, 2016
AB			**EQ 4.5MG BASE**	**A204572**	**003**	Mar 25, 2016
AB			**EQ 6MG BASE**	**A204572**	**004**	Mar 25, 2016
AB		CADILA PHARMS LTD	**EQ 1.5MG BASE**	**A203844**	**001**	Feb 13, 2017
AB			**EQ 3MG BASE**	**A203844**	**002**	Feb 13, 2017
AB			**EQ 4.5MG BASE**	**A203844**	**003**	Feb 13, 2017
AB			**EQ 6MG BASE**	**A203844**	**004**	Feb 13, 2017
AB		CHARTWELL RX	**EQ 1.5MG BASE**	**A207797**	**001**	Sep 28, 2017
AB			**EQ 3MG BASE**	**A207797**	**002**	Sep 28, 2017
AB			**EQ 4.5MG BASE**	**A207797**	**003**	Sep 28, 2017
AB			**EQ 6MG BASE**	**A207797**	**004**	Sep 28, 2017
AB	!	DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001**	Oct 31, 2007
AB			**EQ 3MG BASE**	**A077130**	**002**	Oct 31, 2007

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB			**EQ 4.5MG BASE**	**A077130**	**003**	Oct 31, 2007
AB	**!**		**EQ 6MG BASE**	**A077130**	**004**	Oct 31, 2007
AB		MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001**	Aug 22, 2014
AB			**EQ 3MG BASE**	**A203148**	**002**	Aug 22, 2014
AB			**EQ 4.5MG BASE**	**A203148**	**003**	Aug 22, 2014
AB			**EQ 6MG BASE**	**A203148**	**004**	Aug 22, 2014
AB		ORBION PHARMS	**EQ 1.5MG BASE**	**A090879**	**001**	Jun 10, 2015
AB			**EQ 3MG BASE**	**A090879**	**002**	Jun 10, 2015
AB			**EQ 4.5MG BASE**	**A090879**	**003**	Jun 10, 2015
AB			**EQ 6MG BASE**	**A090879**	**004**	Jun 10, 2015
AB		WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001**	Jan 08, 2008
AB			**EQ 3MG BASE**	**A077129**	**002**	Jan 08, 2008
AB			**EQ 4.5MG BASE**	**A077129**	**003**	Jan 08, 2008
AB			**EQ 6MG BASE**	**A077129**	**004**	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

AB	**+!**	ORGANON LLC	**EQ 10MG BASE**	**N020864**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001**	Feb 18, 2016
AB			**EQ 10MG BASE**	**A203269**	**002**	Feb 18, 2016
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202490**	**002**	Dec 31, 2012
AB		CHARTWELL RX	**EQ 5MG BASE**	**A077526**	**001**	Mar 26, 2013
AB			**EQ 10MG BASE**	**A077526**	**002**	Mar 26, 2013
AB		CREEKWOOD PHARMS	**EQ 5MG BASE**	**A202047**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202047**	**002**	Dec 31, 2012
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203147**	**001**	Feb 11, 2014
AB			**EQ 10MG BASE**	**A203147**	**002**	Feb 11, 2014
AB		PHARMOBEDIENT	**EQ 5MG BASE**	**A201993**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201993**	**002**	Dec 31, 2012
AB		TEVA PHARMS	**EQ 5MG BASE**	**A077263**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A077263**	**002**	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

AB	**+!**	ORGANON	**EQ 10MG BASE**	**N020865**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A203062**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203062**	**002**	Jul 01, 2013
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203146**	**001**	Sep 19, 2014
AB			**EQ 10MG BASE**	**A203146**	**002**	Sep 19, 2014
AB		PANACEA	**EQ 5MG BASE**	**A204722**	**001**	Jan 11, 2017
AB			**EQ 10MG BASE**	**A204722**	**002**	Jan 11, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		CAPLIN	**50MG/5ML (10MG/ML)**	**A216234**	**001**	Mar 02, 2023
AP			**100MG/10ML (10MG/ML)**	**A216234**	**002**	Mar 02, 2023
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A206206**	**001**	Apr 12, 2017
AP			**100MG/10ML (10MG/ML)**	**A206206**	**002**	Apr 12, 2017
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A078651**	**001**	Dec 29, 2008
AP			**100MG/10ML (10MG/ML)**	**A078651**	**002**	Dec 29, 2008
AP	**!**	GLAND	**50MG/5ML (10MG/ML)**	**A205656**	**001**	Apr 04, 2018
AP	**!**		**100MG/10ML (10MG/ML)**	**A205656**	**002**	Apr 04, 2018
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A078519**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078519**	**002**	Nov 26, 2008
AP		KNACK	**50MG/5ML (10MG/ML)**	**A213476**	**001**	Jan 06, 2026
AP			**100MG/10ML (10MG/ML)**	**A213476**	**002**	Jan 06, 2026
AP		MANKIND PHARMA	**50MG/5ML (10MG/ML)**	**A219674**	**001**	May 29, 2025
AP			**100MG/10ML (10MG/ML)**	**A219674**	**002**	May 29, 2025
AP		MEITHEAL	**50MG/5ML (10MG/ML)**	**A213453**	**001**	May 08, 2023
AP			**100MG/10ML (10MG/ML)**	**A213453**	**002**	May 08, 2023
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A079199**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A079199**	**002**	Nov 26, 2008
AP		PIRAMAL CRITICAL	**50MG/5ML (10MG/ML)**	**A210437**	**001**	Aug 13, 2019
AP			**100MG/10ML (10MG/ML)**	**A210437**	**002**	Aug 13, 2019
AP		PRINSTON INC	**50MG/5ML (10MG/ML)**	**A212668**	**001**	May 26, 2022

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP			**100MG/10ML (10MG/ML)**	**A212668**	**002**	May 26, 2022
AP		SAGENT PHARMS INC	**50MG/5ML (10MG/ML)**	**A091458**	**001**	Jul 28, 2010
AP			**100MG/10ML (10MG/ML)**	**A091458**	**002**	Jul 28, 2010
AP		SANDOZ	**50MG/5ML (10MG/ML)**	**A079195**	**001**	Dec 05, 2008
AP			**100MG/10ML (10MG/ML)**	**A079195**	**002**	Dec 05, 2008
AP		SHANDONG	**50MG/5ML (10MG/ML)**	**A215684**	**001**	Jul 12, 2024
AP			**100MG/10ML (10MG/ML)**	**A215684**	**002**	Jul 12, 2024
AP		STERISCIENCE	**50MG/5ML (10MG/ML)**	**A217092**	**001**	Jul 22, 2024
AP		TAMARANG	**50MG/5ML (10MG/ML)**	**A091115**	**001**	Aug 27, 2012
AP			**100MG/10ML (10MG/ML)**	**A091115**	**002**	Aug 27, 2012
AP		WEST WARD PHARM CORP	**50MG/5ML (10MG/ML)**	**A204679**	**001**	Feb 28, 2017
AP			**100MG/10ML (10MG/ML)**	**A204679**	**002**	Feb 28, 2017

SOLUTION;INTRAVENOUS

ROCURONIUM BROMIDE

	+!	B BRAUN MEDICAL	50MG/5ML (10MG/ML)	N219108	001	Oct 24, 2025
	+!	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	N217472	001	Jun 09, 2025
	+!		100MG/10ML (10MG/ML)	N217472	002	Jun 09, 2025

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

	+!	ARCUTIS	0.15%	N215985	002	Jul 09, 2024
	+!		0.3%	N215985	001	Jul 29, 2022
	+!		0.05%	N215985	003	Oct 04, 2025

FOAM;TOPICAL

ZORYVE

	+!	ARCUTIS	0.3%	N217242	001	Dec 15, 2023

TABLET;ORAL

DALIRESP

AB	**+**	ASTRAZENECA	**250MCG**	**N022522**	**002**	Jan 23, 2018
AB	**+!**		**500MCG**	**N022522**	**001**	Feb 28, 2011

ROFLUMILAST

AB		ALKEM LABS LTD	**250MCG**	**A212490**	**001**	Apr 18, 2023
AB			**500MCG**	**A212490**	**002**	Apr 18, 2023
AB		AUROBINDO PHARMA LTD	**250MCG**	**A213298**	**002**	Jan 31, 2025
AB			**500MCG**	**A213298**	**001**	Apr 17, 2023
AB		HETERO LABS LTD III	**250MCG**	**A208213**	**002**	Apr 18, 2023
AB			**500MCG**	**A208213**	**001**	Nov 23, 2018
AB		MICRO LABS	**250MCG**	**A208180**	**002**	Apr 18, 2023
AB			**500MCG**	**A208180**	**001**	Mar 22, 2019
AB		MSN	**250MCG**	**A208256**	**001**	Sep 07, 2022
AB			**500MCG**	**A208256**	**002**	Sep 07, 2022
AB		PHARMOBEDIENT	**500MCG**	**A208257**	**001**	Jul 13, 2018
AB		PRINSTON INC	**500MCG**	**A208299**	**001**	May 10, 2022
AB		STRIDES PHARMA	**250MCG**	**A208247**	**002**	Jun 20, 2023
AB			**500MCG**	**A208247**	**001**	Mar 30, 2020
AB		ZYDUS PHARMS	**250MCG**	**A208303**	**002**	Apr 18, 2023
AB			**500MCG**	**A208303**	**001**	Feb 10, 2022

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

	+!	TERSERA	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

AP	**+!**	BRISTOL-MYERS	**10MG/VIAL**	**N022393**	**001**	Nov 05, 2009

ROMIDEPSIN

AP		FRESENIUS KABI USA	**10MG/VIAL**	**A206254**	**001**	Oct 12, 2021

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.25MG BASE**	**A204022**	**001**	Feb 28, 2017
AB			**EQ 0.5MG BASE**	**A204022**	**002**	Feb 28, 2017
AB			**EQ 1MG BASE**	**A204022**	**003**	Feb 28, 2017
AB			**EQ 2MG BASE**	**A204022**	**004**	Feb 28, 2017
AB			**EQ 3MG BASE**	**A204022**	**005**	Feb 28, 2017
AB			**EQ 4MG BASE**	**A204022**	**006**	Feb 28, 2017

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 5MG BASE	A204022	007	Feb 28, 2017
AB	ALEMBIC LTD	EQ 0.25MG BASE	A090429	001	Mar 24, 2010
AB		EQ 0.5MG BASE	A090429	002	Mar 24, 2010
AB		EQ 1MG BASE	A090429	003	Mar 24, 2010
AB		EQ 2MG BASE	A090429	004	Mar 24, 2010
AB		EQ 3MG BASE	A090429	005	Mar 24, 2010
AB		EQ 4MG BASE	A090429	006	Mar 24, 2010
AB		EQ 5MG BASE	A090429	007	Mar 24, 2010
AB	CHARTWELL RX	EQ 0.25MG BASE	A079050	001	May 29, 2008
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008
AB		EQ 1MG BASE	A079050	003	May 29, 2008
AB		EQ 2MG BASE	A079050	004	May 29, 2008
AB		EQ 3MG BASE	A079050	005	May 29, 2008
AB		EQ 4MG BASE	A079050	006	May 29, 2008
AB		EQ 5MG BASE	A079050	007	May 29, 2008
AB	GLENMARK PHARMS LTD	EQ 0.25MG BASE	A090135	001	Feb 25, 2010
AB		EQ 0.5MG BASE	A090135	002	Feb 25, 2010
AB		EQ 1MG BASE	A090135	003	Feb 25, 2010
AB		EQ 2MG BASE	A090135	004	Feb 25, 2010
AB		EQ 3MG BASE	A090135	005	Feb 25, 2010
AB		EQ 4MG BASE	A090135	006	Feb 25, 2010
AB		EQ 5MG BASE	A090135	007	Feb 25, 2010
AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012
AB	ORBION PHARMS	EQ 0.25MG BASE	A079229	001	Nov 28, 2012
AB		EQ 0.5MG BASE	A079229	002	Nov 28, 2012
AB		EQ 1MG BASE	A079229	003	Nov 28, 2012
AB		EQ 2MG BASE	A079229	004	Nov 28, 2012
AB		EQ 3MG BASE	A079229	005	Nov 28, 2012
AB		EQ 4MG BASE	A079229	006	Nov 28, 2012
AB		EQ 5MG BASE	A079229	007	Nov 28, 2012
AB !	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008
AB		EQ 0.5MG BASE	A078110	002	May 05, 2008
AB		EQ 1MG BASE	A078110	003	May 05, 2008
AB		EQ 2MG BASE	A078110	004	May 05, 2008
AB		EQ 3MG BASE	A078110	005	May 05, 2008
AB		EQ 4MG BASE	A078110	006	May 05, 2008
AB		EQ 5MG BASE	A078110	007	Jul 11, 2008
AB	ZYDUS LIFESCIENCES	EQ 0.25MG BASE	A090411	001	Jun 01, 2009
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012
AB		EQ 4MG BASE	A090869	002	May 17, 2012
AB		EQ 6MG BASE	A090869	003	May 17, 2012
AB		EQ 8MG BASE	A090869	004	May 17, 2012
AB		EQ 12MG BASE	A090869	005	May 17, 2012
AB	ALEMBIC	EQ 2MG BASE	A202786	001	Apr 22, 2013
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013
AB	CHARTWELL RX	EQ 2MG BASE	A091395	001	Aug 27, 2012
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012
AB !	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012
AB		EQ 4MG BASE	A201576	002	Jun 06, 2012

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 6MG BASE	A201576	003	Jun 06, 2012
AB		EQ 8MG BASE	A201576	004	Jun 06, 2012
AB		EQ 12MG BASE	A201576	005	Jun 06, 2012
AB	ELITE LABS INC	EQ 2MG BASE	A217862	001	Nov 10, 2025
AB		EQ 4MG BASE	A217862	002	Nov 10, 2025
AB		EQ 6MG BASE	A217862	003	Nov 10, 2025
AB		EQ 8MG BASE	A217862	004	Nov 10, 2025
AB		EQ 12MG BASE	A217862	005	Nov 10, 2025
AB	PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022
AB		EQ 4MG BASE	A204413	002	May 11, 2022
AB		EQ 6MG BASE	A204413	003	May 11, 2022
AB		EQ 8MG BASE	A204413	004	May 11, 2022
AB		EQ 12MG BASE	A204413	005	May 11, 2022
AB	SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012
AB		EQ 4MG BASE	A201047	003	Jun 06, 2012
AB		EQ 6MG BASE	A201047	004	Jun 06, 2012
AB		EQ 8MG BASE	A201047	005	Jun 06, 2012
AB		EQ 12MG BASE	A201047	006	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	20MG/10ML (2MG/ML)	N020533	001	May 01, 1998
AP	+		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996
AP	+		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998
AP	+		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996
AP	+		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996
AP	+		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996
AP	+		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996
AP	+!		200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996
AP	+		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996
AP	+		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011
AP	+		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

AP	AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023
AP		400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023
AP		500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023
AP		1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023
AP	ANTHEA PHARMA	20MG/10ML (2MG/ML)	A219883	004	Oct 08, 2025
AP		40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025
AP		100MG/20ML (5MG/ML)	A219883	005	Oct 08, 2025
AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025
AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025
AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020
AP		200MG/100ML (2MG/ML)	A212808	005	May 23, 2024
AP		400MG/200ML (2MG/ML)	A212808	006	May 23, 2024
AP	EUGIA PHARMA	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016
AP	GLAND	200MG/100ML (2MG/ML)	A210102	001	Aug 18, 2022
AP		400MG/200ML (2MG/ML)	A210102	002	Aug 18, 2022
AP	HIKMA	200MG/100ML (2MG/ML)	A211907	001	Aug 15, 2024
AP		40MG/20ML (2MG/ML)	A214074	001	Jul 20, 2020
AP		150MG/30ML (5MG/ML)	A214074	002	Jul 20, 2020
AP		150MG/20ML (7.5MG/ML)	A214074	003	Jul 20, 2020
AP		200MG/20ML (10MG/ML)	A214074	004	Jul 20, 2020
AP		400MG/200ML (2MG/ML)	A211907	002	Aug 15, 2024
AP		500MG/100ML (5MG/ML)	A211907	003	Aug 15, 2024
AP	INFORLIFE	200MG/100ML (2MG/ML)	A206166	001	Jun 11, 2018
AP		400MG/200ML (2MG/ML)	A206166	002	Jun 11, 2018
AP		500MG/100ML (5MG/ML)	A206166	003	Jun 11, 2018
AP		1GM/200ML (5MG/ML)	A206166	004	Jun 11, 2018
AP	KINDOS	20MG/10ML (2MG/ML)	A218713	001	Jul 30, 2024

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		**40MG/20ML (2MG/ML)**	**A218713**	**002**	Jul 30, 2024
AP		**100MG/20ML (5MG/ML)**	**A218713**	**003**	Jul 30, 2024
AP		**100MG/10ML (10MG/ML)**	**A218713**	**004**	Jul 30, 2024
AP		**150MG/30ML (5MG/ML)**	**A218713**	**005**	Jul 30, 2024
AP		**150MG/20ML (7.5MG/ML)**	**A218713**	**006**	Jul 30, 2024
AP		**200MG/20ML (10MG/ML)**	**A218713**	**007**	Jul 30, 2024
AP	MYLAN LABS LTD	**200MG/100ML (2MG/ML)**	**A206091**	**001**	Oct 26, 2023
AP		**400MG/200ML (2MG/ML)**	**A206091**	**002**	Oct 26, 2023
AP	NAVINTA LLC	**150MG/30ML (5MG/ML)**	**A078601**	**002**	Jul 17, 2014
AP		**200MG/20ML (10MG/ML)**	**A078601**	**003**	Jul 17, 2014
AP	RISING	**200MG/100ML (2MG/ML)**	**A204636**	**001**	Mar 16, 2018
AP		**400MG/200ML (2MG/ML)**	**A204636**	**002**	Mar 16, 2018
AP		**150MG/30ML (5MG/ML)**	**A203955**	**001**	Apr 11, 2016
AP	SOMERSET THERAPS LLC	**20MG/10ML (2MG/ML)**	**A207636**	**001**	Jun 15, 2018
AP		**40MG/20ML (2MG/ML)**	**A207636**	**002**	Jun 15, 2018
AP		**100MG/20ML (5MG/ML)**	**A207636**	**003**	Jun 15, 2018
AP		**100MG/10ML (10MG/ML)**	**A207636**	**006**	Jun 15, 2018
AP		**150MG/30ML (5MG/ML)**	**A207636**	**004**	Jun 15, 2018
AP		**150MG/20ML (7.5MG/ML)**	**A207636**	**005**	Jun 15, 2018
AP		**200MG/20ML (10MG/ML)**	**A207636**	**007**	Jun 15, 2018

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	**+**	ASTRAZENECA	**EQ 5MG BASE**	**N021366**	**002**	Aug 12, 2003
AB	**+**		**EQ 10MG BASE**	**N021366**	**003**	Aug 12, 2003
AB	**+**		**EQ 20MG BASE**	**N021366**	**004**	Aug 12, 2003
AB	**+!**		**EQ 40MG BASE**	**N021366**	**005**	Aug 12, 2003

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	**EQ 5MG BASE**	**A206434**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A206434**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A206434**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A206434**	**004**	Oct 31, 2016
AB	ALKEM LABS LTD	**EQ 5MG BASE**	**A206465**	**001**	Mar 21, 2017
AB		**EQ 10MG BASE**	**A206465**	**002**	Mar 21, 2017
AB		**EQ 20MG BASE**	**A206465**	**003**	Mar 21, 2017
AB		**EQ 40MG BASE**	**A206465**	**004**	Mar 21, 2017
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A079170**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079170**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079170**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079170**	**004**	Jul 19, 2016
AB	BIOCON PHARMA	**EQ 5MG BASE**	**A207752**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207752**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207752**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207752**	**004**	Oct 31, 2016
AB	CADILA PHARMS LTD	**EQ 5MG BASE**	**A207453**	**001**	Nov 23, 2016
AB		**EQ 10MG BASE**	**A207453**	**002**	Nov 23, 2016
AB		**EQ 20MG BASE**	**A207453**	**003**	Nov 23, 2016
AB		**EQ 40MG BASE**	**A207453**	**004**	Nov 23, 2016
AB	CHANGZHOU PHARM	**EQ 5MG BASE**	**A207408**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207408**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207408**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207408**	**004**	Oct 31, 2016
AB	CHARTWELL RX	**EQ 5MG BASE**	**A079168**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079168**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079168**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079168**	**004**	Jul 19, 2016
AB	GLENMARK SPECLT	**EQ 5MG BASE**	**A079172**	**001**	Jul 19, 2016
AB		**EQ 10MG BASE**	**A079172**	**002**	Jul 19, 2016
AB		**EQ 20MG BASE**	**A079172**	**003**	Jul 19, 2016
AB		**EQ 40MG BASE**	**A079172**	**004**	Jul 19, 2016
AB	HETERO LABS LTD V	**EQ 5MG BASE**	**A207616**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207616**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207616**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207616**	**004**	Oct 31, 2016
AB	MSN	**EQ 5MG BASE**	**A208898**	**001**	Nov 22, 2017
AB		**EQ 10MG BASE**	**A208898**	**002**	Nov 22, 2017
AB		**EQ 20MG BASE**	**A208898**	**003**	Nov 22, 2017

ROSUVASTATIN CALCIUM
TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		**EQ 40MG BASE**	**A208898**	**004**	Nov 22, 2017
AB	RENATA	**EQ 5MG BASE**	**A207062**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A207062**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A207062**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A207062**	**004**	Oct 31, 2016
AB	SCIEGEN PHARMS	**EQ 5MG BASE**	**A206381**	**001**	Apr 24, 2019
AB		**EQ 10MG BASE**	**A206381**	**002**	Apr 24, 2019
AB		**EQ 20MG BASE**	**A206381**	**003**	Apr 24, 2019
AB		**EQ 40MG BASE**	**A206381**	**004**	Apr 24, 2019
AB	SHANDONG	**EQ 5MG BASE**	**A207375**	**001**	May 07, 2019
AB		**EQ 10MG BASE**	**A207375**	**002**	May 07, 2019
AB		**EQ 20MG BASE**	**A207375**	**003**	May 07, 2019
AB		**EQ 40MG BASE**	**A207375**	**004**	May 07, 2019
AB	TORRENT	**EQ 5MG BASE**	**A201619**	**001**	Oct 31, 2016
AB		**EQ 10MG BASE**	**A201619**	**002**	Oct 31, 2016
AB		**EQ 20MG BASE**	**A201619**	**003**	Oct 31, 2016
AB		**EQ 40MG BASE**	**A201619**	**004**	Oct 31, 2016
AB	UMEDICA	**EQ 5MG BASE**	**A207626**	**001**	Apr 09, 2019
AB		**EQ 10MG BASE**	**A207626**	**002**	Apr 09, 2019
AB		**EQ 20MG BASE**	**A207626**	**003**	Apr 09, 2019
AB		**EQ 40MG BASE**	**A207626**	**004**	Apr 09, 2019
AB	WATSON LABS INC	**EQ 5MG BASE**	**A079167**	**001**	Apr 29, 2016
AB		**EQ 10MG BASE**	**A079167**	**002**	Apr 29, 2016
AB		**EQ 20MG BASE**	**A079167**	**003**	Apr 29, 2016
AB		**EQ 40MG BASE**	**A079167**	**004**	Apr 29, 2016
AB	ZHEJIANG JINGXIN	**EQ 5MG BASE**	**A206513**	**001**	Mar 01, 2019
AB		**EQ 10MG BASE**	**A206513**	**002**	Mar 01, 2019
AB		**EQ 20MG BASE**	**A206513**	**003**	Mar 01, 2019
AB		**EQ 40MG BASE**	**A206513**	**004**	Mar 01, 2019
AB	ZHEJIANG YONGTAI	**EQ 5MG BASE**	**A212059**	**001**	Nov 04, 2019
AB		**EQ 10MG BASE**	**A212059**	**002**	Nov 04, 2019
AB		**EQ 20MG BASE**	**A212059**	**003**	Nov 04, 2019
AB		**EQ 40MG BASE**	**A212059**	**004**	Nov 04, 2019

ROTIGOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+!		2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82
INJECTABLE;INJECTION
CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

SOLUTION;INTRAVENOUS
RUBY-FILL

	JUBILANT	N/A	N202153	001	Sep 30, 2016

RUCAPARIB CAMSYLATE
TABLET;ORAL
RUBRACA

+	PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 250MG BASE	N209115	003	May 01, 2017
+!		EQ 300MG BASE	N209115	002	Dec 19, 2016

RUFINAMIDE
SUSPENSION;ORAL
BANZEL

AB	**+!**	EISAI INC	**40MG/ML**	**N201367**	**001**	Mar 03, 2011

RUFINAMIDE

AB		ALKEM LABS LTD	**40MG/ML**	**A213410**	**001**	Feb 23, 2021
AB		AUROBINDO PHARMA	**40MG/ML**	**A216549**	**001**	Oct 26, 2022
AB		BIONPHARMA	**40MG/ML**	**A211388**	**001**	Apr 23, 2019
AB		CHARTWELL RX	**40MG/ML**	**A214009**	**001**	Nov 07, 2022
AB		HETERO LABS LTD III	**40MG/ML**	**A216841**	**001**	Dec 05, 2023
AB		HIKMA	**40MG/ML**	**A207363**	**001**	Apr 23, 2019
AB		LUPIN LTD	**40MG/ML**	**A213457**	**001**	Dec 18, 2020

RUFINAMIDE						
SUSPENSION;ORAL						
RUFINAMIDE						
AB		MSN	**40MG/ML**	**A214817**	**001**	Apr 15, 2025
TABLET;ORAL						
BANZEL						
AB	+	EISAI INC	**200MG**	**N021911**	**002**	Nov 14, 2008
AB	+!		**400MG**	**N021911**	**003**	Nov 14, 2008
RUFINAMIDE						
AB		AUROBINDO PHARMA	**200MG**	**A217230**	**001**	Jun 16, 2023
AB			**400MG**	**A217230**	**002**	Jun 16, 2023
AB		GLENMARK PHARMS LTD	**200MG**	**A205075**	**001**	May 16, 2016
AB			**400MG**	**A205075**	**002**	May 16, 2016
AB		HETERO LABS LTD III	**200MG**	**A204993**	**001**	May 11, 2021
AB			**400MG**	**A204993**	**002**	May 11, 2021
AB		HIKMA	**200MG**	**A204988**	**001**	May 16, 2016
AB			**400MG**	**A204988**	**002**	May 16, 2016
AB		LUPIN LTD	**200MG**	**A204964**	**002**	Aug 17, 2022
AB			**400MG**	**A204964**	**003**	Aug 17, 2022
AB		MICRO LABS	**200MG**	**A216688**	**001**	May 15, 2023
AB			**400MG**	**A216688**	**002**	May 15, 2023
AB		PHARMOBEDIENT	**200MG**	**A205095**	**001**	May 16, 2016
AB			**400MG**	**A205095**	**002**	May 16, 2016
		LUPIN LTD	100MG	A204964	001	Aug 17, 2022
RUXOLITINIB PHOSPHATE						
CREAM;TOPICAL						
OPZELURA						
	+!	INCYTE CORP	EQ 1.5% BASE	N215309	001	Sep 21, 2021
TABLET;ORAL						
JAKAFI						
	+	INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011
	+		EQ 10MG BASE	N202192	002	Nov 16, 2011
	+		EQ 15MG BASE	N202192	003	Nov 16, 2011
	+		EQ 20MG BASE	N202192	004	Nov 16, 2011
	+!		EQ 25MG BASE	N202192	005	Nov 16, 2011
SACUBITRIL; VALSARTAN						
CAPSULE, PELLETS;ORAL						
ENTRESTO SPRINKLE						
	+	NOVARTIS	6MG;6MG	N218591	001	Apr 12, 2024
	+!		15MG;16MG	N218591	002	Apr 12, 2024
TABLET;ORAL						
ENTRESTO						
AB	+	NOVARTIS PHARMS CORP	**24MG;26MG**	**N207620**	**001**	Jul 07, 2015
AB	+		**49MG;51MG**	**N207620**	**002**	Jul 07, 2015
AB	+!		**97MG;103MG**	**N207620**	**003**	Jul 07, 2015
SACUBITRIL AND VALSARTAN						
AB		ALEMBIC	**24MG;26MG**	**A213682**	**001**	May 28, 2024
AB			**49MG;51MG**	**A213682**	**002**	May 28, 2024
AB			**97MG;103MG**	**A213682**	**003**	May 28, 2024
AB		ALKEM LABS LTD	**24MG;26MG**	**A213764**	**001**	Sep 16, 2024
AB			**49MG;51MG**	**A213764**	**002**	Sep 16, 2024
AB			**97MG;103MG**	**A213764**	**003**	Sep 16, 2024
AB		BIOCON PHARMA	**24MG;26MG**	**A213680**	**001**	Aug 30, 2024
AB			**49MG;51MG**	**A213680**	**002**	Aug 30, 2024
AB			**97MG;103MG**	**A213680**	**003**	Aug 30, 2024
AB		CRYSTAL	**24MG;26MG**	**A213605**	**001**	May 28, 2024
AB			**49MG;51MG**	**A213605**	**002**	May 28, 2024
AB			**97MG;103MG**	**A213605**	**003**	May 28, 2024
AB		DR REDDYS	**24MG;26MG**	**A213627**	**001**	Jan 13, 2025
AB			**49MG;51MG**	**A213627**	**002**	Jan 13, 2025
AB			**97MG;103MG**	**A213627**	**003**	Jan 13, 2025
AB		HETERO LABS LTD III	**24MG;26MG**	**A213668**	**001**	Jul 17, 2025
AB			**49MG;51MG**	**A213668**	**002**	Jul 17, 2025
AB			**97MG;103MG**	**A213668**	**003**	Jul 17, 2025
AB		LAURUS	**24MG;26MG**	**A213676**	**001**	May 28, 2024
AB			**49MG;51MG**	**A213676**	**002**	May 28, 2024
AB			**97MG;103MG**	**A213676**	**003**	May 28, 2024
AB		LUPIN	**24MG;26MG**	**A213808**	**001**	Jan 08, 2025
AB			**49MG;51MG**	**A213808**	**002**	Jan 08, 2025
AB			**97MG;103MG**	**A213808**	**003**	Jan 08, 2025
AB		MACLEODS PHARMS LTD	**24MG;26MG**	**A213728**	**001**	Oct 16, 2024

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB			**49MG;51MG**	**A213728**	**002**	Oct 16, 2024
AB			**97MG;103MG**	**A213728**	**003**	Oct 16, 2024
AB		MSN	**24MG;26MG**	**A213748**	**001**	Jul 16, 2025
AB			**49MG;51MG**	**A213748**	**002**	Jul 16, 2025
AB			**97MG;103MG**	**A213748**	**003**	Jul 16, 2025
AB		NOVUGEN PHARMA SDN	**24MG;26MG**	**A213611**	**001**	Jul 16, 2025
AB			**49MG;51MG**	**A213611**	**002**	Jul 16, 2025
AB			**97MG;103MG**	**A213611**	**003**	Jul 16, 2025
AB		TORRENT	**24MG;26MG**	**A213604**	**001**	Aug 22, 2024
AB			**49MG;51MG**	**A213604**	**002**	Aug 22, 2024
AB			**97MG;103MG**	**A213604**	**003**	Aug 22, 2024
AB		ZYDUS PHARMS	**24MG;26MG**	**A213719**	**001**	Jul 09, 2024
AB			**49MG;51MG**	**A213719**	**002**	Jul 09, 2024
AB			**97MG;103MG**	**A213719**	**003**	Jul 09, 2024

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB		MSN	**EQ 50MG BASE**	**A215978**	**001**	Dec 31, 2024
AB			**EQ 100MG BASE**	**A215978**	**002**	Dec 31, 2024
AB		PRINSTON INC	**EQ 50MG BASE**	**A215739**	**001**	Apr 25, 2024
AB			**EQ 100MG BASE**	**A215739**	**002**	Apr 25, 2024
AB		ZENARA	**EQ 50MG BASE**	**A215913**	**001**	Jun 13, 2025
AB			**EQ 100MG BASE**	**A215913**	**002**	Jun 13, 2025

XADAGO

AB	**+**	MDD US	**EQ 50MG BASE**	**N207145**	**001**	Mar 21, 2017
AB	**+!**		**EQ 100MG BASE**	**N207145**	**002**	Mar 21, 2017

SALMETEROL XINAFOATE

POWDER;INHALATION

SEREVENT

+!	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG/PACKET**	**N205065**	**001**	Dec 19, 2013
AB	**+**		**500MG/PACKET**	**N205065**	**002**	Oct 27, 2015

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	**100MG/PACKET**	**A215420**	**001**	Aug 18, 2022
AB			**500MG/PACKET**	**A215420**	**002**	Aug 18, 2022
AB		DR REDDYS	**100MG/PACKET**	**A209452**	**001**	Mar 30, 2021
AB			**500MG/PACKET**	**A215798**	**001**	May 13, 2022
AB		PH HEALTH	**100MG/PACKET**	**A207207**	**001**	Aug 20, 2019
AB			**500MG/PACKET**	**A210027**	**001**	Aug 20, 2019
AB		TP ANDA HOLDINGS	**100MG/PACKET**	**A216432**	**001**	Sep 03, 2025
AB			**500MG/PACKET**	**A216432**	**002**	Sep 03, 2025

ZELVYSIA

AB		AUCTA	**100MG/PACKET**	**A218645**	**001**	Apr 29, 2025
AB			**500MG/PACKET**	**A218645**	**002**	Apr 29, 2025

TABLET;ORAL

KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG**	**N022181**	**001**	Dec 13, 2007

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	**100MG**	**A215534**	**001**	Aug 23, 2022
AB		AUROBINDO PHARMA	**100MG**	**A216797**	**001**	Jun 09, 2025
AB		DR REDDYS	**100MG**	**A207685**	**001**	Jun 15, 2021
AB		PH HEALTH	**100MG**	**A207200**	**001**	May 10, 2019
AB		ZENARA	**100MG**	**A218797**	**001**	Jun 11, 2025

SARECYCLINE HYDROCHLORIDE

TABLET;ORAL

SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521	001	Oct 01, 2018
+		EQ 100MG BASE	N209521	002	Oct 01, 2018
+!		EQ 150MG BASE	N209521	003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

SAXAGLIPTIN

AB		AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A205972**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A205972**	**002**	Jul 31, 2023
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A205994**	**001**	Jul 31, 2023
AB			**EQ 5MG BASE**	**A205994**	**002**	Jul 31, 2023
AB		MYLAN	**EQ 2.5MG BASE**	**A205980**	**001**	Jul 31, 2023
AB	**!**		**EQ 5MG BASE**	**A205980**	**002**	Jul 31, 2023

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB		ACTAVIS LABS UT INC	**1MG/72HR**	**A208769**	**001**	Jan 10, 2022
AB		AMNEAL	**1MG/72HR**	**A218384**	**001**	Jun 09, 2025
AB		MYLAN TECHNOLOGIES	**1MG/72HR**	**A203753**	**001**	Jun 19, 2019
AB		PADAGIS US	**1MG/72HR**	**A078830**	**001**	Jan 30, 2015
AB		RHODES PHARMS	**1MG/72HR**	**A215329**	**001**	May 06, 2024
AB	**!**	RICONPHARMA LLC	**1MG/72HR**	**A212342**	**001**	Nov 24, 2020
AB		ZYDUS PHARMS	**1MG/72HR**	**A217893**	**001**	Aug 29, 2024

TRANSDERM SCOP

AB	**+**	BAXTER HLTHCARE CORP	**1MG/72HR**	**N017874**	**001**	

SEBETRALSTAT

TABLET;ORAL

EKTERLY

	+!	KALVISTA	300MG	N219301	001	Jul 03, 2025

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

	+!	EVOFEM INC	2GM/PACKET	N209363	001	Sep 15, 2017

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION;INTRAVENOUS

CHIRHOSTIM

	+!	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
	+		40MCG/VIAL	N021256	002	Jun 21, 2007

SELADELPAR LYSINE

CAPSULE;ORAL

LIVDELZI

	+!	GILEAD SCIENCES INC	EQ 10MG BASE	N217899	001	Aug 14, 2024

SELEGILINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EMSAM

	+!	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
	+		9MG/24HR	N021336	002	Feb 27, 2006
	+		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX	**5MG**	**A075321**	**001**	Dec 04, 1998
AB		NOVITIUM PHARMA	**5MG**	**A075352**	**001**	Nov 30, 1998
AB		RISING	**5MG**	**A206803**	**001**	Apr 02, 2019

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX	**5MG**	**A074871**	**001**	Jun 06, 1997
AB		I3 PHARMS	**5MG**	**A074672**	**001**	Apr 01, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

	+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006

SELENIOUS ACID

SOLUTION;INTRAVENOUS

SELENIOUS ACID

AP	**+!**	AM REGENT	**EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)**	**N209379**	**003**	Aug 30, 2021
AP	**+!**		**EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)**	**N209379**	**002**	Jan 25, 2021
AP	**+!**		**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**N209379**	**001**	Apr 30, 2019
AP		ASPIRO	**EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)**	**A219633**	**001**	Jun 11, 2025

SELENIOUS ACID						
SOLUTION;INTRAVENOUS						
SELENIOUS ACID						
AP		**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**A219633**	**002**	Jun 11, 2025
AP	CIPLA	**EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)**	**A218661**	**001**	Jul 21, 2025
AP		**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**A218661**	**002**	Jul 21, 2025
AP	GLAND	**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**A219629**	**001**	Jul 08, 2025
AP	RK PHARMA	**EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)**	**A218536**	**001**	Dec 31, 2025
AP		**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**A218536**	**002**	Dec 31, 2025
AP	SUN PHARM	**EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)**	**A219547**	**001**	Feb 20, 2025
SELENIUM SULFIDE						
LOTION/SHAMPOO;TOPICAL						
SELENIUM SULFIDE						
!	PADAGIS US	2.5%	A089996	001	Jan 10, 1991	
SELEXIPAG						
POWDER;INTRAVENOUS						
UPTRAVI						
+!	ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021	
TABLET;ORAL						
SELEXIPAG						
AB	ALEMBIC	**0.2MG**	**A214414**	**001**	Oct 11, 2023	
AB		**0.4MG**	**A214414**	**002**	Oct 11, 2023	
AB		**0.6MG**	**A214414**	**003**	Oct 11, 2023	
AB		**0.8MG**	**A214414**	**004**	Oct 11, 2023	
AB		**1.4MG**	**A214414**	**005**	Oct 11, 2023	
AB		**1.6MG**	**A214414**	**006**	Oct 11, 2023	
UPTRAVI						
AB	**+** ACTELION	**0.2MG**	**N207947**	**001**	Dec 21, 2015	
AB	**+!**	**0.4MG**	**N207947**	**002**	Dec 21, 2015	
AB	**+**	**0.6MG**	**N207947**	**003**	Dec 21, 2015	
AB	**+**	**0.8MG**	**N207947**	**004**	Dec 21, 2015	
AB	**+**	**1.4MG**	**N207947**	**007**	Dec 21, 2015	
AB	**+**	**1.6MG**	**N207947**	**008**	Dec 21, 2015	
+		1MG	N207947	005	Dec 21, 2015	
+		1.2MG	N207947	006	Dec 21, 2015	
SELINEXOR						
TABLET;ORAL						
XPOVIO						
+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	
+		20MG	N212306	001	Jul 03, 2019	
+		40MG	N212306	002	Apr 15, 2021	
+		50MG	N212306	003	Apr 15, 2021	
+!		60MG	N212306	004	Apr 15, 2021	
+		80MG	N212306	006	Oct 20, 2025	
SELPERCATINIB						
CAPSULE;ORAL						
RETEVMO						
+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	
+!		80MG	N213246	002	May 08, 2020	
TABLET;ORAL						
RETEVMO						
+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	
+		80MG	N218160	002	Apr 10, 2024	
+		120MG	N218160	003	Apr 10, 2024	
+!		160MG	N218160	004	Apr 10, 2024	
SELUMETINIB SULFATE						
CAPSULE;ORAL						
KOSELUGO						
+	ASTRAZENECA	EQ 10MG BASE	N213756	001	Apr 10, 2020	
+!		EQ 25MG BASE	N213756	002	Apr 10, 2020	
GRANULE;ORAL						
KOSELUGO						
+	ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	
+!		EQ 7.5MG BASE	N219943	002	Sep 10, 2025	

SEMAGLUTIDE						
SOLUTION;SUBCUTANEOUS						
OZEMPIC						
+!	NOVO	2MG/3ML (0.68MG/ML)	N209637	004	Oct 06, 2022
+!		4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019
+!		8MG/3ML (2.68MG/ML)	N209637	003	Mar 28, 2022
WEGOVY					
+!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021
+!		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021
+!		1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021
+!		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021
+!		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021
TABLET;ORAL					
RYBELSUS					
+!	NOVO	1.5MG	N213051	004	Dec 09, 2024
+!		3MG	N213051	001	Sep 20, 2019
+!		4MG	N213051	005	Dec 09, 2024
+!		7MG	N213051	002	Sep 20, 2019
+!		9MG	N213051	006	Dec 09, 2024
+!		14MG	N213051	003	Sep 20, 2019
WEGOVY					
+	NOVO	1.5MG	N218316	001	Dec 22, 2025
+		4MG	N218316	002	Dec 22, 2025
+		9MG	N218316	003	Dec 22, 2025
+!		25MG	N218316	004	Dec 22, 2025
SEPIAPTERIN					
POWDER;ORAL					
SEPHIENCE					
+	PTC THERAP	250MG/PACKET	N219666	001	Jul 28, 2025
+!		1GM/PACKET	N219666	002	Jul 28, 2025
SERTACONAZOLE NITRATE					
CREAM;TOPICAL					
ERTACZO					
+!	LACER PHARMA	2%	N021385	001	Dec 10, 2003
SERTRALINE HYDROCHLORIDE					
CAPSULE;ORAL					
SERTRALINE HYDROCHLORIDE					
AB **+!**	ALMATICA	**EQ 150MG BASE**	**N215133**	**001**	Oct 04, 2021
AB **+**		**EQ 200MG BASE**	**N215133**	**002**	Oct 04, 2021
AB	ZENARA	**EQ 150MG BASE**	**A218853**	**001**	Jul 16, 2025
AB		**EQ 200MG BASE**	**A218853**	**002**	Jul 16, 2025
CONCENTRATE;ORAL					
SERTRALINE HYDROCHLORIDE					
AA	AUROBINDO PHARMA	**EQ 20MG BASE/ML**	**A078861**	**001**	Oct 31, 2008
AA	STRIDES PHARMA	**EQ 20MG BASE/ML**	**A076934**	**001**	Jun 30, 2006
ZOLOFT					
AA **+!**	VIATRIS	**EQ 20MG BASE/ML**	**N020990**	**001**	Dec 07, 1999
TABLET;ORAL					
SERTRALINE HYDROCHLORIDE					
AB	ACCORD HLTHCARE	**EQ 25MG BASE**	**A202825**	**001**	Nov 07, 2014
AB		**EQ 50MG BASE**	**A202825**	**002**	Nov 07, 2014
AB		**EQ 100MG BASE**	**A202825**	**003**	Nov 07, 2014
AB	ASCENT PHARMS INC	**EQ 25MG BASE**	**A214790**	**001**	May 03, 2021
AB		**EQ 50MG BASE**	**A214790**	**002**	May 03, 2021
AB		**EQ 100MG BASE**	**A214790**	**003**	May 03, 2021
AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A077206**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077206**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077206**	**003**	Feb 06, 2007
AB	GRANULES	**EQ 25MG BASE**	**A078403**	**001**	Jan 08, 2008
AB		**EQ 50MG BASE**	**A078403**	**002**	Jan 08, 2008
AB		**EQ 100MG BASE**	**A078403**	**003**	Jan 08, 2008
AB	HERITAGE	**EQ 25MG BASE**	**A076465**	**001**	Aug 11, 2006
AB		**EQ 50MG BASE**	**A076465**	**002**	Aug 11, 2006
AB		**EQ 100MG BASE**	**A076465**	**003**	Aug 11, 2006
AB	INVAGEN PHARMS	**EQ 25MG BASE**	**A077397**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077397**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077397**	**003**	Feb 06, 2007
AB	LUPIN	**EQ 25MG BASE**	**A077670**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077670**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077670**	**003**	Feb 06, 2007
AB	OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB			**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB			**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB		PHARMACO	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007
AB		REYOUNG	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB			**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB			**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB		SCIEGEN PHARMS	**EQ 25MG BASE**	**A076442**	**001**	Apr 30, 2007
AB			**EQ 50MG BASE**	**A076442**	**002**	Apr 30, 2007
AB			**EQ 100MG BASE**	**A076442**	**003**	Apr 30, 2007
AB		STRIDES PHARMA	**EQ 25MG BASE**	**A076881**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076881**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076881**	**003**	Feb 06, 2007

ZOLOFT

AB	**+**	VIATRIS	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB	**+**		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB	**+!**		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991

SETMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

IMCIVREE

+!	RHYTHM	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N213793	001	Nov 25, 2020

SEVABERTINIB

TABLET;ORAL

HYRNUO

+!	BAYER HEALTHCARE	10MG	N219972	001	Nov 19, 2025

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

AB	**+**	GENZYME	**800MG/PACKET**	**N022318**	**001**	Aug 12, 2009
AB	**+!**		**2.4GM/PACKET**	**N022318**	**002**	Feb 18, 2009

SEVELAMER CARBONATE

AB		AUROBINDO PHARMA	**800MG/PACKET**	**A207624**	**001**	Jun 13, 2017
AB			**2.4GM/PACKET**	**A207624**	**002**	Jun 13, 2017
AB		BIONPHARMA	**800MG/PACKET**	**A209374**	**001**	May 17, 2021
AB		CHARTWELL RX	**800MG/PACKET**	**A217319**	**001**	Mar 02, 2023
AB			**2.4GM/PACKET**	**A217319**	**002**	Mar 02, 2023
AB		DR REDDYS	**800MG/PACKET**	**A210464**	**001**	Oct 25, 2018
AB			**2.4GM/PACKET**	**A210464**	**002**	Oct 25, 2018
AB		IMPAX	**800MG/PACKET**	**A211316**	**001**	Nov 20, 2020
AB			**2.4GM/PACKET**	**A211316**	**002**	Nov 20, 2020
AB		MACLEODS PHARMS LTD	**800MG/PACKET**	**A207291**	**001**	Apr 25, 2024
AB			**2.4GM/PACKET**	**A207291**	**002**	Apr 25, 2024
AB		STRIDES PHARMA INTL	**800MG/PACKET**	**A211917**	**001**	Sep 08, 2023
AB			**2.4GM/PACKET**	**A211917**	**002**	Sep 08, 2023

TABLET;ORAL

RENVELA

AB	**+!**	SANOFI	**800MG**	**N022127**	**001**	Oct 19, 2007

SEVELAMER CARBONATE

AB		AMNEAL PHARMS CO	**800MG**	**A207288**	**001**	Nov 28, 2017
AB		ARTHUR GRP	**800MG**	**A200959**	**001**	Mar 20, 2018
AB		AUROBINDO PHARMA	**800MG**	**A207179**	**001**	Jul 17, 2017
AB		DR REDDYS	**800MG**	**A206094**	**001**	Sep 29, 2017
AB		INVAGEN PHARMS	**800MG**	**A203860**	**001**	Oct 26, 2017
AB		MACLEODS PHARMS LTD	**800MG**	**A206100**	**001**	Apr 19, 2023
AB		MICRO LABS	**800MG**	**A215537**	**001**	Feb 07, 2022
AB		NAVINTA LLC	**800MG**	**A219931**	**001**	Oct 27, 2025
AB		RISING	**800MG**	**A204451**	**001**	Nov 29, 2018
AB		SHANDONG XINHUA	**800MG**	**A215998**	**001**	Oct 24, 2024
AB		STRIDES PHARMA	**800MG**	**A211915**	**001**	May 09, 2024
AB		ZYDUS PHARMS	**800MG**	**A207759**	**001**	Aug 11, 2020

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	**+**	GENZYME	**400MG**	**N021179**	**001**	Jul 12, 2000
AB	**+!**		**800MG**	**N021179**	**002**	Jul 12, 2000

SEVELAMER HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	**400MG**	**A204724**	**001**	Feb 08, 2019
AB			**800MG**	**A204724**	**002**	Feb 08, 2019
AB		LUPIN LTD	**400MG**	**A213145**	**001**	Jun 16, 2021
AB			**800MG**	**A213145**	**002**	Jun 16, 2021
AB		MACLEODS PHARMS LTD	**400MG**	**A206883**	**001**	May 26, 2023
AB			**800MG**	**A206883**	**002**	May 26, 2023
AB		NAVINTA LLC	**800MG**	**A218966**	**001**	Feb 03, 2025
BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023
BX			800MG	A212599	002	Jul 11, 2023

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

AN		BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN		HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN		SHANDONG	**100%**	**A214382**	**001**	Aug 18, 2023
AN		SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015

SOJOURN

AN		PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007

ULTANE

AN	**+!**	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995

SILDENAFIL CITRATE

FILM;ORAL

VYBRIQUE

	+	IBSA	EQ 25MG BASE	N210858	001	Dec 16, 2025
	+		EQ 50MG BASE	N210858	002	Dec 16, 2025
	+		EQ 75MG BASE	N210858	003	Dec 16, 2025
	+!		EQ 100MG BASE	N210858	004	Dec 16, 2025

FOR SUSPENSION;ORAL

REVATIO

AB	**+!**	VIATRIS	**EQ 10MG BASE/ML**	**N203109**	**001**	Aug 30, 2012

SILDENAFIL CITRATE

AB		AJANTA PHARMA LTD	**EQ 10MG BASE/ML**	**A212883**	**001**	Nov 27, 2019
AB		ALKEM LABS LTD	**EQ 10MG BASE/ML**	**A212440**	**001**	Nov 27, 2019
AB		AMNEAL PHARMS	**EQ 10MG BASE/ML**	**A211092**	**001**	Nov 27, 2019
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE/ML**	**A214773**	**001**	Dec 23, 2022
AB		CHARTWELL RX	**EQ 10MG BASE/ML**	**A213814**	**001**	Apr 29, 2021
AB		HETERO LABS LTD V	**EQ 10MG BASE/ML**	**A213014**	**001**	May 11, 2021
AB		INVAGEN PHARMS	**EQ 10MG BASE/ML**	**A213041**	**001**	Aug 06, 2020
AB		MSN	**EQ 10MG BASE/ML**	**A214641**	**001**	Feb 08, 2022
AB		NOVITIUM PHARMA	**EQ 10MG BASE/ML**	**A212260**	**001**	May 31, 2019
AB		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A211534**	**001**	May 29, 2020
AB		ZYDUS LIFESCIENCES	**EQ 10MG BASE/ML**	**A215708**	**001**	Sep 29, 2022

SOLUTION;INTRAVENOUS

REVATIO

AP	**+!**	VIATRIS	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009

SILDENAFIL CITRATE

AP		EUGIA PHARMA	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015

TABLET;ORAL

REVATIO

AB	**+!**	VIATRIS	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005

SILDENAFIL CITRATE

AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A210394**	**001**	May 04, 2018
AB			**EQ 25MG BASE**	**A206401**	**001**	Oct 12, 2018
AB			**EQ 50MG BASE**	**A206401**	**002**	Oct 12, 2018
AB			**EQ 100MG BASE**	**A206401**	**003**	Oct 12, 2018
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB		AMNEAL PHARMS NY	**EQ 25MG BASE**	**A202023**	**001**	Jun 27, 2018
AB			**EQ 50MG BASE**	**A202023**	**002**	Jun 27, 2018
AB			**EQ 100MG BASE**	**A202023**	**003**	Jun 27, 2018
AB		APPCO	**EQ 25MG BASE**	**A207178**	**001**	Mar 02, 2020
AB			**EQ 50MG BASE**	**A207178**	**002**	Mar 02, 2020
AB			**EQ 100MG BASE**	**A207178**	**003**	Mar 02, 2020
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB			**EQ 25MG BASE**	**A203962**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A203962**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A203962**	**003**	Jun 11, 2018
AB		CADILA PHARMS LTD	**EQ 25MG BASE**	**A218045**	**001**	Nov 28, 2023
AB			**EQ 50MG BASE**	**A218045**	**002**	Nov 28, 2023
AB			**EQ 100MG BASE**	**A218045**	**003**	Nov 28, 2023
AB		CHARTWELL RX	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB			**EQ 25MG BASE**	**A212051**	**001**	Mar 22, 2019
AB			**EQ 50MG BASE**	**A212051**	**002**	Mar 22, 2019
AB			**EQ 100MG BASE**	**A212051**	**003**	Mar 22, 2019
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB			**EQ 25MG BASE**	**A202659**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A202659**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A202659**	**003**	Jun 11, 2018
AB		JUBILANT GENERICS	**EQ 20MG BASE**	**A202954**	**001**	Mar 06, 2025
AB			**EQ 25MG BASE**	**A201156**	**001**	Dec 20, 2024
AB			**EQ 50MG BASE**	**A201156**	**002**	Dec 20, 2024
AB			**EQ 100MG BASE**	**A201156**	**003**	Dec 20, 2024
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB			**EQ 25MG BASE**	**A202255**	**001**	Apr 19, 2023
AB			**EQ 50MG BASE**	**A202255**	**002**	Apr 19, 2023
AB			**EQ 100MG BASE**	**A202255**	**003**	Apr 19, 2023
AB		NOVITIUM PHARMA	**EQ 25MG BASE**	**A216383**	**001**	Aug 29, 2023
AB			**EQ 50MG BASE**	**A216383**	**002**	Aug 29, 2023
AB			**EQ 100MG BASE**	**A216383**	**003**	Aug 29, 2023
AB		REYOUNG	**EQ 25MG BASE**	**A208494**	**001**	Jun 12, 2020
AB			**EQ 50MG BASE**	**A208494**	**002**	Jun 12, 2020
AB			**EQ 100MG BASE**	**A208494**	**003**	Jun 12, 2020
AB		RUBICON RESEARCH	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB			**EQ 25MG BASE**	**A204882**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A204882**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A204882**	**003**	Jun 11, 2018
AB		SUNSHINE	**EQ 25MG BASE**	**A213032**	**001**	Jun 11, 2020
AB			**EQ 50MG BASE**	**A213032**	**002**	Jun 11, 2020
AB			**EQ 100MG BASE**	**A213032**	**003**	Jun 11, 2020
AB		TEVA	**EQ 25MG BASE**	**A077342**	**001**	Mar 09, 2016
AB			**EQ 50MG BASE**	**A077342**	**002**	Mar 09, 2016
AB			**EQ 100MG BASE**	**A077342**	**003**	Mar 09, 2016
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB		TORRENT	**EQ 25MG BASE**	**A091448**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A091448**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A091448**	**003**	Jun 11, 2018
AB		TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB		UMEDICA	**EQ 25MG BASE**	**A209302**	**003**	Jun 15, 2021
AB			**EQ 50MG BASE**	**A209302**	**001**	Aug 25, 2020
AB			**EQ 100MG BASE**	**A209302**	**002**	Aug 25, 2020
AB		WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012

VIAGRA

AB	**+**	VIATRIS	**EQ 25MG BASE**	**N020895**	**001**	Mar 27, 1998
AB	**+**		**EQ 50MG BASE**	**N020895**	**002**	Mar 27, 1998
AB	**+!**		**EQ 100MG BASE**	**N020895**	**003**	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB		AJANTA PHARMA LTD	**4MG**	**A211060**	**001**	Dec 03, 2018
AB			**8MG**	**A211060**	**002**	Dec 03, 2018
AB		AMNEAL PHARMS CO	**4MG**	**A209745**	**001**	Dec 03, 2018
AB			**8MG**	**A209745**	**002**	Dec 03, 2018
AB		AUROBINDO PHARMA LTD	**4MG**	**A210626**	**001**	Dec 10, 2018
AB			**8MG**	**A210626**	**002**	Dec 10, 2018
AB		CHARTWELL RX	**4MG**	**A204726**	**001**	Mar 31, 2017
AB			**8MG**	**A204726**	**002**	Mar 31, 2017
AB		CREEKWOOD PHARMS	**4MG**	**A213230**	**001**	Jan 03, 2022
AB			**8MG**	**A213230**	**002**	Jan 03, 2022
AB		HETERO LABS LTD V	**4MG**	**A204793**	**001**	Feb 14, 2020
AB			**8MG**	**A204793**	**002**	Feb 14, 2020
AB	**!**	LUPIN LTD	**4MG**	**A206541**	**001**	Dec 03, 2018
AB			**8MG**	**A206541**	**002**	Dec 03, 2018

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB		MACLEODS PHARMS LTD	**4MG**	**A211166**	**001**	Dec 03, 2018
AB			**8MG**	**A211166**	**002**	Dec 03, 2018
AB		MSN	**4MG**	**A210687**	**001**	Dec 03, 2018
AB			**8MG**	**A210687**	**002**	Dec 03, 2018
AB		PRINSTON INC	**4MG**	**A209029**	**001**	Jan 04, 2022
AB			**8MG**	**A209029**	**002**	Jan 04, 2022

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	**+!**	KING PHARMS LLC	**1%**	**N017381**	**001**	

SSD

AB	**+!**	DR REDDYS	**1%**	**N018578**	**001**	Feb 25, 1982

THERMAZENE

AB		THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

	+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016
	+!		40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB			**10MG**	**A078155**	**002**	Feb 26, 2008
AB			**20MG**	**A078155**	**003**	Feb 26, 2008
AB			**40MG**	**A078155**	**004**	Feb 26, 2008
AB			**80MG**	**A078155**	**001**	Feb 26, 2008
AB		AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB			**10MG**	**A077691**	**002**	Dec 20, 2006
AB			**20MG**	**A077691**	**003**	Dec 20, 2006
AB			**40MG**	**A077691**	**004**	Dec 20, 2006
AB			**80MG**	**A077691**	**005**	Dec 20, 2006
AB		BIOCON PHARMA	**5MG**	**A078034**	**001**	Dec 20, 2006
AB			**10MG**	**A078034**	**002**	Dec 20, 2006
AB			**20MG**	**A078034**	**003**	Dec 20, 2006
AB			**40MG**	**A078034**	**004**	Dec 20, 2006
AB			**80MG**	**A078034**	**005**	Dec 20, 2006
AB		HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB			**10MG**	**A200895**	**002**	Nov 25, 2014
AB			**20MG**	**A200895**	**003**	Nov 25, 2014
AB			**40MG**	**A200895**	**004**	Nov 25, 2014
AB			**80MG**	**A200895**	**005**	Nov 25, 2014
AB		INVAGEN PHARMS	**5MG**	**A206557**	**005**	Oct 27, 2025
AB			**10MG**	**A206557**	**001**	Nov 13, 2017
AB			**20MG**	**A206557**	**002**	Nov 13, 2017
AB			**40MG**	**A206557**	**003**	Nov 13, 2017
AB			**80MG**	**A206557**	**004**	Nov 13, 2017
AB		LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB			**10MG**	**A078103**	**001**	May 11, 2007
AB			**20MG**	**A078103**	**002**	May 11, 2007
AB			**40MG**	**A078103**	**003**	May 11, 2007
AB	**!**		**80MG**	**A078103**	**004**	May 11, 2007
AB		MICRO LABS	**5MG**	**A090383**	**001**	Sep 16, 2011
AB			**10MG**	**A090383**	**002**	Sep 16, 2011
AB			**20MG**	**A090383**	**003**	Sep 16, 2011
AB			**40MG**	**A090383**	**004**	Sep 16, 2011
AB			**80MG**	**A090383**	**005**	Sep 16, 2011
AB		OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB			**10MG**	**A078735**	**002**	Aug 30, 2010
AB			**20MG**	**A078735**	**003**	Aug 30, 2010
AB			**40MG**	**A078735**	**004**	Aug 30, 2010
AB			**80MG**	**A078735**	**005**	Aug 30, 2010
AB		RISING	**5MG**	**A077752**	**005**	Jan 23, 2008
AB			**10MG**	**A077752**	**001**	Dec 20, 2006
AB			**20MG**	**A077752**	**002**	Dec 20, 2006
AB			**40MG**	**A077752**	**003**	Dec 20, 2006
AB			**80MG**	**A077752**	**004**	Dec 20, 2006
AB		YILING	**10MG**	**A211394**	**001**	Nov 27, 2024
AB			**20MG**	**A211394**	**002**	Nov 27, 2024

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

AB			**40MG**	**A211394**	**003**	Nov 27, 2024
AB			**80MG**	**A211394**	**004**	Nov 27, 2024
AB		ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB			**10MG**	**A077837**	**002**	Dec 20, 2006
AB			**20MG**	**A077837**	**003**	Dec 20, 2006
AB			**40MG**	**A077837**	**004**	Dec 20, 2006
AB			**80MG**	**A077837**	**005**	Dec 20, 2006

ZOCOR

AB	**+**	ORGANON	**5MG**	**N019766**	**001**	Dec 23, 1991
AB	**+**		**10MG**	**N019766**	**002**	Dec 23, 1991
AB	**+**		**20MG**	**N019766**	**003**	Dec 23, 1991
AB	**+**		**40MG**	**N019766**	**004**	Dec 23, 1991

SINCALIDE
POWDER;INTRAVENOUS
KINEVAC

AP	**+!**	BRACCO	**0.005MG/VIAL**	**N017697**	**001**	

SINCALIDE

AP	**+!**	MAIA PHARMS INC	**0.005MG/VIAL**	**N210850**	**001**	Nov 22, 2022

SINECATECHINS
OINTMENT;TOPICAL
VEREGEN

	+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006

SIPONIMOD
TABLET;ORAL
MAYZENT

	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021
	+!		EQ 2MG BASE	N209884	002	Mar 26, 2019

SIROLIMUS
GEL;TOPICAL
HYFTOR

	+!	NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022

POWDER;INTRAVENOUS
FYARRO

	+!	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021

SOLUTION;ORAL
RAPAMUNE

AA	**+!**	PF PRISM CV	**1MG/ML**	**N021083**	**001**	Sep 15, 1999

SIROLIMUS

AA		AMNEAL	**1MG/ML**	**A211212**	**001**	Oct 18, 2019
AA		APOTEX	**1MG/ML**	**A211406**	**001**	Oct 22, 2019
AA		HETERO LABS LTD V	**1MG/ML**	**A215080**	**001**	Sep 16, 2024
AA		MSN	**1MG/ML**	**A216728**	**001**	Jan 19, 2023
AA		NOVITIUM PHARMA	**1MG/ML**	**A211040**	**001**	Jan 28, 2019
AA		RISING	**1MG/ML**	**A215116**	**001**	Jul 15, 2025

TABLET;ORAL
RAPAMUNE

AB	**+**	PF PRISM CV	**0.5MG**	**N021110**	**004**	Jan 25, 2010
AB	**+**		**1MG**	**N021110**	**001**	Aug 25, 2000
AB	**+!**		**2MG**	**N021110**	**002**	Aug 22, 2002

SIROLIMUS

AB		ALKEM LABS LTD	**0.5MG**	**A214753**	**001**	Mar 12, 2021
AB			**1MG**	**A214753**	**002**	Mar 12, 2021
AB			**2MG**	**A214753**	**003**	Mar 12, 2021
AB		DR REDDYS	**1MG**	**A201578**	**001**	Oct 27, 2014
AB			**2MG**	**A201578**	**002**	Oct 27, 2014
AB		GLENMARK PHARMS LTD	**0.5MG**	**A208691**	**001**	Oct 16, 2020
AB			**1MG**	**A208691**	**002**	Oct 16, 2020
AB			**2MG**	**A208691**	**003**	Oct 16, 2020
AB		ZYDUS PHARMS	**1MG**	**A201676**	**001**	Feb 15, 2023
AB			**2MG**	**A201676**	**002**	Feb 15, 2023
AB			**0.5MG**	**A201676**	**003**	Jan 08, 2014

SITAGLIPTIN

TABLET;ORAL

ZITUVIO

	+	ZYDUS LIFESCIENCES	25MG	N211566	001	Oct 18, 2023
	+		50MG	N211566	002	Oct 18, 2023
	+!		100MG	N211566	003	Oct 18, 2023

SITAGLIPTIN HYDROCHLORIDE

SOLUTION;ORAL

BRYNOVIN

	+!	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025

SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUVIA

AB	**+**	MERCK SHARP DOHME	**EQ 25MG BASE**	**N021995**	**001**	Oct 16, 2006
AB	**+**		**EQ 50MG BASE**	**N021995**	**002**	Oct 16, 2006
AB	**+!**		**EQ 100MG BASE**	**N021995**	**003**	Oct 16, 2006

SITAGLIPTIN PHOSPHATE

AB		WATSON LABS INC	**EQ 25MG BASE**	**A202327**	**001**	Dec 30, 2025
AB			**EQ 50MG BASE**	**A202327**	**002**	Dec 30, 2025
AB			**EQ 100MG BASE**	**A202327**	**003**	Dec 30, 2025

SODIUM ACETATE

SOLUTION;INTRAVENOUS

SODIUM ACETATE

AP		AMNEAL	**100MEQ/50ML (2MEQ/ML)**	**A218469**	**001**	Aug 08, 2025
AP			**200MEQ/100ML (2MEQ/ML)**	**A218469**	**002**	Aug 08, 2025
AP	**!**	FRESENIUS KABI USA	**400MEQ/100ML (4MEQ/ML)**	**A206687**	**001**	Oct 30, 2017
AP		HIKMA	**40MEQ/20ML (2MEQ/ML)**	**A216920**	**001**	Mar 15, 2024
AP			**100MEQ/50ML (2MEQ/ML)**	**A216920**	**002**	Mar 15, 2024
AP			**200MEQ/100ML (2MEQ/ML)**	**A216920**	**003**	Mar 15, 2024
AP	**+!**	HOSPIRA	**40MEQ/20ML (2MEQ/ML)**	**N018893**	**001**	May 04, 1983
AP	**+!**		**100MEQ/50ML (2MEQ/ML)**	**N018893**	**002**	Sep 02, 2014
AP	**+!**		**200MEQ/100ML (2MEQ/ML)**	**N018893**	**003**	Sep 02, 2014
AP		MILLA PHARMS	**40MEQ/20ML (2MEQ/ML)**	**A214805**	**004**	Jan 22, 2024
AP			**100MEQ/50ML (2MEQ/ML)**	**A214805**	**001**	May 04, 2021
AP			**200MEQ/100ML (2MEQ/ML)**	**A214805**	**003**	May 04, 2021
AP			**400MEQ/100ML (4MEQ/ML)**	**A214805**	**002**	Aug 25, 2023
AP		SOMERSET THERAPS LLC	**100MEQ/50ML (2MEQ/ML)**	**A219826**	**001**	Sep 18, 2025
AP			**200MEQ/100ML (2MEQ/ML)**	**A219826**	**002**	Sep 18, 2025

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	**!**	AILEX PHARMS LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A207096**	**001**	Feb 24, 2016
AP		MAIA PHARMS INC	**10%;10% (5GM/50ML;5GM/50ML)**	**A208521**	**001**	May 08, 2017
AP	**+!**		**10%;10% (2GM/20ML;2GM/20ML)**	**N215025**	**001**	Jun 10, 2021
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A205880**	**001**	Aug 04, 2016
AP			**10%;10% (2GM/20ML; 2GM/20ML)**	**A217526**	**001**	Jul 14, 2023

SODIUM BICARBONATE

SOLUTION;INTRAVENOUS

SODIUM BICARBONATE

AP		ANTHEA PHARMA	**50MEQ/50ML (1MEQ/ML)**	**A219701**	**001**	Jun 26, 2025
AP	**!**	EXELA PHARMA	**5MEQ/10ML (0.5MEQ/ML)**	**A211091**	**001**	Jun 20, 2019
AP	**!**		**10MEQ/10ML (1MEQ/ML)**	**A211091**	**003**	Jun 20, 2019
AP	**!**		**44.6MEQ/50ML (0.9MEQ/ML)**	**A211091**	**002**	Jun 20, 2019
AP	**!**		**50MEQ/50ML (1MEQ/ML)**	**A211091**	**004**	Jun 20, 2019
AP		FRESENIUS KABI USA	**2.5MEQ/5ML (0.5MEQ/ML)**	**A206688**	**001**	Aug 25, 2025
AP			**50MEQ/50ML (1MEQ/ML)**	**A206688**	**002**	Aug 25, 2025
AP	**!**	HOSPIRA	**2.5MEQ/5ML (0.5MEQ/ML)**	**A202981**	**001**	Mar 04, 2016
AP			**5MEQ/10ML (0.5MEQ/ML)**	**A202679**	**001**	Mar 07, 2017
AP			**10MEQ/10ML (1MEQ/ML)**	**A202495**	**001**	Mar 06, 2017
AP			**44.6MEQ/50ML (0.9MEQ/ML)**	**A202494**	**001**	Mar 06, 2017
AP			**50MEQ/50ML (1MEQ/ML)**	**A202432**	**001**	Sep 26, 2017
AP			**50MEQ/50ML (1MEQ/ML)**	**A202494**	**002**	Mar 06, 2017
AP		INTL MEDICATION SYS	**50MEQ/50ML (1MEQ/ML)**	**A203449**	**001**	Sep 19, 2017
AP		LONG GROVE PHARMS	**50MEQ/50ML (1MEQ/ML)**	**A216042**	**001**	Feb 27, 2024
AP		OMNIVIUM PHARMS	**50MEQ/50ML (1MEQ/ML)**	**A216364**	**001**	Jun 15, 2023
AP		STERISCIENCE	**50MEQ/50ML (1MEQ/ML)**	**A217594**	**001**	Jun 28, 2023

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	B BRAUN	**450MG/100ML**	**N019635**	**001**	Mar 09, 1988
AP	+!	BAXTER HLTHCARE	**450MG/100ML**	**N018016**	**001**	
AP		FRESENIUS KABI USA	**450MG/100ML**	**A208122**	**001**	Jul 23, 2018
AP		HOSPIRA	**450MG/100ML**	**N019759**	**001**	Jun 08, 1988
AP	+!	OTSUKA ICU MEDCL	**450MG/100ML**	**N018090**	**001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+!	B BRAUN	**900MG/100ML**	**N017464**	**001**	
AP	+!		**900MG/100ML**	**N019635**	**002**	Mar 09, 1988
AP		FRESENIUS KABI USA	**900MG/100ML**	**A207310**	**001**	Sep 19, 2017
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001**	Apr 12, 2007
AP		GVS TM	**900MG/100ML**	**A076316**	**001**	Oct 27, 2004
AP	+!	HOSPIRA	**900MG/100ML**	**N019480**	**001**	Sep 17, 1985
AP		LABORATORIOS GRIFOLS	**900MG/100ML**	**A207956**	**001**	May 25, 2017
AP	+!	OTSUKA ICU MEDCL	**900MG/100ML**	**N016366**	**001**	

SODIUM CHLORIDE 23.4%

AP		FRESENIUS KABI USA	**234MG/ML**	**A212248**	**001**	Apr 28, 2021
AP			**234MG/ML**	**A217796**	**001**	Jul 11, 2023

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	**3GM/100ML**	**N019635**	**003**	Mar 09, 1988
AP	+!	BAXTER HLTHCARE	**3GM/100ML**	**N019022**	**001**	Nov 01, 1983
AP		FRESENIUS KABI USA	**3GM/100ML**	**A209476**	**001**	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N019635**	**004**	Mar 09, 1988
AP	+	BAXTER HLTHCARE	**5GM/100ML**	**N019022**	**002**	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+!	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SOLUTION;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**90MG/10ML (9MG/ML)**	**A088911**	**002**	May 17, 1985
AP			**270MG/30ML (9MG/ML)**	**A088911**	**001**	Feb 07, 1985
AP	+!	HOSPIRA	**90MG/10ML (9MG/ML)**	**N018800**	**001**	Oct 29, 1982
AP	+!		**180MG/20ML (9MG/ML)**	**N018800**	**002**	Oct 29, 1982
AP	+!		**270MG/30ML (9MG/ML)**	**N018800**	**003**	Oct 29, 1982

SODIUM CHLORIDE 0.9%

AP		HIKMA	**90MG/10ML (9MG/ML)**	**A201833**	**002**	Jan 07, 2015
AP		NEXUS	**90MG/10ML (9MG/ML)**	**A217535**	**001**	Aug 23, 2023
AP			**180MG/20ML (9MG/ML)**	**A217535**	**002**	Aug 23, 2023
AP		SPECTRA MDCL DEVICES	**45MG/5ML (9MG/ML)**	**A206171**	**001**	Jul 21, 2017
AP			**90MG/10ML (9MG/ML)**	**A206171**	**002**	Jul 21, 2017

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	**450MG/50ML (9MG/ML)**	**N016677**	**003**	
AP	+		**450MG/50ML (9MG/ML)**	**N020178**	**002**	Dec 07, 1992
AP	+!		**900MG/100ML**	**N016677**	**001**	
AP	+!		**900MG/100ML**	**N020178**	**001**	Dec 07, 1992
AP	!	FRESENIUS KABI USA	**90MG/10ML (9MG/ML)**	**A088912**	**001**	Jan 10, 1985
AP	!		**180MG/20ML (9MG/ML)**	**A088912**	**002**	Jan 10, 1985
AP	!		**270MG/30ML (9MG/ML)**	**A088912**	**003**	Jan 10, 1985
AP	+!	HOSPIRA	**90MG/10ML (9MG/ML)**	**N018803**	**001**	Oct 29, 1982
AP	+!		**180MG/20ML (9MG/ML)**	**N018803**	**002**	Oct 29, 1982
AP	+!		**450MG/50ML (9MG/ML)**	**N018803**	**003**	Oct 29, 1982
AP	+		**450MG/50ML (9MG/ML)**	**N019465**	**002**	Jul 15, 1985
AP	+!		**900MG/100ML**	**N019465**	**001**	Jul 15, 1985
AP		NEPHRON	**450MG/50ML (9MG/ML)**	**A211968**	**001**	Apr 23, 2020
AP			**900MG/100ML**	**A211968**	**002**	Apr 23, 2020
AP	!	TARO	**45MG/5ML (9MG/ML)**	**A077407**	**001**	Aug 11, 2006
AP	!		**90MG/10ML (9MG/ML)**	**A077407**	**002**	Aug 11, 2006

SODIUM CHLORIDE 0.9%

	+	B BRAUN	90MG/10ML (9MG/ML)	N019635	005	Aug 08, 2016
		HIKMA	18MG/2ML (9MG/ML)	A201833	001	Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	225MG/25ML (9MG/ML)	N016677	004	Oct 30, 1985
	!	FRESENIUS KABI USA	18MG/2ML (9MG/ML)	A088912	004	Nov 29, 1985

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

AP		FRESENIUS KABI USA	**100MEQ/40ML (2.5MEQ/ML)**	**A212070**	**002**	Apr 28, 2021
AP	+!	HOSPIRA	**100MEQ/40ML (2.5MEQ/ML)**	**N018897**	**002**	Jul 20, 1984

SODIUM CHLORIDE							
SOLUTION;INTRAVENOUS							
SODIUM CHLORIDE 23.4%							
AP		FRESENIUS KABI USA	**400MEQ/100ML (4MEQ/ML)**	**A212070**	**003**	Feb 14, 2022
AP	**+!**	HOSPIRA	**400MEQ/100ML (4MEQ/ML)**	**N018897**	**003**	Jun 18, 2020
SODIUM CHLORIDE 14.6%							
		FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021
SOLUTION;IRRIGATION							
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AT	**+!**	B BRAUN	**900MG/100ML**	**N016733**	**001**		
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**		
AT			**900MG/100ML**	**N017867**	**001**		
AT		FRESENIUS KABI USA	**900MG/100ML**	**A213688**	**001**	Jun 24, 2024
AT	**+**	OTSUKA ICU MEDCL	**900MG/100ML**	**N017514**	**001**		
AT			**900MG/100ML**	**N018314**	**001**		
SOLUTION FOR SLUSH;IRRIGATION							
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985
SODIUM FERRIC GLUCONATE COMPLEX							
INJECTABLE;INJECTION							
FERRLECIT							
AB	**+!**	SANOFI AVENTIS US	**EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)**	**N020955**	**001**	Feb 18, 1999
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE							
AB		HIKMA	**EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)**	**A078215**	**001**	Mar 31, 2011
SODIUM FLUORIDE F-18							
INJECTABLE;INTRAVENOUS							
SODIUM FLUORIDE F-18							
AP		3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001**	Oct 19, 2015
AP		BAMF	**10-200mCi/ML**	**A216126**	**001**	Dec 06, 2022
AP		BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001**	Jan 09, 2015
AP		CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001**	Jul 30, 2015
AP		JUBILANT DRAXIMAGE	**10-200mCi/ML**	**A203968**	**001**	Oct 23, 2015
AP		KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001**	May 19, 2016
AP		MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001**	Nov 17, 2015
AP		MIPS CRF	**10-200mCi/ML**	**A204517**	**001**	Jul 21, 2015
AP		NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001**	Nov 28, 2014
AP		NUKEMED	**10-200mCi/ML**	**A203912**	**001**	Apr 22, 2015
AP	**!**	PETNET	**10-200mCi/ML**	**A203890**	**001**	Sep 28, 2015
AP		PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001**	Feb 27, 2015
AP		SOFIE	**10-200mCi/ML**	**A203592**	**001**	Aug 18, 2015
AP		UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001**	Apr 20, 2015
	!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014
SODIUM IODIDE I-123							
CAPSULE;ORAL							
SODIUM IODIDE I 123							
AA	**+!**	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001**	May 27, 1982
AA	**+!**		**200uCi**	**N018671**	**002**	May 27, 1982
AA		CURIUM	**100uCi**	**A071909**	**001**	Feb 28, 1989
AA			**200uCi**	**A071910**	**001**	Feb 28, 1989
SODIUM IODIDE I-131							
CAPSULE;ORAL							
SODIUM IODIDE I 131							
	+	JUBILANT	0.009-0.1mCi	N021305	006	May 19, 2005
SOLUTION;ORAL							
HICON							
AA	**+!**	JUBILANT	**250-1000mCi**	**N021305**	**007**	Dec 05, 2011
SODIUM IODIDE I 131							
AA		INTL ISOTOPES	**250-1000mCi**	**A209166**	**001**	Feb 05, 2020
SODIUM NITRITE							
SOLUTION;INTRAVENOUS							
SODIUM NITRITE							
	+!	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE						
SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS						
NITHIODOTE						
	+!	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011
SODIUM NITROPRUSSIDE						
INJECTABLE;INJECTION						
SODIUM NITROPRUSSIDE						
AP		AMNEAL	**25MG/ML**	**A209493**	**001**	Nov 07, 2017
AP		BE PHARMS	**25MG/ML**	**A214971**	**001**	Jul 12, 2021
AP		CAPLIN	**25MG/ML**	**A211016**	**001**	Nov 29, 2019
AP		DR REDDYS	**25MG/ML**	**A210114**	**001**	Apr 10, 2019
AP	!	MICRO LABS	**25MG/ML**	**A209352**	**001**	Dec 08, 2017
AP		MYLAN LABS LTD	**25MG/ML**	**A210763**	**001**	Apr 17, 2018
AP		NEXUS	**25MG/ML**	**A207499**	**001**	May 25, 2017
AP		PHARMOBEDIENT	**25MG/ML**	**A209584**	**001**	Aug 10, 2018
AP		SAGENT PHARMS INC	**25MG/ML**	**A207426**	**001**	Dec 08, 2016
AP		SLATE RUN PHARMA	**25MG/ML**	**A214199**	**001**	Aug 25, 2020
AP		SOMERSET THERAPS LLC	**25MG/ML**	**A210882**	**001**	Aug 17, 2018
SOLUTION;INTRAVENOUS						
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%						
AP	**+!**	EXELA PHARMA	**20MG/100ML (0.2MG/ML)**	**N209387**	**003**	Jul 13, 2018
AP	**+!**		**50MG/100ML (0.5MG/ML)**	**N209387**	**001**	Mar 08, 2017
SODIUM NITROPRUSSIDE						
AP		SLATE RUN PHARMA	**20MG/100ML (0.2MG/ML)**	**A215846**	**002**	Aug 26, 2022
AP			**50MG/100ML (0.5MG/ML)**	**A215846**	**003**	Aug 26, 2022
			10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022
SODIUM OXYBATE						
FOR SUSPENSION, EXTENDED RELEASE;ORAL						
LUMRYZ						
	+!	AVADEL CNS	4.5GM/PACKET	N214755	001	May 01, 2023
	+		6GM/PACKET	N214755	002	May 01, 2023
	+		7.5GM/PACKET	N214755	003	May 01, 2023
	+		9GM/PACKET	N214755	004	May 01, 2023
SOLUTION;ORAL						
SODIUM OXYBATE						
AA		AMNEAL	**0.5GM/ML**	**A203631**	**001**	Sep 10, 2025
AA		ASCENT PHARMS INC	**0.5GM/ML**	**A210523**	**001**	Nov 05, 2025
XYREM						
AA	**+!**	JAZZ PHARMS	**0.5GM/ML**	**N021196**	**001**	Jul 17, 2002
SODIUM PHENYLBUTYRATE						
FOR SUSPENSION;ORAL						
OLPRUVA						
	+	ACER	0.5GM/PACKET	N214860	007	Oct 10, 2025
	+		1GM/PACKET	N214860	008	Oct 10, 2025
	+		2GM/PACKET	N214860	001	Dec 22, 2022
	+		3GM/PACKET	N214860	002	Dec 22, 2022
	+		4GM/PACKET	N214860	003	Dec 22, 2022
	+!		5GM/PACKET	N214860	004	Dec 22, 2022
	+		6GM/PACKET	N214860	005	Dec 22, 2022
	+		6.67GM/PACKET	N214860	006	Dec 22, 2022
PELLETS;ORAL						
PHEBURANE						
	+!	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022
POWDER;ORAL						
BUPHENYL						
AB	**+!**	HORIZON THERAP US	**3GM/TEASPOONFUL**	**N020573**	**001**	Apr 30, 1996
SODIUM PHENYLBUTYRATE						
AB		PH HEALTH	**3GM/TEASPOONFUL**	**A203918**	**001**	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	**3GM/TEASPOONFUL**	**A202819**	**001**	Mar 22, 2013
TABLET;ORAL						
BUPHENYL						
AB	**+!**	HORIZON THERAP US	**500MG**	**N020572**	**001**	May 13, 1996
SODIUM PHENYLBUTYRATE						
AB		GLENMARK PHARMS LTD	**500MG**	**A216462**	**001**	Nov 01, 2022
AB		PH HEALTH	**500MG**	**A204395**	**001**	Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

	!	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION;INTRAVENOUS

SODIUM PHOSPHATES

AP		AM REGENT	**1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)**	**A218314**	**001**	Jun 21, 2024
AP			**4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)**	**A218314**	**002**	Jun 21, 2024
AP			**13.4GM/50ML;13.8GM/50ML (268MG/ML;276MG/ML)**	**A218314**	**003**	Jun 21, 2024
AP	!	FRESENIUS KABI USA	**1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)**	**A209997**	**001**	Mar 30, 2022
AP			**4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)**	**A209997**	**002**	Mar 30, 2022
AP	!		**13.4GM/50ML;13.8GM/50ML (268MG/ML;276MG/ML)**	**A209997**	**003**	Mar 30, 2022

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)**	**N018892**	**001**	May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	!	KVK TECH	**454GM/BOT**	**A040905**	**001**	Mar 30, 2009

KIONEX

AA		ANI PHARMS	**454GM/BOT**	**A040029**	**001**	Feb 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		AJENAT PHARMS	**454GM/BOT**	**A205727**	**001**	Feb 23, 2016
AA		CHARTWELL RX	**454GM/BOT**	**A206815**	**001**	Feb 18, 2016
AA		CMP PHARMA INC	**454GM/BOT**	**A089910**	**001**	Jan 19, 1989
AA		EPIC PHARMA LLC	**453.6GM/BOT**	**A202333**	**001**	Mar 19, 2014
AA		NUVO PHARMS INC	**454GM/BOT**	**A204071**	**001**	Nov 28, 2014
AA		UPSHER SMITH LABS	**453.6GM/BOT**	**A090313**	**001**	Dec 21, 2011

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARMS INC	15GM/BOT	A204071	002	Nov 28, 2014

SUSPENSION;ORAL, RECTAL

KIONEX

AA		ANI PHARMS	**15GM/60ML**	**A040028**	**001**	Sep 17, 2007

SODIUM POLYSTYRENE SULFONATE

AA		LYNE	**15GM/60ML**	**A214912**	**001**	Jun 10, 2025

SPS

AA	**+!**	CMP PHARMA INC	**15GM/60ML**	**A087859**	**001**	Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		HIKMA	**60MG/2ML (30MG/ML)**	**A209937**	**001**	Dec 09, 2019

SOTRADECOL

AP	**!**	MYLAN INSTITUTIONAL	**60MG/2ML (30MG/ML)**	**A040541**	**002**	Nov 12, 2004
	!		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

PEDMARK

	+!	FENNEC PHARMS INC	12.5GM/100ML (125MG/ML)	N212937	001	Sep 20, 2022

SODIUM THIOSULFATE

	+!	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

	+	ASTRAZENECA	5GM/PACKET	N207078	001	May 18, 2018
	+!		10GM/PACKET	N207078	002	May 18, 2018

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

	+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019
	+!		200MG/PACKET	N212480	002	Aug 28, 2019

SOFOSBUVIR

TABLET;ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019
+!		400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021
+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	200MG;50MG	N208341	002	Mar 19, 2020
+!		400MG;100MG	N208341	001	Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

+!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017

SOFPIRONIUM BROMIDE

GEL, METERED;TOPICAL

SOFDRA

+!	BOTANIX SB	EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347	001	Jun 18, 2024

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	ALEMBIC	**5MG**	**A205575**	**001**	May 20, 2019
AB		**10MG**	**A205575**	**002**	May 20, 2019
AB	ALKEM LABS LTD	**5MG**	**A210224**	**001**	May 20, 2019
AB		**10MG**	**A210224**	**002**	May 20, 2019
AB	ANNORA PHARMA	**5MG**	**A215761**	**001**	Jun 15, 2022
AB		**10MG**	**A215761**	**002**	Jun 15, 2022
AB	AUROBINDO PHARMA	**5MG**	**A206817**	**001**	Dec 27, 2022
AB		**10MG**	**A206817**	**002**	Dec 27, 2022
AB	BOSTAL	**5MG**	**A210281**	**001**	May 20, 2019
AB		**10MG**	**A210281**	**002**	May 20, 2019
AB	CHARTWELL RX	**5MG**	**A210582**	**001**	May 20, 2019
AB		**10MG**	**A210582**	**002**	May 20, 2019
AB	GLENMARK SPECLT	**5MG**	**A209239**	**001**	May 20, 2019
AB		**10MG**	**A209239**	**002**	May 20, 2019
AB	JUBILANT GENERICS	**5MG**	**A205484**	**001**	Oct 02, 2024
AB		**10MG**	**A205484**	**002**	Oct 02, 2024
AB	MACLEODS PHARMS LTD	**5MG**	**A204374**	**001**	Feb 20, 2024
AB		**10MG**	**A204374**	**002**	Feb 20, 2024
AB	MSN	**5MG**	**A210688**	**001**	May 20, 2019
AB		**10MG**	**A210688**	**002**	May 20, 2019
AB	NOVITIUM PHARMA	**5MG**	**A212214**	**001**	Sep 26, 2019
AB		**10MG**	**A212214**	**002**	Sep 26, 2019
AB	QILU	**5MG**	**A209333**	**001**	May 20, 2019
AB		**10MG**	**A209333**	**002**	May 20, 2019
AB	RISING	**5MG**	**A211423**	**001**	Dec 11, 2019
AB		**10MG**	**A211423**	**002**	Dec 11, 2019
AB	SCIEGEN PHARMS	**5MG**	**A211657**	**001**	May 20, 2019
AB **!**		**10MG**	**A211657**	**002**	May 20, 2019
AB	TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB		**10MG**	**A091464**	**002**	Apr 02, 2014
AB	UNICHEM	**5MG**	**A211701**	**001**	Aug 27, 2019
AB		**10MG**	**A211701**	**002**	Aug 27, 2019
AB	WATSON LABS INC	**5MG**	**A202551**	**001**	May 20, 2019
AB		**10MG**	**A202551**	**002**	May 20, 2019

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019
+!		EQ 150MG BASE	N211230	002	Jun 17, 2019

SONIDEGIB PHOSPHATE							
CAPSULE;ORAL							
ODOMZO							
	+!	SUN PHARM	EQ 200MG BASE		N205266	001	Jul 24, 2015
SORAFENIB TOSYLATE							
TABLET;ORAL							
NEXAVAR							
AB	**+!**	BAYER HLTHCARE	**EQ 200MG BASE**		**N021923**	**001**	Dec 20, 2005
SORAFENIB TOSYLATE							
AB		DR REDDYS	**EQ 200MG BASE**		**A216073**	**001**	Jun 07, 2022
AB		MYLAN	**EQ 200MG BASE**		**A207012**	**001**	Sep 10, 2020
AB		TEVA PHARMS USA INC	**EQ 200MG BASE**		**A209567**	**001**	Nov 12, 2020
AB		TORRENT	**EQ 200MG BASE**		**A217095**	**001**	Apr 12, 2023
AB		YABAO PHARM	**EQ 200MG BASE**		**A209050**	**001**	Nov 09, 2022
SORBITOL							
SOLUTION;IRRIGATION							
SORBITOL 3% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE	3GM/100ML		N017863	001	
SORBITOL 3.3% IN PLASTIC CONTAINER							
		B BRAUN	3.3GM/100ML		N016741	001	
SOTAGLIFLOZIN							
TABLET;ORAL							
INPEFA							
	+	LEXICON PHARMS INC	200MG		N216203	001	May 26, 2023
	+!		400MG		N216203	002	May 26, 2023
SOTALOL HYDROCHLORIDE							
SOLUTION;INTRAVENOUS							
SOTALOL HYDROCHLORIDE							
	+!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)		N022306	001	Jul 02, 2009
SOLUTION;ORAL							
SOTYLIZE							
	+!	AZURITY	5MG/ML (5MG/ML)		N205108	001	Oct 22, 2014
TABLET;ORAL							
BETAPACE							
AB	**+**	LEGACY PHARMA	**80MG**		**N019865**	**001**	Oct 30, 1992
AB	**+**		**120MG**		**N019865**	**005**	Apr 20, 1994
AB	**+!**		**160MG**		**N019865**	**002**	Oct 30, 1992
AB	**+**		**240MG**		**N019865**	**003**	Oct 30, 1992
BETAPACE AF							
AB	**+**	LEGACY PHARMA	**80MG**		**N021151**	**001**	Feb 22, 2000
AB	**+**		**120MG**		**N021151**	**002**	Feb 22, 2000
AB	**+!**		**160MG**		**N021151**	**003**	Feb 22, 2000
SORINE							
AB		AIPING PHARM INC	**80MG**		**A075500**	**001**	Apr 27, 2001
AB			**120MG**		**A075500**	**004**	Apr 27, 2001
AB			**160MG**		**A075500**	**002**	Apr 27, 2001
AB			**240MG**		**A075500**	**003**	Apr 27, 2001
SOTALOL HYDROCHLORIDE							
AB		APOTEX	**80MG**		**A076140**	**001**	Sep 26, 2002
AB			**80MG**		**A076214**	**001**	Aug 27, 2003
AB			**120MG**		**A076140**	**002**	Sep 26, 2002
AB			**120MG**		**A076214**	**002**	Aug 27, 2003
AB			**160MG**		**A076140**	**003**	Sep 26, 2002
AB			**160MG**		**A076214**	**003**	Aug 27, 2003
AB			**240MG**		**A076140**	**004**	Sep 26, 2002
AB		AUROBINDO PHARMA USA	**80MG**		**A077616**	**001**	Feb 07, 2007
AB			**120MG**		**A077616**	**002**	Feb 07, 2007
AB			**160MG**		**A077616**	**003**	Feb 07, 2007
AB		EPIC PHARMA LLC	**80MG**		**A077070**	**001**	Nov 04, 2005
AB			**120MG**		**A077070**	**002**	Nov 04, 2005
AB			**160MG**		**A077070**	**003**	Nov 04, 2005
AB		OXFORD PHARMS	**80MG**		**A075563**	**001**	Nov 07, 2003
AB			**120MG**		**A075563**	**002**	Nov 07, 2003
AB			**160MG**		**A075563**	**003**	Nov 07, 2003
AB			**240MG**		**A075563**	**004**	Nov 07, 2003
AB		REGCON HOLDINGS	**80MG**		**A207428**	**001**	Oct 21, 2016
AB			**80MG**		**A207429**	**001**	Nov 02, 2018
AB			**120MG**		**A207428**	**002**	Oct 21, 2016
AB			**120MG**		**A207429**	**002**	Nov 02, 2018

SOTALOL HYDROCHLORIDE
TABLET;ORAL
SOTALOL HYDROCHLORIDE

AB			**160MG**	**A207428**	**003**	Oct 21, 2016
AB			**160MG**	**A207429**	**003**	Nov 02, 2018
AB		TEVA	**80MG**	**A075429**	**001**	May 01, 2000
AB			**120MG**	**A075429**	**002**	May 01, 2000
AB			**160MG**	**A075429**	**003**	May 01, 2000
AB			**240MG**	**A075429**	**004**	May 01, 2000

SOTORASIB
TABLET;ORAL
LUMAKRAS

	+	AMGEN INC	120MG	N214665	001	May 28, 2021
	+		240MG	N214665	003	Jun 26, 2024
	+!		320MG	N214665	002	Jan 20, 2023

SOYBEAN OIL
INJECTABLE;INJECTION
INTRALIPID 20%

AP	**+!**	FRESENIUS	**20%**	**N018449**	**001**	
AP	**+!**		**20%**	**N020248**	**001**	Aug 07, 1996

NUTRILIPID 20%

AP	**+!**	B BRAUN	**20%**	**N019531**	**002**	May 28, 1993

INTRALIPID 30%

	+!	FRESENIUS	30%	N019942	001	Dec 30, 1993

SPARSENTAN
TABLET;ORAL
FILSPARI

	+	TRAVERE	200MG	N216403	001	Feb 17, 2023
	+!		400MG	N216403	002	Feb 17, 2023

SPINOSAD
SUSPENSION;TOPICAL
NATROBA

	+!	CIPHER	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE
SUSPENSION;ORAL
CAROSPIR

AB	**+!**	CMP DEV LLC	**25MG/5ML**	**N209478**	**001**	Aug 04, 2017

SPIRONOLACTONE

AB		AMNEAL	**25MG/5ML**	**A215572**	**001**	Sep 05, 2023
AB		HETERO LABS LTD III	**25MG/5ML**	**A218085**	**001**	Feb 21, 2025

TABLET;ORAL
ALDACTONE

AB	**+**	PFIZER	**25MG**	**N012151**	**009**	Dec 30, 1983
AB	**+**		**50MG**	**N012151**	**008**	Dec 30, 1982
AB	**+!**		**100MG**	**N012151**	**010**	Dec 30, 1983

SPIRONOLACTONE

AB		ACCORD HLTHCARE	**25MG**	**A203512**	**001**	Sep 19, 2016
AB			**50MG**	**A203512**	**002**	Sep 19, 2016
AB			**100MG**	**A203512**	**003**	Sep 19, 2016
AB		AMNEAL PHARMS	**25MG**	**A091426**	**001**	Jul 02, 2010
AB			**50MG**	**A091426**	**002**	Jul 02, 2010
AB			**100MG**	**A091426**	**003**	Jul 02, 2010
AB		ANNORA PHARMA	**25MG**	**A217761**	**001**	Jul 25, 2025
AB			**50MG**	**A217761**	**002**	Jul 25, 2025
AB			**100MG**	**A217761**	**003**	Jul 25, 2025
AB		AUROBINDO PHARMA	**25MG**	**A202187**	**001**	Mar 06, 2014
AB			**50MG**	**A202187**	**002**	Mar 06, 2014
AB			**100MG**	**A202187**	**003**	Mar 06, 2014
AB		GRAVITI PHARMS	**25MG**	**A219494**	**001**	Jan 23, 2025
AB			**50MG**	**A219494**	**002**	Jan 23, 2025
AB			**100MG**	**A219494**	**003**	Jan 23, 2025
AB		JUBILANT GENERICS	**25MG**	**A203253**	**001**	Apr 23, 2014
AB			**50MG**	**A203253**	**002**	Apr 23, 2014
AB			**100MG**	**A203253**	**003**	Apr 23, 2014
AB		MYLAN	**25MG**	**A040424**	**001**	Aug 20, 2001
AB			**50MG**	**A040424**	**002**	Aug 20, 2001
AB			**100MG**	**A040424**	**003**	Aug 20, 2001
AB		OXFORD PHARMS	**25MG**	**A040750**	**001**	Aug 29, 2006
AB			**50MG**	**A040750**	**002**	Aug 29, 2006
AB			**100MG**	**A040750**	**003**	Aug 29, 2006

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB		SUN PHARM INDUSTRIES	**25MG**	**A089424**	**001**	Jul 23, 1986
AB			**50MG**	**A089424**	**002**	Aug 11, 1999
AB			**100MG**	**A089424**	**003**	Aug 11, 1999
AB		ZYDUS PHARMS	**25MG**	**A205936**	**001**	Jul 18, 2018
AB			**50MG**	**A205936**	**002**	Jul 18, 2018
AB			**100MG**	**A205936**	**003**	Jul 18, 2018

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100%**	**N018802**	**001**	Oct 27, 1982

STERILE WATER FOR INJECTION

AP		AM REGENT	**100% (10ML)**	**A217341**	**001**	Aug 29, 2023
AP			**100% (20ML)**	**A217341**	**002**	Aug 29, 2023
AP			**100% (5ML)**	**A217341**	**003**	Feb 09, 2024
AP		FRESENIUS KABI USA	**100%**	**A209689**	**001**	Nov 24, 2017
AP		HIKMA	**100% (10ML)**	**A206369**	**001**	Sep 02, 2015
AP			**100%**	**A212735**	**001**	Jan 31, 2023
AP	**+!**	HOSPIRA	**100% (10ML)**	**N018801**	**002**	Oct 27, 1982
AP	**+!**		**100% (20ML)**	**N018801**	**003**	Oct 27, 1982
AP	**!**	MEDEFIL INC	**100% (5ML)**	**A211188**	**004**	Dec 02, 2019
AP			**100% (10ML)**	**A211188**	**005**	Dec 02, 2019
AP		NEPHRON	**100% (5ML)**	**A211222**	**001**	Feb 10, 2021
AP		NEXUS	**100% (10ML)**	**A217536**	**001**	Jul 11, 2023
AP			**100% (20ML)**	**A217536**	**002**	Jul 11, 2023

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**100%**	**N019633**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**100%**	**N018632**	**001**	Jun 30, 1982
AP	**+!**		**100%**	**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**	**A088400**	**001**	Jan 16, 1984
AP	**+!**	OTSUKA ICU MEDCL	**100%**	**N018233**	**001**	
AP	**+!**		**100%**	**N019869**	**001**	Dec 26, 1989

STERILE WATER FOR INJECTION

+!	HOSPIRA	100% (50ML)	N018801	004	Oct 27, 1982
+!		100% (100ML)	N018801	005	Oct 27, 1982
+!		100% (5.2ML)	N018801	006	May 02, 2023
	MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019
!		100% (2.5ML)	A211188	002	Dec 02, 2019
!		100% (3ML)	A211188	003	Dec 02, 2019

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT	**+**	BAXTER HLTHCARE	**100%**	**N017428**	**001**	

STERILE WATER FOR IRRIGATION

AT		FRESENIUS KABI USA	**100%**	**A216123**	**001**	Aug 12, 2024

STERILE WATER IN PLASTIC CONTAINER

AT	**+**	B BRAUN	**100%**	**N016734**	**001**	
AT		BAXTER HLTHCARE	**100%**	**N017866**	**001**	
AT		OTSUKA ICU MEDCL	**100%**	**N017513**	**001**	
AT			**100%**	**N018313**	**001**	

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

+	BIOCODEX SA	250MG	N206709	001	Aug 20, 2018
+!		500MG	N206709	002	Aug 20, 2018

FOR SUSPENSION;ORAL

DIACOMIT

+	BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018
+!		500MG/PACKET	N207223	002	Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

!	XGEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	**+!**	Q BIOMED	**1mCi/ML**	**N020134**	**001**	Jun 18, 1993

STRONTIUM CHLORIDE SR-89

AP		Q BIOMED	**1mCi/ML**	**A075941**	**001**	Jan 06, 2003

SUCCIMER

CAPSULE;ORAL

CHEMET

	+!	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	**+!**	SANDOZ	**20MG/ML**	**N008453**	**002**	

QUELICIN

AP	**+!**	HOSPIRA	**20MG/ML**	**N008845**	**006**	

SUCCINYLCHOLINE CHLORIDE

AP		AMNEAL	**20MG/ML**	**A211432**	**001**	Nov 16, 2018
AP		AMRING PHARMS	**20MG/ML**	**A210231**	**001**	Jun 04, 2018
AP		ASPIRO	**20MG/ML**	**A213810**	**001**	May 04, 2020
AP		BAXTER HLTHCARE CORP	**20MG/ML**	**A218878**	**001**	Sep 24, 2024
AP		BE PHARMS	**20MG/ML**	**A216003**	**001**	Feb 07, 2022
AP		DEVA HOLDING AS	**20MG/ML**	**A214491**	**001**	Dec 21, 2020
AP		DR REDDYS	**20MG/ML**	**A210698**	**001**	Aug 02, 2019
AP		FRESENIUS KABI USA	**20MG/ML**	**A211346**	**001**	Nov 20, 2020
AP			**20MG/ML**	**A217885**	**001**	Feb 21, 2025
AP		GLAND	**20MG/ML**	**A214246**	**001**	Jun 16, 2020
AP		HIKMA	**20MG/ML**	**A213229**	**001**	Jun 12, 2020
AP		MEITHEAL	**20MG/ML**	**A214514**	**001**	Oct 19, 2021
AP		MICRO LABS	**20MG/ML**	**A214879**	**001**	Nov 24, 2020
AP		REGCON HOLDINGS	**20MG/ML**	**A214308**	**001**	May 22, 2020
AP		SAGENT PHARMS INC	**20MG/ML**	**A215022**	**001**	Mar 29, 2021
AP		SOMERSET THERAPS LLC	**20MG/ML**	**A211589**	**001**	Jan 15, 2020
AP		UMEDICA	**20MG/ML**	**A211625**	**001**	May 19, 2020
AP	!	ZYDUS PHARMS	**20MG/ML**	**A209467**	**001**	May 04, 2018

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP		DR REDDYS	**100MG/5ML (20MG/ML)**	**A218467**	**001**	Jan 17, 2024
AP		FRESENIUS KABI USA	**100MG/5ML (20MG/ML)**	**A217884**	**001**	Feb 11, 2025
AP	**+!**	HIKMA	**100MG/5ML (20MG/ML)**	**N215143**	**001**	Aug 20, 2021
AP		STERISCIENCE	**100MG/5ML (20MG/ML)**	**A217873**	**001**	Jul 09, 2024

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

AB	**+!**	ABBVIE	**1GM/10ML**	**N019183**	**001**	Dec 16, 1993

SUCRALFATE

AB		ABON PHARMS LLC	**1GM/10ML**	**A216726**	**001**	Mar 21, 2024
AB		AMNEAL	**1GM/10ML**	**A209356**	**001**	Dec 02, 2019
AB		COSETTE	**1GM/10ML**	**A217126**	**001**	Nov 13, 2024
AB		GLENMARK PHARMS LTD	**1GM/10ML**	**A212141**	**001**	Jan 05, 2026
AB		MYLAN	**1GM/10ML**	**A212913**	**001**	Sep 12, 2022
AB		PADAGIS US	**1GM/10ML**	**A211780**	**001**	Apr 14, 2025
AB		PD PARTNERS	**1GM/10ML**	**A213549**	**001**	Jan 17, 2024
AB		STRIDES PHARMA	**1GM/10ML**	**A216474**	**001**	May 21, 2024
AB		VISTAPHARM LLC	**1GM/10ML**	**A211884**	**001**	Mar 15, 2022

TABLET;ORAL

CARAFATE

AB	**+!**	ABBVIE	**1GM**	**N018333**	**001**	

SUCRALFATE

AB		AMNEAL PHARMS	**1GM**	**A215576**	**001**	Apr 15, 2022
AB		CHARTWELL RX	**1GM**	**A074415**	**001**	Jun 08, 1998
AB		TEVA	**1GM**	**A070848**	**001**	Mar 29, 1996
AB		ZYDUS LIFESCIENCES	**1GM**	**A215705**	**001**	May 03, 2023

SUFENTANIL CITRATE
INJECTABLE;INJECTION
SUFENTA PRESERVATIVE FREE

AP	**+!**	RISING	**EQ 0.05MG BASE/ML**	**N019050**	**001**	May 04, 1984

SUFENTANIL CITRATE

AP		HIKMA	**EQ 0.05MG BASE/ML**	**A074413**	**001**	Dec 15, 1995
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001**	Dec 11, 1996

SUGAMMADEX SODIUM
SOLUTION;INTRAVENOUS
BRIDION

AP	**+**	MSD SUB MERCK	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**N022225**	**002**	Dec 15, 2015
AP	**+!**		**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022225**	**001**	Dec 15, 2015

SUGAMMADEX SODIUM

AP		ASPIRO	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**A214337**	**001**	Jun 09, 2023
AP			**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**A214337**	**002**	Jun 09, 2023
AP		B BRAUN MEDICAL	**EQ 200MG BASE/2ML (EQ 100MG BASE/ML)**	**A214279**	**001**	Aug 05, 2025

SULCONAZOLE NITRATE
CREAM;TOPICAL
EXELDERM

	+!	JOURNEY	1%	N018737	001	Feb 28, 1989

SOLUTION;TOPICAL
EXELDERM

	+!	JOURNEY	1%	N018738	001	Aug 30, 1985

SULFACETAMIDE SODIUM
LOTION;TOPICAL
KLARON

AB	**+!**	BAUSCH	**10%**	**N019931**	**001**	Dec 23, 1996

SULFACETAMIDE SODIUM

AB		FOUGERA PHARMS	**10%**	**A077015**	**001**	Nov 17, 2006
AB		PADAGIS US	**10%**	**A078649**	**001**	Mar 23, 2009

OINTMENT;OPHTHALMIC
SULFACETAMIDE SODIUM

	!	PADAGIS US	10%	A080029	001	

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT	**!**	BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994
AT		CHARTWELL RX	**10%**	**A089560**	**001**	Oct 18, 1988

SULFADIAZINE
TABLET;ORAL
SULFADIAZINE

	!	EPIC PHARMA LLC	500MG	A040091	001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE;INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	**!**	PHARMOBEDIENT	**80MG/ML;16MG/ML**	**A206607**	**001**	Aug 30, 2017
AP		SOMERSET	**80MG/ML;16MG/ML**	**A212231**	**001**	Jun 26, 2019
AP		TEVA PHARMS USA	**80MG/ML;16MG/ML**	**A073303**	**001**	Oct 31, 1991

SUSPENSION;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	**!**	AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB		CHARTWELL MOLECULAR	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007
AB		NOVITIUM PHARMA	**200MG/5ML;40MG/5ML**	**A214330**	**001**	Feb 08, 2022
AB		PRASCO	**200MG/5ML;40MG/5ML**	**A077612**	**001**	Nov 13, 2006

SULFATRIM PEDIATRIC

AB		PHARM ASSOC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983

TABLET;ORAL
BACTRIM

AB	**+**	SUN PHARM INDUSTRIES	**400MG;80MG**	**N017377**	**001**	

BACTRIM DS

AB	**+!**	SUN PHARM INDUSTRIES	**800MG;160MG**	**N017377**	**002**	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB			**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB		AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB			**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB		CHARTWELL MOLECULES	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB			**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB		GLENMARK PHARMS LTD	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010

SULFAMETHOXAZOLE; TRIMETHOPRIM						
TABLET;ORAL						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB			**800MG;160MG**	**A090828**	**001**	Dec 22, 2010
AB		SUN PHARM INDUSTRIES	**400MG;80MG**	**A071017**	**002**	Aug 25, 1986
AB			**800MG;160MG**	**A071017**	**001**	Aug 25, 1986
AB		VISTA PHARMS	**400MG;80MG**	**A076817**	**001**	Oct 07, 2005
AB			**800MG;160MG**	**A076817**	**002**	Oct 07, 2005
SULFASALAZINE						
TABLET;ORAL						
AZULFIDINE						
AB	**+!**	PFIZER	**500MG**	**N007073**	**001**	
SULFASALAZINE						
AB		CHARTWELL	**500MG**	**A080197**	**001**	
AB		NUVO PHARMS INC	**500MG**	**A040349**	**001**	Jan 11, 2002
AB		RISING	**500MG**	**A219046**	**001**	Nov 04, 2025
AB		WATSON LABS	**500MG**	**A085828**	**001**	
TABLET, DELAYED RELEASE;ORAL						
AZULFIDINE EN-TABS						
AB	**+!**	PFIZER	**500MG**	**N007073**	**002**	Apr 06, 1983
SULFASALAZINE						
AB		NUVO PHARMS INC	**500MG**	**A075339**	**001**	Jan 11, 2002
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES						
FOR SUSPENSION;INTRAVENOUS						
LUMASON						
	+!	BRACCO	60.7MG/25MG	N203684	001	Oct 15, 2014
SULINDAC						
TABLET;ORAL						
SULINDAC						
AB		EPIC PHARMA	**150MG**	**A072711**	**002**	Mar 25, 1991
AB			**200MG**	**A072711**	**001**	Mar 25, 1991
AB		SUN PHARM INDUSTRIES	**150MG**	**A072050**	**001**	Apr 17, 1991
AB			**200MG**	**A072051**	**001**	Apr 17, 1991
AB		WATSON LABS	**150MG**	**A071891**	**001**	Apr 03, 1990
AB	**!**		**200MG**	**A071795**	**001**	Apr 03, 1990
SUMATRIPTAN						
SPRAY;NASAL						
IMITREX						
AB	**+!**	GLAXOSMITHKLINE	**5MG/SPRAY**	**N020626**	**001**	Aug 26, 1997
AB	**+!**		**20MG/SPRAY**	**N020626**	**003**	Aug 26, 1997
SUMATRIPTAN						
AB		CIPLA	**20MG/SPRAY**	**A214209**	**001**	Feb 22, 2021
AB		LANNETT CO INC	**5MG/SPRAY**	**A204841**	**001**	Feb 19, 2016
AB			**20MG/SPRAY**	**A204841**	**002**	Feb 19, 2016
AB		PADAGIS ISRAEL	**5MG/SPRAY**	**A213465**	**002**	Sep 21, 2020
AB			**20MG/SPRAY**	**A213465**	**001**	Sep 21, 2020
AB		REGCON HOLDINGS	**20MG/SPRAY**	**A208967**	**001**	Feb 17, 2021
TOSYMRA						
	+!	TONIX MEDS	10MG/SPRAY	N210884	001	Jan 25, 2019
SUMATRIPTAN SUCCINATE						
INJECTABLE;SUBCUTANEOUS						
IMITREX STATDOSE						
AB	**+!**	GLAXOSMITHKLINE	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**N020080**	**002**	Feb 01, 2006
AB	**+!**		**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**003**	Dec 23, 1996
SUMATRIPTAN SUCCINATE						
AB		ALEMBIC	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**A213518**	**001**	Nov 06, 2025
AB			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A213518**	**002**	Nov 06, 2025
AB		DR REDDYS	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090495**	**001**	Jan 29, 2014
AB		SUN PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090358**	**001**	Jun 21, 2011
AP		CAPLIN	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A213998**	**001**	Jul 13, 2021
AP	**!**	EUGIA PHARMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A202758**	**001**	Apr 23, 2013
AP		FRESENIUS KABI USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079242**	**001**	Mar 02, 2009
AP		HIKMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079123**	**001**	Feb 06, 2009
AP			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A200183**	**001**	Sep 16, 2013
AP		ONESOURCE SPECIALTY	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A215651**	**001**	Nov 21, 2024
AP		WOCKHARDT BIO AG	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078593**	**001**	Feb 06, 2009

SUMATRIPTAN SUCCINATE

POWDER;NASAL

ONZETRA XSAIL

+!	CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+	TONIX MEDS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016

TABLET;ORAL

IMITREX

AB	**+**	GLAXOSMITHKLINE	**EQ 25MG BASE**	**N020132**	**002**	Jun 01, 1995
AB	**+**		**EQ 50MG BASE**	**N020132**	**003**	Jun 01, 1995
AB	**+!**		**EQ 100MG BASE**	**N020132**	**001**	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078327**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078327**	**003**	Aug 10, 2009
AB		DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076847**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076847**	**003**	Aug 10, 2009
AB		IPCA LABS LTD	**EQ 25MG BASE**	**A206019**	**001**	Jul 15, 2025
AB			**EQ 50MG BASE**	**A206019**	**002**	Jul 15, 2025
AB			**EQ 100MG BASE**	**A206019**	**003**	Jul 15, 2025
AB		MYLAN	**EQ 25MG BASE**	**A077744**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A077744**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A077744**	**003**	Aug 10, 2009
AB		ORBION PHARMS	**EQ 25MG BASE**	**A078284**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078284**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078284**	**003**	Aug 10, 2009
AB		VKT PHARMA	**EQ 25MG BASE**	**A219036**	**001**	Dec 31, 2024
AB			**EQ 50MG BASE**	**A219036**	**002**	Dec 31, 2024
AB			**EQ 100MG BASE**	**A219036**	**003**	Dec 31, 2024
AB		WATSON LABS	**EQ 25MG BASE**	**A076933**	**001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076933**	**002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076933**	**003**	Aug 10, 2009
AB		ZHEJIANG	**EQ 25MG BASE**	**A200263**	**001**	Jun 19, 2012
AB			**EQ 50MG BASE**	**A200263**	**002**	Jun 19, 2012
AB			**EQ 100MG BASE**	**A200263**	**003**	Jun 19, 2012

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB		DR REDDYS	**EQ 12.5MG BASE**	**A215843**	**001**	Apr 11, 2022
AB			**EQ 25MG BASE**	**A215843**	**002**	Apr 11, 2022
AB			**EQ 37.5MG BASE**	**A215843**	**003**	Apr 11, 2022
AB			**EQ 50MG BASE**	**A215843**	**004**	Apr 11, 2022
AB		EUGIA PHARMA	**EQ 12.5MG BASE**	**A218615**	**001**	Mar 14, 2024
AB			**EQ 25MG BASE**	**A218615**	**002**	Mar 14, 2024
AB			**EQ 37.5MG BASE**	**A218615**	**003**	Mar 14, 2024
AB			**EQ 50MG BASE**	**A218615**	**004**	Mar 14, 2024
AB		FOSUN WANBANG	**EQ 12.5MG BASE**	**A218012**	**001**	Aug 21, 2023
AB			**EQ 25MG BASE**	**A218012**	**002**	Aug 21, 2023
AB			**EQ 37.5MG BASE**	**A218012**	**003**	Aug 21, 2023
AB			**EQ 50MG BASE**	**A218012**	**004**	Aug 21, 2023
AB		MSN	**EQ 12.5MG BASE**	**A214824**	**001**	Feb 14, 2025
AB			**EQ 25MG BASE**	**A214824**	**002**	Feb 14, 2025
AB			**EQ 37.5MG BASE**	**A214824**	**003**	Feb 14, 2025
AB			**EQ 50MG BASE**	**A214824**	**004**	Feb 14, 2025
AB		MYLAN	**EQ 12.5MG BASE**	**A201275**	**001**	Dec 06, 2021
AB			**EQ 25MG BASE**	**A201275**	**002**	Dec 06, 2021
AB			**EQ 37.5MG BASE**	**A201275**	**003**	Dec 06, 2021
AB			**EQ 50MG BASE**	**A201275**	**004**	Dec 06, 2021
AB		NATCO PHARMA	**EQ 12.5MG BASE**	**A218024**	**001**	Oct 24, 2023
AB			**EQ 25MG BASE**	**A218024**	**002**	Oct 24, 2023
AB			**EQ 37.5MG BASE**	**A218024**	**003**	Oct 24, 2023
AB			**EQ 50MG BASE**	**A218024**	**004**	Oct 24, 2023
AB		SUN PHARM	**EQ 12.5MG BASE**	**A213914**	**001**	Aug 16, 2021
AB			**EQ 25MG BASE**	**A213914**	**002**	Aug 16, 2021
AB			**EQ 37.5MG BASE**	**A213914**	**003**	Aug 16, 2021
AB			**EQ 50MG BASE**	**A213914**	**004**	Aug 16, 2021
AB		TEVA PHARMS USA	**EQ 12.5MG BASE**	**A213803**	**001**	Nov 30, 2021
AB			**EQ 25MG BASE**	**A213803**	**002**	Nov 30, 2021
AB			**EQ 37.5MG BASE**	**A213803**	**003**	Nov 30, 2021
AB			**EQ 50MG BASE**	**A213803**	**004**	Nov 30, 2021

SUNITINIB MALATE

CAPSULE;ORAL

SUTENT

AB	**+**	CPPI CV	**EQ 12.5MG BASE**	**N021938**	**001**	Jan 26, 2006
AB	**+**		**EQ 25MG BASE**	**N021938**	**002**	Jan 26, 2006
AB	**+**		**EQ 37.5MG BASE**	**N021938**	**004**	Mar 31, 2009
AB	**+!**		**EQ 50MG BASE**	**N021938**	**003**	Jan 26, 2006

SUNVOZERTINIB

TABLET;ORAL

ZEGFROVY

+	DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025
+!		200MG	N219839	002	Jul 02, 2025

SUVOREXANT

TABLET;ORAL

BELSOMRA

+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
+		10MG	N204569	002	Aug 13, 2014
+		15MG	N204569	003	Aug 13, 2014
+!		20MG	N204569	004	Aug 13, 2014

SUZETRIGINE

TABLET;ORAL

JOURNAVX

+!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025

TACROLIMUS

CAPSULE;ORAL

PROGRAF

AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB	**+**		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB	**+!**		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994

TACROLIMUS

AB	AJENAT PHARMS	**EQ 0.5MG BASE**	**A206651**	**001**	Nov 30, 2017
AB		**EQ 1MG BASE**	**A206651**	**002**	Nov 30, 2017
AB		**EQ 5MG BASE**	**A206651**	**003**	Nov 30, 2017
AB	ALKEM LABS LTD	**EQ 0.5MG BASE**	**A203740**	**001**	Nov 12, 2020
AB		**EQ 1MG BASE**	**A203740**	**002**	Nov 12, 2020
AB		**EQ 5MG BASE**	**A203740**	**003**	Nov 12, 2020
AB	BIOCON PHARMA	**EQ 0.5MG BASE**	**A212297**	**001**	Nov 10, 2020
AB		**EQ 1MG BASE**	**A212297**	**002**	Nov 10, 2020
AB		**EQ 5MG BASE**	**A212297**	**003**	Nov 10, 2020
AB	CONCORD BIOTECH LTD	**EQ 0.5MG BASE**	**A213112**	**001**	Nov 10, 2020
AB		**EQ 1MG BASE**	**A213112**	**002**	Nov 10, 2020
AB		**EQ 5MG BASE**	**A213112**	**003**	Nov 10, 2020
AB	DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB		**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB		**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB	GLENMARK PHARMS LTD	**EQ 0.5MG BASE**	**A206662**	**001**	Nov 10, 2020
AB		**EQ 1MG BASE**	**A206662**	**002**	Nov 10, 2020
AB		**EQ 5MG BASE**	**A206662**	**003**	Nov 10, 2020
AB	MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB		**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB		**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB	PANACEA	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB		**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB		**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB	SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB		**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB		**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB	STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB		**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB		**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014
BX	ACCORD HLTHCARE	EQ 0.5MG BASE	A091195	001	Aug 31, 2011
BX		EQ 1MG BASE	A091195	002	Aug 31, 2011
BX		EQ 5MG BASE	A091195	003	Aug 31, 2011

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N204096**	**001**	Jul 19, 2013
AB	**+**		**EQ 1MG BASE**	**N204096**	**002**	Jul 19, 2013
AB	**+!**		**EQ 5MG BASE**	**N204096**	**003**	Jul 19, 2013

TACROLIMUS

AB	CHENGDU	**EQ 0.5MG BASE**	**A215012**	**001**	Jan 25, 2024

TACROLIMUS						
CAPSULE, EXTENDED RELEASE;ORAL						
TACROLIMUS						
AB			**EQ 1MG BASE**	**A215012**	**002**	Jan 25, 2024
AB			**EQ 5MG BASE**	**A215012**	**003**	Jan 25, 2024
FOR SUSPENSION;ORAL						
PROGRAF						
	+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
	+!		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018
INJECTABLE;INJECTION						
PROGRAF						
AP	**+!**	ASTELLAS	**EQ 5MG BASE/ML**	**N050709**	**001**	Apr 08, 1994
TACROLIMUS						
AP		NEXUS	**EQ 5MG BASE/ML**	**A217108**	**001**	Feb 12, 2025
OINTMENT;TOPICAL						
PROTOPIC						
AB	**+!**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+!**		**0.1%**	**N050777**	**002**	Dec 08, 2000
TACROLIMUS						
AB		ACCORD HLTHCARE	**0.03%**	**A211688**	**001**	Jan 31, 2019
AB			**0.1%**	**A211688**	**002**	Jan 31, 2019
AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
AB		GLENMARK PHARMS LTD	**0.03%**	**A210393**	**002**	Aug 16, 2023
AB			**0.1%**	**A210393**	**001**	Apr 16, 2018
BX		ENCUBE	0.1%	A212387	001	Oct 10, 2023
TABLET, EXTENDED RELEASE;ORAL						
ENVARSUS XR						
	+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
	+		EQ 1MG BASE	N206406	002	Jul 10, 2015
	+!		EQ 4MG BASE	N206406	003	Jul 10, 2015
TADALAFIL						
SUSPENSION;ORAL						
TADLIQ						
	+!	CMP DEV LLC	20MG/5ML	N214522	001	Jun 17, 2022
TABLET;ORAL						
CIALIS						
AB1	**+**	LILLY	**5MG**	**N021368**	**001**	Nov 21, 2003
AB1	**+**		**10MG**	**N021368**	**002**	Nov 21, 2003
AB1	**+!**		**20MG**	**N021368**	**003**	Nov 21, 2003
TADALAFIL						
AB1		ACCORD HLTHCARE	**2.5MG**	**A209167**	**001**	Mar 26, 2019
AB1			**5MG**	**A209167**	**002**	Mar 26, 2019
AB1			**10MG**	**A209167**	**003**	Oct 23, 2019
AB1			**20MG**	**A209167**	**004**	Mar 26, 2019
AB1		AJANTA PHARMA LTD	**2.5MG**	**A209654**	**001**	Mar 26, 2019
AB1			**5MG**	**A209654**	**002**	Mar 26, 2019
AB1			**10MG**	**A209654**	**003**	Mar 26, 2019
AB1			**20MG**	**A209654**	**004**	Mar 26, 2019
AB1		ALEMBIC	**2.5MG**	**A204809**	**001**	Mar 26, 2019
AB1			**5MG**	**A204809**	**002**	Mar 26, 2019
AB1			**10MG**	**A204809**	**003**	Mar 26, 2019
AB1			**20MG**	**A204809**	**004**	Mar 26, 2019
AB1		AMNEAL PHARMS CO	**2.5MG**	**A209744**	**001**	Mar 26, 2019
AB1			**5MG**	**A209744**	**002**	Mar 26, 2019
AB1			**10MG**	**A209744**	**003**	Mar 26, 2019
AB1			**20MG**	**A209744**	**004**	Mar 26, 2019
AB1		AUROBINDO PHARMA LTD	**2.5MG**	**A206285**	**001**	Mar 26, 2019
AB1			**5MG**	**A206285**	**002**	Mar 26, 2019
AB1			**10MG**	**A206285**	**003**	Mar 26, 2019
AB1			**20MG**	**A206285**	**004**	Mar 26, 2019
AB1		CIPLA	**2.5MG**	**A209539**	**001**	Mar 26, 2019
AB1			**5MG**	**A209539**	**002**	Mar 26, 2019
AB1			**10MG**	**A209539**	**003**	Mar 26, 2019
AB1			**20MG**	**A209539**	**004**	Mar 26, 2019
AB1		DR REDDYS	**2.5MG**	**A210069**	**001**	Mar 26, 2019
AB1			**5MG**	**A210069**	**002**	Mar 26, 2019
AB1			**10MG**	**A210069**	**003**	Mar 26, 2019
AB1			**20MG**	**A210069**	**004**	Mar 26, 2019
AB1		FOURRTS LABS	**2.5MG**	**A217606**	**001**	Aug 13, 2024
AB1			**5MG**	**A217606**	**002**	Aug 13, 2024

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1		10MG	A217606	003	Aug 13, 2024
AB1		20MG	A217606	004	Aug 13, 2024
AB1	HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020
AB1		5MG	A208824	002	Oct 27, 2020
AB1		10MG	A208824	003	Oct 27, 2020
AB1		20MG	A208824	004	Oct 27, 2020
AB1	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019
AB1		5MG	A209908	002	Mar 26, 2019
AB1		10MG	A209908	003	Mar 26, 2019
AB1		20MG	A209908	004	Mar 26, 2019
AB1	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019
AB1		5MG	A210567	002	Mar 26, 2019
AB1		10MG	A210567	003	Mar 26, 2019
AB1		20MG	A210567	004	Mar 26, 2019
AB1	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019
AB1		5MG	A207244	002	Oct 07, 2019
AB1		10MG	A207244	003	Oct 07, 2019
AB1		20MG	A207244	004	Oct 07, 2019
AB1	NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023
AB1		10MG	A215949	002	Mar 03, 2023
AB1		20MG	A215949	003	Mar 03, 2023
AB1	PRINSTON INC	2.5MG	A210609	001	Aug 11, 2022
AB1		5MG	A210609	002	Aug 11, 2022
AB1		10MG	A210609	003	Aug 11, 2022
AB1		20MG	A210609	004	Aug 11, 2022
AB1	QILU PHARM HAINAN	2.5MG	A210420	001	Mar 26, 2019
AB1		5MG	A210420	002	Mar 26, 2019
AB1		10MG	A210420	003	Mar 26, 2019
AB1		20MG	A210420	004	Mar 26, 2019
AB1	SHANDONG	2.5MG	A216279	002	Dec 04, 2024
AB1		5MG	A216279	003	Dec 04, 2024
AB1		10MG	A216279	004	Dec 04, 2024
AB1		20MG	A216279	001	Mar 04, 2024
AB1	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019
AB1		5MG	A208934	002	Mar 26, 2019
AB1		10MG	A208934	003	Mar 26, 2019
AB1		20MG	A208934	004	Mar 26, 2019
AB1	SUNSHINE	2.5MG	A211335	001	Mar 26, 2019
AB1		5MG	A211335	002	Mar 26, 2019
AB1		10MG	A211335	003	Mar 26, 2019
AB1		20MG	A211335	004	Mar 26, 2019
AB1	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018
AB1		5MG	A090141	002	May 22, 2018
AB1		10MG	A090141	003	May 22, 2018
AB1		20MG	A090141	004	May 22, 2018
AB1	TORRENT	2.5MG	A211839	001	Mar 26, 2019
AB1		5MG	A211839	002	Mar 26, 2019
AB1		10MG	A211839	003	Mar 26, 2019
AB1		20MG	A211839	004	Mar 26, 2019
AB1	UMEDICA	2.5MG	A211298	001	Oct 23, 2020
AB1		5MG	A211298	002	Oct 23, 2020
AB1		10MG	A211298	003	Oct 23, 2020
AB1		20MG	A211298	004	Oct 23, 2020
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019
AB1		5MG	A209250	002	Mar 26, 2019
AB1		10MG	A209250	003	Mar 26, 2019
AB1		20MG	A209250	004	Mar 26, 2019
AB1	VKT PHARMA	2.5MG	A215556	001	Nov 04, 2021
AB1		5MG	A215556	002	Nov 04, 2021
AB1		10MG	A215556	003	Nov 04, 2021
AB1		20MG	A215556	004	Nov 04, 2021
AB1	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019
AB1		5MG	A205885	002	Mar 29, 2019
AB1		10MG	A205885	003	Mar 29, 2019
AB1		20MG	A205885	004	Mar 29, 2019
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019
AB1		5MG	A206693	002	Mar 26, 2019
AB1		10MG	A206693	003	Mar 26, 2019
AB1		20MG	A206693	004	Mar 26, 2019

TADALAFIL

TABLET;ORAL

ADCIRCA

AB2	**+!**	ELI LILLY CO	**20MG**	**N022332**	**001**	May 22, 2009

ALYQ

AB2		TEVA PHARMS INC	**20MG**	**A216932**	**001**	Oct 12, 2022
AB2		TEVA PHARMS USA	**20MG**	**A209942**	**001**	Feb 05, 2019

TADALAFIL

AB2		AJANTA PHARMA LTD	**20MG**	**A210392**	**001**	Feb 05, 2019
AB2		AUROBINDO PHARMA LTD	**20MG**	**A206286**	**001**	Feb 05, 2019
AB2		CHARTWELL RX	**20MG**	**A210572**	**001**	Feb 05, 2019
AB2		CIPLA	**20MG**	**A210255**	**001**	Feb 05, 2019
AB2		DR REDDYS	**20MG**	**A210145**	**001**	Feb 05, 2019
AB2		HETERO LABS LTD III	**20MG**	**A209907**	**001**	Feb 05, 2019
AB2		MACLEODS PHARMS LTD	**20MG**	**A207290**	**001**	Oct 16, 2019
AB2		PRINSTON INC	**20MG**	**A210608**	**001**	Aug 11, 2022
AB2		SUNSHINE	**20MG**	**A213496**	**001**	Nov 23, 2020
AB2		TORRENT	**20MG**	**A212062**	**001**	Mar 26, 2019

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

	+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

	+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

	+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018

KRINTAFEL

	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT		INGENUS PHARMS LLC	**0.0015%**	**A218002**	**001**	Apr 05, 2024
AT		MICRO LABS	**0.0015%**	**A209051**	**001**	Aug 19, 2019
AT		SANDOZ	**0.0015%**	**A209040**	**001**	Jan 28, 2022

ZIOPTAN

AT	**+!**	THEA PHARMA	**0.0015%**	**N202514**	**001**	Feb 10, 2012

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

	+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024
	+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024
	+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024
	+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024
	+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024
	+!		EQ 1MG BASE	N217439	006	Mar 07, 2024

TALC

AEROSOL;INTRAPLEURAL

SCLEROSOL

	+!	SCIARRA LABS	4GM/SPRAY	N020587	001	Dec 24, 1997

POWDER;INTRAPLEURAL

STERITALC

	+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017
	+		3GM/VIAL	N205555	002	May 01, 2017
	+!		4GM/VIAL	N205555	003	May 01, 2017

TALC

	+!	SCIARRA LABS	5GM/BOT	N021388	001	Dec 15, 2003

TALETRECTINIB ADIPATE

CAPSULE;ORAL

IBTROZI

	+!	NUVATION	EQ 200MG BASE	N219713	001	Jun 11, 2025

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

	+!	MAYNE PHARMA COMMRCL	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATE

AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		DR REDDYS LABS SA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**!**		**EQ 20MG BASE**	**A075797**	**002**	Feb 20, 2003
AB		EUGIA PHARMA	**EQ 10MG BASE**	**A213358**	**001**	Aug 14, 2020
AB			**EQ 20MG BASE**	**A213358**	**002**	Aug 14, 2020
AB		MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
AB		ZYDUS PHARMS	**EQ 10MG BASE**	**A206694**	**001**	Oct 27, 2017
AB			**EQ 20MG BASE**	**A206694**	**002**	Oct 27, 2017

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB		ALKEM LABS LTD	**0.4MG**	**A207405**	**001**	Aug 11, 2017
AB		ASCENT PHARMS INC	**0.4MG**	**A214730**	**001**	May 04, 2022
AB		AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013
AB		CHARTWELL RX	**0.4MG**	**A211885**	**001**	Oct 17, 2019
AB		IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010
AB		MACLEODS PHARMS LTD	**0.4MG**	**A204645**	**001**	Jan 20, 2017
AB		RISING	**0.4MG**	**A219767**	**001**	May 01, 2025
AB		SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010
AB		SCIEGEN PHARMS	**0.4MG**	**A078938**	**001**	Apr 27, 2010
AB		SYNTHON BV	**0.4MG**	**A078801**	**001**	Apr 27, 2010
AB		TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010
AB	**!**	ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

TABLET;ORAL

NUCYNTA

	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008
	+		EQ 75MG BASE	N022304	002	Nov 20, 2008
	+!		EQ 100MG BASE	N022304	003	Nov 20, 2008

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011
	+		EQ 100MG BASE	N200533	002	Aug 25, 2011
	+		EQ 150MG BASE	N200533	003	Aug 25, 2011
	+		EQ 200MG BASE	N200533	004	Aug 25, 2011
	+!		EQ 250MG BASE	N200533	005	Aug 25, 2011

TAPINAROF

CREAM;TOPICAL

VTAMA

	+!	ORGANON LLC	1%	N215272	001	May 23, 2022

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

AB	**+!**	VANDA PHARMS INC	**20MG**	**N205677**	**001**	Jan 31, 2014

TASIMELTEON

AB		APOTEX	**20MG**	**A211607**	**001**	Dec 20, 2022
AB		MSN	**20MG**	**A211654**	**001**	Jan 12, 2023
AB		TEVA PHARMS USA INC	**20MG**	**A211601**	**001**	Dec 12, 2022

SUSPENSION;ORAL

HETLIOZ LQ

	+!	VANDA PHARMS INC	4MG/ML	N214517	001	Dec 01, 2020

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB		ALEMBIC	**5%**	**A212188**	**001**	Oct 21, 2020
AB		CHARTWELL RX	**5%**	**A211963**	**001**	Feb 03, 2021
AB		CIPLA	**5%**	**A212224**	**001**	Feb 09, 2021
AB	**!**	ENCUBE	**5%**	**A211297**	**001**	Oct 13, 2020
AB		LUPIN LTD	**5%**	**A212168**	**001**	Feb 08, 2021

TAVABOROLE
SOLUTION;TOPICAL
TAVABOROLE
AB PADAGIS US **5%** **A211848 001** Oct 13, 2020
AB ZYDUS LIFESCIENCES **5%** **A212294 001** Apr 10, 2023

TAZAROTENE
AEROSOL, FOAM;TOPICAL
FABIOR
+! MAYNE PHARMA 0.1% N202428 001 May 11, 2012
CREAM;TOPICAL
AVAGE
AB **+!** ALMIRALL **0.1%** **N021184 003** Sep 30, 2002
TAZAROTENE
AB COSETTE **0.05%** **A208662 002** Mar 10, 2025
AB **0.1%** **A208662 001** Dec 22, 2017
AB LONG GROVE PHARMS **0.05%** **A214560 001** Nov 24, 2025
AB PADAGIS ISRAEL **0.05%** **A217075 001** Jul 15, 2024
AB SUN PHARMA CANADA **0.1%** **A208258 001** Apr 03, 2017
TAZORAC
AB **+!** ALMIRALL **0.05%** **N021184 001** Sep 29, 2000
AB **+!** **0.1%** **N021184 002** Sep 29, 2000
GEL;TOPICAL
TAZAROTENE
AB COSETTE **0.05%** **A215433 001** Sep 13, 2022
AB **0.1%** **A214136 001** Sep 13, 2022
AB PADAGIS ISRAEL **0.05%** **A213079 001** Apr 25, 2023
AB **0.1%** **A213079 002** Apr 25, 2023
AB SOLARIS PHARMA CORP **0.05%** **A213644 001** Mar 20, 2023
AB **0.1%** **A213644 002** Mar 20, 2023
TAZORAC
AB **+!** ALMIRALL **0.05%** **N020600 001** Jun 13, 1997
AB **+!** **0.1%** **N020600 002** Jun 13, 1997
LOTION;TOPICAL
ARAZLO
+! BAUSCH 0.045% N211882 001 Dec 18, 2019

TAZEMETOSTAT HYDROBROMIDE
TABLET;ORAL
TAZVERIK
+! EPIZYME INC EQ 200MG BASE N211723 001 Jan 23, 2020

TECHNETIUM TC-99M BICISATE KIT
INJECTABLE;INJECTION
NEUROLITE
+! LANTHEUS MEDCL N/A N020256 001 Nov 23, 1994

TECHNETIUM TC-99M EXAMETAZIME KIT
INJECTABLE;INJECTION
CERETEC
+! GE HEALTHCARE N/A N019829 001 Dec 30, 1988
POWDER;INTRAVENOUS
DRAX EXAMETAZIME
JUBILANT N/A N208870 001 Aug 17, 2017

TECHNETIUM TC-99M LABELED CARBON
AEROSOL;INHALATION
TECHNEGAS KIT
+! CYCLOMEDICA N/A N022335 001 Sep 29, 2023

TECHNETIUM TC-99M MEBROFENIN KIT
INJECTABLE;INJECTION
CHOLETEC
AP **+!** BRACCO **N/A** **N018963 001** Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN
AP SUN PHARM INDS INC **N/A** **A078242 001** Jan 29, 2008

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-25
+! JUBILANT N/A N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
CIS-MDP
AP SUN PHARM INDS INC **N/A** **N018124 001**
TECHNETIUM TC-99M MEDRONATE KIT
AP CARDINAL HEALTH 414 **N/A** **N018107 001**

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3
AP **+!** CURIUM **N/A** **N019882 001** Jun 15, 1990
TECHNETIUM TC99M MERTIATIDE KIT
AP MEDI-RADIOPHARMA **N/A** **A206489 001** Feb 06, 2020
AP SUN PHARM INDS INC **N/A** **A208994 001** Jul 12, 2019
POWDER;INTRAVENOUS
TECHNETIUM TC 99M MERTIATIDE KIT
+! JUBILANT DRAXIMAGE N/A N216820 001 Jan 30, 2023

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN HDP
+! CURIUM N/A N018321 001

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
DRAXIMAGE DTPA
AP **+!** JUBILANT **N/A** **N018511 001** Dec 29, 1989
TECHNETIUM TC-99M PENTETATE KIT
AP CURIUM **N/A** **A215146 001** Mar 26, 2025

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO
AP SUN PHARM INDS INC **N/A** **N019039 001** Jun 30, 1987
TECHNESCAN PYP KIT
AP CURIUM **N/A** **N017538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG
+! CURIUM N/A N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
CARDIOLITE
AP **+!** LANTHEUS MEDCL **N/A** **N019785 001** Dec 21, 1990
TECHNETIUM TC 99M SESTAMIBI
AP CARDINAL HEALTH 414 **N/A** **A078809 001** Apr 28, 2009
AP CURIUM **N/A** **A078098 001** Sep 22, 2008
AP JUBILANT DRAXIMAGE **N/A** **A078806 001** Apr 29, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INTRAVENOUS
TECHNELITE
+! LANTHEUS MEDCL 1-20 CI/GENERATOR N017771 002 Feb 12, 2014
ULTRA-TECHNEKOW V4
+! CURIUM 1-19 CI/GENERATOR N017243 003 Feb 18, 2014

TECHNETIUM TC-99M SUCCIMER
POWDER;INTRAVENOUS
NEPHROSCAN
+! THERAGNOSTICS N/A N214993 001 Feb 18, 2022

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
AN-SULFUR COLLOID
AP **+!** SUN PHARM INDS INC **N/A** **N017858 001**
TECHNETIUM TC-99M SULFUR COLLOID KIT
AP JUBILANT **N/A** **A213516 001** Nov 09, 2023

TECHNETIUM TC-99M TETROFOSMIN KIT
INJECTABLE;INJECTION
MYOVIEW
+! MEDI-PHYSICS N/A N020372 001 Feb 09, 1996
MYOVIEW 30ML
+! MEDI-PHYSICS N/A N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT							
INJECTABLE;INJECTION							
LYMPHOSEEK KIT							
	+!	CARDINAL HEALTH 414	N/A		N202207	001	Mar 13, 2013
TECOVIRIMAT							
CAPSULE;ORAL							
TPOXX							
	+!	SIGA TECHNOLOGIES	200MG		N208627	001	Jul 13, 2018
SOLUTION;INTRAVENOUS							
TPOXX							
	+!	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)		N214518	001	May 18, 2022
TEDIZOLID PHOSPHATE							
POWDER;INTRAVENOUS							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG/VIAL		N205436	001	Jun 20, 2014
TABLET;ORAL							
SIVEXTRO							
	+!	CUBIST PHARMS LLC	200MG		N205435	001	Jun 20, 2014
TEDUGLUTIDE							
POWDER;SUBCUTANEOUS							
GATTEX KIT							
	+!	TAKEDA PHARMS USA	5MG/VIAL		N203441	001	Dec 21, 2012
TELAVANCIN HYDROCHLORIDE							
POWDER;INTRAVENOUS							
VIBATIV							
	+!	CUMBERLAND	EQ 750MG BASE/VIAL		N022110	002	Sep 11, 2009
TELMISARTAN							
TABLET;ORAL							
MICARDIS							
AB	**+**	BOEHRINGER INGELHEIM	**40MG**		**N020850**	**001**	Nov 10, 1998
TELMISARTAN							
AB		ALEMBIC	**20MG**		**A202130**	**001**	Jul 07, 2014
AB			**40MG**		**A202130**	**002**	Jul 07, 2014
AB			**80MG**		**A202130**	**003**	Jul 07, 2014
AB		AMNEAL PHARMS	**20MG**		**A204415**	**001**	Sep 08, 2015
AB			**40MG**		**A204415**	**002**	Sep 08, 2015
AB			**80MG**		**A204415**	**003**	Sep 08, 2015
AB		AUROBINDO PHARMA	**20MG**		**A206511**	**001**	Sep 03, 2015
AB			**40MG**		**A206511**	**002**	Sep 03, 2015
AB			**80MG**		**A206511**	**003**	Sep 03, 2015
AB		CADILA PHARMS LTD	**20MG**		**A208605**	**001**	Jul 25, 2017
AB			**40MG**		**A208605**	**002**	Jul 25, 2017
AB			**80MG**		**A208605**	**003**	Jul 25, 2017
AB		CHARTWELL RX	**20MG**		**A078710**	**001**	Jan 08, 2014
AB			**40MG**		**A078710**	**002**	Jan 08, 2014
AB			**80MG**		**A078710**	**003**	Jan 08, 2014
AB		GLENMARK PHARMS LTD	**20MG**		**A090032**	**001**	Jul 07, 2014
AB			**40MG**		**A090032**	**002**	Jul 07, 2014
AB			**80MG**		**A090032**	**003**	Jul 07, 2014
AB		INVENTIA	**20MG**		**A205150**	**001**	Oct 30, 2015
AB			**40MG**		**A205150**	**002**	Oct 30, 2015
AB	**!**		**80MG**		**A205150**	**003**	Oct 30, 2015
AB		JUBILANT GENERICS	**20MG**		**A204164**	**001**	Aug 22, 2016
AB			**40MG**		**A204164**	**002**	Aug 22, 2016
AB			**80MG**		**A204164**	**003**	Aug 22, 2016
AB		MACLEODS PHARMS LTD	**20MG**		**A203986**	**001**	Jan 15, 2025
AB			**40MG**		**A203986**	**002**	Jan 15, 2025
AB			**80MG**		**A203986**	**003**	Jan 15, 2025
AB		MANKIND PHARMA	**20MG**		**A218157**	**001**	Oct 15, 2024
AB			**40MG**		**A218157**	**002**	Oct 15, 2024
AB			**80MG**		**A218157**	**003**	Oct 15, 2024
AB		MICRO LABS	**20MG**		**A207016**	**001**	Oct 03, 2017
AB			**40MG**		**A207016**	**002**	Oct 03, 2017
AB			**80MG**		**A207016**	**003**	Oct 03, 2017
AB		MYLAN	**20MG**		**A202397**	**001**	Jul 07, 2014
AB			**40MG**		**A202397**	**002**	Jul 07, 2014
AB			**80MG**		**A202397**	**003**	Jul 07, 2014
AB		PRINSTON INC	**20MG**		**A207882**	**001**	May 03, 2017
AB			**40MG**		**A207882**	**002**	May 03, 2017

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB			**80MG**	**A207882**	**003**	May 03, 2017
AB		SANDOZ	**20MG**	**A203867**	**001**	Nov 03, 2014
AB			**40MG**	**A203867**	**002**	Nov 03, 2014
AB			**80MG**	**A203867**	**003**	Nov 03, 2014
AB		TORRENT	**20MG**	**A203171**	**001**	Jul 07, 2014
AB			**40MG**	**A203171**	**002**	Jul 07, 2014
AB			**80MG**	**A203171**	**003**	Jul 07, 2014
AB		ZYDUS PHARMS	**20MG**	**A203325**	**001**	Aug 26, 2014
AB			**40MG**	**A203325**	**002**	Aug 26, 2014
AB			**80MG**	**A203325**	**003**	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

	+!	TERSERA	EQ 250MG BASE	N208794	001	Feb 28, 2017

TEMAZEPAM

CAPSULE;ORAL

RESTORIL

AB	**+**	SPECGX LLC	**7.5MG**	**N018163**	**003**	Oct 25, 1991
AB	**+**		**15MG**	**N018163**	**001**	
AB	**+**		**22.5MG**	**N018163**	**004**	Nov 02, 2004
AB	**+!**		**30MG**	**N018163**	**002**	

TEMAZEPAM

AB		ACTAVIS ELIZABETH	**15MG**	**A071620**	**002**	Aug 07, 1987
AB			**30MG**	**A071620**	**001**	Aug 07, 1987
AB		ALEMBIC	**7.5MG**	**A211542**	**001**	Nov 23, 2018
AB			**15MG**	**A211542**	**002**	Nov 23, 2018
AB			**22.5MG**	**A211542**	**003**	Nov 23, 2018
AB			**30MG**	**A211542**	**004**	Nov 23, 2018
AB		ALKEM LABS LTD	**7.5MG**	**A217875**	**001**	Aug 24, 2023
AB			**15MG**	**A217875**	**002**	Aug 24, 2023
AB			**22.5MG**	**A217875**	**003**	Aug 24, 2023
AB			**30MG**	**A217875**	**004**	Aug 24, 2023
AB		CHARTWELL RX	**15MG**	**A071427**	**001**	Jan 12, 1988
AB			**30MG**	**A071428**	**001**	Jan 12, 1988
AB		NOVEL LABS INC	**7.5MG**	**A071457**	**002**	Jun 22, 2012
AB			**15MG**	**A071456**	**001**	Apr 21, 1987
AB			**22.5MG**	**A071457**	**003**	Jun 22, 2012
AB			**30MG**	**A071457**	**001**	Apr 21, 1987
AB		PRINSTON INC	**7.5MG**	**A201781**	**001**	Jun 04, 2015
AB			**15MG**	**A201781**	**002**	Jun 04, 2015
AB			**22.5MG**	**A201781**	**003**	Jun 04, 2015
AB			**30MG**	**A201781**	**004**	Jun 04, 2015

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB		ACCORD HLTHCARE	**5MG**	**A201528**	**001**	Feb 27, 2017
AB			**20MG**	**A201528**	**002**	Feb 27, 2017
AB			**100MG**	**A201528**	**003**	Feb 27, 2017
AB			**140MG**	**A201528**	**004**	Feb 27, 2017
AB			**180MG**	**A201528**	**005**	Feb 27, 2017
AB			**250MG**	**A201528**	**006**	Feb 27, 2017
AB		AMNEAL PHARMS	**5MG**	**A203691**	**001**	May 08, 2015
AB			**20MG**	**A203691**	**002**	May 08, 2015
AB			**100MG**	**A203691**	**003**	May 08, 2015
AB			**140MG**	**A203691**	**004**	May 08, 2015
AB			**180MG**	**A203691**	**005**	May 08, 2015
AB	**!**		**250MG**	**A203691**	**006**	May 08, 2015
AB		CHARTWELL	**5MG**	**A206413**	**001**	Apr 12, 2016
AB			**20MG**	**A206413**	**002**	Apr 12, 2016
AB			**100MG**	**A206413**	**003**	Apr 12, 2016
AB			**140MG**	**A206413**	**004**	Apr 12, 2016
AB			**180MG**	**A206413**	**005**	Apr 12, 2016
AB			**250MG**	**A206413**	**006**	Apr 12, 2016
AB		CHEMI SPA	**5MG**	**A204639**	**001**	Nov 23, 2016
AB			**20MG**	**A204639**	**002**	Nov 23, 2016
AB			**100MG**	**A204639**	**003**	Nov 23, 2016
AB			**140MG**	**A204639**	**004**	Nov 23, 2016
AB			**180MG**	**A204639**	**005**	Nov 23, 2016

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB		**250MG**	**A204639**	**006**	Nov 23, 2016
AB	DEVA HOLDING AS	**5MG**	**A207658**	**001**	Apr 26, 2017
AB		**20MG**	**A207658**	**002**	Apr 26, 2017
AB		**100MG**	**A207658**	**003**	Apr 26, 2017
AB		**140MG**	**A207658**	**004**	Apr 26, 2017
AB		**180MG**	**A207658**	**005**	Apr 26, 2017
AB		**250MG**	**A207658**	**006**	Apr 26, 2017
AB	EIRGEN	**100MG**	**A203898**	**003**	Feb 10, 2016
AB		**140MG**	**A203898**	**004**	Feb 10, 2016
AB		**180MG**	**A203898**	**005**	Feb 10, 2016
AB		**250MG**	**A203898**	**006**	Feb 10, 2016
AB	HETERO LABS LTD V	**5MG**	**A210030**	**001**	Aug 23, 2024
AB		**20MG**	**A210030**	**002**	Aug 23, 2024
AB		**100MG**	**A210030**	**003**	Aug 23, 2024
AB		**140MG**	**A210030**	**004**	Aug 23, 2024
AB		**180MG**	**A210030**	**005**	Aug 23, 2024
AB		**250MG**	**A210030**	**006**	Aug 23, 2024
AB	RISING	**5MG**	**A206309**	**001**	Apr 27, 2016
AB		**20MG**	**A206309**	**002**	Apr 27, 2016
AB		**100MG**	**A206309**	**003**	Apr 27, 2016
AB		**140MG**	**A206309**	**004**	Apr 27, 2016
AB		**180MG**	**A206309**	**005**	Apr 27, 2016
AB		**250MG**	**A206309**	**006**	Apr 27, 2016
AB	SUN PHARM	**5MG**	**A201742**	**001**	Feb 12, 2014
AB		**20MG**	**A201742**	**002**	Feb 12, 2014
AB		**100MG**	**A201742**	**003**	Feb 12, 2014
AB		**140MG**	**A201742**	**004**	Feb 12, 2014
AB		**180MG**	**A201742**	**005**	Feb 12, 2014
AB		**250MG**	**A201742**	**006**	Feb 12, 2014
AB	ZYDUS PHARMS	**5MG**	**A206750**	**001**	Jul 31, 2017
AB		**20MG**	**A206750**	**002**	Jul 31, 2017
AB		**100MG**	**A206750**	**003**	Jul 31, 2017
AB		**140MG**	**A206750**	**004**	Jul 31, 2017
AB		**180MG**	**A206750**	**005**	Jul 31, 2017
AB		**250MG**	**A206750**	**006**	Jul 31, 2017

POWDER;INTRAVENOUS

TEMODAR

+!	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TEMSIROLIMUS

AP	ACCORD HLTHCARE	**25MG/ML (25MG/ML)**	**A203153**	**001**	Jul 30, 2018
AP	GLAND	**25MG/ML (25MG/ML)**	**A207383**	**001**	Aug 16, 2019

TORISEL

AP	**+!** PF PRISM CV	**25MG/ML (25MG/ML)**	**N022088**	**001**	May 30, 2007

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

IBSRELA

+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019

XPHOZAH

+	ARDELYX INC	EQ 20MG BASE	N213931	002	Oct 17, 2023
+!		EQ 30MG BASE	N213931	003	Oct 17, 2023

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE

AB	LUPIN LTD	**EQ 25MG BASE**	**A214226**	**001**	Mar 30, 2023

VEMLIDY

AB	**+!** GILEAD SCIENCES INC	**EQ 25MG BASE**	**N208464**	**001**	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER;ORAL

VIREAD

+!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA	**150MG**	**A090647**	**001**	Jan 26, 2018
AB		**200MG**	**A090647**	**002**	Jan 26, 2018
AB		**250MG**	**A090647**	**003**	Jan 26, 2018

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB			**300MG**	**A090647**	**004**	Jan 26, 2018
AB		CHARTWELL	**300MG**	**A206481**	**001**	Jul 26, 2018
AB		CIPLA	**300MG**	**A078800**	**001**	Jan 26, 2018
AB		HETERO LABS LTD III	**300MG**	**A090636**	**001**	Jan 26, 2018
AB		MACLEODS PHARMS LTD	**300MG**	**A203232**	**001**	Jan 26, 2018
AB		MICRO LABS	**300MG**	**A206157**	**001**	Dec 18, 2025
AB		PHARMOBEDIENT	**300MG**	**A079071**	**001**	Feb 29, 2024
AB		QILU	**200MG**	**A209498**	**001**	Mar 02, 2018
AB			**250MG**	**A209498**	**002**	Mar 02, 2018
AB			**300MG**	**A209498**	**003**	Mar 02, 2018
AB		REYOUNG	**300MG**	**A211337**	**001**	Mar 02, 2023
AB		STRIDES PHARMA	**300MG**	**A090742**	**001**	Jan 26, 2018
AB		TEVA PHARMS USA	**150MG**	**A091612**	**002**	Jan 26, 2018
AB			**200MG**	**A091612**	**003**	Jan 26, 2018
AB			**250MG**	**A091612**	**004**	Jan 26, 2018
AB			**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+**	GILEAD SCIENCES INC	**150MG**	**N021356**	**002**	Jan 18, 2012
AB	**+**		**200MG**	**N021356**	**003**	Jan 18, 2012
AB	**+**		**250MG**	**N021356**	**004**	Jan 18, 2012
AB	**+!**		**300MG**	**N021356**	**001**	Oct 26, 2001

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL

TEPMETKO

	+!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 1MG BASE**	**A219482**	**001**	May 12, 2025
AB			**EQ 2MG BASE**	**A219482**	**002**	May 12, 2025
AB			**EQ 5MG BASE**	**A219482**	**003**	May 12, 2025
AB			**EQ 10MG BASE**	**A219482**	**004**	May 12, 2025
AB		APNAR PHARMA LP	**EQ 1MG BASE**	**A074823**	**001**	Mar 30, 1998
AB			**EQ 2MG BASE**	**A074823**	**002**	Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823**	**003**	Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823**	**004**	Mar 30, 1998
AB		BIONPHARMA	**EQ 1MG BASE**	**A075667**	**001**	Jul 28, 2000
AB			**EQ 2MG BASE**	**A075667**	**002**	Jul 28, 2000
AB			**EQ 5MG BASE**	**A075667**	**003**	Jul 28, 2000
AB			**EQ 10MG BASE**	**A075667**	**004**	Jul 28, 2000
AB		HERITAGE PHARMA AVET	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB			**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB			**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB			**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB	**!**	JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004
AB			**EQ 2MG BASE**	**A075317**	**002**	Dec 20, 2004
AB			**EQ 5MG BASE**	**A075317**	**003**	Dec 20, 2004
AB			**EQ 10MG BASE**	**A075317**	**004**	Dec 20, 2004

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	**!**	AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297**	**001**	Jul 02, 2007
AB		CHARTWELL	**EQ 250MG BASE**	**A078199**	**001**	Jul 02, 2007
AB		EMED MEDCL	**EQ 250MG BASE**	**A077919**	**001**	Jul 02, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078157**	**001**	Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533**	**001**	Jul 02, 2007
AB		ORBION PHARMS	**EQ 250MG BASE**	**A078163**	**001**	Jul 02, 2007
AB		SENORES PHARMS	**EQ 250MG BASE**	**A076390**	**001**	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP		AREVA PHARMS	**1MG/ML**	**A200122**	**001**	Nov 08, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887**	**001**	May 26, 2004
AP	**!**	HIKMA FARMACEUTICA	**1MG/ML**	**A078630**	**001**	May 20, 2009

TERBUTALINE SULFATE

TABLET;ORAL

BRETHINE							
AB	**+**	ANI PHARMS	**2.5MG**	**N017849**	**001**		
AB	**+**		**5MG**	**N017849**	**002**		
TERBUTALINE SULFATE							
AB		IMPAX LABS	**2.5MG**	**A075877**	**001**	Jun 26, 2001	
AB			**5MG**	**A075877**	**002**	Jun 26, 2001	
AB		LANNETT CO INC	**2.5MG**	**A077152**	**001**	Mar 25, 2005	
AB	**!**		**5MG**	**A077152**	**002**	Mar 25, 2005	
AB		TWI PHARMS	**2.5MG**	**A211832**	**001**	Jun 19, 2020	
AB			**5MG**	**A211832**	**002**	Jun 19, 2020	

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE							
AB		FOUGERA PHARMS	**0.4%**	**A076712**	**001**	Feb 18, 2005	
AB	**!**	SUN PHARMA CANADA	**0.4%**	**A076043**	**001**	Jan 19, 2005	
BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	
BX	!	SUN PHARMA CANADA	0.8%	A075953	001	Apr 06, 2004	

SUPPOSITORY;VAGINAL

TERCONAZOLE							
AB	**!**	PADAGIS ISRAEL	**80MG**	**A077149**	**001**	Mar 17, 2006	
AB		SUN PHARMA CANADA	**80MG**	**A077553**	**001**	Mar 09, 2007	

TERIFLUNOMIDE

TABLET;ORAL

AUBAGIO							
AB	**+**	SANOFI AVENTIS US	**7MG**	**N202992**	**001**	Sep 12, 2012	
AB	**+!**		**14MG**	**N202992**	**002**	Sep 12, 2012	
TERIFLUNOMIDE							
AB		ACCORD HLTHCARE	**7MG**	**A209690**	**001**	Jan 07, 2019	
AB			**14MG**	**A209690**	**002**	Jan 07, 2019	
AB		ALEMBIC	**7MG**	**A209572**	**001**	Apr 19, 2019	
AB			**14MG**	**A209572**	**002**	Apr 19, 2019	
AB		AUROBINDO PHARMA	**7MG**	**A209638**	**001**	Oct 26, 2018	
AB			**14MG**	**A209638**	**002**	Oct 26, 2018	
AB		BIOCON PHARMA	**7MG**	**A209639**	**001**	Mar 13, 2023	
AB			**14MG**	**A209639**	**002**	Mar 13, 2023	
AB		GLENMARK SPECLT	**7MG**	**A209663**	**001**	Nov 15, 2018	
AB			**14MG**	**A209663**	**002**	Nov 15, 2018	
AB		HETERO LABS LTD V	**7MG**	**A209598**	**001**	Mar 13, 2023	
AB			**14MG**	**A209598**	**002**	Mar 13, 2023	
AB		MSN	**7MG**	**A209623**	**001**	Apr 24, 2019	
AB			**14MG**	**A209623**	**002**	Apr 24, 2019	
AB		NATCO	**7MG**	**A209555**	**001**	May 15, 2023	
AB			**14MG**	**A209555**	**002**	May 15, 2023	
AB		SANDOZ	**7MG**	**A209710**	**001**	Jan 03, 2019	
AB			**14MG**	**A209710**	**002**	Jan 03, 2019	
AB		SOLA PHARMS	**7MG**	**A209677**	**002**	Sep 28, 2023	
AB			**14MG**	**A209677**	**001**	Jun 17, 2020	
AB		TEVA PHARMS USA	**7MG**	**A209700**	**001**	Sep 04, 2018	
AB			**14MG**	**A209700**	**002**	Sep 04, 2018	
AB		ZYDUS PHARMS	**7MG**	**A209668**	**001**	Nov 30, 2018	
AB			**14MG**	**A209668**	**002**	Nov 30, 2018	

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

FORTEO							
AP	**+!**	LILLY	**0.56MG/2.24ML (0.25MG/ML)**	**N021318**	**002**	Jun 25, 2008	
TERIPARATIDE							
AP	**+!**	ALMAJECT	**0.56MG/2.24ML (0.25MG/ML)**	**N218771**	**001**	Jun 04, 2024	
AP		AMPHASTAR PHARMS INC	**0.56MG/2.24ML (0.25MG/ML)**	**A213641**	**001**	Dec 12, 2025	
AP		APOTEX	**0.56MG/2.24ML (0.25MG/ML)**	**A211097**	**001**	Nov 16, 2023	
AP		TEVA PHARMS USA	**0.56MG/2.24ML (0.25MG/ML)**	**A208569**	**001**	Nov 16, 2023	
BONSITY							
		ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	

TERLIPRESSIN ACETATE							
POWDER;INTRAVENOUS							
TERLIVAZ							
	+!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022
TESTOSTERONE							
GEL;TRANSDERMAL							
ANDROGEL							
AB1	**+**	BESINS HLTHCARE	**25MG/2.5GM PACKET**	**N021015**	**001**	Feb 28, 2000
AB1	**+**		**50MG/5GM PACKET**	**N021015**	**002**	Feb 28, 2000
TESTOSTERONE							
AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001**	Jan 27, 2006
AB1	**!**		**50MG/5GM PACKET**	**A076737**	**002**	Jan 27, 2006
AB1		ENCUBE	**25MG/2.5GM PACKET**	**A212984**	**003**	Jul 11, 2024
AB1			**50MG/5GM PACKET**	**A212984**	**001**	Nov 09, 2021
AB1		STRIDES PHARMA INTL	**25MG/2.5GM PACKET**	**A076744**	**001**	May 23, 2007
AB1			**50MG/5GM PACKET**	**A076744**	**002**	May 23, 2007
ANDROGEL							
AB2	**+**	BESINS HLTHCARE	**1.62% (20.25MG/1.25GM PACKET)**	**N022309**	**002**	Sep 07, 2012
AB2	**+**		**1.62% (40.5MG/2.5GM PACKET)**	**N022309**	**003**	Sep 07, 2012
TESTIM							
AB2	**+!**	ENDO OPERATIONS	**50MG/5GM PACKET**	**N021454**	**001**	Oct 31, 2002
TESTOSTERONE							
AB2		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM PACKET)**	**A204570**	**002**	Jul 17, 2020
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A204570**	**003**	Jul 17, 2020
AB2			**50MG/5GM PACKET**	**A091073**	**001**	Sep 18, 2017
AB2		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM PACKET)**	**A205781**	**001**	Jul 12, 2017
AB2	**!**		**1.62% (40.5MG/2.5GM PACKET)**	**A205781**	**002**	Jul 12, 2017
VOGELXO							
AB2		UPSHER SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002**	Jun 04, 2014
GEL, METERED;NASAL							
NATESTO							
	+!	ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014
GEL, METERED;TRANSDERMAL							
ANDROGEL							
AB	**+!**	BESINS HLTHCARE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001**	Apr 29, 2011
TESTOSTERONE							
AB		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204570**	**001**	Apr 10, 2019
AB		AMNEAL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A207373**	**001**	Apr 10, 2019
AB		ENCUBE	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208620**	**001**	Apr 10, 2019
AB		LUPIN	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208560**	**001**	Apr 10, 2019
AB		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001**	Aug 04, 2015
AB		XIROMED	**1.62% (20.25MG/1.25GM ACTUATION)**	**A210835**	**001**	Apr 16, 2020
ANDROGEL							
AB1	**+**	BESINS HLTHCARE	**12.5MG/1.25GM ACTUATION**	**N021015**	**003**	Sep 26, 2003
TESTOSTERONE							
AB1	**!**	ACTAVIS LABS UT INC	**12.5MG/1.25GM ACTUATION**	**A076737**	**003**	Mar 09, 2015
AB1		ENCUBE	**12.5MG/1.25GM ACTUATION**	**A212984**	**002**	Feb 09, 2024
VOGELXO							
BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014
TESTOSTERONE							
	!	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015
PELLET;IMPLANTATION							
TESTOPEL							
	!	ENDO OPERATIONS	75MG	A080911	001	
SOLUTION, METERED;TRANSDERMAL							
TESTOSTERONE							
AT		ACTAVIS LABS UT INC	**30MG/1.5ML ACTUATION**	**A205328**	**001**	Aug 07, 2017
AT		CIPLA	**30MG/1.5ML ACTUATION**	**A209533**	**001**	Jan 29, 2018
AT		LUPIN LTD	**30MG/1.5ML ACTUATION**	**A208061**	**001**	Oct 23, 2017
AT	**!**	PADAGIS ISRAEL	**30MG/1.5ML ACTUATION**	**A204255**	**001**	Feb 28, 2017
TESTOSTERONE CYPIONATE							
INJECTABLE;INJECTION							
DEPO-TESTOSTERONE							
AO	**+!**	PFIZER	**100MG/ML**	**A085635**	**002**	
AO	**+!**		**200MG/ML**	**A085635**	**003**	
TESTOSTERONE CYPIONATE							
AO		AM REGENT	**200MG/ML**	**A207742**	**001**	Jun 16, 2017
AO		CIPLA	**100MG/ML**	**A210362**	**001**	Jun 19, 2018
AO			**200MG/ML**	**A210362**	**002**	Jun 19, 2018
AO		EUGIA PHARMA	**100MG/ML**	**A211817**	**001**	Oct 20, 2023
AO			**200MG/ML**	**A211817**	**002**	Oct 20, 2023

TESTOSTERONE CYPIONATE						
INJECTABLE;INJECTION						
TESTOSTERONE CYPIONATE						
AO		HIKMA	**100MG/ML**	**A090387**	**001**	Jul 15, 2010
AO			**200MG/ML**	**A090387**	**002**	Jul 15, 2010
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001**	May 01, 2012
AO		PADAGIS US	**200MG/ML**	**A040530**	**001**	Jan 31, 2005
AO		SANDOZ	**100MG/ML**	**A040615**	**001**	Aug 10, 2006
AO			**200MG/ML**	**A040615**	**002**	Aug 10, 2006
AO		WILSHIRE PHARMS INC	**200MG/ML**	**A206368**	**001**	Apr 24, 2019
AO		XIROMED	**100MG/ML**	**A215351**	**001**	Apr 13, 2023
AO			**200MG/ML**	**A215351**	**002**	Apr 13, 2023
SOLUTION;INTRAMUSCULAR						
AZMIRO						
	+!	AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022
TESTOSTERONE ENANTHATE						
INJECTABLE;INJECTION						
TESTOSTERONE ENANTHATE						
AO		EUGIA PHARMA	**200MG/ML**	**A212659**	**001**	Feb 28, 2024
AO	**!**	HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012
AO		NEXUS	**200MG/ML**	**A040575**	**001**	Jun 14, 2006
SOLUTION;SUBCUTANEOUS						
XYOSTED (AUTOINJECTOR)						
	+!	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+!		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+!		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018
TESTOSTERONE UNDECANOATE						
CAPSULE;ORAL						
JATENZO						
	+	TOLMAR	158MG	N206089	001	Mar 27, 2019
	+		198MG	N206089	002	Mar 27, 2019
	+!		237MG	N206089	003	Mar 27, 2019
KYZATREX						
	+	MARIUS	150MG	N213953	002	Jul 27, 2022
	+!		200MG	N213953	003	Jul 27, 2022
TLANDO						
	+!	VERITY	112.5MG	N208088	001	Mar 28, 2022
INJECTABLE;INTRAMUSCULAR						
AVEED						
	+!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014
TETRABENAZINE						
TABLET;ORAL						
TETRABENAZINE						
AB		ACTAVIS LABS FL INC	**25MG**	**A206686**	**001**	Jul 07, 2017
AB		ADAPTIS	**12.5MG**	**A213316**	**001**	Jan 22, 2020
AB			**25MG**	**A213316**	**002**	Jan 22, 2020
AB		APOTEX	**12.5MG**	**A206093**	**001**	Mar 17, 2020
AB			**25MG**	**A206093**	**002**	Mar 17, 2020
AB		BIONPHARMA	**12.5MG**	**A208826**	**001**	Dec 18, 2017
AB			**25MG**	**A208826**	**002**	Dec 18, 2017
AB		CHARTWELL RX	**12.5MG**	**A210544**	**001**	Apr 20, 2018
AB			**25MG**	**A210544**	**002**	Apr 20, 2018
AB		DR REDDYS	**12.5MG**	**A209284**	**001**	Jan 08, 2018
AB			**25MG**	**A209284**	**002**	Jan 08, 2018
AB		HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016
AB			**25MG**	**A204574**	**002**	Feb 03, 2016
AB		MYLAN	**12.5MG**	**A207682**	**001**	Jan 31, 2017
AB			**25MG**	**A207682**	**002**	Jan 31, 2017
XENAZINE						
AB	**+**	BAUSCH	**12.5MG**	**N021894**	**001**	Aug 15, 2008
AB	**+!**		**25MG**	**N021894**	**002**	Aug 15, 2008
TETRACAINE HYDROCHLORIDE						
SOLUTION;OPHTHALMIC						
TETRACAINE HYDROCHLORIDE						
AB1	**+!**	BAUSCH LOMB IRELAND	**0.5%**	**N210821**	**001**	Mar 12, 2019
AB1		SOMERSET THERAPS LLC	**0.5%**	**A217227**	**001**	Dec 20, 2024
	+!	ALCON LABS	0.5%	N208135	001	Feb 29, 2016

TETRACYCLINE HYDROCHLORIDE							
CAPSULE;ORAL							
ACHROMYCIN V							
AB	**+**	AVET	**250MG**	**N050278**	**003**		
AB	**+**		**500MG**	**N050278**	**001**		
TETRACYCLINE HYDROCHLORIDE							
AB		AMNEAL PHARMS NY	**250MG**	**A210674**	**001**	Sep 18, 2018	
AB	**!**		**500MG**	**A210674**	**002**	Sep 18, 2018	
AB		BRECKENRIDGE	**250MG**	**A210662**	**001**	Nov 07, 2018	
AB			**500MG**	**A210662**	**002**	Nov 07, 2018	
AB		CHARTWELL TETRA	**250MG**	**A062752**	**001**	Aug 12, 1988	
AB			**500MG**	**A062752**	**002**	Aug 12, 1988	
AB		NOVITIUM PHARMA	**250MG**	**A212635**	**001**	Mar 03, 2020	
AB			**500MG**	**A212635**	**002**	Mar 03, 2020	
AB		WATSON LABS	**250MG**	**A061837**	**001**		
AB			**500MG**	**A061837**	**002**		
TABLET;ORAL							
SUMYCIN							
		STRIDES PHARMA INTL	250MG	A061147	001		
	!		500MG	A061147	004		
TETRAHYDROZOLINE HYDROCHLORIDE							
SOLUTION;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.05%	A086576	002		
			0.1%	A086576	001		
SPRAY;NASAL							
TYZINE							
	!	FOUGERA PHARMS	0.1%	A086576	003		
THALIDOMIDE							
CAPSULE;ORAL							
THALOMID							
	+	BRISTOL-MYERS	50MG	N020785	001	Jul 16, 1998	
	+		100MG	N020785	002	Jan 17, 2003	
	+		150MG	N020785	004	Jan 10, 2007	
	+!		200MG	N020785	003	Jan 17, 2003	
THALLOUS CHLORIDE TL-201							
INJECTABLE;INJECTION							
THALLOUS CHLORIDE TL 201							
	+!	CURIUM	1mCi/ML	N018150	001		
THEOPHYLLINE							
CAPSULE, EXTENDED RELEASE;ORAL							
THEO-24							
		ENDO OPERATIONS	100MG	A087943	002	Aug 22, 1983	
	+		200MG	A087943	001	Aug 22, 1983	
			300MG	A087943	003	Aug 22, 1983	
	!		400MG	A087943	004	Feb 28, 1992	
SOLUTION;ORAL							
THEOPHYLLINE							
AA	**!**	CHARTWELL MOLECULAR	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011	
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012	
SOLUTION, ELIXIR;ORAL							
ELIXOPHYLLIN							
AA	**+!**	SOLIS PHARMS	**80MG/15ML**	**A085186**	**001**		
THEOPHYLLINE							
AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016	
TABLET, EXTENDED RELEASE;ORAL							
THEOPHYLLINE							
AB		ALEMBIC	**300MG**	**A090430**	**001**	Oct 27, 2010	
AB	**!**		**450MG**	**A090430**	**002**	Oct 27, 2010	
AB		AMNEAL	**300MG**	**A216276**	**001**	Mar 20, 2023	
AB			**450MG**	**A216276**	**002**	Mar 20, 2023	
AB		ANNORA PHARMA	**300MG**	**A217422**	**001**	Sep 08, 2023	
AB			**450MG**	**A217422**	**002**	Sep 08, 2023	
AB		BIONPHARMA	**300MG**	**A216300**	**001**	Apr 26, 2023	
AB			**450MG**	**A216300**	**002**	Apr 26, 2023	
AB		GLENMARK PHARMS LTD	**300MG**	**A212184**	**001**	Jun 03, 2021	
AB			**400MG**	**A090355**	**001**	Jul 13, 2010	
AB			**450MG**	**A212184**	**002**	Jun 03, 2021	
AB			**600MG**	**A090355**	**002**	Jul 13, 2010	
AB		HARMAN FINOCHEM	**300MG**	**A214806**	**001**	Oct 24, 2023	

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB			**450MG**	**A214806**	**002**	Oct 24, 2023
AB		HERITAGE PHARMA AVET	**300MG**	**A089763**	**001**	Apr 30, 1990
AB			**450MG**	**A081236**	**001**	Nov 09, 1992
AB		MPP PHARMA	**400MG**	**A040560**	**003**	Apr 21, 2006
AB	**!**		**600MG**	**A040560**	**002**	Apr 21, 2006
AB		NOSTRUM PHARMS LLC	**300MG**	**A087400**	**002**	Jan 11, 1983
AB			**450MG**	**A087400**	**005**	Aug 09, 2023
AB	**+**	RHODES PHARMS	**400MG**	**A040086**	**002**	Sep 01, 1982
AB		STRIDES PHARMA	**300MG**	**A215312**	**001**	Sep 05, 2024
AB			**450MG**	**A215312**	**002**	Sep 05, 2024
AB		TEVA PHARMS INC	**300MG**	**A216961**	**001**	Oct 12, 2022
AB			**450MG**	**A216961**	**002**	Oct 12, 2022
AB		VELZEN PHARMA PVT	**300MG**	**A214950**	**001**	Jan 30, 2023
AB			**450MG**	**A214950**	**002**	Jan 30, 2023
AB		ZYDUS LIFESCIENCES	**300MG**	**A218063**	**001**	May 21, 2024
AB			**450MG**	**A218063**	**002**	May 21, 2024
		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985
			200MG	A087400	004	Feb 21, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP		ASPIRO	**100MG/ML**	**A218471**	**001**	Nov 06, 2024
AP		CAPLIN	**100MG/ML**	**A215692**	**001**	Mar 06, 2023
AP		DR REDDYS	**100MG/ML**	**A080571**	**001**	
AP		EUGIA PHARMA	**100MG/ML**	**A208703**	**001**	Apr 20, 2022
AP	**+!**	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP		GLAND	**100MG/ML**	**A217800**	**001**	Feb 24, 2025
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012
AP		ONESOURCE SPECIALTY	**100MG/ML**	**A217181**	**001**	Oct 29, 2024
AP		SAGENT PHARMS INC	**100MG/ML**	**A206106**	**001**	Dec 01, 2017
AP		WEST-WARD PHARMS INT	**100MG/ML**	**A080575**	**001**	
	!	DR REDDYS	200MG/ML	A080571	002	

THIOGUANINE

TABLET;ORAL

THIOGUANINE

	+!	WAYLIS THERAP	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

		MYLAN	10MG	A088004	002	Mar 15, 1983
			25MG	A088004	003	Mar 15, 1983
			50MG	A088004	004	Mar 15, 1983
	!		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

AP		DR REDDYS	**15MG/VIAL**	**A210337**	**001**	May 04, 2018
AP		HENGRUI PHARMA	**15MG/VIAL**	**A209150**	**001**	May 04, 2018
AP		PENN LIFE	**15MG/VIAL**	**A208242**	**001**	Jan 10, 2020
AP		REGCON HOLDINGS	**15MG/VIAL**	**A211831**	**001**	Dec 08, 2021
AP	**!**	WEST-WARD PHARMS INT	**15MG/VIAL**	**A075547**	**001**	Apr 02, 2001

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP	**+!**	ADIENNE SA	**15MG/VIAL**	**N208264**	**001**	Jan 26, 2017
AP	**+!**		**100MG/VIAL**	**N208264**	**002**	Jan 26, 2017

THIOTEPA

AP		GLAND	**15MG/VIAL**	**A214222**	**001**	Mar 08, 2021
AP			**100MG/VIAL**	**A214222**	**002**	Jan 03, 2022
AP		HIKMA	**100MG/VIAL**	**A211755**	**001**	Sep 05, 2023
AP		MEITHEAL	**15MG/VIAL**	**A216037**	**001**	Dec 26, 2023
AP			**100MG/VIAL**	**A216037**	**002**	Dec 26, 2023
AP		MSN	**15MG/VIAL**	**A213049**	**001**	Mar 04, 2020
AP			**100MG/VIAL**	**A213049**	**002**	Mar 04, 2020
AP		REGCON HOLDINGS	**15MG/VIAL**	**A217559**	**001**	Aug 20, 2024

THIOTEPA

POWDER;INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

+!	ADIENNE SA	200MG	N208264	003	Apr 10, 2025

SOLUTION;INTRAVENOUS

TEPYLUTE

+!	SHORLA	15MG/1.5ML (10MG/ML)	N216984	001	Jun 25, 2024
+!		100MG/10ML (10MG/ML)	N216984	002	Feb 26, 2025

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB	AMNEAL	**1MG**	**A215456**	**001**	Feb 28, 2022
AB		**2MG**	**A215456**	**002**	Feb 28, 2022
AB		**5MG**	**A215456**	**003**	Feb 28, 2022
AB		**10MG**	**A215456**	**004**	Feb 28, 2022
AB	NOVITIUM PHARMA	**1MG**	**A211642**	**001**	Apr 05, 2019
AB		**2MG**	**A211642**	**002**	Apr 05, 2019
AB !		**5MG**	**A211642**	**003**	Apr 05, 2019
AB		**10MG**	**A211642**	**004**	Apr 05, 2019
AB	RISING	**1MG**	**A071093**	**002**	Jun 23, 1987
AB		**2MG**	**A071093**	**003**	Jun 23, 1987
AB		**5MG**	**A071093**	**004**	Jun 23, 1987
AB		**10MG**	**A071093**	**001**	Jun 23, 1987

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

GABITRIL

AB +	CEPHALON	**2MG**	**N020646**	**005**	Apr 16, 1999
AB +!		**4MG**	**N020646**	**001**	Sep 30, 1997
AB +		**12MG**	**N020646**	**002**	Sep 30, 1997
AB +		**16MG**	**N020646**	**003**	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB	MSN	**2MG**	**A214816**	**001**	Nov 16, 2021
AB		**4MG**	**A214816**	**002**	Nov 16, 2021
AB		**12MG**	**A214816**	**003**	Nov 16, 2021
AB		**16MG**	**A214816**	**004**	Nov 16, 2021

TICAGRELOR

TABLET;ORAL

BRILINTA

AB +	ASTRAZENECA	**60MG**	**N022433**	**002**	Sep 03, 2015
AB +!		**90MG**	**N022433**	**001**	Jul 20, 2011

TICAGRELOR

AB	ALEMBIC	**60MG**	**A208576**	**002**	Oct 28, 2025
AB		**90MG**	**A208576**	**001**	May 01, 2025
AB	ALKEM LABS LTD	**60MG**	**A210219**	**001**	Oct 28, 2025
AB		**90MG**	**A208567**	**001**	Apr 21, 2023
AB	AMNEAL	**60MG**	**A208531**	**002**	Oct 28, 2025
AB	APOTEX	**60MG**	**A208584**	**002**	Oct 28, 2025
AB		**90MG**	**A208584**	**001**	May 01, 2025
AB	CHANGZHOU PHARM	**60MG**	**A216187**	**001**	Oct 28, 2025
AB		**90MG**	**A216187**	**002**	Oct 28, 2025
AB	DR REDDYS	**60MG**	**A208541**	**002**	Oct 28, 2025
AB		**90MG**	**A208541**	**001**	Oct 29, 2024
AB	HISUN PHARM HANGZHOU	**90MG**	**A208575**	**001**	Jan 23, 2019
AB	INVAGEN PHARMS	**60MG**	**A208537**	**002**	Oct 28, 2025
AB		**90MG**	**A208537**	**001**	May 05, 2025
AB	MACLEODS PHARMS LTD	**60MG**	**A212258**	**001**	Oct 28, 2025
AB		**90MG**	**A212258**	**002**	Oct 28, 2025
AB	MSN	**60MG**	**A208596**	**002**	Oct 28, 2025
AB		**90MG**	**A208596**	**001**	Apr 07, 2020
AB	MYLAN	**60MG**	**A208597**	**001**	Jul 09, 2021
AB		**90MG**	**A208597**	**002**	Jul 09, 2021
AB	PRINSTON INC	**90MG**	**A208599**	**001**	Aug 16, 2024
AB	SCIEGEN PHARMS	**60MG**	**A218962**	**001**	Oct 28, 2025
AB		**90MG**	**A218962**	**002**	Oct 28, 2025
AB	SUNSHINE	**60MG**	**A208508**	**002**	Oct 28, 2025
AB		**90MG**	**A208508**	**001**	Apr 06, 2020
AB	TARO	**60MG**	**A211498**	**001**	Oct 28, 2025
AB		**90MG**	**A211498**	**002**	Oct 28, 2025
AB	WATSON LABS INC	**60MG**	**A208390**	**001**	Sep 04, 2018
AB		**90MG**	**A208390**	**002**	Sep 04, 2018

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

AP		AMNEAL	**50MG/VIAL**	**N211158**	**001**	Aug 02, 2018
AP		APOTEX	**50MG/VIAL**	**A204439**	**001**	Dec 21, 2018
AP		EUGIA PHARMA	**50MG/VIAL**	**A206335**	**001**	Jun 11, 2019
AP	**+!**	FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001**	Dec 01, 2016
AP		MEITHEAL	**50MG/VIAL**	**A214020**	**001**	May 13, 2021
AP		SANDOZ	**50MG/VIAL**	**A091620**	**001**	May 27, 2015

TYGACIL

AP	**+!**	PF PRISM CV	**50MG/VIAL**	**N021821**	**001**	Jun 15, 2005

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	**+!**	THEA PHARMA	**0.5%**	**N020439**	**002**	Mar 31, 1995

TIMOLOL

AT		SOMERSET	**0.5%**	**A216654**	**001**	Oct 10, 2024

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB	**!**	ALEMBIC	**EQ 0.25% BASE**	**A212942**	**001**	Oct 22, 2020
AB	**!**		**EQ 0.5% BASE**	**A212942**	**002**	Oct 22, 2020
AB		DR REDDYS	**EQ 0.25% BASE**	**A215733**	**001**	Sep 22, 2022
AB			**EQ 0.5% BASE**	**A215733**	**002**	Sep 22, 2022
AB		EUGIA PHARMA	**EQ 0.5% BASE**	**A213540**	**001**	Mar 23, 2023
AB		GLAND	**EQ 0.25% BASE**	**A214645**	**001**	Jun 24, 2022
AB			**EQ 0.5% BASE**	**A214645**	**002**	Feb 14, 2023
AB	**+!**	SANDOZ	**EQ 0.25% BASE**	**N020963**	**001**	Oct 21, 1998
AB	**+!**		**EQ 0.5% BASE**	**N020963**	**002**	Oct 21, 1998
AB		SOMERSET THERAPS LLC	**EQ 0.25% BASE**	**A210640**	**001**	Sep 16, 2024
AB			**EQ 0.5% BASE**	**A210640**	**002**	Sep 16, 2024

TIMOPTIC-XE

AB	**+**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N020330**	**001**	Nov 04, 1993
AB	**+**		**EQ 0.5% BASE**	**N020330**	**002**	Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1		CAPLIN	**EQ 0.5% BASE**	**A218460**	**001**	Aug 07, 2024
AT1		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001**	Apr 30, 2008
AT1			**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1		MANKIND PHARMA	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009
AT1			**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009
AT1		MICRO LABS	**EQ 0.25% BASE**	**A217343**	**001**	May 26, 2023
AT1			**EQ 0.5% BASE**	**A217343**	**002**	May 26, 2023
AT1		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	**!**	SANDOZ	**EQ 0.25% BASE**	**A074261**	**001**	Apr 28, 1995
AT1	**!**		**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995
AT1		SOMERSET	**EQ 0.25% BASE**	**A217764**	**002**	Jul 03, 2024
AT1			**EQ 0.5% BASE**	**A217764**	**001**	Jul 03, 2024

TIMOPTIC

AT1	**+**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N018086**	**001**	
AT1	**+**		**EQ 0.5% BASE**	**N018086**	**002**	

ISTALOL

AT2	**+!**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004

TIMOLOL MALEATE

AT2		SOMERSET THERAPS LLC	**EQ 0.5% BASE**	**A216653**	**001**	Jul 03, 2024
AT3		AMRING PHARMS	**EQ 0.25% BASE**	**A212592**	**001**	Dec 13, 2021
AT3			**EQ 0.5% BASE**	**A212592**	**002**	Dec 13, 2021
AT3		EPIC PHARMA LLC	**EQ 0.5% BASE**	**A212291**	**001**	Sep 11, 2020
AT3		INGENUS PHARMS LLC	**EQ 0.25% BASE**	**A216533**	**001**	Sep 13, 2022
AT3			**EQ 0.5% BASE**	**A216533**	**002**	Sep 13, 2022
AT3		MICRO LABS	**EQ 0.5% BASE**	**A216596**	**001**	Sep 07, 2022
AT3		SENTISS PHARMA	**EQ 0.5% BASE**	**A217195**	**001**	May 08, 2023

TIMOPTIC IN OCUDOSE

AT3	**+!**	BAUSCH AND LOMB INC	**EQ 0.25% BASE**	**N019463**	**001**	Nov 05, 1986
AT3	**+!**		**EQ 0.5% BASE**	**N019463**	**002**	Nov 05, 1986

TABLET;ORAL

TIMOLOL MALEATE

AB		MYLAN	**5MG**	**A072668**	**002**	Jun 08, 1990
AB			**10MG**	**A072668**	**003**	Jun 08, 1990

TIMOLOL MALEATE

TABLET;ORAL

TIMOLOL MALEATE

AB	!		**20MG**	**A072668**	**001**	Jun 08, 1990
AB		RISING	**5MG**	**A207556**	**001**	May 02, 2019
AB			**10MG**	**A207556**	**002**	May 02, 2019
AB			**20MG**	**A207556**	**003**	May 02, 2019

TINIDAZOLE

TABLET;ORAL

TINDAMAX

AB	+	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004
AB	+!		**500MG**	**N021618**	**002**	May 17, 2004

TINIDAZOLE

AB		CHARTWELL RX	**250MG**	**A202044**	**001**	Apr 30, 2012
AB			**500MG**	**A202044**	**002**	Apr 30, 2012
AB		EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015
AB			**500MG**	**A203808**	**002**	Aug 04, 2015
AB		THINQ PHARM-CRO PVT	**250MG**	**A202489**	**001**	Oct 09, 2013
AB			**500MG**	**A202489**	**002**	Oct 09, 2013

TIOPRONIN

TABLET;ORAL

THIOLA

AB	+!	MISSION PHARMA	**100MG**	**N019569**	**001**	Aug 11, 1988

TIOPRONIN

AB		TEVA PHARMS USA INC	**100MG**	**A214326**	**001**	Apr 26, 2021

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

AB	+	MISSION PHARMACAL	**100MG**	**N211843**	**001**	Jun 28, 2019
AB	+!		**300MG**	**N211843**	**002**	Jun 28, 2019

TIOPRONIN

AB		AMNEAL	**100MG**	**A216278**	**002**	Aug 29, 2025
AB			**300MG**	**A216278**	**001**	Aug 15, 2023
AB		PH HEALTH	**100MG**	**A217219**	**001**	Feb 24, 2023
AB			**300MG**	**A217219**	**002**	Feb 24, 2023
AB		TEVA PHARMS INC	**100MG**	**A216456**	**001**	Jul 22, 2024
AB			**300MG**	**A216456**	**002**	Jul 22, 2024

VENXXIVA

AB		TORRENT	**100MG**	**A216990**	**001**	Jan 30, 2024
AB			**300MG**	**A216990**	**002**	Jan 30, 2024

TIOTROPIUM BROMIDE

POWDER;INHALATION

SPIRIVA

AB	+!	BOEHRINGER INGELHEIM	**EQ 0.018MG BASE/INH**	**N021395**	**001**	Jan 30, 2004

TIOTROPIUM BROMIDE

AB		LUPIN	**EQ 0.018MG BASE/INH**	**A211287**	**001**	Jun 20, 2023

SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
	+!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

AB	+	TAIHO ONCOLOGY	**EQ 6.14MG BASE;15MG**	**N207981**	**001**	Sep 22, 2015
AB	+!		**EQ 8.19MG BASE;20MG**	**N207981**	**002**	Sep 22, 2015

TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE

AB		MSN	**EQ 6.14MG BASE;15MG**	**A214024**	**001**	Jan 08, 2025
AB			**EQ 8.19MG BASE;20MG**	**A214024**	**002**	Jan 08, 2025
AB		NATCO	**EQ 6.14MG BASE;15MG**	**A214008**	**001**	Jun 13, 2023
AB			**EQ 8.19MG BASE;20MG**	**A214008**	**002**	Jun 13, 2023

TIPRANAVIR

CAPSULE;ORAL

APTIVUS

	+!	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005

TIRBANIBULIN						
OINTMENT;TOPICAL						
KLISYRI						
+!	ALMIRALL	1%		N213189	001	Dec 14, 2020
TIROFIBAN HYDROCHLORIDE						
SOLUTION;INJECTION						
AGGRASTAT						
+!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)		N020912	002	Aug 31, 2016
SOLUTION;INTRAVENOUS						
AGGRASTAT						
AP +	MEDICURE	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**		**N020913**	**002**	May 17, 2002
AP **+!**		**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**		**N020913**	**003**	Apr 20, 2000
TIROFIBAN HYDROCHLORIDE						
AP	EUGIA PHARMA	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**		**A216379**	**001**	May 01, 2023
AP		**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**		**A216379**	**002**	May 01, 2023
AP	GLAND	**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**		**A206888**	**001**	Apr 08, 2021
AP	NEXUS	**EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)**		**A213947**	**001**	Feb 07, 2023
AP		**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**		**A213947**	**002**	Jul 24, 2023
TIRZEPATIDE						
SOLUTION;SUBCUTANEOUS						
MOUNJARO						
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N215866	007	Jul 28, 2023
+!		5MG/0.5ML (5MG/0.5ML)		N215866	008	Jul 28, 2023
+!		7.5MG/0.5ML (7.5MG/0.5ML)		N215866	009	Jul 28, 2023
+!		10MG/0.5ML (10MG/0.5ML)		N215866	010	Jul 28, 2023
+!		12.5MG/0.5ML (12.5MG/0.5ML)		N215866	011	Jul 28, 2023
+!		15MG/0.5ML (15MG/0.5ML)		N215866	012	Jul 28, 2023
MOUNJARO (AUTOINJECTOR)						
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N215866	001	May 13, 2022
+!		5MG/0.5ML (5MG/0.5ML)		N215866	002	May 13, 2022
+!		7.5MG/0.5ML (7.5MG/0.5ML)		N215866	003	May 13, 2022
+!		10MG/0.5ML (10MG/0.5ML)		N215866	004	May 13, 2022
+!		12.5MG/0.5ML (12.5MG/0.5ML)		N215866	005	May 13, 2022
+!		15MG/0.5ML (15MG/0.5ML)		N215866	006	May 13, 2022
ZEPBOUND						
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N217806	007	Mar 28, 2024
+!		5MG/0.5ML (5MG/0.5ML)		N217806	008	Mar 28, 2024
+!		7.5MG/0.5ML (7.5MG/0.5ML)		N217806	009	Mar 28, 2024
+!		10MG/0.5ML (10MG/0.5ML)		N217806	010	Mar 28, 2024
+!		12.5MG/0.5ML (12.5MG/0.5ML)		N217806	011	Mar 28, 2024
+!		15MG/0.5ML (15MG/0.5ML)		N217806	012	Mar 28, 2024
ZEPBOUND (AUTOINJECTOR)						
+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N217806	001	Nov 08, 2023
+!		5MG/0.5ML (5MG/0.5ML)		N217806	002	Nov 08, 2023
+!		7.5MG/0.5ML (7.5MG/0.5ML)		N217806	003	Nov 08, 2023
+!		10MG/0.5ML (10MG/0.5ML)		N217806	004	Nov 08, 2023
+!		12.5MG/0.5ML (12.5MG/0.5ML)		N217806	005	Nov 08, 2023
+!		15MG/0.5ML (15MG/0.5ML)		N217806	006	Nov 08, 2023
TIVOZANIB HYDROCHLORIDE						
CAPSULE;ORAL						
FOTIVDA						
+	AVEO PHARMS	EQ 0.89MG BASE		N212904	001	Mar 10, 2021
+!		EQ 1.34MG BASE		N212904	002	Mar 10, 2021
TIZANIDINE HYDROCHLORIDE						
CAPSULE;ORAL						
TIZANIDINE HYDROCHLORIDE						
AB	ALEMBIC	**EQ 2MG BASE**		**A213223**	**001**	Jan 13, 2020
AB		**EQ 4MG BASE**		**A213223**	**002**	Jan 13, 2020
AB		**EQ 6MG BASE**		**A213223**	**003**	Jan 13, 2020
AB	ALKEM LABS LTD	**EQ 2MG BASE**		**A212196**	**001**	Mar 27, 2019
AB		**EQ 4MG BASE**		**A212196**	**002**	Mar 27, 2019
AB		**EQ 6MG BASE**		**A212196**	**003**	Mar 27, 2019
AB	ANDA REPOSITORY	**EQ 4MG BASE**		**A213365**	**001**	May 13, 2024
AB		**EQ 6MG BASE**		**A213365**	**002**	May 13, 2024
AB	APOTEX INC	**EQ 2MG BASE**		**A078868**	**001**	Feb 03, 2012
AB		**EQ 4MG BASE**		**A078868**	**002**	Feb 03, 2012
AB		**EQ 6MG BASE**		**A078868**	**003**	Feb 03, 2012

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL						
TIZANIDINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**EQ 2MG BASE**	**A213544**	**001**	Mar 24, 2020
AB			**EQ 4MG BASE**	**A213544**	**002**	Mar 24, 2020
AB			**EQ 6MG BASE**	**A213544**	**003**	Mar 24, 2020
AB		CADILA PHARMS LTD	**EQ 2MG BASE**	**A210021**	**001**	Mar 26, 2019
AB			**EQ 4MG BASE**	**A210021**	**002**	Mar 26, 2019
AB			**EQ 6MG BASE**	**A210021**	**003**	Mar 26, 2019
AB		JUBILANT GENERICS	**EQ 2MG BASE**	**A209605**	**001**	Aug 04, 2017
AB			**EQ 4MG BASE**	**A209605**	**002**	Aug 04, 2017
AB			**EQ 6MG BASE**	**A209605**	**003**	Aug 04, 2017
AB		NOVAST LABS	**EQ 2MG BASE**	**A210267**	**001**	Mar 12, 2019
AB			**EQ 4MG BASE**	**A210267**	**002**	Mar 12, 2019
AB			**EQ 6MG BASE**	**A210267**	**003**	Mar 12, 2019
AB		RUBICON RESEARCH	**EQ 2MG BASE**	**A213798**	**001**	May 27, 2020
AB			**EQ 4MG BASE**	**A213798**	**002**	May 27, 2020
AB			**EQ 6MG BASE**	**A213798**	**003**	May 27, 2020
AB		ZYDUS PHARMS	**EQ 2MG BASE**	**A208622**	**001**	Mar 03, 2017
AB			**EQ 4MG BASE**	**A208622**	**002**	Mar 03, 2017
AB			**EQ 6MG BASE**	**A208622**	**003**	Mar 03, 2017
ZANAFLEX						
AB	**+**	LEGACY PHARMA USA	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB	**+**		**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+!**		**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002
TIZANIDINE HYDROCHLORIDE						
	!	RUBICON RESEARCH	EQ 8MG BASE	A213798	004	Aug 28, 2025
SOLUTION;ORAL						
ONTRALFY						
	+!	FIDELITY BIOPHARMA	EQ 2MG BASE/5ML	N216190	001	Dec 12, 2024
TABLET;ORAL						
TIZANIDINE HYDROCHLORIDE						
AB		ALKEM LABS LTD	**EQ 2MG BASE**	**A211798**	**001**	Jan 25, 2019
AB			**EQ 4MG BASE**	**A211798**	**002**	Jan 25, 2019
AB		APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB			**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB		CADILA	**EQ 2MG BASE**	**A208187**	**001**	Mar 09, 2018
AB			**EQ 4MG BASE**	**A208187**	**002**	Mar 09, 2018
AB		DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB			**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB		EPIC PHARMA LLC	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB			**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB		OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB			**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB		RISING	**EQ 2MG BASE**	**A076354**	**001**	Mar 28, 2003
AB			**EQ 4MG BASE**	**A076354**	**002**	Mar 28, 2003
AB			**EQ 4MG BASE**	**A218920**	**002**	Aug 07, 2024
AB			**EQ 2MG BASE**	**A218920**	**001**	Aug 07, 2024
AB		SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB			**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB		UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012
ZANAFLEX						
AB	**+!**	LEGACY PHARMA USA	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN

OINTMENT;OPHTHALMIC						
TOBREX						
	+!	NOVARTIS	0.3%	N050555	001	
POWDER;INHALATION						
TOBI PODHALER						
	+!	VIATRIS	28MG	N201688	001	Mar 22, 2013
SOLUTION;INHALATION						
BETHKIS						
AN	**+!**	CHIESI	**300MG/4ML**	**N201820**	**001**	Oct 12, 2012
KITABIS PAK						
AN		PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014
TOBI						
AN	**+!**	VIATRIS	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997
TOBRAMYCIN						
AN		ALKEM LABS LTD	**300MG/5ML**	**A212848**	**001**	Apr 01, 2021
AN		AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN		DR REDDYS LABS SA	**300MG/5ML**	**A207080**	**001**	Jul 09, 2018
AN		HIKMA	**300MG/5ML**	**A201422**	**001**	May 28, 2014
AN		LUPIN	**300MG/5ML**	**A208964**	**001**	Mar 22, 2017
AN		MANKIND PHARMA	**300MG/5ML**	**A214478**	**001**	Jun 30, 2023
AN			**300MG/4ML**	**A216725**	**001**	Sep 22, 2022
AN		MICRO LABS	**300MG/5ML**	**A217344**	**001**	Jul 27, 2023
AN		SUN PHARM	**300MG/5ML**	**A207136**	**001**	Dec 26, 2019
AN		TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013
AN			**300MG/4ML**	**A210915**	**001**	Jun 26, 2019

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT		ALEMBIC	**0.3%**	**A211847**	**001**	Apr 19, 2019
AT		BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993
AT		CHARTWELL RX	**0.3%**	**A065026**	**001**	Sep 11, 2001
AT		GLAND	**0.3%**	**A212628**	**001**	Mar 09, 2021
AT	**!**	SOMERSET THERAPS LLC	**0.3%**	**A207444**	**001**	Jun 28, 2017

TOBREX

AT		SANDOZ	**0.3%**	**A062535**	**001**	Dec 13, 1984

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP		BAXTER HLTHCARE CORP	**EQ 40MG BASE/ML**	**A206965**	**001**	Jul 01, 2016
AP	**!**	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001**	Nov 29, 2002
AP	**!**		**EQ 40MG BASE/ML**	**A065122**	**002**	Nov 29, 2002
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001**	Jul 13, 2004
AP		GLAND	**EQ 10MG BASE/ML**	**A209621**	**001**	Feb 11, 2021
AP			**EQ 40MG BASE/ML**	**A209621**	**002**	Feb 11, 2021
AP			**EQ 1.2GM BASE/VIAL**	**A211189**	**001**	May 18, 2021
AP		HIKMA	**EQ 40MG BASE/ML**	**A063117**	**001**	Apr 26, 1991
AP		HOSPIRA	**EQ 40MG BASE/ML**	**A063111**	**001**	Apr 30, 1991
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001**	Mar 11, 2008
AP		SLATE RUN PHARMA	**EQ 1.2GM BASE/VIAL**	**A217029**	**001**	Feb 01, 2023
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001**	Sep 16, 2014
AP	**!**	XGEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001**	Aug 17, 2001

TOBRAMYCIN SULFATE (PHARMACY BULK)

AP	**!**	FRESENIUS KABI USA	**EQ 40MG BASE/ML**	**A065120**	**001**	Nov 29, 2002
AP		GLAND	**EQ 40MG BASE/ML**	**A209346**	**001**	Feb 09, 2021

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

	+!	PFIZER	EQ 1MG BASE/ML	N213082	001	Sep 25, 2020

TABLET;ORAL

XELJANZ

	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012
	+!		EQ 10MG BASE	N203214	002	May 30, 2018

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB CITRATE

AB		AJANTA PHARMA LTD	**EQ 11MG BASE**	**A219542**	**001**	Aug 19, 2025
AB		BIOCON PHARMA	**EQ 11MG BASE**	**A219442**	**001**	Nov 17, 2025
AB		SINOTHERAPEUTICS INC	**EQ 11MG BASE**	**A216001**	**001**	Sep 30, 2025

XELJANZ XR

AB	**+**	PFIZER	**EQ 11MG BASE**	**N208246**	**001**	Feb 23, 2016
	+!		EQ 22MG BASE	N208246	002	Dec 12, 2019

TOFERSEN

SOLUTION;INTRATHECAL

QALSODY

	+!	BIOGEN MA	100MG/15ML (6.7MG/ML)	N215887	001	Apr 25, 2023

TOLCAPONE

TABLET;ORAL

TASMAR

AB	**+!**	BAUSCH	**100MG**	**N020697**	**001**	Jan 29, 1998

TOLCAPONE

AB		NOVAST LABS	**100MG**	**A208937**	**001**	Aug 07, 2018

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

	!	RISING	EQ 400MG BASE	A073393	001	May 27, 1993

TABLET;ORAL

TOLMETIN SODIUM

	!	RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA

AB	**+**	UPJOHN	**2MG**	**N021228**	**001**	Dec 22, 2000
AB	**+!**		**4MG**	**N021228**	**002**	Dec 22, 2000

TOLTERODINE TARTRATE

AB		AJANTA PHARMA LTD	**2MG**	**A213397**	**001**	May 19, 2020
AB			**4MG**	**A213397**	**002**	May 19, 2020
AB		HETERO LABS LTD III	**2MG**	**A206419**	**001**	Dec 12, 2017
AB			**4MG**	**A206419**	**002**	Dec 12, 2017
AB		INVENTIA HLTHCARE	**2MG**	**A204562**	**001**	Aug 19, 2019
AB			**4MG**	**A204562**	**002**	Aug 19, 2019
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001**	Nov 22, 2016
AB			**4MG**	**A079141**	**002**	Nov 22, 2016
AB		TORRENT	**2MG**	**A203016**	**001**	Aug 11, 2015
AB			**4MG**	**A203016**	**002**	Aug 11, 2015
AB		UNICHEM	**2MG**	**A216917**	**001**	Aug 27, 2024
AB			**4MG**	**A216917**	**002**	Aug 27, 2024
AB		UTOPIC PHARMS	**2MG**	**A213858**	**001**	Feb 02, 2021
AB			**4MG**	**A213858**	**002**	Feb 02, 2021

TABLET;ORAL

DETROL

AB	**+**	UPJOHN	**1MG**	**N020771**	**001**	Mar 25, 1998
AB	**+!**		**2MG**	**N020771**	**002**	Mar 25, 1998

TOLTERODINE TARTRATE

AB		HETERO LABS LTD V	**1MG**	**A204397**	**001**	Aug 02, 2021
AB			**2MG**	**A204397**	**002**	Aug 02, 2021
AB		IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB			**2MG**	**A077006**	**002**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB			**2MG**	**A203409**	**002**	Aug 31, 2015
AB		PTS CONSULTING	**1MG**	**A204721**	**001**	Jan 24, 2020
AB			**2MG**	**A204721**	**002**	Jan 24, 2020
AB		RISING	**1MG**	**A210775**	**001**	Dec 30, 2019
AB			**2MG**	**A210775**	**002**	Dec 30, 2019
AB		UNICHEM	**1MG**	**A205399**	**001**	Aug 05, 2020
AB			**2MG**	**A205399**	**002**	Aug 05, 2020

TOLVAPTAN

TABLET;ORAL

JYNARQUE

AB	**+!**	OTSUKA	**45MG**	**N204441**	**003**	Apr 23, 2018
AB	**+**		**90MG**	**N204441**	**005**	Apr 23, 2018

TOLVAPTAN

AB		APOTEX	**45MG**	**A218381**	**003**	Nov 10, 2025
AB			**90MG**	**A218381**	**005**	Nov 10, 2025
AB		LUPIN LTD	**45MG**	**A216063**	**003**	Apr 23, 2025
AB			**90MG**	**A216063**	**005**	Apr 23, 2025

SAMSCA

AB1	**+**	OTSUKA	**15MG**	**N022275**	**001**	May 19, 2009
AB1	**+!**		**30MG**	**N022275**	**002**	May 19, 2009

TOLVAPTAN

AB1		ALKEM LABS LTD	**15MG**	**A211891**	**003**	Sep 06, 2022
AB1			**30MG**	**A211891**	**001**	May 19, 2020
AB1		APOTEX	**15MG**	**A207605**	**002**	Sep 06, 2022
AB1			**30MG**	**A207605**	**001**	May 19, 2020
AB1		HETERO LABS LTD V	**15MG**	**A205646**	**002**	Sep 06, 2022
AB1			**30MG**	**A205646**	**001**	Jul 16, 2021
AB1		MSN	**15MG**	**A216949**	**001**	Jun 21, 2023
AB1			**30MG**	**A216949**	**002**	Jun 21, 2023
AB1		PH HEALTH	**15MG**	**A206119**	**001**	Feb 15, 2022
AB1			**30MG**	**A206119**	**002**	Feb 15, 2022

JYNARQUE

AB2	**+**	OTSUKA	**15MG**	**N204441**	**001**	Apr 23, 2018
AB2	**+**		**30MG**	**N204441**	**002**	Apr 23, 2018

TOLVAPTAN

TABLET;ORAL

JYNARQUE						
AB2	+		**60MG**	**N204441**	**004**	Apr 23, 2018
TOLVAPTAN						
AB2		APOTEX	**15MG**	**A218381**	**001**	Nov 10, 2025
AB2			**30MG**	**A218381**	**002**	Nov 10, 2025
AB2			**60MG**	**A218381**	**004**	Nov 10, 2025
AB2		LUPIN LTD	**15MG**	**A216063**	**001**	Apr 23, 2025
AB2			**30MG**	**A216063**	**002**	Apr 23, 2025
AB2			**60MG**	**A216063**	**004**	Apr 23, 2025
		ALKEM LABS LTD	60MG	A211891	002	May 19, 2020

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX						
AB	+	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	+!		**25MG**	**N020844**	**002**	Oct 26, 1998
TOPIRAMATE						
AB		ALKEM LABS LTD	**15MG**	**A218482**	**001**	Jun 13, 2024
AB			**25MG**	**A218482**	**002**	Jun 13, 2024
AB		ANDA REPOSITORY	**15MG**	**A218642**	**001**	Oct 10, 2024
AB			**25MG**	**A218642**	**002**	Oct 10, 2024
AB		AUROBINDO PHARMA LTD	**15MG**	**A215449**	**001**	Sep 27, 2023
AB			**25MG**	**A215449**	**002**	Sep 27, 2023
AB		GLENMARK PHARMS LTD	**15MG**	**A217869**	**001**	Jul 16, 2024
AB			**25MG**	**A217869**	**002**	Jul 16, 2024
AB		RUBICON RESEARCH	**15MG**	**A216683**	**001**	May 27, 2025
AB			**25MG**	**A216683**	**002**	May 27, 2025
AB			**50MG**	**A216683**	**003**	May 27, 2025
AB		STRIDES PHARMA	**15MG**	**A078418**	**001**	Oct 14, 2009
AB			**25MG**	**A078418**	**002**	Oct 14, 2009
AB		TWI PHARMS	**15MG**	**A217694**	**001**	Dec 05, 2023
AB			**25MG**	**A217694**	**002**	Dec 05, 2023
AB		ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB			**25MG**	**A078877**	**002**	Oct 14, 2009
AB			**50MG**	**A078877**	**003**	Oct 23, 2024

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE						
AB1		ACTAVIS LABS FL	**25MG**	**A206210**	**001**	Mar 10, 2023
AB1			**50MG**	**A206210**	**002**	Mar 10, 2023
AB1			**100MG**	**A206210**	**003**	Mar 10, 2023
AB1			**200MG**	**A206210**	**004**	Mar 10, 2023
AB1		AJANTA PHARMA LTD	**25MG**	**A215663**	**001**	Aug 15, 2023
AB1			**50MG**	**A215663**	**002**	Aug 15, 2023
AB1			**100MG**	**A215663**	**003**	Aug 15, 2023
AB1			**200MG**	**A215663**	**004**	Aug 15, 2023
AB1		ALKEM LABS LTD	**25MG**	**A217248**	**001**	Jun 20, 2023
AB1			**50MG**	**A217248**	**002**	Jun 20, 2023
AB1			**100MG**	**A217248**	**003**	Jun 20, 2023
AB1			**200MG**	**A217248**	**004**	Jun 20, 2023
AB1		DR REDDYS	**25MG**	**A217231**	**001**	Nov 17, 2023
AB1			**50MG**	**A217231**	**002**	Nov 17, 2023
AB1			**100MG**	**A217231**	**003**	Nov 17, 2023
AB1			**200MG**	**A217231**	**004**	Nov 17, 2023
AB1		LUPIN LTD	**25MG**	**A215561**	**001**	Jul 11, 2024
AB1			**50MG**	**A215561**	**002**	Jul 11, 2024
AB1			**100MG**	**A215561**	**003**	Jul 11, 2024
AB1			**200MG**	**A215561**	**004**	Jul 11, 2024
AB1		PH HEALTH	**25MG**	**A205976**	**002**	May 04, 2023
AB1			**50MG**	**A205976**	**003**	May 04, 2023
AB1			**100MG**	**A205976**	**004**	May 04, 2023
AB1			**200MG**	**A205976**	**001**	Mar 01, 2023
AB1		ZYDUS	**25MG**	**A207382**	**001**	Nov 24, 2017
AB1			**50MG**	**A207382**	**002**	Nov 24, 2017
AB1			**100MG**	**A207382**	**003**	Nov 24, 2017
AB1			**200MG**	**A207382**	**004**	Oct 30, 2023
TROKENDI XR						
AB1	+	SUPERNUS PHARMS	**25MG**	**N201635**	**001**	Aug 16, 2013
AB1	+		**50MG**	**N201635**	**002**	Aug 16, 2013
AB1	+		**100MG**	**N201635**	**003**	Aug 16, 2013

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

TROKENDI XR

AB1	**+!**		**200MG**	**N201635**	**004**	Aug 16, 2013

QUDEXY XR

AB2	**+**	UPSHER SMITH LABS	**25MG**	**N205122**	**001**	Mar 11, 2014
AB2	**+**		**50MG**	**N205122**	**002**	Mar 11, 2014
AB2	**+**		**100MG**	**N205122**	**003**	Mar 11, 2014
AB2	**+**		**150MG**	**N205122**	**004**	Mar 11, 2014
AB2	**+!**		**200MG**	**N205122**	**005**	Mar 11, 2014

TOPIRAMATE

AB2		AJANTA PHARMA LTD	**25MG**	**A219564**	**001**	Sep 02, 2025
AB2			**50MG**	**A219564**	**002**	Sep 02, 2025
AB2			**100MG**	**A219564**	**003**	Sep 02, 2025
AB2			**150MG**	**A219564**	**004**	Sep 02, 2025
AB2			**200MG**	**A219564**	**005**	Sep 02, 2025
AB2		AMTA	**25MG**	**A218695**	**001**	Dec 03, 2024
AB2			**50MG**	**A218695**	**002**	Dec 03, 2024
AB2			**100MG**	**A218695**	**003**	Dec 03, 2024
AB2			**150MG**	**A218695**	**004**	Dec 03, 2024
AB2			**200MG**	**A218695**	**005**	Dec 03, 2024
AB2		GLENMARK PHARMS LTD	**25MG**	**A210278**	**001**	Feb 01, 2021
AB2			**50MG**	**A210278**	**002**	Feb 01, 2021
AB2			**100MG**	**A210278**	**003**	Feb 01, 2021
AB2			**150MG**	**A210278**	**004**	Feb 01, 2021
AB2			**200MG**	**A210278**	**005**	Feb 01, 2021
AB2		XIAMEN LP PHARM CO	**25MG**	**A215638**	**001**	Nov 05, 2024
AB2			**50MG**	**A215638**	**002**	Nov 05, 2024
AB2			**100MG**	**A215638**	**003**	Nov 05, 2024
AB2			**150MG**	**A215638**	**004**	Nov 05, 2024
AB2			**200MG**	**A215638**	**005**	Nov 05, 2024
AB2		ZYDUS	**25MG**	**A208949**	**001**	Nov 29, 2022
AB2			**50MG**	**A208949**	**002**	Nov 29, 2022
AB2			**100MG**	**A208949**	**003**	Nov 29, 2022
AB2			**150MG**	**A208949**	**004**	Nov 29, 2022
AB2			**200MG**	**A208949**	**005**	Nov 29, 2022

SOLUTION;ORAL

EPRONTIA

AB	**+!**	AZURITY	**25MG/ML**	**N214679**	**001**	Nov 05, 2021

TOPIRAMATE

AB		ALKEM LABS LTD	**25MG/ML**	**A217795**	**001**	Oct 31, 2024

TABLET;ORAL

TOPAMAX

AB	**+**	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB	**+**		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	**+!**		**100MG**	**N020505**	**001**	Dec 24, 1996
AB	**+**		**200MG**	**N020505**	**002**	Dec 24, 1996

TOPIRAMATE

AB		ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB			**50MG**	**A076311**	**002**	Mar 27, 2009
AB			**100MG**	**A076311**	**003**	Mar 27, 2009
AB			**200MG**	**A076311**	**004**	Mar 27, 2009
AB		ASCENT PHARMS INC	**25MG**	**A215414**	**001**	Aug 26, 2021
AB			**50MG**	**A215414**	**002**	Aug 26, 2021
AB			**100MG**	**A215414**	**003**	Aug 26, 2021
AB			**200MG**	**A215414**	**004**	Aug 26, 2021
AB		AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB			**50MG**	**A078462**	**002**	Mar 27, 2009
AB			**100MG**	**A078462**	**003**	Mar 27, 2009
AB			**200MG**	**A078462**	**004**	Mar 27, 2009
AB		CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB			**50MG**	**A076343**	**002**	Mar 27, 2009
AB			**100MG**	**A076343**	**003**	Mar 27, 2009
AB			**200MG**	**A076343**	**004**	Mar 27, 2009
AB		GLENMARK PHARMS LTD	**25MG**	**A077627**	**001**	Mar 27, 2009
AB			**50MG**	**A077627**	**002**	Mar 27, 2009
AB			**100MG**	**A077627**	**003**	Mar 27, 2009
AB			**200MG**	**A077627**	**004**	Mar 27, 2009
AB		INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB			**50MG**	**A079162**	**002**	Mar 27, 2009
AB			**100MG**	**A079162**	**003**	Mar 27, 2009
AB			**200MG**	**A079162**	**004**	Mar 27, 2009

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB		PHARMACO	**25MG**	**A077733**	**001**	Mar 27, 2009
AB			**50MG**	**A077733**	**002**	Mar 27, 2009
AB			**100MG**	**A077733**	**003**	Mar 27, 2009
AB			**200MG**	**A077733**	**004**	Mar 27, 2009
AB		SUN PHARM	**25MG**	**A090278**	**001**	Mar 27, 2009
AB			**50MG**	**A090278**	**002**	Mar 27, 2009
AB			**100MG**	**A090278**	**003**	Mar 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB			**50MG**	**A090162**	**002**	Mar 27, 2009
AB			**100MG**	**A090162**	**003**	Mar 27, 2009
AB			**200MG**	**A090162**	**004**	Feb 19, 2013
AB		ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB			**50MG**	**A078235**	**002**	Mar 27, 2009
AB			**100MG**	**A078235**	**003**	Mar 27, 2009
AB			**200MG**	**A078235**	**004**	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

	+	SANDOZ	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
	+!		EQ 1MG BASE	N020981	002	Oct 11, 2007

INJECTABLE;INJECTION

HYCAMTIN

AP	**+!**	SANDOZ	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996

TOPOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP		ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP		FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010
AP		NOVAST LABS	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP		SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011
AP		TEYRO LABS	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204406**	**002**	Jul 06, 2017
AP	**+!**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017

TOREMIFENE CITRATE

TABLET;ORAL

TOREMIFENE CITRATE

AB		MSN	**EQ 60MG BASE**	**A212818**	**001**	Aug 18, 2020
AB	**!**	RISING	**EQ 60MG BASE**	**A208813**	**001**	Dec 04, 2018

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB		AUROBINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB			**10MG**	**A078249**	**002**	Oct 17, 2007
AB			**20MG**	**A078249**	**003**	Oct 17, 2007
AB			**100MG**	**A078249**	**004**	Oct 17, 2007
AB		COREPHARMA	**5MG**	**A076894**	**001**	May 31, 2005
AB			**10MG**	**A076894**	**002**	May 31, 2005
AB			**20MG**	**A076894**	**003**	May 31, 2005
AB			**100MG**	**A076894**	**004**	May 31, 2005
AB		HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB			**10MG**	**A079234**	**002**	Jan 27, 2009
AB			**20MG**	**A079234**	**003**	Jan 27, 2009
AB			**100MG**	**A079234**	**004**	Jan 27, 2009
AB		HIKMA	**20MG**	**A076943**	**003**	Mar 01, 2005
AB		PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB			**10MG**	**A076346**	**002**	May 30, 2003
AB	**!**		**20MG**	**A076346**	**003**	May 30, 2003
AB			**100MG**	**A076346**	**004**	Oct 19, 2004
AB		STRIDES PHARMA INTL	**5MG**	**A076226**	**001**	May 27, 2003
AB			**5MG**	**A090613**	**001**	Mar 22, 2011
AB			**10MG**	**A076226**	**002**	May 27, 2003
AB			**10MG**	**A090613**	**002**	Mar 22, 2011
AB			**20MG**	**A076226**	**003**	May 27, 2003
AB			**20MG**	**A090613**	**003**	Mar 22, 2011

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB			**100MG**	**A076226**	**004**	May 27, 2003
AB			**100MG**	**A090613**	**004**	Mar 22, 2011

SOAANZ

	+	SARFE PHARMS	40MG	N213218	003	Nov 17, 2021

TOVORAFENIB

FOR SUSPENSION;ORAL

OJEMDA

	+!	DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024

TABLET;ORAL

OJEMDA

	+!	DAY ONE BIOPHARMS	100MG	N217700	001	Apr 23, 2024

TRABECTEDIN

POWDER;INTRAVENOUS

YONDELIS

	+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRADIPITANT

CAPSULE;ORAL

NEREUS

	+!	VANDA PHARMS INC	85MG	N220152	001	Dec 30, 2025

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CONZIP

	+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
	+		200MG	N022370	002	May 07, 2010
	+		300MG	N022370	003	May 07, 2010

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A203494**	**001**	Mar 31, 2014
AB		CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB		GRAVITI PHARMS	**50MG**	**A075968**	**001**	Jun 25, 2002
AB			**100MG**	**A075968**	**002**	Aug 02, 2024
AB		RUBICON RESEARCH	**50MG**	**A208708**	**001**	Jun 28, 2019
AB	!		**100MG**	**A208708**	**002**	Jun 28, 2019
AB		SENORES PHARMS	**50MG**	**A090404**	**001**	Jan 31, 2011
AB		STRIDES PHARMA	**50MG**	**A202075**	**001**	Nov 28, 2011
AB		SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		UNICHEM	**50MG**	**A211825**	**001**	Aug 09, 2019
		RUBICON RESEARCH	25MG	A208708	003	Nov 27, 2023
			75MG	A208708	004	Apr 04, 2024

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1	!	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		MACLEODS PHARMS LTD	**100MG**	**A209404**	**001**	Jan 31, 2025
AB1			**200MG**	**A209404**	**002**	Jan 31, 2025
AB1			**300MG**	**A209404**	**003**	Jan 31, 2025

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL

MEKINIST

	+!	NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023

TABLET;ORAL

MEKINIST

	+	NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013
	+!		EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007
AB			**2MG**	**A078438**	**002**	Jun 12, 2007
AB			**4MG**	**A078438**	**003**	Jun 12, 2007
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008
AB			**2MG**	**A078508**	**001**	Jun 18, 2008
AB			**4MG**	**A078508**	**002**	Jun 18, 2008

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007
AB			**2MG**	**A077522**	**002**	Jun 12, 2007
AB	!		**4MG**	**A077522**	**003**	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

	GLENMARK PHARMS LTD	1MG;240MG	A079135	004	Aug 30, 2010
		2MG;180MG	A079135	001	May 26, 2010
		2MG;240MG	A079135	002	May 26, 2010
!		4MG;240MG	A079135	003	May 05, 2010

TRANEXAMIC ACID

INJECTABLE;INJECTION

CYKLOKAPRON

AP	**+!**	PFIZER	**100MG/ML**	**N019281**	**001**	Dec 30, 1986

TRANEXAMIC ACID

AP		AM REGENT	**100MG/ML**	**A201885**	**001**	Aug 10, 2011
AP		AMNEAL PHARMS CO	**100MG/ML**	**A208840**	**001**	Feb 28, 2017
AP		APOTEX	**100MG/ML**	**A209860**	**001**	Jan 14, 2020
AP		AVET LIFESCIENCES	**100MG/ML**	**A203521**	**001**	Aug 12, 2014
AP		CAPLIN	**100MG/ML**	**A212360**	**001**	Jul 17, 2019
AP		EPIC PHARMA LLC	**100MG/ML**	**A202373**	**001**	Nov 17, 2011
AP		EUGIA PHARMA	**100MG/ML**	**A205035**	**001**	Jan 14, 2016
AP		GLAND	**100MG/ML**	**A207239**	**001**	Feb 13, 2017
AP		HERITAGE	**100MG/ML**	**A202436**	**001**	Feb 11, 2014
AP		MICRO LABS	**100MG/ML**	**A206713**	**001**	Jun 27, 2017
AP		MILLA PHARMS	**100MG/ML**	**A212676**	**001**	Jul 17, 2019
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011
AP		XGEN PHARMS	**100MG/ML**	**A201580**	**001**	Jun 14, 2013

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

AP		AMNEAL	**1GM/100ML (10MG/ML)**	**A217155**	**001**	Oct 16, 2023
AP	**+!**	EXELA PHARMA	**1GM/100ML (10MG/ML)**	**N212020**	**001**	Apr 15, 2019
AP		FRESENIUS KABI USA	**1GM/100ML (10MG/ML)**	**A218242**	**001**	Aug 15, 2024
AP		GLAND	**1GM/100ML (10MG/ML)**	**A218599**	**001**	Apr 16, 2024
AP		HERITAGE	**1GM/100ML (10MG/ML)**	**A218896**	**001**	Jun 02, 2025
AP		NEXUS	**1GM/100ML (10MG/ML)**	**A216877**	**001**	Apr 16, 2024

TABLET;ORAL

LYSTEDA

AB	**+!**	AMRING PHARMS	**650MG**	**N022430**	**001**	Nov 13, 2009

TRANEXAMIC ACID

AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012
AB		ANI PHARMS	**650MG**	**A203256**	**001**	Jul 25, 2016
AB		APPCO	**650MG**	**A218729**	**001**	Jun 11, 2025
AB		AUROBINDO PHARMA USA	**650MG**	**A205133**	**001**	Sep 21, 2015
AB		BIONPHARMA	**650MG**	**A219123**	**001**	Aug 19, 2025
AB		RUBICON RESEARCH	**650MG**	**A218320**	**001**	Jun 11, 2024

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

AB	**+!**	ADVANZ PHARMA	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985

TRANYLCYPROMINE SULFATE

AB		CROSSMEDIKA SA	**EQ 10MG BASE**	**A213503**	**001**	Jun 27, 2022
AB		NOVITIUM PHARMA	**EQ 10MG BASE**	**A206856**	**001**	Apr 17, 2018
AB		STRIDES PHARMA INTL	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006

TRAVOPROST

IMPLANT;INTRACAMERAL

IDOSE TR

	+!	GLAUKOS	75MCG	N218010	001	Dec 13, 2023

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

AT2	**+!**	SANDOZ	**0.004%**	**N021994**	**001**	Sep 21, 2006

TRAVOPROST

AT2		ALEMBIC	**0.004%**	**A214687**	**001**	Dec 17, 2025
AT2		APOTEX	**0.004%**	**A203431**	**001**	Jul 10, 2015
AT2		GLAND	**0.004%**	**A218159**	**001**	Jul 12, 2024
AT2		MICRO LABS	**0.004%**	**A203767**	**001**	Mar 19, 2021
AT2		MYLAN	**0.004%**	**A205050**	**001**	Jul 07, 2017

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT2		SOMERSET THERAPS LLC	**0.004%**	**A217228**	**001**	Sep 23, 2024
	!	CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

SOLUTION;ORAL

RALDESY

	+!	KAMAT	10MG/ML	N218637	001	Nov 26, 2024

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A206923**	**001**	Sep 08, 2017
AB			**100MG**	**A206923**	**002**	Sep 08, 2017
AB			**150MG**	**A206923**	**003**	Sep 08, 2017
AB			**300MG**	**A206923**	**004**	Sep 08, 2017
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	!	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		AUROBINDO PHARMA	**50MG**	**A204852**	**001**	Feb 05, 2020
AB			**100MG**	**A204852**	**002**	Feb 05, 2020
AB			**150MG**	**A204852**	**003**	Feb 05, 2020
AB			**300MG**	**A204852**	**004**	Feb 05, 2020
AB		CROSSMEDIKA SA	**50MG**	**A211116**	**001**	May 20, 2024
AB			**100MG**	**A211116**	**002**	May 20, 2024
AB			**150MG**	**A211116**	**003**	May 20, 2024
AB			**300MG**	**A211116**	**004**	May 20, 2024
AB		GRANULES	**50MG**	**A218988**	**001**	Aug 08, 2024
AB			**100MG**	**A218988**	**002**	Aug 08, 2024
AB			**150MG**	**A218988**	**003**	Aug 08, 2024
AB			**300MG**	**A218988**	**004**	Aug 08, 2024
AB		GRAVITI PHARMS	**50MG**	**A217740**	**001**	Aug 27, 2024
AB			**100MG**	**A217740**	**002**	Aug 27, 2024
AB			**150MG**	**A217740**	**003**	Aug 27, 2024
AB			**300MG**	**A217740**	**004**	Aug 27, 2024
AB		OXFORD PHARMS	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDUSTRIES	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013
AB		ZYDUS PHARMS	**50MG**	**A205253**	**001**	Oct 10, 2017
AB			**100MG**	**A205253**	**002**	Oct 10, 2017
AB			**150MG**	**A205253**	**003**	Oct 10, 2017
AB			**300MG**	**A205253**	**004**	Oct 10, 2017

TREOSULFAN

POWDER;INTRAVENOUS

GRAFAPEX

	+!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025
	+!		5GM/VIAL	N214759	002	Jan 21, 2025

TREPROSTINIL

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

AP	**+!**	UNITED THERAP	**1MG/ML**	**N021272**	**001**	May 21, 2002
AP	**+!**		**2.5MG/ML**	**N021272**	**002**	May 21, 2002
AP	**+!**		**5MG/ML**	**N021272**	**003**	May 21, 2002
AP	**+!**		**10MG/ML**	**N021272**	**004**	May 21, 2002

TREPROSTINIL

AP		ALEMBIC GLOBAL	**1MG/ML**	**A211574**	**001**	Feb 11, 2021
AP			**2.5MG/ML**	**A211574**	**002**	Feb 11, 2021
AP			**5MG/ML**	**A211574**	**003**	Feb 11, 2021
AP			**10MG/ML**	**A211574**	**004**	Feb 11, 2021
AP		DR REDDYS	**1MG/ML**	**A210214**	**001**	May 22, 2020

TREPROSTINIL						
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS						
TREPROSTINIL						
AP			**2.5MG/ML**	**A210214**	**002**	May 22, 2020
AP			**5MG/ML**	**A210214**	**003**	May 22, 2020
AP			**10MG/ML**	**A210214**	**004**	May 22, 2020
AP		SANDOZ	**1MG/ML**	**A203649**	**001**	Nov 30, 2017
AP			**2.5MG/ML**	**A203649**	**002**	Nov 30, 2017
AP			**5MG/ML**	**A203649**	**003**	Nov 30, 2017
AP			**10MG/ML**	**A203649**	**004**	Nov 30, 2017
AP		TEVA PHARMS USA	**1MG/ML**	**A206648**	**001**	Sep 26, 2019
AP			**2.5MG/ML**	**A206648**	**002**	Sep 26, 2019
AP			**5MG/ML**	**A206648**	**003**	Sep 26, 2019
AP			**10MG/ML**	**A206648**	**004**	Sep 26, 2019
REMODULIN						
	+!	UNITED THERAP	0.4MG/ML	N021272	008	Sep 28, 2023
POWDER;INHALATION						
TYVASO DPI						
	+!	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022
	+!		0.032MG/INH	N214324	002	May 23, 2022
	+!		0.048MG/INH	N214324	003	May 23, 2022
	+!		0.064MG/INH	N214324	004	May 23, 2022
	+!		0.08MG/INH	N214324	005	Oct 24, 2024
SOLUTION;INHALATION						
TYVASO						
	+!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009
TREPROSTINIL DIOLAMINE						
TABLET, EXTENDED RELEASE;ORAL						
ORENITRAM						
	+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
	+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
	+!		EQ 1MG BASE	N203496	003	Dec 20, 2013
	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
	+		EQ 5MG BASE	N203496	005	Oct 07, 2016
TREPROSTINIL SODIUM						
POWDER;INHALATION						
YUTREPIA						
	+!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025
	+!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025
	+!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025
	+!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025
TRETINOIN						
CAPSULE;ORAL						
TRETINOIN						
AB		GLENMARK PHARMS LTD	**10MG**	**A208279**	**001**	Dec 23, 2016
AB	**!**	PH HEALTH	**10MG**	**A201687**	**001**	Oct 24, 2012
CREAM;TOPICAL						
AVITA						
AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997
RETIN-A						
AB	**+!**	BAUSCH	**0.025%**	**N019049**	**001**	Sep 16, 1988
AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**	
TRETINOIN						
AB		ALEMBIC	**0.025%**	**A218399**	**001**	Aug 14, 2025
AB			**0.1%**	**A217804**	**001**	Apr 29, 2024
AB		ENCUBE	**0.025%**	**A217831**	**001**	Jul 10, 2025
AB		PADAGIS US	**0.025%**	**A075264**	**001**	Dec 24, 1998
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998
AB		SUN PHARMA CANADA	**0.025%**	**A215713**	**001**	Jan 05, 2023
AB			**0.1%**	**A211645**	**001**	Jan 22, 2019
AB		ZYDUS LIFESCIENCES	**0.1%**	**A218561**	**001**	Apr 25, 2024
RETIN-A						
AB1	**+!**	VALEANT BERMUDA	**0.05%**	**N017522**	**001**	
TRETINOIN						
AB1		PADAGIS US	**0.05%**	**A075265**	**001**	Dec 24, 1998
AB1		SUN PHARMA CANADA	**0.05%**	**A211644**	**001**	Jan 25, 2019
RENOVA						
	+!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

TRETINOIN

GEL;TOPICAL

ATRALIN

AB	**+!**	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007

RETIN-A

AB	**+!**	BAUSCH	**0.01%**	**N017955**	**001**	
AB	**+!**	VALEANT INTL	**0.025%**	**N017579**	**002**	

RETIN-A-MICRO

AB	**+!**	BAUSCH	**0.08%**	**N020475**	**003**	Jan 28, 2014

TRETINOIN

AB		AUROBINDO PHARMA LTD	**0.01%**	**A218246**	**001**	Jan 13, 2025
AB			**0.025%**	**A218245**	**001**	Feb 27, 2025
AB		ENCUBE	**0.01%**	**A217588**	**001**	Mar 03, 2025
AB			**0.025%**	**A217587**	**001**	Mar 03, 2025
AB		MYLAN	**0.05%**	**A207955**	**001**	Aug 13, 2015
AB		PADAGIS US	**0.01%**	**A075589**	**001**	Jun 11, 2002
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000

TRETINOIN MICROSPHERE

AB		ENCUBE	**0.08%**	**A215609**	**001**	Aug 22, 2023

RETIN-A MICRO

	+!	BAUSCH	0.04%	N020475	002	May 10, 2002
	+!		0.1%	N020475	001	Feb 07, 1997

RETIN-A-MICRO

	+!	BAUSCH	0.06%	N020475	004	Oct 23, 2017

LOTION;TOPICAL

ALTRENO

	+!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		ALKEM LABS LTD	**0.025%**	**A207651**	**001**	Dec 26, 2017
AT			**0.1%**	**A207651**	**002**	Dec 26, 2017
AT			**0.5%**	**A207651**	**003**	Dec 26, 2017
AT		CHARTWELL RX	**0.025%**	**A208763**	**001**	Feb 01, 2017
AT			**0.1%**	**A208763**	**002**	Feb 01, 2017
AT			**0.5%**	**A208763**	**003**	Feb 01, 2017
AT		COSETTE	**0.025%**	**A089797**	**001**	May 31, 1991
AT			**0.1%**	**A089798**	**001**	May 31, 1991
AT		ENCUBE	**0.1%**	**A208848**	**001**	Sep 18, 2017
AT	**+!**	FOUGERA PHARMS	**0.025%**	**A085692**	**001**	
AT	**+!**		**0.1%**	**A085692**	**003**	
AT	**+!**		**0.5%**	**A085692**	**002**	
AT		MACLEODS PHARMS LTD	**0.025%**	**A209535**	**001**	May 18, 2018
AT			**0.1%**	**A209535**	**002**	May 18, 2018
AT			**0.5%**	**A209535**	**003**	May 18, 2018
AT		MICRO LABS	**0.025%**	**A040671**	**001**	Jun 09, 2006
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006
AT		PADAGIS US	**0.025%**	**A086413**	**002**	
AT			**0.1%**	**A086413**	**003**	
AT			**0.5%**	**A086413**	**001**	
AT		TARO	**0.1%**	**A040039**	**001**	Nov 26, 1997

TRIDERM

AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

	+!	PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017

INJECTABLE;INJECTION

KENALOG-10

AB	**+**	APOTHECON	**10MG/ML**	**N012041**	**001**	

KENALOG-40

AB	**+!**	APOTHECON	**40MG/ML**	**N014901**	**001**	

TRIAMCINOLONE ACETONIDE

AB		ALEMBIC	**40MG/ML**	**A218601**	**001**	Oct 17, 2025
AB		AMNEAL	**40MG/ML**	**A207550**	**001**	Dec 11, 2017
AB		DR REDDYS	**10MG/ML**	**A218773**	**001**	Mar 12, 2025
AB			**40MG/ML**	**A218421**	**001**	Apr 11, 2025
AB		EUGIA PHARMA	**40MG/ML**	**A212400**	**001**	Jul 05, 2022
AB		HIKMA	**40MG/ML**	**A215254**	**001**	Dec 09, 2024
AB		LONG GROVE PHARMS	**40MG/ML**	**A213543**	**001**	Jan 19, 2022

TRIAMCINOLONE ACETONIDE							
INJECTABLE;INJECTION							
TRIAMCINOLONE ACETONIDE							
AB		MYLAN LABS LTD	**40MG/ML**	**A212567**	**001**	Nov 02, 2022
AB		TEVA PHARMS USA	**40MG/ML**	**A209852**	**001**	Oct 05, 2018
KENALOG-80							
	+!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019
INJECTABLE;INTRAVITREAL							
TRIESENCE							
	+!	HARROW EYE	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007
LOTION;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		COSETTE	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		EPIC PHARMA LLC	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		MICRO LABS	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT	!	PHARMOBEDIENT	**0.025%**	**A088450**	**001**	Apr 01, 1985
AT	!		**0.1%**	**A088451**	**001**	Apr 03, 1985
AT		QUAGEN	**0.025%**	**A213559**	**001**	Jul 01, 2020
AT			**0.1%**	**A213559**	**002**	Jul 01, 2020
OINTMENT;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		CHARTWELL RX	**0.05%**	**A214532**	**001**	Jan 27, 2023
AT			**0.1%**	**A207365**	**001**	Oct 12, 2018
AT		COSETTE	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT	!	ENCUBE	**0.05%**	**A212384**	**001**	Nov 29, 2019
AT			**0.1%**	**A205373**	**001**	May 13, 2016
AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**	
AT			**0.1%**	**A085691**	**003**	
AT			**0.5%**	**A085691**	**002**	
AT		MACLEODS PHARMS LTD	**0.025%**	**A209828**	**001**	Nov 23, 2018
AT			**0.05%**	**A216625**	**001**	Aug 18, 2023
AT			**0.1%**	**A209828**	**002**	Nov 23, 2018
AT			**0.5%**	**A209828**	**003**	Nov 23, 2018
AT		PADAGIS ISRAEL	**0.05%**	**A212460**	**001**	Feb 05, 2021
AT	+!	PADAGIS US	**0.025%**	**A087385**	**002**	
AT	+!		**0.1%**	**A087385**	**003**	
AT	+!		**0.5%**	**A087385**	**001**	
AT		SENORES PHARMS	**0.05%**	**A213619**	**001**	Nov 10, 2020
AT		STRIDES PHARMA	**0.05%**	**A212356**	**001**	Jun 01, 2020
AT		SUN PHARMA CANADA	**0.1%**	**A040037**	**001**	Sep 30, 1994
PASTE;DENTAL							
TRIAMCINOLONE ACETONIDE							
AT		COSETTE	**0.1%**	**A205592**	**001**	Jan 12, 2017
AT		QUAGEN	**0.1%**	**A214582**	**001**	Dec 09, 2022
AT		RISING	**0.1%**	**A040771**	**001**	Jul 01, 2010
AT	!	SUN PHARMA CANADA	**0.1%**	**A070730**	**001**	Oct 01, 1986
SPRAY;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	!	PADAGIS ISRAEL	**0.147MG/GM**	**A205782**	**001**	Apr 13, 2015
AT		RISING	**0.147MG/GM**	**A206786**	**001**	Sep 08, 2017
AT		SCIEGEN PHARMS	**0.147MG/GM**	**A207094**	**001**	Dec 07, 2016
SUSPENSION;INJECTION							
XIPERE							
	+!	BAUSCH AND LOMB INC	40MG/ML	N211950	001	Oct 22, 2021
TRIAMTERENE							
CAPSULE;ORAL							
DYRENIUM							
AB	+	ADVANZ PHARMA	**50MG**	**N013174**	**001**	
AB	+!		**100MG**	**N013174**	**002**	
TRIAMTERENE							
AB		AGNITIO	**50MG**	**A211581**	**001**	Aug 19, 2019
AB			**100MG**	**A211581**	**002**	Aug 19, 2019
AB		BIOCON GENERICS	**50MG**	**A214768**	**001**	Jul 06, 2022
AB			**100MG**	**A214768**	**002**	Jul 06, 2022

TRIAZOLAM
TABLET;ORAL
HALCION

AB	**+**	PFIZER	**0.125MG**	**N017892**	**003**	Apr 26, 1985
AB	**+!**		**0.25MG**	**N017892**	**001**	Nov 15, 1982

TRIAZOLAM

AB		BRECKENRIDGE	**0.125MG**	**A216890**	**001**	Nov 08, 2022
AB			**0.25MG**	**A216890**	**002**	Nov 08, 2022
AB		NOVAST LABS	**0.125MG**	**A214219**	**001**	Oct 20, 2020
AB			**0.25MG**	**A214219**	**002**	Oct 20, 2020
AB		ZYDUS PHARMS	**0.125MG**	**A213003**	**001**	Dec 28, 2022
AB			**0.25MG**	**A213003**	**002**	Dec 28, 2022

TRICLABENDAZOLE
TABLET;ORAL
EGATEN

	+!	NOVARTIS	250MG	N208711	001	Feb 13, 2019

TRIENTINE HYDROCHLORIDE
CAPSULE;ORAL
SYPRINE

AB	**+!**	BAUSCH	**250MG**	**N019194**	**001**	Nov 08, 1985

TRIENTINE HYDROCHLORIDE

AB		DR REDDYS	**250MG**	**A211076**	**001**	Jul 03, 2019
AB		ECI PHARMS LLC	**250MG**	**A209945**	**001**	Aug 13, 2021
AB		HETERO LABS LTD III	**250MG**	**A216356**	**001**	Jun 23, 2022
AB		MSN	**250MG**	**A211134**	**001**	May 22, 2019
AB		NAVINTA LLC	**250MG**	**A211251**	**001**	Jan 16, 2019
AB		PH HEALTH	**250MG**	**A210096**	**001**	Sep 25, 2019
AB		RISING	**250MG**	**A212238**	**001**	Feb 20, 2020
AB		WATSON LABS TEVA	**250MG**	**A207567**	**001**	Feb 07, 2018
AB		ZYDUS PHARMS	**250MG**	**A211554**	**001**	Apr 26, 2019
		RISING	500MG	A212238	002	Sep 22, 2023

TRIENTINE TETRAHYDROCHLORIDE
TABLET;ORAL
CUVRIOR

	+!	ORPHALAN	300MG	N215760	001	Apr 28, 2022

TRIFAROTENE
CREAM;TOPICAL
AKLIEF

	+!	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019

TRIFLUOPERAZINE HYDROCHLORIDE
TABLET;ORAL
TRIFLUOPERAZINE HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001**	Jul 07, 1997
AB			**EQ 2MG BASE**	**A040209**	**002**	Jul 07, 1997
AB			**EQ 5MG BASE**	**A040209**	**003**	Jul 07, 1997
AB	**!**		**EQ 10MG BASE**	**A040209**	**004**	Jul 07, 1997
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**	
AB			**EQ 2MG BASE**	**A085786**	**001**	
AB			**EQ 5MG BASE**	**A085789**	**001**	
AB			**EQ 10MG BASE**	**A085788**	**001**	

TRIFLURIDINE
SOLUTION/DROPS;OPHTHALMIC
TRIFLURIDINE

AT		SANDOZ	**1%**	**A074311**	**001**	Oct 06, 1995

VIROPTIC

AT	**+!**	MONARCH PHARMS	**1%**	**N018299**	**001**	

TRIHEPTANOIN
LIQUID;ORAL
DOJOLVI

	+!	ULTRAGENYX PHARM INC	100% w/w	N213687	001	Jun 30, 2020

TRIHEXYPHENIDYL HYDROCHLORIDE
ELIXIR;ORAL
TRIHEXYPHENIDYL HYDROCHLORIDE

AA		CHARTWELL RX	**2MG/5ML**	**A040251**	**001**	Sep 27, 1999
AA	**!**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001**	Apr 17, 1997

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001**	Nov 17, 2010
AA			**5MG**	**A091630**	**002**	Nov 17, 2010
AA		NOVITIUM PHARMA	**2MG**	**A040254**	**001**	Dec 24, 1998
AA			**5MG**	**A040254**	**002**	Dec 24, 1998
AA	**!**	WATSON LABS	**2MG**	**A084363**	**001**	
AA	**!**		**5MG**	**A084364**	**001**	

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

COSELA

	+!	PHARMACOSMOS	EQ 300MG BASE/VIAL	N214200	001 Feb 12, 2021

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	**!**	HERITAGE PHARMA AVET	**300MG**	**A205950**	**001**	Nov 21, 2023
AB		LUPIN	**300MG**	**A076546**	**001**	Aug 20, 2003

INJECTABLE;INJECTION

TIGAN

AP	**+!**	PH HEALTH	**100MG/ML**	**N017530**	**001**	

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		BPI LABS	**100MG/ML**	**A219606**	**001**	Oct 16, 2025

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	**+!**	DR REDDYS LABS SA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		NOVITIUM PHARMA	**100MG**	**A216393**	**001**	Oct 28, 2022
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB		BRECKENRIDGE	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB	**!**		**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		ELITE LABS INC	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	AZURITY	EQ 22.5MG BASE/VIAL	N208956	001 Jun 29, 2017

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+!	VERITY	EQ 3.75MG BASE/VIAL	N020715	001 Jun 15, 2000
	+!		EQ 11.25MG BASE/VIAL	N021288	001 Jun 29, 2001
	+!		EQ 22.5MG BASE/VIAL	N022437	001 Mar 10, 2010

TROFINETIDE

FOR SOLUTION;ORAL

DAYBUE STIX

	+!	ACADIA PHARMS INC	5000MG/PACKET	N219884	001 Dec 11, 2025
	+!		6000MG/PACKET	N219884	002 Dec 11, 2025
	+!		8000MG/PACKET	N219884	003 Dec 11, 2025

SOLUTION;ORAL

DAYBUE

	+!	ACADIA PHARMS INC	200MG/ML	N217026	001 Mar 10, 2023

TROMETHAMINE

SOLUTION;INJECTION

THAM

AP	**+!**	HOSPIRA	**18GM/500ML (3.6GM/100ML)**	**N013025**	**002**

TROMETHAMINE

AP		B BRAUN MEDICAL	**18GM/500ML (3.6GM/100ML)**	**A211558**	**001**	Dec 09, 2024
AP		MILLA PHARMS	**18GM/500ML (3.6GM/100ML)**	**A213116**	**001**	Dec 31, 2024

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

AT	**+!**	ALCON LABS INC	**1%**	**A084306**	**001**		
AT	**+!**	SANDOZ	**0.5%**	**A084305**	**001**		

TROPICACYL

AT		EPIC PHARMA LLC	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT		RISING	**1%**	**A040315**	**001**	Sep 29, 2000

TROPICAMIDE

AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994
AT		SOMERSET THERAPS LLC	**1%**	**A207524**	**001**	Dec 12, 2019

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

AB	**!**	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		GRANULES	**60MG**	**A213185**	**001**	Apr 23, 2020
AB		PADAGIS US	**60MG**	**A201291**	**001**	May 24, 2013
AB		UTOPIC PHARMS	**60MG**	**A214760**	**001**	Apr 30, 2021

TABLET;ORAL

TROSPIUM CHLORIDE

AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB		CHARTWELL RX	**20MG**	**A215781**	**001**	Feb 16, 2022
AB	**!**	GLENMARK PHARMS LTD	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016
AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016
AB		MACLEODS PHARMS LTD	**20MG**	**A206472**	**001**	Jun 18, 2024
AB		PADAGIS US	**20MG**	**A091573**	**001**	Nov 17, 2010

TROSPIUM CHLORIDE; XANOMELINE TARTRATE

CAPSULE;ORAL

COBENFY

+!	BRISTOL-MYERS	20MG;EQ 50MG BASE	N216158	001	Sep 26, 2024
+		20MG;EQ 100MG BASE	N216158	002	Sep 26, 2024
+		30MG;EQ 125MG BASE	N216158	003	Sep 26, 2024

TRYPAN BLUE

SOLUTION;OPHTHALMIC

VISIONBLUE

+!	DORC	0.06%	N021670	001	Dec 16, 2004

TUCATINIB

TABLET;ORAL

TUKYSA

+	SEAGEN	50MG	N213411	001	Apr 17, 2020
+!		150MG	N213411	002	Apr 17, 2020

UBROGEPANT

TABLET;ORAL

UBRELVY

+	ABBVIE	50MG	N211765	001	Dec 23, 2019
+!		100MG	N211765	002	Dec 23, 2019

ULIPRISTAL ACETATE

TABLET;ORAL

ELLA

AB	**+!**	LAB HRA PHARMA	**30MG**	**N022474**	**001**	Aug 13, 2010

LOGILIA

AB		TEVA PHARMS USA	**30MG**	**A207952**	**001**	Feb 13, 2017

UMECLIDINIUM BROMIDE

POWDER;INHALATION

INCRUSE ELLIPTA

+!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

ANORO ELLIPTA

+!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013

UPADACITINIB

SOLUTION;ORAL

RINVOQ LQ

	+!	ABBVIE	1MG/ML	N218347	001	Apr 26, 2024

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

	+	ABBVIE	15MG	N211675	001	Aug 16, 2019
	+		30MG	N211675	002	Jan 14, 2022
	+!		45MG	N211675	003	Mar 16, 2022

URIDINE TRIACETATE

GRANULE;ORAL

VISTOGARD

	+!	BTG INTL	10GM/PACKET	N208159	001	Dec 11, 2015

XURIDEN

	+!	BTG INTL	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	**+!**	TEVA BRANDED PHARM	**300MG**	**N019594**	**002**	Dec 31, 1987

URSODIOL

AB		ABHAI LLC	**300MG**	**A210707**	**001**	May 17, 2018
AB		AUROBINDO PHARMA LTD	**300MG**	**A214849**	**001**	Nov 28, 2022
AB		CHARTWELL RX	**300MG**	**A213555**	**001**	Aug 17, 2020
AB		EPIC PHARMA	**300MG**	**A075517**	**001**	Mar 14, 2000
AB		HIBROW HLTHCARE	**300MG**	**A212452**	**001**	Oct 30, 2019
AB		LANNETT CO INC	**300MG**	**A079082**	**001**	Dec 15, 2008
AB		RISING	**300MG**	**A213200**	**001**	Feb 12, 2020
AB		RK PHARMA	**300MG**	**A214329**	**001**	Jul 28, 2021
AB		STRIDES PHARMA	**300MG**	**A210344**	**001**	Jan 22, 2021
AB		ZYDUS LIFESCIENCES	**300MG**	**A214295**	**001**	Oct 16, 2020
	!	LGM PHARMA	200MG	A205789	001	May 08, 2020
	!		400MG	A205789	002	May 08, 2020

TABLET;ORAL

URSODIOL

AB		EPIC PHARMA LLC	**250MG**	**A214717**	**001**	Aug 14, 2024
AB			**500MG**	**A214717**	**002**	Aug 14, 2024
AB		GLENMARK PHARMS LTD	**250MG**	**A090801**	**001**	Jul 12, 2011
AB			**500MG**	**A090801**	**002**	Jul 12, 2011
AB		PH HEALTH	**250MG**	**A202540**	**001**	Feb 14, 2013
AB			**500MG**	**A202540**	**002**	Feb 14, 2013
AB		STRIDES PHARMA	**250MG**	**A213504**	**001**	Aug 20, 2020
AB			**500MG**	**A213504**	**002**	Aug 20, 2020
AB		ZYDUS LIFESCIENCES	**250MG**	**A211145**	**001**	Oct 30, 2018
AB	**!**		**500MG**	**A211145**	**002**	Oct 30, 2018

VADADUSTAT

TABLET;ORAL

VAFSEO

	+	AKEBIA	150MG	N215192	001	Mar 27, 2024
	+		300MG	N215192	002	Mar 27, 2024
	+!		450MG	N215192	003	Mar 27, 2024

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090682**	**002**	May 24, 2010
AB		CHARTWELL RX	**EQ 500MG BASE**	**A090216**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090216**	**002**	May 24, 2010
AB		HETERO LABS LTD V	**EQ 500MG BASE**	**A203047**	**001**	Apr 08, 2015
AB			**EQ 1GM BASE**	**A203047**	**002**	Apr 08, 2015
AB		JUBILANT GENERICS	**EQ 500MG BASE**	**A201506**	**001**	Apr 03, 2012
AB			**EQ 1GM BASE**	**A201506**	**002**	Apr 03, 2012
AB		MYLAN PHARMS INC	**EQ 500MG BASE**	**A078518**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A078518**	**002**	May 24, 2010
AB		RISING	**EQ 500MG BASE**	**A079012**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A079012**	**002**	May 24, 2010
AB		SUN PHARM INDS LTD	**EQ 500MG BASE**	**A076588**	**001**	Jan 31, 2007
AB			**EQ 1GM BASE**	**A076588**	**002**	Jan 31, 2007
AB		YILING	**EQ 500MG BASE**	**A209553**	**001**	Mar 18, 2020
AB			**EQ 1GM BASE**	**A209553**	**002**	Mar 18, 2020
AB		ZYDUS LIFESCIENCES	**EQ 500MG BASE**	**A079137**	**001**	Dec 29, 2017

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB			**EQ 1GM BASE**	**A079137**	**002**	Dec 29, 2017

VALTREX

AB	+	GLAXOSMITHKLINE	**EQ 500MG BASE**	**N020487**	**001**	Jun 23, 1995
AB	+!		**EQ 1GM BASE**	**N020487**	**002**	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

AB	+	NEUROCRINE	**EQ 40MG BASE**	**N209241**	**001**	Apr 11, 2017
AB	+!		**EQ 80MG BASE**	**N209241**	**002**	Oct 04, 2017

VALBENAZINE TOSYLATE

AB		LUPIN LTD	**EQ 40MG BASE**	**A216064**	**001**	Apr 05, 2024
AB			**EQ 80MG BASE**	**A216064**	**002**	Apr 05, 2024

INGREZZA

	+	NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021

INGREZZA SPRINKLE

	+	NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024
	+		EQ 60MG BASE	N218390	002	Apr 30, 2024
	+!		EQ 80MG BASE	N218390	003	Apr 30, 2024

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB	**+!**	CHEPLAPHARM	**50MG/ML**	**N022257**	**001**	Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**50MG/ML**	**A205220**	**001**	Jul 18, 2016
AB		AJANTA PHARMA LTD	**50MG/ML**	**A212890**	**001**	Jan 13, 2020
AB		APPCO	**50MG/ML**	**A216317**	**001**	Apr 11, 2023
AB		AUROBINDO PHARMA	**50MG/ML**	**A215124**	**001**	Nov 17, 2022
AB		GRANULES	**50MG/ML**	**A213306**	**001**	Jan 31, 2020
AB		HETERO LABS LTD V	**50MG/ML**	**A211475**	**001**	Oct 04, 2022
AB		MSN	**50MG/ML**	**A210169**	**001**	Feb 17, 2022

TABLET;ORAL

VALCYTE

AB	**+!**	CHEPLAPHARM	**EQ 450MG BASE**	**N021304**	**001**	Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

AB		AJANTA PHARMA LTD	**EQ 450MG BASE**	**A212234**	**001**	Dec 26, 2019
AB		AUROBINDO PHARMA LTD	**EQ 450MG BASE**	**A204750**	**001**	Mar 31, 2016
AB		DR REDDYS	**EQ 450MG BASE**	**A203511**	**001**	Nov 04, 2014
AB			**EQ 450MG BASE**	**A206876**	**001**	Dec 12, 2017
AB		HETERO LABS LTD V	**EQ 450MG BASE**	**A205166**	**001**	Mar 18, 2016
AB		SOMERSET THERAPS LLC	**EQ 450MG BASE**	**A212876**	**001**	Jun 11, 2024
AB		SPH ZHONGXI PHARM	**EQ 450MG BASE**	**A218027**	**001**	Apr 16, 2025
AB		STRIDES PHARMA INTL	**EQ 450MG BASE**	**A200790**	**001**	Nov 04, 2014

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

AP		FRESENIUS KABI USA	**EQ 100MG BASE/ML**	**A076539**	**001**	Jun 26, 2003
AP	**!**	HIKMA FARMACEUTICA	**EQ 100MG BASE/ML**	**A078523**	**001**	Feb 17, 2010
AP		SAGENT	**EQ 100MG BASE/ML**	**A076295**	**001**	Nov 14, 2002

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	**!**	BIONPHARMA	**250MG**	**A073484**	**001**	Jun 29, 1993
AB		CATALENT	**250MG**	**A073229**	**001**	Oct 29, 1991

SYRUP;ORAL

VALPROIC ACID

AA		ANI PHARMS	**250MG/5ML**	**A073178**	**001**	Aug 25, 1992
AA		CHARTWELL RX	**250MG/5ML**	**A075782**	**001**	Dec 22, 2000
AA	**!**	PHARM ASSOC	**250MG/5ML**	**A075379**	**001**	Dec 15, 2000
AA		QUAGEN	**250MG/5ML**	**A090517**	**001**	May 28, 2010

VALRUBICIN

SOLUTION;INTRAVESICAL

VALRUBICIN

AO		HIKMA	**40MG/ML**	**A206430**	**001**	Apr 19, 2019

VALSTAR PRESERVATIVE FREE

AO	**+!**	ENDO OPERATIONS	**40MG/ML**	**N020892**	**001**	Sep 25, 1998

VALSARTAN

SOLUTION;ORAL

VALSARTAN

AB	**!**	NOVITIUM PHARMA	**4MG/ML**	**A214102**	**001**	Nov 02, 2021
AB		RUBICON	**4MG/ML**	**A216460**	**001**	Jun 05, 2025

TABLET;ORAL

DIOVAN

AB	**+**	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB	**+**		**80MG**	**N021283**	**001**	Jul 18, 2001
AB	**+**		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	**+!**		**320MG**	**N021283**	**003**	Jul 18, 2001

VALSARTAN

AB		ALEMBIC	**40MG**	**A091367**	**001**	Jan 05, 2015
AB			**80MG**	**A091367**	**002**	Jan 05, 2015
AB			**160MG**	**A091367**	**003**	Jan 05, 2015
AB			**320MG**	**A091367**	**004**	Jan 05, 2015
AB		ALKEM LABS LTD	**40MG**	**A205536**	**001**	Mar 12, 2019
AB			**80MG**	**A205536**	**002**	Mar 12, 2019
AB			**160MG**	**A205536**	**003**	Mar 12, 2019
AB			**320MG**	**A205536**	**004**	Mar 12, 2019
AB		AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB			**80MG**	**A204011**	**002**	Jan 11, 2016
AB			**160MG**	**A204011**	**003**	Jan 11, 2016
AB			**320MG**	**A204011**	**004**	Jan 11, 2016
AB		AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB			**80MG**	**A202223**	**002**	Jan 05, 2015
AB			**160MG**	**A202223**	**003**	Jan 05, 2015
AB			**320MG**	**A202223**	**004**	Jan 05, 2015
AB		DR REDDYS	**40MG**	**A201618**	**001**	Oct 05, 2021
AB			**80MG**	**A201618**	**002**	Oct 05, 2021
AB			**160MG**	**A201618**	**003**	Oct 05, 2021
AB			**320MG**	**A201618**	**004**	Oct 05, 2021
AB		HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB			**80MG**	**A203311**	**002**	Jan 05, 2015
AB			**160MG**	**A203311**	**003**	Jan 05, 2015
AB			**320MG**	**A203311**	**004**	Jan 05, 2015
AB		JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB			**80MG**	**A203536**	**002**	Jan 05, 2015
AB			**160MG**	**A203536**	**003**	Jan 05, 2015
AB			**320MG**	**A203536**	**004**	Jan 05, 2015
AB		LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB			**80MG**	**A201677**	**002**	Jan 05, 2015
AB			**160MG**	**A201677**	**003**	Jan 05, 2015
AB			**320MG**	**A201677**	**004**	Jan 05, 2015
AB		MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB			**80MG**	**A202696**	**002**	Sep 16, 2016
AB			**160MG**	**A202696**	**003**	Sep 16, 2016
AB			**320MG**	**A202696**	**004**	Sep 16, 2016
AB		MYLAN	**40MG**	**A090866**	**001**	Jan 05, 2015
AB			**80MG**	**A090866**	**002**	Jan 05, 2015
AB			**160MG**	**A090866**	**003**	Jan 05, 2015
AB			**320MG**	**A090866**	**004**	Jan 05, 2015
AB		OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB			**80MG**	**A077492**	**002**	Jun 26, 2014
AB			**160MG**	**A077492**	**003**	Jun 26, 2014
AB			**320MG**	**A077492**	**004**	Jun 26, 2014
AB		PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB			**80MG**	**A204821**	**002**	Jun 09, 2015
AB			**160MG**	**A204821**	**003**	Jun 09, 2015
AB			**320MG**	**A204821**	**004**	Jun 09, 2015
AB		SCIEGEN PHARMS	**40MG**	**A204038**	**001**	Oct 27, 2021
AB			**80MG**	**A204038**	**002**	Oct 27, 2021
AB			**160MG**	**A204038**	**003**	Oct 27, 2021
AB			**320MG**	**A204038**	**004**	Oct 27, 2021
AB		SQUARE PHARMS PLC	**40MG**	**A205347**	**001**	Apr 09, 2018

VALSARTAN						
TABLET;ORAL						
VALSARTAN						
AB			**80MG**	**A205347**	**002**	Apr 09, 2018
AB			**160MG**	**A205347**	**003**	Apr 09, 2018
AB			**320MG**	**A205347**	**004**	Apr 09, 2018
AB		ZYDUS LIFESCIENCES	**40MG**	**A218991**	**001**	Jul 22, 2024
AB			**80MG**	**A218991**	**002**	Jul 22, 2024
AB			**160MG**	**A218991**	**003**	Jul 22, 2024
AB			**320MG**	**A218991**	**004**	Jul 22, 2024
VAMOROLONE						
SUSPENSION;ORAL						
AGAMREE						
	+!	CATALYST PHARMS	40MG/ML	N215239	001	Oct 26, 2023
VANCOMYCIN HYDROCHLORIDE						
CAPSULE;ORAL						
VANCOCIN HYDROCHLORIDE						
AB	**+**	ANI PHARMS	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	**+!**		**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986
VANCOMYCIN HYDROCHLORIDE						
AB		LUPIN LTD	**EQ 125MG BASE**	**A090439**	**001**	Jan 28, 2015
AB			**EQ 250MG BASE**	**A090439**	**002**	Jan 28, 2015
AB		ORIENT PHARMA CO LTD	**EQ 125MG BASE**	**A210729**	**001**	Apr 29, 2019
AB			**EQ 250MG BASE**	**A210729**	**002**	Apr 29, 2019
AB		STRIDES PHARMA	**EQ 125MG BASE**	**A065490**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065490**	**002**	Apr 09, 2012
FOR SOLUTION;ORAL						
FIRVANQ KIT						
AB	**+!**	AZURITY	**EQ 25MG BASE/ML**	**N208910**	**001**	Jan 26, 2018
AB	**+!**		**EQ 50MG BASE/ML**	**N208910**	**002**	Jan 26, 2018
VANCOMYCIN HYDROCHLORIDE						
AB		ALKEM LABS LTD	**EQ 25MG BASE/ML**	**A214913**	**001**	Nov 14, 2022
AB			**EQ 50MG BASE/ML**	**A214913**	**002**	Nov 14, 2022
VANCOCIN HYDROCHLORIDE						
	!	ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983
INJECTABLE;INJECTION						
VANCOMYCIN HYDROCHLORIDE						
AP		ASPIRO	**EQ 500MG BASE/VIAL**	**A216591**	**001**	Jul 06, 2022
AP			**EQ 1GM BASE/VIAL**	**A216591**	**002**	Jul 06, 2022
AP		EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A205780**	**001**	Mar 31, 2016
AP			**EQ 1GM BASE/VIAL**	**A205780**	**002**	Mar 31, 2016
AP			**EQ 5GM BASE/VIAL**	**A205779**	**001**	Mar 29, 2016
AP			**EQ 10GM BASE/VIAL**	**A205779**	**002**	Mar 29, 2016
AP	**!**	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A062663**	**001**	Mar 17, 1987
AP			**EQ 750MG BASE/VIAL**	**A062663**	**005**	Aug 17, 2016
AP	**!**		**EQ 1GM BASE/VIAL**	**A062663**	**002**	Jul 31, 1987
AP	**!**		**EQ 5GM BASE/VIAL**	**A062663**	**003**	Jun 03, 1988
AP	**!**		**EQ 10GM BASE/VIAL**	**A062663**	**004**	Nov 28, 1997
AP		GLAND	**EQ 500MG BASE/VIAL**	**A205694**	**001**	Jan 21, 2016
AP			**EQ 1GM BASE/VIAL**	**A205694**	**002**	Jan 21, 2016
AP			**EQ 5GM BASE/VIAL**	**A205694**	**003**	Jun 06, 2023
AP			**EQ 10GM BASE/VIAL**	**A205694**	**004**	Jun 06, 2023
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A204107**	**001**	Dec 28, 2015
AP			**EQ 1GM BASE/VIAL**	**A203300**	**002**	Aug 11, 2020
AP			**EQ 1GM BASE/VIAL**	**A204107**	**002**	Dec 28, 2015
AP			**EQ 5GM BASE/VIAL**	**A204360**	**001**	Oct 15, 2018
AP			**EQ 10GM BASE/VIAL**	**A204360**	**002**	Oct 15, 2018
AP		HIKMA PHARMS	**EQ 750MG BASE/VIAL**	**A206616**	**001**	Oct 03, 2018
AP	**!**	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062911**	**001**	Aug 04, 1988
AP	**!**		**EQ 500MG BASE/VIAL**	**A062931**	**001**	Oct 29, 1992
AP			**EQ 750MG BASE/VIAL**	**A062912**	**002**	Jan 07, 2009
AP			**EQ 750MG BASE/VIAL**	**A062933**	**002**	May 27, 2009
AP	**!**		**EQ 1GM BASE/VIAL**	**A062912**	**001**	Aug 04, 1988
AP	**!**		**EQ 1GM BASE/VIAL**	**A062933**	**001**	Oct 29, 1992
AP	**!**		**EQ 5GM BASE/VIAL**	**A063076**	**001**	Dec 21, 1990
AP			**EQ 10GM BASE/VIAL**	**A063076**	**002**	Sep 14, 2020
AP		MEDIMETRIKS PHARMS	**EQ 500MG BASE/VIAL**	**A065401**	**001**	Jun 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065401**	**002**	Jun 30, 2008
AP		MEITHEAL	**EQ 500MG BASE/VIAL**	**A215197**	**001**	Jul 28, 2022
AP			**EQ 750MG BASE/VIAL**	**A215195**	**001**	Sep 15, 2022
AP			**EQ 1GM BASE/VIAL**	**A215197**	**002**	Jul 28, 2022

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP			**EQ 5GM BASE/VIAL**	**A215196**	**001**	Jul 27, 2022
AP			**EQ 10GM BASE/VIAL**	**A215196**	**002**	Jul 27, 2022
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A065397**	**001**	Dec 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065397**	**002**	Dec 30, 2008
AP			**EQ 5GM BASE/VIAL**	**A065432**	**001**	Dec 30, 2008
AP	**!**		**EQ 10GM BASE/VIAL**	**A091554**	**001**	Sep 19, 2011
AP		SAGENT PHARMS	**EQ 5GM BASE/VIAL**	**A200837**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A200837**	**002**	Sep 02, 2014
AP		SLATE RUN PHARMA	**EQ 500MG BASE/VIAL**	**A212332**	**001**	Jun 12, 2019
AP			**EQ 1GM BASE/VIAL**	**A212332**	**002**	Jun 12, 2019
AP			**EQ 5GM BASE/VIAL**	**A215821**	**001**	Nov 18, 2021
AP			**EQ 10GM BASE/VIAL**	**A215821**	**002**	Nov 18, 2021
AP		XELLIA PHARMS APS	**EQ 5GM BASE/VIAL**	**A204125**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A204125**	**002**	Dec 28, 2015
	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		EUGIA PHARMA	**EQ 1.25GM BASE/VIAL**	**A217401**	**001**	Aug 04, 2023
AP			**EQ 1.5GM BASE/VIAL**	**A217401**	**002**	Aug 04, 2023
AP		GLAND	**EQ 750MG BASE/VIAL**	**A218140**	**001**	Mar 21, 2025
AP			**EQ 1.25GM BASE/VIAL**	**A218140**	**002**	Mar 21, 2025
AP			**EQ 1.5GM BASE/VIAL**	**A218140**	**003**	Mar 21, 2025
AP		HIKMA	**EQ 1.25GM BASE/VIAL**	**A217489**	**001**	Jun 29, 2023
AP			**EQ 1.5GM BASE/VIAL**	**A217489**	**002**	Jun 29, 2023
AP	**+!**	MYLAN LABS LTD	**EQ 750MG BASE/VIAL**	**N209481**	**002**	Jul 10, 2018
AP	**+!**		**EQ 1.25GM BASE/VIAL**	**N209481**	**003**	Jul 10, 2018
AP	**+!**		**EQ 1.5GM BASE/VIAL**	**N209481**	**004**	Jul 10, 2018
AP		STERISCIENCE	**EQ 750MG BASE/VIAL**	**A215324**	**001**	Oct 02, 2025
AP			**EQ 1.25GM BASE/VIAL**	**A215324**	**002**	Oct 02, 2025
AP			**EQ 1.5GM BASE/VIAL**	**A215324**	**003**	Oct 02, 2025
	+!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024
	+!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016

POWDER;INTRAVENOUS, ORAL

VANCOMYCIN HYDROCHLORIDE

+!	ZHEJIANG NOVUS PHARM	EQ 1.5MG BASE/VIAL	N210274	007	Aug 01, 2025
+!		EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023
+!		EQ 750MG BASE/VIAL	N210274	005	Aug 01, 2025
+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023
+!		EQ 1.25GM BASE/VIAL	N210274	006	Aug 01, 2025
+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023
+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023

SOLUTION;INTRAVENOUS

TYZAVAN

+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019
+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020
+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993
+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010
+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999
+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024
+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024

VANDETANIB

TABLET;ORAL

CAPRELSA

+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
+!		300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

VARDENAFIL HYDROCHLORIDE

AB		ALEMBIC	**EQ 2.5MG BASE**	**A214031**	**001**	Aug 04, 2020
AB			**EQ 5MG BASE**	**A214031**	**002**	Aug 04, 2020
AB			**EQ 10MG BASE**	**A214031**	**003**	Aug 04, 2020
AB			**EQ 20MG BASE**	**A214031**	**004**	Aug 04, 2020
AB		CROSSMEDIKA SA	**EQ 2.5MG BASE**	**A209057**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A209057**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A209057**	**003**	Oct 31, 2018
AB			**EQ 20MG BASE**	**A209057**	**004**	Oct 31, 2018
AB		MACLEODS PHARMS LTD	**EQ 2.5MG BASE**	**A204632**	**001**	Oct 22, 2019
AB			**EQ 5MG BASE**	**A204632**	**002**	Oct 22, 2019
AB			**EQ 10MG BASE**	**A204632**	**003**	Oct 22, 2019
AB			**EQ 20MG BASE**	**A204632**	**004**	Oct 22, 2019
AB		TEVA PHARMS	**EQ 2.5MG BASE**	**A091347**	**001**	May 03, 2012
AB			**EQ 5MG BASE**	**A091347**	**002**	May 03, 2012
AB			**EQ 10MG BASE**	**A091347**	**003**	May 03, 2012
AB			**EQ 20MG BASE**	**A091347**	**004**	May 03, 2012
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A208960**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A208960**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A208960**	**003**	Oct 31, 2018
AB	**!**		**EQ 20MG BASE**	**A208960**	**004**	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB	**!**	ALEMBIC	**10MG**	**A208324**	**001**	Nov 16, 2018
AB		MACLEODS PHARMS LTD	**10MG**	**A205988**	**001**	Mar 10, 2020

VARENICLINE TARTRATE

SPRAY;NASAL

TYRVAYA

	+!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021

TABLET;ORAL

CHANTIX

AB	**+**	PF PRISM CV	**EQ 0.5MG BASE**	**N021928**	**001**	May 10, 2006
AB	**+**		**EQ 1MG BASE**	**N021928**	**002**	May 10, 2006

VARENICLINE TARTRATE

AB		AJANTA PHARMA LTD	**EQ 0.5MG BASE**	**A213019**	**001**	Mar 19, 2024
AB			**EQ 1MG BASE**	**A213019**	**002**	Mar 19, 2024
AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A214557**	**001**	Aug 23, 2023
AB			**EQ 1MG BASE**	**A214557**	**002**	Aug 23, 2023
AB		APOTEX	**EQ 0.5MG BASE**	**A201962**	**001**	Jan 25, 2023
AB			**EQ 1MG BASE**	**A201962**	**002**	Jan 25, 2023
AB		AUROBINDO PHARMA	**EQ 0.5MG BASE**	**A214595**	**001**	May 02, 2025
AB			**EQ 1MG BASE**	**A214595**	**002**	May 02, 2025
AB		DR REDDYS	**EQ 0.5MG BASE**	**A215931**	**001**	Oct 01, 2024
AB			**EQ 1MG BASE**	**A215931**	**002**	Oct 01, 2024
AB		HETERO LABS LTD III	**EQ 0.5MG BASE**	**A214571**	**001**	Oct 23, 2023
AB			**EQ 1MG BASE**	**A214571**	**002**	Oct 23, 2023
AB		KANCHAN HLTHCARE	**EQ 0.5MG BASE**	**A217151**	**001**	Jul 25, 2023
AB			**EQ 1MG BASE**	**A217151**	**002**	Jul 25, 2023
AB		LUPIN LTD	**EQ 0.5MG BASE**	**A211862**	**001**	Dec 04, 2023
AB			**EQ 1MG BASE**	**A211862**	**002**	Dec 04, 2023
AB		MACLEODS PHARMS LTD	**EQ 0.5MG BASE**	**A215048**	**001**	Dec 09, 2024
AB			**EQ 1MG BASE**	**A215048**	**002**	Dec 09, 2024
AB		MANKIND PHARMA	**EQ 0.5MG BASE**	**A214255**	**001**	Aug 01, 2023
AB			**EQ 1MG BASE**	**A214255**	**002**	Aug 01, 2023
AB		MICRO LABS	**EQ 0.5MG BASE**	**A218302**	**001**	Oct 29, 2025
AB			**EQ 1MG BASE**	**A218302**	**002**	Oct 29, 2025
AB		NE RX PHARMA	**EQ 0.5MG BASE**	**A217283**	**001**	Mar 06, 2024
AB			**EQ 1MG BASE**	**A217283**	**002**	Mar 06, 2024
AB		PH HEALTH	**EQ 0.5MG BASE**	**A201785**	**001**	Aug 11, 2021
AB	**!**		**EQ 1MG BASE**	**A201785**	**002**	Aug 11, 2021
AB		PHARMOBEDIENT	**EQ 0.5MG BASE**	**A202019**	**001**	Feb 28, 2024
AB			**EQ 1MG BASE**	**A202019**	**002**	Feb 28, 2024
AB		REGCON HOLDINGS	**EQ 0.5MG BASE**	**A219106**	**001**	Oct 29, 2024
AB			**EQ 1MG BASE**	**A219106**	**002**	Oct 29, 2024
AB		SHILPA	**EQ 0.5MG BASE**	**A216615**	**001**	Apr 08, 2025
AB			**EQ 1MG BASE**	**A216615**	**002**	Apr 08, 2025
AB		VIWIT PHARM	**EQ 0.5MG BASE**	**A212879**	**001**	May 06, 2025
AB			**EQ 1MG BASE**	**A212879**	**002**	May 06, 2025
AB		ZYDUS	**EQ 0.5MG BASE**	**A216723**	**001**	Jun 12, 2023
AB			**EQ 1MG BASE**	**A216723**	**002**	Jun 12, 2023

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

AP		AMNEAL	**20UNITS/ML (20UNITS/ML)**	**A212944**	**001**	Aug 05, 2022
AP		AMPHASTAR PHARMS INC	**20UNITS/ML (20UNITS/ML)**	**A211857**	**001**	Jul 18, 2022
AP		CIPLA	**20UNITS/100ML (0.2UNITS/ML)**	**A217987**	**001**	Dec 06, 2023
AP		DR REDDYS	**20UNITS/ML (20UNITS/ML)**	**A213988**	**001**	May 08, 2024
AP		EAGLE PHARMS	**20UNITS/ML (20UNITS/ML)**	**A211538**	**001**	Dec 15, 2021
AP		EUGIA PHARMA	**20UNITS/ML (20UNITS/ML)**	**A214314**	**001**	Aug 15, 2022
AP		FRESENIUS KABI USA	**20UNITS/ML (20UNITS/ML)**	**A213206**	**001**	May 26, 2023
AP		GLAND	**20UNITS/ML (20UNITS/ML)**	**A216963**	**001**	Feb 09, 2024

VASOPRESSIN IN DEXTROSE 5%

AP		GLAND	**40UNITS/100ML (0.4UNITS/ML)**	**A216963**	**002**	Aug 22, 2025

VASOSTRICT

AP	**+!**	PH HEALTH	**20UNITS/ML (20UNITS/ML)**	**N204485**	**001**	Apr 17, 2014
AP	**+!**		**20UNITS/100ML (0.2UNITS/ML)**	**N204485**	**005**	Apr 21, 2021
AP	**+!**		**40UNITS/100ML (0.4UNITS/ML)**	**N204485**	**003**	Apr 15, 2020

VASOPRESSIN

	+!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020
	+!		200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

	+!	BAXTER HLTHCARE CORP	20UNITS/100ML (0.2UNITS/ML)	N217569	001	Sep 29, 2023
	+!		40UNITS/100ML (0.4UNITS/ML)	N217569	002	Sep 29, 2023
	+!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024
	+!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024

VASOSTRICT

	+!	PH HEALTH	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP		EUGIA PHARMA	**10MG/VIAL**	**A206670**	**001**	Dec 20, 2018
AP			**20MG/VIAL**	**A206670**	**002**	Dec 20, 2018
AP		GLAND	**10MG/VIAL**	**A205390**	**001**	May 26, 2016
AP			**20MG/VIAL**	**A205390**	**002**	May 26, 2016
AP		HIKMA	**10MG/VIAL**	**A075549**	**001**	Jun 13, 2000
AP			**10MG/VIAL**	**A203725**	**001**	Jul 30, 2019
AP			**20MG/VIAL**	**A075549**	**002**	Jun 13, 2000
AP			**20MG/VIAL**	**A203725**	**002**	Jul 30, 2019
AP		HOSPIRA	**10MG/VIAL**	**A075164**	**001**	Oct 21, 1999
AP			**20MG/VIAL**	**A075164**	**002**	Oct 21, 1999
AP		MEITHEAL	**10MG/VIAL**	**A074688**	**001**	Aug 25, 1999
AP			**20MG/VIAL**	**A074688**	**002**	Aug 25, 1999
AP		MYLAN LABS LTD	**10MG/VIAL**	**A090243**	**001**	May 11, 2010
AP			**20MG/VIAL**	**A090243**	**002**	May 11, 2010
AP		SAGENT PHARMS INC	**10MG/VIAL**	**A078274**	**001**	Dec 29, 2008
AP			**20MG/VIAL**	**A078274**	**002**	Dec 29, 2008
AP	**!**	SUN PHARM	**10MG/VIAL**	**A079001**	**001**	Jun 17, 2009
AP	**!**		**20MG/VIAL**	**A079001**	**002**	Jun 17, 2009

VEMURAFENIB

TABLET;ORAL

ZELBORAF

	+!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX

TABLET;ORAL

VENCLEXTA

	+	ABBVIE	10MG	N208573	001	Apr 11, 2016
	+		50MG	N208573	002	Apr 11, 2016
	+!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE BESYLATE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE BESYLATE

	+!	ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	+	UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997
AB	+!		EQ 150MG BASE	N020699	004	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024
AB		EQ 75MG BASE	A217767	002	Jun 06, 2024
AB		EQ 150MG BASE	A217767	003	Jun 06, 2024
AB	ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019
AB		EQ 75MG BASE	A212277	002	Jul 08, 2019
AB		EQ 150MG BASE	A212277	003	Jul 08, 2019
AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011
AB		EQ 75MG BASE	A200834	002	Apr 14, 2011
AB		EQ 150MG BASE	A200834	003	Apr 14, 2011
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011
AB		EQ 75MG BASE	A078421	002	May 06, 2011
AB		EQ 150MG BASE	A078421	003	May 06, 2011
AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023
AB		EQ 75MG BASE	A217390	002	May 18, 2023
AB		EQ 150MG BASE	A217390	003	May 18, 2023
AB	INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020
AB		EQ 75MG BASE	A203332	002	Mar 12, 2020
AB		EQ 150MG BASE	A203332	003	Mar 12, 2020
AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001	Oct 05, 2017
AB		EQ 75MG BASE	A204889	002	Oct 05, 2017
AB		EQ 150MG BASE	A204889	003	Oct 05, 2017
AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018
AB		EQ 75MG BASE	A201272	002	Nov 23, 2018
AB		EQ 150MG BASE	A201272	003	Nov 23, 2018
AB	ORBION PHARMS	EQ 37.5MG BASE	A091123	001	Jul 11, 2011
AB		EQ 75MG BASE	A091123	002	Jul 11, 2011
AB		EQ 150MG BASE	A091123	003	Jul 11, 2011
AB	SCIEGEN PHARMS	EQ 37.5MG BASE	A078865	001	Apr 14, 2011
AB		EQ 75MG BASE	A078865	002	Apr 14, 2011
AB		EQ 150MG BASE	A078865	003	Apr 14, 2011
AB	TEVA	EQ 37.5MG BASE	A076565	001	Jun 28, 2010
AB		EQ 75MG BASE	A076565	002	Jun 28, 2010
AB		EQ 150MG BASE	A076565	003	Jun 28, 2010
AB	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021
AB		EQ 75MG BASE	A214654	002	Aug 06, 2021
AB		EQ 150MG BASE	A214654	003	Aug 06, 2021
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011
AB		EQ 75MG BASE	A090174	002	Apr 14, 2011
AB		EQ 150MG BASE	A090174	003	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932	001	Dec 14, 2010
AB		EQ 37.5MG BASE	A078932	002	Dec 14, 2010
AB		EQ 50MG BASE	A078932	003	Dec 14, 2010
AB		EQ 75MG BASE	A078932	004	Dec 14, 2010
AB		EQ 100MG BASE	A078932	005	Dec 14, 2010
AB	AUROBINDO PHARMA	EQ 25MG BASE	A090555	001	Apr 07, 2010
AB		EQ 37.5MG BASE	A090555	002	Apr 07, 2010
AB		EQ 50MG BASE	A090555	003	Apr 07, 2010
AB		EQ 75MG BASE	A090555	004	Apr 07, 2010
AB		EQ 100MG BASE	A090555	005	Apr 07, 2010
AB	CADILA PHARMS LTD	EQ 25MG BASE	A206250	001	Nov 21, 2018
AB		EQ 37.5MG BASE	A206250	002	Nov 21, 2018
AB		EQ 50MG BASE	A206250	003	Nov 21, 2018
AB		EQ 75MG BASE	A206250	004	Nov 21, 2018
AB		EQ 100MG BASE	A206250	005	Nov 21, 2018
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A078301	001	Jun 13, 2008
AB		EQ 37.5MG BASE	A078301	002	Jun 13, 2008
AB		EQ 50MG BASE	A078301	003	Jun 13, 2008
AB		EQ 75MG BASE	A078301	004	Jun 13, 2008
AB		EQ 100MG BASE	A078301	005	Jun 13, 2008
AB	HERITAGE	EQ 25MG BASE	A078554	001	Jan 09, 2009
AB		EQ 37.5MG BASE	A078554	002	Jan 09, 2009
AB		EQ 50MG BASE	A078554	003	Jan 09, 2009

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			**EQ 75MG BASE**	**A078554**	**004**	Jan 09, 2009
AB			**EQ 100MG BASE**	**A078554**	**005**	Jan 09, 2009
AB		SUN PHARM INDS INC	**EQ 25MG BASE**	**A078627**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A078627**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A078627**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A078627**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A078627**	**005**	Jun 13, 2008
AB		TEVA	**EQ 25MG BASE**	**A076690**	**001**	Aug 03, 2006
AB			**EQ 37.5MG BASE**	**A076690**	**002**	Aug 03, 2006
AB	**!**		**EQ 50MG BASE**	**A076690**	**003**	Aug 03, 2006
AB			**EQ 75MG BASE**	**A076690**	**004**	Aug 03, 2006
AB			**EQ 100MG BASE**	**A076690**	**005**	Aug 03, 2006
AB		YAOPHARMA CO LTD	**EQ 25MG BASE**	**A202036**	**001**	May 28, 2015
AB			**EQ 37.5MG BASE**	**A202036**	**002**	May 28, 2015
AB			**EQ 50MG BASE**	**A202036**	**003**	May 28, 2015
AB			**EQ 75MG BASE**	**A202036**	**004**	May 28, 2015
AB			**EQ 100MG BASE**	**A202036**	**005**	May 28, 2015
AB		ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077653**	**001**	Jun 13, 2008
AB			**EQ 37.5MG BASE**	**A077653**	**002**	Jun 13, 2008
AB			**EQ 50MG BASE**	**A077653**	**003**	Jun 13, 2008
AB			**EQ 75MG BASE**	**A077653**	**004**	Jun 13, 2008
AB			**EQ 100MG BASE**	**A077653**	**005**	Jun 13, 2008

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ABON PHARMS LLC	**EQ 150MG BASE**	**A217841**	**001**	Feb 07, 2025
AB			**EQ 225MG BASE**	**A217841**	**002**	Feb 07, 2025
AB		ADAPTIS	**EQ 75MG BASE**	**A213927**	**001**	Jan 21, 2021
AB		AJANTA PHARMA LTD	**EQ 37.5MG BASE**	**A214691**	**001**	Apr 12, 2023
AB			**EQ 75MG BASE**	**A214691**	**002**	Apr 12, 2023
AB			**EQ 150MG BASE**	**A214691**	**003**	Apr 12, 2023
AB			**EQ 225MG BASE**	**A214691**	**004**	Apr 12, 2023
AB		ALKEM LABS LTD	**EQ 37.5MG BASE**	**A214127**	**001**	Jun 10, 2021
AB			**EQ 75MG BASE**	**A214127**	**002**	Jun 10, 2021
AB			**EQ 150MG BASE**	**A214127**	**003**	Jun 10, 2021
AB			**EQ 225MG BASE**	**A214127**	**004**	Jun 10, 2021
AB		ASCENT PHARMS INC	**EQ 37.5MG BASE**	**A214419**	**001**	Oct 21, 2020
AB			**EQ 75MG BASE**	**A214419**	**002**	Oct 21, 2020
AB			**EQ 150MG BASE**	**A214419**	**003**	Oct 21, 2020
AB			**EQ 225MG BASE**	**A214419**	**004**	Oct 21, 2020
AB		CADILA PHARMS LTD	**EQ 75MG BASE**	**A211323**	**001**	Aug 29, 2019
AB			**EQ 150MG BASE**	**A211323**	**002**	Aug 29, 2019
AB			**EQ 225MG BASE**	**A211323**	**003**	Aug 29, 2019
AB		DEXCEL	**EQ 150MG BASE**	**A209193**	**001**	Oct 31, 2019
AB			**EQ 225MG BASE**	**A209193**	**002**	Oct 31, 2019
AB		MPP PHARMA	**EQ 150MG BASE**	**A205468**	**002**	Mar 24, 2017
AB			**EQ 225MG BASE**	**A205468**	**003**	Mar 24, 2017
AB	**+**	OSMOTICA PHARM US	**EQ 37.5MG BASE**	**N022104**	**001**	May 20, 2008
AB	**+**		**EQ 75MG BASE**	**N022104**	**002**	May 20, 2008
AB	**+!**		**EQ 150MG BASE**	**N022104**	**003**	May 20, 2008
AB	**+**		**EQ 225MG BASE**	**N022104**	**004**	May 20, 2008
AB		SOMERSET THERAPS LLC	**EQ 150MG BASE**	**A214609**	**001**	Jun 30, 2021
AB			**EQ 225MG BASE**	**A214609**	**002**	Jun 30, 2021
AB		UNIQUE	**EQ 37.5MG BASE**	**A216044**	**001**	Nov 28, 2022
AB			**EQ 75MG BASE**	**A216044**	**002**	Nov 28, 2022
AB			**EQ 150MG BASE**	**A216044**	**003**	Nov 28, 2022
AB			**EQ 225MG BASE**	**A216044**	**004**	Nov 28, 2022
AB		ZYDUS PHARMS	**EQ 37.5MG BASE**	**A215622**	**001**	Aug 30, 2022
AB			**EQ 75MG BASE**	**A215622**	**002**	Aug 30, 2022
AB			**EQ 150MG BASE**	**A215622**	**003**	Aug 30, 2022
AB			**EQ 225MG BASE**	**A215622**	**004**	Aug 30, 2022

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	**120MG**	**A075138**	**001**	Apr 20, 1999
AB			**180MG**	**A075138**	**002**	Apr 20, 1999
AB			**240MG**	**A075138**	**003**	Apr 20, 1999

VERELAN

AB	**+**	AZURITY	**120MG**	**N019614**	**001**	May 29, 1990

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	**+**		**180MG**	**N019614**	**003**	Jan 09, 1992
AB	**+**		**240MG**	**N019614**	**002**	May 29, 1990
	+!		360MG	N019614	004	May 10, 1996

VERELAN PM

	+	AZURITY	100MG	N020943	001	Nov 25, 1998
	+		200MG	N020943	002	Nov 25, 1998
	+!		300MG	N020943	003	Nov 25, 1998

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP		ASPIRO	**2.5MG/ML**	**A218218**	**001**	Nov 13, 2025
AP	**!**	EUGIA PHARMA	**2.5MG/ML**	**A212965**	**001**	Jul 06, 2020
AP		FRESENIUS KABI USA	**2.5MG/ML**	**A216471**	**001**	Apr 23, 2024
AP		GLAND	**2.5MG/ML**	**A214361**	**001**	Oct 15, 2020
AP		HERITAGE	**2.5MG/ML**	**A215829**	**001**	Mar 17, 2022
AP		MANKIND PHARMA	**2.5MG/ML**	**A214653**	**001**	Jun 15, 2022
AP		ZYDUS PHARMS	**2.5MG/ML**	**A214215**	**001**	Oct 15, 2020

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL	**5MG/2ML (2.5MG/ML)**	**A210994**	**001**	Jul 13, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A210994**	**002**	Jul 13, 2018
AP		CAPLIN	**5MG/2ML (2.5MG/ML)**	**A213232**	**001**	Mar 25, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213232**	**002**	Mar 25, 2020
AP		EXELA PHARMA	**5MG/2ML (2.5MG/ML)**	**N018925**	**001**	Mar 30, 1984
AP	**!**	HOSPIRA	**5MG/2ML (2.5MG/ML)**	**A070738**	**001**	May 06, 1987
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A075136**	**001**	Oct 20, 1998
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A070737**	**001**	May 06, 1987
AP	**!**		**10MG/4ML (2.5MG/ML)**	**A070737**	**002**	May 06, 1987
AP		MICRO LABS	**5MG/2ML (2.5MG/ML)**	**A211370**	**001**	Dec 28, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211370**	**002**	Dec 28, 2018
AP		NEPHRON	**5MG/2ML (2.5MG/ML)**	**A213352**	**002**	Sep 16, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213352**	**001**	Mar 17, 2020
AP		SOMERSET	**5MG/2ML (2.5MG/ML)**	**A211035**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211035**	**002**	Jun 18, 2018
AP		SOMERSET THERAPS LLC	**5MG/2ML (2.5MG/ML)**	**A211015**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211015**	**002**	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE	**40MG**	**A071881**	**002**	Oct 14, 2015
AB			**80MG**	**A071881**	**003**	Apr 05, 1988
AB	**!**		**120MG**	**A071881**	**001**	Apr 05, 1988
AB		WATSON LABS	**40MG**	**A072924**	**001**	Jun 29, 1993
AB			**80MG**	**A070995**	**001**	Oct 01, 1986
AB			**120MG**	**A070994**	**001**	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	**120MG**	**A206173**	**003**	Nov 14, 2022
AB			**180MG**	**A206173**	**001**	May 05, 2017
AB			**240MG**	**A206173**	**002**	May 05, 2017
AB	**!**	GLENMARK PHARMS LTD	**120MG**	**A090700**	**001**	Aug 03, 2011
AB	**!**		**180MG**	**A090700**	**002**	Aug 03, 2011
AB	**!**		**240MG**	**A078906**	**001**	Sep 17, 2009
AB		STRIDES PHARMA INTL	**120MG**	**A075072**	**001**	May 25, 1999
AB			**240MG**	**A075072**	**003**	May 25, 1999
AB		ZYDUS LIFESCIENCES	**120MG**	**A219252**	**001**	Nov 24, 2025
AB			**180MG**	**A219252**	**002**	Nov 24, 2025
AB			**240MG**	**A219252**	**003**	Nov 24, 2025

VERICIGUAT

TABLET;ORAL

VERQUVO

	+	MSD	2.5MG	N214377	001	Jan 19, 2021
	+		5MG	N214377	002	Jan 19, 2021
	+!		10MG	N214377	003	Jan 19, 2021

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000

VIBEGRON

TABLET;ORAL

GEMTESA

	+!	SUMITOMO PHARMA AM	75MG	N213006	001	Dec 23, 2020

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	**+!**	LUNDBECK PHARMS LLC	**500MG/PACKET**	**N022006**	**001**	Aug 21, 2009

VIGABATRIN

AA		ALKEM LABS LTD	**500MG/PACKET**	**A213375**	**001**	Dec 02, 2020
AA		AMNEAL PHARMS	**500MG/PACKET**	**A210155**	**001**	Mar 13, 2018
AA		ANNORA PHARMA	**500MG/PACKET**	**A213519**	**001**	Jan 26, 2021
AA		AUROBINDO PHARMA LTD	**500MG/PACKET**	**A213899**	**001**	Sep 29, 2021
AA		DR REDDYS	**500MG/PACKET**	**A211481**	**001**	Nov 20, 2018
AA		INVAGEN PHARMS	**500MG/PACKET**	**A211592**	**001**	Dec 03, 2019
AA		MSN	**500MG/PACKET**	**A215363**	**001**	Sep 07, 2022
AA		PH HEALTH	**500MG/PACKET**	**A208218**	**001**	Apr 27, 2017
AA		TEVA PHARMS USA	**500MG/PACKET**	**A209824**	**001**	Apr 23, 2018

VIGADRONE

AA		AUCTA	**500MG/PACKET**	**A210196**	**001**	Jun 21, 2018

VIGPODER

AA		PYROS PHARMS	**500MG/PACKET**	**A214961**	**001**	Jun 24, 2022

SOLUTION;ORAL

VIGAFYDE

	+!	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024

TABLET;ORAL

SABRIL

AB	**+!**	LUNDBECK PHARMS LLC	**500MG**	**N020427**	**001**	Aug 21, 2009

VIGABATRIN

AB		AUROBINDO PHARMA LTD	**500MG**	**A215601**	**001**	May 10, 2022
AB		CARNEGIE	**500MG**	**A215519**	**001**	Apr 28, 2023
AB		DEXCEL	**500MG**	**A215109**	**001**	Sep 23, 2021
AB		DR REDDYS	**500MG**	**A211539**	**001**	Jan 29, 2021
AB		HIKMA	**500MG**	**A213104**	**001**	Aug 29, 2022
AB		TEVA PHARMS USA	**500MG**	**A209822**	**001**	Jan 14, 2019
AB		UPSHER SMITH LABS	**500MG**	**A214749**	**001**	Jun 29, 2023
AB		ZYDUS LIFESCIENCES	**500MG**	**A215707**	**001**	Jan 19, 2022

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	**+!**	ABBVIE	**10MG**	**N022567**	**001**	Jan 21, 2011
AB	**+**		**20MG**	**N022567**	**002**	Jan 21, 2011
AB	**+**		**40MG**	**N022567**	**003**	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**10MG**	**A208209**	**001**	Apr 27, 2021
AB			**20MG**	**A208209**	**002**	Apr 27, 2021
AB			**40MG**	**A208209**	**003**	Apr 27, 2021
AB		ALEMBIC	**10MG**	**A208202**	**001**	Jan 10, 2020
AB			**20MG**	**A208202**	**002**	Jan 10, 2020
AB			**40MG**	**A208202**	**003**	Jan 10, 2020
AB		APOTEX	**10MG**	**A208228**	**001**	Jul 07, 2023
AB			**20MG**	**A208228**	**002**	Jul 07, 2023
AB			**40MG**	**A208228**	**003**	Jul 07, 2023
AB		INVAGEN PHARMS	**10MG**	**A208200**	**001**	Apr 07, 2021
AB			**20MG**	**A208200**	**003**	Dec 06, 2022
AB			**40MG**	**A208200**	**002**	Apr 07, 2021
AB		TEVA PHARMS USA	**10MG**	**A208212**	**001**	Sep 30, 2019
AB			**20MG**	**A208212**	**002**	Sep 30, 2019
AB			**40MG**	**A208212**	**003**	Sep 30, 2019

VILOXAZINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021
+		EQ 150MG BASE	N211964	002	Apr 02, 2021
+!		EQ 200MG BASE	N211964	003	Apr 02, 2021

VILTOLARSEN
SOLUTION;INTRAVENOUS
VILTEPSO

+!	NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154	001	Aug 12, 2020

VIMSELTINIB
CAPSULE;ORAL
ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025
+		20MG	N219304	002	Feb 14, 2025
+!		30MG	N219304	003	Feb 14, 2025

VINBLASTINE SULFATE
INJECTABLE;INJECTION
VINBLASTINE SULFATE

!	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
!	HIKMA	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE
INJECTABLE;INJECTION
VINCRISTINE SULFATE PFS

!	HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP		DR REDDYS	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP		HIKMA	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003
AP			**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003
AP	**!**	JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012

VISMODEGIB
CAPSULE;ORAL
ERIVEDGE

+!	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE
INJECTABLE;INJECTION
AQUASOL A

+!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	

VOCLOSPORIN
CAPSULE;ORAL
LUPKYNIS

+!	AURINIA	7.9MG	N213716	001	Jan 22, 2021

VONOPRAZAN FUMARATE
TABLET;ORAL
VOQUEZNA

+	PHATHOM	EQ 10MG BASE	N215151	001	Nov 01, 2023
+!		EQ 20MG BASE	N215151	002	Nov 01, 2023

VORASIDENIB
TABLET;ORAL
VORANIGO

+	SERVIER	10MG	N218784	001	Aug 06, 2024
+!		40MG	N218784	002	Aug 06, 2024

VORICONAZOLE
FOR SUSPENSION;ORAL
VFEND

AB	**+!**	PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003

VORICONAZOLE

AB		AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB		HETERO LABS LTD V	**200MG/5ML**	**A211598**	**001**	Aug 08, 2025
AB		NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016
AB		ZHEJIANG POLY PHARM	**200MG/5ML**	**A216805**	**001**	Jan 02, 2024

VORICONAZOLE						
POWDER;INTRAVENOUS						
VFEND						
AP	**+!**	PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002
VORICONAZOLE						
AP		ASPIRO	**200MG/VIAL**	**A218533**	**001**	Apr 03, 2024
AP		GLAND	**200MG/VIAL**	**A211099**	**001**	Mar 31, 2020
AP		HIKMA	**200MG/VIAL**	**N208562**	**001**	Mar 09, 2017
AP		MEITHEAL	**200MG/VIAL**	**A214516**	**001**	May 09, 2022
AP		SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012
AP		SLATE RUN PHARMA	**200MG/VIAL**	**A211661**	**001**	Nov 30, 2018
AP		UBI	**200MG/VIAL**	**A211264**	**001**	Mar 09, 2023
AP		ZYDUS PHARMS	**200MG/VIAL**	**A208983**	**001**	Jul 16, 2018
SOLUTION;INTRAVENOUS						
VORICONAZOLE						
	!	HAINAN POLY PHARM	200MG/20ML (10MG/ML)	A220043	001	Nov 14, 2025
TABLET;ORAL						
VFEND						
AB	**+**	PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002
AB	**+!**		**200MG**	**N021266**	**002**	May 24, 2002
VORICONAZOLE						
AB		AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016
AB			**200MG**	**A206181**	**002**	May 24, 2016
AB		AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016
AB			**200MG**	**A206837**	**002**	Jan 22, 2016
AB		CADILA	**50MG**	**A206747**	**001**	May 24, 2016
AB			**200MG**	**A206747**	**002**	May 24, 2016
AB		CHARTWELL RX	**50MG**	**A207371**	**001**	May 24, 2016
AB			**200MG**	**A207371**	**002**	May 24, 2016
AB		EPIC PHARMA LLC	**50MG**	**A207049**	**001**	Sep 07, 2016
AB			**200MG**	**A207049**	**002**	Sep 07, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015
AB			**200MG**	**A203503**	**002**	Sep 02, 2015
AB		MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010
AB			**200MG**	**A090547**	**002**	Apr 22, 2010
AB		PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016
AB			**200MG**	**A206654**	**002**	Aug 08, 2016
AB		RISING	**50MG**	**A206762**	**001**	May 24, 2016
AB			**200MG**	**A206762**	**002**	May 24, 2016
AB		SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011
AB			**200MG**	**A200265**	**002**	Dec 12, 2011
VORINOSTAT						
CAPSULE;ORAL						
ZOLINZA						
	+!	MSD SUB MERCK	100MG	N021991	001	Oct 06, 2006
VORTIOXETINE HYDROBROMIDE						
TABLET;ORAL						
TRINTELLIX						
	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013
	+		EQ 10MG BASE	N204447	002	Sep 30, 2013
	+!		EQ 20MG BASE	N204447	004	Sep 30, 2013
VOSORITIDE						
POWDER;SUBCUTANEOUS						
VOXZOGO						
	+!	BIOMARIN PHARM	0.4MG/VIAL	N214938	001	Nov 19, 2021
	+!		0.56MG/VIAL	N214938	002	Nov 19, 2021
	+!		1.2MG/VIAL	N214938	003	Nov 19, 2021
VUTRISIRAN SODIUM						
SOLUTION;SUBCUTANEOUS						
AMVUTTRA						
	+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022
WARFARIN SODIUM						
TABLET;ORAL						
JANTOVEN						
AB		UPSHER SMITH LABS	**1MG**	**A040416**	**001**	Oct 02, 2003
AB			**2MG**	**A040416**	**002**	Oct 02, 2003
AB			**2.5MG**	**A040416**	**003**	Oct 02, 2003
AB			**3MG**	**A040416**	**004**	Oct 02, 2003
AB			**4MG**	**A040416**	**005**	Oct 02, 2003

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB		**5MG**	**A040416**	**006**	Oct 02, 2003
AB		**6MG**	**A040416**	**007**	Oct 02, 2003
AB		**7.5MG**	**A040416**	**008**	Oct 02, 2003
AB		**10MG**	**A040416**	**009**	Oct 02, 2003

WARFARIN SODIUM

AB	AMNEAL PHARMS	**1MG**	**A202202**	**001**	Mar 04, 2013
AB		**2MG**	**A202202**	**002**	Mar 04, 2013
AB		**2.5MG**	**A202202**	**003**	Mar 04, 2013
AB		**3MG**	**A202202**	**004**	Mar 04, 2013
AB		**4MG**	**A202202**	**005**	Mar 04, 2013
AB		**5MG**	**A202202**	**006**	Mar 04, 2013
AB		**6MG**	**A202202**	**007**	Mar 04, 2013
AB		**7.5MG**	**A202202**	**008**	Mar 04, 2013
AB		**10MG**	**A202202**	**009**	Mar 04, 2013
AB	INVAGEN PHARMS	**1MG**	**A090935**	**001**	May 25, 2011
AB		**2MG**	**A090935**	**002**	May 25, 2011
AB		**2.5MG**	**A090935**	**003**	May 25, 2011
AB		**3MG**	**A090935**	**004**	May 25, 2011
AB		**4MG**	**A090935**	**005**	May 25, 2011
AB		**5MG**	**A090935**	**006**	May 25, 2011
AB		**6MG**	**A090935**	**007**	May 25, 2011
AB		**7.5MG**	**A090935**	**008**	May 25, 2011
AB		**10MG**	**A090935**	**009**	May 25, 2011
AB	PLIVA	**1MG**	**A040616**	**009**	Jul 05, 2006
AB		**2MG**	**A040616**	**001**	Jul 05, 2006
AB		**2.5MG**	**A040616**	**002**	Jul 05, 2006
AB		**3MG**	**A040616**	**003**	Jul 05, 2006
AB		**4MG**	**A040616**	**004**	Jul 05, 2006
AB		**5MG**	**A040616**	**005**	Jul 05, 2006
AB		**6MG**	**A040616**	**006**	Jul 05, 2006
AB		**7.5MG**	**A040616**	**007**	Jul 05, 2006
AB **!**		**10MG**	**A040616**	**008**	Jul 05, 2006
AB	TARO	**1MG**	**A040301**	**002**	Jul 15, 1999
AB		**2MG**	**A040301**	**003**	Jul 15, 1999
AB		**2.5MG**	**A040301**	**004**	Jul 15, 1999
AB		**3MG**	**A040301**	**005**	Jul 15, 1999
AB		**4MG**	**A040301**	**006**	Jul 15, 1999
AB		**5MG**	**A040301**	**007**	Jul 15, 1999
AB		**6MG**	**A040301**	**008**	Jul 15, 1999
AB		**7.5MG**	**A040301**	**009**	Jul 15, 1999
AB		**10MG**	**A040301**	**001**	Jul 15, 1999
AB	ZYDUS PHARMS USA	**1MG**	**A040663**	**001**	May 30, 2006
AB		**2MG**	**A040663**	**002**	May 30, 2006
AB		**2.5MG**	**A040663**	**003**	May 30, 2006
AB		**3MG**	**A040663**	**004**	May 30, 2006
AB		**4MG**	**A040663**	**005**	May 30, 2006
AB		**5MG**	**A040663**	**006**	May 30, 2006
AB		**6MG**	**A040663**	**007**	May 30, 2006
AB		**7.5MG**	**A040663**	**008**	May 30, 2006
AB		**10MG**	**A040663**	**009**	May 30, 2006

XENON XE-129 HYPERPOLARIZED

GAS;INHALATION

XENOVIEW

+!	POLAREAN	N/A	N214375	001	Dec 23, 2022

XENON XE-133

GAS;INHALATION

XENON XE 133

	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982
		20mCi/VIAL	N018327	002	Mar 09, 1982
	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
		20mCi/VIAL	N017284	002	

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB **+**	STRIDES PHARMA INTL	**10MG**	**N020547**	**003**	Sep 17, 1999
AB **+!**		**20MG**	**N020547**	**001**	Sep 26, 1996

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

AB		ANNORA PHARMA	**10MG**	**A212475**	**001**	Sep 10, 2020
AB			**20MG**	**A212475**	**002**	Sep 10, 2020
AB		AUROBINDO PHARMA	**10MG**	**A213163**	**001**	Nov 27, 2023
AB			**20MG**	**A213163**	**002**	Nov 27, 2023
AB		DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB			**20MG**	**A090372**	**002**	Nov 18, 2010
AB		RISING PHARMS	**10MG**	**A204928**	**001**	Aug 25, 2022
AB			**20MG**	**A204928**	**002**	Aug 25, 2022

ZALEPLON

CAPSULE;ORAL

ZALEPLON

AB		AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB			**10MG**	**A078829**	**002**	Jun 06, 2008
AB		CHARTWELL MOLECULAR	**5MG**	**A077505**	**001**	Jun 20, 2008
AB			**10MG**	**A077505**	**002**	Jun 20, 2008
AB		HIKMA	**5MG**	**A077237**	**001**	Jun 06, 2008
AB			**10MG**	**A077237**	**002**	Jun 06, 2008
AB		ORBION PHARMS	**5MG**	**A090374**	**001**	Sep 17, 2009
AB			**10MG**	**A090374**	**002**	Sep 17, 2009
AB		UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB	**!**		**10MG**	**A078989**	**002**	Jun 06, 2008

ZANAMIVIR

POWDER;INHALATION

RELENZA

+!	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999

ZANUBRUTINIB

TABLET;ORAL

BRUKINSA

+!	BEONE MEDICINES USA	160MG	N218785	001	Jun 10, 2025

ZAVEGEPANT HYDROCHLORIDE

SPRAY, METERED;NASAL

ZAVZPRET

+!	PFIZER	EQ 10MG BASE/SPRAY	N216386	001	Mar 09, 2023

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

+!	TERSERA	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

ZIDOVUDINE

CAPSULE;ORAL

RETROVIR

AB	**+!**	VIIV HLTHCARE	**100MG**	**N019655**	**001**	Mar 19, 1987

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	**100MG**	**A078128**	**001**	Mar 27, 2006
AB		CIPLA LTD	**100MG**	**A078349**	**001**	May 23, 2007

INJECTABLE;INJECTION

RETROVIR

+!	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990

SOLUTION;ORAL

RETROVIR

AA	**+!**	VIIV HLTHCARE	**50MG/5ML**	**N019910**	**001**	Sep 28, 1989

ZIDOVUDINE

AA		AUROBINDO	**50MG/5ML**	**A077268**	**001**	Sep 19, 2005
AA		CIPLA LTD	**50MG/5ML**	**A077981**	**001**	Jun 26, 2008

TABLET;ORAL

ZIDOVUDINE

AB		AUROBINDO	**300MG**	**A077267**	**001**	Sep 19, 2005
AB		CIPLA	**300MG**	**A090561**	**001**	Oct 27, 2010
AB	**!**	HETERO LABS LTD III	**300MG**	**A090092**	**001**	Apr 25, 2008

ZIFTOMENIB

CAPSULE;ORAL

KOMZIFTI

	+!	KURA	200MG	N220305	001	Nov 13, 2025

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB		AIZANT	**600MG**	**A211390**	**001**	Oct 23, 2020
AB		ANNORA PHARMA	**600MG**	**A215742**	**001**	Oct 11, 2022
AB	**!**	RISING	**600MG**	**A204929**	**001**	Mar 17, 2017
AB		STRIDES PHARMA INTL	**600MG**	**A212670**	**001**	Dec 16, 2019

ZILUCOPLAN SODIUM

SOLUTION;SUBCUTANEOUS

ZILBRYSQ

	+!	UCB INC	EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML)	N216834	001	Oct 17, 2023
	+!		EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML)	N216834	002	Oct 17, 2023
	+!		EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML)	N216834	003	Oct 17, 2023

ZINC ACETATE

CAPSULE;ORAL

GALZIN

	+	ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

AP		EXELA PHARMA	**EQ 1MG ZINC/ML**	**A212007**	**001**	May 21, 2021
AP		RK PHARMA	**EQ 1MG ZINC/ML**	**A217625**	**001**	Apr 14, 2025
AP		SOMERSET	**EQ 1MG ZINC/ML**	**A216152**	**001**	Oct 16, 2024

ZINC CHLORIDE IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**EQ 1MG ZINC/ML**	**N018959**	**001**	Jun 26, 1986

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

AP	**+!**	AM REGENT	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**N209377**	**003**	Apr 15, 2020
AP	**+!**		**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**N209377**	**002**	Jul 18, 2019
AP	**+!**		**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**N209377**	**001**	Jul 18, 2019
AP		APOTEX	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A218059**	**002**	Oct 28, 2024
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A218059**	**001**	Jun 10, 2024
AP		ASPIRO	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A219585**	**001**	May 01, 2025
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A219585**	**002**	May 01, 2025
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A219585**	**003**	May 01, 2025
AP		FRESENIUS KABI USA	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A216145**	**001**	Dec 27, 2022
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A216145**	**002**	Dec 27, 2022
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A216145**	**003**	Dec 27, 2022
AP		GLAND	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A216249**	**003**	Sep 01, 2023
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A216249**	**001**	May 03, 2022
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A216249**	**002**	May 03, 2022
AP		NIVAGEN PHARMS INC	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A214597**	**001**	Jul 05, 2024
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A214597**	**002**	Jul 05, 2024
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A214597**	**003**	Jul 05, 2024
AP		RK PHARMA	**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A217624**	**001**	Jun 10, 2025
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A217624**	**002**	Jun 10, 2025
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A217624**	**003**	Jun 10, 2025
AP		SOMERSET THERAPS LLC	**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A216135**	**001**	Jul 17, 2024
AP			**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A216135**	**002**	Jul 17, 2024
AP		ZYDUS PHARMS	**EQ 30MG BASE/10ML (EQ 3MG BASE/ML)**	**A217074**	**003**	Aug 22, 2023
AP			**EQ 10MG BASE/10ML (EQ 1MG BASE/ML)**	**A217074**	**001**	Aug 22, 2023
AP			**EQ 25MG BASE/5ML (EQ 5MG BASE/ML)**	**A217074**	**002**	Aug 22, 2023

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	**+!**	VIATRIS	**EQ 20MG BASE**	**N020825**	**001**	Feb 05, 2001
AB	**+**		**EQ 40MG BASE**	**N020825**	**002**	Feb 05, 2001
AB	**+**		**EQ 60MG BASE**	**N020825**	**003**	Feb 05, 2001
AB	**+**		**EQ 80MG BASE**	**N020825**	**004**	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX	**EQ 20MG BASE**	**A077561**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561**	**004**	Mar 02, 2012
AB		AUROBINDO PHARMA	**EQ 20MG BASE**	**A204117**	**001**	Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117**	**002**	Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117**	**003**	Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117**	**004**	Dec 27, 2016
AB		CHARTWELL RX	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB			**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB			**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB			**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204375**	**001**	Feb 17, 2017
AB			**EQ 40MG BASE**	**A204375**	**002**	Feb 17, 2017
AB			**EQ 60MG BASE**	**A204375**	**003**	Feb 17, 2017
AB			**EQ 80MG BASE**	**A204375**	**004**	Feb 17, 2017
AB		SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB			**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB			**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB			**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012
AB		ZYDUS LIFESCIENCES	**EQ 20MG BASE**	**A208988**	**001**	Aug 22, 2017
AB			**EQ 40MG BASE**	**A208988**	**002**	Aug 22, 2017
AB			**EQ 60MG BASE**	**A208988**	**003**	Aug 22, 2017
AB			**EQ 80MG BASE**	**A208988**	**004**	Aug 22, 2017

ZIPRASIDONE MESYLATE

POWDER;INTRAMUSCULAR

GEODON

AP	**+!**	VIATRIS	**EQ 20MG BASE/VIAL**	**N020919**	**001**	Jun 21, 2002

ZIPRASIDONE MESYLATE

AP		GLAND	**EQ 20MG BASE/VIAL**	**A211908**	**001**	Dec 26, 2019
AP		MSN	**EQ 20MG BASE/VIAL**	**A216091**	**001**	Sep 15, 2022
AP		STERISCIENCE	**EQ 20MG BASE/VIAL**	**A217595**	**001**	Sep 03, 2025

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

AP	**+!**	SANDOZ	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC

AP	**!**	GLAND	**EQ 4MG BASE/100ML**	**A205749**	**001**	Jun 29, 2018

ZOLEDRONIC ACID

AP		ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP		AMNEAL	**EQ 4MG BASE/100ML**	**A210174**	**001**	Oct 27, 2017
AP		AVET LIFESCIENCES	**EQ 4MG BASE/5ML**	**A201783**	**001**	Mar 12, 2013
AP		BPI LABS	**EQ 4MG BASE/5ML**	**A207341**	**001**	Dec 29, 2017
AP		CHARTWELL RX	**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP			**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP	**!**	DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP		EPIC PHARMA LLC	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP			**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP		FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP		GLAND	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP			**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP			**EQ 5MG BASE/100ML**	**A209578**	**001**	Aug 08, 2019
AP		HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP		HOSPIRA INC	**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP	**+!**	INFORLIFE	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP			**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP		MEITHEAL	**EQ 5MG BASE/100ML**	**A213371**	**001**	Jun 05, 2023
AP		MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A203841**	**001**	Feb 14, 2017
AP			**EQ 5MG BASE/100ML**	**A205254**	**001**	Oct 27, 2017
AP		SAGENT PHARMS INC	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP		USV	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

ZOLIFLODACIN

FOR SUSPENSION;ORAL

NUZOLVENCE

	+!	ENTASIS THERAP	3GM/PACKET	N219491	001	Dec 12, 2025

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

AB		PADAGIS ISRAEL	**2.5MG/SPRAY**	**A212469**	**001**	Sep 30, 2021
AB			**5MG/SPRAY**	**A212469**	**002**	Sep 30, 2021

ZOMIG

AB	**+!**	AMNEAL	**2.5MG/SPRAY**	**N021450**	**003**	Sep 16, 2013
AB	**+!**		**5MG/SPRAY**	**N021450**	**004**	Sep 30, 2003

TABLET;ORAL

ZOLMITRIPTAN

AB		AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB	**!**		**5MG**	**A204041**	**002**	May 20, 2016
AB		ALEMBIC	**2.5MG**	**A204232**	**001**	Sep 30, 2015
AB			**5MG**	**A204232**	**002**	Sep 30, 2015
AB		AUROBINDO PHARMA	**2.5MG**	**A207021**	**001**	May 11, 2016
AB			**5MG**	**A207021**	**002**	May 11, 2016
AB		CHARTWELL RX	**2.5MG**	**A206973**	**001**	Jun 30, 2017
AB			**5MG**	**A206973**	**002**	Jun 30, 2017
AB		GLENMARK PHARMS LTD	**2.5MG**	**A201779**	**001**	May 14, 2013
AB			**5MG**	**A201779**	**002**	May 14, 2013
AB		JUBILANT GENERICS	**2.5MG**	**A202279**	**001**	Nov 20, 2014
AB			**5MG**	**A202279**	**002**	Nov 20, 2014
AB		ORBION PHARMS	**2.5MG**	**A203726**	**001**	Oct 21, 2019
AB			**5MG**	**A203726**	**002**	Oct 21, 2019
AB		PLD ACQUISITIONS LLC	**2.5MG**	**A207867**	**001**	Feb 27, 2017
AB			**5MG**	**A207867**	**002**	Feb 27, 2017
AB		ZYDUS PHARMS	**2.5MG**	**A203019**	**001**	Jul 11, 2018
AB			**5MG**	**A203019**	**002**	Jul 11, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB		ALEMBIC	**2.5MG**	**A205074**	**001**	Dec 01, 2016
AB			**5MG**	**A205074**	**002**	Dec 01, 2016
AB		GLENMARK PHARMS LTD	**2.5MG**	**A202560**	**001**	May 14, 2013
AB			**5MG**	**A202560**	**002**	May 14, 2013
AB		JUBILANT GENERICS	**2.5MG**	**A202956**	**001**	Sep 17, 2015
AB			**5MG**	**A202956**	**002**	Sep 17, 2015
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A202890**	**001**	May 15, 2013
AB	**!**		**5MG**	**A202890**	**002**	May 15, 2013

ZOLPIDEM TARTRATE

CAPSULE;ORAL

ZOLPIDEM TARTRATE

	+!	ALMATICA	7.5MG	N215721	001	May 09, 2023

TABLET;ORAL

AMBIEN

AB	**+**	COSETTE	**5MG**	**N019908**	**001**	Dec 16, 1992
AB	**+!**		**10MG**	**N019908**	**002**	Dec 16, 1992

ZOLPIDEM TARTRATE

AB		ACME LABS	**5MG**	**A077214**	**001**	Apr 23, 2007
AB			**10MG**	**A077214**	**002**	Apr 23, 2007
AB		AUROBINDO PHARMA	**5MG**	**A078413**	**001**	May 04, 2007
AB			**10MG**	**A078413**	**002**	May 04, 2007
AB		CHARTWELL MOLECULAR	**5MG**	**A077388**	**001**	Jul 30, 2012
AB			**10MG**	**A077388**	**002**	Jul 30, 2012
AB		SANDOZ	**5MG**	**A077322**	**001**	Apr 23, 2007
AB			**10MG**	**A077322**	**002**	Apr 23, 2007
AB		TEVA	**5MG**	**A076410**	**001**	Apr 23, 2007
AB			**10MG**	**A076410**	**002**	Apr 23, 2007
AB		TORRENT PHARMS	**5MG**	**A077903**	**001**	Aug 17, 2007
AB			**10MG**	**A077903**	**002**	Aug 17, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	**+**	VIATRIS	**5MG**	**N021997**	**001**	Mar 13, 2009
AB	**+!**		**10MG**	**N021997**	**002**	Mar 13, 2009

ZOLPIDEM TARTRATE

AB		DR REDDYS	**1.75MG**	**A204503**	**001**	Nov 18, 2016
AB			**3.5MG**	**A204503**	**002**	Nov 18, 2016

ZOLPIDEM TARTRATE

TABLET;SUBLINGUAL

ZOLPIDEM TARTRATE

AB		NOVEL LABS INC	**1.75MG**	**A204299**	**001**	Jun 03, 2015
AB	!		**3.5MG**	**A204299**	**002**	Jun 03, 2015
AB		PH HEALTH	**1.75MG**	**A204229**	**001**	Sep 11, 2017
AB			**3.5MG**	**A204229**	**002**	Sep 11, 2017
AB			**5MG**	**A201509**	**001**	Aug 01, 2016
AB			**10MG**	**A201509**	**002**	Aug 01, 2016

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	+	COSETTE	**6.25MG**	**N021774**	**002**	Sep 02, 2005
AB	+!		**12.5MG**	**N021774**	**001**	Sep 02, 2005

ZOLPIDEM TARTRATE

AB		LUPIN LTD	**6.25MG**	**A078970**	**001**	Sep 11, 2013
AB			**12.5MG**	**A078970**	**002**	Sep 11, 2013
AB		SANDOZ	**6.25MG**	**A090107**	**001**	Jul 01, 2011
AB			**12.5MG**	**A090107**	**002**	Jul 01, 2011
AB		SUN PHARM	**6.25MG**	**A204170**	**001**	Jan 24, 2017
AB			**12.5MG**	**A204170**	**002**	Jan 24, 2017

ZONGERTINIB

TABLET;ORAL

HERNEXEOS

+!	BOEHRINGER INGELHEIM	60MG	N219042	001	Aug 08, 2025

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+	ADVANZ PHARMA	**25MG**	**N020789**	**003**	Aug 22, 2003
AB	+!		**100MG**	**N020789**	**001**	Mar 27, 2000

ZONISAMIDE

AB		AUROBINDO PHARMA LTD	**25MG**	**A077645**	**002**	Sep 29, 2006
AB			**50MG**	**A077645**	**003**	Sep 29, 2006
AB			**100MG**	**A077645**	**001**	Dec 22, 2005
AB		BIONPHARMA	**25MG**	**A077813**	**001**	Aug 16, 2006
AB			**50MG**	**A077813**	**002**	Aug 16, 2006
AB			**100MG**	**A077813**	**003**	Aug 16, 2006
AB		GLENMARK PHARMS INC	**25MG**	**A077651**	**001**	Jan 30, 2006
AB			**50MG**	**A077651**	**002**	Jan 30, 2006
AB			**100MG**	**A077651**	**003**	Jan 30, 2006
AB		GRANULES	**25MG**	**A077636**	**003**	Jul 27, 2006
AB			**50MG**	**A077636**	**002**	Jul 27, 2006
AB			**100MG**	**A077636**	**001**	Dec 22, 2005
AB		INVAGEN PHARMS	**25MG**	**A077869**	**001**	May 31, 2006
AB			**50MG**	**A077869**	**002**	May 31, 2006
AB			**100MG**	**A077869**	**003**	May 31, 2006
AB		UNICHEM	**25MG**	**A214492**	**001**	Jan 26, 2021
AB			**50MG**	**A214492**	**002**	Jan 26, 2021
AB			**100MG**	**A214492**	**003**	Jan 26, 2021
AB		ZYDUS LIFESCIENCES	**25MG**	**A077625**	**001**	Oct 16, 2006
AB			**50MG**	**A077625**	**002**	Oct 16, 2006
AB			**100MG**	**A077625**	**003**	Oct 16, 2006

SUSPENSION;ORAL

ZONISADE

+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022

ZURANOLONE

CAPSULE;ORAL

ZURZUVAE

+	BIOGEN INC	20MG	N217369	001	Oct 31, 2023
+		25MG	N217369	002	Oct 31, 2023
+!		30MG	N217369	003	Oct 31, 2023

ACETAMINOPHEN

SUPPOSITORY;RECTAL					
ACETAMINOPHEN					
	PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
		650MG	A070608	001	Dec 01, 1986
+	TARO	120MG	N018337	003	Sep 12, 1983
+		325MG	N018337	002	
INFANTS' FEVERALL					
+	TARO	80MG	N018337	004	Aug 26, 1992
TABLET, EXTENDED RELEASE;ORAL					
ACETAMINOPHEN					
	AUROBINDO PHARMA LTD	650MG	A207229	001	Nov 09, 2016
	GRANULES	650MG	A211544	001	Apr 16, 2019
	MARKSANS PHARMA	650MG	A215486	001	Aug 25, 2021
	OHM LABS	650MG	A076200	001	Mar 19, 2002
	PERRIGO	650MG	A075077	001	Feb 25, 2000
TYLENOL					
+!	KENVUE BRANDS	650MG	N019872	001	Jun 08, 1994
+!		650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL					
ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	AUROBINDO PHARMA LTD	250MG;250MG;65MG	A211695	001	Feb 02, 2022
	GRANULES	250MG;250MG;65MG	A214039	001	Feb 23, 2021
	PERRIGO	250MG;250MG;65MG	A075794	001	Nov 26, 2001
EXCEDRIN (MIGRAINE RELIEF)					
+!	HALEON US HOLDINGS	250MG;250MG;65MG	N020802	001	Jan 14, 1998

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL					
ACETAMINOPHEN AND IBUPROFEN					
	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024
	BIONPHARMA	250MG;125MG	A216999	001	Aug 01, 2023
	DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024
	GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024
	GRANULES	250MG;125MG	A216592	001	Jul 13, 2023
	L PERRIGO CO	250MG;125MG	A214836	001	Feb 28, 2023
	LNK INTL INC	250MG;125MG	A220126	001	Dec 11, 2025
	MARKSANS PHARMA	250MG;125MG	A216994	001	Jul 10, 2023
	TARO	250MG;125MG	A219053	001	Jan 02, 2026
ADVIL DUAL ACTION WITH ACETAMINOPHEN					
+!	HALEON US HOLDINGS	250MG;125MG	N211733	001	Feb 28, 2020

ADAPALENE

GEL;TOPICAL					
ADAPALENE					
	GLENMARK PHARMS INC	0.1%	A091314	001	Jul 01, 2010
	P AND L	0.1%	A090962	001	Jun 02, 2010
	SUN PHARMA CANADA	0.1%	A215940	001	Jan 14, 2022
DIFFERIN					
+!	GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC					
ALCAFTADINE					
	ALEMBIC	0.25%	A209290	001	Oct 02, 2024
	GLAND	0.25%	A209706	001	Mar 01, 2024
LASTACAFT					
+!	ABBVIE	0.25%	N022134	001	Jul 28, 2010

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL					
AVAGARD					
+!	3M	61%;1%	N021074	001	Jun 07, 2001

ASPIRIN

CAPSULE;ORAL					
VAZALORE					
+	PLX PHARMA	81MG	N203697	002	Feb 26, 2021
+!		325MG	N203697	001	Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM;TOPICAL					
ANTHELIOS SX					
+!	LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006
CAPITAL SOLEIL 15					
+!	LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM;TOPICAL					
ANTHELIOS 20					
+!	LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006
ANTHELIOS 40					
+!	LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+!		2%;3%;10%;5%	N022009	002	Oct 29, 2009

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL					
ASTEPRO ALLERGY					
+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	001	Jun 17, 2021
AZELASTINE HYDROCHLORIDE					
	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024
AZELASTINE HYDROCHLORIDE ALLERGY					
	APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024
	AUROBINDO PHARMA	0.2055MG/SPRAY	A216561	001	Jan 27, 2025
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY					
	APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024
CHILDREN'S ASTEPRO ALLERGY					
+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	002	Jun 17, 2021

BENTOQUATAM

LOTION;TOPICAL					
IVY BLOCK					
+!	STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC					
BRIMONIDINE TARTRATE					
	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024
LUMIFY					
+!	BAUSCH AND LOMB INC	0.025%	N208144	001	Dec 22, 2017
LUMIFY PRESERVATIVE FREE					
+!	BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024

BUDESONIDE

SPRAY, METERED;NASAL					
BUDESONIDE					
	APOTEX	0.032MG/SPRAY	A078949	002	Nov 20, 2015
RHINOCORT ALLERGY					
+!	KENVUE BRANDS	0.032MG/SPRAY	N020746	003	Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL					
BUTENAFINE HYDROCHLORIDE					
	SUN PHARMA CANADA	1%	A205181	001	Nov 16, 2017
LOTRIMIN ULTRA					
+!	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL					
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE					
	PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
PEPCID COMPLETE					
+!	KENVUE BRANDS	800MG;10MG;165MG	N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	AUROBINDO PHARMA LTD	10MG	A209107	001	Jul 20, 2018
+	BIONPHARMA	5MG	N022429	001	Jul 23, 2009
+!		10MG	N022429	004	Jul 23, 2009
	CATALENT	10MG	A213105	001	Sep 21, 2020
	ONESOURCE SPECIALTY	10MG	A205291	001	Jul 21, 2017
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AUROBINDO PHARMA LTD	10MG	A209107	002	Jul 20, 2018

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
+	BIONPHARMA	5MG	N022429	003	Jul 23, 2009
+!		10MG	N022429	002	Jul 23, 2009
SOLUTION;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
	APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013
		5MG/5ML	A090254	002	Apr 09, 2008
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019
	TARO	5MG/5ML	A090182	002	Apr 22, 2008
		5MG/5ML	A201546	001	May 20, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
	APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
	TARO	5MG/5ML	A090182	001	Apr 22, 2008
		5MG/5ML	A201546	002	May 20, 2011
CHILDREN'S ZYRTEC ALLERGY					
+!	KENVUE BRANDS	5MG/5ML	N022155	002	Nov 16, 2007
CHILDREN'S ZYRTEC HIVES					
+!	KENVUE BRANDS	5MG/5ML	N022155	001	Nov 16, 2007
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE					
	REGCON HOLDINGS	10MG	A218895	001	Oct 03, 2024
CETIRIZINE HYDROCHLORIDE ALLERGY					
	AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
		10MG	A078780	004	Jan 21, 2010
	APOTEX INC	5MG	A078317	001	Dec 27, 2007
		10MG	A078317	002	Dec 27, 2007
	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
		10MG	A090760	003	Aug 05, 2015
	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
		10MG	A076047	002	Dec 27, 2007
	DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
		10MG	A078343	003	Jan 15, 2008
	GLENMARK PHARMS INC	5MG	A078427	003	Dec 28, 2007
		10MG	A078427	004	Dec 28, 2007
	GRANULES	10MG	A209274	001	Dec 22, 2017
	MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
		10MG	A078933	002	Jun 15, 2010
	MYLAN	5MG	A076677	001	Dec 27, 2007
		10MG	A076677	002	Dec 27, 2007
	ORBION PHARMS	5MG	A078862	001	Feb 19, 2009
		10MG	A078862	002	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
		10MG	A078336	002	Dec 27, 2007
	PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
		10MG	A077946	002	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
		10MG	A077498	002	Dec 27, 2007
	UNIQUE	5MG	A077829	001	Aug 26, 2009
		10MG	A077829	004	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
		10MG	A078343	002	Jan 15, 2008
	MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
		10MG	A078933	004	Jun 15, 2010
	MYLAN	5MG	A076677	004	Dec 27, 2007
		10MG	A076677	003	Dec 27, 2007
	ORBION PHARMS	5MG	A078862	003	Feb 19, 2009
		10MG	A078862	004	Feb 19, 2009
	PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES					
		10MG	A078336	004	Dec 27, 2007
	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
		10MG	A077498	004	Dec 27, 2007
	UNIQUE	5MG	A077829	003	Aug 26, 2009
!		10MG	A077829	002	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
		10MG	A078780	002	Jan 21, 2010
	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
		10MG	A090760	004	Aug 05, 2015
ZYRTEC ALLERGY					
+	KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007
+!		10MG	N019835	004	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
		10MG	A091116	002	Feb 19, 2015
	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
		10MG	A206793	002	Mar 08, 2016
	SANDOZ	5MG	A078692	001	Feb 14, 2008
!		10MG	A078692	002	Feb 14, 2008
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
CHILDREN'S ZYRTEC ALLERGY					
+	KENVUE BRANDS	2.5MG	N021621	007	Nov 30, 2020
+		10MG	N021621	004	Nov 16, 2007
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	10MG	A213557	001	Sep 11, 2020
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PERRIGO R AND D	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY					
+!	KENVUE BRANDS	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008
	PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR					
+!	KENVUE BRANDS	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL					
EXIDINE					
+!	XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL					
CHLORHEXIDINE GLUCONATE					
+!	SAGE PRODS	2%	N021669	001	Apr 25, 2005
READYPREP CHG					
+!	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018
SOLUTION;TOPICAL					
CHG SCRUB					
	ECOLAB	4%	N019258	002	Jul 22, 1986
CHLORHEXIDINE GLUCONATE					
	BAJAJ	0.75%	N020111	001	Sep 11, 1997
CIDA-STAT					
	ECOLAB	2%	N019258	001	Jul 22, 1986
EXIDINE					
+!	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984
HIBICLENS					
+!	MOLNLYCKE HLTH	4%	N017768	001	

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL					
HIBISTAT					
+!	MOLNLYCKE HLTH	0.5%	N018300	001	
SPONGE;TOPICAL					
BIOSCRUB					
	GRIFFEN	4%	N019822	001	Mar 31, 1989
CHLORHEXIDINE GLUCONATE					
!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL					
SOLUPREP S					
+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018
SPONGE;TOPICAL					
CHLORAPREP ONE-STEP					
+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006
+!		2%;70% (1ML)	N020832	008	Oct 23, 2008
CHLORAPREP ONE-STEP FREPP					
+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
CHLORAPREP WITH TINT					
+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006
SWAB;TOPICAL					
CHLORAPREP ONE-STEP SEPP					
+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
CHLORAPREP SINGLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005
CHLORAPREP TRIPLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
PREVANTICS MAXI SWABSTICK					
+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
PREVANTICS SWAB					
+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
PREVANTICS SWABSTICK					
+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL					
CHLORPHENIRAMINE MALEATE					
!	AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL					
ADVIL ALLERGY AND CONGESTION RELIEF					
+!	HALEON US HOLDINGS	4MG;200MG;10MG	N022113	001	Dec 21, 2011
ADVIL MULTI-SYMPTOM COLD & FLU					
+!	HALEON US HOLDINGS	4MG;200MG;10MG	N022113	002	Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL					
CHILDREN'S ADVIL ALLERGY SINUS					
+!	HALEON US HOLDINGS	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
TABLET;ORAL					
ADVIL ALLERGY SINUS					
+!	HALEON US HOLDINGS	2MG;200MG;30MG	N021441	001	Dec 19, 2002

CIMETIDINE

TABLET;ORAL					
CIMETIDINE					
	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998
TAGAMET HB					
+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996

CLOTRIMAZOLE

CREAM;VAGINAL					
CLOTRIMAZOLE					
!	P AND L	1%	A074165	001	Jul 16, 1993
	SUN PHARMA CANADA	1%	A072641	001	Dec 04, 1995
TRIVAGIZOLE 3					
	SUN PHARMA CANADA	2%	N021143	001	Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	DR REDDYS	30MG;600MG	A217340	001	Aug 01, 2023
		60MG;1.2GM	A217340	002	Aug 01, 2023
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018
	SUN PHARM	30MG;600MG	A214781	001	Jul 01, 2021
		60MG;1.2GM	A214781	002	Jul 01, 2021

MUCINEX DM

+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+!		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM

+!	RB HLTH	30MG;600MG;110MG	N217338	001	Dec 22, 2025

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

	AMNEAL	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016
	AUROLIFE PHARMA LLC	1%	A204306	001	May 06, 2019
	CIPLA	1%	A209903	001	Aug 03, 2018
	ENCUBE	1%	A210986	001	Jan 27, 2020
	PERRIGO PHARMA INTL	1%	A211253	001	May 16, 2019

VOLTAREN ARTHRITIS PAIN

+!	HALEON US HOLDINGS	1%	N022122	001	Oct 17, 2007

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+!	HALEON US HOLDINGS	38MG;200MG	N021394	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	AUROBINDO PHARMA	38MG;200MG	A216204	001	May 31, 2022
	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008
	PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+!	HALEON US HOLDINGS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019
	BIONPHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	ONESOURCE SPECIALTY	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM					
+!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE					
	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018
	COREPHARMA	25MG;220MG	A211830	001	Aug 22, 2019
	GRANULES	25MG;220MG	A213663	001	Sep 24, 2020
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019

DOCOSANOL

CREAM;TOPICAL

ABREVA					
+!	HALEON US HOLDINGS	10%	N020941	001	Jul 25, 2000
DOCOSANOL					
	ALEMBIC	10%	A215839	001	May 03, 2022
	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024
	DR REDDYS	10%	A214613	001	Oct 03, 2025
		10%	A215505	001	Oct 23, 2025
	P AND L	10%	A208754	001	Nov 19, 2018
	P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022
	SUN PHARMA CANADA	10%	A214454	001	Oct 26, 2023

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE					
	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996
UNISOM					
+!	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED;INHALATION

PRIMATENE MIST					
+!	ARMSTRONG PHARMS	0.125MG/INH	N205920	001	Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA	EQ 20MG BASE	A209339	001	Oct 16, 2017
	DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024
		EQ 20MG BASE	A207673	001	May 15, 2018
	GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024
	GRAVITI PHARMS	EQ 20MG BASE	A216349	001	Jun 24, 2022
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023
	HETERO LABS LTD III	EQ 20MG BASE	A212507	001	Jun 02, 2020
	MARKSANS PHARMA	EQ 20MG BASE	A217264	001	Sep 29, 2023
	PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020
NEXIUM 24HR					
+!	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023
	DR REDDYS	EQ 20MG BASE	A211571	001	May 14, 2020
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020
NEXIUM 24HR					
+!	ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE					
	ANNORA PHARMA	10MG	A215766	001	Nov 08, 2021
		20MG	A215766	002	Nov 08, 2021
	ASCENT PHARMS INC	10MG	A216030	001	Nov 03, 2021
		20MG	A216030	002	Nov 03, 2021
	AUROBINDO PHARMA	10MG	A206531	001	Apr 26, 2016
		20MG	A206531	002	Apr 26, 2016
	CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024
		20MG	A218003	002	May 28, 2024
	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	GLENMARK PHARMS INC	10MG	A077146	001	Mar 07, 2005

FAMOTIDINE

TABLET;ORAL					
FAMOTIDINE					
		20MG	A090837	001	Aug 04, 2010
	GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024
		20MG	A218461	002	Mar 14, 2024
	MARKSANS PHARMA	10MG	A217543	001	Mar 08, 2023
		20MG	A217543	002	Mar 08, 2023
	P AND L	10MG	A075512	001	Jul 26, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
	PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
	VKT PHARMA	10MG	A215822	001	Jan 28, 2022
		20MG	A215822	002	Jan 28, 2022
PEPCID AC					
+	KENVUE BRANDS	10MG	N020325	001	Apr 28, 1995
+!		20MG	N020325	002	Sep 23, 2003
TABLET, CHEWABLE;ORAL					
PEPCID AC					
+!	KENVUE BRANDS	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL					
CHILDREN'S ALLEGRA ALLERGY					
+!	CHATTEM SANOFI	30MG/5ML	N201373	001	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	P AND L	30MG/5ML	A203330	001	Nov 18, 2014
	TARO	30MG/5ML	A208123	001	Nov 09, 2017
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
!	P AND L	30MG/5ML	A203330	002	Nov 18, 2014
	TARO	30MG/5ML	A208123	002	Nov 09, 2017
FEXOFENADINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	30MG/5ML	A213466	001	May 23, 2023
TABLET;ORAL					
ALLEGRA ALLERGY					
+	CHATTEM SANOFI	60MG	N020872	007	Jan 24, 2011
+!		180MG	N020872	010	Jan 24, 2011
ALLEGRA HIVES					
+!	CHATTEM SANOFI	180MG	N020872	009	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	AUROBINDO PHARMA LTD	30MG	A202039	001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT	30MG	A079112	002	Feb 08, 2012
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	TEVA	30MG	A076447	005	Apr 13, 2011
	WOCKHARDT	30MG	A079112	001	Feb 08, 2012
FEXOFENADINE HYDROCHLORIDE					
	CONTRACT PHARMACAL	60MG	A219032	001	Feb 28, 2025
		180MG	A219032	002	Feb 28, 2025
	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020
		180MG	A212971	002	Feb 24, 2020
FEXOFENADINE HYDROCHLORIDE ALLERGY					
	AUROBINDO PHARMA LTD	60MG	A202039	002	Nov 19, 2014
		180MG	A202039	003	Nov 19, 2014
	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
		180MG	A076502	008	Apr 12, 2011
	GRANULES	60MG	A211075	001	Oct 18, 2019
		180MG	A211075	002	Oct 18, 2019
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
		180MG	A204097	003	Aug 19, 2016
	RISING	60MG	A077081	006	Jul 21, 2011
		180MG	A077081	008	Jul 21, 2011
	SCIEGEN PHARMS	60MG	A204507	002	Sep 16, 2015
		180MG	A204507	003	Sep 16, 2015
	SUN PHARM INDS	180MG	A091567	006	Feb 06, 2012
	TEVA	60MG	A076447	006	Apr 13, 2011
		180MG	A076447	008	Apr 13, 2011
	UNIQUE	180MG	A210137	001	Aug 13, 2018

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

	WOCKHARDT	60MG	A079112	004	Feb 08, 2012
		180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
		180MG	A076502	009	Apr 12, 2011
	RISING	60MG	A077081	007	Jul 21, 2011
		180MG	A077081	009	Jul 21, 2011
	SCIEGEN PHARMS	60MG	A204507	004	Sep 16, 2015
		180MG	A204507	005	Sep 16, 2015
	SUN PHARM INDS	180MG	A091567	005	Feb 06, 2012
	TEVA	60MG	A076447	007	Apr 13, 2011
	WOCKHARDT	60MG	A079112	003	Feb 08, 2012
		180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	60MG;120MG	A209116	001	Oct 30, 2017
	DR REDDYS	60MG;120MG	A076667	001	Nov 18, 2014
		60MG;120MG	A215434	001	May 31, 2022
	DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011
	L PERRIGO CO	60MG;120MG	A216792	001	Oct 07, 2025
	SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+!	HALEON US HOLDINGS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+	HALEON US HOLDINGS	0.05MG/SPRAY	N205434	001	Jul 23, 2014

FLUTICASONE PROPIONATE

	APOTEX	0.05MG/SPRAY	A208150	001	Feb 29, 2016
	AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024
!	HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016
	RUBICON	0.05MG/SPRAY	A219060	001	Aug 15, 2025

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
	AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
		1.2GM	A207342	002	Jul 11, 2018
	AUROBINDO PHARMA	600MG	A210453	001	Oct 21, 2019
		1.2GM	A210453	002	Oct 21, 2019
	DR REDDYS	600MG	A215932	001	Mar 15, 2022
		1.2GM	A215932	002	Mar 15, 2022
	GRANULES	600MG	A213420	001	May 08, 2020
		1.2GM	A213420	002	May 08, 2020
	GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
		1.2GM	A209215	002	Sep 06, 2017
	MARKSANS PHARMA	600MG	A217780	001	Aug 21, 2023
		1.2GM	A217780	002	Aug 21, 2023
	OHM LABS INC	600MG	A209254	001	Jul 16, 2018
		1.2GM	A209254	002	Jul 16, 2018
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
		1.2GM	A078912	002	Nov 05, 2020

MUCINEX

+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+!		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020
		1.2GM;120MG	A213203	002	Mar 25, 2020
	DR REDDYS	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
	L PERRIGO CO	600MG;60MG	A214407	001	Feb 01, 2022
		1.2GM;120MG	A214407	002	Feb 01, 2022
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020
		1.2GM;120MG	A212542	002	Apr 28, 2020
MUCINEX D					
+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL					
ADVIL LIQUI-GELS					
+!	HALEON US HOLDINGS	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS					
+!	HALEON US HOLDINGS	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN					
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018
		EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023
	BIONPHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	ONESOURCE SPECIALTY	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
MIDOL LIQUID GELS					
+!	BIONPHARMA	200MG	N021472	001	Oct 18, 2002
SUSPENSION;ORAL					
CHILDREN'S ADVIL					
	HALEON US HOLDINGS	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED					
	HALEON US HOLDINGS	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S IBUPROFEN					
	PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN					
+!	KENVUE BRANDS	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN					
	ANNORA PHARMA	100MG/5ML	A210602	001	Nov 23, 2018
	AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018
	P AND L	100MG/5ML	A074916	001	Apr 30, 1999
	PAI HOLDINGS PHARM	100MG/5ML	A214789	001	Nov 08, 2024
	STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021
	SUN PHARMA CANADA	100MG/5ML	A209207	001	Jun 27, 2017
SUSPENSION/DROPS;ORAL					
CHILDREN'S MOTRIN					
+!	KENVUE BRANDS	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN					
	AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024
	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
	L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
	SUN PHARMA CANADA	40MG/ML	A217261	001	Aug 08, 2023
	TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
INFANT'S ADVIL					
+!	HALEON US HOLDINGS	50MG/1.25ML	N020812	002	Jan 12, 2000
TABLET;ORAL					
ADVIL					
+!	HALEON US HOLDINGS	200MG	N018989	001	May 18, 1984

IBUPROFEN

TABLET;ORAL					
IBUPROFEN					
	ADAPTIS	200MG	A072299	001	Jul 01, 1988
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
		200MG	A072199	001	May 23, 1988
	AUROBINDO PHARMA	200MG	A208865	001	Nov 08, 2017
	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
	DR REDDYS	200MG	A075661	001	Dec 12, 2001
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
	GRANULES	200MG	A202312	001	Oct 07, 2016
	GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
	LNK	200MG	A075010	001	Mar 01, 1999
		200MG	A075139	001	Mar 01, 1999
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
		200MG	A091239	001	Feb 01, 2011
	MCNEIL	200MG	A073019	001	Mar 30, 1994
	PERRIGO	200MG	A072096	001	Dec 08, 1987
!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
	PH HEALTH	200MG	A071229	001	Apr 01, 1987
	SHANDONG XINHUA	200MG	A207095	001	May 05, 2017
		200MG	A207095	002	Aug 21, 2018
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
		200MG	A091355	001	Apr 04, 2011
JUNIOR STRENGTH ADVIL					
	HALEON US HOLDINGS	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH MOTRIN					
	KENVUE BRANDS	100MG	N020602	001	Jun 10, 1996
MOTRIN IB					
+	KENVUE BRANDS	200MG	N019012	003	Dec 17, 1990
TABLET, CHEWABLE;ORAL					
CHILDREN'S ADVIL					
	HALEON US HOLDINGS	50MG	N020944	001	Dec 18, 1998
IBUPROFEN					
!	PERRIGO	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL					
	HALEON US HOLDINGS	100MG	N020944	002	Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL					
ADVIL					
+!	HALEON US HOLDINGS	EQ 200MG BASE	N201803	001	Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL					
ADVIL CONGESTION RELIEF					
+!	HALEON US HOLDINGS	200MG;10MG	N022565	001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE					
	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL					
ADVIL COLD AND SINUS					
+!	HALEON US HOLDINGS	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235	001	Dec 01, 2017
SUSPENSION;ORAL					
CHILDREN'S ADVIL COLD					
	HALEON US HOLDINGS	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002
CHILDREN'S MOTRIN COLD					
+!	KENVUE BRANDS	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000
TABLET;ORAL					
ADVIL COLD AND SINUS					
+!	HALEON US HOLDINGS	200MG;30MG	N019771	001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	200MG;30MG	A213565	001	Mar 10, 2023
	STRIDES PHARMA	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS					
	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET;ORAL
SINE-AID IB

	KENVUE BRANDS	200MG;30MG	N019899	001	Dec 31, 1992

IODINE POVACRYLEX; ISOPROPYL ALCOHOL
SPONGE;TOPICAL
DURAPREP

+!	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

ISOPROPYL ALCOHOL
SOLUTION;TOPICAL
ZURAGARD

+!	ZUREX PHARMA	70%	N210872	001	Apr 26, 2019

IVERMECTIN
LOTION;TOPICAL
IVERMECTIN

	TARO	0.5%	A210720	001	May 06, 2020

SKLICE

+!	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012

KETOCONAZOLE
SHAMPOO;TOPICAL
NIZORAL ANTI-DANDRUFF

+!	KRAMER	1%	N020310	001	Oct 10, 1997

KETOTIFEN FUMARATE
SOLUTION/DROPS;OPHTHALMIC
ALAWAY

+!	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006

CHILDREN'S ALAWAY

+	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	002	Feb 11, 2015

KETOTIFEN FUMARATE

	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
	SENTISS	EQ 0.025% BASE	A077958	001	Jul 26, 2007
	UNICHEM	EQ 0.025% BASE	A204059	001	Jun 01, 2020

ZADITOR

!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008

LANSOPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
	GLENMARK PHARMS INC	15MG	A202727	001	May 18, 2012
	NATCO	15MG	A203306	001	Jan 13, 2016
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012

PREVACID 24 HR

+!	PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

	DEXCEL	15MG	N208025	001	Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL
XYZAL ALLERGY 24HR

+!	CHATTEM SANOFI	2.5MG/5ML	N209090	001	Jan 31, 2017

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

	DR REDDYS	5MG	A210375	001	Jan 19, 2018
	HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020
	PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019
	SANKALP LIFECARE	5MG	A211551	001	Nov 20, 2018

XYZAL ALLERGY 24HR

+!	CHATTEM SANOFI	5MG	N209089	001	Jan 31, 2017

LEVONORGESTREL
TABLET;ORAL
ATHENTIA NEXT

	AUROBINDO PHARMA	1.5MG	A206867	001	Dec 08, 2015

FALLBACK SOLO

	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014

HER STYLE

	NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016

LEVONORGESTREL

TABLET;ORAL					
LEVONORGESTREL					
	ANNORA PHARMA	1.5MG	A219102	001	Sep 30, 2025
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018
	NAARI PTE	1.5MG	A202380	001	May 29, 2015
		1.5MG	A207660	001	May 02, 2019
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
	PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
	XIROMED	1.5MG	A202739	001	Oct 31, 2014
		1.5MG	A205329	001	Sep 18, 2018
OPCICON ONE-STEP					
	SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
PLAN B ONE-STEP					
+!	FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA	2MG	A220372	001	Dec 29, 2025
+	BIONPHARMA	1MG	N021855	001	Aug 04, 2005
+!		2MG	N021855	002	Aug 04, 2005
	ONESOURCE SPECIALTY	2MG	A213070	001	Aug 11, 2021
SOLUTION;ORAL					
IMODIUM A-D					
+!	KENVUE BRANDS	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE					
	BIONPHARMA	1MG/7.5ML	A220100	001	Sep 19, 2025
	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
TABLET;ORAL					
IMODIUM A-D					
+!	KENVUE BRANDS	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA	2MG	A206548	001	Dec 15, 2015
	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
	LNK	2MG	A076497	001	Jun 10, 2003
	MARKSANS PHARMA	2MG	A220153	001	Nov 17, 2025
	OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+!	KENVUE BRANDS	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
	AUROBINDO PHARMA LTD	2MG;125MG	A211059	001	Dec 14, 2020
	BIONPHARMA	2MG;125MG	A213484	001	Sep 10, 2021
	GUARDIAN DRUG	2MG;125MG	A214541	001	May 27, 2021
	HETERO LABS LTD V	2MG;125MG	A211438	001	Jun 17, 2021
	PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018

LORATADINE

CAPSULE;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
LORATADINE					
	AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023
	BIONPHARMA	10MG	A202538	001	Dec 21, 2018
	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
SYRUP;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
	HETERO LABS LTD III	1MG/ML	A210409	001	May 07, 2021
	LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
	PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
	TARO	1MG/ML	A076805	001	Aug 20, 2004
		1MG/ML	A201865	001	Jul 31, 2015
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004

LORATADINE

TABLET;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
CLARITIN HIVES RELIEF					
+!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
LORATADINE					
	ANDA REPOSITORY	10MG	A207569	001	Mar 12, 2019
	APOTEX	10MG	A076471	001	Feb 14, 2006
	AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
	GRANULES	10MG	A210722	001	Dec 23, 2019
	HETERO LABS LTD V	10MG	A211718	001	Jul 28, 2023
	MARKSANS PHARMA	10MG	A219223	001	Nov 21, 2024
	MYLAN	10MG	A076154	001	Aug 20, 2003
	PERRIGO	10MG	A076301	001	Jun 25, 2004
	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
	UNIQUE PHARM	10MG	A214684	001	Jan 07, 2021
TABLET, CHEWABLE;ORAL					
CHILDREN'S CLARITIN					
+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018
LORATADINE					
	PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
	SUN PHARM	5MG	A210088	001	Apr 16, 2018
		10MG	A210088	002	Apr 25, 2025
TABLET, ORALLY DISINTEGRATING;ORAL					
ALAVERT					
	FDN CONSUMER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB					
+!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
CLARITIN REDITABS					
+!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+!		10MG	N020704	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
	RUBICON RESEARCH	10MG	A214280	001	Sep 10, 2020
	TENSHI	5MG	A212795	001	Sep 18, 2020
		10MG	A213294	001	Oct 30, 2020
LORATADINE REDIDOSE					
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
CLARITIN-D					
+!	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR					
+!	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
	BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024
	P AND L	10MG;240MG	A075706	001	Feb 21, 2003
	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
		10MG;240MG	A075989	001	Mar 04, 2004
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL					
SALONPAS					
+!	HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+		3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL					
MICONAZOLE 3 COMBINATION PACK					
	PERRIGO	2%,4%	A076357	001	Mar 30, 2004
MONISTAT 3 COMBINATION PACK					
+	MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+!	MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001
CREAM;VAGINAL					
MICONAZOLE 3					
	SUN PHARMA CANADA	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7					
	P AND L	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE					
	PERRIGO	2%	A074760	001	May 15, 1997
	PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
	SUN PHARMA CANADA	2%	A074444	001	Jan 13, 1997
MONISTAT 3					
+!	MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7					
+!	MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991
CREAM, INSERT;TOPICAL, VAGINAL					
MICONAZOLE NITRATE					
	PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MONISTAT 1 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001
CREAM, SUPPOSITORY;TOPICAL, VAGINAL					
M-ZOLE 3 COMBINATION PACK					
	COSETTE	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE COMBINATION PACK					
	L PERRIGO CO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 3 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996
MONISTAT 7 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993
SUPPOSITORY;VAGINAL					
MICONAZOLE NITRATE					
	COSETTE	100MG	A073507	001	Nov 19, 1993
MONISTAT 7					
+!	MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL					
MEN'S ROGAINE					
+!	KENVUE BRANDS	5%	N021812	001	Jan 20, 2006
MINOXIDIL					
	PERRIGO PHARMA INTL	5%	A091344	001	Apr 28, 2011
MINOXIDIL (FOR MEN)					
	AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024
	P AND L	5%	A208092	001	Feb 17, 2017
	TARO	5%	A209074	001	Dec 31, 2018
MINOXIDIL (FOR WOMEN)					
	AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024
	P AND L	5%	A208092	002	Jul 27, 2017
	TARO	5%	A209074	002	Apr 22, 2019
WOMEN'S ROGAINE					
+!	KENVUE BRANDS	5%	N021812	002	Feb 28, 2014
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999
	P AND L	2%	A074588	001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)					
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999
	TARO	2%	A218175	001	Nov 26, 2024
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	AUROBINDO PHARMA LTD	5%	A075438	001	Feb 27, 2003
	P AND L	5%	A075518	001	Nov 17, 2000
	PERRIGO	5%	A075598	001	Jun 13, 2001
	TARO	5%	A217998	001	Jun 30, 2025
ROGAINE (FOR MEN)					
+!	KENVUE BRANDS	2%	N019501	002	Feb 09, 1996

MINOXIDIL

SOLUTION;TOPICAL

ROGAINE (FOR WOMEN)

+!	KENVUE BRANDS	2%	N019501	003	Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+!	KENVUE BRANDS	5%	N020834	001	Nov 14, 1997

THEROXIDIL

	PURE SOURCE	2%	A078176	001	Nov 09, 2007
		5%	A076239	001	Aug 24, 2004

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

+!	PERRIGO PHARMA INTL	0.05MG/SPRAY	N215712	001	Mar 17, 2022

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

	AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024
	PADAGIS ISRAEL	4MG/SPRAY	A211951	001	Jun 21, 2022
	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019

NARCAN

+!	EMERGENT	4MG/SPRAY	N208411	001	Nov 18, 2015

RIVIVE

+!	HARM REDUCTION THERP	3MG/SPRAY	N217722	001	Jul 28, 2023

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

	ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
	RISING	0.025%;0.3%	A202795	001	Jan 24, 2013

NAPHCON-A

+!	ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994

OPCON-A

+!	BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994

VISINE

+!	KENVUE BRANDS	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+!	BIONPHARMA	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PATHEON SOFTGELS	EQ 200MG BASE	A214463	001	Jan 10, 2023
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018

TABLET;ORAL

ALEVE

+!	BAYER	220MG	N020204	002	Jan 11, 1994

NAPROXEN SODIUM

	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
	HETERO LABS LTD V	220MG	A211065	001	Oct 28, 2022
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011
	PERRIGO	220MG	A074661	001	Jan 13, 1997
	YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022
	DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
!	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICODERM CQ					
+	CHATTEM SANOFI	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996
NICOTINE					
	DIFGEN PHARMS	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE					
+	HALEON US HOLDINGS	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000
NICORETTE (MINT)					
+	HALEON US HOLDINGS	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998
NICOTINE POLACRILEX					
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
		EQ 2MG BASE	A076777	001	Sep 16, 2004
		EQ 4MG BASE	A076779	001	Sep 16, 2004
		EQ 4MG BASE	A076789	001	Sep 16, 2004
	P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
		EQ 2MG BASE	A076569	001	Jul 29, 2004
		EQ 2MG BASE	A078699	001	Dec 29, 2008
		EQ 2MG BASE	A079044	001	Jul 08, 2009
		EQ 2MG BASE	A079216	001	Jul 08, 2009
		EQ 2MG BASE	A204794	001	May 10, 2016
		EQ 4MG BASE	A074707	001	Mar 19, 1999
		EQ 4MG BASE	A076568	002	Jul 29, 2004
		EQ 4MG BASE	A078697	001	Dec 29, 2008
		EQ 4MG BASE	A079038	001	Jul 08, 2009
		EQ 4MG BASE	A079219	001	Jul 08, 2009
		EQ 4MG BASE	A204833	001	Feb 26, 2016
	PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
		EQ 2MG BASE	A078547	001	May 24, 2007
		EQ 2MG BASE	A091349	001	Jul 20, 2011
		EQ 2MG BASE	A206394	001	Dec 15, 2016
		EQ 4MG BASE	A078326	001	Oct 30, 2006
		EQ 4MG BASE	A078546	001	May 24, 2007
		EQ 4MG BASE	A091354	001	Jul 20, 2011
		EQ 4MG BASE	A206393	001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE					
+	HALEON US HOLDINGS	EQ 2MG BASE	N021330	001	Oct 31, 2002
+		EQ 2MG BASE	N022360	001	May 18, 2009
+!		EQ 4MG BASE	N021330	002	Oct 31, 2002
+!		EQ 4MG BASE	N022360	002	May 18, 2009
NICOTINE POLACRILEX					
	AUROBINDO PHARMA	EQ 2MG BASE	A213266	001	Aug 03, 2021
		EQ 4MG BASE	A213266	002	Aug 03, 2021
	AUROBINDO PHARMA LTD	EQ 2MG BASE	A215357	001	May 13, 2022
		EQ 4MG BASE	A215357	002	May 13, 2022
	DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020
		EQ 2MG BASE	A212983	001	Feb 21, 2020
		EQ 2MG BASE	A213233	001	Aug 04, 2020
		EQ 2MG BASE	A215276	001	Jul 17, 2025
		EQ 4MG BASE	A212796	002	Jan 08, 2020
		EQ 4MG BASE	A212983	002	Feb 21, 2020
		EQ 4MG BASE	A213233	002	Aug 04, 2020
		EQ 4MG BASE	A215276	002	Jul 17, 2025
	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019
		EQ 2MG BASE	A209206	001	Jun 26, 2018
		EQ 2MG BASE	A209519	001	Jul 02, 2018
		EQ 2MG BASE	A209520	001	Oct 31, 2019
		EQ 2MG BASE	A210711	001	Oct 31, 2019
		EQ 2MG BASE	A210712	001	Sep 06, 2019
		EQ 2MG BASE	A212056	001	Jul 26, 2019

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

	EQ 2MG BASE	A212057	001	May 14, 2020
	EQ 4MG BASE	A208875	002	Oct 31, 2019
	EQ 4MG BASE	A209206	002	Jun 26, 2018
	EQ 4MG BASE	A209519	002	Jul 02, 2018
	EQ 4MG BASE	A209520	002	Oct 31, 2019
	EQ 4MG BASE	A210711	002	Oct 31, 2019
	EQ 4MG BASE	A210712	002	Sep 06, 2019
	EQ 4MG BASE	A212056	002	Jul 26, 2019
	EQ 4MG BASE	A212057	002	May 14, 2020
PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
	EQ 2MG BASE	A090821	001	Jul 10, 2009
	EQ 4MG BASE	A077007	002	Jan 31, 2006
	EQ 4MG BASE	A090821	002	Jul 10, 2009
PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019
	EQ 4MG BASE	A207868	002	Feb 07, 2019
PPI-DAC	EQ 2MG BASE	A090711	001	Jul 10, 2009
	EQ 2MG BASE	A203690	001	Oct 09, 2012
	EQ 4MG BASE	A090711	002	Jul 10, 2009
	EQ 4MG BASE	A203690	002	Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+!	HALEON US HOLDINGS	75MG	N020555	001	May 09, 1996

NORGESTREL

TABLET;ORAL

OPILL

+!	LABORATOIRE HRA	0.075MG	N017031	001	

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

ALEMBIC	EQ 0.1% BASE	A209919	001	Dec 07, 2018
	EQ 0.2% BASE	A209420	001	Apr 29, 2019
APOTEX	EQ 0.1% BASE	A078350	001	Dec 07, 2015
	EQ 0.2% BASE	A090918	001	Dec 05, 2017
BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015
BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017
	EQ 0.2% BASE	A206087	001	Dec 05, 2017
EUGIA PHARMA	EQ 0.1% BASE	A204812	001	Dec 18, 2015
	EQ 0.2% BASE	A209995	001	Apr 04, 2019
FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025
GLAND	EQ 0.1% BASE	A209619	001	Aug 02, 2019
	EQ 0.2% BASE	A209752	001	May 20, 2020
	EQ 0.7% BASE	A213514	001	Jan 06, 2026
GLENMARK PHARMS INC	EQ 0.1% BASE	A200810	001	Jun 28, 2017
	EQ 0.2% BASE	A219557	001	Feb 28, 2025
RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018
	EQ 0.2% BASE	A204620	001	Jun 16, 2020
SOMERSET	EQ 0.2% BASE	A215006	001	Dec 18, 2024
SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015
USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015

PATADAY ONCE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.2% BASE	N021545	001	Dec 22, 2004
+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015

PATADAY TWICE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.1% BASE	N020688	001	Dec 18, 1996

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM					
CAPSULE, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	DEXCEL	EQ 20MG BASE	A216096	001	May 24, 2022
!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA	EQ 20MG BASE	A206877	001	Jun 06, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020
	MARKSANS PHARMA	EQ 20MG BASE	A218829	001	Aug 07, 2025
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020
PRILOSEC OTC					
+!	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003
OMEPRAZOLE; SODIUM BICARBONATE					
CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	AUROBINDO PHARMA	20MG;1.1GM	A204923	001	Nov 07, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS	20MG;1.1GM	A203345	001	Mar 16, 2018
ZEGERID OTC					
+!	RILEY CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009
FOR SUSPENSION;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	DR REDDYS	20MG/PACKET;1.68GM/PACKET	A217784	001	May 09, 2024
ZEGERID OTC					
+!	RILEY CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013
ORLISTAT					
CAPSULE;ORAL					
ALLI					
+!	HALEON US HOLDINGS	60MG	N021887	001	Feb 07, 2007
OXYBUTYNIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYTROL FOR WOMEN					
+!	ABBVIE	3.9MG/24HR	N202211	001	Jan 25, 2013
OXYMETAZOLINE HYDROCHLORIDE					
SOLUTION/DROPS;OPHTHALMIC					
VISINE L.R.					
+!	KENVUE BRANDS	0.025%	N019407	001	Mar 31, 1989
PERMETHRIN					
LOTION;TOPICAL					
NIX					
+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990
PERMETHRIN					
	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001
POLYETHYLENE GLYCOL 3350					
FOR SOLUTION;ORAL					
MIRALAX					
+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006
+!		17GM/PACKET	N022015	002	Oct 06, 2006
POLYETHYLENE GLYCOL 3350					
	ANI PHARMS	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
		17GM/PACKET	A202850	002	Nov 30, 2021
	ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021
		17GM/PACKET	A214990	002	Apr 14, 2021
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
		17GM/PACKET	A209017	002	Apr 23, 2024
	LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
		17GM/PACKET	A091077	002	Jun 27, 2011
	NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
	PPI-DAC	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009
	SHREE HARI INTL	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	STRIDES PHARMA	17GM/SCOOPFUL	A203928	001	Aug 24, 2016

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

		17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

!	MISSION PHARMACAL	65MG/ML	A206211	001	Mar 24, 2016

TABLET;ORAL

IOSAT

+	ANBEX	65MG	N018664	002	May 12, 2011
+!		130MG	N018664	001	Oct 14, 1982

THYROSAFE

!	BTG INTL	65MG	A076350	001	Sep 10, 2002
		130MG	A076350	002	Apr 02, 2025

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	120MG	A209008	001	Jun 09, 2017
!	AUROBINDO PHARMA LTD	240MG	A218854	001	Dec 29, 2025
!	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
		EQ 150MG BASE	A078192	001	Aug 31, 2007

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+!	KARO HLTHCARE	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+!	KARO HLTHCARE	1%	N020980	001	Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

	SUN PHARMA CANADA	1%	A077511	001	Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+!	KARO HLTHCARE	1%	N021124	001	Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT

+!	KARO HLTHCARE	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

	PERRIGO	6.5%	A075915	001	Nov 21, 2001

VAGISTAT-1

+!	COMBE	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+!	CHATTEM SANOFI	0.055MG/SPRAY	N020468	002	Oct 11, 2013

TRIAMCINOLONE ACETONIDE

	APOTEX	0.055MG/SPRAY	A214615	001	Jan 19, 2023
	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	002	Nov 14, 2014

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

NONE

FRESENIUS KABI AG	N125695	Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

SOLUTION; STORAGE/PROCESSING ONLY

NONE

HAEMONETICS MANUFACTURING INC	N760305	Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

SOLUTION; STORAGE/PROCESSING ONLY

NONE		
CITRA LABS LLC	N020037	Aug 26, 2003
ACD-A SOLUTION		
TERUMO BCT INC	A010228	Feb 25, 2002
ADSOL WITH ACD-A		
FENWAL INC	N000922	Aug 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A		
HAEMONETICS CORP	A980728	Feb 06, 2002
ADDITIVE SOLUTION 3; AS-3		
TERUMO BCT INC	N001214	May 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION A (ACD-A)		
TERUMO BCT INC	A110057	May 11, 2012

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

SOLUTION; STORAGE/PROCESSING ONLY

NONE		
FENWAL INC	N160918	Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

SOLUTION; STORAGE/PROCESSING ONLY

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3		
HAEMONETICS CORP	N000127	Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

NONE		
TERUMO MEDICAL CORP	N820528	Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

SOLUTION; STORAGE/PROCESSING ONLY

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC)	N770420	May 12, 1978
FENWAL INC		

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

SOLUTION; STORAGE/PROCESSING ONLY

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC	N940404	Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

NONE

HAEMONETICS MANUFACTURING INC	N800077	Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

ADSOL IN PLASTIC CONTAINER

FENWAL INC	N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

SOLUTION; STORAGE/PROCESSING ONLY

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC	N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPHARMA	N040083	Nov 21, 2005

NONE

TERUMO BCT INC	A070025	Jan 06, 2009

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

SOLUTION; STORAGE/PROCESSING ONLY

NONE

FENWAL INC	N170401	Dec 06, 1977
	N811012	Jun 28, 1983
GLOBAL LIFE SCIENCE SOLUTIONS USA, LLC	N800222	Aug 23, 1982
TERUMO MEDICAL CORP	N781211	JUN 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

SOLUTION; STORAGE/PROCESSING ONLY

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC	N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

SOLUTION; STORAGE/PROCESSING ONLY

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP	N880217	Oct 07, 1988

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

SOLUTION; STORAGE/PROCESSING ONLY

AS-3 NUTRICEL ADDITIVE SYSTEM 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML

HAEMONETICS MANUFACTURING INC	N820915	Oct 19, 1984

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

NONE

BAXTER HEALTHCARE CORPORATION	N980123	Mar 03, 2000
LABORATORIES GRIFOIS, S.A.	A125697	Oct 25, 2019
TERUMO BCT	A125608	Jun 26, 2018
CSL PLASMA INC	A125750	Apr 25, 2022

ANTICOAGULANT SODIUM CITRATE SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

TRICITRASOL

CITRA LABS, LLC	N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

SOLUTION; STORAGE/PROCESSING ONLY

NONE

FENWAL INC	N770923	Jan 20, 1978
TERUMO MEDICAL CORP	N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

SOLUTION; STORAGE/PROCESSING ONLY

NONE

MACOPHARMA	N125552	Dec 21, 2016

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INTRAVENOUS

LMD IN GLASS BOTTLE 10GM/100ML

HOSPIRA INC	A720563	Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INTRAVENOUS

LMD IN PLASTIC CONTAINER 10GM/100ML;0.9GM/100ML

HOSPIRA INC	A720562	Oct 30, 1992

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INTRAVENOUS

HEXTEND	6GM/100ML		
BIOTIME INC		N200952	Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INTRAVENOUS

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	6GM/100ML		
HOSPIRA INC		A740193	Jan 30, 1995
NONE	6GM/100ML		
TEVA PHARMACEUTICALS USA INC		A740592	Nov 12, 1998

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

SOLUTION; STORAGE/PROCESSING ONLY

ISOPLATE SOLUTION			
TERUMO BCT		N090067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

SOLUTION; STORAGE/PROCESSING ONLY

LEUKOSEP HWB-600-XL			
HEMERUS MEDICAL, LLC		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

SOLUTION; STORAGE/PROCESSING ONLY

REJUVESOL			
CITRA LABS LLC		N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

SOLUTION; STORAGE/PROCESSING ONLY

INTERSOL SOLUTION	2.26GM/500ML;2.21GM/500ML; 1.59GM/500ML;1.53GM/500ML; 0.465GM/500ML		
FRESENIUS KABI USA, LLC		N080041	Dec 09, 2009

ABACAVIR SULFATE					
TABLET;ORAL					
ABACAVIR SULFATE					
	APOTEX INC	EQ 300MG BASE	A201570	001	Dec 17, 2012
ZIAGEN					
+	VIIV HLTHCARE	EQ 300MG BASE **	N020977	001	Dec 17, 1998
ABACAVIR SULFATE; LAMIVUDINE					
TABLET;ORAL					
ABACAVIR SULFATE AND LAMIVUDINE					
	AUROBINDO PHARMA	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017
	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024
	TEVA PHARMS USA	EQ 600MG BASE;300MG	A079246	001	Sep 29, 2016
	ZYDUS PHARMS	EQ 600MG BASE;300MG	A208990	001	Nov 15, 2018
EPZICOM					
+	VIIV HLTHCARE	EQ 600MG BASE;300MG **	N021652	001	Aug 02, 2004
TABLET, FOR SUSPENSION;ORAL					
ABACAVIR SULFATE AND LAMIVUDINE					
+	PHARMOBEDIENT	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE					
TABLET;ORAL					
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE					
	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912	001	Dec 05, 2013
TRIZIVIR					
+	VIIV HLTHCARE	EQ 300MG BASE;150MG;300MG **	N021205	001	Nov 14, 2000
ABAMETAPIR					
LOTION;TOPICAL					
XEGLYZE					
+	HATCHTECH	0.74%	N206966	001	Jul 24, 2020
ABARELIX					
INJECTABLE;INTRAMUSCULAR					
PLENAXIS					
	SPECIALITY EUROPEAN	100MG/VIAL	N021320	001	Nov 25, 2003
ABIRATERONE ACETATE					
TABLET;ORAL					
ABIRATERONE ACETATE					
	TEVA PHARMS USA	125MG	A212206	001	Jun 24, 2022
		250MG	A208432	001	Oct 31, 2018
		500MG	A210726	001	Jan 26, 2023
ACAMPROSATE CALCIUM					
TABLET, DELAYED RELEASE;ORAL					
ACAMPROSATE CALCIUM					
	BARR LABS DIV TEVA	333MG	A200143	001	Nov 18, 2013
CAMPRAL					
+	FOREST LABS	333MG **	N021431	001	Jul 29, 2004
ACARBOSE					
TABLET;ORAL					
ACARBOSE					
	DASH PHARMS	25MG	A091053	001	Jan 06, 2011
		50MG	A091053	002	Jan 06, 2011
		100MG	A091053	003	Jan 06, 2011
	HANGZHOU ZHONGMEI	25MG	A213821	001	Aug 18, 2020
		50MG	A213821	002	Aug 18, 2020
		100MG	A213821	003	Aug 18, 2020
PRECOSE					
+	BAYER HLTHCARE	25MG **	N020482	004	May 29, 1997
+		50MG **	N020482	001	Sep 06, 1995
+		100MG **	N020482	002	Sep 06, 1995
ACEBUTOLOL HYDROCHLORIDE					
CAPSULE;ORAL					
ACEBUTOLOL HYDROCHLORIDE					
	PHARMOBEDIENT	EQ 200MG BASE	A074288	001	Apr 24, 1995
		EQ 400MG BASE	A074288	002	Apr 24, 1995
SECTRAL					
+	PROMIUS PHARMA	EQ 200MG BASE **	N018917	001	Dec 28, 1984
+		EQ 400MG BASE **	N018917	003	Dec 28, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN				
INJECTABLE;INJECTION				
INJECTAPAP				
ORTHO MCNEIL PHARM	100MG/ML	N017785	001	Mar 07, 1986
POWDER;INTRAVENOUS				
ACETAMINOPHEN				
+ RISING	1GM/VIAL	N206610	001	Jan 15, 2021
SOLUTION;INTRAVENOUS				
ACETAMINOPHEN				
ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022
OFIRMEV				
+ MALLINCKRODT HOSP	1GM/100ML (10MG/ML) **	N022450	001	Nov 02, 2010
SUPPOSITORY;RECTAL				
ACEPHEN				
COSETTE	120MG	A072218	001	Mar 27, 1992
	120MG	N018060	001	
	325MG	A072344	001	Mar 27, 1992
	325MG	N018060	003	Dec 18, 1986
	650MG	A072237	001	Mar 27, 1992
	650MG	N018060	002	
ACETAMINOPHEN				
ABLE	120MG	A073106	001	Feb 27, 1995
	325MG	A073107	001	Feb 27, 1995
	650MG	A073108	001	Feb 27, 1995
ACINO PRODS	120MG	A071010	001	May 12, 1987
	650MG	A071011	001	May 12, 1987
+ TARO	650MG	N018337	001	
NEOPAP				
POLYMEDICA	120MG	N016401	001	
TYLENOL				
J AND J CONSUMER INC	120MG	N017756	002	
	650MG	N017756	001	
TABLET, EXTENDED RELEASE;ORAL				
ACETAMINOPHEN				
HERITAGE	650MG	A207035	001	May 31, 2018
SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011
	650MG	A090205	001	Nov 18, 2009
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE				
CAPSULE;ORAL				
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE				
MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
	150MG;180MG;30MG	A081096	001	Oct 26, 1990
	150MG;180MG;60MG	A081097	001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2				
+ SCHERER LABS	150MG;180MG;15MG	A085640	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3				
+ SCHERER LABS	150MG;180MG;30MG	A085639	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4				
SCHERER LABS	150MG;180MG;60MG	A085638	001	
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE				
TABLET;ORAL				
APADAZ				
+ ZEVRA THERAP	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019
+	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018
+	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019
ACETAMINOPHEN; BUTALBITAL				
CAPSULE;ORAL				
BANCAP				
FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986
BUCET				
MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985
PHRENILIN FORTE				
VALEANT	650MG;50MG	A088831	001	Jun 19, 1985
TENCON				
MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990
TRIAPRIN				
DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

	ALVOGEN	300MG;50MG	A207635	001	Jun 05, 2017
		325MG;50MG	A205120	001	Oct 30, 2015
	HALSEY	325MG;50MG	A089568	001	Oct 05, 1988
+	WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984

BUTAPAP

	MIKART	650MG;50MG	A089988	001	Oct 26, 1992

PHRENILIN

+	VALEANT	325MG;50MG **	A087811	001	Jun 19, 1985

SEDAPAP

	MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN

	SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984
	GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985
		325MG;50MG;40MG	A088765	001	Mar 27, 1985
		325MG;50MG;40MG	A089067	001	Apr 19, 1985
	HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022
		325MG;50MG;40MG	A215135	002	Mar 25, 2022
		500MG;50MG;40MG	A040261	001	Oct 28, 1998
	KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017
	MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985

ESGIC-PLUS

	MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996

FEMCET

	MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985

MEDIGESIC PLUS

	US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986

TRIAD

	MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
		500MG;50MG;40MG	A040394	001	Jul 23, 2001
	ALVOGEN	325MG;50MG;40MG	A204984	001	Jan 10, 2017
	GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
	HIKMA	500MG;50MG;40MG	A040336	001	Aug 18, 1999
	HIKMA PHARMS	325MG;50MG;40MG	A089718	001	Jun 12, 1995
	MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
	MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
	NESHER PHARMS	325MG;50MG;40MG	A211543	001	Jul 17, 2020
	SPECGX LLC	325MG;50MG;40MG	A087804	001	Jan 24, 1985
	STRIDES PHARMA	325MG;50MG;40MG	A203647	001	Sep 21, 2020
	SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601	001	Jul 29, 2005
	VINTAGE PHARMS	500MG;50MG;40MG	A040513	001	Aug 25, 2003
	WATSON LABS	325MG;50MG;40MG	A089536	001	Feb 16, 1988
		500MG;50MG;40MG	A040267	001	Jul 30, 1998

ESGIC

	FOREST PHARMS	325MG;50MG;40MG	A089660	001	Dec 23, 1988

ESGIC-PLUS

	MIKART	500MG;50MG;40MG	A089451	001	May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	ABLE	325MG;50MG;40MG;30MG	A076528	001	Aug 21, 2003
	HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618	001	Mar 23, 2001
	PHARMOBEDIENT	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002
	STRIDES PHARMA	325MG;50MG;40MG;30MG	A204649	001	Jul 08, 2020

PHRENILIN WITH CAFFEINE AND CODEINE

	VALEANT	325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL					
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
	MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
DHC PLUS					
	PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
SYNALGOS-DC-A					
	LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986
TREZIX					
	KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014
TABLET;ORAL					
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE					
	PHARMOBEDIENT	325MG;30MG;16MG	A204209	001	Sep 30, 2016
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE					
	BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
	MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
	WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL					
TAVIST ALLERGY/SINUS/HEADACHE					
	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
	TEVA	300MG;15MG	A088537	001	Jun 04, 1984
		300MG;30MG	A088324	001	Dec 29, 1983
		300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2					
	ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3					
+	ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4					
+	ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3					
	SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3					
	ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4					
	ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	
SOLUTION;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
+	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992
	CHARTWELL MOLECULAR	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011
	DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
	PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996
	PHARMOBEDIENT	120MG/5ML;12MG/5ML	A087006	001	
	STRIDES PHARMA	120MG/5ML;12MG/5ML	A086366	001	
TYLENOL W/ CODEINE					
+	ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	
SUSPENSION;ORAL					
CAPITAL AND CODEINE					
	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001	
TABLET;ORAL					
ACETAMINOPHEN AND CODEINE PHOSPHATE					
	ABLE	300MG;30MG	A040452	001	Aug 01, 2002
		300MG;60MG	A040459	001	Aug 01, 2002
	AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
		300MG;15MG	A089481	001	Mar 03, 1987
		300MG;30MG	A089479	001	Mar 03, 1987
		300MG;30MG	A089482	001	Mar 03, 1987
		300MG;60MG	A089480	001	Mar 03, 1987
		300MG;60MG	A089483	001	Mar 03, 1987
	ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985
		300MG;30MG	A088629	003	Mar 06, 1985
+		300MG;60MG	A088629	001	Mar 06, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	CHARTWELL	300MG;15MG	A089997	001	Dec 28, 1994
		300MG;30MG	A089998	001	Dec 28, 1994
		300MG;60MG	A089999	001	Dec 28, 1994
	DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
		300MG;15MG	A088353	001	Feb 06, 1984
		300MG;30MG	A040223	002	Nov 18, 1997
		300MG;30MG	A088354	001	Feb 06, 1984
		300MG;60MG	A040223	003	Nov 18, 1997
		300MG;60MG	A088355	001	Feb 06, 1984
	EVERYLIFE	325MG;30MG	A085217	001	
	FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
		300MG;60MG	A081249	001	Jul 16, 1992
	HALSEY	300MG;15MG	A083871	001	
		300MG;30MG	A083872	001	
		300MG;60MG	A086549	001	
	KV PHARM	300MG;30MG	A085288	001	
		300MG;60MG	A085365	001	
		325MG;15MG	A085364	001	
		325MG;45MG **	A085363	001	
	LEDERLE	300MG;30MG	A087141	001	
	MIKART	300MG;30MG	A089238	001	Feb 25, 1986
		300MG;60MG	A089244	001	Feb 25, 1986
		650MG;30MG	A089231	001	Mar 03, 1986
		650MG;60MG	A089363	001	Sep 09, 1991
	MUTUAL PHARM	300MG;15MG	A085795	001	
		300MG;30MG	A085794	001	
		300MG;60MG	A087653	001	Apr 13, 1982
	PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
+	PUREPAC PHARM	300MG;30MG	A086681	001	
		300MG;30MG	A089080	001	Jul 17, 1986
		300MG;60MG	A086683	001	
	RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
		300MG;30MG	A089673	003	Feb 10, 1988
		300MG;60MG	A089673	001	Feb 10, 1988
	ROXANE	300MG;15MG	A084659	001	
		300MG;30MG	A084656	001	
		300MG;60MG	A084667	001	
		500MG;15MG	A089511	001	Apr 25, 1989
		500MG;30MG	A089512	001	Apr 25, 1989
		500MG;60MG	A089513	001	Apr 25, 1989
+	SANDOZ	300MG;15MG	A087433	001	
		300MG;30MG	A085291	002	
+		300MG;30MG	A085917	001	
		300MG;60MG	A085964	001	
		300MG;60MG	A087423	001	
	SUN PHARM INDS LTD	300MG;30MG	A085868	001	
	SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
		300MG;30MG	A089184	001	Oct 18, 1985
		300MG;30MG	A089253	001	May 19, 1986
		300MG;60MG	A089185	001	Oct 18, 1985
		300MG;60MG	A089254	001	May 19, 1986
	USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
		300MG;60MG	A087920	001	Jun 22, 1982
	VALEANT PHARM INTL	300MG;30MG	A085896	001	
	VITARINE	300MG;30MG	A085676	001	
	WARNER CHILCOTT	300MG;15MG	A085992	001	
		300MG;30MG	A085218	002	
		300MG;60MG	A087306	001	
	WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
		300MG;30MG	A087276	001	May 26, 1982
		300MG;60MG	A087275	001	May 26, 1982
	WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
		300MG;30MG	A040443	002	Jan 22, 2003
		300MG;60MG	A040443	003	Jan 22, 2003
	WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
		300MG;60MG	A085607	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL				
CAPITAL AND CODEINE				
	CARNRICK	325MG;30MG	A083643 001	
CODRIX				
	WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
		500MG;30MG	A040441 001	Mar 27, 2003
		500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
	GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4				
	GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3				
	VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4				
	VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
	ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE				
	ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056 001	
		325MG;15MG **	A085056 002	
		325MG;30MG **	A085056 003	
		325MG;60MG **	A085056 004	
TYLENOL W/ CODEINE NO. 1				
	JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2				
+	JANSSEN PHARMS	300MG;15MG	A085055 002	
TYLENOL W/ CODEINE NO. 3				
+	JANSSEN PHARMS	300MG;30MG	A085055 003	
TYLENOL W/ CODEINE NO. 4				
+	JANSSEN PHARMS	300MG;60MG	A085055 004	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
DRIXORAL PLUS				
	SCHERING PLOUGH	500MG;3MG;60MG	N019453 001	May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL				
ACETAMINOPHEN AND HYDROCODONE BITARTRATE				
	CENT PHARMS	500MG;5MG	A088898 001	Mar 27, 1985
ALLAY				
	IVAX PHARMS	500MG;5MG	A089907 001	Jan 13, 1989
BANCAP HC				
	FOREST PHARMS	500MG;5MG	A087961 001	Mar 17, 1983
CO-GESIC				
	CENT PHARMS	500MG;5MG	A089360 001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	MALLINCKRODT	500MG;5MG	A088956 001	Jul 19, 1985
		500MG;5MG	A089006 001	Aug 09, 1985
	MIKART	500MG;5MG	A081067 001	Nov 30, 1989
		500MG;5MG	A081068 001	Nov 30, 1989
		500MG;5MG	A081069 001	Nov 30, 1989
		500MG;5MG	A081070 001	Nov 30, 1989
		500MG;5MG	A089008 001	Feb 21, 1986
LORCET-HD				
	MALLINCKRODT	500MG;5MG	A087336 001	Jul 08, 1982
SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482 001	Sep 25, 2003
	GENUS	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012
	MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418 001	Jun 27, 2001
	MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508 001	Aug 29, 2003
	MIKART	500MG/15ML;5MG/15ML	A081226 001	Oct 27, 1992
		500MG/15ML;5MG/15ML	A089557 001	Apr 29, 1992
		500MG/15ML;7.5MG/15ML	A081051 001	Aug 28, 1992
	NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002
	PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182 001	Mar 13, 1998
	TRIS PHARMA INC	300MG/15ML;10MG/15ML	A201295 002	Dec 30, 2021
		325MG/15ML;7.5MG/15ML	A201295 001	Dec 30, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016
TABLET;ORAL				
ANEXSIA				
MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	300MG;5MG	A206470	001	Jun 02, 2016
	300MG;7.5MG	A206470	002	Jun 02, 2016
	300MG;10MG	A206470	003	Jun 02, 2016
ALVOGEN	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS	300MG;10MG	A207137	001	Nov 29, 2016
AMNEAL PHARMS NY	300MG;5MG	A206869	001	Jun 23, 2017
	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006
	300MG;7.5MG	A040658	002	Mar 24, 2006
	300MG;10MG	A040658	003	Jun 23, 2004
	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;7.5MG	A040432	001	Jan 22, 2003
	325MG;10MG	A040248	002	Apr 28, 2000
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010
	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOVEL LABS INC	300MG;5MG	A206142	001	Nov 14, 2016
	300MG;7.5MG	A206142	002	Nov 14, 2016
	300MG;10MG	A206142	003	Nov 14, 2016
	325MG;5MG	A206245	001	Dec 01, 2016
	325MG;7.5MG	A206245	002	Dec 01, 2016
	325MG;10MG	A206245	003	Dec 01, 2016
PH HEALTH	300MG;5MG	A090415	001	Jan 24, 2011
	300MG;7.5MG	A090415	002	Jan 24, 2011
	300MG;10MG	A090415	003	Jan 24, 2011
PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021
	325MG;7.5MG	A214928	002	Dec 30, 2021
	325MG;10MG	A214928	003	Dec 30, 2021
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018
	300MG;7.5MG	A207808	002	Mar 30, 2018
	300MG;10MG	A207808	003	Mar 30, 2018
SANALUZ	325MG;5MG	A211690	001	Feb 07, 2020
	325MG;7.5MG	A211690	002	Feb 07, 2020
	325MG;10MG	A211690	003	Feb 07, 2020
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
STRIDES PHARMA INTL	300MG;5MG	A205001	001	Jul 05, 2016
	300MG;7.5MG	A205001	002	Jul 05, 2016
	300MG;10MG	A205001	003	Jul 05, 2016
SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008
	325MG;7.5MG	A090118	002	Dec 23, 2008
	325MG;10MG	A090118	003	Dec 23, 2008
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
NORCO				
APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
	325MG;5MG	A040099	001	Jun 25, 1997
	325MG;5MG	A040148	005	Jul 07, 2014
	325MG;7.5MG	A040148	003	Sep 12, 2000
	325MG;10MG	A040148	001	Feb 14, 1997
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL				
ACETAMINOPHEN AND IBUPROFEN				
STRIDES PHARMA	250MG;125MG	A217241	001	Jan 17, 2025

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL				
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL				
OXYCODONE AND ACETAMINOPHEN				
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX				
ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX				
JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
SOLUTION;ORAL				
OXYCODONE AND ACETAMINOPHEN				
SANKALP LIFECARE	325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021
SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN				
PH HEALTH	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014
ROXICET				
HIKMA	325MG/5ML;5MG/5ML **	A089351	001	Dec 03, 1986
TABLET;ORAL				
OXYCODONE 2.5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500				
BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
	325MG;7.5MG	A040800	001	Apr 03, 2012
	325MG;10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
	650MG;10MG	A040789	002	Nov 27, 2007
BARR	325MG;5MG	A087406	001	
CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019
	325MG;7.5MG	A207834	002	Aug 15, 2019
	325MG;10MG	A207834	003	Aug 15, 2019
DR REDDYS LABS SA	325MG;2.5MG	A090177	001	Oct 20, 2008
	325MG;5MG	A090177	002	Oct 20, 2008
	325MG;7.5MG	A090177	003	Oct 20, 2008
	325MG;10MG	A090177	004	Oct 20, 2008
	500MG;7.5MG	A090177	005	Oct 20, 2008
	650MG;10MG	A090177	006	Oct 20, 2008
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
LANNETT CO INC	325MG;5MG	A207333	001	Sep 25, 2017
	325MG;10MG	A207333	002	Sep 25, 2017
MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
	650MG;10MG	A040550	002	Jun 30, 2004
MIKART	400MG;2.5MG	A040679	001	May 16, 2006
	400MG;5MG	A040687	001	Apr 27, 2006
	400MG;7.5MG	A040698	001	Apr 27, 2006
	400MG;10MG	A040692	001	Apr 27, 2006
	500MG;10MG	A040676	001	Apr 19, 2006
NESHER PHARMS	325MG;2.5MG	A210079	001	Dec 28, 2017
	325MG;5MG	A210079	002	Dec 28, 2017
	325MG;7.5MG	A210079	003	Dec 28, 2017
	325MG;10MG	A210079	004	Dec 28, 2017
PH HEALTH	325MG;2.5MG	A090733	001	Jul 11, 2013
	325MG;5MG	A040105	001	Jul 30, 1996
	325MG;7.5MG	A090734	001	Jul 11, 2013
	325MG;10MG	A090734	002	Jul 11, 2013
SANALUZ	325MG;5MG	A207574	001	Dec 13, 2016
SUN PHARM INDS INC	325MG;2.5MG	A090535	001	Dec 26, 2013
	325MG;5MG	A090535	002	Dec 26, 2013
	325MG;7.5MG	A090535	003	Dec 26, 2013
	325MG;10MG	A090535	004	Dec 26, 2013
WATSON LABS	325MG;5MG	A040171	001	Oct 30, 1997
	325MG;7.5MG	A040535	001	Sep 05, 2003
	325MG;10MG	A040535	002	Sep 05, 2003
	500MG;7.5MG	A040371	001	Dec 29, 2000
	650MG;10MG	A040371	002	Dec 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE				
TABLET;ORAL				
PERCOCET				
+	ENDO OPERATIONS	325MG;5MG **	A085106 002	
	VINTAGE PHARMS LLC	500MG;7.5MG	A040341 001	Jul 26, 1999
		650MG;10MG	A040341 002	Jul 26, 1999
ROXICET				
+	HIKMA	325MG;5MG **	A087003 001	
ROXICET 5/500				
	ROXANE	500MG;5MG	A089775 001	Jan 12, 1989
TABLET, EXTENDED RELEASE;ORAL				
XARTEMIS XR				
+	MALLINCKRODT INC	325MG;7.5MG **	N204031 001	Mar 11, 2014
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE				
CAPSULE;ORAL				
TYLOX				
	ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375 001	
ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
	GAVIS PHARMS	650MG;EQ 25MG BASE	A076202 001	Aug 02, 2002
	WATSON LABS	650MG;EQ 25MG BASE	A074699 001	Mar 24, 2000
TALACEN				
	SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458 001	Sep 23, 1982
ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE				
TABLET;ORAL				
DARVOCET				
	AAIPHARMA LLC	325MG;32.5MG	N016844 001	
DOLENE AP-65				
	LEDERLE	650MG;65MG	A085100 001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
	MYLAN	325MG;32MG	A083689 001	
		650MG;65MG	A083978 001	
	SANDOZ	650MG;65MG	A089959 001	Jul 18, 1989
	VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003
	WATSON LABS	650MG;65MG	A040139 001	Dec 16, 1996
WYGESIC				
	CARACO	650MG;65MG	A084999 001	
ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE				
TABLET;ORAL				
DARVOCET A500				
	XANODYNE PHARM	500MG;100MG	A076429 001	Sep 10, 2003
DARVOCET-N 100				
	XANODYNE PHARM	650MG;100MG	N017122 002	
DARVOCET-N 50				
	XANODYNE PHARM	325MG;50MG	N017122 001	
PROPACET 100				
	TEVA	650MG;100MG	A070107 001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
	ABLE	650MG;100MG	A075838 001	Jul 11, 2001
	ACTAVIS ELIZABETH	650MG;100MG	A070910 001	Jan 02, 1987
	CORNERSTONE	325MG;100MG	A076743 001	May 07, 2004
		500MG;100MG	A076750 001	Jun 28, 2004
	HALSEY	325MG;50MG	A072105 001	May 13, 1988
		650MG;100MG	A072106 001	May 13, 1988
	IVAX SUB TEVA PHARMS	650MG;100MG	A070146 001	Aug 02, 1985
	MALLINCKRODT	650MG;100MG	A075738 001	Feb 02, 2001
	MIRROR PHARMS	650MG;100MG	A077821 001	Feb 11, 2008
	MUTUAL PHARM	325MG;50MG	A070115 001	Jun 12, 1985
		650MG;100MG	A070116 001	Jun 12, 1985
		650MG;100MG	A070615 001	Mar 21, 1986
		650MG;100MG	A070771 001	Mar 21, 1986
		650MG;100MG	A070775 001	Mar 21, 1986
	MYLAN	650MG;100MG	A072195 001	Feb 16, 1988
	MYLAN PHARMS INC	650MG;100MG	A070145 001	Jun 12, 1985
	SANDOZ	650MG;100MG	A070443 001	Jan 23, 1986
	SUPERPHARM	650MG;100MG	A071319 001	Jan 06, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE					
TABLET;ORAL					
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN					
	TEVA	650MG;100MG	A070732	001	Jan 03, 1986
		650MG;100MG	A074119	001	Dec 19, 1994
	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
		650MG;100MG	A074843	001	Feb 12, 1997
	WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
		650MG;100MG	A070399	001	Dec 18, 1986
	WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
		650MG;100MG	A076609	001	Nov 16, 2004
	WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
		650MG;100MG	A077677	002	Mar 16, 2007
ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE					
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
	CHARTWELL RX	325MG;37.5MG	A076475	001	Apr 21, 2005
	GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006
	MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017
	MPP PHARMA	325MG;37.5MG	A078778	001	Apr 07, 2014
	SUN PHARM INDS INC	325MG;37.5MG	A077184	001	Dec 16, 2005
ULTRACET					
+	JANSSEN PHARMS	325MG;37.5MG **	N021123	001	Aug 15, 2001
ACETAZOLAMIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
ACETAZOLAMIDE					
	RISING	500MG	A203917	001	Jun 18, 2019
DIAMOX					
+	TEVA BRANDED PHARM	500MG **	N012945	001	
TABLET;ORAL					
ACETAZOLAMIDE					
	AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023
		250MG	A211151	002	Sep 11, 2023
	ALRA	250MG	A083320	001	
	ASCOT	250MG	A087686	001	Oct 20, 1982
	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020
		250MG	A207503	002	Apr 30, 2020
	HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
		250MG	A089753	001	Jun 22, 1988
	TORRENT	125MG	A213706	001	Jan 26, 2024
		250MG	A213706	002	Jan 26, 2024
	VANGARD	250MG	A087654	001	Feb 05, 1982
	WATSON LABS	250MG	A084498	002	
DIAMOX					
+	TEVA BRANDED PHARM	125MG **	N008943	001	
+		250MG **	N008943	002	
ACETAZOLAMIDE SODIUM					
INJECTABLE;INJECTION					
ACETAZOLAMIDE SODIUM					
	HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
	PH HEALTH	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017
DIAMOX					
+	TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	
ACETIC ACID, GLACIAL					
SOLUTION/DROPS;OTIC					
ACETASOL					
	ACTAVIS MID ATLANTIC	2%	A087146	001	
ACETIC ACID					
	CHARTWELL RX	2%	A040166	001	Jul 26, 1996
	KV PHARM	2%	A085493	001	
	SUN PHARMA CANADA	2%	A088638	001	Sep 06, 1984
ORLEX					
	WARNER CHILCOTT	2%	A086845	001	
VOSOL					
+	HIKMA	2% **	N012179	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETIC ACID, GLACIAL; ALUMINUM ACETATE				
SOLUTION/DROPS;OTIC				
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE				
BAUSCH AND LOMB	2%;0.79%		A040063 001	Feb 25, 1994
BOROFAIR				
PHARMAFAIR	2%;0.79%		A088606 001	Aug 21, 1985
DOMEBORO				
+ BAYER PHARMS	2%;0.79%		A084476 001	
ACETIC ACID, GLACIAL; DESONIDE				
SOLUTION/DROPS;OTIC				
TRIDESILON				
BAYER PHARMS	2%;0.05%		N017914 001	
ACETIC ACID, GLACIAL; HYDROCORTISONE				
SOLUTION/DROPS;OTIC				
ACETASOL HC				
ACTAVIS MID ATLANTIC	2%;1%		A087143 001	Jan 13, 1982
ACETIC ACID W/ HYDROCORTISONE				
KV PHARM	2%;1%		A085492 001	
HYDROCORTISONE AND ACETIC ACID				
BAUSCH AND LOMB	2%;1%		A040097 001	Oct 31, 1994
WOCKHARDT	2%;1%		A040168 001	Aug 30, 1996
ORLEX HC				
WARNER CHILCOTT	2%;1%		A086844 001	
ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE				
SUSPENSION/DROPS;OTIC				
NEO-CORT-DOME				
BAYER PHARMS	2%;1%;EQ 0.35% BASE		N050238 001	
ACETOHEXAMIDE				
TABLET;ORAL				
ACETOHEXAMIDE				
ANI PHARMS	250MG		A070870 002	Feb 09, 1987
	500MG		A070870 001	Feb 09, 1987
USL PHARMA	250MG		A070753 001	Nov 03, 1986
	500MG		A070754 001	Nov 03, 1986
WATSON LABS TEVA	250MG		A071893 001	Nov 25, 1987
	500MG		A071894 001	Nov 25, 1987
DYMELOR				
LILLY	250MG		N013378 002	
	500MG		N013378 001	
ACETOPHENAZINE MALEATE				
TABLET;ORAL				
TINDAL				
SCHERING	20MG		N012254 002	
ACETRIZOATE SODIUM				
SOLUTION;INTRAUTERINE				
SALPIX				
ORTHO MCNEIL PHARM	53%		N009008 001	
ACETYLCHOLINE CHLORIDE				
FOR SOLUTION;OPHTHALMIC				
MIOCHOL				
+ NOVARTIS	20MG/VIAL **		N016211 001	
ACETYLCYSTEINE				
INJECTABLE;INTRAVENOUS				
ACETYLCYSTEINE				
EXELA PHARMA	6GM/30ML (200MG/ML)		A204797 001	Apr 15, 2021
SOLUTION;INHALATION, ORAL				
ACETYLCYSTEINE				
EXELA PHARMA	20%		A205643 001	Nov 01, 2023
HOSPIRA	10%		A071364 001	May 01, 1989
	20%		A071365 001	May 01, 1989
ROXANE	10%		A072323 001	Apr 30, 1992
	10%		A072621 001	Sep 30, 1992
	20%		A072324 001	Apr 30, 1992
	20%		A072622 001	Sep 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL				
MUCOMYST				
+	APOTHECON	10% **	N013601 002	
+		20% **	N013601 001	
MUCOSIL-10				
	DEY	10%	A070575 001	Oct 14, 1986
MUCOSIL-20				
	DEY	20%	A070576 001	Oct 14, 1986
TABLET, EFFERVESCENT;ORAL				
CETYLEV				
+	ARBOR PHARMS LLC	500MG	N207916 001	Jan 29, 2016
+		2.5GM	N207916 002	Jan 29, 2016

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL				
LEGUBETI				
+	GALEPHAR	EQ 500MG BASE/PACKET	N215040 001	Feb 13, 2024
+		EQ 2.5GM BASE/PACKET	N215040 002	Feb 13, 2024

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION;INHALATION				
MUCOMYST W/ ISOPROTERENOL				
	MEAD JOHNSON	10%;0.05%	N017366 001	

ACETYLDIGITOXIN

TABLET;ORAL				
ACYLANID				
	NOVARTIS	0.1MG	N009436 001	

ACITRETIN

CAPSULE;ORAL				
ACITRETIN				
	MYLAN	17.5MG	A203707 001	Sep 10, 2015
		22.5MG	A203707 002	Sep 10, 2015
SORIATANE				
+	STIEFEL LABS INC	10MG **	N019821 001	Oct 28, 1996
+		17.5MG **	N019821 003	Aug 06, 2009
+		22.5MG **	N019821 004	Aug 06, 2009
+		25MG **	N019821 002	Oct 28, 1996

ACRISORCIN

CREAM;TOPICAL				
AKRINOL				
	SCHERING	2MG/GM	N012470 001	

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL				
SEMPREX-D				
+	ENDO OPERATIONS	8MG;60MG **	N019806 001	Mar 25, 1994

ACYCLOVIR

CAPSULE;ORAL				
ACYCLOVIR				
	ACTAVIS ELIZABETH	200MG	A074906 001	Aug 26, 1997
	AUROBINDO PHARMA USA	200MG	A074727 001	Apr 22, 1997
	CHARTWELL MOLECULES	200MG	A074872 001	Apr 22, 1997
	IVAX SUB TEVA PHARMS	200MG	A074674 001	Apr 22, 1997
	LEK PHARM	200MG	A074750 001	Apr 22, 1997
	MYLAN	200MG	A074977 001	Apr 13, 1998
	RANBAXY	200MG	A074975 001	Sep 30, 1998
	ROXANE	200MG	A074570 002	Apr 22, 1997
	STRIDES PHARMA INTL	200MG	A074833 001	Apr 22, 1997
	TEVA	200MG	A074828 001	Apr 22, 1997
	TEVA PHARMS	200MG	A074914 001	Nov 26, 1997
	WATSON LABS	200MG	A075101 001	Apr 15, 1998
ZOVIRAX				
+	PHARMOBEDIENT	200MG **	N018828 001	Jan 25, 1985
CREAM;TOPICAL				
ACYCLOVIR				
	CIPLA	5%	A212981 001	May 02, 2025

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACYCLOVIR					
OINTMENT;OPHTHALMIC					
AVACLYR					
+	FERA PHARMS LLC	3% **	N202408	001	Mar 29, 2019
OINTMENT;TOPICAL					
ACYCLOVIR					
	APOTEX	5%	A210774	001	Sep 06, 2019
	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017
	CIPLA	5%	A211794	001	Jan 18, 2019
	COSETTE	5%	A205591	001	Nov 13, 2017
	PADAGIS ISRAEL	5%	A205659	001	Feb 20, 2019
	PRINSTON INC	5%	A212202	001	Nov 15, 2021
SUSPENSION;ORAL					
ACYCLOVIR					
	HIKMA	200MG/5ML	A077026	001	Jun 07, 2005
	VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021
ZOVIRAX					
+	PHARMOBEDIENT	200MG/5ML **	N019909	001	Dec 22, 1989
TABLET;BUCCAL					
SITAVIG					
+	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013
TABLET;ORAL					
ACYCLOVIR					
	ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
		800MG	A074870	002	Jun 05, 1997
	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
		800MG	A074834	002	Apr 24, 1997
	IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
		800MG	A074836	002	Apr 22, 1997
	LEK PHARM	400MG	A074658	001	Apr 22, 1997
		800MG	A074658	002	Apr 22, 1997
	MYLAN	400MG	A074976	001	Apr 13, 1998
		800MG	A074976	002	Apr 13, 1998
	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
		800MG	A074980	002	Sep 30, 1998
	TEVA	200MG **	A074556	001	Apr 22, 1997
	TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
		800MG	A075021	002	Mar 18, 1998
ZOVIRAX					
+	PHARMOBEDIENT	400MG **	N020089	001	Apr 30, 1991
+		800MG **	N020089	002	Apr 30, 1991
ACYCLOVIR SODIUM					
INJECTABLE;INJECTION					
ACYCLOVIR					
	ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
ACYCLOVIR SODIUM					
	APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
		EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
	CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
	DR REDDYS	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
		EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
	HIKMA	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
		EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
		EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
		EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
	PHARMOBEDIENT	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
	TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
		EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACYCLOVIR SODIUM				
INJECTABLE;INJECTION				
ACYCLOVIR SODIUM				
	EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
	EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017
ZOVIRAX				
+ GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603	003	Aug 30, 1983
+	EQ 500MG BASE/VIAL **	N018603	001	Oct 22, 1982
+	EQ 1GM BASE/VIAL **	N018603	002	Jun 29, 1989
ADAPALENE				
LOTION;TOPICAL				
DIFFERIN				
+ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010
SOLUTION;TOPICAL				
DIFFERIN				
+ GALDERMA LABS LP	0.1% **	N020338	001	May 31, 1996
ADAPALENE; BENZOYL PEROXIDE				
GEL;TOPICAL				
ADAPALENE AND BENZOYL PEROXIDE				
ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015
ADEFOVIR DIPIVOXIL				
TABLET;ORAL				
HEPSERA				
+ GILEAD	10MG **	N021449	001	Sep 20, 2002
ADENOSINE				
INJECTABLE;INJECTION				
ADENOCARD				
+ ASTELLAS	3MG/ML **	N019937	002	Oct 30, 1989
ADENOSINE				
AM REGENT	3MG/ML	A090010	001	Apr 28, 2009
HIKMA	3MG/ML	A076501	001	Jun 16, 2004
PHARMOBEDIENT	3MG/ML	A078640	001	Mar 21, 2014
TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
	3MG/ML	A078676	001	Jul 31, 2008
WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009
SOLUTION;INTRAVENOUS				
ADENOSCAN				
+ ASTELLAS	60MG/20ML (3MG/ML) **	N020059	001	May 18, 1995
+	90MG/30ML (3MG/ML) **	N020059	002	May 18, 1995
ADENOSINE				
HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014
	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014
ALATROFLOXACIN MESYLATE				
INJECTABLE;INJECTION				
TROVAN PRESERVATIVE FREE				
PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997
ALBENDAZOLE				
TABLET;ORAL				
ALBENDAZOLE				
CHARTWELL RX	200MG	A211636	001	Jun 10, 2020
CIPLA LTD	200MG	A210434	001	Sep 21, 2018
STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018
ALBENZA				
+ IMPAX LABS INC	200MG **	N020666	001	Jun 11, 1996
ALBUTEROL				
AEROSOL, METERED;INHALATION				
ALBUTEROL				
ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALBUTEROL				
AEROSOL, METERED;INHALATION				
VENTOLIN				
	GLAXOSMITHKLINE	0.09MG/INH	N018473 001	
ALBUTEROL SULFATE				
CAPSULE;INHALATION				
VENTOLIN ROTACAPS				
	GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489 001	May 04, 1988
POWDER, METERED;INHALATION				
PROAIR DIGIHALER				
+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636 002	Dec 21, 2018
SOLUTION;INHALATION				
ACCUNEB				
+	PHARMOBEDIENT	EQ 0.021% BASE **	N020949 002	Apr 30, 2001
+		EQ 0.042% BASE **	N020949 001	Apr 30, 2001
ALBUTEROL SULFATE				
	ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533 001	Sep 26, 1995
	APOTEX INC	EQ 0.021% BASE	A078623 001	Apr 05, 2010
		EQ 0.042% BASE	A078623 002	Apr 05, 2010
		EQ 0.083% BASE	A075717 001	Feb 02, 2007
		EQ 0.5% BASE	A076391 001	Apr 01, 2003
	BAUSCH	EQ 0.083% BASE	A075358 001	Mar 29, 2000
		EQ 0.5% BASE	A075050 001	Jun 18, 1998
	COPLEY PHARM	EQ 0.083% BASE	A073495 001	May 28, 1993
		EQ 0.5% BASE	A073307 001	Nov 27, 1991
	EPIC PHARMA LLC	EQ 0.083% BASE	A075063 001	Feb 09, 1999
	LANDELA PHARM	EQ 0.083% BASE	A077569 001	Apr 04, 2006
	PHARMOBEDIENT	EQ 0.083% BASE **	A072652 001	Feb 21, 1992
	ROXANE	EQ 0.083% BASE	A075129 001	Feb 13, 2001
	TEVA PHARMS	EQ 0.083% BASE	A075343 001	Nov 09, 1999
	WATSON LABS	EQ 0.021% BASE	A077772 001	Sep 25, 2007
		EQ 0.042% BASE	A077772 002	Sep 25, 2007
	WATSON LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003
	WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394 001	Nov 22, 1999
PROVENTIL				
+	SCHERING	EQ 0.083% BASE **	N019243 002	Jan 14, 1987
+		EQ 0.5% BASE **	N019243 001	Jan 14, 1987
VENTOLIN				
+	GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773 001	Apr 23, 1992
		EQ 0.5% BASE **	N019269 002	Jan 16, 1987
SYRUP;ORAL				
ALBUTEROL SULFATE				
	ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262 001	Mar 30, 1999
	COSETTE	EQ 2MG BASE/5ML	A074454 001	Sep 25, 1995
	HIKMA	EQ 2MG BASE/5ML	A074749 001	Jan 30, 1998
	MOVA	EQ 2MG BASE/5ML	A074302 001	Sep 30, 1994
	WATSON LABS	EQ 2MG BASE/5ML	A073165 001	Apr 29, 1993
PROVENTIL				
+	SCHERING	EQ 2MG BASE/5ML **	N018062 001	Jan 19, 1983
VENTOLIN				
	GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621 001	Jun 10, 1987
TABLET;ORAL				
ALBUTEROL SULFATE				
	AM THERAP	EQ 2MG BASE	A072449 001	Dec 05, 1989
		EQ 4MG BASE	A072450 001	Dec 05, 1989
	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657 001	May 14, 2020
		EQ 4MG BASE	A213657 002	May 14, 2020
	CHARTWELL RX	EQ 2MG BASE	A072151 001	Dec 05, 1989
		EQ 4MG BASE	A072151 002	Dec 05, 1989
	COPLEY PHARM	EQ 2MG BASE	A072966 001	Nov 22, 1991
		EQ 4MG BASE	A072967 001	Nov 22, 1991
	HIBROW HLTHCARE	EQ 2MG BASE	A213524 001	Oct 08, 2020
		EQ 4MG BASE	A213524 002	Oct 08, 2020
	PLIVA	EQ 2MG BASE	A072316 001	Dec 05, 1989
		EQ 4MG BASE	A072317 001	Dec 05, 1989
	STRIDES PHARMA INTL	EQ 2MG BASE	A072860 002	Dec 20, 1989
		EQ 4MG BASE	A072860 001	Dec 20, 1989
	TEVA	EQ 2MG BASE	A072619 001	Dec 05, 1989
		EQ 2MG BASE	A072779 001	Jun 25, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 2MG BASE	A072764	001	Aug 28, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991

PROVENTIL

+ SCHERING	EQ 2MG BASE **	N017853	001	May 07, 1982
+	EQ 4MG BASE **	N017853	002	May 07, 1982

VENTOLIN

GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986
	EQ 4MG BASE	N019112	002	Jul 10, 1986

TABLET, EXTENDED RELEASE;ORAL

ALBUTEROL SULFATE

RISING	EQ 4MG BASE	A078092	002	Jan 29, 2007
	EQ 8MG BASE	A078092	001	Jan 29, 2007

PROVENTIL

SCHERING	EQ 4MG BASE	N019383	001	Jul 13, 1987

VOLMAX

+ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992
+	EQ 8MG BASE	N019604	001	Dec 23, 1992

VOSPIRE ER

STRIDES PHARMA INTL	EQ 4MG BASE	A076130	002	Sep 26, 2002
	EQ 8MG BASE	A076130	003	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

COMBIVENT

BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AIPING PHARM INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006
APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007
LUOXIN AUROVITAS	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007
WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007

DUONEB

+ PHARMOBEDIENT	EQ 0.083% BASE;0.017% **	N020950	001	Mar 21, 2001

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

EUGIA PHARMA	0.25%	A210659	001	Jun 23, 2023

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ACLOVATE

+ FOUGERA PHARMS	0.05% **	N018707	001	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

GLENMARK PHARMS LTD	0.05%	A079061	001	Jun 23, 2009

OINTMENT;TOPICAL

ACLOVATE

+ FOUGERA PHARMS	0.05% **	N018702	001	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

GLENMARK PHARMS LTD	0.05%	A079227	001	Jul 30, 2009

ALCOHOL				
SOLUTION;INTRA-ARTERIAL				
ABLYSINOL				
+	BPI LABS	99% (1ML) **	N207987 001	Jun 21, 2018
ALENDRONATE SODIUM				
SOLUTION;ORAL				
FOSAMAX				
+	MERCK	EQ 70MG BASE/75ML **	N021575 001	Sep 17, 2003
TABLET;ORAL				
ALENDRONATE SODIUM				
	APOTEX	EQ 5MG BASE	A077982 001	Aug 04, 2008
		EQ 10MG BASE	A077982 002	Aug 04, 2008
		EQ 35MG BASE	A077982 003	Aug 04, 2008
		EQ 70MG BASE	A077982 004	Aug 04, 2008
	CHARTWELL RX	EQ 5MG BASE	A075871 001	Apr 22, 2009
		EQ 5MG BASE	A079049 003	Aug 04, 2008
		EQ 10MG BASE	A075871 002	Apr 22, 2009
		EQ 10MG BASE	A079049 004	Aug 04, 2008
		EQ 35MG BASE	A075871 004	Apr 22, 2009
		EQ 35MG BASE	A079049 001	Aug 04, 2008
		EQ 40MG BASE	A075871 003	Apr 22, 2009
		EQ 70MG BASE	A075871 005	Apr 22, 2009
		EQ 70MG BASE	A079049 002	Aug 04, 2008
	IMPAX LABS INC	EQ 5MG BASE	A075710 001	Feb 06, 2008
		EQ 10MG BASE	A075710 002	Feb 06, 2008
		EQ 35MG BASE	A075710 003	Feb 06, 2008
		EQ 40MG BASE	A075710 004	Feb 06, 2008
		EQ 70MG BASE	A075710 005	Feb 06, 2008
	JUBILANT CADISTA	EQ 5MG BASE	A090557 001	Feb 18, 2010
		EQ 10MG BASE	A090557 002	Feb 18, 2010
		EQ 35MG BASE	A090557 003	Feb 18, 2010
		EQ 70MG BASE	A090557 004	Feb 18, 2010
	MYLAN	EQ 35MG BASE	A078638 001	Aug 04, 2008
		EQ 70MG BASE	A078638 002	Aug 04, 2008
	RISING	EQ 5MG BASE	A076584 001	Aug 04, 2008
		EQ 10MG BASE	A076584 002	Aug 04, 2008
		EQ 35MG BASE	A076584 003	Aug 04, 2008
		EQ 70MG BASE	A076584 004	Aug 04, 2008
	TEVA PHARMS	EQ 35MG BASE	A076184 002	Aug 04, 2008
		EQ 70MG BASE	A076184 001	Feb 06, 2008
FOSAMAX				
+	ORGANON	EQ 5MG BASE **	N020560 003	Apr 25, 1997
+		EQ 10MG BASE **	N020560 001	Sep 29, 1995
+		EQ 35MG BASE **	N020560 004	Oct 20, 2000
+		EQ 40MG BASE **	N020560 002	Sep 29, 1995
ALFENTANIL HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALFENTANIL				
	HOSPIRA	EQ 0.5MG BASE/ML	A075221 001	Oct 28, 1999
ALFUZOSIN HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
ALFUZOSIN HYDROCHLORIDE				
	CHARTWELL RX	10MG	A079056 001	Jul 18, 2011
	PHARMOBEDIENT	10MG	A079014 001	Jul 18, 2011
	SUN PHARM	10MG	A079057 001	Jul 18, 2011
	TORRENT PHARMS	10MG	A079054 001	Jul 18, 2011
	WOCKHARDT BIO AG	10MG	A090221 001	Aug 10, 2012
ALISKIREN HEMIFUMARATE				
CAPSULE, PELLET;ORAL				
TEKTURNA				
+	NODEN PHARMA	EQ 37.5MG BASE	N210709 001	Nov 14, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010
	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010
	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010
	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+	NODEN PHARMA	EQ 150MG BASE;12.5MG **	N022107	001	Jan 18, 2008
+		EQ 150MG BASE;25MG **	N022107	002	Jan 18, 2008
+		EQ 300MG BASE;12.5MG **	N022107	003	Jan 18, 2008
+		EQ 300MG BASE;25MG **	N022107	004	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL

VALTURNA

NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
	EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALKAVERVIR

TABLET;ORAL

VERILOID

3M	2MG	N007336	002	
	3MG	N007336	003	

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AIPING PHARM INC	100MG	A070268	001	Dec 31, 1985
IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011
	300MG	A090637	002	Mar 16, 2011
LUPIN LTD	100MG	A211807	001	Dec 14, 2023
	300MG	A211807	002	Dec 14, 2023
MUTUAL PHARM	100MG	A070466	001	Dec 24, 1985
	300MG	A070467	001	Dec 24, 1985
NORTHSTAR HLTHCARE	100MG	A078253	001	Sep 11, 2007
	300MG	A078253	002	Sep 11, 2007
PURACAP PHARM	100MG	A070150	001	Dec 10, 1985
	300MG	A070147	001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579	001	Apr 14, 1986
	300MG	A070580	001	Apr 14, 1986
SANDOZ	300MG	A070269	001	Dec 31, 1985
SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007
	300MG	A078390	002	Aug 30, 2007
SUPERPHARM	100MG	A070950	001	Nov 30, 1988
	300MG	A070951	001	Nov 30, 1988
WATSON LABS	100MG	N018241	001	Nov 16, 1984
	100MG	N018785	001	Sep 28, 1984
	300MG	N018241	002	Nov 16, 1984
	300MG	N018785	002	Sep 28, 1984

LOPURIN

ABBOTT	100MG	N018297	001	
	300MG	N018297	002	

ALLOPURINOL; LESINURAD				
TABLET;ORAL				
DUZALLO				
+	IRONWOOD PHARMS INC	200MG;200MG	N209203 001	Aug 18, 2017
+		300MG;200MG	N209203 002	Aug 18, 2017
ALMOTRIPTAN MALATE				
TABLET;ORAL				
AXERT				
+	JANSSEN PHARMS	EQ 6.25MG BASE **	N021001 001	May 07, 2001
+		EQ 12.5MG BASE **	N021001 002	May 07, 2001
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE				
TABLET;ORAL				
OSENI				
+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE **	N022426 004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE **	N022426 006	Jan 25, 2013
ALOSETRON HYDROCHLORIDE				
TABLET;ORAL				
ALOSETRON HYDROCHLORIDE				
	HIKMA	EQ 0.5MG BASE	A200652 001	May 04, 2015
		EQ 1MG BASE	A200652 002	May 04, 2015
	PH HEALTH	EQ 0.5MG BASE	A206113 001	Feb 23, 2018
		EQ 1MG BASE	A206113 002	Feb 23, 2018
ALPRAZOLAM				
SOLUTION;ORAL				
ALPRAZOLAM				
	ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993
TABLET;ORAL				
ALPRAZOLAM				
	ANI PHARMS	0.25MG	A074085 001	Feb 16, 1994
		0.5MG	A074085 002	Feb 16, 1994
		1MG	A074085 003	Feb 16, 1994
		2MG	A074085 004	Feb 26, 1996
	APOTEX INC	0.25MG	A077741 001	Jan 19, 2007
		0.5MG	A077741 002	Jan 19, 2007
		1MG	A077741 003	Jan 19, 2007
		2MG	A077741 004	Jan 19, 2007
	CHARTWELL RX	0.25MG	A207507 001	Jul 09, 2018
		0.5MG	A207507 002	Jul 09, 2018
		1MG	A207507 003	Jul 09, 2018
		2MG	A207507 004	Jul 09, 2018
	IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
		0.5MG	A074294 002	Jul 29, 1994
		1MG	A074294 003	Jul 29, 1994
		2MG	A074294 004	Jul 29, 1994
	MYLAN	0.25MG	A074215 001	Jan 27, 1994
		0.5MG	A074215 002	Jan 27, 1994
		1MG	A074215 003	Jan 27, 1994
		2MG	A074215 004	Jan 27, 1994
	OXFORD PHARMS	0.25MG	A078491 001	Sep 25, 2008
		0.5MG	A078491 002	Sep 25, 2008
		1MG	A078491 003	Sep 25, 2008
		2MG	A078491 004	Dec 12, 2008
	PHARMOBEDIENT	0.25MG	A074046 001	Oct 19, 1993
		0.5MG	A074046 002	Oct 19, 1993
		1MG	A074046 003	Oct 19, 1993
		2MG	A074046 004	May 07, 1997
	ROXANE	0.25MG	A074199 001	Oct 19, 1993
		0.5MG	A074199 002	Oct 19, 1993
		1MG	A074199 003	Oct 19, 1993
	SUN PHARM	0.25MG	A090082 001	Jun 17, 2010
		0.5MG	A090082 002	Jun 17, 2010
		1MG	A090082 003	Jun 17, 2010
		2MG	A090082 004	Jun 17, 2010
	WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
		0.25MG	A074479 001	Jan 21, 1997
		0.5MG	A074456 002	Aug 31, 1995
		0.5MG	A074479 002	Jan 21, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALPRAZOLAM					
TABLET;ORAL					
ALPRAZOLAM					
		1MG	A074456	003	Aug 31, 1995
		1MG	A074479	003	Jan 21, 1997
TABLET, EXTENDED RELEASE;ORAL					
ALPRAZOLAM					
	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010
		1MG	A077198	002	May 13, 2010
		2MG	A077198	003	May 13, 2010
		3MG	A077198	004	May 13, 2010
	ANI PHARMS	0.5MG	A077725	001	Jul 31, 2006
		0.5MG	A077979	001	Feb 28, 2007
		1MG	A077725	002	Jul 31, 2006
		1MG	A077979	002	Feb 28, 2007
		2MG	A077725	004	Jul 31, 2006
		2MG	A077979	003	Feb 28, 2007
		3MG	A077725	003	Jul 31, 2006
		3MG	A077979	004	Feb 28, 2007
	APOTEX INC	0.5MG	A078449	001	Nov 12, 2008
		1MG	A078449	004	Dec 23, 2015
		2MG	A078449	002	Nov 12, 2008
		3MG	A078449	003	Nov 12, 2008
	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
		1MG	A078489	002	Oct 17, 2008
		2MG	A078489	003	Oct 17, 2008
		3MG	A078489	004	Oct 17, 2008
	IMPAX LABS	0.5MG	A077968	004	May 24, 2007
		1MG	A077968	003	May 24, 2007
		2MG	A077968	002	May 24, 2007
		3MG	A077968	001	May 24, 2007
	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007
		1MG	A077996	002	Jan 31, 2007
		2MG	A077996	003	Jan 31, 2007
		3MG	A077996	004	Jan 31, 2007
	PH HEALTH	0.5MG	A078442	001	Oct 15, 2007
		0.5MG	A078469	001	Sep 29, 2011
		1MG	A078442	002	Oct 15, 2007
		1MG	A078469	002	Sep 29, 2011
		2MG	A078442	003	Oct 15, 2007
		2MG	A078469	003	Sep 29, 2011
		3MG	A078442	004	Oct 15, 2007
		3MG	A078469	004	Sep 29, 2011
	PHARMOBEDIENT	0.5MG	A077391	002	Jan 26, 2006
		1MG	A077391	003	Jan 26, 2006
		2MG	A077391	004	Jan 26, 2006
		3MG	A077391	001	Jan 26, 2006
	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
		1MG	A077777	002	Jun 30, 2006
		2MG	A077777	003	Jun 30, 2006
		3MG	A077777	004	Jun 30, 2006
TABLET, ORALLY DISINTEGRATING;ORAL					
NIRAVAM					
+	UCB INC	0.25MG **	N021726	001	Jan 19, 2005
+		0.5MG **	N021726	002	Jan 19, 2005
+		1MG **	N021726	003	Jan 19, 2005
+		2MG **	N021726	004	Jan 19, 2005
ALPROSTADIL					
INJECTABLE;INJECTION					
CAVERJECT					
+	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996
		0.005MG/ML	N020755	001	Oct 31, 1997
		0.01MG/ML	N020755	002	Oct 01, 1997
		0.02MG/ML	N020755	003	Oct 01, 1997
EDEX					
	ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALPROSTADIL					
SUPPOSITORY;URETHRAL					
MUSE					
+	VIATRIS	0.125MG	N020700	001	Nov 19, 1996
+		0.25MG	N020700	002	Nov 19, 1996
+		0.5MG	N020700	003	Nov 19, 1996
+		1MG	N020700	004	Nov 19, 1996
ALSEROXYLON					
TABLET;ORAL					
RAUTENSIN					
	NOVARTIS	2MG	N009215	001	
RAUWILOID					
	3M	2MG	N008867	001	
ALTRETAMINE					
CAPSULE;ORAL					
HEXALEN					
+	EISAI INC	50MG	N019926	001	Dec 26, 1990
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE					
TABLET, CHEWABLE;ORAL					
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE					
	PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMCOAT					
	GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987
FOAMICON					
	NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989
GAVISCON					
+	CHATTEM SANOFI	80MG;20MG **	N018685	001	Dec 09, 1983
+		160MG;40MG **	N018685	002	Dec 09, 1983
ALVIMOPAN					
CAPSULE;ORAL					
ENTEREG					
+	CUBIST PHARMS	12MG **	N021775	001	May 20, 2008
AMANTADINE HYDROCHLORIDE					
CAPSULE;ORAL					
AMANTADINE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
	CHARTWELL MOLECULAR	100MG	A209221	001	Jun 15, 2017
	INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016
	WATSON LABS	100MG	A071382	001	Jan 21, 1987
	WATSON LABS INC	100MG	A208107	001	Dec 06, 2016
SYMADINE					
	SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL					
+	ENDO PHARMS	100MG **	N016020	001	
CAPSULE, EXTENDED RELEASE;ORAL					
AMANTADINE HYDROCHLORIDE					
	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024
SYRUP;ORAL					
AMANTADINE HYDROCHLORIDE					
	ADAPTIS	50MG/5ML	A075819	001	Sep 11, 2002
	CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004
	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
	PH HEALTH	50MG/5ML	A077992	001	Dec 12, 2006
	TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
SYMMETREL					
+	ENDO PHARMS	50MG/5ML **	N016023	002	
TABLET;ORAL					
AMANTADINE HYDROCHLORIDE					
	ADAPTIS	100MG	A212407	001	May 27, 2022
	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017
	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018
SYMMETREL					
+	ENDO PHARMS	100MG **	N018101	001	
TABLET, EXTENDED RELEASE;ORAL					
OSMOLEX ER					
+	SUPERNUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018
+		EQ 161MG BASE	N209410	004	Apr 22, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMANTADINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
OSMOLEX ER				
+		EQ 193MG BASE	N209410 002	Feb 16, 2018
+		EQ 258MG BASE	N209410 003	Feb 16, 2018
AMBENONIUM CHLORIDE				
TABLET;ORAL				
MYTELASE				
	SANOFI AVENTIS US	10MG	N010155 002	
AMBRISENTAN				
TABLET;ORAL				
AMBRISENTAN				
	PH HEALTH	5MG	A209509 001	Apr 10, 2019
		10MG	A209509 002	Apr 10, 2019
AMCINONIDE				
CREAM;TOPICAL				
CYCLOCORT				
+	ASTELLAS	0.025% **	N018116 001	
+		0.1% **	N018116 002	
LOTION;TOPICAL				
CYCLOCORT				
+	ASTELLAS	0.1%	N019729 001	Jun 13, 1988
OINTMENT;TOPICAL				
AMCINONIDE				
	TARO PHARM INDS	0.1%	A076367 001	Mar 19, 2003
CYCLOCORT				
+	ASTELLAS	0.1% **	N018498 001	
AMDINOCILLIN				
INJECTABLE;INJECTION				
COACTIN				
	ROCHE	250MG/VIAL	N050565 001	Dec 21, 1984
		500MG/VIAL	N050565 002	Dec 21, 1984
		1GM/VIAL	N050565 003	Dec 21, 1984
AMIFOSTINE				
INJECTABLE;INJECTION				
AMIFOSTINE				
	EUGIA PHARMA SPECLTS	500MG/VIAL	A204363 001	Jul 17, 2017
	SUN PHARM	500MG/VIAL	A077126 001	Mar 14, 2008
ETHYOL				
	COSETTE	375MG/VIAL	N020221 002	Sep 10, 1999
+		500MG/VIAL **	N020221 001	Dec 08, 1995
AMIKACIN SULFATE				
INJECTABLE;INJECTION				
AMIKACIN SULFATE				
	ABBOTT	EQ 250MG BASE/ML	A063265 001	Nov 30, 1994
		EQ 250MG BASE/ML	A063266 001	Oct 31, 1994
	FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605 001	Dec 09, 2015
	HIKMA	EQ 50MG BASE/ML	A063274 001	May 18, 1992
		EQ 250MG BASE/ML	A063275 001	May 18, 1992
	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994
		EQ 50MG BASE/ML	A063350 001	Jul 30, 1993
		EQ 62.5MG BASE/ML	A063283 001	Oct 31, 1994
		EQ 250MG BASE/ML	A063264 001	Nov 30, 1994
		EQ 250MG BASE/ML	A063350 002	Jul 30, 1993
		EQ 250MG BASE/ML	A064098 001	Jun 26, 1995
		EQ 250MG BASE/ML	A064099 001	Jun 20, 1995
	IGI LABS INC	EQ 50MG BASE/ML	A063167 001	Dec 14, 1995
		EQ 250MG BASE/ML	A063169 001	Dec 14, 1995
	MEITHEAL	EQ 50MG BASE/ML	A064045 001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	HOSPIRA	EQ 500MG BASE/100ML	A064146 001	Apr 02, 1997
AMIKIN				
	APOTHECON	EQ 50MG BASE/ML	A062311 001	
		EQ 50MG BASE/ML	A062562 001	Sep 20, 1984
+		EQ 50MG BASE/ML **	N050495 001	
		EQ 250MG BASE/ML	A062311 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMIKACIN SULFATE				
INJECTABLE;INJECTION				
AMIKIN				
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987
AMILORIDE HYDROCHLORIDE				
TABLET;ORAL				
AMILORIDE HYDROCHLORIDE				
CHARTWELL RX	5MG	A204180	001	Aug 07, 2015
AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
CHARTWELL RX	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE				
PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50				
+ MERCK	EQ 5MG ANHYDROUS;50MG **	N018201	001	
AMINO ACIDS				
INJECTABLE;INJECTION				
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE				
HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N017673	003	
AMINOSYN 10% (PH6)				
ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985
AMINOSYN 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004	
AMINOSYN 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N017673	001	
AMINOSYN 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)				
ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985
AMINOSYN 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004	
AMINOSYN 8.5% (PH6)				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE HBC 6.9%				
B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
FREAMINE III 10%				
B BRAUN	10% (10GM/100ML)	N016822	005	
FREAMINE III 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	004	
HEPATAMINE 8%				
B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NEPHRAMINE 5.4%				
B BRAUN	5.4% (5.4GM/100ML)	N017766	001	
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE				
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG /100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML ;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019682	003	Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	004	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	005	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML	N020147	001	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	007	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	008	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	009	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	010	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020147	006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003	

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018804	002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;	N018875	002	Aug 08, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER

	234MG/100ML			

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N019493	001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38MG/100ML	N017957	001	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003	

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173	001	Oct 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001	

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
TRAVASOL 8.5% W/ ELECTROLYTES				
	BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493 002	
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
AMINOSYN 7% W/ ELECTROLYTES				
	ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	
AMINOSYN 8.5% W/ ELECTROLYTES				
	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673 005	
AMINOCAPROIC ACID				
INJECTABLE;INJECTION				
AMICAR				
+	EPIC PHARMA LLC	250MG/ML **	N015229 002	
AMINOCAPROIC ACID				
	ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
	BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
	HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988
SOLUTION;ORAL				
AMINOCAPROIC ACID				
	EPIC PHARMA LLC	0.25GM/ML	A074759 001	Sep 02, 1998
	TARO	0.25GM/ML	A214458 001	Mar 24, 2023
	VISTAPHARM LLC	0.25GM/ML	A212814 001	Feb 26, 2020
TABLET;ORAL				
AMINOCAPROIC				
	HIKMA	500MG	A075602 001	May 24, 2001
AMINOCAPROIC ACID				
	ADAPTIS	500MG	A212110 001	Jun 14, 2021
	ANI PHARMS	500MG	A211629 001	Dec 14, 2020
AMINOGLUTETHIMIDE				
TABLET;ORAL				
CYTADREN				
	NOVARTIS	250MG	N018202 001	
AMINOHIPPURATE SODIUM				
INJECTABLE;INJECTION				
AMINOHIPPURATE SODIUM				
	MERCK	20%	N005619 001	
AMINOPHYLLINE				
ENEMA;RECTAL				
SOMOPHYLLIN				
	FISONS	300MG/5ML	N018232 001	Apr 02, 1982
INJECTABLE;INJECTION				
AMINOPHYLLIN				
+	GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982
+		25MG/ML	A087621 001	May 24, 1982
AMINOPHYLLINE				
	ABRAXIS PHARM	25MG/ML	A084568 001	
		25MG/ML	A087200 001	
		25MG/ML	A087250 001	Jan 06, 1982
		25MG/ML	A087886 001	Aug 30, 1983
		25MG/ML	A088407 001	Jan 25, 1984
	AM REGENT	25MG/ML	A087600 001	
	ELKINS SINN	25MG/ML	A087239 001	
	HOSPIRA	25MG/ML	A087601 001	Jul 23, 1982
	INTL MEDICATION	25MG/ML	A087209 001	Feb 01, 1982
		25MG/ML	A087867 001	Nov 10, 1983
		25MG/ML	A087868 001	Nov 10, 1983
	KING PHARMS	25MG/ML	A086606 001	
	LUITPOLD	25MG/ML	A087240 001	
	LYPHOMED	25MG/ML	A087431 001	
	PHARMA SERVE NY	25MG/ML	A087387 001	Jun 03, 1983
		25MG/ML	A087392 001	Dec 15, 1983
	SMITH AND NEPHEW	25MG/ML	A088429 001	May 30, 1985
		25MG/ML	A088749 001	May 30, 1985
	TEVA PARENTERAL	25MG/ML	A081142 001	Sep 25, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOPHYLLINE

INJECTABLE;INJECTION				
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984
SOLUTION;ORAL				
AMINOPHYLLINE				
MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466	001	
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045	001	
SUPPOSITORY;RECTAL				
TRUPHYLLINE				
COSETTE	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983
TABLET;ORAL				
AMINOPHYLLIN				
GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	
AMINOPHYLLINE				
ANI PHARMS	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
CHARTWELL MOLECULAR	100MG	A084588	001	
	200MG	A084588	002	
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
HIKMA INTL PHARMS	100MG	A084540	001	
	200MG	A085003	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	
	200MG	A085289	001	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	
TABLET, DELAYED RELEASE;ORAL				
AMINOPHYLLINE				
IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOPHYLLINE
TABLET, EXTENDED RELEASE;ORAL
PHYLLOCONTIN
PHARM RES ASSOC 225MG A086760 001

AMINOSALICYLATE SODIUM
POWDER;ORAL
P.A.S. SODIUM
CENTURY PHARMS 4GM/PACKET A080947 001
SODIUM AMINOSALICYLATE
HEXCEL 100% A080097 001
TABLET;ORAL
PARASAL SODIUM
PANRAY 500MG N006811 006
1GM N006811 011
SODIUM P.A.S.
LANNETT 500MG A080138 002
TEEBACIN
CONSOLIDATED MIDLAND 500MG N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID
TABLET;ORAL
NEOPASALATE
MEDPOINTE PHARM HLC 846MG;112MG A080059 002

AMINOSALICYLIC ACID
TABLET;ORAL
PARASAL
PANRAY 500MG N006811 001
1GM N006811 002

AMINOSALICYLIC ACID RESIN COMPLEX
POWDER;ORAL
REZIPAS
BRISTOL MYERS SQUIBB EQ 500MG BASE/GM N009052 001

AMIODARONE HYDROCHLORIDE
INJECTABLE;INJECTION
AMIODARONE HYDROCHLORIDE
BEDFORD 50MG/ML A076018 001 Oct 15, 2002
BEDFORD LABS 50MG/ML A076299 001 Oct 24, 2002
BEN VENUE 50MG/ML A076088 001 Oct 15, 2002
DR REDDYS 50MG/ML A076163 001 Sep 05, 2003
EPIC PHARMA LLC 50MG/ML A076232 001 Jul 05, 2006
EUGIA PHARMA 50MG/ML A204550 001 Oct 25, 2017
HOSPIRA 50MG/ML A075955 001 Oct 18, 2002
50MG/ML A076108 001 Oct 15, 2002
50MG/ML A203884 001 Nov 25, 2013
50MG/ML A203885 001 Nov 25, 2013
INTL MEDICATION SYS 50MG/ML N021594 001 Feb 04, 2004
PAR STERILE PRODUCTS 50MG/ML A076394 001 Apr 25, 2003
CORDARONE
+ WYETH PHARMS INC 50MG/ML ** N020377 001 Aug 03, 1995
NEXTERONE
+ BAXTER HLTHCARE 50MG/ML ** N022325 001 Dec 24, 2008
TABLET;ORAL
AMIODARONE HYDROCHLORIDE
PHARMOBEDIENT 200MG A075188 001 Feb 24, 1999
TARO 300MG A076362 002 Dec 02, 2003
400MG A076362 001 Nov 29, 2002
TEVA 200MG A074895 001 Apr 16, 1999
UPSHER SMITH LABS 200MG A075315 001 Dec 23, 1998
400MG A075315 002 Jun 30, 2000
CORDARONE
+ WYETH PHARMS 200MG ** N018972 001 Dec 24, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE;ORAL				
ENDEP				
+	ROCHE	40MG/ML **	A085749 001	
INJECTABLE;INJECTION				
AMITRIPTYLINE HYDROCHLORIDE				
	WATSON LABS	10MG/ML	A085594 001	
ELAVIL				
	ASTRAZENECA	10MG/ML	N012704 001	
TABLET;ORAL				
AMITID				
	BRISTOL MYERS SQUIBB	10MG	A086454 001	
		25MG	A086454 002	
		50MG	A086454 003	
		75MG	A086454 004	
		100MG	A086454 005	
AMITRIL				
	WARNER CHILCOTT	10MG	A083939 001	
		25MG	A083937 001	
		50MG	A083938 002	
		75MG	A084957 001	
		100MG	A085093 001	
		150MG	A086295 001	
AMITRIPTYLINE HYDROCHLORIDE				
	AM THERAP	25MG	A088672 001	Nov 20, 1984
		50MG	A088673 001	Nov 20, 1984
		75MG	A088674 001	Nov 20, 1984
		100MG	A088675 001	Nov 20, 1984
	ANI PHARMS	10MG	A085031 002	
		25MG	A085031 001	
		50MG	A085031 003	
		75MG	A085031 004	
	AUROBINDO PHARMA USA	10MG	A086009 002	
		25MG	A086009 003	
		50MG	A086009 001	
		75MG	A086009 004	
		100MG	A086009 005	
		150MG	A086009 006	
	BRECKENRIDGE	10MG	A216243 001	Jun 06, 2022
		25MG	A216243 002	Jun 06, 2022
		50MG	A216243 003	Jun 06, 2022
		75MG	A216243 004	Jun 06, 2022
		100MG	A216243 005	Jun 06, 2022
		150MG	A216243 006	Jun 06, 2022
	COPLEY PHARM	10MG	A088421 001	Apr 30, 1984
		25MG	A088422 001	Apr 30, 1984
		50MG	A088423 001	Apr 30, 1984
		75MG	A088424 001	Apr 30, 1984
		100MG	A088425 001	Apr 30, 1984
		150MG	A088426 001	Apr 30, 1984
	HALSEY	10MG	A085923 001	
		25MG	A085922 001	
		50MG	A085925 001	
		50MG	A087557 001	Mar 05, 1982
		75MG	A085926 001	May 20, 1983
		100MG	A085927 001	May 20, 1983
	LEDERLE	10MG	A086744 001	
		10MG	A087366 001	Jan 04, 1982
		25MG	A086746 001	
		25MG	A087367 001	May 03, 1982
		50MG	A086743 001	
		50MG	A087181 001	Jan 04, 1982
		75MG	A086745 001	
		75MG	A087369 001	Jan 04, 1982
		100MG	A086747 001	
		100MG	A087368 001	May 03, 1982
		150MG	A087370 001	Jan 04, 1982
	MUTUAL PHARM	10MG	A085744 001	
		25MG	A085627 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PH HEALTH	10MG	A040218 001	Sep 11, 1997
	25MG	A040218 002	Sep 11, 1997
	50MG	A040218 003	Sep 11, 1997
	75MG	A040218 004	Sep 11, 1997
	100MG	A040218 005	Sep 11, 1997
	150MG	A040218 006	Sep 11, 1997
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983
	50MG	A088105 001	Jul 18, 1983
	75MG	A088078 001	Sep 16, 1983
	75MG	A088106 001	Jul 18, 1983
	100MG	A088079 001	Sep 16, 1983
	100MG	A088107 001	Jul 18, 1983
ROXANE	10MG	A086002 001	
	10MG	A086144 001	
	25MG	A085944 001	
	25MG	A086145 001	
	50MG	A085945 001	
	50MG	A086143 001	
	75MG	A086004 001	
	75MG	A086147 001	
	100MG	A086003 001	
	100MG	A086146 001	
	150MG	A086090 001	
	150MG	A086148 001	
SUN PHARM INDS INC	10MG	A040816 002	Jun 27, 2008
	25MG	A040816 001	Jun 27, 2008
	50MG	A040816 003	Jun 27, 2008
	75MG	A040816 004	Jun 27, 2008
	100MG	A040816 005	Jun 27, 2008
	150MG	A040816 006	Jun 27, 2008
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
AMITRIPTYLINE HYDROCHLORIDE				
		100MG	A086336 001	
		150MG	A086335 001	
	USL PHARMA	25MG	A087775 001	Feb 10, 1982
	VANGARD	10MG	A087632 001	Feb 01, 1982
		50MG	A087616 001	Feb 08, 1982
		75MG	A087617 001	Feb 05, 1982
		100MG	A087639 001	Feb 08, 1982
	WATSON LABS	10MG	A085816 001	
		10MG	A088620 001	Mar 02, 1984
		25MG	A085817 001	
		25MG	A088621 001	Mar 02, 1984
		50MG	A085815 001	
		50MG	A088622 001	Mar 02, 1984
		75MG	A085819 001	
		75MG	A088633 001	Mar 02, 1984
		100MG	A085820 001	
		100MG	A088634 001	Mar 02, 1984
		150MG	A085821 001	
		150MG	A088635 001	Mar 02, 1984
	WEST WARD	10MG	A087647 001	Mar 05, 1982
		25MG	A087278 001	
ELAVIL				
+	ASTRAZENECA	10MG **	N012703 001	
+		25MG **	N012703 003	
+		50MG **	N012703 004	
+		75MG **	N012703 005	
+		100MG **	N012703 006	
+		150MG **	N012703 007	
ENDEP				
	ROCHE	10MG	A083639 001	
		25MG	A083639 002	
		50MG	A083639 003	
		75MG	A083639 004	
		100MG	A083639 005	
		150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL				
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE				
	CHARTWELL RX	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
		EQ 25MG BASE;10MG	A072278 001	May 09, 1988
	HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
		EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
	MICRO LABS	EQ 12.5MG BASE;5MG	A211925 001	Feb 02, 2022
		EQ 25MG BASE;10MG	A211925 002	Feb 02, 2022
	TP ANDA HOLDINGS	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
		EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
	USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
		EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
LIMBITROL				
+	CHARTWELL RX	EQ 12.5MG BASE;5MG **	N016949 001	
LIMBITROL DS				
+	CHARTWELL RX	EQ 25MG BASE;10MG **	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL				
ETRAFON 2-10				
	SCHERING	10MG;2MG **	N014713 007	
ETRAFON 2-25				
	SCHERING	25MG;2MG **	N014713 004	
ETRAFON-A				
	SCHERING	10MG;4MG **	N014713 002	
ETRAFON-FORTE				
	SCHERING	25MG;4MG **	N014713 006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
	CHARTWELL RX	10MG;2MG	A073007 001	Oct 17, 1991
		10MG;4MG	A073009 001	Oct 17, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL					
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE					
		25MG;2MG	A073008	001	Oct 17, 1991
		25MG;4MG	A073010	001	Oct 17, 1991
		50MG;4MG	A071863	001	Dec 21, 1987
	FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987
		10MG;4MG	A071862	001	Dec 21, 1987
		25MG;2MG	A071063	001	Nov 27, 1987
		25MG;4MG	A071064	001	Nov 27, 1987
	IVAX SUB TEVA PHARMS	10MG;2MG	A070935	001	Sep 11, 1986
		10MG;4MG	A070937	001	Sep 11, 1986
		25MG;2MG	A070936	001	Sep 11, 1986
		25MG;4MG	A070938	001	Sep 11, 1986
		50MG;4MG	A070939	001	Sep 12, 1986
	PAR PHARM	10MG;2MG	A070565	001	Sep 11, 1986
		10MG;4MG	A070620	001	Sep 11, 1986
		25MG;2MG	A070621	001	Sep 11, 1986
		25MG;4MG	A070595	001	Sep 11, 1986
		50MG;4MG	A070574	001	Sep 11, 1986
	SUN PHARM INDUSTRIES	10MG;2MG	A071077	001	Nov 12, 1986
		10MG;4MG	A071078	001	Nov 12, 1986
		25MG;2MG	A070297	001	Nov 12, 1986
		25MG;4MG	A071079	001	Nov 12, 1986
	WATSON LABS	10MG;2MG	A070373	001	Aug 25, 1986
		10MG;2MG	A072539	001	Feb 15, 1989
		10MG;4MG	A070375	001	Aug 25, 1986
		10MG;4MG	A072540	001	Feb 15, 1989
		25MG;2MG	A070374	001	Aug 25, 1986
		25MG;2MG	A072541	001	Feb 15, 1989
		25MG;4MG	A070376	001	Aug 25, 1986
		25MG;4MG	A072134	001	Feb 15, 1989
		50MG;4MG	A070377	001	Nov 04, 1986
		50MG;4MG	A071558	001	Mar 02, 1987
		50MG;4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10					
	NEW RIVER	10MG;2MG **	N014715	004	
TRIAVIL 2-25					
	NEW RIVER	25MG;2MG **	N014715	002	
TRIAVIL 4-10					
	NEW RIVER	10MG;4MG **	N014715	003	
TRIAVIL 4-25					
	NEW RIVER	25MG;4MG **	N014715	005	
TRIAVIL 4-50					
	NEW RIVER	50MG;4MG **	N014715	006	

AMLEXANOX

PASTE;DENTAL					
APHTHASOL					
	ULURU	5%	N020511	001	Dec 17, 1996
PATCH;TOPICAL					
AMLEXANOX					
	ULURU	2MG	N021727	001	Sep 29, 2004

AMLODIPINE BENZOATE

SUSPENSION;ORAL					
AMLODIPINE BENZOATE					
	AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL					
SDAMLO					
+	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025
+		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025
+		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025
TABLET;ORAL					
AMLODIPINE BESYLATE					
	AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
		EQ 5MG BASE	A078477	002	Jan 16, 2008
		EQ 10MG BASE	A078477	003	Jan 16, 2008
	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	EQ 5MG BASE	A076859	002	Sep 10, 2007
	EQ 10MG BASE	A076859	003	Sep 10, 2007
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007
	EQ 5MG BASE	A077262	002	Jul 09, 2007
	EQ 10MG BASE	A077262	003	Jul 09, 2007
HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011
	EQ 5MG BASE	A077771	002	Apr 12, 2011
	EQ 10MG BASE	A077771	003	Apr 12, 2011
MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005
	EQ 5MG BASE	A076418	002	Oct 03, 2005
	EQ 10MG BASE	A076418	003	Oct 03, 2005
PHARMOBEDIENT	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SCIEGEN PHARMS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007
	EQ 5MG BASE	A077759	002	Jul 09, 2007
	EQ 10MG BASE	A077759	003	Jul 09, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
	EQ 5MG BASE	A078231	002	Nov 30, 2007
	EQ 10MG BASE	A078231	003	Nov 30, 2007
SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007
	EQ 5MG BASE	A077974	002	Jul 09, 2007
	EQ 10MG BASE	A077974	003	Jul 09, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007
TORRENT PHARMS	EQ 2.5MG BASE	A078573	001	Sep 22, 2008
	EQ 5MG BASE	A078573	002	Sep 22, 2008
	EQ 10MG BASE	A078573	003	Sep 22, 2008
WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007
	EQ 5MG BASE	A077671	002	Jul 19, 2007
	EQ 10MG BASE	A077671	003	Jul 19, 2007
WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007
	EQ 5MG BASE	A078500	002	Sep 06, 2007
	EQ 10MG BASE	A078500	003	Sep 06, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

+	SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
+		EQ 5MG BASE	N022026	002	Sep 27, 2007
+		EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
	EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
	EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018
CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010
	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010
	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010
PHARMOBEDIENT	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
RISING	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
	EQ 5MG BASE;10MG	A077375	002	May 21, 2010
	EQ 5MG BASE;20MG	A077375	003	May 21, 2010
	EQ 10MG BASE;20MG	A077375	004	May 21, 2010
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
	EQ 5MG BASE;10MG	A077179	002	May 18, 2007
	EQ 5MG BASE;20MG	A077179	003	May 18, 2007
	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011
	EQ 10MG BASE;20MG	A077179	004	May 18, 2007
	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018
+		EQ 10MG BASE;200MG	N210045	003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016
	EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016
	EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012
	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012
	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012
	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012
	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012
TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015
	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015
	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015
	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015
	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL

WIDAPLIK

+	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025
+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025
+		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018
	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018
	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018
	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018
GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017
	EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017
	EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017
	EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017
	EQ 5MG BASE;40MG	A207450	002	May 15, 2017
	EQ 10MG BASE;20MG	A207450	003	May 15, 2017
	EQ 10MG BASE;40MG	A207450	004	May 15, 2017
TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016
	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016
	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016
	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016
TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016
	EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016
	EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016
	EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

ALEMBIC	EQ 5MG BASE;40MG	A205234	001	Nov 17, 2016
	EQ 5MG BASE;80MG	A205234	003	Nov 17, 2016
	EQ 10MG BASE;40MG	A205234	002	Nov 17, 2016
	EQ 10MG BASE;80MG	A205234	004	Nov 17, 2016
TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014
	EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014
	EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014
	EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014

TWYNSTA

+	BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG **	N022401	001	Oct 16, 2009
+		EQ 5MG BASE;80MG **	N022401	003	Oct 16, 2009
+		EQ 10MG BASE;40MG **	N022401	002	Oct 16, 2009
+		EQ 10MG BASE;80MG **	N022401	004	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015
	EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015
	EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015
	EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015
TORRENT	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015
	EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015
	EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015
	EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015

AMLODIPINE MALEATE

TABLET;ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435	001	Oct 31, 2003
	5MG	N021435	002	Oct 31, 2003
	10MG	N021435	003	Oct 31, 2003

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015
ESSENTIAL ISOTOPES	3.75mCi-260mCi/ML	A205687	001	Dec 17, 2015
SHERTECH LABS LLC	3.75mCi-260mCi/ML	A204366	001	Sep 19, 2014
SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014
WISCONSIN	3.75mCi-260mCi/ML	A204356	001	Dec 18, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMMONIUM CHLORIDE				
INJECTABLE;INJECTION				
AMMONIUM CHLORIDE				
	ABBOTT	5MEQ/ML	A083130 001	
	GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE				
	MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%				
	B BRAUN	40MEQ/100ML	A085734 001	
AMMONIUM LACTATE				
CREAM;TOPICAL				
AMMONIUM LACTATE				
	WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006
LAC-HYDRIN				
+	SUN PHARM INDS INC	EQ 12% BASE **	N020508 001	Aug 29, 1996
LOTION;TOPICAL				
AMMONIUM LACTATE				
	WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002
LAC-HYDRIN				
+	SUN PHARM INDS INC	EQ 12% BASE **	N019155 001	Apr 24, 1985
AMODIAQUINE HYDROCHLORIDE				
TABLET;ORAL				
CAMOQUIN HYDROCHLORIDE				
	PARKE DAVIS	EQ 200MG BASE	N006441 001	
AMOXAPINE				
TABLET;ORAL				
AMOXAPINE				
	WATSON PHARMS TEVA	25MG	A072418 001	Aug 01, 1989
		50MG	A072419 001	Aug 01, 1989
		100MG	A072420 001	May 11, 1989
		150MG	A072421 001	May 11, 1989
ASENDIN				
	LEDERLE	25MG	N018021 001	
		50MG	N018021 002	
		100MG	N018021 003	
		150MG	N018021 004	
AMOXICILLIN				
CAPSULE;ORAL				
AMOXICILLIN				
	LABS ATRAL	250MG	A062528 001	Aug 07, 1985
		500MG	A062528 002	Aug 07, 1985
	MYLAN	250MG	A062067 001	
		500MG	A062067 002	
	STRIDES PHARMA INTL	250MG	A062884 001	Feb 25, 1988
		500MG	A062881 001	Feb 25, 1988
	SUN PHARM INDS LTD	250MG	A065016 001	Apr 08, 1999
		500MG	A065016 002	Apr 08, 1999
	TEVA	250MG	A062853 001	Dec 22, 1987
		250MG	A063030 001	Feb 28, 1989
		500MG	A062854 001	Dec 22, 1987
		500MG	A063031 001	Feb 28, 1989
AMOXIL				
+	GLAXOSMITHKLINE	250MG **	N050459 001	
+		500MG **	N050459 002	
TRIMOX				
	APOTHECON	250MG	A061885 001	
		250MG	A062098 001	
		250MG	A062152 001	
		250MG	A063099 001	Mar 20, 1992
		500MG	A061885 002	
		500MG	A062098 002	
		500MG	A062152 002	
		500MG	A063099 002	Mar 20, 1992
UTIMOX				
	PARKE DAVIS	250MG	A062107 001	
		500MG	A062107 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN

CAPSULE;ORAL				
WYMOX				
	WYETH AYERST	250MG	A062120 001	
		500MG	A062120 002	
FOR SUSPENSION;ORAL				
AMOXICILLIN				
	CHARTWELL RX	125MG/5ML	A062059 001	
		250MG/5ML	A062059 002	
	MYLAN	125MG/5ML	A062090 001	
		250MG/5ML	A062090 002	
	PH HEALTH	125MG/5ML	A062927 001	Nov 25, 1988
		250MG/5ML	A062927 002	Nov 25, 1988
	SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002
		400MG/5ML	A065113 002	Nov 29, 2002
	TEVA	125MG/5ML	A061931 001	
		125MG/5ML	A062946 001	Nov 01, 1988
		250MG/5ML	A063001 001	Jan 06, 1989
AMOXIL				
+	GLAXOSMITHKLINE	50MG/ML **	N050460 005	
+		125MG/5ML **	N050460 001	
+		250MG/5ML **	N050460 002	
+	US ANTIBIOTICS	200MG/5ML **	N050760 001	Apr 15, 1999
LAROTID				
+	GLAXOSMITHKLINE	50MG/ML **	N050460 006	
POLYMOX				
	APOTHECON	125MG/5ML	A061851 001	
		125MG/5ML	A062323 001	
		250MG/5ML	A061851 002	
		250MG/5ML	A062323 002	
TRIMOX				
	APOTHECON	50MG/ML	A061886 001	
		125MG/5ML	A061886 002	
		125MG/5ML	A062099 001	
		125MG/5ML	A062154 001	
		125MG/5ML	A062885 001	Mar 08, 1988
		250MG/5ML	A061886 003	
		250MG/5ML	A062099 002	
		250MG/5ML	A062154 002	
		250MG/5ML	A062885 002	Mar 08, 1988
UTIMOX				
	PARKE DAVIS	125MG/5ML	A062127 001	
		250MG/5ML	A062127 002	
WYMOX				
	WYETH AYERST	125MG/5ML	A062131 001	
		250MG/5ML	A062131 002	
TABLET;ORAL				
AMOXICILLIN				
	CHARTWELL RX	875MG	A065344 001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059 001	Nov 24, 2000
		875MG	A065059 002	Nov 24, 2000
AMOXIL				
+	US ANTIBIOTICS	500MG **	N050754 002	Jul 10, 1998
+		875MG **	N050754 001	Jul 10, 1998
TABLET, CHEWABLE;ORAL				
AMOXICILLIN				
	APOTHECON	125MG	A064131 001	May 06, 1996
		250MG	A064131 002	May 06, 1996
	CHARTWELL RX	125MG	A064139 001	Jan 29, 1996
		250MG	A064139 002	Jan 29, 1996
	HIKMA	125MG	A205274 001	Jun 25, 2020
		250MG	A205274 002	Jun 25, 2020
	SUN PHARM INDS LTD	125MG	A065021 001	Dec 23, 1999
		200MG	A065060 001	Nov 29, 2000
		250MG	A065021 002	Dec 23, 1999
		400MG	A065060 002	Nov 29, 2000
	TEVA	125MG	A064031 001	Dec 19, 1996
		250MG	A064031 002	Dec 19, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN

TABLET, CHEWABLE;ORAL					
AMOXIL					
+	US ANTIBIOTICS	125MG **	N050542	002	
		200MG	N050761	001	Apr 15, 1999
+		250MG **	N050542	001	
		400MG	N050761	002	Apr 15, 1999
TABLET, EXTENDED RELEASE;ORAL					
MOXATAG					
+	PRAGMA	775MG	N050813	001	Jan 23, 2008
TABLET, FOR SUSPENSION;ORAL					
AMOXICILLIN					
	AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007
		400MG	A065324	002	Jan 17, 2007
DISPERMOX					
	RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003
		400MG	A065080	001	Aug 11, 2003
		600MG	A065159	001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL					
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)					
	ANI PHARMS	500MG;500MG;30MG	A200218	001	Aug 30, 2013
PREVPAC (COPACKAGED)					
+	TAKEDA PHARMS USA	500MG;500MG;30MG **	N050757	001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL					
OMECLAMOX-PAK					
+	CUMBERLAND	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003
		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003
		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007
AUGMENTIN '200'					
+	US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996
AUGMENTIN '400'					
+	US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996
TABLET;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009
		500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009
		875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008
	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002
	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002
		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002
AUGMENTIN '250'					
+	US ANTIBIOTICS	250MG;EQ 125MG BASE **	N050564	001	Aug 06, 1984
AUGMENTIN '500'					
+	US ANTIBIOTICS	500MG;EQ 125MG BASE **	N050564	002	Aug 06, 1984
TABLET, CHEWABLE;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM					
	CHARTWELL RX	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002
		400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002
	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003
		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003
AUGMENTIN '125'					
+	US ANTIBIOTICS	125MG;EQ 31.25MG BASE **	N050597	001	Jul 22, 1985
AUGMENTIN '200'					
+	US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
AUGMENTIN '250'					
+	US ANTIBIOTICS	250MG;EQ 62.5MG BASE **	N050597	002	Jul 22, 1985
AUGMENTIN '400'					
+	US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN; CLAVULANATE POTASSIUM				
TABLET, EXTENDED RELEASE;ORAL				
AUGMENTIN XR				
+ US ANTIBIOTICS	1GM;EQ 62.5MG BASE **		N050785 001	Sep 25, 2002
AMPHETAMINE				
SUSPENSION, EXTENDED RELEASE;ORAL				
ADZENYS ER				
+ NEOS THERAPS INC	EQ 1.25MG BASE/ML		N204325 001	Sep 15, 2017
AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE				
CAPSULE;ORAL				
DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG **		A083564 001	
	2.5MG;2.5MG;2.5MG;2.5MG **		A083564 002	
	3.75MG;3.75MG;3.75MG;3.75MG **		A083564 003	
	5MG;5MG;5MG;5MG **		A083564 004	
TABLET;ORAL				
DELCOBESE				
TEVA	1.25MG;1.25MG;1.25MG;1.25MG		A083563 004	
	2.5MG;2.5MG;2.5MG;2.5MG		A083563 003	
	3.75MG;3.75MG;3.75MG;3.75MG		A083563 002	
	5MG;5MG;5MG;5MG		A083563 001	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE				
CAPSULE, EXTENDED RELEASE;ORAL				
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG		A211876 001	Jun 24, 2020
	2.5MG;2.5MG;2.5MG;2.5MG		A211876 002	Jun 24, 2020
	3.75MG;3.75MG;3.75MG;3.75MG		A211876 003	Jun 24, 2020
	5MG;5MG;5MG;5MG		A211876 004	Jun 24, 2020
	6.25MG;6.25MG;6.25MG;6.25MG		A211876 005	Jun 24, 2020
	7.5MG;7.5MG;7.5MG;7.5MG		A211876 006	Jun 24, 2020
NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG		A210080 001	Jul 17, 2019
	2.5MG;2.5MG;2.5MG;2.5MG		A210080 002	Jul 17, 2019
	3.75MG;3.75MG;3.75MG;3.75MG		A210080 003	Jul 17, 2019
	5MG;5MG;5MG;5MG		A210080 004	Jul 17, 2019
	6.25MG;6.25MG;6.25MG;6.25MG		A210080 005	Jul 17, 2019
	7.5MG;7.5MG;7.5MG;7.5MG		A210080 006	Jul 17, 2019
PH HEALTH	1.25MG;1.25MG;1.25MG;1.25MG		A206159 001	May 31, 2019
	2.5MG;2.5MG;2.5MG;2.5MG		A206159 002	May 31, 2019
	3.75MG;3.75MG;3.75MG;3.75MG		A206159 003	May 31, 2019
	5MG;5MG;5MG;5MG		A206159 004	May 31, 2019
	6.25MG;6.25MG;6.25MG;6.25MG		A206159 005	May 31, 2019
	7.5MG;7.5MG;7.5MG;7.5MG		A206159 006	May 31, 2019
SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG		A211715 001	May 17, 2019
	2.5MG;2.5MG;2.5MG;2.5MG		A211715 002	May 17, 2019
	3.75MG;3.75MG;3.75MG;3.75MG		A211715 003	May 17, 2019
	5MG;5MG;5MG;5MG		A211715 004	May 17, 2019
	6.25MG;6.25MG;6.25MG;6.25MG		A211715 005	May 17, 2019
	7.5MG;7.5MG;7.5MG;7.5MG		A211715 006	May 17, 2019
TEVA	1.25MG;1.25MG;1.25MG;1.25MG		A077488 001	Apr 29, 2013
	2.5MG;2.5MG;2.5MG;2.5MG		A077488 002	Apr 29, 2013
	3.75MG;3.75MG;3.75MG;3.75MG		A077488 003	Apr 29, 2013
	5MG;5MG;5MG;5MG		A077488 004	Apr 29, 2013
	6.25MG;6.25MG;6.25MG;6.25MG		A077488 005	Apr 29, 2013
	7.5MG;7.5MG;7.5MG;7.5MG		A077488 006	Apr 29, 2013
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE				
BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG		A076536 001	Feb 12, 2013
	2.5MG;2.5MG;2.5MG;2.5MG		A076536 002	Feb 12, 2013
	3.75MG;3.75MG;3.75MG;3.75MG		A076536 003	Feb 12, 2013
	5MG;5MG;5MG;5MG		A076536 004	Feb 12, 2013
	6.25MG;6.25MG;6.25MG;6.25MG		A076536 005	Feb 12, 2013
	7.5MG;7.5MG;7.5MG;7.5MG		A076536 006	Feb 12, 2013
TABLET;ORAL				
ADDERALL 10				
+ TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **		N011522 007	Feb 13, 1996
ADDERALL 12.5				
+ TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **		N011522 012	Aug 31, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL					
ADDERALL 15					
+	TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522	013	Aug 31, 2000
ADDERALL 20					
+	TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522	008	Feb 13, 1996
ADDERALL 30					
+	TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522	010	May 12, 1997
ADDERALL 5					
+	TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522	009	May 12, 1997
ADDERALL 7.5					
+	TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522	011	Aug 31, 2000
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021
		1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021
		2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021
		3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021
		3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021
		5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021
		7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021
	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL					
BIPHETAMINE 12.5					
	UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	
BIPHETAMINE 20					
	UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003	
BIPHETAMINE 7.5					
	UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	

AMPHETAMINE SULFATE

TABLET;ORAL					
AMPHETAMINE SULFATE					
	DR REDDYS LABS SA	5MG	A213898	001	Jul 14, 2020
		10MG	A213898	002	Jul 14, 2020
	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021
		10MG	A212186	002	Jan 27, 2021
+	LANNETT	5MG	A083901	001	Aug 31, 1984
+		10MG	A083901	002	Aug 31, 1984
	NOVAST LABS	5MG	A213763	001	Aug 24, 2020
		10MG	A213763	002	Aug 24, 2020
	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021
		10MG	A213852	002	Sep 07, 2021
	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021
		10MG	A214574	002	Jan 27, 2021
TABLET, ORALLY DISINTEGRATING;ORAL					
EVEKEO ODT					
+	AZURITY	2.5MG **	N209905	005	Apr 16, 2021
+		5MG	N209905	001	Jan 30, 2019
+		10MG	N209905	002	Jan 30, 2019
+		15MG	N209905	003	Jan 30, 2019
+		20MG	N209905	004	Jan 30, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHOTERICIN B				
CREAM;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050314	001	
INJECTABLE;INJECTION				
AMPHOTERICIN B				
ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995
FUNGIZONE				
APOTHECON	50MG/VIAL	A060517	001	
INJECTABLE, LIPID COMPLEX;INJECTION				
ABELCET				
+ LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995
AMPHOTEC				
ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
	100MG/VIAL	N050729	002	Nov 22, 1996
LOTION;TOPICAL				
FUNGIZONE				
APOTHECON	3%	A060570	001	
OINTMENT;TOPICAL				
FUNGIZONE				
APOTHECON	3%	N050313	001	
SUSPENSION;ORAL				
FUNGIZONE				
BRISTOL MYERS SQUIBB	100MG/ML	N050341	003	
AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860	001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860	002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860	003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860	004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860	005	Feb 05, 1988
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936	005	
	EQ 250MG BASE/VIAL	A061936	001	
	EQ 500MG BASE/VIAL	A061936	002	
	EQ 1GM BASE/VIAL	A061936	003	
	EQ 2GM BASE/VIAL	A061936	004	
EUGIA PHARMA SPECLTS	EQ 125MG BASE/VIAL	A065499	001	Aug 17, 2010
HIKMA	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986
HOSPIRA	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015
	EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015
	EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015
	EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015
	EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015
HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634	002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634	003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565	001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565	002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565	003	Jun 24, 1986
ONESOURCE SPECIALTY	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014
	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816	001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816	002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816	003	Oct 24, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN SODIUM

INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
	EQ 1GM BASE/VIAL	A062816	004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816	005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994	001	Sep 15, 1988
OMNIPEN-N				
WYETH AYERST	EQ 125MG BASE/VIAL	A060626	001	
	EQ 125MG BASE/VIAL	A062718	001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626	002	
	EQ 250MG BASE/VIAL	A062718	002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626	003	
	EQ 500MG BASE/VIAL	A062718	003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626	004	
	EQ 1GM BASE/VIAL	A062718	004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626	005	
	EQ 2GM BASE/VIAL	A062718	005	Dec 16, 1986
PENBRITIN-S				
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072	001	
+	EQ 250MG BASE/VIAL **	N050072	002	
+	EQ 500MG BASE/VIAL **	N050072	003	
+	EQ 1GM BASE/VIAL **	N050072	004	
+	EQ 2GM BASE/VIAL **	N050072	005	
+	EQ 4GM BASE/VIAL **	N050072	006	
POLYCILLIN-N				
BRISTOL	EQ 125MG BASE/VIAL **	N050309	001	
	EQ 250MG BASE/VIAL **	N050309	002	
	EQ 500MG BASE/VIAL **	N050309	003	
	EQ 1GM BASE/VIAL **	N050309	004	
	EQ 2GM BASE/VIAL **	N050309	005	
TOTACILLIN-N				
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677	001	
	EQ 250MG BASE/VIAL	A060677	002	
	EQ 500MG BASE/VIAL	A060677	003	
	EQ 1GM BASE/VIAL	A060677	004	
	EQ 1GM BASE/VIAL	A062727	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677	005	
	EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677	006	
POWDER;INTRAVENOUS				
AMPICILLIN SODIUM				
SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987
	EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION				
AMPICILLIN AND SULBACTAM				
ASTRAL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016
EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010
HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002
HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011
	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011
MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007
SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006
UNASYN				
PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992
	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL				
AMCILL				
	PARKE DAVIS	EQ 250MG BASE	A062041 001	
		EQ 500MG BASE	A062041 002	
AMPICILLIN TRIHYDRATE				
	BELCHER PHARMS	EQ 250MG BASE	A061602 001	
		EQ 500MG BASE	A061602 002	
	CHARTWELL RX	EQ 250MG BASE	A061502 001	
		EQ 500MG BASE	A061502 002	
	IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001	
		EQ 500MG BASE	A060765 002	
	LEDERLE	EQ 250MG BASE	A062208 001	
		EQ 500MG BASE	A062208 002	
	MYLAN	EQ 250MG BASE	A061755 001	
		EQ 500MG BASE	A061755 002	
	PUREPAC PHARM	EQ 250MG BASE	A061853 001	
		EQ 500MG BASE	A061853 002	
	SANDOZ	EQ 250MG BASE	A064082 001	Aug 29, 1995
	STRIDES PHARMA INTL	EQ 250MG BASE	A062883 001	Feb 25, 1988
		EQ 500MG BASE	A062882 001	Feb 25, 1988
	VITARINE	EQ 250MG BASE	A061387 001	
		EQ 500MG BASE	A061387 003	
OMNIPEN (AMPICILLIN)				
	WYETH AYERST	250MG	A060624 001	
		500MG	A060624 002	
PENBRITIN				
	WYETH AYERST	EQ 250MG BASE	A060908 001	
		EQ 500MG BASE	A060908 002	
PFIZERPEN-A				
	PFIZER	EQ 250MG BASE	A062050 001	
		EQ 500MG BASE	A062050 002	
POLYCILLIN				
	BRISTOL	EQ 250MG BASE	N050310 001	
		EQ 500MG BASE	N050310 002	
PRINCIPEN				
	APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
		EQ 500MG BASE	A062888 002	Mar 04, 1988
	BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
		EQ 500MG BASE	A061392 002	
PRINCIPEN '250'				
	APOTHECON	EQ 250MG BASE	A062157 002	
+		EQ 250MG BASE	N050056 001	
PRINCIPEN '500'				
	APOTHECON	EQ 500MG BASE	A062157 001	
+		EQ 500MG BASE	N050056 002	
TOTACILLIN				
	GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
		EQ 250MG BASE	A062212 001	
		EQ 500MG BASE	A060060 002	
		EQ 500MG BASE	A062212 002	
FOR SUSPENSION;ORAL				
AMCILL				
	PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
		EQ 250MG BASE/5ML	A062030 002	
AMPICILLIN TRIHYDRATE				
	BELCHER PHARMS	EQ 125MG BASE/5ML	A061601 001	
		EQ 250MG BASE/5ML	A061601 002	
	MYLAN	EQ 125MG BASE/5ML	A061829 002	
		EQ 250MG BASE/5ML	A061829 001	
	PH HEALTH	EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989
		EQ 250MG BASE/5ML	A062982 002	Feb 10, 1989
	PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001	
		EQ 250MG BASE/5ML	A061980 002	
	TEVA	EQ 125MG BASE/5ML	A061370 001	
		EQ 250MG BASE/5ML	A061370 002	
OMNIPEN (AMPICILLIN)				
	WYETH AYERST	100MG/ML	A060625 001	
		125MG/5ML	A060625 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL				
OMNIPEN (AMPICILLIN)				
		250MG/5ML	A060625 003	
		500MG/5ML	A060625 004	
PENBRITIN				
	WYETH AYERST	EQ 100MG BASE/ML	N050019 001	
		EQ 125MG BASE/5ML	N050019 002	
		EQ 250MG BASE/5ML	N050019 003	
PFIZERPEN-A				
	PFIZER	EQ 125MG BASE/5ML	A062049 001	
		EQ 250MG BASE/5ML	A062049 002	
POLYCILLIN				
	APOTHECON	EQ 125MG BASE/5ML	A062297 001	
		EQ 250MG BASE/5ML	A062297 002	
	BRISTOL	EQ 100MG BASE/ML	N050308 004	
		EQ 125MG BASE/5ML	N050308 001	
		EQ 250MG BASE/5ML	N050308 002	
		EQ 500MG BASE/5ML	N050308 003	
PRINCIPEN				
	APOTHECON	EQ 100MG BASE/ML	A061394 001	
		EQ 125MG BASE/5ML	A061394 002	
		EQ 250MG BASE/5ML	A061394 003	
PRINCIPEN '125'				
	APOTHECON	EQ 125MG BASE/5ML	A060127 002	
		EQ 125MG BASE/5ML	A062151 001	
PRINCIPEN '250'				
	APOTHECON	EQ 250MG BASE/5ML	A060127 001	
		EQ 250MG BASE/5ML	A062151 002	
TOTACILLIN				
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001	
		EQ 125MG BASE/5ML	A062223 001	
		EQ 250MG BASE/5ML	A060666 002	
		EQ 250MG BASE/5ML	A062223 002	
TABLET, CHEWABLE;ORAL				
POLYCILLIN				
	BRISTOL	EQ 125MG BASE	N050093 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL				
PRINCIPEN W/ PROBENECID				
	APOTHECON	EQ 389MG BASE;111MG	A062150 001	
		EQ 389MG BASE;111MG	N050488 001	
FOR SUSPENSION;ORAL				
POLYCILLIN-PRB				
	APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898 001	
	BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457 001	
PROBAMPACIN				
	COSETTE	EQ 3.5GM BASE/BOT;1GM/BOT	A061741 001	

AMPRENAVIR

CAPSULE;ORAL				
AGENERASE				
	GLAXOSMITHKLINE	50MG	N021007 001	Apr 15, 1999
		150MG	N021007 002	Apr 15, 1999
SOLUTION;ORAL				
AGENERASE				
+	GLAXOSMITHKLINE	15MG/ML **	N021039 001	Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL				
AGRYLIN				
+	TAKEDA PHARMS USA	EQ 1MG BASE **	N020333 002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE				
	BARR LABS	EQ 0.5MG BASE	A076530 001	Apr 18, 2005
		EQ 1MG BASE	A076530 002	Apr 18, 2005
	CHARTWELL RX	EQ 0.5MG BASE	A076683 001	Apr 18, 2005
		EQ 1MG BASE	A076683 002	Apr 18, 2005
	RISING	EQ 0.5MG BASE	A077613 001	Jun 27, 2006
		EQ 1MG BASE	A077613 002	Jun 27, 2006
	ROXANE	EQ 0.5MG BASE	A076489 001	Apr 18, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ANAGRELIDE HYDROCHLORIDE
CAPSULE;ORAL
ANAGRELIDE HYDROCHLORIDE

	EQ 1MG BASE	A076489	002	Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE	A076417	001	Apr 18, 2005
	EQ 1MG BASE	A076417	002	Apr 18, 2005

ANASTROZOLE
TABLET;ORAL
ANASTROZOLE

APOTEX INC	1MG	A200654	001	May 11, 2012
CHARTWELL MOLECULAR	1MG	A091331	001	Jan 05, 2011
CHARTWELL RX	1MG	A090732	001	Jun 28, 2010
FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010
HIKMA	1MG	A078485	001	Jun 28, 2010
IMPAX LABS INC	1MG	A091242	001	May 31, 2012
PHARMOBEDIENT	1MG	A091051	001	Jun 28, 2010
SANDOZ	1MG	A079007	001	Jun 28, 2010
SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011
SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010
WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010

ANGIOTENSIN II ACETATE
SOLUTION;INTRAVENOUS
GIAPREZA

+	LA JOLLA PHARMA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017

ANILERIDINE HYDROCHLORIDE
TABLET;ORAL
LERITINE

MERCK	EQ 25MG BASE	N010585	002

ANILERIDINE PHOSPHATE
INJECTABLE;INJECTION
LERITINE

MERCK	25MG/ML	N010520	003

ANISINDIONE
TABLET;ORAL
MIRADON

SCHERING	50MG	N010909	003

ANISOTROPINE METHYLBROMIDE
TABLET;ORAL
ANISOTROPINE METHYLBROMIDE

WATSON LABS	50MG	A086046	001

VALPIN 50

ENDO PHARMS	50MG	N013428	001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
VASOCON-A

NOVARTIS	0.5%;0.05%	N018746	002	Jul 11, 1994

APIXABAN
TABLET;ORAL
APIXABAN

APOTEX	2.5MG	A210091	001	Feb 16, 2024
	5MG	A210091	002	Feb 16, 2024
AUROBINDO PHARMA LTD	2.5MG	A210026	001	May 26, 2023
	5MG	A210026	002	May 26, 2023
BIONPHARMA	2.5MG	A210152	001	Apr 08, 2020
	5MG	A210152	002	Apr 08, 2020
BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021
	5MG	A209845	002	Jul 26, 2021
HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023
	5MG	A210066	002	Nov 21, 2023
IMPAX	2.5MG	A209810	001	Feb 14, 2025
	5MG	A209810	002	Feb 14, 2025
MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025
	5MG	A210067	002	Feb 27, 2025
MICRO LABS	2.5MG	A210013	001	Dec 23, 2019
	5MG	A210013	002	Dec 23, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

APIXABAN					
TABLET;ORAL					
APIXABAN					
	MYLAN	2.5MG	A210128	001	Dec 23, 2019
		5MG	A210128	002	Dec 23, 2019
	TORRENT	2.5MG	A210156	001	Dec 17, 2024
		5MG	A210156	002	Dec 17, 2024
	ZYDUS PHARMS	2.5MG	A210185	001	Feb 27, 2023
		5MG	A210185	002	Feb 27, 2023
APOMORPHINE HYDROCHLORIDE					
FILM;SUBLINGUAL					
KYNMOBI					
+	SUMITOMO PHARMA AM	10MG	N210875	001	May 21, 2020
+		15MG	N210875	002	May 21, 2020
+		20MG	N210875	003	May 21, 2020
+		25MG	N210875	004	May 21, 2020
+		30MG	N210875	005	May 21, 2020
INJECTABLE;SUBCUTANEOUS					
APOKYN					
	MDD US	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004
APREMILAST					
TABLET;ORAL					
APREMILAST					
	AMNEAL	10MG	A211782	001	Jun 30, 2021
		20MG	A211782	002	Jun 30, 2021
		30MG	A211782	003	Jun 30, 2021
	AUROBINDO PHARMA LTD	10MG	A211716	001	Jul 19, 2023
		20MG	A211716	002	Jul 19, 2023
		30MG	A211716	003	Jul 19, 2023
	DR REDDYS	10MG	A211756	001	Jul 14, 2023
		20MG	A211756	002	Jul 14, 2023
		30MG	A211756	003	Jul 14, 2023
	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023
		20MG	A211674	002	Oct 16, 2023
		30MG	A211674	003	Oct 16, 2023
	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024
		20MG	A211788	002	Nov 25, 2024
		30MG	A211788	003	Nov 25, 2024
	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022
		20MG	A211897	002	Aug 18, 2022
		30MG	A211897	003	Aug 18, 2022
	TORRENT	10MG	A211834	001	Jun 20, 2025
		20MG	A211834	002	Jun 20, 2025
		30MG	A211834	003	Jun 20, 2025
	UNICHEM	10MG	A211819	001	Feb 17, 2021
		20MG	A211819	002	Feb 17, 2021
		30MG	A211819	003	Feb 17, 2021
APREPITANT					
CAPSULE;ORAL					
EMEND					
+	MSD	40MG **	N021549	003	Jun 30, 2006
ARBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
GENESA					
	GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997
ARDEPARIN SODIUM					
INJECTABLE;INJECTION					
NORMIFLO					
+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227	002	May 23, 1997
+		10,000 UNITS/0.5ML **	N020227	001	May 23, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ARFORMOTEROL TARTRATE					
SOLUTION;INHALATION					
ARFORMOTEROL TARTRATE					
	GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021
BROVANA					
+	LUPIN	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006
ARGATROBAN					
INJECTABLE;INJECTION					
ARGATROBAN					
	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015
+	SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000
INJECTABLE;INTRAVENOUS					
ARGATROBAN IN 0.9% SODIUM CHLORIDE					
	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014
ARGATROBAN IN SODIUM CHLORIDE					
+	CIPLA	50MG/50ML (1MG/ML) **	N022434	001	Jun 29, 2011
SOLUTION;INTRAVENOUS					
ARGATROBAN IN DEXTROSE					
	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011
ARIPIPRAZOLE					
FILM;ORAL					
MEZOFY					
+	CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025
+		10MG	N211448	002	Apr 15, 2025
+		15MG	N211448	003	Apr 15, 2025
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR					
ARIPIPRAZOLE					
	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024
		400MG/VIAL	A216608	002	Dec 03, 2024
INJECTABLE;INTRAMUSCULAR					
ABILIFY					
	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006
SOLUTION;ORAL					
ABILIFY					
+	OTSUKA	1MG/ML **	N021713	001	Dec 10, 2004
TABLET;ORAL					
ABILIFY MYCITE KIT					
+	OTSUKA	2MG	N207202	001	Nov 13, 2017
+		5MG	N207202	002	Nov 13, 2017
+		10MG	N207202	003	Nov 13, 2017
+		15MG	N207202	004	Nov 13, 2017
+		20MG	N207202	005	Nov 13, 2017
+		30MG	N207202	006	Nov 13, 2017
ARIPIPRAZOLE					
	AIPING PHARM INC	2MG	A091279	001	Jan 09, 2017
		5MG	A091279	002	Jan 09, 2017
		10MG	A091279	003	Jan 09, 2017
		15MG	A091279	004	Jan 09, 2017
		20MG	A091279	005	Jan 09, 2017
		30MG	A091279	006	Jan 09, 2017
	LUPIN	2MG	A205589	001	Mar 18, 2024
		5MG	A205589	002	Mar 18, 2024
		10MG	A205589	003	Mar 18, 2024
		15MG	A205589	004	Mar 18, 2024
		20MG	A205589	005	Mar 18, 2024
		30MG	A205589	006	Mar 18, 2024
	RISING	2MG	A206240	001	Sep 19, 2018
		5MG	A206240	002	Sep 19, 2018
		10MG	A206240	003	Sep 19, 2018
		15MG	A206240	004	Sep 19, 2018
		20MG	A206240	005	Sep 19, 2018
		30MG	A206240	006	Sep 19, 2018
	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015
		5MG	A078607	002	Apr 28, 2015
		10MG	A078608	001	Apr 28, 2015
		15MG	A078708	001	Apr 28, 2015
		20MG	A078708	002	Apr 28, 2015
		30MG	A078708	003	Apr 28, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ARIPIPRAZOLE

TABLET;ORAL					
ARIPIPRAZOLE					
	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019
		5MG	A090472	002	Jan 07, 2019
		10MG	A090472	003	Jan 07, 2019
		15MG	A090472	004	Jan 07, 2019
		20MG	A090472	005	Jan 07, 2019
		30MG	A090472	006	Jan 07, 2019
TABLET, ORALLY DISINTEGRATING;ORAL					
ABILIFY					
+	OTSUKA	10MG **	N021729	002	Jun 07, 2006
+		15MG **	N021729	003	Jun 07, 2006
+		20MG **	N021729	004	Jun 07, 2006
+		30MG **	N021729	005	Jun 07, 2006

ARMODAFINIL

TABLET;ORAL					
ARMODAFINIL					
	COREPHARMA	50MG	A201514	001	Mar 25, 2019
		150MG	A201514	002	Mar 25, 2019
		250MG	A201514	003	Mar 25, 2019
	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012
NUVIGIL					
+	NUVO PHARMS	100MG **	N021875	002	Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE;INJECTION					
ARSENIC TRIOXIDE					
	EUGIA PHARMA	2MG/ML	A214011	001	Oct 15, 2021
	NOVAST LABS	2MG/ML	A209315	002	Jan 14, 2021
TRISENOX					
+	CEPHALON	1MG/ML **	N021248	001	Sep 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE					
	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010
ULTACAN					
	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017
ULTACAN FORTE					
	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS					
M.V.I. PEDIATRIC					
+	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION					
BEROCCA PN					
	ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071	003	Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION					
M.V.C. 9+3					
	ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440	002	Aug 08, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809	004	Aug 08, 1985
+	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004

MVC PLUS

WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT

+ HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809	005	Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176	001	Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

TARO	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A207498	001	Jun 28, 2024

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

+ HESP	162.5MG	N200671	001	Sep 04, 2015

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317	001	Oct 18, 2001

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

BAYER	650MG	N016030	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN
TABLET, EXTENDED RELEASE;ORAL
MEASURIN

	BAYER	650MG	N016030	002	

ASPIRIN; BUTALBITAL
TABLET;ORAL
AXOTAL

	SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	LGM PHARMA	500MG;50MG;40MG	A205230	001	Oct 18, 2021
	WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985

FIORINAL

+	ALLERGAN	325MG;50MG;40MG **	N017534	005	Apr 16, 1986

TABLET;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983
	FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984
	HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986
+	HIKMA INTL PHARMS	325MG;50MG;40MG **	A086162	002	Feb 16, 1984
	IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984
	PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983
	QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985
	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016
	WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984

FIORINAL

+	ALLERGAN	325MG;50MG;40MG **	N017534	003	Apr 16, 1986

LANORINAL

	LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
CAPSULE;ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	DR REDDYS LABS SA	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015
	NOVITIUM PHARMA	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999
	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995

FIORINAL W/CODEINE

+	ALLERGAN	325MG;50MG;40MG;30MG **	N019429	003	Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
CAPSULE;ORAL
SYNALGOS-DC

+	SUN PHARM INDUSTRIES	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
TABLET;ORAL
INVAGESIC

	CHARTWELL RX	385MG;30MG;25MG	A074817	001	Nov 27, 1996

INVAGESIC FORTE

	CHARTWELL RX	770MG;60MG;50MG	A074817	002	Nov 27, 1996

NORGESIC

+	BAUSCH	385MG;30MG;25MG **	N013416	003	Oct 27, 1982

NORGESIC FORTE

+	BAUSCH	770MG;60MG;50MG **	N013416	004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996
		770MG;60MG;50MG	A074654	002	Dec 31, 1996
	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999
		770MG;60MG;50MG	A074988	002	Apr 30, 1999

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
CAPSULE;ORAL
COMPOUND 65

	ALRA	389MG;32.4MG;65MG	A084553	002	Aug 17, 1983

DARVON COMPOUND

	XANODYNE PHARM	389MG;32.4MG;32MG	N010996	006	Mar 08, 1983

DARVON COMPOUND-65

	XANODYNE PHARM	389MG;32.4MG;65MG	N010996	007	Mar 08, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL					
PROPOXYPHENE COMPOUND 65					
	IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077	002	Dec 07, 1984
+	SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983
	TEVA	389MG;32.4MG;65MG	A089025	001	Mar 29, 1985
PROPOXYPHENE COMPOUND-65					
	SANDOZ	389MG;32.4MG;65MG	A083101	002	Jun 24, 1985
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE					
	WATSON LABS	389MG;32.4MG;65MG	A085732	002	Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET;ORAL					
CARISOPRODOL AND ASPIRIN					
	CHARTWELL RX	325MG;200MG	A089594	001	Mar 31, 1989
	GENUS	325MG;200MG	A040116	001	Apr 25, 1996
	NOVAST LABS	325MG;200MG	A040832	001	Jan 07, 2010
	OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997
CARISOPRODOL COMPOUND					
	WATSON LABS	325MG;200MG	A088809	001	Oct 03, 1985
SOMA COMPOUND					
	MEDA PHARMS	325MG;200MG **	N012365	005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL					
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE					
	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010
	OXFORD PHARMS	325MG;200MG;16MG	A040283	001	Dec 29, 1998
	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996
SOMA COMPOUND W/ CODEINE					
	MEDA PHARMS	325MG;200MG;16MG **	N012366	002	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL					
AGGRENOX					
+	BOEHRINGER INGELHEIM	25MG;200MG **	N020884	001	Nov 22, 1999
ASPIRIN AND DIPYRIDAMOLE					
	ANI PHARMS	25MG;200MG	A206964	001	Jan 18, 2017
	CHARTWELL MOLECULAR	25MG;200MG	A204552	001	Mar 20, 2019
	SUN PHARM	25MG;200MG	A208572	001	Aug 21, 2018

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL					
AZDONE					
	SCHWARZ PHARMA	500MG;5MG **	A089420	001	Jan 25, 1988
VICOPRIN					
	ABBOTT	500MG;5MG	A086333	001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL					
EQUAGESIC					
	SUN PHARM INDUSTRIES	325MG;200MG	N011702	003	Dec 29, 1983
MEPRO-ASPIRIN					
	SANDOZ	325MG;200MG	A089127	001	Mar 02, 1987
MEPROBAMATE AND ASPIRIN					
	PAR PHARM	325MG;200MG	A089126	001	Aug 19, 1986
MICRAININ					
	MEDPOINTE PHARM HLC	325MG;200MG	A084978	001	
Q-GESIC					
	QUANTUM PHARMICS	325MG;200MG	A088740	001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL					
METHOCARBAMOL AND ASPIRIN					
	IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
	MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
	PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
	STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995
ROBAXISAL					
+	ROBINS AH	325MG;400MG	N012281	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

+	GENUS LIFESCIENCES	81MG;40MG	N205103	001	Sep 14, 2016
+		325MG;40MG	N205103	002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011
DR REDDYS LABS SA	325MG;4.8355MG	A091670	001	Mar 16, 2011

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982

OXYCODONE AND ASPIRIN

ANI PHARMS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998
SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982

PERCODAN

ENDO OPERATIONS	325MG;4.5MG;0.38MG **	N007337	006	

PERCODAN-DEMI

ENDO OPERATIONS	325MG;2.25MG;0.19MG **	N007337	005	

ROXIPRIN

ROXANE	325MG;4.5MG;0.38MG	A087743	001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN COMPOUND

+	SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891	001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG;20MG	N021387	001	Jun 24, 2003
	81MG;40MG	N021387	002	Jun 24, 2003
	81MG;80MG	N021387	003	Jun 24, 2003
	325MG;20MG	N021387	004	Jun 24, 2003
	325MG;40MG	N021387	005	Jun 24, 2003
	325MG;80MG	N021387	006	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG;65MG	N010996	005	

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE;ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016829	001	

TABLET;ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016863	001	

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AMNEAL	EQ 100MG BASE	A209717	001	Jun 01, 2020
	EQ 150MG BASE	A209717	002	Jun 01, 2020
	EQ 200MG BASE	A209717	003	Jun 01, 2020
	EQ 300MG BASE	A209717	004	Jun 01, 2020
CIPLA	EQ 100MG BASE	A200626	001	Aug 09, 2018
	EQ 150MG BASE	A200626	002	Aug 09, 2018
	EQ 200MG BASE	A200626	003	Aug 09, 2018
	EQ 300MG BASE	A200626	004	Aug 09, 2018
MYLAN	EQ 150MG BASE	A208177	001	Sep 24, 2018
	EQ 200MG BASE	A208177	002	Sep 24, 2018
	EQ 300MG BASE	A208177	003	Sep 24, 2018
ZYDUS PHARMS	EQ 150MG BASE	A210575	001	Jun 04, 2020
	EQ 200MG BASE	A210575	002	Jun 04, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATAZANAVIR SULFATE					
CAPSULE;ORAL					
ATAZANAVIR SULFATE					
		EQ 300MG BASE	A210575	003	Jun 04, 2020
REYATAZ					
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567	001	Jun 20, 2003
+		EQ 150MG BASE **	N021567	002	Jun 20, 2003
ATENOLOL					
INJECTABLE;INJECTION					
TENORMIN					
+	ASTRAZENECA	0.5MG/ML **	N019058	001	Sep 13, 1989
TABLET;ORAL					
ATENOLOL					
	ABLE	25MG	A076907	001	Jul 30, 2004
		50MG	A076907	002	Jul 30, 2004
		100MG	A076907	003	Jul 30, 2004
	APOTHECON	50MG	A073317	001	Mar 20, 1992
		100MG	A073318	001	Mar 20, 1992
	CHARTWELL RX	25MG	A074265	001	Feb 28, 1994
		50MG	A074265	002	Feb 28, 1994
		100MG	A074265	003	Feb 28, 1994
	IPCA LABS LTD	25MG	A077877	001	Dec 27, 2006
		50MG	A077877	002	Dec 27, 2006
		100MG	A077877	003	Dec 27, 2006
	MYLAN	25MG	A074126	003	Aug 26, 1998
		50MG	A074126	001	Mar 23, 1994
		100MG	A074126	002	Mar 23, 1994
	NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009
		50MG	A078254	002	Sep 25, 2009
		100MG	A078254	003	Sep 25, 2009
	NOSTRUM LABS	50MG	A074127	001	Feb 21, 1995
		100MG	A074127	002	Feb 21, 1995
	NOVITIUM PHARMA	25MG	A074099	001	Apr 28, 1992
		50MG	A073542	001	Dec 19, 1991
		100MG	A073543	001	Dec 19, 1991
	PLIVA	25MG	A074101	001	Jul 17, 1997
		50MG	A074101	002	Jul 17, 1997
		100MG	A074101	003	Jul 17, 1997
	SCS	50MG	A073676	001	Oct 30, 1992
		100MG	A073676	002	Oct 30, 1992
	SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007
		50MG	A078210	002	Jul 10, 2007
		100MG	A078210	003	Jul 10, 2007
	SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997
		50MG	A073475	001	Mar 30, 1993
		100MG	A073476	001	Mar 30, 1993
	TEVA	50MG	A073315	001	May 28, 1993
		100MG	A073316	001	May 28, 1993
	TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
		100MG	A074120	002	Feb 24, 1995
	WATSON LABS	50MG	A073352	001	Dec 27, 1991
	WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991
ATENOLOL; CHLORTHALIDONE					
TABLET;ORAL					
ATENOLOL AND CHLORTHALIDONE					
	AUROBINDO PHARMA USA	50MG;25MG	A074203	001	Oct 31, 1993
		100MG;25MG	A074203	002	Oct 31, 1993
	NOSTRUM LABS	50MG;25MG	A074404	001	May 14, 1998
		100MG;25MG	A074404	002	May 14, 1998
	PLIVA	50MG;25MG	A074107	001	Sep 24, 1997
		100MG;25MG	A074107	002	Sep 24, 1997
	SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993
		100MG;25MG	A073582	001	Apr 29, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

STRATTERA

	LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002
+		EQ 10MG BASE	N021411	002	Nov 26, 2002
+		EQ 18MG BASE	N021411	003	Nov 26, 2002
+		EQ 25MG BASE	N021411	004	Nov 26, 2002
+		EQ 40MG BASE	N021411	005	Nov 26, 2002
+		EQ 60MG BASE	N021411	006	Nov 26, 2002
+		EQ 80MG BASE	N021411	007	Feb 14, 2005
+		EQ 100MG BASE	N021411	008	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

	CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023
		EQ 20MG BASE	A212103	002	Oct 16, 2023
		EQ 40MG BASE	A212103	003	Oct 16, 2023
		EQ 80MG BASE	A212103	004	Oct 16, 2023
	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017
		EQ 20MG BASE	A204846	002	Jan 09, 2017
		EQ 40MG BASE	A204846	003	Jan 09, 2017
		EQ 80MG BASE	A204846	004	Jan 09, 2017
	LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022
		EQ 20MG BASE	A216848	002	Nov 03, 2022
		EQ 40MG BASE	A216848	003	Nov 03, 2022
		EQ 80MG BASE	A216848	004	Nov 03, 2022
	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019
		EQ 20MG BASE	A204991	002	Mar 06, 2019
		EQ 40MG BASE	A204991	003	Mar 06, 2019
		EQ 80MG BASE	A204991	004	Mar 06, 2019
	PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020
		EQ 20MG BASE	A208478	002	Jun 23, 2020
	STRIDES PHARMA	EQ 10MG BASE	A217634	001	Dec 21, 2023
		EQ 20MG BASE	A217634	002	Dec 21, 2023
		EQ 40MG BASE	A217634	003	Dec 21, 2023
		EQ 80MG BASE	A217634	004	Dec 21, 2023
	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011
		EQ 20MG BASE	A076477	002	Nov 30, 2011
		EQ 40MG BASE	A076477	003	Nov 30, 2011
		EQ 80MG BASE	A076477	004	Nov 30, 2011
	TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
		EQ 20MG BASE	A078773	002	May 29, 2012
		EQ 40MG BASE	A078773	003	May 29, 2012
		EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

+	ORGANON	EQ 10MG BASE;10MG **	N200153	001	May 03, 2013
+		EQ 20MG BASE;10MG **	N200153	002	May 03, 2013
+		EQ 40MG BASE;10MG **	N200153	003	May 03, 2013
+		EQ 80MG BASE;10MG **	N200153	004	May 03, 2013

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

	APOTEX	750MG/5ML	A209750	001	Oct 11, 2017
	LUPIN LTD	750MG/5ML	A209105	001	Sep 11, 2018

TABLET;ORAL

MEPRON

+	GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

	BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
	EUGIA PHARMA	10MG/ML	A206011	001	Apr 08, 2015
	HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
		10MG/ML	A074740	001	Mar 28, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATRACURIUM BESYLATE				
INJECTABLE;INJECTION				
ATRACURIUM BESYLATE				
PHARMOBEDIENT	10MG/ML	A206096	001	Jun 22, 2017
TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE				
BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
EUGIA PHARMA	10MG/ML	A206010	001	Apr 08, 2015
HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
	10MG/ML	A074639	001	Mar 25, 1997
	10MG/ML	A074741	001	Mar 28, 1997
PHARMOBEDIENT	10MG/ML	A206001	001	Apr 07, 2017
WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM				
+ HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE				
+ HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983
ATROPINE				
SOLUTION;INTRAMUSCULAR				
ATROPEN				
+ MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+	EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+	EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+	EQ 2MG SULFATE/0.7ML	N017106	001	
ATROPINE				
ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
ATROPINE (AUTOINJECTOR)				
RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018
ATROPINE SULFATE				
AEROSOL, METERED;INHALATION				
ATROPINE SULFATE				
US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
SOLUTION;INTRAVENOUS				
ATROPINE SULFATE				
+ ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE				
TABLET;ORAL				
MOTOFEN HALF-STRENGTH				
LEGACY PHARMA	0.025MG;0.5MG	N017744	001	
ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE				
CAPSULE;ORAL				
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE				
SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION;ORAL				
COLONAID				
MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
LOMANATE				
ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
LOMOTIL				
GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	
TABLET;ORAL				
COLONAID				
MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
DI-ATRO				
MD PHARM	0.025MG;2.5MG	A085266	001	
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE				
ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
DR REDDYS LABS SA	0.025MG;2.5MG	A210789	001	Jun 03, 2020
FOSUN PHARMA	0.025MG;2.5MG	A086173	001	
HEATHER	0.025MG;2.5MG	A086798	001	
HIKMA	0.025MG;2.5MG	A087765	001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509	001	
KV PHARM	0.025MG;2.5MG	A085659	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL					
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE					
	LEDERLE	0.025MG;2.5MG	A086950	001	
	PARKE DAVIS	0.025MG;2.5MG	A087131	001	
	PHARMOBEDIENT	0.025MG;2.5MG	A085762	001	
	PVT FORM	0.025MG;2.5MG	A085766	001	
	R AND S PHARMA	0.025MG;2.5MG	A085035	001	
	ROXANE	0.025MG;2.5MG	A086057	001	
	STRIDES PHARMA INTL	0.025MG;2.5MG	A040357	001	May 02, 2000
	SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506	001	
	UPSHER SMITH LABS	0.025MG;2.5MG	A210571	001	Aug 31, 2018
	USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
	VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
	WATSON LABS	0.025MG;2.5MG	A085876	001	
LO-TROL					
	VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983
LOGEN					
	SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985
LONOX					
	FOSUN PHARMA	0.025MG;2.5MG	A085311	002	
LOW-QUEL					
	HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION					
ENLON-PLUS					
	PHARMOBEDIENT	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991
+		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION					
ATROPINE AND DEMEROL					
	ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
		0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
		0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982
MEPERIDINE AND ATROPINE SULFATE					
	WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
		0.4MG/ML;75MG/ML	A085121	002	
		0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR					
ATNAA					
	US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL					
SHADE UVAGUARD					
+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS					
AZACITIDINE					
	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019
	PHARMOBEDIENT	100MG/VIAL	A204949	001	Apr 28, 2016

AZATADINE MALEATE

TABLET;ORAL					
OPTIMINE					
	SCHERING	1MG	N017601	001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
TRINALIN					
	SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AZATHIOPRINE				
TABLET;ORAL				
IMURAN				
+	LEGACY PHARMA	25MG **	N016324 002	
AZATHIOPRINE SODIUM				
INJECTABLE;INJECTION				
IMURAN				
+	CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391 001	
AZELAIC ACID				
AEROSOL, FOAM;TOPICAL				
AZELAIC ACID				
	AUROBINDO PHARMA USA	15%	A210928 001	Oct 07, 2020
AZELASTINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AZELASTINE HYDROCHLORIDE				
	EPIC PHARMA LLC	0.05%	A203660 001	Nov 08, 2016
	SUN PHARM	0.05%	A078738 001	Jun 21, 2010
OPTIVAR				
+	RISING	0.05% **	N021127 001	May 22, 2000
SPRAY, METERED;NASAL				
ASTELIN				
+	RISING	0.137MG/SPRAY **	N020114 001	Nov 01, 1996
ASTEPRO				
+	VIATRIS	0.137MG/SPRAY **	N022203 001	Oct 15, 2008
		0.2055MG/SPRAY **	N022203 002	Aug 31, 2009
AZELASTINE HYDROCHLORIDE				
	AMNEAL	0.2055MG/SPRAY	A208199 001	Dec 15, 2017
	APOTEX INC	0.2055MG/SPRAY	A201846 001	Aug 31, 2012
	AUROBINDO PHARMA LTD	0.2055MG/SPRAY	A212775 001	Nov 12, 2020
	BIONPHARMA	0.137MG/SPRAY	A090176 001	Jul 28, 2015
	HIKMA	0.137MG/SPRAY	A091444 001	Oct 24, 2014
		0.2055MG/SPRAY	A207243 001	Sep 22, 2017
	PADAGIS ISRAEL	0.2055MG/SPRAY	A202743 001	May 08, 2014
		0.2055MG/SPRAY	A216801 001	May 08, 2024
	PADAGIS US	0.137MG/SPRAY	A202609 001	Mar 17, 2017
	SCIEGEN PHARMS	0.2055MG/SPRAY	A210032 001	Aug 23, 2019
	SUN PHARM	0.137MG/SPRAY	A090423 001	May 23, 2012
AZILSARTAN KAMEDOXOMIL				
TABLET;ORAL				
AZILSARTAN MEDOXOMIL				
	LUPIN LTD	EQ 40MG MEDOXOMIL	A214489 001	Jul 20, 2022
		EQ 80MG MEDOXOMIL	A214489 002	Jul 20, 2022
AZITHROMYCIN				
CAPSULE;ORAL				
ZITHROMAX				
+	PFIZER	EQ 250MG BASE **	N050670 001	Nov 01, 1991
FOR SUSPENSION;ORAL				
AZITHROMYCIN				
	AMNEAL	EQ 100MG BASE/5ML	A205666 001	Jul 19, 2018
		EQ 200MG BASE/5ML	A205666 002	Jul 19, 2018
	SANDOZ	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006
		EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006
	TARO	EQ 200MG BASE/5ML	A211521 001	Dec 11, 2019
	TEVA PHARMS	EQ 100MG BASE/5ML	A065419 001	Jun 24, 2008
		EQ 200MG BASE/5ML	A065419 002	Jun 24, 2008
ZITHROMAX				
+	PFIZER	EQ 1GM BASE/PACKET	N050693 001	Sep 28, 1994
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
ZMAX				
+	PF PRISM CV	EQ 2GM BASE/BOT	N050797 001	Jun 10, 2005
INJECTABLE;INJECTION				
AZITHROMYCIN				
	HIKMA	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007
	HOSPIRA	EQ 500MG BASE/VIAL	A065511 001	Jun 26, 2009
	PHARMOBEDIENT	EQ 500MG BASE/VIAL	A065506 001	Mar 24, 2009
	RISING	EQ 500MG BASE/VIAL	A204732 001	Jan 26, 2017
	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923 001	Apr 02, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AZITHROMYCIN				
INJECTABLE;INJECTION				
AZITHROMYCIN				
TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006
	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006
TABLET;ORAL				
AZITHROMYCIN				
APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011
	EQ 500MG BASE	A065509	001	Jul 13, 2011
	EQ 600MG BASE	A065508	001	Jul 13, 2011
AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007
EXTROVIS	EQ 500MG BASE	A065366	001	May 30, 2007
PHARMOBEDIENT	EQ 250MG BASE	A065365	001	May 30, 2007
	EQ 500MG BASE	A211318	001	Mar 17, 2021
TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005
	EQ 600MG BASE	A065150	001	Nov 14, 2005
YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022
ZYDUS PHARMS	EQ 250MG BASE	A213275	001	Apr 11, 2023
	EQ 500MG BASE	A213056	001	Apr 07, 2023
ZITHROMAX				
+ PFIZER	EQ 600MG BASE **	N050730	001	Jun 12, 1996
AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE				
FOR SUSPENSION, TABLET;ORAL				
TROVAN/ZITHROMAX COMPLIANCE PAK				
PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762	001	Dec 18, 1998
AZLOCILLIN SODIUM				
INJECTABLE;INJECTION				
AZLIN				
BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982
AZTREONAM				
INJECTABLE;INJECTION				
AZACTAM				
BRISTOL MYERS SQUIBB	500MG/VIAL **	N050580	001	Dec 31, 1986
AZACTAM IN PLASTIC CONTAINER				
BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989
+	20MG/ML	N050632	002	May 24, 1989
+	40MG/ML	N050632	001	May 24, 1989
AZTREONAM				
HIKMA	1GM/VIAL	A065286	001	Mar 23, 2011
	2GM/VIAL	A065286	002	Mar 23, 2011
BACAMPICILLIN HYDROCHLORIDE				
FOR SUSPENSION;ORAL				
SPECTROBID				
PFIZER	125MG/5ML	N050556	001	Mar 23, 1982
TABLET;ORAL				
SPECTROBID				
PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983
BACITRACIN				
OINTMENT;OPHTHALMIC				
BACIGUENT				
PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	
BACITRACIN				
LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BACITRACIN				
OINTMENT;TOPICAL				
BACITRACIN				
COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987
POWDER;FOR RX COMPOUNDING				
BACI-RX				
X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	
BACITRACIN				
APOTHEKERNES	5,000,000 UNITS/BOT	A061699	001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456	001	Jul 27, 1983
BACITRACIN ZINC				
POWDER;FOR RX COMPOUNDING				
ZIBA-RX				
X GEN PHARMS	500,000 UNITS/BOT	A061737	001	
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CORTISPORIN				
+ CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416	002	
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE				
SCIEGEN PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389	001	Jul 02, 1982
OINTMENT;TOPICAL				
CORTISPORIN				
+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **	N050168	002	May 04, 1984
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381	001	Sep 06, 1985
BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;TOPICAL				
LANABIOTIC				
COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499	001	Jun 03, 1985
BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386	001	Sep 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN				
PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167	001	
NEO-POLYCIN				
DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC				
SCIEGEN PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004
OINTMENT;TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833	001	Nov 09, 1987
BACITRACIN ZINC; POLYMYXIN B SULFATE				
AEROSOL;TOPICAL				
POLYSPORIN				
GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167	002	Mar 01, 1985
OINTMENT;OPHTHALMIC				
BACITRACIN ZINC AND POLYMYXIN B SULFATE				
SCIEGEN PHARMS	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995
OCUMYCIN				
PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430	001	Apr 08, 1983
POLYSPORIN				
MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BACITRACIN ZINC; POLYMYXIN B SULFATE				
OINTMENT;TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
	NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987
BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	
BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
MYCITRACIN				
	PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	
BACITRACIN; POLYMYXIN B SULFATE				
DISC;TOPICAL				
LANABIOTIC				
	COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986
BACLOFEN				
GRANULES;ORAL				
LYVISPAH				
+	AMNEAL	5MG/PACKET	N215422 001	Nov 22, 2021
+		10MG/PACKET	N215422 002	Nov 22, 2021
+		20MG/PACKET	N215422 003	Nov 22, 2021
INJECTABLE;INTRATHECAL				
BACLOFEN				
	HERITAGE	0.5MG/ML	A216309 001	Aug 10, 2023
		2MG/ML	A216309 002	Aug 10, 2023
SOLUTION;ORAL				
OZOBAX				
+	METACEL PHARMS LLC	5MG/5ML	N208193 001	Sep 18, 2019
TABLET;ORAL				
BACLOFEN				
	IMPAX	5MG	A077971 003	Jul 07, 2021
		10MG	A077971 001	Oct 26, 2007
		20MG	A077971 002	Oct 26, 2007
	PHARMOBEDIENT	10MG	A077181 001	Jul 29, 2005
		20MG	A077121 002	Jul 29, 2005
	SOMERSET THERAPS LLC	10MG	A090334 001	Feb 18, 2010
		20MG	A090334 002	Feb 18, 2010
	SUN PHARM INDS INC	10MG	A077862 001	Aug 14, 2006
		20MG	A077862 002	Aug 14, 2006
	TEVA	10MG	A073043 001	Feb 27, 1992
		20MG	A073044 001	Feb 27, 1992
	USL PHARMA	10MG	A071260 001	May 06, 1988
		20MG	A071261 001	May 06, 1988
	WATSON LABS	10MG	A072824 001	Sep 18, 1991
		10MG	A073092 001	Jan 28, 1994
		10MG	A074698 001	Aug 20, 1996
		20MG	A072825 001	Sep 18, 1991
		20MG	A073093 001	Jan 28, 1994
		20MG	A074698 002	Aug 20, 1996
LIORESAL				
+	NOVARTIS	10MG **	N017851 001	
+		20MG **	N017851 003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING;ORAL				
KEMSTRO				
+	UCB INC	10MG **	N021589 001	Oct 30, 2003
+		20MG **	N021589 002	Oct 30, 2003
BALOXAVIR MARBOXIL				
TABLET;ORAL				
XOFLUZA				
+	GENENTECH INC	20MG **	N210854 001	Oct 24, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BALSALAZIDE DISODIUM				
TABLET;ORAL				
BALSALAZIDE DISODIUM				
AARXION ANDA HLDING	1.1GM	A206336	001	Sep 08, 2015
GIAZO				
+ VALEANT PHARMS INTL	1.1GM **	N022205	001	Feb 03, 2012
BARICITINIB				
TABLET;ORAL				
BARICITINIB				
AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024
	2MG	A217542	002	Jul 22, 2024
BARIUM SULFATE				
FOR SUSPENSION;ORAL				
E-Z-CAT DRY				
+ BRACCO	40%	N208036	003	Jan 03, 2017
BECLOMETHASONE DIPROPIONATE				
AEROSOL, METERED;INHALATION				
BECLOVENT				
GLAXOSMITHKLINE	0.042MG/INH	N018153	001	
QVAR 40				
+ TEVA BRANDED PHARM	0.04MG/INH **	N020911	002	Sep 15, 2000
QVAR 80				
+ TEVA BRANDED PHARM	0.08MG/INH **	N020911	001	Sep 15, 2000
VANCERIL				
SCHERING	0.042MG/INH	N017573	001	
VANCERIL DOUBLE STRENGTH				
SCHERING	0.084MG/INH	N020486	001	Dec 24, 1996
AEROSOL, METERED;NASAL				
BECONASE				
GLAXOSMITHKLINE	0.042MG/INH	N018584	001	
VANCENASE				
SCHERING	0.042MG/INH	N018521	001	
BECLOMETHASONE DIPROPIONATE MONOHYDRATE				
SPRAY, METERED;NASAL				
BECONASE AQ				
+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987
VANCENASE AQ				
SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987
	EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996
BENAZEPRIL HYDROCHLORIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE				
GENPHARM	5MG	A076476	001	Feb 11, 2004
	10MG	A076476	002	Feb 11, 2004
	20MG	A076476	003	Feb 11, 2004
	40MG	A076476	004	Feb 11, 2004
RISING	5MG	A076430	001	Feb 11, 2004
	10MG	A076430	002	Feb 11, 2004
	20MG	A076430	003	Feb 11, 2004
	40MG	A076430	004	Feb 11, 2004
LOTENSIN				
+ VALIDUS PHARMS	5MG **	N019851	001	Jun 25, 1991
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ANI PHARMS	5MG;6.25MG	A076348	001	Feb 11, 2004
	10MG;12.5MG	A076348	002	Feb 11, 2004
	20MG;12.5MG	A076348	003	Feb 11, 2004
	20MG;25MG	A076348	004	Feb 11, 2004
AUROBINDO PHARMA USA	5MG;6.25MG	A076688	001	Feb 11, 2004
	10MG;12.5MG	A076688	002	Feb 11, 2004
	20MG;12.5MG	A076688	003	Feb 11, 2004
	20MG;25MG	A076688	004	Feb 11, 2004
MYLAN PHARMS INC	5MG;6.25MG	A076612	001	Feb 11, 2004
	10MG;12.5MG	A076612	002	Feb 11, 2004
	20MG;12.5MG	A076612	003	Feb 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	20MG;25MG	A076612	004	Feb 11, 2004
SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005
	10MG;12.5MG	A077483	002	Sep 08, 2005
	20MG;12.5MG	A077483	003	Sep 08, 2005
	20MG;25MG	A077483	004	Sep 08, 2005
LOTENSIN HCT				
+ VALIDUS PHARMS	5MG;6.25MG **	N020033	001	May 19, 1992
BENDAMUSTINE HYDROCHLORIDE				
POWDER;INTRAVENOUS				
BENDAMUSTINE HYDROCHLORIDE				
APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023
	100MG/VIAL	A204230	002	Jun 05, 2023
BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023
	100MG/VIAL	A205447	002	Feb 14, 2023
NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023
	100MG/VIAL	A206554	002	Jun 07, 2023
PHARMOBEDIENT	25MG/VIAL	A204104	001	Apr 28, 2023
	100MG/VIAL	A204104	002	Apr 28, 2023
SOLUTION;INTRAVENOUS				
BENDAMUSTINE HYDROCHLORIDE				
+ DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025
+ HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022
+	100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022
+	200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022
TREANDA				
+ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013
+	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013
BENDROFLUMETHIAZIDE				
TABLET;ORAL				
NATURETIN-10				
APOTHECON	10MG	N012164	003	
NATURETIN-2.5				
APOTHECON	2.5MG	N012164	001	
NATURETIN-5				
APOTHECON	5MG	N012164	002	
BENDROFLUMETHIAZIDE; NADOLOL				
TABLET;ORAL				
CORZIDE				
+ KING PHARMS LLC	5MG;40MG **	N018647	001	May 25, 1983
+	5MG;80MG **	N018647	002	May 25, 1983
NADOLOL AND BENDROFLUMETHIAZIDE				
IMPAX LABS	5MG;40MG	A077833	001	Mar 30, 2007
	5MG;80MG	A077833	002	Mar 30, 2007
NATCO PHARMA	5MG;40MG	A078688	001	Feb 15, 2008
	5MG;80MG	A078688	002	Feb 15, 2008
BENOXINATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BENOXINATE HYDROCHLORIDE				
SOLA BARNES HIND	0.4%	A084149	001	
BENTIROMIDE				
SOLUTION;ORAL				
CHYMEX				
SAVAGE LABS	500MG/7.5ML	N018366	001	Dec 29, 1983
BENZONATATE				
CAPSULE;ORAL				
BENZONATATE				
ACELLA	100MG	A091310	001	Jan 16, 2015
	200MG	A091310	002	Jan 16, 2015
ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019
CHARTWELL RX	100MG	A210562	001	Nov 09, 2018
	150MG	A210562	002	Nov 09, 2018
	200MG	A210562	003	Nov 09, 2018
MIKART	100MG	A040851	001	Nov 09, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENZONATATE				
CAPSULE;ORAL				
BENZONATATE				
	150MG	A040851	002	Nov 09, 2009
	200MG	A040851	003	Nov 09, 2009
NESHER PHARMS	100MG	A040795	001	Oct 31, 2007
	200MG	A040795	002	Oct 31, 2007
SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008
	200MG	A040587	002	Mar 19, 2008
TESSALON				
+ PFIZER	200MG **	N011210	003	Jun 25, 1999
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE				
GEL;TOPICAL				
BENZACLIN				
+ BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000
	5%;EQ 1% BASE	N050756	002	Apr 20, 2007
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
CHARTWELL RX	5%;1.2%	A203688	001	Aug 25, 2016
BENZOYL PEROXIDE; ERYTHROMYCIN				
GEL;TOPICAL				
AKTIPAK				
+ BIOFRONTERA	5%;3%	N050769	001	Nov 27, 2000
ERYTHROMYCIN AND BENZOYL PEROXIDE				
ENCUBE	5%;3%	A065112	001	Mar 29, 2004
BENZPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
BENZPHETAMINE HYDROCHLORIDE				
AVET LIFESCIENCES	50MG	A202061	001	Jan 27, 2012
EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007
IMPAX LABS	50MG	A040845	001	Nov 18, 2008
SCINOPHARM TAIWAN	50MG	A040578	001	Apr 17, 2006
SPECGX LLC	50MG	A040773	001	Apr 25, 2007
TEDOR PHARM	25MG	A040747	002	Nov 20, 2015
	50MG	A040747	001	Mar 30, 2007
DIDREX				
+ PFIZER	25MG **	N012427	003	
+	50MG **	N012427	002	
BENZQUINAMIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMETE-CON				
PFIZER	EQ 50MG BASE/VIAL	N016820	001	
SUPPOSITORY;RECTAL				
EMETE-CON				
ROERIG	EQ 100MG BASE	N016818	006	
BENZTHIAZIDE				
TABLET;ORAL				
AQUATAG				
SOLVAY	25MG	N016001	001	
	50MG	N016001	002	
BENZTHIAZIDE				
PVT FORM	50MG	A083206	001	
EXNA				
AH ROBINS INC	50MG	N012489	001	
FOVANE				
PFIZER	50MG	N012128	002	
URESE				
PFIZER	25MG	N012128	003	
BENZTROPINE MESYLATE				
INJECTABLE;INJECTION				
BENZTROPINE MESYLATE				
LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010
COGENTIN				
+ EPIC PHARMA LLC	1MG/ML **	N012015	001	
TABLET;ORAL				
BENZTROPINE MESYLATE				
INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENZTROPINE MESYLATE				
TABLET;ORAL				
BENZTROPINE MESYLATE				
	1MG	A090294	002	Mar 29, 2010
	2MG	A090294	003	Mar 29, 2010
LANNETT CO INC	0.5MG **	A088877	001	Apr 11, 1985
	1MG **	A088894	001	Apr 11, 1985
	2MG **	A088895	001	Apr 11, 1985
OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008
	1MG	A040706	003	Feb 14, 2008
	2MG	A040706	001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514	001	Jan 31, 1984
	1MG	A088510	001	Jan 31, 1984
	2MG	A088511	001	Jan 31, 1984
USL PHARMA	0.5MG	A089211	001	Jun 14, 1988
	1MG	A089212	001	Jun 14, 1988
	2MG	A089213	001	Jun 14, 1988
COGENTIN				
+ MERCK	0.5MG **	N009193	004	
+	1MG **	N009193	003	
+	2MG **	N009193	002	
BENZYL ALCOHOL				
LOTION;TOPICAL				
ULESFIA				
+ SHIONOGI INC	5% **	N022129	001	Apr 09, 2009
BENZYL BENZOATE				
EMULSION;TOPICAL				
BENZYL BENZOATE				
LANNETT	50%	A084535	001	
BEPRIDIL HYDROCHLORIDE				
TABLET;ORAL				
BEPADIN				
MEDPOINTE PHARM HLC	200MG	N019001	001	Dec 28, 1990
	300MG	N019001	002	Dec 28, 1990
	400MG	N019001	003	Dec 28, 1990
VASCOR				
JOHNSON AND JOHNSON	200MG	N019002	001	Dec 28, 1990
	300MG	N019002	002	Dec 28, 1990
	400MG	N019002	003	Dec 28, 1990
BETA CAROTENE				
CAPSULE;ORAL				
SOLATENE				
ROCHE	30MG	N017589	001	
BETAMETHASONE				
CREAM;TOPICAL				
CELESTONE				
SCHERING	0.2%	N014762	001	
SYRUP;ORAL				
CELESTONE				
MERCK SHARP DOHME	0.6MG/5ML	N014215	002	
TABLET;ORAL				
CELESTONE				
SCHERING	0.6MG	N012657	003	
BETAMETHASONE BENZOATE				
CREAM;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N016998	002	
GEL;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N017244	001	
LOTION;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N017528	001	
OINTMENT;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N018089	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019138	001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072536	001	Jan 31, 1990
	EQ 0.05% BASE	A074579	001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136	001	Jun 26, 1984
SUN PHARMA CANADA	EQ 0.05% BASE	A071143	001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476	001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017536	001	
CREAM, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004
GLENMARK PHARMS INC	EQ 0.05% BASE	A078930	001	Sep 23, 2008
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408	001	Jan 31, 1986
DIPROLENE AF				
+ ORGANON	EQ 0.05% BASE **	N019555	001	Apr 27, 1987
DISC;TOPICAL				
DIPROSONE				
SCHERING	EQ 0.1% BASE	N017829	001	
GEL, AUGMENTED;TOPICAL				
DIPROLENE				
SCHERING	EQ 0.05% BASE	N019408	002	Nov 22, 1991
LOTION;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	A070273	001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE				
ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281	001	Jul 31, 1985
ALPHARMA US PHARMS	EQ 0.05% BASE	A071085	001	Feb 03, 1987
COSETTE	EQ 0.05% BASE	A071882	001	Jun 06, 1988
HIKMA	EQ 0.05% BASE	A209896	001	Feb 06, 2018
SHREE HARI INTL	EQ 0.05% BASE	A070274	001	Aug 12, 1985
SUN PHARMA CANADA	EQ 0.05% BASE	A072276	001	Aug 24, 1988
	EQ 0.05% BASE	A074272	001	Sep 30, 1994
DIPROSONE				
+ SCHERING	EQ 0.05% BASE **	N017781	001	
LOTION, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
HIKMA	EQ 0.05% BASE	A208849	001	Oct 11, 2019
DIPROLENE				
+ ORGANON	EQ 0.05% BASE **	N019716	001	Aug 01, 1988
OINTMENT;TOPICAL				
ALPHATREX				
SAVAGE LABS	EQ 0.05% BASE	N019143	001	Sep 04, 1984
BETAMETHASONE DIPROPIONATE				
PERRIGO NEW YORK	EQ 0.05% BASE	A072526	001	Jan 31, 1990
PHARMADERM	EQ 0.05% BASE	N019140	001	Sep 04, 1984
SUN PHARMA CANADA	EQ 0.05% BASE	A074271	001	Sep 15, 1994
TEVA	EQ 0.05% BASE	A071477	001	Aug 10, 1987
DIPROSONE				
SCHERING	EQ 0.05% BASE	N017691	001	
OINTMENT, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017
SUN PHARMA CANADA	EQ 0.05% BASE	A076753	001	Oct 12, 2004
SPRAY;TOPICAL				
BETAMETHASONE DIPROPIONATE				
SUN PHARMA CANADA	EQ 0.05% BASE/SPRAY	A211722	001	Jun 17, 2020

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL				
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE				
GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023
OINTMENT;TOPICAL				
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE				
CHARTWELL RX	0.064%;0.005%	A201615	001	Jan 14, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

GLENMARK SPECLT	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015

LOTRISONE

+ ORGANON	EQ 0.05% BASE;1% **	N018827	001	Jul 10, 1984

LOTION;TOPICAL

LOTRISONE

+ MERCK SHARP DOHME	EQ 0.05% BASE;1% **	N020010	001	Dec 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS	EQ 3MG BASE/ML	A085738	001	

CELESTONE

+ SCHERING	EQ 3MG BASE/ML **	N017561	001	

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

NOVAST LABS	0.12%	A207144	001	May 24, 2017

LUXIQ

+ PHARMOBEDIENT	0.12% **	N020934	001	Feb 28, 1999

CREAM;TOPICAL

BETADERM

ROACO	EQ 0.1% BASE	N018839	001	Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK	EQ 0.1% BASE	A070053	001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860	002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485	001	May 29, 1987
SUN PHARMA CANADA	EQ 0.1% BASE	A070062	001	May 14, 1985

BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018862	001	Aug 31, 1983

VALISONE

SCHERING	EQ 0.01% BASE	N016322	002	
	EQ 0.1% BASE	N016322	001	

LOTION;TOPICAL

BETA-VAL

COSETTE	EQ 0.1% BASE	A070072	001	Jun 27, 1985

BETAMETHASONE VALERATE

PHARMADERM	EQ 0.1% BASE	N018870	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484	001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883	001	Apr 22, 1988

BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018867	001	Aug 31, 1983

VALISONE

SCHERING	EQ 0.1% BASE	N016932	001	

OINTMENT;TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK	EQ 0.1% BASE	A071478	001	Dec 23, 1987
PHARMADERM	EQ 0.1% BASE	N018864	001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987

BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983

VALISONE

SCHERING	EQ 0.1% BASE	N016740	001	

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
PHARMOBEDIENT	EQ 0.5% BASE	A075386	001	Jun 30, 2000

TABLET;ORAL

KERLONE

SANOFI AVENTIS US	10MG **	N019507	001	Oct 27, 1989
	20MG **	N019507	002	Oct 27, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE				
TABLET;ORAL				
KERLEDEX				
SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992
BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETOPTIC PILO				
ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997
BETAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HISTALOG				
LILLY	50MG/ML	N009344	001	
BETHANECHOL CHLORIDE				
INJECTABLE;INJECTION				
URECHOLINE				
+ TEVA BRANDED PHARM	5MG/ML **	N006536	001	
TABLET;ORAL				
BETHANECHOL CHLORIDE				
ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004
	25MG	A040554	001	Oct 28, 2004
	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IMPAX LABS	5MG	A040721	001	Nov 01, 2006
	10MG	A040721	002	Nov 01, 2006
	25MG	A040721	003	Nov 01, 2006
	50MG	A040721	004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
LANNETT CO INC	5MG	A040677	002	Mar 27, 2008
	10MG	A040677	003	Mar 27, 2008
	25MG	A040677	004	Mar 27, 2008
	50MG	A040677	001	Mar 27, 2008
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
	10MG	A040897	002	Apr 22, 2009
	25MG	A040897	003	Apr 22, 2009
	50MG	A040897	004	Apr 22, 2009
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	
	10MG	A085842	001	
	25MG	A084441	001	
	25MG	A085229	001	
	25MG	A085839	001	
	50MG	A087397	001	
	50MG	A087444	001	
WOCKHARDT	5MG	A040532	001	Sep 29, 2003
	10MG	A040533	001	Sep 29, 2003
	25MG	A040534	001	Sep 29, 2003
	50MG	A040518	001	Sep 29, 2003
MYOTONACHOL				
GLENWOOD	5MG	A084188	001	
	10MG	A084188	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETHANECHOL CHLORIDE

TABLET;ORAL				
MYOTONACHOL				
	25MG	A084188	004	
URECHOLINE				
ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985
+	10MG	A088440	001	May 29, 1984
+	25MG	A088441	001	May 29, 1984
	50MG	A089096	001	Dec 19, 1985
+ TEVA BRANDED PHARM	5MG **	N006536	003	
+	10MG **	N006536	002	
+	25MG **	N006536	004	
+	50MG **	N006536	005	

BETHANIDINE SULFATE

TABLET;ORAL				
TENATHAN				
ROBINS AH	10MG	N017675	001	
	25MG	N017675	002	

BETRIXABAN

CAPSULE;ORAL				
BEVYXXA				
+ PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017
+	80MG	N208383	002	Jun 23, 2017

BEXAROTENE

CAPSULE;ORAL				
BEXAROTENE				
CIPLA	75MG	A210352	001	Dec 10, 2024

BICALUTAMIDE

TABLET;ORAL				
BICALUTAMIDE				
APOTEX	50MG	A200274	001	May 21, 2015
FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010
KUDCO IRELAND	50MG	A077995	001	Jul 06, 2009
RISING	50MG	A079185	001	Jul 06, 2009
ROXANE	50MG	A078285	001	Mar 24, 2011
SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009
TEVA	50MG	A076932	001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC				
BIMATOPROST				
HIKMA	0.03%	A203299	001	Nov 08, 2018
LUPIN LTD	0.03%	A203991	001	Feb 20, 2015
LUMIGAN				
+ ABBVIE	0.03% **	N021275	001	Mar 16, 2001
SOLUTION/DROPS;TOPICAL				
BIMATOPROST				
HIKMA	0.03%	A203051	001	Oct 09, 2018

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL				
AKINETON				
ABBVIE	2MG	N012003	001	

BIPERIDEN LACTATE

INJECTABLE;INJECTION				
AKINETON				
ABBVIE	5MG/ML	N012418	002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL				
HALFLYTELY				
+ BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **	N021551	003	Jul 16, 2010
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL				
NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	A202217	001	Aug 20, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

+	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **	N050719	001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	DASH PHARMS NATCO	5MG	A075831	001	Dec 14, 2005
		10MG	A075831	002	Dec 14, 2005
	TEVA PHARMS	5MG	A075644	001	Jun 26, 2001
		10MG	A075644	002	Jun 26, 2001

ZEBETA

+	TEVA BRANDED PHARM	5MG **	N019982	002	Jul 31, 1992
+		10MG **	N019982	001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672	001	Sep 25, 2000
		5MG;6.25MG	A075672	002	Sep 25, 2000
		10MG;6.25MG	A075672	003	Sep 25, 2000
	APOTHECON	2.5MG;6.25MG	A075642	002	Dec 27, 2000
		5MG;6.25MG	A075642	001	Dec 27, 2000
		10MG;6.25MG	A075642	003	Dec 27, 2000
	CHARTWELL RX	2.5MG;6.25MG	A075527	001	Sep 25, 2000
		5MG;6.25MG	A075527	003	Sep 25, 2000
		10MG;6.25MG	A075527	002	Sep 25, 2000
	IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632	001	Sep 27, 2000
		5MG;6.25MG	A075632	002	Sep 27, 2000
		10MG;6.25MG	A075632	003	Sep 27, 2000
	TEVA	2.5MG;6.25MG	A075686	001	Jan 19, 2001
		5MG;6.25MG	A075686	002	Jan 19, 2001
		10MG;6.25MG	A075686	003	Jan 19, 2001
	WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000
		5MG;6.25MG	A075469	002	Sep 25, 2000
		10MG;6.25MG	A075469	003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION

TORNALATE

	SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984

SOLUTION;INHALATION

TORNALATE

	SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

	APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017
	EUGIA PHARMA	250MG/VIAL	A205962	001	Jul 27, 2018
	HOSPIRA	250MG/VIAL	A090811	001	Jul 14, 2015
		250MG/VIAL	A090816	001	Jul 14, 2015

SOLUTION;INTRAVENOUS

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017
+		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLENOXANE

+	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443	001	
+		EQ 30 UNITS BASE/VIAL **	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019
	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
		EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996
	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000
		EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BOCEPREVIR					
CAPSULE;ORAL					
VICTRELIS					
	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011
BORTEZOMIB					
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS					
BORTEZOMIB					
	ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022
	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022
	PHARMOBEDIENT	3.5MG/VIAL	A205160	001	Oct 31, 2022
	SCINOPHARM TAIWAN	3.5MG/VIAL	A216912	001	Sep 26, 2023
	TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022
POWDER;INTRAVENOUS					
BORTEZOMIB					
	DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019
	FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017
SOLUTION;INTRAVENOUS					
BORTEZOMIB					
+	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML) **	N215441	001	Jul 26, 2022
+		3.5MG/1.4ML (2.5MG/ML) **	N215441	002	Jul 26, 2022
+	MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022
+		3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022
BOSENTAN					
TABLET;ORAL					
BOSENTAN					
	ALEMBIC	62.5MG	A211461	001	Jan 23, 2020
		125MG	A211461	002	Jan 23, 2020
	ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019
		125MG	A206002	002	Apr 26, 2019
	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019
		125MG	A209742	002	Apr 26, 2019
	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020
		125MG	A210342	002	Jan 03, 2020
	HIKMA	62.5MG	A208695	001	Apr 26, 2019
		125MG	A208695	002	Apr 26, 2019
	MYLAN	62.5MG	A205173	001	Jan 15, 2020
		125MG	A205173	002	Jan 15, 2020
	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019
		125MG	A206987	002	Apr 26, 2019
	PH HEALTH	62.5MG	A205699	001	Apr 26, 2019
		125MG	A205699	002	Apr 26, 2019
BRETYLIUM TOSYLATE					
INJECTABLE;INJECTION					
BRETYLIUM TOSYLATE					
	ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
		100MG/ML	A071298	001	Feb 13, 1987
	ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
		50MG/ML	A071152	001	Aug 10, 1987
		50MG/ML	A071153	001	Aug 10, 1987
	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018
	HIKMA	50MG/ML	A070545	001	May 14, 1986
		50MG/ML	A070546	001	May 14, 1986
+	HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
		50MG/ML	N019033	001	Apr 29, 1986
	INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
	LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%					
	ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
		400MG/100ML	N019005	003	Apr 29, 1986
		800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
		200MG/100ML	N019121	002	Apr 29, 1986
		400MG/100ML	N019121	003	Apr 29, 1986
	BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
		400MG/100ML	N019837	001	Apr 12, 1989
	HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
		400MG/100ML	N019008	003	Apr 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BRETYLIUM TOSYLATE				
INJECTABLE;INJECTION				
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL				
HOSPIRA	50MG/ML	N017954	001	
BREXANOLONE				
SOLUTION;INTRAVENOUS				
ZULRESSO				
+ SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019
BREXPIPRAZOLE				
TABLET;ORAL				
BREXPIPRAZOLE				
AJANTA PHARMA LTD	0.25MG	A213718	001	Feb 03, 2023
	0.5MG	A213718	002	Feb 03, 2023
	1MG	A213718	003	Feb 03, 2023
	2MG	A213718	004	Feb 03, 2023
	3MG	A213718	005	Feb 03, 2023
	4MG	A213718	006	Feb 03, 2023
ALKEM LABS LTD	0.25MG	A213782	001	Nov 28, 2023
	0.5MG	A213782	002	Nov 28, 2023
	1MG	A213782	003	Nov 28, 2023
	2MG	A213782	004	Nov 28, 2023
	3MG	A213782	005	Nov 28, 2023
	4MG	A213782	006	Nov 28, 2023
AMNEAL	0.25MG	A213562	001	Jan 31, 2023
	0.5MG	A213562	002	Jan 31, 2023
	1MG	A213562	003	Jan 31, 2023
	2MG	A213562	004	Jan 31, 2023
	3MG	A213562	005	Jan 31, 2023
	4MG	A213562	006	Jan 31, 2023
APOTEX	0.25MG	A213731	001	Feb 24, 2025
	0.5MG	A213731	002	Feb 24, 2025
	1MG	A213731	003	Feb 24, 2025
	2MG	A213731	004	Feb 24, 2025
	3MG	A213731	005	Feb 24, 2025
AUROBINDO PHARMA LTD	0.25MG	A213659	001	Nov 02, 2023
	0.5MG	A213659	002	Nov 02, 2023
	1MG	A213659	003	Nov 02, 2023
	2MG	A213659	004	Nov 02, 2023
	3MG	A213659	005	Nov 02, 2023
	4MG	A213659	006	Nov 02, 2023
CHARTWELL RX	0.25MG	A213758	001	Oct 25, 2023
	0.5MG	A213758	002	Oct 25, 2023
	1MG	A213758	003	Oct 25, 2023
	2MG	A213758	004	Oct 25, 2023
	3MG	A213758	005	Oct 25, 2023
	4MG	A213758	006	Oct 25, 2023
HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023
	0.5MG	A213669	002	Nov 20, 2023
	1MG	A213669	003	Nov 20, 2023
	2MG	A213669	004	Nov 20, 2023
	3MG	A213669	005	Nov 20, 2023
	4MG	A213669	006	Nov 20, 2023
LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023
	0.5MG	A213512	002	Mar 17, 2023
	1MG	A213512	003	Mar 17, 2023
	2MG	A213512	004	Mar 17, 2023
	3MG	A213512	005	Mar 17, 2023
	4MG	A213512	006	Mar 17, 2023
SANDOZ	0.25MG	A213570	001	Sep 26, 2022
	0.5MG	A213570	002	Sep 26, 2022
	1MG	A213570	003	Sep 26, 2022
	2MG	A213570	004	Sep 26, 2022
	3MG	A213570	005	Sep 26, 2022
	4MG	A213570	006	Sep 26, 2022
TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022
	0.5MG	A213692	002	Aug 11, 2022

BREXPIPRAZOLE

TABLET;ORAL				
BREXPIPRAZOLE				
	1MG	A213692	003	Aug 11, 2022
	2MG	A213692	004	Aug 11, 2022
	3MG	A213692	005	Aug 11, 2022
	4MG	A213692	006	Aug 11, 2022
ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023
	0.5MG	A213660	002	Jan 10, 2023
	1MG	A213660	003	Jan 10, 2023
	2MG	A213660	004	Jan 10, 2023
	3MG	A213660	005	Jan 10, 2023
	4MG	A213660	006	Jan 10, 2023

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC				
ALPHAGAN				
+ ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025
	0.15%	A216772	001	Jun 12, 2024

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC				
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE				
AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC				
BRINZOLAMIDE				
PADAGIS US	1%	A211914	001	Jul 28, 2023

BRIVARACETAM

TABLET;ORAL				
BRIVARACETAM				
AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023
	100MG	A214848	002	Jan 06, 2023
LUPIN LTD	10MG	A214918	001	Dec 20, 2022
	25MG	A214918	002	Dec 20, 2022
	50MG	A214918	003	Dec 20, 2022
	75MG	A214918	004	Dec 20, 2022
	100MG	A214918	005	Dec 20, 2022
SUNSHINE	10MG	A214748	001	Jun 09, 2022
	25MG	A214748	002	Jun 09, 2022
	50MG	A214748	003	Jun 09, 2022
	75MG	A214748	004	Jun 09, 2022
	100MG	A214748	005	Jun 09, 2022
ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022
	25MG	A214501	002	Oct 03, 2022
	50MG	A214501	003	Oct 03, 2022
	75MG	A214501	004	Oct 03, 2022
	100MG	A214501	005	Oct 03, 2022

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC				
BROMDAY				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
BROMFENAC SODIUM				
AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
APOTEX	EQ 0.09% ACID	A202435	001	Jun 19, 2014
	EQ 0.09% ACID	A202620	001	Jun 23, 2014
CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015
COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
RISING	EQ 0.09% ACID	A203368	001	Jun 03, 2019
XIBROM				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL				
BROMOCRIPTINE MESYLATE				
	LEK PHARM	EQ 5MG BASE	A075100 001	Dec 10, 1998
TABLET;ORAL				
BROMOCRIPTINE MESYLATE				
	AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962 001	Sep 24, 2004

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
AMBODRYL				
	PARKE DAVIS	25MG	N007984 001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP;ORAL				
AMBENYL				
	FOREST LABS	12.5MG/5ML;10MG/5ML	N009319 006	Jan 10, 1984
BROMANYL				
	ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343 001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
	WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626 001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL				
BROMPHENIRAMINE MALEATE				
	ALPHARMA US PHARMS	2MG/5ML	A086936 001	
	KV PHARM	2MG/5ML	A085466 001	
	PHARM ASSOC	2MG/5ML	A087517 001	
	USL PHARMA	2MG/5ML	A087964 001	Jan 25, 1983
INJECTABLE;INJECTION				
BROMPHENIRAMINE MALEATE				
	WATSON LABS	10MG/ML	A083821 001	
		100MG/ML	A083820 001	
DIMETANE-TEN				
	WYETH AYERST	10MG/ML	N011418 002	
TABLET;ORAL				
BROMPHENIRAMINE MALEATE				
	BARR	4MG	A084468 001	
	IVAX SUB TEVA PHARMS	4MG	A084351 001	
	NEWTRON PHARMS	4MG	A086987 001	
	NEXGEN PHARMA INC	4MG	A086187 001	
	PAR PHARM	4MG	A087009 001	
	PIONEER PHARMS	4MG	A088604 001	Jul 13, 1984
	UPSHER SMITH LABS	4MG	A083215 001	
	VITARINE	4MG	A085850 001	
	WATSON LABS	4MG	A083123 001	
		4MG	A085769 001	
DIMETANE				
	WYETH CONS	4MG	N010799 003	
TABLET, EXTENDED RELEASE;ORAL				
DIMETANE				
	WYETH CONS	8MG	N010799 010	Jun 10, 1983
		12MG	N010799 011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL				
BROMANATE DM				
	ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722 001	Mar 07, 1985
BROMFED-DM				
	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681 001	Dec 22, 1988
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
	RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202955 001	Nov 05, 2020
	TARO	2MG/5ML;10MG/5ML;30MG/5ML	A205112 001	Feb 27, 2017
DIMETANE-DX				
+	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279 001	Aug 24, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE					
	ALZA	16MG;240MG	N019672	001	Mar 29, 1996
BUCLIZINE HYDROCHLORIDE					
TABLET;ORAL					
BUCLADIN-S					
	STUART PHARMS	50MG	N010911	006	
BUDESONIDE					
AEROSOL, METERED;NASAL					
RHINOCORT					
	ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
CAPSULE, DELAYED RELEASE;ORAL					
BUDESONIDE					
	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014
	NATCO	3MG	A206724	001	Nov 23, 2016
	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017
ORTIKOS					
+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019
+		9MG	N211929	002	Jun 13, 2019
POWDER, METERED;INHALATION					
PULMICORT					
	ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
		0.32MG/INH	N020441	003	Jun 24, 1997
SUSPENSION;INHALATION					
BUDESONIDE					
	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013
		0.5MG/2ML	A201966	002	Sep 27, 2013
		1MG/2ML	A201966	001	Sep 27, 2013
BUMETANIDE					
INJECTABLE;INJECTION					
BUMETANIDE					
	HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
		0.25MG/ML	A074332	001	Oct 31, 1994
	TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997
BUMEX					
+	VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983
BUPIVACAINE					
INJECTABLE, LIPOSOMAL;INJECTION					
BUPIVACAINE LIPOSOME					
	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024
		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024
SOLUTION;INFILTRATION					
POSIMIR					
+	INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021
BUPIVACAINE HYDROCHLORIDE					
IMPLANT;IMPLANTATION					
XARACOLL					
+	INNOCOLL PHARMS	100MG	N209511	001	Aug 28, 2020
INJECTABLE;INJECTION					
BUPIVACAINE HYDROCHLORIDE					
	CIVICA	0.5%	A211096	001	Feb 19, 2019
	HOSPIRA	0.25%	A070586	001	Mar 03, 1987
		0.25%	N018053	002	
		0.5%	N018053	001	
		0.75%	A070587	001	Mar 03, 1987
		0.75%	N018053	003	
BUPIVACAINE HYDROCHLORIDE KIT					
	HOSPIRA	0.075%	N019978	001	Sep 03, 1992
		0.114%	N019978	002	Sep 03, 1992
		0.23%	N019978	003	Sep 03, 1992
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
		0.5%	A076012	002	Jan 09, 2002
		0.75%	A076012	003	Jan 09, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;SPINAL				
BUPIVACAINE HYDROCHLORIDE				
	BAXTER HLTHCARE CORP	0.75%	A207266 001	Jul 25, 2016
SENSORCAINE				
	FRESENIUS KABI USA	0.75%	A071202 001	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
	HOSPIRA	0.25%;0.005MG/ML	A071166 001	Jun 16, 1988
		0.5%;0.005MG/ML	A071169 001	Jun 16, 1988
		0.75%;0.005MG/ML	A071171 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION				
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE				
+	HOSPIRA	0.5%;0.0091MG/ML	N022046 001	Jul 13, 1983

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DUOCAINE				
	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR				
ZYNRELEF KIT				
+	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)	N211988 001	May 12, 2021
+		300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)	N211988 003	May 12, 2021

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL				
BUPRENORPHINE				
	MYLAN TECH VIATRIS	5MCG/HR	A210162 001	May 03, 2021
		7.5MCG/HR	A210162 002	May 03, 2021
		10MCG/HR	A210162 003	May 03, 2021
		15MCG/HR	A210162 004	May 03, 2021
		20MCG/HR	A210162 005	May 03, 2021
	STRIDES PHARMA INTL	7.5MCG/HR	A207490 005	Mar 21, 2023

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION				
PROBUPHINE				
+	REACX PHARMS	EQ 80MG BASE/IMPLANT	N204442 001	May 26, 2016
INJECTABLE;INJECTION				
BUPRENEX				
+	INDIVIOR	EQ 0.3MG BASE/ML **	N018401 001	
BUPRENORPHINE HYDROCHLORIDE				
	AM REGENT	EQ 0.3MG BASE/ML	A078331 001	Mar 27, 2007
TABLET;SUBLINGUAL				
BUPRENORPHINE HYDROCHLORIDE				
	BARR	EQ 2MG BASE	A090360 001	May 07, 2010
		EQ 8MG BASE	A090360 002	May 07, 2010
	PHARMOBEDIENT	EQ 2MG BASE	A201066 001	Mar 06, 2015
		EQ 8MG BASE	A201066 002	Mar 06, 2015
SUBUTEX				
+	INDIVIOR	EQ 2MG BASE **	N020732 002	Oct 08, 2002
+		EQ 8MG BASE **	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL				
BUNAVAIL				
+	BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637 001	Jun 06, 2014
+		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637 002	Jun 06, 2014
+		EQ 6.3MG BASE;EQ 1MG BASE	N205637 003	Jun 06, 2014
FILM;SUBLINGUAL				
CASSIPA				
+	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042 001	Sep 07, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020
		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020
	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014
		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014
SUBOXONE					
+	INDIVIOR	EQ 2MG BASE;EQ 0.5MG BASE **	N020733	001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE **	N020733	002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET;ORAL					
BUPROPION HYDROCHLORIDE					
	HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999
		100MG	A075310	002	Nov 29, 1999
	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017
		100MG	A207389	002	Sep 18, 2017
	INVATECH	75MG	A075613	002	Oct 10, 2000
		100MG	A075613	001	Oct 10, 2000
WELLBUTRIN					
+	GLAXOSMITHKLINE	50MG **	N018644	001	Dec 30, 1985
+		75MG **	N018644	002	Dec 30, 1985
+		100MG **	N018644	003	Dec 30, 1985
TABLET, EXTENDED RELEASE;ORAL					
BUPROPION HYDROCHLORIDE					
	ACTAVIS LABS FL INC	300MG	A077715	002	Jun 13, 2007
	AUROBINDO PHARMA USA	150MG	A090942	001	Jul 14, 2010
		300MG	A090942	002	Jul 14, 2010
	CHARTWELL RX	150MG	A076834	001	Jul 14, 2005
	IMPAX LABS	150MG	A077415	001	Nov 26, 2008
		200MG	A076711	001	Dec 03, 2004
		300MG	A077415	002	Dec 15, 2006
	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016
		150MG	A206556	001	Aug 26, 2016
		150MG	A206674	002	Feb 09, 2016
		200MG	A206674	003	Feb 09, 2016
		300MG	A206556	002	Aug 26, 2016
	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013
		150MG	A202774	002	Oct 11, 2013
		150MG	A202775	001	Oct 11, 2013
		150MG	A207459	001	Jun 30, 2017
		200MG	A202774	003	Oct 11, 2013
		300MG	A207459	002	Jun 30, 2017
	PH HEALTH	100MG	A091459	001	Jun 09, 2011
		150MG	A077284	001	Dec 14, 2006
		150MG	A091459	002	Jun 09, 2011
		150MG	A091520	001	Jun 09, 2011
		200MG	A091459	003	Jun 09, 2011
		300MG	A077284	002	Dec 14, 2006
	RISING	150MG	A090941	001	May 03, 2010
	SANDOZ	100MG	A076845	001	Jul 14, 2005
		150MG	A076845	002	Jul 14, 2005
	SUN PHARM	100MG	A078866	001	Apr 06, 2010
		150MG	A078866	002	Apr 06, 2010
		150MG	A200216	001	Nov 30, 2020
		150MG	A200695	001	Dec 18, 2014
		200MG	A078866	003	Apr 06, 2010
		300MG	A203650	001	Dec 31, 2020
	TORRENT	100MG	A203969	001	Oct 31, 2014
		150MG	A203969	002	Oct 31, 2014
		200MG	A203969	003	Oct 31, 2014
	TWI PHARMS	150MG	A210081	001	Nov 03, 2017
		300MG	A210081	002	Nov 03, 2017
	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010
		150MG	A077455	002	Mar 12, 2008
		200MG	A077455	003	Jul 19, 2010
	WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
		150MG	A201331	002	Aug 30, 2012
		200MG	A201331	003	Aug 30, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPROPION HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
WELLBUTRIN SR				
	GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996
ZYBAN				
	GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997
+		150MG **	N020711 003	May 14, 1997
BUSPIRONE HYDROCHLORIDE				
CAPSULE;ORAL				
BUSPAR				
+	BRISTOL MYERS SQUIBB	5MG **	N021190 001	Dec 20, 2000
+		7.5MG **	N021190 002	Dec 20, 2000
+		10MG **	N021190 003	Dec 20, 2000
+		15MG **	N021190 004	Dec 20, 2000
TABLET;ORAL				
BUSPAR				
+	BRISTOL MYERS SQUIBB	5MG **	N018731 001	Sep 29, 1986
+		10MG **	N018731 002	Sep 29, 1986
+		15MG **	N018731 003	Apr 22, 1996
+		30MG **	N018731 004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE				
	AMNEAL PHARMS CO	5MG	A208829 001	May 24, 2017
		7.5MG	A208829 002	May 24, 2017
		10MG	A208829 003	May 24, 2017
		15MG	A208829 004	May 24, 2017
		30MG	A208829 005	May 24, 2017
	EGIS	5MG	A075119 001	Mar 14, 2002
		10MG	A075119 002	Mar 14, 2002
		15MG	A075119 003	Jan 23, 2003
	IVAX SUB TEVA PHARMS	5MG **	A075385 001	Mar 01, 2002
		10MG **	A075385 002	Mar 01, 2002
		15MG **	A075385 003	Mar 01, 2002
	MYLAN	5MG	A075467 001	Feb 28, 2002
		7.5MG	A075467 002	Mar 28, 2001
		10MG	A075467 003	Feb 28, 2002
		15MG	A075467 004	Feb 28, 2002
	NESHER PHARMS	5MG	A075572 001	Feb 27, 2002
		10MG	A075572 002	Feb 27, 2002
		15MG	A075572 003	Feb 27, 2002
BUSULFAN				
INJECTABLE;INJECTION				
BUSULFAN				
	ACTAVIS	6MG/ML	A205139 001	Dec 08, 2017
	AM REGENT	6MG/ML	A202259 001	Dec 22, 2015
	APOTEX	6MG/ML	A210448 001	May 07, 2019
	ARTHUR GRP	6MG/ML	A205106 001	Sep 21, 2018
	EUGIA PHARMA	6MG/ML	A215102 001	Jun 25, 2024
	NEXUS	6MG/ML	A207794 001	Jan 14, 2019
	PHARMOBEDIENT	6MG/ML	A205184 001	Jul 13, 2018
BUTABARBITAL SODIUM				
CAPSULE;ORAL				
BUTICAPS				
	MEDPOINTE PHARM HLC	15MG	A085381 001	
		30MG	A085381 002	
		50MG	A085381 003	
		100MG	A085381 004	
ELIXIR;ORAL				
BUTABARB				
	ALPHARMA US PHARMS	30MG/5ML	A085873 001	
BUTABARBITAL SODIUM				
	WOCKHARDT	30MG/5ML	A085383 001	
BUTALAN				
	LANNETT	33.3MG/5ML	A085880 001	
BUTISOL SODIUM				
	MEDA PHARMS	30MG/5ML	A085380 001	
SARISOL				
	HALSEY	30MG/5ML	A084723 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUTABARBITAL SODIUM				
TABLET;ORAL				
BUTABARBITAL				
BUNDY	30MG	A085550	001	
BUTABARBITAL SODIUM				
SANDOZ	15MG	A084292	003	Feb 09, 1982
+	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	
BUTISOL SODIUM				
PHARMOBEDIENT	15MG **	N000793	002	
+	30MG	N000793	004	
	50MG **	N000793	003	
	100MG **	N000793	005	
SARISOL NO. 1				
HALSEY	15MG	A084719	001	
SARISOL NO. 2				
HALSEY	30MG	A084719	002	
SODIUM BUTABARBITAL				
HIKMA	15MG	A085418	001	
	30MG	A085432	001	
IVAX SUB TEVA PHARMS	15MG	A083484	001	
	30MG	A084040	001	
LANNETT	15MG	A085849	001	
	30MG	A085866	001	
	100MG	A085881	001	
MARSHALL PHARMA	16.2MG	A083524	001	
	32.4MG	A083858	001	
BUTENAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
MENTAX				
+ PHARMOBEDIENT	1%	N020524	001	Oct 18, 1996
MENTAX-TC				
PHARMOBEDIENT	1%	N021408	001	Oct 17, 2002
BUTOCONAZOLE NITRATE				
CREAM;VAGINAL				
BUTOCONAZOLE NITRATE				
PADAGIS US	2%	N019881	001	Feb 07, 1997
FEMSTAT				
ROCHE PALO	2%	N019215	001	Nov 25, 1985
FEMSTAT 3				
+ BAYER	2%	N020421	001	Dec 21, 1995
SUPPOSITORY;VAGINAL				
FEMSTAT				
ROCHE PALO	100MG	N019359	001	Nov 25, 1985
BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE				
BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001
HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009
HOSPIRA	1MG/ML	A075342	001	Nov 04, 1999
	1MG/ML	A075559	001	Mar 20, 2000
	2MG/ML	A075342	002	Nov 04, 1999
	2MG/ML	A075559	002	Mar 20, 2000
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001
	2MG/ML	A075695	002	Oct 23, 2001
HOSPIRA	1MG/ML	A074620	001	Jan 22, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
	1MG/ML	A075170	001	Sep 28, 1998
	2MG/ML	A074620	002	Jan 22, 1997
	2MG/ML	A075170	002	Sep 28, 1998
STADOL				
+ APOTHECON	2MG/ML **	N017857	004	
STADOL PRESERVATIVE FREE				
+ APOTHECON	1MG/ML **	N017857	001	
+	2MG/ML **	N017857	002	
SPRAY, METERED;NASAL				
BUTORPHANOL TARTRATE				
RISING	1MG/SPRAY	A075759	001	Aug 08, 2001
STADOL				
+ BRISTOL MYERS SQUIBB	1MG/SPRAY **	N019890	001	Dec 12, 1991
CABAZITAXEL				
SOLUTION;INTRAVENOUS				
CABAZITAXEL				
+ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021
+ ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024
APOTEX	60MG/1.5ML (40MG/ML)	A207736	001	Feb 10, 2023
BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022
MYLAN LABS LTD	60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023
CABERGOLINE				
TABLET;ORAL				
CABERGOLINE				
ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008
APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013
IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007
PHARMOBEDIENT	0.5MG	A202947	001	Dec 02, 2013
DOSTINEX				
+ PFIZER	0.5MG **	N020664	001	Dec 23, 1996
CAFFEINE CITRATE				
SOLUTION;INTRAVENOUS				
CAFFEINE CITRATE				
EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015
SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009
SOLUTION;ORAL				
CAFCIT				
+ HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **	N020793	002	Apr 12, 2000
CAFFEINE CITRATE				
AM REGENT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009
SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009
CAFFEINE; ERGOTAMINE TARTRATE				
SUPPOSITORY;RECTAL				
CAFERGOT				
+ NOVARTIS	100MG;2MG **	N009000	002	
TABLET;ORAL				
CAFERGOT				
+ CHARTWELL RX	100MG;1MG	A084294	001	
NOVARTIS	100MG;1MG	N006620	001	
ERGOTAMINE TARTRATE AND CAFFEINE				
HIKMA INTL PHARMS	100MG;1MG	A040510	001	Sep 17, 2004
WIGRAINE				
ORGANON USA INC	100MG;1MG	A086562	001	
CALCIFEDIOL				
CAPSULE;ORAL				
CALDEROL				
ORGANON USA INC	0.02MG	N018312	001	
	0.05MG	N018312	002	

CALCIPOTRIENE				
CREAM;TOPICAL				
CALCIPOTRIENE				
CHARTWELL RX	0.005%	A200935	001	May 30, 2012
SOLUTION;TOPICAL				
CALCIPOTRIENE				
CHARTWELL RX	0.005%	A077029	001	Nov 20, 2009
HIKMA	0.005%	A077579	001	Nov 19, 2009
DOVONEX				
+ LEO PHARM	0.005% **	N020611	001	Mar 03, 1997
CALCITONIN HUMAN				
INJECTABLE;INJECTION				
CIBACALCIN				
NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
CALCITONIN SALMON				
INJECTABLE;INJECTION				
CALCIMAR				
+ SANOFI AVENTIS US	200 IU/ML **	N017769	001	
	400 IU/VIAL	N017497	001	
CALCITONIN-SALMON				
IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995
MIACALCIN				
+ MYLAN IRELAND LTD	100 IU/ML **	N017808	001	Jul 03, 1986
SPRAY, METERED;NASAL				
MIACALCIN				
+ PHARMOBEDIENT	200 IU/SPRAY **	N020313	002	Aug 17, 1995
CALCITONIN SALMON RECOMBINANT				
SPRAY, METERED;NASAL				
FORTICAL				
UPSHER SMITH LABS	200 IU/SPRAY **	N021406	001	Aug 12, 2005
CALCITRIOL				
CAPSULE;ORAL				
CALCITRIOL				
SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019
	0.5MCG	A204556	002	Feb 21, 2019
INJECTABLE;INJECTION				
CALCIJEX				
+ ABBVIE	0.001MG/ML **	N018874	001	Sep 25, 1986
+	0.002MG/ML **	N018874	002	Sep 25, 1986
CALCITRIOL				
AM REGENT	0.001MG/ML	A075746	001	Sep 26, 2003
	0.002MG/ML	A075746	002	Sep 26, 2003
FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
	0.002MG/ML	A075836	002	Dec 31, 2002
FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
	0.002MG/ML	A075766	002	Feb 20, 2003
HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
	0.002MG/ML	A075816	002	Jan 16, 2004
LONG GROVE PHARMS	0.002MG/ML	A078066	002	Jan 29, 2008
ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006
TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003
	0.002MG/ML	A075823	002	Mar 31, 2003
CALCIUM ACETATE				
CAPSULE;ORAL				
CALCIUM ACETATE				
AMNEAL PHARMS	667MG	A201658	001	Oct 06, 2014
LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016
PHOSLO				
FRESENIUS MEDCL CARE	333.5MG	N021160	001	Apr 02, 2001
	667MG	N021160	002	Apr 02, 2001
PHOSLO GELCAPS				
+ FRESENIUS MEDCL CARE	667MG **	N021160	003	Apr 02, 2001
SOLUTION;ORAL				
PHOSLYRA				
+ FRESENIUS MEDCL CARE	667MG/5ML	N022581	001	Apr 18, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM ACETATE

TABLET;ORAL

CALCIUM ACETATE

	HIKMA	667MG	A077693	001	Jan 30, 2008

ELIPHOS

	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008

PHOSLO

+	FRESENIUS MEDCL CARE	667MG **	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

	PERRIGO R AND D	800MG;10MG;165MG	A204782	001	Aug 29, 2016

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+	WARNER CHILCOTT	EQ 500MG BASE;35MG **	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

METHOTREXATE SODIUM

	EPIC PHARMA LLC	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N020079	001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	VANTIVE US HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

	VANTIVE US HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867	001	Dec 20, 1993
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML **	N017390	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	001	Aug 26, 1983
	510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	003	Aug 26, 1983
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER				
B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	002	Aug 26, 1983
	510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	004	Aug 26, 1983
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	002	
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	003	
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001	
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	007	Jan 29, 1986
		26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	005	Nov 02, 1983
		26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460	009	Jan 29, 1986
		26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374	004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER					
	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018254	001	
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256	001	
		33MG/100ML;5GM/100ML;30MG/100ML;	N020000	001	Apr 17, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	860MG/100ML			
BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634	002	Feb 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S

FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510	001	
MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499	001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988
+		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021
+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	004	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+	OTSUKA ICU MEDCL	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989

SOLUTION;IRRIGATION

BALANCED SALT

EPIC PHARMA LLC	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A075503	001	Sep 27, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION					
PLASMA-LYTE R IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML; 640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ACETATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG /100ML	N018725	001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721	001	Nov 09, 1982
SOLUTION;IRRIGATION					
RINGER'S IN PLASTIC CONTAINER					
	ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION					
LACTATED RINGER'S IN PLASTIC CONTAINER					
	ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019485	001	Oct 24, 1985
	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018023	001	
	MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018417	001	
SOLUTION;IRRIGATION					
LACTATED RINGER'S IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019933	001	Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION					
CALCIUM GLUCEPTATE					
+	ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
		EQ 90MG CALCIUM/5ML	A083159	001	
	ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
	LILLY	EQ 90MG CALCIUM/5ML	N006470	001	

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS					
CALCIUM GLUCONATE IN SODIUM CHLORIDE					
+	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021
+		2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE;INJECTION					
ISOPAQUE 440					
	GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847	001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE;INJECTION					
ISOPAQUE 280					
	GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506	001	

CANDESARTAN CILEXETIL

TABLET;ORAL					
CANDESARTAN CILEXETIL					
	APOTEX	4MG	A202079	001	Jan 10, 2014
		8MG	A202079	002	Jan 10, 2014
		16MG	A202079	003	Jan 10, 2014
		32MG	A202079	004	Jan 10, 2014

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE					
	APOTEX INC	16MG;12.5MG	A202884	001	Dec 04, 2012
		32MG;12.5MG	A202884	002	Dec 04, 2012
		32MG;25MG	A202884	003	Jun 03, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CANDICIDIN				
OINTMENT;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	0.6MG/GM	A061596 001	
TABLET;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	3MG	A061613 001	
CAPECITABINE				
TABLET;ORAL				
CAPECITABINE				
	AMNEAL PHARMS	150MG	A204741 001	Feb 28, 2017
		500MG	A204741 002	Feb 28, 2017
	HIKMA	150MG	A200483 001	Jul 14, 2016
		500MG	A200483 002	Jul 14, 2016
	SUN PHARM	150MG	A204668 001	Jun 21, 2019
		500MG	A204668 002	Jun 21, 2019
CAPREOMYCIN SULFATE				
INJECTABLE;INJECTION				
CAPASTAT SULFATE				
+	EPIC PHARMA LLC	EQ 1GM BASE/VIAL **	N050095 001	
CAPREOMYCIN SULFATE				
	HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796 001	Oct 18, 2018
	PHARMOBEDIENT	EQ 1GM BASE/VIAL	A202634 001	Nov 27, 2017
CAPTOPRIL				
TABLET;ORAL				
CAPOTEN				
+	AARXION ANDA HLDING	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995
CAPTOPRIL				
	APOTHECON	12.5MG	A074472 001	Mar 31, 1995
		25MG	A074472 002	Mar 31, 1995
		50MG	A074472 003	Mar 31, 1995
		100MG	A074472 004	Mar 31, 1995
	AUROBINDO PHARMA USA	12.5MG	A074434 001	Feb 13, 1996
		25MG	A074434 002	Feb 13, 1996
		50MG	A074434 003	Feb 13, 1996
		100MG	A074434 004	Feb 13, 1996
	CHARTWELL RX	12.5MG	A074363 001	Nov 09, 1995
		12.5MG	A074519 001	Feb 13, 1996
		25MG	A074363 002	Nov 09, 1995
		25MG	A074519 002	Feb 13, 1996
		50MG	A074363 003	Nov 09, 1995
		50MG	A074519 003	Feb 13, 1996
		100MG	A074363 004	Nov 09, 1995
		100MG	A074519 004	Feb 13, 1996
	COSETTE	12.5MG	A074433 001	Feb 13, 1996
		12.5MG	A074462 001	Feb 13, 1996
		12.5MG	A074483 001	Feb 13, 1996
		25MG	A074433 002	Feb 13, 1996
		25MG	A074462 002	Feb 13, 1996
		25MG	A074483 002	Feb 13, 1996
		50MG	A074433 003	Feb 13, 1996
		50MG	A074462 003	Feb 13, 1996
		50MG	A074483 003	Feb 13, 1996
		100MG	A074433 004	Feb 13, 1996
		100MG	A074462 004	Feb 13, 1996
		100MG	A074483 004	Feb 13, 1996
	DAVA PHARMS INC	12.5MG	A074423 001	Feb 13, 1996
		25MG	A074423 002	Feb 13, 1996
		50MG	A074423 003	Feb 13, 1996
		100MG	A074423 004	Feb 13, 1996
	EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
		25MG	A074748 002	May 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL				
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019
	25MG	A212223	002	Oct 30, 2019
	50MG	A212223	003	Oct 30, 2019
	100MG	A212223	004	Oct 30, 2019
STRIDES PHARMA INTL	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
TEVA	12.5MG	A074322	001	Feb 13, 1996
	25MG	A074322	002	Feb 13, 1996
	50MG	A074322	003	Feb 13, 1996
	100MG	A074322	004	Feb 13, 1996
WATSON LABS	12.5MG	A074386	001	May 23, 1996
	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074386	002	May 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074386	003	May 23, 1996
	50MG	A074451	003	Feb 13, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074386	004	May 23, 1996
	100MG	A074451	004	Feb 13, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPOZIDE 25/15				
+ APOTHECON	25MG;15MG **	N018709	001	Oct 12, 1984
CAPOZIDE 25/25				
+ APOTHECON	25MG;25MG **	N018709	002	Oct 12, 1984
CAPOZIDE 50/15				
+ APOTHECON	50MG;15MG **	N018709	004	Oct 12, 1984
CAPOZIDE 50/25				
+ APOTHECON	50MG;25MG **	N018709	003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE				
COSETTE	25MG;15MG	A074827	001	Dec 29, 1997
	25MG;25MG	A074827	002	Dec 29, 1997
	50MG;15MG	A074827	004	Dec 29, 1997
	50MG;25MG	A074827	003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
	25MG;25MG	A075055	002	Jun 18, 1998
	50MG;15MG	A075055	004	Jun 18, 1998
	50MG;25MG	A075055	003	Jun 18, 1998
STRIDES PHARMA INTL	25MG;15MG	A074788	001	Dec 29, 1997
	25MG;25MG	A074788	002	Dec 29, 1997
	50MG;15MG	A074788	004	Dec 29, 1997
	50MG;25MG	A074788	003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBACHOL				
SOLUTION;INTRAOCULAR				
CARBACHOL				
PHARMAFAIR	0.01%		A070292 001	May 21, 1986
CARBASTAT				
NOVARTIS	0.01%		A073677 001	Apr 28, 1995
CARBAMAZEPINE				
CAPSULE, EXTENDED RELEASE;ORAL				
CARBAMAZEPINE				
TARO	100MG		A201106 001	Jun 21, 2013
	200MG		A201106 002	Jun 21, 2013
	300MG		A201106 003	Jun 21, 2013
SOLUTION;INTRAVENOUS				
CARNEXIV				
+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)		N206030 001	Oct 07, 2016
SUSPENSION;ORAL				
CARBAMAZEPINE				
TARO	100MG/5ML		A075875 001	Dec 21, 2000
TABLET;ORAL				
CARBAMAZEPINE				
ACTAVIS ELIZABETH	200MG		A071696 001	Nov 09, 1987
INWOOD LABS	200MG		A070231 001	Aug 14, 1986
PLIVA	200MG		A071479 001	Jul 24, 1987
RK PHARMA	200MG		A214328 001	Aug 16, 2021
TORRENT PHARMS	100MG		A077272 001	Dec 07, 2005
	300MG		A077272 003	Dec 07, 2005
	400MG		A077272 004	Dec 07, 2005
USL PHARMA	200MG		A070300 001	May 15, 1986
WARNER CHILCOTT	200MG		A070429 001	Jan 02, 1987
TERIL				
TARO	200MG		A076525 001	Sep 26, 2003
TABLET, CHEWABLE;ORAL				
CARBAMAZEPINE				
JUBILANT CADISTA	100MG		A071940 001	Feb 01, 1988
TEGRETOL				
+ NOVARTIS	100MG **		N018281 001	
TABLET, EXTENDED RELEASE;ORAL				
CARBAMAZEPINE				
AJANTA PHARMA LTD	100MG		A216193 001	Mar 24, 2023
	200MG		A216193 002	Mar 24, 2023
	400MG		A216193 003	Mar 24, 2023
AMNEAL PHARMS	100MG		A212704 001	Sep 22, 2023
	200MG		A212704 002	Sep 22, 2023
	400MG		A212704 003	Sep 22, 2023
APOTEX	100MG		A213159 001	Mar 08, 2024
	200MG		A213159 002	Mar 08, 2024
	400MG		A213159 003	Mar 08, 2024
OSMOTICA PHARM US	100MG		A215664 001	Oct 22, 2024
	200MG		A215664 002	Oct 22, 2024
	400MG		A215664 003	Oct 22, 2024
CARBENICILLIN DISODIUM				
INJECTABLE;INJECTION				
GEOPEN				
ROERIG	EQ 1GM BASE/VIAL		N050306 001	
	EQ 2GM BASE/VIAL		N050306 004	
	EQ 5GM BASE/VIAL		N050306 002	
	EQ 10GM BASE/VIAL		N050306 006	
	EQ 30GM BASE/VIAL		N050306 007	
PYOPEN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL		N050298 001	
	EQ 2GM BASE/VIAL		N050298 002	
	EQ 5GM BASE/VIAL		N050298 003	
	EQ 10GM BASE/VIAL		N050298 006	
	EQ 20GM BASE/VIAL		N050298 007	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBENICILLIN INDANYL SODIUM

TABLET;ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE	N050435	001	

CARBIDOPA

TABLET;ORAL				
CARBIDOPA				
ALVOGEN	25MG	A204291	001	Jan 08, 2016
ANI PHARMS	25MG	A203261	001	Mar 10, 2014

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL				
CARBIDOPA, LEVODOPA AND ENTACAPONE				
PHARMOBEDIENT	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020
	18.75MG;200MG;75MG	A203424	002	Aug 13, 2020
	25MG;200MG;100MG	A203424	003	Aug 13, 2020
	31.25MG;200MG;125MG	A203424	004	Aug 13, 2020
	37.5MG;200MG;150MG	A203424	005	Aug 13, 2020
	50MG;200MG;200MG	A203424	006	Aug 13, 2020
SUN PHARM	25MG;200MG;100MG	A079085	001	May 10, 2012
	37.5MG;200MG;150MG	A079085	002	May 10, 2012
WOCKHARDT LTD	12.5MG;200MG;50MG	A090786	001	Nov 20, 2012
	18.75MG;200MG;75MG	A090833	001	Nov 20, 2012
	25MG;200MG;100MG	A090833	002	Nov 20, 2012
	31.25MG;200MG;125MG	A090833	003	Nov 20, 2012
	37.5MG;200MG;150MG	A090833	004	Nov 20, 2012
	50MG;200MG;200MG	A090833	005	Nov 20, 2012

CARBIDOPA; LEVODOPA

TABLET;ORAL				
CARBIDOPA AND LEVODOPA				
ANI PHARMS	10MG;100MG	A073587	002	Jun 29, 1995
	25MG;100MG	A073587	001	Jun 29, 1995
	25MG;250MG	A073587	003	Jun 29, 1995
APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008
	25MG;100MG	A077120	002	Jun 02, 2008
	25MG;250MG	A077120	003	Jun 02, 2008
PHARMOBEDIENT	10MG;100MG	A090324	001	Sep 28, 2009
	25MG;250MG	A090324	003	Sep 28, 2009
SCS	10MG;100MG	A074080	001	Mar 25, 1994
	25MG;100MG	A074080	002	Mar 25, 1994
	25MG;250MG	A074080	003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381	001	Sep 28, 1993
	25MG;100MG	A073382	001	Sep 28, 1993
	25MG;250MG	A073383	001	Sep 28, 1993
ZYDUS PHARMS	10MG;100MG	A215999	001	Apr 04, 2023
	25MG;100MG	A215999	002	Apr 04, 2023
	25MG;250MG	A215999	003	Apr 04, 2023
TABLET, EXTENDED RELEASE;ORAL				
CARBIDOPA AND LEVODOPA				
APOTEX	25MG;100MG	A076212	001	Jun 16, 2004
	50MG;200MG	A076212	002	Jun 16, 2004
KV PHARM	50MG;200MG	A076663	001	Jun 24, 2004
SINEMET CR				
+ ORGANON LLC	25MG;100MG **	N019856	002	Dec 24, 1992
+	50MG;200MG **	N019856	001	May 30, 1991
TABLET, FOR SUSPENSION;ORAL				
CARBILEV				
RANBAXY	10MG;100MG	A076643	001	Jun 10, 2005
	25MG;100MG	A076643	002	Jun 10, 2005
	25MG;250MG	A076643	003	Jun 10, 2005
TABLET, ORALLY DISINTEGRATING;ORAL				
CARBIDOPA AND LEVODOPA				
IMPAX LABS	10MG;100MG	A090631	001	Jun 08, 2010
	25MG;100MG	A090631	002	Jun 08, 2010
	25MG;250MG	A090631	003	Jun 08, 2010
PARCOPA				
UCB INC	10MG;100MG **	A076699	001	Aug 27, 2004
	25MG;100MG **	A076699	002	Aug 27, 2004
	25MG;250MG **	A076699	003	Aug 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBINOXAMINE MALEATE				
ELIXIR;ORAL				
CLISTIN				
+ MCNEIL	4MG/5ML **	N008955 001		
SOLUTION;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG/5ML	A090418 001	May 04, 2010	
PH HEALTH	4MG/5ML	A040814 001	Feb 26, 2008	
TABLET;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG	A090417 001	Aug 23, 2010	
SENORES PHARMS	4MG	A090435 001	Apr 15, 2010	
STRIDES PHARMA INTL	4MG	A040639 002	May 30, 2008	
CLISTIN				
+ ORTHO MCNEIL PHARM	4MG **	N008915 001		
CARBOPLATIN				
INJECTABLE;INJECTION				
CARBOPLATIN				
CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	
	150MG/VIAL	A077383 002	Jan 27, 2006	
	450MG/VIAL	A077383 003	Jan 27, 2006	
FRESENIUS KABI USA	50MG/VIAL	A076235 001	Oct 14, 2004	
	150MG/VIAL	A076235 002	Oct 14, 2004	
	450MG/VIAL	A076235 003	Oct 14, 2004	
HIKMA	50MG/VIAL	A076099 001	Oct 14, 2004	
	150MG/VIAL	A076099 002	Oct 14, 2004	
	450MG/VIAL	A076099 003	Oct 14, 2004	
HOSPIRA	50MG/VIAL	A076473 001	Oct 27, 2004	
	150MG/VIAL	A076473 002	Oct 27, 2004	
	450MG/VIAL	A076473 003	Oct 27, 2004	
NATCO PHARMA USA	50MG/VIAL	A091510 001	May 29, 2012	
	150MG/VIAL	A091510 002	May 29, 2012	
	450MG/VIAL	A091510 003	May 29, 2012	
PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004	
	150MG/VIAL	A076602 002	Nov 16, 2004	
	450MG/VIAL	A076602 003	Nov 16, 2004	
SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005	
	150MG/VIAL	A076959 002	Mar 18, 2005	
	450MG/VIAL	A076959 003	Mar 18, 2005	
WATSON LABS TEVA	50MG/VIAL	A076162 001	Oct 14, 2004	
	150MG/VIAL	A076162 002	Oct 14, 2004	
	450MG/VIAL	A076162 003	Oct 14, 2004	
PARAPLATIN				
+ CORDEN PHARMA	50MG/VIAL **	N019880 001	Mar 03, 1989	
+	150MG/VIAL **	N019880 002	Mar 03, 1989	
+	450MG/VIAL **	N019880 003	Mar 03, 1989	
INJECTABLE;INTRAVENOUS				
CARBOPLATIN				
ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	
	150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	
	450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	
	600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	
FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432 001	Sep 29, 2006	
	150MG/15ML (10MG/ML)	A077432 002	Sep 29, 2006	
	450MG/45ML (10MG/ML)	A077432 003	Sep 29, 2006	
	50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004	
	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006	
	150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004	
	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006	
	450MG/45ML (10MG/ML)	A077247 003	Oct 21, 2004	
MEITHEAL	50MG/5ML (10MG/ML)	A077096 001	Jun 14, 2005	
	150MG/15ML (10MG/ML)	A077096 002	Jun 14, 2005	
	450MG/45ML (10MG/ML)	A077096 003	Jun 14, 2005	
	600MG/60ML (10MG/ML)	A077096 004	Jun 03, 2013	
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009	
	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009	
	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009	
PHARMOBEDIENT	50MG/5ML (10MG/ML)	A077998 001	Apr 24, 2007	
	50MG/5ML (10MG/ML)	A091063 001	Nov 09, 2011	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007
	150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011
	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007
	450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011
	600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011
	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011
PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008
	150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008
	450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008
	600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005
	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005
	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005
	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005

PARAPLATIN

+ CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
+	150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
+	450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003
+	600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004

SOLUTION;INTRAVENOUS

KYXATA

+ AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020
	60MG/VIAL	A209425	001	Mar 16, 2020
BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021
	60MG/VIAL	A209330	002	Jun 11, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022
	EQ 3MG BASE	A213932	002	Sep 30, 2022
	EQ 4.5MG BASE	A213932	003	Sep 30, 2022
	EQ 6MG BASE	A213932	004	Sep 30, 2022
ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022
	EQ 3MG BASE	A213984	002	Sep 09, 2022
	EQ 4.5MG BASE	A213984	003	Sep 09, 2022
	EQ 6MG BASE	A213984	004	Sep 09, 2022

CARISOPRODOL

CAPSULE;ORAL

SOMA

+ MYLAN SPECIALITY LP	250MG	N011792	003	

TABLET;ORAL

CARISOPRODOL

ABLE	350MG	A040421	001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A089566	001	Aug 30, 1988
STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015
	350MG	A205513	002	Nov 12, 2015
SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARISOPRODOL				
TABLET;ORAL				
CARISOPRODOL				
	WATSON LABS TEVA	350MG	A086179 001	
RELA				
	SCHERING	350MG	N012155 001	
CARMUSTINE				
INJECTABLE;INJECTION				
CARMUSTINE				
	ACCORD HLTHCARE	100MG/VIAL	A214117 001	Dec 27, 2022
	HENGRUI PHARMA	100MG/VIAL	A211202 001	Mar 12, 2021
	NOVAST LABS	100MG/VIAL	A211011 001	Jun 21, 2022
	PHARMOBEDIENT	100MG/VIAL	A215368 001	Mar 03, 2023
POWDER;INTRAVENOUS				
CARMUSTINE				
+	ACCORD HLTHCARE	50MG/VIAL	N215000 001	May 16, 2022
+		300MG/VIAL	N215000 002	May 16, 2022
CARPHENAZINE MALEATE				
CONCENTRATE;ORAL				
PROKETAZINE				
	WYETH AYERST	50MG/ML	N014173 001	
TABLET;ORAL				
PROKETAZINE				
	WYETH AYERST	12.5MG	N012768 001	
		25MG	N012768 002	
		50MG	N012768 004	
CARPROFEN				
TABLET;ORAL				
RIMADYL				
	ROCHE	100MG	N018550 002	Dec 31, 1987
		150MG	N018550 003	Dec 31, 1987
CARTEOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
CARTEOLOL HYDROCHLORIDE				
	APOTEX INC	1%	A076097 001	Feb 06, 2002
	BAUSCH AND LOMB	1%	A075546 001	Jan 20, 2000
OCUPRESS				
+	NOVARTIS	1% **	N019972 001	May 23, 1990
TABLET;ORAL				
CARTROL				
	ABBVIE	2.5MG	N019204 001	Dec 28, 1988
		5MG	N019204 002	Dec 28, 1988
		10MG	N019204 003	Dec 28, 1988
CARVEDILOL				
TABLET;ORAL				
CARVEDILOL				
	HIKMA	3.125MG	A077887 001	Sep 07, 2007
		6.25MG	A077887 002	Sep 07, 2007
		12.5MG	A077887 003	Sep 07, 2007
		25MG	A077887 004	Sep 07, 2007
	PHARMOBEDIENT	3.125MG	A077316 001	Sep 05, 2007
		6.25MG	A077316 002	Sep 05, 2007
		12.5MG	A077316 003	Sep 05, 2007
		25MG	A077316 004	Sep 05, 2007
	PLIVA HRVATSKA DOO	3.125MG	A078240 001	Oct 30, 2007
		6.25MG	A078240 002	Oct 30, 2007
		12.5MG	A078240 003	Oct 30, 2007
		25MG	A078240 004	Oct 30, 2007
	SUN PHARM INDS INC	3.125MG	A077346 004	Sep 05, 2007
		6.25MG	A077346 001	Sep 05, 2007
		12.5MG	A077346 002	Sep 05, 2007
		25MG	A077346 003	Sep 05, 2007
	SUN PHARM INDS LTD	3.125MG	A076989 001	Sep 05, 2007
		6.25MG	A076989 002	Sep 05, 2007
		12.5MG	A076989 003	Sep 05, 2007
		25MG	A076989 004	Sep 05, 2007
	TARO	3.125MG	A077780 001	Sep 05, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARVEDILOL				
TABLET;ORAL				
CARVEDILOL				
	6.25MG	A077780	002	Sep 05, 2007
	12.5MG	A077780	003	Sep 05, 2007
	25MG	A077780	004	Sep 05, 2007
CASPOFUNGIN ACETATE				
POWDER;INTRAVENOUS				
CANCIDAS				
+ MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+	70MG/VIAL	N021227	002	Jan 26, 2001
CASPOFUNGIN ACETATE				
CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018
	70MG/VIAL	A209489	002	Jul 12, 2018
PHARMOBEDIENT	50MG/VIAL	A207650	001	Sep 29, 2017
	70MG/VIAL	A207650	002	Sep 29, 2017
XELLIA PHARMS APS	50MG/VIAL	A205923	001	Jul 02, 2018
	70MG/VIAL	A205923	002	Jul 02, 2018
CEFACLOR				
CAPSULE;ORAL				
CECLOR				
+ LILLY	EQ 250MG BASE **	N050521	001	
+	EQ 500MG BASE **	N050521	002	
CEFACLOR				
CEPH INTL	EQ 250MG BASE	A062205	001	
	EQ 500MG BASE	A062205	002	
CHARTWELL RX	EQ 250MG BASE	A064148	001	May 23, 1996
	EQ 500MG BASE	A064148	002	May 23, 1996
DAVA PHARMS INC	EQ 250MG BASE	A064107	001	Apr 27, 1995
	EQ 500MG BASE	A064107	002	Apr 27, 1995
HIKMA	EQ 250MG BASE	A065350	001	Apr 03, 2007
	EQ 500MG BASE	A065350	002	Apr 03, 2007
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061	001	Apr 27, 1995
	EQ 500MG BASE	A064061	002	Apr 27, 1995
RANBAXY	EQ 250MG BASE	A064156	001	Aug 28, 1997
	EQ 500MG BASE	A064156	002	Aug 28, 1997
TEVA	EQ 250MG BASE	A064081	001	Sep 16, 1996
	EQ 250MG BASE	A064145	001	Jun 24, 1996
	EQ 500MG BASE	A064081	002	Sep 16, 1996
	EQ 500MG BASE	A064145	002	Jun 24, 1996
FOR SUSPENSION;ORAL				
CECLOR				
+ LILLY	EQ 125MG BASE/5ML **	N050522	001	
+	EQ 250MG BASE/5ML **	N050522	002	
CEFACLOR				
DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110	001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206	001	
	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206	002	
	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070	001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204	001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205	001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206	001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207	001	Feb 18, 1998
TABLET, CHEWABLE;ORAL				
RANICLOR				
RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFACLOR

TABLET, CHEWABLE;ORAL				
RANICLOR				
	EQ 187MG BASE	A065092	002	Dec 22, 2003
	EQ 250MG BASE	A065092	003	Dec 22, 2003
	EQ 375MG BASE	A065092	004	Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL				
CECLOR CD				
LILLY	EQ 375MG BASE **	N050673	001	Jun 28, 1996
	EQ 500MG BASE **	N050673	002	Jun 28, 1996
CEFACLOR				
WORLD GEN	EQ 500MG BASE	A065057	001	Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
CEFADROXIL				
CHARTWELL RX	EQ 500MG BASE	A065309	001	Sep 18, 2006
CSPC OUYI	EQ 500MG BASE	A205072	001	Jul 28, 2017
HIKMA	EQ 500MG BASE	A065311	001	Feb 07, 2006
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766	001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017	001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015	001	Jun 22, 1999
SANDOZ	EQ 500MG BASE	A062291	001	
TEVA	EQ 500MG BASE	A062695	001	Feb 10, 1989
DURICEF				
WARNER CHILCOTT	EQ 250MG BASE	N050512	002	
+	EQ 500MG BASE **	N050512	001	
ULTRACEF				
BRISTOL	EQ 500MG BASE	A062378	001	Mar 16, 1982
FOR SUSPENSION;ORAL				
CEFADROXIL				
ANI PHARMS	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334	001	
	EQ 250MG BASE/5ML	A062334	002	
	EQ 500MG BASE/5ML	A062334	003	
CHARTWELL RX	EQ 250MG BASE/5ML	A065307	002	Oct 16, 2006
	EQ 500MG BASE/5ML	A065307	003	Oct 16, 2006
HIKMA PHARMS	EQ 250MG BASE/5ML	A091036	001	Nov 28, 2012
	EQ 500MG BASE/5ML	A091036	002	Nov 28, 2012
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003
	EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003
	EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003
DURICEF				
+ WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527	002	
+	EQ 250MG BASE/5ML **	N050527	003	
+	EQ 500MG BASE/5ML **	N050527	001	
ULTRACEF				
BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982
TABLET;ORAL				
CEFADROXIL				
CHARTWELL RX	EQ 1GM BASE	A065301	001	Sep 18, 2006
HIKMA	EQ 1GM BASE	A065260	001	Mar 30, 2006
RANBAXY	EQ 1GM BASE	A065018	001	Apr 23, 1999
DURICEF				
+ WARNER CHILCOTT	EQ 1GM BASE **	N050528	001	
ULTRACEF				
APOTHECON	EQ 1GM BASE	A062390	001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408	001	Aug 31, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFAMANDOLE NAFATE				
INJECTABLE;INJECTION				
MANDOL				
	LILLY	EQ 500MG BASE/VIAL	N050504 001	
		EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
		EQ 1GM BASE/VIAL	N050504 002	
		EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
		EQ 2GM BASE/VIAL	N050504 003	
		EQ 10GM BASE/VIAL	N050504 004	
CEFAZOLIN SODIUM				
INJECTABLE;INJECTION				
ANCEF				
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL **	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
		EQ 20MG BASE/ML	A063002 002	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983
CEFAZOLIN AND DEXTROSE				
	B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
CEFAZOLIN SODIUM				
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
		EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
		EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
		EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
	AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
		EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
		EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
		EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
		EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
		EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
		EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
		EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
		EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	DR REDDYS	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
		EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
		EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
		EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
		EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
		EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	FACTA FARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991
		EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991
		EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991
		EQ 20GM BASE/VIAL	A063209 002	Apr 30, 1999
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169 001	Aug 14, 1998
		EQ 1GM BASE/VIAL **	A064169 002	Aug 14, 1998
		EQ 10GM BASE/VIAL **	A064170 001	Mar 18, 1998
		EQ 20GM BASE/VIAL **	A064170 002	Mar 18, 1998
	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
	HIKMA	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
		EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
		EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
		EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
		EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
		EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
	HOSPIRA	EQ 1GM BASE/VIAL	A201654 001	Feb 03, 2016
	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFAZOLIN SODIUM				
INJECTABLE;INJECTION				
CEFAZOLIN SODIUM				
	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005
SANDOZ	EQ 1GM BASE/VIAL	A065345	001	May 09, 2007
STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 500MG BASE/VIAL	A061773	002	
	EQ 1GM BASE/VIAL	A061773	003	
	EQ 10GM BASE/VIAL	A061773	004	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985
CEFDINIR				
CAPSULE;ORAL				
OMNICEF				
+ ABBVIE	300MG **	N050739	001	Dec 04, 1997
FOR SUSPENSION;ORAL				
OMNICEF				
+ ABBVIE	125MG/5ML **	N050749	001	Dec 04, 1997
+	250MG/5ML **	N050749	002	Jul 29, 2004
CEFDITOREN PIVOXIL				
TABLET;ORAL				
SPECTRACEF				
VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
	400MG	N021222	002	Jul 21, 2008
CEFEPIME HYDROCHLORIDE				
INJECTABLE;INJECTION				
CEFEPIME HYDROCHLORIDE				
ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020
	EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020
CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007
	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007
	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012
	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007
	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012
MAXIPIME				
+ HOSPIRA INC	EQ 500MG BASE/VIAL **	N050679	001	Jan 18, 1996
+	EQ 1GM BASE/VIAL **	N050679	002	Jan 18, 1996
+	EQ 2GM BASE/VIAL **	N050679	003	Jan 18, 1996
CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM				
POWDER;INTRAVENOUS				
EXBLIFEP				
+ ORCHID PHARMA	EQ 2GM BASE/VIAL;0.5GM/VIAL	N216165	001	Feb 22, 2024
CEFIXIME				
FOR SUSPENSION;ORAL				
CEFIXIME				
CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017
	200MG/5ML	A206144	002	Nov 17, 2017
SUPRAX				
+ LEDERLE	100MG/5ML **	N050622	001	Apr 28, 1989
LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004
TABLET;ORAL				
CEFIXIME				
FDC LTD	400MG	A206358	001	Dec 17, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFIXIME

TABLET;ORAL				
SUPRAX				
+	LEDERLE	200MG **	N050621 001	Apr 28, 1989
+		400MG **	N050621 002	Apr 28, 1989
	LUPIN PHARMS	400MG	A065130 001	Feb 12, 2004
TABLET, CHEWABLE;ORAL				
SUPRAX				
	LUPIN LTD	100MG	A065380 001	Oct 25, 2010
		150MG	A065380 002	Oct 25, 2010
		200MG	A065380 003	Oct 25, 2010

CEFMENOXIME HYDROCHLORIDE

INJECTABLE;INJECTION				
CEFMAX				
	TAP PHARM	EQ 500MG BASE/VIAL	N050571 001	Dec 30, 1987
		EQ 1GM BASE/VIAL	N050571 002	Dec 30, 1987
		EQ 2GM BASE/VIAL	N050571 003	Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE;INJECTION				
ZEFAZONE				
+	PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637 001	Dec 11, 1989
+		EQ 2GM BASE/VIAL **	N050637 002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
+	PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683 001	Dec 29, 1992
+		EQ 40MG BASE/ML **	N050683 002	Dec 29, 1992

CEFONICID SODIUM

INJECTABLE;INJECTION				
MONOCID				
	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579 001	May 23, 1984
		EQ 1GM BASE/VIAL	A063295 001	Jul 26, 1993
		EQ 1GM BASE/VIAL	N050579 002	May 23, 1984
		EQ 2GM BASE/VIAL	N050579 003	May 23, 1984
		EQ 10GM BASE/VIAL	N050579 004	May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE;INJECTION				
CEFOBID				
	PFIZER	EQ 1GM BASE/VIAL	A063333 001	Mar 31, 1995
		EQ 1GM BASE/VIAL	N050551 001	Nov 18, 1982
		EQ 2GM BASE/VIAL	A063333 002	Mar 31, 1995
		EQ 2GM BASE/VIAL	N050551 002	Nov 18, 1982
		EQ 10GM BASE/VIAL	N050551 003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
	PFIZER	EQ 20MG BASE/ML	N050613 002	Jul 31, 1987
		EQ 40MG BASE/ML	N050613 001	Jul 23, 1986

CEFORANIDE

INJECTABLE;INJECTION				
PRECEF				
	APOTHECON	500MG/VIAL	A062579 001	Nov 26, 1984
		1GM/VIAL	A062579 002	Nov 26, 1984
		2GM/VIAL	A062579 003	Nov 26, 1984
		10GM/VIAL	A062579 004	Nov 26, 1984
		20GM/VIAL	A062579 005	Nov 26, 1984
	BRISTOL	500MG/VIAL	N050554 001	May 24, 1984
		1GM/VIAL	N050554 002	May 24, 1984
		2GM/VIAL	N050554 003	May 24, 1984
		10GM/VIAL	N050554 004	May 24, 1984
		20GM/VIAL	N050554 005	May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE;INJECTION				
CEFOTAXIME				
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200 001	Mar 24, 2000
		EQ 1GM BASE/VIAL	A064200 002	Mar 24, 2000
		EQ 2GM BASE/VIAL	A064200 003	Mar 24, 2000
		EQ 10GM BASE/VIAL	A064201 001	Mar 24, 2000
		EQ 20GM BASE/VIAL	A064201 002	Mar 24, 2000
	HIKMA	EQ 500MG BASE/VIAL	A065072 001	Nov 20, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFOTAXIME SODIUM					
INJECTABLE;INJECTION					
CEFOTAXIME					
		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002
		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002
		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002
	WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER					
	B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER					
	B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM					
	AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
		EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
		EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
	HOSPIRA	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
		EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
		EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
		EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
		EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
		EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006
	LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
		EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
		EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
	WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008
		EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008
CLAFORAN					
	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+	STERIMAX	EQ 500MG BASE/VIAL **	N050547	001	
+		EQ 1GM BASE/VIAL **	N050547	002	
+		EQ 2GM BASE/VIAL **	N050547	003	
+		EQ 10GM BASE/VIAL **	N050547	004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985
		EQ 40MG BASE/ML	N050596	004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985
		EQ 40MG BASE/ML	N050596	003	May 20, 1985
CEFOTETAN DISODIUM					
INJECTABLE;INJECTION					
CEFOTAN					
	PAI HOLDINGS PHARM	EQ 10GM BASE/VIAL **	N050588	003	Apr 25, 1988
	TELIGENT	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER					
	PAI HOLDINGS PHARM	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993
CEFOTETAN					
	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
	HIKMA	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011
		EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011
	WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER					
+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007
CEFOTIAM HYDROCHLORIDE					
INJECTABLE;INJECTION					
CERADON					
	TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFOXITIN SODIUM

INJECTABLE;INJECTION					
CEFOXITIN					
	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
	FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
		EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
		EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006
		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006
		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006
MEFOXIN					
	PHARMOBEDIENT	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+		EQ 1GM BASE/VIAL **	N050517	001	
		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+		EQ 2GM BASE/VIAL **	N050517	002	
+		EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
MEFOXIN IN PLASTIC CONTAINER					
	PHARMOBEDIENT	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE;INJECTION					
CEFPIRAMIDE SODIUM					
	WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
		EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
		EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL					
BANAN					
	SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
		EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL					
	CHARTWELL RX	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009
		EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009
	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
		EQ 100MG BASE/5ML	A065082	002	May 31, 2002
VANTIN					
+	PFIZER	EQ 50MG BASE/5ML **	N050675	001	Aug 07, 1992
+		EQ 100MG BASE/5ML **	N050675	002	Aug 07, 1992
TABLET;ORAL					
BANAN					
	SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
		EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL					
	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
		EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN					
+	PFIZER	EQ 100MG BASE **	N050674	001	Aug 07, 1992
+		EQ 200MG BASE **	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION;ORAL					
CEFPROZIL					
	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012
		250MG/5ML	A065351	002	Feb 29, 2012
	CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005
		250MG/5ML	A065236	002	Dec 08, 2005
	ORCHID HLTHCARE	125MG/5ML	A065284	002	Dec 30, 2005
		250MG/5ML	A065284	001	Dec 30, 2005
	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
		250MG/5ML	A065202	002	Jun 30, 2006
	SANDOZ	125MG/5ML	A065257	001	Dec 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFPROZIL

FOR SUSPENSION;ORAL				
CEFPROZIL				
	250MG/5ML	A065257	002	Dec 08, 2005
CEFZIL				
+ CORDEN PHARMA	125MG/5ML **	N050665	001	Dec 23, 1991
+	250MG/5ML **	N050665	002	Dec 23, 1991
TABLET;ORAL				
CEFPROZIL				
APOTEX INC	250MG	A065327	001	Mar 26, 2008
	500MG	A065327	002	Mar 26, 2008
ORCHID HLTHCARE	250MG	A065267	001	Dec 19, 2005
	500MG	A065267	002	Dec 19, 2005
RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006
WOCKHARDT	250MG	A065428	001	Jun 14, 2007
	500MG	A065428	002	Jun 14, 2007
CEFZIL				
+ CORDEN PHARMA	250MG **	N050664	001	Dec 23, 1991
+	500MG **	N050664	002	Dec 23, 1991

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS				
CEFTAROLINE FOSAMIL				
APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021
	600MG/VIAL	A208075	002	Sep 21, 2021

CEFTAZIDIME

INJECTABLE;INJECTION				
CEFTAZIDIME				
ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985
AUROBINDO PHARMA LTD	500MG/VIAL	A065481	001	May 28, 2010
	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010
WOCKHARDT	1GM/VIAL	A065196	001	Oct 15, 2008
CEFTAZIDIME IN DEXTROSE CONTAINER				
+ B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
+	EQ 2GM BASE	N050823	002	Jun 13, 2011
CEPTAZ				
GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990
FORTAZ				
+ PAI HOLDINGS PHARM	500MG/VIAL **	N050578	001	Jul 19, 1985
+	1GM/VIAL **	N050578	002	Jul 19, 1985
+	2GM/VIAL **	N050578	003	Jul 19, 1985
+	6GM/VIAL **	N050578	004	Jul 19, 1985
PENTACEF				
GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992
	10GM/VIAL	A064008	002	Mar 31, 1992
TAZICEF				
HOSPIRA	500MG/VIAL	A062662	001	Mar 06, 1986
TAZIDIME				
LILLY	1GM/VIAL	A062655	001	Nov 20, 1985
	2GM/VIAL	A062655	002	Nov 20, 1985
TAZIDIME IN PLASTIC CONTAINER				
LILLY	1GM/VIAL	A062739	001	Jul 10, 1986
	2GM/VIAL	A062739	002	Jul 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTAZIDIME SODIUM				
INJECTABLE;INJECTION				
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
		EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
		EQ 40MG BASE/ML	A063221 003	Apr 29, 1993
FORTAZ IN PLASTIC CONTAINER				
	PAI HOLDINGS PHARM	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989
+		EQ 20MG BASE/ML	N050634 002	Apr 28, 1989
+		EQ 40MG BASE/ML	N050634 003	Apr 28, 1989
CEFTIBUTEN DIHYDRATE				
CAPSULE;ORAL				
CEDAX				
	BURKE THERAP	EQ 400MG BASE	N050685 002	Dec 20, 1995
FOR SUSPENSION;ORAL				
CEDAX				
+	BURKE THERAP	EQ 90MG BASE/5ML **	N050686 001	Dec 20, 1995
+		EQ 180MG BASE/5ML **	N050686 002	Dec 20, 1995
CEFTIZOXIME SODIUM				
INJECTABLE;INJECTION				
CEFIZOX				
	ASTELLAS	EQ 500MG BASE/VIAL	N050560 001	Sep 15, 1983
		EQ 1GM BASE/VIAL	A063294 002	Mar 31, 1994
		EQ 1GM BASE/VIAL	N050560 002	Sep 15, 1983
		EQ 2GM BASE/VIAL	A063294 003	Mar 31, 1994
		EQ 2GM BASE/VIAL	N050560 003	Sep 15, 1983
		EQ 10GM BASE/VIAL	N050560 005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER				
	ASTELLAS	EQ 20MG BASE/ML	N050589 001	Oct 03, 1984
		EQ 40MG BASE/ML	N050589 002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER				
	ASTELLAS	EQ 20MG BASE/ML	N050589 003	Apr 13, 1995
		EQ 40MG BASE/ML	N050589 004	Apr 13, 1995
CEFTRIAXONE SODIUM				
INJECTABLE;INJECTION				
CEFTRIAXONE				
	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068 001	Jan 07, 2013
	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504 001	Jul 31, 2008
	BEDFORD	EQ 10GM BASE/VIAL	A065475 001	Aug 18, 2008
	FACTA FARMA	EQ 10GM BASE/VIAL	A065269 001	Feb 28, 2007
	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252 001	Feb 15, 2006
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005
		EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012
		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005
		EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012
		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005
	LUPIN	EQ 10GM BASE/VIAL	A065263 001	Sep 12, 2006
	TEVA	EQ 10GM BASE/VIAL	A065274 001	May 01, 2006
ROCEPHIN				
	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239 001	Aug 13, 1993
		EQ 500MG BASE/VIAL	A062654 001	Apr 30, 1987
		EQ 500MG BASE/VIAL	A063239 002	Aug 13, 1993
		EQ 1GM BASE/VIAL	A062654 002	Apr 30, 1987
		EQ 1GM BASE/VIAL	A063239 003	Aug 13, 1993
		EQ 2GM BASE/VIAL	A062654 003	Apr 30, 1987
+		EQ 10GM BASE/VIAL **	N050585 005	Dec 21, 1984
	ROCHE	EQ 250MG BASE/VIAL	A062510 001	Mar 12, 1985
		EQ 500MG BASE/VIAL	A062510 002	Mar 12, 1985
		EQ 1GM BASE/VIAL	A062510 003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER				
+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624 001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624 002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624 003	Feb 11, 1987
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
CEFTRIAXONE				
	ASTRAL	EQ 250MG BASE/VIAL	A091049 001	Jun 11, 2018
		EQ 500MG BASE/VIAL	A091049 002	Jun 11, 2018
		EQ 1GM BASE/VIAL	A091049 003	Jun 11, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTRIAXONE SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

	EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018
AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024
	EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024
	EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024
	EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024
FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
	EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
	EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
	EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
LUPIN	EQ 250MG BASE/VIAL	A065125	001	Sep 30, 2003
	EQ 500MG BASE/VIAL	A065125	002	Sep 30, 2003
	EQ 1GM BASE/VIAL	A065125	003	Sep 30, 2003
	EQ 2GM BASE/VIAL	A065125	004	Sep 30, 2003
TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007

ROCEPHIN

+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585	001	Dec 21, 1984
+		EQ 500MG BASE/VIAL **	N050585	002	Dec 21, 1984
+		EQ 1GM BASE/VIAL **	N050585	003	Dec 21, 1984
+		EQ 2GM BASE/VIAL **	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997

CEFUROXIME AXETIL

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

TABLET;ORAL

CEFTIN

+	GLAXOSMITHKLINE	EQ 125MG BASE **	N050605	001	Dec 28, 1987
+		EQ 250MG BASE **	N050605	002	Dec 28, 1987
+		EQ 500MG BASE **	N050605	003	Dec 28, 1987

CEFUROXIME AXETIL

ANI PHARMS	EQ 250MG BASE	A065190	001	Oct 18, 2004
	EQ 500MG BASE	A065190	002	Oct 18, 2004
APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002
	EQ 500MG BASE	A065069	002	Oct 02, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003
LUPIN	EQ 250MG BASE	A065135	001	Jul 25, 2003
	EQ 500MG BASE	A065135	002	Jul 25, 2003
RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN	EQ 750MG BASE/VIAL	N050780	001	Feb 21, 2001
+	EQ 1.5GM BASE/VIAL	N050780	002	Feb 21, 2001

CEFUROXIME SODIUM

ACS DOBFAR SPA	EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997
FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
HIKMA	EQ 7.5GM BASE/VIAL	A065046	001	Jan 09, 2004
HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008
	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008
	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986

ZINACEF

+ PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL **	N050558	003	Oct 19, 1983
+	EQ 7.5GM BASE/VIAL **	N050558	004	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

PAI HOLDINGS PHARM	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

ZINACEF

+ PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL **	N050558	002	Oct 19, 1983

INJECTABLE;INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AMNEAL PHARMS	50MG	A208833	001	May 31, 2018
	100MG	A208833	002	May 31, 2018
	200MG	A208833	003	May 31, 2018
	400MG	A208833	004	May 31, 2018
JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CELECOXIB					
CAPSULE;ORAL					
CELECOXIB					
		100MG	A207061	002	Apr 04, 2017
		200MG	A207061	003	Apr 04, 2017
		400MG	A207061	004	Apr 04, 2017
	PANGEA	200MG	A212925	001	Dec 09, 2020
		400MG	A212925	002	Dec 09, 2020
	PHARMOBEDIENT	50MG	A078857	001	May 30, 2014
		100MG	A078857	002	Feb 11, 2015
		200MG	A078857	003	Feb 11, 2015
		400MG	A078857	004	Feb 11, 2015
	STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025
		200MG	A213127	002	Apr 29, 2025
		400MG	A213127	003	Apr 29, 2025
	UNICHEM	50MG	A213301	001	Jan 12, 2021
		100MG	A213301	002	Jan 12, 2021
		200MG	A213301	003	Jan 12, 2021
		400MG	A213301	004	Jan 12, 2021
	YABAO PHARM	100MG	A212564	001	Apr 10, 2023
		200MG	A212564	002	Apr 10, 2023
		400MG	A212564	003	Apr 10, 2023
	ZYDUS PHARMS	50MG	A205938	001	Jul 14, 2025
		100MG	A205938	002	Jul 14, 2025
		200MG	A205938	003	Jul 14, 2025
		400MG	A205938	004	Jul 14, 2025
CELECOXIB; TRAMADOL HYDROCHLORIDE					
TABLET;ORAL					
SEGLENTIS					
+	KOWA PHARMS	56MG;44MG	N213426	001	Oct 15, 2021
CELLULOSE SODIUM PHOSPHATE					
POWDER;ORAL					
CALCIBIND					
	MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
		300GM/BOT	N018757	003	Oct 16, 1984
CEPHALEXIN					
CAPSULE;ORAL					
CEPHALEXIN					
	APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
		EQ 250MG BASE	A063063	001	Sep 29, 1989
		EQ 250MG BASE	A063186	001	Dec 30, 1994
		EQ 500MG BASE	A062974	001	Nov 23, 1988
		EQ 500MG BASE	A063063	002	Sep 29, 1989
		EQ 500MG BASE	A063186	002	Dec 30, 1994
	BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
		EQ 500MG BASE	A062775	001	Apr 22, 1987
	FACTA FARMA	EQ 250MG BASE	A062118	001	
		EQ 500MG BASE	A062118	002	
	HIKMA	EQ 250MG BASE	A065215	001	Jan 24, 2006
		EQ 500MG BASE	A065215	002	Jan 24, 2006
	IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
		EQ 500MG BASE	A061969	002	
	PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
		EQ 500MG BASE	A062809	002	Apr 22, 1987
	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
		EQ 500MG BASE	A062869	001	Mar 17, 1988
	SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987
		EQ 500MG BASE	A062791	002	Jun 11, 1987
	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
		EQ 500MG BASE	A065007	002	Sep 16, 1999
	TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
		EQ 250MG BASE	A062821	001	Feb 05, 1988
		EQ 500MG BASE	A062761	001	Apr 24, 1987
		EQ 500MG BASE	A062823	001	Feb 05, 1988
	YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
		EQ 500MG BASE	A062871	001	Jul 05, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALEXIN

CAPSULE;ORAL				
KEFLEX				
+	PRAGMA	EQ 250MG BASE **	N050405 002	
+		EQ 333MG BASE **	N050405 004	May 12, 2006
+		EQ 500MG BASE **	N050405 003	
+		EQ 750MG BASE **	N050405 005	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
	APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
		EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
	BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
		EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
	CHARTWELL RX	EQ 125MG BASE/5ML	A065326 001	Jul 10, 2006
		EQ 250MG BASE/5ML	A065326 002	Jul 10, 2006
	FACTA FARMA	EQ 100MG BASE/ML **	A062117 001	
		EQ 125MG BASE/5ML **	A062117 002	
		EQ 250MG BASE/5ML **	A062117 003	
	HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
		EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
		EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
	TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
		EQ 125MG BASE/5ML	A062873 001	May 23, 1988
		EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
		EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
	VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
		EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
KEFLEX				
+	PRAGMA	EQ 100MG BASE/ML **	N050406 003	
+		EQ 125MG BASE/5ML **	N050406 001	
+		EQ 250MG BASE/5ML **	N050406 002	
TABLET;ORAL				
CEPHALEXIN				
	BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
		EQ 500MG BASE	A062827 001	Aug 17, 1987
	VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
		EQ 500MG BASE	A062863 002	Aug 11, 1988
		EQ 1GM BASE	A062863 003	Aug 11, 1988
KEFLET				
	LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
+		EQ 250MG BASE **	N050440 003	Feb 26, 1987
		EQ 500MG BASE	A062745 002	Dec 01, 1986
+		EQ 500MG BASE **	N050440 001	
		EQ 1GM BASE	N050440 002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
	RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
		EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL				
KEFTAB				
	LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
		EQ 333MG BASE	N050614 003	May 16, 1988
		EQ 500MG BASE	N050614 002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE;ORAL				
KAFOCIN				
	LILLY	250MG	N050219 001	

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION				
CEPHALOTHIN				
	INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
		EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
		EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
		EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547	001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548	001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547	002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548	002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666	002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666	001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464	001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464	002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464	003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422	005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730	001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422	004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730	002	Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	002	Jan 31, 1984

KEFLIN

LILLY	EQ 1GM BASE/VIAL	N050482	001	
	EQ 2GM BASE/VIAL	N050482	002	
	EQ 4GM BASE/VIAL	N050482	003	
	EQ 20GM BASE/VIAL	N050482	007	

KEFLIN IN PLASTIC CONTAINER

LILLY	EQ 1GM BASE/VIAL	A062549	001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549	002	Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435	001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435	002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435	003	Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION

CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446	005	
	EQ 1GM BASE/VIAL	A061769	001	
	EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446	001	
	EQ 2GM BASE/VIAL	A061769	002	
	EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	

CEPHAPIRIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
HIKMA	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE;ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	

CEPHRADINE

BARR	250MG	A062850	001	Apr 22, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHRADINE

CAPSULE;ORAL				
CEPHRADINE				
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988
VELOSEF				
APOTHECON	250MG	A061764	001	
	500MG	A061764	002	
VELOSEF '250'				
ERSANA	250MG	N050548	001	
VELOSEF '500'				
ERSANA	500MG	N050548	002	
FOR SUSPENSION;ORAL				
ANSPOR				
GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	
CEPHRADINE				
BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987
VELOSEF '125'				
APOTHECON	125MG/5ML	A061763	001	
VELOSEF '250'				
APOTHECON	250MG/5ML	A061763	002	
INJECTABLE;INJECTION				
VELOSEF				
APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	
TABLET;ORAL				
VELOSEF				
BRISTOL MYERS SQUIBB	1GM	N050530	001	

CERITINIB

CAPSULE;ORAL				
ZYKADIA				
+ NOVARTIS	150MG	N205755	001	Apr 29, 2014

CERIVASTATIN SODIUM

TABLET;ORAL				
BAYCOL				
BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE;INJECTION				
TYMTRAN				
PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
APOTEX	10MG	A207235	001	Aug 12, 2016
SOLUTION;ORAL				
CETIRIZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL					
CETIRIZINE HYDROCHLORIDE					
	TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008
	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008
	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
	PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008
	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008
	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
	PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008
	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008
	TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012
ZYRTEC					
+	J AND J CONSUMER INC	5MG/5ML **	N020346	001	Sep 27, 1996
TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	AIPING PHARM INC	5MG	A202277	002	Mar 11, 2014
		10MG	A202277	004	Mar 11, 2014
	CIPLA LTD	5MG	A077318	001	Jul 25, 2013
		10MG	A077318	002	Jul 25, 2013
	HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007
		10MG	A078615	004	Dec 28, 2007
	SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
		10MG	A077499	002	Dec 27, 2007
	TARO	5MG	A078072	001	Jul 22, 2009
		5MG	A078072	003	Jul 22, 2009
	TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
		10MG	A079191	004	Apr 15, 2010
	UNICHEM	5MG	A078680	003	Jun 26, 2009
		10MG	A078680	004	Jun 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES					
	AIPING PHARM INC	5MG	A202277	001	Mar 11, 2014
		10MG	A202277	003	Mar 11, 2014
	SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
		10MG	A077499	004	Dec 27, 2007
	UNICHEM	5MG	A078680	001	Jun 26, 2009
		10MG	A078680	002	Jun 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	TARO	10MG	A078072	002	Jul 22, 2009
		10MG	A078072	004	Jul 22, 2009
	TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
		10MG	A079191	002	Apr 15, 2010
ZYRTEC HIVES					
+	KENVUE BRANDS	5MG	N019835	005	Nov 16, 2007
+		10MG	N019835	006	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CETIRIZINE HYDROCHLORIDE ALLERGY					
	SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
		10MG	A077631	003	Jan 11, 2008
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
		10MG	A077631	002	Jan 11, 2008
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	SUN PHARM	5MG	A090142	001	Aug 30, 2011
		10MG	A090142	002	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	SUN PHARM	5MG	A090142	003	Aug 30, 2011
		10MG	A090142	004	Aug 30, 2011
CHILDREN'S ZYRTEC ALLERGY					
+	KENVUE BRANDS	5MG **	N021621	003	Nov 16, 2007
CHILDREN'S ZYRTEC HIVES RELIEF					
+	KENVUE BRANDS	5MG **	N021621	005	Nov 16, 2007
+		10MG **	N021621	006	Nov 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	5MG;120MG	A212409	001	Mar 08, 2023
	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024

CETRORELIX ACETATE
POWDER;SUBCUTANEOUS
CETROTIDE

+	EMD SERONO INC	EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL
FOR SUSPENSION;INTRATRACHEAL
EXOSURF NEONATAL

	GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044	001	Aug 02, 1990

CEVIMELINE HYDROCHLORIDE
CAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

	APOTEX INC	30MG	A091260	001	Aug 25, 2011

CHENODIOL
TABLET;ORAL
CHENIX

+	LEADIANT BIOSCI INC	250MG **	N018513	002	Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE
SYRUP;ORAL
ULO

	3M	25MG/5ML	N012126	001	

CHLORAMPHENICOL
CREAM;TOPICAL
CHLOROMYCETIN

	PARKE DAVIS	1%	N050183	001	

FOR SOLUTION;OPHTHALMIC
CHLOROMYCETIN

	PARKEDALE	25MG/VIAL	N050143	001	

INJECTABLE;INJECTION
CHLOROMYCETIN

	PARKE DAVIS	250MG/ML	N050153	001	

OINTMENT;OPHTHALMIC
CHLORAMPHENICOL

	ALTANA	1%	A060133	001	

CHLOROFAIR

	PHARMAFAIR	1%	A062439	001	Apr 21, 1983

CHLOROMYCETIN

	PARKEDALE	1%	N050156	001	

CHLOROPTIC S.O.P.

	ALLERGAN	1%	A061187	001	

ECONOCHLOR

	ALCON	1%	A061648	001	

SOLUTION/DROPS;OPHTHALMIC
CHLORAMPHENICOL

	ALCON	0.5%	A062628	001	Sep 25, 1985
	EPIC PHARMA LLC	0.5%	A062042	001	

CHLOROFAIR

	PHARMAFAIR	0.5%	A062437	001	Apr 14, 1983

CHLOROPTIC

	ALLERGAN	0.5%	N050091	001	

ECONOCHLOR

	ALCON	0.5%	A061645	001	

OPHTHOCHLOR

	PARKEDALE	0.5%	A061220	001	

OPTOMYCIN

	OPTOPICS	0.5%	A062171	001	Mar 31, 1982

SOLUTION/DROPS;OTIC
CHLOROMYCETIN

	PARKEDALE	0.5%	N050205	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION				
CHLORAMPHENICOL				
	ELKINS SINN	EQ 1GM BASE/VIAL	A062406 001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE				
	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982
	GRUPPO LEPETIT	EQ 1GM BASE/VIAL	A062278 001	
CHLOROMYCETIN				
+	PARKEDALE	EQ 1GM BASE/VIAL	N050155 001	
MYCHEL-S				
	ANGUS	EQ 1GM BASE/VIAL	A060132 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC				
CHLOROMYCETIN HYDROCORTISONE				
	PARKEDALE	12.5MG/VIAL;25MG/VIAL	N050202 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
OPHTHOCORT				
	PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM	N050201 002	

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
CHLOROMYXIN				
	PARKE DAVIS	1%;10,000 UNITS/GM	N050203 002	

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT;OPHTHALMIC				
CHLOROPTIC-P S.O.P.				
	ALLERGAN	1%;0.5%	A061188 001	

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE;ORAL				
LIBRELEASE				
	VALEANT PHARM INTL	30MG	N017813 001	Sep 12, 1983
TABLET;ORAL				
LIBRITABS				
	VALEANT PHARM INTL	5MG	A085482 001	
		10MG	A085481 001	
		25MG	A085488 001	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL				
A-POXIDE				
	ABBOTT	5MG	A085447 001	
		5MG	A085517 001	
		10MG	A085447 002	
		10MG	A085518 001	
		25MG	A085447 003	
		25MG	A085513 001	
CHLORDIAZACHEL				
	RACHELLE	5MG	A085086 001	
		10MG	A084639 001	
		25MG	A085087 001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
	ASCOT	5MG	A087525 001	Jan 07, 1982
		10MG	A087524 001	Jan 07, 1982
		25MG	A087512 001	Jan 07, 1982
	FERRANTE	5MG	A085118 001	
		10MG	A085119 001	
		25MG	A085120 001	
	HALSEY	5MG	A085340 001	
		10MG	A085339 001	
		25MG	A084685 001	
	IMPAX LABS	5MG	A086213 001	
		10MG	A085113 001	
		25MG	A086212 001	
	IVAX SUB TEVA PHARMS	5MG	A083741 001	
		10MG	A083742 001	
		25MG	A083570 001	
	LEDERLE	5MG	A086892 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL				
CHLORDIAZEPOXIDE HYDROCHLORIDE				
		5MG	A087234 001	
		10MG	A086876 001	
		10MG	A087037 001	
		25MG	A086893 001	
		25MG	A087231 001	
	MAST MM	10MG	A086217 001	
	MYLAN	5MG	A084886 001	
		10MG	A084601 001	
		25MG	A084887 001	
	PARKE DAVIS	5MG	A085163 001	
		10MG	A084598 001	
		25MG	A085164 001	
	PIONEER PHARMS	10MG	A089533 001	Jul 15, 1988
		25MG	A089558 001	Jul 15, 1988
	PUREPAC PHARM	5MG	A085155 001	
		10MG	A084939 002	
		25MG	A085144 001	
	ROXANE	5MG	A084706 001	
		10MG	A084700 001	
		25MG	A084705 001	
	SUPERPHARM	5MG	A088987 001	Apr 25, 1985
		10MG	A088986 001	Apr 25, 1985
		25MG	A088988 001	Apr 25, 1985
	TEVA	5MG	A088705 001	Jan 18, 1985
		10MG	A088706 001	Jan 18, 1985
		25MG	A086494 001	
		25MG	A088707 001	Jan 18, 1985
	UPSHER SMITH LABS	5MG	A084919 001	
+		10MG	A084920 001	
		25MG	A084823 001	
	USL PHARMA	5MG	A084644 001	
		10MG	A084623 001	
		25MG	A084645 001	
	VANGARD	5MG	A088129 001	Mar 28, 1983
		10MG	A088010 001	Mar 28, 1983
		25MG	A088130 001	Mar 28, 1983
	WATSON LABS	5MG	A086383 001	
		10MG	A086294 001	
		25MG	A086382 001	
	WEST WARD	5MG	A085014 001	
		10MG	A085000 001	
		25MG	A085294 001	
LIBRIUM				
+	VALEANT PHARM INTL	5MG **	N012249 002	
+		10MG **	N012249 001	
+		25MG **	N012249 003	
LYGEN				
	ALRA	5MG	A085107 001	
		10MG	A085009 001	
		25MG	A085108 001	
INJECTABLE;INJECTION				
LIBRIUM				
	BAUSCH	100MG/AMP	N012301 001	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL				
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE				
	TEVA PHARMS USA	5MG;2.5MG	A211476 001	Nov 02, 2021
	TORRENT	5MG;2.5MG	A217385 001	Dec 14, 2023

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET;ORAL				
MENRIUM 10-4				
	ROCHE	10MG;0.4MG	N014740 006	
MENRIUM 5-2				
	ROCHE	5MG;0.2MG	N014740 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED				
TABLET;ORAL				
MENRIUM 5-4				
ROCHE	5MG;0.4MG	N014740	004	
CHLORHEXIDINE GLUCONATE				
SOLUTION;DENTAL				
CHLORHEXIDINE GLUCONATE				
SCIEGEN PHARMS	0.12%	A074356	001	May 07, 1996
PAROEX				
SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005
PERIOGARD				
COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994
SOLUTION;TOPICAL				
BRIAN CARE				
SOAPCO	4%	A071419	001	Dec 17, 1987
EXIDINE				
XTTRIUM	2.5%	N019421	001	Dec 17, 1985
MICRODERM				
J AND J	4%	A072255	001	Apr 15, 1991
PREVACARE R				
J AND J	0.5%	A072292	001	Jan 28, 1992
STERI-STAT				
MATRIX MEDCL	4%	A070104	001	Jul 24, 1986
SPONGE;TOPICAL				
CHLORHEXIDINE GLUCONATE				
KENDALL IL	4%	N019490	001	Mar 27, 1987
E-Z SCRUB				
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000
HIBICLENS				
+ MOLNLYCKE HLTH	4% **	N018423	001	
MICRODERM				
J AND J	4%	A072295	001	Feb 28, 1991
PHARMASEAL SCRUB CARE				
CAREFUSION 2200	4%	N019793	001	Dec 02, 1988
TABLET;DENTAL				
PERIOCHIP				
+ DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998
CHLORMERODRIN HG-197				
INJECTABLE;INJECTION				
CHLORMERODRIN HG 197				
BRACCO	0.6-1.4mCi/ML	N017269	001	
CHLORMEZANONE				
TABLET;ORAL				
TRANCOPAL				
SANOFI AVENTIS US	100MG	N011467	003	
	200MG	N011467	005	
CHLOROPROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHLOROPROCAINE HYDROCHLORIDE				
HOSPIRA	2%	A087447	001	Apr 16, 1982
	3%	A087446	001	Apr 16, 1982
NESACAINE				
+ FRESENIUS KABI USA	1%	N009435	001	
NESACAINE-MPF				
FRESENIUS KABI USA	2%	N009435	003	
	3%	N009435	004	
SOLUTION;INTRATHECAL				
CLOROTEKAL				
+ B BRAUN MEDICAL	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017
CHLOROQUINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARALEN HYDROCHLORIDE				
SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLOROQUINE PHOSPHATE

TABLET;ORAL				
ARALEN				
+	SANOFI AVENTIS US	500MG **	N006002 001	
CHLOROQUINE PHOSPHATE				
	HIKMA PHARMS	250MG **	A083082 001	
		500MG **	A083082 002	Sep 17, 1999
	IPCA LABS LTD	250MG	A090610 001	Dec 03, 2009
		500MG	A090249 001	Dec 03, 2009
	MD PHARM	250MG	A087228 001	
	PUREPAC PHARM	250MG	A080886 001	
	TEVA	250MG	A087504 001	Jan 13, 1982
	WATSON LABS	250MG	A087979 001	Dec 21, 1982
		500MG	A088030 001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET;ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
	SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860 002	

CHLOROTHIAZIDE

TABLET;ORAL				
CHLOROTHIAZIDE				
	ABC HOLDING	250MG	A085569 001	
	HIKMA INTL PHARMS	250MG	A086028 001	Jul 14, 1982
		500MG	A087736 001	Jul 14, 1982
	LEDERLE	250MG	A086940 001	
		500MG	A086938 001	
	PHARMOBEDIENT	250MG	A084217 002	
		500MG	A084217 001	
	SANDOZ	250MG	A085485 001	
	WATSON LABS	250MG	A085165 001	
		250MG	A085173 001	
		250MG	A086795 001	Aug 15, 1983
		500MG	A084026 001	Sep 01, 1982
		500MG	A086796 001	Aug 15, 1983
DIURIL				
+	RISING	250MG **	N011145 004	
+		500MG **	N011145 002	

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION				
CHLOROTHIAZIDE SODIUM				
	RK PHARMA	EQ 500MG BASE/VIAL	A202493 001	Jun 18, 2014
DIURIL				
+	RISING	EQ 500MG BASE/VIAL **	N011145 005	

CHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL				
ALDOCLOR-150				
	MERCK	150MG;250MG	N016016 001	
ALDOCLOR-250				
	MERCK	250MG;250MG	N016016 002	
METHYLDOPA AND CHLOROTHIAZIDE				
	PAR PHARM	150MG;250MG	A070783 001	Nov 06, 1987
		250MG;250MG	A070654 001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CHLOROTHIAZIDE AND RESERPINE				
	HIKMA	250MG;0.125MG	A088557 001	Dec 22, 1983
		500MG;0.125MG	A088365 001	Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE				
	WATSON LABS	250MG;0.125MG	A084853 001	
		500MG;0.125MG	A088151 001	Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE				
	PHARMOBEDIENT	250MG;0.125MG	A087744 001	May 06, 1982
		500MG;0.125MG	A087745 001	May 06, 1982
DIUPRES-250				
	MERCK	250MG;0.125MG	N011635 003	Aug 26, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLOROTHIAZIDE; RESERPINE				
TABLET;ORAL				
DIUPRES-500				
MERCK	500MG;0.125MG	N011635	006	Aug 26, 1987
CHLOROTRIANISENE				
CAPSULE;ORAL				
CHLOROTRIANISENE				
BANNER PHARMACAPS	12MG	A084652	001	
TACE				
SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	
CHLOROXINE				
SHAMPOO;TOPICAL				
CAPITROL				
WESTWOOD SQUIBB	2%	N017594	001	
CHLORPHENESIN CARBAMATE				
TABLET;ORAL				
MAOLATE				
PAMLAB LLC	400MG	N014217	002	
CHLORPHENIRAMINE MALEATE				
CAPSULE, EXTENDED RELEASE;ORAL				
CHLORPHENIRAMINE MALEATE				
AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
TELDRIN				
GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	
INJECTABLE;INJECTION				
CHLOR-TRIMETON				
SCHERING PLOUGH	10MG/ML	N008826	001	
	100MG/ML	N008794	001	
CHLORPHENIRAMINE MALEATE				
BEL MAR	10MG/ML	A080821	001	
ELKINS SINN	10MG/ML	A080797	001	
WATSON LABS	10MG/ML	A083593	001	
	10MG/ML	A086096	001	
	100MG/ML	A086095	001	
PYRIDAMAL 100				
BEL MAR	100MG/ML	A083733	001	
SYRUP;ORAL				
CHLOR-TRIMETON				
SCHERING	2MG/5ML	N006921	006	
CHLORPHENIRAMINE MALEATE				
PHARM ASSOC	2MG/5ML	A087520	001	Feb 10, 1982
TABLET;ORAL				
ANTAGONATE				
BAYER PHARMS	4MG	A083381	001	
CHLOR-TRIMETON				
SCHERING	4MG	N006921	002	
CHLORPHENIRAMINE MALEATE				
ANABOLIC	4MG	A083078	001	
AUROLIFE PHARMA LLC	4MG	A080961	001	
BELL PHARMA	4MG	A083062	001	
ELKINS SINN	4MG	A080938	001	
IMPAX LABS	4MG	A080809	001	
IVAX SUB TEVA PHARMS	4MG	A080779	001	
KV PHARM	4MG	A087164	001	
LEDERLE	4MG	A086941	001	
NEWTRON PHARMS	4MG	A086519	001	
PANRAY	4MG	A083243	001	
PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SUN PHARM INDUSTRIES	4MG	A080700	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE MALEATE

TABLET;ORAL				
CHLORPHENIRAMINE MALEATE				
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
WEST WARD	4MG	A083787	001	
KLOROMIN				
HALSEY	4MG	A083629	001	
PHENETRON				
LANNETT	4MG	A080846	001	
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	8MG **	N007638	001	
+	12MG **	N007638	002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE				
ALZA	16MG	N019746	002	Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE				
ACELLA	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017
TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015
VITUZ				
+ PERSION	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015
SCIEGEN PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017
TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838	001	Nov 26, 2014
ZUTRIPRO				
+ PERSION	4MG/5ML;5MG/5ML;60MG/5ML **	N022439	001	Jun 08, 2011

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
COLD CAPSULE IV				
GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985
COLD CAPSULE V				
GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIAMINIC-12				
NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
CODIMAL-L.A. 12				
SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
ISOCLOR				
FISONS	8MG;120MG	N018747	001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE				
CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
	12MG;120MG	N018843	001	Mar 18, 1985
KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001	

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
CODEPREX				
LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004
PENNTUSS				
FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985
TUZISTRA XR				
+ TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX				
CAPSULE, EXTENDED RELEASE;ORAL				
TUSSICAPS				
ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007
SUSPENSION, EXTENDED RELEASE;ORAL				
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX				
NEOS THERAPS INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012
TUSSIONEX PENNKINETIC				
+ UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111	001	Dec 31, 1987
CHLORPHENTERMINE HYDROCHLORIDE				
TABLET;ORAL				
PRE-SATE				
PARKE DAVIS	EQ 65MG BASE	N014696	001	
CHLORPROMAZINE				
SUPPOSITORY;RECTAL				
THORAZINE				
+ GLAXOSMITHKLINE	25MG **	N009149	024	
+	100MG **	N009149	033	
CHLORPROMAZINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
THORAZINE				
GLAXOSMITHKLINE	30MG	N011120	016	
	75MG	N011120	017	
	150MG	N011120	018	
	200MG	N011120	019	
	300MG	N011120	020	
CONCENTRATE;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
HIKMA	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983
SONAZINE				
SAPTALIS PHARMS	30MG/ML	A080983	004	
	100MG/ML	A080983	005	
THORAZINE				
+ GLAXOSMITHKLINE	30MG/ML **	N009149	032	
+	100MG/ML **	N009149	043	
INJECTABLE;INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
ABRAXIS PHARM	25MG/ML	A084911	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	
THORAZINE				
+ GLAXOSMITHKLINE	25MG/ML **	N009149	011	
SYRUP;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A086712	001	
SONAZINE				
CHARTWELL RX	10MG/5ML	A083040	001	
THORAZINE				
+ GLAXOSMITHKLINE	10MG/5ML **	N009149	022	
TABLET;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
CHARTWELL RX	10MG **	A080439	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE				
	25MG **		A080439 002	
	50MG **		A080439 003	
	100MG **		A080439 004	
	200MG **		A080439 005	
CYCLE	10MG		A085331 001	
	25MG		A085331 002	
	50MG		A085331 003	
	100MG		A085331 004	
	200MG		A085331 005	
IVAX SUB TEVA PHARMS	10MG		A083549 001	
	25MG		A083549 002	
	50MG		A083549 003	
	100MG		A083574 001	
	200MG		A083575 001	
KV PHARM	10MG		A085750 002	Jan 04, 1982
	25MG		A085751 001	
	50MG		A085484 001	
	100MG		A085752 001	
	200MG		A085748 002	Jan 04, 1982
LEDERLE	10MG		A084803 001	
	25MG		A084801 001	
	50MG		A084800 001	
	100MG		A084789 001	
	200MG		A084802 001	
PUREPAC PHARM	10MG		A080403 004	
	25MG		A080403 001	
	50MG		A080403 002	
	100MG		A080403 003	
	200MG		A080403 005	
PVT FORM	25MG		A080340 001	
	50MG		A080340 002	
	200MG		A080340 003	
SUN PHARM	10MG		A214256 001	Oct 26, 2020
	25MG		A214256 002	Oct 26, 2020
	50MG		A214256 003	Oct 26, 2020
	100MG		A214256 004	Oct 26, 2020
	200MG		A214256 005	Oct 26, 2020
VANGARD	10MG		A088038 001	Aug 16, 1982
	25MG		A087645 001	
	50MG		A087646 001	
WATSON LABS	10MG		A085959 001	
	25MG		A085956 001	
	50MG		A085960 001	
	100MG		A085957 001	
	200MG		A085958 001	
WEST WARD	10MG		A087783 001	Sep 16, 1982
	25MG		A087865 001	Sep 16, 1982
	50MG		A087878 001	Sep 15, 1982
	100MG		A087884 001	Sep 15, 1982
	200MG		A087880 001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG		A086886 001	
	25MG		A084423 001	
	50MG		A086887 001	
	100MG		A086888 001	
	200MG		A086885 001	
THORAZINE				
GLAXOSMITHKLINE	10MG **		N009149 002	
	25MG **		N009149 007	
	50MG **		N009149 013	
	100MG **		N009149 018	
	200MG **		N009149 020	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROPAMIDE				
TABLET;ORAL				
CHLORPROPAMIDE				
ANI PHARMS	100MG	A088768	001	Oct 11, 1984
	100MG	A088812	001	Oct 19, 1984
	100MG	A088840	001	Oct 25, 1984
	100MG	A088918	001	Oct 16, 1984
	100MG	A088921	001	Apr 12, 1985
	100MG	A089446	001	Nov 17, 1986
	250MG	A087353	001	
	250MG	A088813	001	Oct 19, 1984
	250MG	A088826	001	Sep 26, 1984
	250MG	A088919	001	Oct 16, 1984
	250MG	A088922	001	Apr 12, 1985
	250MG	A089447	001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
PHARMOBEDIENT	100MG	A088549	002	Jun 01, 1984
	250MG	A088549	001	Jun 01, 1984
RISING	100MG	A088725	001	Aug 31, 1984
	250MG	A088726	001	Aug 31, 1984
SANDOZ	250MG	A084669	001	
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852	001	Sep 26, 1984
DIABINESE				
+ PFIZER	100MG	N011641	003	
+	250MG	N011641	006	
GLUCAMIDE				
ANI PHARMS	250MG	A088641	001	Oct 11, 1984
CHLORPROTHIXENE				
CONCENTRATE;ORAL				
TARACTAN				
ROCHE	100MG/5ML	N016149	002	
INJECTABLE;INJECTION				
TARACTAN				
ROCHE	12.5MG/ML	N012487	001	
TABLET;ORAL				
TARACTAN				
ROCHE	10MG	N012486	005	
	25MG	N012486	004	
	50MG	N012486	003	
	100MG	N012486	001	
CHLORTETRACYCLINE HYDROCHLORIDE				
OINTMENT;OPHTHALMIC				
AUREOMYCIN				
LEDERLE	1%	N050404	001	
CHLORTHALIDONE				
TABLET;ORAL				
CHLORTHALIDONE				
ABBOTT	25MG	A087364	001	
	50MG	A087384	001	
AIPING PHARM INC	25MG	A087381	002	
	50MG	A087381	001	
ANI PHARMS	25MG	A087296	001	
	25MG	A087706	001	
	25MG	A088164	001	Jan 09, 1984
	50MG	A087689	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

ASCOT	25MG	A087698	001	Oct 20, 1982
	50MG	A087699	001	Oct 20, 1982
BARR LABS INC	25MG	A088902	001	Sep 19, 1985
	50MG	A088903	001	Sep 19, 1985
COSETTE	50MG	A088651	001	May 30, 1985
DAVA PHARMS INC	25MG	A087451	001	
	50MG	A087450	001	
IVAX PHARMS	25MG	A087555	001	
	50MG	A087176	001	
	50MG	A087947	001	Feb 27, 1984
KV PHARM	25MG	A087311	001	
	50MG	A087312	001	
MUTUAL PHARM	25MG	A087292	001	
	25MG	A089738	001	Sep 19, 1988
	50MG	A087293	001	
	50MG	A089739	001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591	001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139	001	Jul 16, 1986
	50MG	A088140	001	Aug 11, 1983
SANDOZ	50MG	A087118	001	
SUNNY	25MG	A209068	001	Jan 25, 2022
	50MG	A209068	002	Jan 25, 2022
SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	

HYGROTON

+	SANOFI AVENTIS US	25MG **	N012283	004	
+		50MG **	N012283	003	

THALITONE

MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179	001	Dec 16, 1987
	15MG;0.2MG	A071178	001	Dec 16, 1987
	15MG;0.3MG	A071142	001	Dec 16, 1987

CLORPRES

NATCO PHARMA	15MG;0.1MG	A071325	003	Feb 09, 1987
	15MG;0.2MG	A071325	002	Feb 09, 1987
	15MG;0.3MG	A071325	001	Feb 09, 1987

COMBIPRES

+	BOEHRINGER INGELHEIM	15MG;0.1MG **	N017503	001	
+		15MG;0.2MG **	N017503	002	
+		15MG;0.3MG **	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE;ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451	001	Dec 31, 1987
	25MG;200MG	N019451	002	Dec 31, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORTHALIDONE; RESERPINE				
TABLET;ORAL				
DEMI-REGROTON				
SANOFI AVENTIS US	25MG;0.125MG	N015103	002	
REGROTON				
SANOFI AVENTIS US	50MG;0.25MG	N015103	001	
CHLORZOXAZONE				
TABLET;ORAL				
CHLORZOXAZONE				
ACME LABS	500MG	A214365	001	Apr 27, 2023
ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
BARR	500MG	A089895	001	May 04, 1988
CHARTWELL RX	250MG	A087981	001	Sep 20, 1983
	375MG	A212053	001	Sep 14, 2020
	750MG	A212053	002	Sep 14, 2020
GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020
	750MG	A212185	002	May 26, 2020
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
RISING	250MG	A089852	001	May 04, 1988
SUN PHARM INDUSTRIES	500MG	A089970	001	Sep 27, 1990
TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020
	750MG	A212898	002	Jun 17, 2020
WATSON LABS	250MG	A086901	001	
	250MG	A086948	001	Aug 09, 1982
	500MG	A040137	001	Aug 09, 1996
	500MG	A081019	001	Jul 29, 1991
	500MG	A081040	001	Aug 22, 1989
PARAFLEX				
+ ORTHO MCNEIL PHARM	250MG **	N011300	003	
PARAFON FORTE DSC				
+ JANSSEN R AND D	500MG **	N011529	002	Jun 15, 1987
STRIFON FORTE DSC				
FERNDALE LABS	500MG	A081008	001	Dec 23, 1988
CHOLESTYRAMINE				
BAR, CHEWABLE;ORAL				
CHOLYBAR				
PARKE DAVIS	EQ 4GM RESIN/BAR	A071621	001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739	001	May 26, 1988
POWDER;ORAL				
CHOLESTYRAMINE				
AIPING PHARM INC	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022
	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022
ANI PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996
IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771	001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771	002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347	002	May 28, 1998
CHOLESTYRAMINE LIGHT				
MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024
	EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998
QUESTRAN				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640	001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640	003	
QUESTRAN LIGHT				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669	001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669	003	Dec 05, 1988
TABLET;ORAL				
QUESTRAN				
APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHOLESTYRAMINE				
TABLET;ORAL				
QUESTRAN				
	EQ 1GM RESIN		A073403 001	Apr 28, 1994
CHOLINE C-11				
INJECTABLE;INTRAVENOUS				
CHOLINE C-11				
UCSF RODIOPHARM	4-33.1mCi/ML		A208444 001	Nov 20, 2017
UNIV TX MD ANDERSON	4-100mCi/ML		A205690 001	Oct 29, 2015
WA UNIV SCH MED	4-33.1mCi/ML		A208413 001	Jan 10, 2017
CHOLINE FENOFIBRATE				
CAPSULE, DELAYED RELEASE;ORAL				
FENOFIBRIC ACID				
MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID		A207796 001	Feb 08, 2024
	EQ 135MG FENOFIBRIC ACID		A207796 002	Feb 08, 2024
PH HEALTH	EQ 45MG FENOFIBRIC ACID		A201573 002	Jul 18, 2013
	EQ 135MG FENOFIBRIC ACID		A201573 001	Jul 18, 2013
PHARMOBEDIENT	EQ 45MG FENOFIBRIC ACID		A200913 001	Mar 25, 2013
	EQ 135MG FENOFIBRIC ACID		A200913 002	Mar 25, 2013
TWI PHARMS	EQ 45MG FENOFIBRIC ACID		A210469 001	Jul 05, 2019
	EQ 135MG FENOFIBRIC ACID		A210469 002	Jul 05, 2019
TRILIPIX				
+ ABBVIE	EQ 45MG FENOFIBRIC ACID		N022224 001	Dec 15, 2008
+	EQ 135MG FENOFIBRIC ACID		N022224 002	Dec 15, 2008
CHROMIC CHLORIDE				
INJECTABLE;INJECTION				
CHROMIC CHLORIDE				
ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML		N019271 001	May 05, 1987
CHROMIC PHOSPHATE P-32				
INJECTABLE;INJECTION				
PHOSPHOCOL P32				
CURIUM	5mCi/ML		N017084 001	
CICLESONIDE				
AEROSOL, METERED;NASAL				
ZETONNA				
+ COVIS	0.037MG/INH		N202129 001	Jan 20, 2012
CICLOPIROX				
GEL;TOPICAL				
CICLOPIROX				
+ ALVOGEN	0.77% **		N020519 001	Jul 21, 1997
SHAMPOO;TOPICAL				
LOPROX				
+ BAUSCH	1%		N021159 001	Feb 28, 2003
SOLUTION;TOPICAL				
CICLOPIROX				
COSETTE	8%		A078233 001	Sep 18, 2007
EPIC PHARMA LLC	8%		A078975 001	Feb 17, 2010
HIKMA	8%		A078270 001	Sep 18, 2007
MYLAN PHARMS INC	8%		A078567 001	Sep 18, 2007
TARO PHARM INDS	8%		A078144 001	Sep 18, 2007
TEVA PHARMS	8%		A078079 001	Sep 18, 2007
PENLAC				
+ VALEANT BERMUDA	8% **		N021022 001	Dec 17, 1999
SUSPENSION;TOPICAL				
CICLOPIROX				
SUN PHARMA CANADA	0.77%		A077092 001	Aug 10, 2005
CIDOFOVIR				
SOLUTION;INTRAVENOUS				
VISTIDE				
+ GILEAD SCIENCES INC	EQ 375MG BASE/5ML (EQ 75MG BASE/ML) **		N020638 001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM					
INJECTABLE;INJECTION					
PRIMAXIN					
	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756	001	Jan 08, 1987
		EQ 500MG BASE/VIAL;500MG/VIAL	A062756	002	Jan 08, 1987
POWDER;INTRAMUSCULAR					
PRIMAXIN					
	MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630	001	Dec 14, 1990
		EQ 750MG BASE/VIAL;750MG/VIAL	N050630	002	Dec 14, 1990
POWDER;INTRAVENOUS					
IMIPENEM AND CILASTATIN					
	HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825	001	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A090825	002	Nov 16, 2011
		EQ 500MG BASE/VIAL;500MG/VIAL	A091007	001	Nov 16, 2011
PRIMAXIN					
+	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL **	N050587	001	Nov 26, 1985
CILOSTAZOL					
TABLET;ORAL					
CILOSTAZOL					
	ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
	AUROBINDO PHARMA USA	50MG	A077019	001	Nov 23, 2004
		100MG	A077019	002	Nov 23, 2004
	CHARTWELL RX	50MG	A077310	001	Nov 08, 2005
		100MG	A077021	001	Nov 23, 2004
	HIKMA	50MG	A077024	001	May 17, 2005
		100MG	A077024	002	May 17, 2005
	IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
	PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
		100MG	A077898	002	Oct 29, 2007
	RISING	50MG	A077323	002	Apr 20, 2006
		100MG	A077323	001	Apr 20, 2006
	SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009
		100MG	A077708	002	Sep 28, 2009
PLETAL					
+	OTSUKA	50MG **	N020863	001	Jan 15, 1999
+		100MG **	N020863	002	Jan 15, 1999
CIMETIDINE					
SUSPENSION;ORAL					
TAGAMET HB 200					
	GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
TABLET;ORAL					
CIMETIDINE					
	APOTEX	100MG	A074948	001	Jun 19, 1998
		200MG	A074948	002	Jul 26, 2002
	CHARTWELL RX	200MG	A074100	001	Jan 31, 1995
		300MG	A074100	002	Jan 31, 1995
		400MG	A074100	003	Jan 31, 1995
		800MG	A074100	004	Jan 31, 1995
	CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
		200MG	A074963	001	Jun 19, 1998
	CYCLE	300MG	A074361	001	Dec 23, 1994
		400MG	A074361	002	Dec 23, 1994
		800MG	A074371	001	Dec 23, 1994
	HIKMA	200MG	A074890	001	Dec 18, 1998
		300MG	A074890	002	Dec 18, 1998
		400MG	A074890	003	Dec 18, 1998
		800MG	A074890	004	Dec 18, 1998
	IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
		200MG	A074424	001	Jul 28, 1995
		200MG	A075345	001	Jun 16, 1999
		300MG	A074401	002	May 30, 1995
		300MG	A074424	002	Jul 28, 1995
		400MG	A074401	003	May 30, 1995
		400MG	A074424	003	Jul 28, 1995
		800MG	A074402	001	May 30, 1995
		800MG	A074424	004	Jul 28, 1995
	NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995
		400MG	A074340	002	Jun 23, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	800MG		A074339 001	Jun 23, 1995
PERRIGO	100MG		A074972 001	Jun 19, 1998
PLIVA	200MG		A074568 001	Feb 27, 1997
	300MG		A074568 002	Feb 27, 1997
	400MG		A074568 003	Feb 27, 1997
	800MG		A074566 001	Feb 27, 1997
SANDOZ	100MG		A075122 001	Jun 19, 1998
	200MG		A074250 001	Jun 29, 1995
	200MG		A075122 002	Jun 19, 1998
	300MG		A074250 002	Jun 29, 1995
	400MG		A074250 003	Jun 29, 1995
	800MG		A074250 004	Jun 29, 1995
TEVA	200MG		A074365 001	Feb 28, 1995
	300MG		A074365 002	Feb 28, 1995
	400MG		A074365 003	Feb 28, 1995
	800MG		A074365 004	Feb 28, 1995
UPSHER SMITH LABS	200MG		A074506 001	Jan 24, 1996
	300MG		A074506 002	Jan 24, 1996
	400MG		A074506 003	Jan 24, 1996
	800MG		A074506 004	Jan 24, 1996
WATSON LABS INC	200MG		A074349 001	Aug 30, 1996
	300MG		A074349 002	Aug 30, 1996
	400MG		A074349 003	Aug 30, 1996
	800MG		A074316 001	Feb 28, 1996
WATSON LABS TEVA	200MG		A075425 001	Jul 29, 1999

TAGAMET

+ GLAXOSMITHKLINE	200MG **		N017920 002	
+	300MG **		N017920 003	
+	400MG **		N017920 004	Dec 14, 1983
+	800MG **		N017920 005	Apr 30, 1986

TAGAMET HB

+ MEDTECH PRODUCTS	100MG **		N020238 001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

COSETTE	EQ 300MG BASE/2ML		A074296 001	Mar 28, 1997
HOSPIRA	EQ 300MG BASE/2ML		A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML		A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML		A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML		A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML		A074353 001	Dec 20, 1994
PH HEALTH	EQ 300MG BASE/2ML		A074005 001	Aug 31, 1994
	EQ 300MG BASE/2ML		A074428 001	Apr 25, 1996
TEVA PARENTERAL	EQ 300MG BASE/2ML		A074252 001	Nov 26, 1997

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML		A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML		A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML		A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML		A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML		A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML		A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML		A074468 002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **		N017939 002	

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE	EQ 6MG BASE/ML **		N019434 001	Oct 31, 1985

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS	EQ 300MG BASE/5ML		A074610 001	Sep 26, 1996
	EQ 300MG BASE/5ML		A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML		A075110 001	Jun 18, 1998
CYCLE	EQ 300MG BASE/5ML		A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML		A074176 001	Jun 01, 1994
PHARM ASSOC	EQ 300MG BASE/5ML		A074553 001	Jan 27, 1997
	EQ 300MG BASE/5ML		A075560 001	Mar 15, 2000
PHARMOBEDIENT CNSLTG	EQ 300MG BASE/5ML		A074757 001	Oct 17, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIMETIDINE HYDROCHLORIDE				
SOLUTION;ORAL				
TAGAMET				
	GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924 001	
CINACALCET HYDROCHLORIDE				
TABLET;ORAL				
CINACALCET HYDROCHLORIDE				
	LUPIN LTD	EQ 30MG BASE	A210548 001	Jun 28, 2019
		EQ 60MG BASE	A210548 002	Jun 28, 2019
		EQ 90MG BASE	A210548 003	Jun 28, 2019
	RISING	EQ 30MG BASE	A203422 001	Oct 16, 2018
		EQ 60MG BASE	A203422 002	Oct 16, 2018
		EQ 90MG BASE	A203422 003	Oct 16, 2018
	STEVENS J	30MG	A204364 001	Dec 02, 2021
		60MG	A204364 002	Dec 02, 2021
		90MG	A204364 003	Dec 02, 2021
	SUN PHARM	EQ 30MG BASE	A207008 001	Oct 11, 2018
		EQ 90MG BASE	A207008 003	Oct 11, 2018
SENSIPAR				
+	AMGEN	EQ 30MG BASE	N021688 001	Mar 08, 2004
+		EQ 60MG BASE	N021688 002	Mar 08, 2004
+		EQ 90MG BASE	N021688 003	Mar 08, 2004
CINOXACIN				
CAPSULE;ORAL				
CINOBAC				
	LILLY	250MG	N018067 001	
		500MG	N018067 002	
CINOXACIN				
	TEVA	250MG	A073005 001	Feb 28, 1992
		500MG	A073006 001	Feb 28, 1992
CIPROFLOXACIN				
INJECTABLE;INJECTION				
CIPRO				
+	BAYER HLTHCARE	400MG/40ML (10MG/ML) **	N019847 001	Dec 26, 1990
+		200MG/20ML (10MG/ML) **	N019847 002	Dec 26, 1990
		1200MG/120ML (10MG/ML) **	N019847 003	Dec 26, 1990
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	200MG/100ML **	N019857 001	Dec 26, 1990
+		400MG/200ML **	N019857 002	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAYER PHARMS	200MG/100ML	N019858 001	Dec 26, 1990
CIPROFLOXACIN				
	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062 001	Apr 29, 2008
		400MG/40ML (10MG/ML)	A078062 002	Apr 29, 2008
	BEDFORD LABS	200MG/20ML (10MG/ML)	A076992 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076992 002	Aug 28, 2006
		1200MG/120ML (10MG/ML)	A076993 001	Aug 28, 2006
	DR REDDYS	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006
	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076484 002	Aug 28, 2006
	HOSPIRA	200MG/20ML (10MG/ML)	A077245 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077245 002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%				
	HIKMA FARMACEUTICA	200MG/100ML	A076757 001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008
		400MG/200ML	A077888 002	Mar 18, 2008
	BAXTER HLTHCARE CORP	200MG/100ML	A078024 001	Mar 18, 2008
		400MG/200ML	A078024 002	Mar 18, 2008
	BEDFORD	200MG/100ML	A078114 001	Mar 18, 2008
		400MG/200ML	A078114 002	Mar 18, 2008
	TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008
		400MG/200ML	A077138 002	Mar 18, 2008
INJECTABLE, SUSPENSION;OTIC				
OTIPRIO				
+	ALK ABELLO	6% (60MG/ML)	N207986 001	Dec 10, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
CIPROFLOXACIN HYDROCHLORIDE				
	AMRING PHARMS	EQ 0.3% BASE	A078598 001	Jan 16, 2008
	PHARMOBEDIENT	EQ 0.3% BASE	A076555 001	Dec 11, 2008
	THE J MOLNER	EQ 0.3% BASE	A076754 001	Jun 09, 2004
TABLET;ORAL				
CIPRO				
+	BAYER HLTHCARE	EQ 750MG BASE **	N019537 004	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE				
	BARR	EQ 250MG BASE	A074124 001	Jun 09, 2004
		EQ 500MG BASE	A074124 002	Jun 09, 2004
		EQ 750MG BASE	A074124 003	Jun 09, 2004
	NATCO	EQ 250MG BASE	A075685 002	Jun 09, 2004
		EQ 500MG BASE	A075685 003	Jun 09, 2004
		EQ 750MG BASE	A075685 001	Jun 09, 2004
	NOSTRUM LABS	EQ 250MG BASE	A076138 001	Jun 09, 2004
		EQ 500MG BASE	A076138 002	Jun 09, 2004
		EQ 750MG BASE	A076138 003	Jun 09, 2004
	PLIVA	EQ 250MG BASE	A076426 002	Jun 15, 2005
		EQ 500MG BASE	A076426 003	Jun 15, 2005
		EQ 750MG BASE	A076426 004	Jun 15, 2005
	RISING	EQ 250MG BASE	A075817 002	Jun 09, 2004
		EQ 750MG BASE	A075817 004	Jun 09, 2004
	SUN PHARM INDS LTD	EQ 250MG BASE	A075747 001	Jun 09, 2004
		EQ 500MG BASE	A075747 002	Jun 09, 2004
		EQ 750MG BASE	A075747 003	Jun 09, 2004
	TARO	EQ 250MG BASE	A076912 002	Oct 06, 2004
		EQ 500MG BASE	A076912 003	Oct 06, 2004
		EQ 750MG BASE	A076912 004	Oct 06, 2004
	TEVA	EQ 250MG BASE	A076136 001	Jun 09, 2004
		EQ 500MG BASE	A076136 002	Jun 09, 2004
		EQ 750MG BASE	A076136 003	Jun 09, 2004
TABLET, EXTENDED RELEASE;ORAL				
PROQUIN XR				
	DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
CIPRO XR				
	BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473 001	Dec 13, 2002
		425.2MG;EQ 574.9MG BASE **	N021473 002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE				
	ANI PHARMS	212.6MG;EQ 287.5MG BASE	A077809 002	Nov 30, 2010
		425.2MG;EQ 574.9MG BASE	A077809 001	Nov 30, 2010
	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007
	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712 001	Dec 11, 2007
	PH HEALTH	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007
		425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007
	RISING	212.6MG;EQ 287.5MG BASE	A078183 001	Mar 22, 2007
		425.2MG;EQ 574.9MG BASE	A078183 002	Mar 22, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
TABLET;ORAL				
PROPULSID				
	JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
		EQ 20MG BASE	N020210 002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL				
PROPULSID QUICKSOLV				
	JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION				
CISATRACURIUM BESYLATE				
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873 001	Jun 16, 2017
	EUGIA PHARMA	EQ 2MG BASE/ML	A209144 001	May 08, 2020
	HAINAN POLY	EQ 2MG BASE/ML	A216538 001	Mar 08, 2024
	PIRAMAL	EQ 2MG BASE/ML	A212432 001	Mar 11, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CISATRACURIUM BESYLATE				
INJECTABLE;INJECTION				
CISATRACURIUM BESYLATE				
	EQ 10MG BASE/ML	A212432	002	Mar 11, 2022
ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Sep 01, 2020
CISATRACURIUM BESYLATE PRESERVATIVE FREE				
ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017
	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017
EUGIA PHARMA	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020
HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024
	EQ 10MG BASE/ML	A216539	002	Aug 27, 2024
NIMBEX				
+ ABBVIE	EQ 2MG BASE/ML **	N020551	001	Dec 15, 1995
NIMBEX PRESERVATIVE FREE				
+ ABBVIE	EQ 2MG BASE/ML **	N020551	003	Dec 15, 1995
+	EQ 10MG BASE/ML **	N020551	002	Dec 15, 1995
CISPLATIN				
INJECTABLE;INJECTION				
CISPLATIN				
BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000
PHARMOBEDIENT	1MG/ML	A091062	001	Apr 18, 2012
TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000
PLATINOL				
+ HQ SPCLT PHARMA	10MG/VIAL	N018057	001	
PLATINOL-AQ				
+ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984
CITALOPRAM HYDROBROMIDE				
CAPSULE;ORAL				
CITALOPRAM HYDROBROMIDE				
PHARMOBEDIENT	EQ 10MG BASE	A077668	001	Feb 28, 2007
	EQ 20MG BASE	A077668	002	Feb 28, 2007
	EQ 40MG BASE	A077668	003	Feb 28, 2007
SOLUTION;ORAL				
CELEXA				
+ FOREST LABS	EQ 10MG BASE/5ML **	N021046	001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE				
PHARM ASSOC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
TABLET;ORAL				
CELEXA				
ABBVIE	EQ 60MG BASE	N020822	004	Jul 17, 1998
CITALOPRAM HYDROBROMIDE				
APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004
	EQ 20MG BASE	A077046	002	Nov 24, 2004
	EQ 40MG BASE	A077046	003	Nov 24, 2004
CHARTWELL RX	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077040	003	Aug 17, 2005
COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004
	EQ 20MG BASE	A077048	002	Nov 16, 2004
	EQ 40MG BASE	A077048	003	Nov 16, 2004
EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004
	EQ 20MG BASE	A077036	002	Oct 28, 2004
	EQ 40MG BASE	A077036	003	Oct 28, 2004
FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004
	EQ 20MG BASE	A077035	002	Oct 28, 2004
	EQ 40MG BASE	A077035	003	Oct 28, 2004
GLENMARK PHARMS LTD	EQ 10MG BASE	A077654	001	Feb 27, 2009
	EQ 20MG BASE	A077654	002	Feb 27, 2009
	EQ 40MG BASE	A077654	003	Feb 27, 2009
HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 10MG BASE	A077034	001	Jun 30, 2005
	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 10MG BASE	A077232	001	Oct 31, 2005
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 20MG BASE	A077034	002	Jun 30, 2005
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 20MG BASE	A077232	002	Oct 31, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CITALOPRAM HYDROBROMIDE					
TABLET;ORAL					
CITALOPRAM HYDROBROMIDE					
		EQ 40MG BASE	A077033	003	Oct 28, 2004
		EQ 40MG BASE	A077034	003	Jun 30, 2005
		EQ 40MG BASE	A077213	003	Mar 31, 2006
		EQ 40MG BASE	A077232	003	Oct 31, 2005
	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015
		EQ 20MG BASE	A205407	002	Dec 23, 2015
		EQ 40MG BASE	A205407	003	Dec 23, 2015
	NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
		EQ 40MG BASE	A077141	001	Apr 10, 2008
	PHARMOBEDIENT	EQ 10MG BASE	A077037	001	Nov 05, 2004
		EQ 10MG BASE	A077039	001	Feb 03, 2005
		EQ 20MG BASE	A077037	002	Nov 05, 2004
		EQ 20MG BASE	A077039	002	Feb 03, 2005
		EQ 40MG BASE	A077037	003	Nov 05, 2004
		EQ 40MG BASE	A077039	003	Feb 03, 2005
	ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
		EQ 20MG BASE	A077041	002	Nov 23, 2004
		EQ 40MG BASE	A077041	003	Nov 23, 2004
	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004
		EQ 20MG BASE	A077032	002	Nov 12, 2004
		EQ 40MG BASE	A077032	003	Nov 12, 2004
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052	001	Jul 03, 2006
		EQ 20MG BASE	A077052	002	Jul 03, 2006
		EQ 40MG BASE	A077052	003	Jul 03, 2006
	TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
		EQ 20MG BASE	A077278	002	Mar 22, 2006
		EQ 40MG BASE	A077278	003	Mar 22, 2006
TABLET, ORALLY DISINTEGRATING;ORAL					
CITALOPRAM HYDROBROMIDE					
+	BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
+		EQ 20MG BASE	N021763	002	Dec 20, 2005
+		EQ 40MG BASE	N021763	003	Dec 20, 2005
CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE					
SOLUTION;IRRIGATION					
IRRIGATING SOLUTION G IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER					
	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE					
FOR SOLUTION;ORAL					
PREPOPIK					
+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET **	N202535	001	Jul 16, 2012
CLADRIBINE					
INJECTABLE;INJECTION					
CLADRIBINE					
	PHARMOBEDIENT	1MG/ML	A200510	001	Oct 06, 2011
LEUSTATIN					
+	JANSSEN PHARMS	1MG/ML **	N020229	001	Feb 26, 1993
CLARITHROMYCIN					
FOR SUSPENSION;ORAL					
BIAXIN					
+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993
		187MG/5ML	N050698	003	Sep 30, 1998
+		250MG/5ML	N050698	002	Dec 23, 1993
CLARITHROMYCIN					
	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007
		250MG/5ML	A065382	002	Aug 30, 2007
TABLET;ORAL					
BIAXIN					
+	ABBVIE	250MG **	N050662	001	Oct 31, 1991
+		500MG **	N050662	002	Oct 31, 1991
CLARITHROMYCIN					
	HIKMA	250MG	A065178	002	May 25, 2004
		500MG	A065178	001	May 25, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLARITHROMYCIN

TABLET;ORAL					
CLARITHROMYCIN					
	IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005
		500MG	A065137	002	May 31, 2005
	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019
		500MG	A206714	002	Apr 25, 2019
	PHARMOBEDIENT	250MG	A065195	001	Mar 11, 2005
		500MG	A065195	002	Mar 11, 2005
	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004
		500MG	A065174	002	Sep 24, 2004
	TEVA	250MG	A065155	001	May 31, 2005
		500MG	A065155	002	May 31, 2005
	WOCKHARDT	250MG	A065266	001	May 31, 2006
		500MG	A065266	002	May 31, 2006
TABLET, EXTENDED RELEASE;ORAL					
BIAXIN XL					
+	ABBVIE	500MG **	N050775	001	Mar 03, 2000
CLARITHROMYCIN					
	ANI PHARMS	500MG	A065250	001	Aug 25, 2005
	LUPIN LTD	500MG	A202532	001	Sep 15, 2015
	RANBAXY	1GM	A065210	001	Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION					
TIMENTIN					
	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER					
	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL					
CLEMASTINE FUMARATE					
	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
	APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000
	TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998
TAVIST					
+	NOVARTIS	EQ 0.5MG BASE/5ML **	N018675	001	Jun 28, 1985
TABLET;ORAL					
CLEMASTINE FUMARATE					
	ANI PHARMS	1.34MG	A073282	001	Jan 31, 1992
		1.34MG	A073282	002	Dec 03, 1992
	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995
	OMNIVIUM PHARMS	2.68MG	A073459	001	Oct 31, 1993
	PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993
TAVIST					
+	NOVARTIS	2.68MG **	N017661	001	
TAVIST-1					
+	HALEON US HOLDINGS	1.34MG **	N020925	001	Aug 21, 1992
	NOVARTIS	1.34MG	N017661	002	
		1.34MG	N017661	003	Aug 21, 1992

CLEVIDIPINE

EMULSION;INTRAVENOUS					
CLEVIPREX					
+	CHIESI	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLIDINIUM BROMIDE

CAPSULE;ORAL					
QUARZAN					
	ROCHE	2.5MG	N010355	001	
		5MG	N010355	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLINDAMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	
CLINDAMYCIN HYDROCHLORIDE				
CHARTWELL MOLECULAR	EQ 150MG BASE	A065243	003	Aug 12, 2005
	EQ 300MG BASE	A065243	001	Aug 12, 2005
COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989
	EQ 300MG BASE	A063029	002	Aug 05, 2005
PHARMOBEDIENT	EQ 75MG BASE	A091225	001	May 31, 2011
	EQ 150MG BASE	A091225	002	May 31, 2011
	EQ 300MG BASE	A091225	003	May 31, 2011
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991
	EQ 150MG BASE	A063083	001	Jul 31, 1991
	EQ 300MG BASE	A063083	002	Mar 18, 2003
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **	A061827	001	
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
EXTROVIS	EQ 75MG BASE/5ML	A203063	001	May 25, 2016
CLINDAMYCIN PHOSPHATE				
AEROSOL, FOAM;TOPICAL				
EVOCLIN				
+ NORVIUM BIOSCIENCE	1% **	N050801	001	Oct 22, 2004
CREAM;VAGINAL				
CLEOCIN				
PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992
GEL;TOPICAL				
CLINDAMYCIN PHOSPHATE				
AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ PFIZER	EQ 6MG BASE/ML **	N050639	001	Aug 30, 1989
+	EQ 12MG BASE/ML **	N050639	002	Aug 30, 1989
+	EQ 18MG BASE/ML **	N050639	003	Apr 10, 1991
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987
	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987
	EQ 150MG BASE/ML	A062943	001	Sep 29, 1988
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007
	EQ 150MG BASE/ML	A065347	001	May 09, 2007
HIKMA	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
RISING	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017
	EQ 150MG BASE/ML	A204749	001	Oct 10, 2017
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION				
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989
SOLUTION;TOPICAL				
CLEOCIN T				
+ PFIZER	EQ 1% BASE **	N050537	001	
PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982
CLINDAMYCIN PHOSPHATE				
BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006
G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988
NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996
PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016
PH HEALTH	EQ 1% BASE	A203343	001	May 29, 2015
VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989
XTTRIUM LABS INC	EQ 1% BASE	A063304	001	Jul 15, 1997
SWAB;TOPICAL				
CLEOCIN				
+ PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL				
NYSTAFORM				
BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBAZAM

SUSPENSION;ORAL				
CLOBAZAM				
ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022
HIKMA	2.5MG/ML	A209715	001	Oct 22, 2018
LUPIN LTD	2.5MG/ML	A210546	001	Dec 28, 2018
PHARMOBEDIENT	2.5MG/ML	A211259	001	Oct 22, 2018
TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020
UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018
VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019
TABLET;ORAL				
CLOBAZAM				
ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019
	20MG	A212398	002	May 23, 2019
APOTEX	10MG	A209853	001	Jun 09, 2020
	20MG	A209853	002	Jun 09, 2020
CHARTWELL MOLECULAR	10MG	A212092	001	Oct 30, 2019
	20MG	A212092	002	Oct 30, 2019
CHARTWELL RX	10MG	A211959	001	Dec 09, 2020
	20MG	A211959	002	Dec 09, 2020
HIKMA	10MG	A208785	001	Oct 22, 2018
	20MG	A208785	002	Oct 22, 2018
NOVITIUM PHARMA	5MG	A209308	003	Oct 19, 2021
	10MG	A209308	001	Oct 22, 2018
	20MG	A209308	002	Oct 22, 2018
TARO	10MG	A209440	001	Oct 22, 2018
	20MG	A209440	002	Oct 22, 2018
ONFI				
+ LUNDBECK PHARMS LLC	5MG **	N202067	001	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL				
CLOBETASOL PROPIONATE				
NOVAST LABS	0.05%	A206805	001	Jul 31, 2017
TARO	0.05%	A208563	001	Mar 14, 2024
OLUX				
+ PHARMOBEDIENT	0.05% **	N021142	001	May 26, 2000
OLUX E				
+ PHARMOBEDIENT	0.05% **	N022013	001	Jan 12, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOBETASOL PROPIONATE

CREAM;TOPICAL					
CLOBETASOL PROPIONATE					
CHARTWELL RX	0.05%		A211207	001	Mar 26, 2021
COSETTE	0.05%		A074139	001	Aug 03, 1994
GLENMARK SPECLT	0.05%		A209095	001	May 10, 2018
PAI HOLDINGS PHARM	0.05%		A209974	001	Apr 17, 2018
TEVA PHARMS USA	0.05%		A074087	001	Feb 16, 1994
CLOBETASOL PROPIONATE (EMOLLIENT)					
ANI PHARMS	0.05%		A075733	001	Aug 22, 2001
CORMAX					
HIKMA	0.05%		A074220	001	May 16, 1997
EMBELINE E					
HIKMA	0.05%		A075325	001	Dec 24, 1998
TEMOVATE					
+ FOUGERA PHARMS	0.05%	**	N019322	001	Dec 27, 1985
TEMOVATE E					
+ FOUGERA PHARMS	0.05%	**	N020340	001	Jun 17, 1994
GEL;TOPICAL					
CLOBETASOL PROPIONATE					
PAI HOLDINGS PHARM	0.05%		A208881	001	Mar 06, 2017
EMBELINE					
HIKMA	0.05%		A076141	001	Apr 12, 2002
TEMOVATE					
+ FOUGERA PHARMS	0.05%	**	N020337	001	Apr 29, 1994
LOTION;TOPICAL					
CLOBETASOL PROPIONATE					
BEACH PRODS	0.05%		A208667	001	Nov 29, 2016
EPIC PHARMA LLC	0.05%		A211348	001	Oct 26, 2018
IMPEKLO					
+ PHARMOBEDIENT	0.05%		N213691	001	May 19, 2020
OINTMENT;TOPICAL					
CLOBETASOL PROPIONATE					
ACTAVIS MID ATLANTIC	0.05%		A074128	001	Aug 03, 1994
AMNEAL	0.05%		A210551	001	Aug 21, 2018
GLENMARK SPECLT	0.05%		A208933	001	Mar 20, 2017
PAI HOLDINGS PHARM	0.05%		A208589	001	Jan 23, 2019
TORRENT	0.05%		A212926	001	Oct 25, 2019
EMBELINE					
HIKMA	0.05%		A074221	001	Mar 31, 1995
TEMOVATE					
+ FOUGERA PHARMS	0.05%	**	N019323	001	Dec 27, 1985
SHAMPOO;TOPICAL					
CLOBETASOL PROPIONATE					
ACTAVIS MID ATLANTIC	0.05%		A078854	001	Jun 07, 2011
HIKMA	0.05%		A209871	001	Oct 27, 2017
SOLUTION;TOPICAL					
CLOBETASOL PROPIONATE					
COSETTE	0.05%		A074331	001	Dec 15, 1995
GLENMARK PHARMS LTD	0.05%		A210190	001	Apr 18, 2018
PRINSTON INC	0.05%		A213139	001	Feb 08, 2021
SUN PHARMA CANADA	0.05%		A075363	001	Dec 29, 2000
WOCKHARDT BIO AG	0.05%		A075205	001	Nov 13, 1998
EMBELINE					
HIKMA	0.05%		A074222	001	Dec 06, 1995
TEMOVATE					
+ FOUGERA PHARMS	0.05%	**	N019966	001	Feb 22, 1990
SPRAY;TOPICAL					
CLOBETASOL PROPIONATE					
APOTEX	0.05%		A210446	001	Apr 17, 2018
GLENMARK SPECLT	0.05%		A209004	001	Mar 26, 2018
LUPIN LTD	0.05%		A208125	001	Mar 26, 2018
MACLEODS PHARMS LTD	0.05%		A214345	001	Dec 02, 2024
SCIEGEN PHARMS	0.05%		A207218	001	Apr 28, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOFARABINE
SOLUTION;INTRAVENOUS
CLOFARABINE

ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017
EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022
HOSPIRA	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018
NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018

CLOLAR

+ GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004

CLOFAZIMINE
CAPSULE;ORAL
LAMPRENE

+ NOVARTIS	50MG	N019500	002	Dec 15, 1986
	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE
CAPSULE;ORAL
ATROMID-S

WYETH AYERST	500MG	N016099	002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATE
TABLET;ORAL
CLOMID

+ SANOFI AVENTIS US	50MG **	N016131	002	

SEROPHENE

EMD SERONO	50MG	N018361	001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

AJANTA PHARMA LTD	25MG	A213897	001	Oct 02, 2020
	50MG	A213897	002	Oct 02, 2020
	75MG	A213897	003	Oct 02, 2020
AMNEAL PHARMS CO	25MG	A208632	001	Oct 31, 2018
	50MG	A208632	002	Oct 31, 2018
	75MG	A208632	003	Oct 31, 2018
PHARMOBEDIENT	25MG	A074947	001	Apr 30, 1998
	50MG	A074947	002	Apr 30, 1998
	75MG	A074947	003	Apr 30, 1998
RK PHARMA	25MG	A213221	001	Jun 22, 2020
	50MG	A213221	002	Jun 22, 2020
	75MG	A213221	003	Jun 22, 2020
TEVA	25MG	A074849	001	Apr 04, 1997
	25MG	A074958	001	Aug 26, 1997
	50MG	A074849	002	Apr 04, 1997
	50MG	A074958	002	Aug 26, 1997
	75MG	A074849	003	Apr 04, 1997
	75MG	A074958	003	Aug 26, 1997
WATSON LABS	25MG	A074600	001	Nov 27, 1996
	25MG	A074751	001	Sep 30, 1998
	50MG	A074600	002	Nov 27, 1996
	50MG	A074751	002	Sep 30, 1998
	75MG	A074600	003	Nov 27, 1996
	75MG	A074751	003	Sep 30, 1998

CLONAZEPAM
TABLET;ORAL
CLONAZEPAM

CHARTWELL RX	0.5MG	A074925	001	Sep 30, 1997
	1MG	A074925	002	Sep 30, 1997
	2MG	A074925	003	Sep 30, 1997
PHARMOBEDIENT	0.5MG	A074940	001	Oct 30, 1997
	1MG	A074940	002	Oct 30, 1997
	2MG	A074940	003	Oct 30, 1997
SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLONAZEPAM				
TABLET;ORAL				
CLONAZEPAM				
	1MG		A075423 002	Apr 27, 2001
	2MG		A075423 003	Apr 27, 2001
TEVA	0.5MG		A074920 001	Aug 04, 1998
	1MG		A074920 002	Aug 04, 1998
	2MG		A074920 003	Aug 04, 1998
WATSON LABS	0.5MG		A074964 001	Dec 30, 1997
	1MG		A074964 002	Dec 30, 1997
	2MG		A074964 003	Dec 30, 1997
KLONOPIN				
CHEPLAPHARM	0.125MG		N017533 005	Apr 09, 1997
	0.25MG		N017533 006	Apr 09, 1997
TABLET, ORALLY DISINTEGRATING;ORAL				
CLONAZEPAM				
SUN PHARM INDS INC	0.125MG		A078654 001	Aug 27, 2014
	0.25MG		A078654 002	Aug 27, 2014
	0.5MG		A078654 003	Aug 27, 2014
	1MG		A078654 004	Aug 27, 2014
	2MG		A078654 005	Aug 27, 2014
KLONOPIN RAPIDLY DISINTEGRATING				
+ ROCHE	0.125MG **		N020813 001	Dec 23, 1997
+	0.25MG **		N020813 002	Dec 23, 1997
+	0.5MG **		N020813 003	Dec 23, 1997
+	1MG **		N020813 004	Dec 23, 1997
+	2MG **		N020813 005	Dec 23, 1997
CLONIDINE				
SUSPENSION, EXTENDED RELEASE;ORAL				
CLONIDINE				
TRIS PHARMA INC	EQ 0.09MG BASE/ML		N022499 001	Dec 03, 2009
SYSTEM;TRANSDERMAL				
CLONIDINE				
INGENUS PHARMS LLC	0.1MG/24HR		A076157 001	Aug 18, 2009
	0.2MG/24HR		A076157 002	Aug 18, 2009
	0.3MG/24HR		A076157 003	Aug 18, 2009
TABLET, EXTENDED RELEASE;ORAL				
NEXICLON XR				
ATHENA	EQ 0.26MG BASE		N022500 002	Dec 03, 2009
CLONIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CLONIDINE HYDROCHLORIDE				
AM REGENT	1MG/10ML (0.1MG/ML)		A091104 001	Oct 08, 2009
	5MG/10ML (0.5MG/ML)		A091104 002	Oct 08, 2009
DURACLON				
+ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML) **		N020615 002	Apr 27, 1999
TABLET;ORAL				
CATAPRES				
+ BOEHRINGER INGELHEIM	0.1MG **		N017407 001	
+	0.2MG **		N017407 002	
+	0.3MG **		N017407 003	
CLONIDINE HYDROCHLORIDE				
AM THERAP	0.1MG		A070881 001	Jul 08, 1986
	0.2MG		A070882 001	Jul 08, 1986
	0.3MG		A070883 001	Jul 08, 1986
DURAMED PHARMS BARR	0.1MG		A071103 001	Aug 14, 1986
	0.2MG		A071102 001	Aug 14, 1986
	0.3MG		A071101 001	Aug 14, 1986
INTERPHARM	0.1MG		A071252 001	Oct 01, 1986
	0.2MG		A071253 001	Oct 01, 1986
	0.3MG		A071254 001	Oct 01, 1986
PAR PHARM	0.1MG		A070461 001	Jul 08, 1986
	0.2MG		A070460 001	Jul 08, 1986
	0.3MG		A070459 001	Jul 08, 1986
RISING	0.1MG		A070317 002	Jul 09, 1987
	0.2MG		A070317 003	Jun 09, 1987
	0.3MG		A070317 001	Jun 09, 1987
SUN PHARM INDS INC	0.1MG		A090329 001	Jul 03, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

		0.2MG	A090329	002	Jul 03, 2014
		0.3MG	A090329	003	Jul 03, 2014
	TEVA	0.1MG	A070747	001	Jul 08, 1986
		0.2MG	A070702	001	Jul 08, 1986
		0.3MG	A070659	001	Jul 08, 1986
	WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
		0.2MG	A072139	001	Jun 13, 1988
		0.3MG	A072140	001	Jun 13, 1988
	WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
		0.1MG	A070965	001	Jul 08, 1986
		0.2MG	A070396	001	Mar 23, 1987
		0.2MG	A070964	001	Jul 08, 1986
		0.3MG	A070397	001	Mar 23, 1987
		0.3MG	A070963	001	Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015
		0.2MG	A202792	002	May 15, 2015
		0.2MG	A203320	002	May 15, 2015
	AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017
	PH HEALTH	0.1MG	A202983	001	Apr 02, 2014
		0.1MG	A202984	001	Sep 30, 2013
		0.2MG	A202983	002	Apr 02, 2014
		0.2MG	A202984	002	Sep 30, 2013
	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018

JENLOGA

+	CONCORDIA PHARMS INC	0.1MG **	N022331	001	Sep 30, 2009
+		0.2MG **	N022331	002	May 25, 2010

KAPVAY

+	CONCORDIA PHARMS INC	0.1MG **	N022331	003	Sep 28, 2010
+		0.2MG **	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013
		EQ 300MG BASE	A202925	002	Mar 27, 2013
	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013
	ANI PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012
		EQ 300MG BASE	A091216	001	May 17, 2012
	CHARTWELL RX	EQ 75MG BASE	A202266	001	Aug 14, 2012
		EQ 300MG BASE	A202266	002	Nov 20, 2012
	RISING	EQ 75MG BASE	A077665	001	May 17, 2012
		EQ 300MG BASE	A077665	002	May 17, 2012
	SUN PHARM	EQ 75MG BASE	A090494	001	May 17, 2012
	SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013
	ZYDUS LIFESCIENCES	EQ 75MG BASE	A201686	001	Oct 10, 2012

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

	ABLE	3.75MG	A071777	001	Jul 14, 1987
		7.5MG	A071778	001	Jul 14, 1987
		15MG	A071779	001	Jul 14, 1987
	AM THERAP	3.75MG	A071429	001	Jun 23, 1987
		7.5MG	A071430	001	Jun 23, 1987
		15MG	A071431	001	Jun 23, 1987
	DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987
		7.5MG	A071510	001	Oct 19, 1987
		15MG	A071511	001	Oct 19, 1987
	DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
		7.5MG	A071743	001	Dec 14, 1987
		15MG	A071744	001	Dec 14, 1987
	GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
		7.5MG	A071728	001	Dec 18, 1987
		15MG	A071729	001	Dec 18, 1987
	PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL					
CLORAZEPATE DIPOTASSIUM					
		7.5MG	A071925	001	Apr 25, 1988
		15MG	A071926	001	Apr 25, 1988
	QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
		7.5MG	A071550	001	Sep 12, 1988
		15MG	A071522	001	Sep 12, 1988
	RISING	3.75MG	A072112	002	Aug 26, 1988
		7.5MG	A072112	003	Aug 26, 1988
		15MG	A072112	001	Aug 26, 1988
	USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
		7.5MG	A071243	001	Jun 23, 1987
		15MG	A071244	001	Jun 23, 1987
	WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
		7.5MG	A071775	001	Mar 01, 1988
		15MG	A071776	001	Mar 01, 1988
	WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
		7.5MG	A071879	001	Mar 15, 1988
		15MG	A071860	001	Mar 15, 1988
TRANXENE					
+	AJENAT PHARMS	3.75MG **	N017105	001	
+		7.5MG **	N017105	002	
+		15MG **	N017105	003	
TABLET;ORAL					
CLORAZEPATE DIPOTASSIUM					
	ABLE	3.75MG	A071780	001	Jun 26, 1987
		7.5MG	A071781	001	Jun 26, 1987
		15MG	A071782	001	Jun 26, 1987
	AM THERAP	3.75MG	A071747	001	Jun 23, 1987
		7.5MG	A071748	001	Jun 23, 1987
		15MG	A071749	001	Jun 23, 1987
	AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990
		7.5MG	A072514	003	May 11, 1990
		15MG	A072514	001	May 11, 1990
	LEDERLE	3.75MG	A072013	001	Dec 15, 1987
		7.5MG	A072014	001	Dec 15, 1987
		15MG	A072015	001	Dec 15, 1987
	PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
		7.5MG	A072331	001	Aug 08, 1988
		15MG	A072332	001	Aug 08, 1988
	QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
		7.5MG	A071731	001	Oct 26, 1987
		15MG	A071702	001	Oct 26, 1987
	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
		7.5MG	A076911	002	Sep 29, 2004
		15MG	A076911	003	Sep 29, 2004
	WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
		7.5MG	A071829	001	Mar 03, 1988
		15MG	A071830	001	Mar 03, 1988
	WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
		7.5MG	A071853	001	Feb 09, 1988
		15MG	A071854	001	Feb 09, 1988
GEN-XENE					
	ALRA	3.75MG	A071787	001	Apr 26, 1988
		7.5MG	A071788	001	Apr 26, 1988
		15MG	A071789	001	Apr 26, 1988
TRANXENE					
+	AJENAT PHARMS	3.75MG **	N017105	006	
+		15MG **	N017105	008	
TRANXENE SD					
+	AJENAT PHARMS	11.25MG **	N017105	005	
+		22.5MG **	N017105	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOTRIMAZOLE				
CREAM;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **	N017619 001		
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183 001		
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **	N018052 002	Nov 30, 1990	
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%	N020574 001	Nov 24, 1998	
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230 002	Dec 26, 1991	
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG	N020526 002	Jul 29, 1996	
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG	N020289 002	Apr 26, 1993	
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG	N020389 002	Jun 23, 1994	
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%	N018813 001	Feb 17, 1984	
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **	N017613 001		
MYCELEX				
+ BAYER HLTHCARE	1% **	N018181 001		
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG	N017717 002	Nov 30, 1990	
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG	N020525 001	Jul 29, 1996	
GYNIX				
TEVA PHARMS	100MG	A073249 001	Feb 13, 1998	
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG	N018182 002	Dec 26, 1991	
MYCELEX-G				
BAYER PHARMS	500MG	N019069 001	Apr 19, 1985	
TROCHE/LOZENGE;ORAL				
MYCELEX				
+ BAYER HLTHCARE	10MG **	N018713 001	Jun 17, 1983	
CLOXACILLIN SODIUM				
CAPSULE;ORAL				
CLOXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE	A061452 001		
	EQ 500MG BASE	A061452 002		
TEVA	EQ 250MG BASE	A062240 001		
	EQ 500MG BASE	A062240 002		
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE	A061806 001		
	EQ 250MG BASE	A062233 001		
	EQ 500MG BASE	A061806 002		
	EQ 500MG BASE	A062233 002		
FOR SOLUTION;ORAL				
CLOXACILLIN SODIUM				
TEVA	EQ 125MG BASE/5ML	A062268 001		
	EQ 125MG BASE/5ML	A062978 001	Apr 06, 1989	
TEGOPEN				
APOTHECON	EQ 125MG BASE/5ML	A061453 001		
	EQ 125MG BASE/5ML	N050192 001		
CLOZAPINE				
TABLET;ORAL				
CLOZAPINE				
DR REDDYS LABS SA	25MG	A203807 001	Sep 17, 2015	
	50MG	A203807 003	Aug 22, 2017	
	100MG	A203807 002	Sep 17, 2015	
	200MG	A203807 004	Aug 22, 2017	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOZAPINE

TABLET;ORAL					
CLOZAPINE					
	MYLAN	12.5MG	A075417	003	Apr 15, 2010
	PAR PHARM	25MG	A075162	001	Apr 26, 2005
		100MG	A075162	002	Apr 26, 2005
	SANDOZ	25MG	A074546	001	Aug 30, 1996
		100MG	A074546	002	Aug 30, 1996
	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002
		50MG	A075713	003	Aug 19, 2005
		100MG	A075713	002	Nov 15, 2002
		200MG	A075713	004	Nov 07, 2017
	ZYDUS PHARMS	25MG	A209480	001	Dec 06, 2017
		50MG	A209480	002	Dec 06, 2017
		100MG	A209480	003	Dec 06, 2017
		200MG	A209480	004	Dec 06, 2017
CLOZARIL					
+	HERITAGE LIFE	50MG **	N019758	003	May 20, 2019
+		200MG **	N019758	004	May 20, 2019
TABLET, ORALLY DISINTEGRATING;ORAL					
FAZACLO ODT					
+	JAZZ	12.5MG **	N021590	004	May 30, 2007
+		25MG **	N021590	001	Feb 10, 2004
+		50MG **	N021590	003	Jun 03, 2005
+		100MG **	N021590	002	Feb 10, 2004
+		150MG **	N021590	005	Jul 09, 2010
+		200MG **	N021590	006	Jul 09, 2010

COBICISTAT

TABLET;ORAL					
COBICISTAT					
	MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024
TYBOST					
+	GILEAD SCIENCES INC	90MG	N203094	002	Jun 20, 2025

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN VC W/ CODEINE					
+	ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **	N008306	005	Apr 02, 1984
PHERAZINE VC W/ CODEINE					
	HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987
PROMETH VC W/ CODEINE					
	CHARTWELL RX	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE					
	HIKMA	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014
PROMETHAZINE VC W/ CODEINE					
	CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
	WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHENERGAN W/ CODEINE					
+	ANI PHARMS	10MG/5ML;6.25MG/5ML **	N008306	004	Apr 02, 1984
PHERAZINE W/ CODEINE					
	HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
+	ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML **	A088763	001	Oct 31, 1984
	HIKMA	10MG/5ML;6.25MG/5ML	A040151	001	Aug 26, 1997
	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988
PROMETHAZINE W/ CODEINE					
	CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985
PROMETHAZINE WITH CODEINE					
	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A040650	001	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL					
ACTIFED W/ CODEINE					
	GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML **	N012575	003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE					
	CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
	WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833 001	Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL				
CODEINE SULFATE				
	HIKMA	30MG/5ML	N202245 001	Jun 30, 2011

COLCHICINE

TABLET;ORAL				
COLCRYS				
+	TAKEDA PHARMS USA	0.6MG **	N022352 001	Jul 29, 2009

COLCHICINE; PROBENECID

TABLET;ORAL				
COLBENEMID				
+	MERCK	0.5MG;500MG **	N012383 001	
PROBEN-C				
	WATSON LABS	0.5MG;500MG	A085552 001	
PROBENECID AND COLCHICINE				
	ANI PHARMS	0.5MG;500MG	A083734 001	
	BEECHAM	0.5MG;500MG	A084321 001	
	IMPAX LABS	0.5MG;500MG	A083720 002	
	SANDOZ	0.5MG;500MG	A086130 001	
PROBENECID W/ COLCHICINE				
	LEDERLE	0.5MG;500MG	A086954 001	
	WATSON LABS	0.5MG;500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL				
WELCHOL				
+	COSETTE	3.75GM	N210895 001	Apr 03, 2019
CAPSULE;ORAL				
WELCHOL				
	COSETTE	375MG	N021141 001	May 26, 2000
FOR SUSPENSION;ORAL				
COLESEVELAM HYDROCHLORIDE				
	IMPAX	3.75GM/PACKET	A212886 001	Jan 18, 2023
	WATSON LABS INC	1.875GM/PACKET	A202178 001	Sep 01, 2020
		3.75GM/PACKET	A202178 002	Sep 01, 2020
WELCHOL				
+	COSETTE	1.875GM/PACKET **	N022362 001	Oct 02, 2009
TABLET;ORAL				
COLESEVELAM HYDROCHLORIDE				
	CHARTWELL RX	625MG	A201354 001	Dec 17, 2020
	INVAGEN PHARMS	625MG	A212602 001	Apr 20, 2020
	MACLEODS PHARMS LTD	625MG	A204893 001	Apr 18, 2025
	UNITED RES LABS	625MG	A213456 001	Jan 21, 2022
	WATSON LABS INC	625MG	A200830 001	Sep 02, 2020

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL				
FLAVORED COLESTID				
+	PFIZER	5GM/PACKET	N017563 001	
+		5GM/SCOOPFUL	N017563 002	

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION				
COLISTIMETHATE SODIUM				
	NEXUS	EQ 150MG BASE/VIAL	A065177 001	Mar 19, 2004
	PHARMOBEDIENT	EQ 150MG BASE/VIAL	A064216 001	Feb 26, 1999

COLISTIN SULFATE

SUSPENSION;ORAL				
COLY-MYCIN S				
	PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CONIVAPTAN HYDROCHLORIDE				
INJECTABLE;INTRAVENOUS				
VAPRISOL				
	CUMBERLAND	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005
COPANLISIB DIHYDROCHLORIDE				
POWDER;INTRAVENOUS				
ALIQOPA				
+	BAYER HEALTHCARE	60MG/VIAL	N209936 001	Sep 14, 2017
COPPER				
INTRAUTERINE DEVICE;INTRAUTERINE				
CU-7				
	GD SEARLE LLC	89MG	N017408 001	
TATUM-T				
	GD SEARLE LLC	120MG	N018205 001	
CORTICOTROPIN				
INJECTABLE;INJECTION				
ACTH				
	PARKEDALE	25 UNITS/VIAL	N008317 002	
		40 UNITS/VIAL	N008317 004	
ACTHAR				
	SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002	
		40 UNITS/VIAL	N007504 003	
ACTHAR GEL				
	MALLINCKRODT IRELAND	40 UNITS/ML	N008372 006	
CORTICOTROPIN				
	ORGANICS LAGRANGE	40 UNITS/ML	N010831 001	
		80 UNITS/ML	N010831 002	
	WATSON LABS	40 UNITS/VIAL	A088772 001	Nov 21, 1984
PURIFIED CORTROPHIN GEL				
	ANI PHARMS	40 UNITS/ML	N008975 001	
CORTICOTROPIN-ZINC HYDROXIDE				
INJECTABLE;INJECTION				
CORTROPHIN-ZINC				
	ANI PHARMS	40 UNITS/ML	N009854 001	
CORTISONE ACETATE				
INJECTABLE;INJECTION				
CORTISONE ACETATE				
	PHARMACIA AND UPJOHN	25MG/ML	N008126 002	
	WATSON LABS	25MG/ML	A083147 003	
		25MG/ML	A085677 001	
		50MG/ML	A083147 004	
		50MG/ML	A085677 002	
CORTONE				
	MERCK	25MG/ML	N007110 002	
		50MG/ML	N007110 003	
TABLET;ORAL				
CORTISONE ACETATE				
	BARR	25MG	A083471 001	
	CHARTWELL MOLECULAR	25MG	A080694 001	
	ELKINS SINN	25MG	A080836 001	
	EVERYLIFE	25MG	A084246 001	
	HEATHER	25MG	A085736 001	
	HIKMA INTL PHARMS	25MG	A080776 002	
	IMPAX LABS	25MG	N009458 001	
	INWOOD LABS	25MG	A080731 001	
	IVAX SUB TEVA PHARMS	25MG	A080630 001	
		25MG	A083536 001	
	PANRAY	5MG	N008284 002	
		25MG	N008284 001	
	PHARMACIA AND UPJOHN	5MG	N008126 003	
		10MG	N008126 004	
		25MG	N008126 001	
	PUREPAC PHARM	25MG	A080493 001	
	VITARINE	25MG	A080333 001	
	WATSON LABS	25MG	A085884 001	
	WHITEWORTH TOWN PLSN	25MG	A080341 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CORTISONE ACETATE
TABLET;ORAL
CORTONE
+ MERCK 25MG ** N007750 003

COSYNTROPIN
INJECTABLE;INJECTION
COSYNTROPIN
PHARMOBEDIENT 0.25MG/VIAL A090574 001 Dec 17, 2009
SOLUTION;INTRAVENOUS
COSYNTROPIN
SANDOZ 0.25MG/ML (0.25MG/ML) N022028 001 Feb 21, 2008

CROMOLYN SODIUM
AEROSOL, METERED;INHALATION
INTAL
KING PHARMS LLC 0.8MG/INH N018887 001 Dec 05, 1985
CAPSULE;INHALATION
INTAL
+ SANOFI AVENTIS US 20MG ** N016990 001
CAPSULE;ORAL
GASTROCROM
UCB INC 100MG N019188 001 Dec 22, 1989
CONCENTRATE;ORAL
CROMOLYN SODIUM
GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009
SOLUTION;INHALATION
CROMOLYN SODIUM
ACTAVIS MID ATLANTIC 10MG/ML A075067 001 Jul 19, 1999
BAUSCH 10MG/ML A075585 001 Dec 21, 2000
EUGIA PHARMA 10MG/ML A074209 001 Apr 26, 1994
HIKMA 10MG/ML A075333 001 Apr 30, 2002
ROXANE 10MG/ML A075175 001 Sep 30, 1999
WATSON LABS 10MG/ML A076469 001 Jun 17, 2005
INTAL
+ KING PHARMS LLC 10MG/ML ** N018596 001 May 28, 1982
SOLUTION/DROPS;OPHTHALMIC
CROLOM
BAUSCH AND LOMB 4% A074443 001 Jan 30, 1995
CROMOLYN SODIUM
APOTEX INC 4% A075615 001 Jan 26, 2001
SCIEGEN PHARMS 4% A074706 001 Apr 29, 1998
CROMOPTIC
KING PHARMS 4% A075088 001 Apr 27, 1999
OPTICROM
+ ALLERGAN 4% ** N018155 001 Oct 03, 1984
SPRAY, METERED;NASAL
CROMOLYN SODIUM
ACTAVIS MID ATLANTIC 5.2MG/SPRAY A074800 001 Jul 26, 2001
HH AND P 5.2MG/SPRAY A077976 001 Sep 07, 2007
PERRIGO 5.2MG/SPRAY A075427 001 Dec 12, 2001
NASALCROM
+ BLACKSMITH BRANDS 5.2MG/SPRAY ** N020463 001 Jan 03, 1997

CROTAMITON
CREAM;TOPICAL
EURAX
+ JOURNEY 10% N006927 001

CRYPTENAMINE ACETATES
INJECTABLE;INJECTION
UNITENSEN
MEDPOINTE PHARM HLC 260CSR UNIT/ML N008814 001

CRYPTENAMINE TANNATES
TABLET;ORAL
UNITENSEN
MEDPOINTE PHARM HLC 260CSR UNIT N009217 001

CUPRIC SULFATE				
INJECTABLE;INJECTION				
CUPRIC SULFATE				
+ ABRAXIS PHARM	EQ 0.4MG COPPER/ML **	N019350 001	May 05, 1987	
APOTEX CORP	EQ 0.4MG COPPER/ML	A218745 001	Aug 19, 2024	
CYANOCOBALAMIN				
GEL, METERED;NASAL				
NASCOBAL				
ENDO OPERATIONS	0.5MG/INH	N019722 001	Nov 05, 1996	
INJECTABLE;INJECTION				
BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798 001		
BETALIN 12				
LILLY	0.1MG/ML	A080855 001		
	1MG/ML	A080855 002		
COBAVITE				
WATSON LABS	0.1MG/ML	A083013 001		
	1MG/ML	A083064 001		
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510 003		
	0.1MG/ML	A080510 001		
	1MG/ML	A080510 002		
DELL LABS	0.03MG/ML	A080689 001		
	0.1MG/ML	A080689 002		
	1MG/ML	A080689 003		
DR REDDYS	0.1MG/ML	A080573 002		
	1MG/ML	A080573 001		
EPIC PHARMA LLC	1MG/ML	A087969 001	Nov 10, 1983	
FRESENIUS KABI USA	0.1MG/ML	A080557 002		
LUITPOLD	0.03MG/ML	A080668 001		
LYPHOMED	1MG/ML	A083075 001		
MYLAN INSTITUTIONAL	1MG/ML	A040451 001	Sep 23, 2003	
SANOFI AVENTIS US	1MG/ML	A080564 001		
SOLOPAK	1MG/ML	A087551 001	Feb 29, 1984	
WARNER CHILCOTT	1MG/ML	N007085 002		
WATSON LABS	0.1MG/ML	A083120 001		
	1MG/ML	A083120 002		
WYETH AYERST	0.1MG/ML	A080554 001		
	1MG/ML	A080554 002		
XIROMED	1MG/ML	A215046 001	Aug 20, 2021	
DODEX				
ACCORD HLTHCARE	1MG/ML	A083022 001		
REDISOL				
MERCK	1MG/ML	N006668 010		
RUBIVITE				
BEL MAR	0.03MG/ML	N010791 004		
	0.05MG/ML	N010791 001		
	0.1MG/ML	N010791 002		
	0.12MG/ML	N010791 005		
	1MG/ML	N010791 003		
RUBRAMIN PC				
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002		
+	1MG/ML **	N006799 004		
+	1MG/ML **	N006799 010	Apr 28, 1988	
RUVITE				
SAVAGE LABS	1MG/ML	A080570 002		
VI-TWEL				
BAYER HLTHCARE	1MG/ML	N007012 002		
SPRAY, METERED;NASAL				
CALOMIST				
PH HEALTH	25MCG/SPRAY	N022102 001	Jul 27, 2007	
NASCOBAL				
+ ENDO OPERATIONS	0.5MG/SPRAY **	N021642 001	Jan 31, 2005	
TABLET;ORAL				
CYANOCOBALAMIN				
WEST WARD	1MG	A084264 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A;N/A

DICOPAC KIT

GE HEALTHCARE	N/A;N/A;N/A	N017406 001	

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE;INJECTION

DEPINAR

ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208 001	

CYCLACILLIN

FOR SUSPENSION;ORAL

CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508 001	
	250MG/5ML	N050508 002	
	500MG/5ML	N050508 003	

TABLET;ORAL

CYCLACILLIN

TEVA	250MG	A062895 001	Aug 04, 1988
	500MG	A062895 002	Aug 04, 1988

CYCLAPEN-W

WYETH AYERST	250MG	N050509 001	
	500MG	N050509 002	

CYCLIZINE LACTATE

INJECTABLE;INJECTION

MAREZINE

GLAXOSMITHKLINE	50MG/ML	N009495 001	

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

APOTEX	15MG	A206703 001	Jul 24, 2018
	30MG	A206703 002	Jul 24, 2018

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AIPING PHARM INC	5MG	A072854 002	Feb 03, 2006
	10MG	A072854 001	Nov 19, 1991
PLIVA	10MG	A074421 001	Sep 29, 1995
RISING	5MG	A073144 002	Feb 03, 2006
	7.5MG	A073144 003	Mar 25, 2013
	10MG	A073144 001	May 30, 1991
SANDOZ	10MG	A073683 001	Feb 26, 1993
SUN PHARM INDS LTD	5MG	A078722 001	May 12, 2008
	7.5MG	A078722 002	May 12, 2008
	10MG	A078722 003	May 12, 2008
WATSON LABS	10MG	A073143 001	Nov 27, 1991
	10MG	A074436 001	Nov 30, 1994

FLEXERIL

+	JANSSEN RES AND DEV	5MG **	N017821 001	
+		10MG **	N017821 002	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AK-PENTOLATE

EPIC PHARMA LLC	1%	A085555 001	

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD	1%	A089162 001	Jan 24, 1991
SCIEGEN PHARMS	0.5%	A205937 001	Dec 09, 2015
SOLA BARNES HIND	1%	A084150 001	
	1%	A084863 001	

PENTOLAIR

PHARMAFAIR	0.5%	A088643 001	Feb 09, 1987
	1%	A088150 001	Feb 25, 1983

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

ANI PHARMS	25MG	A207014 001	Mar 19, 2018
	50MG	A207014 002	Mar 19, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYCLOPHOSPHAMIDE					
INJECTABLE;INJECTION					
CYCLOPHOSPHAMIDE					
	BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
		200MG/VIAL	A088372	001	Jul 03, 1986
		500MG/VIAL	A088373	001	Jul 03, 1986
		1GM/VIAL	A088374	001	Sep 24, 1986
CYTOXAN					
+	BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+		200MG/VIAL **	N012142	002	
CYTOXAN (LYOPHILIZED)					
+	BAXTER HLTHCARE	500MG/VIAL **	N012142	003	
+		500MG/VIAL **	N012142	008	Jan 04, 1984
+		1GM/VIAL **	N012142	004	Aug 30, 1982
+		1GM/VIAL **	N012142	010	Sep 24, 1985
+		2GM/VIAL **	N012142	005	Aug 30, 1982
+		2GM/VIAL **	N012142	009	Dec 10, 1985
LYOPHILIZED CYTOXAN					
+	BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+		200MG/VIAL **	N012142	007	Dec 10, 1985
NEOSAR					
	BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
		200MG/VIAL	A087442	002	Feb 16, 1982
		500MG/VIAL	A087442	003	Feb 16, 1982
		1GM/VIAL	A087442	004	Jul 08, 1983
		2GM/VIAL	A087442	005	Mar 30, 1989
	TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
		200MG/VIAL	A040015	002	Apr 29, 1993
		500MG/VIAL	A040015	003	Apr 29, 1993
		1GM/VIAL	A040015	004	Apr 29, 1993
		2GM/VIAL	A040015	005	Apr 29, 1993
TABLET;ORAL					
CYCLOPHOSPHAMIDE					
	ROXANE	25MG	A040032	001	Aug 17, 1999
		50MG	A040032	002	Aug 17, 1999
CYCLOSPORINE					
CAPSULE;ORAL					
GENGRAF					
	ABBVIE	50MG	A065003	002	May 12, 2000
NEORAL					
+	NOVARTIS	50MG **	N050715	003	Jul 14, 1995
EMULSION;OPHTHALMIC					
CYCLOSPORINE					
	APOTEX	0.05%	A207606	001	Jan 12, 2023
SOLUTION;ORAL					
CYCLOSPORINE					
	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000
	DR REDDYS LABS SA	100MG/ML	A065054	001	Dec 18, 2001
	PHARM ASSOC	100MG/ML	A065167	001	Jan 05, 2005
	PHARMOBEDIENT CNSLTG	100MG/ML	A065133	001	Sep 17, 2004
CYCLOTHIAZIDE					
TABLET;ORAL					
ANHYDRON					
	LILLY	2MG	N013157	002	
FLUIDIL					
	PHARMACIA AND UPJOHN	2MG	N018173	001	
CYCRIMINE HYDROCHLORIDE					
TABLET;ORAL					
PAGITANE					
	LILLY	1.25MG	N008951	001	
		2.5MG	N008951	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
+	ACTAVIS MID ATLANTIC	2MG/5ML **	A086833	001	
	HALSEY	2MG/5ML	A089199	001	Jul 03, 1986
	MORTON GROVE	2MG/5ML	A087001	001	Nov 04, 1982
	NASKA	2MG/5ML	A089021	001	Dec 21, 1987
	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016
	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013
	TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021
PERIACTIN					
+	MERCK	2MG/5ML **	N013220	002	
TABLET;ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
	AM THERAP	4MG	A088798	001	Feb 15, 1985
	ASCOT	4MG	A087685	001	Oct 25, 1982
	CHARTWELL RX	4MG	A086808	001	
	DURAMED PHARMS BARR	4MG	A088232	001	Oct 25, 1983
	HALSEY	4MG	A089057	001	Jul 03, 1986
+	HERITAGE PHARMA	4MG **	A087056	001	
	KV PHARM	4MG	A086737	001	
	MD PHARM	4MG	A087566	001	Nov 10, 1982
	MYLAN	4MG	A086678	001	
	PIONEER PHARMS	4MG	A087839	001	Feb 08, 1984
	PLIVA	4MG	A088205	001	Jul 26, 1983
	RISING	4MG	A207783	001	Dec 29, 2016
	STRIDES PHARMA INTL	4MG	A087129	001	
	SUPERPHARM	4MG	A087405	001	
	VITARINE	4MG	A087284	001	
	WATSON LABS	4MG	A085245	001	
		4MG	A086165	001	
		4MG	A086580	001	
PERIACTIN					
+	MERCK	4MG **	N012649	001	

CYSTEINE HYDROCHLORIDE

INJECTABLE;INJECTION					
CYSTEINE HYDROCHLORIDE					
+	HOSPIRA	7.25% **	N019523	001	Oct 22, 1986
SOLUTION;INTRAVENOUS					
ELCYS					
+	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023
NOURESS					
+	BAXTER HLTHCARE CORP	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019

CYTARABINE

INJECTABLE;INJECTION					
CYTARABINE					
	MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020
		20MG/ML	A206190	001	Nov 09, 2017
	PHARMOBEDIENT	20MG/ML	A200916	001	Dec 13, 2011
	RISING	20MG/ML	A200914	001	Dec 13, 2011
+	TEVA PARENTERAL	100MG/VIAL **	N016793	001	
+		500MG/VIAL **	N016793	002	
+		1GM/VIAL **	N016793	003	Dec 21, 1987
+		2GM/VIAL **	N016793	004	Dec 21, 1987
CYTOSAR-U					
	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998
		500MG/VIAL	A075206	002	Dec 30, 1998
		1GM/VIAL	A075206	004	Dec 30, 1998
		2GM/VIAL	A075206	003	Dec 30, 1998
INJECTABLE, LIPOSOMAL;INJECTION					
DEPOCYT					
+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL				
DABIGATRAN ETEXILATE MESYLATE				
BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024
	EQ 110MG BASE	A207922	003	Dec 19, 2024
	EQ 150MG BASE	A207922	002	Dec 19, 2024

DACARBAZINE

INJECTABLE;INJECTION				
DACARBAZINE				
ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
	200MG/VIAL	A070990	001	Aug 28, 1986
HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001
DTIC-DOME				
+ BAYER HLTHCARE	100MG/VIAL **	N017575	001	
+	200MG/VIAL **	N017575	002	

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL				
DAKLINZA				
+ BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
+	EQ 60MG BASE	N206843	002	Jul 24, 2015
+	EQ 90MG BASE	N206843	003	Apr 13, 2016

DACTINOMYCIN

INJECTABLE;INJECTION				
COSMEGEN				
+ RECORDATI RARE	0.5MG/VIAL **	N050682	001	
DACTINOMYCIN				
AM REGENT	0.5MG/VIAL	A202562	001	Aug 23, 2013
HIKMA	0.5MG/VIAL	A090304	001	Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL				
DALFAMPRIDINE				
HIKMA	10MG	A206646	001	Oct 24, 2018
RISING	10MG	A206858	001	Jul 06, 2020
SUN PHARM	10MG	A208292	001	May 21, 2019

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS				
SYNERCID				
+ KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999
	420MG/VIAL;180MG/VIAL	N050748	002	Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE;INJECTION				
FRAGMIN				
PFIZER	7,500 IU/0.75ML	N020287	008	Apr 04, 2002
INJECTABLE;SUBCUTANEOUS				
FRAGMIN				
PFIZER	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE;INJECTION				
ORGARAN				
ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996

DANAZOL

CAPSULE;ORAL				
DANAZOL				
AM THERAP	200MG	A071569	001	Dec 30, 1987
DANOCRINE				
SANOFI AVENTIS US	50MG **	N017557	003	
	100MG **	N017557	004	
	200MG **	N017557	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DANTROLENE SODIUM
INJECTABLE;INJECTION
DANTROLENE SODIUM

	EUGIA PHARMA SPECLTS	20MG/VIAL	A205239	001	Feb 18, 2016

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR

+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019
+		10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
TABLET;ORAL
QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019
+		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPIPRAZOLE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

	BARADAINA LLC	0.5%	A204902	001	May 30, 2019
+	FERA PHARMS	0.5% **	N019849	001	Dec 31, 1990

DAPRODUSTAT
TABLET;ORAL
JESDUVROQ

+	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023
+		2MG	N216951	002	Feb 01, 2023
+		4MG	N216951	003	Feb 01, 2023
+		6MG	N216951	004	Feb 01, 2023
+		8MG	N216951	005	Feb 01, 2023

DAPSONE
GEL;TOPICAL
DAPSONE

	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023
		7.5%	A212657	001	Nov 01, 2023

TABLET;ORAL
DAPSONE

	ALVOGEN	25MG	A205429	001	Jan 07, 2016
		100MG	A205429	002	Jan 07, 2016
	CHARTWELL RX	25MG	A204074	001	May 10, 2016
		100MG	A204074	002	May 10, 2016
	TARO	25MG	A209430	001	Mar 01, 2019
		100MG	A209430	002	Mar 01, 2019

DAPTOMYCIN
POWDER;INTRAVENOUS
CUBICIN

	CUBIST PHARMS LLC	250MG/VIAL **	N021572	001	Sep 12, 2003
+		500MG/VIAL **	N021572	002	Sep 12, 2003

CUBICIN RF

+	CUBIST PHARMS LLC	500MG/VIAL **	N021572	003	Jul 06, 2016

DAPTOMYCIN

	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024
	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021
	HOSPIRA	500MG/VIAL	A202857	001	Sep 12, 2014
+	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024

DAPZURA RT

+	BAXTER HLTHCARE CORP	500MG/VIAL **	N213645	001	Jan 25, 2022

DARIFENACIN HYDROBROMIDE
TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

	JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016
		EQ 15MG BASE	A205550	002	Oct 12, 2016
	PH HEALTH	EQ 7.5MG BASE	A091190	001	Mar 13, 2015
		EQ 15MG BASE	A091190	002	Mar 13, 2015
	XIROMED	EQ 7.5MG BASE	A209571	002	Oct 22, 2019
		EQ 15MG BASE	A209571	001	Oct 22, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DARIFENACIN HYDROBROMIDE				
TABLET, EXTENDED RELEASE;ORAL				
ENABLEX				
+ ABBVIE	EQ 7.5MG BASE **	N021513	001	Dec 22, 2004
+	EQ 15MG BASE **	N021513	002	Dec 22, 2004
DARUNAVIR				
TABLET;ORAL				
DARUNAVIR				
TEVA PHARMS USA	600MG	A202118	001	Nov 21, 2017
PREZISTA				
+ JANSSEN PRODS	300MG **	N021976	001	Jun 23, 2006
+	400MG **	N021976	003	Oct 21, 2008
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR				
TABLET;ORAL				
VIEKIRA PAK (COPACKAGED)				
+ ABBVIE	EQ 250MG BASE;12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR				
TABLET, EXTENDED RELEASE;ORAL				
VIEKIRA XR				
+ ABBVIE	EQ 200MG BASE;8.33MG;50MG;33.33MG **	N208624	001	Jul 22, 2016
DAUNORUBICIN CITRATE				
INJECTABLE, LIPOSOMAL;INJECTION				
DAUNOXOME				
GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996
DAUNORUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
CERUBIDINE				
SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876	001	
WYETH AYERST	EQ 20MG BASE/VIAL **	N050484	001	
DAUNORUBICIN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001
HISUN PHARM HANGZHOU	EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019
TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212	001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212	002	May 03, 1999
DECAMETHONIUM BROMIDE				
INJECTABLE;INJECTION				
SYNCURINE				
GLAXOSMITHKLINE	1MG/ML	N006931	002	
DECITABINE				
INJECTABLE;INTRAVENOUS				
DACOGEN				
+ OTSUKA	50MG/VIAL **	N021790	001	May 02, 2006
DECITABINE				
CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017
EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021
LUPIN LTD	50MG/VIAL	A210756	001	Nov 09, 2018
POWDER;INTRAVENOUS				
DECITABINE				
+ SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014
DEFERASIROX				
GRANULE;ORAL				
DEFERASIROX				
AMNEAL	90MG	A214194	003	Aug 02, 2021
	180MG	A214194	001	Feb 09, 2021
	360MG	A214194	002	Feb 09, 2021
PHARMOBEDIENT	90MG	A213146	001	May 03, 2024
	180MG	A213146	002	May 03, 2024
	360MG	A213146	003	May 03, 2024
TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021
	180MG	A214180	002	Nov 19, 2021
	360MG	A214180	003	Nov 19, 2021
TABLET;ORAL				
DEFERASIROX				
CIPLA	90MG	A211852	001	Feb 11, 2020
	180MG	A211852	003	Jun 15, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEFERASIROX				
TABLET;ORAL				
DEFERASIROX				
	360MG	A211852	002	Feb 11, 2020
STEVENS J	90MG	A210727	001	Dec 27, 2019
	180MG	A210727	003	Jun 15, 2020
	360MG	A210727	002	Dec 27, 2019
SUN PHARM	90MG	A211641	001	Jan 02, 2020
	180MG	A211641	003	Jun 15, 2020
	360MG	A211641	002	Jan 02, 2020
TEVA PHARMS USA	90MG	A209223	001	Nov 25, 2019
	180MG	A209223	003	Apr 24, 2020
	360MG	A209223	002	Nov 25, 2019
TABLET, FOR SUSPENSION;ORAL				
DEFERASIROX				
PHARMOBEDIENT	125MG	A206585	001	May 17, 2024
	250MG	A206585	002	May 17, 2024
	500MG	A206585	003	May 17, 2024
TORRENT	125MG	A209426	001	Nov 05, 2024
	250MG	A209426	002	Nov 05, 2024
	500MG	A209426	003	Nov 05, 2024
ZYDUS PHARMS	125MG	A208882	001	May 05, 2020
	250MG	A208882	002	May 05, 2020
	500MG	A208882	003	May 05, 2020
DEFERIPRONE				
SOLUTION;ORAL				
FERRIPROX				
+ CHIESI	80MG/ML	N208030	002	Apr 20, 2018
DEFEROXAMINE MESYLATE				
INJECTABLE;INJECTION				
DEFEROXAMINE MESYLATE				
DR REDDYS	500MG/VIAL	A076806	001	Mar 31, 2006
	2GM/VIAL	A076806	002	Mar 31, 2006
DESFERAL				
+ MITEM PHARMA	2GM/VIAL **	N016267	002	May 25, 2000
DELAVIRDINE MESYLATE				
TABLET;ORAL				
RESCRIPTOR				
+ VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
+	200MG	N020705	002	Jul 14, 1999
DEMECARIUM BROMIDE				
SOLUTION/DROPS;OPHTHALMIC				
HUMORSOL				
MERCK	0.125%	N011860	002	
	0.25%	N011860	001	
DEMECLOCYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
DECLOMYCIN				
LEDERLE	150MG	N050262	001	
SYRUP;ORAL				
DECLOMYCIN				
LEDERLE	75MG/5ML	N050257	001	
TABLET;ORAL				
DECLOMYCIN				
COREPHARMA	75MG **	N050261	001	
	150MG **	N050261	002	
	300MG **	N050261	003	
DEMECLOCYCLINE HYDROCHLORIDE				
BARR	150MG	A065171	001	Dec 13, 2004
	300MG	A065171	002	Dec 13, 2004
IMPAX LABS	150MG	A065094	001	Mar 22, 2004
	300MG	A065094	002	Mar 22, 2004

DESERPIDINE

TABLET;ORAL				
HARMONYL				
	ABBVIE	0.1MG	N010796 001	
		0.25MG	N010796 002	

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ORETICYL 25				
	ABBVIE	0.125MG;25MG	N012148 001	
ORETICYL 50				
	ABBVIE	0.125MG;50MG	N012148 003	
ORETICYL FORTE				
	ABBVIE	0.25MG;25MG	N012148 002	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET;ORAL				
ENDURONYL				
	ABBOTT	0.25MG;5MG	N012775 001	
ENDURONYL FORTE				
	ABBOTT	0.5MG;5MG	N012775 002	
METHYCLOTHIAZIDE AND DESERPIDINE				
	WATSON LABS	0.25MG;5MG	A088486 001	Aug 10, 1984
		0.5MG;5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PERTOFRANE				
	SANOFI AVENTIS US	25MG	N013621 001	
		50MG	N013621 002	
TABLET;ORAL				
DESIPRAMINE HYDROCHLORIDE				
	ANI PHARMS	10MG	A205153 001	Oct 28, 2016
		25MG	A071803 002	Dec 08, 1987
		25MG	A205153 002	Oct 28, 2016
		50MG	A071803 003	Dec 08, 1987
		50MG	A205153 003	Oct 28, 2016
		75MG	A071803 004	Dec 08, 1987
		75MG	A205153 004	Oct 28, 2016
		100MG	A071803 001	May 29, 1997
		100MG	A205153 005	Oct 28, 2016
		150MG	A071803 005	May 29, 1997
		150MG	A205153 006	Oct 28, 2016
	USL PHARMA	25MG	A071864 001	Sep 09, 1987
		50MG	A071865 001	Sep 09, 1987
		75MG	A071866 001	Sep 09, 1987
		100MG	A071867 001	Sep 09, 1987

DESLANOSIDE

INJECTABLE;INJECTION				
CEDILANID-D				
	NOVARTIS	0.2MG/ML	N009282 002	

DESLORATADINE

SOLUTION;ORAL				
CLARINEX				
+	ORGANON LLC	0.5MG/ML **	N021300 001	Sep 01, 2004
DESLORATADINE				
	TARO	0.5MG/ML	A202592 001	Jun 30, 2015
TABLET;ORAL				
DESLORATADINE				
	CHARTWELL RX	5MG	A078364 001	Dec 03, 2010
	DASH PHARMS	5MG	A078351 001	Feb 10, 2012
	PERRIGO	5MG	A078361 001	Dec 22, 2011
	SUN PHARM INDS	5MG	A078359 001	Nov 16, 2010
TABLET, ORALLY DISINTEGRATING;ORAL				
CLARINEX				
+	ORGANON	2.5MG **	N021312 002	Jul 14, 2005
+		5MG **	N021312 001	Jun 26, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESLORATADINE; PSEUDOEPHEDRINE SULFATE					
TABLET, EXTENDED RELEASE;ORAL					
CLARINEX D 24 HOUR					
+	ORGANON	5MG;240MG **	N021605	001	Mar 03, 2005
DESMOPRESSIN ACETATE					
INJECTABLE;INJECTION					
DDAVP					
	NORDIC PHARMA	0.015MG/ML	N018938	002	Apr 25, 1995
DESMOPRESSIN ACETATE					
	AM REGENT	0.004MG/ML	A091374	001	Feb 14, 2019
	BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
	HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000
	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013
DESMOPRESSIN ACETATE PRESERVATIVE FREE					
	BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000
SOLUTION;NASAL					
CONCENTRAID					
	FERRING	0.01%	N019776	001	Dec 26, 1990
DDAVP					
+	FERRING PHARMS INC	0.01%	N017922	001	
DESMOPRESSIN ACETATE					
	SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012
SPRAY, METERED;NASAL					
DDAVP					
+	FERRING PHARMS INC	0.01MG/SPRAY **	N017922	002	Feb 06, 1989
DDAVP (NEEDS NO REFRIGERATION)					
+	FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)					
	SUN PHARM	0.01MG/SPRAY	A078271	001	Dec 23, 2013
MINIRIN					
+	FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
NOCTIVA					
+	ACERUS PHARMS	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
+		0.00166MG/SPRAY	N201656	002	Mar 03, 2017
STIMATE					
	FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994
STIMATE (NEEDS NO REFRIGERATION)					
+	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007
TABLET;ORAL					
DESMOPRESSIN ACETATE					
	ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005
		0.2MG	A076470	002	Jul 01, 2005
	FERRING	0.1MG	N021795	001	May 08, 2008
		0.2MG	N021795	002	May 08, 2008
	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015
		0.2MG	A201831	002	May 28, 2015
	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006
		0.2MG	A077122	002	Jan 25, 2006
	NATCO PHARMA USA	0.1MG	A200653	001	Jun 27, 2014
		0.2MG	A200653	002	Jun 27, 2014
TABLET;SUBLINGUAL					
NOCDURNA					
+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
+		0.0553MG	N022517	002	Jun 21, 2018
DESOGESTREL; ETHINYL ESTRADIOL					
TABLET;ORAL-21					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
ORTHO-CEPT					
+	JANSSEN PHARMS	0.15MG;0.03MG **	N020301	001	Dec 14, 1992
TABLET;ORAL-28					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	DR REDDYS LABS SA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008
		0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,	A077182	001	Jan 24, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28					
DESOGESTREL AND ETHINYL ESTRADIOL					
	0.025MG				
XIROMED	0.15MG;0.03MG		A202085	001	May 20, 2015
EMOQUETTE					
PH HEALTH	0.15MG;0.03MG		A076675	001	Feb 25, 2011
KIMIDESS					
PH HEALTH	0.15MG,N/A;0.02MG,0.01MG		A076681	001	Apr 30, 2015
MIRCETTE					
+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **		N020713	001	Apr 22, 1998
ORTHO-CEPT					
+ JANSSEN PHARMS	0.15MG;0.03MG **		N020301	002	Dec 14, 1992

DESONIDE

AEROSOL, FOAM;TOPICAL					
VERDESO					
+ ALMIRALL	0.05%		N021978	001	Sep 19, 2006
CREAM;TOPICAL					
DESONIDE					
GLENMARK SPECLT	0.05%		A209729	001	Jul 24, 2017
+ PADAGIS US	0.05%		N017010	001	
GEL;TOPICAL					
DESONATE					
+ LEO PHARMA AS	0.05% **		N021844	001	Oct 20, 2006
LOTION;TOPICAL					
DESONIDE					
GLENMARK SPECLT	0.05%		A209494	001	Sep 26, 2017
PAI HOLDINGS PHARM	0.05%		A207855	001	Sep 28, 2017
DESOWEN					
GALDERMA LABS LP	0.05%		A072354	001	Jan 24, 1992
OINTMENT;TOPICAL					
DESONIDE					
GLENMARK PHARMS LTD	0.05%		A209996	001	Sep 15, 2017
HIKMA	0.05%		A208836	001	Mar 27, 2017
PAI HOLDINGS PHARM	0.05%		A212002	001	Mar 12, 2019
DESOWEN					
GALDERMA LABS LP	0.05%		A071425	001	Jun 15, 1988

DESOXIMETASONE

CREAM;TOPICAL					
DESOXIMETASONE					
COSETTE	0.25%		A209595	001	Mar 04, 2020
SCIEGEN PHARMS	0.05%		A203787	001	Jan 06, 2017
	0.25%		A203234	001	Jun 12, 2015
TOPICORT					
+ TARO	0.25% **		N017856	001	
TOPICORT LP					
+ TARO	0.05% **		N018309	001	
GEL;TOPICAL					
TOPICORT					
+ TARO	0.05% **		N018586	001	Mar 29, 1982
OINTMENT;TOPICAL					
DESOXIMETASONE					
ALTANA	0.25%		A073440	001	Apr 01, 1998
COSETTE	0.25%		A206740	001	Dec 23, 2016
GLENMARK PHARMS LTD	0.25%		A202838	001	Sep 20, 2013
PAI HOLDINGS PHARM	0.25%		A208101	001	Feb 25, 2016
TOPICORT					
TARO	0.25%		A074286	001	Jun 07, 1996
+	0.25% **		N018763	001	Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE;INJECTION					
DOCA					
ORGANON USA INC	5MG/ML		N001104	001	
PELLET;IMPLANTATION					
PERCORTEN					
NOVARTIS	125MG		N005151	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESOXYCORTICOSTERONE PIVALATE				
INJECTABLE;INJECTION				
PERCORTEN				
NOVARTIS	25MG/ML	N008822	001	
DESVENLAFAXINE				
TABLET, EXTENDED RELEASE;ORAL				
KHEDEZLA				
OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
	100MG	N204683	002	Jul 10, 2013
DESVENLAFAXINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE				
+ SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014
+	EQ 100MG BASE	N205583	002	Jan 28, 2014
TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013
	EQ 100MG BASE	N205208	002	Oct 11, 2013
DESVENLAFAXINE SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE SUCCINATE				
PHARMOBEDIENT	EQ 50MG BASE	A204095	001	Jun 29, 2015
	EQ 100MG BASE	A204095	002	Jun 29, 2015
DEUTETRABENAZINE				
TABLET;ORAL				
DEUTETRABENAZINE				
AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024
	9MG	A215971	002	Dec 26, 2024
	12MG	A215971	003	Dec 26, 2024
DEXAMETHASONE				
AEROSOL;TOPICAL				
AEROSEB-DEX				
ALLERGAN HERBERT	0.01% **	A083296	002	
DECASPRAY				
+ MERCK	0.04% **	N012731	002	
ELIXIR;ORAL				
DECADRON				
MERCK	0.5MG/5ML	N012376	002	
DEXAMETHASONE				
ALPHARMA US PHARMS	0.5MG/5ML	A088997	001	Oct 10, 1986
+ PHARMOBEDIENT CNSLTG	0.5MG/5ML	A088254	001	Jul 27, 1983
HEXADROL				
ASPEN GLOBAL INC	0.5MG/5ML	N012674	001	
GEL;TOPICAL				
DECADERM				
MERCK	0.1%	N013538	001	
SUSPENSION/DROPS;OPHTHALMIC				
DEXAMETHASONE				
WATSON LABS	0.1%	A089170	001	May 09, 1989
TABLET;ORAL				
DECADRON				
+ MERCK	0.25MG **	N011664	004	
+	0.5MG **	N011664	001	
+	0.75MG **	N011664	002	
+	1.5MG **	N011664	003	
+	4MG **	N011664	005	
+	6MG **	N011664	006	Jul 30, 1982
DEXAMETHASONE				
BAUSCH	1.5MG	A040700	001	Aug 15, 2008
CHARTWELL RX	1.5MG	A085456	001	
IMPAX LABS	0.75MG	A085376	001	
KEY THERAP	1.5MG	A088237	001	Apr 28, 1983
PANGEA	0.25MG	A088149	001	Apr 28, 1983
PHOENIX LABS NY	0.75MG	A083806	001	
PRASCO	0.75MG	A080399	001	
PVT FORM	0.75MG	A083420	001	
ROXANE	0.25MG	A084614	001	
SUN PHARM INDUSTRIES	0.25MG	A084013	001	
	0.25MG	A084764	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE				
TABLET;ORAL				
DEXAMETHASONE				
	0.5MG		A084084 001	
	0.5MG		A084766 001	
	0.75MG		A084081 001	
	0.75MG		A084765 001	
	1.5MG		A084086 001	
	1.5MG		A084763 001	
UPSHER SMITH	0.75MG		A087534 001	
	1.5MG		A087533 001	
WATSON LABS	0.25MG		A085455 001	
	0.5MG		A085458 001	
	0.75MG		A080968 001	
	0.75MG		A084457 001	
	0.75MG		A085818 001	
	1.5MG		A085840 001	
WHITEWORTH TOWN PLSN	0.75MG		A084327 001	
DEXONE 0.5				
SOLVAY	0.5MG		A084991 001	
DEXONE 0.75				
SOLVAY	0.75MG		A084993 001	
DEXONE 1.5				
SOLVAY	1.5MG		A084990 001	
DEXONE 4				
SOLVAY	4MG		A084992 001	
HEXADROL				
ASPEN GLOBAL INC	0.5MG		N012675 004	
	0.75MG		N012675 007	
	1.5MG		N012675 009	
	4MG		N012675 010	
DEXAMETHASONE ACETATE				
INJECTABLE;INJECTION				
DECADRON-LA				
+ MERCK	EQ 8MG BASE/ML **		N016675 001	
DEXAMETHASONE ACETATE				
WATSON LABS	EQ 8MG BASE/ML		A084315 001	
WATSON LABS TEVA	EQ 16MG BASE/ML		A087711 001	May 24, 1982
DEXAMETHASONE SODIUM PHOSPHATE				
AEROSOL;NASAL				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH		N014242 001	
AEROSOL, METERED;INHALATION				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH		N013413 001	
CREAM;TOPICAL				
DECADRON				
MERCK	EQ 0.1% PHOSPHATE		N011983 002	
INJECTABLE;INJECTION				
DECADRON				
+ MERCK	EQ 4MG PHOSPHATE/ML **		N012071 002	
+	EQ 24MG PHOSPHATE/ML **		N012071 004	
DEXACEN-4				
CENT PHARMS	EQ 4MG PHOSPHATE/ML		A084342 001	
DEXAMETHASONE				
ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML		A088448 001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML		A088469 001	Jan 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE				
BEL MAR	EQ 4MG PHOSPHATE/ML		A084752 001	
DELL LABS	EQ 4MG PHOSPHATE/ML		A083161 001	
DR REDDYS	EQ 4MG PHOSPHATE/ML		A089169 001	Apr 09, 1986
EPIC PHARMA LLC	EQ 4MG PHOSPHATE/ML		A084493 001	
EUGIA PHARMA	EQ 4MG PHOSPHATE/ML		A206781 001	Dec 01, 2015
	EQ 10MG PHOSPHATE/ML		A210967 001	Jun 07, 2019
GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML		A214890 002	Jul 28, 2023
	EQ 10MG PHOSPHATE/ML		A214890 001	Jul 07, 2023
HIKMA	EQ 4MG PHOSPHATE/ML		A211451 001	Aug 01, 2023
INTL MEDICATION	EQ 20MG PHOSPHATE/ML		A088522 001	Feb 17, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
DEXAMETHASONE SODIUM PHOSPHATE				
+	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440 001	Jul 21, 1982
	LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
	TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
		EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
	WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
		EQ 4MG PHOSPHATE/ML	A084355 001	
		EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
		EQ 24MG PHOSPHATE/ML	A085606 001	
	WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	
HEXADROL				
+	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002	
+		EQ 10MG PHOSPHATE/ML **	N014694 003	
		EQ 20MG PHOSPHATE/ML	N014694 004	
OINTMENT;OPHTHALMIC				
DECADRON				
	MERCK	EQ 0.05% PHOSPHATE	N011977 001	
DEXAIR				
	PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982
MAXIDEX				
	ALCON	EQ 0.05% PHOSPHATE	A083342 001	
SOLUTION/DROPS;OPHTHALMIC				
DEXAIR				
	PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE				
	SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
		EQ 0.1% PHOSPHATE	A084173 001	
SOLUTION/DROPS;OPHTHALMIC, OTIC				
DECADRON				
+	MERCK	EQ 0.1% PHOSPHATE **	N011984 001	
DEXAMETHASONE SODIUM PHOSPHATE				
	SANDOZ	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985
SOLUTION/DROPS;OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
	EPIC PHARMA LLC	EQ 0.1% PHOSPHATE	A084855 001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DECADRON W/ XYLOCAINE				
	MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	
SOLUTION/DROPS;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
	PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983
SUSPENSION/DROPS;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC				
TOBRAMYCIN AND DEXAMETHASONE				
AMNEAL	0.1%;0.3%	A212991	001	Jul 15, 2021

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL				
DISOMER				
SCHERING	2MG/5ML	N011814	002	
TABLET;ORAL				
DISOMER				
SCHERING	2MG	N011814	001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL				
DISOPHROL				
SCHERING	2MG;60MG	N012394	002	
TABLET, EXTENDED RELEASE;ORAL				
BROMPHERIL				
COPLEY PHARM	6MG;120MG	A089116	001	Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013
DISOBROM				
SANDOZ	6MG;120MG	A070770	001	Sep 30, 1991
DISOPHROL				
SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982
DRIXORAL				
+ SCHERING PLOUGH	6MG;120MG **	N013483	003	Sep 13, 1982
RESPORAL				
PIONEER PHARMS	6MG;120MG	A089139	001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
+ PAI HOLDINGS PHARM	2MG/5ML **	A088251	001	Mar 23, 1984
POLARAMINE				
SCHERING	2MG/5ML	A086837	001	Jul 19, 1982
TABLET;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
ANI PHARMS	2MG	A088682	001	Jan 17, 1986
POLARAMINE				
+ SCHERING	2MG	A086835	001	

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
DEXILANT SOLUTAB				
+ TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DEXMEDETOMIDINE HYDROCHLORIDE				
AM REGENT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017
PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021
WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
DEXMETHYLPHENIDATE HYDROCHLORIDE				
AUROLIFE PHARMA LLC	5MG	A204266	001	Aug 25, 2015
	10MG	A204266	002	Aug 25, 2015
	15MG	A204266	003	Aug 25, 2015
	20MG	A204266	004	Dec 21, 2015
	25MG	A204266	005	May 04, 2021
	30MG	A202580	001	Aug 28, 2013
	35MG	A204266	006	May 04, 2021
	40MG	A204266	007	Aug 25, 2015
SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021
	10MG	A206734	002	Nov 05, 2021
	15MG	A206734	003	Nov 05, 2021
	20MG	A206734	004	Nov 05, 2021
	25MG	A206734	005	Nov 05, 2021
	30MG	A206734	006	Nov 05, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXMETHYLPHENIDATE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
DEXMETHYLPHENIDATE HYDROCHLORIDE				
	35MG	A206734	007	Nov 05, 2021
	40MG	A206734	008	Nov 05, 2021
TABLET;ORAL				
DEXMETHYLPHENIDATE HYDROCHLORIDE				
BIONPHARMA	5MG	A209754	001	Mar 24, 2020
	10MG	A209754	002	Mar 24, 2020
LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017
	5MG	A209468	002	Sep 25, 2017
	10MG	A209468	003	Sep 25, 2017
RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017
	5MG	A208756	002	Nov 20, 2017
	10MG	A208756	003	Nov 20, 2017
TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007
	5MG	A077107	001	Jan 29, 2007
	10MG	A077107	002	Jan 29, 2007
DEXRAZOXANE HYDROCHLORIDE				
INJECTABLE;INJECTION				
TOTECT				
+ CLINIGEN	EQ 500MG BASE/VIAL **	N022025	001	Sep 06, 2007
ZINECARD				
+ PFIZER	EQ 250MG BASE/VIAL **	N020212	001	May 26, 1995
+	EQ 500MG BASE/VIAL **	N020212	002	May 26, 1995
DEXTROAMPHETAMINE SULFATE				
CAPSULE;ORAL				
DEXAMPEX				
TEVA	15MG	A085355	001	
CAPSULE, EXTENDED RELEASE;ORAL				
DEXTROAMPHETAMINE SULFATE				
ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004
NESHER PHARMS	5MG	A209111	001	Jun 27, 2017
	10MG	A209111	002	Jun 27, 2017
	15MG	A209111	003	Jun 27, 2017
PHARMOBEDIENT	5MG	A206735	001	Jan 27, 2016
	10MG	A206735	002	Jan 27, 2016
	15MG	A206735	003	Jan 27, 2016
SENORES PHARMS	5MG	A076137	001	Jan 18, 2002
	10MG	A076137	002	Jan 18, 2002
	15MG	A076137	003	Jan 18, 2002
STRIDES PHARMA	5MG	A205077	001	Jun 21, 2019
	10MG	A205077	002	Jun 21, 2019
	15MG	A205077	003	Jun 21, 2019
ELIXIR;ORAL				
DEXEDRINE				
GLAXOSMITHKLINE	5MG/5ML **	A083902	001	
TABLET;ORAL				
DEXAMPEX				
TEVA	5MG	A083735	001	
	10MG	A083735	002	
DEXEDRINE				
+ GLAXOSMITHKLINE	5MG **	A084935	001	
DEXTROAMPHETAMINE SULFATE				
ANI PHARMS	5MG	A085370	001	
EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014
	10MG	A090652	002	Mar 07, 2014
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
NESHER PHARMS	5MG	A040365	001	Oct 31, 2002
	5MG	A206588	001	Mar 28, 2016
	10MG	A040367	001	Oct 31, 2002
	10MG	A206588	002	Mar 28, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE				
	PUREPAC PHARM	5MG	A084125 001	
	SANDOZ	10MG	A085371 001	
	STRIDES PHARMA INTL	5MG	A040299 001	May 13, 1999
	TRIS PHARMA INC	5MG	A206095 001	Aug 18, 2022
		10MG	A206095 002	Aug 18, 2022
	VITARINE	5MG	A084986 001	
		10MG	A085892 001	
DEXTROSTAT				
+	SHIRE	5MG **	A084051 001	
+		10MG **	A084051 002	
FERNDEX				
	FERNDALE LABS	5MG	A084001 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHERAZINE DM				
	HALSEY	15MG/5ML;6.25MG/5ML	A088913 001	Mar 02, 1987
PROMETH W/ DEXTROMETHORPHAN				
	G AND W LABS INC	15MG/5ML;6.25MG/5ML **	A088762 001	Oct 31, 1984
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
	HIKMA	15MG/5ML;6.25MG/5ML	A040027 001	Jul 31, 1996

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML	N018046 001	
	MILES	10GM/100ML	N018504 001	
DEXTROSE 2.5% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML	N018358 001	
		2.5GM/100ML	N019626 001	Feb 02, 1988
DEXTROSE 20% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	20GM/100ML **	N017521 004	
DEXTROSE 30% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	30GM/100ML **	N017521 003	
DEXTROSE 38.5% IN PLASTIC CONTAINER				
	ABBOTT	38.5GM/100ML	N018923 001	Sep 19, 1984
DEXTROSE 40% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	40GM/100ML **	N017521 002	
DEXTROSE 5%				
	AM REGENT	50MG/ML	A217263 001	Apr 08, 2024
DEXTROSE 5% IN PLASTIC CONTAINER				
	DHL	5GM/100ML	N019971 001	Sep 28, 1995
+	ICU MEDICAL INC	50MG/ML	N019222 001	Jul 13, 1984
DEXTROSE 50% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	50GM/100ML **	N017521 001	
	ICU MEDICAL INC	50GM/100ML	N019894 001	Dec 26, 1989
DEXTROSE 60%				
	B BRAUN	60GM/100ML	N017995 002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER				
	B BRAUN	60GM/100ML	N017995 001	
+	BAXTER HLTHCARE	60GM/100ML **	N017521 005	Mar 26, 1982
		60GM/100ML	N020047 002	Jul 02, 1991
	HOSPIRA	60GM/100ML	N019346 001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER				
	B BRAUN	7.7GM/100ML	N019626 003	Feb 02, 1988
DEXTROSE 70% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	70GM/100ML **	N017521 006	Mar 26, 1982

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION				
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION				
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION				
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843	001	Aug 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001	
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION				
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;37MG/100ML	N019699	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;75MG/100ML	N018744	001	Nov 09, 1982
	5GM/100ML;75MG/100ML	N019699	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;110MG/100ML	N019699	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML	N018744	002	Nov 09, 1982
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982
	5GM/100ML;220MG/100ML	N019699	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML	N018744	004	Nov 09, 1982
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML	N018371	003	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION				
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N019870	001	Jun 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML	N018840 001	Jun 29, 1983	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%				
B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268 009		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268 004		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268 005		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268 006		
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268 011	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268 012	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268 013	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268 014	Jan 18, 1986	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%				
B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268 010		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268 001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268 002		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268 003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 002		
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365 002	Jul 05, 1983	
+	5GM/100ML;149MG/100ML;225MG/100ML **	N018365 006	Mar 28, 1988	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 001	Jan 17, 1986	
	5GM/100ML;149MG/100ML;300MG/100ML	N018876 006	Mar 28, 1988	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002	Mar 24, 1988	
+	5GM/100ML;149MG/100ML;900MG/100ML	N019691 004	Mar 24, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML;225MG/100ML **	N018365 008	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 007	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006	Mar 28, 1988	
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006	Mar 24, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;298MG/100ML;225MG/100ML **	N018365 009	Mar 28, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876 008	Mar 28, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;298MG/100ML;450MG/100ML	N018362 007	Mar 28, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;298MG/100ML;900MG/100ML	N019691 008	Mar 24, 1988	
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876 002	Jan 17, 1986	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML;225MG/100ML **	N018365 003	Jul 05, 1983	
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876 003	Jan 17, 1986	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;298MG/100ML;225MG/100ML **	N018365	004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;225MG/100ML **	N018365	007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988
	5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988
+	5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+ OTSUKA ICU MEDCL	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988
+	5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;200MG/100ML	N018386	001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;450MG/100ML	N018229	001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	10GM/100ML;900MG/100ML	N018047	001	
BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696	001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML;450MG/100ML	N018030	001	
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096	001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML;900MG/100ML	N018376	001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ABBOTT	3.3GM/100ML;300MG/100ML	N018055	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;110MG/100ML	N018030	005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;200MG/100ML	N018030	004	
MILES	5GM/100ML;200MG/100ML	N018399	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;225MG/100ML	N019482	001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;300MG/100ML	N019486	001	Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML;330MG/100ML	N018030	003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;450MG/100ML	N019484	001	Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030	002	
MILES	5GM/100ML;450MG/100ML	N018400	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
ABBOTT	5GM/100ML;900MG/100ML	N019483	001	Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026	001	
MILES	5GM/100ML;900MG/100ML	N018500	001	

DEXTROTHYROXINE SODIUM

TABLET;ORAL

CHOLOXIN			
ABBVIE	1MG	N012302	005
	2MG	N012302	002
	4MG	N012302	004
	6MG	N012302	006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEZOCINE				
INJECTABLE;INJECTION				
DALGAN				
ASTRAZENECA	5MG/ML	N019082	001	Dec 29, 1989
	10MG/ML	N019082	002	Dec 29, 1989
	15MG/ML	N019082	003	Dec 29, 1989
DIATRIZOATE MEGLUMINE				
INJECTABLE;INJECTION				
ANGIOVIST 282				
BAYER HLTHCARE	60%	A087726	001	Sep 23, 1982
CARDIOGRAFIN				
BRACCO	85%	N011620	002	
DIATRIZOATE MEGLUMINE				
BRACCO	76%	N010040	017	
HYPAQUE				
GE HEALTHCARE	30%	N016403	002	
	60%	N016403	001	
RENO-60				
BRACCO	60%	N010040	016	
RENO-DIP				
BRACCO	30%	N010040	012	
UROVIST MEGLUMINE DIU/CT				
BAYER HLTHCARE	30%	A087739	001	Sep 23, 1982
SOLUTION;URETERAL				
RENO-30				
BRACCO	30%	N010040	021	
UROVIST CYSTO				
BAYER HLTHCARE	30%	A087729	001	Sep 23, 1982
UROVIST CYSTO PEDIATRIC				
BAYER HLTHCARE	30%	A087731	001	Sep 23, 1982
SOLUTION;URETHRAL				
HYPAQUE-CYSTO				
GE HEALTHCARE	30%	N016403	003	
DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM				
INJECTABLE;INJECTION				
ANGIOVIST 292				
BAYER HLTHCARE	52%;8%	A087724	001	Sep 23, 1982
ANGIOVIST 370				
BAYER HLTHCARE	66%;10%	A087723	001	Sep 23, 1982
DIATRIZOATE-60				
INTL MEDICATION	52%;8%	A088166	001	Jun 17, 1983
HYPAQUE-76				
GE HEALTHCARE	66%;10%	A086505	001	
HYPAQUE-M,75%				
GE HEALTHCARE	50%;25%	N010220	003	
HYPAQUE-M,90%				
GE HEALTHCARE	60%;30%	N010220	002	
MD-60				
MALLINCKRODT	52%;8%	A087074	001	
MD-76				
MALLINCKRODT	66%;10%	A087073	001	
MD-76R				
+ LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989
RENOCAL-76				
BRACCO	66%;10%	A089347	001	Jun 01, 1988
RENOGRAFIN-60				
BRACCO	52%;8%	N010040	006	
RENOGRAFIN-76				
+ BRACCO	66%;10%	N010040	001	
RENOVIST				
BRACCO	34.3%;35%	N010040	020	
RENOVIST II				
BRACCO	28.5%;29.1%	N010040	019	
SOLUTION;ORAL, RECTAL				
GASTROVIST				
BAYER HLTHCARE	66%;10%	A087728	001	Sep 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE				
SOLUTION;INTRAUTERINE				
SINOGRAFIN				
+ BRACCO	52.7%;26.8%	N011324	002	
DIATRIZOATE SODIUM				
FOR SOLUTION;ORAL, RECTAL				
HYPAQUE				
GE HEALTHCARE	100%	N011386	001	
INJECTABLE;INJECTION				
HYPAQUE				
GE HEALTHCARE	25%	N009561	003	
	50%	N009561	001	
MD-50				
MALLINCKRODT	50%	A087075	001	
UROVIST SODIUM 300				
BAYER HLTHCARE	50%	A087725	001	Sep 23, 1982
SOLUTION;ORAL, RECTAL				
HYPAQUE				
GE HEALTHCARE	40%	N011386	003	
SOLUTION;URETERAL				
HYPAQUE SODIUM 20%				
GE HEALTHCARE	20%	N009561	002	
DIAZEPAM				
CAPSULE, EXTENDED RELEASE;ORAL				
VALRELEASE				
ROCHE	15MG	N018179	001	
GEL;RECTAL				
DIASTAT				
+ BAUSCH	5MG/ML (5MG/ML) **	N020648	002	Jul 29, 1997
+	10MG/2ML (5MG/ML) **	N020648	003	Jul 29, 1997
+	15MG/3ML (5MG/ML) **	N020648	004	Jul 29, 1997
+	20MG/4ML (5MG/ML) **	N020648	005	Jul 29, 1997
INJECTABLE;INJECTION				
DIAZEPAM				
ABRAXIS PHARM	5MG/ML	A070662	001	Jun 25, 1986
HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985
	5MG/ML	A070312	001	Dec 16, 1985
	5MG/ML	A071308	001	Jul 17, 1987
	5MG/ML	A071309	001	Jul 17, 1987
	5MG/ML	A071310	001	Jul 17, 1987
	10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985
HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987
MARSAM PHARMS LLC	5MG/ML	A072371	001	Jan 29, 1993
PARENTA PHARMS	5MG/ML	A076815	001	Apr 15, 2004
US ARMY	5MG/ML **	N020124	001	Dec 05, 1990
WARNER CHILCOTT	5MG/ML	A071613	001	Oct 22, 1987
	5MG/ML	A071614	001	Oct 22, 1987
WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986
	5MG/ML	A070911	001	Aug 28, 1986
	5MG/ML	A070912	001	Aug 28, 1986
	5MG/ML	A070930	001	Dec 01, 1986
WATSON LABS INC	5MG/ML	A072370	001	Jan 29, 1993
	5MG/ML	A072397	001	Jan 29, 1993
DIZAC				
PHARMACIA AND UPJOHN	5MG/ML **	N019287	001	Jun 18, 1993
VALIUM				
+ ROCHE	5MG/ML **	N016087	001	
TABLET;ORAL				
DIAZEPAM				
ACTAVIS ELIZABETH	2MG	A070781	001	Mar 19, 1986
	5MG	A070706	001	Mar 19, 1986
	10MG	A070707	001	Mar 19, 1986
BARR	2MG	A070152	001	Nov 01, 1985
	10MG	A070154	001	Nov 01, 1985
CHARTWELL RX	2MG	A070302	001	Dec 20, 1985
	5MG	A070303	001	Dec 20, 1985
	10MG	A070304	001	Dec 20, 1985
DURAMED PHARMS BARR	2MG	A070894	001	Aug 27, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIAZEPAM					
TABLET;ORAL					
DIAZEPAM					
		5MG	A070895	001	Aug 27, 1986
		10MG	A070896	001	Aug 27, 1986
	FERNDALE LABS	2MG	A070903	001	Apr 01, 1987
		5MG	A070904	001	Apr 01, 1987
		10MG	A070905	001	Apr 01, 1987
	HALSEY	2MG	A070987	001	Aug 15, 1986
		5MG	A070996	001	Aug 15, 1986
		10MG	A070956	001	Aug 15, 1986
	IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
		5MG	A070361	001	Sep 04, 1985
		10MG	A070362	001	Sep 04, 1985
	MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
	PH HEALTH	2MG	A070228	002	Sep 26, 1985
		5MG	A070228	003	Sep 26, 1985
		10MG	A070228	001	Sep 26, 1985
	PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
		5MG	A070788	001	Aug 02, 1988
		10MG	A070776	001	Aug 02, 1988
	ROXANE	2MG	A070356	001	Jun 17, 1986
		5MG	A070357	001	Jun 17, 1986
		10MG	A070358	001	Jun 17, 1986
	TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
	VIRTUS	2MG	A070462	001	Feb 25, 1986
		5MG	A070463	001	Feb 25, 1986
	WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
		5MG	A070210	001	Sep 04, 1985
		10MG	A070222	001	Sep 04, 1985
	WATSON LABS	2MG	A070456	001	Nov 01, 1985
		5MG	A070457	001	Nov 01, 1985
		10MG	A070458	001	Nov 01, 1985
Q-PAM					
	QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
		2MG	A072431	001	Apr 29, 1988
		5MG	A070424	001	Dec 12, 1985
		5MG	A072432	001	Apr 29, 1988
		10MG	A070425	001	Dec 12, 1985
		10MG	A072433	001	Apr 29, 1988
DIAZOXIDE					
CAPSULE;ORAL					
PROGLYCEM					
	TEVA BRANDED PHARM	50MG	N017425	001	
		100MG	N017425	002	
INJECTABLE;INJECTION					
DIAZOXIDE					
	ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT					
	SCHERING	15MG/ML	N016996	001	
DIBUCAINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
HEAVY SOLUTION NUPERCAINE					
	NOVARTIS	2.5MG/ML	N006203	001	
DICHLORPHENAMIDE					
TABLET;ORAL					
DARANIDE					
+	XERIS	50MG **	N011366	001	
DICLOFENAC					
CAPSULE;ORAL					
ZORVOLEX					
+	ZYLA	18MG **	N204592	001	Oct 18, 2013
+		35MG **	N204592	002	Oct 18, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOFENAC POTASSIUM				
TABLET;ORAL				
CATAFLAM				
+ NOVARTIS	25MG **	N020142	001	Nov 24, 1993
+	50MG **	N020142	002	Nov 24, 1993
DICLOFENAC POTASSIUM				
CHARTWELL RX	50MG	A075582	001	Feb 23, 2001
SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998
DICLOFENAC SODIUM				
GEL;TOPICAL				
DICLOFENAC SODIUM				
HIKMA	1%	A209484	001	Nov 21, 2018
SOLARAZE				
+ FOUGERA PHARMS	3% **	N021005	001	Oct 16, 2000
SOLUTION;INTRAVENOUS				
DICLOFENAC SODIUM				
RISING	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019
DYLOJECT				
+ JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML) **	N022396	001	Dec 23, 2014
SOLUTION;TOPICAL				
DICLOFENAC SODIUM				
APOTEX	1.5%	A202027	001	May 27, 2014
PAI HOLDINGS PHARM	1.5%	A202769	001	Jul 08, 2015
RISING	1.5%	A206715	001	Aug 07, 2017
TWI PHARMS	1.5%	A202393	001	Nov 24, 2014
PENNSAID				
+ HORIZON	2% **	N204623	001	Jan 16, 2014
+ NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009
SOLUTION/DROPS;OPHTHALMIC				
DICLOFENAC SODIUM				
FALCON PHARMS	0.1%	N020809	001	May 04, 1998
SCIEGEN PHARMS	0.1%	A077845	001	Apr 17, 2008
VOLTAREN				
+ NOVARTIS	0.1%	N020037	001	Mar 28, 1991
TABLET, DELAYED RELEASE;ORAL				
DICLOFENAC SODIUM				
CHARTWELL RX	25MG	A074376	001	Sep 28, 1995
	50MG	A074376	002	Sep 28, 1995
	75MG	A074394	001	Nov 30, 1995
MICRO LABS	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997
VOLTAREN				
+ NOVARTIS	25MG **	N019201	001	Jul 28, 1988
+	50MG **	N019201	002	Jul 28, 1988
+	75MG **	N019201	003	Jul 28, 1988
TABLET, EXTENDED RELEASE;ORAL				
DICLOFENAC SODIUM				
ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001
VOLTAREN-XR				
+ NOVARTIS	100MG **	N020254	001	Mar 08, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014
	75MG;0.2MG	A200540	002	Mar 14, 2014
SANDOZ	50MG;0.2MG	A200158	001	May 09, 2013
	75MG;0.2MG	A200158	002	May 09, 2013
ZYDUS PHARMS	50MG;0.2MG	A206771	001	Jun 12, 2023
	75MG;0.2MG	A206771	002	Jun 12, 2023

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

CHARTWELL RX	EQ 125MG BASE	A061454	002	
	EQ 250MG BASE	A061454	001	
	EQ 500MG BASE	A061454	003	

DYCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A060254	002	
	EQ 250MG BASE	A062238	001	
	EQ 500MG BASE	A060254	003	
	EQ 500MG BASE	A062238	002	

PATHOCIL

+ WYETH AYERST	EQ 250MG BASE **	N050011	002	
+	EQ 500MG BASE **	N050011	003	Mar 28, 1983

FOR SUSPENSION;ORAL

DICLOXACILLIN SODIUM

APOTHECON	EQ 62.5MG BASE/5ML	A061455	001	

DYNAPEN

APOTHECON	EQ 62.5MG BASE/5ML	N050337	002	

PATHOCIL

WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001	

DICUMAROL

CAPSULE;ORAL

DICUMAROL

LILLY	25MG	N005509	003	
	50MG	N005509	001	

TABLET;ORAL

DICUMAROL

ABBVIE	25MG	N005545	003	
	50MG	N005545	004	
	100MG	N005545	005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

+ ALLERGAN	10MG **	N007409	003	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
SUN PHARM INDUSTRIES	10MG	A084505	001	Oct 21, 1986
WATSON LABS	10MG	A083179	001	Feb 12, 1986

INJECTABLE;INJECTION

BENTYL

+ ABBVIE	10MG/ML	N008370	001	Oct 15, 1984

BENTYL PRESERVATIVE FREE

+ ABBVIE	10MG/ML **	N008370	002	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

DR REDDYS	10MG/ML	A080614	001	Feb 11, 1986
HIKMA	10MG/ML	A210788	001	Feb 11, 2019
NEXUS	10MG/ML	A206468	001	Feb 01, 2019
PRAXGEN PHARMS	10MG/ML	A212058	001	Apr 26, 2019
RENEW PHARMS	10MG/ML	A207084	001	May 04, 2018

SYRUP;ORAL

BENTYL

+ APTALIS PHARMA US	10MG/5ML **	N007961	002	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A084479	001	

TABLET;ORAL

BENTYL

+ ALLERGAN	20MG **	N007409	001	Oct 15, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICYCLOMINE HYDROCHLORIDE

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS	20MG	A088585	001	Aug 20, 1986
SUN PHARM INDUSTRIES	20MG	A084600	001	Jul 29, 1985
WATSON LABS	20MG	A084361	001	Feb 06, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008
	200MG	A090094	002	Sep 24, 2008
	250MG	A090094	003	Sep 24, 2008
	400MG	A090094	004	Sep 24, 2008
BARR	200MG	A077167	001	Dec 03, 2004
	250MG	A077167	002	Dec 03, 2004
	400MG	A077167	003	Dec 03, 2004
PHARMOBEDIENT	125MG	A090788	001	Apr 08, 2010
	200MG	A090788	002	Apr 08, 2010
	250MG	A090788	003	Apr 08, 2010
	400MG	A090788	004	Apr 08, 2010

VIDEX EC

+ BRISTOL MYERS SQUIBB	125MG **	N021183	001	Oct 31, 2000
+	200MG **	N021183	002	Oct 31, 2000
+	250MG **	N021183	003	Oct 31, 2000
+	400MG **	N021183	004	Oct 31, 2000

FOR SOLUTION;ORAL

DIDANOSINE

AUROBINDO PHARMA	10MG/ML	A078112	001	Mar 08, 2007

VIDEX

+ BRISTOL	10MG/ML	N020156	001	Oct 09, 1991
BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003	Oct 09, 1991
	167MG/PACKET	N020155	004	Oct 09, 1991
	250MG/PACKET	N020155	005	Oct 09, 1991
	375MG/PACKET	N020155	006	Oct 09, 1991

TABLET, CHEWABLE;ORAL

VIDEX

+ BRISTOL MYERS SQUIBB	25MG **	N020154	002	Oct 09, 1991
+	50MG **	N020154	003	Oct 09, 1991
+	100MG **	N020154	004	Oct 09, 1991
+	150MG **	N020154	005	Oct 09, 1991
+	200MG **	N020154	006	Oct 28, 1999

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

AUROBINDO	100MG	A077275	001	Aug 14, 2012
	150MG	A077275	002	Aug 14, 2012
	200MG	A077275	003	Aug 14, 2012

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM	0.01%	N006110	005

DV

SANOFI AVENTIS US	0.01%	A083518	001

ESTRAGUARD

SOLVAY	0.01%	A084436	001

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US	0.7MG	A083517	001

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE	50MG	N006459	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL				
DIETHYLPROPION HYDROCHLORIDE				
CHARTWELL RX	25MG		A088267 001	Aug 25, 1983
	25MG		A088268 001	Aug 25, 1983
EPIC PHARMA LLC	25MG		A040828 001	Nov 05, 2008
SANDOZ	25MG		A085916 001	
TEVA	25MG		A088642 001	Sep 20, 1984
UCB INC	25MG		A085544 001	
WATSON LABS	25MG		A085741 001	
TENUATE				
+ MPP PHARMA	25MG **		N011722 002	
SANOFI AVENTIS US	25MG		N017668 001	
TEPANIL				
3M	25MG		N011673 001	
TABLET, EXTENDED RELEASE;ORAL				
TENUATE				
SANOFI AVENTIS US	75MG		N017669 001	
TENUATE DOSPAN				
+ ANI PHARMS	75MG **		N012546 001	
TEPANIL TEN-TAB				
3M	75MG		N017956 001	

DIETHYLSTILBESTROL

INJECTABLE;INJECTION			
STILBESTROL			
BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003	
	0.5MG/ML	N004056 004	
	1MG/ML	N004056 005	
	5MG/ML	N004056 006	
SUPPOSITORY;VAGINAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004040 001	
	0.5MG	N004040 002	
STILBESTROL			
BRISTOL MYERS SQUIBB	0.1MG	N004056 001	
	0.5MG	N004056 002	
TABLET;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004041 002	
	0.5MG	N004041 003	
	1MG	N004041 004	
	5MG	N004041 005	
STILBESTROL			
TABLICAPS	0.5MG	A083004 001	
	1MG	A083002 001	
	5MG	A083006 001	
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056 007	
	0.25MG	N004056 017	
	0.5MG	N004056 008	
	1MG	N004056 009	
	5MG	N004056 010	
TABLET, DELAYED RELEASE;ORAL			
DIETHYLSTILBESTROL			
LILLY	0.1MG	N004039 002	
	0.25MG	N004039 005	
	0.5MG	N004039 003	
	1MG	N004039 004	
	5MG	N004039 006	
STILBESTROL			
TABLICAPS	0.5MG	A083003 001	
	1MG	A083005 001	
	5MG	A083007 001	
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056 011	
	0.5MG	N004056 012	
	1MG	N004056 013	
	5MG	N004056 014	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE;INJECTION				
STILPHOSTROL				
	BAYER PHARMS	250MG/5ML	N010010 001	
TABLET;ORAL				
STILPHOSTROL				
	BAYER PHARMS	50MG	N010010 002	

DIFLORASONE DIACETATE

CREAM;TOPICAL				
DIFLORASONE DIACETATE				
	ANI PHARMS	0.05%	A076263 001	Dec 20, 2002
	AVONDALE PHARMS	0.05%	A075187 001	Mar 30, 1998
FLORONE				
	PFIZER	0.05% **	N017741 001	
FLORONE E				
	PFIZER	0.05%	N019259 001	Aug 28, 1985
PSORCON				
+	TARO PHARMS NORTH	0.05% **	N020205 001	Nov 20, 1992
OINTMENT;TOPICAL				
DIFLORASONE DIACETATE				
	SCIEGEN PHARMS	0.05%	A206572 001	Jul 24, 2015
PSORCON				
+	PFIZER	0.05%	N019260 001	Aug 28, 1985
PSORCON E				
	PFIZER	0.05%	N017994 001	

DIFLUNISAL

TABLET;ORAL				
DIFLUNISAL				
	ANI PHARMS	500MG	A074604 001	Jun 10, 1996
	DASTECH INTL	250MG	A073562 001	Nov 27, 1992
		500MG	A073563 001	Nov 27, 1992
	PUREPAC PHARM	250MG	A074285 001	May 07, 1996
		500MG	A074285 002	May 07, 1996
	TEVA	250MG	A073679 001	Jul 31, 1992
	WATSON LABS	250MG	A074400 001	Jul 17, 1997
		500MG	A074400 002	Jul 17, 1997
DOLOBID				
+	MERCK	250MG **	N018445 001	Apr 19, 1982
+		500MG **	N018445 002	Apr 19, 1982

DIGITOXIN

INJECTABLE;INJECTION				
CRYSTODIGIN				
	LILLY	0.2MG/ML	A084100 005	

DIGOXIN

CAPSULE;ORAL				
LANOXICAPS				
	GLAXOSMITHKLINE LLC	0.05MG	N018118 002	Jul 26, 1982
		0.1MG	N018118 003	Jul 26, 1982
		0.15MG	N018118 004	Sep 24, 1984
		0.2MG	N018118 001	Jul 26, 1982
INJECTABLE;INJECTION				
DIGOXIN				
	ABRAXIS PHARM	0.25MG/ML	A083217 001	
	HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996
		0.25MG/ML	A040206 001	Aug 28, 1998
	WYETH AYERST	0.25MG/ML	A084386 001	
DIGOXIN PEDIATRIC				
	HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996
TABLET;ORAL				
DIGOXIN				
	IMPAX LABS	0.125MG	A078556 001	Jul 20, 2009
		0.25MG	A078556 002	Jul 20, 2009
LANOXIN				
+	ADVANZ PHARMA	0.1875MG	N020405 003	Sep 30, 1997
		0.375MG	N020405 005	Sep 30, 1997
		0.5MG	N020405 006	Sep 30, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION				
D.H.E. 45				
+	BAUSCH	1MG/ML **	N005929 001	
DIHYDROERGOTAMINE MESYLATE				
	BAXTER HLTHCARE CORP	1MG/ML	A216747 001	Jan 07, 2025
	CIPLA	1MG/ML	A212334 001	Sep 20, 2024
SPRAY, METERED;NASAL				
DIHYDROERGOTAMINE MESYLATE				
	AMNEAL	0.5MG/SPRAY	A214105 001	Jan 04, 2022

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
EMBOLEX				
	NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885 001	Nov 30, 1984
		0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885 002	Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
CARDIZEM SR				
+	BIOVAIL	60MG **	N019471 001	Jan 23, 1989
+		90MG **	N019471 002	Jan 23, 1989
+		120MG **	N019471 003	Jan 23, 1989
+		180MG **	N019471 004	Jan 23, 1989
DILACOR XR				
+	ALLERGAN	120MG **	N020092 001	May 29, 1992
+		180MG **	N020092 002	May 29, 1992
+		240MG **	N020092 003	May 29, 1992
DILT-CD				
	APOTEX	120MG	A076151 001	May 20, 2004
		180MG	A076151 002	May 20, 2004
		240MG	A076151 003	May 20, 2004
		300MG	A076151 004	May 20, 2004
DILTIAZEM HYDROCHLORIDE				
	ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997
		180MG	A074852 002	Oct 10, 1997
		240MG	A074852 003	Oct 10, 1997
	BIOVAIL	60MG	A074845 001	Sep 15, 1999
		90MG	A074845 002	Sep 15, 1999
		120MG	A074845 003	Sep 15, 1999
		120MG	N020939 001	Jan 28, 2000
		180MG	N020939 002	Jan 28, 2000
		240MG	N020939 003	Jan 28, 2000
		300MG	N020939 004	Jan 28, 2000
		360MG	N020939 005	Sep 14, 2001
		420MG	N020939 006	Sep 14, 2001
	NESHER PHARMS	120MG	A076563 002	Sep 12, 2006
		180MG	A076563 003	Sep 12, 2006
		240MG	A076563 004	Sep 12, 2006
		300MG	A076563 005	Sep 12, 2006
		360MG	A076563 006	Sep 12, 2006
		420MG	A076563 001	Sep 12, 2006
	PH HEALTH	360MG	A209766 001	May 30, 2018
	PHARMOBEDIENT	120MG	A075124 002	Mar 18, 1998
		180MG	A075124 003	Mar 18, 1998
		240MG	A075124 001	Mar 18, 1998
	SUN PHARM	120MG	A090421 001	Nov 15, 2010
		120MG	A090492 001	Oct 28, 2011
		120MG	A203023 001	Jun 08, 2017
		180MG	A090421 002	Nov 15, 2010
		180MG	A090492 002	Oct 28, 2011
		180MG	A203023 002	Jun 08, 2017
		240MG	A090421 003	Nov 15, 2010
		240MG	A090492 003	Oct 28, 2011
		240MG	A203023 003	Jun 08, 2017
		300MG	A090421 004	Nov 15, 2010
		300MG	A090492 004	Oct 28, 2011
		300MG	A203023 004	Jun 08, 2017
		360MG	A090421 005	Nov 15, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
DILTIAZEM HYDROCHLORIDE					
	360MG		A090492	005	Oct 28, 2011
TEVA	60MG		A074079	001	Nov 30, 1993
	90MG		A074079	002	Nov 30, 1993
	120MG		A074079	003	Nov 30, 1993
DILTZAC					
APOTEX	120MG		A076395	001	Feb 01, 2006
	180MG		A076395	002	Feb 01, 2006
	240MG		A076395	003	Feb 01, 2006
	300MG		A076395	004	Feb 01, 2006
	360MG		A076395	005	Feb 01, 2006
TAZTIA XT					
ACTAVIS LABS FL INC	120MG		A075401	001	Apr 10, 2003
	180MG		A075401	002	Apr 10, 2003
	240MG		A075401	003	Apr 10, 2003
	300MG		A075401	004	Apr 10, 2003
	360MG		A075401	005	Apr 10, 2003
INJECTABLE;INJECTION					
CARDIZEM					
BIOVAIL	100MG/VIAL **		N020792	001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **		N020027	001	Oct 24, 1991
+	25MG/VIAL **		N020027	003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE					
DR REDDYS	5MG/ML		A074894	001	Aug 26, 1997
EUGIA PHARMA	5MG/ML		A216552	001	Mar 29, 2023
HIKMA FARMACEUTICA	5MG/ML		A202651	001	Aug 09, 2012
HOSPIRA	5MG/ML		A074941	001	Apr 15, 1998
	5MG/ML		A075004	001	Feb 16, 2000
	5MG/ML		A075106	001	Apr 29, 1999
INTL MEDICATION	5MG/ML		A075749	001	Nov 21, 2001
MYLAN LABS LTD	5MG/ML		A075375	001	Sep 30, 1999
SOLUTION;INTRAVENOUS					
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%					
+ EXELA PHARMA	125MG/125ML (1MG/ML) **		N215252	001	Oct 28, 2021
+	250MG/250ML (1MG/ML) **		N215252	002	Oct 28, 2021
TABLET;ORAL					
DILTIAZEM HYDROCHLORIDE					
APOTHECON	30MG		A074051	001	Mar 31, 1993
	60MG		A074051	002	Mar 31, 1993
	90MG		A074051	003	Mar 31, 1993
	120MG		A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG		A074093	001	Nov 05, 1992
	60MG		A074093	002	Nov 05, 1992
	90MG		A074093	003	Nov 05, 1992
	120MG		A074093	004	Nov 05, 1992
EDENBRIDGE PHARMS	30MG		A211596	001	Nov 18, 2019
	60MG		A211596	002	Nov 18, 2019
	90MG		A211596	003	Nov 18, 2019
	120MG		A211596	004	Nov 18, 2019
IVAX SUB TEVA PHARMS	30MG		A074168	001	Mar 03, 1995
	60MG		A074168	002	Mar 03, 1995
	90MG		A074168	003	Mar 03, 1995
	120MG		A074168	004	Mar 03, 1995
RISING	30MG		A072838	004	Nov 05, 1992
	60MG		A072838	003	Nov 05, 1992
	90MG		A072838	002	Nov 05, 1992
	120MG		A072838	001	Nov 05, 1992
TEVA	30MG		A074084	001	Feb 25, 1994
	60MG		A074084	002	Feb 25, 1994
TEVA PHARMS	30MG		A074067	001	Nov 05, 1992
	60MG		A074067	002	Nov 05, 1992
	90MG		A074067	003	Nov 05, 1992
	120MG		A074067	004	Nov 05, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM MALATE				
TABLET, EXTENDED RELEASE;ORAL				
TIAMATE				
	MERCK	EQ 120MG HYDROCHLORIDE	N020506 001	Oct 04, 1996
		EQ 180MG HYDROCHLORIDE	N020506 002	Oct 04, 1996
		EQ 240MG HYDROCHLORIDE	N020506 003	Oct 04, 1996
DILTIAZEM MALATE; ENALAPRIL MALEATE				
TABLET, EXTENDED RELEASE;ORAL				
TECZEM				
	BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507 001	Oct 04, 1996
DIMENHYDRINATE				
INJECTABLE;INJECTION				
DIMENHYDRINATE				
	BAXTER HLTHCARE	50MG/ML	A084767 001	
	WATSON LABS	50MG/ML	A083531 001	
+	WATSON LABS TEVA	50MG/ML	A080615 001	
	WYETH AYERST	50MG/ML	A084316 001	
LIQUID;ORAL				
DIMENHYDRINATE				
	ALRA	12.5MG/4ML	A080715 001	
TABLET;ORAL				
DIMENHYDRINATE				
	HEATHER	50MG	A080841 001	
	NEXGEN PHARMA INC	50MG	A085985 001	
+	WATSON LABS	50MG	A085166 001	
DIMETHYL FUMARATE				
CAPSULE, DELAYED RELEASE;ORAL				
DIMETHYL FUMARATE				
	CIPLA	120MG	A210305 001	Sep 24, 2020
		240MG	A210305 002	Sep 24, 2020
	SAWAI USA	120MG	A210285 001	Dec 21, 2021
		240MG	A210285 002	Dec 21, 2021
	TORRENT	120MG	A210390 001	Jan 06, 2025
		240MG	A210390 002	Jan 06, 2025
	ZYDUS PHARMS	120MG	A210538 001	Sep 24, 2020
		240MG	A210538 002	Sep 24, 2020
DIMETHYL SULFOXIDE				
SOLUTION;INTRAVESICAL				
DIMETHYL SULFOXIDE				
	MYLAN INSTITUTIONAL	50%	A076185 001	Nov 29, 2002
DIMYRISTOYL LECITHIN; PERFLEXANE				
INJECTABLE;INTRAVENOUS				
IMAGENT				
	VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191 001	May 31, 2002
DINOPROST TROMETHAMINE				
INJECTABLE;INJECTION				
PROSTIN F2 ALPHA				
	PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	
DINOPROSTONE				
SUPPOSITORY;VAGINAL				
PROSTIN E2				
+	PFIZER	20MG	N017810 001	
DIPHEMANIL METHYLSULFATE				
TABLET;ORAL				
PRANTAL				
	SCHERING	100MG	N008114 004	
DIPHENHYDRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENADRYL				
	MCNEIL CONS	25MG	N005845 007	
		50MG	N005845 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
	ALRA	25MG	A080519 004	
		50MG	A080519 003	
	ANABOLIC	50MG	A083275 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
ELKINS SINN	25MG	A085701	001	
	50MG	A085701	002	
FOSUN PHARMA	25MG	A080832	001	
	25MG	A080845	002	
	50MG	A080832	002	
	50MG	A080845	001	
HALSEY	50MG	A087914	001	Jun 04, 1984
HEATHER	25MG	A084524	001	
	50MG	A083953	001	
HERITAGE PHARMA	50MG	A080727	001	
	50MG	A080738	001	
HIKMA INTL PHARMS	50MG	A083567	001	
IMPAX LABS	25MG	A080807	001	
	50MG	A080807	002	
IVAX SUB TEVA PHARMS	25MG	A080762	001	
	50MG	A080762	002	
LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	
ELIXIR;ORAL				
BELIX				
HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
BENADRYL				
MCNEIL CONS	12.5MG/5ML	N005845	004	
DIBENIL				
CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
DIPHEN				
USL PHARMA	12.5MG/5ML	A084640	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
	KV PHARM	12.5MG/5ML	A085621 001	
	LANNETT	12.5MG/5ML	A080939 002	
	LEDERLE	12.5MG/5ML	A086937 001	
	MK LABS	12.5MG/5ML	A083088 002	
	NASKA	12.5MG/5ML	A088680 001	May 31, 1985
	PERRIGO	12.5MG/5ML	A083063 001	
	PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
	PVT FORM	12.5MG/5ML	A085287 001	
	ROXANE	12.5MG/5ML	A080643 001	
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
INJECTABLE;INJECTION				
BENADRYL				
	MCNEIL CONS	10MG/ML	N006146 001	
+		50MG/ML **	N006146 002	
BENADRYL PRESERVATIVE FREE				
+	MCNEIL CONS	50MG/ML **	N009486 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
	BEL MAR	10MG/ML	A080822 001	
	DR REDDYS	10MG/ML	A080873 001	
		50MG/ML	A080873 002	
	HIKMA	50MG/ML	A083183 001	
	HOSPIRA	50MG/ML	A040140 001	Nov 20, 1998
	LYPHOMED	10MG/ML	A087066 001	
	WATSON LABS	10MG/ML	A083533 001	
	WYETH AYERST	50MG/ML	A080577 001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE				
	ABRAXIS PHARM	50MG/ML	A080586 002	
	DR REDDYS	50MG/ML	A080873 003	
	INTL MEDICATION	50MG/ML	A084094 001	
SYRUP;ORAL				
ANTITUSSIVE				
	PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
BELDIN				
	HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
BENYLIN				
	PARKE DAVIS	12.5MG/5ML	N006514 004	
DIPHEN				
	MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
	CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
	SCIEGEN PHARMS	12.5MG/5ML	A072416 001	Sep 28, 1990
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN				
	LANNETT CO INC	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44				
	WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL				
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE				
	P AND L	25MG;220MG	A207597 001	Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
	PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014 001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
	GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
	GLAXOSMITHKLINE	5MG	N011945 001	
DIPIVEFRIN HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
	EPIC PHARMA LLC	0.1%	A074382 001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
	BAUSCH AND LOMB	0.1%	A074188 001	May 19, 1995
	FALCON PHARMS	0.1%	A073636 001	Jun 30, 1994
PROPINE				
	ALLERGAN	0.1%	N018239 001	
DIPYRIDAMOLE				
INJECTABLE;INJECTION				
DIPYRIDAMOLE				
	DR REDDYS	5MG/ML	A074952 001	Nov 26, 1997
	EUGIA PHARMA SPECLTS	5MG/ML	A075769 001	Nov 27, 2002
	FRESENIUS KABI USA	5MG/ML	A074956 001	Sep 30, 1998
	HOSPIRA	5MG/ML	A074601 001	Dec 19, 1997
IV PERSANTINE				
+	BOEHRINGER INGELHEIM	5MG/ML **	N019817 001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
	ANI PHARMS	25MG	A086944 002	Apr 16, 1991
		50MG	A086944 001	Feb 25, 1992
		75MG	A086944 003	Feb 25, 1992
	CHARTWELL RX	25MG	A040898 001	Apr 23, 2008
		50MG	A040898 002	Apr 23, 2008
		75MG	A040898 003	Apr 23, 2008
	GLENMARK GENERICS	25MG	A088999 001	Feb 05, 1991
		50MG	A089000 001	Feb 05, 1991
		75MG	A089001 001	Feb 05, 1991
	PUREPAC PHARM	25MG	A089425 001	Jul 12, 1990
		50MG	A089426 001	Jul 12, 1990
		75MG	A089427 001	Jul 12, 1990
	WATSON LABS	50MG	A087160 001	Jun 07, 1996
PERSANTINE				
+	BOEHRINGER INGELHEIM	25MG **	N012836 003	Dec 22, 1986
+		50MG **	N012836 004	Feb 06, 1987
+		75MG **	N012836 005	Feb 06, 1987
DIRITHROMYCIN				
TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
	LILLY RES LABS	250MG	N050678 001	Jun 19, 1995
DISOPYRAMIDE PHOSPHATE				
CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
	INTERPHARM	EQ 100MG BASE	A071190 001	Jan 15, 1987
		EQ 150MG BASE	A071191 001	Jan 15, 1987
	IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186 001	Nov 18, 1985
		EQ 150MG BASE	A070187 001	Nov 18, 1985
	MYLAN	EQ 100MG BASE	A070138 001	Jun 14, 1985
		EQ 150MG BASE	A070139 001	Jun 14, 1985
	RISING	EQ 100MG BASE	A070470 001	Dec 10, 1985
		EQ 150MG BASE	A070471 001	Dec 10, 1985
	SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351 001	Dec 17, 1985
		EQ 150MG BASE	A070352 001	Dec 17, 1985
	SUPERPHARM	EQ 100MG BASE	A070940 001	Feb 09, 1987
		EQ 150MG BASE	A070941 001	Feb 09, 1987
	WATSON LABS	EQ 100MG BASE	A070240 001	Feb 02, 1986
		EQ 150MG BASE	A070241 001	Feb 02, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
DISOPYRAMIDE PHOSPHATE				
	NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISULFIRAM					
TABLET;ORAL					
ANTABUSE					
+	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983
+		500MG	A088483	001	Dec 08, 1983
+	TEVA WOMENS	250MG **	N007883	003	
+		500MG **	N007883	002	
DISULFIRAM					
	DASH PHARMS	250MG	A203916	001	Mar 04, 2015
		500MG	A203916	002	Mar 04, 2015
	HIKMA	250MG	A202652	001	Feb 05, 2014
		500MG	A202652	002	Feb 05, 2014
	STRIDES PHARMA INTL	250MG	A088792	001	Aug 14, 1984
		500MG	A088793	001	Aug 14, 1984
	WATSON LABS	250MG	A086889	001	
		250MG	A087973	001	Aug 05, 1983
		500MG	A087974	001	Aug 05, 1983
	WATSON LABS TEVA	500MG	A086890	001	
DIVALPROEX SODIUM					
CAPSULE, DELAYED REL PELLETS;ORAL					
DIVALPROEX SODIUM					
	RISING	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011
	TEVA PHARMS USA	EQ 125MG VALPROIC ACID	A211505	001	Nov 17, 2020
TABLET, DELAYED RELEASE;ORAL					
DEPAKOTE CP					
	ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
		EQ 500MG BASE	N019794	002	Jul 11, 1990
DIVALPROEX SODIUM					
	ACTAVIS LABS FL INC	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011
	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008
		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008
		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008
	MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
		EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
		EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008
	PH HEALTH	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008
	PHARMOBEDIENT	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009
		EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009
		EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009
	TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
		EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
		EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008
TABLET, EXTENDED RELEASE;ORAL					
DIVALPROEX SODIUM					
	COSETTE	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009
	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009
		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009
	PH HEALTH	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009
		EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009
	YICHANG HUMANWELL	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021
		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021
DOBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
DOBUTAMINE HYDROCHLORIDE					
	BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
	DR REDDYS	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
	HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995
		EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
	LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
	TELIGENT	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
	TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
	WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
	WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%					
	HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
		EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
		EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOBUTAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
DOBUTREX					
+	LILLY	EQ 12.5MG BASE/ML **	N017820	002	
DOCETAXEL					
INJECTABLE;INJECTION					
DOCEFREZ					
+	SUN PHARM	20MG/VIAL	N022534	001	May 03, 2011
+		80MG/VIAL	N022534	002	May 03, 2011
DOCETAXEL					
+	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
		80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017
		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
	EUGIA PHARMA	20MG/2ML (10MG/ML)	A214575	001	Jun 25, 2021
		80MG/8ML (10MG/ML)	A214575	002	Jun 25, 2021
		160MG/16ML (10MG/ML)	A214575	003	Jun 25, 2021
	HENGRUI PHARMA	40MG/ML	A203170	001	Feb 15, 2017
+	HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
	PHARMOBEDIENT	20MG/ML (20MG/ML)	A203892	001	May 11, 2023
		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023
	SUN PHARM	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019
		80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019
		160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019
	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015
		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015
TAXOTERE					
+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010
+		40MG/ML **	N020449	001	May 14, 1996
+		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010
DOFETILIDE					
CAPSULE;ORAL					
DOFETILIDE					
	NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019
		0.25MG	A212410	002	Dec 27, 2019
		0.5MG	A212410	003	Dec 27, 2019
	PRINSTON INC	0.125MG	A211223	001	Dec 17, 2019
		0.25MG	A211223	002	Dec 17, 2019
		0.5MG	A211223	003	Dec 17, 2019
	RK PHARMA	0.125MG	A215323	001	Apr 14, 2022
		0.25MG	A215323	002	Apr 14, 2022
		0.5MG	A215323	003	Apr 14, 2022
	TEVA PHARMS USA	0.125MG	A210018	001	Apr 15, 2022
		0.25MG	A210018	002	Apr 15, 2022
		0.5MG	A210018	003	Apr 15, 2022
DOLASETRON MESYLATE					
INJECTABLE;INJECTION					
ANZEMET					
+	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001
TABLET;ORAL					
ANZEMET					
+	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOLUTEGRAVIR SODIUM

TABLET;ORAL					
TIVICAY					
+	VIIV HLTHCARE	EQ 10MG BASE **	N204790	002	Jun 09, 2016
+		EQ 25MG BASE **	N204790	003	Jun 09, 2016

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL					
ARICEPT					
+	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
SYSTEM;TRANSDERMAL					
ADLARITY					
+	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022
+		10MG/DAY	N212304	002	Mar 11, 2022
TABLET;ORAL					
DONEPEZIL HYDROCHLORIDE					
	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
		10MG	A201335	002	Aug 29, 2011
	ACTAVIS ELIZABETH	23MG	A202415	001	Dec 17, 2015
	AIPING PHARM INC	5MG	A090290	001	May 31, 2011
		10MG	A090290	002	May 31, 2011
	APOTEX	5MG	A078841	001	Jun 02, 2011
		10MG	A078841	002	Jun 02, 2011
	CHARTWELL RX	23MG	A203419	001	Apr 12, 2016
	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011
		10MG	A077344	002	May 31, 2011
	HIKMA PHARMS	5MG	A090247	001	May 31, 2011
		10MG	A090247	002	May 31, 2011
	HISUN PHARM HANGZHOU	23MG	A202410	001	Mar 24, 2017
	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012
		10MG	A201634	002	Jun 13, 2012
	NATCO PHARMA	5MG	A090521	001	May 31, 2011
		10MG	A090521	002	May 31, 2011
	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016
	PH HEALTH	23MG	A202542	001	Jul 24, 2013
	RISING	23MG	A202656	001	Oct 22, 2015
	SUN PHARM	23MG	A204293	001	Jun 05, 2015
	SUN PHARM INDS	5MG	A090493	001	May 31, 2011
		10MG	A090493	002	May 31, 2011
	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010
		10MG	A076786	002	Nov 26, 2010
	UNICHEM	5MG	A203656	001	Jun 23, 2016
		10MG	A203656	002	Jun 23, 2016
	WOCKHARDT	5MG	A091267	001	May 31, 2011
		10MG	A091267	002	May 31, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
ARICEPT ODT					
+	EISAI INC	5MG	N021720	001	Oct 18, 2004
+		10MG	N021720	002	Oct 18, 2004
DONEPEZIL HYDROCHLORIDE					
	AIPING PHARM INC	5MG	A091198	001	May 10, 2011
		10MG	A091198	002	May 10, 2011
	CHARTWELL RX	5MG	A078388	002	Nov 26, 2010
		10MG	A078388	001	Nov 26, 2010
	SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
		10MG	A077975	001	Dec 11, 2009
	UNICHEM	5MG	A204831	001	Nov 10, 2016
		10MG	A204831	002	Nov 10, 2016
	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011
		10MG	A090175	002	May 10, 2011

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION					
DOPAMINE HYDROCHLORIDE					
	ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
		80MG/ML	A070657	001	Jan 24, 1989
	ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
		40MG/ML	A070058	001	Mar 20, 1985
		80MG/ML	A070013	001	Jun 12, 1985
		80MG/ML	A070059	001	Mar 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE				
	160MG/ML	A070364	001	Dec 04, 1985
AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
	80MG/ML	A070820	001	Feb 11, 1987
	160MG/ML	A070826	001	Feb 11, 1987
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%				
+ B BRAUN	80MG/100ML	N019099	002	Oct 15, 1986
+	320MG/100ML	N019099	004	Oct 15, 1986
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER				
+ B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986
+	160MG/100ML	N019099	003	Oct 15, 1986
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORIPENEM

INJECTABLE;INTRAVENOUS

DORIBAX				
+ SHIONOGI INC	250MG/VIAL **	N022106	002	Oct 05, 2010
+	500MG/VIAL **	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE				
AM REGENT	EQ 2% BASE	A079186	001	Nov 18, 2009
HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008
ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013
TRUSOPT				
+ MSD SUB MERCK	EQ 2% BASE **	N020408	001	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE				
CHARTWELL MOLECULAR	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014
HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008
RUBICON RESEARCH	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
ANI PHARMS	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
PLIVA	EQ 1MG BASE	A075750	001	Jun 08, 2001
	EQ 2MG BASE	A075750	002	Jun 08, 2001
	EQ 4MG BASE	A075750	003	Jun 08, 2001
	EQ 8MG BASE	A075750	004	Jun 08, 2001
STRIDES PHARMA INTL	EQ 1MG BASE	A076161	001	Jun 10, 2004
	EQ 2MG BASE	A076161	002	Jun 10, 2004
	EQ 4MG BASE	A076161	003	Jun 10, 2004
	EQ 8MG BASE	A076161	004	Jun 10, 2004
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000
	EQ 2MG BASE	A075426	002	Oct 18, 2000
	EQ 4MG BASE	A075426	003	Oct 18, 2000
	EQ 8MG BASE	A075426	004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022
DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
LANNETT CO INC	EQ 10MG BASE	A212997	001	Jul 24, 2020
	EQ 25MG BASE	A212997	002	Jul 24, 2020
	EQ 50MG BASE	A212997	003	Jul 24, 2020
	EQ 75MG BASE	A212997	004	Jul 24, 2020
	EQ 100MG BASE	A212997	005	Jul 24, 2020
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL					
DOXEPIN HYDROCHLORIDE					
		EQ 50MG BASE	N016987	003	
		EQ 75MG BASE	N016987	006	
		EQ 100MG BASE	N016987	004	
		EQ 150MG BASE	N016987	007	Apr 13, 1987
	PH HEALTH	EQ 10MG BASE	A071422	002	Nov 09, 1987
		EQ 25MG BASE	A071422	003	Nov 09, 1987
		EQ 50MG BASE	A071422	004	Nov 09, 1987
		EQ 75MG BASE	A071422	005	Nov 09, 1987
		EQ 100MG BASE	A071422	001	Nov 09, 1987
	PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
		EQ 25MG BASE	A072109	001	Dec 28, 1990
		EQ 50MG BASE	A073055	001	Dec 28, 1990
		EQ 75MG BASE	A072386	001	Sep 08, 1988
		EQ 100MG BASE	A072110	001	Sep 08, 1988
		EQ 150MG BASE	A072387	001	Sep 08, 1988
	QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
		EQ 25MG BASE	A070973	001	Sep 29, 1987
		EQ 50MG BASE	A070931	001	Sep 29, 1987
		EQ 75MG BASE	A070932	001	Sep 29, 1987
		EQ 100MG BASE	A072375	001	Mar 15, 1989
		EQ 150MG BASE	A072376	001	Mar 15, 1989
	SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
		EQ 25MG BASE	A070827	001	May 15, 1986
		EQ 50MG BASE	A070828	001	May 15, 1986
		EQ 75MG BASE	A070825	001	May 15, 1986
		EQ 100MG BASE	A071562	001	Mar 02, 1987
	SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502	001	Feb 18, 1988
		EQ 50MG BASE	A071653	001	Feb 18, 1988
		EQ 75MG BASE	A071654	001	Feb 18, 1988
		EQ 100MG BASE	A071521	001	Feb 18, 1988
	TARO	EQ 10MG BASE	A213063	001	Jul 01, 2020
		EQ 25MG BASE	A213063	002	Jul 01, 2020
		EQ 50MG BASE	A213063	003	Jul 01, 2020
		EQ 75MG BASE	A213063	004	Jul 01, 2020
		EQ 100MG BASE	A213063	005	Jul 01, 2020
	WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
		EQ 10MG BASE	A071485	001	Apr 30, 1987
		EQ 10MG BASE	A072985	001	Mar 29, 1991
		EQ 25MG BASE	A070953	001	May 15, 1986
		EQ 25MG BASE	A071486	001	Apr 30, 1987
		EQ 25MG BASE	A072986	001	Mar 29, 1991
		EQ 50MG BASE	A070954	001	May 15, 1986
		EQ 50MG BASE	A071238	001	Apr 30, 1987
		EQ 75MG BASE	A071326	001	Apr 30, 1987
		EQ 75MG BASE	A071763	001	Feb 09, 1988
		EQ 100MG BASE	A070955	001	May 15, 1986
		EQ 100MG BASE	A071239	001	Apr 30, 1987
		EQ 150MG BASE	A071764	001	Feb 09, 1988
	WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991
SINEQUAN					
+ PFIZER		EQ 10MG BASE **	N016798	003	
+		EQ 25MG BASE **	N016798	001	
+		EQ 50MG BASE **	N016798	002	
+		EQ 75MG BASE **	N016798	006	
+		EQ 100MG BASE **	N016798	005	
+		EQ 150MG BASE **	N016798	007	
CONCENTRATE;ORAL					
DOXEPIN HYDROCHLORIDE					
	PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
	PHARMOBEDIENT CNSLTG	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988
	TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987
SINEQUAN					
+ PFIZER		EQ 10MG BASE/ML **	N017516	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXERCALCIFEROL					
CAPSULE;ORAL					
DOXERCALCIFEROL					
	HIKMA	0.5MCG	A091433	001	Sep 23, 2011
		1MCG	A091433	002	Jan 14, 2014
		2.5MCG	A091433	003	Jan 14, 2014
HECTOROL					
+	SANOFI	0.5MCG	N020862	002	Apr 23, 2004
+		1MCG	N020862	003	Jul 13, 2009
+		2.5MCG	N020862	001	Jun 09, 1999
INJECTABLE;INJECTION					
DOXERCALCIFEROL					
	AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017
		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017
		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017
	EPIC PHARMA LLC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016
		4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015
	EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022
+	HOSPIRA	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018
+		10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018
	LUPIN LTD	4MCG/2ML (2MCG/ML)	A210801	001	Nov 01, 2018
	SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019
		4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019
HECTOROL					
+	SANOFI	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000
+		4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000
DOXORUBICIN HYDROCHLORIDE					
INJECTABLE;INJECTION					
ADRIAMYCIN PFS					
	PFIZER	2MG/ML	A063165	001	Jan 30, 1991
		200MG/100ML	A063165	002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE					
	ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012
	HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019
	HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012
	MYLAN LABS LTD	10MG/VIAL	A200170	001	Oct 28, 2011
	PFIZER	10MG/VIAL	N050467	001	
		20MG/VIAL	N050467	003	May 20, 1985
		50MG/VIAL	N050467	002	
		150MG/VIAL	N050467	004	Jul 22, 1987
+		150MG/75ML	N050629	003	Mar 28, 2011
	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995
		10MG/VIAL	A063097	001	May 21, 1990
		20MG/VIAL	A063097	002	May 21, 1990
		50MG/VIAL	A063097	003	May 21, 1990
		200MG/100ML	A063336	004	Feb 28, 1995
	PHARMOBEDIENT	2MG/ML	A200901	001	Feb 14, 2012
	TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995
		200MG/100ML	A064140	002	Jul 28, 1995
RUBEX					
	BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
		50MG/VIAL	A062926	002	Apr 13, 1989
		100MG/VIAL	A062926	003	Apr 13, 1989
DOXYCYCLINE					
CAPSULE;ORAL					
DOXYCYCLINE					
	COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015
		EQ 75MG BASE	A204446	002	May 28, 2015
		EQ 100MG BASE	A204446	003	May 28, 2015
	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011
	RISING	EQ 50MG BASE	A208942	001	Jan 21, 2021
		EQ 75MG BASE	A208942	002	Jan 21, 2021
		EQ 100MG BASE	A208942	003	Jan 21, 2021
	SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
		EQ 100MG BASE	A065032	002	Jun 30, 2000
	STRIDES PHARMA	EQ 150MG BASE	A202778	001	Jun 08, 2012
	STRIDES PHARMA INTL	EQ 75MG BASE	A065055	004	Apr 18, 2005
	WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE				
CAPSULE;ORAL				
DOXYCYCLINE				
	EQ 100MG BASE		A065041 002	Apr 28, 2000
FOR SUSPENSION;ORAL				
DOXYCHEL				
RACHELLE	EQ 25MG BASE/5ML		A061720 001	
VIBRAMYCIN				
+ PFIZER	EQ 25MG BASE/5ML **		N050006 001	
TABLET;ORAL				
DOXYCYCLINE				
CHARTWELL RX	EQ 50MG BASE		A065377 001	Nov 07, 2006
	EQ 75MG BASE		A065377 002	Nov 07, 2006
	EQ 100MG BASE		A065377 003	Nov 07, 2006
	EQ 150MG BASE		A065427 001	Jun 07, 2007
SANDOZ INC	EQ 50MG BASE		A065353 001	Nov 27, 2006
	EQ 75MG BASE		A065353 002	Nov 27, 2006
	EQ 100MG BASE		A065353 003	Nov 27, 2006
SUN PHARM INDUSTRIES	EQ 50MG BASE		A065471 001	Apr 17, 2009
	EQ 75MG BASE		A065471 002	Apr 17, 2009
	EQ 100MG BASE		A065471 003	Apr 17, 2009
DOXYCYCLINE CALCIUM				
SUSPENSION;ORAL				
VIBRAMYCIN				
+ PFIZER	EQ 50MG BASE/5ML		N050480 001	
DOXYCYCLINE HYCLATE				
CAPSULE;ORAL				
ACTICLATE CAP				
+ CHARTWELL RX	EQ 75MG BASE		N208253 001	Apr 26, 2016
DOXY-LEMMON				
TEVA	EQ 50MG BASE		A062497 001	Aug 23, 1984
	EQ 100MG BASE		A062497 002	Jun 15, 1984
DOXYCYCLINE HYCLATE				
AJANTA PHARMA LTD	EQ 50MG BASE		A211012 001	Sep 24, 2018
	EQ 100MG BASE		A211012 002	Sep 24, 2018
BIONPHARMA	EQ 50MG BASE		A209393 001	Dec 10, 2020
	EQ 100MG BASE		A209393 002	Dec 10, 2020
HALSEY	EQ 50MG BASE		A062119 002	May 24, 1985
	EQ 100MG BASE		A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE		A062463 001	Dec 07, 1983
	EQ 100MG BASE		A062463 002	Dec 07, 1983
HIKMA INTL PHARMS	EQ 20MG BASE		A065103 001	May 13, 2005
INTERPHARM	EQ 50MG BASE		A062763 001	Sep 02, 1988
	EQ 100MG BASE		A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE		A062418 001	Jan 28, 1983
	EQ 100MG BASE		A062418 002	Jan 28, 1983
NESHER PHARMS	EQ 50MG BASE		A208263 001	Nov 22, 2021
	EQ 100MG BASE		A208263 002	Nov 22, 2021
PAR PHARM	EQ 50MG BASE		A062434 001	Oct 19, 1984
	EQ 100MG BASE		A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE		A062631 001	Jul 24, 1986
	EQ 100MG BASE		A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE		A062479 001	Dec 23, 1983
	EQ 100MG BASE		A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE		A062469 001	Oct 31, 1984
	EQ 100MG BASE		A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE		A062594 001	Dec 05, 1985
	EQ 100MG BASE		A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE		A061717 001	
	EQ 50MG BASE		A062142 001	
	EQ 100MG BASE		A061717 002	
	EQ 100MG BASE		A062142 002	
ZHEJIANG YONGTAI	EQ 50MG BASE		A212610 001	Mar 31, 2020
	EQ 100MG BASE		A212610 002	Mar 31, 2020
PERIOSTAT				
+ COLLAGENEX	EQ 20MG BASE **		N050744 001	Sep 30, 1998
VIBRAMYCIN				
+ PFIZER	EQ 50MG BASE **		N050007 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE

CAPSULE;ORAL				
VIBRAMYCIN				
+		EQ 100MG BASE	N050007 002	
CAPSULE, COATED PELLETS;ORAL				
DOXYCYCLINE HYCLATE				
	PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL				
DORYX				
+	MAYNE PHARMA	EQ 75MG BASE	N050582 002	Aug 13, 2001
+		EQ 100MG BASE	N050582 001	Jul 22, 1985
	WARNER CHILCOTT	EQ 100MG BASE	A062653 001	Oct 30, 1985
DOXYCYCLINE HYCLATE				
	BAUSCH	EQ 75MG BASE	A065281 001	Dec 21, 2005
		EQ 100MG BASE	A065281 002	Dec 21, 2005
INJECTABLE;INJECTION				
DOXYCHEL HYCLATE				
	RACHELLE	EQ 100MG BASE/VIAL	A061953 001	
DOXYCYCLINE				
	HIKMA	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983
		EQ 100MG BASE/VIAL	A062569 001	Mar 09, 1988
		EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983
		EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988
DOXYCYCLINE HYCLATE				
	AMNEAL	EQ 100MG BASE/VIAL	A217487 001	Dec 04, 2024
VIBRAMYCIN				
+	PFIZER	EQ 100MG BASE/VIAL **	N050442 002	
+		EQ 200MG BASE/VIAL **	N050442 001	
SYSTEM, EXTENDED RELEASE;PERIODONTAL				
ATRIDOX				
+	DEN-MAT	50MG	N050751 001	Sep 03, 1998
TABLET;ORAL				
DOXY-LEMMON				
	TEVA	EQ 100MG BASE	A062581 001	Mar 15, 1985
DOXYCYCLINE HYCLATE				
	ALEMBIC	EQ 100MG BASE	A210536 001	May 14, 2020
	AMNEAL	EQ 100MG BASE	A216599 001	Oct 24, 2022
	AMNEAL PHARMS CO	EQ 75MG BASE	A209372 001	Oct 06, 2017
		EQ 150MG BASE	A209372 002	Oct 06, 2017
	AVET LIFESCIENCES	EQ 100MG BASE	A209969 001	Nov 09, 2018
	HEATHER	EQ 100MG BASE	A062462 001	May 11, 1983
	HERITAGE PHARMA	EQ 20MG BASE	A065163 001	May 13, 2005
	INTERPHARM	EQ 100MG BASE	A062764 001	Sep 02, 1988
	MUTUAL PHARM	EQ 100MG BASE	A062391 001	Sep 30, 1982
	MYLAN	EQ 100MG BASE	A062432 001	Feb 15, 1983
	ORYZA	EQ 100MG BASE	A213475 001	Mar 10, 2021
	PHARMOBEDIENT	EQ 100MG BASE	A209560 001	Apr 15, 2024
	PRAXGEN	EQ 100MG BASE	A212487 001	Mar 30, 2022
	RISING	EQ 75MG BASE	A209987 001	Oct 05, 2020
		EQ 150MG BASE	A209987 002	Oct 05, 2020
	SUPERPHARM	EQ 100MG BASE	A062494 001	Feb 20, 1985
	TORRENT	EQ 75MG BASE	A214356 001	Apr 15, 2024
		EQ 150MG BASE	A214356 002	Apr 15, 2024
	WARNER CHILCOTT	EQ 100MG BASE	A062593 001	Aug 28, 1985
	WATSON LABS	EQ 50MG BASE	A062392 001	Mar 31, 1983
		EQ 100MG BASE	A062392 002	Mar 31, 1983
LYMEPAK				
+	CHARTWELL PHARMA	EQ 100MG BASE	N209844 001	Jun 15, 2018
PERIOSTAT				
+	GALDERMA LABS LP	EQ 20MG BASE **	N050783 001	Feb 02, 2001
VIBRA-TABS				
+	PFIZER	EQ 100MG BASE **	N050533 001	
TABLET, DELAYED RELEASE;ORAL				
DORYX				
+	MAYNE PHARMA	EQ 50MG BASE **	N050795 006	Dec 19, 2014
+		EQ 75MG BASE **	N050795 001	May 06, 2005
+		EQ 100MG BASE **	N050795 002	May 06, 2005
+		EQ 150MG BASE **	N050795 003	Jun 20, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL				
DORYX MPC				
+	MAYNE PHARMA	EQ 120MG BASE **	N050795 008	May 20, 2016
DOXYCYCLINE HYCLATE				
	AUROBINDO PHARMA USA	EQ 150MG BASE	A091052 001	Feb 08, 2012
	IMPAX LABS INC	EQ 75MG BASE	A090505 001	Dec 28, 2010
		EQ 100MG BASE	A090505 002	Dec 28, 2010
	LUPIN	EQ 50MG BASE	A208741 001	Aug 11, 2023
		EQ 60MG BASE	A208741 002	Aug 11, 2023
		EQ 75MG BASE	A208741 003	Aug 11, 2023
		EQ 80MG BASE	A208741 004	Aug 11, 2023
		EQ 100MG BASE	A208741 005	Aug 11, 2023
		EQ 120MG BASE	A208741 006	Aug 11, 2023
		EQ 150MG BASE	A208741 007	Aug 11, 2023
		EQ 200MG BASE	A208741 008	Aug 11, 2023
	RISING	EQ 50MG BASE	A090431 003	May 23, 2016
		EQ 75MG BASE	A090431 001	Dec 28, 2010
		EQ 80MG BASE	A090431 004	Apr 29, 2016
		EQ 100MG BASE	A090431 002	Dec 28, 2010
		EQ 200MG BASE	A090431 005	May 19, 2016
	ZYDUS PHARMS	EQ 75MG BASE	A206772 001	Dec 21, 2018
		EQ 100MG BASE	A206772 002	Dec 21, 2018
		EQ 150MG BASE	A206772 003	Dec 21, 2018

DOXYLAMINE SUCCINATE

CAPSULE;ORAL				
UNISOM				
	PFIZER	25MG	N019440 001	Feb 05, 1986
TABLET;ORAL				
DECAPRYN				
	SANOFI AVENTIS US	12.5MG	N006412 015	
		25MG	N006412 014	
DOXY-SLEEP-AID				
	PAR PHARM	25MG	A070156 001	Jul 02, 1987
DOXYLAMINE SUCCINATE				
	COPLEY PHARM	25MG	A088900 002	Feb 12, 1988
	QUANTUM PHARMICS	25MG	A088603 001	Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
BENDECTIN				
	SANOFI AVENTIS US	10MG;10MG **	N010598 002	
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE				
	ACTAVIS LABS FL INC	20MG;20MG	A212472 001	Mar 01, 2022

DROMOSTANOLONE PROPIONATE

INJECTABLE;INJECTION				
DROLBAN				
	LILLY	50MG/ML	N012936 001	

DRONABINOL

CAPSULE;ORAL				
DRONABINOL				
	HIKMA	2.5MG	A079217 001	Jun 20, 2014
		5MG	A079217 002	Jun 20, 2014
		10MG	A079217 003	Jun 20, 2014
	INSYS THERAP	2.5MG	A078501 001	Aug 19, 2011
		5MG	A078501 002	Aug 19, 2011
		10MG	A078501 003	Aug 19, 2011
	LANNETT CO INC	2.5MG	A201463 001	May 18, 2018
		5MG	A201463 002	May 18, 2018
		10MG	A201463 003	May 18, 2018
	SVC PHARMA	2.5MG	A078292 001	Jun 27, 2008
		5MG	A078292 002	Jun 27, 2008
		10MG	A078292 003	Jun 27, 2008
SOLUTION;ORAL				
SYNDROS				
+	BENUVIA OPERATIONS	5MG/ML **	N205525 001	Mar 23, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DROPERIDOL

INJECTABLE;INJECTION					
DROPERIDOL					
	ABRAXIS PHARM	2.5MG/ML	A070992	001	Nov 17, 1986
		2.5MG/ML	A070993	001	Nov 17, 1986
	ASTRAZENECA	2.5MG/ML	A072018	001	Oct 20, 1988
	HOSPIRA	2.5MG/ML	A071645	001	Apr 07, 1988
		2.5MG/ML	A071981	001	Feb 29, 1988
		2.5MG/ML	A072272	001	Aug 31, 1995
	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988
		2.5MG/ML	A072020	001	Oct 19, 1988
		2.5MG/ML	A072021	001	Oct 19, 1988
	LUITPOLD	2.5MG/ML	A072335	001	Oct 24, 1988
	SMITH AND NEPHEW	2.5MG/ML	A071750	001	Sep 06, 1988
	SOLOPAK	2.5MG/ML	A071754	001	Sep 06, 1988
		2.5MG/ML	A071755	001	Sep 06, 1988
	WATSON LABS	2.5MG/ML	A073520	001	Nov 27, 1991
		2.5MG/ML	A073521	001	Nov 27, 1991
		2.5MG/ML	A073523	001	Nov 27, 1991
INAPSINE					
+	RISING	2.5MG/ML	N016796	001	

DROPERIDOL; FENTANYL CITRATE

INJECTABLE;INJECTION					
FENTANYL CITRATE AND DROPERIDOL					
	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026	001	Apr 13, 1989
		2.5MG/ML;EQ 0.05MG BASE/ML	A072027	001	Apr 13, 1989
		2.5MG/ML;EQ 0.05MG BASE/ML	A072028	001	Apr 13, 1989
	HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982	001	May 04, 1988
INNOVAR					
	EPIC PHARMA LLC	2.5MG/ML;EQ 0.05MG BASE/ML	N016049	001	

DROSPIRENONE

TABLET, CHEWABLE;ORAL					
DROSPIRENONE					
+	EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL					
DROSPIRENONE AND ETHINYL ESTRADIOL					
	BARR	3MG;0.02MG	A078515	001	Mar 30, 2009
	JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017
KYRA					
	SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019
TABLET;ORAL-28					
DROSPIRENONE AND ETHINYL ESTRADIOL					
	APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016
	BARR	3MG;0.03MG	A077527	001	May 09, 2008
	JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018
KEMEYA					
	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019

DROXIDOPA

CAPSULE;ORAL					
DROXIDOPA					
	CHARTWELL RX	100MG	A214217	001	May 05, 2022
		200MG	A214217	002	May 05, 2022
		300MG	A214217	003	May 05, 2022
	HIKMA	100MG	A212835	001	Feb 18, 2021
		200MG	A212835	002	Feb 18, 2021
		300MG	A212835	003	Feb 18, 2021
	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021
		200MG	A211652	002	Feb 18, 2021
		300MG	A211652	003	Feb 18, 2021
	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021
		200MG	A213162	002	Feb 18, 2021
		300MG	A213162	003	Feb 18, 2021
	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021
		200MG	A213661	002	Feb 18, 2021
		300MG	A213661	003	Feb 18, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DULOXETINE HYDROCHLORIDE				
CAPSULE, DELAYED REL PELLETS;ORAL				
CYMBALTA				
+ LILLY	EQ 20MG BASE	N021427	001	Aug 03, 2004
+	EQ 30MG BASE	N021427	002	Aug 03, 2004
+	EQ 60MG BASE	N021427	004	Aug 03, 2004
DULOXETINE HYDROCHLORIDE				
ADAPTIS	EQ 20MG BASE	A090723	001	Dec 11, 2013
	EQ 30MG BASE	A090723	002	Dec 11, 2013
	EQ 60MG BASE	A090723	003	Dec 11, 2013
APOTEX	EQ 20MG BASE	A202045	001	Jun 11, 2014
	EQ 30MG BASE	A202045	002	Jun 11, 2014
	EQ 60MG BASE	A202045	003	Jun 11, 2014
PH HEALTH	EQ 20MG BASE	A090780	001	Oct 28, 2015
	EQ 30MG BASE	A090780	002	Oct 28, 2015
	EQ 60MG BASE	A090780	003	Oct 28, 2015
SUN PHARM	EQ 20MG BASE	A090745	001	Dec 11, 2013
	EQ 30MG BASE	A090745	002	Dec 11, 2013
	EQ 60MG BASE	A090745	003	Dec 11, 2013
TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013
	EQ 30MG BASE	A090783	002	Dec 11, 2013
	EQ 60MG BASE	A090783	003	Dec 11, 2013
TORRENT	EQ 20MG BASE	A090774	001	Dec 11, 2013
	EQ 30MG BASE	A090774	002	Dec 11, 2013
	EQ 60MG BASE	A090774	003	Dec 11, 2013
YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019
	EQ 30MG BASE	A207219	002	Aug 16, 2019
	EQ 60MG BASE	A207219	003	Aug 16, 2019
DUTASTERIDE				
CAPSULE;ORAL				
DUTASTERIDE				
ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015
APOTEX	0.5MG	A204292	001	Nov 24, 2015
HERITAGE PHARMS INC	0.5MG	A207935	001	Oct 13, 2017
HIKMA	0.5MG	A202204	001	Nov 23, 2015
PH HEALTH	0.5MG	A202421	001	Nov 20, 2015
PHARMOBEDIENT	0.5MG	A203241	001	Jun 14, 2016
	0.5MG	A204705	001	Nov 20, 2015
RISING	0.5MG	A202530	001	Nov 20, 2015
STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018
DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE				
ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975	001	Nov 20, 2015
DYCLONINE HYDROCHLORIDE				
SOLUTION;TOPICAL				
DYCLONE				
+ ASTRAZENECA	0.5% **	N009925	002	
+	1% **	N009925	001	
DYDROGESTERONE				
TABLET;ORAL				
GYNOREST				
+ SOLVAY	5MG **	N017388	001	
+	10MG **	N017388	002	
DYPHYLLINE				
ELIXIR;ORAL				
NEOTHYLLINE				
TEVA	160MG/15ML	N007794	003	
INJECTABLE;INJECTION				
NEOTHYLLINE				
TEVA	250MG/ML	N009088	001	
TABLET;ORAL				
DILOR				
SAVAGE LABS	200MG	A084514	001	
DILOR-400				
SAVAGE LABS	400MG	A084751	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DYPHYLLINE				
TABLET;ORAL				
LUFYLLIN				
PHARMOBEDIENT	200MG		A084566 001	
	400MG		A084566 002	
NEOTHYLLINE				
TEVA	200MG		N007794 001	
	400MG		N007794 002	
ECHOTHIOPHATE IODIDE				
FOR SOLUTION;OPHTHALMIC				
PHOSPHOLINE IODIDE				
FERA PHARMS LLC	0.03%		N011963 002	
	0.06%		N011963 004	
	0.25%		N011963 003	
ECONAZOLE NITRATE				
CREAM;TOPICAL				
ECONAZOLE NITRATE				
AUROBINDO PHARMA USA	1%		A210364 001	Apr 18, 2018
CHARTWELL RX	1%		A076075 001	Nov 26, 2002
ENCUBE	1%		A076574 001	Dec 17, 2004
SPECTAZOLE				
+ ALVOGEN	1% **		N018751 001	Dec 23, 1982
EDARAVONE				
SOLUTION;INTRAVENOUS				
EDARAVONE				
LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)		A218354 001	May 06, 2024
RADICAVA				
+ TANABE PHARMA	30MG/100ML (0.3MG/ML)		N209176 001	May 05, 2017
EDETATE CALCIUM DISODIUM				
INJECTABLE;INJECTION				
CALCIUM DISODIUM VERSENATE				
+ BAUSCH	200MG/ML **		N008922 001	
TABLET;ORAL				
CALCIUM DISODIUM VERSENATE				
BAUSCH	500MG		N008922 002	
EDROPHONIUM CHLORIDE				
INJECTABLE;INJECTION				
EDROPHONIUM CHLORIDE				
HOSPIRA	10MG/ML		A040131 001	Feb 24, 1998
WATSON LABS	10MG/ML		A040044 001	Mar 20, 1996
EDROPHONIUM CHLORIDE PRESERVATIVE FREE				
WATSON LABS	10MG/ML		A040043 001	Mar 20, 1996
ENLON				
PHARMOBEDIENT	10MG/ML		A088873 001	Aug 06, 1985
REVERSOL				
ORGANON USA INC	10MG/ML		A089624 001	May 13, 1988
TENSILON				
+ PAI HOLDINGS PHARM	10MG/ML **		N007959 001	
TENSILON PRESERVATIVE FREE				
+ PAI HOLDINGS PHARM	10MG/ML **		N007959 002	
EFAVIRENZ				
CAPSULE;ORAL				
SUSTIVA				
+ BRISTOL MYERS SQUIBB	50MG **		N020972 001	Sep 17, 1998
+	100MG **		N020972 002	Sep 17, 1998
+	200MG **		N020972 003	Sep 17, 1998
TABLET;ORAL				
EFAVIRENZ				
AUROBINDO PHARMA	600MG		A205322 001	Aug 30, 2018
MYLAN	600MG		A091471 001	Feb 17, 2016
STRIDES PHARMA	600MG		A078509 001	Jun 16, 2021
SUSTIVA				
+ BRISTOL MYERS SQUIBB	300MG **		N021360 001	Feb 01, 2002
+	600MG **		N021360 002	Feb 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
ATRIPLA					
+	GILEAD SCIENCES	600MG;200MG;300MG **	N021937	001	Jul 12, 2006
EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE					
	CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE					
	MYLAN	600MG;200MG;300MG	A209061	001	Sep 05, 2024
EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
+	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018
	MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019
SYMFI LO					
+	MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018
EFINACONAZOLE					
SOLUTION;TOPICAL					
EFINACONAZOLE					
	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021
	LUPIN LTD	10%	A212169	001	Mar 02, 2022
	PADAGIS US	10%	A211851	001	Dec 16, 2020
	ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022
EFLORNITHINE HYDROCHLORIDE					
CREAM;TOPICAL					
VANIQA					
+	ABBVIE	13.9%	N021145	001	Jul 27, 2000
INJECTABLE;INJECTION					
ORNIDYL					
	SANOFI AVENTIS US	200MG/ML	N019879	002	Nov 28, 1990
ELBASVIR; GRAZOPREVIR					
TABLET;ORAL					
ZEPATIER					
+	MSD SUB MERCK	50MG;100MG	N208261	001	Jan 28, 2016
ELETRIPTAN HYDROBROMIDE					
TABLET;ORAL					
ELETRIPTAN HYDROBROMIDE					
	STEVENS J	EQ 20MG BASE	A206787	001	May 25, 2018
		EQ 40MG BASE	A206787	002	May 25, 2018
	YUNG SHIN PHARM	EQ 20MG BASE	A209680	001	Jul 13, 2020
		EQ 40MG BASE	A209680	002	Jul 13, 2020
ELIGLUSTAT TARTRATE					
CAPSULE;ORAL					
ELIGLUSTAT TARTRATE					
	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024
	DR REDDYS	EQ 84MG BASE	A212449	001	Aug 17, 2022
	TEVA PHARMS USA INC	EQ 84MG BASE	A212474	001	Dec 27, 2021
ELTROMBOPAG OLAMINE					
TABLET;ORAL					
PROMACTA					
+	NOVARTIS	EQ 100MG ACID **	N022291	005	Nov 16, 2012
ELUXADOLINE					
TABLET;ORAL					
ELUXADOLINE					
	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025
		100MG	A213522	002	Mar 14, 2025
ELVITEGRAVIR					
TABLET;ORAL					
VITEKTA					
+	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014
+		150MG	N203093	002	Sep 24, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EMEDASTINE DIFUMARATE				
SOLUTION/DROPS;OPHTHALMIC				
EMADINE				
+ NOVARTIS	0.05%	N020706	001	Dec 29, 1997
EMPAGLIFLOZIN				
TABLET;ORAL				
EMPAGLIFLOZIN				
ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022
	25MG	A212138	002	Aug 03, 2022
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE				
TABLET;ORAL				
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE				
ZYDUS PHARMS	5MG;500MG	A212198	001	Jul 07, 2022
	5MG;1GM	A212198	002	Jul 07, 2022
	12.5MG;500MG	A212198	003	Jul 07, 2022
	12.5MG;1GM	A212198	004	Jul 07, 2022
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE				
TABLET;ORAL				
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE				
APOTEX	120MG;EQ 15MG BASE	A214053	001	May 17, 2024
	200MG;EQ 25MG BASE	A214053	002	May 17, 2024
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE				
TABLET;ORAL				
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE				
APOTEX	200MG;300MG	A208740	001	Jun 16, 2021
CIPLA	200MG;300MG	A090958	001	Apr 02, 2021
ENALAPRIL MALEATE				
FOR SOLUTION;ORAL				
EPANED KIT				
+ AZURITY	1MG/ML **	N204308	001	Aug 13, 2013
TABLET;ORAL				
ENALAPRIL MALEATE				
APOTHECON	2.5MG	A075583	001	Aug 22, 2000
	5MG	A075583	002	Aug 22, 2000
	10MG	A075583	003	Aug 22, 2000
	20MG	A075583	004	Aug 22, 2000
AUROBINDO PHARMA USA	2.5MG	A075480	001	Aug 22, 2000
	5MG	A075480	002	Aug 22, 2000
	10MG	A075480	003	Aug 22, 2000
	20MG	A075480	004	Aug 22, 2000
CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
	5MG	A075370	002	Aug 22, 2000
	10MG	A075369	001	Aug 22, 2000
	20MG	A075369	002	Aug 22, 2000
MYLAN	2.5MG	A075472	001	Aug 22, 2000
	5MG	A075472	002	Aug 22, 2000
	10MG	A075472	003	Aug 22, 2000
	20MG	A075472	004	Aug 22, 2000
REGCON HOLDINGS	2.5MG	A075621	001	Aug 22, 2000
	5MG	A075621	002	Aug 22, 2000
	10MG	A075621	003	Aug 22, 2000
	20MG	A075621	004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
	5MG	A075501	002	Aug 22, 2000
	10MG	A075501	003	Aug 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ENALAPRIL MALEATE					
TABLET;ORAL					
ENALAPRIL MALEATE					
		20MG	A075501	004	Aug 22, 2000
ENALAPRIL MALEATE; FELODIPINE					
TABLET, EXTENDED RELEASE;ORAL					
LEXXEL					
	ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
		5MG;5MG	N020668	001	Dec 27, 1996
ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	5MG;12.5MG	A076116	001	Sep 19, 2001
		10MG;25MG	A076116	002	Sep 19, 2001
	COSETTE	5MG;12.5MG	A075727	001	Sep 18, 2001
		10MG;25MG	A075727	002	Sep 18, 2001
	IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
		10MG;25MG	A075736	002	Mar 25, 2003
	MPP PHARMA	5MG;12.5MG	A076486	001	Oct 27, 2004
		10MG;25MG	A076486	002	Oct 27, 2004
	RISING	5MG;12.5MG	A075624	001	Sep 18, 2001
		10MG;25MG	A075624	002	Sep 18, 2001
ENALAPRILAT					
INJECTABLE;INJECTION					
ENALAPRILAT					
	HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
		1.25MG/ML	A075458	001	Aug 22, 2000
		1.25MG/ML	A075571	001	Aug 22, 2000
VASOTEC					
+	BIOVAIL LABS INTL	1.25MG/ML **	N019309	001	Feb 09, 1988
ENCORAFENIB					
CAPSULE;ORAL					
BRAFTOVI					
+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018
ENFLURANE					
LIQUID;INHALATION					
ENFLURANE					
	ABBOTT	99.9%	A070803	001	Sep 08, 1987
	PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994
ETHRANE					
	BAXTER HLTHCARE	99.9% **	N017087	001	
ENFUVIRTIDE					
INJECTABLE;SUBCUTANEOUS					
FUZEON					
+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003
ENOXACIN					
TABLET;ORAL					
PENETREX					
	SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
		400MG	N019616	005	Dec 31, 1991
ENOXAPARIN SODIUM					
INJECTABLE;SUBCUTANEOUS					
LOVENOX (PRESERVATIVE FREE)					
+	SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164	006	Jun 02, 2000
ENTACAPONE					
TABLET;ORAL					
ENTACAPONE					
	PHARMOBEDIENT	200MG	A202394	001	May 13, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ENTECAVIR
TABLET;ORAL
ENTECAVIR

ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017
	1MG	A205824	002	Aug 25, 2017
BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018
	1MG	A208721	002	Mar 15, 2018
CHARTWELL RX	0.5MG	A206294	001	Nov 23, 2016
	0.5MG	A206672	001	May 11, 2017
	1MG	A206294	002	Nov 23, 2016
	1MG	A206672	002	May 11, 2017
PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017
	1MG	A208782	002	Oct 10, 2017
RISING	0.5MG	A206226	001	Mar 26, 2019
	1MG	A206226	002	Mar 26, 2019
SUNSHINE	0.5MG	A211978	001	May 20, 2020
	1MG	A211978	002	May 20, 2020
SWISS PHARM	0.5MG	A212106	001	Aug 10, 2020
	1MG	A212106	002	Aug 10, 2020
TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014
	1MG	A202122	002	Aug 26, 2014
YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019
	1MG	A212201	002	Nov 04, 2019

ENZALUTAMIDE
CAPSULE;ORAL
ENZALUTAMIDE

ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021
APOTEX	40MG	A209645	001	Apr 22, 2022
ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024

EPHEDRINE HYDROCHLORIDE
SOLUTION;INTRAVENOUS
REZIPRES

+	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021
+		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021
+		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021
+		47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023

EPHEDRINE SULFATE
SOLUTION;INTRAVENOUS
EPHEDRINE SULFATE

RENEW PHARMS	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017
ZYDUS PHARMS	50MG/ML (50MG/ML)	A217276	001	May 16, 2023

EPINASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
ELESTAT

+	ALLERGAN	0.05% **	N021565	001	Oct 16, 2003

EPINASTINE HYDROCHLORIDE

CHARTWELL RX	0.05%	A203384	001	Dec 07, 2016
EPIC PHARMA LLC	0.05%	A204055	001	May 05, 2017
PHARMOBEDIENT	0.05%	A090870	001	Mar 14, 2011
SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011

EPINEPHRINE
AEROSOL, METERED;INHALATION
BRONKAID MIST

STERLING	0.25MG/INH	N016803	001	

EPINEPHRINE

ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001	

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR

VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPINEPHRINE				
INJECTABLE;INTRAMUSCULAR				
EPIPEN E Z PEN				
	VIATRIS	0.3MG/DELIVERY	N019430 003	Aug 03, 1995
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
TWINJECT				
	IMPAX	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004
		EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS				
EPINEPHRINE				
	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568 001	Jul 06, 2018
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS				
SYMJEPI				
+	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534 002	Sep 27, 2018
SOLUTION;INTRAVENOUS				
EPINEPHRINE				
+	BPI LABS	1MG/ML (1MG/ML) **	N205029 003	May 12, 2023
EPINEPHRINE BITARTRATE				
AEROSOL, METERED;INHALATION				
BRONITIN MIST				
	WYETH CONS	0.3MG/INH	N016126 002	
MEDIHALER-EPI				
	3M	0.3MG/INH	N010374 003	
EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.005MG/ML;1% **	N017751 006	
+		0.005MG/ML;1.5% **	N017751 007	
+	DENTSPLY PHARM	0.005MG/ML;1.5% **	N021384 001	
EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CITANEST FORTE				
	ASTRAZENECA	0.005MG/ML;4%	N014763 008	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.005MG/ML;0.5% **	N017751 004	
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE				
	CARLISLE	0.01MG/ML;2%	A084720 001	
		0.02MG/ML;2%	A084732 001	
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
	BELMORA LLC	0.01MG/ML;2%	A080504 004	Oct 19, 1983
		0.02MG/ML;2%	A080504 005	Oct 19, 1983
	EASTMAN KODAK	0.01MG/ML;2%	A040057 002	Feb 26, 1993
		0.02MG/ML;2%	A040057 001	Feb 26, 1993
	HOSPIRA	0.005MG/ML;1%	A089649 001	Jun 21, 1988
		0.005MG/ML;1.5%	A089650 001	Jun 21, 1988
		0.01MG/ML;2%	A078772 001	May 12, 2008
		0.02MG/ML;2%	A078772 002	May 12, 2008
	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406 001	
		0.01MG/ML;2%	A080406 002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
	ABBOTT	0.01MG/ML;1%	A083154 001	
	BEL MAR	0.01MG/ML;1%	A080820 001	
		0.01MG/ML;2%	A080757 001	
	DELL LABS	0.01MG/ML;1%	A083389 001	
		0.01MG/ML;2%	A083390 001	
	INTL MEDICATION	0.01MG/ML;1%	A086402 001	
	WATSON LABS	0.01MG/ML;1%	A080377 003	
		0.01MG/ML;1%	A085463 001	
		0.01MG/ML;2%	A080377 004	
LIDOCATON				
	PHARMATON	0.01MG/ML;2%	A084729 001	Aug 17, 1983
		0.02MG/ML;2%	A084728 001	Aug 17, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
OCTOCAINE				
SEPTODONT	0.01MG/ML;2%		A084048 001	
	0.02MG/ML;2%		A084048 002	
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2% **		N021381 001	
	0.02MG/ML;2% **		N021381 002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%		N010418 006	
	0.005MG/ML;1.5%		N010418 010	
	0.005MG/ML;2%		N010418 008	
+ FRESENIUS KABI USA	0.01MG/ML;2%		N006488 003	
PATCH;IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH		N021504 001	May 06, 2004
SOLUTION;IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%		N020530 001	Dec 21, 1995
SOLUTION;IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%		N021486 001	Oct 26, 2004
EPINEPHRINE; PROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%		A080758 001	
	0.02MG/ML;2%		A080759 001	
EPIRUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
EPIRUBICIN HYDROCHLORIDE				
ACTAVIS TOTOWA	10MG/5ML (2MG/ML)		A065445 001	Sep 18, 2008
	50MG/25ML (2MG/ML)		A065445 002	Sep 18, 2008
	200MG/100ML (2MG/ML)		A065445 003	Sep 18, 2008
EBEWE PHARMA	50MG/25ML (2MG/ML)		A065339 001	Dec 22, 2009
	200MG/100ML (2MG/ML)		A065339 002	Dec 22, 2009
FRESENIUS KABI USA	10MG/5ML (2MG/ML)		A065408 001	Oct 15, 2007
	50MG/25ML (2MG/ML)		A065408 002	Oct 15, 2007
	150MG/75ML (2MG/ML)		A065408 003	Oct 15, 2007
	200MG/100ML (2MG/ML)		A065408 004	Oct 15, 2007
	200MG/100ML (2MG/ML)		A065411 001	Aug 20, 2007
	50MG/25ML (2MG/ML)		A065411 002	Aug 20, 2007
HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)		A090075 001	Mar 25, 2010
	200MG/100ML (2MG/ML)		A090075 002	Mar 25, 2010
HOSPIRA	10MG/5ML (2MG/ML)		A065343 001	Apr 19, 2007
	50MG/25ML (2MG/ML)		A065343 002	Apr 19, 2007
	150MG/75ML (2MG/ML)		A065343 003	Apr 19, 2007
	200MG/100ML (2MG/ML)		A065343 004	Apr 19, 2007
PHARMOBEDIENT	50MG/25ML (2MG/ML)		A090266 001	Apr 15, 2011
	200MG/100ML (2MG/ML)		A090266 002	Apr 15, 2011
	50MG/25ML (2MG/ML)		A065371 001	Nov 28, 2007
	50MG/25ML (2MG/ML)		A091599 001	Mar 12, 2012
	200MG/100ML (2MG/ML)		A065371 002	Nov 28, 2007
	200MG/100ML (2MG/ML)		A091599 002	Mar 12, 2012
POWDER;INTRAVENOUS				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	50MG/VIAL		N050807 001	Sep 15, 2006
	200MG/VIAL		N050807 002	Sep 15, 2006
EPLERENONE				
TABLET;ORAL				
EPLERENONE				
AARXION ANDA HLDING	25MG		A203896 001	Feb 02, 2017
	50MG		A203896 002	Feb 02, 2017
INSPRA				
UPJOHN	100MG		N021437 003	Sep 27, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPOPROSTENOL SODIUM
INJECTABLE;INJECTION
FLOLAN
+ GLAXOSMITHKLINE LLC EQ 0.5MG BASE/VIAL N020444 001 Sep 20, 1995
+ EQ 1.5MG BASE/VIAL N020444 002 Sep 20, 1995

EPROSARTAN MESYLATE
TABLET;ORAL
EPROSARTAN MESYLATE
PHARMOBEDIENT EQ 400MG BASE A202012 001 Nov 16, 2011
EQ 600MG BASE A202012 002 Nov 16, 2011
TEVETEN
ABBVIE EQ 300MG BASE ** N020738 004 Dec 22, 1997
+ EQ 400MG BASE ** N020738 005 Dec 22, 1997
+ EQ 600MG BASE ** N020738 006 May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
TEVETEN HCT
ABBVIE 600MG;12.5MG N021268 001 Nov 01, 2001
600MG;25MG N021268 002 Nov 01, 2001

EPTIFIBATIDE
INJECTABLE;INJECTION
EPTIFIBATIDE
ACCORD HLTHCARE 2MG/ML A205557 001 Nov 06, 2017
75MG/100ML A205557 002 Nov 06, 2017
AMNEAL PHARMS 2MG/ML A205581 001 Dec 08, 2016
75MG/100ML A205581 002 Dec 08, 2016
BAXTER HLTHCARE CORP 2MG/ML A208554 001 Nov 23, 2018
HYBIO 2MG/ML A207864 001 Mar 20, 2020
75MG/100ML A207864 002 Mar 20, 2020
RISING 2MG/ML A204589 001 Apr 18, 2017
75MG/100ML A204589 002 Apr 18, 2017
TEVA PHARMS USA 75MG/100ML A091555 001 Jun 05, 2015
USV 2MG/ML A204361 001 Mar 14, 2019
2MG/ML A204362 001 Mar 11, 2019
75MG/100ML A204361 002 Mar 14, 2019
INTEGRILIN
+ MSD SUB MERCK 2MG/ML ** N020718 001 May 18, 1998
+ 75MG/100ML ** N020718 002 May 18, 1998

ERGOCALCIFEROL
CAPSULE;ORAL
DELTALIN
LILLY 50,000 IU A080884 001
ERGOCALCIFEROL
SIGMAPHARM LABS LLC 50,000 IU A091004 001 Jul 14, 2010
SUN PHARM INDS INC 50,000 IU A040865 001 Dec 29, 2009
VITAMIN D
CHARTWELL MOLECULAR 50,000 IU A080825 001
CHASE CHEM 50,000 IU A080747 001
EVERYLIFE 50,000 IU A080956 001
IMPAX LABS 50,000 IU A080951 001
VITARINE 50,000 IU A084053 001
WEST WARD 50,000 IU A083102 001

ERGOLOID MESYLATES
CAPSULE;ORAL
HYDERGINE LC
NOVARTIS 1MG N018706 001 Jan 18, 1983
SOLUTION;ORAL
HYDERGINE
NOVARTIS 1MG/ML N018418 001
TABLET;ORAL
ERGOLOID MESYLATES
MUTUAL PHARM 1MG A088891 001 Nov 01, 1985
SUN PHARM INDUSTRIES 1MG A081113 001 Oct 31, 1991
WATSON LABS 1MG A086433 001 May 27, 1982
1MG A087244 001 Aug 16, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERGOLOID MESYLATES				
TABLET;ORAL				
GERIMAL				
WATSON LABS	1MG		A088207 001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG **		N017993 003	
+	1MG **		N017993 001	
TABLET;SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG		A085153 001	
	1MG		A087417 001	
CIRCANOL				
3M	0.5MG		A084868 001	
	1MG		A085809 001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG		A085020 002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG		A085899 001	
	0.5MG		A086265 001	
	1MG		A085900 001	
	1MG		A086264 001	
LEDERLE	0.5MG		A086984 001	
	1MG		A086985 001	
SUN PHARM INDUSTRIES	0.5MG		A087407 001	
	1MG		A087552 001	
SUPERPHARM	0.5MG		A089233 001	Sep 23, 1986
	1MG		A089234 001	Sep 23, 1986
VANGARD	0.5MG		A088013 001	Sep 20, 1982
	1MG		A088014 001	Sep 20, 1982
WATSON LABS	0.5MG		A084930 001	
	0.5MG		A087233 001	
	1MG		A085177 001	
	1MG		A087183 001	
GERIMAL				
WATSON LABS	0.5MG		A086189 001	
	1MG		A086188 001	
HYDERGINE				
NOVARTIS	0.5MG		N009087 002	
	1MG		N009087 001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG		A087186 001	
	1MG		A087185 001	
ERGOTAMINE TARTRATE				
AEROSOL, METERED;INHALATION				
MEDIHALER ERGOTAMINE				
3M	0.36MG/INH		N012102 001	
TABLET;SUBLINGUAL				
ERGOSTAT				
WATSON LABS INC	2MG		A088337 001	Jun 08, 1984
WIGRETTES				
ORGANON USA INC	2MG		A086750 001	Jul 29, 1982
ERLOTINIB HYDROCHLORIDE				
TABLET;ORAL				
ERLOTINIB HYDROCHLORIDE				
ACCORD HLTHCARE	EQ 25MG BASE		A211083 001	Jul 02, 2020
	EQ 100MG BASE		A211083 002	Jul 02, 2020
	EQ 150MG BASE		A211083 003	Jul 02, 2020
APOTEX	EQ 25MG BASE		A208396 001	Nov 05, 2019
	EQ 100MG BASE		A208396 002	Nov 05, 2019
	EQ 150MG BASE		A208396 003	Nov 05, 2019
EUGIA PHARMA	EQ 25MG BASE		A216342 001	Jun 22, 2022
	EQ 100MG BASE		A216342 002	Jun 22, 2022
	EQ 150MG BASE		A216342 003	Jun 22, 2022
NATCO PHARMA LTD	EQ 25MG BASE		A208488 001	Nov 05, 2019
	EQ 100MG BASE		A208488 002	Nov 05, 2019
	EQ 150MG BASE		A208488 003	Nov 05, 2019
SUN PHARM	EQ 25MG BASE		A210300 001	Nov 05, 2019
	EQ 100MG BASE		A210300 002	Nov 05, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL				
ERLOTINIB HYDROCHLORIDE				
	EQ 150MG BASE	A210300	003	Nov 05, 2019
TARCEVA				
+ OSI PHARMS	EQ 25MG BASE **	N021743	001	Nov 18, 2004
+	EQ 100MG BASE **	N021743	002	Nov 18, 2004
+	EQ 150MG BASE **	N021743	003	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
ERTAPENEM SODIUM				
SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023

ERTUGLIFLOZIN

TABLET;ORAL				
ERTUGLIFLOZIN				
AUROBINDO PHARMA LTD	5MG	A216947	001	Jul 13, 2023
	15MG	A216947	002	Jul 13, 2023
HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024
	15MG	A217071	002	Sep 17, 2024
HIKMA	5MG	A216842	001	Jan 21, 2025
	15MG	A216842	002	Jan 21, 2025

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL				
ERYC				
PARKE DAVIS	250MG	A062546	001	Jul 25, 1985
	250MG	A062618	001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG	A062338	001	
ERYC 125				
PARKE DAVIS	125MG	A062648	001	Oct 24, 1985
ERYC SPRINKLES				
HOSPIRA	125MG	N050593	001	Jul 22, 1985
ERYTHROMYCIN				
BARR	250MG	A063098	001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
PHARMOBEDIENT	2%	A065009	001	Mar 18, 2002
EMGEL				
ALTANA	2%	A063107	001	Aug 23, 1991
ERYGEL				
+ MYLAN	2%	N050617	001	Oct 21, 1987
ERYTHROMYCIN				
ENCUBE	2%	A208154	001	Jul 19, 2017
LOTION;TOPICAL				
E-SOLVE 2				
SYOSSET	2%	A062467	001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
PADAGIS US	0.5%	A062447	001	Sep 26, 1983
PHARMADERM	5MG/GM	A062446	001	Sep 26, 1983
PHARMAFAIR	5MG/GM	A062481	001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5% **	N050368	001	
OINTMENT;TOPICAL				
AKNE-MYCIN				
+ BAUSCH	2%	N050584	001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING				
ERYTHROMYCIN				
PADDOCK LLC	100%	N050610	001	Nov 07, 1986
SOLUTION;TOPICAL				
A/T/S				
TARO	2%	A062405	001	Nov 18, 1982
C-SOLVE-2				
FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985
ERYDERM				
ARBOR PHARMS INC	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN				
SOLUTION;TOPICAL				
ERYTHRO-STATIN				
EPIC PHARMA LLC	2%	A064101	001	Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH	2%	A064039	001	Jan 27, 1994
FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997
LILLY	2%	N050532	001	
PAI HOLDINGS PHARM	2%	A208100	001	Nov 20, 2017
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
PHARMOBEDIENT CNSLTG	2%	A062825	001	Oct 23, 1987
RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM	2%	A062522	001	Jan 24, 1985
STATICIN				
+ WESTWOOD SQUIBB	1.5% **	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2% **	A062436	001	Mar 09, 1983
SWAB;TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
+ JOHNSON AND JOHNSON	2% **	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006
PHARMOBEDIENT	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET;ORAL				
ERYTHROMYCIN				
AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018
	500MG	A209720	002	Mar 09, 2018
ZYDUS PHARMS	250MG	A215440	001	Aug 31, 2023
	500MG	A215440	002	Aug 31, 2023
TABLET, COATED PARTICLES;ORAL				
PCE				
+ AZURITY	333MG	N050611	001	Sep 09, 1986
+	500MG	N050611	002	Aug 22, 1990
TABLET, DELAYED RELEASE;ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	
ERYTHROMYCIN ESTOLATE				
CAPSULE;ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE	A062162	001	
	EQ 250MG BASE	A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001	
WATSON LABS	EQ 250MG BASE	A062087	001	
ILOSONE				
LILLY	EQ 125MG BASE	A061897	001	
	EQ 250MG BASE	A061897	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ESTOLATE

FOR SUSPENSION;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE/5ML	A061893 001	
SUSPENSION;ORAL				
ERYTHROMYCIN ESTOLATE				
	ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
		EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
	COSETTE	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
		EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
	LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982
ILOSONE				
	LILLY	EQ 125MG BASE/5ML	A061894 001	
		EQ 125MG BASE/5ML	N050010 001	
		EQ 250MG BASE/5ML	A061894 002	
		EQ 250MG BASE/5ML	N050010 002	
SUSPENSION/DROPS;ORAL				
ILOSONE				
	LILLY	EQ 100MG BASE/ML	A061894 003	
TABLET;ORAL				
ILOSONE				
	LILLY	EQ 500MG BASE	A061896 001	
TABLET, CHEWABLE;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE	A061895 001	
		EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL				
ILOSONE SULFA				
	LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
	PH HEALTH	EQ 200MG BASE/5ML	A211991 001	Oct 23, 2019
		EQ 400MG BASE/5ML	A211991 002	Oct 23, 2019
PEDIAMYCIN				
	ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
SUSPENSION;ORAL				
E-MYCIN E				
	PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
		EQ 400MG BASE/5ML	A062198 002	
E.E.S. 200				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001	
E.E.S. 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML **	A061639 002	
ERYTHROMYCIN ETHYLSUCCINATE				
	ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
		EQ 400MG BASE/5ML	A062200 002	
	DISTA	EQ 200MG BASE/5ML	A062177 001	
		EQ 400MG BASE/5ML	A062177 002	
	NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
	PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
		EQ 400MG BASE/5ML	A062231 002	
	PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
		EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985
PEDIAMYCIN				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
PEDIAMYCIN 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
WYAMYCIN E				
	WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
		EQ 400MG BASE/5ML	A062123 001	
SUSPENSION/DROPS;ORAL				
PEDIAMYCIN				
	ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	
TABLET;ORAL				
E.E.S. 400				
	PHARMOBEDIENT	EQ 400MG BASE	A061905 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ETHYLSUCCINATE				
TABLET;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
AUROBINDO PHARMA USA	EQ 400MG BASE	A062847	001	Sep 14, 1988
BARR	EQ 400MG BASE	A062256	001	
TABLET, CHEWABLE;ORAL				
E.E.S.				
AZURITY	EQ 200MG BASE	N050297	002	
ERYPED				
AZURITY	EQ 200MG BASE	N050297	003	Jul 05, 1988
PEDIAMYCIN				
ROSS LABS	EQ 200MG BASE	A062306	001	
ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL				
GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL				
BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759	001	May 20, 1988
ERYZOLE				
ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062758	001	Jun 15, 1988
PEDIAZOLE				
ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML **	N050529	001	
ERYTHROMYCIN GLUCEPTATE				
INJECTABLE;INJECTION				
ILOTYCIN GLUCEPTATE				
DISTA	EQ 250MG BASE/VIAL	N050370	001	
	EQ 500MG BASE/VIAL	N050370	002	
	EQ 1GM BASE/VIAL	N050370	003	
ERYTHROMYCIN LACTOBIONATE				
INJECTABLE;INJECTION				
ERYTHROCIN				
ABBOTT	EQ 500MG BASE/VIAL	A062586	001	Jan 04, 1988
	EQ 1GM BASE/VIAL	A062586	002	Jan 04, 1988
HOSPIRA	EQ 500MG BASE/VIAL	N050182	002	
	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986
	EQ 1GM BASE/VIAL	N050182	003	
+	EQ 1GM BASE/VIAL	N050609	002	Sep 24, 1986
ERYTHROMYCIN				
ELKINS SINN	EQ 500MG BASE/VIAL	A062563	001	Mar 28, 1985
	EQ 1GM BASE/VIAL	A062563	002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062604	001	Nov 24, 1986
	EQ 1GM BASE/VIAL	A062604	002	Nov 24, 1986
BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062993	001	May 09, 1989
	EQ 1GM BASE/VIAL	A062993	002	May 09, 1989
EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020
TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253	001	Jul 30, 1993
	EQ 1GM BASE/VIAL	A063253	002	Jul 30, 1993
ERYTHROMYCIN STEARATE				
TABLET;ORAL				
BRISTAMYCIN				
BRISTOL	EQ 250MG BASE	A061304	001	
	EQ 250MG BASE	A061887	001	
ERYPAR				
PARKE DAVIS	EQ 250MG BASE	A062032	001	
	EQ 500MG BASE	A062032	002	
WARNER CHILCOTT	EQ 250MG BASE	A062322	001	
ERYTHROCIN STEARATE				
AZURITY	EQ 125MG BASE	A060359	002	
	EQ 250MG BASE	A060359	001	
	EQ 500MG BASE	A060359	003	
ERYTHROMYCIN STEARATE				
ANI PHARMS	EQ 250MG BASE	A061461	001	
	EQ 250MG BASE	A061591	001	
	EQ 500MG BASE	A061461	002	
	EQ 500MG BASE	A063179	001	May 15, 1990
LEDERLE	EQ 250MG BASE	A062089	001	
	EQ 500MG BASE	A062089	002	
PHARMOBEDIENT	EQ 250MG BASE	A061505	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN STEARATE				
TABLET;ORAL				
ERYTHROMYCIN STEARATE				
	EQ 500MG BASE		A061505 002	
PUREPAC PHARM	EQ 250MG BASE		A061743 001	
WATSON LABS	EQ 250MG BASE		A062121 002	
	EQ 500MG BASE		A062121 001	
ETHRIL 250				
BRISTOL MYERS SQUIBB	EQ 250MG BASE		A061605 001	
ETHRIL 500				
BRISTOL MYERS SQUIBB	EQ 500MG BASE		A061605 002	
PFIZER-E				
PFIZER	EQ 250MG BASE		A061791 001	
	EQ 500MG BASE		A061791 002	
WYAMYCIN S				
WYETH AYERST	EQ 250MG BASE		A061675 001	
	EQ 500MG BASE		A061675 002	
ESCITALOPRAM OXALATE				
CAPSULE;ORAL				
ESCITALOPRAM OXALATE				
RISING	EQ 5MG BASE		A077660 001	Jul 31, 2007
	EQ 10MG BASE		A077660 002	Jul 31, 2007
	EQ 20MG BASE		A077660 003	Jul 31, 2007
SOLUTION;ORAL				
ESCITALOPRAM OXALATE				
ANTRIM PHARMS LLC	EQ 5MG BASE/5ML		A203967 001	May 26, 2015
SUN PHARMA CANADA	EQ 5MG BASE/5ML		A079121 001	May 03, 2012
LEXAPRO				
+ ABBVIE	EQ 5MG BASE/5ML **		N021365 001	Nov 27, 2002
TABLET;ORAL				
ESCITALOPRAM OXALATE				
AIPING PHARM INC	EQ 5MG BASE		A077512 001	Sep 12, 2012
	EQ 10MG BASE		A077512 002	Sep 12, 2012
	EQ 20MG BASE		A077512 003	Sep 12, 2012
HIKMA PHARMS	EQ 5MG BASE		A078766 001	Sep 11, 2012
	EQ 10MG BASE		A078766 002	Sep 11, 2012
	EQ 20MG BASE		A078766 003	Sep 11, 2012
NOVITIUM PHARMA	EQ 5MG BASE		A077550 001	May 14, 2015
	EQ 10MG BASE		A077550 002	May 14, 2015
	EQ 20MG BASE		A077550 003	May 14, 2015
TEVA PHARMS USA	EQ 5MG BASE		A076765 001	Mar 14, 2012
	EQ 10MG BASE		A076765 002	Mar 14, 2012
	EQ 20MG BASE		A076765 003	Mar 14, 2012
ESMOLOL HYDROCHLORIDE				
INJECTABLE;INJECTION				
BREVIBLOC				
BAXTER HLTHCARE	10MG/ML		N019386 003	Aug 15, 1988
	20MG/ML		N019386 007	May 28, 2003
ESMOLOL HYDROCHLORIDE				
AM REGENT	10MG/ML		A201126 001	Feb 20, 2015
FRESENIUS KABI USA	10MG/ML		A076573 001	May 02, 2005
	20MG/ML		A076573 002	Aug 23, 2023
ESOMEPRAZOLE MAGNESIUM				
CAPSULE, DELAYED REL PELLETS;ORAL				
ESOMEPRAZOLE MAGNESIUM				
AMNEAL PHARMS NY	EQ 20MG BASE		A209647 001	Apr 10, 2019
	EQ 40MG BASE		A209647 002	Apr 10, 2019
CIPLA	EQ 20MG BASE		A078003 001	Jan 26, 2015
	EQ 40MG BASE		A078003 002	Jan 26, 2015
GLENMARK SPECLT	EQ 20MG BASE		A209495 001	May 10, 2019
	EQ 40MG BASE		A209495 002	May 10, 2019
HEC PHARM	EQ 20MG BASE		A207265 002	May 18, 2018
	EQ 40MG BASE		A207265 001	May 18, 2018
HETERO LABS LTD III	EQ 20MG BASE		A202784 001	Sep 21, 2015
	EQ 40MG BASE		A202784 002	Sep 21, 2015
MACLEODS PHARMS LTD	EQ 20MG BASE		A208511 001	Oct 23, 2024
	EQ 40MG BASE		A208511 002	Oct 23, 2024
TORRENT	EQ 20MG BASE		A203636 001	Oct 19, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL				
ESOMEPRAZOLE MAGNESIUM				
	EQ 40MG BASE		A203636 002	Oct 19, 2015
CAPSULE, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE MAGNESIUM				
AMNEAL PHARMS NY	EQ 20MG BASE		A209716 001	Jun 05, 2019
HETERO LABS LTD III	EQ 20MG BASE		A208939 001	May 28, 2020
PHARMOBEDIENT	EQ 20MG BASE		A212376 001	Oct 16, 2019
TABLET, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE MAGNESIUM				
P AND L	EQ 20MG BASE		A209202 001	Mar 05, 2019
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE MAGNESIUM				
+ DEXCEL	EQ 20MG BASE		N214278 001	Oct 20, 2020

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL				
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM				
ACTAVIS LABS FL INC	EQ 20MG BASE;375MG		A204470 001	Aug 24, 2022
	EQ 20MG BASE;500MG		A204470 002	Aug 24, 2022
PHARMOBEDIENT	EQ 20MG BASE;375MG		A204920 001	Jul 20, 2021
	EQ 20MG BASE;500MG		A204920 002	Jul 20, 2021
VIMOVO				
+ HORIZON	EQ 20MG BASE;375MG **		N022511 002	Apr 30, 2010
+	EQ 20MG BASE;500MG **		N022511 001	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS				
ESOMEPRAZOLE SODIUM				
ACCORD HLTHCARE	EQ 40MG BASE/VIAL		A205379 001	Sep 25, 2015
EUGIA PHARMA	EQ 20MG BASE/VIAL		A204657 001	Aug 10, 2016
	EQ 40MG BASE/VIAL		A204657 002	Aug 10, 2016
PHARMOBEDIENT	EQ 20MG BASE/VIAL		A202686 001	May 17, 2017
	EQ 40MG BASE/VIAL		A202686 002	May 17, 2017
SUN PHARM	EQ 20MG BASE/VIAL		A200882 001	Mar 18, 2013
	EQ 40MG BASE/VIAL		A200882 002	Mar 18, 2013
NEXIUM IV				
+ ASTRAZENECA	EQ 20MG BASE/VIAL **		N021689 001	Mar 31, 2005
+	EQ 40MG BASE/VIAL **		N021689 002	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL				
ESOMEPRAZOLE STRONTIUM				
+ BELCHER	24.65MG		N202342 001	Aug 06, 2013
+	49.3MG		N202342 002	Aug 06, 2013

ESTAZOLAM

TABLET;ORAL				
PROSOM				
+ ABBOTT	1MG **		N019080 001	Dec 26, 1990
+	2MG **		N019080 002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL				
ALORA				
ABBVIE	0.025MG/24HR		N020655 004	Apr 05, 2002
	0.05MG/24HR		N020655 001	Dec 20, 1996
	0.075MG/24HR		N020655 002	Dec 20, 1996
	0.1MG/24HR		N020655 003	Dec 20, 1996
FEMPATCH				
PARKE DAVIS	0.025MG/24HR		N020417 001	Dec 03, 1996
GEL;TOPICAL				
ESTROGEL				
ASCEND THERAPS US	0.06%		N021166 001	Feb 09, 2004
SYSTEM;TRANSDERMAL				
ESCLIM				
WOMEN FIRST HLTHCARE	0.025MG/24HR		N020847 001	Aug 04, 1998
	0.0375MG/24HR		N020847 002	Aug 04, 1998
	0.05MG/24HR		N020847 003	Aug 04, 1998
	0.075MG/24HR		N020847 004	Aug 04, 1998
	0.1MG/24HR		N020847 005	Aug 04, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRADIOL					
SYSTEM;TRANSDERMAL					
ESTRADERM					
+	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
+		0.1MG/24HR	N019081	003	Sep 10, 1986
ESTRADIOL					
	ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
		0.075MG/24HR	N021048	002	Sep 20, 1999
		0.1MG/24HR	N021048	003	Sep 20, 1999
VIVELLE					
	SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000
		0.0375MG/24HR	N020323	001	Oct 28, 1994
		0.05MG/24HR	N020323	002	Oct 28, 1994
		0.075MG/24HR	N020323	003	Oct 28, 1994
		0.1MG/24HR	N020323	004	Oct 28, 1994
TABLET;ORAL					
ESTRACE					
	BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993
+		1MG	A084499	001	
+		2MG	A084500	001	
ESTRADIOL					
	LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998
		1MG	A040138	002	Jan 30, 1998
		2MG	A040138	003	Jan 30, 1998
	PHARMOBEDIENT	0.5MG	A040326	001	Apr 21, 1999
		1MG	A040326	002	Apr 21, 1999
		2MG	A040326	003	Apr 21, 1999
	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996
		1MG	A040114	001	Mar 14, 1996
		2MG	A040114	002	Mar 14, 1996
	USL PHARMA	0.5MG	A040297	001	Apr 17, 2002
		1MG	A040297	002	Apr 17, 2002
		2MG	A040297	003	Apr 17, 2002
GYNODIOL					
	DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
		1MG	A040212	002	Dec 29, 1997
		1.5MG	A040212	003	Dec 29, 1997
		2MG	A040212	004	Dec 29, 1997
INNOFEM					
	NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
		1MG	A040312	002	Nov 19, 1999
		2MG	A040312	003	Nov 19, 1999
TABLET;VAGINAL					
VAGIFEM					
+	NOVO NORDISK INC	25MCG **	N020908	001	Mar 26, 1999
ESTRADIOL ACETATE					
TABLET;ORAL					
FEMTRACE					
+	APIL	0.45MG	N021633	001	Aug 20, 2004
+		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004
ESTRADIOL CYPIONATE					
INJECTABLE;INJECTION					
DEPO-ESTRADIOL					
	PFIZER	1MG/ML	A085470	001	
		3MG/ML	A085470	002	
ESTRADIOL CYPIONATE					
	DR REDDYS	5MG/ML	A085620	001	
ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE					
INJECTABLE;INTRAMUSCULAR					
LUNELLE					
+	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML **	N020874	001	Oct 05, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION				
DEPO-TESTADIOL				
	PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE				
	WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL				
ESTRASORB				
+	EXELTIS USA INC	0.25%	N021371 001	Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE;INJECTION				
DELESTROGEN				
+	PH HEALTH	40MG/ML **	N009402 003	
ESTRADIOL VALERATE				
	DR REDDYS	20MG/ML	A083547 001	
		40MG/ML	A083714 001	
	FOSUN PHARMA	10MG/ML	A040628 001	Oct 04, 2007
		20MG/ML	A040628 002	Oct 04, 2007
		40MG/ML	A040628 003	Oct 04, 2007
	WATSON LABS	10MG/ML	A083546 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION				
DITATE-DS				
	SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE				
	WATSON LABS	4MG/ML;90MG/ML	A085865 001	
		8MG/ML;180MG/ML	A085860 001	

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL				
ACTIVELLA				
+	AMNEAL	0.5MG;0.1MG **	N020907 002	Dec 28, 2006
ESTRADIOL AND NORETHINDRONE ACETATE				
	TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012
ETYQA				
	AUROBINDO PHARMA LTD	0.5MG;0.1MG	A214729 001	Jun 30, 2023
		1MG;0.5MG	A214729 002	Jun 30, 2023

ESTRADIOL; NORGESTIMATE

TABLET;ORAL				
ESTRADIOL AND NORGESTIMATE				
	BARR	1MG,1MG;N/A,0.09MG	A076812 001	Apr 29, 2005
PREFEST				
+	TEVA WOMENS	1MG,1MG;N/A,0.09MG **	N021040 001	Oct 22, 1999

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL				
ESTRADIOL AND PROGESTERONE				
	AMNEAL PHARMS	1MG;100MG	A214293 001	May 16, 2022

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL				
EMCYT				
+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045 001	

ESTROGENS, CONJUGATED

TABLET;ORAL				
PREMARIN				
	WYETH PHARMS	2.5MG	N004782 002	

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM;VAGINAL				
SYNTHETIC CONJUGATED ESTROGENS A				
	TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008
TABLET;ORAL				
CENESTIN				
+	ASPEN	0.3MG **	N020992 001	Jun 21, 2002
+		0.45MG **	N020992 005	Feb 05, 2004
+		0.625MG **	N020992 002	Mar 24, 1999
+		0.9MG **	N020992 003	Mar 24, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL				
CENESTIN				
+	1.25MG **	N020992	004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL				
ENJUVIA				
ASPEN	0.3MG	N021443	001	Dec 20, 2004
	0.45MG	N021443	002	Dec 20, 2004
	0.625MG **	N021443	003	May 10, 2004
	0.9MG	N021443	005	Apr 27, 2007
	1.25MG **	N021443	004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28				
PREMPHASE (PREMARIN;CYCRIN 14/14)				
WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303	002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)				
WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303	001	Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET;ORAL				
MILPREM-200				
MEDPOINTE PHARM HLC	0.45MG;200MG	N011045	002	
MILPREM-400				
MEDPOINTE PHARM HLC	0.45MG;400MG	N011045	001	
PMB 200				
WYETH AYERST	0.45MG;200MG	N010971	005	
PMB 400				
WYETH AYERST	0.45MG;400MG	N010971	003	

ESTROGENS, ESTERIFIED

TABLET;ORAL				
AMNESTROGEN				
BRISTOL MYERS SQUIBB	0.3MG	A083266	001	
	0.625MG	A083266	002	
	1.25MG	A083266	003	
	2.5MG	A083266	004	
ESTERIFIED ESTROGENS				
PVT FORM	0.625MG	A083414	001	
	1.25MG	A083765	001	
	2.5MG	A085907	001	
SANDOZ	1.25MG	A085302	001	
ESTRATAB				
SOLVAY	0.3MG	A086715	001	
	0.625MG	A083209	001	
	1.25MG	A083856	001	
	2.5MG	A083857	001	
EVEX				
ROCHE PALO	0.625MG	A084215	001	
	1.25MG	A083376	002	
FEMOGEN				
PVT FORM	0.625MG	A085076	001	
	1.25MG	A085008	001	
	2.5MG	A085007	001	
MENEST				
MONARCH PHARMS	0.3MG	A084951	001	
	0.625MG	A084948	001	
	1.25MG	A084950	001	
	2.5MG	A084949	001	

ESTRONE

INJECTABLE;INJECTION				
ESTROGENIC SUBSTANCE				
WYETH AYERST	2MG/ML	A083488	001	
ESTRONE				
DR REDDYS	5MG/ML	A085239	001	
WATSON LABS	2MG/ML	A083397	001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
WATSON LABS	2MG/ML	A085237	001	Nov 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRONE				
INJECTABLE;INJECTION				
THEELIN				
PARKEDALE	1MG/ML	N003977	001	
	2MG/ML	N003977	002	
	5MG/ML	N003977	003	
ESTROPIPATE				
CREAM;VAGINAL				
OGEN				
PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001	
TABLET;ORAL				
ESTROPIPATE				
BARR	0.75MG	A040135	001	Nov 27, 1996
	1.5MG	A040135	002	Nov 27, 1996
	3MG	A040135	003	Nov 27, 1996
DURAMED PHARMS BARR	0.75MG	A040296	001	Nov 01, 1999
	1.5MG	A040296	002	Nov 01, 1999
	3MG	A040296	003	Nov 01, 1999
PHARMOBEDIENT	0.75MG	A040359	001	Aug 26, 1999
	1.5MG	A040359	002	Aug 26, 1999
	3MG	A040359	003	Aug 26, 1999
WATSON LABS	0.75MG	A081213	001	Sep 23, 1993
	1.5MG	A081214	001	Sep 23, 1993
	6MG	A081216	001	Sep 23, 1993
WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993
OGEN .625				
+ PFIZER	0.75MG	A083220	001	
OGEN 1.25				
+ PFIZER	1.5MG	A083220	002	
OGEN 2.5				
+ PFIZER	3MG	A083220	003	
ORTHO-EST				
SUN PHARM INDS INC	0.75MG	A089567	001	Feb 27, 1991
	1.5MG	A089582	001	Jul 17, 1991
ESZOPICLONE				
TABLET;ORAL				
ESZOPICLONE				
CHARTWELL RX	1MG	A091165	001	Jul 14, 2011
	2MG	A091165	002	Jul 14, 2011
	3MG	A091165	003	Jul 14, 2011
HIKMA	1MG	A091153	001	Apr 15, 2014
	2MG	A091153	002	Apr 15, 2014
	3MG	A091153	003	Apr 15, 2014
IPCA LABS LTD	1MG	A206222	001	Dec 29, 2023
	2MG	A206222	002	Dec 29, 2023
	3MG	A206222	003	Dec 29, 2023
PHARMOBEDIENT	1MG	A203087	001	May 08, 2019
	2MG	A203087	002	May 08, 2019
	3MG	A203087	003	May 08, 2019
ETHACRYNATE SODIUM				
INJECTABLE;INJECTION				
ETHACRYNATE SODIUM				
MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016
ETHACRYNIC ACID				
TABLET;ORAL				
EDECRIN				
BAUSCH	50MG	N016092	002	
ETHACRYNIC ACID				
ALVOGEN	25MG	A205709	001	Jul 24, 2018
HIKMA	25MG	A207262	001	Feb 23, 2017
PH HEALTH	25MG	A208501	001	Jul 21, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE
BARR 400MG A076057 001 Nov 26, 2001
MYAMBUTOL
KANCHAN HLTHCARE 200MG N016320 002
500MG N016320 004

ETHCHLORVYNOL
CAPSULE;ORAL
ETHCHLORVYNOL
BANNER PHARMACAPS 100MG A084463 001
200MG A084463 002
500MG A084463 003
750MG A084463 004
PLACIDYL
ABBVIE 100MG N010021 004
200MG N010021 007
500MG N010021 002
750MG N010021 010

ETHINAMATE
CAPSULE;ORAL
VALMID
DISTA 500MG N009750 001

ETHINYL ESTRADIOL
TABLET;ORAL
ESTINYL
SCHERING 0.02MG N005292 001
0.05MG N005292 002
0.5MG N005292 003
FEMINONE
PHARMACIA AND UPJOHN 0.05MG N016649 001
LYNORAL
ORGANON USA INC 0.01MG N005490 003
0.05MG N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
TABLET;ORAL-21
DEMULEN 1/35-21
GD SEARLE LLC 0.035MG;1MG ** N018168 001
DEMULEN 1/50-21
GD SEARLE LLC 0.05MG;1MG N016927 001
ZOVIA 1/35E-21
WATSON PHARMS TEVA 0.035MG;1MG A072720 001 Dec 30, 1991
ZOVIA 1/50E-21
WATSON LABS 0.05MG;1MG A072722 001 Dec 30, 1991
TABLET;ORAL-28
DEMULEN 1/35-28
GD SEARLE LLC 0.035MG;1MG ** N018160 001
DEMULEN 1/50-28
GD SEARLE LLC 0.05MG;1MG ** N016936 001
ZOVIA 1/35E-28
DR REDDYS LABS SA 0.035MG;1MG A072721 001 Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL
RING;VAGINAL
VERARING
DR REDDYS LABS SA 0.015MG/24HR;0.12MG/24HR A207577 001 Dec 09, 2021

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
TABLET;ORAL-28
NORQUEST FE
PFIZER 0.035MG;75MG;1MG N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE
TABLET;ORAL-28
NORLESTRIN FE 1/50
PARKE DAVIS 0.05MG;75MG;1MG N016766 001
NORLESTRIN FE 2.5/50
PARKE DAVIS 0.05MG;75MG;2.5MG N016854 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL					
FAYOSIM					
	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
	DR REDDYS LABS SA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011
LYBREL					
+	WYETH PHARMS INC	0.02MG;0.09MG **	N021864	001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT					
	TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998
SYLEVIA					
	SUN PHARM	0.03MG;0.15MG	A202988	001	Feb 06, 2019
TABLET;ORAL-21					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	001	Mar 27, 1997
AVIANE-21					
	DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001
ENPRESSE-21					
	DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001
LESSINA-21					
	BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003
LEVORA 0.15/30-21					
	WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993
NORDETTE-21					
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982
PORTIA-21					
	BARR	0.03MG;0.15MG	A075866	001	May 23, 2002
TRIPHASIL-21					
+	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192	001	Nov 01, 1984
TRIVORA-21					
	DR REDDYS LABS SA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997
TABLET;ORAL-28					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	002	Mar 27, 1997
CERINTA					
	SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019
ELIFEMME					
	XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014
		0.03MG;0.15MG	A201095	001	Dec 08, 2014
	BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003
	XIROMED	0.02MG;0.1MG	A202247	001	Dec 08, 2014
		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018
NORDETTE-28					
+	TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782	001	Jul 21, 1982
ORSYTHIA					
	PH HEALTH	0.02MG;0.1MG	A077099	001	May 11, 2011
TRIPHASIL-28					
+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
ORTHO EVRA					
+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov 20, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL					
FEMCON FE					
+	APIL	0.035MG;0.4MG **	N021490	001	Nov 14, 2003
TABLET;ORAL-21					
BALZIVA-21					
	BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY					
	ALLERGAN	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992
MODICON 21					
	ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001	
N.E.E. 1/35 21					
	LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010
		0.035MG;0.5MG	A070684	001	Jan 29, 1987
	WATSON PHARMS TEVA	0.035MG;1MG	A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991
NORINYL 1+35 21-DAY					
	ALLERGAN	0.035MG;1MG	N017565	001	
NORTREL 0.5/35-21					
	BARR	0.035MG;0.5MG	A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21					
	ORTHO MCNEIL PHARM	0.035MG;1MG **	N017489	002	
ORTHO-NOVUM 10/11-21					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **	N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985	001	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT	0.035MG;0.4MG **	N018127	001	
OVCON-50					
	WARNER CHILCOTT	0.05MG;1MG	N018128	001	
TRI-NORINYL 21-DAY					
	DR REDDYS LABS SA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984
TABLET;ORAL-28					
BREVICON 28-DAY					
	ALLERGAN	0.035MG;0.5MG	N017743	001	
CYCLAFEM 0.5/35					
	PH HEALTH	0.035MG;0.5MG	A203413	001	Dec 16, 2015
CYCLAFEM 1/35					
	PH HEALTH	0.035MG;1MG	A076337	001	Nov 12, 2010
CYCLAFEM 7/7/7					
	PH HEALTH	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010
GENCEPT 10/11-28					
	BARR LABS	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992
MODICON 28					
+	JANSSEN PHARMS	0.035MG;0.5MG	N017735	001	
N.E.E. 1/35 28					
	LPI	0.035MG;1MG	A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071546	001	Feb 09, 1989
NORETHIN 1/35E-28					
	WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	DR REDDYS LABS SA	0.035MG;0.5MG	A070686	001	Jan 29, 1987
	MYLAN LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486	001	Dec 28, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE					
TABLET;ORAL-28					
NORETHINDRONE AND ETHINYL ESTRADIOL					
		0.035MG;0.5MG	A200488	001	Oct 21, 2015
		0.035MG;1MG	A200489	001	Oct 21, 2015
	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393	001	Feb 04, 2010
	XIROMED	0.035MG;0.4MG	A200897	001	May 11, 2015
		0.05MG;1MG	A203006	001	Aug 05, 2013
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991
NORINYL 1+35 28-DAY					
	ALLERGAN	0.035MG;1MG	N017565	002	
ORTHO-NOVUM 1/35-28					
+	JANSSEN PHARMS	0.035MG;1MG **	N017919	002	
ORTHO-NOVUM 10/11-28					
+	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28					
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **	N019004	002	Apr 04, 1984
ORTHO-NOVUM 7/7/7-28					
+	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG **	N018985	002	Apr 04, 1984
OVCON-35					
+	WARNER CHILCOTT LLC	0.035MG;0.4MG **	N017716	001	
OVCON-50					
	WARNER CHILCOTT LLC	0.05MG;1MG **	N017576	001	
PIRMELLA 1/35					
	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013
PIRMELLA 7/7/7					
	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013
RHUZDAH					
	AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022
TABLET, CHEWABLE;ORAL					
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
+	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE					
CAPSULE;ORAL					
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021
	DR REDDYS LABS SA	0.02MG;1MG	A213901	001	Apr 28, 2022
TABLET;ORAL					
FEMHRT					
+	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
+		0.005MG;1MG **	N021065	002	Oct 15, 1999
LOESTRIN 24 FE					
+	TEVA BRANDED PHARM	0.02MG;1MG **	N021871	001	Feb 17, 2006
MINASTRIN 24 FE					
+	APIL	0.02MG;1MG **	N203667	001	May 08, 2013
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017
		0.005MG;1MG	A207259	001	Dec 27, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009
		0.02MG;1MG	A207514	001	Sep 11, 2017
	APOTEX	0.02MG;1MG	A208639	001	Mar 21, 2018
	XIROMED	0.02MG;1MG	A202742	001	Oct 30, 2014
		0.02MG;1MG	A206120	001	Sep 12, 2017
OSHIH					
	AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023
TABLET;ORAL-21					
ESTROSTEP 21					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	001	Oct 09, 1996
GILDESS 1.5/30					
	PH HEALTH	0.03MG;1.5MG	A077075	002	Jul 24, 2012
GILDESS 1/20					
	PH HEALTH	0.02MG;1MG	A077077	002	Jul 24, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21				
LOESTRIN 21 1.5/30				
+ TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001	
LOESTRIN 21 1/20				
+ TEVA BRANDED PHARM	0.02MG;1MG **	N017876	001	
LOESTRIN FE 1.5/30				
+ TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001	
MICROGESTIN 1.5/30				
DR REDDYS LABS SA	0.03MG;1.5MG	A075548	002	Jul 30, 2003
MICROGESTIN 1/20				
DR REDDYS LABS SA	0.02MG;1MG	A075647	002	Jul 30, 2003
NORLESTRIN 21 1/50				
PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50				
PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TRI-LEGEST 21				
BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007
TABLET;ORAL-28				
ESTROSTEP FE				
+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	002	Oct 09, 1996
GILDESS FE 1.5/30				
PH HEALTH	0.03MG;1.5MG	A077075	001	Apr 28, 2005
GILDESS FE 1/20				
PH HEALTH	0.02MG;1MG	A077077	001	May 20, 2005
LOESTRIN FE 1/20				
+ TEVA BRANDED PHARM	0.02MG;1MG **	N017354	001	
MICROGESTIN FE 1.5/30				
DR REDDYS LABS SA	0.03MG;1.5MG	A075548	001	Feb 05, 2001
MICROGESTIN FE 1/20				
DR REDDYS LABS SA	0.02MG;1MG	A075647	001	Feb 05, 2001
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
DR REDDYS LABS SA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010
NORLESTRIN 28 1/50				
PARKE DAVIS	0.05MG;1MG	N016723	001	
TABLET, CHEWABLE, TABLET;ORAL				
LO MINASTRIN FE				
+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21				
ORTHO CYCLEN-21				
JANSSEN PHARMS	0.035MG;0.25MG **	N019653	001	Dec 29, 1989
ORTHO TRI-CYCLEN				
JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **	N019697	002	Jul 03, 1992
TABLET;ORAL-28				
NORGESTIMATE AND ETHINYL ESTRADIOL				
MYLAN	0.035MG;0.25MG	A201896	001	Jan 27, 2016
NAARI PTE	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870	001	Nov 12, 2015
	0.035MG;0.25MG	A203865	001	Oct 27, 2015
WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011
	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076626	001	Aug 17, 2006
	0.035MG;0.25MG	A076627	001	Aug 17, 2006
XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015
	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016
ORTHO CYCLEN-28				
+ JANSSEN PHARMS	0.035MG;0.25MG **	N019653	002	Dec 29, 1989
ORTHO TRI-CYCLEN				
+ JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **	N019697	001	Jul 03, 1992
ORTHO TRI-CYCLEN LO				
+ JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **	N021241	001	Aug 22, 2002
TRI-PREVIFEM				
PH HEALTH	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,	A076335	001	Mar 26, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORGESTIMATE				
TABLET;ORAL-28				
TRI-PREVIFEM				
	0.25MG			
ETHINYL ESTRADIOL; NORGESTREL				
TABLET;ORAL-21				
LO/OVRAL				
+ CADENCE HEALTH	0.03MG;0.3MG		N017612 001	
LOW-OGESTREL-21				
DR REDDYS LABS SA	0.03MG;0.3MG		A075288 001	Jul 28, 1999
OGESTREL 0.5/50-21				
WATSON LABS	0.05MG;0.5MG **		A075406 001	Dec 15, 1999
OVRAL				
WYETH PHARMS	0.05MG;0.5MG		N016672 001	
TABLET;ORAL-28				
LO/OVRAL-28				
+ WYETH PHARMS	0.03MG;0.3MG **		N017802 001	
NORGESTREL AND ETHINYL ESTRADIOL				
MYLAN LABS LTD	0.03MG;0.3MG		A201828 001	Jun 21, 2016
	0.05MG;0.5MG		A202875 001	May 08, 2017
OGESTREL 0.5/50-28				
WATSON LABS	0.05MG;0.5MG		A075406 002	Dec 15, 1999
OVRAL-28				
WYETH PHARMS	0.05MG;0.5MG		N016806 001	
ETHIONAMIDE				
TABLET;ORAL				
TRECATOR				
+ WYETH PHARMS	250MG		N013026 002	
ETHOPROPAZINE HYDROCHLORIDE				
TABLET;ORAL				
PARSIDOL				
PARKE DAVIS	10MG		N009078 003	
	50MG		N009078 006	
	100MG		N009078 008	
ETHOSUXIMIDE				
SYRUP;ORAL				
ETHOSUXIMIDE				
TEVA PHARMS	250MG/5ML		A081306 001	Jul 30, 1993
ETHOTOIN				
TABLET;ORAL				
PEGANONE				
+ RECORDATI RARE	250MG		N010841 001	
	500MG		N010841 003	
ETHOXZOLAMIDE				
TABLET;ORAL				
CARDRASE				
PHARMACIA AND UPJOHN	62.5MG		N011047 002	
	125MG		N011047 001	
ETHAMIDE				
ALLERGAN	125MG		N016144 001	
ETHYLESTRENOL				
ELIXIR;ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG/5ML		N014006 002	
TABLET;ORAL				
MAXIBOLIN				
ORGANON USA INC	2MG		N014005 002	
ETHYNODIOL DIACETATE; MESTRANOL				
TABLET;ORAL-20				
OVULEN				
GD SEARLE LLC	1MG;0.1MG		N016029 002	
TABLET;ORAL-21				
OVULEN-21				
GD SEARLE LLC	1MG;0.1MG		N016029 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHYNODIOL DIACETATE; MESTRANOL				
TABLET;ORAL-28				
OVULEN-28				
GD SEARLE LLC	1MG;0.1MG		N016705 001	
ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+ ASTRAZENECA	0.5% **		N017751 003	
+	1% **		N017751 005	
ETIDRONATE DISODIUM				
INJECTABLE;INJECTION				
DIDRONEL				
MGI PHARMA INC	50MG/ML		N019545 001	Apr 20, 1987
TABLET;ORAL				
DIDRONEL				
+ APIL	200MG **		N017831 001	
+	400MG **		N017831 002	
ETIDRONATE DISODIUM				
PHARMOBEDIENT	200MG		A075800 001	Jan 24, 2003
	400MG		A075800 002	Jan 24, 2003
ETODOLAC				
CAPSULE;ORAL				
ETODOLAC				
ANI PHARMS	200MG		A074840 001	Aug 29, 1997
	200MG		A074844 001	Dec 23, 1997
	200MG		A074899 001	Jul 08, 1997
	300MG		A074840 002	Aug 29, 1997
	300MG		A074844 002	Dec 23, 1997
	300MG		A074899 002	Jul 08, 1997
BIOPHARM	300MG		A074929 001	Jan 30, 1998
CHARTWELL MOLECULES	200MG		A074842 001	Jul 17, 1997
	300MG		A074842 002	Jul 17, 1997
MYLAN	200MG		A075071 001	Sep 30, 1998
	300MG		A075071 002	Sep 30, 1998
NATCO PHARMA	200MG		A074932 001	May 16, 1997
	300MG		A074932 002	May 16, 1997
SANDOZ	200MG		A074942 001	Sep 30, 1997
	300MG		A074942 002	Sep 30, 1997
LODINE				
+ WYETH PHARMS INC	200MG **		N018922 002	Jan 31, 1991
+	300MG		N018922 003	Jan 31, 1991
TABLET;ORAL				
ETODOLAC				
ANDA REPOSITORY	400MG		A074839 001	Jul 11, 1997
BIOPHARM	400MG		A074927 001	Oct 30, 1997
CHARTWELL MOLECULES	400MG		A074841 001	Jun 27, 1997
IVAX SUB TEVA PHARMS	400MG		A074883 001	Feb 28, 1997
	500MG		A074883 002	Nov 20, 1998
MYLAN	400MG		A075012 001	Sep 30, 1998
	500MG		A075012 002	Sep 30, 1998
NATCO PHARMA	400MG		A075104 001	Feb 06, 1998
	500MG		A075104 002	Nov 20, 1998
OXFORD PHARMS	400MG		A074819 001	Feb 28, 1997
	500MG		A074819 002	Apr 28, 1998
RANBAXY LABS LTD	400MG		A075226 001	Nov 24, 1998
	500MG		A075226 002	Nov 24, 1998
SHREE HARI INTL	400MG		A074846 001	Feb 28, 1997
TEVA	400MG		A074847 001	Apr 23, 1999
	400MG		A075009 001	Nov 26, 1997
	500MG		A074847 002	Apr 23, 1999
	500MG		A075009 002	Dec 28, 1999
WATSON LABS	400MG		A074892 001	Apr 16, 1997
	400MG		A075069 001	Apr 16, 1998
	500MG		A074892 002	Oct 29, 1998
LODINE				
+ WYETH PHARMS INC	400MG **		N018922 004	Jul 29, 1993
+	500MG **		N018922 005	Jun 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETODOLAC					
TABLET, EXTENDED RELEASE;ORAL					
ETODOLAC					
	ACTAVIS ELIZABETH	400MG	A075696	001	Jul 31, 2000
	ANI PHARMS	400MG	A075943	001	Jul 26, 2002
		500MG	A075943	002	Jul 26, 2002
		600MG	A075943	003	Jul 26, 2002
	WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
		500MG	A075829	002	Nov 30, 2001
LODINE XL					
	WYETH PHARMS INC	400MG **	N020584	001	Oct 25, 1996
		500MG **	N020584	003	Jan 20, 1998
+		600MG **	N020584	002	Oct 25, 1996
ETOMIDATE					
INJECTABLE;INJECTION					
ETOMIDATE					
	AVET LIFESCIENCES	2MG/ML	A204618	001	Aug 13, 2014
	LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009
	PH HEALTH	2MG/ML	A091297	001	Jun 20, 2012
	RISING	2MG/ML	A078289	001	Jan 02, 2009
ETONOGESTREL					
IMPLANT;IMPLANTATION					
IMPLANON					
	ORGANON	68MG/IMPLANT	N021529	001	Jul 17, 2006
ETOPOSIDE					
CAPSULE;ORAL					
VEPESID					
+	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986
+		100MG	N019557	002	Dec 30, 1986
INJECTABLE;INJECTION					
ETOPOSIDE					
	DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017
	DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017
	HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
		20MG/ML	A074351	001	Aug 30, 1995
	PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996
	PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
	TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994
	WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996
	WATSON LABS INC	20MG/ML	A074968	001	Jan 09, 1998
TOPOSAR					
	TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995
VEPESID					
+	CORDEN PHARMA	20MG/ML **	N018768	001	Nov 10, 1983
ETOPOSIDE PHOSPHATE					
INJECTABLE;INJECTION					
ETOPOPHOS PRESERVATIVE FREE					
	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906	001	Feb 27, 1998
		EQ 1GM BASE/VIAL	N020906	002	Feb 27, 1998
ETRAVIRINE					
TABLET;ORAL					
ETRAVIRINE					
	AMNEAL	25MG	A214196	001	Jun 14, 2021
ETRETINATE					
CAPSULE;ORAL					
TEGISON					
	ROCHE	10MG	N019369	001	Sep 30, 1986
		25MG	N019369	002	Sep 30, 1986
EVANS BLUE					
INJECTABLE;INJECTION					
EVANS BLUE					
	PARKE DAVIS	0.5% **	N008041	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EVEROLIMUS

TABLET;ORAL					
EVEROLIMUS					
	MYLAN	2.5MG	A212936	001	Jun 08, 2020
		5MG	A212936	002	Jun 08, 2020
		7.5MG	A212936	003	Jun 08, 2020
		10MG	A212936	004	Jun 08, 2020
TABLET, FOR SUSPENSION;ORAL					
EVEROLIMUS					
	MYLAN	2MG	A210130	001	Apr 19, 2019
		3MG	A210130	002	Apr 19, 2019
		5MG	A210130	003	Apr 19, 2019

EXEMESTANE

TABLET;ORAL					
EXEMESTANE					
	ALVOGEN	25MG	A200898	001	Jul 28, 2014
	AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018
	DR REDDYS LABS SA	25MG	A208764	001	Aug 08, 2019
	HIKMA	25MG	A077431	001	Apr 01, 2011

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS					
BYDUREON					
+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012
BYDUREON PEN					
+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014
INJECTABLE;SUBCUTANEOUS					
BYETTA					
+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005
SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS					
BYDUREON BCISE					
+	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EZETIMIBE

TABLET;ORAL					
EZETIMIBE					
	APOTEX	10MG	A208332	001	Jun 12, 2017
	MACLEODS PHARMS LTD	10MG	A211159	001	Apr 29, 2024
	RISING	10MG	A201790	001	Apr 26, 2019
	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET;ORAL					
ROSZET					
+	ALTHERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021
+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021

EZETIMIBE; SIMVASTATIN

TABLET;ORAL					
EZETIMIBE AND SIMVASTATIN					
	AMNEAL PHARMS CO	10MG;10MG	A208831	001	Nov 21, 2017
		10MG;20MG	A208831	002	Nov 21, 2017
		10MG;40MG	A208831	003	Nov 21, 2017
		10MG;80MG	A208831	004	Nov 21, 2017
	ANI PHARMS	10MG;10MG	A201890	001	Apr 26, 2017
		10MG;20MG	A201890	002	Apr 26, 2017
		10MG;40MG	A201890	003	Apr 26, 2017
		10MG;80MG	A201890	004	Apr 26, 2017
	SCIEGEN PHARMS	10MG;10MG	A211663	001	Dec 10, 2024
		10MG;20MG	A211663	002	Dec 10, 2024
		10MG;40MG	A211663	003	Dec 10, 2024
		10MG;80MG	A211663	004	Dec 10, 2024
	TORRENT	10MG;10MG	A209461	001	Jan 27, 2025
		10MG;20MG	A209461	002	Jan 27, 2025
		10MG;40MG	A209461	003	Jan 27, 2025
		10MG;80MG	A209461	004	Jan 27, 2025

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EZOGABINE

TABLET;ORAL					
POTIGA					
+	GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
+		200MG	N022345	002	Jun 10, 2011
+		300MG	N022345	003	Jun 10, 2011
+		400MG	N022345	004	Jun 10, 2011

FAMCICLOVIR

TABLET;ORAL					
FAMCICLOVIR					
	CIPLA	125MG	A078278	001	Mar 21, 2011
		250MG	A078278	002	Mar 21, 2011
		500MG	A078278	003	Mar 21, 2011
	HIKMA	125MG	A090128	001	Mar 21, 2011
		250MG	A090128	002	Mar 21, 2011
		500MG	A090128	003	Mar 21, 2011
	NATCO PHARMA	125MG	A201333	001	Mar 24, 2011
		250MG	A201333	002	Mar 24, 2011
		500MG	A201333	003	Mar 24, 2011
FAMVIR					
+	NOVARTIS	125MG **	N020363	003	Dec 11, 1995
+		250MG **	N020363	001	Apr 26, 1996
+		500MG **	N020363	002	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION;ORAL					
FAMOTIDINE					
	BIONPHARMA	40MG/5ML	A219153	001	Jun 23, 2025
PEPCID					
+	SALIX PHARMS	40MG/5ML **	N019527	001	Feb 02, 1987
INJECTABLE;INJECTION					
FAMOTIDINE					
	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707	001	Apr 16, 2001
	HIKMA	10MG/ML	A075799	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075705	001	Apr 16, 2001
		10MG/ML	A075870	001	Nov 23, 2001
		10MG/ML	A075905	001	Nov 23, 2001
	ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022
FAMOTIDINE PRESERVATIVE FREE					
	APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
	EPIC PHARMA LLC	10MG/ML	A076324	001	Nov 27, 2002
	HIKMA	10MG/ML	A075789	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
	EPIC PHARMA LLC	10MG/ML	A076322	001	Nov 27, 2002
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER					
	ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001
PEPCID					
+	MERCK	10MG/ML **	N019510	001	Nov 04, 1986
PEPCID PRESERVATIVE FREE					
+	MERCK	10MG/ML **	N019510	004	Nov 04, 1986
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
+	MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994
TABLET;ORAL					
FAMOTIDINE					
	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
		40MG	A075650	002	Sep 14, 2001
	APOTEX	10MG	A075610	001	Mar 12, 2002
		20MG	A075611	001	Jul 23, 2001
		40MG	A075611	002	Jul 23, 2001
	MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
		40MG	A075457	002	Apr 18, 2001
	NATCO PHARMA	10MG	A075674	001	Dec 21, 2001
	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005
		40MG	A077352	001	Jul 27, 2005
	SANDOZ	10MG	A076101	001	Oct 21, 2002
		20MG	A075607	001	May 10, 2001
		20MG	A075793	001	Apr 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FAMOTIDINE					
TABLET;ORAL					
FAMOTIDINE					
		40MG	A075607	002	May 10, 2001
		40MG	A075793	002	Apr 16, 2001
	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009
		20MG	A090283	002	Nov 17, 2009
	SUN PHARM INDUSTRIES	20MG	A075639	002	Dec 12, 2001
		40MG	A075639	001	Dec 12, 2001
	TEVA	10MG	A075312	001	May 31, 2001
		20MG	A075311	001	Apr 16, 2001
		40MG	A075311	002	Apr 16, 2001
	WATSON LABS	10MG	A075404	001	Nov 28, 2001
		20MG	A075062	002	Apr 16, 2001
		40MG	A075062	001	Apr 16, 2001
PEPCID					
+	BAUSCH	20MG **	N019462	001	Oct 15, 1986
+		40MG **	N019462	002	Oct 15, 1986
PEPCID AC					
	J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999
TABLET, CHEWABLE;ORAL					
FAMOTIDINE					
	PERRIGO	10MG	A075715	001	Aug 22, 2003
PEPCID AC					
+	KENVUE BRANDS	10MG **	N020801	001	Sep 24, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
FLUXID					
	UCB INC	20MG	N021712	001	Sep 24, 2004
		40MG	N021712	002	Sep 24, 2004
PEPCID RPD					
	MERCK	20MG	N020752	001	May 28, 1998
		40MG	N020752	002	May 28, 1998
FAMOTIDINE; IBUPROFEN					
TABLET;ORAL					
DUEXIS					
+	HORIZON	26.6MG;800MG **	N022519	001	Apr 23, 2011
IBUPROFEN AND FAMOTIDINE					
	AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025
	TEVA PHARMS USA	26.6MG;800MG	A211278	001	Oct 29, 2021
	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024
FEBUXOSTAT					
TABLET;ORAL					
FEBUXOSTAT					
	LUPIN LTD	40MG	A205406	001	Jan 17, 2024
		80MG	A205406	002	Jan 17, 2024
	PHARMOBEDIENT	40MG	A205385	001	Jul 01, 2019
		80MG	A205385	002	Jul 01, 2019
	TORRENT	40MG	A211837	001	Dec 19, 2023
		80MG	A211837	002	Dec 19, 2023
FELBAMATE					
SUSPENSION;ORAL					
FELBATOL					
+	MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993
TABLET;ORAL					
FELBAMATE					
	ALVOGEN	400MG	A204595	001	Jan 11, 2016
		600MG	A204595	002	Jan 11, 2016
FELODIPINE					
TABLET, EXTENDED RELEASE;ORAL					
FELODIPINE					
	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016
		5MG	A203983	002	Aug 19, 2016
		10MG	A203983	003	Aug 19, 2016
	MYLAN	2.5MG	A078855	001	Apr 17, 2008
		5MG	A078855	002	Apr 17, 2008
		10MG	A078855	003	Apr 17, 2008
	SUN PHARM INDUSTRIES	2.5MG	A075896	001	Nov 02, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FELODIPINE					
TABLET, EXTENDED RELEASE;ORAL					
FELODIPINE					
		5MG	A075896	002	Nov 02, 2004
		10MG	A075896	003	Nov 02, 2004
	WOCKHARDT BIO AG	2.5MG	A091484	001	Aug 15, 2012
		5MG	A091484	002	Aug 15, 2012
		10MG	A091484	003	Aug 15, 2012
PLENDIL					
+	ASTRAZENECA	2.5MG **	N019834	004	Sep 22, 1994
+		5MG **	N019834	001	Jul 25, 1991
+		10MG **	N019834	002	Jul 25, 1991
FENOFIBRATE					
CAPSULE;ORAL					
ANTARA (MICRONIZED)					
+	LUPIN	30MG **	N021695	004	Oct 18, 2013
		87MG	N021695	002	Nov 30, 2004
+		90MG **	N021695	005	Oct 18, 2013
FENOFIBRATE (MICRONIZED)					
	IMPAX LABS	67MG	A075868	001	Oct 27, 2003
		134MG	A075868	002	Oct 27, 2003
		200MG	A075868	003	Oct 27, 2003
	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017
		134MG	A207378	002	Mar 28, 2017
		200MG	A207378	003	Mar 28, 2017
	NOVAST LABS	67MG	A207564	001	Apr 19, 2019
		134MG	A207564	002	Apr 19, 2019
		200MG	A207564	003	Apr 19, 2019
	PHARMOBEDIENT	43MG	A202579	001	Jan 10, 2013
		130MG	A202579	002	Jan 10, 2013
	RISING	67MG	A202676	001	Oct 23, 2012
		134MG	A202676	002	Oct 23, 2012
		200MG	A202676	003	Oct 23, 2012
	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014
		130MG	A201748	002	Oct 31, 2014
LIPIDIL					
	ABBVIE	100MG	N019304	001	Dec 31, 1993
LIPOFEN					
	CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
TRICOR (MICRONIZED)					
+	ABBVIE	67MG **	N019304	002	Feb 09, 1998
+		134MG **	N019304	003	Jun 30, 1999
+		200MG **	N019304	004	Jun 30, 1999
TABLET;ORAL					
FENOFIBRATE					
	ALEMBIC	54MG	A213252	001	Jan 17, 2020
		160MG	A213252	002	Jan 17, 2020
	BAUSCH	48MG	A090715	001	Apr 05, 2012
		145MG	A090715	002	Apr 05, 2012
	MYLAN	54MG	A076520	001	Oct 25, 2007
		107MG	A076520	002	Dec 29, 2005
		160MG	A076520	003	Oct 25, 2007
	SUN PHARM	48MG	A200884	001	Sep 07, 2017
		145MG	A200884	002	Sep 07, 2017
	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005
		160MG	A076635	003	Oct 31, 2005
FENOGLIDE					
+	SALIX	40MG	N022118	001	Aug 10, 2007
+		120MG	N022118	002	Aug 10, 2007
TRICOR					
+	ABBVIE	48MG **	N021656	001	Nov 05, 2004
+		54MG **	N021203	001	Sep 04, 2001
+		145MG **	N021656	002	Nov 05, 2004
+		160MG **	N021203	003	Sep 04, 2001
TRIGLIDE					
	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005
+		160MG	N021350	002	May 07, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENOFIBRIC ACID				
TABLET;ORAL				
FIBRICOR				
+ ATHENA	35MG	N022418	001	Aug 14, 2009
+	105MG	N022418	002	Aug 14, 2009
FENOLDOPAM MESYLATE				
INJECTABLE;INJECTION				
CORLOPAM				
+ HOSPIRA	EQ 10MG BASE/ML **	N019922	001	Sep 23, 1997
FENOLDOPAM MESYLATE				
HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004
LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003
SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007
FENOPROFEN CALCIUM				
CAPSULE;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023
	EQ 300MG BASE	A215548	002	May 16, 2023
	EQ 400MG BASE	A215548	003	May 16, 2023
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988
RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991
NALFON				
+ PHARMACO	EQ 200MG BASE **	N017604	003	
	EQ 300MG BASE **	N017604	002	
+	EQ 400MG BASE **	N017604	004	Jul 21, 2009
TABLET;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
ANI PHARMS	EQ 600MG BASE	A072274	001	May 02, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988
PHARMACO	EQ 600MG BASE	A072267	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
RISING	EQ 600MG BASE	A072396	001	Oct 17, 1988
STRIDES PHARMA INTL	EQ 600MG BASE	A072429	001	Aug 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902	001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988
NALFON				
+ DISTA	EQ 600MG BASE **	N017710	001	
FENTANYL				
FILM, EXTENDED RELEASE;TRANSDERMAL				
DURAGESIC-100				
+ JANSSEN PHARMS	100MCG/HR **	N019813	001	Aug 07, 1990
DURAGESIC-12				
+ JANSSEN PHARMS	12.5MCG/HR **	N019813	005	Feb 04, 2005
DURAGESIC-25				
+ JANSSEN PHARMS	25MCG/HR **	N019813	004	Aug 07, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENTANYL					
FILM, EXTENDED RELEASE;TRANSDERMAL					
DURAGESIC-37					
+	JANSSEN PHARMS	37.5MCG/HR **	N019813	006	Jan 24, 2018
DURAGESIC-50					
+	JANSSEN PHARMS	50MCG/HR **	N019813	003	Aug 07, 1990
DURAGESIC-75					
+	JANSSEN PHARMS	75MCG/HR **	N019813	002	Aug 07, 1990
FENTANYL-100					
	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007
	LAVIPHARM LABS	100MCG/HR	A077051	004	Aug 04, 2006
	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007
	NOVEN	100MCG/HR	A077775	004	Oct 16, 2009
	ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24, 2023
FENTANYL-12					
	ZYDUS PHARMS	12.5MCG/HR	A209655	001	Jan 24, 2023
FENTANYL-25					
	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007
	LAVIPHARM LABS	25MCG/HR	A077051	001	Aug 04, 2006
	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007
	NOVEN	25MCG/HR	A077775	001	Oct 16, 2009
	ZYDUS PHARMS	25MCG/HR	A209655	002	Jan 24, 2023
FENTANYL-37					
	ZYDUS PHARMS	37.5MCG/HR	A209655	003	Jan 24, 2023
FENTANYL-50					
	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007
	LAVIPHARM LABS	50MCG/HR	A077051	002	Aug 04, 2006
	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007
	NOVEN	50MCG/HR	A077775	002	Oct 16, 2009
	ZYDUS PHARMS	50MCG/HR	A209655	004	Jan 24, 2023
FENTANYL-62					
	ZYDUS PHARMS	62.5MCG/HR	A209655	005	Jan 24, 2023
FENTANYL-75					
	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007
	LAVIPHARM LABS	75MCG/HR	A077051	003	Aug 04, 2006
	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
	NOVEN	75MCG/HR	A077775	003	Oct 16, 2009
	ZYDUS PHARMS	75MCG/HR	A209655	006	Jan 24, 2023
FENTANYL-87					
	ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24, 2023
SPRAY;SUBLINGUAL					
SUBSYS					
+	BTCP PHARMA	0.1MG **	N202788	001	Jan 04, 2012
+		0.2MG **	N202788	002	Jan 04, 2012
+		0.4MG **	N202788	003	Jan 04, 2012
+		0.6MG **	N202788	004	Jan 04, 2012
+		0.8MG **	N202788	005	Jan 04, 2012
+		1.2MG **	N202788	006	Aug 30, 2012
+		1.6MG **	N202788	007	Aug 30, 2012
FENTANYL CITRATE					
FILM;BUCCAL					
ONSOLIS					
	ADALVO	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
		EQ 0.4MG BASE	N022266	002	Jul 16, 2009
		EQ 0.6MG BASE	N022266	003	Jul 16, 2009
		EQ 0.8MG BASE	N022266	004	Jul 16, 2009
		EQ 1.2MG BASE	N022266	005	Jul 16, 2009
INJECTABLE;INJECTION					
FENTANYL CITRATE					
	ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
		EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
	WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE					
	DR REDDYS	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998
	HOSPIRA	EQ 0.05MG BASE/ML	A072786	001	Sep 24, 1991
SOLUTION;INTRAVENOUS					
FENTANYL CITRATE					
+	EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML) **	N215870	001	Feb 08, 2023

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENTANYL CITRATE

SOLUTION;INTRAVENOUS				
FENTANYL CITRATE				
+		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) **	N215870 002	Feb 08, 2023
SPRAY, METERED;NASAL				
LAZANDA				
+	BTCP PHARMA	EQ 0.1MG BASE **	N022569 001	Jun 30, 2011
+		EQ 0.3MG BASE **	N022569 003	Dec 21, 2015
+		EQ 0.4MG BASE **	N022569 002	Jun 30, 2011
TABLET;BUCCAL, SUBLINGUAL				
FENTANYL CITRATE				
	DR REDDYS LABS SA	EQ 0.1MG BASE	A206329 001	Aug 22, 2022
		EQ 0.2MG BASE	A206329 002	Aug 22, 2022
		EQ 0.3MG BASE	A206329 003	Aug 22, 2022
		EQ 0.4MG BASE	A206329 004	Aug 22, 2022
		EQ 0.6MG BASE	A206329 005	Aug 22, 2022
		EQ 0.8MG BASE	A206329 006	Aug 22, 2022
	WATSON LABS	EQ 0.1MG BASE	A079075 001	Jan 07, 2011
		EQ 0.2MG BASE	A079075 002	Jan 07, 2011
		EQ 0.4MG BASE	A079075 003	Jan 07, 2011
		EQ 0.6MG BASE	A079075 004	Jan 07, 2011
		EQ 0.8MG BASE	A079075 005	Jan 07, 2011
FENTORA				
+	CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006
+		EQ 0.2MG BASE	N021947 002	Sep 25, 2006
+		EQ 0.3MG BASE **	N021947 006	Mar 02, 2007
+		EQ 0.4MG BASE	N021947 003	Sep 25, 2006
+		EQ 0.6MG BASE	N021947 004	Sep 25, 2006
+		EQ 0.8MG BASE	N021947 005	Sep 25, 2006
TABLET;SUBLINGUAL				
ABSTRAL				
+	SENTYNL THERAPS INC	EQ 0.1MG BASE **	N022510 001	Jan 07, 2011
+		EQ 0.2MG BASE **	N022510 002	Jan 07, 2011
+		EQ 0.3MG BASE **	N022510 003	Jan 07, 2011
+		EQ 0.4MG BASE **	N022510 004	Jan 07, 2011
+		EQ 0.6MG BASE **	N022510 005	Jan 07, 2011
+		EQ 0.8MG BASE **	N022510 006	Jan 07, 2011
FENTANYL CITRATE				
	ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338 001	Nov 17, 2017
		EQ 0.2MG BASE	A207338 002	Nov 17, 2017
		EQ 0.3MG BASE	A207338 003	Nov 17, 2017
		EQ 0.4MG BASE	A207338 004	Nov 17, 2017
		EQ 0.6MG BASE	A207338 005	Nov 17, 2017
		EQ 0.8MG BASE	A207338 006	Nov 17, 2017
TROCHE/LOZENGE;ORAL				
FENTANYL				
	CEPHALON	EQ 0.1MG BASE	N020195 007	Oct 30, 1995
		EQ 0.2MG BASE	N020195 001	Oct 04, 1993
		EQ 0.3MG BASE	N020195 002	Oct 04, 1993
		EQ 0.4MG BASE	N020195 003	Oct 04, 1993
TROCHE/LOZENGE;TRANSMUCOSAL				
ACTIQ				
+	CEPHALON	EQ 0.2MG BASE	N020747 001	Nov 04, 1998
+		EQ 0.4MG BASE	N020747 002	Nov 04, 1998
+		EQ 0.6MG BASE	N020747 003	Nov 04, 1998
+		EQ 0.8MG BASE	N020747 004	Nov 04, 1998
+		EQ 1.2MG BASE	N020747 005	Nov 04, 1998
+		EQ 1.6MG BASE	N020747 006	Nov 04, 1998
FENTANYL CITRATE				
	PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009
		EQ 0.4MG BASE	A077312 002	Oct 30, 2009
		EQ 0.6MG BASE	A077312 003	Oct 30, 2009
		EQ 0.8MG BASE	A077312 004	Oct 30, 2009
		EQ 1.2MG BASE	A077312 005	Oct 30, 2009
		EQ 1.6MG BASE	A077312 006	Oct 30, 2009
	SPECGX LLC	EQ 0.2MG BASE	A078907 001	Oct 30, 2009
		EQ 0.4MG BASE	A078907 002	Oct 30, 2009
		EQ 0.6MG BASE	A078907 003	Oct 30, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENTANYL CITRATE					
TROCHE/LOZENGE;TRANSMUCOSAL					
FENTANYL CITRATE					
		EQ 0.8MG BASE	A078907	004	Oct 30, 2009
		EQ 1.2MG BASE	A078907	005	Oct 30, 2009
		EQ 1.6MG BASE	A078907	006	Oct 30, 2009
FENTANYL HYDROCHLORIDE					
SYSTEM;IONTOPHORESIS, TRANSDERMAL					
IONSYS					
+	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006
FERRIC AMMONIUM CITRATE					
FOR SOLUTION;ORAL					
FERRISELTZ					
	OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997
FERRIC DERISOMALTOSE					
SOLUTION;INTRAVENOUS					
MONOFERRIC					
+	PHARMACOSMOS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020
+		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020
FERRIC PYROPHOSPHATE CITRATE					
POWDER;INTRAVENOUS					
TRIFERIC					
+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016
SOLUTION;INTRAVENOUS					
TRIFERIC					
+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015
+		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015
TRIFERIC AVNU					
+	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020
FERROUS CITRATE, FE-59					
INJECTABLE;INJECTION					
FERROUS CITRATE FE 59					
	MALLINCKRODT	25uCi/ML	N016729	001	
FERROUS SULFATE; FOLIC ACID					
CAPSULE;ORAL					
FOLVRON					
	LEDERLE	182MG;0.33MG	N006012	003	
FERUMOXIDES					
INJECTABLE;INJECTION					
FERIDEX I.V.					
	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996
FERUMOXSIL					
SUSPENSION;ORAL					
GASTROMARK					
	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996
FESOTERODINE FUMARATE					
TABLET, EXTENDED RELEASE;ORAL					
FESOTERODINE FUMARATE					
	ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023
		8MG	A205012	002	Jan 04, 2023
	ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023
		8MG	A204868	002	Jan 04, 2023
	ANI PHARMS	4MG	A204504	001	Jan 04, 2023
		8MG	A204504	002	Jan 04, 2023
	CHARTWELL RX	4MG	A204983	001	Jan 05, 2023
		8MG	A204983	002	Jan 05, 2023
FEXOFENADINE HYDROCHLORIDE					
CAPSULE;ORAL					
ALLEGRA					
	CHATTEM SANOFI	60MG **	N020625	001	Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE					
	BARR	60MG	A076169	001	Jul 13, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL					
ALLEGRA					
+	CHATTEM SANOFI	30MG/5ML **	N021963	001	Oct 16, 2006
CHILDREN'S ALLEGRA HIVES					
+	CHATTEM SANOFI	30MG/5ML **	N201373	002	Jan 24, 2011
FEXOFENADINE HYDROCHLORIDE					
	P AND L	30MG/5ML	A201311	001	Jul 25, 2012
TABLET;ORAL					
ALLEGRA HIVES					
+	CHATTEM SANOFI	60MG	N020872	008	Jan 24, 2011
CHILDREN'S ALLEGRA ALLERGY					
+	CHATTEM SANOFI	30MG **	N020872	005	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES					
+	CHATTEM SANOFI	30MG	N020872	006	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	RISING	30MG	A077081	004	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	RISING	30MG	A077081	005	Jul 21, 2011
	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
FEXOFENADINE HYDROCHLORIDE					
	BARR	30MG	A076191	001	Aug 31, 2005
		60MG	A076191	002	Aug 31, 2005
		180MG	A076191	003	Aug 31, 2005
	RISING	30MG	A077081	002	Apr 11, 2008
FEXOFENADINE HYDROCHLORIDE ALLERGY					
	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
FEXOFENADINE HYDROCHLORIDE HIVES					
	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
TABLET, ORALLY DISINTEGRATING;ORAL					
CHILDREN'S ALLEGRA ALLERGY					
+	CHATTEM SANOFI	30MG	N021909	002	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES					
+	CHATTEM SANOFI	30MG **	N021909	003	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
	DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
	DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025
	BARR	60MG;120MG	A076236	001	Apr 14, 2005
	IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010

FINAFLOXACIN

SUSPENSION/DROPS;OTIC					
XTORO					
+	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014

FINASTERIDE

TABLET;ORAL					
FINASTERIDE					
	ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013
	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007
	CIPLA	1MG	A077335	001	Nov 20, 2014
	GEDEON RICHTER USA	5MG	A077251	001	Dec 22, 2006
	IVAX SUB TEVA PHARMS	5MG	A076340	001	Jun 19, 2006
	MYLAN	5MG	A077578	001	Dec 18, 2006
	NATCO PHARMA	1MG	A078161	001	Nov 05, 2013
	TEVA	1MG	A076905	001	Nov 05, 2013

FINASTERIDE; TADALAFIL

CAPSULE;ORAL					
ENTADFI					
+	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021
FINASTERIDE AND TADALAFIL					
	ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FINGOLIMOD HYDROCHLORIDE				
CAPSULE;ORAL				
FINGOLIMOD HYDROCHLORIDE				
	CHARTWELL RX	EQ 0.5MG BASE	A207971 001	Jun 29, 2020
	MYLAN	EQ 0.5MG BASE	A208005 001	Jan 19, 2021
	SUN PHARM	EQ 0.5MG BASE	A208014 001	Dec 04, 2019
	TEVA PHARMS USA	EQ 0.25MG BASE	A212152 001	Nov 12, 2021
FLAVOXATE HYDROCHLORIDE				
TABLET;ORAL				
FLAVOXATE HYDROCHLORIDE				
	IMPAX PHARMS	100MG	A076234 001	Aug 28, 2003
URISPAS				
	ORTHO MCNEIL JANSSEN	100MG	N016769 001	
FLECAINIDE ACETATE				
TABLET;ORAL				
FLECAINIDE ACETATE				
	ANI PHARMS	50MG	A076030 001	Oct 28, 2002
		100MG	A076030 002	Oct 28, 2002
		150MG	A076030 003	Oct 28, 2002
	CHARTWELL	50MG	A079164 001	Jul 09, 2009
		100MG	A079164 002	Jul 09, 2009
		150MG	A079164 003	Jul 09, 2009
TAMBOCOR				
+	ALVOGEN	50MG **	N018830 004	Aug 23, 1988
+		100MG **	N018830 001	Oct 31, 1985
+		150MG **	N018830 003	Jun 03, 1988
		200MG **	N018830 002	Oct 31, 1985
FLORBETAPIR F-18				
SOLUTION;INTRAVENOUS				
AMYVID				
+	AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008 001	Apr 06, 2012
+		10-30ML (13.5-51mCi/ML)	N202008 002	Apr 06, 2012
FLORTAUCIPIR F-18				
SOLUTION;INTRAVENOUS				
TAUVID				
+	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123 001	May 28, 2020
+		50ML (8.1-51mCi/ML)	N212123 002	May 28, 2020
FLOXURIDINE				
INJECTABLE;INJECTION				
FLOXURIDINE				
	AM REGENT	500MG/VIAL	A203008 001	Nov 22, 2017
FUDR				
+	HOSPIRA	500MG/VIAL **	N016929 001	
FLUCONAZOLE				
FOR SUSPENSION;ORAL				
FLUCONAZOLE				
	HIKMA	50MG/5ML	A076246 001	Jul 29, 2004
		200MG/5ML	A076246 002	Jul 29, 2004
	IVAX SUB TEVA PHARMS	50MG/5ML	A077523 001	Sep 12, 2007
		200MG/5ML	A077523 002	Sep 12, 2007
	SUN PHARM INDS LTD	50MG/5ML	A076332 001	Jul 29, 2004
		200MG/5ML	A076332 002	Jul 29, 2004
	TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006
		200MG/5ML	A076918 002	Dec 18, 2006
INJECTABLE;INJECTION				
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	PFIZER	200MG/100ML (2MG/ML)	N019950 003	Sep 29, 1992
+		400MG/200ML (2MG/ML)	N019950 005	Jul 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9%				
+	PFIZER	200MG/100ML (2MG/ML)	N019950 001	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950 006	Jan 29, 1990
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	PFIZER	200MG/100ML (2MG/ML)	N019950 002	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950 004	Jan 29, 1990
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUCONAZOLE

INJECTABLE;INJECTION				
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER				
	400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012
HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004
PHARMOBEDIENT	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005
WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010
	400MG/200ML (2MG/ML)	A077988	002	May 26, 2010
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%				
BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010
	400MG/200ML (2MG/ML)	A077947	002	May 26, 2010
DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TABLET;ORAL				
FLUCONAZOLE				
ANI PHARMS	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004
GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
IVAX SUB TEVA PHARMS	50MG	A076077	001	Jul 29, 2004
	100MG	A076077	002	Jul 29, 2004
	150MG	A076077	003	Jul 29, 2004
	200MG	A076077	004	Jul 29, 2004
LUPIN LTD	50MG	A209146	001	Oct 20, 2023
	100MG	A209146	002	Oct 20, 2023
	150MG	A209146	003	Oct 20, 2023
	200MG	A209146	004	Oct 20, 2023
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PHARMOBEDIENT	50MG	A076351	001	Jul 29, 2004
	100MG	A076351	002	Jul 29, 2004
	150MG	A076351	003	Jul 29, 2004
	200MG	A076351	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
TARO	50MG	A076507	001	Jul 29, 2004
	100MG	A076507	002	Jul 29, 2004
	150MG	A076507	003	Jul 29, 2004
	200MG	A076507	004	Jul 29, 2004
TEVA	50MG	A074681	001	Jul 29, 2004
	100MG	A074681	002	Jul 29, 2004
	150MG	A074681	003	Jul 29, 2004
	200MG	A074681	004	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUCYTOSINE				
CAPSULE;ORAL				
FLUCYTOSINE				
HIKMA	250MG	A206550	001	Oct 17, 2017
	500MG	A206550	002	Oct 17, 2017
STRIDES PHARMA	250MG	A207536	001	Jun 18, 2018
	500MG	A207536	002	Jun 18, 2018
FLUDARABINE PHOSPHATE				
INJECTABLE;INJECTION				
FLUDARA				
+ GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991
FLUDARABINE PHOSPHATE				
ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017
EXTROVIS	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007
RISING	50MG/VIAL	A200648	001	Oct 16, 2012
+ SANDOZ	50MG/2ML (25MG/ML) **	N022137	001	Sep 21, 2007
TABLET;ORAL				
OFORTA				
SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
FLUDEOXYGLUCOSE F-18				
INJECTABLE;INJECTION				
FLUDEOXYGLUCOSE F18				
+ DOWNSTATE CLINCL	4-40mCi/ML **	N020306	001	Aug 19, 1994
+	4-90mCi/ML **	N020306	002	Sep 25, 2001
INJECTABLE;INTRAVENOUS				
FLUDEOXYGLUCOSE F18				
ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014
+ FEINSTEIN	20-200mCi/ML **	N021870	001	Aug 19, 2005
HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016
MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013
UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020
+ WEILL MEDCL COLL	10-100mCi/ML **	N021768	001	Aug 05, 2004
WISCONSIN	20-500mCi/ML	A203709	001	Oct 23, 2013
FLUDROCORTISONE ACETATE				
TABLET;ORAL				
FLORINEF				
+ CASPER PHARMA LLC	0.1MG **	N010060	001	
FLUDROCORTISONE ACETATE				
BARR	0.1MG	A040425	001	Jan 21, 2003
CHARTWELL RX	0.1MG	A216013	001	Oct 27, 2022
HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011
FLUMAZENIL				
INJECTABLE;INJECTION				
FLUMAZENIL				
DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004
	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004
RISING	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008
ROMAZICON				
+ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073	001	Dec 20, 1991
+	0.5MG/5ML (0.1MG/ML) **	N020073	002	Dec 20, 1991
FLUMETHASONE PIVALATE				
CREAM;TOPICAL				
LOCORTEN				
NOVARTIS	0.03%	N016379	001	
FLUNISOLIDE				
AEROSOL, METERED;INHALATION				
AEROBID				
ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
AEROSPAN HFA				
+ PHARMOBEDIENT	0.078MG/INH	N021247	001	Jan 27, 2006
SPRAY, METERED;NASAL				
FLUNISOLIDE				
APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUNISOLIDE				
SPRAY, METERED;NASAL				
NASALIDE				
+ IVAX RES	0.025MG/SPRAY **	N018148	001	
NASAREL				
TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995
FLUOCINOLONE ACETONIDE				
CREAM;TOPICAL				
FLUOCET				
ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
FLUOCINOLONE ACETONIDE				
ALLIED	0.01%	A088047	001	Dec 16, 1982
ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
COSETTE	0.025%	A089525	001	Jul 26, 1988
INVATECH	0.025%	A088045	001	Dec 16, 1982
PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
	0.025%	A086811	001	Mar 04, 1982
PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
	0.025%	A088506	001	Aug 02, 1984
SUN PHARMA CANADA	0.01%	A040035	001	Oct 31, 1994
	0.01%	A087102	001	Apr 27, 1982
	0.025%	A040042	001	Oct 31, 1994
	0.025%	A087104	001	Apr 27, 1982
USL PHARMA	0.01%	A088757	001	Feb 11, 1985
	0.025%	A088756	001	Mar 28, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.01%	A088174	001	May 06, 1983
	0.025%	A088173	001	Mar 09, 1983
SYNALAR-HP				
MEDIMETRIKS PHARMS	0.2%	N016161	002	
GEL;TOPICAL				
FLUONID				
ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
OIL;TOPICAL				
FLUOCINOLONE ACETONIDE				
AMNEAL	0.01%	A201759	001	Oct 17, 2011
	0.01%	A201764	001	Oct 17, 2011
GLENMARK PHARMS LTD	0.01%	A210556	001	Oct 25, 2018
SCIEGEN PHARMS	0.01%	A091514	001	Jun 25, 2015
FLUOCINONIDE ACETONIDE				
GLENMARK PHARMS LTD	0.01%	A210539	001	Oct 26, 2018
OIL/DROPS;OTIC				
FLUOCINOLONE ACETONIDE				
AMNEAL	0.01%	A091306	001	Oct 17, 2011
SCIEGEN PHARMS	0.01%	A202705	001	Sep 09, 2016
FLUOCINONIDE ACETONIDE				
GLENMARK PHARMS LTD	0.01%	A211815	001	Dec 14, 2018
OINTMENT;TOPICAL				
FLUOCINOLONE ACETONIDE				
PHARMADERM	0.025%	A088046	001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
SUN PHARMA CANADA	0.025%	A040041	001	Sep 15, 1994
USL PHARMA	0.025%	A088742	001	Feb 08, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983
SHAMPOO;TOPICAL				
CAPEX				
+ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
SOLUTION;TOPICAL				
FLUOCINOLONE ACETONIDE				
ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016
ALLIED	0.01%	A088048	001	Dec 16, 1982
ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
COSETTE	0.01%	A207441	001	Sep 28, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOCINOLONE ACETONIDE
SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

	PAI HOLDINGS PHARM	0.01%	A088312	001	Jan 27, 1984
	PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984

FLUONID

	ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983

FLUOTREX

	SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983

FLUOCINONIDE
CREAM;TOPICAL
FLUOCINONIDE

	AMNEAL	0.1%	A211111	001	Jun 04, 2018
	GLENMARK PHARMS LTD	0.1%	A091282	001	Jul 14, 2014
	PADAGIS ISRAEL	0.1%	A090256	001	Jan 14, 2014
	PAI HOLDINGS PHARM	0.1%	A211758	001	Apr 03, 2019
	PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
+	SUN PHARMA CANADA	0.05% **	N019117	001	Jun 26, 1984

LIDEX

+	ALVOGEN	0.05% **	N016908	002	

LIDEX-E

+	ALVOGEN	0.05% **	N016908	003	

GEL;TOPICAL
FLUOCINONIDE

+	ALVOGEN	0.05% **	N017373	001	
	COSETTE	0.05%	A072537	001	Feb 07, 1989

OINTMENT;TOPICAL
FLUOCINONIDE

	PAI HOLDINGS PHARM	0.05%	A207680	001	Sep 28, 2018

LIDEX

+	ALVOGEN	0.05% **	N016909	002	

SOLUTION;TOPICAL
FLUOCINONIDE

	COSETTE	0.05%	A071535	001	Dec 02, 1988
	SCIEGEN PHARMS	0.05%	A207554	001	Mar 18, 2019
	SUN PHARMA CANADA	0.05%	A072857	001	Aug 02, 1989
	TEVA	0.05%	A072511	001	Feb 07, 1989
	TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990

LIDEX

+	ALVOGEN	0.05% **	N018849	001	Apr 06, 1984

FLUORESCEIN SODIUM
INJECTABLE;INJECTION
FUNDUSCEIN-25

+	NOVARTIS	25% **	N017869	001	

INJECTABLE;INTRAVENOUS
AK-FLUOR 25%

+	LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008

FLUOROMETHOLONE
CREAM;TOPICAL
OXYLONE

	PHARMACIA AND UPJOHN	0.025%	N011748	001	

OINTMENT;OPHTHALMIC
FML

+	ALLERGAN	0.1%	N017760	001	Sep 04, 1985

SUSPENSION/DROPS;OPHTHALMIC
FLUOR-OP

	NOVARTIS	0.1%	A070185	001	Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN
SUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

	HARROW EYE	0.1%;0.3%	N050628	001	Jul 21, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOROMETHOLONE; SULFACETAMIDE SODIUM					
SUSPENSION/DROPS;OPHTHALMIC					
FML-S					
	ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989
FLUOROURACIL					
CREAM;TOPICAL					
FLUOROPLEX					
+	CHARTWELL RX	1%	N016988	001	
FLUOROURACIL					
	EXTROVIS	0.5%	A203122	001	Apr 20, 2015
INJECTABLE;INJECTION					
ADRUCIL					
	PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
+		50MG/ML **	N017959	001	
	TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
		50MG/ML	A081225	001	Aug 28, 1991
FLUOROURACIL					
	ABIC	50MG/ML	A088929	001	Mar 04, 1986
	ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
		50MG/ML	A089428	001	Jan 12, 1987
		50MG/ML	A089519	001	Mar 12, 1987
	ACCORD HLTHCARE	2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007
	BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
	FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
		50MG/ML	A040379	001	Nov 15, 2000
	MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
	NOVAST LABS	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019
		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019
		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019
		5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019
	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
	SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
		50MG/ML	A088767	001	Dec 28, 1984
		50MG/ML	A089434	001	Mar 26, 1987
	SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+		500MG/10ML (50MG/ML) **	N012209	001	
+		2.5GM/50ML (50MG/ML) **	N012209	002	Jul 29, 2016
	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000
		2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000
		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000
SOLUTION;TOPICAL					
EFUDEX					
+	EXTROVIS	5% **	N016831	002	
FLUOROPLEX					
	ELORAC	1%	N016765	001	
FLUOXETINE HYDROCHLORIDE					
CAPSULE;ORAL					
FLUOXETINE					
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
		EQ 20MG BASE	A075787	002	Jan 29, 2002
	WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
		EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE					
	ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020
		EQ 20MG BASE	A202729	002	Aug 27, 2020
		EQ 40MG BASE	A202729	003	Aug 27, 2020
	ANI PHARMS	EQ 10MG BASE	A076287	001	May 20, 2008
		EQ 20MG BASE	A076287	002	May 20, 2008
	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002
		EQ 20MG BASE	A074803	001	Aug 02, 2001
		EQ 40MG BASE	A076251	001	May 18, 2005
	CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
		EQ 20MG BASE	A076022	002	Jan 30, 2002
	CHARTWELL RX	EQ 10MG BASE	A078143	001	Jan 16, 2008
		EQ 20MG BASE	A078143	002	Jan 16, 2008
		EQ 40MG BASE	A078143	003	Jan 16, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL					
FLUOXETINE HYDROCHLORIDE					
	CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
		EQ 20MG BASE	A076165	002	Feb 01, 2002
	NATCO PHARMA USA	EQ 10MG BASE	A078045	001	Nov 17, 2008
		EQ 20MG BASE	A078045	002	Nov 17, 2008
	PHARMOBEDIENT	EQ 10MG BASE	A075207	001	Jan 30, 2002
		EQ 10MG BASE	A075577	001	Jan 29, 2002
		EQ 20MG BASE	A075207	002	Jan 30, 2002
		EQ 20MG BASE	A075577	002	Jan 29, 2002
		EQ 40MG BASE	A075207	003	May 25, 2007
	REGCON HOLDINGS	EQ 10MG BASE	A075807	001	Jan 29, 2002
		EQ 20MG BASE	A075807	002	Jan 29, 2002
	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008
		EQ 20MG BASE	A077469	002	Nov 17, 2008
	SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002
		EQ 20MG BASE	A075658	002	Jan 29, 2002
	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004
PROZAC					
	ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
SARAFEM					
+	ELI LILLY AND CO	EQ 10MG BASE **	N018936	007	Jul 06, 2000
+		EQ 20MG BASE **	N018936	008	Jul 06, 2000
CAPSULE, DELAYED REL PELLETS;ORAL					
FLUOXETINE HYDROCHLORIDE					
	BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010
PROZAC WEEKLY					
+	LILLY	EQ 90MG BASE **	N021235	001	Feb 26, 2001
SOLUTION;ORAL					
FLUOXETINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
	BAJAJ	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002
	CHARTWELL MOLECULAR	EQ 20MG BASE/5ML	A076458	001	May 14, 2004
	PHARMOBEDIENT CNSLTG	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002
PROZAC					
+	LILLY	EQ 20MG BASE/5ML **	N020101	001	Apr 24, 1991
TABLET;ORAL					
FLUOXETINE HYDROCHLORIDE					
	BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
	CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022
		EQ 20MG BASE	A211444	002	Sep 13, 2022
	FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002
	G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019
	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
		EQ 40MG BASE	A075865	003	Aug 30, 2004
	RISING	EQ 10MG BASE	A075755	001	Aug 02, 2001
		EQ 20MG BASE	A075755	002	Aug 02, 2001
	SOMERSET THERAPS LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019
		EQ 20MG BASE	A211696	002	Jan 30, 2019
	TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002
		EQ 20MG BASE	A075872	002	Jan 04, 2019
	TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018
+	TWI PHARMS	EQ 60MG BASE	N202133	001	Oct 06, 2011
PROZAC					
+	LILLY	EQ 10MG BASE **	N020974	001	Mar 09, 1999
+		EQ 20MG BASE **	N020974	002	Mar 09, 1999
SARAFEM					
+	APIL	EQ 10MG BASE **	N021860	001	May 19, 2006
+		EQ 15MG BASE **	N021860	002	May 19, 2006
+		EQ 20MG BASE **	N021860	003	May 19, 2006
SELFEMRA					
	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014
		EQ 15MG BASE	A200151	002	Feb 03, 2014
		EQ 20MG BASE	A200151	003	Feb 03, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOXETINE HYDROCHLORIDE; OLANZAPINE				
CAPSULE;ORAL				
SYMBYAX				
+ LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007
+	EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003
+	EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003
+	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003
+	EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003
FLUOXYMESTERONE				
TABLET;ORAL				
ANDROID-F				
VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983
HALOTESTIN				
PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	
ORA-TESTRYL				
BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	
FLUPHENAZINE DECANOATE				
INJECTABLE;INJECTION				
FLUPHENAZINE DECANOATE				
HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996
PROLIXIN DECANOATE				
+ BRISTOL MYERS SQUIBB	25MG/ML **	N016727	001	
FLUPHENAZINE ENANTHATE				
INJECTABLE;INJECTION				
PROLIXIN ENANTHATE				
APOTHECON	25MG/ML **	N016110	001	
FLUPHENAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML **	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985
ELIXIR;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
+ APOTHECON	2.5MG/5ML **	N012145	003	
INJECTABLE;INJECTION				
PROLIXIN				
APOTHECON	2.5MG/ML **	N011751	005	
TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
APOTEX	1MG	A216649	001	Jul 15, 2022
	2.5MG	A216649	002	Jul 15, 2022
	5MG	A216649	003	Jul 15, 2022
	10MG	A216649	004	Jul 15, 2022
PRASCO	1MG	A089804	002	Aug 12, 1988
	2.5MG	A089804	003	Aug 12, 1988
	5MG	A089804	004	Aug 12, 1988
	10MG	A089804	001	Aug 12, 1988
SANDOZ	1MG	A089586	002	Oct 16, 1987
	2.5MG	A089586	003	Oct 16, 1987
	5MG	A089586	004	Oct 16, 1987
	10MG	A089586	001	Oct 16, 1987
TORRENT	1MG	A217094	001	Jan 22, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
	2.5MG	A217094	002	Jan 22, 2024
	5MG	A217094	003	Jan 22, 2024
	10MG	A217094	004	Jan 22, 2024
TWI PHARMS	1MG	A215848	004	Dec 14, 2022
	2.5MG	A215848	001	Apr 01, 2022
	5MG	A215848	002	Apr 01, 2022
	10MG	A215848	003	Apr 01, 2022
WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987
PERMITIL				
SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	
PROLIXIN				
+ APOTHECON	1MG **	N011751	004	
+	2.5MG **	N011751	001	
+	5MG **	N011751	003	
+	10MG **	N011751	002	
TABLET, EXTENDED RELEASE;ORAL				
PERMITIL				
SCHERING	1MG	N012419	004	

FLUPREDNISOLONE

TABLET;ORAL				
ALPHADROL				
PHARMACIA AND UPJOHN	1.5MG	N012259	002	

FLURANDRENOLIDE

CREAM;TOPICAL				
CORDRAN SP				
+ INA PHARMS	0.025% **	N012806	003	
+	0.05%	N012806	002	
FLURANDRENOLIDE				
CHARTWELL RX	0.05%	A205342	001	Apr 13, 2016
LOTION;TOPICAL				
CORDRAN				
+ INA PHARMS	0.05% **	N013790	001	
FLURANDRENOLIDE				
ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
CHARTWELL RX	0.05%	A205343	001	Dec 22, 2016
OINTMENT;TOPICAL				
CORDRAN				
+ INA PHARMS	0.025% **	N012806	004	
+	0.05%	N012806	001	

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL				
CORDRAN N				
LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001	
OINTMENT;TOPICAL				
CORDRAN N				
LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL				
DALMANE				
VALEANT PHARM INTL	15MG **	N016721	001	
+	30MG **	N016721	002	
FLURAZEPAM HYDROCHLORIDE				
CHARTWELL RX	15MG	A071205	001	Nov 25, 1986
	30MG	A071068	001	Nov 25, 1986
HALSEY	15MG	A071808	001	Jan 07, 1988
	30MG	A071809	001	Jan 07, 1988
HIKMA	30MG	A071108	001	Dec 08, 1986
HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLURAZEPAM HYDROCHLORIDE					
CAPSULE;ORAL					
FLURAZEPAM HYDROCHLORIDE					
	NOVITIUM PHARMA	15MG	A070444	001	Mar 20, 1986
		30MG	A070445	001	Mar 20, 1986
	PUREPAC PHARM	15MG	A071927	001	Sep 09, 1987
		30MG	A071551	001	Sep 09, 1987
	RISING	15MG	A071717	002	Jul 31, 1991
		30MG	A071717	001	Jul 31, 1991
	SUN PHARM INDUSTRIES	15MG	A070454	001	Aug 04, 1986
		30MG	A070455	001	Aug 04, 1986
	SUPERPHARM	15MG	A071659	001	Aug 04, 1988
		30MG	A071660	001	Aug 04, 1988
	USL PHARMA	15MG	A070562	001	Jul 09, 1987
		30MG	A070563	001	Jul 09, 1987
	WARNER CHILCOTT	15MG	A071767	001	Dec 04, 1987
		30MG	A071768	001	Dec 04, 1987
FLURBIPROFEN					
TABLET;ORAL					
ANSAID					
+	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988
+		100MG	N018766	003	Oct 31, 1988
FLURBIPROFEN					
	IVAX SUB TEVA PHARMS	50MG	A074411	001	May 31, 1995
		100MG	A074411	002	May 31, 1995
	NATCO PHARMA	50MG	A074358	001	Jun 20, 1994
		100MG	A074358	002	Jun 20, 1994
	PLIVA	50MG	A074647	001	Apr 01, 1997
		100MG	A074647	002	Apr 01, 1997
	RISING	50MG	A074448	001	Jul 28, 1995
		100MG	A074448	002	Jul 28, 1995
	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001
		100MG	A075058	002	Apr 27, 2001
	TEVA	50MG	A074405	002	May 24, 1995
		100MG	A074405	001	May 24, 1995
	THERAGEN	100MG	A074560	002	May 16, 1997
FLURBIPROFEN SODIUM					
SOLUTION/DROPS;OPHTHALMIC					
OCUFEN					
+	ALLERGAN	0.03% **	N019404	001	Dec 31, 1986
FLUTAMIDE					
CAPSULE;ORAL					
EULEXIN					
+	SCHERING	125MG **	N018554	001	Jan 27, 1989
FLUTAMIDE					
	ACTAVIS LABS FL INC	125MG	A075820	001	Sep 18, 2001
	CHARTWELL RX	125MG	A075818	001	Sep 18, 2001
	CIPLA	125MG	A075780	001	Sep 19, 2001
	PHARMOBEDIENT	125MG	A076224	001	May 09, 2003
FLUTEMETAMOL F-18					
INJECTABLE;INTRAVENOUS					
VIZAMYL					
+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013
FLUTICASONE PROPIONATE					
AEROSOL, METERED;INHALATION					
FLOVENT					
	GLAXOSMITHKLINE	0.044MG/INH	N020548	001	Mar 27, 1996
		0.11MG/INH	N020548	002	Mar 27, 1996
		0.22MG/INH	N020548	003	Mar 27, 1996
CREAM;TOPICAL					
CUTIVATE					
+	FOUGERA PHARMS	0.05% **	N019958	001	Dec 18, 1990
FLUTICASONE PROPIONATE					
	NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUTICASONE PROPIONATE					
LOTION;TOPICAL					
CUTIVATE					
+	FOUGERA PHARMS	0.05% **	N021152	001	Mar 31, 2005
FLUTICASONE PROPIONATE					
	GLENMARK PHARMS LTD	0.05%	A090759	001	May 02, 2011
OINTMENT;TOPICAL					
CUTIVATE					
+	FOUGERA PHARMS	0.005% **	N019957	001	Dec 14, 1990
FLUTICASONE PROPIONATE					
	BRIGHT	0.005%	A215343	001	Sep 01, 2023
	CHARTWELL RX	0.005%	A076300	001	May 14, 2004
	TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005
POWDER;INHALATION					
ARMONAIR DIGIHALER					
+	TEVA PHARM	0.03MG/INH	N208798	008	Apr 08, 2022
+		0.055MG/INH	N208798	004	Feb 20, 2020
+		0.113MG/INH	N208798	005	Feb 20, 2020
+		0.232MG/INH	N208798	006	Feb 20, 2020
ARMONAIR RESPICLICK					
+	TEVA PHARM	0.03MG/INH	N208798	007	Jul 09, 2021
+		0.055MG/INH	N208798	001	Jan 27, 2017
+		0.113MG/INH	N208798	002	Jan 27, 2017
+		0.232MG/INH	N208798	003	Jan 27, 2017
FLOVENT					
	GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
		0.088MG/INH	N020549	002	Nov 07, 1997
		0.22MG/INH	N020549	003	Nov 07, 1997
SPRAY, METERED;NASAL					
FLONASE					
+	HALEON US HOLDINGS	0.05MG/SPRAY **	N020121	001	Oct 19, 1994
FLUTICASONE PROPIONATE					
	HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008
		0.05MG/SPRAY	A208024	001	Apr 17, 2019
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE					
POWDER;INHALATION					
AIRDUO DIGIHALER					
+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019
+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019
FLUVASTATIN SODIUM					
CAPSULE;ORAL					
LESCOL					
+	NOVARTIS	EQ 20MG BASE **	N020261	001	Dec 31, 1993
+		EQ 40MG BASE **	N020261	002	Dec 31, 1993
TABLET, EXTENDED RELEASE;ORAL					
FLUVASTATIN SODIUM					
	PHARMOBEDIENT	EQ 80MG BASE	A202458	001	Sep 11, 2015
FLUVOXAMINE MALEATE					
CAPSULE, EXTENDED RELEASE;ORAL					
FLUVOXAMINE MALEATE					
	TORRENT	100MG	A203240	001	Oct 31, 2014
		150MG	A203240	002	Oct 31, 2014
LUVOX CR					
+	JAZZ PHARMS	100MG **	N022033	001	Feb 28, 2008
+		150MG **	N022033	002	Feb 28, 2008
TABLET;ORAL					
FLUVOXAMINE MALEATE					
	ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
		50MG	A075901	002	Dec 28, 2000
		100MG	A075901	003	Dec 28, 2000
	ANI PHARMS	25MG	A075897	001	Jan 25, 2001
		25MG	A075898	001	Mar 12, 2001
		50MG	A075897	002	Jan 25, 2001
		50MG	A075898	002	Mar 12, 2001
		100MG	A075897	003	Jan 25, 2001
		100MG	A075898	003	Mar 12, 2001
	CHARTWELL RX	25MG	A075900	001	Feb 23, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUVOXAMINE MALEATE				
TABLET;ORAL				
FLUVOXAMINE MALEATE				
	50MG	A075900	002	Feb 23, 2006
	100MG	A075900	003	Feb 23, 2006
HERITAGE PHARMA	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001
MYLAN	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
QUAGEN	25MG	A075889	001	Nov 29, 2000
	50MG	A075889	002	Nov 29, 2000
	100MG	A075889	003	Nov 29, 2000
SUN PHARM INDUSTRIES	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
TEVA	25MG	A075893	001	Sep 10, 2002
	50MG	A075893	002	Sep 10, 2002
	100MG	A075893	003	Sep 10, 2002
UPSHER SMITH LABS	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001
LUVOX				
+ SOLVAY	25MG **	N020243	001	Dec 05, 1994
+	50MG **	N020243	002	Dec 05, 1994
+	100MG **	N020243	003	Dec 05, 1994
+	150MG **	N020243	004	Dec 05, 1994
FOLIC ACID				
INJECTABLE;INJECTION				
FOLIC ACID				
BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
FOLVITE				
+ WYETH PHARMS INC	5MG/ML **	N005897	008	
TABLET;ORAL				
FOLIC ACID				
BARR	1MG	A089177	001	Jan 08, 1986
CONTRACT PHARMACAL	1MG	A085061	001	
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
HIKMA PHARMS	1MG	A080600	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG **	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PH HEALTH	1MG	A040756	001	Jun 04, 2010
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOLIC ACID				
TABLET;ORAL				
FOLVITE				
	WYETH PHARMS INC	1MG **	N005897 004	
FOMEPIZOLE				
INJECTABLE;INJECTION				
ANTIZOL				
+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML) **	N020696 001	Dec 04, 1997
FOMEPIZOLE				
	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033 001	Apr 07, 2009
FOMIVIRSEN SODIUM				
INJECTABLE;INJECTION				
VITRAVENE PRESERVATIVE FREE				
	NOVARTIS	6.6MG/ML	N020961 001	Aug 26, 1998
FONDAPARINUX SODIUM				
INJECTABLE;SUBCUTANEOUS				
FONDAPARINUX SODIUM				
	BRIGHTGENE	2.5MG/0.5ML	A218312 001	Dec 18, 2024
	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493 001	Aug 19, 2024
		5MG/0.4ML	A216493 002	Aug 19, 2024
		7.5MG/0.6ML	A216493 003	Aug 19, 2024
		10MG/0.8ML	A216493 004	Aug 19, 2024
FORMOTEROL FUMARATE				
POWDER;INHALATION				
FORADIL				
+	NOVARTIS	0.012MG/INH **	N020831 001	Feb 16, 2001
FORADIL CERTIHALER				
	NOVARTIS	0.0085MG/INH	N021592 001	Dec 15, 2006
FOSAMPRENAVIR CALCIUM				
SUSPENSION;ORAL				
LEXIVA				
+	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116 001	Jun 14, 2007
TABLET;ORAL				
LEXIVA				
+	VIIV HLTHCARE	EQ 700MG BASE **	N021548 001	Oct 20, 2003
FOSAPREPITANT DIMEGLUMINE				
POWDER;INTRAVENOUS				
EMEND				
+	MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023 001	Jan 25, 2008
FOSAPREPITANT DIMEGLUMINE				
	ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025 001	Aug 26, 2020
	APOTEX	EQ 150MG BASE/VIAL	A205020 001	Sep 05, 2019
	GENEYORK PHARMS	EQ 150MG BASE/VIAL	A211624 001	Sep 05, 2019
	LUPIN LTD	EQ 150MG BASE/VIAL	A210689 001	Sep 05, 2019
	MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015 001	Sep 05, 2019
	NAVINTA LLC	EQ 150MG BASE/VIAL	A212957 002	Aug 20, 2020
	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683 001	May 16, 2023
	PRAXGEN	EQ 150MG BASE/VIAL	A213199 001	Oct 04, 2021
	SANDOZ	EQ 150MG BASE/VIAL	A203939 001	Dec 08, 2020
FOSCARNET SODIUM				
SOLUTION;INTRAVENOUS				
FOSCARNET SODIUM				
	HOSPIRA	6GM/250ML (24MG/ML)	A077174 001	May 31, 2005
		12GM/500ML (24MG/ML)	A077174 002	May 31, 2005
FOSCAVIR				
+	CLINIGEN HLTHCARE	12GM/500ML (24MG/ML)	N020068 002	Sep 27, 1991
FOSFOMYCIN TROMETHAMINE				
FOR SOLUTION;ORAL				
MONUROL				
+	ZAMBON SPA	EQ 3GM BASE/PACKET **	N050717 001	Dec 19, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOSINOPRIL SODIUM

TABLET;ORAL					
FOSINOPRIL SODIUM					
	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
		20MG	A076620	002	Oct 15, 2004
		40MG	A076620	003	Oct 15, 2004
	APOTEX	10MG	A076906	001	May 17, 2005
		20MG	A076906	002	May 17, 2005
		40MG	A076906	003	May 17, 2005
	RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
		20MG	A076580	002	Apr 23, 2004
		40MG	A076580	003	Apr 23, 2004
	UPSHER SMITH LABS	10MG	A076188	001	Oct 08, 2004
		20MG	A076188	002	Oct 08, 2004
		40MG	A076188	003	Oct 08, 2004
	WATSON LABS	10MG	A076987	001	Dec 23, 2004
		10MG	A077531	001	Aug 31, 2006
		20MG	A076987	002	Dec 23, 2004
		20MG	A077531	002	Aug 31, 2006
		40MG	A076987	003	Dec 23, 2004
		40MG	A077531	003	Aug 31, 2006
MONOPRIL					
+	BRISTOL MYERS SQUIBB	10MG **	N019915	002	May 16, 1991
+		20MG **	N019915	003	May 16, 1991
+		40MG **	N019915	004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE					
	ANI PHARMS	10MG;12.5MG	A076608	001	Dec 03, 2004
		10MG;12.5MG	A077144	001	Aug 16, 2005
		20MG;12.5MG	A076608	002	Dec 03, 2004
		20MG;12.5MG	A077144	002	Aug 16, 2005
	CHARTWELL RX	10MG;12.5MG	A079025	001	Sep 17, 2010
		20MG;12.5MG	A079025	002	Sep 17, 2010
	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006
		20MG;12.5MG	A077705	002	Aug 14, 2006
	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004
		20MG;12.5MG	A076739	002	Dec 17, 2004
	TEVA	10MG;12.5MG	A076945	001	Jul 05, 2006
		20MG;12.5MG	A076945	002	Jul 05, 2006
MONOPRIL-HCT					
+	BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286	002	Nov 30, 1994
+		20MG;12.5MG **	N020286	001	Nov 30, 1994

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS					
AKYNZEO					
+	HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION					
FOSPHENYTOIN SODIUM					
	AM REGENT	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007
		EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010
	AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008
	APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
	DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007
	HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007
	PHARMOBEDIENT	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010
SOLUTION;INTRAVENOUS					
SESQUIENT					
+	LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020
+		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOSPROPOFOL DISODIUM				
SOLUTION;INTRAVENOUS				
LUSEDRA				
EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008
FROVATRIPTAN SUCCINATE				
TABLET;ORAL				
FROVATRIPTAN SUCCINATE				
PHARMOBEDIENT	EQ 2.5MG BASE	A202931	001	Aug 28, 2014
FULVESTRANT				
SOLUTION;INTRAMUSCULAR				
FASLODEX				
+ ASTRAZENECA	125MG/2.5ML (50MG/ML)	N021344	002	Apr 25, 2002
FULVESTRANT				
APOTEX	250MG/5ML (50MG/ML)	A211730	001	Jun 11, 2021
AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019
EUGIA PHARMA	250MG/5ML (50MG/ML)	A208811	001	Jul 23, 2019
FURAZOLIDONE				
SUSPENSION;ORAL				
FUROXONE				
SHIRE	50MG/15ML	N011323	002	
TABLET;ORAL				
FUROXONE				
SHIRE	100MG	N011270	002	
FUROSEMIDE				
INJECTABLE;INJECTION				
FUROSEMIDE				
ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
+ AM REGENT	10MG/ML **	N018579	001	Nov 30, 1983
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
HIKMA	10MG/ML	A071439	001	Sep 14, 1990
HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
	10MG/ML	A074337	001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025	001	
MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986
	10MG/ML	A070078	001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420	001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
	10MG/ML	A070604	001	Jan 02, 1987
WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982
LASIX				
+ SANOFI AVENTIS US	10MG/ML **	N016363	001	
SOLUTION;ORAL				
FUROSEMIDE				
PHARMOBEDIENT CNSLTG	10MG/ML	A070655	001	Oct 02, 1987
LASIX				
+ SANOFI AVENTIS US	10MG/ML	N017688	001	
TABLET;ORAL				
FUROSEMIDE				
ANI PHARMS	20MG	A071379	001	Jan 02, 1987
	40MG	A070413	001	Feb 26, 1986
	80MG	A071594	001	Feb 09, 1988
CHARTWELL RX	20MG	N018413	001	Nov 30, 1983
	40MG	N018413	002	Nov 30, 1983
EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984
INTL MEDICATION	20MG	N018753	001	Feb 28, 1984
	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983
	40MG	N018868	002	Jun 28, 1983
PHARMOBEDIENT	20MG	N018487	001	
	40MG	N018487	002	
	80MG	A070082	001	Oct 29, 1986
SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FUROSEMIDE					
TABLET;ORAL					
FUROSEMIDE					
		40MG	A091258	002	Apr 01, 2014
		40MG	N018790	001	Nov 29, 1983
		80MG	A091258	003	Apr 01, 2014
	SUN PHARM INDUSTRIES	20MG	A070043	001	Sep 26, 1985
		80MG	A070100	001	Jan 26, 1988
	SUPERPHARM	20MG	N018370	002	Jun 26, 1984
		40MG	N018370	001	Feb 10, 1983
	WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
		40MG	N018419	002	Jan 31, 1983
		80MG	N018419	003	Nov 13, 1984
	WATSON LABS	20MG	A070412	001	Feb 26, 1986
		20MG	N018369	001	May 14, 1982
		40MG	A070450	001	Nov 22, 1985
		40MG	N018369	002	May 14, 1982
	WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985
		80MG	A070528	001	Jan 07, 1986
LASIX					
+	VALIDUS PHARMS	20MG	N016273	002	
+		40MG	N016273	001	
+		80MG	N016273	003	
GABAPENTIN					
CAPSULE;ORAL					
GABAPENTIN					
	CHARTWELL RX	100MG	A091008	001	Oct 26, 2017
		300MG	A091008	002	Oct 26, 2017
		400MG	A091008	003	Oct 26, 2017
	HIKMA	100MG	A078150	001	Sep 25, 2007
		300MG	A078150	002	Sep 25, 2007
		400MG	A078150	003	Sep 25, 2007
	IPCA LABS LTD	100MG	A208928	001	Nov 20, 2023
		300MG	A208928	002	Nov 20, 2023
		400MG	A208928	003	Nov 20, 2023
	PHARMOBEDIENT	100MG	A090158	001	Feb 14, 2011
		300MG	A090158	002	Feb 14, 2011
		400MG	A090158	003	Feb 14, 2011
	SANDOZ	100MG	A075428	001	Jan 24, 2006
		100MG	A075539	001	Apr 06, 2005
		300MG	A075428	002	Jan 24, 2006
		300MG	A075539	002	Apr 06, 2005
		400MG	A075428	003	Jan 24, 2006
		400MG	A075539	003	Apr 06, 2005
	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005
		100MG	A077242	001	Aug 24, 2006
		300MG	A076606	002	Oct 07, 2005
		300MG	A077242	002	Aug 24, 2006
		400MG	A076606	003	Oct 07, 2005
		400MG	A077242	003	Aug 24, 2006
	SUN PHARM INDUSTRIES	100MG	A076537	001	Jun 30, 2005
		300MG	A076537	002	Jun 30, 2005
		400MG	A076537	003	Jun 30, 2005
	TARO	100MG	A077261	001	Aug 02, 2013
		300MG	A077261	002	Aug 02, 2013
		400MG	A077261	003	Aug 02, 2013
	TEVA PHARMS	100MG	A075435	001	Oct 08, 2004
		300MG	A075435	002	Oct 08, 2004
		400MG	A075435	003	Oct 08, 2004
	WATSON LABS	100MG	A075485	003	May 11, 2007
		300MG	A075485	002	May 11, 2007
		400MG	A075485	001	May 11, 2007
SOLUTION;ORAL					
GABAPENTIN					
	TARO	250MG/5ML	A076672	001	Jul 03, 2013
TABLET;ORAL					
GABAPENTIN					
	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004
		800MG	A075694	002	Oct 21, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GABAPENTIN

TABLET;ORAL

GABAPENTIN

APOTEX	100MG	A077894	001	Oct 10, 2006
	300MG	A077894	002	Oct 10, 2006
	400MG	A077894	003	Oct 10, 2006
CHARTWELL RX	600MG	A076120	001	Jan 27, 2006
	800MG	A076120	002	Jan 27, 2006
HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011
	800MG	A078782	002	Jul 21, 2011
INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012
	800MG	A202764	002	Oct 16, 2012
IPCA LABS LTD	600MG	A209855	001	May 29, 2024
	800MG	A209855	002	May 29, 2024
IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005
	800MG	A076017	005	Apr 29, 2005
LUPIN LTD	600MG	A209306	001	Aug 24, 2018
	800MG	A209306	002	Aug 24, 2018
PHARMOBEDIENT	600MG	A090335	001	Jun 01, 2010
	800MG	A090335	002	Jun 01, 2010
RANBAXY	600MG	A076605	001	Sep 14, 2005
	800MG	A076605	002	Sep 14, 2005
SENORES PHARMS	600MG	A076877	001	Jul 06, 2006
	800MG	A076877	002	Jul 06, 2006
SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006
	800MG	A077525	002	Aug 24, 2006
TEVA	600MG	A075827	001	Dec 15, 2004
	800MG	A075827	002	Dec 15, 2004
TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017
	800MG	A205807	002	Mar 10, 2017

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

+ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007
+	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION;INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE;INJECTION

MAGNEVIST

+ BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+	469.01MG/ML	N021037	001	Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

GADOTERATE MEGLUMINE

HENGRUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022
	3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022
	5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022
	7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022
	37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+	9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GALANTAMINE HYDROBROMIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
GALANTAMINE HYDROBROMIDE					
	IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009
		EQ 16MG BASE	A078484	002	May 27, 2009
		EQ 24MG BASE	A078484	003	May 27, 2009
	PHARMOBEDIENT	EQ 8MG BASE	A090900	001	Jan 24, 2011
		EQ 16MG BASE	A090900	002	Jan 24, 2011
		EQ 24MG BASE	A090900	003	Jan 24, 2011
RAZADYNE ER					
+	JANSSEN PHARMS	EQ 8MG BASE **	N021615	001	Apr 01, 2005
+		EQ 16MG BASE **	N021615	002	Apr 01, 2005
+		EQ 24MG BASE **	N021615	003	Apr 01, 2005
SOLUTION;ORAL					
RAZADYNE					
	JANSSEN PHARMS	4MG/ML **	N021224	001	Jun 22, 2001
TABLET;ORAL					
GALANTAMINE HYDROBROMIDE					
	APOTEX INC	EQ 4MG BASE	A077781	001	Sep 27, 2011
		EQ 8MG BASE	A077781	002	Sep 27, 2011
		EQ 12MG BASE	A077781	003	Sep 27, 2011
	CHARTWELL RX	EQ 4MG BASE	A077587	001	Jul 09, 2009
		EQ 8MG BASE	A077587	002	Jul 09, 2009
		EQ 12MG BASE	A077587	003	Jul 09, 2009
	HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009
		EQ 8MG BASE	A077585	002	Sep 15, 2009
		EQ 12MG BASE	A077585	003	Sep 15, 2009
	HIKMA	EQ 4MG BASE	A077608	001	Feb 11, 2009
		EQ 8MG BASE	A077608	002	Feb 11, 2009
		EQ 12MG BASE	A077608	003	Feb 11, 2009
	MYLAN	EQ 4MG BASE	A077590	001	May 29, 2009
		EQ 8MG BASE	A077590	002	May 29, 2009
		EQ 12MG BASE	A077590	003	May 29, 2009
	PHARMOBEDIENT	EQ 4MG BASE	A077603	001	Aug 28, 2008
		EQ 8MG BASE	A077603	002	Aug 28, 2008
		EQ 12MG BASE	A077603	003	Aug 28, 2008
RAZADYNE					
+	JANSSEN PHARMS	EQ 4MG BASE **	N021169	001	Feb 28, 2001
+		EQ 8MG BASE **	N021169	002	Feb 28, 2001
+		EQ 12MG BASE **	N021169	003	Feb 28, 2001
GALLAMINE TRIETHIODIDE					
INJECTABLE;INJECTION					
FLAXEDIL					
	DAVIS AND GECK	20MG/ML	N007842	001	
		100MG/ML	N007842	002	
GALLIUM CITRATE GA-67					
INJECTABLE;INJECTION					
GALLIUM CITRATE GA 67					
	GE HEALTHCARE	1mCi/ML	N017700	001	
	LANTHEUS MEDCL	2mCi/ML	N017478	001	
NEOSCAN					
	GE HEALTHCARE	2mCi/ML	N017655	001	
GALLIUM NITRATE					
INJECTABLE;INJECTION					
GANITE					
	CHAPTER 7 TRUSTEE	25MG/ML **	N019961	002	Jan 17, 1991
GANCICLOVIR					
CAPSULE;ORAL					
CYTOVENE					
+	ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+		500MG **	N020460	002	Dec 12, 1997
GANCICLOVIR					
	RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
		500MG	A076457	002	Jun 27, 2003
IMPLANT;IMPLANTATION					
VITRASERT					
	BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GANCICLOVIR				
SOLUTION;INTRAVENOUS				
GANZYK-RTU				
+ EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017
GANCICLOVIR SODIUM				
INJECTABLE;INJECTION				
CYTOVENE				
+ CHEPLAPHARM	EQ 500MG BASE/VIAL **	N019661	001	Jun 23, 1989
GANCICLOVIR SODIUM				
AM REGENT	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013
CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019
ONESOURCE SPECIALTY	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017
GATIFLOXACIN				
SOLUTION/DROPS;OPHTHALMIC				
GATIFLOXACIN				
APOTEX INC	0.3%	A079084	001	Aug 19, 2011
HIKMA	0.5%	A203189	001	Sep 03, 2014
LUPIN LTD	0.5%	A202653	001	Aug 28, 2013
RISING	0.5%	A206446	001	Jun 08, 2018
ZYMAR				
+ ALLERGAN	0.3% **	N021493	001	Mar 28, 2003
GEFITINIB				
TABLET;ORAL				
IRESSA				
ASTRAZENECA	250MG	N021399	001	May 05, 2003
GEMCITABINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
GEMCITABINE HYDROCHLORIDE				
ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011
ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016
	1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016
	2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016
ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016
AM REGENT	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013
	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013
APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017
	1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017
	2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017
EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063	001	Sep 11, 2012
	EQ 1GM BASE/VIAL	A202063	002	Sep 11, 2012
HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012
	EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012
HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021
	EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021
PHARMOBEDIENT	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011
SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011
	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011
GEMZAR				
+ LILLY	EQ 200MG BASE/VIAL **	N020509	001	May 15, 1996
+	EQ 1GM BASE/VIAL **	N020509	002	May 15, 1996
SOLUTION;INTRAVENOUS				
AVGEMSI				
+ AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025
INFUGEM				
+ SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+	EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+	EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+	EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+	EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GEMCITABINE HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
INFUGEM				
+	EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+	EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+	EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+	EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+	EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018
GEMFIBROZIL				
CAPSULE;ORAL				
GEMFIBROZIL				
NATCO	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID				
PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	
TABLET;ORAL				
GEMFIBROZIL				
APOTEX	600MG	A075034	001	Jul 20, 1998
CADILA	600MG	A204189	001	Aug 28, 2018
CHARTWELL RX	600MG	A074615	001	Sep 29, 1995
HIKMA PHARMS	600MG	A078599	001	Aug 16, 2010
PHARMOBEDIENT	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
TEVA	600MG	A074256	001	Oct 31, 1993
WATSON LABS	600MG	A074156	001	Oct 24, 1994
	600MG	A074442	001	Apr 28, 1995
GEMIFLOXACIN MESYLATE				
TABLET;ORAL				
FACTIVE				
+ LG CHEM LTD	EQ 320MG BASE **	N021158	001	Apr 04, 2003
GEMIFLOXACIN MESYLATE				
ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015
GENTAMICIN SULFATE				
CREAM;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060462	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
SUN PHARMA CANADA	EQ 0.1% BASE	A062427	001	May 26, 1983
INJECTABLE;INJECTION				
APOGEN				
KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	
BRISTAGEN				
BRISTOL	EQ 40MG BASE/ML	A062288	001	
GARAMYCIN				
SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	
GENTAFAIR				
PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
GENTAMICIN				
INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982
GENTAMICIN SULFATE				
ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE

INJECTABLE;INJECTION				
GENTAMICIN SULFATE				
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
EUGIA PHARMA	EQ 10MG BASE/ML	A215236	001	Jan 08, 2024
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983
	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE;INTRATHECAL				
GARAMYCIN				
+ SCHERING	EQ 2MG BASE/ML **	N050505	001	
OINTMENT;OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE				
OINTMENT;OPHTHALMIC				
GENTACIDIN				
	NOVARTIS	EQ 0.3% BASE	A062501 001	Jul 26, 1984
GENTAFAIR				
	PHARMAFAIR	EQ 3MG BASE/GM	A062443 001	May 26, 1983
GENTAMICIN SULFATE				
	SCIEGEN PHARMS	EQ 0.3% BASE	A064093 001	Aug 31, 1995
OINTMENT;TOPICAL				
GARAMYCIN				
	SCHERING	EQ 0.1% BASE **	A060463 001	
GENTAFAIR				
	PHARMAFAIR	EQ 0.1% BASE	A062444 001	May 26, 1983
GENTAMICIN SULFATE				
	ALPHARMA US PHARMS	EQ 0.1% BASE	A062496 001	Mar 14, 1984
	ENCUBE	EQ 0.1% BASE	A209233 001	Dec 31, 2018
	PHARMADERM	EQ 0.1% BASE	A062534 001	Oct 10, 1984
	SUN PHARMA CANADA	EQ 0.1% BASE	A062477 001	Dec 23, 1983
SOLUTION/DROPS;OPHTHALMIC				
GARAMYCIN				
+	SCHERING	EQ 0.3% BASE **	N050039 002	
GENOPTIC				
	ALLERGAN	EQ 0.3% BASE	A062452 001	Oct 10, 1984
GENTACIDIN				
	NOVARTIS	EQ 0.3% BASE	A062480 001	Mar 30, 1984
GENTAFAIR				
	PHARMAFAIR	EQ 0.3% BASE	A062440 001	May 03, 1983
GENTAK				
	PHARMOBEDIENT	EQ 0.3% BASE	A064163 001	Oct 12, 2001
GENTAMICIN SULFATE				
	ALCON PHARMS LTD	EQ 0.3% BASE	A062523 001	Nov 25, 1985
	EPIC PHARMA LLC	EQ 0.3% BASE	A062635 001	Jan 08, 1987
	PACO	EQ 3MG BASE/ML	A062932 001	Nov 07, 1988
GENTAMICIN SULFATE; PREDNISOLONE ACETATE				
OINTMENT;OPHTHALMIC				
PRED-G				
+	ALLERGAN	EQ 0.3% BASE;0.6%	N050612 001	Dec 01, 1989
SUSPENSION/DROPS;OPHTHALMIC				
PRED-G				
+	ALLERGAN	EQ 0.3% BASE;1%	N050586 001	Jun 10, 1988
GENTIAN VIOLET				
SUPPOSITORY;VAGINAL				
GVS				
	SAVAGE LABS	0.4%	A083513 001	
TAMPON;VAGINAL				
GENAPAX				
	KEY PHARMS	5MG	A085017 001	
GLATIRAMER ACETATE				
FOR SOLUTION;SUBCUTANEOUS				
COPAXONE				
+	TEVA PHARMS USA	20MG/VIAL	N020622 001	Dec 20, 1996
GLIMEPIRIDE				
TABLET;ORAL				
AMARYL				
+	SANOFI AVENTIS US	1MG **	N020496 001	Nov 30, 1995
+		2MG **	N020496 002	Nov 30, 1995
+		4MG **	N020496 003	Nov 30, 1995
GLIMEPIRIDE				
	ACTAVIS LABS FL INC	1MG	A076995 001	Apr 27, 2010
		2MG	A076995 002	Apr 27, 2010
		4MG	A076995 003	Apr 27, 2010
	EPIC PHARMA LLC	1MG	A077274 001	Oct 06, 2005
		2MG	A077274 002	Oct 06, 2005
		4MG	A077274 003	Oct 06, 2005
	HIKMA PHARMS	1MG	A078952 001	Aug 01, 2013
		2MG	A078952 002	Aug 01, 2013
		4MG	A078952 003	Aug 01, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLIMEPIRIDE

TABLET;ORAL				
GLIMEPIRIDE				
	MYLAN	1MG	A077486 001	Feb 10, 2006
		2MG	A077486 002	Feb 10, 2006
		4MG	A077486 003	Feb 10, 2006
	QUAGEN	1MG	A077624 001	Nov 28, 2005
		2MG	A077624 002	Nov 28, 2005
		4MG	A077624 003	Nov 28, 2005
	RANBAXY	3MG	A077366 001	Oct 06, 2005
		6MG	A077366 002	Oct 06, 2005
	RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005
		2MG	A076875 002	Oct 06, 2005
		4MG	A076875 003	Oct 06, 2005
		8MG	A076875 004	Oct 06, 2005
	SENORES PHARMS	1MG	A076802 001	Oct 06, 2005
		2MG	A076802 002	Oct 06, 2005
		4MG	A076802 003	Oct 06, 2005
	WATSON LABS	1MG	A077280 001	Feb 03, 2006
		2MG	A077280 002	Feb 03, 2006
		4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL				
AVANDARYL				
+	SB PHARMCO	1MG;4MG **	N021700 001	Nov 23, 2005
+		2MG;4MG **	N021700 002	Nov 23, 2005
+		2MG;8MG **	N021700 004	Mar 30, 2007
+		4MG;4MG **	N021700 003	Nov 23, 2005
+		4MG;8MG **	N021700 005	Mar 30, 2007
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE				
	TEVA PHARMS USA	1MG;4MG	A078709 001	Apr 01, 2016
		2MG;4MG	A078709 002	Apr 01, 2016
		2MG;8MG	A078709 004	Apr 01, 2016
		4MG;4MG	A078709 003	Apr 01, 2016
		4MG;8MG	A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL				
GLIPIZIDE				
	ACCORD HLTHCARE	5MG	A074550 001	Sep 11, 1997
		10MG	A074550 002	Sep 11, 1997
	AIPING PHARM INC	5MG	A074305 001	Apr 07, 1995
		10MG	A074305 002	Apr 07, 1995
	ANI PHARMS	5MG	A074387 001	Mar 04, 1996
		10MG	A074387 002	Mar 04, 1996
	BARR LABS INC	5MG	A074619 001	Apr 04, 1997
		10MG	A074619 002	Apr 04, 1997
	CHARTWELL RX	5MG	A074542 001	Jun 20, 1995
		10MG	A074542 002	Jun 20, 1995
	PHARMOBEDIENT	5MG	A074438 001	Jun 20, 1995
		10MG	A074438 002	Jun 20, 1995
	SUN PHARM INDS INC	5MG	A077820 001	Jul 11, 2006
		10MG	A077820 002	Jul 11, 2006
	WATSON LABS	5MG	A074370 001	Nov 22, 1994
		10MG	A074370 002	Nov 22, 1994
GLUCOTROL				
+	PFIZER	2.5MG **	N017783 003	May 11, 1993
+		5MG **	N017783 001	May 08, 1984
+		10MG **	N017783 002	May 08, 1984
TABLET, EXTENDED RELEASE;ORAL				
GLIPIZIDE				
	PH HEALTH	5MG	A076159 002	Sep 20, 2013
		10MG	A076159 001	Sep 20, 2013
	PHARMOBEDIENT	2.5MG	A202298 001	May 19, 2015
		5MG	A202298 002	May 19, 2015
		10MG	A202298 003	May 19, 2015
GLUCOTROL XL				
+	PFIZER	2.5MG	N020329 003	Aug 10, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

NOVITIUM PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007
	2.5MG;500MG	A078083	002	Apr 12, 2007
	5MG;500MG	A078083	003	Apr 12, 2007
SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008
	2.5MG;500MG	A077620	002	Jan 11, 2008
	5MG;500MG	A077620	003	Jan 11, 2008

METAGLIP

+ BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460	001	Oct 21, 2002
+	2.5MG;500MG **	N021460	002	Oct 21, 2002
+	5MG;500MG **	N021460	003	Oct 21, 2002

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

+ LILLY	1MG/VIAL **	N020928	001	Sep 11, 1998

SOLUTION;SUBCUTANEOUS

GVOKE PFS

+ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGON

+ LILLY	EQ 1MG BASE/VIAL **	N012122	001	
+	EQ 10MG BASE/VIAL **	N012122	002	

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGEN

+ NOVO NORDISK	EQ 1MG BASE/VIAL **	N020918	001	Jun 22, 1998

POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

GLUCAGEN

+ NOVO NORDISK	EQ 1MG BASE/VIAL **	N020918	002	Jun 22, 1998

GLUTETHIMIDE

CAPSULE;ORAL

DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	

TABLET;ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
UCB INC	500MG	A085171	001	
UPSHER SMITH LABS	500MG	A083234	002	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDE

TABLET;ORAL

GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002
AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007
	2.5MG	A077537	002	Oct 18, 2007
	5MG	A077537	003	Oct 18, 2007
CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016
	2.5MG	A203581	002	Apr 14, 2016
	5MG	A203581	003	Apr 14, 2016

GLYBURIDE (MICRONIZED)

CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
HIKMA	1.5MG	A075890	001	Jul 31, 2003
	3MG	A075890	002	Jul 31, 2003
	6MG	A075890	003	Jul 31, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLYBURIDE

TABLET;ORAL				
GLYBURIDE (MICRONIZED)				
	NATCO PHARMA	1.5MG	A074792 001	Jun 26, 1998
		3MG	A074792 002	Jun 26, 1998
		6MG	A074792 003	Aug 17, 1999
	SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
		3MG	N020055 002	Apr 17, 1992
		6MG	N020055 003	Mar 08, 2000
	STRIDES PHARMA INTL	1.5MG	A074591 001	Dec 22, 1997
		3MG	A074591 002	Dec 22, 1997
		4.5MG	A074591 003	Dec 22, 1997
		6MG	A074591 004	Dec 22, 1997
GLYNASE				
+	PFIZER	1.5MG	N020051 001	Mar 04, 1992
+		3MG	N020051 002	Mar 04, 1992
+		4.5MG **	N020051 003	Sep 24, 1993
+		6MG	N020051 004	Sep 24, 1993
MICRONASE				
+	PFIZER	1.25MG **	N017498 001	May 01, 1984
		2.5MG	N017498 002	May 01, 1984
+		5MG **	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL				
GLUCOVANCE				
+	BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178 001	Jul 31, 2000
+		2.5MG;500MG **	N021178 002	Jul 31, 2000
+		5MG;500MG **	N021178 003	Jul 31, 2000
GLYBURIDE AND METFORMIN HYDROCHLORIDE				
	IMPAX LABS INC	1.25MG;250MG	A076731 001	Nov 19, 2004
		2.5MG;500MG	A076731 002	Nov 19, 2004
		5MG;500MG	A076731 003	Nov 19, 2004
	TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005
		2.5MG;500MG	A076821 002	Jan 27, 2005
		5MG;500MG	A076821 003	Jan 27, 2005

GLYCINE

SOLUTION;IRRIGATION				
GLYCINE 1.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
	HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

INJECTABLE;INJECTION				
GLYCOPYRROLATE				
	ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
	APOTEX	0.2MG/ML	A210246 001	Oct 29, 2019
	EUGIA PHARMA	0.2MG/ML	A210244 001	Nov 28, 2018
	HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
	LUPIN LTD	0.2MG/ML	A213655 001	Feb 07, 2023
	MANKIND PHARMA	0.2MG/ML	A217354 001	Feb 27, 2023
	TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
	WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983
	XIROMED	0.2MG/ML	A212227 001	Mar 04, 2021
	ZYDUS PHARMS	0.2MG/ML	A214213 001	Nov 09, 2021
ROBINUL				
	ROBINS AH	0.2MG/ML	N014764 001	
POWDER;INHALATION				
SEEBRI NEOHALER				
+	NOVARTIS	15.6MCG/INH	N207923 001	Oct 29, 2015
SOLUTION;INHALATION				
LONHALA MAGNAIR KIT				
+	SUMITOMO PHARMA AM	25MCG/ML	N208437 001	Dec 05, 2017
SOLUTION;INTRAMUSCULAR, INTRAVENOUS				
GLYRX-PF				
+	EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997 001	Jul 11, 2018
+		0.6MG/3ML (0.2MG/ML)	N210997 004	Dec 14, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLYCOPYRROLATE				
TABLET;ORAL				
GLYCOPYRROLATE				
CHARTWELL RX	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	
TABLET, ORALLY DISINTEGRATING;ORAL				
DARTISLA ODT				
EDENBRIDGE PHARMS	0.85MG	N215019	002	Oct 11, 2023
+	1.7MG	N215019	001	Dec 16, 2021
GLYCOPYRROLATE; INDACATEROL MALEATE				
POWDER;INHALATION				
UTIBRON NEOHALER				
+ NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015
GONADORELIN ACETATE				
INJECTABLE;INJECTION				
LUTREPULSE KIT				
FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989
GONADORELIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
FACTREL				
HIKMA	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
SOLUTION/DROPS;OPHTHALMIC				
NEO-POLYCIN				
DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788	001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383	001	Aug 31, 1982
GRANISETRON HYDROCHLORIDE				
INJECTABLE;INJECTION				
GRANISETRON HYDROCHLORIDE				
AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010
BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
EPIC PHARMA LLC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009
EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016
PHARMOBEDIENT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017
SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008
WOCKHARDT USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078566	001	Feb 29, 2008
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078565	001	Jun 30, 2008
YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION				
KYTRIL				
+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239 003	Sep 17, 2004
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239 004	Mar 11, 1994
+		EQ 3MG BASE/ML **	N020239 001	Dec 29, 1993
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239 002	Mar 11, 1994
SOLUTION;ORAL				
GRANISOL				
	INTRA SANA LABS	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
KYTRIL				
+	ROCHE	EQ 2MG BASE/10ML **	N021238 001	Jun 27, 2001
TABLET;ORAL				
GRANISETRON HYDROCHLORIDE				
	APOTEX INC	EQ 1MG BASE	A078843 001	Feb 27, 2008
	AUROBINDO PHARMA USA	EQ 1MG BASE	A078725 001	Jan 30, 2008
	BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
	EPIC PHARMA LLC	EQ 1MG BASE	A078260 001	Dec 31, 2007
	HIKMA	EQ 1MG BASE	A077842 001	Dec 31, 2007
	TARO	EQ 1MG BASE	A090817 001	May 28, 2010
	TEVA PHARMS	EQ 1MG BASE	A078080 001	Dec 31, 2007
KYTRIL				
+	ROCHE	EQ 1MG BASE **	N020305 001	Mar 16, 1995
+		EQ 2MG BASE **	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
RAXAR				
	OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
		EQ 400MG BASE	N020695 002	May 14, 1998
		EQ 600MG BASE	N020695 003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL				
GRISACTIN				
	WYETH AYERST	125MG	N050051 002	
		250MG	N050051 001	
SUSPENSION;ORAL				
GRIFULVIN V				
+	JOHNSON AND JOHNSON	125MG/5ML **	N050448 001	
TABLET;ORAL				
GRIFULVIN V				
	J AND J	125MG	A060618 001	
		250MG	A060618 002	
		500MG	A060618 003	
	VALEANT LUXEMBOURG	125MG	A062279 001	
		250MG **	A062279 002	
GRISACTIN				
	WYETH AYERST	500MG	A060212 001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL				
GRIFULVIN V				
	VALEANT LUXEMBOURG	125MG/5ML **	A062483 001	Jan 26, 1984
TABLET;ORAL				
GRIFULVIN V				
	VALEANT LUXEMBOURG	500MG	A062279 003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
GRISACTIN ULTRA				
	WYETH AYERST	125MG	A062178 001	
		165MG	A062438 001	Nov 17, 1983
		250MG	A062178 002	
		330MG	A062438 002	Nov 17, 1983
ULTRAGRIS-165				
	PLIVA	165MG	A062645 001	Jun 30, 1992
ULTRAGRIS-330				
	PLIVA	330MG	A062646 001	Jun 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

CHARTWELL RX	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015

OBREDON

+ SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014

TABLET;ORAL

XTRELUS

+ ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+ CHARTWELL RX	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

GRANULES	600MG;60MG	A216082	001	Aug 22, 2022
	1.2GM;120MG	A216082	002	Aug 22, 2022

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074149	002	Apr 07, 1995
	EQ 8MG BASE	A074267	002	Jun 01, 1994
CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994

WYTENSIN

WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985

ISMELIN

NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ESIMIL

NOVARTIS	10MG;25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
	EQ 2MG BASE	A074762	002	Jun 25, 1997

TENEX

+ PROMIUS PHARMA	EQ 1MG BASE **	N019032	001	Oct 27, 1986
+	EQ 2MG BASE **	N019032	002	Nov 07, 1988
	EQ 3MG BASE **	N019032	003	Nov 07, 1988

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015
	EQ 2MG BASE	A202238	002	Oct 20, 2015
	EQ 3MG BASE	A202238	003	Oct 20, 2015
	EQ 4MG BASE	A202238	004	Oct 20, 2015
PHARMOBEDIENT	EQ 1MG BASE	A202578	001	Jun 02, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GUANFACINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
	EQ 2MG BASE	A202578	002	Jun 02, 2015
	EQ 3MG BASE	A202578	003	Jun 02, 2015
	EQ 4MG BASE	A202578	004	Jun 02, 2015
SUN PHARM	EQ 1MG BASE	A205689	001	Nov 16, 2017
	EQ 2MG BASE	A205689	002	Nov 16, 2017
	EQ 3MG BASE	A205689	003	Nov 16, 2017
	EQ 4MG BASE	A205689	004	Nov 16, 2017
GUANIDINE HYDROCHLORIDE				
TABLET;ORAL				
GUANIDINE HYDROCHLORIDE				
MERCK SHARP DOHME	125MG	N001546	001	
HALAZEPAM				
TABLET;ORAL				
PAXIPAM				
SCHERING	20MG	N017736	003	
	40MG	N017736	004	
HALCINONIDE				
CREAM;TOPICAL				
HALOG				
+ WESTWOOD SQUIBB	0.025%	N017818	001	
HALOG-E				
SUN PHARM INDS INC	0.1%	N018234	001	
OINTMENT;TOPICAL				
HALOG				
+ BRISTOL MYERS SQUIBB	0.025%	N018125	001	
+ SUN PHARM INDS INC	0.1%	N017824	001	
HALOBETASOL PROPIONATE				
CREAM;TOPICAL				
HALOBETASOL PROPIONATE				
SUN PHARMA CANADA	0.05%	A077227	001	Aug 04, 2005
ULTRAVATE				
+ SUN PHARM INDS INC	0.05% **	N019967	001	Dec 27, 1990
LOTION;TOPICAL				
HALOBETASOL PROPIONATE				
PADAGIS ISRAEL	0.05%	A211464	001	Jun 03, 2020
OINTMENT;TOPICAL				
HALOBETASOL PROPIONATE				
COSETTE	0.05%	A077721	001	Sep 07, 2006
ENCUBE	0.05%	A209978	001	Mar 20, 2018
FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004
SUN PHARMA CANADA	0.05%	A076994	001	Dec 16, 2004
ULTRAVATE				
+ SUN PHARM INDS INC	0.05% **	N019968	001	Dec 17, 1990
HALOFANTRINE HYDROCHLORIDE				
TABLET;ORAL				
HALFAN				
GLAXOSMITHKLINE	250MG	N020250	001	Jul 24, 1992
HALOPERIDOL				
TABLET;ORAL				
HALDOL				
+ ORTHO MCNEIL	0.5MG **	N015921	001	
+	1MG **	N015921	002	
+	2MG **	N015921	003	
+	5MG **	N015921	004	
+	10MG **	N015921	005	
+	20MG **	N015921	006	Feb 02, 1982
HALDOL SOLUTAB				
ORTHO MCNEIL PHARM	1MG	N017079	001	
HALOPERIDOL				
ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022
	1MG	A200854	002	Jul 01, 2022
	2MG	A200854	003	Jul 01, 2022
	5MG	A200854	004	Jul 01, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	10MG	A200854	005	Jul 01, 2022
	20MG	A200854	006	Jul 01, 2022
AIPING PHARM INC	0.5MG	A071128	001	Feb 17, 1987
	1MG	A071129	001	Feb 17, 1987
	20MG	A071133	001	May 12, 1987
CHARTWELL RX	2MG	A071209	004	Nov 17, 1986
DURAMED PHARMS BARR	0.5MG	A071216	001	Dec 04, 1986
	1MG	A071217	001	Dec 04, 1986
	2MG	A071218	001	Dec 04, 1986
	5MG	A071219	001	Dec 04, 1986
	10MG	A071220	001	Jul 07, 1987
	20MG	A071221	001	Jul 07, 1987
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
STRIDES PHARMA INTL	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

+ JANSSEN PHARMS	EQ 50MG BASE/ML	N018701	001	Jan 14, 1986
+	EQ 100MG BASE/ML	N018701	002	Jan 31, 1997

HALOPERIDOL DECANOATE

HIKMA	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998
HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPERIDOL DECANOATE				
INJECTABLE;INJECTION				
HALOPERIDOL DECANOATE				
	EQ 100MG BASE/ML		A075176 002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML		A076463 001	Jun 24, 2005
	EQ 100MG BASE/ML		A076463 002	Jun 24, 2005
TEVA PHARMS USA	EQ 50MG BASE/ML		A075393 001	May 11, 1999
	EQ 100MG BASE/ML		A075393 002	May 11, 1999
HALOPERIDOL LACTATE				
CONCENTRATE;ORAL				
HALDOL				
+ ORTHO MCNEIL	EQ 2MG BASE/ML **		N015922 001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML		A070318 001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML		A070710 001	Mar 07, 1986
SCS	EQ 2MG BASE/ML		A070726 001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML		A071015 001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML		A071617 001	Dec 01, 1988
HALOPERIDOL INTENSOL				
HIKMA	EQ 2MG BASE/ML		A072045 001	Apr 12, 1988
INJECTABLE;INJECTION				
HALDOL				
+ JANSSEN PHARMS	EQ 5MG BASE/ML **		N015923 001	
HALOPERIDOL				
ABRAXIS PHARM	EQ 5MG BASE/ML		A071187 001	Jan 20, 1987
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML		A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML		A076828 001	Aug 25, 2004
EPIC PHARMA LLC	EQ 5MG BASE/ML		A204849 001	Sep 06, 2017
FOSUN PHARMA	EQ 5MG BASE/ML		A076464 001	Sep 29, 2004
FRESENIUS KABI USA	EQ 5MG BASE/ML		A210356 001	Jul 01, 2019
GLAND PHARMA LTD	EQ 5MG BASE/ML		A076774 001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML		A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML		A072517 001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML		A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML		A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML		A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML		A070864 001	Dec 14, 1987
TEVA PHARMS USA	EQ 5MG BASE/ML		A076035 001	Aug 29, 2001
WATSON LABS	EQ 5MG BASE/ML		A070713 001	May 17, 1988
	EQ 5MG BASE/ML		A070714 001	May 17, 1988
	EQ 5MG BASE/ML		A070744 001	May 17, 1988
SOLUTION;ORAL				
HALOPERIDOL LACTATE				
ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML		A074536 001	Nov 02, 1995
HALOPROGIN				
CREAM;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%		N016942 001	
SOLUTION;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%		N016943 001	
HALOTHANE				
LIQUID;INHALATION				
FLUOTHANE				
WYETH AYERST	99.99% **		N011338 001	
HALOTHANE				
BH	99.99%		A084977 001	
HALOCARBON	99.99%		A080810 001	
HOSPIRA	99.99%		A083254 001	
HEPARIN CALCIUM				
INJECTABLE;INJECTION				
CALCIPARINE				
SANOFI AVENTIS US	25,000 UNITS/ML		N018237 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN LOCK FLUSH

	HOSPIRA	100 UNITS/ML	N005264	010	
	INTL MEDICATION	10 UNITS/ML	A086357	001	
		500 UNITS/ML	A086357	002	
	LUITPOLD	10 UNITS/ML	A089063	001	Oct 09, 1985
		100 UNITS/ML	A089064	001	Oct 09, 1985
	PARKE DAVIS	10 UNITS/ML	N017346	006	
	SMITH AND NEPHEW	10 UNITS/ML	A087904	001	Apr 20, 1983
		10 UNITS/ML	A087958	001	Apr 20, 1983
		10 UNITS/ML	A088458	001	Jul 26, 1984
		10 UNITS/ML	A088580	001	Oct 25, 1984
		100 UNITS/ML	A087906	001	Apr 20, 1983
		100 UNITS/ML	A087959	001	Apr 20, 1983
		100 UNITS/ML	A088460	001	Jul 26, 1984
		100 UNITS/ML	A088581	001	Oct 25, 1984
	SOLOPAK	10 UNITS/ML	A087903	001	Apr 20, 1983
		10 UNITS/ML	A088457	001	Oct 25, 1984
		100 UNITS/ML	A087905	001	Apr 20, 1983
		100 UNITS/ML	A088459	001	Jul 26, 1984

HEPARIN SODIUM

	ABRAXIS PHARM	1,000 UNITS/ML	N017033	001	
		1,000 UNITS/ML	N017979	001	
		5,000 UNITS/ML	N017979	003	
		10,000 UNITS/ML	N017979	002	
	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008	
		5,000 UNITS/ML	N000552	009	
		10,000 UNITS/ML	N000552	010	
	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
	CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011
	CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
		5,000 UNITS/ML	N017130	002	
		10,000 UNITS/ML	N017130	003	
		20,000 UNITS/ML	N017130	004	
	DELL LABS	1,000 UNITS/ML	N017540	001	
		5,000 UNITS/ML	N017540	002	
		10,000 UNITS/ML	N017540	003	
		20,000 UNITS/ML	N017540	004	
		40,000 UNITS/ML	N017540	005	
	DR REDDYS	1,000 UNITS/ML	A040007	001	Jun 07, 1996
		1,000 UNITS/ML	N017064	002	
		2,500 UNITS/ML	N017064	015	
		3,000 UNITS/ML	N017064	016	
		4,000 UNITS/ML	N017064	017	
		5,000 UNITS/ML	N017064	003	
		6,000 UNITS/ML	N017064	018	
		7,500 UNITS/ML	N017064	019	
		10,000 UNITS/ML	N017064	004	
		20,000 UNITS/ML	N017064	005	
		40,000 UNITS/ML	N017064	006	
	EPIC PHARMA LLC	1,000 UNITS/ML	N017486	001	
		5,000 UNITS/ML	N017486	002	
		10,000 UNITS/ML	N017486	003	
		20,000 UNITS/ML	N017486	004	
		40,000 UNITS/ML	N017486	005	
	FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
		5,000 UNITS/ML **	N017029	002	
		10,000 UNITS/ML	N017651	003	
		20,000 UNITS/ML	N017651	008	
+	HIKMA	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	
+		7,500 UNITS/ML **	N017007	003	
+		10,000 UNITS/ML **	N017007	004	
+		15,000 UNITS/ML **	N017007	005	
+		20,000 UNITS/ML **	N017007	006	
	HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM					
		10,000 UNITS/ML	A040095	001	Jul 26, 1996
	LILLY	1,000 UNITS/ML	N005521	001	
		10,000 UNITS/ML	N005521	002	
		20,000 UNITS/ML	N005521	004	
	LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
	PARKE DAVIS	1,000 UNITS/ML	N017346	001	
		5,000 UNITS/ML	N017346	002	
		7,500 UNITS/ML	N017346	003	
		10,000 UNITS/ML	N017346	004	
		20,000 UNITS/ML	N017346	005	
+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
+		5,000 UNITS/ML	N201370	002	Jul 21, 2011
+		10,000 UNITS/ML	N201370	003	Jul 21, 2011
	PHARM SPEC	1,000 UNITS/ML	N017780	001	
		5,000 UNITS/ML	N017780	002	
		10,000 UNITS/ML	N017780	003	
		20,000 UNITS/ML	N017780	004	
		40,000 UNITS/ML	N017780	005	
	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
		5,000 UNITS/ML	N004570	002	
		10,000 UNITS/ML	N004570	003	
	PHARMOBEDIENT	20,000 UNITS/ML	A203852	001	Nov 30, 2017
	SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
	SOLOPAK	1,000 UNITS/ML	A087043	001	
		5,000 UNITS/ML	A087077	001	
		5,000 UNITS/0.5ML	A087395	001	
		10,000 UNITS/ML	A087107	001	
		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML **	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
	HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
		10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
		10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	5,000 UNITS/100ML **	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%					
	HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
		5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	200 UNITS/100ML **	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%					
+	FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
		10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%					
	HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
		10,000 UNITS/100ML	N018911	008	Jan 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML **	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML **	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML **	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML **	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
+ PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ASPEN GLOBAL INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	
SODIUM HEPARIN				
ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

HETACILLIN

FOR SUSPENSION;ORAL				
VERSAPEN				
	BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001	
		EQ 112.5MG AMPICIL/5ML	N050060 001	
		EQ 112.5MG AMPICIL/ML	N050060 003	
		EQ 225MG AMPICIL/5ML	A061398 002	

HETACILLIN POTASSIUM

CAPSULE;ORAL				
VERSAPEN-K				
	BRISTOL	EQ 225MG AMPICIL	A061396 001	
		EQ 450MG AMPICIL	A061396 002	

HEXACHLOROPHENE

AEROSOL;TOPICAL				
SEPTISOL				
	VESTAL LABS	0.23%	N017424 001	
TURGEX				
	XTTRIUM	3%	N018375 001	
EMULSION;TOPICAL				
HEXA-GERM				
	HUNTINGTON LABS	3%	N017411 001	
PHISOHEX				
	SANOFI AVENTIS US	3%	N006882 001	
		3%	N008402 001	
SOY-DOME				
	BAYER PHARMS	3%	N017405 001	
TURGEX				
	XTTRIUM	3%	N019055 001	Nov 30, 1984
SOAP;TOPICAL				
GAMOPHEN				
	ARBROOK	2%	N006270 003	
SOLUTION;TOPICAL				
DIAL				
	DIAL	0.25%	N017421 002	
GERMA-MEDICA				
	HUNTINGTON LABS	1%	N017412 001	
GERMA-MEDICA "MG"				
	HUNTINGTON LABS	0.25%	N017412 002	
SEPTI-SOFT				
	CALGON	0.25%	N017460 001	
SEPTISOL				
	VESTAL LABS	0.25%	N017423 001	
SPONGE;TOPICAL				
E-Z SCRUB				
	BECTON DICKINSON	450MG	N017452 001	
HEXASCRUB				
	PROF DSPLS	3%	N018363 001	
PHISO-SCRUB				
	SANOFI AVENTIS US	3%	N017446 001	
SCRUBTEAM SURGICAL SPONGEBRUSH				
	3M	330MG	N017413 001	

HEXAFLUORENIUM BROMIDE

INJECTABLE;INJECTION				
MYLAXEN				
	MEDPOINTE PHARM HLC	20MG/ML	N009789 003	

HEXOCYCLIUM METHYLSULFATE

TABLET;ORAL				
TRAL				
	ABBVIE	25MG	N010599 001	

HEXYLCAINE HYDROCHLORIDE

SOLUTION;TOPICAL				
CYCLAINE				
	MERCK	5%	N008472 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HISTAMINE PHOSPHATE
INJECTABLE;INJECTION
HISTAMINE PHOSPHATE

LILLY	EQ 0.1MG BASE/ML	N000734	003	
	EQ 0.2MG BASE/ML	N000734	002	
	EQ 1MG BASE/ML	N000734	001	

HISTRELIN ACETATE
IMPLANT;SUBCUTANEOUS
VANTAS

+ ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004

INJECTABLE;INJECTION
SUPPRELIN

SHIRE	EQ 0.2MG BASE/ML	N019836	001	Dec 24, 1991
	EQ 0.5MG BASE/ML	N019836	002	Dec 24, 1991
	EQ 1MG BASE/ML	N019836	003	Dec 24, 1991

HOMATROPINE METHYLBROMIDE
TABLET;ORAL
HOMAPIN-10

MISSION PHARMA	10MG	A086308	001	

HOMAPIN-5

MISSION PHARMA	5MG	A086309	001	

TABLET, CHEWABLE;ORAL
EQUIPIN

MISSION PHARMA	3MG	A086310	001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP;ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008
IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285	001	Jul 19, 1999
SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019
SCIEGEN PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017

HYDROPANE

HALSEY	1.5MG/5ML;5MG/5ML	A088066	001	Jun 28, 1985

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000
NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011

TUSSIGON

KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985

HYDRALAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
APRESOLINE

+ NOVARTIS	20MG/ML **	N008303	003	

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
PHARMOBEDIENT	20MG/ML	A203110	001	Jun 29, 2015
	20MG/ML	A204680	001	Apr 28, 2016
SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET;ORAL
APRESOLINE

+ NOVARTIS	10MG **	N008303	004	
+	25MG **	N008303	001	
+	50MG **	N008303	002	
+	100MG **	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013
	25MG	A091679	002	Mar 04, 2013
	50MG	A091679	003	Mar 04, 2013
	100MG	A091679	004	Mar 04, 2013
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008
	25MG	A090255	002	Dec 15, 2008
	50MG	A090255	003	Dec 15, 2008
	100MG	A090255	004	Dec 15, 2008
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024
	25MG	A211010	002	Aug 21, 2024
	50MG	A211010	003	Aug 21, 2024
	100MG	A211010	004	Aug 21, 2024
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
PHARMOBEDIENT	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
RISING	10MG	A209251	001	Jul 09, 2018
	25MG	A209251	002	Jul 09, 2018
	50MG	A209251	003	Jul 09, 2018
	100MG	A209251	004	Jul 09, 2018
STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TP ANDA HOLDINGS	10MG	A089359	001	Jul 25, 1986
	25MG	A089258	001	May 05, 1986
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
UPSHER SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
APRESAZIDE				
+ NOVARTIS	25MG;25MG	A084735	001	
+	50MG;50MG	A084810	001	
	100MG;50MG	A084811	001	
HYDRA-ZIDE				
STRIDES PHARMA INTL	100MG;50MG	A088961	001	Oct 21, 1985
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;25MG	A087608	001	Feb 08, 1982
	50MG;50MG	A087213	001	Feb 08, 1982
	100MG;50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200	001	Feb 09, 1987
	50MG;50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457	001	Mar 04, 1982
	50MG;50MG	A085446	001	Mar 04, 1982
	100MG;50MG	A085440	001	Mar 04, 1982
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50				
IVAX PHARMS	100MG;50MG	A088358	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25				
IVAX PHARMS	25MG;25MG	A088356	001	Apr 10, 1984
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50				
IVAX PHARMS	50MG;50MG	A088357	001	Apr 10, 1984
TABLET;ORAL				
APRESOLINE-ESIDRIX				
NOVARTIS	25MG;15MG	N012026	002	
HYDRALAZINE AND HYDROCHLOROTHIAZIDE				
WATSON LABS	25MG;15MG	A085827	001	
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE				
WATSON LABS	25MG;15MG	A085373	001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CAM-AP-ES				
CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
MYLAN	25MG;15MG;0.1MG	A087085	001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	25MG;15MG;0.1MG	A085771	001	
HYDRAP-ES				
SANDOZ	25MG;15MG;0.1MG	A084876	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
WATSON LABS	25MG;15MG;0.1MG	A083770	001	
HYDROSERPINE PLUS (R-H-H)				
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
SOLVAY	25MG;15MG;0.1MG	A088376	001	Oct 28, 1983
SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001	
	25MG;15MG;0.1MG	A087556	001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
LEDERLE	25MG;15MG;0.1MG	A087709	001	May 13, 1982
SER-A-GEN				
SOLVAY	25MG;15MG;0.1MG	A087210	001	
SER-AP-ES				
NOVARTIS	25MG;15MG;0.1MG	N012193	005	
UNIPRES				
SOLVAY	25MG;15MG;0.1MG	A085893	001	
	25MG;15MG;0.1MG	A086298	001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET;ORAL				
DRALSERP				
SANDOZ	25MG;0.1MG	A084617	001	
SERPASIL-APRESOLINE				
NOVARTIS	25MG;0.1MG	N009296	004	
	50MG;0.2MG	N009296	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
HYDROCHLOROTHIAZIDE				
ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010
APOTEX	12.5MG	A078389	001	May 16, 2008
CHARTWELL MOLECULAR	12.5MG	A091662	001	Jan 27, 2012
HIKMA INTL PHARMS	12.5MG	A077885	001	Nov 26, 2007
IPCA LABS LTD	12.5MG	A079237	001	Apr 02, 2009
IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005
QUAGEN	12.5MG	A075640	001	Jan 28, 2000
SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014
SOLUTION;ORAL				
HYDROCHLOROTHIAZIDE				
MORTON GROVE	50MG/5ML	A089661	001	Jun 20, 1988
+ ROXANE	50MG/5ML **	A088587	001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL				
ROXANE	100MG/ML	A088588	001	Jul 02, 1984
TABLET;ORAL				
ESIDRIX				
NOVARTIS	25MG	N011793	005	
	50MG	N011793	008	
	100MG	N011793	009	
HYDRO-D				
HALSEY	25MG	A086504	001	
	50MG	A083891	002	
HYDROCHLOROTHIAZIDE				
ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
APOTEX	25MG	A040774	001	Oct 03, 2007
	50MG	A040774	002	Oct 03, 2007
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	
	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	25MG	A087565	001	Mar 09, 1982
	50MG	A083965	001	
	50MG	A084912	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
	50MG	A084878	001	
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IPCA LABS LTD	12.5MG	A040807	001	Jul 20, 2007
	25MG	A040807	002	Jul 20, 2007
	50MG	A040807	003	Jul 20, 2007
IVAX SUB TEVA PHARMS	50MG	A084658	001	
+	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
PHARMOBEDIENT	12.5MG	A040770	001	Jan 23, 2007
	25MG	A040735	002	Jan 23, 2007
	50MG	A040735	003	Jan 23, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE				
PRINSTON INC	25MG	A040412	001	Mar 29, 2002
	50MG	A040412	002	Mar 29, 2002
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
	25MG	A040810	001	Mar 27, 2007
	50MG	A040810	002	Mar 27, 2007
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	
	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRODIURIL				
+ MERCK	25MG **	N011835	003	
+	50MG **	N011835	006	
+	100MG **	N011835	007	
ORETIC				
ABBVIE	25MG	N011971	001	
	50MG	N011971	002	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE				
+ SANOFI AVENTIS US	12.5MG;75MG **	N020758	001	Sep 30, 1997
+	25MG;300MG **	N020758	004	Mar 15, 2005
IRBESARTAN AND HYDROCHLOROTHIAZIDE				
APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012
	12.5MG;300MG	A201505	002	Oct 15, 2012
ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016
	12.5MG;300MG	A203036	002	Jan 15, 2016
	25MG;300MG	A203036	003	Jan 15, 2016
LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013
	12.5MG;300MG	A201524	002	Feb 27, 2013
PHARMOBEDIENT	12.5MG;150MG	A077969	001	Sep 27, 2012
	12.5MG;300MG	A077969	002	Sep 27, 2012
	25MG;300MG	A077969	003	Jul 20, 2016
TEVA	25MG;300MG	A077369	003	Mar 30, 2012
UNICHEM	12.5MG;150MG	A207018	001	Sep 19, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL					
IRBESARTAN AND HYDROCHLOROTHIAZIDE					
	12.5MG;300MG		A207018	002	Sep 19, 2017
WATSON LABS INC	12.5MG;150MG		A091539	001	Oct 22, 2012
	12.5MG;300MG		A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET;ORAL					
NORMOZIDE					
SCHERING	25MG;100MG		N019046	001	Apr 06, 1987
	25MG;200MG		N019046	002	Apr 06, 1987
	25MG;300MG		N019046	003	Apr 06, 1987
	25MG;400MG		N019046	004	Apr 06, 1987
TRANDATE HCT					
GLAXOSMITHKLINE	25MG;100MG		N019174	001	Apr 10, 1987
	25MG;200MG		N019174	002	Apr 10, 1987
	25MG;300MG		N019174	003	Apr 10, 1987
	25MG;400MG		N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL					
LISINOPRIL AND HYDROCHLOROTHIAZIDE					
CHARTWELL RX	12.5MG;10MG		A075776	001	Jul 01, 2002
	12.5MG;20MG		A075776	002	Jul 01, 2002
	25MG;20MG		A075776	003	Jul 01, 2002
EPIC PHARMA LLC	12.5MG;10MG		A075926	001	Jul 01, 2002
	12.5MG;20MG		A075926	002	Jul 01, 2002
	25MG;20MG		A075926	003	Jul 01, 2002
HIKMA INTL PHARMS	12.5MG;10MG		A076265	001	Jul 08, 2002
	12.5MG;20MG		A076265	002	Jul 08, 2002
	25MG;20MG		A076265	003	Jul 08, 2002
PHARMOBEDIENT	12.5MG;10MG		A076113	001	Jul 01, 2002
	12.5MG;20MG		A076113	002	Jul 01, 2002
	25MG;20MG		A076113	003	Jul 01, 2002
TEVA	12.5MG;10MG		A075869	001	Jul 01, 2002
	12.5MG;20MG		A075869	002	Jul 01, 2002
	25MG;20MG		A075869	003	Jul 01, 2002
PRINZIDE					
+ MERCK	12.5MG;10MG **		N019778	003	Nov 18, 1993
+	12.5MG;20MG **		N019778	001	Feb 16, 1989
+	25MG;20MG **		N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL					
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
APOTEX	12.5MG;50MG		A090150	001	Oct 06, 2010
	12.5MG;100MG		A090150	002	Aug 11, 2010
	25MG;100MG		A090150	003	Oct 06, 2010
GRANULES	12.5MG;50MG		A218015	001	Sep 29, 2023
	12.5MG;100MG		A218015	002	Sep 29, 2023
	25MG;100MG		A218015	003	Sep 29, 2023
HIKMA	12.5MG;50MG		A077732	002	Oct 06, 2010
	12.5MG;100MG		A077732	001	Apr 06, 2010
	25MG;100MG		A077732	003	Oct 06, 2010
IPCA LABS LTD	12.5MG;50MG		A201682	001	Mar 01, 2013
	12.5MG;100MG		A201682	002	Mar 01, 2013
	25MG;100MG		A201682	003	Mar 01, 2013
MYLAN	12.5MG;50MG		A091652	001	Oct 06, 2010
	12.5MG;100MG		A091652	002	Apr 06, 2010
	25MG;100MG		A091652	003	Oct 06, 2010
TORRENT PHARMS	12.5MG;50MG		A090528	001	Oct 06, 2010
	12.5MG;100MG		A090528	003	Apr 06, 2010
	25MG;100MG		A090528	002	Oct 06, 2010
WATSON LABS	12.5MG;50MG		A200180	001	Jan 12, 2011
	12.5MG;100MG		A200180	002	Jan 12, 2011
	25MG;100MG		A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL					
ALDORIL 15					
	MERCK	15MG;250MG	N013402	001	
ALDORIL 25					
	MERCK	25MG;250MG	N013402	002	
ALDORIL D30					
	MERCK	30MG;500MG	N013402	003	
ALDORIL D50					
	MERCK	50MG;500MG	N013402	004	
METHYLDOPA AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	15MG;250MG	A070182	001	Jan 15, 1986
		25MG;250MG	A070183	001	Jan 15, 1986
		30MG;500MG	A070543	001	Jan 15, 1986
		50MG;500MG	A070544	001	Jan 15, 1986
	DAVA PHARMS INC	15MG;250MG	A072507	001	Jun 02, 1989
		25MG;250MG	A072508	001	Jun 02, 1989
		30MG;500MG	A072509	001	Jun 02, 1989
		50MG;500MG	A072510	001	Jun 02, 1989
	IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
		25MG;250MG	A071459	001	Mar 08, 1988
		30MG;500MG	A071460	001	Mar 08, 1988
		50MG;500MG	A071461	001	Mar 08, 1988
	PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
		25MG;250MG	A071898	001	Nov 23, 1987
		30MG;500MG	A071899	001	Nov 23, 1987
		50MG;500MG	A071900	001	Nov 23, 1987
	PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
		25MG;250MG	A070688	001	Apr 24, 1986
		30MG;500MG	A070854	001	Oct 08, 1986
		50MG;500MG	A070689	001	Apr 24, 1986
	RISING	15MG;250MG	A070265	002	Jan 23, 1986
		25MG;250MG	A070265	001	Jan 23, 1986
	SANDOZ	15MG;250MG	A070829	001	Mar 09, 1987
		25MG;250MG	A070830	001	Mar 09, 1987
	STRIDES PHARMA INTL	15MG;250MG	A070616	001	Feb 02, 1987
		25MG;250MG	A070612	001	Feb 02, 1987
		30MG;500MG	A070613	001	Feb 02, 1987
		50MG;500MG	A070614	001	Feb 02, 1987
	TEVA	15MG;250MG	A071819	001	Apr 08, 1988
		25MG;250MG	A071820	001	Apr 08, 1988
		30MG;500MG	A071821	001	Apr 08, 1988
		50MG;500MG	A071822	001	Apr 08, 1988
	WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
		15MG;250MG	A070958	001	Feb 06, 1989
		15MG;250MG	A071920	001	Aug 29, 1988
		25MG;250MG	A070366	001	Apr 16, 1986
		25MG;250MG	A070959	001	Jan 19, 1989
		25MG;250MG	A071921	001	Aug 29, 1988
		30MG;500MG	A070367	001	Mar 19, 1986
		30MG;500MG	A071069	001	Jan 19, 1989
		30MG;500MG	A071922	001	Aug 29, 1988
		50MG;500MG	A070368	001	Apr 16, 1986
		50MG;500MG	A070960	001	Feb 06, 1989
		50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL					
DUTOPROL					
+	CONCORDIA	12.5MG;EQ 25MG TARTRATE **	N021956	001	Aug 28, 2006
+		12.5MG;EQ 50MG TARTRATE **	N021956	002	Aug 28, 2006
+		12.5MG;EQ 100MG TARTRATE **	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL					
LOPRESSOR HCT					
+	VALIDUS PHARMS	25MG;100MG **	N018303	002	Dec 31, 1984
+		50MG;100MG **	N018303	003	Dec 31, 1984
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE					
	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL				
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE				
	25MG;100MG	A090654	002	Jan 19, 2012
	50MG;100MG	A090654	003	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL				
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008
	12.5MG;15MG	A090096	002	Sep 25, 2008
	25MG;15MG	A090096	003	Sep 25, 2008
GLENMARK PHARMS	12.5MG;7.5MG	A090718	001	Mar 17, 2010
	12.5MG;15MG	A090718	002	Mar 17, 2010
	25MG;15MG	A090718	003	Mar 17, 2010
HERITAGE	12.5MG;7.5MG	A202150	001	Mar 07, 2014
	12.5MG;15MG	A202150	002	Mar 07, 2014
	25MG;15MG	A202150	003	Mar 07, 2014
UNIRETIC				
UCB INC	12.5MG;7.5MG **	N020729	001	Jun 27, 1997
	12.5MG;15MG **	N020729	003	Feb 14, 2002
	25MG;15MG **	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL				
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE				
NATCO PHARMA USA	12.5MG;20MG	A078827	001	Oct 26, 2016
	12.5MG;40MG	A078827	002	Oct 26, 2016
	25MG;40MG	A078827	003	Oct 26, 2016
TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017
	12.5MG;40MG	A200532	002	Apr 24, 2017
	25MG;40MG	A200532	003	Apr 24, 2017
TORRENT	12.5MG;20MG	A206515	001	May 03, 2017
	12.5MG;40MG	A206515	002	May 03, 2017
	25MG;40MG	A206515	003	May 03, 2017
ZYDUS PHARMS	12.5MG;20MG	A206377	001	Feb 24, 2023
	12.5MG;40MG	A206377	002	Feb 24, 2023
	25MG;40MG	A206377	003	Feb 24, 2023

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET;ORAL				
VISKAZIDE				
NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
	25MG;10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
INDERIDE LA 120/50				
WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50				
WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985
INDERIDE LA 80/50				
WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985
TABLET;ORAL				
INDERIDE-40/25				
+ WYETH PHARMS INC	25MG;40MG **	N018031	001	
INDERIDE-80/25				
+ WYETH PHARMS INC	25MG;80MG **	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE				
DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
	25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
	25MG;80MG	A070852	001	May 15, 1986
ANI PHARMS	25MG;40MG	A070705	002	Oct 01, 1986
	25MG;40MG	A072043	002	Mar 14, 1988
	25MG;80MG	A070705	001	Oct 01, 1986
	25MG;80MG	A072043	001	Mar 14, 1988
CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987
	25MG;80MG	A071061	001	Aug 26, 1987
IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL					
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
		25MG;80MG	A071553	001	Dec 01, 1988
	RISING	25MG;40MG	A070947	002	Mar 04, 1987
		25MG;80MG	A070947	001	Apr 01, 1987
	WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
		25MG;80MG	A071772	001	Jan 26, 1988
	WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
		25MG;40MG	A071498	001	Dec 18, 1991
		25MG;80MG	A070305	001	Apr 18, 1986
		25MG;80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL					
ACCURETIC					
+	PFIZER PHARMS	12.5MG;EQ 10MG BASE **	N020125	001	Dec 28, 1999
+		12.5MG;EQ 20MG BASE **	N020125	002	Dec 28, 1999
+		25MG;EQ 20MG BASE **	N020125	003	Dec 28, 1999
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013
		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013
		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013
	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011
		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011
		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011
	PHARMOBEDIENT	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005
		12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005
		25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005
	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL					
H.R.-50					
	WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	
HYDRO-RESERP					
	ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"					
	SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"					
	SANDOZ	50MG;0.125MG	A085213	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE					
	IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
		25MG;0.125MG	A083571	001	
		50MG;0.1MG	A083568	001	
		50MG;0.125MG	A083573	001	
	PHARMERAL	25MG;0.125MG	A085421	001	
		50MG;0.125MG	A085420	001	
	ROXANE	50MG;0.125MG	A084603	001	
	WATSON LABS	25MG;0.125MG	A084466	001	
		25MG;0.125MG	A085317	001	
		25MG;0.125MG	A086330	002	
		50MG;0.125MG	A083666	001	
		50MG;0.125MG	A084467	001	
		50MG;0.125MG	A086331	001	
HYDROPRES 25					
	MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50					
	MERCK	50MG;0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE					
	BARR	25MG;0.125MG	A084580	001	
		50MG;0.125MG	A084579	001	
	SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50					
	WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1					
	NOVARTIS	25MG;0.1MG	N011878	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
SERPASIL-ESIDRIX #2				
	NOVARTIS	50MG;0.1MG	N011878 005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL				
ALDACTAZIDE				
+	PFIZER	50MG;50MG	N012616 005	Dec 30, 1982
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE				
	ASCOT	25MG;25MG	A088025 001	Nov 23, 1984
	CHARTWELL RX	25MG;25MG	A086881 001	
	MUTUAL PHARM	25MG;25MG	A087267 001	
	PUREPAC PHARM	25MG;25MG	A087999 001	Nov 06, 1985
	SUPERPHARM	25MG;25MG	A089137 001	Aug 26, 1985
	WATSON LABS	25MG;25MG	A087398 001	
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE				
	IVAX PHARMS	25MG;25MG	A087004 002	May 24, 1982
	LEDERLE	25MG;25MG	A087511 001	
	PARKE DAVIS	25MG;25MG	A087948 001	Feb 22, 1983
	PUREPAC PHARM	25MG;25MG	A088054 001	Aug 18, 1983
	UPSHER SMITH	25MG;25MG	A087553 001	
	USL PHARMA	25MG;25MG	A087651 001	
	VANGARD	25MG;25MG	A087655 001	
	WATSON LABS	25MG;25MG	A085974 001	
		25MG;25MG	A086026 001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL				
TELMISARTAN AND HYDROCHLOROTHIAZIDE				
	MACLEODS PHARMS LTD	12.5MG;40MG	A204169 001	Nov 02, 2015
		12.5MG;80MG	A204169 002	Nov 02, 2015
		25MG;80MG	A204169 003	Nov 02, 2015
	MANKIND PHARMA	12.5MG;40MG	A218406 001	Mar 03, 2025
		12.5MG;80MG	A218406 002	Mar 03, 2025
		25MG;80MG	A218406 003	Mar 03, 2025
	NATCO	12.5MG;40MG	A091648 001	Feb 25, 2014
		12.5MG;80MG	A091648 002	Feb 25, 2014
		25MG;80MG	A091648 003	Feb 25, 2014
	TORRENT	12.5MG;40MG	A201192 001	Feb 25, 2014
		12.5MG;80MG	A201192 002	Feb 25, 2014
		25MG;80MG	A201192 003	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL				
TIMOLIDE 10-25				
	MERCK	25MG;10MG	N018061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL				
DYAZIDE				
+	GLAXOSMITHKLINE LLC	25MG;37.5MG **	N016042 003	Mar 03, 1994
		25MG;50MG **	N016042 002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
	ANI PHARMS	25MG;37.5MG	A074970 001	Jan 06, 1998
		25MG;50MG	A074259 001	Mar 30, 1995
	CHARTWELL RX	25MG;50MG	A073191 001	Jul 31, 1991
	DURAMED PHARMS BARR	25MG;37.5MG	A075052 001	Jun 18, 1999
	MACLEODS PHARMS LTD	25MG;37.5MG	A214611 001	Jan 28, 2025
	NOVARTIS	25MG;37.5MG	A074857 001	Sep 09, 1997
	PHARMOBEDIENT	25MG;37.5MG	A074701 001	Jun 07, 1996
	VITARINE	25MG;50MG	A071737 001	Feb 12, 1988
TABLET;ORAL				
TRIAMTERENE AND HYDROCHLOROTHIAZIDE				
	AM THERAP	50MG;75MG	A072022 001	Apr 17, 1988
	ANI PHARMS	50MG;75MG	A073467 001	Jan 31, 1996
	PLIVA	25MG;37.5MG	A074026 001	Apr 26, 1996
	QUANTUM PHARMICS	50MG;75MG	A071980 001	Apr 17, 1988
	WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL					
VALSARTAN AND HYDROCHLOROTHIAZIDE					
	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
		12.5MG;160MG	A203026	002	Mar 21, 2013
		12.5MG;320MG	A203026	003	Mar 21, 2013
		25MG;160MG	A203026	004	Mar 21, 2013
		25MG;320MG	A203026	005	Mar 21, 2013
	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013
		12.5MG;160MG	A091519	002	Mar 21, 2013
		12.5MG;320MG	A091519	003	Mar 21, 2013
		25MG;160MG	A091519	004	Mar 21, 2013
		25MG;320MG	A091519	005	Mar 21, 2013
	ZYDUS LIFESCIENCES	12.5MG;80MG	A203000	001	Mar 15, 2019
		12.5MG;160MG	A203000	002	Mar 15, 2019
		12.5MG;320MG	A203000	003	Mar 15, 2019
		25MG;160MG	A203000	004	Mar 15, 2019
		25MG;320MG	A203000	005	Mar 15, 2019

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL					
ZOHYDRO ER					
+	RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013
+		15MG	N202880	002	Oct 25, 2013
+		20MG	N202880	003	Oct 25, 2013
+		30MG	N202880	004	Oct 25, 2013
+		40MG	N202880	005	Oct 25, 2013
+		50MG	N202880	006	Oct 25, 2013
TABLET, EXTENDED RELEASE;ORAL					
HYSINGLA ER					
+	PURDUE PHARMA LP	120MG	N206627	007	Nov 20, 2014
VANTRELA ER					
+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017
+		30MG	N207975	002	Jan 17, 2017
+		45MG	N207975	003	Jan 17, 2017
+		60MG	N207975	004	Jan 17, 2017
+		90MG	N207975	005	Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL					
HYDROCODONE					
	STRIDES PHARMA	5MG;200MG	A077723	003	Nov 06, 2006
HYDROCODONE BITARTRATE AND IBUPROFEN					
	ANI PHARMS	5MG;200MG	A077454	001	Jun 23, 2010
	STRIDES PHARMA	7.5MG;200MG	A077723	001	Nov 06, 2006
		10MG;200MG	A077723	002	Nov 06, 2006
	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013
		5MG;200MG	A091633	002	May 28, 2013
		7.5MG;200MG	A091633	003	May 28, 2013
		10MG;200MG	A091633	004	May 28, 2013
	TEVA	7.5MG;200MG	A076023	001	Apr 11, 2003
REPREXAIN					
	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
		10MG;200MG	A076642	004	Oct 19, 2007
VICOPROFEN					
+	ABBVIE	7.5MG;200MG **	N020716	001	Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL					
CODAMINE					
	ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL					
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015
	PADAGIS US	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014
	SCIEGEN PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019
	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014
REZIRA					
+	PERSION	5MG/5ML;60MG/5ML **	N022442	001	Jun 08, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTAMATE HYDROCHLORIDE				
OINTMENT;TOPICAL				
MAGNACORT				
PFIZER	0.5%	N010554	001	
HYDROCORTISONE				
AEROSOL;TOPICAL				
AEROSEB-HC				
ALLERGAN HERBERT	0.5%	A085805	001	
CREAM;TOPICAL				
CORT-DOME				
BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	
DERMACORT				
MONARCH PHARMS	1%	A083011	002	
ELDECORT				
VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	
FLEXICORT				
WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982
H-CORT				
PHARM ASSOC	0.5%	A086823	001	
HC #1				
BAYER PHARMS	0.5%	A080438	001	
HC #4				
BAYER PHARMS	1%	A080438	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	
HI-COR				
C AND M PHARMA	2.5%	A080483	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	
	1%	A080848	003	
AMBIX	1%	A086080	001	
	2.5%	A086271	001	
CHARTWELL MOLECULAR	2.5%	A040503	001	Mar 12, 2004
ENCUBE	2.5%	A203810	001	Jul 23, 2018
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	
HYTONE				
+ VALEANT INTL	1% **	A080472	003	
+	2.5% **	A080472	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE

CREAM;TOPICAL				
NOGENIC HC				
IVAX PHARMS	1%	A087427	001	Apr 04, 1988
NUTRACORT				
BAUSCH	0.5%	A080442	002	
	1%	A080442	003	
PENECORT				
ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
PROCTOCORT				
MONARCH PHARMS	1%	A083011	001	
SYNACORT				
BAUSCH	0.5%	A087459	001	
+	1%	A087458	001	
+	2.5%	A087457	001	
ENEMA;RECTAL				
HYDROCORTISONE				
TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994
GEL;TOPICAL				
NUTRACORT				
+ HEALTHPOINT	1% **	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
BAUSCH	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%	A086824	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982
CHARTWELL MOLECULAR	2.5%	A040417	001	Jul 30, 2003
ENCUBE	2.5%	A203804	001	Jul 27, 2018
FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000
MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662	001	
	1%	A085663	001	
SUN PHARMA CANADA	2.5%	A040247	001	Jul 23, 1999
TARO	1%	A089024	001	Feb 12, 1986
HYTONE				
+ VALEANT INTL	1% **	A080473	003	
+	2.5% **	A080473	004	Nov 30, 1982
NUTRACORT				
DOW PHARM	0.5%	A080443	002	
	1%	A080443	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE

LOTION;TOPICAL				
NUTRACORT				
	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PADAGIS US	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
SUN PHARMA CANADA	1%	A086257	001	
	2.5%	A040310	001	Dec 29, 2000
TARO	0.5%	A086256	001	
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
+ DERMIK LABS	1% **	A080474	003	
+	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
+ ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
CHARTWELL MOLECULAR	20MG	A085070	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015
	10MG	A083365	003	Feb 23, 2015
	20MG	A083365	001	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE				
TABLET;ORAL				
HYDROCORTISONE				
STRIDES PHARMA INTL	5MG	A040761	001	Jul 16, 2007
	10MG	A040761	002	Jul 16, 2007
	20MG	A040761	003	Jul 16, 2007
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	
TABLET;VAGINAL				
CORTRIL				
PFIPHARMECS	10MG	N009796	001	
HYDROCORTISONE ACETATE				
CREAM;TOPICAL				
CARMOL HC				
+ FOUGERA PHARMS	1%	A080505	001	
HEMSOL-HC				
ABLE	1%	A081274	001	Jun 19, 1992
HYDROCORTISONE ACETATE				
CENCI	1%	A080419	001	Jan 25, 1982
IMPERIUM	2.5%	A040259	001	Jul 29, 1999
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
+	1%	A086052	001	
MICORT-HC				
LEGACY PHARMA	2%	A040398	001	Mar 29, 2002
U-CORT				
SUN PHARMA CANADA	1%	A089472	001	Jun 13, 1988
INJECTABLE;INJECTION				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	50MG/ML	N009378	002	
CORTRIL				
PFIZER	25MG/ML	N009164	001	
HYDROCORTISONE ACETATE				
BEL MAR	25MG/ML	A083739	001	
	50MG/ML	A083739	002	
EPIC PHARMA LLC	25MG/ML	N009637	001	
	50MG/ML	N009637	002	
WATSON LABS	25MG/ML	A083128	001	
	25MG/ML	A083759	001	
	50MG/ML	A083759	002	
	50MG/ML	A085214	001	
HYDROCORTONE				
MERCK	25MG/ML	N008228	001	
	50MG/ML	N008228	004	
LOTION;TOPICAL				
DRICORT				
INGRAM PHARM	0.5%	A086207	001	
OINTMENT;OPHTHALMIC				
HYDROCORTISONE ACETATE				
FERA PHARMS	0.5%	A080828	001	
OINTMENT;OPHTHALMIC, OTIC				
HYDROCORTONE				
MERCK	1.5%	N009018	003	
OINTMENT;TOPICAL				
CORTEF ACETATE				
PHARMACIA AND UPJOHN	1%	N008917	002	
+	2.5% **	N008917	001	
PASTE;TOPICAL				
ORABASE HCA				
COLGATE	0.5%	A083205	001	
POWDER;FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
X GEN PHARMS	100%	A085981	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001	
		2.5%;EQ 3.5MG BASE/GM	A061049 002	
OINTMENT;OPHTHALMIC				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001	
		1.5%;EQ 3.5MG BASE/GM	A060610 002	
OINTMENT;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001	
		1%;EQ 3.5MG BASE/GM	A060751 002	
		2.5%;EQ 3.5MG BASE/GM	A060751 003	
SUSPENSION/DROPS;OPHTHALMIC				
COR-OTICIN				
	EPIC PHARMA LLC	1.5%;EQ 3.5MG BASE/ML	A060188 001	
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002	
		1.5%;EQ 3.5MG BASE/ML	A060612 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL				
CORTISPORIN				
+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050218 001	Aug 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC				
TERRA-CORTRIL				
	PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
	GENUS	1%;1%	A089440 001	May 17, 1988
LOTION;TOPICAL				
PRAMOSONE				
	FERNDALE LABS	0.5%;1%	A083213 002	

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL				
HYDROCORTISONE BUTYRATE				
	GLENMARK PHARMS LTD	0.1%	A202145 001	Sep 27, 2013
LOCOID				
	YAMANOUCHI	0.1%	N018795 001	Jan 07, 1983
LOTION;TOPICAL				
LOCOID				
+	BAUSCH	0.1%	N022076 001	May 18, 2007
OINTMENT;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019106 001	Jul 03, 1984
SOLUTION;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019819 001	Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL				
CORTEF				
	PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900 001	

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL				
PANDEL				
+	ANI PHARMS	0.1%	N020453 001	Feb 28, 1997

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
HYDROCORTONE				
+	MERCK	EQ 50MG BASE/ML **	N012052 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
A-HYDROCORT				
	ABBOTT	EQ 100MG BASE/VIAL	A085928 001	
		EQ 100MG BASE/VIAL	A089577 001	Apr 11, 1989
		EQ 250MG BASE/VIAL	A089578 001	Apr 11, 1989
		EQ 500MG BASE/VIAL	A089579 001	Apr 11, 1989
		EQ 1GM BASE/VIAL	A089580 001	Apr 11, 1989
	HOSPIRA	EQ 100MG BASE/VIAL	A040666 001	Apr 06, 2006
		EQ 100MG BASE/VIAL	A085929 001	
		EQ 250MG BASE/VIAL	A085930 001	
		EQ 500MG BASE/VIAL	A085931 001	
		EQ 1GM BASE/VIAL	A085932 001	
HYDROCORTISONE SODIUM SUCCINATE				
	ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667 001	Jun 08, 1984
		EQ 100MG BASE/VIAL	A088712 001	Jun 08, 1984
		EQ 250MG BASE/VIAL	A088668 001	Jun 08, 1984
		EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
		EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
		EQ 250MG BASE/VIAL	A087567 001	
		EQ 500MG BASE/VIAL	A087568 001	
		EQ 1GM BASE/VIAL	A087569 001	
	INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
	WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
		EQ 100MG BASE/VIAL	A084738 001	
		EQ 250MG BASE/VIAL	A084737 001	
		EQ 500MG BASE/VIAL	A084747 001	
		EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL				
HYDROCORTISONE VALERATE				
	COSETTE	0.2%	A074489 001	Aug 12, 1998
	GLENMARK PHARMS LTD	0.2%	A211129 001	Oct 12, 2018
WESTCORT				
+	SUN PHARM INDS INC	0.2% **	N017950 001	
OINTMENT;TOPICAL				
HYDROCORTISONE VALERATE				
	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
	GLENMARK PHARMS LTD	0.2%	A211750 001	Dec 14, 2018
WESTCORT				
+	SUN PHARM INDS INC	0.2% **	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORT-DOME				
	BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
		1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
CORTISPORIN				
+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **	N050479 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216 001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982
OTOCORT				
	WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	
SUSPENSION/DROPS;OPHTHALMIC				
CORTISPORIN				
	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985
SUSPENSION/DROPS;OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
OTICAIR				
	PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
SUSPENSION/DROPS;OTIC				
OTOBIONE				
	SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
OTOCORT				
	WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985
PEDIOTIC				
	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987
HYDROCORTISONE; POLYMYXIN B SULFATE				
SOLUTION/DROPS;OTIC				
OTOBIOTIC				
	SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
PYOCIDIN				
	FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	
HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE				
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
	LEDERLE	1.5%;1%	N050272 001	
HYDROCORTISONE; UREA				
CREAM;TOPICAL				
ALPHADERM				
	BIOGLAN	1%;10%	A086008 001	
CALMURID HC				
	PHARMACIA AND UPJOHN	1%;10%	A083947 001	
HYDROFLUMETHIAZIDE				
TABLET;ORAL				
DIUCARDIN				
	WYETH AYERST	50MG	A083383 001	
HYDROFLUMETHIAZIDE				
	PAR PHARM	50MG	A088850 001	May 31, 1985
	WATSON LABS	50MG	A088031 001	Apr 06, 1983
		50MG	A088528 001	Aug 15, 1984
SALURON				
+	SHIRE LLC	50MG	N011949 001	
HYDROFLUMETHIAZIDE; RESERPINE				
TABLET;ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
	USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983
	WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983
		50MG;0.125MG	A088110 001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
	IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985
	PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985
SALUTENSIN				
	SHIRE	50MG;0.125MG	N012359 003	
SALUTENSIN-DEMI				
	SHIRE	25MG;0.125MG	N012359 004	
HYDROGEN PEROXIDE				
SOLUTION;TOPICAL				
ESKATA				
+	ACLARIS	40%	N209305 001	Dec 14, 2017
HYDROMORPHONE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
PALLADONE				
	PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
		16MG	N021044 002	Sep 24, 2004
		24MG	N021044 003	Sep 24, 2004
		32MG	N021044 004	Sep 24, 2004
INJECTABLE;INJECTION				
DILAUDID-HP				
+	FRESENIUS KABI USA	10MG/ML	N019034 001	Jan 11, 1984
		250MG/VIAL	N019034 002	Aug 04, 1994
HYDROMORPHONE HYDROCHLORIDE				
	BARR	10MG/ML	A076444 001	Apr 25, 2003
	HOSPIRA	10MG/ML	A074598 001	Jun 19, 1997
	WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROMORPHONE HYDROCHLORIDE

SOLUTION;ORAL					
HYDROMORPHONE HYDROCHLORIDE					
	GENUS	5MG/5ML	A207108	001	Apr 22, 2020
TABLET;ORAL					
HYDROMORPHONE HYDROCHLORIDE					
	GENUS	2MG	A077471	002	Dec 09, 2009
		4MG	A077471	003	Dec 09, 2009
		8MG	A077471	001	Dec 09, 2009
	HIKMA	4MG	A074597	003	May 29, 2009
		8MG	A074597	001	Jul 29, 1998
	MPP PHARMA	8MG	A076723	001	Oct 18, 2005
	NESHER PHARMS	2MG	A077311	001	Nov 09, 2005
		4MG	A077311	002	Nov 09, 2005
		8MG	A077311	003	Nov 09, 2005
TABLET, EXTENDED RELEASE;ORAL					
EXALGO					
+	SPECGX LLC	8MG **	N021217	001	Mar 01, 2010
+		12MG **	N021217	002	Mar 01, 2010
+		16MG **	N021217	003	Mar 01, 2010
+		32MG **	N021217	004	Aug 24, 2012
HYDROMORPHONE HYDROCHLORIDE					
	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014
		12MG	A202144	002	May 12, 2014
		16MG	A202144	003	May 12, 2014
		32MG	A202144	004	Jun 30, 2016

HYDROXOCOBALAMIN

INJECTABLE;INJECTION					
ALPHAREDISOL					
	MERCK	1MG/ML	A080778	001	
CYANOKIT					
	BTG INTL	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006
HYDROXOCOBALAMIN					
	ABRAXIS PHARM	1MG/ML	A084921	001	
	WATSON LABS	1MG/ML	A085528	001	
HYDROXOMIN					
	BEL MAR	1MG/ML	A084629	001	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS;OPHTHALMIC					
PAREDRINE					
	PHARMICS	1%	N000004	004	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC					
PAREMYD					
+	EPIC PHARMA LLC	1%;0.25%	N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL					
HYDROXYCHLOROQUINE SULFATE					
	HIKMA PHARMS	200MG	A040760	001	Aug 15, 2007
	WATSON LABS	200MG	A040133	001	Nov 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION					
HYDROXYPROGESTERONE CAPROATE					
	ALLERGAN	125MG/ML	N017439	001	
		250MG/ML	N017439	002	
	EPIC PHARMA LLC	125MG/ML	N018004	001	
SOLUTION;INTRAMUSCULAR					
DELALUTIN					
+	BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML) **	N010347	004	
+		125MG/ML (125MG/ML) **	N016911	001	
+		250MG/ML (250MG/ML) **	N010347	002	
+		250MG/ML (250MG/ML) **	N016911	002	
HYDROXYPROGESTERONE CAPROATE					
	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015
	EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYPROPYL CELLULOSE				
INSERT;OPHTHALMIC				
LACRISERT				
+ BAUSCH AND LOMB INC	5MG	N018771	001	
HYDROXYSTILBAMIDINE ISETHIONATE				
INJECTABLE;INJECTION				
HYDROXYSTILBAMIDINE ISETHIONATE				
SANOFI AVENTIS US	225MG/AMP	N009166	001	
HYDROXYUREA				
CAPSULE;ORAL				
DROXIA				
+ WAYLIS THERAP	200MG	N016295	002	Feb 25, 1998
+	300MG	N016295	003	Feb 25, 1998
+	400MG	N016295	004	Feb 25, 1998
HYDROXYUREA				
BARR	250MG	A075143	002	Sep 21, 2000
BARR LABS INC	250MG	A075020	002	Jun 26, 2000
	500MG	A075020	001	Jul 30, 1998
ROXANE	500MG	A074476	001	Aug 18, 1995
TABLET;ORAL				
HYDROXYUREA				
BARR	1GM	A075734	001	Aug 29, 2000
HYDROXYZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
HYDROXYZINE				
BAXTER HLTHCARE	50MG/ML	A085551	002	
HYDROXYZINE HYDROCHLORIDE				
ALTANA	25MG/ML	A087273	001	Apr 20, 1982
	50MG/ML	A087273	002	Apr 20, 1982
BAXTER HLTHCARE	25MG/ML	A085551	001	
DR REDDYS	50MG/ML	A085779	001	
FRESENIUS KABI USA	25MG/ML	A087329	001	
	25MG/ML	A088184	001	Mar 31, 1983
	50MG/ML	A087329	002	
	50MG/ML	A088185	001	Mar 31, 1983
HOSPIRA	25MG/ML	A087416	001	
	50MG/ML	A086821	001	
	50MG/ML	A087546	001	
PHARMAFAIR	25MG/ML	A088862	001	Feb 14, 1986
	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAX				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
+ PFIZER	25MG/ML **	N011111	001	
+	50MG/ML **	N011111	002	
SYRUP;ORAL				
ATARAX				
ROERIG	10MG/5ML **	N010485	001	
HYDROXYZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
HIKMA	10MG/5ML	A040010	001	Oct 28, 1994
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
RISING	10MG/5ML	A086880	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

ATARAX					
+	PFIZER	10MG **	N010392	001	
+		25MG **	N010392	004	
+		50MG **	N010392	006	
+		100MG **	N010392	005	
HYDROXYZINE HYDROCHLORIDE					
	ABLE	10MG	A040559	001	Jul 22, 2004
		25MG	A040562	001	Jul 22, 2004
		50MG	A040563	001	Jul 22, 2004
	ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
		25MG	A089072	001	Jul 22, 1986
		50MG	A089073	001	Jul 22, 1986
	HALSEY	10MG	A089366	001	May 02, 1988
		25MG	A089117	001	May 02, 1988
		50MG	A089396	001	May 02, 1988
	IVAX PHARMS	10MG	A087216	001	
		25MG	A087410	001	
		50MG	A087411	001	
	KV PHARM	10MG	A087819	001	Jun 23, 1982
		25MG	A087820	001	Jun 23, 1982
		50MG	A087821	001	Jun 23, 1982
		100MG	A087822	001	Jun 23, 1982
	MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
		25MG	A087857	001	Apr 18, 1983
		50MG	A087860	001	Apr 18, 1983
	PLIVA	100MG	A081054	001	Sep 25, 1995
	PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
		25MG	A088121	001	Sep 25, 1984
		50MG	A088122	001	Sep 25, 1984
	QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
		25MG	A088551	001	Oct 22, 1985
		50MG	A088529	001	Oct 22, 1985
	RISING	10MG	A091176	001	Jun 07, 2010
		25MG	A091176	002	Jun 07, 2010
		50MG	A091176	003	Jun 07, 2010
	SANDOZ	10MG	A087246	002	
		25MG	A085247	001	
		50MG	A087245	001	
	SOMERSET THERAPS LLC	10MG	A040812	001	Mar 12, 2008
		25MG	A040812	002	Mar 12, 2008
		50MG	A040812	003	Mar 12, 2008
	STRIDES PHARMA INTL	10MG	A087602	001	Jan 22, 1982
		25MG	A087603	001	Jan 22, 1982
+		50MG	A087604	001	Jan 22, 1982
	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
		25MG	A040899	002	Jun 10, 2008
		50MG	A040899	003	Jun 10, 2008
	SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
		25MG	A089382	001	May 19, 1986
		50MG	A089383	001	May 19, 1986
		100MG	A087862	001	Apr 18, 1983
	SUPERPHARM	10MG	A088794	001	Dec 05, 1984
		25MG	A088795	001	Dec 05, 1984
		50MG	A088796	001	Dec 05, 1984
	USL PHARMA	10MG	A089121	001	Mar 20, 1986
		25MG	A089122	001	Mar 20, 1986
		50MG	A089123	001	Mar 20, 1986
	WATSON LABS	10MG	A081149	001	Mar 18, 1994
		10MG	A086827	001	
		10MG	A088348	001	Sep 15, 1983
		25MG	A081150	001	Mar 18, 1994
		25MG	A086829	001	
		25MG	A088349	001	Sep 15, 1983
		50MG	A081151	001	Mar 18, 1994
		50MG	A086836	001	
		50MG	A088350	001	Sep 15, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE PAMOATE				
CAPSULE;ORAL				
HY-PAM "25"				
	TEVA	EQ 25MG HYDROCHLORIDE	A088713 001	Mar 04, 1985
HYDROXYZINE PAMOATE				
	BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127 001	Jun 28, 1991
	DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593 001	Feb 29, 1984
		EQ 50MG HYDROCHLORIDE	A088594 001	Feb 29, 1984
		EQ 100MG HYDROCHLORIDE	A088595 001	Feb 29, 1984
	IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761 001	Mar 05, 1982
		EQ 50MG HYDROCHLORIDE	A087760 001	Mar 05, 1982
	PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656 001	Jun 11, 1982
		EQ 25MG HYDROCHLORIDE	A089145 001	Mar 17, 1986
		EQ 50MG HYDROCHLORIDE	A087657 001	Jun 11, 1982
		EQ 50MG HYDROCHLORIDE	A089146 001	Mar 17, 1986
		EQ 100MG HYDROCHLORIDE	A087658 001	Jun 11, 1982
	SANDOZ	EQ 50MG HYDROCHLORIDE	A081128 001	Jun 28, 1991
		EQ 100MG HYDROCHLORIDE	A081129 001	Jun 28, 1991
	SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031 001	Jan 02, 1987
		EQ 50MG HYDROCHLORIDE	A089032 001	Jan 02, 1987
		EQ 100MG HYDROCHLORIDE	A089033 001	Jan 02, 1987
	VANGARD	EQ 25MG HYDROCHLORIDE	A088392 001	Sep 19, 1983
		EQ 50MG HYDROCHLORIDE	A088393 001	Sep 19, 1983
	WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165 001	Jul 31, 1991
		EQ 25MG HYDROCHLORIDE	A086698 001	
		EQ 25MG HYDROCHLORIDE	A086840 001	Jul 01, 1982
		EQ 50MG HYDROCHLORIDE	A086695 001	
		EQ 50MG HYDROCHLORIDE	A086705 001	Jul 01, 1982
		EQ 50MG HYDROCHLORIDE	A087767 001	Aug 16, 1982
		EQ 100MG HYDROCHLORIDE	A086697 001	
		EQ 100MG HYDROCHLORIDE	A086728 001	Oct 05, 1982
		EQ 100MG HYDROCHLORIDE	A087790 001	Aug 16, 1982
VISTARIL				
+	PFIZER	EQ 100MG HYDROCHLORIDE **	N011459 006	
SUSPENSION;ORAL				
VISTARIL				
+	PFIZER	EQ 25MG HYDROCHLORIDE/5ML **	N011795 001	
IBANDRONATE SODIUM				
INJECTABLE;INTRAVENOUS				
BONIVA				
+	ROCHE	EQ 3MG BASE/3ML **	N021858 001	Jan 06, 2006
IBANDRONATE SODIUM				
	AVET LIFESCIENCES	EQ 3MG BASE/3ML	A203987 001	Sep 02, 2014
	NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329 001	Jun 16, 2021
	SUN PHARM	EQ 3MG BASE/3ML	A090853 001	Feb 14, 2014
TABLET;ORAL				
BONIVA				
+	HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455 001	May 16, 2003
+		EQ 150MG BASE **	N021455 002	Mar 24, 2005
IBANDRONATE SODIUM				
	PHARMOBEDIENT	EQ 150MG BASE	A078995 001	Mar 19, 2012
	SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996 001	Aug 15, 2012
	WATSON LABS TEVA	EQ 150MG BASE	A079003 001	Mar 20, 2012
IBRUTINIB				
CAPSULE;ORAL				
IBRUTINIB				
	ZYDUS LIFESCIENCES	70MG	A211344 001	Mar 31, 2021
		140MG	A211344 002	Mar 31, 2021
TABLET;ORAL				
IMBRUVICA				
+	PHARMACYCLICS LLC	560MG	N210563 004	Feb 16, 2018
IBUPROFEN				
CAPSULE;ORAL				
IBUPROFEN				
	CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998
MIDOL				
	BAYER	200MG **	A070626 001	Sep 02, 1987
		200MG **	A071002 001	Sep 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

SOLUTION;INTRAVENOUS					
CALDOLOR					
	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009
SUSPENSION;ORAL					
CHILDREN'S ADVIL					
	HALEON US HOLDINGS	100MG/5ML	N019833	002	Sep 19, 1989
CHILDREN'S ELIXSURE					
	MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004
IBU					
	ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989
IBUPROFEN					
	ARISE	100MG/5ML	A200457	001	Aug 18, 2011
	PAI HOLDINGS PHARM	100MG/5ML	A205647	001	Nov 03, 2016
MOTRIN					
+	MCNEIL CONSUMER	100MG/5ML **	N019842	001	Sep 19, 1989
SUSPENSION/DROPS;ORAL					
IBUPROFEN					
	STRIDES PHARMA	50MG/1.25ML	A214071	001	Jun 09, 2022
MOTRIN					
	MCNEIL	40MG/ML	N020476	001	May 25, 1995
PEDIATRIC ADVIL					
+	HALEON US HOLDINGS	100MG/2.5ML	N020812	001	Jan 30, 1998
TABLET;ORAL					
ACHES-N-PAIN					
	LEDERLE	200MG	A071065	001	May 28, 1987
CAP-PROFEN					
	PERRIGO	200MG	A072097	001	Dec 08, 1987
IBU					
	BASF	400MG	A070083	001	Feb 22, 1985
		400MG	N018197	001	
		600MG	A070088	001	Feb 08, 1985
		600MG	A070099	001	Mar 29, 1985
		800MG	A070745	001	Jul 23, 1986
IBU-TAB					
	ALRA	400MG	A071058	001	Aug 11, 1988
		600MG	A071059	001	Aug 11, 1988
		800MG	A071965	001	Aug 11, 1988
IBU-TAB 200					
	ALRA	200MG	A071057	001	Aug 11, 1988
IBUPRIN					
	PLIVA	200MG	A071773	001	Jul 16, 1987
IBUPROFEN					
	ABBOTT	600MG	A070556	001	Jun 14, 1985
		800MG	A071264	001	Jul 25, 1986
	ADAPTIS	200MG	A071265	001	Oct 15, 1986
		200MG	A071265	002	Sep 10, 1987
	ANI PHARMS	200MG	A071144	001	Jan 20, 1987
		200MG	A072901	001	Dec 19, 1991
		200MG	A072903	001	Dec 19, 1991
	CONTRACT PHARMACAL	200MG	A071735	001	Sep 10, 1987
		200MG	A073691	001	Feb 25, 1994
		200MG	A074931	001	Jul 20, 1998
	HALSEY	200MG	A071027	001	Sep 29, 1987
		300MG	A071028	001	Mar 23, 1987
		400MG	A071029	001	Mar 23, 1987
		600MG	A071030	001	Mar 23, 1987
		800MG	A072137	001	Feb 05, 1988
	IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
		200MG	A072040	001	Apr 29, 1988
		400MG	A071145	001	Sep 23, 1986
		600MG	A071146	001	Sep 23, 1986
		800MG	A071769	001	May 08, 1987
	J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
	L PERRIGO CO	400MG	A077114	001	Jul 18, 2005
		600MG	A077114	002	Jul 18, 2005
		800MG	A077114	003	Jul 18, 2005
	LEDERLE	400MG	A070629	001	Sep 19, 1986
		600MG	A070630	001	Sep 19, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

TABLET;ORAL

IBUPROFEN

LEINER	300MG	A071266	001	Oct 15, 1986
LNK	100MG	A076741	001	Jun 17, 2004
MCNEIL	600MG	A070476	001	Jun 16, 1986
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM	200MG	A071163	001	Jul 15, 1986
OHM LABS	400MG	A070818	001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986
PAR PHARM	300MG	A070328	001	Aug 06, 1985
PERRIGO	200MG	A072098	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PH HEALTH	200MG	A071639	001	Feb 02, 1988
	200MG	A072249	001	Jan 10, 1989
	300MG	A071230	001	Oct 22, 1986
	400MG	A071231	001	Oct 22, 1986
	400MG	A071644	001	Feb 01, 1988
	600MG	A071232	001	Oct 22, 1986
	800MG	A072004	001	Nov 18, 1987
PHARMOBEDIENT	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
RISING	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	400MG	A072064	001	Jan 14, 1988
	600MG	A072065	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
STRIDES PHARMA	200MG	A206989	001	Jun 29, 2018
	200MG	A207052	001	May 30, 2017
STRIDES PHARMA INTL	200MG	A070481	001	Sep 24, 1986
	200MG	A071575	001	May 08, 1987
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986
SUN PHARM INDUSTRIES	200MG	A070493	001	Dec 24, 1985
	200MG	A070908	001	Sep 26, 1986
	200MG	A071462	001	Oct 02, 1986
	400MG	A070079	001	Jul 24, 1985
	600MG	A070080	001	Jul 24, 1985
	800MG	A071448	001	Feb 18, 1987
SUNSHINE	400MG	A204062	001	Sep 10, 2018
	600MG	A204062	002	Sep 10, 2018
	800MG	A204062	003	Sep 10, 2018
SUPERPHARM	600MG	A070709	001	Apr 25, 1986
TEVA	200MG	A073141	001	May 29, 1992
	400MG	A073343	001	Jun 30, 1992
	600MG	A073344	001	Jun 30, 1992
	800MG	A073345	001	Jun 30, 1992
ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020
WATSON LABS	200MG	A070435	001	Mar 05, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN					
TABLET;ORAL					
IBUPROFEN					
	200MG		A071765	001	Sep 04, 1987
	200MG		A071905	001	Mar 08, 1988
	300MG		A071338	001	Dec 01, 1986
	400MG		A070038	001	Sep 06, 1985
	400MG		A070436	001	Aug 21, 1985
	600MG		A070041	001	Sep 06, 1985
	600MG		A070437	001	Aug 21, 1985
	800MG		A071547	001	Jul 02, 1987
	800MG		A071911	001	Oct 13, 1987
YICHANG HUMANWELL	200MG		A214003	001	Oct 19, 2020
IBUPROHM					
OHM LABS	200MG		A071214	001	Dec 01, 1986
	400MG		A070469	001	Aug 29, 1985
JUNIOR STRENGTH IBUPROFEN					
L PERRIGO CO	100MG		A075367	001	Apr 22, 1999
MEDIPREN					
MCNEIL	200MG		A070475	001	Feb 06, 1986
	200MG		A071215	001	Jun 26, 1986
MIDOL					
BAYER	200MG		A070591	001	Sep 02, 1987
	200MG		A071001	001	Sep 02, 1987
MOTRIN					
+ MCNEIL CONSUMER	300MG **		N017463	003	
+	400MG **		N017463	002	
+	600MG **		N017463	004	
+	800MG **		N017463	005	May 22, 1985
MCNEIL PED	100MG		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN					
KENVUE BRANDS	200MG		N019012	004	Feb 25, 2000
NUPRIN					
BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
	200MG		A072036	001	Feb 16, 1988
KENVUE BRANDS	200MG		N019012	001	May 18, 1984
	200MG		N019012	002	Jul 29, 1987
RUFEN					
BASF	600MG		N018197	002	Mar 05, 1984
TAB-PROFEN					
PERRIGO	200MG		A072095	001	Dec 08, 1987
TABLET, CHEWABLE;ORAL					
CHILDREN'S MOTRIN					
+ KENVUE BRANDS	50MG		N020601	001	Nov 15, 1996
IBUPROFEN					
PERRIGO	50MG		A076359	001	Jan 16, 2004
JUNIOR STRENGTH MOTRIN					
+ KENVUE BRANDS	100MG		N020601	003	Nov 15, 1996
MOTRIN					
MCNEIL PED	50MG		N020135	001	Nov 16, 1994
	100MG		N020135	002	Nov 16, 1994
IBUPROFEN SODIUM					
TABLET;ORAL					
IBUPROFEN SODIUM					
PERRIGO R AND D	EQ 200MG BASE		A206581	001	Aug 03, 2015
IBUPROFEN; OXYCODONE HYDROCHLORIDE					
TABLET;ORAL					
COMBUNOX					
+ FOREST LABS	400MG;5MG **		N021378	001	Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN					
ACTAVIS ELIZABETH	400MG;5MG		A078769	001	Jan 04, 2008
BARR LABS INC	400MG;5MG		A078316	001	Nov 29, 2007
WATSON LABS	400MG;5MG		A078394	001	Nov 26, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE				
SUSPENSION;ORAL				
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
PERRIGO	100MG/5ML;15MG/5ML		A076478 001	Nov 05, 2003
TABLET;ORAL				
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
CONTRACT PHARMACAL	200MG;30MG		A075588 001	Apr 08, 2002
IBUTILIDE FUMARATE				
INJECTABLE;INJECTION				
IBUTILIDE FUMARATE				
LUITPOLD	0.1MG/ML		A090240 001	Jan 11, 2010
MYLAN INSTITUTIONAL	0.1MG/ML		A090924 001	Jan 11, 2010
ICATIBANT ACETATE				
INJECTABLE;SUBCUTANEOUS				
ICATIBANT ACETATE				
CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A213054 001	Oct 05, 2020
GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A213222 001	May 21, 2021
IDARUBICIN HYDROCHLORIDE				
POWDER;INTRAVENOUS				
IDAMYCIN				
PFIZER	5MG/VIAL		N050661 002	Sep 27, 1990
	10MG/VIAL		N050661 001	Sep 27, 1990
	20MG/VIAL		N050661 003	Apr 25, 1995
IDARUBICIN HYDROCHLORIDE				
TEVA PARENTERAL	5MG/VIAL		A065037 003	May 01, 2002
	10MG/VIAL		A065037 002	May 01, 2002
	20MG/VIAL		A065037 001	May 01, 2002
SOLUTION;INTRAVENOUS				
IDARUBICIN HYDROCHLORIDE				
FRESENIUS KABI USA	5MG/5ML (1MG/ML)		A065440 001	Aug 04, 2009
	10MG/10ML (1MG/ML)		A065440 002	Aug 04, 2009
	20MG/20ML (1MG/ML)		A065440 003	Aug 04, 2009
RISING	5MG/5ML (1MG/ML)		A200144 001	Oct 11, 2012
	10MG/10ML (1MG/ML)		A200144 002	Oct 11, 2012
	20MG/20ML (1MG/ML)		A200144 003	Oct 11, 2012
SANDOZ	5MG/5ML (1MG/ML)		A091293 001	Mar 29, 2011
	10MG/10ML (1MG/ML)		A091293 002	Mar 29, 2011
	20MG/20ML (1MG/ML)		A091293 003	Mar 29, 2011
IDOXURIDINE				
OINTMENT;OPHTHALMIC				
STOXIL				
GLAXOSMITHKLINE	0.5%		N015868 001	
SOLUTION/DROPS;OPHTHALMIC				
DENDRID				
+ ALCON	0.1%		N014169 001	
HERPLEX				
ALLERGAN	0.1%		N013935 002	
STOXIL				
GLAXOSMITHKLINE	0.1%		N013934 001	
IFOSFAMIDE				
INJECTABLE;INJECTION				
IFOSFAMIDE				
EXTROVIS	1GM/20ML (50MG/ML)		A201689 001	Nov 26, 2012
	3GM/60ML (50MG/ML)		A201689 002	Nov 26, 2012
FRESENIUS KABI USA	1GM/20ML (50MG/ML)		A090181 001	Sep 22, 2009
	3GM/60ML (50MG/ML)		A090181 002	Sep 22, 2009
IFOSFAMIDE; MESNA				
INJECTABLE;INJECTION				
IFEX/MESNEX KIT				
BAXTER HLTHCARE	1GM/VIAL;100MG/ML		N019763 003	Oct 10, 1992
	3GM/VIAL;100MG/ML		N019763 004	Oct 10, 1992
INJECTABLE;INTRAVENOUS				
IFOSFAMIDE/MESNA KIT				
TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)		A075874 001	Feb 26, 2002
	3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)		A075874 002	Feb 26, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ILOPERIDONE					
TABLET;ORAL					
ILOPERIDONE					
	INVENTIA	1MG	A207231	001	Nov 28, 2016
		2MG	A207231	002	Nov 28, 2016
		4MG	A207231	003	Nov 28, 2016
		6MG	A207231	004	Nov 28, 2016
		8MG	A207231	005	Nov 28, 2016
		10MG	A207231	006	Nov 28, 2016
		12MG	A207231	007	Nov 28, 2016
	LUPIN LTD	1MG	A206890	001	May 05, 2022
		2MG	A206890	002	May 05, 2022
		4MG	A206890	003	May 05, 2022
		6MG	A206890	004	May 05, 2022
		8MG	A206890	005	May 05, 2022
		10MG	A206890	006	May 05, 2022
		12MG	A206890	007	May 05, 2022
	TARO	1MG	A207098	001	Jul 22, 2019
		2MG	A207098	002	Jul 22, 2019
		4MG	A207098	003	Jul 22, 2019
		6MG	A207098	004	Jul 22, 2019
		8MG	A207098	005	Jul 22, 2019
		10MG	A207098	006	Jul 22, 2019
		12MG	A207098	007	Jul 22, 2019
ILOPROST					
SOLUTION;INHALATION					
VENTAVIS					
+	ACTELION	10MCG/ML (10MCG/ML) **	N021779	002	Dec 08, 2005
		20MCG/2ML (10MCG/ML) **	N021779	001	Dec 29, 2004
+		20MCG/ML (20MCG/ML) **	N021779	003	Aug 07, 2009
IMATINIB MESYLATE					
CAPSULE;ORAL					
GLEEVEC					
+	NOVARTIS	EQ 50MG BASE **	N021335	001	May 10, 2001
+		EQ 100MG BASE **	N021335	002	May 10, 2001
TABLET;ORAL					
IMATINIB MESYLATE					
	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019
		EQ 400MG BASE	A207495	002	Feb 08, 2019
	HIKMA	EQ 100MG BASE	A207586	001	Jul 13, 2018
		EQ 400MG BASE	A207586	002	Jul 13, 2018
	NOVITIUM PHARMA	EQ 100MG BASE	A205990	001	Feb 08, 2019
		EQ 400MG BASE	A205990	002	Feb 08, 2019
IMIPRAMINE HYDROCHLORIDE					
CONCENTRATE;ORAL					
IMIPRAMINE HYDROCHLORIDE					
	NOVARTIS	25MG/ML	A086765	001	
INJECTABLE;INJECTION					
TOFRANIL					
	NOVARTIS	12.5MG/ML	N011838	002	
TABLET;ORAL					
IMIPRAMINE HYDROCHLORIDE					
	CHARTWELL	10MG	A090441	002	Mar 11, 2010
		25MG	A090441	003	Mar 11, 2010
		50MG	A090441	001	Mar 11, 2010
	LEDERLE	10MG	A086269	001	
		25MG	A086267	001	
		50MG	A086268	001	
	PAR PHARM	10MG	A089422	001	Jul 14, 1987
		25MG	A089497	001	Jul 14, 1987
	ROXANE	10MG	A083799	001	
		25MG	A083799	002	
		50MG	A083799	003	
	SANDOZ	10MG	A085200	001	
		25MG	A084869	002	
		50MG	A085133	001	
+	SPECGX LLC	10MG	A087846	002	May 22, 1984
+		25MG	A087846	003	May 22, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
SUN PHARM INDUSTRIES	10MG	A081048	001	Jun 05, 1990
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982
	25MG	A087619	001	Feb 09, 1982
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	
TOFRANIL				
+ SPECGX LLC	50MG	A087846	001	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE;ORAL				
IMIPRAMINE PAMOATE				
RISING	EQ 75MG HYDROCHLORIDE	A202338	001	Jun 28, 2013
	EQ 100MG HYDROCHLORIDE	A202338	002	Jun 28, 2013
	EQ 125MG HYDROCHLORIDE	A202338	003	Jun 28, 2013
	EQ 150MG HYDROCHLORIDE	A202338	004	Jun 28, 2013
TOFRANIL-PM				
+ SPECGX LLC	EQ 75MG HYDROCHLORIDE **	N017090	001	
+	EQ 100MG HYDROCHLORIDE **	N017090	004	
+	EQ 125MG HYDROCHLORIDE **	N017090	003	
+	EQ 150MG HYDROCHLORIDE **	N017090	002	

IMIQUIMOD

CREAM;TOPICAL				
ALDARA				
+ BAUSCH	5% **	N020723	001	Feb 27, 1997
IMIQUIMOD				
APOTEX INC	5%	A091308	001	Apr 06, 2012
COSETTE	5%	A200481	001	Apr 18, 2011
ENCUBE	5%	A091044	001	Feb 28, 2011
STRIDES PHARMA	5%	A202002	001	Jun 24, 2014

INAMRINONE LACTATE

INJECTABLE;INJECTION				
AMRINONE LACTATE				
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR				
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984

INDACATEROL MALEATE				
POWDER;INHALATION				
ARCAPTA NEOHALER				
+	NOVARTIS	EQ 75MCG BASE	N022383 001	Jul 01, 2011
INDAPAMIDE				
TABLET;ORAL				
INDAPAMIDE				
	ANI PHARMS	1.25MG	A074498 002	Feb 12, 1998
		1.25MG	A075201 001	Dec 04, 1998
		2.5MG	A074498 001	Oct 31, 1996
		2.5MG	A075201 002	Dec 04, 1998
	AUROBINDO PHARMA USA	1.25MG	A075105 001	Jul 23, 1998
		2.5MG	A075105 002	Jul 23, 1998
	CHARTWELL RX	1.25MG	A074594 001	May 23, 1996
		2.5MG	A074594 002	May 23, 1996
	TEVA	1.25MG	A074665 001	Apr 04, 1997
		2.5MG	A074665 002	Apr 04, 1997
	WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
		2.5MG	A074585 002	Sep 26, 1996
LOZOL				
+	SANOFI AVENTIS US	1.25MG **	N018538 002	Apr 29, 1993
+		2.5MG **	N018538 001	Jul 06, 1983
INDECAINIDE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
DECABID				
	LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
		EQ 75MG BASE	N019693 002	Dec 29, 1989
		EQ 100MG BASE	N019693 003	Dec 29, 1989
INDINAVIR SULFATE				
CAPSULE;ORAL				
CRIXIVAN				
	MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
+		EQ 200MG BASE	N020685 003	Mar 13, 1996
		EQ 333MG BASE	N020685 005	Dec 17, 1998
+		EQ 400MG BASE	N020685 001	Mar 13, 1996
INDIUM IN-111 CHLORIDE				
INJECTABLE;INJECTION				
INDICLOR				
+	GE HEALTHCARE	2mCi/0.2ML	N019862 001	Dec 29, 1992
INDIUM IN 111 CHLORIDE				
+	CURIUM	5mCi/0.5ML	N019841 001	Sep 27, 1994
INDOCYANINE GREEN				
INJECTABLE;INJECTION				
IC-GREEN				
	RENEW PHARMS	10MG/VIAL **	N011525 003	
		40MG/VIAL **	N011525 004	
		50MG/VIAL **	N011525 002	
INDOMETHACIN				
CAPSULE;ORAL				
INDO-LEMMON				
	TEVA	25MG	A070266 001	Nov 07, 1985
		50MG	A070267 001	Nov 07, 1985
INDOCIN				
+	ZYLA LIFE SCIENCES	25MG **	N016059 001	
+		50MG **	N016059 002	
INDOMETHACIN				
	ABLE	25MG	A076666 001	Dec 17, 2003
		50MG	A076666 002	Dec 17, 2003
	ANI PHARMS	25MG	A071148 001	Mar 18, 1987
		50MG	A071149 001	Mar 18, 1987
	CYCLE	25MG	A070353 001	Jun 18, 1985
		50MG	A070354 001	Jun 18, 1985
	DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
		50MG	A070327 001	Oct 18, 1985
	HALSEY	25MG	A070782 001	Jun 03, 1987
		50MG	A070635 001	Jun 03, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INDOMETHACIN					
CAPSULE;ORAL					
INDOMETHACIN					
	HERITAGE	25MG	N018851	001	May 18, 1984
		50MG	N018851	002	May 18, 1984
	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986
		50MG	A070756	001	Feb 12, 1986
	IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
		50MG	N018730	002	May 04, 1984
	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017
		50MG	A205215	002	Aug 25, 2017
	MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
		50MG	A070068	001	Oct 03, 1986
	PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
		50MG	N018806	002	Nov 23, 1984
	PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
		50MG	A070592	001	Aug 11, 1986
	RISING	25MG	N018858	001	Apr 20, 1984
		50MG	A070624	001	Sep 04, 1985
		50MG	N018858	002	Apr 20, 1984
	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
		50MG	A091401	002	Mar 28, 2013
	SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
		50MG	A070900	001	Feb 09, 1987
	SUPERPHARM	25MG	A070487	001	Oct 10, 1986
		50MG	A070488	001	Oct 10, 1986
	TEVA	25MG	A071342	001	Apr 18, 1988
		50MG	A071343	001	Apr 18, 1988
	WATSON LABS	25MG	A070529	001	Oct 18, 1985
		25MG	A070784	001	Aug 20, 1986
		25MG	A072996	001	Jul 31, 1991
		25MG	N018690	001	Jul 31, 1984
		50MG	A070530	001	Oct 18, 1985
		50MG	A070785	001	Aug 20, 1986
		50MG	A071635	001	May 18, 1987
		50MG	A072997	001	Jul 31, 1991
		50MG	N018690	002	Jul 31, 1984
TIVORBEX					
+	GENUS	20MG	N204768	001	Feb 24, 2014
+		40MG	N204768	002	Feb 24, 2014
CAPSULE, EXTENDED RELEASE;ORAL					
INDOCIN SR					
+	ZYLA	75MG **	N018185	001	Feb 23, 1982
INDOMETHACIN					
	ABLE	75MG	A076114	001	Feb 06, 2002
	AUROBINDO PHARMA	75MG	A204243	001	Dec 27, 2016
	INWOOD LABS	75MG	A072410	001	Mar 15, 1989
	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015
	MYLAN	75MG	A202139	001	Mar 20, 2014
	SANDOZ	75MG	A074464	001	May 28, 1998
	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013
SUPPOSITORY;RECTAL					
INDOCIN					
+	ZYLA LIFE SCIENCES	50MG **	N017814	001	Aug 13, 1984
SUSPENSION;ORAL					
INDOMETHACIN					
	HIKMA	25MG/5ML	A071412	001	Mar 18, 1987
INDOMETHACIN SODIUM					
INJECTABLE;INJECTION					
INDOCIN					
+	RECORDATI RARE	EQ 1MG BASE/VIAL **	N018878	001	Jan 30, 1985
INDOMETHACIN SODIUM					
	HIKMA	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008
	HOSPIRA	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016
	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INFIGRATINIB PHOSPHATE				
CAPSULE;ORAL				
TRUSELTIQ				
+	HELSINN HLTHCARE	25MG	N214622 001	May 28, 2021
+		100MG	N214622 002	May 28, 2021
INGENOL MEBUTATE				
GEL;TOPICAL				
INGENOL MEBUTATE				
	PADAGIS ISRAEL	0.015%	A209018 001	Jan 07, 2019
		0.05%	A209019 001	Jan 09, 2019
PICATO				
+	LEO LABS	0.015%	N202833 001	Jan 23, 2012
+		0.05%	N202833 002	Jan 23, 2012
INOTERSEN SODIUM				
SOLUTION;SUBCUTANEOUS				
TEGSEDI				
+	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)	N211172 001	Oct 05, 2018
INULIN				
INJECTABLE;INJECTION				
INULIN AND SODIUM CHLORIDE				
	ISO TEX	100MG/ML	N002282 001	
INVERT SUGAR				
INJECTABLE;INJECTION				
TRAVERT 10% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	10GM/100ML	N016717 001	
IOBENGUANE I-131				
SOLUTION;INTRAVENOUS				
AZEDRA				
+	PROGENICS PHARMS INC	15mCi/ML	N209607 001	Jul 30, 2018
IOBENGUANE SULFATE I-123				
SOLUTION;INTRAVENOUS				
IOBENGUANE I-123				
	BWXT MEDCL	10mCi/5ML (2mCi/ML)	A213637 001	Dec 09, 2024
IOBENGUANE SULFATE I-131				
INJECTABLE;INJECTION				
IOBENGUANE SULFATE I 131				
	PHARMALUCENCE	2.3mCi/ML	N020084 001	Mar 25, 1994
IOCETAMIC ACID				
TABLET;ORAL				
CHOLEBRINE				
	MALLINCKRODT	750MG	N017129 001	
IODAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
RENOVUE-65				
	BRACCO	65%	N017902 001	
RENOVUE-DIP				
	BRACCO	24%	N017903 001	
IODIPAMIDE MEGLUMINE				
INJECTABLE;INJECTION				
CHOLOGRAFIN MEGLUMINE				
	BRACCO	10.3%	N009321 007	
+		52%	N009321 003	
IODIPAMIDE SODIUM				
INJECTABLE;INJECTION				
CHOLOGRAFIN SODIUM				
	BRACCO	20%	N009321 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IODIXANOL				
INJECTABLE;INJECTION				
VISIPAQUE 270				
GE HEALTHCARE	55%	N020808	001	Aug 29, 1997
IODOHIPPURATE SODIUM I-123				
INJECTABLE;INJECTION				
NEPHROFLOW				
GE HEALTHCARE	1mCi/ML	N018289	001	Dec 28, 1984
IODOHIPPURATE SODIUM I-131				
INJECTABLE;INJECTION				
HIPPURAN I 131				
MALLINCKRODT	0.25mCi/ML	N016666	001	
HIPPUTOPE				
BRACCO	1-2mCi/VIAL	N015419	002	
IODOHIPPURATE SODIUM I 131				
PHARMALUCENCE	0.2mCi/ML	N017313	001	
IODOXAMATE MEGLUMINE				
INJECTABLE;INJECTION				
CHOLOVUE				
BRACCO	9.9%	N018077	001	
	40.3%	N018076	001	
IOFETAMINE HYDROCHLORIDE I-123				
INJECTABLE;INJECTION				
SPECTAMINE				
IMP	1mCi/ML	N019432	001	Dec 24, 1987
IOHEXOL				
FOR SOLUTION;ORAL				
ORALTAG				
INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015
INJECTABLE;INJECTION				
OMNIPAQUE 210				
GE HEALTHCARE	45.3%	N018956	006	Jun 30, 1989
SOLUTION;INJECTION, ORAL, RECTAL				
OMNIPAQUE 240				
GE HEALTHCARE	51.8%	N020608	001	Oct 24, 1995
SOLUTION;URETHRAL				
OMNIPAQUE 70				
GE HEALTHCARE	15.1%	N018956	007	Jun 01, 1994
IOMEPROL				
SOLUTION;INTRA-ARTERIAL				
IOMERVU				
+ BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216016	002	Nov 27, 2024
+	17.5GM IODINE/50ML (350MG IODINE/ML)	N216016	006	Nov 27, 2024
+	20GM IODINE/50ML (400MG IODINE/ML)	N216016	010	Nov 27, 2024
+	25GM IODINE/100ML (250MG IODINE/ML)	N216016	001	Nov 27, 2024
+	30GM IODINE/100ML (300MG IODINE/ML)	N216016	003	Nov 27, 2024
+	35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024
+	40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024
+	60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024
+	45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024
+	52.5GM IODINE/150ML (350MG IODINE/ML	N216016	008	Nov 27, 2024
+	60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024
+	70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024
+	80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024
SOLUTION;INTRAVENOUS				
IOMERVU				
+ BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024
+	17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024
+	20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024
+	25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024
+	30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024
+	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024
+	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024
+	60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024
+	45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024
+	52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOMEPROL				
SOLUTION;INTRAVENOUS				
IOMERVU				
+	60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024
+	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024
+	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024
IOPAMIDOL				
INJECTABLE;INJECTION				
IOPAMIDOL				
BAXTER HLTHCARE	41%	A074629	001	Nov 06, 1996
	51%	A074629	004	Mar 31, 1998
	61%	A074629	002	Nov 06, 1996
	76%	A074629	003	Nov 06, 1996
HOSPIRA	61%	A074734	001	Dec 10, 1996
	76%	A074734	002	Dec 10, 1996
IOPAMIDOL-200				
COOK IMAGING	41%	A074881	001	Jul 28, 2000
HOSPIRA	41%	A074898	001	Dec 30, 1997
IOPAMIDOL-200 IN PLASTIC CONTAINER				
HOSPIRA	41%	A074636	001	Dec 30, 1997
IOPAMIDOL-250				
COOK IMAGING	51%	A074881	002	Jul 28, 2000
FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997
HOSPIRA	51%	A074898	002	Dec 30, 1997
	51%	A075005	001	Feb 24, 1998
IOPAMIDOL-250 IN PLASTIC CONTAINER				
HOSPIRA	51%	A074636	002	Dec 30, 1997
IOPAMIDOL-300				
ABBVIE	61%	A074638	001	Apr 30, 1997
COOK IMAGING	61%	A074881	003	Jul 28, 2000
FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997
HOSPIRA	61%	A074898	003	Dec 30, 1997
	61%	A075005	002	Feb 24, 1998
IOPAMIDOL-300 IN PLASTIC CONTAINER				
HOSPIRA	61%	A074636	003	Dec 30, 1997
	61%	A074637	001	Apr 03, 1997
IOPAMIDOL-370				
COOK IMAGING	76%	A074881	004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997
HOSPIRA	76%	A074898	004	Dec 30, 1997
	76%	A075005	003	Feb 24, 1998
IOPAMIDOL-370 IN PLASTIC CONTAINER				
HOSPIRA	76%	A074636	004	Dec 30, 1997
ISOVUE-128				
BRACCO	26%	N018735	005	Oct 21, 1986
ISOVUE-200				
BRACCO	41%	N020327	001	Oct 12, 1994
ISOVUE-250				
+ BRACCO	51%	N020327	002	Oct 12, 1994
SCANLUX-300				
SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010
SCANLUX-370				
SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010
IOPANOIC ACID				
TABLET;ORAL				
TELEPAQUE				
GE HEALTHCARE	500MG	N008032	001	
IOPHENDYLATE				
INJECTABLE;INJECTION				
PANTOPAQUE				
ALCON	100%	N005319	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOPROMIDE

INJECTABLE;INJECTION					
ULTRAVIST (PHARMACY BULK)					
+	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
ULTRAVIST 150					
+	BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995
ULTRAVIST 240					
+	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER					
+	BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION					
CONRAY 30					
+	LIEBEL-FLARSHEIM	30%	N016983	001	
CONRAY 43					
+	LIEBEL-FLARSHEIM	43%	N013295	002	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE;INJECTION					
VASCORAY					
	MALLINCKRODT	52%;26%	N016783	001	

IOTHALAMATE SODIUM

INJECTABLE;INJECTION					
ANGIO-CONRAY					
	MALLINCKRODT	80%	N013319	001	
CONRAY 325					
	MALLINCKRODT	54.3%	N017685	001	
CONRAY 400					
	MALLINCKRODT	66.8%	N014295	001	

IOTROLAN

INJECTABLE;INTRATHECAL					
OSMOVIST 190					
	BAYER HLTHCARE	40.6%	N019580	001	Dec 07, 1989
OSMOVIST 240					
	BAYER HLTHCARE	51.3%	N019580	002	Dec 07, 1989

IOVERSOL

INJECTABLE;INJECTION					
OPTIRAY 160					
	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988
OPTIRAY 240					
+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988
		51%	N020923	001	May 28, 1998
OPTIRAY 300					
+	LIEBEL-FLARSHEIM	64%	N020923	004	May 13, 1999

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE;INJECTION					
HEXABRIX					
	GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985

IOXILAN

INJECTABLE;INJECTION					
OXILAN-300					
	GUERBET	62%	N020316	001	Dec 21, 1995
OXILAN-350					
	GUERBET	73%	N020316	002	Dec 21, 1995

IPODATE CALCIUM

GRANULE;ORAL					
ORAGRAFIN CALCIUM					
	BRACCO	3GM/PACKET	N012968	001	

IPODATE SODIUM

CAPSULE;ORAL					
BILIVIST					
	BAYER HLTHCARE	500MG	A087768	001	Aug 11, 1982
ORAGRAFIN SODIUM					
	BRACCO	500MG	N012967	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IPRATROPIUM BROMIDE				
AEROSOL, METERED;INHALATION				
ATROVENT				
BOEHRINGER INGELHEIM	0.018MG/INH	N019085	001	Dec 29, 1986
SOLUTION;INHALATION				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.02% **	N020228	001	Sep 29, 1993
IPRATROPIUM BROMIDE				
ACTAVIS MID ATLANTIC	0.02%	A075111	001	Apr 22, 1999
APOTEX INC	0.02%	A075441	001	Mar 28, 2001
BAUSCH	0.02%	A075835	001	Oct 15, 2001
LANDELA PHARM	0.02%	A077072	001	Jul 19, 2005
PHARMOBEDIENT	0.02%	A074755	001	Jan 10, 1997
ROXANE	0.02%	A075867	001	Jul 22, 2002
SUN PHARM	0.02%	A207903	001	Jan 03, 2017
TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000
WATSON LABS	0.02%	A076291	001	May 09, 2005
ZENNOVA	0.02%	A075507	001	Jan 19, 2001
SPRAY, METERED;NASAL				
ATROVENT				
+ BOEHRINGER INGELHEIM	0.021MG/SPRAY **	N020393	001	Oct 20, 1995
+	0.042MG/SPRAY **	N020394	001	Oct 20, 1995
IPRATROPIUM BROMIDE				
AUROBINDO PHARMA USA	0.021MG/SPRAY	A075552	001	Mar 31, 2003
	0.042MG/SPRAY	A075553	001	Mar 31, 2003
IRBESARTAN				
TABLET;ORAL				
AVAPRO				
+ SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997
IRBESARTAN				
AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
	150MG	A203685	002	Dec 10, 2015
	300MG	A203685	003	Dec 10, 2015
APOTEX INC	75MG	A200832	001	Oct 15, 2012
	150MG	A200832	002	Oct 15, 2012
	300MG	A200832	003	Oct 15, 2012
CHARTWELL RX	75MG	A203161	001	Sep 27, 2012
	150MG	A203161	002	Sep 27, 2012
	300MG	A203161	003	Sep 27, 2012
HIKMA	75MG	A090201	001	Oct 15, 2012
	150MG	A090201	002	Oct 15, 2012
	300MG	A090201	003	Oct 15, 2012
IPCA LABS LTD	75MG	A211056	001	May 22, 2024
	150MG	A211056	002	May 22, 2024
	300MG	A211056	003	May 22, 2024
LUPIN LTD	75MG	A201531	001	Oct 15, 2012
	150MG	A201531	002	Oct 15, 2012
	300MG	A201531	003	Oct 15, 2012
WATSON LABS INC	75MG	A090720	001	Oct 12, 2012
	150MG	A090720	002	Oct 12, 2012
	300MG	A090720	003	Oct 12, 2012
YILING	75MG	A200461	001	Sep 27, 2012
	150MG	A200461	002	Sep 27, 2012
	300MG	A200461	003	Sep 27, 2012
IRINOTECAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IRINOTECAN HYDROCHLORIDE				
CHARTWELL RX	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010
	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010
CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008
	100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008
EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012
	100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012
FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008
HENGRUI PHARMA	40MG/2ML (20MG/ML)	A090675	002	Dec 16, 2011
	100MG/5ML (20MG/ML)	A090675	001	Dec 16, 2011
HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IRINOTECAN HYDROCHLORIDE					
INJECTABLE;INJECTION					
IRINOTECAN HYDROCHLORIDE					
		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009
	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008
		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008
	SANDOZ	40MG/2ML (20MG/ML)	A077994	001	Feb 27, 2008
		40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009
		100MG/5ML (20MG/ML)	A077994	002	Feb 27, 2008
		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009
	SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008
		100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008
	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008
		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008
IRON DEXTRAN					
INJECTABLE;INJECTION					
DEXFERRUM					
	AM REGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
IRON DEXTRAN					
	SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
PROFERDEX					
	NEW RIVER	EQ 50MG IRON/ML	N017807	001	
IRON SUCROSE					
INJECTABLE;INTRAVENOUS					
VENOFER					
	AM REGENT	EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013
		EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005
ISOETHARINE HYDROCHLORIDE					
SOLUTION;INHALATION					
BETA-2					
	NEPHRON	1%	A086711	001	
BRONKOSOL					
	SANOFI AVENTIS US	0.25%	N012339	009	
		1%	N012339	008	
ISOETHARINE HYDROCHLORIDE					
	ALPHARMA US PHARMS	1%	A087101	001	
+	ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982
		0.062%	A089614	001	Jun 13, 1991
+		0.125%	A087938	001	Nov 15, 1982
		0.125%	A089615	001	Jun 13, 1991
+		0.167%	A088470	001	Mar 14, 1984
		0.167%	A089616	001	Jun 13, 1991
+		0.2%	A088471	001	Mar 14, 1984
		0.2%	A089617	001	Jun 13, 1991
+		0.25%	A088472	001	Mar 14, 1984
		0.25%	A089618	001	Jun 13, 1991
	BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
		0.14%	A088145	001	Mar 26, 1984
		0.25%	A088146	001	Aug 01, 1983
	DEY	0.08%	A088187	001	Dec 03, 1982
		0.1%	A087389	001	
		0.17%	A087390	001	
		0.25%	A088188	001	Dec 03, 1982
+		1%	A086763	001	
	INTL MEDICATION	0.077%	A086651	001	
		0.08%	A086651	002	
		0.1%	A086651	003	
		0.143%	A086651	004	
		0.167%	A086651	005	
		0.2%	A086651	006	
		0.25%	A086651	007	
		1%	A086651	008	
	PARKE DAVIS	0.5%	A085997	001	
		1%	A085889	001	
	ROXANE	0.1%	A087396	001	
		0.125%	A087025	001	
		0.167%	A088226	001	Sep 16, 1983
		0.2%	A087324	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
ISOETHARINE HYDROCHLORIDE				
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986
ISOETHARINE MESYLATE				
AEROSOL, METERED;INHALATION				
BRONKOMETER				
SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984
ISOFLURANE				
LIQUID;INHALATION				
ISOFLURANE				
HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995
ISOFLUROPHATE				
OINTMENT;OPHTHALMIC				
FLOROPRYL				
MERCK	0.025%	N010656	001	
ISONIAZID				
INJECTABLE;INJECTION				
NYDRAZID				
SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	
SYRUP;ORAL				
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
RIMIFON				
ROCHE	50MG/5ML	N008420	001	
TABLET;ORAL				
DOW-ISONIAZID				
DOW PHARM	300MG	A080330	002	
HYZYD				
MEDPOINTE PHARM HLC	100MG	A080134	003	
	300MG	A080134	004	
INH				
NOVARTIS	300MG	A080935	001	
ISONIAZID				
DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
+ EPIC PHARMA LLC	100MG **	N008678	002	
+	300MG **	N008678	003	
GENUS	100MG	A080936	001	
	300MG	A080937	002	
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MK LABS	100MG	A080941	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISONIAZID				
TABLET;ORAL				
ISONIAZID				
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
SUN PHARM INDUSTRIES	100MG	A080136	001	
	300MG	A083633	001	
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID				
CHARTWELL MOLECULAR	50MG	A080140	001	
	100MG	A080140	002	
	300MG	A089776	001	Jun 13, 1988
NYDRAZID				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	
ISONIAZID; PYRAZINAMIDE; RIFAMPIN				
TABLET;ORAL				
RIFATER				
+ SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994
ISONIAZID; RIFAMPIN				
CAPSULE;ORAL				
RIFAMATE				
SANOFI AVENTIS US	150MG;300MG	A061884	001	
RIFAMPIN AND ISONIAZID				
HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005
ISOPROPAMIDE IODIDE				
TABLET;ORAL				
DARBID				
GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	
ISOPROTERENOL HYDROCHLORIDE				
AEROSOL, METERED;INHALATION				
ISOPROTERENOL HYDROCHLORIDE				
3M	0.12MG/INH	N010375	004	
ALPHARMA US PHARMS	0.12MG/INH	A085904	001	
ISUPREL				
SANOFI AVENTIS US	0.103MG/INH	N011178	001	
DISC;INHALATION				
NORISODRINE AEROTROL				
ABBOTT	0.25%	N016814	001	
INJECTABLE;INJECTION				
ISOPROTERENOL HYDROCHLORIDE				
ABRAXIS PHARM	0.2MG/ML	A083431	001	
AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018
	0.2MG/ML	A211738	001	Jun 28, 2019
EUGIA PHARMA	0.2MG/ML	A211864	001	Feb 09, 2021
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	
PHARMOBEDIENT	0.2MG/ML	A212573	001	Sep 06, 2022
ZYDUS PHARMS	0.2MG/ML	A215557	001	Apr 14, 2023
ISUPREL				
+ BAUSCH	0.2MG/ML **	N010515	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOPROTERENOL HYDROCHLORIDE				
SOLUTION;INHALATION				
AEROLONE				
LILLY	0.25%	N007245 001		
ISOPROTERENOL HYDROCHLORIDE				
ARMOUR PHARM	0.031%	A087935 001		Nov 18, 1982
	0.062%	A087936 001		Nov 18, 1982
DEY	0.5%	A086764 001		Jan 04, 1982
PARKE DAVIS	0.25%	A085994 001		
	0.5%	A085540 001		
ISUPREL				
SANOFI AVENTIS US	0.5%	N006327 002		
	1%	N006327 003		
VAPO-ISO				
FISONS	0.5%	N016813 001		
TABLET;RECTAL, SUBLINGUAL				
ISUPREL				
SANOFI AVENTIS US	10MG	N006328 001		
	15MG	N006328 002		
ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE				
AEROSOL, METERED;INHALATION				
DUO-MEDIHALER				
3M	0.16MG/INH;0.24MG/INH	N013296 001		
ISOPROTERENOL SULFATE				
AEROSOL, METERED;INHALATION				
MEDIHALER-ISO				
3M	0.08MG/INH	N010375 003		
POWDER;INHALATION				
NORISODRINE				
ABBVIE	10%	N006905 003		
	25%	N006905 002		
ISOSORBIDE				
SOLUTION;ORAL				
ISMOTIC				
ALCON	100GM/220ML	N017063 001		
ISOSORBIDE DINITRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
DILATRATE-SR				
+ ENDO OPERATIONS	40MG	N019790 001		Sep 02, 1988
ISORDIL				
WYETH AYERST	40MG	N012882 002		Jul 29, 1988
TABLET;ORAL				
ISORDIL				
+ BAUSCH	10MG **	N012093 002		Jul 29, 1988
+	20MG **	N012093 006		Jul 29, 1988
+	30MG **	N012093 005		Jul 29, 1988
ISOSORBIDE DINITRATE				
ANI PHARMS	10MG	A086032 001		Jan 07, 1988
HIKMA INTL PHARMS	30MG	A040591 001		Jan 10, 2007
SUN PHARM INDUSTRIES	5MG	A086166 002		Sep 19, 1986
	10MG	A086169 001		Sep 19, 1986
	20MG	A086167 001		Sep 19, 1986
	30MG	A087564 001		Sep 18, 1986
SUPERPHARM	5MG	A089190 001		Feb 17, 1987
	10MG	A089191 001		Feb 17, 1987
	20MG	A089192 001		Feb 17, 1987
WATSON LABS	5MG	A086034 001		Jan 06, 1988
SORBITRATE				
ASTRAZENECA	5MG	N016192 001		Apr 01, 1996
	10MG	N016192 002		Apr 01, 1996
	20MG	A086405 002		Aug 21, 1990
	30MG	A088124 001		Aug 21, 1990
	40MG	A088125 001		Aug 21, 1990
TABLET;SUBLINGUAL				
ISORDIL				
+ BIOVAIL	2.5MG **	N012940 004		Jul 29, 1988
+	5MG **	N012940 003		Jul 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOSORBIDE DINITRATE					
TABLET;SUBLINGUAL					
ISORDIL					
+		10MG **	N012940	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	HIKMA INTL PHARMS	2.5MG	A086055	002	Oct 29, 1987
		5MG	A086055	001	Nov 02, 1987
	SANDOZ	2.5MG	A086225	001	Feb 19, 1988
		5MG	A086222	001	Feb 19, 1988
	SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
		5MG	A086168	001	Sep 18, 1986
		10MG	A087545	001	Sep 18, 1986
	WATSON LABS	2.5MG **	A086033	001	Feb 26, 1988
	WATSON LABS TEVA	5MG **	A086031	001	Sep 29, 1987
SORBITRATE					
	ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
		5MG	N016191	001	Apr 01, 1996
TABLET, CHEWABLE;ORAL					
SORBITRATE					
	ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
		10MG	N016776	003	Apr 01, 1996
TABLET, EXTENDED RELEASE;ORAL					
ISORDIL					
	WYETH AYERST	40MG	N012882	001	Jul 29, 1988
ISOSORBIDE DINITRATE					
	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008
	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998
ISOSORBIDE MONONITRATE					
TABLET;ORAL					
ISMO					
	PROMIUS PHARMA	20MG	N019091	001	Dec 30, 1991
ISOSORBIDE MONONITRATE					
	ANI PHARMS	20MG	A075147	001	Nov 27, 1998
	HIKMA PHARMS	20MG	A075361	001	Oct 05, 2000
TABLET, EXTENDED RELEASE;ORAL					
IMDUR					
+	SCHERING PLOUGH	30MG **	N020225	001	Aug 12, 1993
+		60MG **	N020225	002	Aug 12, 1993
+		120MG **	N020225	003	Mar 30, 1995
ISOSORBIDE MONONITRATE					
	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017
		60MG	A209684	002	Oct 24, 2017
		120MG	A209684	003	Oct 24, 2017
	ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998
		60MG	A075306	002	Dec 31, 1998
	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998
	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006
		60MG	A076813	001	Jan 07, 2005
	IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
		60MG	A075448	001	Jun 19, 2000
		120MG	A075448	003	Aug 07, 2001
	SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999
	STRIDES PHARMA INTL	30MG	A090598	001	Aug 11, 2010
		60MG	A090598	002	Aug 11, 2010
		120MG	A090598	003	Aug 11, 2010
	ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024
		60MG	A218255	002	Feb 15, 2024
		120MG	A218255	003	Feb 15, 2024
ISOSULFAN BLUE					
SOLUTION;SUBCUTANEOUS					
ISOSULFAN BLUE					
	EUGIA PHARMA	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016
	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A211869	001	Sep 08, 2022
	SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019
	SOMERSET THERAPS LLC	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019
LYMPHAZURIN					
+	COVIDIEN	50MG/5ML (10MG/ML) **	N018310	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOTRETINOIN					
CAPSULE;ORAL					
ABSORICA LD					
+	SUN PHARM	20MG	N211913	003	Nov 05, 2019
+		28MG	N211913	005	Nov 05, 2019
ACCUTANE					
+	HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
+		20MG **	N018662	004	Mar 28, 1983
+		40MG **	N018662	003	May 07, 1982
SOTRET					
	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
		20MG	A076041	002	Dec 24, 2002
		30MG	A076503	001	Jun 20, 2003
		40MG	A076041	003	Dec 24, 2002
ISRADIPINE					
CAPSULE;ORAL					
DYNACIRC					
+	SMITHKLINE BEECHAM	2.5MG **	N019546	001	Dec 20, 1990
+		5MG **	N019546	002	Dec 20, 1990
TABLET, EXTENDED RELEASE;ORAL					
DYNACIRC CR					
+	GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
+		10MG **	N020336	002	Jun 01, 1994
ISRADIPINE					
	PHARMOBEDIENT	5MG	A201067	001	Nov 27, 2015
		10MG	A201067	002	Nov 27, 2015
ITRACONAZOLE					
CAPSULE;ORAL					
ITRACONAZOLE					
	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016
	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017
	MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012
	STRIDES PHARMA	100MG	A206410	001	Jul 02, 2019
INJECTABLE;INJECTION					
SPORANOX					
	JANSSEN PHARMS	10MG/ML	N020966	001	Mar 30, 1999
SOLUTION;ORAL					
ITRACONAZOLE					
	APOTEX	10MG/ML	A208481	001	Aug 02, 2019
SPORANOX					
+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997
TABLET;ORAL					
ONMEL					
+	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010
IVERMECTIN					
LOTION;TOPICAL					
IVERMECTIN					
	TEVA PHARMS USA	0.5%	A212485	001	Mar 21, 2022
TABLET;ORAL					
STROMECTOL					
+	MERCK SHARP DOHME	6MG **	N050742	001	Nov 22, 1996
KANAMYCIN SULFATE					
CAPSULE;ORAL					
KANTREX					
	APOTHECON	EQ 500MG BASE	A060516	001	
		EQ 500MG BASE	A061911	001	
		EQ 500MG BASE	A062726	001	Mar 06, 1987
INJECTABLE;INJECTION					
KANAMYCIN					
	HIKMA	EQ 75MG BASE/2ML	A062324	001	
		EQ 500MG BASE/2ML	A062324	002	
		EQ 1GM BASE/3ML	A062324	003	
KANAMYCIN SULFATE					
	ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
		EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
		EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
	FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KANAMYCIN SULFATE				
INJECTABLE;INJECTION				
KANAMYCIN SULFATE				
	EQ 1GM BASE/3ML		A065111 002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML		A062466 001	Sep 30, 1983
	EQ 1GM BASE/3ML		A062466 002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML		A063021 001	Jul 31, 1992
	EQ 500MG BASE/2ML		A063022 001	Jul 31, 1992
	EQ 1GM BASE/3ML		A063025 001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML		A062668 001	May 07, 1987
	EQ 500MG BASE/2ML		A062672 001	May 07, 1987
	EQ 1GM BASE/3ML		A062669 001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML		A062605 003	Feb 26, 1986
	EQ 500MG BASE/2ML		A062605 001	Feb 26, 1986
	EQ 1GM BASE/3ML		A062605 002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML		A063092 001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML		A062520 003	May 09, 1985
KANTREX				
APOTHECON	EQ 75MG BASE/2ML		A061655 003	
	EQ 75MG BASE/2ML		A061901 003	
	EQ 75MG BASE/2ML		A062564 001	Sep 21, 1984
	EQ 500MG BASE/2ML		A061655 001	
	EQ 500MG BASE/2ML		A061901 001	
	EQ 500MG BASE/2ML		A062564 002	Sep 21, 1984
	EQ 1GM BASE/3ML		A061655 002	
	EQ 1GM BASE/3ML		A061901 002	
	EQ 1GM BASE/3ML		A062564 003	Sep 21, 1984
KLEBCIL				
KING PHARMS	EQ 75MG BASE/2ML		A062170 001	
	EQ 500MG BASE/2ML		A062170 002	
	EQ 1GM BASE/3ML		A062170 003	
KETOCONAZOLE				
AEROSOL, FOAM;TOPICAL				
EXTINA				
+ RISING	2% **		N021738 001	Jun 12, 2007
CREAM;TOPICAL				
NIZORAL				
+ JANSSEN PHARMA	2% **		N019084 001	Dec 31, 1985
GEL;TOPICAL				
XOLEGEL				
+ INA PHARMS	2%		N021946 001	Jul 28, 2006
SHAMPOO;TOPICAL				
NIZORAL				
+ JANSSEN PHARMS	2% **		N019927 001	Aug 31, 1990
SUSPENSION;ORAL				
NIZORAL				
JANSSEN PHARMA	100MG/5ML		A070767 001	Nov 07, 1986
TABLET;ORAL				
KETOCONAZOLE				
AAIPHARMA LLC	200MG		A075341 001	Jul 27, 1999
AUROBINDO PHARMA USA	200MG		A075597 001	Dec 23, 1999
CHARTWELL RX	200MG		A074971 001	Jun 15, 1999
HERITAGE PHARMA	200MG		A075362 001	Jun 15, 1999
SUN PHARM INDUSTRIES	200MG		A075314 001	Jun 15, 1999
TEVA	200MG		A075273 001	Jun 15, 1999
NIZORAL				
+ JANSSEN PHARMS	200MG **		N018533 001	
KETOPROFEN				
CAPSULE;ORAL				
KETOPROFEN				
RISING	50MG		A074024 001	Dec 29, 1995
	50MG		A074035 002	Dec 31, 1996
	75MG		A074024 002	Dec 29, 1995
	75MG		A074035 003	Dec 31, 1996
TEVA	25MG		A073515 001	Dec 22, 1992
	75MG		A073517 001	Dec 22, 1992
ORUDIS				
+ WYETH AYERST	25MG **		N018754 001	Jul 31, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOPROFEN

CAPSULE;ORAL					
ORUDIS					
+		50MG **	N018754	002	Jan 09, 1986
+		75MG **	N018754	003	Jan 09, 1986
CAPSULE, EXTENDED RELEASE;ORAL					
KETOPROFEN					
	ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
		150MG	A075270	003	Mar 24, 1999
		200MG	A075270	001	Mar 24, 1999
	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
	MYLAN	100MG	A075679	003	Feb 20, 2002
		150MG	A075679	002	Feb 20, 2002
ORUVAIL					
+	WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+		150MG **	N019816	002	Feb 08, 1995
+		200MG **	N019816	001	Sep 24, 1993
FILM;ORAL					
NEXCEDE					
	NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
TABLET;ORAL					
ACTRON					
	BAYER	12.5MG	N020499	001	Oct 06, 1995
KETOPROFEN					
	PERRIGO	12.5MG	A075364	001	Feb 07, 2002
ORUDIS KT					
+	WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION					
KETOROLAC TROMETHAMINE					
	AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004
		30MG/ML	A076209	002	Jul 21, 2004
	APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
		30MG/ML	A077201	001	Oct 14, 2005
	APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
		30MG/ML	A075348	002	Nov 28, 2000
	BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001
		30MG/ML	A075631	001	Jun 29, 2001
	BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
		30MG/ML	A075230	001	Oct 25, 1999
	EUGIA PHARMA	15MG/ML	A212939	001	Oct 20, 2020
		30MG/ML	A212939	002	Oct 20, 2020
	FRESENIUS KABI USA	15MG/ML	A203242	001	Oct 07, 2015
	GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
		30MG/ML	A076722	002	Jul 27, 2004
	HIKMA	15MG/ML **	A075222	001	Apr 26, 1999
		15MG/ML	A075299	001	Nov 03, 1999
		30MG/ML **	A075222	002	Apr 26, 1999
		30MG/ML **	A075228	001	Apr 26, 1999
		30MG/ML	A075299	002	Nov 03, 1999
	HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
		15MG/ML	A074993	001	Jan 27, 1999
		30MG/ML	A074801	002	Jun 05, 1997
		30MG/ML	A074993	002	Jan 27, 1999
	LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008
		30MG/ML	A078145	002	Jan 14, 2008
	ONESOURCE SPECIALTY	15MG/ML	A078299	001	Jul 16, 2007
		15MG/ML	A201155	001	Aug 04, 2014
		30MG/ML	A078299	002	Jul 16, 2007
		30MG/ML	A201155	002	Aug 04, 2014
	SANDOZ	15MG/ML	A076271	001	Oct 06, 2004
	SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008
		30MG/ML	A078737	002	Oct 06, 2008
	WOCKHARDT BIO AG	30MG/ML	A077943	001	Mar 27, 2007
TORADOL					
+	ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+		30MG/ML **	N019698	002	Nov 30, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOROLAC TROMETHAMINE				
SOLUTION/DROPS;OPHTHALMIC				
ACULAR PRESERVATIVE FREE				
	ALLERGAN	0.5%	N020811 001	Nov 03, 1997
KETOROLAC TROMETHAMINE				
	CHARTWELL RX	0.5%	A078434 001	Nov 05, 2009
	EPIC PHARMA LLC	0.4%	A078399 001	Nov 05, 2009
		0.45%	A203376 001	Feb 10, 2014
	EUGIA PHARMA	0.4%	A205191 001	Nov 15, 2018
		0.5%	A205190 001	Dec 03, 2020
	SANDOZ	0.4%	A078721 001	Nov 05, 2009
	SUN PHARM	0.5%	A090017 001	Nov 05, 2009
TABLET;ORAL				
KETOROLAC TROMETHAMINE				
	ATNAHS PHARMA US	10MG	A216407 001	Oct 21, 2022
	CHARTWELL RX	10MG	A074790 001	Jun 26, 1997
	PLIVA	10MG	A075284 001	Jun 23, 1999
	WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL				
+	ROCHE PALO	10MG **	N019645 001	Dec 20, 1991
KETOTIFEN FUMARATE				
DRUG-ELUTING CONTACT LENS;OPHTHALMIC				
ACUVUE THERAVISION WITH KETOTIFEN				
+	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388 001	Feb 25, 2022
SOLUTION/DROPS;OPHTHALMIC				
ALAWAY				
	BAUSCH AND LOMB INC	EQ 0.025% BASE	A208158 001	Sep 24, 2020
ZADITOR				
+	ALCON PHARMA	EQ 0.025% BASE **	N021066 002	Oct 19, 2006
KRYPTON, KR-81M				
GAS;INHALATION				
MPI KRYPTON 81M GENERATOR				
	GE HEALTHCARE	N/A	N018088 001	
L-GLUTAMINE				
FOR SOLUTION;ORAL				
NUTRESTORE				
+	EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004
LABETALOL HYDROCHLORIDE				
INJECTABLE;INJECTION				
LABETALOL HYDROCHLORIDE				
	APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
	HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
	ONESOURCE SPECIALTY	5MG/ML	A079134 001	Feb 03, 2010
	RISING	5MG/ML	A075524 001	Nov 29, 1999
NORMODYNE				
+	SCHERING	5MG/ML **	N018686 001	Aug 01, 1984
TRANDATE				
+	SEBELA IRELAND LTD	5MG/ML **	N019425 001	Dec 31, 1985
SOLUTION;INTRAVENOUS				
LABETALOL HYDROCHLORIDE				
+	HIKMA	10MG/2ML (5MG/ML)	N213330 005	Mar 18, 2022
TABLET;ORAL				
LABETALOL HYDROCHLORIDE				
	APOTHECON	100MG	A075223 001	Nov 20, 1998
		200MG	A075223 002	Nov 20, 1998
		300MG	A075223 003	Nov 20, 1998
	TEVA	100MG	A074989 001	Sep 30, 1998
		200MG	A074989 002	Sep 30, 1998
		300MG	A074989 003	Sep 30, 1998
	UNICHEM	100MG	A212719 001	Aug 08, 2022
		200MG	A212719 002	Aug 08, 2022
		300MG	A212719 003	Aug 08, 2022
NORMODYNE				
+	SCHERING	100MG **	N018687 001	Aug 31, 1987
+		200MG **	N018687 002	Aug 01, 1984
+		300MG **	N018687 003	Aug 01, 1984
+		400MG **	N018687 004	Aug 01, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LABETALOL HYDROCHLORIDE				
TABLET;ORAL				
TRANDATE				
+ ALVOGEN	100MG **	N018716	001	May 24, 1985
+	200MG **	N018716	002	Aug 01, 1984
+	300MG **	N018716	003	Aug 01, 1984
+	400MG **	N018716	004	Aug 01, 1984
LACOSAMIDE				
SOLUTION;ORAL				
LACOSAMIDE				
AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024
TABLET;ORAL				
LACOSAMIDE				
ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022
	100MG	A205011	002	Jul 12, 2022
	150MG	A205011	003	Jul 12, 2022
	200MG	A205011	004	Jul 12, 2022
ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023
	100MG	A204855	002	Jan 05, 2023
	150MG	A204855	003	Jan 05, 2023
	200MG	A204855	004	Jan 05, 2023
AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022
	100MG	A204857	002	Mar 17, 2022
	150MG	A204857	003	Mar 17, 2022
	200MG	A204857	004	Mar 17, 2022
APOTEX	50MG	A214567	001	Sep 23, 2022
	100MG	A214567	002	Sep 23, 2022
	150MG	A214567	003	Sep 23, 2022
	200MG	A214567	004	Sep 23, 2022
ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023
	100MG	A204947	002	Dec 15, 2023
	150MG	A204947	003	Dec 15, 2023
	200MG	A204947	004	Dec 15, 2023
LACTITOL				
FOR SOLUTION;ORAL				
PIZENSY				
+ BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020
LACTULOSE				
SOLUTION;ORAL				
CHRONULAC				
+ SANOFI AVENTIS US	10GM/15ML **	N017884	001	
CONSTILAC				
ALRA	10GM/15ML	A071054	001	Jul 26, 1988
CONSTULOSE				
ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
DUPHALAC				
SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE				
TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE				
ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007
HIKMA	10GM/15ML	A073591	001	May 29, 1992
	10GM/15ML	A074076	001	Jul 03, 1995
MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
PACO	10GM/15ML	A073160	001	Aug 25, 1992
VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992
LAXILOSE				
NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993
SOLUTION;ORAL, RECTAL				
ACILAC				
NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
CEPHULAC				
+ SANOFI AVENTIS US	10GM/15ML **	N017657	001	
CHOLAC				
ALRA	10GM/15ML	A071331	001	Jul 26, 1988
ENULOSE				
ACTAVIS MID ATLANTIC	10GM/15ML	A071548	001	Aug 15, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LACTULOSE				
SOLUTION;ORAL, RECTAL				
GENERLAC				
	MORTON GROVE	10GM/15ML	A071842 001	Sep 27, 1988
HEPTALAC				
	TEVA PHARMS	10GM/15ML	A073504 001	May 28, 1993
LACTULOSE				
	ANI PHARMS	10GM/15ML	A090426 001	Nov 21, 2008
	PACO	10GM/15ML	A072029 001	Aug 25, 1992
	PAI HOLDINGS PHARM	10GM/15ML	A074077 001	Jul 03, 1995
	ROXANE	10GM/15ML	A073590 001	May 29, 1992
	SOLVAY	10GM/15ML	N017906 001	
PORTALAC				
	SOLVAY	10GM/15ML	A072374 001	Mar 22, 1989
LAMIVUDINE				
SOLUTION;ORAL				
EPIVIR-HBV				
+	GLAXOSMITHKLINE	5MG/ML	N021004 001	Dec 08, 1998
TABLET;ORAL				
EPIVIR-HBV				
+	GLAXOSMITHKLINE	100MG	N021003 001	Dec 08, 1998
LAMIVUDINE				
	AUROBINDO PHARMA LTD	150MG	A202032 001	Nov 17, 2011
		300MG	A202032 002	Nov 17, 2011
	AUROBINDO PHARMA USA	100MG	A204002 001	Dec 31, 2014
	BRECKENRIDGE	150MG	A203586 001	Nov 21, 2016
	NATCO	150MG	A204528 001	Mar 04, 2016
		300MG	A204528 002	Mar 04, 2016
	PHARMOBEDIENT	150MG	A078545 001	Mar 05, 2019
		300MG	A078545 002	Mar 05, 2019
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE				
TABLET;ORAL				
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE				
+	MICRO LABS	150MG;200MG;300MG	N205626 001	Aug 13, 2018
LAMIVUDINE; RALTEGRAVIR POTASSIUM				
TABLET;ORAL				
DUTREBIS				
	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510 001	Feb 06, 2015
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE				
TABLET;ORAL				
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE				
+	AUROBINDO PHARMA LTD	300MG;300MG	N022344 001	May 15, 2018
TEMIXYS				
+	CHARTWELL RX	300MG;300MG	N211284 001	Nov 16, 2018
LAMIVUDINE; ZIDOVUDINE				
TABLET;ORAL				
COMBIVIR				
+	VIIV HLTHCARE	150MG;300MG **	N020857 001	Sep 26, 1997
LAMIVUDINE AND ZIDOVUDINE				
	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012
	CHARTWELL RX	150MG;300MG	A079081 001	May 25, 2011
	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012
	NATCO	150MG;300MG	A204005 001	Aug 28, 2014
	PHARMACARE	150MG;300MG	N022018 001	Mar 17, 2017
	PHARMOBEDIENT	150MG;300MG	A079079 001	Aug 12, 2019
LAMOTRIGINE				
TABLET;ORAL				
LAMICTAL				
+	GLAXOSMITHKLINE LLC	50MG **	N020241 006	Dec 27, 1994
+		250MG **	N020241 004	Dec 27, 1994
LAMOTRIGINE				
	ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011
		100MG	A078669 002	Apr 08, 2011
		150MG	A078669 003	Apr 08, 2011
		200MG	A078669 004	Apr 08, 2011
	AIPING PHARM INC	25MG	A078645 001	Jan 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LAMOTRIGINE

TABLET;ORAL				
LAMOTRIGINE				
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010
	100MG	A077783	002	Nov 01, 2010
	150MG	A077783	003	Nov 01, 2010
	200MG	A077783	004	Nov 01, 2010
GRANULES	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
NATCO PHARMA	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
PHARMOBEDIENT	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
RISING	25MG	A077420	001	Jan 27, 2009
	100MG	A077420	002	Jan 27, 2009
	150MG	A077420	003	Jan 27, 2009
	200MG	A077420	004	Jan 27, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006
ZENNOVA	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
TABLET, EXTENDED RELEASE;ORAL				
LAMOTRIGINE				
RUBICON RESEARCH	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013
TORRENT	200MG	A203370	004	Dec 23, 2013
TABLET, FOR SUSPENSION;ORAL				
LAMICTAL CD				
GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE				
CHARTWELL RX	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011
	25MG	A200220	002	Feb 28, 2011
PHARMOBEDIENT	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
TARO	5MG	A079204	001	Feb 04, 2009
	25MG	A079204	002	Feb 04, 2009
TEVA	5MG	A076420	001	Jun 21, 2006
	25MG	A076420	002	Jun 21, 2006

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE				
AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016
	30MG	A203957	002	Oct 14, 2016
KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013
	30MG	A091212	002	Sep 16, 2013
LANNETT CO INC	15MG	A207157	001	Sep 29, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE				
	MACLEODS PHARMS LTD	15MG	A208671 001	Nov 04, 2024
		30MG	A208671 002	Nov 04, 2024
	MYLAN	15MG	A203187 001	Jun 01, 2016
	NOVITIUM PHARMA	15MG	A203964 001	Oct 17, 2018
		30MG	A203964 002	Oct 17, 2018
	SANDOZ	15MG	A090331 001	Apr 23, 2010
		30MG	A090331 002	Apr 23, 2010
	SUN PHARM	15MG	A202637 001	Sep 13, 2013
		30MG	A091509 001	Sep 13, 2013
PREVACID				
+	TAKEDA PHARMS USA	15MG **	N020406 001	May 10, 1995
FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
	TAKEDA PHARMS NA	15MG/PACKET	N021281 001	May 03, 2001
		30MG/PACKET	N021281 002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
+	TAKEDA PHARMS NA	30MG/VIAL **	N021566 001	May 27, 2004
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
LANSOPRAZOLE				
	ANI PHARMS	15MG	A078730 001	Oct 15, 2010
		30MG	A078730 002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
PREVACID NAPRAPAC 250 (COPACKAGED)				
+	TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507 002	Nov 14, 2003
PREVACID NAPRAPAC 375 (COPACKAGED)				
	TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507 003	Nov 14, 2003
PREVACID NAPRAPAC 500 (COPACKAGED)				
	TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507 004	Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL				
FOSRENOL				
	TAKEDA PHARMS USA	EQ 250MG BASE	N021468 001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL				
VIRAC REX				
	CHESEBROUGH PONDS	0.5%;1.8%	N011914 001	

LASMIDITAN SUCCINATE

TABLET;ORAL				
REYVOW				
+	ELI LILLY AND CO	EQ 200MG BASE	N211280 003	Dec 18, 2020

LATANOPROST

EMULSION;OPHTHALMIC				
XELPROS				
+	SUN PHARM	0.005%	N206185 001	Sep 12, 2018
SOLUTION/DROPS;OPHTHALMIC				
LATANOPROST				
	APOTEX INC	0.005%	A077697 001	Mar 22, 2011
	EPIC PHARMA LLC	0.005%	A090887 001	Jul 19, 2011
	EUGIA PHARMA	0.005%	A206519 001	Sep 03, 2019
	PHARMOBEDIENT	0.005%	A202077 001	Feb 11, 2013

LEFLUNOMIDE

TABLET;ORAL				
LEFLUNOMIDE				
	BARR	10MG	A077083 001	Sep 13, 2005
		20MG	A077083 002	Sep 13, 2005
	SANDOZ	10MG	A077085 001	Sep 13, 2005
		20MG	A077085 002	Sep 13, 2005
	TEVA PHARMS	10MG	A077084 001	Sep 13, 2005
		20MG	A077084 002	Sep 13, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LENALIDOMIDE					
CAPSULE;ORAL					
LENALIDOMIDE					
	TORRENT	10MG	A213405	001	Feb 17, 2023
		20MG	A213405	003	Aug 03, 2023
		25MG	A213405	002	Feb 17, 2023
LESINURAD					
TABLET;ORAL					
ZURAMPIC					
+	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015
LETROZOLE					
TABLET;ORAL					
LETROZOLE					
	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012
	CARNEGIE	2.5MG	A091191	001	Jun 03, 2011
	CHARTWELL RX	2.5MG	A202716	001	May 16, 2013
	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011
	HIKMA	2.5MG	A090838	001	Jun 03, 2011
	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016
	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011
	LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
		2.5MG	A202048	001	Oct 29, 2014
	PHARMOBEDIENT	2.5MG	A078190	001	Dec 24, 2008
	STRIDES PHARMA INTL	2.5MG	A090789	001	Jun 03, 2011
	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
	SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011
LEUCOVORIN CALCIUM					
FOR SOLUTION;ORAL					
LEUCOVORIN CALCIUM					
	HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987
INJECTABLE;INJECTION					
LEUCOVORIN CALCIUM					
	ABIC	EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
	ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
	ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
		EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
+	HOSPIRA	EQ 50MG BASE/VIAL **	N008107	002	
+		EQ 100MG BASE/VIAL **	N008107	004	May 23, 1988
+		EQ 350MG BASE/VIAL **	N008107	005	Apr 05, 1989
	PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
	PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
		EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993
		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997
LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	AM REGENT	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
WELLCOVORIN					
	GLAXOSMITHKLINE	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
		EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
		EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
SOLUTION;INTRAMUSCULAR, INTRAVENOUS					
LEUCOVORIN CALCIUM					
	ABIC	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	A089352	001	Jun 01, 1988
+	HOSPIRA	EQ 3MG BASE/ML (EQ 3MG BASE/ML) **	N008107	001	
	NOVAST LABS	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018
LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	HIKMA	EQ 300MG BASE/30ML (EQ 10MG BASE/ML)	A040347	001	Apr 25, 2000
		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040347	002	Apr 25, 2000
	HOSPIRA	EQ 100MG BASE/10ML (EQ 10MG BASE/ML) **	A040147	001	Jun 25, 1997
		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A040147	002	Jun 25, 1997
	TEVA PARENTERAL	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040332	001	Jun 28, 1999
WELLCOVORIN					
	GLAXOSMITHKLINE	EQ 5MG BASE/ML (EQ 5MG BASE/ML)	A087439	001	Oct 19, 1982
		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A087439	002	Oct 19, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEUCOVORIN CALCIUM				
TABLET;ORAL				
LEUCOVORIN CALCIUM				
	ANI PHARMS	EQ 15MG BASE	A075327 001	Mar 24, 1999
	PAR PHARM	EQ 5MG BASE	A071600 001	Oct 14, 1987
		EQ 25MG BASE	A071598 001	Oct 14, 1987
	PHARMACHEMIE	EQ 5MG BASE	A073099 001	Mar 28, 1997
		EQ 25MG BASE	A073101 001	Mar 28, 1997
	XANODYNE PHARM	EQ 5MG BASE	N018459 001	Jan 30, 1986
		EQ 10MG BASE	A071962 001	Nov 19, 1987
		EQ 15MG BASE	A071104 001	Mar 04, 1987
WELLCOVORIN				
+	GLAXOSMITHKLINE	EQ 5MG BASE **	N018342 001	Jul 08, 1983
+		EQ 25MG BASE **	N018342 002	Jul 08, 1983
LEUPROLIDE ACETATE				
IMPLANT;IMPLANTATION				
VIADUR				
	ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088 001	Mar 03, 2000
INJECTABLE;INJECTION				
LUPRON DEPOT				
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011 001	Oct 22, 1990
POWDER;INTRAMUSCULAR				
LUPRON DEPOT-PED KIT				
+	ABBVIE ENDOCRINE INC	3.75MG,7.5MG **	N020263 003	Apr 16, 1993
+		7.5MG,7.5MG **	N020263 004	Apr 16, 1993
SOLUTION;SUBCUTANEOUS				
LEUPROLIDE ACETATE				
	GENZYME	14MG/2.8ML (1MG/0.2ML)	A075721 001	Nov 29, 2001
	PH HEALTH	14MG/2.8ML (1MG/0.2ML)	A217437 001	Jun 09, 2025
LUPRON				
+	ABBVIE ENDOCRINE INC	14MG/2.8ML (1MG/0.2ML) **	N019010 001	Apr 09, 1985
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE				
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL				
LUPANETA PACK				
+	ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696 001	Dec 14, 2012
+		11.25MG/VIAL,N/A;N/A,5MG	N203696 002	Dec 14, 2012
LEVALBUTEROL HYDROCHLORIDE				
SOLUTION;INHALATION				
LEVALBUTEROL HYDROCHLORIDE				
	MANKIND PHARMA	EQ 0.0103% BASE	A218770 001	Oct 21, 2024
		EQ 0.021% BASE	A218770 002	Oct 21, 2024
		EQ 0.042% BASE	A218770 003	Oct 21, 2024
	PHARMOBEDIENT	EQ 0.0103% BASE	A077800 001	Mar 15, 2013
		EQ 0.021% BASE	A077800 002	Mar 15, 2013
		EQ 0.042% BASE	A077800 003	Mar 15, 2013
	SUN PHARM	EQ 0.0103% BASE	A207820 001	Nov 05, 2018
		EQ 0.021% BASE	A207820 002	Nov 05, 2018
		EQ 0.042% BASE	A207820 003	Nov 05, 2018
XOPENEX				
+	HIKMA	EQ 0.0103% BASE **	N020837 003	Jan 30, 2002
+		EQ 0.021% BASE **	N020837 001	Mar 25, 1999
+		EQ 0.042% BASE **	N020837 002	Mar 25, 1999
+		EQ 0.25% BASE **	N020837 004	Jul 18, 2003
LEVALLORPHAN TARTRATE				
INJECTABLE;INJECTION				
LORFAN				
	ROCHE	1MG/ML	N010423 001	
LEVAMISOLE HYDROCHLORIDE				
TABLET;ORAL				
ERGAMISOL				
	JANSSEN PHARMA	EQ 50MG BASE	N020035 001	Jun 18, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVAMLODIPINE MALEATE					
TABLET;ORAL					
CONJUPRI					
+	CSPC OUYI	EQ 1.25MG BASE	N212895	001	Dec 19, 2019
+		EQ 2.5MG BASE	N212895	002	Dec 19, 2019
+		EQ 5MG BASE	N212895	003	Dec 19, 2019
LEVETIRACETAM					
INJECTABLE;INTRAVENOUS					
LEVETIRACETAM					
	AM REGENT	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012
	EPIC PHARMA LLC	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018
	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010
	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016
	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010
LEVETIRACETAM IN SODIUM CHLORIDE					
+	HQ SPCLT PHARMA	250MG/50ML (5MG/ML) **	N202543	004	Dec 14, 2020
SOLUTION;ORAL					
LEVETIRACETAM					
	APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011
	HIKMA	100MG/ML	A090601	001	Feb 28, 2012
	LUPIN LTD	100MG/ML	A090893	001	Oct 17, 2011
	PHARMOBEDIENT CNSLTG	100MG/ML	A090028	001	Mar 03, 2010
	STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023
	TOLMAR	100MG/ML	A079107	001	Jan 15, 2009
TABLET;ORAL					
LEVETIRACETAM					
	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011
		500MG	A090843	002	Feb 14, 2011
		750MG	A090843	003	Feb 14, 2011
		1GM	A090843	004	Feb 14, 2011
	ACTAVIS LABS FL INC	250MG	A077408	001	Mar 02, 2009
		500MG	A077408	002	Mar 02, 2009
		750MG	A077408	003	Mar 02, 2009
	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015
		1GM	A205102	003	Dec 16, 2015
	FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009
		500MG	A077324	002	Jan 15, 2009
		750MG	A077324	003	Jan 15, 2009
		1GM	A077324	004	Jan 15, 2009
	GRANULES	250MG	A217878	001	Jun 13, 2023
		500MG	A217878	002	Jun 13, 2023
		750MG	A217878	003	Jun 13, 2023
		1GM	A217878	004	Jun 13, 2023
	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009
		500MG	A078234	002	Jan 15, 2009
		750MG	A078234	003	Jan 15, 2009
	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016
		500MG	A090906	001	Nov 05, 2010
		750MG	A090906	003	Oct 31, 2016
		1GM	A090906	004	Oct 31, 2016
	MPP PHARMA	250MG	A090511	001	Aug 18, 2011
		500MG	A090511	002	Aug 18, 2011
		750MG	A090511	003	Aug 18, 2011
		1GM	A090511	004	Aug 18, 2011
	MYLAN	250MG	A076919	001	Nov 04, 2008
		250MG	A078731	001	Feb 10, 2009
		500MG	A078731	002	Feb 10, 2009
		750MG	A078731	003	Feb 10, 2009
		1GM	A078731	004	Feb 10, 2009
	STRIDES PHARMA	250MG	A078042	001	Jan 15, 2009
		500MG	A078042	002	Jan 15, 2009
		750MG	A078042	003	Jan 15, 2009
		1GM	A078042	004	Jan 15, 2009
	TARO	250MG	A078960	004	Feb 01, 2010
		500MG	A078960	003	Feb 01, 2010
		750MG	A078960	002	Feb 01, 2010
		1GM	A078960	001	Feb 01, 2010
	TEVA PHARMS	250MG	A078101	001	Jan 15, 2009
		500MG	A078101	002	Jan 15, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVETIRACETAM				
TABLET;ORAL				
LEVETIRACETAM				
	750MG		A078101 003	Jan 15, 2009
	1GM		A078101 004	Jan 15, 2009
WATSON LABS INC	250MG		A078797 002	Jan 15, 2009
	500MG		A078797 003	Jan 15, 2009
	750MG		A078797 004	Jan 15, 2009
	1GM		A078797 001	Jan 15, 2009
TABLET, EXTENDED RELEASE;ORAL				
ELEPSIA XR				
+ TRIPOINT	1GM		N204417 001	Dec 20, 2018
+	1.5GM		N204417 002	Dec 20, 2018
LEVETIRACETAM				
ACTAVIS ELIZABETH	500MG		A091557 001	Sep 12, 2011
	750MG		A091557 002	Sep 12, 2011
ADAPTIS	500MG		A202167 001	Sep 04, 2015
	750MG		A202167 002	Sep 04, 2015
APOTEX	1GM		A202958 001	Feb 25, 2015
AUROBINDO PHARMA USA	500MG		A200475 001	Dec 19, 2011
	750MG		A200475 002	Dec 19, 2011
	1GM		A200475 003	Dec 07, 2015
CHARTWELL RX	500MG		A091291 001	Sep 12, 2011
	750MG		A091291 002	Sep 12, 2011
LOTUS PHARM CO LTD	500MG		A202095 002	Jun 06, 2016
	750MG		A202095 001	Jun 06, 2016
PH HEALTH	500MG		A091360 001	Oct 04, 2011
	750MG		A091360 002	Oct 04, 2011
PHARMADAX INC	500MG		A201464 001	May 25, 2012
	750MG		A201464 002	May 25, 2012
PRINSTON INC	500MG		A202533 001	Jul 20, 2012
	750MG		A202533 002	Jul 20, 2012
ROUSES POINT PHARMS	500MG		A202524 001	Aug 27, 2012
	750MG		A202524 002	Aug 27, 2012
SANDOZ	500MG		A091668 001	Nov 01, 2012
	750MG		A091668 002	Nov 01, 2012
SUN PHARM	500MG		A203059 001	Sep 09, 2013
	750MG		A203059 002	Sep 09, 2013
SUN PHARM INDUSTRIES	500MG		A091285 001	Sep 12, 2011
	750MG		A091285 002	Sep 12, 2011
TEVA PHARMS	500MG		A091430 001	Sep 12, 2011
	750MG		A091430 002	Sep 12, 2011
TABLET, FOR SUSPENSION;ORAL				
SPRITAM				
+ APRECIA PHARMS	750MG		N207958 003	Jul 31, 2015
+	1GM		N207958 004	Jul 31, 2015
LEVOBETAXOLOL HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETAXON				
ALCON PHARMS LTD	EQ 0.5% BASE		N021114 001	Feb 23, 2000
LEVOBUNOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AKBETA				
EPIC PHARMA LLC	0.25%		A074779 001	Oct 29, 1996
	0.5%		A074780 001	Oct 29, 1996
BETAGAN				
+ ALLERGAN	0.25% **		N019814 001	Jun 28, 1989
LEVOBUNOLOL HYDROCHLORIDE				
ALCON LABS INC	0.25%		A074851 001	Oct 28, 1996
APOTEX INC	0.25%		A075473 001	Aug 03, 2000
	0.5%		A075475 001	Aug 03, 2000
BAUSCH AND LOMB	0.25%		A074307 001	Mar 04, 1994
CHARTWELL RX	0.5%		A074850 001	Oct 28, 1996

LEVOBUPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHIROCAINE				
+	PURDUE PHARMA LP	EQ 2.5MG BASE/ML **	N020997 001	Aug 05, 1999
+		EQ 5MG BASE/ML **	N020997 002	Aug 05, 1999
+		EQ 7.5MG BASE/ML **	N020997 003	Aug 05, 1999
LEVOCABASTINE HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
LIVOSTIN				
	NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
LEVOCARNITINE				
INJECTABLE;INJECTION				
LEVOCARNITINE				
	TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
SOLUTION;ORAL				
CARNITOR				
	LEADIANT BIOSCI INC	1GM/10ML	N018948 002	Apr 27, 1988
LEVOCARNITINE				
	HIKMA	1GM/10ML	A077399 001	Oct 25, 2007
LEVOCETIRIZINE DIHYDROCHLORIDE				
SOLUTION;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
	APOTEX	2.5MG/5ML	A202915 001	Aug 21, 2014
	TARO	2.5MG/5ML	A202673 001	Jul 26, 2013
XYZAL				
+	CHATTEM SANOFI	2.5MG/5ML **	N022157 001	Jan 28, 2008
TABLET;ORAL				
LEVOCETIRIZINE DIHYDROCHLORIDE				
	APOTEX	5MG	A203027 001	Feb 13, 2015
		5MG	A211443 001	Apr 21, 2021
	GRANULES	5MG	A090486 001	Mar 26, 2013
	IPCA LABS LTD	5MG	A204626 001	May 06, 2024
	SUN PHARM INDS LTD	5MG	A201653 001	Jun 26, 2015
	US ANTIBIOTICS	5MG	A204323 001	Dec 20, 2016
XYZAL				
+	CHATTEM SANOFI	5MG **	N022064 001	May 25, 2007
LEVODOPA				
CAPSULE;ORAL				
BENDOPA				
	VALEANT PHARM INTL	100MG	N016948 003	
		250MG	N016948 001	
		500MG	N016948 002	
DOPAR				
	SHIRE	100MG	N016913 003	
		250MG	N016913 001	
		500MG	N016913 002	
LARODOPA				
	ROCHE	100MG	N016912 002	
		250MG	N016912 001	
		500MG	N016912 006	
TABLET;ORAL				
DOPAR				
	SHIRE	250MG	N016913 004	
		500MG	N016913 005	
LARODOPA				
	ROCHE	100MG	N016912 005	
		250MG	N016912 003	
		500MG	N016912 004	
LEVOFLOXACIN				
INJECTABLE;INJECTION				
LEVAQUIN				
+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML) **	N020635 001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML) **	N020635 004	Dec 20, 1996
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635 002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635 003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635 005	Dec 20, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOFLOXACIN

INJECTABLE;INJECTION				
LEVOFLOXACIN				
AVET LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013
	EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013
BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013
EUGIA PHARMA	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013
	EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013
HOSPIRA	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015
PHARMOBEDIENT	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011
ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017
	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013
	EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013
	EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013
EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016
	EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016
	EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016
KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024
	EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024
	EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024
SOLUTION;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004
SOLUTION/DROPS;OPHTHALMIC				
IQUIX				
+ SANTEN	1.5% **	N021571	001	Mar 01, 2004
LEVOFLOXACIN				
PHARMOBEDIENT	0.5%	A204899	001	Dec 08, 2017
SCIEGEN PHARMS	0.5%	A090268	001	Dec 20, 2010
WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011
QUIXIN				
+ SANTEN	0.5% **	N021199	001	Aug 18, 2000
TABLET;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG **	N020634	001	Dec 20, 1996
+	500MG **	N020634	002	Dec 20, 1996
+	750MG **	N020634	003	Sep 08, 2000
LEVOFLOXACIN				
APOTEX INC	250MG	A090787	001	Sep 29, 2011
	500MG	A090787	002	Sep 29, 2011
	750MG	A090787	003	Sep 29, 2011
CHARTWELL RX	250MG	A090367	001	Jun 20, 2011
	500MG	A090367	002	Jun 20, 2011
	750MG	A090367	003	Jun 20, 2011
JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015
	500MG	A203613	002	Jun 19, 2015
NATCO PHARMA	250MG	A076276	001	Jun 20, 2011
	500MG	A076276	002	Jun 20, 2011
	750MG	A077097	001	Jun 20, 2011
SANDOZ	250MG	A077438	001	Jun 20, 2011
	500MG	A077438	002	Jun 20, 2011
	750MG	A077438	003	Jun 20, 2011
TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011
	500MG	A090722	002	Jun 20, 2011
	750MG	A090722	003	Jun 20, 2011
WATSON LABS INC	250MG	A201484	001	Nov 22, 2013
	500MG	A201484	002	Nov 22, 2013
	750MG	A201484	003	Nov 22, 2013

LEVOLEUCOVORIN

POWDER;INTRAVENOUS				
KHAPZORY				
+ ACROTECH BIOPHARMA	300MG/VIAL	N211226	002	Oct 19, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS				
FUSILEV				
+ ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008
LEVOLEUCOVORIN CALCIUM				
ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017
+	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016
AMNEAL	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017
HIKMA	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016
MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019
SOLUTION;INTRAVENOUS				
FUSILEV				
+ ACROTECH BIOPHARMA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **	N020140	002	Apr 29, 2011
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140	003	Apr 29, 2011
LEVOLEUCOVORIN CALCIUM				
MEITHEAL	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019
NOVAST LABS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018
PHARMOBEDIENT	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015
PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021
SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015

LEVOMEPROMAZINE

INJECTABLE;INJECTION				
LEVOPROME				
IMMUNEX	20MG/ML	N015865	001	

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE;ORAL				
ORLAAM				
+ ROXANE	10MG/ML **	N020315	001	Jul 09, 1993

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
LEVOMILNACIPRAN HYDROCHLORIDE				
AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019
	EQ 40MG BASE	A210790	002	Feb 04, 2019
	EQ 80MG BASE	A210790	003	Feb 04, 2019
	EQ 120MG BASE	A210790	004	Feb 04, 2019
AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023
	EQ 40MG BASE	A210826	002	Jan 06, 2023
	EQ 80MG BASE	A210826	003	Jan 06, 2023
	EQ 120MG BASE	A210826	004	Jan 06, 2023
HIKMA	EQ 20MG BASE	A210732	001	Nov 05, 2020
	EQ 40MG BASE	A210732	002	Nov 05, 2020
	EQ 80MG BASE	A210732	003	Nov 05, 2020
	EQ 120MG BASE	A210732	004	Nov 05, 2020

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
SOLVAY	0.05MG/ML;2%	A085010	001	
CARBOCAINE W/ NEO-COBEFRIN				
EASTMAN KODAK	0.05MG/ML;2%	N012125	002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
SEPTODONT	0.05MG/ML;2%	A084697	001	
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN				
DENTSPLY PHARM	0.05MG/ML;2%	A089517	001	Apr 14, 1988
SCANDONEST L				
DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN				
EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592	007	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVONORGESTREL				
IMPLANT;IMPLANTATION				
JADELLE				
+	POPULATION COUNCIL	75MG/IMPLANT **	N020544 001	Nov 01, 1996
LEVONORGESTREL				
	WYETH PHARMS INC	75MG/IMPLANT	N020627 001	Aug 15, 1996
NORPLANT				
	POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER				
	WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990
TABLET;ORAL				
LEVONORGESTREL				
	ALVOGEN	1.5MG	A202246 001	Jun 05, 2015
	FDN CONSUMER	0.75MG **	A078665 001	Aug 28, 2009
		1.5MG	A200670 001	Jul 12, 2012
	L PERRIGO CO	0.75MG	A090740 001	Dec 30, 2010
	LOTUS PHARM CO LTD	0.75MG	A202684 001	Sep 02, 2016
	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
	WATSON LABS	0.75MG	A078666 001	Jun 24, 2009
	XIROMED	0.75MG	A202740 001	Sep 02, 2016
PLAN B				
+	FDN CONSUMER	0.75MG **	N021045 001	Jul 28, 1999
+		0.75MG **	N021045 002	Aug 24, 2006
LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS				
CAPSULE;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE	N012928 006	
		EQ 100MG BASE	N012928 004	
SUSPENSION;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE/5ML	N012928 002	
LEVORPHANOL TARTRATE				
INJECTABLE;INJECTION				
LEVO-DROMORAN				
	VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991
TABLET;ORAL				
LEVO-DROMORAN				
+	VALEANT PHARM INTL	2MG **	N008720 001	Dec 19, 1991
LEVORPHANOL TARTRATE				
	HIKMA	1MG	A074278 002	Jun 18, 2018
		3MG	A074278 003	Jun 18, 2018
LEVOTHYROXINE SODIUM				
CAPSULE;ORAL				
LEVOTHYROXINE SODIUM				
	ANI PHARMS	0.075MG	A211369 001	Oct 28, 2020
		0.088MG	A213256 001	Jan 06, 2021
		0.1MG	A213256 002	Jan 06, 2021
		0.112MG	A211369 003	Apr 16, 2021
		0.125MG	A213256 003	Jan 06, 2021
		0.137MG	A211369 005	May 02, 2023
		0.15MG	A211369 002	Oct 28, 2020
		0.175MG	A211369 006	May 02, 2023
		0.2MG	A211369 004	Nov 09, 2022
POWDER;INTRAVENOUS				
LEVOTHYROXINE SODIUM				
	DR REDDYS	100MCG/VIAL	A208837 001	Mar 27, 2020
	PH HEALTH	200MCG/VIAL	A205366 001	Dec 07, 2015
TABLET;ORAL				
EUTHYROX				
	EMD SERONO INC	0.3MG	N021292 012	May 31, 2002
LEVOTHYROXINE SODIUM				
	AMNEAL	0.025MG	A210831 001	Feb 19, 2019
		0.05MG	A210831 002	Feb 19, 2019
		0.075MG	A210831 003	Feb 19, 2019
		0.088MG	A210831 004	Feb 19, 2019
		0.1MG	A210831 005	Feb 19, 2019
		0.112MG	A210831 006	Feb 19, 2019
		0.125MG	A210831 007	Feb 19, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOTHYROXINE SODIUM				
TABLET;ORAL				
LEVOTHYROXINE SODIUM				
	0.137MG	A210831	008	Feb 19, 2019
	0.15MG	A210831	009	Feb 19, 2019
	0.175MG	A210831	010	Feb 19, 2019
	0.2MG	A210831	011	Feb 19, 2019
	0.3MG	A210831	012	Feb 19, 2019
AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024
	0.15MG	A216414	002	Jul 16, 2024
	0.175MG	A216414	003	Jul 16, 2024
	0.2MG	A216414	004	Jul 16, 2024
	0.3MG	A216414	005	Jul 16, 2024
MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
	0.05MG	A076752	002	Jun 16, 2005
	0.075MG	A076752	003	Jun 16, 2005
	0.088MG	A076752	004	Jun 16, 2005
	0.1MG	A076752	005	Jun 16, 2005
	0.112MG	A076752	006	Jun 16, 2005
	0.125MG	A076752	007	Jun 16, 2005
	0.15MG	A076752	008	Jun 16, 2005
	0.175MG	A076752	009	Jun 16, 2005
	0.2MG	A076752	010	Jun 16, 2005
	0.3MG	A076752	011	Jun 16, 2005
LEVOXYL				
+ KING PHARMS	0.3MG **	N021301	012	May 25, 2001
LIDOCAINE				
AEROSOL;ORAL				
XYLOCAINE				
ASTRAZENECA	10%	N014394	001	
FILM, EXTENDED RELEASE;BUCCAL				
DENTIPATCH				
NOVEN	23MG/PATCH	N020575	001	May 21, 1996
OINTMENT;TOPICAL				
ALPHACAINE				
CARLISLE	5%	A084944	001	
	5%	A084946	001	
	5%	A084947	001	
LIDOCAINE				
BELMORA LLC	5%	A080210	001	
COSETTE	5%	A211019	001	Dec 12, 2018
ENCUBE	5%	A205318	001	Feb 01, 2016
GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019
RISING	5%	A208604	001	Sep 20, 2017
TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018
VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017
XYLOCAINE				
+ ASTRAZENECA	5% **	N008048	001	
PATCH;TOPICAL				
DENTIPATCH				
NOVEN	46.1MG/PATCH	N020575	002	May 21, 1996
LIDOCAINE				
NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020
SOLUTION;TOPICAL				
XYLOCAINE				
ASTRAZENECA	5%	N014127	001	
SUPPOSITORY;RECTAL				
XYLOCAINE				
ASTRAZENECA	100MG	N013077	001	
LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE				
CARLISLE	2%	A084721	001	
LIDOCAINE HYDROCHLORIDE				
ABBOTT	10%	A087980	001	Feb 02, 1983
	20%	A089362	001	May 25, 1988
ABRAXIS PHARM	1%	A080420	001	
	1%	A086761	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE					
	1.5%		A080420	005	
	2%		A080420	002	
	2%		A080420	004	
	2%		A086761	002	
	2%		N017508	001	
	4%		N017508	002	
	20%		N017508	004	
AM REGENT	1%		A080850	001	
	1%		A091564	001	Aug 14, 2015
BEL MAR	1%		A080710	001	
	2%		A080760	001	
BELMORA LLC	2%		A080504	001	
DELL LABS	1%		A083387	001	
	2%		A083388	001	
ELKINS SINN	0.5%		A085131	001	
	4%		A084626	001	
EPIC PHARMA LLC	1%		A085037	001	
	2%		A085037	002	
GD SEARLE LLC	1%		A083135	001	
	2%		A083135	002	
HOSPIRA	1%		A040013	001	Jun 23, 1995
+	1%		A083158	001	
	1.5%		A088330	001	May 17, 1984
+	2%		A083158	002	
	2%		A088331	001	May 17, 1984
	20%		A083158	003	
INTL MEDICATION	1%		N017701	002	
	2%		N017701	001	
	1GM/VIAL		N018543	001	
	2GM/VIAL		N018543	002	
LUITPOLD	2%		A083198	001	
LYPHOMED	1%		A080390	001	
	2%		A080390	002	
MILES	1%		A080414	001	
	2%		A080414	002	
RISING	0.5%		A091056	001	Dec 08, 2010
	0.5%		A091058	001	Sep 30, 2010
	1%		A091056	002	Dec 08, 2010
	1%		A091058	002	Sep 30, 2010
	2%		A202242	001	Apr 11, 2014
WATSON LABS	1%		A080377	001	
	1%		A083627	001	
	2%		A080377	002	
	2%		A083627	002	
WYETH AYERST	1%		A083083	001	
	2%		A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	100MG/100ML		N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	200MG/100ML		N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%					
HOSPIRA	200MG/100ML		A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER					
ABBOTT	200MG/100ML		N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML		N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	400MG/100ML		N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%					
HOSPIRA	400MG/100ML		A083158	006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER					
HOSPIRA	400MG/100ML		N018388	002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER					
B BRAUN	800MG/100ML		N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER					
HOSPIRA	800MG/100ML		N018388	003	Nov 05, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER					
	HOSPIRA	1.5%	A088326	001	Jul 31, 1984
		10%	A088367	001	Jul 31, 1984
		20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	EUGIA PHARMA	1%	A203040	001	Mar 14, 2013
		2%	A203040	002	Mar 14, 2013
	EXTROVIS	2%	A090665	001	Sep 27, 2010
	INTL MEDICATION	4%	N017702	002	
		20%	N017702	001	
LIDOCATON					
	PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN					
	MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE					
	ASTRAZENECA	1%	N010418	005	
		1.5%	N010418	009	
		2%	N010418	007	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4%	N010417	001	
XYLOCAINE DENTAL					
	DENTSPLY PHARM	2%	N021380	001	
XYLOCAINE PRESERVATIVE FREE					
+	FRESENIUS KABI USA	1% **	N016801	005	Jan 19, 1988
+		2% **	N016801	001	
+		4% **	N016801	002	
		10% **	N016801	003	
+		20% **	N016801	004	
INJECTABLE;SPINAL					
XYLOCAINE 1.5% W/ DEXTROSE 7.5%					
	FRESENIUS KABI USA	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%					
	ASTRAZENECA	5%	N010496	002	Jul 07, 1982
JELLY;TOPICAL					
ANESTACON					
	BIONPHARMA	2%	A080429	001	
LIDOCAINE HYDROCHLORIDE					
	COSETTE	2%	A081318	001	Apr 29, 1993
	WATSON LABS INC	2%	A040837	001	Mar 23, 2011
XYLOCAINE					
+	EPIC PHARMA LLC	2% **	N008816	001	
SOLUTION;ORAL					
LIDOCAINE HYDROCHLORIDE					
	HIKMA	2%	A040014	001	Jul 10, 1995
LIDOCAINE HYDROCHLORIDE VISCOUS					
	ACTAVIS MID ATLANTIC	2%	A086578	001	
	INTL MEDICATION	2%	A086389	001	Feb 02, 1982
XYLOCAINE VISCOUS					
+	FRESENIUS KABI USA	2% **	N009470	001	
SOLUTION;TOPICAL					
LARYNGOTRACHEAL ANESTHESIA KIT					
	KENDALL IL	4%	A087931	001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE					
	PACO	4%	A089688	001	Jun 30, 1989
LTA II KIT					
	HOSPIRA	4%	A080409	001	
		4%	A088542	001	Jul 31, 1984
PEDIATRIC LTA KIT					
	ABBOTT	2%	A088572	001	Jul 31, 1984
	HOSPIRA	2%	A085995	001	
XYLOCAINE 4% PRESERVATIVE FREE					
+	FRESENIUS KABI USA	4% **	N010417	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE
INJECTABLE;INJECTION
TERRAMYCIN

PFIZER	2%;50MG/ML	A060567 001	
	2%;125MG/ML	A060567 002	

LIDOCAINE; PRILOCAINE
CREAM;TOPICAL
EMLA

+ TEVA BRANDED PHARM	2.5%;2.5% **	N019941 001	Dec 30, 1992

LIDOCAINE AND PRILOCAINE

CHARTWELL RX	2.5%;2.5%	A213253 001	Sep 21, 2020
HIKMA	2.5%;2.5%	A076290 001	Sep 25, 2003
PAI HOLDINGS PHARM	2.5%;2.5%	A205887 001	Jun 29, 2018

DISC;TOPICAL
EMLA

ASTRAZENECA	2.5%;2.5%	N020962 001	Feb 04, 1998

LIDOCAINE; TETRACAINE
PATCH;TOPICAL
SYNERA

+ GALEN SPECIALTY	70MG;70MG	N021623 001	Jun 23, 2005

LIFITEGRAST
SOLUTION/DROPS;OPHTHALMIC
LIFITEGRAST

EUGIA PHARMA	5%	A215063 001	Nov 07, 2023
INGENUS PHARMS LLC	5%	A215058 001	Oct 03, 2024
MICRO LABS	5%	A215081 001	Aug 04, 2023

LINACLOTIDE
CAPSULE;ORAL
LINACLOTIDE

AUROBINDO PHARMA	145MCG	A209611 001	Feb 07, 2023
	290MCG	A209611 002	Feb 07, 2023
MYLAN	145MCG	A209564 001	Feb 09, 2021
	290MCG	A209564 002	Feb 09, 2021

LINCOMYCIN HYDROCHLORIDE
CAPSULE;ORAL
LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
	EQ 500MG BASE	N050316 002	

INJECTABLE;INJECTION
LINCOMYCIN HYDROCHLORIDE

SLATE RUN PHARMA	EQ 300MG BASE/ML	A216662 001	Dec 21, 2022
SLAYBACK	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991

LINDANE
CREAM;TOPICAL
KWELL

REED AND CARNRICK	1%	A084218 001	
	1%	N006309 001	

LOTION;TOPICAL
GAMENE

SOLA BARNES HIND	1%	A084989 001	

KWELL

REED AND CARNRICK	1%	A084218 002	
	1%	N006309 003	

LINDANE

OLTA PHARMS	1%	A087313 001	
WOCKHARDT BIO AG	1%	A088190 001	Aug 16, 1984

SCABENE

STIEFEL	1%	A086769 001	

SHAMPOO;TOPICAL
GAMENE

SOLA BARNES HIND	1%	A084988 001	

KWELL

REED AND CARNRICK	1%	A084219 001	
	1%	N010718 001	

LINDANE

OLTA PHARMS	1%	A087266 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LINDANE				
SHAMPOO;TOPICAL				
LINDANE				
	WOCKHARDT BIO AG	1%	A088191 001	Sep 18, 1984
SCABENE				
	STIEFEL	1%	A087940 001	Apr 08, 1983
LINEZOLID				
SOLUTION;INTRAVENOUS				
LINEZOLID				
	HOSPIRA	600MG/300ML (2MG/ML)	A205442 001	Jul 07, 2015
	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222 001	Jun 27, 2012
ZYVOX				
+	PFIZER	400MG/200ML (2MG/ML) **	N021131 002	Apr 18, 2000
TABLET;ORAL				
LINEZOLID				
	AMNEAL PHARMS	600MG	A204536 001	Dec 21, 2015
	GATE PHARMS	600MG	A091210 001	Feb 05, 2016
	MACLEODS PHARMS LTD	600MG	A210378 001	Oct 10, 2024
	TEVA PHARMS USA	600MG	A078061 001	May 18, 2015
ZYVOX				
+	PFIZER	400MG **	N021130 001	Apr 18, 2000
+		600MG	N021130 002	Apr 18, 2000
LIOTHYRONINE SODIUM				
INJECTABLE;INJECTION				
TRIOSTAT				
+	PH HEALTH	EQ 0.01MG BASE/ML **	N020105 001	Dec 31, 1991
TABLET;ORAL				
LIOTHYRONINE SODIUM				
	PHARMOBEDIENT	EQ 0.005MG BASE	A090326 001	Jul 14, 2009
		EQ 0.025MG BASE	A090326 002	Jul 14, 2009
		EQ 0.05MG BASE	A090326 003	Jul 14, 2009
	WATSON LABS	EQ 0.025MG BASE	A085755 001	Jan 25, 1982
		EQ 0.05MG BASE	A085753 001	Feb 03, 1982
LIOTRIX (T4;T3)				
TABLET;ORAL				
EUTHROID-0.5				
	PARKE DAVIS	0.03MG;0.0075MG	N016680 001	
EUTHROID-1				
	PARKE DAVIS	0.06MG;0.015MG	N016680 002	
EUTHROID-2				
	PARKE DAVIS	0.12MG;0.03MG	N016680 003	
EUTHROID-3				
	PARKE DAVIS	0.18MG;0.045MG	N016680 004	
THYROLAR-0.25				
+	ALLERGAN	0.0125MG;0.0031MG	N016807 001	
THYROLAR-0.5				
+	ALLERGAN	0.025MG;0.0063MG	N016807 005	
THYROLAR-1				
+	ALLERGAN	0.05MG;0.0125MG	N016807 004	
THYROLAR-2				
+	ALLERGAN	0.1MG;0.025MG	N016807 002	
THYROLAR-3				
+	ALLERGAN	0.15MG;0.0375MG	N016807 003	
THYROLAR-5				
	ALLERGAN	0.25MG;0.0625MG	N016807 006	
LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	ACCORD HLTHCARE	2.5MG	A202554 001	Jul 30, 2013
		5MG	A202554 002	Jul 30, 2013
		10MG	A202554 003	Jul 30, 2013
		20MG	A202554 004	Jul 30, 2013
		30MG	A202554 005	Jul 30, 2013
		40MG	A202554 006	Jul 30, 2013
	HERITAGE PHARMA	2.5MG	A075752 001	Jul 01, 2002
		5MG	A075752 002	Jul 01, 2002
		10MG	A075752 003	Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	20MG	A075752	004	Jul 01, 2002
	30MG	A075752	005	Jul 01, 2002
	40MG	A075752	006	Jul 01, 2002
HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002
	5MG	A076063	002	Jul 01, 2002
	10MG	A076063	003	Jul 01, 2002
	20MG	A076063	004	Jul 01, 2002
	30MG	A076063	006	Jun 27, 2003
	40MG	A076063	005	Jul 01, 2002
RISING	2.5MG	A075999	001	Jul 01, 2002
	5MG	A075999	002	Jul 01, 2002
	10MG	A075999	003	Jul 01, 2002
	20MG	A075999	004	Jul 01, 2002
	30MG	A075999	005	Jul 01, 2002
	40MG	A075999	006	Jul 01, 2002
STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002
	5MG	A076071	002	Jul 01, 2002
	10MG	A076071	003	Jul 01, 2002
	20MG	A076071	004	Jul 01, 2002
	30MG	A076071	005	Jul 01, 2002
	40MG	A076071	006	Jul 01, 2002
TEVA	2.5MG	A075783	001	Jul 01, 2002
	5MG	A075783	002	Jul 01, 2002
	10MG	A075783	003	Jul 01, 2002
	20MG	A075783	004	Jul 01, 2002
	30MG	A075783	005	Jul 01, 2002
	40MG	A075783	006	Jul 01, 2002
PRINIVIL				
MERCK	2.5MG	N019558	006	Jan 28, 1994
	5MG	N019558	001	Dec 29, 1987
	10MG	N019558	002	Dec 29, 1987
	20MG	N019558	003	Dec 29, 1987
	40MG	N019558	004	Oct 25, 1988
LITHIUM CARBONATE				
CAPSULE;ORAL				
ESKALITH				
NOVEN THERAP	300MG	N016860	001	
LITHIUM CARBONATE				
ABLE	150MG	A076823	001	Jun 29, 2004
	300MG	A076121	001	Sep 27, 2001
	300MG	A076823	002	Jun 29, 2004
	600MG	A076823	003	Jun 29, 2004
APOTEX INC	300MG	A076795	001	Nov 22, 2004
PHARMOBEDIENT	150MG	A076243	002	Feb 24, 2003
	300MG	A076243	001	Jun 27, 2002
	600MG	A078763	001	Apr 15, 2008
USL PHARMA	300MG	A072542	001	Feb 01, 1989
WATSON LABS	300MG	A070407	001	Mar 19, 1987
LITHONATE				
SOLVAY	300MG	N016782	001	
TABLET;ORAL				
ESKALITH				
JDS PHARMS	300MG	N017971	001	
LITHANE				
BAYER PHARMS	300MG	N018833	001	Jul 18, 1985
LITHIUM CARBONATE				
HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010
PFIZER	300MG	N016834	001	
LITHOTABS				
SOLVAY	300MG	N016980	001	
TABLET, EXTENDED RELEASE;ORAL				
ESKALITH CR				
JDS PHARMS	450MG **	N018152	001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG	A076382	001	Apr 21, 2003
ALEMBIC	300MG	A204445	001	Jun 10, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LITHIUM CARBONATE					
TABLET, EXTENDED RELEASE;ORAL					
LITHIUM CARBONATE					
	HERITAGE PHARMA	300MG	A076170	001	Jun 10, 2002
		450MG	A076366	001	Aug 21, 2003
	HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003
	PHARMOBEDIENT	300MG	A202288	001	Jun 29, 2012
		450MG	A202219	001	Aug 08, 2012
LITHIUM CITRATE					
SYRUP;ORAL					
LITHIUM CITRATE					
+	HIKMA	EQ 300MG CARBONATE/5ML **	N018421	001	
	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986
LITHONATE					
	SOLVAY	EQ 300MG CARBONATE/5ML	N017672	001	
LODOXAMIDE TROMETHAMINE					
SOLUTION/DROPS;OPHTHALMIC					
ALOMIDE					
+	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993
LOMEFLOXACIN HYDROCHLORIDE					
TABLET;ORAL					
MAXAQUIN					
	PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992
LOMITAPIDE MESYLATE					
CAPSULE;ORAL					
JUXTAPID					
+	CHIESI	EQ 40MG BASE	N203858	005	Apr 23, 2015
+		EQ 60MG BASE	N203858	006	Apr 23, 2015
LOMUSTINE					
CAPSULE;ORAL					
GLEOSTINE					
+	AZURITY	5MG	N017588	004	Dec 19, 2014
LOPERAMIDE HYDROCHLORIDE					
CAPSULE;ORAL					
IMODIUM					
	J AND J CONSUMER INC	2MG **	N017690	001	
+		2MG **	N017694	001	
LOPERAMIDE HYDROCHLORIDE					
	CHARTWELL RX	2MG	A072993	001	Aug 28, 1992
	ROXANE	2MG	A073080	001	Nov 27, 1991
	TEVA	2MG	A073122	001	Aug 30, 1991
SOLUTION;ORAL					
IMODIUM					
	JANSSEN PHARMS	1MG/5ML	N019037	001	Jul 31, 1984
IMODIUM A-D					
+	KENVUE BRANDS	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE					
	ALLIED	1MG/5ML	A073079	001	Apr 30, 1992
	ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
	DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
	PAI HOLDINGS	1MG/5ML	A074352	001	Nov 17, 1995
	PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
	TEVA	1MG/5ML	A073478	001	Jun 23, 1995
	WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997
TABLET;ORAL					
LOPERAMIDE HYDROCHLORIDE					
	ABLE	2MG	A073528	001	Nov 30, 1993
	CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
	PERRIGO	2MG	A074194	001	Oct 30, 1992
TABLET, CHEWABLE;ORAL					
IMODIUM A-D EZ CHEWS					
+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL				
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
GRANULES	2MG;125MG	A215981	001	Aug 29, 2022
SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006
TABLET, CHEWABLE;ORAL				
IMODIUM MULTI-SYMPTOM RELIEF				
+ J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LOPINAVIR; RITONAVIR

CAPSULE;ORAL				
KALETRA				
ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000
SOLUTION;ORAL				
LOPINAVIR AND RITONAVIR				
LANNETT CO INC	80MG/ML;20MG/ML	A207407	001	Dec 27, 2016

LORACARBEF

CAPSULE;ORAL				
LORABID				
KING PHARMS	200MG	N050668	001	Dec 31, 1991
	400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION;ORAL				
LORABID				
KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
	200MG/5ML	N050667	002	Dec 31, 1991

LORATADINE

CAPSULE;ORAL				
LORATADINE				
CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025
ONESOURCE SPECIALTY	10MG	A211926	001	Jan 15, 2020
SUSPENSION;ORAL				
LORATADINE				
+ SUN PHARMA CANADA	1MG/ML	N021734	001	Oct 04, 2005
SYRUP;ORAL				
CLARITIN HIVES RELIEF				
+ BAYER HEALTHCARE LLC	1MG/ML **	N020641	003	Nov 19, 2003
LORATADINE				
PHARM ASSOC	1MG/ML	A075565	001	Oct 05, 2004
RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004
TEVA	1MG/ML	A075505	001	Nov 07, 2003
TABLET;ORAL				
LORATADINE				
PERRIGO	10MG	N021512	001	Jun 24, 2004
PHARMOBEDIENT	10MG	A075790	001	Nov 07, 2008
	10MG	A078447	001	Aug 12, 2011
TABLET, ORALLY DISINTEGRATING;ORAL				
LORATADINE				
ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004

LORAZEPAM

CONCENTRATE;ORAL				
LORAZEPAM				
CHARTWELL MOLECULAR	2MG/ML	A079244	001	Apr 28, 2009
HIKMA	2MG/ML	A200169	001	Jan 30, 2012
LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013
INJECTABLE;INJECTION				
LORAZEPAM				
BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
	4MG/ML	A077076	002	Jul 13, 2005
CAPLIN	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LORAZEPAM

INJECTABLE;INJECTION				
LORAZEPAM				
EPIC PHARMA LLC	2MG/ML	A074974	001	Jul 23, 1998
HIKMA	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	2MG/ML	A074282	001	May 27, 1994
	2MG/ML	A074300	001	Apr 12, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074282	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
PH HEALTH	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
PHARMOBEDIENT	2MG/ML	A074535	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
RISING	2MG/ML	A200217	001	Apr 04, 2017
	2MG/ML	A200542	001	Apr 28, 2017
	4MG/ML	A200217	002	Apr 04, 2017
	4MG/ML	A200542	002	Apr 28, 2017
WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
	4MG/ML	A074276	002	Apr 15, 1994
LORAZEPAM PRESERVATIVE FREE				
BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
	4MG/ML	A077074	002	Jul 13, 2005
SOLUTION;ORAL				
LORAZEPAM				
ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
TABLET;ORAL				
LORAZ				
QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985
LORAZEPAM				
AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010
	1MG	A078826	002	Jun 23, 2010
	2MG	A078826	003	Jun 23, 2010
CHARTWELL RX	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
RISING	0.5MG	A077657	001	Mar 16, 2006
	1MG	A077657	002	Mar 16, 2006
	2MG	A077657	003	Mar 16, 2006
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
TP ANDA HOLDINGS	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LORAZEPAM
TABLET;ORAL
LORAZEPAM

	0.5MG		A071117 001	Jul 24, 1986
	1MG		A071087 001	Mar 23, 1987
	1MG		A071118 001	Jul 24, 1986
	2MG		A071088 001	Mar 23, 1987
	2MG		A071110 001	Jul 24, 1986

LOSARTAN POTASSIUM
TABLET;ORAL
LOSARTAN POTASSIUM

APOTEX	25MG		A218551 001	Jun 04, 2024
	50MG		A218551 002	Jun 04, 2024
	100MG		A218551 003	Jun 04, 2024
APOTEX CORP	25MG		A090790 001	Oct 06, 2010
	50MG		A090790 002	Oct 06, 2010
	100MG		A090790 003	Oct 06, 2010
HIKMA	25MG		A077459 001	Oct 06, 2010
	50MG		A077459 002	Oct 06, 2010
	100MG		A077459 003	Oct 06, 2010
HISUN PHARM HANGZHOU	25MG		A204795 001	Apr 04, 2019
	50MG		A204795 002	Apr 04, 2019
	100MG		A204795 003	Apr 04, 2019
IPCA LABS LTD	25MG		A200290 001	Aug 30, 2013
	50MG		A200290 002	Aug 30, 2013
	100MG		A200290 003	Aug 30, 2013
MYLAN	25MG		A091590 001	Oct 06, 2010
	50MG		A091590 002	Oct 06, 2010
	100MG		A091590 003	Oct 06, 2010
TEVA	25MG		A076958 001	Apr 06, 2010
	50MG		A076958 002	Apr 06, 2010
	100MG		A076958 003	Apr 06, 2010
TORRENT PHARMS	25MG		A090467 001	Oct 06, 2010
	50MG		A090467 002	Oct 06, 2010
	100MG		A090467 003	Oct 06, 2010

LOTEPREDNOL ETABONATE
GEL;OPHTHALMIC
LOTEPREDNOL ETABONATE

HIKMA	0.5%		A213956 001	Nov 29, 2023

SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX

PHARMOS	0.5%		N020841 001	Mar 09, 1998

LOVASTATIN
TABLET;ORAL
LOVASTATIN

AUROBINDO PHARMA USA	10MG		A075451 001	Dec 17, 2001
	10MG		A075935 001	Dec 17, 2001
	20MG		A075451 002	Dec 17, 2001
	20MG		A075935 002	Dec 17, 2001
	40MG		A075451 003	Dec 17, 2001
	40MG		A075935 003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG		A077520 001	Apr 14, 2006
	20MG		A077520 002	Apr 14, 2006
	40MG		A077520 003	Apr 14, 2006

MEVACOR

+	MERCK	10MG **		N019643 002	Mar 28, 1991
+		20MG **		N019643 003	Aug 31, 1987
+		40MG **		N019643 004	Dec 14, 1988

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

COVIS	10MG		N021316 001	Jun 26, 2002
+	20MG		N021316 002	Jun 26, 2002
+	40MG		N021316 003	Jun 26, 2002
+	60MG		N021316 004	Jun 26, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL				
LOXITANE C				
	TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658 001	
INJECTABLE;INJECTION				
LOXITANE IM				
	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039 001	

LOXAPINE SUCCINATE

CAPSULE;ORAL				
LOXAPINE SUCCINATE				
	RISING	EQ 5MG BASE	A076762 001	Nov 01, 2004
		EQ 10MG BASE	A076762 002	Nov 01, 2004
		EQ 25MG BASE	A076762 003	Nov 01, 2004
		EQ 50MG BASE	A076762 004	Nov 01, 2004
LOXITANE				
+	TEVA BRANDED PHARM	EQ 5MG BASE **	N017525 001	
+		EQ 10MG BASE **	N017525 002	
+		EQ 25MG BASE **	N017525 003	
+		EQ 50MG BASE **	N017525 004	
TABLET;ORAL				
LOXITANE				
+	TEVA BRANDED PHARM	EQ 10MG BASE **	N017525 006	
+		EQ 25MG BASE **	N017525 007	
+		EQ 50MG BASE **	N017525 008	

LUBIPROSTONE

CAPSULE;ORAL				
LUBIPROSTONE				
	AMNEAL	8MCG	A209450 001	Nov 30, 2021
		24MCG	A209450 002	Nov 30, 2021
	PH HEALTH	8MCG	A201442 001	Jun 27, 2022
		24MCG	A201442 002	Jun 27, 2022

LUCINACTANT

SUSPENSION;INTRATRACHEAL				
SURFAXIN				
	LEES PHARM HK	8.5ML	N021746 001	Mar 06, 2012

LURASIDONE HYDROCHLORIDE

TABLET;ORAL				
LURASIDONE HYDROCHLORIDE				
	AMNEAL PHARMS CO	20MG	A208002 001	Jan 03, 2019
		40MG	A208002 002	Jan 03, 2019
		60MG	A208002 003	Jan 03, 2019
		80MG	A208002 004	Jan 03, 2019
		120MG	A208002 005	Jan 03, 2019
	SUN PHARM	120MG	A208066 005	Jan 04, 2019
	TEVA PHARMS USA	20MG	A208060 001	May 17, 2019
		40MG	A208060 002	May 17, 2019
		60MG	A208060 003	May 17, 2019
		80MG	A208060 004	May 17, 2019
		120MG	A208060 005	May 17, 2019
	WATSON LABS TEVA	20MG	A208016 001	Feb 02, 2021
		40MG	A208016 002	Feb 02, 2021
		60MG	A208016 003	Feb 02, 2021
		80MG	A208016 004	Feb 02, 2021
		120MG	A208016 005	Feb 02, 2021

LYPRESSIN

SOLUTION;NASAL				
DIAPID				
	NOVARTIS	0.185MG/ML	N016755 001	

MACIMORELIN ACETATE

FOR SOLUTION;ORAL				
MACRILEN				
+	NOVO	EQ 60MG BASE/POUCH	N205598 001	Dec 20, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MACITENTAN

TABLET;ORAL					
MACITENTAN					
	APOTEX	10MG	A211195	001	Jan 09, 2024
	MYLAN	10MG	A211161	001	Dec 03, 2025
	SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025
	TORRENT	10MG	A211107	001	Aug 05, 2024
	ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL					
MAFENIDE ACETATE					
	NOVAST LABS	5%	A206716	001	Jul 31, 2017
	PH HEALTH	5%	A201511	001	Feb 12, 2013
SULFAMYLON					
+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
PLASMA-LYTE 56 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION					
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER					
	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION					
ISOLYTE S IN PLASTIC CONTAINER					
	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001	
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5					
	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022
SOLUTION;IRRIGATION					
PHYSIOSOL IN PLASTIC CONTAINER					
	HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001	
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER					
	HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982
SYNOVALYTE IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N019326	001	Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET;ORAL					
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE					
	SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009
		343MG;40MG;750MG	N022456	002	Dec 04, 2009
TABLET, CHEWABLE;ORAL					
ZEGERID					
	SANTARUS	700MG;20MG;600MG	N021850	001	Mar 24, 2006
		700MG;40MG;600MG	N021850	002	Mar 24, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION					
MAGNESIUM SULFATE IN PLASTIC CONTAINER					
	MYLAN LABS LTD	4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018
SOLUTION;INTRAMUSCULAR, INTRAVENOUS					
MAGNESIUM SULFATE					
	EXELA PHARMA	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL					
SUCLEAR					
+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **	N203595	001	Jan 18, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE				
POWDER;ORAL				
COLPREP KIT				
+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553 001	Dec 27, 2016
MALATHION				
LOTION;TOPICAL				
MALATHION				
	PHARMOBEDIENT	0.5%	A078743 001	Mar 06, 2009
OVIDE				
+	TARO	0.5% **	N018613 001	Aug 02, 1982
MANGAFODIPIR TRISODIUM				
INJECTABLE;INJECTION				
TESLASCAN				
	IC TARGETS	37.9MG/ML	N020652 001	Nov 26, 1997
MANGANESE CHLORIDE TETRAHYDRATE				
FOR SOLUTION;ORAL				
LUMENHANCE				
	BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
MANGANESE SULFATE				
INJECTABLE;INJECTION				
MANGANESE SULFATE				
+	ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML **	N019228 001	May 05, 1987
MANNITOL				
INJECTABLE;INJECTION				
MANNITOL 10%				
	B BRAUN	10GM/100ML	N016080 002	
	HOSPIRA	10GM/100ML	N016269 002	
	MILES	10GM/100ML	N016472 002	
MANNITOL 10% IN PLASTIC CONTAINER				
	OTSUKA ICU MEDCL	10GM/100ML	N019603 002	Jan 08, 1987
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER				
	B BRAUN	10GM/100ML	N016080 006	
MANNITOL 15%				
	B BRAUN	15GM/100ML	N016080 003	
	HOSPIRA	15GM/100ML	N016269 003	
	MILES	15GM/100ML	N016472 005	
MANNITOL 15% IN PLASTIC CONTAINER				
	OTSUKA ICU MEDCL	15GM/100ML	N019603 003	Jan 08, 1990
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%				
	B BRAUN	15GM/100ML	N016080 005	
MANNITOL 20%				
	B BRAUN	20GM/100ML	N014738 001	
		20GM/100ML	N016080 004	
	HOSPIRA	20GM/100ML	N016269 004	
	MILES	20GM/100ML	N016472 004	
MANNITOL 25%				
	ABRAXIS PHARM	12.5GM/50ML	A086754 001	
	HOSPIRA	12.5GM/50ML	N016269 005	
	IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
		12.5GM/50ML	A089240 001	May 06, 1987
	INTL MEDICATION	12.5GM/50ML	A083051 001	
	LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
	MERCK	12.5GM/50ML	N005620 001	
	WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983
MANNITOL 5%				
	B BRAUN	5GM/100ML	N016080 001	
	HOSPIRA	5GM/100ML	N016269 001	
MANNITOL 5% IN PLASTIC CONTAINER				
	OTSUKA ICU MEDCL	5GM/100ML	N019603 001	Jan 08, 1987
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%				
	B BRAUN	5GM/100ML	N016080 007	
SOLUTION;IRRIGATION				
RESECTISOL				
	B BRAUN	5GM/100ML	N016704 002	
RESECTISOL IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML	N016772 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MANNITOL; SORBITOL				
SOLUTION;IRRIGATION				
SORBITOL-MANNITOL				
	HOSPIRA	540MG/100ML;2.7GM/100ML	A080224 001	
SORBITOL-MANNITOL IN PLASTIC CONTAINER				
	HOSPIRA	540MG/100ML;2.7GM/100ML	N017636 001	
MAPROTILINE HYDROCHLORIDE				
TABLET;ORAL				
LUDIOMIL				
	NOVARTIS	25MG	N017543 001	
		50MG	N017543 002	
		75MG	N017543 003	Sep 30, 1982
MAPROTILINE HYDROCHLORIDE				
	AM THERAP	25MG	A072129 001	Jan 14, 1988
		50MG	A072130 001	Jan 14, 1988
		75MG	A072131 001	Jan 14, 1988
	HERITAGE PHARMA	25MG	A072162 001	Jun 01, 1988
		50MG	A072163 001	Jun 01, 1988
	RISING	25MG	A072285 002	Oct 03, 1988
		50MG	A072285 001	Oct 03, 1988
		75MG	A072285 003	Oct 03, 1988
	WATSON LABS	25MG	A071943 001	Dec 30, 1987
		50MG	A071944 001	Dec 30, 1987
		75MG	A071945 001	Dec 30, 1987
		75MG	A072164 001	Jun 01, 1988
MARAVIROC				
TABLET;ORAL				
SELZENTRY				
+	VIIV HLTHCARE	25MG **	N022128 003	Nov 04, 2016
+		75MG **	N022128 004	Nov 04, 2016
MASOPROCOL				
CREAM;TOPICAL				
ACTINEX				
	UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992
MAZINDOL				
TABLET;ORAL				
MAZANOR				
	WYETH AYERST	1MG	N017980 002	
		2MG	N017980 001	
SANOREX				
+	NOVARTIS	1MG **	N017247 001	
+		2MG **	N017247 002	
MEBENDAZOLE				
TABLET, CHEWABLE;ORAL				
VERMOX				
+	JANSSEN PHARMS	100MG **	N017481 001	
+		500MG	N208398 001	Oct 19, 2016
MEBUTAMATE				
TABLET;ORAL				
DORMATE				
	MEDPOINTE PHARM HLC	600MG	N017374 001	
MECAMYLAMINE HYDROCHLORIDE				
TABLET;ORAL				
INVERSINE				
+	TARGACEPT	2.5MG **	N010251 001	
MECHLORETHAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MUSTARGEN				
+	RECORDATI RARE	10MG/VIAL	N006695 001	

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253 001	
	25MG	A085252 001	
ANABOLIC	25MG	A085891 001	
ANI PHARMS	12.5MG	A084657 002	
	12.5MG	A085269 001	
	12.5MG	A088732 001	Dec 11, 1985
	25MG	A084657 001	
	25MG	A085740 001	
BUNDY	12.5MG	A084382 001	
	25MG	A084872 001	
HERITAGE	12.5MG	A205136 001	Feb 22, 2019
	25MG	A205136 002	Feb 22, 2019
	50MG	A205136 003	Feb 22, 2019
INVAGEN PHARMS	12.5MG	A200432 001	Feb 17, 2022
	25MG	A200432 002	Feb 17, 2022
	50MG	A200432 003	Feb 17, 2022
IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
KV PHARM	12.5MG	A085524 001	
	25MG	A085523 001	
PLIVA	25MG	A088734 001	Dec 11, 1985
RISING	12.5MG	A040179 001	Jan 30, 1997
	25MG	A040179 002	Jan 30, 1997
STRIDES PHARMA INTL	50MG	A089674 001	Mar 31, 1988
SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
	25MG	A089114 001	Aug 20, 1985
UDL	12.5MG	A088256 001	Jun 13, 1983
	25MG	A088257 001	Jun 13, 1983
VANGARD	12.5MG	A087877 001	Apr 20, 1982
	25MG	A087620 001	Jan 04, 1982
WATSON LABS	12.5MG	A085195 001	

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

INVAGEN PHARMS	25MG	A200791 001	Feb 17, 2022
IVAX SUB TEVA PHARMS	25MG	A084976 001	
NEXGEN PHARMA INC	25MG	A086392 001	
PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518 001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
	EQ 100MG BASE	A071381 001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
	EQ 100MG BASE	A071363 001	Feb 10, 1987
ANI PHARMS	EQ 50MG BASE	A071469 002	Apr 15, 1987
	EQ 100MG BASE	A071469 001	Apr 15, 1987
BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
	EQ 100MG BASE	A072809 001	Mar 20, 1989
CHARTWELL RX	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
	EQ 100MG BASE	A072078 001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710 001	Jun 15, 1988
	EQ 100MG BASE	A071684 001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400 001	Nov 25, 1986
	EQ 50MG BASE	A071640 001	Aug 11, 1987
	EQ 100MG BASE	A070401 001	Nov 25, 1986
	EQ 100MG BASE	A071641 001	Aug 11, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MECLOFENAMATE SODIUM				
CAPSULE;ORAL				
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	
MEDROXYPROGESTERONE ACETATE				
INJECTABLE;INJECTION				
DEPO-PROVERA				
+ PFIZER	100MG/ML **	N012541	002	
+	400MG/ML	N012541	003	
MEDROXYPROGESTERONE ACETATE				
CIPLA	150MG/ML	A210335	001	Jan 25, 2019
HIKMA	150MG/ML	A214309	001	Jan 05, 2023
SANDOZ	150MG/ML	A078711	001	May 20, 2009
SUN PHARM	150MG/ML	A210760	001	May 01, 2019
	150MG/ML	A210761	001	Apr 24, 2019
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984
MEDRYSONE				
SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	
MEFENAMIC ACID				
CAPSULE;ORAL				
MEFENAMIC ACID				
CHARTWELL RX	250MG	A209209	001	Sep 18, 2020
MPP PHARMA	250MG	A090359	001	Feb 05, 2013
MEFLOQUINE HYDROCHLORIDE				
TABLET;ORAL				
LARIAM				
+ ROCHE	250MG **	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA	250MG	A076523	001	Oct 01, 2004
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
US ARMY WALTER REED	250MG **	N019578	001	May 02, 1989
MEGESTROL ACETATE				
SUSPENSION;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	40MG/ML **	N020264	001	Sep 10, 1993
MEGACE ES				
+ ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005
MEGESTROL ACETATE				
CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017
HIKMA	40MG/ML	A075997	001	Feb 15, 2002
	40MG/ML	A203960	001	Jun 09, 2017
TEVA PHARMS	40MG/ML	A075681	001	May 05, 2003
TABLET;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	20MG **	N016979	001	
+	40MG **	N016979	002	
MEGESTROL ACETATE				
HIKMA	20MG	A074458	001	Sep 29, 1995
	40MG	A074458	002	Sep 29, 1995
TEVA	40MG	A074745	001	Feb 27, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEGESTROL ACETATE				
TABLET;ORAL				
MEGESTROL ACETATE				
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987
MELOXICAM				
CAPSULE;ORAL				
VIVLODEX				
+ ICEUTICA OPERATIONS	5MG **	N207233	001	Oct 22, 2015
+	10MG **	N207233	002	Oct 22, 2015
SOLUTION;INTRAVENOUS				
ANJESO				
+ BAUDAX	30MG/ML (30MG/ML) **	N210583	001	Feb 20, 2020
TABLET;ORAL				
MELOXICAM				
CHARTWELL RX	7.5MG	A077936	001	Jul 19, 2006
	15MG	A077936	002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006
	15MG	A078039	002	Dec 14, 2006
IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006
	15MG	A077930	002	Jul 19, 2006
LUPIN PHARMS	7.5MG	A077944	001	Jul 19, 2006
	15MG	A077944	002	Jul 19, 2006
MYLAN	7.5MG	A077934	001	Jul 20, 2006
	15MG	A077934	002	Jul 20, 2006
NATCO PHARMA	7.5MG	A077923	001	Jul 19, 2006
	15MG	A077923	002	Jul 19, 2006
ROXANE	7.5MG	A077925	001	Jul 19, 2006
	15MG	A077925	002	Jul 19, 2006
SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006
	15MG	A077937	002	Jul 19, 2006
TARO	7.5MG	A078102	001	Nov 07, 2006
	15MG	A078102	002	Nov 07, 2006
TP ANDA HOLDINGS	7.5MG	A077935	001	Jul 19, 2006
	15MG	A077935	002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006
	15MG	A077933	002	Jul 19, 2006
MOBIC				
+ BOEHRINGER INGELHEIM	7.5MG **	N020938	001	Apr 13, 2000
+	15MG **	N020938	002	Aug 23, 2000
TABLET, ORALLY DISINTEGRATING;ORAL				
QMIIZ ODT				
+ TERSERA	7.5MG **	N211210	001	Oct 19, 2018
+	15MG **	N211210	002	Oct 19, 2018
MELPHALAN				
TABLET;ORAL				
ALKERAN				
+ APOTEX	2MG **	N014691	002	
MELPHALAN				
ALVOGEN	2MG	A207809	001	Mar 22, 2017
MELPHALAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALKERAN				
+ APOTEX	EQ 50MG BASE/VIAL **	N020207	001	Nov 18, 1992
MELPHALAN HYDROCHLORIDE				
ALMAJECT	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019
MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009
NOVAST LABS	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020
PH HEALTH	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016
USWM	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019
POWDER;INTRAVENOUS				
MELPHALAN HYDROCHLORIDE				
ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEMANTINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
MEMANTINE HYDROCHLORIDE				
ANI PHARMS	7MG	A205365	001	Feb 28, 2020
	14MG	A205365	002	Feb 28, 2020
	21MG	A205365	003	Feb 28, 2020
	28MG	A205365	004	Feb 28, 2020
APOTEX	7MG	A206135	001	Nov 22, 2016
	14MG	A206135	002	Nov 22, 2016
	21MG	A206135	003	Nov 22, 2016
	28MG	A206135	004	Nov 22, 2016
PH HEALTH	7MG	A205784	001	Jun 09, 2017
	14MG	A205784	002	Jun 09, 2017
	21MG	A205784	003	Jun 09, 2017
	28MG	A205784	004	Jun 09, 2017
SUN PHARM	7MG	A205905	001	Sep 28, 2016
	14MG	A205905	002	Sep 28, 2016
	21MG	A205905	003	Sep 28, 2016
	28MG	A205905	004	Sep 28, 2016
NAMENDA XR				
+ ABBVIE	7MG **	N022525	001	Jun 21, 2010
+	14MG	N022525	002	Jun 21, 2010
+	21MG	N022525	003	Jun 21, 2010
+	28MG	N022525	004	Jun 21, 2010
SOLUTION;ORAL				
MEMANTINE HYDROCHLORIDE				
SCIEGEN PHARMS	2MG/ML	A205446	001	Dec 07, 2015
NAMENDA				
+ ALLERGAN	2MG/ML **	N021627	001	Apr 18, 2005
TABLET;ORAL				
MEMANTINE HYDROCHLORIDE				
CHARTWELL	5MG	A090244	001	Jul 11, 2018
	10MG	A090244	002	Jul 11, 2018
HIKMA	5MG	A208173	001	Feb 28, 2020
	10MG	A208173	002	Feb 28, 2020
JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015
	10MG	A091585	002	Oct 13, 2015
LANNETT CO INC	5MG	A207236	001	Nov 10, 2016
	10MG	A207236	002	Nov 10, 2016
ORBION PHARMS	5MG	A090044	001	Mar 12, 2012
	10MG	A090044	002	Mar 12, 2012
POINTVIEW HLDINGS	5MG	A090073	001	Sep 04, 2015
	10MG	A090073	002	Sep 04, 2015
RISING	5MG	A079225	001	Jan 30, 2015
	10MG	A079225	002	Jan 30, 2015
TEVA PHARMS	5MG	A090052	001	Oct 25, 2011
	10MG	A090052	002	Oct 25, 2011
TORRENT	5MG	A200155	001	Oct 13, 2015
	10MG	A200155	002	Oct 13, 2015
MENADIOL SODIUM DIPHOSPHATE				
INJECTABLE;INJECTION				
KAPPADIONE				
LILLY	10MG/ML	N005725	001	
SYNKAYVITE				
ROCHE	5MG/ML	N003718	004	
	10MG/ML	N003718	006	
	37.5MG/ML	N003718	008	
TABLET;ORAL				
SYNKAYVITE				
ROCHE	5MG	N003718	010	
MENADIONE				
TABLET;ORAL				
MENADIONE				
LILLY	5MG	N002139	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPENZOLATE BROMIDE					
SOLUTION;ORAL					
CANTIL					
	SANOFI AVENTIS US	25MG/5ML	N010679	004	
TABLET;ORAL					
CANTIL					
+	SANOFI AVENTIS US	25MG	N010679	003	
MEPERIDINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
DEMEROL					
	QUAGEN	25MG/ML	N005010	007	
		50MG/ML	N005010	002	
		75MG/ML	N005010	009	
		100MG/ML	N005010	003	
MEPERIDINE HYDROCHLORIDE					
	ABBOTT	25MG/ML	A080388	001	
		50MG/ML	A080385	001	
		50MG/ML	A080387	001	
		75MG/ML	A080389	001	
		100MG/ML	A080386	001	
	BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
		50MG/ML	A088280	001	Jun 15, 1984
		75MG/ML	A088281	001	Jun 15, 1984
		100MG/ML	A088282	001	Jun 15, 1984
	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
		50MG/ML	A089782	001	Mar 31, 1989
		50MG/ML	A089783	001	Mar 31, 1989
		50MG/ML	A089784	001	Mar 31, 1989
		75MG/ML	A089785	001	Mar 31, 1989
		100MG/ML	A089786	001	Mar 31, 1989
		100MG/ML	A089787	001	Mar 31, 1989
		100MG/ML	A089788	001	Mar 31, 1989
	INTL MEDICATION	10MG/ML	A086332	001	
	PARKE DAVIS	50MG/ML	A080364	002	
		75MG/ML	A080364	003	
		100MG/ML	A080364	001	
	WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992
		100MG/ML	A073445	001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE					
	HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
+	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984
	INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
	SPECGX LLC	10MG/ML	A040163	001	May 12, 1997
	WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992
SYRUP;ORAL					
DEMEROL					
	QUAGEN	50MG/5ML **	N005010	005	
TABLET;ORAL					
DEMEROL					
+	QUAGEN	50MG **	N005010	001	
+		100MG **	N005010	004	
MEPERIDINE HYDROCHLORIDE					
	BARR	50MG	A088639	001	Jul 02, 1984
		100MG	A088640	001	Sep 19, 1984
	DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999
		100MG	A040318	002	Oct 05, 1999
	GENUS	75MG	A040893	002	Jun 24, 2009
		100MG	A040893	003	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009
	HIKMA	50MG	A040110	001	Mar 12, 1997
		100MG	A040110	002	Mar 12, 1997
	SPECGX LLC	50MG	A040352	001	Jun 13, 2000
		100MG	A040352	002	Jun 13, 2000
	STRIDES PHARMA INTL	50MG	A040191	001	Dec 17, 1998
		100MG	A040191	002	Dec 17, 1998
	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002
		100MG	A040446	002	Aug 08, 2002
	SUN PHARM INDUSTRIES	50MG	A080448	001	
		100MG	A080448	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPERIDINE HYDROCHLORIDE				
TABLET;ORAL				
MEPERIDINE HYDROCHLORIDE				
WATSON LABS	50MG	A040186	001	Jun 30, 1997
	100MG	A040186	002	Jun 30, 1997
WYETH AYERST	50MG	A080454	001	
MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MEPERGAN				
HIKMA	25MG/ML;25MG/ML	N011730	001	
MEPHENTERMINE SULFATE				
INJECTABLE;INJECTION				
WYAMINE SULFATE				
BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002	
	EQ 30MG BASE/ML	N008248	001	
MEPHENYTOIN				
TABLET;ORAL				
MESANTOIN				
+ NOVARTIS	100MG **	N006008	001	
MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE				
SOLVAY	3%	A084777	002	Apr 18, 1982
CARBOCAINE				
+ EASTMAN KODAK	3% **	N012125	003	
+ HOSPIRA	1%	N012250	001	
+	1.5%	N012250	005	
+	2%	N012250	002	
ISOCAINE HYDROCHLORIDE				
SEPTODONT	3%	A080925	001	
MEPIVACAINE HYDROCHLORIDE				
BELMORA LLC	3%	A083559	001	
HOSPIRA INC	3%	A040806	001	Apr 28, 2008
INTL MEDICATION SYS	1%	A087509	001	Oct 05, 1982
WATSON LABS	1%	A088769	001	Nov 20, 1984
	2%	A088770	001	Nov 20, 1984
POLOCAINE				
DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984
MEPREDNISONE				
TABLET;ORAL				
BETAPAR				
SCHERING	4MG	N016053	002	
MEPROBAMATE				
CAPSULE;ORAL				
EQUANIL				
WYETH AYERST	400MG	N012455	002	
CAPSULE, EXTENDED RELEASE;ORAL				
MEPROSPAN				
MEDPOINTE PHARM HLC	200MG	N011284	001	
	400MG	N011284	002	
TABLET;ORAL				
AMOSENE				
FERNDALE LABS	400MG	A084030	001	
BAMATE				
ALRA	200MG	A080380	001	
	400MG	A080380	002	
EQUANIL				
WYETH AYERST	200MG	N010028	005	
	400MG	N010028	004	
MEPRIAM				
TEVA	400MG	N016069	001	
MEPROBAMATE				
ACELLA	400MG	A084153	001	
BARR	600MG	A084230	001	
CHARTWELL MOLECULAR	200MG	N014882	002	
	400MG	N014882	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

	ELKINS SINN	200MG		N015426 002	
		400MG		N015426 001	
	HEATHER	400MG		N016928 003	
		600MG		A084329 001	
	IMPAX LABS	200MG		N014322 002	
		400MG		N014322 001	
	IVAX SUB TEVA PHARMS	200MG		N015438 001	
		400MG		N015438 002	
		600MG		A084181 001	
	LEDERLE	400MG		A086299 001	
	LEE KM	400MG		A089538 001	Nov 25, 1987
	MALLARD	400MG		N015072 002	
	MK LABS	200MG		N014368 004	
		400MG		N014368 002	
	MYLAN	400MG		A083618 001	
	NEXGEN PHARMA INC	200MG		A084220 001	
		400MG		A084589 001	
	PARKE DAVIS	200MG		A084744 001	
		400MG		A084744 002	
	PERRIGO	200MG		A084546 001	
		400MG		A084547 001	
	PHARMAVITE	400MG		A084438 001	
	PUREPAC PHARM	200MG		A084804 001	
		400MG		A084804 002	
	PVT FORM	400MG		N014601 001	
	RISING	400MG		A080655 001	
	ROXANE	600MG		A084332 001	
	SANDOZ	200MG		N014547 002	
		400MG		N014547 001	
	SCHERER LABS	400MG		A083343 001	
	SOLVAY	200MG		A084435 001	
	STANLABS PHARM	200MG		N014474 002	
		400MG		N014474 004	
	SUN PHARM INDUSTRIES	200MG		A080699 001	
		400MG		A080699 002	
	TABLICAPS	400MG		A083494 001	
	TARO	200MG		A200998 001	May 23, 2011
		400MG		A200998 002	May 23, 2011
	USL PHARMA	200MG		A087825 001	Mar 18, 1982
		400MG		A087826 001	Mar 18, 1982
	VALEANT PHARM INTL	200MG		N015139 006	
		400MG		N015139 005	
	VANGARD	400MG		A088011 001	Jul 14, 1982
+	WATSON LABS	200MG		A083304 001	
		200MG		A085720 001	
+		400MG		A083308 001	
		400MG		A085721 001	
		600MG		A084274 001	
		600MG		A085719 001	
	WEST WARD	200MG		N015417 003	
		400MG		N015417 002	
	WHITEWORTH TOWN PLSN	200MG		A083830 001	
		400MG		A083442 001	

MILTOWN

+	MEDPOINTE PHARM HLC	200MG **		N009698 004	
+		400MG **		N009698 002	
		600MG		A083919 001	

NEURAMATE

	HALSEY	200MG		N014359 002	
		400MG		N014359 001	

TRANMEP

	SOLVAY	400MG		A084369 001	
		400MG		N016249 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEQUINOL; TRETINOIN				
SOLUTION;TOPICAL				
SOLAGE				
	ALMIRALL	2%;0.01%	N020922 001	Dec 10, 1999
MEROPENEM				
INJECTABLE;INJECTION				
MEROPENEM				
	DAEWOONG PHARM CO	500MG/VIAL	A204854 001	Dec 18, 2015
		1GM/VIAL	A204854 002	Dec 18, 2015
	HOSPIRA INC	500MG/VIAL	A090940 001	Jun 22, 2010
		1GM/VIAL	A090940 002	Jun 22, 2010
	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011
		1GM/VIAL	A091201 002	Mar 29, 2011
MERREM IV				
+	PFIZER	500MG/VIAL	N050706 003	Jun 21, 1996
+		1GM/VIAL	N050706 001	Jun 21, 1996
MERSALYL SODIUM; THEOPHYLLINE				
INJECTABLE;INJECTION				
MERSALYL-THEOPHYLLINE				
	WATSON LABS	100MG/ML;50MG/ML	A084875 001	
MESALAMINE				
CAPSULE, DELAYED RELEASE;ORAL				
DELZICOL				
+	ABBVIE	400MG	N204412 001	Feb 01, 2013
CAPSULE, EXTENDED RELEASE;ORAL				
MESALAMINE				
	TEVA PHARMS USA	375MG	A209970 001	May 06, 2022
ENEMA;RECTAL				
MESALAMINE				
	G AND W LABS INC	4GM/60ML	A076841 001	Sep 30, 2004
SUPPOSITORY;RECTAL				
CANASA				
	ABBVIE	500MG	N021252 001	Jan 05, 2001
MESALAMINE				
	AMNEAL	1GM	A210509 001	Jan 02, 2020
ROWASA				
+	MEDA PHARMS	500MG **	N019919 001	Dec 18, 1990
TABLET, DELAYED RELEASE;ORAL				
ASACOL				
	APIL	400MG	N019651 001	Jan 31, 1992
ASACOL HD				
+	ABBVIE	800MG **	N021830 001	May 29, 2008
MESALAMINE				
	MYLAN	1.2GM	A203574 001	Nov 20, 2018
MESNA				
INJECTABLE;INTRAVENOUS				
MESNA				
	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012
	RISING	100MG/ML	A203364 001	Jul 18, 2014
	TEVA PHARMS USA	100MG/ML	A075764 001	Apr 27, 2001
MESORIDAZINE BESYLATE				
CONCENTRATE;ORAL				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016997 001	
INJECTABLE;INJECTION				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016775 001	
TABLET;ORAL				
SERENTIL				
	NOVARTIS	EQ 10MG BASE **	N016774 001	
		EQ 25MG BASE **	N016774 002	
		EQ 50MG BASE **	N016774 003	
		EQ 100MG BASE **	N016774 004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20				
NORINYL				
	ACTAVIS LABS UT INC	0.1MG;2MG	N013625 004	
TABLET;ORAL-21				
NORETHIN 1/50M-21				
	HERITAGE PHARMA	0.05MG;1MG	A071539 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070758 001	Jul 01, 1988
NORINYL 1+50 21-DAY				
	ACTAVIS LABS UT INC	0.05MG;1MG	N013625 002	
NORINYL 1+80 21-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016724 001	
ORTHO-NOVUM 1/50 21				
	ORTHO MCNEIL PHARM	0.05MG;1MG	N012728 004	
ORTHO-NOVUM 1/80 21				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 001	
ORTHO-NOVUM 10-21				
	ORTHO MCNEIL PHARM	0.06MG;10MG	N012728 001	
ORTHO-NOVUM 2-21				
	ORTHO MCNEIL PHARM	0.1MG;2MG	N012728 005	
TABLET;ORAL-28				
NORETHIN 1/50M-28				
	HERITAGE PHARMA	0.05MG;1MG	A071540 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070759 001	Jul 01, 1988
NORINYL 1+50 28-DAY				
+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659 001	
NORINYL 1+80 28-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016725 001	
ORTHO-NOVUM 1/50 28				
	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709 001	
ORTHO-NOVUM 1/80 28				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 002	

MESTRANOL; NORETHYNODREL

TABLET;ORAL				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 008	
		0.15MG;9.85MG	N010976 005	
TABLET;ORAL-20				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 004	
ENOVID-E				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 006	
TABLET;ORAL-21				
ENOVID-E 21				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 007	

METAPROTERENOL SULFATE

AEROSOL, METERED;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.65MG/INH	N016402 001	
SOLUTION;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.4%	N018761 002	Oct 10, 1986
		0.6%	N018761 001	Jun 30, 1983
		5%	N017659 001	
METAPROTERENOL SULFATE				
	APOTEX INC	0.4%	A075402 001	Feb 28, 2001
		0.6%	A075403 001	Feb 28, 2001
	ASTRAZENECA	0.4%	A071275 001	Jul 27, 1988
		0.6%	A071018 001	Jul 27, 1988
	DEY	0.33%	A071806 001	Aug 05, 1988
		0.5%	A071805 001	Aug 05, 1988
		5%	A070805 001	Aug 17, 1987
	MYLAN SPECIALITY LP	0.4%	A071786 001	Aug 05, 1988
		0.6%	A070804 001	Aug 17, 1987
	NEPHRON	0.4%	A071855 001	Jul 14, 1988
		0.6%	A071726 001	Jul 14, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METAPROTERENOL SULFATE				
SOLUTION;INHALATION				
METAPROTERENOL SULFATE				
WOCKHARDT	0.4%	A075586	001	May 30, 2002
	0.6%	A075586	002	May 30, 2002
	5%	A072190	001	Jun 07, 1988
PROMETA				
MURO	5%	A073340	001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG/5ML	N017571	001	
METAPROTERENOL SULFATE				
APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
COSETTE	10MG/5ML	A072761	001	Feb 27, 1992
G AND W LABS INC	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
STRIDES PHARMA INTL	10MG	A072024	001	Jun 28, 1988
	20MG	A072025	001	Jun 28, 1988
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991
METARAMINOL BITARTRATE				
INJECTABLE;INJECTION				
ARAMINE				
+ MERCK	EQ 10MG BASE/ML **	N009509	002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	
METAXALONE				
TABLET;ORAL				
METAXALONE				
NOVAST LABS	800MG	A213836	001	Oct 21, 2020
RISING	800MG	A208774	001	Sep 24, 2018
SKELAXIN				
+ KING PHARMS	400MG **	N013217	001	
+	800MG **	N013217	003	Aug 30, 2002
METFORMIN HYDROCHLORIDE				
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
RIOMET ER				
+ SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019
SOLUTION;ORAL				
RIOMET				
+ RANBAXY	500MG/5ML **	N021591	001	Sep 11, 2003
TABLET;ORAL				
GLUCOPHAGE				
+ EMD SERONO INC	500MG **	N020357	001	Mar 03, 1995
+	625MG **	N020357	003	Nov 05, 1998
+	750MG **	N020357	004	Nov 05, 1998
+	850MG **	N020357	002	Mar 03, 1995
+	1GM **	N020357	005	Nov 05, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AARXION ANDA HLDING	500MG	A205330	001	Oct 31, 2017
	850MG	A205330	002	Oct 31, 2017
	1GM	A205330	003	Oct 31, 2017
AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006
	850MG	A077880	002	Jun 05, 2006
	1GM	A077880	003	Jun 05, 2006
APOTEX	500MG	A075984	001	Apr 23, 2002
	500MG	A090666	001	Dec 07, 2011
	850MG	A075984	002	Apr 23, 2002
	850MG	A090666	002	Dec 07, 2011
	1GM	A075984	003	Apr 23, 2002
	1GM	A090666	003	Dec 07, 2011
BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
GLENMARK PHARMS LTD	500MG	A078170	001	May 23, 2008
	850MG	A078170	002	May 23, 2008
	1GM	A078170	003	May 23, 2008
HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002
	850MG	A075978	002	Jan 25, 2002
	1GM	A075978	003	Nov 05, 2002
INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008
	850MG	A079148	002	Nov 25, 2008
	1GM	A079148	003	Nov 25, 2008
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
	1GM	A075975	003	Jan 24, 2002
PHARMOBEDIENT	500MG	A075969	001	Jan 29, 2002
	500MG	A075976	001	Jan 24, 2002
	850MG	A075969	002	Jan 29, 2002
	850MG	A075976	002	Jan 24, 2002
	1GM	A075969	003	Jan 29, 2002
	1GM	A075976	003	Jan 24, 2002
PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006
	850MG	A077853	002	Jul 28, 2006
	1GM	A077853	003	Jul 28, 2006
SANDOZ	500MG	A075985	001	Jan 25, 2002
	850MG	A075985	002	Jan 25, 2002
	1GM	A075985	003	Jan 25, 2002
SUN PHARM INDS INC	500MG	A075967	001	Jan 29, 2002
	850MG	A075967	002	Jan 29, 2002
	1GM	A075967	003	Jan 29, 2002
SUN PHARM INDUSTRIES	500MG	A076038	001	Feb 21, 2002
	850MG	A076038	002	Feb 21, 2002
	1GM	A076038	003	Feb 21, 2002
SUNSHINE	500MG	A208999	001	Oct 12, 2018
	850MG	A208999	002	Oct 12, 2018
	1GM	A208999	003	Oct 12, 2018
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002
TORRENT PHARMS	500MG	A077711	001	Jan 24, 2007
	850MG	A077711	002	Jan 24, 2007
	1GM	A077711	003	Jan 24, 2007
WATSON LABS	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002
	1GM	A075979	003	Jan 24, 2002
WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002
	850MG	A075961	002	Jan 25, 2002
	1GM	A075961	003	Jan 25, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
FORTAMET					
+	ANDRX LABS LLC	500MG **	N021574	001	Apr 27, 2004
+		1GM **	N021574	002	Apr 27, 2004
GLUCOPHAGE XR					
+	EMD SERONO INC	500MG **	N021202	001	Oct 13, 2000
+		750MG **	N021202	004	Apr 11, 2003
GLUMETZA					
+	SANTARUS INC	500MG	N021748	001	Jun 03, 2005
+		1GM	N021748	002	Jun 03, 2005
METFORMIN HYDROCHLORIDE					
	ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
		750MG	A076878	001	Apr 13, 2005
	ACTAVIS LABS FL INC	500MG	A076172	001	Jun 16, 2004
	APOTEX	500MG	A076706	001	Dec 14, 2004
		750MG	A076706	002	Dec 29, 2005
	BARR	500MG	A076496	001	Nov 25, 2005
		750MG	A076863	001	Oct 14, 2004
	IMPAX LABS	500MG	A076249	001	Jul 30, 2004
		750MG	A076985	001	Sep 13, 2005
	IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
	MACLEODS PHARMS LTD	1GM	A211163	001	Mar 13, 2024
	PHARMOBEDIENT	500MG	A076650	001	Sep 13, 2005
		750MG	A077113	001	Sep 08, 2005
	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
		750MG	A077211	001	Jun 29, 2005
	SANDOZ	500MG	A076223	001	Dec 14, 2004
	SUN PHARM	500MG	A202917	001	Aug 01, 2016
		1GM	A202917	002	Aug 01, 2016
	SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006
		750MG	A077336	002	Feb 09, 2006
	SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
	TORRENT	500MG	A090014	001	Dec 30, 2009
	TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
	TWI PHARMS	500MG	A213247	001	Sep 29, 2021
		1GM	A213247	002	Sep 29, 2021
	UTOPIC PHARMS	500MG	A213394	001	Aug 03, 2021
		1GM	A213394	002	Aug 03, 2021
	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL					
ACTOPLUS MET					
+	TAKEDA PHARMS USA	500MG;EQ 15MG BASE **	N021842	001	Aug 29, 2005
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE					
	CHARTWELL RX	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013
		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013
	PHARMOBEDIENT	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011
TABLET, EXTENDED RELEASE;ORAL					
ACTOPLUS MET XR					
+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL					
PRANDIMET					
+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008
REPAGLINIDE AND METFORMIN HYDROCHLORIDE					
	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
		500MG;2MG	A200624	002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL					
AVANDAMET					
+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDAMET				
+		1GM;EQ 4MG BASE **	N021410 005	Aug 25, 2003
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE				
	TEVA	500MG;EQ 2MG BASE	A077337 001	May 07, 2014
		500MG;EQ 1MG BASE	A077337 005	May 19, 2017
		500MG;EQ 4MG BASE	A077337 002	May 07, 2014
		1GM;EQ 4MG BASE	A077337 004	May 07, 2014
		1GM;EQ 2MG BASE	A077337 003	May 07, 2014
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
KOMBIGLYZE XR				
+	ASTRAZENECA AB	500MG;EQ 5MG BASE **	N200678 001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE **	N200678 003	Nov 05, 2010
+		1GM;EQ 5MG BASE **	N200678 002	Nov 05, 2010
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE				
	SUN PHARM	500MG;EQ 5MG BASE	A206081 001	Jul 31, 2023
		1GM;EQ 2.5MG BASE	A206081 002	Jul 31, 2023
		1GM;EQ 5MG BASE	A206081 003	Jul 31, 2023
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE				
TABLET, EXTENDED RELEASE;ORAL				
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE				
	PH HEALTH	500MG;EQ 50MG BASE	A204144 001	Jun 04, 2025
		1GM;EQ 50MG BASE	A204144 002	Jun 04, 2025
		1GM;EQ 100MG BASE	A204144 003	Jun 04, 2025
METHACHOLINE CHLORIDE				
FOR SOLUTION;INHALATION				
PROVOCHOLINE				
+	METHAPHARM	1600MG/VIAL	N019193 002	Aug 29, 2016
METHACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641 001	
		EQ 280MG BASE	A060641 002	
SYRUP;ORAL				
RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641 003	
METHADONE HYDROCHLORIDE				
CONCENTRATE;ORAL				
METHADONE HYDROCHLORIDE				
	LANNETT CO INC	10MG/ML	A212094 001	Mar 03, 2021
POWDER;FOR RX COMPOUNDING				
METHADONE HYDROCHLORIDE				
	MALLINCKRODT INC	50GM/BOT	N006383 002	
		100GM/BOT	N006383 003	
		500GM/BOT	N006383 004	
SOLUTION;ORAL				
METHADONE HYDROCHLORIDE				
	VISTAPHARM LLC	5MG/5ML	A090707 001	Jun 30, 2010
		10MG/5ML	A090707 002	Jun 30, 2010
SYRUP;ORAL				
DOLOPHINE HYDROCHLORIDE				
	HIKMA	10MG/30ML	N006134 004	
TABLET;ORAL				
DOLOPHINE HYDROCHLORIDE				
+	HIKMA	5MG **	N006134 002	
+		10MG **	N006134 010	
METHADONE HYDROCHLORIDE				
	ROXANE	40MG	A074081 001	Apr 28, 1995
	SUN PHARM INDUSTRIES	5MG	A208305 001	Mar 30, 2018
		10MG	A208305 002	Mar 30, 2018
	VISTAPHARM LLC	5MG	A040241 001	May 29, 1998
		10MG	A040241 002	May 29, 1998
METHADOSE				
	SPECGX LLC	5MG	A040050 001	Apr 15, 1993
		10MG	A040050 002	Apr 15, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHADONE HYDROCHLORIDE				
TABLET, DISPERSIBLE;ORAL				
WESTADONE				
SANDOZ	2.5MG	N017108	001	
TABLET, EFFERVESCENT;ORAL				
WESTADONE				
SANDOZ	5MG	N017108	002	
	10MG	N017108	003	
	40MG	N017108	004	
METHAMPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
METHAMPEX				
TEVA	10MG	A083889	001	
METHAMPHETAMINE HYDROCHLORIDE				
ABLE	5MG	A040529	001	Feb 25, 2004
REXAR	5MG	A084931	001	
	10MG	A084931	002	
TEVA	5MG	A086359	001	
TABLET, EXTENDED RELEASE;ORAL				
DESOXYN				
AJENAT PHARMS	5MG	N005378	004	
	10MG	N005378	003	
	15MG	N005378	005	
METHANTHELINE BROMIDE				
TABLET;ORAL				
BANTHINE				
SHIRE	50MG	N007390	001	
METHARBITAL				
TABLET;ORAL				
GEMONIL				
ABBVIE	100MG	N008322	001	
METHAZOLAMIDE				
TABLET;ORAL				
METHAZOLAMIDE				
APPLIED ANAL	25MG	A040011	001	Jul 17, 1997
	50MG	A040011	002	Jul 17, 1997
ATHEM	25MG	A040102	001	Aug 28, 1996
	50MG	A040102	002	Aug 28, 1996
NEPTAZANE				
+ LEDERLE	25MG **	N011721	002	Nov 25, 1991
+	50MG **	N011721	001	
METHDILAZINE				
TABLET, CHEWABLE;ORAL				
TACARYL				
WESTWOOD SQUIBB	3.6MG	N011950	009	
METHDILAZINE HYDROCHLORIDE				
SYRUP;ORAL				
METHDILAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	4MG/5ML	A087122	001	
TACARYL				
WESTWOOD SQUIBB	4MG/5ML	N011950	007	
TABLET;ORAL				
TACARYL				
WESTWOOD SQUIBB	8MG	N011950	006	
METHENAMINE HIPPURATE				
TABLET;ORAL				
METHENAMINE HIPPURATE				
IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003
METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
APOTHECON	EQ 900MG BASE/VIAL	A061449	001	
	EQ 900MG BASE/VIAL	N050117	001	
	EQ 3.6GM BASE/VIAL	A061449	002	
	EQ 3.6GM BASE/VIAL	N050117	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
	EQ 5.4GM BASE/VIAL		A061449 003	
	EQ 5.4GM BASE/VIAL		N050117 003	
METHIMAZOLE				
TABLET;ORAL				
METHIMAZOLE				
AIPING PHARM INC	20MG		A040547 004	Feb 18, 2005
DISCOVERY THERAP	15MG		A040619 003	Jul 12, 2005
MYLAN	20MG		A040350 003	Jun 07, 2001
SUN PHARM INDS INC	5MG		A040870 001	Sep 25, 2007
	10MG		A040870 002	Sep 25, 2007
TAPAZOLE				
+ KING PHARMS	5MG **		N007517 002	
+	10MG **		N007517 004	
KING PHARMS LLC	5MG		A040320 001	Mar 31, 2000
	10MG		A040320 002	Mar 31, 2000
METHIXENE HYDROCHLORIDE				
TABLET;ORAL				
TREST				
NOVARTIS	1MG		N013420 001	
METHOCARBAMOL				
INJECTABLE;INJECTION				
METHOCARBAMOL				
DR REDDYS	100MG/ML		A086459 001	
MARSAM PHARMS LLC	100MG/ML		A089849 001	Dec 27, 1991
SOLUTION;IM-IV				
METHOCARBAMOL				
BAXTER HLTHCARE CORP	1GM/10ML	(100MG/ML)	A215065 001	Jul 14, 2022
NAVINTA LLC	1GM/10ML	(100MG/ML)	A206071 001	Nov 24, 2017
PHARMOBEDIENT	1GM/10ML	(100MG/ML)	A204404 001	Dec 05, 2014
TABLET;ORAL				
DELAXIN				
FERNDALE LABS	500MG		A085454 001	
FORBAXIN				
FOREST LABS	750MG		A085136 001	
METHOCARBAMOL				
ABLE	500MG		A040413 001	Mar 17, 2003
	750MG		A040413 002	Mar 17, 2003
AIPING PHARM INC	500MG		A084616 001	
	750MG		A084615 001	
AM THERAP	500MG		A089417 001	Feb 11, 1987
	750MG		A089418 001	Feb 11, 1987
ANI PHARMS	500MG		A084277 001	
	750MG		A084276 002	
ASCOT	500MG		A087660 001	Oct 27, 1982
	750MG		A087661 001	Oct 27, 1982
CHARTWELL MOLECULAR	500MG		A084756 002	Mar 31, 2003
	750MG		A084756 001	
CLONMEL HLTHCARE	500MG		A085961 001	
	750MG		A085963 001	
HEATHER	500MG		A084675 001	
	750MG		A084924 001	
HIKMA INTL PHARMS	500MG		A085159 001	
	750MG		A085123 001	
IMPAX LABS	500MG		A084927 001	
	750MG		A084928 001	
INWOOD LABS	500MG		A085137 001	
IVAX SUB TEVA PHARMS	500MG		A084648 001	
	750MG		A084649 001	
KV PHARM	500MG		A085660 001	
	750MG		A085658 001	
MYLAN	500MG		A084259 001	
	750MG		A084323 001	
NYLOS	750MG		A085033 001	
PIONEER PHARMS	500MG		A088731 001	Dec 13, 1985
	750MG		A089082 001	Dec 13, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOCARBAMOL				
TABLET;ORAL				
METHOCARBAMOL				
PURACAP PHARM	500MG		A084231 002	
	750MG		A084471 001	
PUREPAC PHARM	500MG		A085718 001	
	750MG		A085718 002	
ROXANE	500MG		A088646 001	Feb 29, 1984
	750MG		A088647 001	Feb 29, 1984
SANDOZ	500MG		A087283 001	
	750MG		A087282 001	
SOLVAY	500MG		A084448 001	
	750MG		A084449 001	
SUN PHARM INDUSTRIES	500MG		A084488 001	
	750MG		A084486 001	
SUPERPHARM	500MG		A087589 001	Jan 22, 1982
	750MG		A087590 001	Jan 22, 1982
TABLICAPS	500MG		A084846 001	
UPSHER SMITH	500MG		A087453 001	
	750MG		A087454 001	
WATSON LABS	500MG		A083605 001	
	500MG		A085180 001	
	750MG		A083605 002	
	750MG		A085192 001	
ROBAXIN				
+ ENDO OPERATIONS	500MG **		N011011 004	
ROBAXIN-750				
+ ENDO OPERATIONS	750MG **		N011011 006	
METHOHEXITAL SODIUM				
INJECTABLE;INJECTION				
BREVITAL SODIUM				
PH HEALTH	200MG/VIAL		N011559 004	Dec 21, 2012
+	2.5GM/VIAL		N011559 002	
	5GM/VIAL		N011559 003	
METHOTREXATE				
SOLUTION;INTRAVENOUS				
METHOTREXATE				
+ ACCORD HLTHCARE	5GM/50ML (100MG/ML)		N214121 001	Aug 24, 2020
SOLUTION;SUBCUTANEOUS				
OTREXUP				
+ ASSERTIO SPECLTY	7.5MG/0.4ML (7.5MG/0.4ML)		N204824 005	Nov 07, 2014
+	10MG/0.4ML (10MG/0.4ML)		N204824 001	Oct 11, 2013
+	12.5MG/0.4ML (12.5MG/0.4ML)		N204824 006	Mar 24, 2016
+	15MG/0.4ML (15MG/0.4ML)		N204824 002	Oct 11, 2013
+	17.5MG/0.4ML (17.5MG/0.4ML)		N204824 007	Mar 24, 2016
+	20MG/0.4ML (20MG/0.4ML)		N204824 003	Oct 11, 2013
+	22.5MG/0.4ML (22.5MG/0.4ML)		N204824 008	Mar 24, 2016
+	25MG/0.4ML (25MG/0.4ML)		N204824 004	Oct 11, 2013
OTREXUP PFS				
+ ASSERTIO SPECLTY	10MG/0.4ML (10MG/0.4ML)		N204824 009	May 31, 2017
+	15MG/0.6ML (15MG/0.6ML)		N204824 010	May 31, 2017
+	17.5MG/0.7ML (17.5MG/0.7ML)		N204824 011	May 31, 2017
+	20MG/0.8ML (20MG/0.8ML)		N204824 012	May 31, 2017
+	22.5MG/0.9ML (22.5MG/0.9ML)		N204824 013	May 31, 2017
+	25MG/ML (25MG/ML)		N204824 014	May 31, 2017
RASUVO				
+ MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)		N205776 009	Jul 10, 2014
REDITREX				
+ NORDIC GRP	7.5MG/0.3ML (7.5MG/0.3ML)		N210737 001	Nov 27, 2019
+	10MG/0.4ML (10MG/0.4ML)		N210737 002	Nov 27, 2019
+	12.5MG/0.5ML (12.5MG/0.5ML)		N210737 003	Nov 27, 2019
+	15MG/0.6ML (15MG/0.6ML)		N210737 004	Nov 27, 2019
+	17.5MG/0.7ML (17.5MG/0.7ML)		N210737 005	Nov 27, 2019
+	20MG/0.8ML (20MG/0.8ML)		N210737 006	Nov 27, 2019
+	22.5MG/ML (22.5MG/ML)		N210737 007	Nov 27, 2019
+	25MG/1ML (25MG/1ML)		N210737 008	Nov 27, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
ABITREXATE					
	ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
		EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
		EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
		EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX					
+	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
		EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
+		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
		EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
		EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF					
+	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982
METHOTREXATE PRESERVATIVE FREE					
	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999
+	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
+		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
METHOTREXATE SODIUM					
	ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
		EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
		EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
		EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
		EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
		EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
	FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999
+	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
+		EQ 20MG BASE/VIAL	N011719	001	
+		EQ 25MG BASE/ML	N011719	005	
+		EQ 50MG BASE/VIAL	N011719	003	
+		EQ 100MG BASE/VIAL	N011719	006	
	NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
	PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE					
	EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012
		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012
		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012
		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012
	EXTROVIS	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012
+	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
MEXATE					
+	BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
+		EQ 50MG BASE/VIAL	A086358	002	
+		EQ 100MG BASE/VIAL	A086358	003	
+		EQ 250MG BASE/VIAL	A086358	004	
MEXATE-AQ					
+	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985
MEXATE-AQ PRESERVED					
	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989
TABLET;ORAL					
METHOTREXATE SODIUM					
	AMNEAL PHARMS	EQ 2.5MG BASE	A210040	001	Dec 22, 2017
	DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999
	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021
+	STRIDES PHARMA INTL	EQ 2.5MG BASE **	N008085	002	
METHOXAMINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
VASOXYL					
	GLAXOSMITHKLINE	10MG/ML	N006772	002	
		20MG/ML	N006772	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOXSALEN

CAPSULE;ORAL				
8-MOP				
+	VALEANT PHARM INTL	10MG	N009048 001	
METHOXSALEN				
	ACTAVIS INC	10MG	A202603 001	Jun 09, 2015
	ANI PHARMS	10MG	A087781 001	Jun 08, 1982
LOTION;TOPICAL				
OXSORALEN				
+	VALEANT PHARM INTL	1%	N009048 002	

METHSCOPOLAMINE BROMIDE

TABLET;ORAL				
METHSCOPOLAMINE BROMIDE				
	CHARTWELL RX	2.5MG	A040624 001	Dec 28, 2006
		5MG	A040624 002	Dec 28, 2006
	PVT FORM	2.5MG	A080970 001	
PAMINE				
	FOUGERA PHARMS	2.5MG **	N008848 001	
PAMINE FORTE				
	FOUGERA PHARMS	5MG **	N008848 002	Mar 25, 2003

METHSUXIMIDE

CAPSULE;ORAL				
CELONTIN				
+	PARKE DAVIS	150MG	N010596 007	

METHYCLOTHIAZIDE

TABLET;ORAL				
AQUATENSEN				
	MEDPOINTE PHARM HLC	5MG	N017364 001	
ENDURON				
+	ABBVIE	2.5MG **	N012524 001	
+		5MG **	N012524 004	
METHYCLOTHIAZIDE				
	CHARTWELL RX	2.5MG	A089835 001	Aug 18, 1988
		5MG	A089837 001	Aug 18, 1988
	IVAX PHARMS	2.5MG	A087913 001	Jun 03, 1982
		5MG	A087786 001	May 18, 1982
	MYLAN	2.5MG	A087671 001	Aug 17, 1982
	PAR PHARM	2.5MG	A089135 001	Feb 12, 1986
		5MG	A089136 001	Feb 12, 1986
	PHARMOBEDIENT	5MG	A087672 001	Aug 17, 1982
	USL PHARMA	5MG	A088745 001	Mar 21, 1985
	WATSON LABS	2.5MG	A085487 001	Mar 11, 1982
		2.5MG	A088750 001	Sep 06, 1984
		5MG	A085476 001	Mar 11, 1982
		5MG	A088724 001	Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET;ORAL				
EUTRON				
	ABBOTT	5MG;25MG	N016047 001	

METHYCLOTHIAZIDE; RESERPINE

TABLET;ORAL				
DIUTENSEN-R				
	MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708 005	

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM;TOPICAL				
METVIXIA				
	GALDERMA LABS LP	EQ 16.8% BASE	N021415 001	Jul 27, 2004

METHYLDOPA

SUSPENSION;ORAL				
ALDOMET				
	MERCK	250MG/5ML	N018389 001	
TABLET;ORAL				
ALDOMET				
+	MERCK	125MG **	N013400 003	
+		250MG **	N013400 001	
+		500MG **	N013400 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLDOPA

TABLET;ORAL

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
	250MG	A070084	001	Oct 15, 1985
	500MG	A070085	001	Oct 15, 1985
CHARTWELL RX	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986
	500MG	A070343	001	Feb 20, 1986
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
STRIDES PHARMA INTL	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
	500MG	A070625	001	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

ALDOMET

+ MERCK	50MG/ML **	N013401	001	

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
AM REGENT	50MG/ML	A071279	001	Oct 02, 1987
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLERGONOVINE MALEATE				
INJECTABLE;INJECTION				
METHERGINE				
+ EDISON THERAPS LLC	0.2MG/ML	N006035 004		
TABLET;ORAL				
METHERGINE				
+ EDISON THERAPS LLC	0.2MG **	N006035 003		
METHYLNALTREXONE BROMIDE				
SOLUTION;SUBCUTANEOUS				
METHYLNALTREXONE BROMIDE				
ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112 001	Aug 26, 2024	
	12MG/0.6ML (12MG/0.6ML)	A208112 002	Aug 26, 2024	
MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592 001	May 28, 2025	
METHYLPHENIDATE				
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL				
COTEMPLA XR-ODT				
+ NEOS THERAPS INC	34.6MG	N205489 004	Aug 19, 2024	
METHYLPHENIDATE				
ACTAVIS ELIZABETH	8.6MG	A210924 001	Jun 19, 2020	
	17.3MG	A210924 002	Jun 19, 2020	
	25.9MG	A210924 003	Jun 19, 2020	
METHYLPHENIDATE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
ADHANSIA XR				
+ PURDUE PHARMA LP	25MG	N212038 001	Feb 27, 2019	
+	35MG	N212038 002	Feb 27, 2019	
+	45MG	N212038 003	Feb 27, 2019	
+	55MG	N212038 004	Feb 27, 2019	
+	70MG	N212038 005	Feb 27, 2019	
+	85MG	N212038 006	Feb 27, 2019	
METHYLPHENIDATE HYDROCHLORIDE				
BARR LABS INC	10MG	A079031 004	Oct 15, 2014	
	20MG	A079031 001	Jul 13, 2012	
	30MG	A079031 002	Jul 13, 2012	
	40MG	A079031 003	Jul 13, 2012	
TEVA PHARMS	40MG	A078873 001	Jul 19, 2012	
	50MG	A078873 002	Jul 19, 2012	
	60MG	A078873 003	Jul 19, 2012	
RITALIN LA				
+ SANDOZ	60MG **	N021284 005	Oct 27, 2014	
SOLUTION;ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
CHARTWELL MOLECULAR	5MG/5ML	A207414 001	Dec 16, 2020	
	10MG/5ML	A207414 002	Dec 16, 2020	
NOVITIUM PHARMA	5MG/5ML	A201466 001	Nov 12, 2013	
	10MG/5ML	A201466 002	Nov 12, 2013	
TABLET;ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
ABLE	5MG	A040404 001	Mar 29, 2001	
	10MG	A040404 002	Mar 29, 2001	
	20MG	A040404 003	Mar 29, 2001	
ACTAVIS ELIZABETH	5MG	A040321 001	Feb 05, 2002	
	10MG	A040321 002	Feb 05, 2002	
	20MG	A040321 003	Feb 05, 2002	
ALVOGEN	5MG	A206840 001	Sep 15, 2016	
	10MG	A206840 002	Sep 15, 2016	
	20MG	A206840 003	Sep 15, 2016	
AUROLIFE PHARMA LLC	5MG	A209276 001	Oct 25, 2018	
	10MG	A209276 002	Oct 25, 2018	
	20MG	A209276 003	Oct 25, 2018	
LANNETT CO INC	5MG	A086429 001		
	10MG	A085799 001		
	20MG	A086428 001		
MOUNTAIN	5MG	A091159 001	Mar 12, 2014	
	10MG	A091159 002	Mar 12, 2014	
	20MG	A091159 003	Mar 12, 2014	
MPP PHARMA	5MG	A207587 001	Mar 03, 2017	
	10MG	A207587 002	Mar 03, 2017	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPHENIDATE HYDROCHLORIDE					
TABLET;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
		20MG	A207587	003	Mar 03, 2017
	WATSON LABS	5MG	A040220	001	Aug 29, 1997
		10MG	A040220	002	Aug 29, 1997
		20MG	A040220	003	Aug 29, 1997
TABLET, CHEWABLE;ORAL					
METHYLIN					
+	SPECGX LLC	2.5MG **	N021475	001	Apr 15, 2003
+		5MG **	N021475	002	Apr 15, 2003
+		10MG **	N021475	003	Apr 15, 2003
METHYLPHENIDATE HYDROCHLORIDE					
	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015
		5MG	A204115	002	Feb 25, 2015
		10MG	A204115	003	Feb 25, 2015
	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017
		5MG	A204954	002	Jan 26, 2017
		10MG	A204954	003	Jan 26, 2017
TABLET, EXTENDED RELEASE;ORAL					
METADATE ER					
	LANNETT CO INC	10MG	A040306	001	Oct 20, 1999
		20MG	A089601	001	Jun 01, 1988
METHYLPHENIDATE HYDROCHLORIDE					
	ABLE	20MG	A076032	001	May 09, 2001
	ALVOGEN	10MG	A204772	001	Feb 29, 2016
		18MG	A210818	001	Nov 30, 2018
		20MG	A204772	002	Feb 29, 2016
		27MG	A210818	002	Nov 30, 2018
		36MG	A210818	003	Nov 30, 2018
		54MG	A210818	004	Nov 30, 2018
	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018
		27MG	A207515	002	Feb 01, 2018
		36MG	A207515	003	Feb 01, 2018
		54MG	A207515	004	Feb 01, 2018
	ANI PHARMS	18MG	A208607	001	Jul 14, 2017
		27MG	A208607	002	Jul 14, 2017
		36MG	A208607	003	Jul 14, 2017
		54MG	A208607	004	Jul 14, 2017
	HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001
	RHODES PHARMS	18MG	A214111	001	May 31, 2022
		27MG	A214111	002	May 31, 2022
		36MG	A214111	003	May 31, 2022
		54MG	A214111	004	May 31, 2022
	STRIDES PHARMA INTL	36MG	A204659	001	Jul 15, 2019
		54MG	A204659	002	Jul 15, 2019
	WATSON LABS	20MG	A040410	001	Feb 09, 2001
RITALIN-SR					
+	NOVARTIS	20MG **	N018029	001	Mar 30, 1982
METHYLPREDNISOLONE					
TABLET;ORAL					
MEDROL					
	PFIZER	24MG	N011153	005	
METHYLPREDNISOLONE					
	AMNEAL	4MG	A207481	001	Sep 21, 2021
		8MG	A207481	002	Sep 21, 2021
		16MG	A207481	003	Sep 21, 2021
		32MG	A207481	004	Sep 21, 2021
	CHARTWELL RX	2MG	A209097	001	Feb 22, 2019
		4MG	A209097	002	Feb 22, 2019
		8MG	A209097	003	Feb 22, 2019
		16MG	A209097	004	Feb 22, 2019
		32MG	A209097	005	Feb 22, 2019
	DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984
	HEATHER	4MG	A085650	001	
	NOVAST LABS	4MG	A210985	001	Jan 09, 2019
	PAR PHARM	16MG	A089207	001	Apr 25, 1988
		24MG	A089208	001	Apr 25, 1988
		32MG	A089209	001	Apr 25, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPREDNISOLONE				
TABLET;ORAL				
METHYLPREDNISOLONE				
PRAXGEN	4MG	A212262	001	Jun 27, 2019
RISING	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982
METHYLPREDNISOLONE ACETATE				
ENEMA;RECTAL				
MEDROL				
PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
INJECTABLE;INJECTION				
M-PREDROL				
BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	
METHYLPREDNISOLONE ACETATE				
EPIC PHARMA LLC	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
SAGENT PHARMS INC	20MG/ML	A201835	001	Jun 27, 2018
TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006
	80MG/ML	A040620	002	Oct 27, 2006
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	
OINTMENT;TOPICAL				
MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
NEO-MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	
METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-METHAPRED				
ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005
	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	
	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008
	EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008
METHYLPREDNISOLONE				
ELKINS SINN	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE				
ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
METHYLPREDNISOLONE SODIUM SUCCINATE				
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015
	EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015
	EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015
	EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984
METHYLPREDNISOLONE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEO-MEDROL				
PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	
METHYLTESTOSTERONE				
CAPSULE;ORAL				
METHYLTESTOSTERONE				
HEATHER	10MG	A084967	001	
TESTRED				
+ BAUSCH	10MG	A083976	001	
VIRILON				
CHARTWELL	10MG	A087750	001	Nov 24, 1982
TABLET;BUCCAL				
ANDROID 5				
VALEANT PHARM INTL	5MG	A087222	001	
ORETON				
SCHERING	10MG	A080281	001	
TABLET;BUCCAL, SUBLINGUAL				
METANDREN				
NOVARTIS	5MG	N003240	004	
	10MG	N003240	001	
	10MG	N003240	005	
	25MG	N003240	003	
METHYLTESTOSTERONE				
IMPAX LABS	10MG	A084287	001	
LILLY	10MG	A080256	001	
	25MG	A080256	002	
PUREPAC PHARM	10MG	A080308	001	
	10MG	A080475	001	
	10MG	A080475	002	
	25MG	A080475	003	
PVT FORM	5MG	A083836	001	
TABLICAPS	10MG	A085125	001	
USL PHARMA	10MG	A080271	001	
TABLET;ORAL				
ANDROID 10				
VALEANT PHARMS NORTH	10MG	A086450	001	
ANDROID 25				
BAUSCH	25MG	A087147	001	
METHYLTESTOSTERONE				
IMPAX LABS	25MG	A084310	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLTESTOSTERONE				
TABLET;ORAL				
METHYLTESTOSTERONE				
INWOOD LABS	10MG		A080839 001	
	25MG		A080973 001	
KV PHARM	10MG		A084312 001	
LANNETT	10MG		A087092 001	Nov 05, 1982
	25MG		A087111 001	Jan 27, 1983
PARKE DAVIS	10MG		A084244 001	
	25MG		A084241 001	
PUREPAC PHARM	10MG		A080309 001	
	25MG		A080310 001	
PVT FORM	5MG		A080214 001	
	10MG		A080214 002	
	25MG		A080214 003	
TABLICAPS	10MG		A080313 001	
	25MG		A085270 001	
WATSON LABS	10MG		A080933 001	
	25MG		A080931 001	
WEST WARD	10MG		A084331 001	
	25MG		A084331 002	
	25MG		A084642 001	
ORETON METHYL				
SCHERING	10MG		N003158 001	
	25MG		N003158 002	
METHYPRYLON				
CAPSULE;ORAL				
NOLUDAR				
ROCHE	300MG		N009660 008	
ELIXIR;ORAL				
NOLUDAR				
ROCHE	50MG/5ML		N009660 007	
TABLET;ORAL				
NOLUDAR				
ROCHE	50MG		N009660 002	
	200MG		N009660 004	
METHYSERGIDE MALEATE				
TABLET;ORAL				
SANSERT				
NOVARTIS	2MG		N012516 001	
METIPRANOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
METIPRANOLOL				
SANDOZ	0.3%		A075720 001	Aug 06, 2001
OPTIPRANOLOL				
+ BAUSCH AND LOMB	0.3% **		N019907 001	Dec 29, 1989
METOCLOPRAMIDE HYDROCHLORIDE				
CONCENTRATE;ORAL				
METOCLOPRAMIDE INTENSOL				
ROXANE	EQ 10MG BASE/ML		A072995 001	Jan 30, 1992
INJECTABLE;INJECTION				
METOCLOPRAMIDE HYDROCHLORIDE				
BEDFORD	EQ 5MG BASE/ML		A072155 001	Mar 30, 1992
	EQ 5MG BASE/ML		A072244 001	Mar 30, 1992
	EQ 5MG BASE/ML		A072247 001	May 18, 1992
FRESENIUS KABI USA	EQ 5MG BASE/ML		A091392 001	Apr 19, 2013
HOSPIRA	EQ 5MG BASE/ML		A070505 001	Jun 23, 1989
	EQ 5MG BASE/ML		A070506 001	Jun 22, 1989
	EQ 5MG BASE/ML		A070847 001	Nov 07, 1988
	EQ 5MG BASE/ML		A071291 001	Mar 03, 1989
	EQ 5MG BASE/ML		A071990 001	Jan 18, 1989
	EQ 5MG BASE/ML		A073117 001	Jan 17, 1991
	EQ 5MG BASE/ML		A074147 001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML		A070293 001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML		A070892 001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML		A070623 001	Mar 02, 1987
	EQ 10MG BASE/2ML		A070622 001	Mar 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOCLOPRAMIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
REGLAN				
+ HIKMA	EQ 5MG BASE/ML **	N017862	001	
	EQ 10MG BASE/ML **	N017862	004	May 28, 1987
SOLUTION;ORAL				
METOCLOPRAMIDE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
CHARTWELL MOLECULAR	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993
VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001
REGLAN				
+ ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
TABLET;ORAL				
CLOPRA				
QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"				
QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON				
KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE				
CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A074478	002	Oct 05, 1995
CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
IMPAX LABS INC	EQ 5MG BASE	A071250	002	Dec 28, 1995
	EQ 10MG BASE	A071250	001	Feb 03, 1988
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
	EQ 10MG BASE	A078374	002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 10MG BASE	A070850	001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
	EQ 10MG BASE	A071536	001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987
TABLET, ORALLY DISINTEGRATING;ORAL				
METOZOLV ODT				
+ SALIX PHARMS	EQ 5MG BASE **	N022246	001	Sep 04, 2009
+	EQ 10MG BASE **	N022246	002	Sep 04, 2009
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005
METOCURINE IODIDE				
INJECTABLE;INJECTION				
METUBINE IODIDE				
LILLY	2MG/ML	N006632	003	
METOLAZONE				
TABLET;ORAL				
DIULO				
GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ANI PHARMS	2.5MG	A075543	001	Jan 06, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOLAZONE					
TABLET;ORAL					
METOLAZONE					
		5MG	A075543	002	Mar 01, 2004
		10MG	A075543	003	Dec 24, 2003
	ROXANE	10MG	A076482	002	Apr 29, 2004
	WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX					
	CHARTWELL MOLECULAR	0.5MG	N019532	001	Oct 30, 1987
ZAROXOLYN					
+	I3 PHARMS	2.5MG **	N017386	001	
+		5MG **	N017386	002	
+		10MG **	N017386	003	
METOPROLOL FUMARATE					
TABLET, EXTENDED RELEASE;ORAL					
LOPRESSOR					
	NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
		EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
		EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
		EQ 400MG TARTRATE	N019786	004	Dec 27, 1989
METOPROLOL SUCCINATE					
TABLET, EXTENDED RELEASE;ORAL					
METOPROLOL SUCCINATE					
	ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637	001	Oct 18, 2022
		EQ 50MG TARTRATE	A215637	002	Oct 18, 2022
		EQ 100MG TARTRATE	A215637	003	Oct 18, 2022
		EQ 200MG TARTRATE	A215637	004	Oct 18, 2022
	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009
		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010
		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010
	GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023
		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023
		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023
		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023
	LUPIN	EQ 25MG TARTRATE	A209272	001	Aug 15, 2023
		EQ 50MG TARTRATE	A209272	002	Aug 15, 2023
		EQ 100MG TARTRATE	A209272	003	Aug 15, 2023
		EQ 200MG TARTRATE	A209272	004	Aug 15, 2023
	NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
		EQ 50MG TARTRATE	A077176	001	May 14, 2008
		EQ 100MG TARTRATE	A076640	002	May 18, 2007
		EQ 200MG TARTRATE	A076640	001	May 18, 2007
	PRINSTON INC	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022
		EQ 200MG TARTRATE	A210597	002	Jan 04, 2022
	SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
		EQ 50MG TARTRATE	A076969	002	May 18, 2007
		EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
		EQ 200MG TARTRATE	A076969	004	Mar 20, 2008
METOPROLOL TARTRATE					
INJECTABLE;INJECTION					
LOPRESSOR					
+	NOVARTIS	1MG/ML **	N018704	001	Mar 30, 1984
METOPROLOL TARTRATE					
	AM REGENT	1MG/ML	A090386	001	Sep 30, 2009
	HOSPIRA	1MG/ML	A074133	001	Dec 21, 1993
		1MG/ML	A075160	001	Jul 06, 1998
	LUITPOLD	1MG/ML	A091307	001	Dec 29, 2010
	ONESOURCE SPECIALTY	1MG/ML	A090317	001	Apr 19, 2010
	WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
TABLET;ORAL					
METOPROLOL TARTRATE					
	APOTHECON	50MG	A074258	001	Jan 27, 1994
		100MG	A074258	002	Jan 27, 1994
	CHARTWELL RX	50MG	A073288	001	Mar 25, 1994
		100MG	A073289	001	Mar 25, 1994
	HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995
		100MG	A074141	002	Jan 31, 1995
	PHARMOBEDIENT	50MG	A073666	001	Dec 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOPROLOL TARTRATE				
TABLET;ORAL				
METOPROLOL TARTRATE				
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004
SUN PHARM INDUSTRIES	25MG	A073654	002	Jul 15, 2009
	50MG	A073654	003	Dec 21, 1993
	100MG	A073654	001	Dec 21, 1993
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994
WATSON LABS	50MG	A074217	001	May 27, 1994
	100MG	A074217	002	May 27, 1994
ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023
	50MG	A212402	002	Apr 19, 2023
	100MG	A212402	003	Apr 19, 2023
METRIZAMIDE				
INJECTABLE;INJECTION				
AMIPAQUE				
GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983
METRONIDAZOLE				
CAPSULE;ORAL				
METRONIDAZOLE				
ABLE	375MG	A076505	001	Nov 13, 2003
GEL;TOPICAL				
METROGEL				
+ GALDERMA LABS LP	0.75% **	N019737	001	Nov 22, 1988
METRONIDAZOLE				
CHARTWELL RX	1%	A090903	001	Jul 22, 2011
GEL;VAGINAL				
METROGEL-VAGINAL				
+ BAUSCH	0.75%	N020208	001	Aug 17, 1992
METRONIDAZOLE				
ENCUBE	0.75%	A077264	001	Oct 31, 2006
	1.3%	A216795	001	Mar 18, 2024
INJECTABLE;INJECTION				
FLAGYL I.V. RTU IN PLASTIC CONTAINER				
PFIZER	500MG/100ML	N018353	002	
METRO I.V.				
B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
METRONIDAZOLE				
ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
HIKMA	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
METRONIDAZOLE IN PLASTIC CONTAINER				
BAXTER HLTHCARE CORP	500MG/100ML	A078084	001	Mar 31, 2008
RISING	500MG/100ML	A205531	001	May 09, 2017
TABLET;ORAL				
FLAGYL				
+ PFIZER	250MG **	N012623	001	
+	500MG **	N012623	003	
METROMIDOL				
LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996
METRONIDAZOLE				
ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METRONIDAZOLE				
TABLET;ORAL				
METRONIDAZOLE				
FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016
	500MG	A207309	002	May 16, 2016
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
LUPIN LTD	250MG	A209096	001	Sep 12, 2017
	500MG	A209096	002	Sep 12, 2017
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985
	500MG	A070039	001	Jan 29, 1985
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982
PROTOSTAT				
ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983
SATRIC				
SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987
TABLET, EXTENDED RELEASE;ORAL				
FLAGYL ER				
+ PFIZER	750MG	N020868	001	Nov 26, 1997
METRONIDAZOLE				
ABLE	750MG	A076462	001	Jun 25, 2003
ALEMBIC	750MG	A090222	001	May 05, 2010
METRONIDAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
FLAGYL I.V.				
PFIZER	EQ 500MG BASE/VIAL **	N018353	001	
METRONIDAZOLE HYDROCHLORIDE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985
METYRAPONE				
TABLET;ORAL				
METOPIRONE				
ESTEVE	250MG	N012911	001	
MEXILETINE HYDROCHLORIDE				
CAPSULE;ORAL				
MEXILETINE HYDROCHLORIDE				
WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998
MEXITIL				
+ BOEHRINGER INGELHEIM	150MG **	N018873	002	Dec 30, 1985
+	200MG **	N018873	003	Dec 30, 1985
+	250MG **	N018873	004	Dec 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE;INJECTION				
MEZLIN				
	BAYER PHARMS	EQ 1GM BASE/VIAL	A062333 001	
		EQ 1GM BASE/VIAL	A062372 005	Jan 13, 1983
		EQ 1GM BASE/VIAL	N050549 001	
		EQ 2GM BASE/VIAL	A062333 002	
		EQ 2GM BASE/VIAL	A062372 001	May 13, 1982
		EQ 2GM BASE/VIAL	N050549 002	
		EQ 3GM BASE/VIAL	A062333 003	
		EQ 3GM BASE/VIAL	A062372 002	May 13, 1982
		EQ 3GM BASE/VIAL	A062697 001	Jan 22, 1987
		EQ 3GM BASE/VIAL	N050549 003	
		EQ 4GM BASE/VIAL	A062333 004	
		EQ 4GM BASE/VIAL	A062372 003	May 13, 1982
		EQ 4GM BASE/VIAL	A062697 002	Jan 22, 1987
		EQ 4GM BASE/VIAL	N050549 004	
		EQ 20GM BASE/VIAL	A062372 004	Mar 02, 1988
		EQ 20GM BASE/VIAL	N050549 005	Mar 02, 1988

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS				
MICAFUNGIN SODIUM				
	APOTEX	EQ 50MG BASE/VIAL	A208366 001	Nov 05, 2020
		EQ 100MG BASE/VIAL	A208366 002	Nov 05, 2020
MYCAMINE				
+	ASTELLAS	EQ 50MG BASE/VIAL	N021506 002	Mar 16, 2005
+		EQ 100MG BASE/VIAL	N021506 003	Jun 27, 2006
POWDER;INTRAVENOUS				
MICAFUNGIN				
+	TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125 001	Jul 30, 2021
+		EQ 100MG BASE/VIAL	N212125 002	Jul 30, 2021

MICONAZOLE

INJECTABLE;INJECTION				
MONISTAT				
	JANSSEN PHARMA	10MG/ML	N018040 001	

MICONAZOLE NITRATE

CREAM;TOPICAL				
MONISTAT-DERM				
	INSIGHT PHARMS	2%	N017494 001	
CREAM;VAGINAL				
MICONAZOLE NITRATE				
	COSETTE	2%	A074366 001	Feb 22, 1996
	TEVA	2%	A074136 001	Jan 04, 1995
	TEVA PHARMS	2%	A074030 001	Oct 30, 1992
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 7 DUAL PACK				
	ACTAVIS MID ATLANTIC	2%,100MG	A074586 001	Jul 17, 1997
MICONAZOLE 7 COMBINATION PACK				
	COSETTE	2%,100MG	A076585 001	Mar 26, 2004
LOTION;TOPICAL				
MONISTAT-DERM				
	INSIGHT PHARMS	2%	N017739 001	
SUPPOSITORY;VAGINAL				
MICONAZOLE NITRATE				
	COSETTE	100MG	A074414 001	Apr 30, 1997
	PERRIGO	100MG	A074395 001	Mar 20, 1997
TAMPON;VAGINAL				
MONISTAT 5				
	PERSONAL PRODS	100MG	N018592 001	Oct 27, 1989

MIDAZOLAM

SOLUTION;INTRAVENOUS				
MIDAZOLAM IN 0.8% SODIUM CHLORIDE				
+	EXELA PHARMA	50MG/50ML (1MG/ML) **	N215868 001	Jul 20, 2022
+		100MG/100ML (1MG/ML)	N215868 002	Jul 20, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIDAZOLAM HYDROCHLORIDE				
INJECTABLE;INJECTION				
MIDAZOLAM HYDROCHLORIDE				
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
EPIC PHARMA LLC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075856	002	Jun 13, 2002
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
PH HEALTH	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SOLUTION;INTRAMUSCULAR				
SEIZALAM				
+ MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018
SYRUP;ORAL				
MIDAZOLAM HYDROCHLORIDE				
PAI HOLDINGS	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003
PHARM ASSOC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998
MIDODRINE HYDROCHLORIDE				
TABLET;ORAL				
MIDODRINE HYDROCHLORIDE				
CHARTWELL RX	2.5MG	A076514	001	Sep 11, 2003
	5MG	A076514	002	Sep 11, 2003
	10MG	A076514	003	Jul 02, 2004
PROAMATINE				
+ TAKEDA PHARMS USA	2.5MG **	N019815	001	Sep 06, 1996
+	5MG **	N019815	002	Sep 06, 1996
+	10MG **	N019815	003	Mar 20, 2002
MIDOSTAURIN				
CAPSULE;ORAL				
MIDOSTAURIN				
TEVA PHARMS	25MG	A216076	001	Apr 29, 2024
MIGLITOL				
TABLET;ORAL				
GLYSET				
+ PFIZER	25MG	N020682	001	Dec 18, 1996
+	50MG	N020682	002	Dec 18, 1996
+	100MG	N020682	003	Dec 18, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIGLUSTAT

CAPSULE;ORAL				
MIGLUSTAT				
CHARTWELL RX	100MG		A209325 001	Feb 03, 2022

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL				
MILNACIPRAN HYDROCHLORIDE				
AMNEAL PHARMS	12.5MG		A205081 001	Apr 22, 2016
	25MG		A205081 002	Apr 22, 2016
	50MG		A205081 003	Apr 22, 2016
	100MG		A205081 004	Apr 22, 2016
BRECKENRIDGE	12.5MG		A205071 001	Jan 27, 2016
	25MG		A205071 002	Jan 27, 2016
	50MG		A205071 003	Jan 27, 2016
	100MG		A205071 004	Jan 27, 2016
HETERO LABS LTD V	12.5MG		A205147 001	Oct 03, 2024
	25MG		A205147 002	Oct 03, 2024
	50MG		A205147 003	Oct 03, 2024
	100MG		A205147 004	Oct 03, 2024

MILRINONE LACTATE

INJECTABLE;INJECTION				
MILRINONE LACTATE				
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML		A076427 001	Sep 21, 2004
GLAND PHARMA LTD	EQ 1MG BASE/ML		A077190 001	Oct 31, 2006
HIKMA	EQ 1MG BASE/ML		A075852 001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML		A075830 001	May 28, 2002
	EQ 1MG BASE/ML		A075884 001	May 28, 2002
INTL MEDICATED	EQ 1MG BASE/ML		A076013 001	Aug 02, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML		A076428 001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5%				
WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)		A077151 002	Jul 20, 2005
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A076414 001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A076259 001	Aug 08, 2002
HIKMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A075510 001	May 28, 2002
HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A075885 001	May 28, 2002
	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)		A075885 002	May 28, 2002
WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A077151 001	Jul 20, 2005
PRIMACOR				
+ SANOFI AVENTIS US	EQ 1MG BASE/ML **		N019436 001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ SANOFI AVENTIS US	EQ 10MG BASE/100ML **		N020343 001	Aug 09, 1994
+	EQ 15MG BASE/100ML **		N020343 002	Aug 09, 1994
+	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **		N020343 003	Aug 09, 1994
+	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **		N020343 004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
DYNACIN				
ALVOGEN	EQ 50MG BASE		A063067 003	Aug 14, 1990
	EQ 75MG BASE		A063067 002	Sep 15, 1999
	EQ 100MG BASE		A063067 001	Jul 31, 1990
MINOCIN				
+ BAUSCH	EQ 75MG BASE **		N050649 003	Feb 12, 2001
TRIAX PHARMS	EQ 50MG BASE		N050315 002	
	EQ 100MG BASE		N050315 001	
MINOCYCLINE HYDROCHLORIDE				
SUN PHARM INDS INC	EQ 50MG BASE		A090867 001	May 13, 2013
	EQ 75MG BASE		A090867 002	May 13, 2013
	EQ 100MG BASE		A090867 003	May 13, 2013
CAPSULE, EXTENDED RELEASE;ORAL				
XIMINO				
JOURNEY	EQ 45MG BASE		N201922 001	Jul 11, 2012
	EQ 67.5MG BASE		N201922 002	Jul 11, 2012
	EQ 90MG BASE		N201922 003	Jul 11, 2012
	EQ 112.5MG BASE		N201922 004	Jul 11, 2012
	EQ 135MG BASE		N201922 005	Jul 11, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION				
MINOCIN				
	LEDERLE	EQ 100MG BASE/VIAL	A062139 001	
SUSPENSION;ORAL				
MINOCIN				
	BAUSCH	EQ 50MG BASE/5ML	N050445 001	
TABLET;ORAL				
MINOCYCLINE HYDROCHLORIDE				
	SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217 001	Jan 29, 2016
		EQ 75MG BASE	A090217 002	Jan 29, 2016
		EQ 100MG BASE	A090217 003	Jan 29, 2016
+	TRIAX PHARMS	EQ 50MG BASE **	N050451 003	Aug 10, 1982
+		EQ 100MG BASE **	N050451 002	Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL				
MINOCYCLINE HYDROCHLORIDE				
	BARR LABS INC	EQ 45MG BASE	A065485 001	Mar 17, 2009
		EQ 65MG BASE	A065485 004	May 18, 2012
		EQ 80MG BASE	A065485 007	Apr 26, 2017
		EQ 90MG BASE	A065485 002	Mar 17, 2009
		EQ 105MG BASE	A065485 008	Apr 26, 2017
		EQ 115MG BASE	A065485 005	May 18, 2012
		EQ 135MG BASE	A065485 003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024 001	Feb 03, 2009
		EQ 90MG BASE	A090024 002	Feb 03, 2009
		EQ 135MG BASE	A090024 003	Feb 03, 2009
	PHARMOBEDIENT	EQ 45MG BASE	A090911 001	Jul 20, 2010
		EQ 90MG BASE	A090911 002	Jul 20, 2010
		EQ 135MG BASE	A090911 003	Jul 20, 2010
	RISING	EQ 55MG BASE	A203443 001	Aug 21, 2019
		EQ 65MG BASE	A201467 001	Jul 30, 2019
		EQ 80MG BASE	A203443 002	Aug 22, 2014
		EQ 105MG BASE	A203443 003	Aug 22, 2014
		EQ 115MG BASE	A201467 002	Jul 30, 2019
	SUN PHARM	EQ 45MG BASE	A204394 001	Dec 30, 2015
		EQ 55MG BASE	A204394 002	Oct 07, 2022
		EQ 65MG BASE	A204394 003	Oct 07, 2022
		EQ 80MG BASE	A204394 004	Dec 30, 2015
		EQ 105MG BASE	A204394 005	Dec 30, 2015
		EQ 115MG BASE	A204394 006	Oct 07, 2022
		EQ 135MG BASE	A204394 007	Dec 30, 2015
	SUN PHARM INDS LTD	EQ 45MG BASE	A091118 001	Sep 25, 2014
		EQ 65MG BASE	A091118 003	Dec 03, 2019
		EQ 80MG BASE	A091118 004	Sep 25, 2014
		EQ 90MG BASE	A091118 005	Sep 25, 2014
		EQ 105MG BASE	A091118 006	Sep 25, 2014
		EQ 115MG BASE	A091118 007	Dec 03, 2019
		EQ 135MG BASE	A091118 008	Sep 25, 2014
	ZYDUS PHARMS	EQ 45MG BASE	A203553 001	Nov 16, 2017
		EQ 55MG BASE	A203553 002	Jun 16, 2023
		EQ 65MG BASE	A203553 003	Jun 16, 2023
		EQ 80MG BASE	A203553 004	Nov 16, 2017
		EQ 90MG BASE	A203553 005	Nov 16, 2017
		EQ 105MG BASE	A203553 006	Nov 16, 2017
		EQ 115MG BASE	A203553 007	Jun 16, 2023
		EQ 135MG BASE	A203553 008	Nov 16, 2017
MINOLIRA				
	EPI HLTH	EQ 105MG BASE	N209269 001	May 08, 2017
		EQ 135MG BASE	N209269 002	May 08, 2017
SOLODYN				
+	BAUSCH	EQ 45MG BASE **	N050808 001	May 08, 2006
+		EQ 55MG BASE **	N050808 008	Aug 27, 2010
+		EQ 65MG BASE **	N050808 004	Jul 23, 2009
+		EQ 80MG BASE **	N050808 007	Aug 27, 2010
+		EQ 90MG BASE **	N050808 002	May 08, 2006
+		EQ 105MG BASE **	N050808 006	Aug 27, 2010
+		EQ 115MG BASE **	N050808 005	Jul 23, 2009
+		EQ 135MG BASE **	N050808 003	May 08, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924	001	Apr 29, 1998
AUROBINDO PHARMA LTD	2%	A074767	001	Feb 28, 1997
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPLEY PHARM	2%	A074500	001	May 23, 1996
HIKMA	2%	A074731	001	Dec 24, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

APOTEX INC	2%	A074924	002	Apr 29, 1998
AUROBINDO PHARMA LTD	2%	A074767	002	Nov 25, 1997
HIKMA	2%	A074731	002	May 11, 2005
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001
AVACOR PRODS	5%	A075619	001	Nov 17, 2000
PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002

TABLET;ORAL

LONITEN

+ PFIZER	2.5MG **	N018154	001	
+	10MG **	N018154	003	

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+ KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

APOTEX	25MG	A209434	001	Jan 02, 2025
	50MG	A209434	002	Jan 02, 2025
SAWAI USA	25MG	A209446	001	Dec 27, 2019
	50MG	A217061	001	May 06, 2025

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
PHARMOBEDIENT	15MG	A076176	001	Jun 19, 2003
	30MG	A076176	002	Jun 19, 2003
	45MG	A076176	003	Jun 19, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003
WATSON LABS	15MG	A076312	001	Jun 19, 2003
	30MG	A076312	002	Jun 19, 2003
	45MG	A076312	003	Jun 19, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIRTAZAPINE					
TABLET;ORAL					
REMERON					
+	ORGANON	45MG **	N020415	003	Mar 17, 1997
TABLET, ORALLY DISINTEGRATING;ORAL					
MIRTAZAPINE					
	ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
		15MG	A077959	001	Feb 14, 2011
		30MG	A076689	002	Aug 31, 2005
		30MG	A077959	002	Feb 14, 2011
		45MG	A076689	003	Aug 31, 2005
		45MG	A077959	003	Feb 14, 2011
	ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
		30MG	A076307	002	Dec 17, 2003
		45MG	A076307	003	Feb 28, 2006
	IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005
		30MG	A076901	002	Jun 28, 2005
		45MG	A076901	003	Jun 28, 2005
MISOPROSTOL					
TABLET;ORAL					
MISOPROSTOL					
	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012
		0.2MG	A091667	002	Jul 25, 2012
MITOMYCIN					
INJECTABLE;INJECTION					
MITOMYCIN					
	EUGIA PHARMA	5MG/VIAL	A216732	001	Oct 30, 2023
		20MG/VIAL	A216732	002	Oct 30, 2023
		40MG/VIAL	A216732	003	Oct 30, 2023
	HIKMA	5MG/VIAL	A064117	001	Apr 19, 1995
	HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995
MITOZYTREX					
+	SUPERGEN	5MG/VIAL **	N050763	001	Nov 14, 2002
MUTAMYCIN					
+	BRISTOL	5MG/VIAL **	N050450	001	
+		20MG/VIAL **	N050450	002	
	BRISTOL MYERS	5MG/VIAL	A062336	001	
		20MG/VIAL	A062336	002	
		40MG/VIAL **	A062336	003	Mar 10, 1988
MITOXANTRONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
MITOXANTRONE HYDROCHLORIDE					
	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
	RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009
		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012
		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009
NOVANTRONE					
+	EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **	N019297	001	Dec 23, 1987
+		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297	002	Dec 23, 1987
+		EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297	003	Dec 23, 1987
MIVACURIUM CHLORIDE					
INJECTABLE;INJECTION					
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER					
	ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
		EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE					
	RISING	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009
SOLUTION;INTRAVENOUS					
MIVACRON					
+	ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098	001	Jan 22, 1992
+		EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992
MIVACURIUM CHLORIDE					
	WOODWARD	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	A209708	001	Oct 12, 2021
		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A209708	002	Oct 12, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MOBOCERTINIB SUCCINATE				
CAPSULE;ORAL				
EXKIVITY				
+ TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021
MODAFINIL				
TABLET;ORAL				
MODAFINIL				
HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012
	200MG	A090543	002	Sep 26, 2012
NATCO PHARMA	100MG	A076594	001	Jul 16, 2012
	200MG	A076594	002	Jul 16, 2012
WATSON LABS INC	100MG	A076715	001	Nov 01, 2012
	200MG	A076715	002	Nov 01, 2012
MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
MOEXIPRIL HYDROCHLORIDE				
APOTEX INC	7.5MG	A078454	001	Jun 02, 2008
	15MG	A078454	002	Jun 02, 2008
UNIVASC				
UCB INC	7.5MG **	N020312	001	Apr 19, 1995
	15MG **	N020312	002	Apr 19, 1995
MOLINDONE HYDROCHLORIDE				
CAPSULE;ORAL				
MOBAN				
+ CHARTWELL RX	5MG **	N017111	001	
+	10MG **	N017111	002	
+	25MG **	N017111	003	
CONCENTRATE;ORAL				
MOBAN				
ENDO PHARMS	20MG/ML	N017938	001	
TABLET;ORAL				
MOBAN				
+ CHARTWELL RX	5MG **	N017111	004	
+	10MG **	N017111	005	
+	25MG **	N017111	006	
+	50MG **	N017111	007	
+	100MG **	N017111	008	
MOMETASONE FUROATE				
CREAM;TOPICAL				
ELOCON				
ORGANON	0.1% **	N019625	001	May 06, 1987
+	0.1% **	N019625	002	Apr 19, 2013
MOMETASONE FUROATE				
CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007
FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005
GLENMARK PHARMS INC	0.1%	A078541	001	May 28, 2008
LOTION;TOPICAL				
ELOCON				
+ ORGANON	0.1% **	N019796	001	Mar 30, 1989
MOMETASONE FUROATE				
COSETTE	0.1%	A077678	001	Nov 21, 2007
GLENMARK PHARMS LTD	0.1%	A090506	001	Aug 09, 2010
SUN PHARMA CANADA	0.1%	A076788	001	Mar 15, 2006
OINTMENT;TOPICAL				
ELOCON				
+ ORGANON	0.1%	N019543	001	Apr 30, 1987
MOMETASONE FUROATE				
ENCUBE	0.1%	A076481	001	Nov 14, 2003
GLENMARK PHARMS INC	0.1%	A078571	001	May 28, 2008
SUN PHARMA CANADA	0.1%	A076624	001	Dec 03, 2004
SPRAY, METERED;NASAL				
MOMETASONE FUROATE				
AMNEAL	0.05MG/SPRAY	A217460	001	Jun 14, 2023
APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024
AUROBINDO PHARMA	0.05MG/SPRAY	A217498	001	Nov 22, 2024
NASPRESS	0.05MG/SPRAY	A211706	001	May 15, 2025

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MOMETASONE FUROATE					
SPRAY, METERED;NASAL					
NASONEX					
+	ORGANON LLC	0.05MG/SPRAY **	N020762	001	Oct 01, 1997
MONOBENZONE					
CREAM;TOPICAL					
BENOQUIN					
	VALEANT PHARM INTL	20%	N008173	003	
MONOCTANOIN					
LIQUID;PERFUSION, BILIARY					
MOCTANIN					
	ETHITEK	100%	N019368	001	Oct 29, 1985
MONTELUKAST SODIUM					
GRANULE;ORAL					
MONTELUKAST SODIUM					
	PHARMOBEDIENT	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012
	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012
TABLET;ORAL					
MONTELUKAST SODIUM					
	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015
	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
	BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020
	HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012
	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017
	PHARMOBEDIENT	EQ 10MG BASE	A079103	001	Aug 03, 2012
	STRIDES PHARMA INTL	EQ 10MG BASE	A091576	001	Aug 03, 2012
TABLET, CHEWABLE;ORAL					
MONTELUKAST SODIUM					
	AIPING PHARM INC	EQ 4MG BASE	A091414	001	Aug 03, 2012
		EQ 5MG BASE	A091414	002	Aug 03, 2012
	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015
		EQ 5MG BASE	A203328	002	Jul 31, 2015
	APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
		EQ 5MG BASE	A201508	002	Aug 03, 2012
	HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012
		EQ 5MG BASE	A091128	002	Aug 03, 2012
	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015
		EQ 5MG BASE	A203795	002	Feb 27, 2015
	NATCO PHARMA	EQ 4MG BASE	A079142	001	Aug 03, 2012
		EQ 5MG BASE	A079142	002	Aug 03, 2012
	PHARMACO	EQ 4MG BASE	A091588	001	Aug 03, 2012
		EQ 5MG BASE	A091588	002	Aug 03, 2012
MORICIZINE HYDROCHLORIDE					
TABLET;ORAL					
ETHMOZINE					
	SHIRE	200MG	N019753	001	Jun 19, 1990
		250MG	N019753	002	Jun 19, 1990
		300MG	N019753	003	Jun 19, 1990
MORPHINE SULFATE					
CAPSULE, EXTENDED RELEASE;ORAL					
AVINZA					
	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002
		45MG	N021260	005	Dec 18, 2008
		60MG	N021260	002	Mar 20, 2002
		75MG	N021260	006	Dec 18, 2008
		90MG	N021260	003	Mar 20, 2002
		120MG	N021260	004	Mar 20, 2002
KADIAN					
+	ALLERGAN	10MG	N020616	008	Apr 20, 2007
+		20MG	N020616	001	Jul 03, 1996
+		30MG	N020616	004	Mar 09, 2001
+		40MG	N020616	009	Jul 09, 2012
+		50MG	N020616	002	Jul 03, 1996
+		60MG	N020616	005	Mar 09, 2001
+		70MG	N020616	010	Jul 09, 2012
+		80MG	N020616	006	Oct 27, 2006
+		100MG	N020616	003	Jul 03, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL					
KADIAN					
+		130MG	N020616	011	Jul 09, 2012
+		150MG	N020616	012	Jul 09, 2012
+		200MG	N020616	007	Feb 27, 2007
MORPHINE SULFATE					
	ANDA REPOSITORY	20MG	A203158	001	Aug 04, 2021
		30MG	A203158	002	Aug 04, 2021
		50MG	A203158	003	Aug 04, 2021
		60MG	A203158	004	Aug 04, 2021
		80MG	A203158	005	Aug 04, 2021
		100MG	A203158	006	Aug 04, 2021
	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016
		30MG	A200411	002	Apr 12, 2016
		40MG	A200411	007	Jul 25, 2018
		50MG	A200411	003	Apr 12, 2016
		60MG	A200411	004	Apr 12, 2016
		80MG	A200411	005	Apr 12, 2016
		100MG	A200411	006	Apr 12, 2016
	STRIDES PHARMA INTL	20MG	A200812	001	Nov 10, 2011
		30MG	A200812	002	Nov 10, 2011
		50MG	A200812	003	Nov 10, 2011
		60MG	A200812	004	Nov 10, 2011
		80MG	A200812	005	Nov 10, 2011
		100MG	A200812	006	Nov 10, 2011
	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014
		30MG	A202718	002	Dec 29, 2014
		40MG	A202718	007	Jun 03, 2015
		50MG	A202718	003	Dec 29, 2014
		60MG	A202718	004	Dec 29, 2014
		70MG	A202718	008	Jun 03, 2015
		80MG	A202718	005	Dec 29, 2014
		100MG	A202718	006	Dec 29, 2014
INJECTABLE;INJECTION					
ASTRAMORPH PF					
	FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986
		0.5MG/ML	A071051	001	Oct 07, 1986
		1MG/ML	A071052	001	Oct 07, 1986
		1MG/ML	A071053	001	Oct 07, 1986
MORPHINE SULFATE					
	HOSPIRA	0.5MG/ML	A071849	001	May 11, 1988
		1MG/ML	A071850	001	May 11, 1988
+	HOSPIRA INC	15MG/ML **	N202515	005	Nov 14, 2011
	ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992
+		1MG/ML **	N019916	001	Oct 30, 1992
+		5MG/ML **	N019916	002	Oct 27, 2006
	SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996
		2MG/ML	N020631	002	Jul 03, 1996
	WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
		0.5MG/ML	A073375	001	Sep 30, 1991
		1MG/ML	A073374	001	Sep 30, 1991
		1MG/ML	A073376	001	Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL					
DEPODUR					
	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
		15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
		20MG/2ML (10MG/ML)	N021671	003	May 18, 2004
SOLUTION;INTRAMUSCULAR					
MORPHINE SULFATE (AUTOINJECTOR)					
+	MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990
SOLUTION;INTRAMUSCULAR, INTRAVENOUS					
MORPHINE SULFATE					
+	FRESENIUS KABI USA	5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
+		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
SOLUTION;ORAL					
MORPHINE SULFATE					
	ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018
		20MG/5ML	A205509	002	Apr 17, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

SOLUTION;ORAL					
MORPHINE SULFATE					
	100MG/5ML		A205509	003	Apr 17, 2018
CHARTWELL MOLECULAR	10MG/5ML		A202309	001	Nov 25, 2015
	20MG/5ML		A202310	001	Oct 30, 2015
	100MG/5ML		N201517	001	Jun 23, 2011
HIKMA	100MG/5ML		A208809	001	Jul 06, 2017
RHODES PHARMS	10MG/5ML		A206308	001	Jun 22, 2017
	20MG/5ML		A206420	001	Jul 12, 2016
	100MG/5ML		A206308	002	Jun 22, 2017
SANKALP LIFECARE	10MG/5ML		A201011	001	Feb 05, 2014
	20MG/5ML		A201011	002	Feb 05, 2014
	100MG/5ML		A201011	003	Oct 06, 2016
TRIS PHARMA INC	20MG/5ML		A203519	001	May 18, 2016
VISTAPHARM	10MG/5ML		A201947	001	Jan 05, 2012
	20MG/5ML		A201947	002	Jan 05, 2012
TABLET;ORAL					
MORPHINE SULFATE					
DR REDDYS LABS SA	15MG		A207270	001	Jan 12, 2022
	30MG		A207270	002	Jan 12, 2022
INGENUS PHARMS NJ	15MG		A215584	001	Feb 07, 2022
	30MG		A215584	002	Feb 07, 2022
TABLET, EXTENDED RELEASE;ORAL					
ARYMO ER					
+ ZYLA	15MG		N208603	001	Jan 09, 2017
+	30MG		N208603	002	Jan 09, 2017
+	60MG		N208603	003	Jan 09, 2017
MORPHABOND ER					
+ OHEMO LIFE	15MG		N206544	001	Oct 02, 2015
+	30MG		N206544	002	Oct 02, 2015
+	60MG		N206544	003	Oct 02, 2015
+	100MG		N206544	004	Oct 02, 2015
MORPHINE SULFATE					
DR REDDYS LABS SA	15MG		A205386	001	Oct 28, 2016
	30MG		A205386	002	Oct 28, 2016
	60MG		A205386	003	Oct 28, 2016
	100MG		A205386	004	Oct 28, 2016
EPIC PHARMA LLC	15MG		A091357	001	Jun 23, 2016
	30MG		A091357	002	Jun 23, 2016
	60MG		A091357	003	Jun 23, 2016
	100MG		A091357	004	Jun 23, 2016
	200MG		A091357	005	Jun 23, 2016
NESHER PHARMS	15MG		A076733	001	May 19, 2004
	30MG		A076720	002	Dec 23, 2005
	60MG		A076720	001	May 19, 2004
	100MG		A077855	001	Sep 27, 2007
	200MG		A077855	002	Sep 27, 2007
NOVEL LABS INC	15MG		A203602	001	Dec 16, 2015
	30MG		A203602	002	Dec 16, 2015
	60MG		A203602	003	Dec 16, 2015
	100MG		A203602	004	Dec 16, 2015
	200MG		A203602	005	Dec 16, 2015
RISING	15MG		A200824	001	Oct 18, 2011
	30MG		A200824	002	Oct 18, 2011
	60MG		A200824	003	Oct 18, 2011
	100MG		A200824	004	Oct 18, 2011
	200MG		A200824	005	Oct 18, 2011
SUN PHARM INDUSTRIES	15MG		A205634	001	Aug 25, 2016
	30MG		A205634	002	Aug 25, 2016
	60MG		A205634	003	Aug 25, 2016
	100MG		A205634	004	Aug 25, 2016
	200MG		A205634	005	Aug 25, 2016
WATSON LABS	100MG		A075656	001	Jan 30, 2001
ORAMORPH SR					
XANODYNE PHARMS INC	15MG		N019977	004	Nov 23, 1994
	30MG		N019977	001	Aug 15, 1991
	60MG		N019977	002	Aug 15, 1991
	100MG		N019977	003	Aug 15, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
EMBEDA				
+	ALPHARMA PHARMS	20MG;0.8MG **	N022321 001	Aug 13, 2009
+		30MG;1.2MG **	N022321 002	Aug 13, 2009
+		50MG;2MG **	N022321 003	Aug 13, 2009
+		60MG;2.4MG **	N022321 004	Aug 13, 2009
+		80MG;3.2MG **	N022321 005	Aug 13, 2009
+		100MG;4MG **	N022321 006	Aug 13, 2009
MOXALACTAM DISODIUM				
INJECTABLE;INJECTION				
MOXAM				
	LILLY	EQ 250MG BASE/VIAL	N050550 001	
		EQ 500MG BASE/VIAL	N050550 002	
		EQ 1GM BASE/VIAL	N050550 003	
		EQ 2GM BASE/VIAL	N050550 004	
		EQ 10GM BASE/VIAL	N050550 008	
MOXIFLOXACIN HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277 001	Nov 30, 2001
SOLUTION/DROPS;OPHTHALMIC				
MOXEZA				
+	HARROW EYE	EQ 0.5% BASE **	N022428 001	Nov 19, 2010
MOXIFLOXACIN HYDROCHLORIDE				
	EPIC PHARMA LLC	EQ 0.5% BASE	A202916 001	Nov 09, 2017
	PHARMOBEDIENT	EQ 0.5% BASE	A206447 001	Mar 30, 2020
TABLET;ORAL				
AVELOX				
+	BAYER HLTHCARE	EQ 400MG BASE **	N021085 001	Dec 10, 1999
MOXIFLOXACIN HYDROCHLORIDE				
	NATCO	EQ 400MG BASE	A204635 001	Aug 31, 2015
MUPIROCIN				
OINTMENT;TOPICAL				
BACTROBAN				
+	GLAXOSMITHKLINE	2% **	N050591 001	Dec 31, 1987
MUPIROCIN CALCIUM				
CREAM;TOPICAL				
BACTROBAN				
+	GLAXOSMITHKLINE	EQ 2% BASE **	N050746 001	Dec 11, 1997
MUPIROCIN				
	PADAGIS ISRAEL	EQ 2% BASE	A212465 001	Aug 03, 2022
OINTMENT;NASAL				
BACTROBAN				
+	GLAXOSMITHKLINE	EQ 2% BASE **	N050703 001	Sep 18, 1995
MYCOPHENOLATE MOFETIL				
CAPSULE;ORAL				
MYCOPHENOLATE MOFETIL				
	APOTEX CORP	250MG	A090419 001	Apr 22, 2009
	DR REDDYS LABS LTD	250MG	A091315 001	Oct 27, 2011
	JUBILANT CADISTA	250MG	A090762 001	Dec 15, 2014
	STRIDES PHARMA INTL	250MG	A090111 001	Dec 22, 2009
	ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009
FOR SUSPENSION;ORAL				
MYCOPHENOLATE MOFETIL				
	TEVA PHARMS USA	200MG/ML	A211272 001	Jan 25, 2022
TABLET;ORAL				
MYCOPHENOLATE MOFETIL				
	AMNEAL	500MG	A090606 001	Jul 16, 2010
	APOTEX	500MG	A090499 001	Apr 22, 2009
	DR REDDYS LABS LTD	500MG	A090464 001	Sep 13, 2010
	JUBILANT CADISTA	500MG	A090661 001	Dec 15, 2014
	TEVA PHARMS	500MG	A065457 001	May 04, 2009
	ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MYCOPHENOLATE MOFETIL HYDROCHLORIDE				
INJECTABLE;INJECTION				
MYCOPHENOLATE MOFETIL HYDROCHLORIDE				
AMNEAL	500MG/VIAL	A211374	001	Mar 05, 2021
MYCOPHENOLATE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
MYCOPHENOLATE SODIUM				
TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014
	EQ 360MG BASE	A202720	002	Oct 30, 2014
NABILONE				
CAPSULE;ORAL				
CESAMET				
+ BAUSCH	1MG	N018677	001	Dec 26, 1985
NABUMETONE				
TABLET;ORAL				
NABUMETONE				
AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010
	750MG	A090516	002	Jul 12, 2010
COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
EPIC PHARMA LLC	500MG	A075590	001	Feb 25, 2002
	750MG	A075590	002	Feb 25, 2002
IMPAX LABS INC	500MG	A075189	001	May 26, 2000
	750MG	A075189	002	Sep 24, 2001
MPP PHARMA	500MG	A090427	001	Dec 30, 2011
	750MG	A090427	002	Dec 30, 2011
OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
	750MG	A079093	002	Feb 27, 2009
RELAFEN				
+ SMITHKLINE BEECHAM	500MG **	N019583	001	Dec 24, 1991
+	750MG **	N019583	002	Dec 24, 1991
NADOLOL				
TABLET;ORAL				
CORGARD				
+ USWM	20MG **	N018063	005	Oct 28, 1986
+	40MG **	N018063	001	
+	80MG **	N018063	002	
	120MG	N018063	003	
	160MG	N018063	004	
NADOLOL				
HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996
	40MG	A074229	002	Aug 30, 1996
	80MG	A074255	001	Jan 24, 1996
	120MG	A074255	002	Jan 24, 1996
	160MG	A074255	003	Jan 24, 1996
NOVAST LABS	20MG	A210786	001	Jun 01, 2018
	40MG	A210786	002	Jun 01, 2018
	80MG	A210786	003	Jun 01, 2018
TEVA PHARMS	80MG	A074368	001	Aug 31, 1994
	120MG	A074368	002	Aug 31, 1994
	160MG	A074368	003	Aug 31, 1994
NAFCILLIN SODIUM				
CAPSULE;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE	N050111	001	
FOR SOLUTION;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE/5ML	N050199	001	
INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
APOTHECON	EQ 500MG BASE/VIAL	A061984	001	
	EQ 1GM BASE/VIAL	A061984	002	
	EQ 2GM BASE/VIAL	A061984	003	
	EQ 4GM BASE/VIAL	A061984	005	
FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019
	EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019
	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020
SANDOZ	EQ 500MG BASE/VIAL	A062527	001	Aug 02, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAFCILLIN SODIUM					
INJECTABLE;INJECTION					
NAFCILLIN SODIUM					
		EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984
		EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986
		EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984
		EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986
		EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984
	WATSON LABS INC	EQ 500MG BASE/VIAL	A062844	001	Oct 26, 1988
		EQ 1GM BASE/VIAL	A062844	002	Oct 26, 1988
		EQ 1.5GM BASE/VIAL	A062844	003	Oct 26, 1988
		EQ 2GM BASE/VIAL	A062844	004	Oct 26, 1988
		EQ 4GM BASE/VIAL	A062844	005	Oct 26, 1988
		EQ 10GM BASE/VIAL	A063008	001	Sep 29, 1988
NALLPEN					
	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999	001	
		EQ 1GM BASE/VIAL	A061999	002	
		EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
		EQ 2GM BASE/VIAL	A061999	003	
		EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
		EQ 10GM BASE/VIAL	A061999	004	
UNIPEN					
	WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+		EQ 500MG BASE/VIAL **	N050320	001	
		EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
		EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+		EQ 2GM BASE/VIAL **	N050320	003	
+		EQ 4GM BASE/VIAL **	N050320	004	
+		EQ 10GM BASE/VIAL **	N050320	005	
+		EQ 20GM BASE/VIAL **	N050320	006	
UNIPEN IN PLASTIC CONTAINER					
+	WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002	
TABLET;ORAL					
UNIPEN					
	WYETH AYERST	EQ 500MG BASE	N050462	001	
NAFTIFINE HYDROCHLORIDE					
CREAM;TOPICAL					
NAFTIN					
+	LEGACY PHARMA	1% **	N019599	001	Feb 29, 1988
NALBUPHINE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NALBUPHINE HYDROCHLORIDE					
	ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
NALBUPHINE					
	ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986
		20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986
		200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986
NALBUPHINE HYDROCHLORIDE					
	ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989
	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986
	DR REDDYS	100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998
		200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998
	IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989
		10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989
		10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989
		20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989
		20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989
		20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989
		100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989
		200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989
	RISING	10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019
		20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019
		100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019
		200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019
NUBAIN					
+	PH HEALTH	10MG/ML (10MG/ML) **	N018024	001	
+		20MG/ML (20MG/ML) **	N018024	002	May 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALBUPHINE HYDROCHLORIDE					
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
NUBAIN					
+		20MG/2ML (10MG/ML) **	N018024	004	
+		100MG/10ML (10MG/ML) **	N018024	003	
+		200MG/10ML (20MG/ML) **	N018024	005	Mar 02, 1984
NALIDIXIC ACID					
SUSPENSION;ORAL					
NEGGRAM					
	SANOFI AVENTIS US	250MG/5ML	N017430	001	
TABLET;ORAL					
NALIDIXIC ACID					
	SUN PHARM INDUSTRIES	250MG	A070270	001	Jun 29, 1988
		500MG	A070271	001	Jun 29, 1988
		1GM	A070272	001	Jun 29, 1988
	WATSON LABS	250MG	A071936	001	Jun 29, 1988
		500MG	A072061	001	Jun 29, 1988
		1GM	A071919	001	Jun 29, 1988
NEGGRAM					
	SANOFI AVENTIS US	250MG	N014214	002	
		500MG	N014214	004	
		1GM	N014214	005	
NALMEFENE HYDROCHLORIDE					
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
REVEX					
+	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020459	001	Apr 17, 1995
+		EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **	N020459	002	Apr 17, 1995
NALOXONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NALOXONE					
	HIKMA	0.4MG/ML	A070298	001	Sep 24, 1986
		0.4MG/ML	A070496	001	Sep 24, 1986
	WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
		0.02MG/ML	A070189	001	Sep 24, 1986
		0.4MG/ML	A070190	001	Sep 24, 1986
		0.4MG/ML	A070191	001	Sep 24, 1986
NALOXONE HYDROCHLORIDE					
	ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
		0.02MG/ML	A070661	001	Nov 17, 1986
		0.4MG/ML	A070649	001	Nov 17, 1986
		1MG/ML	A071604	001	Dec 16, 1988
	ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
	CHARTWELL RX	0.4MG/ML	A207846	001	Dec 17, 2018
	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019
	HIKMA	0.02MG/ML	A071272	001	May 24, 1988
		1MG/ML	A071273	001	May 24, 1988
		1MG/ML	A071274	001	May 24, 1988
		1MG/ML	A071287	001	May 24, 1988
	HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
		0.02MG/ML	A070252	001	Jan 16, 1987
		0.02MG/ML	A070253	001	Jan 16, 1987
		0.4MG/ML	A070254	001	Jan 07, 1987
		0.4MG/ML	A070255	001	Jan 07, 1987
	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
		0.02MG/ML	A072083	001	Apr 11, 1989
		0.02MG/ML	A072084	001	Apr 11, 1989
		0.02MG/ML	A072085	001	Apr 11, 1989
		0.4MG/ML	A072086	001	Apr 11, 1989
		0.4MG/ML	A072087	001	Apr 11, 1989
		0.4MG/ML	A072088	001	Apr 11, 1989
		0.4MG/ML	A072089	001	Apr 11, 1989
		0.4MG/ML	A072090	001	Apr 11, 1989
		1MG/ML	A072091	001	Apr 11, 1989
		1MG/ML	A072092	001	Apr 11, 1989
		1MG/ML	A072093	001	Apr 11, 1989
	INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
		0.4MG/ML	A070639	001	Sep 24, 1986
		1MG/ML	A072115	001	Apr 27, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION					
NALOXONE HYDROCHLORIDE					
	MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
	PH HEALTH	0.4MG/ML	A211286	001	Jan 17, 2020
	SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
		0.4MG/ML	A071681	001	Nov 17, 1987
		0.4MG/ML	A071682	001	Nov 17, 1987
	SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
		0.4MG/ML	A071683	001	Nov 17, 1987
	WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN					
+	ADAPT	0.02MG/ML **	N016636	002	
+		0.4MG/ML **	N016636	001	
+		1MG/ML **	N016636	003	Jun 14, 1982
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
EVZIO (AUTOINJECTOR)					
+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016
NALOXONE HYDROCHLORIDE (AUTOINJECTOR)					
+	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022
SPRAY;NASAL					
NALOXONE HYDROCHLORIDE					
	PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025
REZENOPY					
+	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024
SPRAY, METERED;NASAL					
NARCAN					
+	EMERGENT	2MG/SPRAY **	N208411	002	Jan 24, 2017

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
TARGINIQ					
+	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
+		10MG;20MG	N205777	002	Jul 23, 2014
+		20MG;40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL					
TALWIN NX					
	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE **	N018733	001	Dec 16, 1982

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR					
NALTREXONE					
	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023

NALTREXONE HYDROCHLORIDE

TABLET;ORAL					
NALTREXONE HYDROCHLORIDE					
	NOVITIUM PHARMA	50MG	A075434	001	Mar 08, 2000
REVIA					
+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
TROXYCA ER					
	PFIZER	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NANDROLONE DECANOATE				
INJECTABLE;INJECTION				
DECA-DURABOLIN				
WOODWARD SPECL	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
+	200MG/ML **	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE				
ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AM REGENT	200MG/ML	A091252	001	Aug 30, 2010
EPIC PHARMA LLC	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
+	200MG/ML	A088128	001	Dec 05, 1983
NANDROLONE PHENPROPIONATE				
INJECTABLE;INJECTION				
DURABOLIN				
ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	
NANDROLONE PHENPROPIONATE				
WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983
NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
ALBALON				
ALLERGAN	0.1% **	A080248	001	
NAFAZAIR				
BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
RISING	0.1%	A083590	001	
NAPHCON FORTE				
+ ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983
NAPROXEN				
TABLET;ORAL				
NAPROSYN				
+ ATNAHS PHARMA US	250MG	N017581	002	
+	375MG	N017581	003	
NAPROXEN				
CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011
	375MG	A091305	002	Aug 24, 2011
	500MG	A091305	003	Aug 24, 2011
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
L PERRIGO CO	250MG	A077339	001	Apr 27, 2005
	375MG	A077339	002	Apr 27, 2005
	500MG	A077339	003	Apr 27, 2005
PHARMOBEDIENT	250MG	A074121	001	Dec 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAPROXEN

TABLET;ORAL				
NAPROXEN				
	375MG	A074121	002	Dec 21, 1993
	500MG	A074121	003	Dec 21, 1993
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995
WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995
TABLET, DELAYED RELEASE;ORAL				
NAPROXEN				
ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998
PLIVA	375MG	A075337	001	May 26, 1999
	500MG	A075337	002	May 26, 1999

NAPROXEN SODIUM

CAPSULE;ORAL				
NAPROXEN SODIUM				
ONESOURCE SPECIALTY	EQ 200MG BASE	A215472	001	Aug 17, 2022
TABLET;ORAL				
ANAPROX				
+ ATNAHS PHARMA US	EQ 250MG BASE **	N018164	001	
NAPROXEN SODIUM				
ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
AMNEAL PHARMS NY	EQ 250MG BASE	A078432	001	Apr 25, 2007
	EQ 500MG BASE	A078432	002	Apr 25, 2007
CONTRACT PHARMACAL	220MG	A074789	001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998
	EQ 500MG BASE	A074480	001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
PHARMOBEDIENT	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAPROXEN SODIUM
TABLET;ORAL
NAPROXEN SODIUM

	EQ 500MG BASE	A074495	002	Dec 05, 1994
SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 250MG BASE	A074198	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
	EQ 500MG BASE	A074198	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
ALEVE-D SINUS & COLD

+	BAYER	220MG;120MG **	N021076	001	Nov 29, 1999

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
TABLET;ORAL
TREXIMET

+	CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015

NARATRIPTAN HYDROCHLORIDE
TABLET;ORAL
AMERGE

+	GLAXOSMITHKLINE LLC	EQ 1MG BASE **	N020763	002	Feb 10, 1998
+		EQ 2.5MG BASE **	N020763	001	Feb 10, 1998

NARATRIPTAN

ANI PHARMS	EQ 1MG BASE	A078751	001	Jul 07, 2010
	EQ 2.5MG BASE	A078751	002	Jul 07, 2010
APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011
	EQ 2.5MG BASE	A091373	002	Apr 22, 2011
AUROBINDO PHARMA USA	EQ 1MG BASE	A202431	001	May 31, 2012
	EQ 2.5MG BASE	A202431	002	May 31, 2012
CHARTWELL RX	EQ 1MG BASE	A090288	001	Jul 07, 2010
	EQ 2.5MG BASE	A090288	002	Jul 07, 2010
SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011

NATEGLINIDE
TABLET;ORAL
NATEGLINIDE

ALVOGEN	60MG	A205055	001	Dec 11, 2015
	120MG	A205055	002	Dec 11, 2015
TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009

STARLIX

+	NOVARTIS	60MG **	N021204	001	Dec 22, 2000
+		120MG **	N021204	002	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
	EQ 5MG BASE	A203741	002	Jun 24, 2015
	EQ 10MG BASE	A203741	003	Jun 24, 2015
	EQ 20MG BASE	A203741	004	Jun 24, 2015
APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024
	EQ 20MG BASE	A209741	002	Feb 27, 2024
CHARTWELL RX	EQ 2.5MG BASE	A213349	001	Mar 31, 2022
	EQ 5MG BASE	A213349	002	Mar 31, 2022
	EQ 10MG BASE	A213349	003	Mar 31, 2022
	EQ 20MG BASE	A213349	004	Mar 31, 2022
WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
	EQ 5MG BASE	A203683	002	Nov 27, 2015
	EQ 10MG BASE	A203683	003	Nov 27, 2015
	EQ 20MG BASE	A203683	004	Nov 27, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEBIVOLOL HYDROCHLORIDE; VALSARTAN				
TABLET;ORAL				
BYVALSON				
+	ABBVIE	EQ 5MG BASE;80MG	N206302 001	Jun 03, 2016
NEDOCROMIL SODIUM				
AEROSOL, METERED;INHALATION				
TILADE				
	KING PHARMS LLC	1.75MG/INH	N019660 001	Dec 30, 1992
SOLUTION;INHALATION				
TILADE				
	SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
SOLUTION/DROPS;OPHTHALMIC				
ALOCRIL				
+	ALLERGAN	2% **	N021009 001	Dec 08, 1999
NEDOCROMIL SODIUM				
	EPIC PHARMA LLC	2%	A090638 001	Aug 22, 2012
NEFAZODONE HYDROCHLORIDE				
TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
	ANI PHARMS	50MG	A076072 001	Sep 16, 2003
		100MG	A076072 002	Sep 16, 2003
		150MG	A076072 003	Sep 16, 2003
		200MG	A076072 004	Sep 16, 2003
		250MG	A076072 005	Sep 16, 2003
	AUROBINDO PHARMA USA	100MG	A076129 002	Sep 16, 2003
		150MG	A076129 003	Sep 16, 2003
		200MG	A076129 004	Sep 16, 2003
		250MG	A076129 005	Sep 16, 2003
	CHARTWELL RX	50MG	A076302 001	Sep 16, 2003
		100MG	A076302 002	Sep 16, 2003
		150MG	A076302 003	Sep 16, 2003
		200MG	A076302 004	Sep 16, 2003
		250MG	A076302 005	Sep 16, 2003
	DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
		100MG	A076309 002	Sep 16, 2003
		150MG	A076309 003	Sep 16, 2003
		200MG	A076309 004	Sep 16, 2003
		250MG	A076309 005	Sep 16, 2003
	IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
		100MG	A075763 002	Sep 16, 2003
		150MG	A075763 003	Sep 16, 2003
		200MG	A075763 004	Sep 16, 2003
		250MG	A075763 005	Sep 16, 2003
	ROXANE	50MG	A076196 001	Sep 16, 2003
		100MG	A076196 002	Sep 16, 2003
		150MG	A076196 003	Sep 16, 2003
		200MG	A076196 004	Sep 16, 2003
		250MG	A076196 005	Sep 16, 2003
	SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
		100MG	A076409 002	Sep 16, 2003
		150MG	A076409 003	Sep 16, 2003
		200MG	A076409 004	Sep 16, 2003
		250MG	A076409 005	Sep 16, 2003
	WATSON LABS	100MG	A076073 002	Sep 16, 2003
		150MG	A076073 003	Sep 16, 2003
		200MG	A076073 004	Sep 16, 2003
		250MG	A076073 005	Sep 16, 2003
SERZONE				
+	BRISTOL MYERS SQUIBB	50MG **	N020152 001	Dec 22, 1994
+		100MG **	N020152 002	Dec 22, 1994
+		150MG **	N020152 003	Dec 22, 1994
+		200MG **	N020152 004	Dec 22, 1994
+		250MG **	N020152 005	Dec 22, 1994
+		300MG **	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER;ORAL				
VIRACEPT				
	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997

NEOMYCIN SULFATE

SOLUTION;ORAL				
MYCIFRADIN				
	PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
NEO-FRADIN				
	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002
TABLET;ORAL				
MYCIFRADIN				
	PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
NEOBIOTIC				
	PFIZER	EQ 350MG BASE	A060475 001	
NEOMYCIN SULFATE				
	BRISTOL MYERS SQUIBB	500MG	A060365 001	
	CHARTWELL MOLECULAR	500MG	A204435 001	Jun 10, 2016
	LANNETT	500MG	A060607 001	
	LILLY	500MG	A060385 001	
	PHARMOBEDIENT	500MG	A065468 001	Mar 29, 2010
	ROXANE	500MG	A062173 001	
	SANDOZ	500MG	A061586 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL				
NEOSPORIN				
	GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985
OINTMENT;OPHTHALMIC				
STATROL				
	ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	
SOLUTION/DROPS;OPHTHALMIC				
STATROL				
	ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
		EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC				
POLY-PRED				
	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
		EQ 3.5MG BASE/GM;0.5%	A061039 001	
SUSPENSION/DROPS;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC				
NEO-HYDELTRASOL				
	MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986
OINTMENT;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEOSTIGMINE METHYLSULFATE				
SOLUTION;INTRAVENOUS				
BLOXIVERZ				
+ EXELA PHARMA	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013
+	10MG/10ML (1MG/ML)	N204078	002	May 31, 2013
NEOSTIGMINE METHYLSULFATE				
AM REGENT	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018
	10MG/10ML (1MG/ML)	A209182	002	May 04, 2018
EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023
	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023
NESIRITIDE				
FOR SOLUTION;INTRAVENOUS				
NATRECOR				
+ SCIOS LLC	1.5MG/VIAL **	N020920	001	Aug 10, 2001
NETILMICIN SULFATE				
INJECTABLE;INJECTION				
NETROMYCIN				
SCHERING	EQ 10MG BASE/ML	N050544	001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003	Feb 28, 1983
NEVIRAPINE				
SUSPENSION;ORAL				
VIRAMUNE				
+ BOEHRINGER INGELHEIM	50MG/5ML **	N020933	001	Sep 11, 1998
TABLET;ORAL				
NEVIRAPINE				
APOTEX INC	200MG	A203021	001	May 22, 2012
PHARMOBEDIENT	200MG	A078864	001	May 22, 2012
PRINSTON INC	200MG	A078644	001	May 22, 2012
STRIDES PHARMA	200MG	A078195	001	May 22, 2012
TECH ORGANIZED	200MG	A203176	001	May 22, 2012
VIRAMUNE				
+ BOEHRINGER INGELHEIM	200MG **	N020636	001	Jun 21, 1996
TABLET, EXTENDED RELEASE;ORAL				
NEVIRAPINE				
ALVOGEN	100MG	A204621	002	Nov 09, 2015
	400MG	A204621	001	Jul 10, 2015
APOTEX	400MG	A205258	001	Apr 03, 2014
AUROBINDO PHARMA	100MG	A208616	001	Nov 23, 2016
	400MG	A207698	001	Feb 28, 2017
CIPLA	400MG	A206448	001	Oct 15, 2015
PHARMOBEDIENT	100MG	A206271	001	Nov 09, 2015
TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017
	400MG	A207467	002	Jul 31, 2017
VIRAMUNE XR				
+ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012
+	400MG	N201152	001	Mar 25, 2011
NIACIN				
CAPSULE;ORAL				
WAMPOCAP				
MEDPOINTE PHARM HLC	500MG	N011073	003	
TABLET;ORAL				
NIACIN				
EVERYLIFE	500MG	A083203	001	
HALSEY	500MG	A083453	001	
HIKMA	500MG	A083718	001	
IMPAX LABS	500MG	A083115	001	
IVAX SUB TEVA PHARMS	500MG	A083180	001	
MK LABS	500MG	A083525	001	
PUREPAC PHARM	500MG	A083271	001	
SANDOZ	500MG	A083306	001	
TABLICAPS	500MG	A084237	001	
WATSON LABS	500MG	A083136	001	
	500MG	A083305	001	
	500MG	A085172	001	
WOCKHARDT	500MG	A081134	001	Apr 28, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIACIN					
TABLET;ORAL					
NICOLAR					
+	SANOFI AVENTIS US	500MG	A083823	001	
TABLET, EXTENDED RELEASE;ORAL					
NIACIN					
	BEIJING	500MG	A214428	001	Nov 22, 2021
		1GM	A214428	002	Nov 22, 2021
	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018
		750MG	A209156	002	May 14, 2018
		1GM	A209156	003	May 14, 2018
	RISING	500MG	A203742	001	Feb 22, 2019
		750MG	A203742	002	Feb 22, 2019
		1GM	A203742	003	Feb 22, 2019
	YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019
		750MG	A212017	002	Jun 10, 2019
		1GM	A212017	003	Jun 10, 2019
	ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025
		750MG	A203285	002	Apr 28, 2025
		1GM	A203285	003	Apr 28, 2025
NIASPAN					
	ABBVIE	375MG	N020381	001	Jul 28, 1997
+		500MG **	N020381	002	Jul 28, 1997
+		750MG **	N020381	003	Jul 28, 1997
+		1GM **	N020381	004	Jul 28, 1997
NIASPAN TITRATION STARTER PACK					
	ABBVIE	375MG;500MG;750MG	N020381	005	Jul 28, 1997
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE					
SUSPENSION;ORAL					
TPN					
	INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378	003	
NICARDIPINE HYDROCHLORIDE					
CAPSULE;ORAL					
CARDENE					
+	CHIESI	20MG **	N019488	001	Dec 21, 1988
+		30MG **	N019488	002	Dec 21, 1988
NICARDIPINE HYDROCHLORIDE					
	ANI PHARMS	20MG	A074439	001	Dec 10, 1996
		20MG	A074540	001	Oct 28, 1996
		30MG	A074439	002	Dec 10, 1996
		30MG	A074540	002	Oct 28, 1996
	PHARMOBEDIENT	20MG	A074642	001	Jul 18, 1996
		30MG	A074642	002	Jul 18, 1996
CAPSULE, EXTENDED RELEASE;ORAL					
CARDENE SR					
+	CHIESI	30MG **	N020005	001	Feb 21, 1992
+		45MG **	N020005	002	Feb 21, 1992
+		60MG **	N020005	003	Feb 21, 1992
INJECTABLE;INJECTION					
CARDENE					
+	CHIESI	25MG/10ML (2.5MG/ML) **	N019734	001	Jan 30, 1992
NICARDIPINE HYDROCHLORIDE					
	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024
	HIKMA	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009
	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009
	SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009
INJECTABLE;INTRAVENOUS					
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER					
+	CHIESI	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008
NICLOSAMIDE					
TABLET, CHEWABLE;ORAL					
NICLOCIDE					
	BAYER PHARMS	500MG	N018669	001	May 14, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTROL					
	MCNEIL CONS	15MG/16HR	N020536	001	Jul 03, 1996
PROSTEP					
	AVEVA	11MG/24HR	N019983	003	Dec 23, 1998
		22MG/24HR	N019983	004	Dec 23, 1998

INHALANT;ORAL

NICOTROL					
+	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX					
	FERTIN PHARMA	EQ 4MG BASE	A214354	001	Dec 21, 2022
	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
		EQ 4MG BASE	A077850	001	Feb 18, 2009
	L PERRIGO CO	EQ 2MG BASE	A076776	001	Sep 16, 2004
		EQ 4MG BASE	A076778	001	Sep 16, 2004
	PERRIGO R AND D	EQ 2MG BASE	A078967	001	Apr 23, 2008
		EQ 4MG BASE	A078968	001	Apr 23, 2008
THRIVE					
	GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658	001	Jun 19, 2007
		EQ 4MG BASE	A077656	001	Jun 19, 2007

NIFEDIPINE

CAPSULE;ORAL

ADALAT					
	BAYER PHARMS	10MG	N019478	001	Nov 27, 1985
		20MG	N019478	002	Sep 17, 1986
NIFEDIPINE					
	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990
	CHASE LABS NJ	10MG	A072409	001	Jul 04, 1990
		20MG	A073421	001	Jun 19, 1991
	TEVA	10MG	A072651	001	Feb 19, 1992
PROCARDIA					
+	PFIZER	20MG **	N018482	002	Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC					
+	NORWICH	30MG **	N020198	001	Apr 21, 1993
+		60MG **	N020198	002	Apr 21, 1993
+		90MG **	N020198	003	Apr 21, 1993
AFEDITAB CR					
	WATSON LABS	60MG	A075659	001	Oct 26, 2001
	WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000
NIFEDIPINE					
	AUROBINDO PHARMA USA	30MG	A090649	001	Jun 21, 2010
		60MG	A090649	002	Jun 21, 2010
		90MG	A090649	003	Jun 21, 2010
	MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
	PH HEALTH	30MG	A077899	001	Dec 13, 2006
		60MG	A077899	002	Dec 13, 2006
		90MG	A077899	003	May 25, 2012
	PHARMOBEDIENT	30MG	A075108	001	Dec 17, 1999
	RISING	30MG	A090602	001	Sep 13, 2010
		30MG	A201071	001	Dec 03, 2010
		60MG	A090602	002	Sep 13, 2010
		60MG	A201071	002	Dec 03, 2010
		90MG	A090602	003	Sep 13, 2010
		90MG	A201071	003	Dec 03, 2010
	SPIL	30MG	A210838	001	Apr 16, 2019
		60MG	A210838	002	Apr 16, 2019
		90MG	A210838	003	Apr 16, 2019
	SWISS PHARM	30MG	A216019	001	Nov 18, 2022
		60MG	A216019	002	Nov 18, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NILUTAMIDE				
TABLET;ORAL				
NILANDRON				
	ADVANZ PHARMA	50MG	N020169 001	Sep 19, 1996
NIMODIPINE				
CAPSULE;ORAL				
NIMODIPINE				
	SOFGEN PHARMS	30MG	A201832 001	Jul 24, 2015
	SUN PHARM INDS INC	30MG	A077067 001	Apr 17, 2007
NIMOTOP				
+	BAYER PHARMS	30MG **	N018869 001	Dec 28, 1988
SOLUTION;ORAL				
NYMALIZE				
+	AZURITY	3MG/ML **	N203340 001	May 10, 2013
NIRAPARIB TOSYLATE				
CAPSULE;ORAL				
ZEJULA				
+	GLAXOSMITHKLINE	EQ 100MG BASE	N208447 001	Mar 27, 2017
NISOLDIPINE				
TABLET, EXTENDED RELEASE;ORAL				
NISOLDIPINE				
	AMTA	8.5MG	A216606 001	Apr 10, 2023
SULAR				
+	COVIS	10MG **	N020356 001	Feb 02, 1995
+		20MG **	N020356 002	Feb 02, 1995
+		25.5MG **	N020356 006	Jan 02, 2008
+		30MG **	N020356 003	Feb 02, 1995
+		40MG **	N020356 004	Feb 02, 1995
NITAZOXANIDE				
FOR SUSPENSION;ORAL				
ALINIA				
+	ROMARK	100MG/5ML	N021498 001	Nov 22, 2002
TABLET;ORAL				
ALINIA				
+	ROMARK	500MG **	N021497 001	Jul 21, 2004
NITISINONE				
CAPSULE;ORAL				
NITISINONE				
	TORRENT	2MG	A215908 001	Jan 09, 2023
		5MG	A215908 002	Jan 09, 2023
		10MG	A215908 003	Jan 09, 2023
		20MG	A215908 004	Jan 09, 2023
NITRIC OXIDE				
GAS;INHALATION				
INOMAX				
+	MALLINCKRODT IRELAND	100PPM **	N020845 002	Dec 23, 1999
NOXIVENT				
	LINDE GAS EQUIP	100PPM	A207141 001	Oct 02, 2018
NITROFURANTOIN				
CAPSULE;ORAL				
NITROFURANTOIN				
	WATSON LABS	50MG	A084326 001	
		100MG	A084326 002	
TABLET;ORAL				
FURADANTIN				
	PROCTER AND GAMBLE	50MG	N008693 001	
		100MG	N008693 002	
FURALAN				
	CHARTWELL MOLECULAR	50MG	A080017 001	
		100MG	A080017 002	
NITROFURANTOIN				
	ELKINS SINN	50MG	A080003 001	
		100MG	A080003 002	
	IVAX SUB TEVA PHARMS	50MG	A080078 002	
		100MG	A080078 001	
	SANDOZ	50MG	A080043 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROFURANTOIN				
TABLET;ORAL				
NITROFURANTOIN				
	100MG		A080043 002	
WATSON LABS	50MG		A080447 001	
	50MG		A085797 001	
	100MG		A080447 002	
	100MG		A085796 001	
WHITEWORTH TOWN PLSN	100MG		A084085 002	
NITROFURANTOIN SODIUM				
INJECTABLE;INJECTION				
IVADANTIN				
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL		N012402 001	
NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN				
ACTAVIS LABS FL INC	25MG		A091095 001	Jun 18, 2015
	50MG		A091095 002	Jun 18, 2015
	100MG		A091095 003	Jun 18, 2015
ATHEM	25MG		A074336 001	Jan 25, 1995
	50MG		A074336 002	Jan 25, 1995
	100MG		A074336 003	Jan 25, 1995
SUN PHARM INDUSTRIES	25MG		A201722 001	Feb 16, 2016
	50MG		A201722 002	Feb 16, 2016
	100MG		A201722 003	Feb 16, 2016
WATSON LABS	25MG		A073696 001	Dec 31, 1992
	50MG		A073696 002	Dec 31, 1992
	100MG		A073696 003	Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE				
WATSON LABS	50MG		A070248 001	Jun 24, 1988
	100MG		A070249 001	Jun 24, 1988
NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)				
ALVOGEN	75MG;25MG		A215002 001	Jul 20, 2022
AMNEAL PHARMS	75MG;25MG		A207372 001	May 15, 2017
CHARTWELL RX	75MG;25MG		A076648 001	Mar 22, 2004
RANBAXY LABS LTD	75MG;25MG		A076951 001	Mar 30, 2005
NITROFURAZONE				
CREAM;TOPICAL				
FURACIN				
SHIRE	0.2%		A083789 001	
DRESSING;TOPICAL				
ACTIN-N				
SHERWOOD MEDCL	0.2%		N017343 001	
OINTMENT;TOPICAL				
FURACIN				
SHIRE	0.2%		N005795 001	
NITROFURAZONE				
AMBIX	0.2%		A086077 001	
LANNETT	0.2%		A084393 001	
PERRIGO NEW YORK	0.2%		A084968 001	
SUN PHARMA CANADA	0.2%		A086156 001	
WENDT	0.2%		A086766 001	
POWDER;TOPICAL				
FURACIN				
SHIRE	0.2%		A083791 001	
SOLUTION;TOPICAL				
NITROFURAZONE				
PERRIGO NEW YORK	0.2%		A085130 001	
WENDT	0.2%		A087081 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROGLYCERIN

AEROSOL;SUBLINGUAL					
NITROLINGUAL					
	POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
FILM, EXTENDED RELEASE;TRANSDERMAL					
MINITRAN					
	BAUSCH	0.4MG/HR	A089773	001	Aug 30, 1996
	VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996
		0.6MG/HR	A089774	001	Aug 30, 1996
	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996
NITROGLYCERIN					
	LANNETT CO INC	0.2MG/HR	A075115	001	Aug 10, 2004
		0.4MG/HR	A075115	002	Aug 10, 2004
	MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
		0.2MG/HR	A074992	003	Nov 12, 1999
		0.4MG/HR	A074992	002	Nov 12, 1999
		0.6MG/HR	A074992	001	Nov 12, 1999
TRANSDERM-NITRO					
+	NOVARTIS	0.1MG/HR **	N020144	001	Feb 27, 1996
+		0.2MG/HR **	N020144	002	Feb 27, 1996
+		0.4MG/HR **	N020144	003	Feb 27, 1996
+		0.6MG/HR **	N020144	004	Feb 27, 1996
+		0.8MG/HR **	N020144	005	Feb 27, 1996
INJECTABLE;INJECTION					
NITRO IV					
	POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
NITRO-BID					
	SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
		10MG/ML	A071159	001	Feb 28, 1990
NITROGLYCERIN					
	ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
		5MG/ML	A071203	001	May 08, 1987
+	HOSPIRA	5MG/ML **	N018531	001	
	INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
	LUITPOLD	5MG/ML	A071492	001	May 24, 1988
	SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
		5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%					
	HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
		10MG/100ML	A071846	001	Aug 31, 1990
		20MG/100ML	A071847	001	Aug 31, 1990
		40MG/100ML	A071848	001	Aug 31, 1990
NITROL					
	RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL					
	POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT					
	PARKE DAVIS	0.8MG/ML	N018588	001	
		5MG/ML	A070863	001	Jan 08, 1987
		5MG/ML	N018588	002	Dec 23, 1983
		10MG/ML	A070871	001	Jan 08, 1987
		10MG/ML	A070872	001	Jan 08, 1987
TRIDIL					
	HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
		5MG/ML	N018537	001	
POWDER;SUBLINGUAL					
GONITRO					
+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
TABLET;SUBLINGUAL					
NITROGLYCERIN					
	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017
		0.4MG	A203693	002	Oct 16, 2017
		0.6MG	A203693	003	Oct 16, 2017
	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018
		0.4MG	A207745	002	May 07, 2018
		0.6MG	A207745	003	May 07, 2018
	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022
		0.4MG	A210153	002	Mar 08, 2022
		0.6MG	A210153	003	Mar 08, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIZATIDINE

CAPSULE;ORAL					
AXID					
	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
		300MG	N019508	002	Apr 12, 1988
NIZATIDINE					
	ANI PHARMS	150MG	A075461	001	Jul 08, 2002
		150MG	A075668	001	Sep 12, 2002
		300MG	A075461	002	Jul 08, 2002
		300MG	A075668	002	Sep 12, 2002
	APOTEX INC	150MG	A076383	001	Jan 23, 2003
		300MG	A076383	002	Jan 23, 2003
	GLENMARK PHARMS INC	150MG	A090618	001	Jul 15, 2011
		300MG	A090618	002	Jul 15, 2011
	MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
		300MG	A075934	002	Jul 09, 2002
	PHARMOBEDIENT	150MG	A075806	001	Jul 05, 2002
		300MG	A075806	002	Jul 05, 2002
SOLUTION;ORAL					
AXID					
+	BRAINTREE	15MG/ML **	N021494	001	May 25, 2004
NIZATIDINE					
	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009

NONOXYNOL-9

AEROSOL;VAGINAL					
DELFEN					
	PERSONAL PRODS	12.5%	N014349	002	
SPONGE;VAGINAL					
TODAY					
+	MAYER LABS INC	1GM	N018683	001	Apr 01, 1983

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
NOREPINEPHRINE BITARTRATE					
	METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004
	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021
	ZYDUS PHARMS	EQ 1MG BASE/ML	A216341	001	Jul 19, 2022

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RAVOCAINE AND NOVOCAIN W/ LEVOPHED					
	EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	

NORETHINDRONE

TABLET;ORAL					
NORLUTIN					
	PARKE DAVIS	5MG	N010895	002	
TABLET;ORAL-28					
MICRONOR					
+	JANSSEN PHARMS	0.35MG **	N016954	001	
NORETHINDRONE					
	AMNEAL PHARMS	0.35MG	A202260	001	Aug 01, 2013

NORETHINDRONE ACETATE

TABLET;ORAL					
AYGESTIN					
+	DURAMED RES	5MG **	N018405	001	Apr 21, 1982
NORETHINDRONE ACETATE					
	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016
NORLUTATE					
	PARKE DAVIS	5MG	N012184	002	

NORFLOXACIN

SOLUTION/DROPS;OPHTHALMIC					
CHIBROXIN					
	MERCK	0.3%	N019757	001	Jun 17, 1991
TABLET;ORAL					
NOROXIN					
+	MERCK	400MG **	N019384	002	Oct 31, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NORTRIPTYLINE HYDROCHLORIDE				
CAPSULE;ORAL				
AVENTYL HYDROCHLORIDE				
LILLY	EQ 10MG BASE	N014684 001		
	EQ 25MG BASE	N014684 002		
NORTRIPTYLINE HYDROCHLORIDE				
ANI PHARMS	EQ 10MG BASE	A074054 001	Dec 31, 1992	
	EQ 25MG BASE	A074054 002	Dec 31, 1992	
	EQ 50MG BASE	A074054 003	Dec 31, 1992	
	EQ 75MG BASE	A074054 004	Dec 31, 1992	
AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835 001	Jun 30, 1997	
	EQ 25MG BASE	A074835 002	Jun 30, 1997	
	EQ 50MG BASE	A074835 003	Jun 30, 1997	
	EQ 75MG BASE	A074835 004	Jun 30, 1997	
RISING	EQ 10MG BASE	A074234 001	Jul 26, 1993	
	EQ 25MG BASE	A074234 002	Jul 26, 1993	
	EQ 50MG BASE	A074234 003	Jul 26, 1993	
	EQ 75MG BASE	A074234 004	Jul 26, 1993	
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996	
	EQ 25MG BASE	A073667 002	Apr 11, 1996	
	EQ 50MG BASE	A073667 003	Apr 11, 1996	
	EQ 75MG BASE	A073667 004	Apr 11, 1996	
ZYDUS LIFESCIENCES	EQ 10MG BASE	A213441 001	Feb 24, 2021	
	EQ 25MG BASE	A213441 002	Feb 24, 2021	
	EQ 50MG BASE	A213441 003	Feb 24, 2021	
	EQ 75MG BASE	A213441 004	Feb 24, 2021	
PAMELOR				
+ SPECGX LLC	EQ 10MG BASE	N018013 001		
+	EQ 25MG BASE	N018013 002		
+	EQ 50MG BASE	N018013 004		
+	EQ 75MG BASE	N018013 003		
SOLUTION;ORAL				
AVENTYL				
+ RANBAXY	EQ 10MG BASE/5ML **	N014685 001		
NORTRIPTYLINE HYDROCHLORIDE				
TARO	EQ 10MG BASE/5ML	A077965 001	Jun 20, 2006	
PAMELOR				
SPECGX LLC	EQ 10MG BASE/5ML	N018012 001		
NYSTATIN				
CREAM;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/GM	A061810 001		
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061445 001		
NYSTATIN				
CHARTWELL RX	100,000 UNITS/GM	A065315 001	May 31, 2006	
SUN PHARMA CANADA	100,000 UNITS/GM	A062457 001	Jul 28, 1983	
LOTION;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233 001		
OINTMENT;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444 001		
PASTILLE;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	200,000 UNITS	N050619 001	Apr 09, 1987	
POWDER;ORAL				
BARSTATIN 100				
BARLAN	100%	A062489 001	Apr 27, 1988	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NYSTATIN

POWDER;ORAL				
NILSTAT				
+ STRIDES PHARMA INTL	100% **	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK LLC	100%	A062613	001	Nov 26, 1985
POWDER;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060578	001	
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006
PHARMOBEDIENT	100,000 UNITS/GM	A065175	001	Dec 17, 2004
SUPPOSITORY;VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478	001	
SUSPENSION;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001	
NILSTAT				
+ CHARTWELL MOLECULES	100,000 UNITS/ML **	N050299	001	
NYSTATIN				
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
COSETTE	100,000 UNITS/ML	A062776	001	Dec 17, 1987
G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
TARO	100,000 UNITS/ML	A062876	001	Feb 29, 1988
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
VISTAPHARM LLC	100,000 UNITS/ML	A064142	001	Jun 25, 1998
	100,000 UNITS/ML	A064142	002	Mar 07, 2011
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
SUN PHARM INDUSTRIES	500,000 UNITS	A062838	001	Dec 22, 1988
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576	002	May 01, 1985
MYLAN	100,000 UNITS/GM;0.1% **	A062606	001	May 15, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYKACET				
	COSETTE	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985
MYTREX F				
	SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597 001	Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010 001	Dec 20, 1988
	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208136 001	Oct 24, 2016
	PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186 002	Jun 06, 1985
	PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657 001	Jul 30, 1986
	SUN PHARMA CANADA	100,000 UNITS/GM;0.1%	A062347 001	Mar 30, 1987
	TORRENT	100,000 UNITS/GM;0.1%	A213142 001	Jul 14, 2020
NYSTATIN TRIAMCINOLONE ACETONIDE				
	PHARMADERM	100,000 UNITS/GM;0.1%	A062596 001	Oct 08, 1985
OINTMENT;TOPICAL				
MYCO-TRIACET II				
	TEVA	100,000 UNITS/GM;0.1%	A062045 002	Nov 26, 1985
MYCOLOG-II				
	MYLAN	100,000 UNITS/GM;0.1% **	A060572 001	Jun 28, 1985
MYKACET				
	COSETTE	100,000 UNITS/GM;0.1%	A062733 001	Mar 06, 1987
MYTREX F				
	SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601 001	Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
	CHARTWELL RX	100,000 UNITS/GM;0.1%	A207316 001	Nov 18, 2019
	CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731 001	Dec 26, 2017
	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300 001	Jun 23, 2016
	PAI HOLDINGS PHARM	100,000 UNITS/GM;0.1%	A208287 001	Dec 30, 2016
	PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280 002	Oct 10, 1985
	PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656 001	Jul 30, 1986
	STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077 001	Jan 29, 2018
NYSTATIN-TRIAMCINOLONE ACETONIDE				
	PHARMADERM	100,000 UNITS/GM;0.1%	A062603 001	Oct 09, 1985

OBETICHOLIC ACID

TABLET;ORAL				
OBETICHOLIC ACID				
	APOTEX	5MG	A214862 001	May 30, 2023
		10MG	A214862 002	May 30, 2023
	LUPIN LTD	5MG	A214980 001	May 30, 2023
		10MG	A214980 002	May 30, 2023
	MSN	5MG	A215017 001	May 30, 2023
		10MG	A215017 002	May 30, 2023
OCALIVA				
+	INTERCEPT PHARMS INC	5MG	N207999 001	May 27, 2016
+		10MG	N207999 002	May 27, 2016

OCTREOTIDE ACETATE

INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
	SHUANGCHENG	EQ 0.1MG BASE/ML	A217860 001	May 02, 2024
	SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329 001	Mar 04, 2008
		EQ 0.05MG BASE/ML	A077372 001	Aug 14, 2007
		EQ 0.1MG BASE/ML	A077329 002	Mar 04, 2008
		EQ 0.1MG BASE/ML	A077372 002	Aug 14, 2007
		EQ 0.2MG BASE/ML	A077330 001	Mar 04, 2008
		EQ 0.2MG BASE/ML	A077373 001	Aug 14, 2007
		EQ 0.5MG BASE/ML	A077329 003	Mar 04, 2008
		EQ 0.5MG BASE/ML	A077372 003	Aug 14, 2007
		EQ 1MG BASE/ML	A077331 001	Mar 04, 2008
		EQ 1MG BASE/ML	A077373 002	Aug 14, 2007
	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011
		EQ 1MG BASE/ML	A090986 002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011
		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011
		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011
SANDOSTATIN				
+	NOVARTIS	EQ 0.2MG BASE/ML **	N019667 004	Jun 12, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OCTREOTIDE ACETATE				
INJECTABLE;INJECTION				
SANDOSTATIN				
+		EQ 1MG BASE/ML **	N019667 005	Jun 12, 1991
OFLOXACIN				
INJECTABLE;INJECTION				
FLOXIN				
	ORTHO MCNEIL PHARM	20MG/ML	N020087 002	Mar 31, 1992
		40MG/ML	N020087 003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
	ORTHO MCNEIL PHARM	400MG/100ML	N020087 001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	ORTHO MCNEIL PHARM	4MG/ML	N020087 004	Mar 31, 1992
		400MG/100ML	N020087 005	Mar 31, 1992
OFLOXACIN				
	BEDFORD	40MG/ML	A075762 001	Jan 16, 2002
SOLUTION/DROPS;OPHTHALMIC				
OFLOXACIN				
	ALVOGEN	0.3%	A076830 001	Aug 31, 2004
	AMNEAL	0.3%	A211524 001	Mar 01, 2024
	EPIC PHARMA LLC	0.3%	A076615 001	May 14, 2004
	SANDOZ	0.3%	A076231 001	May 14, 2004
		0.3%	A076848 001	Nov 25, 2008
SOLUTION/DROPS;OTIC				
FLOXIN OTIC				
+	DAIICHI	0.3% **	N020799 001	Dec 16, 1997
OFLOXACIN				
	ALVOGEN	0.3%	A090395 001	Aug 11, 2009
	HIKMA	0.3%	A076616 001	Mar 17, 2008
	SANDOZ	0.3%	A078222 001	Mar 17, 2008
TABLET;ORAL				
FLOXIN				
+	JANSSEN PHARMS	200MG **	N019735 001	Dec 28, 1990
+		300MG **	N019735 002	Dec 28, 1990
+		400MG **	N019735 003	Dec 28, 1990
OFLOXACIN				
	CHARTWELL RX	200MG	A076093 001	Sep 02, 2003
		300MG	A076093 002	Sep 02, 2003
	RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003
		300MG	A076220 002	Sep 02, 2003
		400MG	A076220 003	Sep 02, 2003
OLANZAPINE				
TABLET;ORAL				
OLANZAPINE				
	AJANTA PHARMA LTD	2.5MG	A206711 001	Aug 30, 2016
		5MG	A206711 002	Aug 30, 2016
		7.5MG	A206711 003	Aug 30, 2016
		10MG	A206711 004	Aug 30, 2016
		15MG	A206711 005	Aug 30, 2016
		20MG	A206711 006	Aug 30, 2016
	HIKMA	2.5MG	A204866 001	Jun 16, 2017
		5MG	A204866 002	Jun 16, 2017
		7.5MG	A204866 003	Jun 16, 2017
		10MG	A204866 004	Jun 16, 2017
		15MG	A204866 005	Jun 16, 2017
		20MG	A204866 006	Jun 16, 2017
	HISUN PHARM HANGZHOU	2.5MG	A206924 001	Dec 31, 2020
		5MG	A206924 002	Dec 31, 2020
		7.5MG	A206924 003	Dec 31, 2020
		10MG	A206924 004	Dec 31, 2020
		15MG	A206924 005	Dec 31, 2020
		20MG	A206924 006	Dec 31, 2020
	INDOCO	2.5MG	A206155 001	Jul 31, 2020
		5MG	A206155 002	Jul 31, 2020
		7.5MG	A206155 003	Jul 31, 2020
		10MG	A206155 004	Jul 31, 2020
		15MG	A206155 005	Jul 31, 2020
		20MG	A206155 006	Jul 31, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OLANZAPINE

TABLET;ORAL				
OLANZAPINE				
IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015
JIANGSU HANSOH PHARM	2.5MG	A209399	001	Sep 24, 2018
	5MG	A209399	002	Sep 24, 2018
	10MG	A209399	003	Sep 24, 2018
NATCO PHARMA	2.5MG	A076866	001	Apr 23, 2012
	5MG	A076866	002	Apr 23, 2012
	7.5MG	A076866	003	Apr 23, 2012
	10MG	A076866	004	Apr 23, 2012
	15MG	A076866	005	Apr 23, 2012
	20MG	A076866	006	Apr 23, 2012
SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012
	5MG	A091038	002	Apr 23, 2012
	7.5MG	A091038	003	Apr 23, 2012
	10MG	A091038	004	Apr 23, 2012
	15MG	A091038	005	Apr 23, 2012
	20MG	A091038	006	Apr 23, 2012
SUNSHINE	2.5MG	A206238	001	Nov 19, 2018
	5MG	A206238	002	Nov 19, 2018
	7.5MG	A206238	003	Nov 19, 2018
	10MG	A206238	004	Nov 19, 2018
	15MG	A206238	005	Nov 19, 2018
	20MG	A206238	006	Nov 19, 2018
TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011
	5MG	A076000	002	Oct 24, 2011
	7.5MG	A076000	003	Oct 24, 2011
	10MG	A076000	004	Oct 24, 2011
	15MG	A076000	005	Oct 24, 2011
TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012
	5MG	A091434	002	Apr 23, 2012
	7.5MG	A091434	003	Apr 23, 2012
	10MG	A091434	004	Apr 23, 2012
	15MG	A091434	005	Apr 23, 2012
	20MG	A091434	006	Apr 23, 2012
TABLET, ORALLY DISINTEGRATING;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017
	10MG	A204320	002	May 30, 2017
	15MG	A204320	003	May 30, 2017
	20MG	A204320	004	May 30, 2017
SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012
	10MG	A090881	002	Feb 28, 2012
	15MG	A090881	003	Feb 28, 2012
	20MG	A090881	004	Feb 28, 2012
ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023
	10MG	A202889	002	Mar 09, 2023
	15MG	A202889	003	Mar 09, 2023
	20MG	A202889	004	Mar 09, 2023

OLAPARIB

CAPSULE;ORAL				
LYNPARZA				
+ ASTRAZENECA	50MG	N206162	001	Dec 19, 2014

OLICERIDINE

SOLUTION;INTRAVENOUS				
OLINVYK				
+ TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020
+	2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020
+	30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020

OLMESARTAN MEDOXOMIL

TABLET;ORAL				
OLMESARTAN MEDOXOMIL				
AMNEAL	5MG	A207480	001	Jul 11, 2023
	20MG	A207480	002	Jul 11, 2023
	40MG	A207480	003	Jul 11, 2023
LUPIN LTD	5MG	A206631	001	Apr 27, 2017
	20MG	A206631	002	Apr 27, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OLMESARTAN MEDOXOMIL

TABLET;ORAL				
OLMESARTAN MEDOXOMIL				
	40MG	A206631	003	Apr 27, 2017
RISING	5MG	A078276	001	Oct 26, 2016
	20MG	A078276	002	Oct 26, 2016
	40MG	A078276	003	Oct 26, 2016
SANDOZ	5MG	A090237	001	Apr 13, 2020
	20MG	A090237	002	Apr 13, 2020
	40MG	A090237	003	Apr 13, 2020
TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017
	20MG	A091079	002	Apr 24, 2017
	40MG	A091079	003	Apr 24, 2017
TORRENT	5MG	A202375	001	Apr 24, 2017
	20MG	A202375	002	Apr 24, 2017
	40MG	A202375	003	Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
OLOPATADINE HYDROCHLORIDE				
FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019
FLORIDA	EQ 0.7% BASE	A208637	001	Feb 19, 2020
SCIEGEN PHARMS	EQ 0.1% BASE	A204532	001	Jan 10, 2017
	EQ 0.2% BASE	A204723	001	Dec 05, 2017
ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015
SPRAY, METERED;NASAL				
OLOPATADINE HYDROCHLORIDE				
HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020
PATANASE				
+ NOVARTIS	0.665MG/SPRAY **	N021861	001	Apr 15, 2008

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS				
SYNRIBO				
+ TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL				
TECHNIVIE				
+ ABBVIE	12.5MG;75MG;50MG **	N207931	001	Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL				
OMEGA-3-ACID ETHYL ESTERS				
ONESOURCE SPECIALTY	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014
SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020
ZYDUS LIFESCIENCES	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL				
OMTRYG				
+ OSMOTICA PHARM US	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL				
EPANOVA				
+ ASTRAZENECA	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL				
OMEPRAZOLE				
LUPIN LTD	40MG	A202384	001	Aug 25, 2015
PHARMOBEDIENT	10MG	A205070	001	Jun 29, 2018
	20MG	A205070	002	Jun 29, 2018
	40MG	A205070	003	Jun 29, 2018
STRIDES PHARMA	10MG	A075876	001	May 29, 2003
	20MG	A075876	002	May 29, 2003
	40MG	A075876	003	Jan 21, 2009
TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL					
PRILOSEC					
+	ASTRAZENECA	10MG **	N019810	003	Oct 05, 1995
+		20MG **	N019810	001	Sep 14, 1989
+		40MG **	N019810	002	Jan 15, 1998
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE					
	APOTEX	20MG	A210070	001	Feb 11, 2019

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213201	001	Apr 28, 2023
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018
TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
OMEPRAZOLE AND SODIUM BICARBONATE					
	CHARTWELL RX	20MG;1.1GM	A204137	001	Jul 15, 2016
	STRIDES PHARMA INTL	20MG;1.1GM	A078966	001	May 25, 2010
		20MG;1.1GM	A201946	001	Jul 15, 2016
		40MG;1.1GM	A078966	002	May 25, 2010
ZEGERID					
+	SALIX	20MG;1.1GM **	N021849	001	Feb 27, 2006
+		40MG;1.1GM **	N021849	002	Feb 27, 2006
FOR SUSPENSION;ORAL					
ZEGERID					
+	SALIX	20MG/PACKET;1.68GM/PACKET **	N021636	001	Jun 15, 2004
+		40MG/PACKET;1.68GM/PACKET **	N021636	002	Dec 21, 2004

ONDANSETRON

FILM;ORAL					
ZUPLENZ					
+	AQUESTIVE	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010
TABLET, ORALLY DISINTEGRATING;ORAL					
ONDANSETRON					
	BARR	4MG	A076693	001	Jun 25, 2007
		8MG	A076693	002	Jun 25, 2007
	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
		8MG	A077717	002	Jun 25, 2007
	PHARMOBEDIENT	4MG	A078139	001	Jun 25, 2007
		8MG	A078139	002	Jun 25, 2007
	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011
		8MG	A078602	002	Feb 24, 2011
	TEVA	4MG	A076810	001	Jun 25, 2007
		8MG	A076810	002	Jun 25, 2007
ZOFRAN ODT					
+	SANDOZ	4MG **	N020781	001	Jan 27, 1999
+		8MG **	N020781	002	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION					
ONDANSETRON HYDROCHLORIDE					
	AM REGENT	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
	APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
	AVET LIFESCIENCES	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010
	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013
	CHARTWELL MOLECULAR	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
	EUGIA PHARMA	EQ 2MG BASE/ML	A202599	001	Dec 21, 2012
	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006
	HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
		EQ 2MG BASE/ML	A077840	001	Jan 19, 2007
	LANNETT CO INC	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010
	LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008
	ONESOURCE SPECIALTY	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008
	PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION					
ONDANSETRON HYDROCHLORIDE					
	RISING	EQ 2MG BASE/ML	A204906	001	Jul 31, 2017
	SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007
	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006
	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
	HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016
	AM REGENT	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006
		EQ 2MG BASE/ML	A079032	001	Nov 18, 2008
	APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
	AVET LIFESCIENCES	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013
	EUGIA PHARMA	EQ 2MG BASE/ML	A202600	001	Dec 21, 2012
	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006
	HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
	ONESOURCE SPECIALTY	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008
	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006
	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008
	TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006
ZOFRAN					
+	SANDOZ	EQ 2MG BASE/ML **	N020007	001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER					
+	GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403	001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE					
+	SANDOZ	EQ 2MG BASE/ML **	N020007	003	Dec 10, 1993
SOLUTION;ORAL					
ONDANSETRON HYDROCHLORIDE					
	PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007
	TARO	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007
ZOFRAN					
+	SANDOZ	EQ 4MG BASE/5ML **	N020605	001	Jan 24, 1997
TABLET;ORAL					
ONDANSETRON HYDROCHLORIDE					
	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007
		EQ 8MG BASE	A077306	002	Jun 25, 2007
	AUROBINDO PHARMA	EQ 24MG BASE	A078539	003	Jul 31, 2007
	CHARTWELL RX	EQ 4MG BASE	A077517	001	Jun 25, 2007
		EQ 8MG BASE	A077517	002	Jun 25, 2007
		EQ 24MG BASE	A077517	003	Jun 25, 2007
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006
		EQ 24MG BASE	A076183	001	Dec 26, 2006
	GLENMARK PHARMS LTD	EQ 24MG BASE	A077535	003	Jun 25, 2007
	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007
		EQ 8MG BASE	A077545	002	Sep 06, 2007
		EQ 24MG BASE	A077545	003	Sep 06, 2007
	PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112	001	Jun 25, 2007
		EQ 8MG BASE	A077112	002	Jun 25, 2007
		EQ 24MG BASE	A077112	003	Jun 25, 2007
	RISING	EQ 4MG BASE	A076930	001	Jun 25, 2007
		EQ 8MG BASE	A076930	002	Jun 25, 2007
		EQ 24MG BASE	A076930	004	Jun 25, 2007
	SUN PHARM INDS (IN)	EQ 4MG BASE	A077050	001	Jun 25, 2007
		EQ 8MG BASE	A077050	002	Jun 25, 2007
	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
		EQ 8MG BASE	A077729	002	Mar 28, 2011
		EQ 24MG BASE	A077729	003	Mar 28, 2011
	TEVA	EQ 4MG BASE	A076252	001	Jun 25, 2007
		EQ 8MG BASE	A076252	002	Jun 25, 2007
		EQ 24MG BASE	A076252	003	Jun 25, 2007
ZOFRAN					
+	SANDOZ	EQ 4MG BASE **	N020103	001	Dec 31, 1992
+		EQ 8MG BASE **	N020103	002	Dec 31, 1992
+		EQ 24MG BASE **	N020103	003	Aug 27, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ORPHENADRINE CITRATE				
INJECTABLE;INJECTION				
NORFLEX				
+	PAI HOLDINGS PHARM	30MG/ML **	N013055 001	
ORPHENADRINE CITRATE				
	WATSON LABS	30MG/ML	A087062 001	
TABLET, EXTENDED RELEASE;ORAL				
NORFLEX				
+	BAUSCH	100MG **	N012157 001	
ORPHENADRINE CITRATE				
	ASCOT	100MG	A088067 001	Apr 06, 1983
	SANDOZ	100MG	A085046 001	
	STEVENS J	100MG	A040368 001	Jun 23, 2000
	WATSON LABS	100MG	A084303 001	
ORPHENADRINE HYDROCHLORIDE				
TABLET;ORAL				
DISIPAL				
	3M	50MG	N010653 001	
OSELTAMIVIR PHOSPHATE				
CAPSULE;ORAL				
OSELTAMIVIR PHOSPHATE				
	ACCORD HLTHCARE	EQ 30MG BASE	A214726 001	Jul 25, 2022
		EQ 45MG BASE	A214726 002	Jul 25, 2022
		EQ 75MG BASE	A214726 003	Jul 25, 2022
	RISING	EQ 30MG BASE	A210157 001	Jan 21, 2021
		EQ 45MG BASE	A210157 002	Jan 21, 2021
		EQ 75MG BASE	A210157 003	Jan 21, 2021
TAMIFLU				
+	ROCHE	EQ 30MG BASE	N021087 003	Jul 02, 2007
+		EQ 45MG BASE	N021087 002	Jul 02, 2007
FOR SUSPENSION;ORAL				
OSELTAMIVIR PHOSPHATE				
	LEADING	EQ 6MG BASE/ML	A214949 001	Feb 28, 2022
TAMIFLU				
	ROCHE	EQ 12MG BASE/ML	N021246 001	Dec 14, 2000
OSILODROSTAT PHOSPHATE				
TABLET;ORAL				
ISTURISA				
+	RECORDATI RARE	EQ 10MG BASE	N212801 003	Mar 06, 2020
OSPEMIFENE				
TABLET;ORAL				
OSPEMIFENE				
	HETERO LABS LTD V	60MG	A215574 001	Feb 13, 2024
OXACILLIN SODIUM				
CAPSULE;ORAL				
BACTOCILL				
	GLAXOSMITHKLINE	EQ 250MG BASE	A061336 001	
		EQ 250MG BASE	A062241 001	
		EQ 500MG BASE	A061336 002	
		EQ 500MG BASE	A062241 002	
OXACILLIN SODIUM				
	ANI PHARMS	EQ 250MG BASE	A062222 001	
		EQ 500MG BASE	A062222 002	
	APOTHECON	EQ 250MG BASE	A061450 002	
		EQ 500MG BASE	A061450 001	
PROSTAPHLIN				
	APOTHECON	EQ 500MG BASE	N050118 002	
FOR SOLUTION;ORAL				
BACTOCILL				
	GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321 001	
OXACILLIN SODIUM				
	APOTHECON	EQ 250MG BASE/5ML	A061457 001	
	TEVA	EQ 250MG BASE/5ML	A062252 001	
PROSTAPHLIN				
	APOTHECON	EQ 250MG BASE/5ML	N050194 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXACILLIN SODIUM

INJECTABLE;INJECTION				
BACTOCILL				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **	A061334	009	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A061334	006	Mar 26, 1982
	EQ 1GM BASE/VIAL **	A062736	001	Dec 19, 1986
	EQ 2GM BASE/VIAL **	A061334	007	Mar 26, 1982
	EQ 2GM BASE/VIAL **	A062736	002	Dec 19, 1986
	EQ 4GM BASE/VIAL **	A061334	008	Mar 26, 1982
	EQ 10GM BASE/VIAL **	A061334	010	
OXACILLIN SODIUM				
+ APOTHECON	EQ 250MG BASE/VIAL **	N050195	001	
+	EQ 500MG BASE/VIAL **	N050195	002	
+	EQ 1GM BASE/VIAL **	N050195	003	
+	EQ 2GM BASE/VIAL **	N050195	004	
+	EQ 4GM BASE/VIAL **	N050195	005	
ELKINS SINN	EQ 250MG BASE/VIAL	A062711	001	Feb 03, 1989
	EQ 500MG BASE/VIAL	A062711	002	Feb 03, 1989
	EQ 1GM BASE/VIAL	A062711	003	Feb 03, 1989
	EQ 2GM BASE/VIAL	A062711	004	Feb 03, 1989
	EQ 4GM BASE/VIAL	A062711	005	Feb 03, 1989
	EQ 10GM BASE/VIAL	A062711	006	Feb 03, 1989
HOSPIRA	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015
	EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995
	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995
	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995
	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995
	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995
ONESOURCE SPECIALTY	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014
PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017
	EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017
	EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017
SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012
	EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012
SANDOZ	EQ 250MG BASE/VIAL	A061490	001	
	EQ 500MG BASE/VIAL	A061490	002	
	EQ 1GM BASE/VIAL	A061490	003	
	EQ 2GM BASE/VIAL	A061490	004	
	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856	001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856	002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A062984	001	Sep 29, 1988
POWDER;INTRAVENOUS				
OXACILLIN SODIUM				
SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986

OXALIPLATIN

INJECTABLE;INTRAVENOUS				
ELOXATIN				
+ SANOFI AVENTIS US	50MG/VIAL **	N021492	001	Aug 09, 2002
+	50MG/10ML (5MG/ML) **	N021759	001	Jan 31, 2005
+	100MG/VIAL **	N021492	002	Aug 09, 2002
+	100MG/20ML (5MG/ML) **	N021759	002	Jan 31, 2005
+	200MG/40ML (5MG/ML) **	N021759	003	Nov 17, 2006
OXALIPLATIN				
ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017
ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012
	100MG/VIAL	A078803	002	Aug 08, 2012
AM REGENT	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017
	100MG/20ML (5MG/ML)	A204378	002	May 12, 2017
CHARTWELL MOLECULAR	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017
	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017
EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017
	100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017
FRESENIUS KABI ONCOL	50MG/VIAL	A078810	001	Aug 07, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXALIPLATIN

INJECTABLE;INTRAVENOUS				
OXALIPLATIN				
	100MG/VIAL	A078810	002	Aug 07, 2009
FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017
	100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017
	200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017
GLAND	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017
HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009
	100MG/VIAL	A078815	002	Sep 30, 2009
MYLAN LABS LTD	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017
NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018
PHARMOBEDIENT	50MG/VIAL	A200979	001	Aug 08, 2012
	100MG/VIAL	A200979	002	Aug 08, 2012
SANDOZ	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009
	50MG/VIAL	A090849	001	Apr 28, 2011
	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009
	100MG/VIAL	A090849	002	Apr 28, 2011
SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009
	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014
	100MG/VIAL	A078818	002	Aug 07, 2009
	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014
	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019

OXAMNIQUINE

CAPSULE;ORAL				
VANSIL				
PFIZER	250MG	N018069	001	

OXANDROLONE

TABLET;ORAL				
OXANDROLONE				
PAR PHARM	2.5MG	A077827	001	Jun 22, 2007
	10MG	A077827	002	Jun 22, 2007
ROXANE	2.5MG	A077249	001	Jul 10, 2007
	10MG	A077249	002	Jul 10, 2007
SANDOZ	2.5MG	A076897	001	Dec 01, 2006
	10MG	A076897	002	Dec 01, 2006
UPSHER SMITH LABS	2.5MG	A076761	001	Dec 01, 2006
	10MG	A078033	001	Mar 22, 2007

OXAPROZIN

TABLET;ORAL				
OXAPROZIN				
AARXION ANDA HLDING	600MG	A075842	001	Apr 12, 2001
ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
PHARMOBEDIENT	600MG	A075851	001	Aug 17, 2001
SANDOZ	600MG	A075850	001	Apr 27, 2001
SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002
TEVA	600MG	A075849	001	Jul 03, 2002
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET;ORAL				
DAYPRO ALTA				
PFIZER	600MG	N020776	001	Oct 17, 2002

OXAZEPAM

CAPSULE;ORAL				
OXAZEPAM				
AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	15MG	A072953	001	Sep 28, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXAZEPAM

CAPSULE;ORAL				
OXAZEPAM				
	30MG	A072954	001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952	001	Sep 28, 1990
SERAX				
+ ALPHARMA US PHARMS	10MG **	N015539	002	
+	15MG **	N015539	004	
+	30MG **	N015539	006	
ZAXOPAM				
QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988
TABLET;ORAL				
OXAZEPAM				
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
SUN PHARM INDUSTRIES	15MG	A070683	001	Jan 16, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987
SERAX				
ALPHARMA US PHARMS	15MG **	N015539	008	

OXCARBAZEPINE

SUSPENSION;ORAL				
OXCARBAZEPINE				
HIKMA	300MG/5ML	A201193	001	Oct 03, 2012
PAI HOLDINGS	300MG/5ML	A211420	001	Jul 09, 2021
TABLET;ORAL				
OXCARBAZEPINE				
HIKMA	150MG	A077795	001	Oct 09, 2007
	300MG	A077795	002	Oct 09, 2007
	600MG	A077795	003	Oct 09, 2007
JUBILANT CADISTA	150MG	A090239	001	Jan 25, 2010
	300MG	A090239	002	Jan 25, 2010
	600MG	A090239	003	Jan 25, 2010
ZYDUS	150MG	A211747	001	Jul 03, 2023
	300MG	A211747	002	Jul 03, 2023
	600MG	A211747	003	Jul 03, 2023
TABLET, EXTENDED RELEASE;ORAL				
OXCARBAZEPINE				
AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025
	300MG	A219241	002	Apr 30, 2025
	600MG	A219241	003	Apr 30, 2025

OXPRENOLOL HYDROCHLORIDE

CAPSULE;ORAL				
TRASICOR				
NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
OXTRIPHYLLINE				
MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
SYRUP;ORAL				
CHOLEDYL				
PARKE DAVIS	50MG/5ML	N009268	011	
OXTRIPHYLLINE PEDIATRIC				
MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983
TABLET, DELAYED RELEASE;ORAL				
CHOLEDYL				
PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	
OXTRIPHYLLINE				
WATSON LABS	100MG	A087866	001	Aug 25, 1983
	200MG	A087835	001	Aug 25, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXTRIPHYLLINE					
TABLET, EXTENDED RELEASE;ORAL					
CHOLEDYL SA					
	WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
		600MG	A086742	001	
OXYBUTYNIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYBUTYNIN					
	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014
GEL, METERED;TRANSDERMAL					
GELNIQUE 3%					
+	ALLERGAN	3%	N202513	001	Dec 07, 2011
OXYBUTYNIN CHLORIDE					
GEL;TRANSDERMAL					
GELNIQUE					
+	ABBVIE	10% (100MG/PACKET) **	N022204	001	Jan 27, 2009
OXYBUTYNIN CHLORIDE					
	CHARTWELL RX	10% (100MG/PACKET)	A207329	001	May 31, 2018
SYRUP;ORAL					
DITROPAN					
+	ORTHO MCNEIL JANSSEN	5MG/5ML **	N018211	001	
OXYBUTYNIN CHLORIDE					
	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004
	PHARM ASSOC	5MG/5ML	A074997	001	Oct 15, 1997
		5MG/5ML	A075137	001	Dec 18, 1998
	PHARMOBEDIENT CNSLTG	5MG/5ML	A074868	001	Feb 12, 1997
TABLET;ORAL					
DITROPAN					
+	JANSSEN PHARMS	5MG **	N017577	001	
OXYBUTYNIN CHLORIDE					
	AVET LIFESCIENCES	5MG	A211682	001	May 10, 2019
	HIBROW HLTHCARE	5MG	A211062	001	Feb 06, 2019
	QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
	USL PHARMA	5MG	A070746	001	Mar 10, 1988
	WATSON LABS	5MG	A072485	001	Apr 19, 1989
TABLET, EXTENDED RELEASE;ORAL					
DITROPAN XL					
+	JANSSEN PHARMS	5MG **	N020897	001	Dec 16, 1998
+		10MG **	N020897	002	Dec 16, 1998
+		15MG **	N020897	003	Jun 22, 1999
OXYBUTYNIN CHLORIDE					
	IMPAX PHARMS	5MG	A076745	002	May 09, 2007
		10MG	A076745	003	May 09, 2007
		15MG	A076745	001	Nov 09, 2006
	PHARMOBEDIENT	5MG	A076702	001	Nov 09, 2006
		10MG	A076644	001	Nov 09, 2006
		15MG	A076644	002	May 10, 2007
OXYCODONE HYDROCHLORIDE					
CAPSULE;ORAL					
OXYCODONE HYDROCHLORIDE					
	DR REDDYS LABS SA	5MG	A203107	001	Jul 26, 2012
	LANNETT CO INC	5MG	A203823	001	Aug 01, 2014
SOLUTION;ORAL					
OXYCODONE HYDROCHLORIDE					
	ANI PHARMS	100MG/5ML	A203447	001	Aug 30, 2017
	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020
		100MG/5ML	A212429	002	Jan 27, 2020
	CHARTWELL MOLECULAR	100MG/5ML	A204085	001	Sep 09, 2014
	DR REDDYS LABS SA	100MG/5ML	A204092	001	Jun 05, 2014
	HIKMA	5MG/5ML	A208817	001	Aug 10, 2017
		100MG/5ML	A203208	001	Jul 12, 2013
		100MG/5ML	A208795	001	Aug 07, 2017
	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015
	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017
	PHARMOBEDIENT	5MG/5ML	A206456	001	Jun 16, 2015
	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020
+	VISTAPHARM LLC	5MG/5ML **	N201194	001	Jan 12, 2012
		100MG/5ML	A202537	001	Jul 30, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYCODONE HYDROCHLORIDE				
TABLET;ORAL				
OXAYDO				
+ ZYLA	5MG	N202080	001	Jun 17, 2011
+	7.5MG	N202080	002	Jun 17, 2011
OXYCODONE HYDROCHLORIDE				
ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015
	15MG	A076636	001	Feb 06, 2004
	30MG	A076636	002	Feb 06, 2004
DR REDDYS LABS SA	5MG	A091313	001	Feb 18, 2011
	10MG	A091313	004	Apr 29, 2016
	15MG	A091313	002	Feb 18, 2011
	20MG	A091313	005	Apr 29, 2016
	30MG	A091313	003	Feb 18, 2011
NESHER PHARMS	5MG	A077290	001	Dec 08, 2005
	10MG	A077290	002	Dec 08, 2005
	15MG	A077290	003	Dec 08, 2005
	20MG	A077290	004	Dec 08, 2005
	30MG	A077290	005	Dec 08, 2005
NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017
	10MG	A204021	002	Jun 12, 2017
	15MG	A204021	003	Jun 12, 2017
	20MG	A204021	004	Jun 12, 2017
	30MG	A204021	005	Jun 12, 2017
SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009
	10MG	A090659	005	Nov 06, 2012
	15MG	A090659	002	Apr 10, 2009
	20MG	A090659	004	Nov 06, 2012
	30MG	A090659	003	Apr 10, 2009
TABLET, EXTENDED RELEASE;ORAL				
ROXICODONE				
ROXANE	10MG	N020932	001	Oct 26, 1998
	30MG	N020932	002	Oct 26, 1998
OXYMETAZOLINE HYDROCHLORIDE				
CREAM;TOPICAL				
OXYMETAZOLINE HYDROCHLORIDE				
SUN PHARMA CANADA	1%	A213584	001	Oct 04, 2021
SOLUTION/DROPS;OPHTHALMIC				
OCUCLEAR				
BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986
OXYMETHOLONE				
TABLET;ORAL				
ANADROL-50				
+ PHARMOBEDIENT	50MG	N016848	001	
OXYMORPHONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
OPANA				
+ ENDO PHARMS	1MG/ML	N011707	002	
	1.5MG/ML	N011707	001	
SUPPOSITORY;RECTAL				
NUMORPHAN				
ENDO PHARMS	5MG	N011738	004	
TABLET;ORAL				
OPANA				
+ ENDO PHARMS	5MG **	N021611	001	Jun 22, 2006
+	10MG **	N021611	002	Jun 22, 2006
OXYMORPHONE HYDROCHLORIDE				
SPECGX LLC	5MG	A202321	001	Apr 25, 2013
	10MG	A202321	002	Apr 25, 2013
TABLET, EXTENDED RELEASE;ORAL				
OPANA ER				
+ ENDO OPERATIONS	5MG **	N021610	001	Jun 22, 2006
+	7.5MG **	N021610	005	Feb 29, 2008
+	10MG **	N021610	002	Jun 22, 2006
+	15MG **	N021610	006	Feb 29, 2008
+	20MG **	N021610	003	Jun 22, 2006
+	30MG **	N021610	007	Feb 29, 2008
+	40MG **	N021610	004	Jun 22, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER					
+	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011
+		7.5MG	N201655	002	Dec 09, 2011
+		10MG	N201655	003	Dec 09, 2011
+		15MG	N201655	004	Dec 09, 2011
+		20MG	N201655	005	Dec 09, 2011
+		30MG	N201655	006	Dec 09, 2011
+		40MG	N201655	007	Dec 09, 2011
OXYMORPHONE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013
		7.5MG	A079046	001	Dec 13, 2010
		10MG	A079046	004	Jul 11, 2013
		15MG	A079046	002	Dec 13, 2010
		20MG	A079046	005	Jul 11, 2013
		30MG	A079046	006	Jul 11, 2013
		40MG	A079046	007	Jul 11, 2013
	HIKMA	5MG	A200822	002	Jul 15, 2013
		7.5MG	A200822	003	Jul 15, 2013
		10MG	A200822	004	Jul 15, 2013
		15MG	A200822	005	Jul 15, 2013
		20MG	A200822	006	Jul 15, 2013
		30MG	A200822	007	Jul 15, 2013
		40MG	A200822	001	Jul 15, 2013
	PAR PHARM	5MG	A200792	001	Oct 24, 2014
		7.5MG	A200792	002	Oct 24, 2014
		10MG	A200792	003	Oct 24, 2014
		15MG	A200792	004	Oct 24, 2014
		20MG	A200792	005	Oct 24, 2014
		30MG	A200792	006	Oct 24, 2014
		40MG	A200792	007	Oct 24, 2014
	SPECGX LLC	5MG	A202946	001	Jun 27, 2014
		7.5MG	A202946	002	Jun 27, 2014
		10MG	A202946	003	Jun 27, 2014
		15MG	A202946	004	Jun 27, 2014
		20MG	A202946	005	Jun 27, 2014
		30MG	A202946	006	Jun 27, 2014
		40MG	A202946	007	Jun 27, 2014
	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015
		7.5MG	A203506	002	Apr 24, 2015
		10MG	A203506	003	Apr 24, 2015
		15MG	A203506	004	Apr 24, 2015
		20MG	A203506	005	Apr 24, 2015
		30MG	A203506	006	Apr 24, 2015
		40MG	A203506	007	Apr 24, 2015

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE					
	WATSON LABS	100MG	A088399	001	Sep 17, 1984
TANDEARIL					
	NOVARTIS	100MG	N012542	004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON				
	PFIZER	10MG	N011612	001

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL				
	NOVARTIS	5MG	N008492	002

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN				
	PFIZER	250MG	N050287	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL				
TERRAMYCIN				
	PFIZER	EQ 125MG BASE/5ML	A060595 001	

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
OXY-KESSO-TETRA				
	FERRANTE	EQ 250MG BASE	A060179 001	
OXYTETRACYCLINE HYDROCHLORIDE				
	HIKMA	EQ 250MG BASE	A060770 001	
	IMPAX LABS	EQ 250MG BASE	A060760 001	
	PROTER	EQ 250MG BASE	A060869 001	
	PUREPAC PHARM	EQ 250MG BASE	A060634 001	
TERRAMYCIN				
	PFIZER	EQ 125MG BASE	N050286 001	
		EQ 250MG BASE	N050286 002	
INJECTABLE;INJECTION				
TERRAMYCIN				
	PFIZER	EQ 250MG BASE/VIAL	A060586 001	
		EQ 500MG BASE/VIAL	A060586 002	

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
TERRAMYCIN W/ POLYMYXIN B SULFATE				
	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015 001	
OINTMENT;OTIC				
TERRAMYCIN W/ POLYMYXIN				
	PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841 001	
TABLET;VAGINAL				
TERRAMYCIN-POLYMYXIN				
	PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001	

OXYTOCIN

INJECTABLE;INJECTION				
OXYTOCIN				
	DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008
		100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 004	Mar 29, 1985
+		2USP UNITS/100ML **	N019185 003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	2USP UNITS/100ML **	N019185 002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 001	Mar 29, 1985
SYNTOCINON				
	NOVARTIS	10USP UNITS/ML	N018245 001	
SOLUTION;NASAL				
SYNTOCINON				
	RTRX	40USP UNITS/ML	N012285 001	

OZENOXACIN

CREAM;TOPICAL				
XEPI				
+	FERRER INTERNACIONAL	1%	N208945 001	Dec 11, 2017

PACLITAXEL

INJECTABLE;INJECTION				
PACLITAXEL				
	ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
	DASH PHARMS	6MG/ML	A091540 001	Sep 29, 2011
	HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
	PHARMOBEDIENT	6MG/ML	A075278 001	Jan 25, 2002
	PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
	SANDOZ	6MG/ML	A078167 001	Dec 26, 2007
	TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002
TAXOL				
+	HQ SPCLT PHARMA	6MG/ML **	N020262 001	Dec 29, 1992

PALBOCICLIB				
TABLET;ORAL				
PALBOCICLIB				
ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024
	100MG	A215570	002	Jun 05, 2024
	125MG	A215570	003	Jun 05, 2024
PALIPERIDONE				
TABLET, EXTENDED RELEASE;ORAL				
INVEGA				
+ JANSSEN PHARMS	1.5MG **	N021999	006	Aug 26, 2008
+	12MG **	N021999	004	Dec 19, 2006
PALIPERIDONE				
ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015
	3MG	A202645	002	Aug 03, 2015
	6MG	A202645	003	Aug 03, 2015
	9MG	A202645	004	Aug 03, 2015
AJANTA PHARMA LTD	3MG	A218514	002	Jun 26, 2024
	6MG	A218514	003	Jun 26, 2024
	9MG	A218514	004	Jun 26, 2024
LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022
	3MG	A208643	002	Jun 29, 2022
	6MG	A208643	003	Jun 29, 2022
	9MG	A208643	004	Jun 29, 2022
PALONOSETRON HYDROCHLORIDE				
CAPSULE;ORAL				
ALOXI				
+ HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233	001	Aug 22, 2008
INJECTABLE;INTRAVENOUS				
ALOXI				
+ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **	N021372	002	Feb 29, 2008
+	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **	N021372	001	Jul 25, 2003
PALONOSETRON HYDROCHLORIDE				
ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021
CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018
DR REDDYS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016
HOSPIRA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018
NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020
QILU PHARM HAINAN	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018
TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018
SOLUTION;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
+ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017
HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016
POSFREA				
+ AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016
PAMIDRONATE DISODIUM				
INJECTABLE;INJECTION				
AREDIA				
+ NOVARTIS	30MG/VIAL **	N020036	001	Oct 31, 1991
	60MG/VIAL	N020036	003	May 06, 1993
	90MG/VIAL	N020036	004	May 06, 1993
PAMIDRONATE DISODIUM				
AESGEN	30MG/VIAL	A075594	001	May 06, 2002
	90MG/VIAL	A075594	002	May 06, 2002
AM REGENT	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008
	90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008
FRESENIUS KABI USA	30MG/VIAL	A075773	001	May 06, 2002
	30MG/10ML (3MG/ML)	A076207	001	May 17, 2002
	90MG/VIAL	A075773	002	May 06, 2002
	90MG/10ML (9MG/ML)	A076207	002	May 17, 2002
MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009
	90MG/VIAL	A078300	002	Mar 10, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PAMIDRONATE DISODIUM				
INJECTABLE;INJECTION				
PAMIDRONATE DISODIUM				
SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008
	90MG/VIAL	A077703	002	Dec 24, 2008
TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002
	90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002
PANCURONIUM BROMIDE				
INJECTABLE;INJECTION				
PANCURONIUM BROMIDE				
ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988
	2MG/ML	A072059	001	Mar 23, 1988
	2MG/ML	A072060	001	Mar 23, 1988
HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989
	2MG/ML	A072321	001	Jan 19, 1989
IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988
	2MG/ML	A072211	001	Mar 31, 1988
	2MG/ML	A072212	001	Mar 31, 1988
	2MG/ML	A072213	001	Mar 31, 1988
PAVULON				
+ ORGANON USA INC	1MG/ML **	N017015	002	
+	2MG/ML **	N017015	001	
PANOBINOSTAT LACTATE				
CAPSULE;ORAL				
FARYDAK				
+ SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015
+	EQ 15MG BASE	N205353	002	Feb 23, 2015
+	EQ 20MG BASE	N205353	003	Feb 23, 2015
PANTOPRAZOLE SODIUM				
INJECTABLE;INTRAVENOUS				
PANTOPRAZOLE SODIUM				
NORVIUM BIOSCIENCE	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018
SANDOZ	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015
SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019
TABLET, DELAYED RELEASE;ORAL				
PANTOPRAZOLE SODIUM				
ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011
	EQ 40MG BASE	A090797	002	Feb 07, 2011
INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019
JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011
	EQ 40MG BASE	A090901	002	Aug 30, 2011
L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014
MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012
	EQ 40MG BASE	A200821	002	Feb 16, 2012
MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024
SUN PHARM	EQ 20MG BASE	A077058	001	Sep 10, 2007
	EQ 40MG BASE	A077058	002	Sep 10, 2007
SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012
	EQ 40MG BASE	A200794	002	May 02, 2012
TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007
	EQ 40MG BASE	A077056	002	Aug 02, 2007
PARAMETHADIONE				
CAPSULE;ORAL				
PARADIONE				
ABBVIE	150MG	N006800	003	
	300MG	N006800	001	
SOLUTION;ORAL				
PARADIONE				
ABBVIE	300MG/ML	N006800	002	
PARAMETHASONE ACETATE				
TABLET;ORAL				
HALDRONE				
LILLY	1MG	N012772	005	
	2MG	N012772	006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PARGYLINE HYDROCHLORIDE

TABLET;ORAL				
EUTONYL				
ABBOTT	10MG		N013448 002	
	25MG		N013448 003	
	50MG		N013448 004	

PARICALCITOL

CAPSULE;ORAL				
PARICALCITOL				
LOTUS PHARM CO LTD	1MCG		A206710 001	Feb 24, 2016
	2MCG		A206710 002	Feb 24, 2016
	4MCG		A206710 003	Feb 24, 2016
ZEMPLAR				
+ ABBVIE	1MCG		N021606 001	May 26, 2005
+	4MCG **		N021606 003	May 26, 2005
SOLUTION;INTRAVENOUS				
PARICALCITOL				
EPIC PHARMA LLC	0.01MG/2ML (0.005MG/ML)		A207692 001	Oct 16, 2017
HIKMA PHARMS	0.002MG/ML (0.002MG/ML)		N205917 001	Nov 18, 2014
	0.005MG/ML (0.005MG/ML)		N205917 002	Nov 18, 2014
	0.01MG/2ML (0.005MG/ML)		N205917 003	Nov 18, 2014
HOSPIRA	0.002MG/ML (0.002MG/ML)		N201657 001	Oct 21, 2014
	0.005MG/ML (0.005MG/ML)		N201657 002	Oct 21, 2014
	0.01MG/2ML (0.005MG/ML)		N201657 003	Oct 21, 2014
RISING	0.002MG/ML (0.002MG/ML)		A203897 001	Nov 02, 2017

PAROMOMYCIN SULFATE

CAPSULE;ORAL				
HUMATIN				
KING PFIZER	EQ 250MG BASE		A062310 001	
PARKEDALE	EQ 250MG BASE		A060521 001	
PAROMOMYCIN SULFATE				
SUN PHARM INDS INC	EQ 250MG BASE		A064171 001	Jun 30, 1997
SYRUP;ORAL				
HUMATIN				
PARKE DAVIS	EQ 125MG BASE/5ML		A060522 001	

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL				
PAXIL				
+ APOTEX	EQ 10MG BASE **		N020885 001	Oct 09, 1998
+	EQ 20MG BASE **		N020885 002	Oct 09, 1998
+	EQ 30MG BASE **		N020885 003	Oct 09, 1998
+	EQ 40MG BASE **		N020885 004	Oct 09, 1998
SUSPENSION;ORAL				
PAROXETINE HYDROCHLORIDE				
APOTEX INC	EQ 10MG BASE/5ML		A077395 001	Dec 05, 2006
PAXIL				
+ APOTEX	EQ 10MG BASE/5ML		N020710 001	Jun 25, 1997
TABLET;ORAL				
PAROXETINE HYDROCHLORIDE				
JUBILANT GENERICS	EQ 10MG BASE		A205528 001	Nov 27, 2015
	EQ 20MG BASE		A205528 002	Nov 27, 2015
	EQ 30MG BASE		A205528 003	Nov 27, 2015
	EQ 40MG BASE		A205528 004	Nov 27, 2015
PHARMOBEDIENT	EQ 10MG BASE		A075716 001	Mar 08, 2004
	EQ 20MG BASE		A075716 002	Mar 08, 2004
	EQ 30MG BASE		A075716 003	Mar 08, 2004
	EQ 40MG BASE		A075716 004	Mar 08, 2004
ROXANE	EQ 10MG BASE		A078026 001	Jun 29, 2007
	EQ 20MG BASE		A078026 002	Jun 29, 2007
	EQ 30MG BASE		A078026 003	Jun 29, 2007
	EQ 40MG BASE		A078026 004	Jun 29, 2007
SUN PHARM INDS INC	EQ 10MG BASE		A078194 001	Jun 29, 2007
	EQ 20MG BASE		A078194 002	Jun 29, 2007
	EQ 30MG BASE		A078194 003	Jun 29, 2007
	EQ 40MG BASE		A078194 004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE		A077082 001	Jun 29, 2007
	EQ 20MG BASE		A077082 002	Jun 29, 2007
	EQ 30MG BASE		A077082 003	Jun 29, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

	EQ 40MG BASE	A077082	004	Jun 29, 2007
UPSHER SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004

PAXIL

APOTEX	EQ 50MG BASE	N020031	004	Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021
	EQ 25MG BASE	A213612	002	Aug 11, 2021
	EQ 37.5MG BASE	A213612	003	May 26, 2022

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003
+		EQ 20MG BASE	N021299	002	Jul 03, 2003
+		EQ 30MG BASE	N021299	003	Jul 03, 2003
+		EQ 40MG BASE	N021299	004	Jul 03, 2003

PATIROMER SORBITEX CALCIUM

POWDER;ORAL

VELTASSA

+	VIFOR PHARMA	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

+	NOVARTIS	EQ 400MG BASE **	N022465	002	Oct 19, 2009

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL

MACUGEN

+	BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023
	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022
BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022
	EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022
BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022
HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022
	EQ 500MG BASE/VIAL	A202111	002	May 25, 2022
	EQ 1GM BASE/VIAL	A202111	003	May 25, 2022
PHARMOBEDIENT	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023

SOLUTION;INTRAVENOUS

PEMETREXED DISODIUM

+	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022
+		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022
+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PEMETREXED DITROMETHAMINE				
POWDER;INTRAVENOUS				
PEMETREXED DITROMETHAMINE				
+ HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022
+	EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022
+	EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022
PEMIROLAST POTASSIUM				
SOLUTION/DROPS;OPHTHALMIC				
ALAMAST				
SANTEN	0.1%	N021079	001	Sep 24, 1999
PEMOLINE				
TABLET;ORAL				
CYLERT				
ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	
PEMOLINE				
ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000
TABLET, CHEWABLE;ORAL				
CYLERT				
ABBOTT	37.5MG	N017703	001	
PEMOLINE				
ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555	001	Feb 18, 2000
PENBUTOLOL SULFATE				
TABLET;ORAL				
LEVATOL				
+ ENDO OPERATIONS	10MG **	N018976	001	Dec 30, 1987
+	20MG **	N018976	004	Jan 05, 1989
PENICILLAMINE				
CAPSULE;ORAL				
CUPRIMINE				
VALEANT PHARMS INTL	125MG	N019853	002	
LUXZYLA				
ANI PHARMS	250MG	A209921	001	May 07, 2019
PENICILLAMINE				
APOTEX	250MG	A213310	001	Apr 28, 2020
TABLET;ORAL				
PENICILLAMINE				
TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020
PENICILLIN G BENZATHINE				
INJECTABLE;INJECTION				
BICILLIN L-A				
+ KING PHARMS LLC	300,000 UNITS/ML	N050141	003	
WYETH AYERST	300,000 UNITS/ML	N050131	001	
PERMAPEN				
CASPER PHARMA LLC	600,000 UNITS/ML	N060014	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN G BENZATHINE				
SUSPENSION;ORAL				
BICILLIN				
	WYETH AYERST	300,000 UNITS/5ML	N050126 002	
TABLET;ORAL				
BICILLIN				
	WYETH AYERST	200,000 UNITS	N050128 001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
BICILLIN C-R				
+	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138 002	
PENICILLIN G POTASSIUM				
FOR SOLUTION;ORAL				
PENICILLIN				
	TEVA	200,000 UNITS/5ML	A060307 002	
		400,000 UNITS/5ML	A060307 004	
PENICILLIN G POTASSIUM				
	MYLAN	200,000 UNITS/5ML	A060752 003	
		250,000 UNITS/5ML	A060752 002	
		400,000 UNITS/5ML	A060752 001	
	PUREPAC PHARM	250,000 UNITS/5ML	A061740 001	
		400,000 UNITS/5ML	A061740 002	
PENICILLIN-2				
	TEVA	250,000 UNITS/5ML	A060307 003	
PENTIDS '200'				
	APOTHECON	200,000 UNITS/5ML	A062149 001	
PENTIDS '400'				
	APOTHECON	400,000 UNITS/5ML	A062149 002	
PFIZERPEN G				
	PFIZER	400,000 UNITS/5ML	A060587 001	
INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
	APOTHECON	1,000,000 UNITS/VIAL	A060362 001	
		5,000,000 UNITS/VIAL	A060362 003	
		10,000,000 UNITS/VIAL	A060362 004	
		20,000,000 UNITS/VIAL	A060362 002	
	CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001	
		1,000,000 UNITS/VIAL	A060806 002	
		5,000,000 UNITS/VIAL	A060806 003	
		10,000,000 UNITS/VIAL	A060806 004	
	LILLY	200,000 UNITS/VIAL	A060384 004	
		500,000 UNITS/VIAL	A060384 003	
		1,000,000 UNITS/VIAL	A060384 002	
		5,000,000 UNITS/VIAL	A060384 001	
		20,000,000 UNITS/VIAL	A060384 005	
		20,000,000 UNITS/VIAL	A060601 001	
	PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001	
		5,000,000 UNITS/VIAL	A062003 002	
	PFIZER	20,000,000 UNITS/VIAL	A060074 003	
	SANDOZ	1,000,000 UNITS/VIAL **	A065079 001	Aug 30, 2002
	WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
		5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
		10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
		20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988
PFIZERPEN				
	PFIZER	1,000,000 UNITS/VIAL **	A060657 001	
TABLET;ORAL				
PENICILLIN G POTASSIUM				
	APOTHECON	250,000 UNITS	A060392 003	
	IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004	
	LILLY	250,000 UNITS	A060403 001	
	MYLAN	200,000 UNITS	A060781 001	
		250,000 UNITS	A060781 002	
		400,000 UNITS	A060781 003	
		500,000 UNITS	A060781 005	
		800,000 UNITS	A060781 004	
	PUREPAC PHARM	200,000 UNITS	A061588 001	
		250,000 UNITS	A061588 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN G POTASSIUM

TABLET;ORAL

PENICILLIN G POTASSIUM				
		400,000 UNITS	A061588 003	
	TEVA	200,000 UNITS	A060306 001	
		250,000 UNITS	A060306 002	
		400,000 UNITS	A060306 003	
		500,000 UNITS	A060306 004	
	WYETH AYERST	200,000 UNITS	A060413 001	
		250,000 UNITS	A060413 002	
		400,000 UNITS	A060413 003	
PENTIDS '200'				
	APOTHECON	200,000 UNITS	A062155 001	
PENTIDS '250'				
	APOTHECON	250,000 UNITS	A062155 002	
PENTIDS '400'				
	APOTHECON	400,000 UNITS	A060392 004	
		400,000 UNITS	A062155 003	
PENTIDS '800'				
	APOTHECON	800,000 UNITS	A060392 005	
		800,000 UNITS	A062155 004	
PFIZERPEN G				
	PFIZER	50,000 UNITS	A060075 001	
		100,000 UNITS	A060075 002	
		200,000 UNITS	A060075 003	
		250,000 UNITS	A060075 004	
		400,000 UNITS	A060075 005	
		800,000 UNITS	A060075 006	

PENICILLIN G PROCAINE

INJECTABLE;INJECTION

DURACILLIN A.S.				
	LILLY	300,000 UNITS/ML	A060093 001	
PENICILLIN G PROCAINE				
	CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001	
		600,000 UNITS/1.2ML	A060800 002	
	PARKE DAVIS	300,000 UNITS/ML	A062029 001	
	PFIZER	300,000 UNITS/VIAL	A060099 001	
		1,500,000 UNITS/VIAL	A060099 002	
PFIZERPEN-AS				
	PFIZER	300,000 UNITS/ML	A060286 001	
		600,000 UNITS/ML	A060286 002	

PENICILLIN G SODIUM

INJECTABLE;INJECTION

PENICILLIN G SODIUM				
	BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001	
	COPANOS	5,000,000 UNITS/VIAL	A061051 001	
	PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001	

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM				
	WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001	Sep 13, 1988

PENICILLIN V

FOR SUSPENSION;ORAL

V-CILLIN				
	LILLY	125MG/0.6ML	A060002 001	

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

BEEPEN-VK				
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001	
		EQ 250MG BASE/5ML	A062270 002	
BETAPEN-VK				
	APOTHECON	EQ 125MG BASE/5ML	A061149 001	
		EQ 250MG BASE/5ML	A061149 002	
LEDERCILLIN VK				
	LEDERLE	EQ 125MG BASE/5ML	A060136 001	
		EQ 250MG BASE/5ML	A060136 002	
PEN-VEE K				
	WYETH AYERST	EQ 125MG BASE/5ML	A060007 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL				
PEN-VEE K				
	EQ 250MG BASE/5ML		A060007 002	
PENAPAR-VK				
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001	
	EQ 250MG BASE/5ML		A062002 002	
PENICILLIN V POTASSIUM				
BELCHER PHARMS	EQ 125MG BASE/5ML		A061529 001	
	EQ 250MG BASE/5ML		A061529 002	
CHARTWELL RX	EQ 125MG BASE/5ML		A062981 001	Feb 10, 1989
	EQ 250MG BASE/5ML		A062981 002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML		A061624 002	
	EQ 250MG BASE/5ML		A061624 001	
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001	
	EQ 250MG BASE/5ML		A061758 002	
PFIZERPEN VK				
PFIZER	EQ 125MG BASE/5ML		A061815 001	
	EQ 250MG BASE/5ML		A061815 002	
V-CILLIN K				
LILLY	EQ 125MG BASE/5ML		A060004 001	
	EQ 250MG BASE/5ML		A060004 002	
VEETIDS				
APOTHECON	EQ 125MG BASE/5ML		A061410 001	
	EQ 250MG BASE/5ML		A061410 002	
VEETIDS '125'				
APOTHECON	EQ 125MG BASE/5ML		A061206 001	
	EQ 125MG BASE/5ML		A062153 001	
VEETIDS '250'				
APOTHECON	EQ 250MG BASE/5ML		A061206 002	
	EQ 250MG BASE/5ML		A062153 002	
TABLET;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 250MG BASE		A062273 001	
	EQ 500MG BASE		A062273 002	
BETAPEN-VK				
BRISTOL	EQ 250MG BASE		A061150 001	
	EQ 500MG BASE		A061150 002	
LEDERCILLIN VK				
LEDERLE	EQ 250MG BASE		A060134 001	
	EQ 500MG BASE		A060134 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE		A060006 001	
	EQ 250MG BASE		A060006 002	
	EQ 500MG BASE		A060006 003	
PENAPAR-VK				
PARKE DAVIS	EQ 250MG BASE		A062001 001	
	EQ 500MG BASE		A062001 002	
PENICILLIN V POTASSIUM				
BELCHER PHARMS	EQ 250MG BASE		A061528 001	
	EQ 500MG BASE		A061528 002	
IVAX SUB TEVA PHARMS	EQ 125MG BASE		A060518 001	
	EQ 250MG BASE		A060518 002	
	EQ 500MG BASE		A060518 003	
MYLAN	EQ 250MG BASE		A061530 001	
	EQ 500MG BASE		A061530 002	
PUREPAC PHARM	EQ 125MG BASE		A061571 001	
	EQ 250MG BASE		A061571 002	
	EQ 500MG BASE		A061571 003	
SANDOZ	EQ 250MG BASE		A064071 001	Nov 30, 1995
	EQ 500MG BASE		A064071 002	Nov 30, 1995
PFIZERPEN VK				
PFIZER	EQ 250MG BASE		A061836 001	
	EQ 500MG BASE		A061836 002	
UTICILLIN VK				
PHARMACIA AND UPJOHN	EQ 250MG BASE		A061651 001	
	EQ 500MG BASE		A061651 002	
V-CILLIN K				
LILLY	EQ 125MG BASE **		A060003 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN V POTASSIUM

TABLET;ORAL				
V-CILLIN K				
		EQ 250MG BASE **	A060003 002	
		EQ 500MG BASE **	A060003 003	
VEETIDS				
	APOTHECON	EQ 250MG BASE	A061411 001	
		EQ 500MG BASE	A061411 002	
VEETIDS '250'				
	APOTHECON	EQ 250MG BASE	A061164 001	
		EQ 250MG BASE	A062156 002	
VEETIDS '500'				
	APOTHECON	EQ 500MG BASE	A061164 002	
		EQ 500MG BASE	A062156 001	

PENTAGASTRIN

INJECTABLE;INJECTION				
PEPTAVLON				
+	WYETH AYERST	0.25MG/ML **	N017048 001	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION				
NEBUPENT				
	FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE;INJECTION				
PENTACARINAT				
	ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE				
	BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
	HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
	WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL				
TALWIN 50				
	SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	

PENTAZOCINE LACTATE

INJECTABLE;INJECTION				
TALWIN				
+	HOSPIRA	EQ 30MG BASE/ML	N016194 001	

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS				
PENTETATE CALCIUM TRISODIUM				
+	HAMELN	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **	N021749 001	Aug 11, 2004

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE;INJECTION				
YTTERBIUM YB 169 DTPA				
	3M	2mCi/ML	N017518 001	

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS				
PENTETATE ZINC TRISODIUM				
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **	N021751 001	Aug 11, 2004

PENTOBARBITAL

ELIXIR;ORAL				
NEMBUTAL				
	SCIEGEN PHARMS	18.2MG/5ML	A083244 001	

PENTOBARBITAL SODIUM

CAPSULE;ORAL				
NEMBUTAL SODIUM				
	EPIC PHARMA LLC	30MG	A084095 001	
		50MG	A084093 001	
		100MG	A083245 001	
PENTOBARBITAL SODIUM				
	LANNETT	50MG	A085937 001	
		100MG	A085915 001	
	VITARINE	100MG	A083284 001	
	WHITEWORTH TOWN PLSN	100MG	A083338 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENTOBARBITAL SODIUM				
CAPSULE;ORAL				
SODIUM PENTOBARBITAL				
ANABOLIC	100MG	A084590	001	
ELKINS SINN	100MG	A083368	001	
EVERYLIFE	100MG	A083259	001	
HALSEY	100MG	A084677	001	
IVAX SUB TEVA PHARMS	50MG	A083461	001	
	100MG	A083461	002	
PARKE DAVIS	100MG	A084156	001	
PERRIGO	100MG	A084560	001	
PUREPAC PHARM	100MG	A083301	001	
VALEANT PHARM INTL	100MG	A083264	001	
WATSON LABS	100MG	A085791	001	
WYETH AYERST	100MG	A083239	001	
INJECTABLE;INJECTION				
PENTOBARBITAL SODIUM				
ELKINS SINN	50MG/ML	A083270	001	
SODIUM PENTOBARBITAL				
WYETH AYERST	50MG/ML	A083261	001	
SUPPOSITORY;RECTAL				
NEMBUTAL				
SCIEGEN PHARMS	30MG	A083247	001	Jan 25, 1982
	60MG	A083247	002	Jan 25, 1982
	120MG	A083247	003	Jan 25, 1982
	200MG	A083247	004	Jan 25, 1982
TABLET;ORAL				
PENTOBARBITAL SODIUM				
VITARINE	100MG	A083285	001	
SODIUM PENTOBARBITAL				
NEXGEN PHARMA INC	100MG	A084238	001	
PENTOLINIUM TARTRATE				
INJECTABLE;INJECTION				
ANSOLYSEN				
WYETH AYERST	10MG/ML	N009372	001	
PENTOSTATIN				
INJECTABLE;INJECTION				
PENTOSTATIN				
RISING	10MG/VIAL	A203554	001	Sep 19, 2014
PENTOXIFYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
PENTOXIFYLLINE				
ANI PHARMS	400MG	A075107	001	Sep 04, 1998
	400MG	A075199	001	Sep 03, 1999
BAUSCH	400MG	A075028	001	Jul 20, 1998
HERITAGE	400MG	A074877	001	Jul 08, 1997
IMPAX LABS	400MG	A075093	001	Aug 10, 1999
PLIVA	400MG	A074874	001	May 25, 1999
PENTOXIL				
UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999
TRENTAL				
+ VALIDUS PHARMS	400MG **	N018631	001	Aug 30, 1984
PERFLUBRON				
LIQUID;ORAL				
IMAGENT				
ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993
PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE				
PASTE;TOPICAL				
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS				
US ARMY MED RES	50%;50%	N021084	001	Feb 17, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PERGOLIDE MESYLATE				
TABLET;ORAL				
PERGOLIDE MESYLATE				
IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003
	EQ 1MG BASE	A076094	003	Sep 04, 2003
STRIDES PHARMA	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988
PERINDOPRIL ERBUMINE				
TABLET;ORAL				
ACEON				
+ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993
+	4MG	N020184	002	Dec 30, 1993
+	8MG	N020184	003	Dec 30, 1993
PERINDOPRIL ERBUMINE				
ANI PHARMS	2MG	A078138	001	Nov 10, 2009
	4MG	A078138	002	Nov 10, 2009
	8MG	A078138	003	Nov 10, 2009
APOTEX	2MG	A090463	001	Aug 30, 2010
	4MG	A090463	002	Aug 30, 2010
	8MG	A090463	003	Aug 30, 2010
HIKMA	2MG	A090072	001	Nov 10, 2009
	4MG	A090072	002	Nov 10, 2009
	8MG	A090072	003	Nov 10, 2009
LUPIN LTD	2MG	A078263	001	Jan 27, 2010
	4MG	A078263	002	Jan 27, 2010
	8MG	A078263	003	Jan 27, 2010
PERMETHRIN				
CREAM;TOPICAL				
PERMETHRIN				
DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023
LOTION;TOPICAL				
NIX				
GLAXOSMITHKLINE	1% **	N019435	001	Mar 31, 1986
PERPHENAZINE				
CONCENTRATE;ORAL				
PERPHENAZINE				
PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001
TRILAFON				
SCHERING	16MG/5ML	N011557	001	
INJECTABLE;INJECTION				
TRILAFON				
SCHERING	5MG/ML	N011213	002	
SYRUP;ORAL				
TRILAFON				
SCHERING	2MG/5ML	N011294	002	
TABLET;ORAL				
PERPHENAZINE				
ANI PHARMS	2MG **	A089707	001	Sep 10, 1987
	4MG **	A089708	001	Sep 10, 1987
	8MG **	A089456	001	Sep 10, 1987
	16MG **	A089457	001	Sep 10, 1987
MYLAN	2MG	A206691	001	Apr 14, 2017
	4MG	A206691	002	Apr 14, 2017
	8MG	A206691	003	Apr 14, 2017
	16MG	A206691	004	Apr 14, 2017
TRILAFON				
+ SCHERING	2MG **	N010775	001	
+	4MG **	N010775	002	
+	8MG **	N010775	003	
+	16MG **	N010775	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PERPHENAZINE

TABLET, EXTENDED RELEASE;ORAL				
TRILAFON				
	SCHERING	8MG	N011361 002	

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL				
TURALIO				
+	DAIICHI SANKYO INC	EQ 200MG BASE	N211810 001	Aug 02, 2019

PHENACEMIDE

TABLET;ORAL				
PHENURONE				
+	ABBVIE	500MG **	N007707 001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL				
AZO GANTANOL				
+	ROCHE	100MG;500MG **	N013294 001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE				
	ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105 001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL				
AZO GANTRISIN				
+	ROCHE	50MG;500MG **	N019358 001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL				
PHENAZINE				
	MAST MM	35MG	A086523 001	
		35MG	A086524 001	
		35MG	A086525 001	
PHENDIMETRAZINE TARTRATE				
	SANDOZ	35MG	A085633 001	
		35MG	A085694 001	
		35MG	A085702 001	
	VIRTUS	35MG	A085695 001	
	VITARINE	35MG	A085634 001	
		35MG	A085645 001	
		35MG	A085670 001	
		35MG	A086403 001	
		35MG	A086408 001	
		35MG	A086410 001	
		35MG	A087424 001	
SPRX-3				
	SOLVAY	35MG	A085897 001	
STATOBEX				
	TEVA	35MG	A085507 001	
X-TROZINE				
	SHIRE RICHWOOD	35MG	A087394 001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE;ORAL				
BONTRIL				
	VALEANT	105MG	A088021 001	Sep 21, 1982
MELFIAT-105				
	NUMARK	105MG	A087487 001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
	GRAHAM DM	105MG	A087214 001	May 26, 1982
		105MG	A088020 001	Aug 16, 1982
		105MG	A088028 001	Aug 16, 1982
		105MG	A088062 001	Sep 13, 1982
		105MG	A088063 001	Sep 10, 1982
		105MG	A088111 001	Oct 18, 1982
	VIRTUS	105MG	A087378 001	
SPRX-105				
	NUMARK	105MG	A088024 001	Dec 22, 1982
X-TROZINE L.A.				
	SHIRE RICHWOOD	105MG	A087371 001	Aug 24, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE

TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655 001		
ALPHAZINE				
SANDOZ	35MG	A085034 001		
CAM-METRAZINE				
ABC HOLDING	35MG	A085511 001		
CAMALL	35MG	A085756 001		
CHARTWELL RX	35MG	A083922 001		
	35MG	A085318 001		
	35MG	A085320 001		
	35MG	A085321 001		
DI-METREX				
PVT FORM	35MG	A085698 001		
MELFIAT				
NUMARK	35MG	A083790 002		
METRA				
FOREST PHARMS	35MG	A083754 001		
PHENAZINE				
MAST MM	35MG	A087305 001		
PHENAZINE-35				
ABC HOLDING	35MG	A085512 001		
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644 001		
	35MG	A083684 001		
	35MG	A083686 001		
	35MG	A083687 001		
	35MG	A084831 001		
	35MG	A084834 001		
	35MG	A084835 001		
CHARTWELL RX	35MG	A085761 001		
	35MG	A085941 001	Jun 27, 1983	
FERNDALE LABS	35MG	A086834 001	Sep 15, 1983	
INWOOD LABS	35MG	A084740 001		
	35MG	A084741 001		
	35MG	A084742 001		
	35MG	A084743 001		
IVAX PHARMS	35MG	A085611 001		
	35MG	A085612 001		
IVAX SUB TEVA PHARMS	35MG	A083682 001		
KV PHARM	35MG	A084138 001		
	35MG	A084141 001		
	35MG	A085525 001		
MFG CHEMISTS	35MG	A085914 001		
MPP PHARMA	35MG	A203600 001	Dec 27, 2017	
NEXGEN PHARMA INC	35MG	A086020 001		
NUMARK	35MG	A083790 001		
PVT FORM	35MG	A085199 001		
	35MG	A085697 001		
SANDOZ	35MG	A085402 001		
	35MG	A085830 001		
	35MG	A086370 001		
SOLVAY	35MG	A083993 001		
UPSHER SMITH LABS	35MG	A084399 001		
USL PHARMA	35MG	A083805 001		
	35MG	A084398 001		
VIRTUS	35MG	A085497 001		
	35MG	A086365 001		
VITARINE	35MG	A085519 001		
	35MG	A086005 001		
	35MG	A086106 001		
WATSON LABS	35MG	A085767 001		
	35MG	A085768 001		
	35MG	A085770 001		
	35MG	A085773 001		
PLEGINE				
WYETH AYERST	35MG **	N012248 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE

TABLET;ORAL				
STATOBEX				
	TEVA	35MG	A086013 001	
STATOBEX-G				
	TEVA	35MG	A085095 001	
X-TROZINE				
	SHIRE RICHWOOD	35MG	A086550 001	
		35MG	A086551 001	
		35MG	A086552 001	
		35MG	A086553 001	
		35MG	A086554 001	

PHENINDIONE

TABLET;ORAL				
HEDULIN				
	SANOFI AVENTIS US	50MG	N008767 002	

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL				
PRELUDIN				
	BOEHRINGER INGELHEIM	25MG	N010460 005	
TABLET, EXTENDED RELEASE;ORAL				
PRELUDIN				
	BOEHRINGER INGELHEIM	50MG	N011752 004	
		75MG	N011752 003	

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIBENZYLINE				
+	ADVANZ PHARMA	10MG	N008708 001	
PHENOXYBENZAMINE HYDROCHLORIDE				
	HIKMA	10MG	A201050 001	Jul 16, 2012

PHENPROCOUMON

TABLET;ORAL				
LIQUAMAR				
	ORGANON USA INC	3MG	N011228 001	

PHENSUXIMIDE

CAPSULE;ORAL				
MILONTIN				
	PARKE DAVIS	500MG	N008855 004	

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL				
ADIPEX-P				
+	TEVA	37.5MG	A088023 001	Aug 02, 1983
FASTIN				
	GLAXOSMITHKLINE	30MG **	N017352 001	
OBESTIN-30				
	FERNDALE LABS	30MG	A087144 001	
OBY-TRIM				
	SHIRE RICHWOOD	30MG	A087764 001	Mar 18, 1982
ONA-MAST				
	MAST MM	30MG	A086511 001	
		30MG	A086516 001	
PHENTERMINE HYDROCHLORIDE				
	ABC HOLDING	30MG	A085411 001	
	ABLE	15MG	A040497 001	Mar 13, 2003
		30MG	A040403 001	Aug 30, 2001
		30MG	A040427 001	Aug 30, 2001
	BARR	15MG	A090591 001	Mar 18, 2010
		30MG	A090591 002	Mar 18, 2010
	CAMALL	15MG	A086735 001	
		30MG	A087226 001	
	CHARTWELL RX	18.75MG	A088576 001	May 23, 1984
		30MG	A085417 001	
		30MG	A086732 002	
		30MG	A087215 001	
		37.5MG	A087915 001	Dec 22, 1983
		37.5MG	A087918 001	Dec 22, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL					
PHENTERMINE HYDROCHLORIDE					
		37.5MG	A087930	001	Oct 14, 1983
		37.5MG	A088610	001	Jun 04, 1984
		37.5MG	A088611	001	Jun 04, 1984
		37.5MG	A088625	001	Aug 23, 1984
	DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
		30MG	A040227	001	Jun 18, 1997
		30MG	A040448	001	Jan 22, 2003
		37.5MG	A040228	001	Jun 19, 1997
	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014
		30MG	A202858	002	Feb 14, 2014
		30MG	A204414	001	May 05, 2014
		37.5MG	A202846	001	Feb 05, 2014
	IVAX PHARMS	30MG	A086329	001	
	LANNETT	15MG	A087022	002	Jan 20, 2012
		30MG	A087022	001	Feb 03, 1983
	LANNETT CO INC	30MG	A091359	001	Jul 16, 2010
		37.5MG	A201961	001	Jul 20, 2011
	SANDOZ	30MG	A087208	001	
		30MG	A087223	001	
		37.5MG	A088414	001	Oct 19, 1983
	SUN PHARM INDUSTRIES	30MG	A040525	001	Oct 23, 2003
		37.5MG	A040527	001	Oct 23, 2003
	TEVA	30MG	A086911	001	
		30MG	A087126	001	
		30MG	A087777	001	Nov 01, 1985
		30MG	A088612	001	Apr 04, 1984
		30MG	A088613	001	Apr 09, 1984
		30MG	A088614	001	Apr 09, 1984
	TG UNITED INC	30MG	A040083	001	Mar 07, 1997
	UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
		30MG	A088430	001	Mar 27, 1984
	USL PHARMA	30MG	A088797	001	Dec 10, 1984
	VITARINE	30MG	A087202	001	
		30MG	A087235	001	
	WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET;ORAL					
ONA-MAST					
	MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE					
	ABLE	37.5MG	A040402	001	Aug 30, 2001
	ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
	BARR	37.5MG	A090470	001	Aug 31, 2009
	CHARTWELL RX	8MG	A083923	001	
		8MG	A085319	001	
		37.5MG	A087805	001	Dec 06, 1982
		37.5MG	A088596	001	Apr 04, 1984
	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014
	IVAX PHARMS	8MG	A085553	001	
	LANNETT	37.5MG	A040555	001	Apr 15, 2005
	NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012
	SANDOZ	8MG	A085671	001	
		8MG	A085689	001	
	SANDOZ INC	30MG	A088605	001	Sep 28, 1987
	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007
+	USL PHARMA	8MG	A083804	001	
		37.5MG	A088910	001	Jul 17, 1985
		37.5MG	A088917	001	Jul 17, 1985
	VITARINE	8MG	A086453	001	
		8MG	A086456	001	
	WATSON LABS	8MG	A085739	001	
TORA					
	SOLVAY	8MG	A084035	001	
WILPO					
+	SANDOZ	8MG **	N012737	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE HYDROCHLORIDE				
TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
CITIUS PHARMS	15MG **	N202088	001	Jun 13, 2011
	30MG **	N202088	002	Jun 13, 2011
	37.5MG **	N202088	003	Mar 27, 2012
PHENTERMINE RESIN COMPLEX				
CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
UCB INC	EQ 15MG BASE **	N011613	004	
	EQ 30MG BASE **	N011613	002	
PHENTERMINE RESIN 30				
QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
LANNETT CO INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	EQ 30MG BASE	A040872	002	Jul 28, 2011
PHENTOLAMINE MESYLATE				
INJECTABLE;INJECTION				
REGITINE				
+ NOVARTIS	5MG/VIAL **	N008278	003	
PHENYL AMINOSALICYLATE				
POWDER;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	50%	N011695	002	
TABLET;ORAL				
PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	500MG	N011695	003	
PHENYLBUTAZONE				
CAPSULE;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087260	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	009	
PHENYLBUTAZONE				
CHARTWELL RX	100MG	A087774	001	Jun 16, 1982
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994	001	Dec 04, 1985
WATSON LABS	100MG	A087756	001	Dec 17, 1982
TABLET;ORAL				
AZOLID				
SANOFI AVENTIS US	100MG	A087091	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	008	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A084339	001	
SUN PHARM INDUSTRIES	100MG	A088863	001	Dec 04, 1985
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982
PHENYLEPHRINE HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
BIORPHEN				
+ DR REDDYS LABS SA	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021
PHENYLEPHRINE HYDROCHLORIDE				
ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020
	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020
	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020
HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024
	50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024
	100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024
PH HEALTH	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018
VAZCULEP				
+ EXELA PHARMA	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014
+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014
+	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC				
+ ANI PHARMS	5MG/5ML;6.25MG/5ML **	N008604	003	Apr 02, 1984
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE				
HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014
PHERAZINE VC				
HALSEY	5MG/5ML;6.25MG/5ML	A088868	001	Mar 02, 1987
PROMETH VC PLAIN				
+ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984
PROMETHAZINE VC PLAIN				
CENCI	5MG/5ML;6.25MG/5ML	A088815	001	Nov 22, 1985
XTTRIUM LABS INC	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

PREFRIN-A				
ALLERGAN	0.12%;0.1%	N007953	001	

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED;OPHTHALMIC

MYDCOMBI				
+ EYENOVIA	2.5%;1%	N215352	001	May 05, 2023

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-30				
VIATRIS	30MG/5ML	N008762	002	
PHENYTOIN				
ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992
PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002
VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001
	125MG/5ML	A040342	002	Aug 18, 2005

PHENYTOIN SODIUM

CAPSULE;ORAL

DIPHENYLAN SODIUM				
CHARTWELL MOLECULAR	30MG PROMPT	A080857	001	
	100MG PROMPT	A080857	002	
EXTENDED PHENYTOIN SODIUM				
ANI PHARMS	100MG EXTENDED	A040435	001	Jun 20, 2003
	100MG EXTENDED	A089441	001	Dec 18, 1986
LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019
MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998
SUN PHARM INDS	200MG EXTENDED	A040731	001	Jun 30, 2008
	300MG EXTENDED	A040731	002	Jun 30, 2008
SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006
UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022
WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007
WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008
PHENYTEX				
WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984
PHENYTOIN SODIUM				
PHARMERAL	100MG PROMPT	A085435	001	
WATSON LABS	100MG PROMPT	A085894	001	
PROMPT PHENYTOIN SODIUM				
ANI PHARMS	100MG PROMPT	A080259	001	
WATSON LABS	100MG PROMPT	A080905	001	

INJECTABLE;INJECTION

DILANTIN				
PARKE DAVIS	50MG/ML	N010151	001	
PHENYTOIN SODIUM				
AM REGENT	50MG/ML	A040781	001	Dec 04, 2007
FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987
	50MG/ML	A089744	001	Dec 18, 1987
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENYTOIN SODIUM					
INJECTABLE;INJECTION					
PHENYTOIN SODIUM					
	WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
	WATSON LABS	50MG/ML	A085434	001	
PHYTONADIONE					
INJECTABLE;INJECTION					
AQUAMEPHYTON					
+	PAI HOLDINGS PHARM	1MG/0.5ML **	N012223	002	
+		10MG/ML **	N012223	001	
KONAKION					
	ROCHE	1MG/0.5ML	N011745	001	
		10MG/ML	N011745	003	
PHYTONADIONE					
	CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022
		10MG/ML	A212424	002	Apr 22, 2022
	GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
		10MG/ML	A084060	002	
VITAMIN K1					
	HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983
TABLET;ORAL					
MEPHYTON					
+	BAUSCH	5MG **	N010104	003	
PHYTONADIONE					
	HIKMA	5MG	A212112	001	Dec 19, 2024
PILOCARPINE					
INSERT, EXTENDED RELEASE;OPHTHALMIC					
OCUSERT PILO-20					
	EPIC PHARMA LLC	5MG	N017431	001	
OCUSERT PILO-40					
	EPIC PHARMA LLC	11MG	N017548	001	
PILOCARPINE HYDROCHLORIDE					
GEL;OPHTHALMIC					
PILOPINE HS					
	ALCON	4%	N018796	001	Oct 01, 1984
PIMAVANSERIN TARTRATE					
CAPSULE;ORAL					
PIMAVANSERIN					
	MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024
	ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024
TABLET;ORAL					
NUPLAZID					
+	ACADIA PHARMS INC	EQ 17MG BASE **	N207318	001	Apr 29, 2016
PIMAVANSERIN					
	ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024
PIMOZIDE					
TABLET;ORAL					
ORAP					
+	TEVA	1MG **	N017473	003	Aug 27, 1997
+		2MG **	N017473	001	Jul 31, 1984
PINACIDIL					
CAPSULE, EXTENDED RELEASE;ORAL					
PINDAC					
	LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
		25MG	N019456	002	Dec 28, 1989
PINDOLOL					
TABLET;ORAL					
PINDOLOL					
	COSETTE	5MG	A073661	001	Oct 31, 1993
		5MG	A073687	001	Feb 26, 1993
		5MG	A074123	001	Apr 17, 1997
		10MG	A073661	002	Oct 31, 1993
		10MG	A073687	002	Feb 26, 1993
		10MG	A074123	002	Apr 17, 1997
	MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
		10MG	A074018	001	Sep 24, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PINDOLOL

TABLET;ORAL					
PINDOLOL					
	NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
		10MG	A074474	002	Oct 28, 1996
	PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
		10MG	A074125	002	Apr 28, 1993
	WATSON LABS	5MG	A074437	001	Feb 27, 1995
		10MG	A074437	002	Feb 27, 1995
	ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017
		10MG	A209866	002	Aug 18, 2017
VISKEN					
+	NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+		10MG **	N018285	002	Sep 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL					
PIOGLITAZONE HYDROCHLORIDE					
	CHARTWELL RX	EQ 15MG BASE	A078383	001	Mar 12, 2013
		EQ 30MG BASE	A078383	002	Mar 12, 2013
		EQ 45MG BASE	A078383	003	Mar 12, 2013
	PHARMOBEDIENT	EQ 15MG BASE	A076801	001	Aug 17, 2012
		EQ 15MG BASE	A078472	001	Feb 13, 2013
		EQ 30MG BASE	A076801	002	Aug 17, 2012
		EQ 30MG BASE	A078472	002	Feb 13, 2013
		EQ 45MG BASE	A076801	003	Aug 17, 2012
		EQ 45MG BASE	A078472	003	Feb 13, 2013
	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013
		EQ 30MG BASE	A091298	002	Feb 13, 2013
		EQ 45MG BASE	A091298	003	Feb 13, 2013

PIPECURONIUM BROMIDE

INJECTABLE;INJECTION					
ARDUAN					
	ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990

PIPERACETAZINE

TABLET;ORAL					
QUIDE					
	DOW PHARM	10MG	N013615	001	
		25MG	N013615	002	

PIPERACILLIN SODIUM

INJECTABLE;INJECTION					
PIPRACIL					
	WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750	001	Oct 13, 1987
+		EQ 2GM BASE/VIAL **	N050545	002	
		EQ 3GM BASE/VIAL	A062750	002	Oct 13, 1987
+		EQ 3GM BASE/VIAL **	N050545	003	
		EQ 4GM BASE/VIAL	A062750	003	Oct 13, 1987
+		EQ 4GM BASE/VIAL **	N050545	004	
+		EQ 40GM BASE/VIAL **	N050545	006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION					
PIPERACILLIN AND TAZOBACTAM					
	ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019
	EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023
		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023
	FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018
	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009
		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009
ZOSYN					
+	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **	N050684	001	Oct 22, 1993
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **	N050684	002	Oct 22, 1993
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **	N050684	003	Oct 22, 1993
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **	N050684	004	Oct 22, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIPERAZINE CITRATE

SYRUP;ORAL				
ANTEPAR				
	GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL				
	SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE				
	BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE				
	ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
	LANNETT	EQ 500MG BASE/5ML	A080963 001	
	LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL				
	SOLVAY	EQ 500MG BASE/5ML	A080992 001	
TABLET;ORAL				
ANTEPAR				
	GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE				
	IMPAX LABS	EQ 250MG BASE	A080874 001	

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL				
RID MOUSSE				
	BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000

PIPOBROMAN

TABLET;ORAL				
VERCYTE				
	ABBOTT	10MG	N016245 001	
		25MG	N016245 002	

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION				
MAXAIR				
	BAUSCH	EQ 0.2MG BASE/INH	N019009 001	Dec 30, 1986
		EQ 0.2MG BASE/INH	N020014 001	Nov 30, 1992

PIRFENIDONE

CAPSULE;ORAL				
PIRFENIDONE				
	APOTEX	267MG	A212687 001	Jun 09, 2023
	CHARTWELL RX	267MG	A212404 001	Aug 28, 2023
TABLET;ORAL				
ESBRIET				
+	LEGACY PHARMA	534MG **	N208780 002	Jan 11, 2017
PIRFENIDONE				
	CHARTWELL RX	267MG	A212403 001	Aug 23, 2023
		801MG	A212403 002	Aug 23, 2023

PIROXICAM

CAPSULE;ORAL				
PIROXICAM				
	BRECKENRIDGE	10MG	A208991 001	Feb 21, 2018
		20MG	A208991 002	Feb 21, 2018
	CYCLE	10MG	A073651 001	Feb 26, 1993
		20MG	A073651 002	Feb 26, 1993
	EGIS	10MG	A074808 001	Jul 08, 1997
		20MG	A074808 002	Jul 08, 1997
	FLAMINGO PHARMS	10MG	A207938 001	Sep 09, 2016
		20MG	A207938 002	Sep 09, 2016
	HIKMA	10MG	A209256 001	Aug 11, 2017
		20MG	A209256 002	Aug 11, 2017
	IVAX SUB TEVA PHARMS	10MG	A074148 001	Jun 03, 1996
		20MG	A074148 002	Jun 03, 1996
	MYLAN	10MG	A074043 001	Sep 22, 1992
		20MG	A074043 002	Sep 22, 1992
	PHARMOBEDIENT	10MG	A074102 001	Jul 31, 1992
		20MG	A074102 002	Jul 31, 1992
	SCS	10MG	A074036 001	May 29, 1992
		20MG	A074036 002	May 29, 1992
	STRIDES PHARMA	10MG	A206136 001	Jun 20, 2017
		20MG	A206136 002	Jun 20, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIROXICAM				
CAPSULE;ORAL				
PIROXICAM				
SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008
	20MG	A073536	001	Mar 12, 1993
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995
PITAVASTATIN MAGNESIUM				
TABLET;ORAL				
ZYPITAMAG				
+ MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017
PITAVASTATIN SODIUM				
TABLET;ORAL				
NIKITA				
+ LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017
+	EQ 2MG BASE	N209875	002	Aug 04, 2017
+	EQ 4MG BASE	N209875	003	Aug 04, 2017
PLERIXAFOR				
SOLUTION;SUBCUTANEOUS				
PLERIXAFOR				
ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023
PLICAMYCIN				
INJECTABLE;INJECTION				
MITHRACIN				
PFIZER	2.5MG/VIAL	N050109	001	
PODOFILOX				
SOLUTION;TOPICAL				
PODOFILOX				
BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010
POLIDOCANOL				
SOLUTION;INTRAVENOUS				
VARITHENA				
+ PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017
POLYESTRADIOL PHOSPHATE				
INJECTABLE;INJECTION				
ESTRADURIN				
WYETH AYERST	40MG/AMP	N010753	001	
POLYETHYLENE GLYCOL 3350				
FOR SOLUTION;ORAL				
GLYCOLAX				
LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004
	17GM/PACKET	A090600	001	Oct 06, 2009
	17GM/SCOOPFUL	A090600	002	Oct 06, 2009
POLYETHYLENE GLYCOL 3350				
BRECKENRIDGE PHARM	17GM/SCOOPFUL	A077736	001	May 26, 2006
NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006
PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006
	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
STRIDES PHARMA INTL	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE				
FOR SOLUTION;ORAL				
LAX-LYTE WITH FLAVOR PACKS				
L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A079232	001	Feb 25, 2010
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
EXTROVIS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010
SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2	A202060	001	Mar 08, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL					
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE		GM/BOT			
TRILYTE					
	AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL					
CLENZ-LYTE					
	PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010
SOLUTION;ORAL					
OCL					
	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL					
COLYTE					
	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET **	N018983	005	Oct 26, 1984
		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET **	N018983	004	Oct 26, 1984
		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT **	N018983	010	Jan 31, 1989
		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT **	N018983	007	Jun 12, 1987
		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET **	N018983	006	Oct 26, 1984
COLYTE WITH FLAVOR PACKS					
	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998
COLYTE-FLAVORED					
	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT **	N018983	008	Nov 14, 1991
		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT **	N018983	009	Nov 14, 1991
GOLYTELY					
+	AZURITY	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992
PEG 3350 AND ELECTROLYTES					
	EXTROVIS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES					
	PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010
FOR SUSPENSION;ORAL					
CO-LAV					
	VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992
COLOVAGE					
	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988
E-Z-EM PREP LYTE					
	E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278	001	Nov 21, 1988
GLYCOPREP					
	GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319	001	Dec 23, 1988
GO-EVAC					
	VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992
PEG-LYTE					
	SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098	001	Aug 31, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYMYXIN B SULFATE				
INJECTABLE;INJECTION				
AEROSPORIN				
	GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036 001	
POLYMYXIN B SULFATE				
	HIKMA	EQ 500,000 UNITS BASE/VIAL	A060716 001	
	PHARMOBEDIENT	EQ 500,000 UNITS BASE/VIAL	A063000 001	Sep 30, 1994
	RISING	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011
POWDER;FOR RX COMPOUNDING				
POLY-RX				
	X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
POLYMYXIN B SULFATE				
	PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983
POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE				
SOLUTION/DROPS;OPHTHALMIC				
POLYTRIM				
+	ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML **	N050567 001	Oct 20, 1988
POLYTHIAZIDE				
TABLET;ORAL				
RENESE				
	PFIZER	1MG	N012845 001	
		2MG	N012845 002	
		4MG	N012845 003	
POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
MINIZIDE				
	PFIZER	0.5MG;EQ 1MG BASE	N017986 001	
		0.5MG;EQ 2MG BASE	N017986 002	
		0.5MG;EQ 5MG BASE	N017986 003	
POLYTHIAZIDE; RESERPINE				
TABLET;ORAL				
RENESE-R				
	PFIZER	2MG;0.25MG	N013636 001	
POMALIDOMIDE				
CAPSULE;ORAL				
POMALIDOMIDE				
	APOTEX	1MG	A210164 001	Jun 11, 2024
		2MG	A210164 002	Jun 11, 2024
		3MG	A210164 003	Jun 11, 2024
		4MG	A210164 004	Jun 11, 2024
	BRECKENRIDGE	1MG	A210111 001	Oct 30, 2020
		2MG	A210111 002	Oct 30, 2020
		3MG	A210111 003	Oct 30, 2020
		4MG	A210111 004	Oct 30, 2020
	EUGIA PHARMA	1MG	A210249 001	Oct 30, 2020
		2MG	A210249 002	Oct 30, 2020
		3MG	A210249 003	Oct 30, 2020
		4MG	A210249 004	Oct 30, 2020
	HETERO LABS LTD V	1MG	A210236 001	Sep 26, 2024
		2MG	A210236 002	Sep 26, 2024
		3MG	A210236 003	Sep 26, 2024
		4MG	A210236 004	Sep 26, 2024
	MYLAN	1MG	A210275 001	Jan 26, 2022
		2MG	A210275 002	Jan 26, 2022
		3MG	A210275 003	Jan 26, 2022
		4MG	A210275 004	Jan 26, 2022
	TEVA PHARMS USA	1MG	A209956 001	May 04, 2022
		2MG	A209956 002	May 04, 2022
		3MG	A209956 003	May 04, 2022
		4MG	A209956 004	May 04, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PONATINIB HYDROCHLORIDE				
TABLET;ORAL				
PONATINIB HYDROCHLORIDE				
APOTEX	EQ 15MG BASE	A215893	001	Jul 14, 2023
	EQ 45MG BASE	A215893	002	Jul 14, 2023
POSACONAZOLE				
TABLET, DELAYED RELEASE;ORAL				
NOXAFIL				
+ MERCK SHARP DOHME	100MG **	N205053	001	Nov 25, 2013
POSACONAZOLE				
ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022
POTASSIUM AMINOSALICYLATE				
CAPSULE;ORAL				
PASKALIUM				
GLENWOOD	500MG	N009395	004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
HEXCEL	100%	A080098	001	
TABLET;ORAL				
PASKALIUM				
GLENWOOD	1GM	N009395	003	
POTASSIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
SAVAGE LABS	8MEQ	A073398	001	Jan 28, 1992
	10MEQ	A072427	001	Mar 28, 1990
KLOR-CON				
UPSHER SMITH LABS	8MEQ	A203106	001	Jul 10, 2015
	10MEQ	A203106	002	Jul 10, 2015
MICRO-K				
+ NESHER PHARMS	8MEQ **	N018238	001	
MICRO-K 10				
+ NESHER PHARMS	10MEQ **	N018238	002	May 14, 1984
POTASSIUM CHLORIDE				
CHARTWELL MOLECULAR	8MEQ	A204210	001	Mar 28, 2016
	10MEQ	A204210	002	Mar 28, 2016
GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016
LUPIN LTD	8MEQ	A203002	001	Dec 18, 2015
	10MEQ	A203002	002	Dec 18, 2015
NESHER PHARMS	10MEQ	A070980	001	Feb 17, 1987
PH HEALTH	8MEQ	A202886	001	Dec 26, 2013
	10MEQ	A202886	002	Dec 26, 2013
STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015
	10MEQ	A205549	002	Dec 08, 2015
TEVA	8MEQ	A073531	001	Apr 26, 1996
	10MEQ	A073532	001	Apr 26, 1996
TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016
	10MEQ	A201944	002	Mar 04, 2016
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
+ KV PHARM	20MEQ/PACKET **	N019561	003	Aug 26, 1988
INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
+ ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
	2MEQ/ML	A085499	001	
EPIC PHARMA LLC	2MEQ/ML	A088286	001	Sep 05, 1985
+ FRESENIUS KABI USA	2MEQ/ML	A080225	001	
	2MEQ/ML	A087817	001	Oct 20, 1982
	3MEQ/ML	A080225	003	
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE

INJECTABLE;INJECTION					
POTASSIUM CHLORIDE					
		3MEQ/ML	A086219	003	
		3MEQ/ML	A086220	001	
		4MEQ/ML	A086219	004	
	HOSPIRA	1MEQ/ML	A080205	003	
		1MEQ/ML	A083345	003	
		1.5MEQ/ML	A083345	001	
		2MEQ/ML	A083345	002	
		2.4MEQ/ML	A080205	004	
		3.2MEQ/ML	A080205	005	
	INTL MEDICATION	2MEQ/ML	A083163	001	
	LILLY	2MEQ/ML	N007865	002	
	LUITPOLD	2MEQ/ML	A080221	001	
		2MEQ/ML	A080736	001	
		2MEQ/ML	A087584	001	
		2MEQ/ML	A087585	001	
	MILES	1MEQ/ML	A080195	002	
		2MEQ/ML	A080195	001	
		3MEQ/ML	A080195	003	
		4MEQ/ML	A080195	004	
	PHARMA SERVE NY	2MEQ/ML	A086297	001	
		2MEQ/ML	A087362	001	Mar 08, 1983
	WATSON LABS	2MEQ/ML	A086208	001	
		2MEQ/ML	A089163	001	Mar 10, 1988
		2MEQ/ML	A089421	001	Jan 02, 1987
		3MEQ/ML	A086210	001	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
+	OTSUKA ICU MEDCL	2.24GM/100ML	N020161	003	Aug 11, 1998
SOLUTION;ORAL					
POTASSIUM CHLORIDE					
	STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022
	TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022
		40MEQ/15ML	A214076	002	Jan 26, 2022
TABLET, EXTENDED RELEASE;ORAL					
K+10					
	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8					
	FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
K-TAB					
+	ABBVIE	8MEQ **	N018279	002	Aug 01, 1988
+		10MEQ **	N018279	001	
+		20MEQ **	N018279	003	Nov 25, 2013
KAON CL					
	SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10					
	SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX					
	APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE					
	AMNEAL	10MEQ	A212861	001	May 08, 2020
		15MEQ	A212861	002	May 08, 2020
		20MEQ	A212861	003	May 08, 2020
	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021
		15MEQ	A214728	002	Mar 31, 2021
		20MEQ	A214728	003	Mar 31, 2021
	BRECKENRIDGE	10MEQ	A213588	001	Aug 21, 2020
		20MEQ	A213588	002	Aug 21, 2020
	CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019
		15MEQ	A206630	002	Mar 29, 2019
		20MEQ	A206630	003	Mar 29, 2019
		20MEQ	A210098	001	Apr 26, 2019
	COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
+	SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+		20MEQ **	N019439	001	Jun 13, 1986
	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016
		10MEQ	A207528	002	Aug 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
POTASSIUM CHLORIDE				
	STRIDES PHARMA	8MEQ	A206881 001	Jan 22, 2019
		10MEQ	A206881 002	Jan 22, 2019
		10MEQ	A210097 001	Jun 17, 2019
SLOW-K				
	NOVARTIS	8MEQ	N017476 002	
TEN-K				
	NOVARTIS	10MEQ	N019381 001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	37MG/100ML;900MG/100ML	N019708 001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	75MG/100ML;900MG/100ML	N019708 002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	110MG/100ML;900MG/100ML	N019708 003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	220MG/100ML;900MG/100ML	N019708 005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
+	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648 003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	300MG/100ML;900MG/100ML	N019708 006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%				
	BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648 004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
	B BRAUN	75MG/100ML;900MG/100ML	N018722 001	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
	B BRAUN	150MG/100ML;900MG/100ML	N018722 002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
	B BRAUN	220MG/100ML;900MG/100ML	N018722 003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	300MG/100ML;900MG/100ML	N018722 004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE;INJECTION				
THAM-E				
	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025 001	

POTASSIUM CITRATE

FOR SOLUTION;ORAL				
POTASSIUM CITRATE				
+	UT SW MEDCTR	10MEQ/PACKET **	N019647 002	Oct 13, 1988
+		20MEQ/PACKET **	N019647 001	Oct 13, 1988
TABLET, EXTENDED RELEASE;ORAL				
POTASSIUM CITRATE				
	TORRENT	5MEQ	A213986 001	Feb 06, 2024
		10MEQ	A213986 002	Feb 06, 2024
		15MEQ	A213986 003	Feb 06, 2024

POTASSIUM IODIDE

SOLUTION;ORAL				
POTASSIUM IODIDE				
+	ROXANE	1GM/ML **	N018551 001	Feb 19, 1982
THYROSHIELD				
	ARCO PHARMS LLC	65MG/ML	A077218 001	Jan 12, 2005
TABLET;ORAL				
THYRO-BLOCK				
	MEDA PHARMS	130MG	N018307 001	

POTASSIUM PERCHLORATE

CAPSULE;ORAL				
PERCHLORACAP				
	MALLINCKRODT	200MG	N017551 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC					
SOLUTION;INTRAVENOUS					
POTASSIUM PHOSPHATES					
+	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019
POVIDONE-IODINE					
SOLUTION;TOPICAL					
E-Z PREP					
	CLINIPAD	10%	N019382	001	Jul 25, 1989
SPONGE;TOPICAL					
E-Z PREP					
	CLINIPAD	5%	N019382	002	Jul 25, 1989
E-Z PREP 220					
	CLINIPAD	5%	N019382	003	Jul 25, 1989
E-Z SCRUB 201					
+	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
E-Z SCRUB 241					
+	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987
PRALIDOXIME CHLORIDE					
INJECTABLE;INJECTION					
PRALIDOXIME CHLORIDE					
	BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982
SOLUTION;INTRAMUSCULAR					
PRALIDOXIME CHLORIDE (AUTOINJECTOR)					
+	MERIDIAN MEDCL TECHN	600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983
TABLET;ORAL					
PROTOPAM CHLORIDE					
	WYETH AYERST	500MG	N014122	002	
PRAMIPEXOLE DIHYDROCHLORIDE					
TABLET;ORAL					
MIRAPEX					
+	BOEHRINGER INGELHEIM	0.125MG **	N020667	001	Jul 01, 1997
+		0.25MG **	N020667	002	Jul 01, 1997
+		0.5MG **	N020667	006	Feb 12, 1998
+		0.75MG **	N020667	007	Jul 30, 2007
+		1MG **	N020667	003	Jul 01, 1997
		1.25MG	N020667	004	Jul 01, 1997
+		1.5MG **	N020667	005	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE					
	ALEMBIC	0.125MG	A078894	001	Oct 08, 2010
		0.25MG	A078894	002	Oct 08, 2010
		0.5MG	A078894	003	Oct 08, 2010
		1MG	A078894	004	Oct 08, 2010
		1.5MG	A078894	005	Oct 08, 2010
	CHARTWELL RX	0.125MG	A090241	001	Oct 08, 2010
		0.25MG	A090241	002	Oct 08, 2010
		0.5MG	A090241	003	Oct 08, 2010
		0.75MG	A090241	004	Oct 08, 2010
		1MG	A090241	005	Oct 08, 2010
		1.5MG	A090241	006	Oct 08, 2010
	HERITAGE PHARMA AVET	0.125MG	A077724	001	Feb 19, 2008
		0.125MG	A078551	001	Oct 08, 2010
		0.125MG	A091254	001	Nov 30, 2010
		0.25MG	A077724	002	Feb 19, 2008
		0.25MG	A078551	002	Oct 08, 2010
		0.25MG	A091254	002	Nov 30, 2010
		0.5MG	A077724	003	Feb 19, 2008
		0.5MG	A078551	003	Oct 08, 2010
		0.5MG	A091254	003	Nov 30, 2010
		0.75MG	A091254	004	Nov 30, 2010
		1MG	A077724	004	Feb 19, 2008
		1MG	A078551	004	Oct 08, 2010
		1MG	A091254	005	Nov 30, 2010
		1.5MG	A077724	005	Feb 19, 2008
		1.5MG	A078551	005	Oct 08, 2010
		1.5MG	A091254	006	Nov 30, 2010
	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
		0.25MG	A202164	002	Sep 20, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
	0.5MG		A202164	003	Sep 20, 2012
	1MG		A202164	004	Sep 20, 2012
	1.5MG		A202164	005	Sep 20, 2012
NATCO	0.125MG		A077854	001	Oct 08, 2010
	0.25MG		A077854	002	Oct 08, 2010
	0.5MG		A077854	003	Oct 08, 2010
	1MG		A077854	004	Oct 08, 2010
	1.5MG		A077854	005	Oct 08, 2010
NATCO PHARMA	0.75MG		A090764	001	Apr 09, 2010
PHARMOBEDIENT	0.125MG		A091450	001	Oct 08, 2010
	0.25MG		A091450	002	Oct 08, 2010
	0.5MG		A091450	003	Oct 08, 2010
	1MG		A091450	004	Oct 08, 2010
	1.5MG		A091450	005	Oct 08, 2010
SANDOZ	0.125MG		A090190	001	Jul 06, 2010
	0.25MG		A090190	002	Jul 06, 2010
	0.5MG		A090190	003	Jul 06, 2010
	0.75MG		A090190	006	Oct 08, 2010
	1MG		A090190	004	Jul 06, 2010
	1.5MG		A090190	005	Jul 06, 2010
SUN PHARM INDS INC	0.125MG		A091683	001	Mar 27, 2013
	0.25MG		A091683	002	Mar 27, 2013
	0.5MG		A091683	003	Mar 27, 2013
	0.75MG		A091683	004	Mar 27, 2013
	1MG		A091683	005	Mar 27, 2013
	1.5MG		A091683	006	Mar 27, 2013
UNICHEM	0.125MG		A207011	001	Dec 19, 2018
	0.25MG		A207011	002	Dec 19, 2018
	0.5MG		A207011	003	Dec 19, 2018
	0.75MG		A207011	004	Dec 19, 2018
	1MG		A207011	005	Dec 19, 2018
	1.5MG		A207011	006	Dec 19, 2018
TABLET, EXTENDED RELEASE;ORAL					
MIRAPEX ER					
+ BOEHRINGER INGELHEIM	0.375MG		N022421	001	Feb 19, 2010
+	0.75MG		N022421	002	Feb 19, 2010
+	1.5MG		N022421	003	Feb 19, 2010
+	2.25MG		N022421	006	Jun 17, 2011
+	3MG		N022421	004	Feb 19, 2010
+	3.75MG		N022421	007	Jun 17, 2011
+	4.5MG		N022421	005	Feb 19, 2010
PRAMIPEXOLE DIHYDROCHLORIDE					
PH HEALTH	0.375MG		A202206	001	Feb 06, 2014
	0.75MG		A202206	002	Feb 06, 2014
	1.5MG		A202206	003	Feb 06, 2014
	2.25MG		A202206	004	Feb 06, 2014
	3MG		A202206	005	Feb 06, 2014
	3.75MG		A202206	006	Feb 06, 2014
	4.5MG		A202206	007	Feb 06, 2014

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS					
SYMLIN					
+ ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)		N021332	002	Sep 25, 2007
+	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)		N021332	003	Sep 25, 2007
	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)		N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET;ORAL					
PRASUGREL					
AMNEAL PHARMS	EQ 5MG BASE		A205913	001	Jun 19, 2018
	EQ 10MG BASE		A205913	002	Jun 19, 2018
ANDA REPOSITORY	EQ 5MG BASE		A205926	001	Jul 07, 2020
	EQ 10MG BASE		A205926	002	Jul 07, 2020
CHARTWELL RX	EQ 5MG BASE		A205790	001	Oct 16, 2017
	EQ 10MG BASE		A205790	002	Oct 16, 2017
LUPIN LTD	EQ 5MG BASE		A205930	001	Jan 09, 2023

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRASUGREL HYDROCHLORIDE					
TABLET;ORAL					
PRASUGREL					
		EQ 10MG BASE	A205930	002	Jan 09, 2023
PRAVASTATIN SODIUM					
TABLET;ORAL					
PRAVACHOL					
+	BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
+		20MG **	N019898	003	Oct 31, 1991
+		40MG **	N019898	004	Mar 22, 1993
+		80MG **	N019898	008	Dec 18, 2001
PRAVASTATIN SODIUM					
	HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018
		40MG	A206061	002	Nov 23, 2018
		80MG	A206061	003	Nov 23, 2018
	PHARMOBEDIENT	10MG	A077013	001	Oct 23, 2006
		10MG	A079187	001	May 27, 2010
		20MG	A077013	002	Oct 23, 2006
		20MG	A079187	002	May 27, 2010
		40MG	A077013	003	Oct 23, 2006
		40MG	A079187	003	May 27, 2010
		80MG	A077013	004	Dec 28, 2007
		80MG	A079187	004	May 27, 2010
	PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
		20MG	A077730	002	Nov 21, 2006
		30MG	A077730	003	Nov 21, 2006
		40MG	A077730	005	Nov 21, 2006
	RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
		20MG	A076445	002	Apr 23, 2007
		40MG	A076445	003	Apr 23, 2007
		80MG	A076445	004	Apr 23, 2007
	ZYDUS PHARMS USA	10MG	A077751	001	Apr 30, 2008
PRAZEPAM					
CAPSULE;ORAL					
CENTRAX					
	PARKE DAVIS	5MG	N018144	001	
		10MG	N018144	002	
		20MG	N018144	003	May 10, 1982
PRAZEPAM					
	USL PHARMA	5MG	A070427	001	Nov 06, 1987
		10MG	A070428	001	Nov 06, 1987
TABLET;ORAL					
CENTRAX					
	PARKE DAVIS	10MG	N017415	001	
PRAZIQUANTEL					
TABLET;ORAL					
BILTRICIDE					
+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982
PRAZOSIN HYDROCHLORIDE					
CAPSULE;ORAL					
PRAZOSIN HYDROCHLORIDE					
	AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
		EQ 2MG BASE	A072783	001	May 16, 1989
		EQ 5MG BASE	A072784	001	May 16, 1989
	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989
		EQ 2MG BASE	A072577	001	May 16, 1989
		EQ 5MG BASE	A072577	003	May 16, 1989
	DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
		EQ 2MG BASE	A072706	001	May 16, 1989
		EQ 5MG BASE	A072707	001	May 16, 1989
	LANNETT CO INC	EQ 1MG BASE	A214083	001	Jan 03, 2024
		EQ 2MG BASE	A214083	002	Jan 03, 2024
		EQ 5MG BASE	A214083	003	Jan 03, 2024
	PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
		EQ 2MG BASE	A072921	001	May 16, 1989
		EQ 5MG BASE	A072992	001	May 16, 1989
	WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
PRAZOSIN HYDROCHLORIDE				
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989
TABLET, EXTENDED RELEASE;ORAL				
MINIPRESS XL				
PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992
PREDNICARBATE				
CREAM;TOPICAL				
DERMATOP E EMOLLIENT				
+ VALEANT BERMUDA	0.1% **	N020279	001	Oct 29, 1993
PREDNICARBATE				
FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006
OINTMENT;TOPICAL				
DERMATOP				
+ VALEANT PHARMS NORTH	0.1% **	N019568	001	Sep 23, 1991
PREDNISOLONE				
CREAM;TOPICAL				
METI-DERM				
SCHERING	0.5%	N010209	002	
SOLUTION;ORAL				
PREDNISOLONE				
HIKMA	15MG/5ML	A040401	001	Feb 27, 2003
IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999
NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002
PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003
PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998
SYRUP;ORAL				
PREDNISOLONE				
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
PHARM ASSOC	5MG/5ML	A040570	001	Aug 25, 2005
PRELONE				
MURO	5MG/5ML	A089654	001	Jan 17, 1989
TABLET;ORAL				
CORTALONE				
HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	
DELTA-CORTEF				
PHARMACIA AND UPJOHN	5MG	N009987	004	
FERNISOLONE-P				
FERNDALE LABS	5MG	A083941	001	
PREDNISOLONE				
BARR	5MG	A084426	002	
BUNDY	5MG	A083675	001	
CHARTWELL RX	5MG	A084542	001	
ELKINS SINN	5MG	A080625	001	
EVERYLIFE	1MG	A084439	001	
	2.5MG	A084439	002	
	5MG	A084439	003	
FERRANTE	2.5MG	A080562	001	
	5MG	A080562	002	
FOSUN PHARMA	5MG	A080339	001	
+ HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
RISING	5MG	A084773	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE

TABLET;ORAL				
PREDNISOLONE				
ROXANE	5MG	A080327	002	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION				
METICORTELONE				
SCHERING	25MG/ML	N010255	002	
PREDNISOLONE ACETATE				
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	
CENT PHARMS	25MG/ML	A084717	001	
	50MG/ML	A084717	002	
EPIC PHARMA LLC	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
WATSON LABS	25MG/ML	A083398	001	
	25MG/ML	A083654	001	
	40MG/ML	A083767	001	
	50MG/ML	A083764	001	
	50MG/ML	A085781	001	
STERANE				
PFIZER	25MG/ML	N011446	001	
SUSPENSION;ORAL				
FLO-PRED				
SUN PHARMA CANADA	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC				
ECONOPRED				
HARROW EYE	0.125%	N017468	001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC				
BLEPHAMIDE S.O.P.				
ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986
CETAPRED				
ALCON	0.25%;10%	A087771	001	Aug 06, 1993
METIMYD				
SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
VASOCIDIN				
NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
SUSPENSION;OPHTHALMIC				
BLEPHAMIDE				
+ ALLERGAN	0.2%;10%	N012813	002	
ISOPTO CETAPRED				
ALCON	0.25%;10%	A087547	001	
SUSPENSION/DROPS;OPHTHALMIC				
METIMYD				
SCHERING	0.5%;10%	N010210	001	
PREDAMIDE				
EPIC PHARMA LLC	0.5%;10%	A088059	001	Jul 29, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM				
SUSPENSION/DROPS;OPHTHALMIC				
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
PREDSULFAIR II				
PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
SULPHRIN				
BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982
PREDNISOLONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
HYDELTRASOL				
MERCK	EQ 20MG PHOSPHATE/ML	N011583	002	
PREDNISOLONE SODIUM PHOSPHATE				
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001	
OINTMENT;OPHTHALMIC, OTIC				
HYDELTRASOL				
MERCK	EQ 0.25% PHOSPHATE	N011028	001	
SOLUTION;ORAL				
ORAPRED				
CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117	001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE				
AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009
BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002
HIKMA	EQ 5MG BASE/5ML	A075183	001	Mar 26, 2003
NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005
	EQ 15MG BASE/5ML	A076988	001	May 24, 2005
PH HEALTH	EQ 15MG BASE/5ML	A079010	001	May 26, 2009
PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002
	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020
PHARMOBEDIENT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004
PHARMOBEDIENT CNSLTG	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002
SOLUTION/DROPS;OPHTHALMIC				
INFLAMASE FORTE				
+ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002	
INFLAMASE MILD				
+ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001	
METRETON				
SCHERING	EQ 0.5% PHOSPHATE	A083834	001	
PREDAIR				
PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984
PREDAIR FORTE				
PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
EPIC PHARMA LLC	EQ 0.11% PHOSPHATE	A083358	001	
	EQ 0.9% PHOSPHATE	A083358	002	
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	
	EQ 0.9% PHOSPHATE	A084168	001	
	EQ 0.9% PHOSPHATE	A084169	001	
	EQ 0.9% PHOSPHATE	A084172	001	
TABLET, ORALLY DISINTEGRATING;ORAL				
PREDNISOLONE SODIUM PHOSPHATE				
RISING	EQ 10MG BASE	A202179	001	Apr 10, 2013
	EQ 15MG BASE	A202179	002	Apr 10, 2013
	EQ 30MG BASE	A202179	003	Apr 10, 2013
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE				
GENUS	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993
SULSTER				
EPIC PHARMA LLC	EQ 0.23% PHOSPHATE;10%	A074511	001	Jul 30, 1996
VASOCIDIN				
+ NOVARTIS	EQ 0.23% PHOSPHATE;10% **	N018988	001	Aug 26, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE TEBUTATE				
INJECTABLE;INJECTION				
HYDELTRA-TBA				
	MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE				
	WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984
PREDNISONE				
SOLUTION;ORAL				
PREDNISONE				
	XTTRIUM LABS INC	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL				
LIQUID PRED				
	MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL				
CORTAN				
	HALSEY	20MG	A087480 001	
DELTA-DOME				
	BAYER PHARMS	5MG	A080293 001	
DELTASONE				
+	PHARMACIA AND UPJOHN	2.5MG **	N009986 005	
+		5MG **	N009986 002	
+		10MG **	N009986 006	
+		20MG **	N009986 007	
+		50MG **	N009986 008	
FERNISONE				
	FERNDALE LABS	5MG	A083364 001	
METICORTEN				
+	SCHERING	1MG **	N009766 002	
+		5MG **	N009766 001	
ORASONE				
	SOLVAY	1MG	A083009 001	
		5MG	A083009 002	
		10MG	A083009 003	
		20MG	A083009 004	
		50MG	A085999 001	
PARACORT				
	PARKE DAVIS	5MG	N010962 002	
PREDNICEN-M				
	SCHWARZ PHARMA	5MG	A084655 001	
PREDNISONE				
	AIPING PHARM INC	5MG	A080336 002	
	AM THERAP	5MG	A089387 001	Nov 06, 1986
		10MG	A089388 001	Nov 06, 1986
		20MG	A089389 001	Nov 06, 1986
	AMNEAL PHARMS NY	5MG	A089597 001	Oct 05, 1987
		10MG	A089598 001	Oct 05, 1987
		20MG	A089599 001	Oct 05, 1987
	BUNDY	5MG	A083676 001	
	CHARTWELL MOLECULAR	5MG	A080514 001	
	CHARTWELL RX	5MG	A083059 001	
	CONTRACT PHARMACAL	5MG	A080209 001	
	DURAMED PHARMS BARR	5MG	A088394 001	Oct 04, 1983
		10MG	A088395 001	Oct 04, 1983
		20MG	A088396 001	Oct 04, 1983
	ELKINS SINN	5MG	A080491 001	
		20MG	A085811 001	
	EVERYLIFE	1MG	A084440 001	
		2.5MG	A084440 002	
		5MG	A084440 003	
	FERRANTE	2.5MG	A080563 001	
		5MG	A080563 002	
	GENEYORK PHARMS	1MG	A211496 001	Dec 28, 2018
		2.5MG	A210525 004	Dec 07, 2018
		5MG	A210525 005	Dec 07, 2018
		10MG	A210525 001	Dec 04, 2018
		20MG	A210525 002	Dec 04, 2018
		50MG	A210525 003	Dec 04, 2018
	HALSEY	5MG	A080300 001	
	HEATHER	5MG	A080320 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL

PREDNISONE

		10MG	A084341	001	
		20MG	A084417	001	
		20MG	A085543	001	
		50MG	A086946	001	
	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
		2.5MG	A040538	001	Jan 08, 2004
		50MG	A088465	001	Jun 01, 1984
	IMPAX LABS	5MG	A080782	001	
	INWOOD LABS	1MG	A080328	001	
		2.5MG	A080306	001	
		5MG	A080279	001	
	IVAX SUB TEVA PHARMS	5MG	A080283	001	
		10MG	A084133	001	
		20MG	A084134	001	
	KV PHARM	5MG	A084236	001	
	LEDERLE	5MG	A086968	001	
	MARSHALL PHARMA	5MG	A080301	001	
	MUTUAL PHARM	5MG	A080701	001	
		10MG	A086595	001	
		20MG	A084634	001	
	NYLOS	5MG	A085115	001	
	PANRAY	1MG	A080350	001	
		2.5MG	A080350	002	
		5MG	A080350	003	
	PHARMAVITE	5MG	A084662	002	
	PHOENIX LABS NY	5MG	A080321	001	
		20MG	A083807	001	
	PUREPAC PHARM	5MG	A080353	001	
		10MG	A086062	001	
		20MG	A086061	001	
	PVT FORM	20MG	A085151	001	
	REXALL	5MG	A080232	001	
	RISING	5MG	A084774	001	
		10MG	A089983	001	Jan 12, 1989
		20MG	A085813	001	
		50MG	A089984	001	Jan 12, 1989
	ROXANE	20MG	N017109	001	
+		25MG	A087833	001	May 04, 1982
	SCHERER LABS	5MG	A080371	001	
	SPERTI	1MG	A080359	001	
		2.5MG	A080359	002	
		5MG	A080359	003	
	SUN PHARM INDUSTRIES	50MG	A086596	001	
	SUPERPHARM	5MG	A088865	001	Oct 25, 1984
		10MG	A088866	001	Oct 25, 1984
		20MG	A088867	001	Oct 25, 1984
	TEVA	5MG	A080397	001	
	UDL	5MG	A087984	001	Jan 18, 1983
		10MG	A087985	001	Jan 18, 1983
		20MG	A087986	001	Jan 18, 1983
	UPSHER SMITH	5MG	A087471	001	
		20MG	A087470	001	
	VALEANT PHARM INTL	5MG	A080237	001	
	VANGARD	5MG	A087682	001	Jan 15, 1982
		20MG	A087701	001	Jan 15, 1982
	VITARINE	5MG	A080334	001	
		5MG	A080506	001	
	WATSON LABS	5MG	A085084	002	
		10MG	A087773	001	Jul 13, 1982
		20MG	A086813	001	
		50MG	A086867	001	
		50MG	A087772	001	Jul 13, 1982
	WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
		5MG	A080343	001	
		10MG	A089028	001	Jul 24, 1986
		20MG	A084913	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL					
SERVISONE					
	LEDERLE	5MG	A080223	001	
TABLET, DELAYED RELEASE;ORAL					
PREDNISONE					
	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017
		2MG	A204867	002	Apr 25, 2017
		5MG	A204867	003	Apr 25, 2017
RAYOS					
+	HORIZON	1MG	N202020	001	Jul 26, 2012
+		2MG	N202020	002	Jul 26, 2012
+		5MG	N202020	003	Jul 26, 2012

PREGABALIN

CAPSULE;ORAL					
PREGABALIN					
	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020
		50MG	A091025	002	Jul 09, 2020
		75MG	A091025	003	Jul 09, 2020
		100MG	A091025	004	Jul 09, 2020
		150MG	A091025	005	Jul 09, 2020
		200MG	A091025	006	Jul 09, 2020
		225MG	A091025	007	Jul 09, 2020
		300MG	A091025	008	Jul 09, 2020
	APOTEX	25MG	A211685	001	Jul 07, 2021
		50MG	A211685	002	Jul 07, 2021
		75MG	A211685	003	Jul 07, 2021
		100MG	A211685	004	Jul 07, 2021
		150MG	A211685	005	Jul 07, 2021
		200MG	A211685	006	Jul 07, 2021
		225MG	A211685	007	Jul 07, 2021
		300MG	A211685	008	Jul 07, 2021
	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023
		50MG	A206452	002	Jul 12, 2023
		75MG	A206452	003	Jul 12, 2023
		100MG	A206452	004	Jul 12, 2023
		150MG	A206452	005	Jul 12, 2023
		200MG	A206452	006	Jul 12, 2023
		225MG	A206452	007	Jul 12, 2023
		300MG	A206452	008	Jul 12, 2023
	CIPLA	25MG	A212280	001	Jan 10, 2020
		50MG	A212280	002	Jan 10, 2020
		75MG	A212280	003	Jan 10, 2020
		100MG	A212280	004	Jan 10, 2020
		150MG	A212280	005	Jan 10, 2020
		200MG	A212280	006	Jan 10, 2020
		225MG	A212280	007	Jan 10, 2020
		300MG	A212280	008	Jan 10, 2020
	LUPIN LTD	25MG	A091040	001	May 03, 2022
		50MG	A091040	002	May 03, 2022
		75MG	A091040	003	May 03, 2022
		100MG	A091040	004	May 03, 2022
		150MG	A091040	005	May 03, 2022
		200MG	A091040	006	May 03, 2022
		225MG	A091040	007	May 03, 2022
		300MG	A091040	008	May 03, 2022
	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024
		50MG	A205924	002	Nov 12, 2024
		75MG	A205924	003	Nov 12, 2024
		100MG	A205924	004	Nov 12, 2024
		150MG	A205924	005	Nov 12, 2024
		200MG	A205924	006	Nov 12, 2024
		225MG	A205924	007	Nov 12, 2024
		300MG	A205924	008	Nov 12, 2024
	PHARMOBEDIENT	25MG	A091228	001	Sep 20, 2019
		50MG	A091228	002	Sep 20, 2019
		75MG	A091228	003	Sep 20, 2019
		100MG	A091228	004	Sep 20, 2019
		150MG	A091228	005	Sep 20, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREGABALIN

CAPSULE;ORAL				
PREGABALIN				
	200MG	A091228	006	Sep 20, 2019
	225MG	A091228	007	Sep 20, 2019
	300MG	A091228	008	Sep 20, 2019
STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024
	50MG	A209883	002	Jan 24, 2024
	75MG	A209883	003	Jan 24, 2024
	100MG	A209883	004	Jan 24, 2024
	150MG	A209883	005	Jan 24, 2024
	200MG	A209883	006	Jan 24, 2024
	225MG	A209883	007	Jan 24, 2024
	300MG	A209883	008	Jan 24, 2024
SUN PHARM	25MG	A091157	001	Nov 29, 2019
	50MG	A091157	002	Nov 29, 2019
	75MG	A091157	003	Nov 29, 2019
	100MG	A091157	004	Nov 29, 2019
	150MG	A091157	005	Nov 29, 2019
	200MG	A091157	006	Nov 29, 2019
	225MG	A091157	007	Nov 29, 2019
	300MG	A091157	008	Nov 29, 2019
TEVA PHARMS	25MG	A091219	001	Jul 19, 2019
	50MG	A091219	002	Jul 19, 2019
	75MG	A091224	001	Jul 19, 2019
	100MG	A091224	002	Jul 19, 2019
	150MG	A091224	003	Jul 19, 2019
	200MG	A091224	004	Jul 19, 2019
	225MG	A091224	005	Jul 19, 2019
	300MG	A091224	006	Jul 19, 2019
ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022
	50MG	A206752	002	Dec 09, 2022
	75MG	A206752	003	Dec 09, 2022
	100MG	A206752	004	Dec 09, 2022
	150MG	A206752	005	Dec 09, 2022
	200MG	A206752	006	Dec 09, 2022
	225MG	A206752	007	Dec 09, 2022
	300MG	A206752	008	Dec 09, 2022
TABLET, EXTENDED RELEASE;ORAL				
PREGABALIN				
ALVOGEN	82.5MG	A211593	001	Apr 13, 2021
	82.5MG	A211687	001	Jul 06, 2021
	165MG	A211593	002	Apr 13, 2021
	165MG	A211687	002	Jul 06, 2021
	330MG	A211593	003	Apr 13, 2021
	330MG	A211687	003	Jul 06, 2021
APOTEX	165MG	A213313	001	Apr 13, 2021
	330MG	A213313	002	Apr 13, 2021
PHARMOBEDIENT	82.5MG	A211948	001	Apr 13, 2021
	165MG	A211967	001	Nov 04, 2021
	330MG	A211431	001	Jul 02, 2021
SCIEGEN PHARMS	82.5MG	A215675	001	Sep 14, 2022
	165MG	A215675	002	Sep 14, 2022
	330MG	A215675	003	Sep 14, 2022
SUN PHARM	82.5MG	A211889	001	Apr 13, 2021
	165MG	A211889	002	Apr 13, 2021
	330MG	A211889	003	Apr 13, 2021
ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022
	165MG	A215577	002	Aug 26, 2022
	330MG	A215577	003	Aug 26, 2022

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
CITANEST			
+ ASTRAZENECA	1% **	N014763	004
+	2% **	N014763	005
+	3% **	N014763	003
CITANEST PLAIN			
+ ASTRAZENECA	4% **	N014763	007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRILOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CITANEST PLAIN DENTAL				
+ DENTSPLY PHARM	4%	N021382	001	
PRIMAQUINE PHOSPHATE				
TABLET;ORAL				
PRIMAQUINE PHOSPHATE				
ALVOGEN	EQ 15MG BASE	A203924	001	Feb 03, 2014
PRIMIDONE				
SUSPENSION;ORAL				
MYSOLINE				
+ FHTA	250MG/5ML	N010401	001	
TABLET;ORAL				
PRIMIDONE				
CHARTWELL RX	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
	250MG	A040667	002	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	
PROBENECID				
TABLET;ORAL				
BENEMID				
+ MERCK	500MG **	N007898	004	
PROBENECID				
AUROBINDO PHARMA USA	500MG	A084211	002	
IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982
PROBUCOL				
TABLET;ORAL				
LORELCO				
SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988
PROCAINAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG	A089219	001	Jul 01, 1986
	375MG	A089219	002	Jul 01, 1986
	500MG	A089219	003	Jul 01, 1986
ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL				
PROCAN				
	500MG		A085079 001	
PROCAPAN				
PANRAY	250MG		A083553 002	
PRONESTYL				
+ APOTHECON	250MG **		N007335 001	
+	375MG **		N007335 004	
+	500MG **		N007335 003	
INJECTABLE;INJECTION				
PROCAINAMIDE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML		A089415 001	Nov 17, 1986
	500MG/ML		A089416 001	Nov 17, 1986
HIKMA	100MG/ML		A089029 001	Apr 17, 1986
HOSPIRA	500MG/ML		A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML		A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML		A088824 001	Nov 20, 1985
	500MG/ML		A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML		A088530 001	Mar 04, 1985
	500MG/ML		A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML		A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML		A089528 001	May 03, 1988
	500MG/ML		A089529 001	May 03, 1988
WATSON LABS	100MG/ML		A087079 001	
	500MG/ML		A087080 001	
WEST-WARD PHARMS INT	500MG/ML		A089030 001	Apr 17, 1986
PRONESTYL				
+ APOTHECON	100MG/ML **		N007335 002	
+	500MG/ML **		N007335 005	
TABLET;ORAL				
PRONESTYL				
APOTHECON	250MG		N017371 001	
	375MG		N017371 002	
	500MG		N017371 003	
TABLET, EXTENDED RELEASE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG		A088958 001	Dec 02, 1985
	250MG		A089369 001	Aug 14, 1987
	500MG		A088959 001	Dec 02, 1985
	500MG		A088974 001	Jul 22, 1985
	500MG		A089369 002	Jan 09, 1987
	750MG		A089369 003	Aug 14, 1987
	750MG		A089438 001	Mar 23, 1987
	1GM		A040111 001	Dec 13, 1996
INWOOD LABS	500MG		A089840 001	Mar 06, 1989
SANDOZ	500MG		A089284 001	Jun 23, 1986
WATSON LABS	250MG		A088533 001	Dec 03, 1984
	250MG		A089026 001	Oct 22, 1985
	500MG		A088534 001	Dec 03, 1984
	500MG		A089027 001	Oct 22, 1985
	750MG		A088535 001	Nov 03, 1984
	750MG		A089042 001	Oct 22, 1985
	1GM		A089520 001	Jan 15, 1987
PROCAN SR				
+ PARKE DAVIS	250MG		A086468 001	
+ PARKEDALE	500MG		A086065 001	
+	750MG		A087510 001	Apr 01, 1982
	1GM		A088489 001	Jan 16, 1985
PROCANBID				
KING PHARMS	500MG		N020545 001	Jan 31, 1996
	1GM		N020545 002	Jan 31, 1996
PRONESTYL-SR				
APOTHECON	500MG		A087361 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NOVOCAIN				
	HOSPIRA	1%	A085362 003	
		2%	A085362 004	
		10%	A086797 001	
PROCAINE HYDROCHLORIDE				
	ABRAXIS PHARM	1%	A080384 002	
		1%	A080421 001	
		2%	A080384 003	
		2%	A080421 002	
	BEL MAR	1%	A080711 001	
		2%	A080756 001	
	ELKINS SINN	1%	A083315 001	
		2%	A083315 002	
	GD SEARLE LLC	1%	A086202 001	
		2%	A086202 002	
	HOSPIRA	1%	A080416 001	
		2%	A080416 002	
	MILES	1%	A080415 001	
		2%	A080415 002	
	WATSON LABS	1%	A080658 001	
		1%	A083535 001	
		2%	A080658 002	
		2%	A083535 002	
PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
		40MG/VIAL;250MG/VIAL	N050276 003	
TETRACYN				
	PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
		40MG/VIAL;250MG/VIAL	A060285 003	
PROCAINE MERETHOXYLLINE; THEOPHYLLINE				
INJECTABLE;INJECTION				
DICURIN PROCAINE				
	LILLY	100MG/ML;50MG/ML	N008869 001	
PROCHLORPERAZINE				
SUPPOSITORY;RECTAL				
COMPAZINE				
+	GLAXOSMITHKLINE	2.5MG **	N011127 003	
+		5MG **	N011127 001	
+		25MG **	N011127 002	
PROCHLORPERAZINE				
	ABLE	2.5MG	A040407 001	Jul 11, 2001
		5MG	A040407 002	Jul 11, 2001
		25MG	A040407 003	Jul 11, 2001
PROCHLORPERAZINE EDISYLATE				
CONCENTRATE;ORAL				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276 001	
PROCHLORPERAZINE				
	ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153 001	Jun 08, 1982
PROCHLORPERAZINE EDISYLATE				
	MORTON GROVE	EQ 10MG BASE/ML	A088598 001	Oct 25, 1984
INJECTABLE;INJECTION				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742 002	
PROCHLORPERAZINE				
	BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759 001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
	HIKMA	EQ 5MG BASE/ML	A089523 001	May 03, 1988
		EQ 5MG BASE/ML	A213630 001	Nov 22, 2022
	HOSPIRA	EQ 5MG BASE/ML	A089703 001	Apr 07, 1988
	MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675 001	Dec 05, 1988
	NEXUS	EQ 5MG BASE/ML	A204860 001	Feb 15, 2019
	SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251 001	Dec 04, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION				
PROCHLORPERAZINE EDISYLATE				
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505	001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605	001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606	001	Jul 08, 1987
WYETH AYERST	EQ 5MG BASE/ML	A086348	001	
SYRUP;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188	001	
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	
TABLET;ORAL				
COMPAZINE				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001	
+	EQ 10MG BASE **	N010571	002	
+	EQ 25MG BASE **	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	
PROCHLORPERAZINE MALEATE				
CHARTWELL RX	EQ 5MG BASE	A040101	001	Jul 19, 1996
	EQ 10MG BASE	A040101	002	Jul 19, 1996
	EQ 25MG BASE	A040101	003	Jul 19, 1996
DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
PHARMOBEDIENT	EQ 5MG BASE	A040185	002	Oct 28, 1996
	EQ 10MG BASE	A040185	001	Oct 28, 1996
TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996
	EQ 10MG BASE	A040120	002	Jul 11, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL				
KEMADRIN				
MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	

PROGESTERONE

CAPSULE;ORAL				
PROGESTERONE				
TEVA PHARMS	100MG	A202121	001	Feb 29, 2012
	200MG	A202121	002	Feb 29, 2012
PROMETRIUM				
ACERTIS PHARMS	300MG	N019781	003	Oct 15, 1999
INJECTABLE;INJECTION				
PROGESTERONE				
ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023
+ ACTAVIS LABS UT INC	50MG/ML **	N017362	002	
AM REGENT	50MG/ML	A090845	001	Jun 22, 2009
LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROGESTERONE				
INSERT, EXTENDED RELEASE;INTRAUTERINE				
PROGESTASERT				
	ALZA	38MG	N017553 001	
SYSTEM;VAGINAL				
MILPROSA				
+	FERRING PHARMS INC	1.78GM	N201110 001	Apr 29, 2020
PROMAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SPARINE				
	WYETH AYERST	30MG/ML	N010942 001	
		100MG/ML	N010942 004	
INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
	WATSON LABS	25MG/ML	A084510 001	
		50MG/ML	A084517 001	
SPARINE				
	HIKMA	25MG/ML	N010349 008	
		50MG/ML	N010349 006	
SYRUP;ORAL				
SPARINE				
	WYETH AYERST	10MG/5ML	N010942 003	
TABLET;ORAL				
SPARINE				
	WYETH AYERST	10MG	N010348 006	
		25MG	N010348 001	
		50MG	N010348 002	
		100MG	N010348 003	
		200MG	N010348 004	
PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
PHENERGAN				
	WYETH AYERST	25MG/ML	N008857 002	
		50MG/ML	N008857 003	
PROMETHAZINE HYDROCHLORIDE				
	ABBOTT	25MG/ML	A084223 001	
		50MG/ML	A084222 001	
	AM REGENT	25MG/ML	A040515 001	Mar 19, 2003
	BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
		50MG/ML	A040524 002	Mar 17, 2004
	EPIC PHARMA LLC	25MG/ML	A083955 002	
		50MG/ML	A083955 001	
	HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000
		50MG/ML	A040372 002	Jun 08, 2000
		50MG/ML	A083838 002	
	MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988
		50MG/ML	A089477 001	May 02, 1988
	MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002
	SANDOZ	25MG/ML	A040593 001	Nov 08, 2006
		50MG/ML	A040593 002	Nov 08, 2006
	TEVA PHARMS USA	25MG/ML **	A040454 001	Aug 22, 2002
		50MG/ML **	A040454 002	Aug 22, 2002
	WATSON LABS	25MG/ML	A083532 001	
		25MG/ML	A084591 001	
		50MG/ML	A080629 002	
		50MG/ML	A083532 002	
	WOCKHARDT BIO AG	25MG/ML	A040785 001	Sep 26, 2008
		50MG/ML	A040785 002	Sep 26, 2008
ZIPAN-25				
	ALTANA	25MG/ML	A083997 001	
ZIPAN-50				
	ALTANA	50MG/ML	A083997 002	
SUPPOSITORY;RECTAL				
PHENERGAN				
+	NORVIUM BIOSCIENCE	12.5MG **	N010926 002	
+		25MG **	N010926 001	
+	PHARMOBEDIENT	50MG **	N011689 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL				
PROMETHACON				
POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	
PROMETHAZINE HYDROCHLORIDE				
ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003
SUN PHARMA CANADA	12.5MG	A040603	001	Oct 26, 2006
	25MG	A040603	002	Oct 26, 2006
WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003
	25MG	A040479	002	Jun 24, 2003
SYRUP;ORAL				
MYMETHAZINE FORTIS				
USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983
PROMETH FORTIS				
ALPHARMA US PHARMS	25MG/5ML	A084772	001	
PROMETH PLAIN				
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953	001	
PROMETHAZINE				
CENCI	6.25MG/5ML	A089013	001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE				
AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009
KV PHARM	6.25MG/5ML	A085388	001	
	25MG/5ML	A085385	001	
PHARM ASSOC	6.25MG/5ML	A087518	001	
SUN PHARMA CANADA	6.25MG/5ML	A040718	001	Apr 04, 2007
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395	001	
PROMETHAZINE HYDROCHLORIDE PLAIN				
+ ANI PHARMS	6.25MG/5ML **	N008381	004	Apr 18, 1984
+	25MG/5ML **	N008381	003	
TABLET;ORAL				
PHENERGAN				
+ DELCOR ASSET CORP	12.5MG **	N007935	002	
+	25MG **	N007935	003	
+	50MG **	N007935	004	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	12.5MG	A084160	001	
	25MG	A084166	001	
	50MG	A084539	001	
ABLE	12.5MG	A040558	001	Jul 01, 2004
	25MG	A040558	002	Jul 01, 2004
	50MG	A040558	003	Jul 01, 2004
AUROBINDO PHARMA USA	12.5MG	A091054	001	Aug 30, 2011
	25MG	A091054	002	Aug 30, 2011
	50MG	A091054	003	Aug 30, 2011
CHARTWELL MOLECULAR	12.5MG	A080949	001	
	25MG	A080949	002	
	50MG	A080949	003	
IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008
	25MG	A040791	003	Feb 12, 2008
	25MG	A084214	002	Jul 07, 1982
	50MG	A040791	001	May 20, 2008
IVAX SUB TEVA PHARMS	12.5MG	A083604	001	
	25MG	A083603	001	
	50MG	A083613	001	
PVT FORM	12.5MG	A083214	001	
	25MG	A083658	001	
RISING	12.5MG	A084233	001	
	25MG	A085146	001	
	50MG	A085146	002	
SANDOZ	12.5MG	A084176	002	May 22, 2009
STRIDES PHARMA	12.5MG	A209177	001	Jun 30, 2017
	25MG	A209177	002	Jun 30, 2017
	50MG	A209177	003	Jun 30, 2017
SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008
	25MG	A040863	002	Dec 30, 2008
	50MG	A040863	003	Dec 30, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL				
PROMETHAZINE HYDROCHLORIDE				
SUN PHARM INDUSTRIES	12.5MG	A084555	001	
	25MG	A084554	001	
	50MG	A084557	001	
TABLICAPS	12.5MG	A084080	001	
	25MG	A084027	001	
TEVA	25MG	A089109	001	Sep 10, 1985
WATSON LABS	12.5MG	A083401	001	
	12.5MG	A083712	001	
	12.5MG	A085986	001	
	25MG	A083204	001	
	25MG	A085684	001	
	50MG	A083403	001	
	50MG	A085664	001	
REMSED				
BRISTOL MYERS SQUIBB	25MG	A083176	002	
	50MG	A083176	001	

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PROPAFENONE HYDROCHLORIDE				
MYLAN	225MG	A203803	001	Apr 29, 2016
	325MG	A203803	002	Apr 29, 2016
	425MG	A203803	003	Apr 29, 2016
TWI PHARMS	225MG	A212928	001	Jun 18, 2020
	325MG	A212928	002	Jun 18, 2020
	425MG	A212928	003	Jun 18, 2020
RYTHMOL SR				
+ GLAXOSMITHKLINE LLC	225MG	N021416	001	Sep 04, 2003
+	325MG	N021416	002	Sep 04, 2003
+	425MG	N021416	003	Sep 04, 2003
TABLET;ORAL				
PROPAFENONE HYDROCHLORIDE				
NESHER PHARMS	150MG	A076193	001	Feb 07, 2002
	225MG	A076193	002	Feb 07, 2002
	300MG	A076193	003	Feb 07, 2002
SUN PHARM INDUSTRIES	150MG	A075998	001	Nov 29, 2001
	225MG	A075998	002	Nov 29, 2001
	300MG	A075998	003	Nov 29, 2001
RYTHMOL				
+ GLAXOSMITHKLINE LLC	150MG **	N019151	001	Nov 27, 1989
+	225MG **	N019151	003	Nov 20, 1992
+	300MG **	N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE;INJECTION				
PRO-BANTHINE				
GD SEARLE LLC	30MG/VIAL	N008843	001	
TABLET;ORAL				
PRO-BANTHINE				
+ SHIRE	7.5MG **	N008732	003	
+	15MG **	N008732	002	
PROPANTHELINE BROMIDE				
ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
HIKMA	7.5MG	A080927	001	
	15MG	A080927	002	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPARACAINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
KAINAIR				
PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
OPHTHAINE				
+ APOTHECON	0.5% **	N008883	001	
OPHTHETIC				
+ ALLERGAN	0.5% **	N012583	001	
PARACAINE				
OPTOPICS	0.5%	A087681	001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	
PROPIOLACTONE				
SOLUTION;IRRIGATION				
BETAPRONE				
FOREST LABS	N/A	N011657	001	
PROPIOMAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
LARGON				
HIKMA	20MG/ML	N012382	002	
PROPOFOL				
INJECTABLE;INJECTION				
DIPRIVAN				
FRESENIUS KABI USA	10MG/ML	N019627	001	Oct 02, 1989
PROPOFOL				
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000
WATSON LABS INC	10MG/ML	A205307	001	Dec 22, 2015
PROPOXYPHENE HYDROCHLORIDE				
CAPSULE;ORAL				
DARVON				
XANODYNE PHARM	32MG	N010997	001	
	65MG	N010997	003	
DOLENE				
HERITAGE PHARMS INC	65MG	A080530	001	
KESSO-GESIC				
MK LABS	65MG	A083544	001	
PROPHENE 65				
HALSEY	65MG	A083538	002	
PROPOXYPHENE HYDROCHLORIDE				
ALRA	65MG	A083184	001	
IMPAX LABS	65MG	A083317	001	
IVAX SUB TEVA PHARMS	32MG	A083597	001	
MUTUAL PHARM	65MG	A083186	001	
MYLAN	32MG	A083528	001	
	65MG	A040569	001	Dec 16, 2004
	65MG	A083299	001	
NEXGEN PHARMA INC	65MG	A083185	001	
PAR PHARM	65MG	A080269	001	
PUREPAC PHARM	65MG	A083278	001	
PVT FORM	32MG	A083464	001	
	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPOXYPHENE HYDROCHLORIDE				
CAPSULE;ORAL				
PROPOXYPHENE HYDROCHLORIDE 65				
WARNER CHILCOTT	65MG	A083786	001	
PROPOXYPHENE NAPSYLATE				
SUSPENSION;ORAL				
DARVON-N				
AAIPHARMA LLC	50MG/5ML	N016861	001	
TABLET;ORAL				
DARVON-N				
XANODYNE PHARM	100MG	N016862	002	
PROPRANOLOL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
PROPRANOLOL HYDROCHLORIDE				
EXTROVIS	60MG	A078022	001	Feb 15, 2007
	80MG	A078022	002	Feb 15, 2007
	120MG	A078022	003	Feb 15, 2007
	160MG	A078022	004	Feb 15, 2007
INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989
LUPIN LTD	60MG	A204349	001	Jan 12, 2024
	80MG	A204349	002	Jan 12, 2024
	120MG	A204349	003	Jan 12, 2024
	160MG	A204349	004	Jan 12, 2024
UPSHER SMITH LABS	60MG	A078311	001	Mar 06, 2009
	80MG	A078311	002	Mar 06, 2009
	120MG	A078311	003	Mar 06, 2009
	160MG	A078311	004	Mar 06, 2009
CONCENTRATE;ORAL				
PROPRANOLOL HYDROCHLORIDE INTENSOL				
ROXANE	80MG/ML	A071388	001	May 15, 1987
INJECTABLE;INJECTION				
PROPRANOLOL HYDROCHLORIDE				
+ BAXTER HLTHCARE CORP	1MG/ML **	N016419	001	
CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000
FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986
SOLUTION;ORAL				
PROPRANOLOL HYDROCHLORIDE				
PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989
SUSPENSION;ORAL				
INDERAL				
WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986
TABLET;ORAL				
INDERAL				
+ WYETH PHARMS	10MG **	N016418	001	
+	20MG **	N016418	003	
+	40MG **	N016418	002	
+	60MG **	N016418	009	Oct 18, 1982
+	80MG **	N016418	004	
+	90MG **	N016418	010	Oct 18, 1982
PROPRANOLOL HYDROCHLORIDE				
AIPING PHARM INC	90MG	A071288	001	Oct 22, 1986
ANI PHARMS	60MG	A071791	001	Jul 15, 1987
	90MG	A071977	001	Apr 06, 1988
CHARTWELL RX	10MG	A070663	001	Jun 13, 1986
	20MG	A070664	001	Jun 13, 1986
	40MG	A070665	001	Jun 13, 1986
	60MG	A070666	001	Oct 10, 1986
	80MG	A070667	001	Jun 13, 1986
DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
	90MG	A071496	001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
INTERPHARM	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
NORTHSTAR HLTHCARE	10MG	A078213	001	Jan 10, 2008
	20MG	A078213	002	Jan 10, 2008
	40MG	A078213	003	Jan 10, 2008
	60MG	A078213	004	Jan 10, 2008
	80MG	A078213	005	Jan 10, 2008
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A071687	001	Jul 05, 1988
	40MG	A071688	001	Jul 05, 1988
	60MG	A072197	001	Jul 05, 1988
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL					
PROPRANOLOL HYDROCHLORIDE					
	40MG		A070142	001	Jul 30, 1985
	40MG		A070380	001	Mar 19, 1987
	60MG		A070143	001	Jan 15, 1987
	60MG		A070178	002	Apr 23, 2018
	60MG		A070381	001	Mar 19, 1987
	60MG		A071098	001	Oct 06, 1986
	80MG		A070144	001	Jul 30, 1985
	80MG		A070382	001	Mar 19, 1987
	80MG		A070551	001	Jul 10, 1986
	90MG		A071183	001	Oct 06, 1986
	90MG		A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG		A070548	001	Jul 10, 1986
	20MG		A070549	001	Apr 11, 1986
	40MG		A070550	001	Apr 11, 1986

PROPYLIODONE

SUSPENSION;INTRATRACHEAL				
DIONOSIL AQUEOUS				
GLAXOSMITHKLINE	50%	N009309	001	
DIONOSIL OILY				
GLAXOSMITHKLINE	60%	N009309	002	

PROPYLTHIOURACIL

TABLET;ORAL				
PROPYLTHIOURACIL				
ABBOTT	50MG	A084075	001	
ANABOLIC	50MG	A080285	001	
ANI PHARMS	50MG	A080215	001	
CHARTWELL MOLECULAR	50MG	A080016	001	
CHARTWELL RX	50MG	A084543	001	
HALSEY	50MG	A080015	001	
IMPAX LABS	50MG	A080159	001	
LILLY	50MG	N006213	001	
SUN PHARM INDUSTRIES	50MG	A083982	001	
TABLICAPS	50MG	A080840	001	
WATSON LABS	50MG	A080932	001	
	50MG	A085201	001	

PROTAMINE SULFATE

POWDER;INTRAVENOUS				
PROTAMINE SULFATE				
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984
SOLUTION;INTRAVENOUS				
PROTAMINE SULFATE				
HIKMA	50MG/5ML (10MG/ML)	A089474	001	Nov 05, 1986
	50MG/5ML (10MG/ML)	A089475	002	Jun 07, 1988
	250MG/25ML (10MG/ML)	A089475	001	Nov 05, 1986
+ LILLY	50MG/5ML (10MG/ML)	N006460	002	
+	250MG/25ML (10MG/ML) **	N006460	003	

PROTEIN HYDROLYSATE

INJECTABLE;INJECTION				
AMINOSOL 5%				
ABBVIE	5%	N005932	012	Jan 31, 1985
HYPROTIGEN 5%				
B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELIN

INJECTABLE;INJECTION				
THYPINONE				
ABBOTT	0.5MG/ML	N017638	001	
THYREL TRH				
FERRING	0.5MG/ML	N018087	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROTOKYLOL HYDROCHLORIDE

TABLET;ORAL				
VENTAIRE				
SANOFI AVENTIS US	2MG	A083459	001	

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
PROTRIPTYLINE HYDROCHLORIDE				
HIKMA	5MG	A078913	001	Sep 16, 2008
	10MG	A078913	002	Sep 16, 2008
VIVACTIL				
CHARTWELL RX	5MG	A073644	001	Aug 24, 1995
	10MG	A073645	001	Aug 24, 1995
TEVA WOMENS	5MG **	N016012	001	
	10MG **	N016012	002	

PRUCALOPRIDE SUCCINATE

TABLET;ORAL				
PRUCALOPRIDE SUCCINATE				
TORRENT	EQ 1MG BASE	A218778	001	Jun 24, 2025
	EQ 2MG BASE	A218778	002	Jun 24, 2025

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
NOVAFED				
SANOFI AVENTIS US	120MG	N017603	001	
SUDAFED 12 HOUR				
+ GLAXOSMITHKLINE	120MG **	N017941	002	
TABLET, EXTENDED RELEASE;ORAL				
SUDAFED 12 HOUR				
MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
SUDAFED 24 HOUR				
+ KENVUE BRANDS	240MG	N020021	002	Dec 15, 1992

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
ACTIFED				
GLAXOSMITHKLINE	120MG;5MG	N018996	001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
KV PHARM	120MG;5MG	A071798	001	Mar 16, 1989
SYRUP;ORAL				
ACTAHIST				
CENCI	30MG/5ML;1.25MG/5ML	A088344	001	Feb 09, 1984
HISTAFED				
CENCI	30MG/5ML;1.25MG/5ML	A088283	001	Apr 20, 1984
MYFED				
USL PHARMA	30MG/5ML;1.25MG/5ML	A088116	001	Mar 04, 1983
TRILITRON				
NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474	001	Feb 12, 1985
TABLET;ORAL				
ALLERFED				
PVT FORM	60MG;2.5MG	A088860	001	Jan 31, 1985
CORPHED				
CHARTWELL RX	60MG;2.5MG	A088602	001	Apr 11, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE				
SANDOZ	60MG;2.5MG	A088193	001	May 17, 1983
TRILITRON				
NEWTRON PHARMS	60MG;2.5MG	A088515	001	Jan 09, 1985
TRIPHED				
TEVA	60MG;2.5MG	A088630	001	May 17, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE				
WATSON LABS	60MG;2.5MG	A088318	002	Jan 13, 1984
WEST WARD	60MG;2.5MG	A088117	001	Apr 19, 1983
TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273	001	Dec 12, 1984
SUPERPHARM	60MG;2.5MG	A088578	001	Feb 21, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
KV PHARM	120MG;5MG	A072758	001	Nov 25, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
PSEUDO-12				
	UCB INC	EQ 60MG HYDROCHLORIDE/5ML	N019401 001	Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
AFRINOL				
+	SCHERING PLOUGH	120MG	N018191 001	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL				
PYRIDOSTIGMINE BROMIDE				
	ANI PHARMS	30MG	A040512 002	Jul 20, 2005
	IMPAX LABS INC	60MG	A040457 001	Dec 26, 2002
	SOLVAY	30MG	A089572 001	Nov 27, 1990
	US ARMY	30MG	N020414 001	Feb 05, 2003
TABLET, EXTENDED RELEASE;ORAL				
PYRIDOSTIGMINE BROMIDE				
	AMNEAL	105MG	N217604 001	Oct 04, 2024

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HEXA-BETALIN				
	LILLY	100MG/ML	A080854 001	
PYRIDOXINE HYDROCHLORIDE				
	BEL MAR	100MG/ML	A080761 001	
	DELL LABS	50MG/ML	A083771 001	
		100MG/ML	A083772 001	
	DR REDDYS	100MG/ML	A080572 001	
	ELKINS SINN	100MG/ML	A080581 001	
	EPIC PHARMA LLC	100MG/ML	A087967 001	Oct 01, 1982
	LUITPOLD	100MG/ML	A080669 001	
	MYLAN INSTITUTIONAL	100MG/ML	A204879 001	Jul 14, 2016
	WATSON LABS	100MG/ML	A083760 001	

PYRILAMINE MALEATE

TABLET;ORAL				
PYRILAMINE MALEATE				
	IMPAX LABS	25MG	A080808 001	
	WATSON LABS	25MG	A085231 001	

PYRIMETHAMINE

TABLET;ORAL				
PYRIMETHAMINE				
	ALVOGEN	25MG	A211271 001	Jul 27, 2021

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL				
FANSIDAR				
	ROCHE	25MG;500MG	N018557 001	

PYRITHIONE ZINC

LOTION;TOPICAL				
HEAD & SHOULDERS CONDITIONER				
	WARNER CHILCOTT	0.3%	N019412 002	Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL				
POVAN				
	PARKE DAVIS	EQ 50MG BASE/5ML	N011964 001	
TABLET;ORAL				
POVAN				
	PARKE DAVIS	EQ 50MG BASE	N012485 002	

QUAZEPAM

TABLET;ORAL				
DORAL				
	GALT PHARMS	7.5MG	N018708 003	Feb 26, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUETIAPINE FUMARATE

TABLET;ORAL					
QUETIAPINE FUMARATE					
	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013
		EQ 50MG BASE	A201762	002	Feb 27, 2013
		EQ 100MG BASE	A201762	003	Feb 27, 2013
		EQ 150MG BASE	A201762	004	Feb 27, 2013
		EQ 200MG BASE	A201762	005	Feb 27, 2013
		EQ 300MG BASE	A201762	006	Feb 27, 2013
		EQ 400MG BASE	A201762	007	Feb 27, 2013
	ALEMBIC	EQ 25MG BASE	A203390	001	Oct 28, 2014
		EQ 50MG BASE	A203390	002	Oct 28, 2014
		EQ 100MG BASE	A203390	003	Oct 28, 2014
		EQ 200MG BASE	A203390	004	Oct 28, 2014
		EQ 300MG BASE	A203390	005	Oct 28, 2014
		EQ 400MG BASE	A203390	006	Oct 28, 2014
	CHARTWELL RX	EQ 25MG BASE	A078679	001	Dec 14, 2012
		EQ 50MG BASE	A078679	002	Dec 14, 2012
		EQ 100MG BASE	A078679	003	Dec 14, 2012
		EQ 150MG BASE	A078679	004	Dec 14, 2012
		EQ 200MG BASE	A078679	005	Dec 14, 2012
		EQ 300MG BASE	A078679	006	Dec 14, 2012
		EQ 400MG BASE	A078679	007	Dec 14, 2012
	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024
		EQ 50MG BASE	A205983	002	May 20, 2024
		EQ 100MG BASE	A205983	003	May 20, 2024
		EQ 200MG BASE	A205983	004	May 20, 2024
		EQ 300MG BASE	A205983	005	May 20, 2024
		EQ 400MG BASE	A205983	006	May 20, 2024
	JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013
	PHARMOBEDIENT	EQ 25MG BASE	A090323	001	Mar 27, 2012
	SUN PHARM	EQ 200MG BASE	A201190	004	Mar 27, 2012
	TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012
		EQ 50MG BASE	A200363	002	Mar 27, 2012
		EQ 100MG BASE	A200363	003	Mar 27, 2012
		EQ 200MG BASE	A200363	004	Mar 27, 2012
		EQ 300MG BASE	A200363	005	Mar 27, 2012
		EQ 400MG BASE	A200363	006	Mar 27, 2012
SEROQUEL					
+	CHEPLAPHARM	EQ 150MG BASE **	N020639	004	Dec 20, 1998
TABLET, EXTENDED RELEASE;ORAL					
QUETIAPINE FUMARATE					
	AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018
	PH HEALTH	EQ 50MG BASE	A090482	001	May 09, 2017
		EQ 150MG BASE	A090482	002	May 09, 2017
		EQ 150MG BASE	A090757	001	Dec 01, 2017
		EQ 200MG BASE	A090482	003	May 09, 2017
		EQ 200MG BASE	A090757	002	Dec 01, 2017
		EQ 300MG BASE	A090482	004	May 09, 2017
		EQ 300MG BASE	A090757	003	Dec 01, 2017
		EQ 400MG BASE	A090482	005	May 09, 2017
		EQ 400MG BASE	A090757	004	Dec 01, 2017
	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017
		EQ 150MG BASE	A206260	002	May 09, 2017
		EQ 200MG BASE	A206260	003	May 09, 2017
		EQ 300MG BASE	A206260	004	May 09, 2017
		EQ 400MG BASE	A206260	005	May 09, 2017
	RISING	EQ 50MG BASE	A202228	001	Feb 02, 2021
		EQ 150MG BASE	A202228	002	Feb 02, 2021
		EQ 200MG BASE	A202228	003	Feb 02, 2021
		EQ 300MG BASE	A202228	004	Feb 02, 2021
		EQ 400MG BASE	A202228	005	Feb 02, 2021

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL					
ACCUPRIL					
+	PFIZER PHARMS	EQ 5MG BASE **	N019885	001	Nov 19, 1991
+		EQ 10MG BASE **	N019885	002	Nov 19, 1991
+		EQ 20MG BASE **	N019885	003	Nov 19, 1991
+		EQ 40MG BASE **	N019885	004	Nov 19, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINAPRIL HYDROCHLORIDE				
TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 5MG BASE	A076459	001	Dec 22, 2004
	EQ 10MG BASE	A076459	002	Dec 22, 2004
	EQ 20MG BASE	A076459	003	Dec 22, 2004
	EQ 40MG BASE	A076459	004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005
	EQ 10MG BASE	A076049	002	Jan 14, 2005
	EQ 20MG BASE	A076049	003	Jan 14, 2005
	EQ 40MG BASE	A076049	004	Jan 14, 2005
ANI PHARMS	EQ 5MG BASE	A075504	001	Aug 24, 2007
	EQ 10MG BASE	A075504	002	Aug 24, 2007
	EQ 20MG BASE	A075504	003	Aug 24, 2007
	EQ 40MG BASE	A075504	004	Aug 24, 2007
APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006
	EQ 10MG BASE	A076240	002	Jan 26, 2006
	EQ 20MG BASE	A076240	003	Jan 26, 2006
	EQ 40MG BASE	A076240	004	Jan 26, 2006
INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007
	EQ 10MG BASE	A078457	002	Aug 24, 2007
	EQ 20MG BASE	A078457	003	Aug 24, 2007
	EQ 40MG BASE	A078457	004	Aug 24, 2007
MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005
	EQ 10MG BASE	A076036	002	Jan 28, 2005
	EQ 20MG BASE	A076036	003	Jan 28, 2005
	EQ 40MG BASE	A076036	004	Jan 28, 2005
PHARMOBEDIENT	EQ 5MG BASE	A076694	001	Dec 23, 2004
	EQ 10MG BASE	A076694	002	Dec 23, 2004
	EQ 20MG BASE	A076694	003	Dec 23, 2004
	EQ 40MG BASE	A076694	004	Dec 23, 2004
SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004
	EQ 5MG BASE	A090800	001	Jun 18, 2009
	EQ 10MG BASE	A076607	002	Dec 15, 2004
	EQ 10MG BASE	A090800	002	Jun 18, 2009
	EQ 20MG BASE	A076607	003	Dec 15, 2004
	EQ 20MG BASE	A090800	003	Jun 18, 2009
	EQ 40MG BASE	A076607	004	Dec 15, 2004
	EQ 40MG BASE	A090800	004	Jun 18, 2009
QUINESTROL				
TABLET;ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG	N016768	002	
	0.2MG	N016768	003	
QUINETHAZONE				
TABLET;ORAL				
HYDROMOX				
LEDERLE	50MG	N013264	001	
QUINETHAZONE; RESERPINE				
TABLET;ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG	N013927	001	
QUINIDINE GLUCONATE				
INJECTABLE;INJECTION				
QUINIDINE GLUCONATE				
+ LILLY	80MG/ML	N007529	002	Feb 10, 1989
TABLET;ORAL				
QUINACT				
BAYER HLTHCARE	266MG	A085978	001	
	400MG	A086099	001	
TABLET, EXTENDED RELEASE;ORAL				
DURAQUIN				
WARNER CHILCOTT	330MG	N017917	001	
QUINAGLUTE				
+ BAYER HLTHCARE	324MG **	N016647	001	
QUINALAN				
CHARTWELL MOLECULAR	324MG	A088081	001	Feb 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINATIME				
WATSON LABS	324MG		A087448 001	
QUINIDINE GLUCONATE				
ANI PHARMS	324MG		A087810 001	Sep 29, 1982
ASCOT	324MG		A088582 001	Jun 17, 1985
CYCLE	324MG		A088431 001	Jan 06, 1984
HALSEY	324MG		A089476 001	Apr 10, 1987
RISING	324MG		A089894 001	Dec 15, 1988
SUPERPHARM	324MG		A089164 001	Nov 21, 1985
WATSON LABS	324MG		A087785 001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET;ORAL

CARDIOQUIN				
PHARM RES ASSOC	275MG		N011642 002	

QUINIDINE SULFATE

CAPSULE;ORAL

CIN-QUIN				
SOLVAY	200MG		A085296 001	
	300MG		A085297 001	
QUINIDINE SULFATE				
LILLY	200MG		A085103 001	

TABLET;ORAL

CIN-QUIN				
+ SOLVAY	100MG		A085299 001	
+	200MG		A084932 001	
	300MG		A085298 001	
QUINIDINE SULFATE				
BARR	200MG		A084177 001	
CHARTWELL MOLECULAR	200MG		A083743 001	
CHARTWELL RX	300MG		A089839 001	Sep 29, 1988
CONTRACT PHARMACAL	200MG		A083808 001	
CYCLE	200MG		A083640 001	
	300MG		A085632 001	
DAVA PHARMS INC	200MG		A087011 001	
ELKINS SINN	200MG		A083622 001	
EVERYLIFE	200MG		A083439 001	
HALSEY	200MG		A083583 001	
HIKMA	200MG		A083862 001	
IMPAX LABS	200MG		A083347 001	
IVAX SUB TEVA PHARMS	200MG		A084549 001	
KING PHARMS	200MG		A085175 001	
KV PHARM	200MG		A085276 001	
LEDERLE	200MG		A086176 001	
LILLY	200MG		A085038 001	
PERRIGO	200MG		A085322 001	
PHARMAVITE	200MG		A084627 001	
PUREPAC PHARM	200MG		A084003 001	
SANDOZ	200MG		A084631 001	
	200MG		A084914 001	
SCHERER LABS	200MG		A085068 001	
SUN PHARM INDUSTRIES	100MG		A081029 001	Apr 14, 1989
	200MG		A081030 001	Apr 14, 1989
	300MG		A081031 001	Apr 14, 1989
SUPERPHARM	200MG		A088973 001	Apr 10, 1985
USL PHARMA	200MG		A087837 001	Apr 14, 1982
VALEANT PHARM INTL	200MG		A083393 001	
VANGARD	200MG		A087909 001	Jul 13, 1982
VINTAGE PHARMS	200MG		A083963 001	
WARNER CHILCOTT	200MG		A083879 001	
WATSON LABS	100MG		A085584 001	
	200MG		A083288 001	
	200MG		A085140 002	
	300MG		A085583 001	
WHITEWORTH TOWN PLSN	200MG		A085444 001	
QUINORA				
KEY PHARMS	200MG		A083576 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINIDINE SULFATE					
TABLET;ORAL					
QUINORA					
+	SCHERING	300MG	A085222	001	
TABLET, EXTENDED RELEASE;ORAL					
QUINIDEX					
	WYETH PHARMS INC	300MG	N012796	002	
QUINIDINE SULFATE					
	COSETTE	300MG	A040045	001	Jun 30, 1994
QUININE SULFATE					
CAPSULE;ORAL					
QUALAQUIN					
+	SUN PHARM INDUSTRIES	324MG **	N021799	001	Aug 12, 2005
QUININE SULFATE					
	AUROBINDO PHARMA USA	324MG	A202581	001	Dec 14, 2012
RABEPRAZOLE SODIUM					
CAPSULE, DELAYED RELEASE;ORAL					
ACIPHEX SPRINKLE					
+	AYTU	5MG	N204736	001	Mar 26, 2013
+		10MG	N204736	002	Mar 26, 2013
TABLET, DELAYED RELEASE;ORAL					
ACIPHEX					
+	WAYLIS THERAP	10MG **	N020973	001	May 29, 2002
RABEPRAZOLE SODIUM					
	PHARMOBEDIENT	20MG	A076885	001	Nov 08, 2013
	TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013
RALTEGRAVIR POTASSIUM					
TABLET;ORAL					
RALTEGRAVIR POTASSIUM					
	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024
RAMELTEON					
TABLET;ORAL					
RAMELTEON					
	GRANULES	8MG	A213186	001	Aug 21, 2020
RAMIPRIL					
CAPSULE;ORAL					
ALTACE					
+	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991
+		2.5MG	N019901	002	Jan 28, 1991
+		5MG	N019901	003	Jan 28, 1991
+		10MG	N019901	004	Jan 28, 1991
RAMIPRIL					
	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014
		2.5MG	A202392	002	Apr 15, 2014
		5MG	A202392	003	Apr 15, 2014
		10MG	A202392	004	Apr 15, 2014
	ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
		2.5MG	A077513	002	Jun 18, 2008
		5MG	A077513	003	Jun 18, 2008
		10MG	A077513	004	Jun 18, 2008
	CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008
		2.5MG	A077514	002	Jun 18, 2008
		5MG	A077514	003	Jun 18, 2008
		10MG	A077514	004	Jun 18, 2008
	CIPLA	1.25MG	A077004	001	Aug 07, 2008
		2.5MG	A077004	002	Aug 07, 2008
		5MG	A077004	003	Aug 07, 2008
		10MG	A077004	004	Aug 07, 2008
	RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
		10MG	A078849	002	Mar 06, 2009
	TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008
		2.5MG	A077470	002	Jun 18, 2008
		5MG	A077470	003	Jun 18, 2008
		10MG	A077470	004	Jun 18, 2008
	WATSON LABS	5MG	A076549	003	Oct 24, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RAMIPRIL				
TABLET;ORAL				
ALTACE				
+ KING PFIZER	1.25MG **	N022021	001	Feb 27, 2007
+	2.5MG **	N022021	002	Feb 27, 2007
+	5MG **	N022021	003	Feb 27, 2007
+	10MG **	N022021	004	Feb 27, 2007
RAMIPRIL				
APOTEX	1.25MG	A091069	001	Dec 02, 2015
	2.5MG	A091069	002	Dec 02, 2015
	5MG	A091069	003	Dec 02, 2015
	10MG	A091069	004	Dec 02, 2015
NATCO PHARMA	1.25MG	A090650	001	Jun 30, 2011
	2.5MG	A090650	002	Jun 30, 2011
	5MG	A090650	003	Jun 30, 2011
	10MG	A090650	004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
	2.5MG	A090697	002	Sep 24, 2009
	5MG	A090697	003	Sep 24, 2009
	10MG	A090697	004	Sep 24, 2009
RANITIDINE BISMUTH CITRATE				
TABLET;ORAL				
TRITEC				
GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
RANITIDINE HYDROCHLORIDE				
CAPSULE;ORAL				
RANITIDINE HYDROCHLORIDE				
AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018
	EQ 300MG BASE	A209859	002	Sep 27, 2018
APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019
	EQ 300MG BASE	A211893	002	Apr 05, 2019
AUROBINDO PHARMA	EQ 150MG BASE	A211058	001	Jul 16, 2018
	EQ 300MG BASE	A211058	002	Jul 16, 2018
NOVITIUM PHARMA	EQ 150MG BASE	A210681	001	Nov 23, 2018
	EQ 300MG BASE	A210681	002	Nov 23, 2018
PHARMOBEDIENT	EQ 150MG BASE	A075564	001	Oct 27, 2000
	EQ 300MG BASE	A075564	002	Oct 27, 2000
TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
	EQ 300MG BASE	A075557	002	Oct 31, 2003
ZANTAC 150				
+ GLAXOSMITHKLINE	EQ 150MG BASE **	N020095	001	Mar 08, 1994
ZANTAC 300				
+ GLAXOSMITHKLINE	EQ 300MG BASE **	N020095	002	Mar 08, 1994
GRANULE, EFFERVESCENT;ORAL				
ZANTAC 150				
GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994
INJECTABLE;INJECTION				
RANITIDINE HYDROCHLORIDE				
BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
HIKMA	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005
	EQ 25MG BASE/ML	A077458	001	Feb 16, 2006
MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016
ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013
ZANTAC				
+ PAI HOLDINGS PHARM	EQ 25MG BASE/ML **	N019090	001	Oct 19, 1984
ZANTAC IN PLASTIC CONTAINER				
PAI HOLDINGS PHARM	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986
SYRUP;ORAL				
RANITIDINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007
AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008
APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
AUROBINDO PHARMA	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010
EPIC PHARMA LLC	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011
LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010
	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010
NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL					
RANITIDINE HYDROCHLORIDE					
		EQ 15MG BASE/ML	A091091	001	Sep 20, 2011
	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007
	RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
	SUN PHARMA CANADA	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011
	TOLMAR	EQ 15MG BASE/ML	A090054	001	Nov 15, 2010
	TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009
	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009
ZANTAC					
+	GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988
TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
	AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006
		EQ 300MG BASE	A077824	002	Oct 13, 2006
	ANI PHARMS	EQ 75MG BASE	A075212	001	Jan 14, 2000
		EQ 75MG BASE	A075296	001	Jan 14, 2000
		EQ 150MG BASE	A074488	001	Jul 31, 1997
		EQ 150MG BASE	A077426	001	Dec 19, 2005
		EQ 300MG BASE	A074488	002	Jul 31, 1997
		EQ 300MG BASE	A077426	002	Dec 19, 2005
	APOTEX	EQ 75MG BASE	A075167	001	May 04, 2000
		EQ 150MG BASE	A074680	001	Sep 12, 1997
		EQ 300MG BASE	A074680	002	Sep 12, 1997
	APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012
	AUROBINDO PHARMA	EQ 75MG BASE	A207579	001	Nov 13, 2017
		EQ 150MG BASE	A207578	001	Nov 13, 2017
	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
		EQ 300MG BASE	A074662	002	Aug 29, 1997
	CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008
		EQ 300MG BASE	A078542	002	Nov 19, 2008
	GRANULES	EQ 150MG BASE	A210243	001	Aug 20, 2018
		EQ 150MG BASE	A210243	002	Aug 20, 2018
	HERITAGE PHARMA AVET	EQ 150MG BASE	A075165	001	Sep 30, 1998
		EQ 300MG BASE	A075165	002	Sep 30, 1998
	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017
		EQ 300MG BASE	A203694	002	Nov 30, 2017
	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997
		EQ 300MG BASE	A074023	002	Aug 22, 1997
	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
		EQ 150MG BASE	A091429	002	May 11, 2011
	PH HEALTH	EQ 150MG BASE	A075180	001	Jan 28, 1999
		EQ 300MG BASE	A075180	002	Jan 28, 1999
	PHARMOBEDIENT	EQ 75MG BASE	A075497	001	Jan 14, 2000
		EQ 150MG BASE	A074552	001	Jul 30, 1998
		EQ 300MG BASE	A074552	002	Jul 30, 1998
	RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
		EQ 150MG BASE	A075000	001	Jan 30, 1998
		EQ 300MG BASE	A075000	002	Jan 30, 1998
	SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
	STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
		EQ 75MG BASE	A209160	001	Mar 05, 2018
		EQ 150MG BASE	A200536	001	Jun 28, 2011
		EQ 150MG BASE	A205512	001	Aug 22, 2016
		EQ 150MG BASE	A209161	001	Feb 22, 2018
		EQ 150MG BASE	A210010	001	Aug 01, 2018
		EQ 300MG BASE	A205512	002	Aug 22, 2016
		EQ 300MG BASE	A210010	002	Aug 01, 2018
	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000
		EQ 150MG BASE	A075439	001	Apr 19, 2000
		EQ 300MG BASE	A075439	002	Apr 19, 2000
	THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019
		EQ 150MG BASE	A210228	001	Aug 30, 2019
	WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997
		EQ 300MG BASE	A074864	002	Oct 20, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANITIDINE HYDROCHLORIDE

TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
	WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
		EQ 75MG BASE	A078884	001	Jul 31, 2008
		EQ 150MG BASE	A078653	001	Nov 26, 2007
		EQ 150MG BASE	A078701	001	Nov 12, 2009
		EQ 300MG BASE	A078701	002	Dec 11, 2009
	WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998
		EQ 300MG BASE	A075208	002	Dec 17, 1998
ZANTAC 150					
+	CHATTEM SANOFI	EQ 150MG BASE	N021698	001	Aug 31, 2004
+		EQ 150MG BASE	N021698	002	Mar 13, 2007
+	GLAXO GRP LTD	EQ 150MG BASE **	N018703	001	Jun 09, 1983
ZANTAC 300					
+	GLAXO GRP LTD	EQ 300MG BASE **	N018703	002	Dec 09, 1985
ZANTAC 75					
+	CHATTEM SANOFI	EQ 75MG BASE	N020520	001	Dec 19, 1995
TABLET, EFFERVESCENT;ORAL					
ZANTAC 150					
	GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994
ZANTAC 25					
	GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004
ZANTAC 75					
+	CHATTEM SANOFI	EQ 75MG BASE **	N020745	001	Feb 26, 1998

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL					
ASPRUZYO SPRINKLE					
+	SPIL	500MG	N216018	001	Feb 28, 2022
+		1GM	N216018	002	Feb 28, 2022
TABLET, EXTENDED RELEASE;ORAL					
RANEXA					
+	MENARINI INTL	500MG **	N021526	002	Jan 27, 2006
+		1GM **	N021526	001	Feb 12, 2007
RANOLAZINE					
	ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021
		1GM	A212930	002	May 18, 2021
	AMNEAL	500MG	A207690	001	Mar 11, 2021
		1GM	A207690	002	Mar 11, 2021
	ANI PHARMS	500MG	A210482	001	Oct 29, 2019
		1GM	A210482	002	Oct 29, 2019
	CIPLA	500MG	A211291	001	May 28, 2019
		1GM	A211291	002	May 28, 2019
	PIRAMAL	500MG	A213085	001	Jul 25, 2023
		1GM	A213085	002	Jul 25, 2023
	SUN PHARM	500MG	A211707	001	May 28, 2019
		1GM	A211707	002	May 28, 2019
	TORRENT	500MG	A210407	001	Feb 04, 2025
		1GM	A210407	002	Feb 04, 2025

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION					
RAPLON					
	ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
		200MG/VIAL	N020984	002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL					
RASAGILINE MESYLATE					
	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013
		EQ 1MG BASE	A201950	002	Sep 12, 2013
	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013
		EQ 1MG BASE	A201823	002	Jul 01, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL				
HIWOLFIA				
BOWMAN PHARMS	50MG	N009276 003		
	50MG	N009276 005		
	100MG	N009276 004		
HYSERPIN				
PHYS PRODS VA	50MG	N010581 001		
KOGLUCOID				
PANRAY	50MG	N009278 001		
	100MG	N009278 002		
RAUDIXIN				
APOTHECON	50MG	N008842 001		
	100MG	N008842 002		
RAUSERPIN				
FERNDALE LABS	50MG	N009926 002		
	100MG	N009926 004		
RAUVAL				
PAL PAK	50MG	N009108 002		
	100MG	N009108 004		
RAUWOLFIA SERPENTINA				
BUNDY	50MG	N009477 001		
	100MG	N009477 002		
HALSEY	50MG	A080498 001		
	100MG	A080498 002		
IMPAX LABS	50MG	N009273 001		
	100MG	N009273 002		
IVAX SUB TEVA PHARMS	50MG	N011521 001		
	100MG	N011521 002		
PUREPAC PHARM	50MG	A080842 001		
	100MG	A080842 002		
PVT FORM	50MG	A080583 001		
	100MG	A080583 002		
SOLVAY	50MG	A080500 001		
	100MG	A080500 002		
TABLICAPS	50MG	A083867 001		
	100MG	A083444 001		
VALEANT PHARM INTL	50MG	N009668 001		
	100MG	N009668 002		
WATSON LABS	50MG	A080907 001		
	100MG	A080914 001		
WOLFINA				
FOREST PHARMS	50MG	N009255 008		
	100MG	N009255 006		

REGORAFENIB

TABLET;ORAL				
REGORAFENIB				
ACTAVIS LABS FL	40MG	A209728 001	Jan 13, 2025	

REMDESIVIR

SOLUTION;INTRAVENOUS				
VEKLURY				
+ GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787 002	Oct 22, 2020	

REPAGLINIDE

TABLET;ORAL				
PRANDIN				
+ GEMINI LABS LLC	0.5MG **	N020741 001	Dec 22, 1997	
+	1MG **	N020741 002	Dec 22, 1997	
+	2MG **	N020741 003	Dec 22, 1997	
REPAGLINIDE				
ACTAVIS TOTOWA	0.5MG	A090008 001	Jan 22, 2014	
	1MG	A090008 002	Jan 22, 2014	
	2MG	A090008 003	Jan 22, 2014	
KENTON	0.5MG	A091517 001	Apr 24, 2015	
	1MG	A091517 002	Apr 24, 2015	
	2MG	A091517 003	Apr 24, 2015	
QUAGEN	0.5MG	A090252 001	Aug 23, 2013	
	1MG	A090252 002	Jan 22, 2014	
	2MG	A090252 003	Jan 22, 2014	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

REPAGLINIDE				
TABLET;ORAL				
REPAGLINIDE				
SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013
	2MG	A077571	003	Jul 11, 2013
RESCINNAMINE				
CAPSULE;ORAL				
CINNASIL				
PANRAY	0.5MG	A084736	001	
TABLET;ORAL				
MODERIL				
PFIZER	0.25MG	N010686	003	
	0.5MG	N010686	006	
RESERPINE				
ELIXIR;ORAL				
SERPASIL				
NOVARTIS	0.2MG/4ML	N009115	005	
INJECTABLE;INJECTION				
SANDRIL				
LILLY	2.5MG/ML	N010012	001	
SERPASIL				
NOVARTIS	2.5MG/ML	N009434	002	
TABLET;ORAL				
HISERPIA				
BOWMAN PHARMS	0.1MG	N009631	002	
	0.25MG	N009631	004	
RAU-SED				
BRISTOL MYERS SQUIBB	0.1MG	N009357	001	
	0.25MG	N009357	004	
	0.5MG	N009357	006	
	1MG	N009357	008	
RESERPINE				
BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
CYCLE	0.1MG	N009859	001	
	0.25MG	N009859	002	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
HIKMA INTL PHARMS	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RESERPINE					
TABLET;ORAL					
RESERPINE					
+	SANDOZ	0.1MG	N009838	001	
+		0.25MG	N009838	002	
	SOLVAY	0.25MG	A080446	001	
	TABLICAPS	0.25MG	A085207	001	
	TEVA	0.1MG	A089020	001	Mar 07, 1985
		0.25MG	A089019	001	Mar 07, 1985
	VALEANT PHARM INTL	0.1MG	N009667	001	
		0.25MG	N009667	002	
	WATSON LABS	0.1MG	A080679	001	
		0.25MG	A080393	001	
		0.25MG	A085401	001	
		1MG	A080749	001	
	WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
		0.25MG	A080723	002	
		1MG	A080723	003	
SANDRIL					
	LILLY	0.1MG	N009376	004	
		0.25MG	N009376	001	
SERPALAN					
	LANNETT	0.1MG	N010124	001	
		0.25MG	N010124	002	
SERPANRAY					
	PANRAY	0.1MG	N009391	001	
		0.25MG	N009391	002	
		1MG	N009391	004	
SERPASIL					
	NOVARTIS	0.1MG	N009115	001	
		0.25MG	N009115	003	
		1MG	N009115	004	
SERPATE					
	VALE	0.1MG	N009453	001	
		0.25MG	N009453	002	
SERPIVITE					
	VITARINE	0.25MG	N009645	002	
RESERPINE; TRICHLORMETHIAZIDE					
TABLET;ORAL					
METATENSIN #2					
	SANOFI AVENTIS US	0.1MG;2MG	N012972	001	
METATENSIN #4					
	SANOFI AVENTIS US	0.1MG;4MG	N012972	002	
NAQUIVAL					
	SCHERING	0.1MG;4MG	N012265	003	
TRICHLORMETHIAZIDE W/ RESERPINE					
	WATSON LABS	0.1MG;4MG	A085248	001	
RETAPAMULIN					
OINTMENT;TOPICAL					
ALTABAX					
+	ALMIRALL	1%	N022055	001	Apr 12, 2007
RIBAVIRIN					
CAPSULE;ORAL					
REBETOL					
	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903	001	Jun 03, 1998
+		200MG **	N020903	002	Jul 25, 2001
RIBASPHERE					
	CHARTWELL RX	200MG	A076203	001	Apr 06, 2004
RIBAVIRIN					
	CHARTWELL RX	200MG	A076192	001	Apr 06, 2004
	TEVA	200MG	A076277	001	Oct 04, 2004
FOR SOLUTION;INHALATION					
VIRAZOLE					
+	BAUSCH	6GM/VIAL	N018859	001	Dec 31, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIBAVIRIN					
SOLUTION;ORAL					
REBETOL					
+	SCHERING	40MG/ML	N021546	001	Jul 29, 2003
TABLET;ORAL					
COPEGUS					
+	ROCHE	200MG **	N021511	001	Dec 03, 2002
+		400MG **	N021511	002	Jun 21, 2005
RIBAVIRIN					
	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014
		400MG	A202546	002	Aug 12, 2014
		500MG	A202546	003	Aug 12, 2014
		600MG	A202546	004	Aug 12, 2014
	CHARTWELL RX	200MG	A077456	001	Dec 05, 2005
		400MG	A077456	002	Dec 05, 2005
		600MG	A077456	003	Dec 05, 2005
	HERITAGE PHARMA AVET	200MG	A077053	001	Dec 05, 2005
	ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007
		500MG	A077094	004	Apr 18, 2008
		600MG	A077094	003	Mar 16, 2007
RIFABUTIN					
CAPSULE;ORAL					
RIFABUTIN					
	LUPIN LTD	150MG	A090033	001	Feb 24, 2014
RIFAMPIN					
CAPSULE;ORAL					
RIFADIN					
+	SANOFI AVENTIS US	150MG **	N050420	002	
+		300MG **	N050420	001	
RIFAMPIN					
	HIKMA	150MG	A065028	001	Mar 14, 2001
		300MG	A065028	002	Mar 14, 2001
INJECTABLE;INJECTION					
RIFAMPIN					
	AVET LIFESCIENCES	600MG/VIAL	A204101	001	Aug 18, 2014
	WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016
RIFAMYCIN SODIUM					
TABLET, DELAYED RELEASE;ORAL					
AEMCOLO					
+	COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018
RILUZOLE					
FILM;ORAL					
EXSERVAN					
+	AQUESTIVE	50MG	N212640	001	Nov 22, 2019
TABLET;ORAL					
RILUTEK					
+	COVIS	50MG	N020599	001	Dec 12, 1995
RILUZOLE					
	APOTEX CORP	50MG	A091300	001	Jun 18, 2013
	DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018
	PHARMOBEDIENT	50MG	A203042	001	Jul 01, 2013
	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013
RIMANTADINE HYDROCHLORIDE					
SYRUP;ORAL					
FLUMADINE					
	FOREST LABS	50MG/5ML	N019650	001	Sep 17, 1993
TABLET;ORAL					
FLUMADINE					
+	SUN PHARM INDS INC	100MG **	N019649	001	Sep 17, 1993
RIMANTADINE HYDROCHLORIDE					
	CHARTWELL RX	100MG	A076375	001	Jan 14, 2003
	IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

	HARROW EYE	1%	N020474	001	Dec 30, 1994

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

+	APIL	5MG	N020835	002	Apr 14, 2000
+		30MG	N020835	001	Mar 27, 1998
+		75MG **	N020835	004	Apr 16, 2007

RISEDRONATE SODIUM

	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019
	PHARMOBEDIENT	5MG	A200477	001	Nov 30, 2015
		30MG	A200477	002	Nov 30, 2015
		35MG	A200477	003	Nov 30, 2015
		75MG	A200477	004	Jun 10, 2014
		150MG	A200477	005	Jun 10, 2014

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

	IMPAX LABS INC	35MG	A205066	001	Jun 29, 2018
	SUN PHARM	35MG	A203925	001	Jul 09, 2019
	ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RISVAN

+	LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024
+		100MG	N214835	002	Mar 29, 2024

RYKINDO

+	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023

SOLUTION;ORAL

RISPERIDONE

	HIKMA	1MG/ML	A076904	001	Jul 29, 2009
	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010
	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009
	PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010
	SUN PHARMA CANADA	1MG/ML	A090347	001	Feb 07, 2011
	WOCKHARDT BIO AG	1MG/ML	A078744	001	Oct 08, 2009

TABLET;ORAL

RISPERDAL

	JANSSEN PHARMS	5MG	N020272	005	Dec 29, 1993

RISPERIDONE

	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008
		0.5MG	A077953	002	Sep 15, 2008
		1MG	A077953	003	Sep 15, 2008
		2MG	A077953	004	Sep 15, 2008
		3MG	A077953	005	Sep 15, 2008
		4MG	A077953	006	Sep 15, 2008
	DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008
		0.5MG	A076288	002	Sep 15, 2008
		1MG	A076288	003	Sep 15, 2008
		2MG	A076288	004	Sep 15, 2008
		3MG	A076288	005	Sep 15, 2008
		4MG	A076288	006	Sep 15, 2008
	HERITAGE PHARMA AVET	0.25MG	A076228	001	Jun 30, 2008
		0.25MG	A077769	001	Oct 16, 2008
		0.5MG	A076228	002	Jun 30, 2008
		0.5MG	A077769	002	Oct 16, 2008
		1MG	A076228	003	Jun 30, 2008
		1MG	A077769	003	Oct 16, 2008
		2MG	A076228	004	Jun 30, 2008
		2MG	A077769	004	Oct 16, 2008
		3MG	A076228	005	Jun 30, 2008
		3MG	A077769	005	Oct 16, 2008
		4MG	A076228	006	Jun 30, 2008
		4MG	A077769	006	Oct 16, 2008
	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010
		0.5MG	A077784	002	Jun 08, 2010
		1MG	A077784	003	Jun 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RISPERIDONE

TABLET;ORAL					
RISPERIDONE					
		2MG	A077784	004	Jun 08, 2010
		3MG	A077784	005	Jun 08, 2010
		4MG	A077784	006	Jun 08, 2010
	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
		0.5MG	A078036	002	Mar 10, 2014
		1MG	A078036	003	Mar 10, 2014
		2MG	A078036	004	Mar 10, 2014
		3MG	A078036	005	Mar 10, 2014
		4MG	A078036	006	Mar 10, 2014
	SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
		0.5MG	A078187	002	Oct 22, 2009
		1MG	A078187	003	Oct 22, 2009
		2MG	A078187	004	Oct 22, 2009
		3MG	A078187	005	Oct 22, 2009
		4MG	A078187	006	Oct 22, 2009
	WATSON LABS	0.25MG	A077860	001	Dec 05, 2008
		0.5MG	A077860	002	Dec 05, 2008
		1MG	A077860	003	Dec 05, 2008
		2MG	A077860	004	Dec 05, 2008
		3MG	A077860	005	Dec 05, 2008
		4MG	A077860	006	Dec 05, 2008
	WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009
		0.5MG	A078740	002	May 29, 2009
		1MG	A078740	003	May 29, 2009
		2MG	A078740	004	May 29, 2009
		3MG	A078740	005	May 29, 2009
		4MG	A078740	006	May 29, 2009
TABLET, ORALLY DISINTEGRATING;ORAL					
RISPERDAL					
+	JANSSEN PHARMS	0.5MG **	N021444	001	Apr 02, 2003
+		1MG **	N021444	002	Apr 02, 2003
+		2MG **	N021444	003	Apr 02, 2003
+		3MG **	N021444	004	Dec 23, 2004
+		4MG **	N021444	005	Dec 23, 2004
RISPERIDONE					
	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011
		1MG	A076996	002	Apr 19, 2011
		2MG	A076996	003	Apr 19, 2011
		3MG	A076996	004	Apr 19, 2011
		4MG	A076996	005	Apr 19, 2011
	CHARTWELL RX	0.5MG	A076908	001	Mar 12, 2012
		1MG	A076908	002	Mar 12, 2012
		2MG	A076908	003	Mar 12, 2012
	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013
		0.5MG	A091537	001	Mar 30, 2011
		1MG	A091537	002	Mar 30, 2011
		2MG	A091537	003	Mar 30, 2011
		3MG	A091537	004	Mar 30, 2011
		4MG	A091537	005	Mar 30, 2011
	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013
		1MG	A078464	002	Apr 08, 2013
		2MG	A078464	003	Apr 08, 2013
		3MG	A078464	004	Apr 08, 2013
		4MG	A078464	005	Apr 08, 2013

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RITODRINE HYDROCHLORIDE					
	ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
		15MG/ML	A071189	001	Jul 23, 1987
	HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
		15MG/ML	A071619	001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991
YUTOPAR					
	ASTRAZENECA	10MG/ML	N018580	001	
		15MG/ML	N018580	002	Sep 27, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RITODRINE HYDROCHLORIDE				
TABLET;ORAL				
YUTOPAR				
	ASTRAZENECA	10MG	N018555 001	
RITONAVIR				
CAPSULE;ORAL				
NORVIR				
	ABBOTT	100MG	N020680 001	Mar 01, 1996
+	ABBVIE	100MG **	N020945 001	Jun 29, 1999
RITONAVIR				
	HIKMA	100MG	A205801 001	Dec 03, 2020
SOLUTION;ORAL				
NORVIR				
+	ABBVIE	80MG/ML	N020659 001	Mar 01, 1996
RIVAROXABAN				
TABLET;ORAL				
RIVAROXABAN				
	INVAGEN PHARMS	10MG	A208543 001	May 14, 2025
		15MG	A208543 002	May 14, 2025
		20MG	A208543 003	May 14, 2025
	MSN	10MG	A208546 002	Oct 24, 2025
		15MG	A208546 003	Oct 24, 2025
		20MG	A208546 004	Oct 24, 2025
RIVASTIGMINE				
FILM, EXTENDED RELEASE;TRANSDERMAL				
RIVASTIGMINE				
	ALVOGEN	4.6MG/24HR	A204403 001	Sep 03, 2015
		9.5MG/24HR	A204403 002	Sep 03, 2015
		13.3MG/24HR	A204403 003	Aug 31, 2015
RIVASTIGMINE TARTRATE				
CAPSULE;ORAL				
EXELON				
+	NOVARTIS	EQ 1.5MG BASE **	N020823 003	Apr 21, 2000
+		EQ 3MG BASE **	N020823 004	Apr 21, 2000
+		EQ 4.5MG BASE **	N020823 005	Apr 21, 2000
+		EQ 6MG BASE **	N020823 006	Apr 21, 2000
RIVASTIGMINE TARTRATE				
	APOTEX INC	EQ 1.5MG BASE	A091072 001	May 16, 2013
		EQ 3MG BASE	A091072 002	May 16, 2013
		EQ 4.5MG BASE	A091072 003	May 16, 2013
		EQ 6MG BASE	A091072 004	May 16, 2013
	SUN PHARM	EQ 1.5MG BASE	A077131 001	Oct 22, 2007
		EQ 3MG BASE	A077131 002	Oct 22, 2007
		EQ 4.5MG BASE	A077131 003	Oct 22, 2007
		EQ 6MG BASE	A077131 004	Oct 22, 2007
SOLUTION;ORAL				
EXELON				
+	NOVARTIS	EQ 2MG BASE/ML	N021025 001	Apr 21, 2000
RIZATRIPTAN BENZOATE				
FILM;ORAL				
RIZAFILM				
+	GENSCO	EQ 10MG BASE	N205394 001	Apr 14, 2023
TABLET;ORAL				
MAXALT				
+	ORGANON LLC	EQ 5MG BASE **	N020864 001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
	APOTEX INC	EQ 5MG BASE	A202244 001	Dec 31, 2012
		EQ 10MG BASE	A202244 002	Dec 31, 2012
	AVET LIFESCIENCES	EQ 5MG BASE	A204090 001	Nov 26, 2013
		EQ 10MG BASE	A204090 002	Nov 26, 2013
	GLENMARK PHARMS LTD	EQ 5MG BASE	A201967 001	Dec 31, 2012
		EQ 10MG BASE	A201967 002	Dec 31, 2012
	INVAGEN PHARMS	EQ 5MG BASE	A204339 001	Jul 01, 2013
		EQ 10MG BASE	A204339 002	Jul 01, 2013
	JUBILANT GENERICS	EQ 5MG BASE	A203252 001	Dec 31, 2014
		EQ 10MG BASE	A203252 002	Dec 31, 2014
	NATCO PHARMA LTD	EQ 5MG BASE	A200482 001	Dec 31, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIZATRIPTAN BENZOATE				
TABLET;ORAL				
RIZATRIPTAN BENZOATE				
	EQ 10MG BASE	A200482	002	Dec 31, 2012
SANDOZ	EQ 5MG BASE	A079230	001	Dec 31, 2012
	EQ 10MG BASE	A079230	002	Dec 31, 2012
UNICHEM	EQ 5MG BASE	A207836	001	Mar 07, 2017
	EQ 10MG BASE	A207836	002	Mar 07, 2017
TABLET, ORALLY DISINTEGRATING;ORAL				
MAXALT-MLT				
+ ORGANON	EQ 5MG BASE **	N020865	001	Jun 29, 1998
RIZATRIPTAN BENZOATE				
APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013
	EQ 10MG BASE	A202477	002	Jul 01, 2013
CHARTWELL RX	EQ 5MG BASE	A078739	001	Jul 01, 2013
	EQ 10MG BASE	A078739	002	Jul 01, 2013
GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013
	EQ 10MG BASE	A201914	002	Jul 01, 2013
JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015
	EQ 10MG BASE	A203334	002	Oct 16, 2015
NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013
	EQ 10MG BASE	A203478	002	Jul 01, 2013
PHARMOBEDIENT	EQ 5MG BASE	A078173	001	Dec 31, 2012
	EQ 10MG BASE	A078173	002	Dec 31, 2012
UNICHEM	EQ 5MG BASE	A207835	001	Mar 07, 2017
	EQ 10MG BASE	A207835	002	Mar 07, 2017
ROCURONIUM BROMIDE				
INJECTABLE;INJECTION				
ROCURONIUM BROMIDE				
HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023
RISING	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024
	100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024
TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008
	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008
ZEMURON				
+ ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214	001	Mar 17, 1994
+	10MG/ML (10MG/ML) **	N020214	002	Mar 17, 1994
+	100MG/10ML (10MG/ML) **	N020214	003	Mar 17, 1994
ROFECOXIB				
SUSPENSION;ORAL				
VIOXX				
MERCK	12.5MG/5ML	N021052	001	May 20, 1999
	25MG/5ML	N021052	002	May 20, 1999
TABLET;ORAL				
VIOXX				
MERCK	12.5MG	N021042	001	May 20, 1999
	25MG	N021042	002	May 20, 1999
	50MG	N021042	003	Feb 25, 2000
ROFLUMILAST				
TABLET;ORAL				
ROFLUMILAST				
SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023
	500MCG	A208236	001	Oct 03, 2018
TORRENT	250MCG	A208272	002	Oct 18, 2024
	500MCG	A208272	001	Aug 06, 2018
ROLAPITANT HYDROCHLORIDE				
EMULSION;INTRAVENOUS				
VARUBI				
+ TERSERA	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017
ROMIDEPSIN				
SOLUTION;INTRAVENOUS				
ROMIDEPSIN				
+ TEVA PHARMS USA INC	10MG/2ML (5MG/ML) **	N208574	001	Mar 13, 2020
+	27.5MG/5.5ML (5MG/ML) **	N208574	002	Mar 13, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL					
REQUIP					
+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE **	N020658	001	Sep 19, 1997
+		EQ 0.5MG BASE **	N020658	002	Sep 19, 1997
+		EQ 1MG BASE **	N020658	003	Sep 19, 1997
+		EQ 2MG BASE **	N020658	004	Sep 19, 1997
+		EQ 3MG BASE **	N020658	006	Jan 27, 1999
+		EQ 4MG BASE **	N020658	007	Jan 27, 1999
+		EQ 5MG BASE **	N020658	005	Sep 19, 1997
ROPINIROLE HYDROCHLORIDE					
	COSETTE	EQ 0.25MG BASE	A077460	001	May 05, 2008
		EQ 0.5MG BASE	A077460	002	May 05, 2008
		EQ 1MG BASE	A077460	003	May 05, 2008
		EQ 2MG BASE	A077460	004	May 05, 2008
		EQ 3MG BASE	A077460	005	May 05, 2008
		EQ 4MG BASE	A077460	006	May 05, 2008
		EQ 5MG BASE	A077460	007	May 19, 2008
	EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008
		EQ 0.5MG BASE	A078230	002	May 20, 2008
		EQ 1MG BASE	A078230	003	May 20, 2008
		EQ 2MG BASE	A078230	004	May 20, 2008
		EQ 3MG BASE	A078230	005	May 20, 2008
		EQ 4MG BASE	A078230	006	May 20, 2008
		EQ 5MG BASE	A078230	007	May 20, 2008
	HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008
		EQ 0.5MG BASE	A077852	002	May 05, 2008
		EQ 1MG BASE	A077852	003	May 05, 2008
		EQ 2MG BASE	A077852	004	May 05, 2008
		EQ 3MG BASE	A077852	005	May 05, 2008
		EQ 4MG BASE	A077852	006	May 05, 2008
		EQ 5MG BASE	A077852	007	May 19, 2008
	PHARMOBEDIENT	EQ 0.25MG BASE	A078881	001	May 05, 2008
		EQ 0.5MG BASE	A078881	002	May 05, 2008
		EQ 1MG BASE	A078881	003	May 05, 2008
		EQ 2MG BASE	A078881	004	May 05, 2008
		EQ 3MG BASE	A078881	005	May 05, 2008
		EQ 4MG BASE	A078881	006	May 05, 2008
		EQ 5MG BASE	A078881	007	May 19, 2008
TABLET, EXTENDED RELEASE;ORAL					
REQUIP XL					
+	GLAXOSMITHKLINE LLC	EQ 2MG BASE **	N022008	001	Jun 13, 2008
+		EQ 3MG BASE **	N022008	002	Jun 13, 2008
+		EQ 4MG BASE **	N022008	003	Jun 13, 2008
+		EQ 6MG BASE **	N022008	006	Apr 10, 2009
+		EQ 8MG BASE **	N022008	004	Jun 13, 2008
+		EQ 12MG BASE **	N022008	005	Oct 31, 2008
ROPINIROLE HYDROCHLORIDE					
	AUROBINDO PHARMA USA	EQ 2MG BASE	A200462	001	Oct 15, 2012
		EQ 3MG BASE	A200462	002	Oct 15, 2012
		EQ 4MG BASE	A200462	003	Oct 15, 2012
		EQ 6MG BASE	A200462	004	Oct 15, 2012
		EQ 8MG BASE	A200462	005	Oct 15, 2012
		EQ 12MG BASE	A200462	006	Oct 15, 2012
	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012
		EQ 4MG BASE	A200431	002	Jun 06, 2012
		EQ 6MG BASE	A200431	003	Jun 06, 2012
		EQ 8MG BASE	A200431	004	Jun 06, 2012
		EQ 12MG BASE	A200431	005	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION					
NAROPIN					
+	FRESENIUS KABI USA	50MG/10ML (5MG/ML) **	N020533	013	May 01, 1998
+		75MG/10ML (7.5MG/ML) **	N020533	012	Sep 24, 1996
ROPIVACAINE HYDROCHLORIDE					
	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014
		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014
		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014
		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROPIVACAINE HYDROCHLORIDE				
SOLUTION;INJECTION				
ROPIVACAINE HYDROCHLORIDE				
	150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014
	200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014
RISING	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014
	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014
	150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014
	200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014
ROSE BENGAL SODIUM I-131				
INJECTABLE;INJECTION				
ROBENGATOPE				
BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	
SODIUM ROSE BENGAL I 131				
SORIN	0.5mCi/ML	N017318	001	
ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDIA				
+ WOODWARD	EQ 2MG BASE **	N021071	002	May 25, 1999
+	EQ 4MG BASE **	N021071	003	May 25, 1999
+	EQ 8MG BASE **	N021071	004	May 25, 1999
ROSIGLITAZONE MALEATE				
ANI PHARMS	EQ 2MG BASE	A076747	001	Jan 25, 2013
	EQ 4MG BASE	A076747	002	Jan 25, 2013
	EQ 8MG BASE	A076747	003	Jan 25, 2013
ROSUVASTATIN CALCIUM				
CAPSULE;ORAL				
EZALLOR SPRINKLE				
+ SUN PHARM	EQ 5MG BASE	N208647	001	Dec 18, 2018
+	EQ 10MG BASE	N208647	002	Dec 18, 2018
+	EQ 20MG BASE	N208647	003	Dec 18, 2018
+	EQ 40MG BASE	N208647	004	Dec 18, 2018
TABLET;ORAL				
ROSUVASTATIN CALCIUM				
AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018
	EQ 10MG BASE	A208850	002	Oct 16, 2018
	EQ 20MG BASE	A208850	003	Oct 16, 2018
	EQ 40MG BASE	A208850	004	Oct 16, 2018
APOTEX	EQ 5MG BASE	A079145	001	Jul 19, 2016
	EQ 10MG BASE	A079145	002	Jul 19, 2016
	EQ 20MG BASE	A079145	003	Jul 19, 2016
	EQ 40MG BASE	A079145	004	Jul 19, 2016
INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021
	EQ 10MG BASE	A207653	002	Feb 05, 2021
	EQ 20MG BASE	A207653	003	Feb 05, 2021
	EQ 40MG BASE	A207653	004	Feb 05, 2021
LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017
	EQ 10MG BASE	A205587	002	Jul 31, 2017
	EQ 20MG BASE	A205587	003	Jul 31, 2017
	EQ 40MG BASE	A205587	004	Jul 31, 2017
MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024
	EQ 10MG BASE	A207296	002	Nov 06, 2024
	EQ 20MG BASE	A207296	003	Nov 06, 2024
	EQ 40MG BASE	A207296	004	Nov 06, 2024
MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025
	EQ 10MG BASE	A206603	002	May 16, 2025
	EQ 20MG BASE	A206603	003	May 16, 2025
	EQ 40MG BASE	A206603	004	May 16, 2025
SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016
	EQ 10MG BASE	A079171	002	Jul 19, 2016
	EQ 20MG BASE	A079171	003	Jul 19, 2016
	EQ 40MG BASE	A079171	004	Jul 19, 2016
STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016
	EQ 10MG BASE	A079161	002	Jul 19, 2016
	EQ 20MG BASE	A079161	003	Jul 19, 2016
	EQ 40MG BASE	A079161	004	Jul 19, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROSUVASTATIN CALCIUM
TABLET;ORAL
ROSUVASTATIN CALCIUM

SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016
	EQ 10MG BASE	A079169	002	Jul 19, 2016
	EQ 20MG BASE	A079169	003	Jul 19, 2016
	EQ 40MG BASE	A079169	004	Jul 19, 2016
SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020
	EQ 10MG BASE	A210667	002	Apr 01, 2020
	EQ 20MG BASE	A210667	003	Apr 01, 2020
	EQ 40MG BASE	A210667	004	Apr 01, 2020
TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016
	EQ 10MG BASE	A079166	002	Jul 19, 2016
	EQ 20MG BASE	A079166	003	Jul 19, 2016
	EQ 40MG BASE	A079166	004	Jul 19, 2016

RUFINAMIDE
TABLET;ORAL
BANZEL

+ EISAI INC	100MG **	N021911	001	Nov 14, 2008

SAFFLOWER OIL
INJECTABLE;INJECTION
LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203	001	

LIPOSYN 20%

ABBOTT	20% (20GM/100ML)	N018614	001	

SAFFLOWER OIL; SOYBEAN OIL
INJECTABLE;INJECTION
LIPOSYN II 10%

HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984

LIPOSYN II 20%

HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984

SAFINAMIDE MESYLATE
TABLET;ORAL
SAFINAMIDE MESYLATE

AUROBINDO PHARMA	EQ 50MG BASE	A215902	001	Jun 14, 2023
	EQ 100MG BASE	A215902	002	Jun 14, 2023

SALMETEROL XINAFOATE
AEROSOL, METERED;INHALATION
SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236	001	Feb 04, 1994

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
INJECTABLE;INJECTION
QUADRAMET

+ LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997

SAQUINAVIR
CAPSULE;ORAL
FORTOVASE

+ HOFFMANN LA ROCHE	200MG **	N020828	001	Nov 07, 1997

SAQUINAVIR MESYLATE
CAPSULE;ORAL
INVIRASE

+ HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995

TABLET;ORAL
INVIRASE

+ HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004

SARALASIN ACETATE
INJECTABLE;INJECTION
SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SAXAGLIPTIN HYDROCHLORIDE				
TABLET;ORAL				
ONGLYZA				
+ ASTRAZENECA AB	EQ 2.5MG BASE **	N022350	001	Jul 31, 2009
+	EQ 5MG BASE **	N022350	002	Jul 31, 2009
SAXAGLIPTIN				
AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023
	EQ 5MG BASE	A205941	002	Jul 31, 2023
SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023
	EQ 5MG BASE	A206078	002	Jul 31, 2023
SECOBARBITAL SODIUM				
CAPSULE;ORAL				
SECOBARBITAL SODIUM				
ANABOLIC	100MG	A084422	001	
BARR	100MG	A084225	001	
EVERYLIFE	100MG	A085895	001	
HALSEY	100MG	A084676	001	
IVAX PHARMS	100MG	A085869	001	
KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	
PARKE DAVIS	100MG	A084762	001	
PERRIGO	100MG	A084561	001	
PUREPAC PHARM	100MG	A085867	001	
VALEANT PHARM INTL	100MG	A085477	001	
VITARINE	100MG	A085898	001	
	100MG	A086273	001	
WATSON LABS	100MG	A085792	001	
WEST WARD	100MG	A084926	001	
WHITEWORTH TOWN PLSN	100MG	A085798	001	
WYETH AYERST	100MG	A086390	001	
SECONAL SODIUM				
VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
	100MG	A086101	002	Oct 03, 1983
INJECTABLE;INJECTION				
SECOBARBITAL SODIUM				
ELKINS SINN	100MG/VIAL	A083281	001	
WYETH AYERST	50MG/ML	A083262	001	
SECONAL SODIUM				
LILLY	50MG/ML **	N007392	002	
SUPPOSITORY;RECTAL				
SECONAL SODIUM				
LILLY	30MG	A086530	001	
	60MG	A086530	002	
	120MG	A086530	003	
	200MG	A086530	004	
SECRETIN				
INJECTABLE;INJECTION				
SECRETIN-FERRING				
FERRING	75CU/VIAL	N018290	001	
SECRETIN SYNTHETIC PORCINE				
FOR SOLUTION;INTRAVENOUS				
SECREFLO				
CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002
SELEGILINE HYDROCHLORIDE				
CAPSULE;ORAL				
ELDEPRYL				
+ QUAGEN	5MG **	N020647	001	May 15, 1996
SELEGILINE HYDROCHLORIDE				
LANNETT CO INC	5MG	A075145	001	Sep 15, 2003
TABLET;ORAL				
SELEGILINE HYDROCHLORIDE				
CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996
	5MG	A074641	001	Aug 02, 1996
COSETTE	5MG	A074744	001	Jan 27, 1997
	5MG	A074756	001	Nov 25, 1998
G AND W LABS INC	5MG	A074537	001	Aug 02, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SELEGILINE HYDROCHLORIDE				
TABLET;ORAL				
SELEGILINE HYDROCHLORIDE				
	KENTON	5MG	A074912 001	Apr 30, 1998
	NOVITIUM PHARMA	5MG	A074866 001	Nov 26, 1997
+	QUAGEN	5MG **	N019334 001	Jun 05, 1989
SELENIOUS ACID				
SOLUTION;INTRAVENOUS				
SELENIOUS ACID				
	FRESENIUS KABI USA	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779 001	Feb 10, 2025
SELENIUM SULFIDE				
LOTION/SHAMPOO;TOPICAL				
EXSEL				
	ALLERGAN HERBERT	2.5%	A083892 001	
SELENIUM SULFIDE				
	ACTAVIS MID ATLANTIC	2.5%	A084394 001	
	COSETTE	2.5%	A086209 001	
	IVAX PHARMS	2.5%	A085777 001	
	PHARMOBEDIENT CNSLTG	2.5%	A088228 001	Sep 01, 1983
SELSUN				
+	CHATTEM	2.5% **	N007936 001	
SELENOMETHIONINE SE-75				
INJECTABLE;INJECTION				
SELENOMETHIONINE SE 75				
	GE HEALTHCARE	250uCi/ML	N017257 001	
	MALLINCKRODT	100uCi/ML	N017098 001	
	PHARMALUCENCE	500uCi/ML	N017322 001	
SETHOTOPE				
	BRACCO	85-550uCi/ML	N017047 001	
SELEXIPAG				
TABLET;ORAL				
SELEXIPAG				
	ZYDUS LIFESCIENCES	0.2MG	A214302 001	Dec 21, 2022
		0.4MG	A214302 002	Dec 21, 2022
		0.6MG	A214302 003	Dec 21, 2022
		0.8MG	A214302 004	Dec 21, 2022
		1MG	A214302 005	Dec 21, 2022
		1.2MG	A214302 006	Dec 21, 2022
		1.4MG	A214302 007	Dec 21, 2022
		1.6MG	A214302 008	Dec 21, 2022
SEMAGLUTIDE				
SOLUTION;SUBCUTANEOUS				
OZEMPIC				
+	NOVO	2MG/1.5ML (1.34MG/ML)	N209637 001	Dec 05, 2017
SERMORELIN ACETATE				
INJECTABLE;INJECTION				
GEREF				
+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863 001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443 001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443 002	Sep 26, 1997
SERTRALINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
SERTRALINE HYDROCHLORIDE				
	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007
TABLET;ORAL				
SERTRALINE HYDROCHLORIDE				
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162 001	Feb 06, 2007
		EQ 50MG BASE	A077162 002	Feb 06, 2007
		EQ 100MG BASE	A077162 003	Feb 06, 2007
	HERITAGE PHARMA AVET	EQ 25MG BASE	A077299 001	Feb 06, 2007
		EQ 25MG BASE	A077345 001	Feb 06, 2007
		EQ 25MG BASE	A077663 001	Feb 06, 2007
		EQ 50MG BASE	A077299 002	Feb 06, 2007
		EQ 50MG BASE	A077345 002	Feb 06, 2007
		EQ 50MG BASE	A077663 002	Feb 06, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SERTRALINE HYDROCHLORIDE

TABLET;ORAL					
SERTRALINE HYDROCHLORIDE					
	EQ 100MG BASE		A077299	003	Feb 06, 2007
	EQ 100MG BASE		A077345	003	Feb 06, 2007
	EQ 100MG BASE		A077663	003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE		A077864	001	Aug 10, 2009
	EQ 50MG BASE		A077864	002	Aug 10, 2009
	EQ 100MG BASE		A077864	003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE		A075719	003	Jun 30, 2006
	EQ 50MG BASE		A075719	001	Jun 30, 2006
	EQ 100MG BASE		A075719	002	Jun 30, 2006
MYLAN PHARMS INC	EQ 25MG BASE		A076540	001	Mar 20, 2007
	EQ 50MG BASE		A076540	002	Mar 20, 2007
	EQ 100MG BASE		A076540	003	Mar 20, 2007
PHARMOBEDIENT	EQ 25MG BASE		A076671	001	Feb 06, 2007
	EQ 50MG BASE		A076671	002	Feb 06, 2007
	EQ 100MG BASE		A076671	003	Feb 06, 2007
QUAGEN	EQ 25MG BASE		A078626	001	Jan 31, 2008
	EQ 50MG BASE		A078626	002	Jan 31, 2008
	EQ 100MG BASE		A078626	003	Jan 31, 2008
SOMERSET THERAPS LLC	EQ 25MG BASE		A077713	001	Feb 06, 2007
	EQ 50MG BASE		A077713	002	Feb 06, 2007
	EQ 100MG BASE		A077713	003	Feb 06, 2007
SUN PHARM INDS (IN)	EQ 25MG BASE		A078108	001	Feb 06, 2007
	EQ 50MG BASE		A078108	002	Feb 06, 2007
	EQ 100MG BASE		A078108	003	Feb 06, 2007
SUN PHARM INDS LTD	EQ 25MG BASE		A077977	001	Feb 06, 2007
	EQ 50MG BASE		A077977	002	Feb 06, 2007
	EQ 100MG BASE		A077977	003	Feb 06, 2007
	EQ 150MG BASE		A077977	004	Feb 06, 2007
	EQ 200MG BASE		A077977	005	Feb 06, 2007
TORRENT PHARMS	EQ 25MG BASE		A077765	001	Feb 06, 2007
	EQ 50MG BASE		A077765	002	Feb 06, 2007
	EQ 100MG BASE		A077765	003	Feb 06, 2007
TP ANDA HOLDINGS	EQ 25MG BASE		A077818	001	Feb 06, 2007
	EQ 50MG BASE		A077818	002	Feb 06, 2007
	EQ 100MG BASE		A077818	003	Feb 06, 2007
ZYDUS	EQ 25MG BASE		A077106	001	Feb 06, 2007
	EQ 50MG BASE		A077106	002	Feb 06, 2007
	EQ 100MG BASE		A077106	003	Feb 06, 2007
ZOLOFT					
+ VIATRIS	EQ 150MG BASE **		N019839	003	Dec 30, 1991
+	EQ 200MG BASE **		N019839	004	Dec 30, 1991

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL					
SEVELAMER CARBONATE					
INVAGEN PHARMS	800MG/PACKET		A206234	001	Jul 12, 2024
	2.4GM/PACKET		A206234	002	Jul 12, 2024
LUPIN LTD	800MG/PACKET		A201513	001	Dec 23, 2021
	2.4GM/PACKET		A201513	002	Dec 23, 2021
TORRENT	800MG/PACKET		A215909	001	Feb 27, 2025
	2.4GM/PACKET		A215909	002	Feb 27, 2025
TABLET;ORAL					
SEVELAMER CARBONATE					
CHARTWELL RX	800MG		A204600	001	Jan 14, 2021
EPIC PHARMA LLC	800MG		A212970	001	Apr 09, 2020
IMPAX LABS INC	800MG		A090975	001	Oct 23, 2017
STRIDES PHARMA INTL	800MG		A201069	001	Aug 05, 2020

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL					
RENAGEL					
GENZYME	403MG		N020926	001	Oct 30, 1998
TABLET;ORAL					
SEVELAMER HYDROCHLORIDE					
RISING	400MG		A201068	001	Dec 14, 2020
	800MG		A201068	002	Dec 14, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SIBUTRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
MERIDIA				
ABBOTT	5MG	N020632	001	Nov 22, 1997
	10MG	N020632	002	Nov 22, 1997
	15MG	N020632	003	Nov 22, 1997
SILDENAFIL CITRATE				
FOR SUSPENSION;ORAL				
SILDENAFIL CITRATE				
GRANULES	EQ 10MG BASE/ML	A214556	001	Dec 01, 2023
LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022
TARO	EQ 10MG BASE/ML	A215522	001	Nov 16, 2021
TRIS PHARMA INC	EQ 10MG BASE/ML	A212312	001	Nov 17, 2021
SUSPENSION;ORAL				
LIQREV				
+ CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023
TABLET;ORAL				
SILDENAFIL CITRATE				
ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013
APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012
MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019
	EQ 50MG BASE	A201171	002	Mar 25, 2019
	EQ 100MG BASE	A201171	003	Mar 25, 2019
MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012
PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020
	EQ 50MG BASE	A205791	002	Apr 23, 2020
WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020
	EQ 50MG BASE	A202506	002	Nov 25, 2020
	EQ 100MG BASE	A202506	003	Nov 25, 2020
SILODOSIN				
CAPSULE;ORAL				
RAPAFLO				
+ ABBVIE	4MG	N022206	001	Oct 08, 2008
+	8MG	N022206	002	Oct 08, 2008
SILODOSIN				
ALEMBIC	4MG	A211731	001	Nov 22, 2019
	8MG	A211731	002	Nov 22, 2019
TORRENT	4MG	A210396	001	Feb 10, 2025
	8MG	A210396	002	Feb 10, 2025
ZYDUS PHARMS	4MG	A204816	001	Dec 08, 2022
	8MG	A204816	002	Dec 08, 2022
SILVER SULFADIAZINE				
CREAM;TOPICAL				
SSD AF				
DR REDDYS	1%	N018578	003	Jul 11, 1990
DRESSING;TOPICAL				
SILDAFLO				
FRANKLIN PHARMS	1%	N019608	001	Nov 30, 1989
SIMEPREVIR SODIUM				
CAPSULE;ORAL				
OLYSIO				
+ JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013
SIMETHICONE-CELLULOSE				
SUSPENSION;ORAL				
SONORX				
BRACCO	7.5MG/ML	N020773	001	Oct 29, 1998
SIMVASTATIN				
TABLET;ORAL				
SIMVASTATIN				
CHARTWELL RX	5MG	A077766	001	Dec 20, 2006
	10MG	A077766	002	Dec 20, 2006
	20MG	A077766	003	Dec 20, 2006
	40MG	A077766	004	Dec 20, 2006
	80MG	A077766	005	Dec 20, 2006
IVAX SUB TEVA PHARMS	5MG	A076052	001	Jun 23, 2006
	10MG	A076052	002	Jun 23, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SIMVASTATIN					
TABLET;ORAL					
SIMVASTATIN					
		20MG	A076052	003	Jun 23, 2006
		40MG	A076052	004	Jun 23, 2006
		80MG	A076052	005	Dec 20, 2006
	PHARMOBEDIENT	5MG	A090868	001	Jun 08, 2010
		10MG	A090868	002	Jun 08, 2010
		20MG	A090868	003	Jun 08, 2010
		40MG	A090868	004	Jun 08, 2010
		80MG	A090868	005	Jun 08, 2010
	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006
		10MG	A076285	002	Dec 20, 2006
		20MG	A076285	003	Dec 20, 2006
		40MG	A076285	004	Dec 20, 2006
		80MG	A076285	005	Jun 23, 2006
	WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006
		10MG	A076685	002	Dec 20, 2006
		20MG	A076685	003	Dec 20, 2006
		40MG	A076685	004	Dec 20, 2006
		80MG	A076685	005	Dec 20, 2006
ZOCOR					
+	ORGANON	80MG **	N019766	005	Jul 10, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
SIMVASTATIN					
+	SYNTHON PHARMS	10MG	N021961	001	Oct 09, 2007
+		20MG	N021961	002	Oct 09, 2007
+		40MG	N021961	003	Oct 09, 2007
+		80MG	N021961	004	Oct 09, 2007
SIMVASTATIN; SITAGLIPTIN PHOSPHATE					
TABLET;ORAL					
JUVISYNC					
+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343	004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343	001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343	005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343	002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343	006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343	003	Oct 07, 2011
SIPONIMOD					
TABLET;ORAL					
SIPONIMOD					
	RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025
		EQ 1MG BASE	A218444	002	Apr 22, 2025
		EQ 2MG BASE	A218444	003	Apr 22, 2025
SIROLIMUS					
SOLUTION;ORAL					
SIROLIMUS					
	TORRENT	1MG/ML	A215016	001	Dec 27, 2021
TABLET;ORAL					
RAPAMUNE					
+	PF PRISM CV	5MG **	N021110	003	Feb 23, 2004
SODIUM BENZOATE; SODIUM PHENYLACETATE					
SOLUTION;INTRAVENOUS					
AMMONUL					
+	BAUSCH	10%;10% (5GM/50ML;5GM/50ML) **	N020645	001	Feb 17, 2005
SOLUTION;ORAL					
UCEPHAN					
	B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987
SODIUM BICARBONATE					
SOLUTION;INTRAVENOUS					
SODIUM BICARBONATE					
	HOSPIRA	44.6MEQ/50ML (0.9MEQ/ML)	A077394	001	Nov 09, 2005
		50MEQ/50ML (1MEQ/ML)	A077394	002	Nov 09, 2005
SODIUM BICARBONATE IN PLASTIC CONTAINER					
+	ABBOTT	44.6MEQ/50ML (0.9MEQ/ML) **	N019443	001	Jun 03, 1986
+		50MEQ/50ML (1MEQ/ML) **	N019443	002	Jun 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM BICARBONATE; TARTARIC ACID					
GRANULE, EFFERVESCENT;ORAL					
BAROS					
	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985
SODIUM CHLORIDE					
AEROSOL, METERED;INHALATION					
BRONCHO SALINE					
+	BLAIREX	0.9%	N019912	001	Sep 03, 1992
INJECTABLE;INJECTION					
SODIUM CHLORIDE					
	ABBOTT	20GM/100ML	N017013	001	
	B BRAUN	20GM/100ML	N017038	001	
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	450MG/100ML	N018184	001	
	MILES	450MG/100ML	N018503	001	
SODIUM CHLORIDE 0.9%					
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012
+		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
+	ABRAXIS PHARM	234MG/ML **	N019329	001	Apr 22, 1987
SOLUTION;INJECTION					
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABRAXIS PHARM	90MG/10ML (9MG/ML)	A088909	002	May 15, 1985
		270MG/30ML (9MG/ML)	A088909	001	Feb 07, 1985
SODIUM CHLORIDE 0.9%					
	HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABBOTT	90MG/10ML (9MG/ML)	N019218	001	Jul 13, 1984
		180MG/20ML (9MG/ML)	N019218	002	Apr 30, 1985
+	HOSPIRA	18MG/2ML (9MG/ML)	N018803	004	Jan 22, 2015
+		27MG/3ML (9MG/ML)	N018803	005	Jan 22, 2015
+		45MG/5ML (9MG/ML)	N018803	006	Jan 22, 2015
+	ICU MEDICAL INC	45MG/5ML (9MG/ML)	N019217	002	Nov 18, 1998
+		90MG/10ML (9MG/ML)	N019217	003	Nov 18, 1998
+		360MG/40ML (9MG/ML)	N019217	004	Apr 01, 1999
	JUBILANT CADISTA	27MG/3ML (9MG/ML)	A203352	002	May 18, 2016
		90MG/10ML (9MG/ML)	A203352	001	May 18, 2016
	MILES	450MG/50ML (9MG/ML)	N018502	002	
		900MG/100ML	N018502	001	
SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE					
+	ICU MEDICAL INC	90MG/10ML (9MG/ML)	N019217	001	Jul 13, 1984
SOLUTION;INTRAVENOUS					
SODIUM CHLORIDE 14.6%					
+	HOSPIRA	50MEQ/20ML (2.5MEQ/ML) **	N018897	001	Jul 20, 1984
SOLUTION;IRRIGATION					
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	450MG/100ML	N017864	001	
		450MG/100ML	N018497	001	Feb 19, 1982
	HOSPIRA	450MG/100ML	N017670	001	
		450MG/100ML	N018380	001	
SODIUM CHLORIDE IN PLASTIC CONTAINER					
	MILES	900MG/100ML	N018247	001	
SODIUM CHROMATE CR-51					
INJECTABLE;INJECTION					
CHROMITOPE SODIUM					
	BRACCO	2mCi/VIAL	N013993	002	
		200uCi/ML	N013993	001	
SODIUM CHROMATE CR 51					
	CURIUM	100uCi/ML	N016708	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS				
FLUORINE F-18				
+	GE HEALTHCARE	2mCi/ML **	N017042 001	
SODIUM FLUORIDE F 18				
+	NIH NCI DCTD	10-200mCi/ML **	N022494 001	Jan 26, 2011
SODIUM FLUORIDE F-18				
	DECATUR	10-200mCi/ML	A204464 001	Oct 21, 2014
	ESSENTIAL ISOTOPES	10-200mCi/ML	A204541 001	Oct 29, 2014
	HOT SHOTS NM LLC	10-200mCi/ML	A204530 001	Jul 29, 2015
	SHERTECH LABS LLC	10-200mCi/ML	A204315 001	Sep 22, 2014
	SOFIE	10-200mCi/ML	A203544 001	Dec 26, 2012
	UCSF RODIOPHARM	10-200mCi/ML	A204437 001	Mar 13, 2014
	UIHC PET IMAGING	10-200mCi/ML	A204462 001	Nov 17, 2015
	UNIV TX MD ANDERSON	10-200mCi/ML	A203247 001	Dec 23, 2013

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL				
COLGATE TOTAL				
+	COLGATE PALMOLIVE	0.24%;0.3%	N020231 001	Jul 11, 1997

SODIUM IODIDE I-123

CAPSULE;ORAL				
SODIUM IODIDE I 123				
	CARDINAL HEALTH 418	400uCi	N018671 003	May 27, 1982
	GE HEALTHCARE	100uCi	N017630 001	
		200uCi	N017630 003	Jan 08, 1993
SOLUTION;ORAL				
SODIUM IODIDE I 123				
	GE HEALTHCARE	2mCi/ML **	N017630 002	

SODIUM IODIDE I-131

CAPSULE;ORAL				
IODOTOPE				
	BRACCO	1-130mCi	N010929 001	
		1-150mCi	N010929 003	
SODIUM IODIDE I 131				
	CIS	50uCi	N017316 001	
		100uCi	N017316 002	
	CURIUM	0.8-100mCi	N016515 002	
+		0.8-100mCi	N016517 001	
		15-100uCi	N016517 002	
	JUBILANT	2-200mCi	N021305 004	Nov 18, 2004
SOLUTION;ORAL				
HICON				
	JUBILANT	1-250mCi/0.25ML	N021305 002	Jan 24, 2003
		1-500mCi/0.5ML	N021305 003	Jan 24, 2003
		1-1000mCi/ML	N021305 005	Apr 04, 2006
IODOTOPE				
	BRACCO	7-106mCi/BOT	N010929 002	
SODIUM IODIDE I 131				
	CARDINAL HLTH 414	250-1000mCi	A213615 001	Jun 12, 2025
+	CURIUM	3.5-150mCi/VIAL	N016515 001	
	SUN PHARM INDS INC	50mCi/ML	N017315 001	

SODIUM LACTATE

INJECTABLE;INJECTION				
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N018186 001	
	BAXTER HLTHCARE	1.87GM/100ML	N016692 001	
	HOSPIRA	1.87GM/100ML	N018249 001	
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER				
	B BRAUN	1.87GM/100ML	N020004 001	Apr 21, 1992
SODIUM LACTATE IN PLASTIC CONTAINER				
+	HOSPIRA	5MEQ/ML	N018947 001	Sep 05, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM MONOFLUOROPHOSPHATE

GEL;DENTAL					
EXTRA-STRENGTH AIM					
	CHESEBROUGH PONDS	1.2%	N019518	002	Aug 06, 1986
PASTE;DENTAL					
EXTRA-STRENGTH AIM					
	CHESEBROUGH PONDS	1.2%	N019518	001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION					
NIPRIDE					
	ROCHE	50MG/VIAL	N017546	001	
NITROPRESS					
	ABBOTT	50MG/VIAL	A071555	001	Nov 16, 1987
+	ABBVIE	50MG/VIAL **	N018450	001	
	HOSPIRA	50MG/VIAL	A070566	001	Jun 09, 1986
	VPNA	25MG/ML	A071961	001	Aug 01, 1988
SODIUM NITROPRUSSIDE					
	ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985
	AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017
	AVET LIFESCIENCES	25MG/ML	A208923	001	Nov 08, 2022
+	BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
	CHARTWELL RX	25MG/ML	A209834	001	Jun 26, 2018
	CIPLA	25MG/ML	A210855	001	Jul 16, 2018
	EPIC PHARMA LLC	25MG/ML	A208635	001	May 04, 2017
	EUGIA PHARMA	25MG/ML	A211934	001	Dec 10, 2020
	SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018
	TEVA PARENTERAL	25MG/ML	A073465	001	Mar 30, 1992
	XIROMED	25MG/ML	A211277	001	Oct 29, 2020
SOLUTION;INTRAVENOUS					
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
+	EXELA PHARMA	10MG/50ML (0.2MG/ML) **	N209387	002	Dec 07, 2017

SODIUM OXYBATE

SOLUTION;ORAL					
SODIUM OXYBATE					
	HIKMA	0.5GM/ML	A202090	001	Jan 17, 2017

SODIUM PHENYLBUTYRATE

TABLET;ORAL					
SODIUM PHENYLBUTYRATE					
	ALVOGEN	500MG	A090910	001	Nov 18, 2011

SODIUM PHENYLBUTYRATE; TAURURSODIOL

FOR SUSPENSION;ORAL					
RELYVRIO					
+	AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022

SODIUM PHOSPHATE P-32

SOLUTION;INJECTION, ORAL					
PHOSPHOTOPE					
	BRACCO	1-8mCi/VIAL	N010927	001	
SODIUM PHOSPHATE P 32					
	MALLINCKRODT	0.67mCi/ML	N011777	001	
		1.5mCi/VIAL	N011777	002	

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL					
OSMOPREP					
+	SALIX PHARMS	0.398GM;1.102GM **	N021892	001	Mar 16, 2006
VISICOL					
	SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL					
KAYEXALATE					
+	CONCORDIA	453.6GM/BOT **	N011287	001	
SODIUM POLYSTYRENE SULFONATE					
	CITRUSPHRMA	454GM/BOT	A040909	001	Dec 03, 2008
+	PAI HOLDINGS PHARM	453.6GM/BOT	A088786	001	Sep 11, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM POLYSTYRENE SULFONATE
SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011
HIKMA	15GM/60ML	A089049	001	Nov 17, 1986
MORTON GROVE	15GM/60ML	A088717	001	Sep 11, 1984
ROXANE	15GM/60ML	A088453	001	Nov 17, 1983

SODIUM SUCCINATE
INJECTABLE;INJECTION
SODIUM SUCCINATE

ELKINS SINN	30%	A080516	001	

SODIUM TETRADECYL SULFATE
INJECTABLE;INJECTION
SOTRADECOL

+	ELKINS SINN	1% **	N005970	004	
+		3% **	N005970	005	

SODIUM THIOSULFATE
INJECTABLE;INJECTION
SODIUM THIOSULFATE

+	US ARMY	250MG/ML	N020166	001	Feb 14, 1992

SOFOSBUVIR
TABLET;ORAL
SOFOSBUVIR

TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022

SOLIFENACIN SUCCINATE
SUSPENSION;ORAL
VESICARE LS

+	ASTELLAS	1MG/ML	N209529	001	May 26, 2020

TABLET;ORAL
SOLIFENACIN SUCCINATE

ACCORD HLTHCARE	5MG	A207477	001	Jan 04, 2022
	10MG	A207477	002	Jan 04, 2022
AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019
	10MG	A205483	002	May 20, 2019
AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019
	10MG	A209719	002	May 20, 2019
BRECKENRIDGE	5MG	A209818	001	May 20, 2019
	10MG	A209818	002	May 20, 2019
CIPLA	5MG	A209839	001	May 20, 2019
	10MG	A209839	002	May 20, 2019
LANNETT CO INC	5MG	A211622	001	Jun 06, 2023
	10MG	A211622	002	Jun 06, 2023
SUNSHINE	5MG	A213346	001	Apr 13, 2020
	10MG	A213346	002	Apr 13, 2020
TORRENT	5MG	A209424	001	Mar 04, 2025
	10MG	A209424	002	Mar 04, 2025
ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020
	10MG	A207721	002	Oct 19, 2020

VESICARE

+	ASTELLAS	5MG	N021518	001	Nov 19, 2004
+		10MG	N021518	002	Nov 19, 2004

SORAFENIB TOSYLATE
TABLET;ORAL
SORAFENIB TOSYLATE

APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025

SORBITOL
SOLUTION;IRRIGATION
SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOTALOL HYDROCHLORIDE

TABLET;ORAL				
BETAPACE				
LEGACY PHARMA	320MG	N019865	004	Oct 30, 1992
BETAPACE AF				
LEGACY PHARMA	40MG	N021151	006	Apr 02, 2003
	60MG	N021151	007	Apr 02, 2003
	100MG	N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE				
IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000
	120MG	A075663	002	Nov 07, 2000
	160MG	A075663	003	Nov 07, 2000
	240MG	A075663	004	Nov 07, 2000
NOVITIUM PHARMA	80MG	A075237	001	May 01, 2000
	120MG	A075237	002	May 01, 2000
	160MG	A075237	003	May 01, 2000
	240MG	A075237	004	May 01, 2000
RISING	80MG	A075725	001	Dec 19, 2000
	120MG	A075725	002	Dec 19, 2000
	160MG	A075725	003	Dec 19, 2000
	240MG	A075725	004	Dec 19, 2000
SUN PHARM INDUSTRIES	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
TEVA	80MG	A076883	001	Jul 26, 2004
	120MG	A076883	002	Jul 26, 2004
	160MG	A076883	003	Jul 26, 2004
UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000
	120MG	A075366	002	May 01, 2000
	160MG	A075366	003	May 01, 2000
	240MG	A075366	004	May 01, 2000
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE;INJECTION				
INTRALIPID 10%				
+ FRESENIUS	10%	N017643	001	
LIPOSYN III 10%				
HOSPIRA	10%	N018969	001	Sep 24, 1984
LIPOSYN III 20%				
HOSPIRA	20%	N018970	001	Sep 25, 1984
LIPOSYN III 30%				
HOSPIRA	30%	N020181	001	Jan 13, 1998
NUTRILIPID 10%				
+ B BRAUN	10%	N019531	001	May 28, 1993
SOYACAL 10%				
ALPHA THERA	10%	N018465	001	Jun 29, 1983
SOYACAL 20%				
ALPHA THERA	20%	N018786	001	Jun 29, 1983
TRAVAMULSION 10%				
BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982
TRAVAMULSION 20%				
BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983

SPARFLOXACIN

TABLET;ORAL				
ZAGAM				
MYLAN	200MG	N020677	001	Dec 19, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SPECTINOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
TROBICIN				
PFIZER	EQ 2GM BASE/VIAL	N050347 001		
	EQ 4GM BASE/VIAL	N050347 002		
SPIRAPRIL HYDROCHLORIDE				
TABLET;ORAL				
RENORMAX				
SCHERING	3MG	N020240 001	Dec 29, 1994	
	6MG	N020240 002	Dec 29, 1994	
	12MG	N020240 003	Dec 29, 1994	
	24MG	N020240 004	Dec 29, 1994	
SPIRONOLACTONE				
TABLET;ORAL				
SPIRONOLACTONE				
ACTAVIS ELIZABETH	25MG	A040353 003	Mar 15, 2006	
	50MG	A040353 001	Jul 29, 1999	
	100MG	A040353 002	Jul 29, 1999	
ASCOT	25MG	A087687 001	Oct 20, 1982	
CHARTWELL RX	25MG	A086809 001		
IVAX PHARMS	25MG	A087108 001		
LEDERLE	25MG	A087634 001		
MUTUAL PHARM	25MG	A087265 001		
PHARMOBEDIENT	25MG	A087086 001		
PUREPAC PHARM	25MG	A087998 001	Oct 14, 1983	
	25MG	A088053 001	Aug 25, 1983	
SUPERPHARM	25MG	A089364 001	Nov 07, 1986	
UPSHER SMITH	25MG	A087554 001		
VANGARD	25MG	A087648 001	Feb 01, 1982	
WARNER CHILCOTT	25MG	A087952 001	Nov 18, 1982	
WATSON LABS	25MG	A086898 002	Mar 02, 1982	
	25MG	A087078 001		
STANOZOLOL				
TABLET;ORAL				
WINSTROL				
+ LUNDBECK INC	2MG	N012885 001	May 14, 1984	
STAVUDINE				
CAPSULE;ORAL				
STAVUDINE				
AUROBINDO PHARMA	15MG	A077672 003	Dec 29, 2008	
	20MG	A077672 004	Dec 29, 2008	
	30MG	A077672 001	Dec 29, 2008	
	40MG	A077672 002	Dec 29, 2008	
HETERO LABS LTD III	15MG	A078957 001	Dec 29, 2008	
	20MG	A078957 002	Dec 29, 2008	
	30MG	A078957 003	Dec 29, 2008	
	40MG	A078957 004	Dec 29, 2008	
PHARMOBEDIENT	15MG	A079069 001	Dec 29, 2008	
	20MG	A079069 002	Dec 29, 2008	
	30MG	A078775 001	Jan 05, 2009	
	30MG	A079069 003	Dec 29, 2008	
	40MG	A078775 002	Jan 05, 2009	
	40MG	A079069 004	Dec 29, 2008	
ZERIT				
BRISTOL	5MG	N020412 001	Jun 24, 1994	
+	15MG **	N020412 002	Jun 24, 1994	
+	20MG **	N020412 003	Jun 24, 1994	
+	30MG **	N020412 004	Jun 24, 1994	
+	40MG **	N020412 005	Jun 24, 1994	
CAPSULE, EXTENDED RELEASE;ORAL				
ZERIT XR				
BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002	
	50MG	N021453 002	Dec 31, 2002	
	75MG	N021453 003	Dec 31, 2002	
	100MG	N021453 004	Dec 31, 2002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

STAVUDINE
FOR SOLUTION;ORAL
STAVUDINE
AUROBINDO PHARMA 1MG/ML A077774 001 Dec 29, 2008
CIPLA LTD 1MG/ML A078030 001 Mar 20, 2009
ZERIT
\+ BRISTOL 1MG/ML ** N020413 001 Sep 06, 1996

STERILE WATER FOR INJECTION
LIQUID;N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER
ABRAXIS PHARM 100% A089099 001 Dec 29, 1987
100% A089100 001 Dec 29, 1987
STERILE WATER FOR INJECTION
HIKMA 100% (20ML) A206369 002 Sep 02, 2015
\+ HOSPIRA 100% (1ML) ** N018801 001 Oct 27, 1982
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
B BRAUN 100% N019077 001 Mar 02, 1984
TARO 100% A077393 001 Aug 11, 2006

STERILE WATER FOR IRRIGATION
LIQUID;IRRIGATION
STERILE WATER IN PLASTIC CONTAINER
MILES 100% N018246 001

STREPTOMYCIN SULFATE
INJECTABLE;INJECTION
STREPTOMYCIN SULFATE
COPANOS EQ 500MG BASE/ML A060684 001
LILLY EQ 1GM BASE/VIAL A060107 001
EQ 1GM BASE/2ML A060404 001
EQ 5GM BASE/VIAL A060107 002
PFIZER EQ 1GM BASE/VIAL ** A060076 001
EQ 1GM BASE/2.5ML A060111 001
EQ 5GM BASE/VIAL ** A060076 002

STREPTOZOCIN
INJECTABLE;INJECTION
ZANOSAR
\+ TEVA PHARMS USA 1GM/VIAL N050577 001 May 07, 1982

SUCCINYLCHOLINE CHLORIDE
INJECTABLE;INJECTION
ANECTINE
SANDOZ 50MG/ML N008453 003
500MG/VIAL N008453 001
1GM/VIAL N008453 004
QUELICIN PRESERVATIVE FREE
\+ HOSPIRA 20MG/ML ** N008845 001
\+ 50MG/ML ** N008845 002
\+ 100MG/ML ** N008845 004
SUCCINYLCHOLINE CHLORIDE
ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020
AMPHASTAR PHARMS INC 20MG/ML A213432 001 Jun 08, 2020
BRECKENRIDGE 20MG/ML A212638 001 Oct 09, 2019
EUGIA PHARMA 20MG/ML A217808 001 Oct 16, 2023
INTL MEDICATION 100MG/VIAL A085400 001 Feb 04, 1982
MANKIND PHARMA 20MG/ML A216127 001 Feb 02, 2023
NEXUS 20MG/ML A213552 001 Oct 27, 2020
ORGANON USA INC 20MG/ML A080997 001
SUCOSTRIN
\+ APOTHECON 20MG/ML N008847 001
\+ 100MG/ML N008847 003

SUCRALFATE
SUSPENSION;ORAL
SUCRALFATE
HIKMA 1GM/10ML A212769 001 Jul 23, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUFENTANIL CITRATE				
INJECTABLE;INJECTION				
SUFENTANIL CITRATE				
WATSON LABS	EQ 0.05MG BASE/ML	A074406	001	Dec 15, 1995
TABLET;SUBLINGUAL				
DSUVIA				
+ VERTICAL PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018
SUGAMMADEX SODIUM				
SOLUTION;INTRAVENOUS				
SUGAMMADEX SODIUM				
ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023
	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023
SULFACETAMIDE SODIUM				
LOTION;TOPICAL				
SULFACETAMIDE SODIUM				
SUN PHARMA CANADA	10%	A078668	001	May 20, 2009
OINTMENT;OPHTHALMIC				
BLEPH-10				
ALLERGAN	10%	A084015	001	
CETAMIDE				
ALCON	10%	A080021	001	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	002	
SULFAIR 10				
PHARMAFAIR	10%	A088000	001	Dec 22, 1982
SOLUTION/DROPS;OPHTHALMIC				
BLEPH-10				
+ ALLERGAN	10%	A080028	001	
BLEPH-30				
ALLERGAN	30%	A080028	002	
ISOPTO CETAMIDE				
ALCON	15%	A080020	002	
OCUSULF-10				
MIZA PHARMS USA	10%	A080660	001	
OCUSULF-30				
MIZA PHARMS USA	30%	A080660	002	
SODIUM SULAMYD				
+ SCHERING	10% **	N005963	001	
+	30% **	N005963	003	
SODIUM SULFACETAMIDE				
EPIC PHARMA LLC	10%	A083021	001	
	15%	A083021	002	
	30%	A083021	003	
SOLA BARNES HIND	10%	A084143	001	
	10%	A084145	001	
	30%	A084146	001	
	30%	A084147	001	
SULF-10				
NOVARTIS	10%	A080025	001	
SULF-15				
NOVARTIS	15%	A089047	001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%	A080024	001	
SULFACETAMIDE SODIUM				
ALCON PHARMS LTD	30%	A089068	001	May 05, 1987
EPIC PHARMA LLC	30%	A040216	001	May 25, 1999
PHARMAFAIR	10%	A088947	001	May 17, 1985
PHARMOBEDIENT	10%	A040215	001	May 25, 1999
SULFAIR 10				
PHARMAFAIR	10%	A087949	001	Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%	A088385	001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%	A088186	001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%	A087818	001	Feb 03, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFACYTINE				
TABLET;ORAL				
RENOQUID				
	GLENWOOD	250MG	N017569 001	
SULFADIAZINE				
TABLET;ORAL				
SULFADIAZINE				
	ABBVIE	300MG	N004125 005	
	CHARTWELL MOLECULAR	500MG	A080084 001	
	EVERYLIFE	500MG	A080088 001	
+	IMPAX LABS	500MG	A080081 001	
	LEDERLE	500MG	N004054 001	
+	LILLY	500MG	N004122 002	
SULFADIAZINE SODIUM				
INJECTABLE;INJECTION				
SULFADIAZINE SODIUM				
	LEDERLE	250MG/ML	N004054 002	
SULFADIAZINE; SULFAMERAZINE				
SUSPENSION;ORAL				
SULFONAMIDES DUPLEX				
	LILLY	250MG/5ML;250MG/5ML	N006317 007	
SULFAMETER				
TABLET;ORAL				
SULLA				
	BAYER HLTHCARE	500MG	N016000 002	
SULFAMETHIZOLE				
TABLET;ORAL				
MICROSUL				
	FOREST PHARMS	1GM	A086012 001	
PROKLAR				
	FOREST PHARMS	500MG	A080273 001	
THIOSULFIL				
	WYETH AYERST	250MG	N008565 001	
		500MG	N008565 004	
SULFAMETHOXAZOLE				
SUSPENSION;ORAL				
GANTANOL				
	ROCHE	500MG/5ML	N013664 002	
TABLET;ORAL				
GANTANOL				
	ROCHE	500MG	N012715 002	
GANTANOL-DS				
	ROCHE	1GM	N012715 003	
SULFAMETHOXAZOLE				
	ASCOT	500MG	A087662 001	Oct 20, 1982
	BARR	500MG	A087189 001	Jul 25, 1983
	HEATHER	500MG	A086163 001	
	RISING	500MG	A085844 001	
	WATSON LABS	500MG	A085053 001	
		1GM	A086000 001	
UROBAK				
	SHIONOGI	500MG	A087307 001	
SULFAMETHOXAZOLE; TRIMETHOPRIM				
INJECTABLE;INJECTION				
BACTRIM				
+	SUN PHARM INDS INC	80MG/ML;16MG/ML **	N018374 001	
SEPTRA				
	MONARCH PHARMS	80MG/ML;16MG/ML **	N018452 001	
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
	ABRAXIS PHARM	80MG/ML;16MG/ML	A070223 001	Dec 29, 1987
	BEDFORD	80MG/ML;16MG/ML	A072383 001	Apr 29, 1992
	HIKMA	80MG/ML;16MG/ML	A070627 001	Dec 29, 1987
		80MG/ML;16MG/ML	A070628 001	Dec 29, 1987
	HOSPIRA	80MG/ML;16MG/ML	A073199 001	Sep 11, 1992
	WATSON LABS	80MG/ML;16MG/ML	A071556 001	Dec 29, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL					
BACTRIM					
+	SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	001	
BACTRIM PEDIATRIC					
	SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **	N017560	002	
SEPTRA					
	MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	001	
SEPTRA GRAPE					
	MONARCH PHARMS	200MG/5ML;40MG/5ML **	N017598	002	Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	ANI PHARMS	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987
	HIKMA	200MG/5ML;40MG/5ML	A074650	001	Dec 29, 1997
	LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021
	TEVA	200MG/5ML;40MG/5ML	N018812	001	Jan 28, 1983
		200MG/5ML;40MG/5ML	N018812	002	Jun 10, 1983
SULFATRIM					
	PHARM ASSOC	200MG/5ML;40MG/5ML	N018615	002	Jan 07, 1983
SULMEPRIM					
	USL PHARMA	200MG/5ML;40MG/5ML	A070063	001	Aug 01, 1986
SULMEPRIM PEDIATRIC					
	USL PHARMA	200MG/5ML;40MG/5ML	A070064	001	Aug 01, 1986
TRIMETH/SULFA					
	ALPHARMA US PHARMS	200MG/5ML;40MG/5ML	A072289	001	May 23, 1988
		200MG/5ML;40MG/5ML	A072398	001	May 23, 1988
	NASKA	200MG/5ML;40MG/5ML	A072399	001	May 23, 1988
TABLET;ORAL					
COTRIM					
	TEVA	400MG;80MG	A070034	001	May 16, 1985
COTRIM D.S.					
	TEVA	800MG;160MG	A070048	001	Mar 18, 1985
SEPTRA					
	MONARCH PHARMS	400MG;80MG	N017376	001	
SEPTRA DS					
	MONARCH PHARMS	800MG;160MG	N017376	002	
SULFAMETHOPRIM					
	NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985
SULFAMETHOPRIM-DS					
	NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	AIPING PHARM INC	400MG;80MG	A070890	002	Nov 13, 1986
		800MG;160MG	A070890	001	Nov 13, 1986
	FOSUN PHARMA	400MG;80MG	N018598	003	May 19, 1982
	HEATHER	400MG;80MG	N018946	001	Aug 10, 1984
		800MG;160MG	N018946	002	Aug 10, 1984
	INTERPHARM	400MG;80MG	A071299	001	Oct 27, 1987
		800MG;160MG	A071300	001	Oct 27, 1987
	MARTEC USA LLC	400MG;80MG	A072408	001	Dec 07, 1988
	MUTUAL PHARM	400MG;80MG	A070006	001	Nov 14, 1984
	PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
		800MG;160MG	A070216	001	Sep 10, 1985
	ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
	TEVA	400MG;80MG	N018242	001	
		800MG;160MG	N018242	002	
	USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985
		800MG;160MG	A070204	001	Nov 08, 1985
	WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
		400MG;80MG	N018852	001	May 09, 1983
		800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
	FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
	HERITAGE PHARMA AVET	800MG;160MG	A070037	001	Jun 02, 1987
	MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
	MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
	ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
	WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH					
	HERITAGE PHARMA AVET	400MG;80MG	A070030	001	Jun 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE; TRIMETHOPRIM				
TABLET;ORAL				
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987
SULFANILAMIDE				
CREAM;VAGINAL				
AVC				
+ PHARMOBEDIENT	15% **	N006530	003	Jan 27, 1987
SULFANILAMIDE				
COSETTE	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL				
AVC				
PHARMOBEDIENT	1.05GM	N006530	004	Jan 27, 1987
SULFAPHENAZOLE				
SUSPENSION;ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	
SULFAPYRIDINE				
TABLET;ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159	001	
SULFASALAZINE				
SUSPENSION;ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET;ORAL				
S.A.S.-500				
SOLVAY	500MG	A083450	001	
SULFASALAZINE				
EPIC PHARMA LLC	500MG	A086184	001	
SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	
TABLET, DELAYED RELEASE;ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052	001	May 24, 1983
SULFINPYRAZONE				
CAPSULE;ORAL				
ANTURANE				
+ NOVARTIS	200MG **	N011556	004	
SULFINPYRAZONE				
BARR	200MG	A087666	001	Sep 17, 1982
IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
PAR PHARM	200MG	A088934	001	Sep 06, 1985
VANGARD	200MG	A088666	001	Feb 17, 1984
TABLET;ORAL				
ANTURANE				
NOVARTIS	100MG **	N011556	003	
SULFINPYRAZONE				
BARR	100MG	A087665	001	Sep 17, 1982
IVAX PHARMS	100MG	A087769	001	Jun 01, 1982
PAR PHARM	100MG	A088933	001	Sep 06, 1985
WATSON LABS	100MG	A087667	001	May 26, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFISOXAZOLE

TABLET;ORAL				
GANTRISIN				
	ROCHE	500MG	N006525 001	
SOSOL				
	MK LABS	500MG	A080036 001	
SOXAZOLE				
	ALRA	500MG	A080366 001	
SULFALAR				
	PARKE DAVIS	500MG	A084955 001	
SULFISOXAZOLE				
	ANI PHARMS	500MG	A080142 001	
	BARR	500MG	A084031 001	
	HEATHER	500MG	A080189 001	
	IMPAX LABS	500MG	A080109 001	
	LANNETT	500MG	A080085 001	
	LEDERLE	500MG	A087649 001	
	PHARMERAL	500MG	A084385 001	
	PUREPAC PHARM	500MG	A080087 001	
	RISING	500MG	A085628 001	
	ROXANE	500MG	A080082 001	
	VALEANT PHARM INTL	500MG	A080268 002	
	VITARINE	500MG	A087332 001	
	WATSON LABS	500MG	A085534 001	
	WEST WARD	500MG	A080379 001	
SULSOXIN				
	SOLVAY	500MG	A080040 001	

SULFISOXAZOLE ACETYL

EMULSION;ORAL				
LIPO GANTRISIN				
	ROCHE	EQ 1GM BASE/5ML	N009182 009	
SUSPENSION;ORAL				
GANTRISIN PEDIATRIC				
	ROCHE	EQ 500MG BASE/5ML	N009182 004	
SYRUP;ORAL				
GANTRISIN				
	ROCHE	EQ 500MG BASE/5ML	N009182 002	

SULFISOXAZOLE DIOLAMINE

INJECTABLE;INJECTION				
GANTRISIN				
	ROCHE	EQ 400MG BASE/ML	N006917 001	
OINTMENT;OPHTHALMIC				
GANTRISIN				
	ROCHE	EQ 4% BASE	N008414 002	
SOLUTION/DROPS;OPHTHALMIC				
GANTRISIN				
	ROCHE	EQ 4% BASE	N007757 002	
SULFISOXAZOLE DIOLAMINE				
	SOLA BARNES HIND	EQ 4% BASE	A084148 001	

SULFOXONE SODIUM

TABLET, DELAYED RELEASE;ORAL				
DIASONE SODIUM				
	ABBVIE	165MG	N006044 003	

SULFUR

POWDER;TOPICAL				
BENSULFOID				
	POYTHRESS	33.32%	N002918 001	

SULINDAC

TABLET;ORAL				
CLINORIL				
+	MERCK	150MG **	N017911 001	
+		200MG **	N017911 002	
SULINDAC				
	ANI PHARMS	150MG	A072973 002	Feb 28, 1992
		200MG	A072973 001	Feb 28, 1992
	CHARTWELL RX	150MG	A072712 001	Aug 30, 1991
		200MG	A072713 001	Aug 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULINDAC				
TABLET;ORAL				
SULINDAC				
EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991
	200MG	A073262	001	Sep 06, 1991
RISING	150MG	A073039	002	Jun 22, 1993
	200MG	A073039	001	Jun 22, 1993
SUMATRIPTAN				
SPRAY;NASAL				
IMITREX				
GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997
SUMATRIPTAN SUCCINATE				
INJECTABLE;SUBCUTANEOUS				
ALSUMA				
MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010
IMITREX				
+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **	N020080	001	Dec 28, 1992
SUMATRIPTAN SUCCINATE				
ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078319	001	Dec 10, 2015
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078319	002	Dec 10, 2015
BAXTER HLTHCARE CORP	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A207101	001	Jan 19, 2023
FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240	002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240	001	Sep 18, 2009
NORVIUM BIOSCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014
ONESOURCE SPECIALTY	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010
PH HEALTH	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009
SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009
TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009
ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010
SUMAVEL DOSEPRO				
+ ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013
+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009
SYSTEM;IONTOPHORESIS				
ZECUITY				
+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013
TABLET;ORAL				
SUMATRIPTAN SUCCINATE				
FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009
	EQ 50MG BASE	A076976	002	Aug 10, 2009
	EQ 100MG BASE	A076976	003	Aug 10, 2009
HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013
	EQ 50MG BASE	A078298	002	May 21, 2013
	EQ 100MG BASE	A078298	003	May 21, 2013
MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009
	EQ 50MG BASE	A077163	002	Nov 02, 2009
	EQ 100MG BASE	A077163	003	Nov 02, 2009
ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009
	EQ 50MG BASE	A078241	002	Aug 10, 2009
	EQ 100MG BASE	A078241	003	Aug 10, 2009
SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009
	EQ 50MG BASE	A078295	002	Aug 10, 2009
	EQ 100MG BASE	A078295	003	Aug 10, 2009
SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009
	EQ 50MG BASE	A076554	002	Aug 10, 2009
	EQ 100MG BASE	A076572	001	Feb 09, 2009
TEVA	EQ 25MG BASE	A076840	001	Feb 09, 2009
	EQ 50MG BASE	A076840	002	Feb 09, 2009
	EQ 100MG BASE	A076840	003	Feb 09, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUPROFEN				
SOLUTION/DROPS;OPHTHALMIC				
PROFENAL				
ALCON	1%	N019387	001	Dec 23, 1988
TACRINE HYDROCHLORIDE				
CAPSULE;ORAL				
COGNEX				
SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993
	EQ 20MG BASE	N020070	002	Sep 09, 1993
	EQ 30MG BASE	N020070	003	Sep 09, 1993
	EQ 40MG BASE	N020070	004	Sep 09, 1993
TACROLIMUS				
CAPSULE;ORAL				
TACROLIMUS				
HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023
	EQ 1MG BASE	A210929	002	Apr 17, 2023
	EQ 5MG BASE	A210929	003	Apr 17, 2023
HERITAGE PHARMA AVET	EQ 5MG BASE	A090402	001	Jul 01, 2010
INJECTABLE;INJECTION				
TACROLIMUS				
HOSPIRA	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017
TADALAFIL				
TABLET;ORAL				
CIALIS				
+ LILLY	2.5MG **	N021368	004	Jan 07, 2008
TADALAFIL				
CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020
	5MG	A210716	002	Dec 29, 2020
	10MG	A210716	003	Dec 29, 2020
	20MG	A210716	004	Dec 29, 2020
NORVIUM BIOSCIENCE	5MG	A206957	001	Apr 29, 2019
PHARMOBEDIENT	20MG	A200630	001	Aug 03, 2018
RISING	2.5MG	A206956	001	Apr 29, 2019
	10MG	A206956	002	Apr 29, 2019
	20MG	A206956	003	Apr 29, 2019
ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023
TABLET, CHEWABLE;ORAL				
CHEWTADZY				
+ B BETTER	5MG	N218527	001	Jun 28, 2024
+	10MG	N218527	002	Jun 28, 2024
+	20MG	N218527	003	Jun 28, 2024
TALAZOPARIB TOSYLATE				
CAPSULE;ORAL				
TALZENNA				
+ PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023
+	EQ 0.25MG BASE	N211651	001	Oct 16, 2018
+	EQ 0.35MG BASE	N211651	006	Jun 20, 2023
+	EQ 0.5MG BASE	N211651	003	Sep 20, 2021
+	EQ 0.75MG BASE	N211651	004	Sep 20, 2021
+	EQ 1MG BASE	N211651	002	Oct 16, 2018
TALBUTAL				
TABLET;ORAL				
LOTUSATE				
SANOFI AVENTIS US	120MG	N009410	005	
TAMOXIFEN CITRATE				
TABLET;ORAL				
NOLVADEX				
+ ASTRAZENECA	EQ 10MG BASE **	N017970	001	
+	EQ 20MG BASE **	N017970	002	Mar 21, 1994
TAMOXIFEN CITRATE				
ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003
	EQ 20MG BASE	A076179	002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011
	EQ 20MG BASE	A090878	002	Sep 23, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TAMOXIFEN CITRATE				
TABLET;ORAL				
TAMOXIFEN CITRATE				
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003
TAMSULOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
FLOMAX				
+ SANOFI	0.4MG	N020579	001	Apr 15, 1997
TAMSULOSIN HYDROCHLORIDE				
PH HEALTH	0.4MG	A202010	001	Jan 04, 2013
PHARMOBEDIENT	0.4MG	A090408	001	Apr 27, 2010
SUN PHARM INDS LTD	0.4MG	A090931	001	Jul 15, 2010
TAPENTADOL HYDROCHLORIDE				
SOLUTION;ORAL				
NUCYNTA				
+ COLLEGIUM PHARM INC	EQ 20MG BASE/ML **	N203794	001	Oct 15, 2012
TAVABOROLE				
SOLUTION;TOPICAL				
KERYDIN				
+ ANACOR PHARMS INC	5% **	N204427	001	Jul 07, 2014
TAVABOROLE				
AMNEAL	5%	A212256	001	Nov 25, 2020
SUN PHARMA CANADA	5%	A212215	001	May 07, 2021
TAZAROTENE				
CREAM;TOPICAL				
TAZAROTENE				
FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019
LOTION;TOPICAL				
TAZAROTENE				
PADAGIS ISRAEL	0.045%	A215393	001	Jul 29, 2025
TECHNETIUM TC-99M APCITIDE				
INJECTABLE;INJECTION				
ACUTECT				
CIS BIO INTL SA	N/A	N020887	001	Sep 14, 1998
TECHNETIUM TC-99M DEPREOTIDE				
INJECTABLE;INJECTION				
NEO TECT KIT				
CIS BIO INTL SA	N/A **	N021012	001	Aug 03, 1999
TECHNETIUM TC-99M DISOFENIN KIT				
INJECTABLE;INJECTION				
HEPATOLITE				
SUN PHARM INDS INC	N/A	N018467	001	Mar 16, 1982
TECHNETIUM TC-99M ETIDRONATE KIT				
INJECTABLE;INJECTION				
CINTICHEM TECHNETIUM 99M HEDSPA				
GE HEALTHCARE	N/A	N017653	001	
MPI STANNOUS DIPHOSPHONATE				
GE HEALTHCARE	N/A	N017667	001	
OSTEOSCAN				
MALLINCKRODT	N/A	N017454	001	
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT				
GE HEALTHCARE	N/A	N017562	001	
TECHNETIUM TC-99M FERPENTETATE KIT				
INJECTABLE;INJECTION				
RENOTEC				
BRACCO	N/A	N017045	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE;INJECTION				
GLUCOSCAN				
	BRISTOL MYERS SQUIBB	N/A	N017907 001	
TECHNESCAN GLUCEPTATE				
	DRAXIMAGE	N/A	N018272 001	Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE;INJECTION				
TECHNESCAN HIDA				
	DRAXIMAGE	N/A	N018489 001	Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE;INJECTION				
DRAXIMAGE MDP-10				
	JUBILANT	N/A	N018035 001	

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION				
AMERSCAN MDP KIT				
	GE HEALTHCARE	N/A	N018335 001	Aug 05, 1982
OSTEOLITE				
	SUN PHARM INDS INC	N/A	N017972 001	
TECHNETIUM TC 99M MPI MDP				
	GE HEALTHCARE	N/A	N018141 001	
		N/A	N018141 002	Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION				
AN-DTPA				
	JUBILANT DRAXIMAGE	N/A	N017714 001	
MPI DTPA KIT - CHELATE				
	GE HEALTHCARE	N/A	N017255 001	
TECHNETIUM TC-99M PENTETATE KIT				
	GE HEALTHCARE	N/A	N017264 002	

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE;INJECTION				
SODIUM POLYPHOSPHATE-TIN KIT				
	GE HEALTHCARE	N/A	N017664 001	

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE;INJECTION				
PYROLITE				
	PHARMALUCENCE	N/A	N017684 001	

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION				
PHOSPHOTEC				
	BRACCO	N/A	N017680 001	

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE;INJECTION				
RBC-SCAN				
	CADEMA	N/A	N020063 001	Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION				
MIRALUMA				
	LANTHEUS MEDCL	N/A	N019785 003	May 23, 1997
TECHNETIUM TC 99M SESTAMIBI				
	SUN PHARM INDS INC	10-30mCi	A079157 001	Jul 10, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION;INJECTION, ORAL				
SODIUM PERTECHNETATE TC 99M				
+	GE HEALTHCARE	2-100mCi/ML **	N017471 001	
+	MALLINCKRODT	10-60mCi/ML **	N017725 001	
	SUN PHARM INDS INC	12mCi/ML	N017321 001	
		24mCi/ML	N017321 002	
		48mCi/ML	N017321 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL				
MINITEC				
	BRACCO	0.22-2.22 CI/GENERATOR	N017339 001	
SOLUTION;INTRAVENOUS				
TECHNELITE				
	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771 001	
ULTRA-TECHNEKOW V4				
	CURIUM	0.25-3 CI/GENERATOR	N017243 002	
SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC				
RADIOGENIX SYSTEM				
+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158 001	Feb 08, 2018
SOLUTION;INTRAVENOUS, ORAL				
DRYTEC				
+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693 002	Dec 13, 2013
		830-16600mCi/GENERATOR	N017693 001	

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION				
MPI DMSA KIDNEY REAGENT				
+	GE HEALTHCARE	N/A **	N017944 001	May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION;INJECTION, ORAL				
TECHNETIUM TC 99M SULFUR COLLOID				
	GE HEALTHCARE	4mCi/ML	N017456 001	
SOLUTION;ORAL				
TECHNETIUM TC 99M SULFUR COLLOID				
	MALLINCKRODT	3mCi/ML	N017724 001	

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL				
TECHNECOLL				
	MALLINCKRODT	N/A	N017059 001	
TECHNETIUM TC 99M TSC				
	GE HEALTHCARE	N/A	N017784 001	
TESULOID				
	BRACCO	N/A	N016923 001	

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE;INJECTION				
CARDIOTEC				
	BRACCO	N/A	N019928 001	Dec 19, 1990

TEGASEROD MALEATE

TABLET;ORAL				
ZELNORM				
+	ALFASIGMA	EQ 2MG BASE	N021200 001	Jul 24, 2002
+		EQ 6MG BASE	N021200 002	Jul 24, 2002

TELAPREVIR

TABLET;ORAL				
INCIVEK				
	VERTEX PHARMS	375MG	N201917 001	May 23, 2011

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS				
VIBATIV				
+	CUMBERLAND	EQ 250MG BASE/VIAL	N022110 001	Sep 11, 2009

TELBIVUDINE

SOLUTION;ORAL				
TYZEKA				
	NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009
TABLET;ORAL				
TYZEKA				
+	NOVARTIS	600MG	N022011 001	Oct 25, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TELITHROMYCIN					
TABLET;ORAL					
KETEK					
	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
		400MG	N021144	001	Apr 01, 2004
TELMISARTAN					
TABLET;ORAL					
MICARDIS					
+	BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000
+		80MG	N020850	002	Nov 10, 1998
TELMISARTAN					
	HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016
		40MG	A205901	002	Apr 22, 2016
		80MG	A205901	003	Apr 22, 2016
	HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019
		40MG	A207843	002	Feb 19, 2019
		80MG	A207843	003	Feb 19, 2019
TEMAZEPAM					
CAPSULE;ORAL					
TEMAZ					
	QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
		30MG	A070547	001	Oct 15, 1985
TEMAZEPAM					
	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016
		15MG	A203482	002	May 23, 2016
		22.5MG	A203482	003	May 23, 2016
		30MG	A203482	004	May 23, 2016
	AUROBINDO PHARMA USA	7.5MG	A070920	002	May 21, 2010
		15MG	A070920	004	Jul 07, 1986
		22.5MG	A070920	003	Jun 12, 2009
		30MG	A070920	001	Jul 10, 1986
	DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
		30MG	A071709	001	Sep 29, 1988
	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009
		15MG	A071174	001	Jul 10, 1986
		22.5MG	A071175	002	Sep 14, 2009
		30MG	A071175	001	Jul 10, 1986
	USL PHARMA	15MG	A070489	001	Jul 07, 1986
		30MG	A070490	001	Jul 07, 1986
	WATSON LABS	15MG	A070383	001	Mar 23, 1987
		15MG	A071446	001	May 21, 1993
		30MG	A070384	001	Mar 23, 1987
		30MG	A071447	001	May 21, 1993
TEMOZOLOMIDE					
CAPSULE;ORAL					
TEMODAR					
+	MERCK SHARP DOHME	5MG	N021029	001	Aug 11, 1999
+		20MG	N021029	002	Aug 11, 1999
+		100MG	N021029	003	Aug 11, 1999
+		140MG	N021029	005	Oct 19, 2006
+		180MG	N021029	006	Oct 19, 2006
+		250MG	N021029	004	Aug 11, 1999
TEMOZOLOMIDE					
	ANI PHARMS	5MG	A203490	001	Jul 13, 2016
		20MG	A203490	002	Jul 13, 2016
		100MG	A203490	003	Jul 13, 2016
		140MG	A203490	004	Jul 13, 2016
		180MG	A203490	005	Jul 13, 2016
		250MG	A203490	006	Jul 13, 2016
	APOTEX	5MG	A204159	001	Jul 05, 2018
		20MG	A204159	002	Jul 05, 2018
		100MG	A204159	003	Jul 05, 2018
		140MG	A204159	004	Jul 05, 2018
		180MG	A204159	005	Jul 05, 2018
		250MG	A204159	006	Jul 05, 2018
	EIRGEN	5MG	A203898	001	Feb 10, 2016
		20MG	A203898	002	Feb 10, 2016
	EXTROVIS	5MG	A205227	001	Jun 29, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TEMOZOLOMIDE					
CAPSULE;ORAL					
TEMOZOLOMIDE					
		20MG	A205227	002	Jun 29, 2016
		100MG	A205227	003	Jun 29, 2016
		140MG	A205227	004	Jun 29, 2016
		180MG	A205227	005	Jun 29, 2016
		250MG	A205227	006	Jun 29, 2016
	HERITAGE	5MG	A078879	001	Mar 01, 2010
		20MG	A078879	002	Mar 01, 2010
		100MG	A078879	003	Mar 01, 2010
		140MG	A078879	005	Mar 01, 2010
		180MG	A078879	006	Mar 01, 2010
		250MG	A078879	004	Mar 01, 2010
	NIVAGEN PHARMS INC	5MG	A213328	001	Nov 23, 2021
		20MG	A213328	002	Nov 23, 2021
		100MG	A213328	003	Nov 23, 2021
		140MG	A213328	004	Nov 23, 2021
		180MG	A213328	005	Nov 23, 2021
		250MG	A213328	006	Nov 23, 2021
	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017
		20MG	A203959	002	Apr 18, 2017
		100MG	A203959	003	Apr 18, 2017
		140MG	A203959	004	Apr 18, 2017
		250MG	A203959	005	Apr 18, 2017
TENAPANOR HYDROCHLORIDE					
TABLET;ORAL					
XPHOZAH					
+	ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023
TENIPOSIDE					
INJECTABLE;INJECTION					
VUMON					
+	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992
TENOFOVIR ALAFENAMIDE FUMARATE					
TABLET;ORAL					
TENOFOVIR ALAFENAMIDE FUMARATE					
	APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024
TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
TENOFOVIR DISOPROXIL FUMARATE					
	CHARTWELL RX	300MG	A209550	001	Feb 26, 2018
	PHARMOBEDIENT	150MG	A206569	001	Nov 27, 2018
		200MG	A206569	002	Nov 27, 2018
		250MG	A206569	003	Nov 27, 2018
		300MG	A206569	004	Nov 27, 2018
TERAZOSIN HYDROCHLORIDE					
CAPSULE;ORAL					
HYTRIN					
+	ABBOTT	EQ 1MG BASE **	N020347	001	Dec 14, 1994
+		EQ 2MG BASE **	N020347	002	Dec 14, 1994
+		EQ 5MG BASE **	N020347	003	Dec 14, 1994
+		EQ 10MG BASE **	N020347	004	Dec 14, 1994
TERAZOSIN HYDROCHLORIDE					
	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001
		EQ 2MG BASE	A075498	002	Apr 12, 2001
		EQ 5MG BASE	A075498	003	Apr 12, 2001
		EQ 10MG BASE	A075498	004	Apr 12, 2001
	PHARMOBEDIENT	EQ 1MG BASE	A075140	002	Feb 11, 2000
		EQ 1MG BASE	A075384	001	Dec 01, 2000
		EQ 2MG BASE	A075140	003	Feb 11, 2000
		EQ 2MG BASE	A075384	002	Dec 01, 2000
		EQ 5MG BASE	A075140	001	Feb 11, 2000
		EQ 5MG BASE	A075384	003	Dec 01, 2000
		EQ 10MG BASE	A075140	004	Feb 11, 2000
		EQ 10MG BASE	A075384	004	Dec 01, 2000
	RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
		EQ 2MG BASE	A076021	002	Aug 22, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
TERAZOSIN HYDROCHLORIDE				
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
SOLUTION;ORAL				
TEZRULY				
+ NOVITIUM PHARMA	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024
TABLET;ORAL				
HYTRIN				
ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
	EQ 2MG BASE	N019057	002	Aug 07, 1987
	EQ 5MG BASE	N019057	003	Aug 07, 1987
	EQ 10MG BASE	N019057	004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
CHARTWELL RX	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074657	004	Apr 28, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 10MG BASE	A074315	004	Dec 31, 1998
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000
TERBINAFINE				
GEL;TOPICAL				
LAMISIL				
KARO HLTHCARE	1%	N020846	001	Apr 29, 1998
TERBINAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
LAMISIL				
NOVARTIS	1% **	N020192	001	Dec 30, 1992
GRANULE;ORAL				
LAMISIL				
+ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007
SOLUTION;TOPICAL				
LAMISIL				
KARO HLTHCARE	1%	N020749	001	Oct 17, 1997
TABLET;ORAL				
LAMISIL				
+ NOVARTIS	EQ 250MG BASE **	N020539	001	May 10, 1996
TERBINAFINE HYDROCHLORIDE				
BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010
CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
NATCO PHARMA	EQ 250MG BASE	A077195	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007
TERBUTALINE SULFATE				
AEROSOL, METERED;INHALATION				
BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985
INJECTABLE;INJECTION				
BRETHINE				
+ PHARMACARE	1MG/ML **	N018571	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERBUTALINE SULFATE				
INJECTABLE;INJECTION				
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466 001		
TERBUTALINE SULFATE				
CHARTWELL INJECTABLE	1MG/ML	A076770 001	Apr 23, 2004	
DR REDDYS	1MG/ML	A076853 001	Jul 20, 2004	
EPIC PHARMA LLC	1MG/ML	A078151 001	Jan 07, 2008	
TABLET;ORAL				
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618 001		
	5MG	N017618 002		
TERCONAZOLE				
CREAM;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	0.8% **	N019964 001	Feb 21, 1991	
TERAZOL 7				
+ JANSSEN PHARMS	0.4% **	N019579 001	Dec 31, 1987	
SUPPOSITORY;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	80MG **	N019641 001	May 24, 1988	
TERCONAZOLE				
FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	
TERIFLUNOMIDE				
TABLET;ORAL				
TERIFLUNOMIDE				
AMNEAL PHARMS CO	7MG	A209613 001	Sep 28, 2018	
	14MG	A209613 002	Sep 28, 2018	
APOTEX	7MG	A209601 001	Nov 02, 2018	
	14MG	A209601 002	Nov 02, 2018	
BRECKENRIDGE	7MG	A209583 001	Sep 24, 2021	
	14MG	A209583 002	Sep 24, 2021	
CONCORD BIOTECH LTD	7MG	A218663 001	Apr 07, 2025	
	14MG	A218663 002	Apr 07, 2025	
SOMERSET THERAPS LLC	7MG	A209702 001	Feb 28, 2020	
	14MG	A209702 002	Feb 28, 2020	
TORRENT	7MG	A209697 001	Apr 04, 2024	
	14MG	A209697 002	Apr 04, 2024	
WATSON LABS TEVA	7MG	A209549 001	Jul 27, 2018	
	14MG	A209549 002	Jul 27, 2018	
TERIPARATIDE				
SOLUTION;SUBCUTANEOUS				
FORTEO				
LILLY	0.75MG/3ML (0.25MG/ML)	N021318 001	Nov 26, 2002	
TERIPARATIDE ACETATE				
INJECTABLE;INJECTION				
PARATHAR				
SANOFI AVENTIS US	200 UNITS/VIAL	N019498 001	Dec 23, 1987	
TESTOLACTONE				
INJECTABLE;INJECTION				
TESLAC				
BRISTOL MYERS SQUIBB	100MG/ML	N016119 001		
TABLET;ORAL				
TESLAC				
BRISTOL MYERS SQUIBB	50MG	N016118 001		
	250MG	N016118 002		
TESTOSTERONE				
FILM, EXTENDED RELEASE;TRANSDERMAL				
ANDRODERM				
+ ABBVIE	2MG/24HR **	N020489 003	Oct 20, 2011	
	2.5MG/24HR	N020489 001	Sep 29, 1995	
+	4MG/24HR **	N020489 004	Oct 20, 2011	
	5MG/24HR	N020489 002	May 02, 1997	
TESTODERM				
ALZA	4MG/24HR	N019762 001	Oct 12, 1993	
	6MG/24HR	N019762 002	Oct 12, 1993	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TESTOSTERONE					
FILM, EXTENDED RELEASE;TRANSDERMAL					
TESTODERM TTS					
	ALZA	5MG/24HR	N020791	001	Dec 18, 1997
GEL;TRANSDERMAL					
TESTOSTERONE					
	ANI PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012
		50MG/5GM PACKET	N202763	002	Feb 14, 2012
	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013
		50MG/5GM PACKET	N203098	003	Jan 31, 2013
GEL, METERED;TRANSDERMAL					
FORTESTA					
+	ENDO OPERATIONS	10MG/0.5GM ACTUATION **	N021463	001	Dec 29, 2010
TESTOSTERONE					
	ALEMBIC	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021
	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013
	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019
INJECTABLE;INJECTION					
TESTOSTERONE					
	DR REDDYS	100MG/ML	A086417	001	Jul 07, 1983
	WATSON LABS	25MG/ML	A086420	001	May 10, 1983
		50MG/ML	A086419	001	Aug 23, 1983
SOLUTION, METERED;TRANSDERMAL					
AXIRON					
+	ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504	001	Nov 23, 2010
TESTOSTERONE					
	ALEMBIC	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021
	APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020
	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021
	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021
TABLET, EXTENDED RELEASE;BUCCAL					
STRIANT					
+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003
TESTOSTERONE CYPIONATE					
INJECTABLE;INJECTION					
DEPO-TESTOSTERONE					
	PFIZER	50MG/ML	A085635	001	
TESTOSTERONE CYPIONATE					
	RISING	200MG/ML	A040652	001	Dec 11, 2006
	SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013
		200MG/ML	A201720	002	Jun 03, 2013
	WATSON LABS	100MG/ML	A084401	001	
		100MG/ML	A086029	001	
		200MG/ML	A084401	002	
	WATSON PHARMS INC	200MG/ML	A086030	001	
TESTOSTERONE ENANTHATE					
INJECTABLE;INJECTION					
DELATESTRYL					
	ENDO PHARMS	200MG/ML **	N009165	001	
+		200MG/ML **	N009165	003	
TESTOSTERONE ENANTHATE					
	RISING	200MG/ML	A040647	001	Oct 05, 2009
	WATSON LABS	100MG/ML	A083667	001	
		100MG/ML	A085599	001	
		200MG/ML	A083667	002	
	WATSON PHARMS INC	200MG/ML	A085598	001	
TESTOSTERONE PROPIONATE					
INJECTABLE;INJECTION					
TESTOSTERONE PROPIONATE					
	BEL MAR	25MG/ML	A080741	001	
		50MG/ML	A080742	001	
		100MG/ML	A080743	001	
	ELKINS SINN	25MG/ML	A080276	001	
	LILLY	50MG/ML	A080254	002	
	WATSON LABS	25MG/ML	A080188	001	
		25MG/ML	A085490	001	
		50MG/ML	A080188	002	
		50MG/ML	A085490	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TESTOSTERONE PROPIONATE				
INJECTABLE;INJECTION				
TESTOSTERONE PROPIONATE				
	100MG/ML		A080188 003	
	100MG/ML		A083595 003	
TESTOSTERONE UNDECANOATE				
CAPSULE;ORAL				
KYZATREX				
+ MARIUS	100MG		N213953 001	Jul 27, 2022
TETRABENAZINE				
TABLET;ORAL				
TETRABENAZINE				
AJANTA PHARMA LTD	12.5MG		A213621 001	Dec 04, 2020
	25MG		A213621 002	Dec 04, 2020
HIKMA	12.5MG		A209739 001	Apr 08, 2019
	25MG		A209739 002	Apr 08, 2019
SUN PHARM	12.5MG		A206129 001	Aug 17, 2015
	25MG		A206129 002	Aug 17, 2015
TETRACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
BRISTACYCLINE				
BRISTOL	250MG		A061658 001	
	250MG		A061888 001	
	500MG		A061658 002	
	500MG		A061888 002	
CYCLOPAR				
WARNER CHILCOTT	250MG		A061725 001	
	250MG		A062175 001	
	250MG		A062332 001	
	500MG		A061725 002	
	500MG		A062332 002	
PANMYCIN				
PHARMACIA AND UPJOHN	250MG		A060347 001	
RETET				
SOLVAY	250MG		A061443 001	
	500MG		A061443 002	
ROBITET				
WYETH AYERST	250MG		A061734 001	
	500MG		A061734 002	
SUMYCIN				
APOTHECON	100MG		A060429 002	
	125MG		A060429 004	
	250MG		A060429 001	
	500MG		A060429 003	
TETRACHEL				
ANGUS	250MG		A060343 001	
	500MG		A060343 003	
TETRACYCLINE HYDROCHLORIDE				
ABBOTT	250MG		A061802 001	
	500MG		A061802 002	
ANI PHARMS	250MG		A061471 001	
AUROBINDO PHARMA USA	250MG		A060783 001	
	500MG		A060783 002	
ELKINS SINN	250MG		A060059 001	
FERRANTE	125MG		A060173 001	
	250MG		A060173 002	
HEATHER	250MG		A061148 001	
	500MG		A061148 002	
HIKMA	250MG		A060768 001	
	500MG		A060768 002	
IMPAX LABS	100MG		A060469 002	
	250MG		A060469 001	
	500MG		A060469 003	
IVAX SUB TEVA PHARMS	250MG		A060704 001	
	500MG		A060704 002	
MAST MM	250MG		A062085 001	
PUREPAC PHARM	250MG		A060290 001	
	500MG		A060290 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
TETRACYCLINE HYDROCHLORIDE				
PVT FORM	250MG	A062686	001	Jul 24, 1986
	500MG	A062686	002	Jul 24, 1986
ROXANE	500MG	A061214	002	
SUN PHARM INDUSTRIES	250MG	A060736	001	
	500MG	A060736	002	
SUPERPHARM	250MG	A062540	001	Mar 21, 1985
	500MG	A062540	002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471	001	
	500MG	A060471	002	
WARNER CHILCOTT	250MG	A062300	001	
	500MG	A062300	002	
WATSON LABS	250MG	A062103	001	
	250MG	A062343	001	
	500MG	A062103	002	
	500MG	A062343	002	
WYETH AYERST	250MG	A061685	001	
	500MG	A061685	002	
TETRACYN				
PFIPHARMECS	250MG	A060082	003	
	500MG	A060082	004	
FIBER, EXTENDED RELEASE;PERIODONTAL				
ACTISITE				
SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994
FOR SOLUTION;TOPICAL				
TOPICYCLINE				
SHIRE	2.2MG/ML	N050493	001	
INJECTABLE;INJECTION				
ACHROMYCIN				
LEDERLE	250MG/VIAL	N050273	002	
	500MG/VIAL	N050273	003	
TETRACYN				
PFIZER	250MG/VIAL	A060096	001	
	500MG/VIAL	A060096	002	
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
STORZ	10MG/GM	N050266	001	
SUSPENSION;ORAL				
ACHROMYCIN V				
LEDERLE	125MG/5ML	N050263	002	
SUMYCIN				
PH HEALTH	125MG/5ML	A060400	001	
TETRACYCLINE HYDROCHLORIDE				
ALPHARMA US PHARMS	125MG/5ML	A060633	001	
FERRANTE	125MG/5ML	A060174	001	
PROTER	125MG/5ML	A060446	001	
PUREPAC PHARM	125MG/5ML	A060291	001	
TETRACYN				
PFIPHARMECS	125MG/5ML	A060095	001	
TETRAMED				
IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001	
SUSPENSION/DROPS;OPHTHALMIC				
ACHROMYCIN				
STORZ	1%	N050268	001	
TABLET;ORAL				
PANMYCIN				
PHARMACIA AND UPJOHN	250MG	A061705	001	
	500MG	A061705	002	
SUMYCIN				
STRIDES PHARMA INTL	50MG	A061147	003	
	100MG	A061147	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TETRACYCLINE PHOSPHATE COMPLEX				
CAPSULE;ORAL				
TETREX				
BRISTOL	EQ 100MG HYDROCHLORIDE		A061653 001	
	EQ 250MG HYDROCHLORIDE		A061653 002	
	EQ 250MG HYDROCHLORIDE		A061889 002	
	EQ 250MG HYDROCHLORIDE		N050212 002	
	EQ 500MG HYDROCHLORIDE		A061653 003	
	EQ 500MG HYDROCHLORIDE		A061889 001	
	EQ 500MG HYDROCHLORIDE		N050212 003	
THALIDOMIDE				
CAPSULE;ORAL				
THALIDOMIDE				
NATCO	150MG		A213267 001	Apr 27, 2023
THALLOUS CHLORIDE TL-201				
INJECTABLE;INJECTION				
THALLOUS CHLORIDE TL 201				
BRACCO	1mCi/ML		N018548 001	Dec 30, 1982
+ GE HEALTHCARE	1mCi/ML		N018110 002	Feb 27, 1996
+ LANTHEUS MEDCL	1mCi/ML **		N017806 001	
TRACE LIFE	1mCi/ML		A075569 001	Nov 21, 2001
INJECTABLE;INTRAVENOUS				
THALLOUS CHLORIDE TL 201				
CURIUM	2mCi/ML		A077698 001	Nov 09, 2006
+ LANTHEUS MEDCL	2mCi/ML **		N017806 002	Oct 09, 1998
THEOPHYLLINE				
CAPSULE;ORAL				
BRONKODYL				
SANOFI AVENTIS US	100MG		A085264 001	
	200MG		A085264 002	
ELIXOPHYLLIN				
FOREST LABS	100MG		A085545 001	Jul 31, 1984
	200MG		A083921 001	Jul 31, 1984
SOMOPHYLLIN-T				
FISONS	100MG		A087155 001	Feb 25, 1985
	200MG		A087155 002	Feb 25, 1985
	250MG		A087155 003	Feb 25, 1985
THEOPHYLLINE				
KV PHARM	100MG		A085263 001	
	200MG		A085263 002	
SCHERER RP	100MG		A084731 002	Nov 07, 1986
	200MG		A084731 001	Nov 07, 1986
	250MG		A084731 003	Nov 07, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
AEROLATE III				
FLEMING PHARMS	65MG		A085075 003	Nov 24, 1986
AEROLATE JR				
FLEMING PHARMS	130MG		A085075 002	Nov 24, 1986
AEROLATE SR				
FLEMING PHARMS	260MG		A085075 001	Nov 24, 1986
ELIXOPHYLLIN SR				
FOREST LABS	125MG		A086826 001	Jan 29, 1985
	250MG		A086826 002	Jan 29, 1985
SLO-BID				
SANOFI AVENTIS US	50MG		A088269 001	Jan 31, 1985
	75MG		A089539 001	May 10, 1989
	100MG		A087892 001	Jan 31, 1985
	125MG		A089540 001	May 10, 1989
	200MG		A087893 001	Jan 31, 1985
	300MG		A087894 001	Jan 31, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	60MG		A085206 001	May 24, 1982
+	125MG		A085203 001	May 24, 1982
	250MG		A085205 001	May 24, 1982
SOMOPHYLLIN-CRT				
GRAHAM DM	50MG		A087763 001	Feb 27, 1985
	100MG		A087194 001	
	200MG		A088382 001	Feb 27, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL				
SOMOPHYLLIN-CRT				
+	250MG		A087193 001	
	300MG		A088383 001	Feb 27, 1985
THEO-DUR				
SCHERING	50MG		A088022 001	Sep 10, 1985
	75MG		A088015 001	Sep 10, 1985
	125MG		A088016 001	Sep 10, 1985
	200MG		A087995 001	Sep 10, 1985
THEOBID				
WHITBY	260MG		A085983 001	Mar 20, 1985
THEOBID JR.				
WHITBY	130MG		A087854 001	Mar 20, 1985
THEOCLEAR L.A.-130				
SCHWARZ PHARMA	130MG		A086569 001	May 27, 1982
THEOCLEAR L.A.-260				
SCHWARZ PHARMA	260MG		A086569 002	May 27, 1982
THEOPHYL-SR				
ORTHO MCNEIL PHARM	125MG		A086480 001	Feb 08, 1985
	250MG		A086471 001	Feb 08, 1985
THEOPHYLLINE				
CENT PHARMS	125MG		A088654 001	Feb 12, 1985
	250MG		A088689 001	Feb 12, 1985
HOSPIRA	100MG		A089976 001	Jan 04, 1995
	200MG		A089977 001	Jan 04, 1995
	300MG		A089932 001	Jan 04, 1995
INWOOD LABS	100MG		A040052 001	Feb 14, 1994
	125MG		A040052 002	Feb 14, 1994
	200MG		A040052 003	Feb 14, 1994
	300MG		A040052 004	Feb 14, 1994
SANDOZ	260MG		A087462 001	May 11, 1982
THEOPHYLLINE-SR				
SCHERER RP	300MG		A088255 001	Jun 12, 1986
THEOVENT				
SCHERING	125MG		A087010 001	Jan 31, 1985
	250MG		A087910 001	Jan 31, 1985
ELIXIR;ORAL				
ELIXOMIN				
CENCI	80MG/15ML		A088303 001	Jan 25, 1984
LANOPHYLLIN				
LANNETT	80MG/15ML		A084578 001	
THEOLIXIR				
PANRAY	80MG/15ML		A084559 001	
THEOPHYL-225				
ORTHO MCNEIL PHARM	112.5MG/15ML		A086485 001	
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML		A089223 001	May 27, 1988
CENCI	80MG/15ML		A087679 001	Apr 15, 1982
CHARTWELL RX	80MG/15ML		A085952 001	
HALSEY	80MG/15ML		A085169 001	
PHARM ASSOC	80MG/15ML		A086720 001	
+ PRECISION DOSE	80MG/15ML		A085863 001	
ROXANE	80MG/15ML		A084739 001	
SUN PHARMA CANADA	80MG/15ML		A089626 001	Oct 28, 1988
WOCKHARDT	80MG/15ML		A086748 001	
INJECTABLE;INJECTION				
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	40MG/100ML		N019083 001	Nov 07, 1984
+	40MG/100ML		N019826 001	Aug 14, 1992
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	80MG/100ML		N019083 002	Nov 07, 1984
+	80MG/100ML		N019826 002	Aug 14, 1992
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	160MG/100ML		N019083 003	Nov 07, 1984
+	160MG/100ML		N019826 003	Aug 14, 1992
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML		N019212 001	Nov 07, 1984
	200MG/100ML		N019826 004	Aug 14, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE					
INJECTABLE;INJECTION					
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER					
+	B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
		400MG/100ML	N019212	002	Nov 07, 1984
		400MG/100ML	N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
		40MG/100ML	N018649	001	Jul 26, 1982
		80MG/100ML	N018649	002	Jul 26, 1982
		160MG/100ML	N018649	003	Jul 26, 1982
		200MG/100ML	N018649	004	Jul 26, 1982
		320MG/100ML	N018649	006	Nov 13, 1985
		400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
+		40MG/100ML	N019211	001	Dec 14, 1984
		80MG/100ML	N019211	002	Dec 14, 1984
+		160MG/100ML	N019211	003	Dec 14, 1984
		200MG/100ML	N019211	004	Dec 14, 1984
+		320MG/100ML	N019211	006	Jan 20, 1988
		400MG/100ML	N019211	005	Dec 14, 1984
SOLUTION;ORAL					
AEROLATE					
	FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR					
	3M	80MG/15ML	A086107	001	
THEOPHYLLINE					
+	ROXANE	80MG/15ML	A087449	001	Sep 15, 1983
SUSPENSION;ORAL					
ELIXICON					
	FOREST LABS	100MG/5ML	A085502	001	
SYRUP;ORAL					
ACCURBRON					
	SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN					
	FERNDALE LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN					
	SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80					
	CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE					
	ALPHARMA US PHARMS	80MG/15ML	A086001	001	
+		150MG/15ML	A086545	001	
TABLET;ORAL					
QUIBRON-T					
	MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
SLO-PHYLLIN					
	SANOFI AVENTIS US	100MG	A085202	001	
		200MG	A085204	001	
THEOCLEAR-100					
	CENT PHARMS	100MG	A085353	002	
THEOCLEAR-200					
	CENT PHARMS	200MG	A085353	001	
THEOLAIR					
	MEDICIS	125MG	A086399	001	
		250MG	A086399	002	
THEOPHYL-225					
	ORTHO MCNEIL PHARM	225MG	A084726	001	
TABLET, CHEWABLE;ORAL					
THEOPHYL					
	ORTHO MCNEIL PHARM	100MG	A086506	001	Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL					
DURAPHYL					
	FOREST LABS	100MG	A088503	001	Apr 03, 1985
		200MG	A088504	001	Apr 03, 1985
		300MG	A088505	001	Apr 03, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
LABID				
	WARNER CHILCOTT	250MG	A087225 001	
QUIBRON-T/SR				
	MONARCH PHARMS	300MG	A087563 001	Jun 21, 1983
SUSTAIRE				
	ROERIG	100MG	A085665 001	
		300MG	A085665 002	
T-PHYL				
	PHARM RES ASSOC	200MG	A088253 001	Aug 17, 1983
THEO-DUR				
+	SCHERING	100MG **	A085328 001	
+		200MG	A086998 001	
+		300MG **	A085328 002	
		450MG	A089131 001	Jun 25, 1986
THEOLAIR-SR				
	3M	200MG	A088369 001	Jul 16, 1987
		250MG	A086363 002	Jul 16, 1987
		300MG	A088364 001	Jul 16, 1987
		500MG	A089132 001	Jul 16, 1987
THEOPHYLLINE				
	ABLE	300MG	A040548 001	Apr 30, 2004
		400MG	A040543 001	Apr 27, 2004
		450MG	A040546 001	Apr 30, 2004
		600MG	A040539 001	Apr 27, 2004
	AJANTA PHARMA LTD	300MG	A218401 002	Mar 26, 2025
		450MG	A218401 001	Jan 13, 2025
	HERITAGE PHARMA AVET	100MG	A089807 001	Apr 30, 1990
		200MG	A089808 001	Apr 30, 1990
	INWOOD LABS	450MG	A040034 001	Apr 28, 1995
	RHODES PHARMS	300MG	A214113 001	May 11, 2023
		600MG	A040086 001	Apr 15, 1996
UNI-DUR				
	SCHERING	400MG	A089822 001	Jan 04, 1995
		600MG	A089823 001	Jan 04, 1995
THEOPHYLLINE SODIUM GLYCINATE				
ELIXIR;ORAL				
SYNOPHYLATE				
	CENT PHARMS	EQ 165MG BASE/15ML	N006333 008	
TABLET;ORAL				
ASBRON				
	NOVARTIS	EQ 150MG BASE	A085148 001	
THIABENDAZOLE				
SUSPENSION;ORAL				
MINTEZOL				
	MERCK SHARP DOHME	500MG/5ML	N016097 001	
TABLET, CHEWABLE;ORAL				
MINTEZOL				
	MERCK SHARP DOHME	500MG	N016096 001	
THIAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BETALIN S				
+	LILLY	100MG/ML	A080853 001	
THIAMINE HYDROCHLORIDE				
	ABRAXIS PHARM	100MG/ML	A080509 001	
	BEL MAR	100MG/ML	A080718 001	
		200MG/ML	A080712 001	
	DELL LABS	100MG/ML	A083775 001	
	EPIC PHARMA LLC	100MG/ML	A087968 001	Oct 01, 1982
	HOSPIRA	100MG/ML	A040079 001	May 03, 1996
	LUITPOLD	100MG/ML	A080667 001	
	PARKE DAVIS	100MG/ML	A080770 001	
	WATSON LABS	100MG/ML	A083534 001	
		200MG/ML	A083534 002	
	WYETH AYERST	100MG/ML	A080553 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIAMYLAL SODIUM				
INJECTABLE;INJECTION				
SURITAL				
PARKEDALE	1GM/VIAL	N007600	003	
	5GM/VIAL	N007600	005	
	10GM/VIAL	N007600	009	
THIETHYLPERAZINE MALATE				
INJECTABLE;INJECTION				
TORECAN				
NOVARTIS	5MG/ML	N012754	002	
THIETHYLPERAZINE MALEATE				
SUPPOSITORY;RECTAL				
TORECAN				
NOVARTIS	10MG	N013247	001	
TABLET;ORAL				
TORECAN				
NOVARTIS	10MG	N012753	001	
THIOPENTAL SODIUM				
SUSPENSION;RECTAL				
PENTOTHAL				
ABBOTT	400MG/GM	N011679	001	
THIORIDAZINE				
SUSPENSION;ORAL				
MELLARIL-S				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML **	N017923	001	
	EQ 100MG HYDROCHLORIDE/5ML **	N017923	002	
THIORIDAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
MELLARIL				
NOVARTIS	30MG/ML **	N011808	012	
	100MG/ML **	N011808	018	
THIORIDAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
ANI PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
EPIC PHARMA LLC	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985
TABLET;ORAL				
MELLARIL				
+ NOVARTIS	10MG **	N011808	003	
+	15MG **	N011808	016	
+	25MG **	N011808	006	
+	50MG **	N011808	011	
+	100MG **	N011808	009	
+	150MG **	N011808	017	
+	200MG **	N011808	015	
THIORIDAZINE HYDROCHLORIDE				
ANI PHARMS	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985
CHARTWELL RX	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL					
THIORIDAZINE HYDROCHLORIDE					
	50MG		A088134	001	Aug 30, 1983
	100MG		A088135	001	Nov 20, 1984
	150MG		A088136	001	Sep 17, 1986
	200MG		A088137	001	Sep 17, 1986
HERITAGE PHARMA AVET	10MG		A088476	001	Nov 08, 1983
	25MG		A088478	001	Nov 08, 1983
	50MG		A088479	001	Nov 08, 1983
	100MG		A088736	001	Jul 24, 1984
MUTUAL PHARM	10MG		A088375	001	Nov 18, 1983
	25MG		A087264	001	Nov 18, 1983
	50MG		A088370	001	Nov 18, 1983
	100MG		A088379	001	Nov 16, 1983
MYLAN	10MG		A088332	001	Jun 27, 1983
	25MG		A088333	001	Jun 27, 1983
	50MG		A088334	001	Jun 27, 1983
	100MG		A088335	001	Nov 18, 1983
PAR PHARM	10MG		A088351	001	Dec 05, 1983
	15MG		A088352	001	Dec 05, 1983
	25MG		A088336	001	Dec 05, 1983
	50MG		A088322	001	Dec 05, 1983
	100MG		A088480	001	Dec 29, 1983
	150MG		A089764	001	Feb 09, 1988
	200MG		A089765	001	Feb 09, 1988
ROXANE	10MG		A088663	001	Mar 15, 1984
	25MG		A088664	001	Mar 15, 1984
	50MG		A088665	001	Mar 15, 1984
	100MG		A089048	001	Feb 26, 1985
SUN PHARM INDUSTRIES	10MG		A089953	004	Aug 01, 1986
	15MG		A088461	001	Nov 18, 1983
	25MG		A089953	003	Aug 01, 1986
	50MG		A089953	002	Aug 01, 1986
	100MG		A089953	001	Oct 07, 1988
	150MG		A088737	001	Sep 26, 1984
	200MG		A088738	001	Oct 16, 1984
SUPERPHARM	10MG		A089103	001	Jul 02, 1985
	25MG		A089104	001	Jul 02, 1985
	50MG		A089105	001	Jul 02, 1985
WATSON LABS	10MG		A088412	001	Sep 12, 1983
	10MG		A088561	001	May 11, 1984
	15MG		A088345	001	Jul 28, 1983
	15MG		A088562	001	May 11, 1984
	25MG		A088296	001	Jul 28, 1983
	25MG		A088755	001	Jul 24, 1984
	50MG		A088323	001	Jul 28, 1983
	50MG		A088563	001	May 11, 1984
	100MG		A088284	001	Aug 25, 1983
	100MG		A088564	001	May 11, 1984
	150MG		A088410	001	Mar 05, 1984
	150MG		A088869	001	Jun 28, 1985
	200MG		A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG		A088477	001	Nov 08, 1983
	25MG		A088567	001	May 11, 1984
	200MG		A088872	001	Apr 26, 1985
WEST WARD	10MG		A088658	001	Mar 26, 1984
	15MG		A088659	001	Mar 26, 1984
	25MG		A088660	001	Mar 26, 1984
	50MG		A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE;INJECTION					
THIOPLEX					
+ IMMUNEX	15MG/VIAL **		N020058	001	Dec 22, 1994
THIOTEPA					
FRESENIUS KABI USA	15MG/VIAL		A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL		N011683	001	
TEVA PARENTERAL	15MG/VIAL **		A075730	001	Apr 20, 2001
	30MG/VIAL **		A075730	002	Apr 20, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIOTHIXENE				
CAPSULE;ORAL				
NAVANE				
+ PFIZER	1MG **	N016584 001		
+	2MG **	N016584 002		
+	5MG **	N016584 003		
+	10MG **	N016584 004		
+	20MG **	N016584 005		
THIOTHIXENE				
AM THERAP	1MG	A071884 001	Aug 12, 1987	
	2MG	A071885 001	Aug 12, 1987	
	5MG	A071886 001	Aug 12, 1987	
	10MG	A071887 001	Aug 12, 1987	
	20MG	A072200 001	Dec 17, 1987	
CHARTWELL RX	1MG	A070600 001	Jun 05, 1987	
	2MG	A070601 001	Jun 05, 1987	
	5MG	A070602 001	Jun 05, 1987	
	10MG	A070603 001	Jun 05, 1987	
EPIC PHARMA LLC	1MG	A071529 002	Jun 24, 1987	
	2MG	A071529 003	Jun 24, 1987	
	5MG	A071529 001	Jun 24, 1987	
	10MG	A071529 004	Jun 24, 1987	
WATSON LABS	2MG	A071626 001	Jun 25, 1987	
	5MG	A071627 001	Jun 25, 1987	
	10MG	A071628 001	Jun 25, 1987	
THIOTHIXENE HYDROCHLORIDE				
CONCENTRATE;ORAL				
NAVANE				
+ PFIZER	EQ 5MG BASE/ML **	N016758 001		
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969 001	Oct 16, 1987	
PACO	EQ 1MG BASE/ML	A071917 001	Sep 20, 1989	
	EQ 5MG BASE/ML	A071939 001	Dec 16, 1988	
TEVA	EQ 5MG BASE/ML	A071184 001	Jun 22, 1987	
TEVA PHARMS	EQ 5MG BASE/ML	A071554 001	Oct 16, 1987	
THIOTHIXENE HYDROCHLORIDE INTENSOL				
HIKMA	EQ 5MG BASE/ML	A073494 001	Jun 30, 1992	
INJECTABLE;INJECTION				
NAVANE				
PFIZER	EQ 2MG BASE/ML	N016904 001		
	EQ 10MG BASE/VIAL	N016904 002		
TIAGABINE HYDROCHLORIDE				
TABLET;ORAL				
GABITRIL				
CEPHALON	6MG	N020646 006	Nov 29, 2005	
	8MG	N020646 007	Nov 29, 2005	
	10MG	N020646 008	Nov 29, 2005	
	20MG	N020646 004	Sep 30, 1997	
TIAGABINE HYDROCHLORIDE				
AMNEAL PHARMS CO	2MG	A208181 001	Dec 08, 2017	
	4MG	A208181 002	Dec 08, 2017	
	12MG	A208181 003	Dec 08, 2017	
	16MG	A208181 004	Dec 08, 2017	
SUN PHARM INDS	2MG	A077555 001	Nov 04, 2011	
	4MG	A077555 002	Nov 04, 2011	
WILSHIRE PHARMS INC	2MG	A206857 001	Oct 13, 2017	
	4MG	A206857 002	Oct 13, 2017	
	12MG	A206857 003	Oct 13, 2017	
	16MG	A206857 004	Oct 13, 2017	
TICAGRELOR				
TABLET;ORAL				
TICAGRELOR				
AMNEAL	90MG	A208531 001	Jan 23, 2019	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497	001	
	EQ 3GM BASE/VIAL	A062690	001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497	002	
	EQ 6GM BASE/VIAL	N050497	003	
	EQ 20GM BASE/VIAL	N050497	004	
	EQ 30GM BASE/VIAL	N050497	005	Apr 04, 1984
TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLID				
ROCHE PALO	125MG	N019979	001	Mar 24, 1993
	250MG	N019979	002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	250MG	A075253	001	Aug 20, 1999
APOTEX	250MG	A075089	001	Jul 01, 1999
CHARTWELL RX	250MG	A075318	001	Aug 20, 1999
	250MG	A075326	001	Aug 20, 1999
MYLAN	250MG	A075161	001	Sep 13, 1999
NATCO PHARMA	250MG	A075316	001	Nov 02, 1999
SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002
TEVA	250MG	A075149	001	Aug 20, 1999
WATSON LABS	250MG	A075309	001	Apr 26, 2000
TIGECYCLINE				
POWDER;INTRAVENOUS				
TIGECYCLINE				
ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018
XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019
TILUDRONATE DISODIUM				
TABLET;ORAL				
SKELID				
+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707	001	Mar 07, 1997
TIMOLOL				
SOLUTION/DROPS;OPHTHALMIC				
BETIMOL				
+ THEA PHARMA	0.25%	N020439	001	Mar 31, 1995
TIMOLOL				
EPIC PHARMA LLC	0.25%	A205309	001	Sep 30, 2016
	0.5%	A205309	002	Sep 30, 2016
TIMOLOL MALEATE				
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024
	EQ 0.5% BASE	A216343	002	May 23, 2024
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
BAUSCH AND LOMB	EQ 0.25% BASE	A074778	001	Mar 25, 1997
	EQ 0.5% BASE	A074776	001	Mar 25, 1997
EPIC PHARMA LLC	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
	EQ 0.5% BASE	A074516	001	Mar 25, 1997
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997
HIKMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002
PHARMOBEDIENT	EQ 0.5% BASE	A074466	001	Mar 25, 1997
TABLET;ORAL				
BLOCADREN				
+ MERCK	5MG **	N018017	001	
+	10MG **	N018017	002	
+	20MG **	N018017	004	
TIMOLOL MALEATE				
ANI PHARMS	5MG	A072917	001	Jul 31, 1991
	10MG	A072918	001	Jul 31, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TIMOLOL MALEATE				
TABLET;ORAL				
TIMOLOL MALEATE				
	20MG		A072919 001	Jul 31, 1991
CHARTWELL RX	5MG		A072550 001	Apr 13, 1989
	10MG		A072551 001	Apr 13, 1989
	20MG		A072552 001	Apr 13, 1989
QUANTUM PHARMICS	5MG		A072466 001	May 19, 1989
	10MG		A072467 001	May 19, 1989
	20MG		A072468 001	May 19, 1989
TEVA	5MG		A072648 001	Jun 16, 1993
	10MG		A072649 001	Jun 16, 1993
	20MG		A072650 001	Jun 16, 1993
USL PHARMA	5MG		A072001 001	Apr 11, 1989
	10MG		A072002 001	Apr 11, 1989
	20MG		A072003 001	Apr 11, 1989
WATSON LABS	5MG		A072269 001	Apr 11, 1989
	10MG		A072270 001	Apr 11, 1989
	20MG		A072271 001	Apr 11, 1989
TINIDAZOLE				
TABLET;ORAL				
TINIDAZOLE				
HIKMA	250MG		A201172 001	Apr 30, 2012
	500MG		A201172 002	Apr 30, 2012
TINZAPARIN SODIUM				
INJECTABLE;INJECTION				
INNOHEP				
LEO PHARMA AS	20,000 IU/ML		N020484 001	Jul 14, 2000
TIOCONAZOLE				
CREAM;TOPICAL				
TZ-3				
PFIZER	1%		N018682 001	Feb 18, 1983
TIOPRONIN				
TABLET;ORAL				
TIOPRONIN				
PH HEALTH	100MG		A216198 001	Jun 02, 2022
TIPRANAVIR				
SOLUTION;ORAL				
APTIVUS				
+ BOEHRINGER INGELHEIM	100MG/ML		N022292 001	Jun 23, 2008
TIROFIBAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
AGGRASTAT				
MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)		N020912 001	May 14, 1998
SOLUTION;INTRAVENOUS				
AGGRASTAT				
MEDICURE	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)		N020913 001	May 14, 1998
TIZANIDINE HYDROCHLORIDE				
CAPSULE;ORAL				
TIZANIDINE HYDROCHLORIDE				
PH HEALTH	EQ 2MG BASE		A207199 001	Mar 14, 2017
	EQ 4MG BASE		A207199 002	Mar 14, 2017
	EQ 6MG BASE		A207199 003	Mar 14, 2017
PHARMOBEDIENT	EQ 2MG BASE		A091502 001	Nov 09, 2012
	EQ 4MG BASE		A091502 002	Nov 09, 2012
	EQ 6MG BASE		A091502 003	Nov 09, 2012
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
ANI PHARMS	EQ 2MG BASE		A076283 001	Jul 12, 2002
	EQ 2MG BASE		A076284 001	Jul 03, 2002
	EQ 2MG BASE		A076321 001	Sep 30, 2004
	EQ 2MG BASE		A076371 001	Apr 09, 2003
	EQ 4MG BASE		A076283 002	Jul 12, 2002
	EQ 4MG BASE		A076284 002	Jul 03, 2002
	EQ 4MG BASE		A076321 002	Sep 30, 2004
	EQ 4MG BASE		A076371 002	Apr 09, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TIZANIDINE HYDROCHLORIDE				
TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
AUROBINDO PHARMA USA	EQ 2MG BASE	A076282	001	Dec 16, 2003
	EQ 4MG BASE	A076282	002	Dec 16, 2003
CHARTWELL RX	EQ 2MG BASE	A076280	001	Nov 26, 2002
	EQ 4MG BASE	A076280	002	Jun 27, 2002
PH HEALTH	EQ 2MG BASE	A207170	001	Jan 26, 2017
	EQ 4MG BASE	A207170	002	Jan 26, 2017
ZANAFLEX				
+ LEGACY PHARMA USA	EQ 2MG BASE **	N020397	002	Feb 04, 2000
TOBRAMYCIN				
SOLUTION;INHALATION				
TOBRAMYCIN				
LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021
PHARMOBEDIENT	300MG/5ML	A209554	001	Oct 13, 2017
SOLUTION/DROPS;OPHTHALMIC				
AKTOB				
EPIC PHARMA LLC	0.3%	A064096	001	Jan 31, 1996
TOBRAMYCIN				
ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994
APOTEX INC	0.3%	A065087	001	Feb 25, 2002
TOBREX				
+ NOVARTIS	0.3% **	N050541	001	
TOBRAMYCIN SULFATE				
INJECTABLE;INJECTION				
NEBCIN				
LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
+	EQ 1.2GM BASE/VIAL **	N050519	001	
TOBRAMYCIN SULFATE				
APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
EPIC PHARMA LLC	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014
EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023
HIKMA	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 10MG BASE/ML	A063112	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
TEVA PHARMS USA	EQ 40MG BASE/ML	A063100	001	Jan 30, 1992
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989
TOBRAMYCIN SULFATE (PHARMACY BULK)				
HOSPIRA	EQ 40MG BASE/ML **	A063116	001	May 18, 1992
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990
TOCAINIDE HYDROCHLORIDE				
TABLET;ORAL				
TONOCARD				
ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOFACITINIB CITRATE

SOLUTION;ORAL				
TOFACITINIB CITRATE				
HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023
TABLET;ORAL				
TOFACITINIB CITRATE				
AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021
MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023
ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023
TABLET, EXTENDED RELEASE;ORAL				
TOFACITINIB CITRATE				
AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024
DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024
ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021
	EQ 22MG BASE	A214264	002	Aug 19, 2021

TOLAZAMIDE

TABLET;ORAL				
TOLAZAMIDE				
BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
CHARTWELL RX	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
COSETTE	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
NATCO	250MG	A070259	001	Jan 02, 1986
	500MG	A070259	003	Mar 17, 1986
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SUN PHARM INDUSTRIES	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	250MG	A070514	001	Jan 09, 1986
	500MG	A070244	001	Aug 01, 1986
	500MG	A070515	001	Jan 09, 1986
TOLINASE				
+ PHARMACIA AND UPJOHN	100MG **	N015500	002	
+	250MG **	N015500	004	
+	500MG **	N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PRISCOLINE				
NOVARTIS	25MG/ML	N006403	005	Feb 22, 1985

TOLBUTAMIDE

TABLET;ORAL				
ORINASE				
PHARMACIA AND UPJOHN	250MG **	N010670	002	
	500MG **	N010670	001	
TOLBUTAMIDE				
ALRA	500MG	A086141	001	
ANI PHARMS	500MG	A087093	001	
ASCOT	500MG	A087541	001	Mar 01, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLBUTAMIDE

TABLET;ORAL

TOLBUTAMIDE

BARR	500MG	A087121	001	
CHARTWELL RX	500MG	A086574	001	
DAVA PHARMS INC	500MG	A086926	001	
PARKE DAVIS	500MG	A086047	001	
PHARMOBEDIENT	500MG	A086445	001	
PUREPAC PHARM	500MG	A088950	001	Jun 17, 1985
SANDOZ	500MG	N012678	001	
SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A086109	001	
	500MG	A087318	001	
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE;INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	

TOLCAPONE

TABLET;ORAL

TASMAR

BAUSCH	200MG	N020697	002	Jan 29, 1998

TOLCAPONE

ALVOGEN	100MG	A207729	001	Jul 29, 2020
DR REDDYS LABS SA	100MG	A210095	001	Aug 01, 2019
PH HEALTH	100MG	A204584	001	Mar 26, 2015

TOLMETIN SODIUM

CAPSULE;ORAL

TOLECTIN DS

+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	

TOLMETIN SODIUM

ANI PHARMS	EQ 400MG BASE	A073308	001	Jan 24, 1992
	EQ 400MG BASE	A073392	001	Jan 24, 1992
	EQ 400MG BASE	A073519	001	May 29, 1992
CHARTWELL RX	EQ 400MG BASE	A073462	001	Apr 30, 1992
SENORES PHARMS	EQ 400MG BASE	A073290	001	Nov 27, 1991
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991

TABLET;ORAL

TOLECTIN

+ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	

TOLECTIN 600

+ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989

TOLMETIN SODIUM

ANI PHARMS	EQ 600MG BASE	A073527	001	Jun 30, 1992
CHARTWELL RX	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
COSETTE	EQ 600MG BASE	A074399	001	Mar 28, 1996
	EQ 600MG BASE	A074729	001	Feb 27, 1997
SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AUROBINDO PHARMA USA	2MG	A201486	001	Oct 31, 2013
	4MG	A201486	002	Oct 31, 2013

TABLET;ORAL

TOLTERODINE TARTRATE

APOTEX CORP	1MG	A200164	001	Sep 25, 2012
	2MG	A200164	002	Sep 25, 2012
PHARMOBEDIENT	1MG	A202641	001	Nov 27, 2012
	2MG	A202641	002	Nov 27, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLVAPTAN				
TABLET;ORAL				
SAMSCA				
+	OTSUKA	60MG **	N022275 003	May 19, 2009
TOPIRAMATE				
CAPSULE;ORAL				
TOPAMAX SPRINKLE				
+	JANSSEN PHARMS	50MG **	N020844 003	Oct 26, 1998
TOPIRAMATE				
	BARR	15MG	A076448 001	Apr 15, 2009
		25MG	A076448 002	Apr 15, 2009
	CHARTWELL RX	15MG	A079206 001	Oct 14, 2009
		25MG	A079206 002	Oct 14, 2009
	TEVA	15MG	A076575 001	Apr 17, 2009
		25MG	A076575 002	Apr 17, 2009
	WATSON LABS	15MG	A077868 001	Apr 15, 2009
		25MG	A077868 002	Apr 15, 2009
CAPSULE, EXTENDED RELEASE;ORAL				
TOPIRAMATE				
	ZYDUS PHARMS	200MG	A216167 001	Feb 09, 2023
TABLET;ORAL				
TOPAMAX				
	JANSSEN PHARMS	300MG	N020505 003	Dec 24, 1996
		400MG	N020505 006	Dec 24, 1996
TOPIRAMATE				
	ACTAVIS TOTOWA	25MG	A078637 001	Feb 27, 2013
		50MG	A078637 002	Feb 27, 2013
		100MG	A078637 003	Feb 27, 2013
		200MG	A078637 004	Feb 27, 2013
	AIPING PHARM INC	25MG	A078499 001	Jan 07, 2010
		50MG	A078499 002	Jan 07, 2010
		100MG	A078499 003	Jan 07, 2010
		200MG	A078499 004	Jan 07, 2010
	ANDA REPOSITORY	25MG	A090353 001	Sep 01, 2010
		50MG	A090353 002	Sep 01, 2010
		100MG	A090353 003	Sep 01, 2010
		200MG	A090353 004	Sep 01, 2010
	BARR	25MG	A076315 001	Mar 27, 2009
		100MG	A076315 002	Mar 27, 2009
		200MG	A076315 003	Mar 27, 2009
	CHARTWELL	25MG	A078410 001	Sep 11, 2013
		50MG	A078410 002	Sep 11, 2013
		100MG	A078410 003	Sep 11, 2013
		200MG	A078410 004	Sep 11, 2013
	HIKMA PHARMS	25MG	A091185 001	Nov 25, 2013
		50MG	A091185 002	Nov 25, 2013
		100MG	A091185 003	Nov 25, 2013
		200MG	A091185 004	Nov 25, 2013
	NATCO	25MG	A076314 001	Mar 27, 2009
		50MG	A076314 002	Mar 27, 2009
		100MG	A076314 003	Mar 27, 2009
		200MG	A076314 004	Mar 27, 2009
	PLIVA HRVATSKA DOO	25MG	A077905 001	Mar 30, 2009
		50MG	A077905 002	Mar 30, 2009
		100MG	A077905 003	Mar 30, 2009
		200MG	A077905 004	Mar 30, 2009
	ROXANE	25MG	A076306 001	Mar 27, 2009
		50MG	A076306 002	Mar 27, 2009
		100MG	A076306 003	Mar 27, 2009
		200MG	A076306 004	Mar 27, 2009
	SUN PHARM	200MG	A090278 004	Mar 27, 2009
	SUN PHARM INDS LTD	25MG	A076327 001	Mar 27, 2009
		100MG	A076327 002	Mar 27, 2009
		200MG	A076327 003	Mar 27, 2009
	TEVA	25MG	A076317 001	Mar 27, 2009
		50MG	A076317 002	Mar 27, 2009
		100MG	A076317 003	Mar 27, 2009
		200MG	A076317 004	Mar 27, 2009
	TORRENT PHARMS	25MG	A079153 001	Mar 27, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOPIRAMATE				
TABLET;ORAL				
TOPIRAMATE				
	50MG		A079153 002	Mar 27, 2009
	100MG		A079153 003	Mar 27, 2009
	200MG		A079153 004	Mar 27, 2009
WATSON LABS	25MG		A077643 001	Mar 27, 2009
	50MG		A077643 002	Mar 27, 2009
	100MG		A077643 003	Mar 27, 2009
	200MG		A077643 004	Mar 27, 2009
TOPOTECAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
TOPOTECAN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 4MG BASE/VIAL		A091376 001	Nov 29, 2010
MEITHEAL	EQ 4MG BASE/VIAL		A201166 001	Aug 08, 2012
RISING	EQ 4MG BASE/VIAL		A091542 001	Aug 28, 2012
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL		A202203 001	Aug 29, 2013
SOLUTION;INTRAVENOUS				
TOPOTECAN				
+ SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **		N200199 001	Feb 25, 2011
+	EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **		N200199 002	Feb 25, 2011
+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **		N200199 003	Feb 25, 2011
TOPOTECAN HYDROCHLORIDE				
DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A206074 001	Nov 24, 2017
MEITHEAL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		N022453 001	Dec 20, 2012
TOREMIFENE CITRATE				
TABLET;ORAL				
FARESTON				
+ KYOWA KIRIN	EQ 60MG BASE		N020497 001	May 29, 1997
TORSEMIDE				
SOLUTION;INTRAVENOUS				
DEMADEX				
+ ROCHE	50MG/5ML (10MG/ML) **		N020137 002	Aug 23, 1993
+	20MG/2ML (10MG/ML) **		N020137 001	Aug 23, 1993
TORSEMIDE				
AM REGENT	20MG/2ML (10MG/ML)		A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)		A090656 002	Apr 21, 2010
HIKMA	20MG/2ML (10MG/ML)		A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)		A078007 002	Jun 11, 2008
TABLET;ORAL				
DEMADEX				
+ PHARMOBEDIENT	5MG **		N020136 001	Aug 23, 1993
+	10MG **		N020136 002	Aug 23, 1993
+	20MG **		N020136 003	Aug 23, 1993
+	100MG **		N020136 004	Aug 23, 1993
SOAANZ				
+ SARFE PHARMS	20MG		N213218 001	Jun 14, 2021
+	60MG		N213218 002	Jun 14, 2021
TORSEMIDE				
HIKMA	5MG		A076943 001	Mar 01, 2005
	10MG		A076943 002	Mar 01, 2005
SUN PHARM INDS	5MG		A078478 001	Feb 26, 2008
	10MG		A078478 002	Feb 26, 2008
	20MG		A078478 003	Feb 26, 2008
	100MG		A078478 004	Feb 26, 2008
TEVA	5MG		A076110 001	May 14, 2002
	10MG		A076110 002	May 14, 2002
	20MG		A076110 003	May 14, 2002
	100MG		A076110 004	May 14, 2002
TRAMADOL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CONZIP				
+ CIPHER PHARMS INC	150MG		N022370 004	Aug 01, 2011
SOLUTION;ORAL				
QDOLO				
+ ATHENA	5MG/ML		N214044 001	Sep 01, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRAMADOL HYDROCHLORIDE					
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
	APOTEX	50MG	A075981	001	Jul 10, 2002
	ASTA	50MG	A075974	001	Jul 12, 2002
	IPCA LABS LTD	50MG	A201973	001	Nov 16, 2012
	IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015
	MYLAN	50MG	A075986	001	Jun 21, 2002
	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
	NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
	PLIVA	50MG	A075982	001	Jul 01, 2002
	PURACAP LABS BLU	50MG	A206706	001	Jul 02, 2019
	SPECGX LLC	50MG	A075983	001	Jun 25, 2002
	SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002
	WATSON LABS	50MG	A075962	001	Jun 24, 2002
ULTRAM					
+	JANSSEN PHARMS	50MG **	N020281	002	Mar 03, 1995
+		100MG **	N020281	001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL					
RYZOLT					
+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008
TRAMADOL HYDROCHLORIDE					
	ACTAVIS ELIZABETH	100MG	A091609	001	Jun 27, 2012
		200MG	A091609	002	Jun 27, 2012
		300MG	A091609	003	Jun 27, 2012
	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015
		200MG	A204421	002	Oct 20, 2015
		300MG	A204421	003	Oct 20, 2015
	MYLAN	100MG	A205257	001	Dec 22, 2015
		200MG	A205257	002	Dec 22, 2015
		300MG	A205257	003	Dec 22, 2015
	PH HEALTH	100MG	A200491	001	Jun 27, 2012
		200MG	A200491	002	Jun 27, 2012
		300MG	A200491	003	Jun 27, 2012
	STRIDES PHARMA INTL	100MG	A078783	001	Nov 13, 2009
		200MG	A078783	002	Nov 13, 2009
		300MG	A078783	003	Sep 20, 2011
	SUN PHARM	100MG	A091607	001	Dec 30, 2011
		100MG	A201384	001	Dec 07, 2011
		200MG	A091607	002	Dec 30, 2011
		200MG	A201384	002	Dec 07, 2011
		300MG	A091607	003	Dec 30, 2011
		300MG	A201384	003	Dec 07, 2011
ULTRAM ER					
+	VALEANT PHARMS	100MG **	N021692	001	Sep 08, 2005
+		200MG **	N021692	002	Sep 08, 2005
+		300MG **	N021692	003	Sep 08, 2005
TABLET, ORALLY DISINTEGRATING;ORAL					
RYBIX ODT					
	SHIONOGI INC	50MG	N021693	001	May 05, 2005
TRAMETINIB DIMETHYL SULFOXIDE					
TABLET;ORAL					
MEKINIST					
+	NOVARTIS	EQ 1MG **	N204114	002	May 29, 2013
TRAMETINIB DIMETHYL SULFOXIDE					
	HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024
		EQ 2MG	A219002	002	Aug 06, 2024

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRANDOLAPRIL

TABLET;ORAL					
MAVIK					
+	ABBVIE	1MG **	N020528	001	Apr 26, 1996
+		2MG **	N020528	002	Apr 26, 1996
+		4MG **	N020528	003	Apr 26, 1996
TRANDOLAPRIL					
	ANDA REPOSITORY	1MG	A078493	001	Aug 25, 2008
		2MG	A078493	002	Aug 25, 2008
		4MG	A078493	003	Aug 25, 2008
	CHARTWELL MOLECULAR	1MG	A077307	002	Jun 12, 2007
		2MG	A077307	001	Jun 12, 2007
		4MG	A077307	003	Jun 12, 2007
	EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007
		2MG	A077256	002	Jun 12, 2007
		4MG	A077256	003	Jun 12, 2007
	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007
		2MG	A078320	002	Jun 12, 2007
		4MG	A078320	003	Jun 12, 2007
	PHARMOBEDIENT	1MG	A078346	001	Apr 28, 2008
		2MG	A078346	002	Apr 28, 2008
		4MG	A078346	003	Apr 28, 2008
	TEVA PHARMS	1MG	A077489	001	Dec 12, 2006
		2MG	A077489	002	Dec 12, 2006
		4MG	A077489	003	Dec 12, 2006
	WATSON LABS	1MG	A077805	001	Jun 12, 2007
		2MG	A077805	002	Jun 12, 2007
		4MG	A077805	003	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
TARKA					
+	ABBVIE	1MG;240MG **	N020591	003	Oct 22, 1996
+		2MG;180MG	N020591	001	Oct 22, 1996
+		2MG;240MG	N020591	004	Oct 22, 1996
+		4MG;240MG	N020591	002	Oct 22, 1996

TRANEXAMIC ACID

INJECTABLE;INJECTION					
TRANEXAMIC ACID					
	CHARTWELL RX	100MG/ML	A202755	001	Feb 25, 2016
	EPIC PHARMA LLC	100MG/ML	A206594	001	Sep 28, 2017
	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012
	RISING	100MG/ML	A206634	001	Jun 09, 2016
	ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017
TABLET;ORAL					
CYKLOKAPRON					
	PHARMACIA AND UPJOHN	500MG	N019280	001	Dec 30, 1986
TRANEXAMIC ACID					
	APOTEX	650MG	A202286	001	Jan 27, 2014

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC					
IZBA					
+	NOVARTIS	0.003% **	N204822	001	May 15, 2014
TRAVATAN					
+	ALCON PHARMS LTD	0.004% **	N021257	001	Mar 16, 2001
TRAVOPROST					
	ALEMBIC	0.004%	A210458	001	Dec 20, 2019
	LUPIN LTD	0.004%	A207040	001	May 03, 2024

TRAZODONE HYDROCHLORIDE

TABLET;ORAL					
DESYREL					
+	PRAGMA	50MG **	N018207	001	
+		100MG **	N018207	002	
+		150MG **	N018207	003	Mar 25, 1985
+		300MG **	N018207	004	Nov 07, 1988
TRAZODONE HYDROCHLORIDE					
	AIPING PHARM INC	100MG	A072483	001	Apr 30, 1990
	ALVOGEN	50MG	A071636	001	Apr 18, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRAZODONE HYDROCHLORIDE					
TABLET;ORAL					
TRAZODONE HYDROCHLORIDE					
		100MG	A071514	001	Apr 18, 1988
	AM THERAP	50MG	A071139	001	Oct 29, 1986
		100MG	A071140	001	Oct 29, 1986
	NATCO	50MG	A071405	001	Feb 27, 1991
		100MG	A071406	001	Feb 27, 1991
	PHARMOBEDIENT	50MG	A090514	001	Jun 02, 2009
		100MG	A090514	002	Jun 02, 2009
		150MG	A090514	003	Jun 02, 2009
		300MG	A090514	004	Jun 02, 2009
	QUANTUM PHARMICS	100MG	A070921	001	Dec 01, 1986
	RISING	50MG	A072484	001	Apr 30, 1990
	TEVA	150MG	A074357	001	Apr 30, 1997
	USL PHARMA	50MG	A070491	001	Apr 29, 1987
		100MG	A070492	001	Apr 29, 1987
	WATSON LABS	50MG	A070857	001	Oct 10, 1986
		50MG	A071112	001	Nov 17, 1986
		100MG	A070858	001	Oct 10, 1986
		100MG	A071113	001	Nov 17, 1986
TRIALODINE					
	QUANTUM PHARMICS	50MG	A070942	001	Dec 01, 1986
TABLET, EXTENDED RELEASE;ORAL					
OLEPTRO					
+	ANGELINI PHARMA	150MG **	N022411	001	Feb 02, 2010
+		300MG **	N022411	002	Feb 02, 2010
TREPROSTINIL					
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS					
REMODULIN					
+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023
+		0.2MG/ML	N021272	007	Sep 28, 2023
+		20MG/ML	N021272	005	Jul 30, 2021
TREPROSTINIL					
	PH HEALTH	1MG/ML	A209382	001	Sep 24, 2019
		2.5MG/ML	A209382	002	Sep 24, 2019
		5MG/ML	A209382	003	Sep 24, 2019
		10MG/ML	A209382	004	Sep 24, 2019
SOLUTION;INTRAVENOUS, SUBCUTANEOUS					
REMODULIN					
	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018
		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018
		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018
		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018
TRETINOIN					
CAPSULE;ORAL					
TRETINOIN					
	BARR LABS INC	10MG	A077684	001	Jun 22, 2007
VESANOID					
+	CHEPLAPHARM	10MG **	N020438	001	Nov 22, 1995
CREAM;TOPICAL					
RENOVA					
+	VALEANT PHARMS NORTH	0.05% **	N019963	001	Dec 29, 1995
TRETINOIN					
	ALLERGAN	0.0375%	A090098	001	Mar 22, 2010
		0.075%	A202209	001	Oct 11, 2012
	ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005
GEL;TOPICAL					
AVITA					
	RISING	0.025%	N020400	001	Jan 29, 1998
TRETINOIN					
	RISING	0.04%	A202567	001	Jul 17, 2013
		0.1%	A202026	001	Jul 17, 2013
SOLUTION;TOPICAL					
RETIN-A					
+	VALEANT INTL	0.05%	N016921	001	
TRETINOIN					
	TEVA PHARMS	0.05%	A074873	001	Jun 19, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRETINOIN				
SOLUTION;TOPICAL				
TRETINOIN				
WOCKHARDT	0.05%	A075260	001	Jan 25, 1999
SWAB;TOPICAL				
RETIN-A				
VALEANT INTL	0.05%	N016921	002	
TRIAMCINOLONE				
TABLET;ORAL				
ARISTOCORT				
ASTELLAS	1MG	N011161	009	
	2MG	N011161	004	
	4MG	N011161	007	
	8MG	N011161	011	
	16MG	N011161	010	
KENACORT				
DELCOR ASSET CORP	1MG	N011283	003	
	2MG	N011283	008	
	4MG	N011283	006	
	8MG	N011283	010	
TRIAMCINOLONE				
BARR	2MG	A084286	001	
	2MG	A084318	001	
	4MG	A084267	001	
	4MG	A084319	001	
	8MG	A084268	001	
	8MG	A084320	001	
IMPAX LABS	4MG	A084340	001	
IVAX SUB TEVA PHARMS	4MG	A083750	001	
MYLAN	2MG	A084406	001	
PUREPAC PHARM	2MG	A084020	002	
	4MG	A084020	003	
ROXANE	2MG	A084708	001	
	4MG	A084709	001	
	8MG	A084707	001	
SANDOZ	4MG	A085601	001	
TEVA	4MG	A084775	001	
WATSON LABS	4MG	A084270	001	
	4MG	A085834	001	
TRIAMCINOLONE ACETONIDE				
AEROSOL, METERED;INHALATION				
AZMACORT				
ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
AEROSOL, METERED;NASAL				
NASACORT				
CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991
CREAM;TOPICAL				
ARISTOCORT				
ASTELLAS	0.025%	A083017	003	
	0.1%	A083016	004	
+	0.5%	A083015	002	
ARISTOCORT A				
ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984
FLUTEX				
IVAX PHARMS	0.025%	A085539	001	
	0.1%	A085539	002	
	0.5%	A085539	003	
KENALOG				
+ DELCOR ASSET CORP	0.5%	A083943	001	
KENALOG-H				
DELCOR ASSET CORP	0.1%	A086240	001	
TRIACET				
TEVA	0.025%	A084908	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE ACETONIDE					
CREAM;TOPICAL					
TRIACET					
		0.1%	A084908	002	
		0.5%	A084908	003	
TRIACORT					
	SOLVAY	0.1%	A087113	001	
TRIAMCINOLONE ACETONIDE					
	ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
	ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
	AMBIX	0.025%	A087932	001	May 09, 1983
	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016
	MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
		0.1%	A088095	001	Sep 01, 1983
		0.5%	A088096	001	Sep 01, 1983
+	NORVIUM BIOSCIENCE	0.025% **	N011601	003	
+		0.1% **	N011601	006	
	PHARMADERM	0.025%	A087990	001	Jul 07, 1983
		0.1%	A087991	001	Jul 07, 1983
		0.5%	A087992	001	Jul 07, 1983
	PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
		0.1%	A087912	001	Aug 10, 1982
		0.5%	A087922	001	Aug 10, 1982
	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019
		0.1%	A210346	002	Feb 11, 2019
		0.5%	A210346	003	Feb 11, 2019
	SUN PHARMA CANADA	0.025%	A040038	001	Oct 26, 1994
		0.025%	A086277	001	
		0.1%	A086276	001	
		0.5%	A086275	001	
	TOPIDERM	0.025%	A089274	001	Feb 21, 1989
		0.1%	A089275	001	Feb 21, 1989
		0.5%	A089276	001	Feb 21, 1989
TRIATEX					
	IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
		0.1%	A087429	001	Nov 01, 1988
		0.5%	A087428	001	Nov 01, 1988
TRYMEX					
	SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
		0.1%	A088197	001	Mar 25, 1983
		0.5%	A088198	001	Mar 25, 1983
GEL;TOPICAL					
ARISTOGEL					
+	ASTELLAS	0.1%	A083380	001	
INJECTABLE;INJECTION					
TRIAMCINOLONE ACETONIDE					
	PARNELL	3MG/ML	N019503	001	Oct 16, 1987
	SANDOZ	10MG/ML	A090166	001	May 27, 2009
		40MG/ML	A090164	001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825	001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL					
TRIVARIS					
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008
LOTION;TOPICAL					
KENALOG					
	DELCOR ASSET CORP	0.025% **	A084343	001	
+		0.025% **	N011602	003	
		0.1% **	A084343	002	
+		0.1% **	N011602	001	
TRIAMCINOLONE ACETONIDE					
	ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
		0.1%	A087192	001	Sep 08, 1982
	BEACH PRODS	0.025%	A204608	001	Jul 07, 2016
	PAI HOLDINGS PHARM	0.1%	A204606	001	Jul 07, 2016
OINTMENT;TOPICAL					
ARISTOCORT					
	ASTELLAS	0.1%	A080750	004	
+		0.5% **	A080745	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE ACETONIDE				
OINTMENT;TOPICAL				
ARISTOCORT A				
ASTELLAS	0.1%	A080750	003	
	0.1%	A088780	001	Oct 01, 1984
+	0.5% **	A080745	003	
	0.5%	A088781	001	Oct 05, 1984
FLUTEX				
IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
	0.1%	A087377	001	Nov 01, 1988
	0.5%	A087376	001	Nov 01, 1988
KENALOG				
+ DELCOR ASSET CORP	0.5% **	A083944	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020
	0.5%	A211315	002	Mar 18, 2020
COSETTE	0.5%	A208925	001	Oct 06, 2017
+ EXTROVIS	0.025% **	N011600	003	
+	0.1% **	N011600	001	
GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016
GLENMARK SPECLT	0.1%	A208320	001	Aug 22, 2017
MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
	0.1%	A088091	001	Sep 01, 1983
	0.5%	A088092	001	Sep 01, 1983
PAI HOLDINGS PHARM	0.5%	A208590	001	Mar 03, 2017
PHARMADERM	0.025%	A088692	001	Aug 02, 1984
	0.1%	A088690	001	Aug 02, 1984
SUN PHARMA CANADA	0.025%	A040040	001	Sep 30, 1994
	0.025%	A040374	001	Jun 05, 2001
	0.1%	A087902	001	Dec 27, 1982
	0.5%	A040386	001	Jun 05, 2001
TRIANEX				
CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995
TRYMEX				
SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
	0.1%	A088691	001	Aug 02, 1984
PASTE;DENTAL				
KENALOG IN ORABASE				
+ DELCOR ASSET CORP	0.1% **	N012097	001	
ORALONE				
SUN PHARMA CANADA	0.1%	A071383	001	Jul 06, 1987
TRIAMCINOLONE ACETONIDE				
SCIEGEN PHARMS	0.1%	A206312	001	Aug 11, 2016
SPRAY;TOPICAL				
KENALOG				
+ SUN PHARM INDS INC	0.147MG/GM **	N012104	001	
SPRAY, METERED;NASAL				
ALLERNAZE				
LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA				
SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE				
PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	001	Jul 30, 2009
TRIAMCINOLONE DIACETATE				
INJECTABLE;INJECTION				
ARISTOCORT				
FOSUN PHARMA	25MG/ML	N011685	003	
+	40MG/ML **	N012802	001	
TRIAMCINOLONE DIACETATE				
EPIC PHARMA LLC	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	
SYRUP;ORAL				
ARISTOCORT				
ASTELLAS	2MG/5ML	N011960	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE DIACETATE				
SYRUP;ORAL				
KENACORT				
	DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515 001	
TRIAMCINOLONE HEXACETONIDE				
INJECTABLE;INJECTION				
ARISTOSPAN				
+	ETHYPHARM	5MG/ML **	N016466 001	
+		20MG/ML **	N016466 002	
TRIAZOLAM				
TABLET;ORAL				
HALCION				
	PFIZER	0.5MG	N017892 002	Nov 15, 1982
TRIAZOLAM				
	HIKMA	0.125MG	A074224 001	Jun 01, 1994
		0.25MG	A074224 002	Jun 01, 1994
	PHARMOBEDIENT	0.125MG	A074031 001	Mar 25, 1994
		0.25MG	A074031 002	Mar 25, 1994
	WATSON LABS	0.125MG	A074445 001	Oct 20, 1995
		0.25MG	A074445 002	Oct 20, 1995
TRICHLORMETHIAZIDE				
TABLET;ORAL				
METAHYDRIN				
	SANOFI AVENTIS US	2MG	N012594 001	Jun 16, 1988
		4MG	N012594 002	Jun 16, 1988
NAQUA				
	SCHERING	2MG	N012265 001	
		4MG	N012265 002	
TRICHLOREX				
	LANNETT	4MG	A083436 001	
		4MG	A085630 001	
TRICHLORMAS				
	MAST MM	4MG	A086259 001	
TRICHLORMETHIAZIDE				
	CHARTWELL RX	4MG	A085568 001	
	IMPAX LABS	4MG	A083967 001	
	PAR PHARM	2MG	A087007 001	
		4MG	A087005 001	
	SANDOZ	4MG	A086171 001	
	WATSON LABS	2MG	A083847 001	
		2MG	A086458 001	
		4MG	A083462 001	
		4MG	A083855 001	
		4MG	A085962 001	
TRICLOFOS SODIUM				
SOLUTION;ORAL				
TRICLOS				
	SANOFI AVENTIS US	1.5GM/15ML	N016830 001	
TABLET;ORAL				
TRICLOS				
	SANOFI AVENTIS US	750MG	N016809 002	
TRIDIHEXETHYL CHLORIDE				
INJECTABLE;INJECTION				
PATHILON				
	LEDERLE	10MG/ML	N009729 001	
TABLET;ORAL				
PATHILON				
	LEDERLE	25MG	N009489 005	
TRIENTINE HYDROCHLORIDE				
CAPSULE;ORAL				
CLOVIQUE				
	CHARTWELL RX	250MG	A209731 001	Oct 21, 2019
TRIENTINE HYDROCHLORIDE				
	ACCORD HLTHCARE	250MG	A212929 001	Aug 30, 2021
	AMNEAL	250MG	A210619 001	Feb 08, 2019
	CHARTWELL RX	250MG	A209415 001	Sep 16, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

	LUPIN LTD	250MG	A211637 001	May 21, 2020

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

STELAZINE

+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552 006	

TRIFLUOPERAZINE HYDROCHLORIDE

	CHARTWELL RX	EQ 10MG BASE/ML	A085787 001	Apr 15, 1982
	WOCKHARDT	EQ 10MG BASE/ML	A088143 001	Jul 26, 1983

INJECTABLE;INJECTION

STELAZINE

+	GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552 005	

TABLET;ORAL

STELAZINE

+	GLAXOSMITHKLINE	EQ 1MG BASE **	N011552 001	
+		EQ 2MG BASE **	N011552 002	
+		EQ 5MG BASE **	N011552 003	
+		EQ 10MG BASE **	N011552 004	

TRIFLUOPERAZINE HYDROCHLORIDE

	ATHEM	EQ 1MG BASE	A040153 001	Oct 25, 1996
		EQ 2MG BASE	A040153 002	Oct 25, 1996
		EQ 5MG BASE	A040153 003	Oct 25, 1996
		EQ 10MG BASE	A040153 004	Oct 25, 1996
	DURAMED PHARMS BARR	EQ 1MG BASE	A088967 001	Apr 23, 1985
		EQ 2MG BASE	A088968 001	Apr 23, 1985
		EQ 5MG BASE	A088969 001	Apr 23, 1985
		EQ 10MG BASE	A088970 001	Apr 23, 1985
	IVAX PHARMS	EQ 1MG BASE	A087612 001	Nov 19, 1982
		EQ 2MG BASE	A087613 001	Nov 19, 1982
		EQ 5MG BASE	A087328 001	Nov 19, 1982
		EQ 10MG BASE	A087614 001	Nov 19, 1982
	WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
		EQ 2MG BASE	A085976 001	Jun 23, 1988
		EQ 5MG BASE	A085973 001	Jun 23, 1988
		EQ 10MG BASE	A088710 001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION;ORAL

VESPRIN

	APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491 004	

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

VESPRIN

	APOTHECON	3MG/ML	N011325 005	
		10MG/ML	N011325 004	
		20MG/ML	N011325 001	

TABLET;ORAL

VESPRIN

	BRISTOL MYERS SQUIBB	10MG	N011123 001	
		25MG	N011123 002	
		50MG	N011123 003	

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

	HIKMA	1%	A205438 001	Jul 28, 2017

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ARTANE

	LEDERLE	5MG	N006773 010	
		5MG	N012947 001	

ELIXIR;ORAL

ARTANE

	LEDERLE	2MG/5ML	N006773 009	

TRIHEXYPHENIDYL HYDROCHLORIDE

	PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIHEXYPHENIDYL HYDROCHLORIDE				
TABLET;ORAL				
ARTANE				
+ LEDERLE	2MG **	N006773	005	
+	5MG **	N006773	003	
TREMIN				
SCHERING	2MG	A080381	001	
	5MG	A080381	003	
TRIHEXYPHENIDYL HYDROCHLORIDE				
HIKMA	2MG	A040337	002	Feb 16, 2000
	5MG	A040337	001	Feb 16, 2000
NYLOS	5MG	A085622	001	
VANGARD	2MG	A088035	001	Jul 30, 1982
WATSON LABS	2MG	A040184	001	Feb 06, 1998
	2MG	A085117	001	
	5MG	A040184	002	Feb 06, 1998
	5MG	A085105	001	
TRILOSTANE				
CAPSULE;ORAL				
MODRASTANE				
BIOENVISION	30MG	N018719	002	Dec 31, 1984
	60MG	N018719	001	Dec 31, 1984
TRIMEPRAZINE TARTRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 5MG BASE	N011316	004	
SYRUP;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316	003	
TRIMEPRAZINE TARTRATE				
ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015	001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285	001	Apr 11, 1985
TABLET;ORAL				
TEMARIL				
ALLERGAN HERBERT	EQ 2.5MG BASE	N011316	001	
TRIMETHADIONE				
CAPSULE;ORAL				
TRIDIONE				
ABBVIE	300MG	N005856	005	
SOLUTION;ORAL				
TRIDIONE				
ABBVIE	200MG/5ML	N005856	002	
TABLET;ORAL				
TRIDIONE				
+ ABBVIE	150MG	N005856	009	
TRIMETHAPHAN CAMSYLATE				
INJECTABLE;INJECTION				
ARFONAD				
ROCHE	50MG/ML	N008983	001	
TRIMETHOBENZAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
TIGAN				
+ KING PHARMS LLC	300MG **	N017531	006	Dec 13, 2001
TRIMETHOBENZAMIDE HYDROCHLORIDE				
SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003
INJECTABLE;INJECTION				
TRIMETHOBENZAMIDE HYDROCHLORIDE				
AM REGENT	100MG/ML	A091330	001	Mar 08, 2011
HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960	001	Apr 04, 1986
	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE				
AM REGENT	100MG/ML	A091329	001	Mar 08, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIMETHOPRIM				
TABLET;ORAL				
PROLOPRIM				
MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982
TRIMETHOPRIM				
SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987
TRIMPEX				
ROCHE	100MG	N017952	001	
TRIMPEX 200				
ROCHE	200MG	N017952	002	Nov 09, 1982
TRIMETHOPRIM HYDROCHLORIDE				
SOLUTION;ORAL				
PRIMSOL				
PANGEA	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995
+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000
TRIMETREXATE GLUCURONATE				
INJECTABLE;INJECTION				
NEUTREXIN				
MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998
TRIMIPRAMINE MALEATE				
CAPSULE;ORAL				
SURMONTIL				
+ TEVA WOMENS	EQ 25MG BASE **	N016792	001	
+	EQ 50MG BASE **	N016792	002	
+	EQ 100MG BASE **	N016792	003	Sep 15, 1982
TRIMIPRAMINE MALEATE				
USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987
TRIOXSALEN				
TABLET;ORAL				
TRISORALEN				
VALEANT PHARM INTL	5MG	N012697	001	
TRIPELENNAMINE CITRATE				
ELIXIR;ORAL				
PBZ				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML	N005914	004	
TRIPELENNAMINE HYDROCHLORIDE				
TABLET;ORAL				
PBZ				
NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	
TRIPELENNAMINE HYDROCHLORIDE				
ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	
	50MG	A085188	001	
TABLET, EXTENDED RELEASE;ORAL				
PBZ-SR				
NOVARTIS	50MG	N010533	002	
	100MG	N010533	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL				
GYNE-SULF				
	COSETTE	3.7%;2.86%;3.42%	A088607 001	Jun 09, 1986
SULTRIN				
	ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794 001	
TRIPLE SULFA				
	ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864 001	Sep 01, 1982
	FOUGERA	3.7%;2.86%;3.42%	A086424 001	
	PADAGIS US	3.7%;2.86%;3.42%	A087285 001	Nov 15, 1982
TRYSUL				
	SAVAGE LABS	3.7%;2.86%;3.42%	A087887 001	Jul 23, 1982
VAGILIA				
	COSETTE	3.7%;2.86%;3.42%	A088821 001	Nov 09, 1987
TABLET;VAGINAL				
SULTRIN				
	ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794 002	
TRIPLE SULFA				
	FOUGERA	184MG;143.75MG;172.5MG	A088463 001	Jan 03, 1985
	PHARMADERM	184MG;143.75MG;172.5MG	A088462 001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTIDIL				
	GLAXOSMITHKLINE	1.25MG/5ML	N011496 002	Jul 01, 1983
MYIDYL				
	USL PHARMA	1.25MG/5ML	A087963 001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	1.25MG/5ML	A085940 001	
	HALSEY	1.25MG/5ML	A088735 001	Jan 17, 1985
	PHARM ASSOC	1.25MG/5ML	A087514 001	Feb 10, 1982
TABLET;ORAL				
ACTIDIL				
	GLAXOSMITHKLINE	2.5MG	N011110 002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE				
	VITARINE	2.5MG	A085610 001	
	WATSON LABS	2.5MG	A085094 001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL				
LANTRISUL				
	LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123 002	
NEOTRIZINE				
	LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317 012	
SULFALOID				
	FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100 001	
SULFOSE				
	WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013 002	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904 002	
TRIPLE SULFA				
	ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280 001	
TRIPLE SULFAS				
	LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920 003	
TABLET;ORAL				
NEOTRIZINE				
	LILLY	167MG;167MG;167MG	N006317 011	
SULFA-TRIPLE #2				
	IMPAX LABS	167MG;167MG;167MG	A080079 001	
SULFALOID				
	FOREST PHARMS	167MG;167MG;167MG	A080099 001	
SULFOSE				
	WYETH AYERST	167MG;167MG;167MG	A080013 001	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904 001	
TRIPLE SULFA				
	PUREPAC PHARM	167MG;167MG;167MG	A080086 001	
TRIPLE SULFAS				
	LEDERLE	167MG;167MG;167MG	N006920 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)				
TABLET;ORAL				
TRIPLE SULFOID				
PAL PAK	167MG;167MG;167MG	A080094	001	
TROGLITAZONE				
TABLET;ORAL				
PRELAY				
SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997
REZULIN				
PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997
TROLAMINE POLYPEPTIDE OLEATE CONDENSATE				
SOLUTION/DROPS;OTIC				
CERUMENEX				
PHARM RES ASSOC	10%	N011340	002	
TROLEANDOMYCIN				
CAPSULE;ORAL				
TAO				
PFIZER	EQ 250MG BASE	N050336	002	
SUSPENSION;ORAL				
TAO				
PFIZER	EQ 125MG BASE/5ML	N050332	001	
TROPICAMIDE				
SOLUTION/DROPS;OPHTHALMIC				
MYDRIACYL				
ALCON	0.5% **	N012111	002	
	1% **	N012111	004	
MYDRIAFAIR				
PHARMAFAIR	0.5%	A088274	001	Sep 16, 1983
	1%	A088230	001	Sep 16, 1983
TROPICAMIDE				
ALCON PHARMS LTD	1%	A089172	001	Dec 28, 1990
EPIC PHARMA LLC	1%	A088447	001	Aug 28, 1985
MIZA PHARMS USA	0.5%	A087636	001	Jul 30, 1982
	1%	A087637	001	Aug 09, 1982
WATSON LABS	0.5%	A089171	001	Dec 28, 1990
TROSPIUM CHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
SANCTURA XR				
+ ALLERGAN	60MG **	N022103	001	Aug 03, 2007
TROSPIUM CHLORIDE				
UPSHER SMITH LABS	60MG	A091635	001	Apr 29, 2015
TABLET;ORAL				
SANCTURA				
+ ALLERGAN	20MG **	N021595	001	May 28, 2004
TROVAFLOXACIN MESYLATE				
TABLET;ORAL				
TROVAN				
PFIZER	EQ 100MG BASE	N020759	001	Dec 18, 1997
	EQ 200MG BASE	N020759	002	Dec 18, 1997
TRYPAN BLUE				
SOLUTION;OPHTHALMIC				
MEMBRANEBLUE				
+ DORC	0.15%	N022278	001	Feb 20, 2009
TUBOCURARINE CHLORIDE				
INJECTABLE;INJECTION				
TUBOCURARINE CHLORIDE				
BRISTOL MYERS SQUIBB	3MG/ML	N005657	001	
HOSPIRA	3MG/ML	N006095	001	
LILLY	3MG/ML	N006325	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TYROPANOATE SODIUM				
CAPSULE;ORAL				
BILOPAQUE				
GE HEALTHCARE	750MG		N013731 001	
UMBRALISIB TOSYLATE				
TABLET;ORAL				
UKONIQ				
+ TG THERAPS	EQ 200MG BASE		N213176 001	Feb 05, 2021
UNOPROSTONE ISOPROPYL				
SOLUTION/DROPS;OPHTHALMIC				
RESCULA				
+ SUCAMPO PHARMA LLC	0.15% **		N021214 001	Aug 03, 2000
URACIL MUSTARD				
CAPSULE;ORAL				
URACIL MUSTARD				
SHIRE	1MG		N012892 001	
UREA				
INJECTABLE;INJECTION				
STERILE UREA				
HOSPIRA	40GM/VIAL		N017698 001	
UREAPHIL				
HOSPIRA	40GM/VIAL		N012154 001	
UREA C-13				
FOR SOLUTION;ORAL				
BREATHTEK UBT FOR H-PYLORI				
OTSUKA AMERICA	EQ 75MG/POUCH		N020586 002	May 10, 2001
HELICOSOL				
METABOLIC SOLUTIONS	125MG/VIAL		N021092 001	Dec 17, 1999
MERETEK UBT KIT (W/ PRANACTIN)				
OTSUKA AMERICA	125MG/VIAL		N020586 001	Sep 17, 1996
PYLORI-CHEK BREATH TEST				
DXS DEVICES	100MG/VIAL		N020900 001	Feb 04, 1999
UREA, C-14				
CAPSULE;ORAL				
PYTEST				
+ AVENT	1uCi		N020617 001	May 09, 1997
PYTEST KIT				
+ AVENT	1uCi **		N020617 002	May 09, 1997
URSODIOL				
CAPSULE;ORAL				
ACTIGALL				
TEVA BRANDED PHARM	150MG **		N019594 001	Dec 31, 1987
URSODIOL				
AMNEAL PHARMS CO	300MG		A211301 001	Oct 16, 2018
IMPAX LABS INC	300MG		A077895 001	Jul 27, 2006
QUAGEN	300MG		A090530 001	Feb 17, 2010
TEVA PHARMS	300MG		A075592 001	May 25, 2000
TABLET;ORAL				
URSO 250				
+ ABBVIE	250MG		N020675 001	Dec 10, 1997
URSO FORTE				
+ ABBVIE	500MG		N020675 002	Jul 21, 2004
URSODIOL				
IMPAX LABS INC	250MG		A200826 001	Dec 23, 2011
	500MG		A200826 002	Dec 23, 2011
TEVA PHARMS USA	250MG		A079184 001	May 13, 2009
	500MG		A079184 002	May 13, 2009
VALACYCLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
AIPING PHARM INC	EQ 500MG BASE		A077478 001	May 24, 2010
	EQ 1GM BASE		A077478 002	May 24, 2010
APOTEX	EQ 500MG BASE		A090500 001	Apr 04, 2014
	EQ 1GM BASE		A090500 002	Apr 04, 2014
CIPLA	EQ 500MG BASE		A077135 001	May 24, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VALACYCLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALACYCLOVIR HYDROCHLORIDE				
	EQ 1GM BASE	A077135	002	May 24, 2010
HIKMA	EQ 500MG BASE	A078656	001	May 24, 2010
	EQ 1GM BASE	A078656	002	May 24, 2010
PHARMOBEDIENT	EQ 500MG BASE	A078070	001	May 24, 2010
	EQ 1GM BASE	A078070	002	May 24, 2010
TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010
	EQ 1GM BASE	A077655	002	May 24, 2010
WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011
	EQ 1GM BASE	A090370	002	Mar 16, 2011
VALBENAZINE TOSYLATE				
CAPSULE;ORAL				
VALBENAZINE TOSYLATE				
ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024
	EQ 60MG BASE	A216137	002	Aug 07, 2024
	EQ 80MG BASE	A216137	003	Aug 07, 2024
VALDECOXIB				
TABLET;ORAL				
BEXTRA				
GD SEARLE	10MG	N021341	002	Nov 16, 2001
	20MG	N021341	003	Nov 16, 2001
VALGANCICLOVIR HYDROCHLORIDE				
TABLET;ORAL				
VALGANCICLOVIR HYDROCHLORIDE				
CIPLA	EQ 450MG BASE	A209672	001	Nov 09, 2018
PHARMOBEDIENT	EQ 450MG BASE	A205151	001	Mar 03, 2021
VALPROATE SODIUM				
INJECTABLE;INJECTION				
DEPACON				
+ ABBVIE	EQ 100MG BASE/ML **	N020593	001	Dec 30, 1996
VALPROATE SODIUM				
PHARMOBEDIENT	EQ 100MG BASE/ML	A208120	001	Dec 22, 2021
VALPROIC ACID				
CAPSULE;ORAL				
DEPAKENE				
+ ABBVIE	250MG **	N018081	001	
VALPROIC ACID				
CHARTWELL RX	250MG	A070631	001	Jun 11, 1987
HIBROW HLTHCARE	250MG	A207611	001	Aug 05, 2019
PAR PHARM	250MG	A070431	001	Feb 28, 1986
SCHERER RP	250MG	A070195	001	Jul 02, 1987
SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+ BIONPHARMA	125MG **	N022152	001	Jul 29, 2008
+	250MG **	N022152	002	Jul 29, 2008
+	500MG **	N022152	003	Jul 29, 2008
SYRUP;ORAL				
DEPAKENE				
+ ABBVIE	250MG/5ML **	N018082	001	
VALPROIC ACID				
HIKMA	250MG/5ML	A074060	001	Jan 13, 1995
LANNETT CO INC	250MG/5ML	A077960	001	Oct 13, 2006
PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005
PHARMOBEDIENT CNSLTG	250MG/5ML	A070868	001	Jul 01, 1986
VALSARTAN				
CAPSULE;ORAL				
DIOVAN				
NOVARTIS	80MG	N020665	001	Dec 23, 1996
	160MG	N020665	002	Dec 23, 1996
SOLUTION;ORAL				
PREXXARTAN				
+ CARMEL BIOSCIENCES	4MG/ML **	N209139	001	Dec 19, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VALSARTAN				
TABLET;ORAL				
VALSARTAN				
IVAX PHARMS	40MG	A077530	001	Jan 04, 2016
	80MG	A077530	002	Jan 04, 2016
	160MG	A077530	003	Jan 04, 2016
	320MG	A077530	004	Jan 04, 2016
SOMERSET THERAPS LLC	40MG	A218169	001	Aug 05, 2024
	80MG	A218169	002	Aug 05, 2024
	160MG	A218169	003	Aug 05, 2024
	320MG	A218169	004	Aug 05, 2024
TORRENT	40MG	A202728	001	Jan 05, 2015
	80MG	A202728	002	Jan 05, 2015
	160MG	A202728	003	Jan 05, 2015
	320MG	A202728	004	Jan 05, 2015
UNICHEM	40MG	A209261	001	May 04, 2018
	80MG	A209261	002	May 04, 2018
	160MG	A209261	003	May 04, 2018
	320MG	A209261	004	May 04, 2018
WATSON LABS INC	40MG	A090642	001	Jan 05, 2015
	80MG	A090642	002	Jan 05, 2015
	160MG	A090642	003	Jan 05, 2015
	320MG	A090642	004	Jan 05, 2015
VANCOMYCIN				
SOLUTION;INTRAVENOUS, ORAL				
VANCOMYCIN				
+ HIKMA	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021
VANCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
VANCOMYCIN HYDROCHLORIDE				
FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012
	EQ 250MG BASE	A065453	002	Jun 18, 2012
PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012
	EQ 250MG BASE	A065478	002	Apr 09, 2012
WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012
	EQ 250MG BASE	A065510	002	Apr 09, 2012
FOR SOLUTION;ORAL				
VANCOCIN HYDROCHLORIDE				
ANI PHARMS	EQ 500MG BASE/6ML	A061667	001	
VANCOLED				
LEDERLE	EQ 250MG BASE/5ML	A063321	002	Oct 15, 1993
	EQ 500MG BASE/6ML	A063321	003	Oct 15, 1993
VANCOMYCIN HYDROCHLORIDE				
AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023
INJECTABLE;INJECTION				
VANCOCIN HYDROCHLORIDE				
STERISCIENCE	EQ 500MG BASE/VIAL **	A060180	001	
	EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984
	EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987
	EQ 500MG BASE/VIAL **	A062812	001	Nov 17, 1987
	EQ 1GM BASE/VIAL **	A060180	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987
	EQ 1GM BASE/VIAL **	A062812	002	Nov 17, 1987
	EQ 10GM BASE/VIAL **	A062812	003	Nov 17, 1987
VANCOLED				
HIKMA	EQ 500MG BASE/VIAL **	A062682	001	Jul 22, 1986
	EQ 1GM BASE/VIAL **	A062682	002	Mar 30, 1988
	EQ 2GM BASE/VIAL **	A062682	003	May 11, 1988
	EQ 5GM BASE/VIAL **	A062682	004	May 11, 1988
	EQ 10GM BASE/VIAL **	A062682	005	May 11, 1988
VANCOMYCIN HYDROCHLORIDE				
AVET LIFESCIENCES	EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013
	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013
	EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013
	EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013
HIKMA	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VANCOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
VANCOMYCIN HYDROCHLORIDE				
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009
KNACK	EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022
	EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022
	EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022
MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010
	EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010
	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012
	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012
TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
	EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
	EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR				
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988
POWDER;INTRAVENOUS				
VANCOMYCIN HYDROCHLORIDE				
+ MYLAN LABS LTD	EQ 250MG BASE/VIAL **	N209481	001	Jul 10, 2018
VARDENAFIL HYDROCHLORIDE				
TABLET;ORAL				
LEVITRA				
+ BAYER HLTHCARE	EQ 2.5MG BASE **	N021400	003	Aug 19, 2003
+	EQ 5MG BASE **	N021400	001	Aug 19, 2003
+	EQ 10MG BASE **	N021400	002	Aug 19, 2003
+	EQ 20MG BASE **	N021400	004	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE				
STEVENS J	EQ 5MG BASE	A210738	001	Oct 31, 2018
	EQ 10MG BASE	A210738	002	Oct 31, 2018
	EQ 20MG BASE	A210738	003	Oct 31, 2018
TABLET, ORALLY DISINTEGRATING;ORAL				
STAXYN				
+ BAYER HLTHCARE	10MG **	N200179	001	Jun 17, 2010
VARENICLINE TARTRATE				
TABLET;ORAL				
VARENICLINE TARTRATE				
PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024
	EQ 1MG BASE	A217115	002	Jul 23, 2024
RHODES PHARMS	EQ 0.5MG BASE	A213268	001	May 21, 2025
	EQ 1MG BASE	A213268	002	May 21, 2025
VASOPRESSIN				
SOLUTION;INTRAVENOUS				
VASOPRESSIN IN SODIUM CHLORIDE 0.9%				
+ LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024
VASOSTRICT				
+ PH HEALTH	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023
+	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020
VASOPRESSIN TANNATE				
INJECTABLE;INJECTION				
PITRESSIN TANNATE				
+ PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
VECURONIUM BROMIDE				
INJECTABLE;INJECTION				
NORCURON				
+ ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+	20MG/VIAL **	N018776	003	Jan 03, 1992
VECURONIUM BROMIDE				
HIKMA	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VECURONIUM BROMIDE				
INJECTABLE;INJECTION				
VECURONIUM BROMIDE				
HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
	20MG/VIAL	A074334	002	Aug 31, 1995
VENLAFAXINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
EFFEXOR XR				
+ UPJOHN	EQ 100MG BASE **	N020699	003	Oct 20, 1997
VENLAFAXINE HYDROCHLORIDE				
ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
	EQ 75MG BASE	A078087	002	Mar 16, 2012
	EQ 150MG BASE	A078087	003	Mar 16, 2012
NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023
	EQ 75MG BASE	A200430	002	Apr 04, 2023
	EQ 150MG BASE	A200430	003	Apr 04, 2023
PHARMOBEDIENT	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
	EQ 75MG BASE	A078789	002	Jun 01, 2011
	EQ 150MG BASE	A078789	003	Jun 01, 2011
TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011
	EQ 75MG BASE	A090899	002	Jun 01, 2011
	EQ 150MG BASE	A090899	003	Jun 01, 2011
VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011
	EQ 75MG BASE	A090071	002	Apr 15, 2011
	EQ 150MG BASE	A090071	003	Apr 15, 2011
TABLET;ORAL				
EFFEXOR				
+ WYETH PHARMS INC	EQ 12.5MG BASE **	N020151	001	Dec 28, 1993
+	EQ 25MG BASE **	N020151	002	Dec 28, 1993
+	EQ 37.5MG BASE **	N020151	006	Dec 28, 1993
+	EQ 50MG BASE **	N020151	003	Dec 28, 1993
+	EQ 75MG BASE **	N020151	004	Dec 28, 1993
+	EQ 100MG BASE **	N020151	005	Dec 28, 1993
VENLAFAXINE HYDROCHLORIDE				
AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010
	EQ 37.5MG BASE	A079098	002	May 11, 2010
	EQ 50MG BASE	A079098	003	May 11, 2010
	EQ 75MG BASE	A079098	004	May 11, 2010
	EQ 100MG BASE	A079098	005	May 11, 2010
CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008
	EQ 37.5MG BASE	A077515	002	Jun 13, 2008
	EQ 50MG BASE	A077515	003	Jun 13, 2008
	EQ 75MG BASE	A077515	004	Jun 13, 2008
	EQ 100MG BASE	A077515	005	Jun 13, 2008
PHARMOBEDIENT	EQ 25MG BASE	A077166	001	Jun 13, 2008
	EQ 37.5MG BASE	A077166	002	Jun 13, 2008
	EQ 50MG BASE	A077166	003	Jun 13, 2008
	EQ 75MG BASE	A077166	004	Jun 13, 2008
	EQ 100MG BASE	A077166	005	Jun 13, 2008
PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517	001	Jun 13, 2008
	EQ 37.5MG BASE	A078517	002	Jun 13, 2008
	EQ 50MG BASE	A078517	003	Jun 13, 2008
	EQ 75MG BASE	A078517	004	Jun 13, 2008
	EQ 100MG BASE	A078517	005	Jun 13, 2008
PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010
	EQ 37.5MG BASE	A090027	002	Aug 04, 2010
	EQ 50MG BASE	A090027	003	Aug 04, 2010
	EQ 75MG BASE	A090027	004	Aug 04, 2010
	EQ 100MG BASE	A090027	005	Aug 04, 2010
TABLET, EXTENDED RELEASE;ORAL				
VENLAFAXINE HYDROCHLORIDE				
SUN PHARM	EQ 37.5MG BASE	A091272	001	Aug 18, 2010
	EQ 75MG BASE	A091272	002	Aug 18, 2010
	EQ 150MG BASE	A091272	003	Aug 18, 2010
	EQ 225MG BASE	A091272	004	Jan 08, 2019
SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022
	EQ 150MG BASE	A214423	002	Jan 04, 2022
TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VENLAFAXINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
VENLAFAXINE HYDROCHLORIDE				
	EQ 75MG BASE	A218180	002	Jan 28, 2025
	EQ 150MG BASE	A218180	003	Jan 28, 2025
	EQ 225MG BASE	A218180	004	Jan 28, 2025
VERAPAMIL HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
VERAPAMIL HYDROCHLORIDE				
RISING	100MG	A078306	001	Aug 09, 2007
	200MG	A078306	002	Aug 09, 2007
	300MG	A078306	003	Aug 09, 2007
INJECTABLE;INJECTION				
CALAN				
GD SEARLE LLC	2.5MG/ML	N019038	001	Mar 30, 1984
ISOPTIN				
+ MT ADAMS	2.5MG/ML **	N018485	001	
VERAPAMIL HYDROCHLORIDE				
ABRAXIS PHARM	2.5MG/ML	A070348	001	May 01, 1986
BEDFORD	2.5MG/ML	A072888	001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577	001	Feb 02, 1987
	2.5MG/ML	A070739	001	May 06, 1987
	2.5MG/ML	A070740	001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451	001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987
SOLUTION;INTRAVENOUS				
VERAPAMIL HYDROCHLORIDE				
EXELA PHARMA	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018
TABLET;ORAL				
CALAN				
PFIZER	40MG **	N018817	003	Feb 23, 1988
+	80MG **	N018817	001	Sep 10, 1984
+	120MG **	N018817	002	Sep 10, 1984
	160MG **	N018817	004	Feb 23, 1988
ISOPTIN				
+ MT ADAMS	40MG **	N018593	003	Nov 23, 1987
+	80MG **	N018593	001	Mar 08, 1982
+	120MG **	N018593	002	Mar 08, 1982
VERAPAMIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
	120MG	A070468	001	Sep 24, 1986
CHARTWELL RX	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	120MG	A070483	001	Sep 24, 1986
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
RISING	80MG	A071483	002	Feb 15, 1989
	120MG	A071483	001	Feb 15, 1989
SUN PHARM INDUSTRIES	80MG	A071489	002	Jan 13, 1988
	120MG	A071489	001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989
	40MG	A072923	001	Jun 29, 1993
	80MG	A070855	001	Sep 24, 1986
	80MG	A071366	001	Oct 01, 1986
	120MG	A070856	001	Sep 24, 1986
	120MG	A071367	001	Oct 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VERAPAMIL HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
CALAN SR				
+ PFIZER	120MG **	N019152	003	Mar 06, 1991
+	180MG **	N019152	002	Dec 15, 1989
+	240MG **	N019152	001	Dec 16, 1986
COVERA-HS				
PFIZER	180MG	N020552	001	Feb 26, 1996
	240MG	N020552	002	Feb 26, 1996
VERAPAMIL HYDROCHLORIDE				
APOTEX CORP	120MG	A200878	001	Apr 20, 2012
	180MG	A200878	002	Apr 20, 2012
	240MG	A200878	003	Apr 20, 2012
IVAX SUB TEVA PHARMS	120MG	A073568	002	Oct 10, 1997
	180MG	A074330	001	Jan 31, 1994
	240MG	A073568	001	Jul 31, 1992
PLIVA	240MG	A072922	001	Mar 01, 1996
RISING	120MG	A074587	002	Feb 21, 1997
	180MG	A074587	003	Sep 09, 1997
	240MG	A074587	001	Mar 23, 1996
SUN PHARM INDS INC	120MG	A090529	001	Dec 30, 2011
	180MG	A090529	002	Dec 30, 2011
	240MG	A090529	003	Dec 30, 2011
VERATRUM VIRIDE ROOT				
TABLET;ORAL				
VERTAVIS				
MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	
VIDARABINE				
INJECTABLE;INJECTION				
VIRA-A				
PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	
OINTMENT;OPHTHALMIC				
VIRA-A				
PARKEDALE	3%	N050486	001	
VIGABATRIN				
FOR SOLUTION;ORAL				
VIGABATRIN				
ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020
CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022
DEXCEL	500MG/PACKET	A214992	001	May 13, 2021
GRANULES	500MG/PACKET	A213469	001	Apr 24, 2020
PROPEL PHARMA	500MG/PACKET	A213390	001	Jul 29, 2021
SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021
ZYDUS LIFESCIENCES	500MG/PACKET	A214671	001	Mar 02, 2023
TABLET;ORAL				
VIGABATRIN				
AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022
VINBLASTINE SULFATE				
INJECTABLE;INJECTION				
VELBAN				
+ LILLY	10MG/VIAL **	N012665	001	
VINBLASTINE SULFATE				
ABRAXIS PHARM	10MG/VIAL	A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565	001	Aug 18, 1987
VINCRISTINE SULFATE				
INJECTABLE;INJECTION				
ONCOVIN				
+ LILLY	1MG/VIAL **	N014103	001	
+	1MG/ML **	N014103	003	Mar 07, 1984
+	5MG/VIAL **	N014103	002	
VINCASAR PFS				
TEVA PARENTERAL	1MG/ML	A071426	001	Jul 17, 1987
VINCREX				
BRISTOL MYERS SQUIBB	5MG/VIAL	A070867	001	Jul 12, 1988
VINCRISTINE SULFATE				
ABIC	1MG/ML	A070873	001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411	001	Sep 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VINCRISTINE SULFATE				
INJECTABLE;INJECTION				
VINCRISTINE SULFATE				
FRESENIUS KABI USA	1MG/ML		A076296 001	Dec 20, 2002
	1MG/ML		A076401 001	Oct 28, 2003
HOSPIRA	1MG/VIAL		A071559 001	Apr 11, 1988
	2MG/VIAL		A071560 001	Apr 11, 1988
	5MG/VIAL		A071561 001	Apr 11, 1988
VINCRISTINE SULFATE PFS				
TEVA PHARMS USA	1MG/ML		A075493 001	Sep 01, 1999
INJECTABLE, LIPOSOMAL;INTRAVENOUS				
MARQIBO KIT				
+ ACROTECH	5MG/5ML (1MG/ML)		N202497 001	Aug 09, 2012
VINORELBINE TARTRATE				
INJECTABLE;INJECTION				
NAVELBINE				
+ PIERRE FABRE	EQ 10MG BASE/ML **		N020388 001	Dec 23, 1994
VINORELBINE TARTRATE				
EBEWE PHARMA	EQ 10MG BASE/ML		A078408 001	Feb 13, 2008
FRESENIUS KABI USA	EQ 10MG BASE/ML		A076849 001	Apr 18, 2005
HOSPIRA	EQ 10MG BASE/ML		A076827 001	Jun 02, 2005
NOVAST LABS	EQ 10MG BASE/ML		A208997 001	Aug 05, 2019
RISING	EQ 10MG BASE/ML		A200148 001	Aug 31, 2012
TEVA PHARMS USA	EQ 10MG BASE/ML		A076028 001	Feb 03, 2003
VIOMYCIN SULFATE				
INJECTABLE;INJECTION				
VIOCIN SULFATE				
PFIZER	EQ 1GM BASE/VIAL		A061086 001	
	EQ 5GM BASE/VIAL		A061086 002	
VITAMIN A				
CAPSULE;ORAL				
AQUASOL A				
ASTRAZENECA	25,000USP UNITS		A083080 002	
	50,000USP UNITS		A083080 001	
VITAMIN A				
BANNER PHARMACAPS	50,000USP UNITS		A083973 001	
CHASE CHEM	50,000 IU		A083351 001	
EVERYLIFE	50,000 IU		A083134 001	
IMPAX LABS	50,000USP UNITS		A080952 001	
WEST WARD	50,000USP UNITS		A080985 001	
VITAMIN A PALMITATE				
CAPSULE;ORAL				
AFAXIN				
STERLING WINTHROP	EQ 50,000 UNITS BASE		A083187 001	
ALPHALIN				
LILLY	EQ 50,000 UNITS BASE		A080883 001	
DEL-VI-A				
DEL RAY LABS	EQ 50,000 UNITS BASE		A080830 001	
VI-DOM-A				
BAYER PHARMS	EQ 50,000 UNITS BASE		A080972 001	
VITAMIN A				
BANNER PHARMACAPS	EQ 50,000 UNITS BASE		A080702 001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE		A080860 001	
CHASE CHEM	EQ 50,000 UNITS BASE		A080746 001	
	EQ 50,000 UNITS BASE		A083207 001	
ELKINS SINN	EQ 50,000 UNITS BASE		A085479 001	
EVERYLIFE	EQ 50,000 UNITS BASE		A080943 001	
	EQ 50,000 UNITS BASE		A083114 001	
IMPAX LABS	EQ 50,000 UNITS BASE		A080953 001	
	EQ 50,000 UNITS BASE		A080955 001	
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE		A083035 001	
	EQ 50,000 UNITS BASE		A083190 001	
MK LABS	EQ 25,000 UNITS BASE		A083457 002	
	EQ 50,000 UNITS BASE		A083457 001	
WEST WARD	EQ 50,000 UNITS BASE		A080967 001	
WHARTON LABS	EQ 50,000 UNITS BASE		A083665 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VITAMIN A PALMITATE				
CAPSULE;ORAL				
VITAMIN A PALMITATE				
ARCUM	EQ 50,000 UNITS BASE	A083311 001		
	EQ 50,000 UNITS BASE	A083321 001		
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001		
	EQ 50,000 UNITS BASE	A083981 001		
VITAMIN A SOLUBILIZED				
TEVA	EQ 50,000 UNITS BASE	A080921 001		
INJECTABLE;INJECTION				
VITAMIN A PALMITATE				
BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001		
VORAPAXAR SULFATE				
TABLET;ORAL				
ZONTIVITY				
+ KEY THERAP	EQ 2.08MG BASE	N204886 001	May 08, 2014	
VORICONAZOLE				
FOR SUSPENSION;ORAL				
VORICONAZOLE				
RISING	200MG/5ML	A202361 001	May 28, 2013	
POWDER;INTRAVENOUS				
VORICONAZOLE				
ALMAJECT	200MG/VIAL	A206398 001	Mar 23, 2016	
EUGIA PHARMA	200MG/VIAL	A212162 001	Feb 02, 2023	
PHARMOBEDIENT	200MG/VIAL	A210849 001	Oct 11, 2022	
TABLET;ORAL				
VORICONAZOLE				
TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	
	200MG	A091658 002	Apr 06, 2012	
VORTIOXETINE HYDROBROMIDE				
TABLET;ORAL				
TRINTELLIX				
+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013	
VOXELOTOR				
TABLET;ORAL				
OXBRYTA				
+ GLOBAL BLOOD THERAPS	300MG	N213137 002	Oct 14, 2022	
+	500MG	N213137 001	Nov 25, 2019	
TABLET, FOR SUSPENSION;ORAL				
OXBRYTA				
+ GLOBAL BLOOD THERAPS	300MG	N216157 001	Dec 17, 2021	
WARFARIN POTASSIUM				
TABLET;ORAL				
ATHROMBIN-K				
PHARM RES ASSOC	2MG	N011771 007		
	5MG	N011771 004		
	10MG	N011771 005		
	25MG	N011771 006		
WARFARIN SODIUM				
INJECTABLE;INJECTION				
COUMADIN				
BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995	
	50MG/VIAL	N009218 020		
	75MG/VIAL	N009218 012		
TABLET;ORAL				
ATHROMBIN				
PHARM RES ASSOC	5MG	N011771 003		
	10MG	N011771 002		
	25MG	N011771 001		
COUMADIN				
+ BRISTOL MYERS SQUIBB	1MG **	N009218 022	Mar 01, 1990	
+	2MG	N009218 013		
+	2.5MG	N009218 018		
+	3MG	N009218 025	Nov 18, 1996	
+	4MG	N009218 023	Aug 24, 1993	
+	5MG	N009218 007		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

WARFARIN SODIUM				
TABLET;ORAL				
COUMADIN				
+	6MG	N009218	026	Nov 18, 1996
+	7.5MG	N009218	016	
+	10MG	N009218	005	
PANWARFIN				
ABBOTT	2MG	N017020	001	
	2.5MG	N017020	002	
	5MG	N017020	003	
	7.5MG	N017020	004	
	10MG	N017020	005	
WARFARIN SODIUM				
AIPING PHARM INC	1MG	A200104	001	Jun 27, 2013
	2MG	A200104	002	Jun 27, 2013
	2.5MG	A200104	003	Jun 27, 2013
	3MG	A200104	004	Jun 27, 2013
	4MG	A200104	005	Jun 27, 2013
	5MG	A200104	006	Jun 27, 2013
	6MG	A200104	007	Jun 27, 2013
	7.5MG	A200104	008	Jun 27, 2013
	10MG	A200104	009	Jun 27, 2013
AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004
BARR	1MG	A040145	001	Mar 26, 1997
	2MG	A040145	002	Mar 26, 1997
	2.5MG	A040145	003	Mar 26, 1997
	3MG	A040145	008	Nov 05, 1998
	4MG	A040145	004	Mar 26, 1997
	5MG	A040145	005	Mar 26, 1997
	6MG	A040145	009	Nov 05, 1998
	7.5MG	A040145	006	Mar 26, 1997
	10MG	A040145	007	Mar 26, 1997
CHARTWELL RX	1MG	A040196	001	Sep 30, 1997
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982
XENON XE-127				
GAS;INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

XENON XE-133				
GAS;INHALATION				
XENON XE 133				
	GE HEALTHCARE	1 CI/AMP	N017256 002	
		10mCi/VIAL	N017687 002	
		20mCi/VIAL	N017687 003	
	GEN ELECTRIC	5-100 CI/CYLINDER	N017550 001	
		0.25-5 CI/AMP	N017550 003	
XENON XE 133-V.S.S.				
	GE HEALTHCARE	10mCi/VIAL	N017687 001	
INJECTABLE;INJECTION				
XENON XE 133				
	GE HEALTHCARE	1.3-1.7 CI/AMP	N017256 001	
	LANTHEUS MEDCL	6.3mCi/ML	N017283 001	
SOLUTION;INHALATION, INJECTION				
XENEISOL				
	MALLINCKRODT	18-25mCi/AMP	N017262 002	
XYLOSE				
POWDER;ORAL				
XYLO-PFAN				
	SAVAGE LABS	25GM/BOT	N017605 001	
XYLOSE				
	LYNE	25GM/BOT	N018856 001	Mar 26, 1987
ZALCITABINE				
TABLET;ORAL				
HIVID				
	ROCHE	0.375MG	N020199 001	Jun 19, 1992
		0.75MG	N020199 002	Jun 19, 1992
ZALEPLON				
CAPSULE;ORAL				
SONATA				
+	PFIZER	5MG	N020859 001	Aug 13, 1999
+		10MG	N020859 002	Aug 13, 1999
ZALEPLON				
	HIKMA PHARMS	5MG	A078147 001	Nov 25, 2008
		10MG	A078147 002	Nov 25, 2008
	NATCO PHARMA	5MG	A077238 001	Jun 06, 2008
		10MG	A077238 002	Jun 06, 2008
	TEVA PHARMS	5MG	A077239 001	Jun 06, 2008
		10MG	A077239 002	Jun 06, 2008
	UPSHER SMITH LABS	5MG	A078095 001	Jun 06, 2008
		5MG	A078706 001	Jun 06, 2008
		10MG	A078095 002	Jun 06, 2008
		10MG	A078706 002	Jun 06, 2008
ZANUBRUTINIB				
CAPSULE;ORAL				
BRUKINSA				
+	BEONE MEDICINES USA	80MG	N213217 001	Nov 14, 2019
ZICONOTIDE ACETATE				
INJECTABLE;INTRATHECAL				
PRIALT				
	TERSERA	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004
ZIDOVUDINE				
INJECTABLE;INJECTION				
ZIDOVUDINE				
	AM REGENT	10MG/ML	A091457 001	May 06, 2010
	LIAONING CHENGDA	10MG/ML	A204538 001	Nov 26, 2013
TABLET;ORAL				
RETROVIR				
	VIIV HLTHCARE	200MG	N020518 001	Dec 19, 1995
+		300MG **	N020518 002	Oct 04, 1996
ZIDOVUDINE				
	AUROBINDO PHARMA	60MG	N022294 001	Jul 23, 2009
	HEC PHARM	300MG	A202058 001	Oct 07, 2011
	HIKMA	300MG	A076844 001	Sep 19, 2005
	PHARMOBEDIENT	100MG	N200732 001	Feb 23, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZIDOVUDINE

TABLET;ORAL				
ZIDOVUDINE				
	300MG		A078922 001	Feb 14, 2008
RANBAXY LABS LTD	300MG		A077327 001	Sep 19, 2005

ZILEUTON

TABLET;ORAL				
ZYFLO				
+ CHIESI	300MG		N020471 001	Dec 09, 1996
+	600MG		N020471 003	Dec 09, 1996
TABLET, EXTENDED RELEASE;ORAL				
ZILEUTON				
LUPIN LTD	600MG		A211972 001	Nov 05, 2019
TEVA PHARMS USA	600MG		A211043 001	May 03, 2022
ZYFLO CR				
+ CHIESI	600MG **		N022052 001	May 30, 2007

ZINC SULFATE

INJECTABLE;INJECTION				
ZINC SULFATE				
ABRAXIS PHARM	EQ 1MG ZINC/ML		N019229 002	May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL				
ZIPRASIDONE HYDROCHLORIDE				
LUPIN PHARMS	EQ 20MG BASE		A077560 001	Mar 02, 2012
	EQ 40MG BASE		A077560 002	Mar 02, 2012
	EQ 60MG BASE		A077560 003	Mar 02, 2012
	EQ 80MG BASE		A077560 004	Mar 02, 2012
MYLAN	EQ 20MG BASE		A202395 001	Oct 10, 2013
	EQ 40MG BASE		A202395 002	Oct 10, 2013
	EQ 60MG BASE		A202395 003	Oct 10, 2013
	EQ 80MG BASE		A202395 004	Oct 10, 2013
SUSPENSION;ORAL				
GEODON				
PFIZER INC	EQ 10MG BASE/ML		N021483 001	Mar 29, 2006

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS				
ZOLEDRONIC ACID				
ACTAVIS INC	EQ 4MG BASE/5ML		A202472 001	Mar 04, 2013
APOTEX	EQ 5MG BASE/100ML		A204367 001	Dec 24, 2015
AVET LIFESCIENCES	EQ 5MG BASE/100ML		A201801 001	Mar 29, 2013
BRECKENRIDGE	EQ 4MG BASE/5ML		A091170 001	Mar 04, 2013
DR REDDYS	EQ 4MG BASE/100ML		A204344 001	Nov 19, 2018
EUGIA PHARMA	EQ 4MG BASE/5ML		A207751 001	Sep 26, 2016
	EQ 5MG BASE/100ML		A209125 001	Dec 08, 2017
HOSPIRA	EQ 4MG BASE/5ML		A090621 001	Mar 19, 2015
NOVAST LABS	EQ 4MG BASE/5ML		A208968 001	Feb 19, 2020
SHILPA	EQ 4MG BASE/5ML		A208513 001	May 15, 2019
SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL		A090018 001	Mar 04, 2013
	EQ 4MG BASE/5ML		A202746 001	Mar 04, 2013
ZOMETA				
+ NOVARTIS	EQ 4MG BASE/VIAL **		N021223 001	Aug 20, 2001
+	EQ 4MG BASE/5ML **		N021223 002	Mar 07, 2003
+	EQ 4MG BASE/100ML **		N021223 003	Jun 17, 2011
SOLUTION;INTRAVENOUS				
ZOLEDRONIC ACID				
HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)		N204016 001	Dec 28, 2015

ZOLMITRIPTAN

TABLET;ORAL				
ZOLMITRIPTAN				
ANI PHARMS	2.5MG		A090861 001	Mar 04, 2014
	5MG		A090861 002	Mar 04, 2014
APOTEX INC	2.5MG		A202078 001	May 14, 2013
	5MG		A202078 002	May 14, 2013
INVAGEN PHARMS	2.5MG		A204284 001	Apr 09, 2014
	5MG		A204284 002	Apr 09, 2014
MACLEODS PHARMS LTD	2.5MG		A203772 001	Sep 30, 2015
	5MG		A203772 002	Sep 30, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZOLMITRIPTAN

TABLET;ORAL					
ZOLMITRIPTAN					
	NATCO PHARMA USA	2.5MG	A203186	001	May 14, 2013
		5MG	A203186	002	May 14, 2013
	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
		5MG	A203476	002	Nov 13, 2014
ZOMIG					
+	IPR	2.5MG **	N020768	001	Nov 25, 1997
+		5MG **	N020768	002	Nov 25, 1997
TABLET, ORALLY DISINTEGRATING;ORAL					
ZOLMITRIPTAN					
	APOTEX INC	2.5MG	A202476	001	May 14, 2013
		5MG	A202476	002	May 14, 2013
	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
		5MG	A204336	002	Oct 22, 2015
	RISING	2.5MG	A202855	001	Sep 20, 2019
		5MG	A202855	002	Sep 20, 2019
ZOMIG-ZMT					
+	ASTRAZENECA	2.5MG **	N021231	001	Feb 13, 2001
+		5MG **	N021231	002	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL					
ZOLPIMIST					
+	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008
TABLET;ORAL					
ZOLPIDEM TARTRATE					
	ANDA REPOSITORY	5MG	A077985	001	Apr 23, 2007
		10MG	A077985	002	Apr 23, 2007
	APOTEX INC	5MG	A077884	001	Apr 23, 2007
		10MG	A077884	002	Apr 23, 2007
	HIKMA	5MG	A078129	001	Apr 30, 2008
		10MG	A078129	002	Apr 30, 2008
	INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007
		10MG	A078184	002	Sep 07, 2007
	MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
		10MG	A078016	002	Apr 23, 2007
	RISING	5MG	A076578	001	Apr 23, 2007
		10MG	A076578	002	Apr 23, 2007
	STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007
		10MG	A076062	002	Apr 23, 2007
	STRIDES PHARMA INTL	5MG	A078616	001	Nov 21, 2008
		10MG	A078616	002	Nov 21, 2008
	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
		10MG	A077359	002	Apr 23, 2007
	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
		10MG	A078055	002	Apr 23, 2007
	SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
		10MG	A077288	002	Apr 23, 2007
	SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
		10MG	A077540	002	Apr 23, 2007
	WATSON LABS	5MG	A077773	001	Apr 23, 2007
		10MG	A077773	002	Apr 23, 2007
	WOCKHARDT	5MG	A078426	001	May 15, 2007
		10MG	A078426	002	May 15, 2007
	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007
		10MG	A077990	002	Apr 23, 2007
TABLET;SUBLINGUAL					
INTERMEZZO					
+	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+		3.5MG	N022328	002	Nov 23, 2011
ZOLPIDEM TARTRATE					
	PHARMOBEDIENT	5MG	A202657	001	Aug 08, 2016
		10MG	A202657	002	Aug 08, 2016
TABLET, EXTENDED RELEASE;ORAL					
ZOLPIDEM TARTRATE					
	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010
		12.5MG	A078179	001	Jun 06, 2011
	ACTAVIS LABS FL INC	6.25MG	A090153	001	Mar 25, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

		12.5MG	A090153	002	Mar 25, 2013
	APOTEX	6.25MG	A200266	001	Sep 10, 2013
		12.5MG	A200266	002	Sep 10, 2013
	BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020
		12.5MG	A213592	002	Jun 04, 2020
	PH HEALTH	6.25MG	A078148	002	Apr 14, 2011
		12.5MG	A078148	001	Dec 03, 2010
	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
		12.5MG	A078483	002	Jun 06, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

+	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
+		10MG	N021412	002	Apr 25, 2007

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

+	ADVANZ PHARMA	50MG **	N020789	002	Aug 22, 2003

ZONISAMIDE

	ANI PHARMS	25MG	A077639	001	Dec 22, 2005
		25MG	A077641	003	Dec 22, 2005
		50MG	A077639	002	Dec 22, 2005
		50MG	A077641	002	Dec 22, 2005
		100MG	A077639	003	Dec 22, 2005
		100MG	A077641	001	Dec 22, 2005
	APOTEX	25MG	A077642	001	Dec 22, 2005
		50MG	A077642	002	Dec 22, 2005
		100MG	A077642	003	Dec 22, 2005
	CHARTWELL RX	25MG	A077650	001	Apr 20, 2006
		50MG	A077650	002	Apr 20, 2006
		100MG	A077650	003	Apr 20, 2006
	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007
		50MG	A077876	002	Feb 21, 2007
		100MG	A077876	003	Feb 21, 2007
	MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025
		50MG	A219507	002	May 12, 2025
		100MG	A219507	003	May 12, 2025
	PHARMOBEDIENT	25MG	A077647	001	Dec 22, 2005
		50MG	A077647	002	Dec 22, 2005
		100MG	A077647	003	Dec 22, 2005
	RISING	25MG	A077637	001	Dec 22, 2005
		50MG	A077637	002	Dec 22, 2005
		100MG	A077637	003	Dec 22, 2005
	ROXANE	25MG	A077648	001	Dec 22, 2005
		50MG	A077648	002	Dec 22, 2005
		100MG	A077648	003	Dec 22, 2005
	SUN PHARM INDS (IN)	25MG	A077634	001	Mar 17, 2006
		50MG	A077634	002	Mar 17, 2006
		100MG	A077634	003	Mar 17, 2006
	SUN PHARM INDUSTRIES	25MG	A077635	001	Dec 22, 2005
		50MG	A077635	002	Dec 22, 2005
		100MG	A077635	003	Dec 22, 2005
	UPSHER SMITH LABS	25MG	A077644	001	Dec 22, 2005
		50MG	A077644	002	Dec 22, 2005
		100MG	A077644	003	Dec 22, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABILIFY, ARIPIPRAZOLE
ABILIFY ASIMTUFII, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCRUFER, FERRIC MALTOL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHAR GEL, CORTICOTROPIN
ACTHAR GEL (AUTOINJECTOR), CORTICOTROPIN
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS XR-ODT, AMPHETAMINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AGAMREE, VAMOROLONE
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AIRSUPRA, ALBUTEROL SULFATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AKEEGA, ABIRATERONE ACETATE
AKLIEF, TRIFAROTENE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAFTADINE, ALCAFTADINE (OTC)
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
ALKINDI SPRINKLE, HYDROCORTISONE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOPRIM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTRENO, TRETINOIN
ALUNBRIG, BRIGATINIB
ALVAIZ, ELTROMBOPAG CHOLINE
ALVESCO, CICLESONIDE
ALVIMOPAN, ALVIMOPAN
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ALYFTREK, DEUTIVACAFTOR
ALYQ, TADALAFIL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBRISENTAN, AMBRISENTAN
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMNESTEEM, ISOTRETINOIN
AMONDYS 45, CASIMERSEN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE, AMPHETAMINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMVUTTRA, VUTRISIRAN SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCOBON, FLUCYTOSINE
ANDROGEL, TESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANGIOTENSIN ll ACETATE, ANGIOTENSIN II ACETATE
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
ANZUPGO, DELGOCITINIB
APALUTAMIDE, APALUTAMIDE
APHEXDA, MOTIXAFORTIDE ACETATE
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE
APONVIE, APREPITANT
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREMILAST, APREMILAST
APREPITANT, APREPITANT
APRETUDE, CABOTEGRAVIR
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQNEURSA, LEVACETYLLEUCINE
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARBLI, LOSARTAN POTASSIUM
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTESUNATE, ARTESUNATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ARTHROTEC, DICLOFENAC SODIUM
ARYNTA, LISDEXAMFETAMINE DIMESYLATE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASCORBIC ACID, ASCORBIC ACID
ASENAPINE MALEATE, ASENAPINE MALEATE
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATMEKSI, METHOCARBAMOL
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVALIQ, ATORVASTATIN CALCIUM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATROPINE SULFATE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
ATTRUBY, ACORAMIDIS HYDROCHLORIDE
ATZUMI, DIHYDROERGOTAMINE MESYLATE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGTYRO, REPOTRECTINIB
AURLUMYN, ILOPROST
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUSTEDO XR, DEUTETRABENAZINE
AUVELITY, BUPROPION HYDROCHLORIDE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANAFIL, AVANAFIL
AVAPRO, IRBESARTAN
AVEED, TESTOSTERONE UNDECANOATE
AVERI, DESOGESTREL
AVGEMSI, GEMCITABINE HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), AVUTOMETINIB POTASSIUM
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXID AR, NIZATIDINE (OTC)
AXITINIB, AXITINIB

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AXTLE, PEMETREXED DIPOTASSIUM
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AYVAKIT, AVAPRITINIB
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE (OTC)
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE, AZILSARTAN KAMEDOXOMIL
AZITHROMYCIN, AZITHROMYCIN
AZMIRO, TESTOSTERONE CYPIONATE
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAFIERTAM, MONOMETHYL FUMARATE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALVERSA, ERDAFITINIB
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BAQSIMI, GLUCAGON
BARACLUDE, ENTECAVIR
BARHEMSYS, AMISULPRIDE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECLOMETHASONE DIPROPIONATE, BECLOMETHASONE DIPROPIONATE
BEIZRAY, DOCETAXEL
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE

APPENDIX A - PRODUCT NAME INDEX

** B **

BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAINE, BETAINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BLUDIGO, INDIGOTINDISULFONATE SODIUM
BLUJEPA, GEPOTIDACIN MESYLATE
BONDLIDO, LIDOCAINE
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BOSUTINIB MONOHYDRATE, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREKIYA (AUTOINJECTOR), DIHYDROERGOTAMINE MESYLATE
BRENZAVVY, BEXAGLIFLOZIN
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BREXAFEMME, IBREXAFUNGERP CITRATE
BREXPIPRAZOLE, BREXPIPRAZOLE
BREYNA, BUDESONIDE
BREZTRI AEROSPHERE, BUDESONIDE
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE (OTC)
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRINSUPRI, BRENSOCATIB
BRINZOLAMIDE, BRINZOLAMIDE
BRISDELLE, PAROXETINE MESYLATE
BRIVARACETAM, BRIVARACETAM
BRIVIACT, BRIVARACETAM
BRIXADI, BUPRENORPHINE
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHITOL, MANNITOL
BRUKINSA, ZANUBRUTINIB
BRYHALI, HALOBETASOL PROPIONATE
BRYNOVIN, SITAGLIPTIN HYDROCHLORIDE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUCAPSOL, BUSPIRONE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYFAVO, REMIMAZOLAM BESYLATE
BYLVAY, ODEVIXIBAT
BYNFEZIA PEN, OCTREOTIDE ACETATE
BYQLOVI, CLOBETASOL PROPIONATE
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABAZITAXEL, CABAZITAXEL
CABENUVA KIT, CABOTEGRAVIR
CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CABTREO, ADAPALENE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CALQUENCE, ACALABRUTINIB MALEATE
CAMBIA, DICLOFENAC POTASSIUM
CAMCEVI ETM, LEUPROLIDE MESYLATE
CAMCEVI KIT, LEUPROLIDE MESYLATE
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CAMZYOS, MAVACAMTEN
CANASA, MESALAMINE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANGRELOR, CANGRELOR
CAPECITABINE, CAPECITABINE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDAMYST, ETRIPAMIL
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB
CARGLUMIC ACID, CARGLUMIC ACID
CARIPRAZINE HYDROCHLORIDE, CARIPRAZINE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETRORELIX ACETATE, CETRORELIX ACETATE
CETROTIDE, CETRORELIX ACETATE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHABELINA FE, ETHINYL ESTRADIOL
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CIBINQO, ABROCITINIB
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARISCAN, GADOTERATE MEGLUMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTIC, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
COBENFY, TROSPIUM CHLORIDE
CODEINE SULFATE, CODEINE SULFATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBOGESIC, ACETAMINOPHEN
COMBOGESIC IV, ACETAMINOPHEN
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUGATED ESTROGENS, ESTROGENS, CONJUGATED
CONRAY, IOTHALAMATE MEGLUMINE
CONTEPO, FOSFOMYCIN DISODIUM
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CORTIFOAM, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
COSELA, TRILACICLIB DIHYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COXANTO, OXAPROZIN
COZAAR, LOSARTAN POTASSIUM
CRENESSITY, CRINECERFONT
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CREXONT, CARBIDOPA
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CTEXLI, CHENODIOL
CUPRIC CHLORIDE, CUPRIC CHLORIDE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUVPOSA, GLYCOPYRROLATE
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYKLX, ARTICAINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTALUX, PAFOLACIANINE SODIUM
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOXAN, CYCLOPHOSPHAMIDE

**** D ****

DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DALBAVANCIN HYDROCHLORIDE, DALBAVANCIN HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DANZITEN, NILOTINIB TARTRATE
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR, DARUNAVIR
DASATINIB, DASATINIB
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
DAWNZERA (AUTOINJECTOR), DONIDALORSEN SODIUM
DAYBUE, TROFINETIDE
DAYBUE STIX, TROFINETIDE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DAYVIGO, LEMBOREXANT
DDAVP, DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFENCATH, HEPARIN SODIUM
DEFERASIROX, DEFERASIROX
DEFERIPRONE, DEFERIPRONE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFINITY RT, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DEFLAZACORT, DEFLAZACORT
DEHYDRATED ALCOHOL, ALCOHOL
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETECTNET, COPPER CU-64 DOTATATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXEDRINE SPANSULE, DEXTROAMPHETAMINE SULFATE
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DHIVY, CARBIDOPA
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DICHLORPHENAMIDE, DICHLORPHENAMIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIFLUPREDNATE, DIFLUPREDNATE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIROXIMEL FUMARATE, DIROXIMEL FUMARATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DIURIL, CHLOROTHIAZIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCIVYX, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DOFETILDE, DOFETILIDE
DOFETILIDE, DOFETILIDE
DOJOLVI, TRIHEPTANOIN
DOLISHALE, ETHINYL ESTRADIOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTELET, AVATROMBOPAG MALEATE
DOPTELET SPRINKLE, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVATO, DOLUTEGRAVIR SODIUM
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DRONABINOL, DRONABINOL
DRONEDARONE HYDROCHLORIDE, DRONEDARONE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DROSPIRENONE AND ESTRADIOL, DROSPIRENONE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIDOPA, DROXIDOPA
DUAC, BENZOYL PEROXIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUOBRII, HALOBETASOL PROPIONATE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURYSTA, BIMATOPROST
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUVOID, BETHANECHOL CHLORIDE
DUVYZAT, GIVINOSTAT HYDROCHLORIDE
DYANAVEL XR, AMPHETAMINE
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z-DISK, BARIUM SULFATE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARAVONE, EDARAVONE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE CALCIUM DISODIUM, EDETATE CALCIUM DISODIUM
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EDURANT PED, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFINACONAZOLE, EFINACONAZOLE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
EKTERLY, SEBETRALSTAT
ELCYS, CYSTEINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIGARD KIT, LEUPROLIDE ACETATE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIQUIS SPRINKLE, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELTROMBOPAG OLAMINE, ELTROMBOPAG OLAMINE
ELUCIREM, GADOPICLENOL
ELURYNG, ETHINYL ESTRADIOL
ELYXYB, CELECOXIB
EMBLAVEO, AVIBACTAM SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMERPHED, EPHEDRINE SULFATE
EMFLAZA, DEFLAZACORT
EMPAVELI, PEGCETACOPLAN
EMROSI, MINOCYCLINE HYDROCHLORIDE
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
EMZAHH, NORETHINDRONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENBUMYST, BUMETANIDE
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENILLORING, ETHINYL ESTRADIOL
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSACOVE, ENSARTINIB HYDROCHLORIDE
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTERO VU 24%, BARIUM SULFATE
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENTRESTO SPRINKLE, SACUBITRIL
ENVARSUS XR, TACROLIMUS
EOHILIA, BUDESONIDE
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, EPINEPHRINE BITARTRATE
EPIOXA HD/EPIOXA KIT, RIBOFLAVIN 5'-PHOSPHATE SODIUM
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPRONTIA, TOPIRAMATE
EPSOLAY, BENZOYL PEROXIDE
EPTIFIBATIDE, EPTIFIBATIDE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIBULIN MESYLATE, ERIBULIN MESYLATE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERMEZA, LEVOTHYROXINE SODIUM
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ERZOFRI, PALIPERIDONE PALMITATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM, ESCITALOPRAM OXALATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAVIRINE, ETRAVIRINE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVRYSDI, RISDIPLAM
EXCEDRIN (MIGRAINE RELIEF), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXEM FOAM KIT, AIR POLYMER-TYPE A
EXEMESTANE, EXEMESTANE
EXENATIDE SYNTHETIC, EXENATIDE SYNTHETIC
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTRANEAL, ICODEXTRIN
EXXUA, GEPIRONE HYDROCHLORIDE
EYSUVIS, LOTEPREDNOL ETABONATE
EZETIMIBE, EZETIMIBE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABHALTA, IPTACOPAN HYDROCHLORIDE
FABIOR, TAZAROTENE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARXIGA, DAPAGLIFLOZIN
FASLODEX, FULVESTRANT
FEBUXOSTAT, FEBUXOSTAT
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMLYV, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENSOLVI KIT, LEUPROLIDE ACETATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FERABRIGHT, FERUMOXYTOL
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FERUMOXYTOL, FERUMOXYTOL
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXINIDAZOLE, FEXINIDAZOLE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIDAXOMICIN, FIDAXOMICIN
FILSPARI, SPARSENTAN
FILSUVEZ, BIRCH TRITERPENES
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINASTERIDE AND TADALAFIL, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
FINZALA, ETHINYL ESTRADIOL
FIORICET W/ CODEINE, ACETAMINOPHEN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLEQSUVY, BACLOFEN
FLOLIPID, SIMVASTATIN
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLURESCEIN SODIUM, FLURESCEIN SODIUM
FLURESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
FLURESCITE, FLURESCEIN SODIUM
FLURODOPA F18, FLURODOPA F-18
FLUROMETHOLONE, FLUROMETHOLONE
FLUROURACIL, FLUROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FLYRCADO, FLURPIRIDAZ F-18
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCINVEZ, FOSAPREPITANT DIMEGLUMINE
FOLIC ACID, FOLIC ACID
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FORTEO, TERIPARATIDE
FORZINITY, ELAMIPRETIDE HYDROCHLORIDE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FOTIVDA, TIVOZANIB HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
FRINDOVYX, CYCLOPHOSPHAMIDE
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FRUZAQLA, FRUQUINTINIB
FULVESTRANT, FULVESTRANT
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN-U/F, GRISEOFULVIN, MICROSIZE
FURADANTIN, NITROFURANTOIN
FUROSCIX, FUROSEMIDE
FUROSEMIDE, FUROSEMIDE
FYARRO, SIROLIMUS
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL
FYREMADEL, GANIRELIX ACETATE

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GADOBUTROL, GADOBUTROL
GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE
GADOTERIDOL, GADOTERIDOL
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALLIUM GA 68 EDOTREOTIDE, GALLIUM GA-68 EDOTREOTIDE
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE
GAVRETO, PRALSETINIB
GEFITINIB, GEFITINIB
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMMILY, ETHINYL ESTRADIOL
GEMTESA, VIBEGRON
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOSYL, NITRIC OXIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL XL, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCEROL PHENYLBUTYRATE, GLYCEROL PHENYLBUTYRATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYRX-PF, GLYCOPYRROLATE
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GOMEKLI, MIRDAMETINIB
GOPRELTO, COCAINE HYDROCHLORIDE
GOZELLIX, GALLIUM GA-68 GOZETOTIDE
GRAFAPEX, TREOSULFAN
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GVOKE HYPOPEN, GLUCAGON
GVOKE KIT, GLUCAGON
GVOKE PFS, GLUCAGON
GVOKE VIALDX, GLUCAGON
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

HABITROL, NICOTINE (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY 24 FE, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE
HALCINONIDE, HALCINONIDE
HALCION, TRIAZOLAM
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOBETASOL PROPIONATE AND TAZAROTENE, HALOBETASOL PROPIONATE
HALOETTE, ETHINYL ESTRADIOL
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARLIKU, NITISINONE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HEMABATE, CARBOPROST TROMETHAMINE
HEMADY, DEXAMETHASONE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEMICLOR, CHLORTHALIDONE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPZATO, MELPHALAN HYDROCHLORIDE
HER STYLE, LEVONORGESTREL (OTC)
HERNEXEOS, ZONGERTINIB
HETLIOZ, TASIMELTEON
HETLIOZ LQ, TASIMELTEON
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYFTOR, SIROLIMUS
HYRNUO, SEVABERTINIB
HYSINGLA ER, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBSRELA, TENAPANOR HYDROCHLORIDE
IBTROZI, TALETRECTINIB ADIPATE
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICATIBANT ACETATE, ICATIBANT ACETATE
ICLEVIA, ETHINYL ESTRADIOL
ICLUSIG, PONATINIB HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IDOSE TR, TRAVOPROST
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE
IHEEZO, CHLOROPROCAINE HYDROCHLORIDE
ILEVRO, NEPAFENAC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMCIVREE, SETMELANOTIDE ACETATE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMKELDI, IMATINIB MESYLATE
IMMPHENTIV, PHENYLEPHRINE HYDROCHLORIDE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDIUM IN-111 PENTETREOTIDE KIT, INDIUM IN-111 PENTETREOTIDE KIT
INDOCIN, INDOMETHACIN
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INGREZZA SPRINKLE, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLEXZO, GEMCITABINE HYDROCHLORIDE
INLURIYO, IMLUNESTRANT TOSYLATE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INPEFA, SOTAGLIFLOZIN
INQOVI, CEDAZURIDINE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPRA, EPLERENONE
INTELENCE, ETRAVIRINE
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
INZIRQO, HYDROCHLOROTHIAZIDE
IODIXANOL, IODIXANOL
IOFLUPANE I-123, IOFLUPANE I-123
IOHEXOL, IOHEXOL
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IQIRVO, ELAFIBRANOR

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
IRON SUCROSE, IRON SUCROSE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISTURISA, OSILODROSTAT PHOSPHATE
ITOVEBI, INAVOLISIB
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
IVERMECTIN, IVERMECTIN (OTC)
IVERMECTIN, IVERMECTIN
IVRA, MELPHALAN HYDROCHLORIDE
IVY BLOCK, BENTOQUATAM (OTC)
IWILFIN, EFLORNITHINE HYDROCHLORIDE
IXEMPRA KIT, IXABEPILONE
IYUZEH, LATANOPROST
IZERVAY, AVACINCAPTAD PEGOL SODIUM

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JASCAYD, NERANDOMILAST
JATENZO, TESTOSTERONE UNDECANOATE
JAVADIN, CLONIDINE HYDROCHLORIDE
JAYPIRCA, PIRTOBRUTINIB
JAYTHARI, DEFLAZACORT
JELMYTO, MITOMYCIN
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL

APPENDIX A - PRODUCT NAME INDEX

**** J ****

JOENJA, LENIOLISIB PHOSPHATE
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JOURNAVX, SUZETRIGINE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYLAMVO, METHOTREXATE
JYNARQUE, TOLVAPTAN

**** K ****

KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KELNOR, ETHINYL ESTRADIOL
KELNOR 1/50, ETHINYL ESTRADIOL
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERENDIA, FINERENONE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KHINDIVI, HYDROCORTISONE
KIMYRSA, ORITAVANCIN DIPHOSPHATE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLAYESTA, NYSTATIN
KLISYRI, TIRBANIBULIN
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOXXADO, NALOXONE HYDROCHLORIDE
KOMZIFTI, ZIFTOMENIB
KONVOMEP, OMEPRAZOLE
KORLYM, MIFEPRISTONE

APPENDIX A - PRODUCT NAME INDEX

**** K ****

KORSUVA, DIFELIKEFALIN ACETATE
KOSELUGO, SELUMETINIB SULFATE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRAZATI, ADAGRASIB
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYGEVVI, DOXECITINE
KYLEENA, LEVONORGESTREL
KYPROLIS, CARFILZOMIB
KYXATA, CARBOPLATIN
KYZATREX, TESTOSTERONE UNDECANOATE

**** L ****

L-GLUTAMINE, L-GLUTAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPIT, NIFURTIMOX
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX ONYU, FUROSEMIDE
LASTACAFT, ALCAFTADINE (OTC)
LATANOPROST, LATANOPROST
LATANOPROSTENE BUNOD, LATANOPROSTENE BUNOD
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAZCLUZE, LAZERTINIB MESYLATE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LENVIMA, LENVATINIB MESYLATE
LEQSELVI, DEURUXOLITINIB PHOSPHATE
LEQVIO, INCLISIRAN SODIUM
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLET, LEVOTHYROXINE SODIUM **
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXETTE, HALOBETASOL PROPIONATE
LEXISCAN, REGADENOSON
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LICART, DICLOFENAC EPOLAMINE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIKMEZ, METRONIDAZOLE
LILETTA, LEVONORGESTREL
LINAGLIPTIN, LINAGLIPTIN
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID

APPENDIX A - PRODUCT NAME INDEX

** L **

LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LIRAGLUTIDE, LIRAGLUTIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITFULO, RITLECITINIB TOSYLATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LIVDELZI, SELADELPAR LYSINE
LIVMARLI, MARALIXIBAT CHLORIDE
LIVTENCITY, MARIBAVIR
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO SIMPESSE, ETHINYL ESTRADIOL
LO-MALMOREDE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOCAMETZ, GALLIUM GA-68 GOZETOTIDE
LOCHOLEST, CHOLESTYRAMINE
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOCO, COLCHICINE
LODOSYN, CARBIDOPA
LOFEXIDINE HYDROCHLORIDE, LOFEXIDINE HYDROCHLORIDE
LOGILIA, ULIPRISTAL ACETATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LOMUSTINE, LOMUSTINE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORBRENA, LORLATINIB
LOREEV XR, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LOTEPREDNOL ETABONATE AND TOBRAMYCIN, LOTEPREDNOL ETABONATE
LOTREL, AMLODIPINE BESYLATE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUBIPROSTONE, LUBIPROSTONE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMI-SPORYN, BACITRACIN ZINC
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIFY PRESERVATIVE FREE, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUMISIGHT, PEGULICIANINE ACETATE
LUMRYZ, SODIUM OXYBATE
LUNESTA, ESZOPICLONE
LUPKYNIS, VOCLOSPORIN
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
LUTATHERA, LUTETIUM LU 177 DOTATATE
LUVOX, FLUVOXAMINE MALEATE
LUZU, LULICONAZOLE
LYBALVI, OLANZAPINE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNKUET, ELINZANETANT
LYNPARZA, OLAPARIB
LYPQOZET, ATORVASTATIN CALCIUM
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID
LYTGOBI, FUTIBATINIB

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MACITENTAN, MACITENTAN
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE, MANGANESE CHLORIDE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARAVIROC, MARAVIROC
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENOSTAR, ESTRADIOL
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERZEE, ETHINYL ESTRADIOL
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOHEXITAL SODIUM, METHOHEXITAL SODIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHSUXIMIDE, METHSUXIMIDE
METHYLDOPA, METHYLDOPA
METHYLENE BLUE, METHYLENE BLUE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE, METHYLPHENIDATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICAFUNGIN, MICAFUNGIN SODIUM
MICAFUNGIN IN SODIUM CHLORIDE 0.9%, MICAFUNGIN SODIUM
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR), MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOSTAURIN, MIDOSTAURIN
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIEBO, PERFLUOROHEXYLOCTANE
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILOPHENE, CLOMIPHENE CITRATE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINZOYA, ETHINYL ESTRADIOL
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIPLYFFA, ARIMOCLOMOL CITRATE
MIRABEGRON, MIRABEGRON
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIUDELLA, COPPER
MODAFINIL, MODAFINIL
MODEYSO, DORDAVIPRONE HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
MONODOX, DOXYCYCLINE
MONOFERRIC, FERRIC DERISOMALTOSE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTPOLY XR, LACOSAMIDE
MOTRIN IB, IBUPROFEN (OTC)
MOUNJARO, TIRZEPATIDE
MOUNJARO (AUTOINJECTOR), TIRZEPATIDE
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4, MAGNESIUM CHLORIDE
MULTRYS, CUPRIC SULFATE
MUPIROCIN, MUPIROCIN

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MUPIROCIN, MUPIROCIN CALCIUM
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAPSSA, OCTREOTIDE ACETATE
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFEMBREE, ESTRADIOL
MYFORTIC, MYCOPHENOLATE SODIUM
MYHIBBIN, MYCOPHENOLATE MOFETIL
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYQORZO, AFICAMTEN
MYRBETRIQ, MIRABEGRON
MYRBETRIQ GRANULES, MIRABEGRON
MYSOLINE, PRIMIDONE
MYTESI, CROFELEMER
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE (OTC)
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATROBA, SPINOSAD
NAYZILAM, MIDAZOLAM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEFFY, EPINEPHRINE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NELARABINE, NELARABINE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER
NEREUS, TRADIPITANT
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXICLON XR, CLONIDINE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXLETOL, BEMPEDOIC ACID
NEXLIZET, BEMPEDOIC ACID
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NEXTSTELLIS, DROSPIRENONE
NIACIN, NIACIN
NIACOR, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILOTINIB D-TARTRATE, NILOTINIB D-TARTRATE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITAZOXANIDE, NITAZOXANIDE
NITHIODOTE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)
NOR-QD, NORETHINDRONE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORITATE, METRONIDAZOLE
NORLIQVA, AMLODIPINE BESYLATE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOURIANZ, ISTRADEFYLLINE
NOXAFIL, POSACONAZOLE
NOXAFIL POWDERMIX KIT, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUBEQA, DAROLUTAMIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULIBRY, FOSDENOPTERIN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMBRINO, COCAINE HYDROCHLORIDE
NUPLAZID, PIMAVANSERIN TARTRATE
NURTEC ODT, RIMEGEPANT SULFATE
NUTRILIPID 20%, SOYBEAN OIL
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NUZOLVENCE, ZOLIFLODACIN
NUZYRA, OMADACYCLINE TOSYLATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGSIVEO, NIROGACESTAT HYDROBROMIDE
OHTUVAYRE, ENSIFENTRINE
OJEMDA, TOVORAFENIB
OJJAARA, MOMELOTINIB DIHYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLPRUVA, SODIUM PHENYLBUTYRATE
OLUMIANT, BARICITINIB
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMLONTI, OMIDENEPAG ISOPROPYL
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
ONAPGO, APOMORPHINE HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGENTYS, OPICAPONE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONPATTRO, PATISIRAN SODIUM
ONSURA, ETHINYL ESTRADIOL
ONTRALFY, TIZANIDINE HYDROCHLORIDE
ONUREG, AZACITIDINE
ONYDA XR, CLONIDINE HYDROCHLORIDE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPFOLDA, MIGLUSTAT
OPILL, NORGESTREL (OTC)
OPIPZA, ARIPIPRAZOLE

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OPSUMIT, MACITENTAN
OPSYNVI, MACITENTAN
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPVEE, NALMEFENE HYDROCHLORIDE
OPZELURA, RUXOLITINIB PHOSPHATE
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORGOVYX, RELUGOLIX
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORLADEYO, BEROTRALSTAT DIHYDROCHLORIDE
ORLYNVAH, PROBENECID
ORMALVI, DICHLORPHENAMIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC, ASPIRIN
ORPHENGESIC FORTE, ASPIRIN
ORSERDU, ELACESTRANT HYDROCHLORIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTEZLA XR, APREMILAST
OTICAIR, HYDROCORTISONE
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXLUMO, LUMASIRAN SODIUM
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZEMPIC, SEMAGLUTIDE

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OZOBAX DS, BACLOFEN
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PALSONIFY, PALTUSOTINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXLOVID (COPACKAGED), NIRMATRELVIR
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDMARK, SODIUM THIOSULFATE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PEMAZYRE, PEMIGATINIB
PEMETREXED, PEMETREXED
PEMETREXED, PEMETREXED DISODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PEMFEXY, PEMETREXED
PENCICLOVIR, PENCICLOVIR
PENICILLAMINE, PENICILLAMINE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERAMPANEL, PERAMPANEL
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOGARD, CHLORHEXIDINE GLUCONATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
PFIZERPEN, PENICILLIN G POTASSIUM
PHEBURANE, SODIUM PHENYLBUTYRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHEXXI, CITRIC ACID
PHILITH, ETHINYL ESTRADIOL
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYRAGO, DASATINIB
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, PIPERACILLIN SODIUM
PIQRAY, ALPELISIB
PIRFENIDONE, PIRFENIDONE
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PIVYA, PIVMECILLINAM HYDROCHLORIDE
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLERIXAFOR, PLERIXAFOR
PLIAGLIS, LIDOCAINE
PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
PODOFILOX, PODOFILOX
POKONZA, POTASSIUM CHLORIDE
POLMON, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PONVORY, PONESIMOD
PORTIA-28, ETHINYL ESTRADIOL
POSACONAZOLE, POSACONAZOLE
POSFREA, PALONOSETRON HYDROCHLORIDE
POSLUMA, FLOTUFOLASTAT F-18 GALLIUM
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, POTASSIUM PHOSPHATE, DIBASIC
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALATREXATE, PRALATREXATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRASUGREL HYDROCHLORIDE, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PREGABALIN, PREGABALIN
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRETOMANID, PRETOMANID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVDUO, GLYCOPYRROLATE
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMOVIR
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PUR-WASH, PURIFIED WATER (OTC)
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLARIFY, PIFLUFOLASTAT F-18
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYQUVI, DEFLAZACORT
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE
PYRUKYND, MITAPIVAT SULFATE

**** Q ****

QALSODY, TOFERSEN
QAMZOVA, MELOXICAM
QBRELIS, LISINOPRIL
QBREXZA, GLYCOPYRRONIUM TOSYLATE
QELBREE, VILOXAZINE HYDROCHLORIDE
QFITLIA, FITUSIRAN SODIUM
QINLOCK, RIPRETINIB
QLOSI, PILOCARPINE HYDROCHLORIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** Q ****

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QULIPTA, ATOGEPANT
QUTENZA, CAPSAICIN
QUVIVIQ, DARIDOREXANT HYDROCHLORIDE
QUZYTTIR, CETIRIZINE HYDROCHLORIDE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADICAVA ORS, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RALDESY, TRAZODONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RALTEGRAVIR POTASSIUM, RALTEGRAVIR POTASSIUM
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAMUNE, SIROLIMUS
RAPIBLYK, LANDIOLOL HYDROCHLORIDE
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECORLEV, LEVOKETOCONAZOLE
RECTIV, NITROGLYCERIN
REDEMPLO, PLOZASIRAN SODIUM
REGADENOSON, REGADENOSON
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETEVMO, SELPERCATINIB
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REVUFORJ, REVUMENIB CITRATE
REXTOVY, NALOXONE HYDROCHLORIDE
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REYVOW, LASMIDITAN SUCCINATE
REZDIFFRA, RESMETIROM
REZLIDHIA, OLUTASIDENIB
REZUROCK, BELUMOSUDIL MESYLATE
REZZAYO, REZAFUNGIN ACETATE
RHAPSIDO, REMIBRUTINIB
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL MESYLATE
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMPIN, RIFAMPIN
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RINVOQ LQ, UPADACITINIB
RIOCIGUAT, RIOCIGUAT
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVAROXABAN, RIVAROXABAN
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIVFLOZA, NEDOSIRAN SODIUM
RIVIVE, NALOXONE HYDROCHLORIDE (OTC)
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMIDEPSIN, ROMIDEPSIN
ROMVIMZA, VIMSELTINIB
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXYBOND, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

RYALTRIS, MOMETASONE FUROATE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYKINDO, RISPERIDONE
RYTARY, CARBIDOPA
RYTELO, IMETELSTAT SODIUM
RYZUMVI, PHENTOLAMINE MESYLATE

**** S ****

SABRIL, VIGABATRIN
SACUBITRIL AND VALSARTAN, SACUBITRIL
SAFINAMIDE MESYLATE, SAFINAMIDE MESYLATE
SAFYRAL, DROSPIRENONE
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECUADO, ASENAPINE
SEGLUROMET, ERTUGLIFLOZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIOUS ACID, SELENIOUS ACID
SELENIUM SULFIDE, SELENIUM SULFIDE
SELEXIPAG, SELEXIPAG
SELZENTRY, MARAVIROC
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPHIENCE, SEPIAPTERIN
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SEZABY, PHENOBARBITAL SODIUM
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SIMBRINZA, BRIMONIDINE TARTRATE
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINCALIDE, SINCALIDE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE
SIVEXTRO, TEDIZOLID PHOSPHATE
SKLICE, IVERMECTIN (OTC)
SKYCLARYS, OMAVELOXOLONE
SKYLA, LEVONORGESTREL
SLYND, DROSPIRENONE
SMOFLIPID 20%, FISH OIL
SOAANZ, TORSEMIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOFDRA, SOFPIRONIUM BROMIDE
SOHONOS, PALOVAROTENE
SOJOURN, SEVOFLURANE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP S, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOOLANTRA, IVERMECTIN
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYKTU, DEUCRAVACITINIB
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SOVUNA, HYDROXYCHLOROQUINE SULFATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR IRRIGATION, STERILE WATER FOR IRRIGATION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBVENITE, LAMOTRIGINE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRALFATE, SUCRALFATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUFLAVE, MAGNESIUM SULFATE
SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SUNITINIB MALATE, SUNITINIB MALATE
SUNLENCA, LENACAPAVIR SODIUM
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUSTOL, GRANISETRON
SUTAB, MAGNESIUM SULFATE
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYFOVRE, PEGCETACOPLAN
SYMBICORT, BUDESONIDE
SYMBICORT AEROSPHERE, BUDESONIDE
SYMBRAVO, MELOXICAM
SYMDEKO (COPACKAGED), IVACAFTOR
SYMFI, EFAVIRENZ
SYMJEPI, EPINEPHRINE
SYMPAZAN, CLOBAZAM
SYMPROIC, NALDEMEDINE TOSYLATE
SYMTUZA, COBICISTAT
SYNALAR, FLUOCINOLONE ACETONIDE
SYNAREL, NAFARELIN ACETATE
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TABRECTA, CAPMATINIB HYDROCHLORIDE
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TADLIQ, TADALAFIL
TAFINLAR, DABRAFENIB MESYLATE
TAFLUPROST, TAFLUPROST
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALICIA, AMOXICILLIN
TALZENNA, TALAZOPARIB TOSYLATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARPEYO, BUDESONIDE
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TASIMELTEON, TASIMELTEON
TASMAR, TOLCAPONE
TAUVID, FLORTAUCIPIR F-18
TAVABOROLE, TAVABOROLE
TAVALISSE, FOSTAMATINIB DISODIUM
TAVNEOS, AVACOPAN
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNEGAS KIT, TECHNETIUM TC-99M LABELED CARBON
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TECHNETIUM TC-99M SULFUR COLLOID KIT, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKTURNA, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMBEXA, BRINCIDOFOVIR
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFOVIR ALAFENAMIDE, TENOFOVIR ALAFENAMIDE FUMARATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TEPADINA, THIOTEPA
TEPADINA AND SODIUM CHLORIDE, THIOTEPA
TEPMETKO, TEPOTINIB HYDROCHLORIDE
TEPYLUTE, THIOTEPA
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TERIPARATIDE, TERIPARATIDE
TERLIVAZ, TERLIPRESSIN ACETATE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIOLA EC, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THYQUIDITY, LEVOTHYROXINE SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** T ****

THYRO-TABS, LEVOTHYROXINE SODIUM **
THYROSAFE, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TIBSOVO, IVOSIDENIB
TICAGRELOR, TICAGRELOR
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIGLUTIK KIT, RILUZOLE
TIKOSYN, DOFETILIDE
TIMOLOL, TIMOLOL
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TISSUEBLUE, BRILLIANT BLUE G
TIVICAY, DOLUTEGRAVIR SODIUM
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TLANDO, TESTOSTERONE UNDECANOATE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TOFACITINIB CITRATE, TOFACITINIB CITRATE
TOLAK, FLUOROURACIL
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
TONMYA, CYCLOBENZAPRINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRALEMENT, CUPRIC SULFATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRETINOIN, TRETINOIN
TRETINOIN MICROSPHERE, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-LINYAH, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIJARDY XR, EMPAGLIFLOZIN
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR
TRILEPTAL, OXCARBAZEPINE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIUMEQ PD, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TROKENDI XR, TOPIRAMATE
TROMETHAMINE, TROMETHAMINE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRUDHESA, DIHYDROERGOTAMINE MESYLATE
TRULANCE, PLECANATIDE
TRUQAP, CAPIVASERTIB
TRUVADA, EMTRICITABINE
TRYNGOLZA (AUTOINJECTOR), OLEZARSEN SODIUM
TRYPTYR, ACOLTREMON
TRYVIO, APROCITENTAN
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUKYSA, TUCATINIB
TURALIO, PEXIDARTINIB HYDROCHLORIDE
TURQOZ, ETHINYL ESTRADIOL
TUXARIN ER, CHLORPHENIRAMINE MALEATE
TWIRLA, ETHINYL ESTRADIOL
TWYNEO, BENZOYL PEROXIDE
TYBLUME, ETHINYL ESTRADIOL
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYMLOS, ABALOPARATIDE
TYRVAYA, VARENICLINE TARTRATE
TYVASO, TREPROSTINIL
TYVASO DPI, TREPROSTINIL
TYZAVAN, VANCOMYCIN HYDROCHLORIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

UBRELVY, UBROGEPANT
UCERIS, BUDESONIDE
ULORIC, FEBUXOSTAT
ULSPIRA, NITRIC OXIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW V4, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE
UPTRAVI, SELEXIPAG
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSODIOL, URSODIOL
UVADEX, METHOXSALEN
UZEDY, RISPERIDONE

**** V ****

VABOMERE, MEROPENEM
VAFSEO, VADADUSTAT
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALBENAZINE TOSYLATE, VALBENAZINE TOSYLATE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM

APPENDIX A - PRODUCT NAME INDEX

** V **

VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTOCO, DIAZEPAM
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANFLYTA, QUIZARTINIB DIHYDROCHLORIDE
VANOS, FLUOCINONIDE
VANRAFIA, ATRASENTAN HYDROCHLORIDE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOPRESSIN, VASOPRESSIN
VASOPRESSIN IN DEXTROSE 5%, VASOPRESSIN
VASOPRESSIN IN SODIUM CHLORIDE 0.9%, VASOPRESSIN
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEKLURY, REMDESIVIR
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, FERRIC OXYHYDROXIDE
VELSIPITY, ETRASIMOD ARGININE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTOLIN HFA, ALBUTEROL SULFATE
VENXXIVA, TIOPRONIN
VEOZAH, FEZOLINETANT
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERKAZIA, CYCLOSPORINE
VERQUVO, VERICIGUAT
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VEVYE, CYCLOSPORINE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VICTOZA, LIRAGLUTIDE

APPENDIX A - PRODUCT NAME INDEX

** V **

VIDAZA, AZACITIDINE
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAFYDE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIGPODER, VIGABATRIN
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIJOICE, ALPELISIB
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VILTEPSO, VILTOLARSEN
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB SULFATE
VIVACAINE, BUPIVACAINE HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE
VIVITROL, NALTREXONE
VIVJOA, OTESECONAZOLE
VIZAMYL, FLUTEMETAMOL F-18
VIZIMPRO, DACOMITINIB
VIZZ, ACECLIDINE HYDROCHLORIDE
VOCABRIA, CABOTEGRAVIR SODIUM
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)
VONJO, PACRITINIB CITRATE
VOQUEZNA, VONOPRAZAN FUMARATE
VOQUEZNA DUAL PAK, AMOXICILLIN
VOQUEZNA TRIPLE PAK, AMOXICILLIN
VORANIGO, VORASIDENIB
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL HC, ACETIC ACID, GLACIAL
VOSTALLY, RAMIPRIL
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VOXZOGO, VOSORITIDE
VOYDEYA, DANICOPAN
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VTAMA, TAPINAROF
VUITY, PILOCARPINE HYDROCHLORIDE
VUMERITY, DIROXIMEL FUMARATE
VUSION, MICONAZOLE NITRATE
VYALEV, FOSCARBIDOPA
VYBRIQUE, SILDENAFIL CITRATE
VYDUO, NEBIVOLOL HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
VYKAT XR, DIAZOXIDE CHOLINE
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE
VYONDYS 53, GOLODIRSEN
VYSCOXA, CELECOXIB
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAINUA (AUTOINJECTOR), EPLONTERSEN SODIUM
WAKIX, PITOLISANT HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
WAYRILZ, RILZABRUTINIB
WEGOVY, SEMAGLUTIDE
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELIREG, BELZUTIFAN
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WINLEVI, CLASCOTERONE
WIXELA INHUB, FLUTICASONE PROPIONATE
WOMEN'S ROGAINE, MINOXIDIL (OTC)
WYNZORA, BETAMETHASONE DIPROPIONATE

**** X ****

XACDURO (COPACKAGED), DURLOBACTAM SODIUM
XACIATO, CLINDAMYCIN PHOSPHATE
XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XCOPRI, CENOBAMATE
XDEMVY, LOTILANER
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELSTRYM, DEXTROAMPHETAMINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENLETA, LEFAMULIN ACETATE
XENON XE 133, XENON XE-133
XENOVIEW, XENON XE-129 HYPERPOLARIZED
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIFYRM, MELOXICAM
XIGDUO XR, DAPAGLIFLOZIN
XIIDRA, LIFITEGRAST
XIPERE, TRIAMCINOLONE ACETONIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOFLUZA, BALOXAVIR MARBOXIL
XOLREMDI, MAVORIXAFOR
XOPENEX HFA, LEVALBUTEROL TARTRATE
XOSPATA, GILTERITINIB FUMARATE
XPHOZAH, TENAPANOR HYDROCHLORIDE
XPOVIO, SELINEXOR
XROMI, HYDROXYUREA
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE

APPENDIX A - PRODUCT NAME INDEX

**** X ****

XULANE, ETHINYL ESTRADIOL
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
XYREM, SODIUM OXYBATE
XYWAV, CALCIUM OXYBATE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

**** Y ****

YAELA, DROSPIRENONE
YARGESA, MIGLUSTAT
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YCANTH, CANTHARIDIN
YEZTUGO, LENACAPAVIR SODIUM
YONDELIS, TRABECTEDIN
YONSA, ABIRATERONE ACETATE
YORVIPATH, PALOPEGTERIPARATIDE
YUPELRI, REVEFENACIN
YUTIQ, FLUOCINOLONE ACETONIDE
YUTREPIA, TREPROSTINIL SODIUM

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAVESCA, MIGLUSTAT
ZAVZPRET, ZAVEGEPANT HYDROCHLORIDE
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEGFROVY, SUNVOZERTINIB
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZELSUVMI, BERDAZIMER SODIUM
ZELVYSIA, SAPROPTERIN DIHYDROCHLORIDE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZEPBOUND, TIRZEPATIDE
ZEPBOUND (AUTOINJECTOR), TIRZEPATIDE
ZEPOSIA, OZANIMOD HYDROCHLORIDE
ZEPZELCA, LURBINECTEDIN
ZERBAXA, CEFTOLOZANE SULFATE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZEVTERA, CEFTOBIPROLE MEDOCARIL SODIUM
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILBRYSQ, ZILUCOPLAN SODIUM
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE
ZIMHI, NALOXONE HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZINC SULFATE, ZINC SULFATE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZITUVIMET, METFORMIN HYDROCHLORIDE
ZITUVIMET XR, METFORMIN HYDROCHLORIDE
ZITUVIO, SITAGLIPTIN
ZOCOR, SIMVASTATIN
ZOKINVY, LONAFARNIB
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLYMBUS, BIMATOPROST
ZOMIG, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISADE, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZORTRESS, EVEROLIMUS
ZORYVE, ROFLUMILAST
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIRAX, ACYCLOVIR
ZTALMY, GANAXOLONE
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUMANDIMINE, DROSPIRENONE
ZUNVEYL, BENZGALANTAMINE GLUCONATE
ZURAGARD, ISOPROPYL ALCOHOL (OTC)
ZURNAI (AUTOINJECTOR), NALMEFENE HYDROCHLORIDE
ZURZUVAE, ZURANOLONE
ZUSDURI, MITOMYCIN
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAXID, GATIFLOXACIN
ZYNRELEF KIT, BUPIVACAINE
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3D IMAGING DRUG
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M
* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M HEALTH CARE
* 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP S, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ****

60 DEGREES PHARMS
* 60 DEGREES PHARMACEUTICALS INC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ****

AAA USA INC
* ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM LU 177 DOTATATE
NETSPOT, GALLIUM DOTATATE GA-68

AADI SUB
* AADI SUBSIDIARY INC
FYARRO, SIROLIMUS

AAIPHARMA LLC
* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

AARXION ANDA HLDING
* AARXION ANDA HOLDING LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

ABBVIE
* ABBVIE
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
* ABBVIE INC
ACULAR LS, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
AVYCAZ, AVIBACTAM SODIUM
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CELEXA, CITALOPRAM HYDROBROMIDE
COMBIGAN, BRIMONIDINE TARTRATE
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DUOPA, CARBIDOPA
DURYSTA, BIMATOPROST
EMBLAVEO, AVIBACTAM SODIUM
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
GENGRAF, CYCLOSPORINE
KALETRA, LOPINAVIR
KYBELLA, DEOXYCHOLIC ACID
LASTACAFT, ALCAFTADINE (OTC)
LATISSE, BIMATOPROST
LEXAPRO, ESCITALOPRAM OXALATE
LINZESS, LINACLOTIDE
LUMIGAN, BIMATOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ABBVIE INC
MAVYRET, GLECAPREVIR
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NORVIR, RITONAVIR
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
OZURDEX, DEXAMETHASONE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
QULIPTA, ATOGEPANT
RECTIV, NITROGLYCERIN
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
RINVOQ LQ, UPADACITINIB
RINVOQ, UPADACITINIB
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SYNTHROID, LEVOTHYROXINE SODIUM **
TEFLARO, CEFTAROLINE FOSAMIL
UBRELVY, UBROGEPANT
ULTANE, SEVOFLURANE
VENCLEXTA, VENETOCLAX
VIBERZI, ELUXADOLINE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUITY, PILOCARPINE HYDROCHLORIDE
VYALEV, FOSCARBIDOPA
ZEMPLAR, PARICALCITOL
ZYMAXID, GATIFLOXACIN

ABBVIE ENDOCRINE INC
* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE

ABHAI LLC
* ABHAI LLC
ATOVAQUONE, ATOVAQUONE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEFLUNOMIDE, LEFLUNOMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC
* ABON PHARMACEUTICALS LLC
ERYTHROMYCIN, ERYTHROMYCIN
GABAPENTIN, GABAPENTIN
SUCRALFATE, SUCRALFATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ABRAXIS PHARM
* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACACIA
* ACACIA PHARMA LTD
BARHEMSYS, AMISULPRIDE
BYFAVO, REMIMAZOLAM BESYLATE

ACADIA PHARMS INC
* ACADIA PHARMACEUTICALS INC
DAYBUE STIX, TROFINETIDE
DAYBUE, TROFINETIDE
NUPLAZID, PIMAVANSERIN TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ACCELRX LABS

* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD

* ACCORD BIOPHARMA INC
CAMCEVI KIT, LEUPROLIDE MESYLATE

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
APIXABAN, APIXABAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CABAZITAXEL, CABAZITAXEL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DEHYDRATED ALCOHOL, ALCOHOL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPLERENONE, EPLERENONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LENALIDOMIDE, LENALIDOMIDE
LETROZOLE, LETROZOLE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACLITAXEL, PACLITAXEL
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
REGADENOSON, REGADENOSON
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC
* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN

ACELLA
* ACELLA PHARMACEUTICALS LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
LACOSAMIDE, LACOSAMIDE
NIFEDIPINE, NIFEDIPINE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC
* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACER
* ACER THERAPEUTICS INC
OLPRUVA, SODIUM PHENYLBUTYRATE

ACERTIS PHARMS
* ACERTIS PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE

ACERUS
* ACERUS PHARMACEUTICALS CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACQ PHARMA

* ACQ PHARMA LLC
MISOPROSTOL, MISOPROSTOL

ACROTECH BIOPHARMA

* ACROTECH BIOPHARMA INC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
KHAPZORY, LEVOLEUCOVORIN

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS

* ACTAVIS LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
OXALIPLATIN, OXALIPLATIN
PEMETREXED, PEMETREXED

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
LAMOTRIGINE, LAMOTRIGINE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
FIDAXOMICIN, FIDAXOMICIN
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
ISOTRETINOIN, ISOTRETINOIN
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
AMPHETAMINE, AMPHETAMINE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
GEFITINIB, GEFITINIB
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LEVETIRACETAM, LEVETIRACETAM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM
OMEPRAZOLE, OMEPRAZOLE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE, PHENTERMINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RAMELTEON, RAMELTEON
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LABORATORIES UT INC
AZELAIC ACID, AZELAIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
FIORICET W/ CODEINE, ACETAMINOPHEN
LIDOCAINE, LIDOCAINE
SCOPOLAMINE, SCOPOLAMINE
TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
PIMECROLIMUS, PIMECROLIMUS
TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LEVETIRACETAM, LEVETIRACETAM
MESALAMINE, MESALAMINE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
VALNAC, BETAMETHASONE VALERATE

* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION

* ACTELION PHARMACEUTICALS US INC
OPSUMIT, MACITENTAN
OPSYNVI, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
ZAVESCA, MIGLUSTAT

ADAMIS PHARMS CORP

* ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE

ADAPTIS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ADAPTIS PHARMA PRIVATE LTD
BICALUTAMIDE, BICALUTAMIDE
DROXIDOPA, DROXIDOPA
DUTASTERIDE, DUTASTERIDE
EPLERENONE, EPLERENONE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN, NAPROXEN
PASER, AMINOSALICYLIC ACID
PREGABALIN, PREGABALIN
TETRABENAZINE, TETRABENAZINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ADARE PHARMS INC
* ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADIENNE SA
* ADIENNE SA
TEPADINA AND SODIUM CHLORIDE, THIOTEPA
TEPADINA, THIOTEPA

ADVANZ PHARMA
* ADVANZ PHARMA (US) CORP
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
PANRETIN, ALITRETINOIN
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE

AET PHARMA
* AET PHARMA US INC
LEFLUNOMIDE, LEFLUNOMIDE
POSACONAZOLE, POSACONAZOLE

AFAXYS
* AFAXYS PHARMA LLC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

AFT PHARMS US
* AFT PHARMACEUTICALS US INC
COMBOGESIC, ACETAMINOPHEN

AGEPHA PHARMA FZ
* AGEPHA PHARMA FZ LLC
LODOCO, COLCHICINE

AGILE
* AGILE THERAPEUTICS INC
TWIRLA, ETHINYL ESTRADIOL

AGIOS PHARMS INC
* AGIOS PHARMACEUTICALS INC
PYRUKYND, MITAPIVAT SULFATE

AGNITIO
* AGNITIO INC
ETHACRYNIC ACID, ETHACRYNIC ACID
PHYTONADIONE, PHYTONADIONE
TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS
* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC
* AILEX PHARMACEUTICALS LLC
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AILEX PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METHIMAZOLE, METHIMAZOLE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
PREVALITE, CHOLESTYRAMINE
RIVAROXABAN, RIVAROXABAN
SORINE, SOTALOL HYDROCHLORIDE

AIRGAS THERAP

* AIRGAS THERAPEUTICS LLC
ULSPIRA, NITRIC OXIDE

AIZANT

* AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PIRFENIDONE, PIRFENIDONE
ZILEUTON, ZILEUTON
* AIZANT DRUG RESEARCH SOLUTIONS PVT LTD
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CAPTOPRIL, CAPTOPRIL
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AJANTA PHARMA LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TOFACITINIB CITRATE, TOFACITINIB CITRATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPIRAMATE, TOPIRAMATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AJENAT PHARMS
* AJENAT PHARMACEUTICALS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CEFIXIME, CEFIXIME
CEPHALEXIN, CEPHALEXIN
CHLORZOXAZONE, CHLORZOXAZONE
DESLORATADINE, DESLORATADINE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
LACOSAMIDE, LACOSAMIDE
LEVETIRACETAM, LEVETIRACETAM
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS
TRANXENE, CLORAZEPATE DIPOTASSIUM

AKARX INC
* AKARX INC
DOPTELET SPRINKLE, AVATROMBOPAG MALEATE
DOPTELET, AVATROMBOPAG MALEATE

AKEBIA
* AKEBIA THERAPEUTICS INC
VAFSEO, VADADUSTAT

ALCON
* ALCON LABORATORIES INC
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
* ALCON RESEARCH LLC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

ALCON LABS
* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
EYSUVIS, LOTEPREDNOL ETABONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALCON LABORATORIES INC
FLUORESCITE, FLUORESCEIN SODIUM
INVELTYS, LOTEPREDNOL ETABONATE
ISOPTO ATROPINE, ATROPINE SULFATE
MYDRIACYL, TROPICAMIDE
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
RHOPRESSA, NETARSUDIL MESYLATE
ROCKLATAN, LATANOPROST
SIMBRINZA, BRIMONIDINE TARTRATE
TRYPTYR, ACOLTREMON

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC

* ALEMBIC PHARMACEUTICALS LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACITRETIN, ACITRETIN
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ALBENDAZOLE, ALBENDAZOLE
ALCAFTADINE, ALCAFTADINE (OTC)
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ASENAPINE MALEATE, ASENAPINE MALEATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BIMATOPROST, BIMATOPROST
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BOSUTINIB MONOHYDRATE, BOSUTINIB MONOHYDRATE
BREXPIPRAZOLE, BREXPIPRAZOLE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARMUSTINE, CARMUSTINE
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DAPSONE, DAPSONE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DASATINIB, DASATINIB
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESONIDE, DESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD

DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LOTEPREDNOL ETABONATE AND TOBRAMYCIN, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MACITENTAN, MACITENTAN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MUPIROCIN, MUPIROCIN CALCIUM
NADOLOL, NADOLOL
NELARABINE, NELARABINE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
RIVAROXABAN, RIVAROXABAN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SACUBITRIL AND VALSARTAN, SACUBITRIL
SELEXIPAG, SELEXIPAG
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERIFLUNOMIDE, TERIFLUNOMIDE
THEOPHYLLINE, THEOPHYLLINE
TICAGRELOR, TICAGRELOR
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ALEMBIC GLOBAL

* ALEMBIC GLOBAL HOLDING SA
TREPROSTINIL, TREPROSTINIL

ALEMBIC LTD

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALEXION PHARMS INC

* ALEXION PHARMACEUTICALS INC
VOYDEYA, DANICOPAN

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALIGNSCIENCE PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE
YUTIQ, FLUOCINOLONE ACETONIDE

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APREMILAST, APREMILAST
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE, AZILSARTAN KAMEDOXOMIL
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBAMAZEPINE, CARBAMAZEPINE
CEFDINIR, CEFDINIR
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN, ERYTHROMYCIN
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EVEROLIMUS, EVEROLIMUS
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD

FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN
ITRACONAZOLE, ITRACONAZOLE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MARINOL, DRONABINOL
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRABEGRON, MIRABEGRON
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NIFEDIPINE, NIFEDIPINE
NIMODIPINE, NIMODIPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIVAROXABAN, RIVAROXABAN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SACUBITRIL AND VALSARTAN, SACUBITRIL
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TICAGRELOR, TICAGRELOR
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLVAPTAN, TOLVAPTAN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ALKERMES
* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES INC
* ALKERMES INC
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTADA, ARIPIPRAZOLE LAUROXIL
LYBALVI, OLANZAPINE

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN
* ALLERGAN INC
OCUFLOX, OFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
* ALLERGAN SALES LLC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CONDYLOX, PODOFILOX
ESTRACE, ESTRADIOL
INFED, IRON DEXTRAN
OXYTROL, OXYBUTYNIN
SAPHRIS, ASENAPINE MALEATE

ALMAJECT
* ALMAJECT INC
TERIPARATIDE, TERIPARATIDE

ALMATICA
* ALMATICA PHARMA INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
GRALISE, GABAPENTIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ALMATICA PHARMA LLC
ESCITALOPRAM, ESCITALOPRAM OXALATE
LOREEV XR, LORAZEPAM
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
ZESTORETIC, HYDROCHLOROTHIAZIDE

ALMIRALL
* ALMIRALL LLC
ACZONE, DAPSONE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
CORDRAN, FLURANDRENOLIDE
KLISYRI, TIRBANIBULIN
SEYSARA, SARECYCLINE HYDROCHLORIDE
TAZORAC, TAZAROTENE
VELTIN, CLINDAMYCIN PHOSPHATE

ALNYLAM PHARMS INC
* ALNYLAM PHARMACEUTICALS INC
AMVUTTRA, VUTRISIRAN SODIUM
GIVLAARI, GIVOSIRAN SODIUM
ONPATTRO, PATISIRAN SODIUM
OXLUMO, LUMASIRAN SODIUM

ALPHA COGNITION
* ALPHA COGNITION INC
ZUNVEYL, BENZGALANTAMINE GLUCONATE

ALTAIRE PHARMS INC
* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALTAIRE PHARMACEUTICALS INC
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
BONSITY, TERIPARATIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM, DISULFIRAM
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
THYRO-TABS, LEVOTHYROXINE SODIUM **

AM GENOMICS

* AMERICAN GENOMICS LLC
CYKLX, ARTICAINE HYDROCHLORIDE

AM REGENT

* AMERICAN REGENT INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ATROPINE SULFATE, ATROPINE SULFATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EPINEPHRINE, EPINEPHRINE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FOMEPIZOLE, FOMEPIZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INJECTAFER, FERRIC CARBOXYMALTOSE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEVOCARNITINE, LEVOCARNITINE
METHOCARBAMOL, METHOCARBAMOL
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MULTRYS, CUPRIC SULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
PACLITAXEL, PACLITAXEL
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
SELENIOUS ACID, SELENIOUS ACID
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TRALEMENT, CUPRIC SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VASOPRESSIN, VASOPRESSIN
VENOFER, IRON SUCROSE
ZINC SULFATE, ZINC SULFATE

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMGEN INC

* AMGEN INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMGEN INC
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
OTEZLA XR, APREMILAST
OTEZLA, APREMILAST

AMICI PHARMA

* AMICI PHARMA INC
CATAFLAM, DICLOFENAC POTASSIUM
DIGOXIN, DIGOXIN

AMICUS THERAP US

* AMICUS THERAPEUTICS US LLC
GALAFOLD, MIGALASTAT HYDROCHLORIDE
OPFOLDA, MIGLUSTAT

AMIVAS

* AMIVAS INC
ARTESUNATE, ARTESUNATE

AMNEAL

* AMNEAL EU LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZACITIDINE, AZACITIDINE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUSULFAN, BUSULFAN
CALCITONIN-SALMON, CALCITONIN SALMON
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CLOFARABINE, CLOFARABINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARUNAVIR, DARUNAVIR
DEFLAZACORT, DEFLAZACORT
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIFLUPREDNATE, DIFLUPREDNATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPINEPHRINE, EPINEPHRINE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETRAVIRINE, ETRAVIRINE
EVEROLIMUS, EVEROLIMUS
EXENATIDE SYNTHETIC, EXENATIDE SYNTHETIC
FLUOROMETHOLONE, FLUOROMETHOLONE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IOHEXOL, IOHEXOL
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LENALIDOMIDE, LENALIDOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL EU LTD
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
NELARABINE, NELARABINE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PLERIXAFOR, PLERIXAFOR
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, POTASSIUM PHOSPHATE, DIBASIC
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPOFOL, PROPOFOL
RISPERIDONE, RISPERIDONE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIOTHIXENE, THIOTHIXENE
TICAGRELOR, TICAGRELOR
TIOPRONIN, TIOPRONIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VASOPRESSIN, VASOPRESSIN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
ACYCLOVIR, ACYCLOVIR
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE (OTC)
BACLOFEN, BACLOFEN
BEXAROTENE, BEXAROTENE
BREKIYA (AUTOINJECTOR), DIHYDROERGOTAMINE MESYLATE
BUPRENORPHINE, BUPRENORPHINE
CABERGOLINE, CABERGOLINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYCLOSPORINE, CYCLOSPORINE
DAPSONE, DAPSONE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ELURYNG, ETHINYL ESTRADIOL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESTRADIOL, ESTRADIOL
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS LLC
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LIDOCAINE, LIDOCAINE
LIORESAL, BACLOFEN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MESALAMINE, MESALAMINE
MUPIROCIN, MUPIROCIN CALCIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
NAPROXEN, NAPROXEN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ONGENTYS, OPICAPONE
PENCICLOVIR, PENCICLOVIR
POSACONAZOLE, POSACONAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
SCOPOLAMINE, SCOPOLAMINE
SIROLIMUS, SIROLIMUS
SODIUM OXYBATE, SODIUM OXYBATE
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
TESTOSTERONE, TESTOSTERONE
TIGECYCLINE, TIGECYCLINE
ZOMIG, ZOLMITRIPTAN

AMNEAL IRELAND LTD

* AMNEAL IRELAND LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BECLOMETHASONE DIPROPIONATE, BECLOMETHASONE DIPROPIONATE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LORAZEPAM, LORAZEPAM
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
PALIPERIDONE, PALIPERIDONE
PARICALCITOL, PARICALCITOL
RIVASTIGMINE, RIVASTIGMINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARGATROBAN, ARGATROBAN
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOBAZAM, CLOBAZAM
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERYTHROMYCIN, ERYTHROMYCIN
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
EZETIMIBE, EZETIMIBE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
NADOLOL, NADOLOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
PREGABALIN, PREGABALIN
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TRANEXAMIC ACID, TRANEXAMIC ACID

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
BEXAROTENE, BEXAROTENE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
ISOTRETINOIN, ISOTRETINOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NY LLC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PROGESTERONE, PROGESTERONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
BAQSIMI, GLUCAGON
CORTROSYN, COSYNTROPIN
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GLUCAGON, GLUCAGON
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
REXTOVY, NALOXONE HYDROCHLORIDE
TERIPARATIDE, TERIPARATIDE
VASOPRESSIN, VASOPRESSIN

AMRING PHARMS

* AMRING PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LYSTEDA, TRANEXAMIC ACID
MESALAMINE, MESALAMINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

AMTA

* AMTA LABS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
MESALAMINE, MESALAMINE
NISOLDIPINE, NISOLDIPINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
EUCRISA, CRISABOROLE

ANBEX

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB

* ANBISON LABORATORY CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANDA REPOSITORY

* ANDA REPOSITORY LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CALCITRIOL, CALCITRIOL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORZOXAZONE, CHLORZOXAZONE
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
FLAC, FLUOCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANDA REPOSITORY LLC
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

ANDAS 5 HOLDING

* ANDAS 5 HOLDING LLC
BACLOFEN, BACLOFEN
CAPTOPRIL, CAPTOPRIL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
RAMELTEON, RAMELTEON

ANDOR PHARMS

* ANDOR PHARMACEUTICALS LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BEXAROTENE, BEXAROTENE
BRETHINE, TERBUTALINE SULFATE
CARBAMAZEPINE, CARBAMAZEPINE
CASODEX, BICALUTAMIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CORTENEMA, HYDROCORTISONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC
FELBAMATE, FELBAMATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LITHOBID, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
LUVOX, FLUVOXAMINE MALEATE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIGLUSTAT, MIGLUSTAT
MISOPROSTOL, MISOPROSTOL
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANI PHARMACEUTICALS INC
NITAZOXANIDE, NITAZOXANIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXISTAT, OXICONAZOLE NITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PINDOLOL, PINDOLOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CITRATE, POTASSIUM CITRATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROIC ACID, VALPROIC ACID
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VEREGEN, SINECATECHINS

ANIMA

* ANIMA PHARMACEUTICALS PVT LTD
TRIACIN-C, CODEINE PHOSPHATE

ANNORA

* ANNORA PHARMA PRIVATE LTD
APREMILAST, APREMILAST
DROXIDOPA, DROXIDOPA
LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA

* ANNORA PHARMA PRIVATE LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
COLCHICINE, COLCHICINE
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELTROMBOPAG OLAMINE, ELTROMBOPAG OLAMINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPLERENONE, EPLERENONE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NIMODIPINE, NIMODIPINE
NITAZOXANIDE, NITAZOXANIDE
NITROFURANTOIN, NITROFURANTOIN
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANNORA PHARMA PRIVATE LTD
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SPIRONOLACTONE, SPIRONOLACTONE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZAFIRLUKAST, ZAFIRLUKAST
ZILEUTON, ZILEUTON

ANTARES PHARMA INC
* ANTARES PHARMA INC
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTHEA PHARMA
* ANTHEA PHARMA PRIVATE LTD
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM BICARBONATE, SODIUM BICARBONATE

ANTIBIOTICE
* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

AOP HLTH US
* AOP HEALTH US LLC
RAPIBLYK, LANDIOLOL HYDROCHLORIDE

APELLIS PHARMS
* APELLIS PHARMACEUTICALS INC
EMPAVELI, PEGCETACOPLAN
SYFOVRE, PEGCETACOPLAN

APGDI
* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ GRANULES, MIRABEGRON
MYRBETRIQ, MIRABEGRON

APIL
* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ATELVIA, RISEDRONATE SODIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP
* APNAR PHARMA LP
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOTEX
* APOTEX INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
AXITINIB, AXITINIB
AZELASTINE HYDROCHLORIDE ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE (OTC)
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBAMAZEPINE, CARBAMAZEPINE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CELECOXIB, CELECOXIB
CILOSTAZOL, CILOSTAZOL
CLADRIBINE, CLADRIBINE
CYCLOSPORINE, CYCLOSPORINE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DASATINIB, DASATINIB
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE, DEXAMETHASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEFITINIB, GEFITINIB
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMATINIB MESYLATE, IMATINIB MESYLATE
IVRA, MELPHALAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LORATADINE, LORATADINE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MOMETASONE FUROATE, MOMETASONE FUROATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRFENIDONE, PIRFENIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
REGADENOSON, REGADENOSON
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVAROXABAN, RIVAROXABAN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TASIMELTEON, TASIMELTEON
TERIPARATIDE, TERIPARATIDE
TETRABENAZINE, TETRABENAZINE
TICAGRELOR, TICAGRELOR
TIGECYCLINE, TIGECYCLINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLVAPTAN, TOLVAPTAN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZINC SULFATE, ZINC SULFATE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APOTEX INC

* APOTEX INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LEVETIRACETAM, LEVETIRACETAM
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE

APOZEAL PHARMS

* APOZEAL PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOZEAL PHARMACEUTICALS INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
RISPERIDONE, RISPERIDONE

APP PHARMS
* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO
* APPCO PHARMA LLC
BUMETANIDE, BUMETANIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MODAFINIL, MODAFINIL
PERPHENAZINE, PERPHENAZINE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
RAMELTEON, RAMELTEON
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

APRECIA PHARMS
* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

ARBOR PHARMS LLC
* ARBOR PHARMACEUTICALS LLC
SKLICE, IVERMECTIN (OTC)

ARCUTIS
* ARCUTIS BIOTHERAPEUTICS INC
ZORYVE, ROFLUMILAST

ARDELYX INC
* ARDELYX INC
IBSRELA, TENAPANOR HYDROCHLORIDE
XPHOZAH, TENAPANOR HYDROCHLORIDE

AREVA PHARMS
* AREVA PHARMACEUTICALS INC
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC
* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ARROW INTL
* ARROW INTERNATIONAL LTD
LENALIDOMIDE, LENALIDOMIDE

ARROWHEAD
* ARROWHEAD PHARMACEUTICALS INC
REDEMPLO, PLOZASIRAN SODIUM

ARS PHARMS OPERATION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ARS PHARMACEUTICALS OPERATIONS INC
NEFFY, EPINEPHRINE

ARTHUR GRP

* ARTHUR GROUP LLC
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
ESTROGEL, ESTRADIOL

ASCENDIS PHARMA BONE

* ASCENDIS PHARMA BONE DISEASES AS
YORVIPATH, PALOPEGTERIPARATIDE

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DRONABINOL, DRONABINOL
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LUBIPROSTONE, LUBIPROSTONE
MELOXICAM, MELOXICAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIRABEGRON, MIRABEGRON
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
RIVAROXABAN, RIVAROXABAN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SODIUM OXYBATE, SODIUM OXYBATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ASIO HOLDINGS

* ASIO HOLDINGS LLC
CAMBIA, DICLOFENAC POTASSIUM
ZIPSOR, DICLOFENAC POTASSIUM

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
CYCLESSA, DESOGESTREL

ASPIRO

* ASPIRO PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ASPIRO PHARMA LTD
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROPOFOL, PROPOFOL
SELENIOUS ACID, SELENIOUS ACID
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZINC SULFATE, ZINC SULFATE

ASSERTIO SPECLTY

* ASSERTIO SPECIALTY PHARMACEUTICALS LLC
SYMPAZAN, CLOBAZAM

ASTELLAS

* ASTELLAS PHARMA US INC
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
CRESEMBA, ISAVUCONAZONIUM SULFATE
IZERVAY, AVACINCAPTAD PEGOL SODIUM
LEXISCAN, REGADENOSON
PROGRAF, TACROLIMUS
VEOZAH, FEZOLINETANT
XOSPATA, GILTERITINIB FUMARATE
XTANDI, ENZALUTAMIDE

ASTRAZENECA

* ASTRAZENECA LP
SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
AIRSUPRA, ALBUTEROL SULFATE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BRILINTA, TICAGRELOR
DALIRESP, ROFLUMILAST
FASLODEX, FULVESTRANT
IRESSA, GEFITINIB
KOSELUGO, SELUMETINIB SULFATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LYNPARZA, OLAPARIB
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
SYMBICORT AEROSPHERE, BUDESONIDE
TAGRISSO, OSIMERTINIB MESYLATE
TRUQAP, CAPIVASERTIB
* ASTRAZENECA UK LTD
CALQUENCE, ACALABRUTINIB
CALQUENCE, ACALABRUTINIB MALEATE
CRESTOR, ROSUVASTATIN CALCIUM

ASTRAZENECA AB

* ASTRAZENECA AB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ASTRAZENECA AB
BREZTRI AEROSPHERE, BUDESONIDE
FARXIGA, DAPAGLIFLOZIN
WAINUA (AUTOINJECTOR), EPLONTERSEN SODIUM
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ATHEM

* ATHEM HOLDINGS LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

ATHENA

* ATHENA BIOSCIENCE LLC
NEXICLON XR, CLONIDINE

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA

* AUCTA PHARMACEUTICALS INC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
DEFERASIROX, DEFERASIROX
MOTPOLY XR, LACOSAMIDE
OXCARBAZEPINE, OXCARBAZEPINE
PYQUVI, DEFLAZACORT
VIGADRONE, VIGABATRIN
ZELVYSIA, SAPROPTERIN DIHYDROCHLORIDE

AURINIA

* AURINIA PHARMACEUTICALS INC
LUPKYNIS, VOCLOSPORIN

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
AFIRMELLE, ETHINYL ESTRADIOL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATENOLOL, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZELASTINE HYDROCHLORIDE ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARBIDOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMZAHH, NORETHINDRONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE, FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
GLYCOPYRROLATE, GLYCOPYRROLATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
INCASSIA, NORETHINDRONE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOTRETINOIN, ISOTRETINOIN
KALLIGA, DESOGESTREL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LO SIMPESSE, ETHINYL ESTRADIOL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MIRTAZAPINE, MIRTAZAPINE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL, NADOLOL
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEXESTA FE, ETHINYL ESTRADIOL
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYSTATIN, NYSTATIN
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POSACONAZOLE, POSACONAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RIBAVIRIN, RIBAVIRIN
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RUFINAMIDE, RUFINAMIDE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDOLAPRIL, TRANDOLAPRIL
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRI-LO-MILI, ETHINYL ESTRADIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARIPIPRAZOLE, ARIPIPRAZOLE
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
BACLOFEN, BACLOFEN
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARIPRAZINE HYDROCHLORIDE, CARIPRAZINE HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DAPSONE, DAPSONE
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
DEFLAZACORT, DEFLAZACORT
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIGOXIN, DIGOXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCOSANOL, DOCOSANOL (OTC)
DOFETILDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FELODIPINE, FELODIPINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCYTOSINE, FLUCYTOSINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
HALOPERIDOL, HALOPERIDOL
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LACTULOSE, LACTULOSE
LANSOPRAZOLE, LANSOPRAZOLE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LINAGLIPTIN, LINAGLIPTIN
LO-ZUMANDIMINE, DROSPIRENONE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MACITENTAN, MACITENTAN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OLANZAPINE, OLANZAPINE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PYRIMETHAMINE, PYRIMETHAMINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIVAROXABAN, RIVAROXABAN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRI-MILI, ETHINYL ESTRADIOL
URSODIOL, URSODIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN
VORICONAZOLE, VORICONAZOLE
ZONISAMIDE, ZONISAMIDE
ZUMANDIMINE, DROSPIRENONE
* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

* AUROBINDO PHARMA USA INC
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLONAZEPAM, CLONAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ELIMITE, PERMETHRIN
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROLIFE PHARMA LLC
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AVADEL CNS
* AVADEL CNS PHARMACEUTICALS LLC
LUMRYZ, SODIUM OXYBATE

AVANIR PHARMS
* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC
* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA
* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVEO PHARMS
* AVEO PHARMACEUTICALS INC
FOTIVDA, TIVOZANIB HYDROCHLORIDE

AVERITAS
* AVERITAS PHARMA INC
MOVANTIK, NALOXEGOL OXALATE
QUTENZA, CAPSAICIN

AVET
* AVET PHARMACEUTICALS INC
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL

AVET LIFESCIENCES
* AVET LIFESCIENCES LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPOFOL, PROPOFOL
TRANEXAMIC ACID, TRANEXAMIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
* AVET LIFESCIENCES PRIVATE LTD
AMPHOTERICIN B, AMPHOTERICIN B
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
FOSCARNET SODIUM, FOSCARNET SODIUM
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AVET LIFESCIENCES PRIVATE LTD
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18
TAUVID, FLORTAUCIPIR F-18

AVION PHARMS

* AVION PHARMACEUTICALS LLC
AVERI, DESOGESTREL
BALCOLTRA, ETHINYL ESTRADIOL
DHIVY, CARBIDOPA
PONSTEL, MEFENAMIC ACID

AVONDALE PHARMS

* AVONDALE PHARMACEUTICALS LLC
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
MELOXICAM, MELOXICAM
NIACOR, NIACIN

AVYXA HOLDINGS

* AVYXA HOLDINGS LLC
AVGEMSI, GEMCITABINE HYDROCHLORIDE
AXTLE, PEMETREXED DIPOTASSIUM
DOCIVYX, DOCETAXEL
FRINDOVYX, CYCLOPHOSPHAMIDE
KYXATA, CARBOPLATIN
POSFREA, PALONOSETRON HYDROCHLORIDE

AXSOME

* AXSOME THERAPEUTICS INC
AUVELITY, BUPROPION HYDROCHLORIDE
SYMBRAVO, MELOXICAM

AXSOME MALTA

* AXSOME MALTA LTD
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE

AYANA PHARMA LTD

* AYANA PHARMA LTD
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

AYRMID PHARMA

* AYRMID PHARMA LTD
APHEXDA, MOTIXAFORTIDE ACETATE

AYTU

* AYTU BIOSCIENCE INC
KARBINAL ER, CARBINOXAMINE MALEATE

AYTU BIOPHARMA

* AYTU BIOPHARMA INC
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

AZURITY

* AZURITY PHARMACEUTICALS INC
ARYNTA, LISDEXAMFETAMINE DIMESYLATE
AZMIRO, TESTOSTERONE CYPIONATE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BRYNOVIN, SITAGLIPTIN HYDROCHLORIDE
DANZITEN, NILOTINIB TARTRATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EPANED, ENALAPRIL MALEATE
EPRONTIA, TOPIRAMATE
EVEKEO, AMPHETAMINE SULFATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLEQSUVY, BACLOFEN
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GOLYTELY, POLYETHYLENE GLYCOL 3350

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AZURITY PHARMACEUTICALS INC
HORIZANT, GABAPENTIN ENACARBIL
JAVADIN, CLONIDINE HYDROCHLORIDE
KATERZIA, AMLODIPINE BENZOATE
KONVOMEP, OMEPRAZOLE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
MYHIBBIN, MYCOPHENOLATE MOFETIL
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NYMALIZE, NIMODIPINE
PREVDUO, GLYCOPYRROLATE
QBRELIS, LISINOPRIL
SOTYLIZE, SOTALOL HYDROCHLORIDE
SUFLAVE, MAGNESIUM SULFATE
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUTAB, MAGNESIUM SULFATE
TRIPTODUR KIT, TRIPTORELIN PAMOATE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE
XATMEP, METHOTREXATE SODIUM
XIFYRM, MELOXICAM
ZONISADE, ZONISAMIDE

**** B ****

B BRAUN

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL

* B BRAUN MEDICAL INC
ACETAMINOPHEN, ACETAMINOPHEN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, PIPERACILLIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SUGAMMADEX SODIUM, SUGAMMADEX SODIUM
TROMETHAMINE, TROMETHAMINE

BAJAJ

* BAJAJ MEDICAL
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
LACTULOSE, LACTULOSE

* BAJAJ MEDICAL LLC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BAMF

* BAMF HEALTH INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BANNER LIFE SCIENCES

* BANNER LIFE SCIENCES LLC
BAFIERTAM, MONOMETHYL FUMARATE

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
JUNEL 1.5/30, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BARR LABORATORIES INC
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
SPRINTEC, ETHINYL ESTRADIOL
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL

* BARR LABORATORIES INC A WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
LANTHANUM CARBONATE, LANTHANUM CARBONATE

* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS

* BARR LABORATORIES LLC (AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC)
DIPYRIDAMOLE, DIPYRIDAMOLE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
JUNEL 1/20, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL

BARR LABS INC

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
ESTRADIOL, ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH

* BAUSCH HEALTH AMERICAS INC
ACANYA, BENZOYL PEROXIDE
BRYHALI, HALOBETASOL PROPIONATE
DUOBRII, HALOBETASOL PROPIONATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
JUBLIA, EFINACONAZOLE
LOCOID, HYDROCORTISONE BUTYRATE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN
SYPRINE, TRIENTINE HYDROCHLORIDE

* BAUSCH HEALTH IRELAND LTD
TARGRETIN, BEXAROTENE

* BAUSCH HEALTH US LLC
ANCOBON, FLUCYTOSINE
APLENZIN, BUPROPION HYDROBROMIDE
ARAZLO, TAZAROTENE
ATIVAN, LORAZEPAM
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
CABTREO, ADAPALENE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH HEALTH US LLC
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
DEMSER, METYROSINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
ELIDEL, PIMECROLIMUS
FLUNISOLIDE, FLUNISOLIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LOCOID, HYDROCORTISONE BUTYRATE
LUZU, LULICONAZOLE
MESTINON, PYRIDOSTIGMINE BROMIDE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
NORITATE, METRONIDAZOLE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
TASMAR, TOLCAPONE
TIAZAC, DILTIAZEM HYDROCHLORIDE
VANOS, FLUOCINONIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
XENAZINE, TETRABENAZINE
XERESE, ACYCLOVIR
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZOVIRAX, ACYCLOVIR
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BRINZOLAMIDE, BRINZOLAMIDE
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TROPICAMIDE, TROPICAMIDE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAUSCH AND LOMB PHARMACEUTICALS INC
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
ATROPINE SULFATE, ATROPINE SULFATE
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY PRESERVATIVE FREE, BRIMONIDINE TARTRATE (OTC)
LUMIFY, BRIMONIDINE TARTRATE (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
MIEBO, PERFLUOROHEXYLOCTANE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
XIIDRA, LIFITEGRAST
XIPERE, TRIAMCINOLONE ACETONIDE

BAUSCH LOMB IRELAND

* BAUSCH AND LOMB IRELAND LTD
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
VISUDYNE, VERTEPORFIN

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYTOXAN, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP
ACETAMINOPHEN, ACETAMINOPHEN
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
CEFAZOLIN IN DEXTROSE, CEFAZOLIN SODIUM
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINOLIPID 20%, OLIVE OIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, EPINEPHRINE BITARTRATE
EPTIFIBATIDE, EPTIFIBATIDE
ERIBULIN MESYLATE, ERIBULIN MESYLATE
FLUMAZENIL, FLUMAZENIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN IN SODIUM CHLORIDE 0.9%, MICAFUNGIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM
REGADENOSON, REGADENOSON
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANSDERM SCOP, SCOPOLAMINE
VASOPRESSIN IN SODIUM CHLORIDE 0.9%, VASOPRESSIN
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER
* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE
* BAYER HEALTHCARE PHARMACEUTICALS INC
HYRNUO, SEVABERTINIB
LAMPIT, NIFURTIMOX
NUBEQA, DAROLUTAMIDE
VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC
* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)

BAYER HLTHCARE
* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
BEYAZ, DROSPIRENONE
CIPRO, CIPROFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAYER HEALTHCARE PHARMACEUTICALS INC
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
KERENDIA, FINERENONE
KYLEENA, LEVONORGESTREL
LYNKUET, ELINZANETANT
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
VITRAKVI, LAROTRECTINIB SULFATE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS

* BE PHARMACEUTICALS AG
DAPTOMYCIN, DAPTOMYCIN
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HEPARIN SODIUM, HEPARIN SODIUM
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

BEACH PRODS

* BEACH PRODUCTS INC
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIJING

* BEIJING SCIECURE PHARMACEUTICAL CO LTD
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

BEIJING JIALIN

* BEIJING JIALIN PHARMACEUTICAL CO LTD
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

BEIJING TIDE PHARM

* BEIJING TIDE PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE

BEIJING YILING

* BEIJING YILING BIO-ENGINEERING TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BEIJING YILING BIO-ENGINEERING TECHNOLOGY CO LTD
ORVATEN, MIDODRINE HYDROCHLORIDE

BEONE MEDICINES USA

* BEONE MEDICINES USA INC
BRUKINSA, ZANUBRUTINIB

BESINS HLTHCARE

* BESINS HEALTHCARE IRELAND LTD
ANDROGEL, TESTOSTERONE

BIOCODEX SA

* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON GENERICS

* BIOCON GENERICS INC
TRIAMTERENE, TRIAMTERENE

BIOCON LTD

* BIOCON LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

BIOCON PHARMA

* BIOCON PHARMA INC
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NITROFURANTOIN, NITROFURANTOIN
OXCARBAZEPINE, OXCARBAZEPINE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
* BIOCON PHARMA LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
DAPTOMYCIN, DAPTOMYCIN
DASATINIB, DASATINIB
EVEROLIMUS, EVEROLIMUS
LENALIDOMIDE, LENALIDOMIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
POSACONAZOLE, POSACONAZOLE
RIVAROXABAN, RIVAROXABAN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SACUBITRIL AND VALSARTAN, SACUBITRIL
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOFACITINIB CITRATE, TOFACITINIB CITRATE

BIOCORRX PHARMS

* BIOCORRX PHARMACEUTICALS INC
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC
ORLADEYO, BEROTRALSTAT DIHYDROCHLORIDE
RAPIVAB, PERAMIVIR

BIOFRONTERA

* BIOFRONTERA INC
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC

* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN INC

* BIOGEN INC
TECFIDERA, DIMETHYL FUMARATE
VUMERITY, DIROXIMEL FUMARATE
ZURZUVAE, ZURANOLONE

BIOGEN MA

* BIOGEN MA INC
QALSODY, TOFERSEN

BIOGEN US

* BIOGEN US CORPORATION

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIOGEN US CORPORATION
SKYCLARYS, OMAVELOXOLONE

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
VOXZOGO, VOSORITIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA

* BIONPHARMA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCITRIOL, CALCITRIOL
CARBAMAZEPINE, CARBAMAZEPINE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXAMETHASONE, DEXAMETHASONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DROXIDOPA, DROXIDOPA
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETRAVIRINE, ETRAVIRINE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
OXCARBAZEPINE, OXCARBAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIONPHARMA INC
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
POTASSIUM CITRATE, POTASSIUM CITRATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
THEOPHYLLINE, THEOPHYLLINE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BIOXCEL
* BIOXCEL THERAPEUTICS INC
IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE

BLUE EARTH
* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18
POSLUMA, FLOTUFOLASTAT F-18 GALLIUM

BLUEPRINT MEDICINES
* BLUEPRINT MEDICINES CORP
AYVAKIT, AVAPRITINIB

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
HERNEXEOS, ZONGERTINIB
JARDIANCE, EMPAGLIFLOZIN
JASCAYD, NERANDOMILAST
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
OFEV, NINTEDANIB ESYLATE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TRIJARDY XR, EMPAGLIFLOZIN

BOSTAL
* BOSTAL LLC
FENOFIBRATE, FENOFIBRATE
METHOCARBAMOL, METHOCARBAMOL
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

BOTANIX SB
* BOTANIX SB INC
SOFDRA, SOFPIRONIUM BROMIDE

BPI LABS
* BPI LABS LLC
ABLYSINOL, ALCOHOL
EPINEPHRINE, EPINEPHRINE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BPI LABS LLC
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-DISK, BARIUM SULFATE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
ENTERO VU 24%, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
TAGITOL V, BARIUM SULFATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE

BRAEBURN

* BRAEBURN INC
BRIXADI, BUPRENORPHINE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
ASENAPINE MALEATE, ASENAPINE MALEATE
DEHYDRATED ALCOHOL, ALCOHOL
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEPRAZOLE, OMEPRAZOLE
PENICILLAMINE, PENICILLAMINE
RIVAROXABAN, RIVAROXABAN
RIVASTIGMINE, RIVASTIGMINE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
OXCARBAZEPINE, OXCARBAZEPINE

BRIDGEBIO PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRIDGEBIO PHARMA INC
ATTRUBY, ACORAMIDIS HYDROCHLORIDE

BRIGHAM WOMENS
* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP
* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRIGHTGENE
* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
ENTECAVIR, ENTECAVIR

BRISTOL
* BRISTOL MYERS SQUIBB CO
AUGTYRO, REPOTRECTINIB
CAMZYOS, MAVACAMTEN
ELIQUIS SPRINKLE, APIXABAN
EVOTAZ, ATAZANAVIR SULFATE
KRAZATI, ADAGRASIB
ONUREG, AZACITIDINE
POMALYST, POMALIDOMIDE
SOTYKTU, DEUCRAVACITINIB
ZEPOSIA, OZANIMOD HYDROCHLORIDE

BRISTOL MYERS SQUIBB
* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
IDHIFA, ENASIDENIB MESYLATE
REVLIMID, LENALIDOMIDE
* BRISTOL MYERS SQUIBB CO
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN

BRISTOL-MYERS
* BRISTOL-MYERS SQUIBB CO
ABRAXANE, PACLITAXEL
COBENFY, TROSPIUM CHLORIDE
INREBIC, FEDRATINIB HYDROCHLORIDE
ISTODAX, ROMIDEPSIN
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

BROOKS STERISCIENCE
* BROOKS STERISCIENCE LTD
MEROPENEM, MEROPENEM

BTG INTL
* BTG INTERNATIONAL INC
AURLUMYN, ILOPROST
CYANOKIT, HYDROXOCOBALAMIN
THYROSAFE, POTASSIUM IODIDE (OTC)
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

BWXT ITG
* BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ****

CADILA
* CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
DESONIDE, DESONIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA HEALTHCARE LTD
RANOLAZINE, RANOLAZINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NATEGLINIDE, NATEGLINIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CALLIDITAS

* CALLIDITAS THERAPEUTICS AB
TARPEYO, BUDESONIDE

CAPLIN

* CAPLIN STERILES LTD
ACETAMINOPHEN, ACETAMINOPHEN
ARGATROBAN, ARGATROBAN
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DIFLUPREDNATE, DIFLUPREDNATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ETOMIDATE, ETOMIDATE
GATIFLOXACIN, GATIFLOXACIN
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LINEZOLID, LINEZOLID
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PARICALCITOL, PARICALCITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CAPLIN STERILES LTD
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARDINAL HLTH 414

* CARDINAL HEALTH 414 LLC
AMMONIA N 13, AMMONIA N-13

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CARNEGIE

* CARNEGIE PHARMACEUTICALS LLC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ETRAVIRINE, ETRAVIRINE
LOMUSTINE, LOMUSTINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
VIGABATRIN, VIGABATRIN

CARWIN PHARM ASSOC

* CARWIN PHARMACEUTICAL ASSOCIATES LLC
CLOTIC, CLOTRIMAZOLE
VYSCOXA, CELECOXIB

CASPER PHARMA LLC

* CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
EDETATE CALCIUM DISODIUM, EDETATE CALCIUM DISODIUM
FURADANTIN, NITROFURANTOIN
LUMI-SPORYN, BACITRACIN ZINC
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
THALITONE, CHLORTHALIDONE
ZYLOPRIM, ALLOPURINOL

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CATALENT PHARMA SOLUTIONS LLC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS

* CATALYST PHARMACEUTICALS INC
AGAMREE, VAMOROLONE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FYCOMPA, PERAMPANEL

CEDIPROF INC

* CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
LEVO-T, LEVOTHYROXINE SODIUM **
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

CEPHALON

* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CHANGZHOU PHARM

* CHANGZHOU PHARMACEUTICAL FACTORY
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TICAGRELOR, TICAGRELOR

CHARTWELL

* CHARTWELL LIFE MOLECULES LLC
ALLOPURINOL, ALLOPURINOL
AMOXICILLIN, AMOXICILLIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
COLOCORT, HYDROCORTISONE
DUTASTERIDE, DUTASTERIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUCONAZOLE, FLUCONAZOLE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXAPROZIN, OXAPROZIN
TEMOZOLOMIDE, TEMOZOLOMIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

* CHARTWELL PHARMA SCIENCE LLC
SULFASALAZINE, SULFASALAZINE

* CHARTWELL SCHEDULED LLC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

CHARTWELL INJECTABLE

* CHARTWELL INJECTABLES LLC
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT

CHARTWELL MOLECULAR

* CHARTWELL MOLECULAR HOLDINGS LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CARVEDILOL, CARVEDILOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL MOLECULAR HOLDINGS LLC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RAMIPRIL, RAMIPRIL
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CHARTWELL MOLECULES

* CHARTWELL MOLECULES LLC
CIMETIDINE, CIMETIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
INDOMETHACIN, INDOMETHACIN
NABUMETONE, NABUMETONE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX

* CHARTWELL RX SCIENCES LLC
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIUM ACETATE, CALCIUM ACETATE
CARBAMAZEPINE, CARBAMAZEPINE
CARISOPRODOL, CARISOPRODOL
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CICLOPIROX, CICLOPIROX
CILOSTAZOL, CILOSTAZOL
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPLERENONE, EPLERENONE
ERGOCALCIFEROL, ERGOCALCIFEROL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROSIZE
FULVICIN-U/F, GRISEOFULVIN, MICROSIZE
GENERLAC, LACTULOSE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LISINOPRIL, LISINOPRIL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHIMAZOLE, METHIMAZOLE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONODOX, DOXYCYCLINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NIACIN, NIACIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REPAGLINIDE, REPAGLINIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUCRALFATE, SUCRALFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHARTWELL RX SCIENCES LLC
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAVABOROLE, TAVABOROLE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TETRABENAZINE, TETRABENAZINE
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN

CHARTWELL TETRA
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM
* CHATTEM INC
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHATTEM SANOFI
* CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

CHEMI SPA
* CHEMI SPA
DECITABINE, DECITABINE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL
* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
ESTRADIOL, ESTRADIOL
NUVESSA, METRONIDAZOLE

CHEMOCENTRYX
* CHEMOCENTRYX INC
TAVNEOS, AVACOPAN

CHENGDU
* CHENGDU SUNCADIA MEDICINE CO LTD
TACROLIMUS, TACROLIMUS

CHENGDU SHUODE
* CHENGDU SHUODE PHARMACEUTICAL CO LTD
METHYLENE BLUE, METHYLENE BLUE
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

CHEPLAPHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CHEPLAPHARM ARZNEIMITTEL GMBH
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
KLONOPIN, CLONAZEPAM
PULMICORT FLEXHALER, BUDESONIDE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROQUEL, QUETIAPINE FUMARATE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT
* CHEPLAPHARM REGISTRATION GMBH
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

CHIA TAI TIANQING
* CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
ERIBULIN MESYLATE, ERIBULIN MESYLATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT

CHIESI
* CHIESI FARMACEUTICI SPA
FILSUVEZ, BIRCH TRITERPENES
JUXTAPID, LOMITAPIDE MESYLATE
MYCAPSSA, OCTREOTIDE ACETATE
* CHIESI USA INC
BETHKIS, TOBRAMYCIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
FERRIPROX, DEFERIPRONE
KENGREAL, CANGRELOR

CHILDRENS HOSP MI
* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHIMERIX
* CHIMERIX INC
MODEYSO, DORDAVIPRONE HYDROCHLORIDE

CHINA RESOURCES
* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN
* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER
* CIPHER PHARMACEUTICALS INC
NATROBA, SPINOSAD

CIPHER PHARMS INC
* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA
* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
AZACITIDINE, AZACITIDINE
BUDESONIDE, BUDESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA LTD
CALCITONIN-SALMON, CALCITONIN SALMON
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DIFLUPREDNATE, DIFLUPREDNATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
EMTRICITABINE, EMTRICITABINE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EXEMESTANE, EXEMESTANE
FENOFIBRATE, FENOFIBRATE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GEFITINIB, GEFITINIB
GLUCAGON, GLUCAGON
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
ICATIBANT ACETATE, ICATIBANT ACETATE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LENALIDOMIDE, LENALIDOMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MELOXICAM, MELOXICAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NILOTINIB D-TARTRATE, NILOTINIB D-TARTRATE
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHYTONADIONE, PHYTONADIONE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RITONAVIR, RITONAVIR
SELENIOUS ACID, SELENIOUS ACID
SUMATRIPTAN, SUMATRIPTAN
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
VASOPRESSIN, VASOPRESSIN
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD
* CIPLA LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZIDOVUDINE, ZIDOVUDINE

CIPLA USA
* CIPLA USA INC
ZEMDRI, PLAZOMICIN SULFATE

CISEN
* CISEN PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

CIVICA
* CIVICA INC
EPHEDRINE SULFATE, EPHEDRINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CLINIGEN HLTHCARE
* CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC
* CLINUVEL INC
SCENESSE, AFAMELANOTIDE

CMP DEV LLC
* CMP DEVELOPMENT LLC
ATORVALIQ, ATORVASTATIN CALCIUM
CAROSPIR, SPIRONOLACTONE
NORLIQVA, AMLODIPINE BESYLATE
TADLIQ, TADALAFIL

CMP PHARMA INC
* CMP PHARMA INC
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE

COLGATE-PALMOLIVE CO
* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC
* COLLEGIUM PHARMACEUTICAL INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
XTAMPZA ER, OXYCODONE

COMBE
* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

COMMAVE THERAP
* COMMAVE THERAPEUTICS SA
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE

CONBA USA
* CONBA USA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ENTECAVIR, ENTECAVIR

CONCORD BIOTECH LTD
* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
TACROLIMUS, TACROLIMUS

CONTRACT PHARMACAL
* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL
* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP
* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

COREPHARMA
* COREPHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DEXAMETHASONE, DEXAMETHASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COREPHARMA LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
MELOXICAM, MELOXICAM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
TORSEMIDE, TORSEMIDE

CORMEDIX
* CORMEDIX INC
DEFENCATH, HEPARIN SODIUM

CORSTASIS THERAP
* CORSTASIS THERAPEUTICS INC
ENBUMYST, BUMETANIDE

COSETTE
* COSETTE PHARMACEUTICALS INC
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
DAPSONE, DAPSONE
DESONIDE, DESONIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIBENZOR, AMLODIPINE BESYLATE
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

COSETTE PHARMS NC
* COSETTE PHARMACEUTICALS NC LABORATORIES LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COSETTE PHARMACEUTICALS NC LABORATORIES LLC
CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CIPROFLOXACIN HYDROCHLORIDE

COVIS

* COVIS PHARMA GMBH
ALVESCO, CICLESONIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
FERABRIGHT, FERUMOXYTOL
FERAHEME, FERUMOXYTOL
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
OMNARIS, CICLESONIDE
PRILOSEC, OMEPRAZOLE MAGNESIUM
SULAR, NISOLDIPINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CREEKWOOD PHARMS

* CREEKWOOD PHARMACEUTICALS LLC
FENOFIBRATE, FENOFIBRATE
HALOPERIDOL, HALOPERIDOL
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
PREGABALIN, PREGABALIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILODOSIN, SILODOSIN

CRESCITA THERAP

* CRESCITA THERAPEUTICS INC
PLIAGLIS, LIDOCAINE

CRINETICS

* CRINETICS PHARMACEUTICALS INC
PALSONIFY, PALTUSOTINE HYDROCHLORIDE

CROSSMEDIKA SA

* CROSSMEDIKA SA
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CRYSTAL

* CRYSTAL PHARMACEUTICAL SUZHOU CO LTD
SACUBITRIL AND VALSARTAN, SACUBITRIL

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GABAPENTIN, GABAPENTIN
IMATINIB MESYLATE, IMATINIB MESYLATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CSPC-NBP PHARM
* CSPC-NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

CUBIST PHARMS LLC
* CUBIST PHARMACEUTICALS LLC
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND
* CUMBERLAND PHARMACEUTICALS INC
SANCUSO, GRANISETRON
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CUMBERLAND PHARMS
* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE

CURIUM
* CURIUM US LLC
DETECTNET, COPPER CU-64 DOTATATE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
IOFLUPANE I-123, IOFLUPANE I-123
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW V4, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

CURRAX
* CURRAX PHARMACEUTICALS LLC
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
SILENOR, DOXEPIN HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM

CUSTOPHARM INC
* CUSTOPHARM INC
CALCITONIN-SALMON, CALCITONIN SALMON

CYCLE
* CYCLE PHARMACEUTICALS LTD
HARLIKU, NITISINONE
NITYR, NITISINONE
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE

CYCLOMEDICA
* CYCLOMEDICA AUSTRALIA PTY LTD
TECHNEGAS KIT, TECHNETIUM TC-99M LABELED CARBON

CYTOKINETICS
* CYTOKINETICS INC
MYQORZO, AFICAMTEN

**** D ****

DAIICHI SANKYO INC
* DAIICHI SANKYO INC
SAVAYSA, EDOXABAN TOSYLATE
TURALIO, PEXIDARTINIB HYDROCHLORIDE
VANFLYTA, QUIZARTINIB DIHYDROCHLORIDE

DAITO
* DAITO PHARMACEUTICAL CO LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DASH PHARMS NATCO
* DASH PHARMACEUTICALS LLC A FULLY OWNED SUB OF NATCO PHARMA LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
MORPHINE SULFATE, MORPHINE SULFATE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DAY ONE BIOPHARMS
* DAY ONE BIOPHARMACEUTICALS INC
OJEMDA, TOVORAFENIB

DECATUR
* DECATUR MEMORIAL HOSP
CHOLINE C-11, CHOLINE C-11

DECIPHERA PHARMS
* DECIPHERA PHARMACEUTICALS LLC
QINLOCK, RIPRETINIB
ROMVIMZA, VIMSELTINIB

DELCATH SYSTEMS INC
* DELCATH SYSTEMS INC
HEPZATO, MELPHALAN HYDROCHLORIDE

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEVA HLDING
* DEVA HOLDING ANONIM SIRKETI
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE

DEVA HOLDING AS
* DEVA HOLDING AS
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CYCLOSPORINE, CYCLOSPORINE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LENALIDOMIDE, LENALIDOMIDE
LEVOCARNITINE, LEVOCARNITINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL
* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DEXCEL LTD
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRAZOLE, OMEPRAZOLE (OTC)

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIFGEN PHARMS

* DIFGEN PHARMACEUTICALS LLC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NICOTINE, NICOTINE (OTC)

DIZAL JIANGSU

* DIZAL (JIANGSU) PHARMACEUTICAL CO LTD
ZEGFROVY, SUNVOZERTINIB

DORC

* DORC INTERNATIONAL BV
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
VERSACLOZ, CLOZAPINE

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
FENOFIBRATE, FENOFIBRATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL
LOPURIN, ALLOPURINOL
NITROGLYCERIN, NITROGLYCERIN
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
SSD, SILVER SULFADIAZINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* DR REDDYS LABORATORIES LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ALBENDAZOLE, ALBENDAZOLE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
CABAZITAXEL, CABAZITAXEL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
CALCITONIN-SALMON, CALCITONIN SALMON
CAPECITABINE, CAPECITABINE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARFILZOMIB, CARFILZOMIB
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR, DARUNAVIR
DASATINIB, DASATINIB
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIAZEPAM, DIAZEPAM
DIFLUPREDNATE, DIFLUPREDNATE
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
EDARAVONE, EDARAVONE
ENALAPRILAT, ENALAPRILAT
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ERIBULIN MESYLATE, ERIBULIN MESYLATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IMATINIB MESYLATE, IMATINIB MESYLATE
LACOSAMIDE, LACOSAMIDE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
LUBIPROSTONE, LUBIPROSTONE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MIDOSTAURIN, MIDOSTAURIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENICILLAMINE, PENICILLAMINE
PHYTONADIONE, PHYTONADIONE
PLERIXAFOR, PLERIXAFOR
POSACONAZOLE, POSACONAZOLE
PRALATREXATE, PRALATREXATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREDNISONE, PREDNISONE
PREGABALIN, PREGABALIN
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
REGADENOSON, REGADENOSON
RIVAROXABAN, RIVAROXABAN
SACUBITRIL AND VALSARTAN, SACUBITRIL
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TETRABENAZINE, TETRABENAZINE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
TICAGRELOR, TICAGRELOR
TIMOLOL MALEATE, TIMOLOL MALEATE
TOPIRAMATE, TOPIRAMATE
TREPROSTINIL, TREPROSTINIL
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VASOPRESSIN, VASOPRESSIN
VIGABATRIN, VIGABATRIN
VINORELBINE TARTRATE, VINORELBINE TARTRATE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE (OTC)
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DR REDDYS LABORATORIES SA
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORZOXAZONE, CHLORZOXAZONE
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ERYC, ERYTHROMYCIN
ESTAZOLAM, ESTAZOLAM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FLUOROURACIL, FLUOROURACIL
HABITROL, NICOTINE (OTC)
HALOETTE, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
MERCAPTOPURINE, MERCAPTOPURINE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METYROSINE, METYROSINE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE, PHENTERMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
RAMELTEON, RAMELTEON
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TOBRAMYCIN, TOBRAMYCIN
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL

DUCHESNAY

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
VELIVET, DESOGESTREL

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

** E **

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

E5 PHARMA INC
* E5 PHARMA INC
  DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS
* EAGLE PHARMACEUTICALS INC
  BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
  BENDEKA, BENDAMUSTINE HYDROCHLORIDE
  PEMFEXY, PEMETREXED
  RYANODEX, DANTROLENE SODIUM
  VASOPRESSIN, VASOPRESSIN

ECI PHARMS LLC
* ECI PHARMACEUTICALS LLC
  TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

ECOLAB
* ECOLAB INC
  CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
  CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EDENBRIDGE PHARMS
* EDENBRIDGE PHARMACEUTICALS LLC
  ALBENDAZOLE, ALBENDAZOLE
  BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
  CARBIDOPA, CARBIDOPA
  COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
  IVERMECTIN, IVERMECTIN
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  TINIDAZOLE, TINIDAZOLE
  YARGESA, MIGLUSTAT
* EDENBRIDGE PHARMACEUTICALS LLC DBA DEXCEL PHARMA USA
  ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

EIRGEN
* EIRGEN PHARMA LTD
  CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
  RAYALDEE, CALCIFEDIOL
  TEMOZOLOMIDE, TEMOZOLOMIDE

EISAI INC
* EISAI INC
  ARICEPT, DONEPEZIL HYDROCHLORIDE
  BANZEL, RUFINAMIDE
  DAYVIGO, LEMBOREXANT
  HALAVEN, ERIBULIN MESYLATE
  LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO
* ELI LILLY AND CO
  INLURIYO, IMLUNESTRANT TOSYLATE
  MOUNJARO (AUTOINJECTOR), TIRZEPATIDE
  MOUNJARO, TIRZEPATIDE
  OLUMIANT, BARICITINIB
  PROZAC, FLUOXETINE HYDROCHLORIDE
  RETEVMO, SELPERCATINIB
  REYVOW, LASMIDITAN SUCCINATE
  VERZENIO, ABEMACICLIB
  ZEPBOUND (AUTOINJECTOR), TIRZEPATIDE
  ZEPBOUND, TIRZEPATIDE

ELI LILLY CO
* ELI LILLY CO
  ADCIRCA, TADALAFIL

ELITE LABS
* ELITE LABORATORIES INC
  NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC
* ELITE LABORATORIES INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELITE LABORATORIES INC
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISRADIPINE, ISRADIPINE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELITE PHARM SOLUTION
* ELITE PHARMACEUTICAL SOLUTION INC
NIFEDIPINE, NIFEDIPINE

EMD SERONO INC
* EMD SERONO INC
CETROTIDE, CETRORELIX ACETATE
EUTHYROX, LEVOTHYROXINE SODIUM **
MAVENCLAD, CLADRIBINE
TEPMETKO, TEPOTINIB HYDROCHLORIDE

EMED MEDCL
* EMED MEDICAL CO LLC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

EMERGE BIOSCIENCE
* EMERGE BIOSCIENCE PTE LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

EMERGENT
* EMERGENT OPERATIONS IRELAND LTD
NARCAN, NALOXONE HYDROCHLORIDE (OTC)

EMERGENT BIODEFENSE
* EMERGENT BIODEFENSE OPERATIONS LANSING INC
TEMBEXA, BRINCIDOFOVIR
* EMERGENT BIODEFENSE OPERATIONS LANSING LLC
TEMBEXA, BRINCIDOFOVIR

EMMAUS MEDCL
* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

ENCUBE
* ENCUBE ETHICALS PRIVATE LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AZELAIC ACID, AZELAIC ACID
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
ESTRADIOL, ESTRADIOL
FLUOCINONIDE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALCINONIDE, HALCINONIDE
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ENCUBE ETHICALS PRIVATE LTD
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
NITROGLYCERIN, NITROGLYCERIN
TACROLIMUS, TACROLIMUS
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TRETINOIN MICROSPHERE, TRETINOIN
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
ADAPALENE, ADAPALENE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
PERMETHRIN, PERMETHRIN

ENDO OPERATIONS

* ENDO OPERATIONS LTD
AVEED, TESTOSTERONE UNDECANOATE
EDEX, ALPROSTADIL
FROVA, FROVATRIPTAN SUCCINATE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
SUPPRELIN LA, HISTRELIN ACETATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE
VALSTAR PRESERVATIVE FREE, VALRUBICIN

ENTASIS THERAP

* ENTASIS THERAPEUTICS INC
NUZOLVENCE, ZOLIFLODACIN
XACDURO (COPACKAGED), DURLOBACTAM SODIUM

EPIC PHARMA

* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA LLC

* EPIC PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUCAPSOL, BUSPIRONE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIC PHARMA LLC
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUPREDNATE, DIFLUPREDNATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMOTIDINE, FAMOTIDINE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
IVERMECTIN, IVERMECTIN
KLAYESTA, NYSTATIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RIFAMPIN, RIFAMPIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SULFADIAZINE, SULFADIAZINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICACYL, TROPICAMIDE
URSODIOL, URSODIOL
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EPIZYME INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIZYME INC
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

ESJAY PHARMA
* ESJAY PHARMA LLC
DRISDOL, ERGOCALCIFEROL
FUROSEMIDE, FUROSEMIDE
HIPREX, METHENAMINE HIPPURATE
PARLODEL, BROMOCRIPTINE MESYLATE
ROCALTROL, CALCITRIOL

ESKAYEF
* ESKAYEF PHARMACEUTICALS LTD
PALIPERIDONE, PALIPERIDONE
PREGABALIN, PREGABALIN

ESPERION THERAPS INC
* ESPERION THERAPEUTICS INC
NEXLETOL, BEMPEDOIC ACID
NEXLIZET, BEMPEDOIC ACID

ESTEVE
* ESTEVE PHARMACEUTICALS SA
LYSODREN, MITOTANE
METOPIRONE, METYRAPONE

ETHYPHARM
* ETHYPHARM INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

ETON
* ETON PHARMACEUTICALS INC
ALKINDI SPRINKLE, HYDROCORTISONE
BETAINE, BETAINE
GALZIN, ZINC ACETATE
KHINDIVI, HYDROCORTISONE
NITISINONE, NITISINONE

EUGIA PHARMA
* EUGIA PHARMA SPECIALITIES LTD
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMPHOTERICIN B, AMPHOTERICIN B
ANASTROZOLE, ANASTROZOLE
AZACITIDINE, AZACITIDINE
AZITHROMYCIN, AZITHROMYCIN
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BROMFENAC SODIUM, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DASATINIB, DASATINIB
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPTIFIBATIDE, EPTIFIBATIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ICATIBANT ACETATE, ICATIBANT ACETATE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LENALIDOMIDE, LENALIDOMIDE
LETROZOLE, LETROZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEROPENEM, MEROPENEM
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PLERIXAFOR, PLERIXAFOR
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POSACONAZOLE, POSACONAZOLE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROGESTERONE, PROGESTERONE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VASOPRESSIN, VASOPRESSIN
VECURONIUM BROMIDE, VECURONIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EUGIA PHARMA SPECLTS

* EUGIA PHARMA SPECIALITIES LTD
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
FLUOROURACIL, FLUOROURACIL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
AZACITIDINE, AZACITIDINE

EVEREST LIFE SCI

* EVEREST LIFE SCIENCES LLC
DAPSONE, DAPSONE

EVITA SOLUTIONS

* EVITA SOLUTIONS LLC
MIFEPRISTONE, MIFEPRISTONE

EVOFEM INC

* EVOFEM INC
PHEXXI, CITRIC ACID
SOLOSEC, SECNIDAZOLE

EVOKE PHARMA INC

* EVOKE PHARMA INC
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE

EVUS

* EVUS HEALTH SOLUTIONS LLC
NITROMIST, NITROGLYCERIN

EXELA PHARMA

* EXELA PHARMA SCIENCES LLC
AKOVAZ, EPHEDRINE SULFATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CUPRIC CHLORIDE, CUPRIC CHLORIDE
ELCYS, CYSTEINE HYDROCHLORIDE
GLYRX-PF, GLYCOPYRROLATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

* EXELTIS USA INC
SLYND, DROSPIRENONE
TYBLUME, ETHINYL ESTRADIOL

EXTROVIS

* EXTROVIS AG
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CARAC, FLUOROURACIL
EFUDEX, FLUOROURACIL

EYEPOINT PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE

EZRA VENTURES

* EZRA VENTURES LLC
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE

**** F ****

FABRE KRAMER

* FABRE KRAMER PHARMACEUTICALS INC
EXXUA, GEPIRONE HYDROCHLORIDE

FAMYGEN LIFE SCI

* FAMYGEN LIFE SCIENCES INC
RYZUMVI, PHENTOLAMINE MESYLATE

FDC LTD

* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
LATANOPROST, LATANOPROST
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

* FOUNDATION CONSUMER BRANDS LLC
ALAVERT, LORATADINE (OTC)
* FOUNDATION CONSUMER HEALTHCARE LLC
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUORODOPA F18, FLUORODOPA F-18

FENNEC PHARMS INC

* FENNEC PHARMACEUTICALS INC
PEDMARK, SODIUM THIOSULFATE

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
GENTAMICIN SULFATE, GENTAMICIN SULFATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE

FERRING

* FERRING PHARMACEUTICALS INC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP, DESMOPRESSIN ACETATE

FIDELITY BIOPHARMA

* FIDELITY BIOPHARMA CO USA
ONTRALFY, TIZANIDINE HYDROCHLORIDE

FLORIDA

* FLORIDA PHARMACEUTICAL PRODUCTS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

FOLDRX PHARMS

* FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FORESEE PHARMS

* FORESEE PHARMACEUTICALS CO LTD
CAMCEVI ETM, LEUPROLIDE MESYLATE

FOSUN PHARMA

* FOSUN PHARMA USA INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

FOSUN WANBANG

* FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO LTD
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
LEFLUNOMIDE, LEFLUNOMIDE
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
SUNITINIB MALATE, SUNITINIB MALATE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PREDNICARBATE, PREDNICARBATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOUGERA PHARMACEUTICALS INC
TERCONAZOLE, TERCONAZOLE

FOURRTS LABS

* FOURRTS INDIA LABORATORIES PRIVATE LTD
TADALAFIL, TADALAFIL

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASCORBIC ACID, ASCORBIC ACID
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DALBAVANCIN HYDROCHLORIDE, DALBAVANCIN HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPINEPHRINE, EPINEPHRINE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4, MAGNESIUM CHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POSACONAZOLE, POSACONAZOLE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, POTASSIUM PHOSPHATE, DIBASIC
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROMIDEPSIN, ROMIDEPSIN
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR IRRIGATION, STERILE WATER FOR IRRIGATION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VASOPRESSIN, VASOPRESSIN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZINC SULFATE, ZINC SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**** G ****

GALDERMA LABS

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GALDERMA LABORATORIES LP
AKLIEF, TRIFAROTENE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALENICUM HLTH
* GALENICUM HEALTH SLU
DIAZEPAM, DIAZEPAM

GALT PHARMS
* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM
ORAVIG, MICONAZOLE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN

GE HEALTHCARE
* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
REGADENOSON, REGADENOSON
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE
* GE HEALTHCARE INC
FLYRCADO, FLURPIRIDAZ F-18

GE HLTHCARE INC
* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GEN ILAC
* GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET ANONIM SIRKETI FABRIKA SUBESI
AMINOCAPROIC ACID, AMINOCAPROIC ACID

GENBIOPRO
* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENENTECH
* GENENTECH INC
ERIVEDGE, VISMODEGIB

GENENTECH INC
* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
EVRYSDI, RISDIPLAM
ITOVEBI, INAVOLISIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GENENTECH INC
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENUS

* GENUS LIFESCIENCES INC
AMCINONIDE, AMCINONIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
POKONZA, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMCINONIDE, AMCINONIDE
LEVOLET, LEVOTHYROXINE SODIUM **
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POKONZA, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

GENZYME

* GENZYME CORP
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE

GENZYME CORP

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE
QFITLIA, FITUSIRAN SODIUM
WAYRILZ, RILZABRUTINIB

GERON

* GERON CORP
RYTELO, IMETELSTAT SODIUM

GILEAD

* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
LETAIRIS, AMBRISENTAN
TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
LIVDELZI, SELADELPAR LYSINE
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
SUNLENCA, LENACAPAVIR SODIUM
TYBOST, COBICISTAT
VEKLURY, REMDESIVIR
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GILEAD SCIENCES INC
VOSEVI, SOFOSBUVIR
YEZTUGO, LENACAPAVIR SODIUM
ZYDELIG, IDELALISIB

GISKIT

* GISKIT PHARMA BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND

* GLAND PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
ALCAFTADINE, ALCAFTADINE (OTC)
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ANGIOTENSIN ll ACETATE, ANGIOTENSIN II ACETATE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BROMFENAC SODIUM, BROMFENAC SODIUM
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CANGRELOR, CANGRELOR
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CETRORELIX ACETATE, CETRORELIX ACETATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DECITABINE, DECITABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EDARAVONE, EDARAVONE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPINEPHRINE, EPINEPHRINE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ERIBULIN MESYLATE, ERIBULIN MESYLATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOMEPIZOLE, FOMEPIZOLE
FOSCARNET SODIUM, FOSCARNET SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LATANOPROST, LATANOPROST
LATANOPROSTENE BUNOD, LATANOPROSTENE BUNOD
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEROPENEM, MEROPENEM
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PLERIXAFOR, PLERIXAFOR
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POSACONAZOLE, POSACONAZOLE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SELENIOUS ACID, SELENIOUS ACID
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMSIROLIMUS, TEMSIROLIMUS
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
TIMOLOL MALEATE, TIMOLOL MALEATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VASOPRESSIN IN DEXTROSE 5%, VASOPRESSIN
VASOPRESSIN, VASOPRESSIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZINC SULFATE, ZINC SULFATE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLEDRONIC, ZOLEDRONIC ACID

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

GLAUKOS

* GLAUKOS CORP
EPIOXA HD/EPIOXA KIT, RIBOFLAVIN 5'-PHOSPHATE SODIUM
IDOSE TR, TRAVOPROST
MITOSOL, MITOMYCIN
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE
* GLAXOSMITHKLINE LLC
BLUJEPA, GEPOTIDACIN MESYLATE
BREXAFEMME, IBREXAFUNGERP CITRATE
OJJAARA, MOMELOTINIB DIHYDROCHLORIDE
ZEJULA, NIRAPARIB TOSYLATE

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE LLC
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
ACETYLCYSTEINE, ACETYLCYSTEINE
ADAPALENE, ADAPALENE (OTC)
CALCIPOTRIENE, CALCIPOTRIENE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
ERIBULIN MESYLATE, ERIBULIN MESYLATE
FAMOTIDINE, FAMOTIDINE (OTC)
FULVESTRANT, FULVESTRANT
IMIQUIMOD, IMIQUIMOD
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ZONISAMIDE, ZONISAMIDE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BRIELLYN, ETHINYL ESTRADIOL
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
CARVEDILOL, CARVEDILOL
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FELODIPINE, FELODIPINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY 24 FE, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HEATHER, NORETHINDRONE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LIDOCAINE, LIDOCAINE
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PIMECROLIMUS, PIMECROLIMUS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RILUZOLE, RILUZOLE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TACROLIMUS, TACROLIMUS
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRETINOIN, TRETINOIN
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

GLENMARK SPECLT

* GLENMARK SPECIALTY SA
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
APREPITANT, APREPITANT
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATOVAQUONE, ATOVAQUONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK SPECIALTY SA
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
DEFERASIROX, DEFERASIROX
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NITROGLYCERIN, NITROGLYCERIN
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RYALTRIS, MOMETASONE FUROATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TERIFLUNOMIDE, TERIFLUNOMIDE

GLW

* GLW PHARMA GMBH
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

GRANATA BIO CORP

* GRANATA BIO CORP
MILOPHENE, CLOMIPHENE CITRATE

GRANULES

* GRANULES INDIA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GABAPENTIN, GABAPENTIN
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

* GRANULES PHARMACEUTICALS INC
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
COLCHICINE, COLCHICINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOFETILIDE, DOFETILIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PENICILLAMINE, PENICILLAMINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GRANULES PHARMACEUTICALS INC
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

GRANULES INDIA

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
* GRAVITI PHARMACEUTICALS PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
FUROSEMIDE, FUROSEMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
SPIRONOLACTONE, SPIRONOLACTONE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

GUANGDONG SUNHO

* GUANGDONG SUNHO PHARMACEUTICAL CO LTD
DOCETAXEL, DOCETAXEL

GUANGZHOU NOVAKEN

* GUANGZHOU NOVAKEN PHARM CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GUARDIAN DRUG

* GUARDIAN DRUG CO
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
* GUARDIAN DRUG CO INC
LEVETIRACETAM, LEVETIRACETAM

GUERBET

* GUERBET
ELUCIREM, GADOPICLENOL
* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

GVS TM

* GVS TM INC
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**** H ****

H2-PHARMA

* H2-PHARMA LLC
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE

HAINAN POLY

* HAINAN POLY PHARM CO LTD
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE
GADOTERIDOL, GADOTERIDOL
IOPAMIDOL, IOPAMIDOL
LACOSAMIDE, LACOSAMIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

HAINAN POLY PHARM

* HAINAN POLY PHARMACEUTICAL CO LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HAINAN POLY PHARMACEUTICAL CO LTD
DAPTOMYCIN, DAPTOMYCIN
GADOBUTROL, GADOBUTROL
LEVETIRACETAM, LEVETIRACETAM
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
VORICONAZOLE, VORICONAZOLE

HALEON US HOLDINGS

* HALEON US HOLDINGS LLC
ABREVA, DOCOSANOL (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ALLI, ORLISTAT (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
EXCEDRIN (MIGRAINE RELIEF), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
INFANT'S ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HANDA THERAP

* HANDA THERAPEUTICS LLC
PHYRAGO, DASATINIB

HANGZHOU BINJIANG

* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TADALAFIL, TADALAFIL

HANGZHOU ZHONGMEI

* HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

HARM REDUCTION THERP

* HARM REDUCTION THERAPEUTICS INC
RIVIVE, NALOXONE HYDROCHLORIDE (OTC)

HARMAN FINOCHEM

* HARMAN FINOCHEM LTD
ALLOPURINOL, ALLOPURINOL
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HARMONY

* HARMONY BIOSCIENCES MANAGEMENT INC
WAKIX, PITOLISANT HYDROCHLORIDE

HARROW EYE

* HARROW EYE LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HARROW EYE LLC
BYQLOVI, CLOBETASOL PROPIONATE
FLAREX, FLUOROMETHOLONE ACETATE
IHEEZO, CHLOROPROCAINE HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
NATACYN, NATAMYCIN
NEVANAC, NEPAFENAC
TOBRADEX ST, DEXAMETHASONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
VERKAZIA, CYCLOSPORINE
VEVYE, CYCLOSPORINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
ZERVIATE, CETIRIZINE HYDROCHLORIDE

HBT LABS INC
* HBT LABS INC
FULVESTRANT, FULVESTRANT

HEBEI CHANGSHAN
* HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

HEC PHARM
* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
LEVOFLOXACIN, LEVOFLOXACIN
OLANZAPINE, OLANZAPINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD
* HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN
* HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE
* HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT

HERITAGE
* HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
CARISOPRODOL, CARISOPRODOL
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEFLUNOMIDE, LEFLUNOMIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

HERITAGE LIFE
* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA
* HERITAGE PHARMA LABS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE

HERITAGE PHARMA AVET
* HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

HERITAGE PHARMS INC
* HERITAGE PHARMACEUTICALS INC
CALCIUM ACETATE, CALCIUM ACETATE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

HERITAGE PHARMS LABS
* HERITAGE PHARMACEUTICALS LABS INC DBA AVET PHARMACEUTICALS LABS INC
BENZONATATE, BENZONATATE

HERON THERAPS INC
* HERON THERAPEUTICS INC
APONVIE, APREPITANT
CINVANTI, APREPITANT
SUSTOL, GRANISETRON
ZYNRELEF KIT, BUPIVACAINE

HETERO LABS
* HETERO LABS LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

HETERO LABS LTD III
* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DARUNAVIR, DARUNAVIR
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HETERO LABS LTD UNIT III
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
EZETIMIBE, EZETIMIBE
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
MARAVIROC, MARAVIROC
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN, NAPROXEN
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXCARBAZEPINE, OXCARBAZEPINE
POSACONAZOLE, POSACONAZOLE
PREGABALIN, PREGABALIN
RANOLAZINE, RANOLAZINE
RITONAVIR, RITONAVIR
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SACUBITRIL AND VALSARTAN, SACUBITRIL
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVANAFIL, AVANAFIL
CAPECITABINE, CAPECITABINE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HETERO LABS LTD UNIT V
COLCHICINE, COLCHICINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELTROMBOPAG OLAMINE, ELTROMBOPAG OLAMINE
ENTECAVIR, ENTECAVIR
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LENALIDOMIDE, LENALIDOMIDE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIRFENIDONE, PIRFENIDONE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIROLIMUS, SIROLIMUS
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
TEMOZOLOMIDE, TEMOZOLOMIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TETRABENAZINE, TETRABENAZINE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE

HETERO LABS LTD VI

* HETERO LABS LTD UNIT VI
AZACITIDINE, AZACITIDINE
BORTEZOMIB, BORTEZOMIB
DECITABINE, DECITABINE
OXALIPLATIN, OXALIPLATIN
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PLERIXAFOR, PLERIXAFOR

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HIBROW HLTHCARE

* HIBROW HEALTHCARE PRIVATE LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIBROW HEALTHCARE PRIVATE LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
BACLOFEN, BACLOFEN
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NIACIN, NIACIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
URSODIOL, URSODIOL

HIKMA

* HIKMA FARMACEUTICA PORTUGAL SA
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
DOCETAXEL, DOCETAXEL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
* HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
* HIKMA PHARMACEUTICALS USA INC
ACARBOSE, ACARBOSE
ACETAMINOPHEN, ACETAMINOPHEN
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALVIMOPAN, ALVIMOPAN
AMICAR, AMINOCAPROIC ACID
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMRINONE LACTATE, INAMRINONE LACTATE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE SULFATE, ATROPINE SULFATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BEXAROTENE, BEXAROTENE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CARBOPLATIN, CARBOPLATIN
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CODEINE SULFATE, CODEINE SULFATE
COMBOGESIC IV, ACETAMINOPHEN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFERIPRONE, DEFERIPRONE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
DURAMORPH PF, MORPHINE SULFATE
EDARAVONE, EDARAVONE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENTANYL CITRATE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMMPHENTIV, PHENYLEPHRINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOXXADO, NALOXONE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LIRAGLUTIDE, LIRAGLUTIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM INTENSOL, LORAZEPAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLENE BLUE, METHYLENE BLUE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC

MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POSACONAZOLE, POSACONAZOLE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
PYRAZINAMIDE, PYRAZINAMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
REGADENOSON, REGADENOSON
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TORSEMIDE, TORSEMIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZAVAN, VANCOMYCIN HYDROCHLORIDE
VALRUBICIN, VALRUBICIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VIGABATRIN, VIGABATRIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VORICONAZOLE, VORICONAZOLE
ZALEPLON, ZALEPLON

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

* HIKMA FARMACEUTICA PORTUGAL SA
OXYTOCIN, OXYTOCIN
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
CAPTOPRIL, CAPTOPRIL
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MITIGARE, COLCHICINE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

HILL DERMAC

* HILL DERMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
SECUADO, ASENAPINE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
CLADRIBINE, CLADRIBINE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
OLANZAPINE, OLANZAPINE
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
TICAGRELOR, TICAGRELOR

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE

HONG KONG

* HONG KONG KING FRIEND INDUSTRIAL CO LTD
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
XENLETA, LEFAMULIN ACETATE

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON THERAPEUTICS USA INC
PROCYSBI, CYSTEAMINE BITARTRATE

HORIZON THERAP US

* HORIZON THERAPEUTICS US HOLDING LLC
BUPHENYL, SODIUM PHENYLBUTYRATE
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
ARGATROBAN, ARGATROBAN
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC

BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOPLATIN, CARBOPLATIN
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DAPTOMYCIN, DAPTOMYCIN
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50%, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME
THAM, TROMETHAMINE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
* HOSPIRA WORLDWIDE, INC
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
DOCETAXEL, DOCETAXEL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HQ SPCLT PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HQ SPECIALTY PHARMA CORP
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CISPLATIN, CISPLATIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE, DILTIAZEM HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEROPENEM, MEROPENEM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA CORP
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

HUMANWELL

* HUMANWELL PHARMACEUTICAL US INC
GABAPENTIN, GABAPENTIN

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL

HUONS

* HUONS CO LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

ROCHE

* HOFFMANN LA ROCHE INC
TAMIFLU, OSELTAMIVIR PHOSPHATE

SHUANGCHENG

* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
EPTIFIBATIDE, EPTIFIBATIDE
PACLITAXEL, PACLITAXEL

**** I ****

I 3 PHARMS

* I 3 PHARMACEUTICALS LLC
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MARAVIROC, MARAVIROC
POSACONAZOLE, POSACONAZOLE

I3 PHARMS

* I3 PHARMACEUTICALS LLC
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RANOLAZINE, RANOLAZINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

IBSA

* IBSA INSTITUT BIOCHIMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE
LIDOCAINE, LIDOCAINE
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM
VYBRIQUE, SILDENAFIL CITRATE

IBSA INST BIO

* IBSA INSTITUT BIOCHIMIQUE SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

IDORSIA
* IDORSIA PHARMACEUTICALS LTD
QUVIVIQ, DARIDOREXANT HYDROCHLORIDE
TRYVIO, APROCITENTAN

IMPAX
* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE
CREXONT, CARBIDOPA
RYTARY, CARBIDOPA
SEVELAMER CARBONATE, SEVELAMER CARBONATE

IMPAX LABS
* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIPYRIDAMOLE, DIPYRIDAMOLE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC
* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEXEDRINE SPANSULE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

IMPAX PHARMS
* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

IMPEL PHARMS
* IMPEL PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IMPEL PHARMACEUTICALS LLC
TRUDHESA, DIHYDROERGOTAMINE MESYLATE

IMS LTD
* INTERNATIONAL MEDICATION SYSTEMS LTD
REGADENOSON, REGADENOSON

INCYTE CORP
* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE
OPZELURA, RUXOLITINIB PHOSPHATE
PEMAZYRE, PEMIGATINIB

INDCHEMIE HEALTH
* INDCHEMIE HEALTH SPECIALTIES PVT LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

INDICUS PHARMA
* INDICUS PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE

INDIES PHARMA
* INDIES PHARMA JAMAICA LTD
REGADENOSON, REGADENOSON

INDIVIOR
* INDIVIOR INC
OPVEE, NALMEFENE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INFORLIFE
* INFORLIFE SA
ACETAMINOPHEN, ACETAMINOPHEN
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
CABERGOLINE, CABERGOLINE
DEHYDRATED ALCOHOL, ALCOHOL
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
TAFLUPROST, TAFLUPROST
TIMOLOL MALEATE, TIMOLOL MALEATE

INNOGENIX
* INNOGENIX LLC
HALOPERIDOL, HALOPERIDOL
METOLAZONE, METOLAZONE
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INNOPHARMA
* INNOPHARMA LICENSING LLC A SUB OF PFIZER INC
PROPOFOL, PROPOFOL

INSMED INC
* INSMED INC
ARIKAYCE KIT, AMIKACIN SULFATE
BRINSUPRI, BRENSOCATIB

INTAS PHARMS USA
* INTAS PHARMACEUTICALS USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTERSECT ENT INC
* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL ISOTOPES
* INTERNATIONAL ISOTOPES INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

INTL MEDICATION SYS
* INTERNATIONAL MEDICATION SYSTEMS LTD
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
DEXTROSE 50%, DEXTROSE
EPINEPHRINE, EPINEPHRINE
IRON SUCROSE, IRON SUCROSE
LORAZEPAM, LORAZEPAM
MORPHINE SULFATE, MORPHINE SULFATE
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA SANA LABS
* INTRA-SANA LABORATORIES LLC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

INTRA-CELLULAR
* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INTRABIO
* INTRABIO INC
AQNEURSA, LEVACETYLLEUCINE

INVAGEN PHARMS
* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CALCIUM ACETATE, CALCIUM ACETATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION, LEUPROLIDE ACETATE
LINAGLIPTIN, LINAGLIPTIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PENICILLAMINE, PENICILLAMINE
PREGABALIN, PREGABALIN
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIMVASTATIN, SIMVASTATIN
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* INVAGEN PHARMACEUTICALS INC
TICAGRELOR, TICAGRELOR
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

INVATECH

* INVATECH PHARMA SOLUTIONS LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM

INVENTIA

* INVENTIA HEALTHCARE LTD
CHLORTHALIDONE, CHLORTHALIDONE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PALIPERIDONE, PALIPERIDONE
TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

IONETIX

* IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IONIS PHARMS INC

* IONIS PHARMACEUTICALS INC
DAWNZERA (AUTOINJECTOR), DONIDALORSEN SODIUM
TRYNGOLZA (AUTOINJECTOR), OLEZARSEN SODIUM

IPCA LABS

* IPCA LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE

IPCA LABS LTD

* IPCA LABORATORIES LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
ETODOLAC, ETODOLAC
FUROSEMIDE, FUROSEMIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

IPSEN

* IPSEN BIOPHARMACEUTICALS INC
BYLVAY, ODEVIXIBAT
IQIRVO, ELAFIBRANOR
ONIVYDE, IRINOTECAN HYDROCHLORIDE
SOHONOS, PALOVAROTENE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

IRONSHORE PHARMS
* IRONSHORE PHARMACEUTICALS INC A WHOLLY OWNED SUB OF COLLEGIUM PHARMACEUTICAL INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISOLOGIC INNOVATIVE
* ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

ISOTEX
* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

ISTX
* ISTX LLC
ZEVTERA, CEFTOBIPROLE MEDOCARIL SODIUM

ITALFARMACO SA
* ITALFARMACO SA
TIGLUTIK KIT, RILUZOLE

ITALFARMACO SPA
* ITALFARMACO SPA
DUVYZAT, GIVINOSTAT HYDROCHLORIDE

ITERUM THERAP
* ITERUM THERAPEUTICS US LTD
ORLYNVAH, PROBENECID

IVAX SUB TEVA PHARMS
* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
BACLOFEN, BACLOFEN
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

IXORA LIFESCIENCE
* IXORA LIFESCIENCE LLP
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
METOLAZONE, METOLAZONE

**** J ****

HENGRUI PHARMA
* JIANGSU HENGRUI PHARMACEUTICALS CO LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GADOBUTROL, GADOBUTROL
IODIXANOL, IODIXANOL
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JIANGSU HENGRUI PHARMACEUTICALS CO LTD
THIOTEPA, THIOTEPA

JANSSEN BIOTECH
* JANSSEN BIOTECH INC
AKEEGA, ABIRATERONE ACETATE
BALVERSA, ERDAFITINIB
ERLEADA, APALUTAMIDE
INLEXZO, GEMCITABINE HYDROCHLORIDE
LAZCLUZE, LAZERTINIB MESYLATE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS
* JANSSEN PHARMACEUTICALS INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
XARELTO, RIVAROXABAN

JANSSEN PRODS
* JANSSEN PRODUCTS LP
EDURANT PED, RILPIVIRINE HYDROCHLORIDE
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D
* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN THERAP
* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ
* JAZZ PHARMACEUTICALS IRELAND LTD
XYWAV, CALCIUM OXYBATE
ZEPZELCA, LURBINECTEDIN

JAZZ PHARMS
* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS INC
* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JAZZ PHARMS RES
* JAZZ PHARMACEUTICALS RESEARCH UK LTD
EPIDIOLEX, CANNABIDIOL

JAZZ PHARMS THERAP
* JAZZ PHARMACEUTICALS THERAPEUTICS INC
VYXEOS, CYTARABINE

JDP
* JDP THERAPEUTICS LLC
QUZYTTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM
* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
AZACITIDINE, AZACITIDINE
BORTEZOMIB, BORTEZOMIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** J **

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
DECITABINE, DECITABINE
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGXI KVVIT PHARM

* JIANGXI KVVIT PHARMACEUTICAL CO LTD
ERIBULIN MESYLATE, ERIBULIN MESYLATE

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOURNEY

* JOURNEY MEDICAL CORP
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
EMROSI, MINOCYCLINE HYDROCHLORIDE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
QBREXZA, GLYCOPYRRONIUM TOSYLATE
ZILXI, MINOCYCLINE HYDROCHLORIDE

JUBILANT

* JUBILANT DRAXIMAGE INC DBA JUBILANT RADIOPHARMA
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNETIUM TC-99M SULFUR COLLOID KIT, TECHNETIUM TC-99M SULFUR COLLOID KIT

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
RISPERIDONE, RISPERIDONE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
TECHNETIUM TC 99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

* JUBILANT GENERICS LTD
BUMETANIDE, BUMETANIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT GENERICS LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
IRBESARTAN, IRBESARTAN
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PERPHENAZINE, PERPHENAZINE
PREGABALIN, PREGABALIN
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J
* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
THYQUIDITY, LEVOTHYROXINE SODIUM
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN
* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC
* KADMON PHARMACEUTICALS LLC
REZUROCK, BELUMOSUDIL MESYLATE

KAI PHARMS INC
* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALEO INC
* KALEO INC
AUVI-Q, EPINEPHRINE

KALVISTA
* KALVISTA PHARMACEUTICALS LTD
EKTERLY, SEBETRALSTAT

KAMAT
* KAMAT PHARMATECH LLC
RALDESY, TRAZODONE HYDROCHLORIDE

KANCHAN HLTHCARE
* KANCHAN HEALTHCARE INC
DEXAMETHASONE, DEXAMETHASONE
LACOSAMIDE, LACOSAMIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

KARO HLTHCARE
* KARO HEALTHCARE INC
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)

KARYOPHARM THERAPS
* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON
* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ANASTROZOLE, ANASTROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
RILUZOLE, RILUZOLE

KENVUE BRANDS

* KENVUE BRANDS LLC
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MEN'S ROGAINE, MINOXIDIL (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
RHINOCORT ALLERGY, BUDESONIDE (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
SINE-AID IB, IBUPROFEN (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KINDEVA

* KINDEVA DRUG DELIVERY LP
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

KINDOS

* KINDOS PHARMACEUTICALS CO LTD
DALBAVANCIN HYDROCHLORIDE, DALBAVANCIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FLUOROURACIL, FLUOROURACIL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

KING PHARMS

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE

KK BCJ-94

* K.K. BCJ-94
RADICAVA ORS, EDARAVONE

KNACK

* KNACK PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KNACK PHARMACEUTICALS INC
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KRAMER

* KRAMER LABORATORIES INC
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KURA

* KURA ONCOLOGY INC
KOMZIFTI, ZIFTOMENIB

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

* KVK TECH INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
NOURIANZ, ISTRADEFYLLINE

**** L ****

L PERRIGO CO

* L PERRIGO CO
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA

* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LAB SALVAT

* LABORATORIOS SALVAT SA
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABORATOIRE HRA

* LABORATOIRE HRA PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LABORATOIRE HRA PHARMA
LEVONORGESTREL, LEVONORGESTREL (OTC)
OPILL, NORGESTREL (OTC)

LABORATORIOS GRIFOLS

* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABS JUVISE

* LABORATOIRES JUVISE PHARMACEUTICALS
PYLERA, BISMUTH SUBCITRATE POTASSIUM

LACER PHARMA

* LACER PHARMA LLC
ERTACZO, SERTACONAZOLE NITRATE
ULTRAVATE, HALOBETASOL PROPIONATE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

LANNETT

* LANNETT CO INC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC

* LANNETT CO INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CODEINE SULFATE, CODEINE SULFATE
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LORATADINE, LORATADINE (OTC)
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METAXALONE, METAXALONE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NIACIN, NIACIN
OMEPRAZOLE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SUMATRIPTAN, SUMATRIPTAN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
URSODIOL, URSODIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

LANTHEUS MEDCL
* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY RT, PERFLUTREN
DEFINITY, PERFLUTREN
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
XENON XE 133, XENON XE-133

LAURUS
* LAURUS LABS LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
FLUCYTOSINE, FLUCYTOSINE
GABAPENTIN, GABAPENTIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
MACITENTAN, MACITENTAN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PIRFENIDONE, PIRFENIDONE
SACUBITRIL AND VALSARTAN, SACUBITRIL

LAVIPHARM
* LAVIPHARM SA
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE

LEADIANT BIOSCI INC
* LEADIANT BIOSCIENCES INC
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING
* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
FOLIC ACID, FOLIC ACID
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LORAZEPAM, LORAZEPAM
METYROSINE, METYROSINE
OXAZEPAM, OXAZEPAM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

LEGACY PHARMA
* LEGACY PHARMA INC
ALA-SCALP, HYDROCORTISONE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BRISDELLE, PAROXETINE MESYLATE
CLODERM, CLOCORTOLONE PIVALATE
CROTAN, CROTAMITON
ESBRIET, PIRFENIDONE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LEGACY PHARMA INC
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

LEGACY PHARMA USA

* LEGACY PHARMA USA INC
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

LENZ THERAP

* LENZ THERAPEUTICS INC
VIZZ, ACECLIDINE HYDROCHLORIDE

LEO PHARMA AS

* LEO PHARMA AS
ANZUPGO, DELGOCITINIB
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
FINACEA, AZELAIC ACID
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

LEXENPHARM

* LEXENPHARM SUZHOU LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE

LEXICON PHARMS INC

* LEXICON PHARMACEUTICALS INC
INPEFA, SOTAGLIFLOZIN

LGM PHARMA

* LGM PHARMA SOLUTIONS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
URSODIOL, URSODIOL

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR

* LIFE MOLECULAR IMAGING LTD
NEURACEQ, FLORBETABEN F-18

LIFSA DRUGS

* LIFSA DRUGS LLC
MARPLAN, ISOCARBOXAZID

LINDE GAS EQUIP

* LINDE GAS AND EQUIPMENT INC
NOXIVENT, NITRIC OXIDE

LIQUIDIA TECH

* LIQUIDIA TECHNOLOGIES INC
YUTREPIA, TREPROSTINIL SODIUM

LIVZON GRP

* LIVZON GROUP PHARMACEUTICAL FACTORY

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LIVZON GROUP PHARMACEUTICAL FACTORY
CETRORELIX ACETATE, CETRORELIX ACETATE

LNHC
* LNHC INC
ZELSUVMI, BERDAZIMER SODIUM

LNK
* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC
* LNK INTERNATIONAL INC
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LONG GROVE PHARMS
* LONG GROVE PHARMACEUTICALS LLC
AK-FLUOR 10%, FLUORESCEIN SODIUM
CALCITRIOL, CALCITRIOL
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
DIAZEPAM, DIAZEPAM
ERIBULIN MESYLATE, ERIBULIN MESYLATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VASOPRESSIN IN SODIUM CHLORIDE 0.9%, VASOPRESSIN

LOREAL USA
* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD
* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
LENALIDOMIDE, LENALIDOMIDE

LOXO ONCOL
* LOXO ONCOLOGY INC
JAYPIRCA, PIRTOBRUTINIB

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID

LUKARE MEDICAL LLC
* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUMICELL
* LUMICELL INC
LUMISIGHT, PEGULICIANINE ACETATE

LUNDBECK NA LTD
* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC
* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUOXIN AUROVITAS
* LUOXIN AUROVITAS PHARMA CHENGDU CO LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

LUPIN
* LUPIN INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ANTARA (MICRONIZED), FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN INC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
BUDESONIDE, BUDESONIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DASATINIB, DASATINIB
DESOXIMETASONE, DESOXIMETASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DRONEDARONE HYDROCHLORIDE, DRONEDARONE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
MIDOSTAURIN, MIDOSTAURIN
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
SACUBITRIL AND VALSARTAN, SACUBITRIL
TESTOSTERONE, TESTOSTERONE
TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUMETANIDE, BUMETANIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LTD

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DARUNAVIR, DARUNAVIR
DAYSEE, ETHINYL ESTRADIOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE, EMTRICITABINE
ENSKYCE, DESOGESTREL
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FYAVOLV, ETHINYL ESTRADIOL
GANIRELIX ACETATE, GANIRELIX ACETATE
GLUCAGON, GLUCAGON
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LIRAGLUTIDE, LIRAGLUTIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEFENAMIC ACID, MEFENAMIC ACID
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINZOYA, ETHINYL ESTRADIOL
MIRABEGRON, MIRABEGRON
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
QUININE SULFATE, QUININE SULFATE
RALTEGRAVIR POTASSIUM, RALTEGRAVIR POTASSIUM
RIVAROXABAN, RIVAROXABAN
RUFINAMIDE, RUFINAMIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILODOSIN, SILODOSIN
SUPRAX, CEFIXIME
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TENOFOVIR ALAFENAMIDE, TENOFOVIR ALAFENAMIDE FUMARATE
TESTOSTERONE, TESTOSTERONE
TOLVAPTAN, TOLVAPTAN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TURQOZ, ETHINYL ESTRADIOL
TYDEMY, DROSPIRENONE
VALBENAZINE TOSYLATE, VALBENAZINE TOSYLATE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VYFEMLA, ETHINYL ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS
* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME

LUYE INNOMIND PHARMA
* LUYE INNOMIND PHARMA (SHIJIAZHUANG) CO LTD
ERZOFRI, PALIPERIDONE PALMITATE

LXO IRELAND
* LXO IRELAND DESIGNATED ACTIVITY CO
GOPRELTO, COCAINE HYDROCHLORIDE

LYNE
* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
NYSTATIN, NYSTATIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

PERRIGO
* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ****

MA GENERAL HOSP
* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD

ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CELECOXIB, CELECOXIB
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIDOCAINE, LIDOCAINE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
NIACIN, NIACIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXCARBAZEPINE, OXCARBAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MACLEODS PHARMACEUTICALS LTD
PERPHENAZINE, PERPHENAZINE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVAROXABAN, RIVAROXABAN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SACUBITRIL AND VALSARTAN, SACUBITRIL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TICAGRELOR, TICAGRELOR
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MADRIGAL

* MADRIGAL PHARMACEUTICALS INC
REZDIFFRA, RESMETIROM

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
ANGIOMAX RTU, BIVALIRUDIN
BACLOFEN, BACLOFEN
DAPTOMYCIN, DAPTOMYCIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
SINCALIDE, SINCALIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT IRELAND

* MALLINCKRODT PHARMACEUTICALS IRELAND LTD
ACTHAR GEL (AUTOINJECTOR), CORTICOTROPIN
ACTHAR GEL, CORTICOTROPIN
INOMAX, NITRIC OXIDE
TERLIVAZ, TERLIPRESSIN ACETATE

MANKIND PHARMA

* MANKIND PHARMA LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
APREMILAST, APREMILAST
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MANKIND PHARMA LTD
ATROPINE SULFATE, ATROPINE SULFATE
BACLOFEN, BACLOFEN
BIMATOPROST, BIMATOPROST
BUMETANIDE, BUMETANIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL
LATANOPROST, LATANOPROST
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
OFLOXACIN, OFLOXACIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
TELMISARTAN, TELMISARTAN
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MARINUS

* MARINUS PHARMACEUTICALS INC
ZTALMY, GANAXOLONE

MARIUS

* MARIUS PHARMACEUTICALS INC
KYZATREX, TESTOSTERONE UNDECANOATE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MARKSANS PHARMA LTD
PARICALCITOL, PARICALCITOL

MAYNE PHARMA
* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
TOLSURA, ITRACONAZOLE
* MAYNE PHARMA LLC
ANNOVERA, ETHINYL ESTRADIOL
BIJUVA, ESTRADIOL
EPSOLAY, BENZOYL PEROXIDE
FABIOR, TAZAROTENE
IMVEXXY, ESTRADIOL
LEXETTE, HALOBETASOL PROPIONATE
NEXTSTELLIS, DROSPIRENONE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE
TWYNEO, BENZOYL PEROXIDE

MAYNE PHARMA COMMRCL
* MAYNE PHARMA COMMERCIAL LLC
SOLTAMOX, TAMOXIFEN CITRATE

MC2
* MC2 THERAPEUTICS LTD
WYNZORA, BETAMETHASONE DIPROPIONATE

MCGUFF
* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCPRF
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDD US
* MDD US OPERATIONS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
XADAGO, SAFINAMIDE MESYLATE
* MDD US OPERATIONS LLC A SUB OF SUPERNUS PHARMACEUTICALS INC
ONAPGO, APOMORPHINE HYDROCHLORIDE

MDGH
* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC
* MEDEFIL INC
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS
* MEDEXUS PHARMA INC
GRAFAPEX, TREOSULFAN
RASUVO, METHOTREXATE

MEDI-PHYSICS
* MEDI-PHYSICS INC DBA GE HEALTHCARE
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT

MEDI-RADIOPHARMA
* MEDI-RADIOPHARMA LTD
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

MEDICAP LABS
* MEDICAP LABORATORIES

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEDICAP LABORATORIES
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

MEDICINES360
* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICURE
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS
* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

MEDLINE INDUSTRIES
* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDRX USA
* MEDRX USA INC
BONDLIDO, LIDOCAINE

MEDTECH PRODUCTS
* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEDUNIK
* MEDUNIK CANADA INC
NITISINONE, NITISINONE
PHEBURANE, SODIUM PHENYLBUTYRATE

MEITHEAL
* MEITHEAL PHARMACEUTICALS INC
ADENOSINE, ADENOSINE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZACITIDINE, AZACITIDINE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLOFARABINE, CLOFARABINE
CONTEPO, FOSFOMYCIN DISODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEITHEAL PHARMACEUTICALS INC
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ETOPOSIDE, ETOPOSIDE
FUROSEMIDE, FUROSEMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHYLENE BLUE, METHYLENE BLUE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NELARABINE, NELARABINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PLERIXAFOR, PLERIXAFOR
REGADENOSON, REGADENOSON
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THIOTEPA, THIOTEPA
TIGECYCLINE, TIGECYCLINE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MELINTA
* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP
* MELINTA THERAPEUTICS LLC
KIMYRSA, ORITAVANCIN DIPHOSPHATE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
* MELINTA THERAPEUTICS LLC A WHOLLY OWNED SUB OF CORMEDIX INC
TOPROL-XL, METOPROLOL SUCCINATE

MERCK
* MERCK AND CO INC
PRIMAXIN, CILASTATIN SODIUM

MERCK AND CO INC
* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE

MERCK SHARP DOHME
* MERCK SHARP AND DOHME CORP
BELSOMRA, SUVOREXANT
JANUVIA, SITAGLIPTIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MERCK SHARP AND DOHME CORP
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
WELIREG, BELZUTIFAN

MERIDIAN BIOSCIENCE

* MERIDIAN BIOSCIENCE ISRAEL LTD
IDKIT:HP, CITRIC ACID

MERZ

* MERZ PHARMACEUTICALS LLC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC

* METACEL PHARMACEUTICALS LLC
OZOBAX DS, BACLOFEN

METHAPHARM

* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

MICRO LABS

* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BACLOFEN, BACLOFEN
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DALFAMPRIDINE, DALFAMPRIDINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHRA-DERM, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
GLIMEPIRIDE, GLIMEPIRIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LATANOPROST, LATANOPROST
LEVETIRACETAM, LEVETIRACETAM
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METOLAZONE, METOLAZONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MICRO LABS LTD
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIRFENIDONE, PIRFENIDONE
PIROXICAM, PIROXICAM
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMVASTATIN, SIMVASTATIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TAFLUPROST, TAFLUPROST
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD
* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA
* MICRO LABS LTD INDIA
ACETAZOLAMIDE, ACETAZOLAMIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDWEST MEDCL
* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART
* MIKART LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHOCARBAMOL, METHOCARBAMOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

MILESTONE PHARMS USA
* MILESTONE PHARMACEUTICALS USA INC
CARDAMYST, ETRIPAMIL

MILLA PHARMS
* MILLA PHARMACEUTICALS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
SODIUM ACETATE, SODIUM ACETATE
TRANEXAMIC ACID, TRANEXAMIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MILLA PHARMACEUTICALS INC
TROMETHAMINE, TROMETHAMINE

MILLICENT

* MILLICENT PHARMA LTD
INTRAROSA, PRASTERONE

MILLICENT PR

* MILLICENT PUERTO RICO LLC
FEMLYV, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIRUM

* MIRUM PHARMACEUTICALS INC
CHOLBAM, CHOLIC ACID
CTEXLI, CHENODIOL
LIVMARLI, MARALIXIBAT CHLORIDE

MISEMER

* MISEMER PHARMACEUTICALS INC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
KETOPROFEN, KETOPROFEN

MISSION PHARMA

* MISSION PHARMACAL CO
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
THIOLA EC, TIOPRONIN

MITEM PHARMA

* MITEM PHARMA INC
DESFERAL, DEFEROXAMINE MESYLATE

MLV

* MLV PHARMA LLC
CARVEDILOL, CARVEDILOL
NYSTATIN, NYSTATIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

MMT

* MERIDIAN MEDICAL TECHNOLOGIES LLC
DUODOTE, ATROPINE

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MOUNTAIN LLC
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE

MPP PHARMA

* MPP PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL, CARISOPRODOL
CLARITHROMYCIN, CLARITHROMYCIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NIACIN, NIACIN
PINDOLOL, PINDOLOL
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

MSD

* MERCK SHARP AND DOHME LLC
EMEND, APREPITANT
PREVYMIS, LETERMOVIR
VERQUVO, VERICIGUAT

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
NOXAFIL POWDERMIX KIT, POSACONAZOLE
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM

MSD SUB MERCK

* MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
SEGLUROMET, ERTUGLIFLOZIN
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
ZOLINZA, VORINOSTAT

MSN

* MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
APREMILAST, APREMILAST
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BORTEZOMIB, BORTEZOMIB
BRIVARACETAM, BRIVARACETAM
BUMETANIDE, BUMETANIDE
CAPECITABINE, CAPECITABINE
CARMUSTINE, CARMUSTINE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DARUNAVIR, DARUNAVIR
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOFETILIDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MSN LABORATORIES PRIVATE LTD
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LEVETIRACETAM, LEVETIRACETAM
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOFEXIDINE HYDROCHLORIDE, LOFEXIDINE HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MACITENTAN, MACITENTAN
MIRABEGRON, MIRABEGRON
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NELARABINE, NELARABINE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLUMIANT, BARICITINIB
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PACLITAXEL, PACLITAXEL
PERAMPANEL, PERAMPANEL
PIRFENIDONE, PIRFENIDONE
PLERIXAFOR, PLERIXAFOR
POSACONAZOLE, POSACONAZOLE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIOCIGUAT, RIOCIGUAT
RIVAROXABAN, RIVAROXABAN
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SACUBITRIL AND VALSARTAN, SACUBITRIL
SAFINAMIDE MESYLATE, SAFINAMIDE MESYLATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIROLIMUS, SIROLIMUS
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TASIMELTEON, TASIMELTEON
TERIFLUNOMIDE, TERIFLUNOMIDE
THIOTEPA, THIOTEPA
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TICAGRELOR, TICAGRELOR
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
TOLVAPTAN, TOLVAPTAN
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE

MSN LABS PVT LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MSN LABORATORIES PRIVATE LTD
AZACITIDINE, AZACITIDINE
LACOSAMIDE, LACOSAMIDE

MSN PHARMS INC

* MSN PHARMACEUTICALS INC
DROXIDOPA, DROXIDOPA

MUNDIPHARMA

* MUNDIPHARMA GMBH
REZZAYO, REZAFUNGIN ACETATE

MYCOVIA PHARMS

* MYCOVIA PHARMACEUTICALS INC
VIVJOA, OTESECONAZOLE

MYLAN

* MYLAN INSTITUTIONAL LLC A VIATRIS CO
ALOPRIM, ALLOPURINOL SODIUM
* MYLAN PHARMACEUTICALS
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* MYLAN PHARMACEUTICALS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAMINOPHEN, ACETAMINOPHEN
ACITRETIN, ACITRETIN
ALLOPURINOL, ALLOPURINOL
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREYNA, BUDESONIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOZAPINE, CLOZAPINE
COLCHICINE, COLCHICINE
CYCLOSPORINE, CYCLOSPORINE
CYSTAGON, CYSTEAMINE BITARTRATE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DAPSONE, DAPSONE
DARUNAVIR, DARUNAVIR
DENAVIR, PENCICLOVIR
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ERMEZA, LEVOTHYROXINE SODIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
IMATINIB MESYLATE, IMATINIB MESYLATE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LINAGLIPTIN, LINAGLIPTIN
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MERCAPTOPURINE, MERCAPTOPURINE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
NISOLDIPINE, NISOLDIPINE
PACLITAXEL, PACLITAXEL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
REGADENOSON, REGADENOSON
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SAXAGLIPTIN, SAXAGLIPTIN HYDROCHLORIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SUCRALFATE, SUCRALFATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TICAGRELOR, TICAGRELOR
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALSARTAN, VALSARTAN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
WIXELA INHUB, FLUTICASONE PROPIONATE
ZONALON, DOXEPIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS INC A VIATRIS CO
DAPTOMYCIN, DAPTOMYCIN

MYLAN ASI

* MYLAN ASI LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN ASI LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
BUSULFAN, BUSULFAN

* MYLAN INSTITUTIONAL LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
BIVALIRUDIN, BIVALIRUDIN
CIDOFOVIR, CIDOFOVIR
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FOMEPIZOLE, FOMEPIZOLE
ISOSULFAN BLUE, ISOSULFAN BLUE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
MIACALCIN, CALCITONIN SALMON
PRETOMANID, PRETOMANID
YUPELRI, REVEFENACIN

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMPHOTERICIN B, AMPHOTERICIN B
CIMDUO, LAMIVUDINE
DAPTOMYCIN, DAPTOMYCIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIFLUPREDNATE, DIFLUPREDNATE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IRON SUCROSE, IRON SUCROSE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LOPINAVIR AND RITONAVIR, LOPINAVIR
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXALIPLATIN, OXALIPLATIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
POSACONAZOLE, POSACONAZOLE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SYMFI, EFAVIRENZ
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVITA, TRETINOIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ESZOPICLONE, ESZOPICLONE
FENOFIBRATE, FENOFIBRATE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

MYLAN SPCLT VIATRIS

* MYLAN SPECIALTY LP A VIATRIS CO
DIPENTUM, OLSALAZINE SODIUM

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
DEPEN, PENICILLAMINE
DYMISTA, AZELASTINE HYDROCHLORIDE
EPIFOAM, HYDROCORTISONE ACETATE
FELBATOL, FELBAMATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL

MYLAN TECH VIATRIS

* MYLAN TECHNOLOGIES INC A VIATRIS CO
METHYLPHENIDATE, METHYLPHENIDATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN TECHNOLOGIES INC
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

** N **

NAARI PTE
* NAARI PTE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NAL PHARM
* NAL PHARMACEUTICAL GROUP LTD
LIDOCAINE, LIDOCAINE

NALPROPION
* NALPROPION PHARMACEUTICALS LLC
CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO
* NANG KUANG PHARMACEUTICAL CO LTD
ICATIBANT ACETATE, ICATIBANT ACETATE
LINEZOLID, LINEZOLID
PEMETREXED DISODIUM, PEMETREXED DISODIUM

NANJING
* NANJING SIMCERE DONGYUAN PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB

NANJING DELOVA
* NANJING DELOVA BIOTECH CO LTD
QAMZOVA, MELOXICAM

NANJING KING FRIEND
* NANJING KING FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
LIRAGLUTIDE, LIRAGLUTIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PROPOFOL, PROPOFOL

NANOMI
* NANOMI BV
RISPERIDONE, RISPERIDONE

NAPO PHARMS INC
* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO
* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
CARISOPRODOL, CARISOPRODOL
EVEROLIMUS, EVEROLIMUS
GEFITINIB, GEFITINIB
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
NITROGLYCERIN, NITROGLYCERIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE

NATCO PHARMA
* NATCO PHARMA LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
SUNITINIB MALATE, SUNITINIB MALATE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
BOSENTAN, BOSENTAN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARGLUMIC ACID, CARGLUMIC ACID
CARMUSTINE, CARMUSTINE
DIAZEPAM, DIAZEPAM
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
MARAVIROC, MARAVIROC
MIGLUSTAT, MIGLUSTAT
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NE RX PHARMA

* NE RX PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METOLAZONE, METOLAZONE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

NEOCUBES PHARMA

* NEOCUBES PHARMA LLP
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE

NEOS THERAPS

* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC

* NEOS THERAPEUTICS INC
COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON

* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
* NEPHRON PHARMACEUTICALS CORPORATION
BUDESONIDE, BUDESONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

NEURELIS INC
* NEURELIS INC
VALTOCO, DIAZEPAM

NEUROCRINE
* NEUROCRINE BIOSCIENCES INC
CRENESSITY, CRINECERFONT
INGREZZA SPRINKLE, VALBENAZINE TOSYLATE
INGREZZA, VALBENAZINE TOSYLATE

NEW HEIGHTSRX
* NEW HEIGHTSRX LLC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN

NEXTWAVE
* NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS
* NEXTWAVE PHARMACEUTICALS INC
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS
* NEXUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
EMERPHED, EPHEDRINE SULFATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
FLUORESCEIN SODIUM, FLUORESCEIN SODIUM
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
METHYLENE BLUE, METHYLENE BLUE
NELARABINE, NELARABINE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
TACROLIMUS, TACROLIMUS
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

NIAGARA PHARMS
* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NIPPON SHINYAKU
* NIPPON SHINYAKU CO LTD
VILTEPSO, VILTOLARSEN

NIVAGEN PHARMS INC
* NIVAGEN PHARMACEUTICALS INC
CALCIUM GLUCONATE, CALCIUM GLUCONATE
DECITABINE, DECITABINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
ZINC SULFATE, ZINC SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

NOBELPHARMA
* NOBELPHARMA CO LTD
HYFTOR, SIROLIMUS

NODEN PHARMA
* NODEN PHARMA DAC
TEKTURNA, ALISKIREN HEMIFUMARATE

NORDIC PHARMA
* NORDIC PHARMA INC
DDAVP, DESMOPRESSIN ACETATE

NORTHLAND
* NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE
* NORTHSTAR HEALTHCARE HOLDINGS LTD
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE

NORTON WATERFORD
* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NORWICH
* NORWICH PHARMACEUTICALS INC
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE

NOSTRUM PHARMS LLC
* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

NOVA LABS LTD
* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE
XROMI, HYDROXYUREA

NOVA PNEUMA
* NOVA PNEUMA INC
ADASUVE, LOXAPINE

NOVADAQ TECH
* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS
* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
COARTEM, ARTEMETHER
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
EGATEN, TRICLABENDAZOLE
ENTRESTO SPRINKLE, SACUBITRIL
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FABHALTA, IPTACOPAN HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LEQVIO, INCLISIRAN SODIUM
LOCAMETZ, GALLIUM GA-68 GOZETOTIDE
MAYZENT, SIPONIMOD
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MYFORTIC, MYCOPHENOLATE SODIUM
NEORAL, CYCLOSPORINE
PIQRAY, ALPELISIB
PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
PROMACTA KIT, ELTROMBOPAG OLAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
PROMACTA, ELTROMBOPAG OLAMINE
RHAPSIDO, REMIBRUTINIB
RYDAPT, MIDOSTAURIN
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
TAFINLAR, DABRAFENIB MESYLATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
TYKERB, LAPATINIB DITOSYLATE
VANRAFIA, ATRASENTAN HYDROCHLORIDE
VIJOICE, ALPELISIB
VOTRIENT, PAZOPANIB HYDROCHLORIDE
ZORTRESS, EVEROLIMUS
ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS
TABRECTA, CAPMATINIB HYDROCHLORIDE

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ENTRESTO, SACUBITRIL
JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE
* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBAMAZEPINE, CARBAMAZEPINE
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL, CARISOPRODOL
CHABELINA FE, ETHINYL ESTRADIOL
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CONJUGATED ESTROGENS, ESTROGENS, CONJUGATED
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DECITABINE, DECITABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOLISHALE, ETHINYL ESTRADIOL
DROSPIRENONE AND ESTRADIOL, DROSPIRENONE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVAST LABORATORIES LTD
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LO-MALMOREDE, ETHINYL ESTRADIOL
MALMOREDE, ETHINYL ESTRADIOL
MELAMISA, DROSPIRENONE
MESALAMINE, MESALAMINE
MESNA, MESNA
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE, NORETHINDRONE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PIMTREA, DESOGESTREL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RANOLAZINE, RANOLAZINE
SETLAKIN, ETHINYL ESTRADIOL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRI-LO-LINYAH, ETHINYL ESTRADIOL
TRIAZOLAM, TRIAZOLAM
YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVATECH SA

* NOVATECH SA
STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVEL LABORATORIES INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVEN

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE
XELSTRYM, DEXTROAMPHETAMINE

NOVITIUM PHARMA

* NOVITIUM PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BETAINE, BETAINE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARBAMAZEPINE, CARBAMAZEPINE
CARGLUMIC ACID, CARGLUMIC ACID
CHLORZOXAZONE, CHLORZOXAZONE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE, CLOTRIMAZOLE
DAPSONE, DAPSONE
DEXAMETHASONE, DEXAMETHASONE
DIAZOXIDE, DIAZOXIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FAMOTIDINE, FAMOTIDINE
FELBAMATE, FELBAMATE
FINASTERIDE AND TADALAFIL, FINASTERIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVITIUM PHARMA LLC
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INZIRQO, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
L-GLUTAMINE, L-GLUTAMINE
LACOSAMIDE, LACOSAMIDE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOFEXIDINE HYDROCHLORIDE, LOFEXIDINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MESALAMINE, MESALAMINE
METHSUXIMIDE, METHSUXIMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METRONIDAZOLE, METRONIDAZOLE
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
NITISINONE, NITISINONE
NITROFURANTOIN, NITROFURANTOIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIFABUTIN, RIFABUTIN
RISPERIDONE, RISPERIDONE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOVUNA, HYDROXYCHLOROQUINE SULFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TADALAFIL, TADALAFIL
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VALSARTAN, VALSARTAN

NOVO

* NOVO NORDISK INC
OZEMPIC, SEMAGLUTIDE
RIVFLOZA, NEDOSIRAN SODIUM
RYBELSUS, SEMAGLUTIDE
SAXENDA, LIRAGLUTIDE
WEGOVY, SEMAGLUTIDE

NOVO NORDISK INC

* NOVO NORDISK INC
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE

NOVUGEN

* NOVUGEN ONCOLOGY SDN BHD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
EVEROLIMUS, EVEROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVUGEN ONCOLOGY SDN BHD
LENALIDOMIDE, LENALIDOMIDE
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
* NOVUGEN PHARMA MALAYSIA SDN BHD
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

NOVUGEN PHARMA SDN
* NOVUGEN PHARMA SDN BHD
SACUBITRIL AND VALSARTAN, SACUBITRIL

NUKEMED
* NUKEMED INC DBA SPECTRONRX
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NUVATION
* NUVATION BIO INC
IBTROZI, TALETRECTINIB ADIPATE

NUVO PHARM
* NUVO PHARMACEUTICAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS
* NUVO PHARMACEUTICALS (IRELAND) DAC
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL

NUVO PHARMS INC
* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFASALAZINE, SULFASALAZINE

NXDC
* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ****

OCULAR THERAPEUTIX
* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

OCUVEX THERAP
* OCUVEX THERAPEUTICS INC
OMLONTI, OMIDENEPAG ISOPROPYL

OHM LABS
* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC
* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
GUAIFENESIN, GUAIFENESIN (OTC)
VALSARTAN, VALSARTAN

OMNIVIUM PHARMS
* OMNIVIUM PHARMACEUTICALS LLC
GLYCOPYRROLATE, GLYCOPYRROLATE
ISONIAZID, ISONIAZID
MONOKET, ISOSORBIDE MONONITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OMNIVIUM PHARMACEUTICALS LLC
NUMBRINO, COCAINE HYDROCHLORIDE
SODIUM BICARBONATE, SODIUM BICARBONATE

OMSAV PHARMA

* OMSAV PHARMA RESEARCH PRIVATE LTD
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

ON TARGET LABS

* ON TARGET LABORATORIES INC
CYTALUX, PAFOLACIANINE SODIUM

ONESOURCE SPECIALTY

* ONESOURCE SPECIALTY PTE LTD
ACETYLCYSTEINE, ACETYLCYSTEINE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BENZONATATE, BENZONATATE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DUTASTERIDE, DUTASTERIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
ICOSAPENT ETHYL, ICOSAPENT ETHYL
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
METHOHEXITAL SODIUM, METHOHEXITAL SODIUM
METHOXSALEN, METHOXSALEN
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXACILLIN SODIUM, OXACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE

ONYX PHARMS AMGEN

* ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORASIS PHARMS

* ORASIS PHARMACEUTICALS LTD
QLOSI, PILOCARPINE HYDROCHLORIDE

ORBION PHARMS

* ORBION PHARMACEUTICALS PRIVATE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORBION PHARMACEUTICALS PRIVATE LTD
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

ORGANON

* ORGANON LLC A SUB OF ORGANON AND CO
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
DIPROLENE, BETAMETHASONE DIPROPIONATE
FOSAMAX, ALENDRONATE SODIUM
HYZAAR, HYDROCHLOROTHIAZIDE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PROPECIA, FINASTERIDE
PROSCAR, FINASTERIDE
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
VYTORIN, EZETIMIBE
ZETIA, EZETIMIBE
ZOCOR, SIMVASTATIN
* ORGANON USA LLC
NEXPLANON, ETONOGESTREL
REMERON, MIRTAZAPINE

ORGANON LLC

* ORGANON LLC
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
CLARINEX-D 12 HOUR, DESLORATADINE
DULERA, FORMOTEROL FUMARATE
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE
VTAMA, TAPINAROF
XACIATO, CLINDAMYCIN PHOSPHATE

ORGANON USA ORGANON

* ORGANON USA LLC A SUB OF ORGANON AND CO
GANIRELIX ACETATE, GANIRELIX ACETATE
NUVARING, ETHINYL ESTRADIOL
REMERON SOLTAB, MIRTAZAPINE

ORIENT PHARMA

* ORIENT PHARMA CO LTD
EZETIMIBE, EZETIMIBE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
GLYBURIDE, GLYBURIDE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORION PHARMA
STALEVO 75, CARBIDOPA

ORPHALAN

* ORPHALAN SA
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE

ORYZA

* ORYZA PHARMACEUTICALS INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY ASIMTUFII, ARIPIPRAZOLE
ABILIFY, ARIPIPRAZOLE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE
SAMSCA, TOLVAPTAN

OTSUKA ICU MEDCL

* OTSUKA ICU MEDICAL LLC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OTSUKA ICU MEDICAL LLC
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

OTSUKA PHARM
* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE

OVERSEAS
* OVERSEAS PHARMACEUTICALS LTD
LEVETIRACETAM, LEVETIRACETAM

OWP PHARMS
* OWP PHARMACEUTICALS INC
SUBVENITE, LAMOTRIGINE

OXFORD PHARMS
* OXFORD PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

OYSTER POINT PHARMA
* OYSTER POINT PHARMA INC
TYRVAYA, VARENICLINE TARTRATE

**** P ****

P AND L
* P AND L DEVELOPMENT LLC
ADAPALENE, ADAPALENE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

P AND L DEV LLC
* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

P AND L DEVELOPMENT
* P AND L DEVELOPMENT LLC
DOCOSANOL, DOCOSANOL (OTC)

PACIFIC PHARMA
* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC
* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE
ZILRETTA, TRIAMCINOLONE ACETONIDE

PADAGIS ISRAEL
* PADAGIS ISRAEL PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUDESONIDE, BUDESONIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESTRADIOL, ESTRADIOL
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIQUIMOD, IMIQUIMOD
IVERMECTIN, IVERMECTIN
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PENCICLOVIR, PENCICLOVIR
PERMETHRIN, PERMETHRIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUMATRIPTAN, SUMATRIPTAN
TAZAROTENE, TAZAROTENE
TERCONAZOLE, TERCONAZOLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

PADAGIS US
* PADAGIS US LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADAGIS US LLC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CENTANY, MUPIROCIN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COMPRO, PROCHLORPERAZINE
CYCLOSPORINE, CYCLOSPORINE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ENTOCORT EC, BUDESONIDE
ERYTHROMYCIN, ERYTHROMYCIN
EVAMIST, ESTRADIOL
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
KETOCONAZOLE, KETOCONAZOLE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PODOFILOX, PODOFILOX
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SCOPOLAMINE, SCOPOLAMINE
SELENIUM SULFIDE, SELENIUM SULFIDE
STIE-CORT, HYDROCORTISONE
SUCRALFATE, SUCRALFATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TAVABOROLE, TAVABOROLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PAI HOLDINGS

* PAI HOLDINGS LLC
LACTULOSE, LACTULOSE
* PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC AND DBA PAI PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC AND DBA PAI PHARMA
ATOVAQUONE, ATOVAQUONE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE

PAI HOLDINGS PHARM

* PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC
CEFOTAN, CEFOTETAN DISODIUM
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

PANACEA

* PANACEA BIOTEC PHARMA LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PANGEA

* PANGEA PHARMACEUTICALS LLC
ERGOMAR, ERGOTAMINE TARTRATE
ETODOLAC, ETODOLAC
OXAPROZIN, OXAPROZIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARATEK PHARMS

* PARATEK PHARMACEUTICALS INC
NUZYRA, OMADACYCLINE TOSYLATE
XHANCE, FLUTICASONE PROPIONATE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
NARDIL, PHENELZINE SULFATE
ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS

* PARKE-DAVIS DIVISION OF PFIZER INC
ZARONTIN, ETHOSUXIMIDE

PATHEON SOFTGELS

* PATHEON SOFTGELS BV
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

PD PARTNERS

* PD PARTNERS III LLC
SUCRALFATE, SUCRALFATE

PENN LIFE

* PENN LIFE SCIENCES LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CARMUSTINE, CARMUSTINE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
THIOTEPA, THIOTEPA

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
PERMETHRIN, PERMETHRIN (OTC)

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MINOXIDIL, MINOXIDIL (OTC)
NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
LORATADINE, LORATADINE (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO R AND D

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)

PETNET

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
CHANTIX, VARENICLINE TARTRATE
INLYTA, AXITINIB
PRISTIQ, DESVENLAFAXINE SUCCINATE
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
AROMASIN, EXEMESTANE
ARTHROTEC, DICLOFENAC SODIUM
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CIBINQO, ABROCITINIB
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PFIZER INC
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOTEC, MISOPROSTOL
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ESTRING, ESTRADIOL
FLAGYL, METRONIDAZOLE
FRAGMIN, DALTEPARIN SODIUM
GLUCOTROL XL, GLIPIZIDE
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IBRANCE, PALBOCICLIB
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LITFULO, RITLECITINIB TOSYLATE
LOMOTIL, ATROPINE SULFATE
LORBRENA, LORLATINIB
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NURTEC ODT, RIMEGEPANT SULFATE
OGEN 5, ESTROPIPATE
PAXLOVID (COPACKAGED), NIRMATRELVIR
PREPIDIL, DINOPROSTONE
PROCARDIA, NIFEDIPINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
SYNAREL, NAFARELIN ACETATE
TALZENNA, TALAZOPARIB TOSYLATE
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
VELSIPITY, ETRASIMOD ARGININE
VIZIMPRO, DACOMITINIB
XELJANZ XR, TOFACITINIB CITRATE
XELJANZ, TOFACITINIB CITRATE
ZAVZPRET, ZAVEGEPANT HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN
ZYVOX, LINEZOLID

* PFIZER LABORATORIES DIV PFIZER INC
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
VISTARIL, HYDROXYZINE PAMOATE

* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER INC

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
LOPID, GEMFIBROZIL

PH HEALTH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PH HEALTH LTD
ADRENALIN, EPINEPHRINE
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
ALVIMOPAN, ALVIMOPAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CHLORZOXAZONE, CHLORZOXAZONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
COLCHICINE, COLCHICINE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
EVEROLIMUS, EVEROLIMUS
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GLYCEROL PHENYLBUTYRATE, GLYCEROL PHENYLBUTYRATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYUREA, HYDROXYUREA
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETALAR, KETAMINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
MICAFUNGIN, MICAFUNGIN SODIUM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYZILRA, ETHINYL ESTRADIOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PH HEALTH LTD
PENICILLAMINE, PENICILLAMINE
PERPHENAZINE, PERPHENAZINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIMOZIDE, PIMOZIDE
PITOCIN, OXYTOCIN
POSACONAZOLE, POSACONAZOLE
PRAZIQUANTEL, PRAZIQUANTEL
PREDNISONE, PREDNISONE
PREVIFEM, ETHINYL ESTRADIOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RISPERIDONE, RISPERIDONE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIOPRONIN, TIOPRONIN
TOLVAPTAN, TOLVAPTAN
TOPIRAMATE, TOPIRAMATE
TRETINOIN, TRETINOIN
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
URSODIOL, URSODIOL
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VASOSTRICT, VASOPRESSIN
VIGABATRIN, VIGABATRIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARMAAND

* PHARMAAND GMBH
RUBRACA, RUCAPARIB CAMSYLATE

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMACIA AND UPJOHN CO LLC
CADUET, AMLODIPINE BESYLATE
DILANTIN, PHENYTOIN

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO
CORTEF, HYDROCORTISONE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE

PHARMACO

* PHARMACO LLC
ETODOLAC, ETODOLAC
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

PHARMACOSMOS

* PHARMACOSMOS AS
COSELA, TRILACICLIB DIHYDROCHLORIDE
MONOFERRIC, FERRIC DERISOMALTOSE

PHARMACYCLICS LLC

* PHARMACYCLICS LLC
IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

PHARMALOGIC

* PHARMALOGIC SOUTH CAROLINA LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMALOGIC HLDGS

* PHARMALOGIC HOLDINGS CORP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMASCIENCE INC

* PHARMASCIENCE INC
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS EUROPE

* PHARMAXIS EUROPE LTD
ARIDOL KIT, MANNITOL
BRONCHITOL, MANNITOL

PHARMING

* PHARMING TECHNOLOGIES BV
JOENJA, LENIOLISIB PHOSPHATE

PHARMOBEDIENT

* PHARMOBEDIENT CONSULTING LLC
ACYCLOVIR, ACYCLOVIR
ALLZITAL, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORTHALIDONE, CHLORTHALIDONE
CLOFARABINE, CLOFARABINE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEFERASIROX, DEFERASIROX
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMOBEDIENT CONSULTING LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EDARAVONE, EDARAVONE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERY-TAB, ERYTHROMYCIN
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LACTULOSE, LACTULOSE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LYPQOZET, ATORVASTATIN CALCIUM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEGESTROL ACETATE, MEGESTROL ACETATE
METHOCARBAMOL, METHOCARBAMOL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POLMON, DEXCHLORPHENIRAMINE MALEATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

PHARMOBEDIENT CNSLTG

* PHARMOBEDIENT CONSULTING
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE

PHATHOM

* PHATHOM PHARMACEUTICALS INC
VOQUEZNA DUAL PAK, AMOXICILLIN
VOQUEZNA TRIPLE PAK, AMOXICILLIN
VOQUEZNA, VONOPRAZAN FUMARATE

PHOTOCURE ASA

* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE

* PIERRE FABRE PHARMACEUTICALS INC
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PINNACLE BIOLGS
* PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL
* PIRAMAL HEALTHCARE UK LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DEFERASIROX, DEFERASIROX
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE

PIRAMAL CRITICAL
* PIRAMAL CRITICAL CARE INC
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL PHARMA
* PIRAMAL PHARMA LTD
ISOFLURANE, ISOFLURANE

PLANO PHARMS
* PLANO PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
HEPARIN SODIUM, HEPARIN SODIUM

PLD ACQUISITIONS
* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC
* PLD ACQUISITIONS LLC
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA
* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA
* PLX PHARMA INC
VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP
* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POINTVIEW HLDINGS
* POINTVIEW HOLDINGS LLC
CARISOPRODOL, CARISOPRODOL
METHOCARBAMOL, METHOCARBAMOL
PREDNISONE, PREDNISONE

POLAREAN
* POLAREAN INC
XENOVIEW, XENON XE-129 HYPERPOLARIZED

POWDER PHARMS
* POWDER PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PPI-DAC
* PERRIGO PHARMA INTERNATIONAL DAC
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

PRASCO
* PRASCO LLC DBA PRASCO LABORATORIES
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ESTRADIOL, ESTRADIOL
MIRTAZAPINE, MIRTAZAPINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

PRECISION DERMAT
* PRECISION DERMATOLOGY INC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC
* PRECISION DOSE INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR
* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRIMUS PHARMS
* PRIMUS PHARMACEUTICALS INC
IMPOYZ, CLOBETASOL PROPIONATE
METAXALONE, METAXALONE
SERNIVO, BETAMETHASONE DIPROPIONATE

PRINSTON INC
* PRINSTON PHARMACEUTICAL INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSULFAN, BUSULFAN
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRINSTON PHARMACEUTICAL INC
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SAFINAMIDE MESYLATE, SAFINAMIDE MESYLATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TICAGRELOR, TICAGRELOR
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE
VYDUO, NEBIVOLOL HYDROCHLORIDE

PRM PHARMA

* PRM PHARMA LLC
HEMICLOR, CHLORTHALIDONE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
PYLARIFY, PIFLUFOLASTAT F-18

PROTEGA PHARMS

* PROTEGA PHARMACEUTICALS INC
ROXYBOND, OXYCODONE HYDROCHLORIDE

PROVENSIS

* PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

* PROVEPHARM SAS
BAL, DIMERCAPROL
BLUDIGO, INDIGOTINDISULFONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PTC THERAP
* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT
SEPHIENCE, SEPIAPTERIN

PTS CONSULTING
* PTS CONSULTING LLC
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

PULMOFLOW INC
* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH
* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP LABS BLU
* PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

PURACAP PHARM
* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC
* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE PHARMA LP
* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
ZURNAI (AUTOINJECTOR), NALMEFENE HYDROCHLORIDE

PURE SOURCE
* PURE SOURCE LLC
THEROXIDIL, MINOXIDIL (OTC)

PYROS PHARMS
* PYROS PHARMACEUTICALS INC
VIGAFYDE, VIGABATRIN
VIGPODER, VIGABATRIN

**** Q ****

Q BIOMED
* Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU
* QILU PHARMACEUTICAL CO LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
AMIKACIN SULFATE, AMIKACIN SULFATE
CETRORELIX ACETATE, CETRORELIX ACETATE
CISPLATIN, CISPLATIN
CYCLOSPORINE, CYCLOSPORINE
EXEMESTANE, EXEMESTANE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Q ****

* QILU PHARMACEUTICAL CO LTD
GANIRELIX ACETATE, GANIRELIX ACETATE
HYDROXYUREA, HYDROXYUREA
ICOSAPENT ETHYL, ICOSAPENT ETHYL
LENALIDOMIDE, LENALIDOMIDE
MEROPENEM, MEROPENEM
MIRABEGRON, MIRABEGRON
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QILU ANTIBIOTICS

* QILU ANTIBIOTICS PHARMACEUTICAL CO LTD
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM

QILU PHARM HAINAN

* QILU PHARMACEUTICAL HAINAN CO LTD
BORTEZOMIB, BORTEZOMIB
BUMETANIDE, BUMETANIDE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GEFITINIB, GEFITINIB
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
POSACONAZOLE, POSACONAZOLE
TADALAFIL, TADALAFIL

QINGDAO BAHEAL PHARM

* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE

QUAGEN

* QUAGEN PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Q ****

* QUAGEN PHARMACEUTICALS LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RITONAVIR, RITONAVIR
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
UREX, METHENAMINE HIPPURATE
VALPROIC ACID, VALPROIC ACID

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ****

R-PHARM US LLC

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

RADIUS

* RADIUS HEALTH INC
BINOSTO, ALENDRONATE SODIUM
TYMLOS, ABALOPARATIDE

RAFA LABS LTD

* RAFA LABORATORIES LTD
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR), MIDAZOLAM HYDROCHLORIDE

RAYNER SURGICAL

* RAYNER SURGICAL INC
OMIDRIA, KETOROLAC TROMETHAMINE

RB HLTH

* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
ISTURISA, OSILODROSTAT PHOSPHATE
NEOPROFEN, IBUPROFEN LYSINE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIGNIFOR, PASIREOTIDE DIASPARTATE

REGCON HOLDINGS

* REGCON HOLDINGS LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
AMINOCAPROIC ACID, AMINOCAPROIC ACID
APIXABAN, APIXABAN
BACLOFEN, BACLOFEN
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CARBIDOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FLECAINIDE ACETATE, FLECAINIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* REGCON HOLDINGS LLC
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
LACOSAMIDE, LACOSAMIDE
LOFEXIDINE HYDROCHLORIDE, LOFEXIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREGABALIN, PREGABALIN
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RIVAROXABAN, RIVAROXABAN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUMATRIPTAN, SUMATRIPTAN
THIOTEPA, THIOTEPA
VARENICLINE TARTRATE, VARENICLINE TARTRATE

RELIANCE LIFE
* RELIANCE LIFE SCIENCES PVT LTD
AZACITIDINE, AZACITIDINE
CAPECITABINE, CAPECITABINE
PEMETREXED DISODIUM, PEMETREXED DISODIUM

RELIANCE LIFE SCI
* RELIANCE LIFE SCIENCES PRIVATE LTD
BORTEZOMIB, BORTEZOMIB
DECITABINE, DECITABINE

REMPEX
* REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
MINOCIN, MINOCYCLINE HYDROCHLORIDE
VABOMERE, MEROPENEM

RENATA
* RENATA PLC
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
RISPERIDONE, RISPERIDONE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

RENEW PHARMS
* RENEW PHARMACEUTICALS LTD
IC-GREEN, INDOCYANINE GREEN
INDOCYANINE GREEN, INDOCYANINE GREEN

RESILIA PHARMS
* RESILIA PHARMACEUTICALS INC
ECOZA, ECONAZOLE NITRATE

REYOUNG
* REYOUNG CORPORATION
FENOFIBRATE (MICRONIZED), FENOFIBRATE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

RHODES PHARMS
* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

* RHODES PHARMACEUTICALS LP
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
MARAVIROC, MARAVIROC
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
SCOPOLAMINE, SCOPOLAMINE
THEOPHYLLINE, THEOPHYLLINE

RHYTHM

* RHYTHM PHARMACEUTICALS INC
IMCIVREE, SETMELANOTIDE ACETATE

RICONPHARMA LLC

* RICONPHARMA LLC
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
FLUNISOLIDE, FLUNISOLIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
OXCARBAZEPINE, OXCARBAZEPINE
SCOPOLAMINE, SCOPOLAMINE

RIGEL PHARMS

* RIGEL PHARMACEUTICALS INC
GAVRETO, PRALSETINIB
REZLIDHIA, OLUTASIDENIB
TAVALISSE, FOSTAMATINIB DISODIUM

RILEY CONSUMER

* RILEY CONSUMER CARE LLC DBA CARLIN CONSUMER HEALTH
ZEGERID OTC, OMEPRAZOLE (OTC)

RISING

* RISING PHARMA HOLDING INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYTARABINE, CYTARABINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PENTOXIFYLLINE, PENTOXIFYLLINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

* RISING PHARMA HOLDINGS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZATHIOPRINE, AZATHIOPRINE
BACLOFEN, BACLOFEN
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BUDESONIDE, BUDESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RISING PHARMA HOLDINGS INC
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARVEDILOL, CARVEDILOL
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CICLOPIROX, CICLOPIROX
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DAPSONE, DAPSONE
DESOXIMETASONE, DESOXIMETASONE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICHLORPHENAMIDE, DICHLORPHENAMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXERCALCIFEROL, DOXERCALCIFEROL
EPLERENONE, EPLERENONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
EXEMESTANE, EXEMESTANE
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
MELOXICAM, MELOXICAM
MESALAMINE, MESALAMINE
METHIMAZOLE, METHIMAZOLE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RISING PHARMA HOLDINGS INC
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATEGLINIDE, NATEGLINIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NITAZOXANIDE, NITAZOXANIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
PERPHENAZINE, PERPHENAZINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PREGABALIN, PREGABALIN
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISPERIDONE, RISPERIDONE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMVASTATIN, SIMVASTATIN
SIROLIMUS, SIROLIMUS
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TROPICACYL, TROPICAMIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZILEUTON, ZILEUTON

* RISING PHARMACEUTICALS
URSODIOL, URSODIOL

RISING PHARMS

* RISING PHARMACEUTICALS INC
ZAFIRLUKAST, ZAFIRLUKAST

RK PHARMA

* RK PHARMA INC
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CUPRIC CHLORIDE, CUPRIC CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RK PHARMA INC
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NADOLOL, NADOLOL
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
SELENIOUS ACID, SELENIOUS ACID
URSODIOL, URSODIOL
ZINC CHLORIDE, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE

ROCHE PALO

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROSEMONT PHARMS

* ROSEMONT PHARMACEUTICALS INC
ATMEKSI, METHOCARBAMOL
VOSTALLY, RAMIPRIL

ROYAL PHARMS

* ROYAL PHARMACEUTICALS LLC
DEHYDRATED ALCOHOL, ALCOHOL

RUBICON

* RUBICON RESEARCH PRIVATE LTD
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
VALSARTAN, VALSARTAN

RUBICON RESEARCH

* RUBICON RESEARCH LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IVERMECTIN, IVERMECTIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RUBICON RESEARCH LTD
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPRESSOR, METOPROLOL TARTRATE
LORATADINE, LORATADINE (OTC)
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREGABALIN, PREGABALIN
PRIMIDONE, PRIMIDONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

RVL PHARMS
* RVL PHARMACEUTICALS INC
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE

** S **

SABA ILAC SANAYI
* SABA ILAC SANAYI VE TICARET AS
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE

SABA ILAC SANAYIVE
* SABA ILAC SANAYIVE TICARET AS
FUROSEMIDE, FUROSEMIDE

SAGE PRODS
* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT
* SAGENT PHARMACEUTICALS
BUMETANIDE, BUMETANIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
VALPROATE SODIUM, VALPROATE SODIUM

SAGENT PHARMS
* SAGENT PHARMACEUTICALS INC
CAFFEINE CITRATE, CAFFEINE CITRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SAGENT PHARMACEUTICALS INC
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

SALERNO PHARMS

* SALERNO PHARMACEUTICALS
FLOLIPID, SIMVASTATIN

SALIX

* SALIX PHARMACEUTICALS INC
APRISO, MESALAMINE
PLENVU, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE
TRULANCE, PLECANATIDE
UCERIS, BUDESONIDE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
MOVIPREP, ASCORBIC ACID
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

SAMSON MEDCL
* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANALUZ
* SANALUZ LLC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
PYRIMETHAMINE, PYRIMETHAMINE
SEROMYCIN, CYCLOSERINE

SANDOZ
* SANDOZ
DOCETAXEL, DOCETAXEL
* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANGIOMAX, BIVALIRUDIN
APREPITANT, APREPITANT
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BORTEZOMIB, BORTEZOMIB
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DUREZOL, DIFLUPREDNATE
EDARAVONE, EDARAVONE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPLERENONE, EPLERENONE
ERIBULIN MESYLATE, ERIBULIN MESYLATE
EXELON, RIVASTIGMINE
EZETIMIBE, EZETIMIBE
FERUMOXYTOL, FERUMOXYTOL
FLUMAZENIL, FLUMAZENIL
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FULVESTRANT, FULVESTRANT
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRON SUCROSE, IRON SUCROSE
ISONIAZID, ISONIAZID
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANORINAL, ASPIRIN
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LATANOPROST, LATANOPROST
LESCOL XL, FLUVASTATIN SODIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LORAZEPAM, LORAZEPAM
LOTREL, AMLODIPINE BESYLATE
MAXITROL, DEXAMETHASONE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYDRIACYL, TROPICAMIDE
NADOLOL, NADOLOL
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEPRAZOLE, OMEPRAZOLE
OMNIPRED, PREDNISOLONE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRFENIDONE, PIRFENIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QOLIANA, BRIMONIDINE TARTRATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RECLAST, ZOLEDRONIC ACID
REGONOL, PYRIDOSTIGMINE BROMIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TACROLIMUS, TACROLIMUS
TAFLUPROST, TAFLUPROST
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TREPROSTINIL, TREPROSTINIL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VIVELLE-DOT, ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

SANKALP LIFECARE
* SANKALP LIFECARE INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

SANOFI
* SANOFI AVENTIS US LLC
FEXINIDAZOLE, FEXINIDAZOLE
* SANOFI GENZYME
RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US
* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
DIABETA, GLYBURIDE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
TAXOTERE, DOCETAXEL

SAPTALIS PHARMS
* SAPTALIS PHARMACEUTICALS LLC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYCLOSPORINE, CYCLOSPORINE
LIKMEZ, METRONIDAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL

SAREPTA THERAPS INC
* SAREPTA THERAPEUTICS INC
AMONDYS 45, CASIMERSEN
EXONDYS 51, ETEPLIRSEN
VYONDYS 53, GOLODIRSEN

SARFE PHARMS
* SARFEZ PHARMACEUTICALS INC
SOAANZ, TORSEMIDE

SATSUMA PHARMS
* SATSUMA PHARMACEUTICALS INC
ATZUMI, DIHYDROERGOTAMINE MESYLATE

SAVIOR LIFETEC CORP
* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA
* SAWAI USA INC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SCHERING
* SCHERING CORP
NOXAFIL, POSACONAZOLE

SCIARRA LABS
* SCIARRA LABORATORIES INC
SCLEROSOL, TALC
TALC, TALC

SCIECURE
* SCIECURE LABORATORIES INC
FOSCARNET SODIUM, FOSCARNET SODIUM

SCIECURE PHARMA INC
* SCIECURE PHARMA INC
CARBAMAZEPINE, CARBAMAZEPINE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS
* SCIEGEN PHARMACEUTICALS INC
ACETIC ACID, ACETIC ACID, GLACIAL
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
EZETIMIBE, EZETIMIBE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LACTULOSE, LACTULOSE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LISINOPRIL, LISINOPRIL
LITHIUM CITRATE, LITHIUM CITRATE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
NABUMETONE, NABUMETONE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PHYTONADIONE, PHYTONADIONE
PIRFENIDONE, PIRFENIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SCIEGEN PHARMACEUTICALS INC
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RIVAROXABAN, RIVAROXABAN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TICAGRELOR, TICAGRELOR
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

SCIENTURE

* SCIENTURE LLC
ARBLI, LOSARTAN POTASSIUM

SCILEX PHARMS

* SCILEX PHARMACEUTICALS INC
ELYXYB, CELECOXIB
GLOPERBA, COLCHICINE
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN

* SCINOPHARM TAIWAN LTD
CLOFARABINE, CLOFARABINE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE

SCPHARMACEUTICALS

* SCPHARMACEUTICALS INC
FUROSCIX, FUROSEMIDE

SEAGEN

* SEAGEN INC
TUKYSA, TUCATINIB

SEBELA WOMENS HLTH

* SEBELA WOMENS HEALTH INC
MIUDELLA, COPPER

SECURA

* SECURA BIO INC
COPIKTRA, DUVELISIB

SENORES PHARMS

* SENORES PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEFERIPRONE, DEFERIPRONE
DESONIDE, DESONIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
GABAPENTIN, GABAPENTIN
IVERMECTIN, IVERMECTIN
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
RISPERIDONE, RISPERIDONE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SENORES PHARMACEUTICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

SENTISS
* SENTISS AG
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
ERYTHROMYCIN, ERYTHROMYCIN
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
OFLOXACIN, OFLOXACIN

SENTISS PHARMA
* SENTISS PHARMA PRIVATE LTD
TIMOLOL MALEATE, TIMOLOL MALEATE

SENTYNL THERAPS INC
* SENTYNL THERAPEUTICS INC
NULIBRY, FOSDENOPTERIN HYDROBROMIDE
ZOKINVY, LONAFARNIB

SEPTODONT
* SEPTODONT INC
DYCLOPRO, DYCLONINE HYDROCHLORIDE
VIVACAINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING
* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC
* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERVIER
* SERVIER PHARMACEUTICALS LLC
TIBSOVO, IVOSIDENIB
VORANIGO, VORASIDENIB

SETON PHARM
* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS
* SETON PHARMACEUTICALS LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG
* SHANDONG ANXIN PHARMACEUTICAL CO LTD
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* SHANDONG NEW TIME PHARMACEUTICAL CO LTD
ISOFLURANE, ISOFLURANE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MILRINONE LACTATE, MILRINONE LACTATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVOFLURANE, SEVOFLURANE
TADALAFIL, TADALAFIL

SHANDONG LUYE
* SHANDONG LUYE PHARMACEUTICAL CO LTD
RYKINDO, RISPERIDONE

SHANDONG XINHUA
* SHANDONG XINHUA PHARMACEUTICAL CO LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
SEVELAMER CARBONATE, SEVELAMER CARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHANGHAI HENGRUI
* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW
* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHIELD TX
* SHIELD TX UK LTD
ACCRUFER, FERRIC MALTOL

SHILPA
* SHILPA MEDICARE LTD
APREMILAST, APREMILAST
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
DOCETAXEL, DOCETAXEL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PEMETREXED, PEMETREXED DISODIUM
VARENICLINE TARTRATE, VARENICLINE TARTRATE

SHILPA MEDICARE
* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHIONOGI INC
* SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE

SHORLA
* SHORLA PHARMA LTD
JYLAMVO, METHOTREXATE
NELARABINE, NELARABINE
TEPYLUTE, THIOTEPA

SHORLA ONCOLOGY
* SHORLA ONCOLOGY
IMKELDI, IMATINIB MESYLATE

SHREE HARI INTL
* SHREE HARI INTERNATIONAL LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

SIGA TECHNOLOGIES
* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC
* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SINOTHERAPEUTICS INC
* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SINOTHERAPEUTICS INC
MESALAMINE, MESALAMINE
POSACONAZOLE, POSACONAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TOFACITINIB CITRATE, TOFACITINIB CITRATE

SK LIFE

* SK LIFE SCIENCE INC
XCOPRI, CENOBAMATE

SLATE RUN PHARMA

* SLATE RUN PHARMACEUTICALS LLC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
CILOSTAZOL, CILOSTAZOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EPTIFIBATIDE, EPTIFIBATIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
METHOCARBAMOL, METHOCARBAMOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

SOBI

* SOBI INC
VONJO, PACRITINIB CITRATE

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PROGESTERONE, PROGESTERONE

SOFIE

* SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOLA PHARMS

* SOLA PHARMACEUTICALS
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DIMETHYL FUMARATE, DIMETHYL FUMARATE
TERIFLUNOMIDE, TERIFLUNOMIDE

SOLARIS PHARMA CORP

* SOLARIS PHARMA CORP
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ESTRADIOL, ESTRADIOL
METRONIDAZOLE, METRONIDAZOLE
NITROGLYCERIN, NITROGLYCERIN
TAZAROTENE, TAZAROTENE

SOLENO THERAP

* SOLENO THERAPEUTICS INC
VYKAT XR, DIAZOXIDE CHOLINE

SOLIS PHARMS

* SOLIS PHARMACEUTICALS INC
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PIROXICAM, PIROXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SOLUBIOMIX

* SOLUBIOMIX LLC
  AMCINONIDE, AMCINONIDE
  COXANTO, OXAPROZIN

SOMERSET

* SOMERSET PHARMACEUTICALS INC
  EMSAM, SELEGILINE
* SOMERSET THERAPEUTICS LLC
  ATROPINE SULFATE, ATROPINE SULFATE
  BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
  BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
  CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
  CALCIUM GLUCONATE, CALCIUM GLUCONATE
  CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
  CUPRIC CHLORIDE, CUPRIC CHLORIDE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  LATANOPROST, LATANOPROST
  OFLOXACIN, OFLOXACIN
  OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
  SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  TIMOLOL, TIMOLOL
  VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
  ZINC CHLORIDE, ZINC CHLORIDE

SOMERSET THERAP

* SOMERSET THERAPEUTICS LLC
  PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
  ACARBOSE, ACARBOSE
  ACETAZOLAMIDE, ACETAZOLAMIDE
  ACETYLCYSTEINE, ACETYLCYSTEINE
  AMINOCAPROIC ACID, AMINOCAPROIC ACID
  ATROPINE SULFATE, ATROPINE SULFATE
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  BACLOFEN, BACLOFEN
  BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
  BIMATOPROST, BIMATOPROST
  BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CABERGOLINE, CABERGOLINE
  CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
  CHLORZOXAZONE, CHLORZOXAZONE
  CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
  CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CYANOCOBALAMIN, CYANOCOBALAMIN
  DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
  DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
  DROXIDOPA, DROXIDOPA
  EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
  FAMOTIDINE, FAMOTIDINE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
  ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
  LACOSAMIDE, LACOSAMIDE
  LAMIVUDINE, LAMIVUDINE
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SOMERSET THERAPEUTICS LLC
METHOCARBAMOL, METHOCARBAMOL
METRONIDAZOLE, METRONIDAZOLE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PREGABALIN, PREGABALIN
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZINC SULFATE, ZINC SULFATE

SPECGX LLC

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
RESTORIL, TEMAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SPECGX LLC
ROXICODONE, OXYCODONE HYDROCHLORIDE

SPECTRA MDCL DEVICES
* SPECTRA MEDICAL DEVICES INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPH ZHONGXI PHARM
* SPH ZHONGXI PHARMACEUTICAL CO LTD
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

SPIL
* SUN PHARMA INDUSTRIES LTD
AMPHOTERICIN B, AMPHOTERICIN B
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE

SPRINGWORKS
* SPRINGWORKS THERAPEUTICS INC
GOMEKLI, MIRDAMETINIB
OGSIVEO, NIROGACESTAT HYDROBROMIDE

SPROUT PHARMS
* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQ INNOVATION
* SQ INNOVATION INC
LASIX ONYU, FUROSEMIDE

SQUARE PHARMS
* SQUARE PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
CALCIUM ACETATE, CALCIUM ACETATE

SQUARE PHARMS PLC
* SQUARE PHARMACEUTICALS PLC
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
METHIMAZOLE, METHIMAZOLE
MIRTAZAPINE, MIRTAZAPINE
VALSARTAN, VALSARTAN

ST RENATUS
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STEALTH BIOTHERAPS
* STEALTH BIOTHERAPEUTICS INC
FORZINITY, ELAMIPRETIDE HYDROCHLORIDE

STEMLINE THERAP
* STEMLINE THERAPEUTICS INC
ORSERDU, ELACESTRANT HYDROCHLORIDE

STERIMAX
* STERIMAX INC
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM

STERINOVA INC
* STERINOVA INC
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

STERISCIENCE
* STERISCIENCE PTE LTD
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOCINVEZ, FOSAPREPITANT DIMEGLUMINE
METHYLENE BLUE, METHYLENE BLUE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM BICARBONATE, SODIUM BICARBONATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STERISCIENCE PTE LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE

STIEFEL

* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
COLCHICINE, COLCHICINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
FLUCYTOSINE, FLUCYTOSINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NITROFURANTOIN, NITROFURANTOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREDNISONE, PREDNISONE
PREGABALIN, PREGABALIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
ROFLUMILAST, ROFLUMILAST
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SUCRALFATE, SUCRALFATE
TACROLIMUS, TACROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
URSODIOL, URSODIOL
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRIDES PHARMA INTL

* STRIDES PHARMA INTERNATIONAL AG
ACCOLATE, ZAFIRLUKAST
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* STRIDES PHARMA INTERNATIONAL AG
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
BUPRENORPHINE, BUPRENORPHINE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CABERGOLINE, CABERGOLINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DOFETILIDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NATEGLINIDE, NATEGLINIDE
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
TORSEMIDE, TORSEMIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZILEUTON, ZILEUTON

STRONGBRIDGE

* STRONGBRIDGE DUBLIN LTD
RECORLEV, LEVOKETOCONAZOLE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUMITOMO PHARMA AM

* SUMITOMO PHARMA AMERICA INC
APTIOM, ESLICARBAZEPINE ACETATE
GEMTESA, VIBEGRON
MYFEMBREE, ESTRADIOL
ORGOVYX, RELUGOLIX

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
ABSORICA LD, ISOTRETINOIN
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
BICALUTAMIDE, BICALUTAMIDE
BOSENTAN, BOSENTAN
BROMSITE, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES LTD
BYNFEZIA PEN, OCTREOTIDE ACETATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CEQUA, CYCLOSPORINE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
DEFERASIROX, DEFERASIROX
DEFLAZACORT, DEFLAZACORT
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOFETILIDE, DOFETILIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ENTACAPONE, ENTACAPONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FEBUXOSTAT, FEBUXOSTAT
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FYREMADEL, GANIRELIX ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
IMATINIB MESYLATE, IMATINIB MESYLATE
LACOSAMIDE, LACOSAMIDE
LENALIDOMIDE, LENALIDOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LORATADINE, LORATADINE (OTC)
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MACITENTAN, MACITENTAN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
ODOMZO, SONIDEGIB PHOSPHATE
OMEPRAZOLE, OMEPRAZOLE (OTC)
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SELENIOUS ACID, SELENIOUS ACID
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TOBRAMYCIN, TOBRAMYCIN
TOPIRAMATE, TOPIRAMATE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
WINLEVI, CLASCOTERONE
YONSA, ABIRATERONE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
HALOG, HALCINONIDE
INDIUM IN-111 PENTETREOTIDE KIT, INDIUM IN-111 PENTETREOTIDE KIT
LEQSELVI, DEURUXOLITINIB PHOSPHATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
SEZABY, PHENOBARBITAL SODIUM
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

SUN PHARMA CANADA

* SUN PHARMA CANADA INC
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ADAPALENE, ADAPALENE (OTC)
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELAIC ACID, AZELAIC ACID
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DOCOSANOL, DOCOSANOL (OTC)
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HALOBETASOL PROPIONATE AND TAZAROTENE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
TAZAROTENE, TAZAROTENE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMA CANADA INC
TOPICORT, DESOXIMETASONE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

SUNNY

* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
LATUDA, LURASIDONE HYDROCHLORIDE

SUNSHINE

* SUNSHINE LAKE PHARMA CO LTD
ARIPIPRAZOLE, ARIPIPRAZOLE
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
FEBUXOSTAT, FEBUXOSTAT
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RANOLAZINE, RANOLAZINE
RIVAROXABAN, RIVAROXABAN
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL
TICAGRELOR, TICAGRELOR

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
GOCOVRI, AMANTADINE HYDROCHLORIDE
OXTELLAR XR, OXCARBAZEPINE
QELBREE, VILOXAZINE HYDROCHLORIDE
TROKENDI XR, TOPIRAMATE

SUVEN PHARMS

* SUVEN PHARMACEUTICALS LTD
CALCIUM ACETATE, CALCIUM ACETATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
MALATHION, MALATHION

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNDAX

* SYNDAX PHARMACEUTICALS INC
REVUFORJ, REVUMENIB CITRATE

SYNTHON BV

* SYNTHON BV
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

SYNTHON PHARMS INC

* SYNTHON PHARMACEUTICALS INC
GLATIRAMER ACETATE, GLATIRAMER ACETATE

** T **

ACME LABS

* THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

GEN HOSP
* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST
* THE METHODIST HOSP RESEARCH INSTITUTE
AMMONIA N 13, AMMONIA N-13
GALLIUM GA 68 EDOTREOTIDE, GALLIUM GA-68 EDOTREOTIDE

METHODIST HOSP RES
* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP
* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAGI
* TAGI PHARMA INC
CHOLESTYRAMINE, CHOLESTYRAMINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE

TAIHO ONCOLOGY
* TAIHO ONCOLOGY INC
INQOVI, CEDAZURIDINE
LONSURF, TIPIRACIL HYDROCHLORIDE
LYTGOBI, FUTIBATINIB

TAKEDA PHARMS USA
* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
ALUNBRIG, BRIGATINIB
CARBATROL, CARBAMAZEPINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
EOHILIA, BUDESONIDE
FIRAZYR, ICATIBANT ACETATE
FOSRENOL, LANTHANUM CARBONATE
FRUZAQLA, FRUQUINTINIB
GATTEX KIT, TEDUGLUTIDE
ICLUSIG, PONATINIB HYDROCHLORIDE
INTUNIV, GUANFACINE HYDROCHLORIDE
KAZANO, ALOGLIPTIN BENZOATE
LIALDA, MESALAMINE
LIVTENCITY, MARIBAVIR
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MYDAYIS, AMPHETAMINE ASPARTATE
NESINA, ALOGLIPTIN BENZOATE
NINLARO, IXAZOMIB CITRATE
OSENI, ALOGLIPTIN BENZOATE
PENTASA, MESALAMINE
PREVACID, LANSOPRAZOLE
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT
VELCADE, BORTEZOMIB
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

TALICIA HOLDINGS

* TALICIA HOLDINGS INC
TALICIA, AMOXICILLIN

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TANABE PHARMA

* TANABE PHARMA CORP
RADICAVA, EDARAVONE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND IBUPROFEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BUMETANIDE, BUMETANIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBAMAZEPINE, CARBAMAZEPINE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DEFERIPRONE, DEFERIPRONE
DESLORATADINE, DESLORATADINE
DESONIDE, DESONIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FELBAMATE, FELBAMATE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
IVERMECTIN, IVERMECTIN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LACTULOSE, LACTULOSE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PERAMPANEL, PERAMPANEL
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RIVAROXABAN, RIVAROXABAN
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
TERIL, CARBAMAZEPINE
TICAGRELOR, TICAGRELOR
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARSUS

* TARSUS PHARMACEUTICALS INC
XDEMVY, LOTILANER

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT PHARMA INC
FLURANDRENOLIDE, FLURANDRENOLIDE

TELIX

* TELIX PHARMACEUTICALS US INC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE

TELIX INNOVATIONS

* TELIX INNOVATIONS SA
GOZELLIX, GALLIUM GA-68 GOZETOTIDE

TENSHI

* TENSHI KAIZEN PVT LTD
LORATADINE, LORATADINE (OTC)

TERSERA

* TERSERA THERAPEUTICS LLC
PRIALT, ZICONOTIDE ACETATE
VARUBI, ROLAPITANT HYDROCHLORIDE
XERMELO, TELOTRISTAT ETIPRATE
ZOLADEX, GOSERELIN ACETATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AUSTEDO XR, DEUTETRABENAZINE
AZILECT, RASAGILINE MESYLATE
UZEDY, RISPERIDONE
* TEVA PHARMACEUTICALS USA INC
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRELONE, PREDNISOLONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
ACTIGALL, URSODIOL
CONDYLOX, PODOFILOX
LOSEASONIQUE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
NOR-QD, NORETHINDRONE
PROAIR HFA, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QUARTETTE, ETHINYL ESTRADIOL
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D LLC
AUSTEDO, DEUTETRABENAZINE
MICROZIDE, HYDROCHLOROTHIAZIDE
PROAIR RESPICLICK, ALBUTEROL SULFATE
QNASL, BECLOMETHASONE DIPROPIONATE
ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS DEVELOPMENT INC
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
LIRAGLUTIDE, LIRAGLUTIDE
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE DIMESYLATE
PYRIMETHAMINE, PYRIMETHAMINE
* TEVA PHARMACEUTICALS USA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CROMOLYN SODIUM, CROMOLYN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

TEVA PHARMS INC

* TEVA PHARMACEUTICALS INC
ALVAIZ, ELTROMBOPAG CHOLINE
ALYQ, TADALAFIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CETRORELIX ACETATE, CETRORELIX ACETATE
DALBAVANCIN HYDROCHLORIDE, DALBAVANCIN HYDROCHLORIDE
MESALAMINE, MESALAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS INC
PACLITAXEL, PACLITAXEL
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TIOPRONIN, TIOPRONIN

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ACITRETIN, ACITRETIN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BEXAROTENE, BEXAROTENE
BUDESONIDE, BUDESONIDE
CLARAVIS, ISOTRETINOIN
COPAXONE, GLATIRAMER ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EPTIFIBATIDE, EPTIFIBATIDE
ESTRADIOL, ESTRADIOL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LOGILIA, ULIPRISTAL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEPRAZOLE, OMEPRAZOLE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TREPROSTINIL, TREPROSTINIL
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE

* TEVA PHARMACEUTICALS USA INC
ALYQ, TADALAFIL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
DAPTOMYCIN, DAPTOMYCIN
DASATINIB, DASATINIB
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
EFINACONAZOLE, EFINACONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
ESTRADIOL, ESTRADIOL
EVEROLIMUS, EVEROLIMUS
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
ICATIBANT ACETATE, ICATIBANT ACETATE
IVERMECTIN, IVERMECTIN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MESALAMINE, MESALAMINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE (OTC)
ONSURA, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENCICLOVIR, PENCICLOVIR
PIRFENIDONE, PIRFENIDONE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIPARATIDE, TERIPARATIDE
TOBRAMYCIN, TOBRAMYCIN
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
FINZALA, ETHINYL ESTRADIOL
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LUBIPROSTONE, LUBIPROSTONE
MIFEPRISTONE, MIFEPRISTONE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PERAMPANEL, PERAMPANEL
PLERIXAFOR, PLERIXAFOR
POTASSIUM CITRATE, POTASSIUM CITRATE
RISPERIDONE, RISPERIDONE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
TASIMELTEON, TASIMELTEON
TIOPRONIN, TIOPRONIN

TEYRO LABS

* TEYRO LABS PRIVATE LTD
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE J MOLNER

* THE J MOLNER CO OU
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

THEA PHARMA

* THEA PHARMA INC
AKTEN, LIDOCAINE HYDROCHLORIDE
AZASITE, AZITHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* THEA PHARMA INC
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
IYUZEH, LATANOPROST
ZIOPTAN, TAFLUPROST
ZOLYMBUS, BIMATOPROST

THEPHARMANETWORK LLC
* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERACOSBIO
* THERACOSBIO LLC
BRENZAVVY, BEXAGLIFLOZIN

THERAGNOSTICS
* THERAGNOSTICS INC
NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER

THERAKOS DEVELOPMENT
* THERAKOS DEVELOPMENT LTD
UVADEX, METHOXSALEN

THERAVIA
* THERAVIA PHARMA
SIKLOS, HYDROXYUREA

THINQ PHARM-CRO PVT
* THINQ PHARMA-CRO PRIVATE LTD
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
FLUCONAZOLE, FLUCONAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
TINIDAZOLE, TINIDAZOLE

TIANJIN KINGYORK
* TIANJIN KINGYORK PHARMACEUTICALS CO LTD
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

TIANJIN TIANYAO
* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
CELECOXIB, CELECOXIB
METHYLPREDNISOLONE, METHYLPREDNISOLONE

TILDE SCIENCES
* TILDE SCIENCES LLC
DARAPRIM, PYRIMETHAMINE

TOLMAR
* TOLMAR INC
ELIGARD KIT, LEUPROLIDE ACETATE
JATENZO, TESTOSTERONE UNDECANOATE
* TOLMAR INTERNATIONAL LTD
FENSOLVI KIT, LEUPROLIDE ACETATE

TONIX
* TONIX PHARMACEUTICALS INC
TONMYA, CYCLOBENZAPRINE HYDROCHLORIDE

TONIX MEDS
* TONIX MEDICINES INC
TOSYMRA, SUMATRIPTAN
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

TORRENT
* TORRENT PHARMA INC
APREPITANT, APREPITANT
ERYTHROMYCIN, ERYTHROMYCIN
ORMALVI, DICHLORPHENAMIDE
* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
ARIPIPRAZOLE, ARIPIPRAZOLE
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LENALIDOMIDE, LENALIDOMIDE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NILOTINIB HYDROCHLORIDE, NILOTINIB HYDROCHLORIDE
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
PAZOPANIB HYDROCHLORIDE, PAZOPANIB HYDROCHLORIDE
PENCICLOVIR, PENCICLOVIR
PREGABALIN, PREGABALIN
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SACUBITRIL AND VALSARTAN, SACUBITRIL
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
TADALAFIL, TADALAFIL
TELMISARTAN, TELMISARTAN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VENXXIVA, TIOPRONIN

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LTD
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
LEVETIRACETAM, LEVETIRACETAM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

TP ANDA HOLDINGS

* TP ANDA HOLDINGS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TP ANDA HOLDINGS LLC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DAPSONE, DAPSONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
NAPROXEN, NAPROXEN
NITROGLYCERIN, NITROGLYCERIN
OXAZEPAM, OXAZEPAM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
PRIMIDONE, PRIMIDONE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE

TRAVERE
* TRAVERE THERAPEUTICS INC
FILSPARI, SPARSENTAN

TRIS PHARMA INC
* TRIS PHARMA INC
DEFLAZACORT, DEFLAZACORT
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYANAVEL XR, AMPHETAMINE
GANIRELIX ACETATE, GANIRELIX ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
ONYDA XR, CLONIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA
* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TWI PHARMS
* TWI PHARMACEUTICALS INC
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NAPRELAN, NAPROXEN SODIUM
NIFEDIPINE, NIFEDIPINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TOPIRAMATE, TOPIRAMATE
ZESTRIL, LISINOPRIL

TWI PHARMS INC
* TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

UBI
* UBI PHARMA INC
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
OLANZAPINE, OLANZAPINE
VORICONAZOLE, VORICONAZOLE

UCB INC
* UCB INC
BRIVIACT, BRIVARACETAM
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
KYGEVVI, DOXECITINE
NAYZILAM, MIDAZOLAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE
ZILBRYSQ, ZILUCOPLAN SODIUM

UCLA BIOMEDICAL
* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM
* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UIHC PET IMAGING
* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM GA 68 EDOTREOTIDE, GALLIUM GA-68 EDOTREOTIDE

ULTRAGENYX PHARM INC
* ULTRAGENYX PHARMACEUTICAL INC
DOJOLVI, TRIHEPTANOIN

UMEDICA
* UMEDICA LABORATORIES PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
EFINACONAZOLE, EFINACONAZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TADALAFIL, TADALAFIL

UNICHEM
* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNICHEM LABORATORIES LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LACOSAMIDE, LACOSAMIDE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METOLAZONE, METOLAZONE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRASUGREL HYDROCHLORIDE, PRASUGREL HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZONISAMIDE, ZONISAMIDE

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM

* UNICHEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UNIQUE

* UNIQUE PHARMACEUTICAL LABORATORIES A DIV OF JB CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

UNIQUE PHARM

* UNIQUE PHARMACEUTICAL LABORATORIES
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARBAMAZEPINE, CARBAMAZEPINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LORATADINE, LORATADINE (OTC)

UNITED GUARDIAN

* UNITED GUARDIAN INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO DPI, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV ALAHAMA BIRM

* UNIV ALABAMA AT BIRMINGHAM
AMMONIA N 13, AMMONIA N-13

UNIV CA LOS ANGELES

* UNIV CALIFORNIA LOS ANGELES
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV OF CA SAN FRAN

* UNIV OF CALIFORNIA SAN FRANCISCO
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV SOUTHERN CA

* UNIV SOUTHERN CALIFORNIA DBA USC MOLECULAR IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV WISCONSIN

* UNIV WISCONSIN SYSTEM
AMMONIA N 13, AMMONIA N-13

UPJOHN

* UPJOHN MANUFACTURING IRELAND UNLTD
LIPITOR, ATORVASTATIN CALCIUM
RELPAX, ELETRIPTAN HYDROBROMIDE
* UPJOHN US 2 LLC
CELEBREX, CELECOXIB
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INSPRA, EPLERENONE
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
XALATAN, LATANOPROST
XANAX XR, ALPRAZOLAM
XANAX, ALPRAZOLAM

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BEXAROTENE, BEXAROTENE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CLOBAZAM, CLOBAZAM
DEFLAZACORT, DEFLAZACORT
DIFLUPREDNATE, DIFLUPREDNATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES LLC
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ETHACRYNIC ACID, ETHACRYNIC ACID
EXEMESTANE, EXEMESTANE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ISOTRETINOIN, ISOTRETINOIN
JANTOVEN, WARFARIN SODIUM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYORISAN, ISOTRETINOIN
NYSTATIN, NYSTATIN
PACERONE, AMIODARONE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUDEXY XR, TOPIRAMATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VIGABATRIN, VIGABATRIN
VOGELXO, TESTOSTERONE

UROGEN PHARMA
* UROGEN PHARMA LTD
JELMYTO, MITOMYCIN
ZUSDURI, MITOMYCIN

US ANTIBIOTICS
* US ANTIBIOTICS LLC
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
LAROTID, AMOXICILLIN

USPHARMA
* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

USV
* USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ZOLEDRONIC ACID, ZOLEDRONIC ACID

USWM
* USWM LLC
IWILFIN, EFLORNITHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

UTILITY THERAP
* UTILITY THERAPEUTICS LTD
PIVYA, PIVMECILLINAM HYDROCHLORIDE

UTOPIC PHARMS
* UTOPIC PHARMACEUTICALS INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**** V ****

VALEANT
* VALEANT PHARMACEUTICALS INTERNATIONAL
MYSOLINE, PRIMIDONE

VALEANT BERMUDA
* VALEANT INTERNATIONAL BERMUDA
RETIN-A, TRETINOIN

VALEANT INTL
* VALEANT INTERNATIONAL BARBADOS SRL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT INTERNATIONAL BARBADOS SRL
  RETIN-A, TRETINOIN
* VALEANT INTERNATIONAL SRL
  BENZAMYCIN, BENZOYL PEROXIDE

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
  LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
  COLAZAL, BALSALAZIDE DISODIUM
  CUPRIMINE, PENICILLAMINE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  NIFEDIPINE, NIFEDIPINE
  RENOVA, TRETINOIN
  RETIN-A, TRETINOIN

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
  BUMEX, BUMETANIDE
  EQUETRO, CARBAMAZEPINE
  LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
  LOPRESSOR, METOPROLOL TARTRATE
  LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
  LOTENSIN, BENAZEPRIL HYDROCHLORIDE
  NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

VANCOCIN ITALIA

* VANCOCIN ITALIA SRL
  MULPLETA, LUSUTROMBOPAG

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
  FANAPT, ILOPERIDONE
  HETLIOZ LQ, TASIMELTEON
  HETLIOZ, TASIMELTEON
  NEREUS, TRADIPITANT
  PONVORY, PONESIMOD

VANTIVE US HLTHCARE

* VANTIVE US HEALTHCARE LLC
  DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  EXTRANEAL, ICODEXTRIN
  PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
  ENVARSUS XR, TACROLIMUS

VELZEN PHARMA PVT

* VELZEN PHARMA PVT LTD
  DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VELZEN PHARMA PVT LTD
NIFEDIPINE, NIFEDIPINE
THEOPHYLLINE, THEOPHYLLINE

VERASTEM INC
* VERASTEM INC
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), AVUTOMETINIB POTASSIUM

VERITY
* VERITY PHARMACEUTICALS INC
TLANDO, TESTOSTERONE UNDECANOATE
TRELSTAR, TRIPTORELIN PAMOATE

VERO BIOTECH INC
* VERO BIOTECH INC
GENOSYL, NITRIC OXIDE

VERONA PHARMA
* VERONA PHARMA INC
OHTUVAYRE, ENSIFENTRINE

VEROSCIENCE
* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERRICA PHARMS
* VERRICA PHARMACEUTICALS INC
YCANTH, CANTHARIDIN

VERTEX PHARMS
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC
* VERTEX PHARMACEUTICALS INC
ALYFTREK, DEUTIVACAFTOR
JOURNAVX, SUZETRIGINE
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS
* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VIATRIS
* VIATRIS SPECIALTY LLC
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
CORTIFOAM, HYDROCORTISONE ACETATE
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORVASC, AMLODIPINE BESYLATE
REVATIO, SILDENAFIL CITRATE
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN
VIAGRA, SILDENAFIL CITRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

VIATRIS SPECIALTY
* VIATRIS SPECIALITY LLC
GASTROCROM, CROMOLYN SODIUM
PERFOROMIST, FORMOTEROL FUMARATE

VICURON HOLDINGS
* VICURON HOLDINGS LLC
ERAXIS, ANIDULAFUNGIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VIFOR FRESENIUS
* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, FERRIC OXYHYDROXIDE

VIFOR INTL
* VIFOR (INTERNATIONAL) INC
KORSUVA, DIFELIKEFALIN ACETATE

VIFOR PHARMA
* VIFOR PHARMA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

VIIV HLTHCARE
* VIIV HEALTHCARE CO
APRETUDE, CABOTEGRAVIR
CABENUVA KIT, CABOTEGRAVIR
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
JULUCA, DOLUTEGRAVIR SODIUM
RETROVIR, ZIDOVUDINE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
SELZENTRY, MARAVIROC
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ PD, ABACAVIR SULFATE
TRIUMEQ, ABACAVIR SULFATE
VOCABRIA, CABOTEGRAVIR SODIUM
ZIAGEN, ABACAVIR SULFATE

VILIN BIO MED
* VILIN BIO MED LTD
BORTEZOMIB, BORTEZOMIB

VISTA PHARMS
* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM LLC
* VISTAPHARM LLC
ARIPIPRAZOLE, ARIPIPRAZOLE
DIGOXIN, DIGOXIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
SUCRALFATE, SUCRALFATE

VISUM PHARM
* VISUM PHARMACEUTICAL CO LTD
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

VITRUVIAS
* VITRUVIAS THERAPEUTICS INC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

VITRUVIAS THERAP
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN

VIVUS LLC
* VIVUS LLC
QSYMIA, PHENTERMINE HYDROCHLORIDE
STENDRA, AVANAFIL

VIWIT PHARM
* VIWIT PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
NITROGLYCERIN, NITROGLYCERIN
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

VKT PHARMA
* VKT PHARMA PRIVATE LTD
FAMOTIDINE, FAMOTIDINE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VKT PHARMA PRIVATE LTD
TADALAFIL, TADALAFIL

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

** W **

WA UNIV SCH MED

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
KELNOR 1/50, ETHINYL ESTRADIOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
BOSENTAN, BOSENTAN
BRINZOLAMIDE, BRINZOLAMIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
METRONIDAZOLE, METRONIDAZOLE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PENICILLAMINE, PENICILLAMINE
PERPHENAZINE, PERPHENAZINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TICAGRELOR, TICAGRELOR

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALVIMOPAN, ALVIMOPAN
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE, BUPRENORPHINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
ISRADIPINE, ISRADIPINE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WAYLIS THERAP

* WAYLIS THERAPEUTICS LLC
ACIPHEX, RABEPRAZOLE SODIUM
AVODART, DUTASTERIDE
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL
FLUTAMIDE, FLUTAMIDE
HYDREA, HYDROXYUREA
JALYN, DUTASTERIDE
LEUKERAN, CHLORAMBUCIL
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LUNESTA, ESZOPICLONE
MYLERAN, BUSULFAN
THIOGUANINE, THIOGUANINE
VALIUM, DIAZEPAM

WES PHARMA INC

* WES PHARMA INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WES PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

WEST WARD
* WEST WARD PHARMACEUTICAL CORP
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP
* WEST WARD PHARMACEUTICAL CORP
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT
* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
BUMETANIDE, BUMETANIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PENTOSTATIN, PENTOSTATIN
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA

WESTMINSTER PHARMS
* WESTMINSTER PHARMACEUTICALS LLC
EPLERENONE, EPLERENONE
LACOSAMIDE, LACOSAMIDE
MIGLITOL, MIGLITOL
POSACONAZOLE, POSACONAZOLE

WILSHIRE PHARMS INC
* WILSHIRE PHARMACEUTICALS INC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
ICATIBANT ACETATE, ICATIBANT ACETATE
MERZEE, ETHINYL ESTRADIOL
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PERPHENAZINE, PERPHENAZINE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

WINDER LABS LLC
* WINDER LABORATOIRIES LLC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE

WOCKHARDT
* WOCKHARDT LTD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

WOCKHARDT BIO AG
* WOCKHARDT BIO AG
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETAMINOPHEN, ACETAMINOPHEN
CAPTOPRIL, CAPTOPRIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
DECITABINE, DECITABINE
ENTACAPONE, ENTACAPONE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT BIO AG
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

WOCKHARDT LTD
* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

WOODWARD
* WOODWARD PHARMA SERVICES LLC
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

WUSM CYCLOTRON
* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WUXI
* WUXI FORTUNE PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

WYETH PHARMS
* WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM

** X **

X-GEN PHARMS INC
* X-GEN PHARMACEUTICALS INC
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

X4 PHARMS
* X4 PHARMACEUTICALS INC
XOLREMDI, MAVORIXAFOR

XCOVERY
* XCOVERY HOLDINGS INC
ENSACOVE, ENSARTINIB HYDROCHLORIDE

XELLIA PHARMS APS
* XELLIA PHARMACEUTICALS APS
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

XERIS
* XERIS PHARMACEUTICALS INC
GVOKE HYPOPEN, GLUCAGON
GVOKE KIT, GLUCAGON
GVOKE PFS, GLUCAGON
GVOKE VIALDX, GLUCAGON
KEVEYIS, DICHLORPHENAMIDE

XGEN PHARMS
* XGEN PHARMACEUTICALS DJB INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DACTINOMYCIN, DACTINOMYCIN
DEHYDRATED ALCOHOL, ALCOHOL
FOLIC ACID, FOLIC ACID
IBUPROFEN LYSINE, IBUPROFEN LYSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** X **

* XGEN PHARMACEUTICALS DJB INC
LEVETIRACETAM, LEVETIRACETAM
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NELARABINE, NELARABINE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID

XIAMEN LP PHARM CO

* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
OPIPZA, ARIPIPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

XIROMED

* XIROMED LLC
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE

* XIROMED PHARMA ESPANA SL
ACYCLOVIR, ACYCLOVIR
ALTAVERA, ETHINYL ESTRADIOL
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CETRORELIX ACETATE, CETRORELIX ACETATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ENILLORING, ETHINYL ESTRADIOL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESTARYLLA, ETHINYL ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FLUOCINONIDE, FLUOCINONIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FULVESTRANT, FULVESTRANT
GEMMILY, ETHINYL ESTRADIOL
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
KETOCONAZOLE, KETOCONAZOLE
LANSOPRAZOLE, LANSOPRAZOLE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LORYNA, DROSPIRENONE
METHYLENE BLUE, METHYLENE BLUE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
PROGESTERONE, PROGESTERONE
RAMELTEON, RAMELTEON
SYEDA, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** X ****

* XIROMED PHARMA ESPANA SL
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

XTM CONSULTING

* XTM CONSULTING LLC
LOPRESSOR, METOPROLOL TARTRATE

XTTRIUM

* XTTRIUM LABORATORIES INC
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**** Y ****

YABAO PHARM

* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE

YAOPHARMA CO LTD

* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL

* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MYCOPHENOLATE SODIUM, MYCOPHENOLATE SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RIVASTIGMINE, RIVASTIGMINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YILING

* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BACLOFEN, BACLOFEN
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE
LAMOTRIGINE, LAMOTRIGINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
SIMVASTATIN, SIMVASTATIN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
ENTECAVIR, ENTECAVIR
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

ZEALAND PHARMA
* ZEALAND PHARMA US INC
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE

ZENARA
* ZENARA PHARMA PRIVATE LTD
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
SAFINAMIDE MESYLATE, SAFINAMIDE MESYLATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

ZEVRA DENMARK
* ZEVRA DENMARK AS
MIPLYFFA, ARIMOCLOMOL CITRATE

ZHEJIANG
* ZHEJIANG BAYSIDE BIOTECH CO LTD
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

ZHEJIANG HISUN PHARM
* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JINGXIN
* ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZHEJIANG JIUZHOU
* ZHEJIANG JIUZHOU BIOPHARMA CO LTD
CARBAMAZEPINE, CARBAMAZEPINE

ZHEJIANG JUTAI PHARM
* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

ZHEJIANG NOVUS PHARM
* ZHEJIANG NOVUS PHARMACEUTICALS CO LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ZHEJIANG POLY PHARM
* ZHEJIANG POLY PHARM CO LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
FLUCONAZOLE, FLUCONAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
VORICONAZOLE, VORICONAZOLE

ZHEJIANG XIANJU
* ZHEJIANG XIANJU PHARMACEUTICAL CO LTD
PREDNISOLONE, PREDNISOLONE

ZHEJIANG YONGTAI
* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GABAPENTIN, GABAPENTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZHUHAI
* ZHUHAI BEIHAI BIOTECH CO LTD
BEIZRAY, DOCETAXEL

ZMI PHARMA
* ZMI PHARMA INC
ZIMHI, NALOXONE HYDROCHLORIDE

ZUREX PHARMA
* ZUREX PHARMA
ZURAGARD, ISOPROPYL ALCOHOL (OTC)

ZYDUS
* ZYDUS WORLDWIDE DMCC
APALUTAMIDE, APALUTAMIDE
DIROXIMEL FUMARATE, DIROXIMEL FUMARATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS WORLDWIDE DMCC
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
TOPIRAMATE, TOPIRAMATE
VARENICLINE TARTRATE, VARENICLINE TARTRATE

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS LIFESCIENCES

* ZYDUS LIFESCIENCES GLOBAL FZE
ACETAZOLAMIDE, ACETAZOLAMIDE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DAPSONE, DAPSONE
DEFLAZACORT, DEFLAZACORT
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
IVERMECTIN, IVERMECTIN
JAYTHARI, DEFLAZACORT
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEFLUNOMIDE, LEFLUNOMIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLENE BLUE, METHYLENE BLUE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZITUVIMET XR, METFORMIN HYDROCHLORIDE
ZITUVIMET, METFORMIN HYDROCHLORIDE
ZITUVIO, SITAGLIPTIN

* ZYDUS LIFESCIENCES LTD
ACYCLOVIR, ACYCLOVIR
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARUNAVIR, DARUNAVIR
DESOXIMETASONE, DESOXIMETASONE
DEXAMETHASONE, DEXAMETHASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FEBUXOSTAT, FEBUXOSTAT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

* ZYDUS LIFESCIENCES LTD
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METRONIDAZOLE, METRONIDAZOLE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
PRUCALOPRIDE SUCCINATE, PRUCALOPRIDE SUCCINATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TAVABOROLE, TAVABOROLE
THEOPHYLLINE, THEOPHYLLINE
TRETINOIN, TRETINOIN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS

* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLCHICINE, COLCHICINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DASATINIB, DASATINIB
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENTECAVIR, ENTECAVIR
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESTRADIOL, ESTRADIOL
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
FULVESTRANT, FULVESTRANT
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
ISOTRETINOIN, ISOTRETINOIN
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
LINEZOLID, LINEZOLID
LUBIPROSTONE, LUBIPROSTONE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

* ZYDUS PHARMACEUTICALS USA INC
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIRABEGRON, MIRABEGRON
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NELARABINE, NELARABINE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALIPERIDONE, PALIPERIDONE
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RAMELTEON, RAMELTEON
RIVASTIGMINE, RIVASTIGMINE
ROFLUMILAST, ROFLUMILAST
SACUBITRIL AND VALSARTAN, SACUBITRIL
SCOPOLAMINE, SCOPOLAMINE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TADALAFIL, TADALAFIL
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERIFLUNOMIDE, TERIFLUNOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZINC SULFATE, ZINC SULFATE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRAZOLE, OMEPRAZOLE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
INDOCIN, INDOMETHACIN
SPRIX, KETOROLAC TROMETHAMINE

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CAPSULE, PELLETS
CAPSULE, TABLET
CAPSULE, TABLET, TABLET
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, INSERT
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOAM
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULES
GUM, CHEWING
IMPLANT
INJECTABLE
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
PELLETS
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION, LIPOSOMAL
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
TABLET
TABLET, CHEWABLE
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
CARDIAC
DENTAL
ENDOCERVICAL
ENDOTRACHEAL
ENTERAL
IMPLANTATION
INHALATION
INJECTION
INTERSTITIAL
INTRA-ANAL
INTRA-ARTERIAL
INTRA-ARTICULAR
INTRACAMERAL
INTRACAVITARY
INTRACRANIAL
INTRADERMAL
INTRAMUSCULAR
INTRAOCULAR
INTRAOSSEOUS
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVITREAL
IRRIGATION
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION
PERIARTICULAR
PERIODONTAL
PYELOCALYCEAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* generally identifies:

- Drugs approved under Section 505(c) of the FD&C Act where FDA has recognized 5-year and/or 3-year periods of exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) pursuant to Section 505(c)(3)(E) and Section 505(j)(5)(F) of the FD&C Act
- Drugs approved under Section 505(c) of the FD&C Act where FDA has recognized Orphan Drug Exclusivity (ODE) pursuant to Section 527 of the FD&C Act
- Drugs approved under Section 505(c) of the FD&C Act where FDA has recognized Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs approved under Section 505(c) of the FD&C Act where FDA has recognized Generating Antibiotic Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under Section 505(j) of the FD&C Act where FDA has recognized 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv) of the FD&C Act
- Generic drugs approved under Section 505(j) of the FD&C Act where FDA has recognized Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act

This section is arranged in alphabetical order by name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple active ingredient, fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each ODE entry listed in the Orange Book. Such descriptions of ODE were included beginning with the 38th edition of the Orange Book. The ODE* code means that the timing of approval of certain follow-on applications may be subject to delay due to ODE for another drug that has the same active moiety.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that certain patent information be filed with all newly submitted new drug applications (NDA) and with certain supplements to approved NDAs. Form FDA 3542a must be used for this pre-approval submission.[1]

The FD&C Act also requires that certain patent information be filed after approval of an NDA. To be considered timely filed, such patent information must be submitted according to the following timeframes:

- not later than 30 days after the date of approval of the NDA[2] or supplement; or
- not later than 30 days after the date of issuance of the patent when a patent is issued after approval of the NDA or supplement.

Form FDA 3542 must be used for these submissions.[3] FDA publishes certain information from Form FDA 3542 in the Orange Book.

The Orange Book includes the patent submission date (i.e., the date on which FDA receives patent information from the NDA holder on Form FDA 3542) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or abbreviated new drug application (ANDA) and whether patent information was submitted before the date on which a 505(b)(2) application or ANDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA) was submitted.[4]

Section 505(c)(2) of the FD&C Act requires, with reference to Section 505(b)(1)(A)(viii) of the FD&C Act, that applicants submit certain patent information for each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug and that:

- claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or
- claims a method of using such drug for which approval has been granted in the application.

This information, as provided by the NDA holder on Form FDA 3542, will be published in the Orange Book, as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.[5]

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. All parts of this Addendum are subject to changes, additions, or deletions.

---

[1] 21 CFR 314.53(c)(2)(i); 21 CFR 314.53(d).
[2] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).
[3] 21 CFR 314.53(c)(2)(ii); 21 CFR 314.53(d).
[4] See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi); see also 21 CFR 314.107(b)(3)(i). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).
[5] 21 CFR 314.53.

The electronic Orange Book, updated regularly, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ						
N 205551 001	8129385	Oct 05, 2027	DS DP		M-294	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD						
N 215413 001	8129385	Oct 05, 2027	DS DP		NPP	Jun 15, 2026
	8129385*PED	Apr 05, 2028			PED	Dec 15, 2026
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
ABALOPARATIDE - TYMLOS						
N 208743 001	10996208	Apr 30, 2038	DP			
	11255842	Jan 10, 2040			U-3322	
	11680942	Jan 10, 2040			U-3322	
	11782041	Apr 30, 2038	DP		U-2009	
	11782041	Apr 30, 2038	DP		U-3543	
	11977067	Apr 30, 2038	DP			
	7803770	Apr 28, 2031			U-2009	
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027			U-2009	
	8748382	Oct 03, 2027			U-3543	
	RE49444	Apr 28, 2031			U-2009	
	RE49444	Apr 28, 2031			U-3543	
ABAMETAPIR - XEGLYZE						
N 206966 001	10292389	Dec 17, 2034	DP		U-2863	
	7812163	Oct 28, 2026	DP		U-2863	
ABEMACICLIB - VERZENIO						
N 208716 001	7855211	Sep 28, 2031	DS DP		U-2135	
	7855211	Sep 28, 2031	DS DP		U-3242	
	7855211	Sep 28, 2031	DS DP		U-3265	
	7855211	Sep 28, 2031	DS DP		U-3546	
ABEMACICLIB - VERZENIO						
N 208716 002	7855211	Sep 28, 2031	DS DP		U-2135	
	7855211	Sep 28, 2031	DS DP		U-3242	
	7855211	Sep 28, 2031	DS DP		U-3265	
	7855211	Sep 28, 2031	DS DP		U-3546	
ABEMACICLIB - VERZENIO						
N 208716 003	7855211	Sep 28, 2031	DS DP		U-2135	
	7855211	Sep 28, 2031	DS DP		U-3242	
	7855211	Sep 28, 2031	DS DP		U-3265	
	7855211	Sep 28, 2031	DS DP		U-3546	
ABEMACICLIB - VERZENIO						
N 208716 004	7855211	Sep 28, 2031	DS DP		U-1981	
	7855211	Sep 28, 2031	DS DP		U-2135	
	7855211	Sep 28, 2031	DS DP		U-3242	
	7855211	Sep 28, 2031	DS DP		U-3265	
	7855211	Sep 28, 2031	DS DP		U-3546	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE - YONSA						
N 210308 001	10292990	May 20, 2034	U-2535			
	9889144	Mar 17, 2034	DP			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 001	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP U-2830			
	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-2830			
	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 002	11091459	Mar 27, 2038	DS DP		NP	Aug 11, 2026
	11207311	Jul 28, 2037	U-2830			
	11673877	Mar 27, 2038	DS DP U-2830			
	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
	12383543	Jul 28, 2037	U-2830			
	8071579	Aug 12, 2027	U-2830			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2830			
	8436185	Apr 24, 2029	DS DP			
	8859562	Aug 04, 2031	U-2830			
ABROCITINIB - CIBINQO						
N 213871 001	9035074	Jan 14, 2036	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 002	9035074	Jan 14, 2036	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 003	9035074	Jan 14, 2036	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP		NPP	Feb 09, 2026
	9549929	Feb 19, 2034	U-3195			
ACALABRUTINIB - CALQUENCE						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519		ODE-274	Nov 21, 2026
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACALABRUTINIB - CALQUENCE						
N 210259 001	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11771696	Jan 21, 2035	U-3710			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	10239883	Jul 11, 2032	U-2666		I-960	Jan 16, 2028
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	11771696	Jan 21, 2035	U-3710			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
ACECLIDINE HYDROCHLORIDE - VIZZ						
N 218585 001	10052313	Mar 24, 2034	DP U-3741		NCE	Jul 31, 2030
	11179328	Mar 24, 2034	U-3741			
	12128036	Oct 08, 2039	U-3741			
	12414942	Mar 15, 2044	U-3741			
	9844537	Mar 24, 2034	DP U-3741			
ACETAMINOPHEN - ACETAMINOPHEN						
A 214331 002					PC	Jan 07, 2026
ACETAMINOPHEN - OFIRMEV						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
	10383834*PED	May 13, 2029				
	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
ACETAMINOPHEN - ACETAMINOPHEN						
N 204767 001	8741959	Apr 19, 2030	DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; IBUPROFEN - COMBOGESIC						
N 209471 001	11197830	Feb 27, 2039	DP U-3553		NP	Mar 01, 2026
	11534407	Feb 27, 2039	DP U-3553			
ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN						
N 211733 001	11918693	Jul 09, 2041	DP			
ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV						
N 215320 001	11213498	Jan 14, 2036	DP		NP	Oct 17, 2026
	11389416	Jul 17, 2035	DP			
	11446266	Oct 26, 2031	U-3744			
	11446266	Oct 26, 2031	U-3745			
	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
	12083087	Jul 17, 2035	U-3744			
	12083087	Jul 17, 2035	U-3745			
	12220392	Oct 26, 2031	U-4306			
	12220392	Oct 26, 2031	U-4307			
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE						
N 021539 001	8148356	May 21, 2026	DP		D-196	Nov 26, 2027
	8722738	Apr 06, 2032	U-1373			
	9327028	Jul 21, 2031	U-1839			
ACETYLCYSTEINE - CETYLEV						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE - CETYLEV						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE LYSINE - LEGUBETI						
N 215040 001					NP	Feb 13, 2027
ACETYLCYSTEINE LYSINE - LEGUBETI						
N 215040 002					NP	Feb 13, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR							
N 202450	001	10085974	Mar 13, 2029	DP U-2513			
		11000517	Mar 13, 2029	DP U-2513			
ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR							
N 210595	001	10085974	Mar 13, 2029	DP U-2513			
		11000517	Mar 13, 2029	DP U-2513			
ACOLTREMON - TRYPTYR							
N 217370	001	10028920	Sep 08, 2031	U-1900		NCE	May 28, 2030
		11850221	Dec 16, 2042	DP U-1900			
		12336971	Dec 16, 2042	U-1900			
		9095609	Sep 08, 2031	DP U-1900			
		9433679	Sep 08, 2031	U-1900			
ACORAMIDIS HYDROCHLORIDE - ATTRUBY							
N 216540	001	10398681	May 05, 2031	DP		NCE	Nov 22, 2029
		10513497	Feb 16, 2038	DS		ODE-506	Nov 22, 2031
		10842777	May 05, 2031	U-4046			
		11058668	Mar 22, 2039	U-4046			
		11260047	Aug 16, 2039	DP			
		11919865	Feb 16, 2038	U-4046			
		12005043	Aug 16, 2039	DP U-4046			
		12070449	Mar 22, 2039	U-4046			
		8877795	May 05, 2031	DP			
		9169214	May 05, 2031	DP U-4046			
		9642838	May 05, 2031	DS DP			
		9913826	May 05, 2031	U-4046			
ACYCLOVIR - AVACLYR							
N 202408	001					ODE-235	Mar 29, 2026
ACYCLOVIR - SITAVIG							
N 203791	001	8592434	Jun 16, 2030	DP U-1460			
		8747896	Jun 03, 2027	DP U-1460			
		8791127	Mar 23, 2027	DP U-1460			
ADAGRASIB - KRAZATI							
N 216340	001	10689377	May 17, 2037	DS DP U-3490		NCE	Dec 12, 2027
		10689377	May 17, 2037	DS DP U-3953		ODE-352	Dec 12, 2029
		12281113	Sep 10, 2041	DS DP			
		12336995	Feb 05, 2041	U-3953			
		12383503	Aug 21, 2043	DP			
ADAPALENE - DIFFERIN							
N 022502	001	7998467	May 31, 2028	DP U-1078			
		8435502	Sep 15, 2026	DP U-1078			
		8709392	Sep 15, 2026	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N 022320	001	8071644	Jul 18, 2027	DP U-1078			
		8080537	Jul 18, 2027	U-1078			
		8129362	Jul 18, 2027	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO						
N 216632 001	10220049	Jun 03, 2029	DP U-3713		NP	Oct 20, 2026
	10624918	Jun 03, 2029	U-3713			
	11389467	Dec 28, 2040	DP U-3713			
	12128059	Jul 31, 2040	DP U-3713			
	12133859	Jul 31, 2040	DP			
	12138278	Jul 31, 2040	DP			
	8288434	Aug 05, 2029	DP U-3713			
	9561208	Jun 03, 2029	DP U-3713			
AFAMELANOTIDE - SCENESSE						
N 210797 001	8334265	Jan 20, 2033	U-2638		ODE-270	Oct 08, 2026
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	10004743	Jul 05, 2030	DP			
	10004743*PED	Jan 05, 2031				
	8426586	Oct 10, 2029	DS			
	8426586*PED	Apr 10, 2030				
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	10004743	Jul 05, 2030	DP			
	10004743*PED	Jan 05, 2031				
	8426586	Oct 10, 2029	DS			
	8426586*PED	Apr 10, 2030				
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	10004743	Jul 05, 2030	DP			
	10004743*PED	Jan 05, 2031				
	8426586	Oct 10, 2029	DS			
	8426586*PED	Apr 10, 2030				
	8545884	Dec 19, 2029	DP			
	8545884*PED	Jun 19, 2030				
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
AFICAMTEN - MYQORZO						
N 219083 001					NCE	Dec 19, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AFICAMTEN - MYQORZO						
N 219083 002					NCE	Dec 19, 2030
AFICAMTEN - MYQORZO						
N 219083 003					NCE	Dec 19, 2030
AFICAMTEN - MYQORZO						
N 219083 004					NCE	Dec 19, 2030
AIR POLYMER-TYPE A - EXEM FOAM KIT						
N 212279 001	9034300	Oct 15, 2030	DP U-2663			
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
ALBUMIN HUMAN - OPTISON						
N 020899 001					NPP	May 09, 2028
ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA						
N 214070 001	9415009	May 28, 2030	U-3509		M-317	Sep 15, 2028
					NP	Jan 10, 2026
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT						
N 021747 001	7396341	Oct 10, 2026	DP	Y		
	7837235	Mar 13, 2028	DP	Y		
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
ALCAFTADINE - LASTACAFT						
N 022134 001	10617695	Mar 19, 2027	DP U-3267			
	8664215	Dec 23, 2027	U-3267			
ALECTINIB HYDROCHLORIDE - ALECENSA						
N 208434 001	10350214	Apr 24, 2035	DP		I-947	Apr 18, 2027
	11433076	Apr 24, 2035	DP		ODE-477	Apr 18, 2031
	9126931	May 29, 2031	DS			
	9365514	Mar 04, 2032	DP			
	9440922	Jun 09, 2030	DP			
ALENDRONATE SODIUM - BINOSTO						
N 202344 001	9592195	Dec 05, 2031	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA						
N 021985 001	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE - TEKTURNA						
N 021985 002	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 001	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 002	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 003	8613949	Dec 21, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO								
N	022545	004	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	001	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	002	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	003	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	004	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	001	8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	002	8168616	Jul 03, 2026	DP			
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	001	10183012	Nov 26, 2028	U-2104			
			8084483	Aug 17, 2029	U-2104			
			8283369	Nov 26, 2028	U-2104			
			8357713	Dec 22, 2029	DP U-2104			
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029	U-2104			
			9216179	Aug 01, 2031	U-2104			
			9956205	Dec 28, 2031	U-2104			
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	002	10183012	Nov 26, 2028	U-2104			
			8084483	Aug 17, 2029	U-2104			
			8283369	Nov 26, 2028	U-2104			
			8357713	Dec 22, 2029	DP U-2104			
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029	U-2104			
			9216179	Aug 01, 2031	U-2104			
			9956205	Dec 28, 2031	U-2104			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	001	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	002	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA								
N	022271	003	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8697125	Jun 16, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO								
N	203414	001	7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8900638	May 24, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO								
N 203414	002		7807689	Jun 27, 2028	DS DP U-1337		M-300	Jul 27, 2026
			8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	001		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	002		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	003		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	004		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	005		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI								
N 022426	006		7807689	Jun 27, 2028	DS DP U-1337			
			8637079	Jun 04, 2029	DP			
ALPELISIB - PIQRAY								
N 212526	001		8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
			8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY								
N 212526	002		8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
			8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY								
N 212526	003		8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
			8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE								
N 215039	001		11433059	Feb 17, 2037	U-4359		ODE-396	Apr 05, 2029
			12427141	Feb 17, 2037	U-4288			
			8227462	Apr 29, 2033	DS DP			
			8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE								
N 215039	002		11433059	Feb 17, 2037	U-4359		ODE-396	Apr 05, 2029
			12427141	Feb 17, 2037	U-4288			
			8227462	Apr 29, 2033	DS DP			
			8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE								
N 215039	003		11433059	Feb 17, 2037	U-4359		ODE-396	Apr 05, 2029
			12427141	Feb 17, 2037	U-4288			
			8227462	Apr 29, 2033	DS DP			
			8476268	Sep 10, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALPELISIB - VIJOICE						
N 218466 001	11433059	Feb 17, 2037	U-4359			
	12427141	Feb 17, 2037	U-4288			
	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
ALVIMOPAN - ENTEREG						
N 021775 001	8946262	Feb 12, 2030	U-1655			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 001	10154971	Dec 04, 2034	U-2459			
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	11903908	Jun 17, 2034	U-3822			
	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 002	10154971	Dec 04, 2034	U-2459			
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	11903908	Jun 17, 2034	U-3822			
	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 001	10512617	Feb 15, 2038	U-2497			
	11890261	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	11890261	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 004	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
AMBRISENTAN - LETAIRIS						
N 022081 001	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
AMBRISENTAN - LETAIRIS						
N 022081 002	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE						
N 208078 001	10626088	Feb 25, 2037	DP			
	10793893	May 26, 2034	U-2956			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE						
N 208078 001	11060128	Jun 29, 2032	U-2956			
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			
AMIKACIN SULFATE - ARIKAYCE KIT						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214	Sep 28, 2025
	10751355	May 15, 2035	U-2414		GAIN	Sep 28, 2030
	11446318	May 15, 2035	U-2414			
	12016873	May 15, 2035	U-2414			
	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
	12377114	May 15, 2035	U-2414			
	8226975	Aug 15, 2028	DP			
	8632804	Dec 05, 2026	U-2416			
	8642075	Dec 05, 2026	DP			
	8679532	Dec 05, 2026	U-2415			
	9566234	Jan 18, 2034	DP U-2415			
	9895385	May 15, 2035	U-2417			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER						
N 200656 001	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER						
N 200656 002	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER						
N 200656 003	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER						
N 200656 004	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER						
N 200656 005	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER						
N 200656 006	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER						
N 200656 007	12390398	May 03, 2036	DP			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
	11135293	Jan 12, 2038	U-3163			
	11179574	Oct 13, 2036	U-804			
	11446512	Jan 17, 2037	U-804			
	11571478	Jan 12, 2038	U-3163			
	11690914	Jan 12, 2038	U-3163			
	11697028	Oct 13, 2036	U-804			
	12290700	Oct 13, 2036	U-804			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N 020965 001	12296011	Jan 12, 2038	U-3163			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	11235169	Oct 15, 2040	U-3303		D-194	Oct 04, 2027
	11540981	Feb 07, 2028	DP			
	12280146	Dec 08, 2043	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 001	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 002	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 003	7635773	Mar 13, 2029	DP			
AMISULPRIDE - BARHEMSYS						
N 209510 001	10525033	Mar 10, 2031	DP			
	11357753	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
AMISULPRIDE - BARHEMSYS						
N 209510 002	10525033	Mar 10, 2031	DP			
	11357753	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BENZOATE - KATERZIA								
N 211340	001		10695329	Oct 16, 2037	DP			
			10799453	Apr 11, 2039	DP			
			10894039	Oct 06, 2037	U-185			
			10894039	Oct 06, 2037	U-3			
			10952998	Oct 06, 2037	DP			
			10959991	Oct 06, 2037	U-158			
			10959991	Oct 06, 2037	U-39			
			11364230	Oct 06, 2037	DP			
			11471409	Oct 06, 2037	U-3447			
			11471409	Oct 06, 2037	U-3448			
			11484498	Oct 06, 2037	DP			
			11701326	Oct 06, 2037	DP			
			11918685	Oct 06, 2037	U-3447			
			11918685	Oct 06, 2037	U-3448			
			12053461	Oct 06, 2037	DP			
			12336984	Oct 06, 2037	U-3447			
			12336984	Oct 06, 2037	U-3448			
			12383498	Oct 06, 2037	DP			
AMLODIPINE BESYLATE - NORLIQVA								
N 214439	001		11253474	Feb 24, 2041	DP U-3309			
			11253474	Feb 24, 2041	DP U-3310			
			11253474	Feb 24, 2041	DP U-3311			
			11458095	Feb 24, 2041	DP U-3309			
			11458095	Feb 24, 2041	DP U-3310			
			11458095	Feb 24, 2041	DP U-3311			
			11723866	Feb 24, 2041	DP U-3309			
			11723866	Feb 24, 2041	DP U-3310			
			11723866	Feb 24, 2041	DP U-3311			
			12005141	Feb 24, 2041	DP U-3309			
			12005141	Feb 24, 2041	DP U-3310			
			12005141	Feb 24, 2041	DP U-3311			
			12226528	Feb 24, 2041	DP U-3309			
			12226528	Feb 24, 2041	DP U-3310			
			12226528	Feb 24, 2041	DP U-3311			
			12440441	Feb 24, 2041	DP U-3309			
			12440441	Feb 24, 2041	DP U-3310			
			12440441	Feb 24, 2041	DP U-3311			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N 210045	001		10350171	Jun 14, 2038	DP			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N 210045	002		10350171	Jun 14, 2038	DP			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI								
N 210045	003		10350171	Jun 14, 2038	DP			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	001		10322117	Jan 23, 2038	DP		NP	Jun 05, 2028
			12465599	Jan 23, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	002		10799487	Jan 23, 2038	DP U-3448		NP	Jun 05, 2028
			12465599	Jan 23, 2038	DP			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	003						NP	Jun 05, 2028
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N 205003	001		7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N 205003	002		7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA								
N 205003	003		7846961	Oct 05, 2029	DS DP U-3			
AMOXICILLIN - MOXATAG								
N 050813	001		8299052	May 07, 2027	U-1304			
			8357394	Dec 08, 2026	DP			
			8778924	Dec 08, 2026	DS DP U-897			
AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK								
N 215152	001		7977488	Aug 11, 2028	DS		NCE	May 03, 2027
			9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA								
N 213004	001		10238606	Feb 12, 2034	DP		NP	Nov 01, 2022
			11135172	Feb 12, 2034	DP U-2660		GAIN	Nov 01, 2027
			11878011	May 27, 2042	U-3816			
			11931463	Feb 12, 2034	DP U-3866			
			9050263	Feb 12, 2034	DP U-2660			
			9498445	Feb 12, 2034	DP U-2660			
			9603806	Feb 12, 2034	DP U-2660			
AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK								
N 215153	001		7977488	Aug 11, 2028	DS		NCE	May 03, 2027
			9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMPHETAMINE - ADZENYS ER								
N 204325	001		8709491	Jun 28, 2032	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	001		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
			9839619	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	002		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
			9839619	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
	9839619	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
	9839619	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
	9839619	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
	9839619	Jun 28, 2032	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS						
N 022063 001	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS						
N 022063 002	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS						
N 022063 003	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026			U-2025	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS						
N 022063 004	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026			U-2025	
AMPHETAMINE SULFATE - EVEKEO ODT						
N 209905 001	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
	11896562	Mar 10, 2037			U-3299	
AMPHETAMINE SULFATE - EVEKEO ODT						
N 209905 002	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
	11896562	Mar 10, 2037			U-3299	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE SULFATE - EVEKEO ODT						
N 209905 003	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
	11896562	Mar 10, 2037			U-3299	
AMPHETAMINE SULFATE - EVEKEO ODT						
N 209905 004	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
	11896562	Mar 10, 2037			U-3299	
AMPHETAMINE SULFATE - EVEKEO ODT						
N 209905 005	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR						
N 208147 001	10086087	Mar 15, 2027	DP			
	11590228	Sep 07, 2036	DP		U-3538	
	8062667	Mar 29, 2029	DP			
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
	9675703	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5						
N 210526 001	11590081	Sep 24, 2038	DP		U-3538	
	12458592	Feb 11, 2040			U-3538	
	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10						
N 210526 002	11590081	Sep 24, 2038	DP		U-3538	
	12458592	Feb 11, 2040			U-3538	
	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15						
N 210526 003	11590081	Sep 24, 2038	DP		U-3538	
	12458592	Feb 11, 2040			U-3538	
	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20						
N 210526 004	11590081	Sep 24, 2038	DP		U-3538	
	12458592	Feb 11, 2040			U-3538	
	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 001	10028995	Dec 18, 2034			U-2338	
	10335451	Dec 16, 2029			U-2581	
	10493124	Dec 18, 2034			U-2679	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 001	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 002	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Nov 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	11559559	Dec 18, 2034	U-3514			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
APALUTAMIDE - ERLEADA						
N 210951 001	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	11963952	Jan 30, 2040	U-3901			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APALUTAMIDE - ERLEADA						
N 210951 001	12303493	Dec 03, 2035	DP			
	12303497	Jan 30, 2040	U-4201			
	12303497	Jan 30, 2040	U-4202			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
APALUTAMIDE - ERLEADA						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	11963952	Jan 30, 2040	U-3901			
	12303493	Dec 03, 2035	DP			
	12303497	Jan 30, 2040	U-4201			
	12303497	Jan 30, 2040	U-4202			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
APIXABAN - ELIQUIS						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1200		PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1301		PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-1302			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APIXABAN - ELIQUIS						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS						
N 202155 003	6967208	Nov 21, 2026	DS DP U-4179		NS	Apr 17, 2028
	6967208*PED	May 21, 2027			PED	Oct 17, 2028
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS SPRINKLE						
N 220073 001	11896586	Nov 22, 2040	DP U-4180		NP	Apr 17, 2028
	11896586*PED	May 22, 2041			PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-4180			
	6967208*PED	May 21, 2027				
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 001	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 002	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 004	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 005	10420763	Jun 11, 2030	DP U-2825			
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
APOMORPHINE HYDROCHLORIDE - ONAPGO						
N 214056 001					NP	Feb 03, 2028
APREMILAST - OTEZLA						
N 205437 001	10092541	May 29, 2034	U-2403		M-299	Jul 20, 2026
	10092541	May 29, 2034	U-2659		NPP	Apr 25, 2027
	10092541*PED	Nov 29, 2034			ODE-248	Jul 19, 2026
	7427638	Feb 16, 2028	DS DP		PED	Jan 19, 2027
	7427638*PED	Aug 16, 2028			PED	Jan 20, 2027
	9872854	May 29, 2034	U-2232		PED	Oct 25, 2027
	9872854	May 29, 2034	U-2233			
	9872854*PED	Nov 29, 2034				
APREMILAST - OTEZLA						
N 205437 002	10092541	May 29, 2034	U-2403		M-299	Jul 20, 2026
	10092541	May 29, 2034	U-2659		NPP	Apr 25, 2027
	10092541*PED	Nov 29, 2034			ODE-248	Jul 19, 2026
	7427638	Feb 16, 2028	DS DP		PED	Jan 19, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA						
N 205437 002	7427638*PED	Aug 16, 2028			PED	Jan 20, 2027
	9872854	May 29, 2034	U-2232		PED	Oct 25, 2027
	9872854	May 29, 2034	U-2233			
	9872854*PED	Nov 29, 2034				
APREMILAST - OTEZLA						
N 205437 003	10092541	May 29, 2034	U-2403		M-299	Jul 20, 2026
	10092541	May 29, 2034	U-2659		NPP	Apr 25, 2027
	10092541*PED	Nov 29, 2034			ODE-248	Jul 19, 2026
	7427638	Feb 16, 2028	DS DP		PED	Jan 19, 2027
	7427638*PED	Aug 16, 2028			PED	Jan 20, 2027
	9872854	May 29, 2034	U-2232		PED	Oct 25, 2027
	9872854	May 29, 2034	U-2233			
	9872854*PED	Nov 29, 2034				
APREMILAST - OTEZLA XR						
N 210745 001	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	11752129	May 27, 2042	DP U-4264		ODE*	Jul 19, 2026
	11752129	May 27, 2042	DP U-4265		PED	Jan 19, 2027
	11752129	May 27, 2042	DP U-4266		PED	Jan 20, 2027
	11969409	May 27, 2042	DP			
	12427136	May 27, 2042	U-1858			
	12427136	May 27, 2042	U-4290			
	12427136	May 27, 2042	U-4291			
	7427638	Feb 16, 2028	DS DP			
APREPITANT - EMEND						
N 021549 001	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 002	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 003	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 207865 001	8258132	Sep 26, 2027	DP U-1916			
APREPITANT - CINVANTI						
N 209296 001	10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-2161			
	10953018	Sep 18, 2035	U-2161			
	11173118	Sep 18, 2035	DP			
	11744800	Sep 18, 2035	DP			
	12115254	Sep 18, 2035	DP			
	12115255	Sep 18, 2035	DP			
	12290520	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREPITANT - CINVANTI						
N 209296 001	9974794	Sep 18, 2035	DP U-2161			
APREPITANT - APONVIE						
N 216457 001	10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-3440			
	10953018	Sep 18, 2035	U-3440			
	11173118	Sep 18, 2035	DP			
	11744800	Sep 18, 2035	DP U-3690			
	11878074	Sep 18, 2035	U-3787			
	12115254	Sep 18, 2035	DP			
	12115255	Sep 18, 2035	DP			
	12290520	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-3440			
	9808465	Sep 18, 2035	U-3440			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-3440			
APROCITENTAN - TRYVIO						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	12297189	Feb 26, 2038	DP			
	8324232	Sep 21, 2029	DS DP U-3878			
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N 022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 001	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 002	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 003	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
ARIMOCLOMOL CITRATE - MIPLYFFA						
N 214927 004	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
ARIPIPRAZOLE - ABILIFY						
N 021436 001	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 002	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - MEZOFY						
N 211448 001	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE - MEZOFY						
N 211448 002	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE - MEZOFY						
N 211448 003	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE - OPIPZA						
N 216655 001	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			
ARIPIPRAZOLE - OPIPZA						
N 216655 002	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			
ARIPIPRAZOLE - OPIPZA						
N 216655 003	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 001	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 002	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039			U-543	
	12311027	Sep 19, 2033	DP		U-543	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039			U-543	
	12311027	Sep 19, 2033	DP		U-543	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2402	
	11097006	Oct 24, 2033	DP		U-764	
	11273158	Apr 06, 2039			U-543	
	11406632	Mar 19, 2035			U-2402	
	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039			U-543	
	12311027	Sep 19, 2033	DP		U-543	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2402			
	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2983			
	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	10016415	Sep 08, 2035	DP			
	10112903	Jun 24, 2030	DS U-543			
	10688091	Aug 17, 2035	DP			
	10849894	Aug 17, 2035	U-543			
	11154552	Aug 17, 2035	DP			
	11273158	Apr 06, 2039	U-543			
	12251381	Apr 06, 2039	U-543			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
ARTESUNATE - ARTESUNATE						
N 213036 001	12121506	Feb 16, 2044	DP		ODE-290	May 26, 2027
ARTICAINE HYDROCHLORIDE - CYKLX						
N 218643 001					NP	Aug 15, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 001	11407735	May 14, 2040	DS		I-953	Oct 29, 2027
	12252478	May 14, 2040	DP		I-954	Oct 29, 2027
	12252479	May 17, 2040	U-1374		M-318	Oct 02, 2028
	8829195	Oct 29, 2035	DS U-1374		NCE	Oct 29, 2026
					ODE-381	Oct 29, 2028
					ODE-382	Oct 29, 2028
					ODE-499	Oct 29, 2031
					ODE-500	Oct 29, 2031
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 002	11407735	May 14, 2040	DS		I-953	Oct 29, 2027
	12252478	May 14, 2040	DP		I-954	Oct 29, 2027
	12252479	May 17, 2040	U-1374		M-318	Oct 02, 2028
	8829195	Oct 29, 2035	DS U-1374		NCE	Oct 29, 2026
					ODE-381	Oct 29, 2028
					ODE-382	Oct 29, 2028
					ODE-499	Oct 29, 2031
					ODE-500	Oct 29, 2031
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 003	11407735	May 14, 2040	DS		M-318	Oct 02, 2028
	12252478	May 14, 2040	DP		NCE	Oct 29, 2026
	12252479	May 17, 2040	U-1374		ODE*	Oct 29, 2028
	8829195	Oct 29, 2035	DS U-1374			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU						
N 209381 001	10016504	Sep 10, 2033	DP			
	10646512	Mar 25, 2032	DP			
	10780112	Mar 09, 2032	DP			
	10792306	Mar 09, 2032	DP U-2310			
	10918723	Sep 10, 2033	U-2310			
	11529368	Mar 09, 2032	DP U-2310			
	12083179	Sep 10, 2033	DP U-2310			
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033	U-2310			
	9592252	Aug 11, 2032	DP U-2310			
	9707297	Sep 10, 2033	DP			
ASENAPINE - SECUADO						
N 212268 001	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	11813364	Sep 22, 2033	DP			
	9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO						
N 212268 002	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	11813364	Sep 22, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE - SECUADO						
N 212268 002	9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO						
N 212268 003	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP		U-2763	
	10814002	Jul 25, 2033	DP		U-2763	
	11123305	Jul 25, 2033	DP			
	11813364	Sep 22, 2033	DP			
	9687474	Jul 25, 2033	DP			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001	7741358	Apr 06, 2026	DS DP		U-1064	
	7741358	Apr 06, 2026	DS DP		U-1960	
	7741358	Apr 06, 2026	DS DP		U-1961	
	7741358	Apr 06, 2026	DS DP		U-1962	
	7741358	Apr 06, 2026	DS DP		U-1963	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 002	7741358	Apr 06, 2026	DS DP		U-1064	
	7741358	Apr 06, 2026	DS DP		U-1960	
	7741358	Apr 06, 2026	DS DP		U-1961	
	7741358	Apr 06, 2026	DS DP		U-1962	
	7741358	Apr 06, 2026	DS DP		U-1963	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 003	7741358	Apr 06, 2026	DS DP		U-1893	
	7741358	Apr 06, 2026	DS DP		U-1966	
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASPIRIN - VAZALORE						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032			U-3559	
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032			U-1731	
	9226892	Sep 29, 2032			U-1732	
	9226892	Sep 29, 2032			U-1733	
ASPIRIN - VAZALORE						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032			U-3559	
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 001	9539214	Mar 13, 2033			U-1902	
	9987231	Jan 02, 2033			U-2324	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 002	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ						
N 206353 001	10039718	Oct 06, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
ATOGEPANT - QULIPTA						
N 215206 001	10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
	12090148	Jul 29, 2041	U-3534		NCE	Sep 28, 2026
	12350259	Feb 27, 2043	U-4234			
	12383545	Jun 06, 2039	U-3534			
	12465598	Sep 27, 2042	U-4355			
	8754096	Jul 19, 2032	DS DP U-3534			
	9499545	Nov 10, 2031	DS DP U-3534			
	9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA						
N 215206 002	10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
	12090148	Jul 29, 2041	U-3534		NCE	Sep 28, 2026
	12383545	Jun 06, 2039	U-3534			
	8754096	Jul 19, 2032	DS DP U-3534			
	9499545	Nov 10, 2031	DS DP U-3534			
	9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA						
N 215206 003	10117836	Jan 30, 2035	DP		I-909	Apr 17, 2026
	12090148	Jul 29, 2041	U-3534		NCE	Sep 28, 2026
	12383545	Jun 06, 2039	U-3534			
	8754096	Jul 19, 2032	DS DP U-3534			
	9499545	Nov 10, 2031	DS DP U-3534			
	9850246	Mar 13, 2033	DS			
ATORVASTATIN CALCIUM - ATORVALIQ						
N 213260 001	11369567	Jun 07, 2037	DP			
	11654106	Jun 07, 2037	DP U-3612			
	11654106	Jun 07, 2037	DP U-3613			
	11925704	Jun 07, 2037	DP U-3853			
	12168069	Jun 07, 2037	DP			
	12370136	Jun 07, 2037	DP			
ATRASENTAN HYDROCHLORIDE - VANRAFIA						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	12370174	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
AVACINCAPTAD PEGOL SODIUM - IZERVAY						
N 217225 001	11273171	Jul 11, 2034	U-3673			
	11491176	Jul 11, 2034	U-3673			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVACINCAPTAD PEGOL SODIUM - IZERVAY						
N 217225 001	12016875	Jul 11, 2034	U-3673			
	7579456	Feb 14, 2026	DS			
	8236773	Nov 11, 2026	U-3673			
	9617546	Feb 14, 2026	DS U-3673			
AVACOPAN - TAVNEOS						
N 214487 001	11603356	Nov 27, 2039	DS DP U-3558		NCE	Oct 07, 2026
	11951214	Nov 27, 2039	DP		ODE-377	Oct 07, 2028
	8445515	Feb 03, 2031	DS DP			
	8906938	Dec 21, 2029	DS DP			
AVAPRITINIB - AYVAKIT						
N 212608 001	11964980	Apr 10, 2040	DS DP		ODE-356	Jun 16, 2028
	11999744	Apr 10, 2040	U-3168		ODE-366	Jan 09, 2027
	12060354	Mar 08, 2042	U-2726		ODE-434	May 22, 2030
	9200002	Oct 15, 2034	DS DP U-2726			
	9200002	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-2726			
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
AVAPRITINIB - AYVAKIT						
N 212608 002	11964980	Apr 10, 2040	DS DP		ODE-356	Jun 16, 2028
	11999744	Apr 10, 2040	U-3168		ODE-366	Jan 09, 2027
	12060354	Mar 08, 2042	U-2726		ODE-434	May 22, 2030
	9200002	Oct 15, 2034	DS DP U-2726			
	9200002	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-2726			
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
AVAPRITINIB - AYVAKIT						
N 212608 003	11964980	Apr 10, 2040	DS DP		ODE-356	Jun 16, 2028
	12060354	Mar 08, 2042	U-2726		ODE-366	Jan 09, 2027
	9200002	Oct 15, 2034	DS DP U-2726		ODE-434	May 22, 2030
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
AVAPRITINIB - AYVAKIT						
N 212608 004	11827642	Oct 15, 2034	DS DP U-3506		I-912	May 22, 2026
	11964980	Apr 10, 2040	DS DP		ODE-356	Jun 16, 2028
	11999744	Apr 10, 2040	U-3168		ODE-366	Jan 09, 2027
	11999744	Apr 10, 2040	U-3506		ODE-434	May 22, 2030
	12252494	Apr 10, 2040	U-3506			
	9200002	Oct 15, 2034	DS DP U-3168			
	9200002	Oct 15, 2034	DS DP U-3506			
	9944651	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-3506			
	9994575	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-3506			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVAPRITINIB - AYVAKIT						
N 212608 005	11964980	Apr 10, 2040	DS DP		ODE-356	Jun 16, 2028
	11999744	Apr 10, 2040	U-3168		ODE-366	Jan 09, 2027
	9200002	Oct 15, 2034	DS DP U-3168		ODE-434	May 22, 2030
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-3168			
AVATROMBOPAG MALEATE - DOPTELET						
N 210238 001	7638536	Jul 28, 2027	DS DP		I-974	Jul 24, 2028
					ODE-246	Jun 26, 2026
AVATROMBOPAG MALEATE - DOPTELET SPRINKLE						
N 219696 001	7638536	Jul 28, 2027	DS DP		NP	Jul 24, 2028
AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
	7612087	Nov 12, 2026	DP			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)						
N 219616 001	11400090	Oct 29, 2038	U-4196		NCE	May 08, 2030
	11517573	Sep 11, 2040	U-4196			
	11517573	Sep 11, 2040	U-4205			
	11873296	Dec 29, 2042	DP U-4196			
	7897792	Feb 09, 2027	DS DP			
	7928109	Aug 21, 2029	DS DP			
	8247411	Apr 17, 2028	DS DP			
AXITINIB - INLYTA						
N 202324 001	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
AXITINIB - INLYTA						
N 202324 002	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AXITINIB - INLYTA							
N 202324	002	10869924	Jan 12, 2037	U-3044			
		10869924*PED	Jul 12, 2037				
		8791140	Dec 14, 2030	DS			
		8791140*PED	Jun 14, 2031				
AZACITIDINE - VIDAZA							
N 050794	001					ODE-399	May 20, 2029
AZACITIDINE - ONUREG							
N 214120	001	11571436	May 14, 2029	DP		ODE-320	Sep 01, 2027
		12053482	May 14, 2029	U-2950			
		8846628	Jun 03, 2030	DP U-2950			
AZACITIDINE - ONUREG							
N 214120	002	11571436	May 14, 2029	DP		ODE-320	Sep 01, 2027
		12053482	May 14, 2029	U-2950			
		8846628	Jun 03, 2030	DP U-2950			
AZELAIC ACID - FINACEA							
N 207071	001	10117812	Oct 18, 2027	DP U-1796			
		7700076	Sep 18, 2027	DP			
		9211259	Feb 28, 2029	U-1796			
		9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001	8071073	Jun 04, 2028	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	002	8071073	Jun 04, 2028	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY							
N 213872	001	8071073	Jun 04, 2028	DP			
AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY							
N 213872	002	8071073	Jun 04, 2028	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	8168620	Feb 24, 2026	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	001	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	002	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	001	9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	002	9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			
BACLOFEN - OZOBAX							
N 208193	001	10610502	Aug 30, 2039	U-2779			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BACLOFEN - LYVISPAH						
N 215422 001	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
	11654124	Jul 29, 2039	DP			
	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH						
N 215422 002	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
	11654124	Jul 29, 2039	DP			
	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH						
N 215422 003	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
	11654124	Jul 29, 2039	DP			
	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
BACLOFEN - FLEQSUVY						
N 215602 001	11324696	Sep 29, 2037	DP			
	11446246	Sep 08, 2037	U-3433			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001	10392406	Apr 27, 2036	DS		M-187	Dec 19, 2027
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	12064438	Oct 09, 2039	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002	10392406	Apr 27, 2036	DS		M-187	Dec 19, 2027
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	12064438	Oct 09, 2039	DP			
	8927710	May 05, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 003	10392406	Apr 27, 2036	DS		M-187	Dec 19, 2027
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	12064438	Oct 09, 2039	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 001	10392406	Apr 27, 2036	DS		M-187	Dec 19, 2027
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 002	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 003	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 003	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
BALSALAZIDE DISODIUM - COLAZAL						
N 020610 001	7452872	Aug 24, 2026			U-141	
	7625884	Aug 24, 2026			U-141	
BALSALAZIDE DISODIUM - GIAZO						
N 022205 001	7452872	Aug 24, 2026			U-1229	
	7625884	Aug 24, 2026			U-1229	
	8497256	Jun 23, 2031			U-1229	
	9192616	Aug 02, 2026			U-1229	
BARICITINIB - OLUMIANT						
N 207924 001	11045474	Nov 30, 2032			U-3372	
	11806555	Nov 02, 2031			U-3500	
	8158616	May 31, 2032	DS DP			
	8420629	Mar 10, 2029			U-247	
	9089574	Nov 30, 2032			U-3372	
	9737469	Nov 02, 2031			U-3500	
BARICITINIB - OLUMIANT						
N 207924 002	11045474	Nov 30, 2032			U-3372	
	11806555	Nov 02, 2031			U-3500	
	8158616	May 31, 2032	DS DP			
	8420629	Mar 10, 2029			U-247	
	9089574	Nov 30, 2032			U-3372	
	9737469	Nov 02, 2031			U-3500	
BARICITINIB - OLUMIANT						
N 207924 003	11045474	Nov 30, 2032			U-3372	
	11806555	Nov 02, 2031			U-3500	
	8158616	May 31, 2032	DS DP			
	9089574	Nov 30, 2032			U-3372	
	9737469	Nov 02, 2031			U-3500	
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE						
N 022247 001	7683051	Mar 10, 2027	DS DP		U-594	
	7683051	Mar 10, 2027	DS DP		U-904	
BECLOMETHASONE DIPROPIONATE - QVAR 80						
N 020911 001	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR 40						
N 020911 002	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 001	10188811	Oct 21, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 002	10188811	Oct 21, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 001	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	10561808	Jan 01, 2032	DP	Y		
	10695512	May 18, 2031	DP	Y		
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP	Y		
	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
	8931476	Jul 17, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 002	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	10561808	Jan 01, 2032	DP	Y		
	10695512	May 18, 2031	DP	Y		
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP	Y		
	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
	11793953	Jan 26, 2038	DP			
	11865247	Jan 26, 2038	DP	Y		
	11896759	Jan 26, 2038	DP	Y		
	11957832	May 05, 2041	DP			
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
	8931476	Jul 17, 2031	DP			
BEDAQUILINE FUMARATE - SIRTURO						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321		M-306	Jun 21, 2027
	8546428	Mar 19, 2029	DS DP U-1321		ODE-251	Aug 09, 2026
					ODE-307	May 27, 2027
BEDAQUILINE FUMARATE - SIRTURO						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321		M-306	Jun 21, 2027
	8546428	Mar 19, 2029	DS DP U-1321		ODE*	Aug 09, 2026
					ODE-307	May 27, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BELINOSTAT - BELEODAQ						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
	8835501	Oct 27, 2027	DP			
BELUMOSUDIL MESYLATE - REZUROCK						
N 214783 001	10183931	Oct 07, 2033	U-3246		NCE	Jul 16, 2026
	10183931	Oct 07, 2033	U-4260		ODE-362	Jul 16, 2028
	10696660	Oct 07, 2033	U-3246			
	10696660	Oct 07, 2033	U-4260			
	11311541	Apr 09, 2035	U-3369			
	12097202	Jul 14, 2042	U-4014			
	8357693	Jun 20, 2034	DS DP U-4259			
BELZUTIFAN - WELIREG						
N 215383 001	12358870	Jun 30, 2042	DP		I-931	Dec 14, 2026
	9908845	Sep 05, 2034	DS DP U-3201		I-968	May 14, 2028
	9908845	Sep 05, 2034	DS DP U-4176		NCE	Aug 13, 2026
	9908845	Sep 05, 2034	DS DP U-4195		ODE-364	Aug 13, 2028
	RE49948	Sep 05, 2034	DS DP U-3201			
	RE49948	Sep 05, 2034	DS DP U-4176			
	RE49948	Sep 05, 2034	DS DP U-4195			
BEMPEDOIC ACID - NEXLETOL						
N 211616 001	11613511	Jun 19, 2040	DS		I-943	Mar 22, 2027
	11744816	Mar 14, 2036	U-3883		I-944	Mar 22, 2027
	11760714	Jun 19, 2040	DP			
	11926584	Jun 19, 2040	U-3873			
	12398087	Jun 19, 2040	DS DP			
	12404227	Jun 19, 2040	DS U-4258			
	7335799	Dec 03, 2030	DS			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET						
N 211617 001	10912751	Mar 14, 2036	U-3224		I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		I-945	Mar 22, 2027
	11613511	Jun 19, 2040	DS			
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11760714	Jun 19, 2040	DP			
	11926584	Jun 19, 2040	U-3873			
	12398087	Jun 19, 2040	DS DP			
	12404227	Jun 19, 2040	DS U-4258			
	7335799	Dec 03, 2030	DS			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001	8883836	Mar 26, 2029	DP		U-1402	
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP		U-1949	
	9533955	Mar 26, 2029	DP		U-1952	
	9533955*PED	Sep 26, 2029				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP		U-1402	
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP		U-1402	
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP		U-1402	
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP		U-1949	
	9533955	Mar 26, 2029	DP		U-1952	
	9533955*PED	Sep 26, 2029				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 003	8344006	Sep 23, 2029	DP		U-1402	
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 004	8344006	Sep 23, 2029	DP		U-1402	
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP		U-1542	
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO						
N 205580 001	10010533	Jan 28, 2031	DP			
	11103483	Jan 28, 2031	DP		U-1971	
	11103483	Jan 28, 2031	DP		U-1972	
	11844783	Jan 28, 2031			U-1542	
	11844783	Jan 28, 2031			U-1971	
	11844783	Jan 28, 2031			U-1972	
	11872214	Jan 28, 2031	DP			
	12138248	Jan 28, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO						
N 205580 001	12350257	Jan 28, 2031	DP U-1542			
	12350257	Jan 28, 2031	DP U-1971			
	12350257	Jan 28, 2031	DP U-1972			
	8609707	Aug 11, 2031	DP U-1971			
	8609707	Aug 11, 2031	DP U-1972			
	8791270	Jan 12, 2026	DP U-1971			
	8791270	Jan 12, 2026	DP U-1972			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA						
N 208194 001	10010533	Jan 28, 2031	DP			
	10052385	Mar 15, 2033	U-1971			
	10052385	Mar 15, 2033	U-1972			
	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
	11844783	Jan 28, 2031	U-1542			
	11844783	Jan 28, 2031	U-1971			
	11844783	Jan 28, 2031	U-1972			
	11872214	Jan 28, 2031	DP			
	12138248	Jan 28, 2031	DP			
	12350257	Jan 28, 2031	DP U-1542			
	12350257	Jan 28, 2031	DP U-1971			
	12350257	Jan 28, 2031	DP U-1972			
	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA						
N 212209 001	11707450	Jul 29, 2042	DP			
	11844784	Jul 29, 2042	DP			
	12208086	Jul 29, 2042	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA								
N 212209	001		12419867	Jul 29, 2042	DP			
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE								
N 211039	001		10293047	Nov 15, 2037	DP		U-2755	
			10632197	Nov 15, 2037	DP		U-2755	
			10842872	Nov 15, 2037			U-3001	
BENZGALANTAMINE GLUCONATE - ZUNVEYL								
N 218549	001		11795176	Jan 13, 2042	DS		U-713	
			12208167	Feb 26, 2044	DP		U-713	
			9763953	Dec 01, 2026			U-713	
BENZGALANTAMINE GLUCONATE - ZUNVEYL								
N 218549	002		11795176	Jan 13, 2042	DS		U-713	
			12208167	Feb 26, 2044	DP		U-713	
			9763953	Dec 01, 2026			U-713	
BENZGALANTAMINE GLUCONATE - ZUNVEYL								
N 218549	003		11795176	Jan 13, 2042	DS		U-713	
			12208167	Feb 26, 2044	DP		U-713	
			9763953	Dec 01, 2026			U-713	
BENZOYL PEROXIDE - EPSOLAY								
N 214510	001		10933046	Feb 19, 2040	DP		U-3357	
			10945987	Feb 19, 2040			U-3356	
			11426378	Aug 18, 2040			U-3356	
			11541026	Feb 19, 2040			U-3356	
			11628155	Dec 27, 2040			U-3356	
			11865100	Feb 19, 2040			U-3357	
			11877997	Feb 19, 2040			U-3356	
			11986456	Feb 19, 2040			U-3947	
			12156946	Feb 03, 2028	DP			
			12257348	May 23, 2041	DP		U-3947	
			12295935	Dec 27, 2040			U-3356	
			12350382	Feb 03, 2028	DP			
			9687465	Nov 27, 2032	DP		U-3356	
			9868103	Aug 08, 2028	DP		U-3356	
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA								
N 050819	001		10220049	Jun 03, 2029	DP		U-916	
			10624918	Jun 03, 2029			U-916	
			8288434	Aug 05, 2029	DP		U-124	
			8663699	Jun 03, 2029			U-124	
			8895070	Jun 03, 2029			U-124	
			9078870	Jun 03, 2029	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON								
N 050819	002		10137142	Jun 03, 2029	DP		U-916	
			10220049	Jun 03, 2029	DP		U-916	
			8288434	Aug 05, 2029	DP		U-1033	
			8288434	Aug 05, 2029	DP		U-124	
			8288434	Aug 05, 2029	DP		U-134	
			8288434	Aug 05, 2029	DP		U-818	
			8288434	Aug 05, 2029	DP		U-916	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON						
N 050819 002	8288434	Aug 05, 2029	DP U-921			
	9504704	Jun 03, 2029	DP U-124			
	9504704	Jun 03, 2029	DP U-134			
	9504704	Jun 03, 2029	DP U-818			
	9504704	Jun 03, 2029	DP U-916			
	9561208	Jun 03, 2029	DP U-916			
BENZOYL PEROXIDE; TRETINOIN - TWYNEO						
N 214902 001	10420743	Jul 12, 2038	U-3194			
	10653899	Dec 30, 2030	DP U-3194			
	11071878	Dec 30, 2030	DP			
	12053546	Jun 29, 2032	DP			
	12070629	Dec 30, 2030	DP U-3987			
	12133919	May 23, 2041	DP U-3987			
	12156946	Feb 03, 2028	DP			
	12257348	May 23, 2041	DP U-3987			
	12295935	Dec 27, 2040	U-3987			
	12357602	Jul 12, 2038	DP U-3987			
	12491163	May 23, 2041	DP U-3987			
	8617580	Feb 03, 2028	DP			
	9868103	Aug 08, 2028	DP U-3194			
BERDAZIMER SODIUM - ZELSUVMI						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 214094 001	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-3010			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-3300			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-3300			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-3300			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-3010			
	12344585*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-3010			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-3300			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-3300			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-3300			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-3010			
	12344585*PED	May 01, 2040				
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 001					NP	Dec 11, 2028
					PED	Jun 11, 2029
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 002					NP	Dec 11, 2028
					PED	Jun 11, 2029
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 003					NP	Dec 11, 2028
					PED	Jun 11, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO						
N 219776 004					NP	Dec 11, 2028
					PED	Jun 11, 2029
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE						
N 022308 001	8415342	Nov 07, 2030			U-80	
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029			U-80	
BETAMETHASONE DIPROPIONATE - SERNIVO						
N 208079 001	10179137	Aug 31, 2030	DP		U-1858	
	9364485	Aug 31, 2030	DP		U-1858	
	9433630	Aug 31, 2030	DP		U-1858	
	9439911	Aug 31, 2030	DP		U-1858	
	9655907	Aug 31, 2030	DP		U-1858	
	9775851	Aug 31, 2030	DP		U-1858	
	9877974	Aug 31, 2030	DP		U-1858	
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR						
N 207589 001	10130640	Jun 10, 2031	DP			
	10130640*PED	Dec 10, 2031				
	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP		U-2627	
	10682364	Jun 10, 2031	DP			
	10688108	Jun 10, 2031			U-2627	
	10716799	Jun 10, 2031	DP			
	9119781	Jun 10, 2031	DP		U-1761	
	9119781	Jun 10, 2031	DP		U-2627	
	9119781*PED	Dec 10, 2031				
	9566286	Jun 10, 2031	DP			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA						
N 213422 001	10265265	Sep 27, 2027	DP			
	11696919	Mar 18, 2039	DP			
	12440499	Mar 18, 2039	DP		U-1408	
BETRIXABAN - BEVYXXA						
N 208383 001	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP		U-2034	
	8557852	Sep 08, 2028			U-1167	
	8557852	Sep 08, 2028			U-2030	
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026			U-1502	
BETRIXABAN - BEVYXXA						
N 208383 002	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP		U-2034	
	8557852	Sep 08, 2028			U-1167	
	8557852	Sep 08, 2028			U-2030	
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026			U-1502	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEXAGLIFLOZIN - BRENZAVVY						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 001	10385067	Jun 19, 2035	U-257		I-942	Feb 23, 2027
	10548846	Nov 08, 2036	DP		M-305	Apr 24, 2027
	11744802	Nov 08, 2036	DP		ODE-256	Jun 18, 2026
	8754065	Aug 15, 2032	DS DP U-257		ODE-468	Feb 23, 2031
	8754065*PED	Feb 15, 2033				
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 002	10385067	Jun 19, 2035	U-257		I-942	Feb 23, 2027
	8754065	Aug 15, 2032	DS DP U-257		ODE-378	Oct 07, 2028
	8754065*PED	Feb 15, 2033			ODE-468	Feb 23, 2031
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
BIMATOPROST - LUMIGAN						
N 022184 001	7851504	Jun 13, 2027	DS DP			
BIMATOPROST - DURYSTA						
N 211911 001	10441543	Dec 19, 2026	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
BIMATOPROST - ZOLYMBUS						
N 217307 001	10314780	Jun 08, 2036	DP U-1295		NDF	Sep 09, 2028
BINIMETINIB - MEKTOVI						
N 210498 001	10005761	Aug 27, 2030	U-2331		I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-3737			
	7777050	Mar 13, 2026	DS DP			
	9314464	Jul 04, 2031	U-2332			
	9314464	Jul 04, 2031	U-3737			
	9562016	Oct 18, 2033	DS DP			
	9598376	Oct 18, 2033	U-2330			
	9850229	Aug 27, 2030	U-2333			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BINIMETINIB - MEKTOVI						
N 210498 001	9980944	Oct 18, 2033	U-2334			
BIRCH TRITERPENES - FILSUVEZ						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
BIVALIRUDIN - ANGIOMAX						
N 020873 001	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
BIVALIRUDIN - ANGIOMAX RTU						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
	12472224	May 20, 2039	DP U-3817			
BOCEPREVIR - VICTRELIS						
N 202258 001	7772178	Nov 11, 2027	DP U-1128			
	8119602	Mar 17, 2027	U-1233			
BORTEZOMIB - BORTEZOMIB						
N 205004 001	8962572	Nov 03, 2032	DP			
BORTEZOMIB - BORTEZOMIB						
N 215331 001	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
	12005069	Sep 23, 2042	DP			
BORTEZOMIB - BORTEZOMIB						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
	11752164	Sep 23, 2042	U-3632			
	11752164	Sep 23, 2042	U-3633			
	12005069	Sep 23, 2042	DP			
BOSENTAN - BOSENTAN						
A 213154 001					PC	Feb 14, 2026
BOSENTAN - TRACLEER						
N 209279 001	7959945	Dec 28, 2027	DP			
	8309126	May 15, 2026	DP			
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 001	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-1283		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3707			
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 001	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 002	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-1283		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3707			
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 003	11103497	Feb 28, 2034	U-3216		I-923	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-1283		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3707			
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 217729 001	11103497	Feb 28, 2034	U-3216		NP	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				
	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
BOSUTINIB MONOHYDRATE - BOSULIF						
N 217729 002	11103497	Feb 28, 2034	U-3216		NP	Sep 26, 2026
	11103497	Feb 28, 2034	U-3217		ODE-444	Sep 26, 2030
	11103497*PED	Aug 28, 2034			PED	Mar 26, 2027
	7417148	Dec 11, 2025	U-3707		PED	Mar 26, 2031
	7417148	Dec 11, 2025	U-3708			
	7417148*PED	Jun 11, 2026				
	7767678	Nov 23, 2026	DS DP			
	7767678*PED	May 23, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF						
N 217729 002	7919625	Dec 11, 2025	DP			
	7919625*PED	Jun 11, 2026				
BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)						
N 210557 001	10286034	Nov 05, 2033	U-2568			
	11590209	Apr 29, 2041	U-3539			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
BRENSOCATIB - BRINSUPRI						
N 217673 001	10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
	10669245	Jan 21, 2035	DS U-4257			
	11655221	Jan 21, 2035	DP U-4257			
	11655222	Jan 21, 2035	DS U-4257			
	11655223	Jan 21, 2035	DS U-4257			
	11655224	Jan 21, 2035	DP U-4257			
	11673871	Jan 21, 2035	DP U-4257			
	11773069	Jan 21, 2035	DP U-4257			
	11814359	Jan 21, 2035	DS U-4257			
	12054465	Jan 21, 2035	DS U-4257			
	12059424	Feb 21, 2040	DP			
	12201638	Mar 01, 2039	DP			
	9522894	Mar 12, 2035	DS			
	9815805	Jan 21, 2035	U-4257			
BRENSOCATIB - BRINSUPRI						
N 217673 002	10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
	10669245	Jan 21, 2035	DS U-4257			
	11655221	Jan 21, 2035	DP U-4257			
	11655222	Jan 21, 2035	DS U-4257			
	11655223	Jan 21, 2035	DS U-4257			
	11655224	Jan 21, 2035	DP U-4257			
	11673871	Jan 21, 2035	DP U-4257			
	11773069	Jan 21, 2035	DP U-4257			
	11814359	Jan 21, 2035	DS U-4257			
	12054465	Jan 21, 2035	DS U-4257			
	12059424	Feb 21, 2040	DP			
	12201638	Mar 01, 2039	DP			
	9522894	Mar 12, 2035	DS			
	9815805	Jan 21, 2035	U-4257			
BREXANOLONE - ZULRESSO						
N 211371 001	10117951	Mar 13, 2029	DP			
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	10940156	Mar 08, 2037	U-2552			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	M-315	May 09, 2028
	7888362*PED	Oct 12, 2026			PED	Nov 10, 2026
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 08, 2027
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
BREXPIPRAZOLE - REXULTI						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	M-315	May 09, 2028
	7888362*PED	Oct 12, 2026			PED	Nov 10, 2026
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 08, 2027
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
BREXPIPRAZOLE - REXULTI						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	M-315	May 09, 2028
	7888362*PED	Oct 12, 2026			PED	Nov 10, 2026
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 08, 2027
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	M-315	May 09, 2028
	7888362*PED	Oct 12, 2026			PED	Nov 10, 2026
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 08, 2027
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
BREXPIPRAZOLE - REXULTI						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	M-315	May 09, 2028
	7888362*PED	Oct 12, 2026			PED	Nov 10, 2026
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 08, 2027
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
BREXPIPRAZOLE - REXULTI						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		M-315	May 09, 2028
	8349840*PED	Oct 12, 2026			PED	Nov 10, 2026
	8618109	Apr 12, 2026	U-3281		PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
BRIGATINIB - ALUNBRIG						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9012462	Apr 28, 2031	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIGATINIB - ALUNBRIG								
N 208772	001		9273077	May 21, 2029	U-2837			
			9611283	Apr 10, 2034	U-2837			
BRIGATINIB - ALUNBRIG								
N 208772	002		10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
			9012462	Apr 28, 2031	DS			
			9273077	May 21, 2029	U-2837			
			9611283	Apr 10, 2034	U-2837			
BRIGATINIB - ALUNBRIG								
N 208772	003		10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
			9012462	Apr 28, 2031	DS			
			9273077	May 21, 2029	U-2837			
			9611283	Apr 10, 2034	U-2837			
BRILLIANT BLUE G - TISSUEBLUE								
N 209569	001						ODE-282	Dec 20, 2026
BRIMONIDINE TARTRATE - MIRVASO								
N 204708	001		10201517	Jun 13, 2031	DP			
			8053427	Jun 13, 2031	DP U-1428			
			8163725	Jun 13, 2031	DP			
			8513247	Mar 25, 2031	DP U-1428			
			8513249	Mar 25, 2031	DP U-1428			
			9861631	Mar 25, 2031	U-1428			
			9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY								
N 208144	001		11596600	Jul 27, 2029	U-2222			
			11833245	Jul 27, 2029	U-2222			
			8293742	Jul 14, 2030	U-2222			
			9259425	Jul 14, 2030	U-2222			
BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE								
N 218424	001		11596600	Jul 27, 2029	U-2222			
			8293742	Jul 14, 2030	U-2222			
			9259425	Jul 14, 2030	U-2222			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA								
N 204251	001		9044484	Oct 30, 2030	DP			
			9421265	Jun 17, 2030	DP			
BRINCIDOFOVIR - TEMBEXA								
N 214460	001		9303051	Aug 31, 2031	DS DP U-3165		ODE-354	Jun 04, 2028
BRINCIDOFOVIR - TEMBEXA								
N 214461	001		10112909	Oct 10, 2034	U-3165		ODE-354	Jun 04, 2028
			10487061	Oct 10, 2034	DP U-3165			
			8962829	Oct 10, 2034	DS DP			
			9303051	Aug 31, 2031	DS DP U-3165			
			9371344	Oct 10, 2034	DP			
BRIVARACETAM - BRIVIACT								
N 205836	001		10729653	Apr 09, 2030	DP			
			6911461	Feb 21, 2026	DS DP U-2295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIVARACETAM - BRIVIACT						
N 205836 002	10729653	Apr 09, 2030	DP			
	6911461	Feb 21, 2026	DS DP		U-2295	
BRIVARACETAM - BRIVIACT						
N 205836 003	10729653	Apr 09, 2030	DP			
	6911461	Feb 21, 2026	DS DP		U-2295	
BRIVARACETAM - BRIVIACT						
N 205836 004	10729653	Apr 09, 2030	DP			
	6911461	Feb 21, 2026	DS DP		U-2295	
BRIVARACETAM - BRIVIACT						
N 205836 005	10729653	Apr 09, 2030	DP			
	6911461	Feb 21, 2026	DS DP		U-2295	
BRIVARACETAM - BRIVIACT						
N 205837 001	6911461	Feb 21, 2026	DS DP		U-1815	
	6911461	Feb 21, 2026	DS DP		U-2130	
BRIVARACETAM - BRIVIACT						
N 205838 001	6911461	Feb 21, 2026	DS DP		U-2295	
BROMFENAC SODIUM - PROLENSA						
N 203168 001	10085958	Nov 19, 2032	DP			
	9517220	Nov 11, 2033			U-1933	
BROMFENAC SODIUM - BROMSITE						
N 206911 001	RE50218	Mar 05, 2029	DP		U-1834	
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688094	Apr 30, 2032			U-2870	
	10688094	Apr 30, 2032			U-2871	
	10688094	Apr 30, 2032			U-2872	
	10688094	Apr 30, 2032			U-2873	
	10688094	Apr 30, 2032			U-2874	
	10688094	Apr 30, 2032			U-2875	
	10688094	Apr 30, 2032			U-2876	
	10688094	Apr 30, 2032			U-2877	
	10688094	Apr 30, 2032			U-2878	
	10688094	Apr 30, 2032			U-2879	
	10688094	Apr 30, 2032			U-2880	
	10688094	Apr 30, 2032			U-2881	
	10688094	Apr 30, 2032			U-2882	
	10688094	Apr 30, 2032			U-2883	
	10688094	Apr 30, 2032			U-2884	
	10688094	Apr 30, 2032			U-2885	
	10688094	Apr 30, 2032			U-2886	
	10688094	Apr 30, 2032			U-2887	
	10688094	Apr 30, 2032			U-2888	
	10688155	Jun 07, 2030			U-2281	
	10688155	Jun 07, 2030			U-2890	
	10688155	Jun 07, 2030			U-2891	
	10688155	Jun 07, 2030			U-2892	
	10688155	Jun 07, 2030			U-2893	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			
	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
	11666567	Apr 30, 2032	U-4015			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	11666567	Apr 30, 2032	U-4016			
	11666567	Apr 30, 2032	U-4017			
	11666567	Apr 30, 2032	U-4018			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			
	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			
	9700555	Apr 30, 2032	DP U-2186			
	9700555	Apr 30, 2032	DP U-2187			
	9700555	Apr 30, 2032	DP U-2188			
	9700555	Apr 30, 2032	DP U-2189			
	9700555	Apr 30, 2032	DP U-2190			
	9700555	Apr 30, 2032	DP U-2191			
	9700555	Apr 30, 2032	DP U-2192			
	9700555	Apr 30, 2032	DP U-2193			
	9700555	Apr 30, 2032	DP U-2194			
	9700555	Apr 30, 2032	DP U-2195			
	9700555	Apr 30, 2032	DP U-2196			
	9700555	Apr 30, 2032	DP U-2197			
	9700555	Apr 30, 2032	DP U-2198			
	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
	9993474	Apr 30, 2032	U-2384			
	9993474	Apr 30, 2032	U-2385			
	9993474	Apr 30, 2032	U-2386			
	9993474	Apr 30, 2032	U-2387			
	9993474	Apr 30, 2032	U-2388			
	9993474	Apr 30, 2032	U-2389			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	9993474	Apr 30, 2032	U-2390			
	9993474	Apr 30, 2032	U-2391			
	9993474	Apr 30, 2032	U-2392			
	9993474	Apr 30, 2032	U-2393			
BUDESONIDE - UCERIS						
N 203634 001	10307375	Sep 07, 2031	DP			
	10660858	Sep 07, 2031	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
BUDESONIDE - ORTIKOS						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE - ORTIKOS						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE - EOHILIA						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
BUDESONIDE - TARPEYO						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-389	Dec 15, 2028
	12171882	Jan 23, 2043	U-4085		ODE-464	Dec 20, 2030
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
	12311057	Jan 23, 2043	DP U-4085			
	12311057	Jan 23, 2043	DP U-4086			
	12311057	Jan 23, 2043	DP U-4204			
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE						
N 212122 001	10716753	May 28, 2030	DP U-2889			
	11331442	Oct 05, 2038	DP			
	11833292	Oct 05, 2038	DP			
	8324266	May 28, 2030	U-2889			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE								
N 212122	001		8703806	May 28, 2030	U-2889			
			8808713	May 28, 2030	DP U-2889			
			8815258	Mar 17, 2031	U-2889			
			9415009	May 28, 2030	U-2889			
			9463161	May 28, 2030	DP U-2889			
BUMETANIDE - ENBUMYST								
N 219500	001		11123319	Dec 04, 2040	DP			
			11260038	Dec 04, 2040	U-4279			
			12329731	Dec 04, 2040	DP U-4279			
BUPIVACAINE - EXPAREL								
N 022496	001		11033495	Jan 22, 2041	DP U-3182		I-929	Nov 09, 2026
			11179336	Jan 22, 2041	DP U-3250			
			11278494	Jan 22, 2041	DP U-3250			
			11304904	Jan 22, 2041	DP U-3346			
			11311486	Jan 22, 2041	DP U-3250			
			11357727	Jan 22, 2041	DP U-3380			
			11426348	Jan 22, 2041	DP U-3380			
			11452691	Jan 22, 2041	DP U-3439			
			11819574	Jan 22, 2041	DP U-3250			
			11819575	Jan 22, 2041	DP U-3250			
			11918565	Feb 02, 2043	U-3841			
			11925706	Jan 22, 2041	DP U-3380			
			11931459	Mar 17, 2042	U-3839			
			11931459	Mar 17, 2042	U-3840			
			12144890	Jan 22, 2041	DP U-4033			
			12151024	Jan 22, 2041	DP U-4037			
			12156940	Jul 02, 2044	DP			
			12226610	Feb 02, 2043	U-4148			
			12226610	Feb 02, 2043	U-4149			
			12226610	Feb 02, 2043	U-4150			
			12251468	Jul 02, 2044	DP U-4152			
			12296047	Jan 22, 2041	DP U-4184			
			12318483	Jul 02, 2044	U-4152			
			12370142	Jul 02, 2044	DP U-4152			
BUPIVACAINE - EXPAREL								
N 022496	002		11033495	Jan 22, 2041	DP U-3182		I-929	Nov 09, 2026
			11179336	Jan 22, 2041	DP U-3250			
			11278494	Jan 22, 2041	DP U-3250			
			11304904	Jan 22, 2041	DP U-3346			
			11311486	Jan 22, 2041	DP U-3250			
			11357727	Jan 22, 2041	DP U-3380			
			11426348	Jan 22, 2041	DP U-3380			
			11452691	Jan 22, 2041	DP U-3439			
			11819574	Jan 22, 2041	DP U-3250			
			11819575	Jan 22, 2041	DP U-3250			
			11918565	Feb 02, 2043	U-3841			
			11925706	Jan 22, 2041	DP U-3380			
			11931459	Mar 17, 2042	U-3839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE - EXPAREL						
N 022496 002	11931459	Mar 17, 2042	U-3840			
	12144890	Jan 22, 2041	DP U-4033			
	12151024	Jan 22, 2041	DP U-4037			
	12156940	Jul 02, 2044	DP			
	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
	12370142	Jul 02, 2044	DP U-4152			
BUPIVACAINE - POSIMIR						
N 204803 001	11400019	Jan 12, 2041	DP			
	11771624	Jan 12, 2041	U-3724			
BUPIVACAINE HYDROCHLORIDE - XARACOLL						
N 209511 001	11746141	Jan 09, 2033	DP			
	RE47826	May 20, 2029	U-2949			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 001	10098957	Apr 20, 2035	U-3118		I-933	Jan 23, 2027
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	10098957	Apr 20, 2035	U-3118		I-933	Jan 23, 2027
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	10098957	Apr 20, 2035	U-3118		I-933	Jan 23, 2027
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	10098957	Apr 20, 2035	U-3118		I-933	Jan 23, 2027
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	11844837	Apr 21, 2036	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPRENORPHINE - SUBLOCADE						
N 209819 001	10198218	Jun 06, 2031	U-2489		M-314	Feb 21, 2028
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	11000520	Nov 06, 2035	U-3111			
	11839611	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - SUBLOCADE						
N 209819 001	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - SUBLOCADE						
N 209819 002	10198218	Jun 06, 2031	U-2489		M-314	Feb 21, 2028
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
	11000520	Nov 06, 2035	U-3111			
	11839611	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - BRIXADI						
N 210136 001	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - BRIXADI						
N 210136 002	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 003	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 004	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 005	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 006	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 007	10912772	Jul 26, 2032	U-3617		NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - BRIXADI						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 001	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 002	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 003	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 004	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 005	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 006	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 007	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 001	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 002	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 003	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	9687454	Aug 07, 2029	DP U-1464			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 004	11135216	Aug 07, 2029	DP U-3111			
	8475832	Mar 26, 2030	DP U-1411			
	9687454	Aug 07, 2029	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 001	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 002	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 003	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL						
N 022497 001	7674479	Aug 23, 2028	DP			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	10058518	Nov 05, 2034	U-3419			
	10064857	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-3419			
	10105327	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-3419			
	10548857	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-3419			
	10772850	Nov 05, 2034	U-3419			
	10780064	Jan 07, 2040	U-3419			
	10780066	Nov 09, 2034	U-3419			
	10786469	Nov 05, 2034	U-3419			
	10786496	Nov 05, 2034	U-3419			
	10799497	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-3419			
	10864209	Nov 05, 2034	U-3419			
	10874663	Nov 05, 2034	U-3419			
	10874664	Nov 05, 2034	U-3419			
	10874665	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-3419			
	10881657	Nov 05, 2034	U-3419			
	10894046	Nov 05, 2034	U-3419			
	10894047	Nov 05, 2034	U-3419			
	10898453	Nov 05, 2034	U-3419			
	10925842	Jan 07, 2040	U-3419			
	10933034	Nov 05, 2034	U-3419			
	10940124	Jan 07, 2040	U-3419			
	10945973	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-3419			
	10966942	Jan 07, 2040	U-3419			
	10966974	Nov 05, 2034	U-3419			
	11020389	Nov 05, 2034	U-3419			
	11058648	Nov 05, 2034	U-3419			
	11065248	Nov 05, 2034	U-3419			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11090300	Nov 05, 2034	U-3419			
	11096937	Nov 05, 2034	U-3419			
	11123343	Nov 05, 2034	U-3419			
	11123344	Nov 05, 2034	U-3419			
	11129826	Nov 05, 2034	U-3419			
	11141388	Nov 05, 2034	U-3419			
	11141416	Nov 05, 2034	U-3419			
	11147808	Nov 05, 2034	U-3419			
	11185515	Nov 05, 2034	U-3419			
	11191739	Nov 05, 2034	DP U-3419			
	11197839	Nov 05, 2034	DP U-3419			
	11207281	Nov 05, 2034	U-3419			
	11213521	Nov 05, 2034	U-3419			
	11229640	Nov 05, 2034	U-3419			
	11234946	Nov 05, 2034	U-3419			
	11253491	Nov 05, 2034	U-3419			
	11253492	Nov 05, 2034	U-3419			
	11273133	Nov 05, 2034	U-3419			
	11273134	Nov 05, 2034	U-3419			
	11285118	Nov 05, 2034	U-3419			
	11285146	Nov 05, 2034	U-3419			
	11291638	Nov 05, 2034	U-3419			
	11291665	Nov 05, 2034	U-3419			
	11298351	Nov 05, 2034	U-3419			
	11298352	Nov 05, 2034	U-3419			
	11311534	Nov 05, 2034	U-3419			
	11344544	Nov 05, 2034	U-3419			
	11357744	Nov 05, 2034	U-3419			
	11364233	Nov 05, 2034	U-3419			
	11382874	Nov 05, 2034	U-3419			
	11419867	Nov 05, 2034	U-3419			
	11426370	Nov 05, 2034	U-3419			
	11426401	Nov 05, 2034	U-3419			
	11433067	Nov 05, 2034	DP U-3419			
	11439636	Nov 05, 2034	U-3419			
	11478468	Nov 05, 2034	U-3419			
	11497721	Nov 05, 2034	U-3419			
	11510918	Nov 05, 2034	U-3419			
	11517542	Nov 05, 2034	U-3419			
	11517543	Nov 05, 2034	U-3419			
	11524007	Nov 05, 2034	U-3419			
	11524008	Nov 05, 2034	U-3419			
	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11571417	Nov 05, 2034	U-3419			
	11576909	Nov 05, 2034	U-3419			
	11590124	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11617728	Nov 05, 2034			U-3419	
	11617747	Nov 05, 2034			U-3563	
	11717518	Jan 20, 2043			U-3419	
	11730706	Jan 23, 2043			U-3419	
	11752144	Feb 23, 2043			U-3419	
	11779579	Nov 05, 2034			U-3419	
	11839612	Mar 02, 2043			U-3419	
	11844797	Apr 20, 2043			U-3778	
	11883373	Jan 23, 2043			U-3419	
	11896563	Dec 01, 2041			U-3419	
	11925636	Jan 20, 2043			U-3419	
	11969421	Nov 05, 2034			U-3419	
	11986444	Feb 15, 2043			U-3419	
	12036191	Feb 15, 2043			U-3419	
	12042473	Feb 23, 2043			U-3419	
	12109178	Nov 05, 2034			U-3419	
	12146889	Feb 23, 2043			U-3419	
	12156914	Jan 20, 2043	DP			
	12310961	Jan 20, 2043			U-3419	
	12357697	Jan 20, 2043			U-3419	
	12390428	Dec 01, 2041			U-3419	
	8569328	Oct 29, 2033	DP		U-3419	
	9168234	Nov 05, 2034			U-3419	
	9198905	Nov 05, 2034			U-3419	
	9205083	Nov 05, 2034			U-3419	
	9238032	Nov 05, 2034			U-3419	
	9278095	Nov 05, 2034			U-3419	
	9314462	Nov 05, 2034			U-3419	
	9370513	Nov 05, 2034			U-3419	
	9375429	Nov 05, 2034			U-3419	
	9408815	Nov 05, 2034			U-3419	
	9421176	Nov 05, 2034			U-3419	
	9457023	Nov 05, 2034			U-3419	
	9457025	Nov 05, 2034			U-3419	
	9474731	Nov 05, 2034			U-3419	
	9486450	Nov 05, 2034			U-3419	
	9700528	Nov 05, 2034			U-3419	
	9700553	Nov 05, 2034			U-3419	
	9707191	Nov 05, 2034			U-3419	
	9763932	Nov 05, 2034			U-3419	
	9861595	Nov 05, 2034			U-3419	
	9867819	Nov 05, 2034			U-3419	
	9968568	Nov 05, 2034			U-3419	
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	10231964	Jul 02, 2034			U-1583	
	10307376	Nov 08, 2027			U-1585	
	10403170	Jun 05, 2033			U-1583	
	10828294	Jul 02, 2034			U-1583	
	10835527	Jul 02, 2034			U-1583	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	11033543	Jan 10, 2031	U-1583			
	11139056	Jun 05, 2033	U-1583			
	11324741	May 29, 2029	U-1583			
	11998542	Jul 02, 2034	U-1583			
	12048769	Nov 08, 2027	U-1585			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
	9248123	Jan 13, 2032	U-1808			
	9633575	Jun 25, 2033	U-1583			
CABAZITAXEL - JEVTANA KIT						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10716777	Oct 27, 2030	U-2856			
	12453712	Oct 27, 2030	U-4334			
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-3200			
	8927592*PED	Apr 27, 2031				
CABOTEGRAVIR - APRETUDE						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	12138264	Sep 15, 2031	DP			
	8410103	Feb 04, 2031	DS DP			
CABOTEGRAVIR SODIUM - VOCABRIA						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Feb 04, 2031	DS DP U-3348			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP U-3348			
	11389447	Jun 30, 2027	U-3405			
	11389448	Apr 13, 2032	DP			
	12138264	Sep 15, 2031	DP U-3348			
	12178815	Jul 18, 2038	U-3348			
	8410103	Feb 04, 2031	DS DP U-3348			
	RE50189	Nov 27, 2031	U-3348			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP U-3348			
	11389447	Jun 30, 2027	U-3405			
	11389448	Apr 13, 2032	DP			
	12138264	Sep 15, 2031	DP U-3348			
	12178815	Jul 18, 2038	U-3348			
	8410103	Feb 04, 2031	DS DP U-3348			
	RE50189	Nov 27, 2031	U-3348			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	12128039	Feb 10, 2032	DP U-1617			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	12128039	Feb 10, 2032	DP U-1617			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	10034873	Jul 18, 2031	U-2488		ODE-227	Jan 14, 2026
	10039757	Jul 18, 2031	U-1480		ODE-375	Sep 17, 2028
	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	11298349	Feb 10, 2032	DP			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	10034873	Jul 18, 2031	U-2488		ODE-227	Jan 14, 2026
	10039757	Jul 18, 2031	U-1480		ODE-375	Sep 17, 2028
	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	11098015	Jan 15, 2030	U-4156			
	11298349	Feb 10, 2032	DP			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	10034873	Jul 18, 2031	U-2488		ODE-227	Jan 14, 2026
	10039757	Jul 18, 2031	U-1480		ODE-375	Sep 17, 2028
	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	11298349	Feb 10, 2032	DP			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CALCIFEDIOL - RAYALDEE						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
	11154509	Apr 25, 2028	U-3815			
	11253528	Mar 14, 2034	DP			
	11801253	Sep 07, 2030	DP U-3721			
	11801253	Sep 07, 2030	DP U-3722			
	11801253	Sep 07, 2030	DP U-3723			
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
	9498486	Apr 25, 2028	U-3814			
	9861644	Mar 14, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIFEDIOL - RAYALDEE						
N 208010 001	9925147	Apr 25, 2028	DP U-2255			
	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
CALCIPOTRIENE - SORILUX						
N 022563 001	8263580	May 07, 2028	DP U-1280			
	8263580	May 07, 2028	DP U-2662			
	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
	8629128	May 26, 2026	DP U-2662			
CALCIUM ACETATE - PHOSLYRA						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
	9089528	Jul 20, 2027	U-1469			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 004	10130646	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 005	10130646	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 210906 003	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	10195168	Jan 11, 2033	DP		ODE-361	Jul 21, 2027
	10213400	Mar 15, 2033	U-2499		ODE-369	Aug 12, 2028
	10213400*PED	Sep 15, 2033			PED	Jan 21, 2028
	10675258	Jan 11, 2033	U-2938			
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	11426373	Sep 19, 2037	U-3432			
	11554102	Jan 11, 2033	DP			
	11986446	Mar 15, 2033	U-3017			
	11986446	Mar 15, 2033	U-3324			
	12138233	Feb 22, 2041	U-4044			
	8591922	Jan 11, 2033	DP			
	8772306	Mar 15, 2033	U-1532			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	8901173	Jan 11, 2033	DP			
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9132107	Jan 11, 2033	DP			
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
CANAGLIFLOZIN - INVOKANA						
N 204042 001	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN - INVOKANA						
N 204042 002	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001	11576894	Jul 06, 2030	DP		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2441		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	11576894	Jul 06, 2030	DP		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2441		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	11576894	Jul 06, 2030	DP		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2441		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	11576894	Jul 06, 2030	DP		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2441		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441		NPP	Dec 18, 2027
	7943582	Feb 26, 2029	DS DP U-2632		PED	Jun 18, 2028
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8513202*PED	Jun 03, 2028				
CANGRELOR - KENGREAL						
N 204958 001	10039780	Jul 10, 2035	U-2260			
	8680052	Mar 09, 2033	U-2979			
	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
	9700575	Jul 10, 2035	DP			
	9925265	May 13, 2029	U-2260			
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10092525	Jun 17, 2035	U-2427		M-270	Oct 20, 2026
	10111840	Jun 17, 2035	U-2442		ODE-326	Jul 31, 2027
	10111840	Jun 17, 2035	U-2443		ODE-332	Jul 31, 2027
	10137095	Jun 17, 2035	U-2454			
	10137095	Jun 17, 2035	U-2455			
	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10849860	Jun 17, 2035	U-2427			
	10849860	Jun 17, 2035	U-2454			
	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11160795	Mar 01, 2041	U-3233			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
	11701330	Jun 17, 2035	U-2780			
	11701330	Jun 17, 2035	U-2781			
	11766411	Jun 17, 2035	U-2781			
	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
	12064399	Jun 17, 2035	U-3988			
	12064399	Jun 17, 2035	U-3989			
	12102619	Mar 01, 2041	U-3233			
	9949937	Jun 17, 2035	U-2421			
	9956183	Jun 17, 2035	U-2422			
	9956183	Jun 17, 2035	U-2423			
	9956184	Jun 17, 2035	U-2424			
	9956185	Jun 17, 2035	U-2425			
	9956186	Jun 17, 2035	U-2426			
CANTHARIDIN - YCANTH						
N 212905 001	11052064	May 28, 2035	DP U-3663		NCE	Jul 21, 2028
	11052064	May 28, 2035	DP U-3665			
	11147790	Aug 22, 2038	DP U-3663			
	11147790	Aug 22, 2038	DP U-3664			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANTHARIDIN - YCANTH						
N 212905 001	12233042	Aug 22, 2038	DP U-3663			
	12290651	Feb 19, 2041	DP			
CAPIVASERTIB - TRUQAP						
N 218197 001	10039766	Apr 16, 2033	U-3762		NCE	Nov 16, 2028
	10059714	Oct 10, 2028	DS DP			
	10654855	Oct 10, 2028	U-3762			
	11760760	Oct 10, 2028	U-3762			
	12252495	Oct 10, 2028	U-3762			
	8101623	Mar 10, 2030	DS DP U-3762			
	9487525	Apr 16, 2033	DS DP			
CAPIVASERTIB - TRUQAP						
N 218197 002	10039766	Apr 16, 2033	U-3762		NCE	Nov 16, 2028
	10059714	Oct 10, 2028	DS DP			
	10654855	Oct 10, 2028	U-3762			
	11760760	Oct 10, 2028	U-3762			
	12252495	Oct 10, 2028	U-3762			
	8101623	Mar 10, 2030	DS DP U-3762			
	9487525	Apr 16, 2033	DS DP			
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 001	10596178	Jul 22, 2035	DP		ODE-291	May 06, 2027
	12084449	Nov 19, 2027	U-2813			
	12208101	Jul 22, 2035	DP			
	7767675	Nov 19, 2032	DS DP			
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 002	10596178	Jul 22, 2035	DP		ODE-291	May 06, 2027
	12084449	Nov 19, 2027	U-2813			
	12208101	Jul 22, 2035	DP			
	7767675	Nov 19, 2032	DS DP			
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
CAPSAICIN - QUTENZA						
N 022395 001	8821920	Mar 26, 2030	DP			
	9226903	Dec 15, 2028	DP			
CARBAMAZEPINE - CARNEXIV						
N 206030 001	11529357	Jan 31, 2040	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028	U-2004			
	9629797	Nov 10, 2028	U-2005			
	9629797	Nov 10, 2028	U-2006			
	9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DHIVY							
N 214869	001	11033521	Mar 28, 2039	DP U-219			
		11033521	Mar 28, 2039	DP U-3304			
		11033521	Mar 28, 2039	DP U-3305			
		11439613	Mar 28, 2039	U-3557			
		11819485	Mar 28, 2039	U-3557			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	001	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
		10292935	Oct 07, 2034	DP U-219			
		10688058	Oct 07, 2034	DP U-219			
		10973769	Oct 07, 2034	DP U-219			
		10987313	Oct 07, 2034	DP U-219			
		11357733	Oct 07, 2034	DP			
		11622941	Oct 07, 2034	DP			
		11666538	Oct 07, 2034	DP U-219			
		11986449	Dec 21, 2041	U-219			
		12064521	Oct 07, 2034	DP			
		12109185	Dec 21, 2041	U-1649			
		12109185	Dec 21, 2041	U-219			
		12109185	Dec 21, 2041	U-4004			
		12109185	Dec 21, 2041	U-4005			
		12128141	Oct 07, 2034	DP U-219			
		12178918	Oct 07, 2034	DP			
		12178919	Oct 07, 2034	DP U-219			
		12194150	Dec 21, 2041	U-219			
		12201596	Dec 21, 2041	U-1649			
		12201596	Dec 21, 2041	U-4004			
		12201596	Dec 21, 2041	U-4005			
		12263148	Dec 21, 2041	U-1649			
		12263148	Dec 21, 2041	U-219			
		12263148	Dec 21, 2041	U-4004			
		12263148	Dec 21, 2041	U-4005			
		12263149	Dec 21, 2041	U-1649			
		12263149	Dec 21, 2041	U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 001	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
	12491164	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 002	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 002	12128141	Oct 07, 2034	DP U-219			
	12178918	Oct 07, 2034	DP			
	12178919	Oct 07, 2034	DP U-219			
	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
	12491164	Oct 07, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 003	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
	12178918	Oct 07, 2034	DP			
	12178919	Oct 07, 2034	DP U-219			
	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 003	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
	12491164	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 004	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
	12178918	Oct 07, 2034	DP			
	12178919	Oct 07, 2034	DP U-219			
	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 004	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
	12491164	Oct 07, 2034	DP			
CARBINOXAMINE MALEATE - KARBINAL ER						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Jun 15, 2027	DP			
CARBOPLATIN - KYXATA						
N 219921 001	12427104	Apr 01, 2045	DP			
CARBOPLATIN - KYXATA						
N 219921 002	12427104	Apr 01, 2045	DP			
CARBOPLATIN - KYXATA						
N 219921 003	12427104	Apr 01, 2045	DP			
CARFILZOMIB - KYPROLIS						
N 202714 001	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CARFILZOMIB - KYPROLIS						
N 202714 002	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARFILZOMIB - KYPROLIS						
N 202714 002	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CARFILZOMIB - KYPROLIS						
N 202714 003	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CARGLUMIC ACID - CARBAGLU						
N 022562 001					ODE-345	Jan 22, 2028
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	7943621	Dec 16, 2028	DS DP			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 001	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 002	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 003	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 004	8101209	Sep 11, 2025	DP			
CASIMERSEN - AMONDYS 45						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10781450	Nov 12, 2030	U-3089		ODE-347	Feb 25, 2028
	9228187	Nov 12, 2030	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
	RE48960	Feb 16, 2029	DS DP U-3087			
	RE48960	Feb 16, 2029	DS DP U-3088			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE						
N 206110 001	9636407	Dec 21, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE									
N 206110	002		9636407	Dec 21, 2032	DP				
CEDAZURIDINE; DECITABINE - INQOVI									
N 212576	001		11963971	Feb 24, 2041	DP			ODE-316	Jul 07, 2027
			12195496	Oct 07, 2040	DP				
			12239653	Feb 24, 2041		U-2865			
			12239653	Feb 24, 2041		U-2866			
			8268800	Aug 22, 2030	DS	U-2864			
			8268800	Aug 22, 2030	DS	U-2865			
			8268800	Aug 22, 2030	DS	U-2866			
			8268800	Aug 22, 2030	DS	U-2867			
			8618075	Oct 16, 2028		U-2864			
			8618075	Oct 16, 2028		U-2867			
			9567363	Oct 16, 2028	DS				
CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP									
N 216165	001		11124526	Nov 07, 2034		U-3852		NCE	Feb 22, 2029
			7687488	Dec 03, 2027	DS DP	U-3851		GAIN	Feb 22, 2034
CEFIDEROCOL SULFATE TOSYLATE - FETROJA									
N 209445	001		10004750	Sep 03, 2035	DS DP			NCE	Nov 14, 2024
			9238657	Nov 14, 2033	DS DP	U-282		GAIN	Nov 14, 2029
			9238657	Nov 14, 2033	DS DP	U-3470			
			9238657	Nov 14, 2033	DS DP	U-3471			
			9949982	Sep 03, 2035	DP				
CEFIXIME - SUPRAX									
N 202091	001		9233112	Dec 14, 2028	DP	U-1676			
CEFTAROLINE FOSAMIL - TEFLARO									
N 200327	001		8247400	Feb 10, 2031	DP	U-282			
			9629861	Sep 21, 2030	DP				
CEFTAROLINE FOSAMIL - TEFLARO									
N 200327	002		8247400	Feb 10, 2031	DP	U-282			
			9629861	Sep 21, 2030	DP				
CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA									
N 218275	001							NCE	Apr 03, 2029
								GAIN	Apr 03, 2034
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA									
N 206829	001		10028963	Sep 07, 2032		U-2565			
			10028963	Sep 07, 2032		U-2566			
			10125149	Aug 14, 2035	DP				
			10376496	Sep 09, 2034		U-2610			
			10376496	Sep 09, 2034		U-2611			
			10420841	Mar 14, 2034		U-1672			
			10420841	Mar 14, 2034		U-2631			
			10420841	Mar 14, 2034		U-3360			
			10420841	Mar 14, 2034		U-3361			
			10933053	Sep 09, 2034		U-3090			
			10933053	Sep 09, 2034		U-3091			
			11278622	Mar 14, 2034		U-3335			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
	9320740	Mar 14, 2034	DP			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
	9872906	Mar 14, 2034	DP			
CELECOXIB - ELYXYB						
N 212157 001	10376527	May 27, 2036	DP U-2718			
	10722456	May 27, 2036	DP U-2718			
	10799517	May 27, 2036	DP U-2718			
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS						
N 213426 001	10238668	Apr 19, 2030	DS DP U-3244			
	10245276	Apr 19, 2030	DS DP			
	10548909	Apr 19, 2030	U-3244			
	11478488	Apr 19, 2030	U-3244			
	8598152	Apr 19, 2030	DS DP			
	8846744	Jun 03, 2031	DP			
	9012440	Apr 19, 2030	DS DP			
CENOBAMATE - XCOPRI						
N 212839 001	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI						
N 212839 002	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI						
N 212839 003	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI						
N 212839 004	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI						
N 212839 005	11654133	Jun 16, 2039	U-3610			
	7598279	Oct 30, 2032	DS			
CENOBAMATE - XCOPRI						
N 212839 006	11654133	Jun 16, 2039	U-3610			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CENOBAMATE - XCOPRI								
N 212839	006		7598279	Oct 30, 2032	DS			
CERITINIB - ZYKADIA								
N 205755	001		7893074	Apr 25, 2026	DS DP			
			7964592	Apr 29, 2028	DS DP			
			8039479	Jun 29, 2030	DS DP			
			8377921	Nov 20, 2027			U-1179	
			8399450	Nov 20, 2027	DS DP			
			8703787	Feb 02, 2032			U-1179	
			9309229	Jan 18, 2032	DS DP			
CERITINIB - ZYKADIA								
N 211225	001		12357630	Dec 13, 2037			U-3096	
			7893074	Apr 25, 2026	DS DP			
			7964592	Apr 29, 2028	DS DP			
			8039479	Jun 29, 2030	DS DP			
			8377921	Nov 20, 2027			U-1179	
			8399450	Nov 20, 2027	DS DP			
			8703787	Feb 02, 2032			U-1179	
			9309229	Jan 18, 2032	DS DP			
CETIRIZINE HYDROCHLORIDE - ZERVIATE								
N 208694	001		8829005	Mar 15, 2030			U-1680	
			8829005*PED	Sep 15, 2030				
			9254286	Jul 09, 2032	DP			
			9254286*PED	Jan 09, 2033				
			9750684	Mar 15, 2030	DP			
			9993471	Mar 15, 2030			U-1680	
CETIRIZINE HYDROCHLORIDE - QUZYTTIR								
N 211415	001		8263581	Feb 28, 2030			U-2635	
			8314083	Feb 28, 2030			U-2634	
			8513259	Feb 11, 2030			U-2636	
			9119771	Feb 11, 2030			U-2635	
			9180090	Feb 11, 2030			U-2635	
CHENODIOL - CTEXLI								
N 219488	001						NP	Feb 21, 2028
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE								
N 021669	001		7427574	Apr 25, 2026	DP			
			7935093	Oct 02, 2027	DP		U-1022	
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	002		7422388	Apr 25, 2027	DP		U-1397	
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	005		7422388	Apr 25, 2027	DP		U-1397	
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
N 020832	007		7422388	Apr 25, 2027	DP		U-1397	
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S								
N 208288	001						M-292	Jan 20, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL									
N 208791	001		8969412	Sep 05, 2026		DP U-2609			
			9504666	Dec 11, 2033		DP			
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO									
N 216227	001		10792271	Sep 15, 2038		DP U-3457			
			11969403	May 14, 2039		DP			
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER									
N 206323	001		9066942	Jan 03, 2032		U-1716			
			9107921	Jan 03, 2032		DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS									
N 021441	001		7863287	Feb 28, 2027		DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR									
N 207768	001		8062667	Mar 29, 2029		DP			
			8790700	Mar 15, 2027		DP			
CICLESONIDE - ALVESCO									
N 021658	002		8371292	Feb 01, 2028		U-1355			
CICLESONIDE - ALVESCO									
N 021658	003		8371292	Feb 01, 2028		U-1355			
CICLESONIDE - OMNARIS									
N 022004	001		8371292	Feb 01, 2028		U-1356			
CICLESONIDE - ZETONNA									
N 202129	001		8371292	Feb 01, 2028		U-1357			
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO									
N 212819	001		8487093	Mar 21, 2033	DS	DP U-2586		NCE	Jul 16, 2024
			8487093	Mar 21, 2033	DS	DP U-2587		NPP	Dec 09, 2028
			8487093	Mar 21, 2033	DS	DP U-2840		GAIN	Jul 16, 2029
CINACALCET HYDROCHLORIDE - SENSIPAR									
N 021688	001		7829595	Sep 22, 2026		DP U-1098			
			9375405	Sep 22, 2026		DP			
CINACALCET HYDROCHLORIDE - SENSIPAR									
N 021688	002		7829595	Sep 22, 2026		DP U-1098			
			9375405	Sep 22, 2026		DP			
CINACALCET HYDROCHLORIDE - SENSIPAR									
N 021688	003		7829595	Sep 22, 2026		DP U-1098			
			9375405	Sep 22, 2026		DP			
CIPROFLOXACIN - OTIPRIO									
N 207986	001		11040004	Nov 12, 2037		U-2252			
			11246863	Nov 27, 2038		DP			
			11369566	Apr 21, 2029		DP			
			8318817	Apr 27, 2030		U-1792			
			9205048	Apr 21, 2029		U-1793			
			9220796	Jul 01, 2035		DP			
			9233068	Dec 11, 2029		DP			
			9603796	Apr 21, 2029	DS	DP U-2252			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL						
N 208251 001	8932610	Mar 24, 2030	DP U-1578			
CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE						
A 218273 001					CGT	Jun 02, 2026
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	10568855	Mar 15, 2033	U-1			
	11337989	Mar 15, 2033	U-1			
	11439610	Mar 15, 2033	DS DP			
	11992472	Mar 15, 2033	U-1			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ						
N 209589 001	10624879	Jun 23, 2034	DP			
	11191753	Jun 23, 2034	U-3261			
	12458634	Jan 27, 2038	DP			
	9827231	Jun 26, 2034	DP U-2162			
CLADRIBINE - MAVENCLAD						
N 022561 001	10849919	Nov 23, 2038	U-3411			
	7713947	Oct 16, 2026	U-2520			
	8377903	May 31, 2026	U-2522			
CLASCOTERONE - WINLEVI						
N 213433 001	10159682	Aug 14, 2028	U-2942			
	11207332	Nov 20, 2028	DP U-3280			
	11938141	Jul 24, 2028	DP			
	12337002	Jul 24, 2028	DP U-3280			
	8143240	Jan 12, 2027	U-2942			
	8785427	Jul 25, 2030	DP			
	9433628	Feb 28, 2029	DP			
	9486458	Jul 24, 2028	U-2942			
CLEVIDIPINE - CLEVIPREX						
N 022156 001	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 002	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 003	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLINDAMYCIN PHOSPHATE - CLINDESSE						
N 050793 001	9789057	Dec 02, 2026	DP U-137			
CLINDAMYCIN PHOSPHATE - XACIATO						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP	Dec 07, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLINDAMYCIN PHOSPHATE - XACIATO								
N 215650	001		12303563	Sep 22, 2036	DP		GAIN	Dec 07, 2029
CLOBAZAM - SYMPAZAN								
N 210833	001		11541002	Jan 31, 2040	DP U-724			
			12290597	Sep 05, 2039	DP U-724			
			12403090	Sep 05, 2039	DP U-724			
CLOBAZAM - SYMPAZAN								
N 210833	002		11541002	Jan 31, 2040	DP U-724			
			12290597	Sep 05, 2039	DP U-724			
			12403090	Sep 05, 2039	DP U-724			
CLOBAZAM - SYMPAZAN								
N 210833	003		11541002	Jan 31, 2040	DP U-724			
CLOBETASOL PROPIONATE - OLUX E								
N 022013	001		8460641	Nov 05, 2028	DP U-1410			
CLOBETASOL PROPIONATE - IMPOYZ								
N 209483	001		10064875	Aug 31, 2030	DP U-1408			
			10064875	Aug 31, 2030	DP U-1858			
			10064875	Aug 31, 2030	DP U-193			
			10064875	Aug 31, 2030	DP U-742			
			10064875	Aug 31, 2030	DP U-88			
			10588914	Aug 31, 2030	DP U-2771			
			9855334	Mar 11, 2035	DP			
			9956231	Aug 31, 2030	DP U-1408			
			9956231	Aug 31, 2030	DP U-1761			
			9956231	Aug 31, 2030	DP U-1858			
			9956231	Aug 31, 2030	DP U-193			
			9956231	Aug 31, 2030	DP U-742			
			9956231	Aug 31, 2030	DP U-88			
CLOBETASOL PROPIONATE - BYQLOVI								
N 218158	001		10588913	May 09, 2036	DP		NP	Mar 04, 2027
			11376262	May 09, 2036	DP U-19			
CLONIDINE - NEXICLON XR								
N 022500	001		8337890	Apr 17, 2027	DP			
			8623409	Sep 08, 2031	DP			
CLONIDINE - NEXICLON XR								
N 022500	002		8337890	Apr 17, 2027	DP			
			8623409	Sep 08, 2031	DP			
CLONIDINE HYDROCHLORIDE - ONYDA XR								
N 217645	001		11918689	Jul 28, 2041	DP U-3944			
			8062667	Mar 29, 2029	DP			
CLONIDINE HYDROCHLORIDE - JAVADIN								
N 220256	001		12233049	Jul 15, 2042	DP			
			12440474	Jul 15, 2042	DP			
CLOTRIMAZOLE - CLOTIC								
N 217628	001		12246006	May 26, 2042	DP U-4276		NP	Sep 26, 2028
							GAIN	Sep 26, 2033

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOZAPINE - VERSACLOZ						
N 203479 001	8057811	May 01, 2028	DP			
COBICISTAT - TYBOST						
N 203094 001	10039718	Oct 06, 2032	DP		ODE-260	Aug 22, 2026
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
COBICISTAT - TYBOST						
N 203094 002	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA						
N 210455 001	10039718	Oct 06, 2032	DP			
	10786518	Jul 19, 2038	U-2978			
	7700645	Dec 26, 2026	DS DP			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA						
N 207561 001	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
	8633219	Apr 30, 2030	DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	8633219*PED	Oct 30, 2030				
		8754065	Aug 15, 2032	DS DP U-257			
		8754065*PED	Feb 15, 2033				
		8981103	Oct 26, 2026	DS DP			
		8981103*PED	Apr 26, 2027				
		9296769	Aug 15, 2032	DS DP U-257			
		9296769*PED	Feb 15, 2033				
		9891239	Sep 03, 2029	DP U-257			
		9891239*PED	Mar 03, 2030				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD							
N 203100	001	10039718	Oct 06, 2032	DP			
		10039718*PED	Apr 06, 2033				
		7176220	Aug 27, 2026	DS DP U-257			
		7176220*PED	Feb 27, 2027				
		7635704	Oct 26, 2026	DS DP U-257			
		7635704*PED	Apr 26, 2027				
		8148374	Sep 03, 2029	DS DP U-1279			
		8633219	Apr 30, 2030	DP U-257			
		8633219*PED	Oct 30, 2030				
		8981103	Oct 26, 2026	DS DP			
		8981103*PED	Apr 26, 2027				
		9891239	Sep 03, 2029	DP U-257			
		9891239*PED	Mar 03, 2030				
COBIMETINIB FUMARATE - COTELLIC							
N 206192	001	10478400	Jun 29, 2036	DS DP U-1776		ODE-416	Oct 28, 2029
		10478400*PED	Dec 29, 2036				
		10590102	Jun 30, 2036	DS DP U-1776			
		10590102*PED	Dec 30, 2036				
		11087354	Jun 22, 2034	U-1776			
		11087354*PED	Dec 22, 2034				
		11254649	Jun 30, 2036	DS DP U-1776			
		11254649*PED	Dec 30, 2036				
		11597699	Oct 05, 2026	U-3554			
		7803839	Nov 10, 2029	DS DP			
		7803839*PED	May 10, 2030				
		8362002	Oct 05, 2026	U-1776			
		8362002*PED	Apr 05, 2027				
COCAINE HYDROCHLORIDE - NUMBRINO							
N 209575	001	10016407	Feb 07, 2037	U-2225			
		10016407	Feb 07, 2037	U-2226			
		10016407	Feb 07, 2037	U-2329			
		10149843	Feb 07, 2037	U-2478			
		10149843	Feb 07, 2037	U-2479			
		10231961	Feb 07, 2037	DP			
		10413505	Feb 07, 2037	U-3014			
		10420760	Feb 07, 2037	U-2478			
		10857095	Feb 07, 2037	U-3014			
		10894012	Feb 07, 2037	U-3014			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COCAINE HYDROCHLORIDE - NUMBRINO						
N 209575 001	10933060	Feb 07, 2037	U-2478			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-3680			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
	9867815	Feb 07, 2037	U-2329			
COCAINE HYDROCHLORIDE - GOPRELTO						
N 209963 001	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
COLCHICINE - COLCRYS						
N 022352 001	7601758	Feb 10, 2029	U-1007			
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
	9399036	Aug 22, 2033	U-1020			
	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - GLOPERBA						
N 210942 001	10226423	Dec 20, 2037	DP			
	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			
	12274751	Nov 22, 2036	U-2814			
	9907751	Nov 22, 2036	DP			
COLCHICINE - LODOCO						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
	12364675	Nov 01, 2033	U-3639			
	9744144	Nov 01, 2033	U-3643			
COPANLISIB DIHYDROCHLORIDE - ALIQOPA						
N 209936 001	10383876	Mar 29, 2032	DS DP			
	9636344	Mar 29, 2032	U-2124			
	RE46856	Oct 22, 2029	DS DP U-2124			
COPPER - PARAGARD T 380A						
N 018680 001					D-193	Jun 28, 2027
COPPER - MIUDELLA						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
COPPER CU-64 DOTATATE - DETECTNET						
N 213227 001	10159759	Aug 23, 2032	U-2951		ODE-317	Sep 03, 2027
	10383961	Jul 02, 2033	U-2951			
	11160888	Aug 23, 2032	U-2951			
	12102696	Sep 03, 2041	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - ACTHAR GEL						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
CORTICOTROPIN - PURIFIED CORTROPHIN GEL						
N 008975 001	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
CORTICOTROPIN - PURIFIED CORTROPHIN GEL						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CORTICOTROPIN - PURIFIED CORTROPHIN GEL						
N 008975 002	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CORTICOTROPIN - PURIFIED CORTROPHIN GEL						
N 008975 002	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
	12324787	Oct 27, 2043	DP			
	12440542	Oct 27, 2043	DP U-3904			
	12440542	Oct 27, 2043	DP U-3905			
	12440542	Oct 27, 2043	DP U-3906			
	12440542	Oct 27, 2043	DP U-3907			
	12440542	Oct 27, 2043	DP U-3908			
	12440542	Oct 27, 2043	DP U-3909			
	12440542	Oct 27, 2043	DP U-3910			
	12440542	Oct 27, 2043	DP U-3911			
	12440542	Oct 27, 2043	DP U-3912			
	12440542	Oct 27, 2043	DP U-3913			
	12440542	Oct 27, 2043	DP U-3914			
	12440542	Oct 27, 2043	DP U-3915			
	12440542	Oct 27, 2043	DP U-3916			
	12440542	Oct 27, 2043	DP U-3917			
	12440542	Oct 27, 2043	DP U-3918			
	12440542	Oct 27, 2043	DP U-3919			
	12440542	Oct 27, 2043	DP U-3920			
	12440542	Oct 27, 2043	DP U-3921			
	12440542	Oct 27, 2043	DP U-3922			
	12440542	Oct 27, 2043	DP U-3923			
	12440542	Oct 27, 2043	DP U-3924			
	12440542	Oct 27, 2043	DP U-3925			
	12440542	Oct 27, 2043	DP U-3926			
CRINECERFONT - CRENESSITY						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049		ODE-503	Dec 13, 2031
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049		ODE-503	Dec 13, 2031
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049		ODE-503	Dec 13, 2031
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRINECERFONT - CRENESSITY						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049		ODE-503	Dec 13, 2031
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
CRISABOROLE - EUCRISA						
N 207695 001	8039451	Jun 29, 2029	DS DP		D-191	Apr 03, 2026
	8039451*PED	Dec 29, 2029				
	8168614	Jan 20, 2030	U-1932			
	8168614*PED	Jul 20, 2030				
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
CRIZOTINIB - XALKORI						
N 202570 001	7825137	May 12, 2027	U-3057		ODE-328	Jan 14, 2028
	7825137	May 12, 2027	U-3058		ODE-407	Jul 14, 2029
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
CRIZOTINIB - XALKORI						
N 202570 002	7825137	May 12, 2027	U-3057		ODE-328	Jan 14, 2028
	7825137	May 12, 2027	U-3058		ODE-407	Jul 14, 2029
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
CRIZOTINIB - XALKORI						
N 217581 001	7825137	May 12, 2027	U-3057			
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
CRIZOTINIB - XALKORI						
N 217581 002	7825137	May 12, 2027	U-3057			
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
CRIZOTINIB - XALKORI						
N 217581 003	7825137	May 12, 2027	U-3057			
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS			
CROFELEMER - MYTESI						
N 202292 001	8962680	Oct 31, 2031	U-1319			
	9585868	Oct 31, 2031	U-1319			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT						
N 209376 001	11786548	Jul 01, 2041	DP			
	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3899			
	12150957	Jul 01, 2041	U-3899			
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT						
N 209376 002	11786548	Jul 01, 2041	DP			
	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3899			
	12150957	Jul 01, 2041	U-3899			
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS						
N 209376 003	11786548	Jul 01, 2041	DP			
	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3900			
	12150957	Jul 01, 2041	U-3900			
CYCLOBENZAPRINE HYDROCHLORIDE - TONMYA						
N 219428 001	10117936	Mar 14, 2034	DP		NP	Aug 15, 2028
	10864175	Mar 14, 2034	DP			
	9636408	Mar 14, 2034	DP			
	9956188	Mar 14, 2034	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 001	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 002	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210735 003	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - FRINDOVYX						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - FRINDOVYX						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - FRINDOVYX						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 001	10993952	Feb 15, 2036	DP			
	12329767	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 002	10993952	Feb 15, 2036	DP			
	12329767	Feb 15, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 003	10993952	Feb 15, 2036	DP			
	12329767	Feb 15, 2036	DP			
CYCLOSPORINE - RESTASIS MULTIDOSE						
N 050790 002	8292129	Feb 25, 2031	DP	Y		
	8561859	Apr 16, 2032	DP	Y		
	9669974	May 11, 2034	DP	Y		
	9676525	Feb 07, 2034	DP	Y		
CYCLOSPORINE - CEQUA						
N 210913 001	10441630	Aug 23, 2033	DP			
	10918694	Feb 28, 2037	DP			
	11951153	Feb 28, 2037	U-1483			
	8980839	Aug 23, 2033	DP U-1483			
	9937225	Aug 23, 2033	DP U-1483			
CYCLOSPORINE - VERKAZIA						
N 214965 001	11612658	Jan 27, 2026	U-3560		ODE-358	Jun 23, 2028
	7973081	Jan 27, 2026	DP			
	8298568	Nov 03, 2027	DP			
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			
CYCLOSPORINE - VEVYE						
N 217469 001	10813976	Sep 22, 2037	DP		NP	May 30, 2026
	11154513	Nov 20, 2038	DP U-1900			
	11413323	Oct 11, 2039	U-3627			
	12059449	Apr 01, 2042	DP U-1483			
	12496326	Sep 29, 2036	U-3627			
	8614178	Dec 13, 2030	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	10143665	Aug 16, 2036	U-1399			
	10143665*PED	Feb 16, 2037				
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP		U-1399	
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP		U-1399	
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	10143665	Aug 16, 2036			U-1399	
	10143665*PED	Feb 16, 2037				
	10328037	Aug 16, 2036			U-1399	
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036			U-1399	
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036			U-1399	
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027			U-1399	
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027			U-1399	
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027			U-1399	
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP		U-1399	
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP		U-1399	
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP		U-1399	
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 001	10143665	Aug 16, 2036			U-1399	
	10143665*PED	Feb 16, 2037				
	10328037	Aug 16, 2036			U-1399	
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036			U-1399	
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036			U-1399	
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027			U-1399	
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027			U-1399	
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027			U-1399	
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 001	9925156	Jan 26, 2027	DP		U-1399	
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP		U-1399	
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP		U-1399	
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 002	10143665	Aug 16, 2036			U-1399	
	10143665*PED	Feb 16, 2037				
	10328037	Aug 16, 2036			U-1399	
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036			U-1399	
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036			U-1399	
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027			U-1399	
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027			U-1399	
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027			U-1399	
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DP		U-1399	
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP		U-1399	
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP		U-1399	
	9925158*PED	Jul 26, 2027				
CYSTEINE HYDROCHLORIDE - ELCYS						
N 210660 001	10478453	Jan 15, 2039	DP		U-2752	
	10583155	Jan 15, 2039	DP		U-2752	
	10653719	Jan 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11510941	Jan 15, 2039	DP			
	11510942	Jan 15, 2039	DP		U-2752	
	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
	11969439	Jan 15, 2039			U-2752	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEINE HYDROCHLORIDE - NOURESS						
N 212535 001	10478453	Jan 15, 2039	DP U-2752			
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10702490	Mar 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
CYTARABINE; DAUNORUBICIN - VYXEOS						
N 209401 001	10028912	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
	10028912	Oct 15, 2032	DP U-3150			
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 001	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 002	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 003	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 001	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 002	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 003	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 004	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 005	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 006	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-908	Mar 16, 2026
	10869869*PED	Feb 28, 2034			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP U-1406		PED	Sep 16, 2026
	7994185	Jan 20, 2030	DS DP U-2031		PED	Sep 16, 2030
	7994185	Jan 20, 2030	DS DP U-2032			
	7994185	Jan 20, 2030	DS DP U-2296			
	7994185*PED	Jul 20, 2030				
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-908	Mar 16, 2026
	10869869*PED	Feb 28, 2034			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP U-1406		PED	Sep 16, 2026
	7994185	Jan 20, 2030	DS DP U-2031		PED	Sep 16, 2030
	7994185	Jan 20, 2030	DS DP U-2032			
	7994185	Jan 20, 2030	DS DP U-2296			
	7994185*PED	Jul 20, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACOMITINIB - VIZIMPRO						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
	7772243	Sep 27, 2032	DS DP			
DACOMITINIB - VIZIMPRO						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
	7772243	Sep 27, 2032	DS DP			
DACOMITINIB - VIZIMPRO						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
	7772243	Sep 27, 2032	DS DP			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	May 23, 2028	U-3499			
DANICOPAN - VOYDEYA						
N 218037 001	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
DANICOPAN - VOYDEYA						
N 218037 002	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
DAPAGLIFLOZIN - FARXIGA						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7851502	Aug 19, 2028	DP		PED	Dec 12, 2027
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN - FARXIGA						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	12213988	Apr 01, 2041	U-4140			
	12213988*PED	Oct 01, 2041				
	12409186	Apr 01, 2041	U-4140			
	12409186*PED	Oct 01, 2041				
	12472194	Jul 18, 2039	U-4346			
	12472194*PED	Jan 18, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 001	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 002	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 003	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 004	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 004	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 001	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 002	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
DAPRODUSTAT - JESDUVROQ						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPRODUSTAT - JESDUVROQ						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 22, 2027	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPSONE - ACZONE						
N 207154 001	11273132	Nov 18, 2033	DP			
DAPTOMYCIN - CUBICIN						
N 021572 002	8003673	Sep 04, 2028	U-1180			
DAPTOMYCIN - CUBICIN RF						
N 021572 003	9138456	Nov 23, 2030	DP			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPZURA RT						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
DAPTOMYCIN - DAPTOMYCIN						
N 217415 001	11759497	Aug 28, 2038	DP			
	12053502	Aug 28, 2038	U-3981			
DAPTOMYCIN - DAPTOMYCIN						
N 217415 002	11759497	Aug 28, 2038	DP			
	12053502	Aug 28, 2038	U-3981			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 001	10023560	Dec 02, 2034	U-620		M-200	Sep 30, 2027
	9732075	Jun 12, 2033	DS DP U-620		M-310	Sep 30, 2027
	9790208	Dec 02, 2034	DS DP		NCE	Apr 07, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 002	10023560	Dec 02, 2034	U-620		M-200	Sep 30, 2027
	9732075	Jun 12, 2033	DS DP U-620		M-310	Sep 30, 2027
	9790208	Dec 02, 2034	DS DP		NCE	Apr 07, 2027
DAROLUTAMIDE - NUBEQA						
N 212099 001	10010530	Jan 28, 2036	DS		I-971	Jun 03, 2028
	10383853	Jan 28, 2036	DS			
	10711013	Oct 27, 2030	DS DP			
	10835515	Jan 28, 2036	DP U-2605			
	10835515	Jan 28, 2036	DP U-4208			
	10835515	Jan 28, 2036	DP U-4209			
	10835515	Jan 28, 2036	DP U-4210			
	11046713	Oct 27, 2030	DS			
	11168058	Feb 27, 2038	DS DP			
	12329742	May 14, 2042	DP			
	8975254	Mar 25, 2033	DS DP U-4208			
	8975254	Mar 25, 2033	DS DP U-4209			
	8975254	Mar 25, 2033	DS DP U-4210			
	9657003	Oct 27, 2030	DS DP U-4208			
	9657003	Oct 27, 2030	DS DP U-4209			
	9657003	Oct 27, 2030	DS DP U-4210			
DARUNAVIR - PREZISTA						
N 021976 001	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 021976 002	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 021976 003	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 021976 004	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 021976 005	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 021976 006	7700645	Dec 26, 2026	DS DP			
DARUNAVIR - PREZISTA						
N 202895 001	7700645	Dec 26, 2026	DS DP			
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
	8188104	May 17, 2029	DS DP U-1636			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Dec 19, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)								
N 206619	001		9006387	Jun 10, 2030	U-1687			
			9044480	Apr 10, 2031	U-1638			
			9139536	Nov 09, 2028	U-1753			
			9629841	Oct 18, 2033	DP U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR								
N 208624	001		10105365	Jan 02, 2035	DP U-1889			
			10201541	May 17, 2032	DP			
			10201584	May 17, 2032	U-1889			
			8188104	May 17, 2029	DS DP U-1636			
			8420596	Apr 10, 2031	DS DP			
			8466159	Sep 04, 2032	U-1637			
			8492386	Sep 04, 2032	U-1840			
			8501238	Sep 17, 2028	DS DP U-1636			
			8642538	Sep 10, 2029	DS DP U-1638			
			8680106	Sep 04, 2032	U-1637			
			8685984	Sep 04, 2032	U-1840			
			8686026	Jun 09, 2031	DP			
			8691938	Apr 13, 2032	DS DP			
			9006387	Jun 10, 2030	U-1687			
			9044480	Apr 10, 2031	U-1638			
			9139536	Nov 09, 2028	U-1753			
			9333204	Jan 02, 2035	DP U-1889			
			9744170	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL								
N 021986	001		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - SPRYCEL								
N 021986	002		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - SPRYCEL								
N 021986	003		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - SPRYCEL								
N 021986	004		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - SPRYCEL								
N 021986	005		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - SPRYCEL								
N 021986	006		7491725	Mar 28, 2026	DS DP			
			7491725*PED	Sep 28, 2026				
DASATINIB - PHYRAGO								
N 216099	001		11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
			11202778	Jan 22, 2041	U-3771			
			11202778	Jan 22, 2041	U-3772			
			11298356	Jan 22, 2041	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - PHYRAGO						
N 216099 001	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASATINIB - PHYRAGO						
N 216099 002	11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASATINIB - PHYRAGO						
N 216099 003	11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASATINIB - PHYRAGO						
N 216099 004	11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - PHYRAGO						
N 216099 004	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASATINIB - PHYRAGO						
N 216099 005	11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASATINIB - PHYRAGO						
N 216099 006	11202778	Jan 22, 2041	U-3770		M-307	Dec 05, 2026
	11202778	Jan 22, 2041	U-3771			
	11202778	Jan 22, 2041	U-3772			
	11298356	Jan 22, 2041	DP			
	11324745	Jan 22, 2041	U-3767			
	11324745	Jan 22, 2041	U-3768			
	11324745	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
	11795204	Jan 06, 2034	U-3752			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
	11795204	Jan 06, 2034	U-3752			
DEFERASIROX - JADENU						
N 206910 001	9283209	Nov 21, 2034	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU						
N 206910 002	9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU						
N 206910 003	9283209	Nov 21, 2034	DS DP			
DEFERIPRONE - FERRIPROX						
N 021825 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 021825 002					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 001	8703156	Oct 26, 2029	DP U-3083		ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 002	8703156	Oct 26, 2029	DP U-3083		ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		ODE-417	Apr 30, 2028
	10940115	Oct 25, 2038	DP U-3083		ODE-420	Apr 30, 2028
	10940116	Oct 25, 2038	DP		ODE-421	Apr 30, 2028
	11357731	Oct 25, 2038	U-3083			
	11458103	Oct 25, 2038	DP			
	11723874	Oct 25, 2038	U-3083			
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	11085043	Jun 22, 2032	DP			
	11236328	Jun 22, 2032	U-3301			
	11746348	Jun 22, 2032	DP			
DEFLAZACORT - EMFLAZA						
N 208684 001					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 002					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 003					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 004					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208685 001					ODE-252	Jun 07, 2026
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	11766468	Apr 27, 2032	U-1978			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	11826397	Apr 27, 2032	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DEGARELIX ACETATE - FIRMAGON						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	11766468	Apr 27, 2032	U-1978			
	11826397	Apr 27, 2032	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	7728143	Jun 19, 2031	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8871938	Sep 23, 2029	DS			
	RE46617	Dec 28, 2029	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	12036219	Jun 02, 2034	U-3967		NCE	Jun 19, 2022
	12138257	May 01, 2032	DP		GAIN	Jun 19, 2027
	7635773	Mar 13, 2029	DP			
	7728143	Jun 19, 2031	DS			
	8252813	Oct 02, 2026	DP U-2028			
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
DELGOCITINIB - ANZUPGO						
N 219155 001	8609647	Sep 19, 2031	DS DP U-4237		NCE	Jul 23, 2030
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	10500214	Mar 02, 2030	DP			
	12161653	Feb 17, 2032	U-1940			
	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
	9949986	Feb 21, 2028	U-1940			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 001	11020448	May 21, 2029	U-2327			
	11963995	May 21, 2029	U-2327			
	9974826	Apr 13, 2030	U-2326			
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 002	10137167	May 21, 2029	U-2327			
	11963995	May 21, 2029	U-2327			
	9974826	Apr 13, 2030	U-2327			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 001	11419914	Jun 15, 2030	U-3431			
	12090190	Jun 15, 2030	DP U-4003			
	9539302	Jun 15, 2030	DP			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 002	11419914	Jun 15, 2030	U-3431			
	12090190	Jun 15, 2030	DP U-4003			
	9539302	Jun 15, 2030	DP			
DESONIDE - VERDESO						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
DESOXIMETASONE - TOPICORT						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 001	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 002	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	8269040	Jul 05, 2027	DS			
DEUCRAVACITINIB - SOTYKTU						
N 214958 001	10000480	Nov 07, 2033	DS DP		NCE	Sep 09, 2027
	11021475	Nov 07, 2033	U-3434			
	RE47929	Nov 07, 2033	DS DP U-3434			
DEURUXOLITINIB PHOSPHATE - LEQSELVI						
N 217900 001	10561659	May 04, 2037	U-3976		NCE	Jul 25, 2029
	11919907	May 21, 2041	DP U-3976			
	12076323	May 04, 2037	U-3976			
	12247034	May 10, 2044	DS DP			
	12285432	Aug 11, 2042	U-3976			
	12364699	Oct 10, 2044	U-3976			
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
	11666566*PED	Mar 18, 2034				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 001	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 001	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	
	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 004	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 004	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 005	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 006	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 006	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 007	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	
	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036			U-1995	
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036			U-1995	
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036			U-1995	
	12016858	Mar 07, 2036			U-3055	
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP		U-1995	
	9550780	Sep 18, 2033	DS DP		U-3055	
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 008	10959996	Mar 07, 2036			U-3055	
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP		U-1995	
	11179386	Mar 15, 2038	DP		U-3055	
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP		U-1995	
	11311488	Jun 10, 2041	DP		U-3055	
	11357772	Mar 07, 2036			U-1995	
	11357772	Mar 07, 2036			U-3055	
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036			U-1995	
	11446291*PED	Sep 07, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 008	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	Jul 10, 2031	DS DP			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4218			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 002	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	Jul 10, 2031	DS DP			
DEXAMETHASONE - DEXTENZA						
N 208742 001	11458041	Nov 16, 2037	U-1680		NPP	Apr 07, 2028
	11458041	Nov 16, 2037	U-3455			
	12144889	Apr 26, 2041	U-1680			
	12150896	Oct 07, 2036	U-1680			
	12150896	Oct 07, 2036	U-3455			
	8409606	May 14, 2030	DP			
	8563027	Feb 12, 2030	U-2487			
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	10022502	Jun 22, 2034	U-2340			
	10028965	May 23, 2034	U-2340			
	10159683	May 23, 2034	DP			
	10799642	May 11, 2032	DP			
	11097061	Jun 23, 2039	DP U-3418			
DEXAMETHASONE - HEMADY						
N 211379 001	10537585	Dec 18, 2037	DP		ODE-271	Oct 03, 2026
	11304961	Dec 18, 2037	DP U-3344			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030			U-949	
	8173158	Mar 17, 2030			U-950	
	8173158	Mar 17, 2030			U-951	
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032			U-1805	
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030			U-949	
	8173158	Mar 17, 2030			U-950	
	8173158	Mar 17, 2030			U-951	
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032			U-1805	
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 002	10016396	Jan 04, 2032	DP			
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 003	10016396	Jan 04, 2032	DP			
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE						
N 206628 003	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE						
N 206628 004	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		M-82	Nov 19, 2028
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
	11786508	Dec 29, 2037	U-3698			
	11806334	Jan 12, 2043	U-3725			
	11839604	Dec 29, 2037	U-3756			
	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	12138247	Jan 12, 2043	U-4029			
	12364683	Jan 12, 2043	U-4029			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		M-82	Nov 19, 2028
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
	11786508	Dec 29, 2037	U-3698			
	11806334	Jan 12, 2043	U-3725			
	11839604	Dec 29, 2037	U-3756			
	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	12138247	Jan 12, 2043	U-4029			
	12364683	Jan 12, 2043	U-4029			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		M-82	Nov 19, 2028
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
	11786508	Dec 29, 2037	U-3698			
	11806334	Jan 12, 2043	U-3725			
	11839604	Dec 29, 2037	U-3756			
	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	12138247	Jan 12, 2043	U-4029			
	12364683	Jan 12, 2043	U-4029			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N	212994	003	10759778	Dec 09, 2037	DP			
			10858341	Dec 09, 2037	U-3094			
			10954213	Dec 09, 2037	U-3094			
			9079928	Jul 27, 2032	DP			
DEXTROAMPHETAMINE - XELSTRYM								
N	215401	001	11559501	Jan 06, 2042	DP			
			9456993	Oct 24, 2033	DP U-3340			
			9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM								
N	215401	002	11559501	Jan 06, 2042	DP			
			9456993	Oct 24, 2033	DP U-3340			
			9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM								
N	215401	003	11559501	Jan 06, 2042	DP			
			9456993	Oct 24, 2033	DP U-3340			
			9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM								
N	215401	004	11559501	Jan 06, 2042	DP			
			9456993	Oct 24, 2033	DP U-3340			
			9474722	Oct 24, 2033	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA								
N	021879	001	7659282	Aug 13, 2026	U-1093			
DIAZEPAM - VALTOCO								
N	211635	001	11241414	Mar 27, 2029	DP		NPP	Apr 15, 2028
			11793786	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			12268664	Mar 27, 2029	DP			
			12324852	Oct 16, 2032	U-4173			
			12337061	Jun 13, 2032	U-4173			
			8895546	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO								
N	211635	002	11241414	Mar 27, 2029	DP		NPP	Apr 15, 2028
			11793786	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			12268664	Mar 27, 2029	DP			
			12324852	Oct 16, 2032	U-4173			
			12337061	Jun 13, 2032	U-4173			
			8895546	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO								
N	211635	003	11241414	Mar 27, 2029	DP		NPP	Apr 15, 2028
			11793786	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			12268664	Mar 27, 2029	DP			
			12324852	Oct 16, 2032	U-4173			
			12337061	Jun 13, 2032	U-4173			
			8895546	Mar 27, 2029	DP			
DIAZOXIDE CHOLINE - VYKAT XR								
N	216665	001	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
			12343348	Nov 12, 2035	U-4211			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 001	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 002	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 003	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DICLOFENAC - ZORVOLEX						
N 204592 001	8679544	Apr 23, 2030	DP			
	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX						
N 204592 002	8679544	Apr 23, 2030	DP			
	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
DICLOFENAC EPOLAMINE - LICART						
N 206976 001	11344520	Feb 20, 2035	U-3393			
	11351133	Feb 20, 2035	U-3393			
DICLOFENAC POTASSIUM - CAMBIA						
N 022165 001	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
	8927604	Jun 16, 2026	U-436			
	9827197	Jun 16, 2026	DP			
DICLOFENAC POTASSIUM - ZIPSOR						
N 022202 001	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC POTASSIUM - ZIPSOR							
N 022202	001	8623920	Feb 24, 2029	U-1482			
		9561200	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID							
N 020947	001	8217078	Jul 10, 2029	U-1248			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001	8217078	Jul 10, 2029	U-1477			
		8252838	Apr 21, 2028	DP U-1489			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8563613	Oct 17, 2027	DP U-1488			
		8618164	Jul 10, 2029	U-1477			
		8741956	Jul 10, 2029	U-1435			
		8871809	Oct 17, 2027	U-1614			
		9066913	Oct 17, 2027	DP U-1488			
		9101591	Oct 17, 2027	DP U-1488			
		9132110	Oct 17, 2027	U-1488			
		9168304	Oct 17, 2027	DP			
		9168305	Oct 17, 2027	U-1488			
		9220784	Oct 17, 2027	U-1488			
		9339551	Oct 17, 2027	U-1488			
		9339552	Oct 17, 2027	DP U-1488			
		9370501	Jul 10, 2029	U-1614			
		9375412	Jul 10, 2029	U-1614			
		9415029	Jul 10, 2029	U-1614			
		9539335	Oct 17, 2027	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA							
N 022252	001	8071577	May 13, 2026	DP U-1			
		8153616	Jan 30, 2028	U-1240			
DIFELIKEFALIN ACETATE - KORSUVA							
N 214916	001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
		10138270	Nov 12, 2027	U-3204			
		10793596	Nov 12, 2027	DS DP U-3204			
		7402564	Nov 12, 2027	DS DP U-3204			
		7713937	Nov 12, 2027	DS DP U-3204			
		7727963	Nov 12, 2027	DS DP U-3204			
		8217007	Nov 12, 2027	U-3204			
		8236766	Nov 12, 2027	U-3204			
		8486894	Nov 12, 2027	U-3204			
		8536131	Nov 12, 2027	DS DP U-3204			
		9334305	Nov 12, 2027	U-3204			
		9359399	Nov 12, 2027	U-3204			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIFELIKEFALIN ACETATE - KORSUVA						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			
	9359399	Nov 12, 2027	U-3204			
DIHYDROERGOTAMINE MESYLATE - TRUDHESA						
N 213436 001	10507295	Dec 25, 2032	DP			
	10940278	Jan 23, 2033	DP			
	11185497	Jan 04, 2039	U-3218			
	11266799	Nov 05, 2036	DP			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			
DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)						
N 215400 001	10532049	Feb 26, 2039	DP			
	11304942	Feb 26, 2039	DP			
	11819501	Feb 26, 2039	U-4188			
	11819501	Feb 26, 2039	U-848			
DIHYDROERGOTAMINE MESYLATE - ATZUMI						
N 217901 001	10758532	Dec 11, 2039	DP		NP	Apr 30, 2028
	10792253	Aug 04, 2037	DP			
	11744967	Oct 12, 2041	DP			
	11872314	Aug 04, 2037	DP			
	12102754	Oct 12, 2041	DP			
	12263162	Dec 11, 2039	DP			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
DIROXIMEL FUMARATE - VUMERITY						
N 211855 001	10080733	Sep 20, 2033	DS DP U-1384			
	8669281	Oct 29, 2033	DS DP			
	9090558	Sep 20, 2033	U-1384			
DOCETAXEL - DOCETAXEL						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCIVYX						
N 215813 001	10398785	Mar 14, 2036	DP			
DOCETAXEL - DOCIVYX						
N 215813 002	10398785	Mar 14, 2036	DP			
DOCETAXEL - DOCIVYX						
N 215813 003	10398785	Mar 14, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOCETAXEL - BEIZRAY						
N 218711 001	11419842	May 16, 2036	DP U-4027			
	11419842	May 16, 2036	DP U-4028			
	11419842	May 16, 2036	DP U-881			
	11419842	May 16, 2036	DP U-937			
	11419842	May 16, 2036	DP U-946			
	12090134	May 16, 2036	DP U-4027			
	12090134	May 16, 2036	DP U-4028			
	12090134	May 16, 2036	DP U-881			
	12090134	May 16, 2036	DP U-937			
	12090134	May 16, 2036	DP U-946			
	12090135	May 16, 2036	DP			
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM - TIVICAY PD						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO						
N 211994 001	11234985	Jan 24, 2031	DP U-257		NPP	Apr 05, 2027
	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA						
N 210192 001	10426780	Jan 24, 2031	DS DP U-257			
	12011506	Sep 05, 2038	DP			
	8129385	Oct 05, 2027	DS DP			
	8129385*PED	Apr 05, 2028				
	9242986	Dec 08, 2029	DS DP			
	9242986*PED	Jun 08, 2030				
DONEPEZIL HYDROCHLORIDE - ARICEPT						
N 022568 001	8481565	Oct 04, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	10016372	Jul 26, 2037			U-3334	
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP		U-3334	
	10966936	Aug 11, 2038	DP		U-3334	
	11103463	Jul 26, 2037			U-3334	
	11648214	Sep 23, 2037	DP		U-3334	
	11679086	May 26, 2037			U-3334	
	12161767	Dec 30, 2036	DS DP		U-3334	
	12168075	Dec 30, 2036			U-3334	
	9993466	Jul 26, 2037	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	10016372	Jul 26, 2037			U-3334	
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP		U-3334	
	10966936	Aug 11, 2038	DP		U-3334	
	11103463	Jul 26, 2037			U-3334	
	11648214	Sep 23, 2037	DP		U-3334	
	11679086	May 26, 2037			U-3334	
	12161767	Dec 30, 2036	DS DP		U-3334	
	12168075	Dec 30, 2036			U-3334	
	9993466	Jul 26, 2037	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 001	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 003	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 004	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)						
N 219407 001	10294477	May 01, 2035	DS DP		U-3010	
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9315811	Oct 21, 2032			U-3010	
	9670492	Aug 28, 2034	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DORAVIRINE - PIFELTRO						
N 210806 001	8486975	Aug 30, 2032	DS DP U-2394			
	8486975	Aug 30, 2032	DS DP U-2630			
	8486975	Aug 30, 2032	DS DP U-3308			
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO						
N 210807 001	10603282	Nov 29, 2036	DP			
	10842751	Nov 29, 2036	DP			
	8486975	Aug 30, 2032	DS DP U-2395			
	8486975	Aug 30, 2032	DS DP U-2629			
	8486975	Aug 30, 2032	DS DP U-3307			
DORDAVIPRONE HYDROCHLORIDE - MODEYSO						
N 219876 001	10172862	Jan 30, 2037	U-4254		NCE	Aug 06, 2030
	10369154	Jan 30, 2037	U-4254			
	11976068	Mar 01, 2036	DP			
	12102639	Jan 30, 2037	U-4254			
	9265765	Jul 26, 2034	DP			
	9629842	Apr 30, 2032	U-4254			
	RE46290	Apr 30, 2032	U-4254			
DOXECITINE; DOXRIBTIMINE - KYGEVVI						
N 219792 001	10471087	Aug 07, 2036	U-4358		NCE	Nov 03, 2030
	11649259	Aug 19, 2040	DP U-4358			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	12083090	May 18, 2027	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	12083090	May 18, 2027	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	002		9107898	May 01, 2028	U-620			
			9486437	May 18, 2027	U-620			
			9532971	Jun 01, 2029	DP			
			9572814	Jul 20, 2027	U-620			
			9861607	May 18, 2027	U-620			
			9907780	Apr 11, 2028	DP			
DOXERCALCIFEROL - HECTOROL								
N 020862	001						M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL								
N 020862	002						M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL								
N 020862	003						M-14	Jun 11, 2028
DOXYCYCLINE - ORACEA								
N 050805	001		7749532	Dec 19, 2027	DP U-1063			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	001		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	002		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	003		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	004		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	005		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX								
N 050795	006		8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	007		8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP U-918			
			9446057	Dec 23, 2034	DP U-918			
			9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC								
N 050795	008		8715724	Feb 03, 2028	DP			
			9295652	Oct 23, 2034	DP U-918			
			9446057	Dec 23, 2034	DP U-918			
			9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA								
N 209661	001		9089489	Feb 18, 2033	DP U-1382			
			9375404	Feb 18, 2033	DP U-1382			
			9526703	Feb 18, 2033	DP U-1382			
			9937132	Feb 18, 2033	DP U-1382			
DRONABINOL - SYNDROS								
N 205525	001		10265293	Aug 06, 2028	DS DP			
			11253472	Aug 06, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DRONABINOL - SYNDROS						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N 022425 001	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			
	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
DROSPIRENONE - SLYND						
N 211367 001	10179140	Jun 28, 2031	U-2553			
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11478487	Jun 28, 2031	DP			
	11504334	Jun 28, 2031	DP			
	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
	12280151	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			
DROSPIRENONE - DROSPIRENONE						
N 216285 001	10179140	Jun 28, 2031	U-2553			
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
	11504334	Jun 28, 2031	DP			
	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
	9603860	Jun 28, 2031	U-2553			
DROSPIRENONE; ESTETROL - NEXTSTELLIS						
N 214154 001	11793760	Jun 17, 2036	DP		NCE	Apr 15, 2026
	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
	12233074	Feb 09, 2043	DP U-3152			
	12427114	Jun 17, 2036	DP U-3152			
	12458649	Oct 01, 2043	U-3152			
	7732430	Jan 15, 2028	DP U-3152			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ESTETROL - NEXTSTELLIS							
N 214154	001	11793760	Jun 17, 2036	DP		NCE	Apr 15, 2026
		11957694	Jun 17, 2036	DP			
		11964055	Jun 17, 2036	DP			
		12233074	Feb 09, 2043	DP U-3152			
		12427114	Jun 17, 2036	DP U-3152			
		12458649	Oct 01, 2043	U-3152			
		7732430	Jan 15, 2028	DP U-3152			
DROSPIRENONE; ESTRADIOL - ANGELIQ							
N 021355	001	8906890	Oct 22, 2031	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ							
N 022532	001	11617751	Jul 17, 2030	DP U-1			
		11617751	Jul 17, 2030	DP U-3572			
		11617751	Jul 17, 2030	DP U-3573			
		11617751	Jul 17, 2030	DP U-3574			
		8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N 022574	001	11617751	Jul 17, 2030	DP U-1			
		11617751	Jul 17, 2030	DP U-3572			
		8617597	Feb 08, 2030	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	001	10413525	Apr 13, 2037	DP			
		10959982	Apr 13, 2037	DP			
		11202772	Apr 13, 2037	DP			
		12171742	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	002	10413525	Apr 13, 2037	DP			
		10959982	Apr 13, 2037	DP			
		11202772	Apr 13, 2037	DP			
		12171742	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	003	10413525	Apr 13, 2037	DP			
		10959982	Apr 13, 2037	DP			
		11202772	Apr 13, 2037	DP			
		12171742	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516	004	10413525	Apr 13, 2037	DP			
		10959982	Apr 13, 2037	DP			
		11202772	Apr 13, 2037	DP			
		12171742	Apr 13, 2037	DP			
		9839626	Apr 13, 2037	DP			
DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)							
N 216974	001	10376499	Nov 17, 2035	DP U-2840		NCE	May 23, 2028
		9309245	Apr 02, 2033	DS		GAIN	May 23, 2033

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)						
N 216974 001	9623014	Apr 02, 2033	U-2840			
	9968593	Nov 17, 2035	DP U-2840			
DUVELISIB - COPIKTRA						
N 211155 001	11312718	Jan 10, 2032	DP			
	12213983	Apr 26, 2035	U-2412			
	8193182	Feb 13, 2030	DS			
	9216982	Jan 05, 2029	U-2412			
	9216982	Jan 05, 2029	U-2413			
	9840505	Jan 10, 2032	U-2412			
	9840505	Jan 10, 2032	U-2413			
	RE46621	May 17, 2032	DS DP			
DUVELISIB - COPIKTRA						
N 211155 002	11312718	Jan 10, 2032	DP			
	12213983	Apr 26, 2035	U-2412			
	8193182	Feb 13, 2030	DS			
	9216982	Jan 05, 2029	U-2412			
	9216982	Jan 05, 2029	U-2413			
	9840505	Jan 10, 2032	U-2412			
	9840505	Jan 10, 2032	U-2413			
	RE46621	May 17, 2032	DS DP			
ECONAZOLE NITRATE - ECOZA						
N 205175 001	10071054	Aug 08, 2031	DP			
EDARAVONE - RADICAVA ORS						
N 215446 001	10987341	Nov 01, 2039	DP		ODE-144	May 12, 2029
	11241416	Nov 01, 2039	DP			
	11478450	Nov 01, 2039	U-3468			
	11826352	Nov 01, 2039	DP			
	11957660	Nov 01, 2039	DP			
	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
	12310946	Nov 12, 2041	U-4111			
	12478611	Nov 12, 2041	U-4111			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 001	7365205	Apr 18, 2027	DS		M-14	Oct 18, 2026
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 002	7365205	Apr 18, 2027	DS		M-14	Oct 18, 2026
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 003	7365205	Apr 18, 2027	DS		M-14	Oct 18, 2026
	9149532	Mar 28, 2028	DP			
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	8598185	Apr 28, 2029	DP			
	9018192	Jun 13, 2026	U-1170			
	9018192	Jun 13, 2026	U-750			
	9545414	Jun 13, 2026	DP U-1170			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	9545414	Jun 13, 2026	DP U-750			
EFINACONAZOLE - JUBLIA						
N 203567 001	10105444	Jul 08, 2030	DP			
	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
	10512640	Jan 03, 2028	U-1969			
	10828293	Oct 02, 2034	U-2720			
	10828369	Jan 03, 2028	DP			
	10864274	Oct 02, 2034	U-2720			
	11213519	Jan 03, 2028	U-2720			
	11654139	Oct 02, 2034	U-1969			
	11872218	Jan 03, 2028	U-1969			
	7214506	Feb 22, 2026	U-281			
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
	9302009	Oct 24, 2030	DP			
	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
	9861698	Jul 08, 2030	DP			
	9877955	Jan 03, 2028	U-1969			
EFLORNITHINE HYDROCHLORIDE - IWILFIN						
N 215500 001					NP	Dec 13, 2026
					ODE-462	Dec 13, 2030
ELACESTRANT HYDROCHLORIDE - ORSERDU						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 03, 2036	U-3524			
	10745343	Jan 05, 2038	U-3523			
	11779552	Oct 10, 2034	U-3524			
	11819480	Feb 28, 2037	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
ELACESTRANT HYDROCHLORIDE - ORSERDU						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 03, 2036	U-3524			
	10745343	Jan 05, 2038	U-3523			
	11779552	Oct 10, 2034	U-3524			
	11819480	Feb 28, 2037	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
ELAFIBRANOR - IQIRVO						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELAFIBRANOR - IQIRVO						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			
ELAGOLIX SODIUM - ORILISSA						
N 210450 001	10537572	Sep 01, 2036	U-2735			
	10682351	Sep 01, 2036	U-2850			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	11690854	Apr 19, 2038	U-3653			
	11707464	Mar 14, 2034	U-3672			
	12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
ELAGOLIX SODIUM - ORILISSA						
N 210450 002	11344551	Mar 14, 2034	U-3388			
	11344551	Mar 14, 2034	U-3389			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3654			
	12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
	11459305	Nov 07, 2028	DP U-2842			
	11542239	Jul 23, 2039	DS DP			
	11690845	Aug 27, 2040	U-3655			
	12083227	Aug 20, 2038	DP U-2842			
	7419983	Jul 06, 2029	DS DP			
ELAMIPRETIDE HYDROCHLORIDE - FORZINITY						
N 215244 001	11083771	Feb 28, 2034	U-4277		NCE	Sep 19, 2030
	11083772	Feb 28, 2034	U-4277			
	11771734	Feb 28, 2034	U-4277			
	12268724	Feb 28, 2034	U-4277			
	7576061	Jan 20, 2026	DS DP			
	9687519	Feb 28, 2034	U-4277			
ELBASVIR; GRAZOPREVIR - ZEPATIER						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813			
	8871759	May 04, 2031	DS DP U-1813			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		M-313	Dec 20, 2027
	10022352	Apr 09, 2027	DP U-3156		ODE-275	Oct 21, 2026
	10081621	Mar 25, 2031	DP U-3032		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-357	Jun 08, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10081621	Mar 25, 2031	DP U-4075		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4221			
	12458635	Aug 13, 2029	DP U-4330			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	RE50453	Jul 10, 2031	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE*	Oct 21, 2026
	10081621	Mar 25, 2031	DP U-4075		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-3158		ODE-357	Jun 08, 2028
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4222			
	12458635	Aug 13, 2029	DP U-4330			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	RE50453	Jul 10, 2031	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10081621	Mar 25, 2031	DP U-4065		ODE-433	Apr 26, 2030
	10239867	Apr 09, 2027	DS DP U-3590		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	12458635	Aug 13, 2029	DP U-4333			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	RE50453	Jul 10, 2031	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NP	Apr 26, 2026
	10081621	Mar 25, 2031	DP U-3600		ODE-433	Apr 26, 2030
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	12350262	Jul 17, 2038	U-4220			
	12458635	Aug 13, 2029	DP U-4333			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8623905	May 01, 2027	DS DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	RE50453	Jul 10, 2031	DS DP			
ELIGLUSTAT TARTRATE - CERDELGA						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
	11458119	Nov 24, 2030	DS DP			
	12465586	Jun 05, 2032	U-3042			
	12465586	Jun 05, 2032	U-3043			
	7196205	Jun 26, 2026	DS			
ELINZANETANT - LYNKUET						
N 219469 001	10195205	May 18, 2036	U-3622		NCE	Oct 24, 2030
	10774091	Mar 13, 2039	DP			
	11787820	Mar 13, 2039	U-3622			
	12264164	Mar 13, 2039	U-3622			
	7683056	Sep 15, 2026	DS DP			
ELTROMBOPAG CHOLINE - ALVAIZ						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
ELTROMBOPAG CHOLINE - ALVAIZ						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
ELTROMBOPAG CHOLINE - ALVAIZ						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
ELTROMBOPAG CHOLINE - ALVAIZ						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 002	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
ELUXADOLINE - VIBERZI						
N 206940 001	10188632	Mar 14, 2033	DP			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELUXADOLINE - VIBERZI						
N 206940 001	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	12097187	Mar 14, 2033	U-3475			
	7741356	May 27, 2029	DS DP			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELUXADOLINE - VIBERZI						
N 206940 002	10188632	Mar 14, 2033	DP			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	11484527	Mar 14, 2033	U-3475			
	7741356	May 27, 2029	DS DP			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELVITEGRAVIR - VITEKTA						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
ELVITEGRAVIR - VITEKTA						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-922	Sep 21, 2026
	10258637*PED	Oct 03, 2034			NPP	Jun 20, 2026
	11090323	Apr 03, 2034	U-3191		PED	Dec 20, 2026
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-3691			
	11813275	Apr 03, 2034	U-3759			
	11813275	Apr 03, 2034	U-3760			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034			U-2292	
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034			U-2290	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	10258637	Apr 03, 2034			U-2290	
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034			U-3191	
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	
	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037			U-4224	
	12364700*PED	Dec 08, 2037				
	12433906	Apr 03, 2034			U-4293	
	12433906	Apr 03, 2034			U-4294	
	12433906	Apr 03, 2034			U-4295	
	12433906	Apr 03, 2034			U-4296	
	12433906	Apr 03, 2034			U-4304	
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-1651	
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027			U-1652	Y
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9173859	May 04, 2027	DP		U-1772	Y
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	10258637	Apr 03, 2034			U-2290	
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034			U-3191	
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037			U-4224	
	12364700*PED	Dec 08, 2037				
	12433906	Apr 03, 2034			U-4293	
	12433906	Apr 03, 2034			U-4294	
	12433906	Apr 03, 2034			U-4295	
	12433906	Apr 03, 2034			U-4296	
	12433906	Apr 03, 2034			U-4304	
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-1651	
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027			U-1652	Y
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9173859	May 04, 2027	DP		U-1772	Y
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037			U-4224	
	12364700*PED	Dec 08, 2037				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	9949998	Jun 11, 2034			U-2731	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 002	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037			U-4224	
	12364700*PED	Dec 08, 2037				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-2730	
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 003	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	11090323	Apr 03, 2034			U-3192	
	11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037			U-4224	
	12364700*PED	Dec 08, 2037				
	7579449	Aug 01, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 003	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10258637*PED	Oct 03, 2034				
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	11090323	Apr 03, 2034	U-3192			
	11090323*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-2730			
	8551957*PED	Apr 14, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	10258637	Apr 03, 2034	U-2290		NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	10258637	Apr 03, 2034	U-2290		M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY						
N 208351 001	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N 202123 001	10857102	Jan 14, 2033	DP			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 001	8754065	Aug 15, 2032	DS DP U-1259		M-316	Jun 20, 2028
	8754065	Aug 15, 2032	DS DP U-1663			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 001	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1259			
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 002	8754065	Aug 15, 2032	DS DP U-1663		M-316	Jun 20, 2028
	8754065*PED	Feb 15, 2033			ODE-457	Jan 07, 2029
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				
ENALAPRIL MALEATE - EPANED KIT						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1892			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	9855214	Nov 06, 2032	DP			
	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
ENALAPRIL MALEATE - EPANED						
N 208686 001	10039745	Mar 25, 2036	DP			
	10154987	Mar 25, 2036	U-1723			
	10154987	Mar 25, 2036	U-185			
	10154987	Mar 25, 2036	U-1892			
	10154987	Mar 25, 2036	U-3			
	10154987	Mar 25, 2036	U-71			
	10772868	Mar 25, 2036	DP			
	10786482	Mar 25, 2036	DP			
	11040023	Mar 25, 2036	DP			
	11141405	Mar 25, 2036	DP			
	11173141	Mar 25, 2036	DP			
	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1892			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
ENASIDENIB MESYLATE - IDHIFA						
N 209606 001	10093654	Aug 01, 2034	DS DP U-2087			
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENASIDENIB MESYLATE - IDHIFA						
N 209606 001	9738625	Aug 01, 2034	DS			
ENASIDENIB MESYLATE - IDHIFA						
N 209606 002	10093654	Aug 01, 2034	DS DP U-2087			
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
ENCORAFENIB - BRAFTOVI						
N 210496 001	10005761	Aug 27, 2030	U-2335		I-928	Oct 11, 2026
	8541575	Feb 26, 2030	DS DP U-2335		I-957	Dec 20, 2027
	8946250	Jul 23, 2029	DS DP		ODE-445	Oct 11, 2030
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
ENCORAFENIB - BRAFTOVI						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-928	Oct 11, 2026
	10005761	Aug 27, 2030	U-2802		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2803		ODE-445	Oct 11, 2030
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9387208	Nov 21, 2032	DP			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENCORAFENIB - BRAFTOVI						
N 210496 002	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
	RE49556	Feb 27, 2030	DS DP			
ENSARTINIB HYDROCHLORIDE - ENSACOVE						
N 218171 001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
ENSARTINIB HYDROCHLORIDE - ENSACOVE						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
ENSIFENTRINE - OHTUVAYRE						
N 217389 001	10945950	Sep 15, 2035	DP		NCE	Jun 26, 2029
	12251384	Jun 25, 2044	DP			
	12409180	Feb 20, 2043	DP			
	9062047	Aug 21, 2031	DS U-3962			
	9956171	Sep 15, 2035	DP U-3962			
ENTRECTINIB - ROZLYTREK						
N 212725 001	10231965	Feb 17, 2035	U-2617		NPP	Oct 20, 2026
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745		ODE-448	Oct 20, 2030
	10738037	May 18, 2037	DS DP U-2946			
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			
	8299057	Mar 10, 2032	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
ENTRECTINIB - ROZLYTREK						
N 212725 002	10231965	Feb 17, 2035	U-2617		NPP	Oct 20, 2026
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745		ODE-448	Oct 20, 2030
	10738037	May 18, 2037	DS DP U-2946			
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTRECTINIB - ROZLYTREK						
N 212725 002	8299057	Mar 10, 2032	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
ENTRECTINIB - ROZLYTREK						
N 218550 001					NP	Oct 20, 2026
					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
					ODE-448	Oct 20, 2030
ENZALUTAMIDE - XTANDI						
N 203415 001	12161628	Feb 23, 2037	U-4101		I-926	Nov 17, 2026
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
	9126941	May 15, 2026	U-3763			
ENZALUTAMIDE - XTANDI						
N 213674 001	11839689	Sep 11, 2033	DP		I-926	Nov 17, 2026
	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
	12502357	Sep 11, 2033	U-4363			
	12502357	Sep 11, 2033	U-4364			
	12502357	Sep 11, 2033	U-4365			
	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
	9126941	May 15, 2026	U-3763			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENZALUTAMIDE - XTANDI						
N 213674 002	11839689	Sep 11, 2033	DP		I-926	Nov 17, 2026
	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
	12447128	Sep 11, 2033	U-4312			
	12447128	Sep 11, 2033	U-4313			
	12447128	Sep 11, 2033	U-4314			
	12502357	Sep 11, 2033	U-4363			
	12502357	Sep 11, 2033	U-4364			
	12502357	Sep 11, 2033	U-4365			
	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	8183274	Aug 24, 2026	U-3763			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
	9126941	May 15, 2026	U-3763			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 001					PC	Feb 21, 2026
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 002					PC	Feb 21, 2026
EPHEDRINE SULFATE - EMERPHED						
N 213407 001	11090278	May 16, 2040	U-3183			
	11241400	May 16, 2040	U-3183			
	11464752	May 16, 2040	DP			
	11478436	May 16, 2040	U-3183			
	11571398	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EMERPHED						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
N 213994 001	10869845	Jan 22, 2040	DP			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
N 213994 002	10869845	Jan 22, 2040	DP			
	12029710	Jan 22, 2040	U-3963			
EPINEPHRINE - AUVI-Q						
N 201739 001	11590286	Dec 12, 2026	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	10688244	Dec 21, 2037	DP U-2980			
	10842938	Dec 21, 2037	DP U-2980			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 002	11590286	Dec 12, 2026	DP			
	11771830	Dec 21, 2037	DP		U-2980	
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
EPINEPHRINE - AUVI-Q						
N 201739 003	10688244	Dec 21, 2037	DP		U-2980	
	10842938	Dec 21, 2037	DP		U-2980	
	11590286	Dec 12, 2026	DP			
	11771830	Dec 21, 2037	DP		U-2980	
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
EPINEPHRINE - ADRENALIN						
N 204200 001	12280024	Mar 13, 2035	DP			
	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035			U-1829	
EPINEPHRINE - ADRENALIN						
N 204640 001	10130592	Mar 13, 2035	DP			
	12280024	Mar 13, 2035	DP			
	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035			U-1829	
EPINEPHRINE - PRIMATENE MIST						
N 205920 001	8367734	Jan 26, 2026	DP			
EPINEPHRINE - SYMJEPI						
N 207534 001	11141540	Oct 20, 2036	DP		U-3379	
EPINEPHRINE - SYMJEPI						
N 207534 002	11141540	Oct 20, 2036	DP		U-3379	
EPINEPHRINE - NEFFY						
N 214697 001	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039			U-3979	
	11173209	Feb 06, 2038			U-3979	
	11191838	Feb 06, 2039	DP		U-3979	
	11717571	Feb 06, 2039			U-3979	
	11744895	Feb 06, 2039			U-3979	
	11918655	Feb 06, 2039	DP		U-3979	
	12324838	Feb 06, 2039	DP			
EPINEPHRINE - NEFFY						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039			U-3979	
	11173209	Feb 06, 2038			U-3979	
	11191838	Feb 06, 2039	DP		U-3979	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - NEFFY								
N 214697	002		11717571	Feb 06, 2039	U-3979			
			11744895	Feb 06, 2039	U-3979			
			11918655	Feb 06, 2039	U-3979			
			12324838	Feb 06, 2039	DP			
EPINEPHRINE - ADRENALIN								
N 215875	001		10653646	Mar 21, 2039	DP			
			11083698	Mar 21, 2039	U-3567			
			11207280	Mar 21, 2039	DP			
			12133837	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN								
N 215875	002		10653646	Mar 21, 2039	DP			
			11083698	Mar 21, 2039	U-3567			
			11207280	Mar 21, 2039	DP			
			12133837	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN								
N 215875	003		10653646	Mar 21, 2039	DP			
			11083698	Mar 21, 2039	U-3567			
			11207280	Mar 21, 2039	DP			
			12133837	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN								
N 215875	004		10653646	Mar 21, 2039	DP			
			11083698	Mar 21, 2039	U-3567			
			11207280	Mar 21, 2039	DP			
			12133837	Mar 21, 2039	DP			
EPINEPHRINE - ADRENALIN								
N 215875	005		10653646	Mar 21, 2039	DP			
			11083698	Mar 21, 2039	U-3567			
			11207280	Mar 21, 2039	DP			
			12133837	Mar 21, 2039	DP			
EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)								
N 217388	001		10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
			8101743	Apr 01, 2026	DS DP		ODE-461	Dec 21, 2030
			9127276	May 01, 2034	DS			
			9181549	May 01, 2034	DS			
EPOPROSTENOL SODIUM - VELETRI								
N 022260	001		8318802	Mar 15, 2027	DP			
			8598227	Feb 02, 2027				
EPOPROSTENOL SODIUM - VELETRI								
N 022260	002		8318802	Mar 15, 2027	DP			
			8598227	Feb 02, 2027				
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA								
N 211109	001		10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
			11578044	Oct 19, 2037	DS		GAIN	Aug 27, 2028
			8796245	Aug 07, 2029	U-2380			
			8906887	Dec 28, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 002	10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
	11578044	Oct 19, 2037	DS		GAIN	Aug 27, 2028
	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
ERDAFITINIB - BALVERSA						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031	U-3805			
	9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031	U-3805			
	9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERDAFITINIB - BALVERSA						
N 212018 003	10898482	Feb 09, 2036	DP		U-3807	
	11077106	Feb 02, 2038			U-3196	
	11077106	Feb 02, 2038			U-3808	
	11684620	Feb 09, 2036			U-3805	
	11684620	Feb 09, 2036			U-3806	
	11684620	Feb 09, 2036			U-3807	
	12037644	Oct 18, 2035			U-3972	
	8895601	Apr 12, 2033	DS DP			
	9464071	Apr 28, 2031			U-3805	
	9902714	Mar 26, 2035	DP			
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	RE46965	Jan 08, 2027	DP			
	RE46965*PED	Jul 08, 2027				
ERTUGLIFLOZIN - STEGLATRO						
N 209803 001	8080580	Jul 13, 2030	DS DP		U-2214	
ERTUGLIFLOZIN - STEGLATRO						
N 209803 002	8080580	Jul 13, 2030	DS DP		U-2214	
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 001	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030			U-2214	
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 002	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030			U-2214	
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 003	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030			U-2214	
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 004	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030			U-2214	
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 001	7326708	Nov 24, 2026	DS DP		U-2214	
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030			U-2214	
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 002	7326708	Nov 24, 2026	DS DP		U-2214	
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP		U-2214	
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030			U-2214	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 001					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 002					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 003					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021365 001					NPP	May 12, 2026
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	10912781	Oct 23, 2028	DP			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	10912781	Oct 23, 2028	DP			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032			U-2041	
	9750747	Aug 24, 2032			U-2121	
	9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	10912781	Oct 23, 2028	DP			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032			U-2041	
	9750747	Aug 24, 2032			U-2121	
	9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 004	10912781	Oct 23, 2028	DP			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032			U-2041	
	9750747	Aug 24, 2032			U-2121	
	9763954	Sep 13, 2028			U-2123	
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
N 205703 001	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
N 205703 002	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM						
N 214278 001	10076494	Dec 08, 2036	DP			
	10835488	Dec 08, 2036	DP			
ESTRADIOL - MINIVELLE						
N 203752 001	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028			U-2086	
	9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE						
N 203752 002	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028			U-2086	
	9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE						
N 203752 003	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028			U-2086	
	9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE						
N 203752 004	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028			U-2086	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - MINIVELLE						
N 203752 004	9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE						
N 203752 005	8231906	Jul 04, 2030	DS DP			
	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP		U-2086	
	9833419	Jul 10, 2028	DP			
ESTRADIOL - IMVEXXY						
N 208564 001	10258630	Nov 21, 2032			U-2316	
	10258630	Nov 21, 2032			U-2317	
	10398708	Nov 21, 2032			U-2317	
	10398708	Nov 21, 2032			U-2614	
	10471072	Nov 21, 2032			U-2316	
	10471072	Nov 21, 2032			U-2317	
	10537581	Nov 21, 2032	DP		U-2316	
	10537581	Nov 21, 2032	DP		U-2317	
	10568891	Nov 21, 2032			U-2316	
	10568891	Nov 21, 2032			U-2317	
	10668082	Nov 21, 2032			U-2316	
	10668082	Nov 21, 2032			U-2317	
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032			U-2316	
	10835487	Nov 21, 2032			U-2317	
	10888516	Nov 21, 2032			U-2316	
	10888516	Nov 21, 2032			U-2317	
	11065197	Nov 21, 2032	DP			
	11116717	Nov 21, 2032	DP			
	11123283	Nov 21, 2032	DP			
	11241445	Nov 21, 2032			U-2316	
	11241445	Nov 21, 2032			U-2317	
	11246875	Nov 21, 2032			U-2316	
	11246875	Nov 21, 2032			U-2317	
	11266661	Feb 02, 2034			U-2316	
	11266661	Feb 02, 2034			U-2317	
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032			U-2316	
	11351182	Nov 21, 2032			U-2317	
	9180091	Nov 21, 2032	DP		U-2316	
	9180091	Nov 21, 2032	DP		U-2317	
	9289382	Nov 21, 2032	DP			
ESTRADIOL - IMVEXXY						
N 208564 002	10258630	Nov 21, 2032			U-2316	
	10258630	Nov 21, 2032			U-2317	
	10398708	Nov 21, 2032			U-2317	
	10398708	Nov 21, 2032			U-2614	
	10471072	Nov 21, 2032			U-2316	
	10471072	Nov 21, 2032			U-2317	
	10537581	Nov 21, 2032	DP		U-2316	
	10537581	Nov 21, 2032	DP		U-2317	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY						
N 208564 002	10568891	Nov 21, 2032	U-2316			
	10568891	Nov 21, 2032	U-2317			
	10668082	Nov 21, 2032	U-2316			
	10668082	Nov 21, 2032	U-2317			
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Nov 21, 2032	U-2316			
	10888516	Nov 21, 2032	U-2317			
	11065197	Nov 21, 2032	DP			
	11116717	Nov 21, 2032	DP			
	11123283	Nov 21, 2032	DP			
	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
	9180091	Nov 21, 2032	DP U-2316			
	9180091	Nov 21, 2032	DP U-2317			
	9289382	Nov 21, 2032	DP			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	11033551	Sep 29, 2037	U-3129		M-289	Jan 27, 2026
	11793812	May 03, 2038	U-2360			
	11795178	Sep 27, 2033	DS DP			
	11957684	Sep 29, 2037	U-3129			
	12325714	Sep 27, 2033	DS DP			
	7300935	Jan 28, 2029	DS			
	8058280	Jan 28, 2026	DS DP			
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 001	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
	10806740	Nov 21, 2032	DP U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
	11529360	Nov 21, 2032	DP			
	11793819	Nov 21, 2032	U-2439			
	11865179	Nov 21, 2032	DS DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 001	8846649	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9006222	Nov 21, 2032	DP U-2439			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	11793819	Nov 21, 2032	U-2439			
	11865179	Nov 21, 2032	DS DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214023 001					CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214023 002					CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 001					CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 002					CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 003					CGT	Apr 15, 2026
ETELCALCETIDE - PARSABIV						
N 208325 001	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	11959486	Jun 27, 2034	DP U-2014			
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETELCALCETIDE - PARSABIV						
N 208325 002	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	11959486	Jun 27, 2034	DP		U-2014	
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP		U-2014	
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP		U-2014	
	9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV						
N 208325 003	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	11959486	Jun 27, 2034	DP		U-2014	
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP		U-2014	
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP		U-2014	
	9820938	Jun 27, 2034	DP			
ETEPLIRSEN - EXONDYS 51						
N 206488 001	10337003	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1919	
	9506058	Mar 14, 2034			U-1918	
	9506058	Mar 14, 2034			U-1919	
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028			U-2097	
ETEPLIRSEN - EXONDYS 51						
N 206488 002	10337003	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1918	
	10364431	Mar 14, 2034			U-1919	
	9506058	Mar 14, 2034			U-1918	
	9506058	Mar 14, 2034			U-1919	
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028			U-2097	
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N 021840 001	7855190	Dec 05, 2028			U-1	
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE						
N 022262 001	7855190	Dec 05, 2028			U-1	
ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA						
N 204017 001	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	9050348	Jul 10, 2028	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE						
N 204061 001	8415332	Mar 11, 2029	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA						
N 208612 001	7838042	Jun 01, 2027	DS		U-3251	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE									
N 022501	001		7704984	Feb 02, 2029		U-1090			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE									
N 204654	001		7704984	Feb 02, 2029		U-1			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV									
N 218718	001		12178824	Jun 24, 2041		DP		NP	Jul 22, 2027
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA									
N 209627	001		10632066	Feb 01, 2039		U-2786			
			10632066	Feb 01, 2039		U-2787			
			10765628	Feb 01, 2039		U-2786			
			10765628	Feb 01, 2039		U-2787			
			10780047	Feb 01, 2039		U-2786			
			10780047	Feb 01, 2039		U-2787			
			10918649	Jun 21, 2039		DP			
			10925882	Jun 21, 2039		DP			
			10940157	Jun 21, 2039		DP			
			11529308	Jun 21, 2039		DP			
			11850251	Jun 21, 2039		U-3785			
			12303518	Jun 21, 2039		DP			
ETONOGESTREL - IMPLANON									
N 021529	001		9757552	Jul 28, 2030		DP U-1			
ETONOGESTREL - NEXPLANON									
N 021529	002		10821277	May 31, 2027		DP			
			8722037	Sep 28, 2027		DP			
			8888745	Aug 28, 2026		DP			
			9757552	Jul 28, 2030		DP U-1			
ETRASIMOD ARGININE - VELSIPITY									
N 216956	001		10301262	Jun 21, 2036	DS	DP		NCE	Oct 12, 2028
			10676435	Jun 21, 2036		U-3731			
			11007175	Jan 06, 2036		U-3730			
			11091435	Jun 21, 2036	DS	DP			
			11884626	Jun 21, 2036		U-3731			
			12156866	Jan 06, 2036		U-4047			
			12377071	Jan 06, 2036		U-4255			
			8580841	Mar 05, 2030	DS	DP			
			9126932	Jul 22, 2029		U-3732			
ETRIPAMIL - CARDAMYST									
N 218571	001							NCE	Dec 12, 2030
EVEROLIMUS - AFINITOR									
N 022334	001		8410131	Nov 01, 2025		U-1368			
			8410131*PED	May 01, 2026					
			9006224	Jul 01, 2028		U-1681			
EVEROLIMUS - AFINITOR									
N 022334	002		8410131	Nov 01, 2025		U-1368			
			8410131*PED	May 01, 2026					
			9006224	Jul 01, 2028		U-1681			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N 022334 003	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 004	8410131	Nov 01, 2025	U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588			
	6515117*PED	Apr 04, 2026				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588			
	6515117*PED	Apr 04, 2026				
	8329648	Aug 18, 2026	U-2588			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON BCISE						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588			
	6515117*PED	Apr 04, 2026				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON BCISE								
N 209210	001		8501698	Jun 20, 2027	U-2588			
			8501698*PED	Dec 20, 2027				
			8895033	Oct 04, 2030	DP U-2589			
			8895033	Oct 04, 2030	DP U-2590			
			8895033	Oct 04, 2030	DP U-2597			
			8895033	Oct 04, 2030	DP U-2601			
			8895033	Oct 04, 2030	DP U-2602			
			8895033	Oct 04, 2030	DP U-3188			
			8895033	Oct 04, 2030	DP U-3189			
			8895033	Oct 04, 2030	DP U-3190			
			8895033*PED	Apr 04, 2031				
			8906851	Aug 18, 2026	U-2588			
			8906851	Aug 18, 2026	U-2589			
			8906851	Aug 18, 2026	U-2590			
			8906851	Aug 18, 2026	U-2593			
			8906851	Aug 18, 2026	U-2597			
			8906851	Aug 18, 2026	U-3188			
			8906851	Aug 18, 2026	U-3189			
			8906851	Aug 18, 2026	U-3190			
			8906851*PED	Feb 18, 2027				
			9884092	Aug 18, 2026	U-2588			
			9884092	Aug 18, 2026	U-2589			
			9884092	Aug 18, 2026	U-2590			
			9884092	Aug 18, 2026	U-2593			
			9884092	Aug 18, 2026	U-2594			
			9884092	Aug 18, 2026	U-2595			
			9884092	Aug 18, 2026	U-2596			
			9884092	Aug 18, 2026	U-2597			
			9884092	Aug 18, 2026	U-3188			
			9884092	Aug 18, 2026	U-3189			
			9884092	Aug 18, 2026	U-3190			
			9884092*PED	Feb 18, 2027				
EZETIMIBE - ZETIA								
N 021445	001		7612058	Oct 30, 2025	U-1027			
			7612058	Oct 30, 2025	U-1173			
			7612058*PED	Apr 30, 2026				
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET								
N 213072	001		10376470	May 01, 2033	DP U-3095			
			9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET								
N 213072	002		10376470	May 01, 2033	DP U-3095			
			9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET								
N 213072	003		10376470	May 01, 2033	DP U-3095			
			9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET								
N 213072	004		10376470	May 01, 2033	DP U-3095			
			9763885	May 01, 2033	DP U-3095			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET							
N 213072	004	10376470	May 01, 2033	DP U-3095			
		9763885	May 01, 2033	DP U-3095			
FAMOTIDINE; IBUPROFEN - DUEXIS							
N 022519	001	8067451	Jul 18, 2026	DP U-1196			
		8309127	Jul 18, 2026	DP			
		8318202	Jul 18, 2026	DP			
		8449910	Jul 18, 2026	DP			
		8501228	Jul 18, 2026	U-1196			
FEBUXOSTAT - ULORIC							
N 021856	001	8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEBUXOSTAT - ULORIC							
N 021856	002	8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEDRATINIB HYDROCHLORIDE - INREBIC							
N 212327	001	10391094	Jun 04, 2032	DP U-2607		ODE-259	Aug 16, 2026
		11400092	Sep 24, 2039	U-3409			
		7528143	Nov 16, 2031	DS DP			
		7825246	Dec 16, 2026	DS			
		8138199	Jun 30, 2028	U-2607			
FENFLURAMINE HYDROCHLORIDE - FINTEPLA							
N 212102	001	10452815	Jun 29, 2038	U-2859	Y	ODE-312	Jun 25, 2027
		10452815*PED	Dec 29, 2038			ODE-393	Mar 25, 2029
		10478441	May 03, 2033	U-2860		PED	Dec 25, 2027
		10478441*PED	Nov 03, 2033			PED	Sep 25, 2029
		10478442	May 03, 2033	U-2860			
		10478442*PED	Nov 03, 2033				
		10603290	Aug 02, 2037	U-2861			
		10603290	Aug 02, 2037	U-3347			
		10603290*PED	Feb 02, 2038				
		10947183	Dec 20, 2036	DS DP			
		10947183*PED	Jun 20, 2037				
		11040018	Aug 02, 2037	U-2861			
		11040018	Aug 02, 2037	U-3347			
		11040018*PED	Feb 02, 2038				
		11406606	Aug 02, 2037	U-3406			
		11406606	Aug 02, 2037	U-3407			
		11406606*PED	Feb 02, 2038				
		11759440	Aug 02, 2037	U-3694			
		11759440*PED	Feb 02, 2038				
		11786487	Aug 02, 2037	U-3733			
		11786487*PED	Feb 02, 2038				
		12097206	May 03, 2033	U-4013			
		12097206*PED	Nov 03, 2033				
		9549909	May 03, 2033	U-2858			
		9549909*PED	Nov 03, 2033				
		9603814	May 03, 2033	U-2858			
		9603814*PED	Nov 03, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENFLURAMINE HYDROCHLORIDE - FINTEPLA						
N 212102 001	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
FENOFIBRIC ACID - FIBRICOR						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENOFIBRIC ACID - FIBRICOR						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENTANYL - SUBSYS						
N 202788 001	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 002	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 003	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 004	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 005	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 006	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 007	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA						
N 021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N 021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N 021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N 021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N 021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - ONSOLIS						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - LAZANDA						
N 022569 001	9731869	Jan 26, 2032	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 002	9731869	Jan 26, 2032	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 003	9731869	Jan 26, 2032	DP			
FENTANYL HYDROCHLORIDE - IONSYS						
N 021338 001	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
	9731121	Oct 17, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2026	DS DP			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2026	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2026	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	11364260	Jan 08, 2027	U-3637		I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2026	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CITRATE - AURYXIA						
N 205874 001	10300039	Jul 21, 2030	U-2549			
	8093423	Apr 21, 2026	U-1577			
	9387191	Jul 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CITRATE - AURYXIA						
N 205874 001	10300039	Jul 21, 2030	U-2549			
	8093423	Apr 21, 2026	U-1577			
	9387191	Jul 21, 2030	DP			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 002	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 003	10414831	Mar 25, 2029	DS DP			
	11633489	Jun 22, 2036	U-3594			
	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC MALTOL - ACCRUFER						
N 212320 001	10179120	Jan 06, 2035	U-2603		NPP	Dec 19, 2028
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	10624855	Nov 26, 2034	DP		NPP	Jul 01, 2027
	10624855*PED	May 26, 2035			PED	Jan 01, 2028
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	11234938	Nov 26, 2034	DP			
	11234938*PED	May 26, 2035				
	11446252	Nov 26, 2034	DP			
	11446252*PED	May 26, 2035				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	10624855	Nov 26, 2034	DP		NPP	Jul 01, 2027
	10624855*PED	May 26, 2035			PED	Jan 01, 2028
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	11234938	Nov 26, 2034	DP			
	11234938*PED	May 26, 2035				
	11446252	Nov 26, 2034	DP			
	11446252*PED	May 26, 2035				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	7816404	Apr 17, 2029	DP U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
FERUMOXYTOL - FERABRIGHT						
N 219868 001					NP	Oct 16, 2028
FERUMOXYTOL - FERABRIGHT						
N 219868 002					NP	Oct 16, 2028
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 001	7807715	Jun 07, 2027	DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 002	7807715	Jun 07, 2027	DP U-913			
	8088398	Jun 07, 2027	DP U-913			
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
FEXINIDAZOLE - FEXINIDAZOLE						
N 214429 001					NCE	Jul 16, 2026
					ODE-359	Jul 16, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY								
N 201373	001		8933097	Aug 02, 2030	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES								
N 201373	002		8933097	Aug 02, 2030	DP			
FEZOLINETANT - VEOZAH								
N 216578	001		10836768	Mar 28, 2034	U-3622		NCE	May 12, 2028
			8871761	Apr 04, 2031	DS			
			9422299	Mar 28, 2034	DS DP U-3622			
			9987274	Mar 28, 2034	U-3622			
FIDAXOMICIN - DIFICID								
N 201699	001		7378508	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
			7863249	Jul 31, 2027	DS DP			
			7906489	Mar 04, 2027	U-2741			
			7906489	Mar 04, 2027	U-319			
			7906489*PED	Sep 04, 2027				
			8859510	Jul 31, 2027	U-2741			
			8859510	Jul 31, 2027	U-319			
			8859510*PED	Jan 31, 2028				
FIDAXOMICIN - DIFICID								
N 213138	001		7378508	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
			7378508*PED	Jan 31, 2028				
			7863249	Jul 31, 2027	DP			
			7863249*PED	Jan 31, 2028				
			7906489	Mar 04, 2027	U-2741			
			7906489*PED	Sep 04, 2027				
			8859510	Jul 31, 2027	U-2741			
			8859510*PED	Jan 31, 2028				
			9808530	May 28, 2034	DP			
			9808530*PED	Nov 28, 2034				
FINAFLOXACIN - XTORO								
N 206307	001		8536167	Aug 08, 2031	U-1679			
			9119859	Jul 02, 2030	U-1679			
			9504691	Nov 21, 2033	DP U-1679			
			9993483	Jul 02, 2030	DP			
FINERENONE - KERENDIA								
N 215341	001		8436180	Apr 12, 2029	DS DP		I-970	Jul 11, 2028
			RE49826	Jul 29, 2035	DS		NCE	Jul 09, 2026
FINERENONE - KERENDIA								
N 215341	002		8436180	Apr 12, 2029	DS DP		I-970	Jul 11, 2028
			RE49826	Jul 29, 2035	DS		NCE	Jul 09, 2026
FINERENONE - KERENDIA								
N 215341	003		8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
			RE49826	Jul 29, 2035	DS		NS	Jul 11, 2028
FINGOLIMOD HYDROCHLORIDE - GILENYA								
N 022527	001		10543179	Dec 25, 2027	U-2719			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINGOLIMOD HYDROCHLORIDE - GILENYA						
N 022527 002	9592208	Mar 30, 2032	DP U-2315			
	9592208*PED	Sep 30, 2032				
FINGOLIMOD LAURYL SULFATE - TASCENSO ODT						
N 214962 001	10555902	Jan 19, 2036	U-3268			
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
FINGOLIMOD LAURYL SULFATE - TASCENSO ODT						
N 214962 002	10555902	Jan 19, 2036	U-3493			
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 001	9566260	Jul 30, 2026	DP U-2366			
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 002	9566260	Jul 30, 2026	DP U-2366			
FITUSIRAN SODIUM - QFITLIA						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FITUSIRAN SODIUM - QFITLIA						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FLIBANSERIN - ADDYI						
N 022526 001	7151103	May 09, 2028	U-1734			
FLORBETABEN F-18 - NEURACEQ						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497			
	9308284	Jul 14, 2032	DP			
FLORBETAPIR F-18 - AMYVID						
N 202008 001	7687052	Apr 30, 2027	DS DP U-4217			
	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID						
N 202008 002	7687052	Apr 30, 2027	DS DP U-4217			
	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID						
N 202008 003	7687052	Apr 30, 2027	DS DP U-4217			
	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID						
N 202008 004	7687052	Apr 30, 2027	DS DP U-4217			
	8506929	Apr 30, 2027	DS DP U-4217			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 001	8932557	May 26, 2032	DS			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 002	8932557	May 26, 2032	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLORTAUCIPIR F-18 - TAUVID						
N 212123 003	8932557	May 26, 2032	DS			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 004	8932557	May 26, 2032	DS			
FLOTUFOLASTAT F-18 GALLIUM - POSLUMA						
N 216023 001	11413360	Nov 22, 2038	DS U-3614		NCE	May 25, 2028
	11413360	Nov 22, 2038	DS U-3615			
	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			
	12357711	Nov 22, 2038	DS			
	12377176	Nov 22, 2038	DS			
	12390540	Aug 23, 2038	DS			
	12427207	Nov 27, 2041	DP			
FLUCICLOVINE F-18 - AXUMIN						
N 208054 001	10010632	Nov 28, 2026	DP			
	10124079	Dec 30, 2035	U-2450			
	10716868	Dec 30, 2035	U-2450			
	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
	11980674	Apr 23, 2042	U-2450			
	9387266	Nov 28, 2026	U-1879			
FLUOCINOLONE ACETONIDE - ILUVIEN						
N 201923 001	8871241	Aug 12, 2027	DP			
	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
FLUOCINOLONE ACETONIDE - YUTIQ						
N 210331 001	7998108	Jan 12, 2028	DP U-3410			
	8871241	Aug 12, 2027	DP			
FLURPIRIDAZ F-18 - FLYRCADO						
N 215168 001	7344702	May 26, 2026	DS		NCE	Sep 27, 2029
	8226929	Jun 21, 2028	U-4011			
	8936777	Jun 30, 2031	U-4011			
	9161997	Feb 04, 2026	DS DP U-4011			
	9603951	May 02, 2031	U-4011			
	9687571	Nov 01, 2032	DP U-4011			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 001	8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 002	8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF						
N 022051 002	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 003					M-290	Mar 01, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA								
N 209482	001	11090294	Nov 29, 2030		U-3202			
		12396986	Nov 29, 2030		DP			
		7488827	Dec 18, 2027	DS	DP			
		8534281	Mar 08, 2030		DP			
		8534281*PED	Sep 08, 2030					
		8746242	Oct 11, 2030		DP			
		8746242*PED	Apr 11, 2031					
		9750726	Nov 29, 2030		DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA								
N 209482	002	12396986	Nov 29, 2030		DP			
		7488827	Dec 18, 2027	DS	DP			
		8534281	Mar 08, 2030		DP			
		8534281*PED	Sep 08, 2030					
		8746242	Oct 11, 2030		DP			
		8746242*PED	Apr 11, 2031					
		9750726	Nov 29, 2030		DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	001	11116721	Feb 26, 2029		DP U-1401		NPP	May 13, 2026
		11116721	Feb 26, 2029		DP U-1691		PED	Nov 13, 2026
		11116721	Feb 26, 2029		DP U-3623			
		11116721*PED	Aug 26, 2029					
		8511304	Jun 14, 2027		DP U-1424			
		8511304	Jun 14, 2027		DP U-1691			
		8511304	Jun 14, 2027		DP U-3623			
		8511304*PED	Dec 14, 2027					
		8534281	Mar 08, 2030		DP			
		8534281*PED	Sep 08, 2030					
		8746242	Oct 11, 2030		DP			
		8746242*PED	Apr 11, 2031					
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	002	11116721	Feb 26, 2029		DP U-1691			
		11116721	Feb 26, 2029		DP U-3623			
		11116721*PED	Aug 26, 2029					
		8511304	Jun 14, 2027		DP U-1691			
		8511304	Jun 14, 2027		DP U-3623			
		8511304*PED	Dec 14, 2027					
		8534281	Mar 08, 2030		DP			
		8534281*PED	Sep 08, 2030					
		8746242	Oct 11, 2030		DP			
		8746242*PED	Apr 11, 2031					
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	003	11116721	Feb 26, 2029		DP U-3623		NS	May 13, 2026
		11116721*PED	Aug 26, 2029				PED	Nov 13, 2026
		8511304	Jun 14, 2027		DP U-3623			
		8511304*PED	Dec 14, 2027					
		8534281	Mar 08, 2030		DP			
		8534281*PED	Sep 08, 2030					
		8746242	Oct 11, 2030		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	003		8746242*PED	Apr 11, 2031				
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	001		7500444	Feb 26, 2026	DP	Y		
			7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE - FLOVENT HFA								
N 021433	002		7500444	Feb 26, 2026	DP	Y		
			7500444*PED	Aug 26, 2026				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	001		10195375	Feb 14, 2031	DP			
			10195375*PED	Aug 14, 2031				
			11969544	Aug 20, 2039	DP			
			11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	002		10195375	Feb 14, 2031	DP			
			10195375*PED	Aug 14, 2031				
			11969544	Aug 20, 2039	DP			
			11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK								
N 208798	003		10195375	Feb 14, 2031	DP			
			10195375*PED	Aug 14, 2031				
			11969544	Aug 20, 2039	DP			
			11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER								
N 208798	004		10195375	Feb 14, 2031	DP			
			10195375*PED	Aug 14, 2031				
			10918816	Dec 14, 2035	DP			
			10918816*PED	Jun 14, 2036				
			11173259	Jul 06, 2040	DP			
			11173259*PED	Jan 06, 2041				
			11344685	Sep 26, 2039	DP			
			11344685*PED	Mar 26, 2040				
			11969544	Aug 20, 2039	DP			
			11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER								
N 208798	005		10195375	Feb 14, 2031	DP			
			10195375*PED	Aug 14, 2031				
			10918816	Dec 14, 2035	DP			
			10918816*PED	Jun 14, 2036				
			11173259	Jul 06, 2040	DP			
			11173259*PED	Jan 06, 2041				
			11344685	Sep 26, 2039	DP			
			11344685*PED	Mar 26, 2040				
			11969544	Aug 20, 2039	DP			
			11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER								
N 208798	006		10195375	Feb 14, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	10195375*PED	Aug 14, 2031				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 007	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 008	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
FLUTICASONE PROPIONATE - XHANCE						
N 209022 001	11554229	Feb 23, 2036	U-2133		I-940	Mar 15, 2027
	12083270	Apr 04, 2031	U-2133			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 001	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 002	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
FOMEPIZOLE - ANTIZOL						
N 020696 001	7553863	Jun 30, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE								
N 208294	001		10716753	May 28, 2030	DP U-2889			
			8324266	May 28, 2030	U-2889			
			8703806	May 28, 2030	U-2889			
			8808713	May 28, 2030	DP U-2889			
			8815258	Mar 17, 2031	U-2889			
			9415009	May 28, 2030	U-2889			
			9463161	May 28, 2030	DP U-2889			
FOSAPREPITANT DIMEGLUMINE - FOCINVEZ								
N 216686	001		11065265	Jan 11, 2039	DP			
			12042504	Jan 11, 2039	DP			
FOSCARBIDOPA; FOSLEVODOPA - VYALEV								
N 216962	001		10174061	Oct 21, 2035	DP U-4030		NP	Oct 16, 2027
			10730895	Oct 21, 2035	DS			
			12251365	Jun 10, 2040	U-4030			
			9446059	Oct 21, 2035	DS DP U-4030			
FOSDENOPTERIN HYDROBROMIDE - NULIBRY								
N 214018	001		7504095	Apr 09, 2029	DP U-3092		NCE	Feb 26, 2026
							ODE-342	Feb 26, 2028
FOSFOMYCIN DISODIUM - CONTEPO								
N 212271	001		10086006	Oct 12, 2034	U-4332			
			11541064	Jan 30, 2039	U-4331			
			9345717	Oct 27, 2034	U-4332			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO								
N 210493	001		10208073	May 23, 2032	U-2301			
			10624911	Jun 02, 2037	DP			
			10717721	May 23, 2032	DS			
			10828297	Dec 17, 2030	U-2301			
			11312698	May 23, 2032	DS DP			
			11529362	Jun 02, 2037	DP			
			12208109	Jun 02, 2037	DP			
			8426450	May 23, 2032	DS DP			
			8895586	May 23, 2032	U-2301			
			9186357	Nov 18, 2030	U-2301			
			9403772	May 23, 2032	DS U-2301			
			9908907	May 23, 2032	DS DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO								
N 210493	002		10208073	May 23, 2032	U-2301			
			10624911	Jun 02, 2037	DP			
			10717721	May 23, 2032	DS			
			10828297	Dec 17, 2030	U-2301			
			11312698	May 23, 2032	DS DP			
			11529362	Jun 02, 2037	DP			
			12208109	Jun 02, 2037	DP			
			8426450	May 23, 2032	DS DP			
			8895586	May 23, 2032	U-2301			
			9186357	Nov 18, 2030	U-2301			
			9403772	May 23, 2032	DS U-2301			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO								
N	210493	002	9908907	May 23, 2032	DS DP			
FOSPHENYTOIN SODIUM - SESQUIENT								
N	210864	001	7635773	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
FOSPHENYTOIN SODIUM - SESQUIENT								
N	210864	002	7635773	Mar 13, 2029	DP			
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
FOSTAMATINIB DISODIUM - TAVALISSE								
N	209299	001	7449458	Sep 04, 2031	DS			
			7538108	Mar 28, 2026	DS		U-2294	
			7989448	Jun 12, 2026	DS		U-2294	
			8163902	Jun 17, 2026	DS		U-2294	
			8211889	Jan 19, 2026	DS			
			8263122	Nov 24, 2030	DP			
			8445485	Jun 17, 2026	DP			
			8652492	Nov 06, 2028	DP			
			8771648	Jul 27, 2032	DP			
			8912170	Jun 17, 2026			U-2294	
			8951504	Jul 27, 2032			U-2294	
			9266912	Jan 19, 2026			U-2294	
			9283238	Jun 17, 2026			U-2294	
			RE48898	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE								
N	209299	002	7449458	Sep 04, 2031	DS			
			7538108	Mar 28, 2026	DS		U-2294	
			7989448	Jun 12, 2026	DS		U-2294	
			8163902	Jun 17, 2026	DS		U-2294	
			8211889	Jan 19, 2026	DS			
			8263122	Nov 24, 2030	DP			
			8445485	Jun 17, 2026	DP			
			8652492	Nov 06, 2028	DP			
			8771648	Jul 27, 2032	DP			
			8912170	Jun 17, 2026			U-2294	
			8951504	Jul 27, 2032			U-2294	
			9266912	Jan 19, 2026			U-2294	
			9283238	Jun 17, 2026			U-2294	
			RE48898	Jan 19, 2026	DP			
FOSTEMSAVIR TROMETHAMINE - RUKOBIA								
N	212950	001	7745625	Nov 19, 2027	DS			
			8168615	Jul 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FRUQUINTINIB - FRUZAQLA						
N 217564 001	10519142	Sep 07, 2035	DS DP U-3753		NCE	Nov 08, 2028
	11046674	Sep 07, 2035	U-3753			
	7829574	Mar 23, 2032	DS DP			
	8212033	May 09, 2028	U-3753			
FRUQUINTINIB - FRUZAQLA						
N 217564 002	10519142	Sep 07, 2035	DS DP U-3753		NCE	Nov 08, 2028
	11046674	Sep 07, 2035	U-3753			
	7829574	Mar 23, 2032	DS DP			
	8212033	May 09, 2028	U-3753			
FULVESTRANT - FULVESTRANT						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
FUROSEMIDE - FUROSCIX						
N 209988 001	10272064	Apr 03, 2034	DP			
	11433044	Apr 03, 2034	U-3462			
	12370168	Apr 03, 2034	DP U-3462			
	9884039	Apr 03, 2034	U-3462			
FUTIBATINIB - LYTGOBI						
N 214801 001	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	11833151	Nov 05, 2039	DP		ODE-410	Sep 30, 2029
	9108973	Feb 13, 2033	DS DP U-3456			
FUTIBATINIB - LYTGOBI						
N 214801 002	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	11833151	Nov 05, 2039	DP		ODE*	Sep 30, 2029
	9108973	Feb 13, 2033	DS DP U-3456			
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 001	8026279	Nov 10, 2026	DS DP			
	8114909	Apr 11, 2026	U-1231			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002	8026279	Nov 10, 2026	DS DP			
	8114909	Apr 11, 2026	U-1231			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GADOPICLENOL - ELUCIREM						
N 216986 001	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 002	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOPICLENOL - ELUCIREM						
N 216986 003	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 004	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 005	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 006	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GADOPICLENOL - ELUCIREM						
N 216986 007	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	11590246	Jan 17, 2040	DP			
	8114863	Sep 19, 2028	DS			
GALLIUM DOTATATE GA-68 - NETSPOT						
N 208547 001	9375498	Aug 10, 2032	DP			
GALLIUM GA-68 EDOTREOTIDE - GALLIUM GA 68 EDOTREOTIDE						
N 210828 001					ODE-383	Aug 21, 2026
					W	Aug 21, 2026
GALLIUM GA-68 GOZETOTIDE - ILLUCCIX						
N 214032 001	11027031	Jul 28, 2035	U-3317			
GALLIUM GA-68 GOZETOTIDE - LOCAMETZ						
N 215841 001	11369590	Aug 15, 2028	DS DP U-3400			
	12109277	Mar 09, 2036	U-4002			
GALLIUM GA-68 GOZETOTIDE - GOZELLIX						
N 219592 001	11027031	Jul 28, 2035	U-3317			
GANAXOLONE - ZTALMY						
N 215904 001	10603308	Aug 10, 2037	U-3374		D-197	Oct 16, 2028
	12115169	Sep 30, 2042	U-3374		NCE	Jun 01, 2027
	12144801	Aug 10, 2037	U-4034		ODE-395	Jun 01, 2029
	12268696	Sep 30, 2042	U-3374			
	7858609	Nov 28, 2026	DP			
	8022054	Nov 28, 2026	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026	U-3374			
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026	U-3374			
GANCICLOVIR - GANZYK-RTU						
N 209347 001	9486530	Sep 02, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 001	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 002	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 003	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 004	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 005	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 006	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 007	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 008	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 009	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 010	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INLEXZO						
N 219683 001	10729823	Aug 19, 2034	DP		NP	Sep 09, 2028
	12403086	Jun 28, 2030	DP			
	12447241	Aug 19, 2034	DP			
	8679094	Apr 15, 2032	DP			
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 001	7538116	Sep 02, 2030	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 002	7538116	Sep 02, 2030	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 003	7538116	Sep 02, 2030	U-3699		NCE	Sep 22, 2028
GEPIRONE HYDROCHLORIDE - EXXUA						
N 021164 004	7538116	Sep 02, 2030	U-3699		NCE	Sep 22, 2028
GEPOTIDACIN MESYLATE - BLUJEPA						
N 218230 001	10702521	Aug 20, 2035	U-4361		I-978	Dec 11, 2028
	11229646	Aug 20, 2035	U-4361		NCE	Mar 25, 2030
	8389524	Feb 12, 2029	DS DP U-4166		GAIN	Mar 25, 2035
GILTERITINIB FUMARATE - XOSPATA						
N 211349 001	10786500	Jul 01, 2036	DP			
	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GILTERITINIB FUMARATE - XOSPATA						
N 211349 001	9487491	Jul 28, 2030	U-2456			
GIVINOSTAT HYDROCHLORIDE - DUVYZAT						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2026	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			
GIVOSIRAN SODIUM - GIVLAARI						
N 212194 001	10119143	Oct 03, 2034	DS DP U-2672		ODE-273	Nov 20, 2026
	10125364	Mar 15, 2033	DS DP U-2672			
	10131907	Aug 24, 2028	DS DP U-2672			
	11028392	Oct 03, 2034	DS DP U-2672			
	8106022	Dec 12, 2029	DS DP U-2672			
	8828956	Dec 04, 2028	DS DP U-2672			
	9133461	Nov 30, 2033	DS DP U-2672			
	9631193	Mar 15, 2033	U-2672			
GLASDEGIB MALEATE - DAURISMO						
N 210656 001	10414748	Apr 13, 2036	DS DP			
	11168066	Apr 13, 2036	U-3254			
	11891372	Apr 13, 2036	U-3254			
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLASDEGIB MALEATE - DAURISMO						
N 210656 002	10414748	Apr 13, 2036	DS DP			
	11168066	Apr 13, 2036	U-3254			
	11891372	Apr 13, 2036	U-3254			
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 209394 001	10028937	Jun 10, 2030	U-2141		I-967	Jun 10, 2028
	10028937	Jun 10, 2030	U-3237		ODE-232	Apr 30, 2026
	10028937	Jun 10, 2030	U-4206		ODE-233	Apr 30, 2026
	10028937*PED	Dec 10, 2030			ODE-372	Jun 10, 2028
	10039754	Jun 10, 2030	U-2141		PED	Oct 30, 2026
	10039754	Jun 10, 2030	U-3237		PED	Oct 30, 2026
	10039754	Jun 10, 2030	U-4206		PED	Dec 10, 2028
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3237			
	10286029	Mar 14, 2034	U-4206			
	10286029*PED	Sep 14, 2034				
	11246866	Jun 24, 2036	DP			
	11246866*PED	Dec 24, 2036				
	11484534	Mar 14, 2034	U-3237			
	11484534	Mar 14, 2034	U-4206			
	11484534*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-3237			
	8648037	Jan 19, 2032	DS DP U-4206			
	8648037*PED	Jul 19, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 209394 001	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-2141			
	9586978	Nov 06, 2030	U-3237			
	9586978	Nov 06, 2030	U-4206			
	9586978*PED	May 06, 2031				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 215110 001	10028937	Jun 10, 2030	U-3238		I-967	Jun 10, 2028
	10028937	Jun 10, 2030	U-4206		ODE-372	Jun 10, 2028
	10028937*PED	Dec 10, 2030			PED	Dec 10, 2028
	10039754	Jun 10, 2030	U-3238			
	10039754	Jun 10, 2030	U-4206			
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3238			
	10286029	Mar 14, 2034	U-4206			
	10286029*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-3238			
	8648037	Jan 19, 2032	DS DP U-4206			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-3238			
	9586978	Nov 06, 2030	U-4206			
	9586978*PED	May 06, 2031				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 001	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 002	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLUCAGON - GLUCAGON						
A 218813 001					CGT	Apr 18, 2026
GLUCAGON - BAQSIMI						
N 210134 001	10213487	Feb 16, 2036	DP U-2604			
	10765602	Sep 23, 2039	DP			
	12370241	Feb 16, 2036	DP U-2604			
GLUCAGON - GVOKE PFS						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
	9649364	Apr 22, 2036	DP U-2742			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLUCAGON - GVOKE PFS						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE KIT						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
GLYCEROL PHENYLBUTYRATE - GLYCEROL PHENYLBUTYRATE						
A 205742 001					PC	Apr 15, 2026
GLYCEROL PHENYLBUTYRATE - RAVICTI						
N 203284 001	10045958	Sep 22, 2030	U-1816			
	10045959	Sep 22, 2030	U-1816			
	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
	10668040	Sep 22, 2030	U-1816			
	8404215	Mar 09, 2032	U-1383	Y		
	8642012	Sep 22, 2030	U-1383			
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
	9561197	Sep 22, 2030	U-1383			
	9962359	Sep 22, 2030	U-1816			
	9999608	Sep 22, 2030	U-1816			
GLYCOPYRROLATE - SEEBRI NEOHALER						
N 207923 001	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			
GLYCOPYRROLATE - LONHALA MAGNAIR KIT						
N 208437 001	10376661	Sep 14, 2035	DP			
	10688518	Nov 12, 2036	DP			
	10744277	Dec 07, 2036	DP U-2941			
	10940110	Feb 26, 2029	DP U-1773			
	11278683	Aug 16, 2026	DP			
	9168556	Sep 01, 2032	DP			
	9265900	Dec 07, 2028	DP			
	9604018	May 16, 2033	DP			
	9789270	Oct 30, 2030	DP			
GLYCOPYRROLATE; INDACATEROL MALEATE - UTIBRON NEOHALER						
N 207930 001	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO								
N 216903	001		10456354	Oct 25, 2038	DP			
			11110054	Oct 25, 2038	DP			
			11938217	Oct 25, 2038	DP			
			12151020	Oct 25, 2038	DP			
			12383491	Oct 25, 2038	DP			
GLYCOPYRRONIUM TOSYLATE - QBREXZA								
N 210361	001		10004717	Feb 28, 2033	DP U-2398			
			10052267	Oct 17, 2028	DP U-2398			
			10543192	Feb 28, 2033	DP			
			10548875	Feb 28, 2033	DS DP U-2398			
			8618160	Dec 10, 2029	DP U-2398			
			8859610	Feb 28, 2033	DP U-2398			
			9259414	Feb 28, 2033	U-2398			
			9744105	Jul 18, 2030	DP U-2398			
GOLODIRSEN - VYONDYS 53								
N 211970	001		RE47691	Jun 28, 2028	DP		ODE-280	Dec 12, 2026
GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON								
N 205474	001		10105324	Nov 13, 2035	DS DP U-2023			
			9549907	Nov 13, 2035	DS DP U-2023			
			9808431	Nov 13, 2035	DS DP U-2023			
HALOBETASOL PROPIONATE - ULTRAVATE								
N 208183	001		8962028	Jun 19, 2033	DP U-1775			
HALOBETASOL PROPIONATE - BRYHALI								
N 209355	001		10478502	Nov 02, 2031	DP U-2625			
			11839656	Nov 02, 2031	U-2625			
			11957753	Nov 02, 2031	DP			
			11986527	Nov 02, 2031	U-2625			
			12076403	Nov 02, 2031	DP			
			8809307	Nov 02, 2031	DP			
HALOBETASOL PROPIONATE - LEXETTE								
N 210566	001		10857159	Nov 30, 2036	DP			
			10857159*PED	May 30, 2037				
			11020407	Nov 30, 2036	DP U-3143			
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII								
N 209354	001		10251895	Jun 06, 2036	DP			
			10426787	Jun 06, 2036	U-2625			
			10478502	Nov 02, 2031	DP U-2625			
			11648256	Jun 06, 2036	DP U-2625			
			11679115	Jun 06, 2036	DP U-2625			
			11839656	Nov 02, 2031	U-2625			
			11957753	Nov 02, 2031	DP			
			11986527	Nov 02, 2031	U-2625			
			12076403	Nov 02, 2031	DP			
			8809307	Nov 02, 2031	DP			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH								
N 214520	001		11738120	Apr 15, 2042	DS DP		NCE	Nov 15, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH						
N 214520 001	7696182	May 16, 2026	DS DP U-3774		GAIN	Nov 15, 2033
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH						
N 214520 002	11738120	Apr 15, 2042	DS DP		NCE	Nov 15, 2028
	7696182	May 16, 2026	DS DP U-3774		GAIN	Nov 15, 2033
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT						
N 022555 001	10556010	Dec 19, 2036	U-2250			
	11235168	Jan 04, 2038	U-2250			
	11311620	Dec 19, 2036	U-2250			
HISTRELIN ACETATE - SUPPRELIN LA						
N 022058 001	8062652	Jun 16, 2026	U-1197			
HYDROCHLOROTHIAZIDE - INZIRQO						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 001	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 003	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 004	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 002	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 001	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 002	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 003	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
HYDROCORTISONE - KHINDIVI						
N 218980 001	11904046	Feb 23, 2043	DP U-4216			
	12133914	Feb 23, 2043	U-4215			
HYDROGEN PEROXIDE - ESKATA						
N 209305 001	10098910	Apr 21, 2035	DP U-2205			
	10493103	Apr 21, 2035	DP			
	10729720	Apr 21, 2035	DP			
	9675639	Jul 04, 2035	DP U-2205			
	9980983	Apr 21, 2035	U-2205			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 007	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROXYUREA - XROMI						
N 216593 001	12409156	Dec 23, 2041	DP		NP	Apr 04, 2027
					ODE-470	Apr 04, 2031
IBREXAFUNGERP CITRATE - BREXAFEMME						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	11534433	Jun 10, 2039	U-3159			
	11534433	Jun 10, 2039	U-3508			
	8188085	Aug 28, 2030	DS DP U-3159			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	9801883*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	9801883*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			
	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-1684			
	11672803	Jun 03, 2031	U-1946			
	11672803	Jun 03, 2031	U-2241			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	11672803	Jun 03, 2031	U-2242			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031			U-1684	
	11672803	Jun 03, 2031			U-1946	
	11672803	Jun 03, 2031			U-2241	
	11672803	Jun 03, 2031			U-2242	
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-2241	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8497277	Dec 28, 2026			U-3422	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 217003 001	10004746	Jun 03, 2031	U-3846		ODE-405	Aug 24, 2029
	10004746	Jun 03, 2031	U-3847		PED	Feb 24, 2030
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 217003 001	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	12201690	Jun 14, 2039	DP			
	12364698	Apr 06, 2036	DP			
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 217003 001	8952015	Dec 28, 2026	U-3845			
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
IBUPROFEN - CALDOLOR						
N 022348 001					NPP	May 11, 2026
IBUPROFEN - CALDOLOR						
N 022348 002	11806400	Mar 16, 2032	U-3746		NPP	May 11, 2026
	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
	9295639	Sep 30, 2029	U-1756			
	9649284	Sep 30, 2029	U-2018			
IBUPROFEN - CALDOLOR						
N 022348 003	11806400	Mar 16, 2032	U-3746		NPP	May 11, 2026
	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
IBUPROFEN LYSINE - NEOPROFEN						
N 021903 001	8415337	Mar 02, 2032	DS DP			
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	11717504	Apr 29, 2030	U-3669			
	12171738	Feb 09, 2030	U-4105			
	8298554	Apr 29, 2030	DP			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	11717504	Apr 29, 2030	U-3669			
	12171738	Feb 09, 2030	U-4105			
	8298554	Apr 29, 2030	DP			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
IDELALISIB - ZYDELIG						
N 205858 001	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
IDELALISIB - ZYDELIG						
N 205858 002	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625		I-939	Apr 02, 2027
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 007	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9157121	Apr 05, 2030	U-1674			
ILOPROST - AURLUMYN						
N 217933 001	12409183	Jul 18, 2044	U-4263		NP	Feb 13, 2027
	12409184	Aug 06, 2041	DP		ODE-465	Feb 13, 2031
IMATINIB MESYLATE - IMKELDI						
N 219097 001	11957681	Apr 27, 2040	DP			
IMETELSTAT SODIUM - RYTELO						
N 217779 001	12171778	Jun 16, 2039	U-3956		ODE-482	Jun 06, 2031
	12442000	Mar 15, 2033	U-3956			
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2026	U-3956			
	9388416	Sep 09, 2026	U-3956			
IMETELSTAT SODIUM - RYTELO						
N 217779 002	12171778	Jun 16, 2039	U-3956		ODE-482	Jun 06, 2031
	12442000	Mar 15, 2033	U-3956			
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2026	U-3956			
	9388416	Sep 09, 2026	U-3956			
IMIQUIMOD - ZYCLARA						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-1455			
	8598196	Aug 18, 2029	U-172			
IMIQUIMOD - ZYCLARA						
N 022483 002	11318130	Dec 11, 2029	U-68			
	8222270	Dec 11, 2029	U-68			
IMLUNESTRANT TOSYLATE - INLURIYO						
N 218881 001	10654866	Jul 11, 2039	DS DP U-4278		NCE	Sep 25, 2030
	11117902	Jul 11, 2039	DS DP U-4278			
INAVOLISIB - ITOVEBI						
N 219249 001	10851091	Jul 01, 2036	DS DP		NCE	Oct 10, 2029
	11028100	Apr 26, 2038	DS DP			
	11760753	Jul 01, 2036	U-4024			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INAVOLISIB - ITOVEBI						
N 219249 001	12410189	Jun 14, 2038	U-4024			
	8242104	Sep 27, 2030	DS DP			
	8343955	Sep 27, 2030	U-4024			
	9650393	Jul 01, 2036	DS DP U-4024			
INAVOLISIB - ITOVEBI						
N 219249 002	10851091	Jul 01, 2036	DS DP		NCE	Oct 10, 2029
	11028100	Apr 26, 2038	DS DP			
	11760753	Jul 01, 2036	U-4024			
	12410189	Jun 14, 2038	U-4024			
	8242104	Sep 27, 2030	DS DP			
	8343955	Sep 27, 2030	U-4024			
	9650393	Jul 01, 2036	DS DP U-4024			
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-4249			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-4249			
	12460206	Aug 18, 2034	DS DP			
	8106022	Dec 12, 2029	DS DP U-4249			
	8222222	Dec 29, 2027	U-4249			
	8809292	May 10, 2027	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4249			
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N 022383 001	8479730	Oct 11, 2028	DP			
INDIGOTINDISULFONATE SODIUM - BLUDIGO						
N 216264 001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
	11499050	Dec 23, 2037	DS			
	11845867	Nov 25, 2036	DS			
INDOCYANINE GREEN - SPY AGENT GREEN KIT						
N 211580 001	10631746	Aug 04, 2035	DP U-2815		I-911	Jun 05, 2026
	11712320	Jul 14, 2039	DP			
	8185176	Jun 04, 2028	U-2462			
	8406860	Apr 09, 2029	U-2463			
	8647605	Feb 11, 2029	U-2464			
	8647605	Feb 11, 2029	U-2468			
INDOMETHACIN - TIVORBEX						
N 204768 001	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX						
N 204768 002	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INFIGRATINIB PHOSPHATE - TRUSELTIQ						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INFIGRATINIB PHOSPHATE - TRUSELTIQ						
N 214622 001	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
INFIGRATINIB PHOSPHATE - TRUSELTIQ						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
INGENOL MEBUTATE - PICATO						
N 202833 001	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO						
N 202833 002	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
INOTERSEN SODIUM - TEGSEDI						
N 211172 001	8697860	Apr 29, 2031	DP			
	9061044	Apr 29, 2031	DS			
	9399774	Apr 29, 2031	U-2430			
IOMEPROL - IOMERVU						
N 216016 001					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 002					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 003					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 004					NCE	Nov 27, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IOMEPROL - IOMERVU						
N 216016 005					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 006					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 007					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 008					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 009					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 010					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 012					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 013					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 001					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 002					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 003					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 004					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 005					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 006					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 007					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 008					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 009					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 010					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 012					NCE	Nov 27, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IOMEPROL - IOMERVU						
N 216017 013					NCE	Nov 27, 2029
IOPAMIDOL - ISOVUE-300						
N 018735 002					I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-370						
N 018735 003					I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-200						
N 018735 006					I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-250						
N 018735 007					I-975	Oct 10, 2028
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP	Y		
IPTACOPAN HYDROCHLORIDE - FABHALTA						
N 218276 001	10093663	Jul 14, 2034	U-3980		I-949	Aug 07, 2027
	10093663	Jul 14, 2034	U-4161		I-963	Mar 20, 2028
	11603363	May 25, 2041	DS DP		NCE	Dec 05, 2028
	11723901	Aug 30, 2038	U-3980		ODE-456	Dec 05, 2030
	11951101	Jul 15, 2041	U-3895			
	12285422	Aug 30, 2038	U-4181			
	12384758	May 17, 2041	U-3980			
	12384758	May 17, 2041	U-4161			
	12453726	Jul 15, 2041	U-4300			
	9682968	Jul 14, 2034	DS DP			
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	10456360	Oct 15, 2036	DP		I-932	Feb 13, 2027
	10980795	Jun 12, 2033	U-1848		ODE-463	Feb 13, 2031
	10993914	Oct 15, 2036	DP			
	11344552	Aug 19, 2036	U-3824			
	11369597	Jun 12, 2033	U-1848			
	12059497	Oct 15, 2036	DP			
	12364691	Jun 12, 2033	U-1848			
	8147867	Aug 29, 2028	DS DP			
	8329213	Jan 06, 2027	DS DP			
	9339497	Jun 12, 2033	U-1848			
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
IRON SUCROSE - IRON SUCROSE						
A 208977 001					CGT	Feb 08, 2026
IRON SUCROSE - IRON SUCROSE						
A 212559 002					CGT	Feb 07, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IRON SUCROSE - IRON SUCROSE						
A 212559 003					CGT	Feb 07, 2026
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	10206879	Sep 14, 2027	DP		NPP	Dec 08, 2026
	10206879*PED	Mar 14, 2028			ODE-305	Mar 06, 2022
	10603280	Sep 14, 2027	DP		ODE-454	Dec 08, 2030
	10603280*PED	Mar 14, 2028			ODE-458	Dec 08, 2030
	6812238	Oct 31, 2025	DS		ODE-90	Mar 06, 2022
	6812238*PED	Apr 30, 2026			PED	Sep 06, 2022
					PED	Sep 06, 2022
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
					GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 002	10206879	Sep 14, 2027	DP		NPP	Dec 08, 2026
	10206879*PED	Mar 14, 2028			ODE*	Mar 06, 2022
	10603280	Sep 14, 2027	DP		ODE-454	Dec 08, 2030
	10603280*PED	Mar 14, 2028			ODE-458	Dec 08, 2030
	6812238	Oct 31, 2025	DS		PED	Sep 06, 2022
	6812238*PED	Apr 30, 2026			PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
					GAIN	Sep 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2025	DS		NPP	Dec 08, 2026
	6812238*PED	Apr 30, 2026			ODE-305	Mar 06, 2022
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					ODE-90	Mar 06, 2022
					PED	Sep 06, 2022
					PED	Sep 06, 2022
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
					GAIN	Sep 06, 2027
					GAIN	Sep 06, 2027
ISOPROPYL ALCOHOL - ZURAGARD						
N 210872 001	10688291	Dec 20, 2034	DP	U-1397		
	8389583	Aug 09, 2029		U-1397		
	8703828	May 23, 2028	DP			
	9629368	May 23, 2028		U-1397		
	9844654	Apr 24, 2036	DP	U-1397		
ISOTRETINOIN - ABSORICA LD						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA LD						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 001	7727993	Jan 28, 2028	DP U-2623			
	8318201	Sep 05, 2027	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 002	7727993	Jan 28, 2028	DP U-2623			
	8318201	Sep 05, 2027	DP			
ITRACONAZOLE - ONMEL						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
ITRACONAZOLE - TOLSURA						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
	10806792	Jun 21, 2033	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
IVABRADINE - CORLANOR						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7361650	Feb 22, 2026	DS DP U-1694		PED	Oct 22, 2026
	7867996	Dec 12, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
IVACAFTOR - KALYDECO						
N 203188 001	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Jun 21, 2028
	11564916	Aug 13, 2029	U-3530			
	11564916*PED	Feb 13, 2030				
	12458635	Aug 13, 2029	DP U-4339			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-1311			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4126			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 001	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4126			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 003	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4128			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 004	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		ODE-247	Jun 21, 2026
	10022352	Apr 09, 2027	DP U-2573		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	10646481	Aug 13, 2029	DP			
		11564916	Aug 13, 2029	U-3527			
		11578062	Mar 25, 2031	DP U-3545			
		11639347	Apr 09, 2027	DS DP U-2569			
		11951212	Apr 14, 2035	DP U-3894			
		12458635	Aug 13, 2029	DP U-4336			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8354427	Jul 06, 2026	U-3021			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
		RE50453	Jul 10, 2031	DS DP			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	10022352	Apr 09, 2027	DP U-2343		ODE-247	Jun 21, 2026
		10022352	Apr 09, 2027	DP U-2573		ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-3022			
		10058546	Jul 15, 2033	U-3023			
		10081621	Mar 25, 2031	DP U-3024			
		10081621	Mar 25, 2031	DP U-3025			
		10206877	Apr 14, 2035	DP U-3026			
		10206877	Apr 14, 2035	DP U-3027			
		10239867	Apr 09, 2027	DS DP U-2512			
		10239867	Apr 09, 2027	DS DP U-2569			
		10646481	Aug 13, 2029	DP			
		11564916	Aug 13, 2029	U-3527			
		11578062	Mar 25, 2031	DP U-3545			
		11639347	Apr 09, 2027	DS DP U-2569			
		12458635	Aug 13, 2029	DP U-4336			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8354427	Jul 06, 2026	U-3021			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8754224	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)						
N 210491 002	9012496	Jul 15, 2033			U-2248	
	9670163	Dec 28, 2026	DP		U-2246	
	9931334	Dec 28, 2026	DP		U-2275	
	9931334	Dec 28, 2026	DP		U-2575	
	9974781	Apr 09, 2027	DP		U-2318	
	9974781	Apr 09, 2027	DP		U-2574	
	RE50453	Jul 10, 2031	DS DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	10076513	Dec 04, 2028	DP		U-2411	
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP		U-2777	
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP		U-3181	
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029			U-3529	
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028			U-3984	
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP		U-4338	
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026			U-1973	
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1911	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP		U-1718	
	8716338	Sep 20, 2030	DP		U-1910	
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026			U-1717	
	8741933	Nov 08, 2026			U-1909	
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029			U-1717	
	8846718	Jul 02, 2029			U-1908	
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028			U-1908	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP		U-1912	
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DS DP			
		9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP		U-1911	
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP		U-2276	
		9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	10597384	Dec 04, 2028	DS DP		U-2777	
		10597384*PED	Jun 04, 2029				
		10646481	Aug 13, 2029	DP			
		10646481*PED	Feb 13, 2030				
		11052075	Dec 04, 2028	DP		U-3181	
		11052075*PED	Jun 04, 2029				
		11564916	Aug 13, 2029			U-3529	
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028			U-3984	
		12065432*PED	Jun 04, 2029				
		12458635	Aug 13, 2029	DP		U-4338	
		12458635*PED	Feb 13, 2030				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		7973038	Nov 08, 2026			U-1973	
		7973038*PED	May 08, 2027				
		8324242	Aug 05, 2027			U-1911	
		8324242*PED	Feb 05, 2028				
		8410274	Dec 28, 2026	DP			
		8410274*PED	Jun 28, 2027				
		8507534	Sep 20, 2030	DS DP			
		8507534*PED	Mar 20, 2031				
		8653103	Dec 04, 2028	DP			
		8653103*PED	Jun 04, 2029				
		8716338	Sep 20, 2030	DP		U-1910	
		8716338*PED	Mar 20, 2031				
		8741933	Nov 08, 2026			U-1909	
		8741933*PED	May 08, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		8846718	Jul 02, 2029			U-1908	
		8846718*PED	Jan 02, 2030				
		8993600	Dec 11, 2030	DP			
		8993600*PED	Jun 11, 2031				
		9150552	Dec 04, 2028			U-1908	
		9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP		U-1912	
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP U-1911			
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP U-2276			
		9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
		10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
		10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
		10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
		11564916	Aug 13, 2029	U-3526			
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028	U-3983			
		12065432*PED	Jun 04, 2029				
		12458635	Aug 13, 2029	DP U-4335			
		12458635*PED	Feb 13, 2030				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		7973038	Nov 08, 2026	U-2374			
		7973038*PED	May 08, 2027				
		8324242	Aug 05, 2027	U-2374			
		8324242*PED	Feb 05, 2028				
		8410274	Dec 28, 2026	DP			
		8410274*PED	Jun 28, 2027				
		8507534	Sep 20, 2030	DS DP			
		8507534*PED	Mar 20, 2031				
		8653103	Dec 04, 2028	DP			
		8653103*PED	Jun 04, 2029				
		8716338	Sep 20, 2030	DP U-2396			
		8716338*PED	Mar 20, 2031				
		8741933	Nov 08, 2026	U-2374			
		8741933*PED	May 08, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		8846718	Jul 02, 2029	U-2375			
		8846718*PED	Jan 02, 2030				
		8993600	Dec 11, 2030	DP			
		8993600*PED	Jun 11, 2031				
		9150552	Dec 04, 2028	U-2375			
		9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP U-2397			
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DP			
		9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP U-2376			
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP U-2376			
		9931334*PED	Jun 28, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4335			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4335			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
IVERMECTIN - SOOLANTRA						
N 206255 001	10206939	Mar 13, 2034	U-1631			
	9089587	Mar 13, 2034	U-1631			
	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
	9782425	Mar 13, 2034	U-1631			
IVOSIDENIB - TIBSOVO						
N 211192 001	10449184	Mar 13, 2035	DP		I-924	Oct 24, 2026
	10610125	Jun 21, 2030	U-2784		ODE-242	May 02, 2026
	10610125	Jun 21, 2030	U-2785		ODE-368	Aug 25, 2028
	10610125	Jun 21, 2030	U-3385		ODE-447	Oct 24, 2030
	10653710	Oct 18, 2036	U-3387			
	10717764	Jan 18, 2033	U-3215			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVOSIDENIB - TIBSOVO						
N 211192 001	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	10980788	Jun 07, 2039	U-3743			
	11667673	Jan 18, 2033	U-3742			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9474779	Aug 19, 2033	DS DP U-3742			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-3742			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			
IXAZOMIB CITRATE - NINLARO						
N 208462 001	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 002	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 003	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXAZOMIB CITRATE - NINLARO								
N	208462	003	9175017	Jun 16, 2029	U-2434			
KETOROLAC TROMETHAMINE - ACULAR LS								
N	021528	001	8008338	May 24, 2027	DS DP U-1181			
KETOROLAC TROMETHAMINE - ACUVAIL								
N	022427	001	7842714	Aug 15, 2029	DS DP			
			8512717	Mar 07, 2028	DP			
			9192571	Mar 07, 2028	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA								
N	205388	001	9066856	Oct 23, 2033	DP			
			9066856*PED	Apr 23, 2034				
			9486406	Oct 23, 2033	DP			
			9486406*PED	Apr 23, 2034				
			9855246	Oct 23, 2033	DP			
KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN								
N	022388	001	9474746	Mar 27, 2028	DP			
			9962376	Jun 27, 2030	DP			
LACOSAMIDE - VIMPAT								
N	022253	001					D-188	Apr 28, 2026
LACOSAMIDE - VIMPAT								
N	022253	002					D-188	Apr 28, 2026
LACOSAMIDE - VIMPAT								
N	022253	003					D-188	Apr 28, 2026
LACOSAMIDE - VIMPAT								
N	022253	004					D-188	Apr 28, 2026
LACOSAMIDE - VIMPAT								
N	022254	001					D-188	Apr 28, 2026
LACOSAMIDE - VIMPAT								
N	022255	001					D-188	Apr 28, 2026
LACOSAMIDE - MOTPOLY XR								
N	216185	001	11337943	Jun 05, 2040	DP U-3660			
			11337943	Jun 05, 2040	DP U-3954			
			11883374	Jun 05, 2040	DP U-3660			
			11883374	Jun 05, 2040	DP U-3954			
			12042474	Jun 05, 2040	DP U-3660			
			12042474	Jun 05, 2040	DP U-3954			
LACOSAMIDE - MOTPOLY XR								
N	216185	002	11337943	Jun 05, 2040	DP U-3660			
			11337943	Jun 05, 2040	DP U-3954			
			11883374	Jun 05, 2040	DP U-3660			
			11883374	Jun 05, 2040	DP U-3954			
			12042474	Jun 05, 2040	DP U-3660			
			12042474	Jun 05, 2040	DP U-3954			
LACOSAMIDE - MOTPOLY XR								
N	216185	003	11337943	Jun 05, 2040	DP U-3660			
			11337943	Jun 05, 2040	DP U-3954			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LACOSAMIDE - MOTPOLY XR						
N 216185 003	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
LACTITOL - PIZENSY						
N 211281 001	10806743	May 12, 2037	U-1516			
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS						
N 206510 001	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
LAMOTRIGINE - LAMICTAL XR						
N 022115 001	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 002	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 003	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 004	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 005	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 006	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - SUBVENITE						
N 218879 001	11596634	May 29, 2040	U-4271			
	11596634	May 29, 2040	U-4272			
	11596634	May 29, 2040	U-4273			
	11612566	May 29, 2040	U-4271			
	11612566	May 29, 2040	U-4272			
	11612566	May 29, 2040	U-4273			
LANDIOLOL HYDROCHLORIDE - RAPIBLYK						
N 217202 001	10722516	Apr 25, 2034	U-4235		NCE	Nov 22, 2029
LANSOPRAZOLE - LANSOPRAZOLE						
N 208025 001	11077055	Apr 21, 2036	DP			
	11986554	Apr 21, 2036	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	8821927	Sep 18, 2029	DS DP			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 001	10005783	Oct 21, 2029	U-2472			
	10047097	Oct 21, 2029	U-2474			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 001	10172861	Nov 16, 2035	DS DP			
	10285993	Nov 16, 2035	U-2470			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 002	10005783	Oct 21, 2029	U-2472			
	10047097	Oct 21, 2029	U-2474			
	10172861	Nov 16, 2035	DS DP			
	10285993	Nov 16, 2035	U-2470			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 211710 001	10005783	Oct 21, 2029	U-2472			
	10045991	Apr 04, 2037	U-2473			
	10047097	Oct 21, 2029	U-2474			
	10137127	Apr 04, 2037	DP			
	10172861	Nov 16, 2035	DS			
	10668072	Apr 04, 2037	DP			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS			
	11191766	Apr 04, 2037	U-2471			
	11337967	May 16, 2037	U-4123			
	11484535	Apr 04, 2037	U-2470			
	11974998	May 16, 2037	U-4124			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2471			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719			
	12071423	Jul 06, 2040	DP			
	12257246	Jul 07, 2030	U-2718			
	7423050	Feb 17, 2028	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719			
	12071423	Jul 06, 2040	DP			
	12257246	Jul 07, 2030	U-2718			
	7423050	Feb 17, 2028	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719			
	12257246	Jul 07, 2030	U-2718			
	7423050	Feb 17, 2028	DS DP U-1719			
LATANOPROST - XELPROS						
N 206185 001	9539262	Oct 15, 2028	U-2400			
	9629852	Sep 12, 2029	DP			
LATANOPROST - IYUZEH						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11020385	Mar 14, 2034	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11197853	Mar 14, 2034	DP			
	11618748	Jan 27, 2030	U-1524			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
LATANOPROSTENE BUNOD - VYZULTA						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
LAZERTINIB MESYLATE - LAZCLUZE						
N 219008 001	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	12138351	Apr 13, 2041	DP			
	12318390	Apr 18, 2038	DP			
	9593098	Oct 13, 2035	DS DP U-3985			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAZERTINIB MESYLATE - LAZCLUZE						
N 219008 002	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	12138351	Apr 13, 2041	DP			
	12318390	Apr 18, 2038	DP			
	9593098	Oct 13, 2035	DS DP U-3985			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE*	Aug 28, 2026
	10039779	Jan 30, 2034	DS DP U-2370			
	10039779*PED	Jul 30, 2034				
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		ODE*	Aug 28, 2026
	10039779*PED	Jul 30, 2034				
	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 001	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 001	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 002	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEFAMULIN ACETATE - XENLETA						
N 211672 001	8071643	Mar 25, 2033	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
	9120727	May 23, 2031	DS DP			
LEFAMULIN ACETATE - XENLETA						
N 211673 001	12121582	Jun 14, 2036	DP		NCE	Aug 19, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEFAMULIN ACETATE - XENLETA						
N 211673 001	8071643	Mar 25, 2033	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
LEMBOREXANT - DAYVIGO						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		M-293	Apr 20, 2026
	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
	8268848	Sep 20, 2031	DS DP U-2791			
LEMBOREXANT - DAYVIGO						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		M-293	Apr 20, 2026
	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
	8268848	Sep 20, 2031	DS DP U-2791			
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	11944611	Aug 28, 2041	U-3507			
	9951043	Feb 28, 2034	DS DP U-3507			
LENACAPAVIR SODIUM - SUNLENCA						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	11944611	Aug 28, 2041	U-3507			
	9951043	Feb 28, 2034	DS DP U-3507			
LENACAPAVIR SODIUM - YEZTUGO						
N 220018 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
	11807625	Nov 25, 2040	U-4190			
	9951043	Feb 28, 2034	DS DP U-4190			
LENACAPAVIR SODIUM - YEZTUGO						
N 220020 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
	9951043	Feb 28, 2034	DS DP U-4190			
LENALIDOMIDE - REVLIMID						
N 021880 001	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 002	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 003	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 004	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 005	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENALIDOMIDE - REVLIMID						
N 021880 006	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	8741929	Mar 08, 2028	U-1983		ODE-245	May 28, 2026
LENIOLISIB PHOSPHATE - JOENJA						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	10259791	Aug 26, 2035	DS		M-14	Apr 03, 2027
	10259791*PED	Feb 26, 2036			PED	Oct 03, 2027
	10407393	Aug 26, 2035	DS			
	10407393*PED	Feb 26, 2036				
	11090386	Feb 23, 2036	U-3519			
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
	12508313	Oct 04, 2030	DP			
	12508313*PED	Apr 04, 2031				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	10259791	Aug 26, 2035	DS		M-14	Apr 03, 2027
	10259791*PED	Feb 26, 2036			PED	Oct 03, 2027
	10407393	Aug 26, 2035	DS			
	10407393*PED	Feb 26, 2036				
	11090386	Feb 23, 2036	U-3519			
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
	12508313	Oct 04, 2030	DP			
	12508313*PED	Apr 04, 2031				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
LESINURAD - ZURAMPIC						
N 207988 001	10183012	Nov 26, 2028	U-2311			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
	9956205	Dec 28, 2031	U-2311			
LETERMOVIR - PREVYMIS						
N 209939 001	RE46791	Jan 18, 2029	DS DP		D-189	Aug 02, 2026
					I-916	Jun 05, 2026
					NPP	Aug 30, 2027
					ODE-423	Jun 05, 2030
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETERMOVIR - PREVYMIS						
N 209939 002	RE46791	Jan 18, 2029	DS DP		D-189	Aug 02, 2026
					I-916	Jun 05, 2026
					NPP	Aug 30, 2027
					ODE-423	Jun 05, 2030
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETERMOVIR - PREVYMIS						
N 209940 001	10603384	Feb 28, 2033	DP		D-189	Aug 02, 2026
	RE46791	Jan 18, 2029	DS DP		I-916	Jun 05, 2026
					NPP	Aug 30, 2027
					ODE-423	Jun 05, 2030
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETERMOVIR - PREVYMIS						
N 209940 002	10603384	Feb 28, 2033	DP		D-189	Aug 02, 2026
	RE46791	Jan 18, 2029	DS DP		I-916	Jun 05, 2026
					NPP	Aug 30, 2027
					ODE-423	Jun 05, 2030
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETERMOVIR - PREVYMIS						
N 219104 001	RE46791	Jan 18, 2029	DS DP		NP	Aug 30, 2027
					ODE*	Jun 05, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LETERMOVIR - PREVYMIS						
N 219104 001					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETERMOVIR - PREVYMIS						
N 219104 002	RE46791	Jan 18, 2029	DS DP		NP	Aug 30, 2027
					ODE*	Jun 05, 2030
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	10799506	Apr 14, 2036	DP		I-951	Sep 17, 2027
	12064434	Apr 14, 2036	DP			
	12419894	Apr 14, 2036	DP			
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			
LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028	U-3611			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	8921326	Feb 05, 2031	DP U-1666			
	9617303	Mar 22, 2028	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021343 001	11771841	Dec 22, 2041	DS DP			
	11931559	Dec 22, 2041	DS			
	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021379 001	11771841	Dec 22, 2041	DS DP			
	11931559	Dec 22, 2041	DS			
	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021488 001	11771841	Dec 22, 2041	DS DP			
	11931559	Dec 22, 2041	DS			
	12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021731 001	11771841	Dec 22, 2041	DS DP			
	11931559	Dec 22, 2041	DS			
	12397120	Dec 22, 2041	U-4001			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - FENSOLVI KIT								
N 213150	001		11771841	Dec 22, 2041	DS DP			
			11931559	Dec 22, 2041	DS			
			12397120	Dec 22, 2041	U-3611			
LEUPROLIDE MESYLATE - CAMCEVI KIT								
N 211488	001		10646572	Jan 16, 2027	DP			
			11717555	Jan 01, 2039	DP			
			12133878	Dec 18, 2037	DP			
			9572857	Jan 16, 2027	DP			
			9744207	Jan 16, 2027	DP			
LEUPROLIDE MESYLATE - CAMCEVI ETM								
N 219745	001						NS	Aug 25, 2028
LEVACETYLLEUCINE - AQNEURSA								
N 219132	001		11400067	Apr 19, 2037	U-4170		NCE	Sep 24, 2029
			12433862	Apr 19, 2037	U-4284		ODE-498	Sep 24, 2031
			12433863	Apr 19, 2037	U-4285			
LEVETIRACETAM - KEPPRA								
N 021035	001		8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N 021035	002		8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N 021035	003		8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA								
N 021035	004		8802142	Jun 07, 2031	DP			
			8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA XR								
N 022285	001		7858122	Sep 17, 2028	DP			
LEVETIRACETAM - KEPPRA XR								
N 022285	002		7858122	Sep 17, 2028	DP			
LEVETIRACETAM - ELEPSIA XR								
N 204417	001		8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Oct 31, 2027	DP			
			8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR								
N 204417	002		8163306	Sep 03, 2027	DP			
			8425938	Feb 22, 2026	DP			
			8431156	Oct 31, 2027	DP			
			8470367	Oct 31, 2027	DP			
			8535717	Feb 22, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - SPRITAM						
N 207958 001	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 002	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 003	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 004	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR						
N 209090 001	8633194	Oct 16, 2027	DP			
LEVODOPA - INBRIJA						
N 209184 001	12458615	Oct 21, 2033	U-2484			
	8545878	Nov 16, 2032	DP			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001	10098877	Jan 10, 2026	U-3283		NCE*	Dec 30, 2026
	10517868	Jan 10, 2026	U-3283		ODE-385	Dec 30, 2028
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	11478471	Jan 10, 2026	U-3283			
	11903940	Mar 02, 2040	U-3821			
	12377096	Mar 02, 2040	U-4236			
	9918984	May 03, 2028	U-3283			
LEVOLEUCOVORIN - KHAPZORY						
N 211226 001	11541012	Mar 25, 2039	DP			
LEVOLEUCOVORIN - KHAPZORY						
N 211226 002	11541012	Mar 25, 2039	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 001	8481598	Mar 02, 2031	U-839		M-304	Mar 24, 2026
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 002	8481598	Mar 02, 2031	U-839		M-304	Mar 24, 2026
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 003	8481598	Mar 02, 2031	U-839		M-304	Mar 24, 2026
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 004	8481598	Mar 02, 2031	U-839		M-304	Mar 24, 2026
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVONORGESTREL - MIRENA						
N 021225 001	10561524	Sep 16, 2029	U-2948			
	11850182	Sep 14, 2029	DP U-3819			
LEVONORGESTREL - SKYLA						
N 203159 001	10561524	Sep 16, 2029	U-2948			
	11628088	Feb 07, 2027	DP			
	11850182	Sep 14, 2029	DP U-3819			
LEVONORGESTREL - LILETTA						
N 206229 001	10028858	Mar 22, 2034	DP U-2348		I-917	Jun 29, 2026
	11090186	Oct 24, 2033	U-2348			
	11571328	Sep 07, 2040	DP			
	12004992	Oct 06, 2033	DS			
LEVONORGESTREL - KYLEENA						
N 208224 001	10561524	Sep 16, 2029	U-2948			
	11628088	Feb 07, 2027	DP			
	11850182	Sep 14, 2029	DP U-3819			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 003	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 004	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 005	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 006	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 007	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 008	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 009	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 010	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 011	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 012	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 001	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 002	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 003	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 004	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 005	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 006	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 007	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 008	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 009	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 010	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 011	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 012	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039			U-3757	
	11241382	Sep 17, 2039			U-3758	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
	11241382	Sep 17, 2039	U-3757			
	11241382	Sep 17, 2039	U-3758			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 001	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 002	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 003	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - THYQUIDITY						
N 214047 001	9050307	Aug 06, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 214253 001	11154498	Jul 20, 2036	DP			
LEVOTHYROXINE SODIUM - ERMEZA						
N 215809 001	9345772	Feb 27, 2035	DP			
LIDOCAINE - ZTLIDO						
N 207962 001	10765640	May 10, 2031	DP			
	10765749	May 10, 2031	DP			
	11278623	May 10, 2031	DP			
	11786455	May 10, 2031	DP		U-2267	
	11793766	May 10, 2031			U-2267	
	9283174	May 10, 2031	DP			
	9925264	May 10, 2031	DP		U-2267	
	9931403	May 10, 2031	DP			
LIDOCAINE - BONDLIDO						
N 215029 001					NP	Sep 24, 2028
LIDOCAINE HYDROCHLORIDE - ZINGO						
N 022114 001	8540665	Oct 22, 2029			U-1438	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIDOCAINE HYDROCHLORIDE - ZINGO						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
LIDOCAINE HYDROCHLORIDE - AKTEN						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
LIDOCAINE; TETRACAINE - PLIAGLIS						
N 021717 001	10350180	Jan 14, 2031	DP			
	10603293	Jan 14, 2031	DP			
	10751305	Jan 14, 2031	DP			
LIFITEGRAST - XIIDRA						
N 208073 001	11058677	Dec 18, 2033	DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			
	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029	U-1900			
	9890141	Oct 21, 2030	DS			
LINACLOTIDE - LINZESS						
N 202811 001	7304036	Aug 30, 2026	DS DP U-1278		I-921	Jun 12, 2026
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-4345			
	7304036*PED	Feb 28, 2027				
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8748573	Oct 30, 2031	U-4345			
	8748573*PED	Apr 30, 2032				
	8802628	Oct 30, 2031	DP			
	8802628*PED	Apr 30, 2032				
	8933030	Feb 17, 2031	DP U-4345			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-4345			
	9708371*PED	Feb 16, 2034				
LINACLOTIDE - LINZESS						
N 202811 002	7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036*PED	Feb 28, 2027				
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8748573*PED	Apr 30, 2032				
	8802628	Oct 30, 2031	DP			
	8802628*PED	Apr 30, 2032				
	8933030	Feb 17, 2031	DP			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1515			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS						
N 202811 002	9708371*PED	Feb 16, 2034				
LINACLOTIDE - LINZESS						
N 202811 003	10675325	Aug 11, 2031	DP		I-921	Jun 12, 2026
	10675325*PED	Feb 11, 2032				
	10702576	Aug 11, 2031	U-1516			
	10702576	Aug 11, 2031	U-3644			
	10702576*PED	Feb 11, 2032				
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-3644			
	7304036*PED	Feb 28, 2027				
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
	9708371*PED	Feb 16, 2034				
LINAGLIPTIN - TRADJENTA						
N 201280 001	10034877	Aug 05, 2029	U-2347		M-295	Jun 20, 2026
	10034877*PED	Feb 05, 2030			PED	Dec 20, 2026
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11911388	Apr 10, 2030	U-3854			
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8853156	Mar 05, 2031	DP U-1642			
	8853156*PED	Sep 05, 2031				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9486526	Aug 05, 2029	U-1915			
	9486526*PED	Feb 05, 2030				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	11911388	Apr 10, 2030	U-3854			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	11911388	Apr 10, 2030	U-3854			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	11911388	Apr 10, 2030	U-3854			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	11911388	Apr 10, 2030	U-3854			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			PED	Dec 20, 2026
	11911388	Apr 10, 2030	U-3854			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
LIRAGLUTIDE - LIRAGLUTIDE						
A 214568 001					PC	Feb 24, 2026
LIRAGLUTIDE - VICTOZA						
N 022341 001	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
LIRAGLUTIDE - SAXENDA						
N 206321 001	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
LISDEXAMFETAMINE DIMESYLATE - ARYNTA						
N 219847 001	11576878	Aug 30, 2040	DP			
	12433859	Apr 16, 2040	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISINOPRIL - QBRELIS						
N 208401 001	10039800	Nov 06, 2035	U-1723			
	10039800	Nov 06, 2035	U-185			
	10039800	Nov 06, 2035	U-1864			
	10039800	Nov 06, 2035	U-1991			
	10039800	Nov 06, 2035	U-3			
	10039800	Nov 06, 2035	U-71			
	10039800	Nov 06, 2035	U-8			
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
	10940177	Nov 06, 2035	DP			
	11179434	Nov 06, 2035	DP			
	11771733	Nov 06, 2035	DP			
	12128083	Nov 06, 2035	DP			
	12186360	Nov 06, 2035	DP			
	12433931	Nov 06, 2035	U-1723			
	12433931	Nov 06, 2035	U-1864			
	12433931	Nov 06, 2035	U-3			
	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	7932268	Aug 19, 2027	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	7932268	Aug 19, 2027	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	7932268	Aug 19, 2027	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	7932268	Aug 19, 2027	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	7932268	Aug 19, 2027	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	7932268	Aug 19, 2027	U-1316			
LONAFARNIB - ZOKINVY						
N 213969 001	7838531	Jul 26, 2029	U-3070		ODE-324	Nov 20, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LONAFARNIB - ZOKINVY									
N 213969	002		7838531	Jul 26, 2029		U-3070		ODE-324	Nov 20, 2027
LORAZEPAM - LOREEV XR									
N 214826	001		8999393	Jan 08, 2034		DP U-3210			
LORAZEPAM - LOREEV XR									
N 214826	002		8999393	Jan 08, 2034		DP U-3210			
LORAZEPAM - LOREEV XR									
N 214826	003		8999393	Jan 08, 2034		DP U-3210			
LORAZEPAM - LOREEV XR									
N 214826	004		8999393	Jan 08, 2034		DP U-3210			
LORLATINIB - LORBRENA									
N 210868	001		10420749	Jul 27, 2036	DS	DP U-2633		ODE-349	Mar 03, 2028
			10420749	Jul 27, 2036	DS	DP U-3096			
			11020376	Jul 27, 2036		DP			
			11299500	Oct 04, 2038	DS				
			8680111	Mar 05, 2033	DS	DP			
LORLATINIB - LORBRENA									
N 210868	002		10420749	Jul 27, 2036	DS	DP U-2633		ODE-349	Mar 03, 2028
			10420749	Jul 27, 2036	DS	DP U-3096			
			11020376	Jul 27, 2036		DP			
			11299500	Oct 04, 2038	DS				
			8680111	Mar 05, 2033	DS	DP			
LOSARTAN POTASSIUM - ARBLI									
N 218772	001		11890273	Oct 07, 2041		DP			
			12156869	Oct 07, 2041		DP U-4158			
			12156869	Oct 07, 2041		DP U-4159			
			12156869	Oct 07, 2041		DP U-4160			
LOTEPREDNOL ETABONATE - LOTEMAX SM									
N 208219	001		10596107	Dec 23, 2036		DP U-2764			
			11534395	Jan 26, 2036		DP U-2764			
LOTEPREDNOL ETABONATE - INVELTYS									
N 210565	001		10058511	May 03, 2033		DP U-2492			
			10646437	May 03, 2033		DP			
			10688045	May 03, 2033		DP			
			10864219	May 03, 2033		U-3011			
			11219597	May 03, 2033		U-3278			
			11219597	May 03, 2033		U-3279			
			11642317	May 03, 2033		DP			
			11872318	May 03, 2033		DP			
			12115246	May 03, 2033		DP U-4025			
			9056057	May 03, 2033		DP U-2491			
			9393213	May 03, 2033		DP			
			9532955	May 03, 2033		U-2491			
			9737491	May 03, 2033		U-2492			
			9827191	May 03, 2033		DP U-2493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	10058511	May 03, 2033	DP U-2492			
	10646436	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
	10857096	May 03, 2033	U-2985			
	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
	11219596	May 03, 2033	U-2985			
	11596599	May 03, 2033	U-2985			
	11642317	May 03, 2033	DP			
	11872318	May 03, 2033	DP			
	12115246	May 03, 2033	DP U-2985			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2985			
LOTILANER - XDEMVY						
N 217603 001	10835517	Dec 14, 2038	U-3674		NCE	Jul 24, 2028
	11197847	Dec 14, 2038	U-3674			
	11690826	Dec 14, 2038	U-3674			
	11690827	Dec 14, 2038	U-3674			
	11752137	Dec 14, 2038	DP			
	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			
	12364685	Dec 14, 2038	DP			
	8383659	Jan 17, 2030	DS DP			
LOXAPINE - ADASUVE						
N 022549 001	8387612	Oct 23, 2026	DP			
LUBIPROSTONE - AMITIZA						
N 021908 001	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8779187	Jan 23, 2027	DP			
LUBIPROSTONE - AMITIZA						
N 021908 002	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	10131907	Aug 24, 2028	DS DP U-2995		ODE-339	Nov 23, 2027
	10435692	Dec 26, 2034	U-2995		ODE-415	Oct 06, 2029
	10465195	Dec 26, 2034	DS DP U-2995			
	10478500	Oct 09, 2035	DS DP U-2995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	10487330	Dec 26, 2034	DS DP U-2995			
	10612024	Aug 14, 2035	DS DP U-2995			
	10612027	Aug 14, 2035	DS DP U-2995			
	11060093	Dec 26, 2034	DS DP U-2995			
	11261447	Nov 20, 2038	DS DP U-2995			
	11401517	Aug 14, 2035	DS DP U-2995			
	11446380	Oct 09, 2035	DS DP			
	8106022	Dec 12, 2029	DS DP U-2995			
	8828956	Dec 04, 2028	DS DP U-2995			
	9828606	Dec 26, 2034	DS DP			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10117867	May 27, 2029	U-3271		I-904	Nov 05, 2028
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-543			
	10960009	Dec 03, 2034	U-814			
	11026951	Dec 03, 2034	U-3274			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	12070459	Aug 30, 2039	DP U-4341			
	12090155	Jul 07, 2040	DP U-4000			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12122792	Dec 10, 2040	DP U-4340			
	12128043	Aug 30, 2039	DP U-3362			
	12128043	Aug 30, 2039	DP U-3363			
	12409176	Mar 15, 2039	U-4261			
	12410195	Dec 10, 2040	DP			
	8598119	Dec 28, 2029	U-543	Y		
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9199995	Mar 12, 2029	U-4343			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Mar 12, 2029	DS DP			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-4344			
	RE48839	Aug 19, 2033	U-814			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	10117867	May 27, 2029	U-3271		I-904	Nov 05, 2028
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	11052084	Aug 30, 2039	DP U-4341			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12122792	Dec 10, 2040	DP U-4340			
	12409176	Mar 15, 2039	U-4261			
	12410195	Dec 10, 2040	DP			
	8648077	Dec 01, 2029	DS DP			
	9168258	May 27, 2029	DP			
	9199995	Mar 12, 2029	U-2713			
	9199995	Mar 12, 2029	U-4343			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Mar 12, 2029	DS			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-4344			
	RE48839	Aug 19, 2033	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	10117867	May 27, 2029	U-3271		I-904	Nov 05, 2028
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	11052084	Aug 30, 2039	DP U-4341			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12122792	Dec 10, 2040	DP U-4019			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	12122792	Dec 10, 2040	DP		U-4020	
	12122792	Dec 10, 2040	DP		U-4340	
	12409176	Mar 15, 2039			U-4261	
	12410195	Dec 10, 2040	DP			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029			U-2713	
	9199995	Mar 12, 2029			U-4343	
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034			U-2714	
	RE48825	Mar 12, 2029	DS			
	RE48839	Aug 19, 2033			U-3271	
	RE48839	Aug 19, 2033			U-4344	
	RE48839	Aug 19, 2033			U-814	
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9259423	May 23, 2031			U-1822	
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP		U-543	
	9827242	May 23, 2031			U-2199	
	9827242	May 23, 2031			U-2201	
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9259423	May 23, 2031			U-1822	
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP		U-543	
	9827242	May 23, 2031			U-2199	
	9827242	May 23, 2031			U-2201	
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9259423	May 23, 2031			U-1822	
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP		U-543	
	9827242	May 23, 2031			U-2199	
	9827242	May 23, 2031			U-2201	
	9907794	May 26, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURBINECTEDIN - ZEPZELCA						
N 213702 001	12324806	May 29, 2040	U-4212		I-977	Oct 02, 2028
	12433890	May 29, 2040	U-4305		ODE-304	Jun 15, 2027
	12440490	May 29, 2040	U-4252			
	7763615	Dec 13, 2029	DS DP U-2836			
	7763615	Dec 13, 2029	DS DP U-4299			
LUSUTROMBOPAG - MULPLETA						
N 210923 001	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
LUTETIUM LU 177 DOTATATE - LUTATHERA						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-479	Apr 23, 2031
	10596278	Jul 25, 2038	DP		PED	Oct 23, 2027
	10596278*PED	Jan 25, 2039			PED	Oct 23, 2031
	11904027	Jul 25, 2038	DP			
	11904027*PED	Jan 25, 2039				
	12144873	Jul 25, 2038	U-4036			
	12144873*PED	Jan 25, 2039				
	12151003	Jul 25, 2038	DP U-4036			
	12151003*PED	Jan 25, 2039				
	12161732	Jul 25, 2038	DP U-4036			
	12161732*PED	Jan 25, 2039				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUTETIUM LU 177 DOTATATE - LUTATHERA						
N 208700 001	12168063	Jul 25, 2038	DP U-4036			
	12168063*PED	Jan 25, 2039				
	12415003	Jul 25, 2038	U-4036			
	12415003*PED	Jan 25, 2039				
	12491272	Jul 25, 2038	U-4036			
	12491272*PED	Jan 25, 2039				
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO						
N 215833 001	10398791	Oct 17, 2034	DS DP		I-965	Mar 28, 2028
	10406240	Aug 15, 2028	DS DP U-4169		NCE	Mar 23, 2027
	11318121	Aug 15, 2028	DS DP U-4169			
	11951190	Nov 12, 2035	U-4169			
	12208102	Sep 18, 2041	U-4169			
MACIMORELIN ACETATE - MACRILEN						
N 205598 001	8192719	Oct 12, 2027	U-2220			
MACITENTAN - OPSUMIT						
N 204410 001	10946015	Sep 11, 2026	DP U-1445		M-187	Feb 28, 2028
	10946015*PED	Mar 11, 2027			PED	Aug 28, 2028
	7094781	Dec 05, 2025	DS DP			
	7094781*PED	Jun 05, 2026				
	8268847	Apr 18, 2029	U-1446			
	8268847*PED	Oct 18, 2029				
	8367685	Oct 04, 2028	DP U-1445			
	8367685*PED	Apr 04, 2029				
	9265762	May 29, 2027	DP U-1820			
	9265762*PED	Nov 29, 2027				
MACITENTAN; TADALAFIL - OPSYNVI						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
	7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
	7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
	8268847*PED	Oct 18, 2029				
MACITENTAN; TADALAFIL - OPSYNVI						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
	7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
	7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
	8268847*PED	Oct 18, 2029				
MAGNESIUM SULFATE - MAGNESIUM SULFATE						
A 219777 001					CGT	Feb 01, 2026
MAGNESIUM SULFATE - MAGNESIUM SULFATE						
A 219777 004					CGT	Feb 01, 2026
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE						
N 215344 001	12239659	Jun 14, 2044	U-4143		NP	Jun 15, 2026
	12290529	Aug 02, 2044	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE								
N 215344	001		12433914	Jun 14, 2044	U-4143			
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB								
N 213135	001		10143656	Aug 04, 2037	DP			
			11033498	Aug 04, 2037	U-3164			
			11382864	Aug 04, 2037	U-3164			
			11638697	Aug 04, 2037	DP			
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT								
N 022372	001						ODE-315	Aug 05, 2027
MALATHION - OVIDE								
N 018613	001		7560445	Feb 01, 2027	DS DP U-986			
			7977324	Aug 14, 2026	DP			
MANNITOL - BRONCHITOL								
N 202049	001						ODE-327	Oct 30, 2027
MARALIXIBAT CHLORIDE - LIVMARLI								
N 214662	001		10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
			11229647	Feb 12, 2040	U-3290		NCE	Sep 29, 2026
			11229647	Feb 12, 2040	U-3974		NPP	Mar 13, 2026
			11229661	Oct 26, 2032	U-3850		ODE-379	Sep 29, 2028
			11260053	May 26, 2031	U-3290		ODE-429	Mar 13, 2030
			11260053	May 26, 2031	U-3974		ODE-471	Mar 13, 2031
			11376251	Oct 26, 2032	U-3290			
			11376251	Oct 26, 2032	U-3974			
			11497745	Feb 12, 2040	U-3290			
			11497745	Feb 12, 2040	U-3974			
			11918578	Feb 12, 2040	U-3290			
			11918578	Feb 12, 2040	U-3974			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 214662	002		10512657	Oct 26, 2032	U-3973		NCE	Sep 29, 2026
			11229661	Oct 26, 2032	U-3973		ODE*	Sep 29, 2028
			12350267	Oct 26, 2032	U-3973		ODE*	Mar 13, 2030
							ODE*	Mar 13, 2031
							ODE-490	Jul 24, 2031
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	001		10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
			11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
			11229661	Oct 26, 2032	U-4186			
			11260053	May 26, 2031	U-4187			
			11376251	Oct 26, 2032	U-4187			
			11497745	Feb 12, 2040	U-4187			
			12296050	Oct 05, 2043	DP U-4186			
			12296050	Oct 05, 2043	DP U-4187			
			12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI								
N 219485	002		10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
			11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
			11229661	Oct 26, 2032	U-4186			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARALIXIBAT CHLORIDE - LIVMARLI						
N 219485 002	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI						
N 219485 003	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI						
N 219485 004	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
MARIBAVIR - LIVTENCITY						
N 215596 001	11684632	Jan 04, 2032	U-3650		NCE	Nov 23, 2026
	12213989	Nov 18, 2042	U-4137		ODE-388	Nov 23, 2028
	12295940	Oct 11, 2043	DS DP			
	12433907	Nov 18, 2042	U-4289			
	12447169	Oct 27, 2031	U-4329			
	12447170	Nov 18, 2042	U-4328			
MAVACAMTEN - CAMZYOS						
N 214998 001	9585883	Jun 19, 2034	U-3373		M-297	Jun 15, 2026
	RE50050	Apr 28, 2036	DS DP		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 002	9585883	Jun 19, 2034	U-3373		M-297	Jun 15, 2026
	RE50050	Apr 28, 2036	DS DP		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 003	9585883	Jun 19, 2034	U-3373		M-297	Jun 15, 2026
	RE50050	Apr 28, 2036	DS DP		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAVACAMTEN - CAMZYOS						
N 214998 004	9585883	Jun 19, 2034	U-3373		M-297	Jun 15, 2026
	RE50050	Apr 28, 2036	DS DP		NCE	Apr 28, 2027
					ODE-398	Apr 28, 2029
MAVORIXAFOR - XOLREMDI						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
	12115156	Dec 11, 2038	DP			
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR						
N 202317 001	7838564	Mar 07, 2026	DP			
	7872050	Jul 08, 2029	U-1427			
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
	9382191	Mar 07, 2026	DP			
MELOXICAM - VIVLODEX						
N 207233 001	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
MELOXICAM - VIVLODEX						
N 207233 002	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
MELOXICAM - ANJESO						
N 210583 001	10709713	May 26, 2030	U-2750			
	10881663	Mar 08, 2039	U-3038			
	11253478	May 26, 2030	DP U-3318			
	11458145	Mar 08, 2039	U-3318			
	9974746	May 26, 2030	DP			
MELOXICAM - QMIIZ ODT						
N 211210 001	8545879	Aug 31, 2030	DP			
MELOXICAM - QMIIZ ODT						
N 211210 002	8545879	Aug 31, 2030	DP			
MELOXICAM - QAMZOVA						
N 217593 001	12059423	Jul 19, 2040	DS DP			
MELOXICAM - XIFYRM						
N 218395 001	12263176	Jul 31, 2041	DP			
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO							
N 215431	001	10265324	Apr 11, 2036	U-1719			
		10363312	Apr 11, 2036	U-1719			
		10369224	Apr 11, 2036	U-4134			
		10426839	Apr 11, 2036	U-4135			
		10463736	Apr 11, 2036	DP			
		10471014	Apr 11, 2036	U-1719			
		10471069	Apr 11, 2036	U-1719			
		10512692	Apr 11, 2036	U-1719			
		10512693	Apr 11, 2036	U-1719			
		10517950	Apr 11, 2036	U-1719			
		10532101	Apr 11, 2036	U-1719			
		10537642	Apr 11, 2036	U-1719			
		10561664	Apr 11, 2036	U-1719			
		10583144	Apr 11, 2036	U-1719			
		10653777	Apr 11, 2036	U-1719			
		10688102	Apr 11, 2036	U-1719			
		10688185	Apr 11, 2036	U-1719			
		10695429	Apr 11, 2036	U-1719			
		10695430	Apr 11, 2036	U-1719			
		10702535	Apr 11, 2036	U-4136			
		10702602	Apr 11, 2036	U-1719			
		10722583	Apr 11, 2036	U-1719			
		10729696	Apr 11, 2036	U-1719			
		10729697	Apr 11, 2036	U-1719			
		10729773	Apr 11, 2036	U-1719			
		10758617	Apr 11, 2036	U-1719			
		10758618	Apr 11, 2036	U-1719			
		10780165	Apr 11, 2036	U-1719			
		10780166	Apr 11, 2036	U-1719			
		10799588	Apr 11, 2036	U-1719			
		10821181	Apr 11, 2036	U-1719			
		10821182	Apr 11, 2036	U-1719			
		10894053	Apr 11, 2036	U-1719			
		10905693	Apr 11, 2036	U-1719			
		10918722	Apr 11, 2036	U-1719			
		10933136	Apr 11, 2036	U-1719			
		10933137	Apr 11, 2036	U-1719			
		10940153	Apr 11, 2036	U-1719			
		10987358	Apr 11, 2036	U-1719			
		11013805	Apr 11, 2036	U-1719			
		11013806	Apr 11, 2036	U-1719			
		11020483	Apr 11, 2036	U-1719			
		11045549	Apr 11, 2036	U-1719			
		11135295	Apr 11, 2036	U-1719			
		11207328	Apr 11, 2036	U-1719			
		11219626	Apr 11, 2036	U-1719			
		11285213	Apr 11, 2036	U-1719			
		11331323	Apr 11, 2036	U-1719			
		11369684	Apr 11, 2036	U-1719			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO								
N 215431	001		11426414	Apr 11, 2036	U-1719			
			11471464	Apr 11, 2036	U-1719			
			11471465	Apr 11, 2036	U-1719			
			11504429	Apr 11, 2036	U-1719			
			11510927	Apr 11, 2036	U-1719			
			11571428	Apr 11, 2036	U-1719			
			11602563	Apr 11, 2036	U-1719			
			11607456	Apr 11, 2036	U-1719			
			11617755	Apr 11, 2036	U-1719			
			11617756	Apr 11, 2036	U-1719			
			11617791	Apr 11, 2036	U-1719			
			11628173	Apr 11, 2036	U-1719			
			11712441	Apr 11, 2036	U-1719			
			11738085	Apr 11, 2036	U-1719			
			11759522	Apr 11, 2036	U-1719			
			11801250	Apr 11, 2036	U-1719			
			11806354	Apr 11, 2036	U-1719			
			11826370	Apr 11, 2036	U-1719			
			11865117	Apr 11, 2036	U-1719			
			12128052	May 28, 2040	U-1719			
			12370196	Dec 29, 2041	U-1719			
			12472256	May 18, 2038	U-4356			
			12472257	May 18, 2038	U-4134			
			12472258	May 18, 2038	DP			
			12485176	Apr 11, 2036	U-4133			
			9821075	Apr 11, 2036	DP U-1719			
MELPHALAN HYDROCHLORIDE - HEPZATO								
N 201848	001		10098997	Nov 07, 2032	DP		NP	Aug 14, 2026
			10195334	Jan 16, 2033	DP		ODE-438	Aug 14, 2030
			10369264	Nov 07, 2032	DP			
			10569004	Nov 07, 2032	U-3680			
			10569004	Nov 07, 2032	U-3683			
			11083831	Dec 30, 2032	DP			
			11241522	Nov 07, 2032	DP			
			11633528	Nov 07, 2032	U-3675			
			11833286	Dec 30, 2032	DP			
			9314561	Feb 07, 2034	DP			
			9707331	Sep 17, 2034	DP			
MELPHALAN HYDROCHLORIDE - EVOMELA								
N 207155	001		10040872	Jan 30, 2034	DP			
			10864183	May 28, 2030	DP			
			10940128	Jun 14, 2030	DP U-3086			
			11020363	May 28, 2030	DP			
			8410077	Mar 13, 2029	DP			
			9200088	Mar 13, 2029	DP			
			9493582	Feb 27, 2033	DP			
MELPHALAN HYDROCHLORIDE - IVRA								
N 217110	001		10537520	Jun 29, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N 022525	001		8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N 022525	002		8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N 022525	003		8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N 022525	004		8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MENTHOL; METHYL SALICYLATE - SALONPAS								
N 022029	001		8809615	Jan 03, 2030	DP			
			9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS								
N 022029	002		8809615	Jan 03, 2030	DP			
			9233184	Aug 01, 2027	DP			
MEROPENEM; VABORBACTAM - VABOMERE								
N 209776	001		10172874	Aug 08, 2031	DP		NCE	Aug 29, 2022
			10183034	Aug 08, 2031	U-2490		GAIN	Aug 29, 2027
			10561675	Aug 08, 2031	U-2490			
			11007206	Aug 08, 2031	U-3128			
			11376237	Apr 06, 2039	U-3421			
			12171772	Aug 08, 2031	DS			
			12478606	Jan 08, 2038	U-3421			
			8680136	Aug 29, 2031	DS DP			
			9694025	Aug 08, 2031	U-2120			
MESALAMINE - SFROWASA								
N 019618	002		7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA								
N 021252	002		8217083	Jun 06, 2028	DP			
			8436051	Jun 06, 2028	DP			
MESALAMINE - APRISO								
N 022301	001		8865688	May 01, 2030	U-1310			
METAXALONE - SKELAXIN								
N 013217	003		7122566	Feb 06, 2026	U-915			
METAXALONE - METAXALONE								
N 022503	001		11918559	Jul 29, 2039	DP			
METFORMIN HYDROCHLORIDE - RIOMET ER								
N 212595	001		9962336	May 01, 2035	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET								
N 021842	001		9101660	Jan 22, 2027	DP			
			9320714	Feb 03, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N 021842 002	9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N 022024 001	7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N 022024 002	7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N 022044 001	7326708	Nov 24, 2026	DP	DS	DP	U-802
	7326708*PED	May 24, 2027				
	8414921	Jul 21, 2028	DP			U-1036
	8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
N 022044 002	7326708	Nov 24, 2026	DP	DS	DP	U-802
	7326708*PED	May 24, 2027				
	8414921	Jul 21, 2028	DP			U-1036
	8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 001	7326708	Nov 24, 2026	DP	DS	DP	U-1227
	7326708*PED	May 24, 2027				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 002	7326708	Nov 24, 2026	DP	DS	DP	U-1227
	7326708*PED	May 24, 2027				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 003	7326708	Nov 24, 2026	DP	DS	DP	U-1227
	7326708*PED	May 24, 2027				
METHOCARBAMOL - ATMEKSI						
N 219843 001	12390439	Oct 09, 2044	DP			U-4253
METHOTREXATE - OTREXUP						
N 204824 001	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			U-1442
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			U-1442
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP			U-1442
	9421333	Mar 19, 2030	DP			U-1442
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 002	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 003	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 004	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 005	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 006	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 007	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 008	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11684723	Mar 10, 2029	DP			
	12357642	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP		U-1442	
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP		U-1442	
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP		U-1442	
	9421333	Mar 19, 2030	DP		U-1442	
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 004	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 005	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 006	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 007	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 008	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 009	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - RASUVO						
N 205776 010	8664231	Jun 01, 2029			U-1442	
METHOTREXATE - JYLAMVO						
N 212479 001	11129833	Oct 28, 2035	DP			
	11771701	Oct 29, 2034	DP		U-3700	
	11771701	Oct 29, 2034	DP		U-3701	
	11771701	Oct 29, 2034	DP		U-3702	
	11771701	Oct 29, 2034	DP		U-3703	
	11771701	Oct 29, 2034	DP		U-3704	
METHOTREXATE SODIUM - XATMEP						
N 208400 001	10231927	Jan 02, 2033			U-1349	
	10231927	Jan 02, 2033			U-1699	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE SODIUM - XATMEP						
N 208400 001	10610485	Jan 02, 2033	DP			
	11116724	Jan 02, 2033	U-1349			
	11116724	Jan 02, 2033	U-1699			
	11969503	Jan 02, 2033	DP			
	12396947	Jan 02, 2033	DP			
	9259427	Jan 02, 2033	DP			
	9855215	Jan 02, 2033	DP			
METHYLENE BLUE - PROVAYBLUE						
N 204630 001					M-303	Jan 08, 2027
METHYLENE BLUE - PROVAYBLUE						
N 204630 002					M-303	Jan 08, 2027
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 002	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 003	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 001	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 002	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 003	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP		U-1415	
	8563033	Feb 15, 2031	DP		U-1415	
	8778390	Feb 15, 2031	DP		U-1543	
	8956649	Feb 15, 2031	DP		U-1665	
	9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	10857143	Aug 14, 2033	DP		U-2993	
	11103494	Aug 14, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	11103495	Aug 14, 2033	DP		U-2993	
	11633389	Aug 14, 2033	DP			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP		U-1827	
	9545399	Aug 14, 2033	DP		U-1827	
	9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032			U-2357	
	10617651	Mar 23, 2032			U-2357	
	10881618	Mar 23, 2032			U-2357	
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032			U-2357	
	11241392	Mar 23, 2032	DP			
	11911518	Mar 23, 2032			U-2357	
	8916588	Mar 23, 2032			U-2357	
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032			U-2357	
	9034902	Mar 23, 2032			U-2357	
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032			U-2357	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032			U-2357	
	10617651	Mar 23, 2032			U-2357	
	10881618	Mar 23, 2032			U-2357	
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032			U-2357	
	11241392	Mar 23, 2032	DP			
	11911518	Mar 23, 2032			U-2357	
	8916588	Mar 23, 2032			U-2357	
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032			U-2357	
	9034902	Mar 23, 2032			U-2357	
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032			U-2357	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032			U-2357	
	10617651	Mar 23, 2032			U-2357	
	10881618	Mar 23, 2032			U-2357	
	10905652	Mar 23, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 003	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	11911518	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	11911518	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	11911518	Mar 23, 2032	U-2357			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 001	10111839	Oct 30, 2035	U-2357			
	10292938	Oct 30, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 001	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 002	10111839	Oct 30, 2035			U-2357	
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 003	10111839	Oct 30, 2035			U-2357	
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 004	10111839	Oct 30, 2035			U-2357	
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 004	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 005	10111839	Oct 30, 2035			U-2357	
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 006	10111839	Oct 30, 2035			U-2357	
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP		U-2357	
	10449159	Oct 30, 2035			U-2357	
	10500162	Oct 30, 2035			U-2357	
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035			U-2357	
	10568841	Oct 30, 2035	DP		U-2357	
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038			U-2357	
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 001	10265308	Feb 03, 2037	DP		U-4032	
	10695336	Feb 03, 2037			U-4032	
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037			U-4032	
	9855258	Feb 03, 2037	DP		U-4032	
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 002	10265308	Feb 03, 2037	DP		U-4032	
	10695336	Feb 03, 2037			U-4032	
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037			U-4032	
	9855258	Feb 03, 2037	DP		U-4032	
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 003	10265308	Feb 03, 2037	DP		U-4032	
	10695336	Feb 03, 2037			U-4032	
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037			U-4032	
	9855258	Feb 03, 2037	DP		U-4032	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 004	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 005	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 006	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
METHYLPHENIDATE HYDROCHLORIDE - RELEXXII						
N 216117 007	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001	11020361	Dec 22, 2029	U-2843			
	11628150	Dec 22, 2029	DP U-2843			
	11813231	Dec 22, 2029	DP U-2843			
	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
	12377064	Nov 17, 2038	U-2843			
	8334281	May 16, 2030	DP U-2843			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METRONIDAZOLE - NUVESSA						
N 205223 001	10238634	Jun 28, 2032	DP			
	10596155	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METRONIDAZOLE - NUVESSA								
N 205223	001		7893097	Feb 19, 2028	DP			
			8658678	Jun 27, 2028	U-1682			
			8877792	Feb 02, 2028	DP			
			8946276	Jun 28, 2032	U-1664			
			9198858	Jun 28, 2032	U-1664			
METRONIDAZOLE - LIKMEZ								
N 216755	001		11541035	Oct 04, 2039	DP			
			12257236	Jan 16, 2039	DP U-3169			
			12257236	Jan 16, 2039	DP U-4163			
			12257236	Jan 16, 2039	DP U-4164			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%								
N 216142	001		12403173	Dec 15, 2037	DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%								
N 216142	002		12403173	Dec 15, 2037	DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%								
N 216142	003		12403173	Dec 15, 2037	DP			
MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE - VUSION								
N 021026	001		8147852	Mar 30, 2028	U-1426			
MIDAZOLAM - NAYZILAM								
N 211321	001		8217033	Jan 18, 2028	DP U-2526		ODE-243	May 17, 2026
			8809322	Jan 18, 2028	DP			
			9289432	Jan 18, 2028	DP U-2526			
			9687495	Jan 18, 2028	DP U-2526			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE								
N 211844	001		10966990	Jun 20, 2038	DP			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE								
N 211844	002		10966990	Jun 20, 2038	DP			
MIDOSTAURIN - RYDAPT								
N 207997	001		7973031	Oct 09, 2028	U-2007			
			8575146	Dec 02, 2030	U-2008			
MIFEPRISTONE - KORLYM								
N 202107	001		10006924	Aug 12, 2036	U-1643			
			10151763	Jan 18, 2037	U-1643			
			10166242	Apr 20, 2036	U-1643			
			10166243	Apr 20, 2036	U-1643			
			10195214	Jun 19, 2037	U-1643			
			10231983	Aug 22, 2038	U-1643			
			10314850	Aug 22, 2038	U-1643			
			10495650	Aug 12, 2036	U-1643			
			10500216	Mar 05, 2033	U-1643			
			10660904	Apr 20, 2036	U-1643			
			10780097	Aug 22, 2038	U-1643			
			10842800	Jun 19, 2037	U-1643			
			10842801	Nov 15, 2032	U-1643			
			11969435	Jun 19, 2037	U-1643			
			12097210	Jun 19, 2037	U-1643			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIFEPRISTONE - KORLYM						
N 202107 001	8921348	Aug 27, 2028	U-1643			
	9829495	Aug 15, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	10076514	Mar 15, 2037	U-2371			
	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	10471053	May 30, 2038	U-2371			
	10525045	Apr 28, 2028	U-2371			
	10792278	May 30, 2038	U-2371			
	10792279	May 30, 2038	U-2371			
	10799491	May 30, 2038	U-2371			
	10806727	May 30, 2038	U-2371			
	10813921	Feb 12, 2029	U-2371			
	10849889	May 30, 2038	U-2371			
	10849890	May 30, 2038	U-2371			
	10857141	May 30, 2038	U-2371			
	10857142	May 30, 2038	U-2371			
	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	10925866	Apr 28, 2028	U-2371			
	11033538	Apr 28, 2028	U-2371			
	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	11458128	May 30, 2038	U-2371			
	11612593	May 30, 2038	DS			
	11612594	May 30, 2038	DS			
	11622962	Mar 17, 2039	DS			
	11633387	May 30, 2038	DS			
	11633388	Mar 25, 2039	U-2371			
	11642334	Feb 20, 2039	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	11666564	May 30, 2038	U-2371			
	11786516	May 30, 2038	DS			
	11813255	May 30, 2038	U-2371			
	11826360	Feb 16, 2039	DS			
	11833164	Jan 11, 2042	U-2371			
	11903938	Aug 17, 2038	DS U-2371			
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS U-2371			
	12042490	May 30, 2038	U-2371			
	12109205	May 30, 2038	DS U-2371			
	12280042	May 30, 2038	DS U-2371			
	8592362	Feb 12, 2029	U-2371	Y		
	9000011	May 16, 2027	U-2371			
	9095584	Feb 12, 2029	U-2371			
	9480682	May 16, 2027	U-2371			
	9987263	May 16, 2027	U-2371			
	9999618	Apr 28, 2028	U-2372			
	9999618	Apr 28, 2028	U-2373			
	RE48608	Oct 20, 2031	U-2371			
MIGLUSTAT - OPFOLDA						
N 215211 001	10208299	Sep 30, 2035	DS DP U-3726		NP	Sep 28, 2026
	10512677	Mar 07, 2033	U-3726			
	10857212	Aug 12, 2037	U-3726			
	10961522	Sep 30, 2035	U-3726			
	11278599	Mar 07, 2033	U-3726			
	11278601	Dec 29, 2036	DP U-3726			
	11753632	Sep 30, 2035	U-3726			
	12246062	Sep 16, 2038	U-3726			
	12414985	Dec 29, 2036	U-3726			
	12419937	Mar 07, 2033	U-3726			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 001	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 002	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 003	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 004	7994220	Sep 19, 2029	U-819			
MINOCYCLINE HYDROCHLORIDE - MINOCIN						
N 050444 001	11944634	Oct 16, 2032	DP			
	12161656	May 12, 2031	DP			
	9084802	May 12, 2031	U-282			
	9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 001	7919483	Mar 07, 2027	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	002	7541347	Apr 02, 2027			U-917	
			7544373	Apr 02, 2027	DP			
			7919483	Mar 07, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	003	7919483	Mar 07, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	004	7919483	Mar 07, 2027			U-1078	
			9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	005	7919483	Mar 07, 2027			U-1078	
			9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	006	7919483	Mar 07, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	007	7919483	Mar 07, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N	050808	008	7919483	Mar 07, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - XIMINO								
N	201922	001	7541347	Apr 02, 2027			U-917	
			7544373	Apr 02, 2027	DP			
			7919483	Mar 07, 2027			U-124	
MINOCYCLINE HYDROCHLORIDE - XIMINO								
N	201922	003	7541347	Apr 02, 2027			U-917	
			7544373	Apr 02, 2027	DP			
			7919483	Mar 07, 2027			U-124	
MINOCYCLINE HYDROCHLORIDE - XIMINO								
N	201922	005	7541347	Apr 02, 2027			U-917	
			7544373	Apr 02, 2027	DP			
			7919483	Mar 07, 2027			U-124	
MINOCYCLINE HYDROCHLORIDE - MINOLIRA								
N	209269	001	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - MINOLIRA								
N	209269	002	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ								
N	212379	001	10086080	Oct 01, 2030			U-2647	
			10137200	Oct 01, 2030			U-2647	
			10213512	Oct 01, 2030	DP		U-2647	
			10265404	Oct 01, 2030	DP			
			10398641	Sep 08, 2037			U-2647	
			10517882	Oct 01, 2030			U-2647	
			10821187	Oct 01, 2030			U-2647	
			10849847	Sep 08, 2037			U-2647	
			8865139	Oct 01, 2030	DP		U-2647	
			8945516	Oct 01, 2030	DP			
			8992896	Oct 01, 2030	DP		U-2647	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - AMZEEQ								
N 212379	001		9675700	Oct 01, 2030	DP U-2647			
MINOCYCLINE HYDROCHLORIDE - ZILXI								
N 213690	001		10213512	Oct 01, 2030	DP U-1631			
			10265404	Oct 01, 2030	DP			
			10322186	Oct 01, 2030	U-1631			
			10946101	Oct 01, 2030	U-1631			
			12138311	Oct 01, 2030	U-1631			
			8865139	Oct 01, 2030	DP U-1631			
			8945516	Oct 01, 2030	DP			
			8992896	Oct 01, 2030	DP U-1631			
			9675700	Oct 01, 2030	DP U-1631			
MINOCYCLINE HYDROCHLORIDE - EMROSI								
N 219015	001		10905664	Jan 07, 2039	U-4043		NP	Nov 01, 2027
			11191740	Jan 07, 2039	U-4043			
			11364212	Jan 07, 2039	U-4043			
MIPOMERSEN SODIUM - KYNAMRO								
N 203568	001		7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ								
N 202611	001		10842780	Sep 28, 2029	DP U-2996			
			10842780	Sep 28, 2029	DP U-3670			
			10842780*PED	Mar 28, 2030				
			11707451	Sep 28, 2029	U-2996			
			11707451	Sep 28, 2029	U-3670			
			11707451*PED	Mar 28, 2030				
			12059409	Sep 28, 2029	DP			
			12059409*PED	Mar 28, 2030				
			12097189	Sep 28, 2029	U-2996			
			12097189	Sep 28, 2029	U-3670			
			12097189*PED	Mar 28, 2030				
			8772315	Oct 30, 2028	U-2300			
			8772315*PED	Apr 30, 2029				
MIRABEGRON - MYRBETRIQ								
N 202611	002		10842780	Sep 28, 2029	DP U-2996			
			10842780	Sep 28, 2029	DP U-3670			
			10842780*PED	Mar 28, 2030				
			11707451	Sep 28, 2029	U-2996			
			11707451	Sep 28, 2029	U-3670			
			11707451*PED	Mar 28, 2030				
			12059409	Sep 28, 2029	DP			
			12059409*PED	Mar 28, 2030				
			12097189	Sep 28, 2029	U-2996			
			12097189	Sep 28, 2029	U-3670			
			12097189*PED	Mar 28, 2030				
			8772315	Oct 30, 2028	U-2300			
			8772315*PED	Apr 30, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIRABEGRON - MYRBETRIQ GRANULES						
N 213801 001	10058536	Mar 31, 2036	DP U-3108			
	10058536*PED	Sep 30, 2036				
MIRDAMETINIB - GOMEKLI						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12090128	Feb 17, 2041	DP U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12357597	Feb 17, 2041	U-4130			
	12390430	Oct 10, 2044	U-4130			
MIRDAMETINIB - GOMEKLI						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
MIRDAMETINIB - GOMEKLI						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIRDAMETINIB - GOMEKLI						
N 219389 002	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	11878049	Jul 31, 2041	U-3782			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	11878049	Jul 31, 2041	U-3782			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321		ODE-392	Feb 17, 2029
	11254652	Nov 21, 2038	DS DP			
	11793806	Apr 12, 2033	U-3320			
	11878049	Jul 31, 2041	U-3782			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
	RE49582	Feb 24, 2031	DS DP			
MITOMYCIN - MITOSOL						
N 022572 001	7806265	Feb 01, 2029	DP			
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MITOMYCIN - MITOSOL						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
MITOMYCIN - JELMYTO						
N 211728 001	12268745	Jan 20, 2031	U-4172		ODE-289	Apr 15, 2027
	9040074	Jan 20, 2031	DP			
	9950069	Jan 20, 2031	DP			
MITOMYCIN - ZUSDURI						
N 215793 001	10039832	Jan 20, 2031	U-4256		NP	Jun 12, 2028
	12440568	Jan 20, 2031	U-4256			
	9040074	Jan 20, 2031	DP U-4256			
	9950069	Jan 20, 2031	DP U-4256			
MOBOCERTINIB SUCCINATE - EXKIVITY						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP		ODE-374	Sep 15, 2028
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 001	11963962	Dec 02, 2040	U-3928		NCE	Sep 15, 2028
	8486941	Jan 03, 2030	DS DP U-1201		ODE-441	Sep 15, 2030
	9809559	Jun 11, 2035	U-1201			
	RE48285	Jun 11, 2035	DS DP U-1201			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 002	11963962	Dec 02, 2040	U-3928		NCE	Sep 15, 2028
	8486941	Jan 03, 2030	DS DP U-1201		ODE-441	Sep 15, 2030
	9809559	Jun 11, 2035	U-1201			
	RE48285	Jun 11, 2035	DS DP U-1201			
MOMELOTINIB DIHYDROCHLORIDE - OJJAARA						
N 216873 003	11963962	Dec 02, 2040	U-3928		NCE	Sep 15, 2028
	8486941	Jan 03, 2030	DS DP U-1201		ODE-441	Sep 15, 2030
	9809559	Jun 11, 2035	U-1201			
	RE48285	Jun 11, 2035	DS DP U-1201			
MOMETASONE FUROATE - SINUVA						
N 209310 001	10232152	Nov 24, 2034	DP U-2272			
	10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
	7544192	Nov 29, 2026	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	10016443	Sep 04, 2034	U-3297			
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	11400101	Sep 04, 2034			U-3297	
	11679210	Sep 03, 2038	DP			
	12064442	Sep 04, 2034			U-3297	
	12303635	Apr 08, 2039	DS DP			
	9078923	Sep 04, 2034	DP		U-3297	
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP		U-3297	
	9937189	Sep 04, 2034	DP			
MONOMETHYL FUMARATE - BAFIERTAM						
N 210296 001	10098863	Feb 27, 2035	DP		U-1384	
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP		U-1384	
	10105337	Feb 27, 2035	DP			
	10918615	Feb 27, 2035	DP		U-1384	
	10918616	Feb 27, 2035			U-1384	
	10918617	Feb 27, 2035	DP			
	10945985	Feb 27, 2035	DP			
	11590095	Feb 27, 2035			U-1384	
	11903918	Feb 27, 2035			U-1384	
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035			U-1384	
	9511043	Feb 27, 2035			U-1384	
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035			U-1384	
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035			U-1384	
	9814692	Feb 27, 2035			U-1384	
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP		U-1384	
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034			U-43	
	9192608	Mar 12, 2034			U-55	
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034			U-43	
	9192608	Mar 12, 2034			U-55	
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034			U-43	
	9192608	Mar 12, 2034			U-55	
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034			U-43	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHINE SULFATE								
N	204223	004	9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N	204223	005	9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	001	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	002	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	003	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER								
N	206544	004	10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - ARYMO ER								
N	208603	001	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N	208603	002	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER								
N	208603	003	9044402	Jul 01, 2033	DP		U-1556	
			9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N	022321	001	7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA								
N	022321	002	7682633	Jun 19, 2027	U-1510			
			7682634	Jun 19, 2027	DP			
			7815934	Dec 12, 2027	DP			
			8158156	Jun 19, 2027	U-1510			
			8623418	Nov 07, 2029	U-1640			
			8846104	Jun 19, 2027	DP			
			8877247	Jun 19, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MOTIXAFORTIDE ACETATE - APHEXDA						
N 217159 001	12257285	Dec 29, 2041	DP		NCE	Sep 08, 2028
	12268725	Dec 29, 2041	DP		ODE-442	Sep 08, 2030
MOXIDECTIN - MOXIDECTIN						
N 210867 001					NPP	Feb 07, 2028
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
MYCOPHENOLATE MOFETIL - MYHIBBIN						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
	12097284	Aug 16, 2039	DP			
	12097285	Aug 16, 2039	DP U-1752			
	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
NALDEMEDINE TOSYLATE - SYMPROIC						
N 208854 001	10952968	May 13, 2033	DS DP			
	12350377	May 13, 2033	DP			
	9108975	Nov 11, 2031	DS DP			
	RE46365	Feb 24, 2031	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
NALMEFENE HYDROCHLORIDE - OPVEE						
N 217470 001	11458091	Jul 10, 2038	DP U-3630		NP	May 22, 2026
	12290596	Aug 04, 2042	U-4182			
NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)						
N 218590 001	11857547	Nov 05, 2039	DP		NP	Aug 07, 2027
	11865112	Nov 05, 2039	DP U-3630			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 001	7786133	Sep 16, 2028	DS DP			
	9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7786133	Sep 16, 2028	DS DP			
	9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	10143972	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10322239	Feb 28, 2031	U-1907			
	10960155	Jun 25, 2026	DP			
	11590286	Dec 12, 2026	DP			
	7731686	Jun 10, 2026	DP			
	7749194	Oct 30, 2028	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - REXTOVY						
N 208969 001					NP	Mar 07, 2026
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)						
N 209862 001	10143792	May 24, 2031			U-2476	
	10220158	Mar 20, 2035	DP		U-2500	
	10322239	Feb 28, 2031			U-1907	
	10960155	Jun 25, 2026	DP			
	11590286	Dec 12, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7749194	Oct 30, 2028	DP			
	7947017	Mar 12, 2028	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP		U-1907	
	9517307	Jul 18, 2034	DP		U-1925	
	9724471	May 23, 2027	DP		U-2092	
NALOXONE HYDROCHLORIDE - KLOXXADO						
N 212045 001	10722510	Aug 26, 2034	DP		U-3110	
	10973814	Aug 26, 2034	DP		U-3110	
	11135155	Aug 26, 2034	DP			
	11617713	Aug 26, 2034	DP		U-3110	
	11628139	Aug 26, 2034	DP		U-3110	
	11975096	Aug 26, 2034	DP			
	12414915	Aug 26, 2034	DP			
NALOXONE HYDROCHLORIDE - ZIMHI						
N 212854 001	11027072	May 24, 2039	DP			
	11571518	Jun 14, 2041	DP		U-3515	
	11571518	Jun 14, 2041	DP		U-3516	
	11571518	Jun 14, 2041	DP		U-3517	
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	10143792	May 24, 2031			U-2476	
	10322239	Feb 28, 2031			U-1907	
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9474869	Feb 28, 2031	DP		U-1907	
	9814838	Feb 28, 2031	DP			
NALOXONE HYDROCHLORIDE - REZENOPY						
N 215487 001					NP	Apr 19, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - RIVIVE								
N 217722	001		11020343	May 11, 2032	U-3671			
			11806428	May 11, 2032	DP			
			12458591	May 11, 2032	U-3671			
NALTREXONE - VIVITROL								
N 021897	001		7919499	Oct 15, 2029	U-1123			
			7919499	Oct 15, 2029	U-1124			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	001		7815934	Dec 12, 2027	DP			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	002		7815934	Dec 12, 2027	DP			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	003		7815934	Dec 12, 2027	DP			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	004		7815934	Dec 12, 2027	DP			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	005		7815934	Dec 12, 2027	DP			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER								
N 207621	006		7815934	Dec 12, 2027	DP			
NAPROXEN SODIUM - NAPROXEN SODIUM								
N 021920	001		10022344	Mar 03, 2026	DP U-1731			
			10022344	Mar 03, 2026	DP U-1732			
			10028925	Mar 03, 2026	DP U-1731			
			10028925	Mar 03, 2026	DP U-1732			
			11090280	Mar 03, 2026	DP U-1731			
			11090280	Mar 03, 2026	DP U-1732			
			9693978	Mar 03, 2026	DP			
			9693979	Mar 03, 2026	DP			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926	001		7332183	Oct 02, 2025	DP U-867			
			7332183*PED	Apr 02, 2026				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET								
N 021926	002		7332183	Oct 02, 2025	DP U-1719			
			7332183*PED	Apr 02, 2026				
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON								
N 206302	001		7803838	Aug 29, 2026	DP			
			7838552	Oct 04, 2027	U-185			
NEDOSIRAN SODIUM - RIVFLOZA								
N 215842	001		10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
			10738311	Oct 09, 2035	DS DP U-3709		NPP	Mar 27, 2028
			11053502	Oct 29, 2035	DS DP		ODE-443	Sep 29, 2030
			11286488	Oct 12, 2038	DS DP U-3709			
			11359203	Oct 09, 2035	DS DP U-3709			
			11661604	Oct 12, 2038	DS DP U-3709			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 002	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		NPP	Mar 27, 2028
	11053502	Oct 29, 2035	DS DP		ODE-443	Sep 29, 2030
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
NEDOSIRAN SODIUM - RIVFLOZA						
N 215842 003	10351854	Oct 09, 2035	DS DP		NCE	Sep 29, 2028
	10738311	Oct 09, 2035	DS DP U-3709		NPP	Mar 27, 2028
	11053502	Oct 29, 2035	DS DP		ODE-443	Sep 29, 2030
	11286488	Oct 12, 2038	DS DP U-3709			
	11359203	Oct 09, 2035	DS DP U-3709			
	11661604	Oct 12, 2038	DS DP U-3709			
NEPAFENAC - NEVANAC						
N 021862 001	7834059	Jan 31, 2027	U-1095			
NEPAFENAC - ILEVRO						
N 203491 001	8921337	Mar 31, 2032	DP			
	9662398	Dec 01, 2030	DP			
NERANDOMILAST - JASCAYD						
N 218764 001	11406638	Oct 22, 2038	U-4297		NCE	Oct 07, 2030
	11813266	Oct 22, 2038	U-4292			
	8609670	Aug 23, 2032	DS			
	8754073	Nov 26, 2029	DS DP U-4298			
	9802954	Feb 19, 2034	U-4298			
NERANDOMILAST - JASCAYD						
N 218764 002	11406638	Oct 22, 2038	U-4297		NCE	Oct 07, 2030
	11813266	Oct 22, 2038	U-4292			
	8609670	Aug 23, 2032	DS			
	8754073	Nov 26, 2029	DS DP U-4298			
	9802954	Feb 19, 2034	U-4298			
NERATINIB MALEATE - NERLYNX						
N 208051 001	10035788	Oct 15, 2028	U-2043			
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7399865	Dec 29, 2030	DS DP			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NERATINIB MALEATE - NERLYNX						
N 208051 001	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
NETARSUDIL MESYLATE - RHOPRESSA						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11020385	Mar 14, 2034	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11618748	Jan 27, 2030	U-1524			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 205718 001	10233154	Sep 25, 2035	DS			
	10676440	Sep 25, 2035	DS DP			
	10828297	Dec 17, 2030	U-2293			
	10961195	Sep 25, 2035	DS DP			
	11559523	Nov 18, 2030	DP U-3522			
	12042494	Nov 18, 2030	DP U-3522			
	8623826	Nov 18, 2030	U-2293			
	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
NEVIRAPINE - VIRAMUNE XR						
N 201152 001	8460704	Mar 12, 2029	U-1409			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER						
N 019734 002	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 003	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 003	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 004	10758616	Apr 18, 2027	DP			
	11547758	Apr 18, 2027	U-1029			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICOTINE POLACRILEX - NICORETTE						
N 018612 002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE						
N 020066 002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NIFURTIMOX - LAMPIT						
N 213464 001					ODE-319	Aug 06, 2027
NIFURTIMOX - LAMPIT						
N 213464 002					ODE-319	Aug 06, 2027
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 001	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Mar 23, 2029
	8293756	Sep 25, 2027	DP			
	8293756*PED	Mar 25, 2028				
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Mar 23, 2029
	8293756	Sep 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	8293756*PED	Mar 25, 2028				
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Mar 23, 2029
	8293756	Sep 25, 2027	DP			
	8293756*PED	Mar 25, 2028				
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB TARTRATE - DANZITEN						
N 219293 001	10874671	Feb 18, 2040	DP			
	11793809	Feb 18, 2040	DP			
	12403140	Feb 18, 2040	DP			
NILOTINIB TARTRATE - DANZITEN						
N 219293 002	10874671	Feb 18, 2040	DP			
	11793809	Feb 18, 2040	DP			
	12403140	Feb 18, 2040	DP			
NIMODIPINE - NYMALIZE						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	11207306	Apr 16, 2038	U-2804			
	11413277	Apr 16, 2038	DP U-2804			
	11806338	Apr 16, 2038	DP			
	12186308	Apr 16, 2038	DP U-2804			
NINTEDANIB ESYLATE - OFEV						
N 205832 001	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NINTEDANIB ESYLATE - OFEV						
N 205832 001	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				
NINTEDANIB ESYLATE - OFEV						
N 205832 002	10105323	Jun 04, 2029	DP		ODE-261	Sep 06, 2026
	10105323*PED	Dec 04, 2029			PED	Mar 06, 2027
	10154990	Jan 08, 2026	U-2620			
	10154990*PED	Jul 08, 2026				
	6762180	Oct 01, 2025	DS DP			
	6762180*PED	Apr 01, 2026				
	9907756	Jun 07, 2029	DP			
	9907756*PED	Dec 07, 2029				
NIRAPARIB TOSYLATE - ZEJULA						
N 208447 001	11091459	Mar 27, 2038	DP		ODE-277	Oct 23, 2026
	11673877	Mar 27, 2038	DP U-3646		ODE-295	Apr 29, 2027
	11673877	Mar 27, 2038	DP U-3647			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 25, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 25, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	11730725	Jan 25, 2039	DP			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 001	11351149	Aug 05, 2041	DS DP U-3629		D-195	Jan 31, 2028
	11541034	Oct 31, 2041	U-3629		NCE	May 25, 2028
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 001	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE-452	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
	12138246	May 19, 2043	U-3754			
	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7795447	Aug 18, 2030	DS			
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 002	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
	12138246	May 19, 2043	U-3754			
	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7795447	Aug 18, 2030	DS			
NIROGACESTAT HYDROBROMIDE - OGSIVEO						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
	12138246	May 19, 2043	U-3754			
	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7795447	Aug 18, 2030	DS			
NITISINONE - ORFADIN						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
NITISINONE - NITYR						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITISINONE - NITYR						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
NITRIC OXIDE - INOMAX						
N 020845 002	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX						
N 020845 003	11931377	Jun 30, 2029	DS DP U-3903			
	11931377*PED	Dec 30, 2029				
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2035	DP U-1823			
	9279794*PED	Aug 19, 2035				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX								
N	020845	003	9408993*PED	Jul 06, 2031				
			9770570	May 03, 2036	U-2148			
			9770570*PED	Nov 03, 2036				
NITRIC OXIDE - INOMAX								
N	020845	004	11931377	Jun 30, 2029	DS DP		U-3903	
NITRIC OXIDE - GENOSYL								
N	202860	001	10213572	Feb 12, 2036	DP			
			10737051	Oct 20, 2035	DP			
			10926054	Aug 13, 2029	DP			
			11103669	Jun 21, 2030	DP			
			11511252	Sep 21, 2029	DP			
			11672938	Jul 22, 2040	U-3037			
			7560076	Apr 21, 2027	DP			
			7618594	Oct 17, 2026	DP			
			7947227	Oct 17, 2026	U-3037			
			8057742	Jan 18, 2026	U-3037			
			8607785	Jul 14, 2030	DP			
			8944049	Aug 13, 2029	DP			
			9604028	Aug 13, 2029	U-2793			
			9701538	Jan 28, 2029	DP			
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY								
N	018705	002	7872049	Mar 12, 2029	DP		U-2223	
NITROGLYCERIN - GONITRO								
N	208424	001	9101592	Mar 11, 2032	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE								
N	214313	001	12097170	Mar 08, 2041	DP		U-3995	
			12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE								
N	214313	002	12097170	Mar 08, 2041	DP		U-3995	
			12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE								
N	214313	003	12097170	Mar 08, 2041	DP		U-3995	
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N	214628	001	10159657	Jan 30, 2038	DP			
			10226436	Jan 30, 2038	DP		U-3461	
			10420735	Jan 30, 2038	DP		U-3461	
			10568850	Jan 30, 2038	DP			
			11413259	Jan 30, 2038	DP		U-3461	
			11602508	Jan 30, 2038	DP			
			12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
N	214628	002	10159657	Jan 30, 2038	DP			
			10226436	Jan 30, 2038	DP		U-3461	
			10420735	Jan 30, 2038	DP		U-3461	
			10568850	Jan 30, 2038	DP			
			11413259	Jan 30, 2038	DP		U-3461	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 214628	002	11602508	Jan 30, 2038	DP			
		12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 214628	003	10159657	Jan 30, 2038	DP			
		10226436	Jan 30, 2038	DP U-3461			
		10420735	Jan 30, 2038	DP U-3461			
		10568850	Jan 30, 2038	DP			
		11413259	Jan 30, 2038	DP U-3461			
		11602508	Jan 30, 2038	DP			
		12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700	001	10888534	Apr 26, 2039	DP			
		RE49422	Feb 26, 2035	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700	002	10888534	Apr 26, 2039	DP			
		RE49422	Feb 26, 2035	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700	003	10251848	Feb 26, 2035	DP			
		10888534	Apr 26, 2039	DP			
		RE49422	Feb 26, 2035	DP			
		RE49443	Feb 26, 2035	DP			
NORGESTREL - OPILL							
N 017031	001					RTO	Jul 13, 2026
NUSINERSEN SODIUM - SPINRAZA							
N 209531	001	10436802	Sep 11, 2035	U-1941			
		10436802	Sep 11, 2035	U-1942			
		10436802	Sep 11, 2035	U-1943			
		10436802	Sep 11, 2035	U-1944			
		10436802	Sep 11, 2035	U-2093			
		10436802	Sep 11, 2035	U-2094			
		12013403	Mar 04, 2036	U-1941			
		12013403	Mar 04, 2036	U-1942			
		12013403	Mar 04, 2036	U-1943			
		12013403	Mar 04, 2036	U-1944			
		12013403	Mar 04, 2036	U-2093			
		12013403	Mar 04, 2036	U-2094			
		7838657	Jul 11, 2027	DS			
		8361977	Dec 23, 2030	DS DP			
		8980853	Nov 24, 2030	U-1941			
		9717750	Jun 17, 2030	U-1942			
		9717750	Jun 17, 2030	U-1943			
		9717750	Jun 17, 2030	U-2093			
		9717750	Jun 17, 2030	U-2094			
		9926559	Jan 09, 2034	U-1943			
OBETICHOLIC ACID - OCALIVA							
N 207999	001	10047117	Sep 06, 2033	U-1854			
		10052337	Apr 26, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OBETICHOLIC ACID - OCALIVA						
N 207999 001	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
OBETICHOLIC ACID - OCALIVA						
N 207999 002	10047117	Sep 06, 2033	U-1854			
	10052337	Apr 26, 2036	DP			
	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA						
N 208232 001	10238709	Feb 03, 2036	U-2857		ODE-474	Jun 26, 2027
	10695397	Feb 03, 2036	U-2857			
	11052126	Feb 03, 2036	U-2857			
	11141457	Dec 28, 2040	U-3232			
	11338011	Feb 03, 2036	U-2857			
	11510963	Feb 03, 2036	U-2857			
	11857595	Feb 03, 2036	U-3784			
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
	12246054	Feb 03, 2036	U-2857			
	12251418	Feb 03, 2036	U-2857			
	8329198	Sep 17, 2029	DP			
	8535695	Sep 17, 2029	U-2857			
	9265812	Sep 17, 2029	DP			
	9566246	Sep 17, 2029	DP			
OCTREOTIDE ACETATE - BYNFEZIA PEN						
N 213224 001	10342850	May 15, 2038	DP			
	11052196	Nov 03, 2040	U-4007			
	11052196	Nov 03, 2040	U-4008			
	11052196	Nov 03, 2040	U-4009			
	11246991	Nov 03, 2040	U-4007			
	11246991	Nov 03, 2040	U-4008			
	11246991	Nov 03, 2040	U-4009			
	11534553	Nov 03, 2040	U-4007			
	11534553	Nov 03, 2040	U-4008			
	11534553	Nov 03, 2040	U-4009			
	12350475	Dec 29, 2041	U-4007			
	12350475	Dec 29, 2041	U-4008			
	12350475	Dec 29, 2041	U-4009			
ODEVIXIBAT - BYLVAY						
N 215498 001	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3648		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 001	10093697	Nov 08, 2031	U-3648		ODE-436	Jun 13, 2030
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	12091394	Jun 20, 2039	DS			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3648		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10093697	Nov 08, 2031	U-3648		ODE-436	Jun 13, 2030
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	12091394	Jun 20, 2039	DS			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3648		NCE	Jul 20, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 003	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10093697	Nov 08, 2031	U-3648		ODE-436	Jun 13, 2030
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	12091394	Jun 20, 2039	DS			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031	U-3186		I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3648		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10093697	Nov 08, 2031	U-3648		ODE-436	Jun 13, 2030
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11583539	Nov 12, 2041	U-3186			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	11801226	Jun 20, 2039	DP			
	11802115	Jun 20, 2039	DP			
	12091394	Jun 20, 2039	DS			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	11707466	Nov 12, 2041	DP			
	11793805	Aug 23, 2031	U-3734			
	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLAPARIB - LYNPARZA						
N 206162 001	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
OLAPARIB - LYNPARZA						
N 208558 001	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	11970530	Oct 25, 2041	U-3929		ODE-283	Dec 27, 2026
	11970530	Oct 25, 2041	U-3930		ODE-306	May 08, 2027
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	12048695	Oct 07, 2029	DP			
	12144810	Oct 07, 2029	DP			
	12178816	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
	8071579	Aug 12, 2027			U-2480	
	8071579	Aug 12, 2027			U-2482	
	8071579	Aug 12, 2027			U-2483	
	8071579	Aug 12, 2027			U-2716	
	8071579	Aug 12, 2027			U-2819	
	8071579	Aug 12, 2027			U-2820	
	8071579	Aug 12, 2027			U-2821	
	8071579	Aug 12, 2027			U-2822	
	8071579	Aug 12, 2027			U-2823	
	8071579	Aug 12, 2027			U-2824	
	8071579	Aug 12, 2027			U-2832	
	8071579	Aug 12, 2027			U-2833	
	8071579	Aug 12, 2027			U-3333	
	8071579	Aug 12, 2027			U-3631	
	8071579	Aug 12, 2027			U-3695	
	8143241	Aug 12, 2027			U-2480	
	8143241	Aug 12, 2027			U-2482	
	8143241	Aug 12, 2027			U-2483	
	8143241	Aug 12, 2027			U-2716	
	8143241	Aug 12, 2027			U-2819	
	8143241	Aug 12, 2027			U-2820	
	8143241	Aug 12, 2027			U-2821	
	8143241	Aug 12, 2027			U-2822	
	8143241	Aug 12, 2027			U-2823	
	8143241	Aug 12, 2027			U-2824	
	8143241	Aug 12, 2027			U-2832	
	8143241	Aug 12, 2027			U-2833	
	8143241	Aug 12, 2027			U-3333	
	8143241	Aug 12, 2027			U-3631	
	8143241	Aug 12, 2027			U-3695	
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031			U-2101	
	8859562	Aug 04, 2031			U-2103	
	8859562	Aug 04, 2031			U-2480	
	8859562	Aug 04, 2031			U-2482	
	8859562	Aug 04, 2031			U-2483	
	8859562	Aug 04, 2031			U-2716	
	8859562	Aug 04, 2031			U-2819	
	8859562	Aug 04, 2031			U-2820	
	8859562	Aug 04, 2031			U-2821	
	8859562	Aug 04, 2031			U-2822	
	8859562	Aug 04, 2031			U-2823	
	8859562	Aug 04, 2031			U-2824	
	8859562	Aug 04, 2031			U-2832	
	8859562	Aug 04, 2031			U-2833	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	8859562	Aug 04, 2031	U-3695			
OLAPARIB - LYNPARZA						
N 208558 002	11633396	Oct 07, 2029	DP		I-914	May 31, 2026
	11970530	Oct 25, 2041	U-3929		ODE-283	Dec 27, 2026
	11970530	Oct 25, 2041	U-3930		ODE-306	May 08, 2027
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	12144810	Oct 07, 2029	DP			
	12178816	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8071579	Aug 12, 2027	U-3695			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-3695			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA								
N 208558	002		8859562	Aug 04, 2031	U-2716			
			8859562	Aug 04, 2031	U-2819			
			8859562	Aug 04, 2031	U-2820			
			8859562	Aug 04, 2031	U-2821			
			8859562	Aug 04, 2031	U-2822			
			8859562	Aug 04, 2031	U-2823			
			8859562	Aug 04, 2031	U-2824			
			8859562	Aug 04, 2031	U-2832			
			8859562	Aug 04, 2031	U-2833			
			8859562	Aug 04, 2031	U-3333			
			8859562	Aug 04, 2031	U-3631			
			8859562	Aug 04, 2031	U-3695			
OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)								
N 218614	001		9127276	May 01, 2034	DS		ODE-515	Dec 19, 2031
			9157082	Apr 27, 2032	U-4050			
			9163239	May 01, 2034	DS			
			9181549	May 01, 2034	DS			
			9593333	Feb 14, 2034	U-4050			
OLICERIDINE - OLINVYK								
N 210730	001		11077098	Mar 23, 2032	DS DP U-2986			
			11931350	Mar 23, 2032	DS U-2986			
			8835488	Mar 23, 2032	DS DP U-2986			
			9309234	Mar 23, 2032	DS DP U-2986			
			9642842	Mar 23, 2032	DP U-2986			
OLICERIDINE - OLINVYK								
N 210730	002		11077098	Mar 23, 2032	DS DP U-2986			
			11931350	Mar 23, 2032	DS U-2986			
			8835488	Mar 23, 2032	DS DP U-2986			
			9309234	Mar 23, 2032	DS DP U-2986			
			9642842	Mar 23, 2032	DP U-2986			
OLICERIDINE - OLINVYK								
N 210730	003		11077098	Mar 23, 2032	DS DP U-2986			
			11931350	Mar 23, 2032	DS U-2986			
			8835488	Mar 23, 2032	DS DP U-2986			
			9309234	Mar 23, 2032	DS DP U-2986			
			9642842	Mar 23, 2032	DP U-2986			
OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%								
N 204508	001						NPP	Apr 24, 2027
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT								
N 203108	001		7727984	Jan 19, 2027	DS			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT								
N 206756	001		7396341	Oct 10, 2026	DP	Y		
			7396341*PED	Apr 10, 2027				
			7727984	Jan 19, 2027	DS			
			7837235	Mar 13, 2028	DP	Y		
			7837235*PED	Sep 13, 2028				
			8733341	Oct 16, 2030	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	9027967	Mar 31, 2027	DP	Y		
OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF						
N 206276 001	8791154	May 19, 2032	DP U-1680			
	9533053	May 19, 2032	DP			
OLUTASIDENIB - REZLIDHIA						
N 215814 001	10414752	Sep 18, 2035	DP		NCE	Dec 01, 2027
	10532047	May 16, 2039	DS		ODE-413	Dec 01, 2029
	10550098	Sep 18, 2035	DP			
	10959994	May 16, 2039	DP			
	11013733	May 16, 2039	U-3496			
	11013734	May 16, 2039	U-3495			
	11376246	May 16, 2039	U-3495			
	11497743	May 16, 2039	U-3495			
	11498913	Sep 18, 2035	DP			
	11723905	Nov 12, 2039	DP			
	11738018	Jul 17, 2039	U-3684			
	12053463	May 16, 2039	DS DP			
	12275715	Sep 18, 2035	DS DP U-3684			
	9834539	Sep 18, 2035	DS DP U-3497			
OMACETAXINE MEPESUCCINATE - SYNRIBO						
N 203585 001	6987103	Oct 26, 2026	U-1300			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209816 001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
	10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
	10383884	Oct 31, 2037	U-2576			
	10835542	Oct 31, 2037	U-2576			
	8383610	Sep 23, 2030	DS			
	9265740	Oct 24, 2030	DP U-1569			
	9314475	Mar 18, 2031	DP			
	9724358	Mar 05, 2029	U-1569			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209817 001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
	10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
	10835542	Oct 31, 2037	U-2576			
	9265740	Mar 05, 2029	DP			
	9724358	Mar 05, 2029	U-1569			
OMAVELOXOLONE - SKYCLARYS						
N 216718 001	11091430	Apr 20, 2029	U-3552		M-270	Dec 20, 2027
	11919838	Apr 20, 2029	U-3862		NCE	Feb 28, 2028
	11919838	Apr 20, 2029	U-3863		ODE-427	Feb 28, 2030
	8124799	Dec 03, 2029	DS			
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE							
N 207931	001	8420596	Apr 10, 2031	DS DP			
		8420596*PED	Oct 10, 2031				
		8642538	Sep 10, 2029	DS DP U-1638			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
		9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA							
N 205060	001	10117844	Jan 04, 2033	U-2447			
		7960370	Dec 20, 2026	DP			
		9050308	Jan 04, 2033	U-1511			
		9050309	Jan 04, 2033	DS			
OMEPRAZOLE - OMEPRAZOLE							
N 209400	001	10076494	Dec 08, 2036	DP			
		10835488	Dec 08, 2036	DP			
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP							
N 213593	001	10751333	Jul 16, 2039	DP			
		11103492	Jul 16, 2039	DP			
		11633478	Jul 16, 2039	DP			
		11771686	Mar 01, 2040	U-623			
		11911473	Jul 16, 2039	U-623			
		11911473	Jul 16, 2039	U-624			
		12042539	Jul 16, 2039	DP			
		12329752	Jul 16, 2039	DP			
		12440566	Jul 16, 2039	DP			
OMIDENEPAG ISOPROPYL - OMLONTI							
N 215092	001	10179127	Jan 08, 2035	DP U-3454		NCE	Sep 22, 2027
		10702511	Jan 08, 2035	DP U-3454			
		10765750	Jan 08, 2035	DP			
		10774072	Jun 10, 2035	DS			
		11197849	Jan 08, 2035	DP U-3454			
		11666563	Jul 16, 2039	U-3454			
		11793798	Jan 08, 2035	DP U-3454			
		12290511	Dec 27, 2038	U-3454			
		12295946	Jan 08, 2035	DP U-3454			
		8648097	Oct 13, 2029	DS DP			
		8685986	Oct 13, 2029	DP			
		9415038	Jan 08, 2035	DP U-3454			
		RE48183	Jan 08, 2035	DP U-3454			
ONDANSETRON - ZUPLENZ							
N 022524	001	8580830	Nov 23, 2029	DP			
		9095577	Jul 13, 2030	DP			
ONDANSETRON - ZUPLENZ							
N 022524	002	8580830	Nov 23, 2029	DP			
		9095577	Jul 13, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OPICAPONE - ONGENTYS						
N 212489 001	10071085	Mar 31, 2030	DP			
	10583130	Mar 31, 2030	U-3869			
	12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
OPICAPONE - ONGENTYS						
N 212489 002	10071085	Mar 31, 2030	DP			
	10583130	Mar 31, 2030	U-3869			
	12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
ORITAVANCIN DIPHOSPHATE - ORBACTIV						
N 206334 001	8420592	Aug 29, 2029	U-1570			
	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
ORITAVANCIN DIPHOSPHATE - KIMYRSA						
N 214155 001	8420592	Aug 29, 2029	U-3101			
	9649352	Jul 16, 2035	DS DP			
	9682061	Apr 26, 2030	U-3101			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 001	10143680	Jul 06, 2035	DP		ODE-286	Mar 06, 2027
	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 002	10143680	Jul 06, 2035	DP		ODE-286	Mar 06, 2027
	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
	8835646	Aug 23, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 002	9434754	Jan 13, 2031	DS			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 003	10143680	Jul 06, 2035	DP		ODE-286	Mar 06, 2027
	10709691	Oct 12, 2035	U-2770			
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	11524951	Jul 25, 2032	DS DP			
	12465608	Nov 26, 2042	U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	11524951	Jul 25, 2032	DS DP			
	12465608	Nov 26, 2042	U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
OSPEMIFENE - OSPHENA						
N 203505 001	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSPEMIFENE - OSPHENA						
N 203505 001	8642079	Jul 09, 2028	DP			
OTESECONAZOLE - VIVJOA						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	11896599	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	11896599	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	11896599	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXYBUTYNIN CHLORIDE - GELNIQUE						
N 022204 001	10449173	Nov 06, 2029	DP	U-2637		
	8920392	Mar 26, 2031	U-1644			
	9259388	Nov 06, 2029	U-1644			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 001	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 002	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 003	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 004	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 005	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	11964056	Aug 24, 2027	DP			
	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	9492393	Aug 24, 2027			U-1556	
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND						
N 209777 001	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND						
N 209777 002	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND						
N 209777 003	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND						
N 209777 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE						
N 208552 001	10335391	Jun 11, 2035			U-2567	
	10751325	Jun 11, 2035			U-2921	
	11517560	Jun 11, 2035			U-3494	
	12350255	Jun 11, 2035			U-3494	
	7812049	May 02, 2028			U-1959	
	8883838	Dec 01, 2031	DP			
	9974773	Jun 11, 2035			U-2306	
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ						
N 212520 001	10799481	Dec 16, 2039			U-2849	
	10814001	Dec 16, 2039	DP			
	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031			U-2849	
	10940138	Dec 16, 2039			U-2849	
	11103482	Dec 16, 2039	DP			
	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039			U-2849	
	11541036	Dec 16, 2039	DP			
	11701343	Dec 16, 2039			U-2849	
	8357714	Aug 26, 2031			U-2849	
	9867808	Aug 26, 2031			U-2849	
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE						
N 208032 001	8580282	Apr 02, 2030	DP		U-1876	
	9308191	Apr 02, 2030	DP		U-1876	
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 001	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 002	8808737	Jun 21, 2027			U-3085	
	8871779	Nov 22, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	003		8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	004		8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	005		8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	006		8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	007		8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	001		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	002		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	003		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	004		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	005		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	006		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 201655	007		7851482	Jul 10, 2029	DS			
			8808737	Jun 21, 2027	U-1598			
			8871779	Nov 22, 2029	DS			
OZANIMOD HYDROCHLORIDE - ZEPOSIA								
N 209899	001		10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
			11680050	Sep 30, 2038	DS DP U-2774			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 001	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	Mar 24, 2033	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 002	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
	11680050	Sep 30, 2038	DS DP U-2774			
	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	Mar 24, 2033	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 003	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
	11680050	Sep 30, 2038	DS DP U-2774			
	11680050	Sep 30, 2038	DS DP U-3740			
	8481573	Mar 24, 2033	DS DP U-2774			
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZENOXACIN - XEPI						
N 208945 001	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
PACLITAXEL - ABRAXANE						
N 021660 001	7758891	Feb 21, 2026	U-1434			
	7758891*PED	Aug 21, 2026				
	8034375	Aug 13, 2026	U-1290			
	8268348	Feb 21, 2026	U-1290			
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
PACRITINIB CITRATE - VONJO						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332		ODE-397	Feb 28, 2029
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291		NCE	Nov 29, 2026
	9061057	Aug 26, 2033	DS DP U-3291		ODE-390	Nov 29, 2028
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	9789208	Aug 26, 2033	DS DP U-3291			
PALBOCICLIB - IBRANCE						
N 207103 001	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 207103 002	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 207103 003	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 212436 001	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 212436 002	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE						
N 212436 003	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 001	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 002	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 003	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 004	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 005	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 005	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
	11666697	Nov 24, 2041	U-3626			
	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 006	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
	11666697	Nov 24, 2041	U-3626			
	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 001	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 002	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 003	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 005	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
PALIPERIDONE PALMITATE - ERZOFRI						
N 216352 006	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
PALOPEGTERIPARATIDE - YORVIPATH						
N 216490 001	11590207	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	12295989	Sep 28, 2037	U-3982			
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
	8906847	Apr 30, 2031	DS DP U-3982			
PALOPEGTERIPARATIDE - YORVIPATH						
N 216490 002	11590207	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	12295989	Sep 28, 2037	U-3982			
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
	8906847	Apr 30, 2031	DS DP U-3982			
PALOPEGTERIPARATIDE - YORVIPATH						
N 216490 003	11590207	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	12295989	Sep 28, 2037	U-3982			
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
	8906847	Apr 30, 2031	DS DP U-3982			
PALOVAROTENE - SOHONOS						
N 215559 001	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALOVAROTENE - SOHONOS						
N 215559 001	11622959	Jun 08, 2037	U-3676			
	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 002	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 003	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 004	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			
PALOVAROTENE - SOHONOS						
N 215559 005	10292954	Aug 31, 2031	U-3676		NCE	Aug 16, 2028
	10864194	Jun 08, 2037	U-3676		ODE-439	Aug 16, 2030
	11622959	Jun 08, 2037	U-3676			
	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
	9314439	Aug 31, 2031	U-3676			
	9789074	Aug 31, 2031	U-3676			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALTUSOTINE HYDROCHLORIDE - PALSONIFY						
N 219070 001	10351547	Jul 12, 2037	DS DP U-4283		NCE	Sep 25, 2030
	10464918	Jan 16, 2039	DS			
	10597377	Jul 12, 2037	DS DP U-4283			
	10875839	Jul 12, 2037	U-4283			
	11266641	Sep 07, 2041	DP U-4283			
	11414397	Jul 12, 2037	DS DP U-4283			
	11957674	Sep 07, 2041	U-4283			
	12208092	Mar 25, 2044	U-4282			
	9896432	Jul 12, 2037	DS DP U-4283			
PALTUSOTINE HYDROCHLORIDE - PALSONIFY						
N 219070 002	10351547	Jul 12, 2037	DS DP U-4283		NCE	Sep 25, 2030
	10464918	Jan 16, 2039	DS			
	10597377	Jul 12, 2037	DS DP U-4283			
	10875839	Jul 12, 2037	U-4283			
	11266641	Sep 07, 2041	DP U-4283			
	11414397	Jul 12, 2037	DS DP U-4283			
	11957674	Sep 07, 2041	U-4283			
	12208092	Mar 25, 2044	U-4282			
	9896432	Jul 12, 2037	DS DP U-4283			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANTOPRAZOLE SODIUM - PROTONIX IV						
N 020988 001					NPP	Aug 12, 2027
PANTOPRAZOLE SODIUM - PROTONIX						
N 022020 001	7544370	Jun 07, 2026	DP			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
	8946251	Aug 04, 2026	DS DP U-904			
	9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 001	7473761	Dec 14, 2026	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 002	7473761	Dec 14, 2026	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 003	7473761	Dec 14, 2026	DS DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 001	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 001	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 002	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 003	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 004	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 005	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	11123363	Oct 08, 2033	U-1766		NPP	Oct 02, 2026
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8337824	May 29, 2030	DS U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 002	11123363	Oct 08, 2033	U-1766		NPP	Oct 02, 2026
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8337824	May 29, 2030	DS U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 003	11123363	Oct 08, 2033	U-1766		NPP	Oct 02, 2026
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8337824	May 29, 2030	DS U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 004	11123363	Oct 08, 2033	U-1766		NS	Oct 02, 2026
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 004	8337824	May 29, 2030	DS U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATISIRAN SODIUM - ONPATTRO						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378		M-270	Jan 13, 2026
	11079379	Aug 27, 2035	DS DP U-2378			
	11141378	Apr 15, 2029	DP			
	8058069	Apr 15, 2029	DP			
	8158601	Nov 10, 2030	DP U-2378			
	8168775	Aug 10, 2032	DS DP U-2378			
	8492359	Apr 15, 2029	DP			
	8642076	Oct 03, 2027	DP			
	8741866	Oct 20, 2029	U-2378			
	8802644	Oct 21, 2030	DP U-2378			
	8822668	Apr 15, 2029	DP U-2378			
	9234196	Oct 20, 2029	DP U-2378			
	9364435	Apr 15, 2029	DP U-2378			
PAZOPANIB HYDROCHLORIDE - PAZOPANIB HYDROCHLORIDE						
A 219922 001					CGT	May 06, 2026
PEGCETACOPLAN - EMPAVELI						
N 215014 001	10035822	Nov 15, 2033	DS		I-972	Jul 28, 2028
	10125171	Aug 02, 2033	DS		M-288	Feb 08, 2026
	10875893	Nov 15, 2033	DS U-3124		NCE	May 14, 2026
	10875893	Nov 15, 2033	DS U-4242		ODE-351	May 14, 2028
	11040107	Apr 09, 2038	DP U-3172			
	11040107	Apr 09, 2038	DP U-3173			
	11040107	Apr 09, 2038	DP U-3174			
	11040107	Apr 09, 2038	DP U-4241			
	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
	11292815	Nov 15, 2033	DS DP U-4242			
	11292815	Nov 15, 2033	DS DP U-4243			
	11661441	Jan 13, 2033	DS U-3124			
	11661441	Jan 13, 2033	DS U-4242			
	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
	11844841	Dec 09, 2038	DP U-4241			
	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
	12290566	Dec 14, 2038	DP U-4238			
	12290566	Dec 14, 2038	DP U-4239			
	12290566	Dec 14, 2038	DP U-4240			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS U-3123			
	9169307	Nov 18, 2027	DS U-4244			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - SYFOVRE						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			
	11661441	Jan 13, 2033	DS U-3540			
	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
	12458695	Dec 14, 2038	DP			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			
	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS U-3541			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 001	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 002	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 003	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 004	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 005	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 006	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 007	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 008	7550433	Jun 02, 2026	U-1238			
	7919461	Jun 02, 2026	U-1238			
PEGULICIANINE ACETATE - LUMISIGHT						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	11592396	Sep 01, 2030	DS			
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEMETREXED - PEMFEXY						
N 209472 001	11793813	Feb 19, 2036	DP			
	12115164	Feb 19, 2036	U-4246			
	12115164	Feb 19, 2036	U-4247			
	12115164	Feb 19, 2036	U-4248			
	9604990	Oct 28, 2035	DS			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 001	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 002	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 003	11147817	Mar 26, 2035	DP			
PEMIGATINIB - PEMAZYRE						
N 213736 001	10131667	Apr 17, 2034	U-2809		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3464		ODE-404	Aug 26, 2029
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			
PEMIGATINIB - PEMAZYRE						
N 213736 002	10131667	Apr 17, 2034	U-2809		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3464		ODE-404	Aug 26, 2029
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			
PEMIGATINIB - PEMAZYRE						
N 213736 003	10131667	Apr 17, 2034	U-2809		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3464		ODE-404	Aug 26, 2029
	11466004	May 03, 2039	U-3465			
	11466004	May 03, 2039	U-3466			
	11628162	Aug 30, 2040	U-3568			
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
	9611267	Jan 30, 2035	DS DP			
PERAMIVIR - RAPIVAB						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMIVIR - RAPIVAB								
N 206426	001		10391075	Feb 12, 2027	U-2622			
			10391075	Feb 12, 2027	U-3069			
			8778997	May 07, 2027	U-1627			
			8778997	May 07, 2027	U-2622			
			8778997	May 07, 2027	U-3069			
PERAMPANEL - FYCOMPA								
N 202834	001		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	002		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	003		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	004		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	005		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 202834	006		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA								
N 208277	001		8772497	Jul 01, 2026	DS			
PERFLUOROHEXYLOCTANE - MIEBO								
N 216675	001		10058615	Sep 12, 2033	U-1900		NCE	May 18, 2028
			10369117	Sep 12, 2033	U-1900			
			10449164	Sep 12, 2033	U-1900			
			10507132	Jun 21, 2037	U-1900			
			10576154	Oct 01, 2035	U-1900			
			11357738	Sep 29, 2036	DP			
PERFLUTREN - DEFINITY								
N 021064	001		10583207	Dec 28, 2035	U-665			
			10583208	Mar 16, 2037	U-665			
			10588988	May 04, 2037	U-665			
			11266750	Mar 16, 2037	U-665			
			11529431	Mar 16, 2037	U-665			
			11857646	Mar 16, 2037	U-665			
			11925695	Mar 16, 2037	U-665			
			12161730	Mar 16, 2037	U-665			
			9789210	Mar 16, 2037	U-665			
PERFLUTREN - DEFINITY RT								
N 021064	002		10022460	Dec 28, 2035	DS DP			
			10583207	Dec 28, 2035	U-665			
			10583208	Mar 16, 2037	U-665			
			10588988	May 04, 2037	U-665			
			11266750	Mar 16, 2037	U-665			
			11395856	Dec 28, 2035	DS DP U-665			
			11529431	Mar 16, 2037	U-665			
			11857646	Mar 16, 2037	U-665			
			11925695	Mar 16, 2037	U-665			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERFLUTREN - DEFINITY RT						
N 021064 002	12161730	Mar 16, 2037	U-665			
	9789210	Mar 16, 2037	U-665			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 001	10189833	May 05, 2036	U-2606		ODE-250	Aug 02, 2026
	10435404	Jul 24, 2038	DP			
	10730876	May 05, 2036	DS			
	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
PEXIDARTINIB HYDROCHLORIDE - TURALIO						
N 211810 002	10189833	May 05, 2036	U-2606		ODE*	Aug 02, 2026
	10435404	Jul 24, 2038	DP			
	10730876	May 05, 2036	DS			
	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
PHENOBARBITAL SODIUM - SEZABY						
N 215910 001	11857683	Apr 07, 2042	DP U-3779		ODE-414	Nov 17, 2029
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 001	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 002	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 003	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	8580298	May 15, 2029	DP		M-308	Sep 13, 2027
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	8580298	May 15, 2029	DP		M-308	Sep 13, 2027
	8580299	Jun 14, 2029	U-3399			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	002	8895057	Jun 09, 2028	U-3398			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	003	8580298	May 15, 2029	DP		M-308	Sep 13, 2027
		8580299	Jun 14, 2029	U-3399			
		8895057	Jun 09, 2028	U-3398			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	004	8580298	May 15, 2029	DP		M-308	Sep 13, 2027
		8580299	Jun 14, 2029	U-3399			
		8895057	Jun 09, 2028	U-3398			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-3398			
PHENTOLAMINE MESYLATE - RYZUMVI							
N 217064	001	10278918	Jan 31, 2034	DP		NP	Sep 25, 2026
		10772829	Jan 31, 2034	DP			
		11090261	Jan 31, 2034	DP			
		11400077	Oct 25, 2039	U-3804			
		11844858	Jan 31, 2034	DP			
		12201615	Dec 25, 2039	U-3804			
		12201616	Oct 25, 2039	U-3804			
		12350366	Jan 31, 2034	DP			
		9795560	Jan 31, 2034	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	002	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV							
N 203826	004	11213480	Sep 26, 2036	DP			
		11471400	Aug 05, 2036	DP			
		12257342	Sep 26, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV							
N 203826	005	11213480	Sep 26, 2036	DP			
		11471400	Aug 05, 2036	DP			
		12257342	Sep 26, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI							
N 215352	001	10839960	Jul 15, 2031	U-3685		NP	May 05, 2026
		11398306	Jul 15, 2031	U-3685			
		11839487	Jul 15, 2031	U-3685			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIFLUFOLASTAT F-18 - PYLARIFY						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	11851407	Jun 09, 2037	DS DP U-3130			
	12070513	Jul 31, 2029	DS DP U-3130			
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
PILOCARPINE HYDROCHLORIDE - VUITY						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
PILOCARPINE HYDROCHLORIDE - QLOSI						
N 217836 001	10639297	Aug 18, 2037	DP U-3741		NP	Oct 17, 2026
	11129812	Aug 18, 2037	U-3741			
	11974986	Aug 18, 2037	U-3741			
	9867810	Aug 18, 2037	DP U-3741			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 002	10517860	Mar 23, 2037	U-1974			
	10953000	Mar 23, 2037	U-1974			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 210793 001	10449185	Aug 27, 2038	DP			
	10646480	Aug 27, 2038	DP			
	10849891	Aug 27, 2038	DP U-1974			
	11452721	Aug 27, 2038	DP			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
PIRFENIDONE - ESBRIET						
N 022535 001	7566729	Apr 22, 2029	U-1600			
	7635707	Apr 22, 2029	U-1609			
	7696236	Dec 18, 2027	U-1601			
	7767225	Sep 22, 2026	DP U-1602			
	7767700	Dec 18, 2027	U-1601			
	7816383	Jan 08, 2030	U-1603			
	7910610	Jan 08, 2030	U-1604			
	7988994	Sep 22, 2026	DP U-1602			
	8013002	Jan 08, 2030	U-1603			
	8084475	Jan 08, 2030	U-1605			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 022535 001	8318780	Jan 08, 2030	U-1606			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	DP U-1608			
	8592462	Apr 22, 2029	U-1609			
	8609701	Apr 22, 2029	U-1610			
	8648098	Jan 08, 2030	U-1611			
	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
PIRFENIDONE - ESBRIET						
N 208780 001	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 001	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
PIRFENIDONE - ESBRIET						
N 208780 002	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 003	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10464905	Dec 16, 2036	U-4362		ODE-451	Dec 01, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10695323	Dec 16, 2036	DS DP U-4362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	10918622	Dec 16, 2036	U-3518			
	10918622	Dec 16, 2036	U-4362			
	12109193	Sep 14, 2041	DP			
	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4362			
	12268666	Jul 29, 2039	DP			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10464905	Dec 16, 2036	U-4362		ODE-451	Dec 01, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10695323	Dec 16, 2036	DS DP U-4362			
	10918622	Dec 16, 2036	U-3518			
	10918622	Dec 16, 2036	U-4362			
	12109193	Sep 14, 2041	DP			
	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4362			
	12268666	Jul 29, 2039	DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 001	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 002	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG						
N 208379 003	8829186	Jan 19, 2031	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 001	8207197	Mar 07, 2030	DS DP		NPP	Jun 21, 2027
	8354430	Feb 06, 2026	U-1101		ODE-255	Aug 14, 2026
	8354430	Feb 06, 2026	U-1102		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1101		ODE-489	Jun 21, 2031
	8486947	Sep 26, 2029	U-1102			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 002	8207197	Mar 07, 2030	DS DP		NPP	Jun 21, 2027
	8354430	Feb 06, 2026	U-1101		ODE-255	Aug 14, 2026
	8354430	Feb 06, 2026	U-1102		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1101		ODE-489	Jun 21, 2031
	8486947	Sep 26, 2029	U-1102			
PLAZOMICIN SULFATE - ZEMDRI						
N 210303 001	8383596	Jun 25, 2032	DS U-2328		NCE	Jun 25, 2023
	8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
	9266919	Nov 21, 2028	U-2328			
	9688711	Nov 21, 2028	DS U-2328			
PLECANATIDE - TRULANCE						
N 208745 001	10011637	Jun 05, 2034	DS			
	11142549	Jun 05, 2034	DP			
	11319346	Mar 01, 2032	DP			
	11834521	Jun 05, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLECANATIDE - TRULANCE						
N 208745 001	12146003	Jun 05, 2034	DP			
	7041786	Jan 30, 2028	DS			
	9610321	Sep 15, 2031	U-1999			
	9610321	Sep 15, 2031	U-2230			
	9616097	Aug 20, 2032	DP			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
PLOZASIRAN SODIUM - REDEMPLO						
N 219947 001	10294474	Mar 07, 2037	DS DP U-4360			
	10597657	Sep 10, 2038	DS DP U-4360			
	11174481	Mar 07, 2037	DS DP			
	11214801	Sep 10, 2038	DS DP U-4360			
	12365899	Sep 10, 2038	DS DP U-4360			
POLIDOCANOL - VARITHENA						
N 205098 001	7814943	Nov 19, 2027	DP U-1461			
	9480652	May 12, 2032	DP			
POMALIDOMIDE - POMALYST						
N 204026 001	10555939	May 19, 2030	DP		ODE-296	May 14, 2027
	10555939*PED	Nov 19, 2030			ODE-297	May 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031			PED	Nov 14, 2027
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 002	10555939	May 19, 2030	DP		ODE-296	May 14, 2027
	10555939*PED	Nov 19, 2030			ODE-297	May 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031			PED	Nov 14, 2027
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 003	10555939	May 19, 2030	DP		ODE-296	May 14, 2027
	10555939*PED	Nov 19, 2030			ODE-297	May 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031			PED	Nov 14, 2027
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 004	10555939	May 19, 2030	DP		ODE-296	May 14, 2027
	10555939*PED	Nov 19, 2030			ODE-297	May 14, 2027
	8828427	Jun 21, 2031	DS DP		PED	Nov 14, 2027
	8828427*PED	Dec 21, 2031			PED	Nov 14, 2027
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11192895	Dec 12, 2033	U-1700		I-934	Mar 19, 2027
	11192895	Dec 12, 2033	U-1701		ODE-472	Mar 19, 2031
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192895	Dec 12, 2033	U-1700		I-934	Mar 19, 2027
	11192895	Dec 12, 2033	U-1701		ODE-472	Mar 19, 2031
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	11192895	Dec 12, 2033	U-1700		I-934	Mar 19, 2027
	11192895	Dec 12, 2033	U-1701		ODE-472	Mar 19, 2031
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 004	11192895	Dec 12, 2033	U-1700		I-934	Mar 19, 2027
	11192895	Dec 12, 2033	U-1701		ODE-472	Mar 19, 2031
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONESIMOD - PONVORY						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONESIMOD - PONVORY						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	11951097	Oct 10, 2042	U-3891			
	12336980	Dec 10, 2035	U-3103			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2029	DS DP			
POSACONAZOLE - NOXAFIL						
N 205053 001					ODE-355	Jun 17, 2028
POSACONAZOLE - NOXAFIL						
N 205596 001	10117951	Mar 13, 2029	DP		ODE-355	Jun 17, 2028
	8410077	Mar 13, 2029	DP			
	9023790	Jul 04, 2031	DP U-1698			
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POSACONAZOLE - NOXAFIL								
N 205596	001		10117951	Mar 13, 2029	DP		ODE-355	Jun 17, 2028
			8410077	Mar 13, 2029	DP			
			9023790	Jul 04, 2031	DP U-1698			
			9023790	Jul 04, 2031	DP U-3160			
			9023790	Jul 04, 2031	DP U-3171			
			9358297	Jun 24, 2031	DP U-3160			
			9358297	Jun 24, 2031	DP U-3171			
			9493582	Feb 27, 2033	DP			
			9750822	Mar 13, 2029	DP			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES								
N 212121	001		10632150	Apr 19, 2039	DP U-2789			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE								
N 212832	004		11813291	Oct 12, 2041	DP U-4185			
			11925661	Oct 12, 2041	DP U-4185			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE								
N 212832	005		11813291	Oct 12, 2041	DP U-4185			
			11925661	Oct 12, 2041	DP U-4185			
PRALSETINIB - GAVRETO								
N 213721	001		10030005	Nov 01, 2036	DS DP U-2952		ODE-318	Sep 04, 2027
			10030005	Nov 01, 2036	DS DP U-3002		ODE-340	Dec 01, 2027
			11273160	Apr 03, 2039	U-2952		ODE-341	Dec 01, 2027
			11872192	Apr 03, 2039	U-2952			
			11963958	Apr 03, 2039	U-2828			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	001		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	002		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	003		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	004		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	005		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	006		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER								
N 022421	007		7695734	Apr 26, 2028	DP			
			8679533	Sep 08, 2029	DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRASTERONE - INTRAROSA						
N 208470 001	8268806	Mar 19, 2031	DP			
	8629129	Aug 07, 2028	DP			
	8957054	Jan 08, 2030			U-1922	
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 001	7799331	Oct 11, 2028	DP		U-1068	
	7799331	Oct 11, 2028	DP		U-139	
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 002	7799331	Oct 11, 2028	DP		U-1068	
	7799331	Oct 11, 2028	DP		U-139	
PREDNISONE - RAYOS						
N 202020 001	9504699	Aug 03, 2027			U-1362	
PREDNISONE - RAYOS						
N 202020 002	9504699	Aug 03, 2027			U-1362	
PREDNISONE - RAYOS						
N 202020 003	8168218	Jan 07, 2028	DP		U-1269	
	9504699	Aug 03, 2027			U-1362	
PREGABALIN - LYRICA CR						
N 209501 001	10022447	Nov 02, 2026			U-2136	
	10022447	Nov 02, 2026			U-2137	
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP		U-2136	
	8945620	Nov 02, 2026	DP		U-2137	
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 002	10022447	Nov 02, 2026			U-2136	
	10022447	Nov 02, 2026			U-2137	
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP		U-2136	
	8945620	Nov 02, 2026	DP		U-2137	
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR						
N 209501 003	10022447	Nov 02, 2026			U-2136	
	10022447	Nov 02, 2026			U-2137	
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP		U-2136	
	8945620	Nov 02, 2026	DP		U-2137	
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PRETOMANID - PRETOMANID						
N 212862 001					NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRETOMANID - PRETOMANID						
N 212862 001					GAIN	Aug 14, 2029
PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH						
N 213972 001	11478428	Dec 23, 2039	DP U-4026		NCE	Oct 25, 2029
	11554112	Apr 01, 2039	U-4026		GAIN	Oct 25, 2034
	12109197	Apr 01, 2039	U-4026			
	7795243	Jun 03, 2029	DS DP U-4026			
PROGESTERONE - PROGESTERONE						
A 218391 001					CGT	Mar 22, 2026
PROGESTERONE - MILPROSA						
N 201110 001	10537584	Feb 03, 2029	DP			
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL						
N 205410 001	8338489	Oct 16, 2028	U-1496			
	8987262	Oct 16, 2028	U-1988			
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 001					M-14	Jul 10, 2028
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 002					M-14	Jul 10, 2028
PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE						
N 217604 001	10881617	Jun 18, 2038	DP			
	10925833	Jun 18, 2038	DP			
	10987311	Jun 18, 2038	DP			
	11229606	Jun 18, 2038	DP			
	11478425	Jun 18, 2038	DP U-4012			
	11666536	Jun 18, 2038	DP			
	11911515	Jun 18, 2038	DP			
	12042559	Jun 18, 2038	DP			
	12233166	Jun 18, 2038	DP			
QUAZEPAM - DORAL						
N 018708 001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL						
N 018708 003	7608616	Jun 03, 2028	U-1012			
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA						
N 216993 001	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA						
N 216993 002	7820657	Sep 26, 2028	DS		NCE	Jul 20, 2028
	7968543	Aug 15, 2029	DP U-3661		ODE-437	Jul 20, 2030
	8129374	Mar 16, 2027	U-3661			
	8357690	Feb 26, 2031	U-3661			
	8557810	Mar 16, 2027	DP			
	8836218	Mar 23, 2030	U-3661			
	8865710	Aug 15, 2029	DP			
	8883783	Mar 16, 2027	DS			
	9555040	May 14, 2030	U-3661			
	9585892	Mar 16, 2027	U-3661			
	9675549	Sep 30, 2033	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 022145 001	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS HD						
N 022145 002	10772888	Mar 30, 2032	U-1663			
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	8771733	Jun 02, 2030	DS DP U-257			
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 001	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 002	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	8771733	Jun 02, 2030	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 205786 001	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
RAMIPRIL - VOSTALLY						
N 219757 001	12343338	Aug 16, 2039	DP U-4233			
RANOLAZINE - ASPRUZYO SPRINKLE						
N 216018 001	11510878	Jan 24, 2038	DP			
RANOLAZINE - ASPRUZYO SPRINKLE						
N 216018 002	10898444	Jan 24, 2038	DP			
	11510878	Jan 24, 2038	DP			
	12161761	Jan 24, 2038	DP			
RASAGILINE MESYLATE - AZILECT						
N 021641 001	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RASAGILINE MESYLATE - AZILECT						
N 021641 002	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN						
N 022161 001	8106183	Feb 02, 2027	DS			
	RE47301	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
	9458107	Apr 08, 2031	DP			
	9957232	Jul 09, 2032	DS			
RELUGOLIX - ORGOVYX						
N 214621 001	10350170	Feb 25, 2036	DP			
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	11583526	Sep 29, 2037	U-3020			
	11795178	Sep 27, 2033	DS DP			
	12097198	Sep 29, 2037	U-3020			
	12144809	Sep 29, 2037	U-4035			
	12325714	Sep 27, 2033	DS DP			
	12336990	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2029	DS			
	8058280	Jan 28, 2026	DS DP			
REMDESIVIR - VEKLURY						
N 214787 001	10065958	Sep 16, 2031	DS		M-301	Jul 13, 2026
	10065958*PED	Mar 16, 2032			PED	Jan 13, 2027
	10675296	Jul 10, 2038	DP			
	10675296*PED	Jan 10, 2039				
	10695361	Sep 16, 2036	U-3831			
	10695361	Sep 16, 2036	U-3832			
	10695361*PED	Mar 16, 2037				
	11007208	Sep 16, 2036	U-3831			
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMDESIVIR - VEKLURY						
N 214787 001	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
REMDESIVIR - VEKLURY						
N 214787 002	10065958	Sep 16, 2031	DS		M-301	Jul 13, 2026
	10065958*PED	Mar 16, 2032			PED	Jan 13, 2027
	10695361	Sep 16, 2036	U-3829			
	10695361	Sep 16, 2036	U-3830			
	10695361*PED	Mar 16, 2037				
	11007208	Sep 16, 2036	U-3829			
	11007208	Sep 16, 2036	U-3830			
	11007208*PED	Mar 16, 2037				
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			
	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMIBRUTINIB - RHAPSIDO						
N 218436 001	10457647	Nov 13, 2034	U-4280		NCE	Sep 30, 2030
	12419889	Jan 20, 2043	U-4281			
	9512084	Nov 13, 2034	DS DP			
REMIMAZOLAM BESYLATE - BYFAVO						
N 212295 001	10052334	Nov 07, 2031	U-2968			
	10195210	Nov 07, 2031	U-2968			
	10342800	Nov 07, 2031	U-2968			
	10472365	Jul 10, 2027	U-2968			
	10722522	Nov 07, 2031	U-2968			
	10961250	Jul 10, 2027	DP U-2968			
	9561236	Apr 30, 2033	U-2968			
	9737547	Nov 07, 2031	U-2968			
	9777007	Jul 10, 2027	DP			
	9827251	Jan 13, 2034	U-2968			
	9914738	Jul 10, 2027	DP			
REPOTRECTINIB - AUGTYRO						
N 218213 001	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE-455	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-483	Jun 13, 2031
	12187739	Jul 05, 2036	DP			
	12310968	Jul 20, 2036	U-3755			
	RE50634	Jan 23, 2035	DS DP			
REPOTRECTINIB - AUGTYRO						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-483	Jun 13, 2031
	12187739	Jul 05, 2036	DP			
	12310968	Jul 20, 2036	U-3755			
	RE50634	Jan 23, 2035	DS DP			
RESMETIROM - REZDIFFRA						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	12377104	Feb 04, 2045	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
RESMETIROM - REZDIFFRA						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	12377104	Feb 04, 2045	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
RESMETIROM - REZDIFFRA						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RESMETIROM - REZDIFFRA						
N 217785 003	12377104	Feb 04, 2045	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
RETAPAMULIN - ALTABAX						
N 022055 001	7875630	Feb 14, 2027	DS			
REVEFENACIN - YUPELRI						
N 210598 001	10550081	Jul 14, 2030	DS			
	11008289	Jul 14, 2030	U-2440			
	11484531	Oct 23, 2039	U-2440			
	11691948	Jul 14, 2030	DP			
	11858898	Jul 14, 2030	DS DP U-2440			
	12048692	Aug 29, 2039	U-2440			
	12285417	Aug 29, 2039	U-2440			
	7288657	Oct 31, 2028	DS			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
REVUMENIB CITRATE - REVUFORJ						
N 218944 001	10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	11479557	Jun 08, 2037	DP U-4045		ODE-502	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ						
N 218944 002	10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	11479557	Jun 08, 2037	DP U-4045		ODE-502	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ						
N 218944 003	10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	11479557	Jun 08, 2037	DP U-4045		ODE-502	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
REZAFUNGIN ACETATE - REZZAYO						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	11712459	Mar 15, 2037	DP U-3566		GAIN	Mar 22, 2035
	11819533	Jul 11, 2038	DS DP U-3566			
	8722619	Mar 02, 2032	DS DP U-3566			
	9526835	Mar 14, 2033	DS DP U-3566			
RIBOCICLIB SUCCINATE - KISQALI						
N 209092 001	10799506	Apr 14, 2036	DP		I-950	Sep 17, 2027
	12064434	Apr 14, 2036	DP			
	12419894	Apr 14, 2036	DP			
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIBOCICLIB SUCCINATE - KISQALI						
N 209092 001	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	8962630	Dec 09, 2029	U-3975			
	8962630	Dec 09, 2029	U-3999			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9416136	Aug 20, 2029	U-3975			
	9416136	Aug 20, 2029	U-3999			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
	9868739	Nov 09, 2031	U-3975			
	9868739	Nov 09, 2031	U-3999			
RIBOFLAVIN 5'-PHOSPHATE SODIUM - EPIOXA HD/EPIOXA KIT						
N 219910 001					NP	Oct 17, 2028
RIFAMYCIN SODIUM - AEMCOLO						
N 210910 001					NCE	Nov 16, 2023
					GAIN	Nov 16, 2028
RIFAXIMIN - XIFAXAN						
N 021361 001	10703763	Feb 27, 2026	U-2848			
	7928115	Jul 24, 2029	U-1121			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS DP U-2848			
	9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
	11779571	Feb 26, 2029	U-3706			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS DP U-1707			
	8741904	Feb 27, 2026	DS DP U-1708			
	8741904	Feb 27, 2026	DS DP U-2847			
	8829017	Jul 24, 2029	U-1562			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029	U-1481			
	9629828	Jul 24, 2029	U-1994			
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N 202022 001					NPP	Mar 15, 2027
					PED	Sep 15, 2027
RILPIVIRINE HYDROCHLORIDE - EDURANT PED						
N 219016 001	11065198	Oct 23, 2037	DP		NP	Mar 15, 2027
					PED	Sep 15, 2027
RILUZOLE - TIGLUTIK KIT						
N 209080 001	8765150	Mar 12, 2029	DP U-2401			
RILZABRUTINIB - WAYRILZ						
N 219685 001	11708370	Feb 20, 2041	DS		NCE	Aug 29, 2030
	12178818	Oct 13, 2040	U-4267			
	8940744	Sep 06, 2033	DS DP U-4270			
	9266895	Sep 06, 2033	DS DP U-4268			
	9580427	Mar 01, 2033	DS DP			
	9994576	Sep 06, 2033	DS DP U-4268			
	9994576	Sep 06, 2033	DS DP U-4269			
RIMEGEPANT SULFATE - NURTEC ODT						
N 212728 001	11083724	Mar 25, 2039	DP U-2718			
	11083724	Mar 25, 2039	DP U-3142			
	8314117	Feb 27, 2034	DS DP U-2718			
	8314117	Feb 27, 2034	DS DP U-3142			
	8759372	Feb 25, 2033	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIOCIGUAT - ADEMPAS						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
RIPRETINIB - QINLOCK						
N 213973 001	10966966	Aug 12, 2040	U-3153		ODE-298	May 15, 2027
	11185535	Dec 30, 2040	DP			
	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	11426390	Aug 12, 2040	U-3416			
	11433056	Aug 12, 2040	U-3423			
	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
	11779572	Oct 06, 2042	U-3714			
	11793795	Dec 30, 2040	DP			
	11801237	Dec 30, 2040	DP U-3219			
	11813251	Aug 12, 2040	U-3750			
	11844788	Dec 30, 2040	DP			
	11850240	Dec 30, 2040	DP			
	11850241	Dec 30, 2040	DP			
	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIPRETINIB - QINLOCK						
N 213973 001	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	12059410	Aug 12, 2040	U-3153			
	12059411	Aug 12, 2040	U-3971			
	12064422	Dec 30, 2040	U-3219			
	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
	12295944	Aug 12, 2040	U-4183			
	12318373	Aug 12, 2040	U-4191			
	12318374	Dec 30, 2040	DP			
	8188113	Jul 27, 2030	DS DP			
	8461179	May 15, 2034	DS DP			
	RE48731	Jun 07, 2032	U-3219			
RISDIPLAM - EVRYSDI						
N 213535 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		ODE-334	Aug 07, 2027
	11938136	Nov 08, 2036	DP		ODE-400	May 27, 2029
	12122789	Apr 15, 2041	DS DP			
	12350273	Oct 01, 2038	U-1943			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
RISDIPLAM - EVRYSDI						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943			
	12122789	Apr 15, 2041	DS DP			
	12350273	Oct 01, 2038	U-1943			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
RISEDRONATE SODIUM - ATELVIA						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
RISPERIDONE - RISPERIDONE						
A 211220 001					CGT	May 12, 2026
RISPERIDONE - RISPERIDONE						
A 211220 002					CGT	May 09, 2026
RISPERIDONE - RISPERIDONE						
A 211220 003					CGT	May 09, 2026
RISPERIDONE - PERSERIS KIT						
N 210655 001	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - PERSERIS KIT						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	11712475	Feb 13, 2028	U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
RISPERIDONE - PERSERIS KIT						
N 210655 002	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	11712475	Feb 13, 2028	U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
RISPERIDONE - RYKINDO						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 001	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - UZEDY						
N 213586 002	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			
	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - UZEDY						
N 213586 003	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			
	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - UZEDY						
N 213586 004	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - UZEDY						
N 213586 005	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - UZEDY						
N 213586 006	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 007	12128132	Sep 11, 2040	DP U-543		NP	Apr 28, 2026
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	9023897	Apr 05, 2033	DP			
RISPERIDONE - RISVAN						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
RISPERIDONE - RISVAN						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
RITLECITINIB TOSYLATE - LITFULO						
N 215830 001	12077533	Dec 03, 2034	U-3994		NCE	Jun 23, 2028
	12116368	Oct 17, 2041	DS			
	9617258	Dec 03, 2034	DS DP			
RIVAROXABAN - XARELTO						
N 022406 001	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 003	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 004	10828310	Jan 31, 2039	U-3207			
	10828310	Jan 31, 2039	U-3208			
	10828310*PED	Jul 31, 2039				
RIZATRIPTAN BENZOATE - RIZAFILM						
N 205394 001	9301948	Jul 30, 2034	DS DP			
ROCURONIUM BROMIDE - ROCURONIUM BROMIDE						
N 219108 001	11998605	Jul 22, 2039	DP			
ROFLUMILAST - ZORYVE						
N 215985 001	10940142	Jun 07, 2037	DP		NPP	Oct 05, 2026
	11129818	Aug 25, 2037	U-3408			
	11129818	Aug 25, 2037	U-3712			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3748			
	11992480	Jun 07, 2037	U-3748			
	12005051	Jun 07, 2037	U-3748			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3748			
	12336983	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3408			
	9907788	Jun 07, 2037	U-3712			
ROFLUMILAST - ZORYVE						
N 215985 002	10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	11129818	Aug 25, 2037	U-3970			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3970			
	11992480	Jun 07, 2037	U-3970			
	12005051	Jun 07, 2037	U-3970			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ZORYVE						
N 215985 002	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3970			
	12336983	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3970			
ROFLUMILAST - ZORYVE						
N 215985 003	10940142	Jun 07, 2037	DP		NS	Oct 04, 2028
	11129818	Aug 25, 2037	U-4301			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-4301			
	11992480	Jun 07, 2037	U-4301			
	12005051	Jun 07, 2037	U-4301			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-4301			
	12336983	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-4301			
ROFLUMILAST - ZORYVE						
N 217242 001	10940142	Jun 07, 2037	DP		I-969	May 22, 2028
	11129818	Aug 25, 2037	U-3773		NP	Dec 15, 2026
	11129818	Aug 25, 2037	U-4203			
	11707454	Dec 03, 2041	U-3773			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3773			
	11819496	Jun 07, 2037	U-4203			
	11992480	Jun 07, 2037	U-3773			
	11992480	Jun 07, 2037	U-4203			
	12005051	Jun 07, 2037	U-3773			
	12005051	Jun 07, 2037	U-4203			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3773			
	12310956	Jun 07, 2037	U-4203			
	12329751	Dec 03, 2041	U-3773			
	12336983	Jun 07, 2037	DP			
	12390453	Jun 07, 2037	DP			
	12453721	Aug 19, 2042	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3773			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ZORYVE						
N 217242 001	9907788	Jun 07, 2037	U-4203			
ROLAPITANT HYDROCHLORIDE - VARUBI						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
ROLAPITANT HYDROCHLORIDE - VARUBI						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
	9101615	Jul 14, 2032	U-1741			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 006	7857802	Nov 28, 2026	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 007	7857802	Nov 28, 2026	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 001	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 002	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 003	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE						
N 208647 004	10413543	Feb 12, 2036	DP			
ROTIGOTINE - NEUPRO						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N 021829 003	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP		U-1272	
	8246979	Sep 01, 2027	DP		U-1273	
	9925150	Mar 01, 2032	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10130636	Aug 17, 2035			U-2012	
	10130636	Aug 17, 2035			U-2101	
	10130636	Aug 17, 2035			U-2273	
	10130636	Aug 17, 2035			U-2830	
	10278974	Feb 10, 2031	DP			
	8071579	Aug 12, 2027			U-2012	
	8071579	Aug 12, 2027			U-2273	
	8071579	Aug 12, 2027			U-2830	
	8143241	Aug 12, 2027			U-2012	
	8143241	Aug 12, 2027			U-2273	
	8143241	Aug 12, 2027			U-2830	
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031			U-2012	
	8859562	Aug 04, 2031			U-2273	
	8859562	Aug 04, 2031			U-2830	
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031			U-2012	
	9861638	Feb 10, 2031			U-2273	
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	10130636	Aug 17, 2035			U-2012	
	10130636	Aug 17, 2035			U-2101	
	10130636	Aug 17, 2035			U-2273	
	10130636	Aug 17, 2035			U-2830	
	10278974	Feb 10, 2031	DP			
	8071579	Aug 12, 2027			U-2012	
	8071579	Aug 12, 2027			U-2273	
	8071579	Aug 12, 2027			U-2830	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	10130636	Aug 17, 2035	U-2012			
	10130636	Aug 17, 2035	U-2101			
	10130636	Aug 17, 2035	U-2273			
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10610530	Jun 12, 2028	U-3229		NPP	Sep 18, 2028
	10610530	Jun 12, 2028	U-3404			
	10610530*PED	Dec 12, 2028				
	10639310	Dec 12, 2026	U-3229			
	10639310*PED	Jun 12, 2027				
	10758543	May 20, 2031	DP			
	10758543*PED	Nov 20, 2031				
	10869870	May 20, 2031	U-3229			
	10869870	May 20, 2031	U-3404			
	10869870*PED	Nov 20, 2031				
	11219624	May 20, 2031	DP U-3229			
	11219624*PED	Nov 20, 2031				
	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			
	11602536	May 05, 2041	U-3550			
	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			
	7598257	Dec 24, 2027	DS DP			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3229			
	8822481	Jun 12, 2028	U-3404			
	8822481*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3229			
	9079912	Dec 12, 2026	U-3404			
	9079912*PED	Jun 12, 2027				
	9974790	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3404			
	9974790*PED	Jun 12, 2027				
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	11058667	May 09, 2036	U-3170			
	11135192	Aug 22, 2033	U-3084			
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	11058667	May 09, 2036	U-3170			
	11135192	Aug 22, 2033	U-3084			
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 003	11058667	May 09, 2036	U-3170			
	11135192	Aug 22, 2033	U-3084			
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SACUBITRIL; VALSARTAN - ENTRESTO								
N 207620	003		9937143	Aug 22, 2033			U-3084	
SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE								
N 218591	001		10722471	Feb 02, 2037	DP		U-3896	
			8877938	May 27, 2027	DS DP			
			9388134	Nov 08, 2026			U-1723	
SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE								
N 218591	002		10722471	Feb 02, 2037	DP		U-3896	
			8877938	May 27, 2027	DS DP			
			9388134	Nov 08, 2026			U-1723	
SAFINAMIDE MESYLATE - XADAGO								
N 207145	001		8076515	Dec 10, 2028	DS DP		U-1993	
			8278485	Jun 08, 2027	DS		U-1993	
			8283380	Mar 21, 2031			U-1993	
SAFINAMIDE MESYLATE - XADAGO								
N 207145	002		8076515	Dec 10, 2028	DS DP		U-1993	
			8278485	Jun 08, 2027	DS		U-1993	
			8283380	Mar 21, 2031			U-1993	
SAPROPTERIN DIHYDROCHLORIDE - KUVAN								
N 022181	001		7566462	Nov 16, 2025	DP			
			7566462*PED	May 16, 2026				
			8003126	Nov 16, 2025				
			8003126*PED	May 16, 2026				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN								
N 205065	001		9216178	Nov 01, 2032	DP			
			9216178*PED	May 01, 2033				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN								
N 205065	002		9216178	Nov 01, 2032	DP			
			9216178*PED	May 01, 2033				
SARECYCLINE HYDROCHLORIDE - SEYSARA								
N 209521	001		8318706	Jan 03, 2032	DS DP		U-2405	
			8513223	Dec 07, 2029			U-2406	
			9255068	Feb 09, 2033	DS DP		U-2407	
			9255068	Feb 09, 2033	DS DP		U-2408	
			9481639	Aug 10, 2028			U-2409	
SARECYCLINE HYDROCHLORIDE - SEYSARA								
N 209521	002		8318706	Jan 03, 2032	DS DP		U-2405	
			8513223	Dec 07, 2029			U-2406	
			9255068	Feb 09, 2033	DS DP		U-2407	
			9255068	Feb 09, 2033	DS DP		U-2408	
			9481639	Aug 10, 2028			U-2409	
SARECYCLINE HYDROCHLORIDE - SEYSARA								
N 209521	003		8318706	Jan 03, 2032	DS DP		U-2405	
			8513223	Dec 07, 2029			U-2406	
			9255068	Feb 09, 2033	DS DP		U-2407	
			9255068	Feb 09, 2033	DS DP		U-2408	
			9481639	Aug 10, 2028			U-2409	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SARECYCLINE HYDROCHLORIDE - SEYSARA						
N 209521 003	8318706	Jan 03, 2032	DS DP U-2405			
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 001	7951400	Nov 30, 2028	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 002	7951400	Nov 30, 2028	DP			
SEBETRALSTAT - EKTERLY						
N 219301 001	10364238	Nov 26, 2035	DS DP		NCE	Jul 03, 2030
	10611758	Nov 26, 2035	U-4223			
	11001578	Nov 26, 2035	DS DP			
	11084809	Nov 26, 2035	DS DP U-4223			
	11198691	Nov 26, 2035	U-4223			
	11230537	Dec 25, 2037	DS DP			
	11234939	Jan 26, 2039	DP U-4223			
	11739068	Jun 23, 2037	U-4223			
SECNIDAZOLE - SOLOSEC						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NCE	Sep 15, 2022
	10335390	Sep 04, 2035	DP U-3270		GAIN	Sep 15, 2027
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SECNIDAZOLE - SOLOSEC						
N 209363 001	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
	12280037	Dec 11, 2041	U-3302			
SELADELPAR LYSINE - LIVDELZI						
N 217899 001	10272058	Mar 19, 2035	U-1854		NCE	Aug 14, 2029
	11406611	Mar 19, 2035	U-1854		ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035	U-1854			
	7301050	Aug 02, 2026	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035	U-1854			
SELENIOUS ACID - SELENIOUS ACID						
N 209379 001	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			
SELENIOUS ACID - SELENIOUS ACID						
N 209379 002	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			
SELENIOUS ACID - SELENIOUS ACID						
N 209379 003	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			
SELEXIPAG - UPTRAVI						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 004	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELINEXOR - XPOVIO						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		ODE-257	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE-310	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE-346	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 001	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 003	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS DP			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 005	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 006	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE-303	May 08, 2027
	10137124*PED	Apr 10, 2038			ODE-409	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE-412	Sep 21, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 213246 001	10172851	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10172851	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3450		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3949		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3950		PED	Nov 29, 2027
	10584124	Oct 10, 2038	DS U-3951		PED	Mar 27, 2028
	10584124*PED	Apr 10, 2039			PED	Mar 27, 2028
	10786489	Oct 10, 2038	DP U-3450		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3949		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3950		PED	Nov 29, 2031
	10786489	Oct 10, 2038	DP U-3951		PED	Nov 29, 2031
	10786489*PED	Apr 10, 2039			PED	Nov 29, 2031
	12138250	Oct 10, 2038	U-3450			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
	12138250*PED	Apr 10, 2039				
SELPERCATINIB - RETEVMO						
N 213246 002	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE-303	May 08, 2027
	10137124*PED	Apr 10, 2038			ODE-409	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE-412	Sep 21, 2029
	10172851	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10172851	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3450		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3949		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3950		PED	Nov 29, 2027
	10584124	Oct 10, 2038	DS U-3951		PED	Mar 27, 2028
	10584124*PED	Apr 10, 2039			PED	Mar 27, 2028
	10786489	Oct 10, 2038	DP U-3450		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3949		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3950		PED	Nov 29, 2031
	10786489	Oct 10, 2038	DP U-3951		PED	Nov 29, 2031
	10786489*PED	Apr 10, 2039			PED	Nov 29, 2031
	12138250	Oct 10, 2038	U-3450			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
	12138250*PED	Apr 10, 2039				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 218160 001	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 002	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 003	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 218160 003	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 004	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001	11813246	Mar 26, 2029	DP		NPP	Sep 10, 2028
	12220403	Mar 26, 2029	DP		NPP	Nov 19, 2028
	12318367	Mar 26, 2029	DP		ODE-288	Apr 10, 2027
	12364684	Mar 26, 2029	U-4357			
	7425637	Mar 13, 2028	DS			
	8178693	Mar 13, 2026	DS DP			
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4357			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	11813246	Mar 26, 2029	DP		NPP	Sep 10, 2028
	12220403	Mar 26, 2029	DP		NPP	Nov 19, 2028
	12318367	Mar 26, 2029	DP		ODE-288	Apr 10, 2027
	12364684	Mar 26, 2029	U-4357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	7425637	Mar 13, 2028	DS			
	8178693	Mar 13, 2026	DS DP			
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4357			
SELUMETINIB SULFATE - KOSELUGO						
N 219943 001	7425637	Mar 13, 2028	DS		NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		NPP	Nov 19, 2028
	9156795	Dec 12, 2026	DS DP		ODE*	Apr 10, 2027
	9562017	Dec 12, 2026	DS U-4357			
SELUMETINIB SULFATE - KOSELUGO						
N 219943 002	7425637	Mar 13, 2028	DS		NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		NPP	Nov 19, 2028
	9156795	Dec 12, 2026	DS DP		ODE*	Apr 10, 2027
	9562017	Dec 12, 2026	DS U-4357			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 27, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	12295988	Oct 10, 2038	U-2628			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10335462	Jun 21, 2033	DP U-2580			
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8129343	Dec 05, 2031	DS DP U-3469			
	8536122	Mar 20, 2026	DS DP U-3469			
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 004	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10086047	Dec 16, 2031	DP		I-976	Oct 17, 2028
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10086047	Dec 16, 2031	DP		I-976	Oct 17, 2028
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10086047	Dec 16, 2031	DP		I-976	Oct 17, 2028
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	11759501	Mar 15, 2033	DP			
	11759502	Mar 15, 2033	DP			
	11759503	Mar 15, 2033	DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 004	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	11833248	Feb 01, 2039	DP U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - RYBELSUS						
N 213051 004	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	11833248	Feb 01, 2039	DP U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 005	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	11833248	Feb 01, 2039	DP U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 006	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	11833248	Feb 01, 2039	DP U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		I-935	Mar 08, 2027
	11318191	Feb 17, 2041	DP U-3162		I-973	Aug 15, 2028
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		I-935	Mar 08, 2027
	11318191	Feb 17, 2041	DP U-3162		I-973	Aug 15, 2028
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		I-935	Mar 08, 2027
	11318191	Feb 17, 2041	DP U-3162		I-973	Aug 15, 2028
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12214017	Aug 24, 2038	DP U-3162			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - WEGOVY						
N 215256 003	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		D-190	Jul 21, 2026
	11318191	Feb 17, 2041	DP U-3162		I-935	Mar 08, 2027
	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	11752198	Aug 24, 2038	DP U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		I-935	Mar 08, 2027
	11318191	Feb 17, 2041	DP U-3162		I-973	Aug 15, 2028
	11478533	May 13, 2040	U-3861			
	11752198	Aug 24, 2038	DP U-3162			
	12029779	Oct 10, 2038	U-3162			
	12214017	Aug 24, 2038	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEPIAPTERIN - SEPHIENCE						
N 219666 001	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
SEPIAPTERIN - SEPHIENCE						
N 219666 002	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE						
A 218853 001					CGT	Jan 18, 2026
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE						
A 218853 002					CGT	Jan 18, 2026
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001	11129869	Jul 04, 2034	DP		NPP	Dec 20, 2027
	8039435	Aug 21, 2032	DS DP		ODE-336	Nov 25, 2027
	9458195	Oct 13, 2027	DS DP		ODE-402	Jun 16, 2029
					ODE-508	Dec 20, 2031
					ODE-509	Dec 20, 2031
SEVABERTINIB - HYRNUO						
N 219972 001	10428063	Jan 25, 2036	DS DP		NCE	Nov 19, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEVELAMER CARBONATE - RENVELA						
N 022318 001	9095509	Dec 06, 2030	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 002	9095509	Dec 06, 2030	DP			
SILDENAFIL CITRATE - REVATIO						
N 021845 001					M-287	Jan 31, 2026
					ODE-469	Jan 31, 2030
SILDENAFIL CITRATE - REVATIO						
N 022473 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - REVATIO						
N 203109 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - LIQREV						
N 214952 001	11337979	Dec 24, 2038	DP U-3582			
	11464778	Dec 24, 2038	DP U-3582			
	11759468	Dec 24, 2038	DP U-3582			
	12005062	Dec 24, 2038	DP U-3582			
	12186321	Dec 24, 2038	DP U-3582			
SIMEPREVIR SODIUM - OLYSIO						
N 205123 001	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			
	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
	9040562	Jul 28, 2026	DS DP U-1467			
	9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
	9856265	Jul 28, 2026	DS DP U-1467			
SIMVASTATIN - FLOLIPID						
N 206679 001	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN - FLOLIPID						
N 206679 002	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 001	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 002	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 003	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 004	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	005		7326708	Apr 11, 2026	DS DP U-1188			
			7326708*PED	Oct 11, 2026				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC								
N 202343	006		7326708	Apr 11, 2026	DS DP U-1188			
			7326708*PED	Oct 11, 2026				
SINCALIDE - SINCALIDE								
N 210850	001		11110063	Apr 20, 2038	DP U-3481			
			11110063	Apr 20, 2038	DP U-3482			
			11110063	Apr 20, 2038	DP U-3483			
			11318100	Apr 20, 2038	DP U-3477			
			11318100	Apr 20, 2038	DP U-3478			
			11318100	Apr 20, 2038	DP U-3479			
			11318100	Apr 20, 2038	DP U-3480			
			11737983	Apr 20, 2038	DP U-3482			
			11737983	Apr 20, 2038	DP U-3689			
SINECATECHINS - VEREGEN								
N 021902	001		7858662	Oct 02, 2026	DP U-172			
SIPONIMOD - MAYZENT								
N 209884	001		11944602	Apr 23, 2036	U-3889			
			12071402	Jan 05, 2032	DP			
			7939519	Aug 27, 2028	DS DP			
			8492441	Nov 30, 2030	U-2511			
SIPONIMOD - MAYZENT								
N 209884	002		11944602	Apr 23, 2036	U-3889			
			12071402	Jan 05, 2032	DP			
			7939519	Aug 27, 2028	DS DP			
			8492441	Nov 30, 2030	U-2511			
SIPONIMOD - MAYZENT								
N 209884	003		11944602	Apr 23, 2036	U-3889			
			12071402	Jan 05, 2032	DP			
			7939519	Aug 27, 2028	DS DP			
			8492441	Nov 30, 2030	U-2511			
SIROLIMUS - FYARRO								
N 213312	001		10206887	Apr 15, 2030	DP		ODE-386	Nov 22, 2028
			10705070	Mar 05, 2036	DP			
			10973806	Jun 29, 2036	U-3258			
			11497737	Oct 28, 2040	DP			
			12061183	Mar 05, 2036	DP			
			12133844	Jun 29, 2036	U-4040			
			12133844	Jun 29, 2036	U-4041			
			12133844	Jun 29, 2036	U-4042			
			8911786	Feb 14, 2029	DP U-3259			
SIROLIMUS - HYFTOR								
N 213478	001						ODE-391	Mar 22, 2029

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SITAGLIPTIN - ZITUVIO						
N 211566 001	10925871	Feb 25, 2035	DP			
SITAGLIPTIN - ZITUVIO						
N 211566 002	10925871	Feb 25, 2035	DP			
SITAGLIPTIN - ZITUVIO						
N 211566 003	10925871	Feb 25, 2035	DP			
SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN						
N 219122 001	11944621	Oct 23, 2040	DP			
	12295953	Oct 23, 2040	DP			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 001	7326708	Nov 24, 2026	DS DP		U-802	
	7326708*PED	May 24, 2027				
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 002	7326708	Nov 24, 2026	DS DP		U-802	
	7326708*PED	May 24, 2027				
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 003	7326708	Nov 24, 2026	DS DP		U-802	
	7326708*PED	May 24, 2027				
SODIUM NITRITE - SODIUM NITRITE						
N 203922 001	8568793	Dec 24, 2031	DS DP			
	9687506	Feb 10, 2030	DP		U-3394	
	9687506	Feb 10, 2030	DP		U-3395	
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N 201444 001	10479686	Jul 07, 2030	DP		U-3390	
	11753301	Feb 10, 2030	DS DP		U-3681	
	12304813	Feb 10, 2030	DP			
	8496973	Mar 29, 2031	DS DP		U-1419	
	8568793	Dec 24, 2031	DS DP			
	9345724	Jul 07, 2030	DS DP		U-2015	
	9585912	Jul 07, 2030	DS DP			
	9687506	Feb 10, 2030	DP		U-3394	
	9687506	Feb 10, 2030	DP		U-3395	
SODIUM OXYBATE - XYREM						
N 021196 001	10213400	Mar 15, 2033			U-2499	
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033			U-1532	
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033			U-3323	
	11253494	Mar 15, 2033			U-3324	
	11253494*PED	Sep 15, 2033				
	11986446	Mar 15, 2033			U-3324	
	8772306	Mar 15, 2033			U-1532	
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033			U-1532	
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033			U-1532	
	9486426*PED	Sep 15, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 001	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP		ODE-494	Oct 16, 2031
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			
	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP		ODE-494	Oct 16, 2031
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11826335	Jul 21, 2037	U-3751			
	11839597	Jul 21, 2037	DP			
	11896572	Jul 21, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 002	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP		ODE-494	Oct 16, 2031
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042	U-3705			
	11839597	Jul 21, 2037	DP			
	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP		ODE-494	Oct 16, 2031
	10952986	Jul 21, 2037	U-3601			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP		U-3580	
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037			U-3579	
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042			U-3578	
	11602512	Jul 21, 2037			U-3577	
	11602513	Jul 21, 2037			U-3576	
	11766418	Jul 21, 2037	DP			
	11779557	Mar 16, 2042			U-3705	
	11839597	Jul 21, 2037	DP			
	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037			U-3934	
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037			U-4006	
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037			U-4022	
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037			U-4189	
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036			U-3502	
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036			U-3502	
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036			U-3502	
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036			U-3502	
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036			U-3502	
	11433041	Oct 17, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 007	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 008	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO						
N 216660 001	10251896	Dec 24, 2033	U-3460		NCE	Sep 29, 2027
	10857162	Dec 24, 2033	U-3460		ODE-411	Sep 29, 2029
	11071742	Dec 24, 2033	DP			
	11583542	Jul 27, 2040	DP			
	9872865	Dec 24, 2033	U-3460			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N 021892 001	7687075	Jun 22, 2028	DS DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	10479686	Jul 07, 2030	DP U-3390			
	11753301	Feb 10, 2030	DS DP U-3682			
	12304813	Feb 10, 2030	DP			
	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
SODIUM THIOSULFATE - PEDMARK						
N 212937 001	10596190	Jan 05, 2038	U-3443	Y	ODE-384	Sep 20, 2029
	11291728	Jul 01, 2039	DP			
	11510984	Jul 01, 2039	DP			
	11617793	Jul 01, 2039	DP			
	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	10300087	Oct 14, 2035	DS U-2312			
	10335432	Feb 10, 2032	U-2312			
	10398730	Feb 10, 2032	U-2312			
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	11738044	Oct 14, 2035	U-2312			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	10300087	Oct 14, 2035	DS U-2312			
	10398730	Feb 10, 2032	U-2312			
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	11738044	Oct 14, 2035	U-2312			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SOFOSBUVIR - SOVALDI						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				
SOFOSBUVIR - SOVALDI						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI						
N 204671 002	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001	10086011	Jan 30, 2034	U-1470		ODE-293	Mar 19, 2027
	10086011*PED	Jul 30, 2034			PED	Sep 19, 2027
	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 002	10086011	Jan 30, 2034	U-1470		ODE-293	Mar 19, 2027
	10086011*PED	Jul 30, 2034			PED	Sep 19, 2027
	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 002	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001	11116783	Jan 30, 2034	DP U-1470		ODE-376	Jun 10, 2028
	11116783*PED	Jul 30, 2034			PED	Dec 10, 2028
	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	11116783	Jan 30, 2034	DP U-1470		ODE*	Mar 19, 2027
	11116783*PED	Jul 30, 2034			PED	Sep 19, 2027
	11707479	Jan 30, 2034	DP U-1470			
	11707479*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	10912814	Jun 01, 2037	DP			
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9868745	Nov 16, 2032	DS DP			
SOFPIRONIUM BROMIDE - SOFDRA						
N 217347 001	10383846	Mar 14, 2034	U-2398		NCE	Jun 20, 2029
	10947192	May 22, 2034	U-2398			
	10952990	May 22, 2034	U-2398			
	10959983	May 22, 2034	U-2398			
	10961191	May 22, 2034	U-2398			
	11026919	May 22, 2034	DP U-2398			
	11034652	May 22, 2034	DP U-2398			
	11052067	May 22, 2034	DP U-2398			
	11084788	May 22, 2034	DP U-2398			
	11123325	Jul 20, 2037	DP U-2398			
	11566000	May 22, 2040	DS DP			
	11584715	May 22, 2040	DS DP			
	12156865	May 22, 2034	DP U-2398			
	12357609	May 22, 2034	DP U-2398			
	12398102	May 22, 2034	DP U-2398			
	8147809	Mar 26, 2027	DS DP			
	8628759	Nov 13, 2026	U-2398			
	9220707	Mar 14, 2034	U-2398			
	9492429	Mar 14, 2034	DP U-2398			
	9895350	Mar 14, 2034	U-2398			
SOLIFENACIN SUCCINATE - VESICARE LS						
N 209529 001	9918970	May 18, 2031	DP			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	10195151	Sep 05, 2037	DP		ODE-254	Jun 17, 2026
	10351517	Jun 07, 2026	U-2548			
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			
	11839598	Mar 19, 2040	U-3765			
	11839599	Mar 19, 2040	U-3764			
	11850226	Mar 19, 2040	U-3775			
	11850227	Mar 19, 2040	U-3775			
	11850228	Mar 19, 2040	U-3775			
	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			
	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	12318362	Mar 19, 2040	U-3765			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			
	8440715	Jun 11, 2031	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	10195151	Sep 05, 2037	DP		ODE-254	Jun 17, 2026
	10351517	Jun 07, 2026	U-2548			
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	11753368	Jun 07, 2026	U-2548			
	11771666	Dec 30, 2042	U-3693			
	11771667	Dec 30, 2042	U-3693			
	11779554	Dec 30, 2042	U-3693			
	11793776	Dec 30, 2042	U-3693			
	11839598	Mar 19, 2040	U-3765			
	11839599	Mar 19, 2040	U-3764			
	11850226	Mar 19, 2040	U-3775			
	11850227	Mar 19, 2040	U-3775			
	11850228	Mar 19, 2040	U-3775			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			
	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			
	8440715	Jun 11, 2031	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	10266523	Mar 30, 2036	DS DP			
	8063043	Sep 15, 2029	DS DP			
	8178563	Jul 24, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
SOTAGLIFLOZIN - INPEFA						
N 216203 001	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
SOTAGLIFLOZIN - INPEFA						
N 216203 002	7781577	May 04, 2028	DS DP U-3628		NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	10512620	Aug 14, 2038	U-2769			
	10512620	Aug 14, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
	11696902	Aug 14, 2038	U-2769			
	12390431	Aug 14, 2038	U-2769			
	12403109	Aug 14, 2028	U-2769			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	11013703	Apr 01, 2034	DP			
	11850222	Nov 19, 2034	U-2096			
	11850222	Nov 19, 2034	U-2494			
	12290495	Apr 01, 2034	U-2096			
	12290495	Apr 01, 2034	U-2494			
	9724297	Aug 31, 2035	DP U-2096			
SOTORASIB - LUMAKRAS						
N 214665 001	10519146	May 21, 2038	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-3306		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-4107		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 002	10519146	May 21, 2038	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-3306		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-4107		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 003	10519146	May 21, 2038	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-3306		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-4107		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SPARSENTAN - FILSPARI						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
	9993461	Mar 29, 2030	U-3993		ODE-389	Feb 17, 2030
					ODE-493	Sep 05, 2031
SPARSENTAN - FILSPARI						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
	9993461	Mar 29, 2030	U-3993		ODE-389	Feb 17, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SPARSENTAN - FILSPARI						
N 216403 002					ODE-493	Sep 05, 2031
SPINOSAD - NATROBA						
N 022408 001	9895388	Nov 25, 2033	U-3365			
SPIRONOLACTONE - CAROSPIR						
N 209478 001	10493083	Oct 28, 2036	DP			
	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
	10888570	Oct 28, 2036	DP			
	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
	11491166	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
STIRIPENTOL - DIACOMIT						
N 206709 001					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 206709 002					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 001					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 002					ODE-403	Jul 14, 2029
SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE						
N 215143 001	12295932	Nov 02, 2041	DP			
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	10896751	Mar 16, 2030	DP			
	11672738	Feb 02, 2038	DP			
	11676691	Mar 16, 2030	DP			
	12033733	Mar 16, 2030	DP			
	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUGAMMADEX SODIUM - BRIDION								
N	022225	001	RE44733	Jan 27, 2026	DS DP U-1794		NPP	Dec 12, 2027
			RE44733*PED	Jul 27, 2026			PED	Jun 12, 2028
SUGAMMADEX SODIUM - BRIDION								
N	022225	002	RE44733	Jan 27, 2026	DS DP U-1794		NPP	Dec 12, 2027
			RE44733*PED	Jul 27, 2026			PED	Jun 12, 2028
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON								
N	203684	001	10232061	Jul 06, 2038	DP			
			10335502	Jul 06, 2038	DP			
			11723869	May 15, 2039	DP U-3666			
			11723869	May 15, 2039	DP U-3667			
			11723869	May 15, 2039	DP U-3668			
SUMATRIPTAN - TOSYMRA								
N	210884	001	10603305	Jun 16, 2030	DP U-1719			
			11337962	Jun 16, 2030	DP U-1719			
			12090139	Jun 16, 2030	DP			
			8268791	May 09, 2026	DP			
			8440631	May 09, 2026	DP U-1719			
			9211282	Jul 19, 2031	DP U-1719			
			9283280	May 09, 2026	DP			
			9610280	Jun 16, 2030	DP U-1719			
			9974770	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO								
N	022239	001	7776007	Nov 22, 2026	DP			
			7901385	Jul 31, 2026	DP			
SUMATRIPTAN SUCCINATE - ALSUMA								
N	022377	001	7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY								
N	202278	001	7973058	Apr 12, 2027	U-1328			
			8155737	Apr 12, 2027	U-1328			
			8366600	Apr 21, 2029	U-1327			
			8470853	Apr 12, 2027	U-1328			
			8597272	Apr 12, 2027	DP			
			8983594	Nov 19, 2030	DP U-1328			
			9272137	Sep 07, 2027	DP			
			9327114	Oct 08, 2032	DP U-1328			
			9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL								
N	206099	001	10076614	Oct 20, 2034	DP			
			10076615	Jul 30, 2029	U-2010			
			10076615	Jul 30, 2029	U-2011			
			10076615	Jul 30, 2029	U-2404			
			10124132	Mar 06, 2027	DP U-1719			
			10124132	Mar 06, 2027	DP U-2010			
			10124132	Mar 06, 2027	DP U-2011			
			10398859	Dec 19, 2027	DP			
			10478574	Nov 04, 2033	U-2404			
			10722667	Dec 30, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL						
N 206099 001	11571531	Feb 23, 2026	U-1809			
	8550073	Oct 22, 2029	DP			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH						
N 208223 001	10537554	Jan 29, 2036	U-72			
	11364224	Jan 29, 2036	U-72			
	12097183	Jan 29, 2036	DP			
SUNVOZERTINIB - ZEGFROVY						
N 219839 001	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUNVOZERTINIB - ZEGFROVY						
N 219839 002	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUVOREXANT - BELSOMRA						
N 204569 001	10098892	May 29, 2033	DP			
	11980623	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 002	10098892	May 29, 2033	DP			
	11980623	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 003	10098892	May 29, 2033	DP			
	11980623	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 004	10098892	May 29, 2033	DP			
	11980623	May 29, 2033	DP			
	7951797	Nov 20, 2029	DS DP U-620			
SUZETRIGINE - JOURNAVX						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
TACROLIMUS - PROGRAF						
N 050708 001					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 002					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 003					ODE-360	Jul 16, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - PROGRAF						
N 050709 001					ODE-360	Jul 16, 2028
TACROLIMUS - ENVARSUS XR						
N 206406 001	10166190	May 30, 2028	DP			
	10864199	May 30, 2028		U-2677		
	10864199	May 30, 2028		U-2678		
	11110081	May 30, 2028		U-2678		
	11123331	May 30, 2028		U-2677		
	11419823	May 30, 2028	DP			
	12083103	May 30, 2028		U-2678		
	12403095	May 30, 2028	DP			
	8664239	Aug 30, 2028		U-1752		
	8664239	Aug 30, 2028		U-2677		
	8664239	Aug 30, 2028		U-2678		
	8685998	Aug 30, 2028	DP	U-1752		
	8685998	Aug 30, 2028	DP	U-2677		
	8685998	Aug 30, 2028	DP	U-2678		
	9549918	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	10166190	May 30, 2028	DP			
	10864199	May 30, 2028		U-2677		
	10864199	May 30, 2028		U-2678		
	11110081	May 30, 2028		U-2678		
	11123331	May 30, 2028		U-2677		
	11419823	May 30, 2028	DP			
	12083103	May 30, 2028		U-2678		
	12403095	May 30, 2028	DP			
	8664239	Aug 30, 2028		U-1752		
	8664239	Aug 30, 2028		U-2677		
	8664239	Aug 30, 2028		U-2678		
	8685998	Aug 30, 2028	DP	U-1752		
	8685998	Aug 30, 2028	DP	U-2677		
	8685998	Aug 30, 2028	DP	U-2678		
	9549918	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	10166190	May 30, 2028	DP			
	10864199	May 30, 2028		U-2677		
	10864199	May 30, 2028		U-2678		
	11110081	May 30, 2028		U-2678		
	11123331	May 30, 2028		U-2677		
	11419823	May 30, 2028	DP			
	12083103	May 30, 2028		U-2678		
	12403095	May 30, 2028	DP			
	8664239	Aug 30, 2028		U-1752		
	8664239	Aug 30, 2028		U-2677		
	8664239	Aug 30, 2028		U-2678		
	8685998	Aug 30, 2028	DP	U-1752		
	8685998	Aug 30, 2028	DP	U-2677		
	8685998	Aug 30, 2028	DP	U-2678		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR								
N 206406	003		9549918	May 30, 2028	DP			
TACROLIMUS - PROGRAF								
N 210115	001						ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF								
N 210115	002						ODE-360	Jul 16, 2028
TADALAFIL - TADLIQ								
N 214522	001		11382917	Dec 24, 2038	DP U-3397			
			11666576	Dec 24, 2038	DP U-3397			
			11975006	Dec 24, 2038	DP U-3397			
			12186322	Dec 24, 2038	DP U-3397			
TAFAMIDIS - VYNDAMAX								
N 212161	001		7214695	Dec 19, 2026	DS DP		ODE-237	May 03, 2026
			7214696	Dec 19, 2026	U-2524			
			9770441	Aug 31, 2035	DS DP U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL								
N 211996	001		7214695	Dec 19, 2026	DS DP		ODE-237	May 03, 2026
			7214696	Dec 19, 2026	U-2524			
TAFENOQUINE SUCCINATE - ARAKODA								
N 210607	001		10342791	Dec 02, 2035	U-2582			
			10888558	Dec 02, 2035	U-2582			
			11744828	Dec 02, 2035	U-2582			
TAFLUPROST - ZIOPTAN								
N 202514	001		10864159	May 28, 2029	DP U-778			
			9999593	May 28, 2029	DP			
TALAZOPARIB TOSYLATE - TALZENNA								
N 211651	001		10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
			10780088	Jul 27, 2029	U-3651			
			8012976	Jul 27, 2029	DS DP			
			8420650	Jul 27, 2029	DS DP			
			8735392	Oct 20, 2031	DS DP			
			9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA								
N 211651	002		10189837	Oct 20, 2031	DS DP			
			8012976	Jul 27, 2029	DS DP			
			8420650	Jul 27, 2029	DS DP			
			8735392	Oct 20, 2031	DS DP			
			9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA								
N 211651	003		10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
			10780088	Jul 27, 2029	U-3651			
			8012976	Jul 27, 2029	DS DP			
			8420650	Jul 27, 2029	DS DP			
			8735392	Oct 20, 2031	DS DP			
			9820985	Jul 27, 2029	U-2437			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 004	10189837	Oct 20, 2031	DS DP			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 005	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Jul 27, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALETRECTINIB ADIPATE - IBTROZI						
N 219713 001	9187489	Jun 03, 2033	DS DP U-4207		NCE	Jun 11, 2030
	9751887	Jun 03, 2033	DS DP U-4207			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 001					NPP	Jul 03, 2026
					PED	Jan 03, 2027
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 002					NPP	Jul 03, 2026
					PED	Jan 03, 2027
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 003					NPP	Jul 03, 2026
					PED	Jan 03, 2027
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 203794 001					NPP	Jul 03, 2026
					PED	Jan 03, 2027
TAPINAROF - VTAMA						
N 215272 001	10195160	May 19, 2036	DP		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-2625		NCE	May 23, 2027
	10426743	May 19, 2036	U-4048			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			
	11497718	Nov 13, 2039	U-4048			
	11590088	Nov 13, 2039	U-2625			
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			
	11938099	Nov 13, 2039	U-4048			
TASIMELTEON - HETLIOZ						
N 205677 001	10071977	Feb 12, 2035	DS DP		ODE-330	Dec 01, 2027
	10149829	Jan 25, 2033	U-2477			
	10149829	Jan 25, 2033	U-3006			
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-2615			
	10376487	Jul 27, 2035	U-3007			
	10449176	Jan 25, 2033	U-2149			
	10610510	Jan 25, 2033	U-2805			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-2615			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
	11141400	Oct 10, 2034	U-2615			
	11141400	Oct 10, 2034	U-3007			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
	11566011	Feb 12, 2035	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ						
N 205677 001	11633377	Jan 25, 2033	U-2149			
	11633377	Jan 25, 2033	U-3003			
	11759446	Feb 21, 2041	U-3003			
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034	U-3007			
	11786502	Oct 10, 2034	U-3739			
	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11833130	Jan 25, 2033	U-2149			
	11833130	Jan 25, 2033	U-3003			
	11850229	Jan 25, 2033	U-3342			
	11850229	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
	9060995	Jan 25, 2033	U-1710			
	9539234	Jan 25, 2033	U-1934			
	9539234	Jan 25, 2033	U-3004			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	9730910	May 17, 2034	U-3005			
	9855241	Jan 25, 2033	U-2149			
	RE46604	Jan 25, 2033	U-2147			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	10071977	Feb 12, 2035	DS DP		ODE-329	Dec 01, 2027
	10149829	Jan 25, 2033	U-3006			
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-3007			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10980770	Jan 25, 2033	U-3106			
	11141400	Oct 10, 2034	U-3007			
	11202770	Dec 11, 2040	DP			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-3003			
	11759446	Feb 21, 2041	U-3003			
	11760740	Feb 12, 2035	DS DP			
	11786502	Oct 10, 2034	U-3007			
	11826339	Jan 25, 2033	U-3342			
	11833130	Jan 25, 2033	U-3003			
	11850229	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ LQ						
N 214517 001	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
	12201604	Jan 25, 2033	U-3003			
	12447141	Dec 11, 2040	U-3003			
	9539234	Jan 25, 2033	U-3004			
	9730910	May 17, 2034	U-3005			
TAZAROTENE - FABIOR						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
	8808716	Feb 24, 2030	DP			
TAZAROTENE - ARAZLO						
N 211882 001	11311482	May 11, 2038	U-2368			
	11679116	Jun 06, 2036	DP			
	12128137	May 11, 2038	DP U-2368			
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	10155002	Sep 12, 2031	U-2736		ODE-299	Jan 23, 2027
	10245269	Apr 11, 2033	U-2737		ODE-314	Jun 18, 2027
	10245269	Apr 11, 2033	U-2851			
	10245269	Apr 11, 2033	U-2854			
	10369155	Oct 16, 2035	U-2736			
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	10786511	Dec 19, 2035	DP			
	10821113	Apr 11, 2033	DS DP			
	11052093	Sep 12, 2031	DS DP U-2736			
	11052093	Sep 12, 2031	DS DP U-2852			
	11052093	Sep 12, 2031	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	12161645	Sep 12, 2031	U-2853			
	12162865	Jun 12, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
	8410088	Jan 23, 2034	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Sep 12, 2031	DS DP			
	9175331	Sep 12, 2031	U-2852			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			
	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Sep 12, 2031	U-2736			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			
	9949999	Sep 12, 2031	U-2851			
TECHNETIUM TC-99M LABELED CARBON - TECHNEGAS KIT						
N 022335 001					NP	Sep 29, 2026
TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML						
N 020372 002	9549999	Mar 10, 2030	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	9439985	Jan 30, 2029	DP			
TECOVIRIMAT - TPOXX						
N 208627 001	11890270	Aug 08, 2032	U-2346			
	12433868	Mar 23, 2031	DP			
	7737168	Sep 04, 2031	U-2346			
	8039504	Jul 23, 2027	DP			
	9339466	Mar 23, 2031	DS DP			
TECOVIRIMAT - TPOXX						
N 214518 001	10576165	Aug 02, 2031	DP			
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205435 001	10065947	Feb 03, 2030	DP		NPP	Apr 04, 2028
	10442829	Feb 03, 2030	DS			
	7816379	Jun 20, 2028	DS DP U-2507			
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	10065947	Feb 03, 2030	DP		NPP	Apr 04, 2028
	10442829	Feb 03, 2030	DS			
	7816379	Jun 20, 2028	DS DP U-2507			
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	10065947	Feb 03, 2030	DP		NPP	Apr 04, 2028
	10442829	Feb 03, 2030	DS			
	7816379	Jun 20, 2028	DS DP U-2507			
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDUGLUTIDE - GATTEX KIT						
N 203441 001	7847061	Nov 01, 2025	U-1320	Y	ODE-240	May 16, 2026
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320	Y		
	9060992*PED	May 01, 2026				
TELAPREVIR - INCIVEK						
N 201917 001	8431615	May 30, 2028	U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N 022110 001	7531623	Jan 01, 2027	DS			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N 022110 002	7531623	Jan 01, 2027	DS			
TELOTRISTAT ETIPRATE - XERMELO						
N 208794 001	7553840	Dec 11, 2027	DS			
	7709493	Feb 28, 2031	DS U-1979			
	7968559	Dec 11, 2027	U-1979			
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028	U-1979			
TEMSIROLIMUS - TORISEL						
N 022088 001	8026276	Jan 20, 2026	DP			
	8791097	May 10, 2032	U-1550			
	8791097	May 10, 2032	U-1551			
	8791097*PED	Nov 10, 2032				
TENAPANOR HYDROCHLORIDE - IBSRELA						
N 211801 001	12016856	Dec 30, 2029	DS DP			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
	9006281	May 02, 2030	U-2626			
	9408840	Dec 30, 2029	U-2626			
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 001	10272079	Apr 10, 2034	U-3736		NP	Oct 17, 2026
	10272079	Apr 10, 2034	U-381			
	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	12016856	Dec 30, 2029	DS DP			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 002	10272079	Apr 10, 2034	U-3736		NP	Oct 17, 2026
	10272079	Apr 10, 2034	U-381			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 002	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	12016856	Dec 30, 2029	DS DP			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
TENAPANOR HYDROCHLORIDE - XPHOZAH						
N 213931 003	10272079	Apr 10, 2034	U-3736		NP	Oct 17, 2026
	10272079	Apr 10, 2034	U-381			
	10940146	Apr 10, 2034	U-3736			
	10940146	Apr 10, 2034	U-381			
	12016856	Dec 30, 2029	DS DP			
	8541448	Aug 01, 2033	DS DP			
	8969377	Dec 30, 2029	DS DP			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
TEPOTINIB HYDROCHLORIDE - TEPMETKO						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
TERAZOSIN HYDROCHLORIDE - TEZRULY						
N 218139 001	11224572	Feb 01, 2041	DP U-3990			
	11224572	Feb 01, 2041	DP U-3991			
	12427108	Feb 01, 2041	DP U-3990			
	12427108	Feb 01, 2041	DP U-3991			
TERIFLUNOMIDE - AUBAGIO						
N 202992 001	6794410	Sep 12, 2026	U-1285			
	6794410*PED	Mar 12, 2027				
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
TERIFLUNOMIDE - AUBAGIO						
N 202992 002	6794410	Sep 12, 2026	U-1285			
	6794410*PED	Mar 12, 2027				
	8802735	Sep 14, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TERIFLUNOMIDE - AUBAGIO						
N 202992 002	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
TERLIPRESSIN ACETATE - TERLIVAZ						
N 022231 001	10335452	Apr 05, 2037	U-3711		NCE	Sep 14, 2027
					ODE-406	Sep 14, 2029
TESTOSTERONE - ANDROGEL						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
TESTOSTERONE - AXIRON						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO						
N 204399 002	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO						
N 204399 003	8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - VOGELXO						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - NATESTO						
N 205488 001	11090312	Mar 17, 2034	U-1616			
	11744838	Mar 17, 2034	U-4366			
	11744838	Mar 17, 2034	U-4367			
TESTOSTERONE CYPIONATE - AZMIRO						
N 216318 001	11311554	Mar 25, 2039	DP			
	11642355	Mar 25, 2039	DP			
	12138271	Mar 25, 2039	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 001	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11813435	Feb 25, 2035	DP			
	11844804	Jun 04, 2033	U-2418			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	11813435	Feb 25, 2035	DP			
	11844804	Jun 04, 2033			U-2418	
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP		U-2418	
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 003	10238662	Feb 19, 2035	DP		U-2418	
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP		U-2418	
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP		U-2418	
	11160751	Oct 07, 2034	DP		U-2418	
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	11813435	Feb 25, 2035	DP			
	11844804	Jun 04, 2033			U-2418	
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP		U-2418	
TESTOSTERONE UNDECANOATE - AVEED						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	May 08, 2027			U-1500	
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 001	10543219	Apr 12, 2030			U-2506	
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030			U-2506	
	11331325	Jan 06, 2027			U-2506	
	11426416	Apr 12, 2030			U-3420	
	11564933	Apr 12, 2039			U-1103	
	8241664	Mar 29, 2029	DP		U-2506	
	8492369	Dec 20, 2030	DP		U-2506	
	8778916	Apr 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	11564933	Apr 12, 2039	U-1103			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	11564933	Apr 12, 2039	U-1103			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - TLANDO						
N 208088 001	10226473	Nov 30, 2030	U-1500			
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	11433083	Nov 30, 2030	U-1500			
	11464735	Apr 28, 2041	DP U-1500			
	11559530	Nov 28, 2037	U-1500			
	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
	12310978	Feb 21, 2039	U-4194			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 001	10576089	Dec 31, 2030	DP U-2506			
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 002	10576089	Dec 31, 2030	DP U-2506			
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 002	11617758	Mar 15, 2033	DP U-2506			
	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX						
N 213953 003	10576089	Dec 31, 2030	DP U-2506			
	10576090	Dec 31, 2030	DP			
	11590146	Dec 31, 2030	DP			
	11617758	Mar 15, 2033	DP U-2506			
	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
THIOTEPA - TEPADINA AND SODIUM CHLORIDE						
N 208264 003	9931458	May 31, 2037	DP			
THIOTEPA - TEPYLUTE						
N 216984 001	11975013	Aug 16, 2041	DP			
THIOTEPA - TEPYLUTE						
N 216984 002	11975013	Aug 16, 2041	DP			
TICAGRELOR - BRILINTA						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
	10300065*PED	Jul 27, 2036				
	8425934	Apr 17, 2030	DP			
	8425934*PED	Oct 17, 2030				
TICAGRELOR - BRILINTA						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
	10300065*PED	Jul 27, 2036				
	8425934	Apr 17, 2030	DP			
	8425934*PED	Oct 17, 2030				
TIGECYCLINE - TYGACIL						
N 021821 001	10588975	Mar 13, 2026	DP			
	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	8975242	Oct 24, 2028	DP			
	9254328	Mar 13, 2026	DP			
	9694078	Mar 13, 2026	DP			
TIGECYCLINE - TIGECYCLINE						
N 211158 001	9855335	Apr 07, 2033	DP			
TIOPRONIN - THIOLA						
N 019569 001					ODE-267	Jun 28, 2026
TIOPRONIN - THIOLA EC						
N 211843 001	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
TIOPRONIN - THIOLA EC						
N 211843 002	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA						
N 021395 001	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP	Y		
	9027967*PED	Sep 30, 2027				
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 001	10456399	Feb 03, 2037	U-3657		ODE-229	Feb 22, 2026
	10456399	Feb 03, 2037	U-3658			
	10457666	Jun 17, 2034	DS DP			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9527833	Jun 17, 2034	DS DP			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 002	10456399	Feb 03, 2037	U-3657		ODE-229	Feb 22, 2026
	10456399	Feb 03, 2037	U-3658			
	10457666	Jun 17, 2034	DS DP			
	10960004	Feb 03, 2037	U-3657			
	10960004	Feb 03, 2037	U-3658			
	9527833	Jun 17, 2034	DS DP			
	9943537	Sep 05, 2034	U-3659			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
	RE46284	Sep 22, 2029	U-3656			
TIRBANIBULIN - KLISYRI						
N 213189 001	10323001	Dec 28, 2027	DP		D-192	Jun 07, 2027
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	11497750	Mar 12, 2038	U-3015			
	7300931	Dec 28, 2030	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 001	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 010	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 012	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 001	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 002	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 003	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 004	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 004	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 005	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 006	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228		NP	Nov 08, 2026
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 007	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 008	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 008	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 009	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 010	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 011	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			
TIRZEPATIDE - ZEPBOUND						
N 217806 012	11357820	Jun 14, 2039	DP		I-958	Dec 20, 2027
	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
	12343382	Jul 22, 2039	U-4227		NCE	May 13, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
	9474780	Jan 05, 2036	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIVOZANIB HYDROCHLORIDE - FOTIVDA								
N 212904	001		11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
			7166722	Nov 16, 2028	DS DP			
TIVOZANIB HYDROCHLORIDE - FOTIVDA								
N 212904	002		11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
			7166722	Nov 16, 2028	DS DP			
TIZANIDINE HYDROCHLORIDE - ONTRALFY								
N 216190	001		12042484	May 07, 2042	DP U-2779			
			12263158	May 07, 2042	DP U-2779			
TOBRAMYCIN - TOBI PODHALER								
N 201688	001		10207066	Nov 04, 2030	DP U-909			
			8869794	Sep 12, 2028	DP U-909			
TOFACITINIB CITRATE - XELJANZ								
N 203214	001		RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
			RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOFACITINIB CITRATE - XELJANZ								
N 203214	002		RE41783	Dec 08, 2025	DS			
			RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR								
N 208246	001		11253523	Mar 14, 2034	U-3326			
			11253523	Mar 14, 2034	U-3327			
			11253523	Mar 14, 2034	U-3328			
			11253523	Mar 14, 2034	U-3329			
			11253523*PED	Sep 14, 2034				
			9937181	Mar 14, 2034	DP			
			9937181*PED	Sep 14, 2034				
			RE41783	Dec 08, 2025	DS			
			RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR								
N 208246	002		10639309	Mar 14, 2034	DP			
			10639309*PED	Sep 14, 2034				
			11253523	Mar 14, 2034	U-3326			
			11253523	Mar 14, 2034	U-3327			
			11253523	Mar 14, 2034	U-3328			
			11253523	Mar 14, 2034	U-3329			
			11253523*PED	Sep 14, 2034				
			RE41783	Dec 08, 2025	DS			
			RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ								
N 213082	001		RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
			RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOFERSEN - QALSODY								
N 215887	001		10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
			10669546	Apr 01, 2035	U-3575		ODE-432	Apr 25, 2030
			10968453	Apr 01, 2035	U-3575			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOLVAPTAN - SAMSCA						
N 022275 001	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 002	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 003	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 001	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 002	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 003	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 004	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE						
N 204441 005	10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
TOPIRAMATE - TOPIRAMATE						
A 216683 003					CGT	Feb 01, 2026
TOPIRAMATE - TOPIRAMATE						
A 217795 001					PC	Jan 05, 2026
TOPIRAMATE - TROKENDI XR						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 001	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 004	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - QUDEXY XR						
N 205122 001	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - EPRONTIA						
N 214679 001	11433046	Aug 21, 2040	U-3413			
	11433046	Aug 21, 2040	U-3414			
	11433046	Aug 21, 2040	U-3415			
	11633374	Aug 21, 2040	DP			
	11826343	Aug 21, 2040	DP			
	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
	12290503	Aug 21, 2040	DP U-3413			
	12290503	Aug 21, 2040	DP U-3414			
	12290503	Aug 21, 2040	DP U-3415			
TORSEMIDE - SOAANZ						
N 213218 001	10154963	Oct 06, 2033	DP			
TORSEMIDE - SOAANZ						
N 213218 002	10154963	Oct 06, 2033	DP			
TOVORAFENIB - OJEMDA						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
TOVORAFENIB - OJEMDA						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
TRABECTEDIN - YONDELIS						
N 207953 001	8895557	Jan 07, 2028	DP			
	8895557*PED	Jul 07, 2028				
TRADIPITANT - NEREUS						
N 220152 001					NCE	Dec 30, 2030
TRAMADOL HYDROCHLORIDE - QDOLO						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
	11752103	Sep 01, 2040	DP U-3197			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-908	Mar 16, 2026
	10869869*PED	Feb 28, 2034			ODE-428	Mar 16, 2030
	7378423	May 29, 2027	DS DP		PED	Sep 16, 2026
	7378423*PED	Nov 29, 2027			PED	Sep 16, 2030
	8580304	Jan 28, 2032	DP			
	8580304*PED	Jul 28, 2032				
	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-908	Mar 16, 2026
	10869869*PED	Feb 28, 2034			ODE-428	Mar 16, 2030
	7378423	May 29, 2027	DS DP		PED	Sep 16, 2026
	7378423*PED	Nov 29, 2027			PED	Sep 16, 2030
	8580304	Jan 28, 2032	DP			
	8580304*PED	Jul 28, 2032				
	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-908	Mar 16, 2026
	10869869*PED	Feb 28, 2034			ODE-428	Mar 16, 2030
	7378423	May 29, 2027	DS DP		PED	Sep 16, 2026
	7378423*PED	Nov 29, 2027			PED	Sep 16, 2030
	8580304	Jan 28, 2032	DP			
	8580304*PED	Jul 28, 2032				
	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 217513 001	7378423*PED	Nov 29, 2027			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-3564		PED	Sep 16, 2026
	8703781*PED	Apr 15, 2031			PED	Sep 16, 2030
TRAVOPROST - TRAVATAN Z						
N 021994 001	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA						
N 204822 001	8178582	Oct 10, 2029	DP			
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			
TRAVOPROST - IDOSE TR						
N 218010 001	10206813	Oct 17, 2030	DP		NP	Dec 13, 2026
	11426306	Oct 17, 2030	DP			
	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 001	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 002	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 003	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 004	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 001	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 002	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - RALDESY						
N 218637 001	8133893	Mar 13, 2029	DS DP			
TREOSULFAN - GRAFAPEX						
N 214759 001	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREOSULFAN - GRAFAPEX						
N 214759 002	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREPROSTINIL - REMODULIN						
N 021272 001	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN						
N 021272 001	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 002	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 003	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 004	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 005	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 006	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 007	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 021272 008	11723887	Dec 15, 2028	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO						
N 022387 001	10376525	May 14, 2027	U-1849			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - TYVASO						
N 022387 001	11723887	Dec 15, 2028	DS			
	11826327	Feb 03, 2042			U-3749	
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028			U-1849	
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 001	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 002	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 003	9593066	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 004	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 001	10421729	Apr 01, 2035	DP			
	10772883	Jun 11, 2030	DP			
	11357782	May 14, 2027			U-1849	
	11723887	Dec 15, 2028	DS			
	11826327	Feb 03, 2042			U-3749	
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 002	10421729	Apr 01, 2035	DP			
	10772883	Jun 11, 2030	DP			
	11357782	May 14, 2027			U-1849	
	11723887	Dec 15, 2028	DS			
	11826327	Feb 03, 2042			U-3749	
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 003	10421729	Apr 01, 2035	DP			
	10772883	Jun 11, 2030	DP			
	11357782	May 14, 2027			U-1849	
	11723887	Dec 15, 2028	DS			
	11826327	Feb 03, 2042			U-3749	
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 004	10421729	Apr 01, 2035	DP			
	10772883	Jun 11, 2030	DP			
	11357782	May 14, 2027			U-1849	
	11723887	Dec 15, 2028	DS			
	11826327	Feb 03, 2042			U-3749	
	9593066	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 005	10421729	Apr 01, 2035	DP			
	10772883	Jun 11, 2030	DP			
	11357782	May 14, 2027			U-1849	
	11723887	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - TYVASO DPI						
N 214324 005	11826327	Feb 03, 2042	U-3749			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9393203	Apr 27, 2026	DP U-1877			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS	Y		
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9393203	Apr 27, 2026	DP U-1877			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9393203	Apr 27, 2026	DP U-1877			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9393203	Apr 27, 2026	DP U-1877			
	9593066	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 005	11723887	Dec 15, 2028	DS		ODE-272	Oct 18, 2026
	7417070	Jul 30, 2026	DS			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 005	8747897	Aug 11, 2031	DP U-2725			
	9393203	Apr 27, 2026	DP U-1877			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS	Y		
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 001	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 002	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 003	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 004	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
TRETINOIN - ALTRENO						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
	11324710	Aug 22, 2038	U-2368			
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N 022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1257			
	8211880	Mar 10, 2029	U-1258			
TRIAMCINOLONE ACETONIDE - ZILRETTA						
N 208845 001	8828440	Aug 04, 2031	DP			
	9555048	Aug 04, 2031	U-2151			
TRIAMCINOLONE ACETONIDE - XIPERE						
N 211950 001	12419833	Apr 16, 2040	DP U-3234			
	8636713	May 02, 2027	U-3234			
	9636332	Nov 08, 2033	U-3234			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRIAMCINOLONE ACETONIDE - XIPERE						
N 211950 001	9937075	May 02, 2034	DP			
TRICLABENDAZOLE - EGATEN						
N 208711 001					ODE-228	Feb 13, 2026
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001	10988436	May 03, 2039	DS		ODE-401	Apr 28, 2029
	11072577	May 03, 2039	U-3370			
	12358861	May 03, 2039	DS DP U-4262			
	12358862	May 03, 2039	DS DP U-4262			
TRIFAROTENE - AKLIEF						
N 211527 001	7807708	Jul 19, 2031	DS DP			
	9084778	May 30, 2033	DP U-134			
	9498465	May 30, 2033	DP U-1033			
TRIHEPTANOIN - DOJOLVI						
N 213687 001	8697748	Apr 28, 2029	DP		ODE-311	Jun 30, 2027
TRILACICLIB DIHYDROCHLORIDE - COSELA						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	11040042	Oct 25, 2031	DP			
	11529352	Jul 23, 2039	U-3504			
	11717523	Mar 14, 2034	U-3678			
	11717523	Mar 14, 2034	U-3679			
	12168666	Nov 13, 2040	DS DP			
	8598186	Dec 30, 2034	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
TRIPTORELIN PAMOATE - TRELSTAR						
N 022437 001	10166181	Jun 30, 2029	DP			
TRIPTORELIN PAMOATE - TRIPTODUR KIT						
N 208956 001	10166181	Jun 30, 2029	DP			
TROFINETIDE - DAYBUE						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	11827600	Jul 12, 2042	DS DP U-3556		ODE-425	Mar 10, 2030
	9212204	Jan 27, 2032	U-3556			
TROFINETIDE - DAYBUE STIX						
N 219884 001					NCE	Mar 10, 2028
					ODE*	Mar 10, 2030
TROFINETIDE - DAYBUE STIX						
N 219884 002					NCE	Mar 10, 2028
					ODE*	Mar 10, 2030

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TROFINETIDE - DAYBUE STIX						
N 219884 003					NCE	Mar 10, 2028
					ODE*	Mar 10, 2030
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 001	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 002	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			
TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY						
N 216158 003	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			
TUCATINIB - TUKYSA						
N 213411 001	11207324	Apr 27, 2038	U-3783		I-906	Jan 19, 2026
	11504370	Mar 25, 2033	U-2788		ODE-309	Apr 17, 2027
	11666572	Apr 27, 2038	U-3783		ODE-422	Jan 19, 2030
	12048698	Apr 27, 2038	U-3783			
	7452895	Nov 16, 2026	DS DP U-2788			
	7452895	Nov 16, 2026	DS DP U-4153			
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
TUCATINIB - TUKYSA						
N 213411 002	11207324	Apr 27, 2038	U-3783		I-906	Jan 19, 2026
	11504370	Mar 25, 2033	U-2788		ODE-309	Apr 17, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TUCATINIB - TUKYSA						
N 213411 002	11666572	Apr 27, 2038	U-3783		ODE-422	Jan 19, 2030
	12048698	Apr 27, 2038	U-3783			
	7452895	Nov 16, 2026	DS DP U-2788			
	7452895	Nov 16, 2026	DS DP U-4153			
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
UBROGEPANT - UBRELVY						
N 211765 001	10117836	Jan 30, 2035	DP			
	11717515	Dec 22, 2041	U-3677			
	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
	12329750	Dec 22, 2041	U-4213			
	12458632	Jan 30, 2035	DP			
	12458633	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Dec 23, 2033	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
UBROGEPANT - UBRELVY						
N 211765 002	10117836	Jan 30, 2035	DP			
	11925709	Jan 30, 2035	DP			
	12070450	Dec 22, 2041	U-3992			
	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
	12458632	Jan 30, 2035	DP			
	12458633	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Dec 23, 2033	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	10159681	Apr 13, 2030	U-2510			
	10772897	Apr 13, 2030	U-2958			
	8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
	9844510	Dec 08, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UMBRALISIB TOSYLATE - UKONIQ						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064			
	10414773	May 26, 2035	DS DP U-3063			
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA						
N 205382 001	7488827	Dec 18, 2027	DS DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	11090294	Nov 29, 2030	U-3203			
	12396986	Nov 29, 2030	DP			
	7488827	Dec 18, 2027	DS DP			
	8511304	Jun 14, 2027	DP U-1476			
	8511304*PED	Dec 14, 2027				
	9750726	Nov 29, 2030	DP			
UPADACITINIB - RINVOQ						
N 211675 001	10519164	Oct 17, 2036	DP		I-919	May 18, 2026
	10597400	Oct 17, 2036	U-3255		I-946	Apr 26, 2027
	10981923	Oct 17, 2036	DS		I-966	Apr 28, 2028
	10981924	Oct 17, 2036	DP		NPP	Apr 26, 2027
	10995095	Oct 17, 2036	U-3298		ODE-481	Apr 26, 2031
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	11365198	Oct 17, 2036	U-3275			
	11365198	Oct 17, 2036	U-3946			
	11512092	Oct 17, 2036	U-3275			
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11524964	Oct 17, 2036	U-3371			
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 001	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11780847	Oct 17, 2036	DP			
	11780848	Oct 17, 2036	U-3371			
	11787815	Oct 17, 2036	DP			
	11795175	Oct 17, 2036	U-3255			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	12077545	Oct 17, 2036	DP			
	12103933	Oct 17, 2036	DP			
	12110297	Oct 17, 2036	DP			
	12110298	Oct 17, 2036	DS DP			
	12365689	Oct 17, 2036	U-3945			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Aug 16, 2033	DS			
UPADACITINIB - RINVOQ						
N 211675 002	10344036	Oct 17, 2036	DP		I-919	May 18, 2026
	10550126	Oct 17, 2036	U-3298		I-946	Apr 26, 2027
	10730883	Oct 17, 2036	DP		NPP	Apr 26, 2027
	10981923	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	11535626	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11767326	Oct 17, 2036	U-3298			
	11773105	Oct 17, 2036	DS DP			
	12077545	Oct 17, 2036	DP			
	12091415	Oct 17, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 002	12110298	Oct 17, 2036	DS DP			
	12116373	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Aug 16, 2033	DS			
UPADACITINIB - RINVOQ						
N 211675 003	10202393	Oct 17, 2036	DP		I-919	May 18, 2026
	10981923	Oct 17, 2036	DS		I-946	Apr 26, 2027
	11186584	Oct 17, 2036	DS		NPP	Apr 26, 2027
	11198697	Oct 17, 2036	DP		ODE-481	Apr 26, 2031
	11564922	Mar 09, 2038	U-3624			
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
	11661425	Oct 17, 2036	DS DP			
	11680069	Oct 17, 2036	DS DP			
	11718627	Oct 17, 2036	DS DP			
	11773105	Oct 17, 2036	DS DP			
	12077545	Oct 17, 2036	DP			
	12110298	Oct 17, 2036	DS DP			
	12134621	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Aug 16, 2033	DS			
UPADACITINIB - RINVOQ LQ						
N 218347 001	10981923	Oct 17, 2036	DS		NP	Apr 26, 2027
	11186584	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11661425	Oct 17, 2036	DS			
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	12110298	Oct 17, 2036	DS			
	12365689	Oct 17, 2036	U-3945			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
URIDINE TRIACETATE - VISTOGARD						
N 208159 001	7776838	Aug 17, 2027	U-1791			
VADADUSTAT - VAFSEO						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VADADUSTAT - VAFSEO						
N 215192 001	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
VADADUSTAT - VAFSEO						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
VADADUSTAT - VAFSEO						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055		ODE-440	Aug 18, 2030
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA SPRINKLE						
N 218390 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA SPRINKLE						
N 218390 001	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA SPRINKLE						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA SPRINKLE						
N 218390 002	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALBENAZINE TOSYLATE - INGREZZA SPRINKLE						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VAMOROLONE - AGAMREE						
N 215239 001	10857161	May 28, 2029	DP U-3747		NCE	Oct 26, 2028
	11382922	Jul 16, 2040	DS DP		ODE-450	Oct 26, 2030
	11471471	Mar 17, 2040	U-3747			
	11690853	Mar 07, 2033	U-3747			
	11833159	May 28, 2029	DP			
	12201639	Mar 17, 2040	DS DP U-3747			
	8334279	May 28, 2029	U-3747			
VANCOMYCIN - VANCOMYCIN						
N 213895 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11000567	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 001	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 002	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
	11628200	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 002	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 003	10039804	Nov 06, 2035	DP		U-282	
	10188697	Nov 06, 2035	DP		U-282	
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035			U-282	
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 004	10039804	Nov 06, 2035	DP		U-282	
	10188697	Nov 06, 2035	DP		U-282	
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035			U-282	
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 005	10039804	Nov 06, 2035	DP		U-282	
	10188697	Nov 06, 2035	DP		U-282	
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035			U-282	
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 006	10039804	Nov 06, 2035	DP		U-282	
	10188697	Nov 06, 2035	DP		U-282	
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035			U-282	
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN						
N 211962 007	10039804	Nov 06, 2035	DP		U-282	
	10188697	Nov 06, 2035	DP		U-282	
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035			U-282	
	11628200	Nov 06, 2035	DP			
	12161690	Nov 06, 2035	DP			
VANDETANIB - CAPRELSA						
N 022405 001	8067427	Aug 08, 2028	DP			
VANDETANIB - CAPRELSA						
N 022405 002	8067427	Aug 08, 2028	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 001	8273876	Jul 23, 2027			U-1288	
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 002	8273876	Jul 23, 2027			U-1288	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 003	8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 004	8273876	Jul 23, 2027	U-1288			
VARDENAFIL HYDROCHLORIDE - STAXYN						
N 200179 001	8613950	Dec 23, 2028	DP			
VARENICLINE TARTRATE - TYRVAYA						
N 213978 001	10456396	Oct 19, 2035	DP U-1900			
	11224598	Oct 19, 2035	U-1900			
	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
	9504644	Oct 19, 2035	U-1900			
	9504645	Oct 19, 2035	DP			
	9532944	Oct 19, 2035	U-1900			
	9597284	Oct 19, 2035	U-1900			
VASOPRESSIN - VASOSTRICT						
N 204485 001	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
	9937223	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	12186362	Jan 30, 2035	DP			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	12186362	Jan 30, 2035	DP			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VASOPRESSIN - VASOSTRICT						
N 204485 004	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	12186362	Jan 30, 2035	DP			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	12186362	Jan 30, 2035	DP			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
N 217569 001	12447190	Sep 27, 2044	DP			
VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
N 217569 002	12447190	Sep 27, 2044	DP			
VEMURAFENIB - ZELBORAF						
N 202429 001	7504509	Oct 22, 2026	DS DP			
	7863288	Jun 20, 2029	DS DP			
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026	U-1418			
	8470818	Aug 02, 2026	U-2164			
	8741920	Jul 27, 2030	DS DP			
	9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA						
N 208573 001	10730873	Nov 21, 2031	DS		ODE-239	May 15, 2026
	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VENETOCLAX - VENCLEXTA						
N 208573 001	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA						
N 208573 002	10730873	Nov 21, 2031	DS		ODE-239	May 15, 2026
	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA						
N 208573 003	10730873	Nov 21, 2031	DS		ODE-239	May 15, 2026
	10993942	Sep 06, 2033	U-3114			
	11110087	Sep 06, 2033	U-3222			
	11110087	Sep 06, 2033	U-3223			
	11369599	May 23, 2032	DP			
	11413282	Sep 06, 2033	U-3412			
	11590128	Sep 06, 2033	U-3548			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE						
N 215429 001	7776358	May 16, 2028	DP			
VERICIGUAT - VERQUVO						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VERICIGUAT - VERQUVO						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VIBEGRON - GEMTESA						
N 213006 001	12102638	Mar 22, 2040	U-3045		I-955	Dec 18, 2027
	12180219	Mar 12, 2034	DS DP			
	12357636	Jul 06, 2042	U-4219			
	8247415	Dec 23, 2034	DS DP U-3045			
	8247415	Dec 23, 2034	DS DP U-4219			
	8653260	Apr 02, 2029	DS			
VIGABATRIN - VIGAFYDE						
N 217684 001	12016857	Aug 16, 2039	DP			
	12290499	Oct 17, 2042	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 001	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727			
	12121523	Sep 04, 2029	U-727			
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 002	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727			
	12121523	Sep 04, 2029	U-727			
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 003	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727			
	12121523	Sep 04, 2029	U-727			
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Apr 02, 2035	DP			
VILTOLARSEN - VILTEPSO						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
	9079934	Apr 03, 2034	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILTOLARSEN - VILTEPSO						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
	9079934	Apr 03, 2034	DS DP			
VIMSELTINIB - ROMVIMZA						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	12285430	Dec 23, 2039	U-4145			
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039	U-4145			
	9181223	Mar 14, 2034	DS DP			
VISMODEGIB - ERIVEDGE						
N 203388 001	7888364	Nov 11, 2028	DS DP			
	9278961	Dec 15, 2028	U-1825			
VOCLOSPORIN - LUPKYNIS						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	11622991	Dec 07, 2037	U-3056			
	7332472	Jan 17, 2026	DS DP U-3056			
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 001	7977488	Aug 11, 2028	DS		I-948	Jul 17, 2027
	9186411	Aug 11, 2030	DP		NCE	May 03, 2027
					NP	Nov 01, 2026
					GAIN	May 03, 2032
VONOPRAZAN FUMARATE - VOQUEZNA						
N 215151 002	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		NP	Nov 01, 2026
					GAIN	May 03, 2032
VORAPAXAR SULFATE - ZONTIVITY						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
VORASIDENIB - VORANIGO						
N 218784 001	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	12433895	Jul 11, 2034	U-4286			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORASIDENIB - VORANIGO						
N 218784 001	9579324	Jul 11, 2034	DS			
VORASIDENIB - VORANIGO						
N 218784 002	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	12433895	Jul 11, 2034	U-4286			
	9579324	Jul 11, 2034	DS			
VORINOSTAT - ZOLINZA						
N 021991 001	7456219	Mar 11, 2027	DS			
	8093295	May 16, 2026	DP			
	8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 001	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	11458134	Jun 15, 2027	DP U-3463		M-232	Aug 23, 2026
	11458134*PED	Dec 15, 2027			PED	Feb 23, 2027
	7144884	Jun 17, 2026	DS DP U-1439			
	7144884*PED	Dec 17, 2026				
	8722684	Jun 30, 2031	DS DP			
	8722684*PED	Dec 30, 2031				
	8969355	Jun 15, 2027	U-1668			
	8969355*PED	Dec 15, 2027				
	9125908	Jun 15, 2027	U-2309			
	9125908*PED	Dec 15, 2027				
	9125909	Jun 15, 2027	U-2309			
	9125909*PED	Dec 15, 2027				
	9125910	Jun 15, 2027	U-2309			
	9125910*PED	Dec 15, 2027				
	9227946	Jun 15, 2027	U-1668			
	9227946*PED	Dec 15, 2027				
	9278096	Mar 21, 2032	U-2436			
	9278096*PED	Sep 21, 2032				
	9861630	Jun 15, 2027	U-1668			
	9861630*PED	Dec 15, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOSORITIDE - VOXZOGO						
N 214938 001	10646550	Aug 01, 2036	DP U-3927		NCE	Nov 19, 2026
	11590204	Aug 01, 2036	DP U-3927		NPP	Oct 20, 2026
	11911446	Aug 01, 2036	U-3927		ODE-387	Nov 19, 2028
	12233106	Jul 11, 2042	U-3927		ODE-449	Oct 20, 2030
	8198242	Jun 11, 2030	DS DP U-3927			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3927			
VOSORITIDE - VOXZOGO						
N 214938 002	10646550	Aug 01, 2036	DP U-3927		NCE	Nov 19, 2026
	11590204	Aug 01, 2036	DP U-3927		NPP	Oct 20, 2026
	11911446	Aug 01, 2036	U-3927		ODE-387	Nov 19, 2028
	12233106	Jul 11, 2042	U-3927		ODE-449	Oct 20, 2030
	8198242	Jun 11, 2030	DS DP U-3927			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3927			
VOSORITIDE - VOXZOGO						
N 214938 003	10646550	Aug 01, 2036	DP U-3927		NCE	Nov 19, 2026
	11590204	Aug 01, 2036	DP U-3927		NPP	Oct 20, 2026
	11911446	Aug 01, 2036	U-3927		ODE-387	Nov 19, 2028
	12233106	Jul 11, 2042	U-3927		ODE-449	Oct 20, 2030
	8198242	Jun 11, 2030	DS DP U-3927			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3927			
VOXELOTOR - OXBRYTA						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP		ODE-394	Dec 17, 2028
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	11944612	Dec 02, 2036	U-3893			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VOXELOTOR - OXBRYTA						
N 213137 002	10017491	Dec 28, 2032	DP		ODE-394	Dec 17, 2028
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	11944612	Dec 02, 2036	U-3893			
	9018210	Nov 25, 2033	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOXELOTOR - OXBRYTA						
N 213137 002	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VOXELOTOR - OXBRYTA						
N 216157 001	10017491	Dec 28, 2032	DP		ODE*	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP		ODE-394	Dec 17, 2028
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	11944612	Dec 02, 2036	U-3893			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VUTRISIRAN SODIUM - AMVUTTRA						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		I-964	Mar 20, 2028
	10208307	Jul 28, 2036	DS DP U-3396		NCE	Jun 13, 2027
	10570391	Nov 16, 2032	DS DP U-3396		ODE-212	Jun 13, 2029
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	12049628	Jul 28, 2036	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
XENON XE-129 HYPERPOLARIZED - XENOVIEW						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
ZANUBRUTINIB - BRUKINSA						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2666		ODE-276	Nov 14, 2026
	10570139	Apr 22, 2034	U-3063		ODE-370	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE-371	Aug 31, 2028
	10570139	Apr 22, 2034	U-3860		ODE-467	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 213217 001	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 213217 001	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
ZANUBRUTINIB - BRUKINSA						
N 218785 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE*	Nov 14, 2026
	10570139	Apr 22, 2034	U-2666		ODE*	Aug 31, 2028
	10570139	Apr 22, 2034	U-3063		ODE*	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE*	Jan 19, 2030
	10570139	Apr 22, 2034	U-3860		ODE*	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 218785 001	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	12233069	Jun 10, 2040	DP			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET						
N 216386 001	8481546	Oct 07, 2031	DS DP U-3555		NCE	Mar 09, 2028
ZIFTOMENIB - KOMZIFTI						
N 220305 001	10077271	Mar 16, 2036	DS DP		NCE	Nov 13, 2030
	10174041	Mar 16, 2036	U-4350			
	10174041	Mar 16, 2036	U-4354			
	10781218	Mar 15, 2037	DS DP			
	10869868	Jan 26, 2037	U-4352			
	10869868	Jan 26, 2037	U-4353			
	11673898	Mar 15, 2037	U-4350			
	11673898	Mar 15, 2037	U-4351			
	11944627	Sep 06, 2038	U-4347			
	11944627	Sep 06, 2038	U-4349			
	12410184	Jul 16, 2044	DS DP U-4347			
	12410184	Jul 16, 2044	DS DP U-4348			
ZILUCOPLAN SODIUM - ZILBRYSQ						
N 216834 001	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZILUCOPLAN SODIUM - ZILBRYSQ						
N 216834 001	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
	11965040	Jun 12, 2035	DP			
ZILUCOPLAN SODIUM - ZILBRYSQ						
N 216834 002	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
	11965040	Jun 12, 2035	DP			
ZILUCOPLAN SODIUM - ZILBRYSQ						
N 216834 003	10106579	Jun 12, 2035	DS DP U-3735		NCE	Oct 17, 2028
	10208089	Jun 12, 2035	DS U-3735		ODE-446	Oct 17, 2030
	10435438	Jun 12, 2035	DS U-3735			
	10562934	Jun 12, 2035	DS			
	10835574	Jun 12, 2035	DP			
	11014965	Jun 12, 2035	DS U-3735			
	11535650	Jun 12, 2035	DP			
	11752190	Jun 12, 2035	DP U-3735			
	11965040	Jun 12, 2035	DP			
ZOLEDRONIC ACID - ZOMETA						
N 021223 003	7932241	Feb 05, 2028	DP			
ZOLEDRONIC ACID - RECLAST						
N 021817 001	7932241	Feb 05, 2028	DP			
ZOLIFLODACIN - NUZOLVENCE						
N 219491 001					NCE	Dec 12, 2030
					GAIN	Dec 12, 2035
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - ZOLPIMIST						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			
ZOLPIDEM TARTRATE - INTERMEZZO						
N 022328 001	7658945	Apr 15, 2027	DP U-1194			
	8242131	Aug 20, 2029	U-1266			
ZOLPIDEM TARTRATE - INTERMEZZO						
N 022328 002	7658945	Apr 15, 2027	DP U-1194			
	8242131	Aug 20, 2029	U-1266			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZONGERTINIB - HERNEXEOS							
N 219042	001	11608343	Jul 21, 2041	DS DP U-4245		NCE	Aug 08, 2030
		12171739	Nov 15, 2026	DS DP			
ZONISAMIDE - ZONISADE							
N 214273	001	11478456	Aug 18, 2038	U-3458			
		11529333	Aug 18, 2038	DP			
		12491179	Aug 18, 2038	DP			
ZURANOLONE - ZURZUVAE							
N 217369	001	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		11884696	Aug 23, 2037	U-2552			
		9512165	Apr 17, 2034	DS DP			
ZURANOLONE - ZURZUVAE							
N 217369	002	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		11884696	Aug 23, 2037	U-2552			
		9512165	Apr 17, 2034	DS DP			
ZURANOLONE - ZURZUVAE							
N 217369	003	10172871	Apr 17, 2034	U-2552		NCE	Oct 31, 2028
		10342810	Apr 17, 2034	U-2552			
		11236121	Aug 23, 2037	DS			
		11884696	Aug 23, 2037	U-2552			
		9512165	Apr 17, 2034	DS DP			

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
ODE*	FDA has not recognized Orphan-Drug Exclusivity (ODE) for this drug, but it contains the same active moiety or moieties as another drug(s) that was eligible for ODE, and also shares ODE-protected use(s) or indication(s) with that drug(s). An application seeking approval for the same active moiety or moieties, including an ANDA that cites this NDA as its basis of submission, may not be approved for such ODE-protected use(s) and indication(s)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL

EXCLUSIVITY DOSING SCHEDULE

D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING

EXCLUSIVITY DOSING SCHEDULE

D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

EXCLUSIVITY DOSING SCHEDULE

D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

EXCLUSIVITY DOSING SCHEDULE

D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

EXCLUSIVITY DOSING SCHEDULE

D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
D-166	BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
D-167	ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
D-168	NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
D-169	ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

EXCLUSIVITY DOSING SCHEDULE

D-170	TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
D-171	REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
D-172	ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-181	DOSING REGIMEN EXTENDING THE CONTRACEPTION USE FROM 5 YEARS TO UP TO 6 YEARS
D-182	NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIBASSOCIATED DIARRHEA
D-183	3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
D-184	NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
D-185	ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
D-186	ADDITION OF A 3-DAY FOSAPREPITANT FOR INJECTION INTRAVENOUS DOSING REGIMEN IN PEDIATRIC PATIENTS FOR THE CURRENTLY APPROVED PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
D-187	ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS
D-188	USE OF ALTERNATE INITIAL DOSING REGIMEN FOR INITIATION OF LACOSAMIDE TREATMENT IN PARTIAL ONSET SEIZURE PATIENTS ≥1 MONTH TO <17 YEARS OF AGE AND IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURE PATIENTS ≥4 TO <17 YEARS
D-189	EXTENSION OF LETERMOVIR DOSING REGIMEN FROM 100 TO 200 DAYS POST-TRANSPLANT FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV SEROPOSITIVE RECIPIENTS (R+) OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT WHO ARE AT RISK FOR LATE CMV INFECTION AND DISEASE
D-190	USE OF SEMAGLUTIDE 1.7 MG SUBCUTANEOUS WEEKLY AS AN ADDITIONAL MAINTENANCE DOSE
D-191	ADDITION OF A ONCE DAILY DOSING REGIMEN
D-192	EXPANSION OF THE TREATMENT FIELD ON THE FACE OR SCALP UP TO 100 CM^2
D-193	NEW INSERTER INTENDED TO FACILITATE SINGLE-HAND PLACEMENT
D-194	INCREASE IN THE APPROVED DOSAGE REGIMEN TO A MAXIMUM APPLICATION AREA OF 60 CM^2 IN TOTAL (CORRESPONDING TO THREE 2 GM TUBES)
D-195	NEW DOSING RECOMMENDATIONS IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING THOSE REQUIRING HEMODIALYSIS BASED ON DATA FROM STUDY C4671028
D-196	ADDITION OF A TWO-BAG DOSING REGIMEN
D-197	REVISED DOSING TITRATION REGIMEN

EXCLUSIVITY INDICATION

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)

EXCLUSIVITY INDICATION

I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM

EXCLUSIVITY INDICATION

I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK

	EXCLUSIVITY INDICATION
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER

EXCLUSIVITY INDICATION

I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11

EXCLUSIVITY INDICATION

I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

EXCLUSIVITY INDICATION

I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET

I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH

I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN

I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS

I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)

I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL

I-229 PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

EXCLUSIVITY INDICATION

I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

EXCLUSIVITY INDICATION

I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR

	EXCLUSIVITY INDICATION
	FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA

EXCLUSIVITY INDICATION

I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

EXCLUSIVITY INDICATION

I-372 NOSOCOMIAL PNEUMONIA

I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS

I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)

I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION

I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION

I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR

I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER

I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION

I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE

I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION

I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE

I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....

I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY

I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

I-393 CHRONIC BACTERIAL PROSTATITIS

I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES

I-395 TO IMPROVE PHYSICAL FUNCTION

I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION

I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY

I-398 IDIOPATHIC SHORT STATURE

I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS

EXCLUSIVITY INDICATION

I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN

EXCLUSIVITY INDICATION

ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM

I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED

I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER

I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE

I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)

I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

I-435 CHRONIC IDIOPATHIC CONSTIPATION

I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS

I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY

I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS

I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS

I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER

I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS

I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)

I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS

I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)

I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE

I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER

I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT

I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN

I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE

EXCLUSIVITY INDICATION

	RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE

EXCLUSIVITY INDICATION

I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER

EXCLUSIVITY INDICATION

I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

EXCLUSIVITY INDICATION

I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER

	EXCLUSIVITY INDICATION
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16

	EXCLUSIVITY INDICATION
	YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

EXCLUSIVITY INDICATION

I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L

EXCLUSIVITY INDICATION

I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY

I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE

I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE

I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT

I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS

I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED

I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS

I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE

I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY

I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE

I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION

I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND

EXCLUSIVITY INDICATION

PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

EXCLUSIVITY INDICATION

I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.

I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.

I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY

I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.

I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION

I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL

I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS

I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY

I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE

I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS

I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN

I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.

I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE

I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)

I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION

I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS

I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY

I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA

I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665

I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

EXCLUSIVITY INDICATION

I-745 MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.

I-746 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS

I-747 FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA

I-748 TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER

I-749 MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

I-750 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-751 TREATMENT OF TARDIVE DYSKINESIA

I-752 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE

I-753 TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY

I-754 TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME

I-755 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY

I-756 EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB

I-757 TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION

I-758 FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV

I-759 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

I-760 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

I-761 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

I-762 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING

I-763 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-764 TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

I-765 ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER

I-766 TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR

I-767 TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON

I-768 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER

I-769 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

EXCLUSIVITY INDICATION

I-770 TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS

I-771 REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA

I-772 FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

I-773 FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES

I-774 TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST

I-775 REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS

I-776 FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY

I-777 CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

I-778 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

I-779 USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

I-780 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

I-781 DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

I-782 REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-783 EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY

I-784 RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

I-785 TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

I-786 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-787 FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

I-788 NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)

I-789 VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

I-790 USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS

EXCLUSIVITY INDICATION

I-791 TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY

I-792 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

I-793 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

I-794 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

I-795 VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

I-796 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)

I-797 USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)

I-798 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)

I-799 TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER

I-800 TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY

I-801 USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)

I-802 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

I-803 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE

I-804 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-805 SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

I-806 EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR DISOPROXIL FUMARATE

I-807 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION

I-808 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

I-809 TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY

I-810 PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING

I-811 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS

I-812 FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX

I-813 TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION

I-814 TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO

EXCLUSIVITY INDICATION

I-815 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS

I-816 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

I-817 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

I-818 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN

I-819 ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE

I-820 INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION

I-821 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE

I-822 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-823 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING

I-824 RIVAROXABAN IN COMBINATION WITH ASPIRIN, IS INDICATED TO REDUCE THE RISK OF MAJOR CV EVENTS (CV DEATH, MI, AND STROKE) IN PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD)

I-825 TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE

I-826 ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

I-827 EXPANDED INDICATION FOR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE

I-828 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING’S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

I-829 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP)

I-830 TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY

I-831 W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS

I-832 TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE

I-833 MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

I-834 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION

I-835 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES

EXCLUSIVITY INDICATION

I-836 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

I-837 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY

I-838 TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) OF THE FEET

I-839 TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE

I-840 TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.

I-841 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS

I-842 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE

I-843 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-844 INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS

I-845 TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST

I-846 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NARCOLEPSY

I-847 EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST

I-848 REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)

I-849 CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS

I-850 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER

I-851 TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS

I-852 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE

I-853 INDICATION OF OSIMERTINIB AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

I-854 FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB

I-855 TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE

I-856 INDICATION FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE TO IMPROVE EXERCISE ABILITY

I-857 TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION

I-858 FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER

I-859 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

EXCLUSIVITY INDICATION

I-860	FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS
I-861	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
I-862	TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR AT LEAST 5 DAYS AND TO REDUCE THE RISK OF RECURRENCE OF VTE IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN PREVIOUSLY TREATED
I-863	TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)
I-864	TREATMENT OF ADULT PATIENTS WITH MAST CELL LEUKEMIA (MCL)
I-865	FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
I-866	FOR THE TREATMENT OF TRICHOMONIASIS CAUSED BY TRICHOMONAS VAGINALIS IN ADULTS
I-867	INDICATED TO REDUCE THE RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD, INCLUDING PATIENTS WHO HAVE RECENTLY UNDERGONE A LOWER EXTREMITY REVASCULARIZATION PROCEDURE DUE TO SYMPTOMATIC PAD
I-868	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
I-869	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
I-870	INDICATED FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
I-871	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)
I-872	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-873	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
I-874	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
I-875	FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-876	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
I-877	INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST
I-878	ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
I-879	TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION
I-880	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-881	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
I-882	INDICATED FOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION) IN ADULTS, AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-883	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE

EXCLUSIVITY INDICATION

I-884 REVISIONS TO THE LABELING TO INCLUDE DATA FOR SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS, AND TO ALLOW FOR AN EXPANSION OF THE INDICATION

I-885 FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY

I-886 TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

I-887 INDICATION FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS WHO ARE 2 YEARS OF AGE AND OLDER

I-888 TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

I-889 TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

I-890 TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA

I-891 TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)

I-892 CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH BARDET-BIEDL SYNDROME (BBS)

I-893 IN COMBINATION WITH AZACITIDINE OR AS MONOTHERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULTS 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

I-894 DABRAFENIB IS INDICATED IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

I-895 TRAMETINIB IS INDICATED IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

I-896 INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

I-897 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE

I-898 FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS

I-899 TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT

I-900 TREATMENT OF ADULT PATIENTS WITH METASTATIC HORMONESENSITIVE PROSTATE CANCER (MHSPC) IN COMBINATION WITH DOCETAXEL

I-901 EXPANDED INDICATION TO INCLUDE LOWERING OF PLASMA OXALATE LEVELS IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)

I-902 TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS

I-903 REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES

I-904 ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADULTS

I-905 ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT AND NONMALIGNANT PULMONARY LESIONS IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CANCER IN THE LUNG

I-906 TUCATINIB IN COMBINATION WITH TRASTUZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE, UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

I-907 TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE (DEFINED AS A HISTORY OF OSTEOPOROTIC FRACTURE OR MULTIPLE RISK FACTORS FOR FRACTURE), OR PATIENTS WHO HAVE FAILED OR ARE INTOLERANT TO OTHER AVAILABLE

	EXCLUSIVITY INDICATION
	OSTEOPOROSIS THERAPY
I-908	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA WITH A BRAF V600 MUTATION WHO REQUIRE SYSTEMIC THERAPY
I-909	PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS
I-911	FOR FLUORESCENCE IMAGING OF LYMPH NODES AND DELINEATION OF LYMPHATIC VESSELS DURING LYMPHATIC MAPPING IN ADULTS WITH BREAST CANCER FOR WHICH THIS PROCEDURE IS A COMPONENT OF INTRAOPERATIVE MANAGEMENT
I-912	TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
I-913	TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE
I-914	IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR THE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED (BRCAM) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
I-915	TREATMENT OF IRON DEFICIENCY IN ADULT PATIENTS WITH HEART FAILURE AND NEW YORK HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY
I-916	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
I-917	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR UP TO 5 YEARS IN PATIENTS WHO CHOOSE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-918	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
I-919	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-920	USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
I-921	TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE
I-922	USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF SUSTAINED DECLINE IN EGFR, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
I-923	FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
I-924	FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-925	TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE
I-926	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS
I-928	ENCORAFENIB IN COMBINATION WITH BINIMETINIB, IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
I-929	INDICATED TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA IN ADULTS VIA A SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA AND VIA AN ADDUCTOR CANAL BLOCK
I-930	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC) WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
I-931	TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND 1 INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
I-932	IN COMBINATION WITH OXALIPLATIN, FLUOROURACIL AND LEUCOVORIN, FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
I-933	REVISIONS TO THE LABELING TO EXPAND THE USE IN CERTAIN SOFT TISSUE AND CERTAIN ORTHOPEDIC SURGICAL PROCEDURES AS WELL AS REVISING THE LIMITATIONS OF USE

EXCLUSIVITY INDICATION

I-934 TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY

I-935 IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT

I-936 TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

I-937 EXPANSION OF THE INDICATION TO INCLUDE PRE AND PERIMENOPAUSAL WOMEN

I-938 TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS FIVE YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

I-939 INDICATED FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS

I-940 TREATMENT OF CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP) IN ADULTS

I-941 IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

I-942 EXPANSION OF INDICATION TO USE OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FOR THE TREATMENT OF HIV-1 INFECTION IN VIROLOGICALLY SUPPRESSED ADULTS AND PEDIATRIC PATIENTS ON A STABLE HIV-1 TREATMENT REGIMEN WITH NO KNOWN RESISTANCE TO BICTEGRAVIR OR TENOFOVIR

I-943 TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND CORONARY REVASCULARIZATION IN ADULTS WHO ARE UNABLE TO TAKE RECOMMENDED STATIN THERAPY (INCLUDING THOSE NOT TAKING A STATIN) WITH ESTABLISHED CARDIOVASCULAR DISEASE (CVD), OR AT HIGH RISK FOR A CVD EVENT BUT WITHOUT ESTABLISHED CVD

I-944 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET, IN COMBINATION WITH OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE WHEN CONCOMITANT LDL-C LOWERING THERAPY IS NOT POSSIBLE, TO REDUCE LDL-C IN ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

I-945 EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET, ALONE OR IN COMBINATION WITH OTHER LDL-C LOWERING THERAPIES, TO REDUCE LDL-C IN ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

I-946 TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OF MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS

I-947 FOR ADJUVANT TREATMENT IN ADULT PATIENTS FOLLOWING TUMOR RESECTION OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) (TUMORS >/= 4 CM OR NODE POSITIVE), AS DETECTED BY AN FDA-APPROVED TEST

I-948 USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS

I-949 FOR THE REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR)>/= 1.5 G/G

I-950 IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE

I-951 FOR THE ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2(HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE

I-952 TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING CONCURRENT OR SEQUENTIAL PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

I-953 TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC
MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP)

EXCLUSIVITY INDICATION

I-954 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP)

I-955 TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY IN ADULT MALES ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

I-956 TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-957 IN COMBINATION WITH CETUXIMAB AND MFOLFOX6, FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

I-958 TREATMENT OF MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) IN ADULTS WITH OBESITY

I-959 EXPANSION OF THE INDICATION TO INCLUDE MONOTHERAPY OF ESKETAMINE FOR TREATMENT-RESISTANT DEPRESSION (TRD)

I-960 IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA (MCL) WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

I-961 TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

I-962 IN COMBINATION WITH PANITUMUMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED PRIOR FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY

I-963 TREATMENT OF ADULTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G), TO REDUCE PROTEINURIA

I-964 TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY, CARDIOVASCULAR HOSPITALIZATIONS AND URGENT HEART FAILURE VISITS

I-965 TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY, AND ARE CONSIDERED APPROPRIATE TO DELAY TAXANE-BASED CHEMOTHERAPY

I-966 TREATMENT OF ADULTS WITH GIANT CELL ARTERITIS

I-967 TREATMENT OF ACUTE HEPATITIS C VIRUS (HCV) INFECTION IN ADULTS AND PEDIATRIC PATIENTS AGES 3 TO LESS THAN 18 YEARS OF AGE

I-968 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)

I-969 TREATMENT OF PLAQUE PSORIASIS OF THE SCALP AND BODY IN PATIENTS 12 YEARS OF AGE AND OLDER

I-970 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE VISITS IN ADULT PATIENTS WITH HEART FAILURE WITH LEFT VENTRICULAR EJECTION FRACTION (LVEF) >= 40%

I-971 DAROLUTAMIDE AS A SINGLE AGENT FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

I-972 TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) TO REDUCE PROTEINURIA

I-973 TREATMENT OF NONCIRRHOTIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), FORMERLY KNOWN AS NONALCOHOLIC STEATOHEPATITIS (NASH), WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) IN ADULTS

I-974 TREATMENT OF THROMBOCYTOPENIA IN PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA, WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

I-975 FOR ORAL ADMINISTRATION TO DELINEATE THE GASTROINTESTINAL TRACT ON COMPUTED

EXCLUSIVITY INDICATION

	TOMOGRAPHY OF THE ABDOMEN AND PELVIS IN ADULT AND PEDIATRIC PATIENTS
I-976	TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE AT HIGH RISK FOR THESE EVENTS
I-977	LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS, CARBOPLATIN, AND ETOPOSIDE
I-978	TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA CAUSED BY SUSCEPTIBLE STRAINS OF NEISSERIA GONORRHOEAE IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 45 KILOGRAMS WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT

EXCLUSIVITY MISCELLANEOUS

M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
M-46	PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
M-47	PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
M-48	CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
M-49	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
M-50	NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD)

EXCLUSIVITY MISCELLANEOUS

	SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
M-51	INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
M-52	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
M-53	FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
M-54	INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
M-55	INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
M-56	INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
M-57	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
M-58	CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
M-59	RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
M-60	CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
M-61	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA

EXCLUSIVITY MISCELLANEOUS

M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL

EXCLUSIVITY MISCELLANEOUS

M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED

EXCLUSIVITY MISCELLANEOUS

NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING

M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS

M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES

M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM

M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD

M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE

M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE

M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION

M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN

M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.

M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT

M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.

M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND

EXCLUSIVITY MISCELLANEOUS

SULFONYLUREA

M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS

M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT

M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN

M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE

M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)

M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"

M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"

M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL

M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

EXCLUSIVITY MISCELLANEOUS

M-179	UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
M-180	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
M-181	UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
M-182	UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
M-183	CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
M-184	UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
M-185	UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
M-186	UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
M-187	ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
M-188	PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
M-189	LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
M-190	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
M-191	ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
M-192	PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
M-193	INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
M-194	INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE
M-195	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17
M-196	REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
M-197	NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
M-198	PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
M-199	INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
M-200	CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
M-201	REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS

EXCLUSIVITY MISCELLANEOUS

INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.

M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.

M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569

M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT

M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY

M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY

M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY

M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE

M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE

M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

M-214 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS

M-215 INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED

M-216 UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER

M-217 INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)

M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY

M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY

M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING

M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)

EXCLUSIVITY MISCELLANEOUS

M-224	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN
M-225	REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES >=6 YEARS TO <18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION
M-226	CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
M-227	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
M-228	INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
M-229	REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
M-230	REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596
M-231	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCICLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3
M-232	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
M-233	INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS
M-234	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
M-235	INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1
M-236	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
M-237	INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS
M-238	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
M-239	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
M-240	INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
M-241	INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD
M-242	INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES
M-243	INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
M-244	INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
M-245	ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA

EXCLUSIVITY MISCELLANEOUS

	FROM THE IMPACT TRIAL
M-246	ADDITION OF STUDY BRF117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN
M-247	REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART
M-248	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
M-249	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4
M-250	REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1
M-251	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
M-252	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
M-253	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
M-254	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
M-255	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4018 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE
M-256	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
M-257	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
M-258	INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
M-259	INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
M-260	INFORMATION ADDED TO THE LABELING DESCRIBING A RANDOMIZED, OPEN-LABEL STUDY THAT EXAMINED THE CONCOMITANT USE OF DIMETHYL FUMARATE AND SEVERAL NON-LIVE VACCINES IN ADULTS 27-55 YEARS OF AGE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
M-261	ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS
M-262	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4
M-263	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
M-264	INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT
M-265	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
M-266	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE
M-267	INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
M-268	ADDITION OF INFORMATION TO THE LABEL REGARDING A CLEAR PRODUCT PRESENTATION AND 26 ML VOLUME PRODUCTS
M-269	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
M-270	INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION
M-271	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY HRA2914-5016

EXCLUSIVITY MISCELLANEOUS

M-272	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
M-273	REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M
M-274	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130
M-275	REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
M-276	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-277	UPDATES THE US PRESCRIBING INFORMATION WITH CLINICAL DATA REGARDING THE USE OF SOFOSBUVIR AND VELPATASVIR FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION IN PEOPLE WHO INJECT DRUGS (PWID), INCLUDING THOSE ON MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER
M-278	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY GO29665
M-279	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF FIGARO-DKD STUDY
M-280	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-281	REVISIONS TO THE LABELING TO PROVIDE FOR THE EXPANSION OF THE USE OF STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS TAKING CLOBAZAM TO INCLUDE PEDIATRIC PATIENTS WHO ARE 6 MONTHS TO LESS THAN 2 YEARS OF AGE AND WEIGHING 7 KG OR MORE
M-282	REVISIONS TO THE LABELING TO ADD THE RESULTS OF A CLINICAL STUDY (TA-303) IN PATIENTS WITH ED FOLLOWING BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY
M-283	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HESTIA3
M-284	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM GALILEO TRIAL
M-285	REVISIONS TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULTS OF STUDY INCB 18424-269
M-286	INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM STUDY ORGN001-102
M-287	LABELING REGARDING NEW DOSING REGIMEN IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND TREATMENT OF PAH IN PEDIATRIC PATIENTS (AGES 1-17)
M-288	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF STUDY APL2-308
M-289	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035
M-290	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HZA114971
M-291	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P145
M-292	REVISIONS TO THE LABELING TO DESCRIBE MODIFIED FORMULATION BASED ON RESULTS OF STUDIES EM-05-014624 AND EM-05-014815
M-293	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E2006-A001-113
M-294	INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY 205860
M-295	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-296	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
M-297	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
M-298	LABELING REVISIONS RELATED TO STUDY D1699CC00001
M-299	CLINICAL STUDY INFORMATION ADDED TO THE LABEL ABOUT THE TREATMENT OF MODERATE TO SEVERE GENITAL PSORIASIS
M-300	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
M-301	CLINICAL STUDY INFORMATION ADDED TO LABEL ABOUT THE TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH SEVERELY REDUCED RENAL FUNCTION (ESTIMATED GLOMERULAR FILTRATION RATE, EGFR < 30 ML/MIN)

EXCLUSIVITY MISCELLANEOUS

M-302	INFORMATION ADDED TO LABELING REGARDING OSTEOSARCOMA
M-303	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
M-304	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM STUDY LVM-MD-11 AND LVM-MD-14
M-305	REVISIONS TO THE LABELING TO INCLUDE INFORMATION FOR PREGNANT INDIVIDUALS
M-306	REVISIONS TO THE LABELING TO REFLECT THE RESULTS OF A CLINICAL STUDY TO FULFILL POST MARKETING REQUIREMENT 1988-001
M-307	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION TO INCLUDE RESULTS FROM A DRUG INTERACTION STUDY WITH GASTRIC ACID REDUCING AGENTS
M-308	INFORMATION ADDED TO THE LABELING TO DESCRIBE A CLINICAL STUDY
M-309	INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS FROM A STUDY TO FULFILL POST MARKETING REQUIREMENT 3809-5
M-310	REVISIONS TO THE CLINICAL STUDIES SECTION TO REFLECT THE RESULTS OF A CLINICAL STUDY TO FULFILL POST-MARKETING REQUIREMENT 4150-1
M-311	REVISIONS TO THE LABELING TO REFLECT THE RESULTS OF STUDY LIBRETTO-431
M-312	REVISIONS TO THE LABELING TO REFLECT THE RESULTS OF STUDY LIBRETTO-531
M-313	LABELING CHANGES BASED UPON RESULTS FROM STUDY 124 (TRIAL 5)
M-314	UPDATES TO THE PRESCRIBING INFORMATION BASED ON RESULTS OF CLINICAL STUDIES
M-315	INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY 6 (NCT03198078), TO FULFILL POSTMARKETING REQUIREMENT 4205-1
M-316	LABELING CHANGES TO INCLUDE THE RESULTS OF STUDY GS-US-216-0128 IN CERTAIN PEDIATRIC PATIENTS
M-317	LABELING REVISIONS TO REFLECT THE RESULTS OF BATURA STUDY
M-318	MODIFICATIONS TO LABELING TO INCLUDE UPDATED RECOMMENDATIONS FOR CYP3A4 INDUCERS AND SUBSTRATES OF BCRP AND UPDATED DATA FOR STRONG CYP3A4 INDUCERS AND OATP1B SUBSTRATES

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
ODE-9	TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-10	FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
ODE-11	TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-12	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-13	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS

ORPHAN DRUG EXCLUSIVITY

	DETECTED BY AN FDA-APPROVED TEST
ODE-14	TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
ODE-15	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
ODE-16	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
ODE-17	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
ODE-19	TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
ODE-20	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE
ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
ODE-31	TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
ODE-32	TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
ODE-33	TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
ODE-34	TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-35	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
ODE-36	ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ODE-37	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-38	PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-39	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.

ORPHAN DRUG EXCLUSIVITY

ODE-40	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
ODE-41	ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
ODE-42	USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-43	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ODE-44	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
ODE-45	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER
ODE-46	IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
ODE-47	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
ODE-48	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
ODE-49	TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
ODE-50	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
ODE-51	TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
ODE-52	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE
ODE-53	TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT)
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY

ORPHAN DRUG EXCLUSIVITY

ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)

ORPHAN DRUG EXCLUSIVITY

ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE
ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).

ORPHAN DRUG EXCLUSIVITY

ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS

ORPHAN DRUG EXCLUSIVITY

ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE

ORPHAN DRUG EXCLUSIVITY

ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

ORPHAN DRUG EXCLUSIVITY

ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

ORPHAN DRUG EXCLUSIVITY

ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-213	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-214	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
ODE-215	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
ODE-216	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-217	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DIESASE
ODE-218	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-219	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-220	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
ODE-221	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
ODE-222	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-223	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
ODE-224	INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-225	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
ODE-226	MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-227	INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE

ORPHAN DRUG EXCLUSIVITY

	BEEN PREVIOUSLY TREATED WITH SORAFENIB
ODE-228	INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
ODE-229	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
ODE-230	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-231	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-232	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
ODE-233	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-234	INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
ODE-235	INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
ODE-236	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-237	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-238	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-239	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-240	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-241	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
ODE-242	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-243	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
ODE-244	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
ODE-245	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
ODE-246	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-247	TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
ODE-248	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
ODE-249	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR

ORPHAN DRUG EXCLUSIVITY

ODE-250	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
ODE-251	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
ODE-252	TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
ODE-253	INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
ODE-254	INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
ODE-255	INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
ODE-256	FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
ODE-257	IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
ODE-258	FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-259	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
ODE-260	INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
ODE-261	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
ODE-262	TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-263	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-264	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-265	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
ODE-266	ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
ODE-267	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
ODE-268	INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-269	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS

ORPHAN DRUG EXCLUSIVITY

ODE-270	INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
ODE-271	INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
ODE-272	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
ODE-273	INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
ODE-274	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-275	INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
ODE-276	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-277	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
ODE-278	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY
ODE-279	INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT’S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
ODE-280	INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
ODE-281	INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-282	INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
ODE-283	MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON >=16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
ODE-284	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
ODE-285	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN 35KG
ODE-286	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING’S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-287	TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
ODE-288	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
ODE-289	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
ODE-290	INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
ODE-291	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
ODE-292	INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST

ORPHAN DRUG EXCLUSIVITY

ODE-293	TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-294	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-295	INDICATED FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-296	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
ODE-297	FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
ODE-298	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
ODE-299	INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
ODE-300	FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-301	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
ODE-302	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-303	ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-304	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-305	TREATMENT OF INVASIVE ASPERGILLOSIS
ODE-306	W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
ODE-307	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-308	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE CAPACITY
ODE-309	INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTATIC SETTING
ODE-310	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
ODE-311	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
ODE-312	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-313	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY

ORPHAN DRUG EXCLUSIVITY

ODE-314 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

ODE-315 FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

ODE-316 TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.

ODE-317 FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS

ODE-318 TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST

ODE-319 INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI

ODE-320 INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY

ODE-321 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS TO LESS THAN 6 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

ODE-322 TREATMENT OF NARCOLEPSY

ODE-323 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA

ODE-324 TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES

ODE-325 TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING ALTERATIONS

ODE-326 TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE

ODE-327 ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST

ODE-328 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE

ODE-329 FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE

ODE-330 THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER

ODE-331 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY

ODE-332 TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

ODE-333 PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

ODE-334 TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER

ODE-335 FOR TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AT LEAST ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020

ODE-336 INDICATED FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS

ORPHAN DRUG EXCLUSIVITY

	OF AGE AND OLDER WITH OBESITY DUE TO PROOPIOMELANOCORTIN (POMC), PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 1 (PCSK1), OR LEPTIN RECEPTOR (LEPR) DEFICIENCY CONFIRMED BY GENETIC TESTING DEMONSTRATING VARIANTS IN POMC, PCSK1, OR LEPR GENES THAT ARE INTERPRETED AS PATHOGENIC, LIKELY PATHOGENIC, OR OF UNCERTAIN SIGNIFICANCE (VUS)
ODE-337	FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-338	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020
ODE-339	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
ODE-340	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-341	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-342	INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
ODE-343	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
ODE-344	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
ODE-345	IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA)
ODE-346	FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIO'S PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019
ODE-347	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
ODE-348	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE IS REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONAL ANTIBODY
ODE-349	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST, EXCLUDING PATIENTS WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB OR CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-350	TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
ODE-351	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-352	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
ODE-353	FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-354	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES
ODE-355	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

ORPHAN DRUG EXCLUSIVITY

ODE-356	FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
ODE-357	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-358	FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
ODE-359	FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG
ODE-360	FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
ODE-361	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-362	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
ODE-363	TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
ODE-364	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
ODE-366	INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS
ODE-367	PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)
ODE-368	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-369	THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
ODE-370	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
ODE-371	TREATMENT OF ADULT PATIENTS WITH WALDENSTRM'S MACROGLOBULINEMIA (WM)
ODE-372	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-373	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-374	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-375	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
ODE-376	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-377	AS AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE ANTI-NEUTROPHIL

ORPHAN DRUG EXCLUSIVITY

	CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS (GRANULOMATOSIS WITH POLYANGIITIS [GPA] AND MICROSCOPIC POLYANGIITIS [MPA])
ODE-378	A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY
ODE-379	FOR TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS) 1 YEAR OF AGE AND OLDER
ODE-380	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
ODE-381	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP) WITH THE T315I MUTATION
ODE-382	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
ODE-383	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR THE LOCALIZATION OF KNOWN SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS
ODE-384	TO REDUCE THE RISK OF OTOTOXICITY ASSOCIATED WITH CISPLATIN IN PEDIATRIC PATIENTS 1 MONTH OF AGE AND OLDER WITH LOCALIZED, NON-METASTATIC SOLID TUMORS
ODE-385	FOR TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-386	FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
ODE-387	TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
ODE-388	FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET
ODE-389	TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G
ODE-390	AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS IN ADULT PATIENTS WITH OVARIAN CANCER
ODE-391	TREATMENT OF FACIAL ANGIOFIBROMA ASSOCIATED WITH TUBEROUS SCLEROSIS IN ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
ODE-392	TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
ODE-393	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-394	FOR TREATMENT OF SICKLE CELL DISEASE (SCD) IN PEDIATRIC PATIENTS 4 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE
ODE-395	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-396	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY
ODE-397	TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L
ODE-398	TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
ODE-399	TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

ORPHAN DRUG EXCLUSIVITY

ODE-400	TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PEDIATRIC PATIENTS BETWEEN BIRTH AND 2 MONTHS OF AGE
ODE-401	TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
ODE-402	FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH MONOGENIC OR SYNDROMIC OBESITY DUE TO BARDET-BIEDL SYNDROME (BBS)
ODE-403	TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS TAKING CLOBAZAM WHO ARE 6 MONTHS TO LESS THAN 2 YEARS OF AGE AND WEIGHING 7 KG OR MORE
ODE-404	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
ODE-405	TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
ODE-406	TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION
ODE-407	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE
ODE-408	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 1 YEAR TO LESS THAN 2 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-409	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-410	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS
ODE-411	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
ODE-412	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-413	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-414	TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS
ODE-415	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER PLASMA OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
ODE-416	TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
ODE-417	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
ODE-418	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
ODE-419	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
ODE-420	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
ODE-421	TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
ODE-422	TREATMENT OF ADULT PATIENTS WITH RAS WILD-TYPE, HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
ODE-423	FOR PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
ODE-424	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR
ODE-425	TREATMENT OF RETT SYNDROME IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
ODE-426	FOR USE IN PATIENTS 18 YEARS OF AGE OR OLDER WHO HAVE LIMITED OR NO ALTERNATIVE

ORPHAN DRUG EXCLUSIVITY

	OPTIONS FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS
ODE-427	TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER
ODE-428	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
ODE-429	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 1 YEAR OF AGE WITH ALAGILLE SYNDROME (ALGS)
ODE-430	TREATMENT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) SYNDROME (APDS) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-431	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULTS WITH NARCOLEPSY
ODE-432	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
ODE-433	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-434	TREATMENT OF ADULT PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
ODE-435	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS 1 MONTH TO LESS THAN 4 MONTHS OF AGE WHO HAVE AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-436	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
ODE-437	FOR USE IN COMBINATION WITH STANDARD INDUCTION AND CONSOLIDATION, AND AS MAINTENANCE THERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 INTERNAL TANDEM DUPLICATION (ITD)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-438	AS A LIVER-DIRECTED TREATMENT FOR ADULT PATIENTS WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES AFFECTING LESS THAN 50% OF THE LIVER AND NO EXTRAHEPATIC DISEASE OR EXTRAHEPATIC DISEASE LIMITED TO THE BONE, LYMPH NODES, SUBCUTANEOUS TISSUES, OR LUNG THAT IS AMENABLE TO RESECTION OR RADIATION
ODE-439	FOR THE REDUCTION IN VOLUME OF NEW HETEROTOPIC OSSIFICATION IN ADULTS AND PEDIATRIC PATIENTS AGED 8 YEARS AND OLDER FOR FEMALES AND 10 YEARS AND OLDER FOR MALES WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
ODE-440	FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-441	TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF OR SECONDARY MF [POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL THROMBOCYTHEMIA (ET)], IN ADULTS WITH ANEMIA
ODE-442	TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-443	TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2
ODE-444	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
ODE-445	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-446	TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN ADULT PATIENTS WHO ARE ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE
ODE-447	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES (MDS) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-448	TREATMENT OF PEDIATRIC PATIENTS OLDER THAN 1 MONTH UP TO 12 YEARS OF AGE WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY

ORPHAN DRUG EXCLUSIVITY

ODE-449	TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
ODE-450	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-451	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR
ODE-452	FOR ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS WHO REQUIRE SYSTEMIC TREATMENT
ODE-453	TREATMENT OF INVASIVE MUCORMYCOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
ODE-454	TREATMENT OF INVASIVE MUCORMYCOSIS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WHO WEIGH 16 KG AND GREATER
ODE-455	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH ADENOCARCINOMA HISTOLOGY
ODE-456	TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-457	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 14 KG TO LESS THAN 25 KG
ODE-458	TREATMENT OF INVASIVE ASPERGILLOSIS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WHO WEIGH 16 KILOGRAMS (KG) AND GREATER
ODE-459	TREATMENT OF INVASIVE ASPERGILLOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
ODE-460	TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
ODE-461	TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-462	TO REDUCE THE RISK OF RELAPSE IN ADULT AND PEDIATRIC PATIENTS WITH HIGH-RISK NEUROBLASTOMA (HRNB) WHO HAVE DEMONSTRATED AT LEAST A PARTIAL RESPONSE TO PRIOR MULTIAGENT, MULTIMODALITY THERAPY INCLUDING ANTI-GD2 IMMUNOTHERAPY
ODE-463	FOR FIRST-LINE TREATMENT OF ADULT PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
ODE-464	TO REDUCE THE LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE PROVIDED FOR IN THE INDICATION APPROVED ON DECEMBER 15, 2021
ODE-465	TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS
ODE-466	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 11 YEARS OF AGE AND OLDER WITH EOSINOPHILIC ESOPHAGITIS (EOE)
ODE-467	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY
ODE-468	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 14 KG TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO KNOWN OR SUSPECTED SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO BICTEGRAVIR OR TENOFOVIR AND WITH KNOWN OR SUSPECTED SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO EMTRICITABINE
ODE-469	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP I) IN PEDIATRIC PATIENTS 1 TO 17 YEARS OLD TO IMPROVE EXERCISE ABILITY AND, IN PEDIATRIC PATIENTS TOO YOUNG TO PERFORM STANDARDIZED EXERCISE TESTING, PULMONARY HEMODYNAMICS THOUGHT TO UNDERLY IMPROVEMENTS IN EXERCISE
ODE-470	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS AGED 6 MONTHS OF AGE TO LESS THAN 2 YEARS, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISES
ODE-471	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 5 YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
ODE-472	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
ODE-473	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS 6 YEARS OF AGE AND OLDER
ODE-474	LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND

ORPHAN DRUG EXCLUSIVITY

	TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
ODE-475	CHRONIC TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I AND WHO FUNCTIONAL CLASS (FC) II-III)
ODE-476	TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-477	ADJUVANT TREATMENT IN ADULT PATIENTS FOLLOWING TUMOR RESECTION OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) (TUMORS GREATER THAN OR EQUAL TO 4 CM OR NODE POSITIVE), AS DETECTED BY AN FDA-APPROVED TEST
ODE-478	TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION
ODE-479	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS), INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS
ODE-480	TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS)
ODE-481	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
ODE-482	TREATMENT OF ADULT PATIENTS WITH LOW - TO INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA REQUIRING 4 OR MORE RED BLOOD CELL UNITS OVER 8 WEEKS WHO HAVE NOT RESPONDED TO OR HAVE LOST RESPONSE TO OR ARE INELIGIBLE FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESA)
ODE-483	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION, ARE LOCALLY ADVANCED OR METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
ODE-484	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
ODE-485	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-486	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA), OR IN PATIENTS UNABLE TO TOLERATE UDCA
ODE-487	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-488	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION
ODE-489	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-490	TREATMENT OF CHOLESTATIC PRURITAS IN PATIENTS 12 MONTHS OF AGE TO LESS THAN 5 YEARS OF AGE WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
ODE-491	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) OR ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION FOLLOWING SURGERY INCLUDING BIOPSY, SUB-TOTAL RESECTION, OR GROSS TOTAL RESECTION
ODE-492	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
ODE-493	TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE

ORPHAN DRUG EXCLUSIVITY

	PROVIDED FOR IN THE INDICATION APPROVED ON FEBRUARY 17, 2023
ODE-494	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-495	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 40 KG WHO ARE KIDNEY TRANSPLANT RECIPIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE [D+/R-])
ODE-496	TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
ODE-497	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER AND WEIGHING AT LEAST 6 KG WHO ARE CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-498	TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC) IN ADULTS AND PEDIATRIC PATIENTS WEIGHING GREATER THAN OR EQUAL TO 15 KG
ODE-499	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), EXCLUDING PATIENTS WITH THE T315I MUTATION
ODE-500	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), EXCLUDING PATIENTS PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS), AND EXCLUDING PATIENTS WITH THE T315I MUTATION
ODE-501	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 2 TO 5 YEARS OF AGE
ODE-502	TREATMENT OF RELAPSED OR REFRACTORY MIXED-PHENOTYPE ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER.
ODE-503	ADJUNCTIVE TREATMENT TO GLUCOCORTICOID REPLACEMENT TO CONTROL ANDROGENS IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)
ODE-504	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
ODE-505	TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOCYTIC LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
ODE-506	TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR DEATH AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-507	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER (MCRC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED PRIOR FLUOROPYRIMIDINE-, OXALIPLATIN-AND IRINOTECAN-BASED CHEMOTHERAPY
ODE-508	TO REDUCE EXCESS BODY WEIGHT AND MAINTAIN WEIGHT REDUCTION LONG TERM IN PEDIATRIC PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WITH SYNDROMIC OR MONOGENIC OBESITY DUE TO BARDET-BIEDL SYNDROME (BBS)
ODE-509	TO REDUCE EXCESS BODY WEIGHT AND MAINTAIN WEIGHT REDUCTION LONG TERM IN PEDIATRIC PATIENTS AGED 2 YEARS TO LESS THAN 6 YEARS WITH SYNDROMIC OR MONOGENIC OBESITY DUE TO PRO-OPIOMELANOCORTIN (POMC), PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 1 (PCSK1), OR LEPTIN RECEPTOR (LEPR) DEFICIENCY AS DETERMINED BY AN FDA-APPROVED TEST DEMONSTRATING VARIANTS IN POMC, PCSK1, OR LEPR GENES THAT ARE INTERPRETED AS PATHOGENIC, LIKELY PATHOGENIC, OR OF UNCERTAIN SIGNIFICANCE (VUS)
ODE-510	ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA B WITH OR WITHOUT FACTOR IX INHIBITORS
ODE-511	ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS

ORPHAN DRUG EXCLUSIVITY

ODE-512	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 2 YEARS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON CLINICAL AND/OR IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 20,2024
ODE-513	AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH ACUTE MYELOID LEUKEMIA (AML)
ODE-514	AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH MYELODYSPLASTIC SYNDROME (MDS)
ODE-515	ADJUNCT TO DIET TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY

PATENT USE

U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE

PATENT USE

U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY

PATENT USE

U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED

PATENT USE

	RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

PATENT USE

U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL

PATENT USE

U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES

PATENT USE

U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS

PATENT USE

U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

PATENT USE

U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF

PATENT USE

	ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF

PATENT USE

	INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS

PATENT USE

U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN

PATENT USE

U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY

PATENT USE

	WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS

PATENT USE

U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

PATENT USE

U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928

PATENT USE

U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.

PATENT USE

U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

PATENT USE

U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

PATENT USE

U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE

PATENT USE

U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATMENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

PATENT USE

U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

PATENT USE

U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION

PATENT USE

U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

PATENT USE

U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF

PATENT USE

	EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

PATENT USE

U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN
U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

PATENT USE

U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

PATENT USE

U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS
U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

PATENT USE

U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE

PATENT USE

	ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

PATENT USE

U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

PATENT USE

U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF

PATENT USE

	HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1144	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1145	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146	REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1148	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1149	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1150	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
U-1151	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
U-1152	CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
U-1153	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
U-1154	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
U-1155	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
U-1156	TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
U-1157	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1158	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1159	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-1160	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER

PATENT USE

U-1161	FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
U-1162	TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
U-1163	METHOD OF TREATING THROMBOSIS
U-1164	METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
U-1165	USE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1166	A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
U-1167	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
U-1168	THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-1169	MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA(INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A

PATENT USE

	SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

PATENT USE

U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN

PATENT USE

U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE

PATENT USE

	HYPERTRIGLYCERIDEMIA
U-1288	TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

PATENT USE

U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT

PATENT USE

U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE

PATENT USE

	VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR

PATENT USE

	EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER

PATENT USE

U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

PATENT USE

U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

PATENT USE

U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511	TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513	TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516	METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
U-1517	TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
U-1518	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
U-1521	MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523	METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526	THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527	FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528	A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531	METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.

PATENT USE

U-1533	PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536	ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537	TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538	ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539	PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540	BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541	TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543	TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)

PATENT USE

U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS

PATENT USE

U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

PATENT USE

U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME
U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

PATENT USE

U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN
U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS
U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA
U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

PATENT USE

U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA
U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS

PATENT USE

U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

PATENT USE

U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE

PATENT USE

	ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER

PATENT USE

	ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF

PATENT USE

U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE

PATENT USE

U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A

PATENT USE

	G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE

PATENT USE

	CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1950	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-1951	TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS

PATENT USE

U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST
U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)

PATENT USE

U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING

PATENT USE

U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH

PATENT USE

	PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2058	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
U-2059	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
U-2060	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
U-2061	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2062	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
U-2063	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2064	DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION

PATENT USE

U-2065	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2066	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
U-2067	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2068	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
U-2069	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2070	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
U-2071	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2072	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2073	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
U-2074	DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2075	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
U-2076	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
U-2077	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
U-2078	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2079	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2080	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2081	DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
U-2082	MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2083	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
U-2084	TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE

PATENT USE

U-2085	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
U-2086	A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
U-2087	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
U-2088	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
U-2089	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
U-2090	FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2091	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-2092	METHOD FOR CONFIRMING DOSE DELIVERY
U-2093	TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
U-2094	TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
U-2095	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
U-2096	SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
U-2097	TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2098	INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2099	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
U-2100	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
U-2101	MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2102	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
U-2103	MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2104	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
U-2105	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2106	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2107	TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
U-2108	TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
U-2109	CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
U-2110	METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT

PATENT USE

	WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
U-2111	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
U-2112	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
U-2113	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
U-2114	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
U-2115	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10
U-2116	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
U-2117	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
U-2118	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
U-2119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
U-2120	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION

PATENT USE

U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE
U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION

PATENT USE

U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION
U-2179	IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION
U-2180	TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
U-2181	TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE
U-2182	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2183	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
U-2184	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
U-2185	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
U-2186	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
U-2187	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
U-2188	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

PATENT USE

U-2189	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
U-2190	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
U-2191	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
U-2192	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
U-2193	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
U-2194	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
U-2195	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87
U-2196	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88
U-2197	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99
U-2198	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100
U-2199	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA
U-2200	COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2201	TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER
U-2202	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2203	A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
U-2204	TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-2205	TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
U-2206	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
U-2207	TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2208	TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
U-2209	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2210	TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
U-2211	TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
U-2212	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2213	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2214	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

PATENT USE

U-2215	ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2216	ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2217	TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2218	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2219	TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
U-2220	A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
U-2221	TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2222	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
U-2223	METHOD OF TREATING ANGINA PECTORIS
U-2224	TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION

PATENT USE

U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND

PATENT USE

	PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2270	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2271	THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
U-2272	TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
U-2273	A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2274	MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
U-2275	TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2276	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2277	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
U-2278	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN
U-2279	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
U-2280	ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
U-2281	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2282	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
U-2283	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
U-2284	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
U-2285	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
U-2286	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14

PATENT USE

U-2287	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
U-2288	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
U-2289	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
U-2290	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2291	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
U-2292	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2293	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY
U-2294	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2295	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2296	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2297	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
U-2298	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2299	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION
U-2300	USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2301	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
U-2302	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2303	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2304	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
U-2305	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2306	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-2307	TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
U-2308	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

PATENT USE

U-2309	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
U-2310	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
U-2311	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
U-2312	TREATMENT OF HYPERKALEMIA IN ADULTS
U-2313	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
U-2314	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
U-2315	TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
U-2316	TREATMENT OF DYSPAREUNIA
U-2317	TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
U-2318	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED

PATENT USE

	WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2342	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2343	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2344	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
U-2345	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
U-2346	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
U-2347	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
U-2348	A METHOD FOR PREVENTION OF PREGNANCY
U-2349	FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
U-2350	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
U-2351	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
U-2352	TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2353	TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2354	COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
U-2355	IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
U-2356	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2357	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-2358	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2359	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2360	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
U-2361	METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS

PATENT USE

U-2362	TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2363	ADMINISTRATION OF RISPERIDONE
U-2364	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2365	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2366	TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
U-2367	USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
U-2368	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-2369	FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
U-2370	FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS
U-2371	THE TREATMENT OF FABRY PATIENTS
U-2372	A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2373	A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2374	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-2375	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-2376	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2377	USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY
U-2378	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
U-2379	USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
U-2380	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-2381	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2382	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2383	METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
U-2384	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-2385	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
U-2386	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
U-2387	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
U-2388	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28

PATENT USE

U-2389	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
U-2390	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
U-2391	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
U-2392	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
U-2393	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
U-2394	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2395	FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2396	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-2397	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-2398	TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-2399	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546
U-2400	REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2401	A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
U-2402	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
U-2403	TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
U-2404	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
U-2405	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2406	A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2407	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2408	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2409	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
U-2410	TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
U-2411	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND

PATENT USE

	IVACAFTOR
U-2412	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
U-2413	FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
U-2414	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

PATENT USE

U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS
U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY

PATENT USE

U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS
U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT
U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
U-2480	MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
U-2481	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
U-2482	TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2483	TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2484	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
U-2485	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
U-2486	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
U-2487	DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
U-2488	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
U-2489	TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
U-2490	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
U-2491	A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
U-2492	A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
U-2493	A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
U-2494	INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING

PATENT USE

U-2495 VENTRICULAR FIBRILLATION

U-2496 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE

U-2497 TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS

U-2498 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877

U-2499 METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM

U-2500 USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE

U-2501 TREATMENT OF PARTIAL-ONSET SEIZURES

U-2502 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT

U-2503 TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

U-2504 TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY

U-2505 TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER

U-2506 METHOD OF TREATING TESTOSTERONE DEFICIENCY

U-2507 METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA

U-2508 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

U-2509 A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

U-2510 A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE

U-2511 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE

U-2512 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR

U-2513 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2514 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2515 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY

U-2516 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-2517 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-2518 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR

PATENT USE

	FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-2519	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2520	TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2521	TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
U-2522	TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2523	TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA
U-2524	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
U-2525	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
U-2526	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2527	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2528	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2529	TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2530	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2531	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2532	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-2533	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
U-2534	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
U-2535	USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
U-2536	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
U-2537	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
U-2538	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
U-2539	IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER

PATENT USE

U-2540	TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
U-2541	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2542	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2543	TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
U-2544	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-2545	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
U-2546	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2547	METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE
U-2548	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
U-2549	CONTROL OF SERUM PHOSPHORUS LEVELS
U-2550	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2551	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2552	METHOD OF TREATING POSTPARTUM DEPRESSION
U-2553	PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
U-2554	TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON
U-2555	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-2556	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2557	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-2558	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
U-2559	USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
U-2560	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
U-2561	USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
U-2562	TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
U-2563	TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
U-2564	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
U-2565	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
U-2566	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
U-2567	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH

PATENT USE

	ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
U-2568	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-2569	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2570	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2571	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2572	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
U-2573	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2574	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2575	TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2576	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
U-2577	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2578	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
U-2579	REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
U-2580	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
U-2581	TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2582	FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
U-2583	TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
U-2584	XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
U-2585	TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
U-2586	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
U-2587	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
U-2588	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
U-2589	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN

PATENT USE

U-2590	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
U-2591	LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2592	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2593	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2594	REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2595	REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2596	REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2597	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
U-2598	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2599	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
U-2600	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2601	STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2602	DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2603	METHOD OF TREATING IRON DEFICIENCY
U-2604	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
U-2605	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
U-2606	TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
U-2607	TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
U-2608	METHOD OF TREATING SCHIZOPHRENIA
U-2609	A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL
U-2610	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2611	TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2612	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER

PATENT USE

U-2613	TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)
U-2614	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
U-2615	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-2616	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
U-2617	TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
U-2618	TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2619	TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2620	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
U-2621	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
U-2622	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER
U-2623	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
U-2624	TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
U-2625	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
U-2626	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR
U-2627	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
U-2628	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
U-2629	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO
U-2630	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
U-2631	TREATMENT OF COMPLICATED URINARY TRACT INFECTION
U-2632	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2633	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
U-2634	METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
U-2635	TREATMENT OF ACUTE URTICARIA
U-2636	METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
U-2637	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
U-2638	INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
U-2639	METHOD OF ACTIVATING RARGAMMA RECEPTOR
U-2640	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
U-2641	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS

PATENT USE

U-2642	METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
U-2643	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
U-2644	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
U-2645	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2646	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2647	TREATMENT OF NON-NODULAR ACNE VULGARIS
U-2648	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2649	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-2650	TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2651	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2652	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-2653	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2654	TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2655	A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
U-2656	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
U-2657	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-2658	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
U-2659	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
U-2660	TREATMENT OF H. PYLORI INFECTION IN ADULTS
U-2661	CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
U-2662	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
U-2663	USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
U-2664	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
U-2665	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2666	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-2667	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
U-2668	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB

PATENT USE

U-2669	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2670	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
U-2671	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2672	TREATMENT OF ACUTE HEPATIC PORPHYRIA
U-2673	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
U-2674	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
U-2675	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-2676	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1
U-2677	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
U-2678	PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
U-2679	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
U-2680	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
U-2681	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
U-2682	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2683	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2684	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2685	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2686	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2687	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2688	USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2689	USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY
U-2690	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2691	USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2692	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2693	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY

PATENT USE

U-2694	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2695	USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2696	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2697	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2698	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2699	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2700	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
U-2701	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2702	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2703	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS
U-2704	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
U-2705	METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
U-2706	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
U-2707	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
U-2708	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U-2709	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2710	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2711	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2712	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2713	MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA
U-2714	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
U-2715	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2

PATENT USE

U-2716	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
U-2717	ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
U-2718	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
U-2719	TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT
U-2720	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-2721	TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT
U-2722	METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF
U-2723	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
U-2724	A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2725	A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2726	TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
U-2727	NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2728	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
U-2729	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
U-2730	METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2731	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
U-2732	METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
U-2733	METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2734	METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
U-2735	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
U-2736	METHOD OF TREATING EPITHELIOID SARCOMA
U-2737	METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
U-2738	METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
U-2739	INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
U-2740	INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2741	TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
U-2742	TREATMENT OF SEVERE HYPOGLYCEMIA
U-2743	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE

PATENT USE

U-2744	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2745	TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2746	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2747	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2748	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2749	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2750	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
U-2751	A TRANSDERMAL METHOD OF CONTRACEPTION
U-2752	METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
U-2753	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-ANTAGONIST
U-2754	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-2755	OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC
U-2756	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2757	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2758	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2759	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
U-2760	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER
U-2761	INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
U-2762	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE
U-2763	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
U-2764	TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
U-2765	TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2766	TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
U-2767	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST

PATENT USE

	40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
U-2768	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
U-2769	DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.
U-2770	CUSHING'S DISEASE
U-2771	TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-2772	MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)
U-2774	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-2775	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2776	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2777	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2778	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2779	TREATMENT OF SPASTICITY
U-2780	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2781	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2782	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2783	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
U-2784	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2785	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2786	METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES
U-2787	METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION
U-2788	TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
U-2789	POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2790	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2791	TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-2792	TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING

PATENT USE

	METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2793	A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
U-2794	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2795	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2796	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2797	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2798	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2799	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2800	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
U-2801	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY
U-2802	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
U-2803	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
U-2804	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
U-2805	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-2806	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD
U-2807	TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION
U-2808	TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2809	FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
U-2810	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-2811	METHOD OF TREATING PARKINSON'S DISEASE
U-2812	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
U-2813	USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION
U-2814	A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
U-2815	MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2816	METHOD FOR TREATING INFLUENZA
U-2817	METHOD OF INHIBITING COMT IN THE PERIPHERY
U-2818	METHOD OF REDUCING O-METHYLATION OF L-DOPA
U-2819	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS

PATENT USE

	RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2820	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2821	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2822	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2823	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2824	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2825	TREATMENT OF "OFF" EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
U-2826	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
U-2827	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2828	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-2829	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
U-2830	A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
U-2831	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
U-2832	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2833	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2834	TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS
U-2835	TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
U-2836	TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.
U-2837	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
U-2838	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2839	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2840	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)
U-2841	USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE

PATENT USE

U-2842	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
U-2843	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
U-2844	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-2845	A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
U-2846	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
U-2847	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
U-2848	TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2849	METHOD OF TREATING BLEPHAROPTOSIS
U-2850	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
U-2851	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
U-2852	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
U-2853	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
U-2854	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
U-2855	XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
U-2856	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST
U-2857	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
U-2858	USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2859	USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2860	USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2861	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2862	USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2863	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
U-2864	METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
U-2865	TREATMENT OF MYELODYSPLASTIC SYNDROME
U-2866	TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
U-2867	METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
U-2868	TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-2869	IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)
U-2870	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2
U-2871	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3

PATENT USE

U-2872 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5

U-2873 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6

U-2874 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8

U-2875 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9

U-2876 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11

U-2877 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12

U-2878 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14

U-2879 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15

U-2880 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17

U-2881 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18

U-2882 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20

U-2883 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21

U-2884 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24

U-2885 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26

U-2886 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27

U-2887 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29

U-2888 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30

U-2889 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2890 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2891 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

PATENT USE

U-2892 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2893 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2894 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2895 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2896 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2897 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9

U-2898 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10

U-2899 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11

U-2900 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13

U-2901 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2902 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2903 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2904 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2905 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2906 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2907 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS

PATENT USE

RECITED IN CLAIM 22

U-2908 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2909 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2910 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2911 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2912 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2913 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2914 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2915 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2916 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2917 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS

U-2918 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2919 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2920 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26

U-2921 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS

U-2922 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2923 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS

PATENT USE

RECITED IN CLAIM 26

U-2924 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2925 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2926 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2927 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2928 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2929 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2930 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2931 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2932 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2933 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2934 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2935 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54

U-2936 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2937 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2938 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB

U-2939 TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS

PATENT USE

	CYTOCHROME P450 MONOOXYGENASE
U-2940	METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
U-2941	A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2942	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
U-2943	TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
U-2944	TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
U-2945	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
U-2946	TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2947	KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2948	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS
U-2949	A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
U-2950	CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
U-2951	USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
U-2952	TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
U-2953	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
U-2954	METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
U-2955	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
U-2956	METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE
U-2957	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2958	A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2959	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>=150 MG/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE
U-2960	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>= 150 MG/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2961	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
U-2962	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2963	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR

PATENT USE

	BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2964	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2965	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2966	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2967	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2968	USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
U-2969	TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2970	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2971	THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-2972	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2973	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER
U-2974	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER
U-2975	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER
U-2976	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER
U-2977	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY
U-2978	TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-2979	METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD
U-2980	METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
U-2981	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED
U-2982	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY
U-2983	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION
U-2984	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC

PATENT USE

	PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
U-2985	A METHOD FOR TREATING DRY EYE IN A PATIENT
U-2986	MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
U-2987	METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
U-2988	REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
U-2989	METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2990	METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2991	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG
U-2992	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG
U-2993	A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
U-2994	REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-2995	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
U-2996	ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2997	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION
U-2998	METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION
U-2999	METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER
U-3000	METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA
U-3001	PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC.
U-3002	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
U-3004	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-3005	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
U-3006	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-3007	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3008	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3009	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3010	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

PATENT USE

U-3011	A METHOD FOR TREATING OCULAR INFLAMMATION
U-3012	TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL
U-3013	TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
U-3014	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
U-3015	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP
U-3016	ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
U-3017	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3018	XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3019	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER THAT IS SEX-HORMONE-DEPENDENT
U-3020	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER
U-3021	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE
U-3022	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, & 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3023	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3024	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3025	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3026	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3027	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3028	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3029	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3030	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3031	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3032	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621

PATENT USE

U-3033	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3034	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3035	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3036	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3037	A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
U-3038	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
U-3039	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-3040	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR
U-3041	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
U-3042	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)
U-3043	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)
U-3044	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-3045	TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-3046	METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3047	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
U-3048	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3049	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3050	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3051	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3052	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG/DL
U-3053	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND ESTABLISHED CV DISEASE OR DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE

PATENT USE

U-3054	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE
U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
U-3056	TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS
U-3057	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3058	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3059	TREATMENT OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3060	TREATMENT OF HIV INFECTION IN ADULTS
U-3061	TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE
U-3062	REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
U-3063	RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
U-3064	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
U-3065	TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3066	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3067	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3068	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3069	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
U-3070	REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
U-3071	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3072	USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3073	USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3074	METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
U-3075	TREATMENT OF ADRENAL INSUFFICIENCY
U-3076	METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3077	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3078	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3079	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3080	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER

PATENT USE

U-3081 A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

U-3082 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY

U-3083 METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

U-3084 TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

U-3085 DOSE MODIFICATION FOR RENAL IMPAIRMENT

U-3086 FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

U-3087 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45

U-3088 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING

U-3089 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION

U-3090 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-3091 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

U-3092 METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A

U-3093 IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY

U-3094 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE

U-3095 TREATMENT OF HYPERLIPIDEMIA

U-3096 TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST

U-3097 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY

U-3098 TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION

U-3099 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT

U-3100 A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR

U-3101 TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT

U-3102 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS

U-3103 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE

U-3104 TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA

U-3105 TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS

U-3106 TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING

PATENT USE

	THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3107	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3108	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON
U-3109	METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA
U-3110	USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS
U-3111	TREATING OPIOID USE DISORDER
U-3112	TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3113	TREATING RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3114	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
U-3115	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3116	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3117	ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
U-3118	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
U-3119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11
U-3120	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12
U-3121	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23
U-3122	ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24
U-3123	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN
U-3124	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN
U-3125	USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA
U-3126	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-3127	REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES
U-3128	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM

PATENT USE

	& VABORBACTAM AS SPECIFIED
U-3129	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
U-3130	METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER
U-3131	USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE
U-3132	INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
U-3133	TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3134	INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3135	TREATING SCHIZOPHRENIA
U-3136	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3137	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3138	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3139	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3140	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3141	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3142	PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
U-3143	FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-3144	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3145	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3146	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3147	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-3148	METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE
U-3149	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3150	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3151	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3152	USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY
U-3153	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
U-3154	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING

PATENT USE

	ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-3155	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3156	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3157	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3158	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3159	TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
U-3160	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
U-3161	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
U-3162	METHOD FOR WEIGHT MANAGEMENT
U-3163	TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
U-3164	GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
U-3165	METHOD OF TREATING HUMAN SMALLPOX DISEASE
U-3166	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARY RELIEF OF THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES: NASAL CONGESTION, RUNNY NOSE, SNEEZING AND ITCHY NOSE
U-3167	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3168	TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
U-3169	TREATMENT OF TRICHOMONIASIS IN ADULTS
U-3170	TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE
U-3171	TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
U-3172	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN
U-3173	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY
U-3174	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS
U-3175	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
U-3176	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
U-3177	TREATMENT OF VENOUS THROMBOTIC DISEASE
U-3178	REDUCE THE RISK OF RECURRENCE OF VENOUS THROMBOTIC DISEASE
U-3179	METHOD OF TREATING FOLLICULAR LYMPHOMA

PATENT USE

U-3180	DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-3181	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET ACCORDING TO CLAIM 1 OF U.S. PATENT NO. 11,052,075, WHERE THE TABLET FURTHER COMPRISES IVACAFTOR
U-3182	METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3183	USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
U-3184	MEKINIST(R) IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3185	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3186	METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3187	METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3188	IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-3189	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
U-3190	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
U-3191	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-3192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
U-3193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
U-3194	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-3195	TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
U-3196	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
U-3197	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3198	METHOD OF TREATING PATIENTS WITH IDIOPATHIC HYPERSOMNIA WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3199	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3200	INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE, A CORTICOSTEROID, AND AN H2-ANTAGONIST

PATENT USE

U-3201	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
U-3202	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL
U-3203	MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-3204	TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)
U-3205	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION AND STROKE) IN PATIENTS WITH CAD
U-3206	REDUCTION OF RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD
U-3207	REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3208	REDUCTION OF RISK OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE IN PATIENTS WITH PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3209	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK MYOCARDIAL INFARCTION IN AN ADULT PATIENT HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND ELEVATED TRIGLYCERIDE LEVELS
U-3210	ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS
U-3211	TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II
U-3212	TREATING SEPTIC SHOCK WITH ANGIOTENSIN II
U-3213	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
U-3214	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3215	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION
U-3216	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
U-3217	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
U-3218	NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-3219	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
U-3220	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-3221	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION
U-3222	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
U-3223	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
U-3224	A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED

PATENT USE

	ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
U-3225	TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY
U-3226	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
U-3227	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
U-3228	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
U-3229	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
U-3230	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
U-3231	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION
U-3232	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL
U-3233	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS
U-3234	TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
U-3235	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-3236	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
U-3237	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-3238	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3239	TREATMENT OF ADVANCED RENAL CELL CARCINOMA (RCC) IN PATIENTS WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY
U-3240	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG/DL, ON ANTICOAGULANT/ANTIPLATELET/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
U-3241	IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%
U-3242	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-3243	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3244	A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
U-3245	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
U-3246	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
U-3247	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE
U-3248	TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION
U-3249	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
U-3250	METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA

PATENT USE

U-3251	ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS
U-3252	USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
U-3253	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367
U-3254	USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-3255	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3256	USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
U-3257	TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS
U-3258	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE BETWEEN ABOUT 56 MG/M2 AND ABOUT 100 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-3259	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
U-3260	METHOD OF TREATING SPASTICITY
U-3261	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY
U-3262	TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR
U-3263	METHOD FOR TREATING SPASTICITY
U-3264	AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3265	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3266	IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN OR IN MEN, FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3267	USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER
U-3268	TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
U-3269	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION
U-3270	TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER
U-3271	TREATMENT OF BIPOLAR DEPRESSION
U-3272	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3274	TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION
U-3275	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3276	TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-3277	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
U-3278	A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY

PATENT USE

U-3279	A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
U-3280	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE
U-3281	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
U-3282	DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE METFORMIN, MONITORING GLYCEMIA, KIDNEY FUNCTION AND VITAMIN B-12 AND ADJUSTING DOSAGE OF METFORMIN AS NEEDED
U-3283	TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
U-3284	PROPHYLAXIS OF THROMBOEMBOLIC DISEASES IN PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE WHO HAVE UNDERGONE THE FONTAN PROCEDURE AND A BODY WEIGHT OF >=50 KG
U-3285	TREATMENT OF DVT AND/OR PE AND REDUCTION IN THE RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (>=50 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT
U-3286	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF 30 KG TO 49.9 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3287	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF >=50 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3288	PROPHYLAXIS OF PE, DVT AND/OR STROKE IN PEDIATRIC PATIENTS (>=50 KG) AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE AFTER FONTAN PROCEDURE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-3289	TREATMENT OF DVT AND/OR PE AND REDUCTION IN RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (30-49.9 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT
U-3290	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)
U-3291	CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS
U-3292	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND TRIGLYCERIDE LEVELS OF ABOUT 500 MG/DL TO ABOUT 2,000 MG/DL
U-3293	METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION
U-3294	METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL
U-3295	METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY
U-3296	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT
U-3297	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
U-3298	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
U-3299	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS
U-3300	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3301	TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)

PATENT USE

U-3302	TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER
U-3303	TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT
U-3304	METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG
U-3305	METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG
U-3306	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-3307	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED
U-3308	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS TO TREAT HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IF VIROLOGICALLY SUPPRESSED
U-3309	NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-3310	NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
U-3311	NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA
U-3312	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3313	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-3314	METHOD OF TREATING IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER HAVING INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3315	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY ADMINISTERING IV AT LEAST ABOUT 0.6 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3316	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6 GRAMS OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3317	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3318	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
U-3319	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3320	METHOD FOR INCREASING THE LIFETIME OF RED BLOOD CELLS (RBCS) FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3321	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG
U-3322	USE FOR DETECTING NEUTRALIZING ANTIBODIES
U-3323	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS WHO ARE CONCOMITANTLY ADMINISTERED A SALT OF GAMMA-HYDROXYBUTYRATE AND DIVALPROEX SODIUM
U-3324	METHOD OF TREATING PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3325	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR

PATENT USE

	HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3326	A METHOD OF TREATING ANKYLOSING SPONDYLITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, AND 87-98
U-3327	A METHOD OF TREATING PSORIATIC ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, AND 87-98
U-3328	A METHOD OF TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 AND 87-98
U-3329	A METHOD OF TREATING ULCERATIVE COLITIS, BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 AND 87-98
U-3330	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
U-3331	TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
U-3332	USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
U-3333	ADJUVANT TREATMENT OF PATIENTS WITH GBRCA-MUTATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE HIGH RISK EARLY BREAST CANCER WHO HAVE BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
U-3334	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-3335	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
U-3336	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
U-3337	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
U-3338	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION
U-3339	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770
U-3340	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
U-3341	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3342	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3343	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3344	A METHOD OF TREATING ADULTS WITH MULTIPLE MYELOMA USING DEXAMETHASONE IN COMBINATION WITH AN ANTI-MYELOMA PRODUCT
U-3345	FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR (AR) PATHWAY INHIBITION AND TAXANE-BASED CHEMOTHERAPY
U-3346	METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
U-3347	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
U-3348	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
U-3349	REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE

PATENT USE

U-3350	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
U-3351	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3352	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3353	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 AND OLDER TO REPLACE CURRENT REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3354	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE
U-3355	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3356	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER
U-3357	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER
U-3358	USE OF VASCEPA TO REDUCE THE INCIDENCE OF MI IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND/OR FLUTTER INSTEAD OF AN INCIDENCE OF MI
U-3359	TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE
U-3360	COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
U-3361	COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
U-3362	TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS
U-3363	TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS
U-3364	TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION
U-3365	THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED
U-3366	VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
U-3367	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
U-3368	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
U-3369	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 AND OLDER WITH SCLERODERMATOUS FORM OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
U-3370	A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
U-3371	TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3372	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
U-3373	TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS

PATENT USE

U-3374	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3375	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-3376	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-3377	TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG
U-3378	MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3379	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF EPINEPHRINE
U-3380	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3381	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
U-3382	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM A GRADE 3 ADVERSE REACTION WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3383	TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE
U-3384	A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE
U-3385	A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)
U-3386	A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML
U-3387	A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE
U-3388	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN
U-3389	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS
U-3390	SODIUM THIOSULFATE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3391	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3392	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-3393	METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED
U-3394	SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3395	SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-3396	AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
U-3397	TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY
U-3398	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
U-3399	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2, AND PATIENTS AGE

PATENT USE

	12-17 WITH BMI >=30 KG/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
U-3400	FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3401	CAROSPIR IS INDICATED AS AN ADD-ON THERAPY FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER AGENTS
U-3402	CAROSPIR IS INDICATED FOR THE MANAGEMENT OF EDEMA IN ADULT CIRRHOTIC PATIENTS WHEN EDEMA IS NOT RESPONSIVE TO FLUID AND SODIUM RESTRICTION
U-3403	METHOD OF REVERSING OR INHIBITING THE PROGRESS OF UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
U-3404	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3405	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY
U-3406	USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-3407	USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME
U-3408	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 12 YEARS OF AGE AND OLDER. (1)
U-3409	TREATING ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS, MONITORING THIAMINE LEVELS AND ADMINISTERING THIAMINE OR A THIAMINE EQUIVALENT
U-3410	A METHOD OF INJECTING AN IMPLANT
U-3411	TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +/- 0.2 MG/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS
U-3412	TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB
U-3413	INDICATED AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, AND SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3414	INDICATED AS INITIAL MONOTHERAPY FOR THE TREATMENT OF PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3415	INDICATED FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN PATIENTS 12 YEARS AND OLDER
U-3416	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR
U-3417	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
U-3418	A METHOD OF LOADING MEDICATION INTO A SYRINGE AND DELIVERING THE MEDICATION TO A TREATMENT SITE
U-3419	DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
U-3420	A METHOD OF TREATING TESTOSTERONE DEFICIENCY IN MEN
U-3421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
U-3422	TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY

PATENT USE

U-3423	METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3424	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-3425	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407
U-3426	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-3427	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-3428	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-3429	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-3430	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-3431	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
U-3432	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB ADMINISTERED BETWEEN 2 AND 4 HOURS AFTER EATING
U-3433	INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS
U-3434	TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY
U-3435	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES
U-3436	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN LESS THAN 15 MINUTES
U-3437	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.7 G OF IRON IN 15 MINUTES
U-3438	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 46.7 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN < 15 MINUTES
U-3439	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA
U-3440	A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-3441	A METHOD OF TREATING CYSTINURIA BY ORALLY ADMINISTERING TIOPRONIN WITH FOOD TO PREVENT CYSTINE STONE FORMATION IN ADULTS AND PEDIATRIC PATIENTS WITH SEVERE HOMOZYGOUS CYSTINURIA
U-3442	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED AT LEAST THREE TYROSINE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
U-3443	A METHOD OF REDUCING OTOTOXICITY IN A HUMAN PEDIATRIC PATIENT ABOUT 5 YEARS OF AGE OR UNDER WITH LOCALIZED MEDULLOBLASTOMA COMPRISING ADMINISTERING SODIUM THIOSULFATE ABOUT SIX HOURS AFTER ADMINISTRATION OF CISPLATIN

PATENT USE

U-3444	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION TWICE PER WEEK IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3445	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3446	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3447	A METHOD OF TREATING CORONARY ARTERY DISEASE
U-3448	A METHOD OF TREATING HYPERTENSION
U-3449	USE IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-3450	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
U-3451	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
U-3452	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
U-3453	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
U-3454	METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS
U-3455	TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING OPHTHALMIC SURGERY
U-3456	METHOD OF TREATING INTRAHEPATIC CHOLANGIOCARCINOMA
U-3457	METHOD OF INDUCING OCULAR ANESTHESIA
U-3458	A METHOD OF TREATING SEIZURES
U-3459	TREATING SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR AND ANOTHER ACTIVE AGENT
U-3460	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
U-3461	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
U-3462	USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE
U-3463	USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS
U-3464	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB
U-3465	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE
U-3466	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG
U-3467	PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-3468	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
U-3469	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3470	METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE

PATENT USE

U-3471 METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE

U-3472 METHOD TO TREAT IDA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER WEIGHING AT LEAST 40 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.6 G OF IRON IN 15 MINUTES OR LESS

U-3473 METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS

U-3474 METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS

U-3475 REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD

U-3476 TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS

U-3477 ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT

U-3478 STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS

U-3479 STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS

U-3480 STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS

U-3481 DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS

U-3482 DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS

U-3483 DIAGNOSTIC IMAGING BY ACCELERATING THE TRAN IT OFA BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT

U-3484 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED

U-3485 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED

U-3486 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA

U-3487 TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

U-3488 TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY

U-3489 TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES

U-3490 TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY

PATENT USE

U-3491	METHOD OF TREATING LYMPHOMA
U-3492	METHOD OF TREATING SARCOMA
U-3493	THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER
U-3494	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS
U-3495	A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
U-3496	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3497	A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG OR 100 MG); TEZ; AND IVA
U-3499	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) IN ADULT AND PEDIATRIC PATIENTS USING A TWO-DOSE REGIMEN OF DALBAVANCIN
U-3500	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
U-3501	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-3502	TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE
U-3503	ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-3504	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3505	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE
U-3506	TREATMENT OF INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)
U-3507	IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION
U-3508	REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
U-3509	AS-NEEDED TREATMENT OR PREVENTION OF BRONCHOCONSTRICTION AND REDUCTION OF THE RISK OF EXACERBATIONS IN PATIENTS WITH ASTHMA 18 YEARS OF AGE AND OLDER
U-3510	COMBINATION TREATMENT OF COLORECTAL CANCER INCLUDING RAS WILD-TYPE HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING UNRESECTABLE OR METASTATIC COLORECTAL CANCER
U-3511	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS AND SYMPTOMS THEREOF
U-3512	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS
U-3513	TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-3514	INCREASING BLOOD PRESSURE IN A PATIENT HAVING DISTRIBUTIVE SHOCK
U-3515	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE
U-3516	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A NEEDLE GUARD
U-3517	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A WINDOW CONFIGURED TO ALLOW THE USER TO VIEW THE OPIOID ANTAGONIST IN THE SYRINGE
U-3518	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR

PATENT USE

U-3519	TREATMENT WITH LENVIMA BY ADMINISTERING LENVIMA AS A SUSPENSION
U-3520	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING A COMPOSITION COMPRISING SOLRIAMFETOL HYDROCHLORIDE AND 2-CHLOROPROPANE, WHEREIN THE COMPOSITION COMPRISES LESS THAN ABOUT 5 PPM 2CHLOROPROPANE
U-3521	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
U-3522	METHOD OF TREATING EMESIS
U-3523	TREATMENT OF AN ER-POSITIVE BREAST CANCER
U-3524	TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
U-3525	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-3526	TREATMENT OF CF IN A PATIENT AGE 1 TO <6 YEARS AND WEIGHING 7 KG OR MORE WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3527	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-3528	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3529	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3530	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3531	TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-3532	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3533	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-3534	PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS
U-3535	A METHOD OF TREATING ANEMIA
U-3536	TREATMENT OF DEPRESSION IN ADULTS WITH MOD AND ACUTE SUICIDAL IDEATION OR BEHAVIOR IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR LX EVERY 2 WEEKS AFTER INDUCTION PHASE
U-3537	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3538	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-3539	TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH
U-3540	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN
U-3541	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERING COMPLEMENT INHIBITOR PEGCETACOPLAN
U-3542	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN AND ALSO ADMINISTERING AN ANTI-VEGF AGENT

PATENT USE

U-3543	TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE
U-3544	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER
U-3545	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11578062 CLAIM 6 OR 13
U-3546	IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE
U-3547	INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE EXPOSURE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
U-3548	TREATMENT OF AML BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE TO ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES PER A DOSE RAMP-UP INCLUDING AN INITIAL 100 MG OR A FINAL 400 MG PER DAY DOSE
U-3549	INTRAVENOUS SOTALOL DOSING REGIMEN FOR USE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
U-3550	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
U-3551	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT
U-3552	TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER
U-3553	A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION
U-3554	AS A SINGLE AGENT FOR THE TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS
U-3555	ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-3556	TREATMENT OF RETT SYNDROME OR A SYMPTOM THEREOF
U-3557	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-3558	AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH TAVNEOS (AVACOPAN) WITH SEVERE ACTIVE ANCA-ASSOCIATED VASCULITIS (GPA AND MPA) IN COMBINATION WITH STANDARD THERAPY INCLUDING GLUCOCORTICOIDS
U-3559	A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
U-3560	FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS IN CHILDREN AND ADULTS
U-3561	TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
U-3562	TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
U-3563	DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
U-3564	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY
U-3565	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY

PATENT USE

U-3566	TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION
U-3567	TO INCREASE MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-3568	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
U-3569	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
U-3570	TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
U-3571	TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
U-3572	RAISE FOLATE LEVELS IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION FOR THE PURPOSE OF REDUCING THE RISK OF A NEURAL TUBE DEFECT IN A PREGNANCY
U-3573	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YEARS OF AGE IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL
U-3574	TREATMENT OF MOOD CHANGES AND/OR ANXIETY AS SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-3575	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE
U-3576	TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-DAILY PHARMACEUTICAL FORMULATION COMPRISING AN OXYBATE
U-3577	TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A SINGLE DAILY, BEDTIME DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION
U-3578	TREATMENT OF NARCOLEPSY, CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION
U-3579	TREATMENT OF NARCOLEPSY AND ASSOCIATED DISORDERS AND SYMPTOMS USING A COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY
U-3580	TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY
U-3581	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN ADULTS WITH NARCOLEPSY
U-3582	LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING
U-3583	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3584	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER
U-3585	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-3586	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG OR 80 MG); TEZ; AND IVA
U-3587	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3588	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE

PATENT USE

	THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3589	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3590	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3591	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3592	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3593	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3594	TREATMENT OF IRON DEFICIENCY ANEMIA (DIA) IN ADULTS PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
U-3595	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US 11426407
U-3596	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3597	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO ANY ONE OF CLAIMS 1-3 AND 7-9 OF US11179367
U-3598	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11147770
U-3599	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 10272046
U-3600	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3601	TREATMENT OF A DISORDER TREATABLE WITH GAMMA-HYDROXYBUTYRATE USING A SINGLE, DAILY DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION
U-3602	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS WITH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3603	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916
U-3604	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770
U-3605	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-3606	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

PATENT USE

	USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-3607	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-3608	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-3609	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-3610	CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
U-3611	TREATMENT OF PEDIATRIC PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY
U-3612	AS AN ADJUNCT TO DIET TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-3613	AS AN ADJUNCT TO OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE IF SUCH TREATMENTS ARE UNAVAILABLE, TO REDUCE LDL-C IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-3614	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY
U-3615	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL
U-3616	A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE
U-3617	A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE. A METHOD OF TREATING OPIOID WITHDRAWAL USING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE
U-3618	A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY
U-3619	A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION
U-3620	A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND/OR THE SYMPTOMS OF OPIOID WITHDRAWAL
U-3621	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE WITH MENOPAUSE
U-3622	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE
U-3623	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
U-3624	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3626	TREATMENT OF SCHIZOPHRENIA BY ADMINISTRATION OF A SIX-MONTH PALIPERIDONE PALMITATE INJECTABLE SUSPENSION FILLED SYRINGE THAT HAS BEEN SHIPPED AND STORED IN A HORIZONAL POSITION
U-3627	TREATMENT OF DRY EYE DISEASE (DED)
U-3628	REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS
U-3629	TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
U-3630	TREATING OPIOID OVERDOSE
U-3631	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE

PATENT USE

U-3632	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA
U-3633	TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA
U-3634	METHOD OF TREATING IDA IN ADULT PATIENTS WEIGHING AT LEAST 46.7 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES
U-3635	METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON IN ABOUT ≤ 15 MIN
U-3636	METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3637	METHOD TO TREAT IRON DEFICIENCY IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3638	A METHOD FOR TREATING AND/OR REDUCING THE RISK OF ACUTE MYOCARDIAL INFARCTION
U-3639	A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
U-3640	A METHOD OF TREATING AND/OR REDUCING THE RISK OF INFLAMMATION, ATHEROSCLEROTIC VASCULAR DISEASE, AND CHOLESTEROL CRYSTAL INDUCED INFLAMMATION WITHIN ATHEROSCLEROTIC PLAQUES
U-3641	A METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT; ACUTE CORONARY SYNDROME, OUT-OF-HOSPITAL CARDIAC ARREST, AND/OR NONCARDIOEMBOLIC ISCHEMIC STROKE
U-3642	A METHOD OF TREATING CARDIOVASCULAR DISEASE
U-3643	METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
U-3644	TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE
U-3645	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION
U-3646	A METHOD OF TREATMENT OF OVARIAN CANCER OR FALLOPIAN TUBE CANCER
U-3647	A METHOD OF TREATMENT OF RECURRENT OVARIAN CANCER OR FALLOPIAN TUBE CANCER ASSOCIATED WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATION
U-3648	METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)
U-3649	METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)
U-3650	TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, WHERE THE PATIENT IS A STEM CELL, KIDNEY, OR LIVER TRANSPLANT RECIPIENT
U-3651	TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE
U-3652	AS AN ADJUNCT TO DIET AND STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3653	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT
U-3654	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
U-3655	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) USING 300 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
U-3656	TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

PATENT USE

U-3657	TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY
U-3658	TREATMENT OF METASTATIC GASTRIC OR GJA IN SEVERELY RENALLY IMPAIRED PATIENTS TREATED WITH AT LEAST TWO LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
U-3659	TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-3660	TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
U-3661	COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AND CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA
U-3662	DEXTROMETHORPHAN AND BUPROPRION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
U-3663	TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-3664	TOPICAL TREATMENT OF SKIN LESIONS CAUSED BY AN INFECTION WITH MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-3665	TOPICAL DELIVERY OF A CANTHARIDIN FORMULATION TO ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR TREATING MOLLUSCUM CONTAGIOSUM
U-3666	USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER
U-3667	USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX
U-3668	USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS
U-3669	USE OF VASCEPA TO REDUCE THE INCIDENCE OF STROKE IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND/OR FLUTTER INSTEAD OF AN INCIDENCE OF STROKE
U-3670	ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER AND WEIGHING 35 KG OR MORE
U-3671	USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE
U-3672	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX FOR UP TO 24 MONTHS
U-3673	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
U-3674	TREATMENT OF DEMODEX BLEPHARITIS VIA TOPICAL ADMINISTRATION TO AN OCULAR SURFACE
U-3675	A PERCUTANEOUS HEPATIC PERFUSION PROCEDURE FOR TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
U-3676	REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA
U-3677	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT WITH SEVERE HEPATIC IMPAIRMENT
U-3678	A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3679	A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3680	A METHOD FOR TREATING A SUBJECT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES

PATENT USE

U-3681	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING
U-3682	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING
U-3683	A METHOD OF TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES
U-3684	A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION
U-3685	METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE
U-3686	TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3687	TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3688	TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING
U-3689	DIAGNOSIS OF GALL BLADDER DISORDERS BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3690	A METHOD FOR PREVENTING OF POST-OPERATIVE NAUSEA AND VOMITING
U-3691	TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
U-3692	A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
U-3693	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
U-3694	METHOD OF REDUCING OR AMELIORATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE WITH STIRIPENTOL THEREBY MODULATING DOWN THE FORMATION OF NORFENFLURAMINE AND RESULTING IN HIGHER LEVELS OF FENFLURAMINE
U-3695	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-3696	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11752106
U-3697	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <6 YEARS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11752106
U-3698	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION
U-3699	TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS
U-3700	TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE
U-3701	TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE
U-3702	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE
U-3703	TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE
U-3704	TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE

PATENT USE

U-3705	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA/HYPOPNEA INDEX ≤15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE
U-3706	TREATMENT OF BLOATING ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) IN ADULT FEMALE SUBJECTS
U-3707	A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
U-3708	A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
U-3709	METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)
U-3710	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ORALLY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH INTRAVENOUS ADMINISTRATION OF OBINUTUZUMAB
U-3711	A METHOD TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION
U-3712	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE OR OLDER
U-3713	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3714	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3715	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER
U-3716	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM) RECEIVING A MODERATE CYP3A INDUCER
U-3717	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER
U-3718	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
U-3719	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3720	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING A MODERATE CYP3A INDUCER
U-3721	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CHOLESTYRAMINE
U-3722	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING PHENOBARBITAL OR OTHER ANTICONVULSANTS
U-3723	TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CYP3A INHIBITORS
U-3724	TO PRODUCE POST-SURGICAL ANALGESIA
U-3725	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT
U-3726	THE TREATMENT OF POMPE PATIENTS
U-3727	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3728	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3729	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3730	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD
U-3731	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED

PATENT USE

U-3732	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE
U-3733	METHOD OF TREATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE OR ITS SALTS PLUS STIRIPENTOL THEREBY REDUCING NORFENFLURAMINE FORMATION WHILE INCREASING THE FENFLURAMINE LEVEL. PATIENTS CAN HAVE E.G. DRAVET OR LGS
U-3734	METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN
U-3735	TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN
U-3736	REDUCTION OF SERUM PHOSPHORUS IN ADULTS
U-3737	MEKTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH ENCORAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
U-3738	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
U-3739	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3740	TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS
U-3741	TREATMENT OF PRESBYOPIA
U-3742	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
U-3743	A METHOD OF TREATING RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3744	METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS
U-3745	METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
U-3746	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ATERIOSIS WITH AQUEOUS COMPOSITION
U-3747	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
U-3748	TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE AND OLDER
U-3749	METHOD OF TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-3750	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH A WILD TYPE KIT MUTATION IN PATIENTS PREVIOUSLY ADMINISTERED THREE OR MORE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
U-3751	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WITH A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION
U-3752	METHOD OF TREATING DIABETIC HYPOGLYCEMIA
U-3753	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY
U-3754	TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS
U-3755	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-3756	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION
U-3757	TREATMENT OF HYPOTHYROIDISM BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST
U-3758	TREATMENT OF PITUITARY THYROTROPIN SUPPRESSION BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST

PATENT USE

U-3759 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN

U-3760 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION IN PATIENTS WITH HEART FAILURE BY ADMINISTRATION OF EMPAGLIFLOZIN

U-3761 ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR

U-3762 TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY

U-3763 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS

U-3764 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING OBSTRUCTIVE SLEEP APNEA (OSA) AND NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT

U-3765 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MODERATE OR SEVERE RENAL IMPAIRMENT

U-3766 REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE AND URGENT HEART FAILURE VISITS IN ADULTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND WITHOUT TYPE II DIABETES

U-3767 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH

U-3768 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH

U-3769 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH

U-3770 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT

U-3771 USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT

U-3772 USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT

U-3773 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER

U-3774 A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER

U-3775 TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT

U-3776 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL

U-3777 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL

U-3778 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT

U-3779 METHOD OF TREATING NEONATAL SEIZURES

U-3780 TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR

U-3781 REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION

U-3782 METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG

PATENT USE

	INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS
U-3783	COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED
U-3784	USE OF ORAL OCTREOTIDE IN COMBINATION WITH A H2-RECEPTOR ANTAGONIST OR ANTACID FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
U-3785	METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG OF ETHINYL ESTRADIOL FOR UP TO 1THIRTEEN 21/7-DAY (IN/OUT) CYCLES
U-3786	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT WITH SEVERE RENAL IMPAIRMENT
U-3787	A METHOD FOR PREVENTING POST-OPERATIVE NAUSEA AND VOMITING
U-3788	METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING ACTIVE PHARMACEUTICAL INGREDIENT TO TREAT AND/OR PREVENT VIRAL INFECTION
U-3789	METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION USING A NITRIC OXIDE RELEASING ACTIVE INGREDIENT
U-3790	METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A NITRIC OXIDE RELEASING TOPICAL COMPOSITION
U-3791	METHOD OF TREATING, PREVENTING, OR REDUCING LESIONS CAUSED BY MOLLUSCUM CONTAGIOSUM
U-3792	METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL NITRIC OXIDE RELEASING COMPONENT
U-3793	METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING API IN A COMBINATION TOPICAL COMPOSITION
U-3794	METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
U-3795	METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
U-3796	METHOD OF PREVENTING AND/OR REDUCING APPEARANCE AND/OR SIZE OF MALIGNANT LESION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
U-3797	METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS
U-3798	METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES A NITRIC OXIDE RELEASING COMPOUND
U-3799	METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES WATER
U-3800	METHOD OF APPLYING RELEASED NITRIC OXIDE TO SKIN FROM COMBINATION INCLUDING ANHYDROUS ALCOHOL GEL
U-3801	METHOD OF INCREASING RELEASE OF NITRIC OXIDE FROM ANHYDROUS ALCOHOL GEL
U-3802	METHOD OF TREATING SKIN AILMENT WITH NITRIC OXIDE RELEASING MACROMOLECULES AND HYDROPHILIC GEL
U-3803	METHOD OF APPLICATION OF TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT DERMATOLOGICAL CONDITION
U-3804	TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS
U-3805	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
U-3806	TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
U-3807	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
U-3808	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS

PATENT USE

U-3809	IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
U-3810	REDUCTION IN LOSS OF KIDNEY FUNCTION AND REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION
U-3811	USE OF BIRCH TRITERPENES FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA
U-3812	TREATMENT OF DEPRESSION IN MDD WITH ACUTE SUICIDAL IDEATION/BEHAVIOR WITH NASALLY ADMINISTERED ESKETAMINE WITH OAD IN A PATIENT WHO HAS MISSED A DOSE IN THE MAINTENANCE PHASE AND HAD WORSENING DEPRESSION SYMPTOMS BY RETURN TO HIGHER DOSING SCHEDULE
U-3813	TREATMENT OF TRD WITH NASALLY ADMINISTERED ESKETAMINE IN CONJUNCTION WITH AN OAD IN A PATIENT WHO HAS MISSED A DOSE DURING THE MAINTENANCE PHASE AND HAD WORSENING OF DEPRESSION SYMPTOM BY RETURNING TO HIGHER DOSING SCHEDULE
U-3814	USE OF SUSTAINED OR EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR 4
U-3815	TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3 OR 4 CKD WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION
U-3816	TREATMENT OF HELICOBACTER PYLORI INFECTION USING THE ADMINISTERED DOSAGE FORMS IN ADULTS WITH DIFFERENT BODY MASS INDEX DETERMINATIONS
U-3817	USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
U-3818	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS, COMPLICATED URINARY TRACT INFECTIONS, AND HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (AT LEAST 31 WEEKS GESTATIONAL AGE)
U-3819	A METHOD OF PREVENTING PREGNANCY BY PROVIDING AN INTRAUTERINE SYSTEM (IUS), HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND MOVING A SLIDER IN THE HANDLE TO RELEASE THE IUS WITHIN THE UTERUS
U-3820	TREATMENT OF EOSINOPHILIC ESOPHAGITIS
U-3821	DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE AN OCT2 SUBSTRATE, MONITORING THE SUBJECT FOR A DOSE LIMITING EVENT AND ADJUSTING THE DOSAGE OF THE OCT2 SUBSTRATE AS NEEDED
U-3822	AS ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-3823	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY
U-3824	TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA IN COMBINATION WITH OXALIPLATIN, FLUOROURACIL, AND LEUCOVORIN
U-3825	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND WORSENING HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION, WITHOUT TYPE II DIABETES, AND HAVING AN HBA1C OF < 5.7%
U-3826	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN EVERY OTHER MONTH
U-3827	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN MONTHLY
U-3828	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN MONTHLY OR EVERY OTHER MONTH
U-3829	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION
U-3830	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG)
U-3831	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) REQUIRING HOSPITALIZATION

PATENT USE

U-3832	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG)
U-3833	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3834	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3835	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3836	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3837	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IF NOT RECOMMENDED
U-3838	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IF NOT RECOMMENDED
U-3839	A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 12 YEARS OLD UNDERGOING CARDIAC SURGERY
U-3840	A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 17 YEARS OLD UNDERGOING SPINE SURGERY
U-3841	A METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE REGIONAL ANALGESIA VIA SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA IN ADULTS
U-3842	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
U-3843	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
U-3844	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION
U-3845	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)
U-3846	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
U-3847	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-3848	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION
U-3849	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA (SLL)
U-3850	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIS (PFIC)
U-3851	USE OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS
U-3852	USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS
U-3853	METHOD FOR LOWERING CHOLESTEROL LEVEL IN A HUMAN
U-3854	LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
U-3855	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION
U-3856	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

PATENT USE

U-3857	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)
U-3858	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
U-3859	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-3860	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY
U-3861	TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
U-3862	METHOD OF TREATING FRIEDRICH'S ATAXIA BY ACTIVATING THE NRF2 PATHWAY
U-3863	METHOD OF TREATING FRIEDRICH'S ATAXIA BY ACTIVATING THE NRF2 PATHWAY WHICH REDUCES OXIDATIVE STRESS
U-3864	METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT
U-3865	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-3866	TREATMENT OF HELICOBACTER PYLORI INFECTION IN ADULTS USING SPECIFIED DOSAGE FORM
U-3867	METHOD FOR REDUCING A COMPOSITE ENDPOINT RISK OF MYOCARDIAL INFARCTION (MI), STROKE, CORONARY REVASCULARIZATION, UNSTABLE ANGINA REQUIRING HOSPITALIZATION, CARDIAC ARREST, AND CARDIOVASCULAR DEATH
U-3868	METHOD FOR REDUCING ACUTE MYOCARDIAL INFARCTION RISK
U-3869	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES
U-3870	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY INCREASING L-DOPA AMOUNTS THAT REACH THE BRAIN
U-3871	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY INHIBITING COMT IN THE PERIPHERY
U-3872	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY REDUCING O-METHYLATION OF L-DOPA
U-3873	A METHOD OF LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN A HUMAN PATIENT IN NEED THEREOF COMPRISING ADMINISTRATION OF BEMPEDOIC ACID ALONE OR IN COMBINATION WITH OTHER LIPID LOWERING THERAPIES
U-3874	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE PATIENTS 2 YEARS OF AGE AND OLDER, WEIGHING AT LEAST 14KG, WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-3875	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) RECEIVING A MODERATE CYP3A INDUCER, IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY
U-3876	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
U-3877	TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, INCLUDING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS
U-3878	TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS
U-3879	TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, INCLUDING AN ANGIOTENSIN RECEPTOR BLOCKER, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS
U-3880	TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION IN ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 25 KG
U-3881	USE OF THE COMBINATION OF MACITENTAN AND TADALAFIL FOR THE CHRONIC TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION
U-3882	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A COMBINATION OF MACITENTAN AND TADALAFIL
U-3883	A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE

PATENT USE

U-3884	A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING A FIXED-DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
U-3885	A METHOD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) USING GIVINOSTAT
U-3886	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN
U-3887	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN
U-3888	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER
U-3889	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS RECEIVING OR WHO MAY RECEIVE A BETA-BLOCKER TREATMENT
U-3890	A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
U-3891	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS BEING TREATED WITH A BETA-BLOCKER OR IN ADULTS REINITIATING TREATMENT
U-3892	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING A HISTORY OF BIPOLAR DISORDERS AND MODERATE OR SEVERE RENAL IMPAIRMENT
U-3893	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10
U-3894	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 11951212
U-3895	TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
U-3896	TREATMENT OF HEART FAILURE WITH ORAL PELLETS
U-3897	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH ITRACONAZOLE
U-3898	USE OF A PHARMACEUTICAL COMPOSITION OF ABOUT 0.5M SODIUM THIOSULFATE, ABOUT 0.004M BORIC ACID, AND A PH OF BETWEEN ABOUT 6.5 AND 8.9 FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR THE TREATMENT OF LOCALIZED CANCER
U-3899	ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
U-3900	NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED
U-3901	TREATMENT OF METASTATIC CASTRATION SENSITIVE PROSTATE CANCER
U-3902	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PRIOR PD-1 OR PD-L1 INHIBITOR THERAPY
U-3903	A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD
U-3904	ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
U-3905	ALLERGIC CONJUNCTIVITIS
U-3906	ANTERIOR SEGMENT INFLAMMATION
U-3907	AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS
U-3908	AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS
U-3909	AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS

PATENT USE

U-3910	AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS
U-3911	AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS
U-3912	ATOPIC DERMATITIS
U-3913	CHORIORETINITIS
U-3914	DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS
U-3915	DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)
U-3916	DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS
U-3917	IRIDOCYCLITIS
U-3918	IRITIS
U-3919	KERATITIS
U-3920	OPTIC NEURITIS
U-3921	SERUM SICKNESS
U-3922	SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA
U-3923	SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)
U-3924	SEVERE PSORIASIS
U-3925	SYMPTOMATIC SARCOIDOSIS
U-3926	TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS
U-3927	USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
U-3928	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION/L
U-3929	MAINTENANCE TREATMENT WITH 15 MG/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF ADVANCED EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS
U-3930	MAINTENANCE TREATMENT WITH 15 MG/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS
U-3931	MAINTENANCE TREATMENT WITH 15 MG/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS
U-3932	TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME
U-3933	TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB
U-3934	TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EDS IN A HUMAN PATIENT WITH A ONCE-NIGHTLY GHB FORMULATION BY INITIATING TREATMENT WITH A DOSE EQUIVALENT TO 4.5 G OF SODIUM OXYBATE AND UPTITRATING IN INCREMENTS EQUIVALENT TO 1.5 G OF SODIUM OXYBATE
U-3935	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION
U-3936	TREATMENT OF ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-3937	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-3938	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)
U-3939	INTRAMUSCULAR ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-3940	TREATMENT OF BIPOLAR DISORDER OR BIPOLAR DEPRESSION, INCLUDING ASSOCIATED DEPRESSIVE EPISODES

PATENT USE

U-3941	ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-3942	TREATMENT OF SCHIZOPHRENIA IN ADULTS BY INTRAMUSCULAR ADMINISTRATION OF EXTENDED RELEASE INJECTABLE COMPOSITION
U-3943	TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTRATION OF EXTENDED RELEASE INJECTABLE COMPOSITION
U-3944	METHOD FOR DELIVERING AN EFFECTIVE AMOUNT OF CLONIDINE FOR A 24-HOUR PERIOD USING A SINGLE ORAL CLONIDINE COMPOSITION ACCORDING TO CLAIM 1 PRIOR TO BED TIME
U-3945	TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3946	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3947	TOPICAL TREATMENT OF ROSACEA
U-3948	USE OF A PHARMACEUTICAL COMPOSITION HAVING ABOUT 0.5M AQUEOUS ANHYDROUS SODIUM THIOSULFATE AND A CONCENTRATION OF BORATE IONS OF LESS THAN 0.05% FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR TREATMENT OF LOCALIZED CANCER
U-3949	ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
U-3950	TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
U-3951	TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
U-3952	USE OF A PHARMACEUTICAL COMPOSITION HAVING A CONCENTRATION OF ABOUT 0.5M AQUEOUS ANHYDROUS SODIUM THIOSULFATE AND ABOUT 0.004M BORIC ACID FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR TREATMENT OF LOCALIZED CANCER
U-3953	TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
U-3954	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
U-3955	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN PATIENTS UNABLE TO TOLERATE UDCA
U-3956	TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA
U-3957	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR COMPRISING ADMINISTERING ONCE DAILY, ONE OR MORE TABLETS COMPRISING RIPRETINIB
U-3958	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED 4 LINES OF PRIOR THERAPY, WHERE THE FIRST LINE OF PRIOR THERAPY IS IMATINIB
U-3959	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 2 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-3960	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED IMATINIB
U-3961	TREATMENT OF ADULT AND PEDIATRIC PATIENTS >12 YEARS WITH SOLID TUMORS AND NTRK GENE FUSION THAT ARE LOCALLY ADVANCED OR METASTATIC OR LIKELY SURGICALLY UNRESECTABLE, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
U-3962	FOR THE MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULT PATIENTS

PATENT USE

U-3963	TREATMENT OF CLINICALLY IMPORTANT HYPOTENSION OCCURRING IN THE SETTING OF ANESTHESIA
U-3964	METHODS OF ADMINISTERING TESTOSTERONE UNDECANOATE FOR RESTORING TESTOSTERONE CONCENTRATION IN A HYPOGONADAL MALE SUBJECT
U-3965	METHODS OF CONTINUING OR DISCONTINUING A DOSAGE REGIMEN OF A TESTOSTERONE UNDECANOATE PHARMACEUTICAL COMPOSITION TO A HYPOGONADAL MALE SUBJECT
U-3966	REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA
U-3967	TREATING AN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) IN AN OVERWEIGHT OR OBESE PATIENT BY INTRAVENOUSLY (IV) ADMINISTERING 300MG OF DELAFLOXACIN OR A PHARMACEUTICALLY ACCEPTABLE SALT, TWICE A DAY
U-3968	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)
U-3969	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)
U-3970	TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS
U-3971	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME
U-3972	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS (Y373C IDENTIFIED) WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
U-3973	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3974	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
U-3975	IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3976	TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA
U-3977	A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
U-3978	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 OR IDH2 MUTATION OR COMBINATION THEREOF FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
U-3979	NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-3980	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
U-3981	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS
U-3982	TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
U-3983	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 1 YEAR TO 5 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AND FORM I LUM AS RECITED IN, E.G., CLAIM 1 OF US 12065432
U-3984	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AND FORM I LUM AS RECITED IN, E.G., CLAIM 1 OF US 12065432
U-3985	FIRST-LINE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 L858R SUBSTITUTION MUTATIONS, IN COMBINATION WITH AMIVANTAMAB
U-3986	A METHOD OF TREATING AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER
U-3987	TOPICAL TREATMENT OF ACNE
U-3988	USE FOR THE TREATMENT OF FOCAL SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT USE

U-3989	USE FOR THE TREATMENT OF FOCAL SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
U-3990	TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN
U-3991	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN
U-3992	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A WEAK OR MODERATE CYP3A4 INDUCER
U-3993	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK FOR DISEASE PROGRESSION
U-3994	METHOD OF TREATING SEVERE ALOPECIA AREATA IN ADULTS AND ADOLESCENTS 12 YEARS AND OLDER BY ADMINISTERING RITLECTINIB
U-3995	TO RESTORE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSIVE STATES
U-3996	FIRST-LINE TREATMENT OF ADULTS PATIENTS WITH ADVANCED RENAL CELL CARCINOMA BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB
U-3997	TREATMENT OF PATIENTS WITH PMMR/NOT MSI-H ADVANCED ENDOMETRIAL CARCINOMA, HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY, AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB
U-3998	ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE
U-3999	IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE
U-4000	TREATMENT OF DEPRESSIVE EPISODES OR MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR II DISORDER
U-4001	TREATMENT OF ADVANCED PROSTATIC CANCER
U-4002	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-4003	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN
U-4004	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION
U-4005	TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION
U-4006	TREATMENT OF A DISORDER TREATABLE WITH GHB USING A SINGLE DOSE OF A GHB FORMULATION IN AN AMOUNT EQUIVALENT TO 3 G TO 12 G OF SODIUM OXYBATE WHERE THE FORMULATION CONTAINS AN IMMEDIATE RELEASE PORTION AND A MODIFIED RELEASE PORTION
U-4007	METHOD OF TREATING ACROMEGALY PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO OR CANNOT BE TREATED WITH SURGICAL RESECTION, PITUITARY IRRADIATION, AND BROMOCRIPTINE MESYLATE AT MAXIMALLY TOLERATED DOSES
U-4008	METHOD OF TREATING PROFUSE WATERY DIARRHEA ASSOCIATED WITH VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)-SECRETING TUMORS
U-4009	METHOD OF TREATING SEVERE DIARRHEA AND FLUSHING EPISODES ASSOCIATED WITH METASTATIC CARCINOID TUMORS
U-4010	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
U-4011	METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) FOR CARDIAC IMAGING
U-4012	PRETREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING
U-4013	A METHOD OF ADJUNCTIVE TREATING, PREVENTING AND/OR AMELIORATING SEIZURES IN A PERSON WITH DRAVET SYNDROME COMPRISING ADMINISTERING FENFLURAMINE OR A SALT THEREOF IN A DOSE OF 0.2 MG/KG/DAY TO 0.5/MG/KG/DAY AND DOSES OF STIRIPENTOL AND CLOBAZAM
U-4014	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH A GRADE 3 INFECTION ADVERSE REACTION

PATENT USE

U-4015	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-4016	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 10, AND 11
U-4017	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 21
U-4018	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 21, AND 22
U-4019	TREATMENT OF BIPOLAR DEPRESSION BY INHIBITING THE 5-HT2A RECEPTOR, INHIBITING THE SEROTONIN TRANSPORTER, AND/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION, OR TREATMENT OF BIPOLAR DISORDER
U-4020	TREATMENT OF SCHIZOPHRENIA BY INHIBITING THE 5-HT2A RECEPTOR, INHIBITING THE SEROTONIN TRANSPORTER, AND/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION, OR TREATMENT OF SCHIZOPHRENIA
U-4021	USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)
U-4022	TREATMENT OF A DISORDER IN A HUMAN PATIENT WITH A ONCE-NIGHTLY GHB FORMULATION BY INITIATING TREATMENT WITH A DOSE EQUIVALENT TO 4.5 G OF SODIUM OXYBATE AND UPTITRATING IN INCREMENTS EQUIVALENT TO 1.5 G OF SODIUM OXYBATE
U-4023	TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-4024	COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
U-4025	A METHOD FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
U-4026	USE IN TREATING UNCOMPLICATED URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR PROTEUS MIRABILIS
U-4027	TREATMENT OF GASTRIC ADENOCARCINOMA
U-4028	TREATMENT OF HEAD AND NECK CANCER
U-4029	ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT
U-4030	TREATMENT OF MOTOR FLUCTUATIONS IN ADULTS WITH ADVANCED PARKINSON'S DISEASE
U-4031	REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA
U-4032	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-4033	METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE POSTSURGICAL LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE POSTSURGICAL REGIONAL ANALGESIA
U-4034	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE-5 (CDLK5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
U-4035	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER, MODIFIED BY DOSE-SEPARATING ADMINISTRATIONS OF RELUGOLIX AND A P-GP INHIBITOR, WHEN CO-ADMINISTRATION OF RELUGOLIX AND THE P-GP INHIBITOR IS UNAVOIDABLE
U-4036	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS), INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS
U-4037	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
U-4038	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES BY ADMINISTERING WITHOUT FOOD
U-4039	ADULT AND PEDIATRIC PATIENTS AS A SOURCE OF SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED

PATENT USE

U-4040	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-4041	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG/M2 OR 56 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-4042	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-4043	EMROSI IS INDICATED TO TREAT INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA IN ADULTS
U-4044	TREATMENT OF IDIOPATHIC HYPERSOMNIA WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB
U-4045	TREATMENT OF RELAPSED OR REFRACTORY ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-4046	TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
U-4047	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE AS CLAIMED
U-4048	TOPICAL TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-4049	ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)
U-4050	USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
U-4051	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB AND MFOLFOX6, FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
U-4052	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11752106
U-4053	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-4054	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING ELX, IVA, AND A SOLID DISPERSION ACCORDING TO US 11578062 CLAIM 1
U-4055	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-4056	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-4057	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG OR 80 MG); TEZ; AND IVA
U-4058	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US 11426407
U-4059	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11179367
U-4060	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11147770
U-4061	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT

PATENT USE

	LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-4062	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 10272046
U-4063	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1
U-4064	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-4065	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-4066	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-4067	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG); TEZ; AND IVA
U-4068	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS HAVING IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA USING A SOLID COMPOSITION OF ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-4069	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG); TEZ; AND IVA
U-4070	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407
U-4071	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11179367
U-4072	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELX, TEZ, AND IVA
U-4073	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-4074	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-4075	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-4076	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION GENE OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-4077	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-4078	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER HAVING IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA USING A SOLID COMPOSITION OF ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-4079	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA WITH ELX, TEZ, AND

PATENT USE

IVA

U-4080 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A SOLID PHARMACEUTICAL COMPOSITION COMPRISING VNZ, TEZ, AMORPHOUS D-IVA, AND <30% CRYSTALLINE D-IVA

U-4081 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR

U-4082 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR

U-4083 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR CALCIUM SALT HYDRATE FORM D, TEZACAFTOR, AND DEUTIVACAFTOR

U-4084 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A PHARMACEUTICAL COMPOSITION COMPRISING VNZ, TEZ, AND D-IVA

U-4085 REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION

U-4086 REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION

U-4087 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ, D-IVA, AND A COMPOSITION ACCORDING TO CLAIM 1 OF US10081621

U-4088 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH 21.4 MG OF VNZ CALCIUM SALT HYDRATE FORM D, 100 MG OF TEZ, AND 250 MG OF D-IVA DAILY

U-4089 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ AND A COMPOSITION ACCORDING TO CLAIM 1 OF US11951212

U-4090 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR

U-4091 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE WITH VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR

U-4092 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ AND A COMPOSITION ACCORDING TO CLAIM 1 OF US10206877

U-4093 TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WITH AT LEAST ONE F508DEL OR G551D AND AN A455E, 2789+5G->A, OR 3849+10KBC->T CFTR MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546 FURTHER COMPRISING VNZ

U-4094 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING VNZ, TEZ, AND D-IVA WITH AT LEAST 90% ISOTOPIC ENRICHMENT FOR EACH DEUTERIUM ATOM

U-4095 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11564916, VNZ, AND TEZ

U-4096 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR, DEUTIVACAFTOR, AND A SOLID DISPERSION ACCORDING TO CLAIM 1 OF US 11,578,062

U-4097 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 9,012,496 FURTHER COMPRISING VNZ

U-4098 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL

PATENT USE

	MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VNZ, TEZ, AND A COMPOSITION ACCORDING TO CLAIM 3 OF US 9,512,079
U-4099	TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE NOT PREVIOUSLY RECEIVED AN ALK-INHIBITOR
U-4100	A METHOD OF TREATING MODERATE TO SEVERE OPIOID USE DISORDER BY ADMINISTERING BUPRENORPHINE ONCE WEEKLY
U-4101	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
U-4102	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
U-4103	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
U-4104	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
U-4105	USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT ON STATIN THERAPY WITH CARDIOVASCULAR-RELATED DISEASE AND ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO ABOUT 500 MG/DL)
U-4106	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO OR MILD RENAL IMPAIRMENT
U-4107	IN COMBINATION WITH PANITUMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER (MCRC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
U-4108	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB
U-4109	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB
U-4110	TREATMENT OF SCHIZOPHRENIA IN A PATIENT PREVIOUSLY BEEN TREATED WITH ONCE-A-MONTH (PP1M) OR ONCE-EVERY-THREE-MONTHS (PP3M) PALIPERIDONE PALMITATE BY SWITCHING TO ONCE-EVERY-SIX-MONTH PALIPERIDONE PALMITATE USING A DOSING WINDOW OF A DOSING REGIMEN
U-4111	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BY ADMINISTERING A LIQUID EDARAVONE COMPOSITION RELATIVE TO THE TIMING AND TYPE OF FOOD CONSUMPTION
U-4112	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS
U-4113	TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE
U-4114	TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84MG WEEKLY OR 1X EVERY TWO WEEKS
U-4115	TREATMENT OF TREATMENT RESISTANT DEPRESSION BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS
U-4116	TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE
U-4117	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84MG WEEKLY OR 1X EVERY TWO WEEKS
U-4118	TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION
U-4119	TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION
U-4120	TREATMENT OF TREATMENT-RESISTANT DEPRESSION WITH NASALLY ADMINISTERED ESKETAMINE IN A PATIENT WHO HAS MISSED A DOSE DURING THE MAINTENANCE PHASE AND HAD

PATENT USE

	WORSENING OF DEPRESSION SYMPTOMS BY RETURNING TO A HIGHER DOSING SCHEDULE
U-4121	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A MODERATE CYP3A4 INHIBITOR
U-4122	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A WEAK CYP3A4 INHIBITOR
U-4123	TREATMENT OF SOLID TUMORS THAT HAVE A NTRK GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
U-4124	TREATMENT OF SOLID TUMORS CHARACTERIZED BY A GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE
U-4125	TREATMENT OF MODERATE TO SEVERE ACUTE PAIN IN ADULTS USING SUZETRIGINE
U-4126	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083
U-4127	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083
U-4128	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083
U-4129	METHOD OF LOWERING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-4130	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION
U-4131	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS
U-4132	A METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT
U-4133	REDUCING TMAX OF ORALLY ADMINISTERED MELOXICAM
U-4134	RAPID DELIVERY OF MELOXICAM TO THE BLOOD OF A HUMAN BEING
U-4135	IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM
U-4136	ACUTE TREATMENT OF MIGRAINE ASSOCIATED WITH ALLODYNIA
U-4137	TREATING POST-TRANSPLANT CMV INFECTION/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 1200 MG MARIBAVIR TWICE DAILY, WHERE THE PATIENT IS CONCOMITANTLY EXPOSED TO OR RECEIVING PHENYTOIN OR PHENOBARBITAL
U-4138	TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE
U-4139	TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE
U-4140	REDUCING THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CV DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CKD AT RISK OF PROGRESSION AND WITHOUT TYPE II DIABETES AFTER AT LEAST 4 MONTHS OF TREATMENT
U-4141	TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 12,214,083
U-4142	ADMINISTERING TREOSULFAN AS A PREPARATIVE REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION
U-4143	GASTROINTESTINAL FLAVORED SOLUTION INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
U-4144	ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CCL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR
U-4145	TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR

PATENT USE

U-4146	FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) USING DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS
U-4147	TREATMENT OF COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS IN ADULT PATIENTS
U-4148	METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA VIA AN ADDUCTOR CANAL BLOCK IN ADULTS
U-4149	METHOD OF INCREASING THE AMOUNT OF TIME BEFORE POSTSURGICAL OPIOID MEDICATION IS ADMINISTERED TO A PATIENT BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
U-4150	METHOD OF REDUCING POSTSURGICAL OPIOID CONSUMPTION BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
U-4151	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, WHEREIN THE DEPIGMENTED AREA IS ≥ 0.5% BSA ON THE FACE, ≥ 3% BSA ON NON-FACIAL AREAS, AND NOT >10% BSA ON TOTAL BODY AREA
U-4152	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA
U-4153	TREATING RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PRIOR TREATMENT
U-4154	TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
U-4155	INTRAUTERINE DEVICE PROMOTING CONTRACEPTION UTILIZING COPPER WITHOUT BLOCKING OPENINGS OF TWO FALLOPIAN TUBES
U-4156	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
U-4157	THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH A COURSE OF CORTICOSTEROIDS AND DID HAVE A CLINICALLY SIGNIFICANT RISE IN INTRAOCULAR PRESSURE
U-4158	A METHOD OF USING LOSARTAN FOR THE REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY
U-4159	A METHOD OF USING LOSARTAN FOR THE TREATMENT OF HYPERTENSION
U-4160	A METHOD OF USING LOSARTAN FOR THE TREATMENT OF DIABETIC NEPHROPATHY WITH AN ELEVATED SERUM CREATININE AND PROTEINURIA IN PATIENTS WITH TYPE 2 DIABETES AND A HISTORY OF HYPERTENSION
U-4161	TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G)
U-4162	TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 25KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-4163	TREATMENT OF AMEBIASIS IN ADULTS AND PEDIATRIC PATIENTS
U-4164	TREATMENT OF ANAEROBIC BACTERIAL INFECTIONS IN ADULTS
U-4165	ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS
U-4166	TREATMENT OF FEMALE ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40 KG WITH UNCOMPLICATED URINARY TRACT INFECTIONS (UUTI) CAUSED BY ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, ENTEROCOCCUS FAECALIS
U-4167	REDUCING HYPERPHAGIC AGGRESSIVE BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS
U-4168	A METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT
U-4169	FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY
U-4170	USE OF LEVACETYLLEUCINE FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC)
U-4171	USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
U-4172	TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER
U-4173	NASAL ADMINISTRATION OF DIAZEPAM FOR THE ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY THAT ARE DISTINCT FROM A

PATENT USE

	PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 2 YEARS OF AGE AND OLDER
U-4174	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
U-4175	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY TWICE-WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
U-4176	TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT FOLLOWING A PROGRAMMED DEATH RECEPTOR-I OR PROGRAMMED DEATH-LIGAND 1 INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
U-4177	CUSHING'S SYNDROME, INCLUDING CUSHING'S DISEASE
U-4178	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT GREATER THAN OR EQUAL TO 35 KG
U-4179	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 4 TO LESS THAN 35 KG
U-4180	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 2.6 TO LESS THAN 4 KG
U-4181	TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
U-4182	EMERGENCY TREATMENT OF A KNOWN OR SUSPECTED OPIOID OVERDOSE/SYMPTOM THEREOF IN A HUMAN CAUSED BY NATURAL OR SYNTHETIC OPIOIDS, SUCH AS REMIFENTANIL-INDUCED RESPIRATORY DEPRESSION, WITH 2.7MG NALMEFENE, ADMINISTERED AS 3MG NALMEFENE HYDROCHLORIDE
U-4183	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
U-4184	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA A NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA
U-4185	METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
U-4186	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) WHO WEIGH 25 KILOGRAMS AND ABOVE
U-4187	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE
U-4188	ACUTE TREATMENT OF CLUSTER HEADACHES
U-4189	METHOD OF DECREASING EXCESSIVE DAYTIME SLEEPINESS BY ORALLY ADMINISTERING A DOSE PROPORTIONAL, PHARMACEUTICAL COMPOSITION COMPRISING IMMEDIATE RELEASE AND MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE PORTIONS ONCE DAILY AT BEDTIME
U-4190	FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION
U-4191	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 3 PALMAR-PLANTAR ERYTHRODYSESTHESIA WHILE BEING ADMINISTERED RIPETRINIB DAILY
U-4192	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4193	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4194	METHODS OF RESTORING TESTOSTERONE CONCENTRATION FOR CONDITIONS ASSOCIATED WITH DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE IN A MALE SUBJECT
U-4195	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)
U-4196	TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH

PATENT USE

DEFACTINIB

U-4197 TREATMENT OF OIC IN ADULTS WITH ADVANCED ILLNESS OR PAIN CAUSED BY ACTIVE CANCER WHO REQUIRE OPIOID DOSAGE ESCALATION FOR PALLIATIVE CARE

U-4198 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC NON-CANCER PAIN, INCLUDING PATIENTS WITH CHRONIC PAIN RELATED TO PRIOR CANCER OR ITS TREATMENT WHO DO NOT REQUIRE FREQUENT (E.G., WEEKLY) OPIOID DOSAGE ESCALATION

U-4199 DEFINITION USE CODE METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE

U-4200 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE

U-4201 DOSAGE MODIFICATION FOLLOWING GRADE 3 TOXICITY OR INTOLERABLE SIDE EFFECT BY DISCONTINUING APALUTAMIDE UNTIL IMPROVEMENT TO ORIGINAL GRADE OR GRADE I IN TREATMENT OF MCRPC PATIENTS THAT INCREASES OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL

U-4202 IMPROVEMENT OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS BY TREATMENT WITH 240 MG ORAL APALUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY

U-4203 TOPICAL TREATMENT OF PLAQUE PSORIASIS OF THE SCALP AND BODY IN PATIENTS 12 YEARS OF AGE AND OLDER

U-4204 TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION

U-4205 TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH AVUTOMETINIB

U-4206 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS

U-4207 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

U-4208 TREATMENT OF ADULT PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (NMCRPC)

U-4209 TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)

U-4210 TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) IN COMBINATION WITH DOCETAXEL

U-4211 TREATING HYPERPHAGIA AND REDUCING HYPERPHAGIC AGGRESSIVE BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS

U-4212 TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE ≥3 HEPATOTOXICITY FROM 3.2 TO 2.6 MG/M2 AND 2.6 TO 2.0 MG/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE IF HEPATOTOXICITY ≤GRADE 1

U-4213 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A BCRP AND/OR P-GP ONLY INHIBITOR

U-4214 A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION

U-4215 TREATMENT OF PRIMARY OR SECONDARY ADRENOCORTICAL INSUFFICIENCY WITH AN ORAL LIQUID FORMULATION OF HYDROCORTISONE

U-4216 TREATMENT OF ADRENAL INSUFFICIENCY WITH AN ORAL LIQUID FORMULATION OF HYDROCORTISONE

U-4217 PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER'S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY

U-4218 TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WITH AT LEAST ONE F508DEL OR G551D AND AN R117H, A455E, 2789+5G->A, OR 3849+10KBC->T CFTR MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF US10058546 CLAIM 1 FURTHER COMPRISING VNZ

PATENT USE

U-4219 TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY IN ADULT MALES ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

U-4220 TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX/TEZ/IVA (100 MG/50 MG/75 MG) + IVA (75 MG)

U-4221 TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX/TEZ/IVA (200 MG/100 MG/150 MG) + IVA (150 MG)

U-4222 TREATMENT OF CF IN PATIENTS AGED 6 TO <12 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING DAILY ELX/TEZ/IVA (100 MG/50 MG/75 MG) + IVA (75 MG)

U-4223 TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-4224 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-4225 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/ 1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-4226 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1 .73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-4227 METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS

U-4228 METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS

U-4229 METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS

U-4230 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS

U-4231 METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS

U-4232 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS

U-4233 VOSTALLY IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE

U-4234 PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS UNDERGOING CONCURRENT TREATMENT WITH A STRONG CYP3A4 INHIBITOR

U-4235 A METHOD OF REDUCING THE HEART RATE OF A SUBJECT SUFFERING FROM SUPRAVENTRICULAR TACHYCARDIA, WHEREIN LANDIOLOL IS ADMINISTERED PARENTERALLY AT A CONSTANT DOSE OF MORE THAN 20 MCG/KG/MIN FOR 2-20 HOURS, WHEREIN THE DOSE IS NOT HIGHER THAN 40 MCG/KG/MIN

U-4236 DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE A MATE1 SUBSTRATE, MONITORING THE SUBJECT FOR A DOSE LIMITING EVENT AND ADJUSTING THE DOSAGE OF THE MATE1 SUBSTRATE AS NEEDED

U-4237 METHOD OF INHIBITING JANUS KINASE 2 OR JANUS KINASE 3 TO TREAT MODERATE TO SEVERE CHRONIC HAND ECZEMA (CHE) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR FOR WHOM TOPICAL CORTICOSTEROIDS ARE NOT ADVISABLE

U-4238 TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF A UNIT DOSE OF PEGCETACOPLAN

PATENT USE

	IN A COMPOSITION OF CLAIM 1
U-4239	TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 35 KG TO LESS THAN 50 KG WITH C3G OR PRIMARY IC-MPGN BY TWICE WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 810 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
U-4240	TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 50 KG OR HIGHER WITH C3G OR PRIMARY IC-MPGN BY TWICE WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OFPEGCETACOPLAN IN A COMPOSITION OF CLAIM 1
U-4241	TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 50 KG OR HIGHER WITH C3 GLOMERULOPATHY OR PRIMARY IMMUNECOMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY
U-4242	TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF PEGCETACOPLAN
U-4243	TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3G OR PRIMARY IC-MPGN BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-MEDIATED DAMAGE
U-4244	TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN
U-4245	USE OF ZONGERTINIB FOR TREATING NON-SMALL CELL LUNG CANCER (NSCLC)
U-4246	FOR USE IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
U-4247	FOR USE IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
U-4248	FOR USE IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA AND/OR LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
U-4249	AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF ADULTS WITH HYPERCHOLESTEROLEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-4250	METHOD OF TREATING HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN WITH FOOD
U-4251	TREATMENT OF HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN
U-4252	TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE 4 THROMBOCYTOPENIA OR GRADE 3 WITH BLEEDING FROM 3.2 TO 2.6 MG/M2 AND 2.6 TO 2.0 MG/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE
U-4253	ATMEKSI IS INDICATED AS AN ADJUNCT TO REST, PHYSICAL THERAPY, AND OTHER MEASURES FOR THE RELIEF AND DISCOMFORT ASSOCIATED WITH ACUTE, PAINFUL MUSCULOSKELETAL CONDITIONS
U-4254	METHOD OF TREATING ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH DIFFUSE MIDLINE GLIOMA HARBORING AN H3 K27M MUTATION WITH PROGRESSIVE DISEASE FOLLOWING PRIOR THERAPY
U-4255	A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD L-ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD
U-4256	TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
U-4257	TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER
U-4258	A METHOD OF TREATING PRIMARY HYPERLIPIDEMIA USING BEMPEDOIC ACID
U-4259	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER THROUGH INHIBITING RHO-ASSOCIATED, COILED-COIL CONTAINING PROTEIN KINASE
U-4260	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12

PATENT USE

	YEARS AND OLDER
U-4261	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
U-4262	A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
U-4263	TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS
U-4264	TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE BY ADMINISTERING APREMILAST WITH FOOD
U-4265	TREATMENT OF PSORIATIC ARTHRITIS BY ADMINISTERING APREMILAST WITH FOOD
U-4266	TREATMENT OF PLAQUE PSORIASIS BY ADMINISTERING APREMILAST WITH FOOD
U-4267	METHOD FOR TREATING ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT, BY ACHIEVING A PLATELET COUNT OF AT LEAST 50,000/UL
U-4268	METHOD OF INHIBITING BRUTON'S TYROSINE KINASE ACTIVITY IN ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-4269	METHOD OF TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-4270	METHOD OF TREATMENT OF ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-4271	ADJUNCTIVE THERAPY FOR PARTIAL-ONSET, PRIMARY GENERALIZED TONIC-CLONIC (PGTC), OR LENNOX-GASTAUT SEIZURES IN PATIENTS 2 YEARS AND OLDER
U-4272	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY MOOD EPISODES
U-4273	CONVERSION TO MONOTHERAPY FOR PARTIAL-ONSET SEIZURES IN PATIENTS 16 YEARS AND OLDER
U-4274	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
U-4275	TREATING HYPERPHAGIA AND REDUCING FOOD-RELATED BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS
U-4276	TREATMENT OF FUNGAL OTIC INFECTION (FUNGAL OTITIS EXTERNA, OTOMYCOSIS) DUE TO ASPERGILLUS SPECIES AND CANDIDA SPECIES
U-4277	METHOD FOR TREATING BARTH SYNDROME IN ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 30KG
U-4278	TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
U-4279	INTRANASAL BUMETANIDE FOR THE TREATMENT OF EDEMA
U-4280	TREATMENT OF CHRONIC AUTOIMMUNE URTICARIA
U-4281	TREATMENT OF CHRONIC SPONTANEOUS URTICARIA
U-4282	TREATMENT OF ADULTS WITH ACROMEGALY WHO HAVE HEPATIC IMPAIRMENT AND AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
U-4283	TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
U-4284	TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF GREATER THAN 3 MONTHS
U-4285	TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF AT LEAST ABOUT 3 MONTHS
U-4286	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
U-4287	DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
U-4288	TREATMENT OF SEVERE PHOSPHATIDYLINOSITOL-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA)-RELATED OVERGROWTH SPECTRUM (PROS) HAVING AN OVERGROWTH OF MULTIPLE TISSUES, THAT REQUIRES SYSTEMIC THERAPY
U-4289	TREATING POST-TRANSPLANT CMV INFECTION/DISEASE REFRACTORY TO GANCICLOVIR,

PATENT USE

	VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 1200 MG MARIBAVIR TWICE DAILY, WHERE PATIENT IS EXPOSED TO/RECEIVING AN IMMUNOSUPPRESSANT AND PHENYTOIN OR PHENOBARBITAL
U-4290	TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
U-4291	TREATMENT OF PSORIATIC ARTHRITIS
U-4292	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE
U-4293	TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
U-4294	TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
U-4295	TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
U-4296	TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
U-4297	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
U-4298	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS
U-4299	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY
U-4300	TREATMENT OF PAROXYSMAL NOCTURAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
U-4301	TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 2 TO 5 YEARS OF AGE
U-4302	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
U-4303	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE
U-4304	TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
U-4305	TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE 4 OR ANY GRADE FEBRILE NEUTROPENIA FROM 3.2 TO 2.6 MG/M2 AND 2.6 TO 2.0 MG/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE
U-4306	METHOD OF TREATING MILD TO MODERATE PAIN (SURGICAL) IN ADULTS
U-4307	METHOD OF TREATING MODERATE TO SEVERE PAIN (SURGICAL) IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS
U-4308	IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4309	IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4310	TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4311	TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE
U-4312	TREATMENT OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING TWO TABLETS

PATENT USE

	EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
U-4313	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
U-4314	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
U-4315	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4316	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NACL, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
U-4317	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
U-4318	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, ABOUT 8.2 MG/ML OF NACL, WHEREIN THE COMPOSITION IS PH 6.5-7.5
U-4319	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A 5 MG/ML, 10 MG/ML, 15 MG/ML, 20 MG/ML, 25 MG/ML, OR 30 MG/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4320	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, ABOUT 6.2-9.5 MG/ML OF NACL, AND OPTIONALLY ABOUT 3.0-7.0 MG/ML PHENOL
U-4321	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, ABOUT 1-3 MG/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4322	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0-9.0 MG/ML OF NACL
U-4323	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4324	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG/ML OF NACL
U-4325	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67-2.68 MG/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4326	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG/ML OF NACL
U-4327	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NUCLEOPHOSMIN 1 (NPM1) MUTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-4328	TREATING POST-TRANSPLANT CMV INFECTION/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 800 OR 1200 MG MARIBAVIR 2X DAILY WHERE PATIENT IS CONCOMITANTLY EXPOSED TO/RECEIVING ANTICONVULSANT, IMMUNOSUPPRESSANT
U-4329	TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, BY ADMINISTERING 400 MG OF MARIBAVIR ORALLY TWICE DAILY
U-4330	TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 12458635 CLAIM 1
U-4331	TREATMENT OF RENALLY IMPAIRED PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS INCLUDING ACUTE PYELONEPHRITIS CAUSED BY SUSCEPTIBLE ISOLATES OF ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE

PATENT USE

U-4332	TREATMENT OF PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS INCLUDING ACUTE PYELONEPHRITIS CAUSED BY SUSCEPTIBLE ISOLATES OF ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE
U-4333	TREATMENT OF CF IN PATIENTS AGED 2 TO < 6 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND/OR IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 12458635 CLAIM 1
U-4334	INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE
U-4335	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 1 YEAR TO 5 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AS RECITED IN, E.G., CLAIM 1 OF US 12458635, AND FORM I LUM
U-4336	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 12458635 CLAIM 1
U-4337	TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO LESS THAN 6 YEARS OLD WHO HAS IN THE CFTR GENE AT LEAST ONE MUTATION RESPONSIVE TO IVA BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12458635
U-4338	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AS RECITED IN, E.G., CLAIM 1 OF US 12458635, AND FORM I LUM
U-4339	TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO HAS IN THE CFTR GENE AT LEAST ONE MUTATION RESPONSIVE TO IVA BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12458635
U-4340	TREATMENT OF MAJOR DEPRESSIVE DISORDER, ADJUNCTIVE TO ANTIDEPRESSANT THERAPY, OR ADJUNCTIVE TO ANTIDEPRESSANT THERAPY BY INHIBITING THE 5-HT2A RECEPTOR AND/OR SEROTONIN TRANSPORTER, AND/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION
U-4341	TREATMENT OF MAJOR DEPRESSIVE DISORDER MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS, ADJUNCTIVE TO ANTIDEPRESSANT TREATMENT
U-4342	TREATMENT OF MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT THERAPY, INCLUDING TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER
U-4343	MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT THERAPY
U-4344	TREATMENT OF MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT TREATMENT
U-4345	METHOD OF TREATING OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER
U-4346	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE AND URGENT HEART FAILURE VISITS IN ADULTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND STRUCTURAL HEART DISEASE AND WITHOUT TYPE II DIABETES
U-4347	METHOD OF TREATING ACUTE MYELOID LEUKEMIA
U-4348	METHOD OF TREATING HEMATOLOGIC MALIGNANCY
U-4349	METHOD OF TREATING ACUTE MYELOID LEUKEMIA WITH ZIFTOMENIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
U-4350	METHOD OF INHIBITING MENIN INTERACTION
U-4351	METHOD OF TREATING LEUKEMIA
U-4352	METHOD OF INHIBITING PROLIFERATION AND/OR INDUCING APOPTOSIS IN A LEUKEMIA CELL WITH A NUCLEOPHOSMIN 1 (NPM1) MUTATION
U-4353	METHOD OF TREATING LEUKEMIA WITH A NUCLEOPHOSMIN 1 (NPM1) MUTATION
U-4354	METHOD OF TREATING MENIN-MEDIATED DISEASE
U-4355	PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE
U-4356	IMPROVING THE PHARMACOKINETICS OF MELOXICAM IN A HUMAN BEING SUFFERING FROM MIGRAINE

PATENT USE

U-4357	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
U-4358	TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS
U-4359	TREATMENT OF SEVERE PHOSPHATIDYLINOSITOL-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA)-RELATED OVERGROWTH SPECTRUM (PROS) HAVING AN OVERGROWTH OF MULTIPLE TISSUES, THAT REQUIRES SYSTEMIC THERAPY AND IS NOT RESPONSIVE TO RAPAMYCIN
U-4360	USE TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
U-4361	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 45 KG WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS WITH UNCOMPLICATED UROGENITAL GONORRHEA CAUSED BY SUSCEPTIBLE STRAINS OF NEISSERIA GONORRHOEAE
U-4362	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR
U-4363	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
U-4364	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
U-4365	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
U-4366	TREATING HYPOGONADOTROPIC HYPOGONADISM BY ADMINISTERING TO A MALE WITH ALLERGIC OR SEASONAL RHINITIS 5.5MG TESTOSTERONE IN 0.122G TESTOSTERONE GEL IN EACH NOSTRIL 3 TIMES DAILY VIA A METERED DOSE PUMP ACTUATABLE 60 TIMES AND CONTAINING 11 G GEL
U-4367	TREATING PRIMARY HYPOGONADISM BY ADMINISTERING TO A MALE WITH ALLERGIC OR SEASONAL RHINITIS 5.5MG TESTOSTERONE IN 0.122G TESTOSTERONE GEL IN EACH NOSTRIL 3 TIMES DAILY VIA A METERED DOSE PUMP ACTUATABLE 60 TIMES AND CONTAINING 11 G GEL
U-4368	A METHOD FOR TREATING METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA2-MUTATION
U-4369	TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA DUE TO NEISSERIA GONORRHOEAE
U-4370	TREATMENT OF A CARDIAC ARRHYTHMIA
U-4371	TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS